PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Wootton, DM; Alevriadou, BR				Wootton, David M.; Alevriadou, B. Rita			The Shear Stress of Busting Blood Clots	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							FLOW		[Wootton, David M.] Cooper Union Adv Sci & Art, Dept Mech Engn, New York, NY 10003 USA; [Wootton, David M.] Cooper Union Adv Sci & Art, Maurice Kanbar Ctr Biomed Engn, New York, NY 10003 USA; [Alevriadou, B. Rita] Ohio State Univ, Dept Biomed Engn, Columbus, OH 43210 USA; [Alevriadou, B. Rita] Ohio State Univ, Dept Internal Med Cardiovasc Med, Columbus, OH USA; [Alevriadou, B. Rita] Ohio State Univ, Dorothy M Davis Heart & Lung Res Inst, Columbus, OH USA	Ohio State University; Ohio State University; Ohio State University	Wootton, DM (corresponding author), Cooper Union Adv Sci & Art, Dept Mech Engn, New York, NY 10003 USA.		Alevriadou, Barbara R/E-2628-2011	Alevriadou, Barbara/0000-0003-1897-755X				Korin N, 2012, SCIENCE, V337, P738, DOI 10.1126/science.1217815; Ruggeri ZM, 2009, MICROCIRCULATION, V16, P58, DOI 10.1080/10739680802651477; Shankaran H, 2003, BLOOD, V101, P2637, DOI 10.1182/blood-2002-05-1550; TILLES AW, 1987, MICROVASC RES, V33, P211, DOI 10.1016/0026-2862(87)90018-5; Wootton DM, 2002, BIOTECHNOL BIOENG, V77, P405, DOI 10.1002/bit.10127	5	10	10	0	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 4	2012	367	14					1361	1363		10.1056/NEJMcibr1207994	http://dx.doi.org/10.1056/NEJMcibr1207994			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	014WJ	23034026				2023-01-03	WOS:000309406100017
J	Guasch, L; Sala, E; Ojeda, MJ; Valls, C; Blade, C; Mulero, M; Blay, M; Ardevol, A; Garcia-Vallve, S; Pujadas, G				Guasch, Laura; Sala, Esther; Jose Ojeda, Maria; Valls, Cristina; Blade, Cinta; Mulero, Miquel; Blay, Mayte; Ardevol, Anna; Garcia-Vallve, Santiago; Pujadas, Gerard			Identification of Novel Human Dipeptidyl Peptidase-IV Inhibitors of Natural Origin (Part II): In Silico Prediction in Antidiabetic Extracts	PLOS ONE			English	Article							INDUCED DIABETIC-RATS; HYPOGLYCEMIC ACTIVITY; RAUWOLFIA-VOMITORIA; MEDICINAL CHEMISTRY; ALKALOIDS; PLANTS; STREPTOZOTOCIN; DRUGS; DATABASE; PRODUCTS	Background: Natural extracts play an important role in traditional medicines for the treatment of diabetes mellitus and are also an essential resource for new drug discovery. Dipeptidyl peptidase IV (DPP-IV) inhibitors are potential candidates for the treatment of type 2 diabetes mellitus, and the effectiveness of certain antidiabetic extracts of natural origin could be, at least partially, explained by the inhibition of DPP-IV. Methodology/Principal Findings: Using an initial set of 29,779 natural products that are annotated with their natural source and an experimentally validated virtual screening procedure previously developed in our lab (Guasch et al.; 2012) [1], we have predicted 12 potential DPP-IV inhibitors from 12 different plant extracts that are known to have antidiabetic activity. Seven of these molecules are identical or similar to molecules with described antidiabetic activity (although their role as DPP-IV inhibitors has not been suggested as an explanation for their bioactivity). Therefore, it is plausible that these 12 molecules could be responsible, at least in part, for the antidiabetic activity of these extracts through their inhibitory effect on DPP-IV. In addition, we also identified as potential DPP-IV inhibitors 6 molecules from 6 different plants with no described antidiabetic activity but that share the same genus as plants with known antidiabetic properties. Moreover, none of the 18 molecules that we predicted as DPP-IV inhibitors exhibits chemical similarity with a group of 2,342 known DPP-IV inhibitors. Conclusions/Significance: Our study identified 18 potential DPP-IV inhibitors in 18 different plant extracts (12 of these plants have known antidiabetic properties, whereas, for the remaining 6, antidiabetic activity has been reported for other plant species from the same genus). Moreover, none of the 18 molecules exhibits chemical similarity with a large group of known DPP-IV inhibitors.	[Guasch, Laura; Sala, Esther; Jose Ojeda, Maria; Valls, Cristina; Blade, Cinta; Mulero, Miquel; Blay, Mayte; Ardevol, Anna; Garcia-Vallve, Santiago; Pujadas, Gerard] Univ Rovira & Virgili, Dept Bioquim & Biotecnol, Grp Recerca Nutrigenom, Tarragona, Catalonia, Spain; [Garcia-Vallve, Santiago; Pujadas, Gerard] CEICS, TECNIO, CTNS, Reus, Catalonia, Spain	Universitat Rovira i Virgili	Pujadas, G (corresponding author), Univ Rovira & Virgili, Dept Bioquim & Biotecnol, Grp Recerca Nutrigenom, Tarragona, Catalonia, Spain.	gerard.pujadas@urv.cat	Mulero, Miquel/L-4672-2014; Pujadas, Gerard/B-1457-2010; Sala, Esther/AAB-4997-2022; MJosé, Ojeda/ABB-5745-2020; Blay, Mayte Dr/B-1680-2009; PUJADAS, GERARD/W-9348-2019; Ardévol, Anna/AAO-6194-2021; Garcia-Vallve, Santi/A-4226-2008; Valls-Bautista, Cristina/K-8769-2014	Mulero, Miquel/0000-0003-2545-2065; Pujadas, Gerard/0000-0003-2598-8089; Blay, Mayte Dr/0000-0002-6256-9847; PUJADAS, GERARD/0000-0003-2598-8089; Ardévol, Anna/0000-0003-0156-7538; Garcia-Vallve, Santi/0000-0002-0348-7497; Valls-Bautista, Cristina/0000-0001-5583-5695; Guasch, Laura/0000-0003-4990-7765; Blade, Cinta/0000-0003-2838-2402; Ojeda Montes, Maria Jose/0000-0002-9290-1935; Sala, Esther/0000-0002-5149-1992	Ministerio de Educacion y Ciencia of the Spanish Government [AGL2011-25831/ALI, AGL2011-23879/ALI]; Generalitat de Catalunya [ACC1O/TECCT11-1-0012]; XRQTC grant; Spanish Government [BES-2009-026450]	Ministerio de Educacion y Ciencia of the Spanish Government(Spanish Government); Generalitat de Catalunya(Generalitat de Catalunya); XRQTC grant; Spanish Government(Spanish GovernmentEuropean Commission)	This research was supported by grants from the Ministerio de Educacion y Ciencia of the Spanish Government (AGL2011-25831/ALI and AGL2011-23879/ALI) and from the Generalitat de Catalunya (ACC1O/TECCT11-1-0012 program and XRQTC grant). N.G.-A. was supported by a pre-doctoral fellowship BES-2009-026450 from the Spanish Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguilar-Santamaria L, 2009, J ETHNOPHARMACOL, V124, P284, DOI 10.1016/j.jep.2009.04.033; Andrade-Cetto A, 2005, J ETHNOPHARMACOL, V99, P325, DOI 10.1016/j.jep.2005.04.019; Augeri DJ, 2005, J MED CHEM, V48, P5025, DOI 10.1021/jm050261p; Bae EY, 2006, PLANTA MED, V72, P945, DOI 10.1055/s-2006-946674; Beek T. A. van, 1984, Tetrahedron, V40, P737, DOI 10.1016/S0040-4020(01)91102-0; Benn MH, 1996, J AGR FOOD CHEM, V44, P2779, DOI 10.1021/jf960175l; BENZI G, 1984, FARMACO-ED SCI, V39, P44; BLACK O. F., 1927, AMER JOUR PHARM, V99, P748; Bnouham M, 2006, INT J DIABETES METAB, V14; BRACK A, 1962, ARCHIV PHARM BERICHT, V295, P510, DOI 10.1002/ardp.19622950706; Brubaker PL, 2004, ENDOCRINOLOGY, V145, P2653, DOI 10.1210/en.2004-0015; Campbell JIA, 2006, J ETHNOPHARMACOL, V104, P379, DOI 10.1016/j.jep.2005.12.029; Chatterjee A, 1955, NATURWISSENSCHAFTEN, V77, P3551; Costantino Luca, 2003, Farmaco, V58, P781; Dixon SL, 2006, J COMPUT AID MOL DES, V20, P647, DOI 10.1007/s10822-006-9087-6; Duan JX, 2010, J MOL GRAPH MODEL, V29, P157, DOI 10.1016/j.jmgm.2010.05.008; El Sayed KA, 1998, J NAT PROD, V61, P848, DOI 10.1021/np980042p; Fu Z, 2011, BRIT J NUTR, V105, P1218, DOI 10.1017/S0007114510004824; Fujii M, 2009, BIOMED PHARMACOTHER, V63, P710, DOI 10.1016/j.biopha.2009.01.006; GHOSH BP, 1958, NATURWISSENSCHAFTEN, V45, P365, DOI 10.1007/BF00600690; Giang PM, 2006, CHEM PHARM BULL, V54, P546, DOI 10.1248/cpb.54.546; Gilg E, 1930, ARCH PHARM WEINHEIM, P233; GORMAN M, 1957, TETRAHEDRON, V1, P328, DOI 10.1016/0040-4020(57)88008-9; GRUESORENSEN G, 1989, CAN J CHEM, V67, P998, DOI 10.1139/v89-152; Guasch L, 2012, IDENTIFICATION NOV 1; HAMMOUDA Y, 1964, J PHARM PHARMACOL, V16, P833, DOI 10.1111/j.2042-7158.1964.tb07420.x; Haque N, 2011, Pak J Biol Sci, V14, P13, DOI 10.3923/pjbs.2011.13.24; Havale SH, 2009, BIOORGAN MED CHEM, V17, P1783, DOI 10.1016/j.bmc.2009.01.061; HOCHSTEIN FA, 1955, J AM CHEM SOC, V77, P3551, DOI 10.1021/ja01618a037; Howes M, 2005, TRADITIONAL MED MODE; ITO K, 1975, YAKUGAKU ZASSHI, V95, P358, DOI 10.1248/yakushi1947.95.3_358; Kar DM, 2006, J ETHNOPHARMACOL, V108, P251, DOI 10.1016/j.jep.2006.05.016; Kashiwaba N, 1997, CHEM PHARM BULL, V45, P545; Kelley LA, 1996, PROTEIN ENG, V9, P1063, DOI 10.1093/protein/9.11.1063; Kim D, 2005, J MED CHEM, V48, P141, DOI 10.1021/jm0493156; KONNO C, 1985, PLANTA MED, V51, P162, DOI 10.1055/s-2007-969437; KONNO C, 1985, PLANTA MED, V51, P160, DOI 10.1055/s-2007-969436; Kuhn B, 2007, CURR TOP MED CHEM, V7, P609, DOI 10.2174/156802607780091064; Kumar A, 2011, PHARM BIOL, V49, P577, DOI 10.3109/13880209.2010.529615; Latha M, 2004, J BIOCHEM MOL TOXIC, V18, P261, DOI 10.1002/jbt.20035; Liu TQ, 2007, NUCLEIC ACIDS RES, V35, pD198, DOI 10.1093/nar/gkl999; Ly TT, 2011, DIABETES CARE, V34, P50, DOI 10.2337/dc10-1042; Malviya N, 2010, ACTA POL PHARM, V67, P113; Meier JJ, 2002, REGUL PEPTIDES, V107, P1, DOI 10.1016/S0167-0115(02)00039-3; MENTLEIN R, 1993, EUR J BIOCHEM, V214, P829, DOI 10.1111/j.1432-1033.1993.tb17986.x; MICHEL KH, 1967, ACTA PHARM SUEC, V4, P97; Modak M, 2007, J CLIN BIOCHEM NUTR, V40, P163, DOI 10.3164/jcbn.40.163; Montagut G, 2010, J NUTR BIOCHEM, V21, P476, DOI 10.1016/j.jnutbio.2009.02.003; Mosihuzzaman M, 1994, Diabetes Res, V26, P127; Na M, 2006, J NAT PROD, V69, P1572, DOI 10.1021/np0601861; NATH M C, 1945, Ann Biochem Exp Med, V5, P101; Nguyen PH, 2010, J NAT PROD, V73, P598, DOI 10.1021/np900745g; Oh WK, 2009, ARCH PHARM RES, V32, P43, DOI 10.1007/s12272-009-1116-2; Osadchii SA, 2007, RUSS CHEM B+, V56, P1261, DOI 10.1007/s11172-007-0191-0; Pinent M, 2004, ENDOCRINOLOGY, V145, P4985, DOI 10.1210/en.2004-0764; Prabhakar PK, 2008, CURR DIABETES REV, V4, P291, DOI 10.2174/157339908786241124; Prabhakar PK, 2011, CHIN J INTEGR MED, V17, P563, DOI 10.1007/s11655-011-0810-3; Qi LW, 2010, CURR TOP MED CHEM, V10, P434, DOI 10.2174/156802610790980620; Roland M., 1959, J PHARM BELG, V14, P347; RONCHETTI F, 1971, PHYTOCHEMISTRY, V10, P1385, DOI 10.1016/S0031-9422(00)84347-2; Sala E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016903; Semwal DK, 2010, J ASIAN NAT PROD RES, V12, P99, DOI 10.1080/10286020903117325; SHABANA MM, 1990, ARCH EXP VET MED, V44, P389; Sheludko Y, 2002, J NAT PROD, V65, P1006, DOI 10.1021/np0200919; SHUKLA K, 1991, Indian Journal of Physiology and Pharmacology, V35, P249; Song EK, 2003, ARCH PHARM RES, V26, P559, DOI 10.1007/BF02976881; TAKAYAMA H, 1988, CHEM PHARM BULL, V36, P3210; Torres JL, 2001, J AGR FOOD CHEM, V49, P4627, DOI 10.1021/jf010368v; Tsutsumi T, 2003, BIOL PHARM BULL, V26, P313, DOI 10.1248/bpb.26.313; USUBILLAGA A, 1988, PHYTOCHEMISTRY, V27, P3031, DOI 10.1016/0031-9422(88)80726-X; van de Venter M, 2008, J ETHNOPHARMACOL, V119, P81, DOI 10.1016/j.jep.2008.05.031; Villasenor IM, 2006, J ETHNOPHARMACOL, V104, P129, DOI 10.1016/j.jep.2005.08.067; Villhauer EB, 2003, J MED CHEM, V46, P2774, DOI 10.1021/jm030091l; Vuksan V, 2005, NUTR METAB CARDIOVAS, V15, P149, DOI 10.1016/j.numecd.2005.05.001; Yin Jun, 2008, Endocrine Metabolic & Immune Disorders-Drug Targets, V8, P99, DOI 10.2174/187153008784534330; Yoshikawa M, 2007, J NAT PROD, V70, P210, DOI 10.1021/np0680580; Zettl H, 2010, CHEMMEDCHEM, V5, P179, DOI 10.1002/cmdc.200900448; Zhang H, 2007, J NAT PROD, V70, P54, DOI 10.1021/np060344o; Zsoldos Z, 2007, J MOL GRAPH MODEL, V26, P198, DOI 10.1016/j.jmgm.2006.06.002	79	14	17	0	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2012	7	9							e44972	10.1371/journal.pone.0044972	http://dx.doi.org/10.1371/journal.pone.0044972			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014RG	23028712	gold, Green Submitted, Green Published			2023-01-03	WOS:000309392800021
J	Einstein, DJ				Einstein, David J.			ON BEING A DOCTOR Knot	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Tufts Med Ctr, Boston, MA 02111 USA	Tufts Medical Center	Einstein, DJ (corresponding author), Tufts Med Ctr, 800 Washington St, Boston, MA 02111 USA.	deinstein@tuftsmedicalcenter.org	Einstein, David/ABB-3748-2020						0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 4	2012	157	5					381	382		10.7326/0003-4819-157-5-201209040-00012	http://dx.doi.org/10.7326/0003-4819-157-5-201209040-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	000BM	22944877				2023-01-03	WOS:000308361500009
J	Preukschas, M; Hagel, C; Schulte, A; Weber, K; Lamszus, K; Sievert, H; Pallmann, N; Bokemeyer, C; Hauber, J; Braig, M; Balabanov, S				Preukschas, Michael; Hagel, Christian; Schulte, Alexander; Weber, Kristoffer; Lamszus, Katrin; Sievert, Henning; Paellmann, Nora; Bokemeyer, Carsten; Hauber, Joachim; Braig, Melanie; Balabanov, Stefan			Expression of Eukaryotic Initiation Factor 5A and Hypusine Forming Enzymes in Glioblastoma Patient Samples: Implications for New Targeted Therapies	PLOS ONE			English	Article							DEOXYHYPUSINE SYNTHASE ACTIVITY; YEAST SACCHAROMYCES-CEREVISIAE; ONTOLOGY LEGO VECTORS; GLIOMA-CELL LINES; PROTEIN EXPRESSION; GROWTH-FACTOR; CANCER-CELLS; AMINO-ACID; INDEPENDENT PREDICTOR; MALIGNANT GLIOMAS	Glioblastomas are highly aggressive brain tumors of adults with poor clinical outcome. Despite a broad range of new and more specific treatment strategies, therapy of glioblastomas remains challenging and tumors relapse in all cases. Recent work demonstrated that the posttranslational hypusine modification of the eukaryotic initiation factor 5A (eIF-5A) is a crucial regulator of cell proliferation, differentiation and an important factor in tumor formation, progression and maintenance. Here we report that eIF-5A as well as the hypusine-forming enzymes deoxyhypusine synthase (DHS) and deoxyhypusine hydroxylase (DOHH) are highly overexpressed in glioblastoma patient samples. Importantly, targeting eIF-5A and its hypusine modification with GC7, a specific DHS-inhibitor, showed a strong antiproliferative effect in glioblastoma cell lines in vitro, while normal human astrocytes were not affected. Furthermore, we identified p53 dependent premature senescence, a permanent cell cycle arrest, as the primary outcome in U87-MG cells after treatment with GC7. Strikingly, combined treatment with clinically relevant alkylating agents and GC7 had an additive antiproliferative effect in glioblastoma cell lines. In addition, stable knockdown of eIF-5A and DHS by short hairpin RNA (shRNA) could mimic the antiproliferative effects of GC7. These findings suggest that pharmacological inhibition of eIF-5A may represent a novel concept to treat glioblastomas and may help to substantially improve the clinical course of this tumor entity.	[Preukschas, Michael; Sievert, Henning; Paellmann, Nora; Bokemeyer, Carsten; Braig, Melanie; Balabanov, Stefan] Univ Med Ctr Hamburg Eppendorf, Hubertus Wald Tumorzentrum, Dept Oncol Haematol & Bone Marrow Transplantat, Sect Pneumol, Hamburg, Germany; [Hagel, Christian] Univ Med Ctr Hamburg Eppendorf, Dept Neuropathol, Hamburg, Germany; [Schulte, Alexander; Lamszus, Katrin] Univ Med Ctr Hamburg Eppendorf, Dept Neurosurg, Hamburg, Germany; [Weber, Kristoffer] Univ Med Ctr Hamburg Eppendorf, Clin Stem Cell Transplantat, Res Dept Cell & Gene Therapy, Hamburg, Germany; [Hauber, Joachim] Leibniz Inst Expt Virol, Heinrich Pette Inst, Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Heinrich Pette Institute	Preukschas, M (corresponding author), Univ Med Ctr Hamburg Eppendorf, Hubertus Wald Tumorzentrum, Dept Oncol Haematol & Bone Marrow Transplantat, Sect Pneumol, Hamburg, Germany.	stefan.balabanov@usz.ch	Balabanov, Stefan/E-9765-2014; /H-8186-2012; Riecken, Kristoffer/AAD-2371-2020	Riecken, Kristoffer/0000-0001-9050-6766	Deutsche Forschungsgemeinschaft (DFG) [BA 3506/1-1, HA 2580/4-1]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	These studies were supported by grants from the Deutsche Forschungsgemeinschaft (DFG) (BA 3506/1-1 and HA 2580/4-1; www.dfg.de). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABBRUZZESE A, 1986, J BIOL CHEM, V261, P3085; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Balabanov S, 2007, BLOOD, V109, P1701, DOI 10.1182/blood-2005-03-037648; BENNE R, 1978, J BIOL CHEM, V253, P3070; Beyer WR, 2002, J VIROL, V76, P1488, DOI 10.1128/JVI.76.3.1488-1495.2002; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Caraglia M, 1997, BIOCHEM J, V324, P737, DOI 10.1042/bj3240737; Caraglia M, 2003, J BIOCHEM, V133, P757, DOI 10.1093/jb/mvg097; Caraglia M, 2001, AMINO ACIDS, V20, P91, DOI 10.1007/s007260170050; Caraglia M, 2011, AMINO ACIDS, P1; Chatterjee I, 2006, MOL GENET GENOMICS, V275, P264, DOI 10.1007/s00438-005-0086-4; Chen W, 2009, CANCER EPIDEM BIOMAR, V18, P400, DOI 10.1158/1055-9965.EPI-08-0754; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; COOPER HL, 1982, CELL, V29, P791, DOI 10.1016/0092-8674(82)90441-X; Eckerich C, 2009, J NEUROCHEM, V109, P969, DOI 10.1111/j.1471-4159.2009.06027.x; Gunther W, 2003, BRIT J CANCER, V88, P463, DOI 10.1038/sj.bjc.6600711; He LR, 2011, INT J CANCER, V129, P143, DOI 10.1002/ijc.25669; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Hirose Y, 2001, CANCER RES, V61, P1957; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; JAKUS J, 1993, J BIOL CHEM, V268, P13151; Jenkins ZA, 2001, GENOMICS, V71, P101, DOI 10.1006/geno.2000.6418; KLIER H, 1995, BIOCHEMISTRY-US, V34, P14693, DOI 10.1021/bi00045a010; Kunkel P, 2001, NEURO-ONCOLOGY, V3, P82, DOI 10.1093/neuonc/3.2.82; Kyrpides NC, 1998, P NATL ACAD SCI USA, V95, P224, DOI 10.1073/pnas.95.1.224; Lam FF, 2010, PROTEOM CLIN APPL, V4, P60, DOI 10.1002/prca.200900084; Lee NP, 2009, INT J CANC, V9999; Li AL, 2004, J BIOL CHEM, V279, P49251, DOI 10.1074/jbc.M407165200; Lu ZJ, 2011, ELECTROPHORESIS, V32, P3612, DOI 10.1002/elps.201100230; Michaelis M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.129; Nishimura K, 2012, AMINO ACIDS, V42, P703, DOI 10.1007/s00726-011-0986-z; Noda SE, 2009, SEMIN RADIAT ONCOL, V19, P171, DOI 10.1016/j.semradonc.2009.02.005; Park MH, 2010, AMINO ACIDS, V38, P491, DOI 10.1007/s00726-009-0408-7; Park MH, 1998, J BIOL CHEM, V273, P1677, DOI 10.1074/jbc.273.3.1677; PARK MH, 1994, J BIOL CHEM, V269, P27827; PARK MH, 1981, P NATL ACAD SCI-BIOL, V78, P2869, DOI 10.1073/pnas.78.5.2869; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rahman-Roblick R, 2007, P NATL ACAD SCI USA, V104, P5401, DOI 10.1073/pnas.0700794104; Reardon DA, 2010, J NEURO-ONCOL, V96, P219, DOI 10.1007/s11060-009-9950-0; Riccardi C, 2006, NAT PROTOC, V1, P1458, DOI 10.1038/nprot.2006.238; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; Shi XP, 1996, BBA-MOL CELL RES, V1310, P119, DOI 10.1016/0167-4889(95)00165-4; SHIBA T, 1971, BIOCHIM BIOPHYS ACTA, V244, P523, DOI 10.1016/0304-4165(71)90069-9; Specht S, 2008, PARASITOL RES, V102, P1177, DOI 10.1007/s00436-008-0891-x; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sun Z, 2010, J CELL PHYSIOL, V223, P798, DOI 10.1002/jcp.22100; Taylor CA, 2007, EXP CELL RES, V313, P437, DOI 10.1016/j.yexcr.2006.09.030; Templin AT, 2011, CELL CYCLE, V10, P1043, DOI 10.4161/cc.10.7.15206; Tome ME, 1997, BIOCHEM J, V328, P847; Tome ME, 1997, BIOL SIGNAL, V6, P150; Van Meir E. G., 2009, CNS CANC MODELS MARK; Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069; Weber K, 2010, GENE THER, V17, P511, DOI 10.1038/gt.2009.149; Weber K, 2008, MOL THER, V16, P698, DOI 10.1038/mt.2008.6; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wick W, 2010, J CLIN ONCOL, V28, pE188, DOI 10.1200/JCO.2009.26.9027; Wolff EC, 2007, AMINO ACIDS, V33, P341, DOI 10.1007/s00726-007-0525-0; Wolff EC, 2011, METHODS MOL BIOL, V720, P195, DOI 10.1007/978-1-61779-034-8_12; Yang GF, 2009, GYNECOL ONCOL, V112, P314, DOI 10.1016/j.ygyno.2008.10.024; Zender L, 2008, CELL, V135, P852, DOI 10.1016/j.cell.2008.09.061; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zuk D, 1998, EMBO J, V17, P2914, DOI 10.1093/emboj/17.10.2914	65	40	42	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 21	2012	7	8							e43468	10.1371/journal.pone.0043468	http://dx.doi.org/10.1371/journal.pone.0043468			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	992PA	22927971	Green Submitted, Green Published, Green Accepted, gold			2023-01-03	WOS:000307789700035
J	Culham, DE; Meinecke, M; Wood, JM				Culham, Doreen E.; Meinecke, Michael; Wood, Janet M.			Impacts of the Osmolality and the Lumenal Ionic Strength on Osmosensory Transporter ProP in Proteoliposomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETAINE CARRIER BETP; ESCHERICHIA-COLI; CORYNEBACTERIUM-GLUTAMICUM; OSMOTIC ACTIVATION; COILED-COIL; WATER; ROLES; SOLUTES; PROTEIN; K+	H+ symporter ProP serves as a paradigm for the study of osmosensing. ProP attains the same activity at the same osmolality when the medium outside cells or proteoliposomes is supplemented with diverse, membrane-impermeant solutes. The osmosensory mechanism of ProP has been probed by varying the solvent within membrane vesicles and proteoliposomes. ProP activation was not ion specific, did not require K+, and could be elicited by large, uncharged solutes polyethylene glycols (PEGS). We hypothesized that ProP is an ionic strength sensor and lumenal macromolecules activate ProP by altering ion activities. The attainable range of lumenal ionic strength was expanded by lowering the phosphate concentration within proteoliposomes. ProP activity at high osmolality, but not the osmolality, yielding half-maximal activity (Pi(1/2)/RT), decreased with the lumenal phosphate concentration. This was attributed to acidification of the proteoliposome lumen due to H+-proline symport. The ionic strength yielding half-maximal ProP activity was more anion-dependent than Pi(1/2)/RT for proteoliposomes loaded with citrate, sulfate, phosphate, chloride, or iodide. The anion effects followed the Hofmeister series. Lumenal bovine serum albumin (BSA) lowered the lumenal ionic strength at which ProP became active. Osmolality measurements documented the non-idealities of solutions including potassium phosphate and other solutes. The impacts of PEGS and BSA on ion activities did not account for their impacts on ProP activity. The effects of the tested solutes on ProP appear to be non-coulombic in nature. They may arise from effects of preferential interactions and macromolecular crowding on the membrane or on ProP.	[Culham, Doreen E.; Meinecke, Michael; Wood, Janet M.] Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada	University of Guelph	Wood, JM (corresponding author), Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada.	jwood@uoguelph.ca	Meinecke, Michael/C-4833-2013	Meinecke, Michael/0000-0003-1414-6951	Canadian Institutes for Health Research Operating [MOP-89990]	Canadian Institutes for Health Research Operating(Canadian Institutes of Health Research (CIHR))	This work was supported by Canadian Institutes for Health Research Operating Grant MOP-89990 (to J. M. W.) and by a travel award by the Muhlenhoff Stiftung (to M. M.).	[Anonymous], 1888, ARCH EXP PATHOL PHAR, DOI DOI 10.1007/BF01918191; BENGA G, 1984, PROG BIOPHYS MOL BIO, V43, P195, DOI 10.1016/0079-6107(84)90014-2; Biemans-Oldehinkel E, 2006, P NATL ACAD SCI USA, V103, P10624, DOI 10.1073/pnas.0603871103; CLEMENT NR, 1981, BIOCHEMISTRY-US, V20, P1534, DOI 10.1021/bi00509a019; Culham DE, 2000, J MOL RECOGNIT, V13, P309, DOI 10.1002/1099-1352(200009/10)13:5<309::AID-JMR505>3.3.CO;2-I; CULHAM DE, 1993, J MOL BIOL, V229, P268, DOI 10.1006/jmbi.1993.1030; Culham DE, 2003, BIOCHEMISTRY-US, V42, P410, DOI 10.1021/bi0264364; Culham DE, 2008, BIOCHEMISTRY-US, V47, P8176, DOI 10.1021/bi800794z; Culham DE, 2008, BIOCHEMISTRY-US, V47, P13584, DOI 10.1021/bi801576x; ERTEL A, 1993, BIOPHYS J, V64, P426, DOI 10.1016/S0006-3495(93)81383-3; Ge L, 2011, P NATL ACAD SCI USA, V108, pE890, DOI 10.1073/pnas.1109597108; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Haussinger D, 2007, METHOD ENZYMOL, V428, P1; Karasawa A, 2011, J BIOL CHEM, V286, P37280, DOI 10.1074/jbc.M111.284059; Keates RAB, 2010, BIOCHEMISTRY-US, V49, P8847, DOI 10.1021/bi101281f; Konopka MC, 2007, METHOD ENZYMOL, V428, P487, DOI 10.1016/S0076-6879(07)28027-9; Koynova R, 1997, EUR BIOPHYS J BIOPHY, V25, P261, DOI 10.1007/s002490050038; Kramer R, 2009, AMINO ACIDS, V37, P487, DOI 10.1007/s00726-009-0271-6; Kung C, 2010, ANNU REV MICROBIOL, V64, P313, DOI 10.1146/annurev.micro.112408.134106; Mahmood NABN, 2006, J BIOL CHEM, V281, P29830, DOI 10.1074/jbc.M604907200; Parsegian VA, 2002, INT REV CYTOL, V215, P1; Pegram LM, 2007, J PHYS CHEM B, V111, P5411, DOI 10.1021/jp070245z; Pegram Laurel M., 2009, V490, P179, DOI 10.1007/978-1-59745-367-7_8; Poolman B, 2004, BBA-BIOMEMBRANES, V1666, P88, DOI 10.1016/j.bbamem.2004.06.013; Poolman B, 2002, MOL MICROBIOL, V44, P889, DOI 10.1046/j.1365-2958.2002.02894.x; Racher KI, 1999, BIOCHEMISTRY-US, V38, P1676, DOI 10.1021/bi981279n; Racher KI, 2001, BIOCHEMISTRY-US, V40, P7324, DOI 10.1021/bi002331u; ROBINSON DR, 1965, J AM CHEM SOC, V87, P2470, DOI 10.1021/ja01089a029; Romantsov T, 2008, J BIOL CHEM, V283, P12314, DOI 10.1074/jbc.M709871200; Romantsov T, 2007, MOL MICROBIOL, V64, P1455, DOI 10.1111/j.1365-2958.2007.05727.x; Rubenhagen R, 2000, J BIOL CHEM, V275, P735, DOI 10.1074/jbc.275.2.735; Rubenhagen R, 2001, EMBO J, V20, P5412, DOI 10.1093/emboj/20.19.5412; SANDERSON PW, 1991, BIOCHIM BIOPHYS ACTA, V1067, P43, DOI 10.1016/0005-2736(91)90024-3; Schiller D, 2006, J BIOL CHEM, V281, P7737, DOI 10.1074/jbc.M513052200; Schiller D, 2004, BIOCHEMISTRY-US, V43, P5583, DOI 10.1021/bi0359628; Schiller D, 2004, FEBS LETT, V563, P108, DOI 10.1016/S0014-5793(04)00279-0; SEIGNEURET M, 1985, FEBS LETT, V188, P101, DOI 10.1016/0014-5793(85)80883-8; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; Tsatskis Y, 2005, J BIOL CHEM, V280, P41387, DOI 10.1074/jbc.M508362200; van der Heide T, 2000, P NATL ACAD SCI USA, V97, P7102, DOI 10.1073/pnas.97.13.7102; van der Heide T, 2001, EMBO J, V20, P7022, DOI 10.1093/emboj/20.24.7022; Von Hippel P. H., 1969, STRUCTURE STABILITY, P417; Waggoner A S, 1979, Methods Enzymol, V55, P689; White GF, 2000, BBA-BIOMEMBRANES, V1468, P175, DOI 10.1016/S0005-2736(00)00255-8; Wood JM, 2011, ANNU REV MICROBIOL, V65, P215, DOI 10.1146/annurev-micro-090110-102815; Wood JM, 1999, MICROBIOL MOL BIOL R, V63, P230, DOI 10.1128/MMBR.63.1.230-262.1999; Zhang WT, 1996, BIOCHEMISTRY-US, V35, P10506, DOI 10.1021/bi960795f; Zhou HX, 2008, ANNU REV BIOPHYS, V37, P375, DOI 10.1146/annurev.biophys.37.032807.125817; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V	49	8	8	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2012	287	33					27813	27822		10.1074/jbc.M112.387936	http://dx.doi.org/10.1074/jbc.M112.387936			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993FF	22740696	Green Published, hybrid			2023-01-03	WOS:000307840700055
J	Lenartowicz, M; Krzeptowski, W; Koteja, P; Chrzascik, K; Moller, LB				Lenartowicz, Malgorzata; Krzeptowski, Wojciech; Koteja, Pawel; Chrzascik, Katarzyna; Moller, Lisbeth Birk			Prenatal Treatment of Mosaic Mice (Atp7a mo-ms) Mouse Model for Menkes Disease, with Copper Combined by Dimethyldithiocarbamate (DMDTC)	PLOS ONE			English	Article							MACULAR MUTANT MOUSE; GENE-EXPRESSION; ANIMAL-MODEL; METALLOTHIONEIN; THERAPY; FETAL; MANIFESTATIONS; METABOLISM; TRANSPORT; ATPASES	Menkes disease is a fatal neurodegenerative disorder in infants caused by mutations in the gene ATP7A which encodes a copper (Cu) transporter. Defects in ATP7A lead to accumulated copper in the small intestine and kidneys and to copper deficiencies in the brain and the liver. The copper level in the kidney in postnatal copper-treated Menkes patients may reach toxic levels. The mouse model, mosaic Atp7a(mo-ms) recapitulates the Menkes phenotype and die about 15.75 +/- 1.5 days of age. In the present study we found that prenatal treatment of mosaic murine fetuses throughout gestation days 7, 11, 15 and 18 with a combination of CuCl2 (50 mg/kg) and dimethyldithiocarbamate (DMDTC) (280 mg/kg) leads to an increase in survival to about 76 +/- 25.3 days, whereas treatment with CuCl2 alone (50 mg/kg) only leads to survival for about 21 days 65 days. These copper-DMDTC treated mutants showed an improved locomotor activity performance and a gain in body mass. In contrast to treatment with CuCl2 alone, a significant increase in the amount of copper was observed in the brain after prenatal copper-DMDTC treatment as well as a decrease in the amount of accumulated copper in the kidney, both leading towards a normalization of the copper level. Although copper-DMDTC prenatal treatment only leads to a small increase in the sub-normal copper concentration in the liver and to an increase of copper in the already overloaded small intestine, the combined results suggest that prenatal copper-DMDTC treatment also should be considered for humans.	[Lenartowicz, Malgorzata] Jagiellonian Univ, Inst Zool, Dept Genet & Evolut, PL-30060 Krakow, Poland; [Krzeptowski, Wojciech] Jagiellonian Univ, Inst Zool, Dept Cell Biol & Imaging, PL-30060 Krakow, Poland; [Koteja, Pawel; Chrzascik, Katarzyna] Inst Environm Sci, Krakow, Poland; [Moller, Lisbeth Birk] Kennedy Ctr, Ctr Appl Human Genet, Glostrup, Denmark	Jagiellonian University; Jagiellonian University	Lenartowicz, M (corresponding author), Jagiellonian Univ, Inst Zool, Dept Genet & Evolut, PL-30060 Krakow, Poland.	malgorzata.lenartowicz@gmail.com	Koteja, Paweł/O-4039-2015; Koteja, Paweł/AAF-7903-2019	Koteja, Paweł/0000-0003-0077-4957; Koteja, Paweł/0000-0003-0077-4957; Moller, Lisbeth/0000-0002-9524-4301				Choi BS, 2009, BRAIN RES, V1248, P14, DOI 10.1016/j.brainres.2008.10.056; Grimes A, 1997, HUM MOL GENET, V6, P1037, DOI 10.1093/hmg/6.7.1037; Gybina AA, 2006, GENES NUTR, V1, P51, DOI 10.1007/BF02829936; Hardman B, 2007, CELL PHYSIOL BIOCHEM, V20, P1073, DOI 10.1159/000110718; Harris ED, 2000, ANNU REV NUTR, V20, P291, DOI 10.1146/annurev.nutr.20.1.291; Heydorn K, 1995, J TRACE ELEM EXP MED, V8, P241; Iwase T, 1996, ACTA NEUROPATHOL, V91, P482, DOI 10.1007/s004010050455; JASIM S, 1985, ACTA PHARMACOL TOX, V57, P262; Kaler SG, 2008, NEW ENGL J MED, V358, P605, DOI 10.1056/NEJMoa070613; KASAMA T, 1989, J NUTR SCI VITAMINOL, V35, P627, DOI 10.3177/jnsv.35.627; Kirby BJ, 1998, J INORG BIOCHEM, V71, P189, DOI 10.1016/S0162-0134(98)10053-3; KLEIN D, 1991, TOXICOL LETT, V56, P61, DOI 10.1016/0378-4274(91)90090-S; Kodama H, 2005, J INHERIT METAB DIS, V28, P971, DOI 10.1007/s10545-005-0150-6; Kodama H, 1999, PEDIATR INT, V41, P423, DOI 10.1046/j.1442-200x.1999.01095.x; Kowal M, 2010, SYST BIOL REPROD MED, V56, P431, DOI 10.3109/19396361003734624; La Fontaine S, 2007, ARCH BIOCHEM BIOPHYS, V463, P149, DOI 10.1016/j.abb.2007.04.021; Lenartowicz M, 2001, FOLIA HISTOCHEM CYTO, V39, P275; Lenartowicz M., 2000, NUTR RES, V10, P1519, DOI [10.1016/S0271-5317(00)00230-X, DOI 10.1016/S0271-5317(00)00230-X]; Lenartowicz M, 2011, GENE EXPR PATTERNS, V11, P41, DOI 10.1016/j.gep.2010.09.001; Lenartowicz M, 2010, BIOL TRACE ELEM RES, V136, P204, DOI 10.1007/s12011-009-8533-4; Lutsenko S, 2007, PHYSIOL REV, V87, P1011, DOI 10.1152/physrev.00004.2006; MCARDLE HJ, 1991, J NUTR, V121, P208, DOI 10.1093/jn/121.2.208; MENKES JH, 1962, PEDIATRICS, V29, P764; MERCER JFB, 1992, J NUTR, V122, P1254, DOI 10.1093/jn/122.6.1254; Mercer JFB, 1998, AM J CLIN NUTR, V67, p1022S, DOI 10.1093/ajcn/67.5.1022S; NAKAGAWA S, 1993, ZOOL SCI, V10, P653; Nelson KT, 2009, BRIT J NUTR, V102, P18, DOI 10.1017/S0007114508162961; Oshio T, 1997, J PEDIATR SURG, V32, P782, DOI 10.1016/S0022-3468(97)90035-X; PHILLIPS M, 1991, BIOL TRACE ELEM RES, V29, P11, DOI 10.1007/BF03032670; Prohaska JR, 2006, COMP BIOCHEM PHYS B, V143, P360, DOI 10.1016/j.cbpb.2005.12.010; Qian YC, 1997, MOL BRAIN RES, V48, P60, DOI 10.1016/S0169-328X(97)00083-1; Reed V, 1997, HUM MOL GENET, V6, P417, DOI 10.1093/hmg/6.3.417; SHIRAISHI N, 1988, BIOL NEONATE, V54, P173; STYRNA J, 1977, GENET POL, V18, P61; SuzukiKurasaki M, 1997, J HISTOCHEM CYTOCHEM, V45, P1493, DOI 10.1177/002215549704501106; TANAKA K, 1990, RES COMMUN CHEM PATH, V69, P217; Tilton F, 2006, TOXICOL APPL PHARM, V216, P55, DOI 10.1016/j.taap.2006.04.014; XU GQ, 1994, BIOL NEONATE, V66, P302; Zaffanello M, 2006, ACTA PAEDIATR, V95, P785, DOI 10.1080/08035250500538957; Zhu D, 2011, J ANIM FEED SCI, V20, P60, DOI 10.22358/jafs/66158/2011	40	12	12	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2012	7	7							e40400	10.1371/journal.pone.0040400	http://dx.doi.org/10.1371/journal.pone.0040400			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975YY	22815746	Green Published, gold, Green Submitted			2023-01-03	WOS:000306548900024
J	Evans, AL; Sahlen, V; Stoen, OG; Fahlman, A; Brunberg, S; Madslien, K; Frobert, O; Swenson, JE; Arnemo, JM				Evans, Alina L.; Sahlen, Veronica; Stoen, Ole-Gunnar; Fahlman, Asa; Brunberg, Sven; Madslien, Knut; Frobert, Ole; Swenson, Jon E.; Arnemo, Jon M.			Capture, Anesthesia, and Disturbance of Free-Ranging Brown Bears (Ursus arctos) during Hibernation	PLOS ONE			English	Article							BLACK BEARS; AMERICANUS; HYDROCHLORIDE; MEDETOMIDINE; PHYSIOLOGY; TILETAMINE; WELFARE	We conducted thirteen immobilizations of previously collared hibernating two-to four-year-old brown bears (Ursus arctos) weighing 21-66 kg in central Sweden in winter 2010 and 2011 for comparative physiology research. Here we report, for the first time, an effective protocol for the capture and anesthesia of free-ranging brown bears during hibernation and an assessment of the disturbance the captures caused. Bears were darted in anthill, soil, or uprooted tree dens on eleven occasions, but two bears in rock dens fled and were darted outside the den. We used medetomidine at 0.02-0.06 mg/kg and zolazepam-tiletamine at 0.9-2.8 mg/kg for anesthesia. In addition, ketamine at 1.5 mg/kg was hand-injected intramuscularly in four bears and in six it was included in the dart at 1.1-3.0 mg/kg. Once anesthetized, bears were removed from the dens. In nine bears, arterial blood samples were analyzed immediately with a portable blood gas analyzer. We corrected hypoxemia in seven bears (PaO2 57-74 mmHg) with supplemental oxygen. We placed the bears back into the dens and antagonized the effect of medetomidine with atipamezole. Capturing bears in the den significantly increased the risk of den abandonment. One of twelve collared bears that were captured remained at the original den until spring, and eleven, left their dens (mean +/- standard deviation) 3.2 +/- 3.6 (range 0.5-10.5) days after capture. They used 1.9 +/- 0.9 intermediate resting sites, during 6.2 +/- 7.8 days before entering a new permanent den. The eleven new permanent dens were located 730 +/- 589 m from the original dens. We documented that it was feasible and safe to capture hibernating brown bears, although they behaved differently than black bears. When doing so, researchers should use 25% of the doses used for helicopter darting during the active period and should consider increased energetic costs associated with den abandonment.	[Evans, Alina L.; Arnemo, Jon M.] Hedmark Univ Coll, Dept Forestry & Wildlife Management, Elverum, Norway; [Evans, Alina L.] Norwegian Sch Vet Sci, Sect Arctic Vet Med, Tromso, Norway; [Sahlen, Veronica; Stoen, Ole-Gunnar; Brunberg, Sven; Swenson, Jon E.] Norwegian Univ Life Sci, Dept Ecol & Nat Resource Management, As, Norway; [Fahlman, Asa] Swedish Univ Agr Sci, Fac Vet Med & Anim Sci, Sect Anesthesiol, Uppsala, Sweden; [Fahlman, Asa] Univ Calgary, Fac Vet Med, Dept Vet Clin & Diagnost Sci, Calgary, AB, Canada; [Madslien, Knut] Natl Vet Inst, Sect Wildlife Hlth, Oslo, Norway; [Frobert, Ole] Orebro Univ Hosp, Dept Cardiol, Orebro, Sweden; [Swenson, Jon E.] Norwegian Inst Nat Res, N-7004 Trondheim, Norway; [Stoen, Ole-Gunnar; Arnemo, Jon M.] Swedish Univ Agr Sci, Dept Wildlife Fish & Environm Studies, S-90183 Umea, Sweden	Inland Norway University of Applied Sciences; Norwegian University of Life Sciences; Norwegian University of Life Sciences; Swedish University of Agricultural Sciences; University of Calgary; Norwegian Veterinary Institute; Orebro University; Norwegian Institute Nature Research; Swedish University of Agricultural Sciences	Evans, AL (corresponding author), Hedmark Univ Coll, Dept Forestry & Wildlife Management, Campus Evenstad, Elverum, Norway.	alina.evans@hihm.com	Evans, Alina/AAH-8881-2019; Fahlman, Asa/AAL-2583-2021; Swenson, Jon/AAE-2890-2019; Støen, Ole-Gunnar/AAY-6457-2020; Swenson, Jon/E-2883-2013	Frobert, Ole/0000-0002-5846-345X; Fahlman, Asa/0000-0003-1246-0197; Fahlman, Asa/0000-0001-9092-5514	Norwegian Directorate for Nature Management; Swedish Environmental Protection Agency; Research Council of Norway; WWF Sweden; Norwegian-American Fulbright Commission; American Scandinavian Foundation; Morris Animal Foundation	Norwegian Directorate for Nature Management; Swedish Environmental Protection Agency; Research Council of Norway(Research Council of Norway); WWF Sweden; Norwegian-American Fulbright Commission; American Scandinavian Foundation; Morris Animal Foundation	The Scandinavian Brown Bear Project is supported by the Norwegian Directorate for Nature Management, the Swedish Environmental Protection Agency, the Research Council of Norway, and WWF Sweden. The Norwegian Directorate for Nature Management, Norwegian-American Fulbright Commission, the American Scandinavian Foundation and the Morris Animal Foundation provided salary and stipend support for Dr. Evans during the study and writing periods. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADDISON EM, 1979, J WILDLIFE DIS, V15, P253, DOI 10.7589/0090-3558-15.2.253; Arinell K, 2012, CTS-CLIN TRANSL SCI, V5, P269, DOI 10.1111/j.1752-8062.2011.00370.x; Arnemo J.M., 2011, BIOMEDICAL PROTOCOL; Asano M, 2007, J VET MED SCI, V69, P433, DOI 10.1292/jvms.69.433; Cattet M, 2008, J MAMMAL, V89, P973, DOI 10.1644/08-MAMM-A-095.1; DoanCrider DL, 1996, J WILDLIFE MANAGE, V60, P398, DOI 10.2307/3802242; Elfstrom M, 2009, URSUS, V20, P85, DOI 10.2192/09GR005.1; ELOWE KD, 1989, J WILDLIFE MANAGE, V53, P962, DOI 10.2307/3809596; Fahlman A, 2011, J ZOO WILDLIFE MED, V42, P1, DOI 10.1638/2008-0117.1; Fahlman A, 2010, J ZOO WILDLIFE MED, V41, P161, DOI 10.1638/2009-0036.1; Fink T, 2011, STEM CELL RES, V7, P89, DOI 10.1016/j.scr.2011.03.003; Friebe A, 2001, URSUS-SERIES, V12, P37; Frobert O, 2010, THROMB J, V8, DOI 10.1186/1477-9560-8-11; Gervasi V, 2006, WILDLIFE SOC B, V34, P1314, DOI 10.2193/0091-7648(2006)34[1314:AIMTMA]2.0.CO;2; Hall LW, 2003, VET ANESTHESIA; Harlow HJ, 2002, J MAMMAL, V83, P1020, DOI 10.1644/1545-1542(2002)083&lt;1020:BMALCB&gt;2.0.CO;2; HISSA R, 1994, COMP BIOCHEM PHYS A, V109, P781, DOI 10.1016/0300-9629(94)90222-4; Hissa R, 1997, ANN ZOOL FENN, V34, P267; JALANKA HH, 1990, J ZOO WILDLIFE MED, V21, P259; Johnson RA, 2006, FLUID ELECTROLYTE AC; Linnell JDC, 2000, WILDLIFE SOC B, V28, P400; Manchi S, 2005, WILDLIFE BIOL, V11, P123, DOI 10.2981/0909-6396(2005)11[123:DBOSBB]2.0.CO;2; Matthews NS, 2003, VET ANAESTH ANALG, V30, P3, DOI 10.1046/j.1467-2995.2003.00121.x; Mortenson J, 2001, J ZOO WILDLIFE MED, V32, P217, DOI 10.1638/1042-7260(2001)032[0217:CCUAAO]2.0.CO;2; Nelson OL, 2010, J COMP PHYSIOL B, V180, P465, DOI 10.1007/s00360-009-0421-x; Powell RA, 2005, J MAMMAL, V86, P1171, DOI 10.1644/05-MAMM-A-014R2.1; Saraux C, 2011, NATURE, V469, P203, DOI 10.1038/nature09630; Seryodkin Ivan V., 2003, Ursus (Knoxville), V14, P153; Storey KB, 2010, GERONTOLOGY, V56, P220, DOI 10.1159/000228829; Swenson JE, 1997, WILDLIFE BIOL, V3, P35, DOI 10.2981/wlb.1997.005; Toien O, 2011, SCIENCE, V331, P906, DOI 10.1126/science.1199435; Tsiouris JA, 2004, CAN J ZOOL, V82, P1468, DOI [10.1139/z04-122, 10.1139/Z04-122]; Vestergaard P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021483	33	54	58	1	54	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2012	7	7							e40520	10.1371/journal.pone.0040520	http://dx.doi.org/10.1371/journal.pone.0040520			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	974VS	22815757	Green Published, gold			2023-01-03	WOS:000306466100039
J	Chiu, CL; Lujic, S; Thornton, C; O'Loughlin, A; Makris, A; Hennessy, A; Lind, JM				Chiu, Christine L.; Lujic, Sanja; Thornton, Charlene; O'Loughlin, Aiden; Makris, Angela; Hennessy, Annemarie; Lind, Joanne M.			Menopausal Hormone Therapy Is Associated with Having High Blood Pressure in Postmenopausal Women: Observational Cohort Study	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; REPLACEMENT THERAPY; CARDIOVASCULAR-DISEASE; RISK-FACTORS; HOT FLUSHES; HYPERTENSION; ESTROGEN; HEALTH; PREVENTION; PREVALENCE	Background: The relationship between menopausal hormone therapy (MHT) and cardiovascular risk remains controversial, with a number of studies advocating the use of MHT in reducing risk of cardiovascular diseases, while others have shown it to increase risk. The aim of this study was to determine the association between menopausal hormone therapy and high blood pressure. Methods and Findings: A total of 43,405 postmenopausal women were included in the study. Baseline data for these women were sourced from the 45 and Up Study, Australia, a large scale study of healthy ageing. These women reported being postmenopausal, having an intact uterus, and had not been diagnosed with high blood pressure prior to menopause. Odds ratios for the association between MHT use and having high blood pressure were estimated using logistic regression, stratified by age (<56 years, 56-61 years, 62-70 years and over 71 years) and adjusted for demographic and lifestyle factors. MHT use was associated with higher odds of having high blood pressure: past menopausal hormone therapy use:,56 years (adjusted odds ratio 1.59, 99% confidence interval 1.15 to 2.20); 56-61 years (1.58, 1.31 to 1.90); 62-70 years (1.26, 1.10 to 1.44). Increased duration of hormone use was associated with higher odds of having high blood pressure, with the effect of hormone therapy use diminishing with increasing age. Conclusions: Menopausal hormone therapy use is associated with significantly higher odds of having high blood pressure, and the odds increase with increased duration of use. High blood pressure should be conveyed as a health risk for people considering MHT use.	[Chiu, Christine L.; Lujic, Sanja; Thornton, Charlene; O'Loughlin, Aiden; Makris, Angela; Hennessy, Annemarie; Lind, Joanne M.] Univ Western Sydney, Sch Med, Penrith, NSW 1797, Australia; [Makris, Angela] Liverpool Hosp, Dept Renal Med, Sydney, NSW, Australia	Western Sydney University; Liverpool Hospital	Chiu, CL (corresponding author), Univ Western Sydney, Sch Med, Penrith, NSW 1797, Australia.	j.lind@uws.edu.au	Hennessy, Annemarie/HGB-5049-2022; Makris, Angela/HJG-7809-2022	Lujic, Sanja/0000-0002-9555-0261; Hennessy, Annemarie/0000-0002-5975-2843; Chiu, Christine L./0000-0002-6411-9719	National Health and Medical Research Council (NHMRC) (Australia)	National Health and Medical Research Council (NHMRC) (Australia)(National Health and Medical Research Council (NHMRC) of Australia)	Dr. Lind is supported by a National Health and Medical Research Council (NHMRC) Fellowship (Australia). www.nhmrc.gov.au. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Australian Institute of Health and Welfare (AIHW), 2003, ACT AUSTR SURV GUID; Banks E, 2008, INT J EPIDEMIOL, V37, P941, DOI 10.1093/ije/dym184; Bauman A F, 2001, TRENDS POPULATION LE; Bechlioulis A, 2010, J CLIN ENDOCR METAB, V95, P1199, DOI 10.1210/jc.2009-2262; Food and Drug Administration DoHaHS, 2009, CONS INF AUD WOM MEN; FORD ES, 1991, HYPERTENSION, V18, P598, DOI 10.1161/01.HYP.18.5.598; Freeman EW, 2007, CLIMACTERIC, V10, P197, DOI 10.1080/13697130601181486; Grodstein F, 2000, ANN INTERN MED, V133, P933, DOI 10.7326/0003-4819-133-12-200012190-00008; Karalis I, 2005, BLOOD PRESSURE, V14, P38, DOI 10.1080/08037050510008788; Kaya C, 2006, CLIMACTERIC, V9, P437, DOI 10.1080/13697130601003094; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; Mealing NM, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-26; Miller VM, 2009, J CARDIOVASC TRANSL, V2, P228, DOI 10.1007/s12265-009-9104-y; Ostchega Y, 2007, J AM GERIATR SOC, V55, P1056, DOI 10.1111/j.1532-5415.2007.01215.x; Perneger TV, 1999, BRIT MED J, V318, P1288; Rossouw JE, 2007, JAMA-J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Sassarini J, 2011, CLIN ENDOCRINOL, V74, P97, DOI 10.1111/j.1365-2265.2010.03921.x; Trial TWGftP, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI DOI 10.1001/JAMA.1995.03520270033028; Tuomikoski P, 2010, ANN MED, V42, P334, DOI 10.3109/07853891003796760; van Ittersum FJ, 1998, AM J HYPERTENS, V11, P1147, DOI 10.1016/S0895-7061(98)00165-4; Wassertheil-Smoller S, 2000, HYPERTENSION, V36, P780, DOI 10.1161/01.HYP.36.5.780	24	30	32	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2012	7	7							e40260	10.1371/journal.pone.0040260	http://dx.doi.org/10.1371/journal.pone.0040260			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973LU	22808129	gold, Green Published, Green Submitted			2023-01-03	WOS:000306362400038
J	Szpilman, D; Bierens, JJLM; Handley, AJ; Orlowski, JP				Szpilman, David; Bierens, Joost J. L. M.; Handley, Anthony J.; Orlowski, James P.			CURRENT CONCEPTS Drowning	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HOSPITAL CARDIAC-ARREST; ACCIDENTAL HYPOTHERMIA; UTSTEIN STYLE; RESUSCITATION; MORTALITY; CHILDREN; RESCUE; PREVENTION; GUIDELINES; EXPERIENCE	ACCORDING TO THE WORLD HEALTH ORGANIZATION (WHO), 0.7% OF ALL deaths worldwide - or more than 500,000 deaths each year(1) - are due to unintentional drowning.(2) Since some cases of fatal drowning are not classified as such according to the codes of the International Classification of Disease, this number underestimates the real figures, even for high-income countries,(3) and does not include drownings that occur as a result of floods, tsunamis, and boating accidents. Drowning is a leading cause of death worldwide among boys 5 to 14 years of age.(2) In the United States, drowning is the second leading cause of injury-related death among children 1 to 4 years of age, with a death rate of 3 per 100,000,(4) and in some countries, such as Thailand, the death rate among 2-year-old children is 107 per 100,000.(5) In many countries in Africa and in Central America, the incidence of drowning is 10 to 20 times as high as the incidence in the United States. Key risk factors for drowning are male sex,(4) age of less than 14 years,(6) alcohol use,(7) low income,(1) poor education,(5) rural residency,(5) aquatic exposure,(6,7) risky behavior,(6,7) and lack of supervision.(6) For people with epilepsy, the risk of drowning is 15 to 19 times as high as the risk for those who do not have epilepsy.(8) Exposure-adjusted, person-time estimates for drowning are 200 times as high as such estimates for deaths from traffic accidents.(9) Coastal drownings are estimated to cost more than $273 million per year in the United States(10) and more than $228 million per year (in U. S. dollars) in Brazil.(11) For every person who dies from drowning, another four persons receive care in the emergency department for nonfatal drowning.(12)	[Szpilman, David] Hosp Municipal Miguel Couto, Adult Intens Care Unit, Rio De Janeiro, Brazil; [Szpilman, David] Corpo Bombeiros Militar, Rio De Janeiro, Brazil; [Bierens, Joost J. L. M.] Soc Prevent People Drowning, Amsterdam, Netherlands; [Handley, Anthony J.] Royal Life Saving Soc UK, Broom, Warwick, England; [Orlowski, James P.] Florida Hosp, Tampa, FL USA; [Orlowski, James P.] Univ S Florida, Tampa, FL USA	Adventist Health Services; AdventHealth; (AdventHealth) West Florida Division; West Florida Hospital; AdventHealth Tampa; State University System of Florida; University of South Florida	Szpilman, D (corresponding author), Av Amer 3555,Bloco 2,Sala 302, BR-22631003 Rio De Janeiro, Brazil.	david@szpilman.com	Szpilman, David/F-1682-2013; Bierens, Joost/AAW-8332-2020	Bierens, Joost/0000-0003-4467-8211; Szpilman, David/0000-0003-3961-3640				[Anonymous], 2008, INF SAUD MIN SAUD BR; [Anonymous], 2003, INJ VIOL PREV NONC D; Baker PA, 2011, ANAESTH INTENS CARE, V39, P675, DOI 10.1177/0310057X1103900423; Beerman S, 2006, DROWNING PREVENTION, P331; Bell GS, 2008, NEUROLOGY, V71, P578, DOI 10.1212/01.wnl.0000323813.36193.4d; Borse NNGJ., 2008, CDC CHILDHOOD INJURY; cdc, 2021, CTR DIS CONTROL PREV; Claesson A, 2008, RESUSCITATION, V76, P381, DOI 10.1016/j.resuscitation.2007.09.003; CM Branche, 2001, LIFE GUARD EFFECTIVE; Cubattoli L, 2009, RESUSCITATION, V80, P1088, DOI 10.1016/j.resuscitation.2009.05.017; Cummings P, 2011, INJURY PREV, V17, P156, DOI 10.1136/ip.2010.028688; Diamond W, 2011, PREHOSP EMERG CARE, V15, P288, DOI 10.3109/10903127.2010.545480; EGGINK WF, 1977, NETH J MED, V20, P162; Eich C, 2007, RESUSCITATION, V75, P42, DOI 10.1016/j.resuscitation.2007.03.013; Foex BA, 2001, EMERG MED J, V18, P465, DOI 10.1136/emj.18.6.465; Gauger PG, 1996, CRIT CARE MED, V24, P16, DOI 10.1097/00003246-199601000-00006; Gilbert M, 2000, LANCET, V355, P375, DOI 10.1016/S0140-6736(00)01021-7; Gregorakos L, 2009, LUNG, V187, P93, DOI 10.1007/s00408-008-9132-4; Grmec S, 2009, INT J EMERG MED, V2, P7, DOI 10.1007/s12245-009-0084-0; Guenther U, 2009, RESUSCITATION, V80, P379, DOI 10.1016/j.resuscitation.2008.11.019; Idris AH, 2003, CIRCULATION, V108, P2565, DOI 10.1161/01.CIR.0000099581.70012.68; International Life Saving Federation Medical Committee, 2008, CLAR STAT CARD RES D; Kapur N, 2009, PEDIATR PULM, V44, P1043, DOI 10.1002/ppul.21088; Kochanek PM, 2010, JAMA-J AM MED ASSOC, V303, P2190, DOI 10.1001/jama.2010.715; Linnan M., 2007, SPECIAL SERIES CHILD; Lu TH, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-30; MANOLIOS N, 1988, MED J AUSTRALIA, V148, P165, DOI 10.5694/j.1326-5377.1988.tb112805.x; Mitchell RJ, 2010, INJURY PREV, V16, P261, DOI 10.1136/ip.2009.024307; Modell JH, 2010, SOUTH MED J, V103, P650, DOI 10.1097/SMJ.0b013e3181e10564; MODELL JH, 1976, CHEST, V70, P231, DOI 10.1378/chest.70.2.231; Moran K., 2011, International Journal of Aquatic Research and Education, V5, P251; Oehmichen Manfred, 2008, Legal Medicine, V10, P1, DOI 10.1016/j.legalmed.2007.05.007; ORLOWSKI JP, 1989, ANN EMERG MED, V18, P1044, DOI 10.1016/S0196-0644(89)80927-8; Orlowski JP, 2001, PEDIATR CLIN N AM, V48, P627, DOI 10.1016/S0031-3955(05)70331-X; Peden M, 2002, INJURY CHART BOOK GR; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Quan L., 2007, Handbook of injury and violence prevention, P81, DOI 10.1007/978-0-387-29457-5_5; Quan L, 2003, INJURY PREV, V9, P163, DOI 10.1136/ip.9.2.163; Rafaat KT, 2008, PEDIATR CRIT CARE ME, V9, P567, DOI 10.1097/PCC.0b013e31818c8955; Soar J, 2010, RESUSCITATION, V81, P1400, DOI 10.1016/j.resuscitation.2010.08.015; Spicer ST, 1999, J AM SOC NEPHROL, V10, P382; STERBA JA, 1985, UNDERSEA BIOMED RES, V12, P139; Szpilman D, 2004, RESUSCITATION, V63, P25, DOI 10.1016/j.resuscitation.2004.03.017; Szpilman D, 1997, CHEST, V112, P660, DOI 10.1378/chest.112.3.660; Szpilman D, 2002, WORLD C DROWN AMST J; Szpilman D, 2006, HDB DROWNING PREVENT, P336; Takano Y, 1999, Nihon Kokyuki Gakkai Zasshi, V37, P997; Tipton MJ, 2011, RESUSCITATION, V82, P819, DOI 10.1016/j.resuscitation.2011.02.021; van Beeck EF, 2005, B WORLD HEALTH ORGAN, V83, P853; vanBerkel M, 1996, INTENS CARE MED, V22, P101, DOI 10.1007/BF01720715; Vanden Hoek TL, 2010, CIRCULATION, V122, pS829, DOI 10.1161/CIRCULATIONAHA.110.971069; Venema AM, 2010, RESUSCITATION, V81, P434, DOI 10.1016/j.resuscitation.2010.01.005; Warner D, 2006, DROWNING PREVENTION, P436; Watson RS, 2001, J TRAUMA, V51, P658, DOI 10.1097/00005373-200110000-00006; Weiss SJ, 2000, RESUSCITATION, V45, P201, DOI 10.1016/S0300-9572(00)00185-4; Wood C, 2010, EMERG MED J, V27, P393, DOI 10.1136/emj.2010.094888; Youn CS, 2009, RESUSCITATION, V80, P778, DOI 10.1016/j.resuscitation.2009.04.007	57	190	200	1	50	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 31	2012	366	22					2102	2110		10.1056/NEJMra1013317	http://dx.doi.org/10.1056/NEJMra1013317			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	949YE	22646632	Bronze			2023-01-03	WOS:000304613400010
J	Van Gulck, E; Bracke, L; Heyndrickx, L; Coppens, S; Atkinson, D; Merlin, C; Pasternak, A; Florence, E; Vanham, G				Van Gulck, Ellen; Bracke, Lotte; Heyndrickx, Leo; Coppens, Sandra; Atkinson, Derek; Merlin, Celine; Pasternak, Alexander; Florence, Eric; Vanham, Guido			Immune and Viral Correlates of "Secondary Viral Control" after Treatment Interruption in Chronically HIV-1 Infected Patients	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; T-CELL RESPONSES; NEUTRALIZING ANTIBODY; ELITE CONTROLLERS; PROLIFERATIVE RESPONSES; ANTIRETROVIRAL THERAPY; HIV NEUTRALIZATION; PLASMA VIREMIA; INFECTION; REPLICATION	Upon interruption of antiretroviral therapy, HIV-infected patients usually show viral load rebound to pre-treatment levels. Four patients, hereafter referred to as secondary controllers (SC), were identified who initiated therapy during chronic infection and, after stopping treatment, could control virus replication at undetectable levels for more than six months. In the present study we set out to unravel possible viral and immune parameters or mechanisms of this phenomenon by comparing secondary controllers with elite controllers and non-controllers, including patients under HAART. As candidate correlates of protection, virus growth kinetics, levels of intracellular viral markers, several aspects of HIV-specific CD4+ and CD8+ T cell function and HIV neutralizing antibodies were investigated. As expected all intracellular viral markers were lower in aviremic as compared to viremic subjects, but in addition both elite and secondary controllers had lower levels of viral unspliced RNA in PBMC as compared to patients on HAART. Ex vivo cultivation of the virus from CD4+ T cells of SC consistently failed in one patient and showed delayed kinetics in the three others. Formal in vitro replication studies of these three viruses showed low to absent growth in two cases and a virus with normal fitness in the third case. T cell responses toward HIV peptides, evaluated in IFN-gamma ELISPOT, revealed no significant differences in breadth, magnitude or avidity between SC and all other patient groups. Neither was there a difference in polyfunctionality of CD4+ or CD8+ T cells, as evaluated with intracellular cytokine staining. However, secondary and elite controllers showed higher proliferative responses to Gag and Pol peptides. SC also showed the highest level of autologous neutralizing antibodies. These data suggest that higher T cell proliferative responses and lower replication kinetics might be instrumental in secondary viral control in the absence of treatment.	[Van Gulck, Ellen; Bracke, Lotte; Heyndrickx, Leo; Coppens, Sandra; Atkinson, Derek; Merlin, Celine; Vanham, Guido] Antwerp ITMA, Inst Trop Med, Dept Biomed Sci, Virol Unit,Microbiol Grp, Antwerp, Belgium; [Pasternak, Alexander] Ctr Infect & Immun Amsterdam CINIMA, Dept Med Microbiol, Lab Expt Virol, Amsterdam, Netherlands; [Florence, Eric] ITMA, Dept Clin Sci, HIV STD Unit, Antwerp, Belgium; [Vanham, Guido] Univ Antwerp, Dept Biomed Sci, Fac Pharmaceut Vet & Biomed Sci, B-2020 Antwerp, Belgium	Institute of Tropical Medicine (ITM); University of Amsterdam; Institute of Tropical Medicine (ITM); University of Antwerp	Van Gulck, E (corresponding author), Antwerp ITMA, Inst Trop Med, Dept Biomed Sci, Virol Unit,Microbiol Grp, Antwerp, Belgium.	evangulck@hotmail.com	Pasternak, Alexander/P-2067-2017	Pasternak, Alexander/0000-0002-4097-4251; Florence, Eric/0000-0002-7004-9120; Atkinson, Derek/0000-0001-6097-3670	Fund for Scientific Research Flanders (FWO) [G.0.370.08.N.10]; IAP (Inter-University Attraction Poles of the Belgian government) [P6/41]; EU Programme EVA Centre for AIDS Reagents, NIBSC, UK (AVIP) [LSHP-CT-2004-503487]	Fund for Scientific Research Flanders (FWO)(FWO); IAP (Inter-University Attraction Poles of the Belgian government); EU Programme EVA Centre for AIDS Reagents, NIBSC, UK (AVIP)	This work was supported by grants from the Fund for Scientific Research Flanders (FWO) (G.0.370.08.N.10) and IAP (Inter-University Attraction Poles, P6/41 of the Belgian government). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Viruses (DU174, 92UG024) and TriMab were provided by the EU Programme EVA Centre for AIDS Reagents, NIBSC, UK (AVIP Contract Number LSHP-CT-2004-503487).	Addo MM, 2002, DNA CELL BIOL, V21, P671, DOI 10.1089/104454902760330219; Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003; Almeida JR, 2007, J EXP MED, V204, P2473, DOI 10.1084/jem.20070784; Almeida JR, 2009, BLOOD, V113, P6351, DOI 10.1182/blood-2009-02-206557; Altfeld M, 2006, PLOS MED, V3, P1851, DOI 10.1371/journal.pmed.0030403; Anzala AO, 1998, LANCET, V351, P1632, DOI 10.1016/S0140-6736(05)77688-1; Bailey JR, 2006, J EXP MED, V203, P1357, DOI 10.1084/jem.20052319; Bailey JR, 2006, J VIROL, V80, P4758, DOI 10.1128/JVI.80.10.4758-4770.2006; Bedimo R, 2006, AIDS RES HUM RETROV, V22, P40, DOI 10.1089/aid.2006.22.40; Beirnaert E, 1998, J VIROL METHODS, V73, P65, DOI 10.1016/S0166-0934(98)00044-5; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001; Binley JM, 2000, J INFECT DIS, V181, P1249, DOI 10.1086/315379; Blankson JN, 2010, DISCOV MED, V9, P261; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; Bradney AP, 1999, J INFECT DIS, V179, P1264, DOI 10.1086/314711; Bunce M., 1995, TISSUE ANTIGENS, V46, P355; Emu B, 2005, J VIROL, V79, P14169, DOI 10.1128/JVI.79.22.14169-14178.2005; Fenyo EM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004505; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Freel SA, 2011, IMMUNOL RES, V49, P135, DOI 10.1007/s12026-010-8177-7; Gray CM, 2009, J VIROL, V83, P470, DOI 10.1128/JVI.01678-08; Guerrero MLF, 2005, CLIN INFECT DIS, V41, P390, DOI 10.1086/431487; Harari A, 2004, BLOOD, V103, P966, DOI 10.1182/blood-2003-04-1203; Heyndrickx L, 2000, J VIROL, V74, P363, DOI 10.1128/JVI.74.1.363-370.2000; Heyndrickx L, 2008, J VIROL METHODS, V148, P166, DOI 10.1016/j.jviromet.2007.11.009; Kaufmann DE, 2004, J VIROL, V78, P4463, DOI 10.1128/JVI.78.9.4463-4477.2004; Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520; KLEIN MR, 1995, TRENDS MICROBIOL, V3, P386, DOI 10.1016/S0966-842X(00)88984-2; Lambotte O, 2009, AIDS, V23, P897, DOI 10.1097/QAD.0b013e328329f97d; Leslie A, 2010, J VIROL, V84, P9879, DOI 10.1128/JVI.00320-10; Lichterfeld M, 2004, J EXP MED, V200, P701, DOI 10.1084/jem.20041270; Lieberman J, 2004, AIDS, V18, P1489, DOI 10.1097/01.aids.0000131320.75396.4d; Mahalanabis M, 2009, J VIROL, V83, P662, DOI 10.1128/JVI.01328-08; Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397; Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845; Miura T, 2009, J VIROL, V83, P140, DOI 10.1128/JVI.01471-08; Mocroft A, 2002, AIDS, V16, P1663, DOI 10.1097/00002030-200208160-00012; Montefiori David C., 2009, V485, P395, DOI 10.1007/978-1-59745-170-3_26; Owen RE, 2010, AIDS, V24, P1095, DOI 10.1097/QAD.0b013e3283377a1e; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; Pasternak AO, 2008, J CLIN MICROBIOL, V46, P2206, DOI 10.1128/JCM.00055-08; Pasternak AO, 2010, AIDS, V24, P1641, DOI 10.1097/QAD.0b013e32833b3171; Pasternak AO, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008490; Pereyra F, 2009, J INFECT DIS, V200, P984, DOI 10.1086/605446; Pilgrim AK, 1997, J INFECT DIS, V176, P924, DOI 10.1086/516508; Ponsaerts P, 2002, LEUKEMIA, V16, P1324, DOI 10.1038/sj.leu.2402511; Resino S, 2003, CLIN EXP IMMUNOL, V131, P130, DOI 10.1046/j.1365-2249.2003.02034.x; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Rowland-Jones S, 1997, ADV IMMUNOL, V65, P277, DOI 10.1016/S0065-2776(08)60745-2; Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104; Scarlatti G, 1996, IMMUNOL LETT, V51, P23, DOI 10.1016/0165-2478(96)02550-3; Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274; Skiest DJ, 2004, JAIDS-J ACQ IMM DEF, V37, P1351, DOI 10.1097/00126334-200411010-00003; Steingrover R, 2008, AIDS, V22, P1583, DOI 10.1097/QAD.0b013e328305bd77; Valentine LE, 2008, J VIROL, V82, P575, DOI 10.1128/JVI.00275-07; Van Gulck E, 2011, AIDS RES THER, V8, DOI 10.1186/1742-6405-8-6; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; Yang OO, 2003, TRENDS IMMUNOL, V24, P67, DOI 10.1016/S1471-4906(02)00034-0; Zhang YJ, 1997, J INFECT DIS, V176, P1180, DOI 10.1086/514111; Zimmerli SC, 2005, P NATL ACAD SCI USA, V102, P7239, DOI 10.1073/pnas.0502393102	62	37	37	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2012	7	5							e37792	10.1371/journal.pone.0037792	http://dx.doi.org/10.1371/journal.pone.0037792			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959YF	22666392	gold, Green Published			2023-01-03	WOS:000305353400049
J	Clouard, C; Jouhanneau, M; Meunier-Salaun, MC; Malbert, CH; Val-Laillet, D				Clouard, Caroline; Jouhanneau, Melanie; Meunier-Salauen, Marie-Christine; Malbert, Charles-Henri; Val-Laillet, David			Exposures to Conditioned Flavours with Different Hedonic Values Induce Contrasted Behavioural and Brain Responses in Pigs	PLOS ONE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; DORSOLATERAL PREFRONTAL CORTEX; PARABRACHIAL NUCLEUS LESIONS; TASTE-AVERSION; INSULAR CORTEX; HUMAN AMYGDALA; UNPLEASANT ODORS; CHORDA TYMPANI; PREFERENCE; RATS	This study investigated the behavioural and brain responses towards conditioned flavours with different hedonic values in juvenile pigs. Twelve 30-kg pigs were given four three-day conditioning sessions: they received three different flavoured meals paired with intraduodenal (i.d.) infusions of 15% glucose (F-Glu), lithium chloride (F-LiCl), or saline (control treatment, F-NaCl). One and five weeks later, the animals were subjected to three two-choice feeding tests without reinforcement to check the acquisition of a conditioned flavour preference or aversion. In between, the anaesthetised pigs were subjected to three (18)FDG PET brain imaging coupled with an olfactogustatory stimulation with the conditioned flavours. During conditioning, the pigs spent more time lying inactive, and investigated their environment less after the F-LiCl than the F-NaCl or F-Glu meals. During the two-choice tests performed one and five weeks later, the F-NaCl and F-Glu foods were significantly preferred over the F-LiCl food even in the absence of i.d. infusions. Surprisingly, the F-NaCl food was also preferred over the F-Glu food during the first test only, suggesting that, while LiCl i.d. infusions led to a strong flavour aversion, glucose infusions failed to induce flavour preference. As for brain imaging results, exposure to aversive or less preferred flavours triggered global deactivation of the prefrontal cortex, specific activation of the posterior cingulate cortex, as well as asymmetric brain responses in the basal nuclei and the temporal gyrus. In conclusion, postingestive visceral stimuli can modulate the flavour/food hedonism and further feeding choices. Exposure to flavours with different hedonic values induced metabolism differences in neural circuits known to be involved in humans in the characterization of food palatability, feeding motivation, reward expectation, and more generally in the regulation of food intake.	[Clouard, Caroline; Jouhanneau, Melanie; Malbert, Charles-Henri; Val-Laillet, David] INRA, ADNC Alimentat & Adaptat Digest Nerveuses & Compo, St Gilles, France; [Clouard, Caroline; Jouhanneau, Melanie; Meunier-Salauen, Marie-Christine] INRA, PEGASE Physiol Environm & Genet Anim & Syst Eleva, St Gilles, France; [Clouard, Caroline; Jouhanneau, Melanie; Meunier-Salauen, Marie-Christine] Agrocampus Ouest, PEGASE Physiol Environm & Genet Anim & Syst Eleva, Rennes, France	INRAE; INRAE; Institut Agro; Agrocampus Ouest	Clouard, C (corresponding author), INRA, ADNC Alimentat & Adaptat Digest Nerveuses & Compo, St Gilles, France.	david.val-laillet@rennes.inra.fr	Clouard, Caroline/K-1255-2014; VAL-LAILLET, David/AAH-6454-2021	Clouard, Caroline/0000-0002-5562-6057; Malbert, Charles-Henri/0000-0002-0665-4545	INRA (Department of Human Alimentation); INRA (Department of Animal Physiology and Livestock Systems); Brittany Region (Region Bretagne); CRITT Sante Bretagne (Centre Regional d'Innovation et de Transfert de Technologies)	INRA (Department of Human Alimentation); INRA (Department of Animal Physiology and Livestock Systems); Brittany Region (Region Bretagne)(Region Bretagne); CRITT Sante Bretagne (Centre Regional d'Innovation et de Transfert de Technologies)	This study was supported by a grant from INRA (Department of Human Alimentation; Department of Animal Physiology and Livestock Systems) and the Brittany Region (Region Bretagne), and especially by the CRITT Sante Bretagne (Centre Regional d'Innovation et de Transfert de Technologies). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ackroff K, 2001, PHYSIOL BEHAV, V72, P691, DOI 10.1016/S0031-9384(01)00442-5; Ackroff K, 2011, PHYSIOL BEHAV, V102, P548, DOI 10.1016/j.physbeh.2011.01.004; Ackroff K, 2010, PHYSIOL BEHAV, V99, P402, DOI 10.1016/j.physbeh.2009.12.012; Ackroff K, 2009, PHYSIOL BEHAV, V97, P406, DOI 10.1016/j.physbeh.2009.03.014; Anderson AK, 2003, NEURON, V39, P581, DOI 10.1016/S0896-6273(03)00504-X; CARMICHAEL ST, 1994, J COMP NEUROL, V346, P403, DOI 10.1002/cne.903460306; Cerf-Ducastel B, 2001, CHEM SENSES, V26, P625, DOI 10.1093/chemse/26.6.625; Costafreda SG, 2008, BRAIN RES REV, V58, P57, DOI 10.1016/j.brainresrev.2007.10.012; Danilova V, 2002, J NEUROPHYSIOL, V88, P579, DOI 10.1152/jn.2002.88.2.579; de Araujo IE, 2005, NEURON, V46, P671, DOI 10.1016/j.neuron.2005.04.021; de Araujo IET, 2003, EUR J NEUROSCI, V18, P2059, DOI 10.1046/j.1460-9568.2003.02915.x; Del Parigi A, 2002, ANN NY ACAD SCI, V967, P389; Desgranges B, 2009, EUR J NEUROSCI, V29, P1654, DOI 10.1111/j.1460-9568.2009.06711.x; Dwyer DM, 2010, PHYSIOL BEHAV, V101, P403, DOI 10.1016/j.physbeh.2010.07.004; Faurion A, 1999, NEUROSCI LETT, V277, P189, DOI 10.1016/S0304-3940(99)00881-2; Galef BG, 2003, LEARN MEMORY, P147; GARCIA J, 1974, SCIENCE, V185, P824, DOI 10.1126/science.185.4154.824; Gaultier A, 2011, EUR J NEUROSCI, V34, P1500, DOI 10.1111/j.1460-9568.2011.07848.x; Gautier JF, 2000, DIABETES, V49, P838, DOI 10.2337/diabetes.49.5.838; Gautier JF, 1999, AM J CLIN NUTR, V70, P806; Gilbert PE, 2003, NEUROBIOL LEARN MEM, V79, P118, DOI 10.1016/S1074-7427(02)00013-8; Gottfried JA, 2002, J NEUROSCI, V22, P10829; Gottfried JA, 2002, J NEUROSCI, V22, P10819; Haber SN, 2010, NEUROPSYCHOPHARMACOL, V35, P4, DOI 10.1038/npp.2009.129; Hellekant G, 1997, J NEUROPHYSIOL, V77, P978, DOI 10.1152/jn.1997.77.2.978; Henkin RI, 2001, J COMPUT ASSIST TOMO, V25, P493, DOI 10.1097/00004728-200107000-00001; Kringelbach ML, 2004, NEUROIMAGE, V21, P781, DOI 10.1016/j.neuroimage.2003.09.063; Kringelbach ML, 2010, DISCOV MED, V9, P579; LAWRENCE A, 1987, ANIM BEHAV, V35, P293, DOI 10.1016/S0003-3472(87)80236-1; Le DSNT, 2006, AM J CLIN NUTR, V84, P725, DOI 10.1093/ajcn/84.4.725; Maddock RJ, 1999, TRENDS NEUROSCI, V22, P310, DOI 10.1016/S0166-2236(98)01374-5; Myers KP, 2007, APPETITE, V48, P123, DOI 10.1016/j.appet.2006.07.077; Myers KP, 2006, DEV PSYCHOBIOL, V48, P380, DOI 10.1002/dev.20147; Navarro M, 2003, BRAIN RES, V990, P195, DOI 10.1016/S0006-8993(03)03530-3; O'Doherty J, 2001, J NEUROPHYSIOL, V85, P1315, DOI 10.1152/jn.2001.85.3.1315; Reilly S, 1999, BRAIN RES BULL, V48, P239, DOI 10.1016/S0361-9230(98)00173-7; Reilly S, 2000, BRAIN RES BULL, V52, P269, DOI 10.1016/S0361-9230(00)00263-X; Reiman EM, 1997, AM J PSYCHIAT, V154, P918; Reiner G, 2009, APPL ANIM BEHAV SCI, V118, P222, DOI 10.1016/j.applanim.2009.02.010; Roman C, 2009, BRAIN RES, V1259, P68, DOI 10.1016/j.brainres.2008.12.058; Royet JP, 2004, CHEM SENSES, V29, P731, DOI 10.1093/chemse/bjh067; Royet JP, 1999, J COGNITIVE NEUROSCI, V11, P94, DOI 10.1162/089892999563166; Royet JP, 2000, J NEUROSCI, V20, P7752; Saikali S, 2010, J NEUROSCI METH, V192, P102, DOI 10.1016/j.jneumeth.2010.07.041; Sclafani A, 2001, BEHAV NEUROSCI, V115, P920, DOI 10.1037//0735-7044.115.4.920; Shepherd GM, 2006, NATURE, V444, P316, DOI 10.1038/nature05405; Small DM, 2001, BRAIN, V124, P1720, DOI 10.1093/brain/124.9.1720; Small DM, 2005, EXP BRAIN RES, V166, P345, DOI 10.1007/s00221-005-2376-9; Small DM, 2003, NEUROIMAGE, V19, P1709, DOI 10.1016/S1053-8119(03)00253-2; Smeets PAM, 2006, AM J CLIN NUTR, V83, P1297, DOI 10.1093/ajcn/83.6.1297; St-Onge MP, 2005, J NUTR, V135, P1014, DOI 10.1093/jn/135.5.1014; Stafstrom-Davis CA, 2001, LEARN MEMORY, V8, P272, DOI 10.1101/lm.42101; Touzani K, 2005, EUR J NEUROSCI, V22, P1767, DOI 10.1111/j.1460-9568.2005.04360.x; Touzani K, 2002, EUR J NEUROSCI, V16, P2425, DOI 10.1046/j.1460-9568.2002.02404.x; Touzani K, 2002, BEHAV NEUROSCI, V116, P256, DOI 10.1037//0735-7044.116.2.256; Touzani K, 2001, BEHAV NEUROSCI, V115, P84, DOI 10.1037//0735-7044.115.1.84; Touzani K, 2007, EUR J NEUROSCI, V26, P1692, DOI 10.1111/j.1460-9568.2007.05798.x; Touzani K, 2010, NEUROBIOL LEARN MEM, V94, P214, DOI 10.1016/j.nlm.2010.05.009; Touzani K, 2009, NEUROBIOL LEARN MEM, V92, P464, DOI 10.1016/j.nlm.2009.06.006; Touzani K, 2009, EUR J NEUROSCI, V30, P289, DOI 10.1111/j.1460-9568.2009.06829.x; Veldhuizen MG, 2010, CHEM SENSES, V35, P121, DOI 10.1093/chemse/bjp089; Wang GJ, 2004, NEUROIMAGE, V21, P1790, DOI 10.1016/j.neuroimage.2003.11.026; WARWICK ZS, 1994, PHYSIOL BEHAV, V55, P501, DOI 10.1016/0031-9384(94)90107-4; Weary DM, 2009, J ANIM SCI, V87, P770, DOI 10.2527/jas.2008-1297; Weary DM, 2006, APPL ANIM BEHAV SCI, V100, P64, DOI 10.1016/j.applanim.2006.04.013; Winston JS, 2005, J NEUROSCI, V25, P8903, DOI 10.1523/JNEUROSCI.1569-05.2005; Zald DH, 2003, BRAIN RES REV, V41, P88, DOI 10.1016/S0165-0173(02)00248-5; Zald DH, 1998, BRAIN, V121, P1143, DOI 10.1093/brain/121.6.1143; Zald DH, 2000, INT J PSYCHOPHYSIOL, V36, P165, DOI 10.1016/S0167-8760(99)00110-5	71	21	21	1	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2012	7	5							e37968	10.1371/journal.pone.0037968	http://dx.doi.org/10.1371/journal.pone.0037968			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UY	22685528	Green Published, gold, Green Submitted			2023-01-03	WOS:000305342300149
J	Goulet, GM; Moreau, P; Robitaille, N; Peretz, I				Goulet, Genevieve Mignault; Moreau, Patricia; Robitaille, Nicolas; Peretz, Isabelle			Congenital Amusia Persists in the Developing Brain after Daily Music Listening	PLOS ONE			English	Article							PITCH DISCRIMINATION; TONE-DEAFNESS; RESPONSES; IDENTIFICATION; PLASTICITY; CHILDREN; RECOVERY; DEFICITS; NETWORK; ENHANCE	Congenital amusia is a neurodevelopmental disorder that affects about 3% of the adult population. Adults experiencing this musical disorder in the absence of macroscopically visible brain injury are described as cases of congenital amusia under the assumption that the musical deficits have been present from birth. Here, we show that this disorder can be expressed in the developing brain. We found that (10-13 year-old) children exhibit a marked deficit in the detection of fine-grained pitch differences in both musical and acoustical context in comparison to their normally developing peers comparable in age and general intelligence. This behavioral deficit could be traced down to their abnormal P300 brain responses to the detection of subtle pitch changes. The altered pattern of electrical activity does not seem to arise from an anomalous functioning of the auditory cortex, because all early components of the brain potentials, the N100, the MMN, and the P200 appear normal. Rather, the brain and behavioral measures point to disrupted information propagation from the auditory cortex to other cortical regions. Furthermore, the behavioral and neural manifestations of the disorder remained unchanged after 4 weeks of daily musical listening. These results show that congenital amusia can be detected in childhood despite regular musical exposure and normal intellectual functioning.	[Goulet, Genevieve Mignault; Moreau, Patricia; Robitaille, Nicolas; Peretz, Isabelle] Univ Montreal, Dept Psychol, Int Lab Brain Mus & Sound Res BRAMS, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Goulet, GM (corresponding author), Univ Montreal, Dept Psychol, Int Lab Brain Mus & Sound Res BRAMS, CP 6128, Montreal, PQ H3C 3J7, Canada.	isabelle.peretz@umontreal.ca			Canadian Institutes of Health Research (CIHR); Canada Research Chair; CIHR; Fonds de Recherche du Quebec; Natural Sciences and Engineering Research Council of Canada (NSERC)	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canada Research Chair(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs); CIHR(Canadian Institutes of Health Research (CIHR)); Fonds de Recherche du Quebec; Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC))	This work was supported by grants from the Canadian Institutes of Health Research (CIHR) and from a Canada Research Chair to I. P., and by fellowships from the CIHR to P. M., from the Fonds de Recherche du Quebec to G.M.G. and from the Collaborative Research and Training Experience Program (CREATE) from the Natural Sciences and Engineering Research Council of Canada (NSERC) to N.R. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angelucci F, 2007, BEHAV PHARMACOL, V18, P491, DOI 10.1097/FBP.0b013e3282d28f50; Avidan G, 2009, CURR BIOL, V19, P1146, DOI 10.1016/j.cub.2009.04.060; Ayotte J, 2002, BRAIN, V125, P238, DOI 10.1093/brain/awf028; Bosnyak DJ, 2004, CEREB CORTEX, V14, P1088, DOI 10.1093/cercor/bhh068; Drayna D, 2001, SCIENCE, V291, P1969, DOI 10.1126/science.291.5510.1969; Engineer ND, 2004, J NEUROPHYSIOL, V92, P73, DOI 10.1152/jn.00059.2004; Foxton JM, 2004, BRAIN, V127, P801, DOI 10.1093/brain/awh105; Fujioka T, 2006, BRAIN, V129, P2593, DOI 10.1093/brain/awl247; Grueter M, 2007, CORTEX, V43, P734, DOI 10.1016/S0010-9452(08)70502-1; Hyde KL, 2004, PSYCHOL SCI, V15, P356, DOI 10.1111/j.0956-7976.2004.00683.x; Hyde KL, 2007, J NEUROSCI, V27, P13028, DOI 10.1523/JNEUROSCI.3039-07.2007; Hyde KL, 2006, BRAIN, V129, P2562, DOI 10.1093/brain/awl204; Hyde KL, 2011, CEREB CORTEX, V21, P292, DOI 10.1093/cercor/bhq094; Hyde KL, 2009, J NEUROSCI, V29, P3019, DOI 10.1523/JNEUROSCI.5118-08.2009; Klingberg T, 2000, NEURON, V25, P493, DOI 10.1016/S0896-6273(00)80911-3; Kraus N, 1996, SCIENCE, V273, P971, DOI 10.1126/science.273.5277.971; Lappe C, 2008, J NEUROSCI, V28, P9632, DOI 10.1523/JNEUROSCI.2254-08.2008; Lebrun MA, 2011, CORTEX IN PRESS; Liu F, 2010, BRAIN, V133, P1682, DOI 10.1093/brain/awq089; Loui P, 2011, FRONTIERS PSYCHOL, P2; Loui P, 2009, J NEUROSCI, V29, P10215, DOI 10.1523/JNEUROSCI.1701-09.2009; Luo Yuejia, 1999, Chinese Medical Sciences Journal, V14, P75; Mandell J, 2007, RESTOR NEUROL NEUROS, V25, P323; McGrath LM, 2006, TRENDS MOL MED, V12, P333, DOI 10.1016/j.molmed.2006.05.007; Merrett DW, 2012, LIFELONG ENGAGEMENT; Moreau P, 2009, ANN NY ACAD SCI, V1169, P191, DOI 10.1111/j.1749-6632.2009.04775.x; Moreno S, 2009, CEREB CORTEX, V19, P712, DOI 10.1093/cercor/bhn120; Naatanen R, 2007, CLIN NEUROPHYSIOL, V118, P2544, DOI 10.1016/j.clinph.2007.04.026; Nan Y, 2010, BRAIN, V133, P2635, DOI 10.1093/brain/awq178; Peretz I, 2005, ANN NEUROL, V58, P478, DOI 10.1002/ana.20606; Peretz I, 2003, ANN NY ACAD SCI, V999, P58, DOI 10.1196/annals.1284.006; Peretz I, 2003, TRENDS COGN SCI, V7, P362, DOI 10.1016/S1364-6613(03)00150-5; Peretz I, 2002, NEURON, V33, P185, DOI 10.1016/S0896-6273(01)00580-3; Peretz I, 2008, MUSIC PERCEPT, V25, P331, DOI 10.1525/MP.2008.25.4.331; Peretz I, 2007, AM J HUM GENET, V81, P582, DOI 10.1086/521337; Peretz I, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00145; Peretz I, 2009, BRAIN, V132, P1277, DOI 10.1093/brain/awp055; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; Raven J, 1998, RAVEN MANUAL SECTION; RECANZONE GH, 1993, J NEUROSCI, V13, P87; Rentfrow PJ, 2006, PSYCHOL SCI, V17, P236, DOI 10.1111/j.1467-9280.2006.01691.x; Sarkamo T, 2008, BRAIN, V131, P866, DOI 10.1093/brain/awn013; Sarkamo T, 2010, J COGNITIVE NEUROSCI, V22, P2716, DOI 10.1162/jocn.2009.21376; Schellenberg EG, 2004, PSYCHOL SCI, V15, P511, DOI 10.1111/j.0956-7976.2004.00711.x; Shahin A, 2003, J NEUROSCI, V23, P5545; Thomas C, 2009, NAT NEUROSCI, V12, P29, DOI 10.1038/nn.2224; Tremblay K, 1998, NEUROREPORT, V9, P3557, DOI 10.1097/00001756-199811160-00003; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Williamson VJ, 2010, MEMORY, V18, P657, DOI 10.1080/09658211.2010.501339; Wiltermuth SS, 2009, PSYCHOL SCI, V20, P1, DOI 10.1111/j.1467-9280.2008.02253.x	50	28	28	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2012	7	5							e36860	10.1371/journal.pone.0036860	http://dx.doi.org/10.1371/journal.pone.0036860			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TW	22606299	Green Submitted, Green Published, gold			2023-01-03	WOS:000305338200050
J	Boyce, N				Boyce, Niall			The art of medicine Outsider Art	LANCET			English	Editorial Material												niall.boyce@lancet.com						GAIMAN N, PUBLICATION LIST	1	1	1	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 21	2012	379	9825					1480	1481		10.1016/S0140-6736(12)60621-7	http://dx.doi.org/10.1016/S0140-6736(12)60621-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	930BJ	22530245				2023-01-03	WOS:000303110200014
J	Melo, JA; Ruvkun, G				Melo, Justine A.; Ruvkun, Gary			Inactivation of Conserved C. elegans Genes Engages Pathogen- and Xenobiotic-Associated Defenses	CELL			English	Article							CAENORHABDITIS-ELEGANS; SIGNALING PATHWAY; PROTEIN; INFECTION; KINASE; MAPK; RNAI; SURVIVAL; IMMUNITY; DAMAGE	The nematode C. elegans is attracted to nutritious bacteria and is repelled by pathogens and toxins. Here we show that RNAi and toxin-mediated disruption of core cellular activities, including translation, respiration, and protein turnover, stimulate behavioral avoidance of normally attractive bacteria. RNAi of these and other essential processes induces expression of detoxification and innate immune effectors, even in the absence of toxins or pathogens. Disruption of core processes in non-neuronal tissues was sufficient to stimulate aversion behavior, revealing a neuroendocrine axis of control that additionally required serotonergic and Jnk kinase signaling pathways. We propose that surveillance pathways overseeing core cellular activities allow animals to detect invading pathogens that deploy toxins and virulence factors to undermine vital host functions. Variation in cellular surveillance and endocrine pathways controlling behavior, detoxification, and immunity selected by past toxin or microbial interactions could underlie aberrant responses to foods, medicines, and microbes.	[Melo, Justine A.; Ruvkun, Gary] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; [Melo, Justine A.; Ruvkun, Gary] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Ruvkun, G (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.	ruvkun@molbio.mgh.harvard.edu	Melo, Justine/AAH-4339-2021	Melo, Justine/0000-0002-7476-0470	Jane Coffin Childs Memorial Fund; Bank of America Charles King Trust; MGH; NIH [DK070147]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK070147] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG043184] Funding Source: NIH RePORTER	Jane Coffin Childs Memorial Fund; Bank of America Charles King Trust; MGH; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank F. Ausubel, D. McEwan, R. Pukkila-Worley, E. Troemel, S. Curran, A. Frand, J. Kim, D. Kim, Y. Tabach, B. Cezairliyan, A. Jose, J. Gray, B. Shtonda, L. Avery, C. Bargmann, and D. Hopwood for helpful discussions, D. Shore for participation in stress reporter assays, E. O'Rourke and B. Samuel for assistance with pharyngeal pumping assays, and Rusty Howson for figure support. We thank the CGC, OMRF knockout consortium, National Bioresource Project of Japan, F. Ausubel, D. Kim, E. Troemel, J. Irazoqui, J. Kaplan, J. Kim, A. Soukas, L. Avery, and R. Losick for strains, and the C. elegans resource Wormbase. For sharing unpublished results, we thank F. Ausubel, D. Kim, E. Troemel, Y. Tabach, L. Avery, and S. Politz. Salary support for J. A. M. was provided by the Jane Coffin Childs Memorial Fund, the Bank of America Charles King Trust, and the MGH Fund for Medical Discovery. This work was funded by NIH grant DK070147.	Bargmann C.I., 2006, CHEMOSENSATION C ELG, DOI [10.1895/wormbook.1.7.1, DOI 10.1895/WORMBOOK.1.7.1]; Bolz DD, 2010, J BIOL CHEM, V285, P10832, DOI 10.1074/jbc.M109.091629; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Calixto A, 2010, NAT METHODS, V7, P554, DOI [10.1038/nmeth.1463, 10.1038/NMETH.1463]; Dunbar TL, 2012, CELL HOST MICROBE, V11, P375, DOI 10.1016/j.chom.2012.02.008; Durieux J, 2011, CELL, V144, P79, DOI 10.1016/j.cell.2010.12.016; Estes KA, 2010, P NATL ACAD SCI USA, V107, P2153, DOI 10.1073/pnas.0914643107; Fukushige T, 1998, DEV BIOL, V198, P286, DOI 10.1016/S0012-1606(98)80006-7; Hao LM, 2006, DEV DYNAM, V235, P1469, DOI 10.1002/dvdy.20721; Hart A. C., 2006, WORMBOOK; Haynes CM, 2010, J CELL SCI, V123, P3849, DOI 10.1242/jcs.075119; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Iordanov MS, 1997, MOL CELL BIOL, V17, P3373, DOI 10.1128/MCB.17.6.3373; Iser WB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017369; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Jones JDG, 2006, NATURE, V444, P323, DOI 10.1038/nature05286; Jose AM, 2009, P NATL ACAD SCI USA, V106, P2283, DOI 10.1073/pnas.0809760106; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kao CY, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001314; Kim DH, 2004, P NATL ACAD SCI USA, V101, P10990, DOI 10.1073/pnas.0403546101; Lamitina T, 2006, P NATL ACAD SCI USA, V103, P12173, DOI 10.1073/pnas.0602987103; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; McEwan DL, 2012, CELL HOST MICROBE, V11, P364, DOI 10.1016/j.chom.2012.02.007; Mizuno T, 2004, EMBO J, V23, P2226, DOI 10.1038/sj.emboj.7600226; Mizuno T, 2008, MOL CELL BIOL, V28, P7041, DOI 10.1128/MCB.00938-08; O'Rourke D, 2006, GENOME RES, V16, P1005, DOI 10.1101/gr.50823006; Powell JR, 2009, P NATL ACAD SCI USA, V106, P2782, DOI 10.1073/pnas.0813048106; Prahlad V, 2008, SCIENCE, V320, P811, DOI 10.1126/science.1156093; Prahlad V, 2011, P NATL ACAD SCI USA, V108, P14204, DOI 10.1073/pnas.1106557108; Pujol N, 2001, CURR BIOL, V11, P809, DOI 10.1016/S0960-9822(01)00241-X; Pujol N, 2008, CURR BIOL, V18, P481, DOI 10.1016/j.cub.2008.02.079; Qadota H, 2007, GENE, V400, P166, DOI 10.1016/j.gene.2007.06.020; Schulenburg H, 2004, PARASITOLOGY, V128, P433, DOI 10.1017/S003118200300461X; Schulenburg H, 2007, MOL MICROBIOL, V66, P563, DOI 10.1111/j.1365-2958.2007.05946.x; Sicard M, 2007, ENVIRON MICROBIOL, V9, P12, DOI 10.1111/j.1462-2920.2006.01099.x; Styer KL, 2008, SCIENCE, V322, P460, DOI 10.1126/science.1163673; Troemel ER, 2006, PLOS GENET, V2, P1725, DOI 10.1371/journal.pgen.0020183; Urano F, 2002, J CELL BIOL, V158, P639, DOI 10.1083/jcb.200203086; Yoneda T, 2004, J CELL SCI, V117, P4055, DOI 10.1242/jcs.01275; Yook K, 2007, GENETICS, V175, P681, DOI 10.1534/genetics.106.060087; Zhang Y, 2005, NATURE, V438, P179, DOI 10.1038/nature04216	42	239	244	1	31	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 13	2012	149	2					452	466		10.1016/j.cell.2012.02.050	http://dx.doi.org/10.1016/j.cell.2012.02.050			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	926BF	22500807	Green Accepted, Bronze			2023-01-03	WOS:000302805600022
J	Stoppe, C; Fries, M; Rossaint, R; Grieb, G; Coburn, M; Simons, D; Brucken, D; Bernhagen, J; Pallua, N; Rex, S				Stoppe, Christian; Fries, Michael; Rossaint, Rolf; Grieb, Gerrit; Coburn, Mark; Simons, David; Bruecken, David; Bernhagen, Juergen; Pallua, Norbert; Rex, Steffen			Blood Levels of Macrophage Migration Inhibitory Factor after Successful Resuscitation from Cardiac Arrest	PLOS ONE			English	Article							AMERICAN-HEART-ASSOCIATION; MYOCARDIAL DYSFUNCTION; COUNCIL GUIDELINES; STROKE FOUNDATION; SERUM-LEVELS; MIF; CARDIOPULMONARY; CYTOKINE; CARE; STATEMENT	Introduction: Ischemia-reperfusion injury following cardiopulmonary resuscitation (CPR) is associated with a systemic inflammatory response, resulting in post-resuscitation disease. In the present study we investigated the response of the pleiotropic inflammatory cytokine macrophage migration inhibitory factor (MIF) to CPR in patients admitted to the hospital after out-of-hospital cardiac arrest (OHCA). To describe the magnitude of MIF release, we compared the blood levels from CPR patients with those obtained in healthy volunteers and with an aged-and gender-matched group of patients undergoing cardiac surgery with the use of extracorporeal circulation. Methods: Blood samples of 17 patients with return of spontaneous circulation (ROSC) after OHCA were obtained upon admission to the intensive care unit, and 6, 12, 24, 72 and 96 h later. Arrest and treatment related data were documented according to the Utstein style. Results: In patients after ROSC, MIF levels at admission (475.2 +/- 157.8 ng/ml) were significantly higher than in healthy volunteers (12.5 +/- 16.9 ng/ml, p<0.007) and in patients after cardiac surgery (78.2 +/- 41.6 ng/ml, p<0.007). Six hours after admission, MIF levels were decreased by more than 50% (150.5 +/- 127.2 ng/ml, p<0.007), but were not further reduced in the subsequent time course and remained significantly higher than the values observed during the ICU stay of cardiac surgical patients. In this small group of patients, MIF levels could not discriminate between survivors and non-survivors and were not affected by treatment with mild therapeutic hypothermia. Conclusion: MIF shows a rapid and pronounced increase following CPR, hence allowing a very early assessment of the inflammatory response. Further studies are warranted in larger patient groups to determine the prognostic significance of MIF.	[Stoppe, Christian; Rossaint, Rolf; Coburn, Mark; Rex, Steffen] Rhein Westfal TH Aachen, Univ Hosp, Dept Anaesthesiol, D-52062 Aachen, Germany; [Stoppe, Christian; Grieb, Gerrit; Simons, David; Bernhagen, Juergen] Rhein Westfal TH Aachen, Univ Hosp, Inst Biochem & Mol Cell Biol, D-52062 Aachen, Germany; [Fries, Michael] Rhein Westfal TH Aachen, Univ Hosp, Dept Intens Care, D-52062 Aachen, Germany; [Grieb, Gerrit; Simons, David; Pallua, Norbert] Rhein Westfal TH Aachen, Univ Hosp, Dept Plast Surg, Burn Unit, D-52062 Aachen, Germany; [Bruecken, David] Rhein Westfal TH Aachen, Univ Hosp, Dept Orthopaed & Trauma Surg Main Focus Trauma Su, D-52062 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital	Stoppe, C (corresponding author), Rhein Westfal TH Aachen, Univ Hosp, Dept Anaesthesiol, D-52062 Aachen, Germany.	christian.stoppe@gmail.com		Coburn, Mark/0000-0002-7930-0270; Rex, Steffen/0000-0002-3536-9321	Deutsche Forschungsgemeinschaft (DFG) [Be1977/4-2 (TP1 of DFG-FOR809), GRK1508/1 (project P13), Ra969/6-1]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	This study was supported by the Deutsche Forschungsgemeinschaft (DFG) grants Be1977/4-2 (TP1 of DFG-FOR809), GRK1508/1 (project P13), and Ra969/6-1 to JB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adrie C, 2002, CIRCULATION, V106, P562, DOI 10.1161/01.CIR.0000023891.80661.AD; Adrie Christophe, 2004, Curr Opin Crit Care, V10, P208, DOI 10.1097/01.ccx.0000126090.06275.fe; Beiser DG, 2009, RESUSCITATION, V80, P624, DOI 10.1016/j.resuscitation.2009.02.011; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; Chagnon F, 2005, CIRC RES, V96, P1095, DOI 10.1161/01.RES.0000168327.22888.4d; Cummins RO, 1997, CIRCULATION, V95, P2213, DOI 10.1161/01.CIR.95.8.2213; Derwall M, 2009, CRIT CARE, V13, DOI 10.1186/cc7785; Fink K, 2010, CRIT CARE, V14, DOI 10.1186/cc9050; Fries M, 2003, RESUSCITATION, V59, P105, DOI 10.1016/S0300-9572(03)00164-3; Fries M, 2009, J CRIT CARE, V24, P453, DOI 10.1016/j.jcrc.2008.10.012; de Mendonca HTF, 2006, CRIT CARE, V10, DOI 10.1186/cc4857; Gando S, 2000, INTENS CARE MED, V26, P38, DOI 10.1007/s001340050009; Gando S, 2001, INTENS CARE MED, V27, P1187, DOI 10.1007/s001340000818; Grenvik ASP., 1981, BRAIN FAILURE RESUSC, P155; Grieb G, 2010, BURNS, V36, P335, DOI 10.1016/j.burns.2009.04.019; Kim JJ, 2011, CRIT CARE, V15, DOI 10.1186/cc10019; Laurent I, 2002, J AM COLL CARDIOL, V40, P2110, DOI 10.1016/S0735-1097(02)02594-9; Laver S, 2004, INTENS CARE MED, V30, P2126, DOI 10.1007/s00134-004-2425-z; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Merk M, 2011, P NATL ACAD SCI USA, V108, pE577, DOI 10.1073/pnas.1102941108; Miller EJ, 2008, NATURE, V451, P578, DOI 10.1038/nature06504; Morand EF, 2006, NAT REV DRUG DISCOV, V5, P399, DOI 10.1038/nrd2029; NEGOVSKY VA, 1995, RESUSCITATION, V30, P23, DOI 10.1016/0300-9572(95)00861-M; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Noels H, 2009, TRENDS CARDIOVAS MED, V19, P76, DOI 10.1016/j.tcm.2009.05.002; Nolan JP, 2010, RESUSCITATION, V81, P1219, DOI 10.1016/j.resuscitation.2010.08.021; Nolan JP, 2005, RESUSCITATION, V67, pS39, DOI 10.1016/j.resuscitation.2005.10.009; Qi D, 2009, J CLIN INVEST, V119, P3807, DOI 10.1172/JCI39738; Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a; Sakuragi Tohru, 2007, Surg Infect (Larchmt), V8, P29, DOI 10.1089/sur.2006.031; Simons D, 2011, J CELL MOL MED, V15, P668, DOI 10.1111/j.1582-4934.2010.01041.x; Stoppe C, 2011, CRIT CARE MED, V39, P1879, DOI 10.1097/CCM.0b013e3182190d48; Trzeciak S, 2009, CRIT CARE MED, V37, P2895, DOI 10.1097/CCM.0b013e3181b01d8c; Yende S, 2009, FASEB J, V23, P2403, DOI 10.1096/fj.09-129445; Zernecke A, 2008, CIRCULATION, V117, P1594, DOI 10.1161/CIRCULATIONAHA.107.729125	40	21	21	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 10	2012	7	4							e33512	10.1371/journal.pone.0033512	http://dx.doi.org/10.1371/journal.pone.0033512			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959FE	22506003	gold, Green Submitted, Green Published			2023-01-03	WOS:000305297500011
J	Greene, JA; Choudhry, NK; Kesselheim, AS; Brennan, TA; Shrank, W				Greene, Jeremy A.; Choudhry, Niteesh K.; Kesselheim, Aaron S.; Brennan, Troyen A.; Shrank, William			Changes in Direct-to-Consumer Pharmaceutical Advertising Following Shifts From Prescription-Only to Over-the-Counter Status	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							DRUGS		[Greene, Jeremy A.; Choudhry, Niteesh K.; Kesselheim, Aaron S.; Shrank, William] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Greene, JA (corresponding author), Johns Hopkins Univ, Baltimore, MD 21218 USA.	greene@jhmi.edu	Kesselheim, Aaron/R-6793-2017	Kesselheim, Aaron/0000-0002-8867-2666				Donohue JM, 2007, NEW ENGL J MED, V357, P673, DOI 10.1056/NEJMsa070502; Faerber AE, 2012, HEALTH COMMUN, V27, P66, DOI 10.1080/10410236.2011.569001; *IMS HLTH, TOT US PROM SPEND TY; Sharfstein JM, 2007, NEW ENGL J MED, V357, P2321, DOI 10.1056/NEJMp0707400; VMS, 2010, ADS PROD SHEET; World Health Organization, ETH CRIT MED DRUG PR	6	11	11	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 12	2012	308	10					973	975		10.1001/2012.jama.10647	http://dx.doi.org/10.1001/2012.jama.10647			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003AA	22968881				2023-01-03	WOS:000308579300015
J	Ropper, AH				Ropper, Allan H.			Hyperosmolar Therapy for Raised Intracranial Pressure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; CEREBROSPINAL-FLUID PRESSURE; SEVERE HEAD-INJURY; HYPERTONIC SALINE; MANNITOL; HYPERTENSION; CHILDREN; DEATH; CARE	A 49-year-old female passenger was thrown against the doorframe during an automobile accident. After being pulled from the car, she opened her eyes intermittently, moaned, and had flexion withdrawal of her limbs (Glasgow Coma Scale score, 8). Her pupils were 5 mm in diameter and reactive to light. Her blood pressure was 165/85 mm Hg, her heart rate 112 beats per minute, and her breathing regular. After her spine was stabilized, she was conveyed to an intensive care unit (ICU). In the ICU, she no longer opened her eyes, had flexion posturing of her arms, and made no verbal responses (Glasgow Coma Scale score, 5). There was a contusion on her right frontal scalp but no sign of other organ injury. Computed tomography showed large regions of frontal brain contusion with surrounding edema (Fig. 1). The patient was intubated, and an external ventricular drain was placed in order to measure intracranial pressure, which was 29 mm Hg with periodic elevations to 36 mm Hg. After drainage of cerebrospinal fluid, the intracranial pressure transiently decreased to 26 mm Hg. The serum sodium concentration was 139 mmol per liter. The neurointensivist recommended an intravenous bolus infusion of 23% saline to reduce intracranial pressure and attain a serum sodium concentration of 150 mmol per liter. The patient's weight was 55 kg.	Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Ropper, AH (corresponding author), Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA.	aropper@partners.org						Adrogue HJ, 2000, NEW ENGL J MED, V342, P1493, DOI 10.1056/NEJM200005183422006; Baker A, 2006, CAN J ANAESTH, V53, P722, DOI 10.1007/BF03021632; Better OS, 1997, KIDNEY INT, V52, P886, DOI 10.1038/ki.1997.409; Bullock MR, 2007, J NEUROTRAUMA S1, V24, pS14; Bullock MR, 2007, J NEUROTRAUM, V24, pvii; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Diringer MN, 2004, NEUROCRIT CARE, V1, P219, DOI 10.1385/NCC:1:2:219; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; JAMES HE, 1977, ACTA NEUROCHIR, V36, P189, DOI 10.1007/BF01405391; JAVID M, 1956, JAMA-J AM MED ASSOC, V160, P943, DOI 10.1001/jama.1956.02960460021006; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kellie George, 1824, Trans Med Chir Soc Edinb, V1, P84; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Koenig MA, 2008, NEUROLOGY, V70, P1023, DOI 10.1212/01.wnl.0000304042.05557.60; Langlois J.A., 2006, TRAUMATIC BRAIN INJU; MCDOWELL ME, 1955, AM J PHYSIOL, V180, P545, DOI 10.1152/ajplegacy.1955.180.3.545; Monro A., 1835, OBSERVATIONS STRUCTU, V1835, P5; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0; Palo J, 1999, LANCET, V354, P1909, DOI 10.1016/S0140-6736(05)76879-3; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Treggiari MM, 2007, NEUROCRIT CARE, V6, P104, DOI 10.1007/s12028-007-0012-1; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Videen TO, 2001, NEUROLOGY, V57, P2120, DOI 10.1212/WNL.57.11.2120; Weed LH, 1919, AM J PHYSIOL, V48, P512, DOI 10.1152/ajplegacy.1919.48.4.512; WISE BL, 1962, J NEUROSURG, V19, P1038, DOI 10.3171/jns.1962.19.12.1038	30	111	119	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 23	2012	367	8					746	752		10.1056/NEJMct1206321	http://dx.doi.org/10.1056/NEJMct1206321			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992CX	22913684				2023-01-03	WOS:000307754200009
J	Opondo, D; Eslami, S; Visscher, S; de Rooij, SE; Verheij, R; Korevaar, JC; Abu-Hanna, A				Opondo, Dedan; Eslami, Saied; Visscher, Stefan; de Rooij, Sophia E.; Verheij, Robert; Korevaar, Joke C.; Abu-Hanna, Ameen			Inappropriateness of Medication Prescriptions to Elderly Patients in the Primary Care Setting: A Systematic Review	PLOS ONE			English	Review							ADVERSE DRUG EVENTS; BEERS CRITERIA; OLDER-ADULTS; OUTPATIENTS; POPULATION; QUALITY; PREVALENCE; VETERANS; DISEASES	Background: Inappropriate medication prescription is a common cause of preventable adverse drug events among elderly persons in the primary care setting. Objective: The aim of this systematic review is to quantify the extent of inappropriate prescription to elderly persons in the primary care setting. Methods: We systematically searched Ovid-Medline and Ovid-EMBASE from 1950 and 1980 respectively to March 2012. Two independent reviewers screened and selected primary studies published in English that measured (in) appropriate medication prescription among elderly persons (>65 years) in the primary care setting. We extracted data sources, instruments for assessing medication prescription appropriateness, and the rate of inappropriate medication prescriptions. We grouped the reported individual medications according to the Anatomical Therapeutic and Chemical (ATC) classification and compared the median rate of inappropriate medication prescription and its range within each therapeutic class. Results: We included 19 studies, 14 of which used the Beers criteria as the instrument for assessing appropriateness of prescriptions. The median rate of inappropriate medication prescriptions (IMP) was 20.5% [IQR 18.1 to 25.6%.]. Medications with largest median rate of inappropriate medication prescriptions were propoxyphene 4.52(0.10-23.30)%, doxazosin 3.96 (0.32 15.70)%, diphenhydramine 3.30(0.02-4.40)% and amitriptiline 3.20 (0.05-20.5)% in a decreasing order of IMP rate. Available studies described unequal sets of medications and different measurement tools to estimate the overall prevalence of inappropriate prescription. Conclusions: Approximately one in five prescriptions to elderly persons in primary care is inappropropriate despite the attention that has been directed to quality of prescription. Diphenhydramine and amitriptiline are the most common inappropriately prescribed medications with high risk adverse events while propoxyphene and doxazoxin are the most commonly prescribed medications with low risk adverse events. These medications are good candidates for being targeted for improvement e. g. by computerized clinical decision support.	[Opondo, Dedan; Eslami, Saied; Abu-Hanna, Ameen] Univ Amsterdam, Acad Med Ctr, Dept Med Informat, NL-1105 AZ Amsterdam, Netherlands; [Visscher, Stefan; Verheij, Robert; Korevaar, Joke C.] Netherlands Inst Hlth Serv Res NIVEL, Utrecht, Netherlands; [de Rooij, Sophia E.] Univ Amsterdam, Acad Med Ctr, Dept Geriatr, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Netherlands Institute for Health Services Research; University of Amsterdam; Academic Medical Center Amsterdam	Opondo, D (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Med Informat, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	d.o.opondo@amc.uva.nl		Abu-Hanna, Ameen/0000-0003-4324-7954				Aparasu RR, 2000, ANN PHARMACOTHER, V34, P338, DOI 10.1345/aph.19006; Aparasu RR, 1997, ANN PHARMACOTHER, V31, P823, DOI 10.1177/106002809703100702; Aparasu RR, 1999, AM J HEALTH-SYST PH, V56, P433, DOI 10.1093/ajhp/56.5.433; Basger BJ, 2008, DRUG AGING, V25, P777, DOI 10.2165/00002512-200825090-00004; Bierman Arlene S, 2007, Am J Geriatr Pharmacother, V5, P147, DOI 10.1016/j.amjopharm.2007.06.005; Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716; Boyd CM, 2011, J AM GERIATR SOC, V59, P797, DOI 10.1111/j.1532-5415.2011.03391.x; Chang CB, 2012, PHARMACOEPIDEM DR S, V21, P1269, DOI 10.1002/pds.3274; Curtis LH, 2004, ARCH INTERN MED, V164, P1621, DOI 10.1001/archinte.164.15.1621; Eslami S, 2010, BRIT J CLIN PHARMACO, V70, P619, DOI 10.1111/j.1365-2125.2010.03614.x; Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716; Fick D, 2012, J AM GERIATR SOC, V60, P616, DOI 10.1111/j.1532-5415.2012.03923.x; Gallagher P, 2008, INT J CLIN PHARM TH, V46, P72; Gallagher P, 2007, J CLIN PHARM THER, V32, P113, DOI 10.1111/j.1365-2710.2007.00793.x; Ghadimi H, 2011, PHARMACOEPIDEM DR S, V20, P482, DOI 10.1002/pds.2106; Goltz L, 2012, INT J CLIN PHARM TH, V50, P185, DOI 10.5414/CP201441; Guaraldo L, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-79; Hanlon JT, 1997, J AM GERIATR SOC, V45, P945, DOI 10.1111/j.1532-5415.1997.tb02964.x; Lai HY, 2009, CLIN THER, V31, P1859, DOI 10.1016/j.clinthera.2009.08.023; Lin HY, 2008, DRUG AGING, V25, P49, DOI 10.2165/00002512-200825010-00006; Lund BC, 2010, ANN PHARMACOTHER, V44, P957, DOI 10.1345/aph.1M657; Maio V, 2010, J CLIN PHARM THER, V35, P219, DOI 10.1111/j.1365-2710.2009.01094.x; Maio V, 2006, AM J MED QUAL, V21, P162, DOI 10.1177/1062860605285475; Maio V, 2006, DRUG AGING, V23, P915, DOI 10.2165/00002512-200623110-00006; Martins SDO, 2006, PHARM WORLD SCI, V28, P296, DOI 10.1007/s11096-006-9046-2; Parker M, 2007, COLORECTAL DIS, V9, P2, DOI 10.1111/j.1463-1318.2007.01368.x; Pugh MJV, 2006, J MANAGE CARE PHARM, V12, P537, DOI 10.18553/jmcp.2006.12.7.537; Pugh MJV, 2005, J AM GERIATR SOC, V53, P1282, DOI 10.1111/j.1532-5415.2005.53402.x; Ryan C, 2009, BRIT J CLIN PHARMACO, V68, P936, DOI 10.1111/j.1365-2125.2009.03531.x; Smeets HM, 2011, J CLIN EPIDEMIOL, V64, P424, DOI 10.1016/j.jclinepi.2010.04.023; Spinewine A, 2007, LANCET, V370, P173, DOI 10.1016/S0140-6736(07)61091-5; Straand J, 1999, FAM PRACT, V16, P380, DOI 10.1093/fampra/16.4.380; Thomsen LA, 2007, ANN PHARMACOTHER, V41, P1411, DOI 10.1345/aph.1H658; van der Hooft CS, 2005, BRIT J CLIN PHARMACO, V60, P137, DOI 10.1111/j.1365-2125.2005.02391.x; Wilde S, 2012, PHARMACOEPIDEM DR S, V16, P658; World Health Organisation Collaborating Center for Drug Statistics Methodology, 2011, GUID ATC CLASS DDD A; Zaveri HG, 2010, INDIAN J PHARMACOL, V42, P95, DOI 10.4103/0253-7613.64499; Zhan CL, 2005, J AM GERIATR SOC, V53, P262, DOI 10.1111/j.1532-5415.2005.53112.x; Zhang YT, 2010, NEW ENGL J MED, V363, P1985, DOI 10.1056/NEJMp1010220	39	166	171	2	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2012	7	8							e43617	10.1371/journal.pone.0043617	http://dx.doi.org/10.1371/journal.pone.0043617			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	999CI	22928004	Green Published, gold			2023-01-03	WOS:000308286300074
J	Raynes, R; Leckey, BD; Nguyen, K; Westerheide, SD				Raynes, Rachel; Leckey, Bruce D., Jr.; Kevin Nguyen; Westerheide, Sandy D.			Heat Shock and Caloric Restriction Have a Synergistic Effect on the Heat Shock Response in a sir2.1-dependent Manner in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIFE-SPAN; DIETARY RESTRICTION; MESSENGER-RNA; DECREASED EXPRESSION; GENE-TRANSCRIPTION; CELL-SURVIVAL; FACTOR-I; PROTEIN; STRESS; HEAT-SHOCK-PROTEIN-70	The heat shock response (HSR) is responsible for maintaining cellular and organismal health through the regulation of proteostasis. Recent data demonstrating that the mammalian HSR is regulated by SIRT1 suggest that this response may be under metabolic control. To test this hypothesis, we have determined the effect of caloric restriction in Caenorhabditis elegans on activation of the HSR and have found a synergistic effect on the induction of hsp70 gene expression. The homolog of mammalian SIRT1 in C. elegans is Sir2.1. Using a mutated C. elegans strain with a sir2.1 deletion, we show that heat shock and caloric restriction cooperate to promote increased survivability and fitness in a sir2.1-dependent manner. Finally, we show that caloric restriction increases the ability of heat shock to preserve movement in a polyglutamine toxicity neurodegenerative disease model and that this effect is dependent on sir2.1.	[Raynes, Rachel; Leckey, Bruce D., Jr.; Kevin Nguyen; Westerheide, Sandy D.] Univ S Florida, Coll Arts & Sci, Dept Cell Biol Microbiol & Mol Biol, Tampa, FL 33620 USA	State University System of Florida; University of South Florida	Westerheide, SD (corresponding author), Univ S Florida, Coll Arts & Sci, Dept Cell Biol Microbiol & Mol Biol, 4202 E Fowler Ave,ISA2015, Tampa, FL 33620 USA.	swesterheide@usf.edu			Department of Cell Biology, Microbiology and Molecular of the University of South Florida; National Institutes of Health; Canadian Institutes of Health Research; Genome Canada; Genome BC; Michael Smith Foundation; National Institutes of Health National Center for Research Resources	Department of Cell Biology, Microbiology and Molecular of the University of South Florida; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Genome Canada(Genome Canada); Genome BC; Michael Smith Foundation(Michael Smith Foundation for Health Research); National Institutes of Health National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported by a departmental start-up grant from the Department of Cell Biology, Microbiology and Molecular of the University of South Florida (to S. D. W.).; We thank Dr. R. I. Morimoto (Northwestern University, Evanston, IL) for providing the C. elegans C12C8.1::GFP, Q0-YFP, Q24-YFP, and Q35-YFP strains. The sir2.1(ok434) IV and sir2.3(ok444) X strains were provided by the C. elegans Gene Knockout Consortium (C. elegans Gene Knockout Facility at the Oklahoma Medical Research Foundation, which is funded by the National Institutes of Health, and the C. elegans Reverse Genetics Core Facility at the University of British Columbia, which is funded by the Canadian Institutes of Health Research, Genome Canada, Genome BC, the Michael Smith Foundation, and the National Institutes of Health). Other strains were provided by the Caenorhabditis Genetics Center, which is funded by the National Institutes of Health National Center for Research Resources. We thank Dr. C. Voisine (Northwestern University) and Dr. James West (College of Wooster, Wooster, OH) for helpful comments and advice.	Akerfelt M, 2010, NAT REV MOL CELL BIO, V11, P545, DOI 10.1038/nrm2938; Anckar J, 2011, ANNU REV BIOCHEM, V80, P1089, DOI 10.1146/annurev-biochem-060809-095203; Anderson RM, 2009, TOXICOL PATHOL, V37, P47, DOI 10.1177/0192623308329476; ANGELIDIS CE, 1991, EUR J BIOCHEM, V199, P35, DOI 10.1111/j.1432-1033.1991.tb16088.x; Bishop NA, 2007, NAT REV GENET, V8, P835, DOI 10.1038/nrg2188; BLAKE MJ, 1991, AM J PHYSIOL, V260, pR663, DOI 10.1152/ajpregu.1991.260.4.R663; Bookout Angie L, 2003, Nucl Recept Signal, V1, pe012; BRENNER S, 1974, GENETICS, V77, P71; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Calamini B, 2012, NAT CHEM BIOL, V8, P185, DOI 10.1038/nchembio.763; CAMPANINI C, 1992, ANN NY ACAD SCI, V663, P442, DOI 10.1111/j.1749-6632.1992.tb38695.x; Chiang WC, 2012, CELL, V148, P322, DOI 10.1016/j.cell.2011.12.019; Cypser JR, 2002, J GERONTOL A-BIOL, V57, pB109, DOI 10.1093/gerona/57.3.B109; DEGUCHI Y, 1988, BIOCHEM BIOPH RES CO, V157, P580, DOI 10.1016/S0006-291X(88)80289-4; Donmez G, 2012, J NEUROSCI, V32, P124, DOI 10.1523/JNEUROSCI.3442-11.2012; Donmez G, 2010, AGING CELL, V9, P285, DOI 10.1111/j.1474-9726.2010.00548.x; Ehrenfried JA, 1996, ANN SURG, V223, P592, DOI 10.1097/00000658-199605000-00015; FAASSEN AE, 1989, EXP CELL RES, V183, P326, DOI 10.1016/0014-4827(89)90393-5; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; FARGNOLI J, 1990, P NATL ACAD SCI USA, V87, P846, DOI 10.1073/pnas.87.2.846; Fujikake N, 2008, J BIOL CHEM, V283, P26188, DOI 10.1074/jbc.M710521200; Giannakou ME, 2008, AGING CELL, V7, P187, DOI 10.1111/j.1474-9726.2007.00362.x; Greer EL, 2009, AGING CELL, V8, P113, DOI 10.1111/j.1474-9726.2009.00459.x; Hansen M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040024; Heydari AR, 1996, DEV GENET, V18, P114, DOI 10.1002/(SICI)1520-6408(1996)18:2&lt;114::AID-DVG4&gt;3.0.CO;2-C; HEYDARI AR, 1993, MOL CELL BIOL, V13, P2909, DOI 10.1128/MCB.13.5.2909; Johnson TE, 2008, EXP GERONTOL, V43, P1, DOI 10.1016/j.exger.2007.09.008; JURIVICH DA, 1994, P NATL ACAD SCI USA, V91, P2280, DOI 10.1073/pnas.91.6.2280; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LEE BS, 1995, P NATL ACAD SCI USA, V92, P7207, DOI 10.1073/pnas.92.16.7207; Lewis JA, 1995, METHOD CELL BIOL, V48, P3; LI GC, 1991, P NATL ACAD SCI USA, V88, P1681, DOI 10.1073/pnas.88.5.1681; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; LIU AYC, 1989, J BIOL CHEM, V264, P12037; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; MCCAY CM, 1989, NUTRITION, V5, P155; Min KJ, 2008, AGING CELL, V7, P199, DOI 10.1111/j.1474-9726.2008.00373.x; Morimoto RI, 2008, GENE DEV, V22, P1427, DOI 10.1101/gad.1657108; Morley JF, 2004, MOL BIOL CELL, V15, P657, DOI 10.1091/mbc.E03-07-0532; Morley JF, 2002, P NATL ACAD SCI USA, V99, P10417, DOI 10.1073/pnas.152161099; PAHLAVANI MA, 1995, EXP CELL RES, V218, P310, DOI 10.1006/excr.1995.1160; RIABOWOL KT, 1988, SCIENCE, V242, P433, DOI 10.1126/science.3175665; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; Steinkraus KA, 2008, AGING CELL, V7, P394, DOI 10.1111/j.1474-9726.2008.00385.x; Torok Z, 2003, P NATL ACAD SCI USA, V100, P3131, DOI 10.1073/pnas.0438003100; von Koskull-Doring P, 2007, TRENDS PLANT SCI, V12, P452, DOI 10.1016/j.tplants.2007.08.014; Wang YM, 2006, MECH AGEING DEV, V127, P48, DOI 10.1016/j.mad.2005.09.005; Waza M, 2005, NAT MED, V11, P1088, DOI 10.1038/nm1298; Westerheide SD, 2009, SCIENCE, V323, P1063, DOI 10.1126/science.1165946; Westerheide SD, 2004, J BIOL CHEM, V279, P56053, DOI 10.1074/jbc.M409267200; Westerheide SD, 2005, J BIOL CHEM, V280, P33097, DOI 10.1074/jbc.R500010200; Yao J, 2006, NATURE, V442, P1050, DOI 10.1038/nature05025; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244	54	48	48	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2012	287	34					29045	29053		10.1074/jbc.M112.353714	http://dx.doi.org/10.1074/jbc.M112.353714			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996HD	22778258	Green Published, hybrid			2023-01-03	WOS:000308074600071
J	Dolan, GP; Myles, PR; Brett, SJ; Enstone, JE; Read, RC; Openshaw, PJM; Semple, MG; Lim, WS; Taylor, BL; McMenamin, J; Nicholson, KG; Bannister, B; Nguyen-Van-Tam, JS				Dolan, Gayle P.; Myles, Puja R.; Brett, Stephen J.; Enstone, Joanne E.; Read, Robert C.; Openshaw, Peter J. M.; Semple, Malcolm G.; Lim, Wei Shen; Taylor, Bruce L.; McMenamin, James; Nicholson, Karl G.; Bannister, Barbara; Nguyen-Van-Tam, Jonathan S.		Influenza Clinical Information Net	The Comparative Clinical Course of Pregnant and Non-Pregnant Women Hospitalised with Influenza A(H1N1)pdm09 Infection	PLOS ONE			English	Article							H1N1 VIRUS-INFECTION; PANDEMIC INFLUENZA; ILLNESS; PNEUMONIA; SAFETY	Introduction: The Influenza Clinical Information Network (FLU-CIN) was established to gather detailed clinical and epidemiological information about patients with laboratory confirmed A(H1N1)pdm09 infection in UK hospitals. This report focuses on the clinical course and outcomes of infection in pregnancy. Methods: A standardised data extraction form was used to obtain detailed clinical information from hospital case notes and electronic records, for patients with PCR-confirmed A(H1N1) pdm09 infection admitted to 13 sentinel hospitals in five clinical 'hubs' and a further 62 non-sentinel hospitals, between 11th May 2009 and 31st January 2010. Outcomes were compared for pregnant and non-pregnant women aged 15-44 years, using univariate and multivariable techniques. Results: Of the 395 women aged 15-44 years, 82 (21%) were pregnant; 73 (89%) in the second or third trimester. Pregnant women were significantly less likely to exhibit severe respiratory distress at initial assessment (OR = 0.49 (95% CI: 0.30-0.82)), require supplemental oxygen on admission (OR = 0.40 (95% CI: 0.20-0.80)), or have underlying co-morbidities (p-trend <0.001). However, they were equally likely to be admitted to high dependency (Level 2) or intensive care (Level 3) and/or to die, after adjustment for potential confounders (adj. OR = 0.93 (95% CI: 0.46-1.92). Of 11 pregnant women needing Level 2/3 care, 10 required mechanical ventilation and three died. Conclusions: Since the expected prevalence of pregnancy in the source population was 6%, our data suggest that pregnancy greatly increased the likelihood of hospital admission with A(H1N1)pdm09. Pregnant women were less likely than nonpregnant women to have respiratory distress on admission, but severe outcomes were equally likely in both groups.	[Dolan, Gayle P.; Myles, Puja R.; Enstone, Joanne E.; Nguyen-Van-Tam, Jonathan S.] Univ Nottingham, Hlth Protect Res Grp, Div Epidemiol & Publ Hlth, City Hosp Nottingham, Nottingham NG7 2RD, England; [Brett, Stephen J.] Imperial Coll Healthcare Natl Hlth Serv Trust, Ctr Perioperat Med & Crit Care Res, London, England; [Read, Robert C.] Univ Sheffield, Royal Hallamshire Hosp, Dept Infect & Immun, Sheffield S10 2JF, S Yorkshire, England; [Openshaw, Peter J. M.] Univ London Imperial Coll Sci Technol & Med, Ctr Resp Infect, Natl Heart & Lung Inst, London, England; [Semple, Malcolm G.] Univ Liverpool, Dept Womens & Childrens Hlth, Inst Translat Med, Liverpool L69 3BX, Merseyside, England; [Lim, Wei Shen] Nottingham Univ Hosp Natl Hlth Serv Trust, Dept Resp Med, Nottingham, England; [Taylor, Bruce L.] Portsmouth Hosp Natl Hlth Serv Trust, Dept Crit Care, Portsmouth, Hants, England; [McMenamin, James] Natl Hlth Serv Natl Serv, Hlth Protect Scotland, Glasgow, Lanark, Scotland; [Nicholson, Karl G.] Univ Hosp Leicester Natl Hlth Serv Trust, Infect Dis Unit, Leicester Royal Infirm, Leicester, Leics, England; [Bannister, Barbara] Dept Hlth, London SE1 6TE, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; Imperial College London; University of Sheffield; Imperial College London; University of Liverpool; Nottingham University Hospital NHS Trust; Portsmouth Hospitals NHS Trust; NHS National Services Scotland; University Hospitals of Leicester NHS Trust; University of Leicester	Dolan, GP (corresponding author), Univ Nottingham, Hlth Protect Res Grp, Div Epidemiol & Publ Hlth, City Hosp Nottingham, Clin Sci Bldg, Nottingham NG7 2RD, England.	Gayle.Dolan@hpa.org.uk	Openshaw, Peter/AAL-9442-2020; Semple, Malcolm Gracie/A-8790-2008; Nguyen-Van-Tam, Jonathan/I-2162-2019	Openshaw, Peter/0000-0002-7220-2555; Semple, Malcolm Gracie/0000-0001-9700-0418; Nguyen-Van-Tam, Jonathan/0000-0003-2579-4655; Read, Robert/0000-0002-4297-6728; Myles, Puja/0000-0002-8976-890X	The Department of Health in England; The Scottish Government Chief Medical Officer and Public Health Directorate; F. Hoffmann-La Roche; GlaxoSmithKline; Baxter AG; Novartis; Sanofi-Pasteur MSD; Astra-Zeneca; F. Hoffman-La Roche Ltd; Pfizer; Roche; National Institute for Health Research; Baxter; UK NIHR Biomedical Research Centre scheme; Medical Research Council [G1000758, G1000758B] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish; Asthma UK [S06/001] Funding Source: researchfish	The Department of Health in England; The Scottish Government Chief Medical Officer and Public Health Directorate; F. Hoffmann-La Roche(Hoffmann-La Roche); GlaxoSmithKline(GlaxoSmithKline); Baxter AG; Novartis(Novartis); Sanofi-Pasteur MSD; Astra-Zeneca(AstraZeneca); F. Hoffman-La Roche Ltd; Pfizer(Pfizer); Roche(Roche Holding); National Institute for Health Research(National Institute for Health Research (NIHR)); Baxter; UK NIHR Biomedical Research Centre scheme(National Institute for Health Research (NIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK	The Department of Health in England was the main funder for FLU-CIN (United Kingdom Influenza Clinical Information Network). The Scottish Government Chief Medical Officer and Public Health Directorate supported the centre in Scotland. Chairmanship of the FLU-CIN Strategy Group (that includes MGS, BB, JSN-V-T, WSL, PJMO, RCR, BLT, SJB, JMcM, JEE and KGN as members) was provided by the Department of Health, England. The FLU-CIN Strategy Group had final responsibility for the interpretation of findings and decision to submit for publication. The other funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; JSN-V-T has received funding to attend influenza related meetings, lecture and consultancy fees and research funding from several influenza antiviral drug and vaccine manufacturers (F. Hoffmann-La Roche, GlaxoSmithKline, Baxter AG, Novartis, Sanofi-Pasteur MSD, Astra-Zeneca). All forms of personal remuneration ceased in September 2010, but influenza-related research funding from GlaxoSmithKline, F. Hoffmann-La Roche and Astra-Zeneca remains current. He is a former employee of SmithKline Beecham plc (now GlaxoSmithKline), Roche Products Ltd, and Aventis-Pasteur MSD (now Sanofi-Pasteur MSD), all prior to 2005, with no outstanding pecuniary interests by way of shareholdings, share options or accrued pension rights. PRM holds an unrestricted educational grant from F. Hoffman-La Roche Ltd for research in the area of pandemic influenza. RCR has received funding for vaccine-related research from Novartis and travel funding from GlaxoSmithKline. WSL has received unrestricted funding from Pfizer (previously Wyeth) for research in the area of pneumonia. SJB has received consultancy fees from GlaxoSmithKline and Baxter. JEE has received consultancy fees from GlaxoSmithKline, and holds an unrestricted educational grant from Astra-Zeneca for influenza-related research. KGN has received H5 avian influenza vaccines from Novartis and H1N1 pandemic influenza vaccines from GlaxoSmithKline and to facilitate MRC and National Institute for Health Research-funded trials. He has received consultancy fees from Novartis and GlaxoSmithKline and lecture fees from Baxter AG. A colleague of KGN at the University Hospitals of Leicester Natioanl Health Service Trust was Principal Investigator and recipient of research funding from Roche on antiviral resistance and from Novartis on pandemic H1N1 vaccines. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. No aspect of the work described in this report was supported or enabled by commercial funding.; We gratefully acknowledge the teams who helped identify cases and collated clinical data: Alison Booth, Margaret Charlesworth, Sarah Rodenhurst, Angela Ballard and Alison Holmes at Imperial College Healthcare NHS Trust, London, UK; Sally Batham, Phayre Parkinson, Tracy Kumar and Aiden Dunphy at the University Hospitals of Leicester NHS Trust, Leicester, UK; Anne Tunbridge, Patty Hempsall, Joyce Linskill, Aimee Turner, Sharon Grindle, Dawn Shevlin and Eric Moulds at Sheffield University Hospitals NHS Trust, Sheffield, UK; Elvina White, Elaine Scott, Jennifer Cater, Erica Sergi and Helen Hill at Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, UK; Deborah Fleetwood, Lorna Roche, Sarah Dyas, and Maria Boswell at the Royal Liverpool and Broadgreen University Hospital's Trust, Liverpool, UK; Gillian Vernon, Gillian Houghton, Heather Longworth and Angela Kerrigan at Liverpool Women's Hospital, Liverpool, UK; Sonia Greenwood, Gemma Thompson, Emily Jarvis and Charlotte Minter at the Nottingham University Hospitals NHS Trust, Nottingham, UK; Kristina Lum Kin, Jacqueline Daglish, Sam Hayton, and Gemma Slinn at Birmingham Children's Hospital, Birmingham, UK; Michelle Lacey, Kevin Rooney, Karen Duffy, Anne Gordon, Eleanor Anderson, Hilary Davison, William Carman, Mark Cotton, Arlene Reynolds, Heather Murdoch, Karen Voy, Rosie Hague and Ali McAllister for their contribution to FLU-CIN in Scotland. Brian Smyth and Cathriona Kearns from the National Public Health Agency, Northern Ireland for identifying cases and facilitating data collection; Teresa Cunningham at the Southern Trust and Leslie Boydell at the Belfast Trust for facilitating data collection. Alemayehu Amberbir, Safaa Al-Badri, Baraa Mahgoob and Nachi Arunachalam at the University of Nottingham for data entry and obtaining background population data; also Graham Watson for database development and support; and Tom Bewick at the Nottingham University Hospitals NHS Trust, Nottingham, UK for manually reviewing the records to identify additional pneumonia cases. We also thank Professor Sir Gordon Duff, Co-Chair of the Scientific Advisory Group for Emergencies, Professor Janet Darbyshire, who Co-Chaired the Influenza Clinical Information Network Strategy Group and Elaine Gadd and Colin Armstrong at the Department of Health, London, UK for their support and constructive remarks; Dr Shona Kelly of the University of Nottingham (now at University of South Australia) for help in developing the initial data collection tool; and Dr Patrick O'Brien of University College London Hospitals NHS Foundation Trust for assistance in further developing the data set. We thank those Chief Executive Officers, clinicians, virologists and managers, too numerous to mention, who were active in notifying cases to FLU-CIN. SJB and PJMO wish to acknowledge the support of the UK NIHR Biomedical Research Centre scheme.	Centers for Disease Control and Prevention, SUMM INFL VACC REC; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Creanga AA, 2011, AM J OBSTET GYNECOL, V204, pS38, DOI 10.1016/j.ajog.2011.02.037; Creanga AA, 2010, OBSTET GYNECOL, V115, P717, DOI 10.1097/AOG.0b013e3181d57947; Department of Health. Launch of the national pandemic flu service, LAUNCH NAT PAND FLU; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Dodds L, 2007, CAN MED ASSOC J, V176, P463, DOI 10.1503/cmaj.061435; Donner B, 2010, DRUG SAFETY, V33, P631, DOI 10.2165/11536370-000000000-00000; European Medicines Agency, 2009, EMEAHA531172; Goodnight William H, 2005, Crit Care Med, V33, pS390, DOI 10.1097/01.CCM.0000182483.24836.66; Harris JW, 1919, J AMER MED ASSOC, V72, P978, DOI 10.1001/jama.1919.02610140008002; Health Protection Agency, 2011, PHARM TREATM PROPHYL; Hewagama S, 2010, CLIN INFECT DIS, V50, P686, DOI 10.1086/650460; Jamieson DJ, 2006, EMERG INFECT DIS, V12, P1638, DOI 10.3201/eid1211.060152; Jimenez MF, 2010, INT J GYNECOL OBSTET, V111, P217, DOI 10.1016/j.ijgo.2010.06.024; Louie JK, 2010, NEW ENGL J MED, V362, P27, DOI 10.1056/NEJMoa0910444; Maravi-Poma E, 2011, CRIT CARE MED, V39, P945, DOI 10.1097/CCM.0b013e318208ee12; Mosby LG, 2011, AM J OBSTET GYNECOL, V205, P10, DOI 10.1016/j.ajog.2010.12.033; Myles PR, 2012, THORAX, V67, P709, DOI 10.1136/thoraxjnl-2011-200266; Myles PR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034428; Newsome Kimberly, 2011, Morbidity and Mortality Weekly Report, V60, P1193; Nguyen-Van-Tam JS, 2010, THORAX, V65, P645, DOI 10.1136/thx.2010.135210; Nuzum JW, 1918, J AMER MED ASSOC, V71, P1562, DOI 10.1001/jama.1918.26020450009011a; Pierce M, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d3214; Rolland-Harris E, 2011, EPIDEMIOL INFECT, V16, P1; Schatz M, 2011, AM J OBSTET GYNECOL, V204, pS64, DOI 10.1016/j.ajog.2011.01.047; Seppelt I, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1279; Siston AM, 2010, JAMA-J AM MED ASSOC, V303, P1517, DOI 10.1001/jama.2010.479; Woolston WJ, 1918, J AMER MED ASSOC, V71, P1898, DOI 10.1001/jama.1918.02600490030008; Yu HJ, 2011, CLIN INFECT DIS, V52, P457, DOI 10.1093/cid/ciq144; Zaman K, 2008, NEW ENGL J MED, V359, P1555, DOI 10.1056/NEJMoa0708630	31	13	14	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 3	2012	7	8							e41638	10.1371/journal.pone.0041638	http://dx.doi.org/10.1371/journal.pone.0041638			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	985QT	22870239	Green Submitted, gold, Green Accepted, Green Published			2023-01-03	WOS:000307284100026
J	Uijen, AA; Heinst, CW; Schellevis, FG; van den Bosch, WJHM; van de Laar, FA; Terwee, CB; Schers, HJ				Uijen, Annemarie A.; Heinst, Claire W.; Schellevis, Francois G.; van den Bosch, Wil J. H. M.; van de Laar, Floris A.; Terwee, Caroline B.; Schers, Henk J.			Measurement Properties of Questionnaires Measuring Continuity of Care: A Systematic Review	PLOS ONE			English	Review							UPDATED METHOD GUIDELINES; SELF-REPORT MEASURE; CARDIAC PATIENTS; HEALTH OUTCOMES; CANCER CARE; VALIDATION; COORDINATION; PERCEPTIONS; QUALITY; RELIABILITY	Background: Continuity of care is widely acknowledged as a core value in family medicine. In this systematic review, we aimed to identify the instruments measuring continuity of care and to assess the quality of their measurement properties. Methods: We did a systematic review using the PubMed, Embase and PsycINFO databases, with an extensive search strategy including 'continuity of care', 'coordination of care', 'integration of care', 'patient centered care', 'case management' and its linguistic variations. We searched from 1995 to October 2011 and included articles describing the development and/or evaluation of the measurement properties of instruments measuring one or more dimensions of continuity of care (1) care from the same provider who knows and follows the patient (personal continuity), (2) communication and cooperation between care providers in one care setting (team continuity), and (3) communication and cooperation between care providers in different care settings (cross-boundary continuity). We assessed the methodological quality of the measurement properties of each instrument using the COSMIN checklist. Results: We included 24 articles describing the development and/or evaluation of 21 instruments. Ten instruments measured all three dimensions of continuity of care. Instruments were developed for different groups of patients or providers. For most instruments, three or four of the six measurement properties were assessed (mostly internal consistency, content validity, structural validity and construct validity). Six instruments scored positive on the quality of at least three of six measurement properties. Conclusions: Most included instruments have problems with either the number or quality of its assessed measurement properties or the ability to measure all three dimensions of continuity of care. Based on the results of this review, we recommend the use of one of the four most promising instruments, depending on the target population Diabetes Continuity of Care Questionnaire, Alberta Continuity of Services Scale-Mental Health, Heart Continuity of Care Questionnaire, and Nijmegen Continuity Questionnaire.	[Uijen, Annemarie A.; Heinst, Claire W.; van den Bosch, Wil J. H. M.; van de Laar, Floris A.; Schers, Henk J.] Radboud Univ Nijmegen, Med Ctr, Dept Primary & Community Care, NL-6525 ED Nijmegen, Netherlands; [Schellevis, Francois G.] Netherlands Inst Hlth Serv Res NIVEL, Utrecht, Netherlands; [Schellevis, Francois G.] Vrije Univ Amsterdam, Med Ctr, Dept Gen Practice, Amsterdam, Netherlands; [Schellevis, Francois G.; Terwee, Caroline B.] Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands; [Terwee, Caroline B.] Vrije Univ Amsterdam, Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands	Radboud University Nijmegen; Netherlands Institute for Health Services Research; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Uijen, AA (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Primary & Community Care, NL-6525 ED Nijmegen, Netherlands.	A.Uijen@elg.umcn.nl	Bosch, W.J.H.M./H-8016-2014; van de Laar, Floris/CAI-2875-2022; van de Laar, F.A./L-4467-2015; Uijen, A.A./L-4701-2015; Schers, H.J./L-4631-2015	van de Laar, Floris/0000-0001-7373-8864; Schers, H.J./0000-0002-9362-9451; Terwee, Caroline/0000-0003-4570-2826	Frans Huygen Stichting	Frans Huygen Stichting	The source of funding: Frans Huygen Stichting. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adair CE, 2005, PSYCHIAT SERV, V56, P1061, DOI 10.1176/appi.ps.56.9.1061; Adair CE, 2003, PSYCHIAT SERV, V54, P1351, DOI 10.1176/appi.ps.54.10.1351; Adair CE, 2004, CONTINUITY MENTAL HL; Ahgren Bengt, 2009, Int J Integr Care, V9, pe03; [Anonymous], 2002, HEALTH CARE; Bull M J, 2000, J Nurs Meas, V8, P41; Casparie AF, 1998, ONDERZOEKSPROGRAMMA; Dobrow Mark J, 2009, Healthc Policy, V5, P35; Dolovich LR, 2004, HEALTH SOC CARE COMM, V12, P475, DOI 10.1111/j.1365-2524.2004.00517.x; Durbin J, 2004, J BEHAV HEALTH SER R, V31, P279; Flocke SA, 1997, J FAM PRACTICE, V45, P64; Furlan AD, 2009, SPINE, V34, P1929, DOI 10.1097/BRS.0b013e3181b1c99f; Gulliford M, 2011, J HEALTH SERV RES PO, V16, P67, DOI 10.1258/jhsrp.2010.010015; Gulliford MC, 2006, ANN FAM MED, V4, P548, DOI 10.1370/afm.578; Hadjistavropoulos HD, 2004, CAN J CARDIOL, V20, P883; Hadjistavropoulos H, 2008, INT J QUAL HEALTH C, V20, P314, DOI 10.1093/intqhc/mzn030; Haggerty JL, 2003, BRIT MED J, V327, P1219, DOI 10.1136/bmj.327.7425.1219; Hanninen J, 2001, DIABETES RES CLIN PR, V51, P21, DOI 10.1016/S0168-8227(00)00198-4; Hess BJ, 2009, ACAD MED, V84, pS109, DOI 10.1097/ACM.0b013e3181b37ac7; Hudon C, 2011, ANN FAM MED, V9, P155, DOI 10.1370/afm.1226; Jee SH, 2006, MED CARE RES REV, V63, P158, DOI 10.1177/1077558705285294; Joyce AS, 2010, COMMUNITY MENT HLT J, V46, P192, DOI 10.1007/s10597-009-9215-6; King M, 2008, BRIT J CANCER, V98, P529, DOI 10.1038/sj.bjc.6604164; Kowalyk KM, 2004, CAN J CARDIOL, V20, P205; Lawrence M, 2012, HEALTH EXPECT, V15, P295, DOI 10.1111/j.1369-7625.2011.00683.x; McGuiness C, 2003, INT J QUAL HEALTH C, V15, P309, DOI 10.1093/intqhc/mzg043; Mead N, 2000, SOC SCI MED, V51, P1087, DOI 10.1016/S0277-9536(00)00098-8; Mokkink LB, 2010, J CLIN EPIDEMIOL, V63, P737, DOI 10.1016/j.jclinepi.2010.02.006; Mokkink LB, 2010, QUAL LIFE RES, V19, P539, DOI 10.1007/s11136-010-9606-8; Mokkink LB, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-22; Moore C, 2003, J GEN INTERN MED, V18, P646, DOI 10.1046/j.1525-1497.2003.20722.x; Rose D, 2009, ACTA PSYCHIAT SCAND, V119, P320, DOI 10.1111/j.1600-0447.2008.01296.x; Schaefer JA, 2004, J STUD ALCOHOL, V65, P513, DOI 10.15288/jsa.2004.65.513; Stange KC, 2009, ANN FAM MED, V7, P293, DOI 10.1370/afm.1023; Strandberg-Larsen Martin, 2009, Int J Integr Care, V9, pe01; Terwee CB, 2009, QUAL LIFE RES, V18, P1115, DOI 10.1007/s11136-009-9528-5; Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012; Terwee CB, 2011, QUAL LIFE RES; Uijen AA, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X652364; Uijen AA, 2012, FAM PRACT, V29, P264, DOI 10.1093/fampra/cmr104; Uijen AA, 2011, J CLIN EPIDEMIOL, V64, P1391, DOI 10.1016/j.jclinepi.2011.03.006; van Tulder M, 2003, SPINE, V28, P1290, DOI 10.1097/01.BRS.0000065484.95996.AF; Ware Norma C, 2003, Ment Health Serv Res, V5, P209, DOI 10.1023/A:1026276918081; Wei XL, 2008, J CLIN EPIDEMIOL, V61, P925, DOI 10.1016/j.jclinepi.2007.12.010; Young JM, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-298	45	62	63	4	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2012	7	7							e42256	10.1371/journal.pone.0042256	http://dx.doi.org/10.1371/journal.pone.0042256			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	982LS	22860100	gold, Green Published, Green Submitted			2023-01-03	WOS:000307045600082
J	Kreutz, M; Giquel, B; Hu, Q; Abuknesha, R; Uematsu, S; Akira, S; Nestle, FO; Diebold, SS				Kreutz, Martin; Giquel, Benoit; Hu, Qin; Abuknesha, Ram; Uematsu, Satoshi; Akira, Shizuo; Nestle, Frank O.; Diebold, Sandra S.			Antibody-Antigen-Adjuvant Conjugates Enable Co-Delivery of Antigen and Adjuvant to Dendritic Cells in Cis but Only Have Partial Targeting Specificity	PLOS ONE			English	Article							AIDED CROSS-PRESENTATION; IN-VIVO; RECEPTOR DEC-205; MURINE DC; RESPONSES; CPG; IMMUNITY; DNA; INDUCTION; OLIGONUCLEOTIDES	Antibody-antigen conjugates, which promote antigen-presentation by dendritic cells (DC) by means of targeted delivery of antigen to particular DC subsets, represent a powerful vaccination approach. To ensure immunity rather than tolerance induction the co-administration of a suitable adjuvant is paramount. However, co-administration of unlinked adjuvant cannot ensure that all cells targeted by the antibody conjugates are appropriately activated. Furthermore, antigen-presenting cells (APC) that do not present the desired antigen are equally strongly activated and could prime undesired responses against self-antigens. We, therefore, were interested in exploring targeted co-delivery of antigen and adjuvant in cis in form of antibody-antigen-adjuvant conjugates for the induction of anti-tumour immunity. In this study, we report on the assembly and characterization of conjugates consisting of DEC205-specific antibody, the model antigen ovalbumin (OVA) and CpG oligodeoxynucleotides (ODN). We show that such conjugates are more potent at inducing cytotoxic T lymphocyte (CTL) responses than control conjugates mixed with soluble CpG. However, our study also reveals that the nucleic acid moiety of such antibody-antigen-adjuvant conjugates alters their binding and uptake and allows delivery of the antigen and the adjuvant to cells partially independently of DEC205. Nevertheless, antibody-antigen-adjuvant conjugates are superior to antibody-free antigen-adjuvant conjugates in priming CTL responses and efficiently induce anti-tumour immunity in the murine B16 pseudo-metastasis model. A better understanding of the role of the antibody moiety is required to inform future conjugate vaccination strategies for efficient induction of anti-tumour responses.	[Kreutz, Martin; Giquel, Benoit; Hu, Qin; Diebold, Sandra S.] Kings Coll London, Peter Gorer Dept Immunobiol, Guys Hosp, London WC2R 2LS, England; [Kreutz, Martin] Radboud Univ Nijmegen, Med Ctr, Dept Tumor Immunol, Nijmegen Ctr Mol Life Sci, NL-6525 ED Nijmegen, Netherlands; [Abuknesha, Ram] Kings Coll London, Div Pharmaceut Sci, London WC2R 2LS, England; [Uematsu, Satoshi; Akira, Shizuo] Osaka Univ, Host Def Lab, WPI Immunol Frontier Res Ctr, Osaka, Japan; [Nestle, Frank O.] Kings Coll London, Cutaneous Med & Immunotherapy Unit, Guys Hosp, London WC2R 2LS, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Radboud University Nijmegen; University of London; King's College London; Osaka University; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Kreutz, M (corresponding author), Kings Coll London, Peter Gorer Dept Immunobiol, Guys Hosp, London WC2R 2LS, England.	sandra.diebold@kcl.ac.uk	Akira, Shizuo/C-3134-2009		Cancer Research UK Career Development Award; Cancer Research UK China Fellowship; Medical Research Council; King's College London; Medical Research Council [MR/J006742/1, G0600698B] Funding Source: researchfish	Cancer Research UK Career Development Award(Cancer Research UK); Cancer Research UK China Fellowship(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); King's College London(General Electric); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was funded by a Cancer Research UK Career Development Award to Sandra Diebold, which also supported Benoit Giquel. Qin Hu received a Cancer Research UK China Fellowship and Martin Kreutz was jointly funded by a Ph.D. studentship from the Medical Research Council and King's College London. No additional external funding was received for this study. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1989, CANC METASTASIS REV, V8, P82; Baenziger S, 2009, BLOOD, V113, P377, DOI 10.1182/blood-2008-04-151712; Blander JM, 2006, NATURE, V440, P808, DOI 10.1038/nature04596; Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598; Bonifaz LC, 2004, J EXP MED, V199, P815, DOI 10.1084/jem.20032220; Bozzacco L, 2010, EUR J IMMUNOL, V40, P36, DOI 10.1002/eji.200939748; Burgdorf S, 2008, NAT IMMUNOL, V9, P558, DOI 10.1038/ni.1601; Burgdorf S, 2006, J IMMUNOL, V176, P6770, DOI 10.4049/jimmunol.176.11.6770; Caminschi I, 2008, BLOOD, V112, P3264, DOI 10.1182/blood-2008-05-155176; Caminschi I, 2009, EUR J IMMUNOL, V39, P931, DOI 10.1002/eji.200839035; Carter RW, 2006, J IMMUNOL, V177, P2276, DOI 10.4049/jimmunol.177.4.2276; Carter RW, 2006, CELL IMMUNOL, V239, P87, DOI 10.1016/j.cellimm.2006.05.001; Cho HJ, 2000, NAT BIOTECHNOL, V18, P509, DOI 10.1038/75365; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cruz LJ, 2010, J CONTROL RELEASE, V144, P118, DOI 10.1016/j.jconrel.2010.02.013; Demangel C, 2005, MOL IMMUNOL, V42, P979, DOI 10.1016/j.molimm.2004.09.034; Diebold SS, 2008, IMMUNOL CELL BIOL, V86, P389, DOI 10.1038/icb.2008.26; Dudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080; Edwards AD, 2003, EUR J IMMUNOL, V33, P827, DOI 10.1002/eji.200323797; Poulin LF, 2010, J EXP MED, V207, P1261, DOI 10.1084/jem.20092618; Gunzer M, 2005, BLOOD, V106, P2424, DOI 10.1182/blood-2005-01-0342; Gurer C, 2008, BLOOD, V112, P1231, DOI 10.1182/blood-2008-03-148072; Hawiger D, 2001, J EXP MED, V194, P769, DOI 10.1084/jem.194.6.769; Heikenwalder M, 2004, NAT MED, V10, P187, DOI 10.1038/nm987; Heit A, 2003, J IMMUNOL, V170, P2802, DOI 10.4049/jimmunol.170.6.2802; Idoyaga J, 2011, P NATL ACAD SCI USA, V108, P2384, DOI 10.1073/pnas.1019547108; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; Johnson TS, 2008, CLIN CANCER RES, V14, P8169, DOI 10.1158/1078-0432.CCR-08-1474; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Kamphorst AO, 2010, J IMMUNOL, V185, P3426, DOI 10.4049/jimmunol.1001205; Kanzler H, 2007, NAT MED, V13, P552, DOI 10.1038/nm1589; KIMURA Y, 1994, J BIOCHEM-TOKYO, V116, P991, DOI 10.1093/oxfordjournals.jbchem.a124658; Mahnke K, 2005, CANCER RES, V65, P7007, DOI 10.1158/0008-5472.CAN-05-0938; Maurer T, 2002, EUR J IMMUNOL, V32, P2356, DOI 10.1002/1521-4141(200208)32:8<2356::AID-IMMU2356>3.0.CO;2-Z; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rajagopal D, 2010, BLOOD, V115, P1949, DOI 10.1182/blood-2009-08-238543; Roberts TL, 2005, J IMMUNOL, V174, P605, DOI 10.4049/jimmunol.174.2.605; Sancho D, 2008, J CLIN INVEST, V118, P2098, DOI 10.1172/JCI34584; Tacken PJ, 2011, BLOOD, V118, P6836, DOI 10.1182/blood-2011-07-367615; Tirapu I, 2009, INT IMMUNOL, V21, P871, DOI 10.1093/intimm/dxp053; Trumpfheller C, 2008, P NATL ACAD SCI USA, V105, P2574, DOI 10.1073/pnas.0711976105; van Broekhoven CL, 2004, CANCER RES, V64, P4357, DOI 10.1158/0008-5472.CAN-04-0138; Waibler Z, 2008, EUR J IMMUNOL, V38, P3127, DOI 10.1002/eji.200838184; Wang B, 2009, ANN NY ACAD SCI, V1174, P6, DOI 10.1111/j.1749-6632.2009.04933.x; Wang H, 2000, P NATL ACAD SCI USA, V97, P847, DOI 10.1073/pnas.97.2.847; Wilson NS, 2003, BLOOD, V102, P2187, DOI 10.1182/blood-2003-02-0513; Zhu FG, 2001, IMMUNOLOGY, V103, P226, DOI 10.1046/j.1365-2567.2001.01222.x	47	50	53	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2012	7	7							e40208	10.1371/journal.pone.0040208	http://dx.doi.org/10.1371/journal.pone.0040208			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973JD	22808118	Green Published, Green Submitted, gold			2023-01-03	WOS:000306355500031
J	Camara, D; Bisanz, C; Barette, C; Van Daele, J; Human, E; Barnard, B; Van Der Straeten, D; Stove, CP; Lambert, WE; Douce, R; Marechal, E; Birkholtz, LM; Cesbron-Delauw, MF; Dumas, R; Rebeille, F				Camara, Djeneb; Bisanz, Cordelia; Barette, Caroline; Van Daele, Jeroen; Human, Esmare; Barnard, Bernice; Van Der Straeten, Dominique; Stove, Christophe P.; Lambert, Willy E.; Douce, Roland; Marechal, Eric; Birkholtz, Lyn-Marie; Cesbron-Delauw, Marie-France; Dumas, Renaud; Rebeille, Fabrice			Inhibition of p-Aminobenzoate and Folate Syntheses in Plants and Apicomplexan Parasites by Natural Product Rubreserine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO SYNTHESIS; ANTHRANILATE SYNTHASE; TOXOPLASMA-GONDII; 4-AMINO-4-DEOXYCHORISMATE SYNTHASE; AMINODEOXYCHORISMATE SYNTHASE; ISOCHORISMATE SYNTHASE; PLASMODIUM-FALCIPARUM; GLUCOSE ESTER; METABOLISM; BIOSYNTHESIS	Glutamine amidotransferase/aminodeoxychorismate synthase (GAT-ADCS) is a bifunctional enzyme involved in the synthesis of p-aminobenzoate, a central component part of folate cofactors. GAT-ADCS is found in eukaryotic organisms autonomous for folate biosynthesis, such as plants or parasites of the phylum Apicomplexa. Based on an automated screening to search for new inhibitors of folate biosynthesis, we found that rubreserine was able to inhibit the glutamine amidotransferase activity of the plant GAT-ADCS with an apparent IC50 of about 8 mu M. The growth rates of Arabidopsis thaliana, Toxoplasma gondii, and Plasmodium falciparum were inhibited by rubreserine with respective IC50 values of 65, 20, and 1 mu M. The correlation between folate biosynthesis and growth inhibition was studied with Arabidopsis and Toxoplasma. In both organisms, the folate content was decreased by 40-50% in the presence of rubreserine. In both organisms, the addition of p-aminobenzoate or 5-formyltetrahydrofolate in the external medium restored the growth for inhibitor concentrations up to the IC50 value, indicating that, within this range of concentrations, rubreserine was specific for folate biosynthesis. Rubreserine appeared to be more efficient than sulfonamides, antifolate drugs known to inhibit the invasion and proliferation of T. gondii in human fibroblasts. Altogether, these results validate the use of the bifunctional GAT-ADCS as an efficient drug target in eukaryotic cells and indicate that the chemical structure of rubreserine presents interesting anti-parasitic (toxoplasmosis, malaria) potential.	[Rebeille, Fabrice] Univ Grenoble 1, PCV iRTSV,Inst Rech Technol & Sci Vivant, CEA Grenoble,CNRS UMR5168,INRA USC1200, Lab Physiol Cellulaire Vegetale,Commissariat Ener, F-38054 Grenoble, France; [Bisanz, Cordelia; Cesbron-Delauw, Marie-France] Univ Grenoble 1, CNRS UMR 5163, Lab Adaptat & Pathogenie Microorganismes, Inst Jean Roget, F-38042 Grenoble, France; [Barette, Caroline] Commissariat Energie Atom Grenoble, Inst Rech Technol & Sci Vivant, Ctr Criblage Mol Bioact, F-38054 Grenoble, France; [Van Daele, Jeroen; Stove, Christophe P.; Lambert, Willy E.] Univ Ghent, Toxicol Lab, B-9000 Ghent, Belgium; [Human, Esmare; Barnard, Bernice; Birkholtz, Lyn-Marie] Univ Pretoria, Dept Biochem, Malaria Res Grp, ZA-0028 Pretoria, South Africa; [Van Der Straeten, Dominique] Univ Ghent, Lab Funct Plant Biol, Dept Physiol, B-9000 Ghent, Belgium	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Ghent University; University of Pretoria; Ghent University	Rebeille, F (corresponding author), Univ Grenoble 1, PCV iRTSV,Inst Rech Technol & Sci Vivant, CEA Grenoble,CNRS UMR5168,INRA USC1200, Lab Physiol Cellulaire Vegetale,Commissariat Ener, 17 Ave Martyrs, F-38054 Grenoble, France.	frebeille@cea.fr	Stove, Christophe/B-6057-2008; Bisanz, Cordelia/M-6063-2014; Birkholtz, Lyn-Marie/AAF-8481-2019; Dumas, Renaud/E-1835-2011; Van Der Straeten, Dominique/E-7385-2016; Birkholtz, Lyn-Marie/E-2939-2010; cesbron delauw, marie france/M-6076-2014	Stove, Christophe/0000-0001-7126-348X; Birkholtz, Lyn-Marie/0000-0001-5888-2905; Van Der Straeten, Dominique/0000-0002-7755-1420; Birkholtz, Lyn-Marie/0000-0001-5888-2905; BARETTE, Caroline/0000-0003-0999-7751	Region Rhone-Alpes; Ghent University [BOF09-GOA-004]; Agence Nationale de la Recherche PlasmoExpress grant	Region Rhone-Alpes(Region Auvergne-Rhone-Alpes); Ghent University(Ghent University); Agence Nationale de la Recherche PlasmoExpress grant(French National Research Agency (ANR))	This work was supported in part the Region Rhone-Alpes (Cluster 9, "Plantacter").; Supported by Ghent University Grant BOF09-GOA-004.; Supported by an Agence Nationale de la Recherche PlasmoExpress grant.	Allen RJW, 2010, MOL BIOCHEM PARASIT, V169, P63, DOI 10.1016/j.molbiopara.2009.09.005; Basset GJC, 2004, P NATL ACAD SCI USA, V101, P1496, DOI 10.1073/pnas.0308331100; Bennett TN, 2004, ANTIMICROB AGENTS CH, V48, P1807, DOI 10.1128/AAC.48.5.1807-1810.2004; Bertino JR, 2009, BEST PRACT RES CL HA, V22, P577, DOI 10.1016/j.beha.2009.09.004; Bhat JY, 2008, BIOCHEM J, V409, P263, DOI 10.1042/BJ20070996; Bisanz C, 2006, BIOCHEM J, V394, P197, DOI 10.1042/BJ20050609; Blancquaert D, 2010, CRIT REV PLANT SCI, V29, P14, DOI 10.1080/07352680903436283; Bulloch EMM, 2004, J AM CHEM SOC, V126, P9912, DOI 10.1021/ja048312f; Camara D, 2011, ARCH BIOCHEM BIOPHYS, V505, P83, DOI 10.1016/j.abb.2010.09.010; De Brouwer V, 2007, PHYTOCHEM ANALYSIS, V18, P496, DOI 10.1002/pca.1006; De Brouwer V, 2010, J CHROMATOGR B, V878, P509, DOI 10.1016/j.jchromb.2009.12.032; de La Garza RID, 2007, P NATL ACAD SCI USA, V104, P4218, DOI 10.1073/pnas.0700409104; Dixon S, 2006, J MED CHEM, V49, P7413, DOI 10.1021/jm0609869; Ellis S, 1943, J PHARMACOL EXP THER, V79, P309; Eudes A, 2008, J BIOL CHEM, V283, P15451, DOI 10.1074/jbc.M709591200; Fox BA, 2002, NATURE, V415, P926, DOI 10.1038/415926a; Hyde JE, 2005, ACTA TROP, V94, P191, DOI 10.1016/j.actatropica.2005.04.002; Kaur K, 2009, BIOORGAN MED CHEM, V17, P3229, DOI 10.1016/j.bmc.2009.02.050; Keller S, 2007, ANGEW CHEM INT EDIT, V46, P8284, DOI 10.1002/anie.200701836; Kerbarh O, 2005, BIOCHEM SOC T, V33, P763, DOI 10.1042/BST0330763; KOZLOWSKI MC, 1995, J AM CHEM SOC, V117, P2128, DOI 10.1021/ja00113a002; Loizeau K, 2008, PLANT PHYSIOL, V148, P2083, DOI 10.1104/pp.108.130336; Massiere F, 1998, CELL MOL LIFE SCI, V54, P205, DOI 10.1007/s000180050145; Meneceur P, 2008, ANTIMICROB AGENTS CH, V52, P1269, DOI 10.1128/AAC.01203-07; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAKAMURA J, 1995, J BIOL CHEM, V270, P23450, DOI 10.1074/jbc.270.40.23450; Nzila A, 2005, TRENDS PARASITOL, V21, P334, DOI 10.1016/j.pt.2005.05.008; Nzila A, 2006, DRUG DISCOV TODAY, V11, P939, DOI 10.1016/j.drudis.2006.08.003; Orsomando G, 2006, PLANT J, V46, P426, DOI 10.1111/j.1365-313X.2006.02685.x; Payne RJ, 2010, ORG BIOMOL CHEM, V8, P3534, DOI 10.1039/c004062b; Payne RJ, 2009, ORG BIOMOL CHEM, V7, P2421, DOI 10.1039/b901694e; Poobrasert O, 1996, J NAT PROD, V59, P1087, DOI 10.1021/np960518+; Quinlivan EP, 2003, J BIOL CHEM, V278, P20731, DOI 10.1074/jbc.M302894200; Rattanachuen W, 2009, MOL BIOCHEM PARASIT, V168, P135, DOI 10.1016/j.molbiopara.2009.07.005; Ravanel S, 2011, ADV BOT RES, V59, P67, DOI 10.1016/B978-0-12-385853-5.00004-0; Rebeille F, 2006, PHYSIOL PLANTARUM, V126, P330, DOI 10.1111/j.1399-3054.2006.00587.x; Rebeille F, 2007, PHOTOSYNTH RES, V92, P149, DOI 10.1007/s11120-007-9167-z; Riedlinger J, 2004, J ANTIBIOT, V57, P271, DOI 10.7164/antibiotics.57.271; Roberts CW, 2002, J INFECT DIS, V185, pS25, DOI 10.1086/338004; ROBINSON B, 1965, J PHARM PHARMACOL, V17, P89, DOI 10.1111/j.2042-7158.1965.tb07619.x; ROUX B, 1992, BIOCHEMISTRY-US, V31, P6904, DOI 10.1021/bi00145a006; Sahr T, 2006, BIOCHEM J, V396, P157, DOI 10.1042/BJ20051851; Salcedo-Sora JE, 2011, J BIOL CHEM, V286, P44659, DOI 10.1074/jbc.M111.286054; Schroder M, 2005, PLANT PHYSIOL, V138, P1926, DOI 10.1104/pp.105.063693; Segel I.H, 1975, ENZYME KINETICS; SIBLEY LD, 1994, P NATL ACAD SCI USA, V91, P5508, DOI 10.1073/pnas.91.12.5508; Siehl DL, 1999, BOOK SOIL P, P171; Smilkstein M, 2004, ANTIMICROB AGENTS CH, V48, P1803, DOI 10.1128/AAC.48.5.1803-1806.2004; Storozhenko S, 2007, NAT BIOTECHNOL, V25, P1277, DOI 10.1038/nbt1351; Wang P, 2004, MOL MICROBIOL, V51, P1425, DOI 10.1111/j.1365-2958.2003.03915.x; Wang P, 2010, MOL BIOCHEM PARASIT, V172, P41, DOI 10.1016/j.molbiopara.2010.03.012; YANG ST, 1987, J PHARMACEUT BIOMED, V5, P383, DOI 10.1016/0731-7085(87)80045-6; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203; Zhang GF, 2005, RAPID COMMUN MASS SP, V19, P963, DOI 10.1002/rcm.1878; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206; Zhang XH, 2001, PLANT PHYSIOL, V127, P131, DOI 10.1104/pp.127.1.131; Ziebart KT, 2010, J MED CHEM, V53, P3718, DOI 10.1021/jm100158v; Ziebart KT, 2010, BIOCHEMISTRY-US, V49, P2851, DOI 10.1021/bi100021x	58	17	17	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2012	287	26					22367	22376		10.1074/jbc.M112.365833	http://dx.doi.org/10.1074/jbc.M112.365833			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	974GH	22577137	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000306418600073
J	Perrone, J; Nelson, LS				Perrone, Jeanmarie; Nelson, Lewis S.			Medication Reconciliation for Controlled Substances - An "Ideal" Prescription-Drug Monitoring Program	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Perrone, Jeanmarie] Univ Penn, Dept Emergency Med, Div Med Toxicol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Nelson, Lewis S.] NYU, Sch Med, Dept Emergency Med, New York, NY USA	University of Pennsylvania; Pennsylvania Medicine; New York University	Perrone, J (corresponding author), Univ Penn, Dept Emergency Med, Div Med Toxicol, Perelman Sch Med, Philadelphia, PA 19104 USA.			Nelson, Lewis/0000-0001-9551-3922				Centers for Disease Control and Prevention (CDC), 2012, MMWR MORB MORTAL WKL, V61, P10; Feldman Lance, 2011, J Pain Palliat Care Pharmacother, V25, P313, DOI 10.3109/15360288.2011.606292; Office of National Drug Control Policy US Executive Office of the President, 2011, EP RESP AM PRESCR DR; Paulozzi LJ, 2012, PAIN MED, V13, P87, DOI 10.1111/j.1526-4637.2011.01260.x	4	66	66	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 21	2012	366	25					2341	2343		10.1056/NEJMp1204493	http://dx.doi.org/10.1056/NEJMp1204493			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	961GH	22646509				2023-01-03	WOS:000305451700003
J	Roecklein, KA; Schumacher, JA; Miller, MA; Ernecoff, NC				Roecklein, Kathryn A.; Schumacher, Julie A.; Miller, Megan A.; Ernecoff, Natalie C.			Cognitive and Behavioral Predictors of Light Therapy Use	PLOS ONE			English	Article							SEASONAL AFFECTIVE-DISORDER; ACUTE-PHASE TREATMENT; DEPRESSION OUTCOMES; REUPTAKE INHIBITORS; MAJOR DEPRESSION; MOOD DISORDERS; BRIGHT-LIGHT; METAANALYSIS; HOMEWORK; ADHERENCE	Objective: Although light therapy is effective in the treatment of seasonal affective disorder (SAD) and other mood disorders, only 53-79% of individuals with SAD meet remission criteria after light therapy. Perhaps more importantly, only 12-41% of individuals with SAD continue to use the treatment even after a previous winter of successful treatment. Method: Participants completed surveys regarding (1) social, cognitive, and behavioral variables used to evaluate treatment adherence for other health-related issues, expectations and credibility of light therapy, (2) a depression symptoms scale, and (3) self-reported light therapy use. Results: Individuals age 18 or older responded (n = 40), all reporting having been diagnosed with a mood disorder for which light therapy is indicated. Social support and self-efficacy scores were predictive of light therapy use (p's<.05). Conclusion: The findings suggest that testing social support and self-efficacy in a diagnosed patient population may identify factors related to the decision to use light therapy. Treatments that impact social support and self-efficacy may improve treatment response to light therapy in SAD.	[Roecklein, Kathryn A.; Miller, Megan A.; Ernecoff, Natalie C.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA; [Schumacher, Julie A.] Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, Jackson, MS 39216 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Mississippi; University of Mississippi Medical Center	Roecklein, KA (corresponding author), Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA.	kroeck@pitt.edu	Roecklein, Kathryn A./G-2942-2014		NCATS NIH HHS [UL1 TR000005] Funding Source: Medline; NCRR NIH HHS [UL1 RR024153] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024153] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Abraham C, 1998, PSYCHOL HEALTH, V13, P569, DOI 10.1080/08870449808407420; Aloia Mark S, 2007, Behav Sleep Med, V5, P89; Austin JT, 1996, PSYCHOL BULL, V120, P338, DOI 10.1037/0033-2909.120.3.338; Bandura A, 1997, AM J HEALTH PROMOT, V12, P8, DOI 10.4278/0890-1171-12.1.8; Baundra A, 1986, SOCIAL FDN THOUGHT A; BORKOVEC TD, 1972, J BEHAV THER EXP PSY, V3, P257, DOI 10.1016/0005-7916(72)90045-6; BURNS DD, 1987, BEHAV RES THER, V25, P223, DOI 10.1016/0005-7967(87)90049-0; BURNS DD, 1991, J CONSULT CLIN PSYCH, V59, P305, DOI 10.1037/0022-006X.59.2.305; Claxton AJ, 2001, CLIN THER, V23, P1296, DOI 10.1016/S0149-2918(01)80109-0; Conner M, 1996, APPETITE, V27, P135, DOI 10.1006/appe.1996.0041; DiClemente C.C., 2002, MOTIVATIONAL INTERVI, V2nd ed., P201; DiMatteo MR, 2000, ARCH INTERN MED, V160, P2101, DOI 10.1001/archinte.160.14.2101; Fishbein M, 2001, HANDBOOK OF HEALTH PSYCHOLOGY, P3; Flory R, 2010, PSYCHIAT RES, V177, P101, DOI 10.1016/j.psychres.2008.08.011; Golden RN, 2005, AM J PSYCHIAT, V162, P656, DOI 10.1176/appi.ajp.162.4.656; Gyurcsik NC, 2011, J HEALTH PSYCHOL, V16, P530, DOI 10.1177/1359105310394229; Lam RW, 2010, INT CLIN PSYCHOPHARM, V25, P199, DOI 10.1097/YIC.0b013e32833948d8; Lundahl BW, 2010, RES SOCIAL WORK PRAC, V20, P137, DOI 10.1177/1049731509347850; Maddux JE, 1996, EXPECTANCIES SHAPE B, P17; MARCUS BH, 1992, HEALTH PSYCHOL, V11, P386, DOI 10.1037/0278-6133.11.6.386; MARCUS BH, 1992, RES Q EXERCISE SPORT, V63, P60, DOI 10.1080/02701367.1992.10607557; Mausbach BT, 2010, COGNITIVE THER RES, V34, P429, DOI 10.1007/s10608-010-9297-z; Michalak EE, 2002, J AFFECT DISORDERS, V68, P341, DOI 10.1016/S0165-0327(00)00320-7; Michalak EE, 2007, PSYCHIAT RES, V149, P315, DOI 10.1016/j.psychres.2006.05.005; Murray G., 2001, SEASONAL AFFECTIVE D, P55; Neimeyer Robert A., 2008, Cognitive Behaviour Therapy, V37, P199, DOI 10.1080/16506070801981240; Pail G, 2011, NEUROPSYCHOBIOLOGY, V64, P152, DOI 10.1159/000328950; Prochaska J. O., 2018, SYSTEMS PSYCHOTHERAP, V9th; PROCHASKA JO, 1988, J CONSULT CLIN PSYCH, V56, P520, DOI 10.1037/0022-006X.56.4.520; Prochaska JO, 1997, HLTH BEHAV HLTH ED T, P60; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rohan KJ, 2009, BEHAV THER, V40, P225, DOI 10.1016/j.beth.2008.06.004; Schwartz PJ, 1996, AM J PSYCHIAT, V153, P1028; Sheeran P, 2003, PERS SOC PSYCHOL B, V29, P205, DOI 10.1177/0146167202239046; Sheeran P.., 2002, EUR REV SOC PSYCHOL, V12, P1, DOI [10.1080/14792772143000003, DOI 10.1080/14792772143000003]; Sirey JA, 2010, AM J GERIAT PSYCHIAT, V18, P554, DOI 10.1097/JGP.0b013e3181cdeb7d; Stepnowsky Carl J Jr, 2002, Sleep Med, V3, P239, DOI 10.1016/S1389-9457(01)00162-9; TERMAN M, 1989, NEUROPSYCHOPHARMACOL, V2, P1, DOI 10.1016/0893-133X(89)90002-X; Thase ME, 2010, INT CLIN PSYCHOPHARM, V25, P189, DOI 10.1097/YIC.0b013e328330adb2; Tuunainen A, 2004, LIGHT THERAPY NONSEA; Watanabe N, 2008, J CLIN PSYCHIAT, V69, P1404, DOI 10.4088/JCP.v69n0908; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; Wilson GT, 2004, CLIN PSYCHOL REV, V24, P361, DOI 10.1016/j.cpr.2004.03.003; WORTHINGTON EL, 1986, J COUNS PSYCHOL, V33, P124; Yovel I, 2007, COGNITIVE THER RES, V31, P385, DOI 10.1007/s10608-006-9065-2	45	6	6	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2012	7	6							e39275	10.1371/journal.pone.0039275	http://dx.doi.org/10.1371/journal.pone.0039275			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	959UV	22720089	gold, Green Published			2023-01-03	WOS:000305341900093
J	Fountzilas, G; Dafni, U; Bobos, M; Batistatou, A; Kotoula, V; Trihia, H; Malamou-Mitsi, V; Miliaras, S; Chrisafi, S; Papadopoulos, S; Sotiropoulou, M; Filippidis, T; Gogas, H; Koletsa, T; Bafaloukos, D; Televantou, D; Kalogeras, KT; Pectasides, D; Skarlos, DV; Koutras, A; Dimopoulos, MA				Fountzilas, George; Dafni, Urania; Bobos, Mattheos; Batistatou, Anna; Kotoula, Vassiliki; Trihia, Helen; Malamou-Mitsi, Vassiliki; Miliaras, Spyros; Chrisafi, Sofia; Papadopoulos, Savvas; Sotiropoulou, Maria; Filippidis, Theodoros; Gogas, Helen; Koletsa, Triantafyllia; Bafaloukos, Dimitrios; Televantou, Despina; Kalogeras, Konstantine T.; Pectasides, Dimitrios; Skarlos, Dimosthenis V.; Koutras, Angelos; Dimopoulos, Meletios A.			Differential Response of Immunohistochemically Defined Breast Cancer Subtypes to Anthracycline-Based Adjuvant Chemotherapy with or without Paclitaxel	PLOS ONE			English	Article							RANDOMIZED PHASE-III; DENSE SEQUENTIAL CHEMOTHERAPY; PROTEIN EXPRESSION; NEOADJUVANT CHEMOTHERAPY; TISSUE MICROARRAYS; PROGNOSTIC VALUE; DOCETAXEL; RISK; EPIRUBICIN; SURVIVAL	Background: The aim of the present study was to investigate the efficacy of adjuvant dose-dense sequential chemotherapy with epirubicin, paclitaxel, and CMF in subgroups of patients with high-risk operable breast cancer, according to tumor subtypes defined by immunohistochemistry (IHC). Materials and Methods: Formalin-fixed paraffin-embedded (FFPE) tumor tissue samples from 1,039 patients participating in two adjuvant dose-dense sequential chemotherapy phase III trials were centrally assessed in tissue micro-arrays by IHC for 6 biological markers, that is, estrogen receptor (ER), progesterone receptor (PgR), HER2, Ki67, cytokeratin 5 (CK5), and EGFR. The majority of the cases were further evaluated for HER2 amplification by FISH. Patients were classified as: luminal A (ER/PgR-positive, HER2-negative, Ki67(low)); luminal B (ER/PgR-positive, HER2-negative, Ki67(high)); luminal-HER2 (ER/PgR-positive, HER2-positive); HER2-enriched (ER-negative, PgR-negative, HER2-positive); triple-negative (TNBC) (ER-negative, PgR-negative, HER2-negative); and basal core phenotype (BCP) (TNBC, CK5-positive and/or EGFR-positive). Results: After a median follow-up time of 105.4 months the 5-year disease-free survival (DFS) and overall survival (OS) rates were 73.1% and 86.1%, respectively. Among patients with HER2-enriched tumors there was a significant benefit in both DFS and OS (log-rank test; p = 0.021 and p = 0.006, respectively) for those treated with paclitaxel. The subtype classification was found to be of both predictive and prognostic value. Setting luminal A as the referent category, the adjusted for prognostic factors HR for relapse for patients with TNBC was 1.91 (95% CI: 1.31-2.80, Wald's p = 0.001) and for death 2.53 (95% CI: 1.62-3.60, p, 0.001). Site of and time to first relapse differed according to subtype. Locoregional relapses and brain metastases were more frequent in patients with TNBC, while liver metastases were more often seen in patients with HER2-enriched tumors. Conclusions: Triple-negative phenotype is of adverse prognostic value for DFS and OS in patients treated with adjuvant dose-dense sequential chemotherapy. In the pre-trastuzumab era, the HER2-enriched subtype predicts favorable outcome following paclitaxel-containing treatment.	[Fountzilas, George] Aristotle Univ Thessaloniki, Sch Med, Dept Med Oncol, Papageorgiou Hosp, GR-54006 Thessaloniki, Greece; [Dafni, Urania] Univ Athens, Sch Nursing, Lab Biostat, Athens, Greece; [Bobos, Mattheos; Chrisafi, Sofia; Televantou, Despina] Aristotle Univ Thessaloniki, Mol Oncol Lab, Hellen Fdn Canc Res, Sch Med, GR-54006 Thessaloniki, Greece; [Batistatou, Anna; Malamou-Mitsi, Vassiliki] Ioannina Univ Hosp, Dept Pathol, Ioannina, Greece; [Kotoula, Vassiliki; Koletsa, Triantafyllia] Aristotle Univ Thessaloniki, Sch Med, Dept Pathol, GR-54006 Thessaloniki, Greece; [Trihia, Helen] Metaxas Canc Hosp, Dept Pathol, Piraeus, Greece; [Miliaras, Spyros] Aristotle Univ Thessaloniki, Sch Med, Dept Surg 1, Papageorgiou Hosp, GR-54006 Thessaloniki, Greece; [Papadopoulos, Savvas] Hygeia Hosp, Dept Pathol, Athens, Greece; [Sotiropoulou, Maria] Alexandra Hosp, Dept Pathol, Athens, Greece; [Filippidis, Theodoros] Micromed Histopathol Lab, Athens, Greece; [Gogas, Helen] Univ Athens, Sch Med, Dept Med 1, Laiko Gen Hosp, GR-11527 Athens, Greece; [Bafaloukos, Dimitrios] Metropolitan Hosp, Dept Med Oncol 1, Piraeus, Greece; [Kalogeras, Konstantine T.] Data Off, Hellen Cooperat Oncol Grp, Translat Res Sect, Athens, Greece; [Pectasides, Dimitrios] Hippokrateion Hosp, Dept Internal Med 2, Oncol Sect, Athens, Greece; [Skarlos, Dimosthenis V.] Metropolitan Hosp, Dept Med Oncol 2, Piraeus, Greece; [Koutras, Angelos] Univ Patras, Sch Med, Univ Hosp, Div Oncol,Dept Med, GR-26110 Patras, Greece; [Dimopoulos, Meletios A.] Univ Athens, Sch Med, Alexandra Hosp, Dept Clin Therapeut, GR-11527 Athens, Greece	Aristotle University of Thessaloniki; Papageorgiou Hospital; National & Kapodistrian University of Athens; Aristotle University of Thessaloniki; University Hospital Ioannina; Aristotle University of Thessaloniki; Aristotle University of Thessaloniki; Papageorgiou Hospital; Hygeia Hospital; Alexandra Hospital; Athens Medical School; Laiko General Hospital; National & Kapodistrian University of Athens; Hellenic Cooperative Oncology Group; Hippokration General Hospital; University of Patras; Alexandra Hospital; Athens Medical School; National & Kapodistrian University of Athens	Fountzilas, G (corresponding author), Aristotle Univ Thessaloniki, Sch Med, Dept Med Oncol, Papageorgiou Hosp, GR-54006 Thessaloniki, Greece.	fountzil@auth.gr	Fountzilas, George/ABF-2139-2020; Bobos, Mattheos/L-5702-2019; Chrisafi, Sofia/AAH-2823-2020; Dafni, Ourania/AAH-4453-2019; Dimopoulos, Meletios Athanasios/AAD-4130-2019	Bobos, Mattheos/0000-0001-5662-9201; Dafni, Ourania/0000-0003-4367-4497; Dimopoulos, Meletios/0000-0001-8990-3254; Fountzilas, George/0000-0001-8045-2186; Koletsa, Triantafyllia/0000-0002-4435-3532; `miliaras, spiros/0000-0003-4983-6821	internal Hellenic Cooperative Oncology Group (HeCOG) [HE R_10/10]	internal Hellenic Cooperative Oncology Group (HeCOG)	This work has been supported by an internal Hellenic Cooperative Oncology Group (HeCOG) grant (HE R_10/10), allocated to the conduct of this work. The Hellenic Cooperative Oncology Group was therefore directly involved in study design, data collection and analysis, decision to publish and preparation of the manuscript.	Albain K, 2012, LANCET, V379, P432, DOI 10.1016/S0140-6736(11)61625-5; Bedard PL, 2010, NAT REV CLIN ONCOL, V7, P22, DOI 10.1038/nrclinonc.2009.186; Blows FM, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000279; Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082; Citron ML, 2004, CANCER INVEST, V22, P555, DOI 10.1081/CNV-200027134; Coombes RC, 2011, J CLIN ONCOL, V29, P3247, DOI 10.1200/JCO.2010.32.7254; Dawood S, 2009, ANN ONCOL, V20, P621, DOI 10.1093/annonc/mdn682; Diallo-Danebrock R, 2007, CLIN CANCER RES, V13, P488, DOI 10.1158/1078-0432.CCR-06-1842; Eiermann W, 2011, J CLIN ONCOL, V29, P3877, DOI 10.1200/JCO.2010.28.5437; Ellis P, 2009, LANCET, V373, P1681, DOI 10.1016/S0140-6736(09)60740-6; Fountzilas G, 2008, ANN ONCOL, V19, P853, DOI [10.1093/annonc/mdm539, 10.1093/annonc/mdm464]; Fountzilas G, 2000, CANCER INVEST, V18, P503, DOI 10.3109/07357900009012188; Fountzilas G, 2005, ANN ONCOL, V16, P1762, DOI 10.1093/annonc/mdi366; Fountzilas G, 1997, EUR J CANCER, V33, P1893, DOI 10.1016/S0959-8049(97)00217-7; GIANNI L, 1995, J NATL CANCER I, V87, P1169, DOI 10.1093/jnci/87.15.1169; Gianni L, 2009, J CLIN ONCOL, V27, P4798, DOI 10.1200/JCO.2008.21.4791; Gogas H, 2012, BREAST CANCER RES TR, V132, P609, DOI 10.1007/s10549-011-1913-4; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Hayes DF, 2007, NEW ENGL J MED, V357, P1496, DOI 10.1056/NEJMoa071167; Hudis CA, 2007, J CLIN ONCOL, V25, P2127, DOI 10.1200/JCO.2006.10.3523; Hugh J, 2009, J CLIN ONCOL, V27, P1168, DOI 10.1200/JCO.2008.18.1024; Iwata H, 2011, JPN J CLIN ONCOL, V41, P867, DOI 10.1093/jjco/hyr081; Jacquemier J, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3051; Jacquin JP, 2012, BREAST CANCER RES TR, V134, P903, DOI 10.1007/s10549-011-1933-0; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; KALLIONIEMI OP, 1991, INT J CANCER, V49, P650, DOI 10.1002/ijc.2910490504; Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kosmidis PA, 2011, ANN ONCOL, V22, P827, DOI 10.1093/annonc/mdq445; Kostopoulos I, 2006, BREAST CANCER RES TR, V96, P251, DOI 10.1007/s10549-005-9062-2; Lin NU, 2007, CLIN CANCER RES, V13, P1648, DOI 10.1158/1078-0432.CCR-06-2478; Martin M, 2010, BREAST CANCER RES TR, V123, P149, DOI 10.1007/s10549-009-0663-z; McShane LM, 2006, BREAST CANCER RES TR, V100, P229, DOI 10.1007/s10549-006-9242-8; Millar EKA, 2009, J CLIN ONCOL, V27, P4701, DOI 10.1200/JCO.2008.21.7075; Miller KD, 2003, ANN ONCOL, V14, P1072, DOI 10.1093/annonc/mdg300; Norton L, 2001, ONCOLOGIST, V6, P30; O'Shaughnessy J, 2002, ONCOLOGIST, V7, P4; Orzano Jennifer A, 2005, Clin Breast Cancer, V6, P402, DOI 10.3816/CBC.2005.n.044; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pestalozzi BC, 2006, ANN ONCOL, V17, P935, DOI 10.1093/annonc/mdl064; Press MF, 2011, J CLIN ONCOL, V29, P859, DOI 10.1200/JCO.2009.27.5644; Psyrri A, 2012, ANN ONCOL, V23, P1422, DOI 10.1093/annonc/mdr527; Qin YY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026946; Razis E, 2011, BREAST CANCER RES TR, V128, P447, DOI 10.1007/s10549-011-1572-5; Roche H, 2006, J CLIN ONCOL, V24, P5664, DOI 10.1200/JCO.2006.07.3916; Schippinger W, 2007, AM J CLIN PATHOL, V128, P630, DOI 10.1309/51KPD70348RP6XTE; Seidman AD, 2005, CANCER CHEMOTH PHARM, V56, pS78, DOI 10.1007/s00280-005-0109-1; Sihto H, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2944; Skacel M, 2002, APPL IMMUNOHISTO M M, V10, P1, DOI 10.1097/00022744-200203000-00001; Skarlos P, 2012, CANCER CHEMOTH PHARM, V69, P533, DOI 10.1007/s00280-011-1730-9; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Vallejos CS, 2010, CLIN BREAST CANCER, V10, P294, DOI 10.3816/CBC.2010.n.038; Vanden Bempt I, 2008, J CLIN ONCOL, V26, P4869, DOI 10.1200/JCO.2007.13.4296; Voduc KD, 2010, J CLIN ONCOL, V28, P1684, DOI 10.1200/JCO.2009.24.9284; Wolff AC, 2007, ARCH PATHOL LAB MED, V131, P18, DOI 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2; Zauderer M, 2009, BREAST CANCER RES TR, V117, P205, DOI 10.1007/s10549-008-0116-0	56	53	55	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 5	2012	7	6							e37946	10.1371/journal.pone.0037946	http://dx.doi.org/10.1371/journal.pone.0037946			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959VI	22679488	Green Published, gold			2023-01-03	WOS:000305343900015
J	Spiegel, DP; Hansen, BC; Byblow, WD; Thompson, B				Spiegel, Daniel P.; Hansen, Bruce C.; Byblow, Winston D.; Thompson, Benjamin			Anodal Transcranial Direct Current Stimulation Reduces Psychophysically Measured Surround Suppression in the Human Visual Cortex	PLOS ONE			English	Article							CROSS-ORIENTATION SUPPRESSION; CAT STRIATE CORTEX; HUMAN MOTOR CORTEX; RECEPTIVE-FIELD; PHOSPHENE THRESHOLDS; SPATIAL-DISTRIBUTION; MOTION PERCEPTION; BRAIN PLASTICITY; INHIBITION; MODULATION	Transcranial direct current stimulation (tDCS) is a safe, non-invasive technique for transiently modulating the balance of excitation and inhibition within the human brain. It has been reported that anodal tDCS can reduce both GABA mediated inhibition and GABA concentration within the human motor cortex. As GABA mediated inhibition is thought to be a key modulator of plasticity within the adult brain, these findings have broad implications for the future use of tDCS. It is important, therefore, to establish whether tDCS can exert similar effects within non-motor brain areas. The aim of this study was to assess whether anodal tDCS could reduce inhibitory interactions within the human visual cortex. Psychophysical measures of surround suppression were used as an index of inhibition within V1. Overlay suppression, which is thought to originate within the lateral geniculate nucleus (LGN), was also measured as a control. Anodal stimulation of the occipital poles significantly reduced psychophysical surround suppression, but had no effect on overlay suppression. This effect was specific to anodal stimulation as cathodal stimulation had no effect on either measure. These psychophysical results provide the first evidence for tDCS-induced reductions of intracortical inhibition within the human visual cortex.	[Spiegel, Daniel P.; Thompson, Benjamin] Univ Auckland, Dept Optometry & Vis Sci, Auckland 1, New Zealand; [Hansen, Bruce C.] Colgate Univ, Dept Psychol, Hamilton, NY 13346 USA; [Hansen, Bruce C.] Colgate Univ, Neurosci Program, Hamilton, NY 13346 USA; [Byblow, Winston D.] Univ Auckland, Dept Sport & Exercise Sci, Auckland 1, New Zealand	University of Auckland; Colgate University; Colgate University; University of Auckland	Spiegel, DP (corresponding author), Univ Auckland, Dept Optometry & Vis Sci, Auckland 1, New Zealand.	b.thompson@auckland.ac.nz	Hansen, Bruce/E-8516-2010; Byblow, Winston/D-3579-2009	Hansen, Bruce/0000-0002-8898-1688; Byblow, Winston/0000-0001-8347-6730; Thompson, Benjamin/0000-0002-3902-2712	Health Research Council of New Zealand Emerging Researcher Grant [09/150]; University of Auckland Faculty Development Research Fund Grant [3622919]	Health Research Council of New Zealand Emerging Researcher Grant; University of Auckland Faculty Development Research Fund Grant	This study was supported by a Health Research Council of New Zealand Emerging Researcher Grant (09/150) to BT and WDB and a University of Auckland Faculty Development Research Fund Grant (3622919) to BT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Accornero N, 2007, EXP BRAIN RES, V178, P261, DOI 10.1007/s00221-006-0733-y; Akasaki T, 2002, NEUROSCI RES, V43, P207, DOI 10.1016/S0168-0102(02)00038-X; Angelakis E., 2011, THE J, V15, P337, DOI [10.1080/10874208.2011.623092, DOI 10.1080/10874208.2011.623092]; Antal A, 2003, EXP BRAIN RES, V150, P375, DOI 10.1007/s00221-003-1459-8; Antal A, 2006, BRAIN RES BULL, V68, P459, DOI 10.1016/j.brainresbull.2005.10.006; Antal A, 2004, INVEST OPHTH VIS SCI, V45, P702, DOI 10.1167/iovs.03-0688; Antal A, 2003, NEUROPSYCHOLOGIA, V41, P1802, DOI 10.1016/S0028-3932(03)00181-7; Antal A, 2001, NEUROREPORT, V12, P3553, DOI 10.1097/00001756-200111160-00036; Antal A, 2004, J COGNITIVE NEUROSCI, V16, P521, DOI 10.1162/089892904323057263; Antal A, 2008, PERCEPTION, V37, P367, DOI 10.1068/p5872; Baroncelli L, 2011, NEURAL PLAST, V2011, DOI 10.1155/2011/286073; Bavelier D, 2010, J NEUROSCI, V30, P14964, DOI 10.1523/JNEUROSCI.4812-10.2010; Bex PJ, 2007, J VISION, V7, DOI 10.1167/7.11.12; BONDS AB, 1989, VISUAL NEUROSCI, V2, P41, DOI 10.1017/S0952523800004314; Bonin V, 2005, J NEUROSCI, V25, P10844, DOI 10.1523/JNEUROSCI.3562-05.2005; Boros K, 2008, EUR J NEUROSCI, V27, P1292, DOI 10.1111/j.1460-9568.2008.06090.x; CAMPBELL FW, 1968, J PHYSIOL-LONDON, V197, P551, DOI 10.1113/jphysiol.1968.sp008574; Cavanaugh JR, 2002, J NEUROPHYSIOL, V88, P2547, DOI 10.1152/jn.00693.2001; Chatrian G. E., 1985, American Journal of EEG Technology, V25, P83; Darrien JH, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-13; Datta A, 2008, J NEURAL ENG, V5, P163, DOI 10.1088/1741-2560/5/2/007; DEANGELIS GC, 1992, J NEUROPHYSIOL, V68, P144, DOI 10.1152/jn.1992.68.1.144; DEANGELIS GC, 1994, J NEUROPHYSIOL, V71, P347, DOI 10.1152/jn.1994.71.1.347; DUFFY FH, 1985, BRAIN RES, V339, P257, DOI 10.1016/0006-8993(85)90090-3; ENGEL SA, 1994, NATURE, V369, P525, DOI 10.1038/369525a0; Freeman TCB, 2002, NEURON, V35, P759, DOI 10.1016/S0896-6273(02)00819-X; Fu Y, 2010, NEUROSCIENCE, V169, P874, DOI 10.1016/j.neuroscience.2010.05.015; Gonzalez-Burgos G, 2011, NEURAL PLAST, V2011, DOI 10.1155/2011/723184; Halko MA, 2011, NEUROIMAGE, V57, P885, DOI 10.1016/j.neuroimage.2011.05.026; HEGGELUND P, 1983, EXP BRAIN RES, V52, P235; Huang SY, 2010, J NEUROSCI, V30, P16636, DOI 10.1523/JNEUROSCI.4384-10.2010; Katzner S, 2011, J NEUROSCI, V31, P5931, DOI 10.1523/JNEUROSCI.5753-10.2011; Kraft A, 2010, EXP BRAIN RES, V207, P283, DOI 10.1007/s00221-010-2453-6; Lang N, 2007, INVEST OPHTH VIS SCI, V48, P5782, DOI 10.1167/iovs.07-0706; Leek MR, 2001, PERCEPT PSYCHOPHYS, V63, P1279, DOI 10.3758/BF03194543; Leventhal AG, 2003, SCIENCE, V300, P812, DOI 10.1126/science.1082874; Li BW, 2006, J NEUROPHYSIOL, V96, P1755, DOI 10.1152/jn.00425.2006; Li G, 2008, NEUROSCIENCE, V155, P914, DOI 10.1016/j.neuroscience.2008.06.032; Maya-Vetencourt JF, 2008, SCIENCE, V320, P385, DOI 10.1126/science.1150516; Meese TS, 2006, J VISION, V6, P1224, DOI 10.1167/6.11.7; MORRONE MC, 1982, PROC R SOC SER B-BIO, V216, P335, DOI 10.1098/rspb.1982.0078; Nitsche MA, 2007, J NEUROPHYSIOL, V97, P3109, DOI 10.1152/jn.01312.2006; Nitsche MA, 2004, EUR J NEUROSCI, V19, P2720, DOI 10.1111/j.0953-816X.2004.03398.x; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Ohtani Y, 2002, VISION RES, V42, P1825, DOI 10.1016/S0042-6989(02)00103-7; Osaki H, 2011, EUR J NEUROSCI, V33, P923, DOI 10.1111/j.1460-9568.2010.07572.x; Petrov Y, 2005, J NEUROSCI, V25, P8704, DOI 10.1523/JNEUROSCI.2871-05.2005; Petrov Y, 2006, J VISION, V6, P224, DOI 10.1167/6.3.4; Priebe NJ, 2006, NAT NEUROSCI, V9, P552, DOI 10.1038/nn1660; Rokem A, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00127; Saint-Amour D, 2005, EUR J NEUROSCI, V21, P1107, DOI 10.1111/j.1460-9568.2005.03914.x; Sale A, 2007, NAT NEUROSCI, V10, P679, DOI 10.1038/nn1899; Sale A, 2010, FRONT CELL NEUROSCI, V4, DOI 10.3389/fncel.2010.00010; Sengpiel F, 2006, CEREB CORTEX, V16, P1750, DOI 10.1093/cercor/bhj110; Smith MA, 2006, J NEUROSCI, V26, P4826, DOI 10.1523/JNEUROSCI.5542-06.2006; Stagg CJ, 2011, CURR BIOL, V21, P480, DOI 10.1016/j.cub.2011.01.069; Stagg CJ, 2011, NEUROSCIENTIST, V17, P37, DOI 10.1177/1073858410386614; Stagg CJ, 2009, J NEUROSCI, V29, P5202, DOI 10.1523/JNEUROSCI.4432-08.2009; Thompson B, 2008, CURR BIOL, V18, P1067, DOI 10.1016/j.cub.2008.06.052; Thompson B, 2012, DEV PSYCHOBIOL, V54, P263, DOI 10.1002/dev.20509; Tyler CW, 1997, SPATIAL VISION, V10, P369, DOI 10.1163/156856897X00294; Walker GA, 2000, VISUAL NEUROSCI, V17, P369, DOI 10.1017/S0952523800173055; Wassef A, 2003, J CLIN PSYCHOPHARM, V23, P601, DOI 10.1097/01.jcp.0000095349.32154.a5; Yang Q, 2002, INVEST OPHTH VIS SCI, V43, P2939; Yoon JH, 2010, J NEUROSCI, V30, P3777, DOI 10.1523/JNEUROSCI.6158-09.2010; Yoon JH, 2009, SCHIZOPHRENIA BULL, V35, P1078, DOI 10.1093/schbul/sbp064; Yu C, 2002, J VISION, V2, DOI 10.1167/2.3.4	68	41	44	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2012	7	5							e36220	10.1371/journal.pone.0036220	http://dx.doi.org/10.1371/journal.pone.0036220			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UN	22563485	Green Published, Green Submitted, gold			2023-01-03	WOS:000305340700034
J	Bouchard, S; Bernier, F; Boivin, E; Morin, B; Robillard, G				Bouchard, Stephane; Bernier, Francois; Boivin, Eric; Morin, Brian; Robillard, Genevieve			Using Biofeedback while Immersed in a Stressful Videogame Increases the Effectiveness of Stress Management Skills in Soldiers	PLOS ONE			English	Article							MENTAL-HEALTH; RESILIENCE; FITNESS; RESPONSES; MILITARY; NEUROENDOCRINE; CORTISOL; SCIENCE; GENDER; IRAQ	This study assessed the efficacy of using visual and auditory biofeedback while immersed in a tridimensional videogame to practice a stress management skill (tactical breathing). All 41 participants were soldiers who had previously received basic stress management training and first aid training in combat. On the first day, they received a 15-minute refresher briefing and were randomly assigned to either: (a) no additional stress management training (SMT) for three days, or (b) 30-minute sessions (one per day for three days) of biofeedback-assisted SMT while immersed in a horror/first-person shooter game. The training was performed in a dark and enclosed environment using a 50-inch television with active stereoscopic display and loudspeakers. On the last day, all participants underwent a live simulated ambush with an improvised explosive device, where they had to provide first aid to a wounded soldier. Stress levels were measured with salivary cortisol collected when waking-up, before and after the live simulation. Stress was also measured with heart rate at baseline, during an apprehension phase, and during the live simulation. Repeated-measure ANOVAs and ANCOVAs confirmed that practicing SMT was effective in reducing stress. Results are discussed in terms of the advantages of the proposed program for military personnel and the need to practice SMT.	[Bouchard, Stephane; Robillard, Genevieve] Univ Quebec Outaouais, Lab Cyberpsychol, Gatineau, PQ, Canada; [Bernier, Francois; Boivin, Eric] Def Res & Dev Canada ValCartier, Quebec City, PQ, Canada; [Morin, Brian] Clin Psychol Cognit, Quebec City, PQ, Canada	University of Quebec; University Quebec Outaouais	Bouchard, S (corresponding author), Univ Quebec Outaouais, Lab Cyberpsychol, Gatineau, PQ, Canada.	stephane.bouchard@uqo.ca	Bernier, Francois/AAP-2174-2020; Bernier, Francois/V-7150-2018		Public Works and Government Services Canada; Canada Research Chairs program; Natural Science and Engineering Research Council of Canada	Public Works and Government Services Canada; Canada Research Chairs program(Canada Research Chairs); Natural Science and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC))	This project was financially supported by a contract from Public Works and Government Services Canada and the financial support of research awards from the Canada Research Chairs program and the Natural Science and Engineering Research Council of Canada awarded to the first author. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adler AB, 2009, J CONSULT CLIN PSYCH, V77, P928, DOI 10.1037/a0016877; Algoe SB, 2011, AM PSYCHOL, V66, P35, DOI 10.1037/a0021720; Bandura A., 1986, SOCIAL FDNS THOUGHTS; Benoit A, 2005, ENTERFACE 2005 SUMM; Bouchard S, J DEFENSE M IN PRESS; Bouchard S., 2011, J COMPUTER INFORM TE, V1, P20; Bouchard S, 2012, POSTTRAUMATIC STRESS, P271; Bouchard S, 2011, STUD COMPUT INTELL, V337, P109; Bouchard S, 2010, CYBERPSYCH BEH SOC N, V13, P83, DOI 10.1089/cyber.2009.0336; Casey GW, 2011, AM PSYCHOL, V66, P1, DOI 10.1037/a0021930; Cohen J., 2013, STAT POWER ANAL BEHA; Cornum R, 2011, AM PSYCHOL, V66, P4, DOI 10.1037/a0021420; Davis SN, 2000, J CLIN ENDOCR METAB, V85, P224, DOI 10.1210/jc.85.1.224; Davydov DM, 2010, CLIN PSYCHOL REV, V30, P479, DOI 10.1016/j.cpr.2010.03.003; Dekker A, P DIGRA TOK JAP; Driskell JE, 2008, PERFORMANCE STRESS, P271; Ferguson K., 2009, GEN PRINCIPLES EMPIR, P532; Good GE, 2005, J CLIN PSYCHOL, V61, P699, DOI 10.1002/jclp.20104; Green G, 2010, SOC SCI MED, V71, P1480, DOI 10.1016/j.socscimed.2010.07.015; Grossman D., 2008, COMBAT PSYCHOL PHYSL; Guest L, 2011, PREDEPLOYEMENT TRAIN; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Homeland Security, 2004, SURV SCOR RES PROJ F; Kashdan TB, 2010, CLIN PSYCHOL REV, V30, P865, DOI 10.1016/j.cpr.2010.03.001; Katertsidis NS, 2009, P 9 INT C INF TECHN; Kennedy R. S., 1993, INT J AVIAT PSYCHOL, V3, P203, DOI [10.1207/s15327108ijap0303_3, DOI 10.1207/S15327108IJAP0303_3]; Kim PY, 2011, MIL PSYCHOL, V23, P65, DOI 10.1080/08995605.2011.534415; Kirk Roger, 1982, EXPT DESIGN PROCEDUR, V2nd; Lazarus R.S., 1984, STRESS APPRAISAL COP; Leal-Cerro A, 2003, J ENDOCRINOL INVEST, V26, P879, DOI 10.1007/BF03345239; Lester PB, 2011, AM PSYCHOL, V66, P77, DOI 10.1037/a0022083; Levant R. F., 1995, NEW PSYCHOL MEN; Masten AS, 2007, DEV PSYCHOPATHOL, V19, P921, DOI 10.1017/S0954579407000442; Mental Health Advisory Team (MHAT) 6, 2009, OP END FREED 2009 AF; Murphy P, 2008, J OCCUP HEALTH, V24, P541; Nakasone A, 2005, 5 INT WORKSH BIOS IN; O'Donohue W.T., 2009, GEN PRINCIPLES EMPIR; OCONNOR PJ, 1987, MED SCI SPORT EXER, V19, P224; Oman D, 2008, INT J PSYCHOL RELIG, V18, P79, DOI 10.1080/10508610701879316; Orvis KA, 2010, MIL PSYCHOL, V22, P143, DOI 10.1080/08995600903417225; Ravaj N, 2005, P DIGRA 2005 C CHANG, P1; Reivich KJ, 2011, AM PSYCHOL, V66, P25, DOI 10.1037/a0021897; Rimmele U, 2007, PSYCHONEUROENDOCRINO, V32, P627, DOI 10.1016/j.psyneuen.2007.04.005; Rosen LN, 2000, MIL MED, V165, P54, DOI 10.1093/milmed/165.1.54; Routhier C, 2007, PROGRAMME ENTR UNPUB; Routhier C, 2009, IND OP READ PERS PER; RUTTER M, 1987, AM J ORTHOPSYCHIAT, V57, P316, DOI 10.1111/j.1939-0025.1987.tb03541.x; Schwartz M. S., 2003, BIOFEEDBACK PRACTITI, V3rd; Shi Y., 2010, INT S QUALITY LIFE T, P28; Stetz MC, 2007, AVIAT SPACE ENVIR MD, V78, pB252; Stuempfle KJ, 2010, WILD ENVIRON MED, V21, P22, DOI 10.1016/j.wem.2009.12.020; Taylor MK, 2011, MIL MED, V12, P1362; Thompson MM, 2006, PSYCHOL SERVING PEAC, P54; Timmerman IGH, 1998, BEHAV RES THER, V36, P863, DOI 10.1016/S0005-7967(98)00053-9; Wexler DB, 2009, MEN THERAPY NEW APPR; Wolpe J., 1990, PRACTICE BEHAV THERA; Yun C, 2009, CHI2009: PROCEEDINGS OF THE 27TH ANNUAL CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS, VOLS 1-4, P2195	57	62	64	5	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2012	7	4							e36169	10.1371/journal.pone.0036169	http://dx.doi.org/10.1371/journal.pone.0036169			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	959TJ	22558370	Green Submitted, gold, Green Published			2023-01-03	WOS:000305336000145
J	Ramasamy, S; Wahab, NA; Abidin, NZ; Manickam, S; Zakaria, Z				Ramasamy, Sujatha; Wahab, Norhanom Abdul; Abidin, Nurhayati Zainal; Manickam, Sugumaran; Zakaria, Zubaidah			Growth Inhibition of Human Gynecologic and Colon Cancer Cells by Phyllanthus watsonii through Apoptosis Induction	PLOS ONE			English	Article							ELLAGIC ACID; BETULINIC ACID; CYCLE ARREST; IN-VITRO; PHENOLIC-COMPOUNDS; PROLIFERATION; ANTITUMOR; AMARUS; LUNG; CHEMOPREVENTION	Phyllanthus watsonii Airy Shaw is an endemic plant found in Peninsular Malaysia. Although there are numerous reports on the anti cancer properties of other Phyllanthus species, published information on the cytotoxicity of P. watsonii are very limited. The present study was carried out with bioassay-guided fractionation approach to evaluate the cytotoxicity and apoptosis induction capability of the P. watsonii extracts and fractions on human gynecologic (SKOV-3 and Ca Ski) and colon (HT-29) cancer cells. P. watsonii extracts exhibited strong cytotoxicity on all the cancer cells studied with IC50 values of <= 20.0 mu g/mL. Hexane extract of P. watsonii was further subjected to bioassay-guided fractionation and yielded 10 fractions (PW-1 -> PW-10). PW-4 -> PW-8 portrayed stronger cytotoxic activity and was further subjected to bioassay-guided fractionation and resulted with 8 sub-fractions (PPWH-1 -> PPWH-8). PPWH-7 possessed greatest cytotoxicity (IC50 values ranged from 0.66 - 0.83 mu g/mL) and was selective on the cancer cells studied. LC-MS/MS analysis of PPWH-7 revealed the presence of ellagic acid, geranic acid, glochidone, betulin, phyllanthin and sterol glucoside. Marked morphological changes, ladder-like appearance of DNA and increment in caspase-3 activity indicating apoptosis were clearly observed in both human gynecologic and colon cancer cells treated with P. watsonii especially with PPWH-7. The study also indicated that P. watsonii extracts arrested cell cycle at different growth phases in SKOV-3, Ca Ski and HT-29 cells. Cytotoxic and apoptotic potential of the endemic P. watsonii was investigated for the first time by bioassay-guided approach. These results demonstrated that P. watsonii selectively inhibits the growth of SKOV-3, Ca Ski and HT-29 cells through apoptosis induction and cell cycle modulation. Hence, P. watsonii has the potential to be further exploited for the discovery and development of new anti cancer drugs.	[Ramasamy, Sujatha; Abidin, Nurhayati Zainal; Manickam, Sugumaran] Univ Malaya, Fac Sci, Inst Biol Sci, Kuala Lumpur, Malaysia; [Wahab, Norhanom Abdul] Univ Malaya, Ctr Fdn Studies Sci, Kuala Lumpur, Malaysia; [Zakaria, Zubaidah] Inst Med Res, Canc Res Ctr, Hematol Unit, Kuala Lumpur 50588, Malaysia	Universiti Malaya; Universiti Malaya; Kementerian Kesihatan Malaysia	Ramasamy, S (corresponding author), Univ Malaya, Fac Sci, Inst Biol Sci, Kuala Lumpur, Malaysia.	sujatha@um.edu.my	ABIDIN, NURHAYATI ZAINAL/B-9429-2010; Manickam, Sugumaran/B-5268-2010; RAMASAMY, SUJATHA/B-9854-2010; ABDUL WAHAB, NORHANOM/B-5207-2010	Manickam, Sugumaran/0000-0003-3125-767X; 	Postgraduate Research Fund (PPP) [UM 524 PS130/2008A, UM PS307/2010A]; University of Malaya	Postgraduate Research Fund (PPP); University of Malaya(Universiti Malaya)	This study was supported by Postgraduate Research Fund (PPP) Grants UM 524 PS130/2008A and UM PS307/2010A, funded by University of Malaya. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aaby K, 2007, J AGR FOOD CHEM, V55, P4395, DOI 10.1021/jf0702592; Abu Bakal MF, 2010, FOOD CHEM TOXICOL, V48, P1688, DOI 10.1016/j.fct.2010.03.046; Aggarwal BB, 2006, BIOCHEM PHARMACOL, V71, P1397, DOI 10.1016/j.bcp.2006.02.009; AVATO P, 1995, PHYTOCHEMISTRY, V40, P141, DOI 10.1016/0031-9422(95)00183-8; Balunas MJ, 2005, LIFE SCI, V78, P431, DOI 10.1016/j.lfs.2005.09.012; Bardon S, 2002, CANCER LETT, V181, P187, DOI 10.1016/S0304-3835(02)00047-2; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Boik J, 2001, NATURAL COMPOUNDS CA; BORENFREUND E, 1985, TOXICOL LETT, V24, P119, DOI 10.1016/0378-4274(85)90046-3; Boyle P, 2008, 1260 INT AG RES CANC, P1; BURKILL I. H., 1966, A Dictionary of the Economic Products of the Malay Peninsula., V2; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Cheng YL, 2004, LIFE SCI, V75, P1579, DOI 10.1016/j.lfs.2004.03.009; Chien SC, 2007, TETRAHEDRON LETT, V48, P1567, DOI 10.1016/j.tetlet.2007.01.011; Cragg GM, 2005, J ETHNOPHARMACOL, V100, P72, DOI 10.1016/j.jep.2005.05.011; Darison GWH, 1988, ENDAU ROMPIN MALAYSI; DAS M, 1985, CARCINOGENESIS, V6, P1409, DOI 10.1093/carcin/6.10.1409; Fjaeraa C, 2009, BIOMED PHARMACOTHER, V63, P254, DOI 10.1016/j.biopha.2008.07.093; GERAN RI, 1972, CANC CHEMOTHER REP, V3, P1; Gosslau A, 2004, NUTRITION, V20, P95, DOI 10.1016/j.nut.2003.09.017; Gurib-Fakim A., 2006, MOL ASPECTS MED, V27, P1, DOI DOI 10.1016/J.MAM.2005.07.008; Hail N, 2008, FREE RADICAL BIO MED, V45, P97, DOI 10.1016/j.freeradbiomed.2008.04.004; Hansakul P., 2009, Songklanakarin Journal of Science and Technology, V31, P273; Harada H, 2002, ANTICANCER RES, V22, P2587; Hu XL, 2010, BIOCHEM BIOPH RES CO, V398, P62, DOI 10.1016/j.bbrc.2010.06.033; Hu YW, 2009, J ETHNOPHARMACOL, V123, P293, DOI 10.1016/j.jep.2009.03.016; Huang ST, 2006, INT IMMUNOPHARMACOL, V6, P870, DOI 10.1016/j.intimp.2005.12.010; Huang ST, 2003, LIFE SCI, V72, P1705, DOI 10.1016/S0024-3205(03)00016-X; Jeena KJ, 1999, CANCER LETT, V136, P11, DOI 10.1016/S0304-3835(98)00294-8; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kajdzanoska M, 2010, MACED J CHEM CHEM EN, V29, P181; Kiemer AK, 2003, J HEPATOL, V38, P289, DOI 10.1016/S0168-8278(02)00417-8; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krithika R, 2009, CHEM-BIOL INTERACT, V181, P351, DOI 10.1016/j.cbi.2009.06.014; Lai CS, 2008, J ETHNOPHARMACOL, V118, P14, DOI 10.1016/j.jep.2008.02.034; Le NTV, 2002, BBA-REV CANCER, V1603, P31, DOI 10.1016/S0304-419X(02)00068-9; Liu J, 2006, CANCER LETT, V242, P133, DOI 10.1016/j.canlet.2005.11.023; Losso JN, 2004, J NUTR BIOCHEM, V15, P672, DOI 10.1016/j.jnutbio.2004.06.004; Mahavorasirikul W, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-55; Maia LF, 2000, J NAT PROD, V63, P1427, DOI 10.1021/np9906323; Malek SNA, 2009, MOLECULES, V14, P1713, DOI 10.3390/molecules14051713; Marston A, 2007, PHYTOCHEMISTRY, V68, P2786, DOI 10.1016/j.phytochem.2007.08.004; MATSUNAGA S, 1993, PHYTOCHEMISTRY, V32, P165, DOI 10.1016/0031-9422(92)80125-X; MILLS JJ, 1995, CANCER RES, V55, P979; Moongkarndi P, 2004, J ETHNOPHARMACOL, V90, P161, DOI 10.1016/j.jep.2003.09.048; Narayanan BA, 1999, CANCER LETT, V136, P215, DOI 10.1016/S0304-3835(98)00323-1; Nayak PS, 2010, B LATINOAM CARIBE PL, V9, P353; Nhan TQ, 2006, AM J PATHOL, V169, P729, DOI 10.2353/ajpath.2006.060105; Nieves-Neira W, 1999, INT J CANCER, V82, P396, DOI 10.1002/(SICI)1097-0215(19990730)82:3<396::AID-IJC13>3.0.CO;2-Z; Panchal RG, 1998, BIOCHEM PHARMACOL, V55, P247, DOI 10.1016/S0006-2952(97)00240-2; PERCHELLET JP, 1992, BASIC LIFE SCI, V59, P783; Popov B, 2005, BIOCHEM BIOPH RES CO, V336, P762, DOI 10.1016/j.bbrc.2005.08.163; Prasanna R, 2009, CELL BIOL INT, V33, P127, DOI 10.1016/j.cellbi.2008.10.006; Rajkapoor B, 2007, BIOSCI BIOTECH BIOCH, V71, P2177, DOI 10.1271/bbb.70149; Ramasamy S, 2011, J MED PLANTS RES, V5, P2267; Reddy BS, 1997, CANCER RES, V57, P420; Santafe G, 2002, J NAT PROD, V65, P1161, DOI 10.1021/np0200459; Schmidt ML, 1997, EUR J CANCER, V33, P2007, DOI 10.1016/S0959-8049(97)00294-3; Schwartz GK, 2005, J CLIN ONCOL, V23, P9408, DOI 10.1200/JCO.2005.01.5594; Shakya R, 2008, J AGR FOOD CHEM, V56, P6949, DOI 10.1021/jf8006618; Sherr CJ, 2000, CANCER RES, V60, P3689; Sheu JH, 2000, J NAT PROD, V63, P149, DOI 10.1021/np9903954; STARK MJ, 1995, CANCER LETT, V96, P15, DOI 10.1016/0304-3835(95)03912-G; Stoner GD, 1997, CANCER LETT, V114, P113, DOI 10.1016/S0304-3835(97)04639-9; Su NW, 2005, J AGR FOOD CHEM, V53, P1949, DOI 10.1021/jf048310e; Sun J, 2006, CANCER LETT, V241, P124, DOI 10.1016/j.canlet.2005.10.027; Tanaka R, 1998, PHYTOCHEMISTRY, V21, P3563; Tang YQ, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0012644, 10.1371/journal.pone.0015631]; Taraphdar AK, 2001, CURR SCI INDIA, V80, P1387; TEEL RW, 1986, CANCER LETT, V30, P329, DOI 10.1016/0304-3835(86)90058-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tokarska-Schlattner M, 2006, CR BIOL, V329, P657, DOI 10.1016/j.crvi.2005.08.007; Wang W, 2009, PROG NEUROBIOL, V89, P1, DOI 10.1016/j.pneurobio.2009.01.007; Wang ZB, 2005, CELL BIOL INT, V29, P489, DOI 10.1016/j.cellbi.2005.04.001; Wick W, 1999, J PHARMACOL EXP THER, V289, P1306; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; Yang Y, 2010, MOLECULES, V15, P7075, DOI 10.3390/molecules15107075; Zhang JH, 2002, TRENDS CELL BIOL, V12, P84, DOI 10.1016/S0962-8924(01)02206-1; Zhang YJ, 2004, BIOL PHARM BULL, V27, P251, DOI 10.1248/bpb.27.251; Zuco V, 2002, CANCER LETT, V175, P17, DOI 10.1016/S0304-3835(01)00718-2	80	27	29	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 20	2012	7	4							e34793	10.1371/journal.pone.0034793	http://dx.doi.org/10.1371/journal.pone.0034793			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UD	22536331	gold, Green Published			2023-01-03	WOS:000305339200020
J	Gnjidic, D; Stanaway, FF; Cumming, R; Waite, L; Blyth, F; Naganathan, V; Handelsman, DJ; Le Couteur, DG				Gnjidic, Danijela; Stanaway, Fiona F.; Cumming, Robert; Waite, Louise; Blyth, Fiona; Naganathan, Vasi; Handelsman, David J.; Le Couteur, David G.			Mild Cognitive Impairment Predicts Institutionalization among Older Men: A Population-Based Cohort Study	PLOS ONE			English	Article							NURSING-HOME PLACEMENT; URINARY-INCONTINENCE; ALZHEIMERS-DISEASE; CARE HOMES; SHORT-FORM; DEMENTIA; ADMISSION; DIAGNOSIS; HEALTH; RELIABILITY	Background: There is a lack of evidence on the contribution of mild cognitive impairment (MCI) to institutionalization in older adults. This study aimed to evaluate a range of risk factors including MCI of institutionalization in older men. Methods: Men aged >= 70 years (n = 1705), participating in the Concord Health and Ageing in Men Project, Sydney, Australia were studied. Participants completed self-reported questionnaires and underwent comprehensive clinical assessments during 2005-2007. Institutionalization was defined as entry into a nursing home facility or hostel at any time over an average of 5 years of follow-up. Cox regression analysis was conducted to generate hazard ratios (HR) with 95% confidence intervals (CI). Results: A total of 125 (7.3%) participants were institutionalized. Piecewise Cox proportional models were generated and divided at 3.4 years (1250 days) of follow-up due to violation of the proportional hazards assumption for the association between MCI and institutionalization (chi(2) = 6.44, p = 0.01). Dementia, disability in Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL), poor grip strength, few social interactions, being a Non-English speaking immigrant and age were predictive of institutionalization during both time periods, whereas MCI (HR = 4.39, 95% CI 2.17-8.87) only predicted institutionalization in the period beyond 3.4 years of follow-up. Being married (HR = 0.42, 95% CI: 0.24-0.72) was protective only during the period after 3.4 years of follow-up. Discussion: In this study, the strongest predictors of institutionalization were dementia, MCI, ADL and IADL disability. MCI was not a predictor of early institutionalization but became a significant predictor beyond 3.4 years of follow-up.	[Gnjidic, Danijela] Royal N Shore Hosp, Dept Clin Pharmacol, Sydney, NSW, Australia; [Gnjidic, Danijela] Royal N Shore Hosp, Dept Aged Care, Sydney, NSW, Australia; [Gnjidic, Danijela; Cumming, Robert; Waite, Louise; Blyth, Fiona; Naganathan, Vasi; Handelsman, David J.; Le Couteur, David G.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia; [Gnjidic, Danijela; Stanaway, Fiona F.; Cumming, Robert; Waite, Louise; Blyth, Fiona; Naganathan, Vasi; Le Couteur, David G.] Concord Hosp, Ctr Educ & Res Ageing, Sydney, NSW, Australia; [Handelsman, David J.; Le Couteur, David G.] Concord Hosp, ANZAC Res Inst, Sydney, NSW, Australia; [Stanaway, Fiona F.; Cumming, Robert] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia; [Gnjidic, Danijela] Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia	Royal North Shore Hospital; University of Sydney; Royal North Shore Hospital; University of Sydney; University of Sydney; Concord Repatriation General Hospital; Concord Repatriation General Hospital; University of Sydney; ANZAC Research Institute; University of Sydney; University of Sydney	Gnjidic, D (corresponding author), Royal N Shore Hosp, Dept Clin Pharmacol, Sydney, NSW, Australia.	danijela.gnjidic@sydney.edu.au	Research Institute, ANZAC/CAE-9030-2022; Ekanayake, Kanchana/P-8817-2016; Handelsman, David/AAR-9580-2021	Handelsman, David/0000-0002-4200-7476; Naganathan, Vasikaran/0000-0001-7243-0796; Waite, Louise/0000-0001-9056-6996; Le Couteur, David/0000-0002-4227-5817	Australian National Health and Medical Research Council (NHMRC) [301916]; Sydney Medical School Foundation; Ageing and Alzheimer's Research Foundation; Geoff and Elaine Penney Ageing Research Unit	Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Sydney Medical School Foundation; Ageing and Alzheimer's Research Foundation; Geoff and Elaine Penney Ageing Research Unit	The CHAMP study is funded by the Australian National Health and Medical Research Council (NHMRC Project Grant No. 301916), Sydney Medical School Foundation and Ageing and Alzheimer's Research Foundation. The authors gratefully acknowledge the funding support from the Geoff and Elaine Penney Ageing Research Unit. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AIHW) AIoHaW, 2011, DRUG STAT SER, V26; AIHW (Australian Institute of Health and Welfare), 2011, AG CAR STAT SER, V35; BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740; Bharucha AJ, 2004, J AM GERIATR SOC, V52, P434, DOI 10.1111/j.1532-5415.2004.52118.x; Busse A, 2006, BRIT J PSYCHIAT, V189, P399, DOI 10.1192/bjp.bp.105.014779; Byrne LMT, 1998, J CLIN EXP NEUROPSYC, V20, P286, DOI 10.1076/jcen.20.2.286.1176; Chan DC, 2003, J GERONTOL A-BIOL, V58, P548; Chukwujama O, 2011, NEW ENGL J MED, V365, P1358, DOI 10.1056/NEJMc1108238; Cohen-Mansfield J, 2011, ARCH GERONTOL GERIAT, V53, P309, DOI 10.1016/j.archger.2010.12.009; Cooper R, 2011, AGE AGEING, V40, P14, DOI 10.1093/ageing/afq117; Cumming RG, 2009, INT J EPIDEMIOL, V38, P374, DOI 10.1093/ije/dyn071; Dudas RB, 2005, AM J GERIAT PSYCHIAT, V13, P218, DOI 10.1176/appi.ajgp.13.3.218; Dunn J E, 1993, J Aging Health, V5, P194, DOI 10.1177/089826439300500203; FILLENBAUM GG, 1981, J GERONTOL, V36, P428, DOI 10.1093/geronj/36.4.428; Fischer P, 2007, NEUROLOGY, V68, P288, DOI 10.1212/01.wnl.0000252358.03285.9d; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gaugler Joseph E, 2007, BMC Geriatr, V7, P13, DOI 10.1186/1471-2318-7-13; Gibson D., 2001, PROJECTIONS OLDER IM; Gnjidic D, 2012, CLIN PHARMACOL THER, V91, P521, DOI 10.1038/clpt.2011.258; GOLDBERG D, 1988, BRIT MED J, V297, P897, DOI 10.1136/bmj.297.6653.897; Grundy E, 2007, AGE AGEING, V36, P424, DOI 10.1093/ageing/afm067; Guo MX, 2012, J NEUROL SCI, V312, P39, DOI 10.1016/j.jns.2011.08.026; He W., 2005, 65 US, P23; Heyman A, 1997, NEUROLOGY, V48, P1304, DOI 10.1212/WNL.48.5.1304; Holroyd-Leduc JM, 2004, J AM GERIATR SOC, V52, P712, DOI 10.1111/j.1532-5415.2004.52207.x; JORM AF, 1994, PSYCHOL MED, V24, P145, DOI 10.1017/S003329170002691X; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; KOENIG HG, 1993, PSYCHOSOMATICS, V34, P61, DOI 10.1016/S0033-3182(93)71928-3; LIEBERMAN MA, 1991, GERONTOLOGIST, V31, P371, DOI 10.1093/geront/31.3.371; Lord SR, 1996, ARCH PHYS MED REHAB, V77, P232, DOI 10.1016/S0003-9993(96)90103-3; Luppa M, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-186; Luppa M, 2010, AGE AGEING, V39, P31, DOI 10.1093/ageing/afp202; Manly JJ, 2008, ANN NEUROL, V63, P494, DOI 10.1002/ana.21326; McCallum J, 2005, AUSTRALAS J AGEING, V24, P169, DOI 10.1111/j.1741-6612.2005.00116.x; McCann M, 2011, AGE AGEING, V40, P358, DOI 10.1093/ageing/afr031; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; Plassman BL, 2008, ANN INTERN MED, V148, P427, DOI 10.7326/0003-4819-148-6-200803180-00005; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; Rowland JT, 2004, INT PSYCHOGERIATR, V118, P111; Thom DH, 1997, AGE AGEING, V26, P367, DOI 10.1093/ageing/26.5.367; Tinetti ME, 1997, NEW ENGL J MED, V337, P1279, DOI 10.1056/NEJM199710303371806; Tuokko H, 2003, ARCH NEUROL-CHICAGO, V60, P577, DOI 10.1001/archneur.60.4.577; Turcotte Martin., 2007, PORTRAIT SENIORS CAN; Waite L, 1999, ALZ DIS ASSOC DIS, V13, P34, DOI 10.1097/00002093-199903000-00005; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; WASHBURN RA, 1993, J CLIN EPIDEMIOL, V46, P153, DOI 10.1016/0895-4356(93)90053-4; Wechsler D., 1987, WECHSLER MEMORY SCAL; Winblad B, 2004, J INTERN MED, V256, P240, DOI 10.1111/j.1365-2796.2004.01380.x; Yaffe K, 2002, JAMA-J AM MED ASSOC, V287, P2090, DOI 10.1001/jama.287.16.2090; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	53	32	33	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2012	7	9							e46061	10.1371/journal.pone.0046061	http://dx.doi.org/10.1371/journal.pone.0046061			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	016YB	23029389	gold, Green Submitted, Green Published			2023-01-03	WOS:000309554700111
J	Gruen, RL; Brohi, K; Schreiber, M; Balogh, ZJ; Pitt, V; Narayan, M; Maier, RV				Gruen, Russell L.; Brohi, Karim; Schreiber, Martin; Balogh, Zsolt J.; Pitt, Veronica; Narayan, Mayur; Maier, Ronald V.			Haemorrhage control in severely injured patients	LANCET			English	Article							ACUTE TRAUMATIC COAGULOPATHY; MASSIVE TRANSFUSION; LYOPHILIZED PLASMA; HYPERTONIC RESUSCITATION; DAMAGE CONTROL; FACTOR-VIIA; PROTEIN-C; FIBRINOGEN; BLOOD; COAGULATION	Most surgeons have adopted damage control surgery for severely injured patients, in which the initial operation is abbreviated after control of bleeding and contamination to allow ongoing resuscitation in the intensive-care unit. Developments in early resuscitation that emphasise rapid control of bleeding, restrictive volume replacement, and prevention or early management of coagulopathy are making definitive surgery during the first operation possible for many patients. Improved topical haemostatic agents and interventional radiology are becoming increasingly useful adjuncts to surgical control of bleeding. Better understanding of trauma-induced coagulopathy is paving the way for the replacement of blind, unguided protocols for blood component therapy with systemic treatments targeting specific deficiencies in coagulation. Similarly, treatments targeting dysregulated inflammatory responses to severe injury are under investigation. As point-of-care diagnostics become more suited to emergency environments, timely targeted intervention for haemorrhage control will result in better patient outcomes and reduced demand for blood products. Our Series paper describes how our understanding of the roles of the microcirculation, inflammation, and coagulation has shaped new and emerging treatment strategies.	[Gruen, Russell L.; Pitt, Veronica] Monash Univ, Natl Trauma Res Inst, Alfred Hosp, Melbourne, Vic 3004, Australia; [Brohi, Karim] Royal London Hosp, Barts & London Sch Med & Dent, Trauma Clin Acad Unit, Ctr Neurosci & Trauma, London E1 1BB, England; [Schreiber, Martin] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA; [Balogh, Zsolt J.] Univ Newcastle, John Hunter Hosp, Dept Trauma, Newcastle, NSW 2300, Australia; [Narayan, Mayur] Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Ctr Injury Prevent & Policy, Baltimore, MD 21201 USA; [Maier, Ronald V.] Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA	Florey Institute of Neuroscience & Mental Health; Monash University; Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London; Oregon Health & Science University; John Hunter Hospital; University of Newcastle; University System of Maryland; University of Maryland Baltimore; Harborview Medical Center; University of Washington; University of Washington Seattle	Gruen, RL (corresponding author), Monash Univ, Natl Trauma Res Inst, Alfred Hosp, 89 Commercial Rd, Melbourne, Vic 3004, Australia.	r.gruen@alfred.org.au	Balogh, Zsolt/A-2002-2010	Balogh, Zsolt/0000-0002-0277-4822	Australian National Health and Medical Research Council Practitioner Fellowship; National Institute for Health Research [RP-PG-0407-10036] Funding Source: researchfish	Australian National Health and Medical Research Council Practitioner Fellowship(National Health and Medical Research Council (NHMRC) of Australia); National Institute for Health Research(National Institute for Health Research (NIHR))	RLG is supported by an Australian National Health and Medical Research Council Practitioner Fellowship. We thank Loretta Piccenna for the illustration, Ornella Clavisi for leading the searches and selection of studies, and Romy Granek, Manda Kaled, and Loyal Pattuwage for screening search outputs.	Achneck HE, 2010, ANN SURG, V251, P217, DOI 10.1097/SLA.0b013e3181c3bcca; Alam HB, 2012, BRIT J SURG, V99, P29, DOI 10.1002/bjs.7756; [Anonymous], COCHRANE DATABASE SY, DOI DOI 10.1002/14651858.CD001319.PUB3; [Anonymous], COCHRANE DATABASE SY; [Anonymous], COCHRANE DATABASE SY; Armand R, 2003, TRANSFUS MED REV, V17, P223, DOI 10.1016/S0887-7963(03)00022-1; Aubron C, 2011, CRIT CARE RESUSC, V13, P67; Ball CG, 2011, CAN J SURG, V54, pE3; Beekley AC, 2008, J TRAUMA, V64, pS28, DOI 10.1097/TA.0b013e318160937e; Boffard KD, 2005, J TRAUMA, V59, P8, DOI 10.1097/01.TA.0000171453.37949.B7; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brohi K, 2008, J TRAUMA, V64, P1211, DOI 10.1097/TA.0b013e318169cd3c; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Bulger EM, 2008, ARCH SURG-CHICAGO, V143, P139, DOI 10.1001/archsurg.2007.41; Bulger EM, 2007, ANN SURG, V245, P635, DOI 10.1097/01.sla.0000251367.44890.ae; Bulger EM, 2011, ANN SURG, V253, P431, DOI 10.1097/SLA.0b013e3181fcdb22; Bunn F, 2004, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/146151858.CD002045.PUB2; Burlew CC, 2011, J AM COLL SURGEONS, V212, P628, DOI 10.1016/j.jamcollsurg.2010.12.020; Carless PA, 2003, COCHRANE DB SYST REV, V1; Casstevens EC, 2010, TRANSFUSION, V50, p36A; Cohen MJ, 2012, ANN SURG, V255, P379, DOI 10.1097/SLA.0b013e318235d9e6; Committee on Tactical Combat Casualty Care, TACT COMB CAS CAR GU; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; Cotton BA, 2011, NEW ENGL J MED, V365, P2039, DOI 10.1056/NEJMc1111095; Cotton BA, 2010, J TRAUMA, V69, pS33, DOI 10.1097/TA.0b013e3181e42411; Darlington DN, 2011, J TRAUMA, V71, P1271, DOI 10.1097/TA.0b013e318214f522; Davenport R, 2011, CRIT CARE MED, V39, P2652, DOI 10.1097/CCM.0b013e3182281af5; Davenport RA, 2009, CURR OPIN ANESTHESIO, V22, P261, DOI 10.1097/ACO.0b013e328325a6d9; Desai KH, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001093; Development Concepts and Doctrine Centre, CLIN GUID OP JOINT D; Doran CM, 2012, J TRAUMA ACUTE CARE, V72, P835, DOI 10.1097/TA.0b013e318248347b; Duchesne JC, 2010, J TRAUMA, V69, P976, DOI 10.1097/TA.0b013e3181f2abc9; Floccard B, 2012, INJURY, V43, P26, DOI 10.1016/j.injury.2010.11.003; Frevert S, 2008, INJURY, V39, P1290, DOI 10.1016/j.injury.2008.07.004; Frith D, 2010, J THROMB HAEMOST, V8, P1919, DOI 10.1111/j.1538-7836.2010.03945.x; Fu CY, 2012, AM J EMERG MED, V30, P207, DOI 10.1016/j.ajem.2010.11.005; Gentile LF, 2012, J TRAUMA ACUTE CARE, V72, P1491, DOI 10.1097/TA.0b013e318256e000; Godier A, 2012, CURR OPIN ANESTHESIO, V25, P242, DOI 10.1097/ACO.0b013e32834fcc3e; Granville-Chapman J, 2011, INJURY, V42, P447, DOI 10.1016/j.injury.2010.09.037; Hamilton GJ, 2011, J TRAUMA, V71, P292, DOI 10.1097/TA.0b013e31821f4234; Hauser CJ, 2010, J TRAUMA, V69, P489, DOI 10.1097/TA.0b013e3181edf36e; Hess JR, 2008, J TRAUMA, V65, P748, DOI 10.1097/TA.0b013e3181877a9c; Ho AMH, 2012, ANESTHESIOLOGY, V116, P716, DOI 10.1097/ALN.0b013e318245c47b; Hubetamann Bjorn, 2011, J Emerg Trauma Shock, V4, P465, DOI 10.4103/0974-2700.86630; Inaba K, 2010, J AM COLL SURGEONS, V211, P573, DOI 10.1016/j.jamcollsurg.2010.06.392; Joseph B, 2012, J TRAUMA ACUTE CARE, V72, P828, DOI 10.1097/TA.0b013e318247c944; Kautza BC, 2012, J TRAUMA ACUTE CARE, V72, P106, DOI 10.1097/TA.0b013e3182410a3c; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; Kragh JF, 2008, J TRAUMA, V64, pS38, DOI 10.1097/TA.0b013e31816086b1; Kragh John F Jr, 2011, US Army Med Dep J, P38; Krieg JC, 2005, J TRAUMA, V59, P659, DOI 10.1097/01.ta.000186544.06101.11; Letoublon C, 2011, J TRAUMA, V70, P1032, DOI 10.1097/TA.0b013e31820e7ca1; Levrat A, 2008, BRIT J ANAESTH, V100, P792, DOI 10.1093/bja/aen083; Levy JH, 2010, LANCET, V376, P3, DOI 10.1016/S0140-6736(10)60939-7; Lpaktchi K, 2007, CRIT CARE MED, V35, P2139, DOI 10.1097/01.CCM.0000280568.61217.26; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; Martinaud C, 2011, J TRAUMA, V71, P1761, DOI 10.1097/TA.0b013e31822f1285; Martini WZ, 2011, MOL MED, V17, P757, DOI 10.2119/molmed.2010.00093; Martini WZ, 2009, J TRAUMA, V67, P202, DOI 10.1097/TA.0b013e3181a602a7; MAZZONI MC, 1988, AM J PHYSIOL, V255, pH629, DOI 10.1152/ajpheart.1988.255.3.H629; McLaughlin DF, 2008, J TRAUMA, V64, pS57, DOI 10.1097/TA.0b013e318160a566; Meng ZH, 2003, J TRAUMA, V55, P886, DOI 10.1097/01.TA.0000066184.20808.A5; Meyer MAS, 2011, VOX SANG, V101, P185, DOI 10.1111/j.1423-0410.2011.01478.x; Mitra B, 2012, INJURY, V43, P33, DOI 10.1016/j.injury.2011.10.011; Mitra B, 2011, RESUSCITATION, V82, P1208, DOI 10.1016/j.resuscitation.2011.04.007; Mitra B, 2012, INJURY, V43, P22, DOI 10.1016/j.injury.2010.10.015; Neal MD, 2012, J TRAUMA ACUTE CARE, V72, P892, DOI 10.1097/TA.0b013e31823d84a7; Plurad DS, 2011, J TRAUMA, V71, P565, DOI 10.1097/TA.0b013e3182213d52; Rees K, 2001, COCHRANE DATABASE SY, V1, pCD002138; Requarth JA, 2011, J TRAUMA, V71, P898, DOI 10.1097/TA.0b013e318227ea50; Rizoli SB, 2011, J TRAUMA, V71, pS427, DOI 10.1097/TA.0b013e318232e5ab; Roberts I, 2011, LANCET, V377, P1096, DOI 10.1016/S0140-6736(11)60278-X; Rourke C, 2012, J THROMB HAEMOST, V10, P1342, DOI 10.1111/j.1538-7836.2012.04752.x; Schochl H, 2011, CRIT CARE, V15, DOI 10.1186/cc10078; Schreiber MA, 2012, BRIT J SURG, V99, P10, DOI 10.1002/bjs.7773; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Sorensen B, 2012, BRIT J SURG, V99, P40, DOI 10.1002/bjs.7770; Sperry JL, 2008, J TRAUMA, V64, P9, DOI 10.1097/TA.0b013e31815dd029; Spinella PC, 2009, J TRAUMA, V66, pS69, DOI 10.1097/TA.0b013e31819d85fb; Spoerke N, 2009, ARCH SURG-CHICAGO, V144, P829, DOI 10.1001/archsurg.2009.154; Stinger HK, 2008, J TRAUMA, V64, pS79, DOI 10.1097/TA.0b013e318160a57b; Sydenham E, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001048.pub3; Szopinski J, 2011, J TRAUMA, V71, P1779, DOI 10.1097/TA.0b013e31823a05b5; Tanaka H, 2000, ARCH SURG-CHICAGO, V135, P326, DOI 10.1001/archsurg.135.3.326; US Army Institute of Surgical Research Clinical Practice Guidelines, FRESH WHOL BLOOD FWB; Van PY, 2011, J TRAUMA, V71, P20, DOI 10.1097/TA.0b013e3182214f44; Wafaisade A, 2010, EMERG MED J, V27, P934, DOI 10.1136/emj.2009.088484; Wang D, 2012, TRANSFUSION, V52, P1184, DOI 10.1111/j.1537-2995.2011.03466.x; Wohlauer MV, 2012, J AM COLL SURGEONS, V214, P739, DOI 10.1016/j.jamcollsurg.2012.01.050; Xiao WZ, 2011, J EXP MED, V208, P2581, DOI 10.1084/jem.20111354; Zink KA, 2009, AM J SURG, V197, P565, DOI 10.1016/j.amjsurg.2008.12.014; Zuidema MY, 2010, WORLD J CARDIOL, V2, P325, DOI 10.4330/wjc.v2.i10.325	93	150	165	2	32	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 22	2012	380	9847					1099	1108		10.1016/S0140-6736(12)61224-0	http://dx.doi.org/10.1016/S0140-6736(12)61224-0			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	007VL	22998719				2023-01-03	WOS:000308916400031
J	Spence, D				Spence, Des			Methadone is no panacea	BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk						[Anonymous], 2012, BBC NEWS	1	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	AUG 22	2012	345								e5670	10.1136/bmj.e5670	http://dx.doi.org/10.1136/bmj.e5670			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	996GV	22915733				2023-01-03	WOS:000308073800004
J	Pochan, DJ				Pochan, Darrin J.			Approaching Asymmetry and Versatility in Polymer Assembly	SCIENCE			English	Editorial Material							MICELLES		Univ Delaware, Newark, DE 19716 USA	University of Delaware	Pochan, DJ (corresponding author), Univ Delaware, Newark, DE 19716 USA.	pochan@udel.edu						Bates FS, 2012, SCIENCE, V336, P434, DOI 10.1126/science.1215368; Bishop KJM, 2009, SMALL, V5, P1600, DOI 10.1002/smll.200900358; Christian DA, 2009, NAT MATER, V8, P843, DOI [10.1038/NMAT2512, 10.1038/nmat2512]; Cui HG, 2007, SCIENCE, V317, P647, DOI 10.1126/science.1141768; Dupont J, 2010, SOFT MATTER, V6, P3654, DOI 10.1039/c0sm00044b; Groschel AH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1707; Grzelczak M, 2010, ACS NANO, V4, P3591, DOI 10.1021/nn100869j; LoPresti C, 2011, ACS NANO, V5, P1775, DOI 10.1021/nn102455z; Moughton AO, 2012, MACROMOLECULES, V45, P2, DOI 10.1021/ma201865s; Pochan DJ, 2011, SOFT MATTER, V7, P2500, DOI 10.1039/c0sm00960a; Rupar PA, 2012, SCIENCE, V337, P559, DOI 10.1126/science.1221206; Wang JY, 2012, J AM CHEM SOC, V134, P5801, DOI 10.1021/ja2066187	12	9	9	1	112	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 3	2012	337	6094					530	531		10.1126/science.1225524	http://dx.doi.org/10.1126/science.1225524			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982PU	22859474				2023-01-03	WOS:000307058700026
J	Yan, R; Ji, HL; Wu, YH; Kerr, PG; Fang, YM; Yang, LZ				Yan, Rong; Ji, Hongli; Wu, Yonghong; Kerr, Philip G.; Fang, Yanming; Yang, Linzhang			An Investigation into the Kinetics and Mechanism of the Removal of Cyanobacteria by Extract of Ephedra equisetina Root	PLOS ONE			English	Article							HYDROGEN-PEROXIDE; GREEN-ALGAE; GENE; EXPOSURE; STRAINS; BLOOMS; GROWTH; STATE; FLAA	An aqueous extract of Ephedra equisetina root was found to induce cyanobacterial cell death. The extract displayed no negative effects on the fish populations but instead, improved the habitat conditions for the growth of macrophytes, zooplankton and bacteria because the inhibiting effects of the extracts on cyanobacteria helped clear up the water column. The removal kinetics of cyanobacteria by E. equisetina extract appears to be a first order process with the rate constant being extract-dose-dependent. Compounds including the flavonoids found in E. equisetina root kill the cyanobacteria in vitro at a dose of 5.0 mu g extract per 100 mL water or above. The extract constituents act to disrupt the thylakoid membrane, interrupt the electronic transport, decrease the effective quantum yield, and eventually lead to the failure of photosynthesis in Microcystis aeruginosa. This study presents an easily-deployed, natural and promising approach for controlling cyanobacterial blooms as an emergency measure, and also provides insight into the dynamics and mechanism of the extract consisting of multiple compounds synergistically removing algae.	[Yan, Rong; Ji, Hongli; Fang, Yanming] Nanjing Forestry Univ, Coll Forest Resource & Environm Sci, Nanjing, Jiangsu, Peoples R China; [Yan, Rong; Wu, Yonghong; Yang, Linzhang] Chinese Acad Sci, Inst Soil Sci, State Key Lab Soil & Sustainable Agr, Nanjing, Jiangsu, Peoples R China; [Kerr, Philip G.] Charles Sturt Univ, Sch Biomed Sci, Wagga Wagga, NSW, Australia	Nanjing Forestry University; Chinese Academy of Sciences; Institute of Soil Science, CAS; Charles Sturt University	Yan, R (corresponding author), Nanjing Forestry Univ, Coll Forest Resource & Environm Sci, Nanjing, Jiangsu, Peoples R China.	yhwu@issas.ac.cn; jwu4@njfu.edu.cn	Kerr, Philip/B-4212-2013; Wu, Yonghong/B-4501-2010	Kerr, Philip/0000-0002-6406-0593; Wu, Yonghong/0000-0002-2985-219X	Priority Academic Program Development of Jiangsu High Education Institutions (PAPD); Doctorate Fellowship Foundation of Nanjing Forestry University; Innovative Project of Graduate Students in University, Jiangsu, China	Priority Academic Program Development of Jiangsu High Education Institutions (PAPD); Doctorate Fellowship Foundation of Nanjing Forestry University; Innovative Project of Graduate Students in University, Jiangsu, China	This work was jointly supported by the Priority Academic Program Development of Jiangsu High Education Institutions (PAPD), the Doctorate Fellowship Foundation of Nanjing Forestry University and the Innovative Project of Graduate Students in University, Jiangsu, China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aliotta G, 2005, J CHEM ECOL, V16, P9; Assmy P., 2009, ENCY MICROBIOLOGY, P27, DOI DOI 10.1016/B978-012373944-5.00001-8; Bagheri-Gavkosh S, 2009, MYCOPATHOLOGIA, V168, P249, DOI 10.1007/s11046-009-9220-x; Baird R.B., 2017, STANDARD METHODS EXA, V23rd; Barrington DJ, 2008, ENVIRON SCI TECHNOL, V42, P8916, DOI 10.1021/es801717y; Chorus I, 1999, TOXIC CYANOBACTERIA, DOI DOI 10.4324/9780203478073; Cook NC, 1996, J NUTR BIOCHEM, V7, P66, DOI 10.1016/0955-2863(95)00168-9; del Pozo R, 2010, AQUAT BOT, V92, P55, DOI 10.1016/j.aquabot.2009.10.003; DeNobel WT, 1997, FEMS MICROBIOL ECOL, V24, P259, DOI 10.1111/j.1574-6941.1997.tb00443.x; Di Giovanni GD, 1999, CURR MICROBIOL, V38, P217, DOI 10.1007/PL00006790; Diaz M, 2007, LIMNOLOGICA, V37, P17, DOI 10.1016/j.limno.2006.08.006; Drabkova M, 2007, ENVIRON SCI TECHNOL, V41, P309, DOI 10.1021/es060746i; Dziga D, 2007, ENVIRON TOXICOL, V22, P341, DOI 10.1002/tox.20276; Ferrier MD, 2005, BIORESOURCE TECHNOL, V96, P1788, DOI 10.1016/j.biortech.2005.01.021; Gobler CJ, 2008, HARMFUL ALGAE, V7, P293, DOI 10.1016/j.hal.2007.12.006; Golterman H. L., 1969, IBP HDB, V8; GRAY DI, 1995, LETT APPL MICROBIOL, V20, P65, DOI 10.1111/j.1472-765X.1995.tb00409.x; HANASAKI Y, 1994, FREE RADICAL BIO MED, V16, P845, DOI 10.1016/0891-5849(94)90202-X; Jersek B, 1999, J CLIN MICROBIOL, V37, P103; Jin Q, 2003, J EXP MAR BIOL ECOL, V293, P41, DOI 10.1016/S0022-0981(03)00214-4; Kim IS, 2010, INT IMMUNOPHARMACOL, V10, P1616, DOI 10.1016/j.intimp.2010.09.019; Kuhnau J, 1976, WORLD REV NUTR DIET, V24, P8; Li FM, 2005, APPL ENVIRON MICROB, V71, P6545, DOI 10.1128/AEM.71.11.6545-6553.2005; Miao SY, 2006, SCI TOTAL ENVIRON, V371, P334, DOI 10.1016/j.scitotenv.2006.07.027; Nakai S, 2000, WATER RES, V34, P3026, DOI 10.1016/S0043-1354(00)00039-7; Nakai S, 2005, HYDROBIOLOGIA, V543, P71, DOI 10.1007/s10750-004-6822-7; NAWWAR MAM, 1984, PHYTOCHEMISTRY, V23, P2937, DOI 10.1016/0031-9422(84)83045-9; Paerl HW, 2008, SCIENCE, V320, P57, DOI 10.1126/science.1155398; RIPPKA R., 1992, PASTEUR CULTURE COLL, V1; Schreiber U, 2002, PHOTOSYNTH RES, V74, P317, DOI 10.1023/A:1021276003145; Sekizuka T, 2007, J BASIC MICROB, V47, P63, DOI 10.1002/jobm.200610194; Shao JH, 2009, CHEMOSPHERE, V75, P924, DOI 10.1016/j.chemosphere.2009.01.021; SIMPSON EH, 1949, NATURE, V163, P688, DOI 10.1038/163688a0; Smith GJ, 2000, J PHOTOCH PHOTOBIO A, V136, P87, DOI 10.1016/S1010-6030(00)00320-8; SPENCER CM, 1988, PHYTOCHEMISTRY, V27, P2397, DOI 10.1016/0031-9422(88)87004-3; Svrcek C, 2004, J ENVIRON ENG SCI, V3, P155, DOI 10.1139/S04-010; Weaver Warren, 1949, DROP CITATION; Wu Y, 2008, ALLELOPATHY J, V22; Wu YH, 2010, BIORESOURCE TECHNOL, V101, P3903, DOI 10.1016/j.biortech.2009.12.144; Yang W.D., 2005, CHIN ENV SCI, V25, P1	40	12	16	2	57	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2012	7	8							e42285	10.1371/journal.pone.0042285	http://dx.doi.org/10.1371/journal.pone.0042285			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984SU	22870313	Green Submitted, Green Published, gold			2023-01-03	WOS:000307212800076
J	Zhu, Q; Talton, J; Zhang, GF; Cunningham, T; Wang, ZJ; Waters, RC; Kirk, J; Eppler, B; Klinman, DM; Sui, YJ; Gagnon, S; Belyakov, IM; Mumper, RJ; Berzofsky, JA				Zhu, Qing; Talton, James; Zhang, Guofeng; Cunningham, Tshaka; Wang, Zijian; Waters, Robert C.; Kirk, James; Eppler, Baerbel; Klinman, Dennis M.; Sui, Yongjun; Gagnon, Susan; Belyakov, Igor M.; Mumper, Russell J.; Berzofsky, Jay A.			Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection	NATURE MEDICINE			English	Article							IN-VIVO EVALUATION; T-CELL RESPONSES; DRUG-DELIVERY; PROTECTS MICE; RECTAL MUCOSA; IMMUNIZATION; COMPARTMENTALIZATION; TRANSMISSION; TECHNOLOGIES; PROTEINS	Both rectal and vaginal mucosal surfaces serve as transmission routes for pathogenic microorganisms. Vaccination through large intestinal mucosa, previously proven protective for both of these mucosal sites in animal studies, can be achieved successfully by direct intracolorectal (i.c.r.) administration, but this route is clinically impractical. Oral vaccine delivery seems preferable but runs the risk of the vaccine's destruction in the upper gastrointestinal tract. Therefore, we designed a large intestine-targeted oral delivery with pH-dependent microparticles containing vaccine nanoparticles, which induced colorectal immunity in mice comparably to colorectal vaccination and protected against rectal and vaginal viral challenge. Conversely, vaccine targeted to the small intestine induced only small intestinal immunity and provided no rectal or vaginal protection, demonstrating functional compartmentalization within the gut mucosal immune system. Therefore, using this oral vaccine delivery system to target the large intestine, but not the small intestine, may represent a feasible new strategy for immune protection of rectal and vaginal mucosa.	[Zhu, Qing; Cunningham, Tshaka; Sui, Yongjun; Gagnon, Susan; Belyakov, Igor M.; Berzofsky, Jay A.] NCI, Vaccine Branch, Ctr Canc Res, US Natl Inst Hlth, Bethesda, MD 20892 USA; [Zhu, Qing] AF Gen Hosp, Dept Oncol, Beijing, Peoples R China; [Zhang, Guofeng] Natl Inst Biomed Imaging & Bioengn, Lab Bioengn & Phys Sci, US Natl Inst Hlth, Bethesda, MD USA; [Wang, Zijian] Jingmeng Res Ctr, Beijing, Peoples R China; [Klinman, Dennis M.] NCI, Expt Immunol Lab, Ctr Canc Res, Frederick, MD 21701 USA; [Belyakov, Igor M.] Univ Michigan, Sch Med, Michigan Nanotechnol Inst Med & Biol Sci, Ann Arbor, MI USA; [Belyakov, Igor M.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA; [Mumper, Russell J.] Univ N Carolina, Eshelman Sch Pharm, Div Mol Pharmaceut, Ctr Nanotechnol Drug Delivery, Chapel Hill, NC USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Biomedical Imaging & Bioengineering (NIBIB); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of North Carolina; University of North Carolina Chapel Hill	Zhu, Q (corresponding author), NCI, Vaccine Branch, Ctr Canc Res, US Natl Inst Hlth, Bethesda, MD 20892 USA.	qing20892@gmail.com; berzofsj@mail.nih.gov	Sui, Yongjun/AAA-3228-2019	Talton, James/0000-0002-4310-661X; Sui, Yongjun/0000-0002-1568-4607	Intramural Research Program of NIH; National Cancer Institute; Center for Cancer Research; Intramural AIDS Targeted Antiviral Program; National Natural Science Foundation of China [31170872]; Collaborative Research and Development Agreement with Nanotherapeutics Inc; NATIONAL CANCER INSTITUTE [ZIABC010852, ZIASC004020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [ZICEB000080] Funding Source: NIH RePORTER	Intramural Research Program of NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural AIDS Targeted Antiviral Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Collaborative Research and Development Agreement with Nanotherapeutics Inc; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	We thank B. Moss and P. Earl (US National Institutes of Health (NIH)) for generously providing vPE16, G. Cohen (University of Pennsylvania) for vaccinia antibodies, the NIH Tetramer Facility for tetramer P18-I10 and BEI Resources for vaccinia recombinant proteins. We also thank J. Hooper, D. Johnson, M. Dobrovolskaia, B. Zolnik, J. Gao and X. Liu for professional comments and help, and J. FitzGerald for electron microscopy. We appreciate Z. Xia, D. Pendleton, D. Li and L. Smith for their technical and secretarial assistance. This research was supported by the Intramural Research Program of NIH, the National Cancer Institute, the Center for Cancer Research and the Intramural AIDS Targeted Antiviral Program, a grant from the National Natural Science Foundation of China (31170872), and a Collaborative Research and Development Agreement with Nanotherapeutics Inc.	Belyakov IM, 2007, J IMMUNOL, V178, P7211, DOI 10.4049/jimmunol.178.11.7211; Belyakov IM, 1998, J CLIN INVEST, V102, P2072, DOI 10.1172/JCI5102; Belyakov IM, 2001, NAT MED, V7, P1320, DOI 10.1038/nm1201-1320; Bott C, 2004, ALIMENT PHARM THER, V20, P347, DOI 10.1111/j.1365-2036.2004.02033.x; Boyer JD, 2007, P NATL ACAD SCI USA, V104, P18648, DOI 10.1073/pnas.0709198104; Cole ET, 2002, INT J PHARMACEUT, V231, P83, DOI 10.1016/S0378-5173(01)00871-7; Critchfield JW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003577; Cronkhite RI, 2004, VACCINE, V22, P2106, DOI 10.1016/j.vaccine.2003.12.012; Desai MP, 1996, PHARMACEUT RES, V13, P1838, DOI 10.1023/A:1016085108889; Ferre AL, 2010, J VIROL, V84, P10354, DOI 10.1128/JVI.00803-10; Fogg C, 2004, J VIROL, V78, P10230, DOI 10.1128/JVI.78.19.10230-10237.2004; Gururajan M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000863; Han M, 2009, J PHARM SCI-US, V98, P2626, DOI 10.1002/jps.21627; Hooper JW, 2003, VIROLOGY, V306, P181, DOI 10.1016/S0042-6822(02)00038-7; Hooper JW, 2000, VIROLOGY, V266, P329, DOI 10.1006/viro.1999.0096; Lehner T, 1996, NAT MED, V2, P767, DOI 10.1038/nm0796-767; Manicassamy S, 2009, SEMIN IMMUNOL, V21, P185, DOI 10.1016/j.smim.2009.05.005; McConnell EL, 2008, VACCINE, V26, P639, DOI 10.1016/j.vaccine.2007.11.071; Miller CJ, 1996, NAT MED, V2, P751, DOI 10.1038/nm0796-751; Mundargi RC, 2008, J CONTROL RELEASE, V125, P193, DOI 10.1016/j.jconrel.2007.09.013; O'Hagan DT, 2006, METHODS, V40, P10, DOI 10.1016/j.ymeth.2006.05.017; Pasare C, 2005, NATURE, V438, P364, DOI 10.1038/nature04267; Price GE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013162; Rassa JC, 2002, P NATL ACAD SCI USA, V99, P2281, DOI 10.1073/pnas.042355399; Schellekens RCA, 2008, J CONTROL RELEASE, V132, P91, DOI 10.1016/j.jconrel.2008.08.008; Schiffer Joshua T, 2010, Proc Natl Acad Sci U S A, V107, P18973, DOI 10.1073/pnas.1006614107; Shang LM, 2008, GASTROENTEROLOGY, V135, P529, DOI 10.1053/j.gastro.2008.04.020; Trinchieri G, 2007, NAT REV IMMUNOL, V7, P179, DOI 10.1038/nri2038; van Ginkel FW, 2000, J IMMUNOL, V165, P4778, DOI 10.4049/jimmunol.165.9.4778; Zhu Q, 2008, MUCOSAL IMMUNOL, V1, P78, DOI 10.1038/mi.2007.3; Zhu Q, 2008, P NATL ACAD SCI USA, V105, P16260, DOI 10.1073/pnas.0805325105; Zhu Q, 2010, J CLIN INVEST, V120, P607, DOI 10.1172/JCI39293	32	126	131	11	128	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2012	18	8					1291	+		10.1038/nm.2866	http://dx.doi.org/10.1038/nm.2866			22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	988DU	22797811	Green Accepted, Green Submitted			2023-01-03	WOS:000307469300037
J	Gupta, A; Ahmad, FJ; Ahmad, F; Gupta, UD; Natarajan, M; Katoch, V; Bhaskar, S				Gupta, Ankan; Ahmad, Farhan J.; Ahmad, Faiz; Gupta, Umesh D.; Natarajan, Mohan; Katoch, Vishwamohan; Bhaskar, Sangeeta			Efficacy of Mycobacterium indicus pranii Immunotherapy as an Adjunct to Chemotherapy for Tuberculosis and Underlying Immune Responses in the Lung	PLOS ONE			English	Article							RESISTANT PULMONARY TUBERCULOSIS; GUINEA-PIG LYMPHOCYTES; INTERFERON-GAMMA; BCG VACCINATION; PROTECTIVE EFFICACY; DNA VACCINE; BOVIS BCG; MICE; VACCAE; INFECTION	Background: The 9-month-long chemotherapy of tuberculosis often results in poor compliance and emergence of drug-resistant strains. So, improved therapeutic strategy is urgently needed. Immunotherapy could be beneficial for the effective management of the disease. Previously we showed the protective efficacy of Mycobacterium indicus pranii (MIP) when given as prophylactic vaccine in animal models of tuberculosis. Methods: We sought to investigate whether MIP can be used as an adjunct to the chemotherapy in guinea pig models of tuberculosis. Efficacy of MIP was evaluated when given subcutaneously or by aerosol. Results: MIP-therapy as an adjunct to the chemotherapy was found to be effective in accelerating bacterial killing and improving organ pathology. MIP-immunotherapy resulted in higher numbers of activated antigen-presenting cells and lymphocytes in the infected lungs and also modulated the granulomatous response. Early increase in protective Th1 immune response was observed in the immunotherapy group. Following subsequent doses of MIP, decrease in the inflammatory response and increase in the immunosuppressive response was observed, which resulted in the improvement of lung pathology. Conclusion: MIP immunotherapy is a valuable adjunct to chemotherapy for tuberculosis. Aerosol route of immunotherapy can play a crucial role for inducing immediate local immune response in the lung.	[Gupta, Ankan; Ahmad, Faiz; Bhaskar, Sangeeta] Natl Inst Immunol, Delhi, India; [Ahmad, Farhan J.] Jamia Hamdard, Fac Pharm, Delhi, India; [Gupta, Umesh D.; Natarajan, Mohan; Katoch, Vishwamohan] Natl JALMA Inst Leprosy & Other Mycobacterial Dis, Expt Anim Facil, Agra, Uttar Pradesh, India; [Gupta, Umesh D.; Natarajan, Mohan; Katoch, Vishwamohan] Natl JALMA Inst Leprosy & Other Mycobacterial Dis, Dept Pathol, Agra, Uttar Pradesh, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII); Jamia Hamdard University; Indian Council of Medical Research (ICMR); ICMR - National JALMA Institute for Leprosy & Other Mycobacterial Diseases, Agra; Indian Council of Medical Research (ICMR); ICMR - National JALMA Institute for Leprosy & Other Mycobacterial Diseases, Agra	Bhaskar, S (corresponding author), Natl Inst Immunol, Delhi, India.	sangeeta@nii.ac.in		Ahmad, Farhan/0000-0002-0740-8573; Bhaskar, Sangeeta/0000-0001-7902-5267; Ahmad, Faiz/0000-0002-0450-042X	National Institute of Immunology from the Department of Biotechnology, Ministry of Science and Technology, Government of India; Department of Biotechnology, Ministry of Science and Technology, Government of India [BT/PRS340/Med/14/619/2005]	National Institute of Immunology from the Department of Biotechnology, Ministry of Science and Technology, Government of India; Department of Biotechnology, Ministry of Science and Technology, Government of India(Department of Biotechnology (DBT) IndiaMinistry of Science and Technology, Government of India)	This research work was supported by the core research grant of the National Institute of Immunology and a research grant (BT/PRS340/Med/14/619/2005) from the Department of Biotechnology, Ministry of Science and Technology, Government of India. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BAHR GM, 1990, TUBERCLE, V71, P259, DOI 10.1016/0041-3879(90)90038-A; Barnes PF, 2003, AM J RESP CRIT CARE, V168, P142, DOI 10.1164/rccm.2305001; Cho H, 2005, INFECT IMMUN, V73, P1367, DOI 10.1128/IAI.73.3.1367-1376.2005; Condos R, 1997, LANCET, V349, P1513, DOI 10.1016/S0140-6736(96)12273-X; Cruz A, 2010, J EXP MED, V207, P1609, DOI 10.1084/jem.20100265; Dietrich J, 2005, J IMMUNOL, V174, P6332, DOI 10.4049/jimmunol.174.10.6332; Dlugovitzky D, 2006, RESP MED, V100, P1079, DOI 10.1016/j.rmed.2005.09.026; Dlugovitzky D, 2011, IMMUNOTHERAPY-UK, V3, P557, DOI [10.2217/IMT.11.6, 10.2217/imt.11.6]; Dlugovitzky D, 2010, IMMUNOTHERAPY-UK, V2, P159, DOI 10.2217/IMT.09.90; Fotedar A, 1978, Lepr India, V50, P520; Garner P, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001166 [doi], DOI 10.1002/14651858.CD001166]; Giosue S, 2000, EUR CYTOKINE NETW, V11, P99; Giri PK, 2006, J INFECTION, V53, P350, DOI 10.1016/j.jinf.2005.12.017; Grahmann PR, 2008, INT J TUBERC LUNG D, V12, P636; Gupta A, 2009, INFECT IMMUN, V77, P223, DOI 10.1128/IAI.00526-08; Ha SJ, 2005, GENE THER, V12, P634, DOI 10.1038/sj.gt.3302465; Ha SJ, 2003, GENE THER, V10, P1592, DOI 10.1038/sj.gt.3302057; Jain R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003869; Jeyanathan M, 2008, J IMMUNOL, V181, P5618, DOI 10.4049/jimmunol.181.8.5618; Jeyanathan M, 2010, TRENDS IMMUNOL, V31, P247, DOI 10.1016/j.it.2010.05.002; Jeyanathan M, 2010, AM J RESP CRIT CARE, V181, P862, DOI 10.1164/rccm.200910-1583OC; Johnson B, 1998, NOVART FDN SYMP, V217, P99, DOI 10.1002/0470846526.ch7; JOHNSON BJ, 1995, CYTOKINES MOL THER, V1, P185; Johnson BJ, 1998, INFECT IMMUN, V66, P2426, DOI 10.1128/IAI.66.6.2426-2433.1998; Johnson CM, 2005, ANTIMICROB AGENTS CH, V49, P4335, DOI 10.1128/AAC.49.10.4335-4338.2005; Johnson JL, 2003, AM J RESP CRIT CARE, V168, P185, DOI 10.1164/rccm.200211-1359OC; Koh WJ, 2004, J KOREAN MED SCI, V19, P167, DOI 10.3346/jkms.2004.19.2.167; KRAAL G, 1986, EUR J IMMUNOL, V16, P1515, DOI 10.1002/eji.1830161208; Lenaerts AJ, 2007, ANTIMICROB AGENTS CH, V51, P3338, DOI 10.1128/AAC.00276-07; Lowrie DB, 1999, NATURE, V400, P269, DOI 10.1038/22326; Ly LH, 2008, AM J RESP CELL MOL, V38, P455, DOI 10.1165/rcmb.2007-0326OC; Mustafa A S, 1978, Lepr India, V50, P534; Mustafa A S, 1978, Lepr India, V50, P498; Mustafa A S, 1978, Lepr India, V50, P509; Ordway D, 2008, CLIN VACCINE IMMUNOL, V15, P1248, DOI 10.1128/CVI.00019-08; Ordway D, 2007, J IMMUNOL, V179, P2532, DOI 10.4049/jimmunol.179.4.2532; Ordway DJ, 2010, ANTIMICROB AGENTS CH, V54, P1820, DOI 10.1128/AAC.01521-09; Pandey R, 2003, J ANTIMICROB CHEMOTH, V52, P981, DOI 10.1093/jac/dkg477; Park SK, 2007, INT J INFECT DIS, V11, P434, DOI 10.1016/j.ijid.2006.12.004; Petrofsky M, 1999, CLIN IMMUNOL, V91, P354, DOI 10.1006/clim.1999.4709; REDDI PP, 1994, INT J LEPROSY, V62, P229; Rodriguez-Guell E, 2008, CLIN VACCINE IMMUNOL, V15, P893, DOI 10.1128/CVI.00477-07; Saini V, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006263; SCHAFER H, 1991, EUR J IMMUNOL, V21, P701, DOI 10.1002/eji.1830210324; Silva CL, 2005, GENE THER, V12, P281, DOI 10.1038/sj.gt.3302418; Skwor TA, 2006, TUBERCULOSIS, V86, P419, DOI 10.1016/j.tube.2005.12.002; STANFORD JL, 1990, TUBERCLE, V71, P87, DOI 10.1016/0041-3879(90)90002-P; STUCK AE, 1989, REV INFECT DIS, V11, P954; TALWAR GP, 1983, INT J LEPROSY, V51, P550; Tateda K, 2001, J IMMUNOL, V166, P3355, DOI 10.4049/jimmunol.166.5.3355; Turner J, 2000, INFECT IMMUN, V68, P1706, DOI 10.1128/IAI.68.3.1706-1709.2000; Turner OC, 2003, INFECT IMMUN, V71, P864, DOI 10.1128/IAI.71.2.864-871.2003; Wallis RS, 2004, CLIN INFECT DIS, V39, P1254, DOI 10.1086/424455; Xu LJ, 2009, CELL MOL IMMUNOL, V6, P67, DOI 10.1038/cmi.2009.9; YADAVA A, 1991, SCAND J IMMUNOL, V34, P23, DOI 10.1111/j.1365-3083.1991.tb01517.x; Yamada H, 2005, EXP ANIM TOKYO, V54, P163, DOI 10.1538/expanim.54.163; Yu DH, 2008, GENE THER, V15, P652, DOI 10.1038/gt.2008.13; Zhang Z, 2009, J CLIN INVEST, V119, P1899, DOI 10.1172/JCI36731	58	45	45	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 26	2012	7	7							e39215	10.1371/journal.pone.0039215	http://dx.doi.org/10.1371/journal.pone.0039215			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012MO	22844392	gold, Green Published, Green Submitted			2023-01-03	WOS:000309240600002
J	Capetti, A; Landonio, S; Meraviglia, P; Di Biagio, A; Lo Caputo, S; Sterrantino, G; Ammassari, A; Menzaghi, B; Franzetti, M; De Socio, GV; Pellicano, G; Mazzotta, E; Soria, A; Meschiari, M; Trezzi, M; Sasset, L; Celesia, BM; Zucchi, P; Melzi, S; Ricci, E; Rizzardini, G				Capetti, Amedeo; Landonio, Simona; Meraviglia, Paola; Di Biagio, Antonio; Lo Caputo, Sergio; Sterrantino, Gaetana; Ammassari, Adriana; Menzaghi, Barbara; Franzetti, Marco; De Socio, Giuseppe Vittorio; Pellicano, Giovanni; Mazzotta, Elena; Soria, Alessandro; Meschiari, Marianna; Trezzi, Michele; Sasset, Lolita; Celesia, Benedetto Maurizio; Zucchi, Patrizia; Melzi, Sara; Ricci, Elena; Rizzardini, Giuliano			96 Week Follow-Up of HIV-Infected Patients in Rescue with Raltegravir Plus Optimized Backbone Regimens: A Multicentre Italian Experience	PLOS ONE			English	Article							LONG-TERM EFFICACY; HIV-1-INFECTED PATIENTS; PROTEASE INHIBITORS; BACKGROUND THERAPY; SAFETY; TRIAL; ETRAVIRINE; COHORT	Background: Long term efficacy of raltegravir (RAL)-including regimens in highly pre-treated HIV-1-infected patients has been demonstrated in registration trials. However, few studies have assessed durability in routine clinical settings. Methods: Antiretroviral treatment-experienced patients initiating a RAL-containing salvage regimen were enrolled. Routine clinical and laboratory follow-up was performed at baseline, week 4, 12, and every 12 weeks thereafter. Data were censored at week 96. Results: Out of 320 patients enrolled, 292 (91.25%) subjects maintained their initial regimen for 96 weeks; 28 discontinued prematurely for various reasons: death (11), viral failure (8), adverse events (5), loss to follow-up (3), consent withdrawal (1). Eight among these 28 subjects maintained RAL but changed the accompanying drugs. The mean CD4+ T-cell increase at week 96 was 227/mm(3); 273 out of 300 patients (91%), who were still receiving RAL at week 96, achieved viral suppression (HIV-1 RNA <50 copies/mL). When analyzing the immuno-virologic outcome according to the number of drugs used in the regimen, 2 (n = 45), 3 (n = 111), 4 (n = 124), or >4 (n = 40), CD4+ T-cell gain was similar across strata: +270, +214, +216, and +240 cells/mm(3), respectively, as was the proportion of subjects with undetectable viral load. Laboratory abnormalities (elevation of liver enzymes, total cholesterol and triglycerides) were rare, ranging from 0.9 to 3.1%. The mean 96-week total cholesterol increase was 23.6 mg/dL. Conclusions: In a routine clinical setting, a RAL-based regimen allowed most patients in salvage therapy to achieve optimal viral suppression for at least 96 weeks, with relevant immunologic gain and very few adverse events.	[Capetti, Amedeo; Landonio, Simona; Zucchi, Patrizia; Melzi, Sara; Ricci, Elena; Rizzardini, Giuliano] Luigi Sacco Hosp, Div Infect Dis 1, Milan, Italy; [Meraviglia, Paola] Luigi Sacco Hosp, Div Infect Dis 2, Milan, Italy; [Di Biagio, Antonio] San Martino Hosp, Infect Dis Clin, Genoa, Italy; [Lo Caputo, Sergio] Santa Maria Annunziata Hosp, Infect Dis Clin, Florence, Italy; [Sterrantino, Gaetana] Careggi Hosp, Div Infect Dis, Florence, Italy; [Ammassari, Adriana] Lazzaro Spallanzani Hosp, Div Infect Dis 3, Rome, Italy; [Menzaghi, Barbara] Osped Circolo, Div Infect Dis, Busto Arsizio, Italy; [Franzetti, Marco] Luigi Sacco Hosp, Div Infect Dis 3, Milan, Italy; [De Socio, Giuseppe Vittorio] Santa Maria della Misericordia Hosp, Div Infect Dis, Perugia, Italy; [Pellicano, Giovanni] Policlin G Martino, Div Infect Dis, Messina, Italy; [Mazzotta, Elena] Santo Spirito Hosp, Div Infect Dis, Pescara, Italy; [Soria, Alessandro] San Gerardo de Tintori Hosp, Infect Dis Clin, Monza, Italy; [Meschiari, Marianna] Azienda Osped Univ Policlin, Infect Dis Clin, Modena, Italy; [Trezzi, Michele] Santa Maria della Misericordia Hosp, Div Infect Dis, Grosseto, Italy; [Sasset, Lolita] Santa Maria della Misericordia Hosp, Div Infect Dis, Rovigo, Italy; [Celesia, Benedetto Maurizio] Univ Catania, ARNAS Azienda Osped Rilievo Nazl & Alta Specializ, Infect Dis Unit, Catania, Italy	University of Milan; Luigi Sacco Hospital; University of Milan; Luigi Sacco Hospital; University of Genoa; IRCCS AOU San Martino IST; University of Florence; Azienda Ospedaliero Universitaria Careggi; IRCCS Lazzaro Spallanzani; University of Milan; Luigi Sacco Hospital; Hospital Santa Maria della Misericordia; AOU Policlinico Gaetano Martino; University of Messina; Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia Hospital; Hospital Santa Maria della Misericordia; Hospital Santa Maria della Misericordia; University of Catania	Capetti, A (corresponding author), Luigi Sacco Hosp, Div Infect Dis 1, Milan, Italy.	capetti.amedeo@hsacco.it	De Socio, Giuseppe Vittorio/H-6237-2012; Meschiari, Marianna/AAC-1916-2022; PELLICANO', GIOVANNI FRANCESCO/W-4077-2019; Di Biagio, Antonio/J-4901-2019; Zucchi, Patrizia/AFQ-5312-2022; celesia, benedetto maurizio/E-4562-2017	De Socio, Giuseppe Vittorio/0000-0001-8774-4843; Meschiari, Marianna/0000-0002-1254-9995; PELLICANO', GIOVANNI FRANCESCO/0000-0002-9640-8742; Di Biagio, Antonio/0000-0003-1436-5089; celesia, benedetto maurizio/0000-0002-6919-1955; Ammassari, Adriana/0000-0002-0284-0340; Lo Caputo, Sergio/0000-0002-4729-7548; SORIA, Alessandro/0000-0002-4447-2574; meraviglia, paola/0000-0002-3356-7199; Ricci, Elena/0000-0001-5279-0444				Caby F, 2010, SCAND J INFECT DIS, V42, P527, DOI 10.3109/00365541003621502; Capetti AF, 2009, JAIDS-J ACQ IMM DEF, V50, P233, DOI 10.1097/QAI.0b013e31818c7e8e; De Socio GVL, 2008, BIOMED PHARMACOTHER, V62, P16, DOI 10.1016/j.biopha.2007.07.012; Engsig Frederik N, 2010, Clin Epidemiol, V2, P145; Fagard C, 2012, JAIDS-J ACQ IMM DEF, V59, P489, DOI 10.1097/QAI.0b013e31824bb720; Grinsztejn B, 2007, LANCET, V369, P1261, DOI 10.1016/S0140-6736(07)60597-2; Martinez E, 2010, AIDS, V24, P1697, DOI 10.1097/QAD.0b013e32833a608a; Masia M, 2010, J INFECTION, V61, P189, DOI 10.1016/j.jinf.2010.04.011; Nozza S, 2010, AIDS, V24, P924, DOI 10.1097/QAD.0b013e3283372d76; Reiss KA, 2010, AIDS, V24, P2757, DOI 10.1097/QAD.0b013e32833fca42; Riddler SA, 2003, JAMA-J AM MED ASSOC, V289, P2978, DOI 10.1001/jama.289.22.2978; Steigbigel RT, 2010, CLIN INFECT DIS, V50, P605, DOI 10.1086/650002; Teague A, 2010, JAIDS-J ACQ IMM DEF, V53, P666, DOI 10.1097/QAI.0b013e3181ba4845; Teppler H, 2011, CURR HIV RES, V9, P40, DOI 10.2174/157016211794582650; Vispo E, 2010, J ANTIMICROB CHEMOTH, V65, P543, DOI 10.1093/jac/dkp446; Wittkop L, 2009, J ANTIMICROB CHEMOTH, V63, P1251, DOI 10.1093/jac/dkp114; Yazdanpanah Y, 2009, CLIN INFECT DIS, V49, P1441, DOI 10.1086/630210; Young B, 2010, HIV CLIN TRIALS, V11, P260, DOI 10.1310/hct1105-260	18	16	16	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2012	7	7							e39222	10.1371/journal.pone.0039222	http://dx.doi.org/10.1371/journal.pone.0039222			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973LU	22808029	Green Published, gold, Green Submitted			2023-01-03	WOS:000306362400009
J	Park, JH; Darvin, P; Lim, EJ; Joung, YH; Hong, DY; Park, EU; Park, SH; Choi, SK; Moon, ES; Cho, BW; Park, KD; Lee, HK; Kim, MJ; Park, DS; Chung, IM; Yang, YM				Park, Jin Hee; Darvin, Pramod; Lim, Eun Joung; Joung, Youn Hee; Hong, Dae Young; Park, Eui U.; Park, Seung Hwa; Choi, Soo Keun; Moon, Eon-Soo; Cho, Byung Wook; Park, Kyung Do; Lee, Hak Kyo; Kim, Myong-Jo; Park, Dong-Sik; Chung, Ill-Min; Yang, Young Mok			Hwanggeumchal sorghum Induces Cell Cycle Arrest, and Suppresses Tumor Growth and Metastasis through Jak2/STAT Pathways in Breast Cancer Xenografts	PLOS ONE			English	Article							FACTOR-I RECEPTOR; SIGNAL TRANSDUCER; IGF-1 EXPRESSION; KINASE-ACTIVITY; HYPOXIA; APOPTOSIS; STAT5B; ACTIVATOR; PROTEIN; PHASE	Background: Cancer is one of the highly virulent diseases known to humankind with a high mortality rate. Breast cancer is the most common cancer in women worldwide. Sorghum is a principal cereal food in many parts of the world, and is critical in folk medicine of Asia and Africa. In the present study, we analyzed the effects of HSE in metastatic breast cancer. Methodology/Principal Findings: Preliminary studies conducted on MDA-MB 231 and MCF-7 xenograft models showed tumor growth suppression by HSE. Western blotting studies conducted both in vivo and in vitro to check the effect of HSE in Jak/STAT pathways. Anti-metastatic effects of HSE were confirmed using both MDA-MB 231 and MCF-7 metastatic animal models. These studies showed that HSE can modulate Jak/STAT pathways, and it hindered the STAT5b/IGF-1R and STAT3/VEGF pathways not only by down-regulating the expression of these signal molecules and but also by preventing their phosphorylation. The expression of angiogenic factors like VEGF, VEGF-R2 and cell cycle regulators like cyclin D, cyclin E, and pRb were found down-regulated by HSE. In addition, it also targets Brk, p53, and HIF-1 alpha for anti-cancer effects. HSE induced G1 phase arrest and migration inhibition in MDA-MB 231 cells. The metastasis of breast cancer to the lungs also found blocked by HSE in the metastatic animal model. Conclusions/Significance: Usage of HS as a dietary supplement is an inexpensive natural cancer therapy, without any side effects. We strongly recommend the use of HS as an edible therapeutic agent as it possesses tumor suppression, migration inhibition, and anti-metastatic effects on breast cancer.	[Park, Jin Hee; Darvin, Pramod; Lim, Eun Joung; Joung, Youn Hee; Yang, Young Mok] Konkuk Univ, Sch Med, Dept Pathol, Seoul, South Korea; [Park, Jin Hee; Darvin, Pramod; Lim, Eun Joung; Joung, Youn Hee; Yang, Young Mok] Konkuk Univ, Inst Biomed Sci & Technol, Seoul, South Korea; [Hong, Dae Young] Konkuk Univ Hosp, Dept Emergency Med, Seoul, South Korea; [Park, Eui U.] Konkuk Univ, Sch Med, Dept Forens Med, Seoul, South Korea; [Park, Seung Hwa] Konkuk Univ, Sch Med, Dept Anat, Seoul, South Korea; [Choi, Soo Keun] Kyung Hee Univ, Coll Hotel & Tourism Management, Dept Culinary & Serv Management, Seoul, South Korea; [Moon, Eon-Soo] Konkuk Univ, Sch Med, Dept Internal Med, Chungju, South Korea; [Cho, Byung Wook] Pusan Natl Univ, Coll Life Sci, Dept Anim Sci, Pusan 609735, South Korea; [Park, Kyung Do; Lee, Hak Kyo] Hankyong Natl Univ, Genom Informat Ctr, Anseong, South Korea; [Kim, Myong-Jo] Kangwon Natl Univ, Dept Appl Plant Sci, Chunchon, South Korea; [Park, Dong-Sik] Rural Dev Adm, Suwon, South Korea; [Chung, Ill-Min] Konkuk Univ, Dept Appl Life Sci, Seoul, South Korea	Konkuk University; Konkuk University Medical Center; Konkuk University; Konkuk University; Konkuk University Medical Center; Konkuk University; Konkuk University Medical Center; Konkuk University; Konkuk University Medical Center; Kyung Hee University; Konkuk University; Konkuk University Medical Center; Pusan National University; Hankyong National University; Kangwon National University; Rural Development Administration (RDA); Konkuk University	Park, JH (corresponding author), Konkuk Univ, Sch Med, Dept Pathol, Glocal Campus, Seoul, South Korea.	ymyang@kku.ac.kr	Darvin, Pramod/M-1730-2019	Darvin, Pramod/0000-0003-3746-109X; Kim, Myong Jo/0000-0003-4378-4071	Next generation BioGreen 21 Programs [PJ0081062011]; Biogreen 21 programs, Rural Development Administration, South Korea [PJ006457]	Next generation BioGreen 21 Programs; Biogreen 21 programs, Rural Development Administration, South Korea(Rural Development Administration (RDA), Republic of Korea)	This work was supported by the Next generation BioGreen 21 Programs (No. PJ0081062011), and partially supported by Biogreen 21 programs (No. PJ006457), Rural Development Administration, South Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Awika JM, 2004, PHYTOCHEMISTRY, V65, P1199, DOI 10.1016/j.phytochem.2004.04.001; Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bernaciak TM, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2341; Carr TP, 2005, J NUTR, V135, P2236, DOI 10.1093/jn/135.9.2236; Chen WJ, 2003, BIOCHEM PHARMACOL, V65, P1777, DOI 10.1016/S0006-2952(03)00156-4; Cho SH, 2000, FASEB J, V14, pA249; Chung IM, 2011, IMMUNOPHARM IMMUNOT, V33, P447, DOI 10.3109/08923973.2010.532804; Chung IM, 2004, KOREAN SOC CROP SCI, V8, P5; Dal Monte M, 2007, INVEST OPHTH VIS SCI, V48, P3480; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Friedman M, 2007, J AGR FOOD CHEM, V55, P243, DOI 10.1021/jf062276h; Funamoto M, 2000, J BIOL CHEM, V275, P10561, DOI 10.1074/jbc.275.14.10561; Girnita L, 2000, CANCER RES, V60, P5278; Gupta K, 2005, POSTGRAD MED J, V81, P236, DOI 10.1136/pgmj.2004.023309; Hennighausen L, 2008, GENE DEV, V22, P711, DOI 10.1101/gad.1643908; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Himpe E, 2009, BIOFACTORS, V35, P76, DOI 10.1002/biof.20; Huang CS, 1998, CANCER RES, V58, P4102; Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Joung YH, 2005, EXP MOL MED, V37, P353, DOI 10.1038/emm.2005.45; Joung YH, 2008, INT J ONCOL, V33, P477, DOI 10.3892/ijo_00000030; Joung YH, 2007, BIOCHEM BIOPH RES CO, V358, P733, DOI 10.1016/j.bbrc.2007.04.201; Jung JE, 2005, FASEB J, V19, P1296, DOI 10.1096/fj.04-3099fje; Key TJ, 2010, LANCET ONCOL, V11, P530, DOI 10.1016/S1470-2045(10)70095-4; Kil HY, 2009, FOOD CHEM, V115, P1234, DOI 10.1016/j.foodchem.2009.01.032; Kurmasheva RT, 2006, BBA-REV CANCER, V1766, P1, DOI 10.1016/j.bbcan.2006.05.003; Larsson O, 2005, BRIT J CANCER, V92, P2097, DOI 10.1038/sj.bjc.6602627; Lee MY, 2006, BREAST, V15, P187, DOI 10.1016/j.breast.2005.05.005; Lim EJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033361; Lim EJ, 2010, INT J ONCOL, V36, P1243, DOI 10.3892/ijo_00000608; Liu L, 2006, ONCOGENE, V25, P4904, DOI 10.1038/sj.onc.1209501; Ludyga N, 2011, MOL BIOSYST, V7, P1603, DOI 10.1039/c0mb00286k; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Mo HB, 1999, J NUTR, V129, P804, DOI 10.1093/jn/129.4.804; Morrissey PA, 1998, INT DAIRY J, V8, P463, DOI 10.1016/S0958-6946(98)00070-3; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Resnik JL, 1998, CANCER RES, V58, P1159; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Ryu HS, 2008, KOREAN J NUTR, V19, P176; SENGER DR, 1986, CANCER RES, V46, P5629; Takahashi H, 2000, BIOCHEM BIOPH RES CO, V267, P388, DOI 10.1006/bbrc.1999.1931; Terman BI, 2001, EINSTEIN Q J BIOL ME, V18, P59; Thomas R, 2009, PROSTATE, V69, P263, DOI 10.1002/pros.20885; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tweardy D, 2011, J CLIN ONCOL, V29, P2443, DOI 10.1200/JCO.2010.34.2014; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARNER TF, 1988, MED HYPOTHESES, V26, P99, DOI 10.1016/0306-9877(88)90060-6; Werner H, 2006, TRENDS ENDOCRIN MET, V17, P236, DOI 10.1016/j.tem.2006.06.007; Werner Haim, 2009, Archives of Physiology and Biochemistry, V115, P58, DOI 10.1080/13813450902783106; Yang LY, 2009, J AGR FOOD CHEM, V57, P1797, DOI 10.1021/jf8035066; Zhao H, 2004, ONCOGENE, V23, P786, DOI 10.1038/sj.onc.1207162	58	34	36	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2012	7	7							e40531	10.1371/journal.pone.0040531	http://dx.doi.org/10.1371/journal.pone.0040531			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	974UB	22792362	Green Submitted, Green Published, gold			2023-01-03	WOS:000306461800103
J	Chen, MB; Zhu, YQ; Xu, JY; Wang, LQ; Liu, CY; Ji, ZY; Lu, PH				Chen, Min-Bin; Zhu, Ya-Qun; Xu, Jun-Ying; Wang, Li-Qiang; Liu, Chao-Ying; Ji, Zhang-Yi; Lu, Pei-Hua			Value of TP53 Status for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-Analysis	PLOS ONE			English	Article							GENE-EXPRESSION; P53 STATUS; PACLITAXEL; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; MUTATIONS; MARKERS; TUMOR; PROLIFERATION	Background: Numerous studies have yielded inconclusive results regarding the relationship between tumor suppressor protein TP53 overexpression and/or TP53 gene mutations and the response to neoadjuvant chemotherapy in patients with breast cancer. The purpose of the current study was therefore to evaluate the relationship between TP53 status and response to chemotherapy in breast cancer. Methods and Findings: A total of 26 previously published eligible studies including 3,476 cases were identified and included in this meta-analysis. TP53 status (over expression of TP53 protein and/or TP53 gene mutations) was associated with good response in breast cancer patients who received neoadjuvant chemotherapy (total objective response: risk ratio [RR] = 1.20, 95% confidence interval [CI] = 1.09-1.33, p < 0.001; pathological objective response: RR = 1.37, 95% CI = 1.20-1.57, p < 0.01; total complete response: RR = 1.33, 95% CI = 1.15-1.53, p, 0.001; pathological complete response: RR = 1.45, 95% CI = 1.25-1.68, p < 0.001). In further stratified analyses, this association also existed among the studies using anthracycline-based neoadjuvant chemotherapy, and the association between response and the presence of gene alterations was stronger than that between response and immunohistochemistry positivity. Conclusion: The results of the present meta-analysis suggest that TP53 status is a predictive factor for response in breast cancer patients undergoing neoadjuvant chemotherapy. Further larger and well-designed prospective studies are required to evaluate the predictive role of TP53 status in clinical practice.	[Chen, Min-Bin; Wang, Li-Qiang; Ji, Zhang-Yi] Jiangsu Univ, Dept Med Oncol, Kunshan Peoples Hosp 1, Kunshan, Peoples R China; [Zhu, Ya-Qun] Soochow Univ, Dept Radiotherapy & Oncol, Affiliated Hosp 2, Suzhou, Peoples R China; [Xu, Jun-Ying; Liu, Chao-Ying] Nanjing Med Univ, Dept Med Oncol, Wuxi Peoples Hosp, Wuxi City, Peoples R China; [Lu, Pei-Hua] Nanjing Med Univ, Dept Gen Surg, Wuxi Peoples Hosp, Wuxi City, Peoples R China	Jiangsu University; Soochow University - China; Jiangnan University; Nanjing Medical University; Jiangnan University; Nanjing Medical University	Lu, PH (corresponding author), Nanjing Med Univ, Dept Gen Surg, Wuxi Peoples Hosp, Wuxi City, Peoples R China.	lphty1_1@yahoo.com.cn		Lu, Peihua/0000-0002-4622-3061	Natural Science Foundation of Jiangsu Province [BK2010160, BK2011374]; National Natural Science Foundation [81108676, 81101801]	Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); National Natural Science Foundation(National Natural Science Foundation of China (NSFC))	This work was supported by the Natural Science Foundation of Jiangsu Province (No. BK2010160, BK2011374) and the National Natural Science Foundation (No. 81108676, 81101801). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aas T, 2003, EUR J CANCER, V39, P438, DOI 10.1016/S0959-8049(02)00732-3; Anelli A, 2003, ANN ONCOL, V14, P428, DOI 10.1093/annonc/mdg104; Berry DA, 2006, JAMA-J AM MED ASSOC, V295, P1658, DOI 10.1001/jama.295.14.1658; Bertheau P, 2007, PLOS MED, V4, P585, DOI 10.1371/journal.pmed.0040090; Bonnefoi H, 2003, ANN ONCOL, V14, P406, DOI 10.1093/annonc/mdg108; Bonnefoi H, 2011, LANCET ONCOL, V12, P527, DOI 10.1016/S1470-2045(11)70094-8; Deissler H, 2004, ONCOL REP, V11, P1281; Geisler S, 2003, CLIN CANCER RES, V9, P5582; Geisler S, 2001, CANCER RES, V61, P2505; Hayes DF, 2007, NEW ENGL J MED, V357, P1496, DOI 10.1056/NEJMoa071167; Kandioler-Eckersberger D, 2000, CLIN CANCER RES, V6, P50; Keam B, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-203; Kim SJ, 2005, CLIN CANCER RES, V11, P8425, DOI 10.1158/1078-0432.CCR-05-0449; Learn PA, 2005, CANCER-AM CANCER SOC, V103, P2252, DOI 10.1002/cncr.21037; Lee J, 2008, CANCER CHEMOTH PHARM, V61, P569, DOI 10.1007/s00280-007-0506-8; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Makris A, 1997, CLIN CANCER RES, V3, P593; Martin-Richard M, 2004, ONCOLOGY-BASEL, V66, P388, DOI 10.1159/000079487; Masuda H, 2011, CANCER CHEMOTH PHARM, V67, P911, DOI 10.1007/s00280-010-1371-4; Mathieu MC, 2004, EUR J CANCER, V40, P342, DOI 10.1016/j.ejca.2003.08.015; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; Ono M, 2011, BREAST CANC RES TREA; Oshima K, 2011, CANCER LETT, V307, P149, DOI 10.1016/j.canlet.2011.03.027; Pakos EE, 2004, CLIN CANCER RES, V10, P6208, DOI 10.1158/1078-0432.CCR-04-0246; Sanchez-Munoz A, 2010, AM J CLIN ONCOL-CANC, V33, P432, DOI 10.1097/COC.0b013e3181b4eff9; Schneider J, 2001, BREAST CANCER RES, V3, P183, DOI 10.1186/bcr293; Shekhar MPV, 2010, MED ONCOL, V27, P466, DOI 10.1007/s12032-009-9235-7; Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725; Tewari M, 2008, SURG ONCOL, V17, P301, DOI 10.1016/j.suronc.2008.03.003; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tiezzi DG, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-36; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Yonemori K, 2009, MED ONCOL, V26, P344, DOI 10.1007/s12032-008-9127-2; Zhou B, 2008, CHINESE MED J-PEKING, V121, P387, DOI 10.1097/00029330-200803010-00001	35	25	25	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2012	7	6							e39655	10.1371/journal.pone.0039655	http://dx.doi.org/10.1371/journal.pone.0039655			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	967FO	22768103	gold, Green Submitted, Green Published			2023-01-03	WOS:000305892100073
J	Franke, AG; Lieb, K; Hildt, E				Franke, Andreas G.; Lieb, Klaus; Hildt, Elisabeth			What Users Think about the Differences between Caffeine and Illicit/Prescription Stimulants for Cognitive Enhancement	PLOS ONE			English	Article							PRESCRIPTION STIMULANTS; ILLICIT USE; MODAFINIL; NEUROENHANCEMENT; METHYLPHENIDATE; AMPHETAMINE; PERFORMANCE; PREVALENCE; STUDENTS; MOTIVES	Pharmacological cognitive enhancement (CE) is a topic of increasing public awareness. In the scientific literature on student use of CE as a study aid for academic performance enhancement, there are high prevalence rates regarding the use of caffeinated substances (coffee, caffeinated drinks, caffeine tablets) but remarkably lower prevalence rates regarding the use of illicit/prescription stimulants such as amphetamines or methylphenidate. While the literature considers the reasons and mechanisms for these different prevalence rates from a theoretical standpoint, it lacks empirical data to account for healthy students who use both, caffeine and illicit/prescription stimulants, exclusively for the purpose of CE. Therefore, we extensively interviewed a sample of 18 healthy university students reporting non-medical use of caffeine as well as illicit/prescription stimulants for the purpose of CE in a face-to-face setting about their opinions regarding differences in general and morally-relevant differences between caffeine and stimulant use for CE. 44% of all participants answered that there is a general difference between the use of caffeine and illicit/prescription stimulants for CE, 28% did not differentiate, 28% could not decide. Furthermore, 39% stated that there is a moral difference, 56% answered that there is no moral difference and one participant was not able to comment on moral aspects. Participants came to their judgements by applying three dimensions: medical, ethical and legal. Weighing the medical, ethical and legal aspects corresponded to the students' individual preferences of substances used for CE. However, their views only partly depicted evidence-based medical aspects and the ethical issues involved. This result shows the need for well-directed and differentiated information to prevent the potentially harmful use of illicit or prescription stimulants for CE.	[Franke, Andreas G.; Lieb, Klaus] Univ Med Ctr, Dept Psychiat & Psychotherapy, Mainz, Germany; [Hildt, Elisabeth] Johannes Gutenberg Univ Mainz, Dept Philosophy, Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Franke, AG (corresponding author), Univ Med Ctr, Dept Psychiat & Psychotherapy, Mainz, Germany.	afranke@uni-mainz.de			German Ministry of Education and Research (BMBF) [01GP0807]	German Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF))	This work was supported by the German Ministry of Education and Research (BMBF) (Project No. 01GP0807) which has supported the work until September 2011. The BMBF had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Berman SM, 2009, MOL PSYCHIATR, V14, P123, DOI 10.1038/mp.2008.90; Bramstedt KA, 2007, SUBST USE MISUSE, V42, P1237, DOI 10.1080/10826080701208962; Bryant A, 2007, SAGE HDB GROUNDED TH; Bublitz JC, 2009, BIOETHICS, V23, P360, DOI 10.1111/j.1467-8519.2009.01725.x; CAPLAN A, 2002, NEUROETHICS MAPPING, P95; Caplan JP, 2007, NEUROPSYCHOL REV, V17, P363, DOI 10.1007/s11065-007-9037-7; Corbin J.M., 2008, BASICS QUALITATIVE R, Vthird, DOI DOI 10.4135/9781452230153.N8; Elliott C, 2000, HASTINGS CENT REP, V30, P7, DOI 10.2307/3528306; Farah MJ, 2004, NAT REV NEUROSCI, V5, P421, DOI 10.1038/nrn1390; Ferre S, 2008, FRONT BIOSCI-LANDMRK, V13, P2391, DOI 10.2741/2852; Fisone G, 2004, CELL MOL LIFE SCI, V61, P857, DOI 10.1007/s00018-003-3269-3; Franke AG, 2011, PHARMACOPSYCHIATRY, V44, P331, DOI 10.1055/s-0031-1286347; Franke AG, 2011, PHARMACOPSYCHIATRY, V44, P60, DOI 10.1055/s-0030-1268417; Franke AG, 2010, BUNDESGESUNDHEITSBLA, V53, P853, DOI 10.1007/s00103-010-1105-0; Franke AG, 2012, PSYCHIAT PR IN PRESS; Greely H, 2008, NATURE, V456, P702, DOI 10.1038/456702a; Hildt E, 2011, NERVENHEILKUNDE, V30, P833; HUGHES JR, 1992, AM J PSYCHIAT, V149, P33; Juengst Eric T., 1998, ENHANCING HUMAN TRAI, P29; Kass LR, 2003, PRESIDENTS COUNCIL B; Killgore WDS, 2008, J SLEEP RES, V17, P309, DOI 10.1111/j.1365-2869.2008.00654.x; Maher B, 2008, NATURE, V452, P674, DOI 10.1038/452674a; Mayring P, 2010, QUALITATIVE INHALTSA, DOI DOI 10.1007/978-3-531-92052-8_42; Metzinger T., 2011, OXFORD HDB NEUROETHI, P245; NEHLIG A, 1992, BRAIN RES REV, V17, P139, DOI 10.1016/0165-0173(92)90012-B; Oades RD, 2005, DEVELOPMENTAL SCI, V8, P122, DOI 10.1111/j.1467-7687.2005.00399.x; Prince J, 2008, J CLIN PSYCHOPHARM, V28, pS39, DOI 10.1097/JCP.0b013e318174f92a; Racine E, 2009, J MED ETHICS, V35, P469, DOI 10.1136/jme.2009.030460; Racine E, 2010, NEUROETHICS-NETH, V3, P1, DOI 10.1007/s12152-008-9023-7; Repantis D, 2010, PHARMACOL RES, V62, P187, DOI 10.1016/j.phrs.2010.04.002; Sahakian B, 2007, NATURE, V450, P1157, DOI 10.1038/4501157a; Satel S, 2006, AM J DRUG ALCOHOL AB, V32, P493, DOI 10.1080/00952990600918965; SCHREIBER GB, 1988, PREV MED, V17, P280, DOI 10.1016/0091-7435(88)90004-7; Sententia W, 2004, ANN NY ACAD SCI, V1013, P221, DOI 10.1196/annals.1305.014; Smith ME, 2011, PSYCHOL BULL, V137, P717, DOI 10.1037/a0023825; Teter CJ, 2006, PHARMACOTHERAPY, V26, P1501, DOI 10.1592/phco.26.10.1501; Teter CJ, 2005, J AM COLL HEALTH, V53, P253, DOI 10.3200/JACH.53.6.253-262; Wesensten NJ, 2005, J SLEEP RES, V14, P255, DOI 10.1111/j.1365-2869.2005.00468.x; Wilens TE, 2008, J CLIN PSYCHOPHARM, V28, pS46, DOI 10.1097/JCP.0b013e318173312f; Wilens TE, 2008, J AM ACAD CHILD PSY, V47, P21, DOI 10.1097/chi.0b013e31815a56f1	40	55	56	0	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2012	7	6							e40047	10.1371/journal.pone.0040047	http://dx.doi.org/10.1371/journal.pone.0040047			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	967FO	22768218	Green Published, Green Submitted, gold			2023-01-03	WOS:000305892100190
J	Peng, CC; Chen, KC; Hsieh, CL; Peng, RY				Peng, Chiung-Chi; Chen, Kuan-Chou; Hsieh, Chiu-Lan; Peng, Robert Y.			Swimming Exercise Prevents Fibrogenesis in Chronic Kidney Disease by Inhibiting the Myofibroblast Transdifferentiation	PLOS ONE			English	Article							SMOOTH-MUSCLE ACTIN; CHRONIC-RENAL-FAILURE; MESANGIAL CELLS; GROWTH-FACTOR; TNF-ALPHA; PHYSICAL-ACTIVITY; CD34 EXPRESSION; GENE-EXPRESSION; PROTEIN-KINASE; NITRIC-OXIDE	Background: The renal function of chronic kidney disease (CKD) patients may be improved by a number of rehabilitative mechanisms. Swimming exercise training was supposed to be beneficial to its recovery. Methodology/Principal Findings: Doxorubicin-induced CKD (DRCKD) rat model was performed. Swimming training was programmed three days per week, 30 or 60 min per day for a total period of 11 weeks. Serum biochemical and pathological parameters were examined. In DRCKD, hyperlipidemia was observed. Active mesangial cell activation was evidenced by overexpression of PDGFR, P-PDGFR, MMP-2, MMP-9, alpha-SMA, and CD34 with a huge amount collagen deposition. Apparent myofibroblast transdifferentiation implicating fibrogenesis in the glomerular mesangium, glomerulonephritis and glomeruloscelorosis was observed with highly elevated proteinuria and urinary BUN excretion. The 60-min swimming exercise but not the 30 min equivalent rescued most of the symptoms. To quantify the effectiveness of exercise training, a physical parameter, i.e. "the strenuosity coefficient" or "the myokine releasing coefficient", was estimated to be 7.154 x 10(-23) pg/mL-J. Conclusions: The 60-min swimming exercise may ameliorate DRCKD by inhibiting the transdifferentiation of myofibroblasts in the glomerular mesangium. Moreover, rehabilitative exercise training to rescue CKD is a personalized remedy. Benefits depend on the duration and strength of exercise, and more importantly, on the individual physiological condition.	[Peng, Chiung-Chi] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan; [Peng, Chiung-Chi] China Med Univ, Grad Inst Rehabil Sci, Dept Phys Therapy, Taichung, Taiwan; [Chen, Kuan-Chou] Taipei Med Univ, Coll Med, Sch Med, Dept Urol, Taipei, Taiwan; [Chen, Kuan-Chou] Taipei Med Univ, Shuang Ho Hosp, Dept Urol, Taipei, Taiwan; [Hsieh, Chiu-Lan] Natl Changhua Univ Educ, Grad Inst Biotechnol, Changhua, Taiwan; [Peng, Robert Y.] Hungkuang Univ, Biotechnol Res Inst, Taichung, Shalu County, Taiwan	Taipei Medical University; China Medical University Taiwan; Taipei Medical University; Taipei Medical University; Shuang Ho Hospital; National Changhua University of Education; Hungkuang University	Peng, CC (corresponding author), Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan.	misspeng@ms2.hinet.net			National Science Council (NSC) [99-2320-B-038-011-MY3, 99-2320-B-039-034]; Chinese Medical University [CMU99-N1-09, CMU100-TS-07]	National Science Council (NSC)(Ministry of Science and Technology, Taiwan); Chinese Medical University(China Medical University)	The authors want to show their gratitude to the financial supports issued by the National Science Council (NSC 99-2320-B-038-011-MY3 and 99-2320-B-039-034) and those offered by Chinese Medical University (CMU99-N1-09 & CMU100-TS-07). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acevedo LM, 2008, J HISTOCHEM CYTOCHEM, V56, P605, DOI 10.1369/jhc.7A7354.2008; Adams GR, 2006, AM J PHYSIOL-RENAL, V290, pF753, DOI 10.1152/ajprenal.00296.2005; Aresu L, 2011, HISTOL HISTOPATHOL, V26, P307, DOI 10.14670/HH-26.307; Aslan R, 1998, T J MED SCI, V28, P411; Bauheter S, 2003, SCIENCE, V262, P436; BELCASTRO AN, 1985, CAN J PHYSIOL PHARM, V63, P1202, DOI 10.1139/y85-198; Bergamaschi CT, 1997, MED SCI SPORT EXER, V29, P169, DOI 10.1097/00005768-199702000-00001; Berk BC, 2011, ANN NY ACAD SCI, V947, P93; BERTANI T, 1982, LAB INVEST, V46, P16; Bloomfield SA, 1993, RESOURCE MANUAL GUID, P115; Bonegio RGB, 2005, J AM SOC NEPHROL, V16, P2063, DOI 10.1681/ASN.2004030180; Boo YC, 2002, J BIOL CHEM, V277, P3388, DOI 10.1074/jbc.M108789200; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bruun JM, 2003, AM J PHYSIOL-ENDOC M, V285, pE527, DOI 10.1152/ajpendo.00110.2003; Bruunsgaard H, 2005, J LEUKOCYTE BIOL, V78, P819, DOI 10.1189/jlb.0505247; Carrero JJ, 2008, BLOOD PURIFICAT, V26, P291, DOI 10.1159/000126926; Chebotareva NV, 2002, TERAPEVT ARKH, V74, P27; Coelho BLP, 2010, J RENAL NUTR, V20, P169, DOI 10.1053/j.jrn.2009.10.007; de Gonzalo-Calvo D, 2012, AGE DORDR       0104; De Moraes R, 2004, J APPL PHYSIOL, V97, P683, DOI 10.1152/japplphysiol.00923.2003; Duzova H, 2009, J SPORT SCI MED, V8, P219; FACKLER MJ, 1995, BLOOD, V85, P3040, DOI 10.1182/blood.V85.11.3040.bloodjournal85113040; Fasshauer M, 2003, DIABETOLOGIA, V46, P1594, DOI 10.1007/s00125-003-1228-z; Fasshauer M, 2003, BIOCHEM BIOPH RES CO, V301, P1045, DOI 10.1016/S0006-291X(03)00090-1; Fock RA, 2007, CYTOKINE, V40, P105, DOI 10.1016/j.cyto.2007.08.007; Galeano B, 2007, J CLIN INVEST, V117, P1585, DOI 10.1172/JCI30954; GHAHARY A, 1993, J LAB CLIN MED, V122, P465; Gluhovschi C, 2008, VIRCHOWS ARCH, V453, P321, DOI 10.1007/s00428-008-0647-0; HARRI M, 1986, ACTA PHYSIOL SCAND, V126, P189, DOI 10.1111/j.1748-1716.1986.tb07805.x; Hasegawa M, 2005, J DERMATOL SCI, V39, P1, DOI 10.1016/j.jdermsci.2005.03.013; HEIFETS M, 1987, KIDNEY INT, V32, P815, DOI 10.1038/ki.1987.281; Ichimura K, 2006, J HISTOCHEM CYTOCHEM, V54, P1291, DOI 10.1369/jhc.6A7000.2006; Jeansson M, 2009, J AM SOC NEPHROL, V20, P114, DOI 10.1681/ASN.2007111205; Jia B, 2012, CLIN HEMORHEOL  0103; Johansen KL, 2007, J AM SOC NEPHROL, V18, P1845, DOI 10.1681/ASN.2007010009; JOHNSON RJ, 1991, J CLIN INVEST, V87, P847, DOI 10.1172/JCI115089; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; KULOZIK M, 1990, J CLIN INVEST, V86, P917, DOI 10.1172/JCI114793; Leber TM, 1997, ANAL BIOCHEM, V249, P24, DOI 10.1006/abio.1997.2170; Li KW, 2009, J OCCUP SAFETY HLTH, V17, P18; Liang YJ, 2009, PEDIATR NEPHROL, V24, P1661, DOI 10.1007/s00467-009-1163-4; MARTINET Y, 1987, NEW ENGL J MED, V317, P202, DOI 10.1056/NEJM198707233170404; Mastorakos George, 2005, Hormones (Athens), V4, P73; Naruse K, 1999, J PATHOL, V189, P105; Nemet D, 2002, PEDIATRICS, V110, P681, DOI 10.1542/peds.110.4.681; Olszanecka-Gliniaowicz M, 2006, ENDOKRYNOL POL, V57, P87; OSATO S, 1990, NEPHRON, V55, P306, DOI 10.1159/000185980; Ostendorf T, 2001, J AM SOC NEPHROL, V12, P909, DOI 10.1681/ASN.V125909; Painter P, 2008, EXERCISE SPORT SCI R, P83; Pedersen BK, 2007, TRENDS PHARMACOL SCI, V28, P152, DOI 10.1016/j.tips.2007.02.002; PELTONEN J, 1991, J INVEST DERMATOL, V97, P240, DOI 10.1111/1523-1747.ep12480289; Peng CC, 2012, J BIOL REGU IN PRESS; Platel D, 1996, CYTOKINE, V8, P895, DOI 10.1006/cyto.1996.0120; POORTMANS JR, 1995, NEPHROLOGIE, V16, P317; Pusztaszeri MP, 2006, J HISTOCHEM CYTOCHEM, V54, P385, DOI 10.1369/jhc.4A6514.2005; Ranieri E, 2001, J NEPHROL, V14, P253; Rankin CA, 1999, J AM SOC NEPHROL, V10, P210; RUBIN K, 1988, LANCET, V1, P1353; Silveira EMS, 2007, CELL BIOCHEM FUNCT, V25, P63, DOI 10.1002/cbf.1365; Steensberg A, 2002, AM J PHYSIOL-ENDOC M, V283, pE1272, DOI 10.1152/ajpendo.00255.2002; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Stump CS, 2011, CARDIORENAL MED, V1, P164, DOI 10.1159/000329929; Tang WW, 1996, AM J PATHOL, V148, P1169; Tschakovsky ME, 2008, APPL PHYSIOL NUTR ME, V33, P151, DOI 10.1139/H07-148; Vierck HB, 2012, EUR J APPL PHYS 0122; Vouldoukis I, 2004, J ETHNOPHARMACOL, V94, P67, DOI 10.1016/j.jep.2004.04.023; Weibel ER, 1979, PRACTICAL METHODS BI, P51; Zeisberg EM, 2008, J AM SOC NEPHROL, V19, P2282, DOI 10.1681/ASN.2008050513	68	33	34	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2012	7	6							e37388	10.1371/journal.pone.0037388	http://dx.doi.org/10.1371/journal.pone.0037388			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	966GL	22761655	Green Published, Green Submitted, gold			2023-01-03	WOS:000305825800005
J	Wardlaw, JM; Murray, V; Berge, E; del Zoppo, G; Sandercock, P; Lindley, RL; Cohen, G				Wardlaw, Joanna M.; Murray, Veronica; Berge, Eivind; del Zoppo, Gregory; Sandercock, Peter; Lindley, Richard L.; Cohen, Geoff			Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis	LANCET			English	Article							INTRAVENOUS ALTEPLASE; THROMBOLYTIC THERAPY; CONTROLLED-TRIAL; POOLED ANALYSIS; DOUBLE-BLIND; RT-PA; ATLANTIS; ECASS; EPITHET; NINDS	Background Recombinant tissue plasminogen activator (rt-PA, alteplase) improved functional outcome in patients treated soon after acute ischaemic stroke in randomised trials, but licensing is restrictive and use varies widely. The IST-3 trial adds substantial new data. We therefore assessed all the evidence from randomised trials for rt-PA in acute ischaemic stroke in an updated systematic review and meta-analysis. Methods We searched for randomised trials of intravenous rt-PA versus control given within 6 h of onset of acute ischaemic stroke up to March 30, 2012. We estimated summary odds ratios (ORs) and 95% CI in the primary analysis for prespecified outcomes within 7 days and at the final follow-up of all patients treated up to 6 h after stroke. Findings In up to 12 trials (7012 patients), rt-PA given within 6 h of stroke significantly increased the odds of being alive and independent (modified Rankin Scale, mRS 0-2) at final follow-up (1611/3483 [46.3%] vs 1434/3404 [42.1%], OR 1.17, 95% CI 1.06-1.29; p=0.001), absolute increase of 42 (19-66) per 1000 people treated, and favourable outcome (mRS 0-1) absolute increase of 55 (95% CI 33-77) per 1000. The benefit of rt-PA was greatest in patients treated within 3 h (mRS 0-2, 365/896 [40.7%] vs 280/883 [31.7%], 1.53, 1.26-1.86, p<0.0001), absolute benefit of 90 (46-135) per 1000 people treated, and mRS 0-1 (283/896 [31.6%] vs 202/883 [22.9%], 1.61, 1.30-1.90; p<0.0001), absolute benefit 87 (46-128) per 1000 treated. Numbers of deaths within 7 days were increased (250/2807 [8.9%] vs 174/2728 [6.4%], 1.44, 1.18-1.76; p=0.0003), but by final follow-up the excess was no longer significant (679/3548 [19.1%] vs 640/3464 [18.5%], 1.06, 0.94-1.20; p=0.33). Symptomatic intracranial haemorrhage (272/3548 [7.7%] vs 63/3463 [1.8%], 3.72, 2.98-4.64; p<0.0001) accounted for most of the early excess deaths. Patients older than 80 years achieved similar benefit to those aged 80 years or younger, particularly when treated early. Interpretation The evidence indicates that intravenous rt-PA increased the proportion of patients who were alive with favourable outcome and alive and independent at final follow-up. The data strengthen previous evidence to treat patients as early as possible after acute ischaemic stroke, although some patients might benefit up to 6 h after stroke.	[Wardlaw, Joanna M.; Sandercock, Peter; Cohen, Geoff] Univ Edinburgh, Western Gen Hosp, Div Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland; [Murray, Veronica] Danderyd Hosp, Karolinska Inst, Stockholm, Sweden; [Berge, Eivind] Oslo Univ Hosp, Dept Internal Med, Oslo, Norway; [del Zoppo, Gregory] Univ Washington, Sch Med, Seattle, WA USA; [Lindley, Richard L.] Univ Sydney, Westmead Hosp, Sydney Med Sch, Sydney, NSW 2006, Australia; [Lindley, Richard L.] Univ Sydney, George Inst Global Hlth, Sydney, NSW 2006, Australia	University of Edinburgh; Danderyds Hospital; Karolinska Institutet; University of Oslo; University of Washington; University of Washington Seattle; University of Sydney; George Institute for Global Health; University of Sydney	Wardlaw, JM (corresponding author), Univ Edinburgh, Western Gen Hosp, Div Clin Neurosci, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	joanna.wardlaw@ed.ac.uk	Wardlaw, Joanna M/Y-3456-2019; Hernandez, María/GYU-3543-2022; Lindley, Richard/B-8148-2013	Wardlaw, Joanna M/0000-0002-9812-6642; Lindley, Richard/0000-0002-0104-5679; Sandercock, Peter/0000-0001-8484-0135	UK Medical Research Council; Stroke Association; University of Edinburgh; National Health Service Health Technology Assessment Programme; Swedish Heart-Lung Fund; AFA Insurances Stockholm (Arbetsmarknadens Partners Forsakringsbolag); Karolinska Institute; Marianne and Marcus Wallenberg Foundation; Research Council of Norway; Oslo University Hospital; Boehringer Ingelheim; MRC [G0800803, G0400069] Funding Source: UKRI; Medical Research Council [G0700704B, G0800803, G0400069] Funding Source: researchfish; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS053716, R37NS038710] Funding Source: NIH RePORTER	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Stroke Association; University of Edinburgh; National Health Service Health Technology Assessment Programme; Swedish Heart-Lung Fund(Swedish Heart-Lung Foundation); AFA Insurances Stockholm (Arbetsmarknadens Partners Forsakringsbolag); Karolinska Institute(Karolinska Institutet); Marianne and Marcus Wallenberg Foundation; Research Council of Norway(Research Council of Norway); Oslo University Hospital; Boehringer Ingelheim(Boehringer Ingelheim); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	UK Medical Research Council, Stroke Association, University of Edinburgh, National Health Service Health Technology Assessment Programme, Swedish Heart-Lung Fund, AFA Insurances Stockholm (Arbetsmarknadens Partners Forsakringsbolag), Karolinska Institute, Marianne and Marcus Wallenberg Foundation, Research Council of Norway, Oslo University Hospital.; JMW, VM, EB, PS, RIL, and GC are all investigators in the IST-3 trial. JMW was a member of the expert neuroradiological adjudication committee for IST-3 and ECASS 3. GdZ was on the data and safety monitoring committees of the ECASS and ECASS II trials funded by Boehringer Ingelheim. JMW has received reimbursement for expenses for speaking at and attending meetings arranged by Boehringer Ingelheim, is not or has not been on any industry expert panels but did provide independent information to Boehringer Ingelheim to assist with the European license application for rt-PA. RIL has received payment in his role as conference Scientific Committee member and for occasional lectures from Boehringer Ingelheim; he has attended national stroke meetings that were organised and funded by Boehringer Ingelheim; and he is not a member of any industry advisory boards. EB and PS have received payment for lectures at meetings arranged by Boehringer Ingelheim, and reimbursement for costs for attending these meetings.	Albers GW, 2002, STROKE, V33, P493, DOI 10.1161/hs0202.102599; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Bhatnagar P, 2011, J NEUROL NEUROSUR PS, V82, P712, DOI 10.1136/jnnp.2010.223149; Clark WM, 1999, JAMA-J AM MED ASSOC, V282, P2019, DOI 10.1001/jama.282.21.2019; Clark WM, 2000, STROKE, V31, P811, DOI 10.1161/01.STR.31.4.811; Davis SM, 2008, LANCET NEUROL, V7, P299, DOI 10.1016/S1474-4422(08)70044-9; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hacke W, 2004, LANCET, V363, P768; Hacke Werner, 2008, N Engl J Med, V359, P1317, DOI 10.1056/NEJMoa0804656; HALEY EC, 1993, STROKE, V24, P1000, DOI 10.1161/01.STR.24.7.1000; Lees Kennedy R, 2010, Lancet, V375, P1695, DOI 10.1016/S0140-6736(10)60491-6; Lorenzano S, 2012, INT J STROKE, V7, P250, DOI 10.1111/j.1747-4949.2011.00747.x; Ma H, 2012, INT J STROKE, V7, P74, DOI 10.1111/j.1747-4949.2011.00730.x; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mishra NK, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6046; MORI E, 1992, NEUROLOGY, V42, P976, DOI 10.1212/WNL.42.5.976; Sandercock P, 2012, LANCET, V379, P2352, DOI 10.1016/S0140-6736(12)60768-5; Slot KB, 2008, BRIT MED J, V336, P376, DOI 10.1136/bmj.39456.688333.BE; Wang Shen-yan, 2003, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V15, P542; Wardlaw JM, 2003, STROKE, V34, P1437, DOI 10.1161/01.STR.0000072513.72262.7E; WARDLAW JM, 1992, STROKE, V23, P1826, DOI 10.1161/01.STR.23.12.1826; Wardlaw JM, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000213; Wardlaw JM, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b4584; Wardlaw JM, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000213.pub2; YAMAGUCHI T, 1993, CEREBROVASC DIS, V3, P269, DOI 10.1159/000108714	26	686	737	3	97	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 23	2012	379	9834					2364	2372		10.1016/S0140-6736(12)60738-7	http://dx.doi.org/10.1016/S0140-6736(12)60738-7			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	961ZV	22632907	Green Published			2023-01-03	WOS:000305509600031
J	Valero-Cabre, A; Wattiez, N; Monfort, M; Francois, C; Rivaud-Pechoux, S; Gaymard, B; Pouget, P				Valero-Cabre, Antoni; Wattiez, Nicolas; Monfort, Morgane; Francois, Chantal; Rivaud-Pechoux, Sophie; Gaymard, Bertrand; Pouget, Pierre			Frontal Non-Invasive Neurostimulation Modulates Antisaccade Preparation in Non-Human Primates	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; POSTERIOR PARIETAL CORTEX; MEMORY-GUIDED SACCADES; EYE FIELD; ELECTRICAL-STIMULATION; VISUAL-CORTEX; CORTICOSPINAL OUTPUT; OWL MONKEYS; RAT-BRAIN; MOTOR	A combination of oculometric measurements, invasive electrophysiological recordings and microstimulation have proven instrumental to study the role of the Frontal Eye Field (FEF) in saccadic activity. We hereby gauged the ability of a non-invasive neurostimulation technology, Transcranial Magnetic Stimulation (TMS), to causally interfere with frontal activity in two macaque rhesus monkeys trained to perform a saccadic antisaccade task. We show that online single pulse TMS significantly modulated antisaccade latencies. Such effects proved dependent on TMS site (effects on FEF but not on an actively stimulated control site), TMS modality (present under active but not sham TMS on the FEF area), TMS intensity (intensities of at least 40% of the TMS machine maximal output required), TMS timing (more robust for pulses delivered at 150 ms than at 100 post target onset) and visual hemifield (relative latency decreases mainly for ipsilateral AS). Our results demonstrate the feasibility of using TMS to causally modulate antisaccade-associated computations in the non-human primate brain and support the use of this approach in monkeys to study brain function and its non-invasive neuromodulation for exploratory and therapeutic purposes.	[Valero-Cabre, Antoni; Wattiez, Nicolas; Monfort, Morgane; Francois, Chantal; Rivaud-Pechoux, Sophie; Gaymard, Bertrand; Pouget, Pierre] Univ Paris 06, CNRS, INSERM, Inst Cerveau & Moelle ICM,UMR 7225,UMRS 975, Paris, France; [Valero-Cabre, Antoni] Boston Univ, Sch Med, Lab Cerebral Dynam Plast & Rehabil, Boston, MA 02118 USA; [Valero-Cabre, Antoni] Open Univ Catalonia UOC, Cognit Neurosci & Informat Technol Res Program, Barcelona, Spain	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Boston University; UOC Universitat Oberta de Catalunya	Valero-Cabre, A (corresponding author), Univ Paris 06, CNRS, INSERM, Inst Cerveau & Moelle ICM,UMR 7225,UMRS 975, Paris, France.	antoni.valerocabre@upmc.fr; pierre.pouget@upmc.fr	Pouget, Pierre/N-8031-2019	Pouget, Pierre/0000-0002-4721-7376; Valero-Cabre, Antoni/0000-0002-5033-2279	Centre National de la Recherche Scientifique, Institut des Sciences Biologiques, Projets Exploratoires Premier Soutien; USA, National Institute of Neurological Disorders and Stroke [R21NSS062317]; european Funding Program FP6; l'Agence National pour la recherche: project eraNET-NEURON BEYONDVIS	Centre National de la Recherche Scientifique, Institut des Sciences Biologiques, Projets Exploratoires Premier Soutien; USA, National Institute of Neurological Disorders and Stroke; european Funding Program FP6; l'Agence National pour la recherche: project eraNET-NEURON BEYONDVIS	This work has been made possible thanks to funding provided by Centre National de la Recherche Scientifique, Institut des Sciences Biologiques, Projets Exploratoires Premier Soutien, 2010. The work of AV-C was also supported by USA, National Institute of Neurological Disorders and Stroke R21NSS062317 and the european Funding Program FP6 and l'Agence National pour la recherche: project eraNET-NEURON BEYONDVIS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen EA, 2007, SCIENCE, V317, P1918, DOI 10.1126/science.1146426; AMASSIAN VE, 1990, ELECTROEN CLIN NEURO, V77, P390, DOI 10.1016/0168-5597(90)90061-H; Amaya F, 2010, CLIN NEUROPHYSIOL, V121, P2143, DOI 10.1016/j.clinph.2010.03.058; Armstrong KM, 2006, NEURON, V50, P791, DOI 10.1016/j.neuron.2006.05.010; Aydin-Abidin S, 2006, J PHYSL; BAKER SN, 1995, J PHYSIOL-LONDON, V488, P795, DOI 10.1113/jphysiol.1995.sp021011; BRUCE CJ, 1985, J NEUROPHYSIOL, V54, P714, DOI 10.1152/jn.1985.54.3.714; Burman DD, 1997, J NEUROPHYSIOL, V77, P2252, DOI 10.1152/jn.1997.77.5.2252; Campana G, 2007, NEUROPSYCHOLOGIA, V45, P2340, DOI 10.1016/j.neuropsychologia.2007.02.009; Condy C, 2005, BIOL PSYCHIAT, V57, P366, DOI 10.1016/j.biopsych.2004.10.036; Corbetta M, 1998, PHILOS T ROY SOC B, V353, P1353, DOI 10.1098/rstb.1998.0289; Ekstrom LB, 2008, SCIENCE, V321, P414, DOI 10.1126/science.1153276; Gaymard B, 1999, EXP BRAIN RES, V129, P288, DOI 10.1007/s002210050899; Gerits A, 2011, EXP BRAIN RES, V212, P143, DOI 10.1007/s00221-011-2710-3; Ghaly RF, 1999, NEUROL RES, V21, P714, DOI 10.1080/01616412.1999.11741003; GOULD HJ, 1986, J COMP NEUROL, V247, P297, DOI 10.1002/cne.902470303; Grosbras MH, 2003, EUR J NEUROSCI, V18, P3121, DOI 10.1111/j.1460-9568.2003.03055.x; Grosbras MH, 2002, J COGNITIVE NEUROSCI, V14, P1109, DOI 10.1162/089892902320474553; Hayashi T, 2004, ANN NEUROL, V56, P77, DOI 10.1002/ana.20151; HUERTA MF, 1987, J COMP NEUROL, V265, P332, DOI 10.1002/cne.902650304; Izawa Y, 2004, J NEUROPHYSIOL, V92, P2248, DOI 10.1152/jn.01021.2003; Izawa Y, 2004, J NEUROPHYSIOL, V92, P2261, DOI 10.1152/jn.00085.2004; Ji RR, 1998, P NATL ACAD SCI USA, V95, P15635, DOI 10.1073/pnas.95.26.15635; Jing HK, 2000, CLIN NEUROPHYSIOL, V111, P1620, DOI 10.1016/S1388-2457(00)00357-6; Kleim JA, 2007, NAT PROTOC, V2, P1675, DOI 10.1038/nprot.2007.206; Liebetanz D, 2003, J PSYCHIATR RES, V37, P277, DOI 10.1016/S0022-3956(03)00017-7; Logothetis NK, NAT NEUROSCI, V13, P1283; Luft AR, 2001, EXP BRAIN RES, V140, P112, DOI 10.1007/s002210100805; Mantovani M, 2006, NEUROCHEM INT, V49, P347, DOI 10.1016/j.neuint.2006.02.008; MARROCCO RT, 1978, BRAIN RES, V146, P23, DOI 10.1016/0006-8993(78)90215-9; Moliadze V, 2003, J PHYSIOL-LONDON, V553, P665, DOI 10.1113/jphysiol.2003.050153; Moore T, 2001, P NATL ACAD SCI USA, V98, P1273, DOI 10.1073/pnas.021549498; Muri RM, 2008, PROG BRAIN RES, V171, P413, DOI 10.1016/S0079-6123(08)00660-2; MURI RM, 1991, EXP BRAIN RES, V86, P219; Nagel M, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-89; Neggers SFW, 2007, J NEUROPHYSIOL, V98, P2765, DOI 10.1152/jn.00357.2007; Nyffeler T, 2008, PROG BRAIN RES, V171, P429, DOI 10.1016/S0079-6123(08)00663-8; O'Shea J, 2004, J COGNITIVE NEUROSCI, V16, P1060, DOI 10.1162/0898929041502634; Olk B, 2006, CEREB CORTEX, V16, P76, DOI 10.1093/cercor/bhi085; Pascual- Leone A, 2001, HDB TRANSCRANIAL MAG; Post A, 1999, EUR J NEUROSCI, V11, P3247, DOI 10.1046/j.1460-9568.1999.00747.x; RIVAUD S, 1994, EXP BRAIN RES, V102, P110; Ro T, 2003, EXP BRAIN RES, V150, P290, DOI 10.1007/s00221-003-1470-0; Ro T, 2002, J CLIN EXP NEUROPSYC, V24, P930, DOI 10.1076/jcen.24.7.930.8385; Ro T, 1999, NEUROPSYCHOLOGIA, V37, P225; SHIBUTANI H, 1984, EXP BRAIN RES, V55, P1; Silvanto J, 2006, J NEUROPHYSIOL, V96, P941, DOI 10.1152/jn.00015.2006; Thickbroom GW, 1996, J NEUROL SCI, V144, P114, DOI 10.1016/S0022-510X(96)00194-3; Valero-Cabre A, 2006, EXP BRAIN RES, V172, P14, DOI 10.1007/s00221-005-0307-4; Valero-Cabre A, 2005, EXP BRAIN RES, V163, P1, DOI 10.1007/s00221-004-2140-6; Valero-Cabre A, 2008, EUR J NEUROSCI, V27, P765, DOI 10.1111/j.1460-9568.2008.06045.x; Valero-Cabre A, 2007, EXP BRAIN RES, V176, P603, DOI 10.1007/s00221-006-0639-8; Wagner T, 2007, ANNU REV BIOMED ENG, V9, P527, DOI 10.1146/annurev.bioeng.9.061206.133100; WESSEL K, 1991, EXP BRAIN RES, V86, P216	55	16	16	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2012	7	6							e38674	10.1371/journal.pone.0038674	http://dx.doi.org/10.1371/journal.pone.0038674			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959WK	22701691	Green Published, gold, Green Submitted			2023-01-03	WOS:000305348400083
J	Moreau, M; Le Tortorec, A; Deleage, C; Brown, C; Denis, H; Satie, AP; Bourry, O; Deureuddre-Bosquet, N; Roques, P; Le Grand, R; Dejucq-Rainsford, N				Moreau, Marina; Le Tortorec, Anna; Deleage, Claire; Brown, Charles; Denis, Helene; Satie, Anne-Pascale; Bourry, Olivier; Deureuddre-Bosquet, Nathalie; Roques, Pierre; Le Grand, Roger; Dejucq-Rainsford, Nathalie			Impact of Short-Term HAART Initiated during the Chronic Stage or Shortly Post-Exposure on SIV Infection of Male Genital Organs	PLOS ONE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; SEMEN-PRODUCING ORGANS; HIV RNA; SEXUAL TRANSMISSION; REPRODUCTIVE-TRACT; T-LYMPHOCYTES; SEMINAL CELLS; MACAQUES; BLOOD	Background: The male genital tract is suspected to constitute a viral sanctuary as persistent HIV shedding is found in the semen of a subset of HIV-infected men receiving effective antiretroviral therapy (HAART). The origin of this persistent shedding is currently unknown. Phylogenetic studies indicated that HIV in semen from untreated men arises from local sources and/or passive diffusion from the blood. We previously demonstrated in human and macaque low levels and localized infection of several semen-producing organs by HIV/SIV. Using a macaque model, this study investigates the impact of short term HAART (2-4 weeks) initiated either during the asymptomatic chronic stage or 4 h post-intravenous inoculation of SIVmac251 on the infection of male genital organs. Methodology/Principal Findings: Short term HAART during the chronic stage decreased blood viral load. No major impact of HAART was observed on SIV DNA levels in male genital organs using a sensitive nested PCR assay. Using in situ hybridization, SIV RNA+ cells were detected in all male genital tract organs from untreated and treated animals with undetectable blood viral load following HAART. Infected CD68+ myeloid cells and CD3+ T lymphocytes were detected pre-and post-HAART. In contrast, short term HAART initiated 4 h post-SIV exposure led to a drastic decrease of the male genital tissues infection, although it failed to prevent systemic infection. In both cases, HAART tended to decrease the number of CD3+ T cells in the male organs. Conclusions: Our results indicate that the established infection of male genital organs is not greatly impacted by short term HAART, whereas the same treatment during pre-acute phase of the infection efficiently impairs viral dissemination to the male genital tract. Further investigations are now needed to determine whether infection of male genital organs is responsible for long term persistent HIV shedding in semen despite HAART.	[Moreau, Marina; Le Tortorec, Anna; Deleage, Claire; Denis, Helene; Satie, Anne-Pascale; Dejucq-Rainsford, Nathalie] Univ Rennes 1, INSERM, IRSET U1085, Inst Federatif Rech 140, Rennes, France; [Bourry, Olivier; Deureuddre-Bosquet, Nathalie; Roques, Pierre; Le Grand, Roger] CEA, DSV, Inst Emerging Dis & Innovat Therapies, Div Immunovirol, Fontenay Aux Roses, France; [Brown, Charles] NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; [Bourry, Olivier; Deureuddre-Bosquet, Nathalie; Roques, Pierre; Le Grand, Roger] Univ Paris 11, UMR E1, Orsay, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; CEA; UDICE-French Research Universities; Universite Paris Saclay; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); UDICE-French Research Universities; Universite Paris Saclay	Moreau, M (corresponding author), Univ Rennes 1, INSERM, IRSET U1085, Inst Federatif Rech 140, Rennes, France.	nathalie.dejucq-rainsford@inserm.fr	Roques, Pierre/M-2212-2013; Le Tortorec, Anna/J-5291-2015; DEJUCQ-RAINSFORD, Nathalie/I-2571-2015	Roques, Pierre/0000-0003-1825-1054; 	ANRS; Sidaction; Inserm; Region Bretagne	ANRS(ANRSFrench National Research Agency (ANR)); Sidaction; Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Region Bretagne(Region Bretagne)	This work was funded by ANRS, Sidaction, Inserm and Region Bretagne. Marina Moreau is the recipient of stipends from Region Bretagne and Sidaction. Claire Deleage and Helene Denis are supported by ANRS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson JA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001053; Annamalai L, 2010, AM J PATHOL, V177, P777, DOI 10.2353/ajpath.2010.091248; Aquaro S, 2006, J LEUKOCYTE BIOL, V80, P1103, DOI 10.1189/jlb.0606376; Barroso PF, 2000, ANN INTERN MED, V133, P280, DOI 10.7326/0003-4819-133-4-200008150-00012; BASKERVILLE A, 1992, J COMP PATHOL, V107, P49, DOI 10.1016/0021-9975(92)90095-C; Benito JM, 2004, AIDS RES HUM RETROV, V20, P227, DOI 10.1089/088922204773004950; Benlhassan-Chahour K, 2003, J VIROL, V77, P12479, DOI 10.1128/JVI.77.23.12479-12493.2003; Bourry O, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-78; Bourry O, 2009, AIDS, V23, P447, DOI 10.1097/QAD.0b013e328321302d; Brown CR, 2007, J VIROL, V81, P5594, DOI 10.1128/JVI.00202-07; Buzon MJ, 2010, NAT MED, V16, P460, DOI 10.1038/nm.2111; Caufour P, 2001, MICROBES INFECT, V3, P181, DOI 10.1016/S1286-4579(01)01370-3; Choo EF, 2000, DRUG METAB DISPOS, V28, P655; Clay CC, 2005, J VIROL, V79, P13759, DOI 10.1128/JVI.79.21.13759-13768.2005; Crowe S, 2003, J LEUKOCYTE BIOL, V74, P635, DOI 10.1189/jlb.0503204; Deleage C, 2011, AM J PATHOL, V179, P2397, DOI 10.1016/j.ajpath.2011.08.005; Dioszeghy V, 2006, J VIROL, V80, P236, DOI 10.1128/JVI.80.1.236-245.2006; Dornadula G, 1999, JAMA-J AM MED ASSOC, V282, P1627, DOI 10.1001/jama.282.17.1627; Ghosn J, 2004, AIDS, V18, P447, DOI 10.1097/00002030-200402200-00011; Gunthard HF, 2001, J INFECT DIS, V183, P1318, DOI 10.1086/319864; Haase AT, 2005, NAT REV IMMUNOL, V5, P783, DOI 10.1038/nri1706; Halfon P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010569; Hirsch V, 1997, J VIROL, V71, P1608, DOI 10.1128/JVI.71.2.1608-1620.1997; HIRSCH VM, 1995, J VIROL, V69, P955, DOI 10.1128/JVI.69.2.955-967.1995; Kotler DP, 1998, AIDS, V12, P597, DOI 10.1097/00002030-199806000-00008; Kwa S, 2011, BLOOD, V118, P2763, DOI 10.1182/blood-2011-02-339515; Lambert-Niclot S, 2010, ANTIMICROB AGENTS CH, V54, P4910, DOI 10.1128/AAC.00725-10; Le Grand R, 2000, AIDS, V14, P1864; Le Tortorec A, 2010, INT J ANDROL, V33, pE98, DOI 10.1111/j.1365-2605.2009.00973.x; Le Tortorec A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001792; Le Tortorec A, 2010, M S-MED SCI, V26, P861, DOI 10.1051/medsci/20102610861; Le Tortorec A, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-119; Leruez-Ville M, 2002, AIDS, V16, P486, DOI 10.1097/00002030-200202150-00023; Livni E, 2004, NUCL MED BIOL, V31, P613, DOI 10.1016/j.nucmedbio.2003.11.006; Marcelin AG, 2008, AIDS, V22, P1677, DOI 10.1097/QAD.0b013e32830abdc8; Mayer KH, 1999, CLIN INFECT DIS, V28, P1252, DOI 10.1086/514775; MILLER CJ, 1994, LAB INVEST, V70, P255; Miller CJ, 2005, J VIROL, V79, P9217, DOI 10.1128/JVI.79.14.9217-9227.2005; North TW, 2010, J VIROL, V84, P2913, DOI 10.1128/JVI.02356-09; Nunnari G, 2002, AIDS, V16, P39, DOI 10.1097/00002030-200201040-00006; Paranjpe S, 2002, AIDS RES HUM RETROV, V18, P1271, DOI 10.1089/088922202320886316; Pasquier C, 2012, ANTIVIRAL T IN PRESS; Pasquier C, 2009, J CLIN MICROBIOL, V47, P2883, DOI 10.1128/JCM.02131-08; Pasquier CJM, 2008, AIDS, V22, P1894, DOI 10.1097/QAD.0b013e3283101281; Pasternak AO, 2008, J CLIN MICROBIOL, V46, P2206, DOI 10.1128/JCM.00055-08; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Pillai SK, 2005, J VIROL, V79, P1734, DOI 10.1128/JVI.79.3.1734-1742.2005; Puaux AL, 2004, VACCINE, V22, P3535, DOI 10.1016/j.vaccine.2004.03.044; PUDNEY J, 1991, AM J PATHOL, V139, P149; Roulet V, 2006, AM J PATHOL, V169, P2094, DOI 10.2353/ajpath.2006.060191; Sellier P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010570; Shehu-Xhilaga M, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-7; Shen CL, 2010, VIROLOGY, V401, P190, DOI 10.1016/j.virol.2010.01.033; Sheth PM, 2009, AIDS, V23, P2050, DOI 10.1097/QAD.0b013e3283303e04; Smith Dawn K., 2005, Morbidity and Mortality Weekly Report, V54, P1; Stuart JWTC, 2000, J ACQ IMMUN DEF SYND, V25, P203, DOI 10.1097/00126334-200011010-00001; Taylor S, 2010, CURR OPIN HIV AIDS, V5, P335, DOI 10.1097/COH.0b013e32833a0b69; Thiebot H, 2005, BLOOD, V105, P2403, DOI 10.1182/blood-2004-01-0025; Thiebot H, 2001, J VIROL, V75, P11594, DOI 10.1128/JVI.75.23.11594-11602.2001; Wang XL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027207; Whitney JB, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001293; Willey S, 2003, AIDS, V17, P183, DOI 10.1097/00002030-200301240-00007; Yeni P, 2008, PRISE CHARGE MED PER; Zhang H, 1998, NEW ENGL J MED, V339, P1803, DOI 10.1056/NEJM199812173392502; Zhou SH, 2004, J VIROL, V78, P3578, DOI 10.1128/JVI.78.7.3578-3600.2004	65	11	12	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 17	2012	7	5							e37348	10.1371/journal.pone.0037348	http://dx.doi.org/10.1371/journal.pone.0037348			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UQ	22615988	Green Published, Green Submitted, gold			2023-01-03	WOS:000305341200066
J	Sangha, JS; Sun, XL; Wally, OSD; Zhang, KB; Ji, XH; Wang, ZM; Wang, YW; Zidichouski, J; Prithiviraj, B; Zhang, JZ				Sangha, Jatinder S.; Sun, Xiaoli; Wally, Owen S. D.; Zhang, Kaibin; Ji, Xiuhong; Wang, Zhimin; Wang, Yanwen; Zidichouski, Jeffrey; Prithiviraj, Balakrishnan; Zhang, Junzeng			Liuwei Dihuang (LWDH), a Traditional Chinese Medicinal Formula, Protects against beta-Amyloid Toxicity in Transgenic Caenorhabditis elegans	PLOS ONE			English	Article							BILOBA EXTRACT EGB-761; INCREASES LIFE-SPAN; OXIDATIVE STRESS; NEURODEGENERATIVE DISEASES; INDUCED IMPAIRMENT; GENE-EXPRESSION; MOUSE MODEL; C-ELEGANS; DECOCTION; AGGREGATION	Liuwei Dihuang (LWDH), a classic Chinese medicinal formula, has been used to improve or restore declined functions related to aging and geriatric diseases, such as impaired mobility, vision, hearing, cognition and memory. Here, we report on the effect and possible mechanisms of LWDH mediated protection of beta-amyloid (A beta) induced paralysis in Caenorhabditis elegans using ethanol extract (LWDH-EE) and water extract (LWDH-WE). Chemical profiling and quantitative analysis revealed the presence of different levels of bioactive components in these extracts. LWDH-WE was rich in polar components such as monosaccharide dimers and trimers, whereas LWDH-EE was enriched in terms of phenolic compounds such as gallic acid and paeonol. In vitro studies revealed higher DPPH radical scavenging activity for LWDH-EE as compared to that found for LWDH-WE. Neither LWDH-EE nor LWDH-WE were effective in inhibiting aggregation of Ab in vitro. By contrast, LWDH-EE effectively delayed A beta induced paralysis in the transgenic C. elegans (CL4176) model which expresses human A beta 1-42. Western blot revealed no treatment induced reduction in Ab accumulation in CL4176 although a significant reduction was observed at an early stage with respect to beta-amyloid deposition in C. elegans strain CL2006 which constitutively expresses human A beta 1-42. In addition, LWDH-EE reduced in vivo reactive oxygen species (ROS) in C. elegans (CL4176) that correlated with increased survival of LWDH-EE treated N2 worms under juglone-induced oxidative stress. Analysis with GFP reporter strain TJ375 revealed increased expression of hsp16.2::GFP after thermal stress whereas a minute induction was observed for sod3::GFP. Quantitative gene expression analysis revealed that LWDH-EE repressed the expression of amy1 in CL4176 while up-regulating hsp16.2 induced by elevating temperature. Taken together, these results suggest that LWDH extracts, particularly LWDH-EE, alleviated beta-amyloid induced toxicity, in part, through up-regulation of heat shock protein, antioxidant activity and reduced ROS in C. elegans.	[Sangha, Jatinder S.; Wally, Owen S. D.; Prithiviraj, Balakrishnan] Nova Scotia Agr Coll, Dept Environm Sci, Truro, NS B2N 5E3, Canada; [Sun, Xiaoli; Zhang, Kaibin; Ji, Xiuhong; Wang, Yanwen; Zidichouski, Jeffrey; Zhang, Junzeng] Natl Res Council Canada, Inst Nutrisci & Hlth, Charlottetown, PE, Canada; [Sun, Xiaoli; Zhang, Kaibin; Wang, Zhimin] China Acad Chinese Med Sci, Inst Chinese Materia Med, Beijing, Peoples R China; [Sun, Xiaoli] Capital Med Univ, Sch Tradit Chinese Med, Beijing, Peoples R China; [Wang, Yanwen] Univ Prince Edward Isl, Dept Biomed Sci, Charlottetown, PE C1A 4P3, Canada; [Zhang, Junzeng] Univ Prince Edward Isl, Dept Chem, Charlottetown, PE C1A 4P3, Canada	Dalhousie University; National Research Council Canada; China Academy of Chinese Medical Sciences; Capital Medical University; University of Prince Edward Island; University of Prince Edward Island	Sangha, JS (corresponding author), Nova Scotia Agr Coll, Dept Environm Sci, Truro, NS B2N 5E3, Canada.	bprithiviraj@nsac.ca; Junzeng.zhang@nrc.gc.ca		Prithiviraj, Balakrishnan/0000-0002-9822-5261	National Research Council Canada - Institute for Nutrisciences and Health; Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences; Natural Sciences and Engineering Council of Canada (NSERC), Nova Scotia Department of Agriculture and Acadian Seaplants Limited; Canadian Institutes of Health Research (CIHR)	National Research Council Canada - Institute for Nutrisciences and Health; Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences; Natural Sciences and Engineering Council of Canada (NSERC), Nova Scotia Department of Agriculture and Acadian Seaplants Limited; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	Financial support for X. Sun and K. Zhang from National Research Council Canada - Institute for Nutrisciences and Health (Drs. Y. Wang, J. Zidichouski, and J. Zhang) and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences (Dr. Z. Wang) is appreciated. B. Prithiviraj's Lab is supported by grants from the Natural Sciences and Engineering Council of Canada (NSERC), Nova Scotia Department of Agriculture and Acadian Seaplants Limited. Y. Wang and J. Zhang are also supported through Canadian Institutes of Health Research (CIHR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbas S, 2010, PHYTOMEDICINE, V17, P902, DOI 10.1016/j.phymed.2010.03.008; Abbas S, 2009, PLANTA MED, V75, P216, DOI 10.1055/s-0028-1088378; Arya U, 2009, EXP GERONTOL, V44, P462, DOI 10.1016/j.exger.2009.02.010; Bastianetto S, 2008, MINI-REV MED CHEM, V8, P429, DOI 10.2174/138955708784223512; Bharadwaj PR, 2009, J CELL MOL MED, V13, P412, DOI 10.1111/j.1582-4934.2009.00609.x; Cao ZM, 2007, J GERONTOL A-BIOL, V62, P1337, DOI 10.1093/gerona/62.12.1337; Cheng XR, 2007, FITOTERAPIA, V78, P175, DOI 10.1016/j.fitote.2006.11.006; Cheng Xiao-rui, 2006, Chinese Pharmacological Bulletin, V22, P921; DaSilva KA, 2010, EXP NEUROL, V223, P311, DOI 10.1016/j.expneurol.2009.08.032; Dosanjh LE, 2010, J ALZHEIMERS DIS, V19, P681, DOI 10.3233/JAD-2010-1267; Dostal V, 2010, JOVE-J VIS EXP, V44, pe2252; Dostal V, 2010, GENETICS, V186, P857, DOI 10.1534/genetics.110.120436; Drake J, 2003, NEUROBIOL AGING, V24, P415, DOI 10.1016/S0197-4580(02)00225-7; Dumont M, 2009, FASEB J, V23, P2459, DOI 10.1096/fj.09-132928; Ewald CY, 2010, BRAIN STRUCT FUNCT, V214, P263, DOI 10.1007/s00429-009-0235-3; Feng J, 2010, SHANDONG J TRADITION, V29, P264; Fonte V, 2008, J BIOL CHEM, V283, P784, DOI 10.1074/jbc.M703339200; Fukumoto LR, 2000, J AGR FOOD CHEM, V48, P3597, DOI 10.1021/jf000220w; Gutierrez-Zepeda A, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-54; Howes MJR, 2003, PHARMACOL BIOCHEM BE, V75, P513, DOI 10.1016/S0091-3057(03)00128-X; Hsieh MT, 2003, BIOL PHARM BULL, V26, P156, DOI 10.1248/bpb.26.156; Janusz M, 2009, FEBS LETT, V583, P190, DOI 10.1016/j.febslet.2008.11.053; Jiang HL, 2003, CURR MED CHEM, V10, P2231, DOI 10.2174/0929867033456747; Johnson JR, 2010, BIOCHEM SOC T, V38, P559, DOI 10.1042/BST0380559; Kaletta T, 2006, NAT REV DRUG DISCOV, V5, P387, DOI 10.1038/nrd2031; Kampkotter A, 2007, PHARMACOL RES, V55, P139, DOI 10.1016/j.phrs.2006.11.006; Link CD, 1999, CELL STRESS CHAPERON, V4, P235, DOI 10.1379/1466-1268(1999)004<0235:DOOSRI>2.3.CO;2; LINK CD, 1995, P NATL ACAD SCI USA, V92, P9368, DOI 10.1073/pnas.92.20.9368; Link CD, 2003, NEUROBIOL AGING, V24, P397, DOI 10.1016/S0197-4580(02)00224-5; Link CD, 2006, EXP GERONTOL, V41, P1007, DOI 10.1016/j.exger.2006.06.059; Liu J, 2011, PHARM CLIN RES CHINE, V19, P227; Liu YanHui, 2009, Chinese Journal of Gerontology, V29, P2455; Luo Y, 2006, LIFE SCI, V78, P2066, DOI 10.1016/j.lfs.2005.12.004; Ma Yuan, 2004, Zhongguo Zhong Xi Yi Jie He Za Zhi, V24, P325; Miksys SL, 2010, CLIN PHARMACOL THER, V88, P427, DOI 10.1038/clpt.2010.198; Moreira Paula I, 2006, Expert Rev Neurother, V6, P897, DOI 10.1586/14737175.6.6.897; Murakami K, 2011, J BIOL CHEM, V286, P44557, DOI 10.1074/jbc.M111.279208; National Pharmacopoeia Committee, 2005, PHARM PEOPL REP CHIN, V1; Ono K, 2004, J NEUROSCI RES, V75, P742, DOI 10.1002/jnr.20025; Prahlad V, 2008, SCIENCE, V320, P811, DOI 10.1126/science.1156093; Re F, 2010, CURR MED CHEM, V17, P2990, DOI 10.2174/092986710791959729; Shukla V, 2011, ADV PHARMACOL SCI, V2011, DOI 10.1155/2011/572634; Smith JV, 2003, J ALZHEIMERS DIS, V5, P287, DOI 10.3233/JAD-2003-5404; Strayer A, 2003, FASEB J, V17, P2305, DOI 10.1096/fj.03-0376fje; Szeto YT, 2009, INT J FOOD SCI NUTR, V60, P662, DOI 10.3109/09637480802012209; Wei X L, 2000, Sheng Li Ke Xue Jin Zhan, V31, P227; Wolozin B, 2011, PROG MOL BIOL TRANSL, V100, P499, DOI 10.1016/B978-0-12-384878-9.00015-7; Wu CR, 2007, J ETHNOPHARMACOL, V113, P79, DOI 10.1016/j.jep.2007.05.003; Wu YJ, 2010, NEUROBIOL AGING, V31, P1055, DOI 10.1016/j.neurobiolaging.2008.07.013; Wu Yanjue, 2005, Current Alzheimer Research, V2, P37, DOI 10.2174/1567205052772768; Wu YJ, 2006, J NEUROSCI, V26, P13102, DOI 10.1523/JNEUROSCI.3448-06.2006; Wu ZX, 2002, CELL MOL BIOL, V48, P725; Xia S, 2010, SHANXI J TRADITIONAL, V31, P614; Xie BG, 2008, J PHARMACEUT BIOMED, V48, P1261, DOI 10.1016/j.jpba.2008.09.011; Yan H, 2007, CLIN INTERV AGING, V2, P201; Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200; Yang S, 2006, J ETHNOPHARMACOL, V106, P166, DOI 10.1016/j.jep.2005.12.017; Ye J, 2009, J PHARMACEUT BIOMED, V49, P638, DOI 10.1016/j.jpba.2008.12.009; Yin F, 2011, NEUROSCI LETT, V492, P76, DOI 10.1016/j.neulet.2011.01.055; Yin F, 2011, NEUROCHEM INT, V58, P399, DOI 10.1016/j.neuint.2010.12.017; Yu YB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009339; Zarse K, 2011, HORM METAB RES, V43, P241, DOI 10.1055/s-0030-1270524; Zhang Q, 2006, J APPL PHYCOL, V18, P445, DOI 10.1007/s10811-006-9048-4; Zhang Wei-Wei, 2011, Sheng Li Xue Bao, V63, P245; Zhao XF, 2007, J CHROMATOGR SCI, V45, P549, DOI 10.1093/chromsci/45.8.549; Zhu K, 2006, CHIN J EXP TRADIT ME, V12, P44; 王迪, 2011, [中国老年学杂志, Chinese Journal of Gerontology], V31, P524; 蒋宁, 2007, [中药药理与临床, Pharmacology and Clinics of Chinese Materia Medica], V23, P45	68	69	75	3	161	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2012	7	8							e43990	10.1371/journal.pone.0043990	http://dx.doi.org/10.1371/journal.pone.0043990			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	997ZH	22952840	gold, Green Published, Green Submitted			2023-01-03	WOS:000308206500036
J	Shukla, NM; Salunke, DB; Balakrishna, R; Mutz, CA; Malladi, SS; David, SA				Shukla, Nikunj M.; Salunke, Deepak B.; Balakrishna, Rajalakshmi; Mutz, Cole A.; Malladi, Subbalakshmi S.; David, Sunil A.			Potent Adjuvanticity of a Pure TLR7-Agonistic Imidazoquinoline Dendrimer	PLOS ONE			English	Article							TOLL-LIKE RECEPTORS; THIOCYANATE ELUTION; STRUCTURAL BIOLOGY; PROTEIN ANTIGENS; CELL-ACTIVATION; PREDICTION; ANTIBODY; PEPTIDE; AGONISTS; INNATE	Engagement of toll-like receptors (TLRs) serve to link innate immune responses with adaptive immunity and can be exploited as powerful vaccine adjuvants for eliciting both primary and anamnestic immune responses. TLR7 agonists are highly immunostimulatory without inducing dominant proinflammatory cytokine responses. We synthesized a dendrimeric molecule bearing six units of a potent TLR7/TLR8 dual-agonistic imidazoquinoline to explore if multimerization of TLR7/8 would result in altered activity profiles. A complete loss of TLR8-stimulatory activity with selective retention of the TLR7-agonistic activity was observed in the dendrimer. This was reflected by a complete absence of TLR8-driven proinflammatory cytokine and interferon (IFN)-gamma induction in human PBMCs, with preservation of TLR7-driven IFN-alpha induction. The dendrimer was found to be superior to the imidazoquinoline monomer in inducing high titers of high-affinity antibodies to bovine alpha-lactalbumin. Additionally, epitope mapping experiments showed that the dendrimer induced immunoreactivity to more contiguous peptide epitopes along the amino acid sequence of the model antigen.	[Shukla, Nikunj M.; Salunke, Deepak B.; Balakrishna, Rajalakshmi; Mutz, Cole A.; Malladi, Subbalakshmi S.; David, Sunil A.] Univ Kansas, Dept Med Chem, Lawrence, KS 66045 USA	University of Kansas	Shukla, NM (corresponding author), Univ Kansas, Dept Med Chem, Lawrence, KS 66045 USA.	sdavid@ku.edu		Salunke, Deepak/0000-0002-1241-9146	National Institutes of Health/National Institute of Allergy and Infectious Diseases [HHSN272200900033C]	National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	work was supported by National Institutes of Health/National Institute of Allergy and Infectious Diseases contract HHSN272200900033C. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Akira S., 1902, ADV IMMUNOL, V78, P1; Botos I, 2011, STRUCTURE, V19, P447, DOI 10.1016/j.str.2011.02.004; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Cottalorda A, 2006, EUR J IMMUNOL, V36, P1684, DOI 10.1002/eji.200636181; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; Gorden KB, 2005, J IMMUNOL, V174, P1259, DOI 10.4049/jimmunol.174.3.1259; Gorski KS, 2006, INT IMMUNOL, V18, P1115, DOI 10.1093/intimm/dxl046; Hood J.D., 2010, HUM VACCINES, V6, P1; Kaisho T, 2002, BBA-MOL CELL RES, V1589, P1, DOI 10.1016/S0167-4889(01)00182-3; Kandimalla ER, 2011, CELL IMMUNOL, V270, P126, DOI 10.1016/j.cellimm.2011.03.027; Kang JY, 2011, ANNU REV BIOCHEM, V80, P917, DOI 10.1146/annurev-biochem-052909-141507; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; Kawai T, 2007, SEMIN IMMUNOL, V19, P24, DOI 10.1016/j.smim.2006.12.004; KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q; Kumagai Yutaro, 2008, Journal of Infection and Chemotherapy, V14, P86, DOI 10.1007/s10156-008-0596-1; Larsen Jens Erik Pontoppidan, 2006, Immunome Res, V2, P2, DOI 10.1186/1745-7580-2-2; MACDONALD RA, 1988, J IMMUNOL METHODS, V106, P191, DOI 10.1016/0022-1759(88)90196-2; Nguyen TB, 2008, MOL PHARMACEUT, V5, P1131, DOI 10.1021/mp8001123; Nociari MM, 1998, J IMMUNOL METHODS, V213, P157, DOI 10.1016/S0022-1759(98)00028-3; PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013; Ponomarenko JV, 2007, BMC STRUCT BIOL, V7, DOI 10.1186/1472-6807-7-64; PULLEN GR, 1986, J IMMUNOL METHODS, V86, P83, DOI 10.1016/0022-1759(86)90268-1; Shukla NM, 2012, J MED CHEM, V55, P1106, DOI 10.1021/jm2010207; Shukla NM, 2011, BIOORG MED CHEM LETT, V21, P3232, DOI 10.1016/j.bmcl.2011.04.050; Shukla NM, 2010, BIOORG MED CHEM LETT, V20, P6384, DOI 10.1016/j.bmcl.2010.09.093; Shukla NM, 2010, J MED CHEM, V53, P4450, DOI 10.1021/jm100358c; Shukla NM, 2009, BIOORG MED CHEM LETT, V19, P2211, DOI 10.1016/j.bmcl.2009.02.100; Sil D, 2007, ANTIMICROB AGENTS CH, V51, P2811, DOI 10.1128/AAC.00200-07; Warshakoon HJ, 2009, HUM VACCINES, V5, P381, DOI 10.4161/hv.5.6.8175	31	62	63	1	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2012	7	8							e43612	10.1371/journal.pone.0043612	http://dx.doi.org/10.1371/journal.pone.0043612			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	998CA	22952720	gold, Green Published, Green Submitted			2023-01-03	WOS:000308213600034
J	June, C; Rosenberg, SA; Sadelain, M; Weber, JS				June, Carl; Rosenberg, Steven A.; Sadelain, Michel; Weber, Jeffrey S.			T-cell therapy at the threshold	NATURE BIOTECHNOLOGY			English	Article								Despite impressive clinical activity in B-cell lymphoma and melanoma, questions remain about the immunobiology of adoptive T-cell therapies.	[June, Carl] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Rosenberg, Steven A.] NCI, Surg Branch, NIH, Bethesda, MD 20892 USA; [Sadelain, Michel] Mem Sloan Kettering Canc Ctr, Ctr Cell Engn, New York, NY 10021 USA; [Weber, Jeffrey S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Donald A Adam Comprehens Melanoma Res Ctr, Tampa, FL 33612 USA	University of Pennsylvania; Pennsylvania Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	June, C (corresponding author), Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA.	cjune@exchange.upenn.edu; sar@nih.gov; m-sadelain@ski.mskcc.org; jeffrey.weber@moffitt.org			Intramural NIH HHS [Z01 BC010984-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC010984, ZIABC010985] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		2010, BLOOD, V116, P4099; 2011, J CLIN ONCOLOGY, V29, P917	2	45	47	0	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2012	30	7					611	614		10.1038/nbt.2305	http://dx.doi.org/10.1038/nbt.2305			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	972QV	22781680	Green Accepted			2023-01-03	WOS:000306293400016
J	Harrison, LEA; Burton, JO; Szeto, CC; Li, PKT; McIntyre, CW				Harrison, Laura E. A.; Burton, James O.; Szeto, Cheuk-Chun; Li, Philip K. T.; McIntyre, Christopher W.			Endotoxaemia in Haemodialysis: A Novel Factor in Erythropoetin Resistance?	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; RECOMBINANT-HUMAN-ERYTHROPOIETIN; PERITONEAL-DIALYSIS PATIENTS; CHRONIC HEART-FAILURE; RECEIVING HEMODIALYSIS; SYSTEMIC INFLAMMATION; BACTERIAL-ENDOTOXIN; DARBEPOETIN ALPHA; ANEMIA; HEMOGLOBIN	Background/Objectives: Translocated endotoxin derived from intestinal bacteria is a driver of systemic inflammation and oxidative stress. Severe endotoxaemia is an underappreciated, but characteristic finding in haemodialysis (HD) patients, and appears to be driven by acute repetitive dialysis induced circulatory stress. Resistance to erythropoietin (EPO) has been identified as a predictor of mortality risk, and associated with inflammation and malnutrition. This study aims to explore the potential link between previously unrecognised endotoxaemia and EPO Resistance Index (ERI) in HD patients. Methodology/Principal Findings: 50 established HD patients were studied at a routine dialysis session. Data collection included weight, BMI, ultrafiltration volume, weekly EPO dose, and blood sampling pre and post HD. ERI was calculated as ratio of total weekly EPO dose to body weight (U/kg) to haemoglobin level (g/dL). Mean haemoglobin (Hb) was 11.3 +/- 1.3 g/dL with a median EPO dose of 10,000 [IQR 7,500-20,000] u/wk and ERI of 13.7 [IQR 6.9-23.3] ((U/Kg)/(g/dL)). Mean pre-HD serum ET levels were significantly elevated at 0.69 +/- 0.30 EU/ml. Natural logarithm (Ln) of ERI correlated to predialysis ET levels (r = 0.324, p = 0.03) with a trend towards association with hsCRP (r = 0.280, p = 0.07). Ln ERI correlated with ultrafiltration volume, a driver of circulatory stress (r = 0.295, p = 0.046), previously identified to be associated with increased intradialytic endotoxin translocation. Both serum ET and ultrafiltration volume corrected for body weight were independently associated with Ln ERI in multivariable analysis. Conclusions: This study suggests that endotoxaemia is a significant factor in setting levels of EPO requirement. It raises the possibility that elevated EPO doses may in part merely be identifying patients subjected to significant circulatory stress and suffering the myriad of negative biological consequences arising from sustained systemic exposure to endotoxin.	[Harrison, Laura E. A.; Burton, James O.; McIntyre, Christopher W.] Royal Derby Hosp, Dept Renal Med, Derby, England; [Szeto, Cheuk-Chun; Li, Philip K. T.] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Peoples R China; [McIntyre, Christopher W.] Univ Nottingham, Sch Grad Entry Med & Hlth, Derby, England	University of Nottingham; Chinese University of Hong Kong; University of Nottingham	Harrison, LEA (corresponding author), Royal Derby Hosp, Dept Renal Med, Derby, England.	chris.mcintyre@nottingham.ac.uk	Szeto, Cheuk Chun/N-4954-2015; Burton, James O/AAQ-7361-2021; McIntyre, Christopher W/O-8927-2014; Li, Philip K. T./D-4051-2017	Szeto, Cheuk Chun/0000-0002-8898-8505; Burton, James O/0000-0003-1176-7592; 				Anker SD, 1997, AM J CARDIOL, V79, P1426, DOI 10.1016/S0002-9149(97)00159-8; Badve SV, 2011, NEPHROLOGY, V16, P144, DOI 10.1111/j.1440-1797.2010.01407.x; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; Brendt P, 2009, ANESTH ANALG, V109, P705, DOI 10.1213/ane.0b013e3181adc80f; Burton JO, 2009, CLIN J AM SOC NEPHRO, V4, P914, DOI 10.2215/CJN.03900808; Carrero JJ, 2010, SEMIN DIALYSIS, V23, P498, DOI 10.1111/j.1525-139X.2010.00784.x; Chan CT, 2002, KIDNEY INT, V61, P2235, DOI 10.1046/j.1523-1755.2002.00362.x; Charalambous BM, 2007, SHOCK, V28, P15, DOI 10.1097/shk.0b013e318033ebc5; DIEBEL L, 1993, SURGERY, V113, P520; Drueke T, 2001, NEPHROL DIAL TRANSPL, V16, P25, DOI 10.1093/ndt/16.suppl_7.25; Drueke TB, 2006, NEW ENGL J MED, V355, P2071, DOI 10.1056/NEJMoa062276; Feng SYS, 2010, AM J PHYSIOL-REG I, V298, pR760, DOI 10.1152/ajpregu.00398.2009; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Gunnell J, 1999, AM J KIDNEY DIS, V33, P63, DOI 10.1016/S0272-6386(99)70259-3; Jakob SM, 2001, CRIT CARE MED, V29, P1393, DOI 10.1097/00003246-200107000-00015; John SG, 2011, CLIN J AM SOC NEPHRO, V6, P2389, DOI 10.2215/CJN.11211210; Kalantar-Zadeh K, 2003, AM J KIDNEY DIS, V42, P761, DOI 10.1016/S0272-6386(03)00915-6; Khanna A, 2001, J SURG RES, V99, P114, DOI 10.1006/jsre.2001.6103; Kotanko P, 2006, NEPHROL DIAL TRANSPL, V21, P2057, DOI 10.1093/ndt/gfl281; Krack A, 2005, EUR HEART J, V26, P2368, DOI 10.1093/eurheartj/ehi389; Locatelli F, 2004, NEPHROL DIAL TRANSPL, V19, P1, DOI 10.1093/ndt/gfh1024; LUMSDEN AB, 1988, HEPATOLOGY, V8, P232, DOI 10.1002/hep.1840080207; Macdougall IC, 2010, NEPHROL DIAL TRANSPL, V25, P914, DOI 10.1093/ndt/gfp550; Mann JFE, 2001, ANN INTERN MED, V134, P629, DOI 10.7326/0003-4819-134-8-200104170-00007; MAXWELL A, 1986, LANCET, V1, P1148; McIntyre CW, 2008, CLIN J AM SOC NEPHRO, V3, P19, DOI 10.2215/CJN.03170707; McIntyre CW, 2011, CLIN J AM SOC NEPHRO, V6, P133, DOI 10.2215/CJN.04610510; Molina M, 2007, NEFROLOGIA, V27, P196; Ofsthun N, 2003, KIDNEY INT, V63, P1908, DOI 10.1046/j.1523-1755.2003.00937.x; Perlman RL, 2005, AM J KIDNEY DIS, V45, P658, DOI 10.1053/j.ajkd.2004.12.021; Peschel T, 2003, EUR J HEART FAIL, V5, P609, DOI 10.1016/S1388-9842(03)00104-1; Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845; RAIJ L, 1973, KIDNEY INT, V4, P57, DOI 10.1038/ki.1973.79; Regidor DL, 2006, J AM SOC NEPHROL, V17, P1181, DOI 10.1681/ASN.2005090997; Richardson D, 2002, NEPHROL DIAL TRANSPL, V17, P53, DOI 10.1093/ndt/17.suppl_1.53; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; STIVELMAN JC, 1989, SEMIN NEPHROL, V9, P8; Szeto CC, 2008, CLIN J AM SOC NEPHRO, V3, P431, DOI 10.2215/CJN.03600807; Weiss G, 2005, NEW ENGL J MED, V352, P1011, DOI 10.1056/NEJMra041809; WINEARLS CG, 1986, LANCET, V2, P1175, DOI 10.1016/S0140-6736(86)92192-6	41	9	9	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2012	7	6							e40209	10.1371/journal.pone.0040209	http://dx.doi.org/10.1371/journal.pone.0040209			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	967FO	22768256	Green Published, Green Submitted, gold			2023-01-03	WOS:000305892100229
J	Liu, SP; Huang, X; Ke, GH; Huang, XW				Liu, Su-Ping; Huang, Xiao; Ke, Gui-Hao; Huang, Xiao-Wei			3D Radiation Therapy or Intensity-Modulated Radiotherapy for Recurrent and Metastatic Cervical Cancer: The Shanghai Cancer Hospital Experience	PLOS ONE			English	Article							GYNECOLOGIC-ONCOLOGY-GROUP; PARAAORTIC LYMPH-NODES; WHOLE PELVIC RADIOTHERAPY; SQUAMOUS-CELL CARCINOMA; GASTROINTESTINAL TOXICITY; PLATINUM COMPOUNDS; RADICAL SURGERY; UTERINE CERVIX; CISPLATIN; HYSTERECTOMY	We evaluate the outcomes of irradiation by using three-dimensional radiation therapy (3D-RT) or intensity-modulated radiotherapy (IMRT) for recurrent and metastatic cervical cancer. Between 2007 and 2010, 50 patients with recurrent and metastatic cervical cancer were treated using 3D-RT or IMRT. The median time interval between the initial treatment and the start of irradiation was 12 (6-51) months. Salvage surgery was performed before irradiation in 5 patients, and 38 patients received concurrent chemotherapy. Sixteen patients underwent 3D-RT, and 34 patients received IMRT. Median follow-up for all the patients was 18.3 months. Three-year overall survival and locoregional control were 56.1% and 59.7%, respectively. Three-year progression-free survival and disease-free survival were 65.3% and 64.3%, respectively. Nine patients developed grade 3 leukopenia. Grade 5 acute toxicity was not observed in any of the patients; however, 2 patients developed Grade 3 late toxicity. 3D-RT or IMRT is effective for the treatment of recurrent and metastatic cervical cancer, with the 3-year overall survival of 56.1%, and its complications are acceptable. Long-term follow-up and further studies are needed to confirm the role of 3D-RT or IMRT in the multimodality management of the disease.	[Liu, Su-Ping; Huang, Xiao; Ke, Gui-Hao; Huang, Xiao-Wei] Fudan Univ, Shanghai Canc Ctr, Dept Gynecol Oncol, Shanghai 200433, Peoples R China	Fudan University	Liu, SP (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Gynecol Oncol, Shanghai 200433, Peoples R China.	smilexiaohuang@sina.com						Ahmed RS, 2004, INT J RADIAT ONCOL, V60, P505, DOI 10.1016/j.ijrobp.2004.03.035; Brixey CJ, 2002, INT J RADIAT ONCOL, V54, P1388, DOI 10.1016/S0360-3016(02)03801-4; BURGHARDT E, 1992, CANCER, V70, P648, DOI 10.1002/1097-0142(19920801)70:3<648::AID-CNCR2820700318>3.0.CO;2-R; DELGADO G, 1990, GYNECOL ONCOL, V38, P352, DOI 10.1016/0090-8258(90)90072-S; Deodato F, 2009, ONCOL REP, V22, P415, DOI 10.3892/or_00000453; DEUTSCH M, 1974, CANCER, V34, P2051, DOI 10.1002/1097-0142(197412)34:6<2051::AID-CNCR2820340625>3.0.CO;2-G; Du XL, 2010, CROAT MED J, V51, P229, DOI 10.3325/cmj.2010.51.229; Grigsby PW, 1998, INT J RADIAT ONCOL, V41, P817, DOI 10.1016/S0360-3016(98)00132-1; Guckenberger M, 2010, RADIOTHER ONCOL, V94, P53, DOI 10.1016/j.radonc.2009.12.004; Hartmann JT, 2003, EXPERT OPIN PHARMACO, V4, P889, DOI 10.1517/eoph.4.6.889.22200; Ito H, 1997, GYNECOL ONCOL, V67, P154, DOI 10.1006/gyno.1997.4855; JOBSEN JJ, 1989, GYNECOL ONCOL, V33, P368, DOI 10.1016/0090-8258(89)90529-5; Kato T, 1992, Gan To Kagaku Ryoho, V19, P695; Keys HM, 1999, NEW ENGL J MED, V340, P1154, DOI 10.1056/NEJM199904153401503; LARSON DM, 1988, GYNECOL ONCOL, V30, P381, DOI 10.1016/0090-8258(88)90252-1; Mabuchi S, 2010, INT J GYNECOL CANCER, V20, P834, DOI 10.1111/IGC.0b013e3181dcadd1; Monk BJ, 2009, J CLIN ONCOL, V27, P4649, DOI 10.1200/JCO.2009.21.8909; Moore DH, 2004, J CLIN ONCOL, V22, P3113, DOI 10.1200/JCO.2004.04.170; Mundt AJ, 2003, INT J RADIAT ONCOL, V56, P1354, DOI 10.1016/S0360-3016(03)00325-0; Mundt AJ, 2002, INT J RADIAT ONCOL, V52, P1330, DOI 10.1016/S0360-3016(01)02785-7; Peters WA, 2000, J CLIN ONCOL, V18, P1606, DOI 10.1200/JCO.2000.18.8.1606; PIVER MS, 1981, AM J OBSTET GYNECOL, V139, P575, DOI 10.1016/0002-9378(81)90519-6; Portelance L, 2001, INT J RADIAT ONCOL, V51, P261, DOI 10.1016/S0360-3016(01)01664-9; POTISH R, 1983, GYNECOL ONCOL, V15, P1, DOI 10.1016/0090-8258(83)90110-5; Roeske JC, 2003, RADIOTHER ONCOL, V69, P201, DOI 10.1016/j.radonc.2003.05.001; Rose PG, 1999, NEW ENGL J MED, V340, P1144, DOI 10.1056/NEJM199904153401502; STEHMAN FB, 1991, CANCER, V67, P2776, DOI 10.1002/1097-0142(19910601)67:11<2776::AID-CNCR2820671111>3.0.CO;2-L; THIGPEN T, 1995, SEMIN ONCOL, V22, P67; VANNAGELL JR, 1979, CANCER, V44, P2354, DOI 10.1002/1097-0142(197912)44:6<2354::AID-CNCR2820440653>3.0.CO;2-J; Wang CJ, 1999, AM J OBSTET GYNECOL, V181, P518, DOI 10.1016/S0002-9378(99)70486-2; Whitney CW, 1999, J CLIN ONCOL, V17, P1339, DOI 10.1200/JCO.1999.17.5.1339; Yamazaki A, 2000, JPN J CLIN ONCOL, V30, P180, DOI 10.1093/jjco/hyd049; Zhang MQ, 2010, INT J RADIAT ONCOL, V78, P821, DOI 10.1016/j.ijrobp.2009.08.069	33	7	9	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2012	7	6							e40299	10.1371/journal.pone.0040299	http://dx.doi.org/10.1371/journal.pone.0040299			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	967FO	22768273	gold, Green Published, Green Submitted			2023-01-03	WOS:000305892100247
J	Gill, L; Santa, J; Peter, DL; Keehn, J				Gill, Lisa; Santa, John; Peter, Doris L.; Keehn, Joel			Lipitor Goes Generic: Business as Usual or More Big Business?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Gill, Lisa; Santa, John; Peter, Doris L.; Keehn, Joel] Consumer Reports, Yonkers, NY 10703 USA		Santa, J (corresponding author), Consumer Reports, 101 Truman Ave, Yonkers, NY 10703 USA.	HealthImpact@cr.consumer.org						Armstrong D, 2011, BLOOMBERG NEWS  1116; Armstrong D, 2011, BLOOMBERG NEWS  1118; Consulate General Shanghai, 2011, CONSUM REP, P30; Consumer Reports Health Best Buy Drugs, 2010, CONSUM REP, P10; Consumer Reports Health Best Buy Drugs, 2010, CONSUM REP, P21; Consumer Reports National Research Center, 2012, CONSUM REP, P5; Consumer Reports National Research Center, 2011, CONSUM REP, P5; Consumer Reports National Research Center, 2012, CONSUM REP, P6; Consumer Reports National Research Center, 2011, CONSUM REP, P27; Wang M., 2011, PROPUBLICA      1114; Wilson D., 2011, NY TIMES, pB1	11	4	4	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 19	2012	156	12					892	894		10.7326/0003-4819-156-12-201206190-00420	http://dx.doi.org/10.7326/0003-4819-156-12-201206190-00420			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992NF	22711082				2023-01-03	WOS:000307783200018
J	Hashimoto, Y; Tazawa, H; Teraishi, F; Kojima, T; Watanabe, Y; Uno, F; Yano, S; Urata, Y; Kagawa, S; Fujiwara, T				Hashimoto, Yuuri; Tazawa, Hiroshi; Teraishi, Fuminori; Kojima, Toru; Watanabe, Yuichi; Uno, Futoshi; Yano, Shuya; Urata, Yasuo; Kagawa, Shunsuke; Fujiwara, Toshiyoshi			The hTERT Promoter Enhances the Antitumor Activity of an Oncolytic Adenovirus under a Hypoxic Microenvironment	PLOS ONE			English	Article							REPLICATION-SELECTIVE VIROTHERAPY; INDUCIBLE FACTOR-I; CANCER STEM-CELLS; TUMOR HYPOXIA; HEPATOCELLULAR CARCINOMAS; DOWN-REGULATION; UP-REGULATION; TELOMERASE; RECEPTOR; EXPRESSION	Hypoxia is a microenvironmental factor that contributes to the invasion, progression and metastasis of tumor cells. Hypoxic tumor cells often show more resistance to conventional chemoradiotherapy than normoxic tumor cells, suggesting the requirement of novel antitumor therapies to efficiently eliminate the hypoxic tumor cells. We previously generated a tumor-specific replication-competent oncolytic adenovirus (OBP-301: Telomelysin), in which the human telomerase reverse transcriptase (hTERT) promoter drives viral E1 expression. Since the promoter activity of the hTERT gene has been shown to be upregulated by hypoxia, we hypothesized that, under hypoxic conditions, the antitumor effect of OBP-301 with the hTERT promoter would be more efficient than that of the wild-type adenovirus 5 (Ad5). In this study, we investigated the antitumor effects of OBP-301 and Ad5 against human cancer cells under a normoxic (20% oxygen) or a hypoxic (1% oxygen) condition. Hypoxic condition induced nuclear accumulation of the hypoxia-inducible factor-1 alpha and upregulation of hTERT promoter activity in human cancer cells. The cytopathic activity of OBP-301 was significantly higher than that of Ad5 under hypoxic condition. Consistent with their cytopathic activity, the replication of OBP-301 was significantly higher than that of Ad5 under the hypoxic condition. OBP-301-mediated E1A was expressed within hypoxic areas of human xenograft tumors in mice. These results suggest that the cytopathic activity of OBP-301 against hypoxic tumor cells is mediated through hypoxia-mediated activation of the hTERT promoter. Regulation of oncolytic adenoviruses by the hTERT promoter is a promising antitumor strategy, not only for induction of tumor-specific oncolysis, but also for efficient elimination of hypoxic tumor cells.	[Hashimoto, Yuuri; Tazawa, Hiroshi; Teraishi, Fuminori; Kojima, Toru; Watanabe, Yuichi; Uno, Futoshi; Yano, Shuya; Kagawa, Shunsuke; Fujiwara, Toshiyoshi] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Surg Gastroenterol, Okayama, Japan; [Tazawa, Hiroshi] Okayama Univ Hosp, Ctr Gene & Cell Therapy, Okayama, Japan; [Urata, Yasuo] Oncolys BioPharma Inc, Tokyo, Japan	Okayama University; Okayama University; Oncolys BioPharma	Hashimoto, Y (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Surg Gastroenterol, Okayama, Japan.	toshi_f@md.okayama-u.ac.jp	TAZAWA, Hiroshi/B-2247-2011; Yano, Shuya/AAL-8028-2020; Kagawa, Shunsuke/B-2189-2011	TAZAWA, Hiroshi/0000-0003-4658-1050; Kagawa, Shunsuke/0000-0002-3610-8211	Ministry of Education, Culture, Sports, Science and Technology of Japan; Ministry of Health, Labour and Welfare of Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan)	This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to TF and FT, http://www.mext.go.jp/english/) and by grants from the Ministry of Health, Labour and Welfare of Japan (to TF, http://www.mhlw.go.jp/english/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson CJ, 2006, ONCOGENE, V25, P61, DOI 10.1038/sj.onc.1209011; Bauerschmitz GJ, 2008, CANCER RES, V68, P5533, DOI 10.1158/0008-5472.CAN-07-5288; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Castelo-Branco P, 2011, CLIN CANCER RES, V17, P111, DOI 10.1158/1078-0432.CCR-10-2075; Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035; Dahl KDC, 2005, MOL BIOL CELL, V16, P1901; Eriksson M, 2007, MOL THER, V15, P2088, DOI 10.1038/sj.mt.6300300; Guo ZS., 2011, VIRUS ADAPT TREAT, V3, P71, DOI DOI 10.2147/VAAT.S17832; Harrison L, 2004, ONCOLOGIST, V9, P31, DOI 10.1634/theoncologist.9-90005-31; Hashimoto Y, 2008, CANCER SCI, V99, P385, DOI 10.1111/j.1349-7006.2007.00665.x; Heddleston JM, 2010, BRIT J CANCER, V102, P789, DOI 10.1038/sj.bjc.6605551; Hernandez-Alcoceba R, 2002, HUM GENE THER, V13, P1737, DOI 10.1089/104303402760293574; Hiyama E, 2007, BRIT J CANCER, V96, P1020, DOI 10.1038/sj.bjc.6603671; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Jiang H, 2007, J NATL CANCER I, V99, P1410, DOI 10.1093/jnci/djm102; Kawashima T, 2004, CLIN CANCER RES, V10, P285, DOI 10.1158/1078-0432.CCR-1075-3; Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kirn D, 2001, NAT MED, V7, P781, DOI 10.1038/89901; Kizaka-Kondoh S, 2009, CANCER SCI, V100, P1366, DOI 10.1111/j.1349-7006.2009.01195.x; Kuster K, 2010, CANCER GENE THER, V17, P141, DOI 10.1038/cgt.2009.49; Kwon OJ, 2010, CLIN CANCER RES, V16, P6071, DOI 10.1158/1078-0432.CCR-10-0664; Lacher MD, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-91; Lacher MD, 2006, CANCER RES, V66, P1648, DOI 10.1158/0008-5472.CAN-05-2328; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Nemunaitis J, 2010, MOL THER, V18, P429, DOI 10.1038/mt.2009.262; Nishi H, 2004, MOL CELL BIOL, V24, P6076, DOI 10.1128/MCB.24.13.6076-6083.2004; Niu JX, 2007, EUR J CANCER PREV, V16, P517, DOI 10.1097/CEJ.0b013e3280145c00; Pipiya T, 2005, GENE THER, V12, P911, DOI 10.1038/sj.gt.3302459; Post DE, 2003, ONCOGENE, V22, P2065, DOI 10.1038/sj.onc.1206464; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Shay Jerry W., 1996, Current Opinion in Oncology, V8, P66, DOI 10.1097/00001622-199601000-00012; Shen BH, 2005, GENE THER, V12, P902, DOI 10.1038/sj.gt.3302448; Short JJ, 2009, MOL CANCER THER, V8, P2096, DOI 10.1158/1535-7163.MCT-09-0367; Tredan O, 2007, J NATL CANCER I, V99, P1441, DOI 10.1093/jnci/djm135; Umeoka T, 2004, CANCER RES, V64, P6259, DOI 10.1158/0008-5472.CAN-04-1335; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yatabe N, 2004, ONCOGENE, V23, P3708, DOI 10.1038/sj.onc.1207460; Yoo YG, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002072; Zhang XC, 2008, CLIN CANCER RES, V14, P2813, DOI 10.1158/1078-0432.CCR-07-1528	46	11	14	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 15	2012	7	6							e39292	10.1371/journal.pone.0039292	http://dx.doi.org/10.1371/journal.pone.0039292			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959WX	22720091	Green Submitted, gold, Green Published			2023-01-03	WOS:000305350000057
J	Haiser, HJ; Turnbaugh, PJ				Haiser, Henry J.; Turnbaugh, Peter J.			Is It Time for a Metagenomic Basis of Therapeutics?	SCIENCE			English	Editorial Material							INTESTINAL MICROBIOTA; GUT FLORA; IDENTIFICATION; METABOLISM; BACTERIA	The trillions of microbes associated with the human body are a key part of a comprehensive view of pharmacology. A mechanistic understanding of how the gut microbiota directly and indirectly affects drug metabolism is beginning to emerge.	[Haiser, Henry J.; Turnbaugh, Peter J.] Harvard Univ, Ctr Syst Biol, Fac Arts & Sci, Cambridge, MA 02138 USA	Harvard University	Turnbaugh, PJ (corresponding author), Harvard Univ, Ctr Syst Biol, Fac Arts & Sci, Cambridge, MA 02138 USA.	pturnbaugh@fas.harvard.edu	Haiser, Henry/AAN-5187-2020	Turnbaugh, Peter/0000-0002-0888-2875	Canadian Institutes of Health Research [MFE-112991] Funding Source: Medline; NIGMS NIH HHS [P50 GM068763] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM068763] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antunes LCM, 2011, ANTIMICROB AGENTS CH, V55, P1494, DOI 10.1128/AAC.01664-10; Blaser M, 2011, NATURE, V476, P393, DOI 10.1038/476393a; Brunton LL, 2011, GOODMAN GILMANS PHAR, V12th; Chang JY, 2008, J INFECT DIS, V197, P435, DOI 10.1086/525047; Claus SP, 2011, MBIO, V2, DOI 10.1128/mBio.00271-10; Clayton TA, 2009, P NATL ACAD SCI USA, V106, P14728, DOI 10.1073/pnas.0904489106; Dethlefsen L, 2011, P NATL ACAD SCI USA, V108, P4554, DOI 10.1073/pnas.1000087107; DOBKIN JF, 1983, SCIENCE, V220, P325; Jernberg C, 2010, MICROBIOL-SGM, V156, P3216, DOI 10.1099/mic.0.040618-0; Ma Q, 2011, PHARMACOL REV, V63, P437, DOI 10.1124/pr.110.003533; Sekirov I, 2008, INFECT IMMUN, V76, P4726, DOI 10.1128/IAI.00319-08; Sousa T, 2008, INT J PHARMACEUT, V363, P1, DOI 10.1016/j.ijpharm.2008.07.009; Wallace BD, 2010, SCIENCE, V330, P831, DOI 10.1126/science.1191175; Wang ZN, 2011, NATURE, V472, P57, DOI 10.1038/nature09922	14	85	94	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 8	2012	336	6086					1253	1255		10.1126/science.1224396	http://dx.doi.org/10.1126/science.1224396			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953WV	22674325				2023-01-03	WOS:000304905300033
J	Sellebjerg, F; Krakauer, M; Limborg, S; Hesse, D; Lund, H; Langkilde, A; Sondergaard, HB; Sorensen, PS				Sellebjerg, Finn; Krakauer, Martin; Limborg, Signe; Hesse, Dan; Lund, Henrik; Langkilde, Annika; Sondergaard, Helle Bach; Sorensen, Per Soelberg			Endogenous and Recombinant Type I Interferons and Disease Activity in Multiple Sclerosis	PLOS ONE			English	Article							GENE-EXPRESSION ANALYSIS; T-CELL-ACTIVATION; BETA TREATMENT; PERIPHERAL-BLOOD; DOUBLE-BLIND; IFN-BETA; CORRELATE; THERAPY; MS; PROLIFERATION	Although treatment of multiple sclerosis (MS) with the type I interferon (IFN) IFN-beta lowers disease activity, the role of endogenous type I IFN in MS remains controversial. We studied CD4+ T cells and CD4+ T cell subsets, monocytes and dendritic cells by flow cytometry and analysed the relationship with endogenous type I IFN-like activity, the effect of IFN-beta therapy, and clinical and magnetic resonance imaging (MRI) disease activity in MS patients. Endogenous type I IFN activity was associated with decreased expression of the integrin subunit CD49d (VLA-4) on CD4+ CD26(high) T cells (Th1 helper cells), and this effect was associated with less MRI disease activity. IFN-beta therapy reduced CD49d expression on CD4+ CD26(high) T cells, and the percentage of CD4+ CD26(high) T cells that were CD49d(high) correlated with clinical and MRI disease activity in patients treated with IFN-beta. Treatment with IFN-beta also increased the percentage of CD4+ T cells expressing CD71 and HLA-DR (activated T cells), and this was associated with an increased risk of clinical disease activity. In contrast, induction of CD71 and HLA-DR was not observed in untreated MS patients with evidence of endogenous type IFN I activity. In conclusion, the effects of IFN-beta treatment and endogenous type I IFN activity on VLA-4 expression are similar and associated with control of disease activity. However, immune-activating effects of treatment with IFN-beta may counteract the beneficial effects of treatment and cause an insufficient response to therapy.	[Sellebjerg, Finn; Krakauer, Martin; Limborg, Signe; Hesse, Dan; Sondergaard, Helle Bach; Sorensen, Per Soelberg] Copenhagen Univ Hosp, Rigshosp, Dept Neurol, Danish Multiple Sclerosis Ctr, Copenhagen, Denmark; [Lund, Henrik] Univ Copenhagen, Hvidovre Hosp, Danish Res Ctr Magnet Resonance, DK-2650 Hvidovre, Denmark; [Langkilde, Annika] Copenhagen Univ Hosp, Rigshosp, Dept Radiol, Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; University of Copenhagen; Rigshospitalet; University of Copenhagen	Sellebjerg, F (corresponding author), Copenhagen Univ Hosp, Rigshosp, Dept Neurol, Danish Multiple Sclerosis Ctr, Copenhagen, Denmark.	sellebjerg@dadlnet.dk	Krakauer, Martin/M-4657-2019	Krakauer, Martin/0000-0002-2191-1861; Sorensen, Per Soelberg/0000-0002-2818-3780; Sellebjerg, Finn/0000-0002-1333-9623; Sondergaard, Helle Bach/0000-0001-9435-0658; Hesse, Dan/0000-0002-9670-6037	Danish Multiple Sclerosis Society; Warwara Larsen Foundation; Johnsen Foundation; Danish Council for Independent Research [271-06-0246]; Danish Council for Strategic Research [2142-08-0039]; Biogen Idec; Merck-Serono; Novartis; Sanofi-Aventis; Teva; Genmab; GSK; Bayer Schering; Baxter; BioMS; Bayer; RoFAR; Roche; Genzyme; Danish Medical Research Council; European Union Sixth Framework Programme: Life sciences, Genomics and Biotechnology for health	Danish Multiple Sclerosis Society; Warwara Larsen Foundation; Johnsen Foundation; Danish Council for Independent Research(Det Frie Forskningsrad (DFF)); Danish Council for Strategic Research(Danske Strategiske Forskningsrad (DSF)); Biogen Idec(Biogen); Merck-Serono(Merck & Company); Novartis(Novartis); Sanofi-Aventis(Sanofi-Aventis); Teva(Teva Pharmaceutical Industries); Genmab(Genmab); GSK(GlaxoSmithKline); Bayer Schering(Bayer AG); Baxter; BioMS; Bayer(Bayer AG); RoFAR; Roche(Roche Holding); Genzyme(Sanofi-AventisGenzyme Corporation); Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Union Sixth Framework Programme: Life sciences, Genomics and Biotechnology for health	This study was supported by grants from the Danish Multiple Sclerosis Society, the Warwara Larsen Foundation, the Johnsen Foundation, the Danish Council for Independent Research [grant 271-06-0246] and the Danish Council for Strategic Research [grant 2142-08-0039]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Finn Sellebjerg has served on scientific advisory boards for and received funding for travel from Biogen Idec, Merck-Serono, Novartis, Sanofi-Aventis and Teva; served as a consultant for Biogen Idec and Novo Nordisk; received speaker honoraria from Bayer-Schering, Biogen Idec, Merck-Serono, Novartis, Sanofi-Aventis and Schering-Ploug; has received research support from Biogen Idec, Merck-Serono, Novartis and Sanofi-Aventis; and serves as section editor on Multiple Sclerosis and Related Disorders. Dan Hesse has received funding for travel from Biogen Idec, Merck-Serono, and Sanofi-Aventis; and received speaker honoraria from Sanofi-Aventis and Biogen Idec. Signe Limborg reports no disclosures. Helle Bach Sondergaard reports no disclosures. Martin Krakauer reports no disclosures. Per Soelberg Sorensen has served on scientific advisory boards Biogen Idec, Merck Serono, Novartis, Genmab, TEVA, Elan, GSK, has been on steering committees or independent data monitoring boards in clinical trials sponsored by Merck Serono, Genmab, TEVA, GSK, Bayer Schering, and has received funding of travel for these activities; has served as Editor-in-Chief of the European Journal of Neurology, and is editorial board member for Therapeutic Advances in Neurological Disorders and Multiple Sclerosis; has received speaker honoraria from Biogen Idec, Merck Serono, TEVA, Bayer Schering, Sanofi-aventis, and Novartis; and has received research support from Biogen Idec, Bayer Schering, Merck Serono, TEVA, Baxter, Sanofi-Aventis, BioMS, Novartis, Bayer, RoFAR, Roche, Genzyme, from the Danish Multiple Sclerosis Society, the Danish Medical Research Council, and the European Union Sixth Framework Programme: Life sciences, Genomics and Biotechnology for health. This does not alter our adherence to all the PLoS ONE policies on sharing data and materials.	Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; Barrau MA, 2000, J NEUROIMMUNOL, V111, P215, DOI 10.1016/S0165-5728(00)00357-X; Buttmann M, 2007, J NEUROIMMUNOL, V190, P170, DOI 10.1016/j.jneuroim.2007.08.009; Calabresi PA, 1997, NEUROLOGY, V49, P1111, DOI 10.1212/WNL.49.4.1111; Comabella M, 2009, BRAIN, V132, P3353, DOI 10.1093/brain/awp228; Dhib-Jalbut S, 2010, NEUROLOGY, V74, pS17, DOI 10.1212/WNL.0b013e3181c97d99; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Ebers GC, 1998, LANCET, V352, P1498, DOI 10.1016/S0140-6736(98)03334-0; HAFLER DA, 1985, NEW ENGL J MED, V312, P1405, DOI 10.1056/NEJM198505303122201; Havenar-Daughton C, 2006, J IMMUNOL, V176, P3315, DOI 10.4049/jimmunol.176.6.3315; Hesse D, 2011, EUR J NEUROL, V18, P266, DOI 10.1111/j.1468-1331.2010.03116.x; Hesse D, 2010, NEUROLOGY, V74, P1455, DOI 10.1212/WNL.0b013e3181dc1a94; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; Jensen J, 2006, J NEUROIMMUNOL, V179, P163, DOI 10.1016/j.jneuroim.2006.06.024; Jensen J, 2005, CYTOKINE, V29, P24, DOI 10.1016/j.cyto.2004.09.005; Jensen J, 2004, J NEUROIMMUNOL, V149, P202, DOI 10.1016/j.jneuroim.2003.12.019; Khoury SJ, 2000, ARCH NEUROL-CHICAGO, V57, P1183, DOI 10.1001/archneur.57.8.1183; Krakauer M, 2006, J NEUROIMMUNOL, V181, P157, DOI 10.1016/j.jneuroim.2006.09.006; Krakauer M, 2006, SCAND J IMMUNOL, V64, P155, DOI 10.1111/j.1365-3083.2006.01788.x; Krug A, 2003, J EXP MED, V197, P899, DOI 10.1084/jem.20021091; Lombardi G, 2000, J IMMUNOL, V165, P3782, DOI 10.4049/jimmunol.165.7.3782; Marrack P, 1999, J EXP MED, V189, P521, DOI 10.1084/jem.189.3.521; Michel L, 2008, J CLIN INVEST, V118, P3411, DOI 10.1172/JCI35365; Ossege LM, 2001, INT IMMUNOPHARMACOL, V1, P1085, DOI 10.1016/S1567-5769(01)00039-X; Ravnborg M, 2010, LANCET NEUROL, V9, P672, DOI 10.1016/S1474-4422(10)70132-0; Sellebjerg F, 2008, MULT SCLER J, V14, P615, DOI 10.1177/1352458507085976; Sellebjerg F, 2005, MULT SCLER J, V11, P641, DOI 10.1191/1352458505ms1217oa; Sellebjerg F, 2009, EUR J NEUROL, V16, P1291, DOI 10.1111/j.1468-1331.2009.02716.x; Sorensen PS, 2009, LANCET NEUROL, V8, P519, DOI 10.1016/S1474-4422(09)70085-7; Stetson DB, 2006, IMMUNITY, V25, P373, DOI 10.1016/j.immuni.2006.08.007; Tough DF, 1996, SCIENCE, V272, P1947, DOI 10.1126/science.272.5270.1947; van Baarsen LGM, 2006, GENES IMMUN, V7, P522, DOI 10.1038/sj.gene.6364324; van der Voort LF, 2010, NEUROLOGY, V75, P1228, DOI 10.1212/WNL.0b013e3181f6c556; Weinberg Andrew D., 2005, Current Drug Targets - Inflammation and Allergy, V4, P195, DOI 10.2174/1568010053586345; Weinstock-Guttman B, 2003, J IMMUNOL, V171, P2694, DOI 10.4049/jimmunol.171.5.2694; Weinstock-Guttman B, 2008, J NEUROIMMUNOL, V205, P113, DOI 10.1016/j.jneuroim.2008.09.004; Wiesemann E, 2008, MULT SCLER J, V14, P166, DOI 10.1177/1352458507081342; Yamaguchi KD, 2008, J NEUROIMMUNOL, V195, P116, DOI 10.1016/j.jneuroim.2007.12.007	38	10	10	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2012	7	6							e35927	10.1371/journal.pone.0035927	http://dx.doi.org/10.1371/journal.pone.0035927			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959WK	22701554	Green Published, gold, Green Submitted			2023-01-03	WOS:000305348400004
J	Farrell, M; Wodak, A; Gowing, L				Farrell, Michael; Wodak, Alex; Gowing, Linda			THERAPEUTICS Maintenance drugs to treat opioid dependence	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							METHADONE-MAINTENANCE; HEROIN-ADDICTS; DOUBLE-BLIND; BUPRENORPHINE; RETENTION; MORTALITY; RISK		[Farrell, Michael] Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2031, Australia; [Wodak, Alex] St Vincents Hosp, Alcohol & Drug Serv, Darlinghurst, NSW 2010, Australia; [Gowing, Linda] Univ Adelaide, Discipline Pharmacol, Adelaide, SA 5005, Australia	University of New South Wales Sydney; St Vincents Hospital Sydney; University of Adelaide	Farrell, M (corresponding author), Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2031, Australia.	michael.farrell@unsw.edu.au	Farrell, Michael P/A-4769-2012; Gowing, Linda/G-1402-2012	Farrell, Michael P/0000-0001-7008-8130; Gowing, Linda/0000-0002-9124-4056	Reckitt Benckiser	Reckitt Benckiser	All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work. The National Drug and Alcohol Research Centre, of which MF is the director, has received unrestricted grant income from Reckitt Benckiser for post-marketing surveillance and for other evaluation of buprenorphine and naloxone combined. MF has participated in workshops in the Asia Pacific region on the development of treatment services and of research with opioid users; these workshops were supported by an unrestricted educational grant from Reckitt Benckiser, paid to the University of Adelaide. The authors declare no other relationships or activities that could appear to have influenced the submitted work.	Amato L, 2008, COCHRANE DB SYST REV, V4; Anchersen K, 2009, ADDICTION, V104, P993, DOI 10.1111/j.1360-0443.2009.02549.x; Bell J, 2009, ADDICTION, V104, P1193, DOI 10.1111/j.1360-0443.2009.02627.x; Burns L, 2007, ADDICTION, V102, P264, DOI 10.1111/j.1360-0443.2006.01651.x; Caplehorn JRM, 1996, SUBST USE MISUSE, V31, P177, DOI 10.3109/10826089609045806; Cornish R, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5475; [Department of Health (England) Scottish Government Welsh Assembly Government Northern Ireland Executive], 2007, DRUG MIS DEP UK GUID; European Monitoring Centre on Drugs and Drug Addiction, 2011, STAND GUID; Farrell M, 1998, BMJ-BRIT MED J, V316, P69; FERRI M, 2010, COCHRANE DB SYST REV, V8; Fischer G, 2006, ADDICTION, V101, P275, DOI 10.1111/j.1360-0443.2006.01321.x; Jaffe JH, 1980, GOODMAN GILMANS PHAR, P535; Jegu J, 2011, BRIT J CLIN PHARMACO, V71, P832, DOI 10.1111/j.1365-2125.2011.03923.x; Mattick RP, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002207.pub3; Mattick RP, 2003, ADDICTION, V98, P441, DOI 10.1046/j.1360-0443.2003.00335.x; Mattick RP, 2009, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD002209; Minozzi S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001333.pub2; Minozzi S, 2008, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD006318.PUB2; National Health and Medical Research Council, 2011, NALTR IMPL TRATM OP; National Institute for Health and Clinical Excellence, 2007, NALTR MAN OP DEP; National Institute for Health and Clinical Excellence, 2007, METH BUPR MAN OP DEP; National Institute for Health and Clinical Excellence, 2007, ANT POSTN MENT HLTH; Oviedo-Joekes E, 2010, J SUBST ABUSE TREAT, V38, P408, DOI 10.1016/j.jsat.2010.03.003; Robertson JR, 2006, ADDICTION, V101, P1752, DOI 10.1111/j.1360-0443.2006.01603.x; Strang J, 2010, LANCET, V375, P1885, DOI 10.1016/S0140-6736(10)60349-2; van den Brink W, 2003, BRIT MED J, V327, P310, DOI 10.1136/bmj.327.7410.310; World Health Organization, 2009, GUID PSYCH ASS PHARM; Zanis DA, 1998, DRUG ALCOHOL DEPEN, V52, P257, DOI 10.1016/S0376-8716(98)00097-0	28	18	18	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 15	2012	344								e2823	10.1136/bmj.e2823	http://dx.doi.org/10.1136/bmj.e2823			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942YF	22589497	Green Submitted			2023-01-03	WOS:000304086900004
J	Akiyama, K; Chen, C; Wang, DD; Xu, XT; Qu, CY; Yamaza, T; Cai, T; Chen, WJ; Sun, LY; Shi, ST				Akiyama, Kentaro; Chen, Chider; Wang, DanDan; Xu, Xingtian; Qu, Cunye; Yamaza, Takayoshi; Cai, Tao; Chen, WanJun; Sun, Lingyun; Shi, Songtao			Mesenchymal-Stem-Cell-Induced Immunoregulation Involves FAS-Ligand-/FAS-Mediated T Cell Apoptosis	CELL STEM CELL			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GROWTH-FACTOR-BETA; TISSUE; TRANSPLANTATION; ACTIVATION; CHEMOKINES; TOLERANCE; RESPONSES; PATHWAY; PROTEIN	Systemic infusion of bone marrow mesenchymal stem cells (BMMSCs) yields therapeutic benefit for a variety of autoimmune diseases, but the underlying mechanisms are poorly understood. Here we show that in mice systemic infusion of BMMSCs induced transient T cell apoptosis via the FAS ligand (FASL)dependent FAS pathway and could ameliorate disease phenotypes in fibrillin-1 mutated systemic sclerosis (SS) and dextran-sulfate-sodium-induced experimental colitis. FASL(-/-) BMMSCs did not induce T cell apoptosis in recipients, and could not ameliorate SS and colitis. Mechanistic analysis revealed that FAS-regulated monocyte chemotactic protein 1 (MCP-1) secretion by BMMSCs recruited T cells for FASL-mediated apoptosis. The apoptotic T cells subsequently triggered macrophages to produce high levels of TGF beta, which in turn led to the upregulation of Ca4(+)CD25(+)Foxp3(+) regulatory T cells and, ultimately, immune tolerance. These data therefore demonstrate a previously unrecognized mechanism underlying BMMSC-based immunotherapy involving coupling via FAS/FASL to induce T cell apoptosis.	[Wang, DanDan; Sun, Lingyun] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Rheumatol & Immunol, Nanjing 210008, Jiangsu, Peoples R China; [Akiyama, Kentaro; Chen, Chider; Xu, Xingtian; Qu, Cunye; Yamaza, Takayoshi; Shi, Songtao] Univ So Calif, Ostrow Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA; [Akiyama, Kentaro] Okayama Univ, Grad Sch, Dept Oral Rehabil & Regenerat Med, Kita Ku, Okayama 7008525, Japan; [Cai, Tao; Chen, WanJun] Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD 20892 USA	Nanjing University; University of Southern California; Okayama University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Sun, LY (corresponding author), Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Rheumatol & Immunol, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China.	lingyunsun2011@yahoo.com.cn; songtaos@usc.edu	XU, XINGTIAN/E-4518-2014; Chen, Chider/L-9880-2016	Chen, Chider/0000-0003-2899-1208; Yamaza, Takayoshi/0000-0001-7055-3370; Cai, Tao/0000-0002-2877-8637	National Institute of Dental and Craniofacial Research, National Institutes of Health, Department of Health and Human Services [RO1DE017449, RO1 DE019932, RO1 DE019413]; California Institute for Regenerative Medicine [RN1-00572]; NIDCR; NIH; China Major International [81120108021]; ClinicalTrials.gov [NCT00962923]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000101, R01DE019932, R01DE017449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE019413] Funding Source: NIH RePORTER	National Institute of Dental and Craniofacial Research, National Institutes of Health, Department of Health and Human Services(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); California Institute for Regenerative Medicine(California Institute for Regenerative Medicine); NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); China Major International; ClinicalTrials.gov; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	Basic research parts of this work were supported by grants from the National Institute of Dental and Craniofacial Research, National Institutes of Health, Department of Health and Human Services (RO1DE017449, RO1 DE019932, and RO1 DE019413 to S.S.), a grant from the California Institute for Regenerative Medicine (RN1-00572 for S.S.), and the Intramural Research Program of NIDCR, NIH (for W.J.C. and T.C.). Clinical studies were supported by a grant from the China Major International (Regional) Joint Research Project (81120108021). ClinicalTrials.gov Identifier: NCT00962923.	Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Alex P, 2009, INFLAMM BOWEL DIS, V15, P341, DOI 10.1002/ibd.20753; Augello A, 2007, ARTHRITIS RHEUM-US, V56, P1175, DOI 10.1002/art.22511; Batten P, 2006, TISSUE ENG, V12, P2263, DOI 10.1089/ten.2006.12.2263; Bernardo ME, 2009, ANN NY ACAD SCI, V1176, P101, DOI 10.1111/j.1749-6632.2009.04607.x; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; Chatenoud L, 1997, J IMMUNOL, V158, P2947; CHATENOUD L, 1994, P NATL ACAD SCI USA, V91, P123, DOI 10.1073/pnas.91.1.123; Chen X, 2006, IMMUNOL CELL BIOL, V84, P413, DOI 10.1111/j.1440-1711.2006.01458.x; Choi H, 2011, BLOOD, V118, P330, DOI 10.1182/blood-2010-12-327353; Gonzalez MA, 2009, GASTROENTEROLOGY, V136, P978, DOI 10.1053/j.gastro.2008.11.041; GREEN MC, 1976, AM J PATHOL, V82, P493; Hohlbaum AM, 2000, J EXP MED, V191, P1209, DOI 10.1084/jem.191.7.1209; Kleinclauss F, 2006, CELL DEATH DIFFER, V13, P41, DOI 10.1038/sj.cdd.4401699; Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7; Liang J, 2009, MULT SCLER J, V15, P644, DOI 10.1177/1352458509104590; Mazar J, 2009, J BIOL CHEM, V284, P22022, DOI 10.1074/jbc.M109.032235; Meisel R, 2004, BLOOD, V103, P4619, DOI 10.1182/blood-2003-11-3909; Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716; Parekkadan B, 2008, STEM CELLS, V26, P1913, DOI 10.1634/stemcells.2007-0790; Park MJ, 2011, ARTHRITIS RHEUM-US, V63, P1668, DOI 10.1002/art.30326; Perruche S, 2008, NAT MED, V14, P528, DOI 10.1038/nm1749; Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889; Polchert D, 2008, EUR J IMMUNOL, V38, P1745, DOI 10.1002/eji.200738129; Rafei M, 2009, J IMMUNOL, V182, P5994, DOI 10.4049/jimmunol.0803962; Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014; Roddy GW, 2011, STEM CELLS, V29, P1572, DOI 10.1002/stem.708; Sato K, 2007, BLOOD, V109, P228, DOI 10.1182/blood-2006-02-002246; Sun LY, 2009, STEM CELLS, V27, P1421, DOI 10.1002/stem.68; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; Uccelli A, 2007, TRENDS IMMUNOL, V28, P219, DOI 10.1016/j.it.2007.03.001; Xu LL, 1996, J LEUKOCYTE BIOL, V60, P365, DOI 10.1002/jlb.60.3.365; Zappia E, 2005, BLOOD, V106, P1755, DOI 10.1182/blood-2005-04-1496; Zhang Q., 2010, J IMMUNOL, V183, P7787; Zhang YY, 2008, J IMMUNOL, V181, P190, DOI 10.4049/jimmunol.181.1.190	35	495	542	1	74	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	1934-5909	1875-9777		CELL STEM CELL	Cell Stem Cell	MAY 4	2012	10	5					544	555		10.1016/j.stem.2012.03.007	http://dx.doi.org/10.1016/j.stem.2012.03.007			12	Cell & Tissue Engineering; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	944WN	22542159	Green Accepted, Green Published, Bronze			2023-01-03	WOS:000304234600013
J	Sami, N; Ali, TS; Wasim, S; Saleem, S				Sami, Neelofar; Ali, Tazeen Saeed; Wasim, Saba; Saleem, Sarah			Risk Factors for Secondary Infertility among Women in Karachi, Pakistan	PLOS ONE			English	Article							MORBIDITY; SERVICE; HEALTH	Background: Secondary infertility in developing countries is mostly attributable to blockage of the fallopian tubes due to adhesions caused by reproductive tract infections. There is a dearth of information on the prevalence and causes of secondary infertility from Pakistan. This paper presents results on factors associated with secondary infertility among married women in Karachi, Pakistan. Methods: A matched case-control study was conducted. Cases were women aged 15-35 years with history of at least one previous conception and currently seeking treatment for secondary infertility. Controls were women residing in the neighborhood of cases with at least one live birth and not taking treatment for secondary infertility. The age of controls was matched by +/- 5 years to that of cases. Data was collected from June to August 2003. Conditional logistic regression was used to determine crude and adjusted odds ratios (OR) with corresponding 95% confidence intervals (CI) for factors associated with secondary infertility. Results: The final multivariate logistic regression model revealed that after adjusting for age, cases were more likely to be the housewives (AOR = 2.6, 95% CI: 1.5-4.4), had used inappropriate material to absorb blood during menstruation (AOR = 9.0, 95% CI: 5.0-16.4), and at their last delivery, had a birth attendant who did not wash hands with soap and water (AOR = 3.0, 95% CI: 1.4-5.7). Moreover, women with secondary infertility were more likely to report current or past history of having STI symptoms (AOR = 3.6, 95% CI: 2.4-5.6) and use of intra-vaginal indigenous medicines during their last postpartum period (AOR = 3.1, 95% CI: 1.6-5.7). Conclusion: We recommend health education and awareness messages for safe practices during menstruation, delivery, and the postpartum period for women in general. Additionally, sanitary napkins should be made available at an affordable cost, and safe delivery kits should contain educational/pictorial brochures for appropriate hand washing skills.	[Sami, Neelofar; Ali, Tazeen Saeed; Wasim, Saba; Saleem, Sarah] Aga Khan Univ, Dept Community Hlth Sci, Karachi, Pakistan; [Ali, Tazeen Saeed] Aga Khan Univ, Sch Nursing, Karachi, Pakistan	Aga Khan University; Aga Khan University	Sami, N (corresponding author), Aga Khan Univ, Dept Community Hlth Sci, Karachi, Pakistan.	neelofar.sami@aku.edu	S Ali, Tazeen/AAC-8790-2022; Ali, Tazeen Saeed/AAW-5284-2020	S Ali, Tazeen/0000-0002-8896-8766; 	Seed Money Grant [SM 020405]	Seed Money Grant	This work was supported by a Seed Money Grant (ID # SM 020405). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abouzahr C, 2003, CONTEMP OBSTET GYNEC, P128; Ali Tazeen Saeed, 2006, J Pak Med Assoc, V56, P99; Ali TS, 2007, J HEALTH POPUL NUTR, V25, P189; Alsaawi M, 2000, GENUS, VLVI, P99; Bhurt Abdul Wahid, 1999, JPMA (Journal of the Pakistan Medical Association), V49, P188; Boivin J, 2007, HUM REPROD, V22, P1506, DOI 10.1093/humrep/dem046; CATES W, 1990, EPIDEMIOL REV, V12, P199, DOI 10.1093/oxfordjournals.epirev.a036054; CHATURVEDI SK, 1993, J PSYCHOSOM RES, V37, P575, DOI 10.1016/0022-3999(93)90051-G; De Silva WI, 1998, SOC BIOL, V45, P223; Durr-e-Nayab, 2005, Pakistan Development Review, V44, P131; Farley TMM, 1988, P AFR POP C DAK; Farr G, 1998, ADV CONTRACEPT, V14, P45, DOI 10.1023/A:1006575610716; Fikree F, 2001, TRADITIONAL PRACTICE; Fikree FF, 2004, SOC SCI MED, V59, P681, DOI 10.1016/j.socscimed.2003.11.034; Ghani Nasreen, 2007, J Pak Med Assoc, V57, P363; Goodburn EA, 1994, INVESTIGATION NATURE; HERNADI Z, 1986, ACTA MED HUNG, V43, P155; Hossain MA, 1989, ROLE TRADITIONAL BIR; Inhorn MC, 1994, ANTHR INFECT DIS INT, P173; KHATAMEE MA, 1988, INT J FERTIL, V33, P246; KOCHAR M, 1980, AM J OBSTET GYNECOL, V138, P872, DOI 10.1016/0002-9378(80)91074-1; Larsen U., 2003, J HLTH POPULATION DE, P1; LARSON E, 1988, INFECT CONT HOSP EP, V9, P28, DOI 10.1086/645729; Lunenfeld B, 2004, HUM REPROD UPDATE, V10, P317, DOI 10.1093/humupd/dmh028; Mathews A, 1995, FOOTSTEPS, V24, P2; Mayaud P., 2001, WOMEN INFERTILITY SU, p71 ; Population Council, 1999, REPR TRACT INF SET F; Qureshi MS, 1991, INFERTILITY PAKISTAN, P222; Saleem S, 2007, OBSTET GYNECOL, V110, P977, DOI 10.1097/01.AOG.0000285653.17869.26; SATHAR Z, 1988, POPUL DEV REV, V14, P415, DOI 10.2307/1972196; Shahid NS, 1996, J DIARRHOEAL DIS RES, V14, P85; Siemer J, 2008, AM J TROP MED HYG, V78, P323, DOI 10.4269/ajtmh.2008.78.323; SPIRA A, 1986, HUM REPROD, V1, P111, DOI 10.1093/oxfordjournals.humrep.a136353; TZONOU A, 1993, J EPIDEMIOL COMMUN H, V47, P36, DOI 10.1136/jech.47.1.36; United Nations, 1993, WOM STAT FERT PAK RE; *WHO, 1991, INF TAB AV DAT PREV; World Health Organization, 1994, CHALL REPR HLTH RES; World Health Organization, 2009, WHO GUID HAND HYG HL; World Health Organization (WHO), 2008, PROP BIRTHS ATT SKIL	39	19	20	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2012	7	4							e35828	10.1371/journal.pone.0035828	http://dx.doi.org/10.1371/journal.pone.0035828			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TJ	22558233	Green Submitted, Green Published, gold			2023-01-03	WOS:000305336000064
J	Ball, LT; Lloyd-Jones, GC; Russell, CA				Ball, Liam T.; Lloyd-Jones, Guy C.; Russell, Christopher A.			Gold-Catalyzed Direct Arylation	SCIENCE			English	Article							(HETERO)ARENES; OXYARYLATION	Biaryls (two directly connected aromatic rings, Ar-1-Ar-2) are common motifs in pharmaceuticals, agrochemicals, and organic materials. Current methods for establishing the Ar-1-Ar-2 bond are dominated by the cross-coupling of aryl halides (Ar-1-X) with aryl metallics (Ar-2-M). We report that, in the presence of 1 to 2 mole percent of a gold catalyst and a mild oxidant, a wide range of arenes (Ar-1-H) undergo site-selective arylation by arylsilanes (Ar-2-SiMe3) to generate biaryls (Ar-1-Ar-2), with little or no homocoupling (Ar-1-Ar-1/Ar-2-Ar-2). Catalysis proceeds at room temperature and tolerates a broad range of functional groups, including those incompatible with cross-coupling. These features expedite biaryl preparation, as demonstrated by synthesis of the nonsteroidal anti-inflammatory diflunisal.					Lloyd-Jones, Guy/A-3417-2009	Ball, Liam/0000-0003-3849-9006; Lloyd-Jones, Guy/0000-0003-2128-6864; Russell, Christopher/0000-0003-2921-5278	Engineering and Physical Sciences Research Council [EP/G036764/1]; AstraZeneca; GlaxoSmithKline; Novartis; Pfizer; Syngenta; University of Bristol; Royal Society	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); Novartis(Novartis); Pfizer(Pfizer); Syngenta(Syngenta); University of Bristol; Royal Society(Royal Society of London)	Experimental procedures and compound characterization data are both presented in the supplementary materials. L. T. B., G.C.L.-J., and C. A. R contributed equally to the conception and direction of this work and to the preparation of the manuscript. L. T. B. conducted all of the experimental work. We thank Umicore AG & Co. KG for the generous donation of HAuCl<INF>4</INF>. L. T. B. thanks the Bristol Chemical Synthesis Doctoral Training Centre, funded by the Engineering and Physical Sciences Research Council (grant EP/G036764/1); AstraZeneca; GlaxoSmithKline; Novartis; Pfizer; Syngenta; and the University of Bristol, for the provision of a Ph.D. studentship. G.C.L.-J. is a Royal Society Wolfson Research Merit Award holder.	Ackermann L, 2009, ANGEW CHEM INT EDIT, V48, P9792, DOI 10.1002/anie.200902996; Alberico D, 2007, CHEM REV, V107, P174, DOI 10.1021/cr0509760; Ball LT, 2012, CHEM-EUR J, V18, P2931, DOI 10.1002/chem.201103061; Ball LT, 2010, ORG LETT, V12, P4724, DOI 10.1021/ol1019162; Ciana CL, 2011, ANGEW CHEM INT EDIT, V50, P458, DOI 10.1002/anie.201004703; Funaki K, 2011, CHEM LETT, V40, P1050, DOI 10.1246/cl.2011.1050; Hachiya H, 2010, ANGEW CHEM INT EDIT, V49, P2202, DOI 10.1002/anie.200906996; HANNAH J, 1978, J MED CHEM, V21, P1093, DOI 10.1021/jm00209a001; Kar A, 2008, CHEM COMMUN, P386, DOI 10.1039/b714928j; Kar A, 2009, J ORGANOMET CHEM, V694, P524, DOI 10.1016/j.jorganchem.2008.11.016; Lafrance M, 2006, J AM CHEM SOC, V128, P16496, DOI 10.1021/ja067144j; Li BJ, 2011, CHEM-EUR J, V17, P1728, DOI 10.1002/chem.201002273; Lyons TW, 2010, CHEM REV, V110, P1147, DOI 10.1021/cr900184e; McGlacken GP, 2009, CHEM SOC REV, V38, P2447, DOI 10.1039/b805701j; Neufeldt SR, 2012, ACCOUNTS CHEM RES, V45, P936, DOI 10.1021/ar300014f; NORMAN ROC, 1976, J CHEM SOC PERK T 1, P1983, DOI 10.1039/p19760001983; Phipps RJ, 2009, SCIENCE, V323, P1593, DOI 10.1126/science.1169975; Rombke P, 2001, J CHEM SOC DALTON, P2482, DOI 10.1039/b104001b; Ruyle W. V., 1973, U. S. Patent, Patent No. [3,714,226, 3714226]; Seechurn CCCJ, 2012, ANGEW CHEM INT EDIT, V51, P5062, DOI 10.1002/anie.201107017; Taylor R., 1990, ELECTROPHILIC AROMAT; Tsuji J., 2004, PALLADIUM REAGENTS C; Wen J, 2008, ANGEW CHEM INT EDIT, V47, P8897, DOI 10.1002/anie.200802526; Yang SD, 2008, ANGEW CHEM INT EDIT, V47, P1473, DOI 10.1002/anie.200704619	24	267	275	3	163	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 28	2012	337	6102					1644	1648		10.1126/science.1225709	http://dx.doi.org/10.1126/science.1225709			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012DJ	23019647	Green Accepted			2023-01-03	WOS:000309215400042
J	Aldini, R; Budriesi, R; Roda, G; Micucci, M; Ioan, P; D'Errico-Grigioni, A; Sartini, A; Guidetti, E; Marocchi, M; Cevenini, M; Rosini, F; Montagnani, M; Chiarini, A; Mazzella, G				Aldini, Rita; Budriesi, Roberta; Roda, Giulia; Micucci, Matteo; Ioan, Pierfranco; D'Errico-Grigioni, Antonia; Sartini, Alessandro; Guidetti, Elena; Marocchi, Margherita; Cevenini, Monica; Rosini, Francesca; Montagnani, Marco; Chiarini, Alberto; Mazzella, Giuseppe			Curcuma longa Extract Exerts a Myorelaxant Effect on the Ileum and Colon in a Mouse Experimental Colitis Model, Independent of the Anti-Inflammatory Effect	PLOS ONE			English	Article							NF-KAPPA-B; TRINITROBENZENE SULFONIC-ACID; INFLAMMATORY-BOWEL-DISEASE; ENTERIC NERVOUS-SYSTEM; DEXTRAN SULFATE SODIUM; ULCERATIVE-COLITIS; SMOOTH-MUSCLE; INTESTINAL INFLAMMATION; MAINTENANCE THERAPY; CELLS	Background: Curcuma has long been used as an anti-inflammatory agent in inflammatory bowel disease. Since gastrointestinal motility is impaired in inflammatory states, the aim of this work was to evaluate if Curcuma Longa had any effect on intestinal mortality Methods: The biological activity of Curcuma extract was evaluated against Carbachol induced contraction in isolated mice intestine. Acute and chronic colitis were induced in Balb/c mice by Dextran Sulphate Sodium administration (5% and 2.5% respectively) and either Curcuma extract (200 mg/kg/day) or placebo was thereafter administered for 7 and 21 days respectively. Spontaneous contractions and the response to Carbachol and Atropine of ileum and colon were studied after colitis induction and Curcuma administration. Results: Curcuma extract reduced the spontaneous contractions in the ileum and colon; the maximal response to Carbachol was inhibited in a non-competitive and reversible manner. Similar results were obtained in ileum and colon from Curcuma fed mice. DSS administration decreased the motility, mainly in the colon and Curcuma almost restored both the spontaneous contractions and the response to Carbachol after 14 days assumption, compared to standard diet, but a prolonged assumption of Curcuma decreased the spontaneous and Carbachol-induced contractions. Conclusions: Curcuma extract has a direct and indirect myorelaxant effect on mouse ileum and colon, independent of the anti-inflammatory effect. The indirect effect is reversible and non-competitive with the cholinergic agent. These results suggest the use of curcuma extract as a spasmolytic agent.	[Aldini, Rita; Roda, Giulia; Sartini, Alessandro; Guidetti, Elena; Marocchi, Margherita; Cevenini, Monica; Montagnani, Marco; Mazzella, Giuseppe] Univ Bologna, Dipartimento Med Clin, Osped Policlin S Orsola, Bologna, Italy; [Aldini, Rita] Univ Bologna, Dipartimento Sci Metalli Elettrochim & Tecn Chim, Bologna, Italy; [Budriesi, Roberta; Micucci, Matteo; Ioan, Pierfranco; Chiarini, Alberto] Univ Bologna, Dipartimento Sci Farmaceut, I-40126 Bologna, Italy; [D'Errico-Grigioni, Antonia; Rosini, Francesca] Univ Bologna, Dipartimento Med Interna Invecchiamento & Malatt, Osped Policlin S Orsola, Bologna, Italy	IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; University of Bologna; University of Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna	Aldini, R (corresponding author), Univ Bologna, Dipartimento Med Clin, Osped Policlin S Orsola, Bologna, Italy.	rita.aldini@unibo.it; roberta.budriesi@unibo.it	Roda, Giulia/E-5521-2011; Sartini, Alessandro/AAN-3396-2020; Micucci, Matteo/AAM-6126-2020; mazzella, giuseppe/A-1865-2016	Sartini, Alessandro/0000-0003-1573-6451; MICUCCI, MATTEO/0000-0003-3525-1531; D'ERRICO, ANTONIETTA/0000-0003-2747-3732; Mazzella, Giuseppe/0000-0001-8656-8112; MONTAGNANI, MARCO/0000-0003-0103-0327	Fondazione del Monte di Bologna e Ravenna; Alisal [Mazz100136- 2010]; MINISTERO DELLE POLITICHE AGRICOLE, ALIMENTARI E FORESTALI [D.M. 11008/7303/10]	Fondazione del Monte di Bologna e Ravenna(Fondazione del Monte di Bologna e Ravenna); Alisal; MINISTERO DELLE POLITICHE AGRICOLE, ALIMENTARI E FORESTALI	This work was supported by grants from Fondazione del Monte di Bologna e Ravenna and from Alisal (Mazz100136- 2010). ALISAL is a project supported by the MINISTERO DELLE POLITICHE AGRICOLE, ALIMENTARI E FORESTALI, with D.M. 11008/7303/10, dated 17/05/2010. The title of the project is: Miglioramento delle proprieta igienico-sanitarie, salutistiche e funzionali di commodity per l'alimentazione dell'uomo e/o degli animali (Improvement of sanitary properties, healthy and functional food commodities for human and/or animals). Prof. Mazzella was supported with materials, reagents, animals. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AHMED T, 2008, PHARM BIOCH BEHAV, V91, P554; Akiho Hirotada, 2011, World J Gastrointest Pathophysiol, V2, P72; AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004; [Anonymous], VERS 3 0 GRAPHPAD SO; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; Aube AC, 1999, NEUROGASTROENT MOTIL, V11, P55; Bharti AC, 2003, BLOOD, V101, P1053, DOI 10.1182/blood-2002-05-1320; Blandizzi C, 2003, BRIT J PHARMACOL, V139, P309, DOI 10.1038/sj.bjp.0705249; Camacho-Barquero L, 2007, INT IMMUNOPHARMACOL, V7, P333, DOI 10.1016/j.intimp.2006.11.006; Claramunt RM, 2009, BIOORGAN MED CHEM, V17, P1290, DOI 10.1016/j.bmc.2008.12.029; Deguchi Y, 2007, DIGEST DIS SCI, V52, P2993, DOI 10.1007/s10620-006-9138-9; Fitzpatrick LR, 2000, DIGEST DIS SCI, V45, P2327, DOI 10.1023/A:1005630723111; Furness JB, 2008, NEUROGASTROENT MOTIL, V20, P32, DOI 10.1111/j.1365-2982.2008.01094.x; Grundy D, 2005, CURR OPIN GASTROEN, V21, P176, DOI 10.1097/01.mog.0000153315.28327.6e; Han SS, 2002, J BIOCHEM MOL BIOL, V35, P337; Hanai H, 2006, CLIN GASTROENTEROL H, V4, P1502, DOI 10.1016/j.cgh.2006.08.008; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; Ihara E, 2009, MOL PHARMACOL, V75, P1031, DOI 10.1124/mol.108.049858; Itthipanichpong C, 2006, J MED ASS THAI S2, V86, pS2999; JACOBSON K, 1995, GASTROENTEROLOGY, V109, P718, DOI 10.1016/0016-5085(95)90378-X; JAIN SK, 1994, CIBA F SYMP, V185, P153; Jian YT, 2005, WORLD J GASTROENTERO, V11, P1747, DOI 10.3748/wjg.v11.i12.1747; Kim GY, 2005, J IMMUNOL, V174, P8116, DOI 10.4049/jimmunol.174.12.8116; Kinoshita K, 2003, AM J PHYSIOL-GASTR L, V285, pG483, DOI 10.1152/ajpgi.00038.2003; Kohno N, 2006, J MED INVESTIG, V53, P277, DOI 10.2152/jmi.53.277; Kondo T, 2011, EUR J PHARMACOL, V670, P236, DOI 10.1016/j.ejphar.2011.08.034; Kumar Anil, 2010, Indian J Physiol Pharmacol, V54, P284; Larmonier CB, 2011, INFLAMM BOWEL DIS, V17, P503, DOI 10.1002/ibd.21391; Lim Allen W, 2011, Therap Adv Gastroenterol, V4, P145, DOI 10.1177/1756283X10382816; Linden D, 2003, BRIT J PHARMACOL, V139, P185, DOI 10.1038/sj.bjp.0705250; Linden DR, 2004, J PHYSIOL-LONDON, V557, P191, DOI 10.1113/jphysiol.2004.062174; Lomax AE, 2005, NEUROGASTROENT MOTIL, V17, P4, DOI 10.1111/j.1365-2982.2004.00607.x; Mattar Mark C, 2011, Gastrointest Cancer Res, V4, P53; Mizuta Y, 2000, GASTROENTEROLOGY, V118, P714, DOI 10.1016/S0016-5085(00)70141-7; Motagally MA, 2009, AM J PHYSIOL-GASTR L, V296, pG1077, DOI 10.1152/ajpgi.00006.2009; Motulsky H, 2003, PRACTICAL GUIDE CURV; Myers BS, 1997, AM J PHYSIOL-GASTR L, V273, pG928, DOI 10.1152/ajpgi.1997.273.4.G928; Negi PS, 1999, J AGR FOOD CHEM, V47, P4297, DOI 10.1021/jf990308d; Papadakis KA, 2000, INFLAMM BOWEL DIS, V6, P303, DOI 10.1002/ibd.3780060408; Pazdrak K, 2004, GASTROENTEROLOGY, V127, P1096, DOI 10.1053/j.gastro.2004.07.008; Qureshi S, 2010, NEUROGASTROENT MOTIL, V22, DOI 10.1111/j.1365-2982.2009.01406.x; Qureshi S, 2010, NEUROGASTROENT MOTIL, V22, pe64; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; REDDY SN, 1991, GASTROENTEROLOGY, V101, P1289, DOI 10.1016/0016-5085(91)90079-Z; Rutgeerts P, 2005, NEW ENGL J MED, V353, P2462, DOI 10.1056/NEJMoa050516; Salh B, 2003, AM J PHYSIOL-GASTR L, V285, pG235, DOI 10.1152/ajpgi.00449.2002; Sato K, 2006, BRIT J PHARMACOL, V148, P200, DOI 10.1038/sj.bjp.0706717; Shimouchi A, 2009, DIGEST DIS SCI, V54, P1725, DOI 10.1007/s10620-008-0550-1; Singh AK, 1996, CANCER LETT, V107, P109, DOI 10.1016/0304-3835(96)04357-1; Singh G, 2010, FOOD CHEM TOXICOL, V48, P1026, DOI 10.1016/j.fct.2010.01.015; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Strober W, 2007, J CLIN INVEST, V117, P514, DOI 10.1172/JCI30587; Sugimoto K, 2002, GASTROENTEROLOGY, V123, P1912, DOI 10.1053/gast.2002.37050; TAKEMASA KENJIRO, 1957, JOUR PHYSIOL SOC JAPAN, V19, P1217; Tallarida RJ, 1987, MANUAL PHARM CALCULA; Tomita R, 1998, J GASTROENTEROL, V33, P48, DOI 10.1007/PL00009965; Triantafillidis JK, 2011, DRUG DES DEV THER, V5, P185, DOI 10.2147/DDDT.S11290; Ukil A, 2003, BRIT J PHARMACOL, V139, P209, DOI 10.1038/sj.bjp.0705241; Vasina V, 2006, AUTON NEUROSCI-BASIC, V126, P264, DOI 10.1016/j.autneu.2006.02.025; Vrees MD, 2002, ARCH SURG-CHICAGO, V137, P439, DOI 10.1001/archsurg.137.4.439; Wirtz S, 2007, NAT PROTOC, V2, P541, DOI 10.1038/nprot.2007.41; Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005; Xu YX, 1997, EXP HEMATOL, V25, P413; Xu YX, 1998, HEMATOPATHOL MOL HEM, V11, P49	64	21	21	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 12	2012	7	9							e44650	10.1371/journal.pone.0044650	http://dx.doi.org/10.1371/journal.pone.0044650			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	005GJ	22984538	gold, Green Published, Green Submitted			2023-01-03	WOS:000308738500071
J	Hsu, SM; Wu, CH; Lee, JH; Hsieh, YJ; Yu, CY; Liao, YJ; Kuo, LC; Liang, JA; Huang, DYC				Hsu, Shih-Ming; Wu, Chin-Hui; Lee, Jeng-Hung; Hsieh, Ya-Ju; Yu, Chun-Yen; Liao, Yi-Jen; Kuo, Li-Cheng; Liang, Ji-An; Huang, David Y. C.			A Study on the Dose Distributions in Various Materials from an Ir-192 HDR Brachytherapy Source	PLOS ONE			English	Article							MONTE-CARLO; GLASS DOSIMETER; GAMMA-RAYS; ANISOTROPY; RECOMMENDATIONS; VERIFICATION; ATTENUATION; DIODE; I-125; TLD	Dose distributions of Ir-192 HDR brachytherapy in phantoms simulating water, bone, lung tissue, water-lung and bone-lung interfaces using the Monte Carlo codes EGS4, FLUKA and MCNP4C are reported. Experiments were designed to gather point dose measurements to verify the Monte Carlo results using Gafchromic film, radiophotoluminescent glass dosimeter, solid water, bone, and lung phantom. The results for radial dose functions and anisotropy functions in solid water phantom were consistent with previously reported data (Williamson and Li). The radial dose functions in bone were affected more by depth than those in water. Dose differences between homogeneous solid water phantoms and solid water-lung interfaces ranged from 0.6% to 14.4%. The range between homogeneous bone phantoms and bone-lung interfaces was 4.1% to 15.7%. These results support the understanding in dose distribution differences in water, bone, lung, and their interfaces. Our conclusion is that clinical parameters did not provide dose calculation accuracy for different materials, thus suggesting that dose calculation of HDR treatment planning systems should take into account material density to improve overall treatment quality.	[Hsu, Shih-Ming] China Med Univ Hosp, Dept Biomed Imaging & Radiol Sci, Taichung, Taiwan; [Wu, Chin-Hui] Natl Tsing Hua Univ, Dept Engn & Syst Sci, Hsinchu, Taiwan; [Lee, Jeng-Hung] Inst Nucl Energy Res, Div Hlth Phys, Longtan, Taiwan; [Hsieh, Ya-Ju] Kaohsiung Med Univ, Dept Med Imaging & Radiol Sci, Kaohsiung, Taiwan; [Yu, Chun-Yen; Liang, Ji-An] China Med Univ Hosp, Dept Radiat Oncol, Taichung, Taiwan; [Liao, Yi-Jen] Taipei Med Univ, Sch Med Lab Sci & Biotechnol, Taipei, Taiwan; [Kuo, Li-Cheng] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Huang, David Y. C.] Rockville Ctr, Fac Mem Sloan Kettering Canc Ctr Rockville Ctr, New York, NY USA	China Medical University Taiwan; China Medical University Hospital - Taiwan; National Tsing Hua University; Institute of Nuclear Energy Research - Taiwan; Kaohsiung Medical University; China Medical University Taiwan; China Medical University Hospital - Taiwan; Taipei Medical University; Memorial Sloan Kettering Cancer Center	Hsu, SM (corresponding author), China Med Univ Hosp, Dept Biomed Imaging & Radiol Sci, Taichung, Taiwan.	huangd@mskcc.org		Kuo, Li Cheng/0000-0003-3740-7085; Hsieh, Ya Ju/0000-0003-2082-9345	China Medical University and Hospital [CMU99-N1-08-1, CMU99-N1-08-2, DMR-98-102]	China Medical University and Hospital(China Medical University)	This work was supported by Grant Nos. CMU99-N1-08-1&2 and DMR-98-102 from the China Medical University and Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Araki F, 2003, MED PHYS, V30, P1976, DOI 10.1118/1.1587451; Chiu-Tsao ST, 2004, MED PHYS, V31, P201, DOI 10.1118/1.1637733; Hoshi Y, 2000, J RADIAT RES, V41, P129, DOI 10.1269/jrr.41.129; Hsu SM, 2008, MED PHYS, V35, P5558, DOI 10.1118/1.3005478; Karaiskos P, 1998, MED PHYS, V25, P1975, DOI 10.1118/1.598371; Kassas B, 2006, J APPL CLIN MED PHYS, V7, P28, DOI 10.1120/jacmp.v7i3.2293; Kirov AS, 1995, PHYS MED BIOL, V40, P2015, DOI 10.1088/0031-9155/40/12/002; MEISBERGER LL, 1968, RADIOLOGY, V90, P953, DOI 10.1148/90.5.953; MEREDITH WJ, 1966, BRIT J RADIOL, V39, P280, DOI 10.1259/0007-1285-39-460-280; Mishra V, 1997, MED PHYS, V24, P751, DOI 10.1118/1.597983; MULLERRUNKEL R, 1994, MED PHYS, V21, P1131, DOI 10.1118/1.597339; NATH R, 1990, MED PHYS, V17, P1032, DOI 10.1118/1.596584; NATH R, 1993, MED PHYS, V20, P1465, DOI 10.1118/1.597110; NATH R, 1995, MED PHYS, V22, P209, DOI 10.1118/1.597458; Niroomand-Rad A, 1998, MED PHYS, V25, P2093, DOI 10.1118/1.598407; Pantelis E, 2005, INT J RADIAT ONCOL, V61, P1596, DOI 10.1016/j.ijrobp.2004.12.065; Sharma SD, 2004, PHYS MED BIOL, V49, P4065, DOI 10.1088/0031-9155/49/17/016; Taylor REP, 2008, MED PHYS, V35, P4933, DOI 10.1118/1.2987676; Tsuda Masayuki, 2000, Igaku Butsuri, V20, P131; Wang RQ, 1996, MED PHYS, V23, P1459, DOI 10.1118/1.597728; WILLIAMSON JF, 1995, MED PHYS, V22, P809, DOI 10.1118/1.597483	21	15	17	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 5	2012	7	9							e44528	10.1371/journal.pone.0044528	http://dx.doi.org/10.1371/journal.pone.0044528			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	001MC	22957078	Green Published, gold, Green Submitted			2023-01-03	WOS:000308463800071
J	Lavik, E; Ustin, J				Lavik, Erin; Ustin, Jeffrey			Leveraging Shear Stress to Bust Clots with Nanoparticles	SCIENCE			English	Editorial Material							PA		[Lavik, Erin; Ustin, Jeffrey] Case Western Reserve Univ, Cleveland, OH 44106 USA	Case Western Reserve University	Lavik, E (corresponding author), Case Western Reserve Univ, Cleveland, OH 44106 USA.	erin.lavik@case.edu		Lavik, Erin/0000-0002-0644-744X				Balucani Clotilde, 2010, Curr Cardiol Rep, V12, P34, DOI 10.1007/s11886-009-0082-0; Chung TW, 2008, BIOMATERIALS, V29, P228, DOI 10.1016/j.biomaterials.2007.09.027; COLLEN D, 1984, ARTERIOSCLEROSIS, V4, P579, DOI 10.1161/01.ATV.4.6.579; Grotta J, 2007, SURG NEUROL, V68, pS12, DOI 10.1016/j.surneu.2007.07.079; Holme MN, 2012, NAT NANOTECHNOL, V7, P536, DOI [10.1038/NNANO.2012.84, 10.1038/nnano.2012.84]; Kibos Ambrose, 2011, Acute Card Care, V13, P136, DOI 10.3109/17482941.2011.606477; Korin N, 2012, SCIENCE, V337, P738, DOI 10.1126/science.1217815; Mukherjee D, 2011, WORLD NEUROSURG, V76, pS85, DOI 10.1016/j.wneu.2011.07.023; Roger VL, 2012, CIRCULATION, V125, P188, DOI 10.1161/CIR.0b013e3182456d46; Silverstein MD, 1998, ARCH INTERN MED, V158, P585, DOI 10.1001/archinte.158.6.585; Wang SS, 2009, J BIOMED MATER RES A, V91A, P753, DOI 10.1002/jbm.a.32234; Wardlaw JM, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000213.pub2	12	11	11	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 10	2012	337	6095					658	659		10.1126/science.1227097	http://dx.doi.org/10.1126/science.1227097			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	986PE	22879494				2023-01-03	WOS:000307354500031
J	Yu, HB; Remer, LA; Chin, M; Bian, HS; Tan, Q; Yuan, TL; Zhang, Y				Yu, Hongbin; Remer, Lorraine A.; Chin, Mian; Bian, Huisheng; Tan, Qian; Yuan, Tianle; Zhang, Yan			Aerosols from Overseas Rival Domestic Emissions over North America	SCIENCE			English	Article							DUST; TRANSPORT; POLLUTION; AERONET; CALIPSO	Many types of aerosols have lifetimes long enough for their transcontinental transport, making them potentially important contributors to air quality and climate change in remote locations. We estimate that the mass of aerosols arriving at North American shores from overseas is comparable with the total mass of particulates emitted domestically. Curbing domestic emissions of particulates and precursor gases, therefore, is not sufficient to mitigate aerosol impacts in North America. The imported contribution is dominated by dust leaving Asia, not by combustion-generated particles. Thus, even a reduction of industrial emissions of the emerging economies of Asia could be overwhelmed by an increase of dust emissions due to changes in meteorological conditions and potential desertification.	[Yu, Hongbin] Univ Maryland, Earth Syst Sci Interdisciplinary Ctr, College Pk, MD 20740 USA; [Yu, Hongbin; Chin, Mian; Bian, Huisheng; Tan, Qian; Yuan, Tianle; Zhang, Yan] NASA, Earth Sci Directorate, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; [Remer, Lorraine A.; Bian, Huisheng; Yuan, Tianle] Univ Maryland Baltimore Cty, Joint Ctr Earth Syst Technol, Baltimore, MD 21228 USA; [Tan, Qian; Zhang, Yan] Univ Space Res Assoc, Goddard Earth Sci Technol & Res Ctr, Columbia, MD 21044 USA	University System of Maryland; University of Maryland College Park; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University System of Maryland; University of Maryland Baltimore County; Universities Space Research Association (USRA)	Yu, HB (corresponding author), Univ Maryland, Earth Syst Sci Interdisciplinary Ctr, College Pk, MD 20740 USA.	hongbin.yu@nasa.gov	Chin, Mian/J-8354-2012; Zhang, Yan/C-4792-2012; Yuan, Tianle/D-3323-2011; Yu, Hongbin/C-6485-2008	Yuan, Tianle/0000-0002-2187-3017; Yu, Hongbin/0000-0003-4706-1575; ZHANG, Yan/0000-0002-6954-5178	NASA [NNXAH66G, NNX11AJ91G]; GMI [NNX10AK61G]	NASA(National Aeronautics & Space Administration (NASA)); GMI	We acknowledge the NASA support of this work via NNXAH66G (The Science of Terra and Aqua Program) and NNX11AJ91G (Atmospheric Composition Modeling and Analysis Program) (H.Y.), both managed by R. Eckman. The NASA Modeling, Analysis, and Prediction program managed by D. Considine is acknowledged for supporting the model development of GOCART (M. C.) and GMI (H. B., under NNX10AK61G). We are grateful to J. Zhang for providing his reprocessed MODIS data, Z. Liu for providing insights in the lidar characterization of Asian dust, and X. Pan for acquiring CALIOP data. The MODIS data were obtained from the NASA Level 1 and Atmosphere Archive and Distribution System. The CALIOP data were obtained from the NASA Langley Research Center Atmospheric Science Data Center.	Bian H, 2009, ATMOS CHEM PHYS, V9, P2375, DOI 10.5194/acp-9-2375-2009; Biscaye PE, 2000, SCIENCE, V290, P2258, DOI 10.1126/science.290.5500.2258; Chin M, 2007, ATMOS CHEM PHYS, V7, P5501, DOI 10.5194/acp-7-5501-2007; Chin M, 2009, ANN GEOPHYS-GERMANY, V27, P3439, DOI 10.5194/angeo-27-3439-2009; Dentener F., 2010, AIR POLLUTION STUDIE, V17; Eck TF, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005274; Hadley OL, 2010, ATMOS CHEM PHYS, V10, P7505, DOI 10.5194/acp-10-7505-2010; Heald CL, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006847; Husar RB, 2001, J GEOPHYS RES-ATMOS, V106, P18317, DOI 10.1029/2000JD900788; Kalashnikova OV, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2008JD010083; KAUFMAN YJ, 2005, J GEOPHYS RES, V110, DOI DOI 10.1029/2003JD004436; Liu J, 2008, ATMOS CHEM PHYS, V8, P3721, DOI 10.5194/acp-8-3721-2008; Liu ZY, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2007JD008878; Maring H, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002536; Prospero JM, 2005, AEROBIOLOGIA, V21, P1, DOI 10.1007/s10453-004-5872-7; Ramanathan V, 2008, NAT GEOSCI, V1, P221, DOI 10.1038/ngeo156; Remer LA, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2007JD009661; Sassen K, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014051; Stith JL, 2009, J GEOPHYS RES-ATMOS, V114, DOI 10.1029/2008JD010924; Su L, 2011, ATMOS CHEM PHYS, V11, P3263, DOI 10.5194/acp-11-3263-2011; Warneke C, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2008GL036194; Winker DM, 2010, B AM METEOROL SOC, V91, P1211, DOI 10.1175/2010BAMS3009.1; Yu H., 2009, ATMOSPHERIC AEROSOL; Yu HB, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000754; Yu HB, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2007JD009349; Yu HB, 2009, J GEOPHYS RES-ATMOS, V114, DOI 10.1029/2008JD010648; Zhu P, 2007, J GEOPHYS RES-SPACE, V112, DOI 10.1029/2006JA011991	27	172	177	1	103	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 3	2012	337	6094					566	569		10.1126/science.1217576	http://dx.doi.org/10.1126/science.1217576			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982PU	22859485				2023-01-03	WOS:000307058700041
J	Rocco, CA; Mecikovsky, D; Aulicino, P; Bologna, R; Sen, L; Mangano, A				Rocco, Carlos A.; Mecikovsky, Debora; Aulicino, Paula; Bologna, Rosa; Sen, Luisa; Mangano, Andrea			Hypercholesterolemia Is Associated with the Apolipoprotein C-III (APOC3) Genotype in Children Receiving HAART: An Eight-Year Retrospective Study	PLOS ONE			English	Article							CARDIOVASCULAR RISK-FACTORS; SINGLE-NUCLEOTIDE POLYMORPHISMS; ANTIRETROVIRAL THERAPY; LIPID ABNORMALITIES; DYSLIPIDEMIA; INDIVIDUALS; CHILDHOOD; GENES; ADOLESCENTS; DISORDERS	Polymorphisms in apolipoprotein genes have shown to be predictors of plasma lipid levels in adult cohorts receiving highly active antiretroviral therapy (HAART). Our objective was to confirm the association between the APOC3 genotype and plasma lipid levels in an HIV-1-infected pediatric cohort exposed to HAART. A total of 130 HIV-1-infected children/adolescents that attended a reference center in Argentina were selected for an 8-year longitudinal study with retrospective data collection. Longitudinal measurements of plasma triglycerides, total cholesterol, HDL-C and LDL-C were analyzed under linear or generalized linear mixed models. The contribution of the APOC3 genotype at sites -482, -455 and 3238 to plasma lipid levels prediction was tested after adjusting for potential confounders. Four major APOC3 haplotypes were observed for sites -482/-455/3238, with estimated frequencies of 0.60 (C/T/C), 0.14 (T/C/C), 0.11 (C/C/C), and 0.11 (T/C/G). The APOC3 genotype showed a significant effect only for the prediction of total cholesterol levels (p < 0.0001). However, the magnitude of the differences observed was dependent on the drug combination (p = 0.0007) and the drug exposure duration at the time of the plasma lipid measurement (p = 0.0002). A lower risk of hypercholesterolemia was predicted for double and triple heterozygous individuals, mainly at the first few months after the initiation of Ritonavir-boosted protease inhibitor-based regimens. We report for the first time a significant contribution of the genotype to total cholesterol levels in a pediatric cohort under HAART. The genetic determination of APOC3 might have an impact on a large portion of HIV-1-infected children at the time of choosing the treatment regimens or on the counter-measures against the adverse effects of drugs.	[Rocco, Carlos A.; Aulicino, Paula; Sen, Luisa; Mangano, Andrea] Hosp Pediat Juan P Garrahan, Lab Biol Celular & Retrovirus, Buenos Aires, DF, Argentina; [Mecikovsky, Debora; Bologna, Rosa] Hosp Pediat Juan P Garrahan, Serv Epidemiol & Infectol, Buenos Aires, DF, Argentina; [Aulicino, Paula; Sen, Luisa; Mangano, Andrea] Consejo Nacl Invest Cient & Tecn, RA-1033 Buenos Aires, DF, Argentina	Hospital de Pediatria Doctor Juan Garrahan; Hospital de Pediatria Doctor Juan Garrahan; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Rocco, CA (corresponding author), Hosp Pediat Juan P Garrahan, Lab Biol Celular & Retrovirus, Buenos Aires, DF, Argentina.	roccocar@yahoo.com			Agencia Nacional de Promocion Cientifica y Tecnologica award [PICT 2006-1235]; CONICET PIP [6057]; Fundacion Fiorini; Fogarty AITRP [D43TW001037]; FOGARTY INTERNATIONAL CENTER [D43TW001037] Funding Source: NIH RePORTER	Agencia Nacional de Promocion Cientifica y Tecnologica award; CONICET PIP(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Fundacion Fiorini; Fogarty AITRP(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	This work was supported by the Agencia Nacional de Promocion Cientifica y Tecnologica award No PICT 2006-1235, CONICET PIP No 6057, Fundacion Fiorini and partially supported by Fogarty AITRP Grant #D43TW001037. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1994, MMWR-MORBID MORTAL W, V43, P1; Arnedo M, 2007, PHARMACOGENET GENOM, V17, P755, DOI 10.1097/FPC.0b013e32814db8b7; Aulchenko YS, 2009, NAT GENET, V41, P47, DOI 10.1038/ng.269; Boes E, 2009, EXP GERONTOL, V44, P136, DOI 10.1016/j.exger.2008.11.003; Bonnet E, 2007, CLIN CHEM LAB MED, V45, P815, DOI 10.1515/CCLM.2007.140; Brewinski M, 2011, J TROP PEDIATRICS, V57, P324, DOI 10.1093/tropej/fmq089; Carter RJ, 2006, JAIDS-J ACQ IMM DEF, V41, P453, DOI 10.1097/01.qai.0000218344.88304.db; Dallinga-Thie GM, 2001, J LIPID RES, V42, P1450; Davis PH, 2001, CIRCULATION, V104, P2815, DOI 10.1161/hc4601.099486; Fauvel J, 2001, AIDS, V15, P2397, DOI 10.1097/00002030-200112070-00007; Foulkes AS, 2006, PLOS MED, V3, P337, DOI 10.1371/journal.pmed.0030052; Hallman DM, 2006, METABOLISM, V55, P1574, DOI 10.1016/j.metabol.2006.07.018; Juonala M, 2008, ARTERIOSCL THROM VAS, V28, P1012, DOI 10.1161/ATVBAHA.108.163329; Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291; Kwiterovich PO, 2008, J CLIN ENDOCR METAB, V93, P4200, DOI 10.1210/jc.2008-1270; Li SX, 2003, JAMA-J AM MED ASSOC, V290, P2271, DOI 10.1001/jama.290.17.2271; Li WW, 1995, J CLIN INVEST, V96, P2601, DOI 10.1172/JCI118324; McCrindle BW, 2007, CIRCULATION, V115, P1948, DOI 10.1161/CIRCULATIONAHA.107.181946; Miserez AR, 2001, AIDS, V15, P2045, DOI 10.1097/00002030-200110190-00020; Resino S, 2008, AIDS RES HUM RETROV, V24, P1477, DOI 10.1089/aid.2008.0037; Rodriguez-Novoa S, 2006, PHARMACOGENOMICS J, V6, P234, DOI 10.1038/sj.tpj.6500374; Rotger M, 2009, CIRC-CARDIOVASC GENE, V2, P621, DOI 10.1161/CIRCGENETICS.109.874412; Sabatti C, 2009, NAT GENET, V41, P35, DOI 10.1038/ng.271; Seldin MF, 2007, AM J PHYS ANTHROPOL, V132, P455, DOI 10.1002/ajpa.20534; Tarr PE, 2005, J INFECT DIS, V191, P1419, DOI 10.1086/429295; Taylor P, 2004, PEDIATRICS, V114, P235; Werner MLF, 2010, J PEDIAT-BRAZIL, V86, P27, DOI [10.1590/S0021-75572010000100006, 10.2223/JPED.1961]; Yang AM, 2003, AIDS, V17, P2142, DOI 10.1097/00002030-200309260-00024	28	7	7	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2012	7	7							e39678	10.1371/journal.pone.0039678	http://dx.doi.org/10.1371/journal.pone.0039678			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979GX	22848358	Green Published, gold, Green Submitted			2023-01-03	WOS:000306806600008
J	Hubbell, JA; Chilkoti, A				Hubbell, Jeffrey A.; Chilkoti, Ashutosh			Nanomaterials for Drug Delivery	SCIENCE			English	Editorial Material							IN-VIVO; NANOPARTICLES; TUMOR; TRANSPORT; PEPTIDES		[Hubbell, Jeffrey A.] Ecole Polytech Fed Lausanne, Sch Life Sci, Inst Bioengn, CH-1015 Lausanne, Switzerland; [Hubbell, Jeffrey A.] Ecole Polytech Fed Lausanne, Sch Engn, CH-1015 Lausanne, Switzerland; [Hubbell, Jeffrey A.] Ecole Polytech Fed Lausanne, Sch Basic Sci, Inst Chem Sci & Engn, CH-1015 Lausanne, Switzerland; [Chilkoti, Ashutosh] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA; [Chilkoti, Ashutosh] Duke Univ, Ctr Biol Inspired Mat & Mat Syst, Durham, NC 27708 USA	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Duke University; Duke University	Hubbell, JA (corresponding author), Ecole Polytech Fed Lausanne, Sch Life Sci, Inst Bioengn, CH-1015 Lausanne, Switzerland.	jeffrey.hubbell@epfl.ch	Hubbell, Jeffrey A/A-9266-2008	Hubbell, Jeffrey A/0000-0003-0276-5456				Baish JW, 2011, P NATL ACAD SCI USA, V108, P1799, DOI 10.1073/pnas.1018154108; Christian DA, 2009, MOL PHARMACEUT, V6, P1343, DOI 10.1021/mp900022m; Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956; Douglas SM, 2012, SCIENCE, V335, P831, DOI 10.1126/science.1214081; Gao WP, 2010, P NATL ACAD SCI USA, V107, P16432, DOI 10.1073/pnas.1006044107; Hatakeyama S, 2011, P NATL ACAD SCI USA, V108, P19587, DOI 10.1073/pnas.1105057108; Hirosue S, 2010, VACCINE, V28, P7897, DOI 10.1016/j.vaccine.2010.09.077; MacKay JA, 2009, NAT MATER, V8, P993, DOI [10.1038/NMAT2569, 10.1038/nmat2569]; Moon JJ, 2011, NAT MATER, V10, P243, DOI 10.1038/NMAT2960; Murakami M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001385; Nembrini C, 2011, P NATL ACAD SCI USA, V108, pE989, DOI 10.1073/pnas.1104264108; Peters D, 2009, P NATL ACAD SCI USA, V106, P9815, DOI 10.1073/pnas.0903369106; Petros RA, 2010, NAT REV DRUG DISCOV, V9, P615, DOI 10.1038/nrd2591; Reddy ST, 2007, NAT BIOTECHNOL, V25, P1159, DOI [10.1038/nbt1332, 10.1038/nbtl332]; Schellenberger V, 2009, NAT BIOTECHNOL, V27, P1186, DOI 10.1038/nbt.1588; von Maltzahn G, 2011, NAT MATER, V10, P545, DOI [10.1038/nmat3049, 10.1038/NMAT3049]; Yoo JW, 2011, NAT REV DRUG DISCOV, V10, P521, DOI 10.1038/nrd3499	17	409	421	4	312	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 20	2012	337	6092					303	305		10.1126/science.1219657	http://dx.doi.org/10.1126/science.1219657			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975WQ	22822138				2023-01-03	WOS:000306542600038
J	Bakalar, N				Bakalar, Nicholas			SENSORY SCIENCE Partners in flavour	NATURE			English	Editorial Material																		Forestell CA, 2007, PEDIATRICS, V120, P1247, DOI 10.1542/peds.2007-0858; Gal D., 2007, SSRN ELIBRARY; Gueguen N, 2004, PERCEPT MOTOR SKILL, V99, P34, DOI 10.2466/PMS.99.5.34-38; Lipchock SV, 2011, CLIN PERINATOL, V38, P627, DOI 10.1016/j.clp.2011.08.008; Ohla K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032434; Talavera K, 2005, NATURE, V438, P1022, DOI 10.1038/nature04248; Zampini M, 2010, CHEMOSENS PERCEPT, V3, P57, DOI 10.1007/s12078-010-9064-2	7	10	10	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 21	2012	486	7403					S4	S5		10.1038/486S4a	http://dx.doi.org/10.1038/486S4a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	046RB	22717401	Bronze			2023-01-03	WOS:000311781000003
J	Kellum, JA; Bellomo, R; Ronco, C				Kellum, John A.; Bellomo, Rinaldo; Ronco, Claudio			Kidney Attack	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ACUTE-RENAL-FAILURE; INJURY; MORTALITY; PNEUMONIA; OUTCOMES		[Kellum, John A.] Univ Pittsburgh, Clin Res Invest & Syst Modeling Acute Illness Ctr, Dept Crit Care Med, Pittsburgh, PA 15261 USA; [Bellomo, Rinaldo] Austin Hosp, Dept Intens Care & Med, Melbourne, Vic 3084, Australia; [Bellomo, Rinaldo] Univ Melbourne, Melbourne, Vic, Australia; [Ronco, Claudio] Osped San Bortolo, Int Renal Res Inst, Dept Nephrol, Vicenza, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; ULSS 8 Berica; Ospedale San Bortolo di Vicenza	Kellum, JA (corresponding author), Univ Pittsburgh, Clin Res Invest & Syst Modeling Acute Illness Ctr, Dept Crit Care Med, Room 604,Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	kellumja@ccm.upmc.edu	Kellum, John/AAP-3072-2020; Kellum, John A/HCH-2944-2022	Kellum, John/0000-0003-1995-2653; Kellum, John A/0000-0003-1995-2653; Ronco, Claudio/0000-0002-6697-4065				Ali T, 2007, J AM SOC NEPHROL, V18, P1292, DOI 10.1681/ASN.2006070756; Amdur RL, 2009, KIDNEY INT, V76, P1089, DOI 10.1038/ki.2009.332; Colpaert K, 2012, CRIT CARE MED, V40, P1164, DOI 10.1097/CCM.0b013e3182387a6b; Foley RN, 2011, NEW ENGL J MED, V365, P1099, DOI 10.1056/NEJMoa1103313; Kidney Disease: Improving Global Outcomes (KDIGO), 2012, KIDNEY INT S, V2, P89; Murugan R, 2010, KIDNEY INT, V77, P527, DOI 10.1038/ki.2009.502; Ricci Z, 2008, KIDNEY INT, V73, P538, DOI 10.1038/sj.ki.5002743; Singbartl K, 2011, KIDNEY INT, V80, P633, DOI 10.1038/ki.2011.201; Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813	9	72	73	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 6	2012	307	21					2265	2266		10.1001/jama.2012.4315	http://dx.doi.org/10.1001/jama.2012.4315			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	952OL	22572776				2023-01-03	WOS:000304801700019
J	Villar, VH; Vogler, O; Martinez-Serra, J; Ramos, R; Calabuig-Farinas, S; Gutierrez, A; Barcelo, F; Martin-Broto, J; Alemany, R				Hugo Villar, Victor; Voegler, Oliver; Martinez-Serra, Jordi; Ramos, Rafael; Calabuig-Farinas, Silvia; Gutierrez, Antonio; Barcelo, Francisca; Martin-Broto, Javier; Alemany, Regina			Nilotinib Counteracts P-Glycoprotein-Mediated Multidrug Resistance and Synergizes the Antitumoral Effect of Doxorubicin in Soft Tissue Sarcomas	PLOS ONE			English	Article							CHRONIC MYELOID-LEUKEMIA; GASTROINTESTINAL STROMAL TUMORS; TYROSINE KINASE INHIBITORS; DOSE DOXORUBICIN; CANCER-THERAPY; CELL-LINES; BCR-ABL; PHASE-I; IMATINIB; SUNITINIB	The therapeutic effect of doxorubicin (DXR) in the treatment of soft tissue sarcomas (STS) is limited by its toxicity and the development of multidrug resistance (MDR), the latter mainly induced by high expression of efflux pumps (e. g., P-glycoprotein [P-gp]). Therefore, the search for alternative therapies, which sensitize these tumors to chemotherapy while maintaining a low toxicity profile, is a rational approach. We assessed efficacy and molecular mechanisms involved in the antiproliferative effects of the tyrosine kinase inhibitors, nilotinib and imatinib, as single agents or in combination with DXR, in human synovial sarcoma SW982 and leiomyosarcoma SK-UT-1 cells. As single compound nilotinib (1-10 mu M) was more potent than imatinib inhibiting the growth of SK-UT-1 and SW982 cells by 33.5-59.6%, respectively. Importantly, only nilotinib synergized the antitumoral effect of DXR (0.05-0.5 mu M) by at least 2-fold, which clearly surpassed the mere sum of effects according to isobolographic analysis. Moreover, nilotinib in combination with DXR had a sustained effect on cell number (-70.3+/-5.8%) even 12 days after withdrawal of drugs compared to DXR alone. On the molecular level, only nilotinib fully blocked FBS-induced ERK1 and p38 MAPK activation, hence, reducing basal and DXR-induced up-regulation of P-gp levels. Moreover, efflux activity of the MDR-related proteins P-gp and MRP-1 was inhibited, altogether resulting in intracellular DXR retention. In high-risk STS tumors 53.8% and 15.4% were positive for P-gp and MRP-1 expression, respectively, with high incidence of P-gp in synovial sarcoma (72.7%). In summary, nilotinib exhibits antiproliferative effects on cellular models of STS and sensitizes them to DXR by reverting DXR-induced P-gp-mediated MDR and inhibiting MRP-1 activity, leading to a synergistic effect with potential for clinical treatment.	[Hugo Villar, Victor; Voegler, Oliver; Martinez-Serra, Jordi; Ramos, Rafael; Calabuig-Farinas, Silvia; Gutierrez, Antonio; Barcelo, Francisca; Martin-Broto, Javier; Alemany, Regina] Univ Balearic Isl, Clin & Translat Res Grp, Dept Biol, Inst Univ Invest Ciencies Salut IUNICS, Palma De Mallorca, Spain; [Martinez-Serra, Jordi; Gutierrez, Antonio] Univ Hosp Son Espases, Dept Hematol, Palma De Mallorca, Spain; [Ramos, Rafael] Univ Hosp Son Espases, Dept Pathol, Palma De Mallorca, Spain; [Calabuig-Farinas, Silvia; Martin-Broto, Javier] Univ Hosp Son Espases, Dept Oncol, Palma De Mallorca, Spain	Universitat de les Illes Balears; Hospital Universitari Son Espases; Hospital Universitari Son Espases; Hospital Universitari Son Espases	Villar, VH (corresponding author), Univ Balearic Isl, Clin & Translat Res Grp, Dept Biol, Inst Univ Invest Ciencies Salut IUNICS, Palma De Mallorca, Spain.	regina.alemany@uib.es	VILLAR, VICTOR H./AAD-2404-2020; Fariñas, Silvia Calabuig/D-8196-2018; IBIS, BIOMARCADORES/P-3515-2015; Alemany, Regina/A-2314-2011; Martinez-Serra, Jordi/C-2535-2009; Martín-Broto, Javier/AAI-2313-2019; Villar, Victor H./GQA-6295-2022; Barceló, Francisca/K-5288-2014; Vögler, Oliver/D-7658-2011; Villar, Victor H./GQR-0553-2022; Gutiérrez, Antonio/AAL-9381-2021	Villar, Victor H./0000-0003-2837-5018; Barceló, Francisca/0000-0002-9158-099X; Villar, Victor H./0000-0003-2837-5018; Martin-Broto, Javier/0000-0001-7350-6916; Alemany, Regina/0000-0003-2180-1213; Calabuig, Silvia/0000-0001-7749-174X	"Jose Ma Buesa del grupo GEIS"; "Asociacion Espanola contra el Cancer (Junta de Baleares)"; Spanish Ministry of Health [EC10-150]; "Conselleria d'Economia, Hisenda i Innovacio (Govern de les Illes Balears)"	"Jose Ma Buesa del grupo GEIS"; "Asociacion Espanola contra el Cancer (Junta de Baleares)"; Spanish Ministry of Health(Instituto de Salud Carlos IIISpanish Government); "Conselleria d'Economia, Hisenda i Innovacio (Govern de les Illes Balears)"	Research was supported by grants "Jose Ma Buesa del grupo GEIS" and the "Asociacion Espanola contra el Cancer (Junta de Baleares)" and by Grand EC10-150 awarded by the Spanish Ministry of Health in 2010 (Independent Clinical Research Call). V. H. V. is supported by a PhD fellowship from the "Conselleria d'Economia, Hisenda i Innovacio (Govern de les Illes Balears)." The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abolhoda A, 1999, CLIN CANCER RES, V5, P3352; Arora A, 2005, J PHARMACOL EXP THER, V315, P971, DOI 10.1124/jpet.105.084145; Barancik M, 2001, EUR J PHARM SCI, V14, P29, DOI 10.1016/S0928-0987(01)00139-7; Breccia M, 2010, LEUKEMIA RES, V34, P129, DOI 10.1016/j.leukres.2009.08.031; Davies A, 2009, LEUKEMIA, V23, P1999, DOI 10.1038/leu.2009.166; DeAngelo DJ, 2010, LEUKEMIA LYMPHOMA, V51, P363, DOI 10.3109/10428190903518295; Debiec-Rychter M, 2004, EUR J CANCER, V40, P689, DOI 10.1016/j.ejca.2003.11.025; Demetri GD, 2006, LANCET, V368, P1329, DOI 10.1016/S0140-6736(06)69446-4; Gonzalez I, 2004, CLIN CANCER RES, V10, P751, DOI 10.1158/1078-0432.CCR-0778-03; Gooskens SLM, 2010, PEDIATR BLOOD CANCER, V55, P369, DOI 10.1002/pbc.22494; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gramza AW, 2009, CLIN CANCER RES, V15, P7510, DOI 10.1158/1078-0432.CCR-09-0190; Gronchi A, 2010, J CLIN ONCOL, V28, p15s; Guo XL, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-375; Hamada A, 2003, J PHARMACOL EXP THER, V307, P824, DOI 10.1124/jpet.103.055574; Hochhaus A, 2009, LEUKEMIA, V23, P1054, DOI 10.1038/leu.2009.38; Moreno BH, 2010, CLIN TRANSL ONCOL, V12, P468, DOI 10.1007/s12094-010-0539-z; Le Cesne A, 2000, J CLIN ONCOL, V18, P2676, DOI 10.1200/JCO.2000.18.14.2676; Lu MS, 2008, J HUAZHONG U SCI-MED, V28, P451, DOI 10.1007/s11596-008-0417-x; Lubieniecka JM, 2005, J SURG ONCOL, V92, P267, DOI 10.1002/jso.20409; Mahadevan D, 2007, ONCOGENE, V26, P3909, DOI 10.1038/sj.onc.1210173; Manley PW, 2010, BIOORGAN MED CHEM, V18, P6977, DOI 10.1016/j.bmc.2010.08.026; Manley PW, 2010, BBA-PROTEINS PROTEOM, V1804, P445, DOI 10.1016/j.bbapap.2009.11.008; Maurel J, 2010, CANCER-AM CANCER SOC, V116, P3692, DOI 10.1002/cncr.25111; Mealey KL, 1998, CANCER LETT, V126, P187, DOI 10.1016/S0304-3835(98)00004-4; Milano A, 2006, CRIT REV ONCOL HEMAT, V59, P74, DOI 10.1016/j.critrevonc.2005.12.002; Montemurro M, 2009, EUR J CANCER, V45, P2293, DOI 10.1016/j.ejca.2009.04.030; Nichols GL, 2003, CANCER INVEST, V21, P758, DOI 10.1081/CNV-120023774; O'Connor R, 2007, ANTICANCER RES, V27, P1267; Peng B, 2005, CLIN PHARMACOKINET, V44, P879, DOI 10.2165/00003088-200544090-00001; Peng CL, 2009, CANCER BIOL THER, V8, P1729, DOI 10.4161/cbt.8.18.9208; Potti A, 2004, ANTICANCER RES, V24, P333; Prenen H, 2006, PHARMACOLOGY, V77, P11, DOI 10.1159/000091943; Quintas-Cardama A, 2008, FUTURE ONCOL, V4, P611, DOI 10.2217/14796694.4.5.611; Reichardt P, 2008, CURR ONCOL REP, V10, P344, DOI 10.1007/s11912-008-0053-4; SCHOENFELD DA, 1982, CANCER, V50, P2757, DOI 10.1002/1097-0142(19821215)50:12<2757::AID-CNCR2820501211>3.0.CO;2-J; Serra JM, 2008, MOL PHARMACOL, V73, P1679, DOI 10.1124/mol.107.043372; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; STEEL GG, 1979, INT J RADIAT ONCOL, V5, P85; Swords R, 2009, DRUG DES DEV THER, V3, P89; Tallarida RJ, 2001, J PHARMACOL EXP THER, V298, P865; Tiwari AK, 2009, BIOCHEM PHARMACOL, V78, P153, DOI 10.1016/j.bcp.2009.04.002; Watanabe T, 2009, MOL CANCER RES, V7, P1582, DOI 10.1158/1541-7786.MCR-09-0064; White DL, 2006, BLOOD, V108, P697, DOI 10.1182/blood-2005-11-4687	44	34	34	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2012	7	5							e37735	10.1371/journal.pone.0037735	http://dx.doi.org/10.1371/journal.pone.0037735			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UY	22662203	Green Published, Green Submitted, gold			2023-01-03	WOS:000305342300093
J	Meeuwsen, EJ; Melis, RJF; Van der Aa, GCHM; Goluke-Willemse, GAM; De Leest, BJM; Van Raak, FHJM; Scholzel-Dorenbos, CJM; Verheijen, DCM; Verhey, FRJ; Visser, MC; Wolfs, CA; Adang, EMM; Rikkert, MGMO				Meeuwsen, Els J.; Melis, Rene J. F.; Van der Aa, Geert C. H. M.; Goluke-Willemse, Gertie A. M.; De Leest, Benoit J. M.; Van Raak, Frank H. J. M.; Scholzel-Dorenbos, Carla J. M.; Verheijen, Desiree C. M.; Verhey, Frans R. J.; Visser, Marieke C.; Wolfs, Claire A.; Adang, Eddy M. M.; Rikkert, Marcel G. M. Olde			Effectiveness of dementia follow-up care by memory clinics or general practitioners: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; DIAGNOSTIC-APPROACH; PRAGMATIC TRIALS; STRATEGY; PEOPLE; VALIDATION; INTENTION; THERAPY; PROGRAM; ENGLAND	Objective To examine the effectiveness of post-diagnosis dementia treatment and coordination of care by memory clinics compared with general practitioners. Design Multicentre randomised controlled trial. Setting Nine memory clinics and 159 general practitioners in the Netherlands. Participants 175 patients with a new diagnosis of mild to moderate dementia living in the community and their informal caregivers. Interventions Usual care provided by memory clinic or general practitioner. Main outcome measures Caregiver rated quality of life of the patient measured with the quality of life in Alzheimer's disease instrument and self perceived burden of the informal caregiver measured with the sense of competence questionnaire (intention to treat analysis). Results The quality of life of the patients in the memory clinic group was 0.5 (95% confidence interval -0.7 to 1.6) points higher than in the general practitioner group. Caregivers' burden was 2.4 (-5.8 to 1.0) points lower in the memory clinic group than in the general practitioner group. Conclusion No evidence was found that memory clinics were more effective than general practitioners with regard to post-diagnosis treatment and coordination care for patients with dementia. Without further evidence on the effectiveness of these modalities, other arguments, such as cost minimisation, patients' preferences, or regional health service planning, can determine which type of dementia care is offered.	[Meeuwsen, Els J.; Melis, Rene J. F.; Scholzel-Dorenbos, Carla J. M.; Rikkert, Marcel G. M. Olde] Radboud Univ Nijmegen, Med Ctr, Dept Geriatr, Alzheimer Ctr Nijmegen, NL-6500 HB Nijmegen, Netherlands; [Van der Aa, Geert C. H. M.] Catharina Hosp, Dept Geriatr, NL-5602 ZA Eindhoven, Netherlands; [Goluke-Willemse, Gertie A. M.] Rijnstate Hosp, Dept Geriatr, NL-6800 TA Arnhem, Netherlands; [De Leest, Benoit J. M.] Elkerliek Hosp, Dept Geriatr, NL-5700 AB Helmond, Netherlands; [Van Raak, Frank H. J. M.] Ctr Land van Cuijk, GGZ Oost Brabant, NL-5830 AC Boxmeer, Netherlands; [Scholzel-Dorenbos, Carla J. M.] Slingeland Hosp, Memory Clin, NL-7000 AD Doetinchem, Netherlands; [Verheijen, Desiree C. M.] Gelderse Vallei Hosp, Dept Geriatr, NL-6710 HN Ede, Netherlands; [Verhey, Frans R. J.; Wolfs, Claire A.] Maastricht Univ, Med Ctr, Alzheimer Ctr Limburg, Dept Psychiat & Neuropsychol, NL-6202 AZ Maastricht, Netherlands; [Visser, Marieke C.] VU Med Ctr Amsterdam, Alzheimer Ctr Amsterdam, Dept Neurol, NL-1007 MB Amsterdam, Netherlands; [Adang, Eddy M. M.] Radboud Univ Nijmegen, Med Ctr, Dept Epidemiol Biostat & HTA, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Catharina Hospital; Rijnstate Hospital; Gelderse Vallei Hospital; Maastricht University; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Radboud University Nijmegen	Meeuwsen, EJ (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Geriatr, Alzheimer Ctr Nijmegen, POB 9101, NL-6500 HB Nijmegen, Netherlands.	E.Meeuwsen@ger.umcn.nl	Adang, E.M.M./L-4169-2015; Rikkert, M.G.M. Olde/H-8078-2014; Rikkert, Marcel Olde/D-9773-2012; Melis, René/J-5943-2012	Rikkert, M.G.M. Olde/0000-0003-1397-1677; Melis, René/0000-0002-7863-4738	ZonMw (Netherlands Organization for Health Research and Development) [945-07-703]; Radboud University Nijmegen Medical Centre	ZonMw (Netherlands Organization for Health Research and Development)(Netherlands Organization for Health Research and Development); Radboud University Nijmegen Medical Centre	This work was supported by ZonMw (Netherlands Organization for Health Research and Development; grant no 945-07-703) and by the Radboud University Nijmegen Medical Centre.	Altman DG, 2005, BRIT MED J, V330, P843, DOI 10.1136/bmj.330.7495.843; Banerjee S, 2010, INT J GERIATR PSYCH, V25, P917, DOI 10.1002/gps.2598; Banerjee S, 2009, INT J GERIATR PSYCH, V24, P15, DOI 10.1002/gps.2090; BOOMSMA LJ, 2005, HUISARTS WET, V48, P124; Borm GF, 2007, J CLIN EPIDEMIOL, V60, P1234, DOI 10.1016/j.jclinepi.2007.02.006; Burns A, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b931; Cahill S, 2010, INT J GERIATR PSYCH, V25, P912, DOI 10.1002/gps.2597; Connelly P, 2010, INT J GERIATR PSYCH, V25, P908, DOI 10.1002/gps.2596; Coombes R, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b550; Craig D., 2004, PSYCHIAT B, V28, P375, DOI [10.1192/pb.28.10.375, DOI 10.1192/PB.28.10.375]; Dam van-Baggen CMJ, 1986, INVENTARISATIELIJST; Department of Health, 2009, LIVING WELL DEMENTIA; Doncaster E, 2011, AGING MENT HEALTH, V15, P23, DOI 10.1080/13607863.2010.519322; Dragkovic I, 2008, INT J GERIATR PSYCH, V23, P119, DOI 10.1002/gps.1848; Eriksson S, 2010, INT J GERIATR PSYCH, V25, P885, DOI 10.1002/gps.2592; EYSENCK SBG, 1972, PSYCHOL MED, V2, P50, DOI 10.1017/S0033291700045608; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Geldmacher DS, 2002, SEMIN NEUROL, V22, P63, DOI 10.1055/s-2002-33049; Graff MJL, 2006, BMJ-BRIT MED J, V333, P1196, DOI 10.1136/bmj.39001.688843.BE; Greaves I, 2010, BRIT J GEN PRACT, V60, P193, DOI 10.3399/bjgp10X483553; Hean S, 2011, J PSYCHIATR MENT HLT, V18, P81, DOI 10.1111/j.1365-2850.2010.01665.x; Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670; Jolley SD, 2006, POSTGRAD MED J, V82, P199, DOI 10.1136/pgmj.2005.040592; Kaufer DI, 2000, J NEUROPSYCH CLIN N, V12, P233, DOI 10.1176/appi.neuropsych.12.2.233; LoGiudice D, 1999, INT J GERIATR PSYCH, V14, P626, DOI 10.1002/(SICI)1099-1166(199908)14:8<626::AID-GPS990>3.0.CO;2-5; Logsdon RG, 2002, PSYCHOSOM MED, V64, P510, DOI 10.1097/00006842-200205000-00016; Manthorpe J, 2010, BRIT J GEN PRACT, V60, P373, DOI 10.3399/bjgp10X501903; Meeuwsen EJ, 2009, J NUTR HEALTH AGING, V13, P242, DOI 10.1007/s12603-009-0066-1; Melis RJF, 2009, J ROY SOC MED, V102, P456, DOI 10.1258/jrsm.2009.090259; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Nederlands Huisarts Genootschap, 2021, NHG STAND DEM M21 VE; Nederlandse Vereniging voor Klinische Geriatrie, 2005, DIAGN MED BEH DEM; Nourhashemi F, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2466; PEARLIN LI, 1978, J HEALTH SOC BEHAV, V19, P2, DOI 10.2307/2136319; Perry M, 2010, J AM GERIATR SOC, V58, P557, DOI 10.1111/j.1532-5415.2010.02726.x; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Ramakers IHGB, 2011, AGING MENT HEALTH, V15, P34, DOI 10.1080/13607863.2010.519321; Roland M, 1998, BRIT MED J, V316, P285, DOI 10.1136/bmj.316.7127.285; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; Spector A, 2003, BRIT J PSYCHIAT, V183, P248, DOI 10.1192/bjp.183.3.248; Spielberger C., 1983, STAI MANUAL; Teunisse S, 1991, Tijdschr Gerontol Geriatr, V22, P53; Unnebrink K, 2001, STAT MED, V20, P3931, DOI 10.1002/sim.1149; van Crevel H, 1999, J NEUROL, V246, P73, DOI 10.1007/s004150050311; VernooijDassen MJFJ, 1996, SOC SCI MED, V43, P41, DOI 10.1016/0277-9536(95)00332-0; Ware JH, 2011, NEW ENGL J MED, V364, P1685, DOI 10.1056/NEJMp1103502; Wolfs CAG, 2008, BRIT J PSYCHIAT, V192, P300, DOI 10.1192/bjp.bp.107.035204; Wolfs CAG, 2009, ARCH GEN PSYCHIAT, V66, P313, DOI 10.1001/archgenpsychiatry.2008.544	48	69	69	1	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 15	2012	344								e3086	10.1136/bmj.e3086	http://dx.doi.org/10.1136/bmj.e3086			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	942YF	22589500	Green Submitted, Green Published, hybrid			2023-01-03	WOS:000304086900008
J	Nahirya-Ntege, P; Cook, A; Vhembo, T; Opilo, W; Namuddu, R; Katuramu, R; Tezikyabbiri, J; Naidoo-James, B; Gibb, D				Nahirya-Ntege, Patricia; Cook, Adrian; Vhembo, Tichaona; Opilo, Wilfred; Namuddu, Rachel; Katuramu, Richard; Tezikyabbiri, Jessica; Naidoo-James, Bethany; Gibb, Diana		ARROW Trial Team	Young HIV-Infected Children and Their Adult Caregivers Prefer Tablets to Syrup Antiretroviral Medications in Africa	PLOS ONE			English	Article							FIXED-DOSE COMBINATION; PEDIATRIC-PATIENTS; ADHERENCE; THERAPY; PHARMACOKINETICS; NEVIRAPINE; LAMIVUDINE; SURVIVAL	Background: Provision of anti-retroviral therapy (ART) for HIV-infected children is complicated using syrup formulations, which are costlier than tablets, harder to transport and store and difficult for health-workers to prescribe and caregivers to administer. Dispersible/crushable tablets may be more appropriate. We studied the acceptability of syrups and scored tablets among young children who used both in the AntiRetroviral Research fOr Watoto (ARROW) trial. Methods: ARROW is an ongoing randomized trial of paediatric ART monitoring and treatment strategies in 1206 children in Uganda and Zimbabwe. 405 children initially received syrups of combination ART including Nevirapine, Zidovudine, Abacavir and Lamivudine before changing, when reaching the 12-<15 kg weightband, to scored adult-dose tablets prescribed according to WHO weightband tables. Caregiver expectations and experiences were collected in questionnaires at their last visit on syrups and after 8 and 24 weeks on tablets. Results: Questionnaires were completed by caregivers of 267 children (median age 2.9 years (IQR 2.5, 3.4)). At last visit on syrups, 79% caregivers reported problems with syrups, mostly related to number, weight, transportation and conspicuousness of bottles. Difficulties taking tablets were expected by 127(48%) caregivers; however, after 8 and 24 weeks, only 26% and 18% reported their children had problems with tablets and no problems were reported with transportation/conspicuousness. Taste, swallowing or vomiting were reported as problems 'sometimes/often' for 14%, 9%, 22% children on syrups and 16%, 9%, 8% on tablets. At last visit on syrups, 74% caregivers expected to prefer tablets but only 27% thought their child would. After 8/24 weeks, 94%/97% caregivers preferred tablets and 57%/59% reported their child did. Conclusions: Most children at about 3 years can take tablets; caregivers and children themselves generally prefer tablets to liquid formulations of HIV medications above this age. Preferences of caregivers and children should be considered when designing and licensing paediatric drug formulations.	[Nahirya-Ntege, Patricia; Katuramu, Richard] MRC UVRI Uganda Res Unit AIDS, Entebbe, Uganda; [Cook, Adrian; Naidoo-James, Bethany; Gibb, Diana] MRC Clin Trials Unit, London, England; [Vhembo, Tichaona] Univ Zimbabwe, Sch Med, Harare, Zimbabwe; [Opilo, Wilfred; Tezikyabbiri, Jessica] Joint Clin Res Ctr, Kampala, Uganda; [Namuddu, Rachel] Mulago Hosp, Baylor Uganda Paediat Infect Dis Clin, Kampala, Uganda	Medical Research Council Clinical Trials Unit; University of Zimbabwe; Joint Clinic Research Center - United Arab Emirates; Baylor College of Medicine; Mulago National Referral Hospital	Nahirya-Ntege, P (corresponding author), MRC UVRI Uganda Res Unit AIDS, Entebbe, Uganda.	adc@ctu.mrc.ac.uk	; Bwakura-Dangarembizi, Mutsa/D-5686-2018	Gibb, Diana/0000-0002-9738-5490; Thomason, Margaret/0000-0003-3590-0140; Kasirye, Phillip/0000-0001-6620-483X; Bwakura-Dangarembizi, Mutsa/0000-0001-7751-6177	UK Medical Research Council; UK Department for International Development [G0300400]; MRC [MC_EX_G0300400] Funding Source: UKRI; Medical Research Council [MC_EX_G0300400] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Department for International Development; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The main trial was funded by the UK Medical Research Council, www.mrc.ac.uk and the UK Department for International Development, www.dfid.gov.uk. Grant number G0300400. First-line drugs were provided by GlaxoSmithKline. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bagenda A, 2011, ANN TROP PAEDIATR, V31, P235, DOI 10.1179/1465328111Y.0000000025; Bagenda A, 2010, 18 INT AIDS C 2010 V; Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015; Calmy A, 2004, LANCET, V364, P329, DOI 10.1016/S0140-6736(04)16716-0; Chokephaibulkit K, 2005, AIDS, V19, P1495, DOI 10.1097/01.aids.0000183625.97170.59; Eldridge K, 2000, Int J Paediatr Dent, V10, P19, DOI 10.1046/j.1365-263x.2000.00168.x; Fillekes Q, 2011, JAIDS-J ACQ IMM DEF, V58, P392, DOI 10.1097/QAI.0b013e318235e560; Garvie PA, 2007, PEDIATRICS, V119, pE893, DOI 10.1542/peds.2006-1488; Gilks CF, 2006, LANCET, V368, P505, DOI 10.1016/S0140-6736(06)69158-7; Gross R, 2006, J INFECT DIS, V194, P1108, DOI 10.1086/507680; Kasirye P, 2012, CLIN PHARMACOL THER, V91, P272, DOI 10.1038/clpt.2011.225; King JR, 2004, HIV CLIN TRIALS, V5, P288, DOI 10.1310/GRQX-761M-DPB1-V9CG; Livshits Z, 2011, CLIN TOXICOL, V49, P747, DOI 10.3109/15563650.2011.602081; Mulenga V, 2010, CLIN INFECT DIS, V51, P1081, DOI 10.1086/656628; Musiime V, 2010, ANTIVIR THER, V15, P1115, DOI 10.3851/IMP1695; Nachega JB, 2006, JAIDS-J ACQ IMM DEF, V43, P78, DOI 10.1097/01.qai.0000225015.43266.46; Pujari SN, 2004, JAIDS-J ACQ IMM DEF, V37, P1566, DOI 10.1097/00126334-200412150-00005; Shingadia D, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.6.e80; Sohn AH, 2007, CURR OPIN HIV AIDS, V2, P426, DOI 10.1097/COH.0b013e3282ced12c; Swan J, 2007, PEDIATRICS, V119, P838, DOI 10.1542/peds.2007-0273; Temple ME, 2001, ANN PHARMACOTHER, V35, P414; Thomson SA, 2009, PEDIATRICS, V123, pE235, DOI 10.1542/peds.2008-2059; UNICEF, 2004, IMPR ACC APPR PAED A; UNICEF WHO, 2010, SOURC PRIC SEL MED C; Walker AS, 2009, AIDS BEHAV, V13, P33, DOI 10.1007/s10461-008-9382-4; World Health Organization, 2010, ANT THER HIV INF INF; Yeung VW, 2005, PHARM WORLD SCI, V27, P399, DOI 10.1007/s11096-005-7911-z	27	28	28	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2012	7	5							e36186	10.1371/journal.pone.0036186	http://dx.doi.org/10.1371/journal.pone.0036186			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959US	22567139	gold, Green Submitted, Green Published			2023-01-03	WOS:000305341500058
J	Shih, CC; Liao, CC; Su, YC; Tsai, CC; Lin, JG				Shih, Chun-Chuan; Liao, Chien-Chang; Su, Yi-Chang; Tsai, Chin-Chuan; Lin, Jaung-Geng			Gender Differences in Traditional Chinese Medicine Use among Adults in Taiwan	PLOS ONE			English	Article							HEALTH INTERVIEW SURVEY; POPULATION-BASED SURVEY; ALTERNATIVE MEDICINE; UNITED-STATES; WESTERN MEDICINE; ACUPUNCTURE USE; NATIONAL-SURVEY; OBESE WOMEN; COMPLEMENTARY; PATTERNS	Objectives: The increasing use of complementary, alternative medicine (CAM) and traditional Chinese medicine (TCM) has attracted attention. We report on the gender difference in TCM use among the general population in Taiwan in a population-based, cross-sectional study. Methods: We collected data on socio-demographic factors, lifestyle and health behavior from the 2001 Taiwan National Health Interview Survey. The medical records of interviewees aged 20-69 years were obtained from National Health Insurance claims data with informed consent. The prevalence of TCM use and the average frequency of TCM use were compared between women and men. Results: Among 14,064 eligible participants, the one-year prevalence of TCM use for women and men was 31.8% and 22.4%, respectively. Compared with men, women had a higher average TCM use frequency (1.55 visits vs. 1.04 visits, p<0.001). This significant difference remained evident after excluding gender-specific diseases (1.43 visits vs. 1.03 visits, p<0.001). The average TCM use frequency was significantly higher in women than in men across all age groups. TCM use correlates differed for women and men. Marital status (odds ratio [OR] = 1.55, 95% confidence interval [CI] = 1.30-1.85), family income and unhealthy lifestyle (OR = 1.50, 95% CI = 1.30-1.74) were factors associated with TCM use in men but not in women. Conclusions: In Taiwan, women used more TCM services than men and the gender differences in the TCM use profile persisted across age groups.	[Shih, Chun-Chuan; Tsai, Chin-Chuan] I Shou Univ, Sch Chinese Med Postbaccalaureate, Kaohsiung Cty, Taiwan; [Shih, Chun-Chuan; Su, Yi-Chang; Lin, Jaung-Geng] China Med Univ, Coll Chinese Med, Grad Inst Chinese Med, Taichung, Taiwan; [Shih, Chun-Chuan] Taipei Chinese Med Assoc, Taipei, Taiwan; [Liao, Chien-Chang] Taipei Med Univ Hosp, Dept Anesthesiol, Taipei, Taiwan; [Liao, Chien-Chang] Taipei Med Univ, Sch Med, Taipei, Taiwan; [Liao, Chien-Chang] Taipei Med Univ Hosp, Ctr Hlth Res, Taipei, Taiwan; [Liao, Chien-Chang] China Med Univ Hosp, Management Off Hlth Data, Taichung, Taiwan	I Shou University; China Medical University Taiwan; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University; Taipei Medical University Hospital; China Medical University Taiwan; China Medical University Hospital - Taiwan	Shih, CC (corresponding author), I Shou Univ, Sch Chinese Med Postbaccalaureate, Kaohsiung Cty, Taiwan.	jglin@mail.cmu.edu.tw		Su, Yi-Chang/0000-0002-8765-5389	Committee on Chinese Medicine and Pharmacy, Department of Health, Taiwan [CCMP98-RD-038]; China Medical University Hospital [1MS1]; Taiwan Department of Health Clinical Trial and Research Center for Excellence [DOH100-TD-B-111-004]; Taiwan Department of Health Cancer Research Center of Excellence [DOH100-TD-C-111-005]	Committee on Chinese Medicine and Pharmacy, Department of Health, Taiwan; China Medical University Hospital; Taiwan Department of Health Clinical Trial and Research Center for Excellence; Taiwan Department of Health Cancer Research Center of Excellence	This study was supported in part by a grant from Committee on Chinese Medicine and Pharmacy, Department of Health, Taiwan (grant number CCMP98-RD-038), China Medical University Hospital (grant number 1MS1), Taiwan Department of Health Clinical Trial and Research Center for Excellence (grant number DOH100-TD-B-111-004) and Taiwan Department of Health Cancer Research Center of Excellence (grant number DOH100-TD-C-111-005). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barnes P. M., 2008, COMPLEMENTARY ALTERN; Bishop FL, 2010, EVID-BASED COMPL ALT, V7, P11, DOI 10.1093/ecam/nen023; Buettner C, 2006, BREAST CANCER RES TR, V100, P219, DOI 10.1007/s10549-006-9239-3; Burke A, 2006, J ALTERN COMPLEM MED, V12, P639, DOI 10.1089/acm.2006.12.639; Chang LC, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-170; Chang PJ, 2010, INT J NURS STUD, V47, P13, DOI 10.1016/j.ijnurstu.2009.06.002; Chen FP, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-26; Chen JX, 2006, J ALTERN COMPLEM MED, V12, P763, DOI 10.1089/acm.2006.12.763; Chen YC, 2008, HEPATO-GASTROENTEROL, V55, P467; Chi CH, 1996, SOC SCI MED, V43, P1329, DOI 10.1016/0277-9536(95)00429-7; Chuang CH, 2007, PHARMACOEPIDEM DR S, V16, P464, DOI 10.1002/pds.1332; Chuang CH, 2006, DRUG SAFETY, V29, P537, DOI 10.2165/00002018-200629060-00006; Chuang CH, 2009, INT J NURS STUD, V46, P787, DOI 10.1016/j.ijnurstu.2008.12.015; Chung V, 2007, J ALTERN COMPLEM MED, V13, P361, DOI 10.1089/acm.2006.6152; Chung VCH, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-207; Daly M, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-10; Davis MP, 2003, ARCH PEDIAT ADOL MED, V157, P393, DOI 10.1001/archpedi.157.4.393; Dello Buono M, 2001, J PSYCHOSOM RES, V50, P147, DOI 10.1016/S0022-3999(00)00223-3; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Hanssen B, 2005, SCAND J PRIM HEALTH, V23, P57, DOI 10.1080/02813430510018419; Hsu CH, 2005, J WOMENS HEALTH, V14, P434, DOI 10.1089/jwh.2005.14.434; Hsu CH, 2009, J WOMENS HEALTH, V18, P813, DOI 10.1089/jwh.2008.1005; Huang N, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-18; Kim M, 2002, J COMMUN HEALTH, V27, P109, DOI 10.1023/A:1014509200352; Lai D, 2007, FAM PRACT, V24, P56, DOI 10.1093/fampra/cml058; Liao CC, 2005, TAIWAN J PUBLIC HLTH, V24, P209; Liao CC, 2006, TAIWAN J PUBLIC HLTH, V25, P223; Loh CH, 2009, SINGAP MED J, V50, P1162; MacPherson H, 2006, COMPLEMENT THER MED, V14, P20, DOI 10.1016/j.ctim.2005.07.006; Oliver MI, 2005, BRIT J PSYCHIAT, V186, P297, DOI 10.1192/bjp.186.4.297; Pu CY, 2008, EUR J CANCER CARE, V17, P340, DOI 10.1111/j.1365-2354.2007.00865.x; Shih CC, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-191; Shih CC, 2009, CHINESE MED J-PEKING, V122, P1544, DOI 10.3760/cma.j.issn.0366-6999.2009.13.013; Shih SF, 2008, SOC SCI MED, V67, P1183, DOI 10.1016/j.socscimed.2008.06.011; Shih Y-T, 2003, TAIWAN J PUBLIC HEAL, V22, P419; Shmueli A, 2004, ISRAEL MED ASSOC J, V6, P3; Sikand A, 1998, ARCH PEDIAT ADOL MED, V152, P1059; Thomas KJ, 2001, COMPLEMENT THER MED, V9, P2, DOI 10.1054/ctim.2000.0407; Tindle HA, 2005, ALTERN THER HEALTH M, V11, P42; Upchurch DM, 2008, WOMEN HEALTH ISS, V18, P62, DOI 10.1016/j.whi.2007.08.003; Wu APW, 2007, FAM MED, V39, P195; Yang YH, 2009, CLIMACTERIC, V12, P541, DOI 10.3109/13697130903060081; Yeh LLL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000719; Zhang ZJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017239	44	70	70	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2012	7	4							e32540	10.1371/journal.pone.0032540	http://dx.doi.org/10.1371/journal.pone.0032540			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	959UP	22539941	Green Published, gold, Green Submitted			2023-01-03	WOS:000305341000004
J	Leake, K; Singhal, J; Nagaprashantha, LD; Awasthi, S; Singhal, SS				Leake, Kathryn; Singhal, Jyotsana; Nagaprashantha, Lokesh Dalasanur; Awasthi, Sanjay; Singhal, Sharad S.			RLIP76 Regulates PI3K/Akt Signaling and Chemo-Radiotherapy Resistance in Pancreatic Cancer	PLOS ONE			English	Article							GLUTATHIONE S-TRANSFERASES; MEDIATES DRUG-RESISTANCE; LUNG-CANCER; K-RAS; EPITHELIAL-CELLS; PROSTATE-CANCER; KIDNEY CANCER; EXPRESSION; GENE; ACTIVATION	Purpose: Pancreatic cancer is an aggressive malignancy with characteristic metastatic course of disease and resistance to conventional chemo-radiotherapy. RLIP76 is a multi-functional cell membrane protein that functions as a major mercapturic acid pathway transporter as well as key regulator of receptor-ligand complexes. In this regard, we investigated the significance of targeting RLIP76 on PI3K/Akt pathway and mechanisms regulating response to chemo-radiotherapy. Research Design and Methods: Cell survival was assessed by MTT and colony forming assays. Cellular levels of proteins and phosphorylation was determined by Western blot analyses. The impact on apoptosis was determined by TUNEL assay. The anti-cancer effects of RLIP76 targeted interventions in vivo were determined using mice xenograft model of the pancreatic cancer. The regulation of doxorubicin transport and radiation sensitivity were determined by transport studies and colony forming assays, respectively. Results: Our current studies reveal an encompassing model for the role of RLIP76 in regulating the levels of fundamental proteins like PI3K, Akt, E-cadherin, CDK4, Bcl2 and PCNA which are of specific importance in the signal transduction from critical upstream signaling cascades that determine the proliferation, apoptosis and differentiation of pancreatic cancer cells. RLIP76 depletion also caused marked and sustained regression of established human BxPC-3 pancreatic cancer tumors in nude mouse xenograft model. RLIP76 turned out to be a major regulator of drug transport along with contributing to the radiation resistance in pancreatic cancer. Conclusions/Significance: RLIP76 represents a mechanistically significant target for developing effective interventions in aggressive and refractory pancreatic cancers.	[Leake, Kathryn; Singhal, Jyotsana; Nagaprashantha, Lokesh Dalasanur; Awasthi, Sanjay; Singhal, Sharad S.] City Hope Natl Med Ctr, Beckman Res Inst, Ctr Comprehens Canc, Dept Diabet & Metab Dis Res, Duarte, CA USA	City of Hope; Beckman Research Institute of City of Hope	Leake, K (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Ctr Comprehens Canc, Dept Diabet & Metab Dis Res, Duarte, CA USA.	ssinghal@coh.org	Awasthi, Sanjay/R-4904-2019	Awasthi, Sanjay/0000-0002-5214-5717; Dalasanur Nagaprashantha, Lokesh PG/0000-0001-7041-1970	NIH [CA 77495]; Cancer Research Foundation of North Texas; NATIONAL CANCER INSTITUTE [R01CA077495] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Research Foundation of North Texas; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by NIH Grant CA 77495 and the Cancer Research Foundation of North Texas. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agbunag C, 2004, CANCER RES, V64, P5659, DOI 10.1158/0008-5472.CAN-04-0807; Aguirre D, 2004, APOPTOSIS, V9, P797, DOI 10.1023/B:APPT.0000045781.46314.e2; Awasthi S, 2000, BIOCHEMISTRY-US, V39, P9327, DOI 10.1021/bi992964c; Awasthi S, 2005, CANCER RES, V65, P6022, DOI 10.1158/0008-5472.CAN-05-0968; Awasthi S, 2003, INT J CANCER, V106, P635, DOI 10.1002/ijc.11260; Awasthi S, 2002, DRUG METAB DISPOS, V30, P1300, DOI 10.1124/dmd.30.12.1300; Awasthi S, 2001, BIOCHEMISTRY-US, V40, P4159, DOI 10.1021/bi002182f; Awasthi S, 2008, CLIN CANCER RES, V14, P4372, DOI 10.1158/1078-0432.CCR-08-0145; Awasthi YC, 2004, FREE RADICAL BIO MED, V37, P607, DOI 10.1016/j.freeradbiomed.2004.05.033; AWASTHI YC, 1981, BLOOD, V58, P733; Campbell PM, 2007, CANCER RES, V67, P2098, DOI 10.1158/0008-5472.CAN-06-3752; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Falasca M, 2011, ANTI-CANCER AGENT ME, V11, P455, DOI 10.2174/187152011795677382; FLAKS B, 1984, ENVIRON HEALTH PERSP, V56, P187, DOI 10.2307/3429845; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Hipfner DR, 1999, J BIOL CHEM, V274, P15420, DOI 10.1074/jbc.274.22.15420; Howlader N, 2011, SEER CANC STAT REV 1; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Karayiannakis AJ, 1998, ANTICANCER RES, V18, P4177; Kokubu N, 1997, BIOCHEM BIOPH RES CO, V230, P398, DOI 10.1006/bbrc.1996.5970; Korc M, 1998, Surg Oncol Clin N Am, V7, P25; Lautier D, 1996, BIOCHEM PHARMACOL, V52, P967, DOI 10.1016/0006-2952(96)00450-9; MARCHAND DH, 1985, BIOCHEM BIOPH RES CO, V128, P360, DOI 10.1016/0006-291X(85)91687-0; Matsumoto J, 2002, JPN J CANCER RES, V93, P1317, DOI 10.1111/j.1349-7006.2002.tb01240.x; Miller KA, 2009, CANCER RES, V69, P3689, DOI 10.1158/0008-5472.CAN-09-0024; Nagaprashantha LD, 2011, BIOCHEM PHARMACOL, V82, P1100, DOI 10.1016/j.bcp.2011.07.078; Nagaprashantha LD, 2011, CARCINOGENESIS, V32, P568, DOI 10.1093/carcin/bgr021; PELLEGATA NS, 1994, CANCER RES, V54, P1556; Perugini RA, 2000, J SURG RES, V90, P39, DOI 10.1006/jsre.2000.5833; POUR PM, 1984, ENVIRON HEALTH PERSP, V56, P229, DOI 10.2307/3429849; Sheikh R, 2010, EXPERT REV ANTICANC, V10, P1647, DOI [10.1586/era.10.148, 10.1586/ERA.10.148]; Singhal J, 2011, CANCER PREV RES, V4, P879, DOI 10.1158/1940-6207.CAPR-11-0025; Singhal SS, 2007, CANCER RES, V67, P4382, DOI 10.1158/0008-5472.CAN-06-4124; Singhal SS, 2011, MOL CANCER THER, V10, P16, DOI 10.1158/1535-7163.MCT-10-0699; Singhal SS, 2010, INT J CANCER, V126, P1327, DOI 10.1002/ijc.24767; Singhal SS, 2009, CANCER RES, V69, P4244, DOI 10.1158/0008-5472.CAN-08-3521; Singhal SS, 2009, BIOCHEM PHARMACOL, V77, P1074, DOI 10.1016/j.bcp.2008.11.013; Singhal SS, 2006, CANCER RES, V66, P2354, DOI 10.1158/0008-5472.CAN-05-3534; Singhal SS, 2005, BIOCHEM PHARMACOL, V70, P481, DOI 10.1016/j.bcp.2005.05.005; Singhal SS, 2003, INT J ONCOL, V22, P365; Strobel K, 2008, J NUCL MED, V49, P1408, DOI 10.2967/jnumed.108.051466; Stuckler D, 2005, CANCER RES, V65, P991; Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Winter JM, 2008, CLIN CANCER RES, V14, P412, DOI 10.1158/1078-0432.CCR-07-0487; Yadav S, 2007, CANCER METAST REV, V26, P59, DOI 10.1007/s10555-007-9043-5	50	38	41	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 3	2012	7	4							e34582	10.1371/journal.pone.0034582	http://dx.doi.org/10.1371/journal.pone.0034582			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	952PZ	22509328	Green Submitted, Green Published, gold			2023-01-03	WOS:000304805900051
J	Idris, NM; Gnanasammandhan, MK; Zhang, J; Ho, PC; Mahendran, R; Zhang, Y				Idris, Niagara Muhammad; Gnanasammandhan, Muthu Kumara; Zhang, Jing; Ho, Paul C.; Mahendran, Ratha; Zhang, Yong			In vivo photodynamic therapy using upconversion nanoparticles as remote-controlled nanotransducers	NATURE MEDICINE			English	Article							PHOTOSENSITIZERS; DELIVERY; CELLS; VITRO; DRUG	Conventional photodynamic therapy (PDT) is limited by the penetration depth of visible light needed for its activation. Here we used mesoporous-silica-coated upconversion fluorescent nanoparticles (UCNs) as a nanotransducer to convert deeply penetrating near-infrared light to visible wavelengths and a carrier of photosensitizers. We also used the multicolor-emission capability of the UCNs at a single excitation wavelength for simultaneous activation of two photosensitizers for enhanced PDT. We showed a greater PDT efficacy with the dual-photosensitizer approach compared to approaches using a single photosensitizer, as determined by enhanced generation of singlet oxygen and reduced cell viability. In vivo studies also showed tumor growth inhibition in PDT-treated mice by direct injection of UCNs into melanoma tumors or intravenous injection of UCNs conjugated with a tumor-targeting agent into tumor-bearing mice. As the first demonstration, to the best of our knowledge, of the photosensitizer-loaded UCN as an in vivo-targeted PDT agent, this finding may serve as a platform for future noninvasive deep-cancer therapy.	[Idris, Niagara Muhammad; Gnanasammandhan, Muthu Kumara; Zhang, Yong] Natl Univ Singapore, Fac Engn, Dept Bioengn, Singapore 117548, Singapore; [Zhang, Jing; Ho, Paul C.] Natl Univ Singapore, Fac Sci, Dept Pharm, Singapore 117548, Singapore; [Mahendran, Ratha] Natl Univ Singapore, Fac Med, Dept Surg, Singapore 117548, Singapore; [Zhang, Yong] Natl Univ Singapore, Nanosci & Nanotechnol Initiat, Singapore 117548, Singapore; [Zhang, Yong] Natl Univ Singapore, Grad Sch Integrat Sci & Engn, Singapore 117548, Singapore	National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore	Zhang, Y (corresponding author), Natl Univ Singapore, Fac Engn, Dept Bioengn, Singapore 117548, Singapore.	biezy@nus.edu.sg	Ho, Paul C/O-9652-2014; Jayakumar, Muthu kumara Gnanasammandhan/G-4965-2016; Zhang, Yong/F-2803-2010; Mahendran, Ratha/B-3827-2012	Ho, Paul C/0000-0001-9213-7116; Jayakumar, Muthu kumara Gnanasammandhan/0000-0003-2524-9104; Zhang, Yong/0000-0002-1303-0458; Muhammad Idris, Niagara/0000-0002-9722-1410	Agency for Science, Technology and Research (A<SUP>star</SUP>STAR) Biomedical Research Council [R-397-000-062-305, R-397-000-119-305]; National University of Singapore	Agency for Science, Technology and Research (A<SUP>star</SUP>STAR) Biomedical Research Council; National University of Singapore(National University of Singapore)	We thank Z.Q. Li, A. Priyam and C. X. Li (Department of Bioengineering, Faculty of Engineering, National University of Singapore) for synthesis of the nanoparticles and S. Rajan for technical support in preparing the schematic illustration. We also acknowledge financial support from the Agency for Science, Technology and Research (A<SUP>star</SUP>STAR) Biomedical Research Council (grants R-397-000-062-305 and R-397-000-119-305) and National University of Singapore.	Auzel F, 2004, CHEM REV, V104, P139, DOI 10.1021/cr020357g; Chatteriee DK, 2008, BIOMATERIALS, V29, P937, DOI 10.1016/j.biomaterials.2007.10.051; Chatterjee DK, 2008, NANOMEDICINE-UK, V3, P73, DOI 10.2217/17435889.3.1.73; Cheng LA, 2011, J PHYS CHEM C, V115, P2686, DOI 10.1021/jp111006z; Frangioni JV, 2003, CURR OPIN CHEM BIOL, V7, P626, DOI 10.1016/j.cbpa.2003.08.007; Gao D, 2006, NANO LETT, V6, P2383, DOI 10.1021/nl0617179; Guo H, 2009, OPT MATER, V31, P583, DOI 10.1016/j.optmat.2008.06.011; Guo HC, 2010, NANOMED-NANOTECHNOL, V6, P486, DOI 10.1016/j.nano.2009.11.004; Heer S, 2004, ADV MATER, V16, P2102, DOI 10.1002/adma.200400772; Idris NM, 2009, BIOMATERIALS, V30, P5104, DOI 10.1016/j.biomaterials.2009.05.062; Joensen J, 2011, PHOTOMED LASER SURG, V29, P145, DOI 10.1089/pho.2010.2793; Kim S, 2007, J AM CHEM SOC, V129, P2669, DOI 10.1021/ja0680257; Konan YN, 2002, J PHOTOCH PHOTOBIO B, V66, P89, DOI 10.1016/S1011-1344(01)00267-6; Kuznetsova NA, 2001, RUSS J GEN CHEM+, V71, P36, DOI 10.1023/A:1012369120376; Laser Institute of America, 2000, Z13612000 ANSI LAS I; Li X, 2011, INT J NANOMED, V6, P1167, DOI 10.2147/IJN.S21445; Li ZQ, 2006, ANGEW CHEM INT EDIT, V45, P7732, DOI 10.1002/anie.200602975; Li ZQ, 2008, ADV MATER, V20, P4765, DOI 10.1002/adma.200801056; Mohapatra S, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/38/385102; Nyk M, 2008, NANO LETT, V8, P3834, DOI 10.1021/nl802223f; Prasad P. N., 2003, INTRO BIOPHOTONICS; Qian HS, 2009, SMALL, V5, P2285, DOI 10.1002/smll.200900692; Wang C, 2011, BIOMATERIALS, V32, P1110, DOI 10.1016/j.biomaterials.2010.09.069; Wang M, 2009, J PHYS CHEM C, V113, P19021, DOI 10.1021/jp906394z; Xiong LQ, 2009, BIOMATERIALS, V30, P5592, DOI 10.1016/j.biomaterials.2009.06.015; Xiong LQ, 2009, ANAL CHEM, V81, P8687, DOI 10.1021/ac901960d; Zhang P, 2007, J AM CHEM SOC, V129, P4526, DOI 10.1021/ja0700707	27	1104	1141	32	1317	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2012	18	10					1580	U190		10.1038/nm.2933	http://dx.doi.org/10.1038/nm.2933			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	017JZ	22983397				2023-01-03	WOS:000309587500038
J	McClelland, L				McClelland, Laura			Terminally ill people shouldn't have to travel abroad for assisted dying	BRITISH MEDICAL JOURNAL			English	Editorial Material									Prince Charles Hosp, Merthyr Tydfil, M Glam, Wales		McClelland, L (corresponding author), Prince Charles Hosp, Merthyr Tydfil, M Glam, Wales.	doctormac@doctors.org.uk							0	1	1	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 14	2012	345								e6201	10.1136/bmj.e6201	http://dx.doi.org/10.1136/bmj.e6201			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	007BZ	22983534				2023-01-03	WOS:000308865100006
J	Hoek, W; Schuurmans, J; Koot, HM; Cuijpers, P				Hoek, Willemijn; Schuurmans, Josien; Koot, Hans M.; Cuijpers, Pim			Effects of Internet-Based Guided Self-Help Problem-Solving Therapy for Adolescents with Depression and Anxiety: A Randomized Controlled Trial	PLOS ONE			English	Article							HOSPITAL ANXIETY; DISC-IV; SYMPTOMS; SCALE; VALIDATION; PREVENTION; DISORDERS; VERSIONS; CHILDREN; EFFICACY	Background: Symptoms of depression and anxiety are highly prevalent in adolescence and they are the cause of considerable suffering. Even so, adolescents are not inclined to seek professional help for emotional problems. Internet-based preventive interventions have been suggested as a feasible method of providing appropriate care to adolescents with internalizing symptoms. The objective of this study was to evaluate the effects of preventive Internet-based (guided) self-help problem-solving therapy (PST) for adolescents reporting mild to moderate symptoms of depression and/or anxiety as compared to a waiting list control group (WL). Methodology/Principal Findings: A total of 45 participants were randomized to the 2 conditions. PST consisted of 5 weekly lessons. Participants were supported by e-mail. Self-report measures of depression and anxiety were filled in at baseline and after 3 weeks, 5 weeks, and 4 months. Of the 45 participants, 28 (62.2%) completed questionnaires after 3 weeks, 28 (62.2%) after 5 weeks, and 27 (60%) after 4 months. Hierarchical linear modeling analyses revealed overall improvement over time for both groups on depressive and anxiety symptoms. However, no significant group x time interactions were found. No differences were found between completers and non-completers. Conclusions/Significance: Results show that depressive and anxiety symptoms declined in both groups. No support was found, however, for the assumption that Internet-based PST was efficacious in reducing depression and anxiety in comparison to the waiting list control group. This finding could represent lack of power.	[Hoek, Willemijn; Schuurmans, Josien; Cuijpers, Pim] Vrije Univ Amsterdam, Dept Clin Psychol, Amsterdam, Netherlands; [Hoek, Willemijn; Koot, Hans M.] EMGO Inst, Amsterdam, Netherlands	Vrije Universiteit Amsterdam	Hoek, W (corresponding author), Vrije Univ Amsterdam, Dept Clin Psychol, Amsterdam, Netherlands.	n.w.hoek@vu.nl	Cuijpers, Pim/G-1703-2013	Koot, Hans/0000-0002-9643-2363; Schuurmans, Josien/0000-0003-4029-1810; Cuijpers, Pim/0000-0001-5497-2743	ZonMw - the Netherlands organisation for Health Research and Development [120610006]	ZonMw - the Netherlands organisation for Health Research and Development(Netherlands Organization for Health Research and Development)	This study is funded by ZonMw - the Netherlands organisation for Health Research and Development, grant number 120610006. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abeles P, 2009, BEHAV COGN PSYCHOTH, V37, P151, DOI 10.1017/S1352465808005067; Andersson G, 2005, BRIT J PSYCHIAT, V187, P456, DOI 10.1192/bjp.187.5.456; Beck A.T., 1996, PSYCHOL CORP; Calear AL, 2009, J CONSULT CLIN PSYCH, V77, P1021, DOI 10.1037/a0017391; Christensen H, 2002, MED J AUSTRALIA, V177, pS122; Christensen H, 2004, BRIT MED J, V328, P265, DOI 10.1136/bmj.37945.566632.EE; Cole DA, 1998, J CONSULT CLIN PSYCH, V66, P451, DOI 10.1037/0022-006X.66.3.451; Cuijpers P, 1997, J BEHAV THER EXP PSY, V28, P139, DOI 10.1016/S0005-7916(97)00005-0; Cuijpers P, 2008, EUR CHILD ADOLES PSY, V17, P32, DOI 10.1007/s00787-007-0631-2; Cuijpers P, 2007, EUR PSYCHIAT, V22, P9, DOI 10.1016/j.eurpsy.2006.11.001; Cunningham MJ, 2009, EUR CHILD ADOLES PSY, V18, P125, DOI 10.1007/s00787-008-0703-y; Eysenbach G, 2005, J MED INTERNET RES, V7, DOI 10.2196/jmir.7.1.e11; GARRISON CZ, 1991, J AM ACAD CHILD PSY, V30, P636, DOI 10.1097/00004583-199107000-00017; Hankin BL, 1998, J ABNORM PSYCHOL, V107, P128, DOI 10.1037/0021-843X.107.1.128; Hoek W, 2012, EUR CHILD A IN PRESS; Hoek W, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-93; Malouff JM, 2007, CLIN PSYCHOL REV, V27, P46, DOI 10.1016/j.cpr.2005.12.005; Nguyen T D, 1983, Eval Program Plann, V6, P299, DOI 10.1016/0149-7189(83)90010-1; O'Kearney Richard, 2006, Cognitive Behaviour Therapy, V35, P43, DOI 10.1080/16506070500303456; O'Kearney R, 2009, DEPRESS ANXIETY, V26, P65, DOI 10.1002/da.20507; Olsson I, 2005, BMC PSYCHIATRY, V5, DOI 10.1186/1471-244X-5-46; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Sawyer MG, 2009, J AFFECT DISORDERS, V117, P48, DOI 10.1016/j.jad.2008.12.013; Shaffer D, 2000, J AM ACAD CHILD PSY, V39, P28, DOI 10.1097/00004583-200001000-00014; Spence SH, 2006, J CONSULT CLIN PSYCH, V74, P614, DOI 10.1037/0022-006X.74.3.614; Spinhoven P, 1997, PSYCHOL MED, V27, P363, DOI 10.1017/S0033291796004382; Tillett J, 2005, J PERINAT NEONAT NUR, V19, P112, DOI 10.1097/00005237-200504000-00007; van der Zanden R, 2012, J MED INTERNET RES, V14, P274, DOI 10.2196/jmir.2033; van Lang NDJ, 2006, BEHAV RES THER, V44, P849, DOI 10.1016/j.brat.2005.06.004; Warmerdam L, 2008, J MED INTERNET RES, V10, DOI [10.2196/jmir.1094, 10.2196/jmir.954]; Wasserman GA, 2002, J AM ACAD CHILD PSY, V41, P314, DOI 10.1097/00004583-200203000-00011; WELLS KB, 1988, J PSYCHIAT RES, V22, P207, DOI 10.1016/0022-3956(88)90006-4; White D, 1999, BRIT J PSYCHIAT, V175, P452, DOI 10.1192/bjp.175.5.452; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	34	49	51	0	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2012	7	8							e43485	10.1371/journal.pone.0043485	http://dx.doi.org/10.1371/journal.pone.0043485			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	998EY	22952691	gold, Green Published, Green Submitted			2023-01-03	WOS:000308221300016
J	Mizuno, N; Varkey, J; Kegulian, NC; Hegde, BG; Cheng, NQ; Langen, R; Steven, AC				Mizuno, Naoko; Varkey, Jobin; Kegulian, Natalie C.; Hegde, Balachandra G.; Cheng, Naiqian; Langen, Ralf; Steven, Alasdair C.			Remodeling of Lipid Vesicles into Cylindrical Micelles by alpha-Synuclein in an Extended alpha-Helical Conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE STRUCTURES; NEURONAL DYSFUNCTION; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; BROKEN HELIX; BINDING; PROTEIN; CELLS; CURVATURE; PHOSPHATIDYLCHOLINE	alpha-Synuclein (alpha S) is a protein with multiple conformations and interactions. Natively unfolded in solution, alpha S accumulates as amyloid in neurological tissue in Parkinson disease and interacts with membranes under both physiological and pathological conditions. Here, we used cryoelectron microscopy in conjunction with electron paramagnetic resonance (EPR) and other techniques to characterize the ability of alpha S to remodel vesicles. At molar ratios of 1: 5 to 1: 40 for protein/lipid (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol), large spherical vesicles are converted into cylindrical micelles similar to 50 angstrom in diameter. Other lipids of the same charge (negative) exhibit generally similar behavior, although bilayer tubes of 150-500 angstrom in width are also produced, depending on the lipid acyl chains. At higher protein/lipid ratios, discoid particles, 70-100 angstrom across, are formed. EPR data show that, on cylindrical micelles, alpha S adopts an extended amphipathic alpha-helical conformation, with its long axis aligned with the tube axis. The observed geometrical relationship between alpha S and the micelle suggests that the wedging of its long alpha-helix into the outer leaflet of a membrane may cause curvature and an anisotropic partition of lipids, leading to tube formation.	[Mizuno, Naoko; Cheng, Naiqian; Steven, Alasdair C.] NIAMS, Struct Biol Lab, NIH, Bethesda, MD 20892 USA; [Varkey, Jobin; Kegulian, Natalie C.; Hegde, Balachandra G.; Langen, Ralf] Univ So Calif, Zilkha Neurogenet Inst, Los Angeles, CA 90033 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of Southern California	Mizuno, N (corresponding author), Max Planck Inst Biochem, Klopferspitz 18, D-82152 Martinsried, Germany.	mizuno@biochem.mpg.de; langen@med.usc.edu; stevena@mail.nih.gov	Hegde, Balachandra/GPS-6028-2022; Kegulian, Natalie/AFF-8981-2022; Varkey, Jobin/I-5845-2019; Mizuno, Naoko/AAY-1926-2021	Mizuno, Naoko/0000-0002-1594-2821; Kegulian, Natalie/0000-0002-8574-1099	National Institutes of Health [2 R01 GM063915]; Intramural Research Program of NIAMS; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR027015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063915] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural Research Program of NIAMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant 2 R01 GM063915 (to R. L.) and the Intramural Research Program of NIAMS.	Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; Bartels T, 2011, NATURE, V477, P107, DOI 10.1038/nature10324; Bodner CR, 2009, J MOL BIOL, V390, P775, DOI 10.1016/j.jmb.2009.05.066; Bortolus M, 2008, J AM CHEM SOC, V130, P6690, DOI 10.1021/ja8010429; Burre J, 2010, SCIENCE, V329, P1663, DOI 10.1126/science.1195227; Cabin DE, 2002, J NEUROSCI, V22, P8797; Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200; Chen M, 2007, J BIOL CHEM, V282, P24970, DOI 10.1074/jbc.M700368200; Chiang YW, 2005, J MAGN RESON, V172, P279, DOI 10.1016/j.jmr.2004.10.012; Cooper AA, 2006, SCIENCE, V313, P324, DOI 10.1126/science.1129462; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Der-Sarkissian A, 2003, J BIOL CHEM, V278, P37530, DOI 10.1074/jbc.M305266200; Dickey A, 2008, BIOPHYS J, V95, P2636, DOI 10.1529/biophysj.107.128074; Drescher M, 2008, CHEMBIOCHEM, V9, P2411, DOI 10.1002/cbic.200800238; Drescher M, 2008, J AM CHEM SOC, V130, P7796, DOI 10.1021/ja801594s; Drescher M, 2010, J AM CHEM SOC, V132, P4080, DOI 10.1021/ja909247j; EDWARDS K, 1993, J COLLOID INTERF SCI, V161, P299, DOI 10.1006/jcis.1993.1470; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Ellis RJ, 2003, NATURE, V425, P27, DOI 10.1038/425027a; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Fauvet B, 2012, J BIOL CHEM, V287, P28243, DOI 10.1074/jbc.M112.383711; Fauvet B, 2012, J BIOL CHEM, V287, P15345, DOI 10.1074/jbc.M111.318949; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Ferreon ACM, 2009, P NATL ACAD SCI USA, V106, P5645, DOI 10.1073/pnas.0809232106; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Gaugler MN, 2012, ACTA NEUROPATHOL, V123, P653, DOI 10.1007/s00401-012-0963-y; Gosavi N, 2002, J BIOL CHEM, V277, P48984, DOI 10.1074/jbc.M208194200; Greten-Harrison B, 2010, P NATL ACAD SCI USA, V107, P19573, DOI 10.1073/pnas.1005005107; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Ibanez P, 2004, LANCET, V364, P1169, DOI 10.1016/S0140-6736(04)17104-3; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Jao CC, 2004, P NATL ACAD SCI USA, V101, P8331, DOI 10.1073/pnas.0400553101; Jao CC, 2008, P NATL ACAD SCI USA, V105, P19666, DOI 10.1073/pnas.0807826105; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jeschke G, 2006, APPL MAGN RESON, V30, P473, DOI 10.1007/BF03166213; Kanazawa T, 2012, BRAIN PATHOL, V22, P67, DOI 10.1111/j.1750-3639.2011.00509.x; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kuwahara T, 2008, HUM MOL GENET, V17, P2997, DOI 10.1093/hmg/ddn198; Kuwahara T, 2012, J BIOL CHEM, V287, P7098, DOI 10.1074/jbc.M111.237131; Lewy F. H., 1912, HDB NEUROLOGIE, V3/11, P920; Lokappa SB, 2011, J BIOL CHEM, V286, P21450, DOI 10.1074/jbc.M111.224055; Ludtke SJ, 2010, METHODS MOL BIOL, V673, P157, DOI 10.1007/978-1-60761-842-3_9; Mizuno N, 2010, J BIOL CHEM, V285, P23349, DOI 10.1074/jbc.M110.143776; Nakamura K, 2011, J BIOL CHEM, V286, P20710, DOI 10.1074/jbc.M110.213538; Nemani VM, 2010, NEURON, V65, P66, DOI 10.1016/j.neuron.2009.12.023; Outeiro TF, 2003, SCIENCE, V302, P1772, DOI 10.1126/science.1090439; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rhoades E, 2006, BIOPHYS J, V90, P4692, DOI 10.1529/biophysj.105.079251; Rieker C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024834; Robotta M, 2011, CHEMPHYSCHEM, V12, P267, DOI 10.1002/cphc.201000815; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1977, CHEM PHYS LIPIDS, V18, P7, DOI 10.1016/0009-3084(77)90023-8; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Shaikh TR, 2008, NAT PROTOC, V3, P1941, DOI 10.1038/nprot.2008.156; SHIBAYAMAIMAZU T, 1993, BRAIN RES, V622, P17, DOI 10.1016/0006-8993(93)90796-P; Silva RAGD, 2008, P NATL ACAD SCI USA, V105, P12176, DOI 10.1073/pnas.0803626105; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Song DD, 2004, EXP NEUROL, V186, P158, DOI 10.1016/S0014-4886(03)00342-X; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Thayanidhi N, 2010, MOL BIOL CELL, V21, P1850, DOI 10.1091/mbc.E09-09-0801; Ulmer TS, 2005, J BIOL CHEM, V280, P9595, DOI 10.1074/jbc.M411805200; Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200; Uversky VN, 2002, NEUROTOXICOLOGY, V23, P527, DOI 10.1016/S0161-813X(02)00067-0; Varkey J, 2010, J BIOL CHEM, V285, P32486, DOI 10.1074/jbc.M110.139576; VINSON PK, 1989, BIOPHYS J, V56, P669, DOI 10.1016/S0006-3495(89)82714-6; WALTER A, 1991, BIOPHYS J, V60, P1315, DOI 10.1016/S0006-3495(91)82169-5; Wang WJ, 2011, APPL CATAL B-ENVIRON, V108, P108, DOI 10.1016/j.apcatb.2011.08.015; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Zhou WB, 2000, BRAIN RES, V866, P33, DOI 10.1016/S0006-8993(00)02215-0	71	85	85	0	51	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2012	287	35					29301	29311		10.1074/jbc.M112.365817	http://dx.doi.org/10.1074/jbc.M112.365817			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	999CO	22767608	hybrid, Green Published			2023-01-03	WOS:000308286900010
J	Chen, F; Feng, YM; Zheng, KE; De Keyzer, F; Li, JJ; Feng, YB; Cona, MM; Wang, HJ; Jiang, YS; Yu, J; Marchal, G; Verfaillie, C; De Geest, B; Oyen, R; Ni, YC				Chen, Feng; Feng, Yingmei; Zheng, Kaier; De Keyzer, Frederik; Li, Junjie; Feng, Yuanbo; Cona, Marlein Miranda; Wang, Huaijun; Jiang, Yansheng; Yu, Jie; Marchal, Guy; Verfaillie, Catherine; De Geest, Bart; Oyen, Raymond; Ni, Yicheng			Enhanced Antitumor Efficacy of a Vascular Disrupting Agent Combined with an Antiangiogenic in a Rat Liver Tumor Model Evaluated by Multiparametric MRI	PLOS ONE			English	Article							ENDOTHELIAL PROGENITOR CELLS; COMBRETASTATIN A-4; CLINICAL MRI; SOLID TUMORS; THALIDOMIDE; THERAPY; CANCER; ANGIOGENESIS; MICROANGIOGRAPHY; NORMALIZATION	A key problem in solid tumor therapy is tumor regrowth from a residual viable rim after treatment with a vascular disrupting agent (VDA). As a potential solution, we studied a combined treatment of a VDA and antiangiogenic. This study was approved by the institutional ethical committee for the use and care of laboratory animals. Rats with implanted liver tumors were randomized into four treatment groups: 1) Zd6126 (Zd); 2) Thalidomide (Tha); 3) Zd in combination with Tha (ZdTha); and 4) controls. Multiparametric MRIs were performed and quantified before and after treatment. Circulating endothelial progenitor cells (EPCs) and plasma stromal cell-derived factor-1 alpha (SDF-1 alpha) were monitored. Tumor apoptosis, necrosis, and microvessels were verified by histopathology. A single use of Zd or Tha did not significantly delay tumor growth. The combined ZdTha showed enhanced antitumor efficacy due to synergistic effects; it induced a cumulative tumor apoptosis or necrosis, which resulted in significant delay in tumor growth and reduction in the viable tumor rim; it also reduced tumor vessel permeability; and it improved tumor hemodynamic indexes, most likely via a transient normalization of tumor vasculature induced by Tha. A stepwise linear regression analysis showed that the apparent diffusion coefficient was an independent predictor of tumor growth. We found no significant increases in Zd-induced circulating EPCs or plasma SDF-1 alpha. ZdTha showed improved therapeutic efficacy in solid tumors compared to either agent alone. The therapeutic effects were successfully tracked in vivo with multiparametric MRI.	[Chen, Feng; De Keyzer, Frederik; Li, Junjie; Feng, Yuanbo; Cona, Marlein Miranda; Wang, Huaijun; Jiang, Yansheng; Yu, Jie; Marchal, Guy; Oyen, Raymond; Ni, Yicheng] Katholieke Univ Leuven, Univ Hosp, Theragnost Lab, Dept Imaging & Pathol, Louvain, Belgium; [Chen, Feng] Southeast Univ, Zhong Da Hosp, Dept Radiol, Nanjing, Jiangsu, Peoples R China; [Feng, Yingmei; Verfaillie, Catherine] Katholieke Univ Leuven, Interdept Stem Cell Inst, Louvain, Belgium; [Zheng, Kaier] Nanjing Med Univ, Dept Radiol, BenQ Med Ctr, Nanjing, Jiangsu, Peoples R China; [De Geest, Bart] Katholieke Univ Leuven, Ctr Mol & Vasc Biol, Louvain, Belgium	KU Leuven; Southeast University - China; KU Leuven; Nanjing Medical University; KU Leuven	Chen, F (corresponding author), Katholieke Univ Leuven, Univ Hosp, Theragnost Lab, Dept Imaging & Pathol, Louvain, Belgium.	feng.chen@med.kuleuven.be	De Keyzer, Frederik/U-7175-2019; Wang, Huaijun/F-3219-2015; De Geest, Bart/AHB-0394-2022; Ni, Yicheng/O-5887-2017; Verfaillie, Catherine/H-5148-2013	Wang, Huaijun/0000-0003-0078-5592; Ni, Yicheng/0000-0002-8553-7565; Verfaillie, Catherine/0000-0001-7564-4079; De Geest, Bart/0000-0001-5580-686X	National Natural Science Foundation of China (NSFC) [30670603]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	This work was partly supported by the National Natural Science Foundation of China (NSFC) project 30670603. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ansiaux R, 2005, CLIN CANCER RES, V11, P743; Blakey DC, 2002, INT J RADIAT ONCOL, V54, P1497, DOI 10.1016/S0360-3016(02)03922-6; Chen F, 2006, RADIOLOGY, V239, P554, DOI 10.1148/radiol.2392050277; Chen F, 2007, METHODS, V43, P12, DOI 10.1016/j.ymeth.2007.03.007; Chen F, 2011, METHODS MOL BIOL, V771, P489, DOI 10.1007/978-1-61779-219-9_26; Dachs GU, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-280; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; Dark GG, 1997, CANCER RES, V57, P1829; DENEKAMP J, 1982, BRIT J CANCER, V46, P711, DOI 10.1038/bjc.1982.263; Feng Y, 2008, ARTERIOSCL THROM VAS, V28, P278, DOI 10.1161/ATVBAHA.107.158741; Figg WD, 2007, BJU INT, V99, P1047, DOI 10.1111/j.1464-410X.2007.06763.x; Freter CE, 2008, ABELOFFS CLIN ONCOLO, P449; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Kanthou C, 2009, INT J EXP PATHOL, V90, P284, DOI 10.1111/j.1365-2613.2009.00651.x; Kiessling F, 2007, EUR RADIOL, V17, P2136, DOI 10.1007/s00330-006-0566-x; Kim JJ, 2005, NAT REV CANCER, V5, P516, DOI 10.1038/nrc1650; Kivivuori SM, 2011, ACTA PAEDIATR, V100, P134, DOI 10.1111/j.1651-2227.2010.01961.x; Kobayashi H, 2010, LANCET ONCOL, V11, P589, DOI 10.1016/S1470-2045(10)70009-7; Lang P, 1998, RADIOLOGY, V206, P227, DOI 10.1148/radiology.206.1.9423677; Lebrin F, 2010, NAT MED, V16, P420, DOI 10.1038/nm.2131; Lin YC, 2006, CLIN CANCER RES, V12, P7165, DOI 10.1158/1078-0432.CCR-06-1393; Ostergaard L, 1996, MAGN RESON MED, V36, P715, DOI 10.1002/mrm.1910360510; Padhani AR, 2010, RADIOLOGY, V256, P348, DOI 10.1148/radiol.10091760; Rajkumar SV, 2000, CANCER TREAT REV, V26, P351, DOI 10.1053/ctrv.2000.0188; Reck M, 2010, NAT REV CLIN ONCOL, V7, P134, DOI 10.1038/nrclinonc.2010.11; Schwartz EL, 2009, CLIN CANCER RES, V15, P2594, DOI 10.1158/1078-0432.CCR-08-2710; Shaked Y, 2006, SCIENCE, V313, P1785, DOI 10.1126/science.1127592; Shaked Y, 2009, CANCER RES, V69, P7524, DOI 10.1158/0008-5472.CAN-09-0381; Siemann DW, 2011, CANCER TREAT REV, V37, P63, DOI 10.1016/j.ctrv.2010.05.001; Siemann DW, 2004, INT J RADIAT ONCOL, V60, P1233, DOI 10.1016/j.ijrobp.2004.08.002; Sleijfer S, 2004, EUR J CANCER, V40, P2377, DOI 10.1016/j.ejca.2004.07.023; Thoeny HC, 2005, NEOPLASIA, V7, P779, DOI 10.1593/neo.04748; Tofts PS, 1997, JMRI-J MAGN RESON IM, V7, P91, DOI 10.1002/jmri.1880070113; Tozer GM, 2005, NAT REV CANCER, V5, P423, DOI 10.1038/nrc1628; van Heeckeren WJ, 2007, CURR OPIN HEMATOL, V14, P468, DOI 10.1097/MOH.0b013e3282a6457f; Wang HJ, 2009, INVEST RADIOL, V44, P44, DOI 10.1097/RLI.0b013e31818e5ace; Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/j.ccr.2004.10.011	37	4	6	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2012	7	7							e41140	10.1371/journal.pone.0041140	http://dx.doi.org/10.1371/journal.pone.0041140			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975YY	22815943	Green Submitted, gold, Green Published			2023-01-03	WOS:000306548900079
J	Smith, B				Smith, Barry			Complexities of flavour	NATURE			English	Editorial Material									Univ London, Sch Adv Study, Inst Philosophy, London WC1E 7HU, England	University of London; University of London School of Advanced Study	Smith, B (corresponding author), Univ London, Sch Adv Study, Inst Philosophy, London WC1E 7HU, England.	barry.smith@sas.ac.uk			AHRC [AH/K503393/1] Funding Source: UKRI; Arts and Humanities Research Council [AH/K503393/1] Funding Source: researchfish	AHRC(UK Research & Innovation (UKRI)Arts & Humanities Research Council (AHRC)); Arts and Humanities Research Council(UK Research & Innovation (UKRI)Arts & Humanities Research Council (AHRC))			0	25	26	3	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 21	2012	486	7403					S6	S6		10.1038/486S6a	http://dx.doi.org/10.1038/486S6a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	046RB	22717402	Bronze			2023-01-03	WOS:000311781000004
J	O'Grady, NP; Murray, PR; Ames, N				O'Grady, Naomi P.; Murray, Patrick R.; Ames, Nancy			Preventing Ventilator-Associated Pneumonia Does the Evidence Support the Practice?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE-UNIT; SUBGLOTTIC SECRETIONS; CONTINUOUS ASPIRATION; ENDOTRACHEAL-TUBE; SELECTIVE DECONTAMINATION; BACTERIAL-COLONIZATION; NOSOCOMIAL PNEUMONIA; CONTROLLED-TRIAL; DIGESTIVE-TRACT; POSITION	Ventilator-associated pneumonia (VAP) is among the most common infections in patients requiring endotracheal tubes with mechanical ventilation. Ventilator-associated pneumonia is associated with increased hospital costs, a greater number of days in the intensive care unit, longer duration of mechanical ventilation, and higher mortality. Despite widely accepted recommendations for interventions designed to reduce rates of VAP, few studies have assessed the ability of these interventions to improve patient outcomes. As the understanding of VAP advances and new technologies to reduce VAP become available, studies should directly assess patient outcomes before the health care community implements specific prevention approaches in clinical practice. JAMA. 2012; 307(23):2534-2539 www.jama.com	[O'Grady, Naomi P.] NIH, Crit Care Med Dept, Ctr Clin, Bethesda, MD 20892 USA; [Murray, Patrick R.] NIH, Dept Lab Med, Ctr Clin, Bethesda, MD 20892 USA; [Ames, Nancy] NIH, Dept Nursing & Patient Care Serv, Ctr Clin, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	O'Grady, NP (corresponding author), NIH, Crit Care Med Dept, Ctr Clin, Bldg 10 Room 2C142,10 Ctr Dr,MSC 1662, Bethesda, MD 20892 USA.	nogrady@mail.cc.nih.gov			Intramural NIH HHS [Z99 CL999999] Funding Source: Medline; CLINICAL CENTER [ZIACL001149] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CLINICAL CENTER		Agbaht K, 2007, CRIT CARE MED, V35, P2064, DOI 10.1097/01.CCM.0000277042.31524.66; Aly H, 2008, PEDIATRICS, V122, P770, DOI 10.1542/peds.2007-1826; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Bahrani-Mougeot FK, 2007, J CLIN MICROBIOL, V45, P1588, DOI 10.1128/JCM.01963-06; Bekaert M, 2011, AM J RESP CRIT CARE, V184, P1133, DOI 10.1164/rccm.201105-0867OC; Berra L, 2003, Minerva Anestesiol, V69, P342; Berra L, 2011, MINERVA ANESTESIOL, V77, P323; Berra L, 2012, CRIT CARE MED, V40, P119, DOI 10.1097/CCM.0b013e31822e9fe3; Berriel-Cass D, 2006, JT COMM J QUAL PATIE, V32, P612, DOI 10.1016/S1553-7250(06)32079-X; Bouza E, 2008, CHEST, V134, P938, DOI 10.1378/chest.08-0103; Chan Ee Yuee, 2007, Evid Based Nurs, V10, P19, DOI 10.1136/ebn.10.1.19; Chastre J, 2002, AM J RESP CRIT CARE, V165, P867, DOI 10.1164/ajrccm.165.7.2105078; Chastre J, 1998, AM J RESP CRIT CARE, V157, P1165, DOI 10.1164/ajrccm.157.4.9708057; Chlebicki MN, 2007, CRIT CARE MED, V35, P595, DOI 10.1097/01.CCM.0000253395.70708.AC; Coffin SE, 2008, INFECT CONT HOSP EP, V29, pS31, DOI 10.1086/591062; Cook D, 1998, JAMA-J AM MED ASSOC, V279, P781, DOI 10.1001/jama.279.10.781; Costerton W, 2003, J CLIN INVEST, V112, P1466, DOI 10.1172/JCI200320365; D'Amico R, 1998, BMJ-BRIT MED J, V316, P1275, DOI 10.1136/bmj.316.7140.1275; de Smet AMGA, 2009, NEW ENGL J MED, V360, P20, DOI 10.1056/NEJMoa0800394; Dodek P, 2004, ANN INTERN MED, V141, P305, DOI 10.7326/0003-4819-141-4-200408170-00011; Drakulovic MB, 1999, LANCET, V354, P1851, DOI 10.1016/S0140-6736(98)12251-1; DUMOULIN GC, 1982, LANCET, V1, P242; Edwards JR, 2009, AM J INFECT CONTROL, V37, P783, DOI 10.1016/j.ajic.2009.10.001; Eggimann P, 2003, INTENS CARE MED, V29, P2086, DOI 10.1007/s00134-003-1991-9; Flanagan JL, 2007, J CLIN MICROBIOL, V45, P1954, DOI 10.1128/JCM.02187-06; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Heo SM, 2008, CLIN INFECT DIS, V47, P1562, DOI 10.1086/593193; Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002; INGLIS TJJ, 1989, J CLIN MICROBIOL, V27, P2014, DOI 10.1128/JCM.27.9.2014-2018.1989; Institute for Healthcare Improvement, IMPL IHI VENT BUNDL; Kollef MH, 2008, JAMA-J AM MED ASSOC, V300, P805, DOI 10.1001/jama.300.7.805; Kollef MH, 1999, CHEST, V116, P1339, DOI 10.1378/chest.116.5.1339; KOLLEF MH, 1993, JAMA-J AM MED ASSOC, V270, P1965, DOI 10.1001/jama.270.16.1965; Kolobow T, 2005, ANESTHESIOLOGY, V102, P1063, DOI 10.1097/00000542-200505000-00028; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Labeau SO, 2011, LANCET INFECT DIS, V11, P845, DOI 10.1016/S1473-3099(11)70127-X; Liberati A, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000022.pub3; Luna CM, 2006, EUR RESPIR J, V27, P158, DOI 10.1183/09031936.06.00049105; Mager DL, 2003, J CLIN PERIODONTOL, V30, P644, DOI 10.1034/j.1600-051X.2003.00376.x; Mauri T, 2010, RESP CARE, V55, P294; Nathens AB, 1999, ARCH SURG-CHICAGO, V134, P170, DOI 10.1001/archsurg.134.2.170; Niel-Weise BS, 2011, CRIT CARE, V15, DOI 10.1186/cc10135; Nolan T, 2006, JAMA-J AM MED ASSOC, V295, P1168, DOI 10.1001/jama.295.10.1168; Oostdijk EAN, 2010, AM J RESP CRIT CARE, V181, P452, DOI 10.1164/rccm.200908-1210OC; Panigada M, 2003, CRIT CARE MED, V31, P729, DOI 10.1097/01.CCM.0000049943.01252.E5; Park David R, 2005, Respir Care, V50, P742; Rea-Neto A, 2008, CRIT CARE, V12, DOI 10.1186/cc6877; Resar R, 2005, JT COMM J QUAL PATIE, V31, P243, DOI 10.1016/S1553-7250(05)31031-2; Schuster SC, 2008, NAT METHODS, V5, P16, DOI 10.1038/NMETH1156; Unahalekhaka A, 2007, JT COMM J QUAL PATIE, V33, P387, DOI 10.1016/S1553-7250(07)33044-4; VALLES J, 1995, ANN INTERN MED, V122, P179, DOI 10.7326/0003-4819-122-3-199502010-00004; van Nieuwenhoven CA, 2006, CRIT CARE MED, V34, P396, DOI 10.1097/01.CCM.0000198529.76602.5E; Warren DK, 2003, CRIT CARE MED, V31, P1312, DOI 10.1097/01.CCM.0000063087.93157.06	53	49	57	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 20	2012	307	23					2534	2539		10.1001/jama.2012.6445	http://dx.doi.org/10.1001/jama.2012.6445			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	960MB	22797453	Green Accepted			2023-01-03	WOS:000305391400030
J	Azzopardi, D; Strohm, B; Linsell, L; Hobson, A; Juszczak, E; Kurinczuk, JJ; Brocklehurst, P; Edwards, AD				Azzopardi, Denis; Strohm, Brenda; Linsell, Louise; Hobson, Anna; Juszczak, Edmund; Kurinczuk, Jennifer J.; Brocklehurst, Peter; Edwards, A. David		UK TOBY Cooling Register	Implementation and Conduct of Therapeutic Hypothermia for Perinatal Asphyxial Encephalopathy in the UK - Analysis of National Data	PLOS ONE			English	Article							HYPOXIC-ISCHEMIC ENCEPHALOPATHY; AMPLITUDE-INTEGRATED ELECTROENCEPHALOGRAM; WHOLE-BODY HYPOTHERMIA; NEONATAL ENCEPHALOPATHY; SYSTEMIC HYPOTHERMIA; MODERATE HYPOTHERMIA; CEREBRAL-PALSY; PROGNOSTIC VALUE; NEWBORN-INFANTS; TRIAL	Background: Delay in implementing new treatments into clinical practice results in considerable health and economic opportunity costs. Data from the UK TOBY Cooling Register provides the opportunity to examine how one new effective therapy for newborn infants suspected of suffering asphyxial encephalopathy - therapeutic hypothermia-was implemented in the UK. Methodology/Principal Findings: We analysed returned data forms from inception of the Register in December 2006 to the end of July 2011. Data forms were received for 1384 (67%) of the 2069 infants registered. The monthly rate of notifications increased from median {IQR} 18 {15-31} to 33 {30-39} after the announcement of the results of the recent TOBY trial, and to 50 {36-55} after their publication. This rate further increased to 70 {64-83} following official endorsement of the therapy, and is now close to the expected numbers of eligible infants. Cooling was started at 3.3 {1.5-5.5} hours after birth and the time taken to achieve the target 33-34 degrees C rectal temperature was 1 {0-3} hours. The rectal temperature was in the target range in 83% of measurements. From 2006 to 2011 there was evidence of extension of treatment to slightly less severely affected infants. 278 of 1362 (20%) infants died at 2.9 {1.4-4.1} days of age. The rates of death fell slightly over the period of the Register and, at two years of age cerebral palsy was diagnosed in 22% of infants; half of these were spastic bilateral. Factors independently associated with adverse outcome were clinical seizures prior to cooling (p<0.001) and severely abnormal amplitude integrated EEG (p<0.001). Conclusions/Significance: Therapeutic hypothermia was implemented appropriately within the UK, with significant benefit to patients and the health economy. This may be due in part to participation by neonatal units in clinical trials, the establishment of the national Register, and its endorsement by advisory bodies.	[Azzopardi, Denis; Edwards, A. David] Univ London Imperial Coll Sci Technol & Med, Ctr Developing Brain, London, England; [Strohm, Brenda; Linsell, Louise; Hobson, Anna; Juszczak, Edmund; Kurinczuk, Jennifer J.] Univ Oxford, Natl Perinatal Epidemiol Unit, Oxford, England; [Brocklehurst, Peter] UCL, Inst Womens Hlth, London, England	Imperial College London; University of Oxford; University of London; University College London	Azzopardi, D (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ctr Developing Brain, London, England.	d.azzopardi@imperial.ac.uk	Edwards, Anthony/HCI-9626-2022	Edwards, Anthony David/0000-0003-4801-7066	MRC [G0100126, MC_U120081323, G0200270] Funding Source: UKRI; Medical Research Council [MC_U120081323, G0200270, G0100126] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AZZOPARDI D, 1989, PEDIATR RES, V25, P445, DOI 10.1203/00006450-198905000-00004; Azzopardi D, 2009, ARCH DIS CHILD-FETAL, V94, pF260, DOI 10.1136/adc.2008.146977; Azzopardi D, 2000, PEDIATRICS, V106, P684, DOI 10.1542/peds.106.4.684; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Blackmon LR, 2006, PEDIATRICS, V117, P942, DOI 10.1542/peds.2005-2950; British Association of Perinatal Medicine, 2010, POS STAT THER COD NE; Cooksey D., 2006, REV UK HLTH RES FUND; CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; Djulbegovic B, 2011, JAMA-J AM MED ASSOC, V305, P2005, DOI 10.1001/jama.2011.650; Edwards AD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c363; Eliasson AC, 2006, DEV MED CHILD NEUROL, V48, P549, DOI 10.1017/S0012162206001162; Evans K, 2001, J Obstet Gynaecol, V21, P114, DOI 10.1080/01443610020025967; GLASZIOU PP, 1995, BMJ-BRIT MED J, V311, P1356, DOI 10.1136/bmj.311.7016.1356; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Grosse SD, 2009, MED CARE, V47, pS94, DOI 10.1097/MLR.0b013e31819c9571; Gunn AJ, 2005, J PERINAT MED, V33, P340, DOI 10.1515/JPM.2005.061; Gunn AJ, 1997, J CLIN INVEST, V99, P248, DOI 10.1172/JCI119153; Gunn AJ, 1998, PEDIATRICS, V102, P885, DOI 10.1542/peds.102.4.885; Gunn AJ, 2008, J PEDIATR-US, V152, P55, DOI 10.1016/j.jpeds.2007.06.003; Hallberg B, 2010, ACTA PAEDIATR, V99, P531, DOI 10.1111/j.1651-2227.2009.01653.x; Iwata O, 2007, BRAIN RES, V1154, P173, DOI 10.1016/j.brainres.2007.03.083; Jacobs SE, 2011, ARCH PEDIAT ADOLESC; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; Kruse M, 2009, DEV MED CHILD NEUROL, V51, P622, DOI 10.1111/j.1469-8749.2008.03190.x; Li Tongchuan, 2009, Hosp Pract (1995), V37, P147, DOI 10.3810/hp.2009.12.269; National Institute for Health and Clinical Excellence, 2010, THER HYP INTR TEMP M; Office for national statistics UK, 2011, UK 13 7 2011 BIRTHS; Palisano RJ, 2000, PHYS THER, V80, P974, DOI 10.1093/ptj/80.10.974; Regier DA, 2010, VALUE HEALTH, V13, P695, DOI 10.1111/j.1524-4733.2010.00731.x; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shankaran S, 2011, PEDIATRICS, V128, pE112, DOI 10.1542/peds.2010-2036; Simbruner G, 2010, PEDIATRICS, V126, pE771, DOI 10.1542/peds.2009-2441; Smith J, 2000, BRIT J OBSTET GYNAEC, V107, P461, DOI 10.1111/j.1471-0528.2000.tb13262.x; Strohm B, 2011, PEDIATRICS, V128, pE450, DOI 10.1542/peds.2010-3508; Thompson CM, 1997, ACTA PAEDIATR, V86, P757, DOI 10.1111/j.1651-2227.1997.tb08581.x; THORESEN M, 1995, PEDIATR RES, V37, P667, DOI 10.1203/00006450-199505000-00019; Thoresen M, 2010, PEDIATRICS, V126, pE131, DOI 10.1542/peds.2009-2938; Zhou WH, 2010, J PEDIATR-US, V157, P367, DOI 10.1016/j.jpeds.2010.03.030	38	94	99	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2012	7	6							e38504	10.1371/journal.pone.0038504	http://dx.doi.org/10.1371/journal.pone.0038504			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UV	22719897	Green Published, gold, Green Submitted			2023-01-03	WOS:000305341900033
J	Chen, HY; Yao, K; Nadas, J; Bode, AM; Malakhova, M; Oi, N; Li, HT; Lubet, RA; Dong, ZG				Chen, Hanyong; Yao, Ke; Nadas, Janos; Bode, Ann M.; Malakhova, Margarita; Oi, Naomi; Li, Haitao; Lubet, Ronald A.; Dong, Zigang			Prediction of Molecular Targets of Cancer Preventing Flavonoid Compounds Using Computational Methods	PLOS ONE			English	Article							RIBOSOMAL S6 KINASE; LIGAND DOCKING; PROTEIN; INHIBITOR; MYRICETIN; PHYTOCHEMICALS; PHYTOESTROGENS; TRANSFORMATION; PROLIFERATION; RESVERATROL	Plant-based polyphenols (i.e., phytochemicals) have been used as treatments for human ailments for centuries. The mechanisms of action of these plant-derived compounds are now a major area of investigation. Thousands of phytochemicals have been isolated, and a large number of them have shown protective activities or effects in different disease models. Using conventional approaches to select the best single or group of best chemicals for studying the effectiveness in treating or preventing disease is extremely challenging. We have developed and used computational-based methodologies that provide efficient and inexpensive tools to gain further understanding of the anticancer and therapeutic effects exerted by phytochemicals. Computational methods involving virtual screening, shape and pharmacophore analysis and molecular docking have been used to select chemicals that target a particular protein or enzyme and to determine potential protein targets for well-characterized as well as for novel phytochemicals.	[Chen, Hanyong; Yao, Ke; Nadas, Janos; Bode, Ann M.; Malakhova, Margarita; Oi, Naomi; Li, Haitao; Dong, Zigang] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; [Lubet, Ronald A.] NCI, Bethesda, MD 20892 USA	University of Minnesota System; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Chen, HY (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu			Hormel Foundation; National Institutes of Health [R37 CA081064, CA120388, ES016548, CA0227501]; National Cancer Institute [HHSN-261200533001C-NO1-CN-53301]; NATIONAL CANCER INSTITUTE [R37CA081064, R01CA120388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016548] Funding Source: NIH RePORTER	Hormel Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by the Hormel Foundation and National Institutes of Health grants R37 CA081064, CA120388, ES016548, CA0227501 and National Cancer Institute Contract No. HHSN-261200533001C-NO1-CN-53301. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; [Anonymous], 2011, GLIDE V5 6 SCHRODING; [Anonymous], 2011, PHASE V3 3 SCHRODING; [Anonymous], 2011, SCHRODINGER SUITE; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Birt DF, 2001, PHARMACOL THERAPEUT, V90, P157, DOI 10.1016/S0163-7258(01)00137-1; Bravo L, 1998, NUTR REV, V56, P317, DOI 10.1111/j.1753-4887.1998.tb01670.x; Cavasotto CN, 2004, J MOL BIOL, V337, P209, DOI 10.1016/j.jmb.2004.01.003; Chen X, 2004, CURR CANCER DRUG TAR, V4, P267, DOI 10.2174/1568009043333041; Cho YY, 2007, CANCER RES, V67, P8104, DOI 10.1158/0008-5472.CAN-06-4668; Cho YY, 2009, CANCER RES, V69, P4398, DOI 10.1158/0008-5472.CAN-08-4959; Cho YY, 2004, CANCER RES, V64, P3855, DOI 10.1158/0008-5472.CAN-04-0201; Clark DE, 2005, CANCER RES, V65, P3108; Cui Y, 2008, CANCER-AM CANCER SOC, V112, P2241, DOI 10.1002/cncr.23398; David JP, 2005, J CLIN INVEST, V115, P664, DOI 10.1172/JCI200522877; DOWNS GM, 1994, J CHEM INF COMP SCI, V34, P1094, DOI 10.1021/ci00021a011; Fitch BG, 2006, LECT NOTES COMPUT SC, V3992, P846, DOI 10.1007/11758525_113; Germain RS, 2005, 2005 International Conference on Hardware/Software Codesign and System Synthesis, P207; Harborne JB, 2000, PHYTOCHEMISTRY, V55, P481, DOI 10.1016/S0031-9422(00)00235-1; Hartshorn MJ, 2007, J MED CHEM, V50, P726, DOI 10.1021/jm061277y; Holder S, 2007, MOL CANCER THER, V6, P163, DOI 10.1158/1535-7163.MCT-06-0397; Hollman PCH, 1999, FOOD CHEM TOXICOL, V37, P937, DOI 10.1016/S0278-6915(99)00079-4; Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Jeong CH, 2009, CANCER RES, V69, P5584, DOI 10.1158/0008-5472.CAN-09-0491; Jung SK, 2008, CANCER RES, V68, P6021, DOI 10.1158/0008-5472.CAN-08-0899; Jung SK, 2010, CARCINOGENESIS, V31, P911, DOI 10.1093/carcin/bgp221; Jung SK, 2010, BIOCHEM PHARMACOL, V79, P1455, DOI 10.1016/j.bcp.2010.01.004; Kang NJ, 2011, CARCINOGENESIS, V32, P921, DOI 10.1093/carcin/bgr022; Kang NJ, 2009, CARCINOGENESIS, V30, P321, DOI 10.1093/carcin/bgn282; Kim JE, 2011, CANCER PREV RES, V4, P582, DOI 10.1158/1940-6207.CAPR-11-0032; Kinoshita T, 2006, BIOFACTORS, V26, P179, DOI 10.1002/biof.5520260303; Kwon JY, 2009, CARCINOGENESIS, V30, P1932, DOI 10.1093/carcin/bgp216; Lee DE, 2011, CARCINOGENESIS, V32, P629, DOI 10.1093/carcin/bgr008; Lee DE, 2010, J BIOL CHEM, V285, P21458, DOI 10.1074/jbc.M109.094797; Lee KW, 2008, CANCER RES, V68, P946, DOI 10.1158/0008-5472.CAN-07-3140; Lee KW, 2011, NAT REV CANCER, V11, P211, DOI 10.1038/nrc3017; Lee KM, 2010, BIOCHEM PHARMACOL, V80, P2042, DOI 10.1016/j.bcp.2010.06.042; Liu KD, 2011, J BIOL CHEM, V286, P2057, DOI 10.1074/jbc.M110.147306; Lyne PD, 2002, DRUG DISCOV TODAY, V7, P1047, DOI 10.1016/S1359-6446(02)02483-2; Malakhova M, 2008, NAT STRUCT MOL BIOL, V15, P112, DOI 10.1038/nsmb1347; Malakhova M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008044; Oi N, 2010, CANCER RES, V70, P9755, DOI 10.1158/0008-5472.CAN-10-2858; Ososki AL, 2003, PHYTOTHER RES, V17, P845, DOI 10.1002/ptr.1364; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Pietta PG, 2000, J NAT PROD, V63, P1035, DOI 10.1021/np9904509; Rester U, 2008, CURR OPIN DRUG DISC, V11, P559; Reynaud J, 2005, NAT PROD REP, V22, P504, DOI 10.1039/b416248j; Rolo-Naranjo A, 2010, J CHEM INF MODEL, V50, P924, DOI 10.1021/ci900358z; Smith JA, 2005, CANCER RES, V65, P1027; Suetsugi M, 2003, MOL CANCER RES, V1, P981; Urusova D, 2011, CANC PREV R IN PRESS; Ververidis Filippos, 2007, Biotechnology Journal, V2, P1214, DOI 10.1002/biot.200700084; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(00)00088-5; Willett P, 1998, J CHEM INF COMP SCI, V38, P983, DOI 10.1021/ci9800211	55	32	32	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2012	7	5							e38261	10.1371/journal.pone.0038261	http://dx.doi.org/10.1371/journal.pone.0038261			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TY	22693608	Green Published, Green Submitted, gold			2023-01-03	WOS:000305338500119
J	Sun, HF; Hou, HL; Lu, P; Zhang, LX; Zhao, FY; Ge, C; Wang, TP; Yao, M; Li, JJ				Sun, Hefen; Hou, Helei; Lu, Ping; Zhang, Lixing; Zhao, Fangyu; Ge, Chao; Wang, Tingpu; Yao, Ming; Li, Jinjun			Isocorydine Inhibits Cell Proliferation in Hepatocellular Carcinoma Cell Lines by Inducing G2/M Cell Cycle Arrest and Apoptosis	PLOS ONE			English	Article							CANCER STEM-CELLS; PHASE; DNA; CHECKPOINT; EXPRESSION; MECHANISM; PHOSPHORYLATION; INACTIVATION; ALKALOIDS; PATHWAYS	The treatment of human hepatocellular carcinoma (HCC) cell lines with (+)-isocorydine, which was isolated and purified from Papaveraceae sp. plants, resulted in a growth inhibitory effect caused by the induction of G2/M phase cell cycle arrest and apoptosis. We report that isocorydine induces G2/M phase arrest by increasing cyclin B1 and p-CDK1 expression levels, which was caused by decreasing the expression and inhibiting the activation of Cdc25C. The phosphorylation levels of Chk1 and Chk2 were increased after ICD treatment. Furthermore, G2/M arrest induced by ICD can be disrupted by Chk1 siRNA but not by Chk2 siRNA. In addition, isocorydine treatment led to a decrease in the percentage of CD133(+) PLC/PRF/5 cells. Interestingly, isocorydine treatment dramatically decreased the tumorigenicity of SMMC-7721 and Huh7 cells. These findings indicate that isocorydine might be a potential therapeutic drug for the chemotherapeutic treatment of HCC.	[Sun, Hefen; Hou, Helei; Lu, Ping; Zhang, Lixing; Ge, Chao; Li, Jinjun] Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst,Renji Hosp, Shanghai 200030, Peoples R China; [Zhao, Fangyu; Yao, Ming] Jiao Tong Univ, Sch Med, Expt Pathol Lab, Shanghai Canc Inst,Renji Hosp, Shanghai 200030, Peoples R China; [Wang, Tingpu] Tianshui Normal Univ, Coll Life Sci & Chem, Tianshui, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Tianshui Normal University	Sun, HF (corresponding author), Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst,Renji Hosp, Shanghai 200030, Peoples R China.	jjli@shsci.org			National Key Sci-Tech Special Project of China [2008ZX10002-022]; National Key Program for Basic Research of China (973) [2009CB521803]; Program Of Shanghai Subject Chief Scientist (A) [09XD1403600]	National Key Sci-Tech Special Project of China; National Key Program for Basic Research of China (973)(National Basic Research Program of China); Program Of Shanghai Subject Chief Scientist (A)	This work was supported in part by grants from the National Key Sci-Tech Special Project of China (2008ZX10002-022), the National Key Program for Basic Research of China (973) (2009CB521803), the Program Of Shanghai Subject Chief Scientist (A) (09XD1403600). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Brand S, 2006, J CELL BIOCHEM, V97, P709, DOI 10.1002/jcb.20672; Chappell WH, 2011, ONCOTARGET, V2, P135, DOI 10.18632/oncotarget.240; Cummings M, 2002, BRIT J HAEMATOL, V116, P421, DOI 10.1046/j.1365-2141.2002.03262.x; Dang Y, 2009, CHINESE CHEM LETT, V20, P1218, DOI 10.1016/j.cclet.2009.05.020; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hoet S, 2004, PLANTA MED, V70, P407, DOI 10.1055/s-2004-818967; HOFFMAN RM, 1980, P NATL ACAD SCI-BIOL, V77, P7306, DOI 10.1073/pnas.77.12.7306; HOFFMAN RM, 1983, BIOCHIM BIOPHYS ACTA, V738, P49, DOI 10.1016/0304-419X(84)90019-2; Huang WW, 2011, INT J ONCOL, V38, P1067, DOI 10.3892/ijo.2011.922; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Ruiz EJ, 2010, CURR BIOL, V20, P717, DOI 10.1016/j.cub.2010.02.050; Lee TKW, 2009, LIVER INT, V29, P955, DOI 10.1111/j.1478-3231.2009.02040.x; Li J, 2005, J BIOL CHEM, V280, P12041, DOI 10.1074/jbc.M412445200; Luo Y, 2001, NEOPLASIA, V3, P411, DOI 10.1038/sj.neo.7900175; Ma S, 2008, ONCOGENE, V27, P1749, DOI 10.1038/sj.onc.1210811; Ma S, 2007, GASTROENTEROLOGY, V132, P2542, DOI 10.1053/j.gastro.2007.04.025; Moon DO, 2010, ONCOL REP, V24, P271, DOI 10.3892/or_00000856; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Ruo X, 1981, CHINESE PHARMACOL B, V16, P118; Saito H, 1998, HEPATOLOGY, V27, P1233, DOI 10.1002/hep.510270508; Scovassi AI, 1998, EUR J HISTOCHEM, V42, P251; Simbulan-Rosenthal CM, 1999, MOL CELL BIOCHEM, V193, P137, DOI 10.1023/A:1006988832729; Sotnikova R, 1997, METHOD FIND EXP CLIN, V19, P589; STERN PH, 1986, J NATL CANCER I, V76, P629, DOI 10.1093/jnci/76.4.629; Stewart ZA, 2003, TRENDS PHARMACOL SCI, V24, P139, DOI 10.1016/S0165-6147(03)00026-9; Visanji JM, 2006, CANCER LETT, V237, P130, DOI 10.1016/j.canlet.2005.05.045; Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004; YANG L, 1990, Yaoxue Xuebao, V25, P859; Yang Yue, 2011, Zhonghua Gan Zang Bing Za Zhi, V19, P686, DOI 10.3760/cma.j.issn.1007-3418.2011.09.013; Yin SY, 2007, INT J CANCER, V120, P1444, DOI 10.1002/ijc.22476; Zhang W, 2010, NAT SCI, V2, P457, DOI [DOI 10.4236/NS.2010.25056, 10.4236/ns.2010.25056]; ZHAO YQ, 1991, ACTA PHARM SINIC, V12, P324	36	45	52	2	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2012	7	5							e36808	10.1371/journal.pone.0036808	http://dx.doi.org/10.1371/journal.pone.0036808			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959VG	22623962	Green Published, gold			2023-01-03	WOS:000305343500029
J	Melzer, A; Cochran, S; Prentice, P; MacDonald, MP; Wang, ZG; Cuschieri, A				Melzer, Andreas; Cochran, Sandy; Prentice, Paul; MacDonald, Michael P.; Wang, Zhigang; Cuschieri, Alfred			Physics and Medicine 3 The importance of physics to progress in medical treatment	LANCET			English	Article							INTENSITY FOCUSED ULTRASOUND; SURGERY; CANCER; IMPLEMENTATION; LITHOTRIPSY; EXPERIENCE; THERAPY; BRAIN	Physics in therapy is as diverse as it is substantial. In this review, we highlight the role of physics-occasionally transitioning into engineering-through discussion of several established and emerging treatments. We specifically address minimal access surgery, ultrasound, photonics, and interventional MRI, identifying areas in which complementarity is being exploited. We also discuss some of the fundamental physical principles involved in the application of each treatment to medical practice.	[Melzer, Andreas; Cochran, Sandy; Prentice, Paul; MacDonald, Michael P.; Wang, Zhigang; Cuschieri, Alfred] Univ Dundee, Inst Med Sci & Technol, Dundee DD2 1FD, Scotland	University of Dundee	Cuschieri, A (corresponding author), Univ Dundee, Inst Med Sci & Technol, Dundee DD2 1FD, Scotland.	a.cuschieri@dundee.ac.uk	MacDonald, Michael P/F-5880-2011; Cochran, Sandy/M-4087-2017; Wang, Zhigang/A-5197-2013; Cuschieri, Alfred/O-4092-2019; Cuschieri, Alfred/A-7634-2013; Melzer, Andreas/D-7832-2012	MacDonald, Michael P/0000-0003-4415-5437; Cochran, Sandy/0000-0001-7324-7790; Wang, Zhigang/0000-0001-8309-7888; Cuschieri, Alfred/0000-0003-0764-5947; Prentice, Paul/0000-0003-2228-3622	Biotechnology and Biological Sciences Research Council; Medical Research Council; Engineering and Physical Sciences Research Council; European Research Council; Northern Research Partnership; European Regional Development Fund; European Union	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); European Research Council(European Research Council (ERC)European Commission); Northern Research Partnership; European Regional Development Fund(European Commission); European Union(European Commission)	We thank Janice Aitken (College of Art and Design University of Dundee) for the production of the figures in this report. Institute for Medical Science and Technology (University of Dundee) academic staff have received financial support from the following funding councils: Biotechnology and Biological Sciences Research Council, Medical Research Council, Engineering and Physical Sciences Research Council, European Research Council, Northern Research Partnership, European Regional Development Fund, European Union Seventh Framework Program.	Baker KG, 2001, PHYS THER, V81, P1351, DOI 10.1093/ptj/81.7.1351; Black PM, 1997, NEUROSURGERY, V41, P831, DOI 10.1097/00006123-199710000-00013; BOYLE WS, 1970, BELL SYST TECH J, V49, P587, DOI 10.1002/j.1538-7305.1970.tb01790.x; Burl M, 1996, MAGNET RESON MED, V36, P491, DOI 10.1002/mrm.1910360326; Christensen CM, 1997, INNOVATORS DILEMMA N; Cleary K, 2006, MINIM INVASIV THER, V15, P101, DOI 10.1080/13645700600674179; Curiel L, 2005, ULTRASOUND MED BIOL, V31, P1461, DOI 10.1016/j.ultrasmedbio.2005.06.013; Cuschieri A, 2005, SURG-J R COLL SURG E, V3, P125, DOI 10.1016/S1479-666X(05)80032-0; Dickinson A, 1998, US patent number, Patent No. 5631704; DOBSON SJ, 1989, J PHYS E SCI INSTRUM, V22, P450, DOI 10.1088/0022-3735/22/7/008; Dubinsky TJ, 2008, AM J ROENTGENOL, V190, P191, DOI 10.2214/AJR.07.2671; Ferrara KW, 2009, ACCOUNTS CHEM RES, V42, P881, DOI 10.1021/ar8002442; FISHER B, 1983, CANCER RES, V43, P1488; Furusawa H, 2006, J AM COLL SURGEONS, V203, P54, DOI 10.1016/j.jamcollsurg.2006.04.002; Gianfelice D, 2008, RADIOLOGY, V249, P355, DOI 10.1148/radiol.2491071523; Hand JW, 1998, ULTRASOUND MED; Hanna GB, 1998, ANN SURG, V227, P481, DOI 10.1097/00000658-199804000-00005; Hoffmann BA, 2010, EUR HEART J, V31, P450, DOI 10.1093/eurheartj/ehp460; Hopkins HH, 1964, UK patent number, Patent No. 954629; Hynynen KH, 2008, MRI GUIDED FOCUSED U; Iddan G, 2000, NATURE, V405, P417, DOI 10.1038/35013140; Immel E, 2006, MINIM INVASIV THER, V15, P85, DOI 10.1080/13645700600641004; Jolesz FA, 2002, CANCER J, V8, pS100; Kawamoto H, 2002, P IEEE, V90, P460, DOI 10.1109/JPROC.2002.1002521; Kennedy A, 1996, EUR J COGN PSYCHOL, V8, P831; Konig K, 2001, OPT LETT, V26, P819, DOI 10.1364/OL.26.000819; Konig K, 2003, J BIOMED OPT, V8, P432, DOI 10.1117/1.1577349; KREMKAU FW, 1979, J CLIN ULTRASOUND, V7, P287, DOI 10.1002/jcu.1870070410; LAUTERBUR PC, 1973, NATURE, V242, P190, DOI 10.1038/242190a0; Lewin JS, 2000, J MAGN RESON IMAGING, V12, P512, DOI 10.1002/1522-2586(200010)12:4<512::AID-JMRI2>3.0.CO;2-3; MAIMAN TH, 1960, NATURE, V187, P493, DOI 10.1038/187493a0; Manke C, 2001, RADIOLOGY, V219, P527, DOI 10.1148/radiology.219.2.r01ma03527; Melzer A, 2006, ISMRM P, V270, P61; Mitragotri S, 2005, NAT REV DRUG DISCOV, V4, P255, DOI 10.1038/nrd1662; Nimsky C, 2004, RADIOLOGY, V233, P67, DOI 10.1148/radiol.2331031352; Oar MA, 2005, CHEM MATER, V17, P2267, DOI 10.1021/cm047825i; Parsons JE, 2006, ULTRASOUND MED BIOL, V32, P115, DOI 10.1016/j.ultrasmedbio.2005.09.005; Pott Peter P, 2005, Comput Aided Surg, V10, P101, DOI 10.1080/10929080500228753; Rieke V, 2008, J MAGN RESON IMAGING, V27, P376, DOI 10.1002/jmri.21265; Robertson VJ, 2001, PHYS THER, V81, P1339, DOI 10.1093/ptj/81.7.1339; Sakimoto T, 2006, LANCET, V367, P1432, DOI 10.1016/S0140-6736(06)68275-5; Schaefers G, 2006, MINIM INVASIV THER, V15, P71, DOI 10.1080/13645700600640865; SHIRAKAWA H, 1977, J CHEM SOC CHEM COMM, P578, DOI 10.1039/c39770000578; Sofer M, 2002, J UROLOGY, V167, P31, DOI 10.1016/S0022-5347(05)65376-1; Szabo TL, 2004, DIAGNOSTIC ULTRASOUN; Tang MX, 2010, P I MECH ENG H, V224, P291, DOI 10.1243/09544119JEIM598; THOMAS DGT, 1986, AM J NEURORADIOL, V7, P161; TOMPSETT MF, 1971, IEEE T ELECTRON DEV, VED18, P992, DOI 10.1109/T-ED.1971.17321; TOMPSETT MF, 1970, APPL PHYS LETT, V17, P111, DOI 10.1063/1.1653327; Truwit CL, 2006, NEUROSURGERY, V58, P338, DOI 10.1227/01.NEU.0000205284.04252.87; Vassar GJ, 1999, J ENDOUROL, V13, P181, DOI 10.1089/end.1999.13.181; Vogl TJ, 1997, MINIM INVASIV THER, V6, P53; Vykhodtseva N, 2008, ULTRASONICS, V48, P279, DOI 10.1016/j.ultras.2008.04.004; Wu J, 2008, ADV DRUG DELIVER REV, V60, P1103, DOI 10.1016/j.addr.2008.03.009; Xiong LL, 2009, J PANCREAS, V10, P123; YAMAGISHI M, 1991, IEEE T ELECTRON DEV, V38, P976, DOI 10.1109/16.78368; Zangos S, 2011, RADIOLOGY, V259, P903, DOI 10.1148/radiol.11101559	57	9	9	0	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 21	2012	379	9825					1534	1543		10.1016/S0140-6736(12)60428-0	http://dx.doi.org/10.1016/S0140-6736(12)60428-0			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930BJ	22516559				2023-01-03	WOS:000303110200032
J	Prina, AM; Deeg, D; Brayne, C; Beekman, A; Huisman, M				Prina, A. Matthew; Deeg, Dorly; Brayne, Carol; Beekman, Aartjan; Huisman, Martijn			The Association between Depressive Symptoms and Non-Psychiatric Hospitalisation in Older Adults	PLOS ONE			English	Article							MYOCARDIAL-INFARCTION; PHYSICAL HEALTH; LATER-LIFE; CES-D; RISK; ONSET; DISABILITY; VALIDITY; OUTCOMES; DISEASE	Background: It is known that people who suffer from depression are more likely to have other physical illnesses, but the extent of the association between depression and non-psychiatric hospitalisation episodes has never been researched in great depth. We therefore aimed to investigate whether depressed middle-aged and older people were more likely to be hospitalised for causes other than mental illnesses, and whether the outcomes for this group of people were less favourable. Methods & Findings: Hospital events from 1995 to 2006 were obtained from the Dutch National Medical Register and linked to participants of the Longitudinal Aging Study Amsterdam (LASA). Linkage was accomplished in 97% of the LASA sample by matching gender, year of birth and postal code. Depression was measured at each wave point of the LASA study using the Centre for Epidemiologic Studies Depression (CES-D). Hospital outcomes including admission, length of stay, readmission and death while in hospital were recorded at 6, 12 and 24 months intervals after each LASA interview. Generalised Estimating Equation models were also used to investigate potential confounders. After 12 months, 14% of depressed people were hospitalised compared to 10% of non-depressed individuals. There was a 2-fold increase in deaths while in hospital amongst the depressed (0.8% vs 0.4%), who also had longer total length of stay (2.6 days vs 1.4 days). Chronic illnesses and functional limitations had major attenuating effects, but depression was found to be an independent risk factor for length of stay after full adjustment (OR = 1.33, 95% CI: 1.22-1.46 after 12 months). Conclusions: Depression in middle and old age is associated with non-psychiatric hospitalisation, longer length of stay and higher mortality in clinical settings. Targeting of this high-risk group could reduce the financial, medical and social burden related to hospital admission.	[Prina, A. Matthew; Brayne, Carol] Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge, England; [Deeg, Dorly; Beekman, Aartjan; Huisman, Martijn] Vrije Univ Amsterdam, Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands; [Deeg, Dorly; Beekman, Aartjan; Huisman, Martijn] Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands; [Deeg, Dorly; Beekman, Aartjan; Huisman, Martijn] Vrije Univ Amsterdam, Med Ctr, Dept Psychiat, Amsterdam, Netherlands; [Huisman, Martijn] Vrije Univ Amsterdam, Dept Sociol, Amsterdam, Netherlands	University of Cambridge; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Prina, AM (corresponding author), Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge, England.	amp68@medschl.cam.ac.uk	Brayne, Carol/AAA-4285-2020; Huisman, Martijn/G-2873-2010; Prina, Matthew/B-4188-2013	Brayne, Carol/0000-0001-5307-663X; Prina, Matthew/0000-0001-6698-3263	Ministry of Health, Welfare and Sports; National Institute for Health Research [NF-SI-0611-10084] Funding Source: researchfish	Ministry of Health, Welfare and Sports; National Institute for Health Research(National Institute for Health Research (NIHR))	The LASA study was primarily funded by the Ministry of Health, Welfare and Sports (to The Longitudinal Aging Study Amsterdam). The funders had no role in the study design, data collection, analysis, decision to publish or preparation of the manuscript. No additional external funding was received for this study.	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Beekman A T, 1994, Tijdschr Gerontol Geriatr, V25, P95; Beekman ATF, 1997, PSYCHOL MED, V27, P231, DOI 10.1017/S0033291796003510; Beekman ATF, 1997, PSYCHOL MED, V27, P1397, DOI 10.1017/S0033291797005734; BERKMAN LF, 1986, AM J EPIDEMIOL, V124, P372, DOI 10.1093/oxfordjournals.aje.a114408; Braam AW, 2005, BRIT J PSYCHIAT, V187, P35, DOI 10.1192/bjp.187.1.35; Bromet E, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-90; (CBS) CBoS, 1993, STAT YB; Covinsky KE, 2010, J AM GERIATR SOC, V58, P551, DOI 10.1111/j.1532-5415.2010.02723.x; Deeg D., 2003, AUTONOMY WELL BEING; Department of Health, 2010, HOSP EP STAT HES; desBruin A., 2004, STAT J UN EC COMM EU, V21, P23; Eisner MD, 2005, ANN ALLERG ASTHMA IM, V94, P566, DOI 10.1016/S1081-1206(10)61135-0; FOELKER GA, 1992, J AM GERIATR SOC, V40, P259, DOI 10.1111/j.1532-5415.1992.tb02079.x; Frasure-Smith N, 2000, J PSYCHOSOM RES, V48, P471, DOI 10.1016/S0022-3999(99)00088-4; Garretsen H, PROBLEEMDRINKEN PREV; Hertzog C., 1990, PSYCHOL ASSESSMENT, V2, P64, DOI [10.1037/1040-3590.2.1.64, DOI 10.1037/1040-3590.2.1.64]; HIMMELFARB S, 1983, J GERONTOL, V38, P333, DOI 10.1093/geronj/38.3.333; Hosaka T, 1999, PSYCHIAT CLIN NEUROS, V53, P491, DOI 10.1046/j.1440-1819.1999.00580.x; Huisman M, 2011, INT J EPIDEMIOL; Kato Naoko, 2009, J Card Fail, V15, P912, DOI 10.1016/j.cardfail.2009.06.442; Katon Wayne J, 2011, Dialogues Clin Neurosci, V13, P7; Knol MJ, 2006, DIABETOLOGIA, V49, P837, DOI 10.1007/s00125-006-0159-x; Kriegsman DMW, 1996, J CLIN EPIDEMIOL, V49, P1407, DOI 10.1016/S0895-4356(96)00274-0; Kronish IM, 2006, J GEN INTERN MED, V21, P1178, DOI 10.1111/j.1525-1497.2006.00586.x; LIANG KY, 1993, ANNU REV PUBL HEALTH, V14, P43, DOI 10.1146/annurev.pu.14.050193.000355; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Ormel J, 1999, PSYCHOL MED, V29, P847, DOI 10.1017/S0033291799008600; Paas G, 2002, RES VALIDITY LMR; Penninx BWJH, 2000, J AFFECT DISORDERS, V61, P1, DOI 10.1016/S0165-0327(00)00152-X; RADLOFF L S, 1986, Clinical Gerontologist, V5, P119; Seedat S, 2009, ARCH GEN PSYCHIAT, V66, P785, DOI 10.1001/archgenpsychiatry.2009.36; Smits CHM, 1997, J AGING HEALTH, V9, P204, DOI 10.1177/089826439700900204; Turner A, 2010, AUST NZ J PSYCHIAT, V44, P658, DOI 10.3109/00048671003646751; Twisk JWR, 1997, INT J SPORTS MED, V18, pS216, DOI 10.1055/s-2007-972718; van Sonsbeek JLA., 1988, MAANDBERICHT GEZONDH, V88, P4; Wolkowitz Owen M, 2011, Dialogues Clin Neurosci, V13, P25; Wulsin LR, 2003, PSYCHOSOM MED, V65, P201, DOI 10.1097/01.PSY.0000058371.50240.E3; Ziegelstein RC, 2000, ARCH INTERN MED, V160, P1818, DOI 10.1001/archinte.160.12.1818	39	37	39	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2012	7	4							e34821	10.1371/journal.pone.0034821	http://dx.doi.org/10.1371/journal.pone.0034821			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	953GO	22496867	Green Published, gold			2023-01-03	WOS:000304855200083
J	Chaccour, CJ; Kaur, H; Mabey, D; Del Pozo, JL				Chaccour, Carlos J.; Kaur, Harparkash; Mabey, David; Del Pozo, Jose L.			Travel and fake artesunate: a risky business	LANCET			English	Editorial Material									[Chaccour, Carlos J.] Univ Navarra Clin, Div Internal Med, Pamplona, Spain; [Chaccour, Carlos J.; Del Pozo, Jose L.] Univ Navarra Clin, Dept Med, Div Infect Dis, Pamplona, Spain; [Del Pozo, Jose L.] Univ Navarra Clin, Div Clin Microbiol & Parasitol, Pamplona, Spain; [Kaur, Harparkash; Mabey, David] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London WC1, England	University of Navarra; University of Navarra; University of Navarra; University of London; London School of Hygiene & Tropical Medicine	Chaccour, CJ (corresponding author), Univ Navarra Clin, Div Internal Med & Infect Dis, Avda Pio XII 36, Pamplona, Spain.	cchaccour@unav.es	Chaccour, Carlos/I-4149-2018; Del Pozo, Jose L/Q-4442-2016	Chaccour, Carlos/0000-0001-9812-050X; Del Pozo, Jose L/0000-0002-5402-3334; Mabey, David/0000-0002-0031-8276				[Anonymous], GUID TREATM MAL; Newton PN, 2006, PLOS MED, V3, P752, DOI 10.1371/journal.pmed.0030197; Newton PN, 2006, LANCET INFECT DIS, V6, P602, DOI 10.1016/S1473-3099(06)70581-3; Newton PN, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001139; Newton PN, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-352	5	10	10	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 22	2012	380	9847					1120	1120		10.1016/S0140-6736(12)60649-7	http://dx.doi.org/10.1016/S0140-6736(12)60649-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	007VL	22998721				2023-01-03	WOS:000308916400033
J	Boyd, M; Mohapi, L				Boyd, Mark; Mohapi, Lerato			STRETCHing delivery of HIV health services	LANCET			English	Editorial Material							ANTIRETROVIRAL THERAPY; CARE		[Boyd, Mark] Univ New S Wales, Kirby Inst, Sydney, NSW 2052, Australia; [Boyd, Mark] St Vincents Hosp, Sydney, NSW 2010, Australia; [Mohapi, Lerato] Univ Witwatersrand, Chris Hani Baragwanath Hosp, Perinatal HIV Res Unit, Johannesburg, South Africa	University of New South Wales Sydney; Kirby Institute; St Vincents Hospital Sydney; University of Witwatersrand	Boyd, M (corresponding author), Univ New S Wales, Kirby Inst, Sydney, NSW 2052, Australia.	mboyd@kirby.unsw.edu.au		Boyd, Mark/0000-0002-6848-3307				Cain LE, 2011, ANN INTERN MED, V154, P509, DOI 10.7326/0003-4819-154-8-201104190-00001; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Emery S, 2008, J INFECT DIS, V197, P1133, DOI 10.1086/586713; Fairall L, 2012, LANCET; Fairall LR, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-21; Fox MP, 2010, AIDS, V24, P2041, DOI 10.1097/QAD.0b013e32833c703e; Funk MJ, 2011, ARCH INTERN MED, V171, P1560, DOI 10.1001/archinternmed.2011.401; Jaffar S, 2009, LANCET, V374, P2080, DOI 10.1016/S0140-6736(09)61674-3; Kitahata MM, 2009, NEW ENGL J MED, V360, P1815, DOI 10.1056/NEJMoa0807252; Sanne I, 2010, LANCET, V376, P33, DOI 10.1016/S0140-6736(10)60894-X; Severe P, 2010, NEW ENGL J MED, V363, P257, DOI 10.1056/NEJMoa0910370; Sterne JAC, 2009, LANCET, V373, P1352, DOI 10.1016/S0140-6736(09)60612-7; The Global Fund to Fight AIDS, WHO WE AR; The United States President's Emergency Plan for AIDS Relief, PEPFAR; UNITAID, CHAIRS STAT CAN WE C; WHO, 2010, ANT THER HIV INF AD	16	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 8	2012	380	9845					865	867		10.1016/S0140-6736(12)60952-0	http://dx.doi.org/10.1016/S0140-6736(12)60952-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	002QL	22901954				2023-01-03	WOS:000308547300007
J	Creixell, P; Schoof, EM; Erler, JT; Linding, R				Creixell, Pau; Schoof, Erwin M.; Erler, Janine T.; Linding, Rune			Navigating cancer network attractors for tumor-specific therapy	NATURE BIOTECHNOLOGY			English	Review							EDGETIC PERTURBATION; SOMATIC MUTATION; MOUSE MODELS; PROTEIN; PHOSPHORYLATION; EVOLUTION; PREDICTION; ONCOGENE; PATHWAY; GROWTH	Cells employ highly dynamic signaling networks to drive biological decision processes. Perturbations to these signaling networks may attract cells to new malignant signaling and phenotypic states, termed cancer network attractors, that result in cancer development. As different cancer cells reach these malignant states by accumulating different molecular alterations, uncovering these mechanisms represents a grand challenge in cancer biology. Addressing this challenge will require new systems-based strategies that capture the intrinsic properties of cancer signaling networks and provide deeper understanding of the processes by which genetic lesions perturb these networks and lead to disease phenotypes. Network biology will help circumvent fundamental obstacles in cancer treatment, such as drug resistance and metastasis, empowering personalized and tumor-specific cancer therapies.	[Erler, Janine T.] Univ Copenhagen, BRIC, Copenhagen, Denmark; [Creixell, Pau; Schoof, Erwin M.; Linding, Rune] Tech Univ Denmark, Dept Syst Biol, Ctr Biol Sequence Anal CBS, C SIG, DK-2800 Lyngby, Denmark	University of Copenhagen; Technical University of Denmark	Erler, JT (corresponding author), Univ Copenhagen, BRIC, Copenhagen, Denmark.	janine.erler@bric.ku.dk; linding@cbs.dtu.dk		Erler, Janine/0000-0001-8675-6527; Schoof, Erwin Marten/0000-0002-3117-7832; Linding, Rune/0000-0003-0420-4839	Danish Council for Independent Research; Career Development Award from Human Frontier Science Program; Novo Nordisk Foundation	Danish Council for Independent Research(Det Frie Forskningsrad (DFF)); Career Development Award from Human Frontier Science Program; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited)	We apologize to our colleagues whose work could not be cited due to space limitations. We thank all members of the C-SIG (DTU), the ErlerLab (BRIC), M. Yaffe (MIT) and N. Brunner (KU) for critical input on this manuscript. R. L. is a Lundbeck Foundation Fellow and is supported by a Sapere Aude Starting Grant from The Danish Council for Independent Research and a Career Development Award from Human Frontier Science Program. J.T.E. is supported by a Hallas Moller Stipend from the Novo Nordisk Foundation. Visit http://www.networkbio.org/, http://www.lindinglab.org/ and http://www.erlerlab.org/ for more information on cancer-related network biology.	Abreu-Martin MT, 1999, AM J PHYSIOL-GASTR L, V276, pG599, DOI 10.1152/ajpgi.1999.276.3.G599; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bendall SC, 2012, NAT BIOTECHNOL, V30, P639, DOI 10.1038/nbt.2283; Bensimon A, 2012, ANNU REV BIOCHEM, V81, P379, DOI 10.1146/annurev-biochem-072909-100424; Blumenthal RD, 2007, MOL BIOTECHNOL, V35, P185, DOI 10.1007/BF02686104; Brehme M, 2009, P NATL ACAD SCI USA, V106, P7414, DOI 10.1073/pnas.0900653106; Brinkworth RI, 2003, P NATL ACAD SCI USA, V100, P74, DOI 10.1073/pnas.0134224100; Capra EJ, 2012, CELL, V150, P222, DOI 10.1016/j.cell.2012.05.033; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Cox TR, 2011, DIS MODEL MECH, V4, P165, DOI 10.1242/dmm.004077; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738; Dixit A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007485; Dreze M, 2009, NAT METHODS, V6, P843, DOI [10.1038/NMETH.1394, 10.1038/nmeth.1394]; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Erler JT, 2012, CELL, V149, P731, DOI 10.1016/j.cell.2012.04.014; Fowler DM, 2010, NAT METHODS, V7, P741, DOI 10.1038/nmeth.1492; Geiger T, 2010, NAT METHODS, V7, P383, DOI 10.1038/nmeth.1446; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Halabi N, 2009, CELL, V138, P774, DOI 10.1016/j.cell.2009.07.038; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hoffman RM, 2010, EXPERT OPIN DRUG DIS, V5, P851, DOI 10.1517/17460441.2010.510129; Hou Y, 2012, CELL, V148, P873, DOI 10.1016/j.cell.2012.02.028; Huang PH, 2007, P NATL ACAD SCI USA, V104, P12867, DOI 10.1073/pnas.0705158104; Huang S, 2000, EXP CELL RES, V261, P91, DOI 10.1006/excr.2000.5044; Hunter KW, 2012, NAT REV CANCER, V12, P144, DOI 10.1038/nrc3206; Janes KA, 2005, SCIENCE, V310, P1646, DOI 10.1126/science.1116598; Jensen LJ, 2002, J MOL BIOL, V319, P1257, DOI 10.1016/S0022-2836(02)00379-0; Jensen PB, 2012, NAT REV GENET, V13, P395, DOI 10.1038/nrg3208; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Jorgensen C, 2009, SCIENCE, V326, P1502, DOI 10.1126/science.1176615; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; KAUFFMAN S, 1987, J THEOR BIOL, V128, P11, DOI 10.1016/S0022-5193(87)80029-2; KAUFFMAN SA, 1989, J THEOR BIOL, V141, P211, DOI 10.1016/S0022-5193(89)80019-0; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Ledford H, 2010, NATURE, V464, P972, DOI 10.1038/464972a; Lee MJ, 2012, CELL, V149, P780, DOI 10.1016/j.cell.2012.03.031; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Lim WA, 2010, CELL, V142, P661, DOI 10.1016/j.cell.2010.08.023; Linding R, 2007, CELL, V129, P1415, DOI 10.1016/j.cell.2007.05.052; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Gonzalez-Angulo AM, 2010, J CLIN ONCOL, V28, P2777, DOI 10.1200/JCO.2009.27.0777; Meyer P, 2011, NAT BIOTECHNOL, V29, P811, DOI 10.1038/nbt.1968; Miller ML, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1159433; Mok J, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000482; NASH J, 1951, ANN MATH, V54, P286, DOI 10.2307/1969529; NASH JF, 1950, P NATL ACAD SCI USA, V36, P48, DOI 10.1073/pnas.36.1.48; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Ng PC, 2006, ANNU REV GENOM HUM G, V7, P61, DOI 10.1146/annurev.genom.7.080505.115630; Nik-Zainal S, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.023; Pawson T, 2008, FEBS LETT, V582, P1266, DOI 10.1016/j.febslet.2008.02.011; Pazos F, 2006, CURR BIOINFORM, V1, P15, DOI 10.2174/157489306775330633; Pe'er D, 2011, CELL, V144, P864, DOI 10.1016/j.cell.2011.03.001; Pedersen MW, 2010, CANCER RES, V70, P588, DOI 10.1158/0008-5472.CAN-09-1417; Prill RJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009202; Puntervoll P, 2003, NUCLEIC ACIDS RES, V31, P3625, DOI 10.1093/nar/gkg545; Reynolds KA, 2011, CELL, V147, P1564, DOI 10.1016/j.cell.2011.10.049; Roque FS, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002141; Russ WP, 2005, NATURE, V437, P579, DOI 10.1038/nature03990; Schoeberl B, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000352; Seet BT, 2006, NAT REV MOL CELL BIO, V7, P473, DOI 10.1038/nrm1960; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Skerker JM, 2008, CELL, V133, P1043, DOI 10.1016/j.cell.2008.04.040; Socolich M, 2005, NATURE, V437, P512, DOI 10.1038/nature03991; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Turk BE, 2008, CURR OPIN CHEM BIOL, V12, P4, DOI 10.1016/j.cbpa.2008.01.018; Uribesalgo I, 2012, CELL CYCLE, V11, P1757, DOI 10.4161/cc.19883; Vidal M, 2011, CELL, V144, P986, DOI 10.1016/j.cell.2011.02.016; Waddington C.H., 1957, ROUTLEDGE LIB EDITIK; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wang XJ, 2012, NAT BIOTECHNOL, V30, P159, DOI 10.1038/nbt.2106; WHO, 2012, WHO FACT SHEET 297; Wong KM, 2011, ANNU REV GENOM HUM G, V12, P407, DOI 10.1146/annurev-genom-082509-141532; Wu M, 2010, NATURE, V463, P545, DOI 10.1038/nature08702; Yang L, 2007, LEUKEMIA, V21, P868, DOI 10.1038/sj.leu.2404624; Zarrinpar A, 2003, NATURE, V426, P676, DOI 10.1038/nature02178; Zhong Q, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.80	81	104	104	1	37	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2012	30	9					842	848		10.1038/nbt.2345	http://dx.doi.org/10.1038/nbt.2345			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	004UD	22965061	Bronze			2023-01-03	WOS:000308705700018
J	Rodger, S; Stephens, E; Clark, M; Ash, S; Hurst, C; Graves, N				Rodger, Sylvia; Stephens, Elizabeth; Clark, Michele; Ash, Susan; Hurst, Cameron; Graves, Nicholas			Productivity and Time Use during Occupational Therapy and Nutrition/Dietetics Clinical Education: A Cohort Study	PLOS ONE			English	Article							LEVEL-II FIELDWORK; DIETETIC INTERNSHIPS; BENEFITS; STUDENTS; COST	Background: Currently in the Australian higher education sector higher productivity from allied health clinical education placements is a contested issue. This paper will report results of a study that investigated output changes associated with occupational therapy and nutrition/dietetics clinical education placements in Queensland, Australia. Supervisors' and students' time use during placements and how this changes for supervisors compared to when students are not present in the workplace is also presented. Methodology/Principal Findings: A cohort design was used with students from four Queensland universities, and their supervisors employed by Queensland Health. There was an increasing trend in the number of occasions of service delivered when the students were present, and a statistically significant increase in the daily mean length of occasions of service delivered during the placement compared to pre-placement levels. Conclusions/Significance: A novel method for estimating productivity and time use changes during clinical education programs for allied health disciplines has been applied. During clinical education placements there was a net increase in outputs, suggesting supervisors engage in longer consultations with patients for the purpose of training students, while maintaining patient numbers. Other activities were reduced. This paper is the first time these data have been shown in Australia and form a sound basis for future assessments of the economic impact of student placements for allied health disciplines.	[Rodger, Sylvia] Univ Queensland, Div Occupat Therapy, Sch Hlth & Rehabil Sci, Brisbane, Qld, Australia; [Stephens, Elizabeth; Clark, Michele; Ash, Susan; Hurst, Cameron; Graves, Nicholas] Queensland Univ Technol, Sch Publ Hlth, Brisbane, Qld 4001, Australia	University of Queensland; Queensland University of Technology (QUT)	Rodger, S (corresponding author), Univ Queensland, Div Occupat Therapy, Sch Hlth & Rehabil Sci, Brisbane, Qld, Australia.	elizabeth.stephens@qut.edu.au	Hurst, Cameron P/P-5175-2017; Ash, Susan/I-9664-2012; Hurst, Cameron/AAD-5753-2019; Martin, Elizabeth/O-3573-2019	Hurst, Cameron P/0000-0002-4577-8962; Ash, Susan/0000-0003-2078-7560; Hurst, Cameron/0000-0002-4577-8962; Martin, Elizabeth/0000-0003-0252-8303; Graves, Nicholas/0000-0002-5559-3267	Queensland Health ClinED Queensland research grant	Queensland Health ClinED Queensland research grant	This manuscript was made possible with funding from Queensland Health ClinED Queensland research grant 2009-2010 (http://www.health.qld.gov.au/clinedq/default.asp). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Brown S, 1990, J AM DENT ASSOC S, V90, pA; BURKHARDT BF, 1985, AM J OCCUP THER, V39, P35, DOI 10.5014/ajot.39.1.35; Campbell AR, 2011, AM J PHARM EDUC, V75, DOI 10.5688/ajpe7518; Chisholm MA, 1997, HOSP PHARM, V32, P370; Chung Y I, 1980, Inquiry, V17, P216; CHUNG YI, 1983, AM J OCCUP THER, V37, P681, DOI 10.5014/ajot.37.10.681; CONKLIN MT, 1994, J AM DIET ASSOC, V94, P174, DOI 10.1016/0002-8223(94)90243-7; Conklin MT, 1995, TOP CLIN NUTR, V10, P71; Demory-Luce D, 1990, J AM DENT ASSOC S, V90, pA; Dietitians Association of Australia, 2009, NAT COMP STAND ENTR; Dillon Loretta Schoen, 2003, J Allied Health, V32, P261; Gilbride JA, 1996, J AM DIET ASSOC, V96, P758, DOI 10.1016/S0002-8223(96)00211-8; Jull, 2011, FOCUS HLTH PROFESSIO, P53; Kincaid C, 2005, 30 ANN SAS US GROUP; Ladyshewsky RK, 1998, PHYS THER, V78, P1288, DOI 10.1093/ptj/78.12.1288; Ladyshewsky RW, 1994, PHYSIOTHER CAN, V46, P89; Leiken A M, 1983, Inquiry, V20, P88; LEIKEN AM, 1983, PHYS THER, V63, P56, DOI 10.1093/ptj/63.1.56; MacKinnon J R, 1986, J Allied Health, V15, P225; McAllister L, 2005, ADV SPEECH LANGUAGE, V7, P138, DOI DOI 10.1080/14417040500181239; McCulloch C.E., 2008, GEN LINEAR MIXED MOD; Mersfelder TL, 2012, ANN PHARMACOTHER, V46, P541, DOI 10.1345/aph.1Q544; MUELLER BA, 1990, DICP ANN PHARMAC, V24, P422, DOI 10.1177/106002809002400416; Murray E, 2000, MED EDUC, V34, P871, DOI 10.1046/j.1365-2923.2000.00757.x; National Allied Health Casemix Committee, 1997, AUSTR ALL HLTH CLASS; PAGE GG, 1987, PHYS THER, V67, P238, DOI 10.1093/ptj/67.2.238; Rodger Sylvia, 2008, J Allied Health, V37, P53; Rose M, 2005, ADV SPEECH LANGUAGE, V7, P158, DOI [10.1080/14417040500181353, DOI 10.1080/14417040500181353]; SHALIK H, 1988, AM J OCCUP THER, V42, P164, DOI 10.5014/ajot.42.3.164; SHALIK LD, 1987, AM J OCCUP THER, V41, P638, DOI 10.5014/ajot.41.10.638; Verbeke G, 2009, SPRINGER SER STAT, P1; World Federation of Occupational Therapists, 2002, MIN STAND ED OCC THE	32	12	12	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2012	7	8							e44356	10.1371/journal.pone.0044356	http://dx.doi.org/10.1371/journal.pone.0044356			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	998EY	22952964	gold, Green Submitted, Green Published			2023-01-03	WOS:000308221300086
J	Fulop, L; Mandity, IM; Juhasz, G; Szegedi, V; Hetenyi, A; Weber, E; Bozso, Z; Simon, D; Benko, R; Kiraly, Z; Martinek, TA				Fueloep, Livia; Mandity, Istvan M.; Juhasz, Gabor; Szegedi, Viktor; Hetenyi, Anasztazia; Weber, Edit; Bozso, Zsolt; Simon, Dora; Benko, Maria; Kiraly, Zoltan; Martinek, Tamas A.			A Foldamer-Dendrimer Conjugate Neutralizes Synaptotoxic beta-Amyloid Oligomers	PLOS ONE			English	Article							A-BETA; PEPTIDE INHIBITORS; SECONDARY STRUCTURES; SYNAPTIC PLASTICITY; BETA(3)-PEPTIDE INHIBITORS; STOICHIOMETRIC INHIBITION; PROTEIN AGGREGATION; MOUSE MODEL; HIV FUSION; AMINO-ACID	Background and Aims: Unnatural self-organizing biomimetic polymers (foldamers) emerged as promising materials for biomolecule recognition and inhibition. Our goal was to construct multivalent foldamer-dendrimer conjugates which wrap the synaptotoxic beta-amyloid (A beta) oligomers with high affinity through their helical foldamer tentacles. Oligomeric A beta species play pivotal role in Alzheimer's disease, therefore recognition and direct inhibition of this undruggable target is a great current challenge. Methods and Results: Short helical beta-peptide foldamers with designed secondary structures and side chain chemistry patterns were applied as potential recognition segments and their binding to the target was tested with NMR methods (saturation transfer difference and transferred-nuclear Overhauser effect). Helices exhibiting binding in the mu M region were coupled to a tetravalent G0-PAMAM dendrimer. In vitro biophysical (isothermal titration calorimetry, dynamic light scattering, transmission electron microscopy and size-exclusion chromatography) and biochemical tests (ELISA and dot blot) indicated the tight binding between the foldamer conjugates and the A beta oligomers. Moreover, a selective low nM interaction with the low molecular weight fraction of the A beta oligomers was found. Ex vivo electrophysiological experiments revealed that the new material rescues the long-term potentiation from the toxic A beta oligomers in mouse hippocampal slices at submicromolar concentration. Conclusions: The combination of the foldamer methodology, the fragment-based approach and the multivalent design offers a pathway to unnatural protein mimetics that are capable of specific molecular recognition, and has already resulted in an inhibitor for an extremely difficult target.	[Fueloep, Livia; Juhasz, Gabor; Hetenyi, Anasztazia; Bozso, Zsolt; Simon, Dora] Univ Szeged, Dept Med Chem, Szeged, Hungary; [Mandity, Istvan M.; Weber, Edit; Martinek, Tamas A.] Univ Szeged, Inst Pharmaceut Chem, Szeged, Hungary; [Szegedi, Viktor] Bay Zoltan Fdn Appl Res BAYGEN, Szeged, Hungary; [Benko, Maria; Kiraly, Zoltan] Univ Szeged, Dept Phys Chem & Mat Sci, Szeged, Hungary	Szeged University; Szeged University; Szeged University	Fulop, L (corresponding author), Univ Szeged, Dept Med Chem, Szeged, Hungary.	martinek@pharm.u-szeged.hu	Fülöp, Livia/GRX-8140-2022; Fülöp, Livia/E-2543-2011; Mandity, Istvan/N-8041-2017	Mandity, Istvan/0000-0003-2865-6143; Hetenyi, Anasztazia/0000-0001-8080-6992; Szegedi, Viktor/0000-0003-4191-379X; Weber, Edit/0000-0002-5904-0619; Fulop, Livia/0000-0002-8010-0129; Juhasz, Gabor/0000-0001-6912-5109	EU FP7 [HEALTH-F2-2007-201159, HEALTH-F2-2007-211696]; COST [CM0803]; Hungarian Research Foundation [NK81371, PD83581, PD83600, K68152]; Hungarian Academy of Sciences, Lendulet programme	EU FP7(European Commission); COST(European Cooperation in Science and Technology (COST)); Hungarian Research Foundation(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); Hungarian Academy of Sciences, Lendulet programme	This work was supported by the EU FP7 (HEALTH-F2-2007-201159, HEALTH-F2-2007-211696 and COST CM0803) (http://cordis.europa.eu/fp7/home_en.html); the Hungarian Research Foundation (NK81371, PD83581, PD83600 and K68152) (http://www.otka.hu/); and the Hungarian Academy of Sciences, Lendulet programme (http://mta.hu/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bales KR, 2006, J CLIN INVEST, V116, P825, DOI 10.1172/JCI27120; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bautista AD, 2010, J AM CHEM SOC, V132, P2904, DOI 10.1021/ja910715u; Bautista AD, 2009, BIOORG MED CHEM LETT, V19, P3736, DOI 10.1016/j.bmcl.2009.05.032; Bett CK, 2010, ACS CHEM NEUROSCI, V1, P608, DOI 10.1021/cn100045q; Blaskovich MA, 2000, NAT BIOTECHNOL, V18, P1065, DOI 10.1038/80257; Bozso Z, 2010, PEPTIDES, V31, P248, DOI 10.1016/j.peptides.2009.12.001; Chafekar SM, 2007, CHEMBIOCHEM, V8, P1857, DOI 10.1002/cbic.200700338; Chen ZJ, 2005, J MOL BIOL, V354, P760, DOI 10.1016/j.jmb.2005.09.055; Choi SH, 2008, J AM CHEM SOC, V130, P6544, DOI 10.1021/ja800355p; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Delsuc N, 2007, ANGEW CHEM INT EDIT, V46, P214, DOI 10.1002/anie.200603390; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; Etienne MA, 2006, J AM CHEM SOC, V128, P3522, DOI 10.1021/ja0600678; Etienne MA, 2005, BIOPOLYMERS, V80, P566; Findeis MA, 1999, BIOCHEMISTRY-US, V38, P6791, DOI 10.1021/bi982824n; Fournel S, 2005, NAT CHEM BIOL, V1, P377, DOI 10.1038/nchembio746; Fukumoto H, 2010, FASEB J, V24, P2716, DOI 10.1096/fj.09-150359; Gademann K, 1999, ANGEW CHEM INT EDIT, V38, P1223, DOI 10.1002/(SICI)1521-3773(19990503)38:9<1223::AID-ANIE1223>3.0.CO;2-A; Gellman SH, 1998, ACCOUNTS CHEM RES, V31, P173, DOI 10.1021/ar960298r; Glabe CG, 2008, J BIOL CHEM, V283, P29639, DOI 10.1074/jbc.R800016200; Goodman CM, 2007, NAT CHEM BIOL, V3, P252, DOI 10.1038/nchembio876; Griffin JH, 2003, J AM CHEM SOC, V125, P6517, DOI 10.1021/ja021273s; Hillen H, 2010, J NEUROSCI, V30, P10369, DOI 10.1523/JNEUROSCI.5721-09.2010; Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142; Horne WS, 2008, ACCOUNTS CHEM RES, V41, P1399, DOI 10.1021/ar800009n; Horne WS, 2008, ANGEW CHEM INT EDIT, V47, P2853, DOI 10.1002/anie.200705315; Horne WS, 2009, P NATL ACAD SCI USA, V106, P14751, DOI 10.1073/pnas.0902663106; Hoyer W, 2008, P NATL ACAD SCI USA, V105, P5099, DOI 10.1073/pnas.0711731105; Imamura Y, 2009, J AM CHEM SOC, V131, P7353, DOI 10.1021/ja9001458; Johnson LM, 2011, J AM CHEM SOC, V133, P10038, DOI 10.1021/ja203358t; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kayed R, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-18; Klyubin I, 2005, NAT MED, V11, P556, DOI 10.1038/nm1234; Kokkoni N, 2006, BIOCHEMISTRY-US, V45, P9906, DOI 10.1021/bi060837s; Kostiainen MA, 2005, ANGEW CHEM INT EDIT, V44, P2556, DOI 10.1002/anie.200500066; Kritzer JA, 2005, J AM CHEM SOC, V127, P14584, DOI 10.1021/ja055050o; Kritzer JA, 2005, J AM CHEM SOC, V127, P4118, DOI 10.1021/ja042933r; Kritzer JA, 2004, J AM CHEM SOC, V126, P9468, DOI 10.1021/ja031625a; Lee EF, 2009, ANGEW CHEM INT EDIT, V48, P4318, DOI 10.1002/anie.200805761; Lelais G, 2006, HELV CHIM ACTA, V89, P361, DOI 10.1002/hlca.339; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; LILIOM K, 1991, J IMMUNOL METHODS, V143, P119, DOI 10.1016/0022-1759(91)90280-S; Liu RT, 2004, BIOCHEMISTRY-US, V43, P6959, DOI 10.1021/bi049933o; Luheshi LM, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000334; Ma T, 2011, J NEUROSCI, V31, P5589, DOI 10.1523/JNEUROSCI.6566-10.2011; Mandity IM, 2009, ANGEW CHEM INT EDIT, V48, P2171, DOI 10.1002/anie.200805095; Martinek TA, 2003, EUR J BIOCHEM, V270, P3657, DOI 10.1046/j.1432-1033.2003.03756.x; McLaurin J, 2002, NAT MED, V8, P1263, DOI 10.1038/nm790; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Michel J, 2009, J AM CHEM SOC, V131, P6356, DOI 10.1021/ja901478e; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Nishikawa K, 2006, FASEB J, V20, P2597, DOI 10.1096/fj.06-6572fje; Pera NP, 2010, CHEMBIOCHEM, V11, P1896, DOI 10.1002/cbic.201000340; Petersson EJ, 2008, J AM CHEM SOC, V130, P821, DOI 10.1021/ja077245x; Pukin AV, 2007, CHEMBIOCHEM, V8, P1500, DOI 10.1002/cbic.200700266; Reinke AA, 2011, CHEM BIOL DRUG DES, V77, P399, DOI 10.1111/j.1747-0285.2011.01110.x; Reinke AA, 2010, J AM CHEM SOC, V132, P17655, DOI 10.1021/ja106291e; Ross NT, 2010, PHILOS T R SOC A, V368, P989, DOI 10.1098/rsta.2009.0210; Sadowsky JD, 2007, J AM CHEM SOC, V129, P139, DOI 10.1021/ja0662523; Sadowsky JD, 2005, J AM CHEM SOC, V127, P11966, DOI 10.1021/ja053678t; Saraogi I, 2009, CHEM SOC REV, V38, P1726, DOI 10.1039/b819597h; Sattin S, 2010, ACS CHEM BIOL, V5, P301, DOI 10.1021/cb900216e; Seebach D, 2008, ACCOUNTS CHEM RES, V41, P1366, DOI 10.1021/ar700263g; Shandler SJ, 2011, J AM CHEM SOC, V133, P12378, DOI 10.1021/ja204215f; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Shukla R, 2005, CHEM COMMUN, P5739, DOI 10.1039/b507350b; Sisu C, 2009, CHEMBIOCHEM, V10, P329, DOI 10.1002/cbic.200800550; Smith TJ, 2006, J AM CHEM SOC, V128, P14456, DOI 10.1021/ja065557e; Soto C, 1996, BIOCHEM BIOPH RES CO, V226, P672, DOI 10.1006/bbrc.1996.1413; Stephens OM, 2005, J AM CHEM SOC, V127, P13126, DOI 10.1021/ja053444+; Takahashi T, 2007, CHEMBIOCHEM, V8, P985, DOI 10.1002/cbic.200700108; Takahashi T, 2010, PROTEINS, V78, P336, DOI 10.1002/prot.22546; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wilson AJ, 2009, CHEM SOC REV, V38, P3289, DOI 10.1039/b807197g; Zameer A, 2008, J MOL BIOL, V384, P917, DOI 10.1016/j.jmb.2008.09.068; Zeng Y, 2010, J ALZHEIMERS DIS, V21, P823, DOI 10.3233/JAD-2010-100264	80	33	34	0	47	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 30	2012	7	7							e39485	10.1371/journal.pone.0039485	http://dx.doi.org/10.1371/journal.pone.0039485			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981EY	22859942	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000306950900007
J	Cheong, H; Lu, C; Lindsten, T; Thompson, CB				Cheong, Heesun; Lu, Chao; Lindsten, Tullia; Thompson, Craig B.			Therapeutic targets in cancer cell metabolism and autophagy	NATURE BIOTECHNOLOGY			English	Review							HISTONE DEACETYLASE INHIBITOR; MALIGNANT GLIOMA-CELLS; PYRUVATE-KINASE M2; ISOLATED RAT HEPATOCYTES; BREAST-CANCER; GLUTAMINE-METABOLISM; TUMOR PROGRESSION; MAMMARY TUMORIGENESIS; INDUCED APOPTOSIS; ARSENIC TRIOXIDE	The metabolism of cancer cells is reprogrammed both by oncogene signaling and by dysregulation of metabolic enzymes. The resulting altered metabolism supports cellular proliferation and survival but leaves cancer cells dependent on a continuous supply of nutrients. Thus, many metabolic enzymes have become targets for new cancer therapies. Recently, two processes-expression of specific isoforms of metabolic enzymes and autophagy-have been shown to be crucial for the adaptation of tumor cells to changes in nutrient availability. An increasing number of approved and experimental therapeutics target these two processes. A better understanding of the molecular basis of cancer-associated metabolic changes may lead to improved cancer therapies.	[Cheong, Heesun; Lu, Chao; Thompson, Craig B.] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Canc Biol & Genet Program, New York, NY 10021 USA; [Lu, Chao] Univ Penn, Perelman Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA; [Lindsten, Tullia] Mem Sloan Kettering Canc Ctr, Program Immunol, Sloan Kettering Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; University of Pennsylvania; Pennsylvania Medicine; Memorial Sloan Kettering Cancer Center	Thompson, CB (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Canc Biol & Genet Program, 1275 York Ave, New York, NY 10021 USA.	craig@mskcc.org	Lu, Chao/E-8047-2012	Lu, Chao/0000-0003-0982-8122; Cheong, Heesun/0000-0003-1946-107X	US National Institutes of Health; National Cancer Institute; NATIONAL CANCER INSTITUTE [P01CA104838] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank members of the Thompson laboratory for helpful discussions. C.B.T. is supported by grants from the US National Institutes of Health and National Cancer Institute.	AHLUWALIA GS, 1990, PHARMACOL THERAPEUT, V46, P243, DOI 10.1016/0163-7258(90)90094-I; Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Boxer MB, 2010, J MED CHEM, V53, P1048, DOI 10.1021/jm901577g; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Bueno V, 2007, TRANSPLANTATION, V84, P1204, DOI 10.1097/01.tp.0000287543.91765.41; Cairns RA, 2007, P NATL ACAD SCI USA, V104, P9445, DOI 10.1073/pnas.0611662104; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Carayol N, 2010, P NATL ACAD SCI USA, V107, P12469, DOI 10.1073/pnas.1005114107; Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260; Cassago A, 2012, P NATL ACAD SCI USA, V109, P1092, DOI 10.1073/pnas.1112495109; Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622; Cheong H, 2011, P NATL ACAD SCI USA, V108, P11121, DOI 10.1073/pnas.1107969108; Cheung CWY, 2010, ANTI-CANCER AGENT ME, V10, P186; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Crazzolara R, 2009, BLOOD, V113, P3297, DOI 10.1182/blood-2008-02-137752; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099; Dimmer KS, 2000, BIOCHEM J, V350, P219, DOI 10.1042/0264-6021:3500219; Ding WX, 2009, MOL CANCER THER, V8, P2036, DOI 10.1158/1535-7163.MCT-08-1169; Ellis L, 2009, BLOOD, V114, P380, DOI 10.1182/blood-2008-10-182758; Eng CH, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000911; Ertmer A, 2007, LEUKEMIA, V21, P936, DOI 10.1038/sj.leu.2404606; Fan QW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001017; Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023; Fujii S, 2008, CANCER SCI, V99, P1813, DOI 10.1111/j.1349-7006.2008.00893.x; Gallagher SM, 2007, CANCER RES, V67, P4182, DOI 10.1158/0008-5472.CAN-06-3184; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gorzalczany Y, 2011, CANCER LETT, V310, P207, DOI 10.1016/j.canlet.2011.07.002; Granchi C, 2011, J MED CHEM, V54, P1599, DOI 10.1021/jm101007q; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Heiden MGV, 2010, SCIENCE, V329, P1492, DOI 10.1126/science.1188015; Hsu KF, 2009, AUTOPHAGY, V5, P451, DOI 10.4161/auto.5.4.7666; Hu WW, 2010, P NATL ACAD SCI USA, V107, P7455, DOI 10.1073/pnas.1001006107; Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71; Jiang JK, 2010, BIOORG MED CHEM LETT, V20, P3387, DOI 10.1016/j.bmcl.2010.04.015; Kanematsu S, 2010, ANTICANCER RES, V30, P3381; Kanzawa T, 2003, CANCER RES, V63, P2103; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Kim MJ, 2011, J BIOL CHEM, V286, P12924, DOI 10.1074/jbc.M110.138958; Kita K, 2012, J BIOL CHEM, V287, P18163, DOI 10.1074/jbc.M112.362699; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Lau A, 2010, MOL CELL BIOL, V30, P3275, DOI 10.1128/MCB.00248-10; Le A, 2012, CELL METAB, V15, P110, DOI 10.1016/j.cmet.2011.12.009; Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107; Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500; Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Maclean KH, 2008, J CLIN INVEST, V118, P79, DOI 10.1172/JCI33700; Martin AP, 2009, MOL PHARMACOL, V76, P327, DOI 10.1124/mol.109.056309; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Mathupala SP, 2009, SEMIN CANCER BIOL, V19, P17, DOI 10.1016/j.semcancer.2008.11.006; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Miao YF, 2010, HEPATO-GASTROENTEROL, V57, P257; Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677; Milano V, 2009, MOL CANCER THER, V8, P394, DOI 10.1158/1535-7163.MCT-08-0669; Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642; Opipari AW, 2004, CANCER RES, V64, P696, DOI 10.1158/0008-5472.CAN-03-2404; Peng G, 2006, MOL CARCINOGEN, V45, P309, DOI 10.1002/mc.20166; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665; Porporato PE, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00049; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Qian WB, 2007, LEUKEMIA RES, V31, P329, DOI 10.1016/j.leukres.2006.06.021; Qing GL, 2010, CANCER RES, V70, P10351, DOI 10.1158/0008-5472.CAN-10-0740; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Rahim R, 2009, ANTI-CANCER DRUG, V20, P736, DOI 10.1097/CAD.0b013e32832f4e50; Robinson MM, 2007, BIOCHEM J, V406, P407, DOI 10.1042/BJ20070039; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102; Sheen JH, 2011, CANCER CELL, V19, P613, DOI 10.1016/j.ccr.2011.03.012; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; Sun QA, 2011, P NATL ACAD SCI USA, V108, P4129, DOI 10.1073/pnas.1014769108; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640; Telang S, 2006, ONCOGENE, V25, P7225, DOI 10.1038/sj.onc.1209709; Tibbetts AS, 2010, ANNU REV NUTR, V30, P57, DOI 10.1146/annurev.nutr.012809.104810; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Vander Heiden MG, 2010, BIOCHEM PHARMACOL, V79, P1118, DOI 10.1016/j.bcp.2009.12.003; Vegran F, 2011, CANCER RES, V71, P2550, DOI 10.1158/0008-5472.CAN-10-2828; Wang JB, 2010, CANCER CELL, V18, P207, DOI 10.1016/j.ccr.2010.08.009; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011; Wei Y, 2010, CLIN CANCER RES, V16, P3923, DOI 10.1158/1078-0432.CCR-10-0032; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Wise DR, 2011, P NATL ACAD SCI USA, V108, P19611, DOI 10.1073/pnas.1117773108; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33; Yang CD, 2009, CANCER RES, V69, P7986, DOI 10.1158/0008-5472.CAN-09-2266; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Yazbeck VY, 2008, EXP HEMATOL, V36, P443, DOI 10.1016/j.exphem.2007.12.008; Ye JB, 2012, P NATL ACAD SCI USA, V109, P6904, DOI 10.1073/pnas.1204176109; Yu Y, 2001, BIOCHEM PHARMACOL, V62, P81, DOI 10.1016/S0006-2952(01)00636-0; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099; Yuneva MO, 2012, CELL METAB, V15, P157, DOI 10.1016/j.cmet.2011.12.015; Zhan TZ, 2011, J CELL BIOCHEM, V112, P849, DOI 10.1002/jcb.22984; Zhu K, 2010, ONCOGENE, V29, P451, DOI 10.1038/onc.2009.343	109	258	267	3	131	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2012	30	7					671	678		10.1038/nbt.2285	http://dx.doi.org/10.1038/nbt.2285			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	972QV	22781696	Green Accepted			2023-01-03	WOS:000306293400026
J	Fong, TG; Jones, RN; Marcantonio, ER; Tommet, D; Gross, AL; Habtemariam, D; Schmitt, E; Yap, L; Inouye, SK				Fong, Tamara G.; Jones, Richard N.; Marcantonio, Edward R.; Tommet, Douglas; Gross, Alden L.; Habtemariam, Daniel; Schmitt, Eva; Yap, Liang; Inouye, Sharon K.			Adverse Outcomes After Hospitalization and Delirium in Persons With Alzheimer Disease	ANNALS OF INTERNAL MEDICINE			English	Article							COGNITIVE IMPAIRMENT; ELDERLY-PATIENTS; DEMENTIA; CARE; DECLINE; ASSOCIATION; FREQUENCY; CONFUSION; COSTS; RISK	Background: Hospitalization, frequently complicated by delirium, can be a life-changing event for patients with Alzheimer disease (AD). Objective: To determine risks for institutionalization, cognitive decline, or death associated with hospitalization and delirium in patients with AD. Design: Prospective cohort enrolled between 1991 and 2006 into the Massachusetts Alzheimer's Disease Research Center (MADRC) patient registry. Setting: Community-based. Participants: 771 persons aged 65 years or older with a clinical diagnosis of AD. Measurements: Hospitalization, delirium, death, and institutionalization were identified through administrative databases. Cognitive decline was defined as a decrease of 4 or more points on the Blessed Information-Memory-Concentration test score. Multivariate analysis was used to calculate adjusted relative risks (RRs). Results: Of 771 participants with AD, 367 (48%) were hospitalized and 194 (25%) developed delirium. Hospitalized patients who did not have delirium had an increased risk for death (adjusted RR, 4.7 95% CI, 1.9 to 11.6]) and institutionalization (adjusted RR, 6.9 [ CI, 4.0 to 11.7]). With delirium, risk for death (adjusted RR, 5.4 [CI, 2.3 to 12.5]) and institutionalization (adjusted RR, 9.3 [CI, 5.5 to 15.7]) increased further. With hospitalization and delirium, the adjusted RR for cognitive decline for patients with AD was 1.6 (CI, 1.2 to 2.3). Among hospitalized patients with AD, 21% of the incidences of cognitive decline, 15% of institutionalization, and 6% of deaths were associated with delirium. Limitations: Cognitive outcome was missing in 291 patients. Sensitivity analysis was performed to test the effect of missing data, and a composite outcome was used to decrease the effect of missing data. Conclusion: Approximately 1 in 8 hospitalized patients with AD who develop delirium will have at least 1 adverse outcome, including death, institutionalization, or cognitive decline, associated with delirium. Delirium prevention may represent an important strategy for reducing adverse outcomes in this population.	[Fong, Tamara G.] Hebrew SeniorLife, Aging Brain Ctr, Inst Aging Res, Boston, MA 02131 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA	Harvard University; Hebrew SeniorLife; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital	Fong, TG (corresponding author), Hebrew SeniorLife, Aging Brain Ctr, Inst Aging Res, 1200 Ctr St, Boston, MA 02131 USA.	tfong@bidmc.harvard.edu	Marcantonio, Edward R/U-3929-2017; Jones, Richard Norman/J-3488-2013; Inouye, Sharon/R-7216-2019	Marcantonio, Edward R/0000-0002-2911-4250; Jones, Richard Norman/0000-0002-1049-218X; 	National Institute on Aging; MADRC; Alzheimer's Association [IIRG-08-88737]; National Institute on Aging [P50AG005134, P01AG031720, K24AG035075]; Aging Brain Center, Institute for Aging Research, Hebrew SeniorLife; NATIONAL INSTITUTE ON AGING [P01AG031720, K24AG035075, K24AG000949, P50AG005134] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); MADRC; Alzheimer's Association(Alzheimer's Association); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Aging Brain Center, Institute for Aging Research, Hebrew SeniorLife; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	National Institute on Aging and the MADRC.; Funded in part by grant IIRG-08-88737 to Dr. Inouye from the Alzheimer's Association and grants P50AG005134 to Drs. Inouye and Yap, P01AG031720 to Dr. Inouye, and K24AG035075 to Dr. Marcantonio from the National Institute on Aging, as well as the Aging Brain Center, Institute for Aging Research, Hebrew SeniorLife.	Avidan MS, 2009, ANESTHESIOLOGY, V111, P964, DOI 10.1097/ALN.0b013e3181bc9719; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cordoba G, 2010, BMJ-BRIT MED J, V341, pc3920; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Ehlenbach WJ, 2010, JAMA-J AM MED ASSOC, V303, P763, DOI 10.1001/jama.2010.167; Epstein RS, 1996, ANN INTERN MED, V124, P832, DOI 10.7326/0003-4819-124-9-199605010-00008; Fick DM, 2005, J GERONTOL A-BIOL, V60, P748, DOI 10.1093/gerona/60.6.748; Fillenbaum G, 2000, NEUROLOGY, V54, P740, DOI 10.1212/WNL.54.3.740; Folstein M F, 1991, Int Psychogeriatr, V3, P169, DOI 10.1017/S1041610291000637; Fong TG, 2009, NEUROLOGY, V72, P1570, DOI 10.1212/WNL.0b013e3181a4129a; Gill TM, 2010, JAMA-J AM MED ASSOC, V304, P1919, DOI 10.1001/jama.2010.1568; GREENLAND S, 1988, AM J EPIDEMIOL, V128, P1185, DOI 10.1093/oxfordjournals.aje.a115073; Inouye SK, 2005, J AM GERIATR SOC, V53, P312, DOI 10.1111/j.1532-5415.2005.53120.x; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; KATZMAN R, 1988, ANN NEUROL, V24, P384, DOI 10.1002/ana.410240306; LOCASCIO JJ, 1995, ARCH NEUROL-CHICAGO, V52, P1087, DOI 10.1001/archneur.1995.00540350081020; Maslow K, 2006, IMPROVING HOSP CARE, P740; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Nguyen LL, 2010, J VASC SURG, V52, P768, DOI 10.1016/j.jvs.2010.03.027; Pedone C, 2005, J GERONTOL A-BIOL, V60, P1576, DOI 10.1093/gerona/60.12.1576; Powell AE, 2003, QUAL SAF HEALTH CARE, V12, P122, DOI 10.1136/qhc.12.2.122; Rahkonen T, 2001, INT PSYCHOGERIATR, V13, P37, DOI 10.1017/S104161020100744X; Rothman KJ, 2005, AM J PUBLIC HEALTH, V95, pS144, DOI 10.2105/AJPH.2004.059204; Rothman KJ, 1998, MODERN EPIDEMIOLOGY; Royston P, 2005, STATA J, V5, P188, DOI 10.1177/1536867X0500500204; Rudolph JL, 2010, J AM GERIATR SOC, V58, P1542, DOI 10.1111/j.1532-5415.2010.02924.x; SALMON DP, 1990, NEUROLOGY, V40, P1225, DOI 10.1212/WNL.40.8.1225; STERN Y, 1987, NEUROLOGY, V37, P1649, DOI 10.1212/WNL.37.10.1649; WEILER PG, 1991, AM J PUBLIC HEALTH, V81, P1153, DOI 10.2105/AJPH.81.9.1153; Witlox J, 2010, JAMA-J AM MED ASSOC, V304, P443, DOI 10.1001/jama.2010.1013; Zhu CW, 2006, NEUROLOGY, V67, P998, DOI 10.1212/01.wnl.0000230160.13272.1b	32	142	145	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 19	2012	156	12					848	U121		10.7326/0003-4819-156-12-201206190-00005	http://dx.doi.org/10.7326/0003-4819-156-12-201206190-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	992NF	22711077	Green Accepted, Green Published			2023-01-03	WOS:000307783200014
J	Mesquita, RC; Han, SW; Miller, J; Schenkel, SS; Pole, A; Esipova, TV; Vinogradov, SA; Putt, ME; Yodh, AG; Busch, TM				Mesquita, Rickson C.; Han, Sung Wan; Miller, Joann; Schenkel, Steven S.; Pole, Andrew; Esipova, Tatiana V.; Vinogradov, Sergei A.; Putt, Mary E.; Yodh, Arjun G.; Busch, Theresa M.			Tumor Blood Flow Differs between Mouse Strains: Consequences for Vasoresponse to Photodynamic Therapy	PLOS ONE			English	Article							FLUCTUATIONS; HYPOXIA; MUSCLE; HETEROGENEITY; VASOMOTION; RADIATION; RESPONSES; PERFUSION; SIGNAL; DAMAGE	Fluctuations in tumor blood flow are common and attributed to factors such as vasomotion or local vascular structure, yet, because vessel structure and physiology are host-derived, animal strain of tumor propagation may further determine blood flow characteristics. In the present report, baseline and stress-altered tumor hemodynamics as a function of murine strain were studied using radiation-induced fibrosacomas (RIF) grown in C3H or nude mice. Fluctuations in tumor blood flow during one hour of baseline monitoring or during vascular stress induced by photodynamic therapy (PDT) were measured by diffuse correlation spectroscopy. Baseline monitoring revealed fluctuating tumor blood flow highly correlated with heart rate and with similar median periods (i.e. similar to 9 and 14 min in C3H and nudes, respectively). However, tumor blood flow in C3H animals was more sensitive to physiologic or stress-induced perturbations. Specifically, PDT-induced vascular insults produced greater decreases in blood flow in the tumors of C3H versus nude mice; similarly, during baseline monitoring, fluctuations in blood flow were more regular and more prevalent within the tumors of C3H mice versus nude mice; finally, the vasoconstrictor L-NNA reduced tumor blood flow in C3H mice but did not affect tumor blood flow in nudes. Underlying differences in vascular structure, such as smaller tumor blood vessels in C3H versus nude animals, may contribute to strain-dependent variation in vascular function. These data thus identify clear effects of mouse strain on tumor hemodynamics with consequences to PDT and potentially other vascular-mediated therapies.	[Mesquita, Rickson C.; Schenkel, Steven S.; Yodh, Arjun G.] Univ Penn, Dept Phys & Astron, Philadelphia, PA 19104 USA; [Mesquita, Rickson C.] Univ Estadual Campinas, Inst Phys, Sao Paulo, Brazil; [Han, Sung Wan; Putt, Mary E.] Univ Penn, Dept Biostat, Philadelphia, PA 19104 USA; [Miller, Joann; Busch, Theresa M.] Univ Penn, Dept Radiat Oncol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Pole, Andrew] New Jersey Inst Technol, Dept Math Sci, Newark, NJ 07102 USA; [Esipova, Tatiana V.; Vinogradov, Sergei A.] Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	University of Pennsylvania; Universidade Estadual de Campinas; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; New Jersey Institute of Technology; University of Pennsylvania	Mesquita, RC (corresponding author), Univ Penn, Dept Phys & Astron, Philadelphia, PA 19104 USA.	buschtm@mail.med.upenn.edu	Busch, Theresa/J-5591-2019; Mesquita, Rickson C/N-9119-2013	Mesquita, Rickson C/0000-0003-1945-6713	National Institutes of Health [CA-085831, CA-087971, CA-087971-S1]; NATIONAL CANCER INSTITUTE [R01CA085831, P01CA087971] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS060653] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the National Institutes of Health through CA-085831, CA-087971, and CA-087971-S1. Some of the authors also acknowledge the following sources: P41-RR002305 (AGY) and R01-NS060653 (RCM, AGY). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baudelet C, 2004, MAGN RESON IMAGING, V22, P905, DOI 10.1016/j.mri.2004.02.005; Baudelet C, 2006, NMR BIOMED, V19, P69, DOI 10.1002/nbm.1002; Becker TL, 2011, BIOMED OPT EXPRESS, V2, P123, DOI 10.1364/BOE.2.000123; Braun RD, 1999, AM J PHYSIOL-HEART C, V277, pH551, DOI 10.1152/ajpheart.1999.277.2.H551; Busch TM, 2009, PHOTOCH PHOTOBIO SCI, V8, P1683, DOI 10.1039/b9pp00004f; Busch TM, 2010, RADIAT RES, V174, P331, DOI 10.1667/RR2075.1; Busch TM, 2002, CANCER RES, V62, P7273; Campen MJ, 2005, J APPL PHYSIOL, V99, P807, DOI 10.1152/japplphysiol.00039.2005; Cardenas-Navia LI, 2008, CANCER RES, V68, P5812, DOI 10.1158/0008-5472.CAN-07-6387; CHAPLIN DJ, 1995, BRIT J CANCER, V71, P1210, DOI 10.1038/bjc.1995.235; CHAPLIN DJ, 1986, INT J RADIAT ONCOL, V12, P1279, DOI 10.1016/0360-3016(86)90153-7; Chen B, 2005, INT J RADIAT ONCOL, V61, P1216, DOI 10.1016/j.ijrobp.2004.08.006; Chen B, 2006, CRIT REV EUKAR GENE, V16, P279, DOI 10.1615/CritRevEukarGeneExpr.v16.i4.10; Dewhirst MW, 1996, BRIT J CANCER, V74, pS247; Durand RE, 1997, RADIOTHER ONCOL, V42, P171, DOI 10.1016/S0167-8140(96)01878-6; Durduran T, 2010, REP PROG PHYS, V73, DOI 10.1088/0034-4885/73/7/076701; Esipova TV, 2011, ANAL CHEM, V83, P8756, DOI 10.1021/ac2022234; Ferretti S, 2009, NEOPLASIA, V11, P874, DOI 10.1593/neo.09554; Fingar VH, 2000, IN VIVO, V14, P93; Guerkan E, 2008, MAMM GENOME, V19, P366, DOI 10.1007/s00335-008-9118-9; GUICHARD M, 1991, RADIOTHER ONCOL, V20, P117, DOI 10.1016/0167-8140(91)90145-7; Hahn SM, 2006, CLIN CANCER RES, V12, P5464, DOI 10.1158/1078-0432.CCR-06-0953; He C, 2008, PHARM RES-DORDR, V25, P1873, DOI 10.1007/s11095-008-9604-5; Hill SA, 1996, BRIT J CANCER, V74, pS260; Khurana M, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3262521; KIANI MF, 1994, AM J PHYSIOL, V266, pH1822, DOI 10.1152/ajpheart.1994.266.5.H1822; Kimura H, 1996, CANCER RES, V56, P5522; Korbelik M, 1999, CANCER RES, V59, P1941; Lanzen J, 2006, CANCER RES, V66, P2219, DOI 10.1158/0008-5472.CAN-03-2958; Marrero A, 2011, PHOTOCHEM PHOTOBIOL, V87, P910, DOI 10.1111/j.1751-1097.2011.00943.x; Mesquita RC, 2011, PHILOS T R SOC A, V369, P4390, DOI 10.1098/rsta.2011.0232; MEYER JU, 1988, MICROVASC RES, V35, P193, DOI 10.1016/0026-2862(88)90062-3; Pigott KH, 1996, RADIOTHER ONCOL, V40, P45, DOI 10.1016/0167-8140(96)01730-6; Pogue BW, 2001, PHOTOCHEM PHOTOBIOL, V74, P700, DOI 10.1562/0031-8655(2001)074<0700:AOTHOP>2.0.CO;2; Pries AR, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000394; SCHECHNER JS, 1992, MICROVASC RES, V44, P27, DOI 10.1016/0026-2862(92)90099-B; Schumacher J, 2001, J CRIT CARE, V16, P1, DOI 10.1053/jcrc.2001.21790; Seshadri M, 2008, CLIN CANCER RES, V14, P2796, DOI 10.1158/1078-0432.CCR-07-4705; Shang Y, 2011, OPT EXPRESS, V19, P20301, DOI 10.1364/OE.19.020301; Skala MC, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3285584; SOLESVIK OV, 1985, EUR J CANCER CLIN ON, V21, P499, DOI 10.1016/0277-5379(85)90044-6; Standish BA, 2007, GASTROINTEST ENDOSC, V66, P326, DOI 10.1016/j.gie.2007.02.040; VAAGE J, 1992, INT J CANCER, V50, P69, DOI 10.1002/ijc.2910500115; Van Bogaert MJV, 2006, GENES BRAIN BEHAV, V5, P139, DOI 10.1111/j.1601-183X.2005.00143.x; Vinogradov SA, 2011, REV SCI INSTRUM, V72, P3396; Yasui H, 2010, CANCER RES, V70, P6427, DOI 10.1158/0008-5472.CAN-10-1350; Yu GQ, 2005, CLIN CANCER RES, V11, P3543, DOI 10.1158/1078-0432.CCR-04-2582	47	17	17	1	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2012	7	5							e37322	10.1371/journal.pone.0037322	http://dx.doi.org/10.1371/journal.pone.0037322			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959VG	22624014	gold, Green Published, Green Submitted			2023-01-03	WOS:000305343500097
J	Fan, VS; Gaziano, JM; Lew, R; Bourbeau, J; Adams, SG; Leatherman, S; Thwin, SS; Huang, GD; Robbins, R; Sriram, PS; Sharafkhaneh, A; Mador, MJ; Sarosi, G; Panos, RJ; Rastogi, P; Wagner, TH; Mazzuca, SA; Shannon, C; Colling, C; Liang, MH; Stoller, JK; Fiore, L; Niewoehner, DE				Fan, Vincent S.; Gaziano, J. Michael; Lew, Robert; Bourbeau, Jean; Adams, Sandra G.; Leatherman, Sarah; Thwin, Soe Soe; Huang, Grant D.; Robbins, Richard; Sriram, Peruvemba S.; Sharafkhaneh, Amir; Mador, M. Jeffery; Sarosi, George; Panos, Ralph J.; Rastogi, Padmashri; Wagner, Todd H.; Mazzuca, Steven A.; Shannon, Colleen; Colling, Cindy; Liang, Matthew H.; Stoller, James K.; Fiore, Louis; Niewoehner, Dennis E.			A Comprehensive Care Management Program to Prevent Chronic Obstructive Pulmonary Disease Hospitalizations A Randomized, Controlled Trial	ANNALS OF INTERNAL MEDICINE			English	Article							SELF-MANAGEMENT; ACUTE EXACERBATIONS; ACTION PLAN; COPD; HEALTH; METAANALYSIS; MORTALITY; DIAGNOSIS; EDUCATION; RECOVERY	Background: Improving a patient's ability to self-monitor and manage changes in chronic obstructive pulmonary disease (COPD) symptoms may improve outcomes. Objective: To determine the efficacy of a comprehensive care management program (CCMP) in reducing the risk for COPD hospitalization. Design: A randomized, controlled trial comparing CCMP with guideline-based usual care. (ClinicalTrials.gov registration number: NCT00395083) Setting: 20 Veterans Affairs hospital-based outpatient clinics. Participants: Patients hospitalized for COPD in the past year. Intervention: The CCMP included COPD education during 4 individual sessions and 1 group session, an action plan for identification and treatment of exacerbations, and scheduled proactive telephone calls for case management. Patients in both the intervention and usual care groups received a COPD informational booklet; their primary care providers received a copy of COPD guidelines and were advised to manage their patients according to these guidelines. Patients were randomly assigned, stratifying by site based on random, permuted blocks of variable size. Measurements: The primary outcome was time to first COPD hospitalization. Staff blinded to study group performed telephone-based assessment of COPD exacerbations and hospitalizations, and all hospitalizations were blindly adjudicated. Secondary outcomes included non-COPD health care use, all-cause mortality, health-related quality of life, patient satisfaction, disease knowledge, and self-efficacy. Results: Of the eligible patients, 209 were randomly assigned to the intervention group and 217 to the usual care group. Citing serious safety concerns, the data monitoring committee terminated the intervention before the trial's planned completion after 426 (44%) of the planned total of 960 patients were enrolled. Mean follow-up was 250 days. When the study was stopped, the 1-year cumulative incidence of COPD-related hospitalization was 27% in the intervention group and 24% in the usual care group (hazard ratio, 1.13 [95% CI, 0.70 to 1.80]; P = 0.62). There were 28 deaths from all causes in the intervention group versus 10 in the usual care group (hazard ratio, 3.00 [CI, 1.46 to 6.17]; P = 0.003). Cause could be assigned in 27 (71%) deaths. Deaths due to COPD accounted for the largest difference: 10 in the intervention group versus 3 in the usual care group (hazard ratio, 3.60 [CI, 0.99 to 13.08]; P = 0.053). Limitations: Available data could not fully explain the excess mortality in the intervention group. Ability to assess the quality of the educational sessions provided by the case managers was limited. Conclusion: A CCMP in patients with severe COPD had not decreased COPD-related hospitalizations when the trial was stopped prematurely. The CCMP was associated with unanticipated excess mortality, results that differ markedly from similar previous trials. A data monitoring committee should be considered in the design of clinical trials involving behavioral interventions.	[Fan, Vincent S.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98108 USA; Vet Affairs Boston Healthcare Syst, Boston, MA USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Montreal Chest Inst, Montreal, PQ, Canada; S Texas Vet Hlth Care Syst, San Antonio, TX USA; Dept Vet Affairs Cooperat Studies Program, Washington, DC USA; Phoenix Vet Affairs Med Ctr, Phoenix, AZ USA; N Florida S Georgia Vet Hlth Syst, Gainesville, FL USA; Michael E DeBakey VA Med Ctr, Houston, TX USA; Vet Affairs Western New York Healthcare Syst, Buffalo, NY USA; Cincinnati Vet Affairs Med Ctr, Cincinnati, OH USA; Dallas Vet Affairs Med Ctr, Dallas, TX USA; Vet Affairs Palo Alto Healthcare Syst, Menlo Pk, CA USA; Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA; Indiana Univ Sch Med, Indianapolis, IN USA; Vet Affairs Cooperat Studies Program Clin Res Pha, Albuquerque, NM USA; Minneapolis Vet Affairs Healthcare Syst, Minneapolis, MN USA; Cleveland Clin, Cleveland, OH 44106 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Brigham & Women's Hospital; McGill University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Indiana University System; Indiana University Bloomington; Cleveland Clinic Foundation	Fan, VS (corresponding author), Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, 1600 S Columbian Way, Seattle, WA 98108 USA.	vincent.fan@va.gov		Sriram, P.S/0000-0002-6103-3573; Wagner, Todd/0000-0001-7625-3504	Veterans Affairs Cooperative Study Program; Veterans Affairs Office of Research and Development [560]	Veterans Affairs Cooperative Study Program; Veterans Affairs Office of Research and Development	Veterans Affairs Cooperative Study Program.; By the Cooperative Studies Program (CSP #560), Veterans Affairs Office of Research and Development.	Adams SG, 2007, ARCH INTERN MED, V167, P551, DOI 10.1001/archinte.167.6.551; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Bandura A, 2001, ANNU REV PSYCHOL, V52, P1, DOI 10.1146/annurev.psych.52.1.1; Bischoff EWMA, 2011, THORAX, V66, P26, DOI 10.1136/thx.2009.127621; Bourbeau J, 2003, ARCH INTERN MED, V163, P585, DOI 10.1001/archinte.163.5.585; Bourbeau J, 2007, CLIN CHEST MED, V28, P617, DOI 10.1016/j.ccm.2007.06.002; Camargo CA, 2008, INTERN EMERG MED, V3, P355, DOI 10.1007/s11739-008-0197-0; Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304; Chandra D, 2009, COPD, V6, P95, DOI 10.1080/15412550902751746; Corson K, 2004, AM J MANAG CARE, V10, P839; Effing T, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002990.pub2; Fan VS, 2005, J GEN INTERN MED, V20, P226, DOI 10.1111/j.1525-1497.2005.40135.x; Gallefoss F, 2000, RESP MED, V94, P279, DOI 10.1053/rmed.1999.0749; Green L, 2005, HLTH PROGRAM PLANNIN, V4th; Gwadry-Sridhar FH, 2004, ARCH INTERN MED, V164, P2315, DOI 10.1001/archinte.164.21.2315; Hermiz O, 2002, BRIT MED J, V325, P938, DOI 10.1136/bmj.325.7370.938; Hilleman DE, 2000, CHEST, V118, P1278, DOI 10.1378/chest.118.5.1278; Jennison C, 1999, GROUP SEQUENTIAL MET; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Jovicic Aleksandra, 2006, BMC Cardiovasc Disord, V6, P43, DOI 10.1186/1471-2261-6-43; Kalbfleisch J.D., 2002, STAT ANAL FAILURE TI; Kanner RE, 2001, AM J RESP CRIT CARE, V164, P358, DOI 10.1164/ajrccm.164.3.2010017; Kazis Lewis E, 2004, J Ambul Care Manage, V27, P263; Langsetmo L, 2008, AM J RESP CRIT CARE, V177, P396, DOI 10.1164/rccm.200708-1290OC; McGhan R, 2007, CHEST, V132, P1748, DOI 10.1378/chest.06-3018; Ofman JJ, 2004, AM J MED, V117, P182, DOI 10.1016/j.amjmed.2004.03.018; Peytremann-Bridevaux I, 2008, AM J MED, V121, P433, DOI 10.1016/j.amjmed.2008.02.009; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Rea H, 2004, INTERN MED J, V34, P608, DOI 10.1111/j.1445-5994.2004.00672.x; Rice KL, 2010, AM J RESP CRIT CARE, V182, P890, DOI 10.1164/rccm.200910-1579OC; Sedeno MF, 2009, COPD, V6, P352, DOI 10.1080/15412550903150252; Seemungal TAR, 1998, AM J RESP CRIT CARE, V157, P1418, DOI 10.1164/ajrccm.157.5.9709032; Seemungal TAR, 2000, AM J RESP CRIT CARE, V161, P1608, DOI 10.1164/ajrccm.161.5.9908022; Soler-Cataluna JJ, 2005, THORAX, V60, P925, DOI 10.1136/thx.2005.040527; Spiegelhalter DJ, 2004, BAYESIAN APPROACHES, DOI DOI 10.1002/0470092602; Sullivan SD, 2000, CHEST, V117, P5; Taylor SJC, 2005, BMJ-BRIT MED J, V331, P485, DOI 10.1136/bmj.38512.664167.8F; The Management of COPD Working Group, 2007, VA DOD CLIN PRACT GU; TSIATIS AA, 1981, BIOMETRIKA, V68, P311, DOI 10.1093/biomet/68.1.311; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Ware JE., 1994, SF 36 PHYS MENTAL HL; Wilkinson TMA, 2004, AM J RESP CRIT CARE, V169, P1298, DOI 10.1164/rccm.200310-1443OC	43	257	263	0	46	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	2012	156	10					673	U46		10.7326/0003-4819-156-10-201205150-00003	http://dx.doi.org/10.7326/0003-4819-156-10-201205150-00003			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	944IQ	22586006				2023-01-03	WOS:000304193400013
J	Blumberg, N; Heal, JM; Phillips, GL; Phipps, RP				Blumberg, Neil; Heal, Joanna M.; Phillips, Gordon L.; Phipps, Richard P.			Platelets-to transfuse or not to transfuse	LANCET			English	Editorial Material							THROMBOSIS; INFLAMMATION; MORTALITY; OUTCOMES; SURGERY		[Blumberg, Neil; Heal, Joanna M.; Phipps, Richard P.] Univ Rochester, Med Ctr, Dept Pathol, Rochester, NY 14642 USA; [Blumberg, Neil; Heal, Joanna M.; Phipps, Richard P.] Univ Rochester, Med Ctr, Dept Lab Med, Rochester, NY 14642 USA; [Phillips, Gordon L.] Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA; [Phipps, Richard P.] Univ Rochester, Med Ctr, Dept Environm Med, Rochester, NY 14642 USA; [Phipps, Richard P.] Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester	Blumberg, N (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, Rochester, NY 14642 USA.	neil_blumberg@urmc.rochester.edu						Blumberg N, 2008, LEUKEMIA, V22, P631, DOI 10.1038/sj.leu.2404920; Blumberg N, 2001, TRANSFUSION, V41, P790, DOI 10.1046/j.1537-2995.2001.41060790.x; Blumberg N, 2009, IMMUNOL RES, V45, P251, DOI 10.1007/s12026-009-8106-9; Cognasse F, 2006, TRANSFUSION, V46, P1184, DOI 10.1111/j.1537-2995.2006.00869.x; Dineen SP, 2009, J SURG RES, V153, P132, DOI 10.1016/j.jss.2008.04.013; Khorana AA, 2008, ARCH INTERN MED, V168, P2377, DOI 10.1001/archinte.168.21.2377; Refaai MA, 2011, THROMB RES, V127, P287, DOI 10.1016/j.thromres.2010.10.012; Semple JW, 2011, NAT REV IMMUNOL, V11, P264, DOI 10.1038/nri2956; Slichter SJ, 2010, NEW ENGL J MED, V362, P600, DOI 10.1056/NEJMoa0904084; Spiess BD, 2004, TRANSFUSION, V44, P1143, DOI 10.1111/j.1537-2995.2004.03322.x; Wagner DD, 2003, ARTERIOSCL THROM VAS, V23, P2131, DOI 10.1161/01.ATV.0000095974.95122.EC; Wandt H, 2012, LANCET; Zeidler K, 2011, TRANSFUSION, V51, P2269, DOI 10.1111/j.1537-2995.2011.03147.x	13	21	21	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 13	2012	380	9850					1287	1289		10.1016/S0140-6736(12)60983-0	http://dx.doi.org/10.1016/S0140-6736(12)60983-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	022BZ	22877505				2023-01-03	WOS:000309931400006
J	James, S; Held, C				James, Stefan; Held, Claes			Improving long-term outcome after myocardial infarction	LANCET			English	Editorial Material							ACUTE CORONARY SYNDROMES; ATHEROTHROMBOTIC EVENTS; CLOPIDOGREL; PREVENTION; VORAPAXAR; SAFETY		[James, Stefan] Uppsala Univ, Dept Med Sci, S-75185 Uppsala, Sweden; Uppsala Univ, Dept Cardiol, S-75185 Uppsala, Sweden; Uppsala Univ, Uppsala Clin Res Ctr, S-75185 Uppsala, Sweden	Uppsala University; Uppsala University; Uppsala University	James, S (corresponding author), Uppsala Univ, Dept Med Sci, S-75185 Uppsala, Sweden.	stefan.james@ucr.uu.se	James, Stefan K/J-4554-2014; Held, Claes/AAA-3973-2021	Held, Claes/0000-0001-9402-7404				Becker RC, 2009, LANCET, V373, P919, DOI 10.1016/S0140-6736(09)60230-0; Bhatt DL, 2006, NEW ENGL J MED, V354, P1706, DOI 10.1056/NEJMoa060989; ClinicalTrials.gov: NCT01225562, 2011, PREV CARD EV EG DEAT; Goto S, 2010, J ATHEROSCLER THROMB, V17, P156, DOI 10.5551/jat.3038; Hamm CW, 2011, EUR HEART J, V32, P2999, DOI 10.1093/eurheartj/ehr236; Mega JL, 2012, NEW ENGL J MED, V366, P9, DOI 10.1056/NEJMoa1112277; Morrow DA, 2012, NEW ENGL J MED, V366, P1404, DOI 10.1056/NEJMoa1200933; Scirica BM, 2012, LANCET; Tricoci P, 2012, NEW ENGL J MED, V366, P20, DOI 10.1056/NEJMoa1109719; Wallentin L, 2009, NEW ENGL J MED, V361, P1045, DOI 10.1056/NEJMoa0904327; Wiviott SD, 2007, NEW ENGL J MED, V357, P2001, DOI 10.1056/NEJMoa0706482	11	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 13	2012	380	9850					1290	1291		10.1016/S0140-6736(12)61383-X	http://dx.doi.org/10.1016/S0140-6736(12)61383-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	022BZ	22932713				2023-01-03	WOS:000309931400007
J	Gao, L; Jiang, T; Guo, J; Liu, Y; Cui, GY; Gu, LZ; Su, LY; Zhang, YD				Gao, Li; Jiang, Teng; Guo, Jun; Liu, Yi; Cui, Guiyun; Gu, Lize; Su, Lingying; Zhang, Yingdong			Inhibition of Autophagy Contributes to Ischemic Postconditioning-Induced Neuroprotection against Focal Cerebral Ischemia in Rats	PLOS ONE			English	Article							ISCHEMIA/REPERFUSION INJURY; HYPOXIA-ISCHEMIA; INFARCT SIZE; NEURON DEATH; CELL-DEATH; IN-VIVO; PATHWAYS; STROKE; MODEL; BRAIN	Background: Ischemic postconditioning (IPOC), or relief of ischemia in a stuttered manner, has emerged as an innovative treatment strategy to reduce programmed cell death, attenuate ischemic injuries, and improve neurological outcomes. However, the mechanisms involved have not been completely elucidated. Recent studies indicate that autophagy is a type of programmed cell death that plays elusive roles in controlling neuronal damage and metabolic homeostasis. This study aims to determine the role of autophagy in IPOC-induced neuroprotection against focal cerebral ischemia in rats. Methodology/Principal Findings: A focal cerebral ischemic model with permanent middle cerebral artery (MCA) occlusion plus transient common carotid artery (CCA) occlusion was established. The autophagosomes and the expressions of LC3/Beclin 1/p62 were evaluated for their contribution to the activation of autophagy. We found that autophagy was markedly induced with the upregulation of LC3/Beclin 1 and downregulation of p62 in the penumbra at various time intervals following ischemia. IPOC, performed at the onset of reperfusion, reduced infarct size, mitigated brain edema, inhibited the induction of LC3/Beclin 1 and reversed the reduction of p62 simultaneously. Rapamycin, an inducer of autophagy, partially reversed all the aforementioned effects induced by IPOC. Conversely, autophagy inhibitor 3-methyladenine (3-MA) attenuated the ischemic insults, inhibited the activation of autophagy, and elevated the expression of anti-apoptotic protein Bcl-2, to an extent comparable to IPOC. Conclusions/Significance: The present study suggests that inhibition of the autophagic pathway plays a key role in IPOC-induced neuroprotection against focal cerebral ischemia. Thus, pharmacological inhibition of autophagy may provide a novel therapeutic strategy for the treatment of stroke.	[Gao, Li; Jiang, Teng; Zhang, Yingdong] Nanjing Med Univ, Affiliated Nanjing Hosp 1, Dept Neurol, Nanjing, Jiangsu, Peoples R China; [Guo, Jun; Gu, Lize] Nanjing Med Univ, Dept Biochem & Mol Biol, Nanjing, Jiangsu, Peoples R China; [Liu, Yi; Su, Lingying] Nanjing Med Univ, Affiliated Nanjing Brain Hosp, Dept Neurol, Nanjing, Jiangsu, Peoples R China; [Cui, Guiyun] Xuzhou Med Coll, Affiliated Hosp, Dept Neurol, Xuzhou, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Xuzhou Medical University	Zhang, YD (corresponding author), Nanjing Med Univ, Affiliated Nanjing Hosp 1, Dept Neurol, Nanjing, Jiangsu, Peoples R China.	zhangyingdong@yahoo.com.cn	zhang, ying/HJB-1230-2022		Medical Science and Technology Development Foundation, Nanjing Department of Health [ZKX09036]	Medical Science and Technology Development Foundation, Nanjing Department of Health	This study was supported by Key Project of Medical Science and Technology Development Foundation, Nanjing Department of Health (NO. ZKX09036, http://www.njh.gov.cn/html/list_83.shtml). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bjorkoy G, 2006, AUTOPHAGY, V2, P138, DOI 10.4161/auto.2.2.2405; Bochelen D, 1999, J PHARMACOL EXP THER, V288, P653; Carloni S, 2008, NEUROBIOL DIS, V32, P329, DOI 10.1016/j.nbd.2008.07.022; Cui DR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035324; Danielisova V, 2009, CELL MOL NEUROBIOL, V29, P871, DOI 10.1007/s10571-009-9369-3; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Gao XW, 2008, J NEUROCHEM, V105, P943, DOI 10.1111/j.1471-4159.2008.05218.x; Ivanes F, 2011, ANTIOXID REDOX SIGN, V14, P811, DOI 10.1089/ars.2010.3354; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kirino T, 2002, J CEREBR BLOOD F MET, V22, P1283, DOI 10.1097/01.WCB.0000040942.89393.88; Koike M, 2008, AM J PATHOL, V172, P454, DOI 10.2353/ajpath.2008.070876; Krolikowski JG, 2006, CAN J ANAESTH, V53, P174, DOI 10.1007/BF03021824; Labrande C, 2006, NEUROSCIENCE, V137, P231, DOI 10.1016/j.neuroscience.2005.08.080; Lajoie C, 2009, CAN J PHYSIOL PHARM, V87, P460, DOI [10.1139/Y09-031, 10.1139/y09-031]; Leconte C, 2009, STROKE, V40, P3349, DOI 10.1161/STROKEAHA.109.557314; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; Park HK, 2009, NEUROSCI LETT, V451, P16, DOI 10.1016/j.neulet.2008.12.019; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Puyal J, 2009, ANN NEUROL, V66, P378, DOI 10.1002/ana.21714; Qin AP, 2010, AUTOPHAGY, V6, P738, DOI 10.4161/auto.6.6.12573; Rami A, 2008, NEUROBIOL DIS, V29, P132, DOI 10.1016/j.nbd.2007.08.005; Sarkar S, 2007, NAT CHEM BIOL, V3, P331, DOI 10.1038/nchembio883; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; Sheng R, 2010, AUTOPHAGY, V6, P482, DOI 10.4161/auto.6.4.11737; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Staat P, 2005, CIRCULATION, V112, P2143, DOI 10.1161/CIRCULATIONAHA.105.558122; Tian FF, 2010, AUTOPHAGY, V6, P1107, DOI 10.4161/auto.6.8.13427; Uchiyama Y, 2008, AUTOPHAGY, V4, P404, DOI 10.4161/auto.5598; Victor ED, 2006, PATHOPHYSIOL, V13, P119; Vigneron F, 2011, CARDIOVASC RES, V90, P49, DOI 10.1093/cvr/cvr002; Wagner C, 2010, MOL CELL BIOCHEM, V339, P135, DOI 10.1007/s11010-009-0377-x; Wang JY, 2011, J NEUROPATH EXP NEUR, V70, P314, DOI 10.1097/NEN.0b013e31821352bd; Wang JK, 2010, BRAIN RES, V1357, P142, DOI 10.1016/j.brainres.2010.08.009; Wen YD, 2008, AUTOPHAGY, V4, P762, DOI 10.4161/auto.6412; Xing BZ, 2008, STROKE, V39, P2362, DOI 10.1161/STROKEAHA.107.507939; Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200; Yuan YJ, 2011, BRAIN RES, V1367, P85, DOI 10.1016/j.brainres.2010.10.017; Zhao H, 2006, J CEREBR BLOOD F MET, V26, P1114, DOI 10.1038/sj.jcbfm.9600348; Zheng YQ, 2009, ACTA PHARMACOL SIN, V30, P919, DOI 10.1038/aps.2009.79; Zhu C, 2005, CELL DEATH DIFFER, V12, P162, DOI 10.1038/sj.cdd.4401545	44	121	138	1	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2012	7	9							e46092	10.1371/journal.pone.0046092	http://dx.doi.org/10.1371/journal.pone.0046092			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022PZ	23029398	Green Published, Green Submitted, gold			2023-01-03	WOS:000309973900088
J	Bonechi, C; Martini, S; Ciani, L; Lamponi, S; Rebmann, H; Rossi, C; Ristori, S				Bonechi, Claudia; Martini, Silvia; Ciani, Laura; Lamponi, Stefania; Rebmann, Herbert; Rossi, Claudio; Ristori, Sandra			Using Liposomes as Carriers for Polyphenolic Compounds: The Case of Trans-Resveratrol	PLOS ONE			English	Article							IN-VIVO; CANCER; SPECTROSCOPY; PERSPECTIVES; RESONANCE; MEMBRANES	Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a polyphenol found in various plants, especially in the skin of red grapes. The effect of resveratrol on human health is the topic of numerous studies. In fact this molecule has shown anti-cancer, anti-inflammatory, blood-sugar-lowering ability and beneficial cardiovascular effects. However, for many polyphenol compounds of natural origin bioavailability is limited by low solubility in biological fluids, as well as by rapid metabolization in vivo. Therefore, appropriate carriers are required to obtain efficient therapeutics along with low administration doses. Liposomes are excellent candidates for drug delivery purposes, due to their biocompatibility, wide choice of physico-chemical properties and easy preparation. In this paper liposome formulations made by a saturated phosphatidyl-choline (DPPC) and cholesterol (or its positively charged derivative DC-CHOL) were chosen to optimize the loading of a rigid hydrophobic molecule such as resveratrol. Plain and resveratrol loaded liposomes were characterized for size, surface charge and structural details by complementary techniques, i.e. Dynamic Light Scattering (DLS), Zeta potential and Small Angle X-ray Scattering (SAXS). Nuclear and Electron Spin magnetic resonances (NMR and ESR, respectively) were also used to gain information at the molecular scale. The obtained results allowed to give an account of loaded liposomes in which resveratrol interacted with the bilayer, being more deeply inserted in cationic liposomes than in zwitterionic liposomes. Relevant properties such as the mean size and the presence of oligolamellar structures were influenced by the loading of RESV guest molecules. The toxicity of all these systems was tested on stabilized cell lines (mouse fibroblast NIH-3T3 and human astrocytes U373-MG), showing that cell viability was not affected by the administration of liposomial resveratrol.	[Bonechi, Claudia; Martini, Silvia; Lamponi, Stefania; Rossi, Claudio] Univ Siena, Dept Pharmaceut, I-53100 Siena, Italy; [Bonechi, Claudia; Martini, Silvia; Lamponi, Stefania; Rossi, Claudio] Univ Siena, Dept Appl Chem, I-53100 Siena, Italy; [Bonechi, Claudia; Martini, Silvia; Lamponi, Stefania; Rossi, Claudio] Univ Siena, CSGI, I-53100 Siena, Italy; [Ciani, Laura; Ristori, Sandra] Univ Florence, Chem Dept Ugo Schiff, Sesto Fiorentino, Italy; [Ciani, Laura; Ristori, Sandra] Univ Florence, CSGI, Sesto Fiorentino, Italy; [Rebmann, Herbert] Phospholipid Res Ctr, Heidelberg, Germany	University of Siena; University of Siena; University of Siena; University of Florence; University of Florence	Bonechi, C (corresponding author), Univ Siena, Dept Pharmaceut, Via Laterina 8, I-53100 Siena, Italy.	ristori@unifi.it	Ristori, Sandra/J-9887-2014; lamponi, stefania/AAM-5490-2021; Ristori, Sandra/ABC-4731-2020	Ristori, Sandra/0000-0003-0708-3956; lamponi, stefania/0000-0002-2788-8797; BONECHI, CLAUDIA/0000-0002-4328-3253; ROSSI, CLAUDIO/0000-0001-6032-1015	Phospholipids Research Center (Heidelberg, Germany)	Phospholipids Research Center (Heidelberg, Germany)	This study was conducted in the framework of a Phospholipids Research Center (Heidelberg, Germany) funded research project. Dr. Herbert Rebmann, a member of the Phospholipids Research Center, took part to the work and co-authored this manuscript. Apart from Dr. Rebmann, who contributed as co-author, the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aggarwal BB, 2004, ANTICANCER RES, V24, P2783; Aziz MH, 2003, INT J ONCOL, V23, P17; Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060; Bonechi C, 2008, MAGN RESON CHEM, V46, P625, DOI 10.1002/mrc.2217; Caddeo C, 2008, INT J PHARMACEUT, V363, P183, DOI 10.1016/j.ijpharm.2008.07.024; CEVC G, 1993, CHEM PHYS LIPIDS, V64, P163, DOI 10.1016/0009-3084(93)90064-A; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Fahr A, 2005, EUR J PHARM SCI, V26, P251, DOI 10.1016/j.ejps.2005.05.012; Fremont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5; Gregoriadis G., 1993, LIPOSOMES DRUG DELIV; Hunter R. J., 1988, ZETA POTENTIAL COLLO; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Kolouchova-Hanzlikova I, 2004, FOOD CHEM, V87, P151, DOI 10.1016/j.foodchem.2004.01.028; KOPPEL DE, 1972, J CHEM PHYS, V57, P4814, DOI 10.1063/1.1678153; Lindner P, 2002, NEUTRON XRAYS LIGHT; Mauer N, 2001, EXPERT OPIN BIOL TH, V6, P923; Morandi S, 2004, BBA-BIOMEMBRANES, V1664, P53, DOI 10.1016/j.bbamem.2004.04.002; Narayanan NK, 2009, INT J CANCER, V125, P1, DOI 10.1002/ijc.24336; Pabst Georg, 2006, Biophysical Reviews and Letters, V1, P57, DOI 10.1142/S1793048006000069; Padamwar MN, 2006, INT J PHARMACEUT, V320, P37, DOI 10.1016/j.ijpharm.2006.04.001; Rius C, 2012, IMMUNOLOGY, V185, P3718; Romberg B, 2006, BIOCONJUGATE CHEM, V17, P860, DOI 10.1021/bc060045a; Rossi C, 2011, SEMIN CANCER BIOL, V21, P207, DOI 10.1016/j.semcancer.2011.04.003; Shu XH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027484; Shu XH, 2010, BIOCHEM PHARMACOL, V79, P1516, DOI 10.1016/j.bcp.2010.01.022; Vartorelli MR, 2008, J PHYS CHEM B, V112, P16830, DOI 10.1021/jp806476a	26	81	81	2	83	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2012	7	8							e41438	10.1371/journal.pone.0041438	http://dx.doi.org/10.1371/journal.pone.0041438			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	999CI	22936976	Green Published, gold, Green Submitted			2023-01-03	WOS:000308286300007
J	Nguyen, NP; Chi, A; Betz, M; Almeida, F; Vos, P; Davis, R; Slane, B; Ceizyk, M; Abraham, D; Smith-Raymond, L; Stevie, M; Jang, S; Gelumbauskas, S; Vinh-Hung, V				Nguyen, Nam P.; Chi, Alexander; Betz, Michael; Almeida, Fabio; Vos, Paul; Davis, Rick; Slane, Benjamin; Ceizyk, Misty; Abraham, Dave; Smith-Raymond, Lexie; Stevie, Michelle; Jang, Siyoung; Gelumbauskas, Steven; Vincent Vinh-Hung			Feasibility of Intensity-Modulated and Image-Guided Radiotherapy for Functional Organ Preservation in Locally Advanced Laryngeal Cancer	PLOS ONE			English	Article							CONCURRENT CHEMOTHERAPY; RADIATION-THERAPY; TARGET COVERAGE; ADVANCED HEAD; NECK-CANCER; FOLLOW-UP; CARCINOMA; RECURRENT; IMPACT; COMPLICATIONS	Purpose: The study aims to assess the feasibility of intensity-modulated and image-guided radiotherapy (IMRT, and IGRT, respectively) for functional preservation in locally advanced laryngeal cancer. A retrospective review of 27 patients undergoing concurrent chemoradiation for locally advanced laryngeal cancers (8 IMRT, 19 IGRT) was undertaken. In addition to regular clinical examinations, all patients had PET imaging at 4 months and 10 months after radiotherapy, then yearly. Loco-regional control, speech quality and feeding-tube dependency were assessed during follow-up visits. Results: At a median follow-up of 20 months (range 6-57 months), four out of 27 patients (14.8%) developed local recurrence and underwent salvage total laryngectomy. One patient developed distant metastases following salvage surgery. Among the 23 patients who conserved their larynx with no sign of recurrence at last follow-up, 22 (95%) reported normal or near normal voice quality, allowing them to communicate adequately. Four patients (14.8%) had long-term tube feeding-dependency because of severe dysphagia (2 patients) and chronic aspiration (2 patients, with ensuing death from aspiration pneumonia in one patient). Conclusions and Clinical Relevance: Functional laryngeal preservation is feasible with IMRT and IGRT for locally advanced laryngeal cancer. However, dysphagia and aspiration remain serious complications, due most likely to high radiation dose delivery to the pharyngeal musculatures.	[Nguyen, Nam P.; Davis, Rick; Slane, Benjamin; Ceizyk, Misty; Abraham, Dave; Smith-Raymond, Lexie; Stevie, Michelle; Gelumbauskas, Steven] Univ Arizona, Dept Radiat Oncol, Tucson, AZ 85721 USA; [Chi, Alexander] W Virginia Univ, Dept Radiat Oncol, Morgantown, WV 26506 USA; [Betz, Michael; Vincent Vinh-Hung] Univ Hosp Geneva, Dept Radiat Oncol, Geneva, Switzerland; [Almeida, Fabio] SW PET CT Inst, Tucson, AZ USA; [Vos, Paul] E Carolina Univ, Dept Biostat, Greenville, NC USA; [Jang, Siyoung] Univ Pittsburgh, Dept Radiat Oncol, Pittsburgh, PA USA	University of Arizona; West Virginia University; University of Geneva; University of North Carolina; East Carolina University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Nguyen, NP (corresponding author), Univ Arizona, Dept Radiat Oncol, Tucson, AZ 85721 USA.	namphong.nguyen@yahoo.com	Vinh-Hung, Vincent/A-5762-2008	Vinh-Hung, Vincent/0000-0002-6403-6120				Braaksma MMJ, 2003, RADIOTHER ONCOL, V66, P291, DOI 10.1016/S0167-8140(03)00038-0; Brouwer J, 2004, EUR ARCH OTO-RHINO-L, V261, P417, DOI 10.1007/s00405-003-0708-6; Brouwer J, 2008, RADIOTHER ONCOL, V87, P217, DOI 10.1016/j.radonc.2008.02.001; Buntzel J, 2007, ANTICANCER RES, V27, P1953; Caglar HB, 2008, INT J RADIAT ONCOL, V72, P1110, DOI 10.1016/j.ijrobp.2008.02.048; Chen AM, 2011, INT J RADIAT ONCOL, V80, P1423, DOI 10.1016/j.ijrobp.2010.04.011; Clark CH, 2004, RADIOTHER ONCOL, V70, P189, DOI 10.1016/j.radonc.2003.10.012; DESANTO LW, 1995, ANN OTO RHINOL LARYN, V104, P763, DOI 10.1177/000348949510401003; Deshmane Vinay H., 1995, Indian Journal of Cancer, V32, P121; Dogan N, 2003, INT J RADIAT ONCOL, V57, P1480, DOI 10.1016/S0360-3016(03)01569-4; Forastiere AA, 2003, NEW ENGL J MED, V349, P2091, DOI 10.1056/NEJMoa031317; Gordin A, 2006, LARYNGOSCOPE, V116, P273, DOI 10.1097/01.mlg.0000197930.93582.32; HILGERS FJM, 1990, CLIN OTOLARYNGOL, V15, P421, DOI 10.1111/j.1365-2273.1990.tb00494.x; Hutcheson KA, 2008, ARCH OTOLARYNGOL, V134, P178, DOI 10.1001/archoto.2007.33; Kuntz AL, 1999, LARYNGOSCOPE, V109, P1334, DOI 10.1097/00005537-199908000-00030; Lee NY, 2007, INT J RADIAT ONCOL, V69, P459, DOI 10.1016/j.ijrobp.2007.03.013; Lefebvre JL, 2009, JNCI-J NATL CANCER I, V101, P142, DOI 10.1093/jnci/djn460; Liberman PHP, 2004, ARCH OTOLARYNGOL, V130, P1265, DOI 10.1001/archotol.130.11.1265; Nguyen N.P., 2012, BMC CANC; Nguyen NP, 2007, LUNG, V185, P243, DOI 10.1007/s00408-007-9016-z; Nguyen NP, 2007, ANTICANCER RES, V27, P1669; Nguyen NP, 2007, ORAL ONCOL, V43, P352, DOI 10.1016/j.oraloncology.2006.04.002; Nguyen NP, 2012, ORAL ONCOL, V48, P653, DOI 10.1016/j.oraloncology.2012.01.016; Nguyen NP, 2011, ORAL ONCOL, V47, P900, DOI 10.1016/j.oraloncology.2011.06.004; Nguyen NP, 2007, ORL-J OTO-RHIN-LARYN, V69, P116, DOI 10.1159/000097843; Oe A, 2007, ANN NUCL MED, V21, P9, DOI 10.1007/BF03033994; Penagaricano JA, 2004, DOSIMETRY, V29, P254; Posner MR, 2009, ANN ONCOL, V20, P921, DOI 10.1093/annonc/mdn752; Rogers SN, 1999, HEAD NECK-J SCI SPEC, V21, P394, DOI 10.1002/(SICI)1097-0347(199908)21:5<394::AID-HED3>3.0.CO;2-Q; Salaun PY, 2007, HEAD NECK-J SCI SPEC, V29, P1125; Sanguineti G, 2007, INT J RADIAT ONCOL, V68, P741, DOI 10.1016/j.ijrobp.2007.01.010; Studer G, 2010, INT J RADIAT ONCOL, V77, P1391, DOI 10.1016/j.ijrobp.2009.07.005; TUPCHONG L, 1991, INT J RADIAT ONCOL, V20, P21, DOI 10.1016/0360-3016(91)90133-O; van Hooren ACG, 2009, EUR ARCH OTO-RHINO-L, V266, P1441, DOI 10.1007/s00405-008-0878-3; WARD PH, 1975, LARYNGOSCOPE, V85, P522, DOI 10.1288/00005537-197503000-00009; WOLF GT, 1991, NEW ENGL J MED, V324, P1685, DOI 10.1056/nejm199106133242402; Zbaren P, 2006, OTOLARYNG HEAD NECK, V135, P838, DOI 10.1016/j.otohns.2006.06.1264; Zevallos JP, 2009, CANCER-AM CANCER SOC, V115, P4636, DOI 10.1002/cncr.24499	38	16	20	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 20	2012	7	8							e42729	10.1371/journal.pone.0042729	http://dx.doi.org/10.1371/journal.pone.0042729			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	991WJ	22916151	gold, Green Published, Green Accepted, Green Submitted			2023-01-03	WOS:000307733800025
J	Ishida, K; Nishizuka, SS; Chiba, T; Ikeda, M; Kume, K; Endo, F; Katagiri, H; Matsuo, T; Noda, H; Iwaya, T; Yamada, N; Fujiwara, H; Takahashi, M; Itabashi, T; Uesugi, N; Maesawa, C; Tamura, G; Sugai, T; Otsuka, K; Koeda, K; Wakabayashi, G				Ishida, Kazushige; Nishizuka, Satoshi S.; Chiba, Takehiro; Ikeda, Miyuki; Kume, Kohei; Endo, Fumitaka; Katagiri, Hirokatsu; Matsuo, Teppei; Noda, Hironobu; Iwaya, Takeshi; Yamada, Noriyuki; Fujiwara, Hisataka; Takahashi, Masanori; Itabashi, Tetsuya; Uesugi, Noriyuki; Maesawa, Chihaya; Tamura, Gen; Sugai, Tamotsu; Otsuka, Koki; Koeda, Keisuke; Wakabayashi, Go			Molecular Marker Identification for Relapse Prediction in 5-FU-Based Adjuvant Chemotherapy in Gastric and Colorectal Cancers	PLOS ONE			English	Article							NF-KAPPA-B; LYSATE MICROARRAYS; GENE-EXPRESSION; JNK ACTIVATION; COLON-CANCER; CELL-LINES; CARCINOMA; INHIBITION; ALPHA; CHEMORESISTANCE	To confirm the clinical significance of NF-kappa B and JNK protein expression from experimentally identified candidates for predicting prognosis for patients with 5-FU treatment, we evaluated the protein expression of surgically removed specimens. A total of 79 specimens were obtained from 30 gastric and 49 colorectal cancer patients who underwent R0 resection followed by postoperative 5-FU based adjuvant chemotherapy. Immunohistochemical examinations of NF-kappa B and JNK on tissue microarrays (TMAs) revealed that significantly shorter time-to-relapse (TTR) in both NF-kappa B(+) and JNK(-) subgroups in both gastric (NF-kappa B(+), p = 0.0002, HR11.7. 95% CI3 3.2-43.4; JNK(-), p = 0.0302, HR4.4, 95% CI 1.2-16.6) and colon (NF-kappa B(+), p = 0.0038, HR36.9, 95% CI 3.2-426.0; JNK(-), p = 0.0098, HR3.2, 95% CI 1.3-7.7) cancers. These protein expression patterns also show strong discriminately power in gastric cancer patients for overall survival rate, suggesting a potential utility as prognostic or chemosensitivity markers. Baseline expression of these proteins using gastric cancer cell lines demonstrated the reciprocal patterns between NF-kappa B and JNK, while 5-FU exposure of these cell lines only induced NF-kappa B, suggesting that NF-kappa B plays a dominant role in the response to 5-FU. Subsequent siRNA experiments confirmed that gene knockdown of NF-kappa B increased 5-FU-specific sensitivity, whereas that of JNK did not affect the chemosensitivity. These results suggest that the expression of these proteins may aid in the decisions involved with adjuvant chemotherapy for gastrointestinal tract cancers.	[Ishida, Kazushige; Nishizuka, Satoshi S.; Chiba, Takehiro; Ikeda, Miyuki; Kume, Kohei; Endo, Fumitaka; Katagiri, Hirokatsu; Matsuo, Teppei; Noda, Hironobu; Iwaya, Takeshi; Fujiwara, Hisataka; Takahashi, Masanori; Itabashi, Tetsuya; Otsuka, Koki; Koeda, Keisuke; Wakabayashi, Go] Iwate Med Univ, Sch Med, Dept Surg, Morioka, Iwate 020, Japan; [Nishizuka, Satoshi S.; Kume, Kohei; Uesugi, Noriyuki; Maesawa, Chihaya; Wakabayashi, Go] Iwate Med Univ, MIAST, Morioka, Iwate 020, Japan; [Iwaya, Takeshi] Kyushu Univ, Med Inst Bioregulat, Dept Surg, Beppu, Oita, Japan; [Kume, Kohei; Maesawa, Chihaya] Iwate Med Univ, Ctr Adv Med Sci, Dept Tumor Biol, Yahaba, Iwate, Japan; [Yamada, Noriyuki; Uesugi, Noriyuki; Sugai, Tamotsu] Iwate Med Univ, Sch Med, Dept Pathol, Div Diagnost Mol Pathol, Morioka, Iwate 020, Japan; [Tamura, Gen] Yamagata Prefectural Cent Hosp, Dept Pathol & Lab Med, Yamagata, Japan	Iwate Medical University; Iwate Medical University; Kyushu University; Iwate Medical University; Iwate Medical University; Yamagata Prefectural Central Hospital	Ishida, K (corresponding author), NCI, Chem Immunol Sect, Cell Biol Lab, NIH, Bethesda, MD 20892 USA.	snishizu@iwate-med.ac.jp			Keiryokai Research Foundation [101]; KAKENHI [21591676]; MIAST (Medical Innovation by Advanced Science and Technology) project of the Ministry of Education, Culture, Sports, Science and Technology, JAPAN; Grants-in-Aid for Scientific Research [24591917] Funding Source: KAKEN	Keiryokai Research Foundation(Keiryokai Research Foundation); KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); MIAST (Medical Innovation by Advanced Science and Technology) project of the Ministry of Education, Culture, Sports, Science and Technology, JAPAN; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by: Keiryokai Research Foundation (101) by S.S.N.; KAKENHI (21591676); Grant-in-Aid for Scientific Research(C) by S.S.N; and MIAST (Medical Innovation by Advanced Science and Technology) project of the Ministry of Education, Culture, Sports, Science and Technology, JAPAN by S.S.N, K. K, N.U., C. M., T. S., and G. W. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aoyama T, 2011, GASTRIC CANC; Aoyama T, 2011, GASTRIC CANCER, V14, P150, DOI 10.1007/s10120-011-0020-x; Bednarski BK, 2008, MOL CANCER THER, V7, P1827, DOI 10.1158/1535-7163.MCT-08-0321; Bourgarel-Rey V, 2001, MOL PHARMACOL, V59, P1165, DOI 10.1124/mol.59.5.1165; Brennan DJ, 2010, NAT REV CANCER, V10, P605, DOI 10.1038/nrc2902; Bubici C, 2004, CELL CYCLE, V3, P1524, DOI 10.4161/cc.3.12.1321; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Cunningham D, 2007, LANCET, V370, P1980, DOI 10.1016/S0140-6736(07)61841-8; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; Giacomini KM, 2010, NAT REV DRUG DISCOV, V9, P215, DOI 10.1038/nrd3028; Gray R, 2007, LANCET, V370, P2020, DOI 10.1016/s0140-6736(07)61866-2; Grem JL, 2001, CLIN CANCER RES, V7, P999; Honda T, 2005, JPN J CLIN ONCOL, V35, P580, DOI 10.1093/jjco/hyi166; Ishida K, 2010, J IWATE MED ASS, V62, P363; Ito N, 1997, JPN J GASTROENTEROL, V30, P741; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kojima M, 2004, ANTICANCER RES, V24, P675; Krueger S, 2006, J BIOL CHEM, V281, P2868, DOI 10.1074/jbc.m511053200; Levidou G, 2007, VIRCHOWS ARCH, V450, P519, DOI 10.1007/s00428-007-0396-5; Lind DS, 2001, SURGERY, V130, P363, DOI 10.1067/msy.2001.116672; Macdonald JS, 2001, NEW ENGL J MED, V345, P725, DOI 10.1056/NEJMoa010187; Matsuyama R, 2006, INT J CANCER, V119, P406, DOI 10.1002/ijc.21843; Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588; Nishizuka S, 2003, P NATL ACAD SCI USA, V100, P14229, DOI 10.1073/pnas.2331323100; Nishizuka S, 2003, CANCER RES, V63, P5243; Nishizuka S, 2008, CURR OPIN BIOTECH, V19, P41, DOI 10.1016/j.copbio.2007.11.007; Nishizuka S, 2008, J PROTEOME RES, V7, P803, DOI 10.1021/pr0702971; O'Connell MJ, 1998, J CLIN ONCOL, V16, P295, DOI 10.1200/JCO.1998.16.1.295; Paoletti X, 2010, JAMA-J AM MED ASSOC, V303, P1729, DOI 10.1001/jama.2010.534; Papa S, 2006, CELL DEATH DIFFER, V13, P712, DOI 10.1038/sj.cdd.4401865; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Ross JS, 2010, AM J CLIN PATHOL, V134, P478, DOI 10.1309/AJCP2Y8KTDPOAORH; Roxburgh C, 2011, INT J COLORECTAL DIS, V26, P483, DOI 10.1007/s00384-010-1120-5; Sakamoto K, 2009, CLIN CANCER RES, V15, P2248, DOI 10.1158/1078-0432.CCR-08-1383; Sakuramoto S, 2007, NEW ENGL J MED, V357, P1810, DOI 10.1056/NEJMoa072252; Sargent D, 2009, J CLIN ONCOL, V27, P872, DOI 10.1200/JCO.2008.19.5362; Sasaki N, 2001, CLIN CANCER RES, V7, P4136; Scartozzi M, 2007, J CLIN ONCOL, V25, P3930, DOI 10.1200/JCO.2007.11.5022; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Shembade N, 2007, EMBO J, V26, P3910, DOI 10.1038/sj.emboj.7601823; Spurrier B, 2008, NAT PROTOC, V3, P1796, DOI 10.1038/nprot.2008.179; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Tian Q, 2004, MOL CELL PROTEOMICS, V3, P960, DOI 10.1074/mcp.M400055-MCP200; Uen YH, 2008, ANN SURG ONCOL, V15, P2120, DOI 10.1245/s10434-008-9961-7; Uetsuka H, 2003, EXP CELL RES, V289, P27, DOI 10.1016/S0014-4827(03)00223-4; Voboril R, 2007, NEOPLASMA, V54, P495; Voboril R, 2004, J SURG RES, V120, P178, DOI 10.1016/j.jss.2003.11.023; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Yamanaka N, 2004, ANTICANCER RES, V24, P1071	52	11	12	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2012	7	8							e43236	10.1371/journal.pone.0043236	http://dx.doi.org/10.1371/journal.pone.0043236			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	988OQ	22905237	Green Published, Green Submitted, gold			2023-01-03	WOS:000307500800062
J	Buxton, OM; Ellenbogen, JM; Wang, W; Carballeira, A; O'Connor, S; Cooper, D; Gordhandas, AJ; McKinney, SM; Solet, JM				Buxton, Orfeu M.; Ellenbogen, Jeffrey M.; Wang, Wei; Carballeira, Andy; O'Connor, Shawn; Cooper, Dan; Gordhandas, Ankit J.; McKinney, Scott M.; Solet, Jo M.			Sleep Disruption due to Hospital Noises A Prospective Evaluation	ANNALS OF INTERNAL MEDICINE			English	Article							NEONATAL INTENSIVE-CARE; AIRCRAFT NOISE; AROUSAL; QUALITY; DEPRIVATION; AGE; IDENTIFICATION; ENVIRONMENT; ACTIVATION; DURATION	Background: Sleep plays a critical role in maintaining health and well-being; however, patients who are hospitalized are frequently exposed to noise that can disrupt sleep. Efforts to attenuate hospital noise have been limited by incomplete information on the interaction between sounds and sleep physiology. Objective: To determine profiles of acoustic disruption of sleep by examining the cortical (encephalographic) arousal responses during sleep to typical hospital noises by sound level and type and sleep stage. Design: 3-day polysomnographic study. Setting: Sound-attenuated sleep laboratory. Participants: Volunteer sample of 12 healthy participants. Intervention: Baseline (sham) night followed by 2 intervention nights with controlled presentation of 14 sounds that are common in hospitals (for example, voice, intravenous alarm, phone, ice machine, outside traffic, and helicopter). The sounds were administered at calibrated, increasing decibel levels (40 to 70 dBA [decibels, adjusted for the range of normal hearing]) during specific sleep stages. Measurements: Encephalographic arousals, by using established criteria, during rapid eye movement (REM) sleep and non-REM (NREM) sleep stages 2 and 3. Results: Sound presentations yielded arousal response curves that varied because of sound level and type and sleep stage. Electronic sounds were more arousing than other sounds, including human voices, and there were large differences in responses by sound type. As expected, sounds in NREM stage 3 were less likely to cause arousals than sounds in NREM stage 2; unexpectedly, the probability of arousal to sounds presented in REM sleep varied less by sound type than when presented in NREM sleep and caused a greater and more sustained elevation of instantaneous heart rate. Limitations: The study included only 12 participants. Results for these healthy persons may underestimate the effects of noise on sleep in patients who are hospitalized. Conclusion: Sounds during sleep influence both cortical brain activity and cardiovascular function. This study systematically quantifies the disruptive capacity of a range of hospital sounds on sleep, providing evidence that is essential to improving the acoustic environments of new and existing health care facilities to enable the highest quality of care.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Brigham & Womens Hosp, Boston, MA USA; Berklee Coll Mus, Boston, MA USA; Cambridge Hlth Alliance, Cambridge, England; Cavanaugh Tocci Assoc, Sudbury, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Massachusetts General Hospital	Buxton, OM (corresponding author), 221 Longwood Ave,BLI438-K, Boston, MA 02115 USA.	orfeu_buxton@hms.harvard.edu		Buxton, Orfeu/0000-0001-5057-633X	Academy of Architecture for Health; Facilities Guidelines Institute; Center for Health Design	Academy of Architecture for Health; Facilities Guidelines Institute; Center for Health Design	This study was funded by investigator-initiated grants (Dr. Solet) from the Academy of Architecture for Health, the Facilities Guidelines Institute, and The Center for Health Design. Sleep laboratory work was completed through the generosity of Massachusetts General Hospital and with acoustic consultation by Cavanaugh Tocci Associates.	Altevogt B.M., 2006, SLEEP DISORDERS SLEE; Ancoli-Israel S, 2005, J AM GERIATR SOC, V53, pS264, DOI 10.1111/j.1532-5415.2005.53392.x; [Anonymous], GUID DES CONSTR HLTH; Bartick Melissa C, 2010, J Hosp Med, V5, pE20, DOI 10.1002/jhm.549; Basner M, 2008, SLEEP MED, V9, P382, DOI 10.1016/j.sleep.2007.07.002; Basner M, 2007, SLEEP, V30, P1349, DOI 10.1093/sleep/30.10.1349; Basner M, 2006, J ACOUST SOC AM, V119, P2772, DOI 10.1121/1.2184247; Basner M, 2010, NOISE HEALTH, V12, P95, DOI 10.4103/1463-1741.63210; Berg S, 2001, SLEEP, V24, P289, DOI 10.1093/sleep/24.3.289; Bonnet MH, 2007, J CLIN SLEEP MED, V3, P133; Bonnet MH, 2007, J CLIN SLEEP MED, V3, P271; Braun AR, 1997, BRAIN, V120, P1173, DOI 10.1093/brain/120.7.1173; Bruck D, 2009, J SLEEP RES, V18, P196, DOI 10.1111/j.1365-2869.2008.00710.x; Busch-Vishniac IJ, 2005, J ACOUST SOC AM, V118, P3629, DOI 10.1121/1.2118327; Buxton OM, 2010, DIABETES, V59, P2126, DOI 10.2337/db09-0699; Cappuccio FP, 2007, HYPERTENSION, V50, P693, DOI 10.1161/HYPERTENSIONAHA.107.095471; Carpenter Dave, 2010, Health Facil Manage, V23, P11; Catcheside PG, 2002, SLEEP, V25, P797, DOI 10.1093/sleep/25.7.797; Cmiel CA, 2004, AM J NURS, V104, P40, DOI 10.1097/00000446-200402000-00019; Cohen S, 2009, ARCH INTERN MED, V169, P62, DOI 10.1001/archinternmed.2008.505; Dang-Vu TT, 2010, CURR BIOL, V20, pR626, DOI 10.1016/j.cub.2010.06.032; DEGENNARO L, 1995, ELECTROEN CLIN NEURO, V95, P252, DOI 10.1016/0013-4694(95)00090-L; Dijk DJ, 2001, SLEEP, V24, P565, DOI 10.1093/sleep/24.5.565; Drummond SPA, 2001, NEUROPSYCHOPHARMACOL, V25, pS68, DOI 10.1016/S0893-133X(01)00325-6; Elmenhorst EM, 2010, INT ARCH OCC ENV HEA, V83, P743, DOI 10.1007/s00420-010-0515-5; Griefahn B, 2008, SLEEP, V31, P569, DOI 10.1093/sleep/31.4.569; Hagerman I, 2005, INT J CARDIOL, V98, P267, DOI 10.1016/j.ijcard.2003.11.006; Halasz P, 2004, J SLEEP RES, V13, P1, DOI 10.1111/j.1365-2869.2004.00388.x; Hoevenaar-Blom MP, 2011, SLEEP, V34, P1487, DOI 10.5665/sleep.1382; Iber C., 2007, RULES TERMINOL TECH, V176, P2012; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; Jha AK, 2008, NEW ENGL J MED, V359, P1921, DOI 10.1056/NEJMsa0804116; Johnson AN, 2003, J PERINAT NEONAT NUR, V17, P280, DOI 10.1097/00005237-200310000-00006; Kahn DM, 1998, CHEST, V114, P535, DOI 10.1378/chest.114.2.535; Landolt HP, 1996, BRAIN RES, V738, P205, DOI 10.1016/S0006-8993(96)00770-6; Mayers AG, 2005, HUM PSYCHOPHARM CLIN, V20, P533, DOI 10.1002/hup.726; McNeer Richard R, 2007, J Clin Monit Comput, V21, P353, DOI 10.1007/s10877-007-9096-6; Montague KN, 2009, AM J NURS, V109, P65, DOI 10.1097/01.NAJ.0000360316.54373.0d; Ohayon MM, 2004, SLEEP, V27, P1255, DOI 10.1093/sleep/27.7.1255; Perrin F, 1999, CLIN NEUROPHYSIOL, V110, P2153, DOI 10.1016/S1388-2457(99)00177-7; Ryherd EE, 2008, J ACOUST SOC AM, V123, P747, DOI 10.1121/1.2822661; Schweitzer PK, 2010, PRINCIPLES PRACTICE, P542; Sforza E, 2000, CLIN NEUROPHYSIOL, V111, P1611, DOI 10.1016/S1388-2457(00)00363-1; Sforza E, 2004, CLIN NEUROPHYSIOL, V115, P2442, DOI 10.1016/j.clinph.2004.06.002; Siegel JM, 2010, PRINCIPLES PRACTICE, P92; Solet JM, 2012, PROG PEDIATR CARDIOL, V33, P85, DOI 10.1016/j.ppedcard.2011.12.014; SOUTHWELL MT, 1995, J ADV NURS, V21, P1101, DOI 10.1046/j.1365-2648.1995.21061101.x; Topf M, 1996, J ADV NURS, V24, P545, DOI 10.1046/j.1365-2648.1996.22315.x; Topf M, 2001, HEART LUNG, V30, P237, DOI 10.1067/mhl.2001.116592; Weinhouse GL, 2009, CRIT CARE, V13, DOI 10.1186/cc8131; Williams AL, 2007, J ACOUST SOC AM, V121, P2681, DOI 10.1121/1.2717500; Witmans M, 2005, J CLIN SLEEP MED, V1, pE488; World Health Organization Regional Office for Europe, 2010, NIGHT NOIS GUID EUR; YINNON AM, 1992, BRIT J CLIN PRACT, V46, P88	54	94	95	1	28	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 7	2012	157	3					170	+		10.7326/0003-4819-156-12-201208070-00472	http://dx.doi.org/10.7326/0003-4819-156-12-201208070-00472			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	992PB	22868834				2023-01-03	WOS:000307789900004
J	Khan, A; Faucett, J; Lichtenberg, P; Kirsch, I; Brown, WA				Khan, Arif; Faucett, James; Lichtenberg, Pesach; Kirsch, Irving; Brown, Walter A.			A Systematic Review of Comparative Efficacy of Treatments and Controls for Depression	PLOS ONE			English	Review							DIAGNOSTIC-CRITERIA; PSYCHOTHERAPY; TRIALS; PLACEBO; PHARMACOTHERAPY; ANTIDEPRESSANTS; METAANALYSIS; SEVERITY	Background: Although previous meta-analyses have examined effects of antidepressants, psychotherapy, and alternative therapies for depression, the efficacy of these treatments alone and in combination has not been systematically compared. We hypothesized that the differences between approved depression treatments and controls would be small. Methods and Findings: The authors first reviewed data from Food and Drug Administration Summary Basis of Approval reports of 62 pivotal antidepressant trials consisting of data from 13,802 depressed patients. This was followed by a systematic review of data from 115 published trials evaluating efficacy of psychotherapies and alternative therapies for depression. The published depression trials consisted of 10,310 depressed patients. We assessed the percentage symptom reduction experienced by the patients based on treatment assignment. Overall, antidepressants led to greater symptom reduction compared to placebo among both unpublished FDA data and published trials (F = 38.5, df = 239, p<0.001). In the published trials we noted that the magnitude of symptom reduction with active depression treatments compared to controls was significantly larger when raters evaluating treatment effects were un-blinded compared to the trials with blinded raters (F = 2.17, df = 313, p<0.05). In the blinded trials, the combination of antidepressants and psychotherapy provided a slight advantage over antidepressants (p = 0.027) and psychotherapy (p = 0.022) alone. The magnitude of symptom reduction was greater with psychotherapies compared to placebo (p = 0.019), treatment-as-usual (p = 0.012) and waiting-list (p<0.001). Differences were not seen with psychotherapy compared to antidepressants, alternative therapies or active intervention controls. Conclusions: In conclusion, the combination of psychotherapy and antidepressants for depression may provide a slight advantage whereas antidepressants alone and psychotherapy alone are not significantly different from alternative therapies or active intervention controls. These data suggest that type of treatment offered is less important than getting depressed patients involved in an active therapeutic program. Future research should consider whether certain patient profiles might justify a specific treatment modality.	[Khan, Arif; Faucett, James] NW Clin Res Ctr, Bellevue, WA USA; [Khan, Arif] Duke Univ, Sch Med, Dept Psychiat, Durham, NC USA; [Lichtenberg, Pesach] Hebrew Univ Jerusalem, Sch Med, Dept Psychiat, IL-91010 Jerusalem, Israel; [Lichtenberg, Pesach] Hebrew Univ Jerusalem, Herzog Hosp, Jerusalem, Israel; [Kirsch, Irving] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Program Placebo Studies, Boston, MA USA; [Kirsch, Irving] Univ Plymouth, Plymouth PL4 8AA, Devon, England; [Brown, Walter A.] Brown Univ, Dept Psychiat & Human Behav, Providence, RI 02912 USA; [Brown, Walter A.] Tufts Univ, Dept Psychiat, Boston, MA 02111 USA	Duke University; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Herzog Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Plymouth; Brown University; Tufts University	Khan, A (corresponding author), NW Clin Res Ctr, Bellevue, WA USA.	akhan@nwcrc.net	Kirsch, Irving/P-9316-2019					Allen JJB, 1998, PSYCHOL SCI, V9, P397, DOI 10.1111/1467-9280.00074; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425596; Coryel W, 2011, AM J PSYCHIAT, V168, P664, DOI 10.1176/appi.ajp.2011.11030510; Cuijpers P, 2010, PSYCHOL MED, V40, P211, DOI 10.1017/S0033291709006114; Cuijpers P, 2008, PSYCHOTHERAPY RANDOM; Cuijpers P, 2008, J CLIN PSYCHIAT, V69, P1675, DOI 10.4088/JCP.v69n1102; Cuijpers P, 2008, J CONSULT CLIN PSYCH, V76, P909, DOI 10.1037/a0013075; Cuijpers P, 2009, DEPRESS ANXIETY, V26, P279, DOI 10.1002/da.20519; FEIGHNER JP, 1972, ARCH GEN PSYCHIAT, V26, P57, DOI 10.1001/archpsyc.1972.01750190059011; Fournier JC, 2010, JAMA-J AM MED ASSOC, V303, P47, DOI 10.1001/jama.2009.1943; Frank JD, 1991, PERSUASION HEALING C; Khan A, 2004, AM J PSYCHIAT, V161, P2045, DOI 10.1176/appi.ajp.161.11.2045; Khan A, 2000, ARCH GEN PSYCHIAT, V57, P311, DOI 10.1001/archpsyc.57.4.311; Khan A, 2002, J CLIN PSYCHOPHARM, V22, P40, DOI 10.1097/00004714-200202000-00007; Khan A, 2001, INT J NEUROPSYCHOPH, V4, P113, DOI 10.1017/S1461145701002322; Khan Arif, 2007, Ann Clin Psychiatry, V19, P31, DOI 10.1080/10401230601163550; Kirsch I., 1998, PREVENTION TREATMENT, V1, DOI 10.1037/1522-3736.1.1.12a; Kushner SC, 2009, DEPRESS ANXIETY, V26, P666, DOI 10.1002/da.20566; Kwan BM, 2010, BEHAV RES THER, V48, P799, DOI 10.1016/j.brat.2010.04.003; Leichsenring F, 2001, CLIN PSYCHOL REV, V21, P401, DOI 10.1016/S0272-7358(99)00057-4; Lichtenberg P, 2010, PSYCHOTHER PSYCHOSOM, V79, P131, DOI 10.1159/000286957; Luborsky L, 2002, CLIN PSYCHOL-SCI PR, V9, P2, DOI 10.1093/clipsy/9.1.2; MARTINSEN EW, 1985, BRIT MED J, V291, P109, DOI 10.1136/bmj.291.6488.109; Mead GE, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004366.pub4; Melander H, 2003, BMJ-BRIT MED J, V326, P1171, DOI 10.1136/bmj.326.7400.1171; Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006; National Collaborating Centre for Mental Health The Royal College of Psychiatrists, 2010, DEPR NICE GUID TREAT; Nierenberg AA, 2010, CNS SPECTRUMS, V15, P146, DOI 10.1017/S1092852900027395; Pampallona S, 2004, ARCH GEN PSYCHIAT, V61, P714, DOI 10.1001/archpsyc.61.7.714; PRIOLEAU L, 1983, BEHAV BRAIN SCI, V6, P275, DOI 10.1017/S0140525X00015867; Raue PJ, 2009, PSYCHIAT SERV, V60, P337, DOI 10.1176/appi.ps.60.3.337; Rosenzweig S, 1936, AM J ORTHOPSYCHIAT, V6, P412, DOI 10.1111/j.1939-0025.1936.tb05248.x; Rutherford BR, 2009, PSYCHOTHER PSYCHOSOM, V78, P172, DOI 10.1159/000209348; Segal Z, 2002, J PSYCHIATR NEUROSCI, V27, P281; Sinyor M, 2010, J CLIN PSYCHIAT, V71, P270, DOI 10.4088/JCP.08r04516blu; Smith CA, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004046.pub3; SPITZER RL, 1978, ARCH GEN PSYCHIAT, V35, P773, DOI 10.1001/archpsyc.1978.01770300115013; Turner Erick H, 2008, N Engl J Med, V358, P252, DOI 10.1056/NEJMsa065779; Ullman D, 2010, HUFFINGTON POST HLTH; United States Department of Justice, 2004, FREED INF ACT GUID; Zimmerman M, 2002, AM J PSYCHIAT, V159, P469, DOI 10.1176/appi.ajp.159.3.469	42	151	153	1	51	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 30	2012	7	7							e41778	10.1371/journal.pone.0041778	http://dx.doi.org/10.1371/journal.pone.0041778			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	981EY	22860015	Green Submitted, Green Published, gold			2023-01-03	WOS:000306950900038
J	Munoz-Pareja, M; Leon-Munoz, LM; Guallar-Castillon, P; Graciani, A; Lopez-Garcia, E; Banegas, JR; Rodriguez-Artalejo, F				Munoz-Pareja, Maritza; Leon-Munoz, Luz M.; Guallar-Castillon, Pilar; Graciani, Auxiliadora; Lopez-Garcia, Esther; Banegas, Jose R.; Rodriguez-Artalejo, Fernando			The Diet of Diabetic Patients in Spain in 2008-2010: Accordance with the Main Dietary Recommendations-A Cross-Sectional Study	PLOS ONE			English	Article							MEDITERRANEAN DIET; US ADULTS; ADHERENCE; POPULATION; MELLITUS; COUNTRIES; HABITS; HEALTH; MEN	Background: No previous study has assessed the diet of the diabetic patients in the general population of an entire country in Europe. This study evaluates accordance of the diet of diabetic adults in Spain with nutritional recommendations of the European Association for the Study of Diabetes (EASD), American Diabetes Association (ADA), and the Mediterranean diet (MD). Methods and Findings: Cross-sectional study conducted in 2008-2010 among 12,948 persons representative of the population aged >= 18 years in Spain. Usual food consumption was assessed with a dietary history. EASD accordance was defined as >= 6 points on a score of 12 nutritional goals, ADA accordance as >= 3 points on a score of 6 goals, and MD accordance as >= 7 points on the Mediterranean Diet Adherence Screener. In the 609 diagnosed diabetic individuals, the diet was rich in saturated fat (11.2% of total energy), but trans fat intake was relatively low (1.1% energy) and monounsaturated fat intake was high (16.1% energy). Carbohydrate intake was relatively low (41.1% energy), but sugar intake was high (16.9% energy). Intake of cholesterol (322 mg/day) and sodium (3.1 g/day) was also high, while fiber intake was insufficient (23.8 g/day). EASD accordance was observed in 48.7% diabetic patients, ADA accordance in 46.3%, and MD accordance in 57.4%. The frequency of EASD, ADA and MD accordance was not statistically different between diagnosed and undiagnosed diabetic individuals. Conclusions: Only about half of diabetic patients in Spain have a diet that is consistent with the major dietary recommendations. The lack of dietary differences between diagnosed and undiagnosed diabetic individuals reflects deficiencies in diabetes management.	[Munoz-Pareja, Maritza; Leon-Munoz, Luz M.; Guallar-Castillon, Pilar; Graciani, Auxiliadora; Lopez-Garcia, Esther; Banegas, Jose R.; Rodriguez-Artalejo, Fernando] Univ Autonoma Madrid, CIBERESP, IdiPaz, Dept Med Prevent & Salud Publ, Madrid, Spain	Autonomous University of Madrid; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP	Munoz-Pareja, M (corresponding author), Univ Autonoma Madrid, CIBERESP, IdiPaz, Dept Med Prevent & Salud Publ, Madrid, Spain.	fernando.artalejo@uam.es	Guallar-Castillon, Pilar/F-1533-2016; León-Muñoz, Luz M/H-8275-2017; Lopez-Garcia, Esther/A-8894-2019; Graciani, Auxiliadora/D-8243-2013	Guallar-Castillon, Pilar/0000-0003-4759-6713; Leon-Munoz, Luz Maria/0000-0001-5447-5907; Graciani, Auxiliadora/0000-0002-6211-587X	Sanofi-Aventis; FIS [PI09/1626]; 'Catedra UAM de Epidemiologia y Control del Riesgo Cardiovascular'	Sanofi-Aventis(Sanofi-Aventis); FIS(Instituto de Salud Carlos III); 'Catedra UAM de Epidemiologia y Control del Riesgo Cardiovascular'	The ENRICA study is funded by Sanofi-Aventis. Additional funding is obtained from FIS grant PI09/1626 and from the 'Catedra UAM de Epidemiologia y Control del Riesgo Cardiovascular'. The ENRICA study is being run by an independent academic steering committee. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amer Diabet Associat, 2008, DIABETES CARE, V31, pS61, DOI 10.2337/dc08-S061; [Anonymous], 1997, Int J Epidemiol, V26 Suppl 1, pS91; [Anonymous], 2012, DIABETES CARE, V35, pS11, DOI [10.2337/dc35-S011, 10.2337/dc12-s004, 10.2337/dc12-s011]; [Anonymous], 1997, Int J Epidemiol, V26 Suppl 1, pS100; [Anonymous], 2009, STATA SURVEY DATA RE; Aromaa A, 2003, EUR J PUBLIC HEALTH, V13, P67, DOI 10.1093/eurpub/13.suppl_1.67; Banegas JR, 2002, J HYPERTENS, V20, P2157, DOI 10.1097/00004872-200211000-00014; *CAN DIAB ASS, 2008, CAN J DIABETES S1, V32, pS40; Connor H, 2003, DIABETIC MED, V20, P786, DOI 10.1046/j.1464-5491.2003.01104.x; Diez-Espino J, 2011, ANN NUTR METAB, V58, P74, DOI 10.1159/000324718; Eilat-Adar S, 2008, J NUTR, V138, P1699, DOI 10.1093/jn/138.9.1699; Esposito K, 2009, DIABETIC MED, V26, P900, DOI 10.1111/j.1464-5491.2009.02798.x; Esposito K, 2011, METAB SYNDR RELAT D, V9, P1, DOI 10.1089/met.2010.0031; Esposito K, 2010, DIABETES RES CLIN PR, V89, P97, DOI 10.1016/j.diabres.2010.04.019; Estruch R, 2006, ANN INTERN MED, V145, P1, DOI 10.7326/0003-4819-145-1-200607040-00004; Garcia-Closas R, 2006, PUBLIC HEALTH NUTR, V9, P53, DOI 10.1079/PHN2005757; Guallar-Castillon P, 2012, NUTR METAB CARDIOVAS, V22, P192, DOI 10.1016/j.numecd.2010.06.004; Gutierrez-Fisac JL, 2012, OBES REV, V13, P388, DOI 10.1111/j.1467-789X.2011.00964.x; Helmer C, 2008, BRIT J NUTR, V99, P632, DOI 10.1017/S0007114507812050; Mann JI, 2004, NUTR METAB CARDIOVAS, V14, P373, DOI 10.1016/S0939-4753(04)80028-0; Manzano P, 2006, J DIABETES COMPLICAT, V20, P361, DOI 10.1016/j.jdiacomp.2005.09.003; Manzano P, 2004, DIABETES CARE, V27, P984, DOI 10.2337/diacare.27.4.984; Mellen PB, 2008, ARCH INTERN MED, V168, P308, DOI 10.1001/archinternmed.2007.119; Nothlings U, 2011, EUR J CLIN NUTR, V65, P635, DOI 10.1038/ejcn.2011.11; Ortega RM, 2005, BR J NUTR, V105, P787; Pols MA, 1997, INT J EPIDEMIOL, V26, pS181, DOI 10.1093/ije/26.suppl_1.S181; Resnick HE, 2006, DIABETES CARE, V29, P531, DOI 10.2337/diacare.29.03.06.dc05-1254; Rivellese AA, 2008, EUR J CLIN NUTR, V62, P660, DOI 10.1038/sj.ejcn.1602755; Rodriguez-Artalejo F, 2011, REV ESP CARDIOL, V64, P876, DOI 10.1016/j.recesp.2011.05.019; Salas-Salvado J, 2011, DIABETES CARE, V34, P14, DOI 10.2337/dc10-1288; Sayon-Orea C, 2011, NUTR METAB CARDIOVAS; Schroder H, 2011, J NUTR, V141, P1140, DOI 10.3945/jn.110.135566; Serra-Majem L, 2007, PUBLIC HEALTH NUTR, V10, P1406, DOI 10.1017/S1368980007001012; Thanopoulou A, 2004, DIABETOLOGIA, V47, P367, DOI 10.1007/s00125-003-1316-0; Toeller M, 1996, DIABETOLOGIA, V39, P929; Tur JA, 2004, BRIT J NUTR, V92, P341, DOI 10.1079/BJN20041209; United States Departament of Agriculture, 2012, WHAT WE EAT AM; Varela-Moreiras G, 2010, EUR J CLIN NUTR, V64, pS37, DOI 10.1038/ejcn.2010.208; Virtanen SM, 2000, EUR J CLIN NUTR, V54, P181, DOI 10.1038/sj.ejcn.1600916; Willett W., 1998, NUTR EPIDEMIOLOGY	40	25	27	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2012	7	6							e39454	10.1371/journal.pone.0039454	http://dx.doi.org/10.1371/journal.pone.0039454			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	964XV	22745757	Green Published, Green Submitted, gold			2023-01-03	WOS:000305730900062
J	Wali, RK; Kunte, DP; De La Cruz, M; Tiwari, AK; Brasky, J; Weber, CR; Gibson, TP; Patel, A; Savkovic, SD; Brockstein, BE; Roy, HK				Wali, Ramesh K.; Kunte, Dhananjay P.; De La Cruz, Mart; Tiwari, Ashish K.; Brasky, Jeffrey; Weber, Christopher R.; Gibson, Tina P.; Patel, Amir; Savkovic, Suzana D.; Brockstein, Bruce E.; Roy, Hemant K.			Topical Polyethylene Glycol as a Novel Chemopreventive Agent for Oral Cancer via Targeting of Epidermal Growth Factor Response	PLOS ONE			English	Article							SQUAMOUS-CELL CARCINOMA; FACTOR RECEPTOR EXPRESSION; TRANS-RETINOIC ACID; COLON CARCINOGENESIS; MOLECULAR-BIOLOGY; HIGH-RISK; PHASE-II; HEAD; TRIAL; INHIBITION	Head and neck squamous cell carcinoma (HNSCC) is a major cause of morbidity and mortality underscoring the need for safe and effective chemopreventive strategies. Targeting epidermal growth factor receptor (EGFR) is attractive in that it is an early critical event in HNSCC pathogenesis. However, current agents lack efficacy or have unacceptable toxicity. Several groups have demonstrated that the over-the-counter medication, polyethylene glycol (PEG) has remarkable chemopreventive efficacy against colon carcinogenesis. Importantly, we reported that this effect is mediated through EGFR internalization/degradation. In the current study, we investigated the chemopreventive efficacy of this agent against HNSCC, using both the well validated animal model 4-NQO (4-nitroquinoline 1-oxide) rat model and cell culture with the human HNSCC cell line SCC-25. We demonstrated that daily topical application of 10% PEG-8000 in the oral cavity (tongue and cavity wall) post 4NQO initiation resulted in a significant reduction in tumor burden (both, tumor size and tumors/tumor bearing rat) without any evidence of toxicity. Immunohistochemical studies depicted decreased proliferation (number of Ki67-positive cells) and reduced expression of EGFR and its downstream effectors cyclin D1 in the tongue mucosa of 4NQO-rats treated with PEG. We showed that EGFR was also markedly downregulated in SCC-25 cells by PEG-8000 with a concomitant induction of G1-S phase cell-cycle arrest, which was potentially mediated through upregulated p21(cip1/waf1). In conclusion, we demonstrate, for the first time, that PEG has promising efficacy and safety as a chemopreventive efficacy against oral carcinogenesis.	[Wali, Ramesh K.; Kunte, Dhananjay P.; De La Cruz, Mart; Tiwari, Ashish K.; Brasky, Jeffrey; Gibson, Tina P.; Patel, Amir; Savkovic, Suzana D.; Brockstein, Bruce E.; Roy, Hemant K.] NorthShore Univ Healthsyst, Dept Med, Evanston, IL USA; [Weber, Christopher R.] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	NorthShore University Health System; University of Chicago	Wali, RK (corresponding author), NorthShore Univ Healthsyst, Dept Med, Evanston, IL USA.	rwali@northshore.org	Roy, Hemant/AAC-9096-2020	Weber, Christopher/0000-0002-2117-3184	National Institute of Health [U01CA111257, R21CA141112, 1R21CA156944-01, RO3CA139528, RO1CA156186]; NATIONAL CANCER INSTITUTE [R03CA139528, U01CA111257, R21CA141112, R21CA156944, R01CA156186] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funding provided by National Institute of Health U01CA111257, R21CA141112, 1R21CA156944-01, RO3CA139528, RO1CA156186. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrawal N, 2011, SCIENCE; Benchekroun MT, 2010, CANCER PREV RES, V3, P800, DOI 10.1158/1940-6207.CAPR-09-0163; Chang SS, 2008, J SURG ONCOL, V97, P640, DOI 10.1002/jso.21023; Cheng AL, 2001, ANTICANCER RES, V21, P2895; Choi Y, 2003, INT J CANCER, V107, P145, DOI 10.1002/ijc.11354; Corpet DE, 2003, CANCER EPIDEM BIOMAR, V12, P391; Corpet DE, 1999, CARCINOGENESIS, V20, P915, DOI 10.1093/carcin/20.5.915; Corpet DE, 2000, CANCER RES, V60, P3160; Dannenberg AJ, 2001, ANN NY ACAD SCI, V952, P109, DOI 10.1111/j.1749-6632.2001.tb02731.x; Dorval E, 2006, GASTROEN CLIN BIOL, V30, P1196, DOI 10.1016/S0399-8320(06)73511-4; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Gu XB, 2008, CLIN CANCER RES, V14, P1840, DOI 10.1158/1078-0432.CCR-07-1811; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kalish LH, 2004, CLIN CANCER RES, V10, P7764, DOI 10.1158/1078-0432.CCR-04-0012; Lee JJ, 2000, CLIN CANCER RES, V6, P1702; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Long NK, 2007, ONCOL REP, V17, P879; Mallery SR, 2008, CANCER RES, V68, P4945, DOI 10.1158/0008-5472.CAN-08-0568; Mulshine JL, 2004, CLIN CANCER RES, V10, P1565, DOI 10.1158/1078-0432.CCR-1020-3; Napier SS, 2008, J ORAL PATHOL MED, V37, P1, DOI 10.1111/j.1600-0714.2007.00579.x; Papaclimitrakopoulou VA, 2008, CLIN CANCER RES, V14, P2095, DOI 10.1158/1078-0432.CCR-07-4024; Papadimitrakopoulou VA, 2009, J CLIN ONCOL, V27, P599, DOI 10.1200/JCO.2008.17.1850; Park K, 2005, J CONTROL RELEASE, V104, P167, DOI 10.1016/j.jconrel.2005.01.013; Parnaud G, 2001, INT J CANCER, V92, P63, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1158>3.3.CO;2-#; Perez-Ordonez B, 2006, J CLIN PATHOL, V59, P445, DOI 10.1136/jcp.2003.007641; Poeta ML, 2007, NEW ENGL J MED, V357, P2552, DOI 10.1056/NEJMoa073770; Putti TC, 2002, HISTOPATHOLOGY, V41, P144, DOI 10.1046/j.1365-2559.2002.01436.x; Roesch-Ely M, 2010, J PATHOL, V221, P462, DOI 10.1002/path.2726; Rosin MP, 2010, CANCER PREV RES, V3, P797, DOI 10.1158/1940-6207.CAPR-10-0114; Roy HK, 2006, MOL CANCER THER, V5, P2060, DOI 10.1158/1535-7163.MCT-06-0054; Roy HK, 2011, INT J ONCOL, V38, P529, DOI 10.3892/ijo.2010.875; Roy HK, 2004, CANCER LETT, V215, P35, DOI 10.1016/j.canlet.2004.05.012; SHIN DM, 1994, CANCER RES, V54, P3153; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Tanaka T, 2011, PATHOLOG RES INT; Tang XH, 2004, CLIN CANCER RES, V10, P301, DOI 10.1158/1078-0432.CCR-0999-3; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Tsao AS, 2009, CANCER PREV RES, V2, P931, DOI 10.1158/1940-6207.CAPR-09-0121; Wali RK, 2008, MOL CANCER THER, V7, P3103, DOI 10.1158/1535-7163.MCT-08-0434	41	12	12	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2012	7	6							e38047	10.1371/journal.pone.0038047	http://dx.doi.org/10.1371/journal.pone.0038047			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UU	22675506	Green Published, Green Submitted, gold			2023-01-03	WOS:000305341700035
J	Myles, PR; Nguyen-Van-Tam, JS; Lim, WS; Nicholson, KG; Brett, SJ; Enstone, JE; McMenamin, J; Openshaw, PJM; Read, RC; Taylor, BL; Bannister, B; Semple, MG				Myles, Puja R.; Nguyen-Van-Tam, Jonathan S.; Lim, Wei Shen; Nicholson, Karl G.; Brett, Stephen J.; Enstone, Joanne E.; McMenamin, James; Openshaw, Peter J. M.; Read, Robert C.; Taylor, Bruce L.; Bannister, Barbara; Semple, Malcolm G.			Comparison of CATs, CURB-65 and PMEWS as Triage Tools in Pandemic Influenza Admissions to UK Hospitals: Case Control Analysis Using Retrospective Data	PLOS ONE			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; PREDICTING MORTALITY; SEVERITY; METAANALYSIS	Triage tools have an important role in pandemics to identify those most likely to benefit from higher levels of care. We compared Community Assessment Tools (CATs), the CURB-65 score, and the Pandemic Medical Early Warning Score (PMEWS); to predict higher levels of care (high dependency - Level 2 or intensive care - Level 3) and/or death in patients at or shortly after admission to hospital with A/H1N1 2009 pandemic influenza. This was a case-control analysis using retrospectively collected data from the FLU-CIN cohort (1040 adults, 480 children) with PCR-confirmed A/H1N1 2009 influenza. Area under receiver operator curves (AUROC), sensitivity, specificity, positive predictive values and negative predictive values were calculated. CATs best predicted Level 2/3 admissions in both adults [AUROC (95% CI): CATs 0.77 (0.73, 0.80); CURB-65 0.68 (0.64, 0.72); PMEWS 0.68 (0.64, 0.73), p<0.001] and children [AUROC: CATs 0.74 (0.68, 0.80); CURB-65 0.52 (0.46, 0.59); PMEWS 0.69 (0.62, 0.75), p<0.001]. CURB-65 and CATs were similar in predicting death in adults with both performing better than PMEWS; and CATs best predicted death in children. CATs were the best predictor of Level 2/3 care and/or death for both adults and children. CATs are potentially useful triage tools for predicting need for higher levels of care and/or mortality in patients of all ages.	[Myles, Puja R.; Nguyen-Van-Tam, Jonathan S.; Enstone, Joanne E.] Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham NG7 2RD, England; [Lim, Wei Shen] Nottingham Univ Hosp NHS Trust, Dept Resp Med, Nottingham, England; [Nicholson, Karl G.] Leicester Royal Infirm, Infect Dis Unit, Univ Hosp Leicester NHS Trust, Leicester, Leics, England; [Brett, Stephen J.] Imperial Coll Healthcare NHS Trust, Ctr Perioperat Med & Crit Care Res, London, England; [McMenamin, James] NHS Natl Serv Scotland, Hlth Protect Scotland, Glasgow, Lanark, Scotland; [Openshaw, Peter J. M.] Univ London Imperial Coll Sci Technol & Med, Ctr Resp Infect, Natl Heart & Lung Inst, London, England; [Read, Robert C.] Univ Sheffield, Royal Hallamshire Hosp, Dept Infect & Immun, Sheffield S10 2JF, S Yorkshire, England; [Taylor, Bruce L.] Portsmouth Hosp NHS Trust, Dept Crit Care, Portsmouth, Hants, England; [Bannister, Barbara] Royal Free Hampstead NHS Trust, Dept Infect Dis, London, England; [Semple, Malcolm G.] Univ Liverpool, Dept Womens & Childrens Hlth, Inst Translat Med, Liverpool L69 3BX, Merseyside, England	University of Nottingham; Nottingham University Hospital NHS Trust; University Hospitals of Leicester NHS Trust; University of Leicester; Imperial College London; NHS National Services Scotland; Imperial College London; University of Sheffield; Portsmouth Hospitals NHS Trust; University of London; University College London; University of Liverpool	Myles, PR (corresponding author), Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham NG7 2RD, England.	m.g.semple@liverpool.ac.uk	Zixuan, Huang/ABI-3557-2020; Nguyen-Van-Tam, Jonathan/I-2162-2019; Openshaw, Peter/AAL-9442-2020; Semple, Malcolm Gracie/A-8790-2008	Nguyen-Van-Tam, Jonathan/0000-0003-2579-4655; Openshaw, Peter/0000-0002-7220-2555; Semple, Malcolm Gracie/0000-0001-9700-0418; Myles, Puja/0000-0002-8976-890X; Read, Robert/0000-0002-4297-6728	Department of Health in England; Scottish Government Chief Medical Officer; Public Health Directorate; Roche; GlaxoSmithKline; Astra-Zeneca; F. Hoffmann-La Roche; Pfizer; UK NIHR Biomedical Research Centre; Medical Research Council [G1000758B, G1000758] Funding Source: researchfish; Asthma UK [S06/001] Funding Source: researchfish	Department of Health in England; Scottish Government Chief Medical Officer; Public Health Directorate; Roche(Roche Holding); GlaxoSmithKline(GlaxoSmithKline); Astra-Zeneca(AstraZeneca); F. Hoffmann-La Roche(Hoffmann-La Roche); Pfizer(Pfizer); UK NIHR Biomedical Research Centre(National Institute for Health Research (NIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK	The Department of Health in England was the main funder for FLU-CIN (United Kingdom Influenza Clinical Information Network). The Scottish Government Chief Medical Officer and Public Health Directorate supported the centre in Scotland. Chairmanship of the FLU-CIN Strategy Group (that includes MGS, BB, JSN-V-T, WSL, PJMO, RCR, BLT, SJB, JMcM, JEE and KGN as members) was provided by the Department of Health, England. The FLU-CIN Strategy Group had final responsibility for the interpretation of findings and decision to submit for publication. The other funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; PRM has received an unrestricted educational grant from Roche to conduct research in the area of pandemic influenza. However, the submitted paper is on work that is independent of this grant. JSN-V-T has received funding to attend influenza related meetings, lecture and consultancy fees and research funding from several influenza antiviral drug and vaccine manufacturers. All forms of personal remuneration ceased in September 2010, but research funding from GlaxoSmithKline, Astra-Zeneca and F. Hoffmann-La Roche is ongoing. He is a former employee of SmithKline Beecham plc. (now GlaxoSmithKline), Roche Products Ltd (UK) and Aventis-Pasteur MSD (now Sanofi-Pasteur MSD), all prior to 2005, with no remaining pecuniary interests by way of share holdings, share options and pension rights. WSL has received unrestricted research funding from Pfizer for an unrelated study of pneumococcal pneumonia. KGN, SJB, JEE, JMcM, PJMO, RCR, BLT, BB and MGS have declared that no competing interests exist. None of the research funding for this particular study was from the "several manufacturers" mentioned nor from GlaxoSmithKline, Astra-Zeneca and F. Hoffmann-La Roche. Dr. Malcolm Gracie Semple is a PLoS ONE Editorial Board member. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.; We gratefully acknowledge individuals who helped identify cases and collated clinical data: Alison Booth, Margaret Charlesworth, Sarah Rodenhurst, Angela Ballard and Alison Holmes at Imperial College Healthcare NHS Trust, London, UK; Sally Batham, Phayre Parkinson, Tracy Kumar, and Aiden Dunphy at the University Hospitals of Leicester NHS Trust, Leicester, UK; Anne Tunbridge, Patty Hempsall, Joyce Linskill, Aimee Turner, Sharon Grindle, Dawn Shevlin and Eric Moulds at Sheffield University Hospitals NHS Trust, Sheffield, UK; Elvina White, Elaine Scott, Jennifer Cater, Erica Sergi and Helen Hill at Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, UK; Deborah Fleetwood, Lorna Roche, Sarah Dyas, and Maria Boswell at the Royal Liverpool and Broadgreen University Hospital's Trust, Liverpool, UK; Gillian Vernon, Gillian Houghton, Heather Longworth and Angela Kerrigan at Liverpool Women's Hospital, Liverpool, UK; Sonia Greenwood, Gemma Thompson, Emily Jarvis, Charlotte Minter at the Nottingham University Hospitals NHS Trust, Nottingham, UK; Kristina Lum Kin, Jacqueline Daglish, Sam Hayton, and Gemma Slinn at Birmingham Children's Hospital, Birmingham, UK; Michelle Lacey, Kevin Rooney, Karen Duffy, Anne Gordon, Eleanor Anderson, Hilary Davison, William Carman, Mark Cotton, Arlene Reynolds, Heather Murdoch, Karen Voy, Rosie Hague and Ali McAllister for their contribution to FLU-CIN in Scotland. Brian Smyth and Cathriona Kearns from the National Public Health Agency, Northern Ireland for identifying cases and facilitating data collection; Teresa Cunningham at the Southern Trust and Leslie Boydell at the Belfast Trust for facilitating data collection. Alemayehu Amberbir, Safaa Al-Badri, Baraa Mahgoob and Nachi Arunachalam at the University of Nottingham for data entry; also Graham Watson for database development and support. We also thank Professor Dame Sally Davies and Professor Janet Darbyshire, who Co-Chaired the Influenza Clinical Information Network Strategy Group, and Professor Sir Gordon Duff, Co-Chair of the Scientific Advisory Group for Emergencies, for their support. SJB and PJMO wish to acknowledge the support of the UK NIHR Biomedical Research Centre scheme.	Akobeng AK, 2007, ACTA PAEDIATR, V96, P644, DOI 10.1111/j.1651-2227.2006.00178.x; *BRIT THOR SOC, 2004, GUID MAN COMM ACQ PN; Challen K, 2007, CRIT CARE, V11, DOI 10.1186/cc5732; Challen K, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-33; Chalmers JD, 2010, THORAX, V65, P878, DOI 10.1136/thx.2009.133280; Department of Health, 2009, PAND FLU MAN DEM CAP; Department of Health & NHS, 2009, 12368 NHS COI DEP HL; Donders ART, 2006, J CLIN EPIDEMIOL, V59, P1087, DOI 10.1016/j.jclinepi.2006.01.014; Goodacre S, 2010, HEALTH TECHNOL ASSES, V14, P173, DOI 10.3310/hta14460-03; Health Protection Agency, 2011, SURV INFL OTH RESP V; Lim WS, 2003, THORAX, V58, P377, DOI 10.1136/thorax.58.5.377; Loke YK, 2010, THORAX, V65, P884, DOI 10.1136/thx.2009.134072; Mulrennan S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012849; Myles PR, 2012, THORAX, V67, P709, DOI 10.1136/thoraxjnl-2011-200266; Nguyen-Van-Tam JS, 2010, THORAX, V65, P645, DOI 10.1136/thx.2010.135210; Simon R, 2010, PERS MED, V7, P33, DOI 10.2217/PME.09.49; ZWEIG MH, 1993, CLIN CHEM, V39, P561	17	10	10	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 3	2012	7	4							e34428	10.1371/journal.pone.0034428	http://dx.doi.org/10.1371/journal.pone.0034428			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	952PZ	22509303	gold, Green Accepted, Green Submitted, Green Published			2023-01-03	WOS:000304805900031
J	Fergusson, DA; Hebert, P; Hogan, DL; LeBel, L; Rouvinez-Bouali, N; Smyth, JA; Sankaran, K; Tinmouth, A; Blajchman, MA; Kovacs, L; Lachance, C; Lee, S; Walker, CR; Hutton, B; Ducharme, R; Balchin, K; Ramsay, T; Ford, JC; Kakadekar, A; Ramesh, K; Shapiro, S				Fergusson, Dean A.; Hebert, Paul; Hogan, Debora L.; LeBel, Louise; Rouvinez-Bouali, Nicole; Smyth, John A.; Sankaran, Koravangattu; Tinmouth, Alan; Blajchman, Morris A.; Kovacs, Lajos; Lachance, Christian; Lee, Shoo; Walker, C. Robin; Hutton, Brian; Ducharme, Robin; Balchin, Katelyn; Ramsay, Tim; Ford, Jason C.; Kakadekar, Ashok; Ramesh, Kuppuchipalayam; Shapiro, Stan			Effect of Fresh Red Blood Cell Transfusions on Clinical Outcomes in Premature, Very Low-Birth-Weight Infants The ARIPI Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICALLY-ILL; DONOR EXPOSURE; CARDIAC-SURGERY; STORAGE LESION; NECROTIZING ENTEROCOLITIS; NEONATAL TRANSFUSIONS; LENGTH; AGE; ASSOCIATION; MORTALITY	Context Even though red blood cells (RBCs) are lifesaving in neonatal intensive care, transfusing older RBCs may result in higher rates of organ dysfunction, nosocomial infection, and length of hospital stay. Objective To determine if RBCs stored for 7 days or less compared with usual standards decreased rates of major nosocomial infection and organ dysfunction in neonatal intensive care unit patients requiring at least 1 RBC transfusion. Design, Setting, and Participants Double-blind, randomized controlled trial in 377 premature infants with birth weights less than 1250 g admitted to 6 Canadian tertiary neonatal intensive care units between May 2006 and June 2011. Intervention Patients were randomly assigned to receive transfusion of RBCs stored 7 days or less (n=188) vs standard-issue RBCs in accordance with standard blood bank practice (n=189). Main Outcome Measures The primary outcome was a composite measure of major neonatal morbidities, including necrotizing enterocolitis, retinopathy of prematurity, bronchopulmonary dysplasia, and intraventricular hemorrhage, as well as death. The primary outcome was measured within the entire period of neonatal intensive care unit stay up to 90 days after randomization. The rate of nosocomial infection was a secondary outcome. Results The mean age of transfused blood was 5.1 (SD, 2.0) days in the fresh RBC group and 14.6 (SD, 8.3) days in the standard group. Among neonates in the fresh RBC group, 99 (52.7%) had the primary outcome compared with 100 (52.9%) in the standard RBC group (relative risk, 1.00; 95% CI, 0.82-1.21). The rate of clinically suspected infection in the fresh RBC group was 77.7% (n=146) compared with 77.2% (n=146) in the standard RBC group (relative risk, 1.01; 95% CI, 0.90-1.12), and the rate of positive cultures was 67.5% (n=127) in the fresh RBC group compared with 64.0% (n=121) in the standard RBC group (relative risk, 1.06; 95% CI, 0.91-1.22). Conclusion In this trial, the use of fresh RBCs compared with standard blood bank practice did not improve outcomes in premature, very low-birth-weight infants requiring a transfusion.	[Fergusson, Dean A.; Hebert, Paul; Hogan, Debora L.; LeBel, Louise; Tinmouth, Alan; Hutton, Brian; Ducharme, Robin; Balchin, Katelyn; Ramsay, Tim] Ottawa Hosp, Res Inst, Clin Epidemiol Program, Ottawa, ON K1H 8L6, Canada; [Fergusson, Dean A.; Hebert, Paul; Rouvinez-Bouali, Nicole; Tinmouth, Alan] Univ Ottawa, Dept Med, Ottawa, ON, Canada; [Hogan, Debora L.; Rouvinez-Bouali, Nicole] Childrens Hosp Eastern Ontario, Ottawa, ON K1H 8L1, Canada; [Hutton, Brian; Ducharme, Robin] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada; [Smyth, John A.; Ramesh, Kuppuchipalayam] Univ British Columbia, Dept Pediat, Childrens & Womens Hlth Ctr British Columbia, Vancouver, BC V6T 1W5, Canada; [Ford, Jason C.] Univ British Columbia, Div Hematopathol, Childrens & Womens Hlth Ctr British Columbia, Vancouver, BC V5Z 1M9, Canada; [Ford, Jason C.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; [Sankaran, Koravangattu; Kakadekar, Ashok] Royal Univ Hosp, Dept Neonatol, Saskatoon, SK S7N 0W8, Canada; [Sankaran, Koravangattu; Kakadekar, Ashok] Univ Saskatchewan, Saskatoon, SK, Canada; [Blajchman, Morris A.] McMaster Univ, Dept Pathol & Med, Hamilton, ON, Canada; [Kovacs, Lajos] McGill Univ, Jewish Gen Hosp, Dept Neonatol, Montreal, PQ H3T 1E2, Canada; [Kovacs, Lajos] McGill Univ, Dept Med, Montreal, PQ, Canada; [Shapiro, Stan] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada; [Lachance, Christian] CHU St Justine, Dept Neonatal, Montreal, PQ, Canada; [Lachance, Christian] Univ Montreal, Montreal, PQ, Canada; [Lee, Shoo] Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, MiCare Res Ctr,Inst Human Dev,Canadian Inst Hlth, Toronto, ON M5G 1X5, Canada; [Lee, Shoo] Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [Walker, C. Robin] Univ Western Ontario, St Josephs Healthcare, London, ON, Canada; [Walker, C. Robin] Univ Western Ontario, London Hlth Sci Ctr, London, ON, Canada; [Walker, C. Robin] Univ Western Ontario, Schulich Sch Med & Dent, London, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; BC Women's Hospital & Health Centre; University of British Columbia; BC Women's Hospital & Health Centre; University of British Columbia; University of British Columbia; University of Saskatchewan; University of Saskatchewan; McMaster University; McGill University; McGill University; McGill University; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); Western University (University of Western Ontario)	Fergusson, DA (corresponding author), Ottawa Hosp, Res Inst, Clin Epidemiol Program, Off L 1298A,501 Smyth Rd,Box 201-B, Ottawa, ON K1H 8L6, Canada.	dafer-gusson@ohri.ca	Rouvinez Bouali, Nicole/AGE-6603-2022	Fergusson, Dean/0000-0002-3389-2485; Ducharme, Robin/0000-0002-5665-7429; Ramsay, Tim/0000-0001-8478-8170; Hutton, Brian/0000-0001-5662-8647	Canadian Institutes for Health Research [MCT 75527]; center for ARIPI; Amgen; Novartis; GlaxoSmithKline; Canadian Blood Services	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); center for ARIPI; Amgen(Amgen); Novartis(Novartis); GlaxoSmithKline(GlaxoSmithKline); Canadian Blood Services	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Rouvinez-Bouali reports receiving a consulting fee from the central coordinating center for ARIPI for adjudication work. Dr Smyth reports receiving payment from Fillmore Riley LLP for expert opinion. Dr Tinmouth reports receiving consulting fees (paid to his institution) from Amgen, Novartis, and GlaxoSmithKline, consulting fees (paid to him) from Canadian Blood Services, and an unrestricted educational grant from Novartis to his institution. Dr Hutton reports receiving consulting fees from Amgen. No other disclosures were reported.; Funding for ARIPI was provided by the Canadian Institutes for Health Research (MCT 75527).	[Anonymous], 2002, PAEDIAT CHILD HLTH, V7, P553; BELL MJ, 1978, ANN SURG, V187, P1, DOI 10.1097/00000658-197801000-00001; Card R T, 1988, Transfus Med Rev, V2, P40, DOI 10.1016/S0887-7963(88)70030-9; ChinYee I, 1997, TRANSFUS SCI, V18, P447, DOI 10.1016/S0955-3886(97)00043-X; Claydon JE, 2007, J PERINATOL, V27, P448, DOI 10.1038/sj.jp.7211766; COOK S, 1993, TRANSFUSION, V33, P379, DOI 10.1046/j.1537-2995.1993.33593255596.x; Dani C, 2001, EARLY HUM DEV, V62, P57, DOI 10.1016/S0378-3782(01)00115-3; DENNIS RC, 1978, ANN THORAC SURG, V26, P17, DOI 10.1016/S0003-4975(10)63624-7; Donadee C, 2011, CIRCULATION, V124, P465, DOI 10.1161/CIRCULATIONAHA.110.008698; Eikelboom JW, 2010, AM HEART J, V159, P737, DOI 10.1016/j.ahj.2009.12.045; Fergusson D, 2003, JAMA-J AM MED ASSOC, V289, P1950, DOI 10.1001/jama.289.15.1950; Fergusson D, 2009, TRANSFUS MED REV, V23, P55, DOI 10.1016/j.tmrv.2008.09.005; Gauvin F, 2010, TRANSFUSION, V50, P1902, DOI 10.1111/j.1537-2995.2010.02661.x; Gruenwald CE, 2008, J THORAC CARDIOV SUR, V136, P1442, DOI 10.1016/j.jtcvs.2008.08.044; Hebert PC, 2005, ANESTH ANALG, V100, P1433, DOI 10.1213/01.ANE.0000148690.48803.27; Ho J, 2003, CRIT CARE MED, V31, pS687, DOI 10.1097/01.CCM.0000099349.17094.A3; Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723; Karam O, 2010, CRIT CARE, V14, DOI 10.1186/cc8953; Keller ME, 2002, J TRAUMA, V53, P1023, DOI 10.1097/00005373-200211000-00037; Koch CG, 2008, NEW ENGL J MED, V358, P1229, DOI 10.1056/NEJMoa070403; Leal-Noval SR, 2003, ANESTHESIOLOGY, V98, P815, DOI 10.1097/00000542-200304000-00005; LIU EA, 1994, J PEDIATR-US, V125, P92, DOI 10.1016/S0022-3476(94)70132-6; MARTIN CM, 1994, CLIN INVEST MED, V17, P124; MCGRADY GA, 1987, AM J EPIDEMIOL, V126, P1165, DOI 10.1093/oxfordjournals.aje.a114754; Offner PJ, 2002, ARCH SURG-CHICAGO, V137, P711, DOI 10.1001/archsurg.137.6.711; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; Pettila V, 2011, CRIT CARE, V15, DOI 10.1186/cc10142; Phelan HA, 2012, AM J SURG, V203, P198, DOI 10.1016/j.amjsurg.2011.05.012; Silliman CC, 1998, J CLIN INVEST, V101, P1458, DOI 10.1172/JCI1841; Silvers KM, 1998, ARCH DIS CHILD-FETAL, V78, pF214, DOI 10.1136/fn.78.3.F214; Strauss RG, 1996, TRANSFUSION, V36, P873, DOI 10.1046/j.1537-2995.1996.361097017172.x; Strauss RG, 2000, J PEDIATR-US, V136, P215, DOI 10.1016/S0022-3476(00)70104-1; Strauss RG, 2002, PEDIAT TRANSFUSION P, P129; Strauss RG, 2009, ROSSIS PRINCIPLES TR; Tinmouth A, 2001, TRANSFUS MED REV, V15, P91, DOI 10.1053/tmrv.2001.22613; Tinmouth A, 2006, TRANSFUSION, V46, P2014, DOI 10.1111/j.1537-2995.2006.01026.x; Vamvakas EC, 1999, TRANSFUSION, V39, P701, DOI 10.1046/j.1537-2995.1999.39070701.x; Walsh TS, 2004, CRIT CARE MED, V32, P364, DOI 10.1097/01.CCM.0000108878.23703.E0; WangRodriguez J, 1996, TRANSFUSION, V36, P64, DOI 10.1046/j.1537-2995.1996.36196190518.x; Weiskopf RB, 2012, ANESTH ANALG, V114, P511, DOI 10.1213/ANE.0b013e318241fcd5; WOLFE LC, 1985, TRANSFUSION, V25, P185, DOI 10.1046/j.1537-2995.1985.25385219897.x; Zallen G, 1999, AM J SURG, V178, P570, DOI 10.1016/S0002-9610(99)00239-1	42	285	295	2	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 10	2012	308	14					1443	1451		10.1001/2012.jama.11953	http://dx.doi.org/10.1001/2012.jama.11953			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	017GY	23045213				2023-01-03	WOS:000309579300023
J	Haas, DM; Caldwell, DM; Kirkpatrick, P; McIntosh, JJ; Welton, NJ				Haas, David M.; Caldwell, Deborah M.; Kirkpatrick, Page; McIntosh, Jennifer J.; Welton, Nicky J.			Tocolytic therapy for preterm delivery: systematic review and network meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OXYTOCIN ANTAGONIST ATOSIBAN; PLACEBO-CONTROLLED TRIAL; MIXED TREATMENT COMPARISONS; PATENT DUCTUS-ARTERIOSUS; MAGNESIUM-SULFATE; PREMATURE LABOR; DOUBLE-BLIND; RANDOMIZED-TRIAL; RITODRINE HYDROCHLORIDE; TRANSDERMAL NITROGLYCERIN	Objective To determine the most effective tocolytic agent at delaying delivery. Design Systematic review and network meta-analysis. Data sources Cochrane Central Register of Controlled Trials, Medline, Medline In-Process, Embase, and CINAHL up to 17 February 2012. Study selection Randomised controlled trials of tocolytic therapy in women at risk of preterm delivery. Data extraction At least two reviewers extracted data on study design, characteristics, number of participants, and outcomes reported (neonatal and maternal). A network meta-analysis was done using a random effects model with drug class effect. Two sensitivity analyses were carried out for the primary outcome; restricted to studies at low risk of bias and restricted to studies excluding women at high risk of preterm delivery (those with multiple gestation and ruptured membranes). Results Of the 3263 titles initially identified, 95 randomized controlled trials of tocolytic therapy were reviewed. Compared with placebo, the probability of delivery being delayed by 48 hours was highest with prostaglandin inhibitors (odds ratio 5.39, 95% credible interval 2.14 to 12.34) followed by magnesium sulfate (2.76, 1.58 to 4.94), calcium channel blockers (2.71, 1.17 to 5.91), beta mimetics (2.41, 1.27 to 4.55), and the oxytocin receptor blocker atosiban (2.02, 1.10 to 3.80). No class of tocolytic was significantly superior to placebo in reducing neonatal respiratory distress syndrome. Compared with placebo, side effects requiring a change of medication were significantly higher for beta mimetics (22.68, 7.51 to 73.67), magnesium sulfate (8.15, 2.47 to 27.70), and calcium channel blockers (3.80, 1.02 to 16.92). Prostaglandin inhibitors and calcium channel blockers were the tocolytics with the best probability of being ranked in the top three medication classes for the outcomes of 48 hour delay in delivery, respiratory distress syndrome, neonatal mortality, and maternal side effects (all cause). Conclusions Prostaglandin inhibitors and calcium channel blockers had the highest probability of delaying delivery and improving neonatal and maternal outcomes.	[Haas, David M.; Kirkpatrick, Page; McIntosh, Jennifer J.] Indiana Univ Sch Med, Dept Obstet & Gynecol, Indianapolis, IN USA; [Caldwell, Deborah M.; Welton, Nicky J.] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England	Indiana University System; Indiana University Bloomington; University of Bristol	Haas, DM (corresponding author), Wishard Mem Hosp, 1001 W 10th St,F5102, Indianapolis, IN 46202 USA.	dahaas@iupui.edu		Welton, Nicky/0000-0003-2198-3205; McIntosh, Jennifer/0000-0002-0299-9589; , Deborah/0000-0001-8014-7480	Indiana University-Purdue University-Indianapolis Signature Center grant; Therapeutics Research in Maternal and Child Health (PREGMED);  [NIH-NICHD K23HD055305]; MRC [G0800800, G0902118, G0802413] Funding Source: UKRI; Medical Research Council [G0802413, G0800800, G0902118] Funding Source: researchfish	Indiana University-Purdue University-Indianapolis Signature Center grant; Therapeutics Research in Maternal and Child Health (PREGMED); ; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This study was supported by grants: NIH-NICHD K23HD055305 (DMH) and the Indiana University-Purdue University-Indianapolis Signature Center grant to the Indiana University Center for Pharmacogenetics and Therapeutics Research in Maternal and Child Health (PREGMED). The funding agencies had no role in the study design, implementation, or preparation of results.	Adam G S, 1966, Aust N Z J Obstet Gynaecol, V6, P294, DOI 10.1111/j.1479-828X.1966.tb00392.x; Al-Omari WR, 2006, EUR J OBSTET GYN R B, V128, P129, DOI 10.1016/j.ejogrb.2005.12.010; Al-Qattan F, 2000, MED PRIN PRACT, V9, P164, DOI 10.1159/000054241; American College of Obstetricians and Gynecologists Committee on Practice Bulletins, 2003, OBSTET GYNECOL, V101, P1039; [Anonymous], 2003, COCHRANE DATABASE SY, DOI DOI 10.1002/14651858.CD002255; Anotayanonth S, 2004, Cochrane Database Syst Rev, pCD004352, DOI 10.1002/14651858.CD004352.pub2; BEALL MH, 1985, AM J OBSTET GYNECOL, V153, P854, DOI 10.1016/0002-9378(85)90689-1; BESINGER RE, 1991, AM J OBSTET GYNECOL, V164, P981, DOI 10.1016/0002-9378(91)90569-D; Bisits A, 2004, AM J OBSTET GYNECOL, V191, P683, DOI 10.1016/j.ajog.2004.02.019; Borna S, 2007, J OBSTET GYNAECOL RE, V33, P631, DOI 10.1111/j.1447-0756.2007.00623.x; Bradburn MJ, 2007, STAT MED, V26, P53, DOI 10.1002/sim.2528; Cabrol D, 2001, EUR J OBSTET GYN R B, V98, P177; Caldwell DM, 2007, LANCET, V369, P270, DOI 10.1016/S0140-6736(07)60138-X; Caldwell DM, 2010, J CLIN EPIDEMIOL, V63, P875, DOI 10.1016/j.jclinepi.2009.08.025; Caldwell DM, 2005, BMJ-BRIT MED J, V331, P897, DOI 10.1136/bmj.331.7521.897; Caldwell DM, 2008, USING MIXED TREATMEN; Cararach V, 2006, EUR J OBSTET GYN R B, V127, P204, DOI 10.1016/j.ejogrb.2005.10.020; CARITIS SN, 1984, AM J OBSTET GYNECOL, V150, P7, DOI 10.1016/S0002-9378(84)80101-5; Caritis SN, 2011, AM J OBSTET GYNECOL, V204, P95, DOI 10.1016/j.ajog.2010.11.041; CHAU AC, 1992, OBSTET GYNECOL, V80, P847; Chou R, 2006, LANCET, V368, P1503, DOI 10.1016/S0140-6736(06)69638-4; Cipriani A, 2009, LANCET, V373, P746, DOI 10.1016/S0140-6736(09)60046-5; Cooper NJ, 2009, STAT MED, V28, P1861, DOI 10.1002/sim.3594; COTTON DB, 1984, J REPROD MED, V29, P92; COX SM, 1990, AM J OBSTET GYNECOL, V163, P767, DOI 10.1016/0002-9378(90)91065-K; Crowther CA, 2006, COCHRANE DB SYST REV; CSAPO AI, 1977, AM J OBSTET GYNECOL, V129, P482, DOI 10.1016/0002-9378(77)90084-9; Dakin H, 2011, STAT MED; De Water MV, 2008, ACTA OBSTET GYN SCAN, V87, P340, DOI 10.1080/00016340801913189; Dempster AP, 1997, STAT COMPUT, V7, P247, DOI 10.1023/A:1018598421607; Dias S, 2011, 4 NICE DSU; Dias S, 2011, TECHNICAL SUPPORT DO; El-Sayed YY, 1999, OBSTET GYNECOL, V93, P79, DOI 10.1016/S0029-7844(98)00337-8; ESSED GGM, 1978, EUR J OBSTET GYN R B, V8, P341, DOI 10.1016/0028-2243(78)90046-1; [范玲 Fan Ling], 2003, [中国实用妇科与产科杂志, Chineses Journal of Practical Gynecology and Obstetrics], V19, P87; Fisk NM, 2001, ACTA OBSTET GYN SCAN, V80, P413; FLOYD RC, 1995, J MATERN-FETAL INVES, V5, P25; Garcia-Velasco JA, 1998, INT J GYNECOL OBSTET, V61, P239, DOI 10.1016/S0020-7292(98)00053-8; GLOCK JL, 1993, AM J OBSTET GYNECOL, V169, P960, DOI 10.1016/0002-9378(93)90035-H; Goldenberg RL, 2000, NEW ENGL J MED, V342, P1500, DOI 10.1056/NEJM200005183422007; Goldenberg RL, 2002, OBSTET GYNECOL, V100, P1020, DOI 10.1016/S0029-7844(02)02212-3; GOODWIN TM, 1994, AM J OBSTET GYNECOL, V170, P474, DOI 10.1016/S0002-9378(94)70214-4; Goodwin TM, 1996, OBSTET GYNECOL, V88, P331, DOI 10.1016/0029-7844(96)00200-1; Grignaffini A, 2007, Minerva Ginecol, V59, P481; Groom KM, 2005, BJOG-INT J OBSTET GY, V112, P725, DOI 10.1111/j.1471-0528.2005.00539.x; GUMMERUS M, 1983, GEBURTSH FRAUENHEILK, V43, P151, DOI 10.1055/s-2008-1037077; Haas DM, 2012, J MATERN-FETAL NEO M, V25, P1646, DOI 10.3109/14767058.2011.650249; Haas DM, 2009, OBSTET GYNECOL, V113, P585, DOI 10.1097/AOG.0b013e318199924a; Haghighi L, 1999, INT J GYNECOL OBSTET, V66, P297, DOI 10.1016/S0020-7292(99)00095-8; HAMILTON BE, 2010, NATL VITAL STAT REP, V58, P1; Hess LW, 1997, AM J OBSTET GYNECOL, V176, P1169; Higgins J.P.T, 2009, COCHRANE HDB SYSTEMA, P187; HOLLANDER DI, 1987, AM J OBSTET GYNECOL, V156, P631, DOI 10.1016/0002-9378(87)90066-4; Holleboom CAG, 1996, BRIT J OBSTET GYNAEC, V103, P695, DOI 10.1111/j.1471-0528.1996.tb09840.x; How HY, 2006, AM J OBSTET GYNECOL, V194, P976, DOI 10.1016/j.ajog.2006.02.030; Husslein P, 2007, J PERINAT MED, V35, P305, DOI 10.1515/JPM.2007.078; INGEMARSSON I, 1976, AM J OBSTET GYNECOL, V125, P520, DOI 10.1016/0002-9378(76)90369-0; Ioannidis JPA, 2009, CAN MED ASSOC J, V181, P488, DOI 10.1503/cmaj.081086; JANKY E, 1990, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V19, P478; Jannet D, 1997, EUR J OBSTET GYN R B, V73, P11, DOI 10.1016/S0301-2115(97)02701-2; Jimenez Aramayo J F, 1990, Ginecol Obstet Mex, V58, P265; Kashanian M, 2005, INT J GYNECOL OBSTET, V91, P10, DOI 10.1016/j.ijgo.2005.06.005; Kashanian M, 2011, INT J GYNECOL OBSTET, V113, P192, DOI 10.1016/j.ijgo.2010.12.019; King J, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001992.pub2; Koks CAM, 1998, EUR J OBSTET GYN R B, V77, P171, DOI 10.1016/S0301-2115(97)00255-8; Kramer WB, 1999, AM J OBSTET GYNECOL, V180, P396, DOI 10.1016/S0002-9378(99)70221-8; KUPFERMINC M, 1993, BRIT J OBSTET GYNAEC, V100, P1090, DOI 10.1111/j.1471-0528.1993.tb15171.x; KURKI T, 1991, OBSTET GYNECOL, V78, P1093; Laohapojanart Nisa, 2007, Journal of the Medical Association of Thailand, V90, P2461; Larmon JE, 1999, AM J OBSTET GYNECOL, V181, P1432, DOI 10.1016/S0002-9378(99)70388-1; LARSEN J F, 1980, British Journal of Obstetrics and Gynaecology, V87, P949, DOI 10.1111/j.1471-0528.1980.tb04457.x; LARSEN JF, 1986, OBSTET GYNECOL, V67, P607, DOI 10.1097/00006250-198605000-00001; LAUERSEN NH, 1977, AM J OBSTET GYNECOL, V127, P837, DOI 10.1016/0002-9378(77)90115-6; LEVENO KJ, 1986, LANCET, V1, P1293; Lin CH, 2009, J FORMOS MED ASSOC, V108, P493, DOI 10.1016/S0929-6646(09)60097-8; Lorzadeh N, 2007, J MED SCI, V7, P640; Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875; Lu G, 2007, STAT MED, V26, P3681, DOI 10.1002/sim.2831; Lu GB, 2006, J AM STAT ASSOC, V101, P447, DOI 10.1198/016214505000001302; Lumley T, 2002, STAT MED, V21, P2313, DOI 10.1002/sim.1201; Lyell DJ, 2007, OBSTET GYNECOL, V110, P61, DOI 10.1097/01.AOG.0000269048.06634.35; Ma L, 1992, Zhonghua Yi Xue Za Zhi, V72, P158; Ma L, 1992, ZHONGINTA YI XUE ZA, V72, P91; Macones GA, 1998, BRIT J OBSTET GYNAEC, V105, P541, DOI 10.1111/j.1471-0528.1998.tb10156.x; Maitra N, 2007, INT J GYNECOL OBSTET, V97, P147, DOI 10.1016/j.ijgo.2007.01.004; Mawaldi L, 2008, INT J GYNECOL OBSTET, V100, P65, DOI 10.1016/j.ijgo.2007.06.047; McWhorter J, 2004, OBSTET GYNECOL, V103, P923, DOI 10.1097/01.AOG.0000124784.48287.15; MERKATZ IR, 1980, OBSTET GYNECOL, V56, P7; MILLER JM, 1982, J REPROD MED, V27, P348; MITAL P, 1992, J ROY SOC HEALTH, V112, P214, DOI 10.1177/146642409211200502; Mittendorf R, 2002, AM J OBSTET GYNECOL, V186, P1111, DOI 10.1067/mob.2002.123544; MORALES WJ, 1989, OBSTET GYNECOL, V74, P567; MORALES WJ, 1993, AM J OBSTET GYNECOL, V169, P97, DOI 10.1016/0002-9378(93)90138-9; Motazedian S, 2010, ANN SAUDI MED, V30, P370, DOI 10.4103/0256-4947.67079; Moutquin JM, 2000, AM J OBSTET GYNECOL, V182, P1191, DOI 10.1067/mob.2000.104950; MOUTQUIN JM, 1992, NEW ENGL J MED, V327, P308; Nassar AH, 2009, AM J PERINAT, V26, P575, DOI 10.1055/s-0029-1220780; Neri I, 2009, AM J PERINAT, V26, P259, DOI 10.1055/s-0028-1103153; NIEBYL JR, 1980, AM J OBSTET GYNECOL, V136, P1014, DOI 10.1016/0002-9378(80)90629-8; NORTON ME, 1993, NEW ENGL J MED, V329, P1602, DOI 10.1056/NEJM199311253292202; Panter KR, 1999, BRIT J OBSTET GYNAEC, V106, P467, DOI 10.1111/j.1471-0528.1999.tb08300.x; Papatsonis D, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004452.pub2; Papatsonis DNM, 1997, OBSTET GYNECOL, V90, P230, DOI 10.1016/S0029-7844(97)00182-8; Parilla BV, 1997, AM J OBSTET GYNECOL, V176, P1166, DOI 10.1016/S0002-9378(97)70330-2; PECKHAM GJ, 1984, J PEDIATR-US, V105, P285, DOI 10.1016/S0022-3476(84)80134-1; Amorim MMR, 2009, REV BRAS GINECOL OBS, V31, P552, DOI 10.1590/S0100-72032009001100005; RASANEN J, 1995, AM J OBSTET GYNECOL, V173, P20, DOI 10.1016/0002-9378(95)90163-9; Raymajhi R, 2003, Kathmandu Univ Med J (KUMJ), V1, P85; READ MD, 1986, BRIT J OBSTET GYNAEC, V93, P933, DOI 10.1111/j.1471-0528.1986.tb08011.x; Roberts D, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004454.pub2; Romero R, 2000, AM J OBSTET GYNECOL, V182, P1173, DOI 10.1067/mob.2000.95834; Roy U K, 1993, J Indian Med Assoc, V91, P8; Sawdy RJ, 2003, AM J OBSTET GYNECOL, V188, P1046, DOI 10.1067/mob.2003.255; Schorr SJ, 1998, SOUTHERN MED J, V91, P1028, DOI 10.1097/00007611-199811000-00007; Sekar KC, 2008, J PERINATOL, V28, pS60, DOI 10.1038/jp.2008.52; Shim JY, 2006, BJOG-INT J OBSTET GY, V113, P1228, DOI 10.1111/j.1471-0528.2006.01053.x; Smith GN, 2007, AM J OBSTET GYNECOL, V196, P37, DOI 10.1016/j.ajog.2006.10.868; Song F, 2003, BMJ-BRIT MED J, V326, P472, DOI 10.1136/bmj.326.7387.472; SPEARING G, 1979, OBSTET GYNECOL, V53, P171; SPELLACY WN, 1979, OBSTET GYNECOL, V54, P220; Spiegelhalter D., 2003, WINBUGS USER MANUAL; Spiegelhalter DJ, 2002, J R STAT SOC B, V64, P583, DOI 10.1111/1467-9868.00353; STEER CM, 1977, AM J OBSTET GYNECOL, V129, P1; Stika CS, 2002, AM J OBSTET GYNECOL, V187, P653, DOI 10.1067/mob.2002.125281; Surichamorn Prayong, 2001, Journal of the Medical Association of Thailand, V84, P98; Sweeting MJ, 2004, STAT MED, V23, P1351, DOI 10.1002/sim.1761; Taherian AA, 2007, J RES MED SCI, V12, P136; TCHILINGUIRIAN NG, 1984, INT J GYNECOL OBSTET, V22, P117, DOI 10.1016/0020-7292(84)90024-9; Thornton S, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2009.01.015; Trabelsi Khaled, 2008, Tunis Med, V86, P43; Wang Hongjing, 2000, Journal of West China University of Medical Sciences, V31, P515; Weerakul W, 2002, INT J GYNECOL OBSTET, V76, P311, DOI 10.1016/S0020-7292(01)00547-1; WEINER CP, 1988, AM J OBSTET GYNECOL, V159, P216, DOI 10.1016/0002-9378(88)90524-8; WILKINS IA, 1988, AM J OBSTET GYNECOL, V159, P685, DOI 10.1016/S0002-9378(88)80035-8; Zhu B, 1996, Zhonghua Fu Chan Ke Za Zhi, V31, P721; ZUCKERMAN H, 1984, J PERINAT MED, V12, P25, DOI 10.1515/jpme.1984.12.1.25	137	211	219	1	30	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 9	2012	345								e6226	10.1136/bmj.e6226	http://dx.doi.org/10.1136/bmj.e6226			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	021TA	23048010	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000309907100001
J	Holmqvist, ME; Neovius, M; Eriksson, J; Mantel, A; Wallberg-Jonsson, S; Jacobsson, LTH; Askling, J				Holmqvist, Marie E.; Neovius, Martin; Eriksson, Jonas; Mantel, Angla; Wallberg-Jonsson, Solveig; Jacobsson, Lennart T. H.; Askling, Johan			Risk of Venous Thromboembolism in Patients With Rheumatoid Arthritis and Association With Disease Duration and Hospitalization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POPULATION	Context Recent reports suggest that rheumatoid arthritis (RA) may be a risk factor for venous thromboembolism (VTE), particularly in conjunction with hospitalization. Using hospitalization data to identify RA and VTE may identify patients when they are at elevated risk for other reasons, obscuring the incompletely understood underlying association between RA and VTE and leading to inappropriate institution or timing of interventions. Objective To estimate risks for VTE in patients with RA, including the relation of these risks to disease duration and hospitalization. Design, Setting, and Patients Prospective, population-based cohort study of 1 prevalent RA cohort (n = 37 856), 1 incident RA cohort (n = 7904), and matched general population comparison cohorts, all from Sweden, with follow-up from 1997 through 2010. Main Outcome Measure First-time VTE. Results Patients with prevalent RA were at greater risk of VTE than the general population (rate, 5.9 [95% CI, 5.1-6.6] vs 2.8 [95% CI, 2.6-3.1] per 1000 person-years (adjusted hazard ratio [HR], 2.0 [95% CI, 1.9-2.2]; P < .001). By the time of RA symptom onset, there was no statistically significant association between a history of VTE and RA (odds ratio, 1.2 [95% CI, 1.0-1.4]; P = .08; 150 events in the RA cohort vs 587 in the comparison cohort). Counting from RA diagnosis, an increased rate in the RA cohort vs the comparison cohort (3.8 [95% CI, 2.5-5.2] vs 2.4 [95% CI, 1.9-2.9] per 1000 person-years; HR, 1.6 [95% CI, 1.1-2.5]; P = .02) was detected within the first year and did not increase further during the first decade. Although rates for VTE following hospitalization were higher, the 1-year rate of VTE per 1000 person-years was not higher in the RA cohort than in the comparison cohort after hospital discharge (11.8 [95% CI, 8.6-15.1] vs 13.1 [11.3-14.8]; HR, 1.0 [95% CI, 0.7-1.4]; P = .90). The rates of VTE increased with age but were largely similar across sex and rheumatoid factor status, as were the HRs for VTE across age, sex, and rheumatoid factor status. Conclusions Compared with the general population, Swedish patients with RA had an elevated risk for VTE that was stable over the first 10 years after diagnosis. Although hospitalization was a risk factor for VTE the first year after discharge, the excess risk was not greater in patients with RA than in the general population. JAMA. 2012;308(13):1350-1356	[Holmqvist, Marie E.; Neovius, Martin; Eriksson, Jonas; Mantel, Angla; Askling, Johan] Karolinska Inst, Dept Med Solna, Clin Epidemiol Unit, SE-17176 Stockholm, Sweden; [Askling, Johan] Karolinska Inst, Dept Med Solna, Rheumatol Unit, SE-17176 Stockholm, Sweden; [Wallberg-Jonsson, Solveig] Univ Hosp, Inst Publ Hlth & Clin Med Rheumatol, Umea, Sweden; [Jacobsson, Lennart T. H.] Malmo Univ Hosp, Rheumatol Unit, Dept Med, Malmo, Sweden	Karolinska Institutet; Karolinska Institutet; Umea University; Lund University; Skane University Hospital	Holmqvist, ME (corresponding author), Karolinska Inst, Dept Med Solna, Clin Epidemiol Unit, T2 01, SE-17176 Stockholm, Sweden.	marie.holmqvist@ki.se		Holmqvist, Marie/0000-0001-8996-5260; Neovius, Martin/0000-0003-2300-3055	Schering-Plough; AstraZeneca; Novo Nordisk; Pfizer; Roche; Swedish Research Council; Swedish program on Chronic inflammation (Combine); Swedish Foundation for Strategic Research	Schering-Plough(Merck & CompanySchering Plough Corporation); AstraZeneca(AstraZeneca); Novo Nordisk(Novo Nordisk); Pfizer(Pfizer); Roche(Roche Holding); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish program on Chronic inflammation (Combine); Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research)	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Neovius reported participating in advisory boards for Pfizer (rheumatology) and Abbott (nonrheumatology) (unrelated to the current work); participating in research projects fully or partly funded by Schering-Plough, AstraZeneca, Novo Nordisk, Pfizer, and Roche (unrelated to the current work); and serving as a consultant (unrelated to rheumatology since 2008) to Pfizer, sanofi-aventis, and Abbott. Dr Wallberg-Jonsson reported serving as an invited speaker at a seminar organized by Roche (unrelated to the current work); contributing to patient information days organized by the Swedish Rheumatism Association (unrelated to the current work); receiving royalties for writing book chapters meant for education in rheumatology and cardiology; and receiving funding from Roche to travel to a conference in 2012. Dr Askling reported receiving grants within a public-private research consortium partly financed by Pfizer and AstraZeneca (unrelated to the current work); serving as an invited speaker at meeting organized by Merck on an unrelated topic; and serving as a member of a safety advisory committee at AstraZeneca.; This research was funded by the Swedish Research Council, Swedish program on Chronic inflammation (Combine), and Swedish Foundation for Strategic Research.	ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Bacani AK, 2012, ARTHRITIS RHEUM-US, V64, P53, DOI 10.1002/art.33322; Bremell T, 2009, SRF REUMA B J SWEDIS, V732, P19; Ludvigsson JF, 2009, EUR J EPIDEMIOL, V24, P659, DOI 10.1007/s10654-009-9350-y; Mameli A, 2009, CLIN EXP RHEUMATOL, V27, P846; Matta F, 2009, THROMB HAEMOSTASIS, V101, P134, DOI 10.1160/TH08-08-0551; McEntegart A, 2001, RHEUMATOLOGY, V40, P640, DOI 10.1093/rheumatology/40.6.640; Neovius M, 2011, ANN RHEUM DIS, V70, P624, DOI 10.1136/ard.2010.133371; Ramagopalan SV, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-1; Sanjeevi CB, 2012, LANCET, V379, P200, DOI 10.1016/S0140-6736(11)61510-9; Seriolo B, 1999, RHEUMATOLOGY, V38, P675, DOI 10.1093/rheumatology/38.7.675; Swedish National Board of Health and Wellfare (Social Styrelsen), NAT PAT REG SOC STYR; WALLBERGJONSSON S, 1993, CLIN RHEUMATOL, V12, P318, DOI 10.1007/BF02231572; World Health Organization (WHO), INT CLASS DIS IDC; Xu J, 2010, HAMOSTASEOLOGIE, V30, P5; Zoller B, 2012, LANCET, V379, P244, DOI 10.1016/S0140-6736(11)61306-8	16	97	98	1	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 3	2012	308	13					1350	1356		10.1001/2012.jama.11741	http://dx.doi.org/10.1001/2012.jama.11741			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	014IV	23032551				2023-01-03	WOS:000309369300029
J	Brewer, C				Brewer, Colin			Assisted dying: "all good doctors do it anyway"	BRITISH MEDICAL JOURNAL			English	Editorial Material									Stapleford Ctr, London SW1W 9NP, England		Brewer, C (corresponding author), Stapleford Ctr, London SW1W 9NP, England.	brewerismo@gmail.com							0	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 28	2012	345								e6536	10.1136/bmj.e6536	http://dx.doi.org/10.1136/bmj.e6536			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	014PD	23045318				2023-01-03	WOS:000309387100004
J	Zhang, H; Yu, CH; Jiang, YP; Peng, C; He, K; Tang, JY; Xin, HL				Zhang, Hong; Yu, Cheng-Hao; Jiang, Yi-Ping; Peng, Cheng; He, Kun; Tang, Jian-Yuan; Xin, Hai-Liang			Protective Effects of Polydatin from Polygonum cuspidatum against Carbon Tetrachloride-Induced Liver Injury in Mice	PLOS ONE			English	Article							NF-KAPPA-B; INDUCED OXIDATIVE STRESS; EXTRACT; RATS; ACTIVATION; FIBROSIS; REGENERATION; INFLAMMATION; HEPATITIS; CARCINOMA	Polydatin is one of main compounds in Polygonum cuspidatum, a plant with both medicinal and nutritional value. The possible hepatoprotective effects of polydatin on acute liver injury mice induced by carbon tetrachloride (CCl4) and the mechanisms involved were investigated. Intraperitoneal injection of CCl4 (50 ml/kg) resulted in a significant increase in the levels of serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) and hepatic malondialdehyde (MDA), also a marked enhancement in the expression of hepatic tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS) and nuclearfactor-kappa B (NF-kappa B). On the other hand, decreased glutathione (GSH) content and activities of glutathione transferase (GST), superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) were observed following CCl4 exposure. Nevertheless, all of these phenotypes were evidently reversed by preadministration of polydatin for 5 continuous days. The mRNA and protein expression levels of hepatic growth factor-beta1 (TGF-beta(1)) were enhanced further by polydatin. These results suggest that polydatin protects mice against CCl4-induced liver injury through antioxidant stress and antiinflammatory effects. Polydatin may be an effective hepatoprotective agent and a promising candidate for the treatment of oxidative stress-and inflammation-related diseases.	[Zhang, Hong; Yu, Cheng-Hao; Peng, Cheng] Chengdu Univ Tradit Chinese Med, Key Lab Standardizat Chinese Herbal Med, Minist Educ, Coll Pharm, Chengdu, Peoples R China; [Zhang, Hong; Jiang, Yi-Ping; He, Kun] Second Mil Med Univ, Sch Pharm, Dept Pharmacognosy, Shanghai, Peoples R China; [Tang, Jian-Yuan] State Food & Drug Adm, Ctr Drug Evaluat, Beijing, Peoples R China; [Xin, Hai-Liang] Second Mil Med Univ, Dept Tradit Chinese Med, Changhai Hosp, Shanghai, Peoples R China	Chengdu University of Traditional Chinese Medicine; Naval Medical University; Naval Medical University	Peng, C (corresponding author), Chengdu Univ Tradit Chinese Med, Key Lab Standardizat Chinese Herbal Med, Minist Educ, Coll Pharm, Chengdu, Peoples R China.	pengchengchengdu@126.com; tangjianyuan163@163.com; hailiangxin@163.com		Peng, Cheng/0000-0003-3303-906X; zhang, hong/0000-0002-6191-0046	National Natural Science Foundation of China [81173462]; Open Research Fund of State Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine Resources [2011012]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Open Research Fund of State Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine Resources	This work was supported by the National Natural Science Foundation of China (81173462) and the Open Research Fund of State Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine Resources (2011012). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Breitkopf K, 2006, Z GASTROENTEROL, V44, P57, DOI 10.1055/s-2005-858989; Campo GM, 2008, BRIT J PHARMACOL, V155, P945, DOI 10.1038/bjp.2008.338; Chang JS, 2005, ANTIVIR RES, V66, P29, DOI 10.1016/j.antiviral.2004.12.006; Du J, 2009, PHYTOMEDICINE, V16, P652, DOI 10.1016/j.phymed.2008.10.001; Fakurazi S, 2008, FOOD CHEM TOXICOL, V46, P2611, DOI 10.1016/j.fct.2008.04.018; Fei HongHua, 2008, Journal of Shandong University (Health Sciences), V46, P43; GOLDBERG DM, 1965, GASTROENTEROLOGY, V49, P256; Gopal N, 2008, FITOTERAPIA, V79, P24, DOI 10.1016/j.fitote.2007.07.006; Gross A, 2009, CHEM-BIOL INTERACT, V178, P56, DOI 10.1016/j.cbi.2008.09.025; He YD, 2012, BRIT J DERMATOL, V167, P941, DOI 10.1111/j.1365-2133.2012.10951.x; Huang B, 2010, FOOD CHEM, V120, P873, DOI 10.1016/j.foodchem.2009.11.020; Huang ZS, 1999, WORLD J GASTROENTERO, V5, P41; Ji H, 2012, BRAIN RES BULL, V87, P50, DOI 10.1016/j.brainresbull.2011.09.021; Jia XY, 2011, FOOD CHEM, V125, P673, DOI 10.1016/j.foodchem.2010.09.062; Kanzler S, 1999, AM J PHYSIOL-GASTR L, V276, pG1059, DOI 10.1152/ajpgi.1999.276.4.G1059; Kim HY, 2011, TOXICOLOGY, V282, P104, DOI 10.1016/j.tox.2011.01.017; Kim KW, 2007, VASC PHARMACOL, V47, P99, DOI 10.1016/j.vph.2007.04.007; Li L, 2013, EXP TOXICOL PATHOL, V65, P73, DOI 10.1016/j.etp.2011.06.003; Li RP, 2012, PHYTOMEDICINE, V19, P677, DOI 10.1016/j.phymed.2012.03.002; Liu HH, 2011, J CELL BIOCHEM, V112, P3695, DOI 10.1002/jcb.23303; Luedde T, 2011, NAT REV GASTRO HEPAT, V8, P108, DOI 10.1038/nrgastro.2010.213; Mehmetcik G, 2008, EXP TOXICOL PATHOL, V60, P475, DOI 10.1016/j.etp.2008.04.014; Miao Q, 2011, PHYTOMEDICINE, V19, P8, DOI 10.1016/j.phymed.2011.06.023; Michalopoulos GK, 2007, J CELL PHYSIOL, V213, P286, DOI 10.1002/jcp.21172; Pan YM, 2007, FOOD CHEM, V105, P1518, DOI 10.1016/j.foodchem.2007.05.039; Ray Gibanananda, 2002, Indian Journal of Experimental Biology, V40, P1213; Recknagel R.O., 2020, HEPATOTOXICOLOGY, P401; RECKNAGEL RO, 1989, PHARMACOL THERAPEUT, V43, P139, DOI 10.1016/0163-7258(89)90050-8; REJ R, 1978, CLIN CHEM, V24, P1971; Rosillo MA, 2011, BIOCHEM PHARMACOL, V82, P737, DOI 10.1016/j.bcp.2011.06.043; Shan B, 2008, FOOD CHEM, V109, P530, DOI 10.1016/j.foodchem.2007.12.064; Shu SY, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-31; Simpson KJ, 1997, J HEPATOL, V27, P1120, DOI 10.1016/S0168-8278(97)80160-2; Singh N, 2008, ENVIRON TOXICOL PHAR, V26, P241, DOI 10.1016/j.etap.2008.05.006; Srivastava A, 2010, FOOD CHEM, V118, P411, DOI 10.1016/j.foodchem.2009.05.014; Taniguchi M, 2004, LIFE SCI, V75, P1539, DOI 10.1016/j.lfs.2004.02.030; Tipoe GL, 2010, TOXICOLOGY, V273, P45, DOI 10.1016/j.tox.2010.04.014; Tung YT, 2009, FOOD CHEM TOXICOL, V47, P1385, DOI 10.1016/j.fct.2009.03.021; Venukumar M R, 2002, Indian J Clin Biochem, V17, P80, DOI 10.1007/BF02867976; Weerachayaphorn J, 2010, J ETHNOPHARMACOL, V129, P254, DOI 10.1016/j.jep.2010.03.026; WILLIAMS AT, 1990, SEMIN LIVER DIS, V10, P279, DOI 10.1055/s-2008-1040483; Wu JG, 2009, PHYTOMEDICINE, V16, P1033, DOI 10.1016/j.phymed.2009.04.005; Xiao J, 2012, J ETHNOPHARMACOL, V139, P462, DOI 10.1016/j.jep.2011.11.033; Xing WW, 2009, BIOMED PHARMACOTHER, V63, P457, DOI 10.1016/j.biopha.2008.06.035; Yang CT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021971; Yener Z, 2009, FOOD CHEM TOXICOL, V47, P418, DOI 10.1016/j.fct.2008.11.031; Zhang H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031157; Zhang RR, 2009, J ETHNOPHARMACOL, V126, P207, DOI 10.1016/j.jep.2009.08.044	48	78	86	0	43	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2012	7	9							e46574	10.1371/journal.pone.0046574	http://dx.doi.org/10.1371/journal.pone.0046574			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022PZ	23029551	Green Submitted, gold, Green Published			2023-01-03	WOS:000309973900185
J	Hernandez, JF; Mantel-Teeuwisse, AK; van Thiel, GJMW; Belitser, SV; Warmerdam, J; de Valk, V; Raaijmakers, JAM; Pieters, T				Hernandez, Juan Francisco; Mantel-Teeuwisse, Aukje K.; van Thiel, Ghislaine J. M. W.; Belitser, Svetlana V.; Warmerdam, Jan; de Valk, Vincent; Raaijmakers, Jan A. M.; Pieters, Toine			A 10-Year Analysis of the Effects of Media Coverage of Regulatory Warnings on Antidepressant Use in The Netherlands and UK	PLOS ONE			English	Article							SUICIDE RATES; RISK; IMPACT; SALES; PRESCRIPTIONS; DEPRESSION; PAROXETINE; PUBLICITY; PATTERNS; CHILDREN	Background: In 2003-2004 and 2007-2008, the regulatory banning of SSRI use in pediatrics and young adults due to concerns regarding suicidality risk coincided with negative media coverage. SSRI use trends were analyzed from 2000-2010 in the Netherlands (NL) and the UK, and whether trend changes might be associated with media coverage of regulatory warnings. Methods: Monthly SSRIs sales were presented as DDDs/1000 inhabitants/day. SSRI-use trends were studied using time-series segmented regression analyses. Timing of trend changes was compared with two periods of media coverage of warnings. Annual Dutch SSRI prescription data were analyzed by age group. Results: Trend changes in SSRI use largely corroborated with the periods of media coverage of warnings. British SSRI use declined from 3.9 to 0.7 DDDs/month (95%CI 3.3;4.5 & 0.5;0.9, respectively) before the first warning period (2003-2004). A small decrease of -0.6 DDDs/month (-1.2; -0.05) was observed in Dutch SSRI use shortly after 2003-2004. From 20072008, British SSRI use stabilized, whilst Dutch SSRI use diminished to -0.04 DDDs/month (-0.4;0.3). Stratified analyses showed a rapid decrease of -1.2 DDDs/month (-2.1;-1.7) in UK paroxetine use before 2003-2004, but only a minimal change in Dutch paroxetine use (-0.3 DDDs/month -0.8;0.2). Other SSRI use, especially (es) citalopram, increased during 2003-2004 in both countries. Significant reductions in Dutch paroxetine use were observed in pediatrics, adolescents, and young adults after 2003-2004. Conclusion: Changes in SSRI use (NL & UK) were associated with the timing of the combined effect of media coverage and regulatory warnings. Our long-term assessment illustrates that changes in SSRI use were temporal, drug-specific and more pronounced in pediatrics and young adults. The twofold increase in SSRI use over one decade indicates that regulatory warnings and media coverage may come and go, but they do not have a significant impact on the overall upward trend of SSRI use as a class in both countries.	[Hernandez, Juan Francisco; Mantel-Teeuwisse, Aukje K.; Belitser, Svetlana V.; Raaijmakers, Jan A. M.; Pieters, Toine] Univ Utrecht, Utrecht Inst Pharmaceut Sci UIPS, Dept Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands; [van Thiel, Ghislaine J. M. W.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Warmerdam, Jan] IMS Hlth, Capelle Aan Den Ijssel, Netherlands; [de Valk, Vincent] Healthcare Insurance Board CVZ, Genees En Hulpmiddelen Informatie Project GIP Dru, Diemen, Netherlands; [Raaijmakers, Jan A. M.] GlaxoSmithKline, External Sci Collaborat Europe, Zeist, Netherlands; [Pieters, Toine] Vrije Univ Amsterdam Med Ctr, EMGO, Amsterdam, Netherlands	Utrecht University; Utrecht University; Utrecht University Medical Center; GlaxoSmithKline; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Pieters, T (corresponding author), Univ Utrecht, Utrecht Inst Pharmaceut Sci UIPS, Dept Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands.	t.pieters@uu.nl	Van Thiel, Ghislaine/R-8977-2019; Mantel-Teeuwisse, Aukje/I-8902-2016	van Thiel, Ghislaine/0000-0003-1799-1894; Pieters, Toine/0000-0002-8156-8436	Dutch Top Institute Pharma [T6-202]; GlaxoSmithKline (GSK); Top Institute Pharma; Dutch Medicines Evaluation Board; Dutch Ministry of Health; Netherlands Organisation for Health Research and Development (ZonMW); Dutch Health Care Insurance Board (CVZ); Royal Dutch Pharmacists Association (KNMP); private-public funded Top Institute Pharma; EU Innovative Medicines Initiative (IMI); EU 7th Framework Program (FP7); Dutch Ministry of Health and industry; Pfizer	Dutch Top Institute Pharma; GlaxoSmithKline (GSK)(GlaxoSmithKline); Top Institute Pharma; Dutch Medicines Evaluation Board; Dutch Ministry of Health; Netherlands Organisation for Health Research and Development (ZonMW)(Netherlands Organization for Health Research and Development); Dutch Health Care Insurance Board (CVZ); Royal Dutch Pharmacists Association (KNMP); private-public funded Top Institute Pharma; EU Innovative Medicines Initiative (IMI); EU 7th Framework Program (FP7); Dutch Ministry of Health and industry; Pfizer(Pfizer)	This study was performed in the context of the Escher project (T6-202), a project of the Dutch Top Institute Pharma. The Division of Pharmacoepidemiology and Clinical Pharmacology, employing authors JFH, AKM, SVB, JAMR and TP, has received unrestricted funding for pharmacoepidemiological research from GlaxoSmithKline (GSK), the private-public funded Top Institute Pharma (www.tipharma.nl, includes co-funding from universities, government, and industry), the Dutch Medicines Evaluation Board, and the Dutch Ministry of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; JAMR is part-time professor at the Utrecht University and vice-president of external scientific collaborations for GSK in Europe, and holds stock in GSK. GSK was a co-funder for this study as part of the Dutch government-led research consortium TI-Pharma-Escher programme. The department of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, has received unrestricted research funding from the Netherlands Organisation for Health Research and Development (ZonMW), the Dutch Health Care Insurance Board (CVZ), the Royal Dutch Pharmacists Association (KNMP), the private-public funded Top Institute Pharma (www.tipharma.nl, includes co-funding from universities, government, and industry), the EU Innovative Medicines Initiative (IMI), EU 7th Framework Program (FP7), the Dutch Medicines Evaluation Board, the Dutch Ministry of Health and industry (including GlaxoSmithKline, Pfizer, and others). JW is director Healthcare Relations at IMS Health in the NL. VV is data manager at the GIP (Drug Information Project) in the NL. Paroxetine is a Glaxo Smith Kline product. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.	Archer DF, 2007, PHARMACOEPIDEM DR S, V16, P28, DOI 10.1002/pds.1342; Baldessarini RJ, 2007, HARVARD REV PSYCHIAT, V15, P133, DOI 10.1080/10673220701551102; BBC, 2001, ANT ADD WARN; BBC, 2002, PAN SECR SER; Boseley S, 2008, PROZAC USED 40M PEOP; Bramness JG, 2007, J AFFECT DISORDERS, V102, P1, DOI 10.1016/j.jad.2006.12.002; Brouneus F, 2005, EUR J CLIN PHARMACOL, V61, P285, DOI 10.1007/s00228-005-0914-9; CBO, 2010, RICHTL MULT RICHTL D; CBS, 2011, BEV; Check E, 2004, NATURE, V431, P122, DOI 10.1038/431122a; Check E, 2004, NATURE, V430, P954, DOI 10.1038/430954a; Cipriani A, 2009, LANCET, V373, P746, DOI 10.1016/S0140-6736(09)60046-5; CVZ, 2012, GIPEILINGEN; EMA, 2008, CHMP ASS REP ANT; EMA, 2005, EUR MED AG FIN REV A; *FDA, 2007, ANT US CHILDR AD AD; FDA, 2004, SUIC CHILDR AD BEING; Gardarsdottir H, 2006, PHARMACOEPIDEM DR S, V15, P338, DOI 10.1002/pds.1223; Geddes JR, 2003, LANCET, V361, P653, DOI 10.1016/S0140-6736(03)12599-8; Gibbons RD, 2007, AM J PSYCHIAT, V164, P1356, DOI 10.1176/appi.ajp.2007.07030454; Grunebaum MF, 2004, J CLIN PSYCHIAT, V65, P1456, DOI 10.4088/JCP.v65n1103; Guardian T, 2001, 4 PEOPL DEAD IS 4 TO; Hall WD, 2003, BRIT MED J, V326, P1008, DOI 10.1136/bmj.326.7397.1008; Healy D, 2006, PLOS MED, V3, P1478, DOI 10.1371/journal.pmed.0030372; Hernandez JF, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000290; Isacsson G, 2009, ACTA PSYCHIAT SCAND, V120, P37, DOI 10.1111/j.1600-0447.2009.01344.x; Kirsch I, 2008, PLOS MED, V5, P260, DOI 10.1371/journal.pmed.0050045; Korkeila J, 2007, J CLIN PSYCHIAT, V68, P505, DOI 10.4088/JCP.v68n0403; Libby AM, 2007, AM J PSYCHIAT, V164, P884, DOI 10.1176/appi.ajp.164.6.884; Libby AM, 2009, ARCH GEN PSYCHIAT, V66, P633, DOI 10.1001/archgenpsychiatry.2009.46; Liem TBY, 2010, EUR J CLIN MICROBIOL, V29, P1301, DOI 10.1007/s10096-010-0990-3; Martin RM, 2006, BRIT J CLIN PHARMACO, V61, P224, DOI 10.1111/j.1365-2125.2005.02527.x; McRae F, 2008, ANTIDEPRESSANTS TAKE; Mebane FE, 2005, PHARMACOEPIDEM DR S, V14, P297, DOI 10.1002/pds.993; Meijer WEE, 2004, EUR J CLIN PHARMACOL, V60, P57, DOI 10.1007/s00228-004-0726-3; MHRA, 2004, REP CSM EXP WORK GRO; Milane MS, 2006, PLOS MED, V3, P816, DOI 10.1371/journal.pmed.0030190; Nemeroff CB, 2007, ARCH GEN PSYCHIAT, V64, P466, DOI 10.1001/archpsyc.64.4.466; NHG, 2009, M44 NHG STAND DEPR S; NICE, 2009, NAT CLIN PRACT GUID; Olfson M, 2008, ARCH GEN PSYCHIAT, V65, P94, DOI 10.1001/archgenpsychiatry.2007.5; R Foundation for Statistical Computing, R PROJECT STAT COMPU; Reid S, 2010, BRIT MED J, P340; Reseland S, 2006, BRIT J PSYCHIAT, V188, P354, DOI 10.1192/bjp.188.4.354; Stolk P, 2008, VALUE HEALTH, V11, P989, DOI 10.1111/j.1524-4733.2008.00331.x; Tonks A, 2002, BRIT MED J, V324, P260, DOI 10.1136/bmj.324.7332.260; Turner EH, 2008, NEW ENGL J MED, V358, P252, DOI 10.1056/NEJMsa065779; Volkers AC, 2007, PHARMACOEPIDEM DR S, V16, P1054, DOI 10.1002/pds.1430; Wadman M, 2004, NATURE, V429, P589, DOI 10.1038/429589a; Wheeler BW, 2008, BMJ-BRIT MED J, V336, P542, DOI 10.1136/bmj.39462.375613.BE; WHO, ATC DDD IND 2011; Wijlaars LPMM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033181; Williams D, 2000, PHARMACOEPIDEM DR S, V9, P313, DOI 10.1002/1099-1557(200007/08)9:4<313::AID-PDS508>3.0.CO;2-F; World Health Organization (WHO), GUID ATC CLASS DDD A; Xianping G, 2002, SEGMENTAL SEMIMARKOV	55	22	22	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 20	2012	7	9							e45515	10.1371/journal.pone.0045515	http://dx.doi.org/10.1371/journal.pone.0045515			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014PT	23029065	Green Published, gold, Green Submitted			2023-01-03	WOS:000309388900067
J	Costantino, G; Ceriani, E; Rusconi, AM; Podda, GM; Montano, N; Duca, P; Cattaneo, M; Casazza, G				Costantino, Giorgio; Ceriani, Elisa; Rusconi, Anna Maria; Podda, Gian Marco; Montano, Nicola; Duca, Piergiorgio; Cattaneo, Marco; Casazza, Giovanni			Bleeding Risk during Treatment of Acute Thrombotic Events with Subcutaneous LMWH Compared to Intravenous Unfractionated Heparin; A Systematic Review	PLOS ONE			English	Review							MOLECULAR-WEIGHT HEPARIN; ACUTE CORONARY SYNDROMES; ACUTE MYOCARDIAL-INFARCTION; PULMONARY-EMBOLISM; CLINICAL-OUTCOMES; ANTITHROMBOTIC THERAPY; VENOUS THROMBOSIS; INITIAL TREATMENT; RANDOMIZED TRIAL; UNSTABLE ANGINA	Background: Low Molecular Weight Heparins (LMWH) are at least as effective antithrombotic drugs as Unfractionated Heparin (UFH). However, it is still unclear whether the safety profiles of LMWH and UFH differ. We performed a systematic review to compare the bleeding risk of fixed dose subcutaneous LMWH and adjusted dose UFH for treatment of venous thromboembolism (VTE) or acute coronary syndromes (ACS). Major bleeding was the primary end point. Methods: Electronic databases (MEDLINE, EMBASE, and the Cochrane Library) were searched up to May 2010 with no language restrictions. Randomized controlled trials in which subcutaneous LMWH were compared to intravenous UFH for the treatment of acute thrombotic events were selected. Two reviewers independently screened studies and extracted data on study design, study quality, incidence of major bleeding, patients' characteristics, type, dose and number of daily administrations of LMWH, co-treatments, study end points and efficacy outcome. Pooled odds ratios (OR) and 95% confidence intervals (CI) were calculated using the random effects model. Results: Twenty-seven studies were included. A total of 14,002 patients received UFH and 14,635 patients LMWH. Overall, no difference in major bleeding was observed between LMWH patients and UFH (OR = 0.79, 95% CI 0.60-1.04). In patients with VTE LMWH appeared safer than UFH, (OR = 0.68, 95% CI 0.47-1.00). Conclusion: The results of our systematic review suggest that the use of LMWH in the treatment of VTE might be associated with a reduction in major bleeding compared with UFH. The choice of which heparin to use to minimize bleeding risk must be based on the single patient, taking into account the bleeding profile of different heparins in different settings.	[Costantino, Giorgio; Ceriani, Elisa; Rusconi, Anna Maria; Montano, Nicola] Univ Milan, Osped L Sacco, Dipartimento Sci Clin L Sacco, Unita Operat Med Interna 2, Milan, Italy; [Podda, Gian Marco; Cattaneo, Marco; Casazza, Giovanni] Univ Milan, Unita Operat Med 3, Osped San Paolo, Dipartimento Med Chirurg & Odonotoiatria, Milan, Italy	University of Milan; Luigi Sacco Hospital; San Paolo-Polo Universitaria Hospital; University of Milan	Costantino, G (corresponding author), Univ Milan, Osped L Sacco, Dipartimento Sci Clin L Sacco, Unita Operat Med Interna 2, Milan, Italy.	giorgic@libero.it	Cattaneo, Marco/AAT-4080-2020; podda, Gianmarco/AAK-4498-2020; costantino, giorgio/AAC-6441-2022; Casazza, Giovanni/G-3661-2012; Duca, Piergiorgio/S-7525-2017	podda, Gianmarco/0000-0002-1791-8905; costantino, giorgio/0000-0002-6391-3849; Casazza, Giovanni/0000-0003-3718-1784; Montano, Nicola/0000-0001-9206-0075; Duca, Piergiorgio/0000-0003-4499-8805; Cattaneo, Marco/0000-0002-7343-4534				[Anonymous], 1991, Thromb Haemost, V65, P251; [Anonymous], 2003, STAT STAT SOFTW REL; Antman EM, 2005, AM HEART J, V149, P217, DOI 10.1016/j.ahj.2004.08.038; Belcaro G, 1999, ANGIOLOGY, V50, P781; Breddin HK, 2001, NEW ENGL J MED, V344, P626, DOI 10.1056/NEJM200103013440902; Campos Jose Victoria, 2002, Arch Cardiol Mex, V72, P209; Claudio Correia L C, 1995, Arq Bras Cardiol, V65, P475; Cohen M, 1997, NEW ENGL J MED, V337, P447, DOI 10.1056/NEJM199708143370702; Cohen M, 2002, AM HEART J, V144, P470, DOI 10.1067/mhj.2002.126115; de Lemos JA, 2004, EUR HEART J, V25, P1688, DOI 10.1016/j.ehj.2004.06.028; de Llano LAP, 2003, ARCH BRONCONEUMOL, V39, P341; Decousus H, 1998, NEW ENGL J MED, V338, P409, DOI 10.1056/NEJM199802123380701; DeEugenio D, 2007, PHARMACOTHERAPY, V27, P691, DOI 10.1592/phco.27.5.691; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Erkens PMG, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001100.pub3; Ferguson JJ, 2004, JAMA-J AM MED ASSOC, V292, P45; Fiessinger JN, 1996, THROMB HAEMOSTASIS, V76, P195; Findik S, 2002, RESPIRATION, V69, P440, DOI 10.1159/000064023; Goldhaber SZ, 1998, ARCH INTERN MED, V158, P2325, DOI 10.1001/archinte.158.21.2325; Goodman SG, 2003, CIRCULATION, V107, P238, DOI 10.1161/01.CIR.0000050144.67910.13; GURFINKEL EP, 1995, J AM COLL CARDIOL, V26, P313, DOI 10.1016/0735-1097(95)80001-W; Harenberg J, 2000, THROMB HAEMOSTASIS, V83, P652; HARENBERG J, 1990, HAEMOSTASIS, V20, P205; Harrington RA, 2008, CHEST, V133, p670S, DOI 10.1378/chest.08-0691; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jimenez D, 2009, THROMB HAEMOSTASIS, V102, P153, DOI 10.1160/TH09-01-0003; Kakkar VV, 2003, THROMB HAEMOSTASIS, V89, P674; Kearon C, 2008, CHEST, V133, p454S, DOI 10.1378/chest.08-0658; Kim JH, 2005, CIRC J, V69, P159, DOI 10.1253/circj.69.159; Kirchmaier CM, 1998, INT ANGIOL, V17, P135; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; Lim W, 2006, ANN INTERN MED, V144, P673, DOI 10.7326/0003-4819-144-9-200605020-00011; LINDMARKER P, 1994, THROMB HAEMOSTASIS, V72, P186; Loke YK, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-32; Luomanmaki K, 1996, J INTERN MED, V240, P85, DOI 10.1046/j.1365-2796.1996.18845000.x; Magee KD, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002132; Malhotra S, 2001, INT J CLIN PHARM TH, V39, P110; Manoukian SV, 2007, J AM COLL CARDIOL, V49, P1362, DOI 10.1016/j.jacc.2007.02.027; Merli G, 2001, ANN INTERN MED, V134, P191, DOI 10.7326/0003-4819-134-3-200102060-00009; Meyer G, 1995, THROMB HAEMOSTASIS, V74, P1432; Montalescot G, 2003, AM J CARDIOL, V91, P925, DOI 10.1016/S0002-9149(03)00105-X; Moreno-Palomares J J, 2001, An Med Interna, V18, P364; Murphy SA, 2007, EUR HEART J, V28, P2077, DOI 10.1093/eurheartj/ehm224; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; PRIME CARE Study Investigators Group, 2005, Indian Heart J, V57, P648; Quinlan DJ, 2004, ANN INTERN MED, V140, P175, DOI 10.7326/0003-4819-140-3-200402030-00008; Riess H, 2003, THROMB HAEMOSTASIS, V90, P252, DOI 10.1160/TH02-09-0061; Sabatine MS, 2005, CIRCULATION, V111, P2042, DOI 10.1161/01.CIR.0000162477.70955.5F; Silvain J, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e553; Simonneau G, 1997, NEW ENGL J MED, V337, P663, DOI 10.1056/NEJM199709043371002; SIMONNEAU G, 1993, ARCH INTERN MED, V153, P1541, DOI 10.1001/archinte.153.13.1541; Stricker H, 1999, THROMB HAEMOSTASIS, V82, P1227; tenCate JW, 1997, NEW ENGL J MED, V337, P657; THERY C, 1992, CIRCULATION, V85, P1380, DOI 10.1161/01.CIR.85.4.1380; Zhang Ye, 2004, Di Yi Jun Yi Da Xue Xue Bao, V24, P81	57	13	15	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2012	7	9							e44553	10.1371/journal.pone.0044553	http://dx.doi.org/10.1371/journal.pone.0044553			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	003VE	22984525	Green Submitted, Green Published, gold			2023-01-03	WOS:000308638700069
J	Schuur, JD; Venkatesh, AK				Schuur, Jeremiah D.; Venkatesh, Arjun K.			The Growing Role of Emergency Departments in Hospital Admissions	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Schuur, Jeremiah D.] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA; [Venkatesh, Arjun K.] Massachusetts Gen Hosp, Brigham & Womens Hosp, Harvard Affiliated Emergency Med Residency Progra, Boston, MA 02114 USA; [Schuur, Jeremiah D.; Venkatesh, Arjun K.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School	Schuur, JD (corresponding author), Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA.							Asplin BR, 2005, JAMA-J AM MED ASSOC, V294, P1248, DOI 10.1001/jama.294.10.1248; BEAL AC, 2007, CLOSING DIVIDE MED H; Newton MF, 2008, JAMA-J AM MED ASSOC, V300, P1914, DOI 10.1001/jama.300.16.1914; Pitts SR, 2010, HEALTH AFFAIR, V29, P1620, DOI 10.1377/hlthaff.2009.1026; Tang N, 2010, JAMA-J AM MED ASSOC, V304, P664, DOI 10.1001/jama.2010.1112	5	253	254	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 2	2012	367	5					391	393		10.1056/NEJMp1204431	http://dx.doi.org/10.1056/NEJMp1204431			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	981VZ	22784039				2023-01-03	WOS:000307001900002
J	Blumenthal, JA; Babyak, MA; O'Connor, C; Keteyian, S; Landzberg, J; Howlett, J; Kraus, W; Gottlieb, S; Blackburn, G; Swank, A; Whellan, DJ				Blumenthal, James A.; Babyak, Michael A.; O'Connor, Christopher; Keteyian, Steven; Landzberg, Joel; Howlett, Jonathan; Kraus, William; Gottlieb, Stephen; Blackburn, Gordon; Swank, Ann; Whellan, David J.			Effects of Exercise Training on Depressive Symptoms in Patients With Chronic Heart Failure The HF-ACTION Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MORTALITY; RISK; EFFICACY; OUTCOMES; INTERVENTION; MANAGEMENT; SERTRALINE; REMISSION; PROGNOSIS; RECOVERY	Context Depression is common in patients with cardiac disease, especially in patients with heart failure, and is associated with increased risk of adverse health outcomes. Some evidence suggests that aerobic exercise may reduce depressive symptoms, but to our knowledge the effects of exercise on depression in patients with heart failure have not been evaluated. Objective To determine whether exercise training will result in greater improvements in depressive symptoms compared with usual care among patients with heart failure. Design, Setting, and Participants Multicenter, randomized controlled trial involving 2322 stable patients treated for heart failure at 82 medical clinical centers in the United States, Canada, and France. Patients who had a left ventricular ejection fraction of 35% or lower, had New York Heart Association class I to IV heart failure, and had completed the Beck Depression Inventory II (BDI-II) score were randomized (1:1) between April 2003 and February 2007. Depressive scores ranged from 0 to 59; scores of 14 or higher are considered clinically significant. Interventions Participants were randomized either to supervised aerobic exercise (goal of 90 min/wk for months 1-3 followed by home exercise with a goal of >= 120 min/wk for months 4-12) or to education and usual guideline-based heart failure care. Main Outcome Measures Composite of death or hospitalization due to any cause and scores on the BDI-II at months 3 and 12. Results Over a median follow-up period of 30 months, 789 patients (68%) died or were hospitalized in the usual care group compared with 759 (66%) in the aerobic exercise group (hazard ratio [HR], 0.89; 95% CI, 0.81 to 0.99; P =. 03). The median BDI-II score at study entry was 8, with 28% of the sample having BDI-II scores of 14 or higher. Compared with usual care, aerobic exercise resulted in lower mean BDI-II scores at 3 months (aerobic exercise, 8.95; 95% CI, 8.61 to 9.29 vs usual care, 9.70; 95% CI, 9.34 to 10.06; difference, -0.76; 95% CI, -1.22 to -0.29; P=.002) and at 12 months (aerobic exercise, 8.86; 95% CI, 8.67 to 9.24 vs usual care, 9.54; 95% CI, 9.15 to 9.92; difference, -0.68; 95% CI, -1.20 to -0.16; P=.01). Conclusions Compared with guideline-based usual care, exercise training resulted in a modest reduction in depressive symptoms, although the clinical significance of this improvement is unknown.	[Blumenthal, James A.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA; [Keteyian, Steven] Henry Ford Hosp, Detroit, MI 48202 USA; [Landzberg, Joel] Hackensack Univ, Med Ctr, Dept Med, Hackensack, NJ USA; [Howlett, Jonathan] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada; [Gottlieb, Stephen] Univ Maryland, Baltimore, MD 21201 USA; [Blackburn, Gordon] Cleveland Clin Fdn, Cleveland, OH 44195 USA; [Swank, Ann] Univ Louisville, Louisville, KY 40292 USA; [Whellan, David J.] Thomas Jefferson Med Ctr, Philadelphia, PA USA	Duke University; Henry Ford Health System; Henry Ford Hospital; Hackensack University Medical Center; Queen Elizabeth II Health Sciences Centre; University System of Maryland; University of Maryland Baltimore; Cleveland Clinic Foundation; University of Louisville; Jefferson University	Blumenthal, JA (corresponding author), Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, POB 3119, Durham, NC 27710 USA.	blume003@mc.duke.edu	Howlett, Jonathan/T-2589-2019	Howlett, Jonathan/0000-0002-0535-9771; Kraus, William E/0000-0003-1930-9684	National Heart, Lung, and Blood Institute [HL080664]; 13 National Heart, Lung, and Blood Institute [5U01-HL063747, 5U01HL066461, HL068973, HL066501, HL066482, HL064250, HL066494, HL064257, HL066497, HL068980, HL064265, HL066491, HL064264]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066494, U01HL066497, U01HL066461, U01HL064265, U01HL066501, U01HL066491, U01HL068973, U01HL064250, U01HL068980, U01HL063747, U01HL064264, U01HL064257, R01HL080664, U01HL066482] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); 13 National Heart, Lung, and Blood Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Dr Blumenthal reported that he was compensated for his work by grant HL080664 from the National Heart, Lung, and Blood Institute. The HF-ACTION was funded by 13 National Heart, Lung, and Blood Institute grants: 5U01-HL063747 to the Duke Clinical Research Institute Coordinating Center (Dr C. O'Connor, principal investigator); 5U01HL066461 to the Economic and Quality of Life (K. Schulman, principal investigator); HL068973 to the U grant enrolling centers-Boston Medical Center (W. Colucci, principal investigator); HL066501 to Case Western Reserve University (I. Pina, principal investigator); HL066482 to Emory University (A. Smith, principal investigator); HL064250 to the Henry Ford Hospital (S. Keteyian, principal investigator); HL066494 to the Ohio State University (W. Abraham, principal investigator); HL064257 to Oregon Health Science University (R. Hershberger, principal investigator); HL066497 University of Alabama (V. Bittner, principal investigator); HL068980 to University of California-Los Angeles (G. Fonarow, principal investigator); HL064265 to the University of Colorado (E. Wolfel, principal investigator); HL066491 to Wake Forest University (D. Kitzman, principal investigator); and HL064264 to Washington University of St Louis (G. Ewald, principal investigator).	American Psychiatric Association, 2000, TASK FORC DSM 4 DIAG; Beck A.T., 1996, BECK DEPRESSION INVE, DOI DOI 10.1037/T00742-000; Berkman LF, 2003, JAMA-J AM MED ASSOC, V289, P3106; Blumenthal JA, 2003, LANCET, V362, P604, DOI 10.1016/S0140-6736(03)14190-6; Blumenthal JA, 1999, ARCH INTERN MED, V159, P2349, DOI 10.1001/archinte.159.19.2349; Blumenthal JA, 2007, PSYCHOSOM MED, V69, P587, DOI 10.1097/PSY.0b013e318148c19a; Bush DE, 2001, AM J CARDIOL, V88, P337, DOI 10.1016/S0002-9149(01)01675-7; COX DR, 1972, J R STAT SOC B, V34, P187; Dunn AL, 2005, AM J PREV MED, V28, P1, DOI 10.1016/j.amepre.2004.09.003; FRANK E, 1991, ARCH GEN PSYCHIAT, V48, P851, DOI 10.1001/archpsyc.1991.01810330075011; FRASURESMITH N, 1995, CIRCULATION, V91, P999, DOI 10.1161/01.CIR.91.4.999; Glassman AH, 2002, JAMA-J AM MED ASSOC, V288, P701, DOI 10.1001/jama.288.6.701; Green CP, 2000, J AM COLL CARDIOL, V35, P1245, DOI 10.1016/S0735-1097(00)00531-3; Guck Thomas P, 2003, Congest Heart Fail, V9, P163, DOI 10.1111/j.1527-5299.2003.01356.x; Harrell Frank E., 2001, REGRESSION MODELING; Haskell WL, 2007, MED SCI SPORT EXER, V39, P1423, DOI [10.1249/mss.0b013e3180616b27, 10.1161/CIRCULATIONAHA.107.185649]; Hoffman BM, 2011, PSYCHOSOM MED, V73, P127, DOI 10.1097/PSY.0b013e31820433a5; Hunt SA, 2005, CIRCULATION, V112, pE154, DOI 10.1161/CIRCULATIONAHA.105.167586; Jiang W, 2001, ARCH INTERN MED, V161, P1849, DOI 10.1001/archinte.161.15.1849; Jiang W, 2007, AM HEART J, V154, P102, DOI 10.1016/j.ahj.2007.03.043; Jiang W, 2011, AM J CARDIOL, V107, P545, DOI 10.1016/j.amjcard.2010.10.013; Lawlor DA, 2001, BMJ-BRIT MED J, V322, P763, DOI 10.1136/bmj.322.7289.763; Lesperance F, 2000, ARCH INTERN MED, V160, P1354, DOI 10.1001/archinte.160.9.1354; Lesperance F, 2002, CIRCULATION, V105, P1049, DOI 10.1161/hc0902.104707; Lichtman JH, 2008, CIRCULATION, V118, P1768, DOI 10.1161/CIRCULATIONAHA.108.190769; Mead GE, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004366.pub4; O'Connor CM, 2010, J AM COLL CARDIOL, V56, P692, DOI 10.1016/j.jacc.2010.03.068; O'Connor CM, 2009, JAMA-J AM MED ASSOC, V301, P1439, DOI 10.1001/jama.2009.454; Rutledge T, 2006, J AM COLL CARDIOL, V48, P1527, DOI 10.1016/j.jacc.2006.06.055; Sherwood A, 2007, ARCH INTERN MED, V167, P367, DOI 10.1001/archinte.167.4.367; Sherwood A, 2011, J AM COLL CARDIOL, V57, P418, DOI 10.1016/j.jacc.2010.09.031; Vaccarino V, 2001, J AM COLL CARDIOL, V38, P199, DOI 10.1016/S0735-1097(01)01334-1; Whellan DJ, 2007, AM HEART J, V153, P201, DOI 10.1016/j.ahj.2006.11.007	33	192	195	1	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 1	2012	308	5					465	474		10.1001/jama.2012.8720	http://dx.doi.org/10.1001/jama.2012.8720			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981DQ	22851113	Bronze, Green Accepted			2023-01-03	WOS:000306947400024
J	Han, RJ; Li, AY; Li, LJ; Kitlinska, JB; Zukowska, Z				Han, Ruijun; Li, Aiyun; Li, Lijun; Kitlinska, Joanna B.; Zukowska, Zofia			Maternal low-protein diet up-regulates the neuropeptide Y system in visceral fat and leads to abdominal obesity and glucose intolerance in a sex- and time-specific manner	FASEB JOURNAL			English	Article						NPY-Y2R; sex differences; metabolic syndrome	ADIPOSE-TISSUE; METABOLIC SYNDROME; FOOD-INTAKE; GROWTH; EXPOSURE; PREGNANCY; INSULIN; WEIGHT; STRESS; CELLS	Neuropeptide Y (NPY) mediates stress-induced obesity in adult male mice by activating its Y2 receptor (Y2R) in visceral adipose tissue (VAT). Here, we studied whether the NPY-Y2R system is also activated by maternal low-protein diet (LPD) and linked to obesity in offspring. Prenatal LPD offspring had lower birth weights compared to normal-protein diet (NPD) offspring. Female prenatal and lactation stress (PLS) offspring from mothers fed an LPD developed abdominal adiposity and glucose intolerance associated with a 5-fold up-regulation of NPY mRNA and a 6-fold up-regulation of Y2R mRNA specifically in VAT, in addition to elevated platelet-rich-plasma (PRP) NPY, compared to control females fed a high-fat diet (HFD). Conversely, PLS male offspring showed lower NPY in PRP, a 10-fold decrease of Y2R mRNA in VAT, lower adiposity, and improved glucose tolerance compared to control males. Interestingly, prenatal LPD offspring cross-fostered to control lactating mothers had completely inverse metabolic and NPY phenotypes. Taken together, these findings suggested that maternal LPD activates the VAT NPY-Y2R system and increases abdominal adiposity and glucose intolerance in a sex-and time-specific fashion, suggesting that the peripheral NPY system is a potential mediator of programming for the offspring's vulnerability to obesity and metabolic syndrome.-Han, R., Li, A., Li, L., Kitlinska, J. B., Zukowska, Z. Maternal low-protein diet up-regulates the neuropeptide Y system in visceral fat and leads to abdominal obesity and glucose intolerance in a sex-and time-specific manner. FASEB J. 26, 3528-3536 (2012). www.fasebj.org	[Han, Ruijun; Zukowska, Zofia] Univ Minnesota, Dept Integrat Biol & Physiol, Stress Physiol Ctr, Minneapolis, MN 55455 USA; [Han, Ruijun; Li, Aiyun; Li, Lijun; Kitlinska, Joanna B.; Zukowska, Zofia] Georgetown Univ, Dept Physiol & Biophys, Washington, DC USA	University of Minnesota System; University of Minnesota Twin Cities; Georgetown University	Han, RJ (corresponding author), Univ Minnesota, Dept Integrat Biol & Physiol, Stress Physiol Ctr, 321 Church St SE, Minneapolis, MN 55455 USA.	rhan@umn.edu	Han, Ruijun/K-6614-2012		U.S. National Institutes of Health [R01HL067357, R37HL055310]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067357, R37HL055310] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by U.S. National Institutes of Health grants R01HL067357 and R37HL055310 to Z.Z. The authors thank Allison Gurney, Amrutesh Puranik, Dalay Hirsch, Jana Strakova, Jixia Liu, Shuangwei Li, and Allan V. Kalueff for their insightful comments and editing. The authors thank Naz Moaddab for the pilot study reporting that prenatal LPD stress increased anxiety in male offspring, with lower NPY levels in the amygdala. The authors declare no conflicts of interest.	Abe K, 2010, EXP BIOL MED, V235, P1179, DOI 10.1258/ebm.2010.009136; ANGUITA RM, 1993, J NUTR, V123, P1421; Bartness TJ, 2002, J CLIN INVEST, V110, P1235, DOI 10.1172/JCI200217047; Bibikova M, 2006, GENOME RES, V16, P1075, DOI 10.1101/gr.5319906; Casson IF, 1997, BRIT MED J, V315, P275, DOI 10.1136/bmj.315.7103.275; Costa E, 2009, EXPERT REV NEUROTHER, V9, P87, DOI 10.1586/14737175.9.1.87; Dunn GA, 2009, ENDOCRINOLOGY, V150, P4999, DOI 10.1210/en.2009-0500; Eriksson JG, 1999, BMJ-BRIT MED J, V318, P427, DOI 10.1136/bmj.318.7181.427; HAHN P, 1984, J NUTR, V114, P1231, DOI 10.1093/jn/114.7.1231; Hales CN, 2003, DIABETOLOGIA, V46, P1013, DOI 10.1007/s00125-003-1131-7; Han R, 2007, DIABETOLOGIA, V50, P1960, DOI 10.1007/s00125-007-0752-7; HEYMANN E, 1984, KLIN WOCHENSCHR, V62, P2, DOI 10.1007/BF01725186; Jaquet D, 2000, J CLIN ENDOCR METAB, V85, P1401, DOI 10.1210/jc.85.4.1401; Kalra SP, 2004, NEUROPEPTIDES, V38, P201, DOI 10.1016/j.npep.2004.06.003; Koulu M, 2004, ANN MED, V36, P232, DOI 10.1080/07853890410031236; Kuo LE, 2007, NAT MED, V13, P803, DOI 10.1038/nm1611; LAW CM, 1992, J EPIDEMIOL COMMUN H, V46, P184, DOI 10.1136/jech.46.3.184; Lee EW, 2003, J CLIN INVEST, V111, P1853, DOI 10.1172/JCI200316929; Li LJ, 2011, J CARDIOVASC TRANSL, V4, P351, DOI 10.1007/s12265-011-9271-5; Lindsay RS, 1996, DIABETOLOGIA, V39, P1299, DOI 10.1007/s001250050573; Lucas A, 1996, BRIT J NUTR, V76, P605, DOI 10.1079/BJN19960066; LUNDBERG JM, 1990, FUNDAM CLIN PHARM, V4, P373, DOI 10.1111/j.1472-8206.1990.tb00692.x; Mashiko S, 2007, MOL PHARMACOL, V71, P602, DOI 10.1124/mol.106.029991; Mentlein R, 1999, REGUL PEPTIDES, V85, P9, DOI 10.1016/S0167-0115(99)00089-0; Nilsson C, 1996, PEPTIDES, V17, P359, DOI 10.1016/0196-9781(96)00013-7; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Ozanne SE, 2004, NATURE, V427, P411, DOI 10.1038/427411b; Ozanne SE, 2004, CLIN SCI, V106, P141, DOI 10.1042/CS20030278; Ozanne SE, 1996, AM J PHYSIOL-ENDOC M, V270, pE559, DOI 10.1152/ajpendo.1996.270.4.E559; Painter RC, 2008, BJOG-INT J OBSTET GY, V115, P1243, DOI 10.1111/j.1471-0528.2008.01822.x; Parker RMC, 1999, EUR J NEUROSCI, V11, P1431, DOI 10.1046/j.1460-9568.1999.00553.x; Pembrey ME, 2010, HUM FERTIL, V13, P268, DOI 10.3109/14647273.2010.524721; Plagemann A, 2002, DIABETES CARE, V25, P16, DOI 10.2337/diacare.25.1.16; RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701; Sainsbury A, 2006, DIABETES, V55, P19; Seckl JR, 2004, EUR J ENDOCRINOL, V151, pU49, DOI 10.1530/eje.0.151u049; Shepherd PR, 1997, BRIT J NUTR, V78, P121, DOI 10.1079/BJN19970124; Shi YC, 2011, OBESITY, V19, P2137, DOI 10.1038/oby.2011.99; Son MY, 2011, J CELL MOL MED, V15, P152, DOI 10.1111/j.1582-4934.2009.00956.x; STANLEY BG, 1992, PEPTIDES, V13, P581, DOI 10.1016/0196-9781(92)90093-I; Tang W, 2008, SCIENCE, V322, P583, DOI 10.1126/science.1156232; URBAN JH, 1993, ENDOCRINOLOGY, V132, P139, DOI 10.1210/en.132.1.139; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; Whitelaw NC, 2008, CURR OPIN GENET DEV, V18, P273, DOI 10.1016/j.gde.2008.07.001; Yang KP, 2008, FASEB J, V22, P2452, DOI 10.1096/fj.07-100735; Zambrano E, 2006, J PHYSIOL-LONDON, V571, P221, DOI 10.1113/jphysiol.2005.100313; Zambrano E, 2005, J PHYSIOL-LONDON, V566, P225, DOI 10.1113/jphysiol.2005.086462; ZukowskaGrojec Z, 1995, ANN NY ACAD SCI, V771, P219, DOI 10.1111/j.1749-6632.1995.tb44683.x	48	29	31	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2012	26	8					3528	3536		10.1096/fj.12-203943	http://dx.doi.org/10.1096/fj.12-203943			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	984BI	22539639	Green Published			2023-01-03	WOS:000307162800039
J	Carey, R; Harber, M				Carey, Renata; Harber, Mark			Kidney dialysis-the need for humanity	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Harber, Mark] Royal Free Hosp, London NW3 2QG, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Harber, M (corresponding author), Royal Free Hosp, Pond St, London NW3 2QG, England.	mark.harber@nhs.net							0	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 19	2012	345								e4492	10.1136/bmj.e4492	http://dx.doi.org/10.1136/bmj.e4492			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	978MA	22815428	Bronze			2023-01-03	WOS:000306744300003
J	Manabe, T; Iglesias, ALH; Manriquez, MEV; Valadez, ELM; Ramos, LA; Izumi, S; Takasaki, J; Kudo, K				Manabe, Toshie; Higuera Iglesias, Anjarath Lorena; Vazquez Manriquez, Maria Eugenia; Martinez Valadez, Eduarda Leticia; Alfaro Ramos, Leticia; Izumi, Shinyu; Takasaki, Jin; Kudo, Koichiro			Socioeconomic Factors Influencing Hospitalized Patients with Pneumonia Due to Influenza A(H1N1)pdm09 in Mexico	PLOS ONE			English	Article							A H1N1 VIRUS; RETROSPECTIVE ANALYSIS; INFECTION; MORTALITY; DEATH	Background: In addition to clinical aspects and pathogen characteristics, people's health-related behavior and socioeconomic conditions can affect the occurrence and severity of diseases including influenza A(H1N1)pdm09. Methodology and Principal Findings: A face-to-face interview survey was conducted in a hospital in Mexico City at the time of follow-up consultation for hospitalized patients with pneumonia due to influenza virus infection. In all, 302 subjects were enrolled and divided into two groups based on the period of hospitalization. Among them, 211 tested positive for influenza A(H1N1)pdm09 virus by real-time reverse-transcriptase-polymerase-chain-reaction during the pandemic period (Group-pdm) and 91 tested positive for influenza A virus in the post-pandemic period (Group-post). All subjects were treated with oseltamivir. Data on the demographic characteristics, socioeconomic status, living environment, and information relating to A(H1N1)pdm09, and related clinical data were compared between subjects in Group-pdm and those in Group-post. The ability of household income to pay for utilities, food, and health care services as well as housing quality in terms of construction materials and number of rooms revealed a significant difference: Group-post had lower socioeconomic status than Group-pdm. Group-post had lower availability of information regarding H1N1 influenza than Group-pdm. These results indicate that subjects in Group-post had difficulty receiving necessary information relating to influenza and were more likely to be impoverished than those in Group-pdm. Possible factors influencing time to seeking health care were number of household rooms, having received information on the necessity of quick access to health care, and house construction materials. Conclusions: Health-care-seeking behavior, poverty level, and the distribution of information affect the occurrence and severity of pneumonia due to H1N1 virus from a socioeconomic point of view. These socioeconomic factors may explain the different patterns of morbidity and mortality for H1N1 influenza observed among different countries and regions.	[Manabe, Toshie; Izumi, Shinyu; Takasaki, Jin; Kudo, Koichiro] Natl Ctr Global Hlth & Med, Dis Control & Prevent Ctr, Tokyo, Japan; [Higuera Iglesias, Anjarath Lorena; Alfaro Ramos, Leticia] Natl Inst Resp Dis, Res Inst, Dept Clin Epidemiol Invest, Mexico City, DF, Mexico; [Vazquez Manriquez, Maria Eugenia] Natl Inst Resp Dis, Dept Pathol, Mexico City, DF, Mexico; [Martinez Valadez, Eduarda Leticia] Natl Inst Resp Dis, Dept Epidemiol, Mexico City, DF, Mexico	National Center for Global Health & Medicine - Japan	Manabe, T (corresponding author), Natl Ctr Global Hlth & Med, Dis Control & Prevent Ctr, Tokyo, Japan.	kudo@dcc.go.jp			Japan Initiative for Global Research Network on Infectious Diseases from the Ministry of Education, Culture, Sports, Science and Technology of Japan	Japan Initiative for Global Research Network on Infectious Diseases from the Ministry of Education, Culture, Sports, Science and Technology of Japan	This work was supported by the Japan Initiative for Global Research Network on Infectious Diseases from the Ministry of Education, Culture, Sports, Science and Technology of Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adeniji KA, 2011, CRIT CARE, V15, DOI 10.1186/cc10001; Bautista E, 2010, NEW ENGL J MED, V362, P1708, DOI 10.1056/NEJMra1000449; Bellon MR, 2005, FOOD POLICY, V30, P476, DOI 10.1016/j.foodpol.2005.09.003; Benner David G., 2010, OPENING GOD0; BLAXTER M, 1987, LANCET, V2, P30; CONEVAL, 2011, SOC GAP IND; Cox CM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029301; Dominguez-Cherit G, 2010, JAMA-J AM MED ASSOC, V302, P1880; Echevarria-Zuno S, 2009, LANCET, V374, P2072, DOI 10.1016/S0140-6736(09)61638-X; Enrique R, 2002, P BAYL U MED CTR, V15, P319; Eugenia-Manjarrez M, 2012, RESP DIS INTECH, P217; Garcia-Garcia L, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3928; Gobierno Federal, MAN VAC 2008 2009; Gozalan A, 2012, JPN J INFECT DIS, V65, P13; Grijalva-Otero I, 2009, ARCH MED RES, V40, P662, DOI 10.1016/j.arcmed.2009.10.010; Iglesias ALH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021838; Louie JK, 2009, JAMA-J AM MED ASSOC, V302, P1896, DOI 10.1001/jama.2009.1583; NORTH F, 1993, BRIT MED J, V306, P361, DOI 10.1136/bmj.306.6874.361; Pelcastre-Villafuerte BE, 2011, CAD SAUDE PUBLICA, V27, P460, DOI 10.1590/S0102-311X2011000300007; Perez-Padilla R, 2009, NEW ENGL J MED, V361, P680, DOI 10.1056/NEJMoa0904252; SALUDE, 2012, SIT ACT EP; SALUDE, 2010, SIT ACT EP; Vasoo S, 2010, EMERG INFECT DIS, V16, P1594, DOI 10.3201/eid1610.091889; Xi XM, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-256; Zarychanski R, 2010, CAN MED ASSOC J, V182, P257, DOI 10.1503/cmaj.091884	25	8	8	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2012	7	7							e40529	10.1371/journal.pone.0040529	http://dx.doi.org/10.1371/journal.pone.0040529			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973LU	22808184	gold, Green Submitted, Green Published			2023-01-03	WOS:000306362400067
J	Champiat, S; Raposo, RAS; Maness, NJ; Lehman, JL; Purtell, SE; Hasenkrug, AM; Miller, JC; Dean, H; Koff, WC; Hong, MA; Martin, JN; Deeks, SG; Spotts, GE; Pilcher, CD; Hecht, FM; Kallas, EG; Garrison, KE; Nixon, DF				Champiat, Stephane; Raposo, Rui Andre Saraiva; Maness, Nicholas J.; Lehman, John L.; Purtell, Sean E.; Hasenkrug, Aaron M.; Miller, Jacob C.; Dean, Hansi; Koff, Wayne C.; Hong, Marisa Ailin; Martin, Jeffrey N.; Deeks, Steven G.; Spotts, Gerald E.; Pilcher, Christopher D.; Hecht, Fredrick M.; Kallas, Esper G.; Garrison, Keith E.; Nixon, Douglas F.			Influence of HAART on Alternative Reading Frame Immune Responses over the Course of HIV-1 Infection	PLOS ONE			English	Article							T-CELL RESPONSES; VIRUS TYPE-1 PROTEASE; VIRAL LOAD; CTL EPITOPES; TRANSLATION INITIATION; SELECTION PRESSURE; SUBTYPE-C; LYMPHOCYTES; GENE; RNA	Background: Translational errors can result in bypassing of the main viral protein reading frames and the production of alternate reading frame (ARF) or cryptic peptides. Within HIV, there are many such ARFs in both sense and the antisense directions of transcription. These ARFs have the potential to generate immunogenic peptides called cryptic epitopes (CE). Both antiretroviral drug therapy and the immune system exert a mutational pressure on HIV-1. Immune pressure exerted by ARF CD8(+) T cells on the virus has already been observed in vitro. HAART has also been described to select HIV-1 variants for drug escape mutations. Since the mutational pressure exerted on one location of the HIV-1 genome can potentially affect the 3 reading frames, we hypothesized that ARF responses would be affected by this drug pressure in vivo. Methodology/Principal findings: In this study we identified new ARFs derived from sense and antisense transcription of HIV-1. Many of these ARFs are detectable in circulating viral proteins. They are predominantly found in the HIV-1 env nucleotide region. We measured T cell responses to 199 HIV-1 CE encoded within 13 sense and 34 antisense HIV-1 ARFs. We were able to observe that these ARF responses are more frequent and of greater magnitude in chronically infected individuals compared to acutely infected patients, and in patients on HAART, the breadth of ARF responses increased. Conclusions/Significance: These results have implications for vaccine design and unveil the existence of potential new epitopes that could be included as vaccine targets.	[Champiat, Stephane; Raposo, Rui Andre Saraiva; Lehman, John L.; Hasenkrug, Aaron M.; Miller, Jacob C.; Nixon, Douglas F.] Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA 94143 USA; [Maness, Nicholas J.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA; [Dean, Hansi; Koff, Wayne C.] Int AIDS Vaccine Initiat, New York, NY USA; [Hong, Marisa Ailin; Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil; [Hong, Marisa Ailin] Adolfo Lutz Inst, Sao Paulo, Brazil; [Martin, Jeffrey N.] Univ Calif San Francisco, San Francisco Gen Hosp, Div Infect Dis, Epidemiol & Prevent Intervent Ctr, San Francisco, CA USA; [Deeks, Steven G.; Spotts, Gerald E.; Pilcher, Christopher D.; Hecht, Fredrick M.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Posit Hlth Program, San Francisco, CA USA; [Lehman, John L.; Purtell, Sean E.; Garrison, Keith E.] St Marys Coll Calif, Dept Biol, Moraga, CA USA	University of California System; University of California San Francisco; University of Wisconsin System; University of Wisconsin Madison; International AIDS Vaccine Initiative; Universidade de Sao Paulo; Instituto Adolfo Lutz; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Saint Mary's College of California	Champiat, S (corresponding author), Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA 94143 USA.	douglas.nixon@ucsf.edu	Nixon, Douglas/AAU-5734-2020; Champiat, Stephane/O-4780-2014	Nixon, Douglas/0000-0002-2801-1786; Champiat, Stephane/0000-0002-0741-2118; Kallas, Esper/0000-0003-2026-6925; Raposo, R. Andre/0000-0001-5435-0290; Hecht, Frederick/0000-0002-5782-1171	International AIDS Vaccine Initiative (IAVI); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027763, K24AI069994] Funding Source: NIH RePORTER	International AIDS Vaccine Initiative (IAVI); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The study was funded by the International AIDS Vaccine Initiative (IAVI), a not for profit organization focused on helping facilitate the discovery of an effective AIDS vaccine. Two scientists from IAVI were involved in the design, analysis and writing of the paper and are included as co-authors. The funders had no role in data collection or decision to publish the manuscript.	Addo MM, 2001, P NATL ACAD SCI USA, V98, P1781, DOI 10.1073/pnas.98.4.1781; Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003; Altfeld M, 2001, J IMMUNOL, V167, P2743, DOI 10.4049/jimmunol.167.5.2743; Bansal A, 2010, J EXP MED, V207, P51, DOI 10.1084/jem.20092060; Berger CT, 2010, J EXP MED, V207, P61, DOI 10.1084/jem.20091808; Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; BRUCE AG, 1986, P NATL ACAD SCI USA, V83, P5062, DOI 10.1073/pnas.83.14.5062; Bullock TNJ, 1996, J EXP MED, V184, P1319, DOI 10.1084/jem.184.4.1319; Bullock TNJ, 1997, J EXP MED, V186, P1051, DOI 10.1084/jem.186.7.1051; Cardinaud S, 2004, J EXP MED, V199, P1053, DOI 10.1084/jem.20031869; FETTEN JV, 1991, J IMMUNOL, V147, P2697; Friedrich TC, 2007, J VIROL, V81, P3465, DOI 10.1128/JVI.02392-06; Garrison KE, 2009, CLIN VACCINE IMMUNOL, V16, P1369, DOI 10.1128/CVI.00410-08; Gatanaga H, 2010, AIDS, V24, pF15, DOI 10.1097/QAD.0b013e328337b010; Goepfert PA, 2008, J EXP MED, V205, P1009, DOI 10.1084/jem.20072457; Ho O, 2006, J IMMUNOL, V176, P2470, DOI 10.4049/jimmunol.176.4.2470; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; John M, 2005, ANTIVIR THER, V10, P551; Karlsson AC, 2003, J VIROL, V77, P6743, DOI 10.1128/JVI.77.12.6743-6752.2003; Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520; Landry S, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-71; Liu JY, 2009, NATURE, V457, P87, DOI 10.1038/nature07469; Ludwig LB, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-80; Mahnke Lisa, 2006, AIDS Res Ther, V3, P21, DOI 10.1186/1742-6405-3-21; Malarkannan S, 1999, IMMUNITY, V10, P681, DOI 10.1016/S1074-7613(00)80067-9; Maness NJ, 2007, J EXP MED, V204, P2505, DOI 10.1084/jem.20071261; Maness NJ, 2010, J IMMUNOL, V184, P67, DOI 10.4049/jimmunol.0903118; Maness NJ, 2009, J VIROL, V83, P10280, DOI 10.1128/JVI.00138-09; Manosuthi W, 2010, AIDS, V24, P411, DOI 10.1097/QAD.0b013e3283350eef; Masemola A, 2004, J VIROL, V78, P3233, DOI 10.1128/JVI.78.7.3233-3243.2004; Mason RA, 2004, J IMMUNOL, V172, P7212, DOI 10.4049/jimmunol.172.11.7212; Mayrand SM, 1998, IMMUNOL TODAY, V19, P551, DOI 10.1016/S0167-5699(98)01342-5; McBratney S, 1993, CURR OPIN CELL BIOL, V5, P961, DOI 10.1016/0955-0674(93)90077-4; McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016/S0140-6736(08)61592-5; Meiklejohn DA, 2004, J IMMUNOL METHODS, V288, P135, DOI 10.1016/j.jim.2004.03.006; MICHAEL NL, 1994, J VIROL, V68, P979, DOI 10.1128/JVI.68.2.979-987.1994; Mueller SM, 2007, J VIROL, V81, P2887, DOI 10.1128/JVI.01547-06; Mueller SM, 2011, JAIDS-J ACQ IMM DEF, V56, P109, DOI 10.1097/QAI.0b013e3181fe946e; Novitsky V, 2002, J VIROL, V76, P10155, DOI 10.1128/JVI.76.20.10155-10168.2002; Probst-Kepper M, 2001, J EXP MED, V193, P1189, DOI 10.1084/jem.193.10.1189; Rimoldi D, 2000, J IMMUNOL, V165, P7253, DOI 10.4049/jimmunol.165.12.7253; Saeterdal I, 2001, P NATL ACAD SCI USA, V98, P13255, DOI 10.1073/pnas.231326898; Samri A, 2000, J VIROL, V74, P9306, DOI 10.1128/JVI.74.19.9306-9312.2000; Saulquin X, 2002, J EXP MED, V195, P353, DOI 10.1084/jem.20011399; Schmitt M, 2000, AIDS, V14, P653, DOI 10.1097/00002030-200004140-00004; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Schwab SR, 2004, PLOS BIOL, V2, P1774, DOI 10.1371/journal.pbio.0020366; Wang RF, 1996, J EXP MED, V183, P1131, DOI 10.1084/jem.183.3.1131; WEISS RB, 1987, COLD SPRING HARB SYM, V52, P687, DOI 10.1101/SQB.1987.052.01.078; Yu XG, 2002, J VIROL, V76, P8690, DOI 10.1128/JVI.76.17.8690-8701.2002	51	13	13	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2012	7	6							e39311	10.1371/journal.pone.0039311	http://dx.doi.org/10.1371/journal.pone.0039311			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	967FO	22768072	Green Published, gold			2023-01-03	WOS:000305892100043
J	Arendash, GW; Mori, T; Dorsey, M; Gonzalez, R; Tajiri, N; Borlongan, C				Arendash, Gary W.; Mori, Takashi; Dorsey, Maggie; Gonzalez, Rich; Tajiri, Naoki; Borlongan, Cesar			Electromagnetic Treatment to Old Alzheimer's Mice Reverses beta-Amyloid Deposition, Modifies Cerebral Blood Flow, and Provides Selected Cognitive Benefit	PLOS ONE			English	Article							HEAD-ONLY EXPOSURE; MOBILE PHONE USE; BRAIN TEMPERATURE; A-BETA; FIELDS; TERM; PERFORMANCE; IMPAIRMENT; DISEASE; MEMORY	Few studies have investigated physiologic and cognitive effects of "long-term" electromagnetic field (EMF) exposure in humans or animals. Our recent studies have provided initial insight into the long-term impact of adulthood EMF exposure (GSM, pulsed/modulated, 918 MHz, 0.25-1.05 W/kg) by showing 6+ months of daily EMF treatment protects against or reverses cognitive impairment in Alzheimer's transgenic (Tg) mice, while even having cognitive benefit to normal mice. Mechanistically, EMF-induced cognitive benefits involve suppression of brain beta-amyloid (A beta) aggregation/deposition in Tg mice and brain mitochondrial enhancement in both Tg and normal mice. The present study extends this work by showing that daily EMF treatment given to very old (21-27 month) Tg mice over a 2-month period reverses their very advanced brain A beta aggregation/deposition. These very old Tg mice and their normal littermates together showed an increase in general memory function in the Y-maze task, although not in more complex tasks. Measurement of both body and brain temperature at intervals during the 2-month EMF treatment, as well as in a separate group of Tg mice during a 12-day treatment period, revealed no appreciable increases in brain temperature (and no/slight increases in body temperature) during EMF "ON" periods. Thus, the neuropathologic/cognitive benefits of EMF treatment occur without brain hyperthermia. Finally, regional cerebral blood flow in cerebral cortex was determined to be reduced in both Tg and normal mice after 2 months of EMF treatment, most probably through cerebrovascular constriction induced by freed/disaggregated A beta (Tg mice) and slight body hyperthermia during "ON" periods. These results demonstrate that long-term EMF treatment can provide general cognitive benefit to very old Alzheimer's Tg mice and normal mice, as well as reversal of advanced A beta neuropathology in Tg mice without brain heating. Results further underscore the potential for EMF treatment against AD.	[Arendash, Gary W.] Univ S Florida, Dept Cell Biol Microbiol & Mol Biol, Tampa, FL 33620 USA; [Arendash, Gary W.] Florida Alzheimers Dis Res Ctr, Tampa, FL USA; [Mori, Takashi] Saitama Med Ctr, Dept Biomed Sci, Kawagoe, Saitama, Japan; [Mori, Takashi] Saitama Med Ctr, Dept Pathol, Kawagoe, Saitama, Japan; [Mori, Takashi] Saitama Med Univ, Kawagoe, Saitama, Japan; [Dorsey, Maggie] Univ S Florida, Hlth Byrd Alzheimers Inst, Tampa, FL USA; [Gonzalez, Rich] SAI Florida, Redington Beach, FL USA; [Tajiri, Naoki; Borlongan, Cesar] Univ S Florida, Morsani Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Tampa, FL USA	State University System of Florida; University of South Florida; Saitama Medical University; Saitama Medical University; Saitama Medical University; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Arendash, GW (corresponding author), Univ S Florida, Dept Cell Biol Microbiol & Mol Biol, Tampa, FL 33620 USA.	arendash@cas.usf.edu	Tajiri, Naoki/K-1230-2012; Borlongan, Cesar/I-5696-2012	Tajiri, Naoki/0000-0003-2189-662X; Borlongan, Cesar/0000-0002-2966-9782	NIA-designated Florida Alzheimer's Disease Research Center [AG025711]; USF/Byrd Alzheimer's Institute; USF Interdisciplinary Research Development Grant; Alzheimer's Drug Discovery Foundation Young Investigator Scholarship; NATIONAL INSTITUTE ON AGING [P50AG025711] Funding Source: NIH RePORTER	NIA-designated Florida Alzheimer's Disease Research Center; USF/Byrd Alzheimer's Institute; USF Interdisciplinary Research Development Grant; Alzheimer's Drug Discovery Foundation Young Investigator Scholarship; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by funds from the NIA-designated Florida Alzheimer's Disease Research Center (AG025711) to G. A., the USF/Byrd Alzheimer's Institute to G. A., and a USF Interdisciplinary Research Development Grant to G. A. and C. V. B. N.T. is a recipient of the 2011 Alzheimer's Drug Discovery Foundation Young Investigator Scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aalto S, 2006, J CEREBR BLOOD F MET, V26, P885, DOI 10.1038/sj.jcbfm.9600279; Ammari M, 2008, BRAIN INJURY, V22, P1021, DOI 10.1080/02699050802530599; Arendash GW, 2007, NEUROSCIENCE, V149, P286, DOI 10.1016/j.neuroscience.2007.08.018; Arendash GW, 2006, NEUROSCIENCE, V142, P941, DOI 10.1016/j.neuroscience.2006.07.021; Arendash GW, 2010, J ALZHEIMERS DIS, V19, P191, DOI 10.3233/JAD-2010-1228; Arendash GW, 2009, J ALZHEIMERS DIS, V17, P661, DOI 10.3233/JAD-2009-1087; Arendash GW, 1999, NEUROSCI LETT, V268, P17, DOI 10.1016/S0304-3940(99)00239-6; Arns M, 2007, INT J NEUROSCI, V117, P1341, DOI 10.1080/00207450600936882; Aydin D, 2011, JNCI-J NATL CANCER I, V103, P1264, DOI 10.1093/jnci/djr244; Barth A, 2012, BIOELECTROMAGNETICS, V33, P159, DOI 10.1002/bem.20697; Besset A, 2005, BIOELECTROMAGNETICS, V26, P102, DOI 10.1002/bem.20053; Borlongan CV, 2004, BRAIN RES, V1009, P26, DOI 10.1016/j.brainres.2004.02.050; Borlongan CV, 2004, BRAIN RES, V1010, P108, DOI 10.1016/j.brainres.2004.02.072; Brambrink AM, 1999, J NEUROSCI METH, V92, P111, DOI 10.1016/S0165-0270(99)00100-4; Cardis E, 2010, INT J EPIDEMIOL, V39, P675, DOI 10.1093/ije/dyq079; Cirrito JR, 2005, NEURON, V48, P913, DOI 10.1016/j.neuron.2005.10.028; Cook CM, 2009, BIOELECTROMAGNETICS, V30, P9, DOI 10.1002/bem.20434; DeBow S, 2003, METHODS, V30, P167, DOI 10.1016/S1046-2023(03)00080-X; Dragicevic N, 2011, NEUROSCIENCE, V185, P135, DOI 10.1016/j.neuroscience.2011.04.012; Dubreuil D, 2003, BEHAV BRAIN RES, V145, P51, DOI 10.1016/S0166-4328(03)00100-1; Dubreuil D, 2002, BEHAV BRAIN RES, V129, P203, DOI 10.1016/S0166-4328(01)00344-8; Echeverria V, 2011, J ALZHEIMERS DIS, V24, P817, DOI 10.3233/JAD-2011-102136; Fritzer G, 2007, BIOELECTROMAGNETICS, V28, P316, DOI 10.1002/bem.20301; Gravitz L, 2011, NATURE, V475, pS9, DOI 10.1038/475S9a; Haarala C, 2003, NEUROREPORT, V14, P2019, DOI 10.1097/00001756-200311140-00003; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; Hardell L, 2008, INT J ONCOL, V32, P1097; Huber R, 2005, EUR J NEUROSCI, V21, P1000, DOI 10.1111/j.1460-9568.2005.03929.x; Ito S, 2007, J NEUROCHEM, V103, P2482, DOI 10.1111/j.1471-4159.2007.04938.x; Juutilainen J, 2011, BIOELECTROMAGNETICS, V32, P511, DOI 10.1002/bem.20652; Khurana VG, 2009, SURG NEUROL, V72, P205, DOI 10.1016/j.surneu.2009.01.019; Krewski D, 2007, J TOXICOL ENV HEAL B, V10, P287, DOI 10.1080/15287390600974973; Kubacki R, 2007, 2 INT C EL FIELDS HL; Kumlin T, 2007, RADIAT RES, V168, P471, DOI 10.1667/RR1002.1; Kwon MS, 2011, BIOELECTROMAGNETICS, V32, P253, DOI 10.1002/bem.20635; Leighty RE, 2004, BEHAV BRAIN RES, V153, P107, DOI 10.1016/j.bbr.2003.11.004; Masuda H, 2011, J APPL PHYSIOL, V110, P142, DOI 10.1152/japplphysiol.01035.2010; Mori T, 2011, J ALZHEIMERS DIS PAR, V1, P2; Mori T, 2012, J BIOL CHEM, V287, P6912, DOI 10.1074/jbc.M111.294025; Nelson MD, 2011, J PHYSIOL-LONDON, V589, P4053, DOI 10.1113/jphysiol.2011.212118; NIGHTINGALE NRV, 1983, PHYS MED BIOL, V28, P897, DOI 10.1088/0031-9155/28/8/002; Nybo L, 2002, J APPL PHYSIOL, V93, P58, DOI 10.1152/japplphysiol.00049.2002; Olcese JM, 2009, J PINEAL RES, V47, P82, DOI 10.1111/j.1600-079X.2009.00692.x; Paris D, 2003, NEUROL RES, V25, P642, DOI 10.1179/016164103101201940; Schuz J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004389; Shimizu H, 1997, MAGNET RESON MED, V37, P833, DOI 10.1002/mrm.1910370606; Sienkiewicz ZJ, 2000, BIOELECTROMAGNETICS, V21, P151, DOI 10.1002/(SICI)1521-186X(200004)21:3<151::AID-BEM1>3.0.CO;2-Q; Swerdlow AJ, 2011, MOBILE PHONES BRAIN, DOI DOI 10.1289/EHP.1103693; Tattersall JEH, 2001, BRAIN RES, V904, P43, DOI 10.1016/S0006-8993(01)02434-9; Valberg PA, 2007, ENVIRON HEALTH PERSP, V115, P416, DOI 10.1289/ehp.9633; Van Leeuwen GMJ, 1999, PHYS MED BIOL, V44, P2367, DOI 10.1088/0031-9155/44/10/301; Volkow ND, 2011, JAMA-J AM MED ASSOC, V305, P808, DOI 10.1001/jama.2011.186	52	70	74	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2012	7	4							e35751	10.1371/journal.pone.0035751	http://dx.doi.org/10.1371/journal.pone.0035751			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959VP	22558216	Green Submitted, gold, Green Published			2023-01-03	WOS:000305345200074
J	Fimognari, C; Lenzi, M; Sestili, P; Turrini, E; Ferruzzi, L; Hrelia, P; Cantelli-Forti, G				Fimognari, Carmela; Lenzi, Monia; Sestili, Piero; Turrini, Eleonora; Ferruzzi, Lorenzo; Hrelia, Patrizia; Cantelli-Forti, Giorgio			Sulforaphane Potentiates RNA Damage Induced by Different Xenobiotics	PLOS ONE			English	Article							IN-VITRO; PHENETHYL ISOTHIOCYANATE; SUPEROXIDE GENERATION; CELLULAR ACCUMULATION; ALKYLATION DAMAGE; OXIDATIVE STRESS; CANCER; THIOREDOXIN; GLUTATHIONE; APOPTOSIS	Background: The isothiocyanate sulforaphane (SFN) possesses interesting anticancer activities. However, recent studies reported that SFN promotes the formation of reactive oxygen species (ROS) as well as DNA breakage. Methodology/Principal Findings: We investigated whether SFN is able to damage RNA, whose loss of integrity was demonstrated in different chronic diseases. Considering the ability of SFN to protect from genotoxicity, we also examined whether SFN is able to protect from RNA damage induced by different chemicals (doxorubicin, spermine, S-nitroso-N-acetylpenicillamine, H2O2). We observed that SFN was devoid of either RNA damaging and RNA protective activity in human leukemic cells. It was able to potentiate the RNA damage by doxorubicin and spermine. In the first case, the effect was attributable to its ability of modulating the bioreductive activation of doxorubicin. For spermine, the effects were mainly due to its modulation of ROS levels produced by spermine metabolism. As to the cytotoxic relevance of the RNA damage, we found that the treatment of cells with a mixture of spermine or doxorubicin plus SFN increased their proapoptotic potential. Thus it is conceivable that the presence of RNA damage might concur to the overall toxic response induced by a chemical agent in targeted cells. Conclusions/Significance: Since RNA is emerging as a potential target for anticancer drugs, its ability to enhance spermine- and doxorubicin-induced RNA damage and cytotoxicity could represent an additional mechanism for the potentiating effects of SFN associated with anticancer drugs.	[Fimognari, Carmela; Lenzi, Monia; Turrini, Eleonora; Ferruzzi, Lorenzo; Hrelia, Patrizia; Cantelli-Forti, Giorgio] Univ Bologna, Dept Pharmacol, Alma Mater Studiorum, Bologna, Italy; [Sestili, Piero] Univ Studi Urbino, Dipartimento Scienze Biomol, Urbino, Italy	University of Bologna; University of Urbino	Fimognari, C (corresponding author), Univ Bologna, Dept Pharmacol, Alma Mater Studiorum, Bologna, Italy.	carmela.fimognari@unibo.it	Turrini, Eleonora/I-3629-2019; Hrelia, Patrizia/AAC-2071-2020; Sestili, Piero/H-6082-2019; Fimognari, Carmela/J-7678-2019	Turrini, Eleonora/0000-0003-4743-1126; Sestili, Piero/0000-0001-9412-1660; Fimognari, Carmela/0000-0002-2461-8214; HRELIA, Patrizia/0000-0002-8415-3711	Ministero dell'Istruzione dell'Universita e della Ricerca [2007SSZMPK]; FIRB Piattaforme/Reti (Basic Research Investment Fund Platforms/Networks) [RBPR05NWWC_002]	Ministero dell'Istruzione dell'Universita e della Ricerca(Ministry of Education, Universities and Research (MIUR)); FIRB Piattaforme/Reti (Basic Research Investment Fund Platforms/Networks)	This work was supported by Ministero dell'Istruzione dell'Universita e della Ricerca (http://sitouniversitario.cineca.it; grant number: 2007SSZMPK) and FIRB Piattaforme/Reti 2006 (Basic Research Investment Fund Platforms/Networks 2006) (http://sitofirb.cineca.it; grant number: RBPR05NWWC_002). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aas PA, 2003, NATURE, V421, P859, DOI 10.1038/nature01363; Antosiewicz J, 2008, PLANTA MED, V74, P1570, DOI 10.1055/s-2008-1081307; Arnold U, 2006, BIOTECHNOL LETT, V28, P1615, DOI 10.1007/s10529-006-9145-0; Baltimore D, 2001, NATURE, V409, P814, DOI 10.1038/35057267; Barcelo S, 1996, CARCINOGENESIS, V17, P277, DOI 10.1093/carcin/17.2.277; Bellacosa A, 2003, CURR BIOL, V13, pR482, DOI 10.1016/S0960-9822(03)00408-1; Bregeon D, 2005, MUTAT RES-FUND MOL M, V577, P293, DOI 10.1016/j.mrfmmm.2005.04.002; Chen YR, 2002, J BIOL CHEM, V277, P39334, DOI 10.1074/jbc.M202070200; Cheung KL, 2010, AAPS J, V12, P87, DOI 10.1208/s12248-009-9162-8; Cho SD, 2005, NUTR CANCER, V52, P213, DOI 10.1207/s15327914nc5202_11; Clarke JD, 2008, CANCER LETT, V269, P291, DOI 10.1016/j.canlet.2008.04.018; Conaway CC, 2001, CHEM RES TOXICOL, V14, P1170, DOI 10.1021/tx010029w; Das KC, 2000, BIOCHEM BIOPH RES CO, V277, P443, DOI 10.1006/bbrc.2000.3689; Drablos F, 2004, DNA REPAIR, V3, P1389, DOI 10.1016/j.dnarep.2004.05.004; Drobnica J., 1977, CYANATES THEIR THIO, P1003; Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367; Fimognari C, 2005, ENVIRON MOL MUTAGEN, V46, P260, DOI 10.1002/em.20156; Fimognari C, 2005, MUTAT RES-GEN TOX EN, V582, P1, DOI 10.1016/j.mrgentox.2004.11.019; Fimognari C, 2008, MUTAT RES-FUND MOL M, V648, P15, DOI 10.1016/j.mrfmmm.2008.09.003; Fimognari C, 2007, MUTAT RES-REV MUTAT, V635, P90, DOI 10.1016/j.mrrev.2006.10.004; Fimognari C, 2009, MUTAT RES-FUND MOL M, V670, P59, DOI 10.1016/j.mrfmmm.2009.07.005; Gaona-Gaona L, 2011, TOXICOLOGY, V286, P20, DOI 10.1016/j.tox.2011.04.014; Hacker A, 2008, CANCER CHEMOTH PHARM, V63, P45, DOI 10.1007/s00280-008-0706-x; Hinman A, 2006, P NATL ACAD SCI USA, V103, P19564, DOI 10.1073/pnas.0609598103; HOUEN G, 1994, ACTA CHEM SCAND, V48, P52, DOI 10.3891/acta.chem.scand.48-0052; Hu Y, 2007, BIOL CHEM, V388, P1069, DOI 10.1515/BC.2007.135; Iordanov MS, 2000, CANCER RES, V60, P1983; Kallifatidis G, 2011, MOL THER, V19, P188, DOI 10.1038/mt.2010.216; Kawakami M, 2005, BIOSCI BIOTECH BIOCH, V69, P2439, DOI 10.1271/bbb.69.2439; Kim H, 2006, CANCER RES, V66, P1740, DOI 10.1158/0008-5472.CAN-05-1568; Kirsch-Volders M, 2003, MUTAT RES-GEN TOX EN, V540, P153, DOI 10.1016/j.mrgentox.2003.07.005; Martinet W, 2004, EUR J CLIN INVEST, V34, P323, DOI 10.1111/j.1365-2362.2004.01343.x; Martinet Wim, 2005, RNA Biol, V2, P4, DOI 10.4161/rna.2.1.1430; Miyoshi N, 2004, CARCINOGENESIS, V25, P567, DOI 10.1093/carcin/bgh051; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Nunomura A, 2007, CURR MED CHEM, V14, P2968, DOI 10.2174/092986707782794078; Nunomura A, 1999, J NEUROSCI, V19, P1959; Nunomura A, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/200682323; Nunomura A, 2006, J NEUROPATH EXP NEUR, V65, P631, DOI 10.1097/01.jnen.0000228136.58062.bf; Oliveira CJR, 2008, NITRIC OXIDE-BIOL CH, V18, P241, DOI 10.1016/j.niox.2008.02.001; Rausch V, 2010, CANCER RES, V70, P5004, DOI 10.1158/0008-5472.CAN-10-0066; Ravi D, 2004, CANCER CHEMOTH PHARM, V54, P449, DOI 10.1007/s00280-004-0833-y; RHEE Y, 1995, NUCLEIC ACIDS RES, V23, P3275, DOI 10.1093/nar/23.16.3275; Rodon J, 2010, ONCOLOGIST, V15, P37, DOI 10.1634/theoncologist.2009-0117; Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-3; Schulenhurg C, 2007, CANCER BIOL THER, V6, P1233; Sestili P, 2010, MUTAT RES-FUND MOL M, V689, P65, DOI 10.1016/j.mrfmmm.2010.05.003; Sharmin S, 2001, BIOCHEM BIOPH RES CO, V282, P228, DOI 10.1006/bbrc.2001.4569; Singh SV, 2005, J BIOL CHEM, V280, P19911, DOI 10.1074/jbc.M412443200; Sinha-Hikim I, 2010, AM J PHYSIOL-CELL PH, V299, pC638, DOI 10.1152/ajpcell.00434.2009; SMITH JA, 1993, J IMMUNOL METHODS, V162, P261, DOI 10.1016/0022-1759(93)90391-J; Tafech A, 2006, CURR MED CHEM, V13, P863, DOI 10.2174/092986706776361021; Wang LG, 2010, INT J ONCOL, V37, P533, DOI 10.3892/ijo_00000702; Witte I, 2007, TOXICOL SCI, V97, P21, DOI 10.1093/toxsci/kfl192; Yoshida K, 2008, TRENDS MOL MED, V14, P305, DOI 10.1016/j.molmed.2008.05.003; Zhang JS, 2003, CARCINOGENESIS, V24, P497, DOI 10.1093/carcin/24.3.497; Zhang YS, 2001, CARCINOGENESIS, V22, P425, DOI 10.1093/carcin/22.3.425; ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399; Zhang YS, 2002, BIOCHEM J, V364, P301, DOI 10.1042/bj3640301; Zhang YS, 2000, CARCINOGENESIS, V21, P1175, DOI 10.1093/carcin/21.6.1175	60	11	11	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2012	7	4							e35267	10.1371/journal.pone.0035267	http://dx.doi.org/10.1371/journal.pone.0035267			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UP	22539965	Green Published, gold, Green Submitted			2023-01-03	WOS:000305341000029
J	Gysels, M; Evans, N; Menaca, A; Andrew, E; Toscani, F; Finetti, S; Pasman, HR; Higginson, I; Harding, R; Pool, R				Gysels, Marjolein; Evans, Natalie; Menaca, Arantza; Andrew, Erin; Toscani, Franco; Finetti, Sylvia; Pasman, H. Roeline; Higginson, Irene; Harding, Richard; Pool, Robert		Project PRISMA	Culture and End of Life Care: A Scoping Exercise in Seven European Countries	PLOS ONE			English	Article							TERMINALLY-ILL PATIENTS; QUALITY-OF-LIFE; ADVANCED CANCER-PATIENTS; WRITTEN ETHICS POLICIES; PALLIATIVE-CARE; ADVANCE DIRECTIVES; INTENSIVE-CARE; HEALTH-CARE; DECISION-MAKING; FAMILY-MEMBERS	Aim: Culture is becoming increasingly important in relation to end of life (EoL) care in a context of globalization, migration and European integration. We explore and compare socio-cultural issues that shape EoL care in seven European countries and critically appraise the existing research evidence on cultural issues in EoL care generated in the different countries. Methods: We scoped the literature for Germany, Norway, Belgium, the Netherlands, Spain, Italy and Portugal, carrying out electronic searches in 16 international and country-specific databases and handsearches in 17 journals, bibliographies of relevant papers and webpages. We analysed the literature which was unearthed, in its entirety and by type (reviews, original studies, opinion pieces) and conducted quantitative analyses for each country and across countries. Qualitative techniques generated themes and sub-themes. Results: A total of 868 papers were reviewed. The following themes facilitated cross-country comparison: setting, caregivers, communication, medical EoL decisions, minority ethnic groups, and knowledge, attitudes and values of death and care. The frequencies of themes varied considerably between countries. Sub-themes reflected issues characteristic for specific countries (e.g. culture-specific disclosure in the southern European countries). The work from the seven European countries concentrates on cultural traditions and identities, and there was almost no evidence on ethnic minorities. Conclusion: This scoping review is the first comparative exploration of the cultural differences in the understanding of EoL care in these countries. The diverse body of evidence that was identified on socio-cultural issues in EoL care, reflects clearly distinguishable national cultures of EoL care, with differences in meaning, priorities, and expertise in each country. The diverse ways that EoL care is understood and practised forms a necessary part of what constitutes best evidence for the improvement of EoL care in the future.	[Gysels, Marjolein; Evans, Natalie; Menaca, Arantza; Andrew, Erin; Pool, Robert] Univ Barcelona, Barcelona Ctr Int Hlth Res, Barcelona, Spain; [Gysels, Marjolein; Higginson, Irene; Harding, Richard] Kings Coll London, Dept Palliat Care Policy & Rehabil, London WC2R 2LS, England; [Toscani, Franco; Finetti, Sylvia] Fdn Lino Maestroni, Ist Ric Med Palliat, Cremona, Italy; [Gysels, Marjolein; Pool, Robert] Univ Amsterdam, Ctr Social Sci & Global Hlth, Amsterdam, Netherlands; [Evans, Natalie; Pasman, H. Roeline] Vrije Univ Amsterdam Med Ctr, Expertise Ctr Palliat Care, Emgo Inst Hlth & Care Res, Dept Publ & Occupat Hlth, Amsterdam, Netherlands	ISGlobal; CRESIB; University of Barcelona; University of London; King's College London; University of Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Gysels, M (corresponding author), Univ Barcelona, Barcelona Ctr Int Hlth Res, Barcelona, Spain.	mhgysels@gmail.com	Evans, Natalie/M-1631-2013; Daveson, Barbara A/G-3122-2012; Murtagh, Fliss/C-3216-2009; Higginson, Irene Julie/C-7309-2012	Evans, Natalie/0000-0001-7124-9282; Murtagh, Fliss/0000-0003-1289-3726; Deliens, Luc/0000-0002-8158-2422; Daveson, Barbara/0000-0001-8039-8749; Koffman, Jonathan/0000-0001-8513-5681; Higginson, Irene Julie/0000-0002-3687-1313; Harding, Richard/0000-0001-9653-8689; Haugen, Dagny Faksvag/0000-0002-8592-4995	European Commission [Health-F2-2008-201655]	European Commission(European CommissionEuropean Commission Joint Research Centre)	PRISMA is funded by the European Commission's Seventh Framework Programme (contract number: Health-F2-2008-201655). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbadie B, 2006, Rev Med Brux, V27, pS287; Abizanda Campos R., 1994, MED INTENSIVA, V18, P100; Abma T A, 2001, Med Health Care Philos, V4, P261, DOI 10.1023/A:1012096917865; Abma TA, 2005, EVAL HEALTH PROF, V28, P90, DOI 10.1177/0163278704273080; Alonso Babarro A, 2002, MED PALIATIVA, V9, P161; Andruccioli J, 2007, J PALLIAT MED, V10, P741, DOI 10.1089/jpm.2006.0200; Andruccioli J, 2009, AM J HOSP PALLIAT ME, V26, P384, DOI 10.1177/1049909109338355; Angel-Lopez-Rey E, 2008, ENFERM CLIN, V18, P115, DOI 10.1016/S1130-8621(08)70712-5; Annunziata MA, 1996, SUPPORT CARE CANCER, V4, P334, DOI 10.1007/BF01788839; [Anonymous], QUALITY DEATH RANKIN; [Anonymous], DAT COMM DIAGN PROGN; Aoun SM, 2005, PALLIATIVE MED, V19, P461, DOI 10.1191/0269216305pm1057oa; Arana M, 1993, ATEN PRIM, V12, P523; Astudillo W, 2005, ALIVIO SITUACIONES D; Aujoulat I, 2002, PATIENT EDUC COUNS, V47, P213, DOI 10.1016/S0738-3991(01)00197-5; Baeke G, 2011, ETHNIC HEALTH, V16, P259, DOI 10.1080/13557858.2011.573538; Bajo Garcia J, 1990, ATEN PRIM, V7, P538; Bayes R, 1999, MED PALIATIVA, V6, P140; Beccaro M, 2006, J EPIDEMIOL COMMUN H, V60, P412, DOI 10.1136/jech.2005.043646; Beccaro M, 2010, J PAIN SYMPTOM MANAG, V39, P1003, DOI 10.1016/j.jpainsymman.2009.11.317; Beck S, 2008, MED HEALTH CARE PHIL, V11, P7, DOI 10.1007/s11019-007-9097-8; Becker G, 2007, J PAIN SYMPTOM MANAG, V33, P711, DOI 10.1016/j.jpainsymman.2006.09.030; Belderrain Belderrain P, 1999, Aten Primaria, V24, P285; Benini F, 2011, ANN I SUPER SANITA, V47, P253, DOI 10.4415/ANN_11_03_03; Bennett MI, 2010, PALLIATIVE MED, V24, P456, DOI 10.1177/0269216310366064; Bernheim JL, 2008, BRIT MED J, V336, P864, DOI 10.1136/bmj.39497.397257.AD; Bickel H, 1998, Z GERONTOL GERIATR, V31, P193, DOI 10.1007/s003910050034; Bilsen J, 2005, PALLIATIVE MED, V19, P151, DOI 10.1191/0269216305pm993oa; Bilsen JJR, 2004, J ADV NURS, V47, P583, DOI 10.1111/j.1365-2648.2004.02982.x; Bilsen J, 2007, SOC SCI MED, V65, P803, DOI 10.1016/j.socscimed.2007.04.016; Bilsen J, 2009, NEW ENGL J MED, V361, P1119, DOI 10.1056/NEJMc0904292; Bock M, 2007, INTENS CARE MED, V33, P1041, DOI 10.1007/s00134-007-0632-0; Borasio GD, 2004, NERVENARZT, V75, P1187, DOI 10.1007/s00115-004-1751-2; Borgsteede SD, 2007, PALLIATIVE MED, V21, P417, DOI 10.1177/0269216307079821; Borgsteede SD, 2006, BRIT J GEN PRACT, V56, P20; Broeckaert B, 2002, ETHICS PALLIATIVE CA, P166; Broeckaert B, 2003, ACTA HOSPITALIA, V43, P9; Buiting HM, 2011, J PAIN SYMPTOM MANAG, V42, P32, DOI 10.1016/j.jpainsymman.2010.10.260; Buiting HM, 2008, EUR J PUBLIC HEALTH, V18, P681, DOI 10.1093/eurpub/ckn084; Bunch Eli Haugen, 2002, Nurs Inq, V9, P187, DOI 10.1046/j.1440-1800.2002.00143.x; Burchardi N, 2005, J NEUROL SCI, V237, P67, DOI 10.1016/j.jns.2005.05.013; Cannaerts N, 2004, QUAL HEALTH RES, V14, P816, DOI 10.1177/1049732304265977; Caro Garcia M P, 2008, Rev Enferm, V31, P54; Cartwright C, 2007, PALLIATIVE MED, V21, P295, DOI 10.1177/0269216307079063; Caruso A, 2000, TUMORI, V86, P199, DOI 10.1177/030089160008600304; Casillas Santana L, 2004, EDUCARE, V21, P6; del Palacio EC, 2007, MED PALIATIVA, V14, P236; CATALANFERNANDEZ JG, 1991, MED CARE, V29, P841, DOI 10.1097/00005650-199109000-00005; Centeno C, 2007, PALLIATIVE MED, V21, P463, DOI 10.1177/0269216307081942; Centeno-Cortes Carlos, 1994, Palliative Medicine, V8, P39, DOI 10.1177/026921639400800107; Chabot BE, 2009, SOC SCI MED, V68, P1745, DOI 10.1016/j.socscimed.2009.03.005; Chambaere Kenneth, 2010, J Pain Symptom Manage, V39, pe5, DOI 10.1016/j.jpainsymman.2009.10.001; Cherny NI, 2010, ANN ONCOL, V21, P615, DOI 10.1093/annonc/mdp581; CIS, 2002, ACT OP MED ANT EUT; CIS, 2008, REL; CIS, 2009, AT PAC CON ENF FAS T; CIS, 1995, PERF ACT SOC ESP; Claessens P, 2007, J HOSPICE PALLIATIVE, V9; Clark D., 2002, ETHICS PALLIATIVE CA; Clark D, 2000, PALLIATIVE MED, V14; Clark D., 1998, MORTALITY, V3, P43, DOI [10.1080/713685885, DOI 10.1080/713685885]; Clark David, 1999, MORTALITY, V4, P225, DOI 10.1080/713685979; Cohen J, 2007, J EPIDEMIOL COMMUN H, V61, P1062, DOI 10.1136/jech.2006.056341; Cohen J, 2006, EUR J PUBLIC HEALTH, V16, P663, DOI 10.1093/eurpub/ckl042; Cohen J, 2006, HEALTH POLICY, V78, P319, DOI 10.1016/j.healthpol.2005.11.003; Cohen J, 2006, SOC SCI MED, V63, P743, DOI 10.1016/j.socscimed.2006.01.026; Cohen J, 2011, J PAIN SYMPTOM MANAG, V42, P839, DOI 10.1016/j.jpainsymman.2011.02.017; Cohen J, 2010, HEALTH PLACE, V16, P784, DOI 10.1016/j.healthplace.2010.04.003; Cohen J, 2010, J CLIN ONCOL, V28, P2267, DOI 10.1200/JCO.2009.23.2850; Corli O, 2009, PALLIATIVE MED, V23, P354, DOI 10.1177/0269216308100772; Cortes CC, 1998, MED CLIN-BARCELONA, V110, P744; Costantini M, 2002, J PAIN SYMPTOM MANAG, V23, P221, DOI 10.1016/S0885-3924(01)00405-5; Costantini M, 2009, ANN ONCOL, V20, P729, DOI 10.1093/annonc/mdn700; Costantini M, 2000, PUBLIC HEALTH, V114, P15, DOI 10.1016/S0033-3506(00)00302-4; Costantini M, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-127; Cosyns M, 2008, Rev Med Brux, V29, P77; Dataanalyis, 2003, COMM DIAGN PROGN ONC; De Bal N, 2006, INT J NURS STUD, V43, P589, DOI 10.1016/j.ijnurstu.2005.08.003; de Casterle BD, 2006, J MED ETHICS, V32, P187, DOI 10.1136/jme.2005.011783; De Conno F, 1996, EUROPEAN J PALLIATIV, V3, P38; de Graaff FM, 2003, INT J NURS STUD, V40, P797, DOI 10.1016/S0020-7489(03)00078-6; de Graaff Fuusje M, 2010, BMC Palliat Care, V9, P19, DOI 10.1186/1472-684X-9-19; de Haan Jurriaan, 2002, Med Law Rev, V10, P57, DOI 10.1093/medlaw/10.1.57; de Vogel-Voogt E, 2007, PALLIATIVE MED, V21, P243, DOI 10.1177/0269216307077352; Linares MD, 2007, ENFERM INTENSIV, V18, P3, DOI 10.1016/S1130-2399(07)74384-5; Delfosse Marie-Luce, 2008, Bull Soc Sci Med Grand Duche Luxemb, P299; Deliens L, 2001, KNAW VERHAN, V102, P121; Deliens L, 2000, LANCET, V356, P1806, DOI 10.1016/S0140-6736(00)03233-5; Denier Y, 2009, MED HLTH CARE PHILOS; Denier Y, 2009, J PALLIAT CARE, V25, P264, DOI 10.1177/082585970902500404; Deschepper R, 2006, BRIT J GEN PRACT, V56, P14; Deschepper R, 2008, PATIENT EDUC COUNS, V71, P52, DOI 10.1016/j.pec.2007.11.015; Desmedt MS, 2011, BMC PALLIAT CARE, V10, DOI 10.1186/1472-684X-10-2; Dierickx K, 1998, ACTA NEUROCHIR, V140, P481, DOI 10.1007/s007010050129; DiMola G, 1996, ANN ONCOL, V7, P907, DOI 10.1093/oxfordjournals.annonc.a010792; Dominguez B, 1985, JANO H, p[654, 57]; Esteban A, 2001, INTENS CARE MED, V27, P1744, DOI 10.1007/s00134-001-1111-7; Evans N, 2012, J PAIN SYMPTOM MANAG, V43, P261, DOI 10.1016/j.jpainsymman.2011.04.012; Evans N, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-141; Ewers M, 2007, J PUBLIC HLTH, V15, P475; Fainsinger RL, 2000, PALLIATIVE MED, V14, P257, DOI 10.1191/026921600666097479; Fainsinger RL, 2003, J PALLIATIVE CARE, V19, P43, DOI 10.1177/082585970301900108; FENIGSEN R, 1990, ISSUES LAW MED, V6, P229; Fernandez Diaz R, 1996, ATEN PRIM, V17, P389; Fernandez Suarez A, 2002, Aten Primaria, V30, P449; Ferrario SR, 2004, PALLIATIVE MED, V18, P129, DOI 10.1191/0269216304pm870oa; Ferrario SR, 2003, HEALTH SOC CARE COMM, V11, P103, DOI 10.1046/j.1365-2524.2003.00410.x; Goncalves JAF, 2010, SUPPORT CARE CANCER, V18, P1271, DOI 10.1007/s00520-009-0743-y; Field A, 2002, SOC WORK HEALTH CARE, V35, P523, DOI 10.1300/J010v35n01_10; Fissell RB, 2005, KIDNEY INT, V68, P1282, DOI 10.1111/j.1523-1755.2005.00525.x; Fonseca AM, 2010, INT J PALLIAT NURS, V16, P476, DOI 10.12968/ijpn.2010.16.10.79214; Forde R, 1997, SOC SCI MED, V45, P887, DOI 10.1016/S0277-9536(96)00430-3; Forde R, 2002, RESUSCITATION, V55, P235, DOI 10.1016/S0300-9572(02)00270-8; Formiga F, 2004, QJM-INT J MED, V97, P803, DOI 10.1093/qjmed/hch135; Francke AL, 2000, PALLIATIEVE ZORG VAN; French J, 1973, Am J Nurs, V73, P502, DOI 10.2307/3422716; Garcia Orellan R, 2003, CUIDADOS PALIATIVOS, P305; Gastmans C, 2006, HEALTH POLICY, V76, P169, DOI 10.1016/j.healthpol.2005.09.003; Gastmans C, 2006, J ADV NURS, V54, P53, DOI 10.1111/j.1365-2648.2006.03790.x; Gastmans C, 2004, J MED ETHICS, V30, P212, DOI 10.1136/jme.2003.005082; Gastmans C, 2006, PATIENT EDUC COUNS, V63, P188, DOI 10.1016/j.pec.2005.10.004; Georges JJ, 2002, J CLIN NURS, V11, P785, DOI 10.1046/j.1365-2702.2002.00654.x; Giannini A, 2003, INTENS CARE MED, V29, P1902, DOI 10.1007/s00134-003-1919-4; Garcia EG, 2005, ENFERM CLIN, V15, P220; Goldsteen M, 2006, PATIENT EDUC COUNS, V64, P378, DOI 10.1016/j.pec.2006.04.008; Gomez Pavon FJ, 2002, CARACTERICAS ANCIANO; Gomez-Batiste X., 2001, Medicina Paliativa, V8, P134; Goncalves J Ferraz, 2003, J Palliat Med, V6, P895, DOI 10.1089/109662103322654776; Goncalves JASF, 2001, SUPPORT CARE CANCER, V9, P4; Gordijn B, 2004, HEALTH CARE ANAL, V12, P195, DOI 10.1023/B:HCAN.0000044926.05523.ef; Grassi L, 2000, SUPPORT CARE CANCER, V8, P40; Groot MM, 2005, PALLIATIVE MED, V19, P111, DOI 10.1191/0269216305pm937oa; Gysels M, 2011, CULTURE PRI IN PRESS; Gysels M, 2007, RES METHODS PALLIATI; Harding R, 2010, EUR J CANCER, V46, P1493, DOI 10.1016/j.ejca.2010.01.035; Hedayat KM, 2002, ITALIAN J PEDIAT, V28, P112; Heller A, 2005, Z GERONTOL GERIATR, V36, P360; Hermsen Maaike A, 2003, Med Health Care Philos, V6, P263, DOI 10.1023/A:1025986700278; Herremans J, 2008, REV MED BRUX, V29; Herremans J, 2008, B SOC SCI MED GRAND, V3, P302; Higginson IJ, 2008, EUR J CANCER, V44, P1414, DOI 10.1016/j.ejca.2008.02.024; HOLLAND JC, 1987, CANCER INVEST, V5, P151, DOI 10.3109/07357908709018468; Houtepen R, 2003, NURS ETHICS, V10, P377, DOI 10.1191/0969733003ne620oa; Houttekier D, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-228; Houttekier D, 2010, J AM GERIATR SOC, V58, P751, DOI 10.1111/j.1532-5415.2010.02771.x; Houttekier D, 2010, HEALTH PLACE, V16, P132, DOI 10.1016/j.healthplace.2009.09.005; Hov R, 2007, J CLIN NURS, V16, P203, DOI 10.1111/j.1365-2702.2006.01427.x; Huijer M, 2000, J MED ETHICS, V26, P358, DOI 10.1136/jme.26.5.358; Hurst SA, 2007, J MED ETHICS, V33, P51, DOI 10.1136/jme.2005.014266; Husebo Bettina Sandgathe, 2005, Tidsskr Nor Laegeforen, V125, P1352; Hynninen M, 2008, ACTA ANAESTH SCAND, V52, P1081, DOI 10.1111/j.1399-6576.2008.01636.x; Inghelbrecht E, 2009, PALLIATIVE MED, V23, P649, DOI 10.1177/0269216309106810; Inghelbrecht E, 2008, INT J NURS STUD, V45, P1022, DOI 10.1016/j.ijnurstu.2007.06.005; Instituto Nacional de Estatistica de Portugal, 2005, OB DISTR GEOGR RES N; Jans J, 2005, J SOC CHRIST ETHICS, V25, P163, DOI 10.5840/jsce200525210; Janssens R, 1999, REPORT CONCEPTS PALL; Jimeno Aranda A, 1993, ATEN PRIM, V11, P120; Jordhoy MS, 2000, LANCET, V356, P888, DOI 10.1016/S0140-6736(00)02678-7; Jordhoy MS, 2001, BRIT J CANCER, V85, P1478, DOI 10.1054/bjoc.2001.2116; Jordhoy MS, 2001, J CLIN ONCOL, V19, P3884, DOI 10.1200/JCO.2001.19.18.3884; Jox RJ, 2008, PALLIATIVE MED, V22, P675, DOI 10.1177/0269216308089303; Jubb AM, 2002, J MED ETHICS, V28, P342, DOI 10.1136/jme.28.6.342; Justinger C, 2009, CHIRURG, V80, P455, DOI 10.1007/s00104-008-1662-z; Kaarbo E, 2011, J CLIN NURS, V20, P1125, DOI 10.1111/j.1365-2702.2009.03171.x; Kaasa S, 2006, PALLIATIVE MED, V20, P727, DOI 10.1177/0269216306072620; Kirschner R, 1998, Gesundheitswesen, V60, P247; Klastersky J, 2004, Rev Med Brux, V25, P69; Kleinman A., 1980, PATIENTS HEALERS CON; Klinkenberg M, 2004, SOC SCI MED, V59, P2467, DOI 10.1016/j.socscimed.2004.04.006; Kuhnlein P, 2008, AMYOTROPH LATERAL SC, V9, P91, DOI 10.1080/17482960701830495; Lafuerza A, 1998, ONCOLOGIA-BARCELONA, V21, P91; Lemiengre J, 2009, MED HLTH CARE PHILOS; Lemiengre J, 2008, PATIENT EDUC COUNS, V71, P293, DOI 10.1016/j.pec.2007.12.010; Lemiengre J, 2007, HEALTH POLICY, V84, P170, DOI 10.1016/j.healthpol.2007.05.007; Levorato A, 2001, SUPPORT CARE CANCER, V9, P420, DOI 10.1007/s005200100267; LINDSETH A, 1994, J ADV NURS, V20, P245, DOI 10.1046/j.1365-2648.1994.20020245.x; Locatelli C, 2010, J GERIATR ONCOL, V1, P73, DOI 10.1016/j.jgo.2010.07.002; Lopez de Maturana A, 1993, Palliat Med, V7, P39, DOI 10.1177/026921639300700107; Lorensen M, 2003, NURS ETHICS, V10, P175, DOI 10.1191/0969733003ne592oa; Lorente Lopez M., 2004, TRAB SOC SALUD, V49, P83; Lucchiari C, 2010, LIFE SPAN DISABIL, V13, P71; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; Maggiore SM, 2005, INTENS CARE MED, V31, P997, DOI 10.1007/s00134-005-2645-x; Mahtani-Chugani V, 2010, PALLIATIVE MED, V24, P787, DOI 10.1177/0269216310380296; Meeussen K, 2011, J PAIN SYMPTOM MANAG, V42, P565, DOI 10.1016/j.jpainsymman.2011.01.011; Meeussen K, 2011, J PAIN SYMPTOM MANAG, V41, P1060, DOI 10.1016/j.jpainsymman.2010.09.020; Menaca A, CRITICAL REV ONCOLOG; Mercadante S, 1996, J PAIN SYMPTOM MANAG, V11, P108, DOI 10.1016/0885-3924(95)00147-6; Miccinesi G, 2005, SOC SCI MED, V60, P1961, DOI 10.1016/j.socscimed.2004.08.061; Miro G, 2006, MED CLIN-BARCELONA, V126, P567, DOI 10.1157/13087707; Molina Linde JM, 2006, MED PALIATIVA, P1311; Molina Linde JM, 2005, MED PAL, V12, P83; Monti M, 2004, SUPPORT CARE CANCER, V12, P752, DOI 10.1007/s00520-004-0617-2; Morasso G, 1997, PSYCHO-ONCOL, V6, P212, DOI 10.1002/(SICI)1099-1611(199709)6:3<212::AID-PON275>3.0.CO;2-X; Morasso G, 2008, PSYCHO-ONCOLOGY, V17, P1073, DOI 10.1002/pon.1332; Morris D, 1999, CULTURE PAIN; Mortier F, 2003, MED DECIS MAKING, V23, P502, DOI 10.1177/0272989X03260137; Muller-Busch HC, 2005, MED HEALTH CARE PHIL, V7, P333; *NIH, 2004, NAT I HLTH STAT OF T; Nordam A, 2003, NURS ETHICS, V10, P388, DOI 10.1191/0969733003ne589oa; Norum Jan, 1993, Tidsskrift for den Norske Laegeforening, V113, P1102; Norum Jan, 1993, Tidsskrift for den Norske Laegeforening, V113, P1107; Norwood F, 2007, MED ANTHROPOL, V26, P139, DOI 10.1080/01459740701283165; Nunez Olarte J M, 2001, Cancer Control, V8, P46; Nyhsen C, 1999, MED KLIN, V94, P536, DOI 10.1007/BF03044950; Nys H, 2000, THEOR MED BIOETH, V21, P425, DOI 10.1023/A:1009921306197; Olano Espinosa E, 1997, Aten Primaria, V19, P483; Oliver C., 2004, MORTALITY, V9, P235, DOI DOI 10.1080/13576270412331272770; Onwuteaka-Philipsen BD, 2006, ARCH INTERN MED, V166, P921, DOI 10.1001/archinte.166.8.921; Onwuteaka-Philipsen BD, 2003, LANCET, V362, P395, DOI 10.1016/S0140-6736(03)14029-9; Osse BHP, 2005, SUPPORT CARE CANCER, V13, P722, DOI 10.1007/s00520-004-0771-6; Osse BHP, 2002, PATIENT EDUC COUNS, V47, P195, DOI 10.1016/S0738-3991(02)00019-8; Osuna E, 1998, J MED ETHICS, V24, P106, DOI 10.1136/jme.24.2.106; Pacheco R, 1989, Med Law, V8, P243; Palomar Gallardo C, 2002, MED PALIATIVA, V9, P3; Palomar Gallardo C, 2001, QUE ENTIENDEN CUIDAD, P37; Pardon K, 2009, PATIENT EDUC COUNS, V77, P421, DOI 10.1016/j.pec.2009.09.011; Payne SA, 2008, PALLIATIVE MED, V22, P336, DOI 10.1177/0269216308090072; Pedersen R, 2008, J MED ETHICS, V34, P230, DOI 10.1136/jme.2006.018531; Pereira SM, 2011, INT J PALLIAT NURS, V17, P373, DOI 10.12968/ijpn.2011.17.8.373; Perez-Carceles M D, 1999, Med Law, V18, P497; Pettila V, 2002, ACTA ANAESTH SCAND, V46, P947, DOI 10.1034/j.1399-6576.2002.460804.x; Pimentel FL, 1999, SUPPORT CARE CANCER, V7, P407, DOI 10.1007/s005200050301; Pinto C, 2009, ONCONEWS, V3, P16; PINZON LCE, 2011, J PAIN SYMPTOM MANAG, V41, P893, DOI DOI 10.1016/J.JPAINSYMMAN.2010.07.016; Pique Prado E, 1999, METAS ENFERMERIA, V2, P47; Porta M, 1997, PALLIATIVE MED, V11, P116, DOI 10.1177/026921639701100205; Poveda de Agustin J, 1992, JANO, V1009, P93; PRONZATO P, 1994, SUPPORT CARE CANCER, V2, P242, DOI 10.1007/BF00365729; Proot IM, 2004, PALLIATIVE MED, V18, P53, DOI 10.1191/0268216304pm818oa; Proot IM, 2003, SCAND J CARING SCI, V17, P113, DOI 10.1046/j.1471-6712.2003.00220.x; Puts M T, 2004, Ned Tijdschr Geneeskd, V148, P277; Ramon I, 2006, REV CLIN ESP, V206, P549, DOI 10.1157/13096302; Richards MA, 1998, PALLIATIVE MED, V12, P399, DOI 10.1191/026921698673432534; Rietjens JAC, 2006, ARCH INTERN MED, V166, P749, DOI 10.1001/archinte.166.7.749; Rietjens JAC, 2005, SOC SCI MED, V61, P1723, DOI 10.1016/j.socscimed.2005.03.024; Riley J, 2005, LANCET, V365, P735; Ringdal GI, 2004, PALLIATIVE MED, V18, P108, DOI 10.1191/0269216304pm878oa; Ringdal GI, 2002, J PAIN SYMPTOM MANAG, V24, P53, DOI 10.1016/S0885-3924(02)00417-7; Ringdal GI, 2001, J PAIN SYMPTOM MANAG, V22, P1016, DOI 10.1016/S0885-3924(01)00363-3; Ripamonti C, 2000, TUMORI J, V86, P412, DOI 10.1177/030089160008600509; Rodriguez G, 2003, NEUROL SCI, V24, P329, DOI 10.1007/s10072-003-0184-1; Rodriguez R, 2005, MED PALIATIVA, V12, P3; Rodriguez Rodriguez C, 2001, CULTURA CUIDADOS, V5, P45; Romoren TI, 2003, AGEING SOC, V23, P471, DOI 10.1017/S0144686X03001247; Rosario Otegui P., 2000, MED Y CULTURA ESTUDI; Rossi PG, 2007, J EPIDEMIOL COMMUN H, V61, P547, DOI 10.1136/jech.2005.045138; Ruiz-Bentez M., 2008, PSICOONCOLOG A, V5, P53, DOI 10.5209/rev_PSIC.2008.v5.n1.16351; Rurup ML, 2012, PALLIATIVE MED, V26, P43, DOI 10.1177/0269216311413836; Rurup ML, 2006, SOC SCI MED, V62, P1552, DOI 10.1016/j.socscimed.2005.08.010; Rurup ML, 2005, J AM GERIATR SOC, V53, P1138, DOI 10.1111/j.1532-5415.2005.53354.x; Saez FDN, 2006, INTENS CARE MED, V32, P1086, DOI 10.1007/s00134-006-0140-7; Safonte-Strumolo N., 2000, FAMILY J COUNSELING, V8, P334, DOI [10.1177/1066480700084002, DOI 10.1177/1066480700084002]; Sahm S, 2005, Med Health Care Philos, V8, P297, DOI 10.1007/s11019-005-2108-8; Sahm S, 2005, SUPPORT CARE CANCER, V13, P206, DOI 10.1007/s00520-004-0725-z; Sahm S, 2005, J MED ETHICS, V31, P437, DOI 10.1136/jme.2004.009605; Sahm SW, 2000, J MED PHILOS, V25, P195, DOI 10.1076/0360-5310(200004)25:2;1-O;FT195; Sanz de la Torre JC, 2000, ENFERMERIA CIENTIFIC, p[220, 17]; Saunders CM, 1997, HOSPICE CARE INT SCI; Schaffer MA, 2007, NURS ETHICS, V14, P242, DOI 10.1177/0969733007073707; Schildmann J, 2006, J MED ETHICS, V32, P567, DOI 10.1136/jme.2005.013904; Rio-Valle JS, 2009, J PALLIAT CARE, V25, P191, DOI 10.1177/082585970902500306; Schou K, 2008, NURS PHILOS, V9, P233, DOI 10.1111/j.1466-769X.2008.00374.x; Sehgal AR, 1996, JAMA-J AM MED ASSOC, V276, P1652, DOI 10.1001/jama.276.20.1652; Servais O, 2001, RECH SOCIOLOGIQUES, V32, P65; Servillo G, 2008, INTENS CARE MED, V34, P1333, DOI 10.1007/s00134-008-1057-0; Seymour J, 2007, SOCIOL HEALTH ILL, V29, P872, DOI 10.1111/j.1467-9566.2007.01045.x; Seymour JE, 2007, SOC SCI MED, V64, P1679, DOI 10.1016/j.socscimed.2006.11.030; Simon-Lorda P, 2008, BIOETHICS, V22, P346, DOI 10.1111/j.1467-8519.2008.00644.x; Smets T, 2011, J PAIN SYMPTOM MANAG, V41, P580, DOI 10.1016/j.jpainsymman.2010.05.015; Solem PE, 1981, TIDSSKRIFT NORSK S1, V1, P7; SOLHEIM K, 1990, Tidsskrift for den Norske Laegeforening, V110, P1957; Solsona JF, 2003, MED CLIN-BARCELONA, V120, P335, DOI 10.1157/13044234; Sorbye L W, 2000, Int J Palliat Nurs, V6, P71; Sorbye LW, 1999, SCAND J CARING SCI, V13, P102, DOI 10.1080/02839319950162642; Sprung CL, 2003, JAMA-J AM MED ASSOC, V290, P790, DOI 10.1001/jama.290.6.790; Sullivan M, 1998, J AM GERIATR SOC, V46, P1251, DOI 10.1111/j.1532-5415.1998.tb04541.x; Surbone A, 2004, CRIT REV ONCOL HEMAT, V52, P165, DOI 10.1016/j.critrevonc.2004.09.002; SURBONE A, 1993, SUPPORT CARE CANCER, V1, P89, DOI 10.1007/BF00366901; Swarte NB, 2003, BMJ-BRIT MED J, V327, P189, DOI 10.1136/bmj.327.7408.189; Tallgren M, 2005, ACTA ANAESTH SCAND, V49, P1092, DOI 10.1111/j.1399-6576.2005.00799.x; TELJE J, 1990, Tidsskrift for den Norske Laegeforening, V110, P1954; The Anne-Mei., 2009, VERLOSSERS NAAST GOD; THOMSEN OO, 1993, LANCET, V341, P473, DOI 10.1016/0140-6736(93)90218-6; Timmermann M, 2009, J PALLIAT CARE, V25, P181, DOI 10.1177/082585970902500305; Tolley DC, 2007, J PAIN SYMPTOM MANAG, V33, P90, DOI 10.1016/j.jpainsymman.2006.10.007; Torjuul Kirsti, 2005, BMC Med Ethics, V6, pE7; Toro LB, 2007, MED PALIATIVA, V14, P164; Toscani F, 2005, J PAIN SYMPTOM MANAG, V30, P33, DOI 10.1016/j.jpainsymman.2005.01.013; Tranoy KE, 1988, MED ETHICS NORWAY MO; Trentin L., 2001, J HEADACHE PAIN, V2, P73, DOI DOI 10.1007/PL00012189; Uceda ME, 2007, MED PALIATIVA, V14, P69; UDEN G, 1992, J ADV NURS, V17, P1028, DOI 10.1111/j.1365-2648.1992.tb02036.x; van Delden JJM, 2004, J MED ETHICS, V30, P447, DOI 10.1136/jme.2002.002857; Van den Block L, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-69; Van den Block L, 2008, ARCH INTERN MED, V168, P1747, DOI 10.1001/archinte.168.16.1747; Van den Block L, 2007, JAMA-J AM MED ASSOC, V298, P1638, DOI 10.1001/jama.298.14.1638; Van den Block L, 2006, J CLIN ONCOL, V24, P2842, DOI 10.1200/JCO.2005.03.7531; Van den Eynden B, 2000, SUPPORT CARE CANCER, V8, P59; van der Heide A, 2003, LANCET, V362, P345, DOI 10.1016/S0140-6736(03)14019-6; Van Marwijk H, 2007, PALLIATIVE MED, V21, P609, DOI 10.1177/0269216307082475; van Oorschot B, 2006, J MED ETHICS, V32, P623, DOI 10.1136/jme.2005.015032; van Oorschot B., 2004, ETHIK MED, V16, P112, DOI [10.1007/s00481-004-0299-9, DOI 10.1007/S00481-004-0299-9]; Van Parys T, 2003, PALLIATIVE MED, V17, P111, DOI 10.1191/0269216303pm763op; Van Rensbergen G, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-178; van Staa AL, 2000, PATIENT EDUC COUNS, V41, P93, DOI 10.1016/S0738-3991(00)00119-1; Van Wesemael Y, 2010, EVALUATION HLTH PROF; Van Wesemael Y, 2009, HEALTH SERV RES, V44, P2180, DOI 10.1111/j.1475-6773.2009.01042.x; Van Wesemael Yanna C, 2009, BMC HLTH SERVICES RE, V9; van Wijmen MPS, 2010, BIOETHICS, V24, P118, DOI 10.1111/j.1467-8519.2009.01788.x; VANDERWAL G, 1992, FAM PRACT, V9, P135, DOI 10.1093/fampra/9.2.135; Varrassi G, 2003, J PAIN SYMPTOM MANAG, V26, P590, DOI 10.1016/S0885-3924(03)00224-0; VERONESI A, 1995, EUR J CANCER, V31A, P425, DOI 10.1016/0959-8049(94)00489-R; Verpoort C, 2004, J ADV NURS, V47, P592, DOI 10.1111/j.1365-2648.2004.03148.x; Vincent JL, 1998, INTENS CARE MED, V24, P1251, DOI 10.1007/s001340050758; VINCENT JL, 1990, INTENS CARE MED, V16, P256, DOI 10.1007/BF01705162; Vincent JL, 1999, CRIT CARE MED, V27, P1626, DOI 10.1097/00003246-199908000-00042; Visentin M, 2001, J PAIN SYMPTOM MANAG, V22, P925, DOI 10.1016/S0885-3924(01)00355-4; Voltz R, 1998, J PAIN SYMPTOM MANAG, V16, P153, DOI 10.1016/S0885-3924(98)00067-0; Voorhees J, 2009, J AM GERIATR SOC, V57, pS76; Wanden-Berghe C, 2009, NUTR HOSP, V24, P732, DOI 10.3305/nh.2009.24.6.4558; Welshman AT, 2003, PALLIATIVE MED, V17, P122, DOI 10.1191/0269216303pm724op; Wood WA, 2009, ONCOLOGIST, V14, P77, DOI 10.1634/theoncologist.2008-0158; Zamperetti N, 2006, INTENS CARE MED, V32, P1620, DOI 10.1007/s00134-006-0330-3; Zylicz Z, 1993, AM J HOSP PALLIAT ME, V4, P30	325	86	86	1	53	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 3	2012	7	4							e34188	10.1371/journal.pone.0034188	http://dx.doi.org/10.1371/journal.pone.0034188			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	952PZ	22509278	gold, Green Published, Green Submitted			2023-01-03	WOS:000304805900016
J	MacArthur, GJ; Minozzi, S; Martin, N; Vickerman, P; Deren, S; Bruneau, J; Degenhardt, L; Hickman, M				MacArthur, Georgie J.; Minozzi, Silvia; Martin, Natasha; Vickerman, Peter; Deren, Sherry; Bruneau, Julie; Degenhardt, Louisa; Hickman, Matthew			Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C-VIRUS; RISK BEHAVIOR; ANTIRETROVIRAL THERAPY; METHADONE TREATMENT; SAN-FRANCISCO; VACCINE TRIAL; NEW-YORK; USERS; INFECTION	Objective To quantify the effect of opiate substitution treatment in relation to HIV transmission among people who inject drugs. Design Systematic review and meta-analysis of prospective published and unpublished observational studies. Data sources Search of Medline, Embase, PsychINFO, and the Cochrane Library from the earliest year to 2011 without language restriction. Review methods We selected studies that directly assessed the impact of opiate substitution treatment in relation to incidence of HIV and studies that assessed incidence of HIV in people who inject drugs and that might have collected data regarding exposure to opiate substitution treatment but not have reported it. Authors of these studies were contacted. Data were extracted by two reviewers and pooled in a meta-analysis with a random effects model. Results Twelve published studies that examined the impact of opiate substitution treatment on HIV transmission met criteria for inclusion, and unpublished data were obtained from three additional studies. All included studies examined methadone maintenance treatment. Data from nine of these studies could be pooled, including 819 incident HIV infections over 23 608 person years of follow-up. Opiate substitution treatment was associated with a 54% reduction in risk of HIV infection among people who inject drugs (rate ratio 0.46, 95% confidence interval 0.32 to 0.67; P<0.001). There was evidence of heterogeneity between studies (I-2=60%, chi(2)=20.12, P=0.010), which could not be explained by geographical region, site of recruitment, or the provision of incentives. There was weak evidence for greater benefit associated with longer duration of exposure to opiate substitution treatment. Conclusion Opiate substitution treatment provided as maintenance therapy is associated with a reduction in the risk of HIV infection among people who inject drugs. These findings, however, could reflect comparatively high levels of motivation to change behaviour and reduce injecting risk behaviour among people who inject drugs who are receiving opiate substitution treatment.	[MacArthur, Georgie J.; Martin, Natasha; Vickerman, Peter; Hickman, Matthew] Univ Bristol, Sch Social & Community Med, Bristol BS8 2PS, Avon, England; [Minozzi, Silvia] Cochrane Drugs & Alcohol Grp, Dept Epidemiol, Lazio Reg Hlth Serv, Rome, Italy; [Martin, Natasha] London Sch Hyg & Trop Med, Dept Global Hlth & Dev, London WC1, England; [Vickerman, Peter] London Sch Hyg & Trop Med, Ctr Res Drugs & Hlth Behav, London WC1, England; [Deren, Sherry] NYU, Coll Nursing, Ctr Drug Use & HIV Res, New York, NY USA; [Bruneau, Julie] Ctr Hosp Univ Montreal, Res Ctr CRCHUM, Montreal, PQ, Canada; [Degenhardt, Louisa] Univ New S Wales, Natl Drug & Alcohol Res Ctr, NHMRC, Sydney, NSW, Australia; [Degenhardt, Louisa] Univ Melbourne, Ctr Hlth Policy Programs & Econ, NHMRC, Melbourne, Vic, Australia	University of Bristol; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; New York University; Universite de Montreal; University of New South Wales Sydney; University of Sydney; University of Melbourne	MacArthur, GJ (corresponding author), Univ Bristol, Sch Social & Community Med, Bristol BS8 2PS, Avon, England.	georgie.macarthur@bristol.ac.uk	Hickman, Matthew/Y-2400-2019; Minozzi, Silvia/ABG-1115-2020; Degenhardt, Louisa J/D-4515-2012	Hickman, Matthew/0000-0001-9864-459X; Minozzi, Silvia/0000-0003-0471-8581; Degenhardt, Louisa J/0000-0002-8513-2218; Vickerman, Peter/0000-0002-8291-5890; Martin, Natasha/0000-0001-8344-1810; MacArthur, Georgie/0000-0003-2047-6519	South West Public Health Training Scheme; MRC New Investigators Award [G0701627]; Nationally Integrated Quantitative Understanding of Addiction Harm (NIQUAD) MRC addiction research cluster; Centre for the Development and Evaluation of Complex Interventions for Public Health Improvement (DECIPHer); UKCRC Public Health Research: Centre of Excellence; British Heart Foundation; Cancer Research UK; Economic and Social Research Council [RES-590-28-0005]; Medical Research Council; Welsh Assembly Government; Wellcome Trust under UK Clinical Research Collaboration [WT087640MA]; ESRC [ES/G007543/1] Funding Source: UKRI; MRC [G0701627, G1000021] Funding Source: UKRI; Economic and Social Research Council [ES/G007543/1] Funding Source: researchfish; Medical Research Council [G1000021, G0701627] Funding Source: researchfish	South West Public Health Training Scheme; MRC New Investigators Award(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Nationally Integrated Quantitative Understanding of Addiction Harm (NIQUAD) MRC addiction research cluster(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Centre for the Development and Evaluation of Complex Interventions for Public Health Improvement (DECIPHer); UKCRC Public Health Research: Centre of Excellence; British Heart Foundation(British Heart Foundation); Cancer Research UK(Cancer Research UK); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Welsh Assembly Government; Wellcome Trust under UK Clinical Research Collaboration(Wellcome Trust); ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	GJM is funded by the South West Public Health Training Scheme; PV is funded by an MRC New Investigators Award (G0701627); MH is supported by the Nationally Integrated Quantitative Understanding of Addiction Harm (NIQUAD) MRC addiction research cluster. The work was undertaken with the support of The Centre for the Development and Evaluation of Complex Interventions for Public Health Improvement (DECIPHer), a UKCRC Public Health Research: Centre of Excellence. Funding from the British Heart Foundation, Cancer Research UK, Economic and Social Research Council (RES-590-28-0005), Medical Research Council, the Welsh Assembly Government and the Wellcome Trust (WT087640MA), under the auspices of the UK Clinical Research Collaboration, is gratefully acknowledged. The funders had no role in the design, execution, and writing up of the study.	Bruandet A, 2006, REV EPIDEMIOL SANTE, V54, p1S15; Bruneau J, 2011, AM J EPIDEMIOL, V173, P1049, DOI 10.1093/aje/kwq479; Celentano DD, 1999, AM J EPIDEMIOL, V149, P15; CHITWOOD DD, 1995, AM J PUBLIC HEALTH, V85, P1538, DOI 10.2105/AJPH.85.11.1538; Cochrane Effectiveness of Practice and Organisation of Care, 2009, SUGG RISK BIAS CRIT; Cornish R, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5475; Degenhardt L, 2012, LANCET, V379, P55, DOI 10.1016/S0140-6736(11)61138-0; Degenhardt L, 2010, LANCET, V376, P285, DOI 10.1016/S0140-6736(10)60742-8; Deren S, 2004, JAIDS-J ACQ IMM DEF, V36, P1067, DOI 10.1097/00126334-200408150-00010; Des Jarlais DC, 2000, AM J PUBLIC HEALTH, V90, P352, DOI 10.2105/AJPH.90.3.352; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; European Centre for Monitoring of Drugs and Drug Addiction European Centre for Disease Control and Prevention, 2012, JOINT EMCDDA ECDC RA; Farrell M, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2823; Gandhi DH, 2003, ADDICTION, V98, P453, DOI 10.1046/j.1360-0443.2003.00334.x; Gowing L, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004145.pub4; Hall W, 2010, ADDICTION, V105, P1332, DOI 10.1111/j.1360-0443.2010.02919.x; Harbord RM, 2008, STATA J, V8, P493, DOI 10.1177/1536867X0800800403; Hedrich D, 2012, ADDICTION, V107, P501, DOI 10.1111/j.1360-0443.2011.03676.x; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Judd A, 2005, BMJ-BRIT MED J, V330, P24, DOI 10.1136/bmj.38286.841227.7C; Kerr T, 2006, JAIDS-J ACQ IMM DEF, V41, P119, DOI 10.1097/01.qai.0000179429.57531.47; Kimber J, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3172; KITAYAPORN D, 1994, AIDS, V8, P1443, DOI 10.1097/00002030-199410000-00011; Kumar MS, 2012, INT J DRUG POLICY, V23, P169, DOI 10.1016/j.drugpo.2011.11.002; Larney S, 2010, ADDICTION, V105, P216, DOI 10.1111/j.1360-0443.2009.02826.x; Liu HJ, 2006, DRUG ALCOHOL DEPEN, V84, P114, DOI 10.1016/j.drugalcdep.2006.01.004; Malta M, 2008, ADDICTION, V103, P1242, DOI 10.1111/j.1360-0443.2008.02269.x; Marmot M, 2005, INT J EPIDEMIOL, V34, P251, DOI 10.1093/ije/dyh372; Mathers BM, 2008, LANCET, V372, P1733, DOI 10.1016/S0140-6736(08)61311-2; Mathers BM, 2010, LANCET, V375, P1014, DOI 10.1016/S0140-6736(10)60232-2; Mattick RP, 2008, COCHRANE DB SYST REV, V3; McFarland W, 2000, J ACQ IMMUN DEF SYND, V23, P426; METZGER DS, 1993, J ACQ IMMUN DEF SYND, V6, P1049; MOSS AR, 1994, AIDS, V8, P223, DOI 10.1097/00002030-199402000-00010; Nelson KE, 2002, AM J EPIDEMIOL, V156, P641, DOI 10.1093/aje/kwf086; Palepua A, 2006, DRUG ALCOHOL DEPEN, V84, P188, DOI 10.1016/j.drugalcdep.2006.02.003; Palmateer N, 2010, ADDICTION, V105, P844, DOI 10.1111/j.1360-0443.2009.02888.x; Peters AD, 1998, DRUG ALCOHOL DEPEN, V50, P47, DOI 10.1016/S0376-8716(97)00161-0; Rhoades HM, 1998, AM J PUBLIC HEALTH, V88, P34, DOI 10.2105/AJPH.88.1.34; Rhodes T, 1999, ADDICTION, V94, P1323, DOI 10.1046/j.1360-0443.1999.94913235.x; Rhodes T, 2006, ADDICTION, V101, P252, DOI 10.1111/j.1360-0443.2006.01317.x; Rhodes T, 2010, BM, V341, P129; Rhodes TE, 2002, COMMENTARY, V113, P16; Roux P, 2008, ADDICTION, V103, P1828, DOI 10.1111/j.1360-0443.2008.02323.x; Ruan YH, 2007, AIDS, V21, pS39, DOI 10.1097/01.aids.0000304695.54884.4f; Schaub M, 2009, EUR ADDICT RES, V15, P157, DOI 10.1159/000217586; SERPELLONI G, 1994, AIDS CARE, V6, P215, DOI 10.1080/09540129408258632; Sharma M, 2007, INT J DRUG POLICY, V18, P92, DOI 10.1016/j.drugpo.2006.11.012; Sharma M, 2009, AIDS, V23, P1405, DOI 10.1097/QAD.0b013e32832bd7c9; SKIDMORE CA, 1990, SCOT MED J, V35, P100, DOI 10.1177/003693309003500402; Smyth BP, 2003, J EPIDEMIOL COMMUN H, V57, P310, DOI 10.1136/jech.57.4.310; Sorensen JL, 2000, DRUG ALCOHOL DEPEN, V59, P17, DOI 10.1016/S0376-8716(99)00104-0; Stachowiak JA, 2006, DRUG ALCOHOL DEPEN, V82, pS7, DOI 10.1016/S0376-8716(06)80002-5; Sterne JAC, 2004, STATA J, V4, P127, DOI 10.1177/1536867X0400400204; Strathdee SA, 2010, LANCET, V376, P268, DOI 10.1016/S0140-6736(10)60743-X; Suntharasamai P, 2009, ADDICTION, V104, P235, DOI 10.1111/j.1360-0443.2008.02436.x; Teesson M, 2006, DRUG ALCOHOL DEPEN, V83, P174, DOI 10.1016/j.drugalcdep.2005.11.009; The Warsaw Declaration, 2003, P 2 INT POL DIAL HIV; Tilson H, 2007, PREVENTING HIV INFEC; Turner KME, 2011, ADDICTION, V106, P1978, DOI 10.1111/j.1360-0443.2011.03515.x; Uuskula A, 2007, INT J STD AIDS, V18, P41, DOI 10.1258/095646207779949907; van Beek I, 1998, BMJ-BRIT MED J, V317, P433, DOI 10.1136/bmj.317.7156.433; Van den Berg C, 2007, ADDICTION, V102, P1454, DOI 10.1111/j.1360-0443.2007.01912.x; Vanichseni S, 2001, AIDS, V15, P397, DOI 10.1097/00002030-200102160-00013; Vickerman P, 2012, ADDICTION, V107, P1984, DOI 10.1111/j.1360-0443.2012.03932.x; Wiessing L, 2011, EUROSURVEILLANCE, V16, P9; Wiessing L, 2008, Euro Surveill, V13; Wiessing L, 2009, AM J PUBLIC HEALTH, V99, P1049, DOI 10.2105/AJPH.2008.141846; WILLIAMS AB, 1992, AIDS CARE, V4, P35, DOI 10.1080/09540129208251618; Yin W, 2010, INT J EPIDEMIOL, V39, pii37; ZANGERLE R, 1992, J ACQ IMMUN DEF SYND, V5, P865; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	72	297	298	1	29	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 4	2012	345								e5945	10.1136/bmj.e5945	http://dx.doi.org/10.1136/bmj.e5945			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	018LH	23038795	Green Accepted, hybrid, Green Published, Green Submitted			2023-01-03	WOS:000309661500001
J	Larena, M; Regner, M; Lobigs, M				Larena, Maximilian; Regner, Matthias; Lobigs, Mario			The Chemokine Receptor CCR5, a Therapeutic Target for HIV/AIDS Antagonists, Is Critical for Recovery in a Mouse Model of Japanese Encephalitis	PLOS ONE			English	Article							WEST-NILE-VIRUS; CD8(+) T-CELLS; MHC CLASS-I; GLYCOSAMINOGLYCAN-BINDING VARIANTS; ADAPTIVE IMMUNE-RESPONSES; CCR5-DEFICIENT MICE; UP-REGULATION; FLAVIVIRUS; INFECTION; DEFICIENCY	Japanese encephalitis is a severe central nervous system (CNS) inflammatory disease caused by the mosquito-borne flavivirus, Japanese encephalitis virus (JEV). In the current study we have investigated the immune responses against JEV in mice lacking expression of the chemokine receptor CCR5, which functions in activation and chemotaxis of leukocytes during infection. We show that CCR5 serves as a host antiviral factor against Japanese encephalitis, with CCR5 deficiency markedly increasing mortality, and viral burden in the CNS. Humoral immune responses, which are essential in recovery from JEV infection, were of similar magnitude in CCR5 sufficient and deficient mice. However, absence of CCR5 resulted in a multifaceted deficiency of cellular immune responses characterized by reduced natural killer and CD8(+) T cell activity, low splenic cellularity, and impaired trafficking of leukocytes to the brain. Interestingly, adoptive transfer of immune spleen cells, depleted of B lymphocytes, increased resistance of CCR5-deficient recipient mice against JEV regardless of whether the cells were obtained from CCR5-deficient or wild-type donor mice, and only when transferred at one but not at three days post-challenge. This result is consistent with a mechanism by which CCR5 expression enhances lymphocyte activation and thereby promotes host survival in Japanese encephalitis.	[Larena, Maximilian; Regner, Matthias; Lobigs, Mario] Australian Natl Univ, John Curtin Sch Med Res, Dept Emerging Pathogens & Vaccines, Canberra, ACT 2601, Australia; [Lobigs, Mario] Univ Queensland, Australian Infect Dis Res Ctr, Sch Chem & Mol Biosci, St Lucia, Qld, Australia	Australian National University; John Curtin School of Medical Research; University of Queensland	Lobigs, M (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Dept Emerging Pathogens & Vaccines, Canberra, ACT 2601, Australia.	Mario.Lobigs@anu.edu.au	lobigs, mario/ABC-5711-2020	larena, maximilian/0000-0003-2327-3063; larena, maximilian/0000-0002-8799-7645				Algood HMS, 2004, J IMMUNOL, V173, P3287; Aliberti J, 2000, NAT IMMUNOL, V1, P83, DOI 10.1038/76957; Alkhatib G, 2009, CURR OPIN HIV AIDS, V4, P96, DOI 10.1097/COH.0b013e328324bbec; Allen SJ, 2007, ANNU REV IMMUNOL, V25, P787, DOI 10.1146/annurev.immunol.24.021605.090529; Ank N, 2005, J VIROL, V79, P9831, DOI 10.1128/JVI.79.15.9831-9841.2005; Belnoue E, 2003, BLOOD, V101, P4253, DOI 10.1182/blood-2002-05-1493; Castellino F, 2006, NATURE, V440, P890, DOI 10.1038/nature04651; Colombage G, 1998, VIROLOGY, V250, P151, DOI 10.1006/viro.1998.9357; Dawson TC, 2000, AM J PATHOL, V156, P1951, DOI 10.1016/S0002-9440(10)65068-7; Erlanger TE, 2009, EMERG INFECT DIS, V15, P1, DOI 10.3201/eid1501.080311; Fadell SA, 2008, EUR J IMMUNOL, V38, P3376, DOI 10.1002/eji.200838628; Floto RA, 2006, SCIENCE, V314, P454, DOI 10.1126/science.1133515; Glass WG, 2005, J EXP MED, V202, P1087, DOI 10.1084/jem.20042530; Glass WG, 2003, J VIROL, V77, P191, DOI 10.1128/JVI.77.1.191-198.2003; Glass WG, 2006, J EXP MED, V203, P35, DOI 10.1084/jem.20051970; Gould EA, 2008, LANCET, V371, P500, DOI 10.1016/S0140-6736(08)60238-X; Halstead Scott B, 2003, Adv Virus Res, V61, P103, DOI 10.1016/S0065-3527(03)61003-1; Hardison JL, 2006, INFECT IMMUN, V74, P135, DOI 10.1128/IAI.74.1.135-143.2006; Hickman HD, 2011, J EXP MED, V208, P2511, DOI 10.1084/jem.20102545; Huffnagle GB, 1999, J IMMUNOL, V163, P4642; Hugues S, 2007, NAT IMMUNOL, V8, P921, DOI 10.1038/ni1495; Kesson AM, 2001, J INFECT DIS, V184, P947, DOI 10.1086/323603; KESSON AM, 1987, J GEN VIROL, V68, P2001, DOI 10.1099/0022-1317-68-7-2001; Khan IA, 2006, PLOS PATHOG, V2, P484, DOI 10.1371/journal.ppat.0020049; KIESSLING R, 1975, EUR J IMMUNOL, V5, P112, DOI 10.1002/eji.1830050208; Kindberg E, 2008, J INFECT DIS, V197, P266, DOI 10.1086/524709; KING NJC, 1988, J GEN VIROL, V69, P2535, DOI 10.1099/0022-1317-69-10-2535; Klein RS, 2008, J INFECT DIS, V197, P183, DOI 10.1086/524692; Kohlmeier JE, 2008, IMMUNITY, V29, P101, DOI 10.1016/j.immuni.2008.05.011; Kohlmeier JE, 2011, J EXP MED, V208, P1621, DOI 10.1084/jem.20102110; Komatsu K, 2008, CURR EYE RES, V33, P736, DOI 10.1080/02713680802344716; Kuziel WA, 2003, ATHEROSCLEROSIS, V167, P25, DOI 10.1016/S0021-9150(02)00382-9; Larena M, 2011, IMMUNOBIOLOGY JAPANE; Larena M, 2011, J VIROL, V85, P5446, DOI 10.1128/JVI.02611-10; Lee E, 2004, J VIROL, V78, P8271, DOI 10.1128/JVI.78.15.8271-8280.2004; Lee E, 2002, J VIROL, V76, P4901, DOI 10.1128/JVI.76.10.4901-4911.2002; Lim JK, 2006, TRENDS IMMUNOL, V27, P308, DOI 10.1016/j.it.2006.05.007; Lim JK, 2010, J INFECT DIS, V201, P178, DOI 10.1086/649426; Lobigs M, 1996, IMMUNOL REV, V152, P5, DOI 10.1111/j.1600-065X.1996.tb00908.x; Lobigs M, 2003, IMMUNOL CELL BIOL, V81, P217, DOI 10.1046/j.1440-1711.2003.01161.x; Lobigs M, 2010, J GEN VIROL, V91, P1407, DOI 10.1099/vir.0.019190-0; Luna RML, 2002, J VIROL, V76, P3202, DOI 10.1128/JVI.76.7.3202-3211.2002; Momburg F, 2001, J VIROL, V75, P5663, DOI 10.1128/JVI.75.12.5663-5671.2001; MULLBACHER A, 1995, IMMUNITY, V3, P207, DOI 10.1016/1074-7613(95)90090-X; Nansen A, 2002, BLOOD, V99, P1237, DOI 10.1182/blood.V99.4.1237; Olive AJ, 2011, MUCOSAL IMMUNOL, V4, P208, DOI 10.1038/mi.2010.58; Peterson KE, 2004, J VIROL, V78, P6449, DOI 10.1128/JVI.78.12.6449-6458.2004; Pulendran B, 2008, J INFECT DIS, V198, P500, DOI 10.1086/590187; Purtha WE, 2007, EUR J IMMUNOL, V37, P1845, DOI 10.1002/eji.200737192; Salazar-Gonzalez JF, 2009, J EXP MED, V206, P1273, DOI 10.1084/jem.20090378; Sato N, 1999, J IMMUNOL, V163, P5519; Shrestha B, 2006, J VIROL, V80, P119, DOI 10.1128/JVI.80.1.119-129.2006; Simon V, 2006, LANCET, V368, P489, DOI 10.1016/S0140-6736(06)69157-5; Solomon T, 2004, NEW ENGL J MED, V351, P370, DOI 10.1056/NEJMra030476; Sorce S, 2011, PROG NEUROBIOL, V93, P297, DOI 10.1016/j.pneurobio.2010.12.003; Souza ALS, 2011, INFECT IMMUN, V79, P1741, DOI 10.1128/IAI.00502-10; Thapa M, 2007, J VIROL, V81, P3704, DOI 10.1128/JVI.02626-06; Tscharke DC, 2005, J EXP MED, V201, P95, DOI 10.1084/jem.20041912; Weiss ID, 2011, CYTOKINE, V54, P249, DOI 10.1016/j.cyto.2011.01.011; Wilkin TJ, 2012, ANNU REV MED, V63, P81, DOI 10.1146/annurev-med-052010-145454; Zhong MX, 2004, INFECT IMMUN, V72, P1057, DOI 10.1128/IAI.72.2.1057-1064.2004	61	27	27	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2012	7	9							e44834	10.1371/journal.pone.0044834	http://dx.doi.org/10.1371/journal.pone.0044834			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014RG	23028638	Green Published, gold, Green Submitted			2023-01-03	WOS:000309392800019
J	Schmidt, SK; Siepmann, S; Kuhlmann, K; Meyer, HE; Metzger, S; Pudelko, S; Leineweber, M; Daubener, W				Schmidt, Silvia K.; Siepmann, Stephan; Kuhlmann, Katja; Meyer, Helmut E.; Metzger, Sabine; Pudelko, Sabine; Leineweber, Margret; Daeubener, Walter			Influence of Tryptophan Contained in 1-Methyl-Tryptophan on Antimicrobial and Immunoregulatory Functions of Indoleamine 2,3-Dioxygenase	PLOS ONE			English	Article							DENDRITIC CELLS; T-CELL; DEXTRO-1-METHYL TRYPTOPHAN; INHIBITION; INTERFERON; GROWTH; IDO; PROLIFERATION; CATABOLITES; TOLERANCE	Indoleamine 2,3-dioxygenase (IDO) has been identified as an important antimicrobial and immunoregulatory effector molecule essential for the establishment of tolerance by regulating local tryptophan (Trp) concentrations. On the other hand, the immunosuppressive capacity of IDO can have detrimental effects for the host as it can lead to deleterious alterations of the immune response by promoting tolerance to some types of tumors. To suppress this disadvantageous IDO effect, the competitive inhibitor 1-Methyl-Tryptophan (1-MT) is being tested in clinical trials. However, it remains inconclusive which stereoisomer of 1-MT is the more effective inhibitor of IDO-mediated immunosuppression. While IDO enzyme activity is more efficiently inhibited by 1-L-MT in cell-free or in vitro settings, 1-D-MT is superior to 1-L-MT in the enhancement of anti-tumor responses in vivo. Here, we present new data showing that commercially available 1-L-MT lots contain tryptophan in amounts sufficient to compensate for the IDO-mediated tryptophan depletion in vitro. The addition of 1-L-MT abrogated IDO-mediated antimicrobial effects and permitted the growth of the tryptophan-auxotroph microorganisms Staphylococcus aureus and Toxoplasma gondii. Consistent with this, the tryptophan within 1-L-MT lots was sufficient to antagonize IDO-mediated inhibition of T cell responses. Mass spectrometry (MS) analysis revealed not only tryptophan within 1-L-MT, but also the incorporation of this tryptophan in bacterial and human proteins that were generated in the presence of 1-L-MT in otherwise tryptophan-free conditions. In summary, these data reveal that tryptophan within 1-L-MT can affect the results of in vitro studies in an L-stereospecific and IDO-independent way.	[Schmidt, Silvia K.; Siepmann, Stephan; Pudelko, Sabine; Leineweber, Margret; Daeubener, Walter] Univ Dusseldorf, Inst Med Microbiol, D-40225 Dusseldorf, Germany; [Schmidt, Silvia K.; Siepmann, Stephan; Pudelko, Sabine; Leineweber, Margret; Daeubener, Walter] Univ Dusseldorf, Hosp Hyg, D-40225 Dusseldorf, Germany; [Kuhlmann, Katja; Meyer, Helmut E.] Ruhr Univ Bochum, Med Proteome Ctr, Bochum, Germany; [Metzger, Sabine] Univ Dusseldorf, Biol Med Res Ctr, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Ruhr University Bochum; Heinrich Heine University Dusseldorf	Schmidt, SK (corresponding author), Univ Dusseldorf, Inst Med Microbiol, D-40225 Dusseldorf, Germany.	silvia.schmidt@uni-duesseldorf.de			German Federal Ministry of Education and Research (BMBF) [01GN0951, 01KI1002E]; German Research Concil (DFG) grant [RU 729]; Manchot Graduate School [TP 11]	German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); German Research Concil (DFG) grant(German Research Foundation (DFG)); Manchot Graduate School	This study was supported by German Federal Ministry of Education and Research (BMBF) grants no. 01GN0951 (WD) and no. 01KI1002E (WD), German Research Concil (DFG) grant no. RU 729 (WD) and Manchot Graduate School TP 11 (WD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams O, 2004, J VIROL, V78, P2632, DOI 10.1128/JVI.78.5.2632-2636.2004; Agaugue S, 2006, J IMMUNOL, V177, P2061, DOI 10.4049/jimmunol.177.4.2061; BILZER T, 1991, VIRCHOWS ARCH A, V418, P281, DOI 10.1007/BF01600156; CADY SG, 1991, ARCH BIOCHEM BIOPHYS, V291, P326, DOI 10.1016/0003-9861(91)90142-6; Capece L, 2010, PROTEINS, V78, P2961, DOI 10.1002/prot.22819; Chauhan N, 2009, J AM CHEM SOC, V131, P4186, DOI 10.1021/ja808326g; Curti A, 2010, HAEMATOL-HEMATOL J, V95, P2022, DOI 10.3324/haematol.2010.025924; DAUBENER W, 1994, J IMMUNOL METHODS, V168, P39, DOI 10.1016/0022-1759(94)90207-0; Divanovic S, 2012, J INFECT DIS, V205, P152, DOI 10.1093/infdis/jir621; Fallarino F, 2006, J IMMUNOL, V176, P6752, DOI 10.4049/jimmunol.176.11.6752; Frumento G, 2002, J EXP MED, V196, P459, DOI 10.1084/jem.20020121; Grohmann U, 2003, TRENDS IMMUNOL, V24, P242, DOI 10.1016/S1471-4906(03)00072-3; Heseler K, 2008, FEMS IMMUNOL MED MIC, V52, P273, DOI 10.1111/j.1574-695X.2007.00374.x; Hou DY, 2007, CANCER RES, V67, P792, DOI 10.1158/0008-5472.CAN-06-2925; Hucke C, 2004, INFECT IMMUN, V72, P2723, DOI 10.1128/IAI.72.5.2723-2730.2004; Liu XQ, 2009, CHINESE MED J-PEKING, V122, P3072, DOI 10.3760/cma.j.issn.0366-6999.2009.24.030; Liu XD, 2009, STUD FUZZ SOFT COMP, V244, P3; Lob S, 2009, CANCER IMMUNOL IMMUN, V58, P153, DOI 10.1007/s00262-008-0513-6; MacKenzie CR, 1999, J MED MICROBIOL, V48, P935, DOI 10.1099/00222615-48-10-935; Mellor AL, 1999, IMMUNOL TODAY, V20, P469, DOI 10.1016/S0167-5699(99)01520-0; Metz R, 2007, CANCER RES, V67, P7082, DOI 10.1158/0008-5472.CAN-07-1872; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Okamoto T, 2007, CYTOTECHNOLOGY, V54, P107, DOI 10.1007/s10616-007-9081-4; Opitz CA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019823; PFEFFERKORN ER, 1984, P NATL ACAD SCI-BIOL, V81, P908, DOI 10.1073/pnas.81.3.908; Qian F, 2009, CANCER RES, V69, P5498, DOI 10.1158/0008-5472.CAN-08-2106; Schmidt SK, 2009, EUR J IMMUNOL, V39, P2755, DOI 10.1002/eji.200939535; Schroten H, 2001, NEUROPEDIATRICS, V32, P206, DOI 10.1055/s-2001-17375; Takikawa O, 2005, BIOCHEM BIOPH RES CO, V338, P12, DOI 10.1016/j.bbrc.2005.09.032; Terness P, 2006, TRENDS IMMUNOL, V27, P68, DOI 10.1016/j.it.2005.12.006; Wiese S, 2007, MOL CELL PROTEOMICS, V6, P2045, DOI 10.1074/mcp.M700169-MCP200; Yuasa HJ, 2010, COMP BIOCHEM PHYS B, V157, P10, DOI 10.1016/j.cbpb.2010.04.006	32	20	22	1	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 13	2012	7	9							e44797	10.1371/journal.pone.0044797	http://dx.doi.org/10.1371/journal.pone.0044797			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	005ZK	23028625	gold, Green Published, Green Submitted			2023-01-03	WOS:000308788700041
J	Lai, XS; Wang, JY; Nabar, NR; Pan, SQ; Tang, CZ; Huang, Y; Hao, MF; Yang, ZH; Ma, CM; Zhang, J; Chew, H; He, ZQ; Yang, JJ; Su, BG; Zhang, J; Liang, J; Sneed, KB; Zhou, SF				Lai, Xinsheng; Wang, Jiayou; Nabar, Neel R.; Pan, Sanqiang; Tang, Chunzhi; Huang, Yong; Hao, Mufeng; Yang, Zhonghua; Ma, Chunmei; Zhang, Jin; Chew, Helen; He, Zhenquan; Yang, Junjun; Su, Baogui; Zhang, Jian; Liang, Jun; Sneed, Kevin B.; Zhou, Shu-Feng			Proteomic Response to Acupuncture Treatment in Spontaneously Hypertensive Rats	PLOS ONE			English	Article							ROSTRAL VENTROLATERAL MEDULLA; RESEARCH-PROGRAM SHARP; OXIDATIVE STRESS; STOP HYPERTENSION; NADPH OXIDASES; BLOOD-PRESSURE; HEART-DISEASE; DOUBLE-BLIND; MECHANISMS; UPDATE	Previous animal and clinical studies have shown that acupuncture is an effective alternative treatment in the management of hypertension, but the mechanism is unclear. This study investigated the proteomic response in the nervous system to treatment at the Taichong (LR3) acupoint in spontaneously hypertensive rats (SHRs). Unanesthetized rats were subject to 5-min daily acupuncture treatment for 7 days. Blood pressure was monitored over 7 days. After euthanasia on the 7th day, rat medullas were dissected, homogenized, and subject to 2D gel electrophoresis and MALDI-TOF analysis. The results indicate that blood pressure stabilized after the 5th day of acupuncture, and compared with non-acupoint treatment, Taichong-acupunctured rat's systolic pressure was reduced significantly (P<0.01), though not enough to bring blood pressure down to normal levels. The different treatment groups also showed differential protein expression: the 2D images revealed 571+/-15 proteins in normal SD rats' medulla, 576+/-31 proteins in SHR's medulla, 597644 proteins in medulla of SHR after acupuncturing Taichong, and 616+/-18 proteins in medulla of SHR after acupuncturing non-acupoint. In the medulla of Taichong group, compared with non-acupoint group, seven proteins were down-regulated: heat shock protein-90, synapsin-1, pyruvate kinase isozyme, NAD-dependent deacetylase sirtuin-2, protein kinase C inhibitor protein 1, ubiquitin hydrolase isozyme L1, and myelin basic protein. Six proteins were up-regulated: glutamate dehydrogenase 1, aldehyde dehydrogenase 2, glutathione S-transferase M5, Rho GDP dissociation inhibitor 1, DJ-1 protein and superoxide dismutase. The altered expression of several proteins by acupuncture has been confirmed by ELISA, Western blot and qRT-PCR assays. The results indicate an increase in antioxidant enzymes in the medulla of the SHRs subject to acupuncture, which may provide partial explanation for the antihypertensive effect of acupuncture. Further studies are warranted to investigate the role of oxidative stress modulation by acupuncture in the treatment of hypertension.	[Lai, Xinsheng; Tang, Chunzhi; Yang, Junjun] Guangzhou Univ Chinese Med, Sch Acupuncture & Moxibust, Dept Acupuncture & Moxibust, Guangzhou, Guangdong, Peoples R China; [Wang, Jiayou; Hao, Mufeng; Yang, Zhonghua; Ma, Chunmei; Zhang, Jin; He, Zhenquan] Guangzhou Univ Chinese Med, Sch Fundamental Med Sci, Dept Human Anat, Guangzhou, Guangdong, Peoples R China; [Nabar, Neel R.; Chew, Helen; Liang, Jun; Zhou, Shu-Feng] Univ S Florida, Coll Pharm, Dept Pharmaceut Sci, Tampa, FL USA; [Pan, Sanqiang; Su, Baogui] Jinan Univ, Sch Med, Dept Human Anat, Guangzhou, Guangdong, Peoples R China; [Huang, Yong] So Med Univ, Sch Chinese Med, Dept Acupuncture & Moxibust, Guangzhou, Guangdong, Peoples R China; [Zhang, Jian] Third Hosp Nanchang, Dept Surg, Nanchang, Jiangxi, Peoples R China; [Sneed, Kevin B.] Univ S Florida, Coll Pharm, Dept Pharmacotherapeut & Clin Res, Tampa, FL USA	Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; State University System of Florida; University of South Florida; Jinan University; Southern Medical University - China; State University System of Florida; University of South Florida	Lai, XS (corresponding author), Guangzhou Univ Chinese Med, Sch Acupuncture & Moxibust, Dept Acupuncture & Moxibust, Guangzhou, Guangdong, Peoples R China.	xmishu@126.com; szhou@health.usf.edu	Wang, Jiayou/AAN-4760-2021; Zhou, Shu-Feng/E-3166-2013	Wang, Jiayou/0000-0001-9697-2004; Zhou, Shu-Feng/0000-0002-5542-6119; Nabar, Neel/0000-0002-9704-3570	National 973 program of China [2006CB504505]; Natural Science Foundation of China [90709027]; University of South Florida College of Pharmacy Startup Fund	National 973 program of China(National Basic Research Program of China); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); University of South Florida College of Pharmacy Startup Fund	The authors appreciate the support by the National 973 program of China (Grant No. 2006CB504505), the Natural Science Foundation of China (Grant No. 90709027), and University of South Florida College of Pharmacy Startup Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AKHMEDOV TI, 1993, TERAPEVT ARKH, V65, P22; ANSHELEVICH YV, 1985, TERAPEVT ARKH, V57, P42; Benter IF, 2011, J CARDIOVASC PHARM, V57, P559, DOI 10.1097/FJC.0b013e31821324b6; Bertoia ML, 2011, HYPERTENSION, V58, P361, DOI 10.1161/HYPERTENSIONAHA.111.175463; Bobkova A S, 1991, Vopr Kurortol Fizioter Lech Fiz Kult, P29; Boshtam M, 2002, INT J VITAM NUTR RES, V72, P309, DOI 10.1024/0300-9831.72.5.309; Burke A, 2006, J ALTERN COMPLEM MED, V12, P639, DOI 10.1089/acm.2006.12.639; Cantwell SL, 2010, TOP COMPANION ANIM M, V25, P53, DOI 10.1053/j.tcam.2009.10.006; Chiu YJ, 1997, CLIN EXP HYPERTENS, V19, P1047, DOI 10.3109/10641969709083204; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; CHRISTE ME, 1994, J MOL CELL CARDIOL, V26, P1371, DOI 10.1006/jmcc.1994.1155; Colombari E, 2001, HYPERTENSION, V38, P549, DOI 10.1161/01.HYP.38.3.549; Datla SR, 2010, HYPERTENSION, V56, P325, DOI 10.1161/HYPERTENSIONAHA.109.142422; DeLano FA, 2005, AM J PHYSIOL-HEART C, V288, pH805, DOI 10.1152/ajpheart.00696.2004; Duan Dong-mei, 2008, Zhongguo Zhen Jiu, V28, P369; Engelhard YN, 2006, AM HEART J, V151, DOI 10.1016/j.ahj.2005.05.008; Friedemann T, 2011, LASERS MED SCI; Harrison DG, 2009, MED CLIN N AM, V93, P621, DOI 10.1016/j.mcna.2009.02.015; Heidenreich PA, 2011, CIRCULATION, V123, P933, DOI 10.1161/CIR.0b013e31820a55f5; Huang H, 1992, J Tradit Chin Med, V12, P133; Huang Xue-Kuan, 2008, Zhen Ci Yan Jiu, V33, P183; Huang YL, 2005, ACUPUNCTURE ELECTRO, V30, P263, DOI 10.3727/036012905815901235; Hwang HS, 2008, EVID-BASED COMPL ALT, V2011, P1; Kalish LA, 2004, CONTROL CLIN TRIALS, V25, P76, DOI 10.1016/j.cct.2003.08.006; Kaplan NM, 2006, HYPERTENSION, V48, P815, DOI 10.1161/01.HYP.0000241069.80574.76; Kearney PM, 2005, LANCET, V365, P217, DOI 10.1016/S0140-6736(05)70151-3; Kim DD, 2006, MICROCIRCULATION, V13, P577, DOI 10.1080/10739680600885210; Kim LW, 2010, ALTERN THER HEALTH M, V16, P18; Kishi T, 2004, CIRCULATION, V109, P2357, DOI 10.1161/01.CIR.0000128695.49900.12; Kizhakekuttu TJ, 2010, CARDIOVASC THER, V28, pe20, DOI 10.1111/j.1755-5922.2010.00137.x; Kumar A, 2009, PHARMACOL THERAPEUT, V124, P259, DOI 10.1016/j.pharmthera.2009.07.003; LI P, 1983, ACUPUNCTURE ELECTRO, V8, P45, DOI 10.3727/036012983816715019; Liu CZ, 2006, NEUROSCI LETT, V393, P45, DOI 10.1016/j.neulet.2005.09.049; Lloyd-Jones D, 2010, CIRCULATION, V121, P948, DOI 10.1161/CIRCULATIONAHA.109.192666; Macklin EA, 2006, HYPERTENSION, V48, P838, DOI 10.1161/01.HYP.0000241090.28070.4c; Meng XZ, 2011, BRAIN RES, V1414, P58, DOI 10.1016/j.brainres.2011.08.004; Paravicini TM, 2008, DIABETES CARE, V31, pS170, DOI 10.2337/dc08-s247; Park JM, 2010, J ALTERN COMPLEM MED, V16, P883, DOI 10.1089/acm.2009.0427; Perez-Vizcaino F, 2009, PHARMACOL REP, V61, P67, DOI 10.1016/S1734-1140(09)70008-8; Peterson JR, 2006, CURR HYPERTENS REP, V8, P232, DOI 10.1007/s11906-006-0056-1; Pimenta E, 2012, HYPERTENS RES, V35, P148, DOI 10.1038/hr.2011.190; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Stocker SD, 2008, CLIN EXP PHARMACOL P, V35, P695, DOI 10.1111/j.1440-1681.2007.04835.x; SUGIOKA K, 1977, AM J CHINESE MED, V5, P39, DOI 10.1142/S0192415X77000051; Wang F, 2011, PEPTIDES, V32, P2394, DOI 10.1016/j.peptides.2011.10.019; YAO T, 1993, SCAND J REHABIL MED, P7; Yin C, 2007, NEUROL RES, V29, pS98, DOI 10.1179/016164107X172220; Yu YP, 2010, BRAIN RES, V1336, P58, DOI 10.1016/j.brainres.2010.04.020; Zhang WG, 2000, P NATL ACAD SCI USA, V97, P9765, DOI 10.1073/pnas.170160397; Zhang Y, 2011, NEUROCHEM RES, V36, P2104, DOI 10.1007/s11064-011-0534-y; Zhou Y, 1995, Zhen Ci Yan Jiu, V20, P55	51	38	43	0	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 12	2012	7	9							e44216	10.1371/journal.pone.0044216	http://dx.doi.org/10.1371/journal.pone.0044216			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	005GJ	22984478	gold, Green Submitted, Green Published			2023-01-03	WOS:000308738500038
J	Alves-Guerra, MC; Aheng, C; Pecqueur, C; Masscheleyn, S; Tharaux, PL; Druilhe, A; Ricquier, D; Challet, E; Miroux, B				Alves-Guerra, Marie-Clotilde; Aheng, Caroline; Pecqueur, Claire; Masscheleyn, Sandrine; Tharaux, Pierre Louis; Druilhe, Anne; Ricquier, Daniel; Challet, Etienne; Miroux, Bruno			Analysis of Uncoupling Protein 2-Deficient Mice upon Anaesthesia and Sedation Revealed a Role for UCP2 in Locomotion	PLOS ONE			English	Article							ALVEOLAR MACROPHAGES; OXIDATIVE STRESS; BROWN ADIPOCYTES; EXPRESSION; OBESITY; DYSFUNCTION; SECRETION; SURVIVAL; CELLS; MODEL	General anaesthesia is associated with hypothermia, oxidative stress, and immune depression. Uncoupling Protein (UCP2) is a member of the mitochondrial carrier family present in many organs including the spleen, the lung and the brain. A role of UCP2 in the activation of the inflammatory/immune cells, in the secretion of hormones, and in the excitability of neurons by regulating the production of reactive oxygen species has been discussed. Because of the side effects of anaesthesia listed above, we aimed to question the expression and the function of UCP2 during anaesthesia. Induction of anaesthesia with ketamine (20 mg/kg) or isoflurane (3.6%) and induction of sedation with the alpha 2 adrenergic receptor agonist medetomidine (0.2 mg/kg) stimulated infiltration of immune cells in the lung and increased UCP2 protein content in the lung, in both immune and non-immune cells. UCP2 content in the lung inversely correlated with body temperature decrease induced by medetomidine treatment. Challenge of the Ucp2(-/-) mice with isoflurane and medetomidine revealed an earlier behavioral recovery phenotype. Transponder analysis of body temperature and activity showed no difference between Ucp2(-/-) and control mice in basal conditions. However, upon an acute decrease of body temperature induced by medetomidine, Ucp2(-/-) mice exhibited increased locomotion activity. Together, these results show that UCP2 is rapidly mobilized during anaesthesia and sedation in immune cells, and suggest a role of UCP2 in locomotion.	[Alves-Guerra, Marie-Clotilde; Aheng, Caroline; Pecqueur, Claire; Ricquier, Daniel] Inst Cochin, CNRS, UMR8104, INSERM,U1016, Paris, France; [Alves-Guerra, Marie-Clotilde; Aheng, Caroline; Pecqueur, Claire; Tharaux, Pierre Louis; Druilhe, Anne; Ricquier, Daniel] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Masscheleyn, Sandrine; Miroux, Bruno] IBPC, CNRS, UMR7099, Lab Biol Physicochim Prot Membranaires, Paris, France; [Masscheleyn, Sandrine; Miroux, Bruno] Univ Paris Diderot, Sorbonne Paris Cite, Paris, France; [Tharaux, Pierre Louis] Paris Ctr Rech Cardiovasc, INSERM, U970, Paris, France; [Druilhe, Anne] Ctr Rech Croissance & Signalisat, INSERM, U845, Paris, France; [Challet, Etienne] Inst Neurosci Cellulaires & Integrat, CNRS, UPR3212, Dept Neurobiol Rythmes, Strasbourg, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Alves-Guerra, MC (corresponding author), Inst Cochin, CNRS, UMR8104, INSERM,U1016, Paris, France.	bruno.miroux@ibpc.fr	Miroux, Bruno/E-9267-2017; Alves-Guerra, Marie-Clotilde/P-4356-2017; Druilhe, Anne/T-1296-2019; Challet, Etienne/ABF-7553-2020; Tharaux, Pierre-Louis/A-9155-2009; Druilhe, Anne/O-8684-2016; Pecqueur, Claire/L-3073-2015	Alves-Guerra, Marie-Clotilde/0000-0002-7918-1216; Druilhe, Anne/0000-0003-0064-110X; Challet, Etienne/0000-0001-9416-9496; Tharaux, Pierre-Louis/0000-0002-6062-5905; Druilhe, Anne/0000-0003-3024-5001; Pecqueur, Claire/0000-0002-7612-1672; Miroux, Bruno/0000-0002-3066-4700	Centre National de la Recherche Scientifique; Agence Nationale de la Recherche [05-JCJC-0092-01]; Institut de Recherche Servier; European Community [LSHM-CT-2003-503041]	Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Agence Nationale de la Recherche(French National Research Agency (ANR)); Institut de Recherche Servier; European Community(European Commission)	This work was supported by the Centre National de la Recherche Scientifique, the Agence Nationale de la Recherche (grant #05-JCJC-0092-01 to BM), the Institut de Recherche Servier (to DR), and the European Community (grant FP6 No LSHM-CT-2003-503041 to DR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allaouchiche B, 2001, ANESTH ANALG, V93, P981, DOI 10.1097/00000539-200110000-00036; Alves-Guerra MC, 2003, J BIOL CHEM, V278, P42307, DOI 10.1074/jbc.M306951200; Alves-Guerra MC, SIGNALLING CELL ADAP, P257; Andrews ZB, 2009, J NEUROSCI, V29, P14057, DOI 10.1523/JNEUROSCI.3890-09.2009; Andrews ZB, 2005, J NEUROSCI, V25, P184, DOI 10.1523/JNEUROSCI.4269-04.2005; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Blanc J, 2003, CIRCULATION, V107, P388, DOI 10.1161/01.CIR.0000051722.66074.60; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Bouillaud F, 2009, BBA-BIOENERGETICS, V1787, P377, DOI 10.1016/j.bbabio.2009.01.003; Delogu G, 2001, ARCH SURG-CHICAGO, V136, P1190, DOI 10.1001/archsurg.136.10.1190; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gnanalingham MG, 2006, J ENDOCRINOL, V188, P375, DOI 10.1677/joe.1.06530; Grasshoff C, 2006, CURR PHARM DESIGN, V12, P3665, DOI 10.2174/138161206778522038; Hurtaud C, 2007, CELL MOL LIFE SCI, V64, P1853, DOI 10.1007/s00018-007-7039-5; Irifune M, 1997, ANESTHESIOLOGY, V86, P464, DOI 10.1097/00000542-199702000-00022; Juttler E, 2007, J NEUROIMMUNOL, V189, P41, DOI 10.1016/j.jneuroim.2007.06.020; KOTANI N, 1995, ANESTH ANALG, V81, P1255, DOI 10.1097/00000539-199512000-00023; Kotani N, 1999, ANESTHESIOLOGY, V91, P187, DOI 10.1097/00000542-199907000-00027; Lahdesmaki J, 2003, NEUROPHARMACOLOGY, V44, P882, DOI 10.1016/S0028-3908(03)00080-7; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Ohlson KBE, 2004, BIOCHEM PHARMACOL, V68, P463, DOI 10.1016/j.bcp.2004.03.028; OHLSON KBE, 1994, ANESTHESIOLOGY, V81, P176, DOI 10.1097/00000542-199407000-00024; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; Richard D, 1999, INT J OBESITY, V23, pS53, DOI 10.1038/sj.ijo.0800947; Rousset S, 2007, FEBS LETT, V581, P479, DOI 10.1016/j.febslet.2007.01.010; Vogler S, 2006, AM J PATHOL, V168, P1570, DOI 10.2353/ajpath.2006.051069; Walder K, 1998, HUM MOL GENET, V7, P1431, DOI 10.1093/hmg/7.9.1431; Yamada S, 2003, J NEUROCHEM, V87, P461, DOI 10.1046/j.1471-4159.2003.02005.x; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	29	3	3	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 10	2012	7	8							e41846	10.1371/journal.pone.0041846	http://dx.doi.org/10.1371/journal.pone.0041846			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	986XO	22900002	gold, Green Published			2023-01-03	WOS:000307380900017
J	Kluin-Nelemans, HC; Hoster, E; Hermine, O; Walewski, J; Trneny, M; Geisler, CH; Stilgenbauer, S; Thieblemont, C; Vehling-Kaiser, U; Doorduijn, JK; Coiffier, B; Forstpointner, R; Tilly, H; Kanz, L; Feugier, P; Szymczyk, M; Hallek, M; Kremers, S; Lepeu, G; Sanhes, L; Zijlstra, JM; Bouabdallah, R; Lugtenburg, PJ; Macro, M; Pfreundschuh, M; Prochazka, V; Di Raimondo, F; Ribrag, V; Uppenkamp, M; Andre, M; Klapper, W; Hiddemann, W; Unterhalt, M; Dreyling, MH				Kluin-Nelemans, H. C.; Hoster, E.; Hermine, O.; Walewski, J.; Trneny, M.; Geisler, C. H.; Stilgenbauer, S.; Thieblemont, C.; Vehling-Kaiser, U.; Doorduijn, J. K.; Coiffier, B.; Forstpointner, R.; Tilly, H.; Kanz, L.; Feugier, P.; Szymczyk, M.; Hallek, M.; Kremers, S.; Lepeu, G.; Sanhes, L.; Zijlstra, J. M.; Bouabdallah, R.; Lugtenburg, P. J.; Macro, M.; Pfreundschuh, M.; Prochazka, V.; Di Raimondo, F.; Ribrag, V.; Uppenkamp, M.; Andre, M.; Klapper, W.; Hiddemann, W.; Unterhalt, M.; Dreyling, M. H.			Treatment of Older Patients with Mantle-Cell Lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROSPECTIVE RANDOMIZED-TRIAL; FLUDARABINE; RITUXIMAB; CYCLOPHOSPHAMIDE; COMBINATION; SURVIVAL; THERAPY; FCM	BACKGROUND The long-term prognosis for older patients with mantle-cell lymphoma is poor. Chemoimmunotherapy results in low rates of complete remission, and most patients have a relapse. We investigated whether a fludarabine-containing induction regimen improved the complete-remission rate and whether maintenance therapy with rituximab prolonged remission. METHODS We randomly assigned patients 60 years of age or older with mantle-cell lymphoma, stage II to IV, who were not eligible for high-dose therapy to six cycles of rituximab, fludarabine, and cyclophosphamide (R-FC) every 28 days or to eight cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) every 21 days. Patients who had a response underwent a second randomization to maintenance therapy with rituximab or interferon alfa, each given until progression. RESULTS Of the 560 patients enrolled, 532 were included in the intention-to-treat analysis for response, and 485 in the primary analysis for response. The median age was 70 years. Although complete-remission rates were similar with R-FC and R-CHOP (40% and 34%, respectively; P = 0.10), progressive disease was more frequent with R-FC (14%, vs. 5% with R-CHOP). Overall survival was significantly shorter with R-FC than with R-CHOP (4-year survival rate, 47% vs. 62%; P = 0.005), and more patients in the R-FC group died during the first remission (10% vs. 4%). Hematologic toxic effects occurred more frequently in the R-FC group than in the R-CHOP group, but the frequency of grade 3 or 4 infections was balanced (17% and 14%, respectively). In 274 of the 316 patients who were randomly assigned to maintenance therapy, rituximab reduced the risk of progression or death by 45% (in remission after 4 years, 58%, vs. 29% with interferon alfa; hazard ratio for progression or death, 0.55; 95% confidence interval, 0.36 to 0.87; P = 0.01). Among patients who had a response to R-CHOP, maintenance therapy with rituximab significantly improved overall survival (4-year survival rate, 87%, vs. 63% with interferon alfa; P = 0.005). CONCLUSIONS R-CHOP induction followed by maintenance therapy with rituximab is effective for older patients with mantle-cell lymphoma. (Funded by the European Commission and others; ClinicalTrials.gov number, NCT00209209.)	[Kluin-Nelemans, H. C.] Univ Groningen, Dept Hematol, Univ Med Ctr Groningen, NL-9700 RB Groningen, Netherlands; [Doorduijn, J. K.] Erasmus Univ, Med Ctr, Dept Hematol, Dr Daniel Den Hoed Canc Ctr, Rotterdam, Netherlands; [Zijlstra, J. M.] Vrije Univ Amsterdam, Med Ctr, Dept Hematol, Amsterdam, Netherlands; [Hoster, E.; Forstpointner, R.; Hiddemann, W.; Unterhalt, M.; Dreyling, M. H.] Univ Hosp, Dept Internal Med 3, Munich, Germany; [Stilgenbauer, S.] Univ Ulm, Dept Internal Med 3, D-7900 Ulm, Germany; [Vehling-Kaiser, U.] Tagesklin Hamatol Onkol, Landshut, Germany; [Kanz, L.] Univ Tubingen, Dept Med 2, Tubingen, Germany; [Hallek, M.] Univ Cologne, Innere Med Klin 1, D-50931 Cologne, Germany; [Kremers, S.] Caritas Krankenhaus, Onkol Zentrum, Lebach, Germany; [Pfreundschuh, M.] Univ Klin Saarlandes, Homburg, Germany; [Uppenkamp, M.] Klinikum Stadt Ludwigshafen, Med Klin A, D-6700 Ludwigshafen, Germany; [Klapper, W.] Univ Kiel, Hematopathol Sect, Dept Pathol, Kiel, Germany; [Klapper, W.] Univ Kiel, Lymph Node Registry, Kiel, Germany; [Hermine, O.] Univ Paris 05, Hop Necker Enfants Malad, AP HP, Dept Hematol, Paris, France; [Thieblemont, C.] Hop St Louis, Dept Hematol, Paris, France; [Coiffier, B.] Ctr Hosp Lyon Sud, Dept Hematol, F-69310 Pierre Benite, France; [Tilly, H.] Ctr Henri Becquerel, F-76038 Rouen, France; [Feugier, P.] Serv Hematol, Vandoevre Les Nancy, France; [Lepeu, G.] Ctr Hosp Henri Duffaut, Avignon, France; [Sanhes, L.] Ctr Hosp Marechal Joffre, Perpignan, France; [Bouabdallah, R.] Serv Hematol, Marseille, France; [Macro, M.] Serv Hematol, Caen, France; [Ribrag, V.] Inst Gustave Roussy, Villejuif, France; [Walewski, J.; Szymczyk, M.] Maria Sklodowska Curie Mem Inst & Canc Ctr, Dept Lymphoproliferat Dis, Warsaw, Poland; [Trneny, M.] Charles Univ Prague, Gen Hosp, Dept Med 1, Prague, Czech Republic; [Prochazka, V.] Palacky Univ, Fac Med & Dent, Dept Hematooncol, CR-77147 Olomouc, Czech Republic; [Geisler, C. H.] Rigshosp, Dept Hematol, DK-2100 Copenhagen, Denmark; [Di Raimondo, F.] Osped Ferratotto, Div Ematol, Catania, Italy; [Andre, M.] Ctr Hosp Univ Mt Godinne, Serv Hematol, Yvoir, Belgium	University of Groningen; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Vrije Universiteit Amsterdam; University of Munich; Ulm University; Eberhard Karls University of Tubingen; University of Cologne; Universitatsklinikum des Saarlandes; Ludwigshafen Hospital; University of Kiel; University of Kiel; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Lyon; UNICANCER; Centre Henri Becquerel; UNICANCER; Gustave Roussy; Charles University Prague; General University Hospital Prague; Palacky University Olomouc; University Hospital Plzen; Rigshospitalet; University of Copenhagen	Kluin-Nelemans, HC (corresponding author), Univ Groningen, Dept Hematol, Univ Med Ctr Groningen, Hanzepl 1, NL-9700 RB Groningen, Netherlands.	j.c.kluin@umcg.nl	Hoster, Eva/M-2795-2019; Klapper, Wolfram/S-6314-2016; Walewski, Jan/ABC-9523-2020; Hallek, Michael/Y-3191-2019; AndrÃ©, Marc/AAP-2355-2020; Hermine, Olivier/Q-7072-2018; Stilgenbauer, Stephan/ABE-6609-2020; Kluin-Nelemans, Johanna C/F-8658-2018; Di Raimondo, Francesco/K-7965-2016; Thieblemont, Catherine/AAZ-8423-2020; Prochazka, Vit/AAI-5809-2020	Hoster, Eva/0000-0002-0749-1389; Hallek, Michael/0000-0002-7425-4455; Kluin-Nelemans, Johanna C/0000-0003-2617-9427; Di Raimondo, Francesco/0000-0002-7749-0293; Thieblemont, Catherine/0000-0002-9941-2448; Hermine, Olivier/0000-0003-2574-3874; Trneny, Marek/0000-0002-6952-6073; Walewski, Jan/0000-0003-4247-2674; Prochazka, Vit/0000-0002-9861-3117	European Commission [LSHC-CT-2004-503351]; Lymphoma Research Foundation; Roche Pharmaceuticals; Bayer Schering Pharma; Schering-Plough	European Commission(European CommissionEuropean Commission Joint Research Centre); Lymphoma Research Foundation; Roche Pharmaceuticals(Roche Holding); Bayer Schering Pharma(Bayer AG); Schering-Plough(Merck & CompanySchering Plough Corporation)	Supported by grants from the European Commission (LSHC-CT-2004-503351), the Lymphoma Research Foundation, Roche Pharmaceuticals, Bayer Schering Pharma, and Schering-Plough.	Catovsky D, 2007, LANCET, V370, P230, DOI 10.1016/S0140-6736(07)61125-8; Cheson BD, 1999, J CLIN ONCOL, V17, P1244, DOI 10.1200/JCO.1999.17.4.1244; Cheson BD, 2000, J CLIN ONCOL, V18, P2531; Cohen BJ, 2001, LEUKEMIA LYMPHOMA, V42, P1015, DOI 10.3109/10428190109097721; Dreyling M, 2005, BLOOD, V105, P2677, DOI 10.1182/blood-2004-10-3883; Dreyling M, 2011, HEMATOL-AM SOC HEMAT, P562, DOI 10.1182/asheducation-2011.1.562; Dreyling Martin, 2009, Hematology Am Soc Hematol Educ Program, P542, DOI 10.1182/asheducation-2009.1.542; Eichhorst B, 2009, LEUKEMIA LYMPHOMA, V50, P171, DOI 10.1080/10428190802688517; Foran JM, 1999, J CLIN ONCOL, V17, P546, DOI 10.1200/JCO.1999.17.2.546; Forstpointner R, 2004, BLOOD, V104, P3064, DOI 10.1182/blood-2004-04-1323; Forstpointner R, 2006, BLOOD, V108, P4003, DOI 10.1182/blood-2006-04-016725; Geisler CH, 2010, HAEMATOL-HEMATOL J, V95, P1241, DOI 10.3324/haematol.2010.025627; Harel S, 2011, SEMIN HEMATOL, V48, P194, DOI 10.1053/j.seminhematol.2011.06.002; Hiddemann W, 2003, SEMIN ONCOL, V30, P16, DOI 10.1053/sonc.2003.50024; Hoster, 2008, BLOOD, V111, P5761; Hoster E, 2008, BLOOD, V111, P558, DOI 10.1182/blood-2007-06-095331; Howard OM, 2002, J CLIN ONCOL, V20, P1288, DOI 10.1200/JCO.20.5.1288; Klapper Wolfram, 2009, J Hematop, V2, P103, DOI 10.1007/s12308-009-0036-x; Lenz G, 2005, J CLIN ONCOL, V23, P1984, DOI 10.1200/JCO.2005.08.133; Perez-Galan P, 2011, BLOOD, V117, P26, DOI 10.1182/blood-2010-04-189977; Rummel MJ, 2010, AM SOC HEM 52 ANN M, P114; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; Swerdlow SH, 2008, WHO CLASSIFICATION T, P229; Unterhalt M, 1996, BLOOD, V88, P1801; Weigert O, 2009, LEUKEMIA LYMPHOMA, V50, P716, DOI 10.1080/10428190902856790; Whitehead J, 1997, DESIGN ANAL SEQUENTI; Zinzani PL, 2000, J CLIN ONCOL, V18, P773, DOI 10.1200/JCO.2000.18.4.773	27	359	374	1	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 9	2012	367	6					520	531		10.1056/NEJMoa1200920	http://dx.doi.org/10.1056/NEJMoa1200920			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	986AE	22873532	Green Published			2023-01-03	WOS:000307310800006
J	Cunha, TF; Bacurau, AVN; Moreira, JBN; Paixao, NA; Campos, JC; Ferreira, JCB; Leal, ML; Negrao, CE; Moriscot, AS; Wisloff, U; Brum, PC				Cunha, Telma F.; Bacurau, Aline V. N.; Moreira, Jose B. N.; Paixao, Nathalie A.; Campos, Juliane C.; Ferreira, Julio C. B.; Leal, Marcelo L.; Negrao, Carlos E.; Moriscot, Anselmo S.; Wisloff, Ulrik; Brum, Patricia C.			Exercise Training Prevents Oxidative Stress and Ubiquitin-Proteasome System Overactivity and Reverse Skeletal Muscle Atrophy in Heart Failure	PLOS ONE			English	Article							CARDIAC-FUNCTION; GENETIC MODEL; PROTEIN EXPRESSION; SATELLITE CELLS; HYPERACTIVITY; MICE; DYSFUNCTION; ANTIOXIDANT; IMPROVES; PATHWAY	Background: Heart failure (HF) is known to lead to skeletal muscle atrophy and dysfunction. However, intracellular mechanisms underlying HF-induced myopathy are not fully understood. We hypothesized that HF would increase oxidative stress and ubiquitin-proteasome system (UPS) activation in skeletal muscle of sympathetic hyperactivity mouse model. We also tested the hypothesis that aerobic exercise training (AET) would reestablish UPS activation in mice and human HF. Methods/Principal Findings: Time-course evaluation of plantaris muscle cross-sectional area, lipid hydroperoxidation, protein carbonylation and chymotrypsin-like proteasome activity was performed in a mouse model of sympathetic hyperactivity-induced HF. At the 7th month of age, HF mice displayed skeletal muscle atrophy, increased oxidative stress and UPS overactivation. Moderate-intensity AET restored lipid hydroperoxides and carbonylated protein levels paralleled by reduced E3 ligases mRNA levels, and reestablished chymotrypsin-like proteasome activity and plantaris trophicity. In human HF (patients randomized to sedentary or moderate-intensity AET protocol), skeletal muscle chymotrypsin-like proteasome activity was also increased and AET restored it to healthy control subjects' levels. Conclusions: Collectively, our data provide evidence that AET effectively counteracts redox imbalance and UPS overactivation, preventing skeletal myopathy and exercise intolerance in sympathetic hyperactivity-induced HF in mice. Of particular interest, AET attenuates skeletal muscle proteasome activity paralleled by improved aerobic capacity in HF patients, which is not achieved by drug treatment itself. Altogether these findings strengthen the clinical relevance of AET in the treatment of HF.	[Cunha, Telma F.; Bacurau, Aline V. N.; Moreira, Jose B. N.; Paixao, Nathalie A.; Campos, Juliane C.; Ferreira, Julio C. B.; Negrao, Carlos E.; Brum, Patricia C.] Univ Sao Paulo, Sch Phys Educ & Sport, Sao Paulo, Brazil; [Leal, Marcelo L.; Moriscot, Anselmo S.] Univ Sao Paulo, Inst Biomed Sci, Sao Paulo, Brazil; [Negrao, Carlos E.] Univ Sao Paulo, Heart Inst InCor, Sao Paulo, Brazil; [Wisloff, Ulrik] Norwegian Univ Sci & Technol, KG Jebsen Ctr Exercise Med, N-7034 Trondheim, Norway	Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Norwegian University of Science & Technology (NTNU)	Cunha, TF (corresponding author), Univ Sao Paulo, Sch Phys Educ & Sport, Sao Paulo, Brazil.	pcbrum@usp.br	Ferreira, Julio Cesar Batista/AEU-0494-2022; Brum, Patricia C/E-6605-2011; Moreira, Jose/G-1556-2014; Wisloff, Ulrik/K-2899-2012; Ferreira, Julio Cesar Batista/I-3177-2012; Cunha, Telma F/I-5222-2016; Moriscot, Anselmo S./C-4506-2012; Campos, Juliane/G-5997-2014; Bacurau, Aline/F-3293-2012; Ferreira, Julio/L-4687-2019; Negrao, Carlos E/C-4281-2012; Bacurau, Aline Villa Nova/AAK-7446-2021	Ferreira, Julio Cesar Batista/0000-0003-2694-239X; Brum, Patricia C/0000-0002-4750-6506; Ferreira, Julio Cesar Batista/0000-0003-2694-239X; Moriscot, Anselmo S./0000-0003-3098-4613; Campos, Juliane/0000-0003-0075-7209; Bacurau, Aline/0000-0002-5129-5115; Bacurau, Aline Villa Nova/0000-0002-5129-5115; Negrao, Carlos Eduardo/0000-0003-4652-1226; Wisloff, Ulrik/0000-0002-7211-3587	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2006/61523-7, 2006/58460-4]; Conselho Nacional de Pesquisa e Desenvolvimento (CNPq) [473251/2009-4, 301519/2008-0, 301867/2010-0]	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Pesquisa e Desenvolvimento (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP #2006/61523-7) and Conselho Nacional de Pesquisa e Desenvolvimento (CNPq #473251/2009-4). PCB and CEN hold scholarships from CNPq (#301519/2008-0 and #301867/2010-0]. TFC held a scholarship from FAPESP (#2006/58460-4). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aiken CT, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.006924; Anker SD, 1997, LANCET, V349, P1050, DOI 10.1016/S0140-6736(96)07015-8; Attaix Didier, 2008, Curr Opin Support Palliat Care, V2, P262, DOI 10.1097/SPC.0b013e3283196ac2; Bacurau AVN, 2009, J APPL PHYSIOL, V106, P1631, DOI 10.1152/japplphysiol.91067.2008; Bartholomeu JB, 2008, J MOL CELL CARDIOL, V45, P240, DOI 10.1016/j.yjmcc.2008.05.011; Barton-Davis ER, 1999, ACTA PHYSIOL SCAND, V167, P301; Batista ML, 2010, CYTOKINE, V49, P102, DOI 10.1016/j.cyto.2009.10.007; Beehler BC, 2006, EXP BIOL MED, V231, P335; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Brum PC, 2002, AM J PHYSIOL-HEART C, V283, pH1838, DOI 10.1152/ajpheart.01063.2001; Bueno CR, 2010, J APPL PHYSIOL, V109, P702, DOI 10.1152/japplphysiol.00281.2010; Choksi KB, 2008, FREE RADICAL BIO MED, V45, P826, DOI 10.1016/j.freeradbiomed.2008.06.006; CHOPRA M, 1992, J CARDIOVASC PHARM, V19, P330, DOI 10.1097/00005344-199203000-00005; Coirault C, 2007, AM J PHYSIOL-HEART C, V292, pH1009, DOI 10.1152/ajpheart.00438.2006; Dalla-Libera L, 2005, BASIC APPL MYOL, V15, P6; Ferreira JCB, 2008, AM J PHYSIOL-REG I, V294, pR26, DOI 10.1152/ajpregu.00424.2007; Ferreira JCB, 2007, CLIN EXP PHARMACOL P, V34, P760, DOI 10.1111/j.1440-1681.2007.04635.x; Ferreira JCB, 2011, LIFE SCI, V88, P578, DOI 10.1016/j.lfs.2011.01.009; Feuerstein G, 1998, Adv Pharmacol, V42, P611; Fulle S, 2004, EXP GERONTOL, V39, P17, DOI 10.1016/j.exger.2003.09.012; Gielen S, 2005, EUR J CARDIOV PREV R, V12, P393, DOI 10.1097/01.hjr.0000174824.94892.43; Gielen S, 2003, J AM COLL CARDIOL, V42, P861, DOI 10.1016/S0735-1097(03)00848-9; Gielen S, 2012, CIRCULATION, V125, P2716, DOI 10.1161/CIRCULATIONAHA.111.047381; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Gomes-Marcondes MCC, 2002, CANCER LETT, V180, P69, DOI 10.1016/S0304-3835(02)00006-X; Goncalves DAP, 2012, AM J PHYSIOL-ENDOC M, V302, pE123, DOI 10.1152/ajpendo.00188.2011; Goncalves DAP, 2009, ENDOCRINOLOGY, V150, P5395, DOI 10.1210/en.2009-0428; Guarnier FA, 2010, MUSCLE NERVE, V42, P950, DOI 10.1002/mus.21798; Hein L, 1999, NATURE, V402, P181, DOI 10.1038/46040; Jackman RW, 2004, AM J PHYSIOL-CELL PH, V287, pC834, DOI 10.1152/ajpcell.00579.2003; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Jamart C, 2011, MUSCLE NERVE, V43, P708, DOI 10.1002/mus.21949; Kuwahara H, 2010, FREE RADICAL BIO MED, V48, P1252, DOI 10.1016/j.freeradbiomed.2010.02.011; Laughlin MH, 2008, J PHYSIOL PHARMACOL, V59, P71; Li YF, 2011, BBA-GENE REGUL MECH, V1809, P141, DOI 10.1016/j.bbagrm.2010.09.001; MANCINI DM, 1992, CIRCULATION, V85, P1364, DOI 10.1161/01.CIR.85.4.1364; Matsuo T, 2005, HEART VESSELS, V20, P8, DOI 10.1007/s00380-004-0793-5; Medeiros A, 2008, J APPL PHYSIOL, V104, P103, DOI 10.1152/japplphysiol.00493.2007; Moylan JS, 2007, MUSCLE NERVE, V35, P411, DOI 10.1002/mus.20743; Muller FL, 2006, FREE RADICAL BIO MED, V40, P1993, DOI 10.1016/j.freeradbiomed.2006.01.036; MURRAY D, 1987, ANESTHESIOLOGY, V67, P211, DOI 10.1097/00000542-198708000-00010; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; Negrao CE, 2008, HEART FAIL REV, V13, P51, DOI 10.1007/s10741-007-9057-7; NOUROOZZADEH J, 1994, ANAL BIOCHEM, V220, P403, DOI 10.1006/abio.1994.1357; Nowis D, 2010, AM J PATHOL, V176, P2658, DOI 10.2353/ajpath.2010.090690; Ohta Y, 2011, AM J PHYSIOL-HEART C, V300, pH1637, DOI 10.1152/ajpheart.01185.2009; Oliveira RSF, 2009, J PHYSIOL-LONDON, V587, P3899, DOI 10.1113/jphysiol.2009.173948; Pellegrino MA, 2011, J PHYSIOL-LONDON, V589, P2147, DOI 10.1113/jphysiol.2010.203232; Pereira MG, 2009, EUR J APPL PHYSIOL, V105, P843, DOI 10.1007/s00421-008-0967-4; Renault V, 2002, EXP GERONTOL, V37, P1229, DOI 10.1016/S0531-5565(02)00129-8; Rolim NPL, 2007, PHYSIOL GENOMICS, V29, P246, DOI 10.1152/physiolgenomics.00188.2006; Schulze PC, 2005, CIRC RES, V97, P418, DOI 10.1161/01.RES.0000179580.72375.c2; Shang F, 2011, FREE RADICAL BIO MED, V51, P5, DOI 10.1016/j.freeradbiomed.2011.03.031; Toth MJ, 2011, J APPL PHYSIOL, V110, P892, DOI 10.1152/japplphysiol.00545.2010; Tsutsui H, 2011, J CLIN BIOCHEM NUTR, V48, P68, DOI 10.3164/jcbn.11-012FR; van Hees HWH, 2008, AM J PHYSIOL-LUNG C, V294, pL1260, DOI 10.1152/ajplung.00035.2008; Vescovo G, 2001, ACTA PHYSIOL SCAND, V171, P305, DOI 10.1046/j.1365-201x.2001.00832.x; von Haehling S, 2010, J CACHEXIA SARCOPENI, V1, P1, DOI 10.1007/s13539-010-0002-6; Willis MS, 2010, CIRC RES, V106, P463, DOI 10.1161/CIRCRESAHA.109.208801; Wisloff U, 2007, CIRCULATION, V115, P3086, DOI 10.1161/CIRCULATIONAHA.106.675041; Zaccagnini G, 2007, J BIOL CHEM, V282, P31453, DOI 10.1074/jbc.M702511200	61	101	106	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 3	2012	7	8							e41701	10.1371/journal.pone.0041701	http://dx.doi.org/10.1371/journal.pone.0041701			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	985QT	22870245	Green Published, Green Submitted, gold			2023-01-03	WOS:000307284100030
J	Dasgupta, N; Davis, J; Funk, MJ; Dart, R				Dasgupta, Nabarun; Davis, Jonathan; Funk, Michele Jonsson; Dart, Richard			Using Poison Center Exposure Calls to Predict Methadone Poisoning Deaths	PLOS ONE			English	Article							PRESCRIPTION OPIOID ANALGESICS; UNITED-STATES; CANCER PAIN; ABUSE; SURVEILLANCE; MORTALITY; ASSOCIATION; MANAGEMENT; TEXAS	Purpose: There are more drug overdose deaths in the Untied States than motor vehicle fatalities. Yet the US vital statistics reporting system is of limited value because the data are delayed by four years. Poison centers report data within an hour of the event, but previous studies suggested a small proportion of poisoning deaths are reported to poison centers (PC). In an era of improved electronic surveillance capabilities, exposure calls to PCs may be an alternate indicator of trends in overdose mortality. Methods: We used PC call counts for methadone that were reported to the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS (R)) System in 2006 and 2007. US death certificate data were used to identify deaths due to methadone. Linear regression was used to quantify the relationship of deaths and poison center calls. Results: Compared to decedents, poison center callers tended to be younger, more often female, at home and less likely to require medical attention. A strong association was found with PC calls and methadone mortality (b = 0.88, se = 0.42, t = 9.5, df = 1, p<0.0001, R-2 = 0.77). These findings were robust to large changes in a sensitivity analysis assessing the impact of underreporting of methadone overdose deaths. Conclusions: Our results suggest that calls to poison centers for methadone are correlated with poisoning mortality as identified on death certificates. Calls received by poison centers may be used for timely surveillance of mortality due to methadone. In the midst of the prescription opioid overdose epidemic, electronic surveillance tools that report in real-time are powerful public health tools.	[Dasgupta, Nabarun; Funk, Michele Jonsson] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27515 USA; [Davis, Jonathan; Dart, Richard] Denver Hlth, Rocky Mt Poison & Drug Ctr, Denver, CO USA; [Dart, Richard] Univ Colorado, Sch Med, Denver, CO USA	University of North Carolina; University of North Carolina Chapel Hill; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Dasgupta, N (corresponding author), Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27515 USA.	nabarund@unc.edu	Funk, Michele Jonsson/F-6885-2011	Funk, Michele Jonsson/0000-0002-3756-7540; Dasgupta, Nabarun/0000-0002-4098-605X; Dart, Richard/0000-0001-5989-9354	UNC/GSK Center for Excellence in Pharmacoepidemiology and Public Health through the University of North Carolina at Chapel Hill	UNC/GSK Center for Excellence in Pharmacoepidemiology and Public Health through the University of North Carolina at Chapel Hill	Dr. Dasgupta received a graduate student fellowship from the UNC/GSK Center for Excellence in Pharmacoepidemiology and Public Health through the University of North Carolina at Chapel Hill. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angalakuditi MV, 2006, AM J HEALTH-SYST PH, V63, P323, DOI 10.2146/ajhp050227; Ayonrinde OT, 2000, MED J AUSTRALIA, V173, P536, DOI 10.5694/j.1326-5377.2000.tb139323.x; Banerji S, 2001, AM J HEALTH-SYST PH, V58, P1811, DOI 10.1093/ajhp/58.19.1811; BLANC PD, 1995, WESTERN J MED, V162, P505; Brands B, 2002, DRUG ALCOHOL DEPEN, V66, P11, DOI 10.1016/S0376-8716(01)00176-4; Breiding MJ, 2006, INJURY PREV, V12, P49, DOI 10.1136/ip.2006.012591; Bryner JK, 2006, ARCH PEDIAT ADOL MED, V160, P1217, DOI 10.1001/archpedi.160.12.1217; Bunn TL, 2010, PHARMACOEPIDEM DR S, V19, P124, DOI 10.1002/pds.1901; Cicero TJ, 2007, PAIN MED, V8, P157, DOI 10.1111/j.1526-4637.2006.00259.x; Cicero TJ, 2005, J PAIN, V6, P662, DOI 10.1016/j.jpain.2005.05.004; Dart RC, 2011, ANN PHARMACOTHER, V45, P424, DOI 10.1345/aph.1P064b; Dasgupta N, 2006, DRUG ALCOHOL DEPEN, V82, P135, DOI 10.1016/j.drugalcdep.2005.08.019; Dasgupta N, 2008, GEOGRAPHY DRUG ADDIC; Dasgupta N, 2010, PAIN MED, V11, P1078, DOI 10.1111/j.1526-4637.2010.00877.x; Dasgupta N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007758; Donaldson AE, 2006, INJURY PREV, V12, P338, DOI 10.1136/ip.2005.011171; Forrester MB, 2007, J TOXICOL ENV HEAL A, V70, P534, DOI 10.1080/15287390600870924; Forrester MB, 2006, J TOXICOL ENV HEAL A, V69, P1145, DOI 10.1080/15287390500360273; Hayes BD, 2009, CLIN TOXICOL, V47, P905, DOI 10.3109/15563650903301702; Hoppe-Roberts JM, 2000, ANN EMERG MED, V35, P440, DOI 10.1067/mem.2000.105932; Hughes AA, 2007, CLIN TOXICOL, V45, P144, DOI 10.1080/15563650600981137; Institute of Medicine, 2011, REL PAIN AM BLUEPR T; KleinSchwartz W, 1997, ANN EMERG MED, V29, P232, DOI 10.1016/S0196-0644(97)70274-9; Kreshak AA, 2009, ANN PHARMACOTHER, V43, P1986, DOI 10.1345/aph.1M454; LINAKIS JG, 1993, ANN EMERG MED, V22, P1822, DOI 10.1016/S0196-0644(05)80408-1; Marquardt KA, 2005, ANN PHARMACOTHER, V39, P1039, DOI 10.1345/aph.1E577; Matlock A, 2011, CLIN TOXICOL, V49, P443, DOI 10.3109/15563650.2011.564585; Paulozzi L., 2007, Morbidity and Mortality Weekly Report, V56, P93; Paulozzi LJ, 2006, PHARMACOEPIDEM DR S, V15, P618, DOI 10.1002/pds.1276; Paulozzi LJ, 2006, AM J PREV MED, V31, P506, DOI 10.1016/j.amepre.2006.08.017; Reifler LM, 2012, PAIN MED; Ripamonti C, 2001, DRUGS, V61, P955, DOI 10.2165/00003495-200161070-00005; Rosenblum A, 2007, DRUG ALCOHOL DEPEN, V90, P64, DOI 10.1016/j.drugalcdep.2007.02.012; Schneider MF, 2009, PHARMACOEPIDEM DR S, V18, P778, DOI 10.1002/pds.1780; Sims SA, 2007, J BIOMED INFORM, V40, P382, DOI 10.1016/j.jbi.2006.10.004; Smith MY, 2008, PHARMACOEPIDEM DR S, V17, P1050, DOI 10.1002/pds.1658; Smith MY, 2006, AM J DRUG ALCOHOL AB, V32, P465, DOI 10.1080/00952990600753982; SOSLOW AR, 1992, AM J EMERG MED, V10, P124, DOI 10.1016/0735-6757(92)90043-W; Spiller HA, 1997, J TOXICOL-CLIN TOXIC, V35, P167, DOI 10.3109/15563659709001188; Spiller HA, 2010, ANN PHARMACOTHER, V44, P1016, DOI 10.1345/aph.1P064; Stephens BG, 2004, AM J FOREN MED PATH, V25, P11, DOI 10.1097/01.paf.0000114041.70865.24; Tormoehlen LM, 2011, CLIN TOXICOL, V49, P492, DOI 10.3109/15563650.2011.587819; Toxic Exposure Surveillance System (TESS), 2002, INSTR AM ASS POIS CO; Vassilev ZP, 2003, J TOXICOL ENV HEAL A, V66, P1905, DOI 10.1080/713853953; Webster LR, 2011, PAIN MED, V12, pS86, DOI 10.1111/j.1526-4637.2011.01132.x; Wysowski DK, 2007, DRUG SAFETY, V30, P533, DOI 10.2165/00002018-200730060-00007	46	18	18	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 19	2012	7	7							e41181	10.1371/journal.pone.0041181	http://dx.doi.org/10.1371/journal.pone.0041181			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981GZ	22829925	gold, Green Published			2023-01-03	WOS:000306956300064
J	Tallis, R				Tallis, Raymond			END OF LIFE CARE Our professional bodies should stop opposing assisted dying	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							DOCTORS; LEGALISATION		[Tallis, Raymond] Univ Manchester, Manchester M13 9PL, Lancs, England; [Tallis, Raymond] Healthcare Profess Assisted Dying, New York, NY USA	University of Manchester	Tallis, R (corresponding author), Univ Manchester, Manchester M13 9PL, Lancs, England.	raymond@rtallis.wanadoo.co.uk						BMA, 2010, RESP PAT REQ REL ASS; Clery E., 2007, BRIT SOCIAL ATTITUDE, P35; Jansen-van der Weide M, 2009, DEATH STUD, V33, P199, DOI 10.1080/07481180802672272; Kmietovicz Z, 2002, BRIT MED J, V324, P11, DOI 10.1136/bmj.324.7328.11; Lee W, 2009, BMC MED ETHICS, V10, DOI 10.1186/1472-6939-10-2; McAndrew Siobhan, 2010, BRIT SOCIAL ATTITUDE, P87; Seale C, 2009, PALLIATIVE MED, V23, P205, DOI 10.1177/0269216308102041; Tallis R, UNBEARABLE SUFFERING; van der Heide A, 2007, NEW ENGL J MED, V356, P1957, DOI 10.1056/NEJMsa071143	9	8	8	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 14	2012	344								e4115	10.1136/bmj.e4115	http://dx.doi.org/10.1136/bmj.e4115			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	961LA	22695307				2023-01-03	WOS:000305464700012
J	Zhang, TY; DeSimone, RA; Jiao, XM; Rohlf, FJ; Zhu, W; Gong, QQ; Hunt, SR; Dassopoulos, T; Newberry, RD; Sodergren, E; Weinstock, G; Robertson, CE; Frank, DN; Li, E				Zhang, Tianyi; DeSimone, Robert A.; Jiao, Xiangmin; Rohlf, F. James; Zhu, Wei; Gong, Qing Qing; Hunt, Steven R.; Dassopoulos, Themistocles; Newberry, Rodney D.; Sodergren, Erica; Weinstock, George; Robertson, Charles E.; Frank, Daniel N.; Li, Ellen			Host Genes Related to Paneth Cells and Xenobiotic Metabolism Are Associated with Shifts in Human Ileum-Associated Microbial Composition	PLOS ONE			English	Article							INFLAMMATORY-BOWEL-DISEASE; ILEAL CROHNS-DISEASE; CLOSTRIDIUM-DIFFICILE; DEFENSIN EXPRESSION; ULCERATIVE-COLITIS; NOD2; ATG16L1; PATHOGENESIS; IMBALANCES; PHENOTYPE	The aim of this study was to integrate human clinical, genotype, mRNA microarray and 16 S rRNA sequence data collected on 84 subjects with ileal Crohn's disease, ulcerative colitis or control patients without inflammatory bowel diseases in order to interrogate how host-microbial interactions are perturbed in inflammatory bowel diseases (IBD). Ex-vivo ileal mucosal biopsies were collected from the disease unaffected proximal margin of the ileum resected from patients who were undergoing initial intestinal surgery. Both RNA and DNA were extracted from the mucosal biopsy samples. Patients were genotyped for the three major NOD2 variants (Leufs1007, R702W, and G908R) and the ATG16L1T300A variant. Whole human genome mRNA expression profiles were generated using Agilent microarrays. Microbial composition profiles were determined by 454 pyrosequencing of the V3-V5 hypervariable region of the bacterial 16 S rRNA gene. The results of permutation based multivariate analysis of variance and covariance (MANCOVA) support the hypothesis that host mucosal Paneth cell and xenobiotic metabolism genes play an important role in host microbial interactions.	[Zhang, Tianyi; Jiao, Xiangmin; Zhu, Wei] SUNY Stony Brook, Dept Appl Math & Stat, Stony Brook, NY 11794 USA; [Zhang, Tianyi; DeSimone, Robert A.; Li, Ellen] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA; [Rohlf, F. James] SUNY Stony Brook, Dept Ecol & Evolut, Stony Brook, NY 11794 USA; [Gong, Qing Qing; Dassopoulos, Themistocles; Newberry, Rodney D.; Li, Ellen] Washington Univ, Dept Med, St Louis Sch Med, St Louis, MO USA; [Hunt, Steven R.] Washington Univ, St Louis Sch Med, Dept Surg, St Louis, MO USA; [Sodergren, Erica; Weinstock, George] Washington Univ, St Louis Sch Med, Genome Inst, St Louis, MO USA; [Robertson, Charles E.] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA; [Frank, Daniel N.] Univ Colorado, Dept Med, Aurora, CO 80309 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Saint Louis University; Washington University (WUSTL); Saint Louis University; Washington University (WUSTL); Saint Louis University; Washington University (WUSTL); University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus	Zhang, TY (corresponding author), SUNY Stony Brook, Dept Appl Math & Stat, Stony Brook, NY 11794 USA.	Ellen.Li@stonybrook.edu	Rohlf, F./AAR-6717-2021; Weinstock, George M/C-6314-2013	Rohlf, F./0000-0003-0522-3679; Weinstock, George M/0000-0002-2997-4592; ROBERTSON, CHARLES/0000-0002-4136-4121; DeSimone, Robert/0000-0002-3484-790X; Jiao, Xiangmin/0000-0002-7111-9813; Newberry, Rodney/0000-0002-4152-5191	National Institutes of Health (NIH) [UH2DK083994]; Crohn's and Colitis Foundation of America; Simons Foundation; Leona M. and Harry B. Helmsley charitable trust through the Sinai-Helmsley Alliance for Research Excellence (SHARE) Network; NIH [R21HG005964]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R21HG005964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574, UH2DK083994] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Crohn's and Colitis Foundation of America; Simons Foundation; Leona M. and Harry B. Helmsley charitable trust through the Sinai-Helmsley Alliance for Research Excellence (SHARE) Network; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported partially by National Institutes of Health (NIH) UH2DK083994, the Crohn's and Colitis Foundation of America, the Simons Foundation and by the Leona M. and Harry B. Helmsley charitable trust through the Sinai-Helmsley Alliance for Research Excellence (SHARE) Network and NIH R21HG005964. The authors acknowledge use of the Washington University Digestive Diseases Research Core Center Tissue Procurement Facility (P30 DK52574). No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham C, 2009, NEW ENGL J MED, V361, P2066, DOI 10.1056/NEJMra0804647; Aitchison J., 2003, STAT ANAL COMPOSITIO; Anderson MJ, 2001, AUSTRAL ECOL, V26, P32, DOI 10.1046/j.1442-9993.2001.01070.x; Bevins CL, 2009, GUT, V58, P882; Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416; Cadwell K, 2010, CELL, V141, P1135, DOI 10.1016/j.cell.2010.05.009; Chen HY, 2011, DIS COLON RECTUM, V54, P1020, DOI 10.1007/DCR.0b013e31821b94b3; Cole JR, 2009, NUCLEIC ACIDS RES, V37, pD141, DOI 10.1093/nar/gkn879; COLLINS MD, 1994, INT J SYST BACTERIOL, V44, P812, DOI 10.1099/00207713-44-4-812; Cuthbert AP, 2002, GASTROENTEROLOGY, V122, P867, DOI 10.1053/gast.2002.32415; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Dieckgraefe BK, 2000, PHYSIOL GENOMICS, V4, P1; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Frank DN, 2007, P NATL ACAD SCI USA, V104, P13780, DOI 10.1073/pnas.0706625104; Frank DN, 2011, TRENDS MICROBIOL, V19, P427, DOI 10.1016/j.tim.2011.06.005; Frank DN, 2011, INFLAMM BOWEL DIS, V17, P179, DOI 10.1002/ibd.21339; Haas BJ, 2011, GENOME RES, V21, P494, DOI 10.1101/gr.112730.110; Hamm CM, 2010, INFLAMM BOWEL DIS, V16, P1649, DOI 10.1002/ibd.21208; Hancock L, 2008, INFLAMM BOWEL DIS, V14, P1667, DOI 10.1002/ibd.20517; Hartupee JC, 2001, BBA-GENE STRUCT EXPR, V1518, P287, DOI 10.1016/S0167-4781(00)00284-0; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; Issa M, 2007, CLIN GASTROENTEROL H, V5, P345, DOI 10.1016/j.cgh.2006.12.028; Khor B, 2011, NATURE, V474, P307, DOI 10.1038/nature10209; Langmann T, 2004, GASTROENTEROLOGY, V127, P26, DOI 10.1053/j.gastro.2004.04.019; Lawrance IC, 2001, HUM MOL GENET, V10, P445, DOI 10.1093/hmg/10.5.445; Lepage P, 2011, GASTROENTEROLOGY, V141, P227, DOI 10.1053/j.gastro.2011.04.011; Lesage S, 2002, AM J HUM GENET, V70, P845, DOI 10.1086/339432; Li E, 2011, PLOS ONE IN PRESS; Nawrocki EP, 2009, BIOINFORMATICS, V25, P1335, DOI 10.1093/bioinformatics/btp157; Nelson RL, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001181.pub3; Ng SC, 2012, INFLAMM BOWEL DIS, V18, P725, DOI 10.1002/ibd.21747; Ogura Y, 2003, GUT, V52, P1591, DOI 10.1136/gut.52.11.1591; Ott R.L., 2015, INTRO STAT METHODS D, V7th ed.; Peterson DA, 2008, CELL HOST MICROBE, V3, P417, DOI 10.1016/j.chom.2008.05.001; Peterson J, 2009, GENOME RES, V19, P2317, DOI 10.1101/gr.096651.109; Petrosino JF, 2009, CLIN CHEM, V55, P856, DOI 10.1373/clinchem.2008.107565; Prescott NJ, 2007, GASTROENTEROLOGY, V132, P1665, DOI 10.1053/j.gastro.2007.03.034; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Rodemann JF, 2007, CLIN GASTROENTEROL H, V5, P339, DOI 10.1016/j.cgh.2006.12.027; Salzman NH, 2010, NAT IMMUNOL, V11, P76, DOI 10.1038/ni.1825; Simms LA, 2008, GUT, V57, P903, DOI 10.1136/gut.2007.142588; Singh W., 2008, THESIS U ICELAND; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105; Sokol H, 2008, INFLAMM BOWEL DIS, V14, P858, DOI 10.1002/ibd.20392; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; Sun JC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011351; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vaughan IP, 2005, J APPL ECOL, V42, P487, DOI 10.1111/j.1365-2664.2005.01038.x; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; WARD RF, 1963, SCIENCE, V140, P978, DOI 10.1126/science.140.3570.978; Waterman M, 2011, INFLAMM BOWEL DIS, V17, P1936, DOI 10.1002/ibd.21579; Wehkamp J, 2005, P NATL ACAD SCI USA, V102, P18129, DOI 10.1073/pnas.0505256102; Willing B, 2009, INFLAMM BOWEL DIS, V15, P653, DOI 10.1002/ibd.20783; Willing BP, 2010, GASTROENTEROLOGY, V139, P1844, DOI 10.1053/j.gastro.2010.08.049; Wu F, 2007, INFLAMM BOWEL DIS, V13, P807, DOI 10.1002/ibd.20110; Yoo SM, 2005, VIROLOGY, V343, P47, DOI 10.1016/j.virol.2005.08.018	58	21	21	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2012	7	6							e30044	10.1371/journal.pone.0030044	http://dx.doi.org/10.1371/journal.pone.0030044			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UV	22719822	Green Published, gold, Green Submitted			2023-01-03	WOS:000305341900005
J	Schmidt, J; Riechers, A; Stoll, R; Amann, T; Fink, F; Spruss, T; Gronwald, W; Konig, B; Hellerbrand, C; Bosserhoff, AK				Schmidt, Jennifer; Riechers, Alexander; Stoll, Raphael; Amann, Thomas; Fink, Florian; Spruss, Thilo; Gronwald, Wolfram; Koenig, Burkhard; Hellerbrand, Claus; Bosserhoff, Anja Katrin			Targeting Melanoma Metastasis and Immunosuppression with a New Mode of Melanoma Inhibitory Activity (MIA) Protein Inhibition	PLOS ONE			English	Article							MALIGNANT-MELANOMA; CELLS; EXPRESSION; MIGRATION; TRANSITION; SECRETION; INVASION; SPECTRA; FAMILY	Melanoma is the most aggressive form of skin cancer, with fast progression and early dissemination mediated by the melanoma inhibitory activity (MIA) protein. Here, we discovered that dimerization of MIA is required for functional activity through mutagenesis of MIA which showed the correlation between dimerization and functional activity. We subsequently identified the dodecapeptide AR71, which prevents MIA dimerization and thereby acts as a MIA inhibitor. Two-dimensional nuclear magnetic resonance (NMR) spectroscopy demonstrated the binding of AR71 to the MIA dimerization domain, in agreement with in vitro and in vivo data revealing reduced cell migration, reduced formation of metastases and increased immune response after AR71 treatment. We believe AR71 is a lead structure for MIA inhibitors. More generally, inhibiting MIA dimerization is a novel therapeutic concept in melanoma therapy.	[Schmidt, Jennifer; Bosserhoff, Anja Katrin] Univ Regensburg, Inst Pathol, Regensburg, Germany; [Riechers, Alexander; Koenig, Burkhard] Univ Regensburg, Inst Organ Chem, D-8400 Regensburg, Germany; [Stoll, Raphael] Ruhr Univ Bochum, Biomol NMR, Fac Chem & Biochem, Bochum, Germany; [Amann, Thomas; Hellerbrand, Claus] Univ Hosp Regensburg, Dept Internal Med 1, Regensburg, Germany; [Fink, Florian; Gronwald, Wolfram] Univ Regensburg, Inst Funct Gen, Regensburg, Germany; [Spruss, Thilo] Univ Regensburg, Inst Pharm, D-8400 Regensburg, Germany	University of Regensburg; University of Regensburg; Ruhr University Bochum; University of Regensburg; University of Regensburg; University of Regensburg	Schmidt, J (corresponding author), Univ Regensburg, Inst Pathol, Regensburg, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Bosserhoff, Anja/GNH-4801-2022; Koenig, Burkhard/O-8172-2019; Koenig, Burkhard/A-1362-2009; Koenig, Burkhard/GRX-2026-2022	Koenig, Burkhard/0000-0002-6131-4850; Koenig, Burkhard/0000-0002-6131-4850; Koenig, Burkhard/0000-0002-6131-4850; Bosserhoff, Anja/0000-0001-8147-394X	German Research Foundation; German Cancer Aid (Deutsche Krebshilfe); Bundesministerium fur Bildung und Forschung; FCI; Proteincenter (NRW Center of Excellence); RUBiospek	German Research Foundation(German Research Foundation (DFG)); German Cancer Aid (Deutsche Krebshilfe)(Deutsche Krebshilfe); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); FCI(Fonds der Chemischen Industrie); Proteincenter (NRW Center of Excellence); RUBiospek	This work was supported by the German Research Foundation and the German Cancer Aid (Deutsche Krebshilfe) to AKB. Furthermore, RS gratefully recognizes generous support from the Bundesministerium fur Bildung und Forschung, FCI, Proteincenter (NRW Center of Excellence), and RUBiospek. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baumann F, 2009, NEURO-ONCOLOGY, V11, P368, DOI 10.1215/15228517-2008-106; BLESCH A, 1994, CANCER RES, V54, P5695; Bosserhoff AK, 1996, J BIOL CHEM, V271, P490, DOI 10.1074/jbc.271.1.490; Bosserhoff AK, 2003, LAB INVEST, V83, P1583, DOI 10.1097/01.LAB.0000097191.12477.5D; Bosserhoff AK, 2002, HISTOL HISTOPATHOL, V17, P289, DOI 10.14670/HH-17.289; Bosserhoff AK, 2001, MELANOMA RES, V11, P417, DOI 10.1097/00008390-200108000-00013; Carrascal MT, 2003, CANCER RES, V63, P491; DAVIS DG, 1985, J AM CHEM SOC, V107, P7197, DOI 10.1021/ja00310a085; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Delano W.L, 2002, DELANO SCI; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Guba M, 2000, BRIT J CANCER, V83, P1216, DOI 10.1054/bjoc.2000.1424; Jachimczak P, 2005, INT J CANCER, V113, P88, DOI 10.1002/ijc.20549; Kuphal S, 2006, ONCOGENE, V25, P103, DOI 10.1038/sj.onc.1209008; Lougheed JC, 2001, P NATL ACAD SCI USA, V98, P5515, DOI 10.1073/pnas.091601698; Massoumi R, 2009, J EXP MED, V206, P221, DOI 10.1084/jem.20082044; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; Moser M, 2002, MOL CELL BIOL, V22, P1438, DOI 10.1128/MCB.22.5.1438-1445.2002; Riechers A, 2009, BIOTECHNIQUES, V47, P837, DOI 10.2144/000113223; Schmidt J, 2010, CELL RES, V20, P1224, DOI 10.1038/cr.2010.121; Schmidt J, 2009, INT J CANCER, V125, P1587, DOI 10.1002/ijc.24508; Schwarten M, 2007, BIOMOL NMR ASSIGM, V1, P105, DOI 10.1007/s12104-007-9030-3; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; Stahlecker J, 2000, ANTICANCER RES, V20, P5041; Stoll R, 2008, CURR PROTEIN PEPT SC, V9, P221, DOI 10.2174/138920308784534014; Stoll R, 2001, EMBO J, V20, P340, DOI 10.1093/emboj/20.3.340; Stoll R, 2006, BIOL CHEM, V387, P1601, DOI 10.1515/BC.2006.199; Tatzel J, 2005, PIGM CELL RES, V18, P92, DOI 10.1111/j.1600-0749.2005.00212.x; Wolf K, 2007, NAT CELL BIOL, V9, P893, DOI 10.1038/ncb1616	29	15	19	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2012	7	5							e37941	10.1371/journal.pone.0037941	http://dx.doi.org/10.1371/journal.pone.0037941			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959WT	22666418	Green Published, Green Submitted, gold			2023-01-03	WOS:000305349600045
J	Sommers, BD; Bindman, AB				Sommers, Benjamin D.; Bindman, Andrew B.			New Physicians, the Affordable Care Act, and the Changing Practice of Medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Sommers, Benjamin D.; Bindman, Andrew B.] US Dept Hlth & Human Serv, Off Hlth Policy, Off Assistant Secretary Planning & Evaluat, Washington, DC 20201 USA; [Sommers, Benjamin D.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Bindman, Andrew B.] Univ Calif San Francisco, Dept Med Hlth Policy Epidemiol & Biostat, San Francisco, CA 94143 USA	Harvard University; Harvard T.H. Chan School of Public Health; University of California System; University of California San Francisco	Sommers, BD (corresponding author), US Dept Hlth & Human Serv, Off Hlth Policy, Off Assistant Secretary Planning & Evaluat, 200 Independence Ave SW,Room 447D, Washington, DC 20201 USA.	bsommers@hsph.harvard.edu						Association of American Medical Colleges, 2000, APPL 1 TIM APPL ACC; Deloitte Center for Health Solutions, PHYS PERSP HLTH CAR; Emanuel EJ, 2012, JAMA-J AM MED ASSOC, V307, P367, DOI 10.1001/jama.2012.19; Huntoon KM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023557; National Resident Matching Program, RES MATCH DAT 2011; Thomson-Reuters, 2011 NAT PHYS SURV F	6	27	27	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 25	2012	307	16					1697	1698		10.1001/jama.2012.523	http://dx.doi.org/10.1001/jama.2012.523			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	930OA	22535852				2023-01-03	WOS:000303147500020
J	Gilhar, A; Etzioni, A; Paus, R				Gilhar, Amos; Etzioni, Amos; Paus, Ralf			Medical Progress Alopecia Areata	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HUMAN HAIR FOLLICLE; HUMAN SCALP EXPLANTS; IMMUNE PRIVILEGE; T-CELLS; C3H/HEJ MOUSE; TOPICAL MINOXIDIL; SUBSTANCE-P; DISEASE; MODEL; GENE	THE IMPACT OF CERTAIN SKIN DISEASES ON THE LIVES OF THOSE AFFECTED tends to be underestimated or even dismissed as simply a "cosmetic problem." Alopecia areata exemplifies such a condition, owing to its substantial disease burden and its often devastating effects on the patient's quality of life and self-esteem.(1,2) Although alopecia areata is one of the most common autoimmune diseases, the pathobiology of this chronic, relapsing hair-loss disorder is not fully understood, and the available therapies are disappointing.(3-6) This review summarizes the pathogenesis, clinical presentation, and management of alopecia areata and synthesizes relevant background information concerning the biologic and pathobiologic features of the hair follicle. Currently available evidence suggests that alopecia areata can be considered a T-cell-mediated autoimmune disease in which the gradual loss of protection provided by immune privilege of the normal hair follicle plays an important role.(7-9)	[Gilhar, Amos] Technion Israel Inst Technol, B Rappaport Fac Med, Skin Res Lab, Haifa, Israel; [Gilhar, Amos] Flieman Hosp, Haifa, Israel; [Etzioni, Amos] Meyers Childrens Hosp, Haifa, Israel; [Paus, Ralf] Univ Lubeck, Dept Dermatol, Lubeck, Germany; [Paus, Ralf] Univ Manchester, Sch Translat Med, Manchester, Lancs, England	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of Lubeck; University of Manchester	Gilhar, A (corresponding author), Technion Israel Inst Technol, B Rappaport Fac Med, Skin Res Lab, Haifa, Israel.	doritg_2000@yahoo.com	Paus, Ralf/B-5279-2015	Paus, Ralf/0000-0002-3492-9358	National Alopecia Areata Foundation; Deutsche Forschungsgemeinschaft (DFG) [GRK 1727]; Shiseido; Henkel; Wolff Pharma; Giuliani; Bayer Germany; Curadis; Pfleger Germany; Unilever UK; Procter Gamble UK	National Alopecia Areata Foundation; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Shiseido; Henkel; Wolff Pharma; Giuliani; Bayer Germany(Bayer AG); Curadis; Pfleger Germany; Unilever UK(Unilever); Procter Gamble UK(Procter & Gamble)	Supported in part by grants from the National Alopecia Areata Foundation (to Dr. Gilhar) and from Deutsche Forschungsgemeinschaft (DFG, GRK 1727 Autoimmunity) (to Dr. Paus). Dr. Paus reports receiving consulting fees from Henkel, Procter & Gamble UK, and Wolff Pharma and royalties from Thieme Publications and, on behalf of his institution, consulting fees from Wolff Pharma, Giuliani, and Bayer Germany and grant support from Shiseido, Henkel, Wolff Pharma, Giuliani, Bayer Germany, Curadis, Pfleger Germany, and Unilever UK. No other potential conflict of interest relevant to this article was reported.	Agesta N, 2002, DERMATOLOGY, V205, P300, DOI 10.1159/000065841; Alkhalifah A, 2010, J AM ACAD DERMATOL, V62, P191, DOI 10.1016/j.jaad.2009.10.031; Alkhalifah A, 2010, J AM ACAD DERMATOL, V62, P177, DOI 10.1016/j.jaad.2009.10.032; Alli R, 2012, J IMMUNOL, V188, P477, DOI 10.4049/jimmunol.1100657; [Anonymous], 2009, WEEDONS SKIN PATHOLO, VI, P422; Barahmani N, 2009, J AM ACAD DERMATOL, V61, P581, DOI 10.1016/j.jaad.2009.04.031; Betz RC, 2008, BRIT J DERMATOL, V158, P389, DOI 10.1111/j.1365-2133.2007.08312.x; Bodemer C, 2000, J INVEST DERMATOL, V114, P112, DOI 10.1046/j.1523-1747.2000.00828.x; Carson MJ, 2006, IMMUNOL REV, V213, P48, DOI 10.1111/j.1600-065X.2006.00441.x; Cetin ED, 2009, AM J DERMATOPATH, V31, P53, DOI 10.1097/DAD.0b013e318185a66e; Chang KH, 2009, J DRUGS DERMATOL, V8, P909; Christoph T, 2000, BRIT J DERMATOL, V142, P862, DOI 10.1046/j.1365-2133.2000.03464.x; Chu SY, 2011, J AM ACAD DERMATOL, V65, P949, DOI 10.1016/j.jaad.2010.08.032; COLOMBE BW, 1995, J AM ACAD DERMATOL, V33, P757; Cotsarelis G, 2006, J INVEST DERMATOL, V126, P1459, DOI 10.1038/sj.jid.5700376; Delamere FM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004413.pub2; Dressel D, 1997, J CUTAN PATHOL, V24, P164, DOI 10.1111/j.1600-0560.1997.tb01571.x; DUVIC M, 1991, ARCH DERMATOL, V127, P64, DOI 10.1001/archderm.127.1.64; Dy LC, 2011, DERMATOL THER, V24, P369, DOI 10.1111/j.1529-8019.2011.01414.x; Farshi S, 2010, INT J DERMATOL, V49, P1188, DOI 10.1111/j.1365-4632.2010.04576.x; FENTON DA, 1983, BRIT MED J, V287, P1015, DOI 10.1136/bmj.287.6398.1015; Ferran M, 2011, J EUR ACAD DERMATOL, V25, P479, DOI 10.1111/j.1468-3083.2010.03770.x; Finner AM, 2011, DERMATOL THER, V24, P348, DOI 10.1111/j.1529-8019.2011.01413.x; Garg S, 2009, SEMIN CUTAN MED SURG, V28, P15, DOI 10.1016/j.sder.2008.12.002; Gilhar A, 1998, J CLIN INVEST, V101, P62, DOI 10.1172/JCI551; Gilhar A, 2001, J INVEST DERMATOL, V117, P1357, DOI 10.1046/j.0022-202x.2001.01583.x; Gilhar A, 2002, ARCH DERMATOL, V138, P916, DOI 10.1001/archderm.138.7.916; GILHAR A, 1992, BRIT J DERMATOL, V126, P166, DOI 10.1111/j.1365-2133.1992.tb07815.x; Gilhar A, 2007, J CLIN INVEST, V117, P2019, DOI 10.1172/JCI31942; GODDARD CJR, 1989, POSTGRAD MED J, V65, P188, DOI 10.1136/pgmj.65.761.188; Goh C, 2006, J EUR ACAD DERMATOL, V20, P1055, DOI 10.1111/j.1468-3083.2006.01676.x; Gregersen PK, 2009, ANNU REV IMMUNOL, V27, P363, DOI 10.1146/annurev.immunol.021908.132653; Harries MJ, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3671; Harries MJ, 2010, AM J PATHOL, V177, P2152, DOI 10.2353/ajpath.2010.100454; Hedstrand H, 1999, J INVEST DERMATOL, V113, P1054, DOI 10.1046/j.1523-1747.1999.00778.x; Hoglund P, 2010, NAT REV IMMUNOL, V10, P724, DOI 10.1038/nri2835; Ito T, 2004, AM J PATHOL, V164, P623, DOI 10.1016/S0002-9440(10)63151-3; Ito T, 2008, J INVEST DERMATOL, V128, P1196, DOI 10.1038/sj.jid.5701183; John KKG, 2011, J INVEST DERMATOL, V131, P1169, DOI 10.1038/jid.2010.427; KALISH RS, 1992, ARCH DERMATOL, V128, P1072, DOI 10.1001/archderm.128.8.1072; Kang H, 2010, J INVEST DERMATOL, V130, P2677, DOI 10.1038/jid.2010.180; Kar BR, 2005, J AM ACAD DERMATOL, V52, P287, DOI 10.1016/j.jaad.2004.10.873; Kemp EH, 2006, HUM IMMUNOL, V67, P535, DOI 10.1016/j.humimm.2006.04.006; KHOURY EL, 1988, J INVEST DERMATOL, V90, P193, DOI 10.1111/1523-1747.ep12462213; Kinori M, 2011, INVEST OPHTH VIS SCI, V52, P4447, DOI 10.1167/iovs.10-7154; Kuchabal SD, 2010, CASE REP DERMATOL, V2, P27, DOI 10.1159/000296271; Kumar V, 2011, AM J PATHOL, V178, P983, DOI 10.1016/j.ajpath.2010.12.007; Kurtev A, 2005, INT J DERMATOL, V44, P457, DOI 10.1111/j.1365-4632.2005.01971.x; Kyriakis KP, 2009, J EUR ACAD DERMATOL, V23, P572, DOI 10.1111/j.1468-3083.2008.02956.x; Luggen P, 2008, J DTSCH DERMATOL GES, V6, P375, DOI 10.1111/j.1610-0387.2007.06608.x; Martinez-Mir A, 2007, AM J HUM GENET, V80, P316, DOI 10.1086/511442; McElwee KJ, 1996, BRIT J DERMATOL, V135, P211, DOI 10.1111/j.1365-2133.1996.tb01149.x; McElwee KJ, 2005, J INVEST DERMATOL, V124, P947, DOI 10.1111/j.0022-202X.2005.23692.x; McMichael AJ, 2007, J AM ACAD DERMATOL, V57, pS49, DOI 10.1016/j.jaad.2006.02.045; MESSENGER AG, 1986, BRIT J DERMATOL, V114, P337, DOI 10.1111/j.1365-2133.1986.tb02825.x; Meyer KC, 2008, BRIT J DERMATOL, V159, P1077, DOI 10.1111/j.1365-2133.2008.08818.x; Muto M, 2011, J DERMATOL SCI, V62, P70, DOI 10.1016/j.jdermsci.2010.10.012; Natarajan K, 2002, ANNU REV IMMUNOL, V20, P853, DOI 10.1146/annurev.immunol.20.100301.064812; Niederkorn JY, 2006, NAT IMMUNOL, V7, P354, DOI 10.1038/ni1328; Ohlmeier MC, 2011, J EUR ACAD DERM 0514; PASCHER F, 1970, DERMATOLOGICA, V141, P193, DOI 10.1159/000252466; PAUS R, 1993, YALE J BIOL MED, V66, P541; Paus R, 2005, TRENDS IMMUNOL, V26, P32, DOI 10.1016/j.it.2004.09.014; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; Paus R, 2009, J INVEST DERMATOL, V129, P1324, DOI 10.1038/jid.2009.111; Peters EMJ, 2007, AM J PATHOL, V171, P1872, DOI 10.2353/ajpath.2007.061206; Petukhova L, 2010, NATURE, V466, P113, DOI 10.1038/nature09114; Picardi A, 2003, PSYCHOSOMATICS, V44, P374, DOI 10.1176/appi.psy.44.5.374; PRICE VH, 1987, J AM ACAD DERMATOL, V16, P730, DOI 10.1016/S0190-9622(87)70095-4; Rodriguez TA, 2010, J AM ACAD DERMATOL, V62, P525, DOI 10.1016/j.jaad.2009.02.006; SAFAVI K, 1992, ARCH DERMATOL, V128, P702, DOI 10.1001/archderm.1992.01680150136027; SCHMOECKEL C, 1979, ARCH DERMATOL, V115, P1254, DOI 10.1001/archderm.115.10.1254; Schneider MR, 2009, CURR BIOL, V19, pR132, DOI 10.1016/j.cub.2008.12.005; Siebenhaar F, 2007, J INVEST DERMATOL, V127, P1489, DOI 10.1038/sj.jid.5700704; Singh TP, 2010, J IMMUNOL, V184, P7257, DOI 10.4049/jimmunol.0903719; Stelekati E, 2009, IMMUNITY, V31, P665, DOI 10.1016/j.immuni.2009.08.022; Sun J, 2008, EXP DERMATOL, V17, P793, DOI 10.1111/j.1600-0625.2008.00773.x; Sundberg JP, 2004, J INVEST DERMATOL, V123, P294, DOI 10.1111/j.0022-202X.2004.23222.x; Tazi-Ahnini R, 2003, HUM GENET, V112, P400, DOI 10.1007/s00439-002-0898-9; Tazi-Ahnini R, 2002, EUR J IMMUNOGENET, V29, P25, DOI 10.1046/j.1365-2370.2002.00271.x; Tobin DJ, 2011, PIGM CELL MELANOMA R, V24, P75, DOI 10.1111/j.1755-148X.2010.00803.x; Tobin DJ, 2003, J INVEST DERM SYMP P, V8, P176, DOI 10.1046/j.1087-0024.2003.00805.x; TOSTI A, 1986, J INVEST DERMATOL, V86, P553, DOI 10.1111/1523-1747.ep12355013; Tosti A, 2003, J AM ACAD DERMATOL, V49, P96, DOI 10.1067/mjd.2003.423; TOSTI A, 1985, DERMATOLOGICA, V170, P69, DOI 10.1159/000249501; Tosti A, 2008, J AM ACAD DERMATOL, V59, P64, DOI 10.1016/j.jaad.2008.03.031; Tosti A, 2009, EXPERT OPIN PHARMACO, V10, P1017, DOI [10.1517/14656560902876368, 10.1517/14656560902876368 ]; Wade MS, 2002, J AM ACAD DERMATOL, V46, P619, DOI 10.1067/mjd.2002.120604; Westerhof W, 2006, PIGMENTARY SYSTEM, P764; Whiting DA, 2003, ARCH DERMATOL, V139, P1555, DOI 10.1001/archderm.139.12.1555; Wiseman MC, 2001, ARCH DERMATOL, V137, P1063; Xiao FL, 2006, PEDIATR DERMATOL, V23, P13, DOI 10.1111/j.1525-1470.2006.00161.x	92	317	327	9	103	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 19	2012	366	16					1515	1525		10.1056/NEJMra1103442	http://dx.doi.org/10.1056/NEJMra1103442			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	927UE	22512484				2023-01-03	WOS:000302934800009
J	Boumendil, A; Angus, DC; Guitonneau, AL; Menn, AM; Ginsburg, C; Takun, K; Davido, A; Masmoudi, R; Doumenc, B; Pateron, D; Garrouste-Orgeas, M; Somme, D; Simon, T; Aegerter, P; Guidet, B				Boumendil, Ariane; Angus, Derek C.; Guitonneau, Anne-Laure; Menn, Anne-Marie; Ginsburg, Christine; Takun, Khalil; Davido, Alain; Masmoudi, Rafik; Doumenc, Benoit; Pateron, Dominique; Garrouste-Orgeas, Maite; Somme, Dominique; Simon, Tabassome; Aegerter, Philippe; Guidet, Bertrand		ICE-CUB Study Grp	Variability of Intensive Care Admission Decisions for the Very Elderly	PLOS ONE			English	Article							PATIENTS AGED 80; PATIENTS REFUSED ADMISSION; QUALITY-OF-LIFE; MEDICARE BENEFICIARIES; TRIAGE DECISIONS; UNIT ADMISSION; SHORT-TERM; MORTALITY; OUTCOMES; OLDER	Although increasing numbers of very elderly patients are requiring intensive care, few large sample studies have investigated ICU admission of very elderly patients. Data on pre triage by physicians from other specialities is limited. This observational cohort study aims at examining inter-hospital variability of ICU admission rates and its association with patients' outcomes. All patients over 80 years possibly qualifying for ICU admission who presented to the emergency departments (ED) of 15 hospitals in the Paris (France) area during a one-year period were prospectively included in the study. Main outcome measures were ICU eligibility, as assessed by the ED and ICU physicians; in-hospital mortality; and vital and functional status 6 months after the ED visit. 2646 patients (median age 86; interquartile range 83-91) were included in the study. 94% of participants completed follow-up (n = 2495). 12.4% (n = 329) of participants were deemed eligible for ICU admission by ED physicians and intensivists. The overall in-hospital and 6-month mortality rates were respectively 27.2% (n = 717) and 50.7% (n = 1264). At six months, 57.5% (n = 1433) of patients had died or had a functional deterioration. Rates of patients deemed eligible for ICU admission ranged from 5.6% to 38.8% across the participating centers, and this variability persisted after adjustment for patients' characteristics. Despite this variability, we found no association between level of ICU eligibility and either in-hospital death or six-month death or functional deterioration. In France, the likelihood that a very elderly person will be admitted to an ICU varies widely from one hospital to another. Influence of intensive care admission on patients' outcome remains unclear.	[Boumendil, Ariane; Guidet, Bertrand] INSERM, U707, Unite Rech Epidemiol Syst Informat & Modelisat, Paris, France; [Boumendil, Ariane; Guidet, Bertrand] Univ Paris 06, UMRS 707, Paris, France; [Boumendil, Ariane; Aegerter, Philippe] Univ Versailles St Quentin, UPRES EA Sante Environm Vieillissement 2506, Paris, France; [Angus, Derek C.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; [Guitonneau, Anne-Laure] Hop Bichat Claude Bernard, AP HP, Emergency Dept, F-75877 Paris, France; [Menn, Anne-Marie] Hop Victor Dupouy, Emergency Dept, Argenteuil, France; [Ginsburg, Christine; Takun, Khalil] Hop Cochin, AP HP, Emergency Dept, F-75674 Paris, France; [Davido, Alain; Masmoudi, Rafik] Hop Europe Georges Pompidou, Emergency Dept, Paris, France; [Doumenc, Benoit] Hop Bicetre, AP HP, Emergency Dept, Paris, France; [Pateron, Dominique] Hop St Antoine, AP HP, Emergency Dept, F-75571 Paris, France; [Garrouste-Orgeas, Maite] St Joseph Hosp Network, Med Surg Intens Care Unit, Paris, France; [Somme, Dominique] Hop Europe Georges Pompidou, AP HP, Geriatr Unit, Paris, France; [Simon, Tabassome] Hop St Antoine, AP HP, Unite Rech Clin Est, F-75571 Paris, France; [Simon, Tabassome] Univ Paris 06, Dept Pharmacol, Paris, France; [Aegerter, Philippe] Hop Ambroise Pare, AP HP, Dept Publ Hlth, Boulogne Billancourt, France; [Guidet, Bertrand] Hop St Antoine, AP HP, Med ICU, F-75571 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Saclay; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Hopital Paris Saint-Joseph; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Boumendil, A (corresponding author), INSERM, U707, Unite Rech Epidemiol Syst Informat & Modelisat, Paris, France.	ariane.boumendil@gmail.com	AEGERTER, Philippe/AAY-6003-2021; Angus, Derek C/E-9671-2012; Somme, Dominique/DEH-7131-2022	AEGERTER, Philippe/0000-0002-9156-5028; SIMON, Tabassome/0000-0002-4550-0450; Boumendil, Ariane/0000-0002-2552-0542	French Ministry of Health (PHRC) [AOM 03 035]; French Society of Intensive Care (SRLF - Bourse "Ethique/Evaluation/Qualite")	French Ministry of Health (PHRC); French Society of Intensive Care (SRLF - Bourse "Ethique/Evaluation/Qualite")	This work was supported by grants from the French Ministry of Health (PHRC AOM 03 035) and from the French Society of Intensive Care (SRLF - Bourse "Ethique/Evaluation/Qualite" 2008). The French ministry of Health and the French Society of Intensive Care had no role in the design and conduct of the study, in the collection, management, analysis, or interpretation of the data, or in the preparation, review, or approval of the manuscript.	Aegerter P, 2005, INTENS CARE MED, V31, P416, DOI 10.1007/s00134-005-2557-9; Angus DC, 2004, CRIT CARE MED, V32, P638, DOI 10.1097/01.CCM.0000114816.62331.08; [Anonymous], 2010, R LANG ENV STAT COMP; [Anonymous], RMS REGRESSION MODEL; Azoulay E, 2001, CRIT CARE MED, V29, P2132, DOI 10.1097/00003246-200111000-00014; Barnato AE, 2004, HEALTH SERV RES, V39, P363, DOI 10.1111/j.1475-6773.2004.00232.x; Boumendil A, 2005, J AM GERIATR SOC, V53, P88, DOI 10.1111/j.1532-5415.2005.53016.x; Boumendil A, 2004, INTENS CARE MED, V30, P647, DOI 10.1007/s00134-003-2150-z; Boumendil A, 2011, ARCH INTERN MED, V171, P1116, DOI 10.1001/archinternmed.2011.102; COOK DJ, 1995, JAMA-J AM MED ASSOC, V273, P703, DOI 10.1001/jama.273.9.703; de Rooij SE, 2006, INTENS CARE MED, V32, P1039, DOI 10.1007/s00134-006-0171-0; de Rooij SEJA, 2008, J AM GERIATR SOC, V56, P816, DOI 10.1111/j.1532-5415.2008.01671.x; Egol A, 1999, CRIT CARE MED, V27, P633; FRISHOLIMA P, 1994, THEOR SURG, V9, P208; Frost DW, 2009, CRIT CARE, V13, DOI 10.1186/cc7791; Garrouste-Orgeas M, 2005, CRIT CARE MED, V33, P750, DOI 10.1097/01.CCM.0000157752.26180.F1; Garrouste-Orgeas M, 2003, INTENS CARE MED, V29, P774, DOI 10.1007/s00134-003-1709-z; Garrouste-Orgeas M, 2006, INTENS CARE MED, V32, P1045, DOI 10.1007/s00134-006-0169-7; Garrouste-Orgeas M, 2009, CRIT CARE MED, V37, P2919, DOI 10.1097/CCM.0b013e3181b019f0; Joynt GM, 2001, INTENS CARE MED, V27, P1459, DOI 10.1007/s001340101041; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Larsen K, 2005, AM J EPIDEMIOL, V161, P81, DOI 10.1093/aje/kwi017; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; Luyt CE, 2007, CRIT CARE MED, V35, P3, DOI 10.1097/01.CCM.0000249832.36518.11; Merlo J, 2006, J EPIDEMIOL COMMUN H, V60, P290, DOI 10.1136/jech.2004.029454; Metcalfe MA, 1997, LANCET, V350, P7, DOI 10.1016/S0140-6736(96)10018-0; MOLLOY DW, 1991, CAN MED ASSOC J, V145, P947; NUCKTON TJ, 1995, ARCH INTERN MED, V155, P1087, DOI 10.1001/archinte.155.10.1087; Rodriguez-Molinero A, 2010, AM J EMERG MED, V28, P757, DOI 10.1016/j.ajem.2009.03.016; Sharma G, 2008, CHEST, V133, P72, DOI 10.1378/chest.07-1007; Shmueli A, 2005, INT J TECHNOL ASSESS, V21, P66, DOI 10.1017/S0266462305050087; Sprung CL, 1997, INTENS CARE MED, V23, P1011, DOI 10.1007/s001340050449; Sprung CL, 1999, CRIT CARE MED, V27, P1073, DOI 10.1097/00003246-199906000-00021; Sprung CL, 2011, CRIT CARE MED; Thiery G, 2005, J CLIN ONCOL, V23, P4406, DOI 10.1200/JCO.2005.01.487; Torres OH, 2006, INTENS CARE MED, V32, P1052, DOI 10.1007/s00134-006-0170-1; Vanhecke TE, 2008, CRIT CARE MED, V36, P812, DOI 10.1097/CCM.0B013E318165FAC7; Wilson DM, 2010, CRIT CARE MED, V38, P303, DOI 10.1097/CCM.0b013e3181b4a263; Wunsch H, 2010, JAMA-J AM MED ASSOC, V303, P849, DOI 10.1001/jama.2010.216; Nguyen YL, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-29	41	103	103	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2012	7	4							e34387	10.1371/journal.pone.0034387	http://dx.doi.org/10.1371/journal.pone.0034387			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	959TP	22509296	Green Accepted, Green Published, gold			2023-01-03	WOS:000305336600029
J	Calvet, X; Ruiz, MA; Dosal, A; Moreno, L; Lopez, M; Figuerola, A; Suarez, D; Miquel, M; Villoria, A; Gene, E				Calvet, Xavier; Angel Ruiz, Miquel; Dosal, Angelina; Moreno, Laura; Lopez, Maria; Figuerola, Ariadna; Suarez, David; Miquel, Mireia; Villoria, Albert; Gene, Emili			Cost-Minimization Analysis Favours Intravenous Ferric Carboxymaltose over Ferric Sucrose for the Ambulatory Treatment of Severe Iron Deficiency	PLOS ONE			English	Article							INFLAMMATORY-BOWEL-DISEASE; OPEN-LABEL; IBD PATIENTS; ANEMIA; SAFETY; MANAGEMENT; EFFICACY; TOLERABILITY; TRIAL	Objective: Intravenous iron is widely used to treat iron deficiency in day-care units. Ferric carboxymaltose (FCM) allows administration of larger iron doses than iron sucrose (IS) in each infusion (1000 mg vs. 200 mg). As FCM reduces the number of infusions required but is more expensive, we performed a cost-minimization analysis to compare the cost impact of the two drugs. Materials and Methods: The number of infusions and the iron dose of 111 consecutive patients who received intravenous iron at a gastrointestinal diseases day-care unit from 8/2007 to 7/2008 were retrospectively obtained. Costs of intravenous iron drugs were obtained from the Spanish regulatory agencies. The accounting department of the Hospital determined hospital direct and indirect costs for outpatient iron infusion. Non-hospital direct costs were calculated on the basis of patient interviews. In the pharmacoeconomic model, base case mean costs per patient were calculated for administering 1000 mg of iron per infusion using FCM or 200 mg using IS. Sensitivity analysis and Monte Carlo simulation were performed. Results: Under baseline assumptions, the estimated cost of iron infusion per patient and year was (SIC)304 for IS and (SIC)274 for FCM, a difference of (SIC)30 in favour of FCM. Adding non-hospital direct costs to the model increased the difference to (SIC)67 ((SIC)354 for IS vs. (SIC)287 for FCM). A Monte Carlo simulation taking into account non-hospital direct costs favoured the use of FCM in 97% of simulations. Conclusion: In this pharmacoeconomic analysis, FCM infusion reduced the costs of iron infusion at a gastrointestinal day-care unit.	[Calvet, Xavier; Dosal, Angelina; Moreno, Laura; Lopez, Maria; Figuerola, Ariadna; Miquel, Mireia; Villoria, Albert] Univ Autonoma Barcelona, Inst Univ Parc Tauli, Hosp Sabadell, Serv Aparell Digestiu, Sabadell, Spain; [Calvet, Xavier; Figuerola, Ariadna; Miquel, Mireia; Villoria, Albert; Gene, Emili] Inst Salud Carlos III, CIBERehd, Barcelona, Spain; [Angel Ruiz, Miquel] Hosp Sabadell, Dept Comptabilitat Analit, Sabadell, Spain; [Suarez, David] Fundacio Parc Tauli, Unitat Epidemiol & Avaluacio, Sabadell, Spain; [Gene, Emili] Univ Autonoma Barcelona, Inst Univ Parc Tauli, Hosp Sabadell, Serv Urgencies, Sabadell, Spain	Autonomous University of Barcelona; Parc Tauli Hospital Universitari; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; Instituto de Salud Carlos III; Autonomous University of Barcelona; Parc Tauli Hospital Universitari; Autonomous University of Barcelona; Parc Tauli Hospital Universitari; Autonomous University of Barcelona; Parc Tauli Hospital Universitari	Calvet, X (corresponding author), Univ Autonoma Barcelona, Inst Univ Parc Tauli, Hosp Sabadell, Serv Aparell Digestiu, Sabadell, Spain.	xcalvet@tauli.cat	Lopez-Arellano, Ma Eugenia/GWV-5056-2022; Calvet, Xavier/H-3288-2019	Calvet, Xavier/0000-0002-6278-9663; Calvet, Xavier/0000-0002-4413-4209; Gene Tous, Emili/0000-0001-8916-2919	Vifor Uriach Pharma S. L.	Vifor Uriach Pharma S. L.	This study was supported in part by a research agreement with Vifor Uriach Pharma S. L. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.	Anker SD, 2009, NEW ENGL J MED, V361, P2436, DOI 10.1056/NEJMoa0908355; [Anonymous], LIST COUNTRIES EUROP; Bager P, 2010, J CROHNS COLITIS, V4, P427, DOI 10.1016/j.crohns.2010.01.007; Bailie GR, 2010, ARZNEIMITTELFORSCH, V60, P386, DOI 10.1055/s-0031-1296303; Bailie GR, 2010, HEMODIAL INT, V14, P47, DOI 10.1111/j.1542-4758.2009.00409.x; Covic A, 2010, NEPHROL DIAL TRANSPL, V25, P2722, DOI 10.1093/ndt/gfq069; Dosal A, 2010, GASTROENT HEPAT-BARC, V33, P479, DOI 10.1016/j.gastrohep.2010.02.011; Evstatiev R, 2011, GASTROENTEROLOGY, V141, P846, DOI 10.1053/j.gastro.2011.06.005; Gisbert JP, 2008, AM J GASTROENTEROL, V103, P1299, DOI 10.1111/j.1572-0241.2008.01846.x; Grimmelt AC, 2009, CLIN NEPHROL, V71, P125; Hayat A, 2008, CLIN MED RES, V6, P93, DOI 10.3121/cmr.2008.811; Johnson DW, 2001, NEPHROL DIAL TRANSPL, V16, P1879, DOI 10.1093/ndt/16.9.1879; Kim YH, 2009, ACTA HAEMATOL-BASEL, V121, P37, DOI 10.1159/000210062; Kociol Robb D, 2010, Ann Intern Med, V152, pJC4, DOI 10.7326/0003-4819-152-8-201004200-02005; Kulnigg S, 2008, AM J GASTROENTEROL, V103, P1182, DOI 10.1111/j.1572-0241.2007.01744.x; Lindgren S, 2009, SCAND J GASTROENTERO, V44, P838, DOI 10.1080/00365520902839667; Littlewood TJ, 2008, BRIT J HAEMATOL, V141, P751, DOI 10.1111/j.1365-2141.2008.07118.x; Lyseng-Williamson KA, 2009, DRUGS, V69, P739, DOI 10.2165/00003495-200969060-00007; Munoz M, 2009, WORLD J GASTROENTERO, V15, P4666, DOI 10.3748/wjg.15.4666; Qunibi WY, 2010, ARZNEIMITTELFORSCH, V60, P399, DOI 10.1055/s-0031-1296304; Rubio C, 2010, PHARMACOECONOMICS SP, P109; Schroder O, 2005, AM J GASTROENTEROL, V100, P2503, DOI 10.1111/j.1572-0241.2005.00250.x; Seid MH, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.07.046; Seril DN, 2006, J CLIN GASTROENTEROL, V40, P391, DOI 10.1097/00004836-200605000-00006	24	40	43	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2012	7	9							e45604	10.1371/journal.pone.0045604	http://dx.doi.org/10.1371/journal.pone.0045604			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014RG	23029129	Green Published, gold			2023-01-03	WOS:000309392800065
J	Motbey, CP; Karanges, E; Li, KM; Wilkinson, S; Winstock, AR; Ramsay, J; Hicks, C; Kendig, MD; Wyatt, N; Callaghan, PD; McGregor, IS				Motbey, Craig P.; Karanges, Emily; Li, Kong M.; Wilkinson, Shane; Winstock, Adam R.; Ramsay, John; Hicks, Callum; Kendig, Michael D.; Wyatt, Naomi; Callaghan, Paul D.; McGregor, Iain S.			Mephedrone in Adolescent Rats: Residual Memory Impairment and Acute but Not Lasting 5-HT Depletion	PLOS ONE			English	Article							MDMA ECSTASY; 3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; BEHAVIORAL SENSITIZATION; 4-METHYLMETHCATHINONE MEPHEDRONE; INCREASED ANXIETY; ETHANOL EXPOSURE; ADULT RATS; METHAMPHETAMINE; NEUROTOXICITY; COMBINATION	Mephedrone (4-methylmethcathinone, MMC) is a popular recreational drug, yet its potential harms are yet to be fully established. The current study examined the impact of single or repeated MMC exposure on various neurochemical and behavioral measures in rats. In Experiment 1 male adolescent Wistar rats received single or repeated (once a day for 10 days) injections of MMC (30 mg/kg) or the comparator drug methamphetamine (METH, 2.5 mg/kg). Both MMC and METH caused robust hyperactivity in the 1 h following injection although this effect did not tend to sensitize with repeated treatment. Striatal dopamine (DA) levels were increased 1 h following either METH or MMC while striatal and hippocampal serotonin (5-HT) levels were decreased 1 h following MMC but not METH. MMC caused greater increases in 5-HT metabolism and greater reductions in DA metabolism in rats that had been previously exposed to MMC. Autoradiographic analysis showed no signs of neuroinflammation ([I-125]CLINDE ligand used as a marker for translocator protein (TSPO) expression) with repeated exposure to either MMC or METH. In Experiment 2, rats received repeated MMC (7.5, 15 or 30 mg/kg once a day for 10 days) and were examined for residual behavioral effects following treatment. Repeated high (30 mg/kg) dose MMC produced impaired novel object recognition 5 weeks after drug treatment. However, no residual changes in 5-HT or DA tissue levels were observed at 7 weeks post-treatment. Overall these results show that MMC causes acute but not lasting changes in DA and 5-HT tissue concentrations. MMC can also cause long-term memory impairment. Future studies of cognitive function in MMC users are clearly warranted.	[Motbey, Craig P.; Karanges, Emily; Hicks, Callum; Kendig, Michael D.; McGregor, Iain S.] Univ Sydney, Sch Psychol, Sydney, NSW 2006, Australia; [Li, Kong M.] Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia; [Wilkinson, Shane] Univ Sydney, Sch Chem, Sydney, NSW 2006, Australia; [Winstock, Adam R.] Univ London, Kings Coll, Inst Psychiat, London WC1E 7HU, England; [Ramsay, John] Univ London, St Georges Coll, TICTAC Commun Ltd, London WC1E 7HU, England; [Wyatt, Naomi; Callaghan, Paul D.] Australian Nucl Sci & Technol Org, Div Life Sci, Sydney, NSW, Australia	University of Sydney; University of Sydney; University of Sydney; University of London; King's College London; University of London; Australian Nuclear Science & Technology Organisation	McGregor, IS (corresponding author), Univ Sydney, Sch Psychol, Sydney, NSW 2006, Australia.	iain.mcgregor@sydney.edu.au	Kendig, Mike/K-3704-2019; Li, Kong M./R-4655-2019	Kendig, Mike/0000-0003-3337-6402; Winstock, Adam/0000-0001-7854-8015; Wyatt, Naomi/0000-0002-5311-1623; mcgregor, iain/0000-0002-9307-7159	Australian Research Council [DP0988609]; National Health and Medical Research Council (NHMRC) [1034649]; Australian Institute of Nuclear Science and Engineering	Australian Research Council(Australian Research Council); National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Australian Institute of Nuclear Science and Engineering	This work was supported by Australian Research Council (DP0988609) and National Health and Medical Research Council (NHMRC) (1034649) grants to IM and a Postgraduate Research Award from the Australian Institute of Nuclear Science and Engineering to CM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Able JA, 2006, BIOL PSYCHIAT, V59, P1219, DOI 10.1016/j.biopsych.2005.09.006; Advisory Council on the Misuse of Drugs (AMCD), 2010, CONS CATH; Angoa-Perez M, 2012, J NEUROCHEM, V120, P1097, DOI 10.1111/j.1471-4159.2011.07632.x; Arlicot N, 2008, EUR J NUCL MED MOL I, V35, P2203, DOI 10.1007/s00259-008-0834-x; Bajaj N, 2010, BMJ Case Rep, V2010, DOI 10.1136/bcr.02.2010.2780; Ball KT, 2006, EUR J NEUROSCI, V24, P217, DOI 10.1111/j.1460-9568.2006.04885.x; Ball KT, 2011, BEHAV PHARMACOL, V22, P847, DOI 10.1097/FBP.0b013e32834d13b4; Baumann MH, 2007, PSYCHOPHARMACOLOGY, V189, P407, DOI 10.1007/s00213-006-0322-6; Baumann MH, 2012, NEUROPSYCHOPHARMACOL, V37, P1192, DOI 10.1038/npp.2011.304; Berton O, 2006, SCIENCE, V311, P864, DOI 10.1126/science.1120972; Brunt TM, 2011, J PSYCHOPHARMACOL, V25, P1543, DOI 10.1177/0269881110378370; Cadet JL, 2007, NEUROTOX RES, V11, P183, DOI 10.1007/BF03033567; Cassel JC, 2005, NEUROPSYCHOPHARMACOL, V30, P1870, DOI 10.1038/sj.npp.1300714; Clemens KJ, 2007, DRUG ALCOHOL DEPEN, V86, P183, DOI 10.1016/j.drugalcdep.2006.06.004; Clemens KJ, 2005, NEUROPHARMACOLOGY, V49, P195, DOI 10.1016/j.neuropharm.2005.03.002; Clemens KJ, 2004, PSYCHOPHARMACOLOGY, V173, P318, DOI 10.1007/s00213-004-1786-x; Corkery J, 2012, PHARMACOLOGY, DOI DOI 10.5772/32935; Dargan PI, 2010, QJM-INT J MED, V103, P875, DOI 10.1093/qjmed/hcq134; Davidson C, 2002, EUR J PHARMACOL, V441, P75, DOI 10.1016/S0014-2999(02)01437-1; Dickson AJ, 2010, J ANAL TOXICOL, V34, P162, DOI 10.1093/jat/34.3.162; Drugs-Forum, 2011, EXP MEPH 4 METH 4 MM; Erowid, 2011, ER EXP VAULTS 4 METH; Fantegrossi WE, 2008, NEUROSCIENCE, V151, P533, DOI 10.1016/j.neuroscience.2007.11.007; Freeman TP, 2012, ADDICTION, V107, P792, DOI 10.1111/j.1360-0443.2011.03719.x; Garrett Gerard, 2010, BMJ Case Rep, V2010, DOI 10.1136/bcr.04.2010.2925; Green AR, 2003, PHARMACOL REV, V55, P463, DOI 10.1124/pr.55.3.3; Gustavsson David, 2009, Lakartidningen, V106, P2769; Hadlock GC, 2011, J PHARMACOL EXP THER, V339, P530, DOI 10.1124/jpet.111.184119; Halpern JH, 2011, ADDICTION, V106, P777, DOI 10.1111/j.1360-0443.2010.03252.x; Kalivas PW, 1998, NEUROPSYCHOPHARMACOL, V18, P469, DOI 10.1016/S0893-133X(97)00195-4; Kehr J, 2011, BRIT J PHARMACOL, V164, P1949, DOI 10.1111/j.1476-5381.2011.01499.x; Kelly JP, 2011, DRUG TEST ANAL, V3, P439, DOI 10.1002/dta.313; Klein C, 2011, PSYCHOPHARMACOLOGY, V218, P443, DOI 10.1007/s00213-011-2342-0; Lukas M, 2011, NEUROPSYCHOPHARMACOL, V36, P2159, DOI 10.1038/npp.2011.95; Malberg JE, 1998, J NEUROSCI, V18, P5086; Martinez-Clemente J, 2012, EUR NEUROPSYCHOPHARM, V22, P231, DOI 10.1016/j.euroneuro.2011.07.009; Maskell PD, 2011, J ANAL TOXICOL, V35, P188, DOI 10.1093/anatox/35.3.188; Mattner F, 2011, EUR J NUCL MED MOL I, V38, P1516, DOI 10.1007/s00259-011-1784-2; McGaw C., 2010, W LONDON MED J, V2, P9; McGregor IS, 2003, PSYCHOPHARMACOLOGY, V168, P465, DOI 10.1007/s00213-003-1452-8; McGregor IS, 2003, NEUROPSYCHOPHARMACOL, V28, P1472, DOI 10.1038/sj.npp.1300185; Meng H, 2012, TOXICOL LETT, V208, P62, DOI 10.1016/j.toxlet.2011.10.010; Meyer JS, 2008, ANN NY ACAD SCI, V1139, P151, DOI 10.1196/annals.1432.029; Motbey CP, 2012, ADDICT BIOL, V17, P409, DOI 10.1111/j.1369-1600.2011.00384.x; Newcombe R., 2009, USE MEPHEDRONE M CAT; Obernier JA, 2002, PHARMACOL BIOCHEM BE, V72, P521, DOI 10.1016/S0091-3057(02)00715-3; Osorio-Olivares M, 2004, BIOORGAN MED CHEM, V12, P4055, DOI 10.1016/j.bmc.2004.05.033; Piper BJ, 2004, PHARMACOL BIOCHEM BE, V79, P723, DOI 10.1016/j.pbb.2004.10.001; Pubill D, 2003, N-S ARCH PHARMACOL, V367, P490, DOI 10.1007/s00210-003-0747-y; Schifano F, 2011, PSYCHOPHARMACOLOGY, V214, P593, DOI 10.1007/s00213-010-2070-x; SYAPIN PJ, 1988, EUR J PHARMACOL, V147, P101, DOI 10.1016/0014-2999(88)90638-3; Szumlinski KK, 2000, PSYCHOPHARMACOLOGY, V151, P234, DOI 10.1007/s002130000478; Torrance H, 2010, FORENSIC SCI INT, V202, pE62, DOI 10.1016/j.forsciint.2010.07.014; van Heeringen C, 2011, NEUROSCI BIOBEHAV R, V35, P688, DOI 10.1016/j.neubiorev.2010.08.007; van Nieuwenhuijzen PS, 2009, NEUROPSYCHOBIOLOGY, V60, P195, DOI 10.1159/000253555; van Nieuwenhuijzen PS, 2010, PSYCHOPHARMACOLOGY, V212, P663, DOI 10.1007/s00213-010-1986-5; Wallace TL, 2001, SYNAPSE, V39, P1, DOI 10.1002/1098-2396(20010101)39:1<1::AID-SYN1>3.0.CO;2-7; Wiley JL, 2008, ADDICT BIOL, V13, P277, DOI 10.1111/j.1369-1600.2007.00077.x; Winstock A, 2011, ADDICTION, V106, P1991, DOI 10.1111/j.1360-0443.2011.03502.x; Winstock AR, 2010, DRUG ALCOHOL REV, V29, P82; Wood DM, 2011, EMERG MED J, V28, P280, DOI 10.1136/emj.2010.092288; Wood DM, 2010, CLIN TOXICOL, V48, P924, DOI 10.3109/15563650.2010.531021; Wood DM, 2010, J MED TOXICOL, V6, P327, DOI 10.1007/s13181-010-0018-5	63	46	46	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2012	7	9							e45473	10.1371/journal.pone.0045473	http://dx.doi.org/10.1371/journal.pone.0045473			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	040HS	23029034	Green Published, gold			2023-01-03	WOS:000311313900142
J	Wang, LY; Li, ST; Dorf, ME				Wang, Lingyan; Li, Shitao; Dorf, Martin E.			NEMO Binds Ubiquitinated TANK-Binding Kinase 1 (TBK1) to Regulate Innate Immune Responses to RNA Viruses	PLOS ONE			English	Article							MEDIATED ANTIVIRAL RESPONSE; I INTERFERON-PRODUCTION; TUMOR-SUPPRESSOR CYLD; KAPPA-B; NEGATIVE REGULATOR; SIGNALING PATHWAY; PROTEIN; IRF3; ACTIVATION; LIGASE	RIG-I-like receptors (RLR) are intracellular sensors utilized by nearly all cell types for recognition of viral RNA, initiation of antiviral defense, and induction of type I interferons (IFN). TBK1 is a critical kinase implicated in RLR-dependent IFN transcription. Posttranslational modification of TBK1 by K63-linked ubiquitin is required for RLR driven signaling. However, the TBK1 ubiquitin acceptor sites and the function of ubiquitinated TBK1 in the signaling cascade are unknown. We now show that TBK1 is ubiquitinated on residues K69, K154, and K372 in response to infection with RNA virus. The K69 and K154 residues are critical for innate antiviral responses and IFN production. Ubiquitinated TBK1 recruits the downstream adaptor NEMO through ubiquitin binding domains. The assembly of the NEMO/TBK1 complex on the mitochondrial protein MAVS leads to activation of TBK1 kinase activity and phosphorylation of the transcription factor, interferon response factor 3. The combined results refine current views of RLR signaling, define the role of TBK1 polyubiquitination, and detail the mechanisms involved in signalosome assembly.	[Wang, Lingyan; Li, Shitao; Dorf, Martin E.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02215 USA	Harvard University; Harvard Medical School	Li, ST (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02215 USA.	shitao_li@hms.harvard.edu; dorf@hms.harvard.edu		Li, Shitao/0000-0002-1398-8519	Public Health Service [AI089829, NS057162, AI099860]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI089829, R21AI099860, R56AI089829] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS057162] Funding Source: NIH RePORTER	Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by Public Health Service grants AI089829, NS057162 and AI099860. S.L. is a John and Virginia Kaneb fellow. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alff PJ, 2008, J VIROL, V82, P9115, DOI 10.1128/JVI.00290-08; Barber GN, 2011, CURR OPIN IMMUNOL, V23, P10, DOI 10.1016/j.coi.2010.12.015; Bhoj VG, 2009, NATURE, V458, P430, DOI 10.1038/nature07959; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Brennan K, 2010, CURR OPIN MICROBIOL, V13, P503, DOI 10.1016/j.mib.2010.05.007; Clark K, 2011, BIOCHEM J, V434, P93, DOI 10.1042/BJ20101701; Cui J, 2012, NAT IMMUNOL, V13, P387, DOI 10.1038/ni.2239; Di YW, 2008, CELL SIGNAL, V20, P705, DOI 10.1016/j.cellsig.2007.12.007; Dixit E, 2010, CELL, V141, P668, DOI 10.1016/j.cell.2010.04.018; Fenner BJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008799; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Friedman CS, 2008, EMBO REP, V9, P930, DOI 10.1038/embor.2008.136; Gack MU, 2007, NATURE, V446, P916, DOI 10.1038/nature05732; Hacker H, 2006, NATURE, V439, P204, DOI 10.1038/nature04369; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Hou FJ, 2011, CELL, V146, P448, DOI 10.1016/j.cell.2011.06.041; Ikeda F, 2007, EMBO J, V26, P3451, DOI 10.1038/sj.emboj.7601773; Kawagoe T, 2009, NAT IMMUNOL, V10, P965, DOI 10.1038/ni.1771; Kawasaki T, 2011, IMMUNOL REV, V243, P61, DOI 10.1111/j.1600-065X.2011.01048.x; Kayagaki N, 2007, SCIENCE, V318, P1628, DOI 10.1126/science.1145918; Koo BK, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001221; Lei CQ, 2010, IMMUNITY, V33, P878, DOI 10.1016/j.immuni.2010.11.021; Li ST, 2006, MOL CELL, V24, P497, DOI 10.1016/j.molcel.2006.10.015; Li ST, 2011, IMMUNITY, V35, P426, DOI 10.1016/j.immuni.2011.06.014; Li S, 2009, MOL CELL, V33, P30, DOI 10.1016/j.molcel.2008.11.023; Liu XY, 2011, J IMMUNOL, V187, P2559, DOI 10.4049/jimmunol.1100963; Ma X, 2012, P NATL ACAD SCI US; Ma YJ, 2012, J VIROL, V86, P2188, DOI 10.1128/JVI.05376-11; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; O'Neill LAJ, 2010, CURR BIOL, V20, pR328, DOI 10.1016/j.cub.2010.01.044; Oganesyan G, 2006, NATURE, V439, P208, DOI 10.1038/nature04374; Otsuka M, 2005, HEPATOLOGY, V41, P1004, DOI 10.1002/hep.20666; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Tanaka Y, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002521; Unterstab G, 2005, P NATL ACAD SCI USA, V102, P13640, DOI 10.1073/pnas.0502883102; Wang C, 2009, NAT IMMUNOL, V10, P744, DOI 10.1038/ni.1742; Yang K, 2006, MOL BIOL CELL, V17, P1461, DOI 10.1091/mbc.E05-09-0853; Zeng WW, 2009, MOL CELL, V36, P315, DOI 10.1016/j.molcel.2009.09.037; Zhang MY, 2008, J BIOL CHEM, V283, P18621, DOI 10.1074/jbc.M801451200; Zhao TJ, 2007, NAT IMMUNOL, V8, P592, DOI 10.1038/ni1465	40	20	22	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2012	7	9							e43756	10.1371/journal.pone.0043756	http://dx.doi.org/10.1371/journal.pone.0043756			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	040HS	23028469	Green Published, gold, Green Submitted			2023-01-03	WOS:000311313900009
J	Onwuteaka-Philipsen, BD; Brinkman-Stoppelenburg, A; Penning, C; de Jong-Krul, GJF; van Delden, JJM; van der Heide, A				Onwuteaka-Philipsen, Bregje D.; Brinkman-Stoppelenburg, Arianne; Penning, Corine; de Jong-Krul, Gwen J. F.; van Delden, Johannes J. M.; van der Heide, Agnes			Trends in end-of-life practices before and after the enactment of the euthanasia law in the Netherlands from 1990 to 2010: a repeated cross-sectional survey	LANCET			English	Article							6 EUROPEAN COUNTRIES; PALLIATIVE CARE; ASSISTED SUICIDE; HASTENED DEATH; DECISIONS; SEDATIVES; OPIOIDS; CANCER; SURVIVAL; BELGIUM	Background In 2002, the euthanasia act came into effect in the Netherlands, which was followed by a slight decrease in the euthanasia frequency. We assessed frequency and characteristics of euthanasia, physician-assisted suicide, and other end-of-life practices in 2010, and assessed trends since 1990. Methods In 1990, 1995, 2001, 2005, and 2010 we did nationwide studies of a stratified sample from the death registry of Statistics Netherlands, to which all deaths and causes were reported. We mailed questionnaires to physicians attending these deaths (2010: n=8496 deaths). All cases were weighted to adjust for the stratification procedure and for differences in response rates in relation to the age, sex, marital status, region of residence, and cause and place of death. Findings In 2010, of all deaths in the Netherlands, 2.8% (95% CI 2.5-3.2; 475 of 6861) were the result of euthanasia. This rate is higher than the 1.7% (1.5-1.8; 294 of 9965) in 2005, but comparable with those in 2001 and 1995. Distribution of sex, age, and diagnosis was stable between 1990 and 2010. In 2010, 77% (3136 of 4050) of all cases of euthanasia or physician-assisted suicide were reported to a review committee (80% [1933 of 2425] in 2005). Ending of life without an explicit patient request in 2010 occurred less often (0.2%; 95% CI 0.1-0.3; 13 of 6861) than in 2005, 2001, 1995, and 1990 (0.8%; 0.6-1.1; 45 of 5197). Continuous deep sedation until death occurred more frequently in 2010 (12.3% [11.6-13.1; 789 of 6861]) than in 2005 (8.2% [7.8-8.6; 521 of 9965]). Of all deaths in 2010, 0.4% (0.3-0.6; 18 of 6861) were the result of the patient's decision to stop eating and drinking to end life; in half of these cases the patient had made a euthanasia request that was not granted. Interpretation Our study provides insight in consequences of regulating euthanasia and physician-assisted suicide within the broader context of end-of-life practices. In the Netherlands the euthanasia law resulted in a relatively transparent practice. Although translating these results to other countries is not straightforward, they can inform the debate on legalisation of assisted dying in other countries.	[Onwuteaka-Philipsen, Bregje D.] Vrije Univ Amsterdam, Med Ctr, Dept Publ & Occupat Hlth, NL-1081 BT Amsterdam, Netherlands; [Onwuteaka-Philipsen, Bregje D.] Vrije Univ Amsterdam, Med Ctr, VUmc Expertise Ctr Palliat Care, EMGO Inst Hlth & Care Res, NL-1081 BT Amsterdam, Netherlands; [Brinkman-Stoppelenburg, Arianne; van der Heide, Agnes] Univ Med Ctr Rotterdam, Dept Publ Hlth, Erasmus MC, Rotterdam, Netherlands; [Penning, Corine; de Jong-Krul, Gwen J. F.] Stat Netherlands, The Hague, Netherlands; [van Delden, Johannes J. M.] Univ Med Ctr Utrecht, Julius Ctr, Utrecht, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Erasmus MC; Utrecht University; Utrecht University Medical Center	Onwuteaka-Philipsen, BD (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Publ & Occupat Hlth, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	b.philipsen@vumc.nl		Stoppelenburg, Arianne/0000-0001-6377-1599	Netherlands Organization for Research and Development (ZonMw)	Netherlands Organization for Research and Development (ZonMw)	The Netherlands Organization for Research and Development (ZonMw).	Bilsen J, 2009, NEW ENGL J MED, V361, P1119, DOI 10.1056/NEJMc0904292; Bosshard G, 2008, J MED ETHICS, V34, P28, DOI 10.1136/jme.2006.018911; Breitbart W, 2000, JAMA-J AM MED ASSOC, V284, P2907, DOI 10.1001/jama.284.22.2907; Chabot BE, 2009, SOC SCI MED, V68, P1745, DOI 10.1016/j.socscimed.2009.03.005; Delbeke E, 2011, EUR J HEALTH LAW, V18, P149, DOI 10.1163/157180911X565191; Deliens L, 2003, LANCET, V362, P1239, DOI 10.1016/S0140-6736(03)14520-5; den Hartogh G, 2003, MED CONTACT, V58, P1063; Dyer C, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6779; Ferrand E, 2011, LANCET, V377, P467, DOI 10.1016/S0140-6736(11)60160-8; Finlay I, 2006, PALLIATIVE MED, V20, P115, DOI 10.1191/0269216306pm1119xx; Fleming JI, 1992, BIOETHICS RES NOTES, V4, P1; Good PD, 2005, INTERN MED J, V35, P512, DOI 10.1111/j.1445-5994.2005.00888.x; Gordijn B, 2004, HEALTH CARE ANAL, V12, P195, DOI 10.1023/B:HCAN.0000044926.05523.ef; Levene IR, 2010, CAN MED ASSOC J, V182, P1330, DOI 10.1503/cmaj.110-2092; Morita T, 2001, J PAIN SYMPTOM MANAG, V21, P282, DOI 10.1016/S0885-3924(01)00258-5; Onwuteaka-Philipsen BD, 2003, LANCET, V362, P395, DOI 10.1016/S0140-6736(03)14029-9; Pereira J, 2011, CURR ONCOL, V18, pE38; Regional Review Committees Euthanasia, 2011, ANN REP 2010; Rodin G, 2007, J PAIN SYMPTOM MANAG, V33, P661, DOI 10.1016/j.jpainsymman.2006.09.034; Seale C, 2009, PALLIATIVE MED, V23, P198, DOI 10.1177/0269216308102042; Sykes N, 2003, LANCET ONCOL, V4, P312, DOI 10.1016/S1470-2045(03)01079-9; TENHAVE HAMJ, 1992, HASTINGS CENT REP, V22, P34, DOI 10.2307/3562563; van der Heide A, 2003, LANCET, V362, P345, DOI 10.1016/S0140-6736(03)14019-6; van der Heide A, 2007, NEW ENGL J MED, V356, P1957, DOI 10.1056/NEJMsa071143; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; van der Steen JT, 2009, J PALLIAT MED, V12, P789, DOI 10.1089/jpm.2009.0049; vanderWal G, 1996, NEW ENGL J MED, V335, P1706	28	190	193	1	76	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 8	2012	380	9845					908	915		10.1016/S0140-6736(12)61034-4	http://dx.doi.org/10.1016/S0140-6736(12)61034-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	002QL	22789501				2023-01-03	WOS:000308547300033
J	Dutra, M; Massumoto, C				Dutra, Mariana; Massumoto, Celso			Cerebral Air Embolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Dutra, Mariana; Massumoto, Celso] Hosp Sirio Libanes, Sao Paulo, Brazil	Hospital Sirio Libanes	Dutra, M (corresponding author), Hosp Sirio Libanes, Sao Paulo, Brazil.	uti@hsl.org.br							0	3	3	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 30	2012	367	9					850	850		10.1056/NEJMicm1108591	http://dx.doi.org/10.1056/NEJMicm1108591			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	996EN	22931319				2023-01-03	WOS:000308067400007
J	Almeida, OP; Yeap, BB; Alfonso, H; Hankey, GJ; Flicker, L; Norman, PE				Almeida, Osvaldo P.; Yeap, Bu B.; Alfonso, Helman; Hankey, Graeme J.; Flicker, Leon; Norman, Paul E.			Older Men Who Use Computers Have Lower Risk of Dementia	PLOS ONE			English	Article							LEISURE ACTIVITIES; WESTERN-AUSTRALIA; ALZHEIMER-DISEASE; STATE-EXAMINATION; INTERNET USAGE; PREVALENCE; ADULTS; POPULATION; LINKAGE; PREVENTION	Objective: To determine if older men who use computers have lower risk of developing dementia. Methods: Cohort study of 5506 community-dwelling men aged 69 to 87 years followed for up to 8.5 years. Use of computers measured as daily, weekly, less than weekly and never. Participants also reported their use of email, internet, word processors, games or other computer activities. The primary outcome was the incidence of ICD-10 diagnosis of dementia as recorded by the Western Australian Data Linkage System. Results: 1857/5506 (33.7%) men reported using computers and 347 (6.3%) received a diagnosis of dementia during an average follow up of 6.0 years (range: 6 months to 8.5 years). The hazard ratio (HR) of dementia was lower among computer users than non-users (HR = 0.62, 95%CI = 0.47-0.81, after adjustment for age, educational attainment, size of social network, and presence of depression or of significant clinical morbidity). The HR of dementia appeared to decrease with increasing frequency of computer use: 0.68 (95%CI = 0.41-1.13), 0.61 (95%CI = 0.39-0.94) and 0.59 (95%CI = 0.40-0.87) for less than weekly, at least weekly and daily. The HR of dementia was 0.66 (95%CI = 0.50-0.86) after the analysis was further adjusted for baseline cognitive function, as measured by the Mini-Mental State Examination. Conclusion: Older men who use computers have lower risk of receiving a diagnosis of dementia up to 8.5 years later. Randomised trials are required to determine if the observed associations are causal.	[Almeida, Osvaldo P.; Alfonso, Helman] Univ Western Australia, Sch Psychiat & Clin Neurosci, Perth, WA 6009, Australia; [Almeida, Osvaldo P.; Alfonso, Helman; Flicker, Leon] Univ Western Australia, Med Res Ctr, Western Australian Ctr Hlth & Ageing, Perth, WA 6009, Australia; [Almeida, Osvaldo P.] Royal Perth Hosp, Dept Psychiat, Perth, WA, Australia; [Yeap, Bu B.; Hankey, Graeme J.; Flicker, Leon] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia; [Yeap, Bu B.] Fremantle Hosp, Dept Endocrinol & Diabet, Fremantle, WA, Australia; [Hankey, Graeme J.] Royal Perth Hosp, Dept Neurol, Perth, WA, Australia; [Flicker, Leon] Royal Perth Hosp, Dept Geriatr Med, Perth, WA, Australia; [Norman, Paul E.] Univ Western Australia, Sch Surg, Perth, WA 6009, Australia	University of Western Australia; University of Western Australia; Royal Perth Hospital; University of Western Australia; University of Western Australia; University of Western Australia; Royal Perth Hospital; University of Western Australia; Royal Perth Hospital; University of Western Australia; University of Western Australia	Almeida, OP (corresponding author), Univ Western Australia, Sch Psychiat & Clin Neurosci, Perth, WA 6009, Australia.	osvaldo.almeida@uwa.edu.au	Norman, Paul E/C-5485-2013; Hankey, Graeme J/H-4968-2014; Almeida, Osvaldo P./A-4925-2008; Flicker, Leon/AAE-1530-2022	Norman, Paul E/0000-0003-3406-0506; Hankey, Graeme J/0000-0002-6044-7328; Almeida, Osvaldo P./0000-0002-8689-6199; Flicker, Leon/0000-0002-3650-0475	National Health and Medical Research Council of Australia [279408, 379600, 403963, 513823]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	Funding provided by National Health and Medical Research Council of Australia project grant numbers 279408, 379600, 403963 and 513823. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABS, 2011, HOUS US INF TECHN AU; Akbaraly TN, 2009, NEUROLOGY, V73, P854, DOI 10.1212/WNL.0b013e3181b7849b; Almeida OP, 1999, INT J GERIATR PSYCH, V14, P858, DOI 10.1002/(SICI)1099-1166(199910)14:10<858::AID-GPS35>3.0.CO;2-8; Almeida OP, 2008, ARCH GEN PSYCHIAT, V65, P1286, DOI 10.1001/archpsyc.65.11.1286; Almeida OP, 2008, ARCH GEN PSYCHIAT, V65, P283, DOI 10.1001/archgenpsychiatry.2007.33; Ball K, 2002, JAMA-J AM MED ASSOC, V288, P2271, DOI 10.1001/jama.288.18.2271; Barnes DE, 2011, LANCET NEUROL, V10, P819, DOI 10.1016/S1474-4422(11)70072-2; Beasley R, 2003, EUR RESPIR J, V21, P374, DOI 10.1183/09031936.03.00039403; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0; FOLSTEIN MF, 1983, ARCH GEN PSYCHIAT, V40, P812; Forette F, 2002, ARCH INTERN MED, V162, P2046, DOI 10.1001/archinte.162.18.2046; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Holman CDJ, 2008, AUST HEALTH REV, V32, P766, DOI 10.1071/AH080766; Holman CDJ, 1999, AUST NZ J PUBL HEAL, V23, P453, DOI 10.1111/j.1467-842X.1999.tb01297.x; Hyde Z, 2010, ANN INTERN MED, V153, P693, DOI 10.7326/0003-4819-153-11-201012070-00002; KOENIG HG, 1993, PSYCHOSOMATICS, V34, P61, DOI 10.1016/S0033-3182(93)71928-3; Lautenschlager NT, 2008, JAMA-J AM MED ASSOC, V300, P1027, DOI 10.1001/jama.300.9.1027; Lazarov O, 2010, TRENDS NEUROSCI, V33, P569, DOI 10.1016/j.tins.2010.09.003; Lobo A, 2007, ACTA PSYCHIAT SCAND, V116, P299, DOI 10.1111/j.1600-0447.2007.01006.x; Norman PE, 2009, INT J EPIDEMIOL, V38, P48, DOI 10.1093/ije/dyn041; Owen AM, 2010, NATURE, V465, P775, DOI 10.1038/nature09042; Pink B, 2008, INTRO SOCIO EC INDEX; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Ritchie K, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3885; Slegers K, 2008, J GERONTOL B-PSYCHOL, V63, pP176, DOI 10.1093/geronb/63.3.P176; Slegers K, 2009, AGING CLIN EXP RES, V21, P43, DOI 10.1007/BF03324898; Small GW, 2009, AM J GERIAT PSYCHIAT, V17, P116, DOI 10.1097/JGP.0b013e3181953a02; Tun PA, 2010, PSYCHOL AGING, V25, P560, DOI 10.1037/a0019543; Verghese J, 2003, NEW ENGL J MED, V348, P2508, DOI 10.1056/NEJMoa022252; Willis SL, 2006, JAMA-J AM MED ASSOC, V296, P2805, DOI 10.1001/jama.296.23.2805; Wimo A, 2010, ALZHEIMERS DEMENT, V6, P98, DOI 10.1016/j.jalz.2010.01.010; Zilkens RR, 2009, NEUROEPIDEMIOLOGY, V32, P61, DOI 10.1159/000170908	34	43	44	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2012	7	8							e44239	10.1371/journal.pone.0044239	http://dx.doi.org/10.1371/journal.pone.0044239			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	998CA	22937167	Green Published, Green Submitted, gold			2023-01-03	WOS:000308213600097
J	Afdhal, NH; Giannini, EG; Tayyab, G; Mohsin, A; Lee, JW; Andriulli, A; Jeffers, L; McHutchison, J; Chen, PJ; Han, KH; Campbell, F; Hyde, D; Brainsky, A; Theodore, D				Afdhal, Nezam H.; Giannini, Edoardo G.; Tayyab, Ghias; Mohsin, Aftab; Lee, Jin-Woo; Andriulli, Angelo; Jeffers, Lennox; McHutchison, John; Chen, Pei-Jer; Han, Kwang-Hyub; Campbell, Fiona; Hyde, Denise; Brainsky, Andres; Theodore, Dickens		ELEVATE Study Grp	Eltrombopag before Procedures in Patients with Cirrhosis and Thrombocytopenia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC LIVER-DISEASE; PORTAL-VEIN THROMBOSIS; COAGULATION; ARTICLE	BACKGROUND Eltrombopag is an oral thrombopoietin-receptor agonist. This study evaluated the efficacy of eltrombopag for increasing platelet counts and reducing the need for platelet transfusions in patients with thrombocytopenia and chronic liver disease who are undergoing an elective invasive procedure. METHODS We randomly assigned 292 patients with chronic liver disease of diverse causes and platelet counts of less than 50,000 per cubic millimeter to receive eltrombopag, at a dose of 75 mg daily, or placebo for 14 days before a planned elective invasive procedure that was performed within 5 days after the last dose. The primary end point was the avoidance of a platelet transfusion before, during, and up to 7 days after the procedure. A key secondary end point was the occurrence of bleeding (World Health Organization [ WHO] grade 2 or higher) during this period. RESULTS A platelet transfusion was avoided in 104 of 145 patients who received eltrombopag (72%) and in 28 of 147 who received placebo (19%) (P<0.001). No significant difference between the eltrombopag and placebo groups was observed in bleeding episodes of WHO grade 2 or higher, which were reported in 17% and 23% of patients, respectively. Thrombotic events of the portal venous system were observed in 6 patients who received eltrombopag, as compared with 1 who received placebo, resulting in the early termination of the study. The incidence and severity of other adverse events were similar in the eltrombopag and placebo groups. CONCLUSIONS Eltrombopag reduced the need for platelet transfusions in patients with chronic liver disease who were undergoing elective invasive procedures, but it was associated with an increased incidence of portal-vein thrombosis, as compared with placebo. (Funded by GlaxoSmithKline; ELEVATE ClinicalTrials.gov number, NCT00678587.)	[Afdhal, Nezam H.] Beth Israel Deaconess Med Ctr, Div Gastroenterol, Ctr Liver, Boston, MA 02215 USA; [Giannini, Edoardo G.] Univ Genoa, Dept Internal Med, Gastroenterol Unit, I-16126 Genoa, Italy; [Andriulli, Angelo] Casa Sollievo Sofferenza Hosp, Div Gastroenterol, Dept Internal Med, San Giovanni Rotondo, Italy; [Tayyab, Ghias] Postgrad Med Inst, Dept Med Gastroenterol & Hepatol, Lahore, Pakistan; [Tayyab, Ghias] Lahore Gen Hosp, Lahore, Pakistan; [Mohsin, Aftab] Serv Inst Med Sci, Serv Hosp Lahore, Dept Gastroenterol, Lahore, Pakistan; [Lee, Jin-Woo] Inha Univ, Sch Med, Dept Internal Med, Div Hepatol, Inchon, South Korea; [Han, Kwang-Hyub] Yonsei Univ, Coll Med, Yonsei Inst Gastroenterol, Yonsei Liver Canc Special Clin,Dept Internal Med, Seoul, South Korea; [Jeffers, Lennox] Univ Miami, Miller Sch Med, Ctr Liver Dis, Miami, FL 33136 USA; [McHutchison, John] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA; [McHutchison, John] Duke Univ, Med Ctr, Div Gastroenterol, Durham, NC USA; [Chen, Pei-Jer] Natl Taiwan Univ, Coll Med, Hepatitis Res Ctr, Dept Internal Med,Grad Inst Clin Med, Taipei 10764, Taiwan; [Chen, Pei-Jer] Natl Taiwan Univ Hosp, Taipei, Taiwan; [Campbell, Fiona; Hyde, Denise] GlaxoSmithKline Stockley Pk, Oncol Clin Dev, Uxbridge, Middx, England; [Brainsky, Andres] GlaxoSmithKline Stockley Pk, Oncol Clin Dev, Collegeville, PA USA; [Theodore, Dickens] GlaxoSmithKline Stockley Pk, Oncol Clin Dev, Res Triangle Pk, NC USA	Harvard University; Beth Israel Deaconess Medical Center; University of Genoa; IRCCS Casa Sollievo Della Sofferenza; Inha University; Yonsei University; Yonsei University Health System; University of Miami; Duke University; Duke University; National Taiwan University; National Taiwan University; National Taiwan University Hospital; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Afdhal, NH (corresponding author), Beth Israel Deaconess Med Ctr, Div Gastroenterol, Ctr Liver, 110 Francis St,Suite 8E, Boston, MA 02215 USA.	nafdhal@bidmc.harvard.edu	Vargas, Hugo E./K-1562-2019; Andriulli, Angelo/B-5027-2017; Rafalskiy, Vladimir V/G-3172-2013; Andreone, Pietro/K-8050-2016; Giannini, Edoardo Giovanni/E-1120-2012	Vargas, Hugo E./0000-0002-7802-688X; Andriulli, Angelo/0000-0001-8862-7083; Rafalskiy, Vladimir V/0000-0002-2503-9580; Andreone, Pietro/0000-0002-4794-9809; Giannini, Edoardo Giovanni/0000-0001-8526-837X; cardenas, andres/0000-0002-0764-7873; Xiol, Xavier/0000-0002-4461-4704; Finazzi, Renato Alberto/0000-0001-5494-1154; Afdhal, Nezam/0000-0002-7342-6593; Chen, Pei-Jer/0000-0001-8316-3785; Kuliczkowski, Kazimierz/0000-0001-6812-1421	Vertex Pharmaceuticals; Merck; Pharmasset; Boehringer Ingelheim; Idera Pharmaceuticals; GlaxoSmithKline; Biolex Therapeutics; FibroGen; Human Genome Sciences; Quest Diagnostics; Novartis; Gilead Sciences; Abbott Laboratories; Bristol-Myers Squibb	Vertex Pharmaceuticals(Vertex Pharmaceuticals); Merck(Merck & Company); Pharmasset; Boehringer Ingelheim(Boehringer Ingelheim); Idera Pharmaceuticals; GlaxoSmithKline(GlaxoSmithKline); Biolex Therapeutics; FibroGen; Human Genome Sciences(GlaxoSmithKline); Quest Diagnostics; Novartis(Novartis); Gilead Sciences(Gilead Sciences); Abbott Laboratories(Abbott Laboratories); Bristol-Myers Squibb(Bristol-Myers Squibb)	Dr. Afdhal reports receiving consulting fees from Vertex Pharmaceuticals, Merck, Pharmasset, Boehringer Ingelheim, Idera Pharmaceuticals, GlaxoSmithKline, Biolex Therapeutics, FibroGen, Human Genome Sciences, Quest Diagnostics, and Novartis; receiving grant support from Vertex Pharmaceuticals, GlaxoSmithKline, Merck, Gilead Sciences, Pharmasset, and Abbott Laboratories; receiving stock options from Medgenics and Spring Bank Pharmaceuticals; receiving travel reimbursement from GlaxoSmithKline and Merck; and being a member of the board for Idenix Pharmaceuticals, Gilead Sciences, Merck, Medgenics, Spring Bank Pharmaceuticals, and Ligand; Dr. Giannini, being a member of the board and receiving grant support, consulting fees, lecture fees, and travel reimbursement from GlaxoSmithKline and participating as an expert witness at a Strategic Advisory Group meeting at the European Medicines Agency concerning eltrombopag for GlaxoSmithKline; Dr. McHutchison, being an employee of and owning stock in Gilead Sciences; Dr. Chen, receiving grant support and lecture fees from Bristol-Myers Squibb; receiving travel reimbursement from Bristol-Myers Squibb and Bayer; and being a member of the board for Bristol-Myers Squibb, Bayer, GlaxoSmithKline, and Roche; Dr. Han, receiving grant support from GlaxoSmithKline; Dr. Hyde, receiving travel reimbursement from GlaxoSmithKline and being an employee of and owning stock in GlaxoSmithKline; Ms. Campbell, being an employee of and owning stock in GlaxoSmithKline and receiving travel reimbursement from GlaxoSmithKline; Dr. Brainsky, being an employee of and owning stock in GlaxoSmithKline and holding two pending patents that relate to eltrombopag; and Dr. Theodore, being an employee of and owning stock in GlaxoSmithKline, and being the co-inventor on two eltrombopag patents held by GlaxoSmithKline. No other conflicts relevant to this article were reported.	Afdhal N, 2008, J HEPATOL, V48, P1000, DOI 10.1016/j.jhep.2008.03.009; Amitrano L, 2007, CLIN LAB, V53, P583; Bashour FN, 2000, AM J GASTROENTEROL, V95, P2936, DOI 10.1016/S0002-9270(00)01117-5; De Stefano V, 2010, INTERN EMERG MED, V5, P487, DOI 10.1007/s11739-010-0413-6; Giannini EG, 2010, CLIN GASTROENTEROL H, V8, P899, DOI 10.1016/j.cgh.2010.06.018; Giannini EG, 2006, ALIMENT PHARM THER, V23, P1055, DOI 10.1111/j.1365-2036.2006.02889.x; Heddle NM, 2003, TRANSFUSION, V43, P742, DOI 10.1046/j.1537-2995.2003.00418.x; Kamath PS, 2001, HEPATOLOGY, V33, P464, DOI 10.1053/jhep.2001.22172; Kulik LM, 2008, HEPATOLOGY, V47, P71, DOI 10.1002/hep.21980; Lisman T, 2010, J HEPATOL, V53, P362, DOI 10.1016/j.jhep.2010.01.042; McHutchison JG, 2007, NEW ENGL J MED, V357, P2227, DOI 10.1056/NEJMoa073255; Peck-Radosavljevic M, 2000, Can J Gastroenterol, V14 Suppl D, p60D; Poordad F, 2007, ALIMENT PHARM THER, V26, P5, DOI 10.1111/j.1365-2036.2007.03510.x; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; Qamar AA, 2009, CLIN GASTROENTEROL H, V7, P689, DOI 10.1016/j.cgh.2009.02.021; Sallah S, 1999, POSTGRAD MED, V106, P187, DOI 10.3810/pgm.1999.10.1.720; Slichter Sherrill J, 2007, Hematology Am Soc Hematol Educ Program, P172, DOI 10.1182/asheducation-2007.1.172; Tripodi A, 2010, INTERN EMERG MED, V5, P7, DOI 10.1007/s11739-009-0302-z; Trotter James F, 2006, Clin Liver Dis, V10, P665, DOI 10.1016/j.cld.2006.08.006	19	208	216	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 23	2012	367	8					716	724		10.1056/NEJMoa1110709	http://dx.doi.org/10.1056/NEJMoa1110709			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992CX	22913681	Green Submitted, Bronze, Green Published			2023-01-03	WOS:000307754200006
J	Clemson, L; Singh, MAF; Bundy, A; Cumming, RG; Manollaras, K; O'Loughlin, P; Black, D				Clemson, Lindy; Singh, Maria A. Fiatarone; Bundy, Anita; Cumming, Robert G.; Manollaras, Kate; O'Loughlin, Patricia; Black, Deborah			Integration of balance and strength training into daily life activity to reduce rate of falls in older people (the LiFE study): randomised parallel trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PHYSICAL-ACTIVITY; DISABILITY INSTRUMENT; ELDERLY-PATIENTS; PREVENT FALLS; EXERCISE; PROGRAM; STYLE; INTERVENTIONS; ASSOCIATION; PERFORMANCE	Objectives To determine whether a lifestyle integrated approach to balance and strength training is effective in reducing the rate of falls in older, high risk people living at home. Design Three arm, randomised parallel trial; assessments at baseline and after six and 12 months. Randomisation done by computer generated random blocks, stratified by sex and fall history and concealed by an independent secure website. Setting Residents in metropolitan Sydney, Australia. Participants Participants aged 70 years or older who had two or more falls or one injurious fall in past 12 months, recruited from Veteran's Affairs databases and general practice databases. Exclusion criteria were moderate to severe cognitive problems, inability to ambulate independently, neurological conditions that severely influenced gait and mobility, resident in a nursing home or hostel, or any unstable or terminal illness that would affect ability to do exercises. Interventions Three home based interventions: Lifestyle integrated Functional Exercise (LiFE) approach (n=107; taught principles of balance and strength training and integrated selected activities into everyday routines), structured programme (n=105; exercises for balance and lower limb strength, done three times a week), sham control programme (n=105; gentle exercise). LiFE and structured groups received five sessions with two booster visits and two phone calls; controls received three home visits and six phone calls. Assessments made at baseline and after six and 12 months. Main outcome measures Primary measure: rate of falls over 12 months, collected by self report. Secondary measures: static and dynamic balance; ankle, knee and hip strength; balance self efficacy; daily living activities; participation; habitual physical activity; quality of life; energy expenditure; body mass index; and fat free mass. Results After 12 months' follow-up, we recorded 172, 193, and 224 falls in the LiFE, structured exercise, and control groups, respectively. The overall incidence of falls in the LiFE programme was 1.66 per person years, compared with 1.90 in the structured programme and 2.28 in the control group. We saw a significant reduction of 31% in the rate of falls for the LiFE programme compared with controls (incidence rate ratio 0.69 (95% confidence interval 0.48 to 0.99)); the corresponding difference between the structured group and controls was non-significant (0.81 (0.56 to 1.17)). Static balance on an eight level hierarchy scale, ankle strength, function, and participation were significantly better in the LiFE group than in controls. LiFE and structured groups had a significant and moderate improvement in dynamic balance, compared with controls. Conclusions The LiFE programme provides an alternative to traditional exercise to consider for fall prevention. Functional based exercise should be a focus for interventions to protect older, high risk people from falling and to improve and maintain functional capacity.	[Clemson, Lindy] Univ Sydney, Ageing Work & Hlth Res Unit, Fac Hlth Sci, Lidcombe, NSW 2141, Australia; [Clemson, Lindy] Univ Sydney, Ctr Excellence Populat Ageing Res, Fac Hlth Sci, Lidcombe, NSW 2141, Australia; [Singh, Maria A. Fiatarone; Bundy, Anita; Manollaras, Kate; O'Loughlin, Patricia; Black, Deborah] Univ Sydney, Fac Hlth Sci, Sydney, NSW 2006, Australia; [Cumming, Robert G.] Univ Sydney, CERA, Sydney, NSW 2006, Australia; [Cumming, Robert G.] Univ Sydney, Fac Med, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney; University of Sydney; University of Sydney; University of Sydney	Clemson, L (corresponding author), Univ Sydney, Ageing Work & Hlth Res Unit, Fac Hlth Sci, Lidcombe, NSW 2141, Australia.	lindy.clemson@sydney.edu.au	black, deborah/C-2829-2017; Cumming, Robert G/R-1548-2016	black, deborah/0000-0001-9174-1565; Cumming, Robert G/0000-0002-0261-6103; Bundy, Anita/0000-0003-4743-9144	National Health and Medical Research Council	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	The trial was funded by a project grant from the National Health and Medical Research Council.	Andersen RE, 1999, JAMA-J AM MED ASSOC, V281, P335, DOI 10.1001/jama.281.4.335; [Anonymous], 2006, STAT MOD DES RAND CO; Baker PS, 2003, J AM GERIATR SOC, V51, P1610, DOI 10.1046/j.1532-5415.2003.51512.x; Beauchet O, 2009, EUR J NEUROL, V16, P786, DOI 10.1111/j.1468-1331.2009.02612.x; Bleijlevens MHC, 2010, BMC GERIATR, V10, DOI 10.1186/1471-2318-10-40; BUCHNER DM, 1993, J AM GERIATR SOC, V41, P321, DOI 10.1111/j.1532-5415.1993.tb06711.x; Campbell AJ, 1997, BMJ-BRIT MED J, V315, P1065, DOI 10.1136/bmj.315.7115.1065; Clemson L, 2004, J AM GERIATR SOC, V52, P1487, DOI 10.1111/j.1532-5415.2004.52411.x; Clemson L, 2012, ENCY BEHAV MED; Clemson L, 2007, LIFESTYLE INTEGRATED; Clemson L, 2010, AUST OCCUP THER J, V57, P42, DOI 10.1111/j.1440-1630.2009.00848.x; Davis JC, 2009, BMJ; Dunn AL, 1999, JAMA-J AM MED ASSOC, V281, P327, DOI 10.1001/jama.281.4.327; Fairhall N, 2011, AGE AGEING, V40, P666, DOI 10.1093/ageing/afr077; Faulkner KA, 2007, J AM GERIATR SOC, V55, P570, DOI 10.1111/j.1532-5415.2007.01147.x; Fiatarone Singh MA, 2003, HELPING ELDERS ACTIV; Finucane F, 1990, VITAL HLTH STAT 1, V25, P1; Friery L, 2007, RASCH ANAL LIFE ASSE; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Haley SM, 2002, J GERONTOL A-BIOL, V57, pM217, DOI 10.1093/gerona/57.4.M217; Irwin M, 2008, METHODOLOGICAL ISSUE; Jaques-Dalcroze E, 1967, RHYTHM MUSIC ED; Jette AM, 2002, J GERONTOL A-BIOL, V57, pM209, DOI 10.1093/gerona/57.4.M209; Kuptniratsaikul V, 2011, CLIN INTERV AGING, V6, P111, DOI 10.2147/CIA.S17851; Linacre JM, 2015, WINSTEPS RASCH MEASU; Liu-Ambrose T, 2012, BR J SPORTS MED; Lord SR, 2003, J AM GERIATR SOC, V51, P1685, DOI 10.1046/j.1532-5415.2003.51551.x; Menz HB, 2005, J GERONTOL A-BIOL, V60, P1546, DOI 10.1093/gerona/60.12.1546; Moher David, 2012, Int J Surg, V10, P28, DOI 10.1016/j.ijsu.2011.10.001; NSW Department of Health, 2007, NSW DEP HLTH ANN REP; Opdenacker J, 2008, PREV MED, V46, P518, DOI 10.1016/j.ypmed.2008.02.017; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341; Robertson MC, 2005, J GERONTOL A-BIOL, V60, P530, DOI 10.1093/gerona/60.4.530; Sherrington C, 2008, J AM GERIATR SOC, V56, P2234, DOI 10.1111/j.1532-5415.2008.02014.x; Silsupadol P, 2009, GAIT POSTURE, V29, P634, DOI 10.1016/j.gaitpost.2009.01.006; Sun SS, 2003, AM J CLIN NUTR, V77, P331, DOI 10.1093/ajcn/77.2.331; Talley KMC, 2008, J AM GERIATR SOC, V56, P328, DOI 10.1111/j.1532-5415.2007.01550.x; Thalheimer W., 2002, CALCULATE EFFECT SIZ; Trombetti A, 2011, ARCH INTERN MED, V171, P525, DOI 10.1001/archinternmed.2010.446; Washburn RA, 1999, J CLIN EPIDEMIOL, V52, P643, DOI 10.1016/S0895-4356(99)00049-9; Watson W, 2010, INCIDENCE COST FALLS; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	43	257	259	0	114	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 7	2012	345								e4547	10.1136/bmj.e4547	http://dx.doi.org/10.1136/bmj.e4547			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	988NA	22872695	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000307496500001
J	Hsiao, CC; Lee, CH; Tsao, LY; Lo, HC				Hsiao, Chien-Chou; Lee, Chien-Hsing; Tsao, Lon-Yen; Lo, Hui-Chen			The Dose-Dependent Immunoregulatory Effects of the Nitric Oxide Synthase Inhibitor N-G-Nitro-L-Arginine Methyl Ester in Rats with Sub-Acute Peritonitis	PLOS ONE			English	Article							TOTAL PARENTERAL-NUTRITION; IMMUNE-SYSTEM; SEPSIS; METABOLISM; PERMEABILITY; ENDOTOXEMIA; RESPONSES; INJURY	Background: Chronic inflammation accompanied by arginine deficiency, immune dysfunction, and excess nitric oxide (NO) production is a clinical condition found in patients with peritonitis. A previous study showed that the nonselective NOS inhibitor N-G-nitro-L-arginine methyl ester (L-NAME) may facilitate the metabolism of the immune nutrient arginine without altering NO homeostasis in rats with sub-acute peritonitis. Here, we investigated the effects of L-NAME on the immunocytic subpopulation distribution and response. Materials and Methods: Male Wistar rats with cecal puncture-induced peritonitis were administered parenteral nutrition solutions supplemented with 0 (CPP group), 5 (LNA group), 25 (MNA group) or 50 (HNA group) mg.kg(-1).day(-1) of L-NAME for 7 days. Parenteral-fed sham-operated rats (TPN group) and orally-fed healthy rats (R group) were included as controls. Results: The TPN group had significantly increased spleen weights and levels of plasma nitrite/nitrate (NOx), circulating white blood cells (WBC), and splenocytic T cells, as well as significantly decreased levels of cytotoxic T-and B-leukocytes and B-splenocytes compared to the R group. The CPP group had significantly decreased levels of plasma NOx and concanavalin (Con) A-stimulated interferon (IFN)-gamma and interleukin (IL)-2 production by leukocytes and significantly increased production of Con A-stimulated tumor necrosis factor (TNF)-alpha and lipopolysaccharide (LPS)-stimulated IFN-gamma in the leukocytes. In addition, the LNA and MNA groups had significantly decreased spontaneous IL-6 and Con A-stimulated TNF-alpha and IFN-gamma production by the leukocytes while the HNA group had significantly increased LPS-stimulated TNF-alpha and Con A-stimulated IFN-gamma and IL-2 production by the splenocytes compared to the CPP group. Conclusions: Low-dose L-NAME infusion may suppress proinflammatory and T-helper-1 (Th1) response in leukocytes, and high-dose infusion may activate the proinflammatory response in splenic macrophages and Th1 response in T-splenocytes in rats with sub-acute peritonitis.	[Hsiao, Chien-Chou; Tsao, Lon-Yen] Changhua Christian Hosp, Clin Nutr Support Serv Team, Dept Pediat, Changhau, Taiwan; [Lee, Chien-Hsing] Changhua Christian Hosp, Div Pediat Surg, Changhau, Taiwan; [Lee, Chien-Hsing] Chang Jung Christian Univ, Grad Inst Med Sci, Tainan, Taiwan; [Lo, Hui-Chen] Fu Jen Catholic Univ, Dept Nutr Sci, New Taipei City, Taiwan	Changhua Christian Hospital; Changhua Christian Hospital; Chang Jung Christian University; Fu Jen Catholic University	Hsiao, CC (corresponding author), Changhua Christian Hosp, Clin Nutr Support Serv Team, Dept Pediat, Changhau, Taiwan.	041663@mail.fju.edu.tw	Lo, Hui-Chen/AAN-5906-2021		National Science Council of the Republic of China [NSC-90-2320-B-371-001]; Changhua Christian Hospital [CCH-4604]	National Science Council of the Republic of China(Ministry of Science and Technology, Taiwan); Changhua Christian Hospital	This work was supported by the National Science Council of the Republic of China (http://web1.nsc.gov.tw/) under grant number NSC-90-2320-B-371-001 and by the Changhua Christian Hospital (http://www.cch.org.tw/) under grant number CCH-4604. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BOUGHTONSMITH NK, 1993, BRIT J PHARMACOL, V110, P1189, DOI 10.1111/j.1476-5381.1993.tb13940.x; Bronte V, 2005, NAT REV IMMUNOL, V5, P641, DOI 10.1038/nri1668; Chaturvedi R, 2010, GASTROENTEROLOGY, V139, P1686, DOI 10.1053/j.gastro.2010.06.060; Chaudhari UP, 2010, INT J PHARMACOL, V6, P183; Chen YH, 2012, JPEN J PARE IN PRESS; Cui L, 2000, NUTRITION, V16, P34, DOI 10.1016/S0899-9007(99)00185-9; Dioguardi FS, 2011, J NUTRIGENET NUTRIGE, V4, P90, DOI 10.1159/000327777; Edfeldt K, 2010, P NATL ACAD SCI USA, V107, P22593, DOI 10.1073/pnas.1011624108; Ferrier ML, 2001, KIDNEY INT, V60, P2343, DOI 10.1046/j.1523-1755.2001.00050.x; Gabbai FB, 1997, J IMMUNOL, V159, P6266; Gavin TP, 2000, J APPL PHYSIOL, V88, P1192, DOI 10.1152/jappl.2000.88.4.1192; GEROULANOS S, 1992, LANCET, V339, P435; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hallemeesch MM, 2002, CLIN NUTR, V21, P111, DOI 10.1054/clnu.2001.0513; Helmer KS, 2003, J SURG RES, V112, P70, DOI 10.1016/S0022-4804(03)00138-0; Hsiao CC, 2011, BIOL PHARM BULL, V34, P177, DOI 10.1248/bpb.34.177; Kobara M, 2003, BASIC RES CARDIOL, V98, P319, DOI 10.1007/s00395-003-0423-x; Lee PY, 2009, AM J PATHOL, V175, P2023, DOI 10.2353/ajpath.2009.090328; Lo HC, 2010, PEDIATR SURG INT, V26, P625, DOI 10.1007/s00383-010-2582-9; Luiking YC, 2007, CRIT CARE MED, V35, pS557, DOI 10.1097/01.CCM.0000279191.44730.A2; Morris DL, 1997, J PHARMACOL TOXICOL, V37, P37, DOI 10.1016/S1056-8719(96)00146-3; Muenzer JT, 2010, INFECT IMMUN, V78, P1582, DOI 10.1128/IAI.01213-09; Munder M, 2009, BRIT J PHARMACOL, V158, P638, DOI 10.1111/j.1476-5381.2009.00291.x; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Nieves C, 2007, JPEN-PARENTER ENTER, V31, P101, DOI 10.1177/0148607107031002101; Ninkovic MB, 2009, GEN PHYSIOL BIOPHYS, V28, P243; OCHOA JB, 1991, ANN SURG, V214, P621, DOI 10.1097/00000658-199111000-00013; Payen D, 1996, CLIN CHEST MED, V17, P333, DOI 10.1016/S0272-5231(05)70318-X; Peranzoni E, 2007, IMMUNOBIOLOGY, V212, P795, DOI 10.1016/j.imbio.2007.09.008; Pratt VC, 1996, JPEN-PARENTER ENTER, V20, P264, DOI 10.1177/0148607196020004264; Rittirsch D, 2008, NAT REV IMMUNOL, V8, P776, DOI 10.1038/nri2402; SHOU J, 1994, AM J SURG, V167, P145, DOI 10.1016/0002-9610(94)90065-5; TAO RC, 1979, J NUTR, V109, P904, DOI 10.1093/jn/109.5.904; Wang HH, 2003, NEPHROL DIAL TRANSPL, V18, P1181, DOI 10.1093/ndt/gfg079; Wildhaber BE, 2005, J SURG RES, V123, P8, DOI 10.1016/j.jss.2004.06.015; Xie YW, 1996, CIRCULATION, V94, P2580, DOI 10.1161/01.CIR.94.10.2580; Yeh CL, 2005, BRIT J NUTR, V93, P267, DOI 10.1079/BJN20041326	37	6	6	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 3	2012	7	8							e42467	10.1371/journal.pone.0042467	http://dx.doi.org/10.1371/journal.pone.0042467			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	985QT	22879994	Green Submitted, Green Published, gold			2023-01-03	WOS:000307284100100
J	Lohse, S; Brunke, C; Derer, S; Peipp, M; Boross, P; Kellner, C; Beyer, T; Dechant, M; van der Winkel, JGJ; Leusen, JHW; Valerius, T				Lohse, Stefan; Brunke, Christina; Derer, Stefanie; Peipp, Matthias; Boross, Peter; Kellner, Christian; Beyer, Thomas; Dechant, Michael; van der Winkel, Jan G. J.; Leusen, Jeanette H. W.; Valerius, Thomas			Characterization of a Mutated IgA2 Antibody of the m(1) Allotype against the Epidermal Growth Factor Receptor for the Recruitment of Monocytes and Macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-ALPHA-RI; TUMOR-ASSOCIATED MACROPHAGES; FAB-ARM EXCHANGE; EFFECTOR MECHANISMS; IMMUNOGLOBULIN-A; IGG4 ANTIBODIES; NEUTROPHILS; CELLS; CD89; THERAPEUTICS	IgA antibodies constitute an important part of the mucosal immune system, but their immunotherapeutic potential remains rather unexplored, in part due to biotechnological issues. For example, the IgA2m(1) allotype carries an unusual heavy and light chain pairing, which may confer production and stability concerns. Here, we report the generation and the biochemical and functional characterization of a P221R-mutated IgA2m(1) antibody against the epidermal growth factor receptor (EGFR). Compared with wild type, the mutated antibody demonstrated heavy chains covalently linked to light chains in monomeric as well as in joining (J)-chain containing dimeric IgA. Functional studies with wild type and mutated IgA2m(1) revealed similar binding to EGFR and direct effector functions such as EGFR down-modulation and growth inhibition. Furthermore, both IgA molecules triggered similar levels of indirect tumor cell killing such as antibody-dependent cell-mediated cytotoxicity (ADCC) by isolated monocytes, activated polymorphonuclear cells, and human whole blood. Interestingly, the dimeric IgA antibodies demonstrated higher efficiency in direct as well as in indirect effector mechanisms compared with their respective monomeric forms. Both wild type and mutated antibody triggered effective Fc alpha RI-mediated tumor cell killing by macrophages already at low effector to target cell ratios. Interestingly, also polarized macrophages mediated significant IgA2-mediated ADCC. M2 macrophages, which have been described as promoting tumor growth and progression, may convert to ADCC-mediating effector cells in the presence of EGFR-directed antibodies. In conclusion, these results provide further insight into the immunotherapeutic potential of recombinant IgA antibodies for tumor immunotherapy and suggest macrophages as an additional effector cell population.	[Lohse, Stefan; Brunke, Christina; Derer, Stefanie; Peipp, Matthias; Kellner, Christian; Valerius, Thomas] Univ Kiel, Div Stem Cell Transplantat & Immunotherapy, Dept Internal Med 2, D-24105 Kiel, Germany; [Beyer, Thomas; Dechant, Michael] Univ Kiel, Dept Internal Med Nephrol & Hypertens 4, D-24105 Kiel, Germany; [Boross, Peter; van der Winkel, Jan G. J.; Leusen, Jeanette H. W.] Univ Med Ctr Utrecht, Dept Immunol, Lab Immunotherapy, NL-3584 EA Utrecht, Netherlands; [van der Winkel, Jan G. J.] Genmab BV, NL-3584 EA Utrecht, Netherlands	University of Kiel; University of Kiel; Utrecht University; Utrecht University Medical Center; Genmab	Valerius, T (corresponding author), Univ Kiel, Div Stem Cell Transplantat & Immunotherapy, Dept Internal Med 2, Schittenhelmstr 12, D-24105 Kiel, Germany.	t.valerius@med2.uni-kiel.de	, Jeanette/AAG-3736-2019; Leusen, Jeanette/I-9010-2014; Valerius, Thomas/A-3086-2011; Derer, Stefanie/B-9963-2014; Derer, Stefanie/B-9300-2017; Peipp, Matthias/A-8775-2013; Boross, Peter/AAD-8928-2022; beyer, thomas/AAN-1789-2020; Lohse, Stefan/P-6627-2016; Kellner, Christian/G-4238-2015	Lohse, Stefan/0000-0003-2529-1900; Kellner, Christian/0000-0002-2562-6902; Leusen, Jeanette/0000-0003-4982-6914; Beyer, Thomas/0000-0002-8308-3918; Peipp, Matthias/0000-0002-5088-3804	German Research Organization (Deutsche Forschungsgemeinschaft) [Va 124/7-1, De 1478/1-1, Lo 1853/1-1]; Wilhelm Sander Foundation [2009.098.1]	German Research Organization (Deutsche Forschungsgemeinschaft)(German Research Foundation (DFG)); Wilhelm Sander Foundation	This work was supported by the German Research Organization (Deutsche Forschungsgemeinschaft, Va 124/7-1, De 1478/1-1, and Lo 1853/1-1) and the Wilhelm Sander Foundation (2009.098.1).	Algars A, 2012, INT J CANCER, V131, P864, DOI 10.1002/ijc.26457; Bakema JE, 2008, J IMMUNOL, V181, P4080, DOI 10.4049/jimmunol.181.6.4080; Beyer T, 2009, J IMMUNOL METHODS, V346, P26, DOI 10.1016/j.jim.2009.05.002; BRUGGEMANN M, 1987, J EXP MED, V166, P1351, DOI 10.1084/jem.166.5.1351; Carter PJ, 2006, NAT REV IMMUNOL, V6, P343, DOI 10.1038/nri1837; Chintalacharuvu KR, 2002, J IMMUNOL, V169, P5072, DOI 10.4049/jimmunol.169.9.5072; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Dechant M, 2002, BLOOD, V100, P4574, DOI 10.1182/blood-2002-03-0687; Dechant M, 2007, J IMMUNOL, V179, P2936, DOI 10.4049/jimmunol.179.5.2936; Di Carlo E, 2001, BLOOD, V97, P339, DOI 10.1182/blood.V97.2.339; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Furtado PB, 2004, J MOL BIOL, V338, P921, DOI 10.1016/j.jmb.2004.03.007; Ghetie V, 2000, ANNU REV IMMUNOL, V18, P739, DOI 10.1146/annurev.immunol.18.1.739; Huls G, 1999, CANCER RES, V59, P5778; Jefferis R, 2009, MABS, V1, P332, DOI 10.4161/mabs.1.4.9122; Johansen FE, 2001, J IMMUNOL, V167, P5185, DOI 10.4049/jimmunol.167.9.5185; Kerkar SP, 2011, J CLIN INVEST, V121, P4746, DOI 10.1172/JCI58814; Kolfschoten MV, 2007, SCIENCE, V317, P1554, DOI 10.1126/science.1144603; Kumar A, 2008, J CLIN ONCOL, V26, P1742, DOI 10.1200/JCO.2007.12.1178; Labrijn AF, 2009, NAT BIOTECHNOL, V27, P767, DOI 10.1038/nbt.1553; Leidi M, 2009, J IMMUNOL, V182, P4415, DOI 10.4049/jimmunol.0713732; Lohse S, 2011, J IMMUNOL, V186, P3770, DOI 10.4049/jimmunol.1003082; Macpherson AJ, 2008, MUCOSAL IMMUNOL, V1, P11, DOI 10.1038/mi.2007.6; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Maruoka T, 2004, IMMUNOGENETICS, V55, P712, DOI 10.1007/s00251-003-0626-1; Monteiro RC, 2003, ANNU REV IMMUNOL, V21, P177, DOI 10.1146/annurev.immunol.21.120601.141011; Novak J, 2008, SEMIN NEPHROL, V28, P78, DOI 10.1016/j.semnephrol.2007.10.009; Oortwijn BD, 2006, J AM SOC NEPHROL, V17, P3529, DOI 10.1681/ASN.2006040388; Otten MA, 2007, J IMMUNOL, V179, P2918, DOI 10.4049/jimmunol.179.5.2918; Pander J, 2011, CLIN CANCER RES, V17, P5668, DOI 10.1158/1078-0432.CCR-11-0239; Peipp M, 2008, CURR OPIN IMMUNOL, V20, P436, DOI 10.1016/j.coi.2008.05.012; Phalipon A, 2003, TRENDS IMMUNOL, V24, P55, DOI 10.1016/S1471-4906(02)00031-5; Pleass RJ, 1996, BIOCHEM J, V318, P771, DOI 10.1042/bj3180771; Reichert JM, 2011, MABS-AUSTIN, V3, P76, DOI 10.4161/mabs.3.1.13895; Rifai A, 2000, J EXP MED, V191, P2171, DOI 10.1084/jem.191.12.2171; Royle L, 2003, J BIOL CHEM, V278, P20140, DOI 10.1074/jbc.M301436200; Schneider-Merck T, 2010, J IMMUNOL, V184, P512, DOI 10.4049/jimmunol.0900847; Senior BW, 2005, J IMMUNOL, V174, P7792, DOI 10.4049/jimmunol.174.12.7792; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; STOPPACCIARO A, 1993, J EXP MED, V178, P151, DOI 10.1084/jem.178.1.151; Togo S, 2003, FEBS LETT, V535, P205, DOI 10.1016/S0014-5793(02)03891-7; TSUZUKIDA Y, 1979, P NATL ACAD SCI USA, V76, P1104, DOI 10.1073/pnas.76.3.1104; Uchida JJ, 2004, J EXP MED, V199, P1659, DOI 10.1084/jem.20040119; van Egmond M, 2000, NAT MED, V6, P680, DOI 10.1038/76261; Wang AC, 1973, J IMMUNOGENET, V1, P31; Woof JM, 2006, J PATHOL, V208, P270, DOI 10.1002/path.1877; Wurm FM, 2004, NAT BIOTECHNOL, V22, P1393, DOI 10.1038/nbt1026; Yin N, 2007, J LEUKOCYTE BIOL, V82, P551, DOI 10.1189/jlb.0207112; Yoo EM, 2011, MOL IMMUNOL, V48, P1818, DOI 10.1016/j.molimm.2011.05.011	49	29	34	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2012	287	30					25139	25150		10.1074/jbc.M112.353060	http://dx.doi.org/10.1074/jbc.M112.353060			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	977IW	22679018	hybrid, Green Published			2023-01-03	WOS:000306651700025
J	Wald, DS; Morris, JK; Wald, NJ				Wald, David S.; Morris, Joan K.; Wald, Nicholas J.			Randomized Polypill Crossover Trial in People Aged 50 and Over	PLOS ONE			English	Article							CARDIOVASCULAR-DISEASE; PREVENTION	Background: A Polypill is proposed for the primary prevention of cardiovascular disease in people judged to be at risk on account of their age alone. Its efficacy in reducing cholesterol and blood pressure is uncertain. Methods: We conducted a randomized double-blind placebo-controlled crossover trial of a Polypill among individuals aged 50+ without a history of cardiovascular disease and compared the reductions with those predicted from published estimates of the effects of the individual drugs. Participants took the Polypill (amlodipine 2.5 mg, losartan 25 mg, hydrochlorothiazide 12.5 mg and simvastatin 40 mg) each evening for 12 weeks and a placebo each evening for 12 weeks in random sequence. The mean within-person differences in blood pressure and low density lipoprotein (LDL) cholesterol at the end of each 12 week period were determined. Results: 84 out of 86 participants completed both treatment periods. The mean systolic blood pressure was reduced by 17.9 mmHg (95% CI, 15.7-20.1) on the Polypill, diastolic blood pressure by 9.8 mmHg (8.1-11.5), and LDL cholesterol by 1.4 mmol/L (1.2-1.6), reductions of 12%, 11%, and 39% respectively. The results were almost identical to those predicted; 18.4 mmHg, 9.7 mmHg, and 1.4 mmol/L respectively. Conclusion: The Polypill resulted in the predicted reductions in blood pressure and LDL cholesterol. Long term reductions of this magnitude would have a substantial effect in preventing heart attacks and strokes.	[Wald, David S.; Morris, Joan K.; Wald, Nicholas J.] Queen Mary Univ London, Wolfson Inst Prevent Med, Barts & London Sch Med & Dent, London, England	University of London; Queen Mary University London	Wald, DS (corresponding author), Queen Mary Univ London, Wolfson Inst Prevent Med, Barts & London Sch Med & Dent, London, England.	d.s.wald@qmul.ac.uk	Wald, Nicholas/AAY-2814-2021; Morris, Joan/AAT-9211-2020; Wald, Nicholas/AAY-8924-2021	Morris, Joan/0000-0002-7164-612X; 	London Charity	London Charity	Cipla provided the Polypill and placebo to the specification of the trial investigators and Barts and the London Charity provided financial support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Cholesterol Treatment Trialists' (CTT) Collaborators, 2012, LANCET; Cilla DD, 1996, J CLIN PHARMACOL, V36, P604, DOI 10.1002/j.1552-4604.1996.tb04224.x; Law MR, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1665; Law MR, 2003, BRIT MED J, V326, P1427, DOI 10.1136/bmj.326.7404.1427; Law MR, 2003, BRIT MED J, V326, P1423, DOI 10.1136/bmj.326.7404.1423; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Lewington S, 2007, LANCET, V370, P1829, DOI 10.1016/S0140-6736(07)61778-4; Malekzadeh F, 2010, INT J CLIN PRACT, V64, P1220, DOI 10.1111/j.1742-1241.2010.02412.x; Mulatero P, 2002, HYPERTENSION, V40, P897, DOI 10.1161/01.HYP.0000038478.59760.41; Rodgers A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019857; Rothwell PM, 2011, LANCET, V377, P31, DOI 10.1016/S0140-6736(10)62110-1; Soliman EZ, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-3; The Indian Polycap Study (TIPS), 2009, LANCET, V373; van Gils PF, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000363; Wald DS, 2011, J EVAL CLIN PRACT, DOI [10.1111/j.1365-2753.2011.01637, DOI 10.1111/J.1365-2753.2011.01637]; Wald NJ, 2011, LANCET, V377, P1649, DOI 10.1016/S0140-6736(11)60665-X; Wald N, 2009, LANCET, V374, P781, DOI 10.1016/S0140-6736(09)61584-1; Wald NJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018742; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419; Wald NJ, 2000, UK Patents, Patent No. [GB0100548, 0100548]; Wald NJ, 2000, United Kingdom, Patents, Patent No. [GB008791 and GB0100548, 008791]	21	96	101	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2012	7	7							e41297	10.1371/journal.pone.0041297	http://dx.doi.org/10.1371/journal.pone.0041297			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975YY	22815989	gold, Green Published, Green Submitted			2023-01-03	WOS:000306548900108
J	Prokopetz, JJZ; Lehmann, LS				Prokopetz, Julian J. Z.; Lehmann, Lisa Soleymani			Redefining Physicians' Role in Assisted Dying	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Prokopetz, Julian J. Z.] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA; [Lehmann, Lisa Soleymani] Brigham & Womens Hosp, Ctr Bioeth, Boston, MA 02115 USA; [Lehmann, Lisa Soleymani] Harvard Univ, Div Med Eth, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Prokopetz, JJZ (corresponding author), Brigham & Womens Hosp, Dept Orthoped Surg, 75 Francis St, Boston, MA 02115 USA.							Curlin FA, 2008, AM J HOSP PALLIAT ME, V25, P112, DOI 10.1177/1049909107310141; Ganzini L, 2009, J PAIN SYMPTOM MANAG, V38, P807, DOI 10.1016/j.jpainsymman.2009.04.026; Lindsay RA, 2009, AM J BIOETHICS, V9, P19, DOI 10.1080/15265160802654137; Smith KA, 2011, J PALLIAT MED, V14, P445, DOI 10.1089/jpm.2010.0425	4	19	21	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2012	367	2					97	99		10.1056/NEJMp1205283	http://dx.doi.org/10.1056/NEJMp1205283			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	972IO	22784111				2023-01-03	WOS:000306270800003
J	Tanaka, M; Mroz, P; Dai, TH; Huang, LY; Morimoto, Y; Kinoshita, M; Yoshihara, Y; Nemoto, K; Shinomiya, N; Seki, S; Hamblin, MR				Tanaka, Masamitsu; Mroz, Pawel; Dai, Tianhong; Huang, Liyi; Morimoto, Yuji; Kinoshita, Manabu; Yoshihara, Yasuo; Nemoto, Koichi; Shinomiya, Nariyoshi; Seki, Suhji; Hamblin, Michael R.			Photodynamic Therapy Can Induce a Protective Innate Immune Response against Murine Bacterial Arthritis via Neutrophil Accumulation	PLOS ONE			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; KAPPA-B ACTIVATION; IN-VIVO; CHOROIDAL NEOVASCULARIZATION; ANTITUMOR IMMUNITY; INFECTIONS; CELLS; VITRO; MICE; PHOTOSENSITIZER	Background: Local microbial infections induced by multiple-drug-resistant bacteria in the orthopedic field can be intractable, therefore development of new therapeutic modalities is needed. Photodynamic therapy (PDT) is a promising alternative modality to antibiotics for intractable microbial infections, and we recently reported that PDT has the potential to accumulate neutrophils into the infected site which leads to resolution of the infection. PDT for cancer has long been known to be able to stimulate the innate and adaptive arms of the immune system. Methodology/Principal Findings: In the present study, a murine methicillin-resistant Staphylococcus aureus (MRSA) arthritis model using bioluminescent MRSA and polystyrene microparticles was established, and both the therapeutic (Th-PDT) and preventive (Pre-PDT) effects of PDT using methylene blue as photosensitizer were examined. Although Th-PDT could not demonstrate direct bacterial killing, neutrophils were accumulated into the infectious joint space after PDT and MRSA arthritis was reduced. With the preconditioning Pre-PDT regimen, neutrophils were quickly accumulated into the joint immediately after bacterial inoculation and bacterial growth was suppressed and the establishment of infection was inhibited. Conclusions/Significance: This is the first demonstration of a protective innate immune response against a bacterial pathogen produced by PDT.	[Tanaka, Masamitsu; Mroz, Pawel; Dai, Tianhong; Huang, Liyi; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Tanaka, Masamitsu; Mroz, Pawel; Dai, Tianhong; Huang, Liyi; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Tanaka, Masamitsu; Yoshihara, Yasuo; Nemoto, Koichi] Natl Def Med Coll, Dept Orthoped Surg, Tokorozawa, Saitama 359, Japan; [Morimoto, Yuji; Shinomiya, Nariyoshi] Natl Def Med Coll, Dept Integrated Physiol & Bionano Med, Tokorozawa, Saitama 359, Japan; [Kinoshita, Manabu; Seki, Suhji] Natl Def Med Coll, Dept Immunol & Microbiol, Tokorozawa, Saitama 359, Japan; [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; National Defense Medical College - Japan; National Defense Medical College - Japan; National Defense Medical College - Japan; Harvard University; Massachusetts Institute of Technology (MIT)	Tanaka, M (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.	moyan@ndmc.ac.jp; hamblin@helix.mgh.harvard.edu	Hamblin, Michael R/H-2758-2019; Dai, Tianhong/P-5961-2018; Shinomiya, Nariyoshi/I-9666-2014; Mroz, Pawel/P-1258-2019; Hamblin, Mike/AAB-2511-2022; MORIMOTO, YUJI/F-2912-2019	Hamblin, Michael R/0000-0001-6431-4605; Dai, Tianhong/0000-0001-8960-8896; Mroz, Pawel/0000-0003-3838-4743; MORIMOTO, YUJI/0000-0001-6494-413X	Ministry of Education, Culture, Sports, Science and Technology of Japan [23659628]; U.S. National Institutes of Health [R01AI050875]; Airlift Research Foundation Extremity Trauma Research Grant [109421]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050875] Funding Source: NIH RePORTER	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Airlift Research Foundation Extremity Trauma Research Grant; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by a Grant-in-Aid for Challenging Exploratory Research (23659628) from the Ministry of Education, Culture, Sports, Science and Technology of Japan to Yuji Morimoto. Liyi Huang and Michael R. Hamblin were supported by U.S. National Institutes of Health grant R01AI050875 to Michael R. Hamblin, and Tianhong Dai by an Airlift Research Foundation Extremity Trauma Research Grant (grant 109421). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BERTHIAUME F, 1994, BIO-TECHNOL, V12, P703, DOI 10.1038/nbt0794-703; Biel MA, 2010, METHODS MOL BIOL, V635, P175, DOI 10.1007/978-1-60761-697-9_13; Bisland SK, 2006, PHOTOCH PHOTOBIO SCI, V5, P31, DOI 10.1039/b507082a; Castano AP, 2008, P NATL ACAD SCI USA, V105, P5495, DOI 10.1073/pnas.0709256105; Castano AP, 2006, NAT REV CANCER, V6, P535, DOI 10.1038/nrc1894; Cecic I, 2002, CANCER LETT, V183, P43, DOI 10.1016/S0304-3835(02)00092-7; Cecic I, 2001, PHOTOCHEM PHOTOBIOL, V74, P712, DOI 10.1562/0031-8655(2001)074<0712:IOSNRI>2.0.CO;2; Chang CJ, 1999, LASER SURG MED, V24, P178, DOI 10.1002/(SICI)1096-9101(1999)24:3<178::AID-LSM2>3.3.CO;2-N; Dai TH, 2010, LASER SURG MED, V42, P38, DOI 10.1002/lsm.20887; deVree WJA, 1996, CANCER RES, V56, P2908; Di Poto A, 2009, BIOMATERIALS, V30, P3158, DOI 10.1016/j.biomaterials.2009.02.038; DRISCOLL KE, 1993, AM J RESP CELL MOL, V8, P311, DOI 10.1165/ajrcmb/8.3.311; Fontana CR, 2009, J PERIODONTAL RES, V44, P751, DOI 10.1111/j.1600-0765.2008.01187.x; Gad F, 2004, PHOTOCH PHOTOBIO SCI, V3, P451, DOI 10.1039/b311901g; Gallo Jiri, 2003, Biomedical Papers (Olomouc), V147, P27; Garg AD, 2011, PHOTOCH PHOTOBIO SCI, V10, P670, DOI 10.1039/c0pp00294a; Gollnick SO, 2003, BRIT J CANCER, V88, P1772, DOI 10.1038/sj.bjc.6600864; Granville DJ, 2000, BLOOD, V95, P256; Hamblin MR, 2002, PHOTOCHEM PHOTOBIOL, V75, P51, DOI 10.1562/0031-8655(2002)075<0051:RCOWIB>2.0.CO;2; HAYATA Y, 1982, CHEST, V81, P269, DOI 10.1378/chest.81.3.269; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; HSIANG YN, 1994, CAN J SURG, V37, P148; Kielian T, 2000, AM J PATHOL, V157, P647, DOI 10.1016/S0002-9440(10)64575-0; Kinoshita M, 2011, INFECT IMMUN, V79, P2670, DOI 10.1128/IAI.01298-10; KONIG K, 1987, J CANCER RES CLIN, V113, P301, DOI 10.1007/BF00396390; Korbelik M, 1999, CANCER RES, V59, P1941; Kousis PC, 2007, CANCER RES, V67, P10501, DOI 10.1158/0008-5472.CAN-07-1778; Kramer M, 1996, OPHTHALMOLOGY, V103, P427; Lambrechts SAG, 2005, PHOTOCH PHOTOBIO SCI, V4, P503, DOI 10.1039/b502125a; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; MacDonald IJ, 2001, J PORPHYR PHTHALOCYA, V5, P105, DOI 10.1002/jpp.328; Massey E, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005341.pub2; MONTEFORT S, 1994, J CLIN INVEST, V93, P1411, DOI 10.1172/JCI117118; Mroz P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015194; NAKAGAWA Y, 1993, CANCER IMMUNOL IMMUN, V37, P157, DOI 10.1007/BF01525429; Neut D, 2007, ACTA ORTHOP, V78, P299, DOI 10.1080/17453670710013843; O'Neill E, 2007, J CLIN MICROBIOL, V45, P1379, DOI 10.1128/JCM.02280-06; Obana A, 1999, LASER SURG MED, V24, P209, DOI 10.1002/(SICI)1096-9101(1999)24:3<209::AID-LSM6>3.0.CO;2-L; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; Patel A, 2008, J BONE JOINT SURG BR, V90B, P1401, DOI 10.1302/0301-620X.90B11.20771; Peng Q, 1997, PHOTOCHEM PHOTOBIOL, V65, P235, DOI 10.1111/j.1751-1097.1997.tb08549.x; Preise D, 2009, CANCER IMMUNOL IMMUN, V58, P71, DOI 10.1007/s00262-008-0527-0; RYTER SW, 1993, PHOTOCHEM PHOTOBIOL, V58, P753, DOI 10.1111/j.1751-1097.1993.tb04964.x; Street CN, 2010, PHOTOMED LASER SURG, V28, pS61, DOI 10.1089/pho.2009.2622; Tanaka M, 2012, PHOTOCHEM PHOTOBIOL, V88, P227, DOI 10.1111/j.1751-1097.2011.01005.x; Tanaka M, 2011, LASER SURG MED, V43, P221, DOI 10.1002/lsm.21037; Tanaka M, 2010, PHOTOCHEM PHOTOBIOL, V86, P403, DOI 10.1111/j.1751-1097.2009.00658.x; TANG G, 1993, NEUROSURGERY, V32, P438, DOI 10.1227/00006123-199303000-00016; Tsuda Y, 2004, IMMUNITY, V21, P215, DOI 10.1016/j.immuni.2004.07.006; Verdrengh M, 1997, INFECT IMMUN, V65, P2517, DOI 10.1128/IAI.65.7.2517-2521.1997; Volanti C, 2002, PHOTOCHEM PHOTOBIOL, V75, P36, DOI 10.1562/0031-8655(2002)075<0036:IOOSIN>2.0.CO;2; Zolfaghari PS, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-27	52	44	44	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 26	2012	7	6							e39823	10.1371/journal.pone.0039823	http://dx.doi.org/10.1371/journal.pone.0039823			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	966AK	22761911	Green Published, Green Submitted, gold			2023-01-03	WOS:000305808700049
J	McPherson, T				McPherson, Tess			PERSONAL VIEW My mum wanted assisted dying but we watched her die slowly and in pain	BRITISH MEDICAL JOURNAL			English	Editorial Material									Churchill Hosp, Oxford OX3 7LJ, England	University of Oxford	McPherson, T (corresponding author), Churchill Hosp, Oxford OX3 7LJ, England.	tess.mcpherson@msd.ox.ac.uk						McPherson A, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2827; Warlow C, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d3424	2	6	6	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUN 14	2012	344								e4007	10.1136/bmj.e4007	http://dx.doi.org/10.1136/bmj.e4007			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	961LA	22695305				2023-01-03	WOS:000305464700009
J	Tang, YM; Luo, DH; Rong, XM; Shi, XL; Peng, Y				Tang, Yamei; Luo, Donghua; Rong, Xiaoming; Shi, Xiaolei; Peng, Ying			Psychological Disorders, Cognitive Dysfunction and Quality of Life in Nasopharyngeal Carcinoma Patients with Radiation-Induced Brain Injury	PLOS ONE			English	Article							EMOTIONAL STATUS; CANCER-PATIENTS; RADIOTHERAPY; THERAPY; IMPACT; RADIONECROSIS; DEPRESSION; ANXIETY	Purpose: To evaluate factors affecting psychology, cognitive function and quality of life (QOL) of nasopharyngeal carcinoma (NPC) patients with radiation-induced brain injury (RI). Methods and Materials: 46 recurrence-free NPC patients with RI and 46 matched control patients without RI were recruited in our study. Subjective and objective symptoms of RI were evaluated with the LENT/SOMA systems. Psychological assessment was measured with Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS). Montreal Cognitive Assessment (MoCA) was carried out in these patients for assessing their cognitive function. QOL was evaluated by means of WHOQOL BREF. Results: Of the patients with RI, 39(84.8%) had depression and 40(87.0%) had anxiety. The patients with RI got higher scores both in SDS and SAS than those without RI (SDS, 63.48 +/- 8.11vs. 58.67 +/- 7.52, p = 0.008; SAS, 67.36 +/- 10.41vs. 60.34 +/- 9.76, p = 0.005). Score in MoCA of patients with RI was significantly lower than that of patients without RI (21.32 +/- 2.45vs. 25.98 +/- 1.73, p<0.001). SAS was positive correlated with post-radiotherapy interval. Both SAS and SDS had a significantly positive correlation with the rank of SOMA, while MoCA had a significantly negative correlation with SOMA. Chemotherapy was a risk factor for cognitive dysfunction. In addition, patients with RI got significantly lower scores in physical health (16.50 +/- 11.05 vs. 35.02 +/- 10.43, p<0.001), psychological health (17.70 +/- 10.33 vs. 39.48 +/- 12.00, p<0.001) and social relationship (48.00 +/- 18.65 vs. 67.15 +/- 19.70, p<0.001) compared with those in patients without RI. Multiple linear regression analysis revealed that anxiety and cognitive impairment were significant predictors of global QOL. Conclusions: NPC patients with RI exhibit negative emotions, impaired cognitive function and QOL. The severity of clinical symptoms of RI plays an important role in both emotions and cognitive function. Anxiety and cognitive impairment are associated with decreased QOL.	[Tang, Yamei; Rong, Xiaoming; Shi, Xiaolei; Peng, Ying] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Neurol, Guangzhou 510275, Guangdong, Peoples R China; [Tang, Yamei; Rong, Xiaoming; Shi, Xiaolei; Peng, Ying] Sun Yat Sen Univ, Key Lab Malignant Tumor Gene Regulat & Target The, Guangdong Higher Educ Inst, Guangzhou 510275, Guangdong, Peoples R China; [Luo, Donghua] Sun Yat Sen Univ, Ctr Canc, Dept Nasopharyngeal Carcinoma, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Tang, YM (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Neurol, Guangzhou 510275, Guangdong, Peoples R China.	yameitang@hotmail.com		Tang, Yamei/0000-0002-6353-6107	National Natural Science Foundation of China (NSFC) [30600164, 81072242, NSFC 30973479]; Yat-Sen Scholarship of Sun Yat-Sen Memorial Hospital for Young Scientist	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Yat-Sen Scholarship of Sun Yat-Sen Memorial Hospital for Young Scientist	The current project was supported by the National Natural Science Foundation of China (NSFC No. 30600164, NSFC No. 81072242 to Y.T. and NSFC 30973479 to Y.P.) and Yat-Sen Scholarship of Sun Yat-Sen Memorial Hospital for Young Scientist. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Behin A, 2004, SEMIN NEUROL, V24, P405, DOI 10.1055/s-2004-861535; Chang HT, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-70; Chen PR, 2005, INT J RADIAT ONCOL, V61, P466, DOI 10.1016/j.ijrobp.2004.05.016; Cheung MC, 2003, CANCER-AM CANCER SOC, V97, P2019, DOI 10.1002/cncr.11295; Cheung MC, 2000, ARCH NEUROL-CHICAGO, V57, P1347, DOI 10.1001/archneur.57.9.1347; Fang FM, 2002, INT J RADIAT ONCOL, V53, P959, DOI 10.1016/S0360-3016(02)02838-9; Frick E, 2007, EUR J CANCER CARE, V16, P130, DOI 10.1111/j.1365-2354.2006.00720.x; Hammerlid E, 2001, HEAD NECK-J SCI SPEC, V23, P113, DOI 10.1002/1097-0347(200102)23:2<113::AID-HED1006>3.0.CO;2-W; Heinonen H, 2004, QUAL LIFE RES, V13, P1347, DOI 10.1023/B:QURE.0000040788.12947.b9; Hsiao KY, 2010, INT J RADIAT ONCOL, V77, P722, DOI 10.1016/j.ijrobp.2009.06.080; Karasawa Kumiko, 2005, Radiat Med, V23, P478; Ku PKM, 2010, LARYNGOSCOPE, V120, P223, DOI 10.1002/lary.20701; Lam LCW, 2003, J NEUROPSYCH CLIN N, V15, P90, DOI 10.1176/appi.neuropsych.15.1.90; Lee PWH, 2007, CANCER-AM CANCER SOC, V109, P1344, DOI 10.1002/cncr.22539; Lue BH, 2008, INT J RADIAT ONCOL, V70, P28, DOI 10.1016/j.ijrobp.2007.06.053; Mystakidou K, 2005, QUAL LIFE RES, V14, P1825, DOI 10.1007/s11136-005-4324-3; Routledge JA, 2003, INT J RADIAT ONCOL, V56, P502, DOI 10.1016/S0360-3016(02)04578-9; Sehlen S, 2000, ONKOLOGIE, V23, P565, DOI 10.1159/000055007; Shin HR, 2010, ASIAN PAC J CANCER P, V11, P11; Tang Y, 2011, STRAHLENTHER ONKOL, V187, P39, DOI 10.1007/s00066-010-2151-0; Wan LS, 2011, BMC CANCER, V11, P128; World Health Organization (WHO), 1998, WHOQOL US MAN; Young YH, 2004, OTOL NEUROTOL, V25, P366, DOI 10.1097/00129492-200405000-00027; Zhang M, 1998, HDB PSYCHIAT SCALES	24	66	76	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2012	7	6							e36529	10.1371/journal.pone.0036529	http://dx.doi.org/10.1371/journal.pone.0036529			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	959TU	22701557	Green Published, gold, Green Submitted			2023-01-03	WOS:000305337600004
J	Chang, MW; Lo, JM; Juan, HF; Chang, HY; Chuang, CY				Chang, Ming-Wei; Lo, Jem-Mau; Juan, Hsueh-Fen; Chang, Hsin-Yi; Chuang, Chun-Yu			Combination of RGD Compound and Low-Dose Paclitaxel Induces Apoptosis in Human Glioblastoma Cells	PLOS ONE			English	Article							ASPARTIC ACID PEPTIDE; THERAPEUTIC TARGETS; ALPHA(V)BETA(3) INTEGRIN; ALPHA-V-BETA-3 INTEGRIN; CANCER; ACTIVATION; EXPRESSION; MULTIFORME; DEATH; CILENGITIDE	Background: Integrins are a family of transmembrane adhesion proteins that mediate cell adhesion and intracellular signaling. Integrin-alpha v beta 3 is expressed on the surface of human glioblastoma cells, and can be further induced by chemical stress. The Arg-Gly-Asp (RGD) motif-containing peptides are specifically bound to integrin-alpha v beta 3, and to inhibit neovasculature underlying competition to normal extracellular matrix proteins. This study employed two types of RGD peptides, cyclic RGD (c(RGDyK)) and bi-cyclic RGD (E[c(RGDyK)] 2) peptide, to human glioblastoma U87MG cells with combination of low dose Paclitaxel (PTX) pre-treatment to augment therapeutic activity for RGD peptide-induced apoptosis. Principal Findings: Human glioblastoma U87MG cells were treated with RGD peptides in the absence or presence of initial exposure to low-dose 10 nM PTX. Results showed that integrin-alpha v beta 3 expressing on the surface of U87MG cells was induced by 10 nM PTX pre-treatment for 12 hrs. Additionally, the U87MG cells pre-treated with PTX and followed by RGD peptides exhibited greater expression of caspases-3, -8 and -9 than those merely treated with single agent of PTX or RGD peptide. Furthermore, the caspase-3, -8 and -9 inhibitor presented significant protection against E[c(RGDyK)] 2 peptide induced U87MG programmed cell death. The increased expression of PTX-induced integrin-alpha v beta 3 was correlated with the enhanced apoptosis in U87MG cells. Conclusions: This study provides a novel concept of targeting integrin-alpha v beta 3 with RGD peptides in combination with low-dose PTX pre-treatment to improve efficiency in human glioblastoma treatment.	[Chang, Ming-Wei; Lo, Jem-Mau; Chuang, Chun-Yu] Natl Tsing Hua Univ, Dept Biomed Engn & Environm Sci, Hsinchu, Taiwan; [Juan, Hsueh-Fen; Chang, Hsin-Yi] Natl Taiwan Univ, Inst Mol & Cellular Biol, Taipei 10764, Taiwan; [Juan, Hsueh-Fen] Natl Taiwan Univ, Dept Life Sci, Taipei 10764, Taiwan	National Tsing Hua University; National Taiwan University; National Taiwan University	Chang, MW (corresponding author), Natl Tsing Hua Univ, Dept Biomed Engn & Environm Sci, Hsinchu, Taiwan.	cychuang@mx.nthu.edu.tw		Chang, Hsin-Yi/0000-0002-2742-0676; JUAN, HSUEH-FEN/0000-0003-4876-3309	National Tsing Hua University [95N2115E1]	National Tsing Hua University	This study was financially funded by National Tsing Hua University (95N2115E1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alghisi GC, 2006, ENDOTHELIUM-J ENDOTH, V13, P113, DOI 10.1080/10623320600698037; Andre N, 2000, CANCER RES, V60, P5349; Banno A, 2008, BIOCHEM SOC T, V36, P229, DOI 10.1042/BST0360229; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; Buckner JC, 2006, J CLIN ONCOL, V24, P3871, DOI 10.1200/JCO.2005.04.6979; Chatterjee S, 2000, J NEURO-ONCOL, V46, P135, DOI 10.1023/A:1006444300504; Chen XY, 2004, J NUCL MED, V45, P1776; Creagh EM, 2001, BIOCHEM SOC T, V29, P696, DOI 10.1042/0300-5127:0290696; Edlund M, 2001, CELL GROWTH DIFFER, V12, P99; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Haas MJ, 2009, SCIBX, V12, P1; HEIMANS JJ, 1994, ANN ONCOL, V5, P951, DOI 10.1093/oxfordjournals.annonc.a058736; Huang TC, 2007, FEBS LETT, V581, P3517, DOI 10.1016/j.febslet.2007.06.067; Kanu OO, 2009, EXPERT OPIN THER TAR, V13, P701, DOI [10.1517/14728220902942348 , 10.1517/14728220902942348]; Karmakar S, 2008, CANCER, V112, P596, DOI 10.1002/cncr.23223; Kim R, 2005, ONCOL REP, V14, P595; Kong F, 2009, J CELL BIOL, V185, P1275, DOI 10.1083/jcb.200810002; Kurenova E, 2004, MOL CELL BIOL, V24, P4361, DOI 10.1128/MCB.24.10.4361-4371.2004; Lai TH, 2009, J CELL PHYSIOL, V218, P334, DOI 10.1002/jcp.21601; Landen CN, 2008, NEOPLASIA, V10, P1259, DOI 10.1593/neo.08740; Lanni JS, 1997, P NATL ACAD SCI USA, V94, P9679, DOI 10.1073/pnas.94.18.9679; Liu ZF, 2009, EUR J NUCL MED MOL I, V36, P1296, DOI 10.1007/s00259-009-1112-2; Louis DN, 2001, AM J PATHOL, V159, P779, DOI 10.1016/S0002-9440(10)61750-6; Lu YJ, 2006, AAPS J, V8, pE466, DOI 10.1208/aapsj080355; Madden HL, 2000, AM J RESP CRIT CARE, V162, P1553, DOI 10.1164/ajrccm.162.4.2001015; Maubant S, 2006, BLOOD, V108, P3035, DOI 10.1182/blood-2006-05-023580; Menendez JA, 2005, ONCOGENE, V24, P761, DOI 10.1038/sj.onc.1208238; Mulgrew K, 2006, MOL CANCER THER, V5, P3122, DOI 10.1158/1535-7163.MCT-06-0356; Nemeth JA, 2007, CANCER INVEST, V25, P632, DOI 10.1080/07357900701522638; Ng SSM, 2007, CANCER GENE THER, V14, P561, DOI 10.1038/sj.cgt.7701038; Park SJ, 2004, J BIOL CHEM, V279, P51057, DOI 10.1074/jbc.M406543200; Puklin-Faucher E, 2009, J BIOL CHEM, V284, P36557, DOI 10.1074/jbc.M109.041194; Reardon DA, 2008, EXPERT OPIN INV DRUG, V17, P1225, DOI 10.1517/13543784.17.8.1225 ; Reardon DA, 2006, ONCOLOGIST, V11, P152, DOI 10.1634/theoncologist.11-2-152; Reardon DA, 2008, J CLIN ONCOL, V26, P5610, DOI 10.1200/JCO.2008.16.7510; Sheppard D, 2003, PHYSIOL REV, V83, P673, DOI 10.1152/physrev.00033.2002; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; Trusolino L, 1998, J CELL BIOL, V142, P1145, DOI 10.1083/jcb.142.4.1145; Tseng S H, 1999, Neuro Oncol, V1, P101, DOI 10.1093/neuonc/1.2.101; Venkatachalam CM, 2003, J MOL GRAPH MODEL, V21, P289, DOI 10.1016/S1093-3263(02)00164-X; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Zhou XM, 2001, J BIOL CHEM, V276, P44762, DOI 10.1074/jbc.M104029200	44	8	8	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 24	2012	7	5							e37935	10.1371/journal.pone.0037935	http://dx.doi.org/10.1371/journal.pone.0037935			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UB	22655084	Green Published, gold, Green Submitted			2023-01-03	WOS:000305338900061
J	Donker, T; Wallinga, J; Slack, R; Grundmann, H				Donker, Tjibbe; Wallinga, Jacco; Slack, Richard; Grundmann, Hajo			Hospital Networks and the Dispersal of Hospital-Acquired Pathogens by Patient Transfer	PLOS ONE			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; LIFE EXPECTANCY; COMMUNITY; TRANSMISSION; DETERMINANT; INFECTIONS; ENGLAND; MRSA	Hospital-acquired infections (HAI) are often seen as preventable incidents that result from unsafe practices or poor hospital hygiene. This however ignores the fact that transmissibility is not only a property of the causative organisms but also of the hosts who can translocate bacteria when moving between hospitals. In an epidemiological sense, hospitals become connected through the patients they share. We here postulate that the degree of hospital connectedness crucially influences the rates of infections caused by hospital-acquired bacteria. To test this hypothesis, we mapped the movement of patients based on the UK-NHS Hospital Episode Statistics and observed that the proportion of patients admitted to a hospital after a recent episode in another hospital correlates with the hospital-specific incidence rate of MRSA bacteraemia as recorded by mandatory reporting. We observed a positive correlation between hospital connectedness and MRSA bacteraemia incidence rate that is significant for all financial years since 2001 except for 2008-09. All years combined, this correlation is positive and significantly different from zero (partial correlation coefficient r = 0.33 (0.28 to 0.38)). When comparing the referral pattern for English hospitals with referral patterns observed in the Netherlands, we predict that English hospitals more likely see a swifter and more sustained spread of HAIs. Our results indicate that hospitals cannot be viewed as individual units but rather should be viewed as connected elements of larger modular networks. Our findings stress the importance of cooperative effects that will have a bearing on the planning of health care systems, patient management and hospital infection control.	[Donker, Tjibbe; Grundmann, Hajo] Univ Groningen, Univ Med Ctr Groningen, Dept Med Microbiol, NL-9713 AV Groningen, Netherlands; [Donker, Tjibbe; Wallinga, Jacco; Grundmann, Hajo] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, NL-3720 BA Bilthoven, Netherlands; [Wallinga, Jacco] Univ Med Ctr Utrecht, Julius Ctr Hlth Res & Primary Care, Utrecht, Netherlands; [Slack, Richard] Hlth Protect Agcy, Nottingham, England	University of Groningen; Netherlands National Institute for Public Health & the Environment; Utrecht University; Utrecht University Medical Center; Health Protection Agency	Donker, T (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Med Microbiol, NL-9713 AV Groningen, Netherlands.	hajo.grundmann@rivm.nl	Wallinga, Jacco/C-4382-2018	Wallinga, Jacco/0000-0003-1725-5627; Donker, Tjibbe/0000-0001-9022-4240	National Institute for Public Health and the Environment (RIVM); Dutch Ministry of Health, Welfare and Sport	National Institute for Public Health and the Environment (RIVM); Dutch Ministry of Health, Welfare and Sport	This study was funded by the Strategic Research Fund of the National Institute for Public Health and the Environment (RIVM) and the Dutch Ministry of Health, Welfare and Sport. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Anderson TK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026798; Ansari F, 2009, CLIN INFECT DIS, V49, P1496, DOI 10.1086/644617; Baquero F, 2004, NAT REV MICROBIOL, V2, P510, DOI 10.1038/nrmicro909; Clauset A, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.026132; Cooper BS, 2004, P NATL ACAD SCI USA, V101, P10223, DOI 10.1073/pnas.0401324101; Cunningham JB, 2005, J HOSP INFECT, V61, P189, DOI 10.1016/j.jhin.2005.04.014; *DEP HLTH, 2007, HOSP ORG SPEC MIX MR; Department of Health website, MRSA SURV SYST RES; Donker T, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000715; Dziekan G, 2000, J HOSP INFECT, V46, P263, DOI 10.1053/jhin.2000.0846; Enright MC, 2002, P NATL ACAD SCI USA, V99, P7687, DOI 10.1073/pnas.122108599; Eveillard M, 2001, INFECT CONT HOSP EP, V22, P693, DOI 10.1086/501847; Grundmann H, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000215; Halwani M, 2006, J HOSP INFECT, V63, P39, DOI 10.1016/j.jhin.2005.10.012; Hao DP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028322; Harbarth S, 2000, J HOSP INFECT, V46, P43, DOI 10.1053/jhin.2000.0798; Health Protection Agency, HLTH PROT AG MAND SU; Higgins A, 2010, J HOSP INFECT, V75, P120, DOI 10.1016/j.jhin.2009.12.014; Huang S, 2010, INFECT CONT HOSP EP, V31, P1160, DOI 10.1086/656747; Iwashyna TJ, 2009, MED CARE, V47, P787, DOI 10.1097/MLR.0b013e318197b1f5; Karkada UH, 2011, INTENS CARE MED, V37; Natarajan M, 2006, J QUANT CRIMINOL, V22, P171, DOI 10.1007/s10940-006-9007-x; Newman MEJ, 2003, SIAM REV, V45, P167, DOI 10.1137/S003614450342480; Raleigh VS, 1997, J EPIDEMIOL COMMUN H, V51, P649, DOI 10.1136/jech.51.6.649; Ravasz E, 2002, SCIENCE, V297, P1551, DOI 10.1126/science.1073374; Robotham JV, 2007, J HOSP INFECT, V65, P93, DOI 10.1016/S0195-6701(07)60023-1; Salathe M, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000736; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725; Vicca AF, 1999, J HOSP INFECT, V43, P109, DOI 10.1053/jhin.1999.0246; Woods LM, 2005, J EPIDEMIOL COMMUN H, V59, P115, DOI 10.1136/jech.2003.013003	32	72	72	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2012	7	4							e35002	10.1371/journal.pone.0035002	http://dx.doi.org/10.1371/journal.pone.0035002			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959VP	22558106	gold, Green Published, Green Submitted			2023-01-03	WOS:000305345200017
J	Hesselink, G; Schoonhoven, L; Barach, P; Spijker, A; Gademan, P; Kalkman, C; Liefers, J; Vernooij-Dassen, M; Wollersheim, H				Hesselink, Gijs; Schoonhoven, Lisette; Barach, Paul; Spijker, Anouk; Gademan, Petra; Kalkman, Cor; Liefers, Janine; Vernooij-Dassen, Myrra; Wollersheim, Hub			Improving Patient Handovers From Hospital to Primary Care A Systematic Review	ANNALS OF INTERNAL MEDICINE			English	Review							LIAISON PHARMACY SERVICE; PATIENTS AFTER-DISCHARGE; ADVERSE DRUG EVENTS; QUALITY-OF-LIFE; HEART-FAILURE; FOLLOW-UP; EMERGENCY-DEPARTMENT; GERIATRIC ASSESSMENT; SUPPORTED DISCHARGE; TRANSITIONAL CARE	Background: Evidence shows that suboptimum handovers at hospital discharge lead to increased rehospitalizations and decreased quality of health care. Purpose: To systematically review interventions that aim to improve patient discharge from hospital to primary care. Data Sources: PubMed, CINAHL, PsycInfo, the Cochrane Library, and EMBASE were searched for studies published between January 1990 and March 2011. Study Selection: Randomized, controlled trials of interventions that aimed to improve handovers between hospital and primary care providers at hospital discharge. Data Extraction: Two reviewers independently abstracted data on study objectives, setting and design, intervention characteristics, and outcomes. Studies were categorized according to methodological quality, sample size, intervention characteristics, outcome, statistical significance, and direction of effects. Data Synthesis: Of the 36 included studies, 25 (69.4%) had statistically significant effects in favor of the intervention group and 34 (94.4%) described multicomponent interventions. Effective interventions included medication reconciliation; electronic tools to facilitate quick, clear, and structured summary generation; discharge planning; shared involvement in follow-up by hospital and community care providers; use of electronic discharge notifications; and Web-based access to discharge information for general practitioners. Statistically significant effects were mostly found in reducing hospital use (for example, rehospitalizations), improvement of continuity of care (for example, accurate discharge information), and improvement of patient status after discharge (for example, satisfaction). Limitations: Heterogeneity of the interventions and study characteristics made meta-analysis impossible. Most studies had diffuse aims and poor descriptions of the specific intervention components. Conclusion: Many interventions have positive effects on patient care. However, given the complexity of interventions and outcome measures, the literature does not permit firm conclusions about which interventions have these effects.	[Hesselink, Gijs] Radboud Univ Nijmegen, Med Ctr, Sci Inst Qual Healthcare IQ Healthcare, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Utrecht, Utrecht, Netherlands	Radboud University Nijmegen; Utrecht University; Utrecht University Medical Center	Hesselink, G (corresponding author), Radboud Univ Nijmegen, Med Ctr, Sci Inst Qual Healthcare IQ Healthcare, POB 9101,IQ 114, NL-6500 HB Nijmegen, Netherlands.	g.hesselink@iq.umcn.nl	Vernooij-Dassen, M.J.F.J./H-8107-2014; Wollersheim, H.C.H./L-4769-2015; Spijker, Anouk/AAD-7834-2020; Barach, Paul/AAX-5315-2020; Hesselink, Gijs/E-1619-2016; Liefers, Janine/I-4359-2016; Schoonhoven, Lisette/O-3330-2013; Kalkman, Cor/O-3215-2019; Barach, paul/B-9915-2016	Barach, Paul/0000-0002-7906-698X; Liefers, Janine/0000-0003-2719-547X; Kalkman, Cor/0000-0002-8372-6960; Barach, paul/0000-0002-7906-698X; Hesselink, Gijs/0000-0003-2532-0724	European Union, the Framework Programme of the European Commission; European Union, the Framework Programme of the European Commission [FP7-HEALTH-F2-2008-223409]; European Union, the Framework Programme of the European Health Commission	European Union, the Framework Programme of the European Commission; European Union, the Framework Programme of the European Commission; European Union, the Framework Programme of the European Health Commission	By the European Union, the Framework Programme of the European Commission (FP7-HEALTH-F2-2008-223409).; Mr. Hesselink: Grant (money to institution): European Union, the Framework Programme of the European Health Commission; Support for travel to meetings for the study or other purposes: European Union, the Framework Programme of the European Health Commission. Dr. Schoonhoven: Grant (money to institution): European Union, the Framework Programme of the European Health Commission. Dr. Barach: Grant (money to institution): European Union, the Framework Programme of the European Health Commission; Support for travel to meetings for the study or other purposes: European Union, the Framework Programme of the European Health Commission. Dr. Gademan: Grant (money to institution): European Union, the Framework Programme of the European Health Commission. Dr. Kalkman: Grant (money to institution): European Union; Support for travel to meetings for the study or other purposes: European Union. Dr. Vernooij-Dassen: Grant (money to institution): European Union; Support for travel to meetings for the study or other purposes: European Union; Employment: Radboud University Nijmegen; Grants/grants pending (money to institution): European Union. Dr. Wollersheim: Grant (money to institution): European Union, the Framework Programme of the European Health Commission; Support for travel to meetings for the study or other purposes: European Union, the Framework Programme of the European Health Commission. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M11-2696.	Afilalo Marc, 2007, CJEM, V9, P79; Akbari A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005471.pub2; Arbaje AI, 2010, J AM GERIATR SOC, V58, P364, DOI 10.1111/j.1532-5415.2009.02682.x; Arora VM, 2009, J HOSP MED, V4, P433, DOI 10.1002/jhm.573; Atwal A, 2002, J ADV NURS, V39, P450, DOI 10.1046/j.1365-2648.2002.02310.x; Avlund K., 2002, SCAND J OCCUP THER, V9, P17; Bolas H, 2004, PHARM WORLD SCI, V26, P114, DOI 10.1023/B:PHAR.0000018601.11248.89; Boockvar K, 2004, ARCH INTERN MED, V164, P545, DOI 10.1001/archinte.164.5.545; Brand Sarah L, 2006, Intensive Crit Care Nurs, V22, P106, DOI 10.1016/j.iccn.2005.04.003; Caplan GA, 2004, J AM GERIATR SOC, V52, P1417, DOI 10.1111/j.1532-5415.2004.52401.x; Chen YF, 2010, INT J MED INFORM, V79, P167, DOI 10.1016/j.ijmedinf.2009.12.006; Chiu WK, 2007, PROF CASE MANAG, V12, P330; Clare J, 1998, Aust J Adv Nurs, V16, P7; Coleman EA, 2003, J AM GERIATR SOC, V51, P549, DOI 10.1046/j.1532-5415.2003.51185.x; Connolly M, 2009, J CLIN NURS, V18, P549, DOI 10.1111/j.1365-2702.2008.02551.x; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; Crotty Maria, 2004, Am J Geriatr Pharmacother, V2, P257, DOI 10.1016/j.amjopharm.2005.01.001; Eggink RN, 2010, PHARM WORLD SCI, V32, P759, DOI 10.1007/s11096-010-9433-6; Forster AJ, 2004, CAN MED ASSOC J, V170, P345; Forster AJ, 2003, ANN INTERN MED, V138, P161, DOI 10.7326/0003-4819-138-3-200302040-00007; Graumlich JF, 2009, J HOSP MED, V4, P356, DOI [10.1002/jhm.469, 10.1002/jhm.565]; Grimshaw J, 2003, QUAL SAF HEALTH CARE, V12, P298, DOI 10.1136/qhc.12.4.298; Hansen LO, 2011, ANN INTERN MED, V155, P520, DOI 10.7326/0003-4819-155-8-201110180-00008; Harrison MB, 2002, MED CARE, V40, P271, DOI 10.1097/00005650-200204000-00003; Helleso R, 2004, INT J MED INFORM, V73, P569, DOI 10.1016/j.ijmedinf.2004.04.009; Helleso Ragnhild, 2010, Int J Integr Care, V10, pe036; Indredavik B, 2000, STROKE, V31, P2989, DOI 10.1161/01.STR.31.12.2989; Institute for Healthcare Improvement, 2012, STAT ACT AV REH STAA; Jack BW, 2009, ANN INTERN MED, V150, P178, DOI 10.7326/0003-4819-150-3-200902030-00007; Johnson JK, 2009, QUAL SAF HEALTH CARE, V18, P244, DOI 10.1136/qshc.2009.032946; King TL, 2008, IMPACT NURSE DRIVEN; Koehler BE, 2009, J HOSP MED, V4, P211, DOI 10.1002/jhm.427; Kripalani S, 2007, JAMA-J AM MED ASSOC, V297, P831, DOI 10.1001/jama.297.8.831; Kwok T, 2004, J AM GERIATR SOC, V52, P1240, DOI 10.1111/j.1532-5415.2004.52351.x; Lalonde L, 2008, AM J HEALTH-SYST PH, V65, P1451, DOI 10.2146/ajhp070565; Lilford R, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c2016; Lim WK, 2003, MED J AUSTRALIA, V178, P262, DOI 10.5694/j.1326-5377.2003.tb05191.x; Lin PC, 2009, J CLIN NURS, V18, P1632, DOI 10.1111/j.1365-2702.2008.02695.x; Macdonald GM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub2; Maslove DM, 2009, J GEN INTERN MED, V24, P995, DOI 10.1007/s11606-009-1053-2; Mayo NE, 2008, AGE AGEING, V37, P32, DOI 10.1093/ageing/afm133; McInnes E, 1999, FAM PRACT, V16, P289, DOI 10.1093/fampra/16.3.289; McKenna H, 2000, J CLIN NURS, V9, P594, DOI 10.1046/j.1365-2702.2000.00384.x; McKeown F, 2007, J CLIN NURS, V16, P469, DOI 10.1111/j.1365-2702.2006.01556.x; Mistiaen P, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004510.pub3; Mistiaen P, 1997, J ADV NURS, V25, P1233, DOI 10.1046/j.1365-2648.1997.19970251233.x; Mistiaen P, 2007, HOSP DISCHARGE PROBL; Mistiaen P, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-47; Moore C, 2003, J GEN INTERN MED, V18, P646, DOI 10.1046/j.1525-1497.2003.20722.x; Murtaugh CM, 2002, MED CARE, V40, P227; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; Naylor MD, 2004, J AM GERIATR SOC, V52, P675, DOI 10.1111/j.1532-5415.2004.52202.x; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; Nazareth I, 2001, AGE AGEING, V30, P33, DOI 10.1093/ageing/30.1.33; Parker S G, 2002, Health Technol Assess, V6, P1; Preen DB, 2005, INT J QUAL HEALTH C, V17, P43, DOI 10.1093/intqhc/mzi002; Raduma-Tomas MA, 2011, BMJ QUAL SAF, V20, P128, DOI 10.1136/bmjqs.2009.034389; RICH MW, 1993, J GEN INTERN MED, V8, P585, DOI 10.1007/BF02599709; Rutherford A, 2001, Aust Fam Physician, V30, P1101; Rytter L, 2010, SCAND J PRIM HEALTH, V28, P146, DOI 10.3109/02813431003764466; Schnipper JL, 2009, ARCH INTERN MED, V169, P771, DOI 10.1001/archinternmed.2009.51; Schnipper JL, 2006, ARCH INTERN MED, V166, P565, DOI 10.1001/archinte.166.5.565; Shepperd S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000313.pub4; Shyu YIL, 2010, J AM GERIATR SOC, V58, P1081, DOI 10.1111/j.1532-5415.2010.02882.x; Siu AL, 1996, ARCH INTERN MED, V156, P76, DOI 10.1001/archinte.156.1.76; Society of Hospital Medicine, 2008, BOOSTING CAR TRANS R; Tripp JS, 2009, DEV EVALUATION NOTIF; van Walraven C, 2002, J GEN INTERN MED, V17, P186, DOI 10.1046/j.1525-1497.2002.10741.x; van Walraven C, 1999, CAN MED ASSOC J, V160, P319; Vuong T., 2008, INT J PHARM PRACT, V16, P127, DOI [DOI 10.1211/ijpp.16.3.0002, 10.1211/ijpp.16.3.0002]; Wells M, 2004, BRIT J CANCER, V91, P651, DOI 10.1038/sj.bjc.6601998	71	213	219	1	57	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 18	2012	157	6					417	U81		10.7326/0003-4819-157-6-201209180-00006	http://dx.doi.org/10.7326/0003-4819-157-6-201209180-00006			20	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	007UB	22986379	Green Published			2023-01-03	WOS:000308912800016
J	Han, SW; Cha, Y; Paquet, A; Huang, WD; Weidler, J; Lie, Y; Sherwood, T; Bates, M; Haddad, M; Park, IH; Oh, DY; Lee, KS; Im, SA; Bang, YJ; Ro, J; Kim, TY				Han, Sae-Won; Cha, Yongjun; Paquet, Agnes; Huang, Weidong; Weidler, Jodi; Lie, Yolanda; Sherwood, Thomas; Bates, Michael; Haddad, Mojgan; Park, In Hae; Oh, Do-Youn; Lee, Keun Seok; Im, Seock-Ah; Bang, Yung-Jue; Ro, Jungsil; Kim, Tae-You			Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer	PLOS ONE			English	Article							ADJUVANT CHEMOTHERAPY; ERBB RECEPTORS; TRASTUZUMAB; EFFICACY; THERAPY; PROTEIN; QUANTITATION; ONCOGENE; ANTIBODY	Background: Lapatinib plus capecitabine is an effective treatment option for trastuzumab-refractory HER2-positive metastatic breast cancer. We have investigated the correlation between quantitative measures of HER2, p95HER2, and HER3 and treatment outcomes using lapatinib and capecitabine. Methods: Total HER2 (H2T), p95HER2 (p95), and total HER3 (H3T) expression were quantified in formalin-fixed paraffinembedded samples using the VeraTag assays. Patients received lapatinib and capecitabine treatment following trastuzumab failure according to the Lapatinib Expanded Access Program. The association between the protein expression levels and clinical outcomes was analyzed. Results: A total of 52 patients were evaluable. H2T level was significantly higher in responders (median 93.49 in partial response, 47.66 in stable disease, and 17.27 in progressive disease; p = 0.020). Longer time-to-progression (TTP) was observed in patients with high H2T [p = 0.018, median 5.2 months in high (> 14.95) vs. 1.8 in low (< 14.95)] and high H3T [p = 0.017, median 5.0 months in high (> 0.605) vs. 2.2 in low (< 0.605)]. Patients having both high H2T and high H3T had significantly longer TTP [adjusted hazard ratio (HR) 0.38 (95% CI 0.20-0.73), p = 0.004] and overall survival [adjusted HR 0.46 (95% CI 0.24-0.89), p = 0.020]. No significant association between p95 and response or survival was observed. Conclusions: These data suggest a correlation between high HER2 and high HER3 expression and treatment outcome, while no significant difference was observed between clinical outcome and p95 expression level in this cohort of HER2-positive, trastuzumab-refractory metastatic breast cancer patients treated with lapatinib and capecitabine.	[Han, Sae-Won; Cha, Yongjun; Oh, Do-Youn; Im, Seock-Ah; Bang, Yung-Jue; Kim, Tae-You] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea; [Han, Sae-Won; Oh, Do-Youn; Im, Seock-Ah; Bang, Yung-Jue; Kim, Tae-You] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea; [Paquet, Agnes; Huang, Weidong; Weidler, Jodi; Lie, Yolanda; Sherwood, Thomas; Bates, Michael; Haddad, Mojgan] Monogram Biosci Inc, San Francisco, CA USA; [Park, In Hae; Lee, Keun Seok; Ro, Jungsil] Natl Canc Ctr, Ctr Breast Canc, Goyang, South Korea; [Kim, Tae-You] Seoul Natl Univ, Dept Mol Med & Biopharmaceut Sci, Grad Sch Convergence Sci & Technol, Seoul, South Korea	Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); National Cancer Center - Korea (NCC); Seoul National University (SNU)	Han, SW (corresponding author), Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea.	jungsro@ncc.re.kr; kimty@snu.ac.kr	Bang, Yung Jue/J-2759-2012; Im, Seock-Ah/J-5620-2012	Bang, Yung Jue/0000-0001-6000-4597; 	Korean Healthcare Technology R&D project, Ministry for Health, Welfare & Family Affairs, Republic of Korea [A091081]; Cancer Research Institute, Seoul National University	Korean Healthcare Technology R&D project, Ministry for Health, Welfare & Family Affairs, Republic of Korea; Cancer Research Institute, Seoul National University	This study was supported by grants from the Korean Healthcare Technology R&D project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (A091081) and from Cancer Research Institute, Seoul National University (2009). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALIMANDI M, 1995, ONCOGENE, V10, P1813; Arribas J, 2011, CANCER RES, V71, P1515, DOI 10.1158/0008-5472.CAN-10-3795; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Goodman LJ, 2009, ASCO M, P1021; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hsieh AC, 2007, BRIT J CANCER, V97, P453, DOI 10.1038/sj.bjc.6603910; Huang WD, 2010, AM J CLIN PATHOL, V134, P303, DOI 10.1309/AJCP3BZY4YAFNTRG; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Larson JS, 2010, PATHOLOG RES INT; Lipton A, 2010, CANCER-AM CANCER SOC, V116, P5168, DOI 10.1002/cncr.25430; Menendez JA, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1773; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Motoyama AB, 2002, CANCER RES, V62, P3151; Naidu R, 1998, BRIT J CANCER, V78, P1385, DOI 10.1038/bjc.1998.689; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Scaltriti M, 2010, CLIN CANCER RES, V16, P2688, DOI 10.1158/1078-0432.CCR-09-3407; Seidman AD, 2001, J CLIN ONCOL, V19, P2587, DOI 10.1200/JCO.2001.19.10.2587; Shi YN, 2009, DIAGN MOL PATHOL, V18, P11, DOI 10.1097/PDM.0b013e31818cbdb2; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smith BL, 2004, BRIT J CANCER, V91, P1190, DOI 10.1038/sj.bjc.6602090; Sperinde J, 2010, CLIN CANCER RES, V16, P4226, DOI 10.1158/1078-0432.CCR-10-0410; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Xia WL, 2004, ONCOGENE, V23, P646, DOI 10.1038/sj.onc.1207166	29	20	25	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2012	7	7							e39943	10.1371/journal.pone.0039943	http://dx.doi.org/10.1371/journal.pone.0039943			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981ER	22848366	Green Submitted, Green Published, gold			2023-01-03	WOS:000306950200015
J	Chisti, MJ; Ahmed, T; Ashraf, H; Faruque, ASG; Bardhan, PK; Dey, SK; Huq, S; Das, SK; Salam, MA				Chisti, Mohammod J.; Ahmed, Tahmeed; Ashraf, Hasan; Faruque, A. S. G.; Bardhan, Pradip K.; Dey, Sanjoy Kumer; Huq, Sayeeda; Das, Sumon Kumar; Salam, Mohammed A.			Clinical Predictors and Outcome of Metabolic Acidosis in Under-Five Children Admitted to an Urban Hospital in Bangladesh with Diarrhea and Pneumonia	PLOS ONE			English	Article							SEVERELY MALNOURISHED CHILDREN; INFLAMMATORY RESPONSE SYNDROME; SEPTIC SHOCK; DEHYDRATION; MANAGEMENT; MORTALITY; INFANTS; MALNUTRITION; FEATURES; SEPSIS	Background: Clinical features of metabolic acidosis and pneumonia frequently overlap in young diarrheal children, resulting in differentiation from each other very difficult. However, there is no published data on the predictors of metabolic acidosis in diarrheal children also having pneumonia. Our objective was to evaluate clinical predictors of metabolic acidosis in under-five diarrheal children with radiological pneumonia, and their outcome. Methods: We prospectively enrolled all under-five children (n = 164) admitted to the Special Care Ward (SCW) of the Dhaka Hospital of icddr, b between September and December 2007 with diarrhea and radiological pneumonia who also had their total serum carbon-dioxide estimated. We compared the clinical features and outcome of children with radiological pneumonia and diarrhea with (n = 98) and without metabolic acidosis (n = 66). Results: Children with metabolic acidosis more often had higher case-fatality (16% vs. 5%, p = 0.039) compared to those without metabolic acidosis on admission. In logistic regression analysis, after adjusting for potential confounders such as age of the patient, fever on admission, and severe wasting, the independent predictors of metabolic acidosis in under-five diarrheal children having pneumonia were clinical dehydration (OR 3.57, 95% CI 1.62-7.89, p = 0.002), and low systolic blood pressure even after full rehydration (OR 1.02, 95% CI 1.01-1.04, p = 0.005). Proportions of children with cough, respiratory rate/minute, lower chest wall indrawing, nasal flaring, head nodding, grunting respiration, and cyanosis were comparable (p>0.05) among the groups. Conclusion and Significance: Under-five diarrheal children with radiological pneumonia having metabolic acidosis had frequent fatal outcome than those without acidosis. Clinical dehydration and persistent systolic hypotension even after adequate rehydration were independent clinical predictors of metabolic acidosis among the children. However, metabolic acidosis in young diarrheal children had no impact on the diagnostic clinical features of radiological pneumonia which underscores the importance of early initiation of appropriate antibiotics to combat morbidity and deaths in such population.	[Chisti, Mohammod J.; Bardhan, Pradip K.] Bangladesh icddr b, Int Ctr Diarhoeal Dis Res, CS, Dhaka, Bangladesh; [Chisti, Mohammod J.; Ahmed, Tahmeed; Ashraf, Hasan; Faruque, A. S. G.; Bardhan, Pradip K.; Huq, Sayeeda; Das, Sumon Kumar] Icddr b, CNFS, Dhaka, Bangladesh; [Dey, Sanjoy Kumer] BSMMU, Dept Neonatol, Dhaka, Bangladesh; [Salam, Mohammed A.] Icddr b, RAS, Dhaka, Bangladesh	International Centre for Diarrhoeal Disease Research (ICDDR); International Centre for Diarrhoeal Disease Research (ICDDR); Bangabandhu Sheikh Mujib Medical University (BSMMU); International Centre for Diarrhoeal Disease Research (ICDDR)	Chisti, MJ (corresponding author), Bangladesh icddr b, Int Ctr Diarhoeal Dis Res, CS, Dhaka, Bangladesh.	chisti@icddrb.org	Das, Sumon Kumar/AAD-1551-2019; Das, Sumon Kumar/T-6384-2019; Chisti, Mohammod J/A-7216-2018; Dey, Sanjoy Kumer/AAN-6937-2020		Dhaka Hospital of International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR) [Gr-00233]	Dhaka Hospital of International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR)	This research study was funded by the Dhaka Hospital of International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B; grant no Gr-00233) and its donors, which provide unrestricted support to ICDDR, B for its operations and research. Current donors providing unrestricted support include: Australian Agency for International Development, Government of the People's Republic of Bangladesh, Canadian International Development Agency, Swedish International Development Cooperation Agency, and the Department for International Development, United Kingdom. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AHMED SM, 1986, SCAND J INFECT DIS, V18, P65, DOI 10.3109/00365548609032308; Ahmed T, 1999, LANCET, V353, P1919, DOI 10.1016/S0140-6736(98)07499-6; Alam Nure H, 2003, Paediatr Drugs, V5, P151, DOI 10.2165/00128072-200305030-00002; Annane D, 2005, LANCET, V365, P63, DOI 10.1016/S0140-6736(04)17667-8; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Chisti MJ, 2011, ANN TROP PAEDIATR, V31, P311, DOI 10.1179/1465328111Y.0000000033; Chisti MJ, 2010, ANN TROP PAEDIATR, V30, P311, DOI 10.1179/146532810X12858955921230; Chisti MJ, 2012, TROP MED INT HLTH; Chisti MJ, 2011, ACTA PAEDIATR, V100, pE275, DOI 10.1111/j.1651-2227.2011.02368.x; Chisti MJ, 2010, TROP MED INT HEALTH, V15, P1322, DOI 10.1111/j.1365-3156.2010.02619.x; Chisti MJ, 2010, PEDIATR CRIT CARE ME, V11, P92, DOI 10.1097/PCC.0b013e3181b063e1; Chisti MJ, 2010, PEDIATR INFECT DIS J, V29, P174, DOI 10.1097/INF.0b013e3181b9a4d5; Chisti MJ, 2009, TROP MED INT HEALTH, V14, P1173, DOI 10.1111/j.1365-3156.2009.02364.x; Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41; Ebrahim GJ, 2011, J TROP PEDIATRICS, V57, P77, DOI 10.1093/tropej/fmr022; Greenbaum LA, 2012, NELSON TXB PAEDIAT, P267; Morgan G, 1997, LANCET, V349, P1693, DOI 10.1016/S0140-6736(96)12038-9; NATHOO KJ, 1987, CENT AFR J MED, V33, P200; RICHARDS L, 1993, PEDIATR INFECT DIS J, V12, P5, DOI 10.1097/00006454-199301000-00003; Said M, 1980, Paediatr Indones, V20, P68; Salam MA, 2002, SAN DIEG CA 42 INT C; Suskind DMK, 1990, MALNOURISHED CHILD; Vega RM, 1997, PEDIATR EMERG CARE, V13, P179, DOI 10.1097/00006565-199706000-00001; WANG F, 1986, NEW ENGL J MED, V315, P1591, DOI 10.1056/NEJM198612183152506; World Health Organization, 1990, AC RESP INF CHILDR C; World Health Organization, 1999, MAN SEV MALN MAN PHY	26	19	19	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 15	2012	7	6							e39164	10.1371/journal.pone.0039164	http://dx.doi.org/10.1371/journal.pone.0039164			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959WX	22720060	Green Published, gold, Green Submitted			2023-01-03	WOS:000305350000045
J	Daley, GQ				Daley, George Q.			The Promise and Perils of Stem Cell Therapeutics	CELL STEM CELL			English	Review							UMBILICAL-CORD BLOOD; PANCREATIC BETA-CELLS; PARKINSONS-DISEASE; SPINAL-CORD; BONE-MARROW; DOPAMINE NEURONS; IN-VIVO; ISLET TRANSPLANTATION; CLINICAL-TRIALS; HUMAN ES	Stem cells are the seeds of tissue repair and regeneration and a promising source for novel therapies. However, apart from hematopoietic stem cell (HSC) transplantation, essentially all other stem cell treatments remain experimental. High hopes have inspired numerous clinical trials, but it has been difficult to obtain unequivocal evidence for robust clinical benefit. In recent years, unproven therapies have been widely practiced outside the standard clinical trial network, threatening the cause of legitimate clinical investigation. Numerous challenges and technical barriers must be overcome before novel stem cell therapies can achieve meaningful clinical impact.	[Daley, George Q.] Childrens Hosp Boston, Howard Hughes Med Inst, Stem Cell Transplantat Program, Div Pediat Hematol Oncol,Manton Ctr Orphan Dis Re, Boston, MA 02115 USA; [Daley, George Q.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA; [Daley, George Q.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Daley, George Q.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Daley, George Q.] Broad Inst, Cambridge, MA 02142 USA; [Daley, George Q.] Harvard Stem Cell Inst, Boston, MA 02138 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University	Daley, GQ (corresponding author), Childrens Hosp Boston, Howard Hughes Med Inst, Stem Cell Transplantat Program, Div Pediat Hematol Oncol,Manton Ctr Orphan Dis Re, Boston, MA 02115 USA.	george.daley@childrens.harvard.edu			NIH [R24DK092760, UO1-HL100001, RC4-DK090913, P50HG005550]; ARRA [RC2-HL102815]; Roche Foundation for Anemia Research; Alex's Lemonade Stand; Ellison Medical Foundation; Doris Duke Medical Foundation; Harvard Stem Cell Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [RC2HL102815, U01HL100001] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG005550] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [RC4DK090913, R24DK092760] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ARRA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Roche Foundation for Anemia Research; Alex's Lemonade Stand; Ellison Medical Foundation(Lawrence Ellison Foundation); Doris Duke Medical Foundation(Doris Duke Charitable Foundation (DDCF)); Harvard Stem Cell Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	G.Q.D. is supported by grants from the NIH (R24DK092760, UO1-HL100001, RC4-DK090913, P50HG005550, and special funds from the ARRA stimulus package- RC2-HL102815), the Roche Foundation for Anemia Research, Alex's Lemonade Stand, Ellison Medical Foundation, Doris Duke Medical Foundation, and the Harvard Stem Cell Institute. G.Q.D. is an affiliate member of the Broad Institute and an investigator of the Howard Hughes Medical Institute and the Manton Center for Orphan Disease Research. Disclosure: GOD is a member of the scientific advisory board and receives consulting fees and holds equity in the following companies that work with stem cells: Johnson & Johnson, Verastem, iPierian, and MPM Capital.	Aboushwareb T, 2008, NAT CLIN PRACT UROL, V5, P621, DOI 10.1038/ncpuro1228; Amariglio N, 2009, PLOS MED, V6, P221, DOI 10.1371/journal.pmed.1000029; Atala A, 2011, BRIT MED BULL, V97, P81, DOI 10.1093/bmb/ldr003; Baker M, 2011, NATURE, V479, P459, DOI 10.1038/479459a; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Benraiss A, 2011, NEUROTHERAPEUTICS, V8, P577, DOI 10.1007/s13311-011-0075-8; Bonner-Weir S, 2005, NAT BIOTECHNOL, V23, P857, DOI 10.1038/nbt1115; Chambers SM, 2009, NAT BIOTECHNOL, V27, P275, DOI 10.1038/nbt.1529; Cheng X, 2012, CELL STEM CELL, V10, P371, DOI 10.1016/j.stem.2012.02.024; Choi YH, 2011, HUM GENE THER, V22, P3, DOI 10.1089/hum.2010.211; Copeland N, 2009, CLIN MED, V9, P342, DOI 10.7861/clinmedicine.9-4-342; D'Amour KA, 2006, NAT BIOTECHNOL, V24, P1392, DOI 10.1038/nbt1259; Daley GQ, 2008, CELL, V132, P544, DOI 10.1016/j.cell.2008.02.009; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Dor Y, 2008, CELL, V132, P183, DOI 10.1016/j.cell.2008.01.004; Fasano CA, 2010, CELL STEM CELL, V6, P336, DOI 10.1016/j.stem.2010.03.001; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; Gallina P, 2010, EXP NEUROL, V222, P30, DOI 10.1016/j.expneurol.2009.12.005; Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826; Gourraud PA, 2012, STEM CELLS, V30, P180, DOI 10.1002/stem.772; Griffin M, 2011, J BONE JOINT SURG BR, V93B, P427, DOI 10.1302/0301-620X.93B4.25249; Grskovic M, 2011, NAT REV DRUG DISCOV, V10, P915, DOI 10.1038/nrd3577; Hargus G, 2010, P NATL ACAD SCI USA, V107, P15921, DOI 10.1073/pnas.1010209107; Harris DT, 2009, BRIT J HAEMATOL, V147, P177, DOI 10.1111/j.1365-2141.2009.07767.x; Hjelmgren J, 2006, PARKINSONISM RELAT D, V12, P443, DOI 10.1016/j.parkreldis.2006.04.006; Hyun I, 2008, CELL STEM CELL, V3, P607, DOI 10.1016/j.stem.2008.11.009; JACOBSON LO, 1951, SCIENCE, V113, P510, DOI 10.1126/science.113.2940.510; Kebriaei P, 2011, CYTOTHERAPY, V13, P262, DOI 10.3109/14653249.2010.549688; Keirstead HS, 2005, J NEUROSCI, V25, P4694, DOI 10.1523/JNEUROSCI.0311-05.2005; Kode JA, 2009, CYTOTHERAPY, V11, P377, DOI 10.1080/14653240903080367; Kogler G, 2004, J EXP MED, V200, P123, DOI 10.1084/jem.20040440; Kriks S, 2011, NATURE, V480, P547, DOI 10.1038/nature10648; Kroon E, 2008, NAT BIOTECHNOL, V26, P443, DOI 10.1038/nbt1393; Lau D, 2008, CELL STEM CELL, V3, P591, DOI 10.1016/j.stem.2008.11.001; Ledford H, 2011, NATURE, V477, P526, DOI 10.1038/477526a; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; LINDVALL O, 1994, ANN NEUROL, V35, P172, DOI 10.1002/ana.410350208; Lindvall O, 2010, J CLIN INVEST, V120, P29, DOI 10.1172/JCI40543; Liu S, 2000, P NATL ACAD SCI USA, V97, P6126, DOI 10.1073/pnas.97.11.6126; LORENZ E, 1951, J NATL CANCER I, V12, P197; Ma YL, 2010, J NUCL MED, V51, P7, DOI 10.2967/jnumed.109.066811; Macchiarini P, 2008, LANCET, V372, P2023, DOI 10.1016/S0140-6736(08)61598-6; McDonald JW, 2006, J NEUROTRAUM, V23, P345, DOI 10.1089/neu.2006.23.345; McDonald JW, 2002, PROG BRAIN RES, V137, P299; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; McKenna D, 2011, INDIAN J MED RES, V134, P261; Menasche P, 2011, J MOL CELL CARDIOL, V50, P258, DOI 10.1016/j.yjmcc.2010.06.010; Nakajima F, 2007, STEM CELLS, V25, P983, DOI 10.1634/stemcells.2006-0566; Nakamura T, 2001, ANN NEUROL, V50, P181, DOI 10.1002/ana.1075; Nicoleau C, 2011, NEUROTHERAPEUTICS, V8, P562, DOI 10.1007/s13311-011-0079-4; Nishida K, 2004, NEW ENGL J MED, V351, P1187, DOI 10.1056/NEJMoa040455; Nistor GI, 2005, GLIA, V49, P385, DOI 10.1002/glia.20127; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Peck M, 2012, CELLS TISSUES ORGANS, V195, P144, DOI 10.1159/000331406; Pelosi E, 2012, BLOOD CELL MOL DIS, V49, P20, DOI 10.1016/j.bcmd.2012.02.007; Piccini P, 2005, BRAIN, V128, P2977, DOI 10.1093/brain/awh649; Piccini P, 1999, NAT NEUROSCI, V2, P1137, DOI 10.1038/16060; Piccini P, 2000, ANN NEUROL, V48, P689, DOI 10.1002/1531-8249(200011)48:5<689::AID-ANA1>3.3.CO;2-E; Prasad VK, 2009, BONE MARROW TRANSPL, V44, P643, DOI 10.1038/bmt.2009.290; Rama P, 2010, NEW ENGL J MED, V363, P147, DOI 10.1056/NEJMoa0905955; Rocha V, 2004, NEW ENGL J MED, V351, P2276, DOI 10.1056/NEJMoa041469; Sanchez-Pernaute R, 2008, BRAIN, V131, P2127, DOI 10.1093/brain/awn144; Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2; Shapiro AMJ, 2006, NEW ENGL J MED, V355, P1318, DOI 10.1056/NEJMoa061267; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Sun Hengyun, 2011, Front Med, V5, P61, DOI 10.1007/s11684-011-0122-1; Tabar V, 2008, NAT MED, V14, P379, DOI 10.1038/nm1732; Taylor CJ, 2005, LANCET, V366, P2019, DOI 10.1016/S0140-6736(05)67813-0; Taylor CJ, 2011, PHILOS T R SOC B, V366, P2312, DOI 10.1098/rstb.2011.0030; Thomas ED, 2005, INT J HEMATOL, V81, P89, DOI 10.1532/IJH97.04197; THOMAS ED, 1957, NEW ENGL J MED, V257, P491, DOI 10.1056/NEJM195709122571102; Tian H, 2010, TISSUE ENG PT A, V16, P1769, DOI [10.1089/ten.tea.2009.0625, 10.1089/ten.TEA.2009.0625]; Tobita M, 2011, DISCOV MED, V11, P160; Tongers J, 2011, EUR HEART J, V32, P1197, DOI 10.1093/eurheartj/ehr018; Trounson A, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-52; Tsai RJ, 2000, NEW ENGL J MED, V343, P86, DOI 10.1056/NEJM200007133430202; Tsubota K, 1999, NEW ENGL J MED, V340, P1697, DOI 10.1056/NEJM199906033402201; Vierbuchen T, 2011, NAT BIOTECHNOL, V29, P892, DOI 10.1038/nbt.1946; Wernig M, 2008, P NATL ACAD SCI USA, V105, P5856, DOI 10.1073/pnas.0801677105; Williams AR, 2011, CIRC RES, V108, P792, DOI 10.1161/CIRCRESAHA.111.242610; Wilson JM, 2009, SCIENCE, V324, P727, DOI 10.1126/science.1174935; Yamanaka S, 2012, CELL STEM CELL, V10, P678, DOI 10.1016/j.stem.2012.05.005; Zhou Q, 2008, NATURE, V455, P627, DOI 10.1038/nature07314	85	182	184	1	48	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	1934-5909	1875-9777		CELL STEM CELL	Cell Stem Cell	JUN 14	2012	10	6					740	749		10.1016/j.stem.2012.05.010	http://dx.doi.org/10.1016/j.stem.2012.05.010			10	Cell & Tissue Engineering; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	965LD	22704514	Green Accepted, Bronze			2023-01-03	WOS:000305768400020
J	Yao, Z; Namkung, W; Ko, EA; Park, J; Tradtrantip, L; Verkman, AS				Yao, Zhen; Namkung, Wan; Ko, Eun A.; Park, Jinhong; Tradtrantip, Lukmanee; Verkman, A. S.			Fractionation of a Herbal Antidiarrheal Medicine Reveals Eugenol as an Inhibitor of Ca2+-Activated Cl- Channel TMEM16A	PLOS ONE			English	Article							SPRAGUE-DAWLEY RATS; CHLORIDE SECRETION; MOLECULAR-BASIS; ESSENTIAL OIL; NEURONS; PHARMACOKINETICS; EXPRESSION; CURRENTS; PROTEIN; INJURY	The Ca2+-activated Cl- channel TMEM16A is involved in epithelial fluid secretion, smooth muscle contraction and neurosensory signaling. We identified a Thai herbal antidiarrheal formulation that inhibited TMEM16A Cl- conductance. C18-reversed-phase HPLC fractionation of the herbal formulation revealed >98% of TMEM16A inhibition activity in one out of approximately 20 distinct peaks. The purified, active compound was identified as eugenol (4-allyl-2-methoxyphenol), the major component of clove oil. Eugenol fully inhibited TMEM16A Cl- conductance with single-site IC50 similar to 150 mu M. Eugenol inhibition of TMEM16A in interstitial cells of Cajal produced strong inhibition of intestinal contraction in mouse ileal segments. TMEM16A Cl- channel inhibition adds to the list of eugenol molecular targets and may account for some of its biological activities.	[Yao, Zhen; Namkung, Wan; Ko, Eun A.; Tradtrantip, Lukmanee; Verkman, A. S.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Yao, Zhen; Namkung, Wan; Ko, Eun A.; Tradtrantip, Lukmanee; Verkman, A. S.] Univ Calif San Francisco, Dept Physiol, San Francisco, CA USA; [Namkung, Wan; Park, Jinhong] Yonsei Univ, Coll Pharm, Yonsei Inst Pharmaceut Sci, Inchon, South Korea	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Yonsei University	Yao, Z (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.	Alan.Verkman@ucsf.edu			National Institutes of Health [DK72517, HL73856, DK35124, DK86125, EB00415, EY13574]; Cystic Fibrosis Foundation; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R37DK035124, P30DK072517, RC1DK086125] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by National Institutes of Health grants DK72517, HL73856, DK35124, DK86125, EB00415, and EY13574 and Research Development Program and Drug Discovery grants from the Cystic Fibrosis Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alqareer A, 2006, J DENT, V34, P747, DOI 10.1016/j.jdent.2006.01.009; Barrett KE, 2000, ANNU REV PHYSIOL, V62, P535, DOI 10.1146/annurev.physiol.62.1.535; BARTELS HA, 1947, AM J ORTHOD ORAL SUR, V33, P458; Baskaran Y, 2010, TOXICOLOGY, V268, P204, DOI 10.1016/j.tox.2009.12.018; Canani RB, 2003, GASTROENTEROLOGY, V124, P368, DOI 10.1053/gast.2003.50056; Chaieb K, 2007, PHYTOTHER RES, V21, P501, DOI 10.1002/ptr.2124; Damiani CEN, 2004, J CARDIOVASC PHARM, V44, P688, DOI 10.1097/00005344-200412000-00011; Deans S. G., 1995, Flavour and Fragrance Journal, V10, P323, DOI 10.1002/ffj.2730100507; Ferrera L, 2010, PHYSIOLOGY, V25, P357, DOI 10.1152/physiol.00030.2010; FISCHER IU, 1990, J CHROMATOGR-BIOMED, V525, P369, DOI 10.1016/S0378-4347(00)83413-1; Guenette SA, 2006, J VET PHARMACOL THER, V29, P265, DOI 10.1111/j.1365-2885.2006.00740.x; Guenette SA, 2007, EUR J PHARMACOL, V562, P60, DOI 10.1016/j.ejphar.2007.01.044; Hartzell C, 2005, ANNU REV PHYSIOL, V67, P719, DOI 10.1146/annurev.physiol.67.032003.154341; Huang F, 2009, P NATL ACAD SCI USA, V106, P21413, DOI 10.1073/pnas.0911935106; Hwang SJ, 2009, J PHYSIOL-LONDON, V587, P4887, DOI 10.1113/jphysiol.2009.176198; Kaur G, 2010, MOL CARCINOGEN, V49, P290, DOI 10.1002/mc.20601; Lee MH, 2005, J DENT RES, V84, P848, DOI 10.1177/154405910508400913; Li HY, 2007, J DENT RES, V86, P898, DOI 10.1177/154405910708600918; Lima FC, 2011, FUND CLIN PHARMACOL, V25, P690, DOI 10.1111/j.1472-8206.2010.00892.x; Lionnet L, 2010, PHYTOTHER RES, V24, P1645, DOI 10.1002/ptr.3174; Liu BY, 2010, J CLIN INVEST, V120, P1240, DOI 10.1172/JCI41084; Magalhaes CB, 2010, J APPL PHYSIOL, V108, P845, DOI 10.1152/japplphysiol.00560.2009; Namkung W, 2011, J BIOL CHEM, V286, P2365, DOI 10.1074/jbc.M110.175109; Namkung W, 2010, FASEB J, V24, P4178, DOI 10.1096/fj.10-160648; Ousingsawat J, 2011, PFLUG ARCH EUR J PHY, V461, P579, DOI 10.1007/s00424-011-0947-0; Pal D, 2010, J DERMATOL SCI, V59, P31, DOI 10.1016/j.jdermsci.2010.04.013; Park CK, 2009, PAIN, V144, P84, DOI 10.1016/j.pain.2009.03.016; Said MM, 2011, FUND CLIN PHARMACOL, V25, P708, DOI 10.1111/j.1472-8206.2010.00900.x; Takahashi A, 2000, J MED MICROBIOL, V49, P801, DOI 10.1099/0022-1317-49-9-801; THOMPSON D, 1989, MOL PHARMACOL, V36, P809; Venkatasubramanian J, 2010, CURR OPIN GASTROEN, V26, P123, DOI 10.1097/MOG.0b013e3283358a45; Wan NK, 2011, FASEB J, V25, P4048, DOI 10.1096/fj.11-191627; Yeon KY, 2011, PAIN, V152, P2108, DOI 10.1016/j.pain.2011.05.018	33	39	41	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2012	7	5							e38030	10.1371/journal.pone.0038030	http://dx.doi.org/10.1371/journal.pone.0038030			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959YF	22666439	gold, Green Published, Green Submitted			2023-01-03	WOS:000305353400071
J	Shahin, J; Harrison, DA; Rowan, KM				Shahin, Jason; Harrison, David A.; Rowan, Kathryn M.			Relation between volume and outcome for patients with severe sepsis in United Kingdom: retrospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							MIX PROGRAM DATABASE; CARE-NATIONAL-AUDIT; LENGTH-OF-STAY; INTENSIVE-CARE; MECHANICAL VENTILATION; HOSPITAL VOLUME; NORTHERN-IRELAND; HEALTH-CARE; MORTALITY; ORGANIZATION	Objective To evaluate whether a relation exists between volume and outcome for admissions with severe sepsis to adult general critical care units in the United Kingdom. Design Retrospective cohort study using data from a pooled case mix and outcome database. Setting Adult general critical care units participating in the case mix programme. Participants Consecutive admissions to participating units for the years 2008-09 meeting objective, standardised criteria for severe sepsis. Main outcome measures Mortality at ultimate discharge from acute hospital. Results The primary exposure was volume of admissions with severe sepsis per unit per year. A multivariable logistic regression analysis, using generalised estimating equations, was used to assess the association between volume, modelled using fractional polynomials, and ultimate acute hospital mortality while adjusting for potential confounders. No relation was seen between volume and outcome for admissions with severe sepsis to adult, general critical care units in the UK. Subgroup analyses tested for interactions between the effect of volume and acute severity of illness or receipt of mechanical ventilation. No significant interactions were found. Conclusions This study showed no relation between volume and outcome in admissions with severe sepsis treated in adult general critical care units in the UK.	[Shahin, Jason] McGill Univ, Dept Crit Care, Dept Med, Div Resp, Montreal, PQ H3G 1A4, Canada; [Shahin, Jason; Harrison, David A.; Rowan, Kathryn M.] ICNARC, London WC1H 9HR, England	McGill University; Intensive Care National Audit & Research Centre	Shahin, J (corresponding author), McGill Univ, Dept Crit Care, Dept Med, Div Resp, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	Jason.shahin@mcgill.ca	Harrison, David A/O-4355-2018	Harrison, David A/0000-0002-9002-9098; Rowan, Kathryn/0000-0001-8217-5602	Fonds de Recherche du Quebec-Sante	Fonds de Recherche du Quebec-Sante(Fonds de la Recherche en Sante du Quebec)	This research received no specific funding. JS was funded through a bursary provided by the Fonds de Recherche du Quebec-Sante.	Angus DC, 2004, LANCET, V363, P1314, DOI 10.1016/S0140-6736(04)16007-8; Castellanos-Ortega A, 2010, CRIT CARE MED, V38, P1036, DOI 10.1097/CCM.0b013e3181d455b6; Christian CK, 2005, WORLD J SURG, V29, P1241, DOI 10.1007/s00268-005-7993-8; Goldfrad CK, 2000, J EPIDEMIOL COMMUNIT, V54, P779; Halm EA, 2002, ANN INTERN MED, V137, P511, DOI 10.7326/0003-4819-137-6-200209170-00012; Harrison DA, 2004, CRIT CARE, V8, pR99, DOI 10.1186/cc2834; Harrison DA, 2006, CRIT CARE, V10, DOI 10.1186/cc4854; Harrison DA, 2007, CRIT CARE MED, V35, P1091, DOI 10.1097/01.CCM.0000259468.24532.44; Jones J, 1995, INT J TECHNOL ASSESS, V11, P762, DOI 10.1017/S0266462300009193; Kahn JM, 2008, CRIT CARE MED, V36, P3085, DOI 10.1097/CCM.0b013e31818c37b2; Kahn JM, 2007, CRIT CARE, V11, DOI 10.1186/cc5776; Kahn JM, 2006, NEW ENGL J MED, V355, P41, DOI 10.1056/NEJMsa053993; Kahn JM, 2009, HEALTH SERV RES, V44, P862, DOI 10.1111/j.1475-6773.2009.00959.x; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; London Trauma Office, 2010, LOND TRAUM SYST; May Susanne, 2005, Dose-Response, V3, P474, DOI 10.2203/dose-response.003.04.004; Nathens AB, 2001, JAMA-J AM MED ASSOC, V285, P1164, DOI 10.1001/jama.285.9.1164; Needham DM, 2006, CRIT CARE MED, V34, P2349, DOI 10.1097/01.CCM.0000233858.85802.5C; Panageas KS, 2003, ANN INTERN MED, V139, P658, DOI 10.7326/0003-4819-139-8-200310210-00009; Parry G, 2003, BRIT MED J, V326, P280; Peelen L, 2007, CRIT CARE, V11, DOI 10.1186/cc5727; Ramnarayan P, 2010, LANCET, V376, P698, DOI 10.1016/S0140-6736(10)61113-0; Reinikainen M, 2010, INTENS CARE MED, V36, P673, DOI 10.1007/s00134-009-1688-9; Royston P., 2008, MULTIVARIABLE MODEL; The Information Centre, 2010, LIST DAT; Tilford JM, 2000, PEDIATRICS, V106, P289, DOI 10.1542/peds.106.2.289	26	40	40	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	MAY 29	2012	344								e3394	10.1136/bmj.e3394	http://dx.doi.org/10.1136/bmj.e3394			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	953GT	22645208	hybrid, Green Published			2023-01-03	WOS:000304855700002
J	Ferreira, SR; Machado, GR; Ferreira, VC; Rodrigues, CFMA; de Moraes, TP; Divino, JC; Olandoski, M; McIntyre, C; Pecoits, R				Ferreira-Filho, Sebastiao R.; Machado, Gilberto R.; Ferreira, Valeria C.; Rodrigues, Carlos F. M. A.; de Moraes, Thyago Proenca; Divino-Filho, Jose C.; Olandoski, Marcia; McIntyre, Christopher; Pecoits-Filho, Roberto		BRAZPD Study Investigators	Back to Basics: Pitting Edema and the Optimization of Hypertension Treatment in Incident Peritoneal Dialysis Patients (BRAZPD)	PLOS ONE			English	Article							BLOOD-PRESSURE CONTROL; CARDIOVASCULAR-DISEASE; VOLUME; FLUID; LONG; THERAPY	Systemic arterial hypertension is an important risk factor for cardiovascular disease that is frequently observed in populations with declining renal function. Initiation of renal replacement therapy at least partially decreases signs of fluid overload; however, high blood pressure levels persist in the majority of patients after dialysis initiation. Hypervolemia due to water retention predisposes peritoneal dialysis (PD) patients to hypertension and can clinically manifest in several forms, including peripheral edema. The approaches to detect edema, which include methods such as bioimpedance, inferior vena cava diameter and biomarkers, are not always available to physicians worldwide. For clinical examinations, the presence of pitting located in the lower extremities and/or over the sacrum to diagnose the presence of peripheral edema in their patients are frequently utulized. We evaluated the impact of edema on the control of blood pressure of incident PD patients during the first year of dialysis treatment. Patients were recruited from 114 Brazilian dialysis centers that were participating in the BRAZPD study for a total of 1089 incident patients. Peripheral edema was diagnosed by the presence of pitting after finger pressure was applied to the edematous area. Patients were divided into 2 groups: those with and without edema according to the monthly medical evaluation. Blood arterial pressure, body mass index, the number of antihypertensive drugs and comorbidities were analyzed. We observed an initial BP reduction in the first five months and a stabilization of blood pressure levels from five to twelve months. The edematous group exhibited higher blood pressure levels than the group without edema during the follow-up. The results strongly indicate that the presence of a simple and easily detectable clinical sign of peripheral edema is a very relevant tool that could be used to re-evaluate not only the patient's clinical hypertensive status but also the PD prescription and patient compliance.	[Ferreira-Filho, Sebastiao R.; Machado, Gilberto R.; Ferreira, Valeria C.; Rodrigues, Carlos F. M. A.] Nefroclin Uberlandia, Uberlandia, MG, Brazil; [Ferreira-Filho, Sebastiao R.; Machado, Gilberto R.] Univ Fed Uberlandia, Uberlandia, MG, Brazil; [de Moraes, Thyago Proenca; Olandoski, Marcia; Pecoits-Filho, Roberto] Pontificia Univ Catolica Parana, Ctr Hlth & Biol Sci, Curitiba, Parana, Brazil; [Divino-Filho, Jose C.] Karolinska Inst, CLINTEC, Div Baxter Novum & Renal Med, Stockholm, Sweden; [McIntyre, Christopher] Univ Nottingham, Fac Med & Hlth Sci, Nottingham NG7 2RD, England	Universidade Federal de Uberlandia; Pontificia Universidade Catolica do Parana; Karolinska Institutet; University of Nottingham	Ferreira, SR (corresponding author), Nefroclin Uberlandia, Uberlandia, MG, Brazil.	sebahferreira@gmail.com	Ferreira-Filho, S R/G-2354-2012; McIntyre, Christopher W/O-8927-2014; de Moraes, Thyago Proenca/M-9400-2014; Pecoits-Filho, Roberto/K-7986-2013; Divino-Filho, Jose/V-5425-2019	Ferreira-Filho, S R/0000-0003-4176-9572; de Moraes, Thyago Proenca/0000-0002-2983-3968; Pecoits-Filho, Roberto/0000-0002-0255-6710; 	Baxter Healthcare	Baxter Healthcare	Baxter Healthcare sponsored this study. During the data collection and analysis, JCDF was employed by Baxter. RPF received a consulting fee and speaker honorarium from Baxter Healthcare. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.	Ates K, 2001, KIDNEY INT, V60, P767, DOI 10.1046/j.1523-1755.2001.060002767.x; Barri YM, 2008, CURR HYPERTENS REP, V10, P39, DOI 10.1007/s11906-008-0009-y; Basile J, 2009, J CLIN HYPERTENSION, P11; Cocchi R, 1999, NEPHROL DIAL TRANSPL, V14, P1536, DOI 10.1093/ndt/14.6.1536; Fernandes N, 2008, KIDNEY INT, V73, pS145, DOI 10.1038/sj.ki.5002616; Fishbane S, 1996, AM J KIDNEY DIS, V28, P257, DOI 10.1016/S0272-6386(96)90309-1; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; Gunal AI, 2001, AM J KIDNEY DIS, V37, P588, DOI 10.1053/ajkd.2001.22085; Katzarski KS, 1999, NEPHROL DIAL TRANSPL, V14, P369, DOI 10.1093/ndt/14.2.369; Lameire N, 1993, Perit Dial Int, V13 Suppl 2, pS394; Lang SM, 1999, PERITON DIALYSIS INT, V19, P143; LEUNISSEN KML, 1993, KIDNEY INT, V43, pS50; Levey AS, 1998, AM J KIDNEY DIS, V32, P853, DOI 10.1016/S0272-6386(98)70145-3; Lynn KL, 2002, KIDNEY INT, V62, P2281, DOI 10.1046/j.1523-1755.2002.00685.x; Mailloux LU, 1998, AM J KIDNEY DIS, V32, P705, DOI 10.1016/S0272-6386(98)70146-5; Menon MK, 2001, NEPHROL DIAL TRANSPL, V16, P2207, DOI 10.1093/ndt/16.11.2207; Rahman M, 1999, AM J KIDNEY DIS, V33, P498, DOI 10.1016/S0272-6386(99)70187-3; SALDANHA LF, 1993, AM J KIDNEY DIS, V21, P184, DOI 10.1016/S0272-6386(12)81091-2; SLINGENEYER A, 1983, NEPHRON, V33, P133, DOI 10.1159/000182927; Tang W, 2009, AM J NEPHROL, V30, P120, DOI 10.1159/000206697; TZAMALOUKAS AH, 1995, J AM SOC NEPHROL, V6, P198; Van Biesen W, 2008, PERITON DIALYSIS INT, V28, P596; van Dijk PCW, 2001, NEPHROL DIAL TRANSPL, V16, P1120, DOI 10.1093/ndt/16.6.1120	23	9	9	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2012	7	5							e36758	10.1371/journal.pone.0036758	http://dx.doi.org/10.1371/journal.pone.0036758			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TH	22649498	Green Published, Green Submitted, gold			2023-01-03	WOS:000305335800015
J	Abdelwahab, MG; Fenton, KE; Preul, MC; Rho, JM; Lynch, A; Stafford, P; Scheck, AC				Abdelwahab, Mohammed G.; Fenton, Kathryn E.; Preul, Mark C.; Rho, Jong M.; Lynch, Andrew; Stafford, Phillip; Scheck, Adrienne C.			The Ketogenic Diet Is an Effective Adjuvant to Radiation Therapy for the Treatment of Malignant Glioma	PLOS ONE			English	Article							KETONE-BODIES; GLIOBLASTOMA CELLS; CANCER-CELLS; BRAIN CANCER; 2-DEOXY-D-GLUCOSE; METABOLISM; GLUCOSE; GROWTH; AKT; RESTRICTION	Introduction: The ketogenic diet (KD) is a high-fat, low-carbohydrate diet that alters metabolism by increasing the level of ketone bodies in the blood. KetoCal (R) (KC) is a nutritionally complete, commercially available 4:1 (fat: carbohydrate+protein) ketogenic formula that is an effective non-pharmacologic treatment for the management of refractory pediatric epilepsy. Diet-induced ketosis causes changes to brain homeostasis that have potential for the treatment of other neurological diseases such as malignant gliomas. Methods: We used an intracranial bioluminescent mouse model of malignant glioma. Following implantation animals were maintained on standard diet (SD) or KC. The mice received 2x4 Gy of whole brain radiation and tumor growth was followed by in vivo imaging. Results: Animals fed KC had elevated levels of beta-hydroxybutyrate (p = 0.0173) and an increased median survival of approximately 5 days relative to animals maintained on SD. KC plus radiation treatment were more than additive, and in 9 of 11 irradiated animals maintained on KC the bioluminescent signal from the tumor cells diminished below the level of detection (p<0.0001). Animals were switched to SD 101 days after implantation and no signs of tumor recurrence were seen for over 200 days. Conclusions: KC significantly enhances the anti-tumor effect of radiation. This suggests that cellular metabolic alterations induced through KC may be useful as an adjuvant to the current standard of care for the treatment of human malignant gliomas.	[Abdelwahab, Mohammed G.; Fenton, Kathryn E.; Preul, Mark C.; Rho, Jong M.; Scheck, Adrienne C.] St Josephs Hosp, Barrow Neurol Inst, Phoenix, AZ USA; [Lynch, Andrew] Danone Res, Ctr Specialised Nutr, Nutricia Adv Med Nutr, Liverpool, Merseyside, England; [Stafford, Phillip] Arizona State Univ, AZ Biodesign, Ctr Innovat Med, Sch Life Sci, Tempe, AZ USA	Barrow Neurological Institute; St. Joseph's Hospital and Medical Center; Danone Nutricia; Arizona State University; Arizona State University-Tempe	Abdelwahab, MG (corresponding author), St Josephs Hosp, Barrow Neurol Inst, Phoenix, AZ USA.	adrienne.scheck@thebni.edu	Scheck, Adrienne/AAH-5040-2020	Scheck, Adrienne/0000-0003-3497-1895	Nutricia Advanced Medical Nutrition through Nutricia North America; Arizona Disease Research Commission [1010]	Nutricia Advanced Medical Nutrition through Nutricia North America(Danone Nutricia); Arizona Disease Research Commission	This work was supported in part by a grant from Nutricia Advanced Medical Nutrition through Nutricia North America, the company that distributes KetoCal (R) in the USA. The funders had no role in data collection and analysis, decision to publish or preparation of the manuscript, but did input to the study design. Web sites: Nutricia - http://nutrition.nutricia.com/ Students Supporting Brain Tumor Research - www.ssbtr.org Arizona Disease Research Commission - http://azdhs.gov/biomedical/ (contract 1010 to ACS) No additional external funding was received for this study.	Abdelwahab MG, 2011, JOVE-J VIS EXP, DOI 10.3791/3403; Baranano Kristin W, 2008, Curr Treat Options Neurol, V10, P410, DOI 10.1007/s11940-008-0043-8; Bonuccelli G, 2010, CELL CYCLE, V9, P3506, DOI 10.4161/cc.9.17.12731; Chautard E, 2010, NEURO-ONCOLOGY, V12, P434, DOI 10.1093/neuonc/nop059; Dwarakanath BS, 2009, FUTURE ONCOL, V5, P581, DOI [10.2217/fon.09.44, 10.2217/FON.09.44]; Eloqayli H, 2011, NEUROCHEM RES, V36, P1566, DOI 10.1007/s11064-011-0485-3; Gupta S, 2009, J CANCER RES THER, V5, P16, DOI 10.4103/0973-1482.55135; Jouanneau E, 2006, CANCER IMMUNOL IMMUN, V55, P254, DOI 10.1007/s00262-005-0040-7; Li HF, 2009, RADIAT ONCOL, V4, DOI 10.1186/1748-717X-4-43; Liang BC, 2011, INT J MOL MED, V27, P159, DOI 10.3892/ijmm.2010.579; Lund TM, 2009, J NEUROCHEM, V110, P80, DOI 10.1111/j.1471-4159.2009.06115.x; Marsh J, 2008, NUTR METAB, V5, DOI 10.1186/1743-7075-5-33; Maschek G, 2004, CANCER RES, V64, P31, DOI 10.1158/0008-5472.CAN-03-3294; Maurer GD, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-315; Mukherjee P, 2004, CLIN CANCER RES, V10, P5622, DOI 10.1158/1078-0432.CCR-04-0308; Mukherjee P, 2002, BRIT J CANCER, V86, P1615, DOI 10.1038/sj.bjc.6600298; Mulrooney TJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018085; NEBELING LC, 1995, J AM DIET ASSOC, V95, P693, DOI 10.1016/S0002-8223(95)00189-1; NEBELING LC, 1995, J AM COLL NUTR, V14, P202; Newcomb EW, 2006, CLIN CANCER RES, V12, P4730, DOI 10.1158/1078-0432.CCR-06-0593; Nicholas MK, 2011, SEMIN ONCOL, V38, P243, DOI 10.1053/j.seminoncol.2011.01.009; Niyazi M, 2011, RADIOTHER ONCOL, V98, P1, DOI 10.1016/j.radonc.2010.11.006; Ralser M, 2008, P NATL ACAD SCI USA, V105, P17807, DOI 10.1073/pnas.0803090105; Robey RB, 2009, SEMIN CANCER BIOL, V19, P25, DOI 10.1016/j.semcancer.2008.11.010; Roesler R, 2010, EXPERT REV ANTICANC, V10, P1735, DOI [10.1586/era.10.167, 10.1586/ERA.10.167]; Ruggiero A, 2006, J NEURO-ONCOL, V77, P89, DOI 10.1007/s11060-005-9011-2; Samala R, 2011, NEUROCHEM INT, V58, P5, DOI 10.1016/j.neuint.2010.10.011; Schiff M, 2011, NUTR REV, V69, P65, DOI 10.1111/j.1753-4887.2010.00363.x; Seyfried Thomas N, 2005, Nutr Metab (Lond), V2, P30, DOI 10.1186/1743-7075-2-30; Seyfried TN, 2010, LANCET ONCOL, V11, P811, DOI 10.1016/S1470-2045(10)70166-2; Seyfried TN, 2003, BRIT J CANCER, V89, P1375, DOI 10.1038/sj.bjc.6601269; Skinner R, 2009, J PEDIATR SURG, V44, P212, DOI 10.1016/j.jpedsurg.2008.10.042; Stafford P, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-74; Wallace DC, 2010, ANNU REV PATHOL-MECH, V5, P297, DOI 10.1146/annurev.pathol.4.110807.092314; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Yamada M, 1999, CANCER CHEMOTH PHARM, V44, P59, DOI 10.1007/s002800050945; Zhou WH, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-5; Zuccoli G, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-33	38	171	181	3	61	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2012	7	5							e36197	10.1371/journal.pone.0036197	http://dx.doi.org/10.1371/journal.pone.0036197			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UN	22563484	Green Published, Green Submitted, gold			2023-01-03	WOS:000305340700033
J	Lee, CC; Ho, HC; Su, YC; Chiu, BCH; Su, YC; Lee, YD; Chou, P; Chien, SH; Huang, YS				Lee, Ching-Chih; Ho, Hsu-Chueh; Su, Yu-Chieh; Chiu, Brian C-H; Su, Yung-Cheng; Lee, Yi-Da; Chou, Pesus; Chien, Sou-Hsin; Huang, Yung-Sung			Increased Risk of Vascular Events in Emergency Room Patients Discharged Home with Diagnosis of Dizziness or Vertigo: A 3-Year Follow-Up Study	PLOS ONE			English	Article							STROKE INCIDENCE; ISCHEMIC-STROKE; POPULATION; MANIFESTATION; DIZZY	Background: Dizziness and vertigo symptoms are commonly seen in emergency room (ER). However, these patients are often discharged without a definite diagnosis. Conflicting data regarding the vascular event risk among the dizziness or vertigo patients have been reported. This study aims to determine the risk of developing stroke or cardiovascular events in ER patients discharged home with a diagnosis of dizziness or vertigo. Methodology: A total of 25,757 subjects with at least one ER visit in 2004 were identified. Of those, 1,118 patients were discharged home with a diagnosis of vertigo or dizziness. A Cox proportional hazard model was performed to compare the three-year vascular event-free survival rates between the dizziness/vertigo patients and those without dizziness/vertigo after adjusting for confounding and risk factors. Results: We identified 52 (4.7%) vascular events in patients with dizziness/vertigo and 454 (1.8%) vascular events in patients without dizziness/vertigo. ER patients discharged home with a diagnosis of vertigo or dizziness had 2-fold (95% confidence interval [CI], 1.35-2.96; p<0.001) higher risk of stroke or cardiovascular events after adjusting for patient characteristics, comorbidities, urbanization level of residence, individual socio-economic status, and initially taking medications after the onset of dizziness or vertigo during the first year. Conclusions: ER patients discharged home with a diagnosis of dizziness or vertigo were at a increased risk of developing subsequent vascular events than those without dizziness/vertigo after the onset of dizziness or vertigo. Further studies are warranted for developing better diagnostic and follow-up strategies in increased risk patients.	[Lee, Ching-Chih; Chou, Pesus] Natl Yang Ming Univ, Community Med Res Ctr, Taipei 112, Taiwan; [Lee, Ching-Chih; Chou, Pesus] Natl Yang Ming Univ, Inst Publ Hlth, Taipei 112, Taiwan; [Lee, Ching-Chih; Ho, Hsu-Chueh] Buddhist Dalin Tzu Chi Gen Hosp, Dept Otolaryngol, Chiayi, Taiwan; [Lee, Yi-Da] Buddhist Dalin Tzu Chi Gen Hosp, Dept Internal Med, Div Cardiol, Chiayi, Taiwan; [Su, Yu-Chieh] Buddhist Dalin Tzu Chi Gen Hosp, Dept Internal Med, Div Hematol Oncol, Chiayi, Taiwan; [Lee, Ching-Chih; Su, Yu-Chieh] Buddhist Dalin Tzu Chi Gen Hosp, Ctr Canc, Chiayi, Taiwan; [Su, Yung-Cheng] Buddhist Dalin Tzu Chi Gen Hosp, Dept Emergency Med, Chiayi, Taiwan; [Huang, Yung-Sung] Buddhist Dalin Tzu Chi Gen Hosp, Div Neurol, Dept Internal Med, Chiayi, Taiwan; [Lee, Ching-Chih] Buddhist Dalin Tzu Chi Gen Hosp, Ctr Clin Epidemiol & Biostat, Chiayi, Taiwan; [Chien, Sou-Hsin] Buddhist Dalin Tzu Chi Gen Hosp, Dept Surg, Div Plast Surg, Chiayi, Taiwan; [Lee, Ching-Chih; Ho, Hsu-Chueh; Su, Yu-Chieh; Su, Yung-Cheng; Chien, Sou-Hsin] Tzu Chi Univ, Sch Med, Hualien, Taiwan; [Chiu, Brian C-H] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Tzu Chi University; University of Chicago	Lee, CC (corresponding author), Natl Yang Ming Univ, Community Med Res Ctr, Taipei 112, Taiwan.	enttcd2@hotamil.com; enttcd@hotamil.com	Su, Yu-Chieh/M-7867-2013	Su, Yu-Chieh/0000-0002-1771-9017	National Health Research Institutes [100363]	National Health Research Institutes(National Health Research Institutes, JapanNational Health Research Institutes - Taiwan)	This study is based in part on data from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health and managed by the National Health Research Institutes (Serial No. 100363). The interpretation and conclusions contained herein do not represent those of the aforementioned institutions.	Bos MJ, 2007, JAMA-J AM MED ASSOC, V298, P2877, DOI 10.1001/jama.298.24.2877; Chase M, 2011, AM J EMERG IN PRESS; Chen CY, 2007, PEDIATRICS, V119, pE435, DOI 10.1542/peds.2006-1477; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; DALLARA J, 1994, AM J EMERG MED, V12, P421, DOI 10.1016/0735-6757(94)90052-3; Engstrom G, 2001, STROKE, V32, P1098, DOI 10.1161/01.STR.32.5.1098; Finnegan JR, 2000, PREV MED, V31, P205, DOI 10.1006/pmed.2000.0702; Karatas M, 2008, NEUROLOGIST, V14, P355, DOI 10.1097/NRL.0b013e31817533a3; Kerber KA, 2006, STROKE, V37, P2484, DOI 10.1161/01.STR.0000240329.48263.0d; Kerber KA, 2010, J EVAL CLIN PRACT, V16, P186, DOI 10.1111/j.1365-2753.2009.01133.x; Kim AS, 2011, ANN EMERG MED, V57, P34, DOI 10.1016/j.annemergmed.2010.06.559; Lee H, 2006, NEUROLOGY, V67, P1178, DOI 10.1212/01.wnl.0000238500.02302.b4; Lee HY, 2004, J NEUROL SCI, V222, P105, DOI 10.1016/j.jns.2004.04.005; Liu C.Y., 2006, J HEALTH MANAG, V4, P1; MADLONKAY DJ, 1985, J FAM PRACTICE, V21, P109; McFadden E, 2009, STROKE, V40, P1070, DOI 10.1161/STROKEAHA.108.533414; Molshatzki N, 2011, MED CARE, V49, P673, DOI 10.1097/MLR.0b013e318222a508; Moon SY, 2006, J KOREAN MED SCI, V21, P539, DOI 10.3346/jkms.2006.21.3.539; National Health Insurance Research Database, 2009, NAT HLTH INS RES DAT; Newman-Toker DE, 2008, MAYO CLIN PROC, V83, P765, DOI 10.4065/83.7.765; Newman-Toker DE, 2006, NAT CLIN PRACT NEURO, V2, P167, DOI 10.1038/ncpneuro0125; NHI, 2008, NHI PROF; Schappert SM, 2006, VITAL HLTH STAT, V13, P1; Schneider AT, 2003, JAMA-J AM MED ASSOC, V289, P343, DOI 10.1001/jama.289.3.343; Seok JI, 2008, J CLIN NEUROL, V4, P107, DOI 10.3988/jcn.2008.4.3.107; Sheu JJ, 2010, STROKE, V41, P244, DOI 10.1161/STROKEAHA.109.567735	26	32	32	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2012	7	4							e35923	10.1371/journal.pone.0035923	http://dx.doi.org/10.1371/journal.pone.0035923			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TJ	22558272	Green Submitted, gold, Green Published			2023-01-03	WOS:000305336000086
J	Mandeville, JS; Bourassa, P; Thomas, TJ; Tajmir-Riahi, HA				Mandeville, Jean-Sebastian; Bourassa, Phillipe; Thomas, Thekkumkattil John; Tajmir-Riahi, Heidar-Ali			Biogenic and Synthetic Polyamines Bind Cationic Dendrimers	PLOS ONE			English	Article							POLYAMIDOAMINE DENDRIMERS; GROWTH-INHIBITION; PAMAM DENDRIMERS; TRANSFER-RNA; CELL-GROWTH; IN-VITRO; ANALOGS; CANCER; METABOLISM; EXPRESSION	Biogenic polyamines are essential for cell growth and differentiation, while polyamine analogues exert antitumor activity in multiple experimental model systems, including breast and lung cancer. Dendrimers are widely used for drug delivery in vitro and in vivo. We report the bindings of biogenic polyamines, spermine (spm), and spermidine (spmd), and their synthetic analogues, 3,7,11,15-tetrazaheptadecane. 4HCl (BE-333) and 3,7,11,15,19-pentazahenicosane.5HCl (BE-3333) to dendrimers of different compositions, mPEG-PAMAM (G3), mPEG-PAMAM (G4) and PAMAM (G4). FTIR and UV-visible spectroscopic methods as well as molecular modeling were used to analyze polyamine binding mode, the binding constant and the effects of polyamine complexation on dendrimer stability and conformation. Structural analysis showed that polyamines bound dendrimers through both hydrophobic and hydrophilic contacts with overall binding constants of Kspm-mPEG-G3 = 7.6 x 10(4) M-1, Kspm-mPEG-PAMAM-G4 = 4.6 x 10(4) M-1, Kspm-PAMAM-G4 = 6.6x10(4) M-1, Kspmd-mPEG-G3 = 1.0x10(5) M-1, Kspmd-mPEG-PAMAM-G4 = 5.5x10(4) M-1, Kspmd-PAMAM-G4 = 9.2 x 10(4) M-1, KBE-333-mPEG-G3 = 4.2x10(4) M-1, KBe-333-mPEG-PAMAM-G4 = 3.2 x 10(4) M-1, KBE-333-PAMAM-G4 = 3.6 x 10(4) M-1, KBE-3333-mPEG-G3 = 2.2x10(4) M-1, KBe-3333-mPEG-PAMAM-G4 = 2.4 x 10(4) M-1, KBE-3333-PAMAM-G4 = 2.3 x 10(4) M-1. Biogenic polyamines showed stronger affinity toward dendrimers than those of synthetic polyamines, while weaker interaction was observed as polyamine cationic charges increased. The free binding energies calculated from docking studies were: -3.2 (spermine), -3.5 (spermidine) and -3.03 (BE-3333) kcal/mol, with the following order of binding affinity: spermidine-PAMAM-G-4>spermine-PAMMAM-G4>BE-3333-PAMAM-G4 consistent with spectroscopic data. Our results suggest that dendrimers can act as carrier vehicles for delivering antitumor polyamine analogues to target tissues.	[Mandeville, Jean-Sebastian; Bourassa, Phillipe; Tajmir-Riahi, Heidar-Ali] Univ Quebec Trois Rivieres, Dept Chim Biol, Trois Rivieres, PQ GA9 5H7, Canada; [Thomas, Thekkumkattil John] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ 08903 USA; [Thomas, Thekkumkattil John] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ USA	University of Quebec; University of Quebec Trois Rivieres; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Mandeville, JS (corresponding author), Univ Quebec Trois Rivieres, Dept Chim Biol, CP 500, Trois Rivieres, PQ GA9 5H7, Canada.	tajmirri@uqtr.ca	Bourassa, Philippe/H-7281-2012	Bourassa, Philippe/0000-0003-2662-2118				Abderrezak A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033102; BERGERON RJ, 1994, J MED CHEM, V37, P3464, DOI 10.1021/jm00047a004; BERGERON RJ, 1988, J MED CHEM, V31, P1183, DOI 10.1021/jm00401a019; Casero RA, 2001, J MED CHEM, V44, P1, DOI 10.1021/jm000084m; Cohen S.S., 1998, GUIDE POLYAMINES, V1st ed.; Connors K, BINDING CONSTANTS ME; D'Agostino L, 2005, FEBS J, V272, P3777, DOI 10.1111/j.1742-4658.2005.04782.x; DAVIDSON NE, 1993, CANCER RES, V53, P2071; Dubeau S, 2010, BIOMACROMOLECULES, V11, P1507, DOI 10.1021/bm100144v; Esseminea J, 2011, INT J BIOL MACROMOL, V49; Faaland CA, 2000, BIOCHEM CELL BIOL, V78, P415, DOI 10.1139/bcb-78-4-415; Froehlich E, 2011, BIOMACROMOLECULES, V12, P511, DOI 10.1021/bm1013102; Galeazzi S, 2010, BIOMACROMOLECULES, V11, P182, DOI 10.1021/bm901055a; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; Ha HC, 1998, P NATL ACAD SCI USA, V95, P11140, DOI 10.1073/pnas.95.19.11140; Hardy JG, 2006, BIOCONJUGATE CHEM, V17, P172, DOI 10.1021/bc050212r; Hawke CJ, 1999, J CHEM SOC PERK T, P1287; HEBY O, 1981, DIFFERENTIATION, V19, P1, DOI 10.1111/j.1432-0436.1981.tb01123.x; Hu JJ, 2010, J PHYS CHEM B, V114, P7148, DOI 10.1021/jp1007889; Huang Y, 2004, MOL CANCER RES, V2, P81; Huang Y, 2006, J BIOL CHEM, V281, P19055, DOI 10.1074/jbc.M600910200; Iyer J, 1998, MACROMOLECULES, V31, P8757, DOI 10.1021/ma980654g; JANSEN JFGA, 1994, SCIENCE, V266, P1226, DOI 10.1126/science.266.5188.1226; JANSEN JFGA, 1995, J AM CHEM SOC, V117, P4417, DOI 10.1021/ja00120a032; JEVPRASCSPHANT R, 2000, INT J PHARMACEUT, V252, P263; Klajnert B, 2007, NEW DEV MUTATION RES, P217; Klajnert B., 2007, DENDRIMERS MED; Kojima C, 2000, BIOCONJUGATE CHEM, V11, P910, DOI 10.1021/bc0000583; Kono K, 1999, BIOCONJUGATE CHEM, V10, P1115, DOI 10.1021/bc990082k; Lee CC, 2005, NAT BIOTECHNOL, V23, P1517, DOI 10.1038/nbt1171; Maiti PK, 2004, MACROMOLECULES, V37, P6236, DOI 10.1021/ma035629b; Malik N, 2000, J CONTROL RELEASE, V65, P133, DOI 10.1016/S0168-3659(99)00246-1; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; McCloskey DE, 2003, J BIOL CHEM, V278, P13881, DOI 10.1074/jbc.M205689200; N'soukpoe-Kossi CN, 2008, BIOMACROMOLECULES, V9, P2712, DOI 10.1021/bm800412r; N'soukpoe-Kossi CN, 2009, BIOCHEM CELL BIOL, V87, P621, DOI [10.1139/O09-036, 10.1139/o09-036]; Ouameur AA, 2004, J BIOL CHEM, V279, P42041, DOI 10.1074/jbc.M406053200; Ouameur AA, 2010, RNA, V16, P1968, DOI 10.1261/rna.1994310; Patri AK, 2002, CURR OPIN CHEM BIOL, V6, P466, DOI 10.1016/S1367-5931(02)00347-2; PEGG AE, 1988, CANCER RES, V48, P759; Popescu MC, 2006, J PHYS CHEM B, V110, P14198, DOI 10.1021/jp061311k; Singh P, 2008, BIOCONJUGATE CHEM, V19, P2239, DOI 10.1021/bc800125u; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852; Thomas T, 2003, J CELL MOL MED, V7, P113, DOI 10.1111/j.1582-4934.2003.tb00210.x; Thomas T, 2002, ONCOL RES, V13, P123; Tkachenko AG, 2003, BIOCHEMISTRY-MOSCOW+, V68, P850, DOI 10.1023/A:1025790729797; Tomalia DA, 2005, PROG POLYM SCI, V30, P294, DOI 10.1016/j.progpolymsci.2005.01.007; Twyman LJ, 1999, TETRAHEDRON LETT, V40, P1743, DOI 10.1016/S0040-4039(98)02680-X; Zhuo RX, 1999, J CONTROL RELEASE, V57, P249, DOI 10.1016/S0168-3659(98)00120-5	51	6	7	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2012	7	4							e36087	10.1371/journal.pone.0036087	http://dx.doi.org/10.1371/journal.pone.0036087			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TJ	22558341	Green Published, Green Submitted, gold			2023-01-03	WOS:000305336000125
J	Kloog, I; Coull, BA; Zanobetti, A; Koutrakis, P; Schwartz, JD				Kloog, Itai; Coull, Brent A.; Zanobetti, Antonella; Koutrakis, Petros; Schwartz, Joel D.			Acute and Chronic Effects of Particles on Hospital Admissions in New-England	PLOS ONE			English	Article							PARTICULATE AIR-POLLUTION; CONGESTIVE-HEART-FAILURE; LONG-TERM EXPOSURE; CASE-CROSSOVER ANALYSIS; FINE PARTICULATE; CARDIOVASCULAR-DISEASE; MEDICARE BENEFICIARIES; MYOCARDIAL-INFARCTION; RESPIRATORY-DISEASES; EMERGENCY ADMISSIONS	Background: Many studies have reported significant associations between exposure to PM2.5 and hospital admissions, but all have focused on the effects of short-term exposure. In addition all these studies have relied on a limited number of PM2.5 monitors in their study regions, which introduces exposure error, and excludes rural and suburban populations from locations in which monitors are not available, reducing generalizability and potentially creating selection bias. Methods: Using our novel prediction models for exposure combining land use regression with physical measurements (satellite aerosol optical depth) we investigated both the long and short term effects of PM2.5 exposures on hospital admissions across New-England for all residents aged 65 and older. We performed separate Poisson regression analysis for each admission type: all respiratory, cardiovascular disease (CVD), stroke and diabetes. Daily admission counts in each zip code were regressed against long and short-term PM2.5 exposure, temperature, socio-economic data and a spline of time to control for seasonal trends in baseline risk. Results: We observed associations between both short-term and long-term exposure to PM2.5 and hospitalization for all of the outcomes examined. In example, for respiratory diseases, for every 10-mu g/m(3) increase in short-term PM2.5 exposure there is a 0.70 percent increase in admissions (CI = 0.35 to 0.52) while concurrently for every 10-mu g/m(3) increase in long-term PM2.5 exposure there is a 4.22 percent increase in admissions (CI = 1.06 to 4.75). Conclusions: As with mortality studies, chronic exposure to particles is associated with substantially larger increases in hospital admissions than acute exposure and both can be detected simultaneously using our exposure models.	[Kloog, Itai; Zanobetti, Antonella; Koutrakis, Petros; Schwartz, Joel D.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Exposure Epidemiol & Risk Program, Boston, MA 02115 USA; [Coull, Brent A.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Kloog, I (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Exposure Epidemiol & Risk Program, 665 Huntington Ave, Boston, MA 02115 USA.	ekloog@hsph.harvard.edu			Harvard Environmental Protection Agency (EPA) Center [R-832416, RD 83479801]; NIH [ES00002, ES012044]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012044, P30ES000002] Funding Source: NIH RePORTER	Harvard Environmental Protection Agency (EPA) Center(United States Environmental Protection Agency); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The research was supported by the Harvard Environmental Protection Agency (EPA) Center, Grants R-832416 and RD 83479801, NIH grants ES00002 and ES012044. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adar SD, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000372; Andersen ZJ, 2011, THORAX; Andersen ZJ, 2012, DIABETES CARE, V35, P92, DOI 10.2337/dc11-1155; [Anonymous], 2000, US CENS POP HOUS; Baja ES, 2010, ENVIRON HEALTH PERSP, V118, P840, DOI 10.1289/ehp.0901396; Bartoli CR, 2009, ENVIRON HEALTH PERSP, V117, P333, DOI 10.1289/ehp.11380; Bauer M, 2010, J AM COLL CARDIOL, V56, P1803, DOI 10.1016/j.jacc.2010.04.065; Brauner EV, 2008, AM J RESP CRIT CARE, V177, P419, DOI 10.1164/rccm.200704-632OC; Brook RD, 2004, CIRCULATION, V109, P2655, DOI 10.1161/01.CIR.0000128587.30041.C8; Brunekreef B, 2002, LANCET, V360, P1233, DOI 10.1016/S0140-6736(02)11274-8; Soares SRC, 2009, ATHEROSCLEROSIS, V207, P368, DOI 10.1016/j.atherosclerosis.2009.04.041; D'Ippoliti D, 2003, EPIDEMIOLOGY, V14, P528, DOI 10.1097/01.ede.0000082046.22919.72; Dominici F, 2006, JAMA-J AM MED ASSOC, V295, P1127, DOI 10.1001/jama.295.10.1127; Engel-Cox JA, 2004, ATMOS ENVIRON, V38, P2495, DOI 10.1016/j.atmosenv.2004.01.039; Fusco D, 2001, EUR RESPIR J, V17, P1143, DOI 10.1183/09031936.01.00005501; Gryparis A, 2009, BIOSTATISTICS, V10, P258, DOI 10.1093/biostatistics/kxn033; Gupta P, 2006, ATMOS ENVIRON, V40, P5880, DOI 10.1016/j.atmosenv.2006.03.016; Halonen JI, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-42; Hansen CS, 2007, TOXICOL APPL PHARM, V219, P24, DOI 10.1016/j.taap.2006.10.032; Hruba F, 2001, J EXPO ANAL ENV EPID, V11, P33, DOI 10.1038/sj.jea.7500141; Ilabaca M, 1999, J AIR WASTE MANAGE, V49, P154, DOI 10.1080/10473289.1999.10463879; Kloog I, 2011, ATMOSPHERIC ENV; Koelemeijer RBA, 2006, ATMOS ENVIRON, V40, P5304, DOI 10.1016/j.atmosenv.2006.04.044; Kramer U, 2010, ENVIRON HEALTH PERSP, V118, P1273, DOI 10.1289/ehp.0901689; Krewski D, 2009, RES REP HLTH EFF I, V2009, P115; Krewski Daniel, 2009, Res Rep Health Eff Inst, P5; Kunzli N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009096; Laden F, 2000, ENVIRON HEALTH PERSP, V108, P941, DOI 10.2307/3435052; LAIRD N, 1981, J AM STAT ASSOC, V76, P231, DOI 10.2307/2287816; Liu Y., 2004, J GEOPHYS RES D, V109, P3269; Madrigano J, 2010, OCCUP ENVIRON MED, V67, P312, DOI 10.1136/oem.2009.046193; Mann JK, 2002, ENVIRON HEALTH PERSP, V110, P1247, DOI 10.1289/ehp.021101247; Medina-Ramon M, 2006, AM J EPIDEMIOL, V163, P579, DOI 10.1093/aje/kwj078; Miller KA, 2007, NEW ENGL J MED, V356, P447, DOI 10.1056/NEJMoa054409; NCDC, 2010, NAT CLIM DAT CTR DAT; O'Neill MS, 2005, CIRCULATION, V111, P2913, DOI 10.1161/CIRCULATIONAHA.104.517110; Ostro B, 2010, ENVIRON HEALTH PERSP, V118, P363, DOI 10.1289/ehp.0901181; Oudin A, 2011, CEREBROVASC DIS, V31, P284, DOI 10.1159/000322600; Paciorek CJ, 2009, ANN APPL STAT, V3, P370, DOI 10.1214/08-AOAS204; Pope CA, 2006, J AIR WASTE MANAGE, V56, P709, DOI 10.1080/10473289.2006.10464545; POPE CA, 1995, INHAL TOXICOL, V7, P1, DOI 10.3109/08958379509014267; Puett RC, 2009, ENVIRON HEALTH PERSP, V117, P1697, DOI 10.1289/ehp.0900572; Schwartz J, 1996, J AIR WASTE MANAGE, V46, P927, DOI 10.1080/10473289.1996.10467528; Schwartz J, 1996, EPIDEMIOLOGY, V7, P20, DOI 10.1097/00001648-199601000-00005; SCHWARTZ J, 1995, AM J EPIDEMIOL, V142, P23, DOI 10.1093/oxfordjournals.aje.a117541; SCHWARTZ J, 1994, AM J EPIDEMIOL, V139, P589, DOI 10.1093/oxfordjournals.aje.a117048; Schwartz J, 1997, EPIDEMIOLOGY, V8, P371, DOI 10.1097/00001648-199707000-00004; Spix C, 1998, ARCH ENVIRON HEALTH, V53, P54, DOI 10.1080/00039899809605689; Sun QH, 2005, JAMA-J AM MED ASSOC, V294, P3003, DOI 10.1001/jama.294.23.3003; Sun QH, 2008, INHAL TOXICOL, V20, P127, DOI [10.1080/08958370701821482, 10.1080/08958370701821482 ]; Symons JM, 2006, AM J EPIDEMIOL, V164, P421, DOI 10.1093/aje/kwj206; USCB, 2000, US CENS BUR 2000; Wellenius GA, 2005, STROKE, V36, P2549, DOI 10.1161/01.STR.0000189687.78760.47; Wellenius GA, 2005, AM J EPIDEMIOL, V161, P1030, DOI 10.1093/aje/kwi135; Wellenius GA, 2003, ENVIRON HEALTH PERSP, V111, P402, DOI 10.1289/ehp.5775; Zanobetti A, 2001, AM J RESP CRIT CARE, V164, P831, DOI 10.1164/ajrccm.164.5.2012039; Zanobetti A, 2005, ENVIRON HEALTH PERSP, V113, P978, DOI 10.1289/ehp.7550; Zanobetti A, 2000, ENVIRON HEALTH PERSP, V108, P1071, DOI 10.2307/3434961; Zanobetti A, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-58; Zeger SL, 2000, ENVIRON HEALTH PERSP, V108, P419, DOI 10.2307/3454382	60	118	120	4	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2012	7	4							e34664	10.1371/journal.pone.0034664	http://dx.doi.org/10.1371/journal.pone.0034664			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959WC	22529923	Green Submitted, gold, Green Published			2023-01-03	WOS:000305347400015
J	Abhari, BA; Cristofanon, S; Kappler, R; von Schweinitz, D; Humphreys, R; Fulda, S				Abhari, B. A.; Cristofanon, S.; Kappler, R.; von Schweinitz, D.; Humphreys, R.; Fulda, S.			RIP1 is required for IAP inhibitor-mediated sensitization for TRAIL-induced apoptosis via a RIP1/FADD/caspase-8 cell death complex	ONCOGENE			English	Article						apoptosis; IAP inhibitor; TRAIL; RIP1; neuroblastoma	NF-KAPPA-B; DRUG-INDUCED APOPTOSIS; TESTING STAGE 1; CANCER-CELLS; DNA-DAMAGE; RECEPTOR; ANTAGONISTS; NECROSIS; CIAP1; IDENTIFICATION	Inhibitor of apoptosis (IAP) proteins represent promising therapeutic targets due to their high expression in many cancers. Here, we report that small-molecule IAP inhibitors at subtoxic concentrations cooperate with monoclonal antibodies against TRAIL receptor 1 (Mapatumumab) or TRAIL-R2 (Lexatumumab) to induce apoptosis in neuroblastoma cells in a highly synergistic manner (combination index <0.1). Importantly, we identify receptor-activating protein 1 (RIP1) as a critical mediator of this synergism. RIP1 is required for the formation of a RIP1/FADD/caspase-8 complex that drives caspase-8 activation, cleavage of Bid into tBid, mitochondrial outer membrane permeabilization, full activation of caspase-3 and caspase-dependent apoptosis. Indeed, knockdown of RIP1 abolishes formation of the RIP1/FADD/caspase-8 complex, caspase activation and apoptosis upon combination treatment. Similarly, inhibition of RIP1 kinase activity by Necrostatin-1 inhibits IAP inhibitor- and TRAIL receptor-triggered apoptosis. In contrast, overexpression of the dominant-negative superrepressor I kappa B alpha-SR or addition of the tumor necrosis factor (TNF)alpha-blocking antibody Enbrel do not interfere with cotreatment-induced apoptosis, pointing to a nuclear factor-kappa B- and TNF alpha-independent mechanism. Of note, IAP inhibitor also sensitizes primary cultured neuroblastoma cells for TRAIL receptor-mediated loss of viability, underscoring the clinical relevance. By identifying RIP1 as a critical mediator of IAP inhibitor- mediated sensitization for Mapatumumab- or Lexatumumab-induced apoptosis, our findings provide new insights into the synergistic interaction of IAP inhibitors together with TRAIL receptor agonists.	[Abhari, B. A.; Cristofanon, S.; Fulda, S.] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60528 Frankfurt, Germany; [Kappler, R.; von Schweinitz, D.] Univ Munich, Dr von Haunerschen Childrens Hosp, Dept Pediat Surg, Munich, Germany; [Humphreys, R.] Human Genome Sci Inc, Oncol Res Dept, Rockville, MD USA	Goethe University Frankfurt; University of Munich; GlaxoSmithKline; Human Genome Sciences Inc	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3A, D-60528 Frankfurt, Germany.	simone.fulda@kgu.de		Fulda, Simone/0000-0002-0459-6417; Kappler, Roland/0000-0002-8581-2803	Deutsche Forschungsgemeinschaft; European Community (ApopTrain, APO-SYS); IAP6/18	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); European Community (ApopTrain, APO-SYS)(European CommissionEuropean Commission Joint Research Centre); IAP6/18	We thank X Wang for providing RIP3 antibody and C Hugenberg for expert secretarial assistance. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, European Community (ApopTrain, APO-SYS) and IAP6/18 (to SF).	Ashkenazi A, 2008, NAT REV DRUG DISCOV, V7, P1001, DOI 10.1038/nrd2637; Bellail AC, 2010, J CELL MOL MED, V14, P1303, DOI 10.1111/j.1582-4934.2009.00777.x; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Biton S, 2011, CELL, V145, P92, DOI 10.1016/j.cell.2011.02.023; Chao B, 2006, inventors; Tetrapeptide analogs. United States patent, Patent No. PCT/US2005/024700; Chou TC, 1991, SYNERGISM ANTAGONISM, P61; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Feoktistova M, 2011, MOL CELL, V43, P449, DOI 10.1016/j.molcel.2011.06.011; Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2006, CANCER RES, V66, P10016, DOI 10.1158/0008-5472.CAN-05-4079; Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137; Fulda S, 2009, INT J CANCER, V124, P511, DOI 10.1002/ijc.24064; Geserick P, 2009, J CELL BIOL, V187, P1037, DOI 10.1083/jcb.200904158; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Houghton PJ, 2012, PEDIATR BLOOD CANCER, V58, P636, DOI 10.1002/pbc.23167; Humphreys RC, 2008, ADV EXP MED BIOL, V615, P127, DOI 10.1007/978-1-4020-6554-5_7; Karl S, 2009, J CELL MOL MED, V13, P4239, DOI 10.1111/j.1582-4934.2009.00888.x; LaCasse EC, 2008, ONCOGENE, V27, P6252, DOI 10.1038/onc.2008.302; Laukens B, 2011, NEOPLASIA, V13, P971, DOI 10.1593/neo.11610; Loder S, 2012, LEUKEMIA, V26, P1020, DOI 10.1038/leu.2011.353; Mader I, 2010, FASEB J, V24, P1997, DOI 10.1096/fj.09-142943; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Naumann I, 2011, CLIN CANCER RES, V17, P3204, DOI 10.1158/1078-0432.CCR-10-2451; Oost TK, 2004, J MED CHEM, V47, P4417, DOI 10.1021/jm040037k; Palacios C, 2010, CANCER LETT, V287, P207, DOI 10.1016/j.canlet.2009.06.012; Petersen SL, 2007, CANCER CELL, V12, P445, DOI 10.1016/j.ccr.2007.08.029; Smith MA, 2010, PEDIATR BLOOD CANCER, V54, P307, DOI 10.1002/pbc.22188; Stadel D, 2010, CLIN CANCER RES, V16, P5734, DOI 10.1158/1078-0432.CCR-10-0985; Straub CS, 2011, CURR TOP MED CHEM, V11, P291; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tenev T, 2011, MOL CELL, V43, P432, DOI 10.1016/j.molcel.2011.06.006; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; Vanlangenakker N, 2011, CELL DEATH DIFFER, V18, P656, DOI 10.1038/cdd.2010.138; Varfolomeev E, 2008, J BIOL CHEM, V283, P24295, DOI 10.1074/jbc.C800128200; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036	41	51	51	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2013	32	27					3263	3273		10.1038/onc.2012.337	http://dx.doi.org/10.1038/onc.2012.337			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	176JZ	22890322				2023-01-03	WOS:000321301600006
J	Clark, AA; Liggett, SB; Munger, SD				Clark, Adam A.; Liggett, Stephen B.; Munger, Steven D.			Extraoral bitter taste receptors as mediators of off-target drug effects	FASEB JOURNAL			English	Article						T2R; gastrointestinal system; respiratory system; gustatory system; side effects	CHEMOSENSORY CELLS; FAMILY; SENSITIVITY; GENES; PHENYLTHIOCARBAMIDE; PERCEPTION; EXPRESSION; SECRETION; SACCHARIN; MOUSE	We present a novel hypothesis that could explain many off-target effects of diverse pharmaceuticals. Specifically, we propose that any drug with a bitter taste could have unintended actions in the body through stimulation of extraoral type 2 taste receptors (T2Rs). T2Rs were first identified in the oral cavity, where they function as bitter taste receptors. However, recent findings indicate that they are also expressed outside the gustatory system, including in the gastrointestinal and respiratory systems. T2R ligands include a diverse array of natural and synthetic compounds, many of which are toxins. Notably, many pharmaceuticals taste bitter, with compounds such as chloroquine, haloperidol, erythromycin, procainamide, and ofloxacin known to activate T2Rs. Bitter-tasting compounds can have specific physiological effects in T2R-expressing cells. For example, T2Rs are found in some gastrointestinal endocrine cells, including those that secrete the peptide hormones (e. g., ghrelin and glucagon-like peptide-1) in response to stimulation by bitter-tasting compounds. In the respiratory system, stimulation of T2Rs expressed in respiratory epithelia and smooth muscle has been implicated in protective airway reflexes, ciliary beating, and bronchodilation. If our hypothesis is confirmed, it would offer a new paradigm for understanding the off-target actions of diverse drugs and could reveal potential new therapeutic targets.-Clark, A. A., Liggett, S. B., Munger, S. D. Extraoral bitter taste receptors as mediators of off-target drug effects. FASEB J. 26, 4827-4831 (2012). www.fasebj.org	[Clark, Adam A.; Munger, Steven D.] Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA; [Clark, Adam A.; Munger, Steven D.] Univ Maryland, Sch Med, Toxicol Program, Baltimore, MD 21201 USA; [Munger, Steven D.] Univ Maryland, Sch Med, Div Endocrinol Diabet & Nutr, Dept Med, Baltimore, MD 21201 USA; [Liggett, Stephen B.] Univ S Florida, Morsani Coll Med, Dept Med, Tampa, FL USA; [Liggett, Stephen B.] Univ S Florida, Morsani Coll Med, Ctr Personalized Med & Genom, Tampa, FL USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Munger, SD (corresponding author), Univ Maryland, Sch Med, Dept Anat & Neurobiol, 20 Penn St,S251, Baltimore, MD 21201 USA.	smung001@umaryland.edu		Liggett, Stephen B./0000-0002-0128-3669	U.S. National Institute on Deafness and Other Communication Disorders [DC-010110]; U.S. National Heart, Lung, and Blood Institute [HL-071609]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071609] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC010110] Funding Source: NIH RePORTER	U.S. National Institute on Deafness and Other Communication Disorders(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); U.S. National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	Support for this work was provided by the U.S. National Institute on Deafness and Other Communication Disorders, grant DC-010110 (to S. D. M.) and the U.S. National Heart, Lung, and Blood Institute, grant HL-071609 (to S. B. L.). The authors declare no conflicts of interest.	Adler E, 2000, CELL, V100, P693, DOI 10.1016/S0092-8674(00)80705-9; An SS, 2012, AM J PHYSIOL-LUNG C, V303, pL304, DOI 10.1152/ajplung.00126.2012; Behrens M, 2004, BIOCHEM BIOPH RES CO, V319, P479, DOI 10.1016/j.bbrc.2004.05.019; Behrens M, 2007, J NEUROSCI, V27, P12630, DOI 10.1523/JNEUROSCI.1168-07.2007; Behrens M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040304; Behrens M, 2011, PHYSIOL BEHAV, V105, P4, DOI 10.1016/j.physbeh.2011.02.010; Behrens M, 2009, J AGR FOOD CHEM, V57, P9860, DOI 10.1021/jf9014334; Brockhoff A, 2007, J AGR FOOD CHEM, V55, P6236, DOI 10.1021/jf070503p; Brockhoff A, 2011, J NEUROSCI, V31, P14775, DOI 10.1523/JNEUROSCI.2923-11.2011; Bufe B, 2005, CURR BIOL, V15, P322, DOI 10.1016/j.cub.2005.01.047; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; Conte C, 2003, PHYSIOL GENOMICS, V14, P73, DOI 10.1152/physiolgenomics.00060.2003; Conte C, 2002, CYTOGENET GENOME RES, V98, P45, DOI 10.1159/000068546; Deshpande DA, 2010, NAT MED, V16, P1299, DOI 10.1038/nm.2237; Dotson CD, 2010, CURR OPIN INVEST DR, V11, P447; Dotson CD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003974; Drewnowski A, 2000, AM J CLIN NUTR, V72, P1424; Finger TE, 2003, P NATL ACAD SCI USA, V100, P8981, DOI 10.1073/pnas.1531172100; Janssen S, 2011, P NATL ACAD SCI USA, V108, P2094, DOI 10.1073/pnas.1011508108; Jeon TI, 2008, J CLIN INVEST, V118, P3693, DOI 10.1172/JCI36461; Kim U, 2005, HUM MUTAT, V26, P199, DOI 10.1002/humu.20203; Kim UK, 2003, SCIENCE, V299, P1221, DOI 10.1126/science.1080190; Krasteva G, 2011, P NATL ACAD SCI USA, V108, P9478, DOI 10.1073/pnas.1019418108; Kuhn C, 2004, J NEUROSCI, V24, P10260, DOI 10.1523/JNEUROSCI.1225-04.2004; Matsunami H, 2000, NATURE, V404, P601, DOI 10.1038/35007072; Meyerhof W, 2010, CHEM SENSES, V35, P157, DOI 10.1093/chemse/bjp092; Mueller KL, 2005, NATURE, V434, P225, DOI 10.1038/nature03352; Pronin AN, 2007, CURR BIOL, V17, P1403, DOI 10.1016/j.cub.2007.07.046; Sainz E, 2007, BIOCHEM J, V403, P537, DOI 10.1042/BJ20061744; Shah AS, 2009, SCIENCE, V325, P1131, DOI 10.1126/science.1173869; Shi P, 2003, MOL BIOL EVOL, V20, P805, DOI 10.1093/molbev/msg083; Shi P, 2007, GENOME RES, V17, P166, DOI 10.1101/gr.6040007; Slack JP, 2010, CURR BIOL, V20, P1104, DOI 10.1016/j.cub.2010.04.043; Soranzo N, 2005, CURR BIOL, V15, P1257, DOI 10.1016/j.cub.2005.06.042; Tizzano M, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-3; Tizzano M, 2010, P NATL ACAD SCI USA, V107, P3210, DOI 10.1073/pnas.0911934107; Wooding S, 2010, CHEM SENSES, V35, P685, DOI 10.1093/chemse/bjq061; Wu SV, 2002, P NATL ACAD SCI USA, V99, P2392, DOI 10.1073/pnas.042617699; Yarmolinsky DA, 2009, CELL, V139, P234, DOI 10.1016/j.cell.2009.10.001; Yasuoka A, 2009, RESULTS PROBL CELL D, V47, P239, DOI 10.1007/400_2008_6	40	84	88	0	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2012	26	12					4827	4831		10.1096/fj.12-215087	http://dx.doi.org/10.1096/fj.12-215087			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	047KD	22964302	Green Published			2023-01-03	WOS:000311838300006
J	Chung, KY; Kim, TH; Manglik, A; Alvares, R; Kobilka, BK; Prosser, RS				Chung, Ka Young; Kim, Tae Hun; Manglik, Aashish; Alvares, Rohan; Kobilka, Brian K.; Prosser, R. Scott			Role of Detergents in Conformational Exchange of a G Protein-coupled Receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE RELAXATION; KCSA POTASSIUM CHANNEL; MODEL-FREE APPROACH; MEMBRANE-PROTEINS; NMR; DYNAMICS; INSIGHTS; LIGAND; STATE; MACROMOLECULES	The G protein-coupled beta(2)-adrenoreceptor (beta(2)AR) signals through the heterotrimeric G proteins G(s) and G(i) and beta-arrestin. As such, the energy landscape of beta(2)AR-excited state conformers is expected to be complex. Upon tagging Cys-265 of beta(2)AR with a trifluoromethyl probe, F-19 NMR was used to assess conformations and possible equilibria between states. Here, we report key differences in beta(2)AR conformational dynamics associated with the detergents used to stabilize the receptor. In dodecyl maltoside (DDM) micelles, the spectra are well represented by a single Lorentzian line that shifts progressively downfield with activation by appropriate ligand. The results are consistent with interconversion between two or more states on a time scale faster than the greatest difference in ligand-dependent chemical shift (i.e. >100 Hz). Given that high detergent off-rates of DDM monomers may facilitate conformational exchange between functional states of beta(2)AR, we utilized the recently developed maltose-neopentyl glycol (MNG-3) diacyl detergent. In MNG-3 micelles, spectra indicated at least three distinct states, the relative populations of which depended on ligand, whereas no ligand-dependent shifts were observed, consistent with the slow exchange limit. Thus, detergent has a profound effect on the equilibrium kinetics between functional states. MNG-3, which has a critical micelle concentration in the nanomolar regime, exhibits an off-rate that is 4 orders of magnitude lower than that of DDM. High detergent off-rates are more likely to facilitate conformational exchange between distinct functional states associated with the G protein-coupled receptor.	[Prosser, R. Scott] Univ Toronto, Dept Chem, UTM, Mississauga, ON L5L 1C6, Canada; [Chung, Ka Young; Manglik, Aashish; Kobilka, Brian K.] Stanford Univ, Dept Mol & Cellular Physiol, Sch Med, Stanford, CA 94305 USA; [Chung, Ka Young] Sungkyunkwan Univ, Sch Pharm, Suwon 440746, South Korea	University of Toronto; University Toronto Mississauga; Stanford University; Sungkyunkwan University (SKKU)	Prosser, RS (corresponding author), Univ Toronto, Dept Chem, UTM, 3359 Mississauga Rd N, Mississauga, ON L5L 1C6, Canada.	scott.prosser@utoronto.ca	Chung, Ka Young/AAO-7984-2020	Kobilka, Brian/0000-0001-5958-3990; Chung, Ka Young/0000-0001-9038-9571	National Institutes of Health [NH028471]; Natural Sciences and Engineering Research Council of Canada (NSERC) [261980]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028471] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported, in whole or in part, by National Institutes of Health Grant NH028471 (to B. K. K.). This work was also supported by Research Discovery Award 261980 from the Natural Sciences and Engineering Research Council of Canada (NSERC; to R. S. P.).	Acosta EJ, 2004, J COLLOID INTERF SCI, V274, P652, DOI 10.1016/j.jcis.2004.03.037; ANIANSSON EA, 1974, J PHYS CHEM-US, V78, P1024, DOI 10.1021/j100603a016; Baker KA, 2007, NAT STRUCT MOL BIOL, V14, P1089, DOI 10.1038/nsmb1311; Bayburt TH, 2010, FEBS LETT, V584, P1721, DOI 10.1016/j.febslet.2009.10.024; Bokoch MP, 2010, NATURE, V463, P108, DOI 10.1038/nature08650; Catoire LJ, 2010, J AM CHEM SOC, V132, P9049, DOI 10.1021/ja101868c; Cavanagh J, 2007, PROTEIN NMR SPECTROSCOPY: PRINCIPLES AND PRACTICE, 2ND EDITION, P1; Chae PS, 2010, NAT METHODS, V7, P1003, DOI 10.1038/NMETH.1526; Chill JH, 2006, PROTEIN SCI, V15, P684, DOI 10.1110/ps.051954706; Deupi X, 2010, PHYSIOLOGY, V25, P293, DOI 10.1152/physiol.00002.2010; Gautier A, 2010, NAT STRUCT MOL BIOL, V17, P768, DOI 10.1038/nsmb.1807; Hiller S, 2008, SCIENCE, V321, P1206, DOI 10.1126/science.1161302; Kang CB, 2011, CURR OPIN CHEM BIOL, V15, P560, DOI 10.1016/j.cbpa.2011.05.025; Kim HJ, 2009, PROG NUCL MAG RES SP, V55, P335, DOI 10.1016/j.pnmrs.2009.07.002; Kobilka B, 2008, TRENDS PHARMACOL SCI, V29, P79, DOI 10.1016/j.tips.2007.11.009; Kobilka BK, 2011, TRENDS PHARMACOL SCI, V32, P213, DOI 10.1016/j.tips.2011.02.005; Kusnetzow AK, 2006, BIOCHEMISTRY-US, V45, P5538, DOI 10.1021/bi060101v; Liang BY, 2007, P NATL ACAD SCI USA, V104, P16140, DOI 10.1073/pnas.0705466104; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Liu JJ, 2012, SCIENCE, V335, P1106, DOI 10.1126/science.1215802; MOLLER JV, 1993, J BIOL CHEM, V268, P18659; Nietlispach D, 2011, CURR OPIN STRUC BIOL, V21, P497, DOI 10.1016/j.sbi.2011.06.009; Popot JL, 2011, ANNU REV BIOPHYS, V40, P379, DOI 10.1146/annurev-biophys-042910-155219; Popot JL, 2010, ANNU REV BIOCHEM, V79, P737, DOI 10.1146/annurev.biochem.052208.114057; Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361; Rasmussen SGF, 2011, NATURE, V469, P175, DOI 10.1038/nature09648; Schnell JR, 2008, NATURE, V451, P591, DOI 10.1038/nature06531; Serebryany E, 2012, BBA-BIOMEMBRANES, V1818, P225, DOI 10.1016/j.bbamem.2011.07.047; Tamm LK, 2006, PROG NUCL MAG RES SP, V48, P201, DOI 10.1016/j.pnmrs.2006.05.005; Tate CG, 2009, CURR OPIN STRUC BIOL, V19, P386, DOI 10.1016/j.sbi.2009.07.004; Thomas MJ, 1999, BBA-BIOMEMBRANES, V1417, P144, DOI 10.1016/S0005-2736(98)00254-5; Traaseth NJ, 2009, P NATL ACAD SCI USA, V106, P10165, DOI 10.1073/pnas.0904290106; Tsamaloukas AD, 2009, LANGMUIR, V25, P4393, DOI 10.1021/la8033935; Van Horn WD, 2009, SCIENCE, V324, P1726, DOI 10.1126/science.1171716; Yao XJ, 2009, P NATL ACAD SCI USA, V106, P9501, DOI 10.1073/pnas.0811437106; Zhou YP, 2008, MOL CELL, V31, P896, DOI 10.1016/j.molcel.2008.08.028	37	71	71	0	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2012	287	43					36305	36311		10.1074/jbc.M112.406371	http://dx.doi.org/10.1074/jbc.M112.406371			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027PA	22893704	hybrid, Green Published			2023-01-03	WOS:000310364000051
J	Scirica, BM; Bonaca, MP; Braunwald, E; De Ferrari, GM; Isaza, D; Lewis, BS; Mehrhof, F; Merlini, PA; Murphy, SA; Sabatine, MS; Tendera, M; Van de Werf, F; Wilcox, R; Morrow, DA				Scirica, Benjamin M.; Bonaca, Marc P.; Braunwald, Eugene; De Ferrari, Gaetano M.; Isaza, Daniel; Lewis, Basil S.; Mehrhof, Felix; Merlini, Piera A.; Murphy, Sabina A.; Sabatine, Marc S.; Tendera, Michal; Van de Werf, Frans; Wilcox, Robert; Morrow, David A.		Tra 2 P-Timi 50 Steering Comm Inve	Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 degrees P-TIMI 50 trial	LANCET			English	Article							ACUTE CORONARY SYNDROMES; ANTIPLATELET THERAPY; RECEPTOR ANTAGONIST; DOUBLE-BLIND; TASK-FORCE; CLOPIDOGREL; ASPIRIN; PRASUGREL; INTERVENTION; GUIDELINES	Background Vorapaxar inhibits platelet activation by antagonising thrombin-mediated activation of the protease-activated receptor 1 on human platelets. The effect of adding other antiplatelet drugs to aspirin for long-term secondary prevention of thrombotic events in stable patients with previous myocardial infarction is uncertain. We tested this effect in a subgroup of patients from the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Methods In TRA 2 degrees P-TIMI 50-a randomised, placebo-controlled, parallel trial-we randomly assigned patients with a history of atherothrombosis to receive vorapaxar (2.5 mg daily) or matching placebo in a 1:1 ratio. Patients, and those giving treatment, assessing outcomes, and analysing results were masked to treatment allocation. Patients with a qualifying myocardial infarction within the previous 2 weeks to 12 months were analysed as a pre-defined subgroup. The primary efficacy endpoint was cardiovascular death, myocardial infarction, or stroke, analysed by intention to treat. We analysed events by Kaplan-Meier analysis and compared groups with a Cox proportional hazard model. TRA 2 degrees P-TIMI 50 is registered at ClinicalTrials.gov (NCT00526474). Findings 17 779 of 26 449 patients had a qualifying myocardial infarction and were assigned treatment (8898 to vorapaxar and 8881 to placebo). Median follow-up was 2.5 years (IQR 2.0-2.9). Cardiovascular death, myocardial infarction, or stroke occurred in 610 of 8898 patients in the vorapaxar group and 750 of 8881 in the placebo group (3-year Kaplan-Meier estimates 8.1% vs 9.7%, HR 0.80, 95% CI 0.72-0.89; p<0.0001). Moderate or severe bleeding was more common in the vorapaxar group versus the placebo group (241/8880 [3.4%, 3-year Kaplan-Meier estimate] vs 151/8849 [2.1%, 3-year Kaplan-Meier estimate], HR 1.61, 95% CI 1.31-1.97; p<0.0001). Intracranial haemorrhage occurred in 43 of 8880 patients (0.6%, 3-year Kaplan-Meier estimate) with vorapaxar versus 28 of 8849 (0.4%, 3-year Kaplan-Meier estimate) with placebo (p=0.076). Other serious adverse events were equally distributed between groups. Interpretation For patients with a history of myocardial infarction, inhibition of protease-activated receptor 1 with vorapaxar reduces the risk of cardiovascular death or ischaemic events when added to standard antiplatelet treatment, including aspirin, and increases the risk of moderate or severe bleeding.	[Scirica, Benjamin M.; Bonaca, Marc P.; Braunwald, Eugene; Murphy, Sabina A.; Sabatine, Marc S.; Morrow, David A.] Harvard Univ, Brigham & Womens Hosp, TIMI Study Grp, Cardiovasc Div,Dept Med,Med Sch, Boston, MA 02115 USA; [De Ferrari, Gaetano M.] Fdn IRCCS Policlin San Matteo, Dept Cardiol, Pavia, Italy; [Isaza, Daniel] Fdn CardioInfantil, Bogota, Colombia; [Lewis, Basil S.] Technion Israel Inst Technol, Lady Davis Carmel Med Ctr, Haifa, Israel; [Lewis, Basil S.] Technion Israel Inst Technol, Ruth & Bruce Rappaport Sch Med, Haifa, Israel; [Mehrhof, Felix] Charite, Dept Cardiol, D-13353 Berlin, Germany; [Merlini, Piera A.] Azienda Osped Niguarda Ca Granda, Div 4, Milan, Italy; [Tendera, Michal] Med Univ Silesia, Katowice, Poland; [Van de Werf, Frans] Katholieke Univ Leuven Hosp, Dept Cardiovasc Med, Louvain, Belgium; [Wilcox, Robert] Univ Nottingham Hosp, Queens Med Ctr, Nottingham NG7 2UH, England	Harvard University; Brigham & Women's Hospital; Harvard Medical School; IRCCS Fondazione San Matteo; Fundacion Cardioinfantil - Instituto de Cardiologia; Clalit Health Services; Carmel Medical Center; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; Medical University Silesia; Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven; University of Nottingham	Scirica, BM (corresponding author), Harvard Univ, Brigham & Womens Hosp, TIMI Study Grp, Cardiovasc Div,Dept Med,Med Sch, Boston, MA 02115 USA.	bscirica@partners.org	Tendera, Michal/AAA-1875-2022; Mehrhof, Felix/AAS-2663-2020; Sabatine, Marc/AAJ-6751-2020; De Ferrari, Gaetano M/K-5188-2016; Bonaca, Marc/AAJ-2397-2021; Domitrz, Izabela/M-8960-2018; Macleod, Malcolm Robert/B-2052-2010	Sabatine, Marc/0000-0002-0691-3359; De Ferrari, Gaetano M/0000-0003-4940-0876; Bonaca, Marc/0000-0002-9860-3584; Domitrz, Izabela/0000-0003-3130-1036; Mehrhof, Felix/0000-0003-0553-4290; Macleod, Malcolm Robert/0000-0001-9187-9839; Tendera, Michal/0000-0002-0812-6113; Van de Werf, Frans/0000-0001-9479-7767	Merck; Abbott; AstraZeneca; Amgen; Bayer Healthcare; Bristol-Myers Squibb; Daichii Sankyo; Eli Lilly; Gilead; GlaxoSmithKline; Merck (SPRI); Novartis; Pfizer; Roche Diagnostics; Sanofi-Aventis; Johnson Johnson; Brigham and Women's Hospital from BRAHMS; Critical Diagnostics; Genzyme; Nanosphere; Takeda; Merck Sharp Dohme; Boehringer Ingelheim; Daiichi Sankyo	Merck(Merck & Company); Abbott(Abbott Laboratories); AstraZeneca(AstraZeneca); Amgen(Amgen); Bayer Healthcare(Bayer AGBayer Healthcare Pharmaceuticals); Bristol-Myers Squibb(Bristol-Myers Squibb); Daichii Sankyo(Daiichi Sankyo Company Limited); Eli Lilly(Eli Lilly); Gilead(Gilead Sciences); GlaxoSmithKline(GlaxoSmithKline); Merck (SPRI); Novartis(Novartis); Pfizer(Pfizer); Roche Diagnostics; Sanofi-Aventis(Sanofi-Aventis); Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Brigham and Women's Hospital from BRAHMS; Critical Diagnostics; Genzyme(Sanofi-AventisGenzyme Corporation); Nanosphere; Takeda(Takeda Pharmaceutical Company Ltd); Merck Sharp Dohme(Merck & Company); Boehringer Ingelheim(Boehringer Ingelheim); Daiichi Sankyo(Daiichi Sankyo Company Limited)	Merck.; The TIMI Study Group has received research grants from Abbott, AstraZeneca, Amgen, Bayer Healthcare, Bristol-Myers Squibb, Daichii Sankyo, Eli Lilly, Gilead, GlaxoSmithKline, Merck (SPRI), Novartis, Pfizer, Roche Diagnostics, Sanofi-Aventis, and Johnson & Johnson and grant support through Brigham and Women's Hospital from BRAHMS, Critical Diagnostics, Genzyme, Nanosphere, Takeda. BMS has served as a consultant for Lexicon, Arena, Gilead, and Eisai. EB has served as a consultant for Merck (no compensation), Amorcyte, Daiichi Sankyo, Medicines Co, Ikaria, CardioRentis, Sanofi-Aventis, and CVRx (no compensation). GMDF has received honoraria from Merck for presentations and participation on advisory boards. BSL has received research support and served on advisory boards for Merck Sharp & Dohme, Bristol-Myers Squibb, AstraZeneca, Sanofi-Aventis, and Bayer Healthcare. FM has served on a national advisory board for vorapaxar for Merck Sharp & Dohme and has received honoraria from Essex Pharma for oral presentations. SAM has served as a consultant for Eli Lilly and Amarin Pharmaceuticals. MSS has served as a consultant for Amgen, AstraZeneca, Bristol-Myers Squibb, Sanofi-Aventis, Daiichi-Sankyo, Eli Lilly, Diasorin, GlaxoSmithKline, Merck, Pfizer, and Sanofi-Aventis and given accredited Continuing Medical Education talks supported by medical education companies that received unrestricted educational grants from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Sanofi-Aventis, Daiichi Sankyo, Eli Lilly. FVdW has received honoraria from Merck for presentations and participation on advisory boards. DAM has served as consultant for Merck (SPRI), Boeringher Ingelheim, CV Therapeutics (now Gilead Sciences), Genentech, Ikaria, Johnson & Johnson, Menarini, Novartis, Servier, and Roche Diagnostics.	Anderson JL, 2011, J AM COLL CARDIOL, V57, pE215, DOI 10.1016/j.jacc.2011.02.011; Antman EM, 2008, J AM COLL CARDIOL, V51, P2028, DOI 10.1016/j.jacc.2007.10.001; Bhatt DL, 2007, J AM COLL CARDIOL, V49, P1982, DOI 10.1016/j.jacc.2007.03.025; Bhatt DL, 2006, NEW ENGL J MED, V354, P1706, DOI 10.1056/NEJMoa060989; Cannon CP, 2001, J AM COLL CARDIOL, V38, P2114, DOI 10.1016/S0735-1097(01)01702-8; Diener HC, 2004, LANCET, V364, P331, DOI 10.1016/S0140-6736(04)16721-4; Eikelboom JW, 2012, CHEST, V141, pE89S, DOI 10.1378/chest.11-2293; Fowkes FGR, 2010, JAMA-J AM MED ASSOC, V303, P841, DOI 10.1001/jama.2010.221; Hamm CW, 2011, EUR HEART J, V32, P2999, DOI 10.1093/eurheartj/ehr236; Levine GN, 2011, J AM COLL CARDIOL, V58, pE44, DOI 10.1016/j.jacc.2011.08.007; Mauri L, 2010, AM HEART J, V160, P1035, DOI 10.1016/j.ahj.2010.07.038; Morrow DA, 2012, NEW ENGL J MED, V366, P1404, DOI 10.1056/NEJMoa1200933; Morrow DA, 2009, AM HEART J, V158, P335, DOI 10.1016/j.ahj.2009.06.027; Sacco RL, 2008, NEW ENGL J MED, V359, P1238, DOI 10.1056/NEJMoa0805002; Steg PG, 2007, JAMA-J AM MED ASSOC, V297, P1197, DOI 10.1001/jama.297.11.1197; Thygesen K, 2007, EUR HEART J, V28, P2525; Tricoci P, 2012, NEW ENGL J MED, V366, P20, DOI 10.1056/NEJMoa1109719; Wallentin L, 2009, NEW ENGL J MED, V361, P1045, DOI 10.1056/NEJMoa0904327; Wiviott SD, 2007, NEW ENGL J MED, V357, P2001, DOI 10.1056/NEJMoa0706482; Wiviott SD, 2011, AM J CARDIOL, V108, P905, DOI 10.1016/j.amjcard.2011.05.020; Yusuf S, 2001, NEW ENGL J MED, V345, P494	21	172	178	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 13	2012	380	9850					1317	1324		10.1016/S0140-6736(12)61269-0	http://dx.doi.org/10.1016/S0140-6736(12)61269-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	022BZ	22932716				2023-01-03	WOS:000309931400030
J	Greene, JA; Jones, DS; Podolsky, SH				Greene, Jeremy A.; Jones, David S.; Podolsky, Scott H.			200TH ANNIVERSARY ARTICLE Therapeutic Evolution and the Challenge of Rational Medicine	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Greene, Jeremy A.] Johns Hopkins Univ, Sch Med, Dept Hist Med, Baltimore, MD 21218 USA; [Greene, Jeremy A.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21218 USA; [Jones, David S.; Podolsky, Scott H.] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA; [Podolsky, Scott H.] Countway Lib Med, Ctr Hist Med, Boston, MA USA; [Jones, David S.] Harvard Univ, Dept Hist Sci, Cambridge, MA 02138 USA	Johns Hopkins University; Johns Hopkins University; Harvard University; Harvard Medical School; Harvard University	Greene, JA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Hist Med, Baltimore, MD 21218 USA.							Brandt Allan M, 1985, NO MAGIC BULLET SOCI; Jones DS, 2002, B HIST MED, V76, P749, DOI 10.1353/bhm.2002.0186; MCKEOWN T, 1962, POP STUD-J DEMOG, V16, P94, DOI 10.2307/2173119; Pernick M, 1987, CALCULUS SUFFERING P; Rosenberg CE, 1979, THERAPEUTIC REVOLUTI, P9; Warner John Harley, 1987, THERAPEUTIC PERSPECT	6	12	14	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 20	2012	367	12					1077	1082		10.1056/NEJMp1113570	http://dx.doi.org/10.1056/NEJMp1113570			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	007AS	22992071	Green Published			2023-01-03	WOS:000308861800001
J	Roland, M; Abel, G				Roland, Martin; Abel, Gary			Reducing emergency admissions: are we on the right track?	BRITISH MEDICAL JOURNAL			English	Editorial Material							CONTROLLED-TRIAL; HOSPITALIZATIONS; IMPACT; CARE		[Roland, Martin; Abel, Gary] Univ Cambridge, Cambridge Ctr Hlth Serv Res, Cambridge CB2 8PN, England	University of Cambridge	Roland, M (corresponding author), Univ Cambridge, Cambridge Ctr Hlth Serv Res, Cambridge CB2 8PN, England.	mr108@cam.ac.uk	Abel, Gary/ABE-1765-2021	Abel, Gary/0000-0003-2231-5161; Roland, Martin/0000-0002-8533-3060				Blunt I, 2010, TRENDS EMERGENCY ADM; Bottle A, 2006, J ROY SOC MED, V99, P406, DOI 10.1258/jrsm.99.8.406; Department of Health, 2010, PAYM RES BACKGR; Evidence Adoption Centre, 2011, EFF PRED MOD TOOLS I; Fan VS, 2012, ANN INTERN MED, V156, P673, DOI 10.7326/0003-4819-156-10-201205150-00003; Gravelle H, 2007, BMJ-BRIT MED J, V334, P31, DOI 10.1136/bmj.39020.413310.55; King's Health Partners, INT CAR PROGR; Munro J, 2005, BRIT J GEN PRACT, V55, P790; NHS Information Centre, 2011, HOSP EP STAT HEADL F; Northamptonshire Observatory, JOINT STRAT NEEDS AS; Nuffield Trust, 2011, PRED RISK HLTH CAR O; Ovretveit J., 2009, REV EVIDENCE WHICH I; Powell Davies G, 2006, COORDINATION CARE PR; Purdy S, 2012, INTERVENTIONS REDUCE; Purdy S., 2010, AVOIDING HOSP ADMISS; Roland M, 2005, BRIT MED J, V330, P289, DOI 10.1136/bmj.330.7486.289; Roland M., 2012, INT J INTEGRATED CAR, V12; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Sargent P, 2008, J NURS MANAGE, V16, P38, DOI 10.1111/j.1365-2934.2007.00785.x; Takahashi PY, 2012, ARCH INTERN MED, V172, P773, DOI 10.1001/archinternmed.2012.256; Wennberg D, 2006, COMBINED PREDICTIVE	21	78	78	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 18	2012	345								e6017	10.1136/bmj.e6017	http://dx.doi.org/10.1136/bmj.e6017			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	011JH	22990102				2023-01-03	WOS:000309160400006
J	Shiao, CC; Ko, WJ; Wu, VC; Huang, TM; Lai, CF; Lin, YF; Chao, CT; Chu, TS; Tsai, HB; Wu, PC; Young, GH; Kao, TW; Huang, JW; Chen, YM; Lin, SL; Wu, MS; Tsai, PR; Wu, KD; Wang, MJ				Shiao, Chih-Chung; Ko, Wen-Je; Wu, Vin-Cent; Huang, Tao-Min; Lai, Chun-Fu; Lin, Yu-Feng; Chao, Chia-Ter; Chu, Tzong-Shinn; Tsai, Hung-Bin; Wu, Pei-Chen; Young, Guang-Huar; Kao, Tze-Wah; Huang, Jenq-Wen; Chen, Yung-Ming; Lin, Shuei-Liong; Wu, Ming-Shou; Tsai, Pi-Ru; Wu, Kwan-Dun; Wang, Ming-Jiuh		Natl Taiwan Univ Hosp Study Grp	U-Curve Association between Timing of Renal Replacement Therapy Initiation and In-Hospital Mortality in Postoperative Acute Kidney Injury	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS; EXTRACORPOREAL MEMBRANE-OXYGENATION; FAILURE ASSESSMENT SCORE; CARDIAC-SURGERY; RISK-FACTORS; DIALYSIS; HEMOFILTRATION; EPIDEMIOLOGY; SURVIVAL; OUTCOMES	Background: Postoperative acute kidney injury (AKI) is associated with poor outcomes in surgical patients. This study aims to evaluate whether the timing of renal replacement therapy (RRT) initiation affects the in-hospital mortality of patients with postoperative AKI. Methodology: This multicenter retrospective observational study, which was conducted in the intensive care units (ICUs) in a tertiary hospital (National Taiwan University Hospital) and its branch hospitals in Taiwan between January, 2002, and April, 2009, included adult patients with postoperative AKI who underwent RRT for predefined indications. The demographic data, comorbid diseases, types of surgery and RRT, and the indications for RRT were documented. Patients were categorized according to the period of time between the ICU admission and RRT initiation as the early (EG, <= 1 day), intermediate (IG, 2-3 days), and late (LG, >= 4 days) groups. The in-hospital mortality rate censored at 180 day was defined as the endpoint. Results: Six hundred forty-eight patients (418 men, mean age 63.0 +/- 15.9 years) were enrolled, and 379 patients (58.5%) died during the hospitalization. Both the estimated probability of death and the in-hospital mortality rates of the three groups represented U-curves. According to the Cox proportional hazard method, LG (hazard ratio, 1.527; 95% confidence interval, 1.152-2.024; P=0.003, compared with IG group), age (1.014; 1.006-1.021), diabetes (1.279; 1.022-1.601; P=0.031), cirrhosis (2.147; 1.421-3.242), extracorporeal membrane oxygenation support (1.811; 1.391-2.359), initial neurological dysfunction (1.448; 1.107-1.894; P = 0.007), pre-RRT mean arterial pressure (0.988; 0.981-0.995), inotropic equivalent (1.006; 1.001-1.012; P = 0.013), APACHE II scores (1.055; 1.037-1.073), and sepsis (1.939; 1.536-2.449) were independent predictors of the inhospital mortality (All P < 0.001 except otherwise stated). Conclusions: The current study found a U-curve association between the timing of the RRT initiation after the ICU admission and patients' in-hospital mortalities, and alerts physicians of certain factors affecting the outcome after the RRT initiation.	[Shiao, Chih-Chung] St Marys Hosp Luodong, Div Nephrol, Dept Internal Med, Yilan, Taiwan; [Shiao, Chih-Chung] St Marys Med Nursing & Management Coll, Yilan, Taiwan; [Ko, Wen-Je; Lin, Yu-Feng; Tsai, Hung-Bin] Natl Taiwan Univ Hosp, Dept Traumatol, Taipei, Taiwan; [Ko, Wen-Je; Young, Guang-Huar; Tsai, Pi-Ru] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; [Wu, Vin-Cent; Lai, Chun-Fu; Chao, Chia-Ter; Chu, Tzong-Shinn; Wu, Pei-Chen; Kao, Tze-Wah; Huang, Jenq-Wen; Chen, Yung-Ming; Lin, Shuei-Liong; Wu, Ming-Shou; Wu, Kwan-Dun] Natl Taiwan Univ Hosp, Div Nephrol, Dept Internal Med, Taipei, Taiwan; [Huang, Tao-Min] Natl Taiwan Univ Hosp, Yun Lin Branch, Div Nephrol, Dept Internal Med, Douliu City, Yunlin County, Taiwan; [Wang, Ming-Jiuh] Natl Taiwan Univ Hosp, Dept Anesthesiol & Forens Med, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Shiao, CC (corresponding author), St Marys Hosp Luodong, Div Nephrol, Dept Internal Med, Yilan, Taiwan.	canon@ntuh.gov.tw	Shiao, Chih-Chung/AAM-2716-2020; Chao, Chia-Ter/H-7994-2019; Huang, Tao Min/C-5379-2011; Tsai, Hung-Bin/G-3761-2011; Lin, Shuei-Liong/AGR-2002-2022	Shiao, Chih-Chung/0000-0003-2220-7574; Chao, Chia-Ter/0000-0003-2892-7986; Huang, Tao Min/0000-0002-9387-0798; Lin, Shuei-Liong/0000-0002-1041-5571; Tsai, Hung-Bin/0000-0002-0689-8339; WU, VIN-CENT/0000-0001-7935-0991; WU, MING-SHIOU/0000-0002-1674-443X; LIN, YU-FENG/0000-0002-4350-7755; CHEN, YUNG-MING/0000-0002-9241-1258; CHU, TZONG-SHINN/0000-0002-5291-2509; LAI, CHUN-FU/0000-0003-2109-1522; HUANG, JENQ-WEN/0000-0001-8011-2317; WU, KWAN-DUN/0000-0002-3339-1509	Ta-Tung Kidney Foundation; Taiwan National Science Council [NSC 96-2314-B-002-164, NSC 96-2314-B-002-033-MY3, NSC 97-2314-B-002-155-MY2, NSC 98-2314-B-002-155-MY4]; NTUH [098-001177, 100-001667]	Ta-Tung Kidney Foundation; Taiwan National Science Council(Ministry of Science and Technology, Taiwan); NTUH	This study was financially supported by The Ta-Tung Kidney Foundation, Taiwan National Science Council (grant NSC 96-2314-B-002-164, NSC 96-2314-B-002-033-MY3, NSC 97-2314-B-002-155-MY2, NSC 98-2314-B-002-155-MY4), and NTUH 098-001177, NTUH 100-001667. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abelha FJ, 2009, CRIT CARE, V13, DOI 10.1186/cc7894; Andrade L, 2007, CLIN J AM SOC NEPHRO, V2, P739, DOI 10.2215/CJN.00680207; Bagshaw SM, 2007, CLIN J AM SOC NEPHRO, V2, P431, DOI 10.2215/CJN.03681106; Bagshaw SM, 2009, J CRIT CARE, V24, P129, DOI 10.1016/j.jcrc.2007.12.017; Balk RA, 2000, CRIT CARE CLIN, V16, P179, DOI 10.1016/S0749-0704(05)70106-8; Bouman CSC, 2002, CRIT CARE MED, V30, P2205, DOI 10.1097/00003246-200210000-00005; Brienza N, 2010, CURR OPIN CRIT CARE, V16, P353, DOI 10.1097/MCC.0b013e32833a9ef5; Chen YS, 2001, J HEART LUNG TRANSPL, V20, P850, DOI 10.1016/S1053-2498(01)00267-4; Clark E, 2012, NEPHROL DIAL TRANSPL, V27, P2761, DOI 10.1093/ndt/gfr740; Coca SG, 2010, KIDNEY INT, V78, P926, DOI 10.1038/ki.2010.259; de Mendonca A, 2000, INTENS CARE MED, V26, P915, DOI 10.1007/s001340051281; Eachempati SR, 2007, J TRAUMA, V63, P987, DOI 10.1097/TA.0b013e3181574930; Elahi M, 2009, EUR J CARDIO-THORAC, V35, P854, DOI 10.1016/j.ejcts.2008.12.019; Garcia-Fernandez N, 2011, BLOOD PURIFICAT, V32, P104, DOI 10.1159/000324195; Gill N, 2005, CHEST, V128, P2847, DOI 10.1378/chest.128.4.2847; Glance LG, 2011, ARCH SURG; Hsu CY, 2008, KIDNEY INT, V74, P101, DOI 10.1038/ki.2008.107; Hsu CY, 2009, CLIN J AM SOC NEPHRO, V4, P891, DOI 10.2215/CJN.05571008; Iyem H, 2009, HEMODIAL INT, V13, P55, DOI 10.1111/j.1542-4758.2009.00347.x; Karvellas CJ, 2011, CRIT CARE, V15, DOI 10.1186/cc10061; Kheterpal S, 2007, ANESTHESIOLOGY, V107, P892, DOI 10.1097/01.anes.0000290588.29668.38; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kolhe Nitin V, 2008, Crit Care, V12 Suppl 1, pS2, DOI 10.1186/cc7003; Lafrance JP, 2010, AM J KIDNEY DIS, V56, P651, DOI 10.1053/j.ajkd.2010.05.011; Lassnigg A, 2004, J AM SOC NEPHROL, V15, P1597, DOI 10.1097/01.ASN.0000130340.93930.DD; Lin YF, 2008, BLOOD PURIFICAT, V26, P547, DOI 10.1159/000178771; Lindenauer PK, 2005, NEW ENGL J MED, V353, P349, DOI 10.1056/NEJMoa041895; Ma YC, 2006, J AM SOC NEPHROL, V17, P2937, DOI 10.1681/ASN.2006040368; Minne L, 2008, CRIT CARE, V12, DOI 10.1186/cc7160; Ng KP, 2012, QJM-INT J MED, V105, P33, DOI 10.1093/qjmed/hcr133; Ostermann M, 2009, CRIT CARE, V13, DOI 10.1186/cc8154; Ostermann M, 2008, CRIT CARE, V12, DOI 10.1186/cc7123; Payen D, 2008, CRIT CARE, V12, DOI 10.1186/cc6916; Piccinni P, 2006, INTENS CARE MED, V32, P80, DOI 10.1007/s00134-005-2815-x; Rondon-Berrios H, 2007, CURR OPIN NEPHROL HY, V16, P64, DOI 10.1097/MNH.0b013e32802ef4a5; Rosner MH, 2006, CLIN J AM SOC NEPHRO, V1, P19, DOI 10.2215/CJN.00240605; Sadis C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000469; Seabra VF, 2008, AM J KIDNEY DIS, V52, P272, DOI 10.1053/j.ajkd.2008.02.371; Shiao CC, 2009, CRIT CARE, V13, DOI 10.1186/cc8147; Tsai CW, 2008, EUR J CARDIO-THORAC, V34, P1158, DOI 10.1016/j.ejcts.2008.07.025; Uchino S, 2007, INT J ARTIF ORGANS, V30, P281, DOI 10.1177/039139880703000402; Uchino S, 2008, NEPHRON CLIN PRACT, V109, pC216, DOI 10.1159/000142931; Uchino S, 2006, CRIT CARE MED, V34, P1913, DOI 10.1097/01.CCM.0000224227.70642.4F; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Waikar SS, 2008, CLIN J AM SOC NEPHRO, V3, P844, DOI 10.2215/CJN.05191107; Wu VC, 2006, CLIN INFECT DIS, V42, P66, DOI 10.1086/498509; Wu VC, 2008, INTENS CARE MED, V34, P101, DOI 10.1007/s00134-007-0813-x; Wu VC, 2007, J AM COLL SURGEONS, V205, P266, DOI 10.1016/j.jamcollsurg.2007.04.006; Wu VC, 2011, KIDNEY INT, V80, P1222, DOI 10.1038/ki.2011.259	49	31	33	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2012	7	8							e42952	10.1371/journal.pone.0042952	http://dx.doi.org/10.1371/journal.pone.0042952			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	998CA	22952623	Green Submitted, Green Published, gold			2023-01-03	WOS:000308213600011
J	Liu, LS; Cao, B; Aa, JY; Zheng, T; Shi, J; Li, MJ; Wang, XW; Zhao, CY; Xiao, WJ; Yu, XY; Sun, RB; Gu, RR; Zhou, J; Wu, L; Hao, G; Zhu, XX; Wang, GJ				Liu, Linsheng; Cao, Bei; Aa, Jiye; Zheng, Tian; Shi, Jian; Li, Mengjie; Wang, Xinwen; Zhao, Chunyan; Xiao, Wenjing; Yu, Xiaoyi; Sun, Runbin; Gu, Rongrong; Zhou, Jun; Wu, Liang; Hao, Gang; Zhu, Xuanxuan; Wang, Guangji			Prediction of the Pharmacokinetic Parameters of Triptolide in Rats Based on Endogenous Molecules in Pre-Dose Baseline Serum	PLOS ONE			English	Article							HUMAN METABOLIC PHENOTYPES; INDUCED HEPATOTOXICITY; PERSONALIZED MEDICINE; OXIDATIVE STRESS; GLUTATHIONE; MODULATION; TOXICITY; RELEASE; LIVER; FOOD	Background: Individual variances usually affect drug metabolism and disposition, and hence result in either ineffectiveness or toxicity of a drug. In addition to genetic polymorphism, the multiple confounding factors of lifestyles, such as dietary preferences, contribute partially to individual variances. However, the difficulty of quantifying individual diversity greatly challenges the realization of individualized drug therapy. This study aims at quantitative evaluating the association between individual variances and the pharmacokinetics. Methodology/Principal Findings: Molecules in pre-dose baseline serum were profiled using gas chromatography mass spectrometry to represent the individual variances of the model rats provided with high fat diets (HFD), routine chows and calorie restricted (CR) chows. Triptolide and its metabolites were determined using high performance liquid chromatography mass spectrometry. Metabonomic and pharmacokinetic data revealed that rats treated with the varied diets had distinctly different metabolic patterns and showed differential C-max values, AUC and drug metabolism after oral administration of triptolide. Rats with fatty chows had the lowest C-max and AUC values and the highest percentage of triptolide metabolic transformation, while rats with CR chows had the highest C-max and AUC values and the least percentage of triptolide transformation. Multivariate linear regression revealed that in baseline serum, the concentrations of creatinine and glutamic acid, which is the precursor of GSH, were linearly negatively correlated to C-max and AUC values. The glutamic acid and creatinine in baseline serum were suggested as the potential markers to represent individual diversity and as predictors of the disposal and pharmacokinetics of triptolide. Conclusions/Significance: These results highlight the robust potential of metabonomics in characterizing individual variances and identifying relevant markers that have the potential to facilitate individualized drug therapy.	[Liu, Linsheng; Cao, Bei; Aa, Jiye; Zheng, Tian; Shi, Jian; Li, Mengjie; Wang, Xinwen; Zhao, Chunyan; Xiao, Wenjing; Yu, Xiaoyi; Sun, Runbin; Gu, Rongrong; Zhou, Jun; Wu, Liang; Hao, Gang; Wang, Guangji] China Pharmaceut Univ, State Key Lab Nat Med, Key Lab Drug Metab & Pharmacokinet, Nanjing, Jiangsu, Peoples R China; [Zhu, Xuanxuan] Jiangsu Prov Hosp Tradit Chinese Med, Nanjing, Jiangsu, Peoples R China	China Pharmaceutical University; Nanjing University of Chinese Medicine	Liu, LS (corresponding author), China Pharmaceut Univ, State Key Lab Nat Med, Key Lab Drug Metab & Pharmacokinet, Nanjing, Jiangsu, Peoples R China.	jiye_2005@yahoo.com.cn; guangjiwang@hotmail.com	li, mengjie/GRS-3931-2022; Shi, Jian/Q-1667-2018; liu, linsheng/AGF-5590-2022; Shi, Jian/Y-9055-2019; Wang, Xinwen/O-2885-2018	Shi, Jian/0000-0003-2609-0094; liu, linsheng/0000-0001-5371-3109; Shi, Jian/0000-0003-2609-0094; Wang, Xinwen/0000-0001-8143-7017	National Natural Science Foundation of the People's Republic of China [81072692/H3110]; Project Program of State Key Laboratory of Natural Medicines, China Pharmaceutical University [JKGP201108-AJY]; National '973' Key Fundamental Program [2011CB505303, 2012CB517606]	National Natural Science Foundation of the People's Republic of China(National Natural Science Foundation of China (NSFC)); Project Program of State Key Laboratory of Natural Medicines, China Pharmaceutical University; National '973' Key Fundamental Program	This work was supported by the National Natural Science Foundation of the People's Republic of China (81072692/H3110), the Project Program of State Key Laboratory of Natural Medicines, China Pharmaceutical University (JKGP201108-AJY), and the National '973' Key Fundamental Program (2011CB505303, 2012CB517606). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	A J, 2005, ANAL CHEM, V77, P8086, DOI 10.1021/ac051211v; Aa JY, 2011, METABOLOMICS, V7, P217, DOI 10.1007/s11306-010-0241-8; Backshall A, 2011, CLIN CANCER RES, V17, P3019, DOI 10.1158/1078-0432.CCR-10-2474; Bernini P, 2009, J PROTEOME RES, V8, P4264, DOI 10.1021/pr900344m; Bronson SL, 2011, BEHAV BRAIN RES, V220, P55, DOI 10.1016/j.bbr.2010.12.040; Brown BL, 1995, TOXICOL LETT, V81, P39, DOI 10.1016/0378-4274(95)03407-2; Chen BJ, 2001, LEUKEMIA LYMPHOMA, V42, P253, DOI 10.3109/10428190109064582; Clayton TA, 2009, P NATL ACAD SCI USA, V106, P14728, DOI 10.1073/pnas.0904489106; Clayton TA, 2006, NATURE, V440, P1073, DOI 10.1038/nature04648; Frade J, 2008, J NEUROCHEM, V105, P1144, DOI 10.1111/j.1471-4159.2008.05216.x; Gao Q, 2010, NEPHROL DIAL TRANSPL, V25, P3539, DOI 10.1093/ndt/gfq245; Gowda GAN, 2010, BIOMARK MED, V4, P299, DOI [10.2217/bmm.10.6, 10.2217/BMM.10.6]; Heinzmann SS, 2012, J PROTEOME RES, V11, P643, DOI 10.1021/pr2005764; Hikim APS, 2000, J ANDROL, V21, P431; Huynh PN, 2000, J ANDROL, V21, P689; Jonsson P, 2005, ANAL CHEM, V77, P5635, DOI 10.1021/ac050601e; Lee D, 2011, CLIN THER, V33, P2038, DOI 10.1016/j.clinthera.2011.10.024; Li HL, 2010, CANCER LETT, V297, P198, DOI 10.1016/j.canlet.2010.05.012; Li J, 2011, HUM MOL GENET, V20, P528, DOI 10.1093/hmg/ddq498; Liu L, 2010, TOXICOLOGY, V271, P57, DOI 10.1016/j.tox.2010.03.004; Mei ZN, 2005, PHARMACOL RES, V51, P345, DOI 10.1016/j.phrs.2004.10.007; Noeman SA, 2011, DIABETOL METAB SYNDR, V3, DOI 10.1186/1758-5996-3-17; O'Sullivan A, 2011, AM J CLIN NUTR, V93, P314, DOI 10.3945/ajcn.110.000950; OGUMA T, 1991, ANTIMICROB AGENTS CH, V35, P1729, DOI 10.1128/AAC.35.9.1729; Persson M, 2006, EUR J NEUROSCI, V24, P1063, DOI 10.1111/j.1460-9568.2006.04974.x; Phapale PB, 2010, CLIN PHARMACOL THER, V87, P426, DOI 10.1038/clpt.2009.296; Santin K, 2011, BRAIN RES, V1421, P1, DOI 10.1016/j.brainres.2011.08.003; Shao F, 2007, BIOL PHARM BULL, V30, P702, DOI 10.1248/bpb.30.702; Spear BB, 2001, TRENDS MOL MED, V7, P201, DOI 10.1016/S1471-4914(01)01986-4; Stella C, 2006, J PROTEOME RES, V5, P2780, DOI 10.1021/pr060265y; Titov DV, 2011, NAT CHEM BIOL, V7, P182, DOI 10.1038/NCHEMBIO.522; Trygg J, 2007, J PROTEOME RES, V6, P469, DOI 10.1021/pr060594q; VANDESTRAAT R, 1987, BIOCHEM PHARMACOL, V36, P2065, DOI 10.1016/0006-2952(87)90132-8; WILLIAMS PEO, 1984, J ANTIMICROB CHEMOTH, V13, P191, DOI 10.1093/jac/13.2.191; Wilson ID, 2009, P NATL ACAD SCI USA, V106, P14187, DOI 10.1073/pnas.0907721106; Winnike JH, 2010, CLIN PHARMACOL THER, V88, P45, DOI 10.1038/clpt.2009.240; WOLD S, 1978, TECHNOMETRICS, V20, P397, DOI 10.2307/1267639; Xu LY, 2008, EUR J PHARM BIOPHARM, V70, P741, DOI 10.1016/j.ejpb.2008.07.017; Xue X, 2011, TOXICOL LETT, V205, P47, DOI 10.1016/j.toxlet.2011.05.003; Yan B, 2009, J APPL PHYSIOL, V106, P531, DOI 10.1152/japplphysiol.90816.2008; Yang SM, 2003, MOL CANCER THER, V2, P65; Yao JC, 2008, BIOL PHARM BULL, V31, P592, DOI 10.1248/bpb.31.592; YOO JSH, 1992, BIOCHEM PHARMACOL, V43, P2535, DOI 10.1016/0006-2952(92)90141-5; Zhang Y, 2010, J IMMUNOL, V184, P3866, DOI 10.4049/jimmunol.0903417; Zhou R, 2005, INT IMMUNOPHARMACOL, V5, P1895, DOI 10.1016/j.intimp.2005.06.009; Zhou SF, 2008, CURR DRUG METAB, V9, P738, DOI 10.2174/138920008786049302	46	12	17	1	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 17	2012	7	8							e43389	10.1371/journal.pone.0043389	http://dx.doi.org/10.1371/journal.pone.0043389			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	996DG	22912866	gold, Green Published, Green Submitted			2023-01-03	WOS:000308063700094
J	Niki, M; Niki, M; Tateishi, Y; Ozeki, Y; Kirikae, T; Lewin, A; Inoue, Y; Matsumoto, M; Dahl, JL; Ogura, H; Kobayashi, K; Matsumoto, S				Niki, Makoto; Niki, Mamiko; Tateishi, Yoshitaka; Ozeki, Yuriko; Kirikae, Teruo; Lewin, Astrid; Inoue, Yusuke; Matsumoto, Makoto; Dahl, John L.; Ogura, Hisashi; Kobayashi, Kazuo; Matsumoto, Sohkichi			A Novel Mechanism of Growth Phase-dependent Tolerance to Isoniazid in Mycobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALASE-PEROXIDASE GENE; HISTONE-LIKE PROTEIN; DNA-BINDING PROTEIN; PENICILLIN TOLERANCE; KATG EXPRESSION; BOVIS BCG; TUBERCULOSIS; RESISTANCE; SMEGMATIS; SUSCEPTIBILITY	Tuberculosis remains one of the most deadly infectious diseases worldwide and is a leading public health problem. Although isoniazid (INH) is a key drug for the treatment of tuberculosis, tolerance to INH necessitates prolonged treatment, which is a concern for effective tuberculosis chemotherapy. INH is a prodrug that is activated by the mycobacterial enzyme, KatG. Here, we show that mycobacterial DNA-binding protein 1 (MDP1), which is a histone-like protein conserved in mycobacteria, negatively regulates katG transcription and leads to phenotypic tolerance to INH in mycobacteria. Mycobacterium smegmatis deficient for MDP1 exhibited increased expression of KatG and showed enhanced INH activation compared with the wild-type strain. Expression of MDP1 was increased in the stationary phase and conferred growth phase-dependent tolerance to INH in M. smegmatis. Regulation of KatG expression is conserved between M. smegmatis and Mycobacterium tuberculosis complex. Artificial reduction of MDP1 in Mycobacterium bovis BCG was shown to lead to increased KatG expression and susceptibility to INH. These data suggest a mechanism by which phenotypic tolerance to INH is acquired in mycobacteria.	[Niki, Makoto; Niki, Mamiko; Tateishi, Yoshitaka; Ozeki, Yuriko; Matsumoto, Sohkichi] Osaka City Univ, Grad Sch Med, Dept Bacteriol, Abeno Ku, Osaka 5458585, Japan; [Ogura, Hisashi] Osaka City Univ, Grad Sch Med, Dept Virol, Abeno Ku, Osaka 5458585, Japan; [Tateishi, Yoshitaka] Toneyama Natl Hosp, Natl Hosp Org, Dept Internal Med, Toyonaka, Osaka 5608552, Japan; [Ozeki, Yuriko] Sonoda Womens Univ, Dept Food & Nutr, Amagasaki, Hyogo 6618520, Japan; [Kirikae, Teruo] Natl Ctr Global Hlth & Med, Shinjuku Ku, Tokyo 1628655, Japan; [Lewin, Astrid] Robert Koch Inst, D-13353 Berlin, Germany; [Inoue, Yusuke; Matsumoto, Makoto] Otsuka Pharmaceut Co Ltd, Microbiol Res Inst, Kawaguchi, Tokushima 7710192, Japan; [Dahl, John L.] Univ Minnesota, Dept Biol, Duluth, MN 55812 USA; [Kobayashi, Kazuo] Natl Inst Infect Dis, Dept Immunol, Shinjuku Ku, Tokyo 1628640, Japan	Osaka Metropolitan University; Osaka Metropolitan University; National Center for Global Health & Medicine - Japan; Robert Koch Institute; Otsuka Pharmaceutical; University of Minnesota System; University of Minnesota Duluth; National Institute of Infectious Diseases (NIID)	Niki, M (corresponding author), Osaka City Univ, Grad Sch Med, Dept Bacteriol, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.	myoshi@med.osaka-cu.ac.jp; sohkichi@med.osaka-cu.ac.jp		Matsumoto, Sohkichi/0000-0002-6106-7538	Ministry of Education, Culture, Sports, Science, and Technology; Ministry of Health, Labor, and Welfare (Research on Emerging and Re-emerging Infectious Diseases, Health Sciences Research Grants); Japan Health Sciences Foundation; United States-Japan Cooperative Medical Science Program against Tuberculosis and Leprosy; Grants-in-Aid for Scientific Research [24501015] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labor, and Welfare (Research on Emerging and Re-emerging Infectious Diseases, Health Sciences Research Grants)(Ministry of Health, Labour and Welfare, Japan); Japan Health Sciences Foundation; United States-Japan Cooperative Medical Science Program against Tuberculosis and Leprosy; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by grants from the Ministry of Education, Culture, Sports, Science, and Technology, the Ministry of Health, Labor, and Welfare (Research on Emerging and Re-emerging Infectious Diseases, Health Sciences Research Grants), The Japan Health Sciences Foundation, and The United States-Japan Cooperative Medical Science Program against Tuberculosis and Leprosy.	Ando H, 2011, MOL MICROBIOL, V79, P1615, DOI 10.1111/j.1365-2958.2011.07547.x; Aoki K, 2004, J BIOL CHEM, V279, P39798, DOI 10.1074/jbc.M402677200; Azam TA, 1999, J BACTERIOL, V181, P6361, DOI 10.1128/JB.181.20.6361-6370.1999; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Blasco B, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002621; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bradley MD, 2007, MICROBIOL-SGM, V153, P2922, DOI 10.1099/mic.0.2007/008565-0; BROWN BA, 1992, ANTIMICROB AGENTS CH, V36, P1987, DOI 10.1128/AAC.36.9.1987; Colangeli R, 2007, PLOS PATHOG, V3, P780, DOI 10.1371/journal.ppat.0030087; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; Dick T, 1998, FEMS MICROBIOL LETT, V163, P159, DOI 10.1111/j.1574-6968.1998.tb13040.x; GOODELL EW, 1978, ANTIMICROB AGENTS CH, V13, P514, DOI 10.1128/AAC.13.3.514; HANDWERGER S, 1985, REV INFECT DIS, V7, P368; Herbert D, 1996, ANTIMICROB AGENTS CH, V40, P2296, DOI 10.1128/AAC.40.10.2296; HEYM B, 1993, J BACTERIOL, V175, P4255, DOI 10.1128/JB.175.13.4255-4259.1993; HILLAR A, 1995, ARCH BIOCHEM BIOPHYS, V323, P438, DOI 10.1006/abbi.1995.0065; HORNE D, 1981, ANTIMICROB AGENTS CH, V20, P128, DOI 10.1128/AAC.20.1.128; Johnsson K, 1997, J BIOL CHEM, V272, P2834, DOI 10.1074/jbc.272.5.2834; Katsube T, 2007, J BACTERIOL, V189, P8241, DOI 10.1128/JB.00550-07; KIM KS, 1987, J ANTIMICROB CHEMOTH, V19, P475, DOI 10.1093/jac/19.4.475; Larsen MH, 2002, MOL MICROBIOL, V46, P453, DOI 10.1046/j.1365-2958.2002.03162.x; Lewin A, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-91; Matsumoto S, 1999, MICROBIOL IMMUNOL, V43, P1027, DOI 10.1111/j.1348-0421.1999.tb01232.x; Matsumoto S, 2000, FEMS MICROBIOL LETT, V182, P297, DOI 10.1016/S0378-1097(99)00606-0; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; Miesel L, 1998, J BACTERIOL, V180, P2459, DOI 10.1128/JB.180.9.2459-2467.1998; Milano A, 2001, J BACTERIOL, V183, P6801, DOI 10.1128/JB.183.23.6801-6806.2001; Nachega JB, 2003, CLIN INFECT DIS, V36, pS24, DOI 10.1086/344657; Ojha A, 2005, CELL, V123, P861, DOI 10.1016/j.cell.2005.09.012; Ormerod LP, 2008, THORAX, V63, P388, DOI 10.1136/thx.2007.077610; PETTIJOHN DE, 1988, J BIOL CHEM, V263, P12793; Pym AS, 2001, MOL MICROBIOL, V40, P879, DOI 10.1046/j.1365-2958.2001.02427.x; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; Rouse DA, 1996, MOL MICROBIOL, V22, P583, DOI 10.1046/j.1365-2958.1996.00133.x; Sekiguchi J, 2007, J CLIN MICROBIOL, V45, P179, DOI 10.1128/JCM.00750-06; Sherman DR, 1996, SCIENCE, V272, P1641, DOI 10.1126/science.272.5268.1641; Smith AL, 2003, CHEST, V123, P1495, DOI 10.1378/chest.123.5.1495; Takatsuka M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020985; Timmins GS, 2004, ANTIMICROB AGENTS CH, V48, P3006, DOI 10.1128/AAC.48.8.3006-3009.2004; TUOMANEN E, 1986, REV INFECT DIS, V8, pS279; Vilcheze C, 2007, ANNU REV MICROBIOL, V61, P35, DOI 10.1146/annurev.micro.61.111606.122346; WALLACE RJ, 1986, J CLIN MICROBIOL, V24, P976, DOI 10.1128/JCM.24.6.976-981.1986; Wallis RS, 1999, ANTIMICROB AGENTS CH, V43, P2600, DOI 10.1128/AAC.43.11.2600; Whiteford DC, 2011, MICROBIOL-SGM, V157, P327, DOI 10.1099/mic.0.045518-0; Wilson TM, 1996, MOL MICROBIOL, V19, P1025, DOI 10.1046/j.1365-2958.1996.449980.x; Yeruva VC, 2006, CLIN VACCINE IMMUNOL, V13, P1137, DOI 10.1128/CVI.00125-06; Yuan Y, 1998, P NATL ACAD SCI USA, V95, P9578, DOI 10.1073/pnas.95.16.9578; Zahrt TC, 2001, MOL MICROBIOL, V39, P1174, DOI 10.1046/j.1365-2958.2001.02321.x; ZHANG Y, 1991, MOL MICROBIOL, V5, P381, DOI 10.1111/j.1365-2958.1991.tb02120.x; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	50	32	32	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2012	287	33					27743	27752		10.1074/jbc.M111.333385	http://dx.doi.org/10.1074/jbc.M111.333385			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	993FF	22648414	Green Published, hybrid			2023-01-03	WOS:000307840700048
J	Kim, D; Yan, YT; Valencia, CA; Liu, RH				Kim, Dongwook; Yan, Yitang; Valencia, C. Alexander; Liu, Rihe			Heptameric Targeting Ligands against EGFR and HER2 with High Stability and Avidity	PLOS ONE			English	Article							SINGLE-CHAIN FV; ANTIGEN-BINDING; DOMAIN; ANTIBODIES; PEPTABODY; AFFINITY; ALPHA	Multivalency of targeting ligands provides significantly increased binding strength towards their molecular targets. Here, we report the development of a novel heptameric targeting system, with general applications, constructed by fusing a target-binding domain with the heptamerization domain of the Archaeal RNA binding protein Sm1 through a flexible hinge peptide. The previously reported affibody molecules against EGFR and HER2, Z(EGFR) and Z(HER2), were used as target binding moieties. The fusion molecules were highly expressed in E. coli as soluble proteins and efficiently self-assembled into multimeric targeting ligands with the heptamer as the predominant form. We demonstrated that the heptameric molecules were resistant to protease-mediated digestion or heat-and SDS-induced denaturation. Surface plasmon resonance (SPR) analysis showed that both heptameric Z(EGFR) and Z(HER2) ligands have a significantly enhanced binding strength to their target receptors with a nearly 100 to 1000 fold increase relative to the monomeric ligands. Cellular binding assays showed that heptameric ligands maintained their target-binding specificities similar to the monomeric forms towards their respective receptor. The non-toxic property of each heptameric ligand was demonstrated by the cell proliferation assay. In general,, the heptamerization strategy we describe here could be applied to the facile and efficient engineering of other protein domain- or short peptide-based affinity molecules to acquire significantly improved target-binding strengths with potential applications in the targeted delivery of various imaging or therapeutic agents..	[Kim, Dongwook; Yan, Yitang; Valencia, C. Alexander; Liu, Rihe] Univ N Carolina, Div Chem Biol & Med Chem, UNC Eshelman Sch Pharm, Chapel Hill, NC 27515 USA; [Kim, Dongwook; Yan, Yitang; Valencia, C. Alexander; Liu, Rihe] Univ N Carolina, Carolina Ctr Genome Sci, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Kim, D (corresponding author), Univ N Carolina, Div Chem Biol & Med Chem, UNC Eshelman Sch Pharm, Chapel Hill, NC 27515 USA.	rliu@email.unc.edu	Ariel, Pablo/AGJ-4118-2022		National Cancer Institute [CA119343, CA151652]; NATIONAL CANCER INSTITUTE [U54CA151652, P30CA016086, U54CA119343] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Cancer Institute to RL. (CA119343 and CA151652). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beck K, 1996, J MOL BIOL, V256, P909, DOI 10.1006/jmbi.1996.0137; Benhabbour SR, 2012, J CONTROL RELEASE, V158, P63, DOI 10.1016/j.jconrel.2011.10.013; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; Bjorkelund H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024739; Borsi L, 2003, BLOOD, V102, P4384, DOI 10.1182/blood-2003-04-1039; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; CROTHERS DM, 1972, IMMUNOCHEMISTRY, V9, P341, DOI 10.1016/0019-2791(72)90097-3; Deyev SM, 2008, BIOESSAYS, V30, P904, DOI 10.1002/bies.20805; Duan J, 2007, BIOCHEMISTRY-US, V46, P12656, DOI 10.1021/bi701215e; Fattah OM, 2006, INT J CANCER, V119, P2455, DOI 10.1002/ijc.21541; Friedman M, 2008, J MOL BIOL, V376, P1388, DOI 10.1016/j.jmb.2007.12.060; Gostring L, 2010, INT J ONCOL, V36, P757, DOI 10.3892/ijo_00000551; Govindarajan S, 2012, BIOMATERIALS, V33, P2570, DOI 10.1016/j.biomaterials.2011.12.003; Ishida S, 2002, P NATL ACAD SCI USA, V99, P14298, DOI 10.1073/pnas.162491399; Kipriyanov SM, 1999, J MOL BIOL, V293, P41, DOI 10.1006/jmbi.1999.3156; Kubetzko S, 2006, J BIOL CHEM, V281, P35186, DOI 10.1074/jbc.M604127200; Leonard D, 2008, J CELL SCI, V121, P3445, DOI 10.1242/jcs.031484; Lyakhov I, 2010, CHEMBIOCHEM, V11, P345, DOI 10.1002/cbic.200900532; Nordberg E, 2010, INT J ONCOL, V36, P967, DOI 10.3892/ijo_00000576; Orlova A, 2006, CANCER RES, V66, P4339, DOI 10.1158/0008-5472.CAN-05-3521; PACK P, 1995, J MOL BIOL, V246, P28, DOI 10.1006/jmbi.1994.0062; Pluckthun A, 1997, IMMUNOTECHNOLOGY, V3, P83, DOI 10.1016/S1380-2933(97)00067-5; Stone E, 2007, J IMMUNOL METHODS, V318, P88, DOI 10.1016/j.jim.2006.10.006; Terskikh AV, 1997, P NATL ACAD SCI USA, V94, P1663, DOI 10.1073/pnas.94.5.1663; Toro I, 2002, J MOL BIOL, V320, P129, DOI 10.1016/S0022-2836(02)00406-0; Toro I, 2001, EMBO J, V20, P2293, DOI 10.1093/emboj/20.9.2293; Trejtnar F, 2002, Q J NUCL MED, V46, P181; YOKOTA T, 1992, CANCER RES, V52, P3402; Zhang JB, 2004, J MOL BIOL, V335, P49, DOI 10.1016/j.jmb.2003.09.034	29	7	9	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2012	7	8							e43077	10.1371/journal.pone.0043077	http://dx.doi.org/10.1371/journal.pone.0043077			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	986WZ	22912791	Green Submitted, gold, Green Published			2023-01-03	WOS:000307378500038
J	Rai, A				Rai, Arti			Use Patents, Carve-Outs, and Incentives - A New Battle in the Drug-Patent Wars	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Duke Univ, Sch Law, Durham, NC 27706 USA	Duke University	Rai, A (corresponding author), Duke Univ, Sch Law, Durham, NC 27706 USA.							Eisenberg Rebecca S, 2005, Yale J Health Policy Law Ethics, V5, P717; Radley DC, 2006, ARCH INTERN MED, V166, P1021, DOI 10.1001/archinte.166.9.1021; Stevens AJ, 2011, NEW ENGL J MED, V364, P535, DOI 10.1056/NEJMsa1008268; 2003, FED REG, V68, P36683	4	11	11	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 9	2012	367	6					491	493		10.1056/NEJMp1206573	http://dx.doi.org/10.1056/NEJMp1206573			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	986AE	22873529	Green Published			2023-01-03	WOS:000307310800003
J	McCrone, P; Sharpe, M; Chalder, T; Knapp, M; Johnson, AL; Goldsmith, KA; White, PD				McCrone, Paul; Sharpe, Michael; Chalder, Trudie; Knapp, Martin; Johnson, Anthony L.; Goldsmith, Kimberley A.; White, Peter D.			Adaptive Pacing, Cognitive Behaviour Therapy, Graded Exercise, and Specialist Medical Care for Chronic Fatigue Syndrome: A Cost-Effectiveness Analysis	PLOS ONE			English	Article							SELF-REPORT	Background: The PACE trial compared the effectiveness of adding adaptive pacing therapy (APT), cognitive behaviour therapy (CBT), or graded exercise therapy (GET), to specialist medical care (SMC) for patients with chronic fatigue syndrome. This paper reports the relative cost-effectiveness of these treatments in terms of quality adjusted life years (QALYs) and improvements in fatigue and physical function. Methods: Resource use was measured and costs calculated. Healthcare and societal costs (healthcare plus lost production and unpaid informal care) were combined with QALYs gained, and changes in fatigue and disability; incremental cost-effectiveness ratios (ICERs) were computed. Results: SMC patients had significantly lower healthcare costs than those receiving APT, CBT and GET. If society is willing to value a QALY at 30,000 pound there is a 62.7% likelihood that CBT is the most cost-effective therapy, a 26.8% likelihood that GET is most cost effective, 2.6% that APT is most cost-effective and 7.9% that SMC alone is most cost-effective. Compared to SMC alone, the incremental healthcare cost per QALY was pound 18,374 for CBT, pound 23,615 for GET and pound 55,235 for APT. From a societal perspective CBT has a 59.5% likelihood of being the most cost-effective, GET 34.8%, APT 0.2% and SMC alone 5.5%. CBT and GET dominated SMC, while APT had a cost per QALY of pound 127,047. ICERs using reductions in fatigue and disability as outcomes largely mirrored these findings. Conclusions: Comparing the four treatments using a health care perspective, CBT had the greatest probability of being the most cost-effective followed by GET. APT had a lower probability of being the most cost-effective option than SMC alone. The relative cost-effectiveness was even greater from a societal perspective as additional cost savings due to reduced need for informal care were likely.	[McCrone, Paul; Knapp, Martin] Kings Coll London, Ctr Econ Mental & Phys Hlth, Hlth Serv & Populat Res Dept, Inst Psychiat, London WC2R 2LS, England; [Sharpe, Michael] Univ Oxford, Univ Dept Psychiat, Oxford, England; [Chalder, Trudie] Kings Coll London, Acad Dept Psychol Med, London WC2R 2LS, England; [Knapp, Martin] London Sch Econ, Personal Social Serv Res Unit, London WC2A 2AE, England; [Johnson, Anthony L.] Inst Publ Hlth, MRC Biostat Unit, Cambridge, England; [Johnson, Anthony L.] MRC Clin Trials Unit, London, England; [Goldsmith, Kimberley A.] Kings Coll London, Dept Biostat, Inst Psychiat, London WC2R 2LS, England; [White, Peter D.] Queen Mary Univ London, Ctr Psychiat, Wolfson Inst Prevent Med, Barts & London Sch Med & Dent, London, England	University of London; King's College London; University of Oxford; University of London; King's College London; University of London; London School Economics & Political Science; MRC Biostatistics Unit; University of Cambridge; Medical Research Council Clinical Trials Unit; University of London; King's College London; University of London; Queen Mary University London	McCrone, P (corresponding author), Kings Coll London, Ctr Econ Mental & Phys Hlth, Hlth Serv & Populat Res Dept, Inst Psychiat, London WC2R 2LS, England.	paul.mccrone@kcl.ac.uk	Goldsmith, Kimberley/B-9107-2011; Chalder, Trudie/A-5717-2011	Goldsmith, Kimberley/0000-0002-0620-7868; Chalder, Trudie/0000-0003-0775-1045; sharpe, michael/0000-0002-6474-9980; Knapp, Martin/0000-0003-1427-0215; McCrone, Paul/0000-0001-7001-4502; White, Peter/0000-0002-8193-5355	United Kingdom Medical Research Council, Department of Health for England, Department for Work and Pensions; Scottish Chief Scientist Office; MRC [G0200434] Funding Source: UKRI; Medical Research Council [G0200434] Funding Source: researchfish	United Kingdom Medical Research Council, Department of Health for England, Department for Work and Pensions; Scottish Chief Scientist Office; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work supported by United Kingdom Medical Research Council, Department of Health for England, Department for Work and Pensions, and Scottish Chief Scientist Office. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barber JA, 1998, BRIT MED J, V317, P1195, DOI 10.1136/bmj.317.7167.1195; Beecham J., 2001, MEASURING MENTAL HLT, P200; Briggs AH, 2001, INT J TECHNOL ASSESS, V17, P69, DOI 10.1017/S0266462301104071; CALSYN RJ, 1993, EVALUATION REV, V17, P353, DOI 10.1177/0193841X9301700306; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; Chisholm D, 2001, BRIT J GEN PRACT, V51, P15; Collin SM, 2011, BMC HLTH SERV RES, V11; Curtis L., 2010, UNIT COSTS HLTH SOCI; Department of Health, 2011, NHS REF COSTS 2009 2; Dolan P, 1995, SOCIAL TARIFF EUROQO; Goldberg RW, 2002, PSYCHIATR SERV, V53, P879, DOI 10.1176/appi.ps.53.7.879; KOOPMANSCHAP MA, 1992, SOC SCI MED, V34, P1005, DOI 10.1016/0277-9536(92)90131-9; Koopmanschap MA, 2008, PHARMACOECONOMICS, V26, P269, DOI 10.2165/00019053-200826040-00001; Manca A, 2005, HEALTH ECON, V14, P487, DOI 10.1002/hec.944; McCrone P, 2004, PSYCHOL MED, V34, P991, DOI 10.1017/S0033291704001928; McCrone P, 2003, PSYCHOL MED, V33, P253, DOI 10.1017/S0033291702006980; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; National Institute for Health and Clinical Excellence, 2007, CLIN GUID CG53 CHRON; NHS Information Centre Prescribing Support Unit (PSU), 2011, PRESCR COST AN ENGL; Office for National Statistics, 2010, ANN SURV HOURS EARN; Patel A, 2005, FAM PRACT, V22, P323, DOI 10.1093/fampra/cmi027; Prins JB, 2006, LANCET, V367, P346, DOI 10.1016/S0140-6736(06)68073-2; Severens JL, 2004, QJM-INT J MED, V97, P153, DOI 10.1093/qjmed/hch029; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; White PD, 2011, LANCET, V377, P823, DOI 10.1016/S0140-6736(11)60096-2; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	26	57	57	0	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2012	7	8							e40808	10.1371/journal.pone.0040808	http://dx.doi.org/10.1371/journal.pone.0040808			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	984SU	22870204	Green Published, gold			2023-01-03	WOS:000307212800010
J	Chu, CL; Yu, YL; Kung, YC; Liao, PY; Liu, KJ; Tseng, YT; Lin, YC; Hsieh, SSY; Chong, PCS; Yang, CY				Chu, Ching-Liang; Yu, Yen-Ling; Kung, Yueh-Chen; Liao, Pei-Yu; Liu, Ko-Jiunn; Tseng, Yen-Tzu; Lin, Yuan-Chuen; Hsieh, Steve Shih-Yang; Chong, Pele Choi-Sing; Yang, Chiou-Ying			The Immunomodulatory Activity of Meningococcal Lipoprotein Ag473 Depends on the Conformation Made up of the Lipid and Protein Moieties	PLOS ONE			English	Article							DENDRITIC CELL ACTIVATION; TOLL-LIKE RECEPTORS; NEISSERIA-MENINGITIDIS; IMMUNE-RESPONSE; PATTERN-RECOGNITION; IN-VIVO; VACCINE; IDENTIFICATION; LIPOPEPTIDES; INDUCTION	We have previously demonstrated that the meningococcal antigen Ag473 in the presence of Freund's adjuvant can elicit protective immune responses in mouse challenge model. In this study, we evaluated the structural requirement for the immunological activity and the possible signaling pathway of recombinant Ag473 antigen produced in E. coli. We found that lipidated Ag473 (L-Ag473) possesses an intrinsic adjuvant activity that could be attributed to its ability to activate dendritic cells and promote their maturation. In addition, we found that L-Ag473 can activate human monocytes and promote maturation of human monocyte-derived dendritic cells. These results provide an indirect support that L-Ag473 may also be immunogenic in human. Interestingly, the observed activity is dependent on the overall conformation of L-Ag473 because heating and proteinase K treatment can diminish and abolish the activity. Furthermore, our data suggest a species-differential TLR recognition of L-Ag473. Overall, these data suggest a new paradigm for the ligand-TLR interaction in addition to demonstrating the self-adjuvanting activity of the vaccine candidate L-Ag473.	[Chu, Ching-Liang] Natl Taiwan Univ, Coll Med, Grad Inst Immunol, Taipei 10764, Taiwan; [Yu, Yen-Ling; Kung, Yueh-Chen; Hsieh, Steve Shih-Yang; Chong, Pele Choi-Sing; Yang, Chiou-Ying] Natl Hlth Res Inst, Vaccine Res & Dev Ctr, Miaoli, Taiwan; [Liao, Pei-Yu; Tseng, Yen-Tzu; Lin, Yuan-Chuen; Yang, Chiou-Ying] Natl Chung Hsing Univ, Inst Mol Biol, Taichung 40227, Taiwan; [Liu, Ko-Jiunn] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan; [Liu, Ko-Jiunn] Taipei Med Univ, Sch Med Lab Sci & Biotechnol, Taipei, Taiwan	National Taiwan University; National Health Research Institutes - Taiwan; National Chung Hsing University; National Health Research Institutes - Taiwan; Taipei Medical University	Chu, CL (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Immunol, Taipei 10764, Taiwan.	cyyang@dragon.nchu.edu.tw	Chong, Pele/E-3855-2010; Liu, Ko-Jiunn/D-2098-2010	Chu, Ching-Liang/0000-0002-8463-526X; Yang, Chiou-Ying/0000-0001-7130-1781	National Health Research Institutes, Taiwan [NHRI-EX96-9613BI]; NTUCM [100R311001]	National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan); NTUCM	This research was supported by grant NHRI-EX96-9613BI from National Health Research Institutes, Taiwan, to CYY, and grant 100R311001 of NTUCM to CLC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adu-Bobie J, 2003, VACCINE, V21, P605, DOI 10.1016/S0264-410X(02)00566-2; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Buckwalter MR, 2009, CURR BIOL, V19, pR355, DOI 10.1016/j.cub.2009.03.012; Cavaillon JM, 2011, LANCET INFECT DIS, V11, P426, DOI 10.1016/S1473-3099(11)70131-1; Chang GC, 2005, CANCER-AM CANCER SOC, V103, P763, DOI 10.1002/cncr.20843; Chen HW, 2009, VACCINE, V27, P1400, DOI 10.1016/j.vaccine.2008.12.043; Dietrich G, 2003, J BACTERIOL, V185, P155, DOI 10.1128/JB.185.1.155-164.2003; Duesberg U, 2002, IMMUNOL LETT, V84, P89, DOI 10.1016/S0165-2478(02)00178-5; Ganapamo F, 2003, EUR J IMMUNOL, V33, P1934, DOI 10.1002/eji.200323655; Goodridge HS, 2009, J IMMUNOL, V182, P1146, DOI 10.4049/jimmunol.182.2.1146; Hoshino K, 2002, INT IMMUNOL, V14, P1225, DOI 10.1093/intimm/dxf089; Hsu CA, 2008, PROTEOMICS, V8, P2115, DOI 10.1002/pmic.200700574; Huang RY, 2010, J IMMUNOL, V184, P6815, DOI 10.4049/jimmunol.0903991; Ishii KJ, 2008, CELL HOST MICROBE, V3, P352, DOI 10.1016/j.chom.2008.05.003; Joffre O, 2009, IMMUNOL REV, V227, P234, DOI 10.1111/j.1600-065X.2008.00718.x; Kimmel SR, 2005, AM FAM PHYSICIAN, V72, P2049; Kurz S, 2003, VACCINE, V21, P768, DOI 10.1016/S0264-410X(02)00596-0; Leng CH, 2010, MOL IMMUNOL, V47, P2015, DOI 10.1016/j.molimm.2010.04.012; Lin CC, 2011, CANCER IMMUNOL IMMUN, V60, P1019, DOI 10.1007/s00262-011-1016-4; Lin MK, 2011, IMMUNOBIOLOGY, V216, P1103, DOI 10.1016/j.imbio.2011.05.002; Lopez-Bravo M, 2008, IMMUNITY, V29, P343, DOI 10.1016/j.immuni.2008.08.008; Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Nahori MA, 2005, J IMMUNOL, V175, P6022, DOI 10.4049/jimmunol.175.9.6022; Okusawa T, 2004, INFECT IMMUN, V72, P1657, DOI 10.1128/IAI.72.3.1657-1665.2004; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Palucka K, 2010, IMMUNITY, V33, P464, DOI 10.1016/j.immuni.2010.10.007; Pasquevich KA, 2010, J IMMUNOL, V184, P5200, DOI 10.4049/jimmunol.0902209; Pizza M, 2000, SCIENCE, V287, P1816, DOI 10.1126/science.287.5459.1816; Sousa CR, 2006, NAT REV IMMUNOL, V6, P476, DOI 10.1038/nri1845; Revets H, 2005, J IMMUNOL, V174, P1097, DOI 10.4049/jimmunol.174.2.1097; Schromm AB, 2007, J BIOL CHEM, V282, P11030, DOI 10.1074/jbc.M700287200; Sung JWC, 2010, VACCINE, V28, P8175, DOI 10.1016/j.vaccine.2010.09.091; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Yang XL, 2008, MICROBES INFECT, V10, P1300, DOI 10.1016/j.micinf.2008.07.029; Yu YL, 2009, EUR J IMMUNOL, V39, P2482, DOI 10.1002/eji.200839039; Zhang HW, 1998, INFECT IMMUN, V66, P5196, DOI 10.1128/IAI.66.11.5196-5201.1998	37	8	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2012	7	7							e40873	10.1371/journal.pone.0040873	http://dx.doi.org/10.1371/journal.pone.0040873			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977TM	22844415	Green Published, gold, Green Submitted			2023-01-03	WOS:000306687700021
J	Cleland, J; Conde-Agudelo, A; Peterson, H; Ross, J; Tsui, A				Cleland, John; Conde-Agudelo, Agustin; Peterson, Herbert; Ross, John; Tsui, Amy			Contraception and health	LANCET			English	Article							SHORT INTERPREGNANCY INTERVAL; INTRAUTERINE-DEVICE USE; MATERNAL MORTALITY; PERINATAL OUTCOMES; NUTRITIONAL-STATUS; RISK; BIRTH; INFANT; CHILD; DISEASE	Increasing contraceptive use in developing countries has cut the number of maternal deaths by 40% over the past 20 years, merely by reducing the number of unintended pregnancies. By preventing high-risk pregnancies, especially in women of high parities, and those that would have ended in unsafe abortion, increased contraceptive use has reduced the maternal mortality ratio-the risk of maternal death per 100 000 livebirths-by about 26% in little more than a decade. A further 30% of maternal deaths could be avoided by fulfilment of unmet need for contraception. The benefits of modern contraceptives to women's health, including non-contraceptive benefits of specific methods, outweigh the risks. Contraception can also improve perinatal outcomes and child survival, mainly by lengthening interpregnancy intervals. In developing countries, the risk of prematurity and low birthweight doubles when conception occurs within 6 months of a previous birth, and children born within 2 years of an elder sibling are 60% more likely to die in infancy than are those born more than 2 years after their sibling.	[Cleland, John] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; [Conde-Agudelo, Agustin] Eunice Kennedy Shriver Natl Inst Hlth & Human Dev, Perinatol Res Branch, Hutzel Womens Hosp, NIH, Bethesda, MD USA; [Conde-Agudelo, Agustin] Eunice Kennedy Shriver Natl Inst Hlth & Human Dev, Perinatol Res Branch, Hutzel Womens Hosp, NIH, Detroit, MI USA; [Peterson, Herbert] Univ N Carolina, Dept Maternal & Child Hlth, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA; [Peterson, Herbert] Univ N Carolina, Sch Med, Dept Obstet & Gynecol, Chapel Hill, NC USA; [Ross, John] Futures Grp Inc, Washington, DC USA; [Tsui, Amy] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Baltimore, MD USA	University of London; London School of Hygiene & Tropical Medicine; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Cleland, J (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.	john.cleland@lshtm.ac.uk	Cleland, John G./AAZ-4185-2020	Cleland, John G./0000-0002-1471-7016	Bill and Melinda Gates Institute	Bill and Melinda Gates Institute	We thank Anyeli Rosas-Bermudez for assistance with the section on perinatal health. AT's participation was supported by funding from the Bill and Melinda Gates Institute to the Johns Hopkins Bloomberg School of Public Health.	Adam I, 2009, J MATERN-FETAL NEO M, V22, P1068, DOI 10.3109/14767050903009222; Ahmed S., 2012, LANCET; Ali MM, 2010, STUD FAMILY PLANN, V41, P129, DOI 10.1111/j.1728-4465.2010.00234.x; Appleby P, 2007, LANCET, V370, P1609, DOI 10.1016/S0140-6736(07)61684-5; ATRASH HK, 1990, OBSTET GYNECOL, V76, P1055; Auger N, 2008, BMC PREGNANCY CHILDB, V8, P7, DOI DOI 10.1186/1471-2393-8-7; Barker DJP, 2007, J INTERN MED, V261, P412, DOI 10.1111/j.1365-2796.2007.01809.x; Beining RM, 2008, ANN EPIDEMIOL, V18, P492, DOI 10.1016/j.annepidem.2007.11.011; Beral V, 2008, LANCET, V371, P303, DOI 10.1016/S0140-6736(08)60167-1; BHATIA JC, 1993, STUD FAMILY PLANN, V24, P310, DOI 10.2307/2939224; Bouvier-Colle MH, 2001, ACTA OBSTET GYN SCAN, V80, P113; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; Canning D, 2011, ASS MATERNAL HLTH IN; Castellsague X, 2011, LANCET ONCOL, V12, P1023, DOI 10.1016/S1470-2045(11)70223-6; Cecatti JG, 2008, MATERN CHILD HLTH J, V12, P275, DOI 10.1007/s10995-007-0219-y; Cibula D, 2010, HUM REPROD UPDATE, V16, P631, DOI 10.1093/humupd/dmq022; Collumbien M., 2004, COMP QUANTIFICATION, P1255; Conde-Agudelo A, 2000, BRIT MED J, V321, P1255, DOI 10.1136/bmj.321.7271.1255; Conde-Agudelo A, 2006, JAMA-J AM MED ASSOC, V295, P1809, DOI 10.1001/jama.295.15.1809; Conde-Agudelo A, 2007, AM J OBSTET GYNECOL, V196, P297, DOI 10.1016/j.ajog.2006.05.055; Curtis KM, 2009, AIDS, V23, pS55, DOI 10.1097/01.aids.0000363778.58203.b6; Darroch Jacqueline E., 2011, ESTIMATING UNINTENDE; DeFranco EA, 2007, AM J OBSTET GYNECOL, V197, p264e1; Dewey KG, 2007, MATERN CHILD NUTR, V3, P151, DOI 10.1111/j.1740-8709.2007.00092.x; FARLEY TMM, 1992, LANCET, V339, P785, DOI 10.1016/0140-6736(92)91904-M; Fikree FF, 1997, ACTA OBSTET GYN SCAN, V76, P637, DOI 10.3109/00016349709024603; FORTNEY JA, 1987, STUD FAMILY PLANN, V18, P109, DOI 10.2307/1966702; FRANKS AL, 1990, AM J OBSTET GYNECOL, V163, P1120, DOI 10.1016/0002-9378(90)90668-W; Garenne M, 1997, Afr J Reprod Health, V1, P14, DOI 10.2307/3583271; Glasier AF, 2003, CONTRACEPTION, V67, P1, DOI 10.1016/S0010-7824(02)00474-2; Goldie SJ, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000264; Grisaru-Granovsky S, 2009, CONTRACEPTION, V80, P512, DOI 10.1016/j.contraception.2009.06.006; Heffron R, 2012, LANCET INFECT DIS, V12, P19, DOI 10.1016/S1473-3099(11)70247-X; HOBCRAFT J, 1983, POPUL INDEX, V49, P585, DOI 10.2307/2737284; Hobcraft J, 1987, INT C BETT HLTH WOM; HOBCRAFT JN, 1985, POP STUD-J DEMOG, V39, P363, DOI 10.1080/0032472031000141576; Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1; Jain AK, 2011, STUD FAMILY PLANN, V42, P247, DOI 10.1111/j.1728-4465.2011.00288.x; KOENIG MA, 1988, STUD FAMILY PLANN, V19, P69, DOI 10.2307/1966492; KOST K, 1991, FAM PLANN PERSPECT, V23, P54, DOI 10.2307/2135450; Magadi M, 2001, J BIOSOC SCI, V33, P375, DOI 10.1017/S0021932001003753; Mahy M, 2003, DEMOGRAPHIC HLTH SUR, V4; Marchbanks PA, 2002, NEW ENGL J MED, V346, P2025, DOI 10.1056/NEJMoa013202; Marston C, 2006, REPORT WHO TECHNICAL; MHANGO C, 1986, STUD FAMILY PLANN, V17, P243, DOI 10.2307/1966974; Nabukera SK, 2008, J OBSTET GYNAECOL RE, V34, P941, DOI 10.1111/j.1447-0756.2008.00808.x; *NAT I POP RES TRA, 2003, BANGL MAT HLTH SERV; Peterson HB, 2008, OBSTET GYNECOL, V111, P189, DOI 10.1097/01.AOG.0000298621.98372.62; Petitti DB, 2003, NEW ENGL J MED, V349, P1443, DOI 10.1056/NEJMcp030751; Rodrigues T, 2008, EUR J OBSTET GYN R B, V136, P184, DOI 10.1016/j.ejogrb.2007.03.014; Ross JA, 2012, MATERN CHILD HLTH J, V16, P456, DOI 10.1007/s10995-011-0777-x; Rutstein SO, 2005, INT J GYNECOL OBSTET, V89, pS7, DOI 10.1016/j.ijgo.2004.11.012; Rutstein SO, 2005, EFFECT BIRTH SPACING; Rutstein SO, 2008, 41 MACR INT DEM HLTH; Sedgh G, 2007, LANCET, V370, P1338, DOI 10.1016/S0140-6736(07)61575-X; Shah I, 2011, INT J GYNECOL OBSTET, V115, P1338; Singh S, 2009, ADDING IT COSTS BENE; Singh S, 2010, STUD FAMILY PLANN, V41, P241, DOI 10.1111/j.1728-4465.2010.00250.x; Smits LJM, 2001, LANCET, V358, P2074, DOI 10.1016/S0140-6736(01)07105-7; Stringer EM, 2009, AIDS, V23, P1377, DOI 10.1097/QAD.0b013e32832cbca8; TRUSSELL J, 1984, STUD FAMILY PLANN, V15, P267, DOI 10.2307/1966071; TUNCER RA, 1995, ACTA OBSTET GYN SCAN, V74, P604, DOI 10.3109/00016349509013470; Ujah IAO, 2003, AFR J REPROD HEALTH, V9, P27; UN Department for Economic and Social Information Analysis Population Division, 1994, HLTH RAT FAM PLANN T; Vessey M, 2010, CONTRACEPTION, V82, P221, DOI 10.1016/j.contraception.2010.04.006; Wee DW, 2010, AM J EPIDEMIOL, V172, P855, DOI 10.1093/aje/kwq207; WHO, 2005, Wkly Epidemiol Rec, V80, P302; Williams EK, 2008, J TROP PEDIATRICS, V54, P321, DOI 10.1093/tropej/fmn027; WINIKOFF B, 1987, STUD FAMILY PLANN, V18, P128, DOI 10.2307/1966808; World Health Organization, HORM CONTR HIV TECHN; World Health Organization, 2013, UNS AB GLOB REG EST; World Health Organization UNICEF UNFPA The World Bank, 2010, TRENDS MAT MOR 1990; Yerushalmy J, 1940, PUBLIC HEALTH REP, V55, P1195, DOI 10.2307/4583352; Zhu BP, 1999, NEW ENGL J MED, V340, P589, DOI 10.1056/NEJM199902253400801	74	358	362	2	67	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 14	2012	380	9837					149	156		10.1016/S0140-6736(12)60609-6	http://dx.doi.org/10.1016/S0140-6736(12)60609-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	973KN	22784533				2023-01-03	WOS:000306359100042
J	Yoshida, M; Takimoto, R; Murase, K; Sato, Y; Hirakawa, M; Tamura, F; Sato, T; Iyama, S; Osuga, T; Miyanishi, K; Takada, K; Hayashi, T; Kobune, M; Kato, J				Yoshida, Makoto; Takimoto, Rishu; Murase, Kazuyuki; Sato, Yasushi; Hirakawa, Masahiro; Tamura, Fumito; Sato, Tsutomu; Iyama, Satoshi; Osuga, Takahiro; Miyanishi, Koji; Takada, Kohichi; Hayashi, Tsuyoshi; Kobune, Masayoshi; Kato, Junji			Targeting Anticancer Drug Delivery to Pancreatic Cancer Cells Using a Fucose-Bound Nanoparticle Approach	PLOS ONE			English	Article							ALVEOLAR MACROPHAGE LECTIN; BINDING-SPECIFICITY; MONOCLONAL-ANTIBODY; ARMING ANTIBODIES; RAT-LIVER; PHASE-I; SERUM; LIPOSOMES; CARCINOMA; THERAPY	Owing to its aggressiveness and the lack of effective therapies, pancreatic ductal adenocarcinoma has a dismal prognosis. New strategies to improve treatment and survival are therefore urgently required. Numerous fucosylated antigens in sera serve as tumor markers for cancer detection and evaluation of treatment efficacy. Increased expression of fucosyltransferases has also been reported for pancreatic cancer. These enzymes accelerate malignant transformation through fucosylation of sialylated precursors, suggesting a crucial requirement for fucose by pancreatic cancer cells. With this in mind, we developed fucose-bound nanoparticles as vehicles for delivery of anticancer drugs specifically to cancer cells. L-fucose-bound liposomes containing Cy5.5 or Cisplatin were effectively delivered into CA19-9 expressing pancreatic cancer cells. Excess L-fucose decreased the efficiency of Cy5.5 introduction by L-fucose-bound liposomes, suggesting L-fucose-receptor-mediated delivery. Intravenously injected L-fucose-bound liposomes carrying Cisplatin were successfully delivered to pancreatic cancer cells, mediating efficient tumor growth inhibition as well as prolonging survival in mouse xenograft models. This modality represents a new strategy for pancreatic cancer cell-targeting therapy.	[Yoshida, Makoto; Takimoto, Rishu; Murase, Kazuyuki; Sato, Yasushi; Hirakawa, Masahiro; Tamura, Fumito; Sato, Tsutomu; Iyama, Satoshi; Osuga, Takahiro; Miyanishi, Koji; Takada, Kohichi; Hayashi, Tsuyoshi; Kato, Junji] Sapporo Med Univ, Sch Med, Dept Internal Med 4, Sapporo, Hokkaido, Japan; [Yoshida, Makoto; Takimoto, Rishu; Hirakawa, Masahiro; Tamura, Fumito; Kato, Junji] Sapporo Med Univ, Grad Sch Med, Div Clin Oncol, Chuo Ku, Sapporo, Hokkaido, Japan; [Sato, Tsutomu; Kobune, Masayoshi] Sapporo Med Univ, Grad Sch Med, Div Mol Oncol, Chuo Ku, Sapporo, Hokkaido, Japan	Sapporo Medical University; Sapporo Medical University; Sapporo Medical University	Yoshida, M (corresponding author), Sapporo Med Univ, Sch Med, Dept Internal Med 4, Sapporo, Hokkaido, Japan.	jkato@sapmed.ac.jp	Iyama, Satoshi/AAA-6237-2019	Miyanishi, Koji/0000-0002-6466-3458; Sato, Yasushi/0000-0002-6776-4609	Ministry of Education, Science, Sports and Culture [21390231]; Grants-in-Aid for Scientific Research [24590985] Funding Source: KAKEN	Ministry of Education, Science, Sports and Culture(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This research was partially supported by the Ministry of Education, Science, Sports and Culture, Grant-in-Aid for Scientific Research (B), 21390231, 2009, to JK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.	ALLEN TM, 1994, TRENDS PHARMACOL SCI, V15, P215, DOI 10.1016/0165-6147(94)90314-X; Arnold DM, 2007, ANN INTERN MED, V146, P25, DOI 10.7326/0003-4819-146-1-200701020-00006; Aubert M, 2000, INT J CANCER, V88, P558, DOI 10.1002/1097-0215(20001115)88:4<558::AID-IJC7>3.0.CO;2-B; Becker DJ, 2003, GLYCOBIOLOGY, V13, p41R, DOI 10.1093/glycob/cwg054; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Damascelli B, 2001, CANCER, V92, P2592, DOI 10.1002/1097-0142(20011115)92:10<2592::AID-CNCR1612>3.0.CO;2-4; Dang SY, 2010, NATURE, V467, P734, DOI 10.1038/nature09406; Deyasi S K, 1975, Indian J Pathol Bacteriol, V18, P16; GUNN FJ, 1994, MOL MICROBIOL, V12, P799, DOI 10.1111/j.1365-2958.1994.tb01066.x; HAKOMORI S, 1983, JNCI-J NATL CANCER I, V71, P231; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HALTIWANGER RS, 1986, J BIOL CHEM, V261, P5696; HALTIWANGER RS, 1986, J BIOL CHEM, V261, P7433; HALTIWANGER RS, 1986, J BIOL CHEM, V261, P7440; Hirai M, 2007, BIOCHEM BIOPH RES CO, V353, P553, DOI 10.1016/j.bbrc.2006.12.060; Jain RK, 2010, NAT REV CLIN ONCOL, V7, P653, DOI 10.1038/nrclinonc.2010.139; Kawakami S, 2000, BBA-GEN SUBJECTS, V1524, P258, DOI 10.1016/S0304-4165(00)00163-X; Keleg Shereen, 2003, Mol Cancer, V2, P14, DOI 10.1186/1476-4598-2-14; KOPROWSKI H, 1981, SCIENCE, V212, P53, DOI 10.1126/science.6163212; Lee SJ, 2002, SCIENCE, V295, P1898, DOI 10.1126/science.1069540; LEHRMAN MA, 1986, J BIOL CHEM, V261, P7426; Lima CMSR, 2002, CURR OPIN ONCOL, V14, P424, DOI 10.1097/01.CCO.0000020621.28068.04; MAGNANI JL, 1982, METHOD ENZYMOL, V83, P235; Mas E, 1998, GLYCOBIOLOGY, V8, P605, DOI 10.1093/glycob/8.6.605; Miyanishi K, 2008, JPN J CLIN ONCOL, V38, P268, DOI 10.1093/jjco/hyn015; Miyazaki K, 2004, CANCER RES, V64, P4498, DOI 10.1158/0008-5472.CAN-03-3614; Moghimi SM, 2006, J LIPOSOME RES, V16, P167, DOI 10.1080/08982100600848801; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Nakao A, 1998, SEMIN SURG ONCOL, V15, P15, DOI 10.1002/(SICI)1098-2388(199807/08)15:1<15::AID-SSU4>3.3.CO;2-G; Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387; Polakis P, 2005, CURR OPIN PHARMACOL, V5, P382, DOI 10.1016/j.coph.2005.04.008; Sagawa T, 2008, HEPATOLOGY, V48, P828, DOI 10.1002/hep.22420; SAKAI T, 1990, CLIN CHEM, V36, P474; Sawke NG, 2010, INDIAN J CANCER, V47, P452, DOI 10.4103/0019-509X.73549; SENIOR JH, 1987, CRC CR REV THER DRUG, V3, P123; Shore S, 2003, ALIMENT PHARM THER, V18, P1049, DOI 10.1111/j.1365-2036.2003.01781.x; Sturgeon CM, 2010, CLIN CHEM, V56, pE1, DOI 10.1373/clinchem.2009.133124; SUGANO K, 1988, JPN J CANCER RES, V79, P618, DOI 10.1111/j.1349-7006.1988.tb00031.x; Symon Z, 1999, CANCER, V86, P72, DOI 10.1002/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.3.CO;2-T; Tajiri M, 2008, GLYCOBIOLOGY, V18, P2, DOI 10.1093/glycob/cwm117; Tawada K, 2009, PANCREAS, V38, P30, DOI 10.1097/MPA.0b013e318183ff73; Tonetti M, 1998, BIOCHIMIE, V80, P923, DOI 10.1016/S0300-9084(00)88889-6; Torchilin Vladimir P, 2010, Handb Exp Pharmacol, P3, DOI 10.1007/978-3-642-00477-3_1; Tsuchida A, 2003, J BIOL CHEM, V278, P22787, DOI 10.1074/jbc.M211034200; von Mehren M, 2003, ANNU REV MED, V54, P343, DOI 10.1146/annurev.med.54.101601.152442; Weiner LM, 2000, ONCOGENE, V19, P6144, DOI 10.1038/sj.onc.1204000; WIESE TJ, 1994, J BIOL CHEM, V269, P22705; Wu AM, 2005, NAT BIOTECHNOL, V23, P1137, DOI 10.1038/nbt1141	49	51	52	1	47	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2012	7	7							e39545	10.1371/journal.pone.0039545	http://dx.doi.org/10.1371/journal.pone.0039545			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973LU	22808043	gold, Green Submitted, Green Published			2023-01-03	WOS:000306362400014
J	Yin, JY; Huang, Q; Zhao, YC; Zhou, HH; Liu, ZQ				Yin, Ji-Ye; Huang, Qiong; Zhao, Ying-Chun; Zhou, Hong-Hao; Liu, Zhao-Qian			Meta-Analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Patients	PLOS ONE			English	Article							SINGLE NUCLEOTIDE POLYMORPHISMS; CISPLATIN-INDUCED CYTOTOXICITY; GENOME-WIDE ASSOCIATION; DNA-REPAIR; GENETIC POLYMORPHISMS; MULTIDRUG-RESISTANCE; SUSCEPTIBILITY LOCUS; ERCC1; SURVIVAL; XPD	Aim: To determine the pharmacogenetics of platinum-based chemotherapy in Non Small Cell Lung Cancer (NSCLC) patients. Methods: Publications were selected from PubMed, Cochrane Library and ISI Web of Knowledge. A meta-analysis was conducted to determine the association between genetic polymorphisms and platinum-based chemotherapy by checking odds ratio (OR) and 95% confidence interval (CI). Results: Data were extracted from 24 publications, which included 11 polymorphisms in 8 genes for meta-analysis. MDR1 C3435T (OR = 1.97, 95% CI: 1.11-3.50, P = 0.02), G2677A/T (OR = 2.61, 95% CI: 1.44-4.74, P = 0.002) and GSTP1 A313G (OR = 0.32, 95% CI: 0.17-0.58, P = 0.0002) were significantly correlated with platinum-based chemotherapy in Asian NSCLC patients. Conclusion: Attention should be paid to MDR1 C3435T, G2677A/T and GSTP1 A313G for personalized chemotherapy treatment for NSCLC patients in Asian population in the future.	[Yin, Ji-Ye; Zhou, Hong-Hao; Liu, Zhao-Qian] Cent S Univ, Inst Clin Pharmacol, Hunan Key Lab Pharmacogenet, Changsha, Hunan, Peoples R China; [Huang, Qiong] Anhui Med Univ, Inst Clin Pharmacol, Key Lab Antiinflammatory & Immunopharmacol Educ M, Hefei, Anhui, Peoples R China; [Zhao, Ying-Chun] Creighton Univ, Osteoporosis Res Ctr, Omaha, NE 68178 USA	Central South University; Anhui Medical University; Creighton University	Yin, JY (corresponding author), Cent S Univ, Inst Clin Pharmacol, Hunan Key Lab Pharmacogenet, Changsha, Hunan, Peoples R China.	liuzhaoqian63@126.com	Yin, Ji-Ye/AAE-6794-2020; Huang, Qiong/HGC-7895-2022; Zhao, Yingchun/F-3683-2012	Huang, Qiong/0000-0002-0570-5961; Zhao, Yingchun/0000-0001-7216-9727; Yin, Ji-Ye/0000-0002-1244-5045; Liu, Zhaoqian/0000-0003-0428-3928	National Natural Science Foundation of China [81173129]; National High-Tech R&D Program of China (863Program) [2009AA022703]; Specialized Research Fund for the Doctoral Program of Higher Education [20113420120006]; BSKY from Anhui Medical University [XJ201021]; Ministry of Education of China	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High-Tech R&D Program of China (863Program)(National High Technology Research and Development Program of China); Specialized Research Fund for the Doctoral Program of Higher Education(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); BSKY from Anhui Medical University; Ministry of Education of China(Ministry of Education, China)	This work was supported by National Natural Science Foundation of China (81173129) (Z.Q.L.), National High-Tech R&D Program of China (863Program) (2009AA022703) (Z.Q.L. and J.Y.Y.), Specialized Research Fund for the Doctoral Program of Higher Education (20113420120006) (Q. H.) and Grants for Scientific Research of BSKY (XJ201021) from Anhui Medical University (Q.H.). J.Y.Y. was supported in part by Scholarship Award for Excellent Doctoral Student granted by the Ministry of Education of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amos CI, 2008, NAT GENET, V40, P616, DOI 10.1038/ng.109; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Booten R, 2006, J THORAC ONCOL, V1, P679, DOI 10.1097/01243894-200609000-00013; Booton R, 2006, CANCER-AM CANCER SOC, V106, P2421, DOI 10.1002/cncr.21885; Camps Carlos, 2003, Clin Lung Cancer, V4, P237, DOI 10.3816/CLC.2003.n.004; Chen SJ, 2010, INT J HYG ENVIR HEAL, V213, P140, DOI 10.1016/j.ijheh.2010.01.004; Chen XX, 2012, CLIN TRANSL ONCOL, V14, P207, DOI 10.1007/s12094-012-0785-3; Cheng HY, 2010, ACTA BIOCH BIOPH SIN, V42, P311, DOI 10.1093/abbs/gmq023; Cheng J, 2012, J CANCER RES CLIN, V138, P231, DOI 10.1007/s00432-011-1090-1; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DerSimonian R, 2007, CONTEMP CLIN TRIALS, V28, P105, DOI 10.1016/j.cct.2006.04.004; Dolan ME, 2004, CANCER RES, V64, P4353, DOI 10.1158/0008-5472.CAN-04-0340; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Feng JF, 2009, LUNG CANCER, V66, P344, DOI 10.1016/j.lungcan.2009.02.015; Feng JF, 2009, ACTA BIOCH BIOPH SIN, V41, P429, DOI 10.1093/abbs/gmp027; Garcia-Campelo R, 2005, EXPERT OPIN PHARMACO, V6, P2015, DOI 10.1517/14656566.6.12.2015; Gautschi O, 2006, LUNG CANCER, V51, P303, DOI 10.1016/j.lungcan.2005.10.025; Giachino DF, 2007, CLIN CANCER RES, V13, P2876, DOI 10.1158/1078-0432.CCR-06-2543; Hall MD, 2008, ANNU REV PHARMACOL, V48, P495, DOI 10.1146/annurev.pharmtox.48.080907.180426; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hildebrandt MAT, 2009, EXPERT OPIN DRUG MET, V5, P745, DOI 10.1517/17425250902973711; Huang QO, 2010, EUR J CLIN PHARMACOL, V66, P1207, DOI 10.1007/s00228-010-0882-6; Huang RS, 2008, MOL CANCER THER, V7, P3038, DOI 10.1158/1535-7163.MCT-08-0248; Huang RS, 2007, AM J HUM GENET, V81, P427, DOI 10.1086/519850; Hung RJ, 2008, NATURE, V452, P633, DOI 10.1038/nature06885; Ishida S, 2002, P NATL ACAD SCI USA, V99, P14298, DOI 10.1073/pnas.162491399; Isla D, 2004, ANN ONCOL, V15, P1194, DOI 10.1093/annonc/mdh319; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kalikaki A, 2009, CLIN LUNG CANCER, V10, P118, DOI 10.3816/CLC.2009.n.015; Katano K, 2002, CANCER RES, V62, P6559; Kimchi-Sarfaty C, 2007, SCIENCE, V315, P525, DOI 10.1126/science.1135308; Kweekel DM, 2005, CANCER TREAT REV, V31, P90, DOI 10.1016/j.ctrv.2004.12.006; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; Li F, 2010, AM J CLIN ONCOL-CANC, V33, P489, DOI 10.1097/COC.0b013e3181b9cedc; Li WY, 2012, LUNG, V190, P91, DOI 10.1007/s00408-011-9338-8; Li YF, 2011, CLIN CANCER RES, V17, P3830, DOI 10.1158/1078-0432.CCR-10-2877; Link E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMoa0801936; MANTEL N, 1959, J NATL CANCER I, V22, P719; Pan JH, 2008, RESPIRATION, V75, P380, DOI 10.1159/000108407; Pan JH, 2009, RESPIRATION, V78, P49, DOI 10.1159/000158454; Park DJ, 2001, CANCER RES, V61, P8654; Ryu JS, 2004, LUNG CANCER, V44, P311, DOI 10.1016/j.lungcan.2003.11.019; Safaei R, 2004, J INORG BIOCHEM, V98, P1607, DOI 10.1016/j.jinorgbio.2004.05.006; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shiraishi K, 2010, J CLIN ONCOL, V28, P4945, DOI 10.1200/JCO.2010.30.5334; Shukla SJ, 2008, PHARMACOGENET GENOM, V18, P253, DOI 10.1097/FPC.0b013e3282f5e605; Stewart DJ, 2007, CRIT REV ONCOL HEMAT, V63, P12, DOI 10.1016/j.critrevonc.2007.02.001; Su D, 2007, LUNG CANCER, V56, P281, DOI 10.1016/j.lungcan.2006.12.002; Sun N, 2010, CANCER CHEMOTH PHARM, V65, P437, DOI 10.1007/s00280-009-1046-1; Sun XC, 2009, LUNG CANCER, V65, P230, DOI 10.1016/j.lungcan.2008.11.014; Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984; Tan XL, 2011, CLIN CANCER RES, V17, P5801, DOI 10.1158/1078-0432.CCR-11-1133; Thorgeirsson TE, 2008, NATURE, V452, P638, DOI 10.1038/nature06846; Tibaldi C, 2008, CLIN CANCER RES, V14, P1797, DOI 10.1158/1078-0432.CCR-07-1364; Vinolas N, 2011, LUNG CANCER, V71, P191, DOI 10.1016/j.lungcan.2010.05.005; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Watson MA, 1998, CARCINOGENESIS, V19, P275, DOI 10.1093/carcin/19.2.275; Wei HB, 2011, ARCH MED RES, V42, P412, DOI 10.1016/j.arcmed.2011.07.008; Wei SZ, 2010, MED ONCOL; Woodahl EL, 2004, CURR DRUG METAB, V5, P11, DOI 10.2174/1389200043489108; Wu XF, 2011, J NATL CANCER I, V103, P817, DOI 10.1093/jnci/djr075; Yao CY, 2009, ASIAN PAC J CANCER P, V10, P859; Yin JY, 2011, CLIN EXP PHARMACOL P, V38, P632, DOI 10.1111/j.1440-1681.2011.05571.x; Yin JY, 2009, PHARMACOGENET GENOM, V19, P206, DOI 10.1097/FPC.0b013e328323f680; Yin Jiye, 2011, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V36, P927, DOI 10.3969/j.issn.1672-7347.2011.10.002; Yu D, 2012, TUMOUR BIOL; Yu DK, 2008, CLIN CANCER RES, V14, P2878, DOI 10.1158/1078-0432.CCR-07-1612; Yu JJ, 2000, INT J ONCOL, V16, P555; Yu M, 2010, CLIN PHARMACOL THER, V87, P330, DOI 10.1038/clpt.2009.242; Zhou CC, 2010, JPN J CLIN ONCOL, V40, P954, DOI 10.1093/jjco/hyq071; Zhou F, 2011, SWISS MED WKLY, V141, DOI 10.4414/smw.2011.13275	72	41	47	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 26	2012	7	6							e38150	10.1371/journal.pone.0038150	http://dx.doi.org/10.1371/journal.pone.0038150			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	966AK	22761669	Green Published, Green Submitted, gold			2023-01-03	WOS:000305808700002
J	Ferri-Lagneau, KF; Moshal, KS; Grimes, M; Zahora, B; Lv, LS; Sang, SM; Leung, TC				Ferri-Lagneau, Karine F.; Moshal, Karni S.; Grimes, Matthew; Zahora, Braden; Lv, Lishuang; Sang, Shengmin; Leung, TinChung			Ginger Stimulates Hematopoiesis via Bmp Pathway in Zebrafish	PLOS ONE			English	Article							BLOOD STEM-CELLS; BONE MORPHOGENETIC PROTEINS; ZINGIBER-OFFICINALE ROSCOE; AORTIC ENDOTHELIUM; EXPRESSION; EMBRYO; VEGF; MOUSE; ERYTHROPOIESIS; PROGENITOR	Background: Anemia is a hematologic disorder with decreased number of erythrocytes. Erythropoiesis, the process by which red blood cells differentiate, are conserved in humans, mice and zebrafish. The only known agents available to treat pathological anemia are erythropoietin and its biologic derivatives. However, erythropoietin therapy elicits unwanted side-effects, high cost and intravenous or subcutaneous injection, warranting the development of a more cost effective and non-peptide alternative. Ginger (Zingiber officinale) has been widely used in traditional medicine; however, to date there is no scientific research documenting the potential of ginger to stimulate hematopoiesis. Methodology/Principal Findings: Here, we utilized gata1:dsRed transgenic zebrafish embryos to investigate the effect of ginger extract on hematopoiesis in vivo and we identified its bioactive component, 10-gingerol. We confirmed that ginger and 10-gingerol promote the expression of gata1 in erythroid cells and increase the expression of hematopoietic progenitor markers cmyb and scl. We also demonstrated that ginger and 10-gingerol can promote the hematopoietic recovery from acute hemolytic anemia in zebrafish, by quantifying the number of circulating erythroid cells in the dorsal aorta using video microscopy. We found that ginger and 10-gingerol treatment during gastrulation results in an increase of bmp2b and bmp7a expression, and their downstream effectors, gata2 and eve1. At later stages ginger and 10-gingerol can induce bmp2b/7a, cmyb, scl and lmo2 expression in the caudal hematopoietic tissue area. We further confirmed that Bmp/Smad pathway mediates this hematopoiesis promoting effect of ginger by using the Bmp-activated Bmp type I receptor kinase inhibitors dorsomorphin, LND193189 and DMH1. Conclusions/Significance: Our study provides a strong foundation to further evaluate the molecular mechanism of ginger and its bioactive components during hematopoiesis and to investigate their effects in adults. Our results will provide the basis for future research into the effect of ginger during mammalian hematopoiesis to develop novel erythropoiesis promoting agents.	[Ferri-Lagneau, Karine F.; Moshal, Karni S.; Grimes, Matthew; Zahora, Braden; Leung, TinChung] N Carolina Cent Univ, Biomed Biotechnol Res Inst, Kannapolis, NC USA; [Lv, Lishuang; Sang, Shengmin] N Carolina Cent Univ, Ctr Excellence Postharvest Technol, N Carolina Agr & Tech State Univ, Kannapolis, NC USA; [Leung, TinChung] N Carolina Cent Univ, Dept Biol, Durham, NC USA	University of North Carolina; North Carolina Central University; University of North Carolina; North Carolina A&T State University; North Carolina Central University; University of North Carolina; North Carolina Central University	Ferri-Lagneau, KF (corresponding author), N Carolina Cent Univ, Biomed Biotechnol Res Inst, N Carolina Res Campus, Kannapolis, NC USA.	tleung@nccu.edu			North Carolina Biotechnology Center [2009-BRG-1213]; National Institutes of Health [CA138277, CA138277S1]; NATIONAL CANCER INSTITUTE [R21CA138277] Funding Source: NIH RePORTER	North Carolina Biotechnology Center; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was partially supported by the North Carolina Biotechnology Center (2009-BRG-1213 to TCL) and the National Institutes of Health (CA138277 and CA138277S1 to SS). No additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beis D, 2005, DEVELOPMENT, V132, P4193, DOI 10.1242/dev.01970; Bertrand JY, 2007, DEVELOPMENT, V134, P4147, DOI 10.1242/dev.012385; Bertrand JY, 2010, NATURE, V464, P108, DOI 10.1038/nature08738; Bhatia M, 1999, J EXP MED, V189, P1139, DOI 10.1084/jem.189.7.1139; Boisset JC, 2010, NATURE, V464, P116, DOI 10.1038/nature08764; Burns CE, 2002, EXP HEMATOL, V30, P1381, DOI 10.1016/S0301-472X(02)00955-4; Butt MS, 2011, CRIT REV FOOD SCI, V51, P383, DOI 10.1080/10408391003624848; Cannon JE, 2010, BRIT J PHARMACOL, V161, P140, DOI 10.1111/j.1476-5381.2010.00871.x; Chen AT, 2009, J CELL BIOCHEM, V108, P35, DOI 10.1002/jcb.22251; CHESEBRO B, 1978, J NATL CANCER I, V60, P239, DOI 10.1093/jnci/60.1.239; CHESEBRO B, 1976, J IMMUNOL, V117, P1267; Ciau-Uitz A, 2010, DEV CELL, V18, P569, DOI 10.1016/j.devcel.2010.02.009; Collery RF, 2011, DEV DYNAM, V240, P712, DOI 10.1002/dvdy.22567; Dalgin G, 2007, DEV BIOL, V310, P454, DOI 10.1016/j.ydbio.2007.08.012; Davidson AJ, 2004, ONCOGENE, V23, P7233, DOI 10.1038/sj.onc.1207943; DETRICH HW, 1995, P NATL ACAD SCI USA, V92, P10713, DOI 10.1073/pnas.92.23.10713; Dick A, 2000, DEVELOPMENT, V127, P343; Dooley KA, 2005, DEV BIOL, V277, P522, DOI 10.1016/j.ydbio.2004.09.004; Fibach E, 2005, Curr Protoc Immunol, VChapter 22, DOI 10.1002/0471142735.im22f07s69; Galloway JL, 2003, CURR TOP DEV BIOL, V53, P139, DOI 10.1016/S0070-2153(03)53004-6; Grassinger J, 2007, CYTOKINE, V40, P165, DOI 10.1016/j.cyto.2007.09.004; Hammerschmidt M, 1996, DEVELOPMENT, V123, P95; Hao J, 2010, ACS CHEM BIOL, V5, P245, DOI 10.1021/cb9002865; Jin H, 2007, BLOOD, V109, P5208, DOI 10.1182/blood-2007-01-069005; Kalev-Zylinska ML, 2002, DEVELOPMENT, V129, P2015; Kishimoto Y, 1997, DEVELOPMENT, V124, P4457; Kissa K, 2010, NATURE, V464, P112, DOI 10.1038/nature08761; Lee HX, 2006, CELL, V124, P147, DOI 10.1016/j.cell.2005.12.018; Lengerke C, 2008, CELL STEM CELL, V2, P72, DOI 10.1016/j.stem.2007.10.022; Leung AYH, 2005, DEV BIOL, V277, P235, DOI 10.1016/j.ydbio.2004.09.032; Leung TC, 2003, DEVELOPMENT, V130, P3639, DOI 10.1242/dev.00558; Leung T, 2006, BLOOD, V108, P160, DOI 10.1182/blood-2005-09-3706; Long QM, 1997, DEVELOPMENT, V124, P4105; Marshall CJ, 2007, BRIT J HAEMATOL, V139, P321, DOI 10.1111/j.1365-2141.2007.06795.x; Miller-Bertoglio VE, 1997, DEV BIOL, V192, P537, DOI 10.1006/dbio.1997.8788; Monteiro R, 2011, EMBO J, V30, P1093, DOI 10.1038/emboj.2011.34; Murayama E, 2006, IMMUNITY, V25, P963, DOI 10.1016/j.immuni.2006.10.015; Ojewole JAO, 2006, PHYTOTHER RES, V20, P764, DOI 10.1002/ptr.1952; Palis J, 1998, BLOOD REV, V12, P106, DOI 10.1016/S0268-960X(98)90022-4; Palis J, 2001, EXP HEMATOL, V29, P927, DOI 10.1016/S0301-472X(01)00669-5; Pimanda JE, 2007, P NATL ACAD SCI USA, V104, P840, DOI 10.1073/pnas.0607196104; Robin C, 2010, INT J DEV BIOL, V54, P1189, DOI 10.1387/ijdb.093040cr; Sang SM, 2009, J AGR FOOD CHEM, V57, P10645, DOI 10.1021/jf9027443; Sbafizadeh E, 2004, COMP BIOCHEM PHYS C, V138, P245, DOI 10.1016/j.cca.2004.05.003; Schmerer M, 2003, BLOOD, V102, P3196, DOI 10.1182/blood-2003-04-1094; Snyder A, 2004, J CELL BIOCHEM, V93, P224, DOI 10.1002/jcb.20191; Tao SJ, 2009, DEVELOPMENT, V136, P2757, DOI 10.1242/dev.034959; Traver D, 2003, NAT IMMUNOL, V4, P1238, DOI 10.1038/ni1007; Wiley DM, 2011, NAT CELL BIOL, V13, P686, DOI 10.1038/ncb2232; Wilkinson JM, 2000, REPROD TOXICOL, V14, P507, DOI 10.1016/S0890-6238(00)00106-4; Wohlmuth H, 2005, J AGR FOOD CHEM, V53, P5772, DOI 10.1021/jf050435b; Xu RH, 1999, DEV BIOL, V208, P352, DOI 10.1006/dbio.1999.9205; Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54	53	22	24	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2012	7	6							e39327	10.1371/journal.pone.0039327	http://dx.doi.org/10.1371/journal.pone.0039327			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	965QG	22761764	gold, Green Submitted, Green Published			2023-01-03	WOS:000305781700030
J	Awasthi, N; Zhang, CH; Ruan, W; Schwarz, MA; Schwarz, RE				Awasthi, Niranjan; Zhang, Changhua; Ruan, Winston; Schwarz, Margaret A.; Schwarz, Roderich E.			Evaluation of Poly-Mechanistic Antiangiogenic Combinations to Enhance Cytotoxic Therapy Response in Pancreatic Cancer	PLOS ONE			English	Article							ACTIVATING POLYPEPTIDE-II; ENDOTHELIAL-GROWTH-FACTOR; TYROSINE KINASE INHIBITOR; CLINICAL-TRIALS; ANTITUMOR-ACTIVITY; TUMOR-GROWTH; PHASE-II; IN-VITRO; EMAP II; GEMCITABINE	Gemcitabine (Gem) has limited clinical benefits in pancreatic ductal adenocarcinoma (PDAC). The present study investigated combinations of gemcitabine with antiangiogenic agents of various mechanisms for PDAC, including bevacizumab (Bev), sunitinib (Su) and EMAP II. Cell proliferation and protein expression were analyzed by WST-1 assay and Western blotting. In vivo experiments were performed via murine xenografts. Inhibition of in vitro proliferation of AsPC-1 PDAC cells by gemcitabine (10 mu M), bevacizumab (1 mg/ml), sunitinib (10 mu M) and EMAP (10 mu M) was 35, 22, 81 and 6 percent; combination of gemcitabine with bevacizumab, sunitinib or EMAP had no additive effects. In endothelial HUVECs, gemcitabine, bevacizumab, sunitinib and EMAP caused 70, 41, 86 and 67 percent inhibition, while combination of gemcitabine with bevacizumab, sunitinib or EMAP had additive effects. In WI-38 fibroblasts, gemcitabine, bevacizumab, sunitinib and EMAP caused 79, 58, 80 and 29 percent inhibition, with additive effects in combination as well. Net in vivo tumor growth inhibition in gemcitabine, bevacizumab, sunitinib and EMAP monotherapy was 43, 38, 94 and 46 percent; dual combinations of Gem+Bev, Gem+Su and Gem+EMAP led to 69, 99 and 64 percent inhibition. Combinations of more than one antiangiogenic agent with gemcitabine were generally more effective but not superior to Gem+Su. Intratumoral proliferation, apoptosis and microvessel density findings correlated with tumor growth inhibition data. Median animal survival was increased by gemcitabine (26 days) but not by bevacizumab, sunitinib or EMAP monotherapy compared to controls (19 days). Gemcitabine combinations with bevacizumab, sunitinib or EMAP improved survival to similar extent (36 or 37 days). Combinations of gemcitabine with Bev+EMAP (43 days) or with Bev+Su+EMAP (46 days) led to the maximum survival benefit observed. Combination of antiangiogenic agents improves gemcitabine response, with sunitinib inducing the strongest effect. These findings demonstrate advantages of combining multi-targeting agents with standard gemcitabine therapy for PDAC.	[Awasthi, Niranjan; Zhang, Changhua; Ruan, Winston; Schwarz, Roderich E.] Univ Texas SW Med Ctr Dallas, Dept Surg, Div Surg Oncol, Dallas, TX 75390 USA; [Schwarz, Margaret A.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Awasthi, Niranjan; Zhang, Changhua; Ruan, Winston; Schwarz, Roderich E.] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Awasthi, N (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Surg, Div Surg Oncol, Dallas, TX 75390 USA.	Roderich.Schwarz@utsouthwestern.edu						Abrams TJ, 2003, MOL CANCER THER, V2, P1011; Awasthi N, 2011, HPB, V13, P597, DOI 10.1111/j.1477-2574.2011.00333.x; Awasthi N, 2011, CANCER CHEMOTH PHARM, V68, P571, DOI 10.1007/s00280-010-1514-7; Awasthi N, 2009, LAB INVEST, V89, P38, DOI 10.1038/labinvest.2008.106; Berger AC, 2000, MICROVASC RES, V60, P70, DOI 10.1006/mvre.2000.2249; Bold RJ, 1999, ANN SURG ONCOL, V6, P279, DOI 10.1007/s10434-999-0279-x; Bramhall SR, 2002, BRIT J CANCER, V87, P161, DOI 10.1038/sj.bjc.6600446; Brennan MF, 2004, SURG ONCOL CLIN N AM, V13, pvii; Brennan Murray F, 2004, Surg Oncol Clin N Am, V13, P555; Cabebe E, 2007, EXPERT OPIN INV DRUG, V16, P467, DOI 10.1517/13543784.16.4.467; Cao HST, 2010, MOL CANCER THER, V9, P2068, DOI 10.1158/1535-7163.MCT-10-0201; Chang YT, 2008, PANCREAS, V37, P145, DOI 10.1097/MPA.0b013e318164548a; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Chow LQM, 2007, J CLIN ONCOL, V25, P884, DOI 10.1200/JCO.2006.06.3602; Costa R, 2009, J CELL BIOCHEM, V108, P1410, DOI 10.1002/jcb.22378; Crippa L, 2008, CANCER RES, V68, P1154, DOI 10.1158/0008-5472.CAN-07-2085; Cuneo KC, 2008, INT J RADIAT ONCOL, V71, P873, DOI 10.1016/j.ijrobp.2008.02.062; Dragovich T, 2008, AM J CLIN ONCOL-CANC, V31, P157, DOI 10.1097/COC.0b013e31815878c9; Fujimoto K, 1998, EUR J CANCER, V34, P1439, DOI 10.1016/S0959-8049(98)00069-0; Garcea G, 2004, EUR J CANCER, V40, P1302, DOI 10.1016/j.ejca.2004.02.015; Hayes AJ, 2000, WESTERN J MED, V172, P39, DOI 10.1136/ewjm.172.1.39; Itakura J, 2000, INT J CANCER, V85, P27; Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kerbel RS, 2006, SCIENCE, V312, P1171, DOI 10.1126/science.1125950; Ko AH, 2008, INVEST NEW DRUG, V26, P463, DOI 10.1007/s10637-008-9127-2; KONNO H, 1995, INT J CANCER, V61, P268, DOI 10.1002/ijc.2910610221; Korc M, 2003, Mol Cancer, V2, P8, DOI 10.1186/1476-4598-2-8; Korc M, 2007, AM J SURG, V194, pS84, DOI 10.1016/j.amjsurg.2007.05.004; Laquente B, 2008, MOL CANCER THER, V7, P638, DOI 10.1158/1535-7163.MCT-07-2122; Lee JJ, 2007, J BIOPHARM STAT, V17, P461, DOI 10.1080/10543400701199593; Lima CMR, 2004, J CLIN ONCOL, V22, P3776, DOI 10.1200/JCO.2004.12.082; Louvet C, 2005, J CLIN ONCOL, V23, P3509, DOI 10.1200/JCO.2005.06.023; Luo JY, 2001, INT J CANCER, V92, P361, DOI 10.1002/ijc.1202; Mendel DB, 2003, CLIN CANCER RES, V9, P327; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; O'Farrell AM, 2003, BLOOD, V101, P3597, DOI 10.1182/blood-2002-07-2307; Ogawa T, 2002, CANCER GENE THER, V9, P633, DOI 10.1038/sj.cgt.7700478; Reni M, 2005, LANCET ONCOL, V6, P369, DOI 10.1016/S1470-2045(05)70175-3; Reznikov A. G., 2007, Experimental Oncology, V29, P267; Rosewicz S, 1997, LANCET, V349, P485; Satoh H, 1998, ACTA ONCOL, V37, P85, DOI 10.1080/028418698423221; Schwarz MA, 1999, J EXP MED, V190, P341, DOI 10.1084/jem.190.3.341; Schwarz MA, 2005, EXP CELL RES, V311, P229, DOI 10.1016/j.yexcr.2005.09.008; Schwarz MA, 2000, MECH DEVELOP, V95, P123, DOI 10.1016/S0925-4773(00)00361-0; Schwarz RE, 2004, J SURG RES, V120, P64, DOI 10.1016/j.jss.2003.10.005; Schwarz RE, 1999, SURGERY, V126, P562, DOI 10.1016/S0039-6060(99)70099-1; Schwarz RE, 2010, CANCER BIOL THER, V9, P632, DOI 10.4161/cbt.9.8.11265; Schwarz RE, 2010, ANN SURG ONCOL, V17, P1442, DOI 10.1245/s10434-009-0879-5; Schwarz RE, 2009, SURGERY, V146, P241, DOI 10.1016/j.surg.2009.04.015; Seandel M, 2006, CLIN CANCER RES, V12, P6203, DOI 10.1158/1078-0432.CCR-06-1292; Wilkowski R, 2006, J PANCREAS, V7, P34; Yang F, 2010, MOL CANCER RES, V8, P35, DOI 10.1158/1541-7786.MCR-09-0220; Zhang HP, 2011, J RADIAT RES, V52, P1, DOI 10.1269/jrr.10013	56	29	30	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 18	2012	7	6							e38477	10.1371/journal.pone.0038477	http://dx.doi.org/10.1371/journal.pone.0038477			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	962XO	22723862	gold, Green Submitted, Green Published			2023-01-03	WOS:000305583300029
J	Bennett, MI; Graham, J; Schmidt-Hansen, M; Prettyjohns, M; Arnold, S				Bennett, Michael I.; Graham, John; Schmidt-Hansen, Mia; Prettyjohns, Matthew; Arnold, Stephanie		Guideline Dev Grp	GUIDELINES Prescribing strong opioids for pain in adult palliative care: summary of NICE guidance	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PREVALENCE; CANCER		[Bennett, Michael I.] Univ Leeds, Leeds Inst Hlth Sci, Leeds LS2 9LJ, W Yorkshire, England; [Graham, John; Schmidt-Hansen, Mia; Prettyjohns, Matthew; Arnold, Stephanie] Natl Collaborating Ctr Canc, Cardiff CF10 3AF, S Glam, Wales	University of Leeds	Bennett, MI (corresponding author), Univ Leeds, Leeds Inst Hlth Sci, Leeds LS2 9LJ, W Yorkshire, England.	m.i.bennett@leeds.ac.uk	Bennett, Michael I/A-1620-2009	Bennett, Michael I/0000-0002-8369-8349; Taubert, Mark/0000-0003-0454-5609; Graham, John/0000-0003-3381-9787				Bennett MI, 2009, PAIN, V143, P192, DOI 10.1016/j.pain.2009.01.016; Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419; Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056; National Institute for Health and Clinical Excellence, 2012, SAF EFF PRESCR STRON; Oldenmenger WH, 2009, EUR J CANCER, V45, P1370, DOI 10.1016/j.ejca.2009.01.007; Solano JP, 2006, J PAIN SYMPTOM MANAG, V31, P58, DOI 10.1016/j.jpainsymman.2005.06.007	6	23	23	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 23	2012	344								e2806	10.1136/bmj.e2806	http://dx.doi.org/10.1136/bmj.e2806			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	949QT	22623631				2023-01-03	WOS:000304591500001
J	Kato, M; Han, TNW; Xie, SH; Shi, K; Du, XL; Wu, LC; Mirzaei, H; Goldsmith, EJ; Longgood, J; Pei, JM; Grishin, NV; Frantz, DE; Schneider, JW; Chen, S; Li, L; Sawaya, MR; Eisenberg, D; Tycko, R; McKnight, SL				Kato, Masato; Han, Tina W.; Xie, Shanhai; Shi, Kevin; Du, Xinlin; Wu, Leeju C.; Mirzaei, Hamid; Goldsmith, Elizabeth J.; Longgood, Jamie; Pei, Jimin; Grishin, Nick V.; Frantz, Douglas E.; Schneider, Jay W.; Chen, She; Li, Lin; Sawaya, Michael R.; Eisenberg, David; Tycko, Robert; McKnight, Steven L.			Cell-free Formation of RNA Granules: Low Complexity Sequence Domains Form Dynamic Fibers within Hydrogels	CELL			English	Article							MESSENGER-RNA; AMYLOID FIBRILS; STRESS GRANULES; P GRANULES; PROTEIN; DROSOPHILA; LOCALIZATION; AGGREGATION; GERMLINE; REGIONS	Eukaryotic cells contain assemblies of RNAs and proteins termed RNA granules. Many proteins within these bodies contain KH or RRM RNA-binding domains as well as low complexity (LC) sequences of unknown function. We discovered that exposure of cell or tissue lysates to a biotinylated isoxazole (b-isox) chemical precipitated hundreds of RNA-binding proteins with significant overlap to the constituents of RNA granules. The LC sequences within these proteins are both necessary and sufficient for b-isox-mediated aggregation, and these domains can undergo a concentration-dependent phase transition to a hydrogel-like state in the absence of the chemical. X-ray diffraction and EM studies revealed the hydrogels to be composed of uniformly polymerized amyloid-like fibers. Unlike pathogenic fibers, the LC sequence-based polymers described here are dynamic and accommodate heterotypic polymerization. These observations offer a framework for understanding the function of LC sequences as well as an organizing principle for cellular structures that are not membrane bound.	[Kato, Masato; Han, Tina W.; Xie, Shanhai; Shi, Kevin; Du, Xinlin; Wu, Leeju C.; Mirzaei, Hamid; Goldsmith, Elizabeth J.; Longgood, Jamie; Pei, Jimin; Grishin, Nick V.; McKnight, Steven L.] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA; [Schneider, Jay W.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA; [Pei, Jimin; Grishin, Nick V.] Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA; [Frantz, Douglas E.] Univ Texas San Antonio, Dept Chem, San Antonio, TX 78249 USA; [Chen, She; Li, Lin] Natl Inst Biol Sci, Beijing 102206, Peoples R China; [Sawaya, Michael R.; Eisenberg, David] Univ Calif Los Angeles, Howard Hughes Med Inst, Dept Chem & Biochem, Los Angeles, CA 90095 USA; [Tycko, Robert] NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas at San Antonio (UTSA); National Institute of Biological Sciences, Beijing; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	McKnight, SL (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA.	steven.mcknight@utsouthwestern.edu		Sawaya, Michael/0000-0003-0874-9043	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK075031] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberti S, 2009, CELL, V137, P146, DOI 10.1016/j.cell.2009.02.044; Anderson P, 2006, J CELL BIOL, V172, P803, DOI 10.1083/jcb.200512082; [Anonymous], 2010, R LANG ENV STAT COMP; ASTBURY WILLIAM THOMAS, 1935, BIOCHEM JOUR, V29, P2351; Bosco DA, 2010, HUM MOL GENET, V19, P4160, DOI 10.1093/hmg/ddq335; Brangwynne CP, 2009, SCIENCE, V324, P1729, DOI 10.1126/science.1172046; Buchan JR, 2011, J CELL SCI, V124, P228, DOI 10.1242/jcs.078444; Buchan JR, 2009, MOL CELL, V36, P932, DOI 10.1016/j.molcel.2009.11.020; BURGIN KE, 1990, J NEUROSCI, V10, P1788; Decker CJ, 2007, J CELL BIOL, V179, P437, DOI 10.1083/jcb.200704147; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Elvira G, 2006, MOL CELL PROTEOMICS, V5, P635, DOI 10.1074/mcp.M500255-MCP200; Frey S, 2007, CELL, V130, P512, DOI 10.1016/j.cell.2007.06.024; Frey S, 2006, SCIENCE, V314, P815, DOI 10.1126/science.1132516; Gallo CM, 2010, SCIENCE, V330, P1685, DOI 10.1126/science.1193697; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; GEDDES AJ, 1968, J MOL BIOL, V32, P343, DOI 10.1016/0022-2836(68)90014-4; Gilks N, 2004, MOL BIOL CELL, V15, P5383, DOI 10.1091/mbc.E04-08-0715; Han TNW, 2012, CELL, V149, P768, DOI 10.1016/j.cell.2012.04.016; Huntley MA, 2002, PROTEINS, V48, P134, DOI 10.1002/prot.10150; Kanai Y, 2004, NEURON, V43, P513, DOI 10.1016/j.neuron.2004.07.022; Kedersha NL, 1999, J CELL BIOL, V147, P1431, DOI 10.1083/jcb.147.7.1431; KELLEY RL, 1993, GENE DEV, V7, P948, DOI 10.1101/gad.7.6.948; Knowles RB, 1996, J NEUROSCI, V16, P7812; LEHMANN R, 1991, DEVELOPMENT, V112, P679; MAHOWALD AP, 1968, J EXP ZOOL, V167, P237, DOI 10.1002/jez.1401670211; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; Meersman F, 2006, BBA-PROTEINS PROTEOM, V1764, P452, DOI 10.1016/j.bbapap.2005.10.021; Michelitsch MD, 2000, P NATL ACAD SCI USA, V97, P11910, DOI 10.1073/pnas.97.22.11910; Micklem DR, 1995, DEV BIOL, V172, P377, DOI 10.1006/dbio.1995.8048; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; Palacios IM, 2001, ANNU REV CELL DEV BI, V17, P569, DOI 10.1146/annurev.cellbio.17.1.569; Pitt JN, 2000, DEV BIOL, V219, P315, DOI 10.1006/dbio.2000.9607; Reijns MAM, 2008, J CELL SCI, V121, P2463, DOI 10.1242/jcs.024976; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Sadek H, 2008, P NATL ACAD SCI USA, V105, P6063, DOI 10.1073/pnas.0711507105; Schneider JW, 2008, NAT CHEM BIOL, V4, P408, DOI 10.1038/nchembio.95; Shastry BS, 2003, NEUROCHEM INT, V43, P1, DOI 10.1016/S0197-0186(02)00196-1; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930; Smith JF, 2006, P NATL ACAD SCI USA, V103, P15806, DOI 10.1073/pnas.0604035103; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; Voronina E, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a002774; Voronina E, 2010, DEVELOPMENT, V137, P1441, DOI 10.1242/dev.047654; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wille H, 1999, BIOPHYS J, V76, P1048, DOI 10.1016/S0006-3495(99)77270-X; Wootton JC, 1996, METHOD ENZYMOL, V266, P554	51	1249	1264	17	247	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 11	2012	149	4					753	767		10.1016/j.cell.2012.04.017	http://dx.doi.org/10.1016/j.cell.2012.04.017			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	941AR	22579281	Green Accepted, Bronze			2023-01-03	WOS:000303934700010
J	Brewer, C				Brewer, Colin			The golden age of the placebo	BRITISH MEDICAL JOURNAL			English	Editorial Material									Stapleford Ctr, London SW1W 9NP, England		Brewer, C (corresponding author), Stapleford Ctr, London SW1W 9NP, England.	brewerismo@gmail.com							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	APR 30	2012	344								e3016	10.1136/bmj.e3016	http://dx.doi.org/10.1136/bmj.e3016			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	939MY	22547647				2023-01-03	WOS:000303816600006
J	Huang, GJ; Ben-David, E; Piella, AST; Edwards, A; Flint, J; Shifman, S				Huang, Guo-Jen; Ben-David, Eyal; Piella, Agne S. Tort; Edwards, Andrew; Flint, Jonathan; Shifman, Sagiv			Neurogenomic Evidence for a Shared Mechanism of the Antidepressant Effects of Exercise and Chronic Fluoxetine in Mice	PLOS ONE			English	Article							ADULT HIPPOCAMPAL NEUROGENESIS; LARGE GENE LISTS; ENVIRONMENTAL ENRICHMENT; BEHAVIOR; DEPRESSION; RESPONSES; NEURONS; ANXIETY; STRESS; MODEL	Several different interventions improve depressed mood, including medication and environmental factors such as regular physical exercise. The molecular pathways underlying these effects are still not fully understood. In this study, we sought to identify shared mechanisms underlying antidepressant interventions. We studied three groups of mice: mice treated with a widely used antidepressant drug - fluoxetine, mice engaged in voluntary exercise, and mice living in an enriched environment. The hippocampi of treated mice were investigated at the molecular and cellular levels. Mice treated with fluoxetine and mice who exercised daily showed, not only similar antidepressant behavior, but also similar changes in gene expression and hippocampal neurons. These changes were not observed in mice with environmental enrichment. An increase in neurogenesis and dendritic spine density was observed following four weeks of fluoxetine treatment and voluntary exercise. A weighted gene co-expression network analysis revealed four different modules of co-expressed genes that were correlated with the antidepressant effect. This network analysis enabled us to identify genes involved in the molecular pathways underlying the effects of fluoxetine and exercise. The existence of both neuronal and gene expression changes common to antidepressant drug and exercise suggests a shared mechanism underlying their effect. Further studies of these findings may be used to uncover the molecular mechanisms of depression, and to identify new avenues of therapy.	[Huang, Guo-Jen] Chang Gung Univ, Coll Med, Dept & Grad Inst Biomed Sci, Tao Yuan, Taiwan; [Ben-David, Eyal; Shifman, Sagiv] Hebrew Univ Jerusalem, Dept Genet, Inst Life Sci, IL-91904 Jerusalem, Israel; [Piella, Agne S. Tort; Edwards, Andrew; Flint, Jonathan] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England	Chang Gung University; Hebrew University of Jerusalem; University of Oxford; Wellcome Centre for Human Genetics	Huang, GJ (corresponding author), Chang Gung Univ, Coll Med, Dept & Grad Inst Biomed Sci, Tao Yuan, Taiwan.	gjh30@mail.cgu.edu.tw; sagiv@vms.huji.ac.il	Shifman, Sagiv/D-8749-2017; Ben-David, Eyal/AAV-4126-2021	Shifman, Sagiv/0000-0003-4071-5361; Ben-David, Eyal/0000-0003-0514-0400; Huang, Guo-Jen/0000-0002-6392-2155; Flint, Jonathan/0000-0002-9427-4429	Chang Gung Memorial Hospital [CMRPD1A0211]; National Science Council of Taiwan [NSC100-2320-B-182-003]; Wellcome Trust; Legacy Heritage Fund program of Israel Science Foundation [1998/08]	Chang Gung Memorial Hospital(Chang Gung Memorial Hospital); National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Wellcome Trust(Wellcome Trust); Legacy Heritage Fund program of Israel Science Foundation	This study was supported by grants from the Chang Gung Memorial Hospital (CMRPD1A0211) and the National Science Council (NSC100-2320-B-182-003) of Taiwan (to GJH), by the Wellcome Trust (to JF), and by the Legacy Heritage Fund program of the Israel Science Foundation (grant no. 1998/08) (to SS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson IM, 2008, J PSYCHOPHARMACOL, V22, P343, DOI 10.1177/0269881107088441; Bjornebekk A, 2005, INT J NEUROPSYCHOPH, V8, P357, DOI 10.1017/S1461145705005122; BODNOFF SR, 1989, PSYCHOPHARMACOLOGY, V97, P277, DOI 10.1007/BF00442264; Dulawa SC, 2005, NEUROSCI BIOBEHAV R, V29, P771, DOI 10.1016/j.neubiorev.2005.03.017; Duman CH, 2008, BRAIN RES, V1199, P148, DOI 10.1016/j.brainres.2007.12.047; Fox C, 2006, BEHAV BRAIN RES, V175, P1, DOI 10.1016/j.bbr.2006.08.016; Greenwood BN, 2003, J NEUROSCI, V23, P2889; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huang GJ, 2008, MOL PSYCHIATR, V13, P119, DOI 10.1038/sj.mp.4002104; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Lawlor DA, 2001, BMJ-BRIT MED J, V322, P763, DOI 10.1136/bmj.322.7289.763; Lee HK, 2004, GENOME RES, V14, P1085, DOI 10.1101/gr.1910904; Miller BH, 2008, NEUROPSYCHOPHARMACOL, V33, P1312, DOI 10.1038/sj.npp.1301497; NJUNGE K, 1991, PHARMACOL BIOCHEM BE, V38, P63, DOI 10.1016/0091-3057(91)90590-X; Russo-Neustadt AA, 2000, NEUROSCIENCE, V101, P305, DOI 10.1016/S0306-4522(00)00349-3; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Snyder JS, 2011, NATURE, V476, P458, DOI 10.1038/nature10287; Tai HC, 2008, NAT REV NEUROSCI, V9, P826, DOI 10.1038/nrn2499; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Zhang B, 2005, STAT APPL GENET MOL, V4, DOI 10.2202/1544-6115.1128	22	36	38	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2012	7	4							e35901	10.1371/journal.pone.0035901	http://dx.doi.org/10.1371/journal.pone.0035901			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959VP	22558262	gold, Green Published, Green Submitted			2023-01-03	WOS:000305345200092
J	Bleicken, S; Garcia-Saez, AJ; Conte, E; Bordignon, E				Bleicken, Stephanie; Garcia-Saez, Ana J.; Conte, Elena; Bordignon, Enrica			Dynamic Interaction of cBid with Detergents, Liposomes and Mitochondria	PLOS ONE			English	Article							CYTOCHROME-C RELEASE; N-TERMINAL FRAGMENT; MEMBRANE PERMEABILIZATION; APOPTOSIS INDUCTION; CONFORMATIONAL-CHANGES; BH3-ONLY PROTEINS; LIPID-MEMBRANES; BH3 DOMAINS; BAX; BCL-X(L)	The BH3-only protein Bid plays a key role in the induction of mitochondrial apoptosis, but its mechanism of action is still not completely understood. Here we studied the two main activation events of Bid: Caspase-8 cleavage and interaction with the membrane bilayer. We found a striking reversible behaviour of the dissociation-association events between the Bid fragments p15 and p7. Caspase-8 cleavage does not induce per se separation of the two Bid fragments, which remain in a stable complex resembling the full length Bid. Detergents trigger a complete dissociation, which can be fully reversed by detergent removal in a range of protein concentrations from 100 mu M down to 500 nM. Incubation of cBid with cardiolipin-containing liposomes leads to partial dissociation of the complex. Only p15 (tBid) fragments are found at the membrane, while p7 shows no tendency to interact with the bilayer, but complete removal of p7 strongly increases the propensity of tBid to become membrane-associated. Despite the striking structural similarities of inactive Bid and Bax, Bid does not form oligomers and reacts differently in the presence of detergents and membranes, highlighting clear differences in the modes of action of the two proteins. The partial dissociation of cBid triggered by the membrane is suggested to depend on the strong and specific interaction between p15 and p7. The reversible disassembly and re-assembly of the cBid molecules at the membrane was as well proven by EPR using spin labeled cBid in the presence of isolated mitochondria. The observed dynamic dissociation of the two Bid fragments could allow the assistance to the pore-forming Bax to occur repeatedly and may explain the proposed "hit-and-run'' mode of action of Bid at the bilayer.	[Bleicken, Stephanie] Max Planck Inst Biochem, Dept Membrane Biochem, D-82152 Martinsried, Germany; [Bleicken, Stephanie; Garcia-Saez, Ana J.] German Canc Res Ctr, D-6900 Heidelberg, Germany; [Bleicken, Stephanie; Garcia-Saez, Ana J.] Max Planck Inst Intelligent Syst, BIOQUANT, Dept Membrane Biophys, Heidelberg, Germany; [Conte, Elena] Univ Bari, Dipartimento Biochim & Biol Mol, CNR, Ctr Studio Mitocondri & Metab Energet, Bari, Italy; [Bordignon, Enrica] ETH, Phys Chem Lab, Zurich, Switzerland	Max Planck Society; Helmholtz Association; German Cancer Research Center (DKFZ); Max Planck Society; Ruprecht Karls University Heidelberg; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomembrane e Bioenergetica (IBBE-CNR); Universita degli Studi di Bari Aldo Moro; Swiss Federal Institutes of Technology Domain; ETH Zurich	Bleicken, S (corresponding author), Max Planck Inst Biochem, Dept Membrane Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.	enrica.bordignon@phys.chem.ethz.ch	Conte, Elena/AAF-4055-2019; Conte, Elena/AAV-3153-2020; Saez, Ana J. Garcia/U-1611-2019	Conte, Elena/0000-0001-8571-5125; Bordignon, Enrica/0000-0003-2450-5161; Bleicken, Stephanie/0000-0002-4789-0974				Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Azarkh M, 2011, J MAGN RESON, V212, P450, DOI 10.1016/j.jmr.2011.07.014; Billen LP, 2008, ONCOGENE, V27, pS93, DOI 10.1038/onc.2009.47; Billen LP, 2008, PLOS BIOL, V6, P1268, DOI 10.1371/journal.pbio.0060147; Bleicken S, 2010, J BIOL CHEM, V285, P6636, DOI 10.1074/jbc.M109.081539; Bleicken S, 2009, J BIOENERG BIOMEMBR, V41, P29, DOI 10.1007/s10863-009-9202-1; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Chipuk JE, 2006, CELL DEATH DIFFER, V13, P1396, DOI 10.1038/sj.cdd.4401963; Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dewson G, 2009, MOL CELL, V36, P696, DOI 10.1016/j.molcel.2009.11.008; DIMITROV DS, 1988, BIOELECTROCH BIOENER, V19, P323, DOI 10.1016/0302-4598(88)80013-8; Edlich F, 2011, CELL, V145, P104, DOI 10.1016/j.cell.2011.02.034; Franco R, 2009, CELL DEATH DIFFER, V16, P1303, DOI 10.1038/cdd.2009.107; Garcia-Saez AJ, 2004, BIOCHEMISTRY-US, V43, P10930, DOI 10.1021/bi036044c; Garcia-Saez AJ, 2009, NAT STRUCT MOL BIOL, V16, P1178, DOI 10.1038/nsmb.1671; Gong XM, 2004, J BIOL CHEM, V279, P28954, DOI 10.1074/jbc.M403490200; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Hinds MG, 2007, CELL DEATH DIFFER, V14, P128, DOI 10.1038/sj.cdd.4401934; Jeschke G, 2006, APPL MAGN RESON, V30, P473, DOI 10.1007/BF03166213; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; Krstic I, 2011, ANGEW CHEM INT EDIT, V50, P5070, DOI 10.1002/anie.201100886; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Kuwana T, 2003, CURR OPIN CELL BIOL, V15, P691, DOI 10.1016/j.ceb.2003.10.004; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lovell JF, 2008, CELL, V135, P1074, DOI 10.1016/j.cell.2008.11.010; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Montessuit S, 2010, CELL, V142, P889, DOI 10.1016/j.cell.2010.08.017; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NAKAMURA GR, 1952, ANAL CHEM, V24, P1372, DOI 10.1021/ac60068a036; Oh KJ, 2005, J BIOL CHEM, V280, P753, DOI 10.1074/jbc.M405428200; Oh KJ, CONFORMATIONAL CHANG, P28924; Pannier M, 2000, J MAGN RESON, V142, P331, DOI 10.1006/jmre.1999.1944; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tait SWG, 2007, J CELL BIOL, V179, P1453, DOI 10.1083/jcb.200707063; Tan KO, 1999, J BIOL CHEM, V274, P23687, DOI 10.1074/jbc.274.34.23687; Yip KW, 2008, ONCOGENE, V27, P6398, DOI 10.1038/onc.2008.307; Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697; Zaltsman Y, 2010, NAT CELL BIOL, V12, P553, DOI 10.1038/ncb2057	50	24	24	2	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2012	7	4							e35910	10.1371/journal.pone.0035910	http://dx.doi.org/10.1371/journal.pone.0035910			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UP	22540011	Green Published, Green Submitted, gold			2023-01-03	WOS:000305341000077
J	Gong, P; Li, CS; Hua, R; Zhao, H; Tang, ZR; Mei, X; Zhang, MY; Cui, J				Gong, Ping; Li, Chun-Sheng; Hua, Rong; Zhao, Hong; Tang, Zi-Ren; Mei, Xue; Zhang, Ming-Yue; Cui, Juan			Mild Hypothermia Attenuates Mitochondrial Oxidative Stress by Protecting Respiratory Enzymes and Upregulating MnSOD in a Pig Model of Cardiac Arrest	PLOS ONE			English	Article							MULTIPLE ORGAN FAILURE; CARDIOPULMONARY-RESUSCITATION; THERAPEUTIC HYPOTHERMIA; MODERATE HYPOTHERMIA; CEREBRAL-ISCHEMIA; GENE-EXPRESSION; PORCINE MODEL; SEX STEROIDS; BRAIN-INJURY; STROKE	Mild hypothermia is the only effective treatment confirmed clinically to improve neurological outcomes for comatose patients with cardiac arrest. However, the underlying mechanism is not fully elucidated. In this study, our aim was to determine the effect of mild hypothermia on mitochondrial oxidative stress in the cerebral cortex. We intravascularly induced mild hypothermia (33 degrees C), maintained this temperature for 12 h, and actively rewarmed in the inbred Chinese Wuzhishan minipigs successfully resuscitated after 8 min of untreated ventricular fibrillation. Cerebral samples were collected at 24 and 72 h following return of spontaneous circulation (ROSC). We found that mitochondrial malondialdehyde and protein carbonyl levels were significantly increased in the cerebral cortex in normothermic pigs even at 24 h after ROSC, whereas mild hypothermia attenuated this increase. Moreover, mild hypothermia attenuated the decrease in Complex I and Complex III (i.e., major sites of reactive oxygen species production) activities of the mitochondrial respiratory chain and increased antioxidant enzyme manganese superoxide dismutase (MnSOD) activity. This increase in MnSOD activity was consistent with the upregulation of nuclear factor erythroid 2-related factor 2 (Nrf2) mRNA and protein expressions, and with the increase of Nrf2 nuclear translocation in normothermic pigs at 24 and 72 h following ROSC, whereas mild hypothermia enhanced these tendencies. Thus, our findings indicate that mild hypothermia attenuates mitochondrial oxidative stress in the cerebral cortex, which may be associated with reduced impairment of mitochondrial respiratory chain enzymes, and enhancement of MnSOD activity and expression via Nrf2 activation.	[Gong, Ping; Li, Chun-Sheng; Hua, Rong; Zhao, Hong; Tang, Zi-Ren; Mei, Xue; Zhang, Ming-Yue; Cui, Juan] Capital Med Univ, Dept Emergency, Beijing Chaoyang Hosp, Beijing, Peoples R China	Capital Medical University	Li, CS (corresponding author), Capital Med Univ, Dept Emergency, Beijing Chaoyang Hosp, Beijing, Peoples R China.	lcscyyy@163.com	Gong, Ping/AAV-1936-2021	Gong, Ping/0000-0001-9910-7948	National Natural Science Foundation of China [30972863]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (No. 30972863, http://159.226.244.22/portal/proj_search.asp). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALMEIDA A, 1995, J NEUROCHEM, V65, P1698; Arnold S, 2009, J NEUROCHEM, V110, P1, DOI 10.1111/j.1471-4159.2009.06133.x; Bakthavatchalu V, 2012, ONCOGENE, V31, P2129, DOI 10.1038/onc.2011.407; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; BELZER FO, 1988, TRANSPLANTATION, V45, P673, DOI 10.1097/00007890-198804000-00001; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Busl KM, 2010, NEUROREHABILITATION, V26, P5, DOI 10.3233/NRE-2010-0531; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Camara AKS, 2004, AM J PHYSIOL-HEART C, V286, pH1289, DOI 10.1152/ajpheart.00811.2003; Carswell HVO, 2000, AM J PHYSIOL-HEART C, V278, pH290, DOI 10.1152/ajpheart.2000.278.1.H290; Chan PH, 2005, ANN NY ACAD SCI, V1042, P203, DOI 10.1196/annals.1338.022; Cherubini A, 2005, FREE RADICAL BIO MED, V39, P841, DOI 10.1016/j.freeradbiomed.2005.06.025; Enna B, 2000, RESUSCITATION, V47, P41, DOI 10.1016/S0300-9572(00)00200-8; Fredriksson K, 2005, ACTA ANAESTH SCAND, V49, P1101, DOI 10.1111/j.1399-6576.2005.00718.x; Fredriksson K, 2006, AM J PHYSIOL-ENDOC M, V291, pE1044, DOI 10.1152/ajpendo.00218.2006; Fredriksson K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003686; Han Y, 2011, AM J EMERG MED, V29, P731, DOI 10.1016/j.ajem.2010.02.005; HANSFORD RG, 1982, MECH AGEING DEV, V19, P191, DOI 10.1016/0047-6374(82)90010-0; Helfaer MA, 1998, STROKE, V29, P824, DOI 10.1161/01.STR.29.4.824; Herlitz J, 2001, RESUSCITATION, V49, P15, DOI 10.1016/S0300-9572(00)00342-7; Herson PS, 2009, SEMIN REPROD MED, V27, P229, DOI 10.1055/s-0029-1216276; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hoye AT, 2008, ACCOUNTS CHEM RES, V41, P87, DOI 10.1021/ar700135m; Huang Q, 2010, J AGR FOOD CHEM, V58, P5194, DOI 10.1021/jf904536v; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Ji XF, 2011, RESUSCITATION   1122; Ji XF, 2011, SHOCK, V35, P530, DOI 10.1097/SHK.0b013e31820e2058; Ji XF, 2010, RESUSCITATION, V81, P1031, DOI 10.1016/j.resuscitation.2010.04.023; Kipp M, 2012, J NEUROENDOCRINOL, V24, P62, DOI 10.1111/j.1365-2826.2011.02163.x; Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200; Lebesgue D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008642; LEI BP, 1994, STROKE, V25, P147, DOI 10.1161/01.STR.25.1.147; MarinGarcia J, 1997, BIOCHEM CELL BIOL, V75, P137, DOI 10.1139/bcb-75-2-137; Marion D, 2009, J NEUROTRAUM, V26, P455, DOI 10.1089/neu.2008.0582; Meybohm P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007588; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Rea TD, 2003, CIRCULATION, V107, P2780, DOI 10.1161/01.CIR.0000070950.17208.2A; Su ZY, 2011, AM J EMERG MED, V29, P913, DOI 10.1016/j.ajem.2010.04.001; Szabo C, 2003, TOXICOL LETT, V140, P105, DOI 10.1016/S0378-4274(02)00507-6; Wang S, 2010, CRIT CARE MED, V38, P2024, DOI 10.1097/CCM.0b013e3181eed90a; Wu JY, 2009, AM J EMERG MED, V27, P823, DOI 10.1016/j.ajem.2008.07.001; Xu LJ, 2002, J CEREBR BLOOD F MET, V22, P21, DOI 10.1097/00004647-200201000-00003; Zhao H, 2005, J CEREBR BLOOD F MET, V25, P1119, DOI 10.1038/sj.jcbfm.9600111; Zhao H, 2012, RESUSCITATION   0112; Zhao H, 2007, J CEREBR BLOOD F MET, V27, P1879, DOI 10.1038/sj.jcbfm.9600540	46	57	68	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 20	2012	7	4							e35313	10.1371/journal.pone.0035313	http://dx.doi.org/10.1371/journal.pone.0035313			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UD	22532848	Green Published, gold, Green Submitted			2023-01-03	WOS:000305339200054
J	James, ND; Hussain, SA; Hall, E; Jenkins, P; Tremlett, J; Rawlings, C; Crundwell, M; Sizer, B; Sreenivasan, T; Hendron, C; Lewis, R; Waters, R; Huddart, RA				James, Nicholas D.; Hussain, Syed A.; Hall, Emma; Jenkins, Peter; Tremlett, Jean; Rawlings, Christine; Crundwell, Malcolm; Sizer, Bruce; Sreenivasan, Thiagarajan; Hendron, Carey; Lewis, Rebecca; Waters, Rachel; Huddart, Robert A.		BC2001 Investigators	Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SYNCHRONOUS CHEMORADIOTHERAPY; CONCURRENT CISPLATIN; CYSTECTOMY; RADIATION; CARCINOMA; MITOMYCIN; RISK; RTOG	Background Radiotherapy is an alternative to cystectomy in patients with muscle-invasive bladder cancer. In other disease sites, synchronous chemoradiotherapy has been associated with increased local control and improved survival, as compared with radiotherapy alone. Methods In this multicenter, phase 3 trial, we randomly assigned 360 patients with muscle-invasive bladder cancer to undergo radiotherapy with or without synchronous chemotherapy. The regimen consisted of fluorouracil (500 mg per square meter of body-surface area per day) during fractions 1 to 5 and 16 to 20 of radiotherapy and mitomycin C (12 mg per square meter) on day 1. Patients were also randomly assigned to undergo either whole-bladder radiotherapy or modified-volume radiotherapy (in which the volume of bladder receiving full-dose radiotherapy was reduced) in a partial 2-by-2 factorial design (results not reported here). The primary end point was survival free of locoregional disease. Secondary end points included overall survival and toxic effects. Results At 2 years, rates of locoregional disease-free survival were 67% (95% confidence interval [CI], 59 to 74) in the chemoradiotherapy group and 54% (95% CI, 46 to 62) in the radiotherapy group. With a median follow-up of 69.9 months, the hazard ratio in the chemoradiotherapy group was 0.68 (95% CI, 0.48 to 0.96; P = 0.03). Five-year rates of overall survival were 48% (95% CI, 40 to 55) in the chemoradiotherapy group and 35% (95% CI, 28 to 43) in the radiotherapy group (hazard ratio, 0.82; 95% CI, 0.63 to 1.09; P = 0.16). Grade 3 or 4 adverse events were slightly more common in the chemoradiotherapy group than in the radiotherapy group during treatment (36.0% vs. 27.5%, P = 0.07) but not during follow-up (8.3% vs. 15.7%, P = 0.07). Conclusions Synchronous chemotherapy with fluorouracil and mitomycin C combined with radiotherapy significantly improved locoregional control of bladder cancer, as compared with radiotherapy alone, with no significant increase in adverse events. (Funded by Cancer Research U.K.; BC2001 Current Controlled Trials number, ISRCTN68324339.)	[James, Nicholas D.] Univ Birmingham, Sch Canc Sci, Birmingham B15 2TT, W Midlands, England; [Hussain, Syed A.] Univ Liverpool, Liverpool L69 3BX, Merseyside, England; [Hall, Emma; Lewis, Rebecca; Waters, Rachel; Huddart, Robert A.] Inst Canc Res, Sutton, Surrey, England; [Jenkins, Peter] Cheltenham Gen Hosp, Cheltenham, Glos, England; [Tremlett, Jean] Brighton & Sussex Univ Hosp Natl Hlth Serv NHS Tr, Brighton, E Sussex, England; [Rawlings, Christine] S Devon Healthcare NHS Fdn, Torquay, England; [Crundwell, Malcolm] Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England; [Sizer, Bruce] Essex Cty Hosp, Colchester, Essex, England; [Sreenivasan, Thiagarajan] United Lincolnshire Hosp NHS Trust, Lincoln, England	University of Birmingham; University of Liverpool; University of London; Institute of Cancer Research - UK; Gloucestershire Hospitals NHS Foundation Trust; Cheltenham General Hospital; University of Exeter	James, ND (corresponding author), Univ Birmingham, Sch Canc Sci, Birmingham B15 2TT, W Midlands, England.	n.d.james@bham.ac.uk	James, Nick/AAL-6802-2020; Hussain, Syed/D-3255-2016	huddart, robert/0000-0003-3604-1990; Hussain, Syed/0000-0003-1552-511X; Hickish, Tamas/0000-0001-6770-7279; Hall, Emma/0000-0001-5999-5020; Landau, David/0000-0003-1770-9086; James, Nicholas/0000-0002-7314-8204	Cancer Research UK [C547/A2606, C547/A6845, C9764/A9904, C1491/A9895, CRUK/01/004]; National Institute for Health Research; Cancer Research U.K.; Cancer Research UK [10588] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR)); Cancer Research U.K.(Cancer Research UK); Cancer Research UK(Cancer Research UK)	Funded by Cancer Research U.K.; BC2001 Current Controlled Trials number, ISRCTN68324339.; Supported by grants (C547/A2606, C547/A6845, C9764/A9904, and C1491/A9895) from Cancer Research UK (trial reference number, CRUK/01/004) and by the National Institute for Health Research (to the National Cancer Research Network).	Ajani JA, 2008, JAMA-J AM MED ASSOC, V299, P1914, DOI 10.1001/jama.299.16.1914; [Anonymous], 1999, LANCET, V354, P1650; Arnott SJ, 1996, LANCET, V348, P1049; Cooke PW, 2000, EUR UROL, V38, P279, DOI 10.1159/000020294; Coppin CML, 1996, J CLIN ONCOL, V14, P2901, DOI 10.1200/JCO.1996.14.11.2901; COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C; Grossman HB, 2003, NEW ENGL J MED, V349, P1880; Grossman HB, 2003, NEW ENGL J MED, V349, P859, DOI 10.1056/NEJMoa022148; Hoskin PJ, 2010, J CLIN ONCOL, V28, P4912, DOI 10.1200/JCO.2010.28.4950; Hussain SA, 2001, ANN ONCOL, V12, P929, DOI 10.1023/A:1011133820532; Hussain SA, 2001, BRIT J CANCER, V85, P16; International Agency for Research on Cancer, GLOBOCAN 2008 CANC I; International Union Against Cancer, 2002, TNM CLASS MAL TUM; Keys HM, 1999, NEW ENGL J MED, V340, P1154, DOI 10.1056/NEJM199904153401503; Keys HM, 1999, NEW ENGL J MED, V341, P708; Med Res Council Adv Bladder Canc Working Party, 1999, LANCET, V354, P533; Morris M, 1999, NEW ENGL J MED, V340, P1137, DOI 10.1056/NEJM199904153401501; *NAT CANC I, COMM TOX CRIT VERS 2; Olivatto LO, 2011, INT J RADIAT ONCOL, V79, P490, DOI 10.1016/j.ijrobp.2009.11.057; PAVY JJ, 1995, RADIOTHER ONCOL, V35, P11, DOI 10.1016/0167-8140(95)97448-M; Rodel C, 2002, J CLIN ONCOL, V20, P3061, DOI 10.1200/JCO.2002.11.027; Rose PG, 1999, NEW ENGL J MED, V340, P1144, DOI 10.1056/NEJM199904153401502; Rose PG, 1999, NEW ENGL J MED, V341, P708; RUBIN P, 1995, INT J RADIAT ONCOL, V31, P1041, DOI 10.1016/0360-3016(95)00057-6; Stein JP, 2001, J CLIN ONCOL, V19, P666, DOI 10.1200/JCO.2001.19.3.666; Wolter P, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.4633	26	560	575	1	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 19	2012	366	16					1477	1488		10.1056/NEJMoa1106106	http://dx.doi.org/10.1056/NEJMoa1106106			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	927UE	22512481				2023-01-03	WOS:000302934800005
J	Hagberg, CE; Mehlem, A; Falkevall, A; Muhl, L; Fam, BC; Ortsater, H; Scotney, P; Nyqvist, D; Samen, E; Lu, L; Stone-Elander, S; Proietto, J; Andrikopoulos, S; Sjoholm, A; Nash, A; Eriksson, U				Hagberg, Carolina E.; Mehlem, Annika; Falkevall, Annelie; Muhl, Lars; Fam, Barbara C.; Ortsater, Henrik; Scotney, Pierre; Nyqvist, Daniel; Samen, Erik; Lu, Li; Stone-Elander, Sharon; Proietto, Joseph; Andrikopoulos, Sofianos; Sjoholm, Ake; Nash, Andrew; Eriksson, Ulf			Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes	NATURE			English	Article							GROWTH-FACTOR-B; OXIDATIVE-PHOSPHORYLATION; GLUCOSE-PRODUCTION; SKELETAL-MUSCLE; METABOLISM; TOLERANCE; ISOFORMS	The prevalence of type 2 diabetes is rapidly increasing, with severe socioeconomic impacts(1,2). Excess lipid deposition in peripheral tissues impairs insulin sensitivity and glucose uptake, and has been proposed to contribute to the pathology of type 2 diabetes(3-5). However, few treatment options exist that directly target ectopic lipid accumulation(6). Recently it was found that vascular endothelial growth factor B (VEGF-B) controls endothelial uptake and transport of fatty acids in heart and skeletal muscle(7). Here we show that decreased VEGF-B signalling in rodent models of type 2 diabetes restores insulin sensitivity and improves glucose tolerance. Genetic deletion of Vegfb in diabetic db/db mice prevented ectopic lipid deposition, increased-muscle glucose uptake and maintained normoglycaemia. Pharmacological inhibition of VEGF-B signalling by antibody administration to db/db mice enhanced glucose tolerance, preserved pancreatic islet architecture, improved beta-cell function and ameliorated dyslipidaemia, key elements of type 2 diabetes and the metabolic syndrome. The potential use of VEGF-B neutralization in type 2 diabetes was further elucidated in rats fed a high-fat diet, in which it normalized insulin sensitivity and increased glucose uptake in skeletal muscle and heart. Our results demonstrate that the vascular endothelium can function as an efficient barrier to excess muscle lipid uptake even under conditions of severe obesity and type 2 diabetes, and that this barrier can be maintained by inhibition of VEGF-B signalling. We propose VEGF-B antagonism as a novel pharmacological approach for type 2 diabetes, targeting the lipid-transport properties of the endothelium to improve muscle insulin sensitivity and glucose disposal.	[Hagberg, Carolina E.; Mehlem, Annika; Falkevall, Annelie; Muhl, Lars; Nyqvist, Daniel; Eriksson, Ulf] Karolinska Inst, Dept Med Biochem & Biophys, Div Vasc Biol, Tissue Biol Grp, SE-17177 Stockholm, Sweden; [Hagberg, Carolina E.; Falkevall, Annelie; Muhl, Lars] Karolinska Inst, Stockholm Branch, Ludwig Inst Canc Res Ltd, SE-17177 Stockholm, Sweden; [Fam, Barbara C.; Proietto, Joseph; Andrikopoulos, Sofianos] Univ Melbourne, Dept Med AH, Heidelberg, Vic 3091, Australia; [Ortsater, Henrik; Sjoholm, Ake] Karolinska Inst, Dept Clin Sci & Educ, Diabet Res Unit, SE-11883 Stockholm, Sweden; [Scotney, Pierre; Nash, Andrew] CSL Ltd, Parkville, Vic 3052, Australia; [Samen, Erik; Lu, Li; Stone-Elander, Sharon] Karolinska Univ Hosp, Dept Neuroradiol, SE-17176 Stockholm, Sweden; [Samen, Erik; Lu, Li; Stone-Elander, Sharon] Karolinska Univ Hosp, Karolinska Expt Res & Imaging Ctr, SE-17176 Stockholm, Sweden; [Samen, Erik; Stone-Elander, Sharon] Karolinska Inst, SE-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Ludwig Institute for Cancer Research; University of Melbourne; Karolinska Institutet; CSL; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Eriksson, U (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Vasc Biol, Tissue Biol Grp, SE-17177 Stockholm, Sweden.	ulf.pe.eriksson@ki.se	Mehlem, Annika/AAB-4883-2022	Hagberg, Carolina/0000-0002-5497-2855; Nyqvist, Daniel/0000-0002-6527-6716	Frans Wilhelm och Waldemar von Frenckells Fond; Wilhelm och Else Stockmanns Stiftelse; Swedish Society for Medical Research; Ludwig Institute for Cancer Research; Novo Nordisk Foundation; Swedish Cancer Foundation; Swedish Research Council; Torsten och Ragnar Soderbergs Stiftelser; Dr Peter Wallenbergs Foundation for Economics and Technology; Swedish Heart and Lung Foundation; Diabetes Foundation; Karolinska Institutet	Frans Wilhelm och Waldemar von Frenckells Fond; Wilhelm och Else Stockmanns Stiftelse; Swedish Society for Medical Research; Ludwig Institute for Cancer Research; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Swedish Cancer Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); Torsten och Ragnar Soderbergs Stiftelser; Dr Peter Wallenbergs Foundation for Economics and Technology; Swedish Heart and Lung Foundation(Swedish Heart-Lung Foundation); Diabetes Foundation; Karolinska Institutet(Karolinska Institutet)	We thank S. Wittgren and A. Gustafsson for technical assistance, and G. Christofori for the RIP VEGF-B mice. C.E.H. was supported by the Frans Wilhelm och Waldemar von Frenckells Fond and Wilhelm och Else Stockmanns Stiftelse. D.N. was supported by the Swedish Society for Medical Research. This study was supported by the Ludwig Institute for Cancer Research, the Novo Nordisk Foundation, the Swedish Cancer Foundation, the Swedish Research Council, Torsten och Ragnar Soderbergs Stiftelser, Dr Peter Wallenbergs Foundation for Economics and Technology, the Swedish Heart and Lung Foundation, the Diabetes Foundation and Karolinska Institutet.	Aase K, 2001, CIRCULATION, V104, P358, DOI 10.1161/01.CIR.104.3.358; Albrecht I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014109; Andrikopoulos S, 2008, AM J PHYSIOL-ENDOC M, V295, pE1323, DOI 10.1152/ajpendo.90617.2008; Bostrom P, 2007, NAT CELL BIOL, V9, P1286, DOI 10.1038/ncb1648; Bostrom P, 2010, DIABETES, V59, P1870, DOI 10.2337/db09-1503; Chaggar PS, 2009, DIABETES VASC DIS RE, V6, P146, DOI 10.1177/1479164109338772; DPP Res Grp, 2002, DIABETES CARE, V25, P2165; Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7; Fujimoto WY., 2000, AM J MED S6A, V108, p9S, DOI DOI 10.1016/S0002-9343(00)00337-5; GENUTH SM, 1971, ENDOCRINOLOGY, V88, P1230, DOI 10.1210/endo-88-5-1230; Hagberg CE, 2010, NATURE, V464, P917, DOI 10.1038/nature08945; Karpanen T, 2008, CIRC RES, V103, P1018, DOI 10.1161/CIRCRESAHA.108.178459; Kawasaki F, 2005, AM J PHYSIOL-ENDOC M, V288, pE510, DOI 10.1152/ajpendo.00128.2004; Kim F, 2008, ARTERIOSCL THROM VAS, V28, P1982, DOI 10.1161/ATVBAHA.108.169722; KRAEGEN EW, 1991, DIABETES, V40, P1397, DOI 10.2337/diabetes.40.11.1397; Kubota T, 2011, CELL METAB, V13, P294, DOI 10.1016/j.cmet.2011.01.018; Lahteenvuo JE, 2009, CIRCULATION, V119, P845, DOI 10.1161/CIRCULATIONAHA.108.816454; Lamont BJ, 2003, DIABETOLOGIA, V46, P1338, DOI 10.1007/s00125-003-1180-y; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Mangiafico SP, 2011, J ENDOCRINOL, V210, P335, DOI 10.1530/JOE-11-0126; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Muoio DM, 2010, NEW ENGL J MED, V363, P291, DOI 10.1056/NEJMcibr1005397; NOLAN CJ, 1994, DIABETOLOGIA, V37, P976, DOI 10.1007/s001250050207; Nyqvist D, 2005, DIABETES, V54, P2287, DOI 10.2337/diabetes.54.8.2287; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; Perseghin G, 1999, DIABETES, V48, P1600, DOI 10.2337/diabetes.48.8.1600; Randle PJ, 1998, DIABETES METAB REV, V14, P263, DOI 10.1002/(SICI)1099-0895(199812)14:4&lt;263::AID-DMR233&gt;3.0.CO;2-C; Samuel VT, 2010, LANCET, V375, P2267, DOI 10.1016/S0140-6736(10)60408-4; Schmitz-Peiffer C, 2010, DIABETES, V59, P2351, DOI 10.2337/db10-0912; SchmitzPeiffer C, 1997, DIABETES, V46, P169, DOI 10.2337/diabetes.46.2.169; Scotney PD, 2002, CLIN EXP PHARMACOL P, V29, P1024, DOI 10.1046/j.1440-1681.2002.03769.x; Sparks LM, 2005, DIABETES, V54, P1926, DOI 10.2337/diabetes.54.7.1926; Stumvoll M, 2005, LANCET, V365, P1333, DOI 10.1016/S0140-6736(05)61032-X; Unger RH, 2002, ANNU REV MED, V53, P319, DOI 10.1146/annurev.med.53.082901.104057; Visinoni S, 2008, AM J PHYSIOL-ENDOC M, V295, pE1132, DOI 10.1152/ajpendo.90552.2008; Wong N, 2011, ENDOCRINOLOGY, V152, P3690, DOI 10.1210/en.2011-0288; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	38	201	218	3	114	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 18	2012	490	7420					426	+		10.1038/nature11464	http://dx.doi.org/10.1038/nature11464			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	021XI	23023133				2023-01-03	WOS:000309918500051
J	Boyce, N				Boyce, Niall			The psychiatrist who wanted to believe	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Boyce, N (corresponding author), The Lancet, London NW1 7BY, England.	niall.boyce@lancet.com						Cornell P, 2012, SAUCER COUNTRY; Mack John. E., 1994, ABDUCTION HUMAN ENCO; Santomauro J, 2007, TALL TALES MIND BRAI, P380; Shermer M., 2002, WHY PEOPLE BELIEVE W	4	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 29	2012	380	9848					1140	1141		10.1016/S0140-6736(12)61655-9	http://dx.doi.org/10.1016/S0140-6736(12)61655-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	012SD	23029669	Bronze			2023-01-03	WOS:000309255900015
J	Oberley-Deegan, RE; Steffan, JJ; Rove, KO; Pate, KM; Weaver, MW; Spasojevic, I; Frederick, B; Raben, D; Meacham, RB; Crapo, JD; Koul, HK				Oberley-Deegan, Rebecca E.; Steffan, Joshua J.; Rove, Kyle O.; Pate, Kathryn M.; Weaver, Michael W.; Spasojevic, Ivan; Frederick, Barbara; Raben, David; Meacham, Randall B.; Crapo, James D.; Koul, Hari K.			The Antioxidant, MnTE-2-PyP, Prevents Side-Effects Incurred by Prostate Cancer Irradiation	PLOS ONE			English	Article							CATALYTIC ANTIOXIDANT; RAT MODEL; RADIATION; INJURY; RADIOTHERAPY; PORPHYRINS; PROTECTS; GROWTH; DAMAGE; CELLS	Prostate cancer is the most commonly diagnosed cancer, with an estimated 240,000 new cases reported annually in the United States. Due to early detection and advances in therapies, more than 90% of patients will survive 10 years post diagnosis and treatment. Radiation is a treatment option often used to treat localized disease; however, while radiation is very effective at killing tumor cells, normal tissues are damaged as well. Potential side-effects due to prostate cancer-related radiation therapy include bowel inflammation, erectile dysfunction, urethral stricture, rectal bleeding and incontinence. Currently, radiation therapy for prostate cancer does not include the administration of therapeutic agents to reduce these side effects and protect normal tissues from radiation-induced damage. In the current study, we show that the small molecular weight antioxidant, MnTE-2-PyP, protects normal tissues from radiation-induced damage in the lower abdomen in rats. Specifically, MnTE-2-PyP protected skin, prostate, and testes from radiation-induced damage. MnTE-2-PyP also protected from erectile dysfunction, a persistent problem regardless of the type of radiation techniques used because the penile neurovascular bundles lay in the peripheral zones of the prostate, where most prostate cancers reside. Based on previous studies showing that MnTE-2-PyP, in combination with radiation, further reduces subcutaneous tumor growth, we believe that MnTE-2-PyP represents an excellent radioprotectant in combination radiotherapy for cancer in general and specifically for prostate cancer.	[Oberley-Deegan, Rebecca E.; Pate, Kathryn M.; Weaver, Michael W.; Crapo, James D.] Natl Jewish Hlth, Dept Med, Div Pulm, Denver, CO USA; [Steffan, Joshua J.; Rove, Kyle O.; Meacham, Randall B.; Koul, Hari K.] Univ Colorado, Sch Med, Dept Surg, Program Urosci,Div Urol, Aurora, CO USA; [Steffan, Joshua J.; Koul, Hari K.] Denver Vet Adm Med Ctr, Denver, CO USA; [Spasojevic, Ivan] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Spasojevic, Ivan] Duke Canc Inst, PD PD Bioanalyt Core Lab, Durham, NC USA; [Frederick, Barbara; Raben, David] Univ Colorado, Hlth Sci Ctr, Dept Canc Biol, Radiat & Canc Biol Div, Aurora, CO USA; [Koul, Hari K.] Univ Colorado, Ctr Comprehens Canc, Aurora, CO USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; Duke University; Duke University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Oberley-Deegan, RE (corresponding author), Natl Jewish Hlth, Dept Med, Div Pulm, Denver, CO USA.	Hari.Koul@ucdenver.edu			Department of Defense Award United States Army Medical Research and Materiel CommandUSAMRMC [07355003]; University of Colorado Academic Enrichment Funds	Department of Defense Award United States Army Medical Research and Materiel CommandUSAMRMC; University of Colorado Academic Enrichment Funds	This work was supported in part by the Department of Defense Award United States Army Medical Research and Materiel CommandUSAMRMC proposal #07355003 (JC) and through University of Colorado Academic Enrichment Funds (HK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Batinic-Haberle I, 1998, J BIOL CHEM, V273, P24521, DOI 10.1074/jbc.273.38.24521; Batinic-Haberle I, 2011, FREE RADICAL BIO MED, V51, P1035, DOI 10.1016/j.freeradbiomed.2011.04.046; Batinic-Haberle I, 2010, ANTIOXID REDOX SIGN, V13, P877, DOI 10.1089/ars.2009.2876; Cooperberg MR, 2010, J CLIN ONCOL, V28, P1117, DOI 10.1200/JCO.2009.26.0133; Dall'Era JE, 2008, INT J IMPOT RES, V20, P307, DOI 10.1038/ijir.2008.1; Day BJ, 1995, J PHARMACOL EXP THER, V275, P1227; Day BJ, 1999, FREE RADICAL BIO MED, V26, P730, DOI 10.1016/S0891-5849(98)00261-5; Day BJ, 1997, ARCH BIOCHEM BIOPHYS, V347, P256, DOI 10.1006/abbi.1997.0341; Elliott SP, 2011, WORLD J UROL, V29, P35, DOI 10.1007/s00345-010-0603-x; Ferrer-Sueta G, 2003, J BIOL CHEM, V278, P27432, DOI 10.1074/jbc.M213302200; Gauter-Fleckenstein B, 2010, FREE RADICAL BIO MED, V48, P1034, DOI 10.1016/j.freeradbiomed.2010.01.020; Gridley DS, 2007, ANTICANCER RES, V27, P3101; Hall EJ, RADIOBIOLOGY RADIOLO, V7th; Hei TK, 2008, J PHARM PHARMACOL, V60, P943, DOI 10.1211/jpp.60.8.0001; Katz A, 2007, CANCER NURS, V30, P302, DOI 10.1097/01.NCC.0000281726.87490.f2; Kimura M, 2012, J SEX MED; Kimura M, 2011, J SEX MED, V8, P2215, DOI 10.1111/j.1743-6109.2011.02351.x; Mao XW, 2009, CURR EYE RES, V34, P62, DOI 10.1080/02713680802546948; Merlin SL, 2001, INT J IMPOT RES, V13, P104, DOI 10.1038/sj.ijir.3900652; Oberley-Deegan RE, 2009, AM J RESP CELL MOL, V41, P170, DOI 10.1165/rcmb.2008-0138OC; Oury TD, 2001, AM J RESP CELL MOL, V25, P164, DOI 10.1165/ajrcmb.25.2.4235; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Spasojevic I, 2008, FREE RADICAL BIO MED, V45, P943, DOI 10.1016/j.freeradbiomed.2008.05.015; Sullivan L, 2009, RADIOTHER ONCOL, V91, P232, DOI 10.1016/j.radonc.2008.11.013; Tse HM, 2004, FREE RADICAL BIO MED, V36, P233, DOI 10.1016/j.freeradbiomed.2003.10.029; van der Wielen GJ, 2009, J SEX MED, V6, P1908, DOI 10.1111/j.1743-6109.2009.01272.x; Vujaskovic Z, 2002, FREE RADICAL BIO MED, V33, P857, DOI 10.1016/S0891-5849(02)00980-2; Zhao W, 2007, BRIT J RADIOL, V80, pS23, DOI 10.1259/bjr/18237646	28	38	40	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 12	2012	7	9							e44178	10.1371/journal.pone.0044178	http://dx.doi.org/10.1371/journal.pone.0044178			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	005GJ	22984473	Green Submitted, Green Published, gold			2023-01-03	WOS:000308738500035
J	Niederer, SA; Lamata, P; Plank, G; Chinchapatnam, P; Ginks, M; Rhode, K; Rinaldi, CA; Razavi, R; Smith, NP				Niederer, Steven Alexander; Lamata, Pablo; Plank, Gernot; Chinchapatnam, Phani; Ginks, Matt; Rhode, Kawal; Rinaldi, Christopher Aldo; Razavi, Reza; Smith, Nicolas Peter			Analyses of the Redistribution of Work following Cardiac Resynchronisation Therapy in a Patient Specific Model	PLOS ONE			English	Article							BUNDLE-BRANCH BLOCK; RESYNCHRONIZATION THERAPY; DILATED CARDIOMYOPATHY; OXYGEN-CONSUMPTION; BLOOD-FLOW; OXIDATIVE-METABOLISM; HEART; EFFICIENCY; PERFUSION; STRAIN	Regulation of regional work is essential for efficient cardiac function. In patients with heart failure and electrical dysfunction such as left branch bundle block regional work is often depressed in the septum. Following cardiac resynchronisation therapy (CRT) this heterogeneous distribution of work can be rebalanced by altering the pattern of electrical activation. To investigate the changes in regional work in these patients and the mechanisms underpinning the improved function following CRT we have developed a personalised computational model. Simulations of electromechanical cardiac function in the model estimate the regional stress, strain and work pre- and post-CRT. These simulations predict that the increase in observed work performed by the septum following CRT is not due to an increase in the volume of myocardial tissue recruited during contraction but rather that the volume of recruited myocardium remains the same and the average peak work rate per unit volume increases. These increases in the peak average rate of work is is attributed to slower and more effective contraction in the septum, as opposed to a change in active tension. Model results predict that this improved septal work rate following CRT is a result of resistance to septal contraction provided by the LV free wall. This resistance results in septal shortening over a longer period which, in turn, allows the septum to contract while generating higher levels of active tension to produce a higher work rate.	[Niederer, Steven Alexander; Chinchapatnam, Phani; Ginks, Matt; Rhode, Kawal; Rinaldi, Christopher Aldo; Razavi, Reza; Smith, Nicolas Peter] Kings Coll London, Imaging Sci & Biomed Engn Div, London WC2R 2LS, England; [Lamata, Pablo; Smith, Nicolas Peter] Univ Oxford, Comp Lab, Oxford OX1 3QD, England; [Plank, Gernot] Med Univ Graz, Inst Biophys, Graz, Austria; [Ginks, Matt; Rinaldi, Christopher Aldo; Razavi, Reza] St Thomas Hosp, Dept Cardiol, London, England	University of London; King's College London; University of Oxford; Medical University of Graz; Guy's & St Thomas' NHS Foundation Trust	Niederer, SA (corresponding author), Kings Coll London, Imaging Sci & Biomed Engn Div, London WC2R 2LS, England.	Nicolas.smith@kcl.ox.ac.uk	Plank, Gernot/C-9498-2011; Lamata, Pablo/E-3251-2010; Lamata, Pablo/AAE-7884-2020; Plank, Gernot/O-3791-2019; Rinaldi, Claudia/GSD-6821-2022	Plank, Gernot/0000-0002-7380-6908; Lamata, Pablo/0000-0002-3097-4928; Lamata, Pablo/0000-0002-3097-4928; Plank, Gernot/0000-0002-7380-6908; Rinaldi, christopher/0000-0002-3930-1957; Rhode, Kawal/0000-0002-4707-7318; Niederer, Steven/0000-0002-4612-6982; Razavi, Reza/0000-0003-1065-3008	U.K. Engineering and Physical Sciences Research Council; St Jude Medical educational grant; Austrian Science Fund (FWF) [F 3201] Funding Source: researchfish; Engineering and Physical Sciences Research Council [EP/H019898/1] Funding Source: researchfish; Medical Research Council [MR/J006742/1] Funding Source: researchfish	U.K. Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); St Jude Medical educational grant; Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This study was funded by the U.K. Engineering and Physical Sciences Research Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Matthew Ginks receives a St Jude Medical educational grant and Christopher Rinaldi receives St Jude educational support and is on advisory boards for St Jude Medical and Medtronic. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.	Bassingthwaighte JB, 1999, AM J CARDIOL, V83, P7; Bogaard MD, 2011, EUR J HEART FAIL, V13, P1126, DOI 10.1093/eurjhf/hfr094; DELHAAS T, 1994, J PHYSIOL-LONDON, V477, P481, DOI 10.1113/jphysiol.1994.sp020209; Deussen A, 1997, PFLUG ARCH EUR J PHY, V433, P488, DOI 10.1007/s004240050304; Dokos S, 2002, AM J PHYSIOL-HEART C, V283, pH2650, DOI 10.1152/ajpheart.00111.2002; Duckett SG, 2011, J AM COLL CARDIOL, V58, P1128, DOI 10.1016/j.jacc.2011.04.042; Durrer D, 1970, TOTAL EXCITATION ISO, P899; GROVER M, 1983, CIRC RES, V53, P72, DOI 10.1161/01.RES.53.1.72; Hill AV, 1938, PROC R SOC SER B-BIO, V126, P136, DOI 10.1098/rspb.1938.0050; HISANO R, 1987, CIRC RES, V61, P318, DOI 10.1161/01.RES.61.3.318; Kass DA, 1999, CIRCULATION, V99, P1567, DOI 10.1161/01.CIR.99.12.1567; Lindner O, 2005, EUR HEART J, V26, P70, DOI 10.1093/eurheartj/ehi046; Lindner O, 2006, J NUCL MED, V47, P378; Nelson GS, 2000, CIRCULATION, V102, P3053; Niederer SA, 2011, CARDIOVASC RES, V89, P336, DOI 10.1093/cvr/cvq318; Nowak B, 2003, J AM COLL CARDIOL, V41, P1523, DOI 10.1016/S0735-1097(03)00257-2; OPIE LH, 1965, J PHYSIOL-LONDON, V180, P529, DOI 10.1113/jphysiol.1965.sp007715; Prinzen FW, 1999, J AM COLL CARDIOL, V33, P1735, DOI 10.1016/S0735-1097(99)00068-6; Suga H, 1979, AM J PHYSIOL, P498; Sundell J, 2004, J AM COLL CARDIOL, V43, P1027, DOI 10.1016/j.jacc.2003.10.044; Ten Tusscher KHWJ, 2006, PROG BIOPHYS MOL BIO, V90, P326, DOI 10.1016/j.pbiomolbio.2005.05.015; Ukkonen H, 2003, CIRCULATION, V107, P28, DOI 10.1161/01.CIR.0000047068.02226.95	22	17	17	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2012	7	8							e43504	10.1371/journal.pone.0043504	http://dx.doi.org/10.1371/journal.pone.0043504			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	998CA	22952697	Green Published, gold, Green Submitted			2023-01-03	WOS:000308213600029
J	Gabrielli, E; Pericolini, E; Cenci, E; Monari, C; Magliani, W; Ciociola, T; Conti, S; Gatti, R; Bistoni, F; Polonelli, L; Vecchiarelli, A				Gabrielli, Elena; Pericolini, Eva; Cenci, Elio; Monari, Claudia; Magliani, Walter; Ciociola, Tecla; Conti, Stefania; Gatti, Rita; Bistoni, Francesco; Polonelli, Luciano; Vecchiarelli, Anna			Antibody Constant Region Peptides Can Display Immunomodulatory Activity through Activation of the Dectin-1 Signalling Pathway	PLOS ONE			English	Article							BETA-GLUCAN RECOGNITION; HUMAN DENDRITIC CELLS; CANDIDA-ALBICANS; THERAPEUTIC ACTIVITY; INNATE IMMUNITY; CRYPTOCOCCUS-NEOFORMANS; LIGHT-CHAINS; HOST-DEFENSE; KAPPA-B; MONOCYTES	We previously reported that a synthetic peptide with sequence identical to a CDR of a mouse monoclonal antibody specific for difucosyl human blood group A exerted an immunomodulatory activity on murine macrophages. It was therapeutic against systemic candidiasis without possessing direct candidacidal properties. Here we demonstrate that a selected peptide, N10K, putatively deriving from the enzymatic cleavage of the constant region (Fc) of human IgG(1), is able to induce IL-6 secretion and pIkB-alpha activation. More importantly, it causes an up-regulation of Dectin-1 expression. This leads to an increased activation of beta-glucan-induced pSyk, CARD9 and pIkB-alpha, and an increase in the production of pro-inflammatory cytokines such as IL-6, IL-12, IL-1 beta and TNF-alpha. The increased activation of this pathway coincides with an augmented phagocytosis of non opsonized Candida albicans cells by monocytes. The findings suggest that some Fc-peptides, potentially deriving from the proteolysis of immunoglobulins, may cause an unexpected immunoregulation in a way reminiscent of innate immunity molecules.	[Gabrielli, Elena; Pericolini, Eva; Cenci, Elio; Monari, Claudia; Bistoni, Francesco; Vecchiarelli, Anna] Univ Perugia, Dept Expt Med & Biochem Sci, Microbiol Sect, I-06100 Perugia, Italy; [Magliani, Walter; Ciociola, Tecla; Conti, Stefania; Polonelli, Luciano] Univ Parma, Dept Pathol & Lab Med, Microbiol Sect, I-43100 Parma, Italy; [Gatti, Rita] Univ Parma, Dept Expt Med, Histol Sect, I-43100 Parma, Italy	University of Perugia; University of Parma; University Hospital of Parma; University of Parma	Gabrielli, E (corresponding author), Univ Perugia, Dept Expt Med & Biochem Sci, Microbiol Sect, I-06100 Perugia, Italy.	vecchiar@unipg.it	Conti, Stefania/N-3558-2015; MONARI, Claudia/AAY-3848-2020; Ciociola, Tecla/AFN-5212-2022; Pericolini, Eva/AAZ-5848-2021; Ciociola, Tecla/HCH-2453-2022; monari, claudia/O-4563-2018	Conti, Stefania/0000-0001-9973-8352; MONARI, Claudia/0000-0002-5027-9367; Ciociola, Tecla/0000-0001-6499-2545; monari, claudia/0000-0002-5027-9367; CENCI, ELIO/0000-0003-0752-7262; Vecchiarelli, Anna/0000-0002-3185-6720; Pericolini, Eva/0000-0002-5299-8197	Italian Ministry of Health [40H39]	Italian Ministry of Health(Ministry of Health, Italy)	The work was supported by funding from Italian Ministry of Health for the National AIDS Research Program (Grant number 40H39). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arruda DC, 2012, J BIOL CHEM, V287, P14912, DOI 10.1074/jbc.M111.322362; BISTONI F, 1986, INFECT IMMUN, V51, P668, DOI 10.1128/IAI.51.2.668-674.1986; Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470; Busetto S, 2004, CYTOM PART A, V58A, P201, DOI 10.1002/cyto.a.20014; Casoli C, 2006, AIDS, V20, P975, DOI 10.1097/01.aids.0000222068.14878.0d; Cenci E, 2006, J LEUKOCYTE BIOL, V79, P40, DOI 10.1189/jlb.0205113; CHAKA W, 1995, CLIN DIAGN LAB IMMUN, V2, P753, DOI 10.1128/CDLI.2.6.753-759.1995; Church LD, 2008, NAT CLIN PRACT RHEUM, V4, P34, DOI 10.1038/ncprheum0681; COHEN S, 1964, ADV IMMUNOL, V4, P287, DOI 10.1016/S0065-2776(08)60710-5; Conti G, 2008, ANTIMICROB AGENTS CH, V52, P4331, DOI 10.1128/AAC.00506-08; Dennehy KM, 2007, J LEUKOCYTE BIOL, V82, P253, DOI 10.1189/jlb.1206753; Ferwerda G, 2008, CELL MICROBIOL, V10, P2058, DOI 10.1111/j.1462-5822.2008.01188.x; Franchi L, 2008, CELL MICROBIOL, V10, P1, DOI 10.1111/j.1462-5822.2007.01059.x; Gabrielli E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008187; Gaffen SL, 2011, IMMUNOL RES, V50, P181, DOI 10.1007/s12026-011-8226-x; Gantner BN, 2005, EMBO J, V24, P1277, DOI 10.1038/sj.emboj.7600594; Goodridge HS, 2009, IMMUNOL REV, V230, P38, DOI 10.1111/j.1600-065X.2009.00793.x; Haas A, 2008, CYTOM PART A, V73A, P799, DOI 10.1002/cyto.a.20598; Hot A, 2011, ANN RHEUM DIS, V70, P727, DOI 10.1136/ard.2010.143768; Jiang K, 2002, J IMMUNOL, V168, P3155, DOI 10.4049/jimmunol.168.7.3155; Kerrigan AM, 2010, IMMUNOL REV, V234, P335, DOI 10.1111/j.0105-2896.2009.00882.x; Lee YG, 2009, INT J BIOCHEM CELL B, V41, P811, DOI 10.1016/j.biocel.2008.08.011; LeibundGut-Landmann S, 2007, NAT IMMUNOL, V8, P630, DOI 10.1038/ni1460; Li M, 2009, CHINESE MED J-PEKING, V122, P496, DOI 10.3760/cma.j.issn.0366-6999.2009.05.003; Magliani W, 2009, CURR MED CHEM, V16, P2305, DOI 10.2174/092986709788453104; Marina-Garcia N, 2009, J IMMUNOL, V182, P4321, DOI 10.4049/jimmunol.0802197; Monari C, 2003, EUR J IMMUNOL, V33, P1041, DOI 10.1002/eji.200323388; Olynych TJ, 2006, J ALLERGY CLIN IMMUN, V118, P837, DOI 10.1016/j.jaci.2006.06.008; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; Pietrella D, 2008, INFECT IMMUN, V76, P4359, DOI 10.1128/IAI.00669-08; Polonelli L, 2003, INFECT IMMUN, V71, P6205, DOI 10.1128/IAI.71.11.6205-6212.2003; Polonelli L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034105; Polonelli L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002371; Reid DM, 2009, CURR OPIN IMMUNOL, V21, P30, DOI 10.1016/j.coi.2009.01.003; Saijo S, 2007, NAT IMMUNOL, V8, P39, DOI 10.1038/ni1425; Saijo S, 2011, INT IMMUNOL, V23, P467, DOI 10.1093/intimm/dxr046; Schroder K, 2010, SCIENCE, V327, P296, DOI 10.1126/science.1184003; Sengul S, 2002, KIDNEY INT, V62, P1977, DOI 10.1046/j.1523-1755.2002.00660.x; Singh RD, 2003, MOL BIOL CELL, V14, P3254, DOI 10.1091/mbc.E02-12-0809; Skrzypek F, 2009, MICROBES INFECT, V11, P661, DOI 10.1016/j.micinf.2009.03.010; Taylor PR, 2007, NAT IMMUNOL, V8, P31, DOI 10.1038/ni1408; Tsoni SV, 2008, ANN NY ACAD SCI, V1143, P45, DOI 10.1196/annals.1443.019; WU TT, 1970, J EXP MED, V132, P211, DOI 10.1084/jem.132.2.211; Yang Z, 2009, IMMUNOBIOLOGY, V214, P321, DOI 10.1016/j.imbio.2008.09.002	44	16	20	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2012	7	8							e43972	10.1371/journal.pone.0043972	http://dx.doi.org/10.1371/journal.pone.0043972			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	995WH	22952831	Green Published, gold, Green Submitted			2023-01-03	WOS:000308044800081
J	Li, S; Roberts, S; Plebanski, M; Gouillou, M; Spelman, T; Latour, P; Jackson, D; Brown, L; Sparrow, RL; Prince, HM; Hart, D; Loveland, BE; Gowans, EJ				Li, Shuo; Roberts, Stuart; Plebanski, Magdalena; Gouillou, Maelenn; Spelman, Tim; Latour, Philippe; Jackson, David; Brown, Lorena; Sparrow, Rosemary L.; Prince, H. Miles; Hart, Derek; Loveland, Bruce E.; Gowans, Eric J.			Induction of Multi-Functional T Cells in a Phase I Clinical Trial of Dendritic Cell Immunotherapy in Hepatitis C Virus Infected Individuals	PLOS ONE			English	Article							TNF-ALPHA; QUALITY; MEMORY	We have previously reported a world-first phase I clinical trial to treat HCV patients using monocyte-derived dendritic cells (Mo-DC) loaded with HCV-specific lipopeptides. While the brief treatment proved to be safe, it failed to reduce the viral load and induced only transient cell-mediated immune responses, measured by IFN gamma ELIspot. Here we reanalysed the PBMC samples from this trial to further elucidate the immunological events associated with the Mo-DC therapy. We found that HCV-specific single-and multi-cytokine secreting T cells were induced by the Mo-DC immunotherapy in some patients, although at irregular intervals and not consistently directed to the same HCV antigen. Despite the vaccination, the responses were generally poor in quality and comprised of primarily single-cytokine secreting cells. The frequency of FOXP3(+) regulatory T cells (Treg) fluctuated following DC infusion and eventually dropped to below baseline by week 12, an interesting trend suggesting that the vaccination may have resulted in a more subtle outcome than was initially apparent. Our data suggested that Mo-DC therapy induced complex immune responses in vivo that may or may not lead to clinical benefit.	[Li, Shuo; Gouillou, Maelenn; Spelman, Tim; Latour, Philippe; Loveland, Bruce E.; Gowans, Eric J.] Burnet Inst, Melbourne, Vic, Australia; [Li, Shuo; Plebanski, Magdalena; Sparrow, Rosemary L.; Loveland, Bruce E.] Monash Univ, Dept Immunol, Melbourne, Vic 3004, Australia; [Roberts, Stuart] Alfred Hosp, Melbourne, Vic, Australia; [Spelman, Tim] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3004, Australia; [Jackson, David; Brown, Lorena] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3052, Australia; [Sparrow, Rosemary L.] Australian Red Cross Blood Serv, Melbourne, Vic, Australia; [Prince, H. Miles] Peter MacCallum Canc Ctr, Ctr Blood Cell Therapies, Melbourne, Australia; [Prince, H. Miles] Univ Melbourne, Melbourne, Vic 3010, Australia; [Hart, Derek] Univ Sydney, Sydney, NSW 2006, Australia; [Gowans, Eric J.] Monash Univ, Dept Microbiol, Melbourne, Vic 3004, Australia; [Gowans, Eric J.] Univ Adelaide, Discipline Surg, Adelaide, SA, Australia	Burnet Institute; Monash University; Florey Institute of Neuroscience & Mental Health; Monash University; University of Melbourne; Australian Red Cross Blood Service; Peter Maccallum Cancer Center; University of Melbourne; University of Sydney; Monash University; University of Adelaide	Li, S (corresponding author), Burnet Inst, Melbourne, Vic, Australia.	shuo.li@burnet.edu.au; eric.gowans@adelaide.edu.au	gowans, eric J/M-3689-2017; Hart, Derek NJ/B-9505-2014; Li, Shuo/A-3994-2019; Plebanski, Magdalena/AAU-3144-2021	Li, Shuo/0000-0002-2763-8624; Brown, Lorena/0000-0001-9342-909X; Sparrow, Rosemary/0000-0002-6689-2983; , Magdalena/0000-0001-6889-3667; Jackson, David/0000-0001-7255-270X	National Health and Medical Research Council (NHMRC) of Australia [433908]; National Institutes of Health [RO1A1054459]; NHMRC	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	The funding for this work was provided by grants from 1. National Health and Medical Research Council (NHMRC) of Australia, ID 433908; 2. National Institutes of Health RO1A1054459; and 3. Private donations. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors thank Calum de Burgh (University of Aberdeen, UK) for general technical assistance; Laurie Lamoreaux (Vaccine Research Centre, NIH) for critical advice on data interpretation; and Geza Paukovics (Burnet Institute) for assistance in flow cytometry. The authors gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute. EJG is a recipient of a NHMRC Senior Research Fellow award. The following reagent was obtained through BEI Resources, NIAID, NIH: Peptide Arrays for Hepatitis C Virus H77.	Ahmed R, 2011, IMMUNOL CELL BIOL, V89, P340, DOI 10.1038/icb.2010.155; Allan SE, 2007, INT IMMUNOL, V19, P345, DOI 10.1093/intimm/dxm014; Banerjee DK, 2006, BLOOD, V108, P2655, DOI 10.1182/blood-2006-03-011353; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Chen X, 2010, CURR DIR AUTOIMMUN, V11, P119, DOI 10.1159/000289201; Currier JR, 2002, J IMMUNOL METHODS, V260, P157, DOI 10.1016/S0022-1759(01)00535-X; Gowans EJ, 2010, J HEPATOL, V53, P599, DOI 10.1016/j.jhep.2010.05.007; Housley WJ, 2011, J IMMUNOL, V186, P6779, DOI 10.4049/jimmunol.1003868; Jones KL, 2008, J VIRAL HEPATITIS, V15, P761, DOI 10.1111/j.1365-2893.2008.01003.x; Kannanganat S, 2007, J VIROL, V81, P8468, DOI 10.1128/JVI.00228-07; Lamoreaux L, 2006, NAT PROTOC, V1, P1507, DOI 10.1038/nprot.2006.268; Li S, 2008, J VIROL, V82, P21, DOI 10.1128/JVI.01768-07; Li S, 2007, IMMUNOL CELL BIOL, V85, P197, DOI 10.1038/sj.icb.7100020; Li S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000707; Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274; Valencia X, 2006, BLOOD, V108, P253, DOI 10.1182/blood-2005-11-4567; Zanin-Zhorov A, 2010, SCIENCE, V328, P372, DOI 10.1126/science.1186068; Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806	18	8	10	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2012	7	8							e39368	10.1371/journal.pone.0039368	http://dx.doi.org/10.1371/journal.pone.0039368			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	988OQ	22905088	Green Submitted, gold, Green Published			2023-01-03	WOS:000307500800001
J	Killen, J; Harrington, M; Fauci, AS				Killen, Jack; Harrington, Mark; Fauci, Anthony S.			MSM, AIDS research activism, and HAART	LANCET			English	Editorial Material									[Killen, Jack] NIH, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA; [Harrington, Mark] Treatment Act Grp, New York, NY USA; [Fauci, Anthony S.] NIAID, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Killen, J (corresponding author), NIH, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA.	jack.killen@nih.gov						Ad-hoc coalition of AIDS and health organisations, 1990, HIV AIDS BIOM RES PR; *CDCP, 1981, MMWR-MORBID MORTAL W, V30, P305; DELANEY M, 1989, J INFECT DIS, V159, P416, DOI 10.1093/infdis/159.3.416; Epstein S., 1996, IMPURE SCI; Food and Drug Administration, EXP ACC EXP APPR NEW; Geffen N., 2010, DEBUNKING DELUSIONS; Goldberg R, C CALL PWAS SAT HIGH; Jennings V, 1990, WASH POST, pB1; Killen John Y., 2008, OXFORD TXB CLIN RES, P97; Nunn Amy, 2009, POLITICS HIST AIDS T; Pozalski I, 1981, MMWR-MORBID MORTAL W, V30, P1; WACHTER RM, 1992, NEW ENGL J MED, V326, P128, DOI 10.1056/NEJM199201093260209	12	11	11	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 28	2012	380	9839					314	316		10.1016/S0140-6736(12)60635-7	http://dx.doi.org/10.1016/S0140-6736(12)60635-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	979TN	22819655				2023-01-03	WOS:000306842800007
J	Golden, CD; Rasolofoniaina, BJR; Anjaranirina, EJG; Nicolas, L; Ravaoliny, L; Kremen, C				Golden, Christopher D.; Rasolofoniaina, B. J. Rodolph; Anjaranirina, E. J. Gasta; Nicolas, Lilien; Ravaoliny, Laurent; Kremen, Claire			Rainforest Pharmacopeia in Madagascar Provides High Value for Current Local and Prospective Global Uses	PLOS ONE			English	Article							PHARMACEUTICALS; CONSERVATION; CONSUMPTION; VALUATION; DRUGS	Botanical diversity provides value to humans through carbon sequestration, air and water purification, and the provisioning of wild foods and ethnomedicines. Here we calculate the value of botanical ethnomedicines in a rainforest region of Madagascar, the Makira Protected Area, using a substitution method that combines replacement costs and choice modeling. The Makira watershed may comprise approximately 0.8% of global botanical diversity and possesses enormous value both in its ability to provision botanical ethnomedicines to local people and as a source of potentially novel pharmaceutical drugs for society as a whole. Approximately 241 locally-recognized species are used as ethnomedicines, including 113 agricultural or weed species. We equated each ethnomedicinal treatment to the monetary value of a comparable pharmaceutical treatment adjusted by personal preferences in perceived efficacy (rather than from known or assumed medicinal equivalency). The benefit value of these botanical ethnomedicines per individual is $5.40-7.90 per year when using the value of highly subsidized Malagasy pharmaceuticals and $100.60-287.40 when using the value of American pharmaceuticals. Using local pharmaceuticals as substitutes, the value per household is $30.24-44.30 per year, equivalent to 43-63% of median annual household income, demonstrating their local importance. Using the value of American pharmaceuticals, the amount is equivalent to 22-63% of the median annual health care expenditures for American adults under 45 in 2006. The potential for developing novel biomedicines from the Makira watershed's unique flora ranges in untapped benefit value from $0.3-5.7 billion for American pharmaceutical companies, non-inclusive of the importance of providing novel medicines and improved healthcare to society. This study provides evidence of the tremendous current local and prospective global value of botanical ethnomedicines and furthers arguments for the conservation of tropical forests for sustainable use.	[Golden, Christopher D.] Harvard Univ, Ctr Environm, Cambridge, MA 02138 USA; [Golden, Christopher D.; Rasolofoniaina, B. J. Rodolph; Anjaranirina, E. J. Gasta; Ravaoliny, Laurent] Madagascar Hlth & Environm Res MAHERY, Maroantsetra, Madagascar; [Golden, Christopher D.; Kremen, Claire] Univ Calif Berkeley, Dept Environm Sci Policy & Management, Berkeley, CA 94720 USA; [Nicolas, Lilien] Maroantsetra Dist Publ Hosp, Maroantsetra, Madagascar	Harvard University; University of California System; University of California Berkeley	Golden, CD (corresponding author), Harvard Univ, Ctr Environm, Cambridge, MA 02138 USA.	cgolden@fas.harvard.edu		Golden, Christopher/0000-0002-0358-4625; Golden, Christopher/0000-0002-2258-7493	National Geographic Society Conservation Trust [C135-08]; Margot Marsh Biodiversity Fund [023815]; Mohamed bin Zayed Species Conservation Fund [1025935]; National Science Foundation [1011714]	National Geographic Society Conservation Trust(National Geographic Society); Margot Marsh Biodiversity Fund; Mohamed bin Zayed Species Conservation Fund; National Science Foundation(National Science Foundation (NSF))	The authors would like to acknowledge financial support by the National Geographic Society Conservation Trust #C135-08, the Margot Marsh Biodiversity Fund # 023815, the Mohamed bin Zayed Species Conservation Fund # 1025935 and the National Science Foundation doctoral dissertation improvement grant # 1011714. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrawal A, 2011, ANNU REV ENV RESOUR, V36, P373, DOI 10.1146/annurev-environ-042009-094508; [Anonymous], R D PROD NEEDS ASS Q; Assessment M. E., 2005, EC HUM WELL BEING SY; Blumenthal M., 1998, COMPLETE GERMAN COMM; CHAO A, 1987, BIOMETRICS, V43, P783, DOI 10.2307/2531532; Colwell R. K., 2005, ESTIMATES STAT ESTIM; Creer DD, 2006, THORAX, V61, P75, DOI 10.1136/thx.2004.027441; Dobbs F, 1996, BRIT J GEN PRACT, V46, P461; Eriksson U, 2001, BMJ-BRIT MED J, V322, P579, DOI 10.1136/bmj.322.7286.579; Ferraro PJ, 2012, REV ENV ECON POLICY, V6, P20, DOI 10.1093/reep/rer019; Fugh-Berman A, 2000, LANCET, V355, P134, DOI 10.1016/S0140-6736(99)06457-0; Godoy R, 2000, NATURE, V406, P62, DOI 10.1038/35017647; Golden CD, 2011, P NATL ACAD SCI USA, V108, P19653, DOI 10.1073/pnas.1112586108; Golden CD, 2009, ORYX, V43, P386, DOI 10.1017/S0030605309000131; Izzo AA, 2009, DRUGS, V69, P1777, DOI 10.2165/11317010-000000000-00000; Kremer M, 2002, J ECON PERSPECT, V16, P67, DOI 10.1257/089533002320950984; Longo LP, 2000, AM FAM PHYSICIAN, V61, P2121; MENDELSOHN R, 1995, ECON BOT, V49, P223, DOI 10.1007/BF02862929; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; NEUMANN AK, 1982, SOC SCI MED, V16, P1817, DOI 10.1016/0277-9536(82)90442-7; Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v; Pagiola S, 2004, 101 WORLD BANK; Pattanayak SK, 2001, LAND ECON, V77, P595, DOI 10.2307/3146943; Rasoanaivo P, 2003, TRADITIONAL MED PROG; Reid W. V., 1993, Biodiversity prospecting: using genetic resources for sustainable development., P1; Schatz G, 2011, PARTING FRIENDS; Schippmann U, 2002, IMPACT CULTIVATION G; Shyamsundar P, 1996, J ENVIRON ECON MANAG, V31, P129, DOI 10.1006/jeem.1996.0036; Walther BA, 1998, PARASITOLOGY, V116, P395, DOI 10.1017/S0031182097002230	29	14	14	1	49	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2012	7	7							e41221	10.1371/journal.pone.0041221	http://dx.doi.org/10.1371/journal.pone.0041221			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	981ER	22848447	Green Published, gold			2023-01-03	WOS:000306950200047
J	Sare, J				Sare, Jeremy			Tensions between drug use policies and infection control	BRITISH MEDICAL JOURNAL			English	Editorial Material												jeremysare@btinternet.com						Cseste J, 2012, INT J DRUG POLICY, V23, P82; Glaister Dan, 2009, GUARDIAN; Global Commission on Drug Policy, 2012, WAR DRUGS HIV AIDS C; Hughes CE, 2010, BRIT J CRIMINOL, V50, P999, DOI 10.1093/bjc/azq038; Inter-Ministerial Group on Drugs, 2012, PUTT FULL REC 1; Mozynski P, 2012, BMJ             0617, V344; United Nations Office on Drugs and Crime, WORLD DRUG REP 2012	7	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUL 23	2012	345								e4930	10.1136/bmj.e4930	http://dx.doi.org/10.1136/bmj.e4930			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	981UP	22826579				2023-01-03	WOS:000306996800010
J	Orlando, UD; Garona, J; Ripoll, GV; Maloberti, PM; Solano, AR; Avagnina, A; Gomez, DE; Alonso, DF; Podesta, EJ				Orlando, Ulises D.; Garona, Juan; Ripoll, Giselle V.; Maloberti, Paula M.; Solano, Angela R.; Avagnina, Alejandra; Gomez, Daniel E.; Alonso, Daniel F.; Podesta, Ernesto J.			The Functional Interaction between Acyl-CoA Synthetase 4, 5-Lipooxygenase and Cyclooxygenase-2 Controls Tumor Growth: A Novel Therapeutic Target	PLOS ONE			English	Article							COX-2 INHIBITORS; GAMMA AGONISTS; PROTEIN-KINASE; MURINE MODEL; MOUSE MODEL; BREAST; CANCER; EXPRESSION; RAT; 5-LIPOXYGENASE	The acyl-CoA synthetase 4 (ACSL4), which esterify mainly arachidonic acid (AA) into acyl-CoA, is increased in breast, colon and hepatocellular carcinoma. The transfection of MCF-7 cells with ACSL4 cDNA transforms the cells into a highly aggressive phenotype and controls both lipooxygenase-5 (LOX-5) and cyclooxygenase-2 (COX-2) metabolism of AA, suggesting a causal role of ACSL4 in tumorigenesis. We hypothesized that ACSL4, LOX-5 and COX-2 may constitute potential therapeutic targets for the control of tumor growth. Therefore, the aim of this study was to use a tetracycline Tet-Off system of MCF-7 xenograft model of breast cancer to confirm the effect of ACSL4 overexpression on tumor growth in vivo. We also aim to determine whether a combinatorial inhibition of the ACSL4-LOX-COX-2 pathway affects tumor growth in vivo using a xenograft model based on MDA-MB-231 cells, a highly aggressive breast cancer cell line naturally overexpressing ACSL4. The first novel finding is that stable transfection of MCF-7 cells with ACSL4 using the tetracycline Tet-Off system of MCF-7 cells resulted in development of growing tumors when injected into nude mice. Tumor xenograft development measured in animals that received doxycycline resulted in tumor growth inhibition. The tumors presented marked nuclear polymorphism, high mitotic index and low expression of estrogen and progesterone receptor. These results demonstrate the transformational capacity of ACSL4 overexpression. We examined the effect of a combination of inhibitors of ACSL4, LOX-5 and COX-2 on MDA-MB-231 tumor xenografts. This treatment markedly reduced tumor growth in doses of these inhibitors that were otherwise ineffective when used alone, indicating a synergistic effect of the compounds. Our results suggest that these enzymes interact functionally and form an integrated system that operates in a concerted manner to regulate tumor growth and consequently may be potential therapeutic targets for the control of proliferation as well as metastatic potential of cancer cells.	[Orlando, Ulises D.; Maloberti, Paula M.; Solano, Angela R.; Podesta, Ernesto J.] Univ Buenos Aires, Sch Med, Inst Invest Biomed INBIOMED, Dept Human Biochem, Buenos Aires, DF, Argentina; [Garona, Juan; Ripoll, Giselle V.; Gomez, Daniel E.; Alonso, Daniel F.] Quilmes Natl Univ, Mol Oncol Lab, Buenos Aires, DF, Argentina; [Avagnina, Alejandra] Hosp Univ Ctr Estudios Med & Invest Clin CEMIC, Pathol Unit, Buenos Aires, DF, Argentina	University of Buenos Aires; Centro de Educacion Medica e Investigaciones Clinicas (CEMIC)	Orlando, UD (corresponding author), Univ Buenos Aires, Sch Med, Inst Invest Biomed INBIOMED, Dept Human Biochem, Buenos Aires, DF, Argentina.	ernestopodesta@yahoo.com.ar	Maloberti, Paula/AAU-5216-2020; Garona, Juan/Q-2306-2019	Garona, Juan/0000-0002-0389-5546; Alonso, Daniel F./0000-0002-0601-613X; Gomez, Daniel E/0000-0002-8629-0787	CONICET [112-200801-01976]; UBA [M059, 20020090200030]; FONCyT [PICT-2010-0498, PICT 1586]; INC (Resolucion Ministerial) [N 148/12]; UNQ [53/1004]	CONICET(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); UBA(University of Buenos Aires); FONCyT(FONCyT); INC (Resolucion Ministerial); UNQ	This work was supported by CONICET (112-200801-01976) http://www.conicet.gov.ar/, Podesta; UBA (M059, 20020090200030) Podesta, Maloberti, http://www.uba.ar/homepage.php; FONCyT (PICT-2010-0498) Podesta, http://www.agencia.mincyt.gov.ar/; INC (Resolucion Ministerial (N 148/12)) http://www.msal.gov.ar/inc/novedades-proy-invest.php, Podesta; UNQ (53/1004) http://www.unq.edu.ar/, Gomez; and FONCyT (PICT 1586) http://www.agencia.mincyt.gov.ar/, Alonso. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akinyeke TO, 2011, CANCER BIOL THER, V11, P1046, DOI 10.4161/cbt.11.12.15709; Al-Alem L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016179; Alvarez-Diaz S, 2010, CELL CYCLE, V9, P32, DOI 10.4161/cc.9.1.10266; ANDERSON WA, 1984, J SUBMICR CYTOL PATH, V16, P673; Askari B, 2007, DIABETES, V56, P1143, DOI 10.2337/db06-0267; Avis I, 2001, FASEB J, V15, P2007, DOI 10.1096/fj.00-0866fje; Bertucci Francois, 2008, J Biol, V7, P6, DOI 10.1186/jbiol67; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Cao Y, 2001, CANCER RES, V61, P8429; Cellai I, 2010, BRIT J CANCER, V102, P685, DOI 10.1038/sj.bjc.6605506; Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100; Chen XX, 2004, CLIN CANCER RES, V10, P6703, DOI 10.1158/1078-0432.CCR-04-0838; Day C, 1999, DIABETIC MED, V16, P179, DOI 10.1046/j.1464-5491.1999.00023.x; Drzewoski J, 2011, POL ARCH MED WEWN, V121, P81, DOI 10.20452/pamw.1029; Eisenberg E, 2003, TRENDS GENET, V19, P362, DOI 10.1016/S0168-9525(03)00140-9; Elston C W, 1998, Clin Oncol (R Coll Radiol), V10, P14, DOI 10.1016/S0936-6555(98)80105-2; Fegn L, 2009, J LARYNGOL OTOL, V123, P880, DOI 10.1017/S0022215109004617; Ferlay J, 2008, INT J CANC; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Gonzalez-Periz A, 2007, CURR TOP MED CHEM, V7, P297, DOI 10.2174/156802607779941378; Half E, 2002, CANCER RES, V62, P1676; Haughian JM, 2012, P NATL ACAD SCI USA, V109, P2742, DOI 10.1073/pnas.1106509108; Huang JW, 2005, MOL PHARMACOL, V67, P1342, DOI 10.1124/mol.104.007732; Hyde CAC, 2009, INT IMMUNOPHARMACOL, V9, P701, DOI 10.1016/j.intimp.2009.02.003; Kang MJ, 1997, P NATL ACAD SCI USA, V94, P2880, DOI 10.1073/pnas.94.7.2880; Kim JH, 2001, J BIOL CHEM, V276, P24667, DOI 10.1074/jbc.M010793200; Kim KY, 2006, BIOCHEM PHARMACOL, V72, P530, DOI 10.1016/j.bcp.2006.05.009; Koga H, 2001, HEPATOLOGY, V33, P1087, DOI 10.1053/jhep.2001.24024; Kundu N, 2002, CANCER RES, V62, P2343; Kundu N, 2001, INT J CANCER, V93, P681, DOI 10.1002/ijc.1397; Larkins TL, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-181; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Luconi M, 2010, ENDOCR-RELAT CANCER, V17, P169, DOI 10.1677/ERC-09-0170; Maloberti PM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015540; Minami CA, 2011, BREAST CANCER-BASIC, V5, P175, DOI 10.4137/BCBCR.S6562; Monaco ME, 2010, TRANSL ONCOL, V3, P91, DOI 10.1593/tlo.09202; Narko K, 2005, PROSTAG OTH LIPID M, V76, P86, DOI 10.1016/j.prostaglandins.2005.01.002; Perera Y, 2008, INT J CANCER, V122, P57, DOI 10.1002/ijc.23013; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pidgeon GP, 2007, CANCER METAST REV, V26, P503, DOI 10.1007/s10555-007-9098-3; Ripoll GV, 2008, ANTICANCER RES, V28, P2607; Robertson FM, 2007, ANTICANCER RES, V27, P719; Scoditti E, 2010, CARDIOVASC RES, V86, P302, DOI 10.1093/cvr/cvp400; Simpson PT, 2005, J PATHOL, V205, P248, DOI 10.1002/path.1691; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405; Soupene E, 2008, EXP BIOL MED, V233, P507, DOI 10.3181/0710-MR-287; Subik K, 2010, BREAST CANCER-BASIC, V4, P35; Sung YK, 2003, CANCER SCI, V94, P421, DOI 10.1111/j.1349-7006.2003.tb01458.x; Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252; Van Horn CG, 2005, BIOCHEMISTRY-US, V44, P1635, DOI 10.1021/bi047721l; Wang MT, 2007, CANCER METAST REV, V26, P525, DOI 10.1007/s10555-007-9096-5; Wei S, 2009, CANCER LETT, V276, P119, DOI 10.1016/j.canlet.2008.08.008; Weng JR, 2006, ENDOCR-RELAT CANCER, V13, P401, DOI 10.1677/erc.1.01182; Yao M, 2005, CLIN CANCER RES, V11, P1618, DOI 10.1158/1078-0432.CCR-04-1696	55	42	45	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 13	2012	7	7							e40794	10.1371/journal.pone.0040794	http://dx.doi.org/10.1371/journal.pone.0040794			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	974CF	22808264	Green Published, gold, Green Submitted			2023-01-03	WOS:000306406700054
J	Chong, URW; Abdul-Rahman, PS; Abdul-Aziz, A; Hashim, OH; Junit, SM				Chong, Ursula Rho Wan; Abdul-Rahman, Puteri Shafinaz; Abdul-Aziz, Azlina; Hashim, Onn Haji; Junit, Sarni Mat			Tamarindus indica Extract Alters Release of Alpha Enolase, Apolipoprotein A-I, Transthyretin and Rab GDP Dissociation Inhibitor Beta from HepG2 Cells	PLOS ONE			English	Article							CHOLESTEROL TRANSPORT; BINDING-PROTEIN; APOA-I; GTPASES; L.; HAMSTERS; PULP	Background: The plasma cholesterol and triacylglycerol lowering effects of Tamarindus indica extract have been previously described. We have also shown that the methanol extract of T. indica fruit pulp altered the expression of lipid-associated genes including ABCG5 and APOAI in HepG2 cells. In the present study, effects of the same extract on the release of proteins from the cells were investigated using the proteomics approach. Methodology/Principal Findings: When culture media of HepG2 cells grown in the absence and presence of the methanol extract of T. indica fruit pulp were subjected to 2-dimensional gel electrophoresis, the expression of seven proteins was found to be significantly different (p<0.03125). Five of the spots were subsequently identified as alpha enolase (ENO1), transthyretin (TTR), apolipoprotein A-I (ApoA-I; two isoforms), and rab GDP dissociation inhibitor beta (GDI-2). A functional network of lipid metabolism, molecular transport and small molecule biochemistry that interconnects the three latter proteins with the interactomes was identified using the Ingenuity Pathways Analysis software. Conclusion/Significance: The methanol extract of T. indica fruit pulp altered the release of ENO1, ApoA-I, TTR and GDI-2 from HepG2 cells. Our results provide support on the effect of T. indica extract on cellular lipid metabolism, particularly that of cholesterol.	[Chong, Ursula Rho Wan; Abdul-Rahman, Puteri Shafinaz; Abdul-Aziz, Azlina; Hashim, Onn Haji; Junit, Sarni Mat] Univ Malaya, Fac Med, Dept Mol Med, Kuala Lumpur, Malaysia; [Abdul-Rahman, Puteri Shafinaz; Abdul-Aziz, Azlina; Hashim, Onn Haji; Junit, Sarni Mat] Univ Malaya, Fac Med, Med Biotechnol Lab, Ctr Prote Res, Kuala Lumpur, Malaysia	Universiti Malaya; Universiti Malaya	Chong, URW (corresponding author), Univ Malaya, Fac Med, Dept Mol Med, Kuala Lumpur, Malaysia.	sarni@um.edu.my	AZIZ, AZLINA ABDUL/B-8303-2010; Hashim, Onn H/B-9459-2010; mat-junit, sarni/J-5838-2015; Rahman, Puteri Shafinaz Akmar Binti Abdul/B-9511-2010; MAT-JUNIT, SARNI/GXW-0277-2022	AZIZ, AZLINA ABDUL/0000-0002-9210-5066; Hashim, Onn H/0000-0002-0196-6793; Rahman, Puteri Shafinaz Akmar Binti Abdul/0000-0002-1818-4552; Mat Junit, Sarni/0000-0002-9813-452X	Ministry of Higher Education, Malaysia [H-20001-00-E000009]; University of Malaya [RG014-09AFR]	Ministry of Higher Education, Malaysia(Ministry of Education, Malaysia); University of Malaya(Universiti Malaya)	The present study was funded by the Ministry of Higher Education, Malaysia (H-20001-00-E000009) and the University of Malaya Research Grant (RG014-09AFR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agola JO, 2011, CLIN GENET, V80, P305, DOI 10.1111/j.1399-0004.2011.01724.x; ALESHIRE SL, 1983, J HISTOCHEM CYTOCHEM, V31, P608, DOI 10.1177/31.5.6341455; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bibitha B, 2002, INDIAN J MICROBIOL, V42, P361; Bottoni P, 2009, BBA-PROTEINS PROTEOM, V1794, P615, DOI 10.1016/j.bbapap.2009.01.006; Chan PT, 1999, J NUTR, V129, P1094, DOI 10.1093/jn/129.6.1094; Chisholm JW, 2002, J LIPID RES, V43, P36; HAGEN GA, 1974, ENDOCRINOLOGY, V95, P1398, DOI 10.1210/endo-95-5-1398; Higa LM, 2008, BBA-PROTEINS PROTEOM, V1784, P1607, DOI 10.1016/j.bbapap.2008.06.015; Holtta-Vuori M, 2002, MOL BIOL CELL, V13, P3107, DOI 10.1091/mbc.E02-01-0025; Iftekhar A S M Maruf, 2006, Pak J Pharm Sci, V19, P125; Jiao R, 2010, J NUTR BIOCHEM, V21, P1134, DOI 10.1016/j.jnutbio.2009.10.007; John J, 2004, ALLELOPATHY J, V14, P43; Linder MD, 2007, MOL BIOL CELL, V18, P47, DOI 10.1091/mbc.E06-07-0575; Liz MA, 2007, J LIPID RES, V48, P2385, DOI 10.1194/jlr.M700158-JLR200; Martinello F, 2006, FOOD CHEM TOXICOL, V44, P810, DOI 10.1016/j.fct.2005.10.011; Metwali M. R., 2003, Egyptian Journal of Microbiology, V38, P105; Ohnsorg PM, 2011, J BIOL CHEM, V286, P7744, DOI 10.1074/jbc.M110.193524; Pancholi V, 1998, J BIOL CHEM, V273, P14503, DOI 10.1074/jbc.273.23.14503; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; RAZ A, 1969, J BIOL CHEM, V244, P3230; Razali N, 2010, GENES NUTR, V5, P331, DOI 10.1007/s12263-010-0187-5; Soccio RE, 2004, ARTERIOSCL THROM VAS, V24, P1150, DOI 10.1161/01.ATV.0000131264.66417.d5; Stenmark H, 2001, GENOME BIOL, V2; Subramanian A, 2000, J BIOL CHEM, V275, P5958, DOI 10.1074/jbc.275.8.5958; Sudjaroen Y, 2005, FOOD CHEM TOXICOL, V43, P1673, DOI 10.1016/j.fct.2005.05.013; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	28	12	14	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2012	7	6							e39476	10.1371/journal.pone.0039476	http://dx.doi.org/10.1371/journal.pone.0039476			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	963VI	22724021	gold, Green Published, Green Submitted			2023-01-03	WOS:000305652700084
J	Grompe, M				Grompe, Markus			Tissue Stem Cells: New Tools and Functional Diversity	CELL STEM CELL			English	Review							LABEL-RETAINING CELLS; PROGENITOR-CELL; SMALL-INTESTINE; HAIR FOLLICLE; MAMMARY-GLAND; SELF-RENEWAL; BETA-CELLS; IN-VITRO; ADULT; LGR5	The detailed understanding of adult tissue stem cells has significance for both regenerative medicine and oncology. This perspective will discuss how major advances in our ability to identify and monitor these cells, which include genetic lineage tracing, FACS purification, and robust in vitro clonogenic assays, have changed our view of their roles in many organs. Label retention and quiescence are no longer considered obligatory stem cell features. Furthermore, some tissues have more than one type of stem cell, each used in only particular situations of regenerative stress. Thus, there is no "one size fits all" adult tissue stem cell paradigm.	Oregon Hlth & Sci Univ, Pape Family Pediat Res Inst, Portland, OR 97239 USA	Oregon Health & Science University	Grompe, M (corresponding author), Oregon Hlth & Sci Univ, Pape Family Pediat Res Inst, 3181 SW Sam Jackson Pk Rd,Mail Code L321, Portland, OR 97239 USA.	grompem@ohsu.edu		Grompe, Markus/0000-0002-6616-4345	NIH [DK51592]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051592, R55DK051592] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH grant DK51592 (M.G.)	Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Burness ML, 2010, SEMIN CANCER BIOL, V20, P107, DOI 10.1016/j.semcancer.2010.05.006; Cabarcas SM, 2011, INT J CANCER, V129, P2315, DOI 10.1002/ijc.26312; Chen JF, 2010, J CELL BIOL, V190, P867, DOI 10.1083/jcb.200911036; Cheung TH, 2012, NATURE, V482, P524, DOI 10.1038/nature10834; Clarke RB, 2003, CELL PROLIFERAT, V36, P45, DOI 10.1046/j.1365-2184.36.s.1.5.x; Claudinot S, 2005, P NATL ACAD SCI USA, V102, P14677, DOI 10.1073/pnas.0507250102; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Criscimanna A, 2011, GASTROENTEROLOGY, V141, P1451, DOI 10.1053/j.gastro.2011.07.003; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Dorrell C, 2011, GENE DEV, V25, P1193, DOI 10.1101/gad.2029411; Duncan AW, 2009, GASTROENTEROLOGY, V137, P466, DOI 10.1053/j.gastro.2009.05.044; Duvillie B, 2003, DIABETES, V52, P2035, DOI 10.2337/diabetes.52.8.2035; Furuyama K, 2011, NAT GENET, V43, P34, DOI 10.1038/ng.722; Garraway IP, 2010, PROSTATE, V70, P491, DOI 10.1002/pros.21083; Greene SB, 2010, RNA BIOL, V7, P300, DOI 10.4161/rna.7.3.11837; Haegebarth A, 2009, AM J PATHOL, V174, P715, DOI 10.2353/ajpath.2009.080758; Ibarra I, 2007, GENE DEV, V21, P3238, DOI 10.1101/gad.1616307; Iverson SV, 2011, HEPATOLOGY, V54, P655, DOI 10.1002/hep.24398; Jaks V, 2010, EXP CELL RES, V316, P1422, DOI 10.1016/j.yexcr.2010.03.014; Kopp JL, 2011, CELL CYCLE, V10, P1921, DOI 10.4161/cc.10.12.16010; Kopp JL, 2011, DEVELOPMENT, V138, P653, DOI 10.1242/dev.056499; Kretzschmar K, 2012, CELL, V148, P33, DOI 10.1016/j.cell.2012.01.002; Lander AD, 2012, BMC BIOL, V10, DOI 10.1186/1741-7007-10-19; Lawson DA, 2007, P NATL ACAD SCI USA, V104, P181, DOI 10.1073/pnas.0609684104; Li LH, 2010, SCIENCE, V327, P542, DOI 10.1126/science.1180794; MACKENZIE IC, 1985, CELL TISSUE RES, V242, P551; Malato Y, 2011, J CLIN INVEST, V121, P4850, DOI 10.1172/JCI59261; Michalopoulos GK, 2010, AM J PATHOL, V176, P2, DOI 10.2353/ajpath.2010.090675; MORRIS RJ, 1994, CELL PROLIFERAT, V27, P279, DOI 10.1111/j.1365-2184.1994.tb01425.x; Ng R, 2012, J CLIN INVEST, V122, P1097, DOI 10.1172/JCI46039; POTTEN C S, 1975, International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine, V27, P413, DOI 10.1080/09553007514550411; Potten CS, 2009, CELL PROLIFERAT, V42, P731, DOI 10.1111/j.1365-2184.2009.00642.x; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shin S, 2011, GENE DEV, V25, P1185, DOI 10.1101/gad.2027811; Smith SM, 2012, METHODS MOL BIOL, V823, P119, DOI 10.1007/978-1-60327-216-2_9; Snippert HJ, 2010, CELL, V143, P134, DOI 10.1016/j.cell.2010.09.016; Snippert HJ, 2010, SCIENCE, V327, P1385, DOI 10.1126/science.1184733; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takeda N, 2011, SCIENCE, V334, P1420, DOI 10.1126/science.1213214; Tanos Tamara, 2008, Breast Dis, V29, P69; Tedesco FS, 2010, J CLIN INVEST, V120, P11, DOI 10.1172/JCI40373; Terskikh VV, 2012, STEM CELL REV REP, V8, P414, DOI 10.1007/s12015-011-9299-6; Tian H, 2011, NATURE, V478, P255, DOI 10.1038/nature10408; van der Kooy D, 2000, SCIENCE, V287, P1439, DOI 10.1126/science.287.5457.1439; Wang X, 2009, NATURE, V461, P495, DOI 10.1038/nature08361; Weissman IL, 2001, ANNU REV CELL DEV BI, V17, P387, DOI 10.1146/annurev.cellbio.17.1.387; Xiang Shuanglin, 2009, V487, P147, DOI 10.1007/978-1-60327-547-7_7; Xu XB, 2008, CELL, V132, P197, DOI 10.1016/j.cell.2007.12.015; Yan KS, 2012, P NATL ACAD SCI USA, V109, P466, DOI 10.1073/pnas.1118857109; Yi R, 2011, J CELL SCI, V124, P1775, DOI 10.1242/jcs.069104; Zhang LA, 2011, CELL STEM CELL, V8, P294, DOI 10.1016/j.stem.2011.01.014	56	42	47	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	1934-5909	1875-9777		CELL STEM CELL	Cell Stem Cell	JUN 14	2012	10	6					685	689		10.1016/j.stem.2012.04.006	http://dx.doi.org/10.1016/j.stem.2012.04.006			5	Cell & Tissue Engineering; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	965LD	22704508	Bronze, Green Accepted			2023-01-03	WOS:000305768400014
J	Walker, G; Venkatachalam, P; Bird, J; Wilson, D; Probert, C				Walker, Gareth; Venkatachalam, Prathima; Bird, Jennifer; Wilson, David; Probert, Chris			Mixed fortunes in the treatment of Crohn's disease	LANCET			English	Editorial Material									[Walker, Gareth; Probert, Chris] Univ Hosp Bristol Trust, Bristol Royal Infirm, Dept Gastroenterol, Bristol, Avon, England; [Venkatachalam, Prathima; Bird, Jennifer] Univ Hosp Bristol Trust, Bristol Royal Infirm, Dept Haematol, Bristol, Avon, England; [Wilson, David] Univ Hosp Bristol Trust, Bristol Royal Infirm, Dept Radiol, Bristol, Avon, England	Bristol Royal Infirmary; Bristol Royal Infirmary; Bristol Royal Infirmary	Walker, G (corresponding author), Frenchay Hosp, Dept Gastroenterol, Frenchay Pk Rd, Bristol BS16 1LE, Avon, England.	gareth.walker@nhs.net		Probert, Christopher/0000-0003-4550-0239				Behr MA, 2010, LANCET, V376, P202, DOI 10.1016/S0140-6736(10)60282-6; Burt RK, 2010, BLOOD, V116, P6123, DOI 10.1182/blood-2010-06-292391; LARVOL L, 1994, NEW ENGL J MED, V331, P883, DOI 10.1056/NEJM199409293311321; Leiper K, 2011, GUT, V60, P1520, DOI 10.1136/gut.2010.225482; Papadakis KA, 2003, GASTROENTEROLOGY, V124, P583, DOI 10.1053/gast.2003.50081	5	1	1	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 9	2012	379	9832					2212	2212		10.1016/S0140-6736(12)60359-6	http://dx.doi.org/10.1016/S0140-6736(12)60359-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	955BA	22682468				2023-01-03	WOS:000304990900038
J	Terzano, C; Di Stefano, F; Conti, V; Di Nicola, M; Paone, G; Petroianni, A; Ricci, A				Terzano, Claudio; Di Stefano, Fabio; Conti, Vittoria; Di Nicola, Marta; Paone, Gregorino; Petroianni, Angelo; Ricci, Alberto			Mixed Acid-Base Disorders, Hydroelectrolyte Imbalance and Lactate Production in Hypercapnic Respiratory Failure: The Role of Noninvasive Ventilation	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; METABOLIC ALKALOSIS; SEVERE SEPSIS; PRIMARY-CARE; HYPOVENTILATION; ACETAZOLAMIDE; FUROSEMIDE; CLEARANCE; MORTALITY; PRESSURE	Background: Hypercapnic Chronic Obstructive Pulmonary Disease (COPD) exacerbation in patients with comorbidities and multidrug therapy is complicated by mixed acid-base, hydro-electrolyte and lactate disorders. Aim of this study was to determine the relationships of these disorders with the requirement for and duration of noninvasive ventilation (NIV) when treating hypercapnic respiratory failure. Methods: Sixty-seven consecutive patients who were hospitalized for hypercapnic COPD exacerbation had their clinical condition, respiratory function, blood chemistry, arterial blood gases, blood lactate and volemic state assessed. Heart and respiratory rates, pH, PaO2 and PaCO2 and blood lactate were checked at the 1st, 2nd, 6th and 24th hours after starting NIV. Results: Nine patients were transferred to the intensive care unit. NIV was performed in 11/17 (64.7%) mixed respiratory acidosis-metabolic alkalosis, 10/36 (27.8%) respiratory acidosis and 3/5 (60%) mixed respiratory-metabolic acidosis patients (p = 0.026), with durations of 45.1 +/- 9.8, 36.2 +/- 8.9 and 53.3 +/- 4.1 hours, respectively (p = 0.016). The duration of ventilation was associated with higher blood lactate (p<0.001), lower pH (p = 0.016), lower serum sodium (p = 0.014) and lower chloride (p = 0.038). Hyponatremia without hypervolemic hypochloremia occurred in 11 respiratory acidosis patients. Hypovolemic hyponatremia with hypochloremia and hypokalemia occurred in 10 mixed respiratory acidosis-metabolic alkalosis patients, and euvolemic hypochloremia occurred in the other 7 patients with this mixed acid-base disorder. Conclusions: Mixed acid-base and lactate disorders during hypercapnic COPD exacerbations predict the need for and longer duration of NIV. The combination of mixed acid-base disorders and hydro-electrolyte disturbances should be further investigated.	[Terzano, Claudio; Di Stefano, Fabio; Conti, Vittoria; Paone, Gregorino; Petroianni, Angelo; Ricci, Alberto] Sapienza Univ Rome, Fondazione Eleonora Lorillard Spencer Cenci, Rome, Italy; [Di Nicola, Marta] Univ G Annunzio Chieti Pescara, Lab Biostat, Dept Biomed Sci, Chieti, Italy	Sapienza University Rome; G d'Annunzio University of Chieti-Pescara	Terzano, C (corresponding author), Sapienza Univ Rome, Fondazione Eleonora Lorillard Spencer Cenci, Rome, Italy.	vittoria_conti@hotmail.com	Conti, Vittoria/J-9229-2016	Conti, Vittoria/0000-0002-1940-2603; TERZANO, CLAUDIO/0000-0002-9851-7731; DI NICOLA, MARTA/0000-0003-1748-1931; Ricci, Alberto/0000-0002-1718-1587				Adrogue HJ, 2000, NEW ENGL J MED, V342, P1493, DOI 10.1056/NEJM200005183422006; Adrogue HJ, 2000, NEW ENGL J MED, V342, P1581, DOI 10.1056/NEJM200005253422107; [Anonymous], GLOB STRAT DIAGN MAN; Baudouin S, 2002, THORAX, V57, P192; Baudouin SV, 1997, THORAX, V52, P401, DOI 10.1136/thx.52.5.401; BEAR R, 1977, CAN MED ASSOC J, V117, P900; Bernardin G, 1996, INTENS CARE MED, V22, P17; Brijker F, 2002, CHEST, V121, P377, DOI 10.1378/chest.121.2.377; Brijker F, 2001, RESP PHYSIOL, V124, P151, DOI 10.1016/S0034-5687(00)00196-1; Confalonieri M, 2005, EUR RESPIR J, V25, P348, DOI 10.1183/09031936.05.00085304; COOPER CB, 1994, CHEST, V105, P335, DOI 10.1378/chest.105.2.335; de Leeuw PW, 2003, EUR RESPIR J, V22, p33S, DOI 10.1183/09031936.03.00000603a; DICKINSON GE, 1981, ANESTH ANALG, V60, P608; Dubin A, 2007, CRIT CARE MED, V35, P1264, DOI 10.1097/01.CCM.0000259536.11943.90; Foucher P, 1998, CHEST, V113, P1580, DOI 10.1378/chest.113.6.1580; Garpestad E, 2007, CHEST, V132, P711, DOI 10.1378/chest.06-2643; GUTIERREZ G, 1993, AM REV RESPIR DIS, V148, P1204, DOI 10.1164/ajrccm/148.5.1204; JAVAHERI S, 1981, RESP PHYSIOL, V45, P141, DOI 10.1016/0034-5687(81)90056-6; JAVAHERI S, 1982, CHEST, V81, P296, DOI 10.1378/chest.81.3.296; JAVAHERI S, 1987, AM REV RESPIR DIS, V136, P1011, DOI 10.1164/ajrccm/136.4.1011; Kaplan LJ, 2004, CRIT CARE MED, V32, P1120, DOI 10.1097/01.CCM.0000125517.28517.74; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KRAMER N, 1995, AM J RESP CRIT CARE, V151, P1799, DOI 10.1164/ajrccm.151.6.7767523; KREISBERG RA, 1972, NEW ENGL J MED, V287, P132, DOI 10.1056/NEJM197207202870307; MIZOCK BA, 1992, CRIT CARE MED, V20, P80, DOI 10.1097/00003246-199201000-00020; Nguyen HB, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-6; Nguyen HB, 2004, CRIT CARE MED, V32, P1637, DOI 10.1097/01.CCM.0000132904.35713.A7; Plant PK, 2000, LANCET, V355, P1931, DOI 10.1016/S0140-6736(00)02323-0; POKORSKI M, 1982, J APPL PHYSIOL, V53, P75, DOI 10.1152/jappl.1982.53.1.75; Price SR, 2001, AM J KIDNEY DIS, V37, pS112, DOI 10.1053/ajkd.2001.20764; Roberts CM, 2011, THORAX, V66, P43, DOI 10.1136/thx.2010.153114; Scott S, 2010, CRIT CARE RES PRACT, V2010, DOI 10.1155/2010/917053; Stewart PA, 1981, UNDERSTAND ACID BASE, P1; STINEBAUGH BJ, 1967, ARCH INTERN MED, V119, P182, DOI 10.1001/archinte.119.2.182; TEASDALE G, 1974, LANCET, V2, P81; Terzano C, 2010, LUNG, V188, P321, DOI 10.1007/s00408-009-9222-y; Ucgun I, 2008, RESPIRATION, V76, P270, DOI 10.1159/000131707; Valenza F, 2005, CRIT CARE, V9, P588, DOI 10.1186/cc3818; van de Ven MJT, 2002, CHEST, V121, P383, DOI 10.1378/chest.121.2.383; Wooten EW, 2004, CRIT CARE, V8, P448, DOI 10.1186/cc2910	40	38	39	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2012	7	4							e35245	10.1371/journal.pone.0035245	http://dx.doi.org/10.1371/journal.pone.0035245			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UP	22539963	gold, Green Published, Green Submitted			2023-01-03	WOS:000305341000027
J	Moore, W				Moore, Wendy			Lister and the reputation robbing historians	BRITISH MEDICAL JOURNAL			English	Editorial Material												wendymoore@ntlworld.com						LISTER, 1867, BRIT MED J, V2, P246	1	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	APR 11	2012	344								e2603	10.1136/bmj.e2603	http://dx.doi.org/10.1136/bmj.e2603			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	927UH	22496304				2023-01-03	WOS:000302935200011
J	Wandt, H; Schaefer-Eckart, K; Wendelin, K; Pilz, B; Wilhelm, M; Thalheimer, M; Mahlknecht, U; Ho, A; Schaich, M; Kramer, M; Kaufmann, M; Leimer, L; Schwerdtfeger, R; Conradi, R; Dolken, G; Klenner, A; Hanel, M; Herbst, R; Junghanss, C; Ehninger, G				Wandt, Hannes; Schaefer-Eckart, Kerstin; Wendelin, Knut; Pilz, Bettina; Wilhelm, Martin; Thalheimer, Markus; Mahlknecht, Ulrich; Ho, Anthony; Schaich, Markus; Kramer, Michael; Kaufmann, Martin; Leimer, Lothar; Schwerdtfeger, Rainer; Conradi, Roland; Doelken, Gottfried; Klenner, Anne; Haenel, Mathias; Herbst, Regina; Junghanss, Christian; Ehninger, Gerhard		Study Alliance Leukemia	Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study	LANCET			English	Article							STRATEGY; CANCER; SAFE	Background Routine prophylactic platelet transfusion is the standard of care for patients with severe thrombocytopenia. We assessed the effect of a new strategy of therapeutic platelet transfusion on the number of transfusions and safety in patients with hypoproliferative thrombocytopenia. Methods We did a multicentre, open-label, randomised parallel-group trial at eight haematology centres in Germany. Patients aged 16-80 years, who were undergoing intensive chemotherapy for acute myeloid leukaemia or autologous haemopoietic stem-cell transplantation for haematological cancers, were randomly assigned via a computer-generated randomisation sequence to receive either platelet transfusion when bleeding occurred (therapeutic strategy) or when morning platelet counts were 10x10(9) per L or lower (prophylactic strategy). Investigators undertaking interventions were not masked to group assignment. The primary endpoint was the number of platelet transfusions. Analysis was by intention to treat. This trial is registered, NCT00521664. Findings 197 patients were assigned the prophylactic strategy and 199 the therapeutic strategy. Of 391 patients analysed, the therapeutic strategy reduced the mean number of platelet transfusions by 33.5% (95% CI 22.2-43.1; p<0.0001) in all patients (2.44 [2.22-2.67] in prophylactic group vs 1.63 [1.42-1.83] in therapeutic group), 31.6% (18.6-42.6; p<0.0001) in those with acute myeloid leukaemia (2.68 [2.35-3.01] vs 1.83 [1.58-2.10]), and 34.2% (6.6-53.7; p=0.0193) in those who had had autologous transplantation (1.80 [1.45-2.15] vs 1.18 [0.82-1.55]. We noted no increased risk of major haemorrhage in patients who had undergone autologous transplantation. In those with acute myeloid leukaemia, risk of non-fatal grade 4 (mostly CNS) bleeding was increased. We recorded 15 cases of non-fatal haemorrhage: four retinal in each transfusion group, and one vaginal and six cerebral in the therapeutic group. 12 patients died in the study: two from fatal cerebral haemorrhages in the therapeutic group, and ten (five in each treatment group) unrelated to major bleeding. Interpretation The therapeutic strategy could become a new standard of care after autologous stem-cell transplantation; however, prophylactic platelet transfusion should remain the standard for patients with acute myeloid leukaemia. The new strategy should be used by some haematology centres only if the staff are well educated and experienced in the new approach and can react in a timely way to first signs of CNS bleeding.	[Wandt, Hannes; Schaefer-Eckart, Kerstin; Wendelin, Knut; Wilhelm, Martin] Klinikum Nurnberg, Med Klin 5, D-90419 Nurnberg, Germany; [Thalheimer, Markus; Mahlknecht, Ulrich; Ho, Anthony] Heidelberg Univ, Med Dept 5, Heidelberg, Germany; [Schaich, Markus; Kramer, Michael; Ehninger, Gerhard] Tech Univ Dresden, Med Clin 1, D-01062 Dresden, Germany; [Kaufmann, Martin; Leimer, Lothar] Robert Bosch Krankenhaus, Stuttgart, Germany; [Schwerdtfeger, Rainer; Conradi, Roland] Deutsch Klin Diagnost, Med Ctr, Wiesbaden, Germany; [Doelken, Gottfried; Klenner, Anne] Ernst Moritz Arndt Univ Greifswald, Greifswald, Germany; [Haenel, Mathias] Klinikum Chemnitz, Med Clin 3, Chemnitz, Germany; [Junghanss, Christian] Univ Rostock, Med Clin 3, Rostock, Germany	Klinikum Nurnberg Nord; Ruprecht Karls University Heidelberg; Technische Universitat Dresden; Bosch; Robert Bosch Krankenhaus; Ernst Moritz Arndt Universitat Greifswald; Chemnitz Clinic; University of Rostock	Wandt, H (corresponding author), Klinikum Nurnberg, Med Klin 5, D-90419 Nurnberg, Germany.	wandt@klinikum-nuernberg.de	Wilhelm, Martin/J-3964-2014; Haenel, Mathias Hänel/AAF-2220-2021	Kramer, Michael/0000-0002-0251-2726; Conradi, Roland/0000-0003-4645-3569	Deutsche Krebshilfe eV (German Cancer Aid); Deutsche Krebshilfe [106226]	Deutsche Krebshilfe eV (German Cancer Aid)(Deutsche Krebshilfe); Deutsche Krebshilfe(Deutsche Krebshilfe)	Deutsche Krebshilfe eV (German Cancer Aid).; The study was supported by a grant from the Deutsche Krebshilfe (number 106226).	Bernstein SH, 1998, BLOOD, V91, P3509, DOI 10.1182/blood.V91.9.3509.3509_3509_3517; Blajchman Morris A, 2008, Hematology Am Soc Hematol Educ Program, P198, DOI 10.1182/asheducation-2008.1.198; Bux J, 2005, VOX SANG, V89, P1, DOI 10.1111/j.1423-0410.2005.00648.x; Friedmann AM, 2002, TRANSFUS MED REV, V16, P34, DOI 10.1053/tmrv.2002.29403; Heddle NM, 2006, TRANSFUSION, V46, P903, DOI 10.1111/j.1537-2995.2006.00822.x; Higby DJ, 1974, TRANSFUSION, V43, P742; McCullough J, 2004, BLOOD, V104, P1534, DOI 10.1182/blood-2003-12-4443; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; MURPHY S, 1982, AM J HEMATOL, V12, P347, DOI 10.1002/ajh.2830120406; PATTEN E, 1992, TRANSFUSION, V32, P381, DOI 10.1046/j.1537-2995.1992.32492263455.x; Rebulla P, 1997, NEW ENGL J MED, V337, P1870, DOI 10.1056/NEJM199712253372602; Sagmeister M, 1999, BLOOD, V93, P3124; Schiffer CA, 2001, J CLIN ONCOL, V19, P1519, DOI 10.1200/JCO.2001.19.5.1519; SCHIFFER CA, 1992, TRANSFUSION, V32, P295, DOI 10.1046/j.1537-2995.1992.32492263438.x; Slichter SJ, 2010, NEW ENGL J MED, V362, P600, DOI 10.1056/NEJMoa0904084; Slichter SJ, 2004, TRANSFUS MED REV, V18, P153, DOI 10.1016/j.tmrv.2004.03.003; SOLOMON J, 1978, LANCET, V1, P267; Stanworth SJ, 2005, BRIT J HAEMATOL, V131, P588, DOI 10.1111/j.1365-2141.2005.05769.x; STANWORTH SJ, 2004, COCHRANE DB SYST REV, V2; Wandt H, 2005, BLOOD, V106, p129A; Wandt H, 2006, BONE MARROW TRANSPL, V37, P387, DOI 10.1038/sj.bmt.1705246	21	218	218	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 13	2012	380	9850					1309	1316		10.1016/S0140-6736(12)60689-8	http://dx.doi.org/10.1016/S0140-6736(12)60689-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	022BZ	22877506				2023-01-03	WOS:000309931400029
J	Steinbrook, R; Sharfstein, JM				Steinbrook, Robert; Sharfstein, Joshua M.			The FDA Safety and Innovation Act	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Steinbrook, Robert] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; [Sharfstein, Joshua M.] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA	Yale University; Maryland Department of Health & Mental Hygiene	Steinbrook, R (corresponding author), Yale Univ, Sch Med, Dept Internal Med, 333 Cedar St,I-456 SHM,POB 208008, New Haven, CT 06520 USA.	rsteinbrook@attglobal.net						Institute of Medicine, 2012, ETH SCI ISS STUD SAF; Institute of Medicine, 2011, MED DEV PUBL HLTH FD	2	4	4	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 10	2012	308	14					1437	1438		10.1001/jama.2012.12829	http://dx.doi.org/10.1001/jama.2012.12829			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	017GY	23047356				2023-01-03	WOS:000309579300020
J	Nolan, JP; Soar, J; Perkins, GD				Nolan, Jerry P.; Soar, Jasmeet; Perkins, Gavin D.			Cardiopulmonary resuscitation	BMJ-BRITISH MEDICAL JOURNAL			English	Review							HOSPITAL CARDIAC-ARREST; CHEST-COMPRESSION; COUNCIL GUIDELINES; LIFE-SUPPORT; SURVIVAL; DEFIBRILLATION; OUTCOMES; CARE; CPR; BYSTANDERS		[Nolan, Jerry P.] Royal United Hosp NHS Trust, Bath BA1 3NG, Avon, England; [Soar, Jasmeet] N Bristol NHS Trust, Southmead Hosp, Bristol, Avon, England; [Perkins, Gavin D.] Univ Warwick, Warwick Med Sch, Warwick, England	North Bristol NHS Trust; Southmead Hospital; University of Warwick	Nolan, JP (corresponding author), Royal United Hosp NHS Trust, Bath BA1 3NG, Avon, England.	jerry.nolan@nhs.net	Soar, Jasmeet/HGA-2279-2022; Nolan, Jerry P./ABF-2561-2020; Perkins, Gavin/E-7613-2010	Soar, Jasmeet/0000-0001-5970-6073; Nolan, Jerry/0000-0003-3141-3812; Perkins, Gavin/0000-0003-3027-7548				Berdowski J, 2010, RESUSCITATION, V81, P1479, DOI 10.1016/j.resuscitation.2010.08.006; Bobrow BJ, 2010, JAMA-J AM MED ASSOC, V304, P1447, DOI 10.1001/jama.2010.1392; Cheskes S, 2011, CIRCULATION, V124, P58, DOI 10.1161/CIRCULATIONAHA.110.010736; Christenson J, 2009, CIRCULATION, V120, P1241, DOI 10.1161/CIRCULATIONAHA.109.852202; Deakin CD, 2010, RESUSCITATION, V81, P1293, DOI 10.1016/j.resuscitation.2010.08.008; Dumas F, 2010, CIRC-CARDIOVASC INTE, V3, P200, DOI 10.1161/CIRCINTERVENTIONS.109.913665; Edelson DP, 2006, RESUSCITATION, V71, P137, DOI 10.1016/j.resuscitation.2006.04.008; Elliott VJ, 2011, RESUSCITATION, V82, P247, DOI 10.1016/j.resuscitation.2010.10.030; Field JM, 2010, CIRCULATION, V122, pS640, DOI 10.1161/CIRCULATIONAHA.110.970889; Hagihara A, 2012, JAMA-J AM MED ASSOC, V307, P1161, DOI 10.1001/jama.2012.294; Heradstveit BE, 2012, RESUSCITATION, V83, P813, DOI 10.1016/j.resuscitation.2012.02.021; Hostler David, 2011, BMJ, V342, pd512, DOI 10.1136/bmj.d512; Hupfl M, 2010, LANCET, V376, P1552, DOI 10.1016/S0140-6736(10)61454-7; Hulleman M, 2012, CIRCULATION, V126, P815, DOI 10.1161/CIRCULATIONAHA.111.089425; Idris AH, 2012, CIRCULATION, V125, P3004, DOI 10.1161/CIRCULATIONAHA.111.059535; Jacobs IG, 2011, RESUSCITATION, V82, P1138, DOI 10.1016/j.resuscitation.2011.06.029; Jones DA, 2011, NEW ENGL J MED, V365, P139, DOI 10.1056/NEJMra0910926; Kitamura T, 2010, LANCET, V375, P1347, DOI 10.1016/S0140-6736(10)60064-5; Koster RW, 2010, RESUSCITATION, V81, P1277, DOI 10.1016/j.resuscitation.2010.08.009; Lloyd MS, 2008, CIRCULATION, V117, P2510, DOI 10.1161/CIRCULATIONAHA.107.763011; Meaney PA, 2010, CRIT CARE MED, V38, P101, DOI 10.1097/CCM.0b013e3181b43282; Merchant RM, 2011, CRIT CARE MED, V39, P2401, DOI 10.1097/CCM.0b013e3182257459; Nolan J, 2010, RESUSCITATION, V81, P1, DOI 10.1016/j.resuscitation.2009.11.016; Nolan JP, 2010, RESUSCITATION, V81, P1219, DOI 10.1016/j.resuscitation.2010.08.021; Nolan JP, 2010, RESUSCITATION, V81, pE26, DOI 10.1016/j.resuscitation.2010.08.022; Nolan JP, 2008, RESUSCITATION, V79, P350, DOI 10.1016/j.resuscitation.2008.09.017; Ogawa T, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c7106; Olasveengen TM, 2009, JAMA-J AM MED ASSOC, V302, P2222, DOI 10.1001/jama.2009.1729; Perkins GD, 2006, RESUSCITATION, V70, P432, DOI 10.1016/j.resuscitation.2006.01.015; Perkins GD, 2012, ANN INTERN MED, V157, P19, DOI 10.7326/0003-4819-157-1-201207030-00005; Perkins GD, 2010, CURR OPIN CRIT CARE, V16, P203, DOI 10.1097/MCC.0b013e328339cf59; Stiell IG, 2012, CRIT CARE MED, V40, P1192, DOI 10.1097/CCM.0b013e31823bc8bb; Tanabe S, 2012, J EMERGENCY MED; Wang HE, 2012, RESUSCITATION, V83, P1061, DOI 10.1016/j.resuscitation.2012.05.018; Wang HE, 2009, ANN EMERG MED, V54, P645, DOI 10.1016/j.annemergmed.2009.05.024; Yeung J, 2009, RESUSCITATION, V80, P743, DOI 10.1016/j.resuscitation.2009.04.012	37	18	18	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 3	2012	345								e6122	10.1136/bmj.e6122	http://dx.doi.org/10.1136/bmj.e6122			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	018KZ	23034844				2023-01-03	WOS:000309660600001
J	Jin, ZD; Zong, CY; Jiang, BC; Zhou, Z; Tong, J; Cao, Y				Jin, Zongda; Zong, Chunyan; Jiang, Bingcheng; Zhou, Zhen; Tong, Jian; Cao, Yi			The Effect of Combined Exposure of 900 MHz Radiofrequency Fields and Doxorubicin in HL-60 Cells	PLOS ONE			English	Article							MICROWAVE-RADIATION; APOPTOSIS; CALCIUM; CANCER; INDUCTION; DAMAGE; RATS	Human promyelocytic leukemia HL-60 cells were pre-exposed to non-ionizing 900 MHz radiofrequency fields (RF) at 12 mu W/cm(2) power density for 1 hour/day for 3 days and then treated with a chemotherapeutic drug, doxorubicin (DOX, 0.125 mg/L). Several end-points related to toxicity, viz., viability, apoptosis, mitochondrial membrane potential (MMP), intracellular free calcium (Ca2+) and Ca2+-Mg2+-ATPase activity were measured. The results obtained in un-exposed and sham-exposed control cells were compared with those exposed to RF alone, DOX alone and RF+DOX. The results indicated no significant differences between un-exposed, sham-exposed control cells and those exposed to RF alone while treatment with DOX alone showed a significant decrease in viability, increased apoptosis, decreased MMP, increased Ca2+ and decreased Ca2+-Mg2+-ATPase activity. When the latter results were compared with cells exposed RF+DOX, the data showed increased cell proliferation, decreased apoptosis, increased MMP, decreased Ca2+ and increased Ca2+-Mg2+-ATPase activity. Thus, RF preexposure appear to protect the HL-60 cells from the toxic effects of subsequent treatment with DOX. These observations were similar to our earlier data which suggested that pre-exposure of mice to 900 MHz RF at 120 mu W/cm(2) power density for 1 hours/day for 14 days had a protective effect in hematopoietic tissue damage induced by subsequent gamma-irradiation.	[Jin, Zongda; Zong, Chunyan; Jiang, Bingcheng; Zhou, Zhen; Tong, Jian; Cao, Yi] Soochow Univ, Sch Publ Hlth, Suzhou, Jiangsu, Peoples R China	Soochow University - China	Cao, Y (corresponding author), Soochow Univ, Sch Publ Hlth, Suzhou, Jiangsu, Peoples R China.	yicao@suda.edu.cn			Ministry of Science and Technology, China [2011CB503700]; National Natural Science Foundation [81020108028]; Priority Academic Program Development of Jiangsu Higher Education Institutions	Ministry of Science and Technology, China(Ministry of Science and Technology, China); National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions	This research was supported by a grant (973 project: 2011CB503700) from Ministry of Science and Technology, China (http://www.973.gov.cn/Default_3.aspx), a grant (81020108028) from National Natural Science Foundation (http://www.nsfc.gov.cn/Portal0/default106.htm), and The Priority Academic Program Development of Jiangsu Higher Education Institutions (http://jsycw.ec.js.edu.cn/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2012, SECT CANC INF; [Anonymous], 2012, CANC FACTS 2012; Arcamone F., 1981, DOXORUBICIN ANTICANC; Armstrong JS, 2006, BIOESSAYS, V28, P253, DOI 10.1002/bies.20370; Beer MH, 2006, MERCK MANUAL DIAGNOS; Burkhardt M, 1996, BIOELECTROMAGNETICS, V17, P483, DOI 10.1002/(SICI)1521-186X(1996)17:6<483::AID-BEM8>3.0.CO;2-#; Cao Y, 2011, INT J RADIAT BIOL, V87, P720, DOI 10.3109/09553002.2010.550981; Cao Y, 2010, J TOXICOL ENV HEAL A, V73, P507, DOI 10.1080/15287390903523451; CARTER SK, 1975, J NATL CANCER I, V55, P1265, DOI 10.1093/jnci/55.6.1265; Chakraborti S, 2007, MOL CELL BIOCHEM, V298, P1, DOI 10.1007/s11010-006-9355-8; Chen ZJ, 2010, MUTAT RES-GEN TOX EN, V695, P16, DOI 10.1016/j.mrgentox.2009.10.001; Comparisons F, 2010, DURG FACTS COMP; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; Delgado-Coello B, 2006, MOL CELL BIOCHEM, V285, P1, DOI 10.1007/s11010-005-9060-z; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Drexler HG, 2005, DRUG DISCOV TODAY DI, V2, P51; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jiang BC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032040; KLUCK RM, 1994, BBA-MOL CELL RES, V1223, P247, DOI 10.1016/0167-4889(94)90233-X; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Mortazavi SMJ, 2011, IRAN J RADIAT RES, V9, P9; Nittby H, 2008, BIOELECTROMAGNETICS, V29, P219, DOI 10.1002/bem.20386; Persson BRR, 1997, WIREL NETW, V3, P455, DOI 10.1023/A:1019150510840; Rezaei PF, 2011, CYTOTECHNOLOGY, V63, P503, DOI 10.1007/s10616-011-9373-6; Sannino A, 2009, RADIAT RES, V171, P735, DOI 10.1667/RR1687.1; Sannino A, 2011, INT J RADIAT BIOL, V87, P993, DOI 10.3109/09553002.2011.574779; Verschaeve L, 2010, MUTAT RES-REV MUTAT, V705, P252, DOI 10.1016/j.mrrev.2010.10.001; Xie SQ, 2008, TOXICOLOGY, V254, P68, DOI 10.1016/j.tox.2008.09.021; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	30	42	43	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2012	7	9							e46102	10.1371/journal.pone.0046102	http://dx.doi.org/10.1371/journal.pone.0046102			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022PZ	23029402	Green Published, Green Submitted, gold			2023-01-03	WOS:000309973900091
J	Fairall, L; Bachmann, MO; Lombard, C; Timmerman, V; Uebel, K; Zwarenstein, M; Boulle, A; Georgeu, D; Colvin, CJ; Lewin, S; Faris, G; Cornick, R; Draper, B; Tshabalala, M; Kotze, E; van Vuuren, C; Steyn, D; Chapman, R; Bateman, E				Fairall, Lara; Bachmann, Max O.; Lombard, Carl; Timmerman, Venessa; Uebel, Kerry; Zwarenstein, Merrick; Boulle, Andrew; Georgeu, Daniella; Colvin, Christopher J.; Lewin, Simon; Faris, Gill; Cornick, Ruth; Draper, Beverly; Tshabalala, Mvula; Kotze, Eduan; van Vuuren, Cloete; Steyn, Dewald; Chapman, Ronald; Bateman, Eric			Task shifting of antiretroviral treatment from doctors to primary-care nurses in South Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial	LANCET			English	Article							EDUCATIONAL OUTREACH; STREAMLINING TASKS; CLINICAL-OUTCOMES; EXPAND TREATMENT; HIV/AIDS CARE; PALSA PLUS; HIV-CARE; PROGRAM; INTERVENTION; INTEGRATION	Background Robust evidence of the effectiveness of task shifting of antiretroviral therapy (ART) from doctors to other health workers is scarce. We aimed to assess the effects on mortality, viral suppression, and other health outcomes and quality indicators of the Streamlining Tasks and Roles to Expand Treatment and Care for HIV (STRETCH) programme, which provides educational outreach training of nurses to initiate and represcribe ART, and to decentralise care. Methods We undertook a pragmatic, parallel, cluster-randomised trial in South Africa between Jan 28, 2008, and June 30, 2010. We randomly assigned 31 primary-care ART clinics to implement the STRETCH programme (intervention group) or to continue with standard care (control group). The ratio of randomisation depended on how many clinics were in each of nine strata. Two cohorts were enrolled: eligible patients in cohort 1 were adults (aged >= 16 years) with CD4 counts of 350 cells per mu L or less who were not receiving ART; those in cohort 2 were adults who had already received ART for at least 6 months and were being treated at enrolment. The primary outcome in cohort 1 was time to death (superiority analysis). The primary outcome in cohort 2 was the proportion with undetectable viral loads (<400 copies per mL) 12 months after enrolment (equivalence analysis, prespecified difference <6%). Patients and clinicians could not be masked to group assignment. The interim analysis was blind, but data analysts were not masked after the database was locked for final analysis. Analyses were done by intention to treat. This trial is registered, number ISRCTN46836853. Findings 5390 patients in cohort 1 and 3029 in cohort 2 were in the intervention group, and 3862 in cohort 1 and 3202 in cohort 2 were in the control group. Median follow-up was 16.3 months (IQR 12.2-18.0) in cohort 1 and 18.0 months (18.0-18.0) in cohort 2. In cohort 1, 997 (20%) of 4943 patients analysed in the intervention group and 747 (19%) of 3862 in the control group with known vital status at the end of the trial had died. Time to death did not differ (hazard ratio [HR] 0.94, 95% CI 0.76-1.15). In a preplanned subgroup analysis of patients with baseline CD4 counts of 201-350 cells per mu L, mortality was slightly lower in the intervention group than in the control group (0.73, 0.54-1.00; p=0.052), but it did not diff er between groups in patients with baseline CD4 of 200 cells per mu L or less (0.94, 0.76-1.15; p=0.577). In cohort 2, viral load suppression 12 months after enrolment was equivalent in intervention (2156 [71%] of 3029 patients) and control groups (2230 [70%] of 3202; risk difference 1.1%, 95% CI-2.4 to 4.6). Interpretation Expansion of primary-care nurses' roles to include ART initiation and represcription can be done safely, and improve health outcomes and quality of care, but might not reduce time to ART or mortality.	[Bachmann, Max O.] Univ E Anglia, Norwich Med Sch, Norwich NR4 7TJ, Norfolk, England; [Fairall, Lara; Timmerman, Venessa; Uebel, Kerry; Zwarenstein, Merrick; Georgeu, Daniella; Faris, Gill; Cornick, Ruth; Draper, Beverly] Univ Cape Town, Lung Inst, Knowledge Translat Unit, ZA-7925 Cape Town, South Africa; [Fairall, Lara; Bateman, Eric] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa; [Boulle, Andrew; Colvin, Christopher J.] Univ Cape Town, Sch Publ Hlth & Family Med, ZA-7925 Cape Town, South Africa; [Lombard, Carl] MRC, Div Biostat, Cape Town, South Africa; [Lewin, Simon] MRC, Hlth Syst Res Unit, Cape Town, South Africa; [Zwarenstein, Merrick] Univ Toronto, Sunnybrook Res Inst, Toronto, ON, Canada; [Zwarenstein, Merrick] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Zwarenstein, Merrick] Karolinska Inst, Stockholm, Sweden; [Zwarenstein, Merrick] Univ Western Ontario, Dept Family Med, London, ON, Canada; [Lewin, Simon] Norwegian Knowledge Ctr Hlth Serv, Oslo, Norway; [Tshabalala, Mvula; Chapman, Ronald] Free State Dept Hlth, Bloemfontein, South Africa; [Kotze, Eduan] Univ Orange Free State, Dept Informat & Comp Sci, Bloemfontein, South Africa; [Uebel, Kerry; van Vuuren, Cloete; Steyn, Dewald] Univ Orange Free State, Dept Med, Bloemfontein, South Africa	University of East Anglia; University of Cape Town; University of Cape Town; University of Cape Town; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Karolinska Institutet; Western University (University of Western Ontario); Norwegian Knowledge Centre for Health Services; University of the Free State; University of the Free State	Bachmann, MO (corresponding author), Univ E Anglia, Norwich Med Sch, Norwich NR4 7TJ, Norfolk, England.	m.bachmann@uea.ac.uk	Zwarenstein, Merrick F/P-5210-2014; Kotzé, Eduan/M-3286-2016; Colvin, Christopher/AAB-8276-2019; Colvin, Christopher/AAQ-1607-2021; Boulle, Andrew/C-1413-2008	Zwarenstein, Merrick F/0000-0003-0162-7027; Kotzé, Eduan/0000-0002-5572-4319; Colvin, Christopher/0000-0002-8930-7863; Boulle, Andrew/0000-0002-7713-8062; Lombard, Carl/0000-0002-2136-6533; Bachmann, Max Oscar/0000-0003-1770-3506; van Vuuren, Cloete/0000-0002-9095-0039; Fairall, Lara/0000-0002-7460-4670	UK Medical Research Council; Development Cooperation Ireland; Canadian International Development Agency; MRC [G0800605] Funding Source: UKRI; Medical Research Council [G0800605] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Development Cooperation Ireland; Canadian International Development Agency; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	UK Medical Research Council, Development Cooperation Ireland, and Canadian International Development Agency.	[Anonymous], 2009, SAMJ S AFR MED J, V99, P284; [Anonymous], 2011, IMPLEMENT SCI, V6, P82; Bachmann MO, 2010, INT J TUBERC LUNG D, V14, P311; Boseley S., 2011, CRISIS LOOMS GLOBAL; Callaghan M, 2010, HUM RESOUR HEALTH, V8, DOI 10.1186/1478-4491-8-8; Chang LW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010923; Colvin CJ, 2010, SAMJ S AFR MED J, V100, P210, DOI 10.7196/SAMJ.4124; Cornell M, 2010, AIDS, V24, P2263, DOI 10.1097/QAD.0b013e32833d45c5; Donner A., STAT MED, V198, P199; Fairall LR, 2008, ARCH INTERN MED, V168, P86, DOI 10.1001/archinternmed.2007.10; Fairall LR, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-21; Fairall LR, 2005, BMJ-BRIT MED J, V331, P750, DOI 10.1136/bmj.331.7519.750; Haines A, 2000, PERSONAL INFORM MED; Ingle SM, 2010, AIDS, V24, P2717, DOI 10.1097/QAD.0b013e32833fb71f; Jaffar S, 2009, LANCET, V374, P2080, DOI 10.1016/S0140-6736(09)61674-3; Knowledge Translation Unit University of Cape Town Lung Institute, 2006, PRACT APPR LUNG HLTH; Medical Research Council, 2002, CLUST RAND TRIALS ME; Sanne I, 2010, LANCET, V376, P33, DOI 10.1016/S0140-6736(10)60894-X; Schull MJ, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-82; Schull MJ, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-118; Selke HM, 2010, JAIDS-J ACQ IMM DEF, V55, P483, DOI 10.1097/QAI.0b013e3181eb5edb; South African National Department of Health, 2004, NAT ANT TREATM GUID; Statistics South Africa, 2005, MORT CAUS DEATH S AF; Uebel KE, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-86; Vickers AJ, 2001, BMJ-BRIT MED J, V323, P1123, DOI 10.1136/bmj.323.7321.1123; WHO, 2008, TASK SHIFT GLOB REC; Zwarenstein M, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2022	27	210	212	5	32	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 8	2012	380	9845					889	898		10.1016/S0140-6736(12)60730-2	http://dx.doi.org/10.1016/S0140-6736(12)60730-2			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	002QL	22901955	Green Published, Bronze			2023-01-03	WOS:000308547300031
J	Kim, J; Kim, CS; Sohn, E; Lee, YM; Jo, K; Kim, JS				Kim, Junghyun; Kim, Chan-Sik; Sohn, Eunjin; Lee, Yun Mi; Jo, Kyuhyung; Kim, Jin Sook			KIOM-79 Protects AGE-Induced Retinal Pericyte Apoptosis via Inhibition of NF-kappaB Activation In Vitro and In Vivo	PLOS ONE			English	Article							GLYCATION END-PRODUCTS; ENDOTHELIAL GROWTH-FACTOR; GOTO-KAKIZAKI RATS; DIABETIC-RETINOPATHY; HIGH GLUCOSE; SERUM-LEVELS; CELLS; EXPRESSION; MICE; STREPTOZOTOCIN	KIOM-79 is an herbal mixture of parched Puerariae radix, gingered Magnoliae cortex, Glycyrrhizae radix and Euphorbiae radix. In the present study, we determined the efficacy and possible mechanism of KIOM-79 on the advanced glycation end product (AGE)-modified bovine serum albumin (BSA)-induced apoptosis of cultured bovine retinal pericytes and rat retinal pericytes in Zucker diabetic fatty (ZDF) rats. Seven-week-old male ZDF rats were treated with KIOM-79 (50 mg/kg body weight) once a day orally for 13 weeks. KIOM-79 significantly inhibited pericyte apoptosis which were induced by the AGE-BSA treatment. The KIOM-79 treatment markedly suppressed the activation of nuclear factor-kappaB (NF-kappa B) through the inhibition of inhibitory kappa B kinase complex. In addition, the oral administration of KIOM-79 inhibited the changes in retinal vasculature (vascular hyperpermeability, acellular capillary). KIOM-79 strongly inhibited pericyte apoptosis, NF-kappa B activation and the expression of pro-apoptotic Bax and tumor necrosis factor-alpha. Our results suggest that KIOM-79 may exert inhibitory effects on AGE-induced pericyte apoptosis by blocking NF-kappa B activation, thereby ameliorating retinal microvascular dysfunction.	[Kim, Junghyun; Kim, Chan-Sik; Sohn, Eunjin; Lee, Yun Mi; Jo, Kyuhyung; Kim, Jin Sook] Korea Inst Oriental Med, Herbal Med Res Div, Tradit Korean Med Based Herbal Drug Res Grp, Taejon, South Korea	Korea Institute of Oriental Medicine (KIOM)	Kim, J (corresponding author), Korea Inst Oriental Med, Herbal Med Res Div, Tradit Korean Med Based Herbal Drug Res Grp, Taejon, South Korea.	jskim@kiom.re.kr			Korea Institute of Oriental Medicine (KIOM) [K12010]	Korea Institute of Oriental Medicine (KIOM)	This research was supported by a grant [K12010] from the Korea Institute of Oriental Medicine (KIOM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AIDA K, 1990, PLANTA MED, V56, P254, DOI 10.1055/s-2006-960950; Alarcon-Aguilara FJ, 1998, J ETHNOPHARMACOL, V61, P101, DOI 10.1016/S0378-8741(98)00020-8; Asnaghi V, 2003, DIABETES, V52, P506, DOI 10.2337/diabetes.52.2.506; Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; Cacicedo JM, 2005, DIABETES, V54, P1838, DOI 10.2337/diabetes.54.6.1838; Cai J, 2008, INVEST OPHTH VIS SCI, V49, P2163, DOI 10.1167/iovs.07-1206; CAPETANDES A, 1990, INVEST OPHTH VIS SCI, V31, P1738; Chen WC, 2004, PLANTA MED, V70, P113, DOI 10.1055/s-2004-815486; Clements RS, 1998, J DIABETES COMPLICAT, V12, P28, DOI 10.1016/S1056-8727(97)00051-2; Denis U, 2002, FREE RADICAL BIO MED, V33, P236, DOI 10.1016/S0891-5849(02)00879-1; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; ENGERMAN RL, 1989, DIABETES, V38, P1203, DOI 10.2337/diabetes.38.10.1203; Hammes HP, 1999, DIABETOLOGIA, V42, P728, DOI 10.1007/s001250051221; Hernandez-Presa MA, 1999, KIDNEY INT, V55, P209, DOI 10.1046/j.1523-1755.1999.00226.x; Hughes S, 2004, INVEST OPHTH VIS SCI, V45, P2795, DOI 10.1167/iovs.03-1312; Jeon YJ, 2006, J ETHNOPHARMACOL, V108, P38, DOI 10.1016/j.jep.2006.04.007; Kaji Y, 2003, INVEST OPHTH VIS SCI, V44, P521, DOI 10.1167/iovs.02-0268; Kang KA, 2005, BIOL PHARM BULL, V28, P1154, DOI 10.1248/bpb.28.1154; Kang KA, 2007, BIOL PHARM BULL, V30, P852, DOI 10.1248/bpb.30.852; Kasper M, 2000, AM J RESP CELL MOL, V23, P485, DOI 10.1165/ajrcmb.23.4.4117; Kim CS, 2007, J ETHNOPHARMACOL, V111, P240, DOI 10.1016/j.jep.2006.11.023; Kim J, 2006, VET PATHOL, V43, P718, DOI 10.1354/vp.43-5-718; Kim KM, 2010, TOXICOL APPL PHARM, V244, P106, DOI 10.1016/j.taap.2009.12.023; Kim YS, 2007, J ETHNOPHARMACOL, V112, P166, DOI 10.1016/j.jep.2007.02.017; Koga K, 2002, INT J CLIN PHARM RES, V22, P13; Kondo T, 2003, CELL STRUCT FUNCT, V28, P145; Kowluru RA, 2003, FREE RADICAL RES, V37, P1169, DOI 10.1080/10715760310001604189; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lecleire-Collet A, 2005, BRIT J OPHTHALMOL, V89, P1631, DOI 10.1136/bjo.2005.079491; Lee HJ, 2006, CARCINOGENESIS, V27, P2455, DOI 10.1093/carcin/bgl104; Meezan E, 2005, J AGR FOOD CHEM, V53, P8760, DOI 10.1021/jf058105e; Mitsuhashi T, 1997, J IMMUNOL METHODS, V207, P79, DOI 10.1016/S0022-1759(97)00110-5; Miura J, 2003, J DIABETES COMPLICAT, V17, P16, DOI 10.1016/S1056-8727(02)00183-6; Mizutani M, 1996, J CLIN INVEST, V97, P2883, DOI 10.1172/JCI118746; Moore TCB, 2003, INVEST OPHTH VIS SCI, V44, P4457, DOI 10.1167/iovs.02-1063; Podesta F, 2000, AM J PATHOL, V156, P1025, DOI 10.1016/S0002-9440(10)64970-X; Romeo G, 2002, DIABETES, V51, P2241, DOI 10.2337/diabetes.51.7.2241; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Sohn EJ, 2007, LIFE SCI, V80, P468, DOI 10.1016/j.lfs.2006.09.037; Stitt Alan W., 2000, Molecular Cell Biology Research Communications, V3, P380, DOI 10.1006/mcbr.2000.0243; Takii H, 2001, BIOL PHARM BULL, V24, P484, DOI 10.1248/bpb.24.484; Tezel G, 2004, BRAIN RES, V996, P202, DOI 10.1016/j.brainres.2003.10.029; Wang YL, 2007, EYE, V21, P1501, DOI 10.1038/sj.eye.6702716; Yamagishi S, 2002, BIOCHEM BIOPH RES CO, V296, P877, DOI 10.1016/S0006-291X(02)00940-3; Yamagishi S, 2002, BIOCHEM BIOPH RES CO, V290, P973, DOI 10.1006/bbrc.2001.6312; Yamagishi Sho-ichi, 2006, Curr Drug Discov Technol, V3, P83, DOI 10.2174/157016306776637555; Yamagishi S, 2006, J BIOL CHEM, V281, P20213, DOI 10.1074/jbc.M602110200; YAMAGISHI SI, 1995, BIOCHEM BIOPH RES CO, V213, P681, DOI 10.1006/bbrc.1995.2185	49	12	14	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 20	2012	7	8							e43591	10.1371/journal.pone.0043591	http://dx.doi.org/10.1371/journal.pone.0043591			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	991WJ	22916281	Green Submitted, Green Published, gold			2023-01-03	WOS:000307733800080
J	Nelson, HD; Walker, M; Zakher, B; Mitchell, J				Nelson, Heidi D.; Walker, Miranda; Zakher, Bernadette; Mitchell, Jennifer			Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendations	ANNALS OF INTERNAL MEDICINE			English	Review							ESTROGEN PLUS PROGESTIN; CONJUGATED EQUINE ESTROGENS; INITIATIVE RANDOMIZED-TRIAL; DOSE TRANSDERMAL ESTRADIOL; CORONARY-HEART-DISEASE; PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; HEALTHY POSTMENOPAUSAL WOMEN; MILD COGNITIVE IMPAIRMENT; BREAST-CANCER INCIDENCE	Background: Menopausal hormone therapy to prevent chronic conditions is currently not recommended because of its adverse effects. Purpose: To update evidence about the effectiveness of hormone therapy in reducing risk for chronic conditions and adverse effects, and to examine whether outcomes vary among women in different subgroups. Data Sources: MEDLINE (January 2002 to November 2011), Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews (through the 3rd quarter of 2011), Scopus, and reference lists. Study Selection: Randomized, placebo-controlled trials of menopausal hormone therapy published in English since 2002 that assessed primary prevention of chronic conditions. Data Extraction: Investigators extracted data on participants, study design, analysis, follow-up, and results; 2 investigators independently rated study quality by using established criteria. Data Synthesis: 9 fair-quality trials met the inclusion criteria. The Women's Health Initiative reported most of the results, had 11 years of follow-up, and had data most applicable to postmenopausal women in the United States. It showed that estrogen plus progestin therapy reduced fractures (46 fewer per 10 000 woman-years) and increased invasive breast cancer (8 more per 10 000 woman-years), stroke (9 more per 10 000 woman-years), deep venous thrombosis (12 more per 10 000 woman-years), pulmonary embolism (9 more per 10 000 woman-years), lung cancer death (5 more per 10 000 woman-years), gallbladder disease (20 more per 10 000 woman-years), dementia (22 more per 10 000 woman-years), and urinary incontinence (872 more per 10 000 woman-years). Estrogen-only therapy reduced fractures (56 fewer per 10 000 woman-years), invasive breast cancer (8 fewer per 10 000 woman-years), and death (2 fewer per 10 000 woman-years) and increased stroke (11 more per 10 000 woman-years), deep venous thrombosis (7 more per 10 000 woman-years), gallbladder disease (33 more per 10 000 woman-years), and urinary incontinence (1271 more per 10 000 woman-years). Outcomes did not consistently differ by age or comorbid conditions. Limitation: Limitations of the trials included low adherence, high attrition, inadequate power to detect risks for some outcomes, and evaluation of few regimens. Conclusion: Estrogen plus progestin and estrogen alone decreased risk for fractures but increased risk for stroke, thromboembolic events, gallbladder disease, and urinary incontinence. Estrogen plus progestin increased risk for breast cancer and probable dementia, whereas estrogen alone decreased risk for breast cancer.	[Nelson, Heidi D.] Oregon Hlth & Sci Univ, Oregon Evidence Based Practice Ctr, Mailcode BICC, Portland, OR 97239 USA; Providence Hlth & Serv, Providence Canc Ctr, Portland, OR USA	Oregon Health & Science University	Nelson, HD (corresponding author), Oregon Hlth & Sci Univ, Oregon Evidence Based Practice Ctr, Mailcode BICC, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	nelsonh@ohsu.edu			AHRQ [HHSA-290-2007-10057-I-EPC3]; Agency for Healthcare Research and Quality	AHRQ(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	By contract HHSA-290-2007-10057-I-EPC3, task order 3, from the AHRQ.; Primary Funding Source: Agency for Healthcare Research and Quality.	American Academy of Family Physicians, 2005, HORM REPL THER; American College of Obstetricians and Gynecologists Women's Health Care Physicians, 2004, Obstet Gynecol, V103, P203; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Anderson GL, 2012, LANCET ONCOL, V13, P476, DOI 10.1016/S1470-2045(12)70075-X; Anderson GL, 2003, JAMA-J AM MED ASSOC, V290, P1739, DOI 10.1001/jama.290.13.1739; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; [Anonymous], 2012, MENOPAUSE, V19, P257, DOI 10.1097/gme.0b013e31824b970a; Berg AO, 2002, ANN INTERN MED, V137, P834, DOI 10.7326/0003-4819-137-10-200211190-00013; Bonds DE, 2006, DIABETOLOGIA, V49, P459, DOI 10.1007/s00125-005-0096-0; Brunner RL, 2005, ARCH INTERN MED, V165, P1976, DOI 10.1001/archinte.165.17.1976; Canadian Task Force on Preventive Health Care, 2004, HORM REPL THER PRIM; Cauley JA, 2003, JAMA-J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729; Cherry N, 2002, LANCET, V360, P2001; Chlebowski RT, 2010, JAMA-J AM MED ASSOC, V304, P1684, DOI 10.1001/jama.2010.1500; Chlebowski RT, 2010, JNCI-J NATL CANCER I, V102, P1413, DOI 10.1093/jnci/djq285; Chlebowski RT, 2009, LANCET, V374, P1243, DOI 10.1016/S0140-6736(09)61526-9; Chlebowski RT, 2004, NEW ENGL J MED, V350, P991, DOI 10.1056/NEJMoa032071; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Cirillo DJ, 2005, JAMA-J AM MED ASSOC, V293, P330, DOI 10.1001/jama.293.3.330; Culhane NS, 2003, J FAM PRACTICE, V52, P754; Curb JD, 2006, ARCH INTERN MED, V166, P772, DOI 10.1001/archinte.166.7.772; Cushman M, 2004, JAMA-J AM MED ASSOC, V292, P1573, DOI 10.1001/jama.292.13.1573; Espeland MA, 2004, JAMA-J AM MED ASSOC, V291, P2959, DOI 10.1001/jama.291.24.2959; Espeland MA, 2010, J AM GERIATR SOC, V58, P1263, DOI 10.1111/j.1532-5415.2010.02953.x; Ettinger B, 2004, OBSTET GYNECOL, V104, P443, DOI 10.1097/01.AOG.0000137833.43248.79; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; Grady D, 1998, CONTROL CLIN TRIALS, V19, P314, DOI 10.1016/S0197-2456(98)00010-5; Grady D, 2002, AM J MED, V113, P543, DOI 10.1016/S0002-9343(02)01270-6; Gramling R, 2009, EPIDEMIOLOGY, V20, P752, DOI 10.1097/EDE.0b013e3181a71279; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Hays J, 2003, NEW ENGL J MED, V348, P1839, DOI 10.1056/NEJMoa030311; Heiss G, 2008, JAMA-J AM MED ASSOC, V299, P1036, DOI 10.1001/jama.299.9.1036; Hendrix SL, 2005, JAMA-J AM MED ASSOC, V293, P935, DOI 10.1001/jama.293.8.935; Hendrix SL, 2006, CIRCULATION, V113, P2425, DOI 10.1161/CIRCULATIONAHA.105.594077; Hendrix Susan L, 2003, J Am Osteopath Assoc, V103, pS3; Hsia J, 2004, CIRCULATION, V109, P620, DOI 10.1161/01.CIR.0000115309.63979.92; Hsia J, 2006, ARCH INTERN MED, V166, P357, DOI 10.1001/archinte.166.3.357; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Johnson MS, 2005, ANN INTERN MED, V142, P855, DOI 10.7326/0003-4819-142-10-200505170-00011; Johnson SR, 2005, OBSTET GYNECOL, V105, P779, DOI 10.1097/01.AOG.0000157116.23249.52; Kanaya AM, 2003, ANN INTERN MED, V138, P1, DOI 10.7326/0003-4819-138-1-200301070-00005; LaCroix AZ, 2011, JAMA-J AM MED ASSOC, V305, P1305, DOI 10.1001/jama.2011.382; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; Margolis KL, 2004, DIABETOLOGIA, V47, P1175, DOI 10.1007/s00125-004-1448-x; Mosca, 2011, CIRCULATION, V123, pE624, DOI 10.1161/CIR.0b013e318222b330; Nelson H.D., 2012, MENOPAUSAL HORMONE T; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Rapp SR, 2003, JAMA-J AM MED ASSOC, V289, P2663, DOI 10.1001/jama.289.20.2663; Resnick SM, 2006, J CLIN ENDOCR METAB, V91, P1802, DOI 10.1210/jc.2005-2097; Resnick SM, 2009, J CLIN ENDOCR METAB, V94, P4152, DOI 10.1210/jc.2009-1340; Ritenbaugh C, 2008, CANCER EPIDEM BIOMAR, V17, P2609, DOI 10.1158/1055-9965.EPI-08-0385; Rossouw JE, 2007, JAMA-J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Steinauer JE, 2005, OBSTET GYNECOL, V106, P940, DOI 10.1097/01.AOG.0000180394.08406.15; Tierney MC, 2009, PSYCHONEUROENDOCRINO, V34, P1065, DOI 10.1016/j.psyneuen.2009.02.009; Toh S, 2010, ANN INTERN MED, V152, P211, DOI 10.7326/0003-4819-152-4-201002160-00005; U.S. Food and Drug Administration, 2010, ESTR ESTR PROG THER; Vickers Madge R, 2007, BMC Womens Health, V7, P2, DOI 10.1186/1472-6874-7-2; Waetjen LE, 2005, OBSTET GYNECOL, V106, P946, DOI 10.1097/01.AOG.0000182576.48290.6d; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; Yaffe K, 2006, ARCH NEUROL-CHICAGO, V63, P945, DOI 10.1001/archneur.63.7.945	64	94	98	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 17	2012	157	2					104	+		10.7326/0003-4819-157-2-201207170-00466	http://dx.doi.org/10.7326/0003-4819-157-2-201207170-00466			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992ON	22786830				2023-01-03	WOS:000307787900016
J	Perner, A; Haase, N; Guttormsen, AB; Tenhunen, J; Klemenzson, G; Aneman, A; Madsen, KR; Moller, MH; Elkjaer, JM; Poulsen, LM; Bendtsen, A; Winding, R; Steensen, M; Berezowicz, P; Soe-Jensen, P; Bestle, M; Strand, K; Wiis, J; White, JO; Thornberg, KJ; Quist, L; Nielsen, J; Andersen, LH; Holst, LB; Thormar, K; Kjaeldgaard, AL; Fabritius, ML; Mondrup, F; Pott, FC; Moller, TP; Winkel, P; Wetterslev, J				Perner, Anders; Haase, Nicolai; Guttormsen, Anne B.; Tenhunen, Jyrki; Klemenzson, Gudmundur; Aneman, Anders; Madsen, Kristian R.; Moller, Morten H.; Elkjaer, Jeanie M.; Poulsen, Lone M.; Bendtsen, Asger; Winding, Robert; Steensen, Morten; Berezowicz, Pawel; Soe-Jensen, Peter; Bestle, Morten; Strand, Kristian; Wiis, Jorgen; White, Jonathan O.; Thornberg, Klaus J.; Quist, Lars; Nielsen, Jonas; Andersen, Lasse H.; Holst, Lars B.; Thormar, Katrin; Kjaeldgaard, Anne-Lene; Fabritius, Maria L.; Mondrup, Frederik; Pott, Frank C.; Moller, Thea P.; Winkel, Per; Wetterslev, Jorn		6S Trial Grp; Scandinavian Critical Care Trials	Hydroxyethyl Starch 130/0.4 versus Ringer's Acetate in Severe Sepsis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE-RENAL-FAILURE; SEPTIC SHOCK; RESUSCITATION; THERAPY; MULTICENTER; MORTALITY; IMPACT; SAFETY; TRIAL; SCORE	BACKGROUND Hydroxyethyl starch (HES) 130/0.4 is widely used for fluid resuscitation in intensive care units (ICUs), but its safety and efficacy have not been established in patients with severe sepsis. METHODS In this multicenter, parallel-group, blinded trial, we randomly assigned patients with severe sepsis to fluid resuscitation in the ICU with either 6% HES 130/0.4 or Ringer's acetate at a dose of up to 33 ml per kilogram of ideal body weight per day. The primary outcome measure was either death or end-stage kidney failure (dependence on dialysis) at 90 days after randomization. RESULTS Of the 804 patients who underwent randomization, 798 were included in the modified intention-to-treat population. The two intervention groups had similar baseline characteristics. At 90 days after randomization, 201 of 398 patients (51%) assigned to HES 130/0.4 had died, as compared with 172 of 400 patients (43%) assigned to Ringer's acetate (relative risk, 1.17; 95% confidence interval [CI], 1.01 to 1.36; P=0.03); 1 patient in each group had end-stage kidney failure. In the 90-day period, 87 patients (22%) assigned to HES 130/0.4 were treated with renal-replacement therapy versus 65 patients (16%) assigned to Ringer's acetate (relative risk, 1.35; 95% CI, 1.01 to 1.80; P=0.04), and 38 patients (10%) and 25 patients (6%), respectively, had severe bleeding (relative risk, 1.52; 95% CI, 0.94 to 2.48; P=0.09). The results were supported by multivariate analyses, with adjustment for known risk factors for death or acute kidney injury at baseline. CONCLUSIONS Patients with severe sepsis assigned to fluid resuscitation with HES 130/0.4 had an increased risk of death at day 90 and were more likely to require renal-replacement therapy, as compared with those receiving Ringer's acetate. (Funded by the Danish Research Council and others; 6S ClinicalTrials.gov number, NCT00962156.)	[Perner, Anders; Haase, Nicolai; Wiis, Jorgen; White, Jonathan O.; Thornberg, Klaus J.; Quist, Lars; Nielsen, Jonas; Andersen, Lasse H.; Holst, Lars B.; Thormar, Katrin] Rigshosp, Copenhagen Univ Hosp, Dept Intens Care, DK-2100 Copenhagen, Denmark; [Winkel, Per; Wetterslev, Jorn] Rigshosp, Copenhagen Univ Hosp, Copenhagen Trial Unit, Ctr Clin Intervent Res, DK-2100 Copenhagen, Denmark; [Madsen, Kristian R.; Kjaeldgaard, Anne-Lene; Fabritius, Maria L.; Mondrup, Frederik] Naestved Hosp, Naestved, Denmark; [Elkjaer, Jeanie M.; Moller, Thea P.] Holbaek Cent Hosp, Holbaek, Denmark; [Poulsen, Lone M.] Koge Hosp, Koge, Denmark; [Bendtsen, Asger] Copenhagen Univ Hosp, Glostrup, Denmark; [Winding, Robert] Herning Hosp, Herning, Denmark; [Steensen, Morten] Copenhagen Univ Hosp, Hvidovre, Denmark; [Berezowicz, Pawel] Vejle Hosp, Vejle, Denmark; [Soe-Jensen, Peter] Copenhagen Univ Hosp, Herlev, Denmark; [Bestle, Morten] Copenhagen Univ Hosp, Hillerod, Denmark; [Guttormsen, Anne B.] Haukeland Hosp, N-5021 Bergen, Norway; [Guttormsen, Anne B.] Univ Bergen, Bergen, Norway; [Strand, Kristian] Stavanger Univ Hosp, Stavanger, Norway; [Tenhunen, Jyrki] Tampere Univ Hosp, Tampere, Finland; [Tenhunen, Jyrki] Uppsala Univ, Uppsala, Sweden; [Klemenzson, Gudmundur] Landspitali, Reykjavik, Iceland; [Aneman, Anders] Liverpool Hosp, Sydney, NSW, Australia	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Holbaek Hospital; University of Copenhagen; Aarhus University; University of Copenhagen; University of Southern Denmark; Lillebaelt Hospital; University of Copenhagen; University of Copenhagen; University of Bergen; Stavanger University Hospital; Tampere University; Tampere University Hospital; Uppsala University; Liverpool Hospital	Perner, A (corresponding author), Rigshosp, Dept Intens Care 4131, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	anders.perner@rh.regionh.dk	Wetterslev, Jørn/ABF-1251-2020; Epelde, Francisco/AAT-7213-2021; Møller, Morten Hylander/AAQ-6891-2020; Moller, Kirsten/A-4751-2009	Wetterslev, Jørn/0000-0001-7778-1771; Epelde, Francisco/0000-0001-5547-4025; Møller, Morten Hylander/0000-0002-6378-9673; Rasmussen, Lars/0000-0002-7480-3004; Moller, Thea Palsgaard/0000-0002-8436-6194; Fabritius, Maria Louise/0000-0002-6497-2963; Perner, Anders/0000-0002-4668-0123; Poulsen, Lone Musaeus/0000-0002-7030-3395; Moller, Thea Palsgaard/0000-0001-7658-2447; Moller, Kirsten/0000-0003-3058-1072; Brunkhorst, Frank Martin/0000-0002-8132-8651; Bestle, Morten/0000-0001-6585-2659; Vested, Matias/0000-0002-5165-2725; Aneman, Anders/0000-0003-2096-5304; Berthelsen, Rasmus Ehrenfreid/0000-0003-1945-0944	Danish Research Council [271-08-0691, 09-066938]; Rigshospitalet Research Council; Scandinavian Society of Anesthesiology and Intensive Care Medicine; ACTA Foundation; Fresenius Kabi	Danish Research Council(Det Frie Forskningsrad (DFF)); Rigshospitalet Research Council; Scandinavian Society of Anesthesiology and Intensive Care Medicine; ACTA Foundation; Fresenius Kabi	Supported by grants from the Danish Research Council (271-08-0691 and 09-066938), the Rigshospitalet Research Council, and the Scandinavian Society of Anesthesiology and Intensive Care Medicine (funded by the ACTA Foundation).; Dr. Perner reports receiving grant support from Fresenius Kabi. No other potential conflict of interest relevant to this article was reported.	Afshari A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005370.pub2; Bagshaw SM, 2006, INT J ARTIF ORGANS, V29, P1023, DOI 10.1177/039139880602901102; Bagshaw SM, 2007, CLIN J AM SOC NEPHRO, V2, P431, DOI 10.2215/CJN.03681106; Bellmann R, 2012, CLIN PHARMACOKINET, V51, P225, DOI 10.2165/11594700-000000000-00000; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Carlsen S, 2011, ACTA ANAESTH SCAND, V55, P394, DOI 10.1111/j.1399-6576.2011.02399.x; Christidis C, 2001, J HEPATOL, V35, P726, DOI 10.1016/S0168-8278(01)00200-8; Clermont G, 2002, KIDNEY INT, V62, P986, DOI 10.1046/j.1523-1755.2002.00509.x; Dellinger RP, 2008, INTENS CARE MED, V34, P17, DOI 10.1007/s00134-007-0934-2; Expert Working Group International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2009, ICH HARMONIZATION TR, V51; Fergusson D, 2002, BMJ-BRIT MED J, V325, P652, DOI 10.1136/bmj.325.7365.652; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Finfer S, 2011, INTENS CARE MED, V37, P86, DOI 10.1007/s00134-010-2039-6; Fluids Study Investigators, 2008, ACTA ANAESTH SCAND, V52, P750, DOI 10.1111/j.1399-6576.2008.01690.x; Guidet B, 2012, CRIT CARE, V16, DOI 10.1186/cc11358; Hartog CS, 2011, ANESTH ANALG, V112, P635, DOI 10.1213/ANE.0b013e31820ad607; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; LEGALL JR, 1994, JAMA-J AM MED ASSOC, V271, P1321; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Perel P, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000567.pub4; Perner A, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-24; Pillebout E, 2005, AM J TRANSPLANT, V5, P1120, DOI 10.1111/j.1600-6143.2005.00852.x; Reinhart K, 2012, INTENS CARE MED, V38, P368, DOI 10.1007/s00134-012-2472-9; Reinikainen M, 2010, INTENS CARE MED, V36, P673, DOI 10.1007/s00134-009-1688-9; Russell JA, 2008, NEW ENGL J MED, V358, P877, DOI 10.1056/NEJMoa067373; Sakr Y, 2007, BRIT J ANAESTH, V98, P216, DOI 10.1093/bja/ael333; Schmidt-Hieber M, 2006, EUR J HAEMATOL, V77, P83, DOI 10.1111/j.1600-0609.2006.00657.x; Schortgen F, 2001, LANCET, V357, P911, DOI 10.1016/S0140-6736(00)04211-2; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Warren BL, 2001, JAMA-J AM MED ASSOC, V286, P1869, DOI 10.1001/jama.286.15.1869; Warren BL, 2002, JAMA-J AM MED ASSOC, V287, P192	33	1191	1271	2	89	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 12	2012	367	2					124	134		10.1056/NEJMoa1204242	http://dx.doi.org/10.1056/NEJMoa1204242			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972IO	22738085				2023-01-03	WOS:000306270800009
J	Kar, UK; Jiang, JN; Champion, CI; Salehi, S; Srivastava, M; Sharma, S; Rabizadeh, S; Niazi, K; Kickhoefer, V; Rome, LH; Kelly, KA				Kar, Upendra K.; Jiang, Janina; Champion, Cheryl I.; Salehi, Sahar; Srivastava, Minu; Sharma, Sherven; Rabizadeh, Shahrooz; Niazi, Kayvan; Kickhoefer, Valerie; Rome, Leonard H.; Kelly, Kathleen A.			Vault Nanocapsules as Adjuvants Favor Cell-Mediated over Antibody-Mediated Immune Responses following Immunization of Mice	PLOS ONE			English	Article							IN-VIVO; ANTIGEN PRESENTATION; CROSS-PRESENTATION; DELIVERY-SYSTEMS; DNA VACCINES; T-CELLS; PROTEIN; VIRUS; NANOPARTICLES; LOCALIZATION	Background: Modifications of adjuvants that induce cell-mediated over antibody-mediated immunity is desired for development of vaccines. Nanocapsules have been found to be viable adjuvants and are amenable to engineering for desired immune responses. We previously showed that natural nanocapsules called vaults can be genetically engineered to elicit Th1 immunity and protection from a mucosal bacterial infection. The purpose of our study was to characterize immunity produced in response to OVA within vault nanoparticles and compare it to another nanocarrier. Methodology and Principal Findings: We characterized immunity resulting from immunization with the model antigen, ovalbumin (OVA) encased in vault nanocapsules and liposomes. We measured OVA responsive CD8(+) and CD4(+) memory T cell responses, cytokine production and antibody titers in vitro and in vivo. We found that immunization with OVA contain in vaults induced a greater number of anti-OVA CD8(+) memory T cells and production of IFN gamma plus CD4(+) memory T cells. Also, modification of the vault body could change the immune response compared to OVA encased in liposomes. Conclusions/Significance: These experiments show that vault nanocapsules induced strong anti-OVA CD8(+) and CD4(+) T cell memory responses and modest antibody production, which markedly differed from the immune response induced by liposomes. We also found that the vault nanocapsule could be modified to change antibody isotypes in vivo. Thus it is possible to create a vault nanocapsule vaccine that can result in the unique combination of immunogen-responsive CD8(+) and CD4(+) T cell immunity coupled with an IgG1 response for future development of vault nanocapsule-based vaccines against antigens for human pathogens and cancer.	[Kar, Upendra K.; Kickhoefer, Valerie; Rome, Leonard H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; [Jiang, Janina; Champion, Cheryl I.; Salehi, Sahar; Kelly, Kathleen A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; [Srivastava, Minu; Sharma, Sherven] Vet Affairs Greater Los Angeles Healthcare Syst, Mol Med Lab, Los Angeles, CA USA; [Rabizadeh, Shahrooz; Niazi, Kayvan] Univ Calif Los Angeles, Samueli Sch Engn, Dept Bioengn, Los Angeles, CA USA; [Rabizadeh, Shahrooz; Niazi, Kayvan; Kickhoefer, Valerie; Rome, Leonard H.; Kelly, Kathleen A.] Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Kar, UK (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.	kkelly@mednet.ucla.edu	Rome, Leonard H/E-8786-2016; Kar, Upendra K/H-5250-2012	Rome, Leonard H/0000-0002-1236-2063; Kar, Upendra K/0000-0003-4065-0860; Kickhoefer, Valerie/0000-0002-0048-0580	National Institutes of Health [AI026328]; Abraxis Bioscience, Inc [20090918]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI026328, R01AI079004, R01AI026328] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Abraxis Bioscience, Inc; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	These studies were supported by the National Institutes of Health, AI026328 (Dr. Kelly), sponsored research award from Abraxis Bioscience, Inc (Dr. Kelly) and 20090918. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahlers JD, 2010, TRENDS MOL MED, V16, P478, DOI 10.1016/j.molmed.2010.07.007; Andrews CD, 2012, MOL PHARMACEUTI 0406, P6; Assudani D, 2008, CANCER RES, V68, P9892, DOI 10.1158/0008-5472.CAN-08-3134; Berger W, 2009, CELL MOL LIFE SCI, V66, P43, DOI 10.1007/s00018-008-8364-z; Bolhassani A, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-3; Brave A, 2007, MOL PHARMACEUT, V4, P18, DOI 10.1021/mp060098+; Burgdorf S, 2008, NAT IMMUNOL, V9, P558, DOI 10.1038/ni.1601; Carstens MG, 2011, VACCINE, V29, P4761, DOI 10.1016/j.vaccine.2011.04.081; Champion CI, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005409; Chou LYT, 2011, CHEM SOC REV, V40, P233, DOI 10.1039/c0cs00003e; FERRARI C, 1992, J VIROL, V66, P2536, DOI 10.1128/JVI.66.4.2536-2540.1992; Flatz L, 2010, NAT MED, V16, P339, DOI 10.1038/nm.2104; Fritsche PJ, 2010, SWISS MED WKLY, V140, P238, DOI smw-12980; FULGINITI VA, 1969, AM J EPIDEMIOL, V89, P435, DOI 10.1093/oxfordjournals.aje.a120956; Guy B, 2007, NAT REV MICROBIOL, V5, P505, DOI 10.1038/nrmicro1681; Haglund K, 2002, J VIROL, V76, P7506, DOI 10.1128/JVI.76.15.7506-7517.2002; Han M, 2011, ACS NANO, V5, P6128, DOI 10.1021/nn2014613; Harnack U, 2010, ANTICANCER RES, V30, P3959; Heath WR, 2001, NAT REV IMMUNOL, V1, P126, DOI 10.1038/35100512; Henriques AM, 2009, INT J PHARMACEUT, V377, P92, DOI 10.1016/j.ijpharm.2009.05.005; Hubbell JA, 2009, NATURE, V462, P449, DOI 10.1038/nature08604; Huber VC, 2006, CLIN VACCINE IMMUNOL, V13, P981, DOI 10.1128/CVI.00156-06; Ingolotti M, 2010, EXPERT REV VACCINES, V9, P747, DOI 10.1586/ERV.10.57; Izquierdo MA, 1996, AM J PATHOL, V148, P877; Joffre O, 2009, IMMUNOL REV, V227, P234, DOI 10.1111/j.1600-065X.2008.00718.x; Kar UK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018758; Kickhoefer VA, 2005, P NATL ACAD SCI USA, V102, P4348, DOI 10.1073/pnas.0500929102; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kickhoefer VA, 2009, ACS NANO, V3, P27, DOI 10.1021/nn800638x; Kim C, 2010, IMMUNOLOGY, V131, P310, DOI 10.1111/j.1365-2567.2010.03338.x; Langridge W, 2010, CURR OPIN INVEST DR, V11, P919; Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510; McNeela EA, 2001, ADV DRUG DELIVER REV, V51, P43, DOI 10.1016/S0169-409X(01)00169-7; Mikyas Y, 2004, J MOL BIOL, V344, P91, DOI 10.1016/j.jmb.2004.09.021; Mitchell DA, 1998, EUR J IMMUNOL, V28, P1923, DOI 10.1002/(SICI)1521-4141(199806)28:06<1923::AID-IMMU1923>3.0.CO;2-9; Mohanan D, 2010, J CONTROL RELEASE, V147, P342, DOI 10.1016/j.jconrel.2010.08.012; Moon JJ, 2011, NAT MATER, V10, P243, DOI 10.1038/NMAT2960; Moser M, 2001, IMMUNOBIOLOGY, V204, P551, DOI 10.1078/0171-2985-00092; Nembrini C, 2011, P NATL ACAD SCI USA, V108, pE989, DOI 10.1073/pnas.1104264108; Ohlschlager P, 2011, INT J CANCER, V128, P473, DOI 10.1002/ijc.25344; Pathak Y., 2009, DRUG DELIVERY NANOPA, P1; Perrie Y, 2008, INT J PHARMACEUT, V364, P272, DOI 10.1016/j.ijpharm.2008.04.036; Poderycki MJ, 2006, BIOCHEMISTRY-US, V45, P12184, DOI 10.1021/bi0610552; Reed SG, 2009, TRENDS IMMUNOL, V30, P23, DOI 10.1016/j.it.2008.09.006; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; Steiner E, 2006, J CELL SCI, V119, P459, DOI 10.1242/jcs.02773; Stephen AG, 2001, J BIOL CHEM, V276, P23217, DOI 10.1074/jbc.C100226200; Suprenant KA, 2002, BIOCHEMISTRY-US, V41, P14447, DOI 10.1021/bi026747e; Tiwari S, 2010, NANOMEDICINE-UK, V5, P1617, DOI [10.2217/nnm.10.128, 10.2217/NNM.10.128]; Walker BD, 2008, SCIENCE, V320, P760, DOI 10.1126/science.1152622; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; Zhong ZH, 2010, INT J PHARMACEUT, V399, P156, DOI 10.1016/j.ijpharm.2010.07.053; Zhou F, 2010, INT REV IMMUNOL, V29, P56, DOI 10.3109/08830180903349644	53	31	33	1	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2012	7	7							e38553	10.1371/journal.pone.0038553	http://dx.doi.org/10.1371/journal.pone.0038553			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973LU	22808011	Green Published, Green Submitted, gold			2023-01-03	WOS:000306362400003
J	Mugusi, S; Ngaimisi, E; Janabi, M; Minzi, O; Bakari, M; Riedel, KD; Burhenne, J; Lindquist, L; Mugusi, F; Sandstrom, E; Aklillu, E				Mugusi, Sabina; Ngaimisi, Eliford; Janabi, Mohamed; Minzi, Omary; Bakari, Muhammad; Riedel, Klaus-Dieter; Burhenne, Juergen; Lindquist, Lars; Mugusi, Ferdinand; Sandstrom, Eric; Aklillu, Eleni			Liver Enzyme Abnormalities and Associated Risk Factors in HIV Patients on Efavirenz-Based HAART with or without Tuberculosis Co-Infection in Tanzania	PLOS ONE			English	Article							DRUG-INDUCED HEPATOTOXICITY; ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; DAR-ES-SALAAM; HEPATITIS-B; ANTITUBERCULOSIS TREATMENT; INFECTED PATIENTS; PLASMA EXPOSURE; VERBAL AUTOPSY; CYP2B6	Objectives: To investigate the timing, incidence, clinical presentation, pharmacokinetics and pharmacogenetic predictors for antiretroviral and anti-tuberculosis drug induced liver injury (DILI) in HIV patients with or without TB co-infection. Methods and Findings: A total of 473 treatment naive HIV patients (253 HIV only and 220 with HIV-TB co-infection) were enrolled prospectively. Plasma efavirenz concentration and CYP2B6*6, CYP3A5*3, *6 and *7, ABCB1 3435C/T and SLCO1B1 genotypes were determined. Demographic, clinical and laboratory data were collected at baseline and up to 48 weeks of antiretroviral therapy. DILI case definition was according to Council for International Organizations of Medical Sciences (CIOMS). Incidence of DILI and identification of predictors was evaluated using Cox Proportional Hazards Model. The overall incidence of DILI was 7.8% (8.3 per 1000 person-week), being non-significantly higher among patients receiving concomitant anti-TB and HAART (10.0%, 10.7per 1000 person-week) than those receiving HAART alone (5.9%, 6.3 per 1000 person-week). Frequency of CYP2B6* 6 allele (p = 0.03) and CYP2B6*6/*6 genotype (p = 0.06) was significantly higher in patients with DILI than those without. Multivariate cox regression model indicated that CYP2B6*6/*6 genotype and anti-HCV IgG antibody positive as significant predictors of DILI. Median time to DILI was 2 weeks after HAART initiation and no DILI onset was observed after 12 weeks. No severe DILI was seen and the gain in CD4 was similar in patients with or without DILI. Conclusions: Antiretroviral and anti-tuberculosis DILI does occur in our setting, presenting early following HAART initiation. DILI seen is mild, transient and may not require treatment interruption. There is good tolerance to HAART and anti-TB with similar immunological outcomes. Genetic make-up mainly CYP2B6 genotype influences the development of efavirenz based HAART liver injury in Tanzanians.	[Mugusi, Sabina; Sandstrom, Eric] Karolinska Inst, Infect Dis Unit, Dept Clin Sci & Educ, Sodersjukhuset, Stockholm, Sweden; [Mugusi, Sabina] Muhimbili Natl Hosp, Dept Internal Med, Dar Es Salaam, Tanzania; [Ngaimisi, Eliford; Aklillu, Eleni] Karolinska Inst, Div Clin Pharmacol, Dept Lab Med, Karolinska Univ Hosp Huddinge, Stockholm, Sweden; [Ngaimisi, Eliford; Minzi, Omary] Muhimbili Univ Hlth & Allied Sci, Unit Pharmacol & Therapeut, Sch Pharm, Dar Es Salaam, Tanzania; [Janabi, Mohamed; Bakari, Muhammad; Mugusi, Ferdinand] Muhimbili Univ Hlth & Allied Sci, Dept Internal Med, Dar Es Salaam, Tanzania; [Riedel, Klaus-Dieter; Burhenne, Juergen] Univ Heidelberg, Dept Clin Pharmacol & Pharmacoepidemiol, Heidelberg, Germany; [Lindquist, Lars] Karolinska Inst, Div Infect Dis, Dept Med, Karolinska Univ Hosp Huddinge, Stockholm, Sweden	Karolinska Institutet; Sodersjukhuset Hospital; Karolinska Institutet; Karolinska University Hospital; Muhimbili University of Health & Allied Sciences; Muhimbili University of Health & Allied Sciences; Ruprecht Karls University Heidelberg; Karolinska Institutet; Karolinska University Hospital	Mugusi, S (corresponding author), Karolinska Inst, Infect Dis Unit, Dept Clin Sci & Educ, Sodersjukhuset, Stockholm, Sweden.	Eleni.Aklillu@ki.se	Aklillu, Eleni/ABG-3461-2021; Burhenne, Jürgen/AAU-2769-2021	Burhenne, Jürgen/0000-0002-2190-1698; Aklillu, Eleni/0000-0002-9788-0790	EDCTP (European & Developing Countries Clinical Trials Partnership) [CT. 2005.32030.001]; SIDA/SAREC [HIV-2006-031, SWE 2007-270]	EDCTP (European & Developing Countries Clinical Trials Partnership); SIDA/SAREC	This study was supported by grants from EDCTP (European & Developing Countries Clinical Trials Partnership), CT. 2005.32030.001 and SIDA/SAREC HIV-2006-031, SWE 2007-270. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrescia N, 2002, J ANTIMICROB CHEMOTH, V50, P763, DOI 10.1093/jac/dkf204; Aklillu E, 2007, PHARMACOGENOMICS ADM, P99; Aklillu E, 2011, EUR J CLIN PHARMACOL, V67, P1139, DOI 10.1007/s00228-011-1065-9; Anderson AM, 2010, WORLD J GASTROENTERO, V16, P4107, DOI 10.3748/wjg.v16.i32.4107; BENICHOU C, 1990, J HEPATOL, V11, P272; Figueroa SC, 2010, THER DRUG MONIT, V32, P579, DOI 10.1097/FTD.0b013e3181f0634c; Cohen K, 2010, CURR OPIN HIV AIDS, V5, P61, DOI 10.1097/COH.0b013e3283339309; Daly AK, 2009, NAT GENET, V41, P816, DOI 10.1038/ng.379; Dean GL, 2002, AIDS, V16, P75, DOI 10.1097/00002030-200201040-00010; Desta Z, 2007, PHARMACOGENOMICS, V8, P547, DOI 10.2217/14622416.8.6.547; Dore GJ, 1999, J INFECT DIS, V180, P607, DOI 10.1086/314942; Fiegenbaum M, 2005, CLIN PHARMACOL THER, V78, P551, DOI 10.1016/j.clpt.2005.08.003; Gounden V, 2010, AIDS RES THER, V7, DOI 10.1186/1742-6405-7-32; Habtewold A, 2011, J ANTIMICROB CHEMOTH, V66, P2350, DOI 10.1093/jac/dkr304; Hoffmann CJ, 2008, AIDS, V22, P67, DOI 10.1097/QAD.0b013e3282f2306e; Hoffmann CJ, 2007, AIDS, V21, P1301, DOI 10.1097/QAD.0b013e32814e6b08; Kalyesubula R, 2011, AFR HEALTH SCI, V11, P16; Kappelhoff BS, 2005, ANTIVIR THER, V10, P489; Kuehl P, 2001, NAT GENET, V27, P383, DOI 10.1038/86882; Kwara A, 2005, INT J TUBERC LUNG D, V9, P248; Lamar Zanetta S, 2011, J Int Assoc Physicians AIDS Care (Chic), V10, P183, DOI 10.1177/1545109711401411; Lopez-Lopez E, 2011, PEDIATR BLOOD CANCER, V57, P612, DOI 10.1002/pbc.23074; Lopman B, 2010, J EPIDEMIOL COMMUN H, V64, P330, DOI 10.1136/jech.2008.081554; Mankhatitham W, 2011, SE ASIAN J TROP MED, V42, P651; Matee MIN, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-21; Mirghani RA, 2006, PHARMACOGENET GENOM, V16, P637, DOI 10.1097/01.fpc.0000230411.89973.1b; Mugusi SF, 2012, ANTIVIR THER, V17, P265, DOI 10.3851/IMP1956; Mukonzo JK, 2009, BRIT J CLIN PHARMACO, V68, P690, DOI 10.1111/j.1365-2125.2009.03516.x; Nelson M, 2003, AIDS, V17, pF7, DOI 10.1097/00002030-200301030-00002; Ngaimisi E, 2011, CLIN PHARMACOL THER, V90, P406, DOI 10.1038/clpt.2011.129; Ngaimisi E, 2010, CLIN PHARMACOL THER, V88, P676, DOI 10.1038/clpt.2010.172; Nyakutira C, 2008, EUR J CLIN PHARMACOL, V64, P357, DOI 10.1007/s00228-007-0412-3; Ocama P, 2010, INT J STD AIDS, V21, P553, DOI 10.1258/ijsa.2010.010027; Patel A, 2004, JAIDS-J ACQ IMM DEF, V37, P1166, DOI 10.1097/01.qai.0000135956.96166.f0; Pukenyte E, 2007, INT J TUBERC LUNG D, V11, P78; Russmann S, 2010, HEPATOLOGY, V52, P748, DOI 10.1002/hep.23720; Saukkonen JJ, 2006, AM J RESP CRIT CARE, V174, P935, DOI 10.1164/rccm.200510-1666ST; Shipton LK, 2009, INT J TUBERC LUNG D, V13, P360; Singla R, 2010, INDIAN J MED RES, V132, P81; Soleman N, 2006, B WORLD HEALTH ORGAN, V84, P239, DOI 10.2471/BLT.05.027003; Stine JG, 2011, EXPERT OPIN DRUG MET, V7, P875, DOI 10.1517/17425255.2011.577415; Tostmann A, 2007, TROP MED INT HEALTH, V12, P852, DOI 10.1111/j.1365-3156.2007.01871.x; Tostmann A, 2008, J GASTROEN HEPATOL, V23, P192, DOI 10.1111/j.1440-1746.2007.05207.x; Tostmann A, 2010, TROP MED INT HEALTH, V15, P268, DOI 10.1111/j.1365-3156.2009.02449.x; Turkova A, 2009, J ANTIMICROB CHEMOTH, V63, P623, DOI 10.1093/jac/dkn548; Ungo JR, 1998, AM J RESP CRIT CARE, V157, P1871, DOI 10.1164/ajrccm.157.6.9711039; Voora D, 2009, J AM COLL CARDIOL, V54, P1609, DOI 10.1016/j.jacc.2009.04.053; Wares DF, 2003, INT J TUBERC LUNG D, V7, P327; World Health Organization, WHOHTMTB2009420, V4th; Yimer G, 2012, PHARMACOGENOMICS J, V12, P499, DOI 10.1038/tpj.2011.34; Yimer G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027810; Yimer G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001809	52	43	46	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2012	7	7							e40180	10.1371/journal.pone.0040180	http://dx.doi.org/10.1371/journal.pone.0040180			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973LU	22808112	Green Published, gold			2023-01-03	WOS:000306362400032
J	Pang, S; Duan, LS; Liu, ZQ; Song, XY; Li, XF; Wang, CJ				Pang, Sen; Duan, Liusheng; Liu, Zhiqian; Song, Xiaoyu; Li, Xuefeng; Wang, Chengju			Co-Induction of a Glutathione-S-transferase, a Glutathione Transporter and an ABC Transporter in Maize by Xenobiotics	PLOS ONE			English	Article							RESISTANCE-ASSOCIATED PROTEIN; HERBICIDE RESISTANCE; DETOXIFICATION; DERIVATIVES; EXPRESSION; SAFENERS; ENZYMES; FAMILY; GENE	Glutathione conjugation reactions are one of the principal mechanisms that plants utilize to detoxify xenobiotics. The induction by four herbicides (2,4-D, atrazine, metolachlor and primisulfuron) and a herbicide safener (dichlormid) on the expression of three genes, ZmGST27, ZmGT1 and ZmMRP1, encoding respectively a glutathione-S-transferase, a glutathione transporter and an ATP-binding cassette (ABC) transporter was studied in maize. The results demonstrate that the inducing effect on gene expression varies with both chemicals and genes. The expression of ZmGST27 and ZmMRP1 was up-regulated by all five compounds, whereas that of ZmGT1 was increased by atrazine, metolachlor, primisulfuron and dichlormid, but not by 2,4-D. For all chemicals, the inducing effect was first detected on ZmGST27. The finding that ZmGT1 is activated alongside ZmGST27 and ZmMRP1 suggests that glutathione transporters are an important component in the xenobiotic detoxification system of plants.	[Pang, Sen; Duan, Liusheng] China Agr Univ, Engn Res Ctr Plant Growth Regulators, Minist Educ, Coll Agron & Biotechnol, Beijing 100094, Peoples R China; [Pang, Sen; Song, Xiaoyu; Li, Xuefeng; Wang, Chengju] China Agr Univ, Coll Sci, Beijing 100094, Peoples R China; [Liu, Zhiqian] Victorian AgriBiosci Ctr, Dept Primary Ind, Biosci Res Div, Bundoora, Vic, Australia	China Agricultural University; China Agricultural University; Victorian Department of Environment & Primary Industries	Pang, S (corresponding author), China Agr Univ, Engn Res Ctr Plant Growth Regulators, Minist Educ, Coll Agron & Biotechnol, Beijing 100094, Peoples R China.	lixuefeng2007@163.com; Wangchengju@cau.edu.cn	Duan, Liusheng/F-8954-2011	Duan, Liusheng/0000-0003-0323-9378	Chinese Universities Scientific Fund [2011JS001]	Chinese Universities Scientific Fund	This study was supported by Chinese Universities Scientific Fund (Project No. 2011JS001). The funders had no role in study design, data collection and analysis, decision to publish, or prepatation of the manuscript.	ALSCHER RG, 1989, PHYSIOL PLANTARUM, V77, P457, DOI 10.1111/j.1399-3054.1989.tb05667.x; ANDERSON MP, 1991, PLANT PHYSIOL, V96, P104, DOI 10.1104/pp.96.1.104; Basantani M, 2011, PESTIC BIOCHEM PHYS, V99, P111, DOI 10.1016/j.pestbp.2010.11.007; BRISTOL DW, 1977, J AGR FOOD CHEM, V25, P1308, DOI 10.1021/jf60214a008; Cagnac O, 2004, PLANT PHYSIOL, V135, P1378, DOI 10.1104/pp.104.039859; Coleman JOD, 1997, TRENDS PLANT SCI, V2, P144, DOI 10.1016/S1360-1385(97)01019-4; Davies J, 1999, PESTIC SCI, V55, P1043, DOI 10.1002/(SICI)1096-9063(199911)55:11&lt;1043::AID-PS60&gt;3.0.CO;2-L; Del Buono D, 2006, PESTIC BIOCHEM PHYS, V85, P61, DOI 10.1016/j.pestbp.2005.09.006; Edwards R, 2000, TRENDS PLANT SCI, V5, P193, DOI 10.1016/S1360-1385(00)01601-0; Edwards R, 1996, PESTIC BIOCHEM PHYS, V54, P96, DOI 10.1006/pest.1996.0013; GAILLARD C, 1994, FEBS LETT, V352, P219, DOI 10.1016/0014-5793(94)00961-9; Hatton PJ, 1996, PESTIC SCI, V46, P267, DOI 10.1002/(SICI)1096-9063(199603)46:3&lt;267::AID-PS347&gt;3.0.CO;2-N; Hatzios KK, 2004, WEED SCI, V52, P454, DOI 10.1614/P2002-168C; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; JEPSON I, 1994, PLANT MOL BIOL, V26, P1855, DOI 10.1007/BF00019498; Klein M, 2006, FEBS LETT, V580, P1112, DOI 10.1016/j.febslet.2005.11.056; Letouze A, 2003, AGRONOMIE, V23, P601, DOI 10.1051/agro:2003036; Lu YP, 1997, P NATL ACAD SCI USA, V94, P8243, DOI 10.1073/pnas.94.15.8243; Marrs KA, 1996, ANNU REV PLANT PHYS, V47, P127, DOI 10.1146/annurev.arplant.47.1.127; MILLER KD, 1994, PESTIC BIOCHEM PHYS, V48, P123, DOI 10.1006/pest.1994.1013; Pang S, 2012, J FOOD AGRIC ENVIRON, V10, P621; Pang S, 2010, PROG BIOCHEM BIOPHYS, V37, P1120, DOI 10.3724/SP.J.1206.2010.00188; Riechers DE, 2010, PLANT PHYSIOL, V153, P3, DOI 10.1104/pp.110.153601; Scarponi L, 2005, J AGR FOOD CHEM, V53, P2483, DOI 10.1021/jf047948n; Swarbreck D, 2003, GENE, V315, P153, DOI 10.1016/S0378-1119(03)00734-0; Theodoulou FL, 2003, PEST MANAG SCI, V59, P202, DOI 10.1002/ps.576; TIMMERMAN KP, 1989, PHYSIOL PLANTARUM, V77, P465, DOI 10.1111/j.1399-3054.1989.tb05668.x; Yuan JS, 2007, TRENDS PLANT SCI, V12, P6, DOI 10.1016/j.tplants.2006.11.001; Zhang MY, 2004, PLANT PHYSIOL, V134, P482, DOI 10.1104/pp.103.030940	29	25	27	1	52	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2012	7	7							e40712	10.1371/journal.pone.0040712	http://dx.doi.org/10.1371/journal.pone.0040712			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973LU	22792398	Green Published, gold, Green Submitted			2023-01-03	WOS:000306362400094
J	Asch, DA; Muller, RW; Volpp, KG				Asch, David A.; Muller, Ralph W.; Volpp, Kevin G.			Automated Hovering in Health Care - Watching Over the 5000 Hours	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							FINANCIAL INCENTIVES		[Asch, David A.; Volpp, Kevin G.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA; [Asch, David A.; Muller, Ralph W.; Volpp, Kevin G.] Univ Penn, Hlth Syst Ctr Innovat Hlth Care Financing, Philadelphia, PA 19104 USA; [Asch, David A.; Volpp, Kevin G.] Univ Penn, Penn CMU Roybal Ctr Behav Econ & Hlth P30, Philadelphia, PA 19104 USA; [Asch, David A.; Muller, Ralph W.; Volpp, Kevin G.] Univ Penn, Ctr Hlth Incent & Behav Econ, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; [Asch, David A.; Volpp, Kevin G.] Univ Penn, Perelman Sch, Philadelphia, PA 19104 USA; [Asch, David A.; Volpp, Kevin G.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; Pennsylvania Medicine; Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; Carnegie Mellon University; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Asch, DA (corresponding author), Univ Penn, Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA.			Asch, David/0000-0002-7970-286X; Volpp, Kevin/0000-0003-1423-4599				Gawande Atul, 2011, NEW YORKER      0124; Long JA, 2012, ANN INTERN MED, V156, P416, DOI 10.7326/0003-4819-156-6-201203200-00004; McGinnis JM, 2002, HEALTH AFFAIR, V21, P78, DOI 10.1377/hlthaff.21.2.78; Volpp KG, 2011, NEW ENGL J MED, V365, P388, DOI 10.1056/NEJMp1105966; Volpp KG, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-272	5	119	119	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 5	2012	367	1					1	3		10.1056/NEJMp1203869	http://dx.doi.org/10.1056/NEJMp1203869			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	968KJ	22716935	Green Published			2023-01-03	WOS:000305979400014
J	Reynolds, EE; Trivedi, NS				Reynolds, Eileen E.; Trivedi, Neha S.			Update: A 47-Year-Old Woman With an Indwelling Intravenous Catheter and Sepsis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MANAGEMENT							Trivedi, Neha/0000-0003-1006-1408				Angus DC, 2011, JAMA-J AM MED ASSOC, V305, P1469, DOI 10.1001/jama.2011.438; Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41	2	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2012	308	1					82	82		10.1001/jama.2012.6665	http://dx.doi.org/10.1001/jama.2012.6665			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971DD	22760292	Green Accepted			2023-01-03	WOS:000306183000027
J	Perkins, GD; Kimani, PK; Bullock, I; Clutton-Brock, T; Davies, RP; Gale, M; Lam, J; Lockey, A; Stallard, N				Perkins, Gavin D.; Kimani, Peter K.; Bullock, Ian; Clutton-Brock, Tom; Davies, Robin P.; Gale, Mike; Lam, Jenny; Lockey, Andrew; Stallard, Nigel		Elect Adv Life Support Collaborato	Improving the Efficiency of Advanced Life Support Training A Randomized, Controlled Trial	ANNALS OF INTERNAL MEDICINE			English	Article							PERSONAL RESUSCITATION MANNEQUIN; CARDIAC-ARREST; CORE COMPETENCES; CARE; EDUCATION; SIMULATION; SKILLS; GUIDELINES; STATEMENT; CONSENSUS	Background: Each year, more than 1.5 million health care professionals receive advanced life support (ALS) training. Objective: To determine whether a blended approach to ALS training that includes electronic learning (e-learning) produces outcomes similar to those of conventional, instructor-led ALS training. Design: Open-label, noninferiority, randomized trial. Randomization, stratified by site, was generated by Sealed Envelope (Sealed Envelope, London, United Kingdom). (International Standardized Randomized Controlled Trial Number Register: ISCRTN86380392) Setting: 31 ALS centers in the United Kingdom and Australia. Participants: 3732 health care professionals recruited between December 2008 and October 2010. Intervention: A 1-day course supplemented with e-learning versus a conventional 2-day course. Measurements: The primary outcome was performance in a cardiac arrest simulation test at the end of the course. Secondary outcomes comprised knowledge- and skill-based assessments, repeated assessment after remediation training, and resource use. Results: 440 of the 1843 participants randomly assigned to the blended course and 444 of the 1889 participants randomly assigned to conventional training did not attend the courses. Performance in the cardiac arrest simulation test after course attendance was lower in the electronic advanced life support (e-ALS) group compared with the conventional advanced life support (c-ALS) group; 1033 persons (74.5%) in the e-ALS group and 1146 persons (80.2%) in the c-ALS group passed (mean difference, -5.7% [95% CI, -8.8% to -2.7%]). Knowledge- and skill-based assessments were similar between groups, as was the final pass rate after remedial teaching, which was 94.2% in the e-ALS group and 96.7% in the c-ALS group (mean difference, -2.6% [CI, -4.1% to 1.2%]). Faculty, catering, and facility costs were $438 per participant for electronic ALS training and $935 for conventional ALS training. Limitations: Many professionals (24%) did not attend the courses. The effect on patient outcomes was not evaluated. Conclusion: Compared with conventional ALS training, an approach that included e-learning led to a slightly lower pass rate for cardiac arrest simulation tests, similar scores on a knowledge test, and reduced costs.	[Perkins, Gavin D.] Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England; Heart England NHS Fdn Trust, Birmingham, W Midlands, England; Royal Coll Physicians, Natl Clin Guideline Ctr, London, England; Resuscitat Council, London, England; Univ Birmingham, Med Sch Birmingham, Birmingham B15 2TT, W Midlands, England; Calderdale Royal Hosp, Salterhebble, Halifax, England; Australian Resuscitat Council, Melbourne, Vic, Australia	University of Warwick; Heart of England NHS Foundation Trust; Royal College of Physicians; University of Birmingham	Perkins, GD (corresponding author), Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England.	g.d.perkins@warwick.ac.uk	Morley, Peter/G-5280-2017; Perkins, Gavin/E-7613-2010	Morley, Peter/0000-0003-2653-090X; Lockey, Andrew/0000-0002-3900-6317; Kimani, Peter/0000-0001-8200-3173; Williams, Daryl/0000-0002-6987-5804; Perkins, Gavin/0000-0003-3027-7548; Davies, Robin/0000-0003-1773-7642; Stallard, Nigel/0000-0001-7781-1512	National Institute of Health Research; Resuscitation Council (UK); National Institute of Health Research Clinician Scientist Award	National Institute of Health Research(National Institute for Health Research (NIHR)); Resuscitation Council (UK); National Institute of Health Research Clinician Scientist Award	National Institute of Health Research and Resuscitation Council (UK).; The study was funded with a grant from the Resuscitation Council (UK). Dr. Perkins was supported by a National Institute of Health Research Clinician Scientist Award.	Barrett H, 2006, INTENS CARE MED, V32, P1371, DOI 10.1007/s00134-006-0215-5; Bjorshol CA, 2009, RESUSCITATION, V80, P898, DOI 10.1016/j.resuscitation.2009.06.009; Cook DA, 2008, JAMA-J AM MED ASSOC, V300, P1181, DOI 10.1001/jama.300.10.1181; Cook DA, 2010, MED EDUC, V44, P765, DOI 10.1111/j.1365-2923.2010.03723.x; Cooper S, 1999, RESUSCITATION, V42, P27, DOI 10.1016/S0300-9572(99)00080-5; Curtis L., UNIT COSTS HLTH SOCI; de Vries W, 2007, RESUSCITATION, V75, P491, DOI 10.1016/j.resuscitation.2007.05.014; Delasobera BE, 2010, RESUSCITATION, V81, P217, DOI 10.1016/j.resuscitation.2009.10.013; Finn J, 2010, RESUSCITATION, V81, P790, DOI 10.1016/j.resuscitation.2010.05.010; Flin R, 2010, BRIT J ANAESTH, V105, P38, DOI 10.1093/bja/aeq134; Gagnon Marie-Pierre, 2007, Inform Prim Care, V15, P83; Graubard BI, 1999, BIOMETRICS, V55, P652, DOI 10.1111/j.0006-341X.1999.00652.x; Hawkes N, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2333; Isbye DL, 2006, RESUSCITATION, V69, P435, DOI 10.1016/j.resuscitation.2005.10.027; Jensen ML, 2009, RESUSCITATION, V80, P903, DOI 10.1016/j.resuscitation.2009.06.005; Kamin C, 2006, ACAD MED, V81, P632, DOI 10.1097/01.ACM.0000232413.43142.8b; LaVange LM, 2001, STAT MED, V20, P2609, DOI 10.1002/sim.732; Moretti MA, 2007, RESUSCITATION, V72, P458, DOI 10.1016/j.resuscitation.2006.06.039; Moule P, 2010, J ADV NURS, V66, P2785, DOI 10.1111/j.1365-2648.2010.05453.x; Napier F, 2009, RESUSCITATION, V80, P1034, DOI 10.1016/j.resuscitation.2009.04.043; O'Dowd A, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b5330; Perkins Gavin, 2002, BMJ, V325, pS81; Perkins GD, 2007, RESUSCITATION, V75, P484, DOI 10.1016/j.resuscitation.2007.05.020; Perkins GD, 2007, RESUSCITATION, V73, P202, DOI 10.1016/j.resuscitation.2007.01.005; Perkins GD, 2010, RESUSCITATION, V81, P877, DOI 10.1016/j.resuscitation.2010.03.019; Perkins GD, 2005, INTENS CARE MED, V31, P1627, DOI 10.1007/s00134-005-2837-4; Piaggio G, 2006, JAMA-J AM MED ASSOC, V295, P1152, DOI 10.1001/jama.295.10.1152; Sandars J., 2010, BMJ-BRIT MED J, V341, pc5214; SCHNEIDER T, 1995, RESUSCITATION, V29, P129, DOI 10.1016/0300-9572(94)00833-2; Schulz KF, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-32; Smith CM, 2007, INTENS CARE MED, V33, P901, DOI 10.1007/s00134-007-0564-8; Soar J, 2010, RESUSCITATION, V81, pE288, DOI 10.1016/j.resuscitation.2010.08.030; Soar J, 2010, RESUSCITATION, V81, P1434, DOI 10.1016/j.resuscitation.2010.08.014; Spearpoint KG, 2009, RESUSCITATION, V80, P638, DOI 10.1016/j.resuscitation.2009.03.002; Yeung JH, 2012, CRIT CARE M IN PRESS, V40; Yeung J, 2011, RESUSCITATION, V82, P657, DOI 10.1016/j.resuscitation.2011.02.035	36	63	66	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2012	157	1					19	28		10.7326/0003-4819-157-1-201207030-00005	http://dx.doi.org/10.7326/0003-4819-157-1-201207030-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992NS	22751757				2023-01-03	WOS:000307784900003
J	Pathak, A; Mahadik, K; Dhaneria, SP; Sharma, A; Eriksson, B; Lundborg, CS				Pathak, Ashish; Mahadik, Kalpana; Dhaneria, Surya Prakesh; Sharma, Ashish; Eriksson, Bo; Lundborg, Cecilia Stalsby			Surveillance of Antibiotic Consumption Using the "Focus of Infection" Approach in 2 Hospitals in Ujjain, India	PLOS ONE			English	Article							ANTIMICROBIAL USE; UNITED-STATES; RESISTANCE; GUIDELINES; ADULTS; MANAGEMENT; CHILDREN; SOCIETY; EUROPE	Antibiotic surveillance initiatives are limited in resource-constrained settings. In the present study, a quantitative comparison of antibiotic use rates for suspected infections in 2 hospitals in India was performed using the "focus of infection" approach to identify targets for quality improvement in antibiotic prescription patterns in hospitalized patients. Methods: This observational study was carried out in one teaching and one nonteaching hospital. All the patients with suspected bacterial etiology were included. Data on the prescribed antibiotics and the focus of infection were prospectively collected using a structured questionnaire. Each diagnosis was further reviewed and confirmed by an independent consultant. The prescribed antibiotics were coded according to the World Health Organization Anatomic Therapeutic Classification (ATC) index with the defined daily dose (DDD) methodology. Focus-specific DDDs were calculated per hundred patient days (DDD/HPD). Results: A total of 6026 patients were included from 72 participating physicians out of available 75 physicians. Overall antibiotic prescribing was higher by 5 percentage points in the teaching hospital (95%) than in the nonteaching hospital (90%). Quinolones (ciprofloxacin constituting 86% of DDD/HPD) were the highest prescribed class in the teaching hospital, and third-generation cephalosporins (with ceftriaxone and ceftriaxone/sulbactam constituting 40% and 28% of the DDD/HPD, respectively), in the nonteaching hospital. The targets identified for improvement were the following: longer than recommended duration of prophylaxis and lack of distinction between prophylaxis and therapy among surgical patients; irrational antibiotic prescribing in gastroenteritis; overuse of quinolones and lack of use of penicillin in pneumonia; overuse of quinolones and lack of use of doxycycline and macrolides in genital infections; and overreliance on antibiotics for treating skin and soft tissue infections. Conclusions: Providing a quantitative comparison of antibiotic use rates for suspected infections, using the "focus of infection" approach along with the ATC/DDD methodology, appears appropriate for identifying targets for quality improvement with regards to antibiotic prescribing.	[Pathak, Ashish; Lundborg, Cecilia Stalsby] Karolinska Inst, Dept Publ Hlth Sci, Div Global Hlth IHCAR, Stockholm, Sweden; [Pathak, Ashish] RD Gardi Med Coll, Dept Pediat, Ujjain, Madhya Pradesh, India; [Mahadik, Kalpana] RD Gardi Med Coll, Dept Obstet & Gynaecol, Ujjain, Madhya Pradesh, India; [Dhaneria, Surya Prakesh] RD Gardi Med Coll, Dept Pharmacol, Ujjain, Madhya Pradesh, India; [Sharma, Ashish] RD Gardi Med Coll, Dept Med, Ujjain, Madhya Pradesh, India; [Eriksson, Bo] Nord Sch Publ Hlth, Gothenburg, Sweden	Karolinska Institutet	Pathak, A (corresponding author), Karolinska Inst, Dept Publ Hlth Sci, Div Global Hlth IHCAR, Stockholm, Sweden.	ashish.pathak@ki.se	Pathak, Ashish/N-2303-2019; Sharma, Ashish/AAJ-2955-2021; Mahadik, Kalpana/AAY-2389-2021; Pathak, Ashish/Y-1821-2019	Pathak, Ashish/0000-0002-7576-895X; Stalsby Lundborg, Cecilia/0000-0001-6525-1861	Swedish Research Council, Sweden [K2007-70X-20514-01-3]; Asia Link [348-2006-6633]	Swedish Research Council, Sweden(Swedish Research Council); Asia Link	This study was supported by a grant from the Swedish Research Council, Sweden (grant number K2007-70X-20514-01-3), and the Asia Link (grant number 348-2006-6633). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abad Cybele L, 2011, Crit Care Clin, V27, pe1, DOI 10.1016/j.ccc.2010.12.001; Ansari F, 2009, CLIN INFECT DIS, V49, P1496, DOI 10.1086/644617; Ashley EA, 2011, TROP MED INT HEALTH, V16, P1167, DOI 10.1111/j.1365-3156.2011.02822.x; Bager F, 2000, INT J ANTIMICROB AG, V14, P271, DOI 10.1016/S0924-8579(00)00135-7; de With K, 2004, INT J ANTIMICROB AG, V24, P213, DOI 10.1016/j.ijantimicag.2004.03.015; Deshpande K, 2004, HEALTH POLICY, V68, P211, DOI 10.1016/j.healthpol.2003.09.012; Dumartin C, 2010, J ANTIMICROB CHEMOTH, V65, P2028, DOI 10.1093/jac/dkq228; Erntell M, 2004, STRAMA POINT PREVELE; Fridkin SK, 1999, CLIN INFECT DIS, V29, P245, DOI 10.1086/520193; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; Hadi U, 2008, CLIN MICROBIOL INFEC, V14, P698, DOI 10.1111/j.1469-0691.2008.02014.x; Jaiyeoba O, 2011, EXPERT REV ANTI-INFE, V9, P61, DOI [10.1586/eri.10.156, 10.1586/ERI.10.156]; Kritsotakis EI, 2006, CLIN MICROBIOL INFEC, V12, P701, DOI 10.1111/j.1469-0691.2006.01415.x; Levy ML, 2010, PRIM CARE RESP J, V19, P21, DOI 10.4104/pcrj.2010.00014; Liu C, 2011, CLIN INFECT DIS, V52, P285, DOI 10.1093/cid/cir034; Mazuski JE, 2007, EXPERT OPIN PHARMACO, V8, P2933, DOI 10.1517/14656566.8.17.2933; Molstad S, 2008, LANCET INFECT DIS, V8, P125, DOI 10.1016/S1473-3099(08)70017-3; Pakyz A, 2008, PHARMACOTHERAPY, V28, P906, DOI 10.1592/phco.28.7.906; Pathak A, 2011, SCAND J INFECT DIS, V43, P479, DOI 10.3109/00365548.2011.554854; Pathak D, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-32; Pittet D, 2008, J HOSP INFECT, V68, P285, DOI 10.1016/j.jhin.2007.12.013; Ramakrishnan K, 2005, AM FAM PHYSICIAN, V71, P933; Reddy KS, 2011, LANCET, V377, P760, DOI 10.1016/S0140-6736(10)61960-5; Song JH, 2011, INT J ANTIMICROB AG, V38, P108, DOI 10.1016/j.ijantimicag.2011.02.017; The National Policy for Containment of Antimicrobial Resistance India, 2011, NAT POL CONT ANT RES; Verbrugh HA, 2003, NETH J MED, V61, P341; *WHO COLL CTR DRUG, 2009, AN THER CHEM ATC CLA; World Health Organization, 2005, IMPR CONT ANT RES WH; Zarb P, 2011, DRUGS, V71, P745, DOI 10.2165/11591180-000000000-00000	29	16	16	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2012	7	6							e38641	10.1371/journal.pone.0038641	http://dx.doi.org/10.1371/journal.pone.0038641			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TQ	22715402	gold, Green Published, Green Submitted			2023-01-03	WOS:000305336800044
J	Yu, H; Chen, JX; Xu, X; Li, Y; Zhao, HH; Fang, YP; Li, XX; Zhou, W; Wang, W; Wang, YH				Yu, Hua; Chen, Jianxin; Xu, Xue; Li, Yan; Zhao, Huihui; Fang, Yupeng; Li, Xiuxiu; Zhou, Wei; Wang, Wei; Wang, Yonghua			A Systematic Prediction of Multiple Drug-Target Interactions from Chemical, Genomic, and Pharmacological Data	PLOS ONE			English	Article							DIVERSITY-ORIENTED SYNTHESIS; SUPPORT VECTOR MACHINE; SIMPLEX-VIRUS TYPE-1; 3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; PROTEIN INTERACTIONS; INTERACTION NETWORKS; INHIBITORY-ACTIVITY; THYMIDINE KINASE; GENE-EXPRESSION; RANDOM FOREST	In silico prediction of drug-target interactions from heterogeneous biological data can advance our system-level search for drug molecules and therapeutic targets, which efforts have not yet reached full fruition. In this work, we report a systematic approach that efficiently integrates the chemical, genomic, and pharmacological information for drug targeting and discovery on a large scale, based on two powerful methods of Random Forest (RF) and Support Vector Machine (SVM). The performance of the derived models was evaluated and verified with internally five-fold cross-validation and four external independent validations. The optimal models show impressive performance of prediction for drug-target interactions, with a concordance of 82.83%, a sensitivity of 81.33%, and a specificity of 93.62%, respectively. The consistence of the performances of the RF and SVM models demonstrates the reliability and robustness of the obtained models. In addition, the validated models were employed to systematically predict known/unknown drugs and targets involving the enzymes, ion channels, GPCRs, and nuclear receptors, which can be further mapped to functional ontologies such as target-disease associations and target-target interaction networks. This approach is expected to help fill the existing gap between chemical genomics and network pharmacology and thus accelerate the drug discovery processes.	[Yu, Hua; Xu, Xue; Fang, Yupeng; Li, Xiuxiu; Zhou, Wei; Wang, Yonghua] NW A&F Univ, Coll Life Sci, Bioinformat Ctr, Yangling, Shaanxi, Peoples R China; [Chen, Jianxin; Zhao, Huihui; Wang, Wei] Beijing Univ Chinese Med, Beijing, Peoples R China; [Li, Yan] Dalian Univ Technol, Dept Chem Engn & Mat Sci, Dalian, Peoples R China; [Wang, Yonghua] NW A&F Univ, State Key Lab Crop Stress Biol Arid Areas, Yangling, Shaanxi, Peoples R China; [Wang, Yonghua] NW A&F Univ, Coll Plant Protect, Yangling, Shaanxi, Peoples R China	Northwest A&F University - China; Beijing University of Chinese Medicine; Dalian University of Technology; Northwest A&F University - China; Northwest A&F University - China	Yu, H (corresponding author), NW A&F Univ, Coll Life Sci, Bioinformat Ctr, Yangling, Shaanxi, Peoples R China.	wangwei@bucm.edu.cn; yh_wang@nwsuaf.edu.cn	Li, Yuan/GXV-1310-2022; Chen, Jianxin/G-5881-2015; Li, Yang/GWM-7879-2022; , Paulin/U-9063-2019; li, yong/HDN-3885-2022	Chen, Jianxin/0000-0003-4067-5638; , Paulin/0000-0001-6045-3712; 	National Natural Science Foundation of China [31170796]; Youth Fund of Northwest A F University; National Basic Research Program of China (973 Program) [2011CB505106]; National Department Public Benefit Research Foundation [200807007]; International Science and Technology Cooperation of China [2008DFA30610]; National Science Foundation of China [30902020, 81173463, 81102730]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Youth Fund of Northwest A F University; National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Department Public Benefit Research Foundation; International Science and Technology Cooperation of China; National Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work is financially supported by the National Natural Science Foundation of China (Grant No. 31170796) and also the Youth Fund of Northwest A & F University. This work was partially supported by the National Basic Research Program of China (973 Program) under grant No. 2011CB505106, the National Department Public Benefit Research Foundation (200807007), the International Science and Technology Cooperation of China (2008DFA30610), and the National Science Foundation of China (30902020, 81173463 and 81102730). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ackerstaff E, 2007, NEOPLASIA, V9, P222, DOI 10.1593/neo.06673; Balakin KV, 2002, J CHEM INF COMP SCI, V42, P1332, DOI 10.1021/ci025538y; Baldi P, 2000, BIOINFORMATICS, V16, P412, DOI 10.1093/bioinformatics/16.5.412; Ballesteros J, 2001, Curr Opin Drug Discov Devel, V4, P561; Biezonski DK, 2010, J NEUROCHEM, V112, P951, DOI 10.1111/j.1471-4159.2009.06515.x; Bock JR, 2005, J CHEM INF MODEL, V45, P1402, DOI 10.1021/ci050006d; Bock JR, 2001, BIOINFORMATICS, V17, P455, DOI 10.1093/bioinformatics/17.5.455; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; BRIDGES CC, 1966, PSYCHOL REP, V18, P851, DOI 10.2466/pr0.1966.18.3.851; Burbidge R, 2001, COMPUT CHEM, V26, P5, DOI 10.1016/S0097-8485(01)00094-8; Buryanovskyy L, 2004, BIOCHEMISTRY-US, V43, P11417, DOI 10.1021/bi049162o; Byvatov E, 2003, J CHEM INF COMP SCI, V43, P1882, DOI 10.1021/ci0341161; Chen X, 2002, NUCLEIC ACIDS RES, V30, P412, DOI 10.1093/nar/30.1.412; Chou KC, 2000, BIOCHEM BIOPH RES CO, V278, P477, DOI 10.1006/bbrc.2000.3815; Datta S, 2003, BIOINFORMATICS, V19, P459, DOI 10.1093/bioinformatics/btg025; Dobson CM, 2004, NATURE, V432, P824, DOI 10.1038/nature03192; Dong J, 2007, BMC SYST BIOL, V1, DOI 10.1186/1752-0509-1-24; Donnelly LE, 2004, AM J PHYSIOL-LUNG C, V287, pL774, DOI 10.1152/ajplung.00110.2004; Doucet JP, 2007, CURR COMPUT-AID DRUG, V3, P263, DOI 10.2174/157340907782799372; Erhan D, 2006, J CHEM INF MODEL, V46, P626, DOI 10.1021/ci050367t; Fleckenstein AE, 2007, ANNU REV PHARMACOL, V47, P681, DOI 10.1146/annurev.pharmtox.47.120505.105140; Frantz S, 2005, NATURE, V437, P942, DOI 10.1038/437942a; Frimurer TM, 2005, BIOORG MED CHEM LETT, V15, P3707, DOI 10.1016/j.bmcl.2005.05.102; Haggarty SJ, 2003, CHEM BIOL, V10, P383, DOI 10.1016/S1074-5521(03)00095-4; Han LY, 2004, NUCLEIC ACIDS RES, V32, P6437, DOI 10.1093/nar/gkh984; Hansen JP, 2002, J PHARMACOL EXP THER, V300, P1093, DOI 10.1124/jpet.300.3.1093; Hao M, 2011, INT J MOL SCI, V12, P1259, DOI 10.3390/ijms12021259; Hao M, 2010, INT J MOL SCI, V11, P3413, DOI 10.3390/ijms11093413; He ZS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009603; Imming P, 2006, NAT REV DRUG DISCOV, V5, P821, DOI 10.1038/nrd2132; Jacob L, 2008, BIOINFORMATICS, V24, P2149, DOI 10.1093/bioinformatics/btn409; Jacoby E, 2003, DRUG NEWS PERSPECT, V16, P93, DOI 10.1358/dnp.2003.16.2.829326; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Karchin R, 2002, BIOINFORMATICS, V18, P147, DOI 10.1093/bioinformatics/18.1.147; KAUFMAN HE, 1985, OPHTHALMOLOGY, V92, P533; KLABUNDE T, 2006, LIGAND DESIGN G PROT, P115; Krejsa CM, 2003, CURR OPIN DRUG DISC, V6, P470; Kuruvilla FG, 2002, NATURE, V416, P653, DOI 10.1038/416653a; Li Y, 2009, QSAR COMB SCI, V28, P396, DOI 10.1002/qsar.200810100; Li YY, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002139; Li ZR, 2006, NUCLEIC ACIDS RES, V34, pW32, DOI 10.1093/nar/gkl305; Lipinski C, 2004, NATURE, V432, P855, DOI 10.1038/nature03193; LYON RA, 1986, PSYCHOPHARMACOLOGY, V88, P525; MacDonald ML, 2006, NAT CHEM BIOL, V2, P329, DOI 10.1038/nchembio790; Mithoefer MC, 2011, J PSYCHOPHARMACOL, V25, P439, DOI 10.1177/0269881110378371; Nagamine M, 2000, J CLIN MICROBIOL, V38, P2750, DOI 10.1128/JCM.38.7.2750-2752.2000; Nagamine N, 2007, BIOINFORMATICS, V23, P2004, DOI 10.1093/bioinformatics/btm266; Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199; Paolini GV, 2006, NAT BIOTECHNOL, V24, P805, DOI 10.1038/nbt1228; Paul SM, 2010, NAT REV DRUG DISCOV, V9, P203, DOI 10.1038/nrd3078; Platt JC, 1999, ADVANCES IN KERNEL METHODS, P185; Roth BL, 2004, NAT REV DRUG DISCOV, V3, P353, DOI 10.1038/nrd1346; Satoh T, 2004, INT J RADIAT ONCOL, V59, P562, DOI 10.1016/j.ijrobp.2004.01.020; Schmitt BM, 2004, CHEMBIOCHEM, V5, P1384, DOI 10.1002/cbic.200400126; Selken J, 2007, PHARMACOL BIOCHEM BE, V86, P622, DOI 10.1016/j.pbb.2007.02.006; Shankaran H, 1999, EUR J PHARMACOL, V385, P103, DOI 10.1016/S0014-2999(99)00728-1; Sprague JE, 2003, J PHARMACOL EXP THER, V305, P159, DOI 10.1124/jpet.102.044982; Sun XL, 2008, MOL DIVERS, V12, P157, DOI 10.1007/s11030-008-9092-x; Suzuki M, 2006, ANTIVIR RES, V72, P157, DOI 10.1016/j.antiviral.2006.05.001; Svetnik V, 2003, J CHEM INF COMP SCI, V43, P1947, DOI 10.1021/ci034160g; VANE JR, 1998, INFLAMM RES, V2, P78, DOI DOI 10.1007/S000110050284; Vapnik VN., 2000, NATURE STAT LEARNING, DOI [10.1007/978-1-4757-3264-1, DOI 10.1007/978-1-4757-3264-1_1]; Waterbury LD, 2006, CURR MED RES OPIN, V22, P1133, DOI 10.1185/030079906X112471; Wild K, 1997, PROTEIN SCI, V6, P2097; WOLD S, 1987, CHEMOMETR INTELL LAB, V2, P37, DOI 10.1016/0169-7439(87)80084-9; Xia Z, 2009, LECT NOTES OPER RES, V11, P123; Yabuuchi H, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.5; Yamanishi Y, 2008, BIOINFORMATICS, V24, pI232, DOI 10.1093/bioinformatics/btn162; Yamanishi Y, 2010, BIOINFORMATICS, V26, pi246, DOI 10.1093/bioinformatics/btq176; Yamanishi Y, 2011, J CHEM INF MODEL, V51, P1183, DOI 10.1021/ci100476q; Zhao CY, 2006, TOXICOLOGY, V217, P105, DOI 10.1016/j.tox.2005.08.019; Zhu SF, 2005, BIOINFORMATICS, V21, P245, DOI 10.1093/bioinformatics/bti1141	73	271	287	5	68	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2012	7	5							e37608	10.1371/journal.pone.0037608	http://dx.doi.org/10.1371/journal.pone.0037608			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959YF	22666371	Green Published, Green Submitted, gold			2023-01-03	WOS:000305353400036
J	Miller, KI; Qing, C; Sze, DMY; Neilan, BA				Miller, Kristin I.; Qing, Chen; Sze, Daniel Man Yuen; Neilan, Brett A.			Investigation of the Biosynthetic Potential of Endophytes in Traditional Chinese Anticancer Herbs	PLOS ONE			English	Article							POLYKETIDE SYNTHASE GENES; NONRIBOSOMAL PEPTIDE SYNTHETASES; PLANT ANTITUMOR AGENTS; FUNGAL ENDOPHYTES; NATURAL-PRODUCTS; ANTIMUTAGENIC ACTIVITY; FUTURE-PROSPECTS; ANTIBIOTICS; NRPS; INHIBITOR	Traditional Chinese medicine encompasses a rich empirical knowledge of the use of plants for the treatment of disease. In addition, the microorganisms associated with medicinal plants are also of interest as the producers of the compounds responsible for the observed plant bioactivity. The present study has pioneered the use of genetic screening to assess the potential of endophytes to synthesize bioactive compounds, as indicated by the presence of non-ribosomal peptide synthetase (NRPS) and polyketide synthase (PKS) genes. The total DNA extracts of 30 traditional Chinese herbs, were screened for functional genes involved in the biosynthesis of bioactive compounds. The four PCR screens were successful in targeting four bacterial PKS, six bacterial NRPS, ten fungal PKS and three fungal NRPS gene fragments. Analysis of the detected endophyte gene fragments afforded consideration of the possible bioactivity of the natural products produced by endophytes in medicinal herbs. This investigation describes a rapid method for the initial screening of medicinal herbs and has highlighted a subset of those plants that host endophytes with biosynthetic potential. These selected plants can be the focus of more comprehensive endophyte isolation and natural product studies.	[Miller, Kristin I.; Sze, Daniel Man Yuen] Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia; [Miller, Kristin I.; Neilan, Brett A.] Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW, Australia; [Qing, Chen] Kunming Med Univ, Yunnan Key Lab Pharmacol Nat Prod, Sch Pharmaceut Sci, Kunming, Peoples R China; [Sze, Daniel Man Yuen] Hong Kong Polytech Univ, Dept Hlth Technol & Informat, Hung Hom Kowloon, Hong Kong, Peoples R China; [Neilan, Brett A.] Univ New S Wales, Australian Ctr Astrobiol, Sydney, NSW, Australia	University of Sydney; University of New South Wales Sydney; Kunming Medical University; Hong Kong Polytechnic University; University of New South Wales Sydney	Miller, KI (corresponding author), Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia.	b.neilan@unsw.edu.au	Neilan, Brett A/I-5767-2012	Neilan, Brett A/0000-0001-6113-772X	Australia-China Special Fund for ST Cooperation [CH070067]; National Natural Science Foundation of China [30811120009]; International Cooperation Foundation of Yunnan Province of China [30811120009]; Australian Research Council [FF0883440]	Australia-China Special Fund for ST Cooperation(Australian GovernmentDepartment of Industry, Innovation and Science); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); International Cooperation Foundation of Yunnan Province of China; Australian Research Council(Australian Research Council)	KIM and DMYS were supported by the Australia-China Special Fund for S&T Cooperation (CH070067) https://grants.innovation.gov.au/ISL/Pages/Doc. aspx?name = ChinaFund.htm. CQ was financially supported by the National Natural Science Foundation of China (No. 30811120009) and the International Cooperation Foundation of Yunnan Province of China (No. 30811120009). BAN was supported by a grant and fellowship from the Australian Research Council (FF0883440) http://www.arc.gov.au/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abascal F, 2005, BIOINFORMATICS, V21, P2104, DOI 10.1093/bioinformatics/bti263; ACTON N, 1985, PLANTA MED, V51, P441, DOI 10.1055/s-2007-969543; Arnold AE, 2003, P NATL ACAD SCI USA, V100, P15649, DOI 10.1073/pnas.2533483100; Ayuso-Sacido A, 2005, MICROB ECOL, V49, P10, DOI 10.1007/s00248-004-0249-6; Bayman P, 1997, NEW PHYTOL, V135, P143, DOI 10.1046/j.1469-8137.1997.00618.x; BIANCHI C, 1975, J PHARM SCI, V64, P1305, DOI 10.1002/jps.2600640809; Bingle LEH, 1999, FUNGAL GENET BIOL, V26, P209, DOI 10.1006/fgbi.1999.1115; Brimble MA, 1999, NAT PROD REP, V16, P267, DOI 10.1039/a804287j; Burns BP, 2005, FEMS MICROBIOL LETT, V243, P293, DOI 10.1016/j.femsle.2004.12.019; Cankar K, 2005, FEMS MICROBIOL LETT, V244, P341, DOI 10.1016/j.femsle.2005.02.008; Castillo UF, 2002, MICROBIOL-SGM, V148, P2675, DOI 10.1099/00221287-148-9-2675; Chen KK, 1924, J PHARMACOL EXP THER, V24, P339; Compant S, 2005, APPL ENVIRON MICROB, V71, P4951, DOI 10.1128/AEM.71.9.4951-4959.2005; Cox RJ, 2007, ORG BIOMOL CHEM, V5, P2010, DOI 10.1039/b704420h; Davydov M, 2000, J ETHNOPHARMACOL, V72, P345, DOI 10.1016/S0378-8741(00)00181-1; de Bruijn I, 2008, J BACTERIOL, V190, P2777, DOI 10.1128/JB.01563-07; de Carvalho CCCR, 2005, APPL MICROBIOL BIOT, V67, P715, DOI 10.1007/s00253-005-1932-3; Ehrenreich IM, 2005, APPL ENVIRON MICROB, V71, P7401, DOI 10.1128/AEM.71.11.7401-7413.2005; Fischbach MA, 2006, CHEM REV, V106, P3468, DOI 10.1021/cr0503097; Gore ME, 2007, FOREST PATHOL, V37, P281, DOI 10.1111/j.1439-0329.2007.00509.x; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Ho LK, 1996, J NAT PROD, V59, P330, DOI 10.1021/np960200h; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; Hoffman MT, 2008, MYCOL RES, V112, P331, DOI 10.1016/j.mycres.2007.10.014; Huang KC, 1999, PHARM CHINESE HERBS; Ishida K, 2009, APPL ENVIRON MICROB, V75, P2017, DOI 10.1128/AEM.02258-08; Jenke-Kodama H, 2005, MOL BIOL EVOL, V22, P2027, DOI 10.1093/molbev/msi193; Johnson R, 2007, FUNGAL GENET BIOL, V44, P1180, DOI 10.1016/j.fgb.2007.04.009; Kannadan S, 2008, FUNCT ECOL, V22, P706, DOI 10.1111/j.1365-2435.2008.01395.x; Keller NP, 2005, NAT REV MICROBIOL, V3, P937, DOI 10.1038/nrmicro1286; Keller NP, 1997, FUNGAL GENET BIOL, V21, P17, DOI 10.1006/fgbi.1997.0970; Kodani S, 1998, J NAT PROD, V61, P1046, DOI 10.1021/np980106w; Kroken S, 2003, P NATL ACAD SCI USA, V100, P15670, DOI 10.1073/pnas.2532165100; Kusari S, 2011, NAT PROD REP, V28, P1203, DOI 10.1039/c1np00030f; LEE H, 1988, MUTAT RES, V204, P229, DOI 10.1016/0165-1218(88)90093-6; Leung D, 2000, J MED CHEM, V43, P305, DOI 10.1021/jm990412m; LI XW, 1986, J BIOGEOGR, V13, P367, DOI 10.2307/2844964; Liao HL, 2008, MOL PLANT MICROBE IN, V21, P469, DOI 10.1094/MPMI-21-4-0469; LIU J, 1989, J BACTERIOL, V171, P791, DOI 10.1128/jb.171.2.791-798.1989; Lopez-Lazaro M, 2003, PLANTA MED, V69, P701, DOI 10.1055/s-2003-42789; Lu YR, 2002, PHYTOCHEMISTRY, V59, P117, DOI 10.1016/S0031-9422(01)00415-0; Mankelow DP, 2000, EXPERT OPIN THER PAT, V10, P1583, DOI 10.1517/13543776.10.10.1583; Marler TE, 2005, HORTSCIENCE, V40, P1607, DOI 10.21273/HORTSCI.40.6.1607; McLeod MP, 2006, P NATL ACAD SCI USA, V103, P15582, DOI 10.1073/pnas.0607048103; Mejia LC, 2008, BIOL CONTROL, V46, P4, DOI 10.1016/j.biocontrol.2008.01.012; Miyazawa M, 1999, J AGR FOOD CHEM, V47, P2163, DOI 10.1021/jf970930a; Moffitt MC, 2001, FEMS MICROBIOL LETT, V196, P207, DOI 10.1111/j.1574-6968.2001.tb10566.x; Moore BS, 2005, ANTON LEEUW INT J G, V87, P49, DOI 10.1007/s10482-004-6541-0; Mootz HD, 2002, CHEMBIOCHEM, V3, P490, DOI 10.1002/1439-7633(20020603)3:6<490::AID-CBIC490>3.0.CO;2-N; MORIKAWA M, 1993, J BACTERIOL, V175, P6459, DOI 10.1128/JB.175.20.6459-6466.1993; Murakami M, 1997, PHYTOCHEMISTRY, V44, P449, DOI 10.1016/S0031-9422(96)00437-2; Namwat W, 2002, GENE, V286, P283, DOI 10.1016/S0378-1119(02)00424-9; Neilan BA, 1999, J BACTERIOL, V181, P4089, DOI 10.1128/JB.181.13.4089-4097.1999; Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v; NiceData, 2004, TRAD CHIN MED NAT SO; Nicholson TP, 2001, CHEM BIOL, V8, P157, DOI 10.1016/S1074-5521(00)90064-4; OKINO T, 1993, TETRAHEDRON LETT, V34, P501, DOI 10.1016/0040-4039(93)85112-A; PERDUE RE, 1970, AMER HORTICULT MAG, V49, P19; Puri SC, 2005, J NAT PROD, V68, P1717, DOI 10.1021/np0502802; Rajbhandari M, 2009, EVID-BASED COMPL ALT, V6, P517, DOI 10.1093/ecam/nem156; Rascher A, 2003, FEMS MICROBIOL LETT, V218, P223, DOI 10.1016/S0378-1097(02)01148-5; Rausch C, 2005, NUCLEIC ACIDS RES, V33, P5799, DOI 10.1093/nar/gki885; Rounge TB, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-396; Rounge TB, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-141; Sauer M, 2002, MYCOL RES, V106, P460, DOI 10.1017/S095375620200566X; Staunton J, 2001, CURR OPIN CHEM BIOL, V5, P159, DOI 10.1016/S1367-5931(00)00185-X; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; STIERLE A, 1993, SCIENCE, V260, P214, DOI 10.1126/science.8097061; Strobel G, 2004, J NAT PROD, V67, P257, DOI 10.1021/np030397v; Strobel GA, 2003, MICROBES INFECT, V5, P535, DOI 10.1016/S1286-4579(03)00073-X; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; van der Bank H, 2001, BIOCHEM SYST ECOL, V29, P241, DOI 10.1016/S0305-1978(00)00064-8; Visca P, 2007, TRENDS MICROBIOL, V15, P22, DOI 10.1016/j.tim.2006.11.004; WALL ME, 1966, J AM CHEM SOC, V88, P3888, DOI 10.1021/ja00968a057; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; Wawrik B, 2005, APPL ENVIRON MICROB, V71, P2232, DOI 10.1128/AEM.71.5.2232-2238.2005; Weber T, 2003, J BIOTECHNOL, V106, P221, DOI 10.1016/j.jbiotec.2003.08.004; Wei W., 2002, COMBINATION APPL; Zhu Y.P., 1998, CHINESE MAT MED CHEM	79	56	61	0	46	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2012	7	5							e35953	10.1371/journal.pone.0035953	http://dx.doi.org/10.1371/journal.pone.0035953			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959VQ	22629306	Green Published, gold			2023-01-03	WOS:000305345300004
J	Loncarevic-Vasiljkovic, N; Pesic, V; Todorovic, S; Popic, J; Smiljanic, K; Milanovic, D; Ruzdijic, S; Kanazir, S				Loncarevic-Vasiljkovic, Natasa; Pesic, Vesna; Todorovic, Smilja; Popic, Jelena; Smiljanic, Kosara; Milanovic, Desanka; Ruzdijic, Sabera; Kanazir, Selma			Caloric Restriction Suppresses Microglial Activation and Prevents Neuroapoptosis Following Cortical Injury in Rats	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; FOOD RESTRICTION; DIETARY RESTRICTION; DAMAGE; AGE; NEURODEGENERATION; MECHANISMS; APOPTOSIS; CYTOKINES; CASPASES	Traumatic brain injury (TBI) is a widespread cause of death and a major source of adult disability. Subsequent pathological events occurring in the brain after TBI, referred to as secondary injury, continue to damage surrounding tissue resulting in substantial neuronal loss. One of the hallmarks of the secondary injury process is microglial activation resulting in increased cytokine production. Notwithstanding that recent studies demonstrated that caloric restriction (CR) lasting several months prior to an acute TBI exhibits neuroprotective properties, understanding how exactly CR influences secondary injury is still unclear. The goal of the present study was to examine whether CR (50% of daily food intake for 3 months) alleviates the effects of secondary injury on neuronal loss following cortical stab injury (CSI). To this end, we examined the effects of CR on the microglial activation, tumor necrosis factor-alpha (TNF-alpha) and caspase-3 expression in the ipsilateral (injured) cortex of the adult rats during the recovery period (from 2 to 28 days) after injury. Our results demonstrate that CR prior to CSI suppresses microglial activation, induction of TNF-alpha and caspase-3, as well as neurodegeneration following injury. These results indicate that CR strongly attenuates the effects of secondary injury, thus suggesting that CR may increase the successful outcome following TBI.	[Loncarevic-Vasiljkovic, Natasa; Pesic, Vesna; Todorovic, Smilja; Popic, Jelena; Smiljanic, Kosara; Milanovic, Desanka; Ruzdijic, Sabera; Kanazir, Selma] Univ Belgrade, Dept Neurobiol, Inst Biol Res, Belgrade, Serbia	University of Belgrade	Loncarevic-Vasiljkovic, N (corresponding author), Univ Belgrade, Dept Neurobiol, Inst Biol Res, Belgrade, Serbia.	selkan@ibiss.bg.ac.rs	Loncarevic-Vasiljkovic, Natasa/AAF-7800-2022; Loncarevic-Vasiljkovic, Natasa/AFK-0840-2022; Kanazir, Selma/E-5495-2015	Loncarevic-Vasiljkovic, Natasa/0000-0002-8350-1390; Loncarevic-Vasiljkovic, Natasa/0000-0002-8350-1390; Kanazir, Selma/0000-0002-7229-5296; Popic, Jelena/0000-0002-0959-3856; Smiljanic, Kosara/0000-0002-6790-5491; Milanovic, Desanka/0000-0001-9799-0335; Pesic, Vesna/0000-0002-1415-5834; Todorovic, Smilja/0000-0001-7155-4914	Ministry of Education and Science, Republic of Serbia [ON173056]	Ministry of Education and Science, Republic of Serbia	This work is funded by the Ministry of Education and Science, Republic of Serbia (grant No ON173056). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arumugam TV, 2010, ANN NEUROL, V67, P41, DOI 10.1002/ana.21798; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Bessis A, 2007, GLIA, V55, P233, DOI 10.1002/glia.20459; Brown GC, 2007, BIOCHEM SOC T, V35, P1119, DOI 10.1042/BST0351119; Brown GC, 2010, MOL NEUROBIOL, V41, P242, DOI 10.1007/s12035-010-8105-9; Bruce-Keller AJ, 1999, ANN NEUROL, V45, P8, DOI 10.1002/1531-8249(199901)45:1<8::AID-ART4>3.0.CO;2-V; Bruce-Keller AJ, 1999, J NEUROSCI RES, V58, P191, DOI 10.1002/(SICI)1097-4547(19991001)58:1<191::AID-JNR17>3.0.CO;2-E; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; Chiba T, 2010, BIOCHEM BIOPH RES CO, V399, P98, DOI 10.1016/j.bbrc.2010.07.048; Chopek JW, 2010, MECH AGEING DEV, V131, P650, DOI 10.1016/j.mad.2010.09.001; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; Hampton DW, 2004, NEUROSCIENCE, V127, P813, DOI 10.1016/j.neuroscience.2004.05.028; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hiona A, 2004, ANN NY ACAD SCI, V1019, P96, DOI 10.1196/annals.1297.018; Jeong MA, 2011, J NEUROTRAUM, V28, P479, DOI 10.1089/neu.2010.1609; Kraft AD, 2009, NEUROTOXICOLOGY, V30, P785, DOI 10.1016/j.neuro.2009.07.001; Lee LW, 2003, NEUROMOL MED, V4, P179, DOI 10.1385/NMM:4:3:179; Loncarevic-Vasiljkovic N, 2009, EXP NEUROL, V220, P198, DOI 10.1016/j.expneurol.2009.08.024; Madinier A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008101; Manzanero Silvia, 2011, Exp Transl Stroke Med, V3, P8, DOI 10.1186/2040-7378-3-8; Mattson MP, 2005, J NUTR BIOCHEM, V16, P129, DOI 10.1016/j.jnutbio.2004.12.007; Neumann H, 2001, GLIA, V36, P191, DOI 10.1002/glia.1108; Pekovic S, 2006, NEUROBIOLOGICAL STUDIES - FROM GENES TO BEHAVIOUR 2006, P143; Raivich G, 2005, TRENDS NEUROSCI, V28, P571, DOI 10.1016/j.tins.2005.09.001; Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Reed JL, 2010, APPL PHYSIOL NUTR ME, V35, P573, DOI 10.1139/H10-046; Roberge MC, 2008, BEHAV BRAIN RES, V187, P123, DOI 10.1016/j.bbr.2007.09.002; Rogove AD, 2002, CELL DEATH DIFFER, V9, P801, DOI 10.1038/sj.cdd.4401041; Sande A, 2010, J VET EMERG CRIT CAR, V20, P177, DOI 10.1111/j.1476-4431.2010.00527.x; Sharma S, 2005, BRAIN RES BULL, V67, P482, DOI 10.1016/j.brainresbull.2005.07.015; Sharma S, 2008, NEUROCHEM RES, V33, P1178, DOI 10.1007/s11064-007-9503-x; Sola E, 2009, OBES SURG, V19, P571, DOI 10.1007/s11695-008-9772-8; Springer JE, 2002, J BIOCHEM MOL BIOL, V35, P94; Tuttolomondo A, 2009, CURR TOP MED CHEM, V9, P1240, DOI 10.2174/156802609789869619; Veenith T, 2009, WORLD J EMERG SURG, V2, P4; Zhang D, 2010, MOL NEUROBIOL, V41, P232, DOI 10.1007/s12035-010-8098-4	39	46	46	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2012	7	5							e37215	10.1371/journal.pone.0037215	http://dx.doi.org/10.1371/journal.pone.0037215			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TM	22615943	Green Submitted, Green Published, gold			2023-01-03	WOS:000305336300079
J	Schmitz, R; Young, RM; Ceribelli, M; Jhavar, S; Xiao, WM; Zhang, MZ; Wright, G; Shaffer, AL; Hodson, DJ; Buras, E; Liu, XL; Powell, J; Yang, YD; Xu, WH; Zhao, H; Kohlhammer, H; Rosenwald, A; Kluin, P; Muller-Hermelink, HK; Ott, G; Gascoyne, RD; Connors, JM; Rimsza, LM; Campo, E; Jaffe, ES; Delabie, J; Smeland, EB; Ogwang, MD; Reynolds, SJ; Fisher, RI; Braziel, RM; Tubbs, RR; Cook, JR; Weisenburger, DD; Chan, WC; Pittaluga, S; Wilson, W; Waldmann, TA; Rowe, M; Mbulaiteye, SM; Rickinson, AB; Staudt, LM				Schmitz, Roland; Young, Ryan M.; Ceribelli, Michele; Jhavar, Sameer; Xiao, Wenming; Zhang, Meili; Wright, George; Shaffer, Arthur L.; Hodson, Daniel J.; Buras, Eric; Liu, Xuelu; Powell, John; Yang, Yandan; Xu, Weihong; Zhao, Hong; Kohlhammer, Holger; Rosenwald, Andreas; Kluin, Philip; Mueller-Hermelink, Hans Konrad; Ott, German; Gascoyne, Randy D.; Connors, Joseph M.; Rimsza, Lisa M.; Campo, Elias; Jaffe, Elaine S.; Delabie, Jan; Smeland, Erlend B.; Ogwang, Martin D.; Reynolds, Steven J.; Fisher, Richard I.; Braziel, Rita M.; Tubbs, Raymond R.; Cook, James R.; Weisenburger, Dennis D.; Chan, Wing C.; Pittaluga, Stefania; Wilson, Wyndham; Waldmann, Thomas A.; Rowe, Martin; Mbulaiteye, Sam M.; Rickinson, Alan B.; Staudt, Louis M.			Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics	NATURE			English	Article							CELL; IMMUNOGLOBULIN; REGION	Burkitt's lymphoma (BL) can often be cured by intensive chemotherapy, but the toxicity of such therapy precludes its use in the elderly and in patients with endemic BL in developing countries, necessitating new strategies(1). The normal germinal centre B cell is the presumed cell of origin for both BL and diffuse large B-cell lymphoma (DLBCL), yet gene expression analysis suggests that these malignancies may use different oncogenic pathways(2). BL is subdivided into a sporadic subtype that is diagnosed in developed countries, the Epstein-Barr-virus-associated endemic subtype, and an HIV-associated subtype, but it is unclear whether these subtypes use similar or divergent oncogenic mechanisms. Here we used high-throughput RNA sequencing and RNA interference screening to discover essential regulatory pathways in BL that cooperate with MYC, the defining oncogene of this cancer. In 70% of sporadic BL cases, mutations affecting the transcription factor TCF3 (E2A) or its negative regulator ID3 fostered TCF3 dependency. TCF3 activated the pro-survival phosphatidylinositol-3-OH kinase pathway in BL, in part by augmenting tonic B-cell receptor signalling. In 38% of sporadic BL cases, oncogenic CCND3 mutations produced highly stable cyclin D3 isoforms that drive cell cycle progression. These findings suggest opportunities to improve therapy for patients with BL.	[Schmitz, Roland; Young, Ryan M.; Ceribelli, Michele; Jhavar, Sameer; Zhang, Meili; Shaffer, Arthur L.; Hodson, Daniel J.; Buras, Eric; Yang, Yandan; Xu, Weihong; Zhao, Hong; Kohlhammer, Holger; Wilson, Wyndham; Waldmann, Thomas A.; Staudt, Louis M.] NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Xiao, Wenming; Liu, Xuelu; Powell, John] NIH, Bioinformat & Mol Anal Sect, Div Computat Biosci, Ctr Informat Technol, Bethesda, MD 20892 USA; [Wright, George] NCI, Biometr Res Branch, DCTD, NIH, Bethesda, MD 20892 USA; [Rosenwald, Andreas; Mueller-Hermelink, Hans Konrad] Univ Wurzburg, Dept Pathol, D-97080 Wurzburg, Germany; [Kluin, Philip] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, NL-9713 GZ Groningen, Netherlands; [Ott, German] Robert Bosch Krankenhaus, Dept Clin Pathol, D-70376 Stuttgart, Germany; [Ott, German] Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70376 Stuttgart, Germany; [Gascoyne, Randy D.; Connors, Joseph M.] British Columbia Canc Agcy, Vancouver, BC V5Z 1L3, Canada; [Rimsza, Lisa M.] Univ Arizona, Dept Pathol, Tucson, AZ 85724 USA; [Campo, Elias] Univ Barcelona, Hosp Clin, E-08036 Barcelona, Spain; [Jaffe, Elaine S.; Pittaluga, Stefania] NCI, Pathol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Delabie, Jan] Univ Hosp, Rikshosp, Pathol Clin, N-0372 Oslo, Norway; [Smeland, Erlend B.] Univ Hosp, Rikshosp, Inst Canc Res, N-0310 Oslo, Norway; [Smeland, Erlend B.] Univ Oslo, Norwegian Radium Hosp, Fac Div, Ctr Canc Biomed, N-0310 Oslo, Norway; [Ogwang, Martin D.] St Marys Hosp Lacor, Gulu 256, Uganda; [Reynolds, Steven J.] NIAID, Div Intramural Res, NIH, Bethesda, MD 20892 USA; [Fisher, Richard I.] Univ Rochester, Sch Med, James P Wilmot Canc Ctr, Rochester, NY 14642 USA; [Braziel, Rita M.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA; [Tubbs, Raymond R.; Cook, James R.] Cleveland Clin, Pathol & Lab Med Inst, Cleveland, OH 44195 USA; [Weisenburger, Dennis D.; Chan, Wing C.] Univ Nebraska Med Ctr, Dept Pathol, Omaha, NE 68198 USA; [Weisenburger, Dennis D.; Chan, Wing C.] Univ Nebraska Med Ctr, Dept Microbiol, Omaha, NE 68198 USA; [Rowe, Martin; Rickinson, Alan B.] Univ Birmingham, Birmingham Canc Res UK Ctr, Sch Canc Sci, Birmingham B15 2TT, W Midlands, England; [Mbulaiteye, Sam M.] NCI, Infect & Immunoepidemiol Branch, Div Canc Epidemiol & Genet, NIH,US Dept HHS, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Center for Information Technology (CIT); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Wurzburg; University of Groningen; Bosch; Robert Bosch Krankenhaus; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; British Columbia Cancer Agency; University of Arizona; University of Barcelona; Hospital Clinic de Barcelona; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; University of Oslo; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Rochester; Oregon Health & Science University; Cleveland Clinic Foundation; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Birmingham; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Staudt, LM (corresponding author), NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	lstaudt@mail.nih.gov	Smeland, Erlend/AAO-3214-2020; Staudt, Louis/AAC-5324-2019; Connors, Joseph/AAF-5284-2019; Mbulaiteye, Sam/O-3056-2019; Wright, George W/M-1660-2017; Campo, Elias/AAC-5593-2019; Gascoyne, Randy D/A-6009-2013; Waldmann, Thomas/AAT-5972-2021; Hodson, Daniel J/K-6817-2016; Rowe, Martin/B-2880-2009; Jaffe, Elaine/G-8981-2014	Connors, Joseph/0000-0002-1361-7531; Mbulaiteye, Sam/0000-0002-8273-9831; Campo, Elias/0000-0001-9850-9793; Gascoyne, Randy D/0000-0002-2610-5690; Waldmann, Thomas/0000-0003-4500-6660; Hodson, Daniel J/0000-0001-6225-2033; Rowe, Martin/0000-0003-4139-7326; Reynolds, Steven/0000-0002-5403-2759; Delabie, Jan/0000-0001-5023-0689; Jaffe, Elaine/0000-0003-4632-0301	NIH, National Cancer Institute, Center for Cancer Research, an NCI SPECS grant [UO1-CA 114778]; Foundation for NIH; Cancer Research UK; Lymphoma/Leukemia Molecular Profiling Project (LLMPP); Dr Mildred Scheel Stiftung fur Krebsforschung (Deutsche Krebshilfe); NCI [N01-C0-12400]; Medical Research Council [G9818340B] Funding Source: researchfish; CENTER FOR INFORMATION TECHNOLOGY [ZIACT000260] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [U01CA114778, ZIASC000550, ZIACP010176, ZIASC004002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000361, ZIAAI001040] Funding Source: NIH RePORTER	NIH, National Cancer Institute, Center for Cancer Research, an NCI SPECS grant; Foundation for NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Research UK(Cancer Research UK); Lymphoma/Leukemia Molecular Profiling Project (LLMPP); Dr Mildred Scheel Stiftung fur Krebsforschung (Deutsche Krebshilfe)(Deutsche Krebshilfe); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); CENTER FOR INFORMATION TECHNOLOGY(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Center for Information Technology (CIT)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research, an NCI SPECS grant (UO1-CA 114778), by the Foundation for NIH, through a gift from the Richard A. Lauderbaugh Memorial Fund, and by Cancer Research UK. This study was conducted under the auspices of the Lymphoma/Leukemia Molecular Profiling Project (LLMPP). R.S. was supported by the Dr Mildred Scheel Stiftung fur Krebsforschung (Deutsche Krebshilfe). D.J.H. is a Kay Kendall Leukaemia Fund Intermediate research fellow. This study used the high-performance computational capabilities of the Biowulf Linux cluster at the National Institutes of Health (http://biowulf.nih.gov). We thank K. Meyer for help with the GEO submission, T. Ellenberger for the TCF3 crystal structure coordinates, B. Tran (Center for Cancer Research Sequencing Facility) and K. Hartman for DNA sequencing and K. Rajewsky for discussions. The DLBCL data set is part of the Cancer Genomics Characterization Initiative (CGCI), supported by NCI contract N01-C0-12400 (http://cgap.nci.nih.gov/cgci.html/) and was obtained from dbGaP at http://www.ncbi.nlm.nih.gov/gap. We thank the participants in the EMBLEM Study (http://emblem.cancer.gov/) in Uganda, the EMBLEM Study staff for collecting and processing the samples and data, and the Government of Uganda for allowing the study to be done and samples to be exported for research.	Cato MH, 2011, MOL CELL BIOL, V31, P127, DOI 10.1128/MCB.00650-10; Dave SS, 2006, NEW ENGL J MED, V354, P2431, DOI 10.1056/NEJMoa055759; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; Kee BL, 2009, NAT REV IMMUNOL, V9, P175, DOI 10.1038/nri2507; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Lohr JG, 2012, P NATL ACAD SCI USA, V109, P3879, DOI 10.1073/pnas.1121343109; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Ngo VN, 2006, NATURE, V441, P106, DOI 10.1038/nature04687; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Orem J, 2008, TROP DOCT, V38, P7, DOI 10.1258/td.2007.060093; Pasqualucci L, 2011, NAT GENET, V43, P830, DOI 10.1038/ng.892; Peled JU, 2010, CELL RES, V20, P631, DOI 10.1038/cr.2010.55; PESCE S, 1993, MOL CELL BIOL, V13, P7874, DOI 10.1128/MCB.13.12.7874; Sander S., 2012, CANC CELL; Srinivasan L, 2009, CELL, V139, P573, DOI 10.1016/j.cell.2009.08.041; Xiao CC, 2008, NAT IMMUNOL, V9, P405, DOI 10.1038/ni1575; Yustein JT, 2007, CURR OPIN HEMATOL, V14, P375, DOI 10.1097/MOH.0b013e3281bccdee	21	562	574	2	99	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 4	2012	490	7418					116	120		10.1038/nature11378	http://dx.doi.org/10.1038/nature11378			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	015LG	22885699	Green Submitted, Green Accepted			2023-01-03	WOS:000309446800044
J	Liu, L; Cui, J; Song, CJ; Bian, JS; Sparatore, A; Del Soldato, P; Wang, XY; Yan, CD				Liu, Lei; Cui, Jie; Song, Cheng-Jie; Bian, Jin-Song; Sparatore, Anna; Del Soldato, Piero; Wang, Xin-Yu; Yan, Chang-Dong			H(2)S-Releasing Aspirin Protects against Aspirin-Induced Gastric Injury via Reducing Oxidative Stress	PLOS ONE			English	Article							HYDROGEN-SULFIDE PROTECTS; INHIBITS SUPEROXIDE FORMATION; CYSTATHIONINE GAMMA-LYASE; LOW-DOSE ASPIRIN; GASTROINTESTINAL COMPLICATIONS; SILDENAFIL ACS6; INDUCED DAMAGE; NADPH OXIDASE; RAT; CELLS	The aim of this study was to examine the effect of ACS14, a hydrogen sulfide (H2S)-releasing derivative of aspirin (Asp), on Asp-induced gastric injury. Gastric hemorrhagic lesions were induced by intragastric administration of Asp (200 mg/kg, suspended in 0.5% carboxymethyl cellulose solutions) in a volume of 1 ml/100 g body weight. ACS14 (1, 5 or 10 mg/kg) was given 30 min before the Asp administration. The total area of gastric erosions, H2S concentration and oxidative stress in gastric tissues were measured three hours after administration of Asp. Treatment with Asp (200 mg/kg), but not ACS14 (430 mg/kg, at equimolar doses to 200 mg/kg Asp), for 3 h significantly increased gastric mucosal injury. The damage caused by Asp was reversed by ACS14 at 1-10 mg/kg in a concentration-dependent manner. ACS14 abrogated Asp-induced upregulation of COX-2 expression, but had no effect on the reduced PGE(2) level. ACS14 reversed the decreased H2S concentrations and blood flow in the gastric tissue in Asp-treated rats. Moreover, ACS14 attenuated Asp-suppressed superoxide dismutase-1 (SOD-1) expression and GSH activity, suggesting that ACS14 may stimulate antioxidants in the gastric tissue. ACS14 also obviously inhibited Asp-induced upregulation of protein expression of oxidases including XOD, p47(phox) and p67(phox). In conclusion, ACS14 protects Asp induced gastric mucosal injury by inhibiting oxidative stress in the gastric tissue.	[Wang, Xin-Yu] Shenzhen Second Peoples Hosp, Dept Endocrinol, Shenzhen, Guangdong, Peoples R China; [Liu, Lei; Cui, Jie; Song, Cheng-Jie; Yan, Chang-Dong] Xuzhou Med Coll, Dept Physiol, Xuzhou, Jiangsu, Peoples R China; [Bian, Jin-Song] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore 117595, Singapore; [Sparatore, Anna] Univ Milan, Dipartimento Sci Farmaceut Pietro Pratesi, Milan, Italy; [Del Soldato, Piero] CTG Pharma, Milan, Italy	Second People's Hospital of Shenzhen; Xuzhou Medical University; National University of Singapore; University of Milan	Wang, XY (corresponding author), Shenzhen Second Peoples Hosp, Dept Endocrinol, Shenzhen, Guangdong, Peoples R China.	wangxy926@yahoo.com; yancd55@163.com	Sparatore, Anna/J-8634-2015	Sparatore, Anna/0000-0003-2135-2649; Bian, Jinsong/0000-0002-7741-598X	China National Science Fund in Jiangsu Province [BK2009088]; National Natural Science Foundation of China [30873055]	China National Science Fund in Jiangsu Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by research grants from China National Science Fund in Jiangsu Province (BK2009088) and National Natural Science Foundation of China (30873055). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Becker JC, 2004, BRIT J CLIN PHARMACO, V58, P587, DOI 10.1111/j.1365-2125.2004.02198.x; Bian JS, 2006, J PHARMACOL EXP THER, V316, P670, DOI 10.1124/jpet.105.092023; Blandizzi C, 2008, DRUG AGING, V25, P197, DOI 10.2165/00002512-200825030-00003; Blandizzi C, 2009, PHARMACOL RES, V59, P90, DOI 10.1016/j.phrs.2008.11.004; Brandes RP, 2008, CURR OPIN LIPIDOL, V19, P513, DOI 10.1097/MOL.0b013e32830c91e3; Brzozowski T, 2000, J PHYSIOL PHARMACOL, V51, P751; D'Argenio G, 2008, BRIT J NUTR, V100, P1228, DOI 10.1017/S0007114508988747; Davies NM, 1997, ALIMENT PHARM THERAP, V11, P1101, DOI 10.1046/j.1365-2036.1997.00247.x; Derry S, 2000, BMJ-BRIT MED J, V321, P1183, DOI 10.1136/bmj.321.7270.1183; Devai I, 2002, ENVIRON TECHNOL, V23, P319, DOI 10.1080/09593332508618412; Elrod JW, 2007, P NATL ACAD SCI USA, V104, P15560, DOI 10.1073/pnas.0705891104; Erdmann K, 2008, BIOCHEM BIOPH RES CO, V368, P937, DOI 10.1016/j.bbrc.2008.02.009; Fiorucci S, 2005, GASTROENTEROLOGY, V129, P1210, DOI 10.1053/j.gastro.2005.07.060; Fiorucci S, 2002, GASTROENTEROLOGY, V123, P1598, DOI 10.1053/gast.2002.36558; Geng B, 2004, BIOCHEM BIOPH RES CO, V318, P756, DOI 10.1016/j.bbrc.2004.04.094; Giustarini D, 2010, FREE RADICAL BIO MED, V48, P1263, DOI 10.1016/j.freeradbiomed.2010.02.014; Goubern M, 2007, FASEB J, V21, P1699, DOI 10.1096/fj.06-7407com; Harrison R, 2002, FREE RADICAL BIO MED, V33, P774, DOI 10.1016/S0891-5849(02)00956-5; Hatazawa R, 2007, AM J PHYSIOL-GASTR L, V293, pG788, DOI 10.1152/ajpgi.00131.2007; Hu LF, 2008, PFLUG ARCH EUR J PHY, V455, P971, DOI 10.1007/s00424-007-0346-8; Hu LF, 2007, J NEUROCHEM, V100, P1121, DOI 10.1111/j.1471-4159.2006.04283.x; Hu LF, 2010, AGING CELL, V9, P135, DOI 10.1111/j.1474-9726.2009.00543.x; Hu LF, 2009, MOL PHARMACOL, V75, P27, DOI 10.1124/mol.108.047985; Kimura H, 2010, AMINO ACIDS; Kimura Y, 2004, FASEB J, V18, P1165, DOI 10.1096/fj.04-1815fje; Kimura Y, 2006, ANTIOXID REDOX SIGN, V8, P661, DOI 10.1089/ars.2006.8.661; Kimura Y, 2010, ANTIOXID REDOX SIGN, V12, P1, DOI 10.1089/ars.2008.2282; Konturek PC, 2008, J PHYSIOL PHARMACOL, V59, P67; Li JM, 2001, CARDIOVASC RES, V52, P477, DOI 10.1016/S0008-6363(01)00407-2; Li L, 2007, FREE RADICAL BIO MED, V42, P706, DOI 10.1016/j.freeradbiomed.2006.12.011; Lu M, 2008, FREE RADICAL BIO MED, V45, P1705, DOI 10.1016/j.freeradbiomed.2008.09.014; Metwally NS, 2011, CANCER CELL INT, V11, DOI 10.1186/1475-2867-11-8; Mizuno H, 1997, GASTROENTEROLOGY, V112, P387, DOI 10.1053/gast.1997.v112.pm9024292; Muzaffar S, 2008, BRIT J PHARMACOL, V155, P984, DOI 10.1038/bjp.2008.326; Muzaffar S, 2008, J VASC RES, V45, P521, DOI 10.1159/000129686; Naesdall J, 2006, DRUG SAFETY, V29, P119; Osborne NN, 2010, INVEST OPHTH VIS SCI, V51, P284, DOI 10.1167/iovs.09-3999; Osborne NN, 2012, NEUROCHEM INT; Pan TT, 2006, J MOL CELL CARDIOL, V40, P119, DOI 10.1016/j.yjmcc.2005.10.003; Patrono C, 2005, NEW ENGL J MED, V353, P2373, DOI 10.1056/NEJMra052717; Pohle T, 2001, ALIMENT PHARM THER, V15, P677, DOI 10.1046/j.1365-2036.2001.00975.x; Qu K, 2008, NEUROCHEM INT, V52, P155, DOI 10.1016/j.neuint.2007.05.016; Rodriguez LAG, 2001, BRIT J CLIN PHARMACO, V52, P563, DOI 10.1046/j.0306-5251.2001.01476.x; Rossoni G, 2010, EUR J PHARMACOL, V648, P139, DOI 10.1016/j.ejphar.2010.08.039; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Sen U, 2011, AM J PHYSIOL-CELL PH, V300, pC155, DOI 10.1152/ajpcell.00143.2010; Shukla N, 2009, BJU INT, V103, P1522, DOI 10.1111/j.1464-410X.2009.08415.x; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; Sorensen HT, 2000, AM J GASTROENTEROL, V95, P2218; Sparatore A, 2009, FREE RADICAL BIO MED, V46, P586, DOI 10.1016/j.freeradbiomed.2008.11.013; Suzuki T, 2008, J PHARMACOL SCI, V106, P469, DOI 10.1254/jphs.FP0071422; Szabo C, 2007, NAT REV DRUG DISCOV, V6, P917, DOI 10.1038/nrd2425; Vacek TP, 2010, AMINO ACIDS, V39, P1161, DOI 10.1007/s00726-010-0550-2; Vulcano M, 2004, J IMMUNOL, V173, P5749, DOI 10.4049/jimmunol.173.9.5749; Wallace JL, 2007, BRIT J PHARMACOL, V152, P421, DOI 10.1038/sj.bjp.0707396; Wallace JL, 2007, GASTROENTEROLOGY, V132, P261, DOI 10.1053/j.gastro.2006.11.042; Wallace JL, 2010, BRIT J PHARMACOL, V159, P1236, DOI 10.1111/j.1476-5381.2009.00611.x; Wang R, 2002, FASEB J, V16, P1792, DOI 10.1096/fj.02-0211hyp; Yang GD, 2008, SCIENCE, V322, P587, DOI 10.1126/science.1162667; Yonezawa D, 2007, TOXICOLOGY, V241, P11, DOI 10.1016/j.tox.2007.07.020; Zhang QY, 2004, BIOCHEM BIOPH RES CO, V317, P30, DOI 10.1016/j.bbrc.2004.02.176	61	28	30	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2012	7	9							e46301	10.1371/journal.pone.0046301	http://dx.doi.org/10.1371/journal.pone.0046301			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022PZ	23029468	Green Published, Green Submitted, gold			2023-01-03	WOS:000309973900127
J	Tomlinson, CL; Patel, S; Meek, C; Herd, CP; Clarke, CE; Stowe, R; Shah, L; Sackley, C; Deane, KHO; Wheatley, K; Ives, N				Tomlinson, Claire L.; Patel, Smitaa; Meek, Charmaine; Herd, Clare P.; Clarke, Carl E.; Stowe, Rebecca; Shah, Laila; Sackley, Catherine; Deane, Katherine H. O.; Wheatley, Keith; Ives, Natalie			Physiotherapy intervention in Parkinson's disease: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIAL; ATTENTION FOCUSED EXERCISE; QUALITY-OF-LIFE; PHYSICAL-THERAPY; MULTIDISCIPLINARY CARE; PEOPLE; GAIT; PROGRAM; WALKING; PERFORMANCE	Objective To assess the effectiveness of physiotherapy compared with no intervention in patients with Parkinson's disease. Design Systematic review and meta-analysis of randomised controlled trials. Data sources Literature databases, trial registries, journals, abstract books, and conference proceedings, and reference lists, searched up to the end of January 2012. Review methods Randomised controlled trials comparing physiotherapy with no intervention in patients with Parkinson's disease were eligible. Two authors independently abstracted data from each trial. Standard meta-analysis methods were used to assess the effectiveness of physiotherapy compared with no intervention. Tests for heterogeneity were used to assess for differences in treatment effect across different physiotherapy interventions used. Outcome measures were gait, functional mobility and balance, falls, clinician rated impairment and disability measures, patient rated quality of life, adverse events, compliance, and economic analysis outcomes. Results 39 trials of 1827 participants met the inclusion criteria, of which 29 trials provided data for the meta-analyses. Significant benefit from physiotherapy was reported for nine of 18 outcomes assessed. Outcomes which may be clinically significant were speed (0.04 m/s, 95% confidence interval 0.02 to 0.06, P<0.001), Berg balance scale (3.71 points, 2.30 to 5.11, P<0.001), and scores on the unified Parkinson's disease rating scale (total score -6.15 points, -8.57 to -3.73, P<0.001; activities of daily living subscore -1.36, -2.41 to -0.30, P=0.01; motor subscore -5.01, -6.30 to -3.72, P<0.001). Indirect comparisons of the different physiotherapy interventions found no evidence that the treatment effect differed across the interventions for any outcomes assessed, apart from motor subscores on the unified Parkinson's disease rating scale (in which one trial was found to be the cause of the heterogeneity). Conclusions Physiotherapy has short term benefits in Parkinson's disease. A wide range of physiotherapy techniques are currently used to treat Parkinson's disease, with little difference in treatment effects. Large, well designed, randomised controlled trials with improved methodology and reporting are needed to assess the efficacy and cost effectiveness of physiotherapy for treating Parkinson's disease in the longer term.	[Tomlinson, Claire L.; Patel, Smitaa; Meek, Charmaine; Stowe, Rebecca; Shah, Laila; Ives, Natalie] Univ Birmingham, Birmingham Clin Trials Unit, Birmingham B15 2TT, W Midlands, England; [Herd, Clare P.; Clarke, Carl E.] Univ Birmingham, Coll Med & Dent Sci, Sch Clin & Expt Med, Birmingham B15 2TT, W Midlands, England; [Clarke, Carl E.] City Hosp, Sandwell & W Birmingham Hosp NHS Trust, Dept Neurol, Birmingham, W Midlands, England; [Sackley, Catherine; Deane, Katherine H. O.] Univ E Anglia, Norwich NR4 7TJ, Norfolk, England; [Wheatley, Keith] Univ Birmingham, Sch Canc Sci, Canc Res UK Clin Trials Unit, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Birmingham; University of Birmingham; University of East Anglia; Cancer Research UK; University of Birmingham	Tomlinson, CL (corresponding author), Univ Birmingham, Birmingham Clin Trials Unit, Birmingham B15 2TT, W Midlands, England.	c.l.smith.1@bham.ac.uk		sackley, catherine/0000-0002-8580-6622; Clarke, Carl/0000-0003-2478-3436; Deane, Katherine/0000-0002-0805-2708; Herd, Clare/0000-0002-1351-1112; Patel, Smitaa/0000-0002-4997-3829; Ives, Natalie/0000-0002-1664-7541; STOWE, REBECCA/0000-0003-4007-6723	Parkinson's UK; UK Department of Health	Parkinson's UK(Parkinson's UK); UK Department of Health	This review was funded by Parkinson's UK and the UK Department of Health, which provided the University of Birmingham Clinical Trials Unit with core support.	Allen NE, 2010, MOVEMENT DISORD, V25, P1217, DOI 10.1002/mds.23082; Almeida QJ, 2012, PARKINSONS DIS-US, V2012, DOI 10.1155/2012/508720; Ashburn A, 2007, J NEUROL NEUROSUR PS, V78, P678, DOI 10.1136/jnnp.2006.099333; Bladh S, 2012, J NEUROL, V259, P729, DOI 10.1007/s00415-011-6254-z; Boehm RL, 2011, MOVEMENT DISORD, V26, pS331; Cakit BD, 2007, CLIN REHABIL, V21, P698, DOI 10.1177/0269215507077269; Canning CG, 2012, CLIN REHABIL; Cerri C, 1994, MOV DISORD S1, V9, P68; Chandler C, 1999, PARKINSONS DIS STUDI, P256; Clarke C., 2006, NATL CLIN GUIDELINE; de Bruin N, 2010, MOVEMENT DISORD, V25, pS697; De Bruin N, 2008, MOV DISORD S1, V23, pS667; Deane K, 2001, COCHRANE DB SYST REV, V3; Deeks J. J., 2001, SYSTEMATIC REV HLTH, V2, P285, DOI DOI 10.1002/9780470693926.CH15; Duncan RP, 2012, NEUROREHAB NEURAL RE, V26, P132, DOI 10.1177/1545968311421614; Ellis T, 2005, ARCH PHYS MED REHAB, V86, P626, DOI 10.1016/j.apmr.2004.08.008; Fisher BE, 2008, ARCH PHYS MED REHAB, V89, P1221, DOI 10.1016/j.apmr.2008.01.013; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; Gage H, 2004, CLIN REHABIL, V18, P463, DOI 10.1191/0269215504cr764oa; Ganesan M, 2010, PARKINSONISM RELA S1, V16, pS66; Goetz CG, 2008, MOVEMENT DISORD, V23, P690, DOI 10.1002/mds.21894; Goodwin VA, 2008, MOVEMENT DISORD, V23, P631, DOI 10.1002/mds.21922; Goodwin VA, 2011, J NEUROL NEUROSUR PS, V82, P1232, DOI 10.1136/jnnp-2011-300919; Haase M, 2011, THESIS PROQUEST; Hackney ME, 2009, PARKINSONISM RELAT D, V15, P644, DOI 10.1016/j.parkreldis.2009.03.003; Homann CN, 1998, MOV DISORD S2, V13, pS234; Keus S, 2004, DUTCH J PHYSIOTHE S1, V114, pS1; Keus SHJ, 2007, PARKINSONISM RELAT D, V13, P115, DOI 10.1016/j.parkreldis.2006.07.007; Keus SHJ, 2007, MOVEMENT DISORD, V22, P451, DOI 10.1002/mds.21244; Keus SHJ, 2009, MOVEMENT DISORD, V24, P1, DOI 10.1002/mds.22141; Klassen L, 2007, PHYSIOTHERAPY S1, V93, pS91; Kurtais Y, 2008, CLIN J SPORT MED, V18, P289, DOI 10.1097/JSM.0b013e318170626d; Kwakkel G, 2007, PARKINSONISM RELAT D, V13, pS478, DOI 10.1016/S1353-8020(08)70053-1; Lehman David A, 2005, J Neurol Phys Ther, V29, P2; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; Mak MKY, 2008, MOVEMENT DISORD, V23, P501, DOI 10.1002/mds.21509; Marjama-Lyons J, 2002, MOV DISORD S5, V17, pS190; Meek C, 2010, MOVEMENT DISORD, V25, pS713; Mehrholz J, 2010, COCHRANE DB SYST REV, V1; Morris ME, 2010, PHYS THER, V90, P280, DOI 10.2522/ptj.20090091; Munneke M, 2010, LANCET NEUROL, V9, P46, DOI 10.1016/S1474-4422(09)70327-8; MUTCH WJ, 1986, BRIT MED J, V293, P675, DOI 10.1136/bmj.293.6548.675; Nieuwboer A, 2007, J NEUROL NEUROSUR PS, V78, P134, DOI 10.1136/jnnp.200X.097923; Nijkrake MJ, 2007, PARKINSONISM RELAT D, V13, pS488, DOI 10.1016/S1353-8020(08)70054-3; Parkinson's Disease Society, 2008, LIF PARK TOD ROOM IM; PERRY J, 1995, STROKE, V26, P982, DOI 10.1161/01.STR.26.6.982; Plant R, 2000, PHYSIOTHERAPY PEOPLE; Post B, 2011, POSTGRAD MED J, V87, P575, DOI 10.1136/pgmj.2011.241604rep; Protas EJ, 2005, NEUROREHABILITATION, V20, P183; Purchas MA, 2007, MOV DISORD S16, V22, pS260; Rascol O, 2002, PARKINSONISM RELAT D, V9, P61, DOI 10.1016/S1353-8020(02)00045-7; Robertson D, 2003, NEUROLOGICAL REHABIL; Robertson D, 2008, PARKINSONS DIS OLDER; Rubenis J, 2007, PARKINSONISM RELAT D, V13, pS495, DOI 10.1016/S1353-8020(08)70055-5; Sage MD, 2009, MOVEMENT DISORD, V24, P1132, DOI 10.1002/mds.22469; Schenkman M, 1998, J AM GERIATR SOC, V46, P1207, DOI 10.1111/j.1532-5415.1998.tb04535.x; Schilling BK, 2008, MOV DISORD S1, V23, pS639; Schmitz-Hubsch T, 2006, MOVEMENT DISORD, V21, P543, DOI 10.1002/mds.20705; Schrag A, 2000, MOVEMENT DISORD, V15, P1112, DOI 10.1002/1531-8257(200011)15:6<1112::AID-MDS1008>3.0.CO;2-A; Schrag A, 2006, MOVEMENT DISORD, V21, P1200, DOI 10.1002/mds.20914; Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI [10.1136/bmj.c332, 10.1186/1741-7015-8-18]; Shankar A, 2009, MOVEMENT DISORD, V24, pS281; Shankar A, 2008, MOV DISORD S1, V23, pS608; Shulman LM, 2010, ARCH NEUROL-CHICAGO, V67, P64, DOI 10.1001/archneurol.2009.295; Stack E, 2012, PARKINSONS DIS-US, V2012, DOI 10.1155/2012/360231; Steffen T, 2008, PHYS THER, V88, P733, DOI 10.2522/ptj.20070214; Stozek J, 2003, NEUROL NEUROCHIR S5, V37, pS67; Taheri H, 2011, J ISFAHAN MED SCH, V29, P1183; Talakad S, 2011, MOVEMENT DISORD, V26, pS173; Thaut MH, 1996, MOVEMENT DISORD, V11, P193, DOI 10.1002/mds.870110213; Tomlinson CL, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002817.pub2; van der Marck MA, 2009, PARKINSONISM RELAT D, V15, pS219, DOI 10.1016/S1353-8020(09)70819-3; van Nimwegen M, 2011, J NEUROL, V258, P2214, DOI 10.1007/s00415-011-6097-7; Yarrow S, 1999, PARKINSONS DIS STUDI, P79	74	179	185	1	74	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 6	2012	345								e5004	10.1136/bmj.e5004	http://dx.doi.org/10.1136/bmj.e5004			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	988MY	22867913	Green Published, Green Submitted, hybrid, Green Accepted			2023-01-03	WOS:000307496300001
J	Tricco, AC; Lillie, E; Soobiah, C; Perrier, L; Straus, SE				Tricco, Andrea C.; Lillie, Erin; Soobiah, Charlene; Perrier, Laure; Straus, Sharon E.			Impact of H1N1 on Socially Disadvantaged Populations: Systematic Review	PLOS ONE			English	Review							INFLUENZA-A H1N1; PANDEMIC INFLUENZA; VIRUS-INFECTION; HOSPITALIZED-PATIENTS; SAURASHTRA REGION; EPIDEMIOLOGIC CHARACTERISTICS; SEASONAL INFLUENZA; PREGNANT-WOMEN; AUSTRALIA; CHILDREN	Background: The burden of H1N1 among socially disadvantaged populations is unclear. We aimed to synthesize hospitalization, severe illness, and mortality data associated with pandemic A/H1N1/2009 among socially disadvantaged populations. Methods/Principal Findings: Studies were identified through searching MEDLINE, EMBASE, scanning reference lists, and contacting experts. Studies reporting hospitalization, severe illness, and mortality attributable to laboratory-confirmed 2009 H1N1 pandemic among socially disadvantaged populations (e. g., ethnic minorities, low-income or lower-middle-income economy countries [LIC/LMIC]) were included. Two independent reviewers conducted screening, data abstraction, and quality appraisal (Newcastle Ottawa Scale). Random effects meta-analysis was conducted using SAS and Review Manager. Conclusions/Significance: Sixty-two studies including 44,777 patients were included after screening 787 citations and 164 full-text articles. The prevalence of hospitalization for H1N1 ranged from 17-87% in high-income economy countries (HIC) and 11-45% in LIC/LMIC. Of those hospitalized, the prevalence of intensive care unit (ICU) admission and mortality was 6-76% and 1-25% in HIC; and 30% and 8-15%, in LIC/LMIC, respectively. There were significantly more hospitalizations among ethnic minorities versus non-ethnic minorities in two studies conducted in North America (1,313 patients, OR 2.26 [95% CI: 1.53-3.32]). There were no differences in ICU admissions (n = 8 studies, 15,352 patients, OR 0.84 [0.69-1.02]) or deaths (n = 6 studies, 14,757 patients, OR 0.85 [95% CI: 0.73-1.01]) among hospitalized patients in HIC. Sub-group analysis indicated that the meta-analysis results were not likely affected by confounding. Overall, the prevalence of hospitalization, severe illness, and mortality due to H1N1 was high for ethnic minorities in HIC and individuals from LIC/LMIC. However, our results suggest that there were little differences in the proportion of hospitalization, severe illness, and mortality between ethnic minorities and non-ethnic minorities living in HIC.	[Tricco, Andrea C.; Lillie, Erin; Soobiah, Charlene; Perrier, Laure; Straus, Sharon E.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Soobiah, Charlene] Hosp Sick Children, Child Hlth Evaluat Sci, Toronto, ON M5G 1X8, Canada; [Straus, Sharon E.] Univ Toronto, Fac Med, Div Geriatr, Toronto, ON, Canada	University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Tricco, AC (corresponding author), St Michaels Hosp, Li Ka Shing Knowledge Inst, 30 Bond St, Toronto, ON M5B 1W8, Canada.	sharon.straus@utoronto.ca	Tricco, Andrea/B-9920-2011; Perrier, Laure/D-4638-2011	Tricco, Andrea/0000-0002-4114-8971; Perrier, Laure/0000-0001-9941-7129	World Health Organization (WHO); Tier 1 Canada Research Chair through the Canadian Institutes for Health Research	World Health Organization (WHO)(World Health Organization); Tier 1 Canada Research Chair through the Canadian Institutes for Health Research	This systematic review was partially funded by the World Health Organization (WHO), Global Influenza Programme (http://www.who.int/influenza/about/en/). The funders had no role in study design, data collection and analysis, decision to publish, or the preparation of the manuscript. Sharon E. Straus is funded by a Tier 1 Canada Research Chair through the Canadian Institutes for Health Research.	[Anonymous], 2009, COCHR HDB SYST REV I; Baker MG, 2009, EURO SURVEILLANCE B, V14; Balish A., 2009, Morbidity and Mortality Weekly Report, V58, P826; Bandaranayake D, 2011, EURO SURVEILLANCE B, V16; Bettinger JA, 2010, VACCINE, V28, P3180, DOI 10.1016/j.vaccine.2010.02.044; Bhopal R, 2004, J EPIDEMIOL COMMUN H, V58, P441, DOI 10.1136/jech.2003.013466; Campbell A, 2010, CAN MED ASSOC J, V182, P349, DOI 10.1503/cmaj.091823; Castrodale L., 2009, Morbidity and Mortality Weekly Report, V58, P1341; Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P941; Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P536; Centers for Disease Control and Prevention (CDC), 2011, INFL DIAGN TEST ALG; Chacko J, 2010, INDIAN J CRIT CARE M, V14, P77, DOI 10.4103/0972-5229.68220; Chien YS, 2010, J INFECTION, V60, P168, DOI 10.1016/j.jinf.2009.12.012; Chitnis Amit S, 2010, WMJ, V109, P201; Chudasama RK, 2011, LUNG INDIA, V28, P11, DOI 10.4103/0970-2113.76294; Chudasama RK, 2010, J INFECT DEV COUNTR, V4, P834, DOI 10.3855/jidc.1049; Chudasama RK, 2010, INDIAN J CRIT CARE M, V14, P113, DOI 10.4103/0972-5229.74169; Chudasama RK, 2010, J PEDIAT SCI, V4, pe27; Chudasama RK, 2010, ONLINE J HLTH ALLIED, V9, P9; Creanga AA, 2010, OBSTET GYNECOL, V115, P717, DOI 10.1097/AOG.0b013e3181d57947; Cretikos M, 2009, EURO SURVEILL, V14; Dee DL, 2011, ANN EPIDEMIOL, V21, P623, DOI 10.1016/j.annepidem.2011.03.002; Dee S, 2010, NEW ZEAL MED J, V123, P45; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Falagas ME, 2011, EPIDEMIOL INFECT, V139, P27, DOI 10.1017/S0950268810002037; Falagas ME, 2010, EUR J CLIN MICROBIOL, V29, P1327, DOI 10.1007/s10096-010-1002-3; Flint SM, 2010, MED J AUSTRALIA, V192, P617, DOI 10.5694/j.1326-5377.2010.tb03654.x; Flint SM, 2009, NO TERRITORY DIS CON, V16, P1; Galante M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031696; Galarce EM, 2011, VACCINE, V29, P5284, DOI 10.1016/j.vaccine.2011.05.014; Gupta BD, 2011, J TROP PEDIATRICS, V57, P87, DOI 10.1093/tropej/fmq048; Hancock K, 2009, NEW ENGL J MED, V361, P1945, DOI 10.1056/NEJMoa0906453; Harris PNA, 2010, COMMUN DIS INTELL, V34, P102; Helferty M, 2010, CAN MED ASSOC J, V182, P1981, DOI 10.1503/cmaj.100746; Higgins AM, 2011, ANAESTH INTENS CARE, V39, P384, DOI 10.1177/0310057X1103900308; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Jain S, 2009, NEW ENGL J MED, V361, P1935, DOI 10.1056/NEJMoa0906695; Jouvet P, 2010, PEDIATR CRIT CARE ME, V11, P603, DOI 10.1097/PCC.0b013e3181d9c80b; Jung J, 2011, 2009 2010 H1N1 RELAT; Kelly H, 2009, EURO SURVEILLANCE B, V14; Kelly PM, 2011, MED J AUSTRALIA, V194, P169, DOI 10.5694/j.1326-5377.2011.tb03764.x; Knight M, 2011, BJOG-INT J OBSTET GY, V118, P232, DOI 10.1111/j.1471-0528.2010.02736.x; Kumar S, 2010, PEDIATR INFECT DIS J, V29, P591, DOI 10.1097/INF.0b013e3181d73e32; Kwan-Gett TS, 2009, DISASTER MED PUBLIC, V3, pS109, DOI 10.1097/DMP.0b013e3181c6b818; La Ruche G, 2009, EUROSURVEILLANCE, V14, P51; Lahlou Amine I, 2011, EURO SURVEILL, V16; Lai PL, 2011, HUM VACCINES, V7, P217, DOI 10.4161/hv.7.0.14607; Landry ML, 2011, CURR OPIN PEDIATR, V23, P91, DOI 10.1097/MOP.0b013e328341ebd9; LaRussa P, 2011, SEMIN RESP CRIT CARE, V32, P393, DOI 10.1055/s-0031-1283279; Lee EH, 2010, CLIN INFECT DIS, V50, P1498, DOI 10.1086/652446; Louie J, 2011, HOSPITALIZATIONS 200; Louriz M, 2010, INT ARCH MED, V3; Martin SS, 2010, CHEST, V137, P1195, DOI 10.1378/chest.10-0032; Miller RR, 2010, CHEST, V137, P752, DOI 10.1378/chest.09-2517; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Naseem A, 2011, JCPSP-J COLL PHYSICI, V21, P97, DOI 02.2011/JCPSP.97102; Nguyen-Van-Tam JS, 2010, THORAX, V65, P645, DOI 10.1136/thx.2010.135210; Oluyomi-Obi T, 2010, J OBSTET GYNAECOL CA, V32, P443, DOI 10.1016/S1701-2163(16)34497-8; Paine S, 2010, Euro Surveill, V15; Parakh A, 2010, INDIAN J PEDIATR, V77, P981, DOI 10.1007/s12098-010-0168-0; Pramanick A, 2011, INT J GYNECOL OBSTET, V113, P32, DOI 10.1016/j.ijgo.2010.10.025; Puvanalingam A, 2011, J Assoc Physicians India, V59, P14; Ramakrishna K, 2011, CLIN MICROBIOL INFEC, V17, P1355, DOI 10.1111/j.1469-0691.2011.03584.x; Rao SRJ, 2011, INDIAN J PATHOL MICR, V54, P323, DOI [10.4103/0377-4929.81588, 10.4103/0377-4929.81618]; Reed C, 2009, EMERG INFECT DIS, V15, P2004, DOI 10.3201/eid1512.091413; Reyes L, 2010, INFLUENZA OTHER RESP, V4, P129, DOI 10.1111/j.1750-2659.2010.00138.x; Ritger K. A., 2009, Morbidity and Mortality Weekly Report, V58, P913; Sachedina N, 2010, LANCET, V376, P1846, DOI 10.1016/S0140-6736(10)61195-6; Satterwhite L, 2010, CRIT CARE MED, V38, P2059, DOI 10.1097/CCM.0b013e3181eb96dc; Schanzer DL, 2007, J OBSTET GYNAECOL CA, V29, P622, DOI 10.1016/S1701-2163(16)32559-2; Scriven J, 2009, CLIN MED, V9, P534, DOI 10.7861/clinmedicine.9-6-534; Seppelt I, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1279; Sharma V, 2010, J INFECT DEV COUNTR, V4, P468, DOI 10.3855/jidc.1007; Siston AM, 2010, JAMA-J AM MED ASSOC, V303, P1517, DOI 10.1001/jama.2010.479; Slopen M. E., 2010, Morbidity and Mortality Weekly Report, V58, P1436; Subramony H, 2010, ANN ACAD MED SINGAP, V39, P283; Truelove SA, 2011, J INFECT DIS, V203, P828, DOI 10.1093/infdis/jiq117; Van Kerkhove MD, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001053; Verrall A, 2010, EMERG INFECT DIS, V16, P100, DOI 10.3201/eid1601.090994; Webb SAR, 2009, NEW ENGL J MED, V361, P1925, DOI 10.1056/NEJMoa0908481; Wells GA, 2011, NEWCASTLE OTTAWA SCA; Wenger JD, 2011, CLIN INFECT DIS, V52, pS189, DOI 10.1093/cid/ciq037; World Bank, 2011, WORLD BANK CLASS; Zarychanski Ryan, 2010, CMAJ, V182, P257, DOI 10.1503/cmaj.091884	84	18	18	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2012	7	6							e39437	10.1371/journal.pone.0039437	http://dx.doi.org/10.1371/journal.pone.0039437			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	965QG	22761796	Green Published, Green Submitted, gold			2023-01-03	WOS:000305781700038
J	Polglase, GR; Miller, SL; Barton, SK; Baburamani, AA; Wong, FY; Aridas, JDS; Gill, AW; Moss, TJM; Tolcos, M; Kluckow, M; Hooper, SB				Polglase, Graeme R.; Miller, Suzanne L.; Barton, Samantha K.; Baburamani, Ana A.; Wong, Flora Y.; Aridas, James D. S.; Gill, Andrew W.; Moss, Timothy J. M.; Tolcos, Mary; Kluckow, Martin; Hooper, Stuart B.			Initiation of Resuscitation with High Tidal Volumes Causes Cerebral Hemodynamic Disturbance, Brain Inflammation and Injury in Preterm Lambs	PLOS ONE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; END-EXPIRATORY PRESSURE; BLOOD-FLOW VELOCITY; WHITE-MATTER INJURY; VENA-CAVA FLOW; INTRAVENTRICULAR HEMORRHAGE; INTRAAMNIOTIC ENDOTOXIN; LUNG MATURATION; NEWBORN-INFANT; FETAL SHEEP	Aims: Preterm infants can be inadvertently exposed to high tidal volumes (V-T) in the delivery room, causing lung inflammation and injury, but little is known about their effects on the brain. The aim of this study was to compare an initial 15 min of high V-T resuscitation strategy to a less injurious resuscitation strategy on cerebral haemodynamics, inflammation and injury. Methods: Preterm lambs at 126 d gestation were surgically instrumented prior to receiving resuscitation with either: 1) High V-T targeting 10-12 mL/kg for the first 15 min (n = 6) or 2) a protective resuscitation strategy (Prot V-T), consisting of prophylactic surfactant, a 20 s sustained inflation and a lower initial V-T (7 mL/kg; n = 6). Both groups were subsequently ventilated with a V-T 7 mL/kg. Blood gases, arterial pressures and carotid blood flows were recorded. Cerebral blood volume and oxygenation were assessed using near infrared spectroscopy. The brain was collected for biochemical and histologic assessment of inflammation, injury, vascular extravasation, hemorrhage and oxidative injury. Unventilated controls (UVC; n = 6) were used for comparison. Results: High V-T lambs had worse oxygenation and required greater ventilatory support than Prot V-T lambs. High V-T resulted in cerebral haemodynamic instability during the initial 15 min, adverse cerebral tissue oxygenation index and cerebral vasoparalysis. While both resuscitation strategies increased lung and brain inflammation and oxidative stress, High V-T resuscitation significantly amplified the effect (p = 0.014 and p<0.001). Vascular extravasation was evident in the brains of 60% of High V-T lambs, but not in UVC or Prot V-T lambs. Conclusion: High V-T resulted in greater cerebral haemodynamic instability, increased brain inflammation, oxidative stress and vascular extravasation than a Prot V-T strategy. The initiation of resuscitation targeting Prot V-T may reduce the severity of brain injury in preterm neonates.	[Polglase, Graeme R.; Miller, Suzanne L.; Barton, Samantha K.; Baburamani, Ana A.; Wong, Flora Y.; Aridas, James D. S.; Moss, Timothy J. M.; Tolcos, Mary; Hooper, Stuart B.] Monash Univ, Monash Inst Med Res, Ritchie Ctr, Clayton, Vic, Australia; [Polglase, Graeme R.; Miller, Suzanne L.; Moss, Timothy J. M.; Hooper, Stuart B.] Monash Univ, Dept Obstet & Gynecol, Clayton, Vic, Australia; [Gill, Andrew W.] Univ Western Australia, Sch Womens & Infants Hlth, Ctr Neonatal Res & Educ, Crawley, WA, Australia; [Kluckow, Martin] Royal N Shore Hosp, Dept Neonatal Med, Sydney, NSW, Australia; [Kluckow, Martin] Univ Sydney, Sydney, NSW 2006, Australia	Monash University; Monash University; University of Western Australia; Royal North Shore Hospital; University of Sydney; University of Sydney	Polglase, GR (corresponding author), Monash Univ, Monash Inst Med Res, Ritchie Ctr, Clayton, Vic, Australia.	graeme.polglase@monash.edu	Baburamani, Ana/J-4920-2019; Moss, Timothy/A-6633-2008; Baburamani, Ana/AGD-2259-2022	Moss, Timothy/0000-0002-9408-4027; Baburamani, Ana/0000-0002-7537-6534; Miller, Suzanne/0000-0002-0451-8304; Barton, Samantha/0000-0001-7601-0238; Kluckow, Martin/0000-0003-1875-7530; Polglase, Graeme/0000-0002-8906-614X; Hooper, Stuart/0000-0003-1676-4825; Tolcos, Mary/0000-0001-6105-4553	Cerebral Palsy Alliance of Australia; North Shore Heart Research Foundation; NHMRC [1026890, 545921]; Victorian Government	Cerebral Palsy Alliance of Australia; North Shore Heart Research Foundation; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Victorian Government	This research was supported by the Cerebral Palsy Alliance of Australia, North Shore Heart Research Foundation, NH&MRC Research Fellowships (GRP: 1026890) and SBH: 545921) and the Victorian Government's Operational Infrastructure Support Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Back SA, 2001, J NEUROSCI, V21, P1302; Bjorklund LJ, 1997, PEDIATR RES, V42, P348; Chiumello D, 1999, AM J RESP CRIT CARE, V160, P109, DOI 10.1164/ajrccm.160.1.9803046; Dani C, 2002, ACTA PAEDIATR, V91, P938, DOI 10.1080/080352502760272623; de Waal KA, 2007, ARCH DIS CHILD-FETAL, V92, P444, DOI 10.1136/adc.2006.103929; DELTORO J, 1991, PEDIATR NEUROL, V7, P3, DOI 10.1016/0887-8994(91)90098-6; DUNCAN A, 1995, PHYS MED BIOL, V40, P295, DOI 10.1088/0031-9155/40/2/007; Elwell C., 1995, HAMAMATSU PHOTONICS; GLEASON CA, 1988, AM J PHYSIOL, V255, pR1049, DOI 10.1152/ajpregu.1988.255.6.R1049; HAYASHI T, 1992, EUR J PEDIATR, V151, P461, DOI 10.1007/BF01959365; Haynes RL, 2003, J NEUROPATH EXP NEUR, V62, P441, DOI 10.1093/jnen/62.5.441; Hillman NH, 2007, AM J RESP CRIT CARE, V176, P575, DOI 10.1164/rccm.200701-051OC; Hillman NH, 2011, AM J PHYSIOL-LUNG C, V300, pL232, DOI 10.1152/ajplung.00294.2010; Hillman NH, 2010, PEDIATR RES, V67, P60, DOI 10.1203/PDR.0b013e3181c1b09e; Ikegami M, 2004, AM J PHYSIOL-LUNG C, V286, pL573, DOI 10.1152/ajplung.00211.2003; Jobe AH, 2008, NEONATOLOGY, V94, P190, DOI 10.1159/000143721; Kallapur SG, 2001, AM J PHYSIOL-LUNG C, V280, pL527, DOI 10.1152/ajplung.2001.280.3.L527; Kallapur SG, 2011, AM J PHYSL LUNG CELL; Khwaja O, 2008, ARCH DIS CHILD-FETAL, V93, pF153, DOI 10.1136/adc.2006.108837; Kluckow M, 2000, ARCH DIS CHILD-FETAL, V82, pF188, DOI 10.1136/fn.82.3.F188; LOU HC, 1979, J PEDIATR-US, V94, P118, DOI 10.1016/S0022-3476(79)80373-X; Meek JH, 1999, ARCH DIS CHILD-FETAL, V81, pF110, DOI 10.1136/fn.81.2.F110; Miletin J, 2008, ARCH DIS CHILD-FETAL, V93, pF368, DOI 10.1136/adc.2007.129304; PERLMAN JM, 1983, NEW ENGL J MED, V309, P204, DOI 10.1056/NEJM198307283090402; Polglase GR, 2008, PEDIATR RES, V64, P517, DOI 10.1203/PDR.0b013e3181841363; Polglase GR, 2008, J APPL PHYSIOL, V105, P603, DOI 10.1152/japplphysiol.00041.2008; Polglase GR, 2012, REPROD FERT DEVELOP, V24, P510, DOI 10.1071/RD11121; Polglase GR, 2012, J APPL PHYSIOL, V112, P481, DOI 10.1152/japplphysiol.00995.2011; Polglase GR, 2010, PEDIATR RES, V67, P630, DOI 10.1203/PDR.0b013e3181dbbd18; Polglase GR, 2009, J APPL PHYSIOL, V106, P1347, DOI 10.1152/japplphysiol.91445.2008; Polglase GR, 2009, PEDIATR RES, V65, P67, DOI 10.1203/PDR.0b013e318189487e; Poulton DA, 2011, RESUSCITATION, V82, P175, DOI 10.1016/j.resuscitation.2010.10.012; RICHARDSON BS, 1989, AM J PHYSIOL, V257, pR1251, DOI 10.1152/ajpregu.1989.257.5.R1251; Rosenbaum JL, 1997, NEUROLOGY, V49, P1035, DOI 10.1212/WNL.49.4.1035; RUDOLPH AM, 1977, AM REV RESPIR DIS, V115, P11; Schmolzer GM, 2010, ARCH DIS CHILD-FETAL, V95, pF393, DOI 10.1136/adc.2009.174003; Schmolzer GM, 2008, J PEDIATR-US, V153, P741, DOI 10.1016/j.jpeds.2008.08.016; Siew ML, 2011, PEDIATR RES, V70, P50, DOI 10.1203/PDR.0b013e31821be094; Sobotka KS, 2011, PEDIAT RES IN PRESS; Stenson BJ, 2006, CLIN PERINATOL, V33, P65, DOI 10.1016/j.clp.2005.11.015; te Pas AB, 2009, PEDIATR RES, V66, P295, DOI 10.1203/PDR.0b013e3181b1bca4; VANBEL F, 1994, PEDIATR RES, V35, P329; Volpe J J, 1998, Semin Pediatr Neurol, V5, P135, DOI 10.1016/S1071-9091(98)80030-2; Wallace MJ, 2010, PED AC SOC ANN M ABS, V4407, P222; WINBERG P, 1990, ACTA PAEDIATR SCAND, V79, P1150; Wong FY, 2010, ANESTHESIOLOGY, V113, P1385, DOI 10.1097/ALN.0b013e3181fc5567; Yanowitz TD, 2002, PEDIATR RES, V51, P310, DOI 10.1203/00006450-200203000-00008	47	91	93	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2012	7	6							e39535	10.1371/journal.pone.0039535	http://dx.doi.org/10.1371/journal.pone.0039535			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	964XV	22761816	Green Published, Green Submitted, gold			2023-01-03	WOS:000305730900072
J	Hannouf, MB; Sehgal, C; Cao, JQ; Mocanu, JD; Winquist, E; Zaric, GS				Hannouf, Malek B.; Sehgal, Chander; Cao, Jeffrey Q.; Mocanu, Joseph D.; Winquist, Eric; Zaric, Gregory S.			Cost-Effectiveness of Adding Cetuximab to Platinum-Based Chemotherapy for First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer	PLOS ONE			English	Article							SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; QUALITY-OF-LIFE; UNKNOWN PRIMARY; PLUS CETUXIMAB; ORPHAN DRUGS; RADIOTHERAPY; PERSPECTIVE; ANTIBODY; ADOPTION	Purpose: To assess the cost effectiveness of adding cetuximab to platinum-based chemotherapy in first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) from the perspective of the Canadian public healthcare system. Methods: We developed a Markov state transition model to project the lifetime clinical and economic consequences of recurrent or metastatic HNSCC. Transition probabilities were derived from a phase III trial of cetuximab in patients with recurrent or metastatic HNSCC. Cost estimates were obtained from London Health Sciences Centre and the Ontario Case Costing Initiative, and expressed in 2011 CAD. A three year time horizon was used. Future costs and health benefits were discounted at 5%. Results: In the base case, cetuximab plus platinum-based chemotherapy compared to platinum-based chemotherapy alone led to an increase of 0.093 QALY and an increase in cost of $36,000 per person, resulting in an incremental cost effectiveness ratio (ICER) of $386,000 per QALY gained. The cost effectiveness ratio was most sensitive to the cost per mg of cetuximab and the absolute risk of progression among patients receiving cetuximab. Conclusion: The addition of cetuximab to standard platinum-based chemotherapy in first-line treatment of patients with recurrent or metastatic HNSCC has an ICER that exceeds $100,000 per QALY gained. Cetuximab can only be economically attractive in this patient population if the cost of cetuximab is substantially reduced or if future research can identify predictive markers to select patients most likely to benefit from the addition of cetuximab to chemotherapy.	[Hannouf, Malek B.; Zaric, Gregory S.] Univ Western Ontario, Dept Epidemiol & Biostat, Schulich Sch Med & Dent, London, ON, Canada; [Sehgal, Chander; Cao, Jeffrey Q.; Mocanu, Joseph D.; Zaric, Gregory S.] Univ Western Ontario, Richard Ivey Sch Business, London, ON, Canada; [Cao, Jeffrey Q.] London Hlth Sci Ctr, London Reg Canc Program, Dept Radiat Oncol, London, ON, Canada; [Winquist, Eric] Univ Western Ontario, Dept Oncol, Schulich Sch Med & Dent, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); Western University (University of Western Ontario)	Hannouf, MB (corresponding author), Univ Western Ontario, Dept Epidemiol & Biostat, Schulich Sch Med & Dent, London, ON, Canada.	gzaric@ivey.uwo.ca	Zaric, Gregory/B-7665-2013; Cao, Jeffrey/AAL-3736-2021		Canadian Institutes of Health Research (CIHR); Natural Sciences and Engineering Research Council of Canada (NSERC)	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC))	Funding was provided by the Canadian Institutes of Health Research (CIHR) Strategic Training Program in Cancer Research and Technology Transfer (CaRTT) and the Natural Sciences and Engineering Research Council of Canada (NSERC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDERSON JA, 1992, J OTOLARYNGOL, V21, P321; Avritscher Elenir B C, 2010, J Support Oncol, V8, P242, DOI 10.1016/j.suponc.2010.09.027; Bank of Canada, 2011, HOM RAT STAT REL INF; BC Cancer Agency, 2010, BCCA PROT SUMM COMB; Bernier J, 2008, NAT CLIN PRACT ONCOL, V5, P705, DOI 10.1038/ncponc1228; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Bonner JA, 2010, LANCET ONCOL, V11, P21, DOI 10.1016/S1470-2045(09)70311-0; Brown B, 2008, VALUE HEALTH, V11, P791, DOI 10.1111/j.1524-4733.2007.00302.x; Canadian Cancer Society National Cancer Institute of Canada, 2009, CAN CANC STAT; Cancer care Ontario, 2004, 115 CANC CAR ONT; Colevas AD, 2006, J CLIN ONCOL, V24, P2644, DOI 10.1200/JCO.2005.05.3348; Cripps C, 2010, CURR ONCOL, V17, P37; Drummond MF, 2007, INT J TECHNOL ASSESS, V23, P36, DOI 10.1017/S0266462307051550; Drummond MF, 2007, J CLIN ONCOL, V25, P191, DOI 10.1200/JCO.2006.07.8956; Ferte C, 2010, ONCOLOGY-BASEL, V78, P87, DOI 10.1159/000306137; Fryback DG, 1997, MED DECIS MAKING, V17, P276, DOI 10.1177/0272989X9701700303; Goldstein NI, 1995, CLIN CANCER RES, V1, P1311; Grutters JPC, 2010, THORAX, V65, P903, DOI 10.1136/thx.2010.136390; Ho C, 2010, CURR ONCOL, V17, P174; Hoch J, 2012, COMMUNICATION; Hughes DA, 2005, QJM-INT J MED, V98, P829, DOI 10.1093/qjmed/hci128; Fernandez-Cotarelo MJ, 2010, TUMORI J, V96, P111, DOI 10.1177/030089161009600118; Kimura H, 2007, CANCER SCI, V98, P1275, DOI 10.1111/j.1349-7006.2007.00510.x; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; Lee KM, 2017, GUID EC EV HLTH TECH, V4th; London Health Sciences Centre: London Regional Cancer Program (LRCP), 2011, FORM; Mavranezouli I, 2010, PHARMACOECONOMICS, V28, P1109, DOI 10.2165/11537300-000000000-00000; McCabe C, 2007, INT J TECHNOL ASSESS, V23, P397; McKenna C, 2011, MED DECIS MAKING, V31, P853, DOI 10.1177/0272989X11399921; Mittmann N, 2010, CURR ONCOL, V17, P7; Mittmann N, 2009, J NATL CANCER I, V101, P1182, DOI 10.1093/jnci/djp232; National Institute for Health and Clinical Excellence (NICE), 2008, NICE TECHN APPR GUID, V145; National institute of health and Clinical Excellence (NICE), 2009, GUID CET TREATM MET; National institute of health and Clinical Excellence (NICE), 2009, MAN SUBM CET TREATM; National Institute of Health and Clinical Excellence (NICE), 2010, GUID CET TREATM REC; Ontario Ministry of Health and Long-Term Care, 2011, ONT CAS COST IN OCCI; Ontario Ministry of Health and Long-Term Care, 2007, ONT HLTH INS OHIP SC; Patented Medicine Prices Review Board, 2009, REP NEW PAT DRUGS ER; Pepper PV, 2000, CLIN INFECT DIS, V30, P157, DOI 10.1086/313601; Pohjolainen V, 2010, INT J EAT DISORDER, V43, P596, DOI 10.1002/eat.20754; Rathcke IO, 1996, LARYNGO RHINO OTOL, V75, P465, DOI 10.1055/s-2007-997616; Sambrook J, 2009, J CLIN ONCOL, V27; Simoens S, 2011, J CLIN PHARM THER, V36, P249, DOI 10.1111/j.1365-2710.2010.01181.x; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Statistics Canada/Health Statistics Division, 2006, MIN IND PUBL; Stenson KM, 2011, OVERVIEW HEAD NECK C; Talmor D, 2008, CRIT CARE MED, V36, P1168, DOI 10.1097/CCM.0b013e318168f649; Van Cutsem E, 2007, J CLIN ONCOL, V25; Vermorken JB, 2008, NEW ENGL J MED, V359, P1116, DOI 10.1056/NEJMoa0802656; WITTES RE, 1977, CANCER TREAT REP, V61, P359	50	26	27	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2012	7	6							e38557	10.1371/journal.pone.0038557	http://dx.doi.org/10.1371/journal.pone.0038557			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	964KK	22745668	Green Published, gold, Green Submitted			2023-01-03	WOS:000305693200014
J	Martino, F; Lorenzen, J; Schmidt, J; Schmidt, M; Broll, M; Gorzig, Y; Kielstein, JT; Thum, T				Martino, Filippo; Lorenzen, Johan; Schmidt, Julius; Schmidt, Mascha; Broll, Michael; Goerzig, Yvonne; Kielstein, Jan T.; Thum, Thomas			Circulating MicroRNAs Are Not Eliminated by Hemodialysis	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS; MIR-210; CANCER; ACTIVATION; EXPRESSION; REVEALS	Background: Circulating microRNAs are stably detectable in serum/plasma and other body fluids. In patients with acute kidney injury on dialysis therapy changes of miRNA patterns had been detected. It remains unclear if and how the dialysis procedure itself affects circulating microRNA level. Methods: We quantified miR-21 and miR-210 by quantitative RT-PCR in plasma of patients with acute kidney injury requiring dialysis and measured pre- and post-dialyser miRNA levels as well as their amount in the collected spent dialysate. Single treatments using the following filters were studied: F60 S (1.3 m(2), Molecular Weight Cut Off (MWCO): 30 kDa, n = 8), AV 1000 S (1.8 m(2), MWCO: 30 kDa, n = 6) and EMiC 2 (1.8 m(2), MWCO: 40 kDa, n = 6). Results: Circulating levels of miR-21 or -210 do not differ between pre- and post-dialyzer blood samples independently of the used filter surface and pore size: miR-21: F60S: p = 0.35, AV 1000 S p = 1.0, EMiC2 p = 1.0; miR-210: F60S: p = 0.91, AV 1000 S p = 0.09, EMiC2 p = 0.31. Correspondingly, only traces of both miRNAs could be found in the collected spent dialysate and ultrafiltrate. Conclusions: In patients with acute kidney injury circulating microRNAs are not removed by dialysis. As only traces of miR-21 and -210 are detected in dialysate and ultrafiltrate, microRNAs in the circulation are likely to be transported by larger structures such as proteins and/or microvesicles. As miRNAs are not affected by dialysis they might be more robust biomarkers of acute kidney injury.	[Martino, Filippo; Lorenzen, Johan; Schmidt, Mascha; Goerzig, Yvonne; Thum, Thomas] Hannover Med Sch, IMTTS, D-3000 Hannover, Germany; [Lorenzen, Johan; Schmidt, Julius; Broll, Michael; Kielstein, Jan T.] Hannover Med Sch, Dept Med, Div Nephrol & Hypertens, D-3000 Hannover, Germany; [Thum, Thomas] IRCCS San Raffaele, Ctr Clin & Basic Res, Rome, Italy	Hannover Medical School; Hannover Medical School; Center Clinical & Basic Research; IRCCS San Raffaele Pisana; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Martino, F (corresponding author), Hannover Med Sch, IMTTS, D-3000 Hannover, Germany.	Thum.Thomas@mh-hannover.de	Kielstein, Jan T./I-2956-2019	Kielstein, Jan T./0000-0001-8110-9064; Lorenzen, Johan/0000-0002-9132-948X; Thum, Thomas/0000-0003-4360-1511	German Federal Ministry of Education and Research [IFB-Tx: 01EO0802]; Deutsche Forschungsgemeinschaft (DFG) [903/7-2]; Fresenius Medical Care	German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Fresenius Medical Care	This work was supported by a grant from the German Federal Ministry of Education and Research (IFB-Tx: 01EO0802 to T.T.) and by Deutsche Forschungsgemeinschaft (DFG 903/7-2 to T.T.) as well as by an unrestricted grant of Fresenius Medical Care to JTK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031; Bihrer V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026971; Chau BN, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003205; Delaloy C, 2010, CELL STEM CELL, V6, P323, DOI 10.1016/j.stem.2010.02.015; Emilian C, 2012, CLIN J AM SOC NEPHRO, V7, P619, DOI 10.2215/CJN.10471011; Fliser D, 2006, NAT CLIN PRACT NEPHR, V2, P32, DOI 10.1038/ncpneph0060; Gupta SK, 2010, CIRC-CARDIOVASC GENE, V3, P484, DOI 10.1161/CIRCGENETICS.110.958363; Kumarswamy R, 2011, RNA BIOL, V8, P706, DOI 10.4161/rna.8.5.16154; Liu G, 2010, J EXP MED, V207, P1589, DOI 10.1084/jem.20100035; Lorenzen JM, 2011, AM J TRANSPLANT, V11, P2221, DOI 10.1111/j.1600-6143.2011.03679.x; Lorenzen JM, 2012, CLIN J AM S IN PRESS; Lorenzen JM, 2012, CLIN J AM SOC NEPHRO, V7, P385, DOI 10.2215/CJN.05690611; Lorenzen JM, 2011, CLIN J AM SOC NEPHRO, V6, P1540, DOI 10.2215/CJN.00430111; McDonald JS, 2011, CLIN CHEM, V57, P833, DOI 10.1373/clinchem.2010.157198; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Nana-Sinkam SP, 2011, MOL ONCOL, V5, P483, DOI 10.1016/j.molonc.2011.10.003; Neal CS, 2011, NEPHROL DIAL TRANSPL, V26, P3794, DOI 10.1093/ndt/gfr485; Sayed D, 2011, PHYSIOL REV, V91, P827, DOI 10.1152/physrev.00006.2010; Shen J, 2011, LAB INVEST, V91, P579, DOI 10.1038/labinvest.2010.194; Taylor DD, 2011, METHODS MOL BIOL, V728, P235, DOI 10.1007/978-1-61779-068-3_15; Thum T, 2007, CIRCULATION, V116, P258, DOI 10.1161/CIRCULATIONAHA.107.687947; Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511; Turchinovich A, 2011, NUCLEIC ACIDS RES, V39, P7223, DOI 10.1093/nar/gkr254; Valera VA, 2011, J CANCER, V2, P515, DOI 10.7150/jca.2.515; van der Fits L, 2011, J INVEST DERMATOL, V131, P762, DOI 10.1038/jid.2010.349; van Rooij E, 2008, P NATL ACAD SCI USA, V105, P13027, DOI 10.1073/pnas.0805038105; Volinia S, 2010, GENOME RES, V20, P589, DOI 10.1101/gr.098046.109; Wu HQ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001020; Xiong YJ, 2010, HEPATOLOGY, V51, P836, DOI 10.1002/hep.23380; Zaman MS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031060; Zampetaki A, 2011, CARDIOVASC RES  1109; Zampetaki A, 2010, CIRC RES, V107, P810, DOI 10.1161/CIRCRESAHA.110.226357; Zarjou A, 2011, AM J PHYSIOL-RENAL, V301, pF793, DOI 10.1152/ajprenal.00273.2011; Zhao XH, 2010, NEURON, V65, P612, DOI 10.1016/j.neuron.2010.02.018	36	40	51	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2012	7	6							e38269	10.1371/journal.pone.0038269	http://dx.doi.org/10.1371/journal.pone.0038269			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TQ	22715378	Green Published, Green Submitted, gold			2023-01-03	WOS:000305336800019
J	Dar, AC; Das, TK; Shokat, KM; Cagan, RL				Dar, Arvin C.; Das, Tirtha K.; Shokat, Kevan M.; Cagan, Ross L.			Chemical genetic discovery of targets and anti-targets for cancer polypharmacology	NATURE			English	Article							CELL-PROLIFERATION; DROSOPHILA MODEL; TYROSINE KINASE; INHIBITOR; PATHWAYS; CARCINOMA; RET; CHROMOSOME; PD-0325901; SORAFENIB	The complexity of cancer has led to recent interest in polypharmacological approaches for developing kinase-inhibitor drugs; however, optimal kinase-inhibition profiles remain difficult to predict. Using a Ret-kinase-driven Drosophila model of multiple endocrine neoplasia type 2 and kinome-wide drug profiling, here we identify that AD57 rescues oncogenic Ret-induced lethality, whereas related Ret inhibitors imparted reduced efficacy and enhanced toxicity. Drosophila genetics and compound profiling defined three pathways accounting for the mechanistic basis of efficacy and dose-limiting toxicity. Inhibition of Ret plus Raf, Src and S6K was required for optimal animal survival, whereas inhibition of the 'anti-target' Tor led to toxicity owing to release of negative feedback. Rational synthetic tailoring to eliminate Tor binding afforded AD80 and AD81, compounds featuring balanced pathway inhibition, improved efficacy and low toxicity in Drosophila and mammalian multiple endocrine neoplasia type 2 models. Combining kinase-focused chemistry, kinome-wide profiling and Drosophila genetics provides a powerful systems pharmacology approach towards developing compounds with a maximal therapeutic index.	[Dar, Arvin C.; Shokat, Kevan M.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94158 USA; [Dar, Arvin C.; Shokat, Kevan M.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA; [Das, Tirtha K.; Cagan, Ross L.] Mt Sinai Sch Med, Dept Dev & Regenerat Biol, New York, NY 10029 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Icahn School of Medicine at Mount Sinai	Shokat, KM (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94158 USA.	shokat@cmp.ucsf.edu	Cagan, Ross Leigh/AAV-9528-2021	Cagan, Ross/0000-0001-5297-450X	National Institutes of Health [R01CA109730, R01CA084309, R01EB001987, P01 CA081403-11]; American Cancer Society [120616-RSGM-11-018-01-CDD, 120886-PFM-11-137-01-DDC]; NATIONAL CANCER INSTITUTE [R01CA084309, R01CA109730, P01CA081403] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB001987] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	We thank the Bloomington Stock Center, Vienna Drosophila RNAi Center and C. Pfleger for reagents. T. K. D. and R. C. were supported by National Institutes of Health grants R01CA109730 and R01CA084309 and American Cancer Society Grant 120616-RSGM-11-018-01-CDD. T. K. D. was also supported by American Cancer Society Grant 120886-PFM-11-137-01-DDC. We thank members of the Shokat and Cagan laboratories for discussions. We thank members of the SelectScreen team at Invitrogen, in particular K. Vogel, for performing kinase-profiling services. K. M. S. thanks NIH R01EB001987, P01 CA081403-11 and The Waxman Foundation.	Ahmad T, 2004, CLIN CANCER RES, V10, p6388S, DOI 10.1158/1078-0432.CCR-040028; Almeida MQ, 2010, CANCER GENET CYTOGEN, V203, P30, DOI 10.1016/j.cancergencyto.2010.09.006; Alon U, 2007, NAT REV GENET, V8, P450, DOI 10.1038/nrg2102; Boss DS, 2009, ONCOLOGIST, V14, P780, DOI 10.1634/theoncologist.2009-0019; Brachmann CB, 2000, CURR BIOL, V10, P547, DOI 10.1016/S0960-9822(00)00474-7; Carlomagno F, 2002, CANCER RES, V62, P7284; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Dar AC, 2008, CHEM BIOL, V15, P1015, DOI 10.1016/j.chembiol.2008.09.007; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Druker BJ, 2008, BLOOD, V112, P4808, DOI 10.1182/blood-2008-07-077958; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Gedaly R, 2010, ANTICANCER RES, V30, P4951; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Guichard A, 1999, DEVELOPMENT, V126, P2663; Haura EB, 2010, CLIN CANCER RES, V16, P2450, DOI 10.1158/1078-0432.CCR-09-1920; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358; Knight ZA, 2010, NAT REV CANCER, V10, P130, DOI 10.1038/nrc2787; LAIRMORE TC, 1993, P NATL ACAD SCI USA, V90, P492, DOI 10.1073/pnas.90.2.492; LoRusso PM, 2010, CLIN CANCER RES, V16, P1924, DOI 10.1158/1078-0432.CCR-09-1883; Mestres J, 2009, MOL BIOSYST, V5, P1051, DOI 10.1039/b905821b; Read RD, 2004, MOL CELL BIOL, V24, P6676, DOI 10.1128/mcb.24.15.6676-6689.2004; Read RD, 2005, GENETICS, V171, P1057, DOI 10.1534/genetics.104.038018; Sawamoto K, 1996, DEV BIOL, V178, P13, DOI 10.1006/dbio.1996.0194; Sun L, 2003, J MED CHEM, V46, P1116, DOI 10.1021/jm0204183; Vidal M, 2006, DEV CELL, V10, P33, DOI 10.1016/j.devcel.2005.11.007; Vidal M, 2005, CANCER RES, V65, P3538, DOI 10.1158/0008-5472.CAN-04-4561; Vidal M, 2007, CANCER RES, V67, P10278, DOI 10.1158/0008-5472.CAN-07-1376; Wells SA, 2012, J CLIN ONCOL, V30, P134, DOI 10.1200/JCO.2011.35.5040; Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720	34	259	261	3	89	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 7	2012	486	7401					80	U101		10.1038/nature11127	http://dx.doi.org/10.1038/nature11127			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953GD	22678283	Green Accepted			2023-01-03	WOS:000304854000030
J	Nuila, R				Nuila, Ricardo			Home: Palliation for Dying Undocumented Immigrants	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEALTH-CARE; TRENDS		Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine	Nuila, R (corresponding author), Baylor Coll Med, Dept Med, Houston, TX 77030 USA.							Brotman B, 2011, CHICAGO TRIBUNE 0102; DuBard CA, 2007, JAMA-J AM MED ASSOC, V297, P1774; DuBard CA, 2007, JAMA-J AM MED ASSOC, V297, P1085, DOI 10.1001/jama.297.10.1085; Gawande A, 2010, NEW YORKER      0802; Okie S, 2007, NEW ENGL J MED, V357, P525, DOI 10.1056/NEJMp078113; Stimpson JP, 2010, HEALTH AFFAIR, V29, P544, DOI 10.1377/hlthaff.2009.0400	6	14	14	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 31	2012	366	22					2047	2048						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	949YE	22646628	Bronze			2023-01-03	WOS:000304613400002
J	Shankaran, S; Pappas, A; McDonald, SA; Vohr, BR; Hintz, SR; Epi, MS; Yolton, K; Gustafson, KE; Leach, TM; Green, C; Bara, R; Huitema, CMP; Ehrenkranz, RA; Tyson, JE; Das, A; Hammond, J; Peralta-Carcelen, M; Evans, PW; Heyne, RJ; Wilson-Costello, DE; Vaucher, YE; Bauer, CR; Dusick, AM; Adams-Chapman, I; Goldstein, RF; Guillet, R; Papile, LA; Higgins, RD				Shankaran, Seetha; Pappas, Athina; McDonald, Scott A.; Vohr, Betty R.; Hintz, Susan R.; Epi, M. S.; Yolton, Kimberly; Gustafson, Kathryn E.; Leach, Theresa M.; Green, Charles; Bara, Rebecca; Huitema, Carolyn M. Petrie; Ehrenkranz, Richard A.; Tyson, Jon E.; Das, Abhik; Hammond, Jane; Peralta-Carcelen, Myriam; Evans, Patricia W.; Heyne, Roy J.; Wilson-Costello, Deanne E.; Vaucher, Yvonne E.; Bauer, Charles R.; Dusick, Anna M.; Adams-Chapman, Ira; Goldstein, Ricki F.; Guillet, Ronnie; Papile, Lu-Ann; Higgins, Rosemary D.		Eunice Kennedy Shriver NICHD Neona	Childhood Outcomes after Hypothermia for Neonatal Encephalopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HYPOXIC-ISCHEMIC ENCEPHALOPATHY; EMERGENCY CARDIOVASCULAR CARE; WHOLE-BODY HYPOTHERMIA; CEREBRAL-PALSY; CARDIOPULMONARY-RESUSCITATION; SYSTEMIC HYPOTHERMIA; PERINATAL ASPHYXIA; SCHOOL-AGE; TERM; ASSOCIATION	BACKGROUND We previously reported early results of a randomized trial of whole-body hypothermia for neonatal hypoxic-ischemic encephalopathy showing a significant reduction in the rate of death or moderate or severe disability at 18 to 22 months of age. Long-term outcomes are now available. METHODS In the original trial, we assigned infants with moderate or severe encephalopathy to usual care (the control group) or whole-body cooling to an esophageal temperature of 33.5 degrees C for 72 hours, followed by slow rewarming (the hypothermia group). We evaluated cognitive, attention and executive, and visuospatial function; neurologic outcomes; and physical and psychosocial health among participants at 6 to 7 years of age. The primary outcome of the present analyses was death or an IQ score below 70. RESULTS Of the 208 trial participants, primary outcome data were available for 190. Of the 97 children in the hypothermia group and the 93 children in the control group, death or an IQ score below 70 occurred in 46 (47%) and 58 (62%), respectively (P = 0.06); death occurred in 27 (28%) and 41 (44%) (P = 0.04); and death or severe disability occurred in 38 (41%) and 53 (60%) (P = 0.03). Other outcome data were available for the 122 surviving children, 70 in the hypothermia group and 52 in the control group. Moderate or severe disability occurred in 24 of 69 children (35%) and 19 of 50 children (38%), respectively (P = 0.87). Attention-executive dysfunction occurred in 4% and 13%, respectively, of children receiving hypothermia and those receiving usual care (P = 0.19), and visuospatial dysfunction occurred in 4% and 3% (P = 0.80). CONCLUSIONS The rate of the combined end point of death or an IQ score of less than 70 at 6 to 7 years of age was lower among children undergoing whole-body hypothermia than among those undergoing usual care, but the differences were not significant. However, hypothermia resulted in lower death rates and did not increase rates of severe disability among survivors. (Funded by the National Institutes of Health and the Eunice Kennedy Shriver NICHD Neonatal Research Network; ClinicalTrials.gov number, NCT00005772.)	[Shankaran, Seetha; Pappas, Athina; Bara, Rebecca] Wayne State Univ, Dept Pediat, Detroit, MI 48202 USA; [McDonald, Scott A.; Das, Abhik; Hammond, Jane] Res Triangle Inst, Stat & Epidemiol Unit, Res Triangle Pk, NC 27709 USA; [Huitema, Carolyn M. Petrie] Res Triangle Inst, Stat & Epidemiol Unit, Rockville, MD USA; [Vohr, Betty R.; Leach, Theresa M.] Brown Univ, Women & Infants Hosp, Dept Pediat, Providence, RI 02908 USA; [Hintz, Susan R.] Stanford Univ, Sch Med, Dept Pediat, Palo Alto, CA 94304 USA; [Yolton, Kimberly] Univ Cincinnati, Dept Pediat, Cincinnati, OH 45221 USA; [Gustafson, Kathryn E.; Goldstein, Ricki F.] Duke Univ, Dept Pediat, Durham, NC 27706 USA; [Green, Charles; Tyson, Jon E.; Evans, Patricia W.] Univ Texas Houston, Sch Med, Dept Pediat, Houston, TX USA; [Ehrenkranz, Richard A.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; [Peralta-Carcelen, Myriam] Univ Alabama Birmingham, Div Neonatol, Birmingham, AL USA; [Heyne, Roy J.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Wilson-Costello, Deanne E.] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; [Vaucher, Yvonne E.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; [Bauer, Charles R.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA; [Dusick, Anna M.] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN USA; [Adams-Chapman, Ira] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA; [Adams-Chapman, Ira] Childrens Healthcare Atlanta, Atlanta, GA USA; [Guillet, Ronnie] Univ Rochester, Sch Med & Dent, Rochester, NY USA; [Papile, Lu-Ann] Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA; [Higgins, Rosemary D.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Neonatal Res Network, NIH, Bethesda, MD USA	Wayne State University; Research Triangle Institute; Research Triangle Institute; Brown University; Women & Infants Hospital Rhode Island; Stanford University; University System of Ohio; University of Cincinnati; Duke University; University of Texas System; University of Texas Health Science Center Houston; Yale University; University of Alabama System; University of Alabama Birmingham; University of Texas System; University of Texas Southwestern Medical Center Dallas; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; University of California System; University of California San Diego; University of Miami; Indiana University System; Indiana University Bloomington; Emory University; Children's Healthcare of Atlanta (CHOA); University of Rochester; University of New Mexico; University of New Mexico's Health Sciences Center; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Shankaran, S (corresponding author), Childrens Hosp Michigan, Div Neonatal Perinatal Med, 3901 Beaubien Blvd, Detroit, MI 48201 USA.	sshankar@med.wayne.edu	Yunkunis, Kimberly/AAO-5605-2021; Das, Abhik/AAF-1883-2020	Das, Abhik/0000-0003-2722-0479; McDonald, Scott/0000-0002-0054-1099; Shankaran, Seetha/0000-0001-5512-9571; Hintz, Susan/0000-0001-7023-4433	National Institutes of Health; Eunice Kennedy Shriver NICHD Neonatal Research Network; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD021373, U10HD027856, U10HD021385, U10HD040461] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024149, UL1RR024148, UL1RR025008] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Eunice Kennedy Shriver NICHD Neonatal Research Network; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Supported by grants from the National Institutes of Health and the Eunice Kennedy Shriver NICHD Neonatal Research Network.	Arnaud C, 2008, PEDIATRICS, V121, P54, DOI 10.1542/peds.2007-0854; Azzopardi DV, 2010, NEW ENGL J MED, V362, P1056; Cans C, 2000, DEV MED CHILD NEUROL, V42, P816, DOI 10.1111/j.1469-8749.2000.tb00695.x; de Vries LS, 2010, ARCH DIS CHILD-FETAL, V95, pF220, DOI 10.1136/adc.2008.148205; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gonzalez FF, 2006, ARCH DIS CHILD-FETAL, V91, pF454, DOI 10.1136/adc.2005.092445; Jacobs SE, 2011, ARCH PEDIAT ADOL MED, V165, P692, DOI 10.1001/archpediatrics.2011.43; Kattwinkel J, 2011, PEDIATRICS, V128, P176, DOI 10.1542/peds.2011-1260; Kattwinkel J, 2010, PEDIATRICS, V126, pE1400, DOI 10.1542/peds.2010-2972E; Marlow N, 2005, ARCH DIS CHILD-FETAL, V90, pF380, DOI 10.1136/adc.2004.067520; Moster D, 2002, ARCH DIS CHILD-FETAL, V86, pF16, DOI 10.1136/fn.86.1.F16; Palisano RJ, 2006, DEV MED CHILD NEUROL, V48, P424, DOI 10.1017/S0012162206000934; Perlman JM, 2010, PEDIATRICS, V126, pE1319, DOI 10.1542/peds.2010-2972B; Robertson CMT., 2003, FETAL NEONATAL BRAIN, V3. Ed, P829; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; SHANKARAN S, 1991, EARLY HUM DEV, V25, P135, DOI 10.1016/0378-3782(91)90191-5; Simbruner G, 2010, PEDIATRICS, V126, pE771, DOI 10.1542/peds.2009-2441; Wake M, 2003, DEV MED CHILD NEUROL, V45, P194, DOI 10.1017/S0012162203000379; Zhou WH, 2010, J PEDIATR-US, V157, P367, DOI 10.1016/j.jpeds.2010.03.030	20	456	472	2	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 31	2012	366	22					2085	2092		10.1056/NEJMoa1112066	http://dx.doi.org/10.1056/NEJMoa1112066			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	949YE	22646631	Green Accepted			2023-01-03	WOS:000304613400008
J	Steinberg, G				Steinberg, Gero			Cytoplasmic Fungal Lipases Release Fungicides from Ultra-Deformable Vesicular Drug Carriers	PLOS ONE			English	Article							TDT 067 TERBINAFINE; ENDOPLASMIC-RETICULUM; CELL-WALL; PATHOGENIC DEVELOPMENT; USTILAGO-MAYDIS; ENDOCYTOSIS; TRANSFERSOMES; ACTIN; DYNAMICS; MOTILITY	The Transfersome (R) is a lipid vesicle that contains membrane softeners, such as Tween 80, to make it ultra-deformable. This feature makes the Transfersome (R) an efficient carrier for delivery of therapeutic drugs across the skin barrier. It was reported that TDT 067 (a topical formulation of 15 mg/ml terbinafine in Transfersome (R) vesicles) has a much more potent antifungal activity in vitro compared with conventional terbinafine, which is a water-insoluble fungicide. Here we use ultra-structural studies and live imaging in a model fungus to describe the underlying mode of action. We show that terbinafine causes local collapse of the fungal endoplasmic reticulum, which was more efficient when terbinafine was delivered in Transfersome (R) vesicles (TFVs). When applied in liquid culture, fluorescently labeled TFVs rapidly entered the fungal cells (T-1/2 similar to 2 min). Entry was F-actin-and ATP-independent, indicating that it is a passive process. Ultra-structural studies showed that passage through the cell wall involves significant deformation of the vesicles, and depends on a high concentration of the surfactant Tween 80 in their membrane. Surprisingly, the TFVs collapsed into lipid droplets after entry into the cell and the terbinafine was released from their interior. With time, the lipid bodies were metabolized in an ATP-dependent fashion, suggesting that cytosolic lipases attack and degrade intruding TFVs. Indeed, the specific monoacylglycerol lipase inhibitor URB602 prevented Transfersome (R) degradation and neutralized the cytotoxic effect of Transfersome (R)-delivered terbinafine. These data suggest that (a) Transfersomes deliver the lipophilic fungicide Terbinafine to the fungal cell wall, (b) the membrane softener Tween 80 allows the passage of the Transfersomes into the fungal cell, and (c) fungal lipases digest the invading Transfersome (R) vesicles thereby releasing their cytotoxic content. As this mode of action of Transfersomes is independent of the drug cargo, these results demonstrate the potential of Transfersomes in the treatment of all fungal diseases.	Univ Exeter, Coll Life & Environm Sci, Exeter, Devon, England	University of Exeter	Steinberg, G (corresponding author), Univ Exeter, Coll Life & Environm Sci, Exeter, Devon, England.	G.Steinberg@exeter.ac.uk			Celtic Pharma Development Services Bermuda Ltd., New York, USA; Celtic Pharma	Celtic Pharma Development Services Bermuda Ltd., New York, USA; Celtic Pharma	This work was supported by Celtic Pharma Development Services Bermuda Ltd., New York, USA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was financially supported by Celtic Pharma. This did not influence the outcome or judgment of the data. This does not alter the author's adherence to all the PLoS ONE policies on sharing data and materials.	Adamikova L, 2004, MOL BIOL CELL, V15, P1969, DOI 10.1091/mbc.E03-09-0675; Ago T, 2001, BIOCHEM BIOPH RES CO, V287, P733, DOI 10.1006/bbrc.2001.5629; Aguilar PS, 2010, P NATL ACAD SCI USA, V107, P4170, DOI 10.1073/pnas.0914094107; Penalva MA, 2010, CURR OPIN MICROBIOL, V13, P684, DOI 10.1016/j.mib.2010.09.005; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Benson Heather A E, 2006, Expert Opin Drug Deliv, V3, P727, DOI 10.1517/17425247.3.6.727; Berepiki A, 2011, NAT REV MICROBIOL, V9, P876, DOI 10.1038/nrmicro2666; Berepiki A, 2010, EUKARYOT CELL, V9, P547, DOI 10.1128/EC.00253-09; Bonilla M, 2002, EMBO J, V21, P2343, DOI 10.1093/emboj/21.10.2343; BORGSTROM B, 1988, BIOCHIM BIOPHYS ACTA, V962, P308, DOI 10.1016/0005-2760(88)90260-3; Brachmann A, 2001, MOL MICROBIOL, V42, P1047, DOI 10.1046/j.1365-2958.2001.02699.x; Casadevall A, 2009, TRENDS MICROBIOL, V17, P158, DOI 10.1016/j.tim.2008.12.005; Cevc G, 1998, BBA-BIOMEMBRANES, V1368, P201, DOI 10.1016/S0005-2736(97)00177-6; Cevc G, 2004, ADV DRUG DELIVER REV, V56, P675, DOI 10.1016/j.addr.2003.10.028; Cevc G, 2001, BBA-BIOMEMBRANES, V1514, P191, DOI 10.1016/S0005-2736(01)00369-8; CEVC G, 1995, J CONTROL RELEASE, V36, P3, DOI 10.1016/0168-3659(95)00056-E; Cevc G, 2010, J CONTROL RELEASE, V141, P277, DOI 10.1016/j.jconrel.2009.10.016; Copland MJ, 2005, IMMUNOL CELL BIOL, V83, P97, DOI 10.1111/j.1440-1711.2005.01315.x; D'Hondt K, 2000, ANNU REV GENET, V34, P255, DOI 10.1146/annurev.genet.34.1.255; Delgado-Alvarez DL, 2010, FUNGAL GENET BIOL, V47, P573, DOI 10.1016/j.fgb.2010.03.004; Detmer SA, 2007, NAT REV MOL CELL BIO, V8, P870, DOI 10.1038/nrm2275; Dimitrov DS, 2004, NAT REV MICROBIOL, V2, P109, DOI 10.1038/nrmicro817; Dufourc Erick J, 2008, J Chem Biol, V1, P63, DOI 10.1007/s12154-008-0010-6; Eisenman HC, 2005, BIOCHEMISTRY-US, V44, P3683, DOI 10.1021/bi047731m; Facanha ALO, 2002, J CELL BIOL, V157, P1029, DOI 10.1083/jcb.200111012; Fischer-Parton S, 2000, J MICROSC-OXFORD, V198, P246, DOI 10.1046/j.1365-2818.2000.00708.x; Foster KW, 2004, J AM ACAD DERMATOL, V50, P748, DOI 10.1016/S0190-9622(03)02117-0; Fuchs U, 2005, MOL BIOL CELL, V16, P2746, DOI 10.1091/mbc.E05-03-0176; Fuchs U, 2006, PLANT CELL, V18, P2066, DOI 10.1105/tpc.105.039388; Ganendren R, 2004, ANTIMICROB AGENTS CH, V48, P1561, DOI 10.1128/AAC.48.5.1561-1569.2004; Ghannoum M, 2012, ANTIMICROBI IN PRESS; Ghannoum M, 2011, J CLIN MICROBIOL, V49, P1716, DOI 10.1128/JCM.00083-11; Ghannoum M, 2011, J AM ACAD DERMATOL, V64, pAB93; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; Gupta PN, 2005, J PHARM PHARMACOL, V57, P295, DOI 10.1211/0022357055515; Haneke E, 1999, J EUR ACAD DERMATOL, V12, pS2, DOI 10.1016/S0926-9959(99)00052-5; HAY RJ, 1993, J AM ACAD DERMATOL, V29, pS50, DOI 10.1016/S0190-9622(08)81838-5; HIROSE S, 1974, J BIOCHEM-TOKYO, V76, P213, DOI 10.1093/oxfordjournals.jbchem.a130549; Hofer C, 2004, CYTOKINE, V25, P141, DOI 10.1016/j.cyto.2003.10.010; Inoue T, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002037; Jacobson ES, 2005, MED MYCOL, V43, P327, DOI 10.1080/13693780412331271081; Jain S, 2003, DRUG DEV IND PHARM, V29, P1013, DOI 10.1081/DDC-120025458; Kaksonen M, 2003, CELL, V115, P475, DOI 10.1016/S0092-8674(03)00883-3; Kato M, 2001, EMBO J, V20, P4035, DOI 10.1093/emboj/20.15.4035; Katz HI, 1999, BRIT J DERMATOL, V141, P26; King AR, 2007, CHEM BIOL, V14, P1357, DOI 10.1016/j.chembiol.2007.10.017; Kulkarni PR, 2011, INT J PHARM SCI RES, V2, P735, DOI 10.13040/IJPSR.0975-8232.2(4).735-41; Latge JP, 2007, MOL MICROBIOL, V66, P279, DOI 10.1111/j.1365-2958.2007.05872.x; Lenz JH, 2006, EMBO J, V25, P2275, DOI 10.1038/sj.emboj.7601119; Levine T, 2005, CURR OPIN CELL BIOL, V17, P362, DOI 10.1016/j.ceb.2005.06.005; LYTLE CD, 1995, APPL ENVIRON MICROB, V61, P643, DOI 10.1128/AEM.61.2.643-649.1995; Mahlert M, 2009, J CELL SCI, V122, P2402, DOI 10.1242/jcs.039354; Pereira RD, 1996, APPL BIOCHEM BIOTECH, V59, P135, DOI 10.1007/BF02787815; PETRANYI G, 1984, SCIENCE, V224, P1239, DOI 10.1126/science.6547247; PLANAS ME, 1992, ANESTH ANALG, V75, P615; Plou FJ, 1998, BIOTECHNOL TECH, V12, P183, DOI 10.1023/A:1008809105270; Read ND, 2003, FUNGAL GENET BIOL, V39, P199, DOI 10.1016/S1087-1845(03)00045-8; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; Riedl J, 2008, NAT METHODS, V5, P605, DOI 10.1038/nmeth.1220; Roberts DT, 1997, DERMATOLOGY, V194, P37, DOI 10.1159/000246183; ROBERTS DT, 1994, J AM ACAD DERMATOL, V31, pS78, DOI 10.1016/S0190-9622(08)81274-1; Rodrigues ML, 2007, EUKARYOT CELL, V6, P48, DOI 10.1128/EC.00318-06; RYDER NS, 1992, BRIT J DERMATOL, V126, P2, DOI 10.1111/j.1365-2133.1992.tb00001.x; RYDER NS, 1985, ANTIMICROB AGENTS CH, V27, P252, DOI 10.1128/AAC.27.2.252; Schuster M, 2012, EMBO J, V31, P214, DOI 10.1038/emboj.2011.361; Schuster M, 2011, P NATL ACAD SCI USA, V108, P3618, DOI 10.1073/pnas.1015839108; Shaw BD, 2011, FUNGAL BIOL-UK, V115, P541, DOI 10.1016/j.funbio.2011.02.010; SHINITZKY M, 1976, BIOCHIM BIOPHYS ACTA, V433, P133, DOI 10.1016/0005-2736(76)90183-8; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; Steinberg G, 1998, J CELL SCI, V111, P2235; Steinberg Gero, 2011, Fungal Biology Reviews, V25, P14, DOI 10.1016/j.fbr.2011.01.008; Straube A, 2001, EMBO J, V20, P5091, DOI 10.1093/emboj/20.18.5091; Tauchi-Sato K, 2002, J BIOL CHEM, V277, P44507, DOI 10.1074/jbc.M207712200; Treichel H, 2010, FOOD BIOPROCESS TECH, V3, P182, DOI 10.1007/s11947-009-0202-2; Tsai B, 2007, ANNU REV CELL DEV BI, V23, P23, DOI 10.1146/annurev.cellbio.23.090506.123454; Upadhyay S, 2008, MOL MICROBIOL, V68, P690, DOI 10.1111/j.1365-2958.2008.06178.x; Voigt CA, 2005, PLANT J, V42, P364, DOI 10.1111/j.1365-313X.2005.02377.x; Wedlich-Soldner R, 2002, MOL BIOL CELL, V13, P965, DOI 10.1091/mbc.01-10-0475; Wedlich-Soldner R, 2000, EMBO J, V19, P1974, DOI 10.1093/emboj/19.9.1974; Zhang Y.Q., 2010, VIRULENCE, V1, P1	81	8	9	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2012	7	5							e38181	10.1371/journal.pone.0038181	http://dx.doi.org/10.1371/journal.pone.0038181			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959WT	22666476	gold, Green Submitted, Green Published			2023-01-03	WOS:000305349600069
J	Wu, CC; Li, XB; Han, TS; Li, P; Wang, JG; Liu, GW; Wang, Z; Ge, CR; Gao, SZ				Wu, ChenChen; Li, XiaoBing; Han, TieSuo; Li, Peng; Wang, JianGuo; Liu, GuoWen; Wang, Zhe; Ge, ChangRong; Gao, ShiZheng			Dietary Pseudopurpurin Improves Bone Geometry Architecture and Metabolism in Red-Bone Guishan Goats	PLOS ONE			English	Article							OVARIECTOMIZED RATS; TRABECULAR BONE; ALIZARIN RED; STRENGTH; CALCIUM; INVITRO; MINERALIZATION; CALVARIA; MADDER	Red-colored bones were found initially in some Guishan goats in the 1980s, and they were designated red-boned goats. However, it is not understood what causes the red color in the bone, or whether the red material changes the bone geometry, architecture, and metabolism of red-boned goats. Pseudopurpurin was identified in the red-colored material of the bone in red-boned goats by high-performance liquid chromatography-electrospray ionization-mass spetrometry and nuclear magnetic resonance analysis. Pseudopurpurin is one of the main constituents of Rubia cordifolia L, which is eaten by the goats. The assessment of the mechanical properties and micro-computed tomography showed that the red-boned goats displayed an increase in the trabecular volume fraction, trabecular thickness, and the number of trabeculae in the distal femur. The mean thickness, inner perimeter, outer perimeter, and area of the femoral diaphysis were also increased. In addition, the trabecular separation and structure model index of the distal femur were decreased, but the bone mineral density of the whole femur and the mechanical properties of the femoral diaphysis were enhanced in the red-boned goats. Meanwhile, expression of alkaline phosphatase and osteocalcin mRNA was higher, and the ratio of the receptor activator of the nuclear factor kappa B ligand to osteoprotegerin was markedly lower in the bone marrow of the red-boned goats compared with common goats. To confirm further the effect of pseudopurpurin on bone geometry, architecture, and metabolism, Wistar rats were fed diets to which pseudopurpurin was added for 5 months. Similar changes were observed in the femurs of the treated rats. The above results demonstrate that pseudopurpurin has a close affinity with the mineral salts of bone, and consequently a high level of mineral salts in the bone cause an improvement in bone strength and an enhancement in the structure and metabolic functions of the bone.	[Wu, ChenChen; Li, XiaoBing; Han, TieSuo; Wang, JianGuo; Liu, GuoWen; Wang, Zhe] Jilin Univ, Coll Anim Sci & Vet Med, Jilin, Jilin, Peoples R China; [Li, Peng] Shenyang Agr Univ, Coll Anim Sci & Vet Med, Liaoning, Peoples R China; [Ge, ChangRong; Gao, ShiZheng] Yunnan Agr Univ, Coll Anim Food & Sci Technol, Yunnan, Peoples R China	Jilin University; Shenyang Agricultural University; Yunnan Agricultural University	Wu, CC (corresponding author), Jilin Univ, Coll Anim Sci & Vet Med, Jilin, Jilin, Peoples R China.	liuguowen2008@163.com; wangzhe500518@sohu.com	LI, Xiaobing/AAB-8762-2019; Li, Xiaobing/B-1267-2019	Li, Xiaobing/0000-0001-9105-6365	National Nature Science Foundation of China; Foundation of Yunnan Province [U0836601]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Foundation of Yunnan Province	This work was supported by National Nature Science Foundation of China and the Foundation of Yunnan Province (No. U0836601). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bae YJ, 2010, CALCIFIED TISSUE INT, V87, P365, DOI 10.1007/s00223-010-9410-z; Bagi CM, 2006, BONE, V38, P136, DOI 10.1016/j.bone.2005.07.028; BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874; Bergh JJ, 2004, ENDOCRINOLOGY, V145, P426, DOI 10.1210/en.2003-0319; BRADBEER JN, 1992, J BONE MINER RES, V7, P905; Fratzl-Zelman N, 1998, BONE, V23, P511, DOI 10.1016/S8756-3282(98)00139-2; Han XL, 2009, BONE, V44, P942, DOI 10.1016/j.bone.2008.12.005; Hott M, 2003, BONE, V33, P115, DOI 10.1016/S8756-3282(03)00115-7; KELLER TS, 1994, J BIOMECH, V27, P1159, DOI 10.1016/0021-9290(94)90056-6; Kiel E. G., 1965, J SOC DYERS COLOUR, V81, P98, DOI [DOI 10.1111/J.1478-4408.1965.TB02647.X, 10.1111/j.1478-4408.1965.tb02647.x]; KIEL EG, 1963, J SOC DYERS COLOUR, V79, P61; Lancianese SL, 2008, BONE, V43, P1039, DOI 10.1016/j.bone.2008.07.247; Macklin CC, 1917, J MED RES, V4, P493; Muller R, 2004, J BONE MINER RES, V19, P1787, DOI 10.1359/JBMR.040809; NEFUSSI JR, 1985, DIFFERENTIATION, V29, P160, DOI 10.1111/j.1432-0436.1985.tb00310.x; Norton SA, 1998, J AM ACAD DERMATOL, V39, P484, DOI 10.1016/S0190-9622(98)70328-7; PUCHTLER H, 1969, J HISTOCHEM CYTOCHEM, V17, P110, DOI 10.1177/17.2.110; RICE JC, 1988, J BIOMECH, V21, P155, DOI 10.1016/0021-9290(88)90008-5; Richter D, 1937, BIOCHEM J, V31, P591, DOI 10.1042/bj0310591; Rico H, 2000, EUR J OBSTET GYN R B, V90, P97, DOI 10.1016/S0301-2115(99)00223-7; SALTMAN PD, 1993, J AM COLL NUTR, V12, P384, DOI 10.1080/07315724.1993.10718327; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Turner CH, 2001, J BONE MINER RES, V16, P1532, DOI 10.1359/jbmr.2001.16.8.1532; Ulrich D, 1999, BONE, V25, P55, DOI 10.1016/S8756-3282(99)00098-8; van der Meulen MCH, 2001, BONE, V29, P101, DOI 10.1016/S8756-3282(01)00491-4	25	4	5	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2012	7	5							e37469	10.1371/journal.pone.0037469	http://dx.doi.org/10.1371/journal.pone.0037469			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959VG	22624037	gold, Green Published, Green Submitted			2023-01-03	WOS:000305343500122
J	Quill, TE; Holloway, RG				Quill, Timothy E.; Holloway, Robert G.			Evidence, Preferences, Recommendations - Finding the Right Balance in Patient Care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Quill, Timothy E.] Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA; [Holloway, Robert G.] Univ Rochester, Med Ctr, Dept Neurol, Palliat Care Div, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Quill, TE (corresponding author), Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA.							Johnson DDP, 2011, NATURE, V477, P317, DOI 10.1038/nature10384; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; Schmaltz SP, 2011, J HOSP MED, V6, P454, DOI 10.1002/jhm.905; Ubel PA, 2005, HEALTH PSYCHOL, V24, pS57, DOI 10.1037/0278-6133.24.4.S57; Zikmund-Fisher BJ, 2010, MED DECIS MAKING, V30, p20S, DOI 10.1177/0272989X09353792	5	63	63	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 3	2012	366	18					1653	1655		10.1056/NEJMp1201535	http://dx.doi.org/10.1056/NEJMp1201535			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	934HH	22551123				2023-01-03	WOS:000303434300001
J	Perez-Martinez, J; Perez-Martinez, FC; Carrion, B; Masia, J; Ortega, A; Simarro, E; Nam-Cha, SH; Cena, V				Perez-Martinez, Juan; Perez-Martinez, Francisco C.; Carrion, Blanca; Masia, Jesus; Ortega, Agustin; Simarro, Esther; Nam-Cha, Syong H.; Cena, Valentin			Aliskiren Prevents the Toxic Effects of Peritoneal Dialysis Fluids during Chronic Dialysis in Rats	PLOS ONE			English	Article							RENIN-ANGIOTENSIN SYSTEM; HIGH GLUCOSE; ULTRAFILTRATION CAPACITY; MESENCHYMAL TRANSITION; MESOTHELIAL CELLS; OXIDATIVE STRESS; SOLUTE TRANSPORT; P38 MAPK; MEMBRANE; DEATH	The benefits of long-term peritoneal dialysis (PD) in patients with end-stage renal failure are short-lived due to structural and functional changes in the peritoneal membrane. In this report, we provide evidence for the in vitro and in vivo participation of the renin-angiotensin-aldosterone system (RAAS) in the signaling pathway leading to peritoneal fibrosis during PD. Exposure to high-glucose PD fluids (PDFs) increases damage and fibrosis markers in both isolated rat peritoneal mesothelial cells and in the peritoneum of rats after chronic dialysis. In both cases, the addition of the RAAS inhibitor aliskiren markedly improved damage and fibrosis markers, and prevented functional modifications in the peritoneal transport, as measured by the peritoneal equilibrium test. These data suggest that inhibition of the RAAS may be a novel way to improve the efficacy of PD by preventing inflammation and fibrosis following peritoneal exposure to high-glucose PDFs.	[Cena, Valentin] Univ Castilla La Mancha, Unidad Asociada Neurodeath, Dept Ciencias Med, CSIC, Albacete, Spain; [Perez-Martinez, Juan; Masia, Jesus; Ortega, Agustin] Complejo Hosp Univ, Dept Nephrol, Albacete, Spain; [Cena, Valentin] Inst Salud Carlos III, CIBERNED, Madrid, Spain; [Perez-Martinez, Francisco C.; Carrion, Blanca] NanoDrugs SL, Dept Res & Dev, Albacete, Spain; [Simarro, Esther] Complejo Hosp Univ, Dept Clin Chem, Albacete, Spain; [Nam-Cha, Syong H.] Complejo Hosp Univ, Dept Pathol, Albacete, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Castilla-La Mancha; CIBERNED; Instituto de Salud Carlos III	Perez-Martinez, J (corresponding author), Complejo Hosp Univ, Dept Nephrol, Albacete, Spain.	valentin.cena@gmail.com	Cena, Valentin/L-1751-2017	Cena, Valentin/0000-0001-8928-3681	Fondo de Investigaciones Sanitarias [PI081434]; Ministerio de Ciencia e Innovacion [BFU2011-30161-C02-01, PI10/01420]; Consejeria de Educacion [PII1I09-0163-4002, POII10-0274-3182]; Consejeria de Salud y Bienestar Social [PI-2009/32]	Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Consejeria de Educacion; Consejeria de Salud y Bienestar Social	This work has been supported, in part, by grants PI081434 from Fondo de Investigaciones Sanitarias, BFU2011-30161-C02-01 from Ministerio de Ciencia e Innovacion and PII1I09-0163-4002 and POII10-0274-3182 from Consejeria de Educacion, JCCM to V.C.; and PI10/01420 from the Fondo de Investigaciones Sanitarias, Ministerio de Ciencia e Innovacion; and PI-2009/32 from Consejeria de Salud y Bienestar Social, JCCM, to J.P.-M. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.	Aroeira LS, 2007, J AM SOC NEPHROL, V18, P2004, DOI 10.1681/ASN.2006111292; Bailie GR, 2005, PHARMACOTHERAPY, V25, P491, DOI 10.1592/phco.25.4.491.61034; Bozkurt D, 2008, PERITON DIALYSIS INT, V28, pS38; Carrion B, 2011, PERITON DIALYSIS INT, V31, P325, DOI 10.3747/pdi.2010.00164; Chaudhary K, 2010, CLIN J AM SOC NEPHRO, V5, P723, DOI 10.2215/CJN.05720809; Chung SH, 2005, NEPHROL DIAL TRANSPL, V20, P1207, DOI 10.1093/ndt/gfh772; Churchill DN, 1998, J AM SOC NEPHROL, V9, P1285; Davies SJ, 2004, KIDNEY INT, V66, P2437, DOI 10.1111/j.1523-1755.2004.66021.x; Davies SJ, 2001, J AM SOC NEPHROL, V12, P1046, DOI 10.1681/ASN.V1251046; Fusshoeller A, 2008, PEDIATR NEPHROL, V23, P19, DOI 10.1007/s00467-007-0541-z; Gotloib L, 2009, CONTRIB NEPHROL, V163, P35, DOI 10.1159/000223778; Ha H, 2000, PERITON DIALYSIS INT, V20, pS10; HEIMBURGER O, 1990, KIDNEY INT, V38, P495, DOI 10.1038/ki.1990.231; Holmes C, 2006, KIDNEY INT, V70, pS104, DOI 10.1038/sj.ki.5001924; Jensen C, 2008, NAT REV DRUG DISCOV, V7, P399, DOI 10.1038/nrd2550; Jiang N, 2008, BLOOD PURIFICAT, V26, P423, DOI 10.1159/000153248; Jordan J, 2000, BRIT J PHARMACOL, V130, P1496, DOI 10.1038/sj.bjp.0703451; Ke CY, 2010, EUR J CLIN INVEST, V40, P301, DOI 10.1111/j.1365-2362.2010.02264.x; Krediet RT, 1999, KIDNEY INT, V55, P341, DOI 10.1046/j.1523-1755.1999.00264.x; Lameire N, 2010, NAT REV NEPHROL, V6, P75, DOI 10.1038/nrneph.2009.210; Lavrentyev EN, 2009, AM J PHYSIOL-HEART C, V296, pH106, DOI 10.1152/ajpheart.00239.2008; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Margetts PJ, 2005, J AM SOC NEPHROL, V16, P425, DOI 10.1681/ASN.2004060436; Mortier S, 2003, BLOOD PURIFICAT, V21, P14, DOI 10.1159/000067867; Muller DN, 2006, CLIN J AM SOC NEPHRO, V1, P221, DOI 10.2215/CJN.01201005; Nagy JA, 1996, KIDNEY INT S, V56, pS2; Nakagami H, 2001, DIABETES, V50, P1472, DOI 10.2337/diabetes.50.6.1472; Nessim SJ, 2010, KIDNEY INT, V78, P23, DOI 10.1038/ki.2010.90; Noh H, 2005, PERITON DIALYSIS INT, V25, P38; Posadas I, 2007, BRIT J PHARMACOL, V150, P577, DOI 10.1038/sj.bjp.0706993; Simoncini S, 2005, INT IMMUNOL, V17, P489, DOI 10.1093/intimm/dxh229; Singh R, 2003, J AM SOC NEPHROL, V14, P873, DOI 10.1097/01.ASN.0000060804.40201.6E; Singh VP, 2008, AM J PHYSIOL-HEART C, V294, pH1675, DOI 10.1152/ajpheart.91493.2007; Singh VP, 2008, DIABETES, V57, P3297, DOI 10.2337/db08-0805; Weber KT, 1999, INT J BIOCHEM CELL B, V31, P395, DOI 10.1016/S1357-2725(98)00125-3; Westermann D, 2008, HYPERTENSION, V52, P1068, DOI 10.1161/HYPERTENSIONAHA.108.116350; Xu ZG, 2003, KIDNEY INT, V63, P958, DOI 10.1046/j.1523-1755.2003.00836.x; Yung S, 2000, KIDNEY INT, V58, P1953, DOI 10.1111/j.1523-1755.2000.00367.x	38	4	4	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2012	7	4							e36268	10.1371/journal.pone.0036268	http://dx.doi.org/10.1371/journal.pone.0036268			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TJ	22558414	Green Published, gold, Green Submitted			2023-01-03	WOS:000305336000175
J	Kusy, S; Ghosn, EEB; Herzenberg, LA; Contag, CH				Kusy, Sophie; Ghosn, Eliver E. B.; Herzenberg, Leonore A.; Contag, Christopher H.			Development of B Cells and Erythrocytes Is Specifically Impaired by the Drug Celastrol in Mice	PLOS ONE			English	Article							KAPPA-B; TRANSCRIPTION FACTORS; RHEUMATOID-ARTHRITIS; GOD VINE; HOOK-F; INHIBITOR; DISEASE; THUNDER; AGENTS; MODEL	Background: Celastrol, an active compound extracted from the root of the Chinese medicine "Thunder of God Vine" (Tripterygium wilfordii), exhibits anticancer, antioxidant and anti-inflammatory activities, and interest in the therapeutic potential of celastrol is increasing. However, described side effects following treatment are significant and require investigation prior to initiating clinical trials. Here, we investigated the effects of celastrol on the adult murine hematopoietic system. Methodology/Principal Findings: Animals were treated daily with celastrol over a four-day period and peripheral blood, bone marrow, spleen, and peritoneal cavity were harvested for cell phenotyping. Treated mice showed specific impairment of the development of B cells and erythrocytes in all tested organs. In bone marrow, these alterations were accompanied by decreases in populations of common lymphoid progenitors (CLP), common myeloid progenitors (CMP) and megakaryocyte-erythrocyte progenitors (MEP). Conclusions/Significance: These results indicate that celastrol acts through regulators of adult hematopoiesis and could be used as a modulator of the hematopoietic system. These observations provide valuable information for further assessment prior to clinical trials.	[Kusy, Sophie; Contag, Christopher H.] Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA; [Ghosn, Eliver E. B.; Herzenberg, Leonore A.] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; [Contag, Christopher H.] Stanford Univ, Dept Radiol, Sch Med, Stanford, CA 94305 USA; [Contag, Christopher H.] Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA; [Kusy, Sophie; Contag, Christopher H.] Stanford Univ, Sch Med, Mol Imaging Program Stanford MIPS, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University; Stanford University	Kusy, S (corresponding author), Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA.	skusy@stanford.edu	Ghosn, Eliver/AAO-5788-2020	Ghosn, Eliver/0000-0001-7258-906X; Contag, Christopher/0000-0002-1011-8278	National Institutes of Health [CA49605, AI076434]; NATIONAL CANCER INSTITUTE [P01CA049605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI076434, R56AI076434] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This research was funded by grants from the National Institutes of Health (CA49605 and AI076434). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbas S, 2007, CLIN CANCER RES, V13, P6769, DOI 10.1158/1078-0432.CCR-07-1536; Ghosn EEB, 2010, P NATL ACAD SCI USA, V107, P2568, DOI 10.1073/pnas.0915000107; Cao YA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020634; Cleren C, 2005, J NEUROCHEM, V94, P995, DOI 10.1111/j.1471-4159.2005.03253.x; Davenport A, 2010, INT J MOL MED, V25, P465, DOI 10.3892/ijmm_00000366; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Grossmann M, 1999, P NATL ACAD SCI USA, V96, P11848, DOI 10.1073/pnas.96.21.11848; Hassane DC, 2008, BLOOD, V111, P5654, DOI 10.1182/blood-2007-11-126003; Kannaiyan R, 2011, CANCER LETT, V303, P9, DOI 10.1016/j.canlet.2010.10.025; Kim DY, 2009, EUR J PHARMACOL, V612, P98, DOI 10.1016/j.ejphar.2009.03.078; Kusy S, 2011, CELL STEM CELL, V8, P412, DOI 10.1016/j.stem.2011.02.005; Lee JH, 2006, BIOCHEM PHARMACOL, V72, P1311, DOI 10.1016/j.bcp.2006.08.014; Lipsky PE, 1997, SEMIN ARTHRITIS RHEU, V26, P713, DOI 10.1016/S0049-0172(97)80040-6; Liu Y, 2006, BLOOD, V108, P123, DOI 10.1182/blood-2005-11-4458; Paris D, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-17; Peng B, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-79; Pinna GF, 2004, BIOCHEM BIOPH RES CO, V322, P778, DOI 10.1016/j.bbrc.2004.07.186; Pyatt DW, 2000, MOL PHARMACOL, V57, P512, DOI 10.1124/mol.57.3.512; TAO XL, 1989, CHINESE MED J-PEKING, V102, P327; Wang SF, 2011, DRUG CHEM TOXICOL, V34, P61, DOI 10.3109/01480545.2010.494664; Yang HJ, 2006, CANCER RES, V66, P4758, DOI 10.1158/0008-5472.CAN-05-4529; Yang Y, 2007, P NATL ACAD SCI USA, V104, P4542, DOI 10.1073/pnas.0700001104; Zhang MY, 1998, BLOOD, V91, P4136, DOI 10.1182/blood.V91.11.4136.411k26_4136_4144	23	17	19	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 24	2012	7	4							e35733	10.1371/journal.pone.0035733	http://dx.doi.org/10.1371/journal.pone.0035733			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959VE	22545133	gold, Green Submitted, Green Published			2023-01-03	WOS:000305343200053
J	Berglund, J				Berglund, Jennifer			Alternative therapies: Desperate measures	NATURE			English	Editorial Material																			0	3	3	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 12	2012	484	7393					S11	S11		10.1038/nature11099	http://dx.doi.org/10.1038/nature11099			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	930OV	22509512	Bronze			2023-01-03	WOS:000303149900053
J	Emmerich, J; Dumarcet, N; Lorence, A				Emmerich, Joseph; Dumarcet, Nathalie; Lorence, Annie			France's New Framework for Regulating Off-Label Drug Use	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Emmerich, Joseph; Dumarcet, Nathalie; Lorence, Annie] Agence Natl Securite Med & Prod Sante, St Denis, France		Emmerich, J (corresponding author), Agence Natl Securite Med & Prod Sante, St Denis, France.							Eichler HG, 2008, NAT REV DRUG DISCOV, V7, P818, DOI 10.1038/nrd2664; FERNER RE, 1996, PRESCRIBERS J, V36, P73; Mello MM, 2009, NEW ENGL J MED, V360, P1557, DOI 10.1056/NEJMhle0807695; Mullard A, 2011, LANCET, V377, P890, DOI 10.1016/S0140-6736(11)60334-6; Stafford RS, 2008, NEW ENGL J MED, V358, P1427, DOI 10.1056/NEJMp0802107	5	43	49	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 4	2012	367	14					1279	1281		10.1056/NEJMp1208347	http://dx.doi.org/10.1056/NEJMp1208347			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	014WJ	23034018				2023-01-03	WOS:000309406100002
J	Bettger, JP; Alexander, KP; Dolor, RJ; Olson, DM; Kendrick, AS; Wing, L; Coeytaux, RR; Graffagnino, C; Duncan, PW				Bettger, Janet Prvu; Alexander, Karen P.; Dolor, Rowena J.; Olson, DaiWai M.; Kendrick, Amy S.; Wing, Liz; Coeytaux, Remy R.; Graffagnino, Carmelo; Duncan, Pamela W.			Transitional Care After Hospitalization for Acute Stroke or Myocardial Infarction A Systematic Review	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED CONTROLLED-TRIAL; EARLY SUPPORTED DISCHARGE; INPATIENT NEUROLOGICAL REHABILITATION; FOLLOW-UP; UNIT SERVICE; COUNSELING INTERVENTION; CARDIAC PATIENTS; INTEGRATED CARE; FAMILY SUPPORT; CLINICAL-TRIAL	Background: Transitional care is a time-limited service to prevent discontinuous care and adverse outcomes, including rehospitalization. Purpose: To describe transitional care interventions and evidence of benefit or harm in patients hospitalized for acute stroke or myocardial infarction (MI). Data Sources: Cumulative Index to Nursing and Allied Health Literature, MEDLINE, Cochrane Database of Systematic Reviews, and EMBASE, supplemented with manual searches of reference lists of relevant studies and review articles (January 2000 to March 2012). Study Selection: 6 reviewers screened 5857 citations to identify English-language reports of trials or observational studies that compared transitional care with usual care among adults hospitalized for stroke or MI and that reported patient, caregiver, process, or systems outcomes within 1 year of hospital discharge. Data Extraction: Data on study design, quality, population, intervention characteristics, and patient-and system-level outcomes were extracted by 3 reviewers and confirmed by 1 additional reviewer. Data Synthesis: 62 articles representing 44 studies of transitional care for either acute stroke (27 studies) or MI (17 studies). Four intervention types were studied: hospital-initiated support (n = 14), patient and family education (n = 7), community-based support (n = 20), and chronic disease management (n = 3). Most studies (68%) were of fair quality. Overall, moderate-strength evidence showed that hospital-initiated support reduced length of stay for patients who had a stroke, and low-strength evidence showed that it reduced mortality for patients who had an MI. Evidence about benefits of other interventions and harms from transitional care services was insufficient. Limitations: Few studies had high-quality research designs. The usual care comparator was often poorly defined. Applicability to U.S. clinical practice was limited; only 6 studies were conducted in the United States. Conclusion: Available evidence shows that hospital-initiated transitional care can improve some outcomes in adults hospitalized for stroke or MI. Finding additional transitional care interventions that improve functional outcomes and prevent rehospitalizations and adverse events is a high priority for the growing population of patients who have an MI or a stroke.	Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA; Wake Forest Baptist Med Ctr, Sticht Ctr Aging Geriatr & Gerontol, Winston Salem, NC USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Wake Forest University; Wake Forest Baptist Medical Center	Bettger, JP (corresponding author), Duke Univ, Med Ctr, Duke Univ Sch Nursing, Box 3322,307 Trent Dr, Durham, NC 27710 USA.	janet.bettger@duke.edu	Olson, DaiWai/I-5932-2019	Olson, DaiWai/0000-0002-9280-078X; Kendrick, Amy/0000-0001-8769-1702; Dolor, Rowena/0000-0001-7317-9468; Duncan, Pamela/0000-0002-4838-3253	AHRQ, U.S. Department of Health and Human Services [290-2007-10066-I]; Agency for Healthcare Research and Quality	AHRQ, U.S. Department of Health and Human Services(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	This project was funded by the AHRQ (contract 290-2007-10066-I), U.S. Department of Health and Human Services.; Primary Funding Source: Agency for Healthcare Research and Quality.	Adams K., 2003, PRIORITY AREAS NATL; Agency for Healthcare Research and Quality, 2008, METH GUID EFF COMP E; Allen K, 2009, J STROKE CEREBROVASC, V18, P443, DOI 10.1016/j.jstrokecerebrovasdis.2009.02.002; Allen Kyle R, 2002, J Stroke Cerebrovasc Dis, V11, P88, DOI 10.1053/jscd.2002.127106; Askim T, 2004, CLIN REHABIL, V18, P238, DOI 10.1191/0269215504cr752oa; Askim T, 2006, J REHABIL MED, V38, P368, DOI 10.1080/16501970600780294; Ayana M, 2001, BMC HEALTH SERV RES, V1, DOI 10.1186/1472-6963-1-1; Bambauer KZ, 2005, PSYCHOSOM MED, V67, P539, DOI 10.1097/01.psy.0000171810.37958.61; Bautz-Holter E, 2002, DISABIL REHABIL, V24, P348, DOI 10.1080/09638280110093677; Boult C, 2009, J AM GERIATR SOC, V57, P2328, DOI 10.1111/j.1532-5415.2009.02571.x; Campaign for Better Care, COMM BAS CAR TRANS P; Carroll DL, 2007, J CARDIOVASC NURS, V22, P313, DOI 10.1097/01.JCN.0000278955.44759.73; Claiborne N, 2006, HEALTH SOC WORK, V31, P87, DOI 10.1093/hsw/31.2.87; Clark MS, 2003, CLIN REHABIL, V17, P703, DOI 10.1191/0269215503cr681oa; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Silva RCE, 2008, CLINICS, V63, P489, DOI 10.1590/S1807-59322008000400013; Donnelly M, 2004, STROKE, V35, P127, DOI 10.1161/01.STR.0000106911.96026.8F; Eagle KA, 2005, J AM COLL CARDIOL, V46, P1242, DOI 10.1016/j.jacc.2004.12.083; Ertel KA, 2007, CLIN REHABIL, V21, P511, DOI 10.1177/0269215507078312; Fjaertoft H, 2005, CEREBROVASC DIS, V19, P376, DOI 10.1159/000085543; Fjaertoft H, 2004, CLIN REHABIL, V18, P580, DOI 10.1191/0269215504cr773oa; Fjaertoft H, 2003, STROKE, V34, P2687, DOI 10.1161/01.STR.0000095189.21659.4F; Geddes JML, 2001, CLIN REHABIL, V15, P589, DOI 10.1191/0269215501cr452oa; Grasel E, 2006, CLIN REHABIL, V20, P577, DOI 10.1191/0269215506cr978oa; Grasel E, 2005, CLIN REHABIL, V19, P725, DOI 10.1191/0269215505cr900oa; Hall Jane P, 2002, Heart Lung Circ, V11, P10, DOI 10.1046/j.1444-2892.2002.00105.x; Hanssen TA, 2007, EUR J CARDIOV PREV R, V14, P429, DOI 10.1097/HJR.0b013e32801da123; Ho PM, 2007, AM HEART J, V154, P489, DOI 10.1016/j.ahj.2007.05.018; Hoenig H, 2000, ARCH PHYS MED REHAB, V81, P853, DOI 10.1053/apmr.2000.5569; Holmqvist LW, 2000, SCAND J REHABIL MED, V32, P173, DOI 10.1080/003655000750060922; Indredavik B, 2000, STROKE, V31, P2989, DOI 10.1161/01.STR.31.12.2989; Johnston M, 2007, DISABIL REHABIL, V29, P1117, DOI 10.1080/03323310600950411; Joubert J, 2006, J CLIN NEUROSCI, V13, P84, DOI 10.1016/j.jocn.2005.07.003; Joubert J, 2009, J NEUROL NEUROSUR PS, V80, P279, DOI 10.1136/jnnp.2008.148122; Joubert J, 2008, CEREBROVASC DIS, V26, P199, DOI 10.1159/000145328; Konetzka RT, 2008, MED CARE RES REV, V65, P40, DOI 10.1177/1077558707307569; Kovoor P, 2006, AM J CARDIOL, V97, P952, DOI 10.1016/j.amjcard.2005.10.040; Krumholz HM, 2006, CIRCULATION, V114, P1432, DOI 10.1161/CIRCULATIONAHA.106.177322; Luszczynska A, 2006, SOC SCI MED, V62, P900, DOI 10.1016/j.socscimed.2005.06.043; Mant J, 2000, LANCET, V356, P808, DOI 10.1016/S0140-6736(00)02655-6; Mant J, 2005, J NEUROL NEUROSUR PS, V76, P1006, DOI 10.1136/jnnp.2004.048991; Mayo NE, 2000, STROKE, V31, P1016, DOI 10.1161/01.STR.31.5.1016; McDonald KM, 2007, AHRQ PUBLICATION, V04(07)-0051-7; National Quality Forum, 2009, MEAS FRAM EV EFF PAT; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; Naylor MD, 2011, HEALTH AFFAIR, V30, P746, DOI 10.1377/hlthaff.2011.0041; Naylor Mary D, 2002, Annu Rev Nurs Res, V20, P127; Olson DM, 2011, AHRQ PUBLICATION, V11(2)-E011; Owens DK, 2010, J CLIN EPIDEMIOL, V63, P513, DOI 10.1016/j.jclinepi.2009.03.009; Ricauda NA, 2004, J AM GERIATR SOC, V52, P278, DOI 10.1111/j.1532-5415.2004.52069.x; Sinclair AJ, 2005, AGE AGEING, V34, P338, DOI 10.1093/ageing/afi116; Sulch D, 2000, STROKE, V31, P1929, DOI 10.1161/01.STR.31.8.1929; Teng J, 2003, STROKE, V34, P528, DOI 10.1161/01.STR.0000049767.14156.2C; Torp CR, 2006, STROKE, V37, P1514, DOI 10.1161/01.STR.0000221793.81260.ed; von Koch L, 2001, CEREBROVASC DIS, V12, P131, DOI 10.1159/000047692; von Koch L, 2000, CLIN REHABIL, V14, P574, DOI 10.1191/0269215500cr364oa; Wolff JL, 2002, ARCH INTERN MED, V162, P2269, DOI 10.1001/archinte.162.20.2269	57	95	96	2	44	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 18	2012	157	6					407	U61		10.7326/0003-4819-157-6-201209180-00004	http://dx.doi.org/10.7326/0003-4819-157-6-201209180-00004			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	007UB	22986378				2023-01-03	WOS:000308912800015
J	Becker, WC; Fiellin, DA				Becker, William C.; Fiellin, David A.			Federal Plan for Prescriber Education on Opioids Misses Opportunities	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							OVERDOSE; PAIN		[Becker, William C.; Fiellin, David A.] Yale Univ, Sch Med, New Haven, CT 06520 USA	Yale University	Becker, WC (corresponding author), Yale Univ, Sch Med, 367 Cedar St,POB 208056, New Haven, CT 06520 USA.	william.becker@yale.edu		Becker, William/0000-0002-0788-1467; Fiellin, David/0000-0002-4006-010X	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [U01AA020795] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA020576, R01DA025991] Funding Source: NIH RePORTER; NIAAA NIH HHS [U01 AA020795] Funding Source: Medline; NIDA NIH HHS [R01 DA020576, R01 DA025991] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		American Medical Association, 2011, 1 AM MED ASS COUNC E; Center for Substance Abuse Treatment, 2004, TREATM IMPR PROT TIP, V40; Centers for Disease Control and Prevention (CDC), 2011, MMWR Morb Mortal Wkly Rep, V60, P869; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Egan JE, 2010, J GEN INTERN MED, V25, P936, DOI 10.1007/s11606-010-1377-y; FDA, 2011, FED REG; Food and Drug Administration, BLUEPR PRESCR CONT E; Holmboe ES, 2008, J CONTIN EDUC HEALTH, V28, pS4, DOI 10.1002/chp.200; Institute of Medicine, 2009, CONFL INT MED RES ED; Institute of Medicine, 2007, FUT DRUG SAF PROM PR; McLellan AT, 2010, ANN INTERN MED, V152, P123, DOI 10.7326/0003-4819-152-2-201001190-00012; Meier Barry, 2007, NY TIMES; Office of National Drug Control Policy US Executive Office of the President, 2011, EP RESP AM PRESCR DR; Rothman DJ, 2009, JAMA-J AM MED ASSOC, V301, P1367, DOI 10.1001/jama.2009.407	14	9	9	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 7	2012	157	3					205	+		10.7326/0003-4819-156-11-201206050-00448	http://dx.doi.org/10.7326/0003-4819-156-11-201206050-00448			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992PB	22868838				2023-01-03	WOS:000307789900007
J	Wang, K; Zhang, R; Xiang, XH; He, F; Lin, LB; Ping, XJ; Yu, L; Han, JS; Zhao, GP; Zhang, QH; Cui, CL				Wang, Ke; Zhang, Rong; Xiang, Xiaohui; He, Fei; Lin, Libo; Ping, Xingjie; Yu, Lei; Han, Jisheng; Zhao, Guoping; Zhang, Qinghua; Cui, Cailian			Differences in Neural-Immune Gene Expression Response in Rat Spinal Dorsal Horn Correlates with Variations in Electroacupuncture Analgesia	PLOS ONE			English	Article							TAIL-FLICK TEST; NEUROPATHIC PAIN; INDIVIDUAL-DIFFERENCES; ACUPUNCTURE ANALGESIA; APJ RECEPTOR; MECHANISMS; CHOLECYSTOKININ; STIMULATION; APELIN; CORD	Background: Electroacupuncture (EA) has been widely used to alleviate diverse pains. Accumulated clinical experiences and experimental observations indicated that significant differences exist in sensitivity to EA analgesia for individuals of patients and model animals. However, the molecular mechanism accounting for this difference remains obscure. Methodology/Principal Findings: We classified model male rats into high-responder (HR; TFL changes >150) and non-responder (NR; TFL changes <= 0) groups based on changes of their pain threshold detected by tail-flick latency (TFL) before and after 2 Hz or 100 Hz EA treatment. Gene expression analysis of spinal dorsal horn (DH) revealed divergent expression in HR and NR after 2 Hz/100 Hz EA. The expression of the neurotransmitter system related genes was significantly highly regulated in the HR animals while the proinflammation cytokines related genes were up-regulated more significantly in NR than that in HR after 2 Hz and 100 Hz EA stimulation, especially in the case of 2 Hz stimulation. Conclusions/Significance: Our results suggested that differential regulation and coordination of neural-immune related genes might play an important role for individual variations in analgesic effects responding to EA in DH. It also provided new candidate genes related to EA responsiveness for future investigation.	[Wang, Ke; He, Fei; Lin, Libo; Zhao, Guoping; Zhang, Qinghua] Chinese Natl Human Genome Ctr Shanghai, Shanghai MOST Key Lab Hlth & Dis Genom, Shanghai, Peoples R China; [Wang, Ke; Xiang, Xiaohui; He, Fei; Zhao, Guoping; Zhang, Qinghua] Natl Engn Res Ctr Biochip Shanghai, Shanghai, Peoples R China; [Zhang, Rong; Xiang, Xiaohui; Ping, Xingjie; Han, Jisheng; Cui, Cailian] Peking Univ, Hlth Sci Ctr, Dept Neurobiol, Neurosci Res Inst, Beijing 100871, Peoples R China; [Zhang, Rong; Xiang, Xiaohui; Ping, Xingjie; Han, Jisheng; Cui, Cailian] Peking Univ, Minist Educ, Key Lab Neurosci, Beijing 100871, Peoples R China; [Zhang, Rong; Xiang, Xiaohui; Ping, Xingjie; Han, Jisheng; Cui, Cailian] Peking Univ, Minist Publ Hlth, Beijing 100871, Peoples R China; [Yu, Lei] Dept Genet, Piscataway, NJ USA; [Yu, Lei] Rutgers State Univ, Ctr Alcohol Studies, Piscataway, NJ 08854 USA; [Zhao, Guoping] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Microbiol, Shatin, Hong Kong, Peoples R China; [Zhao, Guoping] Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China	Peking University; Peking University; Peking University; Rutgers State University New Brunswick; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital	Wang, K (corresponding author), Chinese Natl Human Genome Ctr Shanghai, Shanghai MOST Key Lab Hlth & Dis Genom, Shanghai, Peoples R China.	gpzhao@sibs.ac.cn; qinghua_zhang@shbiochip.com; clcui@bjmu.edu.cn	Zhang, Rong/O-5078-2017; ping, xingjie/AAW-4597-2020; Xiang, Xiaohui/D-8093-2015	Zhang, Rong/0000-0002-6889-5571; Xiang, Xiaohui/0000-0002-5762-5007; Cui, Cailian/0000-0002-8638-8258; Zhao, Guo-Ping/0000-0002-7621-6620	National Basic Research Program of China [973-2007CB512501]; China Postdoctoral Science Foundation [20100480643]; National Natural Science Foundation of China [30801491]	National Basic Research Program of China(National Basic Research Program of China); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Basic Research Program of China (No. 973-2007CB512501), China Postdoctoral Science Foundation (No. 20100480643), and National Natural Science Foundation of China (No. 30801491). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almeida RT, 2008, BRAIN RES, V1188, P54, DOI 10.1016/j.brainres.2007.10.060; [Anonymous], 1998, JAMA, V280, P1518; Basbaum AI, 2009, CELL, V139, P267, DOI 10.1016/j.cell.2009.09.028; Beurel E, 2010, TRENDS IMMUNOL, V31, P24, DOI 10.1016/j.it.2009.09.007; Chae Y, 2006, J PHYSIOL SCI, V56, P425, DOI 10.2170/physiolsci.RP010206; Cidral-Filho FJ, 2011, NEUROSCIENCE; DAMORE A, 1992, J PHARMACOL TOXICOL, V27, P197, DOI 10.1016/1056-8719(92)90041-X; Fukazawa Y, 2007, J PHARMACOL SCI, V104, P159, DOI 10.1254/jphs.FP0070475; Gao YZ, 2007, AM J CHINESE MED, V35, P767, DOI 10.1142/S0192415X07005259; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gold MS, 2010, NAT MED, V16, P1248, DOI 10.1038/nm.2235; Guo W, 2007, J NEUROSCI, V27, P6006, DOI 10.1523/JNEUROSCI.0176-07.2007; Han JS, 2011, PAIN, V152, pS41, DOI 10.1016/j.pain.2010.10.012; Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hutchinson MR, 2008, BRAIN BEHAV IMMUN, V22, P1178, DOI 10.1016/j.bbi.2008.05.004; IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.2307/1390807; Kalea AZ, 2010, CURR OPIN INVEST DR, V11, P273; Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594; Kim SK, 2009, GENES BRAIN BEHAV, V8, P174, DOI 10.1111/j.1601-183X.2008.00459.x; Kim SK, 2007, BRAIN RES BULL, V74, P357, DOI 10.1016/j.brainresbull.2007.07.006; Ko ES, 2006, PEPTIDES, V27, P1841, DOI 10.1016/j.peptides.2006.01.002; Koo ST, 2008, PAIN, V135, P11, DOI 10.1016/j.pain.2007.04.034; Kuner R, 2010, NAT MED, V16, P1258, DOI 10.1038/nm.2231; Lau WK, 2008, NEUROSCIENCE, V155, P463, DOI 10.1016/j.neuroscience.2008.06.016; Le Bars D, 2001, PHARMACOL REV, V53, P597; Lee DK, 2000, J NEUROCHEM, V74, P34, DOI 10.1046/j.1471-4159.2000.0740034.x; Lee G, 2002, NEUROSCI LETT, V325, P17, DOI 10.1016/S0304-3940(02)00214-8; Li HK, 2008, J PROTEOME RES, V7, P4775, DOI 10.1021/pr800352k; O'Carroll AM, 2000, BBA-GENE STRUCT EXPR, V1492, P72, DOI 10.1016/S0167-4781(00)00072-5; Paola FA, 2003, J SPINAL CORD MED, V26, P12; Park JH, 2010, BRAIN RES, V1322, P24, DOI 10.1016/j.brainres.2010.02.001; Ren K, 2009, BRAIN RES REV, V60, P57, DOI 10.1016/j.brainresrev.2008.12.020; Robinson GE, 2004, SCIENCE, V304, P397, DOI 10.1126/science.1095766; Silva JRT, 2011, J PAIN, V12, P51, DOI 10.1016/j.jpain.2010.04.008; Smyth GK., 2004, STAT APPL GENET MOL, V3, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Somers DL, 2009, J PAIN, V10, P221, DOI 10.1016/j.jpain.2008.08.008; Strand AD, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030059; Sun JB, 2010, J MAGN RESON IMAGING, V32, P298, DOI 10.1002/jmri.22238; Tang NM, 1997, PAIN, V71, P71, DOI 10.1016/S0304-3959(97)03341-1; Tanga FY, 2005, P NATL ACAD SCI USA, V102, P5856, DOI 10.1073/pnas.0501634102; Tjolsen Arne, 1993, Tidsskrift for den Norske Laegeforening, V113, P2921; Todd AJ, 2010, NAT REV NEUROSCI, V11, P823, DOI 10.1038/nrn2947; Uceyler N, 2009, EXP BRAIN RES, V196, P67, DOI 10.1007/s00221-009-1755-z; Ulett GA, 1998, BIOL PSYCHIAT, V44, P129, DOI 10.1016/S0006-3223(97)00394-6; Wan Y, 2001, PAIN, V91, P5, DOI 10.1016/S0304-3959(00)00416-4; Wang K, 2010, J NEUROCHEM, V113, P1436, DOI 10.1111/j.1471-4159.2010.06679.x; Wang LN, 2006, BRAIN RES, V1120, P46, DOI 10.1016/j.brainres.2006.08.077; Weyerbacher Amanda R, 2010, Pain, V148, P237, DOI 10.1016/j.pain.2009.11.003; Xiao HS, 2002, P NATL ACAD SCI USA, V99, P8360, DOI 10.1073/pnas.122231899; Xing GG, 2007, EXP NEUROL, V208, P323, DOI 10.1016/j.expneurol.2007.09.004; Xu N, 2009, PEPTIDES, V30, P1153, DOI 10.1016/j.peptides.2009.02.011; Yang NL, 2008, J CELL BIOCHEM, V103, P1760, DOI 10.1002/jcb.21562; Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004; ZHOU Y, 1993, NEUROPEPTIDES, V24, P139, DOI 10.1016/0143-4179(93)90077-N	55	13	15	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 3	2012	7	8							e42331	10.1371/journal.pone.0042331	http://dx.doi.org/10.1371/journal.pone.0042331			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	985QT	22879942	Green Published, gold			2023-01-03	WOS:000307284100069
J	Pan, H; Cui, BL; Zhang, DG; Farrar, J; Law, F; Ba-Thein, W				Pan, Hui; Cui, Binglin; Zhang, Dangui; Farrar, Jeremy; Law, Frieda; Ba-Thein, William			Prior Knowledge, Older Age, and Higher Allowance Are Risk Factors for Self-Medication with Antibiotics among University Students in Southern China	PLOS ONE			English	Article							ANTIMICROBIAL DRUGS; RESISTANCE; CHILDREN; COMMUNITY; ANTIMALARIALS; POPULATION; NIGERIA; EUROPE	Background: Self-medication with antibiotics (SMA) has been reported among university students in many countries, but little research has been done on this issue in China. The objective of this study was to evaluate knowledge and behaviors of university students and risk factors concerning SMA. Methodology/Principal Findings: Using a novel questionnaire-based data collection instrument, an anonymous online survey was conducted with the students of Shantou University (STU), a university comprising 8 schools/colleges in eastern Guangdong, China. Of 1,300 respondents (13.8% of total eligible participants), 47.8% had self-treated with antibiotics. Logistic regression analysis identified prior knowledge of antibiotics (PKA), older age, and higher monthly allowance as independent risk factors for SMA. PKA significantly influenced students' knowledge about antibiotics, their uses, and common adverse reactions (all p, 0.05). Among self-medicated students, 61.7% used antibiotics at least twice in the previous year. Community pharmacies were the major source of self-prescribed antibiotics. Reported common indications for SMA were sore throat (59.7%), fever (38.2%), cough (37.4%), runny nose (29.3%), and nasal congestion (28.7%). While 74.1% of self-medication episodes were based on students' own experiences, only 31.1% of students claimed to understand the package insert. Alteration of antibiotics and dosage during the course of self-treatment was made by 63.8% and 55.6% of students, respectively. At least two kinds of antibiotics were simultaneously taken by 82.6% of students. The majority of self-medicated students failed to complete the course of antibiotics. Adverse reactions were reported by 16.3% of students. Amoxicillin was the most common antibiotic used for self-medication. Conclusions: High prevalence of SMA was noted among STU students. Presence of risk factors and risk-associated behaviors/attitudes in the study population calls for focused educational intervention and stricter governmental legislation and regulation of antibiotic use and sale in pharmacies.	[Pan, Hui; Cui, Binglin; Zhang, Dangui; Farrar, Jeremy; Ba-Thein, William] Shantou Univ, Shantou Oxford Clin Res Unit, Coll Med, Shantou, Guangdong, Peoples R China; [Farrar, Jeremy] Univ Oxford, Clin Res Unit, Hosp Trop Dis, Wellcome Trust Major Overseas Programme, Ho Chi Minh City, Vietnam; [Law, Frieda] Shantou Univ, Consultant Off, Coll Med, Shantou, Guangdong, Peoples R China; [Ba-Thein, William] Shantou Univ, Dept Microbiol & Immunol, Coll Med, Shantou, Guangdong, Peoples R China	Shantou University; University of Oxford; Shantou University; Shantou University	Pan, H (corresponding author), Shantou Univ, Shantou Oxford Clin Res Unit, Coll Med, Shantou, Guangdong, Peoples R China.	wbathein@stu.edu.cn	Zhang, Dangui/CAE-9930-2022; Farrar, Jeremy J./HGA-7610-2022	Pan, Hui/0000-0001-6873-5749; Farrar, Jeremy/0000-0002-2700-623X	Li Ka Shing Foundation; Shantou University Medical College; Li Ka Shing Foundation-University of Oxford Global Health Programme [B9RSRT0-14]	Li Ka Shing Foundation; Shantou University Medical College; Li Ka Shing Foundation-University of Oxford Global Health Programme	This study was supported by the Li Ka Shing Foundation, Shantou University Medical College, and the Li Ka Shing Foundation-University of Oxford Global Health Programme (grant no. B9RSRT0-14). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Azzam Sayer I., 2007, International Journal of Occupational Medicine and Environmental Health, V20, P373, DOI 10.2478/v10001-007-0038-9; Awad A, 2005, J PHARM PHARM SCI, V8, P326; Awad AI, 2007, ANN PHARMACOTHER, V41, P1249, DOI 10.1345/aph.1K068; Bi P, 2000, SOC SCI MED, V50, P1445, DOI 10.1016/S0277-9536(99)00304-4; Buke AC, 2003, INT J ANTIMICROB AG, V21, P63, DOI 10.1016/S0924-8579(02)00272-8; Buke C, 2005, J INFECTION, V51, P135, DOI 10.1016/j.jinf.2004.12.001; Chen Q, 2008, J NW U NATL NATURAL, V29, P90; Chen Y, 2003, CHINESE RURAL HLTH S, V23, P52; Duong DV, 1997, TROP MED INT HEALTH, V2, P1133, DOI 10.1046/j.1365-3156.1997.d01-213.x; Esimone CO, 2007, PHARM WORLD SCI, V29, P655, DOI 10.1007/s11096-007-9124-0; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; Grigoryan L, 2006, EMERG INFECT DIS, V12, P452, DOI 10.3201/eid1203.050992; Hadi U, 2008, INT J INFECT DIS, V12, P622, DOI 10.1016/j.ijid.2008.01.002; Han F, 2011, J LIAONING U TCM, V13, P139; Harbarth S, 2005, EMERG INFECT DIS, V11, P794, DOI 10.3201/eid1106.050167; Kristiansson C, 2008, TROP MED INT HEALTH, V13, P434, DOI 10.1111/j.1365-3156.2008.02019.x; Kumarasamy KK, 2010, LANCET INFECT DIS, V10, P597, DOI 10.1016/S1473-3099(10)70143-2; Larsson M, 2000, TROP MED INT HEALTH, V5, P711, DOI 10.1046/j.1365-3156.2000.00630.x; Lewis K, 2009, CAN MED ASSOC J, V181, pE237, DOI 10.1503/cmaj.109-3070; Li J, 2008, CHINESE MED ETHICS, V21, P94; Li M, 2011, SOCIAL SCI J U SHANX, V23, P17; Liu M, 2009, J PEDIAT PHARM, V15, P34; McNulty CAM, 2006, EMERG INFECT DIS, V12, P1523, DOI 10.3201/eid1210.051471; Morgan DJ, 2011, LANCET INFECT DIS, V11, P692, DOI 10.1016/S1473-3099(11)70054-8; Mu S, 2001, CLIN FOCUS, V16, P540; Sapkota AR, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-610; SCHORLING JB, 1991, INT J EPIDEMIOL, V20, P293, DOI 10.1093/ije/20.1.293; Skliros E, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-58; Togoobaatar G, 2010, B WORLD HEALTH ORGAN, V88, P930, DOI 10.2471/BLT.10.079004; Xing Y, 2007, CHINESE J SCH DOCTOR, V21, P287; [徐京杭 XU Jinghang], 2007, [中国实用内科杂志, Chinese Journal of Practical Internal Medicine], V27, P1692; Ye L, 2005, CHINESE NURSING RES, V19, P2373; 杨永弘, 2002, [中国实用儿科杂志, Chinese Journal of Practical Pediatrics], V17, P148	33	84	86	3	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2012	7	7							e41314	10.1371/journal.pone.0041314	http://dx.doi.org/10.1371/journal.pone.0041314			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977GL	22911779	gold, Green Published, Green Submitted			2023-01-03	WOS:000306644600070
J	Russell, SJ; Peng, KW; Bell, JC				Russell, Stephen J.; Peng, Kah-Whye; Bell, John C.			Oncolytic virotherapy	NATURE BIOTECHNOLOGY			English	Review							VESICULAR STOMATITIS-VIRUS; HERPES-SIMPLEX-VIRUS; MEDIATED GENE-EXPRESSION; NONLINEAR DOSE-RESPONSE; MESENCHYMAL STEM-CELLS; TUMOR-SPECIFIC DEFECTS; MEASLES-VIRUS; INTRATUMORAL SPREAD; T-CELLS; PHASE-I	Oncolytic virotherapy is an emerging treatment modality that uses replication-competent viruses to destroy cancers. Recent advances include preclinical proof of feasibility for a single-shot virotherapy cure, identification of drugs that accelerate intratumoral virus propagation, strategies to maximize the immunotherapeutic action of oncolytic viruses and clinical confirmation of a critical viremic threshold for vascular delivery and intratumoral virus replication. The primary clinical milestone has been completion of accrual in a phase 3 trial of intratumoral herpes simplex virus therapy using talimogene laherparepvec for metastatic melanoma. Key challenges for the field are to select 'winners' from a burgeoning number of oncolytic platforms and engineered derivatives, to transiently suppress but then unleash the power of the immune system to maximize both virus spread and anticancer immunity, to develop more meaningful preclinical virotherapy models and to manufacture viruses with orders-of-magnitude higher yields than is currently possible.	[Russell, Stephen J.; Peng, Kah-Whye] Mayo Clin, Dept Mol Med, Rochester, MN 55905 USA; [Bell, John C.] Ottawa Hosp Res Inst, Ctr Canc Therapeut, Ottawa, ON, Canada; [Bell, John C.] Jennerex Biotherapeut, San Francisco, CA USA	Mayo Clinic; University of Ottawa; Ottawa Hospital Research Institute	Russell, SJ (corresponding author), Mayo Clin, Dept Mol Med, Rochester, MN 55905 USA.	sjr@mayo.edu	Kostov, Daniel/J-4106-2017	Kostov, Daniel/0000-0002-9721-320X; Russell, Stephen/0000-0002-0799-6432	Mayo Foundation; Mayo Clinic Comprehensive Cancer Center [CA15083]; National Cancer Institute [CA100634, CA129966, CA118488, CA129193, CA136547, CA136393]; Richard M. Schulze Family Foundation; Ontario Institute for Cancer Research; Terry Fox Foundation; Ottawa Regional Cancer Foundation; US National Institutes of Health; Al and Mary Agnes McQuinn and Minnesota Partnership for Biotechnology; NATIONAL CANCER INSTITUTE [R01CA118488, P30CA015083, R01CA129966, R01CA136547, P50CA136393, R01CA129193, R01CA168719, R01CA100634] Funding Source: NIH RePORTER	Mayo Foundation; Mayo Clinic Comprehensive Cancer Center; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Richard M. Schulze Family Foundation; Ontario Institute for Cancer Research; Terry Fox Foundation; Ottawa Regional Cancer Foundation; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Al and Mary Agnes McQuinn and Minnesota Partnership for Biotechnology; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	S.J.R. and K.-W.P. acknowledge funding support from the Mayo Foundation, Mayo Clinic Comprehensive Cancer Center (CA15083), US National Institutes of Health and National Cancer Institute (CA100634, CA129966, CA118488, CA129193, CA136547 and CA136393), Richard M. Schulze Family Foundation, Al and Mary Agnes McQuinn and Minnesota Partnership for Biotechnology. J.C.B. is supported by the Ontario Institute for Cancer Research, the Terry Fox Foundation and the Ottawa Regional Cancer Foundation.	Alain T, 2010, P NATL ACAD SCI USA, V107, P1576, DOI 10.1073/pnas.0912344107; Alemany R, 2000, J GEN VIROL, V81, P2605, DOI 10.1099/0022-1317-81-11-2605; Altomonte J, 2008, MOL THER, V16, P146, DOI 10.1038/sj.mt.6300343; ASADA T, 1974, CANCER, V34, P1907, DOI 10.1002/1097-0142(197412)34:6<1907::AID-CNCR2820340609>3.0.CO;2-4; Au GG, 2005, INT J ONCOL, V26, P1471; Ayala-Breton C, 2012, HUM GENE THER, V23, P484, DOI 10.1089/hum.2011.146; Bachtarzi H, 2011, J CONTROL RELEASE, V150, P196, DOI 10.1016/j.jconrel.2010.10.011; Banaszynski LA, 2008, NAT MED, V14, P1123, DOI 10.1038/nm.1754; Banaszynski LA, 2006, CELL, V126, P995, DOI 10.1016/j.cell.2006.07.025; Barnett FH, 1999, CANCER GENE THER, V6, P14, DOI 10.1038/sj.cgt.7700003; Barton KN, 2008, MOL THER, V16, P1761, DOI 10.1038/mt.2008.172; Bessis N, 2004, GENE THER, V11, pS10, DOI 10.1038/sj.gt.3302364; Breitbach CJ, 2011, NATURE, V477, P99, DOI 10.1038/nature10358; Breitbach CJ, 2011, MOL THER, V19, P886, DOI 10.1038/mt.2011.26; Bridle BW, 2010, CYTOKINE GROWTH F R, V21, P143, DOI 10.1016/j.cytogfr.2010.02.009; Brown CW, 2009, J VIROL, V83, P552, DOI 10.1128/JVI.01921-08; Byrnes AP, 2000, J VIROL, V74, P644, DOI 10.1128/JVI.74.2.644-651.2000; Cattaneo R, 2008, NAT REV MICROBIOL, V6, P529, DOI 10.1038/nrmicro1927; Cawood R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016152; Cawood R, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000440; Chang HM, 2004, P NATL ACAD SCI USA, V101, P9578, DOI 10.1073/pnas.0400567101; Chen HH, 2011, MOL THER, V19, P67, DOI 10.1038/mt.2010.209; Chen NH, 2011, VIROLOGY, V409, P328, DOI 10.1016/j.virol.2010.10.021; Chiocca EA, 2008, CURR OPIN MOL THER, V10, P38; Croyle MA, 2004, J VIROL, V78, P912, DOI 10.1128/JVI.78.2.912-921.2004; Diallo JS, 2010, MOL THER, V18, P1123, DOI 10.1038/mt.2010.67; Diaz RM, 2007, CANCER RES, V67, P2840, DOI 10.1158/0008-5472.CAN-06-3974; Dingli D, 2004, BLOOD, V103, P1641, DOI 10.1182/blood-2003-07-2233; Dingli D, 2003, J CELL BIOCHEM, V90, P1079, DOI 10.1002/jcb.10714; Diop-Frimpong B, 2011, P NATL ACAD SCI USA, V108, P2909, DOI 10.1073/pnas.1018892108; Dorer DE, 2009, ADV DRUG DELIVER REV, V61, P554, DOI 10.1016/j.addr.2009.03.013; Doronin K, 2000, J VIROL, V74, P6147, DOI 10.1128/JVI.74.13.6147-6155.2000; Doronin K, 2009, HUM GENE THER, V20, P975, DOI 10.1089/hum.2009.028; Driessen WHP, 2009, ADV GENET, V67, P103, DOI 10.1016/S0065-2660(09)67004-8; Duncan R, 2006, NAT REV CANCER, V6, P688, DOI 10.1038/nrc1958; Dwyer RM, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt25; Eager RM, 2011, CANCER GENE THER, V18, P305, DOI 10.1038/cgt.2011.7; Edge RE, 2008, MOL THER, V16, P1437, DOI 10.1038/mt.2008.130; Eto Y, 2008, INT J PHARM, V354, P3, DOI 10.1016/j.ijpharm.2007.08.025; Fang J, 2011, ADV DRUG DELIVER REV, V63, P136, DOI 10.1016/j.addr.2010.04.009; Fisher KD, 2010, ADV DRUG DELIVER REV, V62, P240, DOI 10.1016/j.addr.2009.12.003; Foka P, 2010, J GENE MED, V12, P956, DOI 10.1002/jgm.1519; Fox ME, 2009, ACCOUNTS CHEM RES, V42, P1141, DOI 10.1021/ar900035f; Galanis E, 2010, CANCER RES, V70, P875, DOI 10.1158/0008-5472.CAN-09-2762; Ganesh S, 2008, CLIN CANCER RES, V14, P3933, DOI 10.1158/1078-0432.CCR-07-4732; Garcia-Castro J, 2010, CANCER GENE THER, V17, P476, DOI 10.1038/cgt.2010.4; Glass M, 2009, NAT METHODS, V6, P577, DOI 10.1038/nmeth.1346; Green NK, 2004, GENE THER, V11, P1256, DOI 10.1038/sj.gt.3302295; Guedan S, 2010, MOL THER, V18, P1275, DOI 10.1038/mt.2010.79; Haisma HJ, 2011, MOL PHARMACEUT, V8, P50, DOI 10.1021/mp100310h; Haisma HJ, 2009, MOL PHARMACEUT, V6, P366, DOI 10.1021/mp8000974; Haller O, 2007, CYTOKINE GROWTH F R, V18, P425, DOI 10.1016/j.cytogfr.2007.06.001; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Haralambieva I, 2007, MOL THER, V15, P588, DOI 10.1038/sj.mt.6300076; Harrington KJ, 2010, CYTOKINE GROWTH F R, V21, P91, DOI 10.1016/j.cytogfr.2010.02.006; Harrington KJ, 2010, CLIN CANCER RES, V16, P4005, DOI 10.1158/1078-0432.CCR-10-0196; Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7; Heo J, 2011, MOL THER, V19, P1170, DOI 10.1038/mt.2011.39; Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607; Hoffmann D, 2006, MOL CANCER THER, V5, P2013, DOI 10.1158/1535-7163.MCT-06-0128; Ikeda K, 1999, NAT MED, V5, P881, DOI 10.1038/11320; Ikeda K, 2000, J VIROL, V74, P4765, DOI 10.1128/JVI.74.10.4765-4775.2000; Ilett EJ, 2009, GENE THER, V16, P689, DOI 10.1038/gt.2009.29; Ilett EJ, 2011, CLIN CANCER RES, V17, P2767, DOI 10.1158/1078-0432.CCR-10-3266; Israyelyan A, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-68; Jacobs A, 2001, LANCET, V358, P727, DOI 10.1016/S0140-6736(01)05904-9; Jain RK, 2010, NAT REV CLIN ONCOL, V7, P653, DOI 10.1038/nrclinonc.2010.139; Jing YQ, 2009, CANCER RES, V69, P1459, DOI 10.1158/0008-5472.CAN-08-2628; Kanai R, 2010, FUTURE ONCOL, V6, P619, DOI [10.2217/fon.10.18, 10.2217/FON.10.18]; Kelly E, 2007, MOL THER, V15, P651, DOI 10.1038/sj.mt.6300108; Kelly EJ, 2008, NAT MED, V14, P1278, DOI 10.1038/nm.1776; Kelly EJ, 2010, J VIROL, V84, P1550, DOI 10.1128/JVI.01788-09; Kelly EJ, 2009, MOL THER, V17, P409, DOI 10.1038/mt.2008.288; Kim JH, 2006, JNCI-J NATL CANCER I, V98, P1482, DOI 10.1093/jnci/djj397; Kirn DH, 2008, CANCER RES, V68, P2071, DOI 10.1158/0008-5472.CAN-07-6515; Kirn DH, 2009, NAT REV CANCER, V9, P64, DOI 10.1038/nrc2545; Knop DR, 2007, BIOTECHNOL PROGR, V23, P715, DOI 10.1021/bp060373p; Koski A, 2009, J GENE MED, V11, P966, DOI 10.1002/jgm.1373; Kottke T, 2008, MOL THER, V16, P1217, DOI 10.1038/mt.2008.83; Kottke T, 2011, NAT MED, V17, P854, DOI 10.1038/nm.2390; Kottke T, 2010, J CLIN INVEST, V120, P1551, DOI 10.1172/JCI41431; Kottke T, 2008, MOL THER, V16, P1910, DOI 10.1038/mt.2008.212; Kottke T, 2009, CLIN CANCER RES, V15, P561, DOI 10.1158/1078-0432.CCR-08-1688; Kuhn I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002409; Kumar CC, 1997, J PHARMACOL EXP THER, V283, P843; Kurozumi K, 2007, JNCI-J NATL CANCER I, V99, P1768, DOI 10.1093/jnci/djm229; Le Boeuf F, 2010, MOL THER, V18, P888, DOI 10.1038/mt.2010.44; Leber MF, 2011, MOL THER, V19, P1097, DOI 10.1038/mt.2011.55; Lee CYF, 2010, MOL THER, V18, P929, DOI 10.1038/mt.2010.26; Lee PY, 2002, J VIROL, V76, P6302, DOI 10.1128/JVI.76.12.6302-631-.2002; Lewis J.A., 2006, DEV BIOL BASEL, V123, P183; Lewis JA, 2006, DEV BIOLOGICALS, V123, P165; Ling XY, 2010, CANCER MICROENVIRON, V3, P83, DOI 10.1007/s12307-010-0041-8; Liu CS, 2010, MOL THER, V18, P1155, DOI 10.1038/mt.2010.43; Liu TC, 2007, NAT CLIN PRACT ONCOL, V4, P101, DOI 10.1038/ncponc0736; Lu MY, 2011, CELL DEATH DIFFER, V18, P925, DOI 10.1038/cdd.2010.160; Lun XQ, 2007, CANCER RES, V67, P8818, DOI 10.1158/0008-5472.CAN-07-1214; Lun XQ, 2010, CANCER RES, V70, P598, DOI 10.1158/0008-5472.CAN-09-1510; MacTavish H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014462; Mader EK, 2009, CLIN CANCER RES, V15, P7246, DOI 10.1158/1078-0432.CCR-09-1292; Manickan E, 2006, MOL THER, V13, P108, DOI 10.1016/j.ymthe.2005.08.007; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; Mastrangelo MJ, 2000, ADV EXP MED BIOL, V465, P391; Mastrangelo MJ, 1999, CANCER GENE THER, V6, P409, DOI 10.1038/sj.cgt.7700066; MATSUMURA Y, 1986, CANCER RES, V46, P6387; Melcher A, 2011, MOL THER, V19, P1008, DOI 10.1038/mt.2011.65; Miyatake S, 1997, J VIROL, V71, P5124, DOI 10.1128/JVI.71.7.5124-5132.1997; Morrison J, 2008, MOL THER, V16, P244, DOI 10.1038/sj.mt.6300363; Morrison J, 2009, HUM GENE THER, V20, P239, DOI 10.1089/hum.2008.167; Muik A, 2011, J VIROL, V85, P5679, DOI 10.1128/JVI.02511-10; Muthana M, 2011, CANCER RES, V71, P1805, DOI 10.1158/0008-5472.CAN-10-2349; Naik S, 2012, LEUKEMIA, V26, P1870, DOI 10.1038/leu.2012.70; Naik S, 2009, EXPERT OPIN BIOL TH, V9, P1163, DOI 10.1517/14712590903170653; Nakamura T, 2005, NAT BIOTECHNOL, V23, P209, DOI 10.1038/nbt1060; Neri D, 2005, NAT REV CANCER, V5, P436, DOI 10.1038/nrc1627; Nguyen TLA, 2008, P NATL ACAD SCI USA, V105, P14981, DOI 10.1073/pnas.0803988105; Oliere S, 2008, J VIROL, V82, P5735, DOI 10.1128/JVI.02601-07; Ong HT, 2007, GENE THER, V14, P324, DOI 10.1038/sj.gt.3302880; Ong HT, 2009, MOL THER, V17, P1012, DOI 10.1038/mt.2009.39; Otsuki A, 2008, MOL THER, V16, P1546, DOI 10.1038/mt.2008.155; Palumbo A, 2011, BRIT J CANCER, V104, P1106, DOI 10.1038/bjc.2011.78; Park BH, 2008, LANCET ONCOL, V9, P533, DOI 10.1016/S1470-2045(08)70107-4; Passer BJ, 2010, CANCER RES, V70, P3890, DOI 10.1158/0008-5472.CAN-10-0155; Patel B, 2011, MOL THER, V19, P1034, DOI 10.1038/mt.2011.44; Peng KW, 2013, GENE THER, V20, P255, DOI 10.1038/gt.2012.31; Peng KW, 2002, NAT MED, V8, P527, DOI 10.1038/nm0502-527; Power AT, 2008, GENE THER, V15, P772, DOI 10.1038/gt.2008.40; Pulido J, 2012, NAT BIOTECHNOL, V30, P336, DOI 10.1038/nbt.2157; Qiao J, 2008, GENE THER, V15, P604, DOI 10.1038/sj.gt.3303098; Qiao J, 2008, CLIN CANCER RES, V14, P259, DOI 10.1158/1078-0432.CCR-07-1510; Reeves PM, 2011, J VIROL, V85, P21, DOI 10.1128/JVI.01814-10; Rodriguez R, 1997, CANCER RES, V57, P2559; Roos FC, 2010, EMBO MOL MED, V2, P275, DOI 10.1002/emmm.201000081; Rudin CM, 2011, CLIN CANCER RES, V17, P888, DOI 10.1158/1078-0432.CCR-10-1706; Russell SJ, 2009, CURR TOP MICROBIOL, V330, P213; RUSSELL SJ, 1994, SEMIN CANCER BIOL, V5, P437; Russell SJ, 2007, TRENDS PHARMACOL SCI, V28, P326, DOI 10.1016/j.tips.2007.05.005; Sanz L, 2002, GENE THER, V9, P1049, DOI 10.1038/sj.gt.3301725; Sauthoff H, 2003, HUM GENE THER, V14, P425, DOI 10.1089/104303403321467199; Schoggins JW, 2011, NATURE, V472, P481, DOI 10.1038/nature09907; Schoofs G, 1998, CYTOTECHNOLOGY, V28, P81, DOI 10.1023/A:1008021428969; Senac JS, 2010, HUM GENE THER, V21, P179, DOI 10.1089/hum.2009.082; Senzer NN, 2009, J CLIN ONCOL, V27, P5763, DOI 10.1200/JCO.2009.24.3675; Serganova I, 2007, NUCL MED BIOL, V34, P791, DOI 10.1016/j.nucmedbio.2007.05.009; Shashkova EV, 2008, CANCER RES, V68, P5896, DOI 10.1158/0008-5472.CAN-08-0488; Shashkova EV, 2009, MOL THER, V17, P2121, DOI 10.1038/mt.2009.217; SOUTHAM CHESTER M., 1960, TRANS NEW YORK ACAD SCI, V22, P657; Stepkowski S M, 2000, Expert Rev Mol Med, V2, P1, DOI 10.1017/S1462399400001769; Stoff-Khalili MA, 2008, BREAST CANCER RES TR, V108, P43, DOI 10.1007/s10549-007-9587-7; Stojdl DF, 2003, CANCER CELL, V4, P263, DOI 10.1016/S1535-6108(03)00241-1; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Sugio K, 2011, CLIN CANCER RES, V17, P2807, DOI 10.1158/1078-0432.CCR-10-2008; Tai CK, 2008, FRONT BIOSCI-LANDMRK, V13, P3083, DOI 10.2741/2910; Tao NJ, 2001, MOL THER, V3, P28, DOI 10.1006/mthe.2000.0227; Thorne SH, 2006, SCIENCE, V311, P1780, DOI 10.1126/science.1121411; Thorne SH, 2007, J CLIN INVEST, V117, P3350, DOI 10.1172/JCI32727; Toth K, 2010, EXPERT OPIN BIOL TH, V10, P353, DOI 10.1517/14712590903559822; Tseng JC, 2010, CANCER GENE THER, V17, P244, DOI 10.1038/cgt.2009.70; Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744; Vandevenne P, 2010, BIOCHEM PHARMACOL, V80, P1955, DOI 10.1016/j.bcp.2010.07.001; Virgin S., 2007, FIELDS VIROLOGY, V1; Wakimoto H, 2002, MOL THER, V5, P275, DOI 10.1006/mthe.2002.0547; Wong RJ, 2001, HUM GENE THER, V12, P253, DOI 10.1089/10430340150218396; Yang L, 2010, TRENDS IMMUNOL, V31, P220, DOI 10.1016/j.it.2010.04.002; Yang XY, 2009, J VIROL METHODS, V155, P44, DOI 10.1016/j.jviromet.2008.09.020; Yun CO, 2008, CURR OPIN MOL THER, V10, P356; Zhang XD, 2011, ONCOL REP, V26, P637, DOI 10.3892/or.2011.1306; Ziegler RJ, 2002, HUM GENE THER, V13, P935, DOI 10.1089/10430340252939041	168	914	982	23	445	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2012	30	7					658	670		10.1038/nbt.2287	http://dx.doi.org/10.1038/nbt.2287			13	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	972QV	22781695	Green Accepted			2023-01-03	WOS:000306293400025
J	Assefa, N; Berhane, Y; Worku, A				Assefa, Nega; Berhane, Yemane; Worku, Alemayehu			Wealth Status, Mid Upper Arm Circumference (MUAC) and Ante Natal Care (ANC) Are Determinants for Low Birth Weight in Kersa, Ethiopia	PLOS ONE			English	Article							PREGNANCY	Background: Low Birth Weight (LBW) is one of the major risk factor for death in early life. However, little is known about predictors of LBW in sub-Saharan Africa. Therefore, the aim of this study was to measure the incidence and determinants of LBW in a rural population of Ethiopia. Methods: An observational cohort study on pregnant women was conducted from December 2009 to November 2010. During the study period 1295 live birth were registered and the weights of 956 children were measured within 24 hours after birth. Socio-demographic, economic, maternal and organizational factors were considered as a predicators of LBW, defined as birth weight below 2500g. Logistic regression was used to analyze the data, odds ratio (OR) and confidence intervals (CI) are reported. Result: The incidence of LBW was 28.3%. It is significantly associated with poverty [OR 2.1; 95% CI: 1.42, 3.05], maternal Mid Upper Arm Circumference (MUAC) less than 23 cm [OR 1.6; 95% CI: 1.19, 2.19], not attending ANC [OR 1.6; 95% CI: 1.12, 2.28], mother's experience of physical violence during pregnancy [OR 1.7; 95% CI: 1.12, 2.48], and longer time to walk to health facility [OR 1.6; 95% CI: 1.11, 2.40]. Conclusion and Recommendation: The incidence of LBW was high in Kersa. Babies born to women who were poor, undernourished, experienced physical violence during pregnancy and who had poor access to health services were more likely to be LBW in this part of the country. In this largely poor community where ANC coverage is low, to reduce the incidence of LBW, it is essential to improve access for maternal health care. The involvement of husbands and the community at large to seek collective action on LBW is essential.	[Assefa, Nega] Haramaya Univ, Coll Hlth Sci, Harar, Ethiopia; [Berhane, Yemane; Worku, Alemayehu] Addis Continental Inst Publ Hlth, Addis Ababa, Ethiopia; [Worku, Alemayehu] Univ Addis Ababa, Sch Publ Hlth, Addis Ababa, Ethiopia	Haramaya University; Addis Continental Institute of Public Health; Addis Ababa University	Assefa, N (corresponding author), Haramaya Univ, Coll Hlth Sci, Harar, Ethiopia.	negaassefa@yahoo.com	Berhane, Yemane/ABB-8154-2020	Assefa, Nega/0000-0003-0341-2329; Berhane, Yemane/0000-0002-2527-1339	Haramaya University, Ethiopia	Haramaya University, Ethiopia	This work was funded by Haramaya University, Ethiopia, as part of Ph.D work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arokiasamy P, 2010, HLTH POLICY PLANNING, P1; Asefa M, 2004, ETHIOP J HLTH SCI, V14, P13; Assefa N, 2011, PREGNANCY R IN PRESS; Badshah S, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-197; Basso O, 2000, INT J EPIDEMIOL, V29, P856, DOI 10.1093/ije/29.5.856; Dey AC, 2007, BANGLADISH J CHILD H, V31, P1; Dubois L, 2006, PEDIATR INT, V48, P470, DOI 10.1111/j.1442-200X.2006.02256.x; Enquoselassie F., 2000, Ethiopian Journal of Health Development, V14, P169; EpiDataAss, 2010, EPIDATA STAT APPL; Ethiopia CSA, 2006, DEM HLTH SURV 2005; Feresu SA, 2004, PAEDIATR PERINAT EP, V18, P154, DOI 10.1111/j.1365-3016.2003.00539.x; FMOH, 2007, HLTH EXT PROGR ETH P; FMOH, 2007, HLTH HLTH REL IND; Gelman A, 2007, STAT SCI, V22, P153, DOI 10.1214/088342306000000691; Grimes DA, 2002, LANCET, V359, P248, DOI 10.1016/S0140-6736(02)07451-2; Janjua ZN, 2008, DETEMINATS LOW BIRTH; Kersa DHO, 2011, HLTH SERVICE COVERAG; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Leal M, 2006, PARENTAL CHILDBIRTH, P40; Lemons JA, 2001, PEDIATRICS, V107, part. no., DOI 10.1542/peds.107.1.e1; Macro O, 2002, UTILIZATION MATERNAL; Mbuagbaw LCE, 2011, MATERN CHILD HLTH J, V15, P1427, DOI 10.1007/s10995-010-0707-3; Mohanty C, 2006, J TROP PEDIATRICS, V52, P24, DOI 10.1093/tropej/fmi059; Mohanty C, 2005, MATERNAL ANTHROPOMET; Moss William, 2002, J Perinatol, V22, P484; Neeti R, 2011, ASIA PAC J PUBLIC HL; Nobile CGA, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-192; OHLSSON A, 2008, DETERMINANTS PREVENT; PETHYBRIDGE RJ, 1974, BRIT J PREV SOC MED, V28, P10; Ricalde AE, 1998, REV SAUDE PUBL, V32, P112, DOI 10.1590/S0034-89101998000200002; Rosen D, 2007, J INTERPERS VIOLENCE, V22, P1305, DOI 10.1177/0886260507304551; Sarkar NN, 2008, J OBSTET GYNAECOL, V28, P266, DOI 10.1080/01443610802042415; Sellstrom E, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-267; Sen J, 2010, J TROP PEDIATRICS, V56, P254, DOI 10.1093/tropej/fmp102; Shah PS, 2011, MATERN CHILD HLTH J, V15, P205, DOI 10.1007/s10995-009-0546-2; StataCorp, 2009, STAT STAT SOFTW REL; Tuniseranee P, 1999, WHO J EPIDEMIOLOGY C, V53, P624; Vahdaninia M, 2008, BMC PREGNANCY CHILDB, V8; Vyas S, 2006, CONSTRUCTING SOCIOEC; World Health Organization, 2005, RES VIOLENCE WOMEN P	41	78	78	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2012	7	6							e39957	10.1371/journal.pone.0039957	http://dx.doi.org/10.1371/journal.pone.0039957			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	967FO	22792140	Green Published, gold, Green Submitted			2023-01-03	WOS:000305892100154
J	Reinders, AATS; Willemsen, ATM; Vos, HPJ; den Boer, JA; Nijenhuis, ERS				Reinders, A. A. T. Simone; Willemsen, Antoon T. M.; Vos, Herry P. J.; den Boer, Johan A.; Nijenhuis, Ellert R. S.			Fact or Factitious? A Psychobiological Study of Authentic and Simulated Dissociative Identity States	PLOS ONE			English	Article							ANIMAL DEFENSIVE REACTIONS; FANTASY PRONENESS; MULTIPLE PERSONALITY; COGNITIVE-PROCESSES; SOMATOFORM DISSOCIATION; SOCIOCOGNITIVE MODEL; DISORDER; PERSISTENCE; TRAUMA; BRAIN	Background: Dissociative identity disorder (DID) is a disputed psychiatric disorder. Research findings and clinical observations suggest that DID involves an authentic mental disorder related to factors such as traumatization and disrupted attachment. A competing view indicates that DID is due to fantasy proneness, suggestibility, suggestion, and role-playing. Here we examine whether dissociative identity state-dependent psychobiological features in DID can be induced in high or low fantasy prone individuals by instructed and motivated role-playing, and suggestion. Methodology/Principal Findings: DID patients, high fantasy prone and low fantasy prone controls were studied in two different types of identity states (neutral and trauma-related) in an autobiographical memory script-driven (neutral or trauma-related) imagery paradigm. The controls were instructed to enact the two DID identity states. Twenty-nine subjects participated in the study: 11 patients with DID, 10 high fantasy prone DID simulating controls, and 8 low fantasy prone DID simulating controls. Autonomic and subjective reactions were obtained. Differences in psychophysiological and neural activation patterns were found between the DID patients and both high and low fantasy prone controls. That is, the identity states in DID were not convincingly enacted by DID simulating controls. Thus, important differences regarding regional cerebral bloodflow and psychophysiological responses for different types of identity states in patients with DID were upheld after controlling for DID simulation. Conclusions/Significance: The findings are at odds with the idea that differences among different types of dissociative identity states in DID can be explained by high fantasy proneness, motivated role-enactment, and suggestion. They indicate that DID does not have a sociocultural (e. g., iatrogenic) origin.	[Reinders, A. A. T. Simone] Kings Coll London, Inst Psychiat, Dept Psychosis Studies, London WC2R 2LS, England; [Reinders, A. A. T. Simone] Univ Groningen, Univ Med Ctr Groningen, Dept Neurosci, Groningen, Netherlands; [Reinders, A. A. T. Simone] Univ Groningen, BCN Neuroimaging Ctr, Groningen, Netherlands; [Willemsen, Antoon T. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Nucl Med & Mol Imaging, Groningen, Netherlands; [den Boer, Johan A.] Univ Groningen, Univ Med Ctr Groningen, Univ Ctr Psychiat, Groningen, Netherlands; [Nijenhuis, Ellert R. S.] Top Referent Trauma Ctr Mental Hlth Care Drenthe, Assen, Netherlands	University of London; King's College London; University of Groningen; University of Groningen; University of Groningen; University of Groningen	Reinders, AATS (corresponding author), Kings Coll London, Inst Psychiat, Dept Psychosis Studies, London WC2R 2LS, England.	a.a.t.s.reinders@gmail.com		Nijenhuis, Ellert/0000-0003-4710-474X	Netherlands Organization for Scientific Research, NWO-VENI [451-07-009]	Netherlands Organization for Scientific Research, NWO-VENI(Netherlands Organization for Scientific Research (NWO))	AATSR is supported by the Netherlands Organization for Scientific Research (www.nwo.nl), NWO-VENI grant no. 451-07-009. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson MC, 2004, SCIENCE, V303, P232, DOI 10.1126/science.1089504; Armony JL, 1997, ANN NY ACAD SCI, V821, P259, DOI 10.1111/j.1749-6632.1997.tb48285.x; Association AP DSM- IV APATF, 2000, DIAGN STAT MAN MENT; Braffman W, 1999, J PERS SOC PSYCHOL, V77, P578, DOI 10.1037/0022-3514.77.3.578; Bremner JD, 2010, PSYCHOL BULL, V136, P1, DOI 10.1037/a0018021; Brett M., 2006, MNI BRAIN TALAIRACH; Brown D., 1998, MEMORY TRAUMA TREATM; Brown D, 1999, J PSYCHIAT LAW, V27, P549, DOI DOI 10.1177/009318539902700308; Camm AJ, 1996, EUR HEART J, V17, P354; Casada JH, 1998, BIOL PSYCHIAT, V44, P1037, DOI 10.1016/S0006-3223(98)00182-6; Coons PM, 2005, CAN J PSYCHIAT, V50, P813, DOI 10.1177/070674370505001217; Draijer N, 1999, J PSYCHIAT L, V27, P423; Driver J, 2001, COGNITION, V79, P39, DOI 10.1016/S0010-0277(00)00124-4; Elzinga BM, 2003, J ABNORM PSYCHOL, V112, P237, DOI 10.1037/0021-843X.112.2.237; Elzinga BM, 1998, CLIN PSYCHOL PSYCHOT, V5, P13, DOI 10.1002/(SICI)1099-0879(199803)5:1<13::AID-CPP148>3.0.CO;2-J; Friston K.J., 1994, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Friston KJ, 1997, TRENDS COGN SCI, V1, P21, DOI 10.1016/S1364-6613(97)01001-2; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; Friston KJ, 1996, NEUROIMAGE, V4, P97, DOI 10.1006/nimg.1996.0033; Friston KJ, 1995, HUM BRAIN MAPP, V3, P165, DOI 10.1002/hbm.460030303; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Giesbrecht T, 2008, E COMMUNICATION 0211; Giesbrecht T, 2008, PSYCHOL BULL, V134, P617, DOI 10.1037/0033-2909.134.5.617; Giesbrecht T, 2007, J NERV MENT DIS, V195, P812, DOI 10.1097/NMD.0b013e3181568137; Giesbrecht T, 2006, PERS INDIV DIFFER, V41, P697, DOI 10.1016/j.paid.2006.02.015; Giesbrecht T, 2010, PSYCHOL BULL, V136, P7, DOI 10.1037/a0018068; Gleaves DH, 1996, PSYCHOL BULL, V120, P42, DOI 10.1037/0033-2909.120.1.42; Goebel R, 2011, BRAIN INNOVATION HOM; Haaksma J, 1994, HEART RATE DEPENDENT, P45; Hamilton JP, 2008, BIOL PSYCHIAT, V63, P1155, DOI 10.1016/j.biopsych.2007.12.015; Huntjens RJC, 2007, BEHAV RES THER, V45, P775, DOI 10.1016/j.brat.2006.07.001; Huntjens RJC, 2006, PSYCHOL MED, V36, P857, DOI 10.1017/S0033291706007100; Huntjens RJC, 2005, CONSCIOUS COGN, V14, P377, DOI 10.1016/j.concog.2004.10.001; Huntjens RJC, 2005, BEHAV RES THER, V43, P243, DOI 10.1016/j.brat.2004.01.007; Huntjens RJC, 2003, J ABNORM PSYCHOL, V112, P290, DOI 10.1037/0021-843X.112.2.290; Huntjens RJC, 2002, MEM COGNITION, V30, P1033, DOI 10.3758/BF03194321; Lancaster JL, 1997, HUM BRAIN MAPP, V5, P238, DOI 10.1002/(SICI)1097-0193(1997)5:4<238::AID-HBM6>3.0.CO;2-4; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Lanius RA, 2004, AM J PSYCHIAT, V161, P36, DOI 10.1176/appi.ajp.161.1.36; Lanius RA, 2010, AM J PSYCHIAT, V167, P640, DOI 10.1176/appi.ajp.2009.09081168; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Levin R, 2004, ASSESSMENT, V11, P160, DOI 10.1177/1073191103256377; Lilienfeld SO, 1999, PSYCHOL BULL, V125, P507, DOI 10.1037/0033-2909.125.5.507; Loewenstein RJ., 2007, TRAUMATIC DISSOCIATI, P275; Mai J.K., 1997, ATLAS HUMAN BRAIN; Merckelbach H, 2000, J NERV MENT DIS, V188, P428, DOI 10.1097/00005053-200007000-00006; Merckelbach H, 2006, PERS INDIV DIFFER, V40, P365, DOI 10.1016/j.paid.2005.07.007; Merckelbach H, 2001, PERS INDIV DIFFER, V31, P987, DOI 10.1016/S0191-8869(00)00201-4; Merckelbach H, 2002, CLIN PSYCHOL REV, V22, P481, DOI 10.1016/S0272-7358(01)00115-5; Merckelbach H, 2001, BEHAV RES THER, V39, P245, DOI 10.1016/S0005-7967(99)00181-3; Merskey H, 2009, REMOVING DID MPD DSM; Nijenhuis ERS, 2011, DISSOCIATION AND THE DISSOCIATIVE DISORDERS: DSM-V AND BEYOND, P337; Nijenhuis ERS, 2011, J TRAUMA DISSOCIATIO, V12, P416, DOI 10.1080/15299732.2011.570592; Nijenhuis ERS, 1998, J TRAUMA STRESS, V11, P243, DOI 10.1023/A:1024447003022; Nijenhuis ERS, 1996, J NERV MENT DIS, V184, P688, DOI 10.1097/00005053-199611000-00006; Nijenhuis ERS, 1998, J ABNORM PSYCHOL, V107, P63, DOI 10.1037/0021-843X.107.1.63; Nijenhuis ERS, 2004, AUST NZ J PSYCHIAT, V38, P678, DOI 10.1080/j.1440-1614.2004.01441.x; Nijenhuis ERS, 2002, CLIN PSYCHOL PSYCHOT, V9, P200, DOI 10.1002/cpp.332; Nijenhuis ERS, 1997, ACTA PSYCHIAT SCAND, V96, P311, DOI 10.1111/j.1600-0447.1997.tb09922.x; O'Neil, 2009, DISSOCIATION DISSOCI; Pavani F, 2003, TRENDS COGN SCI, V7, P407, DOI 10.1016/S1364-6613(03)00189-X; Piper A, 2005, CAN J PSYCHIAT, V50, P814, DOI 10.1177/070674370505001220; Piper A, 2004, CAN J PSYCHIAT, V49, P678, DOI 10.1177/070674370404901005; Piper A, 2004, CAN J PSYCHIAT, V49, P592, DOI 10.1177/070674370404900904; Pope HG, 2006, PSYCHOTHER PSYCHOSOM, V75, P19, DOI 10.1159/000089223; Poulsen B. C., 2003, CONT HYPNOSIS, V20, P198, DOI DOI 10.1002/CH.278; Price CJ, 1997, NEUROIMAGE, V5, P261, DOI 10.1006/nimg.1997.0269; Price CJ, 1997, HUM BRAIN MAPP, V5, P264, DOI 10.1002/(SICI)1097-0193(1997)5:4<264::AID-HBM11>3.0.CO;2-E; PUTNAM FW, 1992, BRIT J PSYCHIAT, V161, P415, DOI 10.1192/bjp.161.3.415b; Rassin E, 2001, J NERV MENT DIS, V189, P478, DOI 10.1097/00005053-200107000-00010; RAUSCHENBERGER SL, 1995, J ABNORM PSYCHOL, V104, P373, DOI 10.1037/0021-843X.104.2.373; Reinders AATS, 2008, NEUROCASE, V14, P44, DOI 10.1080/13554790801992768; Reinders AATS, 2006, BIOL PSYCHIAT, V60, P730, DOI 10.1016/j.biopsych.2005.12.019; Reinders AATS, 2005, EUR J NEUROSCI, V22, P524, DOI 10.1111/j.1460-9568.2005.04212.x; Reinders AATS, 2003, NEUROIMAGE, V20, P2119, DOI 10.1016/j.neuroimage.2003.08.021; Reinders AATS, 2002, NEUROIMAGE, V17, P1844, DOI 10.1006/nimg.2002.1318; Sar V, 2001, J TRAUMA DISSOCIATIO, V1, P67, DOI DOI 10.1300/J229v01n04_04; Sar V, 2005, CAN J PSYCHIAT, V50, P813, DOI 10.1177/070674370505001218; Schwabe L, 2008, NEUROBIOL LEARN MEM, V90, P495, DOI 10.1016/j.nlm.2008.07.015; SILVA CE, 1992, J PERS SOC PSYCHOL, V63, P847, DOI 10.1037/0022-3514.63.5.847; Simeon D, 2000, AM J PSYCHIAT, V157, P1782, DOI 10.1176/appi.ajp.157.11.1782; Spanos N.P., 1996, MULTIPLE IDENTITIES; SPANOS NP, 1994, PSYCHOL BULL, V116, P143, DOI 10.1037/0033-2909.116.1.143; Spiegel D, 2006, AM J PSYCHIAT, V163, P566, DOI 10.1176/appi.ajp.163.4.566; SPIEGEL D, 1984, PSYCHIAT CLIN N AM, V7, P101; Steinberg M, 1993, STRUCTURED CLIN INTE; Talairach J., 1988, CO PLANAR STEREOTAXI; Van der Hart O., 2006, HAUNTED SELF STRUCTU; White NM, 2009, BEHAV BRAIN RES, V199, P3, DOI 10.1016/j.bbr.2008.12.003; Xiao ZP, 2006, AM J PSYCHIAT, V163, P1388, DOI 10.1176/appi.ajp.163.8.1388; [No title captured]	91	54	54	2	75	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2012	7	6							e39279	10.1371/journal.pone.0039279	http://dx.doi.org/10.1371/journal.pone.0039279			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	967FO	22768068	Green Published, gold			2023-01-03	WOS:000305892100039
J	Shinoda, M; Ando, T; El-Omar, EM; Takashi, H; Suzuki, T; Murayama, M; Morise, K; Goto, H				Shinoda, Masataka; Ando, Takafumi; El-Omar, Emad M.; Takashi, Hitomi; Suzuki, Takahisa; Murayama, Mutsumi; Morise, Kazuhiro; Goto, Hidemi			Programmed Chemotherapy for Patients with Metastatic Unresectable Gastric Cancer	PLOS ONE			English	Article							PHASE-III TRIAL; PLUS CISPLATIN; S-1; PACLITAXEL; 5-FLUOROURACIL; COMBINATION; I/II; IRINOTECAN; INFUSION	Background: Recent advances in the treatment of metastatic unresectable gastric cancers (MGC) include the development of new antitumor drugs and new regimens for their use. However, the selection of individually designed regimens by gastric cancer (GC) subtype remains problematic. Here, we investigated the clinical usefulness of programmed chemotherapy. Methodology/Principal Findings: MGC patients were classified into three groups by clinical condition. We implemented a chemotherapy program consisting of S-1 combination regimens. Median survival time (MST) of level 1 patients was 416 days (95% CI: 313-506 days), with an overall response rate of 47%. MSTs of level 2 and 3 patients were 208 (95% CI: 153-287 days) and 95 days (95% CI: 28-136 days), respectively. Grade 3-4 toxicities were neutropenia in 12% and anorexia in 6%. All treatment-related toxicities were resolved, and no treatment-related deaths occurred. Conclusions/Significance: This program provided reasonable selection of case-matching regimens and may improve the survival of patients with MGC. Further, it may represent the first clinical tool to provide efficient chemotherapy course selection for MGC. Ongoing analysis of newly developed drugs and regimens will allow the efficacy of this chemotherapy program to be improved.	[Shinoda, Masataka; Ando, Takafumi; Morise, Kazuhiro; Goto, Hidemi] Nagoya Univ, Dept Gastroenterol, Grad Sch Med, Nagoya, Aichi, Japan; [Shinoda, Masataka; Takashi, Hitomi; Suzuki, Takahisa; Murayama, Mutsumi] Toyota Mem Hosp, Dept Gastroenterol, Toyota, Japan; [El-Omar, Emad M.] Univ Aberdeen, Dept Med & Therapeut, Aberdeen, Scotland	Nagoya University; University of Aberdeen	Shinoda, M (corresponding author), Nagoya Univ, Dept Gastroenterol, Grad Sch Med, Nagoya, Aichi, Japan.	takafumiando-gi@umin.ac.jp	El-Omar, Emad/AAT-7780-2021	El-Omar, Emad/0000-0002-0011-3924				Arai T, 2003, JPN J CANC CLIN, V49, P621; Fujitani K, 2005, ONCOLOGY-BASEL, V69, P414, DOI 10.1159/000089996; Futatsuki K, 1994, JPN J CANC CHEMOTHER, V21, P1033; HEIDELBERGER C, 1957, NATURE, V179, P663, DOI 10.1038/179663a0; Iwase H, 2005, ANTICANCER RES, V25, P1297; Katsube T, 2007, ANTI-CANCER DRUG, V18, P605, DOI 10.1097/CAD.0b013e3280262460; Koizumi W, 2000, ONCOLOGY-BASEL, V58, P191, DOI 10.1159/000012099; Koizumi W, 2003, BRIT J CANCER, V89, P2207, DOI 10.1038/sj.bjc.6601413; Koizumi W, 2008, LANCET ONCOL, V9, P215, DOI 10.1016/S1470-2045(08)70035-4; Mochiki E, 2006, BRIT J CANCER, V95, P1642, DOI 10.1038/sj.bjc.6603497; Narahara H, 2008, ONCOLOGY-BASEL, V74, P37, DOI 10.1159/000138978; Ohtsu A, 2003, J CLIN ONCOL, V21, P54, DOI 10.1200/JCO.2003.04.130; Shirasaka T, 1996, ANTI-CANCER DRUG, V7, P548, DOI 10.1097/00001813-199607000-00010; Sugimachi K, 1999, ONCOLOGY-BASEL, V57, P202, DOI 10.1159/000012032; Sugimoto N, 2009, JPN J CANC CHEMOTHER, V36, P417; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Trotti A, 2000, INT J RADIAT ONCOL, V47, P13, DOI 10.1016/S0360-3016(99)00559-3; Uedo N, 2007, ONCOLOGY-BASEL, V73, P65, DOI 10.1159/000120630; Yamada Y, 2001, ANN ONCOL, V12, P1133, DOI 10.1023/A:1011680507956; Yamada Yasuhide, 2003, Int J Clin Oncol, V8, P374, DOI 10.1007/s10147-003-0359-z; Yano T, 2003, JPN J CANC CLIN, V49, P583; Yoshida K, 2006, CLIN CANCER RES, V12, P3402, DOI 10.1158/1078-0432.CCR-05-2425	22	0	0	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 26	2012	7	6							e38652	10.1371/journal.pone.0038652	http://dx.doi.org/10.1371/journal.pone.0038652			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	966AK	22761692	Green Published, gold, Green Submitted			2023-01-03	WOS:000305808700007
J	Hernandez, JM; Stein, A; Behrmann, E; Riedel, D; Cypionka, A; Farsi, Z; Walla, PJ; Raunser, S; Jahn, R				Hernandez, Javier M.; Stein, Alexander; Behrmann, Elmar; Riedel, Dietmar; Cypionka, Anna; Farsi, Zohreh; Walla, Peter J.; Raunser, Stefan; Jahn, Reinhard			Membrane Fusion Intermediates via Directional and Full Assembly of the SNARE Complex	SCIENCE			English	Article							HEMIFUSION; EXOCYTOSIS; PROMOTES; VISUALIZATION; SYNAPTOTAGMIN; MECHANISMS; RESOLUTION; RELEASE; DOCKING; LIPIDS	Cellular membrane fusion is thought to proceed through intermediates including docking of apposed lipid bilayers, merging of proximal leaflets to form a hemifusion diaphragm, and fusion pore opening. A membrane-bridging four-helix complex of soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) mediates fusion. However, how assembly of the SNARE complex generates docking and other fusion intermediates is unknown. Using a cell-free reaction, we identified intermediates visually and then arrested the SNARE fusion machinery when fusion was about to begin. Partial and directional assembly of SNAREs tightly docked bilayers, but efficient fusion and an extended form of hemifusion required assembly beyond the core complex to the membrane-connecting linkers. We propose that straining of lipids at the edges of an extended docking zone initiates fusion.	[Hernandez, Javier M.; Stein, Alexander; Riedel, Dietmar; Cypionka, Anna; Farsi, Zohreh; Jahn, Reinhard] Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany; [Cypionka, Anna; Walla, Peter J.] Max Planck Inst Biophys Chem, AG Biomol Spect & Single Mol Detect, D-37077 Gottingen, Germany; [Walla, Peter J.] Tech Univ Carolo Wilhelmina Braunschweig, Inst Phys & Theoret Chem, Dept Biophys Chem, D-38106 Braunschweig, Germany; [Behrmann, Elmar; Raunser, Stefan] Max Planck Inst Mol Physiol, Dept Phys Biochem, D-44227 Dortmund, Germany	Max Planck Society; Max Planck Society; Braunschweig University of Technology; Max Planck Society	Jahn, R (corresponding author), Max Planck Inst Biophys Chem, Dept Neurobiol, Fassberg 11, D-37077 Gottingen, Germany.	rjahn@gwdg.de	Behrmann, Elmar/I-5808-2015; Raunser, Stefan/AHE-1573-2022; Stein, Alexander/I-4950-2012	Behrmann, Elmar/0000-0001-6794-3669; Stein, Alexander/0000-0002-2696-0611; Farsi, Zohreh/0000-0001-7274-981X; Jahn, Reinhard/0000-0003-1542-3498; Raunser, Stefan/0000-0001-9373-3016	National Institutes of Health [3P01GM072694-05S1]; German Research Foundation [RA 1781/1-1, SFB 803]; Fonds der Chemischen Industrie [684052, 166660, 661218]; National Commission for Scientific and Technological Research of Chile; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM072694] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); German Research Foundation(German Research Foundation (DFG)); Fonds der Chemischen Industrie(Fonds der Chemischen IndustrieEuropean Commission); National Commission for Scientific and Technological Research of Chile; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank G. van den Bogaart, J. Risselada, J. Chua, R. Klemm, and T. Rapoport for critical review; G. Weber for providing the ribbon structure; and O. Hofnagel and U. Ries for valuable technical assistance. Funding was generously provided by the National Institutes of Health (3P01GM072694-05S1 to R. J.), the German Research Foundation (RA 1781/1-1 to S. R. and SFB 803 to R. J. and P. J. W.), the "Fonds der Chemischen Industrie" grant 684052 to E. B. and grants 166660 and 661218 to P. J. W., and a doctoral fellowship from the National Commission for Scientific and Technological Research of Chile to J. M. H. Additional data described in the manuscript are presented in the supplementary materials.	Bhalla A, 2006, NAT STRUCT MOL BIOL, V13, P323, DOI 10.1038/nsmb1076; Chernomordik LV, 2008, NAT STRUCT MOL BIOL, V15, P675, DOI 10.1038/nsmb.1455; Cypionka A, 2009, P NATL ACAD SCI USA, V106, P18575, DOI 10.1073/pnas.0906677106; Fasshauer D, 2004, J BIOL CHEM, V279, P7613, DOI 10.1074/jbc.M312064200; Grafmuller A, 2009, BIOPHYS J, V96, P2658, DOI 10.1016/j.bpj.2008.11.073; Hofmann MW, 2006, J MOL BIOL, V364, P1048, DOI 10.1016/j.jmb.2006.09.077; Kinnunen PKJ, 2000, BIOSCIENCE REP, V20, P465, DOI 10.1023/A:1010402819509; Malinin VS, 2004, BIOPHYS J, V86, P2951, DOI 10.1016/S0006-3495(04)74346-5; Martens S, 2007, SCIENCE, V316, P1205, DOI 10.1126/science.1142614; Mima J, 2008, EMBO J, V27, P2031, DOI 10.1038/emboj.2008.139; Nikolaus J, 2010, BIOPHYS J, V98, P1192, DOI 10.1016/j.bpj.2009.11.042; Pobbati AV, 2006, SCIENCE, V313, P673, DOI 10.1126/science.1129486; Risselada HJ, 2011, CHEMBIOCHEM, V12, P1049, DOI 10.1002/cbic.201100020; Rizo J, 2006, TRENDS CELL BIOL, V16, P339, DOI 10.1016/j.tcb.2006.04.006; Scheidt HA, 2004, BBA-BIOMEMBRANES, V1663, P97, DOI 10.1016/j.bbamem.2004.02.004; Schwartz ML, 2009, J CELL BIOL, V185, P535, DOI 10.1083/jcb.200811082; Siddiqui TJ, 2007, MOL BIOL CELL, V18, P2037, DOI 10.1091/mbc.E07-01-0049; Stein A, 2009, NATURE, V460, P525, DOI 10.1038/nature08156; Stevens MJ, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.188102; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; van den Bogaart G, 2011, NAT STRUCT MOL BIOL, V18, P805, DOI 10.1038/nsmb.2061; van den Bogaart G, 2010, NAT STRUCT MOL BIOL, V17, P358, DOI 10.1038/nsmb.1748; Walter AM, 2010, J CELL BIOL, V188, P401, DOI 10.1083/jcb.200907018; Wang L, 2002, CELL, V108, P357, DOI 10.1016/S0092-8674(02)00632-3; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wong JL, 2007, DEV CELL, V12, P653, DOI 10.1016/j.devcel.2007.02.007; Xu YB, 2005, NAT STRUCT MOL BIOL, V12, P417, DOI 10.1038/nsmb921; Xu Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022012; Yang Y, 2010, P NATL ACAD SCI USA, V107, P22145, DOI 10.1073/pnas.1006899108; Yoon TY, 2006, P NATL ACAD SCI USA, V103, P19731, DOI 10.1073/pnas.0606032103	30	159	160	0	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2012	336	6088					1581	1584		10.1126/science.1221976	http://dx.doi.org/10.1126/science.1221976			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	961ZE	22653732	Green Accepted, Green Submitted			2023-01-03	WOS:000305507500058
J	Cantor, JD				Cantor, Julie D.			Court-Ordered Care - A Complication of Pregnancy to Avoid	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									UCLA Sch Law, Los Angeles, CA USA		Cantor, JD (corresponding author), UCLA Sch Law, Los Angeles, CA USA.							ACOG Committee on Ethics, 2005, Obstet Gynecol, V106, P1127; Adams SF, 2003, CLIN PERINATOL, V30, P127, DOI 10.1016/S0095-5108(02)00082-9; Roth Rachel, 2000, MAKING WOMEN PAY HID; Samuels TA, 2007, WOMEN HEALTH ISS, V17, P107, DOI 10.1016/j.whi.2006.12.001	4	16	16	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 14	2012	366	24					2237	2240						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	957PD	22693994				2023-01-03	WOS:000305174100001
J	Chen, X; Pan, LQ; Naranmandura, H; Zeng, S; Chen, SQ				Chen, Xuan; Pan, Li Qiang; Naranmandura, Hua; Zeng, Su; Chen, Shu Qing			Influence of Various Polymorphic Variants of Cytochrome P450 Oxidoreductase (POR) on Drug Metabolic Activity of CYP3A4 and CYP2B6	PLOS ONE			English	Article							ANTLEY-BIXLER-SYNDROME; MUTANT P450 OXIDOREDUCTASE; GENETIC-VARIATION; DISORDERED STEROIDOGENESIS; NADPH-P450 OXIDOREDUCTASE; HEME OXYGENASE; IN-VITRO; REDUCTASE; MUTATIONS; SYSTEM	Cytochrome P450 oxidoreductase (POR) is known as the sole electron donor in the metabolism of drugs by cytochrome P450 (CYP) enzymes in human. However, little is known about the effect of polymorphic variants of POR on drug metabolic activities of CYP3A4 and CYP2B6. In order to better understand the mechanism of the activity of CYPs affected by polymorphic variants of POR, six full-length mutants of POR (e.g., Y181D, A287P, K49N, A115V, S244C and G413S) were designed and then co-expressed with CYP3A4 and CYP2B6 in the baculovirus-Sf9 insect cells to determine their kinetic parameters. Surprisingly, both mutants, Y181D and A287P in POR completely inhibited the CYP3A4 activity with testosterone, while the catalytic activity of CYP2B6 with bupropion was reduced to approximately similar to 70% of wild-type activity by Y181D and A287P mutations. In addition, the mutant K49N of POR increased the CLint (Vmax/Km) of CYP3A4 up to more than 31% of wild-type, while it reduced the catalytic efficiency of CYP2B6 to 74% of wild-type. Moreover, CLint values of CYP3A4-POR (A115V, G413S) were increased up to 36% and 65% of wild-type respectively. However, there were no appreciable effects observed by the remaining two mutants of POR (i.e., A115V and G413S) on activities of CYP2B6. In conclusion, the extent to which the catalytic activities of CYP were altered did not only depend on the specific POR mutations but also on the isoforms of different CYP redox partners. Thereby, we proposed that the POR-mutant patients should be carefully monitored for the activity of CYP3A4 and CYP2B6 on the prescribed medication.	[Chen, Xuan; Pan, Li Qiang; Naranmandura, Hua; Chen, Shu Qing] Zhejiang Univ, Coll Pharmaceut Sci, Dept Pharmacol Toxicol & Biochem Pharmaceut, Hangzhou 310003, Zhejiang, Peoples R China; [Zeng, Su] Zhejiang Univ, Coll Pharmaceut Sci, Dept Drug Metab & Pharmaceut Anal, Hangzhou 310003, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University	Chen, X (corresponding author), Zhejiang Univ, Coll Pharmaceut Sci, Dept Pharmacol Toxicol & Biochem Pharmaceut, Hangzhou 310003, Zhejiang, Peoples R China.	narenman@zju.edu.cn; chenshuqing@zju.edu.cn	Naranmandura, Hua/C-6499-2015	Naranmandura, Hua/0000-0003-0799-2340; Chen, Shuqing/0000-0002-0792-3735	National Natural Science Foundation of China [81001477]; National Science and Technology Major Projects for "Major New Drugs Innovation and Development" of China [2012ZX09506001-004]; Zhejiang Provincial Natural Science Foundation of China [R2110231]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Major Projects for "Major New Drugs Innovation and Development" of China; Zhejiang Provincial Natural Science Foundation of China(Natural Science Foundation of Zhejiang Province)	The authors wish to acknowledge the National Natural Science Foundation of China (No. 81001477), National Science and Technology Major Projects for "Major New Drugs Innovation and Development" of China (No. 2012ZX09506001-004) and Zhejiang Provincial Natural Science Foundation of China (No. R2110231). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrawal V, 2008, PHARMACOGENET GENOM, V18, P569, DOI 10.1097/FPC.0b013e32830054ac; Agrawal V, 2010, PHARMACOGENET GENOM, V20, P611, DOI 10.1097/FPC.0b013e32833e0cb5; Arlt W, 2004, LANCET, V363, P2128, DOI 10.1016/S0140-6736(04)16503-3; BLACK SD, 1982, J BIOL CHEM, V257, P5929; Bonina TA, 2005, BIOCHEMISTRY-MOSCOW+, V70, P357, DOI 10.1007/s10541-005-0122-3; Dhir V, 2007, MOL ENDOCRINOL, V21, P1958, DOI 10.1210/me.2007-0066; Eichelbaum M, 2006, ANNU REV MED, V57, P119, DOI 10.1146/annurev.med.56.082103.104724; Faucette SR, 2000, DRUG METAB DISPOS, V28, P1222; Fluck CE, 2004, NAT GENET, V36, P228, DOI 10.1038/ng1300; Fluck CE, 2007, FUND CLIN PHARMACOL, V21, P399, DOI 10.1111/j.1472-8206.2007.00520.x; Fluck CE, 2010, BIOCHEM BIOPH RES CO, V401, P149, DOI 10.1016/j.bbrc.2010.09.035; Gu J, 2003, J BIOL CHEM, V278, P25895, DOI 10.1074/jbc.M303125200; Guengerich FP, 2004, DRUG METAB REV, V36, P159, DOI 10.1081/DMR-120033996; Han JF, 2006, TOXICOL SCI, V91, P42, DOI 10.1093/toxsci/kfj139; Hart SN, 2008, EXPERT OPIN DRUG MET, V4, P439, DOI [10.1517/17425255.4.4.439, 10.1517/17425255.4.4.439 ]; Hart SN, 2007, DRUG METAB PHARMACOK, V22, P322, DOI 10.2133/dmpk.22.322; Henderson CJ, 2003, J BIOL CHEM, V278, P13480, DOI 10.1074/jbc.M212087200; Huang N, 2008, P NATL ACAD SCI USA, V105, P1733, DOI 10.1073/pnas.0711621105; Huang NW, 2005, AM J HUM GENET, V76, P729, DOI 10.1086/429417; ILAN Z, 1981, J BIOL CHEM, V256, P66; Ingelman-Sundberg M, 2007, PHARMACOL THERAPEUT, V116, P496, DOI 10.1016/j.pharmthera.2007.09.004; Kranendonk M, 2008, ARCH BIOCHEM BIOPHYS, V475, P93, DOI 10.1016/j.abb.2008.04.014; Lo HR, 2004, BIOTECHNOL PROGR, V20, P354, DOI 10.1021/bp034132i; Marohnic CC, 2006, J BIOL CHEM, V281, P35975, DOI 10.1074/jbc.M607095200; Marohnic CC, 2010, DRUG METAB DISPOS, V38, P332, DOI 10.1124/dmd.109.030445; Meyer UA, 2004, NAT REV GENET, V5, P669, DOI 10.1038/nrg1428; Miller WL, 2009, MOL CELL ENDOCRINOL, V300, P180, DOI 10.1016/j.mce.2008.09.017; Miller WL, 2011, MOL CELL ENDOCRINOL, P174; Moutinho D, 2012, DRUG METAB DISPOS, DOI [10.1124/dmd.1111.042820, DOI 10.1124/DMD.1111.042820]; Moutinho D, 2012, DRUG METAB DISPOS, V40, P754, DOI 10.1124/dmd.111.042820; OMURA T, 1964, J BIOL CHEM, V239, P2370; Oneda B, 2009, PHARMACOGENET GENOM, V19, P877, DOI 10.1097/FPC.0b013e32833225e7; Otto DME, 2003, MOL CELL BIOL, V23, P6103, DOI 10.1128/MCB.23.17.6103-6116.2003; Ozdemir V, 2000, PHARMACOGENETICS, V10, P373, DOI 10.1097/00008571-200007000-00001; Panda SP, 2006, J BIOL CHEM, V281, P34246, DOI 10.1074/jbc.M601041200; Pandey AV, 2007, MOL ENDOCRINOL, V21, P2579, DOI 10.1210/me.2007-0245; Pandey AV, 2010, BIOCHEM BIOPH RES CO, V400, P374, DOI 10.1016/j.bbrc.2010.08.072; Sandee D, 2010, PHARMACOGENET GENOM, V20, P677, DOI 10.1097/FPC.0b013e32833f4f9b; SCHACTER BA, 1972, J BIOL CHEM, V247, P3601; Shen AL, 2002, J BIOL CHEM, V277, P6536, DOI 10.1074/jbc.M111408200; Sim SC, 2009, PHARMACOGENET GENOM, V19, P565, DOI 10.1097/FPC.0b013e32832af5b7; Wang HN, 2011, BIOCHEM PHARMACOL, V82, P1757, DOI 10.1016/j.bcp.2011.08.004; Wang RW, 1997, DRUG METAB DISPOS, V25, P502; Wang SL, 2007, DRUG METAB DISPOS, V35, P176, DOI 10.1124/dmd.106.011056; Zanger UM, 2008, ANAL BIOANAL CHEM, V392, P1093, DOI 10.1007/s00216-008-2291-6; Zhang HM, 2011, J PHARMACOL EXP THER, V338, P803, DOI 10.1124/jpet.111.183111; Zhang XL, 2011, DRUG METAB DISPOS, V39, P1433, DOI 10.1124/dmd.111.038836; Zhou SF, 2008, CURR DRUG METAB, V9, P310, DOI 10.2174/138920008784220664	48	26	29	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2012	7	6							e38495	10.1371/journal.pone.0038495	http://dx.doi.org/10.1371/journal.pone.0038495			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UJ	22719896	Green Submitted, gold, Green Published			2023-01-03	WOS:000305340000026
J	Osterholt, HCD; Dannevig, I; Wyckoff, MH; Liao, J; Akgul, Y; Ramgopal, M; Mija, DS; Cheong, N; Longoria, C; Mahendroo, M; Nakstad, B; Saugstad, OD; Savani, RC				Osterholt, Helene C. D.; Dannevig, Ingrid; Wyckoff, Myra H.; Liao, Jie; Akgul, Yucel; Ramgopal, Mrithyunjay; Mija, Dan S.; Cheong, Naeun; Longoria, Christopher; Mahendroo, Mala; Nakstad, Britt; Saugstad, Ola D.; Savani, Rashmin C.			Antioxidant Protects against Increases in Low Molecular Weight Hyaluronan and Inflammation in Asphyxiated Newborn Pigs Resuscitated with 100% Oxygen	PLOS ONE			English	Article							BRONCHOALVEOLAR LAVAGE FLUID; N-ACETYLCYSTEINE IMPROVES; ROOM-AIR RESUSCITATION; LESS OXIDATIVE STRESS; NITRIC-OXIDE; NEONATAL RESUSCITATION; SUPEROXIDE-DISMUTASE; PEROXYNITRITE; INJURY; ACID	Background: Newborn resuscitation with 100% oxygen is associated with oxidative-nitrative stresses and inflammation. The mechanisms are unclear. Hyaluronan (HA) is fragmented to low molecular weight (LMW) by oxidative-nitrative stresses and can promote inflammation. We examined the effects of 100% oxygen resuscitation and treatment with the antioxidant, N-acetylcysteine (NAC), on lung 3-nitrotyrosine (3-NT), LMW HA, inflammation, TNF alpha and IL1 beta in a newborn pig model of resuscitation. Methods & Principal Findings: Newborn pigs (n = 40) were subjected to severe asphyxia, followed by 30 min ventilation with either 21% or 100% oxygen, and were observed for the subsequent 150 minutes in 21% oxygen. One 100% oxygen group was treated with NAC. Serum, bronchoalveolar lavage (BAL), lung sections, and lung tissue were obtained. Asphyxia resulted in profound hypoxia, hypercarbia and metabolic acidosis. In controls, HA staining was in airway subepithelial matrix and no 3-NT staining was seen. At the end of asphyxia, lavage HA decreased, whereas serum HA increased. At 150 minutes after resuscitation, exposure to 100% oxygen was associated with significantly higher BAL HA, increased 3NT staining, and increased fragmentation of lung HA. Lung neutrophil and macrophage contents, and serum TNF alpha and IL1 beta were higher in animals with LMW than those with HMW HA in the lung. Treatment of 100% oxygen animals with NAC blocked nitrative stress, preserved HMW HA, and decreased inflammation. In vitro, peroxynitrite was able to fragment HA, and macrophages stimulated with LMW HA increased TNF alpha and IL1 beta expression. Conclusions & Significance: Compared to 21%, resuscitation with 100% oxygen resulted in increased peroxynitrite, fragmentation of HA, inflammation, as well as TNF alpha and IL1 beta expression. Antioxidant treatment prevented the expression of peroxynitrite, the degradation of HA, and also blocked increases in inflammation and inflammatory cytokines. These findings provide insight into potential mechanisms by which exposure to hyperoxia results in systemic inflammation.	[Osterholt, Helene C. D.; Dannevig, Ingrid; Nakstad, Britt] Akershus Univ Hosp, Dept Pediat, Lorenskog, Norway; [Osterholt, Helene C. D.; Dannevig, Ingrid; Nakstad, Britt] Univ Oslo, Inst Clin Med, Oslo, Norway; [Osterholt, Helene C. D.; Dannevig, Ingrid] Univ Oslo, Rikshosp, Oslo Univ Hosp, Inst Surg Res, N-0027 Oslo, Norway; [Saugstad, Ola D.] Univ Oslo, Rikshosp, Oslo Univ Hosp, Dept Pediat Res, N-0027 Oslo, Norway; [Akgul, Yucel; Mahendroo, Mala] Univ Texas SW Med Ctr Dallas, Dept Obstet & Gynecol, Dallas, TX 75390 USA; [Wyckoff, Myra H.; Liao, Jie; Ramgopal, Mrithyunjay; Mija, Dan S.; Cheong, Naeun; Longoria, Christopher; Savani, Rashmin C.] Univ Texas SW Med Ctr Dallas, Div Pulm & Vasc Biol, Dept Pediat, Dallas, TX 75390 USA; [Wyckoff, Myra H.; Liao, Jie; Ramgopal, Mrithyunjay; Mija, Dan S.; Cheong, Naeun; Longoria, Christopher; Savani, Rashmin C.] Univ Texas SW Med Ctr Dallas, Div Neonatal Perinatal Med, Dept Pediat, Dallas, TX 75390 USA	University of Oslo; University of Oslo; University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Osterholt, HCD (corresponding author), Akershus Univ Hosp, Dept Pediat, Lorenskog, Norway.	rashmin.savani@utsouthwestern.edu	Akgul, Yucel/M-1745-2013; Rashmin C. Savani, MBChB/AAG-2041-2021; Saugstad, Ola/AAS-9041-2021	Rashmin C. Savani, MBChB/0000-0002-9533-5422; Saugstad, Ola/0000-0002-3166-5254; akgul, yucel/0000-0001-8880-9821	Norwegian South East Health Trust; William Buchanan Chair awarded; Ikaria Therapeutics	Norwegian South East Health Trust; William Buchanan Chair awarded; Ikaria Therapeutics	This project was funded by the Norwegian South East Health Trust, The William Buchanan Chair awarded to RCS and a research grant award to MHW and RCS from Ikaria Therapeutics. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AKATSUKA M, 1993, J PHARM PHARMACOL, V45, P110, DOI 10.1111/j.2042-7158.1993.tb03693.x; Akgul Y, 2012, ENDOCRINOLO IN PRESS; Alonso-Spilsbury M, 2005, ANIM REPROD SCI, V90, P1, DOI 10.1016/j.anireprosci.2005.01.007; ANDERSON B, 1991, AM REV RESPIR DIS, V143, P284, DOI 10.1164/ajrccm/143.2.284; Andresen JH, 2008, NEONATOLOGY, V94, P279, DOI 10.1159/000151647; Ara J, 1998, P NATL ACAD SCI USA, V95, P7659, DOI 10.1073/pnas.95.13.7659; Banks BA, 1998, PEDIATRICS, V101, P870, DOI 10.1542/peds.101.5.870; Beckman JS, 2000, SEMIN PERINATOL, V24, P37, DOI 10.1016/S0146-0005(00)80053-1; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; BJERMER L, 1987, BRIT MED J, V295, P803, DOI 10.1136/bmj.295.6602.803; Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8; Chan Emily, 2007, Proc West Pharmacol Soc, V50, P53; Cheung PY, 2011, JOVE-J VIS EXP, DOI 10.3791/3166; CROSS CE, 1994, LANCET, V344, P930, DOI 10.1016/S0140-6736(94)92275-6; Deguine V, 1998, INT J BIOL MACROMOL, V22, P17, DOI 10.1016/S0141-8130(97)00084-6; Doroszko A, 2010, SHOCK, V34, P592, DOI 10.1097/SHK.0b013e3181e14f1d; Ducrocq C, 1999, CELL MOL LIFE SCI, V55, P1068, DOI 10.1007/s000180050357; Ezaki S, 2009, J CLIN BIOCHEM NUTR, V44, P111, DOI 10.3164/jcbn.08-221; FREEMAN BA, 1982, LAB INVEST, V47, P412; Gao F, 2008, J BIOL CHEM, V283, P6058, DOI 10.1074/jbc.M709273200; Gow AJ, 2001, J CELL PHYSIOL, V187, P277, DOI 10.1002/jcp.1085; Gow AJ, 1996, FEBS LETT, V385, P63, DOI 10.1016/0014-5793(96)00347-X; HADDAD IY, 1993, AM J PHYSIOL, V265, pL555, DOI 10.1152/ajplung.1993.265.6.L555; HALLGREN R, 1985, BRIT MED J, V290, P1778, DOI 10.1136/bmj.290.6484.1778; HALLGREN R, 1989, AM REV RESPIR DIS, V139, P682; HELLSTROM S, 1987, ACTA OTO-LARYNGOL, P54; Hrabarova E, 2011, GEN PHYSIOL BIOPHYS, V30, P223, DOI 10.4149/gpb_2011_03_223; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; Jiang D, 2007, ANNU REV CELL DEV BI, V23, P435, DOI 10.1146/annurev.cellbio.23.090506.123337; Johnson ST, 2007, SHOCK, V28, P484, DOI 10.1097/shk.0b013e31804f775d; Johnson ST, 2009, NEONATOLOGY, V96, P162, DOI 10.1159/000210089; Kattwinkel J, 2010, CIRCULATION, V122, pS909, DOI 10.1161/CIRCULATIONAHA.110.971119; KING SR, 1991, SURGERY, V109, P76; Lee TF, 2011, SHOCK, V35, P428, DOI 10.1097/SHK.0b013e3181fffec2; LEVINE S, 1990, CRIT CARE CLIN, V6, P505; Li M, 1997, ARCH BIOCHEM BIOPHYS, V341, P245, DOI 10.1006/abbi.1997.9970; Liu JQ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015322; Liu JQ, 2010, J NEUROTRAUM, V27, P1865, DOI 10.1089/neu.2010.1325; MACLEAN D, 1976, SCIENCE, V194, P199, DOI 10.1126/science.959848; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; Manzanares D, 2007, AM J RESP CELL MOL, V37, P160, DOI 10.1165/rcmb.2006-0413OC; Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361; McKee CM, 1997, J BIOL CHEM, V272, P8013, DOI 10.1074/jbc.272.12.8013; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; Moseley R, 1997, BBA-MOL BASIS DIS, V1362, P221, DOI 10.1016/S0925-4439(97)00083-5; Munkeby BH, 2005, PEDIATR RES, V58, P542, DOI 10.1203/01.PDR.0000179407.46810.2D; Munkeby BH, 2004, PEDIATR RES, V56, P783, DOI 10.1203/01.PDR.0000141988.89820.E3; NETTELBLADT O, 1989, AM REV RESPIR DIS, V140, P1028, DOI 10.1164/ajrccm/140.4.1028; NETTELBLADT O, 1989, AM REV RESPIR DIS, V139, P759, DOI 10.1164/ajrccm/139.3.759; NOBLE PW, 1993, J CLIN INVEST, V91, P2368, DOI 10.1172/JCI116469; Obladen M, 2009, NEONATOLOGY, V95, P91, DOI 10.1159/000151761; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Richmond S, 2008, SEMIN FETAL NEONAT M, V13, P368, DOI 10.1016/j.siny.2008.04.002; RIPELLINO JA, 1985, J HISTOCHEM CYTOCHEM, V33, P1060, DOI 10.1177/33.10.4045184; Royall J A, 1995, New Horiz, V3, P113; Saugstad OD, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e1; Saugstad OD, 2003, PEDIATRICS, V112, P296, DOI 10.1542/peds.112.2.296; Saugstad OD, 2008, NEONATOLOGY, V94, P176, DOI 10.1159/000143397; Savani RC, 2000, AM J RESP CELL MOL, V23, P475, DOI 10.1165/ajrcmb.23.4.3944; Savani RC, 2000, AM J PHYSIOL-LUNG C, V279, pL743, DOI 10.1152/ajplung.2000.279.4.L743; SAVANI RC, 1995, P W PHARMACOL SOC, V38, P131; SAVANI RC, 2003, LUNG BIOL HEALTH DIS, V168, P73; Solberg R, 2010, PEDIATR RES, V67, P250, DOI 10.1203/PDR.0b013e3181cde843; Souza JM, 1999, ARCH BIOCHEM BIOPHYS, V371, P169, DOI 10.1006/abbi.1999.1480; STRACHAN RK, 1990, ANN RHEUM DIS, V49, P949, DOI 10.1136/ard.49.11.949; Sugiura H, 2011, NITRIC OXIDE-BIOL CH, V25, P138, DOI 10.1016/j.niox.2011.03.079; SUZUKI Y, 1993, AGENTS ACTIONS, V38, P32, DOI 10.1007/BF02027210; Tabima DM, 2012, FREE RADICAL BIOL ME; TAMOTO K, 1994, MICROBIOL IMMUNOL, V38, P73, DOI 10.1111/j.1348-0421.1994.tb01746.x; Taylor KR, 2007, J BIOL CHEM, V282, P18265, DOI 10.1074/jbc.M606352200; Teder P, 1997, AM J RESP CELL MOL, V17, P376, DOI 10.1165/ajrcmb.17.3.2698; Turanlahti M, 2000, ACTA PAEDIATR, V89, P966, DOI 10.1080/080352500750043440; Tyree MM, 2006, PEDIATR RES, V59, P423, DOI 10.1203/01.pdr.0000199908.30751.ef; URMAN B, 1991, FERTIL STERIL, V56, P563; Vento M, 2005, AM J RESP CRIT CARE, V172, P1393, DOI 10.1164/rccm.200412-1740OC; Vento M, 2009, PEDIATRICS, V124, pE439, DOI 10.1542/peds.2009-0434; WALDENSTROM A, 1991, J CLIN INVEST, V88, P1622, DOI 10.1172/JCI115475; WELLS AF, 1990, TRANSPLANTATION, V50, P240, DOI 10.1097/00007890-199008000-00014; WELLS AF, 1992, ARTHRITIS RHEUM, V35, P391, DOI 10.1002/art.1780350405; Wyckoff M, 2007, PEDIATR RES, V61, P415, DOI 10.1203/pdr.0b013e3180332c45; Yamasaki K, 2009, J BIOL CHEM, V284, P12762, DOI 10.1074/jbc.M806084200	82	22	23	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2012	7	6							e38839	10.1371/journal.pone.0038839	http://dx.doi.org/10.1371/journal.pone.0038839			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TU	22701723	Green Published, gold, Green Submitted			2023-01-03	WOS:000305337600050
J	Tivnan, A; Orr, WS; Gubala, V; Nooney, R; Williams, DE; McDonagh, C; Prenter, S; Harvey, H; Domingo-Fernandez, R; Bray, IM; Piskareva, O; Ng, CY; Lode, HN; Davidoff, AM; Stallings, RL				Tivnan, Amanda; Orr, Wayne Shannon; Gubala, Vladimir; Nooney, Robert; Williams, David E.; McDonagh, Colette; Prenter, Suzanne; Harvey, Harry; Domingo-Fernandez, Raquel; Bray, Isabella M.; Piskareva, Olga; Ng, Catherine Y.; Lode, Holger N.; Davidoff, Andrew M.; Stallings, Raymond L.			Inhibition of Neuroblastoma Tumor Growth by Targeted Delivery of MicroRNA-34a Using Anti-Disialoganglioside GD(2) Coated Nanoparticles	PLOS ONE			English	Article							IN-VIVO; CANCER-CELLS; DOWN-REGULATION; MYCN ONCOGENE; LUNG-CANCER; PHASE-I; N-MYC; EXPRESSION; THERAPY; SUPPRESSOR	Background: Neuroblastoma is one of the most challenging malignancies of childhood, being associated with the highest death rate in paediatric oncology, underlining the need for novel therapeutic approaches. Typically, patients with high risk disease undergo an initial remission in response to treatment, followed by disease recurrence that has become refractory to further treatment. Here, we demonstrate the first silica nanoparticle-based targeted delivery of a tumor suppressive, proapoptotic microRNA, miR-34a, to neuroblastoma tumors in a murine orthotopic xenograft model. These tumors express high levels of the cell surface antigen disialoganglioside GD2 (GD(2)), providing a target for tumor-specific delivery. Principal Findings: Nanoparticles encapsulating miR-34a and conjugated to a GD(2) antibody facilitated tumor-specific delivery following systemic administration into tumor bearing mice, resulted in significantly decreased tumor growth, increased apoptosis and a reduction in vascularisation. We further demonstrate a novel, multi-step molecular mechanism by which miR-34a leads to increased levels of the tissue inhibitor metallopeptidase 2 precursor (TIMP2) protein, accounting for the highly reduced vascularisation noted in miR-34a-treated tumors. Significance: These novel findings highlight the potential of anti-GD(2)-nanoparticle-mediated targeted delivery of miR-34a for both the treatment of GD(2)-expressing tumors, and as a basic discovery tool for elucidating biological effects of novel miRNAs on tumor growth.	[Tivnan, Amanda; Prenter, Suzanne; Harvey, Harry; Domingo-Fernandez, Raquel; Bray, Isabella M.; Piskareva, Olga; Stallings, Raymond L.] Royal Coll Surgeons Ireland, Dept Mol & Cellular Therapeut, Dublin 2, Ireland; [Tivnan, Amanda; Prenter, Suzanne; Harvey, Harry; Domingo-Fernandez, Raquel; Bray, Isabella M.; Piskareva, Olga; Stallings, Raymond L.] Our Ladys Childrens Hosp, Natl Childrens Res Ctr, Dublin, Ireland; [Orr, Wayne Shannon; Ng, Catherine Y.; Davidoff, Andrew M.] St Jude Childrens Res Hosp, Dept Surg, Memphis, TN 38105 USA; [Orr, Wayne Shannon; Davidoff, Andrew M.] Univ Tennessee, Ctr Hlth Sci, Dept Surg, Memphis, TN 38163 USA; [Gubala, Vladimir; Nooney, Robert; Williams, David E.; McDonagh, Colette] Dublin City Univ, Biomed Diagnost Inst, Dublin 9, Ireland; [Lode, Holger N.] Ernst Moritz Arndt Univ Greifswald, Dept Paediat & Paediat Haematol Oncol, Greifswald, Germany	Royal College of Surgeons - Ireland; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; Trinity College Dublin; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Dublin City University; Ernst Moritz Arndt Universitat Greifswald	Tivnan, A (corresponding author), Royal Coll Surgeons Ireland, Dept Mol & Cellular Therapeut, Dublin 2, Ireland.	rstallings@rcsi.ie	Stallings, Raymond/A-7213-2008; Williams, David E/B-3222-2012	Williams, David E/0000-0003-4123-5626; Harvey, Harry/0000-0001-9542-7530; Gubala, Vladimir/0000-0001-6301-3632; McDonagh, Colette/0000-0003-2786-8785; Lode, Holger/0000-0002-1201-208X	Science Foundation Ireland [07/IN.1/B1776, 10/CE/B1821]; Children's Medical and Research Foundation; HRB PhD Scholars Programme in Diagnostics and Therapeutics for Human Disease [PHD/2007/11]; Assisi Foundation of Memphis; US Public Health Service [CA23099]; Cancer Center Support Grant from the National Cancer Institute [21766]; American Lebanese Syrian Associated Charities (ALSAC); NATIONAL CANCER INSTITUTE [P01CA023099] Funding Source: NIH RePORTER	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Children's Medical and Research Foundation; HRB PhD Scholars Programme in Diagnostics and Therapeutics for Human Disease; Assisi Foundation of Memphis; US Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); Cancer Center Support Grant from the National Cancer Institute; American Lebanese Syrian Associated Charities (ALSAC)(American Lebanese Syrian Associated Charities (ALSAC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Science Foundation Ireland Principal Investigator Award (07/IN.1/B1776) (RLS), the Children's Medical and Research Foundation (RLS), the HRB PhD Scholars Programme in Diagnostics and Therapeutics for Human Disease (PHD/2007/11) (HH), the Assisi Foundation of Memphis (AMD), the US Public Health Service Childhood Solid Tumor Program Project Grant No. CA23099 (AMD), the Cancer Center Support Grant No. 21766 from the National Cancer Institute (AMD), and by the American Lebanese Syrian Associated Charities (ALSAC) (AMD). This material is based upon research supported by the Science Foundation Ireland, under Grant No. 10/CE/B1821 (RN). Human/mouse chimeric antibody ch14.18/CHO was made available by a European effort through SIOPN (President Assoc. Prof. R. Ladenstein) funded by charities throughout Europe. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aixinjueluo W, 2005, J BIOL CHEM, V280, P29828, DOI 10.1074/jbc.M414041200; Ashley CE, 2011, NAT MATER, V10, P389, DOI [10.1038/NMAT2992, 10.1038/nmat2992]; Barbe C., 2004, ADV MATER, V16, P8; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Bray I, 2011, CANCER LETT, V303, P56, DOI 10.1016/j.canlet.2011.01.016; Bray I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007850; Buckley PG, 2010, CLIN CANCER RES, V16, P2971, DOI 10.1158/1078-0432.CCR-09-3215; Chen YX, 2007, CANCER RES, V67, P976, DOI 10.1158/0008-5472.CAN-06-3667; Chen YC, 2010, MOL THER, V18, P1650, DOI 10.1038/mt.2010.136; Cheung NKV, 2000, CLIN CANCER RES, V6, P2653; Cole KA, 2008, MOL CANCER RES, V6, P735, DOI 10.1158/1541-7786.MCR-07-2102; Das S, 2010, CANCER RES, V70, P7874, DOI 10.1158/0008-5472.CAN-10-1534; Di Paolo D, 2011, MOL THER; Dickson PV, 2007, J PEDIATR SURG, V42, P1172, DOI 10.1016/j.jpedsurg.2007.02.027; Esquela-Kerscher A, 2008, CELL CYCLE, V7, P759, DOI 10.4161/cc.7.6.5834; FATTAL E, 1991, J MICROENCAPSUL, V8, P29, DOI 10.3109/02652049109021855; Finnie KS, 2009, J SOL-GEL SCI TECHN, V49, P12, DOI 10.1007/s10971-008-1847-4; Foley NH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-83; Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236; Foster-Waldl E, 2005, MOL IMMUNOL, V42, P319, DOI 10.1016/j.molimm.2004.07.011; Godfried MB, 2002, ONCOGENE, V21, P2097, DOI 10.1038/sj.onc.1205259; Gubala V, 2011, ANAL ADV ARTICLE; Gubala V, 2010, TALANTA, V81, P1833, DOI 10.1016/j.talanta.2010.03.048; Haber M, 1999, ONCOGENE, V18, P2777, DOI 10.1038/sj.onc.1202859; HANDGRETINGER R, 1995, EUR J CANCER, V31A, P261, DOI 10.1016/0959-8049(94)00413-Y; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hobley G, 2008, SYNLETT, P1510, DOI 10.1055/s-2007-1077795; Hom C, 2009, J MATER CHEM, V19, P6308, DOI 10.1039/b904197d; Imai M, 2005, CANCER RES, V65, P10562, DOI 10.1158/0008-5472.CAN-05-1894; Kang J, 2008, ONCOGENE, V27, P3999, DOI 10.1038/onc.2008.15; Kim M, 2011, LANCET ONCOL, V12, P319, DOI 10.1016/S1470-2045(11)70067-5; Kim VN, 2005, MOL CELLS, V19, P1; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Lin RJ, 2010, CANCER RES, V70, P7841, DOI 10.1158/0008-5472.CAN-10-0970; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu HQ, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-51; Lode HN, 1997, J NATL CANCER I, V89, P1586, DOI 10.1093/jnci/89.21.1586; Luan SH, 2010, ARCH MED RES, V41, P67, DOI 10.1016/j.arcmed.2010.02.007; Mestdagh P, 2010, ONCOGENE, V29, P1394, DOI 10.1038/onc.2009.429; MUELLER BM, 1990, J IMMUNOL, V144, P1382; Murphy DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008154; Murray JL, 1996, J IMMUNOTHER, V19, P206, DOI 10.1097/00002371-199605000-00005; Navid F, 2010, CURR CANCER DRUG TAR, V10, P200, DOI 10.2174/156800910791054167; Nooney RI, 2009, ANAL BIOANAL CHEM, V393, P1143, DOI 10.1007/s00216-008-2418-9; Pagnan G, 2000, J NATL CANCER I, V92, P253, DOI 10.1093/jnci/92.3.253; Pang RTK, 2010, CARCINOGENESIS, V31, P1037, DOI 10.1093/carcin/bgq066; Park JH, 2009, NAT MATER, V8, P331, DOI [10.1038/NMAT2398, 10.1038/nmat2398]; Park SJ, 2008, LANGMUIR, V24, P12134, DOI 10.1021/la8028885; Patil YB, 2010, BIOMATERIALS, V31, P358, DOI 10.1016/j.biomaterials.2009.09.048; Patterson DM, 2011, ANGIOGENESIS ADV ONL; Porro A, 2010, J BIOL CHEM, V285, P19532, DOI 10.1074/jbc.M109.078584; Ritter G, 1991, Semin Cancer Biol, V2, P401; Schulte JH, 2008, INT J CANCER, V122, P699, DOI 10.1002/ijc.23153; Schulte JH, 2010, INT J CANCER, V127, P2374, DOI 10.1002/ijc.25436; Seo DW, 2011, PEPTIDES, V32, P1840, DOI 10.1016/j.peptides.2011.08.010; Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092-8674(03)00551-8; Stallings RL, 2009, CURR PHARM DESIGN, V15, P456, DOI 10.2174/138161209787315837; Stallings RL, 2010, EXPERT OPIN THER TAR, V14, P951, DOI 10.1517/14728222.2010.510136; Sun F, 2008, FEBS LETT, V582, P1564, DOI 10.1016/j.febslet.2008.03.057; Tivnan A, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-33; Trang P, 2011, MOL THER; Wagner LM, 2009, J CELL BIOCHEM, V107, P46, DOI 10.1002/jcb.22094; Wallace M, 1997, AN H ANALG, V85, P2; Weeraratne SD, 2011, NEURO-ONCOLOGY, V13, P165, DOI 10.1093/neuonc/noq179; Wei JS, 2008, ONCOGENE, V27, P5204, DOI 10.1038/onc.2008.154; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; Wiggins JF, CANC RES, V70, P5923; Williams RF, 2010, J PEDIATR SURG, V45, P1103, DOI 10.1016/j.jpedsurg.2010.02.073; WU ZL, 1986, CANCER RES, V46, P440; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yu AL, 1998, J CLIN ONCOL, V16, P2169, DOI 10.1200/JCO.1998.16.6.2169; Yu AL, 2010, NEW ENGL J MED, V363, P1324, DOI 10.1056/NEJMoa0911123; Zeng Y, 2005, MOL IMMUNOL, V42, P1311, DOI 10.1016/j.molimm.2004.12.018; Zeytin HE, 2000, CANCER GENE THER, V7, P1426, DOI 10.1038/sj.cgt.7700240	74	178	189	0	49	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2012	7	5							e38129	10.1371/journal.pone.0038129	http://dx.doi.org/10.1371/journal.pone.0038129			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UY	22662276	Green Published, Green Submitted, Green Accepted, gold			2023-01-03	WOS:000305342300168
J	Offit, PA				Offit, Paul A.			Studying Complementary and Alternative Therapies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Offit, Paul A.] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA; [Offit, Paul A.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Offit, PA (corresponding author), Childrens Hosp Philadelphia, Div Infect Dis, 34th St & Civ Ctr Blvd,ARB,Room 1202C, Philadelphia, PA 19104 USA.	offit@email.chop.edu						Bjelakovic G, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007176; Mielczarek E. V., 2012, SKEPTICAL INQUIRER, V36, P36; Moyer CS, 2012, AMEDNEWS        0220; Offit PaulA., 2008, AUTISMS FALSE PROPHE, DOI 10.7312/offi14636; Park Robert L., 2000, VOODOO SCI ROAD FOOL; Shapiro R., 2008, SUCKERS ALTERNATIVE; Wang SS, 2011, WALL STREET J   1025, pD1	7	22	22	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 2	2012	307	17					1803	1804		10.1001/jama.2012.518	http://dx.doi.org/10.1001/jama.2012.518			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933TV	22550193				2023-01-03	WOS:000303386800017
J	Schwartz, SR; Rees, H; Mehta, S; Venter, WDF; Taha, TE; Black, V				Schwartz, Sheree R.; Rees, Helen; Mehta, Shruti; Venter, Willem Daniel Francois; Taha, Taha E.; Black, Vivian			High Incidence of Unplanned Pregnancy after Antiretroviral Therapy Initiation: Findings from a Prospective Cohort Study in South Africa	PLOS ONE			English	Article							CONTRACEPTIVE USE; HORMONAL CONTRACEPTION; WOMEN; PREVENTION; INTENTIONS; FERTILITY	Background: Increased fertility rates in HIV-infected women receiving antiretroviral therapy (ART) have been attributed to improved immunological function; it is unknown to what extent the rise in pregnancy rates is due to unintended pregnancies. Methods: Non-pregnant women ages 18-35 from four public-sector ART clinics in Johannesburg, South Africa, were enrolled into a prospective cohort and followed from August 2009-March 2011. Fertility intentions, contraception and pregnancy status were measured longitudinally at participants' routine ART clinic visits. Findings: Of the 850 women enrolled, 822 (97%) had at least one follow-up visit and contributed 745.2 person-years (PY) at-risk for incident pregnancy. Overall, 170 pregnancies were detected in 161 women (incidence rate [IR]: 21.6/100 PY [95% confidence interval (CI): 18.5-25.2]). Of the 170 pregnancies, 105 (62%) were unplanned. Unmet need for contraception was 50% higher in women initiating ART in the past year as compared to women on ART> 1 year (prevalence ratio 1.5 [95% CI: 1.1-2.0]); by two years post-ART initiation, nearly one quarter of women had at least one unplanned pregnancy. Cumulative incidence of pregnancy was equally high among recent ART initiators and ART experienced participants: 23.9% [95% CI: 16.4-34.1], 15.9% [12.0-20.8], and 21.0% [16.8-26.1] for women on ART 0-1 yr, >1 yr-2 yrs, and >2 yrs respectively (log-rank, p = 0.54). Eight hormonal contraceptive failures were detected [IR: 4.4 [95% CI: 2.2-8.9], 7/8 among women using injectable methods. Overall 47% (80/170) of pregnancies were not carried to term. Conclusions: Rates of unintended pregnancies among women on ART are high, including women recently initiating ART with lower CD4 counts and higher viral loads. A substantial burden of pregnancy loss was observed. Integration of contraceptive services and counselling into ART care is necessary to reduce maternal and child health risks related to mistimed and unwanted pregnancies. Further research into injectable contraceptive failures on ART is warranted.	[Schwartz, Sheree R.; Rees, Helen; Venter, Willem Daniel Francois; Black, Vivian] Univ Witwatersrand, Wits Reprod Hlth & HIV Inst, Johannesburg, South Africa; [Schwartz, Sheree R.; Mehta, Shruti; Taha, Taha E.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA	University of Witwatersrand; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Schwartz, SR (corresponding author), Univ Witwatersrand, Wits Reprod Hlth & HIV Inst, Johannesburg, South Africa.	sschwartz@wrhi.ac.za		Taha, Taha/0000-0001-9814-4894; Venter, Willem/0000-0002-4157-732X; Rees, Helen/0000-0003-1442-6734	United States Centers for Disease Control and Prevention (CDC) public health dissertation [1R36PS001584-01]; Johns Hopkins Bloomberg School of Public Health [1R36PS001584-01]; Johns Hopkins Bloomberg School of Public Health Global Field Experience Fund; PEPFAR (President's Emergency Plan For AIDS Relief); United States Agency for International Development; NATIONAL CENTER FOR HIV, VIRAL HEPATITIS, STDS AND TB PREVENTION [R36PS001584] Funding Source: NIH RePORTER	United States Centers for Disease Control and Prevention (CDC) public health dissertation(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Johns Hopkins Bloomberg School of Public Health(Johns Hopkins University); Johns Hopkins Bloomberg School of Public Health Global Field Experience Fund(Johns Hopkins University); PEPFAR (President's Emergency Plan For AIDS Relief); United States Agency for International Development(United States Agency for International Development (USAID)); NATIONAL CENTER FOR HIV, VIRAL HEPATITIS, STDS AND TB PREVENTION(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This study received funding from the United States Centers for Disease Control and Prevention (CDC) public health dissertation grant 1R36PS001584-01. SS received support from grant 1R36PS001584-01, the Department of Epidemiology Doctoral Student Fund at the Johns Hopkins Bloomberg School of Public Health, and the Johns Hopkins Bloomberg School of Public Health Global Field Experience Fund. The research was conducted in clinics supported by PEPFAR (President's Emergency Plan For AIDS Relief) and the United States Agency for International Development. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Cejtin HE, 2006, OBSTET GYNECOL, V108, P1423, DOI 10.1097/01.AOG.0000245442.29969.5c; Cooper D, 2009, AIDS BEHAV, V13, pS38, DOI 10.1007/s10461-009-9550-1; Cooper ER, 2002, J ACQ IMMUN DEF SYND, V29, P484, DOI 10.1097/00126334-200204150-00009; Coutsoudis A, 2010, AIDS, V24, P2859, DOI 10.1097/QAD.0b013e32834041b7; Department of Health SA, 2004, NAT ANT TREATM GUID; Desgrees-du-Lou A, 2002, INT J STD AIDS, V13, P462, DOI 10.1258/09564620260079617; El-Ibiary SY, 2008, EUR J CONTRACEP REPR, V13, P123, DOI 10.1080/13625180701829952; Gray RH, 1998, LANCET, V351, P98, DOI 10.1016/S0140-6736(97)09381-1; Heffron R, 2012, LANCET INFECT DIS, V12, P19, DOI 10.1016/S1473-3099(11)70247-X; Homsy J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004149; Kaida A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013868; Kaida A, 2011, AM J PUBLIC HEALTH, V101, P350, DOI 10.2105/AJPH.2009.177469; Karim SSA, 2011, AIDS, V25, P957, DOI 10.1097/QAD.0b013e32834541d9; Makumbi FE, 2011, AIDS RES TREAT, V2011, DOI 10.1155/2011/519492; Morrison CS, 2007, AIDS, V21, P85, DOI 10.1097/QAD.0b013e3280117c8b; Myer L, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000229; Nattabi B, 2009, AIDS BEHAV, V13, P949, DOI 10.1007/s10461-009-9537-y; Ngure K, 2009, AIDS, V23, pS89, DOI 10.1097/01.aids.0000363781.50580.03; Polis CB, 2010, AIDS, V24, P1937, DOI 10.1097/QAD.0b013e32833b3282; Reid SE, 2010, JAIDS-J ACQ IMM DEF, V53, P606, DOI 10.1097/QAI.0b013e3181bc4869; Reynolds HW, 2006, SEX TRANSM DIS, V33, P350, DOI 10.1097/01.olq.0000194602.01058.e1; Rubin D. B., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Schwartz SR, 2012, AIDS BEHAV, V16, P69, DOI 10.1007/s10461-011-9981-3; Stringer EM, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.03.031; Sweat MD, 2004, AIDS, V18, P1661, DOI 10.1097/01.aids.0000131353.06784.8f; Trussell J, 2004, CONTRACEPTIVE TECHNO; UNAIDS, 2010, UNAIDS REP GLOB AIDS; World Health Organization, 2010, PMTCT STRAT VIS 2010; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	29	104	106	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2012	7	4							e36039	10.1371/journal.pone.0036039	http://dx.doi.org/10.1371/journal.pone.0036039			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TJ	22558319	Green Submitted, Green Published, gold			2023-01-03	WOS:000305336000110
J	Glasmacher, E; Agrawal, S; Chang, AB; Murphy, TL; Zeng, WW; Vander Lugt, B; Khan, AA; Ciofani, M; Spooner, CJ; Rutz, S; Hackney, J; Nurieva, R; Escalante, CR; Ouyang, WJ; Littman, DR; Murphy, KM; Singh, H				Glasmacher, Elke; Agrawal, Smita; Chang, Abraham B.; Murphy, Theresa L.; Zeng, Wenwen; Vander Lugt, Bryan; Khan, Aly A.; Ciofani, Maria; Spooner, Chauncey J.; Rutz, Sascha; Hackney, Jason; Nurieva, Roza; Escalante, Carlos R.; Ouyang, Wenjun; Littman, Dan R.; Murphy, Kenneth M.; Singh, Harinder			A Genomic Regulatory Element That Directs Assembly and Function of Immune-Specific AP-1-IRF Complexes	SCIENCE			English	Article							TRANSCRIPTION FACTOR IRF4; FACTOR BATF CONTROLS; CELL-DIFFERENTIATION; FAMILY; ACTIVATION; EXPRESSION; PROGRAM; ABSENCE; MEMBER; ROLES	Interferon regulatory factor 4 (IRF4) and IRF8 regulate B, T, macrophage, and dendritic cell differentiation. They are recruited to cis-regulatory Ets-IRF composite elements by PU.1 or Spi-B. How these IRFs target genes in most T cells is enigmatic given the absence of specific Ets partners. Chromatin immunoprecipitation sequencing in T helper 17 (T(H)17) cells reveals that IRF4 targets sequences enriched for activating protein 1 (AP-1)-IRF composite elements (AICEs) that are co-bound by BATF, an AP-1 factor required for T(H)17, B, and dendritic cell differentiation. IRF4 and BATF bind cooperatively to structurally divergent AICEs to promote gene activation and T(H)17 differentiation. The AICE motif directs assembly of IRF4 or IRF8 with BATF heterodimers and is also used in T(H)2, B, and dendritic cells. This genomic regulatory element and cognate factors appear to have evolved to integrate diverse immunomodulatory signals.	[Murphy, Theresa L.; Murphy, Kenneth M.] Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Pathol & Immunol, St Louis, MO 63110 USA; [Glasmacher, Elke; Agrawal, Smita; Chang, Abraham B.; Zeng, Wenwen; Vander Lugt, Bryan; Spooner, Chauncey J.; Rutz, Sascha; Ouyang, Wenjun; Singh, Harinder] Genentech Inc, Dept Discovery Immunol, San Francisco, CA 94080 USA; [Khan, Aly A.] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Khan, Aly A.] Univ Chicago, Inst Syst & Genom Biol, Chicago, IL 60637 USA; [Ciofani, Maria] NYU, Howard Hughes Med Inst, Skirball Inst Biomol Med, New York, NY 10016 USA; [Hackney, Jason] Genentech Inc, Dept Bioinformat & Computat Biol, San Francisco, CA 94080 USA; [Nurieva, Roza] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77054 USA; [Escalante, Carlos R.] Virginia Commonwealth Univ, Sch Med, Dept Physiol & Biophys, Richmond, VA 23219 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Roche Holding; Genentech; University of Chicago; University of Chicago; Howard Hughes Medical Institute; New York University; Roche Holding; Genentech; University of Texas System; UTMD Anderson Cancer Center; Virginia Commonwealth University	Murphy, KM (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Pathol & Immunol, St Louis, MO 63110 USA.	kmurphy@pathology.wustl.edu; harindsi@gene.com	Glasmacher, Elke/B-8939-2015; Ouyang, Wenjun/ABA-8763-2020; Zeng, Wenwen/D-7276-2017	Glasmacher, Elke/0000-0003-1265-2543; Zeng, Wenwen/0000-0001-8544-3318; Ciofani, Maria/0000-0001-6472-5260; Hackney, Jason/0000-0002-5922-563X; Ouyang, Wenjun/0000-0002-1811-5864	NIH [RC1 AI087266, RC4 AI092765]; Crohn's and Colitis Foundation of America; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [RC4AI092765, RC1AI087266] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Crohn's and Colitis Foundation of America; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank K. Dong for insightful discussions and suggestions and the fluorescence-activated cell sorting (FACS), antibody engineering, DNA sequencing, microarray, and oligonucleotide synthesis facilities at Genentech for providing valuable reagents and technical assistance. The data presented in the manuscript are tabulated in the main paper and the supplementary materials. Reagents will be provided upon request. D.R.L. and K.M.M. are Howard Hughes Medical Institute investigators. D.R.L. also acknowledges funding from NIH grants RC1 AI087266 and RC4 AI092765, and M. C. was supported by a fellowship from the Crohn's and Colitis Foundation of America. Genentech, Incorporated, has filed a provisional patent application that is focused on targeting of IRF4-BATF complexes in the context of T<INF>H</INF>17-mediated inflammatory or autoimmune diseases. The complete gene expression and ChIPseq data sets can be accessed at www.ncbi.nlm.nih.gov/projects/geo/query/acc.cgi?acc=GSE40483.	Bollig N, 2012, P NATL ACAD SCI USA, V109, P8664, DOI 10.1073/pnas.1205834109; BOVOLENTA C, 1994, P NATL ACAD SCI USA, V91, P5046, DOI 10.1073/pnas.91.11.5046; Brass AL, 1999, EMBO J, V18, P977, DOI 10.1093/emboj/18.4.977; Brass AL, 1996, GENE DEV, V10, P2335, DOI 10.1101/gad.10.18.2335; Brustle A, 2007, NAT IMMUNOL, V8, P958, DOI 10.1038/ni1500; De Silva NS, 2012, IMMUNOL REV, V247, P73, DOI 10.1111/j.1600-065X.2012.01113.x; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Ise W, 2011, NAT IMMUNOL, V12, P536, DOI 10.1038/ni.2037; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Kimura A, 2008, P NATL ACAD SCI USA, V105, P9721, DOI 10.1073/pnas.0804231105; Klein U, 2006, NAT IMMUNOL, V7, P773, DOI 10.1038/ni1357; Kwon H, 2009, IMMUNITY, V31, P941, DOI 10.1016/j.immuni.2009.10.008; Lee CG, 2009, MOL IMMUNOL, V46, P613, DOI 10.1016/j.molimm.2008.07.037; Lohoff M, 2005, NAT REV IMMUNOL, V5, P125, DOI 10.1038/nri1552; Lohoff M, 2002, P NATL ACAD SCI USA, V99, P11808, DOI 10.1073/pnas.182425099; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Mathur AN, 2007, J IMMUNOL, V178, P4901, DOI 10.4049/jimmunol.178.8.4901; MATSUYAMA T, 1995, NUCLEIC ACIDS RES, V23, P2127, DOI 10.1093/nar/23.12.2127; Rengarajan J, 2002, J EXP MED, V195, P1003, DOI 10.1084/jem.20011128; Schraml BU, 2009, NATURE, V460, P405, DOI 10.1038/nature08114; Sciammas R, 2006, IMMUNITY, V25, P225, DOI 10.1016/j.immuni.2006.07.009; Tamura T, 2005, J IMMUNOL, V174, P2573, DOI 10.4049/jimmunol.174.5.2573; Tamura T, 2008, ANNU REV IMMUNOL, V26, P535, DOI 10.1146/annurev.immunol.26.021607.090400; Tussiwand R, 2012, NATURE, V490, P502, DOI 10.1038/nature11531; Yang XXO, 2008, IMMUNITY, V28, P29, DOI 10.1016/j.immuni.2007.11.016; Zheng Y, 2009, NATURE, V458, P351, DOI 10.1038/nature07674	27	232	240	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 16	2012	338	6109					975	980		10.1126/science.1228309	http://dx.doi.org/10.1126/science.1228309			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	037DY	22983707	Green Accepted			2023-01-03	WOS:000311083600051
J	Gornall, J				Gornall, Jonathan			SMOKING CESSATION Electronic cigarettes: medical device or consumer product?	BRITISH MEDICAL JOURNAL			English	Editorial Material												jgornall@mac.com						MHRA, 2010, PUBL CONS MLX 364 RE; MHRA, 2010, DRUG SAFETY UPDATE, V3, P6; MHRA (Medicines Healthcare products Regulatory Agency), 2010, CONS LETT MLX 364 RE	3	5	5	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 25	2012	345								e6417	10.1136/bmj.e6417	http://dx.doi.org/10.1136/bmj.e6417			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	014ON	23014904				2023-01-03	WOS:000309385500010
J	Thayanithy, V; Park, C; Sarver, AL; Kartha, RV; Korpela, DM; Graef, AJ; Steer, CJ; Modiano, JF; Subramanian, S				Thayanithy, Venugopal; Park, ChangWon; Sarver, Aaron L.; Kartha, Reena V.; Korpela, Derek M.; Graef, Ashley J.; Steer, Clifford J.; Modiano, Jaime F.; Subramanian, Subbaya			Combinatorial Treatment of DNA and Chromatin-Modifying Drugs Cause Cell Death in Human and Canine Osteosarcoma Cell Lines	PLOS ONE			English	Article							VALPROIC ACID; MICRORNA EXPRESSION; GENE-EXPRESSION; DOWN-REGULATION; AMPLIFICATION; INHIBITION; MODULATION; ACTIVATION; APOPTOSIS; CLUSTER	Downregulation of microRNAs (miRNAs) at the 14q32 locus stabilizes the expression of cMYC, thus significantly contributing to osteosarcoma (OS) pathobiology. Here, we show that downregulation of 14q32 miRNAs is epigenetically regulated. The predicted promoter regions of miRNA clusters at 14q32 locus showed no recurrent patterns of differential methylation, but Saos2 cells showed elevated histone deacetylase (HDAC) activity. Treatment with 4-phenylbutyrate increased acetylation of histones associated with 14q32 miRNAs, but interestingly, robust restoration of 14q32 miRNA expression, attenuation of cMYC expression, and induction of apoptosis required concomitant treatment with 5-Azacytidine, an inhibitor of DNA methylation. These events were associated with genome-wide gene expression changes including induction of proapoptotic genes and downregulation of cell cycle genes. Comparable effects were achieved in human and canine OS cells using the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA/Vorinostat) and the DNA methylation inhibitor Zebularine (Zeb), with significantly more pronounced cytotoxicity in cells whose molecular phenotypes were indicative of aggressive biological behavior. These results suggested that the combination of these chromatin-modifying drugs may be a useful adjuvant in the treatment of rapidly progressive OS.	[Thayanithy, Venugopal; Subramanian, Subbaya] Univ Minnesota, Dept Surg, Minneapolis, MN 55455 USA; [Park, ChangWon; Steer, Clifford J.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; [Sarver, Aaron L.; Modiano, Jaime F.; Subramanian, Subbaya] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA; [Kartha, Reena V.] Univ Minnesota, Coll Pharm, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA; [Korpela, Derek M.; Graef, Ashley J.; Modiano, Jaime F.] Univ Minnesota, Dept Vet Clin Sci, St Paul, MN 55108 USA; [Steer, Clifford J.] Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Thayanithy, V (corresponding author), Univ Minnesota, Dept Surg, Box 242 UMHC, Minneapolis, MN 55455 USA.	subree@umn.edu	MODIANO, JAIME/K-3583-2019; Kartha, Reena/AAG-3969-2021; Thayanithy, Venugopal/C-2777-2013; Fiumefreddo, Andrea/T-2977-2019	MODIANO, JAIME/0000-0001-6398-7648; Kartha, Reena/0000-0002-1692-1539; Subramanian, Subbaya/0000-0002-2544-480X	University of Minnesota Academic Health Center; Masonic Cancer Center, University of Minnesota; Wyckoff Rein in Sarcoma Foundation; AKC Canine Health Foundation; Van Sloun Foundation; Kate Koogler Canine Cancer Fund	University of Minnesota Academic Health Center; Masonic Cancer Center, University of Minnesota(University of Minnesota System); Wyckoff Rein in Sarcoma Foundation; AKC Canine Health Foundation; Van Sloun Foundation; Kate Koogler Canine Cancer Fund	This study was supported by a grant from the University of Minnesota Academic Health Center, by a translational research grant from the Masonic Cancer Center, University of Minnesota, and by grants from the Wyckoff Rein in Sarcoma Foundation, the AKC Canine Health Foundation, the Van Sloun Foundation, and the Kate Koogler Canine Cancer Fund (JFM and SS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agueli C, 2010, AM J HEMATOL, V85, P575, DOI 10.1002/ajh.21758; Al-Romaih K, 2007, CANCER CELL INT, V7, DOI 10.1186/1475-2867-7-14; BOGENMANN E, 1987, CANCER RES, V47, P3808; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Carraway HE, 2007, J CLIN ONCOL, V25, P1955, DOI 10.1200/JCO.2006.09.8293; Catalano MG, 2006, J ENDOCRINOL, V191, P465, DOI 10.1677/joe.1.06970; Fan JB, 2004, GENOME RES, V14, P878, DOI 10.1101/gr.2167504; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Hagan JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004352; Haller F, 2010, J PATHOL, V220, P71, DOI 10.1002/path.2610; Imai T, 2003, ONCOGENE, V22, P9231, DOI 10.1038/sj.onc.1207184; Kansara M, 2007, DNA CELL BIOL, V26, P1, DOI 10.1089/dna.2006.0505; Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678; Kim MS, 2003, CANCER RES, V63, P7291; Kircher M, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-346; LADANYI M, 1993, DIAGN MOL PATHOL, V2, P163, DOI 10.1097/00019606-199303000-00024; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Lu XY, 2008, MOL CANCER RES, V6, P937, DOI 10.1158/1541-7786.MCR-07-2115; Marchion DC, 2005, CANCER RES, V65, P3815, DOI 10.1158/0008-5472.CAN-04-2478; Marulanda German A, 2008, Cancer Control, V15, P13; Mirabello L, 2009, CANCER-AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121; Moriarty B, 2011, C GEN ENG SING; Munster P, 2007, J CLIN ONCOL, V25, P1979, DOI 10.1200/JCO.2006.08.6165; Oberg AL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020465; Pallasch CP, 2009, BLOOD, V114, P3255, DOI 10.1182/blood-2009-06-229898; Pasic I, 2010, CANCER RES, V70, P160, DOI 10.1158/0008-5472.CAN-09-1902; Riccardi C, 2006, NAT PROTOC, V1, P1458, DOI 10.1038/nprot.2006.238; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Sarver A, 2011, PREFECT POLICE F PEC; Sarver AL, 2010, LAB INVEST, V90, P753, DOI 10.1038/labinvest.2010.53; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Scott MC, 2011, BONE, V49, P356, DOI 10.1016/j.bone.2011.05.008; Seitz H, 2004, GENOME RES, V14, P1741, DOI 10.1101/gr.2743304; Stadtfeld M, 2010, NATURE, V465, P175, DOI 10.1038/nature09017; Takahashi N, 2009, HUM MOL GENET, V18, P1879, DOI 10.1093/hmg/ddp108; Thayanithy V, 2012, BONE, V50, P171, DOI 10.1016/j.bone.2011.10.012; Thomas R, 2005, GENOME RES, V15, P1831, DOI 10.1101/gr.3825705; Thomas R, 2009, CHROMOSOME RES, V17, P365, DOI 10.1007/s10577-009-9028-z; Watanabe K, 2005, CELL DEATH DIFFER, V12, P10, DOI 10.1038/sj.cdd.4401507; Wittenburg LA, 2011, CANCER CHEMOTH PHARM, V67, P83, DOI 10.1007/s00280-010-1287-z; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105	42	45	47	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 5	2012	7	9							e43720	10.1371/journal.pone.0043720	http://dx.doi.org/10.1371/journal.pone.0043720			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	001MC	22957032	Green Submitted, Green Published, gold			2023-01-03	WOS:000308463800024
J	Pieramico, V; Esposito, R; Sensi, F; Cilli, F; Mantini, D; Mattei, PA; Frazzini, V; Ciavardelli, D; Gatta, V; Ferretti, A; Romani, GL; Sensi, SL				Pieramico, Valentina; Esposito, Roberto; Sensi, Francesca; Cilli, Franco; Mantini, Dante; Mattei, Peter A.; Frazzini, Valerio; Ciavardelli, Domenico; Gatta, Valentina; Ferretti, Antonio; Romani, Gian Luca; Sensi, Stefano L.			Combination Training in Aging Individuals Modifies Functional Connectivity and Cognition, and Is Potentially Affected by Dopamine-Related Genes	PLOS ONE			English	Article							RESTING-STATE NETWORKS; ALZHEIMERS-DISEASE; DEFAULT-MODE; RECEPTOR GENE; BRAIN; POLYMORPHISMS; ASSOCIATION; EXERCISE; HIPPOCAMPUS; DYSFUNCTION	Background: Aging is a major co-risk factor in many neurodegenerative diseases. Cognitive enrichment positively affects the structural plasticity of the aging brain. In this study, we evaluated effects of a set of structured multimodal activities (Combination Training; CT) on cognitive performances, functional connectivity, and cortical thickness of a group of healthy elderly individuals. CT lasted six months. Methodology: Neuropsychological and occupational performances were evaluated before and at the end of the training period. fMRI was used to assess effects of training on resting state network (RSN) functional connectivity using Independent Component Analysis (ICA). Effects on cortical thickness were also studied. Finally, we evaluated whether specific dopamine-related genes can affect the response to training. Principal Findings: Results of the study indicate that CT improves cognitive/occupational performances and reorganizes functional connectivity. Intriguingly, individuals responding to CT showed specific dopamine-related genotypes. Indeed, analysis of dopamine-related genes revealed that carriers of DRD3 ser9gly and COMT Val158Met polymorphisms had the greatest benefits from exposure to CT. Conclusions and Significance: Overall, our findings support the idea that exposure to a set of structured multimodal activities can be an effective strategy to counteract aging-related cognitive decline and also indicate that significant capability of functional and structural changes are maintained in the elderly.	[Pieramico, Valentina; Esposito, Roberto; Mantini, Dante; Mattei, Peter A.; Frazzini, Valerio; Ferretti, Antonio; Romani, Gian Luca; Sensi, Stefano L.] Univ G dAnnunzio, Dept Neurosci & Imaging, Chieti, Italy; [Pieramico, Valentina; Sensi, Francesca; Cilli, Franco; Frazzini, Valerio; Ciavardelli, Domenico; Sensi, Stefano L.] Univ G dAnnunzio, Ctr Excellence Aging, Mol Neurol Unit, Chieti, Italy; [Mantini, Dante] Catholic Univ Louvain, Dept Neurosci, Lab Neuro & Psychophysiol, B-3000 Louvain, Belgium; [Ciavardelli, Domenico] Kore Univ Enna, Sch Motor Sci, Dept Biochem, Enna, Italy; [Gatta, Valentina] Univ G dAnnunzio, Dept Psychol Sci, Chieti, Italy; [Gatta, Valentina] Univ G dAnnunzio, Ctr Excellence Aging, Funct Genom Unit, Chieti, Italy; [Sensi, Stefano L.] Univ Calif Irvine, Dept Neurol, Irvine, CA 92717 USA; [Sensi, Stefano L.] Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92717 USA	G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; Universite Catholique Louvain; Universita Kore di ENNA; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; University of California System; University of California Irvine; University of California System; University of California Irvine	Pieramico, V (corresponding author), Univ G dAnnunzio, Dept Neurosci & Imaging, Chieti, Italy.	ssensi@uci.edu	Mantini, Dante/D-6989-2014; Mattei, Peter/J-6661-2012; Gatta, Valentina/G-5765-2014; Sensi, Stefano L./J-3164-2016; Sensi, Stefano L./O-1335-2019; Frazzini, Valerio/R-3643-2016	Mantini, Dante/0000-0001-6485-5559; Sensi, Stefano L./0000-0002-0710-2574; Sensi, Stefano L./0000-0002-0710-2574; Esposito, Roberto/0000-0003-4708-6860; Mattei, Peter A./0000-0002-7343-5625; GATTA, Valentina/0000-0002-9999-5823; Frazzini, Valerio/0000-0003-1187-3352; FERRETTI, Antonio/0000-0002-8459-0129	Italian Department of Education	Italian Department of Education	SLS is supported by funds from the Italian Department of Education [Fondo per gli Investimenti della Ricerca di Base (FIRB) 2003; programmi di ricerca di rilevante interesse nazionale (PRIN) 2008]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Backman L, 2010, NEUROSCI BIOBEHAV R, V34, P670, DOI 10.1016/j.neubiorev.2009.12.008; BEISCHLAG TV, 1995, BIOCHEMISTRY-US, V34, P5960, DOI 10.1021/bi00017a025; Belleville S, 2011, BRAIN, V134, P1623, DOI 10.1093/brain/awr037; Bennett S, 2011, AUST OCCUP THER J, V58, P155, DOI 10.1111/j.1440-1630.2011.00930.x; Bertolino A, 2006, BIOL PSYCHIAT, V60, P1250, DOI 10.1016/j.biopsych.2006.03.078; Black KJ, 2002, P NATL ACAD SCI USA, V99, P17113, DOI 10.1073/pnas.012260599; Boyke J, 2008, J NEUROSCI, V28, P7031, DOI 10.1523/JNEUROSCI.0742-08.2008; Broyd SJ, 2009, NEUROSCI BIOBEHAV R, V33, P279, DOI 10.1016/j.neubiorev.2008.09.002; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Buckner RL, 2005, J NEUROSCI, V25, P7709, DOI 10.1523/JNEUROSCI.2177-05.2005; Colcombe SJ, 2006, J GERONTOL A-BIOL, V61, P1166, DOI 10.1093/gerona/61.11.1166; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; Daniels JK, 1996, AM J PSYCHIAT, V153, P268; Deco G, 2011, NAT REV NEUROSCI, V12, P43, DOI 10.1038/nrn2961; Deweerdt S, 2011, NATURE, V475, pS16, DOI 10.1038/475S16a; Dubois B, 2000, NEUROLOGY, V55, P1621, DOI 10.1212/WNL.55.11.1621; Engvig A, 2010, NEUROIMAGE, V52, P1667, DOI 10.1016/j.neuroimage.2010.05.041; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; Esposito F, 2005, NEUROIMAGE, V25, P193, DOI 10.1016/j.neuroimage.2004.10.042; Fabel K, 2009, FRONT NEUROSCI-SWITZ, V3, DOI 10.3389/neuro.22.002.2009; Fisher Anne G, 2007, Scand J Occup Ther, V14, P240, DOI 10.1080/11038120601182958; Fleisher AS, 2009, NEUROIMAGE, V47, P1678, DOI 10.1016/j.neuroimage.2009.06.021; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gill M, 1997, MOL PSYCHIATR, V2, P311, DOI 10.1038/sj.mp.4000290; Grady CL, 2010, CEREB CORTEX, V20, P1432, DOI 10.1093/cercor/bhp207; GRANDY DK, 1993, HUM MOL GENET, V2, P2197, DOI 10.1093/hmg/2.12.2197-a; Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101; Ho AMC, 2008, ANN NY ACAD SCI, V1139, P20, DOI 10.1196/annals.1432.054; Horner Michael David, 2002, Appl Neuropsychol, V9, P114, DOI 10.1207/S15324826AN0902_7; Hyvarinen A, 1999, IEEE T NEURAL NETWOR, V10, P626, DOI 10.1109/72.761722; Izaki Y, 2008, EUR J NEUROSCI, V27, P3029, DOI 10.1111/j.1460-9568.2008.06284.x; Joyce JN, 2005, DRUG DISCOV TODAY, V10, P917, DOI 10.1016/S1359-6446(05)03491-4; Kelly AMC, 2005, CEREB CORTEX, V15, P1089, DOI 10.1093/cercor/bhi005; Kempermann G, 2008, TRENDS NEUROSCI, V31, P163, DOI 10.1016/j.tins.2008.01.002; Kempermann G, 2010, FRONT NEUROSCI-SWITZ, V4, DOI 10.3389/fnins.2010.00189; Kikuchi M, 2011, J NEUROSCI, V31, P11193, DOI 10.1523/JNEUROSCI.2535-11.2011; Koch W, 2010, NEUROIMAGE, V51, P280, DOI 10.1016/j.neuroimage.2009.12.008; Lewisa CM, 2009, P NATL ACAD SCI USA, V106, P17558, DOI 10.1073/pnas.0902455106; Lu Y, 2011, J NEUROSCI, V31, P11762, DOI 10.1523/JNEUROSCI.2707-11.2011; Mantini D, 2007, P NATL ACAD SCI USA, V104, P13170, DOI 10.1073/pnas.0700668104; Mantini D, 2009, RADIOLOGY, V253, P797, DOI 10.1148/radiol.2533090602; McKeown MJ, 1998, HUM BRAIN MAPP, V6, P160, DOI 10.1002/(SICI)1097-0193(1998)6:3<160::AID-HBM5>3.3.CO;2-R; McNab F, 2009, SCIENCE, V323, P800, DOI 10.1126/science.1166102; Mill J, 2004, AM J MED GENET B, V125B, P38, DOI 10.1002/ajmg.b.20127; Mintun MA, 2006, NEUROLOGY, V67, P446, DOI 10.1212/01.wnl.0000228230.26044.a4; Pascual-Leone A, 2005, ANNU REV NEUROSCI, V28, P377, DOI 10.1146/annurev.neuro.27.070203.144216; Qi ZG, 2010, NEUROIMAGE, V50, P48, DOI 10.1016/j.neuroimage.2009.12.025; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Retz W, 2003, J NEURAL TRANSM, V110, P561, DOI 10.1007/s00702-002-0805-5; Reuter-Lorenz PA, 2005, NEUROPSYCHOLOGIA, V43, P1307, DOI 10.1016/j.neuropsychologia.2004.12.007; Rocca MA, 2010, NEUROLOGY, V74, P1252, DOI 10.1212/WNL.0b013e3181d9ed91; ROSENZWEIG MR, 1978, BRAIN RES, V153, P563, DOI 10.1016/0006-8993(78)90340-2; ROSSINI ED, 1994, PERCEPT MOTOR SKILL, V78, P625, DOI 10.2466/pms.1994.78.2.625; Rybakowski JK, 2005, J NEURAL TRANSM, V112, P1575, DOI 10.1007/s00702-005-0292-6; Sambataro F, 2010, NEUROBIOL AGING, V31, P839, DOI 10.1016/j.neurobiolaging.2008.05.022; Scarmeas N, 2001, NEUROLOGY, V57, P2236, DOI 10.1212/WNL.57.12.2236; Small SA, 2011, NAT REV NEUROSCI, V12, P585, DOI 10.1038/nrn3085; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Sperling RA, 2009, NEURON, V63, P178, DOI 10.1016/j.neuron.2009.07.003; Stokes PRA, 2011, NEUROPSYCHOPHARMACOL, V36, P763, DOI 10.1038/npp.2010.210; Swart M, 2011, NEUROIMAGE, V55, P338, DOI 10.1016/j.neuroimage.2010.12.017; Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4; Ursini G, 2011, J NEUROSCI, V31, P6692, DOI 10.1523/JNEUROSCI.6631-10.2011; VALENSTEIN E, 1987, BRAIN, V110, P1631, DOI 10.1093/brain/110.6.1631; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Voss MW, 2011, J APPL PHYSIOL, V111, P1505, DOI 10.1152/japplphysiol.00210.2011; Voss MW, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00032; Wang L, 2006, NEUROIMAGE, V31, P496, DOI 10.1016/j.neuroimage.2005.12.033; Wong AHC, 2000, EUR J PHARMACOL, V410, P183	70	51	55	0	43	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2012	7	8							e43901	10.1371/journal.pone.0043901	http://dx.doi.org/10.1371/journal.pone.0043901			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	998CA	22937122	Green Published, gold			2023-01-03	WOS:000308213600056
J	Haneef, J; Parvathy, M; Thankayyan, RSK; Sithul, H; Sreeharshan, S				Haneef, Jazir; Parvathy, M.; Thankayyan, Santhosh Kumar R.; Sithul, Hima; Sreeharshan, Sreeja			Bax Translocation Mediated Mitochondrial Apoptosis and Caspase Dependent Photosensitizing Effect of Ficus religiosa on Cancer Cells	PLOS ONE			English	Article							CYTOCHROME-C RELEASE; AQUEOUS EXTRACT; CLEAVAGE; ACTIVATION; PATHWAYS; THERAPY; STRESS; AGENTS; DEATH; CYCLE	The main aim of the present work was to investigate the potential effect of acetone extract of Ficus religosa leaf (FAE) in multiple apoptosis signalling in human breast cancer cells. FAE treatment significantly induced dose and time dependent, irreversible inhibition of breast cancer cell growth with moderate toxicity to normal breast epithelial cells. This observation was validated using Sulforhodamine B assay. Cell cycle analysis by Flow cytometry showed cell cycle arrest in G1 phase and induction of sub-G0 peak. FAE induced chromatin condensation and displayed an increase in apoptotic population in Annexin V-FITC/PI (Fluorescein isothiocyanate/Propidium iodide) double staining. FAE stimulated the loss of mitochondrial membrane potential in multiple breast cancer cell lines when compared to normal diploid cells. To understand the role of Bax in FAE induced apoptosis, we employed a sensitive cell based platform of MCF-7 cells expressing Bax-EGFP. Bax translocation to mitochondria was accompanied by the disruption of mitochondrial membrane potential and marked elevation in LEHDase activity (Caspase 9). Consistent with this data, FAE induced Caspase activation as evidenced by ratio change in FRET Caspase sensor expressing MCF-7 cell line and cleavage of prominent Caspases and PARP. Interestingly, FAE accelerated cell death in a mitochondrial dependent manner in continuous live cell imaging mode indicating its possible photosensitizing effect. Intracellular generation of reactive oxygen species (ROS) by FAE played a critical role in mediating apoptotic cell death and photosensitizing activity. FAE induced dose and time dependent inhibition of cancer cell growth which was associated with Bax translocation and mitochondria mediated apoptosis with the activation of Caspase 9 dependent Caspase cascade. FAE also possessed strong photosensitizing effect on cancer cell line that was mediated through rapid mitochondrial transmembrane potential loss and partial Caspase activation involving generation of intracellular ROS.	[Haneef, Jazir; Parvathy, M.; Thankayyan, Santhosh Kumar R.; Sithul, Hima; Sreeharshan, Sreeja] Rajiv Gandhi Ctr Biotechnol, Canc Res Program, Thiruvananthapuram, Kerala, India	Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB)	Haneef, J (corresponding author), Rajiv Gandhi Ctr Biotechnol, Canc Res Program, Thiruvananthapuram, Kerala, India.	trsanthosh@rgcb.res.in; sreejasreeharshan@yahoo.com			University Grants Commission (UGC); Council of Scientific and Industrial Research (CSIR), Government of India	University Grants Commission (UGC)(University Grants Commission, India); Council of Scientific and Industrial Research (CSIR), Government of India(Council of Scientific & Industrial Research (CSIR) - India)	This work was supported by grants from University Grants Commission (UGC) and Council of Scientific and Industrial Research (CSIR), Government of India, as Senior Research Fellowships to Dr. Haneef and Dr. Parvathy M respectively. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aggarwal BB, 2006, BIOCHEM PHARMACOL, V71, P1397, DOI 10.1016/j.bcp.2006.02.009; Aiyegoro OA, 2009, J MED PLANTS RES, V3, P1147; Aqil F, 2003, WORLD J MICROB BIOT, V19, P653, DOI 10.1023/A:1025128104056; Benjamin CW, 1998, MOL PHARMACOL, V53, P446, DOI 10.1124/mol.53.3.446; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Chang CC, 2002, J FOOD DRUG ANAL, V10, P178; Cho SG, 2002, J BIOCHEM MOL BIOL, V35, P24, DOI 10.5483/BMBRep.2002.35.1.024; Choi HY, 2009, J POLYM ENG, V29, P1, DOI 10.1515/POLYENG.2009.29.1-3.1; Choudhary G.P., 2006, PLANTA INDICA, V2, P17; Cisowska A, 2011, NAT PROD COMMUN, V6, P149; Denecker G, 2000, FEBS LETT, V465, P47, DOI 10.1016/S0014-5793(99)01702-0; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Fulda S, 2004, ONCOGENE, V23, P6702, DOI 10.1038/sj.onc.1207630; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Grabley S, 2000, SPR DESKT EDIT CHEM, P3; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gulecha V, 2011, ASIAN PAC J TROP MED, V4, P526, DOI 10.1016/S1995-7645(11)60139-9; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Joseph J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020114; Joy B, 2010, MOL CARCINOGEN, V49, P324, DOI 10.1002/mc.20599; Jung HW, 2008, PHYTOTHER RES, V22, P1064, DOI 10.1002/ptr.2442; Kasibhatla S, 2003, MOL CANCER THER, V2, P573; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kirana H, 2009, INDIAN J EXP BIOL, V47, P822; Kwang SA, 2007, MOL PHARM, V71, P209; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lam M, 2001, J BIOL CHEM, V276, P47379, DOI 10.1074/jbc.M107678200; McDonald S, 2001, FOOD CHEM, V73, P73, DOI 10.1016/S0308-8146(00)00288-0; Meng JR, 2009, CANCER BIOL THER, V8, P2073, DOI 10.4161/cbt.8.21.9844; Naira N., 2009, INTERNET J ALTERN ME, V6, P2; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Panchal RG, 1998, BIOCHEM PHARMACOL, V55, P247, DOI 10.1016/S0006-2952(97)00240-2; Pandit R, 2010, J ETHNOPHARMACOL, V128, P462, DOI 10.1016/j.jep.2010.01.025; Ratnasooriya WD, 1998, MED SCI RES, V26, P817; Schwartz GK, 2005, J CLIN ONCOL, V23, P9408, DOI 10.1200/JCO.2005.01.5594; Seervi M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.90; Sheetal A, 2008, INDIAN J PHARM SCI, V70, P31; Shishodia S., 2006, ANTICANCER POTENTIAL; Shoeb M., 2006, BANGL J PHARMACOL, V1, P35, DOI [10.3329/bjp.v1i2.486, DOI 10.3329/BJP.V1I2.486]; Singh D, 2011, J ETHNOPHARMACOL, V134, P565, DOI 10.1016/j.jep.2011.01.046; Singh D, 2009, J ETHNOPHARMACOL, V123, P330, DOI 10.1016/j.jep.2009.02.042; Sirisha N., 2010, International Journal of PharmTech Research, V2, P2174; Sreelekshmi R., 2007, Natural Product Radiance, V6, P377; Taskeen A, 2009, NEW YORK SCI J, V2, P32; TENNANT JR, 1964, TRANSPLANTATION, V2, P685, DOI 10.1097/00007890-196411000-00001; Trease G, 2002, PHARMACOGNOSY; VANDELOOSDRECHT AA, 1994, J IMMUNOL METHODS, V174, P311, DOI 10.1016/0022-1759(94)90034-5; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Vinutha B, 2007, J ETHNOPHARMACOL, V109, P359, DOI 10.1016/j.jep.2006.06.014; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108	51	28	28	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2012	7	7							e40055	10.1371/journal.pone.0040055	http://dx.doi.org/10.1371/journal.pone.0040055			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	974UB	22792212	gold, Green Submitted, Green Published			2023-01-03	WOS:000306461800034
J	Ginn, AN; Wiklendt, AM; Gidding, HF; George, N; O'Driscoll, JS; Partridge, SR; O'Toole, BI; Perri, RA; Faoagali, J; Gallagher, JE; Lipman, J; Iredell, JR				Ginn, Andrew N.; Wiklendt, Agnieszka M.; Gidding, Heather F.; George, Narelle; O'Driscoll, James S.; Partridge, Sally R.; O'Toole, Brian I.; Perri, Rita A.; Faoagali, Joan; Gallagher, John E.; Lipman, Jeffrey; Iredell, Jonathan R.			The Ecology of Antibiotic Use in the ICU: Homogeneous Prescribing of Cefepime but Not Tazocin Selects for Antibiotic Resistant Infection	PLOS ONE			English	Article							FIELD GEL-ELECTROPHORESIS; STAPHYLOCOCCUS-AUREUS; POSSIBLE SIGNAL; APACHE-II; METAANALYSIS; RESTRICTION; DECONTAMINATION; IDENTIFICATION; CEPHALOSPORIN; COLONIZATION	Background: Antibiotic homogeneity is thought to drive resistance but in vivo data are lacking. In this study, we determined the impact of antibiotic homogeneity per se, and of cefepime versus antipseudomonal penicillin/beta-lactamase inhibitor combinations (APP-beta), on the likelihood of infection or colonisation with antibiotic resistant bacteria and/or two commonly resistant nosocomial pathogens (methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa). A secondary question was whether antibiotic cycling was associated with adverse outcomes including mortality, length of stay, and antibiotic resistance. Methods: We evaluated clinical and microbiological outcomes in two similar metropolitan ICUs, which both alternated cefepime with APP-beta in four-month cycles. All microbiological isolates and commensal samples were analysed for the presence of antibiotic-resistant bacteria including MRSA and P. aeruginosa. Results: Length of stay, mortality and overall antibiotic resistance were unchanged after sixteen months. However, increased colonisation and infection by antibiotic-resistant bacteria were observed in cefepime cycles, returning to baseline in APP-beta cycles. Cefepime was the strongest risk factor for acquisition of antibiotic-resistant infection. Conclusions: Ecological effects of different beta-lactam antibiotics may be more important than specific activity against the causative agents or the effect of antibiotic homogeneity in selection for antibiotic resistance. This has important implications for antibiotic policy.	[Ginn, Andrew N.; Wiklendt, Agnieszka M.; Partridge, Sally R.; O'Toole, Brian I.; Iredell, Jonathan R.] Westmead Hosp, Ctr Infect Dis & Microbiol, Sydney, NSW, Australia; [Ginn, Andrew N.; Wiklendt, Agnieszka M.; Partridge, Sally R.; Iredell, Jonathan R.] Univ Sydney, Ctr Res Excellence Crit Infect, Sydney, NSW 2006, Australia; [Ginn, Andrew N.; Wiklendt, Agnieszka M.; Partridge, Sally R.; Iredell, Jonathan R.] Univ Sydney, Sydney Inst Emerging Infect & Biosecur, Sydney, NSW 2006, Australia; [Ginn, Andrew N.; Partridge, Sally R.; Perri, Rita A.; Iredell, Jonathan R.] Westmead Millennium Inst, Westmead, NSW, Australia; [Gidding, Heather F.] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia; [George, Narelle; Faoagali, Joan] Royal Brisbane Hosp, Brisbane, Qld 4029, Australia; [O'Driscoll, James S.; Gallagher, John E.] Westmead Hosp, Intens Care Unit, Sydney, NSW, Australia; [Perri, Rita A.] Westmead Hosp, Ludwig Engel Ctr Resp Res, Sydney, NSW, Australia; [Faoagali, Joan] Princess Alexandra Hosp, Dept Microbiol, Brisbane, Qld 4102, Australia; [Lipman, Jeffrey] Univ Queensland, Intens Care Unit, Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia	University of Sydney; University of Sydney; University of Sydney; University of Sydney; Westmead Institute for Medical Research; University of New South Wales Sydney; Kirby Institute; Royal Brisbane & Women's Hospital; University of Sydney; University of Sydney; Royal Brisbane & Women's Hospital; University of Queensland	Ginn, AN (corresponding author), Westmead Hosp, Ctr Infect Dis & Microbiol, Sydney, NSW, Australia.	jonathan.iredell@sydney.edu.au	faoagali, joan l/H-6374-2013; Partridge, Sally R/Q-9374-2019; Lipman, Jeffrey/G-2211-2010	faoagali, joan l/0000-0003-4785-7995; Lipman, Jeffrey/0000-0002-5965-9876; Ginn, Andrew/0000-0002-4356-2615; O'Toole, Brian/0000-0002-3825-0772; Gidding, Heather/0000-0001-7595-9281	Australia and New Zealand Intensive Care Foundation; New South Wales Health (CIDM-Public Health Capacity Building grant); National Health and Medical Research Council of Australia [512396, 1001020]	Australia and New Zealand Intensive Care Foundation; New South Wales Health (CIDM-Public Health Capacity Building grant); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by grants from the Australia and New Zealand Intensive Care Foundation; New South Wales Health (CIDM-Public Health Capacity Building grant); and the National Health and Medical Research Council of Australia grant numbers 512396 and 1001020 (Centre for Research Excellence in Critical Infection). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antibiotic Expert Group, 2010, THER GUID ANT; Antonopoulos DA, 2009, INFECT IMMUN, V77, P2367, DOI 10.1128/IAI.01520-08; Banin E, 2005, P NATL ACAD SCI USA, V102, P11076, DOI 10.1073/pnas.0504266102; Beardmore RE, 2010, MATH BIOSCI ENG, V7, P923, DOI 10.3934/mbe.2010.7.923; Bergstrom CT, 2004, P NATL ACAD SCI USA, V101, P13285, DOI 10.1073/pnas.0402298101; Borg MA, 2010, AM J INFECT CONTROL, V38, P212, DOI 10.1016/j.ajic.2009.07.010; Breslow MJ, 2012, CHEST, V141, P245, DOI 10.1378/chest.11-0330; Brown EM, 2005, J ANTIMICROB CHEMOTH, V55, P6, DOI 10.1093/jac/dkh482; Cadena J, 2007, BONE MARROW TRANSPL, V40, P151, DOI 10.1038/sj.bmt.1705704; de Araujo OR, 2007, BRAZ J INFECT DIS, V11, P277, DOI 10.1590/S1413-86702007000200022; de Smet AMGA, 2009, NEW ENGL J MED, V360, P20, DOI 10.1056/NEJMoa0800394; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Gilbert DN, 2009, SANFORD GUIDE ANTIMI; Jernberg C, 2010, MICROBIOL-SGM, V156, P3216, DOI 10.1099/mic.0.040618-0; Kho ME, 2007, AM J CRIT CARE, V16, P378; Kim PW, 2010, CLIN INFECT DIS, V51, P1351, DOI 10.1086/657248; Kim PW, 2010, CLIN INFECT DIS, V51, P381, DOI 10.1086/655131; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kollef MH, 1997, AM J RESP CRIT CARE, V156, P1040, DOI 10.1164/ajrccm.156.4.9701046; Kumar A, 2006, J INFECT DIS, V193, P251, DOI 10.1086/498909; Kumar A, 2006, CRIT CARE MED, V34, P1589, DOI 10.1097/01.CCM.0000217961.75225.E9; Leibovici L, 2010, CLIN INFECT DIS, V51, P1350, DOI 10.1086/657247; Leibovici L, 2010, LANCET INFECT DIS, V10, P293, DOI 10.1016/S1473-3099(10)70070-0; Lepelletier D, 2006, EUR J CLIN MICROBIOL, V25, P600, DOI 10.1007/s10096-006-0184-1; Levin BR, 2004, P NATL ACAD SCI USA, V101, P13101, DOI 10.1073/pnas.0404970101; Malhotra-Kumar S, 2010, J CLIN MICROBIOL, V48, P1040, DOI 10.1128/JCM.01745-09; Martinez JA, 2006, CRIT CARE MED, V34, P329, DOI 10.1097/01.CCM.0000195010.63855.45; Masterton RG, 2005, J ANTIMICROB CHEMOTH, V55, P1, DOI 10.1093/jac/dkh506; Merlino J, 1996, J CLIN MICROBIOL, V34, P1788, DOI 10.1128/JCM.34.7.1788-1793.1996; Murchan S, 2003, J CLIN MICROBIOL, V41, P1574, DOI 10.1128/JCM.41.4.1574-1585.2003; Nerandzic MM, 2011, ANTIMICROB AGENTS CH, V55, P2174, DOI 10.1128/AAC.01612-10; Oostdijk EAN, 2010, AM J RESP CRIT CARE, V181, P452, DOI 10.1164/rccm.200908-1210OC; Owens RC, 2008, CLIN INFECT DIS, V46, pS19, DOI 10.1086/521859; Paterson DL, 2004, CLIN INFECT DIS, V38, pS341, DOI 10.1086/382690; Paul M, 2006, J ANTIMICROB CHEMOTH, V57, P176, DOI 10.1093/jac/dki448; Rahal JJ, 1998, JAMA-J AM MED ASSOC, V280, P1233, DOI 10.1001/jama.280.14.1233; Sandiumenge A, 2006, J ANTIMICROB CHEMOTH, V57, P1197, DOI 10.1093/jac/dkl097; Sarraf-Yazdi S, 2012, J SURG RES; Schweizer ML, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-279; Song XY, 2010, INFECT CONT HOSP EP, V31, P177, DOI 10.1086/649797; Sullivan A, 2001, Lancet Infect Dis, V1, P101, DOI 10.1016/S1473-3099(01)00066-4; Summers WC, 1998, DIAGN MICR INFEC DIS, V30, P131, DOI 10.1016/S0732-8893(97)00214-9; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; Towne TG, 2009, LANCET INFECT DIS, V9, P4, DOI 10.1016/S1473-3099(08)70288-3; van Loon HJ, 2005, AM J RESP CRIT CARE, V171, P480, DOI 10.1164/rccm.200401-070OC; Villers D, 1998, ANN INTERN MED, V129, P182, DOI 10.7326/0003-4819-129-3-199808010-00003; Warren DK, 2004, CRIT CARE MED, V32, P2450, DOI 10.1097/01.CCM.0000147685.79487.28; Westphal JF, 1997, ANTIMICROB AGENTS CH, V41, P1636, DOI 10.1128/AAC.41.8.1636; Yahav D, 2007, LANCET INFECT DIS, V7, P338, DOI 10.1016/S1473-3099(07)70109-3	49	20	20	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2012	7	6							e38719	10.1371/journal.pone.0038719	http://dx.doi.org/10.1371/journal.pone.0038719			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	965QG	22761698	Green Submitted, Green Published, gold			2023-01-03	WOS:000305781700009
J	Thangaratinam, S; Rogozinska, E; Jolly, K; Glinkowski, S; Roseboom, T; Tomlinson, JW; Kunz, R; Mol, BW; Coomarasamy, A; Khan, KS				Thangaratinam, S.; Rogozinska, E.; Jolly, K.; Glinkowski, S.; Roseboom, T.; Tomlinson, J. W.; Kunz, R.; Mol, B. W.; Coomarasamy, A.; Khan, K. S.			Effects of interventions in pregnancy on maternal weight and obstetric outcomes: meta-analysis of randomised evidence	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LIFE-STYLE INTERVENTION; GESTATIONAL DIABETES-MELLITUS; CORONARY-HEART-DISEASE; PRENATAL EXPOSURE; PHYSICAL-ACTIVITY; CONTROLLED-TRIAL; ENDURANCE EXERCISE; SYSTEMATIC REVIEWS; AEROBIC EXERCISE; DIETARY PATTERNS	Objective To evaluate the effects of dietary and lifestyle interventions in pregnancy on maternal and fetal weight and to quantify the effects of these interventions on obstetric outcomes. Design Systematic review and meta-analysis. Data sources Major databases from inception to January 2012 without language restrictions. Study selection Randomised controlled trials that evaluated any dietary or lifestyle interventions with potential to influence maternal weight during pregnancy and outcomes of pregnancy. Data synthesis Results summarised as relative risks for dichotomous data and mean differences for continuous data. Results We identified 44 relevant randomised controlled trials (7278 women) evaluating three categories of interventions: diet, physical activity, and a mixed approach. Overall, there was 1.42 kg reduction (95% confidence interval 0.95 to 1.89 kg) in gestational weight gain with any intervention compared with control. With all interventions combined, there were no significant differences in birth weight (mean difference -50 g, -100 to 0 g) and the incidence of large for gestational age (relative risk 0.85, 0.66 to 1.09) or small for gestational age (1.00, 0.78 to 1.28) babies between the groups, though by itself physical activity was associated with reduced birth weight (mean difference -60 g, -120 to -10 g). Interventions were associated with a reduced the risk of pre-eclampsia (0.74, 0.60 to 0.92) and shoulder dystocia (0.39, 0.22 to 0.70), with no significant effect on other critically important outcomes. Dietary intervention resulted in the largest reduction in maternal gestational weight gain (3.84 kg, 2.45 to 5.22 kg), with improved pregnancy outcomes compared with other interventions. The overall evidence rating was low to very low for important outcomes such as pre-eclampsia, gestational diabetes, gestational hypertension, and preterm delivery. Conclusions Dietary and lifestyle interventions in pregnancy can reduce maternal gestational weight gain and improve outcomes for both mother and baby. Among the interventions, those based on diet are the most effective and are associated with reductions in maternal gestational weight gain and improved obstetric outcomes.	[Thangaratinam, S.; Rogozinska, E.; Khan, K. S.] Queen Mary Univ London, Barts & London Sch Med & Dent, Ctr Primary Care & Publ Hlth, Womens Hlth Res Unit, London, England; [Jolly, K.] Univ Birmingham, Dept Publ Hlth Epidemiol & Biostat, Birmingham B15 2TT, W Midlands, England; [Glinkowski, S.] Arcana Inst, Krakow, Poland; [Roseboom, T.; Mol, B. W.] Univ Amsterdam, Acad Med Ctr, Dept Obstet & Gynaecol, NL-1105 AZ Amsterdam, Netherlands; [Tomlinson, J. W.; Coomarasamy, A.] Univ Birmingham, Sch Clin & Expt Med, Birmingham B15 2TT, W Midlands, England; [Kunz, R.] Univ Basel, BICE, Basel, Switzerland	University of London; Queen Mary University London; University of Birmingham; University of Amsterdam; Academic Medical Center Amsterdam; University of Birmingham; University of Basel	Thangaratinam, S (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, Ctr Primary Care & Publ Hlth, Womens Hlth Res Unit, London, England.	s.thangaratinam@qmul.ac.uk	Thangaratinam, Shakila/AAP-3724-2021; Rogozinska, Ewelina/C-1096-2018; Khan, Khalid S/AAT-8824-2020; Jolly, Kate/AAA-1341-2019; Mol, Ben/I-4526-2012	Thangaratinam, Shakila/0000-0002-4254-460X; Rogozinska, Ewelina/0000-0003-3455-0644; Khan, Khalid S/0000-0001-5084-7312; Jolly, Kate/0000-0002-6224-2115; Tomlinson, Jeremy/0000-0002-3170-8533; Roseboom, Tessa/0000-0003-0564-5994	National Institute for Health Research (NIHR) HTA (Health Technology Assessment) UK [09/27/06]; National Institute for Health Research [09/27/06] Funding Source: researchfish	National Institute for Health Research (NIHR) HTA (Health Technology Assessment) UK; National Institute for Health Research(National Institute for Health Research (NIHR))	This study was funded by the National Institute for Health Research (NIHR) HTA (Health Technology Assessment) UK programme 09/27/06. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the HTA programme, NIHR, NHS, or the Department of Health.	[Anonymous], 2006, NICE CLIN GUID 43 OB; [Anonymous], 2003, STAT STAT SOFTW REL; [Anonymous], 2011, REV MAN COMP PROGR V; Asbee SM, 2009, OBSTET GYNECOL, V113, P305, DOI 10.1097/AOG.0b013e318195baef; Baciuk Erica P, 2008, Reprod Health, V5, P10, DOI 10.1186/1742-4755-5-10; Badrawi H, 1992, J PERINAT MED, V20, P203; Barakat R, 2009, INT J OBESITY, V33, P1048, DOI 10.1038/ijo.2009.150; Barakat R, 2011, BR J SPORTS MED 0926; Bechtel-Blackwell Deborah A, 2002, Clin Nurs Res, V11, P450, DOI 10.1177/105477302237456; Bell R, 2000, AUST NZ J OBSTET GYN, V40, P70, DOI 10.1111/j.1479-828X.2000.tb03171.x; Boney CM, 2005, PEDIATRICS, V115, pE290, DOI 10.1542/peds.2004-1808; Briley C, 2002, J AM DIET ASSOC, V102, P984, DOI 10.1016/S0002-8223(02)90225-7; BUNG P, 1991, DIABETES, V40, P182, DOI 10.2337/diab.40.2.S182; Campbell F, 2009, SYSTEMATIC REV DIETA; Carmichael SL, 2003, AM J EPIDEMIOL, V158, P1127, DOI 10.1093/aje/kwg286; Cavalcante Sergio R, 2009, Reprod Health, V6, P1, DOI 10.1186/1742-4755-6-1; Clapp JF, 2000, AM J OBSTET GYNECOL, V183, P1484, DOI 10.1067/mob.2000.107096; Clapp JF, 1997, ARCH GYNECOL OBSTET, V260, P101; CLAPP JF, 1990, AM J OBSTET GYNECOL, V163, P1805, DOI 10.1016/0002-9378(90)90754-U; CLAPP JF, 1990, AM J OBSTET GYNECOL, V163, P1799, DOI 10.1016/0002-9378(90)90753-T; Clarke PE, 2004, MIDWIFERY, V20, P133, DOI 10.1016/j.midw.2003.11.003; Cochrane Adverse Effects Sub-Group of the Cochrane Non-Randomised Study Methods Group, 2011, INCL ADV EFF SYST RE; Dale E, 1982, Can J Appl Sport Sci, V7, P98; de Rooij SR, 2007, AM J CLIN NUTR, V86, P1219, DOI 10.1093/ajcn/86.4.1219; de Rooij SR, 2006, PSYCHONEUROENDOCRINO, V31, P1257, DOI 10.1016/j.psyneuen.2006.09.007; Drake AJ, 2010, REPRODUCTION, V140, P387, DOI 10.1530/REP-10-0077; ERKKOLA R, 1976, SCAND J CLIN LAB INV, V36, P747, DOI 10.3109/00365517609081933; ERKKOLA R, 1976, ANN CLIN RES, V8, P15; Ferrara A, 2011, DIABETES CARE, V34, P1519, DOI 10.2337/dc10-2221; Garshasbi A, 2005, INT J GYNECOL OBSTET, V88, P271, DOI 10.1016/j.ijgo.2004.12.001; Glasziou P, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3852; Gomez-Tabarez G, 1994, REV COLOMB OBSTET GI, V45, P313; GREGORY PB, 1987, AM J PERINAT, V4, P365, DOI 10.1055/s-2007-999810; Gross H, 2004, CLIN EFFECTIVENESS N, V8, P161, DOI DOI 10.1016/J.CEIN.2005.03.002; Guelinckx I, 2010, AM J CLIN NUTR, V91, P373, DOI 10.3945/ajcn.2009.28166; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P995, DOI 10.1136/bmj.39490.551019.BE; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Haakstad LAH, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-66; HATCH MC, 1993, AM J EPIDEMIOL, V137, P1105, DOI 10.1093/oxfordjournals.aje.a116614; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Hopkins SA, 2010, J CLIN ENDOCR METAB, V95, P2080, DOI 10.1210/jc.2009-2255; Huang TT, 2011, MIDWIFERY, V27, P257, DOI 10.1016/j.midw.2009.06.009; Hui A, 2012, BJOG-INT J OBSTET GY, V119, P70, DOI 10.1111/j.1471-0528.2011.03184.x; Hui HL., 2006, CAN J DIABETES, V30, P169, DOI DOI 10.1016/S1499-2671(06)02010-7; Jackson RA, 2011, PATIENT EDUC COUNS, V83, P203, DOI 10.1016/j.pec.2010.05.019; Jeffries K, 2009, MED J AUSTRALIA, V191, P429, DOI 10.5694/j.1326-5377.2009.tb02877.x; Khaledan A, 2010, HAYAT, V16, P55; KHAN K, 2001, UNDERTAKING SYSTEMAT; Khan KS, 2003, BRIT J ANAESTH, V91, P767; Khoury J, 2005, AM J OBSTET GYNECOL, V193, P1292, DOI 10.1016/j.ajog.2005.05.016; Knudsen VK, 2008, EUR J CLIN NUTR, V62, P463, DOI 10.1038/sj.ejcn.1602745; KULPA PJ, 1987, AM J OBSTET GYNECOL, V156, P1395, DOI 10.1016/0002-9378(87)90006-8; Lambert PC, 2002, J CLIN EPIDEMIOL, V55, P86, DOI 10.1016/S0895-4356(01)00414-0; Landon MB, 2009, NEW ENGL J MED, V361, P1339, DOI 10.1056/NEJMoa0902430; Lee G, 1996, Mod Midwife, V6, P28; LENDERS CM, 1994, J ADOLESCENT HEALTH, V15, P596, DOI 10.1016/1054-139X(94)90145-S; Lenders CM, 1997, J NUTR, V127, P1113, DOI 10.1093/jn/127.6.1113; Lewis G., 2007, SAVING MOTHERS LIVES; Loke YK, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-32; Lumey LH, 2009, AM J CLIN NUTR, V89, P1737, DOI 10.3945/ajcn.2008.27038; Magann EF, 2002, OBSTET GYNECOL, V99, P466, DOI 10.1016/S0029-7844(01)01754-9; Marquez-Sterling S, 2000, MED SCI SPORT EXER, V32, P58; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; *NAT AUD OFF, 2001, TACKL OB ENGL; National Institute for Health and Clinical Excellence (NICE), 2010, DIET INT PHYS ACT IN; Neugebauer R, 1999, JAMA-J AM MED ASSOC, V282, P455, DOI 10.1001/jama.282.5.455; NEY D, 1982, DIABETES CARE, V5, P529, DOI 10.2337/diacare.5.5.529; NHS Information Centre, 2008, HLTH SURV ENGL 2006; Ong MJ, 2009, DIABETES METAB, V35, P418, DOI 10.1016/j.diabet.2009.04.008; Painter RC, 2006, AM J HUM BIOL, V18, P853, DOI 10.1002/ajhb.20564; Phelan S, 2011, AM J CLIN NUTR, V93, P772, DOI 10.3945/ajcn.110.005306; Polley BA, 2002, INT J OBESITY, V26, P1494, DOI 10.1038/sj.ijo.0802130; Prevedel Tânia Terezinha Scudeller, 2003, Rev. Bras. Ginecol. Obstet., V25, P53, DOI 10.1590/S0100-72032003000100008; Qiu CF, 2008, AM J HYPERTENS, V21, P903, DOI 10.1038/ajh.2008.209; Quinlivan JA, 2011, AUST NZ J OBSTET GYN, V51, P141, DOI 10.1111/j.1479-828X.2010.01268.x; Rae A, 2000, AUST NZ J OBSTET GYN, V40, P416, DOI 10.1111/j.1479-828X.2000.tb01172.x; Ramachenderan J, 2008, AUST NZ J OBSTET GYN, V48, P228, DOI 10.1111/j.1479-828X.2008.00860.x; Rasmussen KM, 2009, WEIGHT GAIN DURING PREGNANCY: REEXAMINING THE GUIDELINES, P1; Ravelli ACJ, 1998, LANCET, V351, P173, DOI 10.1016/S0140-6736(97)07244-9; RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701; Ray JG, 2006, BJOG-INT J OBSTET GY, V113, P379, DOI 10.1111/j.1471-0528.2006.00889.x; Roseboom TJ, 2000, HEART, V84, P595, DOI 10.1136/heart.84.6.595; Roseboom TJ, 2000, AM J CLIN NUTR, V72, P1101; Santos IA, 2005, OBSTET GYNECOL, V106, P243, DOI 10.1097/01.AOG.0000171113.36624.86; Schramm WF, 1996, AM J EPIDEMIOL, V143, P211; Sedaghati P., 2007, GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE, V166, P209; Stanner SA, 1997, BMJ-BRIT MED J, V315, P1342, DOI 10.1136/bmj.315.7119.1342; Stein AD, 2007, AM J CLIN NUTR, V85, P869, DOI 10.1093/ajcn/85.3.869; Sterne JAC, 2001, BMJ-BRIT MED J, V323, P101, DOI 10.1136/bmj.323.7304.101; Streuling I, 2010, AM J CLIN NUTR, V92, P678, DOI 10.3945/ajcn.2010.29363; Thangaratinam S, 2010, BJOG-INT J OBSTET GY, V117, P1309, DOI 10.1111/j.1471-0528.2010.02670.x; Thangaratinam S, HLTH TECHNO IN PRESS; Thompson SG, 2005, LANCET, V365, P341, DOI 10.1016/S0140-6736(05)17790-3; Thornton YS, 2009, J NATL MED ASSOC, V101, P569, DOI 10.1016/S0027-9684(15)30942-1; Vinter CA, 2011, DIABETES CARE, V34, P2502, DOI 10.2337/dc11-1150; Vujkovic M, 2007, OBSTET GYNECOL, V110, P378, DOI 10.1097/01.AOG.0000268799.37044.c3; Wolff S, 2008, INT J OBESITY, V32, P495, DOI 10.1038/sj.ijo.0803710; Yazdy MM, 2010, AM J EPIDEMIOL, V171, P407, DOI 10.1093/aje/kwp395; Yeo S, 2000, J REPROD MED, V45, P293	99	527	539	9	39	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 17	2012	344								e2088	10.1136/bmj.e2088	http://dx.doi.org/10.1136/bmj.e2088			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	946NT	22596383	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000304359400001
J	Milstein, A; Shortell, S				Milstein, Arnold; Shortell, Stephen			Innovations in Care Delivery to Slow Growth of US Health Spending	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CONTROLLED-TRIAL		[Milstein, Arnold] Stanford Univ, Sch Med, Clin Excellence Res Ctr, Stanford, CA 94305 USA; [Shortell, Stephen] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	Stanford University; University of California System; University of California Berkeley	Milstein, A (corresponding author), Stanford Univ, Sch Med, Clin Excellence Res Ctr, 366 Galvez St,334, Stanford, CA 94305 USA.	amilstein@stanford.edu						[Anonymous], IMPR PAT FLOW THROUG; [Anonymous], HLTH AFFAIRS; Berwick DM, 2003, JAMA-J AM MED ASSOC, V289, P1969, DOI 10.1001/jama.289.15.1969; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Milstein A, 2009, HEALTH AFFAIR, V28, P1317, DOI 10.1377/hlthaff.28.5.1317; Naylor MD, 2004, J AM GERIATR SOC, V52, P675, DOI 10.1111/j.1532-5415.2004.52202.x; Needleman J, 2011, NEW ENGL J MED, V364, P1037, DOI 10.1056/NEJMsa1001025; Orszag P, FOREIGN AFFAIRS; Riley GF, 2010, HEALTH SERV RES, V45, P565, DOI 10.1111/j.1475-6773.2010.01082.x; Zuvekas SH, 2007, HEALTH AFFAIR, V26, P249, DOI 10.1377/hlthaff.26.1.249	10	14	14	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 10	2012	308	14					1439	1440		10.1001/jama.2012.12659	http://dx.doi.org/10.1001/jama.2012.12659			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	017GY	23047357				2023-01-03	WOS:000309579300021
J	Kim, H; Kang, HJ; Kim, HJ; Jang, MK; Kim, NH; Oh, Y; Han, BD; Choi, JY; Kim, CW; Lee, JW; Park, KD; Shin, HY; Ahn, HS				Kim, Hyery; Kang, Hyoung Jin; Kim, Hyo Jeong; Jang, Mi Kyung; Kim, Nam Hee; Oh, Yongtaek; Han, Byoung-Don; Choi, Ji-Yeob; Kim, Chul Woo; Lee, Ji Won; Park, Kyung Duk; Shin, Hee Young; Ahn, Hyo Seop			Pharmacogenetic Analysis of Pediatric Patients with Acute Lymphoblastic Leukemia: A Possible Association between Survival Rate and ITPA Polymorphism	PLOS ONE			English	Article							INOSINE-TRIPHOSPHATE-PYROPHOSPHATASE; MULTIFACTOR DIMENSIONALITY REDUCTION; CHILDRENS CANCER GROUP; DETECTING GENE-GENE; MERCAPTOPURINE METABOLISM; TREATMENT RESPONSE; DRUG-THERAPY; RISK; GENOTYPE; INTENSIFICATION	Genetic polymorphisms are important factors in the effects and toxicity of chemotherapeutics. To analyze the pharmacogenetic and ethnic differences in chemotherapeutics, major genes implicated in the treatment of acute lymphoblastic leukemia (ALL) were analyzed. Eighteen loci of 16 genes in 100 patients with ALL were analyzed. The distribution of variant alleles were CYP3A4*1B (0%), CYP3A5*3 (0%), GSTM1 (21%), GSTP1 (21%), GSTT1 (16%), MDR1 exon 21 (77%), MDR1 exon 26 (61%), MTHFR 677 (63%), MTHFR 1298 (29%), NR3C1 1088 (0%), RFC1 80 (68%), TPMT combined genotype (7%), VDR intron 8 (11%), VDR FokI (83%), TYMS enhancer repeat (22%) and ITPA 94 (30%). The frequencies of single nucleotide polymorphisms (SNPs) of 10 loci were statistically different from those in Western Caucasians. Dose percents (actual/planned dose) or toxicity of mercaptopurine and methotrexate were not related to any SNPs. Event free survival (EFS) rate was lower in ITPA variants, and ITPA 94 AC/AA variant genotypes were the only independent risk factor for lower EFS in multivariate analysis, which was a different pharmacogenetic implication from Western studies. This study is the first pharmacogenetic study in Korean pediatric ALL. Our result suggests that there are other possible pharmacogenetic factors besides TPMT or ITPA polymorphisms which influence the metabolism of mercaptopurine in Asian populations.	[Kim, Hyery; Kang, Hyoung Jin; Kim, Hyo Jeong; Jang, Mi Kyung; Kim, Nam Hee; Lee, Ji Won; Park, Kyung Duk; Shin, Hee Young; Ahn, Hyo Seop] Seoul Natl Univ, Coll Med, Canc Res Inst, Dept Pediat, Seoul, South Korea; [Kim, Hyery] Seoul Natl Univ, Coll Med, Dept Pediat, SMG SNU Boramae Med Ctr, Seoul, South Korea; [Oh, Yongtaek; Han, Byoung-Don] YeBT Co LTD, Seoul, South Korea; [Choi, Ji-Yeob] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea; [Kim, Chul Woo] Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 151, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University (SNU)	Kang, HJ (corresponding author), Seoul Natl Univ, Coll Med, Canc Res Inst, Dept Pediat, Seoul, South Korea.	kanghj@snu.ac.kr	Shin, Hee Young/J-2766-2012; Kang, Hyoung Jin/J-2730-2012; Choi, Ji-Yeob/J-2796-2012		National R&D Program for Cancer Control, Ministry for Ministry for Health & Welfare, Republic of Korea [0520290]; Korea Health 21 R&D project, Ministry for Health & Welfare, Republic of Korea [A030001]	National R&D Program for Cancer Control, Ministry for Ministry for Health & Welfare, Republic of Korea; Korea Health 21 R&D project, Ministry for Health & Welfare, Republic of Korea	This study was supported by a grant from the National R&D Program for Cancer Control, Ministry for Ministry for Health & Welfare, Republic of Korea (0520290) and by a grant of the Korea Health 21 R&D project, Ministry for Health & Welfare, Republic of Korea (A030001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adam de Beaumais T, 2012, EUR J CLIN PHARM; Aplenc R, 2005, CANCER RES, V65, P2482, DOI 10.1158/0008-5472.CAN-04-2606; Bhatia S, 2002, BLOOD, V100, P1957, DOI 10.1182/blood-2002-02-0395; Broxson EH, 2005, PEDIATR BLOOD CANCER, V44, P226, DOI 10.1002/pbc.20202; Cheok MH, 2006, NAT REV CANCER, V6, P117, DOI 10.1038/nrc1800; Cunningham L, 2007, EXPERT OPIN PHARMACO, V8, P2519, DOI 10.1517/14656566.8.15.2519; de Wildt SN, 2011, EXPERT OPIN DRUG MET, V7, P935, DOI 10.1517/17425255.2011.577739; Distelhorst CW, 2002, CELL DEATH DIFFER, V9, P6, DOI 10.1038/sj.cdd.4400969; Dorababu P, 2012, EUR J CLIN PHARMACOL, V68, P379, DOI 10.1007/s00228-011-1133-1; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; Felix CA, 1998, P NATL ACAD SCI USA, V95, P13176, DOI 10.1073/pnas.95.22.13176; Ganiere-Monteil C, 2004, EUR J CLIN PHARMACOL, V60, P89, DOI 10.1007/s00228-004-0732-5; Gao LB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020157; Gaynon PS, 2010, LEUKEMIA, V24, P285, DOI 10.1038/leu.2009.262; GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163-7258(85)90083-X; Hahn LW, 2003, BIOINFORMATICS, V19, P376, DOI 10.1093/bioinformatics/btf869; Huang MY, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-50; Hutchinson RJ, 2003, J CLIN ONCOL, V21, P1790, DOI 10.1200/JCO.2003.03.009; Kadan-Lottick NS, 2003, JAMA-J AM MED ASSOC, V290, P2008, DOI 10.1001/jama.290.15.2008; Kang HJ, 2008, MOL CELL PROBE, V22, P193, DOI 10.1016/j.mcp.2008.02.001; Lange BJ, 2002, BLOOD, V99, P825, DOI 10.1182/blood.V99.3.825; Marinaki AM, 2004, PHARMACOGENETICS, V14, P181, DOI 10.1097/00008571-200403000-00006; Marsh S, 2009, CLIN PHARMACOL THER, V85, P139, DOI 10.1038/clpt.2008.219; Phillips EM, 2007, SOC FORCES, V86, P795, DOI 10.1093/sf/86.2.795; Pollock BH, 2000, J CLIN ONCOL, V18, P813, DOI 10.1200/JCO.2000.18.4.813; Pui CH, 2008, LANCET, V371, P1030, DOI 10.1016/S0140-6736(08)60457-2; Relling MV, 1999, BLOOD, V93, P2817; Ritchie MD, 2003, GENET EPIDEMIOL, V24, P150, DOI 10.1002/gepi.10218; Rocha JCC, 2005, BLOOD, V105, P4752, DOI 10.1182/blood-2004-11-4544; Stanulla M, 2005, JAMA-J AM MED ASSOC, V293, P1485, DOI 10.1001/jama.293.12.1485; Stevens JC, 2003, J PHARMACOL EXP THER, V307, P573, DOI 10.1124/jpet.103.054841; Stocco G, 2009, CLIN PHARMACOL THER, V85, P164, DOI 10.1038/clpt.2008.154; Stocco G, 2010, EXPERT OPIN DRUG SAF, V9, P23, DOI 10.1517/14740330903426151; Tanaka Y, 2011, HUM MOL GENET, V20, P3507, DOI 10.1093/hmg/ddr249; Wang WG, 2001, CANCER RES, V61, P5505; Whitfield GK, 1999, J CELL BIOCHEM, P110; Wu JC, 2010, J BIOL CHEM, V285, P15126, DOI 10.1074/jbc.M110.110619; Wu LM, 2007, J SURG ONCOL, V96, P62, DOI 10.1002/jso.20774; Xiang Q, 2010, J CLIN PHARMACOL, V50, P659, DOI 10.1177/0091270009347867	39	33	36	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2012	7	9							e45558	10.1371/journal.pone.0045558	http://dx.doi.org/10.1371/journal.pone.0045558			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	016YB	23029095	gold, Green Published, Green Submitted			2023-01-03	WOS:000309554700046
J	Solverson, P; Murali, SG; Litscher, SJ; Blank, RD; Ney, DM				Solverson, Patrick; Murali, Sangita G.; Litscher, Suzanne J.; Blank, Robert D.; Ney, Denise M.			Low Bone Strength Is a Manifestation of Phenylketonuria in Mice and Is Attenuated by a Glycomacropeptide Diet	PLOS ONE			English	Article							MINERAL DENSITY; NUTRITIONAL MANAGEMENT; CHILDREN; OSTEOPENIA; GROWTH; PKU	Purpose: Phenylketonuria (PKU), caused by phenylalanine (phe) hydroxylase loss of function mutations, requires a low-phe diet plus amino acid (AA) formula to prevent cognitive impairment. Glycomacropeptide (GMP), a low-phe whey protein, provides a palatable alternative to AA formula. Skeletal fragility is a poorly understood chronic complication of PKU. We sought to characterize the impact of the PKU genotype and dietary protein source on bone biomechanics. Procedures: Wild type (WT; Pah(+/+)) and PKU (Pah(enu2/enu2)) mice on a C57BL/6J background were fed high-phe casein, low-phe AA, and low-phe GMP diets between 3 to 23 weeks of age. Following euthanasia, femur biomechanics were assessed by 3-point bending and femoral diaphyseal structure was determined. Femoral ex vivo bone mineral density (BMD) was assessed by dual-enengy x-ray absorptiometry. Whole bone parameters were used in prinicipal component analysis. Data were analyzed by 3-way ANCOVA with genotype, sex, and diet as the main factors. Findings: Regardless of diet and sex, PKU femora were more brittle, as manifested by lower post-yield displacement, weaker, as manifested by lower energy and yield and maximal loads, and showed reduced BMD compared with WT femora. Four principal components accounted for 87% of the variance and all differed significantly by genotype. Regardless of genotype and sex, the AA diet reduced femoral cross-sectional area and consequent maximal load compared with the GMP diet. Conclusions: Skeletal fragility, as reflected in brittle and weak femora, is an inherent feature of PKU. This PKU bone phenotype is attenuated by a GMP diet compared with an AA diet.	[Solverson, Patrick; Murali, Sangita G.; Ney, Denise M.] Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA; [Litscher, Suzanne J.; Blank, Robert D.] William S Middleton Vet Hosp, Geriatr Res Educ & Clin Ctr, Madison, WI USA; [Litscher, Suzanne J.; Blank, Robert D.] Univ Wisconsin, Sch Med & Publ Hlth, Div Endocrinol Diabet & Metab, Dept Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; Geriatric Research Education & Clinical Center; University of Wisconsin System; University of Wisconsin Madison	Ney, DM (corresponding author), Univ Wisconsin, Dept Nutr Sci, 1415 Linden Dr, Madison, WI 53706 USA.	ney@nutrisci.wisc.edu	Solverson, Patrick/AAM-4697-2021; Blank, Robert D./V-5995-2019	Blank, Robert D./0000-0003-2950-1944; Solverson, Patrick/0000-0003-0858-9844	National Phenylketonuria Alliance, United States Department of Agriculture HATCH Grant [WIS01517]; National Institutes of Health [R01- AR-54753]; Office of Research and Development, Biomedical Laboratory R&D Service, Department of Veterans Affairs (RDB); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR054753] Funding Source: NIH RePORTER	National Phenylketonuria Alliance, United States Department of Agriculture HATCH Grant; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Office of Research and Development, Biomedical Laboratory R&D Service, Department of Veterans Affairs (RDB)(US Department of Veterans Affairs); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by the National Phenylketonuria Alliance, United States Department of Agriculture HATCH Grant WIS01517, and National Institutes of Health Grant R01- AR-54753. This material is based upon work supported by the Office of Research and Development, Biomedical Laboratory R&D Service, Department of Veterans Affairs (RDB) and performed in part in the Geriatrics Research, Education, and Clinical Center at the William S. Middleton Memorial Veterans Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Qadreh A, 1998, ACTA PAEDIATR, V87, P1162; ALLEN JR, 1994, AM J CLIN NUTR, V59, P419, DOI 10.1093/ajcn/59.2.419; Ambroszkiewicz J, 2004, EUR J PEDIATR, V163, P177, DOI 10.1007/s00431-003-1394-5; [Anonymous], 2000, NIH Consens Statement, V17, P1; Becker R.A., 1988, NEW S LANGUAGE PROGR; Blank R. D., 2008, P447, DOI 10.1007/978-0-387-73906-9_16; BONADIO J, 1993, J CLIN INVEST, V92, P1697, DOI 10.1172/JCI116756; de Groot MJ, 2012, MOL GENET METAB, V105, P566, DOI 10.1016/j.ymgme.2012.01.006; Enns GM, 2010, MOL GENET METAB, V101, P99, DOI 10.1016/j.ymgme.2010.05.017; Franco GEL, 2004, J CLIN DENSITOM, V7, P326; Fratzl P., 2008, P1, DOI 10.1007/978-0-387-73906-9_1; Frost HM, 2001, ANAT RECORD, V262, P398, DOI 10.1002/ar.1049; Greeves LG, 1997, ACTA PAEDIATR, V86, P242, DOI 10.1111/j.1651-2227.1997.tb08882.x; Harding CO, 2006, GENE THER, V13, P457, DOI 10.1038/sj.gt.3302678; Koch R, 2002, J INHERIT METAB DIS, V25, P333, DOI 10.1023/A:1020158631102; Koura HM, 2011, ARCH MED SCI, V7, P493, DOI 10.5114/aoms.2011.23417; LaClair CE, 2009, J FOOD SCI, V74, pE199, DOI 10.1111/j.1750-3841.2009.01134.x; LAKES R, 1993, NATURE, V361, P511, DOI 10.1038/361511a0; Leppanen OV, 2008, J BIOMECH, V41, P1623, DOI 10.1016/j.jbiomech.2008.03.017; MacDonald A, 2004, J INHERIT METAB DIS, V27, P363, DOI 10.1023/B:BOLI.0000031099.79046.65; MacDonald A, 2000, EUR J PEDIATR, V159, pS136, DOI 10.1007/PL00014375; Macleod Erin L, 2010, Ann Nestle Eng, V68, P58, DOI 10.1159/000312813; Mardia K. V., 1979, MULTIVARIATE ANAL; Marini JC, 2007, HUM MUTAT, V28, P209, DOI 10.1002/humu.20429; MCDONALD JD, 1990, P NATL ACAD SCI USA, V87, P1965, DOI 10.1073/pnas.87.5.1965; MCMURRY MP, 1992, AM J CLIN NUTR, V55, P997, DOI 10.1093/ajcn/55.5.997; Millet P, 2005, CLIN BIOCHEM, V38, P1127, DOI 10.1016/j.clinbiochem.2005.09.002; Modan-Moses D, 2007, J INHERIT METAB DIS, V30, P202, DOI 10.1007/s10545-007-0462-9; Nagasaka H, 2011, J BONE MINER METAB, V29, P737, DOI 10.1007/s00774-011-0276-6; Ney DM, 2009, J INHERIT METAB DIS, V32, P32, DOI 10.1007/s10545-008-0952-4; Pearson K, 1901, PHILOS MAG, V2, P559, DOI 10.1080/14786440109462720; Perez-Duenas B, 2002, ACTA PAEDIATR, V91, P899, DOI 10.1080/080352502760148603; Roato I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014167; Robey P.G., 2008, PRIMER METABOLIC BON, V7, P32; ROGERS QR, 1965, J NUTR, V87, P267, DOI 10.1093/jn/87.3.267; Saless N, 2011, BONE, V48, P647, DOI 10.1016/j.bone.2010.10.165; Saless N, 2009, FASEB J, V23, P2142, DOI 10.1096/fj.08-118679; Schwahn B, 1998, ACTA PAEDIATR, V87, P61, DOI 10.1080/08035259850157886; Sievanen H, 2007, PLOS MED, V4, P407, DOI 10.1371/journal.pmed.0040027; Solverson P, 2012, AM J PHYSIOL-ENDOC M, V302, pE885, DOI 10.1152/ajpendo.00647.2011; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756-3282(93)90081-K; van Calcar SC, 2009, AM J CLIN NUTR, V89, P1068, DOI 10.3945/ajcn.2008.27280; Van Calcar SC, 2012, J ACAD NUTR IN PRESS; Venables W.N., 2002, MODERN APPL STAT S; Walter JH, 2002, LANCET, V360, P55, DOI 10.1016/S0140-6736(02)09334-0; Yannicelli S, 2002, J INHERIT METAB DIS, V25, P347, DOI 10.1023/A:1020191515173; Zeman J, 1999, ACTA PAEDIATR, V88, P1348, DOI 10.1080/080352599750030068	48	41	45	1	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2012	7	9							e45165	10.1371/journal.pone.0045165	http://dx.doi.org/10.1371/journal.pone.0045165			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	040HS	23028819	Green Published, gold, Green Submitted			2023-01-03	WOS:000311313900088
J	Shu, CC; Wu, VC; Yang, FJ; Pan, SC; Lai, TS; Wang, JY; Wang, JT; Lee, LN				Shu, Chin-Chung; Wu, Vin-Cent; Yang, Feng-Jung; Pan, Sung-Ching; Lai, Tai-Shuan; Wang, Jann-Yuan; Wang, Jann-Tay; Lee, Li-Na			Predictors and Prevalence of Latent Tuberculosis Infection in Patients Receiving Long-Term Hemodialysis and Peritoneal Dialysis	PLOS ONE			English	Article							STAGE RENAL-DISEASE; GAMMA RELEASE ASSAY; CHRONIC KIDNEY-DISEASE; QUANTIFERON-TB GOLD; MYCOBACTERIUM-TUBERCULOSIS; ACTIVE TUBERCULOSIS; SKIN-TEST; RISK; DIAGNOSIS; ASSOCIATION	Background: Tuberculosis is a common infectious disease in long-term dialysis patients. The prevalence of latent tuberculosis infection (LTBI) in this population is unclear, particularly in those receiving peritoneal dialysis (PD). This study investigated the prevalence of LTBI in patients receiving either hemodialysis (HD) or PD to determine predictors of LTBI and indeterminate results of interferon-gamma release assay. Methods: Patients receiving long-term (>= 3 months) HD or PD from March 2011 to February 2012 in two medical centers were prospectively enrolled. QuantiFERON-Gold in tube (QFT) test was used to determine the status of LTBI after excluding active tuberculosis. The LTBI prevalence was determined in patients receiving different dialysis modes to obtain predictors of LTBI and QFT-indeterminate results. Results: Of 427 patients enrolled (124 PD and 303 HD), 91 (21.3%) were QFT-positive, 316 (74.0%) QFT-negative, and 20 (4.7%) QFT-indeterminate. The prevalence of LTBI was similar in the PD and HD groups. Independent predictors of LTBI were old age (OR: 1.034 [1.013-1.056] per year increment), TB history (OR: 6.467 [1.985-21.066]), and current smoker (OR: 2.675 [1.061-6.747]). Factors associated with indeterminate QFT results were HD (OR: 10.535 [1.336-83.093]), dialysis duration (OR: 1.113 [1.015-1.221] per year increment), anemia (OR: 8.760 [1.014-75.651]), and serum albumin level (OR: 0.244 [0.086-0.693] per 1 g/dL increment). Conclusion: More than one-fifth of dialysis patients have LTBI. The LTBI prevalence is similar in PD and HD patients but is higher in the elderly, current smokers, and those with prior TB history. Such patients require closer follow-up. Repeated or alternative test may be required for malnutrition patients who received long length of HD.	[Shu, Chin-Chung] Natl Taiwan Univ Hosp, Dept Traumatol, Taipei, Yun Lin County, Taiwan; [Shu, Chin-Chung; Wu, Vin-Cent; Wang, Jann-Yuan; Wang, Jann-Tay] Natl Taiwan Univ, Coll Internal Med, Taipei 10764, Taiwan; [Yang, Feng-Jung] Natl Taiwan Univ Hosp, Dept Internal Med, Yun Lin Branch, Taipei 100, Yun Lin County, Taiwan; [Lai, Tai-Shuan] Natl Taiwan Univ Hosp, Dept Internal Med, Bei Hu Branch, Taipei 100, Yun Lin County, Taiwan; [Lee, Li-Na] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Yun Lin County, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Shu, CC (corresponding author), Natl Taiwan Univ Hosp, Dept Traumatol, Taipei, Yun Lin County, Taiwan.	jywang@ntu.edu.tw	Yang, Feng-Jung/GYU-9337-2022; Yang, Feng-Jung/AAK-9946-2020	Yang, Feng-Jung/0000-0003-1235-1943; LEE, LI-NA/0000-0002-7654-2450; WANG, JANN-TAY/0000-0002-0924-3469; SHU, CHIN-CHUNG/0000-0003-0311-5148; WU, VIN-CENT/0000-0001-7935-0991; PAN, SUNG-CHING/0000-0003-3154-6690; WANG, JANN-YUAN/0000-0003-3406-366X; Lai, Tai-Shuan/0000-0002-0552-372X	Institute of Biotechnology and Medicine Industry in Taiwan	Institute of Biotechnology and Medicine Industry in Taiwan	This study was funded by Institute of Biotechnology and Medicine Industry in Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2000, MMWR Recomm Rep, V49, P1; [Anonymous], 1997, AM J KIDNEY DIS, V30, pS15; Banach DB, 2011, INT J TUBERC LUNG D, V15, P1623, DOI 10.5588/ijtld.11.0017; Bates MN, 2007, ARCH INTERN MED, V167, P335, DOI 10.1001/archinte.167.4.335; BROCK I, 2004, AM J RESP CRIT CARE, V170, P65; Centers of Disease Control DoH R. O. C. (Taiwan), 2010, CDC ANN REP 2011; Chavers BM, 2007, J AM SOC NEPHROL, V18, P952, DOI 10.1681/ASN.2006040406; Christopoulos AI, 2006, INT UROL NEPHROL, V38, P745, DOI 10.1007/s11255-006-9051-3; Chung WK, 2010, CLIN MICROBIOL INFEC, V16, P960, DOI 10.1111/j.1469-0691.2009.02949.x; de Cal M, 2008, BLOOD PURIFICAT, V26, P249, DOI 10.1159/000122110; Diel R, 2008, AM J RESP CRIT CARE, V177, P1164, DOI 10.1164/rccm.200711-1613OC; Dobler CC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029563; Dyrhol-Riise AM, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-57; Fabrizi F, 2012, DIGEST DIS SCI, V57, P1366, DOI 10.1007/s10620-011-1987-1; Fang HC, 2004, INT J TUBERC LUNG D, V8, P92; Hill CJ, 2012, J RENAL CARE, V38, P12, DOI 10.1111/j.1755-6686.2012.00273.x; Jasmer RM, 2000, AM J RESP CRIT CARE, V162, P1648, DOI 10.1164/ajrccm.162.5.2003028; Jick SS, 2006, ARTHRIT RHEUM-ARTHR, V55, P19, DOI 10.1002/art.21705; Lai CC, 2010, EMERG INFECT DIS, V16, P294, DOI 10.3201/eid1602.090675; Lalvani A, 2001, AM J RESP CRIT CARE, V163, P824, DOI 10.1164/ajrccm.163.4.2009100; Lange B, 2010, EUR RESPIR J, V35, P1179, DOI 10.1183/09031936.00122109; Lee SSJ, 2009, INFECTION, V37, P96, DOI 10.1007/s15010-008-8082-3; Lee SSJ, 2010, CLIN J AM SOC NEPHRO, V5, P1451, DOI 10.2215/CJN.01790210; Lin HH, 2009, AM J RESP CRIT CARE, V180, P475, DOI 10.1164/rccm.200904-0549OC; Lukowsky LR, 2012, AM J NEPHROL, V35, P548, DOI 10.1159/000338673; LUNDIN AP, 1979, AM J MED, V67, P597, DOI 10.1016/0002-9343(79)90240-7; Palomar R, 2011, NEFROLOGIA, V31, P169, DOI 10.3265/Nefrologia.pre2011.Jan.10765; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; Rose DN, 2000, ARCH INTERN MED, V160, P1513, DOI 10.1001/archinte.160.10.1513; Sester M, 2004, KIDNEY INT, V65, P1826, DOI 10.1111/j.1523-1755.2004.00586.x; Shu CC, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-48; Shu CC, 2010, MEDICINE, V89, P53, DOI 10.1097/MD.0b013e3181cafcd3; Simsek H, 2010, JPN J INFECT DIS, V63, P99; Smirnoff M, 1998, CHEST, V113, P25, DOI 10.1378/chest.113.1.25; Stevens LA, 2010, ADV CHRONIC KIDNEY D, V17, P293, DOI 10.1053/j.ackd.2010.03.010; Triverio PA, 2009, NEPHROL DIAL TRANSPL, V24, P1952, DOI 10.1093/ndt/gfn748; Vacher-Coponat H, 2008, NEPHROL DIAL TRANSPL, V23, P1406, DOI 10.1093/ndt/gfm596; Venkata RKC, 2007, CLIN NEPHROL, V67, P217; Wang JY, 2012, J INFECTION, V64, P291, DOI 10.1016/j.jinf.2011.11.028; Yu MC, 1999, J FORMOS MED ASSOC, V98, P496	40	29	30	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 20	2012	7	8							e42592	10.1371/journal.pone.0042592	http://dx.doi.org/10.1371/journal.pone.0042592			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	991WJ	22916137	Green Submitted, Green Published, gold			2023-01-03	WOS:000307733800021
J	de Moura, MB; Vincent, G; Fayewicz, SL; Bateman, NW; Hood, BL; Sun, M; Suhan, J; Duensing, S; Yin, Y; Sander, C; Kirkwood, JM; Becker, D; Conrads, TP; Van Houten, B; Moschos, SJ				de Moura, Michelle Barbi; Vincent, Garret; Fayewicz, Shelley L.; Bateman, Nicholas W.; Hood, Brian L.; Sun, Mai; Suhan, Joseph; Duensing, Stefan; Yin, Yan; Sander, Cindy; Kirkwood, John M.; Becker, Dorothea; Conrads, Thomas P.; Van Houten, Bennett; Moschos, Stergios J.			Mitochondrial Respiration - An Important Therapeutic Target in Melanoma	PLOS ONE			English	Article							CELL LINES; METABOLISM; EXPRESSION; FLUX; LIPOGENESIS; SURVIVAL; GROWTH; OXYGEN	The importance of mitochondria as oxygen sensors as well as producers of ATP and reactive oxygen species (ROS) has recently become a focal point of cancer research. However, in the case of melanoma, little information is available to what extent cellular bioenergetics processes contribute to the progression of the disease and related to it, whether oxidative phosphorylation (OXPHOS) has a prominent role in advanced melanoma. In this study we demonstrate that compared to melanocytes, metastatic melanoma cells have elevated levels of OXPHOS. Furthermore, treating metastatic melanoma cells with the drug, Elesclomol, which induces cancer cell apoptosis through oxidative stress, we document by way of stable isotope labeling with amino acids in cell culture (SILAC) that proteins participating in OXPHOS are downregulated. We also provide evidence that melanoma cells with high levels of glycolysis are more resistant to Elesclomol. We further show that Elesclomol upregulates hypoxia inducible factor 1-alpha (HIF-1 alpha), and that prolonged exposure of melanoma cells to this drug leads to selection of melanoma cells with high levels of glycolysis. Taken together, our findings suggest that molecular targeting of OXPHOS may have efficacy for advanced melanoma.	[de Moura, Michelle Barbi; Bateman, Nicholas W.; Van Houten, Bennett] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA; [Vincent, Garret; Fayewicz, Shelley L.; Yin, Yan; Sander, Cindy; Kirkwood, John M.; Moschos, Stergios J.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA; [Hood, Brian L.; Conrads, Thomas P.] Inova Hlth Syst, Womens Hlth Integrated Res Ctr, Gynecol Canc Ctr Excellence, Annandale, VA USA; [Sun, Mai] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA; [Suhan, Joseph] Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA; [Duensing, Stefan] Urol Univ Klin Heidelberg, Sekt Mol Uroonkol, Heidelberg, Germany; [Becker, Dorothea] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Inova Health System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University; Ruprecht Karls University Heidelberg; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	de Moura, MB (corresponding author), Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA.	stergios_moschos@med.unc.edu	Van Houten, Bennett/K-2284-2019	Sun, Mai/0000-0003-0489-1616	Career Development Award of a SPORE in Skin Cancer [P50CA121973]; Pennsylvania Department of Health PA CURE award; NATIONAL CANCER INSTITUTE [P50CA121973] Funding Source: NIH RePORTER	Career Development Award of a SPORE in Skin Cancer; Pennsylvania Department of Health PA CURE award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a Career Development Award of a SPORE in Skin Cancer (P50CA121973) to SJM, and a Pennsylvania Department of Health PA CURE award to BVH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Berridge MV, 2010, REJUV RES, V13, P139, DOI 10.1089/rej.2009.0948; Birket MJ, 2011, J CELL SCI, V124, P348, DOI 10.1242/jcs.072272; Blackman RK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029798; Boisvert-Adamo K, 2009, MOL CANCER RES, V7, P549, DOI 10.1158/1541-7786.MCR-08-0358; Brand MD, 2010, EXP GERONTOL, V45, P466, DOI 10.1016/j.exger.2010.01.003; Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; de Moura MB, 2010, ENVIRON MOL MUTAGEN, V51, P391, DOI 10.1002/em.20575; Dykstra KM, 2010, MOL BIOL CELL, V21, P1556, DOI 10.1091/mbc.E09-12-1002; Eberle J, 2008, CURR GENOMICS, V9, P409, DOI 10.2174/138920208785699571; Farmer PJ, 2003, PIGM CELL RES, V16, P273, DOI 10.1034/j.1600-0749.2003.00046.x; Filipp FV, 2012, PIGM CELL MELANOMA R, V25, P375, DOI 10.1111/j.1755-148X.2012.00989.x; Flint MS, 2009, PSYCHONEUROENDOCRINO, V34, P1533, DOI 10.1016/j.psyneuen.2009.05.008; Foley KP, 2007, AACR NCI EORTC S MOL; Ganter B, 2008, CURR OPIN DRUG DISC, V11, P86; Gnaiger E, 1998, J EXP BIOL, V201, P1129; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hauschild A, 2009, ASCO ANN M ORL FL; Hersey P, 2009, CLIN CANCER RES, V15, P6490, DOI 10.1158/1078-0432.CCR-09-0251; Hill BG, 2009, BIOCHEM J, V424, P99, DOI 10.1042/BJ20090934; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Huttemann M, 2008, J BIOENERG BIOMEMBR, V40, P445, DOI 10.1007/s10863-008-9169-3; Jonas EA, 2004, P NATL ACAD SCI USA, V101, P13590, DOI 10.1073/pnas.0401372101; KALLINOWSKI F, 1989, CANCER RES, V49, P3759; Kirshner JR, 2008, MOL CANCER THER, V7, P2319, DOI 10.1158/1535-7163.MCT-08-0298; Kong Q, 2000, MED HYPOTHESES, V55, P29, DOI 10.1054/mehy.1999.0982; Kuphal S, 2010, EUR J CANCER, V46, P1159, DOI 10.1016/j.ejca.2010.01.031; Manola J, 2000, J CLIN ONCOL, V18, P3782, DOI 10.1200/JCO.2000.18.22.3782; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Meyskens FL, 2001, PIGM CELL RES, V14, P148, DOI 10.1034/j.1600-0749.2001.140303.x; Moschos SJ, 2009, CANCER BIOL THER, V8, P1815, DOI 10.4161/cbt.8.19.9435; Nakajima EC, 2012, MOL CARCINOG; O'Day S, 2009, J CLIN ONCOL, V27, P5452, DOI 10.1200/JCO.2008.17.1579; PARCE JW, 1989, SCIENCE, V246, P243, DOI 10.1126/science.2799384; Qian W, 2010, METHODS, V51, P452, DOI 10.1016/j.ymeth.2010.03.006; Scott DA, 2011, J BIOL CHEM, V286, P42626, DOI 10.1074/jbc.M111.282046; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Silverthorn CF, 2010, MELANOMA RES, V20, P61, DOI 10.1097/CMR.0b013e328333d8c2; Sondergaard JN, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-39; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Vlashi E, 2011, P NATL ACAD SCI USA, V108, P16062, DOI 10.1073/pnas.1106704108; Wang XH, 2011, CANCER RES, V71, P7410, DOI 10.1158/0008-5472.CAN-10-1134; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wu M, 2007, AM J PHYSIOL-CELL PH, V292, pC125, DOI 10.1152/ajpcell.00247.2006; Zhuang LQ, 2010, MODERN PATHOL, V23, P45, DOI 10.1038/modpathol.2009.129	47	77	77	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 17	2012	7	8							e40690	10.1371/journal.pone.0040690	http://dx.doi.org/10.1371/journal.pone.0040690			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	996DG	22912665	Green Submitted, Green Published, gold, Green Accepted			2023-01-03	WOS:000308063700001
J	Korin, N; Kanapathipillai, M; Matthews, BD; Crescente, M; Brill, A; Mammoto, T; Ghosh, K; Jurek, S; Bencherif, SA; Bhatta, D; Coskun, AU; Feldman, CL; Wagner, DD; Ingber, DE				Korin, Netanel; Kanapathipillai, Mathumai; Matthews, Benjamin D.; Crescente, Marilena; Brill, Alexander; Mammoto, Tadanori; Ghosh, Kaustabh; Jurek, Samuel; Bencherif, Sidi A.; Bhatta, Deen; Coskun, Ahmet U.; Feldman, Charles L.; Wagner, Denisa D.; Ingber, Donald E.			Shear-Activated Nanotherapeutics for Drug Targeting to Obstructed Blood Vessels	SCIENCE			English	Article							VON-WILLEBRAND-FACTOR; PLATELET-AGGREGATION; WALL SHEAR; NANOPARTICLES; FIBRINOLYSIS; STABILITY; ADHESION; PLGA; MICE	Obstruction of critical blood vessels due to thrombosis or embolism is a leading cause of death worldwide. Here, we describe a biomimetic strategy that uses high shear stress caused by vascular narrowing as a targeting mechanism-in the same way platelets do-to deliver drugs to obstructed blood vessels. Microscale aggregates of nanoparticles were fabricated to break up into nanoscale components when exposed to abnormally high fluid shear stress. When coated with tissue plasminogen activator and administered intravenously in mice, these shear-activated nanotherapeutics induce rapid clot dissolution in a mesenteric injury model, restore normal flow dynamics, and increase survival in an otherwise fatal mouse pulmonary embolism model. This biophysical strategy for drug targeting, which lowers required doses and minimizes side effects while maximizing drug efficacy, offers a potential new approach for treatment of life-threatening diseases that result from acute vascular occlusion.	[Korin, Netanel; Kanapathipillai, Mathumai; Bencherif, Sidi A.; Ingber, Donald E.] Harvard Univ, Wyss Inst Biologically Inspired Engn, Boston, MA 02115 USA; [Matthews, Benjamin D.; Mammoto, Tadanori; Ghosh, Kaustabh; Jurek, Samuel; Ingber, Donald E.] Harvard Univ, Sch Med, Childrens Hosp Boston, Vasc Biol Program,Dept Pathol, Boston, MA 02115 USA; [Matthews, Benjamin D.; Mammoto, Tadanori; Ghosh, Kaustabh; Jurek, Samuel; Ingber, Donald E.] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Surg, Boston, MA 02115 USA; [Matthews, Benjamin D.] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Med, Boston, MA 02115 USA; [Crescente, Marilena; Brill, Alexander; Wagner, Denisa D.] Childrens Hosp Boston, Program Cellular & Mol Med, Immune Dis Inst, Boston, MA 02115 USA; [Crescente, Marilena; Brill, Alexander; Wagner, Denisa D.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Bencherif, Sidi A.; Bhatta, Deen; Ingber, Donald E.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA; [Coskun, Ahmet U.] Northeastern Univ, Boston, MA 02115 USA; [Feldman, Charles L.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA	Harvard University; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Harvard Medical School; Harvard University; Northeastern University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Ingber, DE (corresponding author), Harvard Univ, Wyss Inst Biologically Inspired Engn, Boston, MA 02115 USA.	don.ingber@wyss.harvard.edu	Brill, Alexander/L-7587-2018; Ingber, Donald E/AAC-5894-2019	Brill, Alexander/0000-0002-4558-0390; Crescente, Marilena/0000-0003-3164-512X; Korin, Netanel/0000-0001-7244-889X; BENCHERIF, SIDI/0000-0002-7704-5608	U.S. Department of Defense [BC074986]; Novartis Pharmaceuticals; Boston Scientific; Wyss Institute for Biologically Inspired Engineering at Harvard University; Wyss Technology Development Fellowship	U.S. Department of Defense(United States Department of Defense); Novartis Pharmaceuticals(Novartis); Boston Scientific(Boston Scientific); Wyss Institute for Biologically Inspired Engineering at Harvard University; Wyss Technology Development Fellowship	We thank D. Huh, K. Roberts, and R. F. Valentini for helpful comments and K. Johnson and D. Stanton for help with the graphics. This work was supported by a U.S. Department of Defense Breast Cancer Innovator award BC074986 (to D. E. I.), grants from Novartis Pharmaceuticals and Boston Scientific (to C. L. F. and A. U. C.), and the Wyss Institute for Biologically Inspired Engineering at Harvard University. N.K. is a recipient of a Wyss Technology Development Fellowship. Harvard University and the authors (D. E. I., N.K., M.K.) have filed two patents related to this work: (i) Shear-Activated Nanotherapeutics for Drug Targeting (patent application pending) and (ii) Shear Controlled Release for Stenotic Lesions and Thrombolytic Therapies (patent application pending WO 2012/074588).	Bark DL, 2010, J BIOMECH, V43, P2970, DOI 10.1016/j.jbiomech.2010.07.011; Bergmeier W, 2006, P NATL ACAD SCI USA, V103, P16900, DOI 10.1073/pnas.0608207103; Chauhan AK, 2006, J EXP MED, V203, P767, DOI 10.1084/jem.20051732; Danielyan K, 2008, CIRCULATION, V118, P1442, DOI 10.1161/CIRCULATIONAHA.107.750257; Di Marco M, 2010, INT J NANOMED, V5, P37; Frenette PS, 1998, BLOOD, V91, P1318, DOI 10.1182/blood.V91.4.1318; Ganguly K, 2006, J PHARMACOL EXP THER, V316, P1130, DOI 10.1124/jpet.105.093450; Goto S, 1999, CIRCULATION, V99, P608, DOI 10.1161/01.CIR.99.5.608; GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245; Ingall TJ, 2004, STROKE, V35, P2418, DOI 10.1161/01.STR.0000140891.70547.56; Kwatkowski TG, 1999, NEW ENGL J MED, V340, P1781; Murciano JC, 2003, NAT BIOTECHNOL, V21, P891, DOI 10.1038/nbt846; Murciano JC, 2002, AM J PHYSIOL-LUNG C, V282, pL529, DOI 10.1152/ajplung.00112.2001; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Nesbitt WS, 2009, NAT MED, V15, P665, DOI 10.1038/nm.1955; Ni HY, 2000, J CLIN INVEST, V106, P385, DOI 10.1172/JCI9896; Rana S, 2010, CURR OPIN CHEM BIOL, V14, P828, DOI 10.1016/j.cbpa.2010.10.001; Ruggeri ZM, 2006, BLOOD, V108, P1903, DOI 10.1182/blood-2006-04-011551; Santander-Ortega MJ, 2007, COLLOID SURFACE A, V296, P132, DOI 10.1016/j.colsurfa.2006.09.036; Santander-Ortega MJ, 2006, J COLLOID INTERF SCI, V302, P522, DOI 10.1016/j.jcis.2006.07.031; SIEGEL JM, 1994, J BIOMECH ENG-T ASME, V116, P446, DOI 10.1115/1.2895795; Straub JA, 2007, INT J PHARM, V328, P35, DOI 10.1016/j.ijpharm.2006.07.052; STRONY J, 1993, AM J PHYSIOL, V265, pH1787; Wechsler LR, 2011, NEW ENGL J MED, V364, P2138, DOI 10.1056/NEJMct1007370; Wootton DM, 1999, ANNU REV BIOMED ENG, V1, P299, DOI 10.1146/annurev.bioeng.1.1.299	25	344	362	15	373	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 10	2012	337	6095					738	742		10.1126/science.1217815	http://dx.doi.org/10.1126/science.1217815			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	986PE	22767894				2023-01-03	WOS:000307354500056
J	Grandgeorge, M; Tordjman, S; Lazartigues, A; Lemonnier, E; Deleau, M; Hausberger, M				Grandgeorge, Marine; Tordjman, Sylvie; Lazartigues, Alain; Lemonnier, Eric; Deleau, Michel; Hausberger, Martine			Does Pet Arrival Trigger Prosocial Behaviors in Individuals with Autism?	PLOS ONE			English	Article							PERVASIVE DEVELOPMENTAL DISORDERS; ANIMAL-ASSISTED THERAPY; SOCIAL-INTERACTION; DIAGNOSTIC INTERVIEW; FACILITATED THERAPY; SPECTRUM DISORDERS; EARLY RECOGNITION; JOINT ATTENTION; CHILDREN; OWNERSHIP	Alteration of social interactions especially prosocial behaviors - an important aspect of development - is one of the characteristics of autistic disorders. Numerous strategies or therapies are used to improve communication skills or at least to reduce social impairments. Animal-assisted therapies are used widely but their relevant benefits have never been scientifically evaluated. In the present study, we evaluated the association between the presence or the arrival of pets in families with an individual with autism and the changes in his or her prosocial behaviors. Of 260 individuals with autism - on the basis of presence or absence of pets - two groups of 12 individuals and two groups of 8 individuals were assigned to: study 1 (pet arrival after age of 5 versus no pet) and study 2 (pet versus no pet), respectively. Evaluation of social impairment was assessed at two time periods using the 36-items ADI-R algorithm and a parental questionnaire about their child-pet relationships. The results showed that 2 of the 36 items changed positively between the age of 4 to 5 (t(0)) and time of assessment (t(1)) in the pet arrival group (study 1): "offering to share" and "offering comfort". Interestingly, these two items reflect prosocial behaviors. There seemed to be no significant changes in any item for the three other groups. The interactions between individuals with autism and their pets were more - qualitatively and quantitatively - reported in the situation of pet arrival than pet presence since birth. These findings open further lines of research on the impact of pet's presence or arrival in families with an individual with autism. Given the potential ability of individuals with autism to develop prosocial behaviors, related studies are needed to better understand the mechanisms involved in the development of such child-pet relationship.	[Grandgeorge, Marine; Lazartigues, Alain; Lemonnier, Eric] CHRU Brest, Hop Bohars, Ctr Ressources Autisme, Bohars, France; [Grandgeorge, Marine; Hausberger, Martine] CNRS, UMR 6552, Lab Ethol Anim & Humaine, Rennes, France; [Tordjman, Sylvie] CHRU Guillaume Regnier, Rennes, France; [Deleau, Michel] Ctr Rech Psychol Cognit & Commun, Rennes, France	CHU Brest; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)	Grandgeorge, M (corresponding author), CHRU Brest, Hop Bohars, Ctr Ressources Autisme, Bohars, France.	marine.grandgeorge@chu-brest.fr	lemonnier, eric/K-1084-2016		Adrienne and Pierre Sommer Foundation; Fondation Sommer	Adrienne and Pierre Sommer Foundation; Fondation Sommer	The Adrienne and Pierre Sommer Foundation gave the financial support for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors declare that they have no financial interests.; We are thankful to Dr. Ann Cloarec, researcher, Ethos laboratory and Zarrin Alavi, (for her pertinent advice) medical writer and translator, Brest University Hospital, Department of Internal Medicine and Chest Diseases; INSERM CIC 0502, to Pr Michel Botbol, CHRU Brest, to families for their participation, to the Fondation Sommer for their support and the French GIS CCS (Groupe d'Interet Scientifique - Comportement Cerveau et Societe)	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anastasi A., 1988, PSYCHOL TESTING; ANDERSON WP, 1992, MED J AUSTRALIA, V157, P298, DOI 10.5694/j.1326-5377.1992.tb137178.x; Bailey C, 1988, DISS ABSTR INT, V48; Baranek GT, 1999, J AUTISM DEV DISORD, V29, P213, DOI 10.1023/A:1023080005650; Barker SB, 2008, J VET MED EDUC, V35, P487, DOI 10.3138/jvme.35.4.487; Baron-Cohen S, 1995, MINDBLINDNESS ESSAY; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; Bass M, 2009, J AUTISM DEV DISORD, V39, P1261, DOI 10.1007/s10803-009-0734-3; Beck AM, 1996, ANNU REV PUBL HEALTH, V17, P247, DOI 10.1146/annurev.pu.17.050196.001335; Beck AM, 2001, ANTHROZOOS, V14, P19, DOI 10.2752/089279301786999599; BECK AM, 1984, J AM VET MED ASSOC, V184, P414; Blue G.F., 1986, CHILDHOOD ED, V63, DOI [10.1080/00094056.1986.10521747, DOI 10.1080/00094056.1986.10521747]; BRICKEL CM, 1982, PSYCHOL REP, V50, P71, DOI 10.2466/pr0.1982.50.1.71; BRUNER JS, 1972, AM PSYCHOL, V27, P687, DOI 10.1037/h0033144; Bryant B, 1986, RELEVANCE FAMILY NEI; Bryant B. K., 1990, Anthrozoos, V3, P253, DOI 10.2752/089279390787057469; Burrows KE, 2008, QUAL HEALTH RES, V18, P1642, DOI 10.1177/1049732308327088; Cain A. O., 1985, MARRIAGE FAM REV, V8, P5; Celani G, 2002, AUTISM, V6, P93, DOI 10.1177/1362361302006001007; Endenburg N, 1996, WALTHAM BOOK HUMAN A, p[1996, 7]; epperberg IM, 1991, J COMP PSYCHOL, V105, P286; Filiatre J. C., 1988, Anthrozoos, V2, P22, DOI 10.2752/089279389787058190; FILIATRE JC, 1986, BEHAV PROCESS, V12, P33, DOI 10.1016/0376-6357(86)90068-9; FRIEDMANN E, 1983, J NERV MENT DIS, V171, P461, DOI 10.1097/00005053-198308000-00002; FRIEDMANN E, 1980, PUBLIC HEALTH REP, V95, P307; Furman W., 1989, WILEY SERIES PERSONA, P151; Gasalberti Denise, 2006, J Pediatr Health Care, V20, P133, DOI 10.1016/j.pedhc.2005.12.015; Gelman R., 1981, SOCIAL COGNITIVE DEV, P43; George H., 1988, INNOVATIVE INTERVENT, P400; Gervais H, 2004, NAT NEUROSCI, V7, P801, DOI 10.1038/nn1291; Glascoe FP, 2005, MENT RETARD DEV D R, V11, P173, DOI 10.1002/mrdd.20068; Glascoe FP, 1997, PEDIATRICS, V99, P830, DOI 10.1542/peds.99.6.830; Grandgeorge M, 2010, COULD BOND ANIMAL AL, V2; Grandgeorge M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004683; Haggerty Davis J., 1989, Anthrozoos, V2, P189, DOI 10.2752/089279389787058046; Hills AM, 1995, ANTHROZOOS, V8, P132, DOI 10.2752/089279395787156347; Hinde R.A., 1979, UNDERSTANDING RELATI; Hubert Montagner, 1995, ENFANT ANIMAL ECOLE; Kaminski M, 2002, CHILD HEALTH CARE, V31, P321, DOI 10.1207/S15326888CHC3104_5; KASARI C, 1990, J AUTISM DEV DISORD, V20, P87, DOI 10.1007/BF02206859; Katcher AH., 2000, HDB ANIMAL ASSISTED, P461; Kenzer AL, 2011, RES AUTISM SPECT DIS, V5, P819, DOI 10.1016/j.rasd.2010.09.011; KIDD AH, 1985, PSYCHOL REP, V57, P15, DOI 10.2466/pr0.1985.57.1.15; Levinson B., 1962, MENT HYG, V179, P46; LORD C, 1989, J AUTISM DEV DISORD, V19, P185, DOI 10.1007/BF02211841; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Lord C, 1997, J AUTISM DEV DISORD, V27, P501, DOI 10.1023/A:1025873925661; Macdonald A, 1981, INTERRELATIONS PEOPL; Martin F, 2002, WESTERN J NURS RES, V24, P657, DOI 10.1177/019394502320555403; Maurer M, 2011, PSYCHIAT ENFANT, V54, P575, DOI 10.3917/psye.542.0575; Maurer M, 2010, ANTHROZOOS, V23, P383, DOI 10.2752/175303710X12750451259453; McConnell SR, 2002, J AUTISM DEV DISORD, V32, P351, DOI 10.1023/A:1020537805154; Melson G. F., 1991, CHILDRENS ENV Q, V8, P55, DOI DOI 10.2307/41514782; Melson G. F., 2005, WHY WILD THINGS ARE; MILLOT JL, 1986, APPL ANIM BEHAV SCI, V16, P383, DOI 10.1016/0168-1591(86)90010-9; MILLOT JL, 1988, BEHAV PROCESS, V17, P1, DOI 10.1016/0376-6357(88)90046-0; MUNDY P, 1995, DEV PSYCHOPATHOL, V7, P63, DOI 10.1017/S0954579400006349; NATHANSON DE, 1993, ANTHROZOOS, V6, P17, DOI 10.2752/089279393787002367; Odendaal JSJ, 2000, J PSYCHOSOM RES, V49, P275, DOI 10.1016/S0022-3999(00)00183-5; OSTERLING J, 1994, J AUTISM DEV DISORD, V24, P247, DOI 10.1007/BF02172225; Osterling JA, 2002, DEV PSYCHOPATHOL, V14, P239, DOI 10.1017/S0954579402002031; Paul ES, 1996, APPL ANIM BEHAV SCI, V47, P17, DOI 10.1016/0168-1591(95)01007-6; Piaget J., 1962, PLAY DREAMS IMITATIO; Pierce K, 1997, J APPL BEHAV ANAL, V30, P157, DOI 10.1901/jaba.1997.30-157; Poresky RH, 1996, ANTHROZOOS, V9, P159, DOI 10.2752/089279396787001437; Poresky RH, 1989, COMPANION ANIMAL BON; Poulin-Dubois D, 2006, J COGN DEV, V7, P431, DOI 10.1207/s15327647jcd0704_1; RALLS K, 1985, CAN J ZOOL, V63, P1050, DOI 10.1139/z85-157; REDEFER LA, 1989, J AUTISM DEV DISORD, V19, P461, DOI 10.1007/BF02212943; ROGE B, 2009, ADAPTATION FRANCAISE; SALOMON A, 1981, CAN MENT HEALTH, V29, P9; Savage-Rumbaugh S., 1994, KANZI APE BRINK HUMA; SERPELL J, 1991, J ROY SOC MED, V84, P717, DOI 10.1177/014107689108401208; SIEGEL B, 1986, J AUTISM DEV DISORD, V16, P275, DOI 10.1007/BF01531660; Tager-Flusberg H, 2000, UNDERSTANDING LANGUA; Tager-Flusberg H, 2007, PEDIATR CLIN N AM, V54, P469, DOI 10.1016/j.pcl.2007.02.011; Tordjman S, 2001, MOL PSYCHIATR, V6, P434, DOI 10.1038/sj.mp.4000873; Travis LL, 1998, MENT RETARD DEV D R, V4, P65, DOI 10.1002/(SICI)1098-2779(1998)4:2<65::AID-MRDD2>3.0.CO;2-W; Triebenbacher SL, 1998, PSYCHOL REP, V82, P191, DOI 10.2466/PR0.82.1.191-200; Turner DC, 2003, ANTHROZOOS, V16, P213, DOI 10.2752/089279303786992143; WING L, 1979, J AUTISM DEV DISORD, V9, P11, DOI 10.1007/BF01531288; Wong HHL, 2006, J AUTISM DEV DISORD, V36, P901, DOI 10.1007/s10803-006-0131-0; World Health Organization, 1994, COMP INT DIAGN INT V	84	50	50	1	131	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2012	7	8							e41739	10.1371/journal.pone.0041739	http://dx.doi.org/10.1371/journal.pone.0041739			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	984SU	22870246	Green Published, Green Submitted, gold			2023-01-03	WOS:000307212800032
J	Guo, YM; Jiang, F; Peng, L; Zhang, J; Geng, FH; Xu, JM; Zhen, CM; Shen, XM; Tong, SL				Guo, Yuming; Jiang, Fan; Peng, Li; Zhang, Jun; Geng, Fuhai; Xu, Jianming; Zhen, Canming; Shen, Xiaoming; Tong, Shilu			The Association between Cold Spells and Pediatric Outpatient Visits for Asthma in Shanghai, China	PLOS ONE			English	Article							AIR-POLLUTION; CARDIOVASCULAR MORTALITY; LUNG-FUNCTION; TEMPERATURE; PREVALENCE; SYMPTOMS; CHILDREN; WEATHER; CLIMATE; IMPACT	Background: Asthma is a serious global health problem. However, few studies have investigated the relationship between cold spells and pediatric outpatient visits for asthma. Objective: To examine the association between cold spells and pediatric outpatient visits for asthma in Shanghai, China. Methods: We collected daily data on pediatric outpatient visits for asthma, mean temperature, relative humidity, and ozone from Shanghai between 1 January 2007 and 31 December 2009. We defined cold spells as four or more consecutive days with temperature below the 5th percentile of temperature during 2007-2009. We used a Poisson regression model to examine the impact of temperature on pediatric outpatient visits for asthma in cold seasons during 2007 and 2009. We examined the effect of cold spells on asthma compared with non-cold spell days. Results: There was a significant relationship between cold temperatures and pediatric outpatient visits for asthma. The cold effects on children's asthma were observed at different lags. The lower the temperatures, the higher the risk for asthma attacks among children. Conclusion: Cold temperatures, particularly cold spells, significantly increase the risk of pediatric outpatient visits for asthma. The findings suggest that asthma children need to be better protected from cold effects in winter.	[Guo, Yuming; Tong, Shilu] Queensland Univ Technol, Sch Publ Hlth, Brisbane, Qld 4001, Australia; [Guo, Yuming; Tong, Shilu] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia; [Jiang, Fan; Shen, Xiaoming] Shanghai Jiao Tong Univ, Shanghai Inst Pediat Translat Med, Dept Dev & Behav Pediat, Shanghai Childrens Med Ctr,Sch Med, Shanghai 200030, Peoples R China; [Jiang, Fan; Zhang, Jun; Shen, Xiaoming] Shanghai Jiao Tong Univ, Shanghai Key Lab Childrens Environm Hlth, Xinhua Hosp, Minist Educ,Sch Med, Shanghai 200030, Peoples R China; [Peng, Li; Geng, Fuhai; Xu, Jianming; Zhen, Canming] Shanghai Meteorol Bur, Shanghai, Peoples R China	Queensland University of Technology (QUT); Queensland University of Technology (QUT); Shanghai Jiao Tong University; Shanghai Jiao Tong University	Guo, YM (corresponding author), Queensland Univ Technol, Sch Publ Hlth, Brisbane, Qld 4001, Australia.	xmshen@shsmu.edu.cn; s.tong@qut.edu.au	Guo, Yuming/I-8353-2018; Jiang, Fan/AHA-6297-2022; Jiang, Fan/AGX-9052-2022	Guo, Yuming/0000-0002-1766-6592; Jiang, Fan/0000-0003-0634-101X	Shanghai Science and Technology Committee [10231203903]; MOE-Shanghai Key Laboratory of Children's Environmental Health [10DZ2272200]; QUT Postgraduate Research Award (QUTPRA); NHMRC Research Fellowship [553043]	Shanghai Science and Technology Committee(Shanghai Science & Technology Committee); MOE-Shanghai Key Laboratory of Children's Environmental Health; QUT Postgraduate Research Award (QUTPRA); NHMRC Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	This work is supported by Shanghai Science and Technology Committee (10231203903), MOE-Shanghai Key Laboratory of Children's Environmental Health (10DZ2272200). YG is supported by the QUT Postgraduate Research Award (QUTPRA); ST is supported by a NHMRC Research Fellowship (#553043). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe T, 2009, AM J EMERG MED, V27, P153, DOI 10.1016/j.ajem.2008.01.013; Andersen ZJ, 2011, THORAX; Anderson BG, 2009, EPIDEMIOLOGY, V20, P205, DOI 10.1097/EDE.0b013e318190ee08; [Anonymous], 2001, R R NEWS; BATES DV, 1995, ENVIRON HEALTH PERSP, V103, P49, DOI 10.2307/3432345; Donaldson GC, 1999, EUR RESPIR J, V13, P844, DOI 10.1034/j.1399-3003.1999.13d25.x; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Epton MJ, 1997, THORAX, V52, P528, DOI 10.1136/thx.52.6.528; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Goodman PG, 2004, ENVIRON HEALTH PERSP, V112, P179, DOI 10.1289/ehp.6451; Guo YM, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-36; Guo YM, 2011, ENVIRON HEALTH PERSP, V119, P1719, DOI 10.1289/ehp.1103598; Guo YM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016511; Guo YM, 2010, SCI TOTAL ENVIRON, V409, P300, DOI 10.1016/j.scitotenv.2010.10.013; Hales S, 1998, ENVIRON HEALTH PERSP, V106, P607, DOI 10.2307/3434236; Harju T, 2010, CLIN RESPIR J, V4, P176, DOI 10.1111/j.1752-699X.2009.00172.x; Huynen MMTE, 2001, ENVIRON HEALTH PERSP, V109, P463, DOI 10.2307/3454704; Hwang BF, 2005, THORAX, V60, P467, DOI 10.1136/thx.2004.033977; Islam T, 2007, THORAX, V62, P957, DOI 10.1136/thx.2007.078964; Khadadah M, 2011, EUROPEAN J APPL PHYS, P1; Knowlton K, 2009, ENVIRON HEALTH PERSP, V117, P61, DOI 10.1289/ehp.11594; Kysely J, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-19; Larsson K, 1998, EUR RESPIR J, V12, P825, DOI 10.1183/09031936.98.12040825; Lee YL, 2003, EUR RESPIR J, V21, P964, DOI 10.1183/09031936.03.00094602; Li M, 2011, J ALLERGY CLIN IMMUN, V128; Lin S, 2009, EPIDEMIOLOGY, V20, P738, DOI 10.1097/EDE.0b013e3181ad5522; Ma W, 2012, INT J BIOMETEOROLOGY; Makinen TM, 2009, RESP MED, V103, P456, DOI 10.1016/j.rmed.2008.09.011; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Mortimer KM, 2002, EUR RESPIR J, V19, P699, DOI 10.1183/09031936.02.00247102; O'Neill MS, 2003, AM J EPIDEMIOL, V157, P1074, DOI 10.1093/aje/kwg096; Pattenden S, 2003, J EPIDEMIOL COMMUN H, V57, P628, DOI 10.1136/jech.57.8.628; Ren C, 2008, OCCUP ENVIRON MED, V65, P255, DOI 10.1136/oem.2007.033878; Rosas I, 1998, ALLERGY, V53, P394, DOI 10.1111/j.1398-9995.1998.tb03911.x; ROSSI OVJ, 1993, THORAX, V48, P244, DOI 10.1136/thx.48.3.244; Shanghai Statistic Bureau, 2010, 6 NAT POP CENS SHANG; Tatum AJ, 2005, IMMUNOL ALLERGY CLIN, V25, P15, DOI 10.1016/j.iac.2004.09.003; Tong SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037500; Wong GWK, 2004, BMJ-BRIT MED J, V329, P486, DOI 10.1136/bmj.329.7464.486; Ye XF, 2012, ENVIRON HEALTH PERSP, V120, P19, DOI [10.1289/ehp.1003198, 10.1289/ehp.120-a19]	40	57	61	1	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2012	7	7							e42232	10.1371/journal.pone.0042232	http://dx.doi.org/10.1371/journal.pone.0042232			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979GX	22848748	Green Published, gold, Green Submitted			2023-01-03	WOS:000306806600174
J	Kipp, W; Konde-Lule, J; Saunders, LD; Alibhai, A; Houston, S; Rubaale, T; Senthilselvan, A; Okech-Ojony, J				Kipp, Walter; Konde-Lule, Joseph; Saunders, L. Duncan; Alibhai, Arif; Houston, Stan; Rubaale, Tom; Senthilselvan, Ambikaipakan; Okech-Ojony, Joa			Antiretroviral Treatment for HIV in Rural Uganda: Two-Year Treatment Outcomes of a Prospective Health Centre/Community-Based and Hospital-Based Cohort	PLOS ONE			English	Article							VIROLOGICAL FAILURE; DRUG-THERAPY; CARE MODEL; PROGRAM; PREDICTORS; HIV/AIDS; ADULTS	Background: In sub-Saharan Africa, a shortage of trained health professionals and limited geographical access to health facilities present major barriers to the expansion of antiretroviral therapy (ART). We tested the utility of a health centre (HC)/community-based approach in the provision of ART to persons living with HIV in a rural area in western Uganda. Methods: The HIV treatment outcomes of the HC/community-based ART program were evaluated and compared with those of an ART program at a best-practice regional hospital. The HC/community-based cohort comprised 185 treatment-naive patients enrolled in 2006. The hospital cohort comprised of 200 patients enrolled in the same time period. The HC/community-based program involved weekly home visits to patients by community volunteers who were trained to deliver antiretroviral drugs to monitor and support adherence to treatment, and to identify and report adverse reactions and other clinical symptoms. Treatment supporters in the homes also had the responsibility to remind patients to take their drugs regularly. ART treatment outcomes were measured by HIV-1 RNA viral load (VL) after two years of treatment. Adherence was determined through weekly pill counts. Results: Successful ART treatment outcomes in the HC/community-based cohort were equivalent to those in the hospital-based cohort after two years of treatment in on-treatment analysis (VL <= 400 copies/mL, 93.0% vs. 87.3%, p = 0.12), and in intention-to-treat analysis (VL <= 400 copies/mL, 64.9% and 62.0%, p = 0.560). In multivariate analysis patients in the HC/community-based cohort were more likely to have virologic suppression compared to hospital-based patients (adjusted OR = 2.47, 95% CI 1.01-6.04). Conclusion: Acceptable rates of virologic suppression were achieved using existing rural clinic and community resources in a HC/community-based ART program run by clinical officers and supported by lay volunteers and treatment supporters. The results were equivalent to those of a hospital-based ART program run primarily by doctors.	[Kipp, Walter; Saunders, L. Duncan; Alibhai, Arif; Senthilselvan, Ambikaipakan] Univ Alberta, Sch Publ Hlth, Dept Publ Hlth Sci, Edmonton, AB, Canada; [Konde-Lule, Joseph] Makerere Univ, Dept Epidemiol & Biostat, Sch Publ Hlth, Kampala, Uganda; [Houston, Stan] Univ Alberta, Dept Med, Fac Med, Edmonton, AB, Canada; [Rubaale, Tom; Okech-Ojony, Joa] Kabarole Dist Hlth Dept, Ft Portal, Uganda	University of Alberta; Makerere University; University of Alberta	Kipp, W (corresponding author), Univ Alberta, Sch Publ Hlth, Dept Publ Hlth Sci, Edmonton, AB, Canada.	walter.kipp@ualberta.ca			Canadian Institutes of Health Research (CIHR) [MOP-74586]	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	The study was financed by the Canadian Institutes of Health Research (CIHR) through grant no. MOP-74586. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barnighausen T, 2007, AIDS PATIENT CARE ST, V21, P799, DOI 10.1089/apc.2007.0193; Chang LVW, 2009, JAIDS-J ACQ IMM DEF, V50, P276, DOI 10.1097/QAI.0b013e3181988375; Chen SCC, 2008, TROP MED INT HEALTH, V13, P513, DOI 10.1111/j.1365-3156.2008.02029.x; Coetzee D, 2004, AIDS, V18, P887, DOI 10.1097/00002030-200404090-00006; Cohen J., 2013, STAT POWER ANAL BEHA; Duff P, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-37; Hladik W, 2008, AIDS, V22, P503, DOI 10.1097/QAD.0b013e3282f470be; Jaffar S, 2009, LANCET, V374, P2080, DOI 10.1016/S0140-6736(09)61674-3; Joint United Nations Programme on HIV/AIDS, 2008, AIDS SCOR UNAIDS REP; Kabugo C, 2005, JAIDS-J ACQ IMM DEF, V38, P578, DOI 10.1097/01.qai.0000134742.26338.2f; Kaleebu P, 2006, AIDS, V20, P1391, DOI 10.1097/01.aids.0000233572.59522.45; Kamya MR, 2007, JAIDS-J ACQ IMM DEF, V46, P187, DOI 10.1097/QAI.0b013e31814278c0; Kipp W, 2010, CURR HIV RES, V8, P179, DOI 10.2174/157016210790442722; Ministry of Health and ORC Macro, 2006, UG HIV AIDS SER SURV; Munoz M, 2010, AIDS BEHAV, V14, P721, DOI 10.1007/s10461-009-9559-5; Paris D, 1999, AIDS RES HUM RETROV, V15, P1631, DOI 10.1089/088922299309676; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; StataCorp, 2005, STAT SOFTW REL 9; Weidle PJ, 2002, LANCET, V360, P34, DOI 10.1016/S0140-6736(02)09330-3; Wringe A, 2010, HEALTH POLICY PLANN, V25, P352, DOI 10.1093/heapol/czq005	20	34	36	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2012	7	7							e40902	10.1371/journal.pone.0040902	http://dx.doi.org/10.1371/journal.pone.0040902			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	975JG	22815862	Green Published, Green Submitted, gold			2023-01-03	WOS:000306507000040
J	McMahon, FJ; Insel, TR				McMahon, Francis J.; Insel, Thomas R.			Pharmacogenomics and Personalized Medicine in Neuropsychiatry	NEURON			English	Editorial Material							ANTIDEPRESSANT; POLYMORPHISMS		[McMahon, Francis J.] NIH, Human Genet Branch, Intramural Res Program, US Dept HHS, Bethesda, MD 20892 USA; [Insel, Thomas R.] NIMH, Off Director, NIH, US Dept HHS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	McMahon, FJ (corresponding author), NIH, Human Genet Branch, Intramural Res Program, US Dept HHS, Bldg 10, Bethesda, MD 20892 USA.	mcmahonf@mail.nih.gov	McMahon, Francis J/A-7290-2009	McMahon, Francis J/0000-0002-9469-305X	Intramural NIH HHS [ZIA MH002844-08] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002844] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bainbridge MN, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002243; Berg AO, 2007, GENET MED, V9, P819, DOI 10.1097/GIM.0b013e31815bf9a3; Binder EB, 2004, NAT GENET, V36, P1319, DOI 10.1038/ng1479; Black JL, 2007, EXPERT OPIN DRUG MET, V3, P21, DOI 10.1517/17425255.3.1.21; Carlquist JF, 2011, CIRCULATION, V124, P2554, DOI 10.1161/CIRCULATIONAHA.111.019737; Chowdhury NI, 2011, CURR PSYCHIAT REP, V13, P156, DOI 10.1007/s11920-011-0185-3; Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a; Committee on a Framework for Developing a New Taxonomy of Disease; National Research Council, 2011, PREC MED BUILD KNOWL; Feero WG, 2010, NEW ENGL J MED, V362, P2001, DOI 10.1056/NEJMra0907175; Hyman SE, 2003, SCIENCE, V299, P350, DOI 10.1126/science.1077141; Khoury MJ, 2010, GENET MED, V12, P680, DOI 10.1097/GIM.0b013e3181f9ad55; MacArthur DG, 2012, SCIENCE, V335, P823, DOI 10.1126/science.1215040; Malhotra D, 2012, CELL, V148, P1223, DOI 10.1016/j.cell.2012.02.039; McMahon FJ, 2006, AM J HUM GENET, V78, P804, DOI 10.1086/503820; Munos B, 2009, NAT REV DRUG DISCOV, V8, P959, DOI 10.1038/nrd2961; Ramsey BW, 2011, NEW ENGL J MED, V365, P1663, DOI 10.1056/NEJMoa1105185; Rembold CM, 1998, BMJ-BRIT MED J, V317, P307, DOI 10.1136/bmj.317.7154.307; Taylor MJ, 2010, BIOL PSYCHIAT, V68, P536, DOI 10.1016/j.biopsych.2010.04.034; Uhr M, 2008, NEURON, V57, P203, DOI 10.1016/j.neuron.2007.11.017; Winner JG, 2010, ACAD PSYCHIATR, V34, P115, DOI 10.1176/appi.ap.34.2.115	20	51	53	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	JUN 7	2012	74	5					773	776		10.1016/j.neuron.2012.05.004	http://dx.doi.org/10.1016/j.neuron.2012.05.004			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	957YQ	22681682	Green Accepted, Bronze			2023-01-03	WOS:000305203400004
J	Barbe, F; Duran-Cantolla, J; Sanchez-de-la-Torre, M; Martinez-Alonso, M; Carmona, C; Barcelo, A; Chiner, E; Masa, JF; Gonzalez, M; Marin, JM; Garcia-Rio, F; de Atauri, JD; Teran, J; Mayos, M; de la Pena, M; Monasterio, C; del Campo, F; Montserrat, JM				Barbe, Ferran; Duran-Cantolla, Joaquin; Sanchez-de-la-Torre, Manuel; Martinez-Alonso, Montserrat; Carmona, Carmen; Barcelo, Antonia; Chiner, Eusebi; Masa, Juan F.; Gonzalez, Monica; Marin, Jose M.; Garcia-Rio, Francisco; Diaz de Atauri, Josefa; Teran, Joaquin; Mayos, Mercedes; de la Pena, Mnica; Monasterio, Carmen; del Campo, Felix; Montserrat, Josep M.		Spanish Sleep Breathing Network	Effect of Continuous Positive Airway Pressure on the Incidence of Hypertension and Cardiovascular Events in Nonsleepy Patients With Obstructive Sleep Apnea A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-PRESSURE; HYPOPNEA; MORTALITY; DISEASE; IMPACT; RISK; METAANALYSIS; ASSOCIATION; OUTCOMES; THERAPY	Context Continuous positive airway pressure (CPAP) is the first-line treatment for patients with symptomatic obstructive sleep apnea (OSA). However, its indication for all patients with sleep-disordered breathing, regardless of daytime symptoms, is unclear. Objective To evaluate the effect of CPAP treatment on the incidence of hypertension or cardiovascular events in a cohort of nonsleepy patients with OSA. Design, Setting, and Patients Multicenter, parallel-group, randomized controlled trial in 14 teaching hospitals in Spain. Between May 2004 and May 2006, 725 consecutive patients were enrolled who had an apnea-hypopnea index of 20 h(-1) or greater and an Epworth Sleepiness Scale score of 10 or less (scores range from 0-24, with values <10 suggesting no daytime sleepiness). Exclusion criteria were previous cardiovascular event, physical or psychological incapacity, chronic disease, or drug or alcohol addiction. Follow-up ended in May 2009. Intervention Patients were allocated to receive CPAP treatment or no active intervention. All participants received dietary counseling and sleep hygiene advice. Main Outcome Measures Incidence of either systemic hypertension (taking antihypertensive medication or blood pressure greater than 140/90 mm Hg) or cardiovascular event (nonfatal myocardial infarction, nonfatal stroke, transient ischemic attack, hospitalization for unstable angina or arrhythmia, heart failure, or cardiovascular death). Results Seven hundred twenty-three patients underwent follow-up for a median of 4 (interquartile range, 2.7-4.4) years (1 patient from each group did not receive allocated treatment); 357 in the CPAP group and 366 in the control group were included in the analysis. In the CPAP group there were 68 patients with new hypertension and 28 cardiovascular events (17 unstable angina or arrhythmia, 3 nonfatal stroke, 3 heart failure, 2 nonfatal myocardial infarction, 2 transient ischemic attack, 1 cardiovascular death). In the control group there were 79 patients with new hypertension and 31 cardiovascular events (11 unstable angina or arrhythmia, 8 nonfatal myocardial infarction, 5 transient ischemic attack, 5 heart failure, 2 nonfatal stroke). The hypertension or cardiovascular event incidence density rate was 9.20 per 100 person-years (95% CI, 7.36-11.04) in the CPAP group and 11.02 per 100 person-years (95% CI, 8.96-13.08) in the control group. The incidence density ratio was 0.83 (95% CI, 0.63-1.1; P=.20). Conclusions In patients with OSA without daytime sleepiness, the prescription of CPAP compared with usual care did not result in a statistically significant reduction in the incidence of hypertension or cardiovascular events. However, the study may have had limited power to detect a significant difference.	[Barbe, Ferran] Hosp Arnau Vilanova, Resp Dept, IRB Lleida, Lleida 25198, Spain; [Duran-Cantolla, Joaquin] Hosp Univ Alava, Vitoria, Spain; [Carmona, Carmen] Hosp Virgen Rocio, Seville, Spain; [Barcelo, Antonia; de la Pena, Mnica] Hosp Univ Son Dureta, Palma de Mallorca, Spain; [Chiner, Eusebi] Hosp Sant Joan, Alacant, Spain; [Masa, Juan F.] Hosp San Pedro Alacantara Hosp, Caceres, Spain; [Gonzalez, Monica] Hosp Marques Valdecilla, Santander, Spain; [Marin, Jose M.] Hosp Miguel Servet, Zaragoza, Spain; [Garcia-Rio, Francisco] Hosp Univ La Paz IdiPAZ, Madrid, Spain; [Diaz de Atauri, Josefa] Hosp 12 Octubre, E-28041 Madrid, Spain; [Teran, Joaquin] Hosp Gen Yague, Burgos, Spain; [Mayos, Mercedes] Hosp Santa Creu & Sant Pau, Barcelona, Spain; [Monasterio, Carmen] Hosp Bellvitge Princeps Espanya, Barcelona, Spain; [Monasterio, Carmen] Hosp Clin Barcelona, Barcelona, Spain; CIBERes, Madrid, Spain	University Hospital Arnau de Vilanova; University Hospital of Araba; Virgen del Rocio University Hospital; Hospital Universitari Son Espases; Hospital Universitari Son Dureta; Hospital Universitario Marques de Valdecilla (HUMV); Miguel Servet University Hospital; Hospital Universitario La Paz; Hospital Universitario 12 de Octubre; Hospital General Yague; Hospital of Santa Creu i Sant Pau; University of Barcelona; Hospital Clinic de Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERES	Barbe, F (corresponding author), Hosp Arnau Vilanova, Resp Dept, IRB Lleida, Rovira Roure 80, Lleida 25198, Spain.	fbarbe@arnau.scs.es	del campo, Felix/G-5716-2017; de la Torre, Manuel Sanchez/B-5578-2009; GONZALEZ, MONICA/AAM-4033-2021; Sánchez-de-la-Torre, Manuel/AAC-9514-2022; Barbé, Ferran/A-5988-2010; del Campo, Felix/H-5601-2016; Martínez-Alonso, Montserrat/B-5582-2009; Garcia-Rio, Francisco/AAC-9981-2020; Caballero Eraso, Candela/F-1455-2015; Cantolla, Joaquin Duran/B-6996-2015; Sanchez-de-la-Torre, Manuel/AAP-2663-2020; Carmona-Bernal, Carmen/C-9429-2015; Garin, Intza/J-4500-2012; IBIS, SUEÑO/I-2520-2016; Capote, Francisco/E-9954-2015; Mediano, Olga/AAZ-2784-2021; Chiner, Eusebi/AAM-5120-2020; Salord Oleo, Neus/AGI-6933-2022	del campo, Felix/0000-0002-4554-2167; de la Torre, Manuel Sanchez/0000-0002-5695-348X; GONZALEZ, MONICA/0000-0003-1516-0181; Barbé, Ferran/0000-0002-2340-8928; del Campo, Felix/0000-0002-4554-2167; Martínez-Alonso, Montserrat/0000-0003-1504-8552; Sanchez-de-la-Torre, Manuel/0000-0002-5695-348X; Mediano, Olga/0000-0001-7824-1523; Salord Oleo, Neus/0000-0002-8384-0878; de la Pena, Monica/0000-0003-3276-776X; MONTSERRAT, Josep Maria/0000-0003-3098-4605; Marin Trigo, Jose Maria/0000-0001-9096-2294; monasterio ponsa, carmen/0000-0002-6142-0565; Barcelo Bennasar, Antonia/0000-0002-3170-5439; Garcia-Rio, Francisco/0000-0002-7227-2238	Instituto de Salud Carlos III [PI 04/0165]; Fondo de Investigaciones Sanitarios, Ministerio de Sanidad y Consumo, Spain; Spanish Respiratory Society (SEPAR) (Barcelona); Resmed (Bella Vista, Australia); Air Products-Carburos Metalicos (Barcelona); Respironics (Murrysville, Pennsylvania); Breas Medical (Madrid, Spain)	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Fondo de Investigaciones Sanitarios, Ministerio de Sanidad y Consumo, Spain; Spanish Respiratory Society (SEPAR) (Barcelona); Resmed (Bella Vista, Australia); Air Products-Carburos Metalicos (Barcelona); Respironics (Murrysville, Pennsylvania); Breas Medical (Madrid, Spain)	This study was funded by the Instituto de Salud Carlos III (PI 04/0165) (Fondo de Investigaciones Sanitarios, Ministerio de Sanidad y Consumo, Spain), Spanish Respiratory Society (SEPAR) (Barcelona), Resmed (Bella Vista, Australia), Air Products-Carburos Metalicos (Barcelona), Respironics (Murrysville, Pennsylvania), and Breas Medical (Madrid, Spain).	Alajmi M, 2007, LUNG, V185, P67, DOI 10.1007/s00408-006-0117-x; Barbe F, 2001, ANN INTERN MED, V134, P1015, DOI 10.7326/0003-4819-134-11-200106050-00007; Barbe F, 2010, AM J RESP CRIT CARE, V181, P718, DOI 10.1164/rccm.200901-0050OC; Bazzano LA, 2007, HYPERTENSION, V50, P417, DOI 10.1161/HYPERTENSIONAHA.106.085175; Buchner NJ, 2007, AM J RESP CRIT CARE, V176, P1274, DOI 10.1164/rccm.200611-1588OC; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Doherty LS, 2005, CHEST, V127, P2076, DOI 10.1378/chest.127.6.2076; Duran J, 2001, AM J RESP CRIT CARE, V163, P685, DOI 10.1164/ajrccm.163.3.2005065; Duran-Cantolla J, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5991; Duran-Cantolla J, 2009, SLEEP MED REV, V13, P323, DOI 10.1016/j.smrv.2008.11.001; Giles TL, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001106.pub3; Gottlieb DJ, 2010, CIRCULATION, V122, P352, DOI 10.1161/CIRCULATIONAHA.109.901801; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Haentjens P, 2007, ARCH INTERN MED, V167, P757, DOI 10.1001/archinte.167.8.757; Hedner J, 2001, AM J RESP CRIT CARE, V163, P5, DOI 10.1164/ajrccm.163.1.ed1400d; Kohler M, 2008, EUR RESPIR J, V32, P1488, DOI 10.1183/09031936.00026608; LAVIE P, 1995, SLEEP, V18, P149, DOI 10.1093/sleep/18.3.149; Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7; Marti S, 2002, EUR RESPIR J, V20, P1511, DOI 10.1183/09031936.02.00306502; Masa JF, 2004, AM J RESP CRIT CARE, V170, P1218, DOI 10.1164/rccm.200312-1787OC; McDaid C, 2009, SLEEP MED REV, V13, P427, DOI 10.1016/j.smrv.2009.02.004; Mo Li, 2007, Zhonghua Yi Xue Za Zhi, V87, P1177; Montserrat JM, 2001, AM J RESP CRIT CARE, V164, P608, DOI 10.1164/ajrccm.164.4.2006034; Nieto FJ, 2000, JAMA-J AM MED ASSOC, V283, P1829, DOI 10.1001/jama.283.14.1829; Peker Y, 2002, AM J RESP CRIT CARE, V166, P159, DOI 10.1164/rccm.2105124; Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901; Punjabi Naresh M, 2008, Proc Am Thorac Soc, V5, P136, DOI 10.1513/pats.200709-155MG; Redline S, 2010, AM J RESP CRIT CARE, V182, P269, DOI 10.1164/rccm.200911-1746OC; Robinson GV, 2006, EUR RESPIR J, V27, P1229, DOI 10.1183/09031936.06.00062805; Rutledge T, 2000, J HYPERTENS, V18, P153, DOI 10.1097/00004872-200018020-00004; Whelton PK, 1998, JAMA-J AM MED ASSOC, V279, P839, DOI 10.1001/jama.279.11.839; Yaggi HK, 2005, NEW ENGL J MED, V353, P2034, DOI 10.1056/NEJMoa043104; Young T, 2008, SLEEP, V31, P1071	33	534	551	2	68	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 23	2012	307	20					2161	2168		10.1001/jama.2012.4366	http://dx.doi.org/10.1001/jama.2012.4366			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	945YX	22618923	Green Published, Bronze			2023-01-03	WOS:000304315200025
J	Smith, CC; Wang, Q; Chin, CS; Salerno, S; Damon, LE; Levis, MJ; Perl, AE; Travers, KJ; Wang, S; Hunt, JP; Zarrinkar, PP; Schadt, EE; Kasarskis, A; Kuriyan, J; Shah, NP				Smith, Catherine C.; Wang, Qi; Chin, Chen-Shan; Salerno, Sara; Damon, Lauren E.; Levis, Mark J.; Perl, Alexander E.; Travers, Kevin J.; Wang, Susana; Hunt, Jeremy P.; Zarrinkar, Patrick P.; Schadt, Eric E.; Kasarskis, Andrew; Kuriyan, John; Shah, Neil P.			Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia	NATURE			English	Article							TYROSINE KINASE DOMAIN; MYELODYSPLASTIC SYNDROME; CRYSTAL-STRUCTURE; INSULIN-RECEPTOR; STRUCTURAL BASIS; BCR-ABL; RESISTANCE; INHIBITOR; AUTOINHIBITION; ACTIVATION	Effective targeted cancer therapeutic development depends upon distinguishing disease-associated 'driver' mutations, which have causative roles in malignancy pathogenesis, from 'passenger' mutations, which are dispensable for cancer initiation and maintenance. Translational studies of clinically active targeted therapeutics can definitively discriminate driver from passenger lesions and provide valuable insights into human cancer biology. Activating internal tandem duplication (ITD) mutations in FLT3 (FLT3-ITD) are detected in approximately 20% of acute myeloid leukaemia (AML) patients and are associated with a poor prognosis(1). Abundant scientific(2) and clinical evidence(1,3), including the lack of convincing clinical activity of early FLT3 inhibitors(4,5), suggests that FLT3-ITD probably represents a passenger lesion. Here we report point mutations at three residues within the kinase domain of FLT3-ITD that confer substantial in vitro resistance to AC220 (quizartinib), an active investigational inhibitor of FLT3, KIT, PDGFRA, PDGFRB and RET6,7; evolution of AC220-resistant substitutions at two of these amino acid positions was observed in eight of eight FLT3-ITD-positive AML patients with acquired resistance to AC220. Our findings demonstrate that FLT3-ITD can represent a driver lesion and valid therapeutic target in human AML. AC220-resistant FLT3 kinase domain mutants represent high-value targets for future FLT3 inhibitor development efforts.	[Smith, Catherine C.; Salerno, Sara; Damon, Lauren E.; Shah, Neil P.] Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA 94143 USA; [Wang, Qi; Kuriyan, John] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; [Chin, Chen-Shan; Travers, Kevin J.; Wang, Susana; Schadt, Eric E.; Kasarskis, Andrew] Pacific Biosci, Menlo Pk, CA 94025 USA; [Levis, Mark J.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Dept Oncol, Baltimore, MD 21231 USA; [Perl, Alexander E.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Hunt, Jeremy P.; Zarrinkar, Patrick P.] Ambit Biosci, San Diego, CA 92121 USA; [Shah, Neil P.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; University of California System; University of California Berkeley; Johns Hopkins University; Johns Hopkins Medicine; University of Pennsylvania; Pennsylvania Medicine; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Shah, NP (corresponding author), Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA 94143 USA.	nshah@medicine.ucsf.edu	Wang, Qi/H-9399-2012	Wang, Qi/0000-0002-9703-1676	Leukemia and Lymphoma Society; Doris Duke Charitable Foundation; NCI Leukemia SPORE [P50 CA100632-06]; NCI [R01 CA12886]; NIH; Art and Alison Kern and the Edward S. Ageno family; NATIONAL CANCER INSTITUTE [P50CA100632, R01CA166616, R01CA128864] Funding Source: NIH RePORTER	Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); NCI Leukemia SPORE; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Art and Alison Kern and the Edward S. Ageno family; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank K. Lin for technical assistance. This work was funded by grants from the Leukemia and Lymphoma Society (to C.C.S. and N.P.S.), the Doris Duke Charitable Foundation (to N.P.S.), NCI Leukemia SPORE P50 CA100632-06 (to M.J.L.), NCI R01 CA12886 (to M.J.L.) and the NIH T-32 Molecular Mechanisms of Cancer (to C.C.S.). C.C.S. would like to acknowledge the EHA/ASH Translational Research Training Institute. N.P.S. would like to thank Art and Alison Kern and the Edward S. Ageno family for their support.	Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650; Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Barbie David A, 2006, Clin Adv Hematol Oncol, V4, P768; BARNARD GA, 1990, STAT MED, V9, P601, DOI 10.1002/sim.4780090606; Benson G, 1999, NUCLEIC ACIDS RES, V27, P573, DOI 10.1093/nar/27.2.573; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; Choudhary C, 2007, BLOOD, V110, P370, DOI 10.1182/blood-2006-05-024018; Cortes J., 2011, 16 C EUR HEM ASS HAE; Fischer T, 2010, J CLIN ONCOL, V28, P4339, DOI 10.1200/JCO.2010.28.9678; Griffith J, 2004, MOL CELL, V13, P169, DOI 10.1016/S1097-2765(03)00505-7; Heidel F, 2006, BLOOD, V107, P293, DOI 10.1182/blood-2005-06-2469; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Knapper S, 2006, BLOOD, V108, P3262, DOI 10.1182/blood-2006-04-015560; Kralovics R, 2006, BLOOD, V108, P1377, DOI 10.1182/blood-2005-11-009605; Lee BH, 2005, ONCOGENE, V24, P7882, DOI 10.1038/sj.onc.1208933; Levinson NM, 2006, PLOS BIOL, V4, P753, DOI 10.1371/journal.pbio.0040144; Metzelder S, 2009, BLOOD, V113, P6567, DOI 10.1182/blood-2009-03-208298; Mol CD, 2003, J BIOL CHEM, V278, P31461, DOI 10.1074/jbc.C300186200; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Scholl S, 2011, ANN HEMATOL, V90, P473, DOI 10.1007/s00277-010-1027-9; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Shih LY, 2004, LEUKEMIA, V18, P466, DOI 10.1038/sj.leu.2403274; Thiede C, 2002, BLOOD, V99, P4326, DOI 10.1182/blood.V99.12.4326; Travers KJ, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq543; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wodicka LM, 2010, CHEM BIOL, V17, P1241, DOI 10.1016/j.chembiol.2010.09.010; YATES F, 1984, J ROY STAT SOC A STA, V147, P426, DOI 10.2307/2981577; Zarrinkar PP, 2009, BLOOD, V114, P2984, DOI 10.1182/blood-2009-05-222034	33	528	558	4	117	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 10	2012	485	7397					260	U153		10.1038/nature11016	http://dx.doi.org/10.1038/nature11016			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	939HJ	22504184	Green Accepted			2023-01-03	WOS:000303799800046
J	Higa, JK; Liang, ZB; Williams, PG; Panee, J				Higa, Jason K.; Liang, Zhibin; Williams, Philip G.; Panee, Jun			Phyllostachys edulis Compounds Inhibit Palmitic Acid-Induced Monocyte Chemoattractant Protein 1 (MCP-1) Production	PLOS ONE			English	Article							NF-KAPPA-B; INSULIN-RESISTANCE; ADIPOSE-TISSUE; BAMBOO EXTRACT; MACROPHAGE ACCUMULATION; INFLAMMATORY DISEASES; LETHEDON-TANNAENSIS; GENE-EXPRESSION; VAR.-HENONIS; IN-VITRO	Background: Phyllostachys edulis Carriere (Poaceae) is a bamboo species that is part of the traditional Chinese medicine pharmacopoeia. Compounds and extracts from this species have shown potential applications towards several diseases. One of many complications found in obesity and diabetes is the link between elevated circulatory free fatty acids (FFAs) and chronic inflammation. This study aims to present a possible application of P. edulis extract in relieving inflammation caused by FFAs. Monocyte chemoattractant protein 1 (MCP-1/CCL2) is a pro-inflammatory cytokine implicated in chronic inflammation. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B) and activator protein 1 (AP-1) are transcription factors activated in response to inflammatory stimuli, and upregulate pro-inflammatory cytokines such as MCP-1. This study examines the effect of P. edulis extract on cellular production of MCP-1 and on the NF-kappa B and AP-1 pathways in response to treatment with palmitic acid (PA), a FFA. Methodology/Principal Findings: MCP-1 protein was measured by cytometric bead assay. NF-kappa B and AP-1 nuclear localization was detected by colorimetric DNA-binding ELISA. Relative MCP-1 mRNA was measured by real-time quantitative PCR. Murine cells were treated with PA to induce inflammation. PA increased expression of MCP-1 mRNA and protein, and increased nuclear localization of NF-kappa B and AP-1. Adding bamboo extract (BEX) inhibited the effects of PA, reduced MCP-1 production, and inhibited nuclear translocation of NF-kappa B and AP-1 subunits. Compounds isolated from BEX inhibited MCP-1 secretion with different potencies. Conclusions/Significance: PA induced MCP-1 production in murine adipose, muscle, and liver cells. BEX ameliorated PA-induced production of MCP-1 by inhibiting nuclear translocation of NF-kappa B and AP-1. Two O-methylated flavones were isolated from BEX with functional effects on MCP-1 production. These results may represent a possible therapeutic application of BEX and its compounds toward alleviating chronic inflammation caused by elevated circulatory FFAs.	[Higa, Jason K.; Panee, Jun] Univ Hawaii, John A Burns Sch Med, Dept Cell & Mol Biol, Honolulu, HI 96822 USA; [Liang, Zhibin; Williams, Philip G.] Univ Hawaii Manoa, Dept Chem, Honolulu, HI 96822 USA	University of Hawaii System; University of Hawaii System; University of Hawaii Manoa	Panee, J (corresponding author), Univ Hawaii, John A Burns Sch Med, Dept Cell & Mol Biol, Honolulu, HI 96822 USA.	junchen@hawaii.edu	Liang, Zhibin/B-9783-2015	Liang, Zhibin/0000-0002-8855-1696; Higa, Jason Kenji/0000-0002-0429-6254; Williams, Philip/0000-0001-8987-0683	National Center for Complementary and Alternative Medicine (NCCAM) [R21 AT003874, R21 AT005139]; National Center for Research Resources [U54RR022762, 5 G12 RR003061, 5P20RR016467-11]; National Institute on Minority Health and Health Disparities from the National Institutes of Health [8 G12 MD007601]; National Institute of General Medical Sciences from the National Institutes of Health [8 P20 GMI 03466-11]; National Center on Minority Health and Health Disparities (NCMHD) [5P20 MD000173-08]; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT005139, R21AT003874] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016467, G12RR003061, U54RR022762] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [U54MD007584, G12MD007601, P20MD000173] Funding Source: NIH RePORTER	National Center for Complementary and Alternative Medicine (NCCAM)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institute on Minority Health and Health Disparities from the National Institutes of Health; National Institute of General Medical Sciences from the National Institutes of Health(General Electric); National Center on Minority Health and Health Disparities (NCMHD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	This work was supported by grants R21 AT003874 (Panee) and R21 AT005139 (Panee) from the National Center for Complementary and Alternative Medicine (NCCAM); grant U54RR022762 (RTRN Small Grant Program) from the National Center for Research Resources; grants from the National Center for Research Resources (5 G12 RR003061) and the National Institute on Minority Health and Health Disparities (8 G12 MD007601) from the National Institutes of Health; grants from the National Center for Research Resources (5P20RR016467-11) and the National Institute of General Medical Sciences (8 P20 GMI 03466-11) from the National Institutes of Health; and grant 5P20 MD000173-08 from National Center on Minority Health and Health Disparities (NCMHD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Fayez M, 2006, CANCER CHEMOTH PHARM, V58, P816, DOI 10.1007/s00280-006-0228-3; ANDERSON JA, 1931, J CHEM SOC, P2624, DOI DOI 10.1039/JR9310002624; Ando C, 2009, FEBS LETT, V583, P3649, DOI 10.1016/j.febslet.2009.10.045; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bensasson RV, 1999, FREE RADICAL BIO MED, V27, P95, DOI 10.1016/S0891-5849(99)00039-8; Beutler B, 2003, CRIT CARE, V7, P39, DOI 10.1186/cc1828; Bhandare AM, 2010, FOOD CHEM TOXICOL, V48, P3412, DOI 10.1016/j.fct.2010.09.013; BICKOFF EM, 1964, J PHARM SCI, V53, P1411, DOI 10.1002/jps.2600531131; Boden G, 2005, DIABETES, V54, P3458, DOI 10.2337/diabetes.54.12.3458; Boden Guenther, 1998, Frontiers in Bioscience, V3, pD169; Bruun JM, 2006, AM J PHYSIOL-ENDOC M, V290, pE961, DOI 10.1152/ajpendo.00506.2005; Cai H, 2004, BRIT J CANCER, V91, P1364, DOI 10.1038/sj.bjc.6602124; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; Choi YJ, 2008, EXP BIOL MED, V233, P580, DOI 10.3181/0707-RM-205; Chou CH, 1982, J CHEM ECOL, V8, P19; Conti P, 2001, ALLERGY ASTHMA PROC, V22, P133, DOI 10.2500/108854101778148737; Del Rosario A, 2012, BR J NUTR, P1; Fujioka S, 2004, MOL CELL BIOL, V24, P7806, DOI 10.1128/MCB.24.17.7806-7819.2004; Greenberg AS, 2006, AM J CLIN NUTR, V83, p461S; Ham I, 2009, IMMUNOPHARM IMMUNOT, V31, P439, DOI 10.1080/08923970902769638; Higa JK, 2011, CYTOKINE, V55, P18, DOI 10.1016/j.cyto.2011.02.019; Higa JK, 2011, BR J NUTR, P1; Hirai S, 2007, LIFE SCI, V81, P1272, DOI 10.1016/j.lfs.2007.09.001; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hong EJ, 2010, J ETHNOPHARMACOL, V128, P594, DOI 10.1016/j.jep.2010.01.045; Hu C, 2000, J AGR FOOD CHEM, V48, P3170, DOI 10.1021/jf0001637; Huber J, 2008, J CLIN ENDOCR METAB, V93, P3215, DOI 10.1210/jc.2007-2630; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jiao JJ, 2007, J AGR FOOD CHEM, V55, P10086, DOI 10.1021/jf0716533; Kanda H, 2006, J CLIN INVEST, V116, P1494, DOI 10.1172/JCI26498; Kannan-Thulasiraman P, 2002, J BIOL CHEM, V277, P41230, DOI 10.1074/jbc.M200379200; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kim DS, 2010, PLANTA MED, V76, P678, DOI 10.1055/s-0029-1240649; Kim F, 2007, CIRC RES, V100, P1589, DOI 10.1161/CIRCRESAHA.106.142851; Kim SH, 2007, IMMUNOPHARM IMMUNOT, V29, P131, DOI 10.1080/08923970701283476; Kong CH, 2010, PEST MANAG SCI, V66, P1018, DOI 10.1002/ps.1976; Kuwabara H, 2003, J NAT PROD, V66, P1273, DOI 10.1021/np030020p; Lee HJ, 2010, FOOD CHEM TOXICOL, V48, P1721, DOI 10.1016/j.fct.2010.03.052; LEE KH, 1981, J NAT PROD, V44, P530, DOI 10.1021/np50017a003; Martin T, 1997, EUR J IMMUNOL, V27, P1091, DOI 10.1002/eji.1830270508; Middleton E, 2000, PHARMACOL REV, V52, P673; Miyata Y, 2011, LIFE SCI, V88, P613, DOI 10.1016/j.lfs.2011.01.024; Monteiro R, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/289645; Nelson DE, 2004, SCIENCE, V306, P704, DOI 10.1126/science.1099962; Oliver E, 2010, P NUTR SOC, V69, P232, DOI 10.1017/S0029665110000042; Oyama T, 2009, CANCER PREV RES, V2, P1031, DOI 10.1158/1940-6207.CAPR-09-0061; Panee J, 2008, PHYTOTHER RES, V22, P675, DOI 10.1002/ptr.2395; Park HJ, 2012, J NUTR, V142, P57, DOI 10.3945/jn.111.148544; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; Sakai Asumi, 2008, Antiviral Chemistry & Chemotherapy, V19, P125; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; UEDA A, 1994, J IMMUNOL, V153, P2052; Ueda A, 1997, J BIOL CHEM, V272, P31092, DOI 10.1074/jbc.272.49.31092; VANE JR, 1990, STROKE, V21, P12; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wenzig E, 2005, J NAT PROD, V68, P289, DOI 10.1021/np049636k; Xiao JN, 2005, INVEST OPHTH VIS SCI, V46, P3777, DOI 10.1167/iovs.05-0724; Yamazaki K, 2007, BIOCHEM SYST ECOL, V35, P743, DOI 10.1016/j.bse.2007.04.013; Yen GC, 2011, J AGR FOOD CHEM, V59, P546, DOI 10.1021/jf1036992; Zahir A, 1996, J NAT PROD, V59, P701, DOI 10.1021/np960336f; Zhang X, 2010, CHEM RES CHINESE U, V26, P161; Zhang Z.Y., 2000, WORLD SCI TECHNOL, V3, P54, DOI [10.3969/j.issn.1674-3849.2000.03.018, DOI 10.3969/J.ISSN.1674-3849.2000.03.018]	62	15	15	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2012	7	9							e45082	10.1371/journal.pone.0045082	http://dx.doi.org/10.1371/journal.pone.0045082			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	040HS	23028772	gold, Green Published			2023-01-03	WOS:000311313900076
J	Mattison, JA; Roth, GS; Beasley, TM; Tilmont, EM; Handy, AM; Herbert, RL; Longo, DL; Allison, DB; Young, JE; Bryant, M; Barnard, D; Ward, WF; Qi, WB; Ingram, DK; de Cabo, R				Mattison, Julie A.; Roth, George S.; Beasley, T. Mark; Tilmont, Edward M.; Handy, April M.; Herbert, Richard L.; Longo, Dan L.; Allison, David B.; Young, Jennifer E.; Bryant, Mark; Barnard, Dennis; Ward, Walter F.; Qi, Wenbo; Ingram, Donald K.; de Cabo, Rafael			Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study	NATURE			English	Article							T-CELL SENESCENCE; DIETARY RESTRICTION; LIFE-SPAN; AGE; MORTALITY; DISEASE; MODEL; RATS; MICE; INFLAMMATION	Calorie restriction (CR), a reduction of 10-40% in intake of a nutritious diet, is often reported as the most robust non-genetic mechanism to extend lifespan and healthspan. CR is frequently used as a tool to understand mechanisms behind ageing and age-associated diseases. In addition to and independently of increasing lifespan, CR has been reported to delay or prevent the occurrence of many chronic diseases in a variety of animals. Beneficial effects of CR on outcomes such as immune function(1,2), motor coordination(3) and resistance to sarcopenia(4) in rhesus monkeys have recently been reported. We report here that a CR regimen implemented in young and older age rhesus monkeys at the National Institute on Aging (NIA) has not improved survival outcomes. Our findings contrast with an ongoing study at the Wisconsin National Primate Research Center (WNPRC), which reported improved survival associated with 30% CR initiated in adult rhesus monkeys (7-14 years)(5) and a preliminary report with a small number of CR monkeys(6). Over the years, both NIA and WNPRC have extensively documented beneficial health effects of CR in these two apparently parallel studies. The implications of the WNPRC findings were important as they extended CR findings beyond the laboratory rodent and to a long-lived primate. Our study suggests a separation between health effects, morbidity andmortality, and similar to what has been shown in rodents(7-9), study design, husbandry and diet composition may strongly affect the life-prolonging effect of CR in a long-lived nonhuman primate.	[Mattison, Julie A.; Tilmont, Edward M.; Handy, April M.; Young, Jennifer E.] NIA, Lab Expt Gerontol, NIH, Anim Ctr, Dickerson, MD 20842 USA; [Roth, George S.] GeroScience, Pylesville, MD 21132 USA; [Beasley, T. Mark] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA; [Handy, April M.] SoBran Inc, Burtonsville, MD 20866 USA; [Herbert, Richard L.] NIAID, NIH, Anim Ctr, Dickerson, MD 20842 USA; [Longo, Dan L.] NIA, Lab Mol Biol & Immunol, NIH, Baltimore, MD 21224 USA; [Allison, David B.] Univ Alabama Birmingham, Off Energet, Birmingham, AL 35294 USA; [Bryant, Mark; Barnard, Dennis] NIH, Off Director, Diagnost & Res Serv Branch, Bethesda, MD 20814 USA; [Ward, Walter F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA; [Qi, Wenbo] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; [Ingram, Donald K.] Louisiana State Univ, Pennington Biomed Res Ctr, Nutr Neurosci & Aging Lab, Baton Rouge, LA 70808 USA; [de Cabo, Rafael] NIA, Lab Expt Gerontol, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Mattison, JA (corresponding author), NIA, Lab Expt Gerontol, NIH, Anim Ctr, 16701 Elmer Sch Rd,Bldg 103, Dickerson, MD 20842 USA.	mattisonj@mail.nih.gov; Donald.Ingram@pbrc.edu; deCaboRa@grc.nia.nih.gov	Longo, Dan L./F-6022-2011; de Cabo, Rafael Carlos/J-5230-2016; de Cabo, Rafael/E-7996-2010; de Cabo, Rafael/J-5230-2016	de Cabo, Rafael Carlos/0000-0003-2830-5693; de Cabo, Rafael/0000-0003-2830-5693; de Cabo, Rafael/0000-0002-3354-2442; Allison, David/0000-0003-3566-9399	NIH, National Institute on Aging; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIGAI001047] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000368, ZIAAG000371] Funding Source: NIH RePORTER	NIH, National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank the animal care staff and technicians, both past and present, especially J. Travis and M. Szarowicz; K. Vaughan for her editorial help; and the many collaborators that have contributed to this project. This research was supported by the Intramural Research Program of the NIH, National Institute on Aging.	Allison P.D., 2010, SURVIVAL ANAL USING; Bodkin NL, 2003, J GERONTOL A-BIOL, V58, P212; Branch-Mays GL, 2008, J PERIODONTOL, V79, P1184, DOI 10.1902/jop.2008.070629 ; Colman R. J., 1998, METHODS AGING RES, P249; Colman RJ, 2008, J GERONTOL A-BIOL, V63, P556, DOI 10.1093/gerona/63.6.556; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Duffy PH, 2001, AGING-CLIN EXP RES, V13, P263; Forster MJ, 2003, FASEB J, V17, P690, DOI 10.1096/fj.02-0533fje; Harper JM, 2006, AGING CELL, V5, P441, DOI 10.1111/j.1474-9726.2006.00236.x; INGRAM DK, 1990, J GERONTOL, V45, pB148, DOI 10.1093/geronj/45.5.B148; Kastman EK, 2010, J NEUROSCI, V30, P7940, DOI 10.1523/JNEUROSCI.0835-10.2010; LANE MA, 1995, J NUTR, V125, P1600; Liao CY, 2010, AGING CELL, V9, P92, DOI 10.1111/j.1474-9726.2009.00533.x; Littell R.C., 2006, SAS SYSTEM MIXED MOD, V2nd; Lomba A, 2009, J NUTRIGENET NUTRIGE, V2, P267, DOI 10.1159/000308465; Mattison JA, 2005, NEUROBIOL AGING, V26, P1117, DOI 10.1016/j.neurobiolaging.2004.09.013; Messaoudi I, 2006, P NATL ACAD SCI USA, V103, P19448, DOI 10.1073/pnas.0606661103; Messaoudi I, 2010, CALORIE RESTRICTION, AGING AND LONGEVITY, P55, DOI 10.1007/978-90-481-8556-6_4; Messaoudi I, 2008, AGING CELL, V7, P908, DOI 10.1111/j.1474-9726.2008.00440.x; MURTAGHMARK CM, 1995, J GERONTOL A-BIOL, V50, pB148, DOI 10.1093/gerona/50A.3.B148; Nadon NL, 2006, AGING CELL, V5, P9, DOI 10.1111/j.1474-9726.2006.00185.x; Omodei D, 2011, FEBS LETT, V585, P1537, DOI 10.1016/j.febslet.2011.03.015; Raman A, 2007, AM J PHYSIOL-ENDOC M, V292, pE101, DOI 10.1152/ajpendo.00127.2006; Redman LM, 2011, ANTIOXID REDOX SIGN, V14, P275, DOI 10.1089/ars.2010.3253; Roncal-Jimenez CA, 2011, METABOLISM, V60, P1259, DOI 10.1016/j.metabol.2011.01.008; Roth GS, 2004, SCIENCE, V305, P1423, DOI 10.1126/science.1102541; Speakman JR, 2007, J NUTR, V137, P1078, DOI 10.1093/jn/137.4.1078; Swindell WR, 2012, AGEING RES REV, V11, P254, DOI 10.1016/j.arr.2011.12.006; Ward WF, 2005, J GERONTOL A-BIOL, V60, P847, DOI 10.1093/gerona/60.7.847; [No title captured]	30	726	745	10	235	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 13	2012	489	7415					318	+		10.1038/nature11432	http://dx.doi.org/10.1038/nature11432			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	003UC	22932268	Green Accepted			2023-01-03	WOS:000308635900047
J	Harris, T; Rhys, GO; Brohi, K				Harris, Tim; Rhys, G. O.; Brohi, Karim			Early fluid resuscitation in severe trauma	BMJ-BRITISH MEDICAL JOURNAL			English	Review							MASSIVE TRANSFUSION; BRAIN-INJURY; HEMORRHAGE; MORTALITY; COAGULOPATHY; IMPACT; SHOCK		[Harris, Tim; Brohi, Karim] Queen Mary Univ London, Barts & London Sch Med & Dent, London, England; [Harris, Tim; Rhys, G. O.; Brohi, Karim] Barts Hlth NHS Trust, London, England	University of London; Queen Mary University London; Barts Health NHS Trust	Harris, T (corresponding author), Royal London Hosp, Dept Emergency Med, London E1 1BB, England.	tim.harris@bartshealth.nhs.uk			Octapharma; Thromboelastometry; National Institute for Health Research [RP-PG-0407-10036] Funding Source: researchfish	Octapharma; Thromboelastometry; National Institute for Health Research(National Institute for Health Research (NIHR))	All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; KB has received unrestricted research funding from Octapharma and Thromboelastometry and has consulted for Haemonetics and Sangart; no other relationships or activities that could appear to have influenced the submitted work.	American College of Surgeons Committee on Trauma, 1997, ADV TRAUM LIF SUPP D; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chytra I, 2007, CRIT CARE, V11, DOI 10.1186/cc5703; Claridge JA, 2000, J TRAUMA, V48, P8, DOI 10.1097/00005373-200001000-00003; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; Davenport R, 2011, CRIT CARE MED, V39, P2652, DOI 10.1097/CCM.0b013e3182281af5; Davenport R, 2011, J TRAUMA, V70, P90, DOI 10.1097/TA.0b013e318202e486; Dutton RP, 2002, J TRAUMA, V52, P1141, DOI 10.1097/00005373-200206000-00020; Eastridge BJ, 2007, J TRAUMA, V63, P291, DOI 10.1097/TA.0b013e31809ed924; Floccard B, 2012, INJURY, V43, P26, DOI 10.1016/j.injury.2010.11.003; Guly HR, 2011, RESUSCITATION, V82, P556, DOI 10.1016/j.resuscitation.2011.01.013; Hess JR, 2008, J TRAUMA, V65, P748, DOI 10.1097/TA.0b013e3181877a9c; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; Larson CR, 2010, J TRAUMA, V69, pS26, DOI 10.1097/TA.0b013e3181e423f4; Ley EJ, 2011, J TRAUMA, V70, P398, DOI 10.1097/TA.0b013e318208f99b; Mapstone J, 2003, J TRAUMA, V55, P571, DOI 10.1097/01.TA.0000062968.69867.6F; McKinley Bruce A, 2003, Curr Opin Crit Care, V9, P292, DOI 10.1097/00075198-200308000-00007; Myburgh J, 2007, NEW ENGL J MED, V357, P874; National Institute for Health and Clinical Excellence, 2004, PREH IN FLUID REPL T, V74; Perel P, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000567.pub4; Rajasekhar A, 2011, CRIT CARE MED, V39, P1507, DOI 10.1097/CCM.0b013e31820eb517; Roberts I, 2005, BRIT MED J, V331, P1094, DOI 10.1136/bmj.331.7525.1094; Santry HP, 2010, SHOCK, V33, P229, DOI 10.1097/SHK.0b013e3181c30f0c; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; SHIRES GT, 1973, SURG CLIN N AM, V53, P1341; Stanworth SJ, 2010, CRIT CARE, V14, DOI 10.1186/cc9394; Strehlow MC, 2010, EMERG MED CLIN N AM, V28, P57, DOI 10.1016/j.emc.2009.09.006; WO CCJ, 1993, CRIT CARE MED, V21, P218, DOI 10.1097/00003246-199302000-00012	33	51	52	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 11	2012	345								e5752	10.1136/bmj.e5752	http://dx.doi.org/10.1136/bmj.e5752			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	007BG	22968721				2023-01-03	WOS:000308863200002
J	Ford, N; Hargreaves, S; Shanks, L				Ford, Nathan; Hargreaves, Sally; Shanks, Leslie			Mortality after Fluid Bolus in Children with Shock Due to Sepsis or Severe Infection: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							PHASE-II TRIAL; AFRICAN CHILDREN; SEPTIC SHOCK; VOLUME EXPANSION; KENYAN CHILDREN; SEVERE MALARIA; RESUSCITATION; MANAGEMENT; ALBUMIN; SALINE	Introduction: Sepsis is one of the leading causes of childhood mortality, yet controversy surrounds the current treatment approach. We conducted a systematic review to assess the evidence base for fluid resuscitation in the treatment of children with shock due to sepsis or severe infection. Methods: We searched 3 databases for randomized trials, quasi-randomized trials, and controlled before-after studies assessing children with septic shock in which at least one group was treated with bolus fluids. The primary outcome was mortality at 48 hours. Assessment of methodological quality followed the GRADE criteria. Relative risks (RRs) and 95% confidence intervals (CI) were calculated and data pooled using fixed-effects method. Results: 13 studies met our inclusion criteria. No bolus has significantly better mortality outcomes at 48 hours for children with general septic shock (RR 0.69; 95% CI 0.54-0.89), and children with malaria (RR 0.64; 95% CI 0.45-0.91) when compared to giving any bolus. This result is largely driven by a single, high quality trial (the FEAST trial). There is no evidence investigating bolus vs no bolus in children with Dengue fever or severe malnutrition. Colloid and crystalloid boluses were found to have similar effects on mortality across all sub-groups (general septic shock, malaria, Dengue fever, and severe malnutrition). Conclusions: The majority of all randomized evidence to date comes from the FEAST trial, which found that fluid boluses were harmful compared to no bolus. Simple algorithms are needed to support health-care providers in the triage of patients to determine who could potentially be harmed by the provision of bolus fluids, and who will benefit.	[Ford, Nathan] Med Sans Frontieres, Geneva, Switzerland; [Ford, Nathan] Univ Cape Town, Ctr Infect Dis Epidemiol & Res, ZA-7925 Cape Town, South Africa; [Hargreaves, Sally] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Infect Dis & Immun, Int Hlth Unit, London, England; [Shanks, Leslie] Med Sans Frontieres, Amsterdam, Netherlands	Doctors Without Borders; University of Cape Town; Imperial College London; Doctors Without Borders	Ford, N (corresponding author), Med Sans Frontieres, Geneva, Switzerland.	Nathan.ford@msf.org		Hargreaves, Sally/0000-0003-2974-4348				Akech S, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010021; Akech S, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4416; Akech SO, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-71; Akech SO, 2010, CRIT CARE MED, V38, P1630, DOI 10.1097/CCM.0b013e3181e81165; Berend K, 2011, NEW ENGL J MED, V365, P1349, DOI 10.1056/NEJMc1108712; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; CARCILLO JA, 1991, JAMA-J AM MED ASSOC, V266, P1242, DOI 10.1001/jama.266.9.1242; Chopra A, 2011, INDIAN J PEDIATR, V78, P833, DOI 10.1007/s12098-011-0366-4; Cifra H, 2003, CRIT CARE SHOCK, V6, P95; Dellinger RP, 2008, INTENS CARE MED, V34, P17, DOI 10.1007/s00134-007-0934-2; Duke T, 2011, LANCET, V378, P1685, DOI 10.1016/S0140-6736(11)60881-7; Dung NM, 1999, CLIN INFECT DIS, V29, P787, DOI 10.1086/520435; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; Ford SR, 2011, NEW ENGL J MED, V365, P1348, DOI 10.1056/NEJMc1108712; Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2; Han YY, 2003, PEDIATRICS, V112, P793, DOI 10.1542/peds.112.4.793; Hicks Peter, 2008, Crit Care Resusc, V10, P8; Kissoon N, 2011, NEW ENGL J MED, V365, P1350, DOI 10.1056/NEJMc1108712; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Maitland K, 2005, CLIN INFECT DIS, V40, P538, DOI 10.1086/427505; Maitland K, 2005, BRIT J HAEMATOL, V128, P393, DOI 10.1111/j.1365-2141.2004.05312.x; Maitland K, 2011, NEW ENGL J MED, V364, P2483, DOI 10.1056/NEJMoa1101549; Nhan NT, 2001, CLIN INFECT DIS, V32, P204, DOI 10.1086/318479; Ribeiro CT, 2011, NEW ENGL J MED, V365, P1348, DOI 10.1056/NEJMc1108712; Santhanam I, 2008, PEDIATR EMERG CARE, V24, P647, DOI 10.1097/PEC.0b013e31818844cf; Scott H, 2011, NEW ENGL J MED, V365, P1350, DOI 10.1056/NEJMc1108712; Upadhyay M, 2005, INDIAN PEDIATR, V42, P223; Wills BA, 2005, NEW ENGL J MED, V353, P877, DOI 10.1056/NEJMoa044057; WILSON RF, 1971, ANN SURG, V174, P939, DOI 10.1097/00000658-197112000-00009	29	36	37	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2012	7	8							e43953	10.1371/journal.pone.0043953	http://dx.doi.org/10.1371/journal.pone.0043953			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	997ZH	22952819	Green Published, gold, Green Submitted			2023-01-03	WOS:000308206500030
J	Mehta, RS; Barlow, WE; Albain, KS; Vandenberg, TA; Dakhil, SR; Tirumali, NR; Lew, DL; Hayes, DF; Gralow, JR; Livingston, RB; Hortobagyi, GN				Mehta, Rita S.; Barlow, William E.; Albain, Kathy S.; Vandenberg, Ted A.; Dakhil, Shaker R.; Tirumali, Nagendra R.; Lew, Danika L.; Hayes, Daniel F.; Gralow, Julie R.; Livingston, Robert B.; Hortobagyi, Gabriel N.			Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FIRST-LINE THERAPY; POSTMENOPAUSAL WOMEN; PHASE-III; ENDOCRINE THERAPY; DOUBLE-BLIND; HORMONAL-THERAPY; RANDOMIZED-TRIAL; 1ST-LINE THERAPY; TAMOXIFEN; ANTIESTROGEN	Background The aromatase inhibitor anastrozole inhibits estrogen synthesis. Fulvestrant binds and accelerates degradation of estrogen receptors. We hypothesized that these two agents in combination might be more effective than anastrozole alone in patients with hormone-receptor (HR)-positive metastatic breast cancer. Methods Postmenopausal women with previously untreated metastatic disease were randomly assigned, in a 1: 1 ratio, to receive either 1 mg of anastrozole orally every day (group 1), with crossover to fulvestrant alone strongly encouraged if the disease progressed, or anastrozole and fulvestrant in combination (group 2). Patients were stratified according to prior or no prior receipt of adjuvant tamoxifen therapy. Fulvestrant was administered intramuscularly at a dose of 500 mg on day 1 and 250 mg on days 14 and 28 and monthly thereafter. The primary end point was progression-free survival, with overall survival designated as a prespecified secondary outcome. Results The median progression-free survival was 13.5 months in group 1 and 15.0 months in group 2 (hazard ratio for progression or death with combination therapy, 0.80; 95% confidence interval [CI], 0.68 to 0.94; P = 0.007 by the log-rank test). The combination therapy was generally more effective than anastrozole alone in all subgroups, with no significant interactions. Overall survival was also longer with combination therapy (median, 41.3 months in group 1 and 47.7 months in group 2; hazard ratio for death, 0.81; 95% CI, 0.65 to 1.00; P = 0.05 by the log-rank test), despite the fact that 41% of the patients in group 1 crossed over to fulvestrant after progression. Three deaths that were possibly associated with treatment occurred in group 2. The rates of grade 3 to 5 toxic effects did not differ significantly between the two groups. Conclusions The combination of anastrozole and fulvestrant was superior to anastrozole alone or sequential anastrozole and fulvestrant for the treatment of HR-positive metastatic breast cancer, despite the use of a dose of fulvestrant that was below the current standard. (Funded by the National Cancer Institute and AstraZeneca; SWOG ClinicalTrials.gov number, NCT00075764.)	[Mehta, Rita S.] Univ Calif Irvine, Med Ctr, Chao Family Comprehens Canc Ctr, Orange, CA 92868 USA; [Barlow, William E.; Lew, Danika L.] SWOG Stat Ctr, Seattle, WA USA; [Gralow, Julie R.] Seattle Canc Care Alliance, Puget Sound Canc Consortium, Seattle, WA USA; [Albain, Kathy S.] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA; [Vandenberg, Ted A.] Natl Canc Inst Canada, Clin Trials Grp, London Hlth Sci Ctr, London, ON, Canada; [Dakhil, Shaker R.] Wichita Community Clin Oncol Program CCOP, Wichita, KS USA; [Tirumali, Nagendra R.] NW CCOP NW Permanente, Portland, OR USA; [Hayes, Daniel F.] Univ Michigan, Ann Arbor, MI 48109 USA; [Livingston, Robert B.] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA; [Hortobagyi, Gabriel N.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA	University of California System; University of California Irvine; Southwest Oncology Group; Seattle Cancer Care Alliance; Loyola University Chicago; London Health Sciences Centre; Queens University - Canada; Canadian Cancer Trials Group; University of Michigan System; University of Michigan; Arizona Center Cancer Care; University of Arizona; University of Texas System; UTMD Anderson Cancer Center	Mehta, RS (corresponding author), Univ Calif Irvine, Med Ctr, Chao Family Comprehens Canc Ctr, 101 City Dr,Bldg 23, Orange, CA 92868 USA.	rsmehta@uci.edu	Hayes, Daniel/ABE-1129-2020		National Cancer Institute [CA32102, CA38926, CA35431, CA35281, CA20319, CA04919, CA67575, CA58861, CA37981, CA46368, CA86780, CA46282, CA63848, CA12644, CA27057, CA95860, CA35119, CA46441, CA11083, CA45450, CA35178]; AstraZeneca; NCI [CA13612, CA58882, CA45377, CA45807, CA58723, C14028, CA128567, CA63844, CA76447, CA58416, CA63850, CA76462, CA35262, CA77202, CCSRI155469]; NATIONAL CANCER INSTITUTE [U10CA037981, U10CA035261, P30CA062203, U10CA086780, U10CA004919, U10CA035090, U10CA058723, U10CA045808, U10CA011083, U10CA073590, U10CA063845, U10CA042777, U10CA035128, U10CA045807, U10CA046368, U10CA012644, U10CA035281, U10CA128567, UG1CA189808, U10CA035176, U10CA076447, U10CA077202, U10CA035119, U10CA035431, U10CA067575, U10CA016385, U10CA032102, U10CA063844, U10CA020319, U10CA038926, U10CA052654, U10CA058416, U10CA046282, U10CA063848, U10CA035178, U10CA045560, U10CA035192, U10CA035262, U10CA095860, U10CA022433, U10CA045450, U10CA027057, U10CA058882, U10CA058861, U10CA013612, U10CA045377, U10CA046441, U10CA063850] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); AstraZeneca(AstraZeneca); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by grants from the National Cancer Institute (CA32102, CA38926, CA35431, CA35281, CA20319, CA04919, CA67575, CA58861, CA37981, CA46368, CA86780, CA46282, CA63848, CA12644, CA27057, CA95860, CA35119, CA46441, CA11083, CA45450, CA35178, CA13612, CA58882, CA45377, CA45807, CA58723, C14028, CA128567, CA22433, CA52654, CA45560, CA35261, CA073590, CA45808, CA35192, CA42777, CA16385, CA35176, CA63845, CA35128, CA35090, CA63844, CA76447, CA58416, CA63850, CA76462, CA35262, CA77202, and CCSRI155469) and AstraZeneca.	Baum M, 2002, LANCET, V359, P2131; Baum M, 2002, LANCET, V360, P1520; Bergh J, 2012, J CLIN ONCOL, V30, P1919, DOI 10.1200/JCO.2011.38.1095; Bonneterre J, 2000, J CLIN ONCOL, V18, P3748, DOI 10.1200/JCO.2000.18.22.3748; Bonneterre J, 2001, CANCER, V92, P2247, DOI 10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y; Dawood S, 2010, ANN ONCOL, V21, P2169, DOI 10.1093/annonc/mdq220; Di Leo A, 2011, J CLIN ONCOL, V29, P2293, DOI 10.1200/JCO.2011.36.8522; Di Leo A, 2010, J CLIN ONCOL, V28, P4594, DOI 10.1200/JCO.2010.28.8415; Goss P, 2007, J CLIN ONCOL, V25, P4961, DOI 10.1200/JCO.2006.09.5455; Howell A, 2004, J CLIN ONCOL, V22, P1605, DOI 10.1200/JCO.2004.02.112; Howell A, 2002, J CLIN ONCOL, V20, P3396, DOI 10.1200/JCO.2002.10.057; INGLE JN, 1991, CANCER-AM CANCER SOC, V67, P886, DOI 10.1002/1097-0142(19910215)67:4<886::AID-CNCR2820670405>3.0.CO;2-O; INGLE JN, 1986, J CLIN ONCOL, V4, P958, DOI 10.1200/JCO.1986.4.6.958; Jelovac D, 2005, CANCER RES, V65, P5439, DOI 10.1158/0008-5472.CAN-04-2782; Macedo LF, 2008, CANCER RES, V68, P3516, DOI 10.1158/0008-5472.CAN-07-6807; Mauri D, 2006, JNCI-J NATL CANCER I, V98, P1285, DOI 10.1093/jnci/djj357; Mouridsen H, 2003, J CLIN ONCOL, V21, P2101, DOI 10.1200/JCO.2003.04.194; Nabholtz JM, 2000, J CLIN ONCOL, V18, P3758, DOI 10.1200/JCO.2000.18.22.3758; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Osborne CK, 2002, J CLIN ONCOL, V20, P3386, DOI 10.1200/JCO.2002.10.058; OSBORNE CK, 1995, J NATL CANCER I, V87, P746, DOI 10.1093/jnci/87.10.746; Paridaens RJ, 2008, J CLIN ONCOL, V26, P4883, DOI 10.1200/JCO.2007.14.4659; Robertson JF, 2001, CANCER RES, V61, P6739; Robertson JFR, 2009, J CLIN ONCOL, V27, P4530, DOI 10.1200/JCO.2008.21.1136; RUBENS RD, 1988, BRIT J CANCER, V58, P626, DOI 10.1038/bjc.1988.273; Rubens RD, 1985, P AN M AM SOC CLIN, V4, P53; Russell CA, 1997, J CLIN ONCOL, V15, P2494, DOI 10.1200/JCO.1997.15.7.2494; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; TORMEY DC, 1983, ANN INTERN MED, V98, P139, DOI 10.7326/0003-4819-98-2-139; Vergote I, 2012, J CLIN ONCOL, V30, P343, DOI 10.1200/JCO.2011.41.3302; WAKELING AE, 1991, CANCER RES, V51, P3867	31	284	302	1	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 2	2012	367	5					435	444		10.1056/NEJMoa1201622	http://dx.doi.org/10.1056/NEJMoa1201622			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981VZ	22853014	Green Accepted, Bronze			2023-01-03	WOS:000307001900008
J	Benevides, RG; Ganne, G; Simoes, RD; Schubert, V; Niemietz, M; Unverzagt, C; Chazalet, V; Breton, C; Varrot, A; Cavada, BS; Imberty, A				Benevides, Raquel Guimaraes; Ganne, Geraldine; Simoes, Rafael da Conceicao; Schubert, Volker; Niemietz, Mathaeus; Unverzagt, Carlo; Chazalet, Valerie; Breton, Christelle; Varrot, Annabelle; Cavada, Benildo Sousa; Imberty, Anne			A Lectin from Platypodium elegans with Unusual Specificity and Affinity for Asymmetric Complex N-Glycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PTEROCARPUS-ANGOLENSIS LECTIN; CONCANAVALIN-A; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; LEGUME LECTINS; BIANTENNARY OLIGOSACCHARIDES; CARBOHYDRATE-BINDING; CORE TRIMANNOSIDE; RECOGNITION; PROTEINS	Lectin activity with specificity for mannose and glucose has been detected in the seed of Platypodium elegans, a legume plant from the Dalbergieae tribe. The gene of Platypodium eleganslectin A has been cloned, and the resulting 261-amino acid protein belongs to the legume lectin family with similarity with Pterocarpus angolensis agglutinin from the same tribe. The recombinant lectin has been expressed in Escherichia coli and refolded from inclusion bodies. Analysis of specificity by glycan array evidenced a very unusual preference for complex type N-glycans with asymmetrical branches. A short branch consisting of one mannose residue is preferred on the 6-arm of the N-glycan, whereas extensions by GlcNAc, Gal, and NeuAc are favorable on the 3-arm. Affinities have been obtained by microcalorimetry using symmetrical and asymmetrical Asn-linked heptasaccharides prepared by the semisynthetic method. Strong affinity with K-d of 4.5 mu M was obtained for both ligands. Crystal structures of Platypodium elegans lectin A complexed with branched trimannose and symmetrical complex-type Asn-linked heptasaccharide have been solved at 2.1 and 1.65 angstrom resolution, respectively. The lectin adopts the canonical dimeric organization of legume lectins. The trimannose bridges the binding sites of two neighboring dimers, resulting in the formation of infinite chains in the crystal. The Asn-linked heptasaccharide binds with the 6-arm in the primary binding site with extensive additional contacts on both arms. The GlcNAc on the 6-arm is bound in a constrained conformation that may rationalize the higher affinity observed on the glycan array for N-glycans with only a mannose on the 6-arm.	[Benevides, Raquel Guimaraes; Ganne, Geraldine; Chazalet, Valerie; Breton, Christelle; Varrot, Annabelle; Cavada, Benildo Sousa; Imberty, Anne] Univ Grenoble 1, CNRS, Ctr Rech Macromol Vegetales, F-38041 Grenoble, France; [Benevides, Raquel Guimaraes; Ganne, Geraldine; Chazalet, Valerie; Breton, Christelle; Varrot, Annabelle; Cavada, Benildo Sousa; Imberty, Anne] Inst Chim Mol Grenoble, CNRS, Ctr Rech Macromol Vegetales, F-38041 Grenoble, France; [Benevides, Raquel Guimaraes; Simoes, Rafael da Conceicao] Univ Fed Ceara, Dept Bioquim & Biol Mol, BR-60440970 Fortaleza, Ceara, Brazil; [Schubert, Volker; Niemietz, Mathaeus; Unverzagt, Carlo] Univ Bayreuth, D-95440 Bayreuth, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universidade Federal do Ceara; University of Bayreuth	Cavada, BS (corresponding author), Univ Grenoble 1, CNRS, Ctr Rech Macromol Vegetales, F-38041 Grenoble, France.	bscavada@ufc.br; imberty@cermav.cnrs.fr	Cavada, Benildo/CEA-4997-2022; Imberty, Anne/P-6451-2018	Cavada, Benildo/0000-0002-5791-6170; Guimaraes Benevides, Raquel/0000-0002-5410-6973; Imberty, Anne/0000-0001-6825-9527; Varrot, Annabelle/0000-0001-6667-8162	CNRS; French Ministry of Research; German Research Foundation (DFG); National Institutes of Health from NIGMS [GM62116]; CAPES; CNPq; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116] Funding Source: NIH RePORTER	CNRS(Centre National de la Recherche Scientifique (CNRS)); French Ministry of Research(Ministry of Research, FranceEuropean Commission); German Research Foundation (DFG)(German Research Foundation (DFG)); National Institutes of Health from NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by CNRS and the French Ministry of Research and the German Research Foundation (DFG).; The glycan microarray analysis was provided by the Consortium for Functional Glycomics funded by National Institutes of Health Grant GM62116 from NIGMS. We acknowledge the European Synchrotron Radiation Facility for provision of synchrotron radiation facilities, and we are grateful for the assistance in using beamline BM30A.; Recipient of CAPES and CNPq grants from the Brazilian government.	Ambrosi M, 2005, ORG BIOMOL CHEM, V3, P1593, DOI 10.1039/b414350g; Buts L, 2006, FEBS J, V273, P2407, DOI 10.1111/j.1742-4658.2006.05248.x; Cavada B. S., 1993, Revista Brasileira de Fisiologia Vegetal, V5, P193; Dam TK, 1998, J BIOL CHEM, V273, P32812, DOI 10.1074/jbc.273.49.32812; Dam TK, 2002, CHEM REV, V102, P387, DOI 10.1021/cr000401x; Delatorre P, 2007, BMC STRUCT BIOL, V7, DOI 10.1186/1472-6807-7-52; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Garcia-Pino A, 2007, PLANT PHYSIOL, V144, P1733, DOI 10.1104/pp.107.100867; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Gourdine JP, 2008, J BIOL CHEM, V283, P30112, DOI 10.1074/jbc.M804353200; Hirsch AM, 1999, CURR OPIN PLANT BIOL, V2, P320, DOI 10.1016/S1369-5266(99)80056-9; IMBERTY A, 1991, GLYCOCONJUGATE J, V8, P456, DOI 10.1007/BF00769847; Kajihara Y, 2004, CHEM-EUR J, V10, P971, DOI 10.1002/chem.200305115; Lameignere E, 2010, GLYCOBIOLOGY, V20, P87, DOI 10.1093/glycob/cwp151; Lorenzi H, 1998, ARVORES BRASILEIRAS; Loris R, 2004, J MOL BIOL, V335, P1227, DOI 10.1016/j.jmb.2003.11.043; Loris R, 2003, J BIOL CHEM, V278, P16297, DOI 10.1074/jbc.M211148200; Loris R, 1996, J BIOL CHEM, V271, P30614, DOI 10.1074/jbc.271.48.30614; Loris R, 1998, BBA-PROTEIN STRUCT M, V1383, P9, DOI 10.1016/S0167-4838(97)00182-9; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Mezzato S, 2010, CARBOHYD RES, V345, P1306, DOI 10.1016/j.carres.2010.02.022; Moothoo DN, 1998, GLYCOBIOLOGY, V8, P173, DOI 10.1093/glycob/8.2.173; Moreira A., 1977, PLANT PHYSIOL, V59, P783; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Olsen LR, 1997, BIOCHEMISTRY-US, V36, P15073, DOI 10.1021/bi971828+; PEUMANS WJ, 1995, PLANT PHYSIOL, V109, P347, DOI 10.1104/pp.109.2.347; Rozwarski DA, 1998, J BIOL CHEM, V273, P32818, DOI 10.1074/jbc.273.49.32818; Rudiger H, 1998, ACTA ANAT, V161, P130; Rudiger H, 2000, CURR MED CHEM, V7, P389, DOI 10.2174/0929867003375164; Seko A, 1997, BBA-GEN SUBJECTS, V1335, P23, DOI 10.1016/S0304-4165(96)00118-3; Sharma V, 1997, J MOL BIOL, V267, P433, DOI 10.1006/jmbi.1996.0863; SHARON N, 1990, FASEB J, V4, P3198, DOI 10.1096/fasebj.4.14.2227211; Sharon N, 1995, ESSAYS BIOCHEM, V30, P59; Srinivas VR, 2001, BBA-GEN SUBJECTS, V1527, P102, DOI 10.1016/S0304-4165(01)00153-2; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WILLIAMS BA, 1992, J BIOL CHEM, V267, P22907; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wright CS, 1996, STRUCTURE, V4, P1339, DOI 10.1016/S0969-2126(96)00141-4; YOUNG NM, 1992, J MOL BIOL, V228, P924, DOI 10.1016/0022-2836(92)90875-K	40	23	23	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2012	287	31					26352	26364		10.1074/jbc.M112.375816	http://dx.doi.org/10.1074/jbc.M112.375816			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980TN	22692206	hybrid, Green Published			2023-01-03	WOS:000306916300061
J	Fukuhara, S; Akizawa, T; Morita, S; Tsubakihara, Y				Fukuhara, Shunichi; Akizawa, Tadao; Morita, Satoshi; Tsubakihara, Yoshiharu			Understanding Measurements of Vitality in Patients with Chronic Kidney Disease: Connecting a Quality-of-Life Scale to Daily Activities	PLOS ONE			English	Article							HEALTH-STATUS	Background: Many patients with chronic kidney disease (CKD) suffer from fatigue caused by anemia, but that anemia can be reversed. Successful treatment can be measured as a decrease in fatigue and an increase in energy or vitality, particularly on the vitality (VT) subscale of the SF-36. Changes in VT scores are most commonly interpreted in terms of minimally important differences or standardized effect sizes, but neither a minimally important difference nor a standardized effect size provides information about how patients' activities are affected. Therefore, we analyzed the association between differences in VT scores and a variable that is meaningful to patients and to society the frequency of going out. Study Design: Questionnaire survey. Analyses of differences among participants at bseline, and analyses of differences within participants over time. Setting and Participants: CKD patients who were not on dialysis and were involved in a study of anti-anemia therapy. Predictor: VT scores. Outcome: Frequency of going out. Measurements: VT scores and the frequency of going out. Results: At baseline, higher VT scores and younger age were associated with going out more often, while sex and the presence of diabetic nephropathy were not associated with the frequency of going out. Greater changes in VT scores over time were associated with greater changes in the frequency of going out, in univariate and multivariate analyses. Conclusions: At baseline, VT was associated with the frequency of going out. Increases in VT were also associated with increases in the frequency of going out. These results show how VT scores can be linked to daily activities that are important to individual patients and to society.	[Fukuhara, Shunichi] Kyoto Univ, Grad Sch Med, Dept Healthcare Epidemiol, Kyoto, Japan; [Akizawa, Tadao] Showa Univ, Sch Med, Dept Med, Div Nephrol, Tokyo 142, Japan; [Morita, Satoshi] Yokohama City Univ, Sch Med, Univ Med Ctr, Dept Biostat & Epidemiol, Yokohama, Kanagawa 232, Japan; [Tsubakihara, Yoshiharu] Osaka Gen Med Ctr, Dept Kidney Dis & Hypertens, Osaka, Japan	Kyoto University; Showa University; Yokohama City University	Fukuhara, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Healthcare Epidemiol, Kyoto, Japan.	fukuhara.shunichi.6m@kyoto-u.ac.jp		Tsubakihara, Yoshiharu/0000-0001-9703-9443	Kyowa Hakko Kirin Co., Ltd (Tokyo, Japan); Kyowa Hakko Kirin Co., Ltd.	Kyowa Hakko Kirin Co., Ltd (Tokyo, Japan); Kyowa Hakko Kirin Co., Ltd.(Kyowa Kirin Ltd)	This study is not a Randomized Controlled Trial. However, the data used in this study were collected as part of such a trial, which was sponsored by Kyowa Hakko Kirin Co., Ltd (Tokyo, Japan). Registration of Clinical Trials: The Cochrane Renal Group registry: autoid 121, crg_id CRG030600049. The authors participated in that trial as advisers and received consultation fees from Kyowa Hakko Kirin Co., Ltd. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akizawa T, 2011, THER APHER DIAL, V15, P431, DOI 10.1111/j.1744-9987.2011.00931.x; Bjorner JB, 2007, CURR MED RES OPIN, V23, P731, DOI 10.1185/030079907X178757; Cohen J., 2013, STAT POWER ANAL BEHA; Drueke TB, 2006, NEW ENGL J MED, V355, P2071, DOI 10.1056/NEJMoa062276; Fukuhara S, 1998, J CLIN EPIDEMIOL, V51, P1037, DOI 10.1016/S0895-4356(98)00095-X; Gandra SR, 2010, AM J KIDNEY DIS, V55, P519, DOI 10.1053/j.ajkd.2009.09.019; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; Leaf DE, 2009, KIDNEY INT, V75, P15, DOI 10.1038/ki.2008.414; Mokkink LB, 2010, QUAL LIFE RES, V19, P539, DOI 10.1007/s11136-010-9606-8; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845; Sato D, 2007, QUAL LIFE RES, V16, P1577, DOI 10.1007/s11136-007-9269-2; Shibayama T, 2007, DIABETES RES CLIN PR, V76, P265, DOI 10.1016/j.diabres.2006.09.017; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485	14	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 12	2012	7	7							e40455	10.1371/journal.pone.0040455	http://dx.doi.org/10.1371/journal.pone.0040455			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	973NH	22808164	Green Submitted, gold, Green Published			2023-01-03	WOS:000306366400024
J	Carson, JL; Grossman, BJ; Kleinman, S; Tinmouth, AT; Marques, MB; Fung, MK; Holcomb, JB; Illoh, O; Kaplan, LJ; Katz, LM; Rao, SV; Roback, JD; Shander, A; Tobian, AAR; Weinstein, R; McLaughlin, LGS; Djulbegovic, B				Carson, Jeffrey L.; Grossman, Brenda J.; Kleinman, Steven; Tinmouth, Alan T.; Marques, Marisa B.; Fung, Mark K.; Holcomb, John B.; Illoh, Orieji; Kaplan, Lewis J.; Katz, Louis M.; Rao, Sunil V.; Roback, John D.; Shander, Aryeh; Tobian, Aaron A. R.; Weinstein, Robert; McLaughlin, Lisa Grace Swinton; Djulbegovic, Benjamin		Clinical Transfusion Med Comm AAB	Red Blood Cell Transfusion: A Clinical Practice Guideline From the AABB	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; CRITICALLY-ILL; RESTRICTIVE TRANSFUSION; RESIDUAL RISK; ADULT TRAUMA; ANEMIA; HIP; REQUIREMENTS; MULTICENTER; STRATEGIES	Description: Although approximately 85 million units of red blood cells (RBCs) are transfused annually worldwide, transfusion practices vary widely. The AABB (formerly, the American Association of Blood Banks) developed this guideline to provide clinical recommendations about hemoglobin concentration thresholds and other clinical variables that trigger RBC transfusions in hemodynamically stable adults and children. Methods: These guidelines are based on a systematic review of randomized clinical trials evaluating transfusion thresholds. We performed a literature search from 1950 to February 2011 with no language restrictions. We examined the proportion of patients who received any RBC transfusion and the number of RBC units transfused to describe the effect of restrictive transfusion strategies on RBC use. To determine the clinical consequences of restrictive transfusion strategies, we examined overall mortality, nonfatal myocardial infarction, cardiac events, pulmonary edema, stroke, thromboembolism, renal failure, infection, hemorrhage, mental confusion, functional recovery, and length of hospital stay. Recommendation 1: The AABB recommends adhering to a restrictive transfusion strategy (7 to 8 g/dL) in hospitalized, stable patients (Grade: strong recommendation; high-quality evidence). Recommendation 2: The AABB suggests adhering to a restrictive strategy in hospitalized patients with preexisting cardiovascular disease and considering transfusion for patients with symptoms or a hemoglobin level of 8 g/dL or less (Grade: weak recommendation; moderate-quality evidence). Recommendation 3: The AABB cannot recommend for or against a liberal or restrictive transfusion threshold for hospitalized, hemodynamically stable patients with the acute coronary syndrome (Grade: uncertain recommendation; very low-quality evidence). Recommendation 4: The AABB suggests that transfusion decisions be influenced by symptoms as well as hemoglobin concentration (Grade: weak recommendation; low-quality evidence).	[Carson, Jeffrey L.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Gen Internal Med, New Brunswick, NJ 08903 USA; Washington Univ, Sch Med, St Louis, MO USA; AABB, Bethesda, MD USA; Johns Hopkins Univ, Sch Med, Bethesda, MD USA; Univ British Columbia, Victoria, BC, Canada; Ottawa Hosp, Res Inst, Ottawa, ON, Canada; Univ Alabama Birmingham, Birmingham, AL USA; Fletcher Allen Hlth Care, Burlington, VT USA; Univ Texas Houston, Med Ctr, Ctr Translat Injury Res, Houston, TX USA; Univ Texas Houston, Med Ctr, Dept Surg, Houston, TX USA; US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD USA; Yale Med Grp, New Haven, CT USA; Univ Iowa, Mississippi Valley Reg Blood Ctr, Davenport, IA USA; Univ Iowa, Carver Coll Med, Davenport, IA USA; Duke Univ, Sch Med, Durham, NC USA; Emory Univ, Sch Med, Atlanta, GA USA; Englewood Hosp & Med Ctr, Englewood, NJ USA; Univ Massachusetts, Sch Med, Worcester, MA USA; Amer Red Cross, Rockville, MD USA; Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA; Res Inst, Tampa, FL USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Washington University (WUSTL); Johns Hopkins University; University of British Columbia; University of Ottawa; Ottawa Hospital Research Institute; University of Alabama System; University of Alabama Birmingham; University of Vermont Medical Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; US Food & Drug Administration (FDA); University of Iowa; University of Iowa; Duke University; Emory University; Englewood Hospital & Medical Center; University of Massachusetts System; University of Massachusetts Worcester; American Red Cross; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Carson, JL (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Gen Internal Med, 125 Paterson St, New Brunswick, NJ 08903 USA.	carson@umdnj.edu	Girelli, Domenico/B-1183-2008; Djulbegovic, Benjamin/I-3661-2012	Girelli, Domenico/0000-0001-9684-1899; Djulbegovic, Benjamin/0000-0003-0671-1447; Marques, Marisa/0000-0002-6689-7856; Grossman, Brenda/0000-0002-1500-8211; Fung, Mark/0000-0001-6081-4151; holcomb, john/0000-0001-8312-9157	AABB, Bethesda, Maryland	AABB, Bethesda, Maryland	Support for the development of this guideline was provided by the AABB, Bethesda, Maryland.	AABB, 2006, AABB POL CONFL INT C; ANDERSON HT, 1978, SURGERY, V84, P8; [Anonymous], 1994, Transfus Med, V4, P251; [Anonymous], ODDS BEING INV FAT A; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; [Australasian Society of Blood Transfusion National Health and Medical Research Council], 2001, CLIN PRACT GUID APPR; Bassand JP, 2007, EUR HEART J, V28, P1598, DOI 10.1093/eurheartj/ehm161; Bennett-Guerrero E, 2010, JAMA-J AM MED ASSOC, V304, P1568, DOI 10.1001/jama.2010.1406; Bierbaum BE, 1999, J BONE JOINT SURG AM, V81A, P2, DOI 10.2106/00004623-199901000-00002; BLAIR SD, 1986, BRIT J SURG, V73, P783, DOI 10.1002/bjs.1800731007; Bracey AW, 1999, TRANSFUSION, V39, P1070, DOI 10.1046/j.1537-2995.1999.39101070.x; Bush RL, 1997, AM J SURG, V174, P143, DOI 10.1016/S0002-9610(97)00073-1; Carless PA, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002042.pub2; Carson JL, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002042.pub3; Carson JL, 2011, NEW ENGL J MED, V365, P2453, DOI 10.1056/NEJMoa1012452; Carson JL, 1996, LANCET, V348, P1055, DOI 10.1016/S0140-6736(96)04330-9; Carson JL, 1998, TRANSFUSION, V38, P522, DOI 10.1046/j.1537-2995.1998.38698326331.x; Colomo A, 2009, HEPATOLOGY, V50, p403A; Corwin HL, 2004, CRIT CARE MED, V32, P39, DOI 10.1097/01.CCM.0000104112.34142.79; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dzik WH, 2003, TRANSFUSION, V43, P1190, DOI 10.1046/j.1537-2995.2003.00523.x; Federowicz I, 1996, TRANSFUSION, V36, P21, DOI 10.1046/j.1537-2995.1996.36196190511.x; FISHER M R, 1956, Br J Clin Pract, V10, P770; FORTUNE JB, 1987, J TRAUMA, V27, P243, DOI 10.1097/00005373-198703000-00003; Foss NB, 2009, TRANSFUSION, V49, P227, DOI 10.1111/j.1537-2995.2008.01967.x; Grover M, 2006, VOX SANG, V90, P105, DOI 10.1111/j.1423-0410.2006.00730.x; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; HAGL S, 1977, BASIC RES CARDIOL, V72, P344, DOI 10.1007/BF02023594; Hajjar LA, 2010, JAMA-J AM MED ASSOC, V304, P1559, DOI 10.1001/jama.2010.1446; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; HEBERT PC, 1995, JAMA-J AM MED ASSOC, V273, P1439, DOI 10.1001/jama.273.18.1439; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; HILL SR, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002042.PUB2; Holle RL., 2011, LIGHTNING FATALITIES; Hutton B, 2005, CAN J ANAESTH, V52, P581, DOI 10.1007/BF03015766; JOHNSON RG, 1992, J THORAC CARDIOV SUR, V104, P307; Kohn L, 2000, Jt Comm J Qual Improv, V26, P227; Lacroix J, 2007, NEW ENGL J MED, V356, P1609, DOI 10.1056/NEJMoa066240; Li GX, 2011, TRANSFUSION, V51, P338, DOI 10.1111/j.1537-2995.2010.02816.x; Linden JV, 1997, TRANSFUSION, V37, P243, DOI 10.1046/j.1537-2995.1997.37297203534.x; Linden JV, 2000, TRANSFUSION, V40, P1207, DOI 10.1046/j.1537-2995.2000.40101207.x; Lotke PA, 1999, J ARTHROPLASTY, V14, P647, DOI 10.1016/S0883-5403(99)90216-4; MacMahon S, 2001, LANCET, V357, P455, DOI 10.1016/S0140-6736(00)04017-4; Marik PE, 2008, CRIT CARE MED, V36, P2667, DOI 10.1097/CCM.0b013e3181844677; Middelburg RA, 2010, TRANSFUSION, V50, P1181, DOI 10.1111/j.1537-2995.2010.02675.x; Minino AM, 2011, DEATHS FINAL DATA 20; Murphy MF, 2001, BRIT J HAEMATOL, V113, P24; Napolitano LM, 2009, J TRAUMA, V67, P1439, DOI 10.1097/TA.0b013e3181ba7074; Napolitano LM, 2009, CRIT CARE MED, V37, P3124, DOI 10.1097/CCM.0b013e3181b39f1b; Popovsky M A, 1996, Immunohematology, V12, P87; So-Osman C, 2010, VOX SANG, V98, P56, DOI 10.1111/j.1423-0410.2009.01225.x; Stehling LC, 1996, ANESTHESIOLOGY, V84, P732; Takei T, 2009, JAIDS-J ACQ IMM DEF, V52, pS127, DOI 10.1097/QAI.0b013e3181baf0ac; Toy P, 2012, BLOOD, V119, P1757, DOI 10.1182/blood-2011-08-370932; U. Food D. Administration, 2011, FAT REP FDA FOLL BLO; U.S. Department of Health and Human Services, 2011, 2009 NAT BLOOD COLL; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; Vuille-Lessard E, 2010, TRANSFUSION, V50, P2117, DOI 10.1111/j.1537-2995.2010.02697.x; Webert KE, 2008, TRANSFUSION, V48, P81, DOI 10.1111/j.1537-2995.2007.01485.x; WILKERSON DK, 1988, SURGERY, V103, P665; Zou SM, 2010, TRANSFUSION, V50, P1495, DOI 10.1111/j.1537-2995.2010.02622.x; Zou SM, 2009, TRANSFUSION, V49, P1609, DOI 10.1111/j.1537-2995.2009.02195.x; Zygun DA, 2009, CRIT CARE MED, V37, P1074, DOI 10.1097/CCM.0b013e318194ad22	63	714	748	5	57	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2012	157	1					49	U95		10.7326/0003-4819-157-1-201206190-00429	http://dx.doi.org/10.7326/0003-4819-157-1-201206190-00429			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992NS	22751760				2023-01-03	WOS:000307784900005
J	Sandercock, P; Wardlaw, JM; Lindley, RI; Dennis, M; Cohen, G; Murray, G; Innes, K; Venables, G; Czlonkowska, A; Kobayashi, A; Ricci, S; Murray, V; Berge, E; Slot, KB; Hankey, GJ; Correia, M; Peeters, A; Matz, K; Lyrer, P; Gubitz, G; Phillips, SJ; Arauz, A; Baigent, C; Chadwick, D; Tyrrell, P; Lowe, G; Farrall, A; von Kummer, R; Cala, L; von Heijne, A; Morris, Z; Adami, A; Potter, G; Brady, N; Collins, R; Bath, P; van Gijn, J; Gray, R; Hart, R; Yusuf, S; Muir, K; Brainin, M; Engelter, S; Terent, A; Norrving, B; Wester, P; Clark, A; Perry, D; Soosay, V; Buchanan, D; Grant, S; Sakka, E; Drever, J; Walker, P; Herath, I; Brown, AL; Chmielnik, P; Armit, C; Walton, A; Hautvast, M; Lewis, S; Heron, G; Odusanya, S; Linksted, P; Kane, I; Whiteley, W; Sellar, R; White, P; Keston, P; Farrell, A; Morris, Z; Miranda, H; Blackwell, L; Celani, MG; Righetti, E; Cenciarelli, S; Mazzoli, T; Cantisani, TA; Bembenek, J; Isaakson, E; Freys, G				Sandercock, Peter; Wardlaw, Joanna M.; Lindley, Richard I.; Dennis, Martin; Cohen, Geoff; Murray, Gordon; Innes, Karen; Venables, Graham; Czlonkowska, Anna; Kobayashi, Adam; Ricci, Stefano; Murray, Veronica; Berge, Eivind; Slot, Karsten Bruins; Hankey, Graeme J.; Correia, Manuel; Peeters, Andre; Matz, Karl; Lyrer, Phillippe; Gubitz, Gord; Phillips, Stephen J.; Arauz, Antonio; Baigent, Colin; Chadwick, David; Tyrrell, Pippa; Lowe, Gordon; Farrall, Andrew; von Kummer, Rudiger; Cala, Lesley; von Heijne, Anders; Morris, Zoe; Adami, Alessandro; Potter, Gillian; Brady, Nick; Collins, Rory; Bath, Philip; van Gijn, Jan; Gray, Richard; Hart, Robert; Yusuf, Salim; Muir, Keith; Brainin, Michael; Engelter, Stefan; Terent, Andreas; Norrving, Bo; Wester, Per; Clark, Alison; Perry, David; Soosay, Vera; Buchanan, David; Grant, Sheila; Sakka, Eleni; Drever, Jonathan; Walker, Pauli; Herath, Indee; Brown, Ann Leigh; Chmielnik, Paul; Armit, Christopher; Walton, Andrea; Hautvast, Mischa; Lewis, Steff; Heron, Graeme; Odusanya, Sylvia; Linksted, Pam; Kane, Ingrid; Whiteley, Will; Sellar, Robin; White, Philip; Keston, Peter; Farrell, Andrew; Morris, Zoe; Miranda, Hector; Blackwell, Lisa; Celani, Maria Grazia; Righetti, Enrico; Cenciarelli, Silvia; Mazzoli, Tatiana; Cantisani, Teresa Anna; Bembenek, Jan; Isaakson, Eva; Freys, Genevieve		IST 3 Collaborative Grp	The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial	LANCET			English	Article							CASE-FATALITY; STATISTICAL-ANALYSIS; RISK-FACTORS; CT; OXFORDSHIRE; MORTALITY; ALTEPLASE; DISEASE; IMPACT; BRAIN	Background Thrombolysis is of net benefit in patients with acute ischaemic stroke, who are younger than 80 years of age and are treated within 4.5 h of onset. The third International Stroke Trial (IST-3) sought to determine whether a wider range of patients might benefit up to 6 h from stroke onset. Methods In this international, multicentre, randomised, open-treatment trial, patients were allocated to 0.9 mg/kg intravenous recombinant tissue plasminogen activator (rt-PA) or to control. The primary analysis was of the proportion of patients alive and independent, as defined by an Oxford Handicap Score (OHS) of 0-2 at 6 months. The study is registered, ISRCTN25765518. Findings 3035 patients were enrolled by 156 hospitals in 12 countries. All of these patients were included in the analyses (1515 in the rt-PA group vs 1520 in the control group), of whom 1617 (53%) were older than 80 years of age. At 6 months, 554 (37%) patients in the rt-PA group versus 534 (35%) in the control group were alive and independent (OHS 0-2; adjusted odds ratio [OR] 1.13, 95% CI 0.95-1.35, p=0.181; a non-significant absolute increase of 14/1000, 95% CI -20 to 48). An ordinal analysis showed a significant shift in OHS scores; common OR 1.27 (95% CI 1.10-1.47, p=0.001). Fatal or non-fatal symptomatic intracranial haemorrhage within 7 days occurred in 104 (7%) patients in the rt-PA group versus 16 (1%) in the control group (adjusted OR 6.94, 95% CI 4.07-11.8; absolute excess 58/1000, 95% CI 44-72). More deaths occurred within 7 days in the rt-PA group (163 [11%]) than in the control group (107 [7%], adjusted OR 1.60, 95% CI 1.22-2.08, p=0.001; absolute increase 37/1000, 95% CI 17-57), but between 7 days and 6 months there were fewer deaths in the rt-PA group than in the control group, so that by 6 months, similar numbers, in total, had died (408 [27%] in the rt-PA group vs 407 [27%] in the control group). Interpretation For the types of patient recruited in IST-3, despite the early hazards, thrombolysis within 6 h improved functional outcome. Benefit did not seem to be diminished in elderly patients.	[Sandercock, Peter] Univ Edinburgh, Western Gen Hosp, Div Clin Neurosci, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland; [Lindley, Richard I.] Univ Sydney, Westmead Hosp, Sydney Med Sch, Sydney, NSW 2006, Australia; [Lindley, Richard I.] Univ Sydney, George Inst Global Hlth, Sydney, NSW 2006, Australia; [Venables, Graham] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England; [Czlonkowska, Anna] Med Univ Warsaw, Warsaw, Poland; [Ricci, Stefano] Osped Citta Castello, Dept Neurol ASL1, Citta Di Castello, Italy; [Murray, Veronica] Karolinska Inst, Stockholm, Sweden; [Berge, Eivind; Slot, Karsten Bruins] Oslo Univ Hosp, Oslo, Norway; [Hankey, Graeme J.] Royal Perth Hosp, Perth, WA, Australia; [Correia, Manuel] Hosp Geral Santo Antonio, Oporto, Portugal; [Peeters, Andre] Clin Univ St Luc, B-1200 Brussels, Belgium; [Matz, Karl] Landesklinikum Donaureg Tulln, Tulln, Austria; [Lyrer, Phillippe] Univ Basel Hosp, CH-4031 Basel, Switzerland; [Gubitz, Gord; Phillips, Stephen J.] Dalhousie Univ, Halifax, NS, Canada; [Gubitz, Gord; Phillips, Stephen J.] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada; [Arauz, Antonio] Inst Nacl Neurol, Mexico City, DF, Mexico; [Baigent, Colin; Collins, Rory; Gray, Richard] Univ Oxford, Oxford, England; [Chadwick, David] Univ Liverpool, Liverpool L69 3BX, Merseyside, England; [Tyrrell, Pippa] Univ Manchester, Manchester, Lancs, England; [Muir, Keith] Univ Glasgow, Inst Neurol Sci, Glasgow, Lanark, Scotland; [Bath, Philip] Univ Nottingham, Nottingham NG7 2RD, England; [van Gijn, Jan] Univ Utrecht, Utrecht, Netherlands; [Hart, Robert; Yusuf, Salim] McMaster Univ, Hamilton, ON L8S 4L8, Canada; [Blackwell, Lisa] Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England	University of Edinburgh; University of Sydney; George Institute for Global Health; University of Sydney; University of Sheffield; Medical University of Warsaw; Karolinska Institutet; University of Oslo; Royal Perth Hospital; University of Western Australia; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; University of Basel; Dalhousie University; Queen Elizabeth II Health Sciences Centre; University of Oxford; University of Liverpool; University of Manchester; University of Glasgow; University of Nottingham; Utrecht University; McMaster University; Radcliffe Infirmary; University of Oxford	Sandercock, P (corresponding author), Univ Edinburgh, Western Gen Hosp, Div Clin Neurosci, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	peter.sandercock@ed.ac.uk	Spratt, Neil J/K-4208-2012; Lueck, Christian Joseph/O-4031-2016; Lindley, Richard/B-8148-2013; Barilaro, Alessandro/AAB-8373-2020; Badve, Monica/W-2187-2017; celani, maria grazia/AAF-4143-2020; Bonati, Leo/G-4058-2012; Brola, Waldemar/D-8813-2014; Gojska-Grymajlo, Anna/F-3147-2012; von Kummer, Rüdiger/AAA-4478-2019; Wardlaw, Joanna M/Y-3456-2019; Ginsberg, Lionel/C-8704-2009; Leńska-Mieciek, Marta/ABH-8893-2020; Balestrino, Maurizio/A-2305-2008; Collins, Rory/ABA-8487-2020; Benedetti, Luana/J-8450-2018; Buchan, Alastair M/B-9095-2009; Zini, Andrea/K-1136-2014; bladin, chris/B-9136-2013; Hernandez, María/GYU-3543-2022; Hill, Michael D/C-9073-2012; Armit, Chris/AAZ-5613-2020; Calleja, Juan/AAX-3777-2020; Werring, David/Q-8435-2019; Demchuk, Andrew M/E-1103-2012; Adami, Alessandro/P-1831-2018; Kobayashi, Adam/AAL-7232-2020; Hankey, Graeme J/H-4968-2014; Macleod, Malcolm Robert/B-2052-2010; Aaseth, Jan/J-6764-2017; Parsons, Mark W./G-3750-2014; Bath, Philip/F-9020-2011	Spratt, Neil J/0000-0002-9023-6177; Lueck, Christian Joseph/0000-0003-1537-7612; Lindley, Richard/0000-0002-0104-5679; Badve, Monica/0000-0002-1115-6719; Bonati, Leo/0000-0003-1163-8133; Brola, Waldemar/0000-0002-7955-3454; Gojska-Grymajlo, Anna/0000-0002-6065-3754; von Kummer, Rüdiger/0000-0003-0119-4604; Wardlaw, Joanna M/0000-0002-9812-6642; Balestrino, Maurizio/0000-0002-5971-2200; Benedetti, Luana/0000-0002-9540-9727; Buchan, Alastair M/0000-0002-2918-5200; Zini, Andrea/0000-0003-1486-4507; Hill, Michael D/0000-0002-6269-1543; Armit, Chris/0000-0002-9952-8141; Calleja, Juan/0000-0002-0423-9719; Werring, David/0000-0003-2074-1861; Demchuk, Andrew M/0000-0002-4930-7789; Adami, Alessandro/0000-0002-9163-4900; Hankey, Graeme J/0000-0002-6044-7328; Macleod, Malcolm Robert/0000-0001-9187-9839; Aaseth, Jan/0000-0002-7518-5703; Yusuf, Salim/0000-0003-4776-5601; Sandercock, Peter/0000-0001-8484-0135; Sudlow, Cathie/0000-0002-7725-7520; Kwan, Joseph/0000-0003-4635-3322; Doig, David/0000-0002-7492-6610; Lundstrom, Erik/0000-0002-5313-9052; White, Philip/0000-0001-6007-6013; Lewis, Steff/0000-0003-1210-2314; Bath, Philip/0000-0003-2734-5132; Cloud, Geoffrey/0000-0002-8365-6907; Bilik, Marta/0000-0001-7049-3988; Karaszewski, Bartosz/0000-0003-2726-0016; Whiteley, William/0000-0002-4816-8991; Emsley, Hedley/0000-0003-0129-4488; Tamburin, Stefano/0000-0002-1561-2187; Murray, Gordon/0000-0001-9866-4734; Damasio, Joana/0000-0002-6539-6398; Czlonkowska, Anna/0000-0002-1956-1866; Wardle, Mark/0000-0002-4543-7068; Randall, Marc/0000-0002-3196-182X; Felgueiras, Rui/0000-0001-9372-8743; Tyrrell, Pippa/0000-0001-9609-1231; corea, francesco/0000-0002-5864-9991; Strain, William/0000-0002-6826-418X; Matz, Karl/0000-0002-2851-9897; Engelter, Stefan/0000-0003-3855-6234; Vucic, Steve/0000-0002-8323-873X; Al-Shahi Salman, Rustam/0000-0002-2108-9222; Gray, Richard/0000-0003-4440-574X; Lenska-Mieciek, Marta/0000-0001-7245-7817; Fiszer, Urszula/0000-0002-9286-2454	UK Medical Research Council; Health Foundation UK; Stroke Association UK; Research Council of Norway; Arbetsmarknadens Partners Forsakringsbolag (AFA) Insurances Sweden; Swedish Heart Lung Fund; Foundation of Marianne and Marcus Wallenberg; Polish Ministry of Science and Education; Australian Heart Foundation; Australian National Health and Medical Research Council (NHMRC); Swiss National Research Foundation; Swiss Heart Foundation; Assessorato alla Sanita; Regione dell'Umbria, Italy; Danube University; Boehringer Ingelheim; Sanofi Synthlabo Aventis; Hoffman La Roche; Novo Nordisk; UK Research Councils Joint Research Equipment Initiative; UK MRC [G0400069, EME 09-800-15]; AFA Insurances (Sweden); Stockholm County Council; Karolinska Institute (Sweden); Government of Poland [2PO5B10928]; Australian Heart Foundation [G 04S 1638]; Australian NHMRC [457343]; Foundation for health and cardio-/neurovascular research, Basel, Switzerland; Danube University, Krems, Austria; NIHR Stroke Research Network; NHS Research Scotland, through the Scottish Stroke Research Network; National Institute for Social Care and Health Research Clinical Research Centre; Scottish Funding Council; Chief Scientist Office of the Scottish Executive; Chest Heart and Stroke Scotland; DesAcc; University of Edinburgh; Danderyd Hospital RD Department; Oslo University Hospital; Dalhousie University; NIHR through the UK Stroke Research Network; MRC [MC_G1002455, G0400069, G0902303, G0800803] Funding Source: UKRI; Medical Research Council [G0902303, G0400069, G0800803, MC_G1002455, G0700704B] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Health Foundation UK; Stroke Association UK; Research Council of Norway(Research Council of Norway); Arbetsmarknadens Partners Forsakringsbolag (AFA) Insurances Sweden; Swedish Heart Lung Fund(Swedish Heart-Lung Foundation); Foundation of Marianne and Marcus Wallenberg; Polish Ministry of Science and Education(Ministry of Science and Higher Education, Poland); Australian Heart Foundation; Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Swiss National Research Foundation(Swiss National Science Foundation (SNSF)); Swiss Heart Foundation; Assessorato alla Sanita; Regione dell'Umbria, Italy; Danube University; Boehringer Ingelheim(Boehringer Ingelheim); Sanofi Synthlabo Aventis; Hoffman La Roche; Novo Nordisk(Novo Nordisk); UK Research Councils Joint Research Equipment Initiative; UK MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); AFA Insurances (Sweden); Stockholm County Council(Stockholm County Council); Karolinska Institute (Sweden)(Karolinska Institutet); Government of Poland; Australian Heart Foundation; Australian NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Foundation for health and cardio-/neurovascular research, Basel, Switzerland; Danube University, Krems, Austria; NIHR Stroke Research Network; NHS Research Scotland, through the Scottish Stroke Research Network; National Institute for Social Care and Health Research Clinical Research Centre; Scottish Funding Council; Chief Scientist Office of the Scottish Executive; Chest Heart and Stroke Scotland; DesAcc; University of Edinburgh; Danderyd Hospital RD Department; Oslo University Hospital; Dalhousie University; NIHR through the UK Stroke Research Network; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	UK Medical Research Council, Health Foundation UK, Stroke Association UK, Research Council of Norway, Arbetsmarknadens Partners Forsakringsbolag (AFA) Insurances Sweden, Swedish Heart Lung Fund, The Foundation of Marianne and Marcus Wallenberg, Polish Ministry of Science and Education, the Australian Heart Foundation, Australian National Health and Medical Research Council (NHMRC), Swiss National Research Foundation, Swiss Heart Foundation, Assessorato alla Sanita, Regione dell'Umbria, Italy, and Danube University.r EB has received honoraria for lectures at meetings arranged by Boehringer Ingelheim, and reimbursement for costs for attending these meetings. AC has received lecture fees and conference travel costs from Boehringer Ingelheim. GB has received honoraria and speaker fees from Boehringer Ingelheim, Sanofi Synthlabo Aventis, Hoffman La Roche, and Novo Nordisk. AK has received lecture fees and conference travel costs from Boehringer Ingelheim. RIL has received payment in his role as conference scientific committee member and for occasional lectures from Boehringer Ingelheim; has attended national stroke meetings organised and funded by Boehringer Ingelheim; and is not a member of any industry advisory boards. PS has received lecture fees (paid to the Division of Clinical Neurosciences, University of Edinburgh) and travel expenses from Boehringer Ingelheim for occasional lectures given at international conferences; and was a member of the Independent Data and Safety Monitoring Board (DSMB) of the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial funded by Boehringer Ingelheim and received attendance fees and travel expenses for attending DSMB meetings (paid to the Division of Clinical Neurosciences, University of Edinburgh). KBS has received an honorarium for a lecture from Boehringer Ingelheim and had costs for participating in scientific meetings reimbursed; is a member of the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) and the Cardiovascular Working Party. The views expressed in this article are the personal views of KBS and should not be understood or quoted as being made on behalf of or reflecting the position of the European Medicines Agency or one of its committees or working parties. VM has received an unrestricted educational grant for a meeting on thrombolysis in stroke at which IST-3 was discussed. JMW received reimbursement for reading CT scans for European Cooperative Acute Stroke Study III (ECASS III) from Boehringer Ingelheim in the form of funding to her department, the Division of Clinical Neurosciences, University of Edinburgh; is the contact reviewer for the Cochrane systematic reviews of thrombolytic treatment for acute stroke; has attended meetings held by Boehringer Ingelheim as an unpaid independent external adviser during the licensing of rt-PA, but was refunded her travel expenses and the time away from work; has attended and spoken at national and international stroke meetings organised and funded by Boehringer Ingelheim for which she received honoraria and travel expenses; and is director of the Brain Research Imaging Centre for Scotland, which is located within the Department of Clinical Neurosciences at the University of Edinburgh, Edinburgh, Scotland and houses a research MRI scanner, which was funded by the UK Research Councils Joint Research Equipment Initiative, supplemented by grants and donations from various other sources including Novartis, Schering, General Electric, and Boehringer Ingelheim.; These commercial sources contributed to the purchase of the scanner, but not the running costs or any individual studies. All other members of the writing committee declare that they have no conflicts of interest.r The IST-3 collaborative group thanks all the patients who participated in the study, and the many individuals not specifically mentioned in the paper who have supported the study. IST-3 is an investigator led trial. The University of Edinburgh and the Lothian Health Board are cosponsors. The start-up phase was supported by a grant from the Stroke Association, UK. The expansion phase was funded by The Health Foundation UK. The main phase of the trial is funded by the following organisations: UK MRC (grant numbers G0400069 and EME 09-800-15) and managed by NIHR on behalf of the MRC-NIHR partnership; The Research Council of Norway; AFA Insurances (Sweden); the Swedish Heart Lung Fund; The Foundation of Marianne and Marcus Wallenberg; Stockholm County Council and Karolinska Institute Joint ALF-project grants (Sweden); the Government of Poland (grant number 2PO5B10928); the Australian Heart Foundation (grant number G 04S 1638); Australian NHMRC (grant number 457343); the Swiss National Research Foundation; the Swiss Heart Foundation; Foundation for health and cardio-/neurovascular research, Basel, Switzerland; the Assessorato alla Sanita, Regione dell'Umbria; Danube University, Krems, Austria. Drug and placebo for the 300 patients in the double-blind component of the start-up phase were supplied by Boehringer Ingelheim. We thank the NIHR Stroke Research Network, NHS Research Scotland, through the Scottish Stroke Research Network, and the National Institute for Social Care and Health Research Clinical Research Centre for their support. The imaging work was undertaken at the Brain Imaging Research Centre, a member of the SINAPSE collaboration, at the Division of Clinical Neurosciences, University of Edinburgh. SINAPSE is funded by the Scottish Funding Council and the Chief Scientist Office of the Scottish Executive. Additional support was received from Chest Heart and Stroke Scotland, DesAcc, University of Edinburgh, Danderyd Hospital R&D Department, Karolinska Institutet, Oslo University Hospital, and the Dalhousie University Internal Medicine Research Fund. This report presents independent research supported by the NIHR through the UK Stroke Research Network. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.	BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; Barber PA, 2000, LANCET, V355, P1670, DOI 10.1016/S0140-6736(00)02237-6; Bath PMW, 2007, STROKE, V38, P1911, DOI 10.1161/STROKEAHA.106.474080; Bembenek J, 2010, INT J STROKE, V5, P430, DOI 10.1111/j.1747-4949.2010.00479.x; Buyse M, 1999, STAT MED, V18, P3435, DOI 10.1002/(SICI)1097-0258(19991230)18:24<3435::AID-SIM365>3.3.CO;2-F; Collins R, 2001, LANCET, V357, P373, DOI 10.1016/S0140-6736(00)03651-5; Cordonnier C, 2009, STROKE, V40, P94, DOI 10.1161/STROKEAHA.108.526996; Farrell C, 2009, EUR RADIOL, V19, P177, DOI 10.1007/s00330-008-1119-2; Feigin VL, 2009, LANCET NEUROL, V8, P355, DOI 10.1016/S1474-4422(09)70025-0; Islam SM, 2008, STROKE, V39, P776, DOI 10.1161/STROKEAHA.107.493643; Kent DM, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-85; Koenig IR, 2008, STROKE, V39, P1821, DOI 10.1161/STROKEAHA.107.505867; Langhorne P, 2002, AGE AGEING, V31, P365, DOI 10.1093/ageing/31.5.365; Lees KR, 2010, LANCET, V375, P1695, DOI 10.1016/S0140-6736(10)60491-6; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Lyden PD, 2012, STROKE, V43, P1691, DOI 10.1161/STROKEAHA.112.656876; McHugh GS, 2010, CLIN TRIALS, V7, P44, DOI 10.1177/1740774509356580; Peto R, 1998, BMJ-BRIT MED J, V317, P1170, DOI 10.1136/bmj.317.7167.1170; Rothwell PM, 2004, LANCET, V363, P1925, DOI 10.1016/S0140-6736(04)16405-2; Sandercock P, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-252; Sandercock P, 2012, INT J STROKE, V7, P186, DOI 10.1111/j.1747-4949.2012.00782.x; Sandercock P, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-37; Sanossian N, 2009, LANCET NEUROL, V8, P1031, DOI 10.1016/S1474-4422(09)70259-5; Slot KB, 2008, BRIT MED J, V336, P376, DOI 10.1136/bmj.39456.688333.BE; Strong K, 2007, LANCET NEUROL, V6, P182, DOI 10.1016/S1474-4422(07)70031-5; VANSWIETEN JC, 1990, J NEUROL NEUROSUR PS, V53, P1080, DOI 10.1136/jnnp.53.12.1080; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Wahlgren N, 2007, LANCET, V369, P275, DOI 10.1016/S0140-6736(07)60149-4; WARDLAW JM, 1994, AM J NEURORADIOL, V15, P1933; Wardlaw JM, 2007, STROKE, V38, P1250, DOI 10.1161/01.STR.0000259715.53166.25; Wardlaw JM, 2012, LANCET, V379, P2364, DOI 10.1016/S0140-6736(12)60738-7; Wardlaw JM, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000213.pub2; Ware JH, 2011, NEW ENGL J MED, V364, P1685, DOI 10.1056/NEJMp1103502; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; Whiteley W, 2006, INT J STROKE, V1, P172, DOI 10.1111/j.1747-4949.2006.00043.x	35	839	871	4	109	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 23	2012	379	9834					2352	2363		10.1016/S0140-6736(12)60768-5	http://dx.doi.org/10.1016/S0140-6736(12)60768-5			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	961ZV	22632908	Green Published			2023-01-03	WOS:000305509600030
J	Ferner, R				Ferner, Robin			Summertime	BRITISH MEDICAL JOURNAL			English	Editorial Material							THALLIUM ACETATE		Birmingham City Hosp, W Midlands Ctr Adverse Drug React, Birmingham B18 7QH, W Midlands, England		Ferner, R (corresponding author), Birmingham City Hosp, W Midlands Ctr Adverse Drug React, Birmingham B18 7QH, W Midlands, England.	R.E.Ferner@bham.ac.uk		Ferner, Robin/0000-0003-3769-1346				[Anonymous], 1847, PLIN NAT HIST 37 BOO; Greenbaum SS, 1931, J AMER MED ASSOC, V96, P1868, DOI 10.1001/jama.1931.27220480003010a; Ingram JT, 1932, BMJ-BRIT MED J, V1932, P8, DOI 10.1136/bmj.1.3704.8; National Institute for Health and Clinical Excellence, ANG MYOC INF MYOC PE; Robb-Smith AHT, 1987, LANCET, V329, P872	5	0	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUN 19	2012	344								e4245	10.1136/bmj.e4245	http://dx.doi.org/10.1136/bmj.e4245			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	965CU	22718967				2023-01-03	WOS:000305744600016
J	Grande, D				Grande, David			The Cost of Drug Coupons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Grande, David] Univ Penn, Perelman Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA; [Grande, David] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Grande, D (corresponding author), 3641 Locust Walk,Colonial Penn Ctr 407, Philadelphia, PA 19104 USA.	dgrande@wharton.upenn.edu	Grande, David/AAJ-8191-2021	Grande, David/0000-0002-6717-6735				Heisler M, 2004, MED CARE, V42, P626, DOI 10.1097/01.mlr.0000129352.36733.cc; Heisler M, 2010, MED CARE, V48, P87, DOI 10.1097/MLR.0b013e3181c12e53; Jackevicius CA, 2012, NEW ENGL J MED, V366, P201, DOI 10.1056/NEJMp1113112; Lipkus IM, 2001, MED DECIS MAKING, V21, P37, DOI 10.1177/0272989X0102100105; Madden JM, 2008, JAMA-J AM MED ASSOC, V299, P1922, DOI 10.1001/jama.299.16.1922; Pharmaceutical Care Management Association, 2011, COP COUP COULD RAIS; Thomas JM, 2012, HIS NAME WAS RICO HE	7	19	20	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 13	2012	307	22					2375	2376		10.1001/jama.2012.5603	http://dx.doi.org/10.1001/jama.2012.5603			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	956UX	22692167				2023-01-03	WOS:000305115900019
J	Wand, BM; Heine, PJ; O'Connell, NE				Wand, Benedict M.; Heine, Peter J.; O'Connell, Neil E.			Should we abandon cervical spine manipulation for mechanical neck pain? Yes	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							HOME EXERCISE; STROKE; RISK		[O'Connell, Neil E.] Brunel Univ, Rehabil Res Ctr, Uxbridge UB8 3PH, Middx, England; [Wand, Benedict M.] Univ Notre Dame Australia, Sch Physiotherapy, Fremantle, WA 6959, Australia; [Heine, Peter J.] Univ Warwick, Div Hlth Sci, Warwick Clin Trials Unit, Coventry CV4 7AL, W Midlands, England	Brunel University; University of Notre Dame Australia; University of Warwick	O'Connell, NE (corresponding author), Brunel Univ, Rehabil Res Ctr, Uxbridge UB8 3PH, Middx, England.	neil.oconnell@brunel.ac.uk	Wand, Benedict/C-3341-2011; O'CONNELL, NEIL/A-6907-2014	O'CONNELL, NEIL/0000-0003-1989-4537; Wand, Benedict/0000-0002-0297-0292				Boyle E, 2009, J MANIP PHYSIOL THER, V32, pS194, DOI 10.1016/j.jmpt.2008.11.019; Bronfort G, 2012, ANN INTERN MED, V156, P1, DOI 10.7326/0003-4819-156-1-201201030-00002; Cassidy JD, 2008, SPINE, V33, pS176, DOI 10.1097/BRS.0b013e3181644600; Debette S, 2009, LANCET NEUROL, V8, P668, DOI 10.1016/S1474-4422(09)70084-5; Ernst E, 2007, J ROY SOC MED, V100, P330, DOI 10.1258/jrsm.100.7.330; Ernst E, 2010, INT J CLIN PRACT, V64, P673, DOI 10.1111/j.1742-1241.2009.02237.x; Evans R, 2012, SPINE, V37, P903, DOI 10.1097/BRS.0b013e31823b3bdf; Gross A, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004249.pub3; Kawchuk GN, 2008, J NEUROL, V255, P371, DOI 10.1007/s00415-008-0667-3; Leaver AM, 2010, ARCH PHYS MED REHAB, V91, P1313, DOI 10.1016/j.apmr.2010.06.006; Rothwell DM, 2001, STROKE, V32, P1054, DOI 10.1161/01.STR.32.5.1054; Smith WS, 2003, NEUROLOGY, V60, P1424, DOI 10.1212/01.WNL.0000063305.61050.E6; Thomas LC, 2011, MANUAL THER, V16, P351, DOI 10.1016/j.math.2010.12.008	13	29	31	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 7	2012	344								e3679	10.1136/bmj.e3679	http://dx.doi.org/10.1136/bmj.e3679			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	957TG	22677796	Green Published, Green Submitted			2023-01-03	WOS:000305185200010
J	van Hagen, P; Hulshof, MCCM; van Lanschot, JJB; Steyerberg, EW; Henegouwen, MIV; Wijnhoven, BPL; Richel, DJ; Nieuwenhuijzen, GAP; Hospers, GAP; Bonenkamp, JJ; Cuesta, MA; Blaisse, RJB; Busch, ORC; ten Kate, FJW; Creemers, GJ; Punt, CJA; Plukker, JTM; Verheul, HMW; Bilgen, EJS; van Dekken, H; van der Sangen, MJC; Rozema, T; Biermann, K; Beukema, JC; Piet, AHM; van Rij, CM; Reinders, JG; Tilanus, HW; van der Gaast, A				van Hagen, P.; Hulshof, M. C. C. M.; van Lanschot, J. J. B.; Steyerberg, E. W.; Henegouwen, M. I. van Berge; Wijnhoven, B. P. L.; Richel, D. J.; Nieuwenhuijzen, G. A. P.; Hospers, G. A. P.; Bonenkamp, J. J.; Cuesta, M. A.; Blaisse, R. J. B.; Busch, O. R. C.; ten Kate, F. J. W.; Creemers, G. -J.; Punt, C. J. A.; Plukker, J. T. M.; Verheul, H. M. W.; Bilgen, E. J. Spillenaar; van Dekken, H.; van der Sangen, M. J. C.; Rozema, T.; Biermann, K.; Beukema, J. C.; Piet, A. H. M.; van Rij, C. M.; Reinders, J. G.; Tilanus, H. W.; van der Gaast, A.		Cross Grp	Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-III TRIAL; PERIOPERATIVE CHEMOTHERAPY; WEEKLY PACLITAXEL; SURGERY; CARCINOMA; CHEMORADIATION; ADENOCARCINOMA; RADIOTHERAPY; CISPLATIN; SURVIVAL	BACKGROUND The role of neoadjuvant chemoradiotherapy in the treatment of patients with esophageal or esophagogastric-junction cancer is not well established. We compared chemoradiotherapy followed by surgery with surgery alone in this patient population. METHODS We randomly assigned patients with resectable tumors to receive surgery alone or weekly administration of carboplatin (doses titrated to achieve an area under the curve of 2 mg per milliliter per minute) and paclitaxel (50 mg per square meter of body-surface area) for 5 weeks and concurrent radiotherapy (41.4 Gy in 23 fractions, 5 days per week), followed by surgery. RESULTS From March 2004 through December 2008, we enrolled 368 patients, 366 of whom were included in the analysis: 275 (75%) had adenocarcinoma, 84 (23%) had squamous-cell carcinoma, and 7 (2%) had large-cell undifferentiated carcinoma. Of the 366 patients, 178 were randomly assigned to chemoradiotherapy followed by surgery, and 188 to surgery alone. The most common major hematologic toxic effects in the chemoradiotherapy-surgery group were leukopenia (6%) and neutropenia (2%); the most common major nonhematologic toxic effects were anorexia (5%) and fatigue (3%). Complete resection with no tumor within 1 mm of the resection margins (R0) was achieved in 92% of patients in the chemoradiotherapy-surgery group versus 69% in the surgery group (P<0.001). A pathological complete response was achieved in 47 of 161 patients (29%) who underwent resection after chemoradiotherapy. Postoperative complications were similar in the two treatment groups, and in-hospital mortality was 4% in both. Median overall survival was 49.4 months in the chemoradiotherapy-surgery group versus 24.0 months in the surgery group. Overall survival was significantly better in the chemoradiotherapy-surgery group (hazard ratio, 0.657; 95% confidence interval, 0.495 to 0.871; P = 0.003). CONCLUSIONS Preoperative chemoradiotherapy improved survival among patients with potentially curable esophageal or esophagogastric-junction cancer. The regimen was associated with acceptable adverse-event rates. (Funded by the Dutch Cancer Foundation [KWF Kankerbestrijding]; Netherlands Trial Register number, NTR487.)	[van der Gaast, A.] Erasmus Univ, Med Ctr, Dr Daniel Den Hoed Canc Ctr, Dept Med Oncol, NL-3000 CA Rotterdam, Netherlands; [van Hagen, P.; van Lanschot, J. J. B.; Wijnhoven, B. P. L.; Tilanus, H. W.] Erasmus Univ, Med Ctr, Dept Surg, NL-3000 CA Rotterdam, Netherlands; [Steyerberg, E. W.] Erasmus Univ, Med Ctr, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands; [ten Kate, F. J. W.; van Dekken, H.; Biermann, K.] Erasmus Univ, Med Ctr, Dept Pathol, NL-3000 CA Rotterdam, Netherlands; [van Rij, C. M.] Erasmus Univ, Med Ctr, Dept Radiat Oncol, NL-3000 CA Rotterdam, Netherlands; [Hulshof, M. C. C. M.] Univ Amsterdam, Acad Med Ctr, Dept Radiat Oncol, NL-1105 AZ Amsterdam, Netherlands; [van Lanschot, J. J. B.; Henegouwen, M. I. van Berge; Busch, O. R. C.] Univ Amsterdam, Acad Med Ctr, Dept Surg, NL-1105 AZ Amsterdam, Netherlands; [Richel, D. J.] Univ Amsterdam, Acad Med Ctr, Dept Med Oncol, NL-1105 AZ Amsterdam, Netherlands; [ten Kate, F. J. W.] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; [Cuesta, M. A.] VU Med Ctr Amsterdam, Dept Surg, Amsterdam, Netherlands; [Verheul, H. M. W.] VU Med Ctr Amsterdam, Dept Med Oncol, Amsterdam, Netherlands; [Piet, A. H. M.] VU Med Ctr Amsterdam, Dept Radiat Oncol, Amsterdam, Netherlands; [van Dekken, H.] St Lucas Andreas Hosp Amsterdam, Dept Pathol, Amsterdam, Netherlands; [Nieuwenhuijzen, G. A. P.] Catharina Hosp, Dept Surg, Eindhoven, Netherlands; [Creemers, G. -J.] Catharina Hosp, Dept Med Oncol, Eindhoven, Netherlands; [van der Sangen, M. J. C.] Catharina Hosp, Dept Radiat Oncol, Eindhoven, Netherlands; [Hospers, G. A. P.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, NL-9713 AV Groningen, Netherlands; [Plukker, J. T. M.] Univ Med Ctr Groningen, Dept Surg, NL-9713 AV Groningen, Netherlands; [Beukema, J. C.] Univ Med Ctr Groningen, Dept Radiat Oncol, NL-9713 AV Groningen, Netherlands; [Bonenkamp, J. J.] Radboud Univ Nijmegen, Med Ctr, Dept Surg, NL-6525 ED Nijmegen, Netherlands; [Punt, C. J. A.] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6525 ED Nijmegen, Netherlands; [Rozema, T.] Radboud Univ Nijmegen, Med Ctr, Dept Radiat Oncol, NL-6525 ED Nijmegen, Netherlands; [Blaisse, R. J. B.] Rijnstate Hosp Arnhem, Dept Med Oncol, Arnhem, Netherlands; [Bilgen, E. J. Spillenaar] Rijnstate Hosp Arnhem, Dept Surg, Arnhem, Netherlands; [Reinders, J. G.] Arnhem Radiotherapeut Inst, Arnhem, Netherlands; [Rozema, T.] Verbeeten Inst Tilburg, Tilburg, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Sint Lucas Andreas Hospital; Catharina Hospital; Catharina Hospital; Catharina Hospital; University of Groningen; University of Groningen; University of Groningen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Rijnstate Hospital; Rijnstate Hospital; Instituut Verbeeten	van der Gaast, A (corresponding author), Erasmus Univ, Med Ctr, Dr Daniel Den Hoed Canc Ctr, Dept Med Oncol, POB 2040f, NL-3000 CA Rotterdam, Netherlands.	a.vandergaast@erasmusmc.nl	Busch, Olivier/AAC-3650-2020; Wijnhoven, Bas/AAF-4838-2020; koning, caro/A-5339-2008; van Krieken, Joannes H J M/D-4138-2009; Verheul, Henk/V-6462-2019; Bergman, Jacques/AAS-2500-2021; Verheul, Henk M.W./J-9775-2013; Bonenkamp, J.J./L-4213-2015; Steyerberg, Ewout/C-1509-2018	van Krieken, Joannes H J M/0000-0001-6544-1040; Verheul, Henk/0000-0001-5981-922X; Hulshof, Maarten CCM/0000-0001-5240-3467; beukema, jannet/0000-0002-1648-6813; Steyerberg, Ewout/0000-0002-7787-0122; van der Sangen, Maurice/0000-0003-1866-7367; Nieuwenhuijzen, Grard/0000-0002-5837-5513; van Berge Henegouwen, Mark/0000-0001-8689-3134; Hospers, Geke/0000-0002-3047-7892	Dutch Cancer Foundation (KWF Kankerbestrijding)	Dutch Cancer Foundation (KWF Kankerbestrijding)	Supported by the Dutch Cancer Foundation (KWF Kankerbestrijding).	Bosset JF, 1997, NEW ENGL J MED, V337, P161, DOI 10.1056/NEJM199707173370304; Burmeister BH, 2005, LANCET ONCOL, V6, P659, DOI 10.1016/S1470-2045(05)70288-6; Chirieac LR, 2005, CANCER-AM CANCER SOC, V103, P1347, DOI 10.1002/cncr.20916; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Fiorica F, 2004, GUT, V53, P925, DOI 10.1136/gut.2003.025080; Gannett David E, 2007, Gastrointest Cancer Res, V1, P132; International Union Against Cancer, 2002, TNM CLASS MAL TUM; Kelsen DP, 1998, NEW ENGL J MED, V339, P1979, DOI 10.1056/NEJM199812313392704; Lee JL, 2004, ANN ONCOL, V15, P947, DOI 10.1093/annonc/mdh219; Lin CC, 2007, ANN ONCOL, V18, P93, DOI 10.1093/annonc/mdl339; MALTHANER R, 2001, COCHRANE DB SYST REV, V1; MANDARD AM, 1994, CANCER, V73, P2680, DOI 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Portale G, 2006, J AM COLL SURGEONS, V202, P588, DOI 10.1016/j.jamcollsurg.2005.12.022; Stahl M, 2009, J CLIN ONCOL, V27, P851, DOI 10.1200/JCO.2008.17.0506; Tepper J, 2008, J CLIN ONCOL, V26, P1086, DOI 10.1200/JCO.2007.12.9593; Trotti A, 2003, SEMIN RADIAT ONCOL, V13, P176, DOI 10.1016/S1053-4296(03)00031-6; Urba SG, 2001, J CLIN ONCOL, V19, P305, DOI 10.1200/JCO.2001.19.2.305; van Heijl M, 2008, BMC Surg, V8, P21, DOI 10.1186/1471-2482-8-21; van Meerten E, 2006, BRIT J CANCER, V94, P1389, DOI 10.1038/sj.bjc.6603134; Walsh TN, 1996, NEW ENGL J MED, V335, P462, DOI 10.1056/NEJM199608153350702; Walsh TN, 1999, NEW ENGL J MED, V341, P384; Ychou M, 2011, J CLIN ONCOL, V29, P1715, DOI 10.1200/JCO.2010.33.0597	25	3326	3344	6	168	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 31	2012	366	22					2074	2084		10.1056/NEJMoa1112088	http://dx.doi.org/10.1056/NEJMoa1112088			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	949YE	22646630	Green Published			2023-01-03	WOS:000304613400007
J	Jenq, G; Tinetti, ME				Jenq, Grace; Tinetti, Mary E.			The Journey Across the Health Care (Dis)Continuum for Vulnerable Patients Policies, Pitfalls, and Possibilities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Jenq, Grace; Tinetti, Mary E.] Yale Univ, Dept Internal Med, Sch Med, New Haven, CT 06520 USA	Yale University	Tinetti, ME (corresponding author), Yale Univ, Dept Internal Med, Sch Med, 333 Cedar St,POB 208025, New Haven, CT 06520 USA.	mary.tinetti@yale.edu						Berkowitz RE, 2011, J AM GERIATR SOC, V59, P1130, DOI 10.1111/j.1532-5415.2011.03417.x; Buntin MB, 2005, HEALTH SERV RES, V40, P413, DOI 10.1111/j.1475-6773.2005.0i366.x; Centers for Medicare & Medicaid Services, HOSP QUAL IN; Goodman DC, HOSPITALIZATION DART; Hartocollis A, 2012, NY TIMES, pA1; Hung WW, 2012, JAMA-J AM MED ASSOC, V307, P2185, DOI 10.1001/jama.2012.4842; (MedPAC) MPAC, 2012, REP C MED PAYM POL M; Samaras N, 2010, ANN EMERG MED, V56, P261, DOI 10.1016/j.annemergmed.2010.04.015	8	9	9	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 23	2012	307	20					2157	2158		10.1001/jama.2012.5566	http://dx.doi.org/10.1001/jama.2012.5566			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	945YX	22618921				2023-01-03	WOS:000304315200023
J	Marin, JM; Agusti, A; Villar, I; Forner, M; Nieto, D; Carrizo, SJ; Barbe, F; Vicente, E; Wei, Y; Nieto, FJ; Jelic, S				Marin, Jose M.; Agusti, Alvar; Villar, Isabel; Forner, Marta; Nieto, David; Carrizo, Santiago J.; Barbe, Ferran; Vicente, Eugenio; Wei, Ying; Nieto, F. Javier; Jelic, Sanja			Association Between Treated and Untreated Obstructive Sleep Apnea and Risk of Hypertension	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSITIVE AIRWAY PRESSURE; MULTIPLE IMPUTATION; ADHERENCE; REGRESSION; COMMITTEE; THERAPY; STROKE; MEN	Context Systemic hypertension is prevalent among patients with obstructive sleep apnea (OSA). Short-term studies indicate that continuous positive airway pressure (CPAP) therapy reduces blood pressure in patients with hypertension and OSA. Objective To determine whether CPAP therapy is associated with a lower risk of incident hypertension. Design, Setting, and Participants A prospective cohort study of 1889 participants without hypertension who were referred to a sleep center in Zaragoza, Spain, for nocturnal polysomnography between January 1, 1994, and December 31, 2000. Incident hypertension was documented at annual follow-up visits up to January 1, 2011. Multivariable models adjusted for confounding factors, including change in body mass index from baseline to censored time, were used to calculate hazard ratios (HRs) of incident hypertension in participants without OSA (controls), with untreated OSA, and in those treated with CPAP therapy according to national guidelines. Main Outcome Measure Incidence of new-onset hypertension. Results During 21 003 person-years of follow-up (median, 12.2 years), 705 cases (37.3%) of incident hypertension were observed. The crude incidence of hypertension per 100 person-years was 2.19 (95% CI, 1.71-2.67) in controls, 3.34 (95% CI, 2.85-3.82) in patients with OSA ineligible for CPAP therapy, 5.84 (95% CI, 4.82-6.86) in patients with OSA who declined CPAP therapy, 5.12 (95% CI, 3.76-6.47) in patients with OSA nonadherent to CPAP therapy, and 3.06 (95% CI, 2.70-3.41) in patients with OSA and treated with CPAP therapy. Compared with controls, the adjusted HRs for incident hypertension were greater among patients with OSA ineligible for CPAP therapy (1.33; 95% CI, 1.01-1.75), among those who declined CPAP therapy (1.96; 95% CI, 1.44-2.66), and among those nonadherent to CPAP therapy (1.78; 95% CI, 1.23-2.58), whereas the HR was lower in patients with OSA who were treated with CPAP therapy (0.71; 95% CI, 0.53-0.94). Conclusion Compared with participants without OSA, the presence of OSA was associated with increased adjusted risk of incident hypertension; however, treatment with CPAP therapy was associated with a lower risk of hypertension. JAMA. 2012;307(20):2169-2176	[Marin, Jose M.; Nieto, David; Carrizo, Santiago J.; Vicente, Eugenio] Hosp Univ Miguel Servet, Resp Dept, Zaragoza 50006, Spain; [Marin, Jose M.; Villar, Isabel; Forner, Marta] Aragon Inst Hlth Sci, Zaragoza, Spain; [Agusti, Alvar] Hosp Clin Barcelona, Inst Invest Biomed Pi Sunyer, Thorax Inst, Barcelona, Spain; [Wei, Ying; Jelic, Sanja] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; [Barbe, Ferran] Hosp Arnau Vilanova, Lleida, Spain; [Marin, Jose M.; Agusti, Alvar; Barbe, Ferran] Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain; [Nieto, F. Javier] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA	Miguel Servet University Hospital; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Columbia University; University Hospital Arnau de Vilanova; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Instituto de Salud Carlos III; University of Wisconsin System; University of Wisconsin Madison	Marin, JM (corresponding author), Hosp Univ Miguel Servet, Resp Dept, Avda Isabel Catolica,1-3, Zaragoza 50006, Spain.	jmmarint@unizar.es	Garcia-Navarro, Alvar Agusti/F-4474-2015; CARRIZO SIERRA, SANTIAGO/AAO-1780-2021; Lavu, Madhav/A-9409-2013; Barbé, Ferran/A-5988-2010	Garcia-Navarro, Alvar Agusti/0000-0003-3271-3788; Barbé, Ferran/0000-0002-2340-8928; Marin Trigo, Jose Maria/0000-0001-9096-2294	National Institutes of Health, National Heart, Lung, and Blood Institute [1R01HL106041-01A1]; Instituto Carlos III, Ministry of Health, Madrid, Spain [FISS PI04/1684, FISS PS09/02449]; Spanish Society of Respiratory Medicine [SEPAR/2007]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL106041] Funding Source: NIH RePORTER	National Institutes of Health, National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Instituto Carlos III, Ministry of Health, Madrid, Spain; Spanish Society of Respiratory Medicine; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Jelic reported receiving grants/pending grants from the National Institutes of Health, National Heart, Lung, and Blood Institute (1R01HL106041-01A1). No other authors reported any financial disclosures.; This work was supported by grants FISS PI04/1684 and FISS PS09/02449 from the Instituto Carlos III, Ministry of Health, Madrid, Spain, and SEPAR/2007 from the Spanish Society of Respiratory Medicine.	Barbe F, 2010, AM J RESP CRIT CARE, V181, P718, DOI 10.1164/rccm.200901-0050OC; CARLSON JT, 1994, AM J RESP CRIT CARE, V150, P72, DOI 10.1164/ajrccm.150.1.8025776; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Epstein LJ, 2009, J CLIN SLEEP MED, V5, P263; HLA KM, 1994, ANN INTERN MED, V120, P382, DOI 10.7326/0003-4819-120-5-199403010-00005; Ip MSM, 2004, AM J RESP CRIT CARE, V169, P348, DOI 10.1164/rccm.200306-767OC; Jelic S, 2010, CIRCULATION, V121, P1014, DOI 10.1161/CIRCULATIONAHA.109.900357; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kales A, 1968, MANUAL STANDARDIZED; Kapur Vishesh, 2002, Sleep Breath, V6, P49, DOI 10.1007/s11325-002-0049-5; LaFleur J, 2011, HEART, V97, P1862, DOI 10.1136/hrt.2011.223289; Lavie P, 2000, BRIT MED J, V320, P479, DOI 10.1136/bmj.320.7233.479; Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7; Montserrat J M, 1998, Arch Bronconeumol, V34, P204; Narkiewicz K, 1998, CIRCULATION, V98, P772, DOI 10.1161/01.CIR.98.8.772; Nieto FJ, 2000, JAMA-J AM MED ASSOC, V283, P1829, DOI 10.1001/jama.283.14.1829; O'Connor GT, 2009, AM J RESP CRIT CARE, V179, P1159, DOI 10.1164/rccm.200712-1809OC; Pan W, 2000, BIOMETRICS, V56, P199, DOI 10.1111/j.0006-341X.2000.00199.x; Markus MRP, 2010, J AM COLL CARDIOL, V56, P65, DOI 10.1016/j.jacc.2010.01.056; Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901; Platt AB, 2010, CHEST, V137, P102, DOI 10.1378/chest.09-0842; Punjabi NM, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000132; SCHOENFELD D, 1981, BIOMETRIKA, V68, P316, DOI 10.1093/biomet/68.1.316; Simpson SH, 2006, BMJ-BRIT MED J, V333, P15, DOI 10.1136/bmj.38875.675486.55; Somers VK, 2008, J AM COLL CARDIOL, V52, P686, DOI 10.1016/j.jacc.2008.05.002; Villar I, 2009, SLEEP, V32, P623, DOI 10.1093/sleep/32.5.623; WEI GCG, 1991, BIOMETRICS, V47, P1297, DOI 10.2307/2532387; Yaggi HK, 2005, NEW ENGL J MED, V353, P2034, DOI 10.1056/NEJMoa043104; Young T, 1997, ARCH INTERN MED, V157, P1746, DOI 10.1001/archinte.157.15.1746; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Young T, 1997, SLEEP, V20, P705, DOI 10.1093/sleep/20.9.705; Young T, 2008, SLEEP, V31, P1071	32	480	501	1	40	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 23	2012	307	20					2169	2176		10.1001/jama.2012.3418	http://dx.doi.org/10.1001/jama.2012.3418			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	945YX	22618924	Green Accepted, Bronze			2023-01-03	WOS:000304315200026
J	Vitovski, S; Chantry, AD; Lawson, MA; Croucher, PI				Vitovski, Srdjan; Chantry, Andrew D.; Lawson, Michelle A.; Croucher, Peter I.			Targeting Tumour-Initiating Cells with TRAIL Based Combination Therapy Ensures Complete and Lasting Eradication of Multiple Myeloma Tumours In Vivo	PLOS ONE			English	Article							APOPTOSIS-INDUCING LIGAND; CANCER STEM-CELLS; CHEMOTHERAPEUTIC DRUGS; DECOY RECEPTORS; PLASMA-CELL; DEATH; LEUKEMIA; EXPRESSION; MELPHALAN; VITRO	Multiple myeloma (MM) remains an incurable disease despite improvements to available treatments and efforts to identify new drug targets. Consequently new approaches are urgently required. We have investigated the potential of native tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), in combination with doxorubicin, to induce apoptotic cell death in phenotypically distinct populations of myeloma cells in vitro and in vivo. The cytotoxic potential of TRAIL alone, and in combination with DOX, was assessed in vitro in purified CD138(+) and CD138(-) cells from the MM cell lines and samples from patients with MM. Mouse xenografts obtained by implanting CD138(-) MM cells were used to assess the efficacy of TRAIL, alone and in combination with DOX, in vivo. CD138(-) cells were shown to be more resistant to the cytotoxic activity of TRAIL than CD138(+) cells and have reduced expression of TRAIL death receptors. This resistance results in preferential killing of CD 138(+) cells during exposure of MM culture to TRAIL. Furthermore, prolonged exposure results in the appearance of TRAIL-resistant CD138(-) cells. However, when TRAIL is combined with doxorubicin, this results in complete eradication of MM cells in vivo. Most importantly, this treatment successfully eliminates CD138(-) cells implicated in tumour initiation and growth maintenance. These findings may explain the failure of current therapies and offer a promising new approach in the quest to cure MM and disseminated cancers.	[Vitovski, Srdjan; Chantry, Andrew D.; Lawson, Michelle A.; Croucher, Peter I.] Univ Sheffield, Sch Med, Dept Human Metab, Mellanby Ctr Bone Res, Sheffield, S Yorkshire, England; [Vitovski, Srdjan] Univ Sheffield, Sch Med, Dept Infect & Immun, Sheffield, S Yorkshire, England; [Croucher, Peter I.] Garvan Inst Med Res, Sydney, NSW, Australia	University of Sheffield; University of Sheffield; Garvan Institute of Medical Research	Vitovski, S (corresponding author), Univ Sheffield, Sch Med, Dept Human Metab, Mellanby Ctr Bone Res, Sheffield, S Yorkshire, England.	P.Croucher@garvan.org.au	Lawson, Michelle/M-6095-2019	Lawson, Michelle/0000-0002-5446-923X; Croucher, Peter/0000-0002-7102-2413; Chantry, Andrew/0000-0002-2797-7626	Leukemia Research Foundation [LRF08008]; Yorkshire Cancer Research grant [YCR121464]; Mrs Janice Gibson and Ernest Heine Family Foundation	Leukemia Research Foundation; Yorkshire Cancer Research grant; Mrs Janice Gibson and Ernest Heine Family Foundation	This work is supported by Leukemia Research Foundation grant LRF08008 (PIC, SV) and Yorkshire Cancer Research grant YCR121464 (SV, PIC). PIC is supported by the Mrs Janice Gibson and Ernest Heine Family Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe S, 2007, EXP MOL PATHOL, V83, P405, DOI 10.1016/j.yexmp.2007.04.001; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bai JR, 2005, CANCER RES, V65, P2344, DOI 10.1158/0008-5472.CAN-04-3502; BERGSAGEL DE, 1979, NEW ENGL J MED, V301, P743, DOI 10.1056/NEJM197910043011402; BILLADEAU D, 1993, J EXP MED, V178, P1023, DOI 10.1084/jem.178.3.1023; Bodmer JL, 2002, TRENDS BIOCHEM SCI, V27, P19, DOI 10.1016/S0968-0004(01)01995-8; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; CUZICK J, 1987, BRIT J CANCER, V55, P523, DOI 10.1038/bjc.1987.107; Dimopoulos M, 2007, NEW ENGL J MED, V357, P2123, DOI 10.1056/NEJMoa070594; Dumitru CA, 2007, APOPTOSIS, V12, P1533, DOI 10.1007/s10495-007-0081-9; Fulda S, 2010, INT J BIOCHEM CELL B, V42, P31, DOI 10.1016/j.biocel.2009.06.010; Fulda S, 2009, INT J CANCER, V124, P511, DOI 10.1002/ijc.24064; Ganten TM, 2006, CLIN CANCER RES, V12, P2640, DOI 10.1158/1078-0432.CCR-05-2635; Gazitt Y, 1999, LEUKEMIA, V13, P1817, DOI 10.1038/sj.leu.2401501; Govindarajan R, 1996, BRIT J HAEMATOL, V95, P349, DOI 10.1046/j.1365-2141.1996.d01-1891.x; GREGORY WM, 1992, J CLIN ONCOL, V10, P334, DOI 10.1200/JCO.1992.10.2.334; HAMBURGER AW, 1977, SCIENCE, V197, P461, DOI 10.1126/science.560061; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hjorth M, 1999, EUR J HAEMATOL, V62, P271; Jagani Z, 2008, ADV EXP MED BIOL, V615, P331, DOI 10.1007/978-1-4020-6554-5_15; Jazirehi AR, 2001, CLIN CANCER RES, V7, P3874; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kim KH, 2000, CLIN CANCER RES, V6, P335; Kyle RA, 2004, NEW ENGL J MED, V351, P1860, DOI 10.1056/NEJMra041875; Kyle RA, 2000, ANN ONCOL, V11, P55, DOI 10.1023/A:1008357107496; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lincz LF, 2001, LEUKEMIA, V15, P1650, DOI 10.1038/sj.leu.2402251; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Matsui W, 2004, BLOOD, V103, P2332, DOI 10.1182/blood-2003-09-3064; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Mitsiades N, 2001, EXPERT OPIN INV DRUG, V10, P1521, DOI 10.1517/13543784.10.8.1521; Morisot S, 2010, LEUKEMIA, V24, P1859, DOI 10.1038/leu.2010.184; Nagane M, 2000, CANCER RES, V60, P847; Pasquali S, 1998, J CLIN ONCOL, V16, P3832; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; San Miguel JF, 2008, NEW ENGL J MED, V359, P906, DOI 10.1056/NEJMoa0801479; Shafee N, 2008, CANCER RES, V68, P3243, DOI 10.1158/0008-5472.CAN-07-5480; Shankar S, 2005, PROSTATE, V62, P165, DOI 10.1002/pros.20126; Shipman CM, 2003, CANCER RES, V63, P912; Singh TR, 2003, CANCER RES, V63, P5390; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Thai L, 2006, CANCER RES, V66, P5363, DOI 10.1158/0008-5472.CAN-05-4386; Vitovski S, 2007, J BIOL CHEM, V282, P31601, DOI 10.1074/jbc.M706078200; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Xin L, 2005, P NATL ACAD SCI USA, V102, P6942, DOI 10.1073/pnas.0502320102; Yones RJ, 2008, BIOL BLOOD MARROW TR, V14, P12, DOI 10.1016/j.bbmt.2007.10.012; Zerafa N, 2005, J IMMUNOL, V175, P5586, DOI 10.4049/jimmunol.175.9.5586	51	12	12	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2012	7	5			1				e35830	10.1371/journal.pone.0035830	http://dx.doi.org/10.1371/journal.pone.0035830			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UR	22615740	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000305341300007
J	Gawande, A				Gawande, Atul			Two Hundred Years of Surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Review									[Gawande, Atul] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Gawande, Atul] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	Gawande, A (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 665 Huntington Ave, Boston, MA 02115 USA.			Gawande, Atul/0000-0002-1824-9176				[Anonymous], 1812, N ENGL J MED SURG, V1, P98; BENNETT AH, 1884, LANCET, V2, P1090; Bigelow HJ., 1846, BOSTON MED SURG J, V35, P309, DOI DOI 10.1056/NEJM184611180351601; BLALOCK A, 1945, JAMA-J AM MED ASSOC, V128, P189, DOI 10.1001/jama.1945.02860200029009; Bobbs JS, 1868, T INDIANA M SOC, V18, P68; Caton D, 2011, ENCY LIFE SCI; Chan CC, 2010, SURV OPHTHALMOL, V55, P393, DOI 10.1016/j.survophthal.2010.02.001; Finney J. M. T., 1932, NEW ENGL J MED, V206, P263; Forssmann W., 1929, KLIN WOCHENSCHR, V8, P2085, DOI DOI 10.1007/BF01875120; Goss F, 1874, BOSTON MED SURG J, V91, P73; GROSS RE, 1952, NEW ENGL J MED, V247, P455, DOI 10.1056/NEJM195209252471301; HARKEN DE, 1948, NEW ENGL J MED, V239, P801, DOI 10.1056/NEJM194811252392201; Hollingham R, 2008, BLOOD GUTS HIST SURG; Hunter W, 1775, LANCET, V12, P769; Kimball G., 1855, BOSTON MED SURG J, V52, P249; Lee PH, 2008, J AM COLL SURGEONS, V207, pS75, DOI 10.1016/j.jamcollsurg.2008.06.186; Lister J, 1867, LANCET, V1, P507, DOI [10.1016/S0140-6736(00)73482-9, DOI 10.1016/S0140-6736(00)73482-9]; Lister J., 1867, LANCET, V1, P326, DOI 10.1016/S0140-6736(02)51192-2; Lister J, 1867, LANCET, V90, P95; Lister J., 1867, LANCET, V1, P507; Liston Robert, 1837, PRACTICAL SURG; Macchiarini P, 2008, LANCET, V372, P2023, DOI 10.1016/S0140-6736(08)61598-6; MASSA DJ, 1950, P STAFF M MAYO CLIN, V25, P413; Munro JC, 1902, NEW ENGL J MED, V146, P58; Nobelprize. org, NOB PRIZ PHYSL MED 1; Nuland SB, 2003, DOCTORS PLAGUE GERMS; Peaslee ER, 1851, BOSTON MED SURG J, V44, P429; Preston, 1831, BOSTON MED SURG J, P92; Rehn L., 1884, BERL KLIN WOCHENSCHR, V21, P163; Richardson RG, 2004, STORY SURG HIST COMM; Robertson HR, 1989, ANN R COLL PHYS SURG, V22, P28; Rutkow IM, 1993, SURG ILLUSTRATED HIS, P333; Simpson JY, 1867, BOSTON MED SURG J, V77, P390; Stanley P., 2003, FEAR PAIN BRIT SURG; Tait RL, 1890, BIRM MED REV, V27, P76; TAIT RL, 1890, BGHAM MED REV, V27, P26; Wangensteen, 1978, RISE SURG EMPIRIC CR; Warren JC, 1812, N ENGL J MED SURG, V1, P194; Watson FS, 1889, BOSTON MED SURG J, V120, P237	39	106	114	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 3	2012	366	18					1716	1723		10.1056/NEJMra1202392	http://dx.doi.org/10.1056/NEJMra1202392			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	934HH	22551130				2023-01-03	WOS:000303434300011
J	Furmaga, H; Carreno, FR; Frazer, A				Furmaga, Havan; Carreno, Flavia Regina; Frazer, Alan			Vagal Nerve Stimulation Rapidly Activates Brain-Derived Neurotrophic Factor Receptor TrkB in Rat Brain	PLOS ONE			English	Article							TREATMENT-RESISTANT DEPRESSION; HIPPOCAMPAL-NEURONS; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; TYROSINE KINASE; FACTOR BDNF; SEROTONIN TRANSPORTER; ANTIDEPRESSANT ACTION; TRUNCATED RECEPTORS; GENE-EXPRESSION	Background: Vagal nerve stimulation (VNS) has been approved for treatment-resistant depression. Many antidepressants increase expression of brain-derived neurotrophic factor (BDNF) in brain or activate, via phosphorylation, its receptor, TrkB. There have been no studies yet of whether VNS would also cause phosphorylation of TrkB. Methods: Western blot analysis was used to evaluate the phosphorylation status of TrkB in the hippocampus of rats administered VNS either acutely or chronically. Acute effects of VNS were compared with those caused by fluoxetine or desipramine (DMI) whereas its chronic effects were compared with those of sertraline or DMI. Results: All treatments, given either acutely or chronically, significantly elevated phosphorylation of tyrosines 705 and 816 on TrkB in the hippocampus. However, only VNS increased the phosphorylation of tyrosine 515, with both acute and chronic administration causing this effect. Pretreatment with K252a, a nonspecific tyrosine kinase inhibitor, blocked the phosphorylation caused by acute VNS at all three tyrosines. Downstream effectors of Y515, namely Akt and ERK, were also phosphorylated after acute treatment with VNS, whereas DMI did not cause this effect. Conclusion: VNS rapidly activates TrkB phosphorylation and this effect persists over time. VNS-induced phosphorylation of tyrosine 515 is distinct from the effect of standard antidepressant drugs.	[Furmaga, Havan; Carreno, Flavia Regina; Frazer, Alan] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA; [Frazer, Alan] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Furmaga, H (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA.	frazer@uthscsa.edu		frazer, alan/0000-0003-1525-9974	National Institute of Mental Health grant [R01 MH082933]; Cyberonics, Inc.; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH082933] Funding Source: NIH RePORTER	National Institute of Mental Health grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Cyberonics, Inc.; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported by National Institute of Mental Health grant R01 MH082933 (Alan Frazer). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Drs. Furmaga and Carreno have no competing interests to declare. Previously, Dr. Frazer received financial compensation as a consultant for Cyberonics, Inc. and had also obtained grant support from them for a preclinical study. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.	Aoki C, 2000, J NEUROSCI RES, V59, P454, DOI 10.1002/(SICI)1097-4547(20000201)59:3<454::AID-JNR21>3.0.CO;2-H; Balkowiec A, 2002, J NEUROSCI, V22, P10399; Belcheva MM, 2002, NEUROSIGNALS, V11, P34, DOI 10.1159/000057320; Benmansour S, 2002, J NEUROSCI, V22, P6766; Benmansour S, 1999, J NEUROSCI, V19, P10494; Benmansour S, 2008, EUR J PHARMACOL, V587, P90, DOI 10.1016/j.ejphar.2008.03.048; Berghuis P, 2005, P NATL ACAD SCI USA, V102, P19115, DOI 10.1073/pnas.0509494102; BIFFO S, 1995, DEVELOPMENT, V121, P2461; Biggio F, 2009, INT J NEUROPSYCHOPH, V12, P1209, DOI 10.1017/S1461145709000200; Blum R, 2005, PHYSIOLOGY, V20, P70, DOI 10.1152/physiol.00042.2004; Bondi CO, 2007, NEUROPSYCHOPHARMACOL; Chen B, 2001, BIOL PSYCHIAT, V50, P260, DOI 10.1016/S0006-3223(01)01083-6; Chen MJ, 2007, CELL SIGNAL, V19, P114, DOI 10.1016/j.cellsig.2006.05.028; Cunningham JT, 2008, NEUROPSYCHOPHARMACOL, V33, P1884, DOI 10.1038/sj.npp.1301570; Dorr AE, 2006, J PHARMACOL EXP THER, V318, P890, DOI 10.1124/jpet.106.104166; Du J, 2003, J CELL BIOL, V163, P385, DOI 10.1083/jcb.200305134; Du J, 2000, J CELL BIOL, V150, P1423, DOI 10.1083/jcb.150.6.1423; Dwivedi Y, 2003, ARCH GEN PSYCHIAT, V60, P804, DOI 10.1001/archpsyc.60.8.804; Eide FF, 1996, J NEUROSCI, V16, P3123; Follesa P, 2007, BRAIN RES, V1179, P28, DOI 10.1016/j.brainres.2007.08.045; Frazer A, 2000, J CLIN PSYCHIAT, V61, P25; Furmaga H, 2011, BIOL PSYCHI IN PRESS; George MS, 2005, BIOL PSYCHIAT, V58, P364, DOI 10.1016/j.biopsych.2005.07.028; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Ji YY, 2005, NAT NEUROSCI, V8, P164, DOI 10.1038/nn1381; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Karege F, 2005, MOL BRAIN RES, V136, P29, DOI 10.1016/j.molbrainres.2004.12.020; Karege F, 2005, BIOL PSYCHIAT, V57, P1068, DOI 10.1016/j.biopsych.2005.01.008; Karege F, 2002, PSYCHIAT RES, V109, P143, DOI 10.1016/S0165-1781(02)00005-7; KASE H, 1986, J ANTIBIOT, V39, P1059, DOI 10.7164/antibiotics.39.1059; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; KNUSEL B, 1994, J NEUROSCI, V14, P1542, DOI 10.1523/JNEUROSCI.14-03-01542.1994; KOIZUMI S, 1988, J NEUROSCI, V8, P715; Krahl SE, 2004, J PSYCHIATR RES, V38, P237, DOI 10.1016/j.jpsychires.2003.11.005; Lee FS, 2002, CYTOKINE GROWTH F R, V13, P11, DOI 10.1016/S1359-6101(01)00024-7; Lee FS, 2002, J BIOL CHEM, V277, P9096, DOI 10.1074/jbc.M107421200; Lewis MA, 2006, MOL PHARMACOL, V69, P1396, DOI 10.1124/mol.105.020255; Lu B, 2003, LEARN MEMORY, V10, P86, DOI 10.1101/lm.54603; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; Manta Stella, 2009, J Psychiatry Neurosci, V34, P272; Meyer-Franke A, 1998, NEURON, V21, P681, DOI 10.1016/S0896-6273(00)80586-3; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MIDDLEMAS DS, 1994, J BIOL CHEM, V269, P5458; Nahas Z, 2005, J CLIN PSYCHIAT, V66, P1097, DOI 10.4088/JCP.v66n0902; NIBUYA M, 1995, J NEUROSCI, V15, P7539; NYE SH, 1992, MOL BIOL CELL, V3, P677, DOI 10.1091/mbc.3.6.677; Pereira DB, 2006, J NEUROSCI RES, V83, P832, DOI 10.1002/jnr.20784; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; RANTAMAKI T, 2007, NEUROPSYCHOPHARMACOL; Rantamaki T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020567; Rose CR, 2003, NATURE, V426, P74, DOI 10.1038/nature01983; Rush AJ, 2005, BIOL PSYCHIAT, V58, P355, DOI 10.1016/j.biopsych.2005.05.024; Russo-Neustadt AA, 2000, NEUROSCIENCE, V101, P305, DOI 10.1016/S0306-4522(00)00349-3; Saarelainen T, 2003, J NEUROSCI, V23, P349; Salio C, 2005, EUR J NEUROSCI, V22, P1951, DOI 10.1111/j.1460-9568.2005.04392.x; Schlaepfer TE, 2008, PSYCHOL MED, V38, P651, DOI 10.1017/S0033291707001924; Shah BH, 2004, TRENDS NEUROSCI, V27, P48, DOI 10.1016/j.tins.2003.11.003; Shimizu E, 2003, BIOL PSYCHIAT, V54, P70, DOI 10.1016/S0006-3223(03)00181-1; Shirayama Y, 2002, J NEUROSCI, V22, P3251, DOI 10.1523/JNEUROSCI.22-08-03251.2002; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; TAPLEY P, 1992, ONCOGENE, V7, P371; Wu CB, 2001, J NEUROSCI, V21, P5406, DOI 10.1523/JNEUROSCI.21-15-05406.2001; Xu HY, 2003, NEUROPSYCHOPHARMACOL, V28, P53, DOI 10.1038/sj.npp.1300009; Ying SW, 2002, J NEUROSCI, V22, P1532, DOI 10.1523/JNEUROSCI.22-05-01532.2002; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000; Yuen EC, 1999, EXP NEUROL, V159, P297, DOI 10.1006/exnr.1999.7148	66	61	62	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2012	7	5							e34844	10.1371/journal.pone.0034844	http://dx.doi.org/10.1371/journal.pone.0034844			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UN	22563458	Green Published, Green Submitted, gold			2023-01-03	WOS:000305340700007
J	Dimberg, LY; Anderson, CK; Camidge, R; Behbakht, K; Thorburn, A; Ford, HL				Dimberg, L. Y.; Anderson, C. K.; Camidge, R.; Behbakht, K.; Thorburn, A.; Ford, H. L.			On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics	ONCOGENE			English	Review						TRAIL; pro-apoptotic receptor agonists; apoptosis; TRAIL resistance; clinical trials	APOPTOSIS-INDUCING LIGAND; X-LINKED INHIBITOR; AGONISTIC MONOCLONAL-ANTIBODY; RECOMBINANT HUMAN APO2L/TRAIL; DEATH RECEPTOR 5; MEDIATED APOPTOSIS; CARCINOMA-CELLS; PHASE-I; PROTEASOME INHIBITION; SIX1 OVEREXPRESSION	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and agonistic antibodies against TRAIL death receptors (DR) kill tumor cells while causing virtually no damage to normal cells. Several novel drugs targeting TRAIL receptors are currently in clinical trials. However, TRAIL resistance is a common obstacle in TRAIL-based therapy and limits the efficiency of these drugs. In this review article we discuss different mechanisms of TRAIL resistance, and how they can be predicted and therapeutically circumvented. In addition, we provide a brief overview of all TRAIL-based clinical trials conducted so far. It is apparent that although the effects of TRAIL therapy are disappointingly modest overall, a small subset of patients responds very well to TRAIL. We argue that the true potential of targeting TRAIL DRs in cancer can only be reached when we find efficient ways to select for those patients that are most likely to benefit from the treatment. To achieve this, it is crucial to identify biomarkers that can help us predict TRAIL sensitivity. Oncogene (2013) 32, 1341-1350; doi:10.1038/onc.2012.164; published online 14 May 2012	[Dimberg, L. Y.; Anderson, C. K.; Behbakht, K.; Ford, H. L.] Univ Colorado, Sch Med, Dept Obstet & Gynecol, Aurora, CO 80045 USA; [Camidge, R.] Univ Colorado, Sch Med, Dept Med, Aurora, CO 80045 USA; [Thorburn, A.; Ford, H. L.] Univ Colorado, Sch Med, Dept Pharmacol, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Ford, HL (corresponding author), Univ Colorado, Sch Med, Dept Obstet & Gynecol, RC2,Room 3100C,MS8613, Aurora, CO 80045 USA.	heide.ford@ucdenver.edu	Camidge, David Ross/AAG-9144-2019	Behbakht, Kian/0000-0003-4793-9958	NIH [CA124545]; Department of Defense (DOD) [BC093627]; Swedish Research Council [2009-618]; DOD Ovarian Cancer Idea Award [OC06143]; Department of Obstetrics and Gynecology Academic Enrichment Fund (AEF), University of Colorado-Denver Hospitals; NATIONAL CANCER INSTITUTE [R01CA124545] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense (DOD)(United States Department of Defense); Swedish Research Council(Swedish Research CouncilEuropean Commission); DOD Ovarian Cancer Idea Award; Department of Obstetrics and Gynecology Academic Enrichment Fund (AEF), University of Colorado-Denver Hospitals; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We apologize to the many investigators whose important works were not cited here owing to space limitations. This work was supported by NIH Grant CA124545 (A Thorburn, K Behbakht and H Ford), Department of Defense (DOD) postdoctoral fellowship BC093627 and Swedish Research Council postdoctoral fellowship 2009-618 (L Dimberg), DOD Ovarian Cancer Idea Award OC06143 (K Behbakht), and Department of Obstetrics and Gynecology Academic Enrichment Fund (AEF), University of Colorado-Denver Hospitals (C Anderson).	Abdulghani J, 2010, EXPERT OPIN THER TAR, V14, P1091, DOI 10.1517/14728222.2010.519701; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Behbakht K, 2007, CANCER RES, V67, P3036, DOI 10.1158/0008-5472.CAN-06-3755; Bevis KS, 2010, GYNECOL ONCOL, V119, P157, DOI 10.1016/j.ygyno.2010.05.034; Bin L, 2007, J BIOL CHEM, V282, P28189, DOI 10.1074/jbc.M704210200; Blay JY, 2008, PHASE 1B OPEN LABEL; Budd RC, 2006, NAT REV IMMUNOL, V6, P196, DOI 10.1038/nri1787; Burns TF, 2001, J BIOL CHEM, V276, P37879; Camidge DR, 2008, EXPERT OPIN BIOL TH, V8, P1167, DOI 10.1517/14712598.8.8.1167 ; Coletta RD, 2008, CANCER RES, V68, P2204, DOI 10.1158/0008-5472.CAN-07-3141; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; Diehl GE, 2004, IMMUNITY, V21, P877, DOI 10.1016/j.immuni.2004.11.008; Earel JK, 2006, CANCER RES, V66, P499, DOI 10.1158/0008-5472.CAN-05-3017; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Ehrlich S, 2003, CYTOKINE, V24, P244, DOI 10.1016/S1043-4666(03)00094-2; Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; Fricker N, 2010, J CELL BIOL, V190, P377, DOI 10.1083/jcb.201002060; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Ganten TM, 2006, CLIN CANCER RES, V12, P2640, DOI 10.1158/1078-0432.CCR-05-2635; Ghiotto F, 2010, CYTOM PART A, V77A, P11, DOI 10.1002/cyto.a.20819; Gillissen B, 2010, J CELL BIOL, V188, P851, DOI 10.1083/jcb.200912070; Golks A, 2005, J BIOL CHEM, V280, P14507, DOI 10.1074/jbc.M414425200; Golks A, 2006, J EXP MED, V203, P1295, DOI 10.1084/jem.20051556; Greco FA, 2008, LUNG CANCER, V61, P82, DOI 10.1016/j.lungcan.2007.12.011; Halaas O, 2000, SCAND J IMMUNOL, V51, P244; Henson ES, 2003, J CELL BIOCHEM, V89, P1177, DOI 10.1002/jcb.10597; Herbst RS, 2010, CLIN CANCER RES, V16, P5883, DOI 10.1158/1078-0432.CCR-10-0631; Herbst RS, 2010, J CLIN ONCOL, V28, P2839, DOI 10.1200/JCO.2009.25.1991; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Horak P, 2005, MOL CANCER RES, V3, P335, DOI 10.1158/1541-7786.MCR-04-0136; Horita H, 2009, J NEURO-ONCOL, V95, P175, DOI 10.1007/s11060-009-9914-4; Hotte SJ, 2008, CLIN CANCER RES, V14, P3450, DOI 10.1158/1078-0432.CCR-07-1416; Imam JS, 2010, ONCOGENE, V29, P4971, DOI 10.1038/onc.2010.233; Jin ZY, 2004, J BIOL CHEM, V279, P35829, DOI 10.1074/jbc.M405538200; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kandasamy K, 2003, CANCER RES, V63, P1712; Kanzler S, 2005, ECCO 13 EUR CANC C, P360; Karapetis CS, 2010, ASCO M, V28, P7535; Karikari CA, 2007, MOL CANCER THER, V6, P957, DOI 10.1158/1535-7163.MCT-06-0634; Kim JY, 2008, J CELL BIOCHEM, V105, P1386, DOI 10.1002/jcb.21958; Kim KH, 2000, CLIN CANCER RES, V6, P335; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kindler, 2009, J CLIN ONCOL, V27, P4501; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Lee TJ, 2009, FREE RADICAL BIO MED, V46, P1639, DOI 10.1016/j.freeradbiomed.2009.03.022; Leong S, 2009, J CLIN ONCOL, V27, P4413, DOI 10.1200/JCO.2008.21.7422; Lincz LF, 2001, LEUKEMIA, V15, P1650, DOI 10.1038/sj.leu.2402251; Logan AE, 2010, APOPTOSIS, V15, P1435, DOI 10.1007/s10495-010-0533-5; LoRusso P, 2007, J CLIN ONCOL, V25; Lu JF, 2011, MOL CANCER THER, V10, P902, DOI 10.1158/1535-7163.MCT-10-0864; MacFarlane M, 2005, CELL DEATH DIFFER, V12, P773, DOI 10.1038/sj.cdd.4401649; Makhov P, 2008, CELL DEATH DIFFER, V15, P1745, DOI 10.1038/cdd.2008.106; Martin S, 2005, CANCER RES, V65, P11447, DOI 10.1158/0008-5472.CAN-05-1494; McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691; Mellier G, 2010, MOL ASPECTS MED, V31, P93, DOI 10.1016/j.mam.2009.12.002; Menke C, 2011, CANCER RES, V71, P1883, DOI 10.1158/0008-5472.CAN-10-2252; Menke C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014527; Micalizzi DS, 2009, J CLIN INVEST, V119, P2678, DOI 10.1172/JCI37815; Mom CH, 2009, CLIN CANCER RES, V15, P5584, DOI 10.1158/1078-0432.CCR-09-0996; Natoni A, 2007, BRIT J HAEMATOL, V139, P568, DOI 10.1111/j.1365-2141.2007.06852.x; Ng CP, 2002, MOL CANCER THER, V1, P1051; Nimmanapalli R, 2001, CANCER RES, V61, P759; Oberst A, 2010, J BIOL CHEM, V285, P16632, DOI 10.1074/jbc.M109.095083; Oberst A, 2011, NATURE, V471, P363, DOI 10.1038/nature09852; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Pacey S, 2005, J CLIN ONCOL, V23, p205S; Paz-Ares L, 2009, J CLIN ONCOL, V27; PEETERS M, 2010, GASTR CANC S ORL FL; Pennarun B, 2010, BBA-REV CANCER, V1805, P123, DOI 10.1016/j.bbcan.2009.11.004; Petak I, 2000, CLIN CANCER RES, V6, P4119; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Pop C, 2011, BIOCHEM J, V433, P447, DOI 10.1042/BJ20101738; Psahoulia FH, 2007, MOL CANCER THER, V6, P2591, DOI 10.1158/1535-7163.MCT-07-0001; Ray S, 2005, APOPTOSIS, V10, P1411, DOI 10.1007/s10495-005-2490-y; Reis CR, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.61; Ricci MS, 2004, MOL CELL BIOL, V24, P8541, DOI 10.1128/MCB.24.19.8541-8555.2004; Rougier, 2009, J CLIN ONCOL, P4130; Saleh MN, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.3537; Saltz, 2009, J CLIN ONCOL, V27, P4079; Sayers TJ, 2006, CANCER IMMUNOL IMMUN, V55, P76, DOI 10.1007/s00262-005-0676-3; Sedger LM, 2002, EUR J IMMUNOL, V32, P2246, DOI 10.1002/1521-4141(200208)32:8<2246::AID-IMMU2246>3.0.CO;2-6; Shenoy K, 2009, CANCER RES, V69, P1941, DOI 10.1158/0008-5472.CAN-08-1996; Sikic BI, 2007, J CLIN ONCOL, V25; Sinicrope FA, 2004, CLIN CANCER RES, V10, P8284, DOI 10.1158/1078-0432.CCR-04-1289; Song JH, 2008, J BIOL CHEM, V283, P25003, DOI 10.1074/jbc.M802511200; Soria JC, 2011, J CLIN ONCOL, V29, P4442, DOI 10.1200/JCO.2011.37.2623; Soria JC, 2010, J CLIN ONCOL, V28, P1527, DOI 10.1200/JCO.2009.25.4847; Stern HM, 2010, CLIN CANCER RES, V16, P1587, DOI 10.1158/1078-0432.CCR-09-3108; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Tolcher AW, 2007, J CLIN ONCOL, V25, P1390, DOI 10.1200/JCO.2006.08.8898; Trauzold A, 2006, ONCOGENE, V25, P7434, DOI 10.1038/sj.onc.1209719; Von Pawel J, 2010, J CLIN ONCOL, V28; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; Wakelee HA, 2010, ANN ONCOL, V21, P376, DOI 10.1093/annonc/mdp292; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wiezorek J, 2010, CLIN CANCER RES, V16, P1701, DOI 10.1158/1078-0432.CCR-09-1692; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Xu LP, 2011, MOL CANCER THER, V10, P550, DOI 10.1158/1535-7163.MCT-10-0571; Yang JK, 2008, YONSEI MED J, V49, P19, DOI 10.3349/ymj.2008.49.1.19; Yee L, 2007, J CLIN ONCOL, V25; Yee L, 2009, J CLIN ONCOL, V27; Younes A VJ, 2005, ASH ANN M, P489; Zerafa N, 2005, J IMMUNOL, V175, P5586, DOI 10.4049/jimmunol.175.9.5586; Zhang LA, 2010, CLIN CANCER RES, V16, P4478, DOI 10.1158/1078-0432.CCR-10-0859; Zheng SJ, 2004, J IMMUNOL, V173, P5652, DOI 10.4049/jimmunol.173.9.5652	110	206	215	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2013	32	11					1341	1350		10.1038/onc.2012.164	http://dx.doi.org/10.1038/onc.2012.164			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22580613	Green Accepted			2023-01-03	WOS:000316455600001
J	Winter, GE; Rix, U; Carlson, SM; Gleixner, KV; Grebien, F; Gridling, M; Muller, AC; Breitwieser, FP; Bilban, M; Colinge, J; Valent, P; Bennett, KL; White, FM; Superti-Furga, G				Winter, Georg E.; Rix, Uwe; Carlson, Scott M.; Gleixner, Karoline V.; Grebien, Florian; Gridling, Manuela; Mueller, Andre C.; Breitwieser, Florian P.; Bilban, Martin; Colinge, Jacques; Valent, Peter; Bennett, Keiryn L.; White, Forest M.; Superti-Furga, Giulio			Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML	NATURE CHEMICAL BIOLOGY			English	Article							CHRONIC MYELOID-LEUKEMIA; C-MYC; GENE-EXPRESSION; SMALL MOLECULES; CANCER; INHIBITOR; MUTATION; PHOSPHORYLATION; TRANSFORMATION; NETWORK	Occurrence of the BCR-ABL(T315I) gatekeeper mutation is among the most pressing challenges in the therapy of chronic myeloid leukemia (CML). Several BCR-ABL inhibitors have multiple targets and pleiotropic effects that could be exploited for their synergistic potential. Testing combinations of such kinase inhibitors identified a strong synergy between danusertib and bosutinib that exclusively affected CML cells harboring BCR-ABL(T315I). To elucidate the underlying mechanisms, we applied a systems-level approach comprising phosphoproteomics, transcriptomics and chemical proteomics. Data integration revealed that both compounds targeted Mapk pathways downstream of BCR-ABL, resulting in impaired activity of c-Myc. Using pharmacological validation, we assessed that the relative contributions of danusertib and bosutinib could be mimicked individually by Mapk inhibitors and collectively by downregulation of c-Myc through Brd4 inhibition. Thus, integration of genome-and proteome-wide technologies enabled the elucidation of the mechanism by which a new drug synergy targets the dependency of BCR-ABL(T315I) CML cells on c-Myc through nonobvious off targets.	[Winter, Georg E.; Rix, Uwe; Grebien, Florian; Gridling, Manuela; Mueller, Andre C.; Breitwieser, Florian P.; Colinge, Jacques; Bennett, Keiryn L.; Superti-Furga, Giulio] Austrian Acad Sci, CeMM Res Ctr Mol Med, A-1010 Vienna, Austria; [Carlson, Scott M.; White, Forest M.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA; [Carlson, Scott M.; White, Forest M.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [Gleixner, Karoline V.; Valent, Peter] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Vienna, Austria; [Bilban, Martin] Med Univ Vienna, Clin Inst Med & Chem Lab Diagnost, Vienna, Austria; [Valent, Peter] Ludwig Boltzmann Cluster Oncol, Vienna, Austria	Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Medical University of Vienna; Medical University of Vienna; Ludwig Boltzmann Institute	Winter, GE (corresponding author), Austrian Acad Sci, CeMM Res Ctr Mol Med, A-1010 Vienna, Austria.	gsuperti@cemm.oeaw.ac.at	Colinge, Jacques/Z-2613-2019; Test, PV/U-9451-2019; Carlson, Scott/E-4606-2010; Superti-Furga, Giulio/F-4755-2015; Grebien, Florian/H-9234-2019; Colinge, Jacques/D-1578-2017; Superti-Furga, Giulio/AAE-5681-2019; Valent, Peter/B-8533-2016; Test, Test/Y-7921-2019; Gamperl, Susi/V-2715-2019	Colinge, Jacques/0000-0003-2466-4824; Carlson, Scott/0000-0003-1996-0012; Superti-Furga, Giulio/0000-0002-0570-1768; Grebien, Florian/0000-0003-4289-2281; Colinge, Jacques/0000-0003-2466-4824; Valent, Peter/0000-0003-0456-5095; Gamperl, Susi/0000-0003-0456-5095; Mueller, Andre/0000-0002-0608-8176; Bennett, Keiryn L./0000-0001-9356-7708; Gleixner, Karoline/0000-0001-5753-0203; White, Forest/0000-0002-1545-1651; Bilban, Martin/0000-0001-7043-7142; Breitwieser, Florian P/0000-0001-6192-0853; Winter, Georg/0000-0001-6606-1437	'GEN-AU' initiative of the Austrian Federal Ministry for Science and Research [PLACEBO GZ BMWF-70.081/0018-II/1a/2008]; Austrian Science Fund [P 24321-B21]; Austrian Science Fund (FWF) [P 24321] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [P30CA014051, U54CA112967] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083273] Funding Source: NIH RePORTER	'GEN-AU' initiative of the Austrian Federal Ministry for Science and Research; Austrian Science Fund(Austrian Science Fund (FWF)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank J. Bradner (Dana Faber Cancer Institute-Harvard Medical School) for providing JQ1S and JQ1R and R. Giambruno, C. Tan, J. Bigenzahn and O. Hantschel for skillful advice and help. We also thank J. Lehar for inspiring discussions and S. Nijman and O. Hantschel for carefully reading this manuscript. We thank Cell Signaling Technology for allowing reproduction of the kinome map. We acknowledge L. Brecker for measuring NMR spectra. The present work was, in part, financed by the 'GEN-AU' initiative of the Austrian Federal Ministry for Science and Research (PLACEBO GZ BMWF-70.081/0018-II/1a/2008) as well as the Austrian Science Fund (P 24321-B21).	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Albajar M, 2011, MOL CANCER RES, V9, P564, DOI 10.1158/1541-7786.MCR-10-0356; Azam M, 2008, NAT STRUCT MOL BIOL, V15, P1109, DOI 10.1038/nsmb.1486; Benassi B, 2006, MOL CELL, V21, P509, DOI 10.1016/j.molcel.2006.01.009; Bixby D, 2011, LEUKEMIA, V25, P7, DOI 10.1038/leu.2010.238; Bliss CI, 1939, ANN APPL BIOL, V26, P585, DOI 10.1111/j.1744-7348.1939.tb06990.x; Borisy AA, 2003, P NATL ACAD SCI USA, V100, P7977, DOI 10.1073/pnas.1337088100; Breitwieser FP, 2011, J PROTEOME RES, V10, P2758, DOI 10.1021/pr1012784; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Cortes JE, 2011, BLOOD, V118, P4567, DOI 10.1182/blood-2011-05-355594; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Donato NJ, 2004, CANCER RES, V64, P2306; Dopazo J, 1997, J MOL EVOL, V44, P226, DOI 10.1007/PL00006139; Druker BJ, 2004, ADV CANCER RES, V91, P1, DOI 10.1016/S0065-230X(04)91001-9; Eide CA, 2011, CANCER RES, V71, P3189, DOI 10.1158/0008-5472.CAN-10-3224; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Grebien F, 2011, CELL, V147, P306, DOI 10.1016/j.cell.2011.08.046; Griswold IJ, 2006, MOL CELL BIOL, V26, P6082, DOI 10.1128/MCB.02202-05; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; Hann SR, 2006, SEMIN CANCER BIOL, V16, P288, DOI 10.1016/j.semcancer.2006.08.004; Hantschel O, 2012, NAT CHEM BIOL, V8, P285, DOI [10.1038/nchembio.775, 10.1038/NCHEMBIO.775]; Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118; Kitano H, 2004, NAT REV CANCER, V4, P227, DOI 10.1038/nrc1300; Knight ZA, 2010, NAT REV CANCER, V10, P130, DOI 10.1038/nrc2787; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Lehar J, 2009, NAT BIOTECHNOL, V27, P659, DOI 10.1038/nbt.1549; Luo B, 2008, P NATL ACAD SCI USA, V105, P20380, DOI 10.1073/pnas.0810485105; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; O'Hare T, 2009, CANCER CELL, V16, P401, DOI 10.1016/j.ccr.2009.09.028; Packer LM, 2011, CANCER CELL, V20, P715, DOI 10.1016/j.ccr.2011.11.004; Palsson B, 2010, NAT CHEM BIOL, V6, P787, DOI 10.1038/nchembio.462; Pan CP, 2009, MOL CELL PROTEOMICS, V8, P2796, DOI 10.1074/mcp.M900285-MCP200; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Quintas-Cardama A, 2009, BLOOD, V113, P1619, DOI 10.1182/blood-2008-03-144790; Rix U, 2010, LEUKEMIA, V24, P44, DOI 10.1038/leu.2009.228; Rix U, 2009, NAT CHEM BIOL, V5, P616, DOI 10.1038/nchembio.216; Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; SETH A, 1991, J BIOL CHEM, V266, P23521; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559	45	79	83	0	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	NOV	2012	8	11					905	912		10.1038/NCHEMBIO.1085	http://dx.doi.org/10.1038/NCHEMBIO.1085			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	023RJ	23023260	Green Accepted, Green Published			2023-01-03	WOS:000310052100009
J	Bayer, H; Essig, K; Stanzel, S; Frank, M; Gildersleeve, JC; Berger, MR; Voss, C				Bayer, Helene; Essig, Katharina; Stanzel, Sven; Frank, Martin; Gildersleeve, Jeffrey C.; Berger, Martin R.; Voss, Cristina			Evaluation of Riproximin Binding Properties Reveals a Novel Mechanism for Cellular Targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME-INACTIVATING PROTEINS; PROSTATE-SPECIFIC ANTIGEN; BREAST-CANCER PATIENTS; HUMAN COLON; SUBMAXILLARY MUCIN; GLYCAN STRUCTURES; GLYCOSYLATION; CARCINOMA; SERUM; BOVINE	Riproximin is a cytotoxic type II ribosome-inactivating protein showing high selectivity for tumor cell lines. Its binding to cell surface glycans is crucial for subsequent internalization and cytotoxicity. In this paper, we describe a unique mechanism of interaction and discuss its implications for the cellular targeting and cytotoxicity of riproximin. On a carbohydrate microarray, riproximin specifically bound to two types of asialo-glycans, namely to bi- and triantennary complex N-glycan structures (NA2/NA3) and to repetitive N-acetyl-D-galactosamine (GalNAc), the so-called clustered Tn antigen, a cancer-specific O-glycan on mucins. Two glycoproteins showing high riproximin binding, the NA3-presenting asialofetuin and the clustered Tn-rich asialo-bovine submaxillary mucin, were subsequently chosen as model glycoproteins to mimic the binding interactions of riproximin with the two types of glycans. ELISA analyses were used to relate the two binding specificities of riproximin to its two sugar binding sites. The ability of riproximin to cross-link the two model proteins revealed that binding of the two types of glycoconjugates occurs within different binding sites. The biological implications of these binding properties were analyzed in cellular assays. The cytotoxicity of riproximin was found to depend on its specific and concomitant interaction with the two glycoconjugates as well as on dynamic avidity effects typical for lectins binding to multivalent glycoproteins. The presence of definite, cancer-related structures on the cells to be targeted determines the therapeutic potency of riproximin. Due to its cross-linking ability, riproximin is expected to show a high degree of specificity for cells exposing both NA2/NA3 and clustered Tn structures.	[Voss, Cristina] Heidelberg Pharma GmbH, Dept Biochem, D-68526 Ladenburg, Germany; [Bayer, Helene; Essig, Katharina; Berger, Martin R.] German Canc Res Ctr, Toxicol & Chemotherapy Unit, D-69120 Heidelberg, Germany; [Stanzel, Sven] German Canc Res Ctr, Dept Biostat, D-69120 Heidelberg, Germany; [Frank, Martin] BIOGNOS AB, S-41705 Gothenburg, Sweden; [Gildersleeve, Jeffrey C.] NCI, Biol Chem Lab, Frederick, MD 21702 USA	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Voss, C (corresponding author), Heidelberg Pharma GmbH, Dept Biochem, Schriesheimer Str 101, D-68526 Ladenburg, Germany.	c.voss@hdpharma.com	Gildersleeve, Jeffrey/N-3392-2014	Frank, Martin/0000-0002-1006-6746; Essig, Katharina/0000-0001-5928-6013; Gildersleeve, Jeffrey/0000-0002-3744-6423	National Institutes of Health, NCI, Intramural Research Program; German Federal Ministry of Economics and Technology [Pro Inno II KF0425101UL6, ZIM KF2301002AJ0]; NATIONAL CANCER INSTITUTE [ZIABC010740] Funding Source: NIH RePORTER	National Institutes of Health, NCI, Intramural Research Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); German Federal Ministry of Economics and Technology(Federal Ministry for Economic Affairs and Energy (BMWi)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported, in whole or in part, by the National Institutes of Health, NCI, Intramural Research Program.; Supported by German Federal Ministry of Economics and Technology Grants Pro Inno II KF0425101UL6 and ZIM KF2301002AJ0.	Abbott KL, 2008, PROTEOMICS, V8, P3210, DOI 10.1002/pmic.200800157; Alley WR, 2012, J PROTEOME RES, V11, P2282, DOI 10.1021/pr201070k; Arnold JN, 2008, PROTEOMICS, V8, P3284, DOI 10.1002/pmic.200800163; Bayer H, 2012, PROTEIN EXPRES PURIF, V82, P97, DOI 10.1016/j.pep.2011.11.018; BHATTACHARYYA L, 1988, ARCH BIOCHEM BIOPHYS, V262, P605, DOI 10.1016/0003-9861(88)90412-2; BRAIN P, 1989, WEED RES, V29, P93, DOI 10.1111/j.1365-3180.1989.tb00845.x; Brockhausen I, 2006, EMBO REP, V7, P599, DOI 10.1038/sj.embor.7400705; Byrd JC, 2004, CANCER METAST REV, V23, P77, DOI 10.1023/A:1025815113599; Campbell Christopher T, 2010, Curr Protoc Chem Biol, V2, P37, DOI 10.1002/9780470559277.ch090228; CHANDRASEKARAN EV, 1983, J BIOL CHEM, V258, P7213; Dam TK, 2007, J BIOL CHEM, V282, P28256, DOI 10.1074/jbc.M704677200; Dam TK, 2010, ADV CARBOHYD CHEM BI, V63, P139, DOI 10.1016/S0065-2318(10)63005-3; Dam TK, 2009, BIOCHEMISTRY-US, V48, P3822, DOI 10.1021/bi9002919; Dam TK, 2005, BIOCHEMISTRY-US, V44, P12564, DOI 10.1021/bi051144z; de Leoz MLA, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002717; de Leoz MLA, 2008, DIS MARKERS, V25, P243, DOI 10.1155/2008/515318; De Meyts P, 2008, TRENDS BIOCHEM SCI, V33, P376, DOI 10.1016/j.tibs.2008.06.003; DOWNS F, 1969, BIOCHEMISTRY-US, V8, P1760, DOI 10.1021/bi00832a060; ENDO Y, 1988, J BIOL CHEM, V263, P8735; Fang M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-215; FODSTAD O, 1984, CANCER RES, V44, P862; Freire T, 2005, CANCER RES, V65, P7880, DOI 10.1158/0008-5472.CAN-04-3746; Girbes T, 2003, CELL MOL BIOL, V49, P537; GREEN ED, 1988, J BIOL CHEM, V263, P18253; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; Horrix C, 2011, CELL MOL LIFE SCI, V68, P1269, DOI 10.1007/s00018-010-0524-2; Inoue M, 2001, CANCER RES, V61, P950; Ju TZ, 2011, ANGEW CHEM INT EDIT, V50, P1770, DOI 10.1002/anie.201002313; Kakugawa Y, 2002, P NATL ACAD SCI USA, V99, P10718, DOI 10.1073/pnas.152597199; Karg SR, 2009, PLANT PHYSIOL BIOCH, V47, P160, DOI 10.1016/j.plaphy.2008.10.005; Kumar SR, 2005, CLIN CANCER RES, V11, P6868, DOI 10.1158/1078-0432.CCR-05-0146; Lattova E, 2010, J PROTEOME RES, V9, P1533, DOI 10.1021/pr9010266; Lee JJ, 2009, STAT BIOPHARM RES, V1, P4, DOI 10.1198/sbr.2009.0001; Li QA, 2010, CHEMBIOCHEM, V11, P1686, DOI 10.1002/cbic.201000235; Li Q, 2010, INT J CANCER, V126, P459, DOI 10.1002/ijc.24716; LIN JY, 1970, NATURE, V227, P292, DOI 10.1038/227292a0; Lloyd KO, 1996, J BIOL CHEM, V271, P33325, DOI 10.1074/jbc.271.52.33325; Machado E, 2011, GLYCOBIOLOGY, V21, P376, DOI 10.1093/glycob/cwq170; Manimala JC, 2006, ANGEW CHEM INT EDIT, V45, P3607, DOI 10.1002/anie.200600591; Nan BC, 1998, GLYCOCONJUGATE J, V15, P1033, DOI 10.1023/A:1006950311937; NILSSON B, 1979, J BIOL CHEM, V254, P4545; Oyelaran O, 2009, J PROTEOME RES, V8, P3529, DOI 10.1021/pr9002245; Peracaula R, 2003, GLYCOBIOLOGY, V13, P457, DOI 10.1093/glycob/cwg041; Reis CA, 2010, J CLIN PATHOL, V63, P322, DOI 10.1136/jcp.2009.071035; Saldova R, 2011, ANN ONCOL, V22, P1113, DOI 10.1093/annonc/mdq570; Sarrats A, 2010, OMICS, V14, P465, DOI 10.1089/omi.2010.0050; SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450; Stirpe F, 2006, CELL MOL LIFE SCI, V63, P1850, DOI 10.1007/s00018-006-6078-7; Storr SJ, 2008, GLYCOBIOLOGY, V18, P456, DOI 10.1093/glycob/cwn022; Strafors P., 2012, ADV EXP MED BIOL, V729, P111; Sujatha MS, 2004, PROTEINS, V55, P44, DOI 10.1002/prot.10612; Tabares G, 2006, GLYCOBIOLOGY, V16, P132, DOI 10.1093/glycob/cwj042; Telford JE, 2011, BIOCHEM SOC T, V39, P327, DOI 10.1042/BST0390327; TETTAMANTI G, 1968, ARCH BIOCHEM BIOPHYS, V124, P41, DOI 10.1016/0003-9861(68)90301-9; TSUJI T, 1986, CARBOHYD RES, V151, P391, DOI 10.1016/S0008-6215(00)90358-6; Varki A, 2009, ESSENTIALS GLYCOBIOL, P1; Vercoutter-Edouart AS, 2008, PROTEOMICS, V8, P3236, DOI 10.1002/pmic.200800151; Voss C, 2006, TOXICOL APPL PHARM, V211, P177, DOI 10.1016/j.taap.2005.05.016; Voss C, 2006, FASEB J, V20, P1194, DOI 10.1096/fj.05-5231fje; Wang DN, 2002, NAT BIOTECHNOL, V20, P275, DOI 10.1038/nbt0302-275; Wu JH, 2006, BIOCHIMIE, V88, P201, DOI 10.1016/j.biochi.2005.07.007	61	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2012	287	43					35873	35886		10.1074/jbc.M112.368548	http://dx.doi.org/10.1074/jbc.M112.368548			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027PA	22872642	hybrid, Green Published			2023-01-03	WOS:000310364000010
J	Spence, D				Spence, Des			Good medicine: homeopathy	BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk						[Anonymous], 2010, NHS NEWS        0727; Kirsch I, 2008, PLOS MED, V5, P260, DOI 10.1371/journal.pmed.0050045; NHS Health and Social Care Information Centre, 2011, PRESCR COST AN ENGL; Starfield B, 2000, JAMA-J AM MED ASSOC, V284, P483, DOI 10.1001/jama.284.4.483	4	4	4	0	11	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 14	2012	345								e6184	10.1136/bmj.e6184	http://dx.doi.org/10.1136/bmj.e6184			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	007BZ	22983533				2023-01-03	WOS:000308865100004
J	Sun, JY; Zhao, XH; Illeperuma, WRK; Chaudhuri, O; Oh, KH; Mooney, DJ; Vlassak, JJ; Suo, ZG				Sun, Jeong-Yun; Zhao, Xuanhe; Illeperuma, Widusha R. K.; Chaudhuri, Ovijit; Oh, Kyu Hwan; Mooney, David J.; Vlassak, Joost J.; Suo, Zhigang			Highly stretchable and tough hydrogels	NATURE			English	Article							DOUBLE-NETWORK GELS; HIGH MECHANICAL STRENGTH; LARGE-STRAIN; FRACTURE; HYSTERESIS; FATIGUE; MODEL	Hydrogels are used as scaffolds for tissue engineering(1), vehicles for drug delivery(2), actuators for optics and fluidics(3), and model extracellular matrices for biological studies(4). The scope of hydrogel applications, however, is often severely limited by their mechanical behaviour(5). Most hydrogels do not exhibit high stretchability; for example, an alginate hydrogel ruptures when stretched to about 1.2 times its original length. Some synthetic elastic hydrogels(6,7) have achieved stretches in the range 10-20, but these values are markedly reduced in samples containing notches. Most hydrogels are brittle, with fracture energies of about 10 J m(-2) (ref. 8), as compared with similar to 1,000 J m(-2) for cartilage(9) and similar to 10,000 J m(-2) for natural rubbers(10). Intense efforts are devoted to synthesizing hydrogels with improved mechanical properties(11-18); certain synthetic gels have reached fracture energies of 100-1,000 J m(-2) (refs 11, 14, 17). Here we report the synthesis of hydrogels from polymers forming ionically and covalently crosslinked networks. Although such gels contain similar to 90% water, they can be stretched beyond 20 times their initial length, and have fracture energies of similar to 9,000 J m(-2). Even for samples containing notches, a stretch of 17 is demonstrated. We attribute the gels' toughness to the synergy of two mechanisms: crack bridging by the network of covalent crosslinks, and hysteresis by unzipping the network of ionic crosslinks. Furthermore, the network of covalent crosslinks preserves the memory of the initial state, so that much of the large deformation is removed on unloading. The unzipped ionic crosslinks cause internal damage, which heals by re-zipping. These gels may serve as model systems to explore mechanisms of deformation and energy dissipation, and expand the scope of hydrogel applications.	[Sun, Jeong-Yun; Illeperuma, Widusha R. K.; Chaudhuri, Ovijit; Mooney, David J.; Vlassak, Joost J.; Suo, Zhigang] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA; [Sun, Jeong-Yun; Oh, Kyu Hwan] Seoul Natl Univ, Dept Mat Sci & Engn, Seoul 151742, South Korea; [Zhao, Xuanhe] Duke Univ, Dept Mech Engn & Mat Sci, Durham, NC 27708 USA; [Mooney, David J.] Harvard Univ, Wyss Inst Biologically Inspired Engn, Cambridge, MA 02138 USA; [Suo, Zhigang] Harvard Univ, Kavli Inst Bionano Sci & Technol, Cambridge, MA 02138 USA	Harvard University; Seoul National University (SNU); Duke University; Harvard University; Harvard University	Suo, ZG (corresponding author), Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA.	suo@seas.harvard.edu	Zhao, Xuanhe/B-1532-2008; oh, kyuhwan/H-5265-2018; Sun, Jeong-Yun/AAR-4630-2020; Suo, Zhigang/B-1067-2008; Sun, Jeong-Yun/F-5662-2012	Zhao, Xuanhe/0000-0001-5387-6186; Suo, Zhigang/0000-0002-4068-4844; Chaudhuri, Ovijit/0000-0002-9287-3401; Mooney, David/0000-0001-6299-1194	ARO [W911NF-09-1-0476]; NSF [CMMI-0800161]; DARPA [W911NF-10-1-0113]; NIH [R37 DE013033]; MRSEC [DMR-0820484]; NSF Research Triangle MRSEC [DMR-1121107]; Haythornthwaite Research Initiation grants; National Research Foundation of Korea (NRF); Ministry of Education, Science and Technology [R11-2005-065]; Alexander von Humboldt Award; Harvard University; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R37DE013033, R01DE013033] Funding Source: NIH RePORTER	ARO; NSF(National Science Foundation (NSF)); DARPA(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MRSEC(National Science Foundation (NSF)); NSF Research Triangle MRSEC; Haythornthwaite Research Initiation grants; National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Alexander von Humboldt Award(Alexander von Humboldt Foundation); Harvard University; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	The work at Harvard was supported by ARO (W911NF-09-1-0476), NSF (CMMI-0800161), DARPA (W911NF-10-1-0113), NIH (R37 DE013033) and MRSEC (DMR-0820484). X.Z. acknowledges the support of the NSF Research Triangle MRSEC (DMR-1121107) and Haythornthwaite Research Initiation grants. K.H.O. is supported by the National Research Foundation of Korea (NRF), funded by the Ministry of Education, Science and Technology (R11-2005-065). Z.S. acknowledges a sabbatical leave at the Karlsruhe Institute of Technology funded by the Alexander von Humboldt Award and by Harvard University.	Baumberger T, 2009, J CHEM PHYS, V130, DOI 10.1063/1.3078267; Brown HR, 2007, MACROMOLECULES, V40, P3815, DOI 10.1021/ma062642y; Calvert P, 2009, ADV MATER, V21, P743, DOI 10.1002/adma.200800534; Discher DE, 2009, SCIENCE, V324, P1673, DOI 10.1126/science.1171643; Dong L, 2006, NATURE, V442, P551, DOI 10.1038/nature05024; EVANS AG, 1990, J AM CERAM SOC, V73, P187, DOI 10.1111/j.1151-2916.1990.tb06493.x; Gong JP, 2003, ADV MATER, V15, P1155, DOI 10.1002/adma.200304907; Haque MA, 2011, MACROMOLECULES, V44, P8916, DOI 10.1021/ma201653t; Haraguchi K, 2002, ADV MATER, V14, P1120, DOI 10.1002/1521-4095(20020816)14:16<1120::AID-ADMA1120>3.0.CO;2-9; Henderson KJ, 2010, MACROMOLECULES, V43, P6193, DOI 10.1021/ma100963m; Hernandez RM, 2010, ADV DRUG DELIVER REV, V62, P711, DOI 10.1016/j.addr.2010.02.004; Huang T, 2007, ADV MATER, V19, P1622, DOI 10.1002/adma.200602533; Hui CY, 2003, P ROY SOC A-MATH PHY, V459, P1489, DOI 10.1098/rspa.2002.1057; JACKSON AP, 1990, BIOMATERIALS, V11, P403, DOI 10.1016/0142-9612(90)90095-8; Kong HJ, 2003, MACROMOLECULES, V36, P4582, DOI 10.1021/ma034137w; LAKE GJ, 1967, PROC R SOC LON SER-A, V300, P108, DOI 10.1098/rspa.1967.0160; LAKE GJ, 1995, RUBBER CHEM TECHNOL, V68, P435, DOI 10.5254/1.3538750; Lee KY, 2001, CHEM REV, V101, P1869, DOI 10.1021/cr000108x; Lin WC, 2010, MACROMOLECULES, V43, P2554, DOI 10.1021/ma901937r; Maldonado-Codina C, 2004, OPHTHAL PHYSL OPT, V24, P551, DOI 10.1111/j.1475-1313.2004.00236.x; Okumura Y, 2001, ADV MATER, V13, P485, DOI 10.1002/1521-4095(200104)13:7<485::AID-ADMA485>3.0.CO;2-T; Qiu Y, 2001, ADV DRUG DELIVER REV, V53, P321, DOI 10.1016/S0169-409X(01)00203-4; Sakai T, 2008, MACROMOLECULES, V41, P5379, DOI 10.1021/ma800476x; Seitz ME, 2009, SOFT MATTER, V5, P447, DOI 10.1039/b810041a; Simha N. K., 2003, J MATER SCI-MATER M, V14, P631; Tanaka Y, 2007, EPL-EUROPHYS LETT, V78, DOI 10.1209/0295-5075/78/56005; Tuncaboylu DC, 2011, MACROMOLECULES, V44, P4997, DOI 10.1021/ma200579v; Wang Q, 2010, NATURE, V463, P339, DOI 10.1038/nature08693; Webber RE, 2007, MACROMOLECULES, V40, P2919, DOI 10.1021/ma062924y; Yu QM, 2009, MACROMOLECULES, V42, P3852, DOI 10.1021/ma900622s	30	3267	3383	417	6347	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 6	2012	489	7414					133	136		10.1038/nature11409	http://dx.doi.org/10.1038/nature11409			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	999WW	22955625	Green Accepted			2023-01-03	WOS:000308347000049
J	Rueger, MA; Keuters, MH; Walberer, M; Braun, R; Klein, R; Sparing, R; Fink, GR; Graf, R; Schroeter, M				Rueger, Maria Adele; Keuters, Meike Hedwig; Walberer, Maureen; Braun, Ramona; Klein, Rebecca; Sparing, Roland; Fink, Gereon Rudolf; Graf, Rudolf; Schroeter, Michael			Multi-Session Transcranial Direct Current Stimulation (tDCS) Elicits Inflammatory and Regenerative Processes in the Rat Brain	PLOS ONE			English	Article							NEURAL STEM-CELLS; NONINVASIVE CORTICAL STIMULATION; CURRENT ELECTRIC-FIELDS; HUMAN MOTOR CORTEX; PROGENITOR CELLS; IN-VIVO; CEREBRAL-CORTEX; ADULT BRAIN; STROKE; MIGRATION	Transcranial direct current stimulation (tDCS) is increasingly being used in human studies as an adjuvant tool to promote recovery of function after stroke. However, its neurobiological effects are still largely unknown. Electric fields are known to influence the migration of various cell types in vitro, but effects in vivo remain to be shown. Hypothesizing that tDCS might elicit the recruitment of cells to the cortex, we here studied the effects of tDCS in the rat brain in vivo. Adult Wistar rats (n = 16) were randomized to either anodal or cathodal stimulation for either 5 or 10 consecutive days (500 mu A, 15 min). Bromodeoxyuridine (BrdU) was given systemically to label dividing cells throughout the experiment. Immunohistochemical analyses ex vivo included stainings for activated microglia and endogenous neural stem cells (NSC). Multi-session tDCS with the chosen parameters did not cause a cortical lesion. An innate immune response with early upregulation of Iba1-positive activated microglia occurred after both cathodal and anodal tDCS. The involvement of adaptive immunity as assessed by ICAM1-immunoreactivity was less pronounced. Most interestingly, only cathodal tDCS increased the number of endogenous NSC in the stimulated cortex. After 10 days of cathodal stimulation, proliferating NSC increased by similar to 60%, with a significant effect of both polarity and number of tDCS sessions on the recruitment of NSC. We demonstrate a pro-inflammatory effect of both cathodal and anodal tDCS, and a polarity-specific migratory effect on endogenous NSC in vivo. Our data suggest that tDCS in human stroke patients might also elicit NSC activation and modulate neuroinflammation.	[Rueger, Maria Adele; Keuters, Meike Hedwig; Walberer, Maureen; Braun, Ramona; Klein, Rebecca; Sparing, Roland; Fink, Gereon Rudolf; Schroeter, Michael] Univ Hosp Cologne, Dept Neurol, Cologne, Germany; [Braun, Ramona] Univ Hosp Cologne, Ctr Med Expt, Cologne, Germany; [Rueger, Maria Adele; Keuters, Meike Hedwig; Walberer, Maureen; Klein, Rebecca; Graf, Rudolf; Schroeter, Michael] Max Planck Inst Neurol Res, D-50931 Cologne, Germany; [Fink, Gereon Rudolf] Res Ctr Juelich, Inst Neurosci & Med INM 3, Cognit Neurol Sect, Julich, Germany	University of Cologne; University of Cologne; Max Planck Society; Helmholtz Association; Research Center Julich	Rueger, MA (corresponding author), Univ Hosp Cologne, Dept Neurol, Cologne, Germany.	adele.rueger@uk-koeln.de	Keuters, Meike/AAQ-2165-2021; Fink, Gereon R./AFW-9377-2022; Fink, Gereon R./E-1616-2012	Fink, Gereon R./0000-0002-8230-1856; Fink, Gereon R./0000-0002-8230-1856; Keuters, Meike Hedwig/0000-0003-4216-1024	Koeln Fortune Program / Faculty of Medicine, University of Cologne, Germany [143/2011]	Koeln Fortune Program / Faculty of Medicine, University of Cologne, Germany	This work was supported by the Koeln Fortune Program / Faculty of Medicine, University of Cologne, Germany (143/2011). The authors gratefully acknowledge a personal grant by Mr. U. Eichrodt to RK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Androutsellis-Theotokis A, 2008, COLD SH Q B, V73, P403, DOI 10.1101/sqb.2008.73.018; Androutsellis-Theotokis A, 2006, NATURE, V442, P823, DOI 10.1038/nature04940; Androutsellis-Theotokis A, 2009, P NATL ACAD SCI USA, V106, P13570, DOI 10.1073/pnas.0905125106; Antal A, 2004, EUR J NEUROSCI, V19, P2888, DOI 10.1111/j.1460-9568.2004.03367.x; Ariza CA, 2010, STEM CELL REV REP, V6, P585, DOI 10.1007/s12015-010-9171-0; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Babona-Pilipos R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023808; Belmadani A, 2006, J NEUROSCI, V26, P3182, DOI 10.1523/JNEUROSCI.0156-06.2006; BINDMAN LJ, 1962, NATURE, V196, P584, DOI 10.1038/196584a0; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; BROWN MJ, 1994, J CELL BIOL, V127, P117, DOI 10.1083/jcb.127.1.117; Butefisch CM, 2004, J NEUROPHYSIOL, V91, P2110, DOI 10.1152/jn.01038.2003; Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Feng JF, 2012, STEM CELLS, V30, P349, DOI 10.1002/stem.779; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Hummel F, 2005, BRAIN, V128, P490, DOI 10.1093/brain/awh369; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Leker RR, 2007, STROKE, V38, P153, DOI 10.1161/01.STR.0000252156.65953.a9; Li L, 2008, STEM CELLS, V26, P2193, DOI 10.1634/stemcells.2007-1022; Liebetanz D, 2006, NEUROSCI LETT, V398, P85, DOI 10.1016/j.neulet.2005.12.058; Liebetanz D, 2002, BRAIN, V125, P2238, DOI 10.1093/brain/awf238; Liebetanz D, 2009, CLIN NEUROPHYSIOL, V120, P1161, DOI 10.1016/j.clinph.2009.01.022; Mabuchi T, 2000, STROKE, V31, P1735, DOI 10.1161/01.STR.31.7.1735; Martino G, 2011, PHYSIOL REV, V91, P1281, DOI 10.1152/physrev.00032.2010; Maysami S, 2008, J CEREBR BLOOD F MET, V28, P1104, DOI 10.1038/jcbfm.2008.4; Monti A, 2008, J NEUROL NEUROSUR PS, V79, P451, DOI 10.1136/jnnp.2007.135277; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Nishimura KY, 1996, J CELL SCI, V109, P199; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; RAPP B, 1988, EUR BIOPHYS J BIOPHY, V16, P313, DOI 10.1007/BF00254068; Rueger MA, 2010, J NEUROSCI, V30, P6454, DOI 10.1523/JNEUROSCI.6092-09.2010; Ruohonen J, 2012, CLIN NEUROPHYSIOL; Ryu JK, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-39; Schlaug G, 2008, ARCH NEUROL-CHICAGO, V65, P1571, DOI 10.1001/archneur.65.12.1571; Schweid L, 2008, EXP BRAIN RES, V186, P409, DOI 10.1007/s00221-007-1245-0; Song B, 2007, NAT PROTOC, V2, P1479, DOI 10.1038/nprot.2007.205; Sparing R, 2009, BRAIN, V132, P3011, DOI 10.1093/brain/awp154; Stagg CJ, 2011, NEUROSCIENTIST, V17, P37, DOI 10.1177/1073858410386614; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Wachter D, 2011, EXP NEUROL, V227, P322, DOI 10.1016/j.expneurol.2010.12.005; Wagner T, 2007, ANNU REV BIOMED ENG, V9, P527, DOI 10.1146/annurev.bioeng.9.061206.133100; Zhang JP, 2011, STEM CELL REV REP, V7, P987, DOI 10.1007/s12015-011-9247-5	44	88	91	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2012	7	8							e43776	10.1371/journal.pone.0043776	http://dx.doi.org/10.1371/journal.pone.0043776			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	999CI	22928032	Green Published, Green Submitted, gold			2023-01-03	WOS:000308286300088
J	van der Weerd, NC; Grooteman, MPC; Bots, ML; van den Dorpel, MA; den Hoedt, CH; Mazairac, AHA; Nube, MJ; Penne, EL; Gaillard, CA; Wetzels, JFM; Wiegerinck, ET; Swinkels, DW; Blankestijn, PJ; ter Wee, PM				van der Weerd, Neelke C.; Grooteman, Muriel P. C.; Bots, Michiel L.; van den Dorpel, Marinus A.; den Hoedt, Claire H.; Mazairac, Albert H. A.; Nube, Menso J.; Penne, E. Lars; Gaillard, Carlo A.; Wetzels, Jack F. M.; Wiegerinck, Erwin T.; Swinkels, Dorine W.; Blankestijn, Peter J.; ter Wee, Piet M.		CONTRAST Investigators	Hepcidin-25 in Chronic Hemodialysis Patients Is Related to Residual Kidney Function and Not to Treatment with Erythropoiesis Stimulating Agents	PLOS ONE			English	Article							SERUM HEPCIDIN; IRON STATUS; ONLINE HEMODIAFILTRATION; ALL-CAUSE; PROHEPCIDIN; FERRITIN; THERAPY; DETERMINANTS; EXPRESSION; RESISTANCE	Hepcidin-25, the bioactive form of hepcidin, is a key regulator of iron homeostasis as it induces internalization and degradation of ferroportin, a cellular iron exporter on enterocytes, macrophages and hepatocytes. Hepcidin levels are increased in chronic hemodialysis (HD) patients, but as of yet, limited information on factors associated with hepcidin-25 in these patients is available. In the current cross-sectional study, potential patient-, laboratory-and treatment-related determinants of serum hepcidin-20 and -25, were assessed in a large cohort of stable, prevalent HD patients. Baseline data from 405 patients (62% male; age 63.7 +/- 13.9 [mean SD]) enrolled in the CONvective TRAnsport STudy (CONTRAST; NCT00205556) were studied. Predialysis hepcidin concentrations were measured centrally with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Patient-, laboratory-and treatment related characteristics were entered in a backward multivariable linear regression model. Hepcidin-25 levels were independently and positively associated with ferritin (p<0.001), hsCRP (p<0.001) and the presence of diabetes (p = 0.02) and inversely with the estimated glomerular filtration rate (p = 0.01), absolute reticulocyte count (p = 0.02) and soluble transferrin receptor (p<0.001). Men had lower hepcidin-25 levels as compared to women (p = 0.03). Hepcidin-25 was not associated with the maintenance dose of erythropoiesis stimulating agents (ESA) or iron therapy. In conclusion, in the currently studied cohort of chronic HD patients, hepcidin-25 was a marker for iron stores and erythropoiesis and was associated with inflammation. Furthermore, hepcidin-25 levels were influenced by residual kidney function. Hepcidin-25 did not reflect ESA or iron dose in chronic stable HD patients on maintenance therapy. These results suggest that hepcidin is involved in the pathophysiological pathway of renal anemia and iron availability in these patients, but challenges its function as a clinical parameter for ESA resistance.	[van der Weerd, Neelke C.; Grooteman, Muriel P. C.; Nube, Menso J.; Penne, E. Lars; Gaillard, Carlo A.; ter Wee, Piet M.] Vrije Univ Amsterdam Med Ctr, Dept Nephrol, Amsterdam, Netherlands; [van der Weerd, Neelke C.] Univ Amsterdam, Acad Med Ctr, Dept Nephrol, NL-1105 AZ Amsterdam, Netherlands; [Grooteman, Muriel P. C.; Nube, Menso J.; ter Wee, Piet M.] Vrije Univ Amsterdam Med Ctr, Inst Cardiovasc Res VU Med Ctr ICaR VU, Amsterdam, Netherlands; [Bots, Michiel L.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [van den Dorpel, Marinus A.; den Hoedt, Claire H.] Maasstad Hosp, Dept Internal Med, Rotterdam, Netherlands; [den Hoedt, Claire H.; Mazairac, Albert H. A.; Penne, E. Lars; Blankestijn, Peter J.] Univ Med Ctr Utrecht, Dept Nephrol, Utrecht, Netherlands; [Wetzels, Jack F. M.] Radboud Univ Nijmegen, Med Ctr, Dept Nephrol, NL-6525 ED Nijmegen, Netherlands; [Wiegerinck, Erwin T.; Swinkels, Dorine W.] Radboud Univ Nijmegen, Med Ctr, Dept Lab Med, Lab Genet Endocrine & Metab Dis, NL-6525 ED Nijmegen, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Utrecht University; Utrecht University Medical Center; Maasstad Hospital; Utrecht University; Utrecht University Medical Center; Radboud University Nijmegen; Radboud University Nijmegen	van der Weerd, NC (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Nephrol, Amsterdam, Netherlands.	n.c.vanderweerd@amc.uva.nl	van Hamersvelt, H.W./L-4348-2015; Gaillard, Carlo/AAC-6729-2022; Gaillard, Carlo/D-1514-2013; Wetzels, Jack F.M./A-1720-2014; Grooteman, Muriel/AAA-2602-2019; Swinkels, Dorine W./H-8098-2014	Gaillard, Carlo/0000-0002-8964-0236; Gaillard, Carlo/0000-0002-8964-0236; Wetzels, Jack F.M./0000-0002-0650-6921; Swinkels, Dorine W./0000-0002-1040-9446; Grooteman, Muriel/0000-0001-5447-2546; van Buren, Marjolijn/0000-0002-1822-6863; Penne, Erik/0000-0002-6018-4679; boer, walther/0000-0001-5048-2755	Dutch Kidney Foundation (Nierstichting Nederland) [C02.2019]; Fresenius Medical Care (The Netherlands); Gambro Lundia AB (Sweden); Dr. E.E. Twiss Fund, Roche Netherlands; International Society of Nephrology/Baxter Extramural Grant Program; Dutch Organization for Health Research and Development (ZonMW) [17088.2802]; Fresenius Medical Care; Roche Netherlands; Baxter Netherlands; Amgen BV Netherlands	Dutch Kidney Foundation (Nierstichting Nederland); Fresenius Medical Care (The Netherlands)(Netherlands Government); Gambro Lundia AB (Sweden); Dr. E.E. Twiss Fund, Roche Netherlands; International Society of Nephrology/Baxter Extramural Grant Program; Dutch Organization for Health Research and Development (ZonMW)(Netherlands Organization for Health Research and Development); Fresenius Medical Care; Roche Netherlands; Baxter Netherlands; Amgen BV Netherlands(Amgen)	The Dutch CONvective TRAnsport STudy is financially supported by a grant from the Dutch Kidney Foundation (Nierstichting Nederland, grant C02.2019) and unrestricted grants from Fresenius Medical Care (The Netherlands) and Gambro Lundia AB (Sweden). Additional support for CONTRAST was received from the Dr. E.E. Twiss Fund, Roche Netherlands; the International Society of Nephrology/Baxter Extramural Grant Program; the Dutch Organization for Health Research and Development (ZonMW, grant 17088.2802); and for this particular study from Amgen BV Netherlands. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; DWS is a co-founder and Medical Director of the "Hepcidinanalysis.com" initiative, which aims to serve the scientific and medical community with high-quality hepcidin-25 measurements (www.hepcidinanalysis.com). The other authors have declared that no competing interests exist. Furthermore, the main study was supported by funding from several commercial sources (Fresenius Medical Care, Gambro Lundia AB (Sweden), Roche Netherlands, Baxter Netherlands and Amgen BV Netherlands). This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.	[Anonymous], 2001, Am J Kidney Dis, V37, pS182; Ashby DR, 2009, KIDNEY INT, V75, P976, DOI 10.1038/ki.2009.21; Babitt JL, 2010, AM J KIDNEY DIS, V55, P726, DOI 10.1053/j.ajkd.2009.12.030; Campostrini N, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/329646; Chiang WC, 2002, CLIN NEPHROL, V58, P363; Costa E, 2009, ACTA HAEMATOL-BASEL, V122, P226, DOI 10.1159/000253590; Coyne DW, 2011, KIDNEY INT, V80, P240, DOI 10.1038/ki.2011.141; Ford BA, 2010, KIDNEY INT, V78, P769, DOI 10.1038/ki.2010.254; Fouque D, 2007, NEPHROL DIAL TRANSPL, V22, P45, DOI 10.1093/ndt/gfm020; Galesloot TE, 2011, BLOOD, V117, pE218, DOI 10.1182/blood-2011-02-337907; Gambino R, 1997, CLIN CHEM, V43, P2408; Grooteman MPC, 2012, J AM SOC NEPHROL, V23, P1087, DOI 10.1681/ASN.2011121140; Jiang F, 2011, DIABETES RES CLIN PR, V93, P43, DOI 10.1016/j.diabres.2011.03.028; Kato A, 2008, AM J NEPHROL, V28, P115, DOI 10.1159/000109968; Kemna EHJM, 2007, CLIN CHEM, V53, P620, DOI 10.1373/clinchem.2006.079186; Kroot JJC, 2011, CLIN CHEM, V57, P1650, DOI 10.1373/clinchem.2009.140053; Kroot JJC, 2010, CLIN CHEM, V56, P1570, DOI 10.1373/clinchem.2010.149187; Kroot JJC, 2009, HAEMATOL-HEMATOL J, V94, P1748, DOI 10.3324/haematol.2009.010322; Kuragano T, 2010, AM J NEPHROL, V31, P534, DOI 10.1159/000312381; Levin A, 2007, AM J KIDNEY DIS, V50, P471; Levin A, 2006, AM J KIDNEY DIS, V47, pS9, DOI 10.1053/j.ajkd.2006.04.023; Locatelli F, 2004, NEPHROL DIAL TRANSPL, V19, P1, DOI 10.1093/ndt/gfh1024; Macdougall IC, 2010, CLIN J AM SOC NEPHRO, V5, P1681, DOI 10.2215/CJN.05990809; Malyszko J, 2009, RENAL FAILURE, V31, P876, DOI 10.3109/08860220903216071; Malyszko J, 2009, KIDNEY BLOOD PRESS R, V32, P235, DOI 10.1159/000235747; Penne EL, 2005, CURR CONTR TRIALS C, V6, DOI 10.1186/1468-6708-6-8; Peters HPE, 2010, NEPHROL DIAL TRANSPL, V25, P848, DOI 10.1093/ndt/gfp546; Singh AK, 2007, KIDNEY INT, V71, P1163, DOI 10.1038/sj.ki.5002223; Swinkels DW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002706; Swinkels DW, 2008, NEPHROL DIAL TRANSPL, V23, P250, DOI 10.1093/ndt/gfn267; Tarng DC, 2002, NEPHROL DIAL TRANSPL, V17, P1063, DOI 10.1093/ndt/17.6.1063; Tessitore N, 2010, NEPHROL DIAL TRANSPL, V25, P3996, DOI 10.1093/ndt/gfq321; Truksa J, 2006, P NATL ACAD SCI USA, V103, P10289, DOI 10.1073/pnas.0603124103; Uehata T, 2012, NEPHROL DIAL TRANSPL, V27, P1076, DOI 10.1093/ndt/gfr431; van der Putten K, 2010, EUR J HEART FAIL, V12, P943, DOI 10.1093/eurjhf/hfq099; Weiss G, 2009, EUR J CLIN INVEST, V39, P883, DOI 10.1111/j.1365-2362.2009.02182.x; Wish JB, 2006, CLIN J AM SOC NEPHRO, V1, pS4, DOI 10.2215/CJN.01490506; Zaritsky J, 2010, CLIN J AM SOC NEPHRO, V5, P1010, DOI 10.2215/CJN.08161109; Zaritsky J, 2009, CLIN J AM SOC NEPHRO, V4, P1051, DOI 10.2215/CJN.05931108; Zaritsky JJ, 2009, KIDNEY INT, V76, P912, DOI 10.1038/ki.2009.272	40	48	48	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 13	2012	7	7							e39783	10.1371/journal.pone.0039783	http://dx.doi.org/10.1371/journal.pone.0039783			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	974CF	22808058	Green Published, Green Submitted, gold			2023-01-03	WOS:000306406700013
J	Li, J; Sun, YA; Ye, JH				Li, Jing; Sun, Yanan; Ye, Jiang-Hong			Electroacupuncture Decreases Excessive Alcohol Consumption Involving Reduction of FosB/Delta FosB Levels in Reward-Related Brain Regions	PLOS ONE			English	Article							VENTRAL TEGMENTAL AREA; RANDOMIZED-CONTROLLED-TRIAL; RECEPTOR AGONIST U50,488H; VOLUNTARY ETHANOL INTAKE; MESSENGER-RNA CONTENT; DELTA-FOSB; COGNITIVE DYSFUNCTION; PREFRONTAL CORTEX; DRUG-ADDICTION; GABAERGIC TAIL	New therapies are needed for alcohol abuse, a major public health problem in the U.S. and worldwide. There are only three FDA-approved drugs for treatment of alcohol abuse (naltrexone, acamprosate and disulfuram). On average these drugs yield only moderate success in reducing long-term alcohol consumption. Electroacupuncture has been shown to alleviate various drugs of abuse, including alcohol. Although previous studies have shown that electroacupuncture reduced alcohol consumption, the underlying mechanisms have not been fully elucidated. Delta FosB and FosB are members of the Fos family of transcription factors implicated in neural plasticity in drug addiction; a connection between electroacupuncture's treatment of alcohol abuse and the Fos family has not been established. In this study, we trained rats to drink large quantities of ethanol in a modified intermittent access two-bottle choice drinking procedure. When rats achieved a stable baseline of ethanol consumption, electroacupuncture (100 Hz or 2 Hz, 30 min each day) was administered at Zusanli (ST36) for 6 consecutive days. The level of FosB/Delta FosB in reward-related brain regions was assessed by immunohistochemistry. We found that the intake of and preference for ethanol in rats under 100 Hz, but not 2 Hz electroacupuncture regiment were sharply reduced. The reduction was maintained for at least 72 hours after the termination of electroacupuncture treatment. Conversely, 100 Hz electroacupuncture did not alter the intake of and preference for the natural rewarding agent sucrose. Additionally, FosB/Delta FosB levels in the prefrontal cortex, striatal region and the posterior region of ventral tegmental area were increased following excessive ethanol consumption, but were reduced after six-day 100 Hz electroacupuncture. Thus, this study demonstrates that six-day 100 Hz electroacupuncture treatment effectively reduces ethanol consumption and preference in rats that chronically drink excessive amount of ethanol. This effect of electroacupuncture may be mediated by down-regulation of FosB/Delta FosB in reward-related brain regions.	[Li, Jing; Ye, Jiang-Hong] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Anesthesiol Pharmacol & Physiol, Newark, NJ 07103 USA; [Sun, Yanan] Beijing Univ Chinese Med, Dong Zhi Men Hosp, Dept Neurol, Key Lab Internal Chinese Med,Minist Educ, Beijing, Peoples R China	Rutgers State University New Brunswick; Rutgers State University Medical Center; Beijing University of Chinese Medicine	Li, J (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Anesthesiol Pharmacol & Physiol, 185 S Orange Ave, Newark, NJ 07103 USA.	ye@umdnj.edu			National Institutes of Health - National Institute on Alcohol Abuse and Alcoholism [AA016964, AA016618]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R21AA016618, R01AA016964] Funding Source: NIH RePORTER	National Institutes of Health - National Institute on Alcohol Abuse and Alcoholism(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	This work was supported by National Institutes of Health - National Institute on Alcohol Abuse and Alcoholism [Grants AA016964 and AA016618]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anton RF, 2006, JAMA-J AM MED ASSOC, V295, P2003, DOI 10.1001/jama.295.17.2003; Bibb JA, 2001, NATURE, V410, P376, DOI 10.1038/35066591; Chen G, 2011, ALCOHOL CLIN EXP RES, V35, P1739, DOI 10.1111/j.1530-0277.2011.01520.x; Cui CL, 2008, NEUROCHEM RES, V33, P2013, DOI 10.1007/s11064-008-9784-8; Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579; Fadda P, 1999, ALCOHOL CLIN EXP RES, V23, P1296, DOI 10.1097/00000374-199908000-00002; Ford CP, 2007, J NEUROPHYSIOL, V97, P883, DOI 10.1152/jn.00963.2006; Han Jisheng, 2011, Front Med, V5, P141, DOI 10.1007/s11684-011-0136-8; Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1; Jeanblanc J, 2009, J NEUROSCI, V29, P13494, DOI 10.1523/JNEUROSCI.2243-09.2009; Jindal V, 2008, J PEDIAT HEMATOL ONC, V30, P431, DOI 10.1097/MPH.0b013e318165b2cc; Karst M, 2002, ADDICT BIOL, V7, P415, DOI 10.1080/1355621021000006017; Kaufling J, 2010, BRIT J PHARMACOL, V161, P1677, DOI 10.1111/j.1476-5381.2010.00984.x; Kaufling J, 2009, J COMP NEUROL, V513, P597, DOI 10.1002/cne.21983; Kim YH, 2005, J ADDICT DIS, V24, P115, DOI 10.1300/J069v24n04_09; Krawczyk DC, 2002, NEUROSCI BIOBEHAV R, V26, P631, DOI 10.1016/S0149-7634(02)00021-0; Kunz S, 2007, ALCOHOL CLIN EXP RES, V31, P436, DOI 10.1111/j.1530-0277.2006.00333.x; Li J, 2010, ALCOHOL CLIN EXP RES, V34; Li J, 2012, J PHARMACOL EXP THER, V341, P196, DOI 10.1124/jpet.111.190058; Li J, 2011, BRAIN RES BULL, V86, P428, DOI 10.1016/j.brainresbull.2011.08.013; Li J, 2011, ADDICT BIOL, V16, P600, DOI 10.1111/j.1369-1600.2011.00344.x; Lindholm S, 2001, BEHAV BRAIN RES, V120, P137, DOI 10.1016/S0166-4328(00)00368-5; Logrip ML, 2008, FASEB J, V22, P2393, DOI 10.1096/fj.07-099135; Logrip ML, 2009, ALCOHOL, V43, P359, DOI 10.1016/j.alcohol.2009.05.001; LU GW, 1983, AM J PHYSIOL, V245, pR606, DOI 10.1152/ajpregu.1983.245.4.R606; Mann K, 2004, ALCOHOL CLIN EXP RES, V28, P51, DOI 10.1097/01.ALC.0000108656.81563.05; Margolis EB, 2006, P NATL ACAD SCI USA, V103, P2938, DOI 10.1073/pnas.0511159103; Margolis EB, 2008, J NEUROSCI, V28, P8908, DOI 10.1523/JNEUROSCI.1526-08.2008; Marinelli PW, 2000, LIFE SCI, V66, P1915, DOI 10.1016/S0024-3205(00)00517-8; Meyers Robert J, 2003, Recent Dev Alcohol, V16, P183; Mitchell JM, 2005, PSYCHOPHARMACOLOGY, V182, P384, DOI 10.1007/s00213-005-0067-7; Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578; Nestler EJ, 2008, PHILOS T R SOC B, V363, P3245, DOI 10.1098/rstb.2008.0067; Nielsen CK, 2008, BIOL PSYCHIAT, V64, P974, DOI 10.1016/j.biopsych.2008.07.018; Overstreet DH, 2008, NEUROCHEM RES, V33, P2166, DOI 10.1007/s11064-008-9791-9; Paxinos G., 2007, RAT BRAIN STEREOTAXI; Perrotti LI, 2008, SYNAPSE, V62, P358, DOI 10.1002/syn.20500; Perrotti LI, 2005, EUR J NEUROSCI, V21, P2817, DOI 10.1111/j.1460-9568.2005.04110.x; POKLIS A, 1982, CLIN CHEM, V28, P2125; Robison AJ, 2011, NAT REV NEUROSCI, V12, P623, DOI 10.1038/nrn3111; Shi XD, 2004, MOL BRAIN RES, V130, P124, DOI 10.1016/j.molbrainres.2004.07.016; Simms JA, 2008, ALCOHOL CLIN EXP RES, V32, P1816, DOI 10.1111/j.1530-0277.2008.00753.x; Stux G., 1987, ACUPUNCTURE TXB ATLA; Vanderschuren LJMJ, 2005, J NEUROSCI, V25, P8665, DOI 10.1523/JNEUROSCI.0925-05.2005; Voorn P, 2004, TRENDS NEUROSCI, V27, P468, DOI 10.1016/j.tins.2004.06.006; Wang GB, 2011, PEPTIDES, V32, P713, DOI 10.1016/j.peptides.2010.12.006; Wee S, 2010, PSYCHOPHARMACOLOGY, V210, P121, DOI 10.1007/s00213-010-1825-8; Winkler A, 1998, NEUROREPORT, V9, P1459, DOI 10.1097/00001756-199805110-00039; Winstanley CA, 2007, J NEUROSCI, V27, P10497, DOI 10.1523/JNEUROSCI.2566-07.2007; Winstanley CA, 2009, PHARMACOL BIOCHEM BE, V93, P278, DOI 10.1016/j.pbb.2008.12.007; Wu LZ, 1999, BRAIN RES, V851, P290, DOI 10.1016/S0006-8993(99)02069-7; Xuei X, 2006, MOL PSYCHIATR, V11, P1016, DOI 10.1038/sj.mp.4001882; Yang CH, 2002, PHARMACOL BIOCHEM BE, V72, P847, DOI 10.1016/S0091-3057(02)00769-4; Yang CH, 2010, ALCOHOL CLIN EXP RES, V34, P2137, DOI 10.1111/j.1530-0277.2010.01310.x; Yoon SS, 2012, PSYCHOPHARMACOLOGY B; Yoshimoto K, 2001, ALCOHOL CLIN EXP RES, V25, p63S; Zachariou V, 2006, NAT NEUROSCI, V9, P205, DOI 10.1038/nn1636; Zhao RJ, 2006, NEUROSCI LETT, V395, P28, DOI 10.1016/j.neulet.2005.10.043	58	22	22	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2012	7	7							e40347	10.1371/journal.pone.0040347	http://dx.doi.org/10.1371/journal.pone.0040347			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973IV	22792289	Green Published, Green Submitted, gold			2023-01-03	WOS:000306354700037
J	Lam, M; Carmichael, AR; Griffiths, HR				Lam, Matt; Carmichael, Amtul R.; Griffiths, Helen R.			An Aqueous Extract of Fagonia cretica Induces DNA Damage, Cell Cycle Arrest and Apoptosis in Breast Cancer Cells via FOXO3a and p53 Expression	PLOS ONE			English	Article							TRANSCRIPTION FACTORS; TUMOR-SUPPRESSOR; SURVIVAL; REPAIR; CHECKPOINTS; PROMOTES; G(1); DIFFERENTIATION; ACTIVATION; PATHWAY	Background: Plants have proved to be an important source of anti-cancer drugs. Here we have investigated the cytotoxic action of an aqueous extract of Fagonia cretica, used widely as a herbal tea-based treatment for breast cancer. Methodology/Principal Findings: Using flow cytometric analysis of cells labeled with cyclin A, annexin V and propidium iodide, we describe a time and dose-dependent arrest of the cell cycle in G0/G1 phase of the cell cycle and apoptosis following extract treatment in MCF-7 (WT-p53) and MDA-MB-231 (mutant-p53) human breast cancer cell lines with a markedly reduced effect on primary human mammary epithelial cells. Analysis of p53 protein expression and of its downstream transcription targets, p21 and BAX, revealed a p53 associated growth arrest within 5 hours of extract treatment and apoptosis within 24 hours. DNA double strand breaks measured as gamma-H2AX were detected early in both MCF-7 and MDA-MB-231 cells. However, loss of cell viability was only partly due to a p53-driven response; as MDA-MB-231 and p53-knockdown MCF-7 cells both underwent cell cycle arrest and death following extract treatment. p53-independent growth arrest and cytotoxicity following DNA damage has been previously ascribed to FOXO3a expression. Here, in MCF-7 and MDA-MB-231 cells, FOXO3a expression was increased significantly within 3 hours of extract treatment and FOXO3 siRNA reduced the extract-induced loss of cell viability in both cell lines. Conclusions/Significance: Our results demonstrate for the first time that an aqueous extract of Fagonia cretica can induce cell cycle arrest and apoptosis via p53-dependent and independent mechanisms, with activation of the DNA damage response. We also show that FOXO3a is required for activity in the absence of p53. Our findings indicate that Fagonia cretica aqueous extract contains potential anti-cancer agents acting either singly or in combination against breast cancer cell proliferation via DNA damage-induced FOXO3a and p53 expression.	[Lam, Matt; Griffiths, Helen R.] Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England; [Carmichael, Amtul R.] Dudley Grp Hosp, Dudley, England	Aston University	Lam, M (corresponding author), Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.	h.r.griffiths@aston.ac.uk	Griffiths, Helen R./E-3453-2013	Griffiths, Helen R./0000-0002-2666-2147; Carmichael, Amtul R/0000-0002-3003-8486				Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Al-Mohanna MA, 2001, CARCINOGENESIS, V22, P573, DOI 10.1093/carcin/22.4.573; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Aristotle L, 2004, ANTICANCER RES, V24, P987; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Ben Sahra I, 2008, INT J OBESITY, V32, pS17; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Boehme KA, 2008, P NATL ACAD SCI USA, V105, P7785, DOI 10.1073/pnas.0703423105; Broude EV, 2007, ONCOGENE, V26, P6954, DOI 10.1038/sj.onc.1210516; Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629; Cheng WL, 2011, PLANTA MED, V77, P164, DOI 10.1055/s-0030-1250177; Chiacchiera F, 2010, CELL CYCLE, V9, P1091, DOI 10.4161/cc.9.6.11035; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Fragkos M, 2009, MOL CELL BIOL, V29, P2828, DOI 10.1128/MCB.01830-08; Gao JC, 2012, INT J ONCOL, V40, P1203, DOI 10.3892/ijo.2011.1293; Gasco M, 2002, BREAST CANCER RES, V4, P70, DOI 10.1186/bcr426; Gross DN, 2009, CURR DIABETES REP, V9, P208, DOI 10.1007/s11892-009-0034-5; Habashy HO, 2011, BREAST CANCER RES TR, V129, P11, DOI 10.1007/s10549-010-1161-z; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342; Helleday T, 2007, DNA REPAIR, V6, P923, DOI 10.1016/j.dnarep.2007.02.006; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ichikawa A, 2008, HUM CELL, V21, P28, DOI 10.1111/j.1749-0774.2008.00048.x; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kim SH, 2010, CANCER PREV RES, V3, P718, DOI 10.1158/1940-6207.CAPR-10-0048; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lei H, 2009, MOL CANCER RES, V7, P1294, DOI 10.1158/1541-7786.MCR-08-0531; Lim LY, 2009, BRIT J CANCER, V101, P1606, DOI 10.1038/sj.bjc.6605335; McNamee LM, 2009, GENETICS, V182, P423, DOI 10.1534/genetics.109.102327; McVean M, 2000, CARCINOGENESIS, V21, P633, DOI 10.1093/carcin/21.4.633; Moll UM, 2003, MOL CANCER RES, V1, P1001; Pellegata NS, 1996, P NATL ACAD SCI USA, V93, P15209, DOI 10.1073/pnas.93.26.15209; Said HM, 1969, HAMDARD PHARMACOPOEI; Shah Manish A, 2003, Cancer Chemother Biol Response Modif, V21, P145; Shapiro GI, 1999, J CLIN INVEST, V104, P1645, DOI 10.1172/JCI9054; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Thompson T, 2010, CANCER BIOL THER, V10, P344, DOI 10.4161/cbt.10.4.12366; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yang JY, 2006, INT J ONCOL, V29, P643; Yin L, 2009, INT J ONCOL, V34, P1691, DOI 10.3892/ijo_00000300; Yoshida K, 2010, CANCER SCI, V101, P831, DOI 10.1111/j.1349-7006.2010.01488.x; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou YY, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1872	46	70	72	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2012	7	6							e40152	10.1371/journal.pone.0040152	http://dx.doi.org/10.1371/journal.pone.0040152			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	966GL	22761954	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000305825800090
J	Gravitz, L				Gravitz, Lauren			FOOD SCIENCE Taste bud hackers	NATURE			English	Editorial Material																		Tieman D, 2012, CURR BIOL, V22, P1035, DOI 10.1016/j.cub.2012.04.016	1	6	6	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 21	2012	486	7403					S14	S15		10.1038/486S14a	http://dx.doi.org/10.1038/486S14a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	046RB	22717397				2023-01-03	WOS:000311781000008
J	Horimatsu, T; Muto, M; Yoda, Y; Yano, T; Ezoe, Y; Miyamoto, S; Chiba, T				Horimatsu, Takahiro; Muto, Manabu; Yoda, Yusuke; Yano, Tomonori; Ezoe, Yasumasa; Miyamoto, Shinichi; Chiba, Tsutomu			Tissue Damage in the Canine Normal Esophagus by Photoactivation with Talaporfin Sodium (Laserphyrin): A Preclinical Study	PLOS ONE			English	Article							SQUAMOUS-CELL CARCINOMA; PHOTODYNAMIC THERAPY; NPE6; CANCER; CHEMORADIOTHERAPY; ESOPHAGECTOMY; LUNG	Background: Treatment failure at the primary site after chemoradiotherapy is a major problem in achieving a complete response. Photodynamic therapy (PDT) with porfimer sodium (Photofrin (R)) has some problems such as the requirement for shielding from light for several weeks and a high incidence of skin phototoxicity. PDT with talaporfin sodium (Laserphyrin) is less toxic and is expected to have a better effect compared with Photofrin PDT. However, Laserphyrin PDT is not approved for use in the esophagus. In this preclinical study, we investigated tissue damage of the canine normal esophagus caused by photoactivation with Laserphyrin. Methodology/Principal Findings: Diode laser irradiation was performed at 60 min after administration. An area 5 cm oral to the esophagogastric junction was irradiated at 25 J/cm(2), 50 J/cm(2), and 100 J/cm(2) using a three-step escalation. The irradiated areas were evaluated endoscopically on postirradiation days 1 and 7, and were subjected to histological examination after autopsy. The areas injured by photoactivation were 52 mm(2), 498 mm(2), and 831 mm(2) after irradiation at 25 J/cm(2), 50 J/cm(2), and 100 J/cm(2), respectively. Tissue injury was observed in the muscle layer or even deeper at any irradiation level and became more severe as the irradiation dose increased. At 100 J/cm(2) both inflammatory changes and necrosis were seen histologically in extra-adventitial tissue. Conclusions/Significance: To minimize injury of the normal esophagus by photoactivation with Laserphyrin, diode laser irradiation at 25 J/cm(2) appears to be safe. For human application, it would be desirable to investigate the optimal laser dose starting from this level.	[Horimatsu, Takahiro; Muto, Manabu; Yoda, Yusuke; Yano, Tomonori; Ezoe, Yasumasa; Miyamoto, Shinichi; Chiba, Tsutomu] Kyoto Univ, Grad Sch Med, Dept Gastroenterol, Kyoto, Japan	Kyoto University	Horimatsu, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Gastroenterol, Kyoto, Japan.	thorimat@kuhp.kyoto-u.ac.jp		Horimatsu, Takahiro/0000-0002-4188-9059	Ministry of Health, Labor, and Welfare of Japan [H21-Rinshokenkyu-Ippan-018]	Ministry of Health, Labor, and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan)	This study was supported in part by grants-in-aid for cancer research from the Ministry of Health (H21-Rinshokenkyu-Ippan-018), Labor, and Welfare of Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AIZAWA K, 1987, PHOTOCHEM PHOTOBIOL, V46, P789, DOI 10.1111/j.1751-1097.1987.tb04849.x; Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071; DOUGHERTY TJ, 1992, EUR J CANCER, V28A, P1734, DOI 10.1016/0959-8049(92)90080-L; DOUGHERTY TJ, 1990, LASER SURG MED, V10, P485, DOI 10.1002/lsm.1900100514; Kato H, 2003, LUNG CANCER, V42, P103, DOI 10.1016/S0169-5002(03)00242-3; MANYAK MJ, 1988, J CLIN ONCOL, V6, P380, DOI 10.1200/JCO.1988.6.2.380; NELSON JS, 1987, CANCER RES, V47, P4681; Overholt BF, 1999, GASTROINTEST ENDOSC, V49, P1, DOI 10.1016/S0016-5107(99)70437-2; PASS HI, 1993, JNCI-J NATL CANCER I, V85, P443, DOI 10.1093/jnci/85.6.443; Savary JF, 1998, ENDOSCOPY, V30, P258, DOI 10.1055/s-2007-1001252; Swisher SG, 2002, J THORAC CARDIOV SUR, V123, P175, DOI 10.1067/mtc.2002.119070; Swisher SG, 2000, J THORAC CARDIOV SUR, V119, P1126, DOI 10.1067/mtc.2000.105644; Usuda J, 2007, LUNG CANCER, V58, P317, DOI 10.1016/j.lungcan.2007.06.026; Usuda J, 2010, CLIN CANCER RES, V16, P2198, DOI 10.1158/1078-0432.CCR-09-2520; Yano T, 2005, GASTROINTEST ENDOSC, V62, P31, DOI 10.1016/S0016-5107(05)00545-6; Yano T, 2011, ENDOSCOPY, V43, P657, DOI 10.1055/s-0030-1256373; Yoshida K, 1993, Gan To Kagaku Ryoho, V20, P2063	17	17	20	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2012	7	6							e38308	10.1371/journal.pone.0038308	http://dx.doi.org/10.1371/journal.pone.0038308			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UV	22719875	Green Published, Green Submitted, gold			2023-01-03	WOS:000305341900023
J	Cassidy, JD; Bronfort, G; Hartvigsen, J				Cassidy, J. David; Bronfort, Gert; Hartvigsen, Jan			Should we abandon cervical spine manipulation for mechanical neck pain? No	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							2000-2010 TASK-FORCE; ARTERY DISSECTION; CASE-CROSSOVER; DISORDERS; STROKE; RISK; BONE; INTERVENTIONS		[Cassidy, J. David] Univ Toronto, Dalla Lana Sch Publ Hlth, Div Epidemiol, Toronto, ON, Canada; [Bronfort, Gert] NW Hlth Sci Univ, Dept Res, Bloomington, MN USA; [Hartvigsen, Jan] Univ So Denmark, Inst Sports Sci & Clin Biomech, Odense, Denmark	University of Toronto; University of Southern Denmark	Cassidy, JD (corresponding author), Univ Toronto, Dalla Lana Sch Publ Hlth, Div Epidemiol, Toronto, ON, Canada.	dcassidy@uhnresearch.ca		Hartvigsen, Jan/0000-0002-5876-7410				Bronfort G, 2012, ANN INTERN MED, V156, P1, DOI 10.7326/0003-4819-156-1-201201030-00002; Cassidy JD, 2008, SPINE, V33, pS176, DOI 10.1097/BRS.0b013e3181644600; Chang CH, 2010, STROKE, V41, P1884, DOI 10.1161/STROKEAHA.110.585828; Guzman J, 2008, SPINE, V33, pS199, DOI 10.1097/BRS.0b013e3181644641; Haldeman S, 2010, J OCCUP ENVIRON MED, V52, P424, DOI 10.1097/JOM.0b013e3181d44f3b; Hurwitz EL, 2012, J ELECTROMYOGR  0128; Hurwitz EL, 2008, SPINE, V33, pS123, DOI 10.1097/BRS.0b013e3181644b1d; Leaver AM, 2010, J PHYSIOTHER, V56, P73, DOI 10.1016/S1836-9553(10)70037-0; Lee VH, 2006, NEUROLOGY, V67, P1809, DOI 10.1212/01.wnl.0000244486.30455.71; Martin BI, 2008, JAMA-J AM MED ASSOC, V299, P656, DOI 10.1001/jama.299.6.656; Rothwell DM, 2001, STROKE, V32, P1054, DOI 10.1161/01.STR.32.5.1054; Salas M, 1999, AM J EPIDEMIOL, V149, P981; Schievink WI, 2001, NEW ENGL J MED, V344, P898, DOI 10.1056/NEJM200103223441206; Smith WS, 2003, NEUROLOGY, V60, P1424, DOI 10.1212/01.WNL.0000063305.61050.E6; van der Velde G, 2008, SPINE, V33, pS184, DOI 10.1097/BRS.0b013e31816454f8	15	25	27	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 7	2012	344								e3680	10.1136/bmj.e3680	http://dx.doi.org/10.1136/bmj.e3680			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	957TG	22677797				2023-01-03	WOS:000305185200011
J	Seshadri, S; Oakeshott, P; Nelson-Piercy, C; Chappell, LC				Seshadri, Srividya; Oakeshott, Pippa; Nelson-Piercy, Catherine; Chappell, Lucy C.			Prepregnancy care	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PREGNANCY OUTCOMES; WOMEN		[Chappell, Lucy C.] Kings Coll London, Womens Hlth Acad Ctr, London SE1 7EH, England; [Seshadri, Srividya; Nelson-Piercy, Catherine] Guys & St Thomas NHS Fdn Trust, London, England; [Oakeshott, Pippa] Univ London, London, England	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London	Chappell, LC (corresponding author), Kings Coll London, Womens Hlth Acad Ctr, London SE1 7EH, England.	lucy.chappell@kcl.ac.uk		Seshadri, Srividya/0000-0003-1967-6089; Oakeshott, Pippa/0000-0003-2568-8211				[Anonymous], 2011, Obstet Gynecol, V117, P1028, DOI 10.1097/AOG.0b013e31821922c2; [Anonymous], 2004, FERT ASS TREATM PEOP; British Thoracic Society Scottish Intercollegiate Guidelines Network, 2008, Thorax, V63 Suppl 4, piv1, DOI 10.1136/thx.2008.097741; Beaulieu DB, 2011, GASTROENTEROL CLIN N, V40, P399, DOI 10.1016/j.gtc.2011.03.006; British Association for Sexual Health and HIV, 2008, UK NAT GUID HIV TEST; De-Regil LM, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007950.pub2; Deshpande NA, 2011, AM J TRANSPLANT, V11, P2388, DOI 10.1111/j.1600-6143.2011.03656.x; Deshpande NA, 2012, LIVER TRANSPL; Hardy JR, 2006, PHARMACOEPIDEM DR S, V15, P555, DOI 10.1002/pds.1269; Hezelgrave NL, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2506; Huusom LD, 2011, BJOG-INT J OBSTET GY, V118, P1, DOI 10.1111/j.1471-0528.2010.02782.x; Johnson Kay, 2006, Morbidity and Mortality Weekly Report, V55, P1; Lazarus JH, 2012, NEW ENGL J MED, V366, P493, DOI 10.1056/NEJMoa1106104; Lazarus JH, 2011, BRIT MED BULL, V97, P137, DOI 10.1093/bmb/ldq039; Macintosh MCM, 2006, BRIT MED J, V333, P177, DOI 10.1136/bmj.38856.692986.AE; NHS UK screening portal, POL DAT; Simmons D, 2010, BEST PRACT RES CL EN, V24, P625, DOI 10.1016/j.beem.2010.05.002; Smyth A, 2010, CLIN J AM SOC NEPHRO, V5, P2060, DOI 10.2215/CJN.00240110; te Velde ER, 2000, LANCET, V355, P1928, DOI 10.1016/S0140-6736(00)02320-5; UK National Screening Committee, 2011, UK NSC POL RUB SUSC; UK National Screening Committee, 2007, SICKL CELL THAL POL; Wahabi HA, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-63; Whitworth M, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007536.pub2	23	25	25	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 31	2012	344								e3467	10.1136/bmj.e3467	http://dx.doi.org/10.1136/bmj.e3467			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	953HG	22654073				2023-01-03	WOS:000304857000002
J	Cerletti, M; Jang, YC; Finley, LWS; Haigis, MC; Wagers, AJ				Cerletti, Massimiliano; Jang, Young C.; Finley, Lydia W. S.; Haigis, Marcia C.; Wagers, Amy J.			Short-Term Calorie Restriction Enhances Skeletal Muscle Stem Cell Function	CELL STEM CELL			English	Article							SATELLITE CELLS; PROGENITOR CELLS; SELF-RENEWAL; REGENERATION; MYOGENESIS; CANCER; MOUSE; FAT	Calorie restriction (CR) extends life span and ameliorates age-related pathologies in most species studied, yet the mechanisms underlying these effects remain unclear. Using mouse skeletal muscle as a model, we show that CR acts in part by enhancing the function of tissue-specific stem cells. Even short-term CR significantly enhanced stem cell availability and activity in the muscle of young and old animals, in concert with an increase in mitochondrial abundance and induction of conserved metabolic and longevity regulators. Moreover, CR enhanced endogenous muscle repair and CR initiated in either donor or recipient animals improved the contribution of donor cells to regenerating muscle after transplant. These studies indicate that metabolic factors play a critical role in regulating stem cell function and that this regulation can influence the efficacy of recovery from injury and the engraftment of transplanted cells.	[Wagers, Amy J.] Harvard Univ, Harvard Stem Cell Inst, Howard Hughes Med Inst, Cambridge, MA 02138 USA; [Cerletti, Massimiliano; Jang, Young C.; Wagers, Amy J.] Harvard Univ, Harvard Stem Cell Inst, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA; [Cerletti, Massimiliano; Jang, Young C.; Wagers, Amy J.] Joslin Diabet Ctr, Boston, MA 02215 USA; [Finley, Lydia W. S.; Haigis, Marcia C.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Howard Hughes Medical Institute; Harvard University; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Wagers, AJ (corresponding author), Harvard Univ, Harvard Stem Cell Inst, Howard Hughes Med Inst, 7 Divin Ave, Cambridge, MA 02138 USA.	amy_wagers@harvard.edu			NIH [P30DK036836, 1R01 AG033053, 1P30 AG031679]; Harvard Stem Cell Institute; Glenn Foundation; NIA [AG032375]; Ellison Medical Foundation; NSF; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG031679, R01AG033053, R01AG032375] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard Stem Cell Institute; Glenn Foundation; NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Ellison Medical Foundation(Lawrence Ellison Foundation); NSF(National Science Foundation (NSF)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors gratefully acknowledge Joslin's HSCl/DERC Flow Cytometry Core (NIH award number P30DK036836) and the HSCRB Flow Cytometry Core at Harvard for excellent flow cytometry support. This work was funded in part by grants from the Harvard Stem Cell Institute, NIH (1R01 AG033053 and 1P30 AG031679), and Glenn Foundation to A.J.W.; grants from the NIA (AG032375), Glenn Foundation, Ellison Medical Foundation, and MDA to M.N.; and an NSF graduate research fellowship to L.F. All experiments involving animals were approved by appropriate Institutional Animal Care and Use Committees. Content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or other funding agencies.	Ahmet I, 2005, CIRCULATION, V112, P3115, DOI 10.1161/CIRCULATIONAHA.105.563817; Anderson RM, 2010, TRENDS ENDOCRIN MET, V21, P134, DOI 10.1016/j.tem.2009.11.005; BAHT HS, 1989, BIOCHEM J, V258, P369, DOI 10.1042/bj2580369; Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4; Cerletti M, 2008, COLD SH Q B, V73, P317, DOI 10.1101/sqb.2008.73.054; Cerletti M, 2008, CELL, V134, P37, DOI 10.1016/j.cell.2008.05.049; Conboy IM, 2002, DEV CELL, V3, P397, DOI 10.1016/S1534-5807(02)00254-X; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Ertl RP, 2008, BLOOD, V111, P1709, DOI 10.1182/blood-2007-01-069807; Fontana L, 2009, EXP GERONTOL, V44, P41, DOI 10.1016/j.exger.2008.04.005; Gerhart-Hines Z, 2007, EMBO J, V26, P1913, DOI 10.1038/sj.emboj.7601633; Hettmer S, 2011, P NATL ACAD SCI USA, V108, P20002, DOI 10.1073/pnas.1111733108; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Jacobs KM, 2008, INT J BIOL SCI, V4, P291; Jang YC, 2011, COLD SPRING HARB S Q; Joe AWB, 2010, NAT CELL BIOL, V12, P153, DOI 10.1038/ncb2015; Kuang SH, 2007, CELL, V129, P999, DOI 10.1016/j.cell.2007.03.044; Marroquin LD, 2007, TOXICOL SCI, V97, P539, DOI 10.1093/toxsci/kfm052; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; McCarthy JJ, 2011, DEVELOPMENT, V138, P3657, DOI 10.1242/dev.068858; Montarras D, 2005, SCIENCE, V309, P2064, DOI 10.1126/science.1114758; Murphy MM, 2011, DEVELOPMENT, V138, P3625, DOI 10.1242/dev.064162; Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036; Russell SJ, 2007, NAT REV MOL CELL BIO, V8, P681, DOI 10.1038/nrm2234; Sacco A, 2008, NATURE, V456, P502, DOI 10.1038/nature07384; Schulz TJ, 2011, P NATL ACAD SCI USA, V108, P143, DOI 10.1073/pnas.1010929108; Sherwood RI, 2004, CELL, V119, P543, DOI 10.1016/j.cell.2004.10.021; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; Tan KY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026406; Tanaka KK, 2009, CELL STEM CELL, V4, P217, DOI 10.1016/j.stem.2009.01.016; Tremblay JP, 1997, BASIC APPL MYOL, V7, P221; Uezumi A, 2010, NAT CELL BIOL, V12, P143, DOI 10.1038/ncb2014; Wagers AJ, 2005, CELL, V122, P659, DOI 10.1016/j.cell.2005.08.021; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	34	260	265	0	32	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	1934-5909			CELL STEM CELL	Cell Stem Cell	MAY 4	2012	10	5					515	519		10.1016/j.stem.2012.04.002	http://dx.doi.org/10.1016/j.stem.2012.04.002			5	Cell & Tissue Engineering; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	944WN	22560075	Green Accepted, Bronze			2023-01-03	WOS:000304234600010
J	Lok, CE; Moist, L; Hemmelgarn, BR; Tonelli, M; Vazquez, MA; Dorval, M; Oliver, M; Donnelly, S; Allon, M; Stanley, K				Lok, Charmaine E.; Moist, Louise; Hemmelgarn, Brenda R.; Tonelli, Marcello; Vazquez, Miguel A.; Dorval, Marc; Oliver, Matthew; Donnelly, Sandra; Allon, Michael; Stanley, Kenneth		Fish Oil Inhibition Stenosis Hemod	Effect of Fish Oil Supplementation on Graft Patency and Cardiovascular Events Among Patients With New Synthetic Arteriovenous Hemodialysis Grafts A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYUNSATURATED FATTY-ACIDS; VASCULAR ACCESS THROMBOSIS; DOUBLE-BLIND; PLUS ASPIRIN; SURVIVAL; DIALYSIS; DISEASE; THERAPY; OMEGA-3-FATTY-ACIDS; MORTALITY	Context Synthetic arteriovenous grafts, an important option for hemodialysis vascular access, are prone to recurrent stenosis and thrombosis. Supplementation with fish oils has theoretical appeal for preventing these outcomes. Objective To determine the effect of fish oil on synthetic hemodialysis graft patency and cardiovascular events. Design, Setting, and Participants The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) study, a randomized, double-blind, controlled clinical trial conducted at 15 North American dialysis centers from November 2003 through December 2010 and enrolling 201 adults with stage 5 chronic kidney disease (50% women, 63% white, 53% with diabetes), with follow-up for 12 months after graft creation. Interventions Participants were randomly allocated to receive fish oil capsules (four 1-g capsules/d) or matching placebo on day 7 after graft creation. Main Outcome Measure Proportion of participants experiencing graft thrombosis or radiological or surgical intervention during 12 months' follow-up. Results The risk of the primary outcome did not differ between fish oil and placebo recipients (48/99 [48%] vs 60/97 [62%], respectively; relative risk, 0.78 [95% CI, 0.60 to 1.03; P=.06]). However, the rate of graft failure was lower in the fish oil group (3.43 vs 5.95 per 1000 access-days; incidence rate ratio [IRR], 0.58 [95% CI, 0.44 to 0.75; P<.001]). In the fish oil group, there were half as many thromboses (1.71 vs 3.41 per 1000 access-days; IRR, 0.50 [95% CI, 0.35 to 0.72; P<.001]); fewer corrective interventions (2.89 vs 4.92 per 1000 access-days; IRR, 0.59 [95% CI, 0.44 to 0.78; P<.001]); improved cardiovascular event-free survival (hazard ratio, 0.43 [95% CI, 0.19 to 0.96; P=.04]); and lower mean systolic blood pressure (-3.61 vs 4.49 mm Hg; difference, -8.10 [95% CI, -15.4 to -0.85]; P=.01). Conclusions Among patients with new hemodialysis grafts, daily fish oil ingestion did not decrease the proportion of grafts with loss of native patency within 12 months. Although fish oil improved some relevant secondary outcomes such as graft patency, rates of thrombosis, and interventions, other potential benefits on cardiovascular events require confirmation in future studies.	[Lok, Charmaine E.] Toronto Gen Hosp, Dept Med, Div Nephrol, Toronto, ON M5G 2C4, Canada; [Lok, Charmaine E.] Univ Toronto, Toronto, ON, Canada; [Moist, Louise] Univ Western Ontario, London, ON, Canada; [Moist, Louise] London Hlth Sci Ctr, London, ON, Canada; [Hemmelgarn, Brenda R.] Univ Calgary, Calgary, AB, Canada; [Tonelli, Marcello] Univ Alberta, Edmonton, AB, Canada; [Vazquez, Miguel A.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Dorval, Marc] Dr Georges L Dumont Univ Hosp Ctr, Moncton, NB, Canada; [Oliver, Matthew] Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON, Canada; [Donnelly, Sandra] St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Allon, Michael] Univ Alabama Birmingham, Birmingham, AL USA; [Stanley, Kenneth] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; Western University (University of Western Ontario); London Health Sciences Centre; University of Calgary; University of Alberta; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Alabama System; University of Alabama Birmingham; Harvard University; Harvard T.H. Chan School of Public Health	Lok, CE (corresponding author), Toronto Gen Hosp, Dept Med, Div Nephrol, 8NU-844,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.	charmaine.lok@uhn.ca	Dorval, Marc/M-7219-2015; Tonelli, Marcello/B-3028-2009; Moist, Louise/G-3334-2011; Hemmelgarn, Brenda R./I-6894-2012	Dorval, Marc/0000-0002-9548-978X; Tonelli, Marcello/0000-0002-0846-3187; Lok, Charmaine/0000-0001-5365-0064	Roche; Merck; Gambro; Baxter; Novartis; University of Alabama at Birmingham; Physician's Services Incorporated Foundation; Canadian Institutes for Health Research (CIHR); Alberta Heritage Foundation; Government of Canada Research Chair; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [K24 DK59818-01, 5UO1 DK082240, R34 DK094115]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK085027, R34DK094115, K24DK059818, U01DK082240] Funding Source: NIH RePORTER	Roche(Roche Holding); Merck(Merck & Company); Gambro; Baxter; Novartis(Novartis); University of Alabama at Birmingham; Physician's Services Incorporated Foundation; Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Alberta Heritage Foundation(Alberta Heritage Foundation for Medical Research); Government of Canada Research Chair; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Moist reported serving as a consultant for Amgen and Leo and receiving payment for lectures from Roche and Merck. Dr Dorval reported serving as a board member for Gambro; serving as a consultant for Gambro; receiving grants or grants pending from Gambro and Baxter; and receiving payment for lectures from Gambro and Novartis. Dr Oliver reported receiving author royalties from UpToDate and that he is the sole owner of Oliver Medical Management Inc, which manufactures dialysis-related software. Dr Allon reported receiving a grant and travel support from the University of Alabama at Birmingham. Dr Stanley reported serving as the FISH study's independent statistician and that he served as Executive Director of the Center for Biostatistics and AIDS Research at Harvard School of Public Health before retiring. No other authors reported disclosures.; This study was supported by peer-reviewed grant funding from the Physician's Services Incorporated Foundation and the Canadian Institutes for Health Research (CIHR). During the study, Drs Lok, Hemmelgarn, and Tonelli were supported by CIHR New Investigator Awards. Dr Lok was also supported by the CIHR Randomized Clinical Trials Mentoring Program. Currently, Drs Hemmelgarn and Tonelli are also supported by Alberta Heritage Foundation for Medical Research Population Scholar Awards; Dr Tonelli is supported by a Government of Canada Research Chair. Dr Allon is supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant K24 DK59818-01. Dr Vazquez is supported by NIDDK grants 5UO1 DK082240 and R34 DK094115.	Adkins Y, 2010, J NUTR BIOCHEM, V21, P781, DOI 10.1016/j.jnutbio.2009.12.004; AGRESTI A, 2007, BUILDING APPL LOGIST; Akoh JA, 2009, J VASC ACCESS, V10, P137; [Anonymous], 2001, Am J Kidney Dis, V37, pS137; [Anonymous], 2020, VOLUME MODE TRAVELIN, V2; [Anonymous], 2012, PRIV IMP ASS APP B C; Bowden RG, 2007, J RENAL NUTR, V17, P126, DOI 10.1053/j.jrn.2006.07.009; Christensen R, 1997, LOG LINEAR MODELS LO; CHURCHILL DN, 1992, AM J KIDNEY DIS, V19, P214, DOI 10.1016/S0272-6386(13)80002-9; Crowther MA, 2002, J AM SOC NEPHROL, V13, P2331, DOI 10.1097/01.ASN.0000027356.16598.99; De Caterina R, 2011, NEW ENGL J MED, V364, P2439, DOI 10.1056/NEJMra1008153; Dember LM, 2004, KIDNEY INT, V66, P390, DOI 10.1111/j.1523-1755.2004.00743.x; DISKIN CJ, 1993, NEPHRON, V64, P1, DOI 10.1159/000187272; Dixon BS, 2009, NEW ENGL J MED, V360, P2191, DOI 10.1056/NEJMoa0805840; Ethier J, 2008, NEPHROL DIAL TRANSPL, V23, P3219, DOI 10.1093/ndt/gfn261; Friedman A, 2006, CLIN J AM SOC NEPHRO, V1, P182, DOI 10.2215/CJN.00740805; Garwood F, 1936, BIOMETRIKA, V28, P437; HOLM S, 1979, SCAND J STAT, V6, P65; Jindal Kailash, 2006, J Am Soc Nephrol, V17, pS1; Kalbfleisch J.D., 1980, STAT ANAL FAILURE TI; Kaufman JS, 2003, J AM SOC NEPHROL, V14, P2313, DOI 10.1097/01.ASN.0000081661.10246.33; Khajehdehi P, 2000, J Ren Nutr, V10, P191, DOI 10.1053/jren.2000.16326; KOBAYASHI K, 1980, THROMB RES, V20, P255, DOI 10.1016/0049-3848(80)90390-4; Kolakowski S, 2003, J VASC SURG, V38, P719, DOI 10.1016/S0741-5214(03)00947-9; Kris-Etherton PM, 2002, CIRCULATION, V106, P2747, DOI 10.1161/01.CIR.0000038493.65177.94; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Lee H, 2002, AM J KIDNEY DIS, V40, P611, DOI 10.1053/ajkd.2002.34924; Lee T, 2011, SEMIN DIALYSIS, V24, P515, DOI 10.1111/j.1525-139X.2011.00969.x; Lok CE, 2007, CLIN TRIALS, V4, P357, DOI 10.1177/1740774507081218; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; Miller PE, 2000, AM J KIDNEY DIS, V36, P68, DOI 10.1053/ajkd.2000.8269; Moist LM, 2003, J AM SOC NEPHROL, V14, P2645, DOI 10.1097/01.ASN.0000089562.98338.60; Moist LM, 2008, CLIN J AM SOC NEPHRO, V3, P1726, DOI 10.2215/CJN.01240308; MUNDA R, 1983, JAMA-J AM MED ASSOC, V249, P219, DOI 10.1001/jama.249.2.219; Nordoy A, 2001, LIPIDS, V36, pS127, DOI 10.1007/s11745-001-0695-7; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Paulson WD, 2012, KIDNEY INT, V81, P132, DOI 10.1038/ki.2011.337; Pei YPC, 2000, KIDNEY INT, V58, P1293, DOI 10.1046/j.1523-1755.2000.00285.x; RYLANCE PB, 1986, NEPHRON, V43, P196, DOI 10.1159/000183829; Schmitz PG, 2002, J AM SOC NEPHROL, V13, P184, DOI 10.1681/ASN.V131184; Schwab SJ, 1999, KIDNEY INT, V55, P2078, DOI 10.1046/j.1523-1755.1999.00409.x; SIMOPOULOS AP, 1991, AM J CLIN NUTR, V54, P438, DOI 10.1093/ajcn/54.3.438; Singh RB, 1997, CARDIOVASC DRUG THER, V11, P485, DOI 10.1023/A:1007757724505; SREEDHARA R, 1994, KIDNEY INT, V45, P1477, DOI 10.1038/ki.1994.192; Studer M, 2005, ARCH INTERN MED, V165, P725, DOI 10.1001/archinte.165.7.725; Thies F, 2003, LANCET, V361, P477, DOI 10.1016/S0140-6736(03)12468-3; van Acker B A, 1987, Nephrol Dial Transplant, V2, P557; Woods JD, 1997, AM J KIDNEY DIS, V30, P50, DOI 10.1016/S0272-6386(97)90564-3; Yevzlin AS, 2010, TRANSL RES, V156, P216, DOI 10.1016/j.trsl.2010.07.004	49	97	98	0	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 2	2012	307	17					1809	1816		10.1001/jama.2012.3473	http://dx.doi.org/10.1001/jama.2012.3473			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933TV	22550196	Green Accepted, Bronze			2023-01-03	WOS:000303386800020
J	Brezinski, EA; Armstrong, AW				Brezinski, Elizabeth A.; Armstrong, April W.			Off-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy	PLOS ONE			English	Review							CHRONIC PLAQUE PSORIASIS; INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY; PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL; CONTROLLED PHASE-III; TO-SEVERE PSORIASIS; DOUBLE-BLIND; CLINICAL-RESPONSE; INFLIXIMAB MONOTHERAPY; ETANERCEPT THERAPY	Objectives: While off-label dosing of biologic treatments may be necessary in selected psoriasis patients, no systematic review exists to date that synthesizes the efficacy and safety of these off-label dosing regimens. The aim of this systematic review is to evaluate efficacy and safety of off-label dosing regimens (dose escalation, dose reduction, and interrupted treatment) with etanercept, adalimumab, infliximab, ustekinumab, and alefacept for psoriasis treatment. Data Sources and Study Selection: We searched OVID Medline from January 1, 1990 through August 1, 2011 for prospective clinical trials that studied biologic therapy for psoriasis treatment in adults. Individual articles were screened for studies that examined escalated, reduced, or interrupted therapy with etanercept, adalimumab, infliximab, ustekinumab, or alefacept. Data Synthesis: A total of 23 articles with 12,617 patients matched the inclusion and exclusion criteria for the systematic review. Data were examined for primary and secondary efficacy outcomes and adverse events including infections, malignancies, cardiovascular events, and anti-drug antibodies. The preponderance of data suggests that continuous treatment with anti-TNF agents and anti-IL12/23 agent was necessary for maintenance of disease control. Among non-responders, dose escalation with etanercept, adalimumab, ustekinumab, and alefacept typically resulted in greater efficacy than standard dosing. Dose reduction with etanercept and alefacept resulted in reduced efficacy. Withdrawal of the examined biologics led to an increase in disease activity; efficacy from retreatment did not result in equivalent initial response rates for most biologics. Safety data on off-label dosing regimens are limited. Conclusion: Dose escalation in non-responders generally resulted in increased efficacy in the examined biologics used to treat moderate-to-severe psoriasis. Continuous treatment with anti-TNF agents and anti-IL12/23 agent results in superior efficacy over interrupted therapy. The decision to use off-label dosing needs to account for both benefits and risks and be individualized to patients' disease severity, quality of life, and existence of comorbidities.	[Brezinski, Elizabeth A.] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA; [Armstrong, April W.] Univ Calif Davis, Dept Dermatol, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis	Brezinski, EA (corresponding author), Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA.	aprilarmstrong@post.harvard.edu						[Anonymous], STEL UST PACK INS; [Anonymous], HUM AD PRESCR INF PA; [Anonymous], AM AL PACK INS; Bartelds GM, 2011, JAMA-J AM MED ASSOC, V305, P1460, DOI 10.1001/jama.2011.406; Cafardi Jennifer A, 2008, Skinmed, V7, P67, DOI 10.1111/j.1751-7125.2008.07346.x; Cassano N, 2010, INT J IMMUNOPATH PH, V23, P797, DOI 10.1177/039463201002300314; *CENT INC, REM INFL PACK INS; Chaudhari U, 2001, LANCET, V357, P1842, DOI 10.1016/S0140-6736(00)04954-0; Dommasch ED, 2011, J AM ACAD DERMATOL, V64, P1035, DOI 10.1016/j.jaad.2010.09.734; Ferrandiz C, 2010, CLIN DERMATOL, V28, P81, DOI 10.1016/j.clindermatol.2009.03.002; Gordon KB, 2006, J DERMATOL TREAT, V17, P9, DOI 10.1080/09546630500472838; Gordon KB, 2006, J AM ACAD DERMATOL, V55, P598, DOI 10.1016/j.jaad.2006.05.027; Gordon Kenneth B, 2003, J Drugs Dermatol, V2, P624; Gottlieb AB, 2004, J AM ACAD DERMATOL, V51, P534, DOI 10.1016/j.jaad.2004.02.021; Gottlieb AB, 2003, J AM ACAD DERMATOL, V48, P829, DOI 10.1067/mjd.2003.307; Gribetz CH, 2005, J AM ACAD DERMATOL, V53, P73, DOI 10.1016/j.jaad.2005.03.053; Guyatt G, 2006, CHEST, V129, P174, DOI 10.1378/chest.129.1.174; Ho VCY, 2001, J AM ACAD DERMATOL, V44, P643, DOI 10.1067/mjd.2001.112400; *IMM CORP, ENBR ET PACK INS; Koo J, 1996, DERMATOL CLIN, V14, P485, DOI 10.1016/S0733-8635(05)70376-4; Krueger G, 2001, ARCH DERMATOL, V137, P280; Krueger GG, 2007, NEW ENGL J MED, V356, P580, DOI 10.1056/NEJMoa062382; Krueger GG, 2002, J AM ACAD DERMATOL, V47, P821, DOI 10.1067/mjd.2002.127247; Kupper TS, 2003, NEW ENGL J MED, V349, P1987, DOI 10.1056/NEJMp038164; Lebwohl M, 2003, ARCH DERMATOL, V139, P719, DOI 10.1001/archderm.139.6.719; Lecluse LLA, 2010, ARCH DERMATOL, V146, P127, DOI 10.1001/archdermatol.2009.347; Leonardi CL, 2003, NEW ENGL J MED, V349, P2014, DOI 10.1056/NEJMoa030409; Leonardi C, 2010, J DRUGS DERMATOL, V9, P928; Leonardi CL, 2008, LANCET, V371, P1665, DOI 10.1016/S0140-6736(08)60725-4; Lowe NJ, 2003, INT J DERMATOL, V42, P224, DOI 10.1046/j.1365-4362.2003.01793.x; Menter A, 2008, J AM ACAD DERMATOL, V58, P106, DOI 10.1016/j.jaad.2007.09.010; Menter A, 2007, J AM ACAD DERMATOL, V56, P31, DOI 10.1016/j.jaad.2006.07.017; Menter A, 2010, J AM ACAD DERMATOL, V63, P448, DOI 10.1016/j.jaad.2009.09.040; MIHATSCH MJ, 1992, BRIT J DERMATOL, V126, P621; Moore A, 2007, J AM ACAD DERMATOL, V56, P598, DOI 10.1016/j.jaad.2006.09.002; Nickoloff BJ, 2006, J AM ACAD DERMATOL, V54, pS143, DOI 10.1016/j.jaad.2005.10.059; Ortonne JP, 2009, BRIT J DERMATOL, V161, P1190, DOI 10.1111/j.1365-2133.2009.09238.x; Ortonne JP, 2003, J EUR ACAD DERMATOL, V17, P12, DOI 10.1046/j.1468-3083.17.s2.3.x; Ortonne JP, 1999, BRIT J DERMATOL, V140, P1; Papp K, 2011, BRIT J DERMATOL, V164, P434, DOI 10.1111/j.1365-2133.2010.10139.x; Papp KA, 2005, BRIT J DERMATOL, V152, P1304, DOI 10.1111/j.1365-2133.2005.06688.x; Papp KA, 2008, LANCET, V371, P1675, DOI 10.1016/S0140-6736(08)60726-6; Prinz JC, 2003, J EUR ACAD DERMATOL, V17, P257, DOI 10.1046/j.1468-3083.2003.00720.x; Rapp SR, 1999, J AM ACAD DERMATOL, V41, P401, DOI 10.1016/S0190-9622(99)70112-X; Reich K, 2005, LANCET, V366, P1367, DOI 10.1016/S0140-6736(05)67566-6; Roberts JL, 2010, J AM ACAD DERMATOL, V62, P968, DOI 10.1016/j.jaad.2009.07.032; Ryan C, 2011, JAMA-J AM MED ASSOC, V306, P864, DOI 10.1001/jama.2011.1211; Schon MP, 2005, NEW ENGL J MED, V352, P1899, DOI 10.1056/NEJMra041320; Stern RS, 2004, J INVEST DERM SYMP P, V9, P136, DOI 10.1046/j.1087-0024.2003.09102.x; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001	50	83	85	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2012	7	4							e33486	10.1371/journal.pone.0033486	http://dx.doi.org/10.1371/journal.pone.0033486			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TP	22509259	Green Published, Green Submitted, gold			2023-01-03	WOS:000305336600012
J	Noh, NA; Fuggetta, G; Manganotti, P; Fiaschi, A				Noh, Nor Azila; Fuggetta, Giorgio; Manganotti, Paolo; Fiaschi, Antonio			Long Lasting Modulation of Cortical Oscillations after Continuous Theta Burst Transcranial Magnetic Stimulation	PLOS ONE			English	Article							HIGH-FREQUENCY; MOTOR CORTEX; THALAMOCORTICAL DYSRHYTHMIA; SYNAPTIC PLASTICITY; EEG; TMS; SYNCHRONIZATION; EXCITABILITY; SYSTEMS; TASK	Transcranial magnetic theta burst stimulation (TBS) differs from other high-frequency rTMS protocols because it induces plastic changes up to an hour despite lower stimulus intensity and shorter duration of stimulation. However, the effects of TBS on neuronal oscillations remain unclear. In this study, we used electroencephalography (EEG) to investigate changes of neuronal oscillations after continuous TBS (cTBS), the protocol that emulates long-term depression (LTD) form of synaptic plasticity. We randomly divided 26 healthy humans into two groups receiving either Active or Sham cTBS as control over the left primary motor cortex (M1). Post-cTBS aftereffects were assessed with behavioural measurements at rest using motor evoked potentials (MEPs) and at active state during the execution of a choice reaction time (RT) task in combination with continuous electrophysiological recordings. The cTBS-induced EEG oscillations were assessed using event-related power (ERPow), which reflected regional oscillatory activity of neural assemblies of theta (4-7.5 Hz), low alpha (8-9.5 Hz), mu (10-12.5 Hz), low beta (13-19.5 Hz), and high beta (20-30 Hz) brain rhythms. Results revealed 20-min suppression of MEPs and at least 30-min increase of ERPow modulation, suggesting that besides MEPs, EEG has the potential to provide an accurate cortical readout to assess cortical excitability and to investigate the interference of cortical oscillations in the human brain post-cTBS. We also observed a predominant modulation of beta frequency band, supporting the hypothesis that cTBS acts more on cortical level. Theta oscillations were also modulated during rest implying the involvement of independent cortical theta generators over the motor network post cTBS. This work provided more insights into the underlying mechanisms of cTBS, providing a possible link between synchronised neural oscillations and LTD in humans.	[Noh, Nor Azila; Fuggetta, Giorgio] Univ Leicester, Sch Psychol, Coll Med Biol Sci & Psychol, Leicester, Leics, England; [Noh, Nor Azila] USIM, Fac Med & Hlth Sci, Dept Basic Med Sci 1, Persiaran MPAJ, Kuala Lumpur, Malaysia; [Fuggetta, Giorgio; Manganotti, Paolo; Fiaschi, Antonio] Univ Verona, Dept Neurol Neuropsychol Morphol & Movement Sci, Sect Clin Neurol, GB Rossi Hosp, I-37100 Verona, Italy	University of Leicester; Universiti Sains Islam Malaysia; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona	Noh, NA (corresponding author), Univ Leicester, Sch Psychol, Coll Med Biol Sci & Psychol, Leicester, Leics, England.	g.fuggetta@le.ac.uk	Manganotti, Paolo/L-1763-2018	Manganotti, Paolo/0000-0001-5305-6268				Aydin-Abidin S, 2008, EXP BRAIN RES, V188, P249, DOI 10.1007/s00221-008-1356-2; Azila Noh N, 2011, HUM BRAIN MAPP; Brignani D, 2008, HUM BRAIN MAPP, V29, P603, DOI 10.1002/hbm.20423; Caplan JB, 2001, J NEUROPHYSIOL, V86, P368, DOI 10.1152/jn.2001.86.1.368; Cardenas-Morales L, 2010, BRAIN TOPOGR, V22, P294, DOI 10.1007/s10548-009-0084-7; Di Lazzaro V, 2008, J PHYSIOL-LONDON, V586, P3871, DOI 10.1113/jphysiol.2008.152736; Di Lazzaro V, 2005, J PHYSIOL-LONDON, V565, P945, DOI 10.1113/jphysiol.2005.087288; Dutilh G, 2009, PSYCHON B REV, V16, P1026, DOI 10.3758/16.6.1026; Formaggio E, 2008, BRAIN TOPOGR, V21, P100, DOI 10.1007/s10548-008-0058-1; Fuggetta G, 2008, HUM BRAIN MAPP, V29, P1, DOI 10.1002/hbm.20371; Grossheinrich N, 2009, BIOL PSYCHIAT, V65, P778, DOI 10.1016/j.biopsych.2008.10.029; Hallett M, 2007, NEURON, V55, P187, DOI 10.1016/j.neuron.2007.06.026; Hernandez RV, 2005, BRAIN RES PROTOC, V15, P6, DOI 10.1016/j.brainresprot.2005.02.003; Huang CC, 2008, NEUROPHARMACOLOGY, V54, P1071, DOI 10.1016/j.neuropharm.2008.02.013; Huang YZ, 2008, CEREB CORTEX, V18, P563, DOI 10.1093/cercor/bhm087; Huang YZ, 2007, CLIN NEUROPHYSIOL, V118, P1028, DOI 10.1016/j.clinph.2007.01.021; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Huerta PT, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-7; Iyer MB, 2003, J NEUROSCI, V23, P10867; Jeanmonod D, 2003, NEUROSURG CLIN N AM, V14, P251, DOI 10.1016/S1042-3680(02)00116-X; Jurcak V, 2007, NEUROIMAGE, V34, P1600, DOI 10.1016/j.neuroimage.2006.09.024; Kahana MJ, 2001, CURR OPIN NEUROBIOL, V11, P739, DOI 10.1016/S0959-4388(01)00278-1; Komssi S, 2006, BRAIN RES REV, V52, P183, DOI 10.1016/j.brainresrev.2006.01.008; LEUNG LWS, 1987, BRAIN RES, V407, P68, DOI 10.1016/0006-8993(87)91220-0; Llinas R, 2005, TRENDS NEUROSCI, V28, P325, DOI 10.1016/j.tins.2005.04.006; Llinas RR, 1999, P NATL ACAD SCI USA, V96, P15222, DOI 10.1073/pnas.96.26.15222; Makeig S, 2002, SCIENCE, V295, P690, DOI 10.1126/science.1066168; Maki H, 2010, CLIN NEUROPHYSIOL, V121, P492, DOI 10.1016/j.clinph.2009.11.078; McAllister SM, 2011, EUR J NEUROSCI, V33, P1916, DOI 10.1111/j.1460-9568.2011.07673.x; Miniussi C, 2010, BRAIN TOPOGR, V22, P249, DOI 10.1007/s10548-009-0083-8; Mochizuki H, 2005, EXP BRAIN RES, V167, P414, DOI 10.1007/s00221-005-0047-5; Mochizuki H, 2007, EXP BRAIN RES, V180, P667, DOI 10.1007/s00221-007-0884-5; Niedermeyer E, 2004, CLIN EEG NEUROSCI, V35, P84, DOI 10.1177/155005940403500206; Nyffeler T, 2006, NEUROSCI LETT, V409, P57, DOI 10.1016/j.neulet.2006.09.011; Okamoto M, 2004, NEUROIMAGE, V21, P99, DOI 10.1016/j.neuroimage.2003.08.026; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Pareti G, 2004, NEUROL SCI, V25, P41, DOI 10.1007/s10072-004-0235-2; Paulus W, 2005, NEURON, V45, P181, DOI 10.1016/j.neuron.2005.01.008; Perfetti B, 2011, J NEUROPHYSIOL, V105, P18, DOI 10.1152/jn.00778.2010; Pfurtscheller G, 2006, NEUROIMAGE, V31, P153, DOI 10.1016/j.neuroimage.2005.12.003; Pfurtscheller G, 1999, CLIN NEUROPHYSIOL, V110, P1842, DOI 10.1016/S1388-2457(99)00141-8; Pineda JA, 2005, BRAIN RES REV, V50, P57, DOI 10.1016/j.brainresrev.2005.04.005; Raghavachari S, 2006, J NEUROPHYSIOL, V95, P1630, DOI 10.1152/jn.00409.2005; Rengachary J, 2011, FRONT HUM NEUROSCI, V5, DOI [10.3389/fnhum.2011.00029, 10.3389/fnhum.2011.00069]; Ridding MC, 2007, NAT REV NEUROSCI, V8, P559, DOI 10.1038/nrn2169; Rosanova M, 2009, J NEUROSCI, V29, P7679, DOI 10.1523/JNEUROSCI.0445-09.2009; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Salenius S, 2003, CURR OPIN NEUROBIOL, V13, P678, DOI 10.1016/j.conb.2003.10.008; Sauseng P, 2008, NEUROSCI BIOBEHAV R, V32, P1001, DOI 10.1016/j.neubiorev.2008.03.014; Schindler K, 2008, NEUROSCI LETT, V436, P31, DOI 10.1016/j.neulet.2008.02.052; Siebner HR, 2003, EXP BRAIN RES, V148, P1, DOI 10.1007/s00221-002-1234-2; SILVA LR, 1991, SCIENCE, V251, P432, DOI 10.1126/science.1824881; Stefan K, 2008, NEUROIMAGE, V40, P265, DOI 10.1016/j.neuroimage.2007.11.037; Stinear CM, 2009, BRAIN STIMUL, V2, P152, DOI 10.1016/j.brs.2009.01.001; Suppa A, 2008, J PHYSIOL-LONDON, V586, P4489, DOI 10.1113/jphysiol.2008.156596; Taylor PCJ, 2008, BEHAV BRAIN RES, V191, P141, DOI 10.1016/j.bbr.2008.03.033; Thickbroom GW, 2007, EXP BRAIN RES, V180, P583, DOI 10.1007/s00221-007-0991-3; Thut G, 2010, BRAIN TOPOGR, V22, P219, DOI 10.1007/s10548-009-0115-4; Thut G, 2010, BRAIN TOPOGR, V22, P215, DOI 10.1007/s10548-009-0128-z; Thut G, 2009, TRENDS COGN SCI, V13, P182, DOI 10.1016/j.tics.2009.01.004; Trippe J, 2009, EXP BRAIN RES, V199, P411, DOI 10.1007/s00221-009-1961-8; Veniero D, 2011, PSYCHOPHYSIOLOGY, V48, P1381, DOI 10.1111/j.1469-8986.2011.01218.x; Zhang YC, 2009, FRONT NEURAL CIRCUIT, V3, DOI 10.3389/neuro.04.020.2009; Ziemann U, 2011, NEUROSCIENTIST, V17, P368, DOI 10.1177/1073858410390225	64	55	56	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2012	7	4							e35080	10.1371/journal.pone.0035080	http://dx.doi.org/10.1371/journal.pone.0035080			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	953GO	22496893	Green Submitted, Green Published, gold			2023-01-03	WOS:000304855200098
J	Fang, Y; Yu, YH; Hou, Q; Zheng, X; Zhang, M; Zhang, DY; Li, JX; Wu, XR; Huang, CS				Fang, Yong; Yu, Yonghui; Hou, Qi; Zheng, Xiao; Zhang, Min; Zhang, Dongyun; Li, Jingxia; Wu, Xue-Ru; Huang, Chuanshu			The Chinese Herb Isolate Isorhapontigenin Induces Apoptosis in Human Cancer Cells by Down-regulating Overexpression of Antiapoptotic Protein XIAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED INHIBITOR; TRAIL-MEDIATED APOPTOSIS; NUCLEAR-FACTOR; GENE PROMOTER; IN-VITRO; EXPRESSION; INDUCTION; ARSENITE; SP1; PROLIFERATION	Although the Chinese herb Gnetum cleistostachyum has been used as a remedy for cancers for hundred years, the active compounds and molecular mechanisms underlying its anti-cancer activity have not been explored. Recently a new derivative of stilbene compound, isorhapontigenin (ISO), was isolated from this Chinese herb. In the present study, we examined the potential of ISO in anti-cancer activity and the mechanisms involved in human cancer cell lines. We found that ISO exhibited significant inhibitory effects on human bladder cancer cell growth that was accompanied by marked apoptotic induction as well as down-regulation of the X-linked inhibitor of apoptosis protein (XIAP). Further studies have shown that ISO down-regulation of XIAP protein expression was only observed in endogenous XIAP, but not in constitutionally exogenously expressed XIAP in the same cells, excluding the possibility of ISO regulating XIAP expression at the level of protein degradation. We also identified that ISO down-regulated XIAP gene transcription via inhibition of Sp1 transactivation. There was no significant effect of ISO on apoptosis and colony formation of cells transfected with exogenous HA-tagged XIAP. Collectively, current studies, for the first time to the best of our knowledge, identify ISO as a major active compound for the anti-cancer activity of G. cleistostachyum by down-regulation of XIAP expression and induction of apoptosis through specific targeting of a SP1 pathway, and cast new light on the treatment of the cancer patients with XIAP overexpression.	[Fang, Yong; Yu, Yonghui; Zheng, Xiao; Zhang, Min; Zhang, Dongyun; Li, Jingxia; Huang, Chuanshu] NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA; [Fang, Yong] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Med Oncol, Hangzhou 310016, Zhejiang, Peoples R China; [Hou, Qi] Mat Med Chinese Acad Med Sci, Beijing 100050, Peoples R China; [Hou, Qi] Peking Union Med Coll, Beijing 100050, Peoples R China; [Wu, Xue-Ru] NYU, Sch Med, Dept Urol, New York, NY 10016 USA; [Wu, Xue-Ru] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA	New York University; Zhejiang University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; New York University; New York University	Huang, CS (corresponding author), 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.	chuanshu.huang@nyumc.org	Yu, Yonghui/AAZ-4093-2021	Huang, Chuanshu/0000-0003-4133-5096; Wu, Xue-Ru/0000-0001-6058-6291	National Institutes of Health from NCI [CA112557]; NIEHS [ES000260, ES010344]; National Science Foundation [NSFC81229002, NSFC30971516]; NATIONAL CANCER INSTITUTE [R01CA112557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010344, P30ES000260] Funding Source: NIH RePORTER	National Institutes of Health from NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Science Foundation(National Science Foundation (NSF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported, in whole or in part, by National Institutes of Health Grants CA112557 from the NCI, ES000260 and ES010344 from the NIEHS, and National Science Foundation Grants NSFC81229002 and NSFC30971516.	Augello C, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-125; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Cai T, 2011, CURR CANCER DRUG TAR, V11, P548, DOI 10.2174/156800911795656001; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; Dai Y, 2009, AM J TRANSL RES, V1, P1; Dai Y, 2009, MOL CANCER THER, V8, P2762, DOI 10.1158/1535-7163.MCT-09-0509; Danson S, 2007, CURR CANCER DRUG TAR, V7, P785, DOI 10.2174/156800907783220471; Ding J, 2006, J BIOL CHEM, V281, P24405, DOI 10.1074/jbc.M600751200; Harding MA, 2010, EUR J CANCER, V46, P1252, DOI 10.1016/j.ejca.2010.02.025; Holt SV, 2011, ONCOL REP, V25, P1177, DOI 10.3892/or.2011.1167; Huang HY, 2007, HUM PATHOL, V38, P1703, DOI 10.1016/j.humpath.2007.04.003; Huang KS, 2002, PLANTA MED, V68, P916, DOI 10.1055/s-2002-34951; Huang KS, 2000, PHYTOCHEMISTRY, V54, P875, DOI 10.1016/S0031-9422(00)00151-5; Ikoma T, 2012, BIOCHEM BIOPH RES CO, V420, P217, DOI 10.1016/j.bbrc.2012.01.157; Jiang C, 2011, MOL MED REP, V4, P667, DOI 10.3892/mmr.2011.472; Kashkar H, 2010, CLIN CANCER RES, V16, P4496, DOI 10.1158/1078-0432.CCR-10-1664; Kim YH, 2004, CARCINOGENESIS, V25, P1813, DOI 10.1093/carcin/bgh188; Krepela E, 2009, INT J ONCOL, V35, P1449, DOI 10.3892/ijo_00000464; Lee TJ, 2006, MOL CANCER THER, V5, P2737, DOI 10.1158/1535-7163.MCT-06-0426; Lewis J, 2004, J BIOL CHEM, V279, P9023, DOI 10.1074/jbc.M312891200; Li HL, 2005, FREE RADICAL BIO MED, V38, P243, DOI 10.1016/j.freeradbiomed.2004.10.020; Liu JY, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.176982; Liu JY, 2010, J BIOL CHEM, V285, P26058, DOI 10.1074/jbc.M110.100271; Liu Y, 2011, J INT MED RES, V39, P1682, DOI 10.1177/147323001103900510; Liu YL, 2004, BIOCHEM PHARMACOL, V67, P777, DOI 10.1016/j.bcp.2003.09.025; Luo WJ, 2008, J BIOL CHEM, V283, P8624, DOI 10.1074/jbc.M707860200; Mehrotra S, 2010, CANCER CELL, V17, P53, DOI 10.1016/j.ccr.2009.11.021; Rajput Sandeep, 2010, Front Biosci (Schol Ed), V2, P176; Seznec J, 2011, J NEURO-ONCOL, V101, P365, DOI 10.1007/s11060-010-0266-x; Shibata T, 2008, ANN SURG ONCOL, V15, P3579, DOI 10.1245/s10434-008-0062-4; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Song L, 2011, ONCOGENE, V30, P1360, DOI 10.1038/onc.2010.506; Wai PY, 2012, WORLD J CLIN ONCOL, V3, P15, DOI 10.5306/wjco.v3.i2.15; Wang SM, 2011, CURR TOP MICROBIOL, V348, P89, DOI 10.1007/82_2010_111; Wang ZH, 2011, INT J ONCOL, V39, P1123, DOI 10.3892/ijo.2011.1115; Yano K, 2011, INT J ONCOL, V38, P365, DOI 10.3892/ijo.2010.874; Yu JX, 2012, J BIOL CHEM, V287, P13752, DOI 10.1074/jbc.M111.337469; Zhang DY, 2010, CANCER RES, V70, P813, DOI 10.1158/0008-5472.CAN-09-0448; Zhang DY, 2009, TOXICOL APPL PHARM, V235, P18, DOI 10.1016/j.taap.2008.11.002; Zhang LA, 2010, CLIN CANCER RES, V16, P4478, DOI 10.1158/1078-0432.CCR-10-0859	40	50	56	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2012	287	42					35234	35243		10.1074/jbc.M112.389494	http://dx.doi.org/10.1074/jbc.M112.389494			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022OF	22896709	Green Published, hybrid			2023-01-03	WOS:000309968000033
J	Wang, J; Guo, JS; Wu, S; Feng, HQ; Sun, SJ; Pan, J; Zhang, J; Beebe, SJ				Wang, Jing; Guo, Jinsong; Wu, Shan; Feng, Hongqing; Sun, Shujun; Pan, Jie; Zhang, Jue; Beebe, Stephen J.			Synergistic Effects of Nanosecond Pulsed Electric Fields Combined with Low Concentration of Gemcitabine on Human Oral Squamous Cell Carcinoma In Vitro	PLOS ONE			English	Article							ELECTROPORATION THERAPY; INDUCE APOPTOSIS; HEAD; CALCIUM; MECHANISMS; DEATH; DRUG; TRANSLOCATION; RESISTANCE; SURVIVAL	Treatment of cancer often involves uses of multiple therapeutic strategies with different mechanisms of action. In this study we investigated combinations of nanosecond pulsed electric fields (nsPEF) with low concentrations of gemcitabine on human oral cancer cells. Cells (Cal-27) were treated with pulse parameters (20 pulses, 100 ns in duration, intensities of 10, 30 and 60 kV/cm) and then cultured in medium with 0.01 mu g/ml gemcitabine. Proliferation, apoptosis/necrosis, invasion and morphology of those cells were examined using MTT, flow cytometry, clonogenics, transwell migration and TEM assay. Results show that combination treatments of gemcitabine and nsPEFs exhibited significant synergistic activities versus individual treatments for inhibiting oral cancer cell proliferation and inducing apoptosis and necrosis. However, there was no apparent synergism for cell invasion. By this we demonstrated synergistic inhibition of Cal-27 cells in vitro by nsPEFs and gemcitabine. Synergistic behavior indicates that these two treatments have different sites of action and combination treatment allows reduced doses of gemcitabine and lower nsPEF conditions, which may provide better treatment for patients than either treatment alone while reducing systemic toxicities.	[Wang, Jing; Guo, Jinsong] Lanzhou Univ, Dept Oral Med, Sch Stomatol, Lanzhou, Gansu, Peoples R China; [Guo, Jinsong; Wu, Shan; Feng, Hongqing; Zhang, Jue] Peking Univ, Coll Engn, Beijing 100871, Peoples R China; [Sun, Shujun; Zhang, Jue] Peking Univ, Acad Adv Interdisciplinary Studies, Beijing 100871, Peoples R China; [Pan, Jie] Peking Univ, Sch Stomatol, Dept Gen Dent, Beijing 100871, Peoples R China; [Beebe, Stephen J.] Old Dominion Univ, Frank Reidy Res Ctr Bioelect, Norfolk, VA USA	Lanzhou University; Peking University; Peking University; Peking University; Old Dominion University	Wang, J (corresponding author), Lanzhou Univ, Dept Oral Med, Sch Stomatol, Lanzhou, Gansu, Peoples R China.	panjie72@sina.com; sbeebe@odu.edu	Feng, Hongqing/I-5222-2019; Zhang, Jue/N-7594-2013; Zhang, Jue/E-2067-2014	Guo, Jinsong/0000-0002-7379-4708; Feng, Hongqing/0000-0003-2767-3080	Gansu Chinese Medicine Funds [GZK-2011-78]; Fundamental Research Funds for the Central Universities [lzujbky-2012-159]; Mr. Fran Reidy, Bioelectrics Inc.	Gansu Chinese Medicine Funds; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Mr. Fran Reidy, Bioelectrics Inc.	This work was supported by Gansu Chinese Medicine Funds (GZK-2011-78), Fundamental Research Funds for the Central Universities (lzujbky-2012-159), and Mr. Fran Reidy, Bioelectrics Inc. The funders had no role in study design, data collection and analysis, decision to publish and preparation of the manuscript. In addition, Mr. Reidy and Bioelectric Inc. have not pre-reviewed or seen the data presented in this manuscript.	Beebe SJ, 2004, PHYSIOL MEAS, V25, P1077, DOI 10.1088/0967-3334/25/4/023; Beebe SJ, 2003, DNA CELL BIOL, V22, P785, DOI 10.1089/104454903322624993; Beebe SJ, 2003, FASEB J, V17, P1493, DOI 10.1096/fj.02-0859fje; Beebe SJ, 2002, IEEE T PLASMA SCI, V30, P286, DOI 10.1109/TPS.2002.1003872; Beebe Stephen J, 2010, Cancers (Basel), V2, P1731, DOI 10.3390/cancers2031731; Boyl P, 2008, WORLD CANC REPORT; BRAAKHUIS BJM, 1991, CANCER RES, V51, P211; Buescher ES, 2004, IEEE T PLASMA SCI, V32, P1563, DOI 10.1109/TPS.2004.832643; Burian M, 2003, ACTA OTO-LARYNGOL, V123, P264, DOI 10.1080/00016480310001114; Carmichael J, 1995, BRIT J CANCER, V8, P21; Chen X, 2012, TECHNOL CANCER RES T, V11, P83, DOI 10.7785/tcrt.2012.500237; Chen XH, 2010, PIGM CELL MELANOMA R, V23, P554, DOI 10.1111/j.1755-148X.2010.00704.x; Chen YW, 2011, MOL BIOSYST, V7, P3065, DOI 10.1039/c1mb05125c; Davalos RV, 2005, ANN BIOMED ENG, V33, P223, DOI 10.1007/s10439-005-8981-8; Dev SB, 2000, IEEE T PLASMA SCI, V28, P206, DOI 10.1109/27.842905; Eguchi Y, 1997, CANCER RES, V57, P1835; Ford WE, 2010, ARCH BIOCHEM BIOPHYS, V497, P82, DOI 10.1016/j.abb.2010.03.008; Frey W, 2006, BIOPHYS J, V90, P3608, DOI 10.1529/biophysj.105.072777; Galmarini Carlos Maria, 2004, BMC Pharmacology, V4, P8, DOI 10.1186/1471-2210-4-8; Galmarini CM, 2001, LEUKEMIA, V15, P875, DOI 10.1038/sj.leu.2402114; Gowrishankar TR, 2006, BIOCHEM BIOPH RES CO, V349, P643, DOI 10.1016/j.bbrc.2006.08.097; Hall EH, 2007, APOPTOSIS, V12, P1721, DOI 10.1007/s10495-007-0083-7; Heller LC, 2011, CLINICAL ASPECTS OF ELECTROPORATION, P159, DOI 10.1007/978-1-4419-8363-3_14; Hofmann GA, 1999, IEEE T BIO-MED ENG, V46, P752, DOI 10.1109/10.764952; Hu Q, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.031902; HUANG P, 1995, SEMIN ONCOL, V22, P19; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Landstrom FJ, 2010, DERMATOL SURG, V36, P1245, DOI 10.1111/j.1524-4725.2010.01617.x; Lawrence TS, 2001, CLIN CANCER RES, V7, P314; LeBlanc AK, 2004, VET RADIOL ULTRASOUN, V45, P466, DOI 10.1111/j.1740-8261.2004.04080.x; Mir Lluis M., 2008, V423, P3, DOI 10.1007/978-1-59745-194-9_1; Mir LM, 1999, ADV DRUG DELIVER REV, V35, P107, DOI 10.1016/S0169-409X(98)00066-0; Nuccitelli R, 2006, BIOCHEM BIOPH RES CO, V343, P351, DOI 10.1016/j.bbrc.2006.02.181; OKINO M, 1987, JPN J CANCER RES, V78, P1319; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Pakhomov AG, 2009, BIOCHEM BIOPH RES CO, V385, P181, DOI 10.1016/j.bbrc.2009.05.035; Panesar K, 2011, US PHARM, V36, P7; Pauwels B, 2005, ONCOLOGIST, V10, P34, DOI 10.1634/theoncologist.10-1-34; Petersen PE, 2009, ORAL ONCOL, V45, P454, DOI 10.1016/j.oraloncology.2008.05.023; PLUNKETT W, 1995, SEMIN ONCOL, V22, P3; PRAUSNITZ MR, 1993, P NATL ACAD SCI USA, V90, P10504, DOI 10.1073/pnas.90.22.10504; Ren W, 2012, BIOCHEM BIOPH RES CO, V421, P808, DOI 10.1016/j.bbrc.2012.04.094; Ren W, 2011, APOPTOSIS, V16, P382, DOI 10.1007/s10495-010-0572-y; Rhodus N, 2007, INSIDE DENT, V3, P1; Schoenbach KH, 2004, P IEEE, V92, P1122, DOI 10.1109/JPROC.2004.829009; Spielmann M, 2001, ONCOLOGY-BASEL, V60, P303, DOI 10.1159/000058524; Stacey M, 2003, MUTAT RES-GEN TOX EN, V542, P65, DOI 10.1016/j.mrgentox.2003.08.006; Sun C, 2004, C P IEEE ENG MED BIO, V7, P5005; Ueno H, 2007, BRIT J CANCER, V97, P145, DOI 10.1038/sj.bjc.6603860; Vernier PT, 2006, PHYS BIOL, V3, P233, DOI 10.1088/1478-3975/3/4/001; Vernier PT, 2011, IEEE ENG MED BIO, P743, DOI 10.1109/IEMBS.2011.6090169; Vernier PT, 2003, IEEE T DIELECT EL IN, V10, P795, DOI 10.1109/TDEI.2003.1237329; Vernier PT, 2003, BIOCHEM BIOPH RES CO, V310, P286, DOI 10.1016/j.bbrc.2003.08.140; White JA, 2004, J BIOL CHEM, V279, P22964, DOI 10.1074/jbc.M311135200; Wu Y, 2009, CLIN THER, V31, P2416, DOI 10.1016/j.clinthera.2009.11.020	55	60	70	1	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 23	2012	7	8							e43213	10.1371/journal.pone.0043213	http://dx.doi.org/10.1371/journal.pone.0043213			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	998GE	22927951	gold, Green Published, Green Submitted			2023-01-03	WOS:000308224700012
J	Muller, FL; Colla, S; Aquilanti, E; Manzo, VE; Genovese, G; Lee, J; Eisenson, D; Narurkar, R; Deng, PN; Nezi, L; Lee, MA; Hu, BL; Hu, J; Sahin, E; Ong, D; Fletcher-Sananikone, E; Ho, D; Kwong, L; Brennan, C; Wang, YA; Chin, L; DePinho, RA				Muller, Florian L.; Colla, Simona; Aquilanti, Elisa; Manzo, Veronica E.; Genovese, Giannicola; Lee, Jaclyn; Eisenson, Daniel; Narurkar, Rujuta; Deng, Pingna; Nezi, Luigi; Lee, Michelle A.; Hu, Baoli; Hu, Jian; Sahin, Ergun; Ong, Derrick; Fletcher-Sananikone, Eliot; Ho, Dennis; Kwong, Lawrence; Brennan, Cameron; Wang, Y. Alan; Chin, Lynda; DePinho, Ronald A.			Passenger deletions generate therapeutic vulnerabilities in cancer	NATURE			English	Article							ENOLASE DEFICIENCY; INHIBITION; REGIONS; CELLS	Inactivation of tumour-suppressor genes by homozygous deletion is a prototypic event in the cancer genome, yet such deletions often encompass neighbouring genes. We propose that homozygous deletions in such passenger genes can expose cancer-specific therapeutic vulnerabilities when the collaterally deleted gene is a member of a functionally redundant family of genes carrying out an essential function. The glycolytic gene enolase 1 (ENO1) in the 1p36 locus is deleted in glioblastoma (GBM), which is tolerated by the expression of ENO2. Here we show that short-hairpin-RNA-mediated silencing of ENO2 selectively inhibits growth, survival and the tumorigenic potential of ENO1-deleted GBM cells, and that the enolase inhibitor phosphonoacetohydroxamate is selectively toxic to ENO1-deleted GBM cells relative to ENO1-intact GBM cells or normal astrocytes. The principle of collateral vulnerability should be applicable to other passenger-deleted genes encoding functionally redundant essential activities and provide an effective treatment strategy for cancers containing such genomic events.	[Muller, Florian L.; Colla, Simona; Aquilanti, Elisa; Manzo, Veronica E.; Genovese, Giannicola; Lee, Jaclyn; Eisenson, Daniel; Narurkar, Rujuta; Deng, Pingna; Nezi, Luigi; Lee, Michelle A.; Hu, Baoli; Hu, Jian; Sahin, Ergun; Ong, Derrick; Fletcher-Sananikone, Eliot; Ho, Dennis; Kwong, Lawrence; Wang, Y. Alan; Chin, Lynda; DePinho, Ronald A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Muller, Florian L.; Colla, Simona; Genovese, Giannicola; Deng, Pingna; Nezi, Luigi; Hu, Baoli; Hu, Jian; Ong, Derrick; Fletcher-Sananikone, Eliot; Kwong, Lawrence; Wang, Y. Alan; Chin, Lynda] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Muller, Florian L.; Colla, Simona; Hu, Jian; Sahin, Ergun; Ong, Derrick; Ho, Dennis; DePinho, Ronald A.] Harvard Univ, Sch Med, Dept Genet & Med, Boston, MA 02115 USA; [Lee, Michelle A.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Hu, Baoli; Wang, Y. Alan; Chin, Lynda; DePinho, Ronald A.] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA; [Brennan, Cameron] Mem Sloan Kettering Canc Ctr, Dept Neurosurg, New York, NY 10065 USA; [DePinho, Ronald A.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	Harvard University; Dana-Farber Cancer Institute; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Memorial Sloan Kettering Cancer Center; University of Texas System; UTMD Anderson Cancer Center	DePinho, RA (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.	rdepinho@mdanderson.org	Nezi, Luigi/AAB-1957-2019; Brennan, Cameron/R-7082-2019	Nezi, Luigi/0000-0002-4670-7656; Brennan, Cameron/0000-0003-4064-8891; DePinho, Ronald/0000-0002-5625-577X; Lee, Jaclyn/0000-0001-9804-6995; Muller, Florian/0000-0001-7568-2948; Colla, Simona/0000-0001-6583-8910; Genovese, Giannicola/0000-0003-1392-9954; Eisenson, Daniel/0000-0003-3868-0403	National Institutes of Health (NIH) [T32-CA009361, P01CA95616]; American Cancer Society [115992-PF-08-261-01-TBE]; Dana-Farber Cancer Institute/Harvard Cancer Center Myeloma SPORE career development grant; Howard Hughes Medical Institute Medical Research Fellowship [57006984]; Harvard PRISE fellowship; Diversity in Health-Related research award [3 P01 CA095616-08S1]; Ben and Catherine Ivy Foundation; NATIONAL CANCER INSTITUTE [P01CA095616, T32CA009361] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Dana-Farber Cancer Institute/Harvard Cancer Center Myeloma SPORE career development grant; Howard Hughes Medical Institute Medical Research Fellowship(Howard Hughes Medical Institute); Harvard PRISE fellowship; Diversity in Health-Related research award; Ben and Catherine Ivy Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank K. Ligon, C. Maire, D. N. Louis, J. Kimand G. Mohapatra for sharing bioinformatics data from their tumour neurosphere banks. We also thank D. Bigner for sharing the D423-MG and D502-MG cell lines and D. N. Louis and J. Kim for sharing the Gli56 cell line. We thank G. Chu and D. Jakubosky for assistance with necropsy and histopathological analysis. F. L. M. was supported by a training grant from the National Institutes of Health (NIH T32-CA009361) and a fellowship from the American Cancer Society (115992-PF-08-261-01-TBE). S. C. was supported by a Dana-Farber Cancer Institute/Harvard Cancer Center Myeloma SPORE career development grant. E. A. was supported by a Howard Hughes Medical Institute Medical Research Fellowship (57006984). V. M. was supported by a Harvard PRISE fellowship. M. A. L. was supported by a Diversity in Health-Related research award (3 P01 CA095616-08S1). F. L. M. thanks J. Mohr for assistance with figure preparations. We also thank K. Muller for assistance with manuscript editing. We thank all members of the DePinho and Chin laboratories for suggestions and discussions. This work is supported by the NIH (P01CA95616 to C. B., L. C. and R. A. D.) and by the Ben and Catherine Ivy Foundation (to R. A. D. and L.C.).	ANDERSON VE, 1984, BIOCHEMISTRY-US, V23, P2779, DOI 10.1021/bi00307a038; Bagchi A, 2008, CANCER RES, V68, P2551, DOI 10.1158/0008-5472.CAN-07-2095; Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768; Brookfield JFY, 1997, ADV GENET, V36, P137, DOI 10.1016/S0065-2660(08)60308-9; Buszczak M, 2007, GENETICS, V175, P1505, DOI 10.1534/genetics.106.065961; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Comi GP, 2001, ANN NEUROL, V50, P202, DOI 10.1002/ana.1095; Costanzo M, 2010, SCIENCE, V327, P425, DOI 10.1126/science.1180823; Cox C, 2005, P NATL ACAD SCI USA, V102, P4542, DOI 10.1073/pnas.0408593102; De Soto Joseph A, 2006, Int J Med Sci, V3, P117; DeLuna A, 2008, NAT GENET, V40, P676, DOI 10.1038/ng.123; Deutscher D, 2006, NAT GENET, V38, P993, DOI 10.1038/ng1856; Druker BJ, 2008, BLOOD, V112, P4808, DOI 10.1182/blood-2008-07-077958; Duncan CD, 2010, ADVANCED CRIME SCENE PHOTOGRAPHY, P1; Guha M, 2011, NAT BIOTECHNOL, V29, P373, DOI 10.1038/nbt0511-373; GuhaChowdhury N, 1997, ORAL MICROBIOL IMMUN, V12, P91, DOI 10.1111/j.1399-302X.1997.tb00623.x; Henrich KO, 2011, CANCER RES, V71, P3142, DOI 10.1158/0008-5472.CAN-10-3014; Jing M, 2007, AM J PHYSIOL-CELL PH, V292, pC477, DOI 10.1152/ajpcell.00196.2006; Joseph J, 1996, J NEUROCHEM, V66, P2484; Kobayakawa K, 2007, NATURE, V450, P503, DOI 10.1038/nature06281; Kotliarov Y, 2006, CANCER RES, V66, P9428, DOI 10.1158/0008-5472.CAN-06-1691; Mueller W, 2007, ONCOGENE, V26, P583, DOI 10.1038/sj.onc.1209805; Navarro MVDS, 2007, FEBS J, V274, P5077, DOI 10.1111/j.1742-4658.2007.06027.x; Peng W. X., 2007, CANCER SCI, V96, P661; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; POYNER RR, 1992, BIOCHEMISTRY-US, V31, P7166, DOI 10.1021/bi00146a020; Raj L, 2011, NATURE, V475, P231, DOI 10.1038/nature10167; Sonnichsen B, 2005, NATURE, V434, P462, DOI 10.1038/nature03353; STEFANINI M, 1972, AM J CLIN PATHOL, V58, P408; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102; Vavouri T, 2008, TRENDS GENET, V24, P485, DOI 10.1016/j.tig.2008.08.005; Weidle UH, 2011, CANCER GENOM PROTEOM, V8, P159; Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003; Yin D, 2009, MOL CANCER RES, V7, P665, DOI 10.1158/1541-7786.MCR-08-0270; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443	37	224	235	1	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 16	2012	488	7411					337	+		10.1038/nature11331	http://dx.doi.org/10.1038/nature11331			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	988OS	22895339	Green Accepted			2023-01-03	WOS:000307501000033
J	Carbonara, S; Bruno, G; Di Ciaula, G; Pantaleo, AD; Angarano, G; Monno, L				Carbonara, Sergio; Bruno, Giuseppe; Di Ciaula, Giuseppe; Pantaleo, Anna Donata; Angarano, Gioacchino; Monno, Laura			Limiting Severe Outcomes and Impact on Intensive Care Units of Moderate-Intermediate 2009 Pandemic Influenza: Role of Infectious Diseases Units	PLOS ONE			English	Article							H1N1 INFLUENZA; RISK-FACTORS; BACTERIAL PNEUMONIA; A(H1N1) INFECTION; HOSPITALIZATION; VIRUS; CLARITHROMYCIN; MACROLIDES; DEATH	Purpose: The rate of severe outcomes of patients with 2009 pandemic (A/H1N1) influenza (2009pI) hospitalized in non-intensive care units (ICUs) has not been defined thus far. This study aims to assess the efficacy of the management of patients with influenza-like illness (ILI) of moderate intermediate severity in an infectious diseases unit (IDU) during the first wave of 2009pI and its influence on the burden of ICUs. Methods: All patients hospitalized from October 27, 2009, to February 5, 2010, with ILI were included in this prospective observational study. The IDU was organized and the staff was trained to provide intermediate care; patients were transferred to the ICU only if they required invasive ventilation, extracorporeal membrane oxygenation, or advanced cardiovascular support. Demographic data, clinical presentation, coexisting medical conditions, and laboratory and radiological findings were recorded and analyzed, as well as treatment and outcome data. Results: Overall, 108 patients (median age 36 years [IQR 27-54], 57.4% males) including 66.7% with >= 1 risk factor for severe influenza, 47.2% with confirmed 2009pI by RT-PCR and 63.9% with pneumonia, were enrolled in the study. All subjects received intravenous fluids and 83.3% were administered oseltamivir, 96.3% antibacterials, 19.4% oxygen therapy without ventilatory support, and 10.2% non-invasive ventilation. A total of 106 (98.1%) subjects were discharged after a 6-day median hospital stay [IQR 4-9]. Two patients (1.9%) were transferred to the ICU. There were no deaths. Conclusions: These results suggest that the aggressive treatment of patients with moderate intermediate severity 2009 pandemic ILI in non-ICU wards may result in a low rate of severe outcomes and brief hospitalization. IDUs, if properly organized for intermediate care, may efficiently provide correct disease management, in addition to complying with infection control requirements, thus reducing the burden of the pandemic on ICUs. Further studies are warranted to evaluate the outcome of patients with moderate intermediate 2009pI in different non-ICU settings.	[Carbonara, Sergio; Bruno, Giuseppe; Di Ciaula, Giuseppe; Pantaleo, Anna Donata; Angarano, Gioacchino; Monno, Laura] Univ Bari, Clin Infect Dis, Sch Med & Surg, Bari, Italy	Universita degli Studi di Bari Aldo Moro	Carbonara, S (corresponding author), Univ Bari, Clin Infect Dis, Sch Med & Surg, Bari, Italy.	s_carbonara@yahoo.it	Carbonara, Sergio/AAE-7283-2022	Carbonara, Sergio/0000-0001-6757-2458; ANGARANO, Gioacchino/0000-0003-3207-7523; MONNO, Laura/0000-0002-2713-4258				Agenzia Italiana del Farmaco, 2008, GAZZETTA UFFICI 0331, V76, P68; Amsden GW, 2005, J ANTIMICROB CHEMOTH, V55, P10, DOI 10.1093/jac/dkh519; Balish A., 2009, Morbidity and Mortality Weekly Report, V58, P826; Bassetti M, 2011, CLIN MICROBIOL INFEC, V17, P247, DOI 10.1111/j.1469-0691.2010.03275.x; Baudouin S, 2002, THORAX, V57, P192; Bermejo-Martin JF, 2009, J INFECT DEV COUNTR, V3, P159, DOI 10.3855/jidc.18; British Thoracic Society Royal College of Physicians London Intensive Care Society, 2008, US NON VENT MAN PAT; Campbell A, 2010, CAN MED ASSOC J, V182, P349, DOI 10.1503/cmaj.091823; Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P536; Centers for Disease Control and Prevention (CDC), 2009, UPD CDC EST 2009 H1N; Charles PGP, 2009, MED J AUSTRALIA, V191, P517, DOI 10.5694/j.1326-5377.2009.tb02922.x; ECDC, 2010, 2009 H1N1 PAND EUR R; European Centre for Disease Prevention and Control (ECDC), 2010, INFL SURV EUR 2008 0; Gilca R, 2011, INFLUENZA OTHER RESP, V5, P247, DOI 10.1111/j.1750-2659.2011.00204.x; Gill JR, 2010, ARCH PATHOL LAB MED, V134, P235, DOI 10.1043/1543-2165-134.2.235; Napolitano L. M., 2009, Morbidity and Mortality Weekly Report, V58, P749; Harper SA, 2009, CLIN INFECT DIS, V48, P1003, DOI 10.1086/598513; Jain S, 2009, NEW ENGL J MED, V361, P1935, DOI 10.1056/NEJMoa0906695; Kumar A, 2009, JAMA-J AM MED ASSOC, V302, P1872, DOI 10.1001/jama.2009.1496; Leelarasamee Amorn, 2008, Journal of the Medical Association of Thailand, V91, P924; Lim WS, 2009, THORAX, V64, P1, DOI 10.1136/thx.2009.121434; Louie J., 2009, Morbidity and Mortality Weekly Report, V58, P1071; Louie JK, 2009, JAMA-J AM MED ASSOC, V302, P1896, DOI 10.1001/jama.2009.1583; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; Mereckiene J, 2008, Euro Surveill, V13; Ministero del Lavoro della Salute e delle Politiche Sociali Dipartimento della prevenzione e della comunicazione Direzione generale della prevenzione sanitaria Ufficio V-Malattie Infettive e Profilassi Internazionale Roma, 2009, 0034102 MIN LAV SAL; Ministero della Salute, 2010, CIRC INFL 2010 2011; Miyamoto D, 2008, BIOL PHARM BULL, V31, P217, DOI 10.1248/bpb.31.217; Morens DM, 2008, J INFECT DIS, V198, P962, DOI 10.1086/591708; Murphy Trudy V., 2008, Morbidity and Mortality Weekly Report, V57, P1; National Center for Immunization and Respiratory Diseases CDC, 2009, MMWR Recomm Rep, V58, P1; Nguyen-Van-Tam JS, 2010, THORAX, V65, P645, DOI 10.1136/thx.2010.135210; Ninomiya Keiko, 2003, Jpn J Antibiot, V56 Suppl A, P84; O'Driscoll BR, 2008, THORAX, V63, DOI 10.1136/thx.2008.102947; de la Tabla VO, 2010, J CLIN MICROBIOL, V48, P3492, DOI 10.1128/JCM.01105-10; Parnham Michael J, 2005, Curr Opin Infect Dis, V18, P125, DOI 10.1097/01.qco.0000160901.71813.fe; Poeppl W, 2011, INFECTION, V39, P341, DOI 10.1007/s15010-011-0121-9; Santa-Olalla Peralta P, 2010, EUROSURVEILLANCE, V15; Sato K, 1998, AM J RESP CRIT CARE, V157, P853, DOI 10.1164/ajrccm.157.3.9703098; SCHWARZMANN SW, 1971, ARCH INTERN MED, V127, P1037, DOI 10.1001/archinte.127.6.1037; STAUDINGER T, 2010, WIEN KLIN WOCHENSCHR, V122, P3, DOI DOI 10.1007/S00508-010-1304-6; Tsigrelis C, 2010, INFECTION, V38, P237, DOI 10.1007/s15010-010-0009-0; Tsurita M, 2001, J PHARMACOL EXP THER, V298, P362; U. K. Department of Health (DH), 2009, PAND H1N1 2009 INFL; Van Kerkhove MD, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001053; Webb SAR, 2009, NEW ENGL J MED, V361, P1925, DOI 10.1056/NEJMoa0908481; White DB, 2009, JAMA-J AM MED ASSOC, V302, P1905, DOI 10.1001/jama.2009.1539; World Health Organization, 2009, HUM INF PAND H1N1 20; World Health Organization, 2009, CLIN MAN HUM INF PAN; World Health Organization (2010), 2009, EV PAND H1N1 2009 AP; World Health Organization (WHO), GUID PHARM MAN PAN 1; Yang SG, 2012, PLOS ONE, V71; Zarychanski R, 2010, CAN MED ASSOC J, V182, P257, DOI 10.1503/cmaj.091884	53	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2012	7	8							e42940	10.1371/journal.pone.0042940	http://dx.doi.org/10.1371/journal.pone.0042940			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	988OQ	22905188	Green Published, gold			2023-01-03	WOS:000307500800031
J	Prasad, R; Vaid, M; Katiyar, SK				Prasad, Ram; Vaid, Mudit; Katiyar, Santosh K.			Grape Proanthocyanidin Inhibit Pancreatic Cancer Cell Growth In Vitro and In Vivo through Induction of Apoptosis and by Targeting the PI3K/Akt Pathway	PLOS ONE			English	Article							ACTIVATED AKT; CARCINOMA-CELLS; CYCLE CONTROL; BCL-2 FAMILY; EXPRESSION; PROTEIN; PHOSPHORYLATION; KINASES; MICE; SKIN	Pancreatic cancer is an aggressive malignancy that is frequently diagnosed at an advanced stage with poor prognosis. Here, we report the chemotherapeutic effects of bioactive proanthocyanidins from grape seeds (GSPs) as assessed using In Vitro and In Vivo models. Treatment of human pancreatic cancer cells (Miapaca-2, PANC-1 and AsPC-1) with GSPs In Vitro reduced cell viability and increased G2/M phase arrest of the cell cycle leading to induction of apoptosis in a dose- and time-dependent manner. The GSPs-induced apoptosis of pancreatic cancer cells was associated with a decrease in the levels of Bcl-2 and Bcl-xl and an increase in the levels of Bax and activated caspase-3. Treatment of Miapaca-2 and PANC-1 cells with GSPs also decreased the levels of phosphatidylinositol-3-kinase (PI3K) and phosphorylation of Akt at ser(473). siRNA knockdown of PI3K from pancreatic cancer cells also reduced the phosphorylation of Akt. Further, dietary administration of GSPs (0.5%, w/w) as a supplemented AIN76A control diet significantly inhibited the growth of Miapaca-2 pancreatic tumor xenografts grown subcutaneously in athymic nude mice, which was associated with: (i) inhibition of cell proliferation, (ii) induction of apoptosis of tumor cells, (iii) increased expression of Bax, reduced expression of anti-apoptotic proteins and activation of caspase-3-positive cells, and (iv) decreased expression of PI3K and p-Akt in tumor xenograft tissues. Together, these results suggest that GSPs may have a potential chemotherapeutic effect on pancreatic cancer cell growth.	[Prasad, Ram; Vaid, Mudit; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA; [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA; [Katiyar, Santosh K.] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL USA; [Katiyar, Santosh K.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Prasad, R (corresponding author), Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.	skatiyar@uab.edu			Veterans Administration Merit Review Award	Veterans Administration Merit Review Award(US Department of Veterans Affairs)	This work was supported by funds from the Veterans Administration Merit Review Award (SKK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; Bondar VM, 2002, MOL CANCER THER, V1, P989; Chadha KS, 2006, ANN SURG ONCOL, V13, P933, DOI 10.1245/ASO.2006.07.011; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; DEMESQUITA HBB, 1991, INT J CANCER, V48, P540, DOI 10.1002/ijc.2910480411; Fahy BN, 2003, BRIT J CANCER, V89, P391, DOI 10.1038/sj.bjc.6601037; GRANA X, 1995, ONCOGENE, V11, P211; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Li J, 2010, AAPS J, V12, P223, DOI 10.1208/s12248-010-9181-5; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Magee CJ, 2002, BEST PRACT RES CL GA, V16, P435, DOI 10.1053/bega.2002.0317; Mantena SK, 2005, J NUTR, V135, P2871, DOI 10.1093/jn/135.12.2871; Mantena SK, 2006, CARCINOGENESIS, V27, P2018, DOI 10.1093/carcin/bgl043; Meeran SM, 2009, CARCINOGENESIS, V30, P520, DOI 10.1093/carcin/bgp019; Mittal A, 2003, CARCINOGENESIS, V24, P1379, DOI 10.1093/carcin/bgg095; Molinari M, 2000, CELL PROLIFERAT, V33, P261, DOI 10.1046/j.1365-2184.2000.00191.x; Nandakumar V, 2008, CANC LETT, V375, P162; Ng SSW, 2001, CLIN CANCER RES, V7, P3269; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Schlieman MG, 2003, BRIT J CANCER, V89, P2110, DOI 10.1038/sj.bjc.6601396; Sharma SD, 2007, MOL CANCER THER, V6, P995, DOI 10.1158/1535-7163.MCT-06-0661; Sharma SD, 2010, MOL CANCER THER, V9, P569, DOI 10.1158/1535-7163.MCT-09-0638; Singh T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027444; Sun Q, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-134; Vaid M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021539; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; Yamamoto S, 2004, CLIN CANCER RES, V10, P2846, DOI 10.1158/1078-0432.CCR-02-1441; Yeo Theresa Pluth, 2002, Curr Probl Cancer, V26, P176, DOI 10.1067/mcn.2002.129579; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	36	62	72	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2012	7	8							e43064	10.1371/journal.pone.0043064	http://dx.doi.org/10.1371/journal.pone.0043064			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	986GX	22905202	gold, Green Published, Green Submitted			2023-01-03	WOS:000307331100082
J	Koole, O; Kalenga, L; Kiumbu, M; Menten, J; Ryder, RW; Mukumbi, H; Colebunders, R				Koole, Olivier; Kalenga, Lucien; Kiumbu, Modeste; Menten, Joris; Ryder, Robert W.; Mukumbi, Henri; Colebunders, Robert			Retention in a NGO Supported Antiretroviral Program in the Democratic Republic of Congo	PLOS ONE			English	Article							SUB-SAHARAN AFRICA; THERAPY PROGRAMS; FOLLOW-UP; SCALE-UP; LOW-INCOME; OUTCOMES; MORTALITY; SURVIVAL; CARE	Background: Retention of patients in ART care is a major challenge in sub-Saharan programs. Retention is also one of the key indicators to evaluate the success of ART programs. Methods and Findings: A retrospective review of 1500 randomly selected medical charts of adult ART patients from a local non-governmental (NGO) supported ART program in the Democratic Republic of Congo (DRC). Retention was defined as any visit to the clinic in the 4 months prior to the abstraction date. Retention over time and across different sites was described. The relationship between patient characteristics and retention rates at 1 year was also examined. 1450 patients were included in the analysis. The overall retention rates were 81.4% (95% CI: 79.3-83.4), 75.2% (95% CI: 72.8-77.3), 65.0% (95% CI: 62.3-67.6) and 57.2% (95% CI: 54.0-60.3) at 6 months, 1 year, 2 years and 3 years respectively. The retention rates between sites varied between 62.1% and 90.6% at 6 months and between 55.5% and 86.2% at 1 year. During multivariable analysis weight below 50 kg (aHR: 1.33, 95% CI: 1.05-1.69), higher WHO stage at initiation (aHR: 1.22, 95% CI 0.85-1.76 for stage 3 and aHR: 2.98, 95% CI: 1.93-4.59 for stage 4), and male sex (aHR: 1.32, 95% CI: 1.05-1.65) remained as significant risk factors for attrition during the first year after ART initiation. Other independent risk factors were year of initiation (aHR: 1.73, 95% CI: 1.26-2.38 for the year 2007 and aHR: 3.06, 95% CI: 2.26-4.14 for the period 2008-2009), and site. Conclusions: Retention is a major problem in DRC, while coverage of patients on ART is still very low. With the flattening of funding for HIV care and treatment in sub-Saharan Africa, and with decreasing funding worldwide, maximizing retention during the much needed scaling-up will even be more important.	[Koole, Olivier; Menten, Joris; Colebunders, Robert] Inst Trop Med, B-2000 Antwerp, Belgium; [Kalenga, Lucien; Mukumbi, Henri] AmoCongo, Lubumbashi, DEM REP CONGO; [Kalenga, Lucien; Kiumbu, Modeste; Mukumbi, Henri] Sch Publ Hlth, Kinshasa, DEM REP CONGO; [Ryder, Robert W.] Univ Calif San Diego, Div Hosp Med, San Diego, CA 92103 USA; [Colebunders, Robert] Univ Antwerp, B-2020 Antwerp, Belgium	Institute of Tropical Medicine (ITM); University of California System; University of California San Diego; University of Antwerp	Koole, O (corresponding author), Inst Trop Med, B-2000 Antwerp, Belgium.	olivierkoole@yahoo.com		Koole, Olivier/0000-0002-1122-5382	Flemish Interuniversity Council [ZRDC 2007 MP037]	Flemish Interuniversity Council	The study was funded by the Flemish Interuniversity Council (ZRDC 2007 MP037). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bisson GP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001725; Boulle A, 2008, B WORLD HEALTH ORGAN, V86, P678, DOI 10.2471/BLT.07.045294; Boyles TH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019201; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Brinkhof MWG, 2008, B WORLD HEALTH ORGAN, V86, P559, DOI 10.2471/BLT.07.044248; Calmy A, 2006, AIDS, V20, P1163, DOI 10.1097/01.aids.0000226957.79847.d6; Charurat M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010584; Coetzee D, 2004, AIDS, V18, P887, DOI 10.1097/00002030-200404090-00006; Cornell M, 2010, AIDS, V24, P2263, DOI 10.1097/QAD.0b013e32833d45c5; Ferradini L, 2006, LANCET, V367, P1335, DOI 10.1016/S0140-6736(06)68580-2; Forster M, 2008, B WORLD HEALTH ORGAN, V86, P939, DOI 10.2471/BLT.07.049908; Fox MP, 2010, TROP MED INT HEALTH, V15, P1, DOI 10.1111/j.1365-3156.2010.02508.x; Giordano TP, 2007, CLIN INFECT DIS, V44, P1493, DOI 10.1086/516778; MacPherson P, 2009, T ROY SOC TROP MED H, V103, P588, DOI 10.1016/j.trstmh.2008.10.001; Massaquoi M, 2009, T ROY SOC TROP MED H, V103, P594, DOI 10.1016/j.trstmh.2009.02.012; May M, 2010, LANCET, V376, P449, DOI 10.1016/S0140-6736(10)60666-6; Ministere du plan et Macro International, 2007, ENQ DEM SANT; MSF Campaign for access to essential medicines, 2009, PUN SUCC EARLY SIGNS; MSF Campaign for access to essential medicines, 2010, 10 CONS AIDS TREATM; Mugyenyi P, 2010, LANCET, V375, P123, DOI 10.1016/S0140-6736(09)62067-5; Programme National Multisectoriel de Lutte contre le SIDA (PNMLS), 2010, RAPP NAT SUIV DECL E; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782; Tassie JM, 2010, JAIDS-J ACQ IMM DEF, V54, P437, DOI 10.1097/QAI.0b013e3181d73e1b; WHO, 2010, ANT THER HIV INF AD; World Health Organization, 2011, TREATM 2 0 FRAM ACT; World Health Organization, 2010, UN ACC SCAL PRIOR HI; Yu JKL, 2007, B WORLD HEALTH ORGAN, V85, P550, DOI 10.2471/BLT.06.037739	28	18	18	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2012	7	7							e40971	10.1371/journal.pone.0040971	http://dx.doi.org/10.1371/journal.pone.0040971			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975JG	22815883	gold, Green Published, Green Accepted, Green Submitted			2023-01-03	WOS:000306507000047
J	Wang, AL; Xu, YQ; Ma, CQ; Gao, C; Li, LX; Wang, Y; Tao, F; Xu, P				Wang, Ailong; Xu, Youqiang; Ma, Cuiqing; Gao, Chao; Li, Lixiang; Wang, Yu; Tao, Fei; Xu, Ping			Efficient 2,3-Butanediol Production from Cassava Powder by a Crop-Biomass-Utilizer, Enterobacter cloacae subsp dissolvens SDM	PLOS ONE			English	Article							L-LACTIC ACID; FERMENTATION; ROOTS; BATCH	Background: 2,3-Butanediol (BD) is considered as one of the key platform chemicals used in a variety of industrial applications. It is crucial to find an efficient sugar-utilizing strain and feasible carbon source for the economical production of BD. Methodology/Principal Findings: Efficient BD production by a newly isolated Enterobacter cloacae subsp. dissolvens SDM was studied using crop-biomass cassava powder as substrate. The culture conditions and fermentation medium for BD production were optimized. Under the optimal conditions, 78.3 g l(-1) of BD was produced after 24 h in simultaneous saccharification and fermentation (SSF), with a yield of 0.42 g BD g(-1) cassava powder and a specific productivity of 3.3 g l(-1) h(-1). A higher BD concentration (93.9 g l(-1)) was produced after 47 h in fed-batch SSF. Conclusions/Significance: The results suggest that strain SDM is a good candidate for the BD production, and cassava powder could be used as an alternative substrate for the efficient production of BD.	[Wang, Ailong; Xu, Youqiang; Ma, Cuiqing; Gao, Chao; Li, Lixiang; Wang, Yu; Xu, Ping] Shandong Univ, State Key Lab Microbial Technol, Jinan 250100, Peoples R China; [Tao, Fei; Xu, Ping] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai 200030, Peoples R China	Shandong University; Shanghai Jiao Tong University	Wang, AL (corresponding author), Shandong Univ, State Key Lab Microbial Technol, Jinan 250100, Peoples R China.	macq@sdu.edu.cn	Tao, Fei/E-5891-2010	Tao, Fei/0000-0002-5997-8770; Ma, Cuiqing/0000-0002-7468-1027; Gao, Chao/0000-0002-5205-0670; Wang, Yu/0000-0002-0957-9245	Chinese National Programs for High Technology Research and Development [2011AA02A207]; Chinese National Natural Science Foundation [30770064]	Chinese National Programs for High Technology Research and Development(National High Technology Research and Development Program of China); Chinese National Natural Science Foundation(National Natural Science Foundation of China (NSFC))	This work was supported by the Chinese National Programs for High Technology Research and Development (2011AA02A207) and the Chinese National Natural Science Foundation (No. 30770064). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Celinska E, 2009, BIOTECHNOL ADV, V27, P715, DOI 10.1016/j.biotechadv.2009.05.002; Cheng KK, 2010, PROCESS BIOCHEM, V45, P613, DOI 10.1016/j.procbio.2009.12.009; Choi GW, 2009, J CHEM TECHNOL BIOT, V84, P547, DOI 10.1002/jctb.2077; Djazuli M, 1999, FOOD CHEM, V65, P523, DOI 10.1016/S0308-8146(98)00218-0; GARG SK, 1995, BIORESOURCE TECHNOL, V51, P103, DOI 10.1016/0960-8524(94)00136-O; Ghofar A, 2005, J BIOSCI BIOENG, V100, P606, DOI 10.1263/jbb.100.606; Gu Y, 2009, J IND MICROBIOL BIOT, V36, P1225, DOI 10.1007/s10295-009-0604-1; Jansen N B, 1983, Adv Biochem Eng Biotechnol, V27, P85; Ji XJ, 2011, BIOTECHNOL ADV, V29, P351, DOI 10.1016/j.biotechadv.2011.01.007; Ji XJ, 2011, APPL MICROBIOL BIOT, V89, P1119, DOI 10.1007/s00253-010-2940-5; Ji XJ, 2010, APPL MICROBIOL BIOT, V85, P1751, DOI 10.1007/s00253-009-2222-2; Ji XJ, 2009, BIORESOURCE TECHNOL, V100, P5214, DOI 10.1016/j.biortech.2009.05.036; Ji XJ, 2009, BIORESOURCE TECHNOL, V100, P3410, DOI 10.1016/j.biortech.2009.02.031; Kostinek M, 2007, INT J FOOD MICROBIOL, V114, P342, DOI 10.1016/j.ijfoodmicro.2006.09.029; Ma CQ, 2009, APPL MICROBIOL BIOT, V82, P49, DOI 10.1007/s00253-008-1732-7; Nie ZK, 2011, APPL BIOCHEM BIOTECH, V163, P946, DOI 10.1007/s12010-010-9098-6; Nitayavardhana S, 2010, BIORESOURCE TECHNOL, V101, P2741, DOI 10.1016/j.biortech.2009.10.075; Papong S, 2010, BIORESOURCE TECHNOL, V101, pS112, DOI 10.1016/j.biortech.2009.09.006; Petrov K, 2010, APPL MICROBIOL BIOT, V87, P943, DOI 10.1007/s00253-010-2545-z; Qin JY, 2006, CHINESE J CHEM ENG, V14, P132, DOI 10.1016/S1004-9541(06)60050-5; Roble ND, 2003, BIOTECHNOL LETT, V25, P1093, DOI 10.1023/A:1024192131343; Saha BC, 1999, APPL MICROBIOL BIOT, V52, P321, DOI 10.1007/s002530051526; Sun LH, 2009, APPL MICROBIOL BIOT, V82, P847, DOI 10.1007/s00253-008-1823-5; Syu MJ, 2001, APPL MICROBIOL BIOT, V55, P10, DOI 10.1007/s002530000486; Thang VH, 2010, APPL BIOCHEM BIOTECH, V161, P157, DOI 10.1007/s12010-009-8770-1; Wang AL, 2010, APPL MICROBIOL BIOT, V87, P965, DOI 10.1007/s00253-010-2557-8; Wang LM, 2010, BIORESOURCE TECHNOL, V101, P7895, DOI 10.1016/j.biortech.2010.05.018; Xiao ZJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008860; Xu YQ, 2012, J BACTERIOL, V194, P897, DOI 10.1128/JB.06495-11; Zeng AP, 2011, CURR OPIN BIOTECH, V22, P749, DOI 10.1016/j.copbio.2011.05.005; Zhang LY, 2010, J IND MICROBIOL BIOT, V37, P857, DOI 10.1007/s10295-010-0733-6	31	42	45	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 5	2012	7	7							e40442	10.1371/journal.pone.0040442	http://dx.doi.org/10.1371/journal.pone.0040442			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	974LI	22792324	Green Published, Green Submitted, gold			2023-01-03	WOS:000306436300067
J	Leys, D; Cordonnier, C				Leys, Didier; Cordonnier, Charlotte			rt-PA for ischaemic stroke: what will the next question be?	LANCET			English	Editorial Material							POOLED ANALYSIS; THROMBOLYSIS; RISK; ALTEPLASE; AGE		[Leys, Didier; Cordonnier, Charlotte] Roger Salengro Hosp, Stroke Unit, Dept Neurol, F-59037 Lille, France	Universite de Lille - ISITE; CHU Lille	Leys, D (corresponding author), Roger Salengro Hosp, Stroke Unit, Dept Neurol, F-59037 Lille, France.	didier.leys@chru-lille.fr	LEYS, Didier/G-2955-2016; Cordonnier, Charlotte/O-3258-2017	LEYS, Didier/0000-0003-4408-4392; Cordonnier, Charlotte/0000-0002-5697-6892				Alshekhlee A, 2011, NEUROLOGY, V76, P1575, DOI 10.1212/WNL.0b013e3182190d37; Busl KM, 2013, J STROKE CEREBROVASC, V22, P718, DOI 10.1016/j.jstrokecerebrovasdis.2011.11.005; Cordonnier C, 2006, NEUROLOGY, V66, P1356, DOI 10.1212/01.wnl.0000210535.20297.ae; Fiehler J, 2007, STROKE, V38, P2738, DOI 10.1161/STROKEAHA.106.480848; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Iadecola C, 2004, NAT REV NEUROSCI, V5, P347, DOI 10.1038/nrn1387; Lees KR, 2010, LANCET, V375, P1695, DOI 10.1016/S0140-6736(10)60491-6; Leys D, 2005, LANCET NEUROL, V4, P752, DOI 10.1016/S1474-4422(05)70221-0; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Meretoja A, 2010, STROKE, V41, P1450, DOI 10.1161/STROKEAHA.109.576140; Mishra NK, 2010, STROKE, V41, P2840, DOI 10.1161/STROKEAHA.110.586206; Neumann-Haefelin T, 2006, STROKE, V37, P2463, DOI 10.1161/01.STR.0000239321.53203.ea; Pendlebury ST, 2009, LANCET NEUROL, V8, P1006, DOI 10.1016/S1474-4422(09)70236-4; Roussel BD, 2009, BRAIN, V132, P2219, DOI 10.1093/brain/awp162; Sandercock P, 2012, LANCET, V379, P2352, DOI 10.1016/S0140-6736(12)60768-5; Teter B, 2002, J NEUROSCI RES, V70, P402, DOI 10.1002/jnr.10441; Wardlaw JM, 2012, LANCET, V379, P2364, DOI 10.1016/S0140-6736(12)60738-7	17	18	18	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 23	2012	379	9834					2320	2321		10.1016/S0140-6736(12)60822-8	http://dx.doi.org/10.1016/S0140-6736(12)60822-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	961ZV	22632906				2023-01-03	WOS:000305509600007
J	Gomes, J; Magalhaes, A; Carvalho, AS; Hernandez, GE; Papp, SL; Head, SR; Michel, V; David, L; Gartner, F; Touati, E; Reis, CA				Gomes, Joana; Magalhaes, Ana; Carvalho, Ana S.; Hernandez, Gilberto E.; Papp, Suzanne L.; Head, Steven R.; Michel, Valerie; David, Leonor; Gaertner, Fatima; Touati, Eliette; Reis, Celso A.			Glycophenotypic Alterations Induced by Pteridium aquilinum in Mice Gastric Mucosa: Synergistic Effect with Helicobacter pylori Infection	PLOS ONE			English	Article							SIALYL-LEWIS-X; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; UDP-GALACTOSE; BRACKEN FERN; INTESTINAL METAPLASIA; EPITHELIAL-CELLS; EXPRESSION; CANCER; FAMILY	The bracken fern Pteridium aquilinum is a plant known to be carcinogenic to animals. Epidemiological studies have shown an association between bracken fern exposure and gastric cancer development in humans. The biological effects of exposure to this plant within the gastric carcinogenesis process are not fully understood. In the present work, effects in the gastric mucosa of mice treated with Pteridium aquilinum were evaluated, as well as molecular mechanisms underlying the synergistic role with Helicobacter pylori infection. Our results showed that exposure to Pteridium aquilinum induces histomorphological modifications including increased expression of acidic glycoconjugates in the gastric mucosa. The transcriptome analysis of gastric mucosa showed that upon exposure to Pteridium aquilinum several glycosyltransferase genes were differently expressed, including Galntl4, C1galt1 and St3gal2, that are mainly involved in the biosynthesis of simple mucin-type carbohydrate antigens. Concomitant treatment with Pteridium aquilinum and infection with Helicobacter pylori also resulted in differently expressed glycosyltransferase genes underlying the biosynthesis of terminal sialylated Lewis antigens, including Sialyl-Lewis x. These results disclose the molecular basis for the altered pattern of glycan structures observed in the mice gastric mucosa. The gene transcription alterations and the induced glycophenotypic changes observed in the gastric mucosa contribute for the understanding of the molecular mechanisms underlying the role of Pteridium aquilinum in the gastric carcinogenesis process.	[Gomes, Joana; Magalhaes, Ana; Carvalho, Ana S.; David, Leonor; Gaertner, Fatima; Reis, Celso A.] Univ Porto, Univ Porto IPATIMUP, Inst Mol Pathol & Immunol, P-4100 Oporto, Portugal; [Gomes, Joana; Michel, Valerie; Touati, Eliette] Inst Pasteur, Unite Pathogenese Helicobacter, Paris, France; [Hernandez, Gilberto E.; Papp, Suzanne L.; Head, Steven R.] Scripps Res Inst, La Jolla, CA 92037 USA; [David, Leonor; Reis, Celso A.] Univ Porto, Fac Med, P-4100 Oporto, Portugal; [Gaertner, Fatima; Reis, Celso A.] Univ Porto, Inst Ciencias Biomed Abel Salazar, P-4100 Oporto, Portugal	Universidade do Porto; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Scripps Research Institute; Universidade do Porto; Universidade do Porto	Gomes, J (corresponding author), Univ Porto, Univ Porto IPATIMUP, Inst Mol Pathol & Immunol, Rua Campo Alegre 823, P-4100 Oporto, Portugal.	celsor@ipatimup.pt	REIS, Celso A/B-9969-2008; de Fátima Gärtner, Maria/A-3530-2010; Magalhaes, Ana/I-1510-2013; Gomes, Joana/K-9031-2013; Magalhaes, Ana/O-9990-2019; David, Leonor/A-4829-2008	REIS, Celso A/0000-0002-0286-6639; de Fátima Gärtner, Maria/0000-0002-5302-0086; Magalhaes, Ana/0000-0003-4863-6668; Gomes, Joana/0000-0002-8832-2703; Magalhaes, Ana/0000-0003-4863-6668; David, Leonor/0000-0003-4207-9258; Touati, Eliette/0000-0002-3450-1773; Carvalho, Ana Sofia/0000-0003-0657-1907	Fundacao para a Ciencia e a Tecnologia - [FCT] [PIC/IC/82716/2007, SFRH/BD/40563/2007, SFRH/BPD/75871/2011]; Programa de Accoes Universitarias Integradas Luso-Francesas - PAULIF [LC/HS/ED/2010-308, F-TC04/11];  [NIGMS-GM62116]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116] Funding Source: NIH RePORTER	Fundacao para a Ciencia e a Tecnologia - [FCT](Portuguese Foundation for Science and Technology); Programa de Accoes Universitarias Integradas Luso-Francesas - PAULIF; ; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by Fundacao para a Ciencia e a Tecnologia - [FCT (PIC/IC/82716/2007), grant number SFRH/BD/40563/2007 to J.G and SFRH/BPD/75871/2011 to A. M.]; and the Programa de Accoes Universitarias Integradas Luso-Francesas - PAULIF [grant number LC/HS/ED/2010-308; F-TC04/11]. The resources and collaborative efforts provided by the Consortium for Functional Glycomics were funded by grant NIGMS-GM62116. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Alonso-Amelot ME, 2001, INT J CANCER, V91, P252, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1028&gt;3.0.CO;2-; AlonsoAmelot ME, 1997, NUTRITION, V13, P694, DOI 10.1016/S0899-9007(97)83017-1; Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; Amado M, 1998, GASTROENTEROLOGY, V114, P462, DOI 10.1016/S0016-5085(98)70529-3; [Anonymous], 1986, IARC Monogr Eval Carcinog Risk Chem Hum, V40, P47; [Anonymous], 1994, IARC Monogr Eval Carcinog Risks Hum, V61, P177; [Anonymous], 2010, GLOBOCAN 2008 CANC I; Atherton JC, 2006, ANNU REV PATHOL-MECH, V1, P63, DOI 10.1146/annurev.pathol.1.110304.100125; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bennett EP, 2012, GLYCOBIOLOGY, V22, P736, DOI 10.1093/glycob/cwr182; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Carvalho AS, 2010, INT J BIOCHEM CELL B, V42, P80, DOI 10.1016/j.biocel.2009.09.010; Chandrasekaran EV, 2011, BIOCHEMISTRY-US, V50, P9475, DOI 10.1021/bi200301w; CORREA P, 1992, CANCER RES, V52, P6735; Dall'Olio F, 2001, GLYCOCONJUGATE J, V18, P841, DOI 10.1023/A:1022288022969; DAVID L, 1992, APMIS, V100, P162; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; Ferrero RL, 1998, INFECT IMMUN, V66, P1349, DOI 10.1128/IAI.66.4.1349-1355.1998; Fieger CB, 2003, J BIOL CHEM, V278, P27390, DOI 10.1074/jbc.M304204200; Filipe MI, 1990, HISTOCHEMISTRY PATHO, P451; Fuster MM, 2005, NAT REV CANCER, V5, P526, DOI 10.1038/nrc1649; GALPIN OP, 1990, BRIT J CANCER, V61, P737, DOI 10.1038/bjc.1990.165; Gomes J, 2012, TOXICOL SCI, V126, P60, DOI 10.1093/toxsci/kfr329; Gornes J, 2009, J HISTOCHEM CYTOCHEM, V57, P79, DOI 10.1369/jhc.2008.952283; Harduin-Lepers A, 2001, BIOCHIMIE, V83, P727, DOI 10.1016/S0300-9084(01)01301-3; Hennet T, 1998, J BIOL CHEM, V273, P58, DOI 10.1074/jbc.273.1.58; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jensen PH, 2008, J AGR FOOD CHEM, V56, P9848, DOI 10.1021/jf801986u; Ju TZ, 2002, J BIOL CHEM, V277, P178, DOI 10.1074/jbc.M109060200; KJELDSEN T, 1988, CANCER RES, V48, P2214; LEE YC, 1993, EUR J BIOCHEM, V216, P377, DOI 10.1111/j.1432-1033.1993.tb18155.x; LEE YC, 1994, J BIOL CHEM, V269, P10028; Linden S, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040002; Liu H, 2009, GASTROENTEROLOGY, V137, P1367, DOI 10.1053/j.gastro.2009.07.041; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Magalhaes A, 2010, BRAZ J MED BIOL RES, V43, P611, DOI 10.1590/S0100-879X2010007500049; Magalhaes A, 2009, GLYCOBIOLOGY, V19, P1525, DOI 10.1093/glycob/cwp131; Mahdavi J, 2002, SCIENCE, V297, P573, DOI 10.1126/science.1069076; Mandel U, 1999, GLYCOBIOLOGY, V9, P43, DOI 10.1093/glycob/9.1.43; Marcos NT, 2008, J CLIN INVEST, V118, P2325, DOI [10.1172/JC134324, 10.1172/JCI34324]; MARLIERE C, 1999, BRACKEN FERN TOXICIT, P144; Matsuda M, 2011, J GASTROEN HEPATOL, V26, P1451, DOI 10.1111/j.1440-1746.2011.06779.x; Ohno T, 2011, J INFECT DIS, V203, P726, DOI 10.1093/infdis/jiq090; Okajima T, 2000, J BIOL CHEM, V275, P6717, DOI 10.1074/jbc.275.10.6717; Ota H, 1998, VIRCHOWS ARCH, V433, P419, DOI 10.1007/s004280050269; Ozawa M, 1996, J BIOCHEM-TOKYO, V119, P302; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Pinho S, 2007, CANCER LETT, V249, P157, DOI 10.1016/j.canlet.2006.08.010; Raman J, 2012, GLYCOBIOLOGY, V22, P768, DOI 10.1093/glycob/cwr183; Rasmussen LH, 2005, CHEMOSPHERE, V58, P823, DOI 10.1016/j.chemosphere.2004.08.088; Reis CA, 1999, CANCER RES, V59, P1003; Reis CA, 2010, J CLIN PATHOL, V63, P322, DOI 10.1136/jcp.2009.071035; ROYSTON P, 1995, APPL STAT-J ROY ST C, V44, P547, DOI 10.2307/2986146; Shahin M, 1999, MUTAT RES-GEN TOX EN, V443, P69, DOI 10.1016/S1383-5742(99)00011-3; Silva E, 2002, VIRCHOWS ARCH, V440, P311, DOI 10.1007/s004280100531; Smith BL, 2004, POISONOUS PLANTS AND RELATED TOXINS, P227, DOI 10.1079/9780851996141.0227; Smyth GK., 2004, STAT APPL GENET MOL, V3, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Solnick JV, 2004, P NATL ACAD SCI USA, V101, P2106, DOI 10.1073/pnas.0308573100; Takashima S, 2008, BIOSCI BIOTECH BIOCH, V72, P1155, DOI 10.1271/bbb.80025; Ten Hagen KG, 2003, GLYCOBIOLOGY, V13, p1R, DOI 10.1093/glycob/cwg007; Tian E, 2009, GLYCOCONJUGATE J, V26, P325, DOI 10.1007/s10719-008-9162-4; Vetter J, 2009, ACTA VET HUNG, V57, P183, DOI 10.1556/AVet.57.2009.1.18; Yamada K, 2007, NAT PROD REP, V24, P798, DOI 10.1039/b614160a; Yasukawa Z, 2005, GLYCOBIOLOGY, V15, P827, DOI 10.1093/glycob/cwi068; Zen K, 1998, AM J PHYSIOL-LUNG C, V275, pL172, DOI 10.1152/ajplung.1998.275.1.L172	66	15	15	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2012	7	6							e38353	10.1371/journal.pone.0038353	http://dx.doi.org/10.1371/journal.pone.0038353			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UV	22719879	Green Published, Green Submitted, gold			2023-01-03	WOS:000305341900025
J	Massaoka, MH; Matsuo, AL; Figueiredo, CR; Farias, CF; Girola, N; Arruda, DC; Scutti, JAB; Romoff, P; Favero, OA; Ferreira, MJP; Lago, JHG; Travassos, LR				Massaoka, Mariana H.; Matsuo, Alisson L.; Figueiredo, Carlos R.; Farias, Camyla F.; Girola, Natalia; Arruda, Denise C.; Scutti, Jorge A. B.; Romoff, Paulete; Favero, Oriana A.; Ferreira, Marcelo J. P.; Lago, Joao H. G.; Travassos, Luiz R.			Jacaranone Induces Apoptosis in Melanoma Cells via ROS-Mediated Downregulation of Akt and p38 MAPK Activation and Displays Antitumor Activity In Vivo	PLOS ONE			English	Article							MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; CANCER-CELLS; PROTEIN-KINASE; CASPASE ACTIVATION; STRESS; PATHWAYS; GROWTH; LEADS; PHOSPHORYLATION; MECHANISMS	Background: Malignant melanoma is a deadly type of metastatic skin cancer with increased incidence over the past 30 years. Despite the advanced knowledge on the biology, immunobiology and molecular genetics of melanoma, the alternatives of treatment are limited with poor prognosis. On clinical trials, natural products and among them redox-active quinones have been tested in the attempt to control the growth of cancer cells. Recently, we isolated jacaranone from Pentacalia desiderabilis, a benzoquinone derivative that showed a broad antitumor activity and protective anti-melanoma effect in a syngeneic model. The purified substance is active at micromolar concentrations, is not hemolytic, and is not toxic in naive mice. Methodology/Principal Findings: The jacaranone antitumor activity was shown against several human cancer cell lines in vitro. Moreover, the induction of apoptosis in murine melanoma cells and jacaranone antitumor activity in vivo, in a melanoma experimental model, were also shown. Jacaranone renders antiproliferative and proapoptotic responses in tumor cells, by acting on Akt and p38 MAPK signaling pathways through generation of reactive oxygen species (ROS). The free radical scavenger N-acetyl-cysteine (NAC) was able to completely suppress cell death induced by jacaranone as it blocked Akt downregulation, p38 MAPK activation as well as upregulation of proapoptotic Bax. Notably, treatment of melanoma growing subcutaneously in mice with jacaranone significantly extended the mean survival times in a dose-dependent manner. Conclusions/Significance: The results provide evidence for the mechanisms of action of jacaranone and emphasize the potential use of this quinone for the treatment of melanoma.	[Massaoka, Mariana H.; Matsuo, Alisson L.; Figueiredo, Carlos R.; Farias, Camyla F.; Girola, Natalia; Arruda, Denise C.; Scutti, Jorge A. B.; Travassos, Luiz R.] Univ Fed Sao Paulo, Unidade Oncol Expt, Sao Paulo, Brazil; [Romoff, Paulete; Favero, Oriana A.; Ferreira, Marcelo J. P.] Univ Presbiteriana Mackenzie, Ctr Ciencias & Humanidades, Sao Paulo, Brazil; [Romoff, Paulete; Favero, Oriana A.; Ferreira, Marcelo J. P.] Univ Presbiteriana Mackenzie, Ctr Ciencias Biol & Saude, Sao Paulo, Brazil; [Lago, Joao H. G.] Univ Fed Sao Paulo, Inst Ciencias Ambientais Quim & Farmaceut, Diadema, SP, Brazil	Universidade Federal de Sao Paulo (UNIFESP); Universidade Presbiteriana Mackenzie; Universidade Presbiteriana Mackenzie; Universidade Federal de Sao Paulo (UNIFESP)	Massaoka, MH (corresponding author), Univ Fed Sao Paulo, Unidade Oncol Expt, Sao Paulo, Brazil.	luiztravassos@gmail.com	Travassos, Luiz R/J-3631-2012; Lago, Joao/W-5238-2019; Romoff, Paulete/AAD-3638-2021; Figueiredo, Carlos Rogerio de/H-1236-2014; Arruda, Denise C/E-2184-2013; Travassos, Luiz/V-2467-2019; , Denise/AAD-1162-2022; Girola, Natalia/L-9060-2017; Fapesp, Biota/F-8655-2017; Ferreira, Marcelo JP/G-6002-2014	Lago, Joao/0000-0002-1193-8374; Figueiredo, Carlos Rogerio de/0000-0003-3680-4070; Arruda, Denise C/0000-0002-8807-8835; Fapesp, Biota/0000-0002-9887-8449; Ferreira, Marcelo JP/0000-0003-1877-1762	State of Sao Paulo Research Support Foundation (FAPESP), Brazil [2010/51423-0]; Brazilian National Research Council (CNPq)	State of Sao Paulo Research Support Foundation (FAPESP), Brazil(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Brazilian National Research Council (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	The State of Sao Paulo Research Support Foundation (FAPESP), Brazil, supported this work through grant 2010/51423-0 as well as the Brazilian National Research Council (CNPq). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai BB, 2006, J BIOL CHEM, V281, P25215, DOI 10.1074/jbc.M512627200; Chang CW, 2009, J BIOL CHEM, V284, P33195, DOI 10.1074/jbc.M109.020586; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Chaudhuri L, 2010, ENVIRON INT, V36, P924, DOI 10.1016/j.envint.2010.01.001; Dai DL, 2005, J CLIN ONCOL, V23, P1473, DOI 10.1200/JCO.2005.07.168; Demain AL, 2011, MICROB BIOTECHNOL, V4, P687, DOI 10.1111/j.1751-7915.2010.00221.x; Dhawan P, 2002, CANCER RES, V62, P7335; Doughan AK, 2007, ANTIOXID REDOX SIGN, V9, P1825, DOI 10.1089/ars.2007.1693; FLUCKIGER R, 1995, METHOD ENZYMOL, V258, P140; Fulda S, 2011, ANTIOXID REDOX SIGN, V15, P2937, DOI 10.1089/ars.2011.4078; Garbe C, 2009, CLIN DERMATOL, V27, P3, DOI 10.1016/j.clindermatol.2008.09.001; Gogas HJ, 2007, CANCER-AM CANCER SOC, V109, P455, DOI 10.1002/cncr.22427; Govindarajan B, 2007, J CLIN INVEST, V117, P719, DOI 10.1172/JCI30102; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Grossman D, 2001, CANCER METAST REV, V20, P3, DOI 10.1023/A:1013123532723; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Izeradjene K, 2005, CANCER RES, V65, P7436, DOI 10.1158/0008-5472.CAN-04-2628; Jerant AF, 2000, AM FAM PHYSICIAN, V62, P357; Jia YT, 2007, J IMMUNOL, V179, P7808, DOI 10.4049/jimmunol.179.11.7808; Jo Y, 2005, ARCH PHARM RES, V28, P885, DOI 10.1007/BF02973871; Kim BJ, 2006, J BIOL CHEM, V281, P21256, DOI 10.1074/jbc.M510644200; Kim BM, 2011, APOPTOSIS, V16, P184, DOI 10.1007/s10495-010-0557-x; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Liao Y, 2003, MOL CELL BIOL, V23, P6836, DOI 10.1128/MCB.23.19.6836-6848.2003; Lin CF, 2004, J BIOL CHEM, V279, P40755, DOI 10.1074/jbc.M404726200; Loizzo MR, 2005, J PHARM PHARMACOL, V57, P897, DOI 10.1211/0022357056398; Lopez-Bergami P, 2011, PIGM CELL MELANOMA R, V24, P902, DOI 10.1111/j.1755-148X.2011.00908.x; Matsuo AL, 2011, BIOCHEM BIOPH RES CO, V411, P449, DOI 10.1016/j.bbrc.2011.06.176; Morais TR, 2012, PARASITOL RES, V110, P95, DOI 10.1007/s00436-011-2454-9; Nagy G, 2003, J IMMUNOL, V171, P5188, DOI 10.4049/jimmunol.171.10.5188; Ollinger Karin, 2002, Subcell Biochem, V36, P151; Park KR, 2011, CANCER LETT, V312, P178, DOI 10.1016/j.canlet.2011.08.001; Pasciu V, 2010, TOXICOL SCI, V114, P101, DOI 10.1093/toxsci/kfp301; PAZ MA, 1991, J BIOL CHEM, V266, P689; Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004; Pfisterer PH, 2010, CURR PHARM DESIGN, V16, P1718; Porras A, 2004, MOL BIOL CELL, V15, P922, DOI 10.1091/mbc.E03-08-0592; POWIS G, 1989, FREE RADICAL BIO MED, V6, P63, DOI 10.1016/0891-5849(89)90162-7; Prasad V, 2006, FREE RADICAL BIO MED, V41, P431, DOI 10.1016/j.freeradbiomed.2006.03.009; Saraste A, 2000, CARDIOVASC RES, V45, P528, DOI 10.1016/S0008-6363(99)00384-3; Shin SW, 2009, CLIN CANCER RES, V15, P5414, DOI 10.1158/1078-0432.CCR-08-3101; Squadrito GL, 2001, FREE RADICAL BIO MED, V31, P1132, DOI 10.1016/S0891-5849(01)00703-1; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009; Verrax J, 2011, ANTI-CANCER AGENT ME, V11, P213, DOI 10.2174/187152011795255902; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Woldemichael GM, 2011, CANCER RES, V71, P134, DOI 10.1158/0008-5472.CAN-10-0757; Xavier CPR, 2009, CANCER LETT, V281, P162, DOI 10.1016/j.canlet.2009.02.041; Xu J, 2002, J BIOL CHEM, V277, P35561, DOI 10.1074/jbc.M203805200; Yin XM, 2000, CELL RES, V10, P161, DOI 10.1038/sj.cr.7290045; Yu DS, 2002, CHEM RES TOXICOL, V15, P832, DOI 10.1021/tx010177m; Zorov DB, 2006, BBA-BIOENERGETICS, V1757, P509, DOI 10.1016/j.bbabio.2006.04.029; Zuo Y, 2009, CELL RES, V19, P449, DOI 10.1038/cr.2009.19	60	44	47	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2012	7	6							e38698	10.1371/journal.pone.0038698	http://dx.doi.org/10.1371/journal.pone.0038698			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959WK	22701695	Green Published, gold, Green Submitted			2023-01-03	WOS:000305348400087
J	Wang, L; Guo, H; Yu, X; Wang, SY; Xu, CH; Fu, F; Jing, XR; Zhang, H; Dong, XZ				Wang, Lei; Guo, Heng; Yu, Xiao; Wang, Shouyan; Xu, Canhua; Fu, Feng; Jing, Xiaorong; Zhang, Hua; Dong, Xiuzhen			Responsive Electrical Stimulation Suppresses Epileptic Seizures in Rats	PLOS ONE			English	Article							LOW-FREQUENCY STIMULATION; INDUCED FOCAL EPILEPSY; CORTICAL STIMULATION; BRAIN-STIMULATION; TEMPORAL-LOBE; IN-VITRO; MODEL; PARAMETERS; EEG	Background: A responsive electrical stimulation pattern based on our recently developed novel seizure prediction method was designed to suppress the penicillin-induced epileptic seizures. Methodology: Seizures were induced by Penicillin injection at rat cortex. A responsive electrical stimulation system was triggered prior to seizures predicted with phase synchronisation. Rats with induced seizures were stimulated by the electrical pulses at a responsive or 1 Hz periodic pattern of an open system. The effectiveness of stimulation on seizures suppression was assessed by measuring the average number and duration of seizures per hour. Results: The prediction algorithm reliably identified seizures in real time and triggered the responsive stimulation. This type of electrical stimulation dramatically suppressed seizure activity and the performance was better than the open stimulation system with fewer and shorter seizures. Conclusions: A responsive electrical stimulation system triggered by the phase synchronisation prediction is able to significantly suppress seizures. Significance: Responsive electrical stimulation could achieve superior treatment performance and reduce power consumption and side effects.	[Wang, Lei; Yu, Xiao; Xu, Canhua; Fu, Feng; Dong, Xiuzhen] Fourth Mil Med Univ, Fac Biomed Engn, Xian 710032, Peoples R China; [Wang, Lei] 323rd Hosp PLA, Xian, Peoples R China; [Guo, Heng; Jing, Xiaorong; Zhang, Hua] Fourth Mil Med Univ, Dept Neurosurg, Tangdu Hosp, Xian 710032, Peoples R China; [Wang, Shouyan] Univ Southampton, Inst Sound & Vibrat Res, Hearing & Balance Ctr, Southampton, Hants, England; [Wang, Shouyan] Chinese Acad Sci, Suzhou Inst Biomed Engn & Technol, Suzhou, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; University of Southampton; Chinese Academy of Sciences; Suzhou Institute of Biomedical Engineering & Technology, CAS	Wang, L (corresponding author), Fourth Mil Med Univ, Fac Biomed Engn, Xian 710032, Peoples R China.	zhanghuadoc@gmail.com; dongxiuzhen@fmmu.edu.cn			National Natural Science Foundation of China [30772221, 50937005]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China [30772221]; and the Key Program of National Natural Science Foundation of China [50937005]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Canan S, 2008, EPILEPSY RES, V82, P7, DOI 10.1016/j.eplepsyres.2008.06.005; Carrington CA, 2007, EPILEPSIA, V48, P1604, DOI 10.1111/j.1528-1167.2007.01077.x; Colpan ME, 2007, EPILEPSIA, V48, P1594, DOI 10.1111/j.1528-1167.2007.01073.x; Engel J, 2003, EPILEPSIA, V44, P741, DOI 10.1046/j.1528-1157.2003.48202.x; Fountas KN, 2007, ACTA NEUROCHIR SUPPL, V97, P357; GAITO J, 1981, CAN J NEUROL SCI, V8, P249, DOI 10.1017/S0317167100043286; GAITO J, 1980, EPILEPSIA, V21, P73, DOI 10.1111/j.1528-1157.1980.tb04046.x; GARDNERMEDWIN AR, 1983, J PHYSIOL-LONDON, V335, P375, DOI 10.1113/jphysiol.1983.sp014540; Goodman JH, 2005, EPILEPSIA, V46, P1, DOI 10.1111/j.0013-9580.2005.03804.x; Kinoshita M, 2005, CLIN NEUROPHYSIOL, V116, P1291, DOI 10.1016/j.clinph.2005.02.010; Kinoshita M, 2004, EPILEPSIA, V45, P787, DOI 10.1111/j.0013-9580.2004.60203.x; Kortelainen J, 2010, IEEE ENG MED BIO, P6674, DOI 10.1109/IEMBS.2010.5627154; Kossoff EH, 2004, EPILEPSIA, V45, P1560, DOI 10.1111/j.0013-9580.2004.26104.x; Lasemidis LD, 2003, IEEE T BIO-MED ENG, V50, P549, DOI 10.1109/TBME.2003.810705; Lesser RP, 1999, NEUROLOGY, V53, P2073, DOI 10.1212/WNL.53.9.2073; Lian J, 2003, J PHYSIOL-LONDON, V547, P427, DOI 10.1113/jphysiol.2002.033209; Liang SF, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/045001; Liebetanz D, 2006, EPILEPSIA, V47, P1216, DOI 10.1111/j.1528-1167.2006.00539.x; Lopez-Meraz ML, 2004, EPILEPSY RES, V59, P95, DOI 10.1016/j.eplepsyres.2004.02.005; Makiranta M, 2005, NEUROIMAGE, V27, P715, DOI 10.1016/j.neuroimage.2005.05.025; MCCREERY DB, 1990, IEEE T BIO-MED ENG, V37, P996, DOI 10.1109/10.102812; Mirski MA, 1997, EPILEPSY RES, V28, P89, DOI 10.1016/S0920-1211(97)00034-X; Morrell M, 2006, CURR OPIN NEUROL, V19, P164, DOI 10.1097/01.wco.0000218233.60217.84; Morrell MJ, 2002, SEMIN NEUROL, V22, P247, DOI 10.1055/s-2002-36645; Nadkarni S, 2005, NEUROLOGY, V64, pS2, DOI 10.1212/WNL.64.12_suppl_3.S2; Osorio I, 2001, J CLIN NEUROPHYSIOL, V18, P533, DOI 10.1097/00004691-200111000-00003; Raghunathan S, 2009, J NEURAL ENG, V6, DOI 10.1088/1741-2560/6/5/056005; Rajdev P, 2011, INT J NEURAL SYST, V21, P151, DOI 10.1142/S0129065711002730; Rosin B, 2011, NEURON, V72, P370, DOI 10.1016/j.neuron.2011.08.023; Schiller Y, 2007, J NEUROPHYSIOL, V97, P1887, DOI 10.1152/jn.00514.2006; Silfverhuth MJ, 2011, SEIZURE-EUR J EPILEP, V20, P513, DOI 10.1016/j.seizure.2011.03.006; Sun FT, 2008, NEUROTHERAPEUTICS, V5, P68, DOI 10.1016/j.nurt.2007.10.069; Sunderam S, 2010, EPILEPSY BEHAV, V17, P6, DOI 10.1016/j.yebeh.2009.10.017; TRANCHINA D, 1986, BIOPHYS J, V50, P1139, DOI 10.1016/S0006-3495(86)83558-5; Velasco F, 2001, STEREOT FUNCT NEUROS, V77, P228, DOI 10.1159/000064611; Wang L, 2011, CLIN NEUROPHYSIOL, V122, P656, DOI 10.1016/j.clinph.2010.09.018; Yao QH, 2008, NEUROSCI LETT, V430, P187, DOI 10.1016/j.neulet.2007.10.024; YUEN TGH, 1981, NEUROSURGERY, V9, P292, DOI 10.1227/00006123-198109000-00013	38	11	12	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2012	7	5							e38141	10.1371/journal.pone.0038141	http://dx.doi.org/10.1371/journal.pone.0038141			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UY	22662277	Green Published, Green Submitted, gold			2023-01-03	WOS:000305342300169
J	Takiyama, K; Okada, M				Takiyama, Ken; Okada, Masato			Recovery in Stroke Rehabilitation through the Rotation of Preferred Directions Induced by Bimanual Movements: A Computational Study	PLOS ONE			English	Article							PRIMARY MOTOR CORTEX; ARM MOVEMENTS; CORTICAL REPRESENTATION; SUPPLEMENTARY MOTOR; MODEL; INFORMATION; POPULATIONS; NETWORKS; MONKEYS	Stroke patients recover more effectively when they are rehabilitated with bimanual movement rather than with unimanual movement; however, it remains unclear why bimanual movement is more effective for stroke recovery. Using a computational model of stroke recovery, this study suggests that bimanual movement facilitates the reorganization of a damaged motor cortex because this movement induces rotations in the preferred directions (PDs) of motor cortex neurons. Although the tuning curves of these neurons differ during unimanual and bimanual movement, changes in PD, but not changes in modulation depth, facilitate such reorganization. In addition, this reorganization was facilitated only when encoding PDs are rotated, but decoding PDs are not rotated. Bimanual movement facilitates reorganization because this movement changes neural activities through inter-hemispheric inhibition without changing cortical-spinal-muscle connections. Furthermore, stronger inter-hemispheric inhibition between motor cortices results in more effective reorganization. Thus, this study suggests that bimanual movement is effective for stroke rehabilitation because this movement rotates the encoding PDs of motor cortex neurons.	[Takiyama, Ken; Okada, Masato] Univ Tokyo, Dept Complex Sci & Engn, Grad Sch Frontier Sci, Chiba, Tokyo, Japan; [Okada, Masato] RIKEN, Brain Sci Inst, Wako, Saitama, Japan	University of Tokyo; RIKEN	Takiyama, K (corresponding author), Univ Tokyo, Dept Complex Sci & Engn, Grad Sch Frontier Sci, Chiba, Tokyo, Japan.	okada@k.u-tokyo.ac.jp	Takiyama, Ken/M-4526-2015	Takiyama, Ken/0000-0003-2252-7826	Japan Society for the Promotion of Science Fellows [10J04910]; Ministry of Education, Culture, Sports, Science, and Technology of Japan [20240020]	Japan Society for the Promotion of Science Fellows(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was partially supported by a Grant-in-Aid for Japan Society for the Promotion of Science Fellows (grant no. 10J04910) and a Grant-in-Aid for Scientific Research (A) (grant no. 20240020) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beer RF, 2004, EXP BRAIN RES, V156, P458, DOI 10.1007/s00221-003-1807-8; Cunningham CL, 2002, ACTA PSYCHOL, V110, P321, DOI 10.1016/S0001-6918(02)00040-9; Dobkin BH, 2004, LANCET NEUROL, V3, P528, DOI 10.1016/S1474-4422(04)00851-8; Donchin O, 2002, J NEUROPHYSIOL, V88, P3498, DOI 10.1152/jn.00335.2001; Ganguly K, 2009, J NEUROSCI, V29, P12948, DOI 10.1523/JNEUROSCI.2471-09.2009; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; Goodall S, 1997, STROKE, V28, P101, DOI 10.1161/01.STR.28.1.101; GOULD HJ, 1986, J COMP NEUROL, V247, P297, DOI 10.1002/cne.902470303; Grefkes C, 2011, BRAIN, P1; Guigon E, 2007, EUR J NEUROSCI, V26, P250, DOI 10.1111/j.1460-9568.2007.05634.x; Han CE, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000133; Latimer CP, 2010, DISABIL REHABIL, V32, P1221, DOI 10.3109/09638280903483877; Li CSR, 2001, NEURON, V30, P593, DOI 10.1016/S0896-6273(01)00301-4; LUKASHIN AV, 1994, NEURAL COMPUT, V6, P19, DOI 10.1162/neco.1994.6.1.19; Morrow MM, 2003, J NEUROPHYSIOL, V89, P2279, DOI 10.1152/jn.00632.2002; Mudie MH, 2000, DISABIL REHABIL, V22, P23, DOI 10.1080/096382800297097; Paz R, 2003, NAT NEUROSCI, V6, P882, DOI 10.1038/nn1097; Reinkensmeyer DJ, 2003, NEURAL COMPUT, V15, P2619, DOI 10.1162/089976603322385090; Rokni U, 2003, J NEUROSCI, V23, P11577; Rokni U, 2007, NEURON, V54, P653, DOI 10.1016/j.neuron.2007.04.030; Rose Dorian K, 2004, Top Stroke Rehabil, V11, P20, DOI 10.1310/XAUM-LPBM-0RXD-RLDK; Rouille EM, 1994, EXP BRAIN RES, P227; SALINAS E, 1995, J NEUROSCI, V15, P6461; Schmidt MF, 2003, J NEUROPHYSIOL, V90, P3931, DOI 10.1152/jn.00003.2003; Schweighofer N, 2009, PHYS THER, V89, P1327, DOI 10.2522/ptj.20080402; Steinberg O, 2002, EUR J NEUROSCI, V15, P1371, DOI 10.1046/j.1460-9568.2002.01968.x; Stevenson IH, 2011, J NEUROPHYSIOL; Taub E, 2002, NAT REV NEUROSCI, V3, P228, DOI 10.1038/nrn754; Todorov E, 2000, NAT NEUROSCI, V3, P391, DOI 10.1038/73964; Verstynen T, 2011, J NEUROSCI, V31, P10050, DOI 10.1523/JNEUROSCI.6525-10.2011	30	14	14	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 24	2012	7	5							e37594	10.1371/journal.pone.0037594	http://dx.doi.org/10.1371/journal.pone.0037594			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UB	22655060	Green Published, gold, Green Submitted			2023-01-03	WOS:000305338900036
J	Saias, T; Lerner, E; Greacen, T; Simon-Vernier, E; Emer, A; Pintaux, E; Guedeney, A; Dugravier, R; Tereno, S; Falissard, B; Tubach, F; Revah-Levy, A				Saias, Thomas; Lerner, Emilie; Greacen, Tim; Simon-Vernier, Elodie; Emer, Alessandra; Pintaux, Eleonore; Guedeney, Antoine; Dugravier, Romain; Tereno, Susana; Falissard, Bruno; Tubach, Florence; Revah-Levy, Anne		CAPEDP Study Grp	Evaluating Fidelity in Home-Visiting Programs a Qualitative Analysis of 1058 Home Visit Case Notes from 105 Families	PLOS ONE			English	Article							IMPLEMENTATION FIDELITY; YOUNG-CHILDREN; PREVENTION PROGRAM; INTERVENTION; ABUSE; OUTCOMES; VIOLENCE; NEGLECT	Objective: Implementation fidelity is a key issue in home-visiting programs as it determines a program's effectiveness in accomplishing its original goals. This paper seeks to evaluate fidelity in a 27-month program addressing maternal and child health which took place in France between 2006 and 2011. Method: To evaluate implementation fidelity, home visit case notes were analyzed using thematic qualitative and computer-assisted linguistic analyses. Results: During the prenatal period, home visitors focused on the social components of the program. Visitors discussed the physical changes in pregnancy, and psychological and social environment issues. Discussing immigration, unstable employment and financial related issues, family relationships and dynamics and maternity services, while not expected, were found in case notes. Conversely, health during pregnancy, early child development and postpartum mood changes were not identified as topics within the prenatal case notes. During the postnatal period, most components of the intervention were addressed: home visitors observed the mother's adaptation to the baby; routine themes such as psychological needs and medical-social networks were evaluated; information on the importance of social support and on adapting the home environment was given; home visitors counseled on parental authority, and addressed mothers' self-esteem issues; finally, they helped to find child care, when necessary. Some themes were not addressed or partially addressed: health education, child development, home environment, mother's education plans and personal routine, partner support and play with the child. Other themes were not expected, but found in the case notes: social issues, mother-family relationship, relation with services, couple issues, quality of maternal behavior and child's language development. Conclusions: In this program, home visitors experienced difficulties addressing some of the objectives because they gave precedence to the families" urgent needs. This research stresses the importance of training home visitors to adapt the intervention to the social, psychological and health needs of families.	[Saias, Thomas; Lerner, Emilie; Greacen, Tim; Emer, Alessandra] Etab Publ Sante Maison Blanche, Lab Rech, Paris, France; [Simon-Vernier, Elodie; Pintaux, Eleonore; Guedeney, Antoine; Dugravier, Romain; Tereno, Susana] Hop Bichat Claude Bernard, Serv Pedopsychiat, F-75877 Paris 18, France; [Guedeney, Antoine; Dugravier, Romain; Falissard, Bruno; Revah-Levy, Anne] Inst Natl Sante & Rech Med, PSIGIAM U669, Paris, France; [Tubach, Florence] Hop Bichat Claude Bernard, Unite Rech Clin Paris Nord, F-75877 Paris 18, France; [Saias, Thomas] Inst Natl Prevent & Educ Sante, St Denis, France; [Saias, Thomas] Univ Quebec, Dept Psychol, Montreal, PQ H3C 3P8, Canada; [Emer, Alessandra] Univ Trent, Labosdif, Rovereto, Italy; [Revah-Levy, Anne] Hop Argenteuil, Ctr Soins Psychotherapeut Transit Adolescents, Argenteuil, France; [Revah-Levy, Anne] Univ Paris 05, Univ Paris 11, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; University of Quebec; University of Quebec Montreal; University of Trento; UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay	Saias, T (corresponding author), Etab Publ Sante Maison Blanche, Lab Rech, Paris, France.	th.saias@gmail.com	; Purper-Ouakil, Diane/AAC-5024-2019	Tereno, Susana/0000-0001-5258-7913; Azria, Elie/0000-0002-6159-6253; Guedeney, Antoine/0000-0002-2346-4495; revah-levy, anne/0000-0003-1805-6275; Purper-Ouakil, Diane/0000-0003-0454-1579	National Ministry of Health Hospital Clinical Research Programme [PHRC AOM 05056]; National Institute for Promotion and Health Education; Clinical Research and Development Department of the APHP	National Ministry of Health Hospital Clinical Research Programme; National Institute for Promotion and Health Education; Clinical Research and Development Department of the APHP	The project was financed with a grant from the National Ministry of Health Hospital Clinical Research Programme (PHRC AOM 05056) and the National Institute for Promotion and Health Education. The sponsor was the Clinical Research and Development Department of the APHP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1969, ATTACHMENT LOSS ATTA; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Bilukha O, 2005, AM J PREV MED, V28, P11, DOI 10.1016/j.amepre.2004.10.004; Breitenstein SM, 2010, NURS RES, V59, P158, DOI 10.1097/NNR.0b013e3181dbb2e2; Breitenstein SM, 2010, RES NURS HEALTH, V33, P164, DOI 10.1002/nur.20373; Bronfenbrenner U, 1979, ECOLOGY HUMAN DEV EX; Center for Early Education and Development, 2009, STEPS EFF ENJ PAR ST; Corbin J.M., 2008, BASICS QUALITATIVE R, Vthird, DOI DOI 10.4135/9781452230153.N8; Durlak JA, 2008, AM J COMMUN PSYCHOL, V41, P327, DOI 10.1007/s10464-008-9165-0; Eames C, 2008, CHILD CARE HLTH DEV, V34, P391, DOI 10.1111/j.1365-2214.2008.00828.x; Fixsen D., 2005, IMPLEMENTATION RES S; Florida State University Center for Prevention and Early Intervention Policy, 2007, PARTN HLTH BAB HOM V; Geeraert L, 2004, CHILD MALTREATMENT, V9, P277, DOI 10.1177/1077559504264265; Glaster B. G., 1967, THEORETICAL SENSITIV; Gomby DS, 2007, CHILD ABUSE NEGLECT, V31, P793, DOI 10.1016/j.chiabu.2007.07.001; Gomby DS, 1999, FUTURE CHILD, V9, P4, DOI 10.2307/1602719; Gross D, 2001, FAM RELAT, V50, P246, DOI 10.1111/j.1741-3729.2001.00246.x; Guedeney A, 2011, CAPEDP RES REPORT; Gurlanick M, 1993, EARLY EDUC DEV, V4, P366; Hebbeler KM, 2002, EARLY CHILD RES Q, V17, P28, DOI 10.1016/S0885-2006(02)00128-X; Hiatt SW, 1997, J COMMUNITY PSYCHOL, V25, P77, DOI 10.1002/(SICI)1520-6629(199701)25:1<77::AID-JCOP6>3.0.CO;2-#; Howard KS, 2009, FUTURE CHILD, V19, P119, DOI 10.1353/foc.0.0032; Kahn J., 2010, WHAT WORKS HOME VISI; Kitzman HJ, 1997, J COMMUNITY PSYCHOL, V25, P95; Knoche LL, 2010, EARLY CHILD RES Q, V25, P299, DOI 10.1016/j.ecresq.2009.05.003; Lee CYS, 2008, PREV SCI, V9, P215, DOI 10.1007/s11121-008-0097-6; Lyons-Ruth K, 2004, J AM ACAD CHILD PSY, V43, P699, DOI 10.1097/01.chi.0000122730.72597.07; Mihalic SF, 2008, IMPLEMENT SCI, V3, DOI 10.1186/1748-5908-3-5; Olds D, 1997, J COMMUNITY PSYCHOL, V25, P9; Perepletchikova F, 2007, J CONSULT CLIN PSYCH, V75, P829, DOI 10.1037/0022-006X.75.6.829; Powers S, 1999, HOME VISITING REACHI; Reinert M, 2001, REV FRANCAISE PSYCHI, V5, P32; Spoth R, 2007, J FAM PSYCHOL, V21, P137, DOI 10.1037/0893-3200.21.2.137; Stevens J., 2005, J AGGRESS MALTREAT T, V11, P75, DOI DOI 10.1300/J146V11N04_04; Sweet MA, 2004, CHILD DEV, V75, P1435, DOI 10.1111/j.1467-8624.2004.00750.x; Tandon SD, 2008, EARLY CHILD RES Q, V23, P419, DOI 10.1016/j.ecresq.2008.02.002; Von Klitzing K, 2011, INT PERSPECTIVES CHI; Weatherston D., 2000, ZERO 3, V21, P3; Woolfolk T., 2009, FAM RELAT, V28, P188; Yang S, 2009, INT J LAW PSYCHIAT, V32, P294, DOI 10.1016/j.ijlp.2009.06.003	40	14	14	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2012	7	5							e36915	10.1371/journal.pone.0036915	http://dx.doi.org/10.1371/journal.pone.0036915			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	959VG	22629341	Green Published, gold, Green Submitted			2023-01-03	WOS:000305343500037
J	Johansson, R; Sjoberg, E; Sjogren, M; Johnsson, E; Carlbring, P; Andersson, T; Rousseau, A; Andersson, G				Johansson, Robert; Sjoberg, Elin; Sjogren, Magnus; Johnsson, Erik; Carlbring, Per; Andersson, Therese; Rousseau, Andreas; Andersson, Gerhard			Tailored vs. Standardized Internet-Based Cognitive Behavior Therapy for Depression and Comorbid Symptoms: A Randomized Controlled Trial	PLOS ONE			English	Article							MENTAL-DISORDERS; PRIMARY-CARE; SELF-HELP; ANXIETY; PSYCHOTHERAPY; METAANALYSIS; PREVALENCE; INVENTORY; SEVERITY; BURDEN	Background and Aims: Major depression can be treated by means of cognitive behavior therapy, delivered via the Internet as guided self-help. Individually tailored guided self-help treatments have shown promising results in the treatment of anxiety disorders. This randomized controlled trial tested the efficacy of an Internet-based individually tailored guided self-help treatment which specifically targeted depression with comorbid symptoms. The treatment was compared both to standardized (non-tailored) Internet-based treatment and to an active control group in the form of a monitored online discussion group. Both guided self-help treatments were based on cognitive behavior therapy and lasted for 10 weeks. The discussion group consisted of weekly discussion themes related to depression and the treatment of depression. Methods: A total of 121 participants with diagnosed major depressive disorder and with a range of comorbid symptoms were randomized to three groups. The tailored treatment consisted of a prescribed set of modules targeting depression as well as comorbid problems. The standardized treatment was a previously tested guided self-help program for depression. Results: From pre-treatment to post-treatment, both treatment groups improved on measures of depression, anxiety and quality of life. The results were maintained at a 6-month follow-up. Subgroup analyses showed that the tailored treatment was more effective than the standardized treatment among participants with higher levels of depression at baseline and more comorbidity, both in terms of reduction of depressive symptoms and on recovery rates. In the subgroup with lower baseline scores of depression, few differences were seen between treatments and the discussion group. Conclusions: This study shows that tailored Internet-based treatment for depression is effective and that addressing comorbidity by tailoring may be one way of making guided self-help treatments more effective than standardized approaches in the treatment of more severe depression.	[Johansson, Robert; Sjoberg, Elin; Sjogren, Magnus; Johnsson, Erik; Andersson, Therese; Andersson, Gerhard] Linkoping Univ, Dept Behav Sci & Learning, Linkoping, Sweden; [Carlbring, Per] Umea Univ, Dept Psychol, S-90187 Umea, Sweden; [Rousseau, Andreas] Linkoping Univ Hosp, Psychiat Clin, S-58185 Linkoping, Sweden; [Andersson, Gerhard] Linkoping Univ, Swedish Inst Disabil Res, Linkoping, Sweden; [Andersson, Gerhard] Karolinska Inst, Psychiat Sect, Dept Clin Neurosci, Stockholm, Sweden	Linkoping University; Umea University; Linkoping University; Linkoping University; Karolinska Institutet	Johansson, R (corresponding author), Linkoping Univ, Dept Behav Sci & Learning, Linkoping, Sweden.	robert.johansson@liu.se	Carlbring, Per/R-1220-2019; Carlbring, Per/D-3628-2009; Andersson, Gerhard/J-8529-2012	Carlbring, Per/0000-0002-2172-8813; Carlbring, Per/0000-0002-2172-8813; Andersson, Gerhard/0000-0003-4753-6745; Johansson, Robert/0000-0001-5547-3866	Swedish Research Council	Swedish Research Council(Swedish Research CouncilEuropean Commission)	The study was funded by a grant from the Swedish Research Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersson G, 2005, BRIT J PSYCHIAT, V187, P456, DOI 10.1192/bjp.187.5.456; Andersson Gerhard, 2011, Cognitive Behaviour Therapy, V40, P57, DOI 10.1080/16506073.2010.529457; Andersson G, 2009, BEHAV RES THER, V47, P175, DOI 10.1016/j.brat.2009.01.010; Andrews G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013196; Barlow DH, 2004, BEHAV THER, V35, P205, DOI 10.1016/S0005-7894(04)80036-4; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Beck A.T., 1996, MANUAL BDI 2, DOI [10.1037/t00742-000, DOI 10.1037/T00742-000]; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Borenstein M., 2009, INTRO META ANAL; Carlbring P, 2007, COMPUT HUM BEHAV, V23, P1421, DOI 10.1016/j.chb.2005.05.002; Carlbring P, 2011, BEHAV RES THER, V49, P18, DOI 10.1016/j.brat.2010.10.002; Cohen J., 2013, STAT POWER ANAL BEHA; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Cox BJ, 1996, BEHAV RES THER, V34, P949, DOI 10.1016/S0005-7967(96)00037-X; Cuijpers P, 2010, PSYCHOL MED, V40, P1943, DOI 10.1017/S0033291710000772; Cuijpers P, 2008, PSYCHOTHER RES, V18, P225, DOI 10.1080/10503300701442027; Cuijpers P, 2008, J CONSULT CLIN PSYCH, V76, P909, DOI 10.1037/a0013075; Dimidjian S, 2006, J CONSULT CLIN PSYCH, V74, P658, DOI 10.1037/0022-006X.74.4.658; Eskin M., 1996, INTRO SWEDISH VERSIO; First M.B., 1997, STRUCTURED CLIN INTE; Fournier JC, 2010, JAMA-J AM MED ASSOC, V303, P47, DOI 10.1001/jama.2009.1943; Frisch MB, 1992, PSYCHOL ASSESS, V4, P92, DOI 10.1037/1040-3590.4.1.92; Gueorguieva R, 2004, ARCH GEN PSYCHIAT, V61, P310, DOI 10.1001/archpsyc.61.3.310; Guy W., 1976, ECDEU ASSESSMENT MAN, P218, DOI DOI 10.1037/E591322011-001; Hollandare F, 2010, J MED INTERNET RES, V12, DOI 10.2196/jmir.1392; Houston TK, 2002, AM J PSYCHIAT, V159, P2062, DOI 10.1176/appi.ajp.159.12.2062; Kaldo V, 2008, BEHAV THER, V39, P348, DOI 10.1016/j.beth.2007.10.003; Kessler D, 2009, LANCET, V374, P628, DOI 10.1016/S0140-6736(09)61257-5; Kessler RC, 1997, J AFFECT DISORDERS, V45, P19, DOI 10.1016/S0165-0327(97)00056-6; Kessler RC, 2007, ANNU REV CLIN PSYCHO, V3, P137, DOI 10.1146/annurev.clinpsy.3.022806.091444; Kessler RC, 2009, EPIDEMIOL PSICHIAT S, V18, P23, DOI 10.1017/S1121189X00001421; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Meyer B, 2009, J MED INTERNET RES, V11, DOI 10.2196/jmir.1151; Persons J., 2008, CASE FORMULATION APP; Robinson E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010942; Silfvernagel K, J MED INTER IN PRESS; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Sturmey P., 2008, BEHAV CASE FORMULATI; SVANBORG P, 1994, ACTA PSYCHIAT SCAND, V89, P21, DOI 10.1111/j.1600-0447.1994.tb01480.x; Titov N, 2011, BEHAV RES THER, V49, P441, DOI 10.1016/j.brat.2011.03.007; Titov N, 2010, BEHAV RES THER, V48, P890, DOI 10.1016/j.brat.2010.05.014; Titov N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010939; Vernmark K, 2010, BEHAV RES THER, V48, P368, DOI 10.1016/j.brat.2010.01.005	43	185	186	0	47	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2012	7	5							e36905	10.1371/journal.pone.0036905	http://dx.doi.org/10.1371/journal.pone.0036905			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	959TM	22615841	Green Published, gold, Green Submitted			2023-01-03	WOS:000305336300049
J	van de Port, IGL; Wevers, LEG; Lindeman, E; Kwakkel, G				van de Port, Ingrid G. L.; Wevers, Lotte E. G.; Lindeman, Eline; Kwakkel, Gert			Effects of circuit training as alternative to usual physiotherapy after stroke: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							6-MINUTE WALK TEST; COMMUNITY AMBULATION; GAIT; IMPACT; REHABILITATION; SPEED; COMPETENCE; THERAPY; TIME	Objective To analyse the effect of task oriented circuit training compared with usual physiotherapy in terms of self reported walking competency for patients with stroke discharged from a rehabilitation centre to their own home. Design Randomised controlled trial with follow-up to 24 weeks. Setting Multicentre trial in nine outpatient rehabilitation centres in the Netherlands Participants Patients with stroke who were able to walk a minimum of 10 m without physical assistance and were discharged from inpatient rehabilitation to an outpatient rehabilitation clinic. Patients were randomly allocated to circuit training or usual physiotherapy, after stratification by rehabilitation centre, with an online randomisation procedure. Intervention Patients in the intervention group received circuit training in 90 minute sessions twice a week for 12 weeks. The training included eight different workstations in a gym and was intended to improve performance in tasks relating to walking competency. The control group received usual outpatient physiotherapy. Main outcome measures The primary outcome was the mobility domain of the stroke impact scale (SIS, version 3.0). Secondary outcomes were standing balance, self reported abilities, gait speed, walking distance, stair climbing, instrumental activities of daily living, fatigue, anxiety, and depression. Differences between groups were analysed according to the intention to treat principle. All outcomes were assessed by blinded observers in a repeated measurement design lasting 24 weeks. Results 126 patients were included in the circuit training group and 124 in the usual care group (control), with data from 125 and 117, respectively, available for analysis. One patient from the circuit training group and seven from the control group dropped out. Circuit training was a safe intervention, and no serious adverse events were reported. There were no significant differences between groups for the stroke impact scale mobility domain (beta=0.05 (SE 0.68), P=0.943) at 12 weeks. Circuit training was associated with significantly higher scores in terms of gait speed (0.09 m/s (SE 0.02), P<0.001), walking distance (20.0 m (SE 7.4), P=0.007), and modified stairs test (-1.6 s (SE 0.7), P=0.015). There were no significant differences between groups for the other secondary outcomes, except for the leisure domain of the Nottingham extended activities of daily living and the memory and thinking domain of the stroke impact scale. With the exception of gait speed (-0.04 m/s (SE 0.02), P=0.040), there were no significant differences between groups at follow-up. Conclusion Task oriented circuit training can safely replace usual physiotherapy for patients with stroke who are discharged from inpatient rehabilitation to the community and need further training in gait and gait related activities as an outpatient.	[van de Port, Ingrid G. L.; Wevers, Lotte E. G.; Lindeman, Eline; Kwakkel, Gert] Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, NL-3583 TM Utrecht, Netherlands; [van de Port, Ingrid G. L.; Wevers, Lotte E. G.; Lindeman, Eline; Kwakkel, Gert] Univ Med Ctr Utrecht, Ctr Excellence Rehabil Med, NL-3583 TM Utrecht, Netherlands; [van de Port, Ingrid G. L.; Wevers, Lotte E. G.; Lindeman, Eline; Kwakkel, Gert] Rehabil Ctr, NL-3583 TM Utrecht, Netherlands; [Kwakkel, Gert] Vrije Univ Amsterdam, Med Ctr, Res Inst MOVE, Dept Rehabil Med, NL-1081 HV Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Vrije Universiteit Amsterdam	Kwakkel, G (corresponding author), Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Hoogstr,Utrecht Rembrandtkade 10, NL-3583 TM Utrecht, Netherlands.	g.kwakkel@vumc.nl	sahely, ahmad/R-6293-2017	Kwakkel, Gert/0000-0002-4041-4043	Netherlands Organisation for Health Research and Development (ZonMw) [80-82310-98-08303]	Netherlands Organisation for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development)	This study was funded by the Netherlands Organisation for Health Research and Development (ZonMw), No 80-82310-98-08303.	Dickstein R, 2008, NEUROREHAB NEURAL RE, V22, P649, DOI [10.1177/15459683080220060201, 10.1177/1545968308315997]; Duncan PW, 2003, ARCH PHYS MED REHAB, V84, P950, DOI 10.1016/S0003-9993(03)00035-2; Duncan PW, 2002, STROKE, V33, P2593, DOI 10.1161/01.STR.0000034395.06874.3E; English C, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007513.pub2; French B, 2008, HEALTH TECHNOL ASSES, V12, P1; Fulk George D., 2008, Physiotherapy Theory and Practice, V24, P195, DOI 10.1080/09593980701588284; Gordon NF, 2004, STROKE, V35, P1230, DOI 10.1161/01.STR.0000127303.19261.19; Kollen B, 2006, ARCH PHYS MED REHAB, V87, P358, DOI 10.1016/j.apmr.2005.11.007; Kwakkel G, 2004, STROKE, V35, P2529, DOI 10.1161/01.STR.0000143153.76460.7d; Kwakkel G, 2006, STROKE, V37, P2348, DOI 10.1161/01.STR.0000238594.91938.1e; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Lloyd-Jones D, 2010, CIRCULATION, V121, P948, DOI 10.1161/CIRCULATIONAHA.109.192666; Lord SE, 2004, ARCH PHYS MED REHAB, V85, P234, DOI 10.1016/j.apmr.2003.05.002; McKevitt C, 2011, STROKE, V42, P1398, DOI 10.1161/STROKEAHA.110.598839; Mead GE, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004366.pub4; Outermans JC, 2010, CLIN REHABIL, V24, P979, DOI 10.1177/0269215509360647; Schmid A, 2007, STROKE, V38, P2096, DOI 10.1161/STROKEAHA.106.475921; Scott NW, 2002, CONTROL CLIN TRIALS, V23, P662, DOI 10.1016/S0197-2456(02)00242-8; Tilson JK, 2010, PHYS THER, V90, P196, DOI 10.2522/ptj.20090079; Twisk JWR, 2004, EUR J EPIDEMIOL, V19, P769, DOI 10.1023/B:EJEP.0000036572.00663.f2; van de Port IG, 2008, J REHABIL MED, V40, P23, DOI 10.2340/16501977-0114; van de Port IGL, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-43; Van Peppen RPS, 2004, CLIN REHABIL, V18, P833, DOI 10.1191/0269215504cr843oa; Veerbeek JM, 2011, STROKE, V42, P1482, DOI 10.1161/STROKEAHA.110.604090; Wevers L, 2009, STROKE, V40, P2450, DOI 10.1161/STROKEAHA.108.541946; Wevers LEG, 2011, J REHABIL MED, V43, P1027, DOI 10.2340/16501977-0881; Zedlitz AMEE, 2012, STROKE, V43, P1046, DOI 10.1161/STROKEAHA.111.632117	27	54	55	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 10	2012	344								e2672	10.1136/bmj.e2672	http://dx.doi.org/10.1136/bmj.e2672			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	942XR	22577186	Green Published, hybrid			2023-01-03	WOS:000304085400001
J	Deo, S; Topp, SM; Garcia, A; Soldner, M; Sokat, KY; Chipukuma, J; Wamulume, CS; Reid, SE; Swann, J				Deo, Sarang; Topp, Stephanie M.; Garcia, Ariel; Soldner, Mallory; Sokat, Kezban Yagci; Chipukuma, Julien; Wamulume, Chibesa S.; Reid, Stewart E.; Swann, Julie			Modeling the Impact of Integrating HIV and Outpatient Health Services on Patient Waiting Times in an Urban Health Clinic in Zambia	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY; GLOBAL HEALTH; SCALE-UP; CARE; AFRICA; PROGRAMS; LESSONS; MALAWI	Background: Rapid scale up of HIV treatment programs in sub-Saharan Africa has refueled the long-standing health policy debate regarding the merits and drawbacks of vertical and integrated system. Recent pilots of integrating outpatient and HIV services have shown an improvement in some patient outcomes but deterioration in waiting times, which can lead to worse health outcomes in the long run. Methods: A pilot intervention involving integration of outpatient and HIV services in an urban primary care facility in Lusaka, Zambia was studied. Data on waiting time of patients during two seven-day periods before and six months after the integration were collected using a time and motion study. Statistical tests were conducted to investigate whether the two observation periods differed in operational details such as staffing, patient arrival rates, mix of patients etc. A discrete event simulation model was constructed to facilitate a fair comparison of waiting times before and after integration. The simulation model was also used to develop alternative configurations of integration and to estimate the resulting waiting times. Results: Comparison of raw data showed that waiting times increased by 32% and 36% after integration for OPD and ART patients respectively (p<0.01). Using simulation modeling, we found that a large portion of this increase could be explained by changes in operational conditions before and after integration such as reduced staff availability (p<0.01) and longer breaks between consecutive patients (p<0.05). Controlling for these differences, integration of services, per se, would have resulted in a significant decrease in waiting times for OPD and a moderate decrease for HIV services. Conclusions: Integrating health services has the potential of reducing waiting times due to more efficient use of resources. However, one needs to ensure that other operational factors such as staff availability are not adversely affected due to integration.	[Deo, Sarang] Indian Sch Business Hyderbad, Hyderabad, Andhra Pradesh, India; [Topp, Stephanie M.; Chipukuma, Julien; Reid, Stewart E.] Ctr Infect Dis Res Zambia, Lusaka, Zambia; [Topp, Stephanie M.] Univ Melbourne, Nossal Inst Global Hlth, Melbourne, Vic, Australia; [Garcia, Ariel; Soldner, Mallory; Swann, Julie] Georgia Inst Technol Dept, Stewart Sch Ind & Syst Engn, Atlanta, GA USA; [Sokat, Kezban Yagci] Northwestern Univ, Evanston, IL USA; [Wamulume, Chibesa S.] Lusaka Hlth Dist, Lusaka, Zambia; [Topp, Stephanie M.; Reid, Stewart E.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA	Indian School of Business (ISB); University of Melbourne; Northwestern University; University of Alabama System; University of Alabama Birmingham	Deo, S (corresponding author), Indian Sch Business Hyderbad, Hyderabad, Andhra Pradesh, India.	sarang_deo@isb.edu	Topp, Stephanie M/H-3923-2019; Deo, Sarang/B-5895-2015	Topp, Stephanie M/0000-0002-3448-7983; Deo, Sarang/0000-0002-3233-6014; Reid, Stewart/0000-0001-7779-4820; Swann, Julie/0000-0003-2151-4396	U.S. Department of Health and Human Services; Centers for Disease Control and Prevention [U62/.CCU12354]	U.S. Department of Health and Human Services; Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	The work reported herein was supported in part by the President's Emergency Plan for AIDS Relief through a multi-country grant to the Elizabeth Glaser Pediatric AIDS Foundation from the U.S. Department of Health and Human Services and Centers for Disease Control and Prevention's Global AIDS Program (cooperative agreement U62/.CCU12354). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Atun RA, 2008, HLTH SYSTEMS POLICY; Bedelu M, 2007, J INFECT DIS, V196, pS464, DOI 10.1086/521114; Bleich SN, 2009, B WORLD HEALTH ORGAN, V87, P271, DOI 10.2471/BLT.07.050401; Brugha R, 2010, HUM RESOUR HEALTH, V8, DOI 10.1186/1478-4491-8-19; Colebunders R, 2007, AIDS CARE, V19, P149, DOI 10.1080/09540120600762078; Doherty T, 2010, TROP MED INT HEALTH, V15, P296, DOI 10.1111/j.1365-3156.2009.02454.x; England R, 2007, BRIT MED J; England R, 2007, BRIT MED J, V335, P565, DOI 10.1136/bmj.39335.520463.94; Ferradini L, 2006, LANCET, V367, P1335, DOI 10.1016/S0140-6736(06)68580-2; Frenk J, 2006, BRIDGING DIVIDE COMP; Garrett L, 2007, FOREIGN AFF, V86, P14; Hardon AP, 2007, AIDS CARE, V19, P658, DOI 10.1080/09540120701244943; Harris JB, 2008, INT J TUBERC LUNG D, V12, P773; Lawn JE, 2008, LANCET, V372, P917, DOI 10.1016/S0140-6736(08)61402-6; Levine R, 2009, JAIDS-J ACQ IMM DEF, V52, pS3, DOI 10.1097/QAI.0b013e3181bbc807; Pfeiffer J, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-3; Price JE, 2009, AIDS CARE, V21, P608, DOI 10.1080/09540120802310957; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Shumbusho F, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000163; Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782; Topp SM, 2011, B WORLD HEALTH ORGAN, V89, P328, DOI 10.2471/BLT.10.084442; Topp SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011522; Wagner G, 2007, AIDS PATIENT CARE ST, V21, P871, DOI 10.1089/apc.2007.0008; World Health Organization, 2010, UN ACC SCAL PRIOR HI	24	25	25	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2012	7	4							e35479	10.1371/journal.pone.0035479	http://dx.doi.org/10.1371/journal.pone.0035479			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	959UP	22545108	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000305341000039
J	Ayele, K; Tesfa, B; Abebe, L; Tilahun, T; Girma, E				Ayele, Ketema; Tesfa, Bisrat; Abebe, Lakew; Tilahun, Tizta; Girma, Eshetu			Self Care Behavior among Patients with Diabetes in Harari, Eastern Ethiopia: The Health Belief Model Perspective	PLOS ONE			English	Article								Background: Diabetes mellitus is a chronic disease that requires lifelong medical treatments and a life style adjustment. To prevent serious morbidity and mortality, it requires dedication to demanding self-care behaviors in multiple domains. The objective of this study was to identify predictors of self care behaviors among patients with diabetes. Methods: From a total of 425 follow up diabetic patients, a quantitative cross sectional study was conducted among 222 of them from three different hospitals in Harar town, from March to April, 2011. The sample was taken using simple random sampling method. Data was collected using pretested questionnaire. Descriptive statistics multiple logistic regression analysis were also used to assess the predicators of self care behaviors among patients with diabetes. Result: Majority of the study respondents 134 (60.4%) were female and the mean age was 49.7 (SD +/- 14.7) years. More than half 147(66.2%) of them were medically diagnosed with type-2 diabetes. 208(93.7%) had general knowledge about diabetes and specific knowledge about diabetes self care 207(93.2%). Large proportion of them had moderate perceived susceptibility 174(78.4%) and severity 112(50.5%). More than half of the respondents 149(67.1%) had less perceived barrier while only 30 (13.5%) of them had high self efficacy to self care practices related to diabetes mellitus. Only 87(39.2%) followed the recommended self care practices on diabetes. Conclusions: Patients with less frequent information were less likely to take diabetes self care. Patients who were more educated, middle income, had high perceived severity of diabetes and less perceived barrier to self care were more likely to take diabetes self care. To increase the self care behavior, diabetes messages should focus on severity of diabetes and how to overcome barriers for self care by segmenting the audiences based on income and educational status with increasing the frequency and reach of message on diabetes.	[Ayele, Ketema] Harar Hlth Sci Coll, Harai, Ethiopia; [Tesfa, Bisrat; Abebe, Lakew; Girma, Eshetu] Jimma Univ, Dept Hlth Educ & Behav Sci, Jimma, Ethiopia; [Tilahun, Tizta] Jimma Univ, Dept Populat & Family Hlth, Jimma, Ethiopia	Jimma University; Jimma University	Ayele, K (corresponding author), Harar Hlth Sci Coll, Harai, Ethiopia.	grm_sht@yahoo.com	Tilahun, Tizta/K-7468-2017	Tilahun, Tizta/0000-0002-3842-9844	Jimma University	Jimma University	This study was funded by Jimma University. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abduelkarem A, CHANGES SOME HLTH IN; Aburuz SM, 2002, INT J PHARM PRACTICE, V10S, P96; Adibe O, 2009, INT J DRUG DEV RES, V1, P85; Bahru Y, 2009, ASSESSMENT DIABETES; Ben Abdelaziz Ahmed, 2006, Tunis Med, V84, P415; Brooke L, 2008, ENV FACTORS DIABETES; Deshmukh S, 2000, INT J DIAB DEV COUNT, V20; Diabetes Monitor, 2005, DIAB MON INF ED SUPP; Elizabeth R, DIABETES SELF CARE A; Julia L, 2010, AUST PRESCR, V33, P138; Katie W, 2005, DIABETES CARE, V28, P1346; Khattab M, 2010, J DIABETES COMPLICAT, V24, P84, DOI 10.1016/j.jdiacomp.2008.12.008; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Lefebvre C., 1998, HLTH ED Q, V15, P299; LESTER FT, 1991, DIABETIC MED, V8, P272, DOI 10.1111/j.1464-5491.1991.tb01585.x; Levetan C, 2003, DIABETES CARE, V26, P1, DOI 10.2337/diacare.26.1.1; Morowati A, 2009, DANESHVAR MED, V16, P81; Okolie VU, 2009, INT J MED MED SCI, V1, P353; Peyrot M, 2005, DIABETIC MED, V22, P1379, DOI 10.1111/j.1464-5491.2005.01644.x; Rachel G, 2006, BRIT J HEALTH PSYCH, V11, P155; Rosenstock M, 1988, HLTH ED Q, V15, P175; Sigurthardottir AK, 2005, J CLIN NURS, V14, P301, DOI 10.1111/j.1365-2702.2004.01043.x; Tan M, 2009, SELF CARE PRACTICES; Venkat N, 2003, DIABETES PANDEMIC PO; *WHO, 2003, DIAB EST PROJ; World Health Organization, 2005, RES HLTH ACT CRIS DI; Yeweyenhareg Feleke, 2005, Ethiopian Journal of Health Development, V19, P203	27	99	103	1	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2012	7	4							e35515	10.1371/journal.pone.0035515	http://dx.doi.org/10.1371/journal.pone.0035515			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959WC	22530039	Green Published, gold, Green Submitted			2023-01-03	WOS:000305347400057
J	Lau, BWM; Lee, JCD; Li, Y; Fung, SMY; Sang, YH; Shen, JG; Chang, RCC; So, KF				Lau, Benson Wui-Man; Lee, Jada Chia-Di; Li, Yue; Fung, Sophia Man-Yuk; Sang, Yan-Hua; Shen, Jiangang; Chang, Raymond Chuen-Chung; So, Kwok-Fai			Polysaccharides from Wolfberry Prevents Corticosterone-Induced Inhibition of Sexual Behavior and Increases Neurogenesis	PLOS ONE			English	Article							LYCIUM-BARBARUM POLYSACCHARIDES; RETINAL GANGLION-CELLS; POSTNATAL NEUROGENESIS; INDUCED DAMAGE; EXPOSURE; PROLIFERATION; MEDICINE; BRAIN	Lycium barbarum, commonly known as wolfberry, has been used as a traditional Chinese medicine for the treatment of infertility and sexual dysfunction. However, there is still a scarcity of experimental evidence to support the pro-sexual effect of wolfberry. The aim of this study is to determine the effect of Lycium barbarum polysaccharides (LBP) on male sexual behavior of rats. Here we report that oral feeding of LBP for 21 days significantly improved the male copulatory performance including increase of copulatory efficiency, increase of ejaculation frequency and shortening of ejaculation latency. Furthermore, sexual inhibition caused by chronic corticosterone was prevented by LBP. Simultaneously, corticosterone suppressed neurogenesis in subventricular zone and hippocampus in adult rats, which could be reversed by LBP. The neurogenic effect of LBP was also shown in vitro. Significant correlation was found between neurogenesis and sexual performance, suggesting that the newborn neurons are associated with reproductive successfulness. Blocking neurogenesis in male rats abolished the pro-sexual effect of LBP. Taken together, these results demonstrate the pro-sexual effect of LBP on normal and sexually-inhibited rats, and LBP may modulate sexual behavior by regulating neurogenesis.	[Lau, Benson Wui-Man; Lee, Jada Chia-Di; Fung, Sophia Man-Yuk; Sang, Yan-Hua; Chang, Raymond Chuen-Chung; So, Kwok-Fai] Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, Pokfulam, Hong Kong, Peoples R China; [Lau, Benson Wui-Man; Lee, Jada Chia-Di; Chang, Raymond Chuen-Chung; So, Kwok-Fai] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Pokfulam, Hong Kong, Peoples R China; [Lau, Benson Wui-Man; Lee, Jada Chia-Di; Li, Yue; Shen, Jiangang; Chang, Raymond Chuen-Chung; So, Kwok-Fai] Univ Hong Kong, Fac Med, Res Ctr Heart Brain Hormone & Hth Aging, Pokfulam, Hong Kong, Peoples R China; [Li, Yue; Shen, Jiangang] Univ Hong Kong, Sch Chinese Med, Hong Kong, Hong Kong, Peoples R China; [Chang, Raymond Chuen-Chung] Univ Hong Kong, LKS Fac Med, Dept Anat, Lab Neurodegenerat Dis, Pokfulam, Hong Kong, Peoples R China; [So, Kwok-Fai] Univ Hong Kong, Guangzhou, Guangdong, Peoples R China; [So, Kwok-Fai] Jinan Univ, Joint Lab Brain Funct & Hlth BFAH, Guangzhou, Guangdong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong; Jinan University	Lau, BWM (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, Pokfulam, Hong Kong, Peoples R China.	hrmaskf@hkucc.hku.hk	Li, Kevin/AAX-1664-2020; Chang, Raymond Chuen-Chung/C-1107-2009	Li, Kevin/0000-0001-8198-9911; Chang, Raymond Chuen-Chung/0000-0001-8538-7993; LAU, Wui Man/0000-0002-4552-2780; So, Kwok-Fai/0000-0003-4039-4246	Azalea Endowment Fund; University of Hong Kong Alzheimer's Disease Research Network under Strategic Research Theme on Healthy Aging; Fundamental Research Funds for the Central Universities [09ykpy25, 09ykpy31]	Azalea Endowment Fund; University of Hong Kong Alzheimer's Disease Research Network under Strategic Research Theme on Healthy Aging; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This study was supported by the Azalea (1972) Endowment Fund, the University of Hong Kong Alzheimer's Disease Research Network under Strategic Research Theme on Healthy Aging and the Fundamental Research Funds for the Central Universities, no. 09ykpy25, 09ykpy31. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Amagase H, 2009, NUTR RES, V29, P19, DOI 10.1016/j.nutres.2008.11.005; Amstislavskaya TG, 2010, PHARMACOL BIOCHEM BE, V96, P211, DOI 10.1016/j.pbb.2010.05.007; Chan HC, 2007, EXP NEUROL, V203, P269, DOI 10.1016/j.expneurol.2006.05.031; Chang RCC, 2008, CELL MOL NEUROBIOL, V28, P643, DOI 10.1007/s10571-007-9181-x; Chen LP, 2011, NEURAL REGEN RES, V6, P1618, DOI 10.3969/j.issn.1673-5374.2011.21.003; Chen X, 2010, NEUROSCIENCE, V165, P705, DOI 10.1016/j.neuroscience.2009.11.007; Chiu K, 2010, J CELL BIOCHEM, V110, P311, DOI 10.1002/jcb.22539; DAS GD, 1971, BRAIN RES, V30, P323, DOI 10.1016/0006-8993(71)90082-5; DAS GD, 1970, BRAIN RES, V21, P122, DOI 10.1016/0006-8993(70)90026-0; Deng HB, 2003, BIOMED ENVIRON SCI, V16, P267; EVERITT BJ, 1990, NEUROSCI BIOBEHAV R, V14, P217, DOI 10.1016/S0149-7634(05)80222-2; Gan L, 2003, EUR J PHARMACOL, V471, P217, DOI 10.1016/S0014-2999(03)01827-2; Gheusi G, 2009, BEHAV BRAIN RES, V200, P315, DOI 10.1016/j.bbr.2009.02.006; Hawken PAR, 2009, BIOL REPROD, V80, P1146, DOI 10.1095/biolreprod.108.075341; Ho YS, 2007, BRAIN RES, V1158, P123, DOI 10.1016/j.brainres.2007.04.075; Ho YS, 2010, AGEING RES REV, V9, P354, DOI 10.1016/j.arr.2009.10.001; Ho YS, 2009, CELL MOL NEUROBIOL, V29, P1233, DOI 10.1007/s10571-009-9419-x; Huang LY, 2002, HORM BEHAV, V41, P343, DOI 10.1006/hbeh.2002.1767; Lau BWM, 2009, NEUROREPORT, V20, P371, DOI 10.1097/WNR.0b013e328324edcd; Lau BWM, 2011, J SEX MED, V8, P1390, DOI 10.1111/j.1743-6109.2010.02081.x; Lau BWM, 2011, CELL TRANSPLANT, V20, P21, DOI 10.3727/096368910X532765; Lau BW, 2010, CELL TRANSPLANT; Lee SH, 2011, NEURAL REGEN RES, V6, P2085, DOI 10.3969/j.issn.1673-5374.2011.27.001; Leuner B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011597; Li M, 2011, CHEMBIOCHEM, V12, P449, DOI 10.1002/cbic.201000570; Li SY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016380; Luo Q, 2006, LIFE SCI, V79, P613, DOI 10.1016/j.lfs.2006.02.012; Luo Q, 2011, PHYTOTHER RES, V25, P694, DOI 10.1002/ptr.3314; Mak GK, 2007, NAT NEUROSCI, V10, P1003, DOI 10.1038/nn1928; Niu AJ, 2008, INT J BIOL MACROMOL, V42, P447, DOI 10.1016/j.ijbiomac.2008.02.003; Slotnick B, 2001, TRENDS COGN SCI, V5, P216, DOI 10.1016/S1364-6613(00)01625-9; Smith MT, 2001, HORM BEHAV, V39, P11, DOI 10.1006/hbeh.2000.1630; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; Wang YR, 2002, J ETHNOPHARMACOL, V82, P169, DOI 10.1016/S0378-8741(02)00169-1; Wen Jing, 2010, Zhongguo Zhong Xi Yi Jie He Za Zhi, V30, P295; Yau SY, 2011, NEURAL REGEN RES, V6, P2645, DOI 10.3969/j.issn.1673-5374.2011.34.001; Yu MS, 2005, EXP GERONTOL, V40, P716, DOI 10.1016/j.exger.2005.06.010	38	44	45	0	48	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2012	7	4							e33374	10.1371/journal.pone.0033374	http://dx.doi.org/10.1371/journal.pone.0033374			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959VO	22523540	Green Published, gold			2023-01-03	WOS:000305345000009
J	Son, S; Kang, AR; Kim, HC; Kwon, T; Park, J; Kim, HK				Son, Seokshin; Kang, Ah Reum; Kim, Hyun-chul; Kwon, Taekyoung; Park, Juyong; Kim, Huy Kang			Analysis of Context Dependence in Social Interaction Networks of a Massively Multiplayer Online Role-Playing Game	PLOS ONE			English	Article								Rapid advances in modern computing and information technology have enabled millions of people to interact online via various social network and gaming services. The widespread adoption of such online services have made possible analysis of large-scale archival data containing detailed human interactions, presenting a very promising opportunity to understand the rich and complex human behavior. In collaboration with a leading global provider of Massively Multiplayer Online Role-Playing Games (MMORPGs), here we present a network science-based analysis of the interplay between distinct types of user interaction networks in the virtual world. We find that their properties depend critically on the nature of the context-interdependence of the interactions, highlighting the complex and multilayered nature of human interactions, a robust understanding of which we believe may prove instrumental in the designing of more realistic future virtual arenas as well as provide novel insights to the science of collective human behavior.	[Son, Seokshin] Seoul Natl Univ, Multimedia & Mobile Commun Lab, Sch Comp Sci & Engn, Seoul, South Korea; [Kang, Ah Reum; Kim, Huy Kang] Korea Univ, Grad Sch Informat Secur, Seoul, South Korea; [Kim, Hyun-chul] Sangmyung Univ, Dept Comp Software Engn, Cheonan, South Korea; [Kwon, Taekyoung; Park, Juyong] Kyung Hee Univ, Dept Phys, Seoul, South Korea	Seoul National University (SNU); Korea University; Sang Myung University; Kyung Hee University	Son, S (corresponding author), Seoul Natl Univ, Multimedia & Mobile Commun Lab, Sch Comp Sci & Engn, Seoul, South Korea.	perturbation@gmail.com; cenda@korea.ac.kr	Park, Juyong/I-2290-2012; Kim, Huy Kang/R-5779-2016	Kim, Huy Kang/0000-0002-0760-8807; Kang, Ah Reum/0000-0002-0732-5313	Kyung Hee University [KHU-20110088]; National Research Foundation of Korea [KRF-20110005409]; Ministry of Knowledge Economy of Korea [NIPA-2012-C1090-1101-0004]; NAP of Korean Research Council of Fundamental Science and Technology	Kyung Hee University; National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Knowledge Economy of Korea(Ministry of Trade, Industry & Energy (MOTIE), Republic of Korea); NAP of Korean Research Council of Fundamental Science and Technology	Funding provided by Kyung Hee University (www.khu.ac.kr): KHU-20110088, National Research Foundation of Korea (www.nrf.re.kr) KRF-20110005409, Ministry of Knowledge Economy of Korea (www.mke.go.kr) NIPA-2012-C1090-1101-0004 and NAP of Korean Research Council of Fundamental Science and Technology (http://www.fif.kr/home.php). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahnert SE, 2008, PHYS REV E, V78, DOI 10.1103/PhysRevE.78.036112; Albert R, 2002, REV MOD PHYS, V74, P47, DOI 10.1103/RevModPhys.74.47; [Anonymous], 2008, NATURE, V455, P1, DOI 10.1038/455001a; Cook K. S., 1991, MACROMICRO LINKAGES, P29; COOK KS, 1983, AM J SOCIOL, V89, P275, DOI 10.1086/227866; COOK KS, 1984, RES SOCIOLOGY ORG, V3, P1; Fortunato S, 2010, PHYS REP, V486, P75, DOI 10.1016/j.physrep.2009.11.002; Kang A, 2011, ADV COMP SC IN PRESS; Kwak H, 2009, IMC'09: PROCEEDINGS OF THE 2009 ACM SIGCOMM INTERNET MEASUREMENT CONFERENCE, P301; Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824; Newman M.E.J., 2010, NETWORKS INTRO OXFOR; Newman MEJ, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.036122; Newman MEJ, 2003, SIAM REV, V45, P167, DOI 10.1137/S003614450342480; Onnela JP, 2007, P NATL ACAD SCI USA, V104, P7332, DOI 10.1073/pnas.0610245104; Park JY, 2007, P NATL ACAD SCI USA, V104, P17916, DOI 10.1073/pnas.0705081104; Son S, 2011, ACM SIGCOMM COMP COM, V41, P414, DOI 10.1145/2043164.2018496; Szell M, 2010, SOC NETWORKS, V32, P313, DOI 10.1016/j.socnet.2010.06.001; Szell M, 2010, P NATL ACAD SCI USA, V107, P13636, DOI 10.1073/pnas.1004008107; Wasserman S, 1994, SOCIAL NETWORK ANAL	19	21	21	1	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2012	7	4							e33918	10.1371/journal.pone.0033918	http://dx.doi.org/10.1371/journal.pone.0033918			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	953GO	22496771	Green Submitted, gold, Green Published			2023-01-03	WOS:000304855200025
J	Law, ME; Corsino, PE; Jahn, SC; Davis, BJ; Chen, S; Patel, B; Pham, K; Lu, J; Sheppard, B; Norgaard, P; Hong, J; Higgins, P; Kim, JS; Luesch, H; Law, BK				Law, M. E.; Corsino, P. E.; Jahn, S. C.; Davis, B. J.; Chen, S.; Patel, B.; Pham, K.; Lu, J.; Sheppard, B.; Norgaard, P.; Hong, J.; Higgins, P.; Kim, J-S; Luesch, H.; Law, B. K.			Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms	ONCOGENE			English	Article						E-cadherin; breast cancer; invasion; glucocorticoid; HDAC inhibitor; PAI-1	DOMAIN-CONTAINING PROTEIN-1; EPITHELIAL TUMOR-CELLS; E-CADHERIN; TYROSINE PHOSPHORYLATION; BETA-CATENIN; BIOLOGICAL SIGNIFICANCE; ADHERENS JUNCTIONS; LOBULAR CARCINOMA; STATISTICAL-MODEL; DOWN-REGULATION	Aggressive cancers often express E-cadherin in cytoplasmic vesicles rather than on the plasma membrane and this may contribute to the invasive phenotype of these tumors. Therapeutic strategies are not currently available that restore the anti-invasive function of E-cadherin in cancers. MDA-MB-231 cells are a frequently used model of invasive triple-negative breast cancer, and these cells express low levels of E-cadherin that is mislocalized to cytoplasmic vesicles. MDA-MB-231 cell lines stably expressing wild-type E-cadherin or E-cadherin fused to glutathione S-transferase or green fluorescent protein were used as experimental systems to probe the mechanisms responsible for cytoplasmic E-cadherin localization in invasive cancers. Although E-cadherin expression partly reduced cell invasion in vitro, E-cadherin was largely localized to the cytoplasm and did not block the invasiveness of the corresponding orthotopic xenograft tumors. Further studies indicated that the glucocorticoid dexamethasone and the highly potent class I histone deacetylase (HDAC) inhibitor largazole cooperated to induce E-cadherin localization to the plasma membrane in triple-negative breast cancers, and to suppress cellular invasion in vitro. Dexamethasone blocked the production of the cleaved form of the CDCP1 (that is, CUB domain-containing protein 1) protein (cCDCP1) previously implicated in the pro-invasive activities of CDCP1 by upregulating the serine protease inhibitor plasminogen activator inhibitor-1. E-cadherin preferentially associated with cCDCP1 compared with the full-length form. In contrast, largazole did not influence CDCP1 cleavage, but increased the association of E-cadherin with gamma-catenin. This effect on E-cadherin/gamma-catenin complexes was shared with the nonisoform selective HDAC inhibitors trichostatin A (TSA) and vorinostat (suberoylanilide hydroxamic acid, SAHA), although largazole upregulated endogenous E-cadherin levels more strongly than TSA. These results demonstrate that glucocorticoids and HDAC inhibitors, both of which are currently in clinical use, cooperate to suppress the invasiveness of breast cancer cells through novel, complementary mechanisms that converge on E-cadherin. Oncogene (2013) 32, 1316-1329; doi:10.1038/onc.2012.138; published online 30 April 2012	[Law, M. E.; Corsino, P. E.; Jahn, S. C.; Davis, B. J.; Pham, K.; Kim, J-S; Law, B. K.] Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA; [Law, M. E.; Corsino, P. E.; Jahn, S. C.; Davis, B. J.; Patel, B.; Pham, K.; Lu, J.; Kim, J-S; Luesch, H.; Law, B. K.] Univ Florida, UF & Shands Canc Ctr, Gainesville, FL 32610 USA; [Chen, S.] Univ Florida, Dept Biol, Gainesville, FL 32610 USA; [Patel, B.; Lu, J.] Univ Florida, Dept Biochem, Gainesville, FL 32610 USA; [Sheppard, B.] Univ Florida, Dept Infect Dis & Pathol, Gainesville, FL 32610 USA; [Norgaard, P.] Univ Copenhagen, Herlev Hosp, Dept Pathol, DK-2730 Herlev, Denmark; [Hong, J.] Duke Univ, Dept Chem, Durham, NC 27706 USA; [Higgins, P.] Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; [Kim, J-S] Univ Florida, Dept Surg, Gainesville, FL 32610 USA; [Luesch, H.] Univ Florida, Dept Med Chem, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Copenhagen; Herlev & Gentofte Hospital; Duke University; Albany Medical College; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Law, BK (corresponding author), Univ Florida, Dept Pharmacol & Therapeut, 1600 SW Archer Rd,Acad Res Bldg,Room R5-210,POB 1, Gainesville, FL 32610 USA.	bklaw@pharmacology.ufl.edu	Law, Brian/L-6043-2019; Lu, Jianrong/F-5240-2013	Lu, Jianrong/0000-0002-4969-6040	Komen for the Cure grant [KG080510]; Florida Department of Health [07BB-8, 09BB-10]; NIH [R01CA138544, DK079879, GM057242]; NATIONAL CANCER INSTITUTE [R01CA138544, R01CA093651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK090115, R01DK079879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057242] Funding Source: NIH RePORTER	Komen for the Cure grant; Florida Department of Health; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Al Reynolds, Vanderbilt University, Nashville, TN for generously providing the E-cadherin/LZRS and pMS vectors and for instruction regarding their use. The Proteomics Division at the Interdisciplinary Center for Biotechnology Research (ICBR) (http://www.biotech.ufl.edu/proteomics/) is acknowledged for the mass spectrometry analysis. This work was supported in part by Komen for the Cure grant KG080510 and Florida Department of Health grants 07BB-8 and 09BB-10 to B Law, and NIH grants R01CA138544 (H Luesch and J Hong), DK079879 (J-S Kim), and GM057242 (PJ Higgins).	Baum B, 2011, J CELL BIOL, V192, P907, DOI 10.1083/jcb.201009141; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Benes CH, 2012, ONCOGENE, V31, P653, DOI 10.1038/onc.2011.262; Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Bhatt AS, 2005, ONCOGENE, V24, P5333, DOI 10.1038/sj.onc.1208582; Boulos F, 2011, AM J SURG PATHOL, V35, P154, DOI 10.1097/PAS.0b013e3182028f79; Brown TA, 2004, J BIOL CHEM, V279, P14772, DOI 10.1074/jbc.M309678200; BUSE P, 1995, J BIOL CHEM, V270, P28223; BUSSO N, 1987, CANCER RES, V47, P364; Casar B, 2012, ONCOGENE, V31, P3924, DOI 10.1038/onc.2011.555; Chytil A, 2004, J BIOL CHEM, V279, P47688, DOI 10.1074/jbc.M405938200; Cole KE, 2011, J AM CHEM SOC, V133, P12474, DOI 10.1021/ja205972n; Corsino PE, 2008, NEOPLASIA, V10, P1240, DOI 10.1593/neo.08710; Cowin P, 2005, CURR OPIN CELL BIOL, V17, P499, DOI 10.1016/j.ceb.2005.08.014; Daniel JM, 2007, BBA-MOL CELL RES, V1773, P59, DOI 10.1016/j.bbamcr.2006.08.052; Dawson S J, 2009, Eur J Cancer, V45 Suppl 1, P27, DOI 10.1016/S0959-8049(09)70013-9; Facina G, 2010, DIAGN CYTOPATHOL, V38, P235, DOI 10.1002/dc.21181; Feltes CM, 2002, CANCER RES, V62, P6688; Gomez-Hernandez J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-692; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; He Y, 2010, J BIOL CHEM, V285, P26162, DOI 10.1074/jbc.M109.096453; Heuberger J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002915; Hiscox S, 1999, BIOCHEM BIOPH RES CO, V261, P406, DOI 10.1006/bbrc.1999.1002; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Law BK, 2002, MOL CELL BIOL, V22, P8184, DOI 10.1128/MCB.22.23.8184-8198.2002; Law M, 2006, CANCER RES, V66, P1070, DOI 10.1158/0008-5472.CAN-05-1672; Levy L, 2004, MOL CELL BIOL, V24, P3404, DOI 10.1128/MCB.24.8.3404-3414.2004; Lewis JE, 1997, J CELL BIOL, V136, P919, DOI 10.1083/jcb.136.4.919; Liu H, 2011, P NATL ACAD SCI USA, V108, P1379, DOI 10.1073/pnas.1017228108; Liu YX, 2010, J PHARMACOL EXP THER, V335, P351, DOI 10.1124/jpet.110.172387; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; Meyers MO, 2011, ANN SURG ONCOL, V18, P2851, DOI 10.1245/s10434-011-1665-8; Miyagawa R, 2010, CORONARY ARTERY DIS, V21, P144, DOI 10.1097/MCA.0b013e328335790e; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; NORDT TK, 1995, CIRCULATION, V91, P764, DOI 10.1161/01.CIR.91.3.764; Ou JN, 2007, BIOCHEM PHARMACOL, V73, P1297, DOI 10.1016/j.bcp.2006.12.032; Pan D, 2011, CANCER RES, V71, P6360, DOI 10.1158/0008-5472.CAN-11-0362; Papageorgis P, 2010, CANCER RES, V70, P968, DOI 10.1158/0008-5472.CAN-09-1872; Pazaiti A, 2011, WOMENS HEALTH, V7, P181, DOI [10.2217/whe.11.5, 10.2217/WHE.11.5]; Pishvaian MJ, 1999, CANCER RES, V59, P947; Querzoli P, 2010, BRIT J CANCER, V103, P1835, DOI 10.1038/sj.bjc.6605991; Rakha EA, 2010, AM J SURG PATHOL, V34, P1472, DOI 10.1097/PAS.0b013e3181f01916; Rubenstein NM, 2003, J BIOL CHEM, V278, P10353, DOI 10.1074/jbc.M213121200; Sheffield J, 2006, PROTEOMICS, V6, P1588, DOI 10.1002/pmic.200500503; Singh R, 2009, EXP CELL RES, V315, P2899, DOI 10.1016/j.yexcr.2009.07.002; Smith AL, 2012, MOL BIOL CELL, V23, P99, DOI 10.1091/mbc.E11-06-0497; Swift S, 2001, Curr Protoc Immunol, VChapter 10, DOI 10.1002/0471142735.im1017cs31; Taori K, 2008, J AM CHEM SOC, V130, P1806, DOI 10.1021/ja7110064; Uekita T, 2008, AM J PATHOL, V172, P1729, DOI 10.2353/ajpath.2008.070981; Voduc KD, 2010, J CLIN ONCOL, V28, P1684, DOI 10.1200/JCO.2009.24.9284; Wolf D, 2002, J BIOL CHEM, V277, P25562, DOI 10.1074/jbc.M201196200; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Wong CH, 2009, CLIN CANCER RES, V15, P2311, DOI 10.1158/1078-0432.CCR-08-2533; Wortmann A, 2011, J BIOL CHEM, V286, P42303, DOI 10.1074/jbc.M111.227462; Ying YC, 2008, ORG LETT, V10, P4021, DOI 10.1021/ol801532s; Ying YC, 2008, J AM CHEM SOC, V130, P8455, DOI 10.1021/ja8013727; ZETTL KS, 1992, P NATL ACAD SCI USA, V89, P9069, DOI 10.1073/pnas.89.19.9069; Zhang XC, 2009, PATHOL RES PRACT, V205, P375, DOI 10.1016/j.prp.2008.08.009; Zhu MM, 2010, J PROTEOMICS, V73, P790, DOI 10.1016/j.jprot.2009.11.002	64	58	58	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 7	2013	32	10					1316	1329		10.1038/onc.2012.138	http://dx.doi.org/10.1038/onc.2012.138			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	22543582	Green Accepted			2023-01-03	WOS:000316454500012
J	Schierbeck, LL; Rejnmark, L; Tofteng, CL; Stilgren, L; Eiken, P; Mosekilde, L; Kober, L; Jensen, JEB				Schierbeck, Louise Lind; Rejnmark, Lars; Tofteng, Charlotte Landbo; Stilgren, Lis; Eiken, Pia; Mosekilde, Leif; Kober, Lars; Jensen, Jens-Erik Beck			Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; ESTROGEN PLUS PROGESTIN; CONJUGATED EQUINE ESTROGENS; SECONDARY PREVENTION; RISK; ATHEROSCLEROSIS; YOUNGER; 17-BETA-ESTRADIOL; MORTALITY; BENEFITS	Objective To investigate the long term effect of hormone replacement therapy on cardiovascular outcomes in recently postmenopausal women. Design Open label, randomised controlled trial. Setting Denmark, 1990-93. Participants 1006 healthy women aged 45-58 who were recently postmenopausal or had perimenopausal symptoms in combination with recorded postmenopausal serum follicle stimulating hormone values. 502 women were randomly allocated to receive hormone replacement therapy and 504 to receive no treatment (control). Women who had undergone hysterectomy were included if they were aged 45-52 and had recorded values for postmenopausal serum follicle stimulating hormone. Interventions In the treatment group, women with an intact uterus were treated with triphasic estradiol and norethisterone acetate and women who had undergone hysterectomy received 2 mg estradiol a day. Intervention was stopped after about 11 years owing to adverse reports from other trials, but participants were followed for death, cardiovascular disease, and cancer for up to 16 years. Sensitivity analyses were carried out on women who took more than 80% of the prescribed treatment for five years. Main outcome measure The primary endpoint was a composite of death, admission to hospital for heart failure, and myocardial infarction. Results At inclusion the women on average were aged 50 and had been postmenopausal for seven months. After 10 years of intervention, 16 women in the treatment group experienced the primary composite endpoint compared with 33 in the control group (hazard ratio 0.48, 95% confidence interval 0.26 to 0.87; P=0.015) and 15 died compared with 26 (0.57, 0.30 to 1.08; P=0.084). The reduction in cardiovascular events was not associated with an increase in any cancer (36 in treated group v 39 in control group, 0.92, 0.58 to 1.45; P=0.71) or in breast cancer (10 in treated group v 17 in control group, 0.58, 0.27 to 1.27; P=0.17). The hazard ratio for deep vein thrombosis (2 in treated group v 1 in control group) was 2.01 (0.18 to 22.16) and for stroke (11 in treated group v 14 in control group) was 0.77 (0.35 to 1.70). After 16 years the reduction in the primary composite outcome was still present and not associated with an increase in any cancer. Conclusions After 10 years of randomised treatment, women receiving hormone replacement therapy early after menopause had a significantly reduced risk of mortality, heart failure, or myocardial infarction, without any apparent increase in risk of cancer, venous thromboembolism, or stroke.	[Schierbeck, Louise Lind; Tofteng, Charlotte Landbo; Jensen, Jens-Erik Beck] Hvidovre Univ Hosp, Dept Endocrinol, DK-2650 Hvidovre, Denmark; [Rejnmark, Lars; Mosekilde, Leif] Arhus Univ Hosp, Dept Med, Aarhus, Denmark; [Rejnmark, Lars; Mosekilde, Leif] Arhus Univ Hosp, Dept Endocrinol & Internal Med, Aarhus, Denmark; [Stilgren, Lis] Svendborg Hosp, Dept Endocrinol, Svendborg, Denmark; [Eiken, Pia] Cent Hosp Hillerod, Dept Cardiol Nephrol & Endocrinol, Hillerod, Denmark; [Kober, Lars] Rigshosp, Dept Cardiol, DK-2100 Copenhagen, Denmark	University of Copenhagen; Aarhus University; Aarhus University; Rigshospitalet; University of Copenhagen	Schierbeck, LL (corresponding author), Hvidovre Univ Hosp, Dept Endocrinol, Kettegard Alle 30, DK-2650 Hvidovre, Denmark.	louise.schierbeck@gmail.com		Rejnmark, Lars/0000-0002-2152-4247; Schierbeck, Louise/0000-0002-1263-8875; Kober, Lars/0000-0002-6635-1466; Jensen, Jens-Erik Beck/0000-0003-4290-0480; Eiken, Pia/0000-0001-7278-5968	University of Aarhus; Karen Elise Jensen's Foundation; Novo Nordic; Novartis; LEO Pharma	University of Aarhus; Karen Elise Jensen's Foundation; Novo Nordic; Novartis(Novartis); LEO Pharma(LEO Pharma)	This study was funded by the University of Aarhus, Karen Elise Jensen's Foundation, Novo Nordic, Novartis, and LEO Pharma. None of the funders had any influence on the study design, interpretation of data, or the decision to publish the results.	Alexandersen P, 1998, ARTERIOSCL THROM VAS, V18, P902, DOI 10.1161/01.ATV.18.6.902; Andersen TF, 1999, DAN MED BULL, V46, P263; Avenell Alison, 2004, Clin Trials, V1, P490, DOI 10.1191/1740774504cn053oa; Dubey RK, 2005, CARDIOVASC RES, V66, P295, DOI 10.1016/j.cardiores.2004.12.012; Fournier A, 2009, J CLIN ONCOL, V27, P5138, DOI 10.1200/JCO.2008.21.6432; GABRIEL SR, 2005, COCHRANE DB SYST REV; Grodstein F, 1998, MATURITAS, V30, P19, DOI 10.1016/S0378-5122(98)00055-3; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Guzic-Salobir B, 2001, J INTERN MED, V250, P508, DOI 10.1046/j.1365-2796.2001.00910.x; Harman SM, 2005, CLIMACTERIC, V8, P3, DOI 10.1080/13697130500042417; Hodis HN, 2003, NEW ENGL J MED, V349, P535, DOI 10.1056/NEJMoa030830; Hodis HN, 2001, ANN INTERN MED, V135, P939, DOI 10.7326/0003-4819-135-11-200112040-00005; Hodis HN, 2011, BRAIN RES, V1379, P244, DOI 10.1016/j.brainres.2010.10.076; Hsia J, 2006, ARCH INTERN MED, V166, P357, DOI 10.1001/archinte.166.3.357; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Jayachandran M, 2005, AM J PHYSIOL-HEART C, V288, pH2355, DOI 10.1152/ajpheart.01108.2004; Jensen L, 2003, J BONE MINER RES, V18, P333, DOI 10.1359/jbmr.2003.18.2.333; Kristensen K, 1999, J ENDOCRINOL, V163, P55, DOI 10.1677/joe.0.1630055; LaCroix AZ, 2011, JAMA-J AM MED ASSOC, V305, P1305, DOI 10.1001/jama.2011.382; Leng XH, 2005, CIRC RES, V97, P415, DOI 10.1161/01.RES.0000181025.43762.cf; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Mosekilde L, 1999, MATURITAS, V31, P207, DOI 10.1016/S0378-5122(99)00006-7; Mosekilde L, 2000, MATURITAS, V36, P181, DOI 10.1016/S0378-5122(00)00158-4; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Norris LA, 2002, MATURITAS, V43, P125, DOI 10.1016/S0378-5122(02)00202-5; Novensa L, 2010, HYPERTENSION, V56, P405, DOI 10.1161/HYPERTENSIONAHA.110.151969; Prentice RL, 2008, AM J EPIDEMIOL, V167, P1207, DOI 10.1093/aje/kwn044; Prentice RL, 2009, AM J EPIDEMIOL, V170, P12, DOI 10.1093/aje/kwp115; Rosano GMC, 2000, J AM COLL CARDIOL, V36, P2154, DOI 10.1016/S0735-1097(00)01007-X; Rossouw JE, 2007, JAMA-J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Salpeter SR, 2009, AM J MED, V122, P1016, DOI 10.1016/j.amjmed.2009.05.021; Salpeter SR, 2006, J GEN INTERN MED, V21, P363, DOI 10.1111/j.1525-1497.2006.00389.x; Salpeter SR, 2004, J GEN INTERN MED, V19, P791, DOI 10.1111/j.1525-1497.2004.30281.x; Sare GM, 2008, EUR HEART J, V29, P2031, DOI 10.1093/eurheartj/ehn299; Simoncini T, 2003, STEROIDS, V68, P831, DOI 10.1016/j.steroids.2003.08.006; Taner MZ, 2006, MATURITAS, V53, P267, DOI 10.1016/j.maturitas.2005.05.010; Vestergaard P, 1997, MATURITAS, V28, P137, DOI 10.1016/S0378-5122(97)00076-5	39	406	438	3	66	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 9	2012	345								e6409	10.1136/bmj.e6409	http://dx.doi.org/10.1136/bmj.e6409			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	021TA	23048011	Green Submitted			2023-01-03	WOS:000309907100002
J	Shiogai, Y; Dhamala, M; Oshima, K; Hasler, M				Shiogai, Yuri; Dhamala, Mukesh; Oshima, Kumiko; Hasler, Martin			Cortico-Cardio-Respiratory Network Interactions during Anesthesia	PLOS ONE			English	Article							FUNCTIONAL CONNECTIVITY; LINEAR-DEPENDENCE; TIME-SERIES; OSCILLATIONS; AWARENESS; FEEDBACK; CORTEX; STATES; SLEEP	General anesthetics are used during medical and surgical procedures to reversibly induce a state of total unconsciousness in patients. Here, we investigate, from a dynamic network perspective, how the cortical and cardiovascular systems behave during anesthesia by applying nonparametric spectral techniques to cortical electroencephalography, electrocardiogram and respiratory signals recorded from anesthetized rats under two drugs, ketamine-xylazine (KX) and pentobarbital (PB). We find that the patterns of low-frequency cortico-cardio-respiratory network interactions may undergo significant changes in network activity strengths and in number of network links at different depths of anesthesia dependent upon anesthetics used.	[Dhamala, Mukesh] Georgia State Univ, Dept Phys & Astron, Neurosci Inst, Ctr Behav Neurosci, Atlanta, GA 30303 USA; [Shiogai, Yuri; Oshima, Kumiko; Hasler, Martin] Ecole Polytech Fed Lausanne, Sch Comp & Commun Sci, Lausanne, Switzerland	University System of Georgia; Georgia State University; Ecole Polytechnique Federale de Lausanne	Dhamala, M (corresponding author), Georgia State Univ, Dept Phys & Astron, Neurosci Inst, Ctr Behav Neurosci, Atlanta, GA 30303 USA.	mdhamala@gsu.edu	Dhamala, Mukesh/AAX-3207-2021		FP6 NEST (Sixth Framework Programme New and Emerging science and technology) Tackling Complexity in science project BRACCIA (Brain, Respiratory and Cardiac Causalities in Anesthesia); National Foundation Career Award [BCS 0955037]; Division Of Behavioral and Cognitive Sci [0955037] Funding Source: National Science Foundation	FP6 NEST (Sixth Framework Programme New and Emerging science and technology) Tackling Complexity in science project BRACCIA (Brain, Respiratory and Cardiac Causalities in Anesthesia); National Foundation Career Award; Division Of Behavioral and Cognitive Sci(National Science Foundation (NSF)NSF - Directorate for Social, Behavioral & Economic Sciences (SBE))	This study was supported by the FP6 NEST (Sixth Framework Programme New and Emerging science and technology) Tackling Complexity in science project BRACCIA (Brain, Respiratory and Cardiac Causalities in Anesthesia) to ICLANOS team. The author MD would also like to acknowledge National Foundation Career Award (BCS 0955037). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Avidan MS, 2008, NEW ENGL J MED, V358, P1097, DOI 10.1056/NEJMoa0707361; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Buzsaki G, 2002, NEURON, V33, P325, DOI 10.1016/S0896-6273(02)00586-X; Dhamala M, 2008, NEUROIMAGE, V41, P354, DOI 10.1016/j.neuroimage.2008.02.020; Dhamala M, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.018701; Eckhorn R, 2001, VIS COGN, V8, P519, DOI 10.1080/13506280143000098; FELDMAN JL, 1988, ANNU REV PHYSIOL, V50, P593; Feldman JL, 2003, ANNU REV NEUROSCI, V26, P239, DOI 10.1146/annurev.neuro.26.041002.131103; Foster BL, 2008, COGN NEURODYNAMICS, V2, P283, DOI 10.1007/s11571-008-9063-z; Galletly DC, 1998, BRIT J ANAESTH, V80, P164, DOI 10.1093/bja/80.2.164; GEWEKE J, 1982, J AM STAT ASSOC, V77, P304, DOI 10.2307/2287238; GEWEKE JF, 1984, J AM STAT ASSOC, V79, P907, DOI 10.2307/2288723; GRANGER CWJ, 1969, ECONOMETRICA, V37, P424, DOI 10.2307/1912791; Hales S, 1733, STATICAL ESSAYS HEAE; Lowe MJ, 1998, NEUROIMAGE, V7, P119, DOI 10.1006/nimg.1997.0315; Musizza B, 2007, J PHYSIOL-LONDON, V580, P315, DOI 10.1113/jphysiol.2006.126748; Nelson LE, 2002, NAT NEUROSCI, V5, P979, DOI 10.1038/nn913; Orser BA, 2008, NEW ENGL J MED, V358, P1189, DOI 10.1056/NEJMe0800998; Pattinson KTS, 2009, NEUROIMAGE, V44, P295, DOI 10.1016/j.neuroimage.2008.09.007; Raeder J, 2003, ADV EXP MED BIOL, V523, P269; Rosenblum MG, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.041909; Rosenblum MG, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.045202; Sebel PS, 2004, ANESTH ANALG, V99, P833, DOI 10.1213/01.ANE.0000130261.90896.6C; Stefanovska A, 2000, PHYS REV LETT, V85, P4831, DOI 10.1103/PhysRevLett.85.4831; Vanhatalo S, 2004, P NATL ACAD SCI USA, V101, P5053, DOI 10.1073/pnas.0305375101; Wixson K, 1987, LAB ANIM SCI, V37, P736	26	5	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2012	7	9							e44634	10.1371/journal.pone.0044634	http://dx.doi.org/10.1371/journal.pone.0044634			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014PP	23028572	Green Submitted, Green Published, gold			2023-01-03	WOS:000309388400030
J	McMullen, SM; Meade, M; Rose, L; Burns, K; Mehta, S; Doyle, R; Henzler, D				McMullen, Sarah M.; Meade, Maureen; Rose, Louise; Burns, Karen; Mehta, Sangeeta; Doyle, Robert; Henzler, Dietrich		CCCTG	Partial Ventilatory Support Modalities in Acute Lung Injury and Acute Respiratory Distress Syndrome-A Systematic Review	PLOS ONE			English	Review							PRESSURE RELEASE VENTILATION; PROPORTIONAL-ASSIST VENTILATION; POSITIVE AIRWAY PRESSURE; INTERMITTENT MANDATORY VENTILATION; END-EXPIRATORY PRESSURE; ADJUSTABLE GAIN FACTORS; CONTROLLED MECHANICAL VENTILATION; CRITICALLY-ILL PATIENTS; GAS-EXCHANGE; BREATHING PATTERN	Purpose: The efficacy of partial ventilatory support modes that allow spontaneous breathing in patients with acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) is unclear. The objective of this scoping review was to assess the effects of partial ventilatory support on mortality, duration of mechanical ventilation, and both hospital and intensive care unit (ICU) lengths of stay (LOS) for patients with ALI and ARDS; the secondary objective was to describe physiologic effects on hemodynamics, respiratory system and other organ function. Methods: MEDLINE (1966-2009), Cochrane, and EmBase (1980-2009) databases were searched using common ventilator modes as keywords and reference lists from retrieved manuscripts hand searched for additional studies. Two researchers independently reviewed and graded the studies using a modified Oxford Centre for Evidence-Based Medicine grading system. Studies in adult ALI/ARDS patients were included for primary objectives and pre-clinical studies for supporting evidence. Results: Two randomized controlled trials (RCTs) were identified, in addition to six prospective cohort studies, one retrospective cohort study, one case control study, 41 clinical physiologic studies and 28 pre-clinical studies. No study was powered to assess mortality, one RCT showed shorter ICU length of stay, and the other demonstrated more ventilator free days. Beneficial effects of preserved spontaneous breathing were mainly physiological effects demonstrated as improvement of gas exchange, hemodynamics and non-pulmonary organ perfusion and function. Conclusions: The use of partial ventilatory support modalities is often feasible in patients with ALI/ARDS, and may be associated with short-term physiological benefits without appreciable impact on clinically important outcomes.	[McMullen, Sarah M.; Doyle, Robert; Henzler, Dietrich] Dalhousie Univ, Dept Anesthesiol & Crit Care Med, Halifax, NS, Canada; [Meade, Maureen] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Meade, Maureen] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Rose, Louise] Univ Toronto, Lawrence S Bloomberg Fac Nursing, Toronto, ON, Canada; [Burns, Karen] Univ Toronto, Interdept Div Crit Care, Toronto, ON, Canada; [Burns, Karen] St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Burns, Karen] Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Mehta, Sangeeta] Univ Toronto, Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; [Mehta, Sangeeta] Univ Toronto, Mt Sinai Hosp, Interdept Div Crit Care Med, Toronto, ON M5G 1X5, Canada	Dalhousie University; McMaster University; McMaster University; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto	McMullen, SM (corresponding author), Dalhousie Univ, Dept Anesthesiol & Crit Care Med, Halifax, NS, Canada.	mail@d-henzler.de	Mehta, Sangeeta/C-4623-2015; Rose, Louise/F-4723-2011	Rose, Louise/0000-0003-1700-3972; Henzler, Dietrich/0000-0001-5511-6885	Dalhousie University, Faculty of Medicine; Canadian Institutes of Health Research	Dalhousie University, Faculty of Medicine; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	The study was supported by Dalhousie University, Faculty of Medicine. KB holds a Clinician Scientist Phase 2 Award from the Canadian Institutes of Health Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexopoulou C, 2007, INTENS CARE MED, V33, P1139, DOI 10.1007/s00134-007-0630-2; Allo JC, 2006, CRIT CARE MED, V34, P2997, DOI 10.1097/01.CCM.0000242520.50665.9F; AMATO MBP, 1992, CHEST, V102, P1225, DOI 10.1378/chest.102.4.1225; Appendini L, 1999, AM J RESP CRIT CARE, V159, P1510, DOI 10.1164/ajrccm.159.5.9804130; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Beck J, 2008, INTENS CARE MED, V34, P316, DOI 10.1007/s00134-007-0882-x; Beck J, 2007, PEDIATR RES, V61, P289, DOI 10.1203/01.pdr.0000257324.22406.93; Berger KI, 1996, CHEST, V109, P1320, DOI 10.1378/chest.109.5.1320; BERNARD GR, 1994, INTENS CARE MED, V20, P225, DOI 10.1007/BF01704707; BEYDON L, 1991, ANESTHESIOLOGY, V75, P730, DOI 10.1097/00000542-199111000-00003; Bigatello LM, 1997, CRIT CARE MED, V25, P267, DOI 10.1097/00003246-199702000-00012; Bosma K, 2007, CRIT CARE MED, V35, P1048, DOI 10.1097/01.CCM.0000260055.64235.7C; Brander L, 2009, CHEST, V135, P695, DOI 10.1378/chest.08-1747; Brander L, 2009, INTENS CARE MED, V35, P1979, DOI 10.1007/s00134-009-1626-x; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; CALZIA E, 1994, AM J RESP CRIT CARE, V150, P904, DOI 10.1164/ajrccm.150.4.7921461; CANE RD, 1991, CHEST, V100, P460, DOI 10.1378/chest.100.2.460; Carvalho AR, 2009, ANESTH ANALG, V109, P856, DOI 10.1213/ane.0b013e3181aff245; Cereda M, 2000, CRIT CARE MED, V28, P1269, DOI 10.1097/00003246-200005000-00002; CHIANG AA, 1994, CRIT CARE MED, V22, P1431, DOI 10.1097/00003246-199409000-00013; CHIN WDN, 1985, CHEST, V88, P503, DOI 10.1378/chest.88.4.503; Chiumello D, 2002, EUR RESPIR J, V20, P925, DOI 10.1183/09031936.02.01552001; Colombo D, 2008, INTENS CARE MED, V34, P2010, DOI 10.1007/s00134-008-1208-3; Dart BW, 2005, J TRAUMA, V59, P71, DOI 10.1097/00005373-200507000-00010; DAVIS K, 1993, ARCH SURG-CHICAGO, V128, P1348; de Abreu MG, 2008, CRIT CARE MED, V36, P818, DOI 10.1097/01.CCM.0000299736.55039.3A; Delaere S, 2003, INTENS CARE MED, V29, P949, DOI 10.1007/s00134-003-1704-4; Dembinski R, 2002, ANESTH ANALG, V94, P1570, DOI 10.1097/00000539-200206000-00037; DOWNS JB, 1974, ARCH SURG-CHICAGO, V109, P519; DUNN RB, 1995, ARCH PHYS MED REHAB, V76, P266, DOI 10.1016/S0003-9993(95)80614-8; El-Khatib M, 2009, RESPIRATION, V77, P154, DOI 10.1159/000139155; Esteban A, 2008, AM J RESP CRIT CARE, V177, P170, DOI 10.1164/rccm.200706-893OC; Fan Eddy, 2008, J Intensive Care Med, V23, P376, DOI 10.1177/0885066608324293; Franz AR, 2001, AM J RESP CRIT CARE, V164, P36, DOI 10.1164/ajrccm.164.1.2006164; Giannouli E, 1999, AM J RESP CRIT CARE, V159, P1716, DOI 10.1164/ajrccm.159.6.9704025; Gonzalez M, 2010, INTENS CARE MED, V36, P817, DOI 10.1007/s00134-010-1837-1; Grasso S, 2000, AM J RESP CRIT CARE, V161, P819, DOI 10.1164/ajrccm.161.3.9902065; GROEGER JS, 1989, CRIT CARE MED, V17, P607, DOI 10.1097/00003246-198907000-00002; Henzler D, 2004, INTENS CARE MED, V30, P935, DOI 10.1007/s00134-003-2146-8; Henzler D, 2010, AM J RESP CRIT CAR S, V181, pA3002; Henzler D, 2006, CRIT CARE MED, V34, P1738, DOI 10.1097/01.CCM.0000218809.49883.54; Henzler D, 2011, CRIT CARE, V15, DOI 10.1186/cc9419; Hering R, 2005, CHEST, V128, P2991, DOI 10.1378/chest.128.4.2991; Hering R, 2003, ANESTHESIOLOGY, V99, P1137, DOI 10.1097/00000542-200311000-00021; Hering R, 2002, INTENS CARE MED, V28, P1426, DOI 10.1007/s00134-002-1442-z; Hering R, 2008, INTENS CARE MED, V34, P523, DOI 10.1007/s00134-007-0957-8; Hormann C, 1997, ACTA ANAESTH SCAND, V41, P152; JOUSELA I, 1992, INTENS CARE MED, V18, P299, DOI 10.1007/BF01706479; Kaplan LJ, 2001, CRIT CARE, V5, P221, DOI 10.1186/cc1027; Kiehl M, 1996, CRIT CARE MED, V24, P780, DOI 10.1097/00003246-199605000-00009; Kondili E, 2006, INTENS CARE MED, V32, P692, DOI 10.1007/s00134-006-0110-0; Kondili E, 2006, ANESTHESIOLOGY, V105, P703, DOI 10.1097/00000542-200610000-00015; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Lamontagne F, 2010, CRIT CARE MED, V38, P2401, DOI 10.1097/CCM.0b013e3181fa0468; Levine S, 2008, NEW ENGL J MED, V358, P1327, DOI 10.1056/NEJMoa070447; Marantz S, 1996, J APPL PHYSIOL, V80, P397, DOI 10.1152/jappl.1996.80.2.397; MATHRU M, 1983, CRIT CARE MED, V11, P359, DOI 10.1097/00003246-198305000-00008; Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637; Mercat A, 2008, JAMA-J AM MED ASSOC, V299, P646, DOI 10.1001/jama.299.6.646; Navalesi P, 1996, AM J RESP CRIT CARE, V154, P1330, DOI 10.1164/ajrccm.154.5.8912744; Neumann P, 2005, CRIT CARE MED, V33, P1090, DOI 10.1097/01.CCM.0000163226.34868.0A; Neumann P, 2002, INTENS CARE MED, V28, P1742, DOI 10.1007/s00134-002-1522-0; Neumann P, 2001, ANESTH ANALG, V92, P950; *OXF CTR EV BAS ME, 2010, LEV EV; Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372; Passam F, 2003, RESPIRATION, V70, P355, DOI 10.1159/000072897; Pedersen T, 2001, ACTA ANAESTH SCAND, V45, P267, DOI 10.1034/j.1399-6576.2001.045003267.x; Peek GJ, 2009, LANCET, V374, P1351, DOI 10.1016/S0140-6736(09)61069-2; PUTENSEN C, 1994, ANESTHESIOLOGY, V81, P921, DOI 10.1097/00000542-199410000-00018; Putensen C, 2004, CRIT CARE, V8, P492, DOI 10.1186/cc2919; Putensen C, 2005, CURR OPIN CRIT CARE, V11, P63, DOI 10.1097/00075198-200502000-00010; PUTENSEN C, 1994, AM J RESP CRIT CARE, V150, P101, DOI 10.1164/ajrccm.150.1.8025733; Putensen C, 2001, AM J RESP CRIT CARE, V164, P43, DOI 10.1164/ajrccm.164.1.2001078; Putensen C, 1999, AM J RESP CRIT CARE, V159, P1241, DOI 10.1164/ajrccm.159.4.9806077; RASANEN J, 1991, CRIT CARE MED, V19, P1234; Rose L, 2008, INTENS CARE MED, V34, P1766, DOI 10.1007/s00134-008-1216-3; ROUBY JJ, 1992, INTENS CARE MED, V18, P69, DOI 10.1007/BF01705035; Saddy F, 2010, INTENS CARE MED, V36, P1417, DOI 10.1007/s00134-010-1808-6; SMITH RA, 1995, CHEST, V107, P805, DOI 10.1378/chest.107.3.805; Spieth PM, 2009, ANESTHESIOLOGY, V110, P342, DOI 10.1097/ALN.0b013e318194d06e; STOCK MC, 1987, CRIT CARE MED, V15, P462, DOI 10.1097/00003246-198705000-00002; Sydow M, 1999, INTENS CARE MED, V25, P634, DOI 10.1007/s001340050917; Tassaux D, 2002, CRIT CARE MED, V30, P801, DOI 10.1097/00003246-200204000-00014; Terragni PP, 2009, ANESTHESIOLOGY, V111, P826, DOI 10.1097/ALN.0b013e3181b764d2; TOKIOKA H, 1989, INTENS CARE MED, V15, P364; Uyar M, 2005, ANAESTH INTENS CARE, V33, P218, DOI 10.1177/0310057X0503300210; Varelmann D, 2008, CRIT CARE, V12, DOI 10.1186/cc7108; Varpula T, 2004, ACTA ANAESTH SCAND, V48, P722, DOI 10.1111/j.0001-5172.2004.00411.x; Varpula T, 2003, ACTA ANAESTH SCAND, V47, P516, DOI 10.1034/j.1399-6576.2003.00109.x; Wrigge H, 2003, ANESTHESIOLOGY, V99, P376, DOI 10.1097/00000542-200308000-00019; Xirouchaki N, 2008, INTENS CARE MED, V34, P2026, DOI 10.1007/s00134-008-1209-2; YOUNES M, 1992, AM REV RESPIR DIS, V145, P121, DOI 10.1164/ajrccm/145.1.121; YOUNES M, 1992, AM REV RESPIR DIS, V145, P114, DOI 10.1164/ajrccm/145.1.114; Zakynthinos SG, 1997, J CRIT CARE, V12, P161, DOI 10.1016/S0883-9441(97)90027-7	94	22	26	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 16	2012	7	8							e40190	10.1371/journal.pone.0040190	http://dx.doi.org/10.1371/journal.pone.0040190			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	993AN	22916094	Green Published, Green Submitted, gold			2023-01-03	WOS:000307824300003
J	van Eijl, S; Zhu, ZY; Cupitt, J; Gierula, M; Gotz, C; Fritsche, E; Edwards, RJ				van Eijl, Sven; Zhu, Zheying; Cupitt, John; Gierula, Magdalena; Goetz, Christine; Fritsche, Ellen; Edwards, Robert J.			Elucidation of Xenobiotic Metabolism Pathways in Human Skin and Human Skin Models by Proteomic Profiling	PLOS ONE			English	Article							GLUTATHIONE S-TRANSFERASES; EPIDERMAL-KERATINOCYTES; HUMAN-LIVER; EXPRESSION; CYTOCHROME-P450; ENZYMES; SPECIFICITY; PROTEINS; CULTURES; FORMS	Background: Human skin has the capacity to metabolise foreign chemicals (xenobiotics), but knowledge of the various enzymes involved is incomplete. A broad-based unbiased proteomics approach was used to describe the profile of xenobiotic metabolising enzymes present in human skin and hence indicate principal routes of metabolism of xenobiotic compounds. Several in vitro models of human skin have been developed for the purpose of safety assessment of chemicals. The suitability of these epidermal models for studies involving biotransformation was assessed by comparing their profiles of xenobiotic metabolising enzymes with those of human skin. Methodology/Principal Findings: Label-free proteomic analysis of whole human skin (10 donors) was applied and analysed using custom-built PROTSIFT software. The results showed the presence of enzymes with a capacity for the metabolism of alcohols through dehydrogenation, aldehydes through dehydrogenation and oxidation, amines through oxidation, carbonyls through reduction, epoxides and carboxylesters through hydrolysis and, of many compounds, by conjugation to glutathione. Whereas protein levels of these enzymes in skin were mostly just 4-10 fold lower than those in liver and sufficient to support metabolism, the levels of cytochrome P450 enzymes were at least 300-fold lower indicating they play no significant role. Four epidermal models of human skin had profiles very similar to one another and these overlapped substantially with that of whole skin. Conclusions/Significance: The proteomics profiling approach was successful in producing a comprehensive analysis of the biotransformation characteristics of whole human skin and various in vitro skin models. The results show that skin contains a range of defined enzymes capable of metabolising different classes of chemicals. The degree of similarity of the profiles of the in vitro models indicates their suitability for epidermal toxicity testing. Overall, these results provide a rational basis for explaining the fate of xenobiotics in skin and will aid chemical safety testing programmes.	[van Eijl, Sven; Zhu, Zheying; Cupitt, John; Gierula, Magdalena; Edwards, Robert J.] Univ London Imperial Coll Sci Technol & Med, Ctr Pharmacol & Therapeut, Div Expt Med, London, England; [Goetz, Christine; Fritsche, Ellen] Univ Dusseldorf, Leibniz Inst Umweltmed Forsch, D-40225 Dusseldorf, Germany; [Fritsche, Ellen] Univ Clin RWTH, Dept Dermatol & Allergol, Aachen, Germany	Imperial College London; Heinrich Heine University Dusseldorf; Leibniz Institut fur Umweltmedizinische Forschung (IUF); RWTH Aachen University; RWTH Aachen University Hospital	Edwards, RJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ctr Pharmacol & Therapeut, Div Expt Med, London, England.	r.edwards@imperial.ac.uk		van Eijl, Sven/0000-0002-7605-473X	European Cosmetics Association (COLIPA), as part of their Alternative Approaches to Animal Testing research programme; Medical Research Council [G0801056B] Funding Source: researchfish	European Cosmetics Association (COLIPA), as part of their Alternative Approaches to Animal Testing research programme; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This study was funded by the European Cosmetics Association (COLIPA), as part of their Alternative Approaches to Animal Testing research programme. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aardema MJ, 2010, MUTAT RES-GEN TOX EN, V701, P123, DOI 10.1016/j.mrgentox.2010.05.017; Abdul-Salam VB, 2010, CIRCULATION, V122, P2058, DOI 10.1161/CIRCULATIONAHA.110.972745; ADEMOLA JI, 1995, CURR PROBL DERMATOL, V22, P201; Afaq F, 2009, J INVEST DERMATOL, V129, P2396, DOI 10.1038/jid.2009.85; Baron JM, 2001, J INVEST DERMATOL, V116, P541, DOI 10.1046/j.1523-1747.2001.01298.x; Boelsma E, 2000, ACTA DERM-VENEREOL, V80, P82; Bonifas J, 2010, TOXICOL IN VITRO, V24, P973, DOI 10.1016/j.tiv.2009.12.023; BOOBIS AR, 1980, BRIT J CLIN PHARMACO, V9, P11, DOI 10.1111/j.1365-2125.1980.tb04790.x; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Casarett L.J., 1996, CASARETT DOULLS TOXI; Chanda S, 2008, DRUG METAB DISPOS, V36, P670, DOI 10.1124/dmd.107.019240; Cheung C, 2003, J DERMATOL SCI, V31, P9, DOI 10.1016/S0923-1811(02)00139-1; Costa C, 2010, TOXICOLOGY, V271, P83, DOI 10.1016/j.tox.2010.02.014; EDWARDS RJ, 1991, METHOD ENZYMOL, V206, P220; Edwards RJ, 1998, BIOCHEM PHARMACOL, V56, P377, DOI 10.1016/S0006-2952(98)00033-1; Gibbs S, 2007, CURR DRUG METAB, V8, P758, DOI 10.2174/138920007782798225; Gotz C, 2012, EXP DERMATOL, V21, P358, DOI 10.1111/j.1600-0625.2012.01486.x; GRANT DM, 1991, MOL PHARMACOL, V39, P184; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Higashi Y, 2004, J INVEST DERMATOL, V122, P1207, DOI 10.1111/j.0022-202X.2004.22416.x; Hoofnagle AN, 2012, CLIN CHEM, V58, P777, DOI 10.1373/clinchem.2011.173856; Hu T, 2010, TOXICOL IN VITRO, V24, P1450, DOI 10.1016/j.tiv.2010.03.013; KAWAKUBO Y, 1990, Skin Pharmacology, V3, P180; Koch I, 2002, DRUG METAB DISPOS, V30, P1108, DOI 10.1124/dmd.30.10.1108; Lilienblum W, 2008, ARCH TOXICOL, V82, P211, DOI 10.1007/s00204-008-0279-9; Luu-The V, 2009, J STEROID BIOCHEM, V116, P178, DOI 10.1016/j.jsbmb.2009.05.011; Oesch F, 2007, DRUG METAB REV, V39, P659, DOI 10.1080/03602530701690366; RAZA H, 1991, J INVEST DERMATOL, V96, P463, DOI 10.1111/1523-1747.ep12470150; Rolsted K, 2008, ARCH DERMATOL RES, V300, P10, DOI 10.1007/s00403-007-0811-4; Schallreuter KU, 1996, ARCH DERMATOL RES, V288, P14, DOI 10.1007/BF02505037; Seidegard J, 1997, ENVIRON HEALTH PERSP, V105, P791, DOI 10.2307/3433285; WARD A, 1995, BIOCHEM PHARMACOL, V49, P1759, DOI 10.1016/0006-2952(95)00087-G; Westlind-Johnsson A, 2003, DRUG METAB DISPOS, V31, P755, DOI 10.1124/dmd.31.6.755; Wiegand C, 2009, SKIN PHARMACOL PHYS, V22, P74, DOI 10.1159/000178866; WILKIN JK, 1987, J INVEST DERMATOL, V88, P452, DOI 10.1111/1523-1747.ep12469846; Zhu ZY, 2008, PROTEOMICS, V8, P1987, DOI 10.1002/pmic.200700901; Zhu ZY, 2002, BIOCHEM BIOPH RES CO, V297, P65, DOI 10.1016/S0006-291X(02)02134-4	37	52	53	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 26	2012	7	7							e41721	10.1371/journal.pone.0041721	http://dx.doi.org/10.1371/journal.pone.0041721			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012MO	22848577	Green Published, Green Submitted, gold			2023-01-03	WOS:000309240600044
J	Nagel, C; Prange, F; Guth, S; Herb, J; Ehlken, N; Fischer, C; Reichenberger, F; Rosenkranz, S; Seyfarth, HJ; Mayer, E; Halank, M; Grunig, E				Nagel, Christian; Prange, Felix; Guth, Stefan; Herb, Jochen; Ehlken, Nicola; Fischer, Christine; Reichenberger, Frank; Rosenkranz, Stephan; Seyfarth, Hans-Juergen; Mayer, Eckhard; Halank, Michael; Gruenig, Ekkehard			Exercise Training Improves Exercise Capacity and Quality of Life in Patients with Inoperable or Residual Chronic Thromboembolic Pulmonary Hypertension	PLOS ONE			English	Article							INTERNATIONAL PROSPECTIVE REGISTRY; BOSENTAN THERAPY; ARTERIAL-HYPERTENSION; FOLLOW-UP; EMBOLISM	Background: Aim of this prospective study was to evaluate the effects of exercise training in patients with inoperable or residual chronic thromboembolic pulmonary hypertension (CTEPH). Methods: Thirty-five consecutive patients with invasively confirmed inoperable or residual CTEPH (16 women; 19 men; mean age 61 +/- 15 years, mean pulmonary artery pressure, 63 +/- 20 mmHg; primary inoperable n = 33, persisting pulmonary hypertension after pulmonary endarterectomy n = 2) on stable disease-targeted medication received exercise training in-hospital for 3 weeks and continued at home for 15 weeks. Medication remained unchanged during the study period. Efficacy parameters have been evaluated at baseline, after 3 and 15 weeks by blinded-observers. Survival rate has been evaluated in a follow-up period of median 36.4 months (interquartile range 26.6-46.6 months). Results: All patients tolerated exercise training without severe adverse events. Patients significantly improved the mean distance walked in 6 minutes compared to baseline by 61 +/- 54 meters after 3 weeks (p < 0.001) and by 71 +/- 70 meters after 15 weeks (p = 0.001), as well as scores of quality-of-life questionnaire, peak oxygen consumption and maximal workload. NT-proBNP improved significantly after 3 weeks of exercise training (p = 0.046). The 1-year survival rate was 97%, 2-year survival rate was 94% and the 3-year-survival 86% respectively. Conclusion: Training as add-on to medical therapy may be effective in patients with CTEPH to improve work capacity, quality of life and further prognostic relevant parameters and possibly improves the 1-, 2- and 3-year survival rate. Further multicentric randomized controlled studies are needed to confirm these promising results.	[Nagel, Christian; Prange, Felix; Herb, Jochen; Ehlken, Nicola; Gruenig, Ekkehard] Univ Heidelberg Hosp, Thoraxclin, Ctr Pulm Hypertens, Heidelberg, Germany; [Guth, Stefan; Mayer, Eckhard] Max Planck Inst Physiol & Clin Res, Kerckhoff Klin, Dept Thorac Surg, Bad Nauheim, Germany; [Fischer, Christine] Heidelberg Univ, Dept Human Genet, Heidelberg, Germany; [Reichenberger, Frank] Univ Giessen Marburg, Dept Pneumol, Giessen, Germany; [Rosenkranz, Stephan] Univ Cologne, Dept Cardiol, D-50931 Cologne, Germany; [Seyfarth, Hans-Juergen] Univ Leipzig, Dept Pneumol, Leipzig, Germany; [Halank, Michael] Univ Dresden, Dept Pneumol, Dresden, Germany	Ruprecht Karls University Heidelberg; Kerckhoff Clinic; Max Planck Society; Ruprecht Karls University Heidelberg; University of Cologne; Leipzig University; Technische Universitat Dresden	Nagel, C (corresponding author), Univ Heidelberg Hosp, Thoraxclin, Ctr Pulm Hypertens, Heidelberg, Germany.	ekkehard.gruenig@thoraxklinik-heidelberg.de	Benjamin, Nicola/AAJ-4360-2021; Reichenberger, Frank/AAJ-7232-2020	Reichenberger, Frank/0000-0003-1136-4769	German patient organization Pulmonale Hypertonie e.V., Rheinstetten, Germany	German patient organization Pulmonale Hypertonie e.V., Rheinstetten, Germany	The study was funded by a grant of the German patient organization Pulmonale Hypertonie e.V., Rheinstetten, Germany. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Becattini C, 2006, CHEST, V130, P172, DOI 10.1378/chest.130.1.172; Bonderman D, 2005, CHEST, V128, P2599, DOI 10.1378/chest.128.4.2599; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Condliffe R, 2008, AM J RESP CRIT CARE, V177, P1122, DOI 10.1164/rccm.200712-1841OC; de Man FS, 2009, EUR RESPIR J, V34, P669, DOI 10.1183/09031936.00027909; Freed DH, 2011, J THORAC CARDIOV SUR, V141, P383, DOI 10.1016/j.jtcvs.2009.12.056; Galie N, 2009, EUR RESPIR J, V34, P1219, DOI 10.1183/09031936.00139009; Ghofrani HA, 2010, EUR RESPIR J, V36, P792, DOI 10.1183/09031936.00182909; Grunig E, 2011, RESPIRATION, V81, P394, DOI 10.1159/000322475; Grunig E, 2012, EUR RESP J; GUYATT GH, 1984, THORAX, V39, P818, DOI 10.1136/thx.39.11.818; Handoko ML, 2009, CIRCULATION, V120, P42, DOI 10.1161/CIRCULATIONAHA.108.829713; Hoeper MM, 2005, CHEST, V128, P2363, DOI 10.1378/chest.128.4.2363; Hoeper MM, 2006, CIRCULATION, V113, P2011, DOI 10.1161/CIRCULATIONAHA.105.602565; Hughes RJ, 2006, EUR RESPIR J, V28, P138, DOI 10.1183/09031936.06.00135905; Jais X, 2008, J AM COLL CARDIOL, V52, P2127, DOI 10.1016/j.jacc.2008.08.059; Jensen KW, 2009, CIRCULATION, V120, P1248, DOI 10.1161/CIRCULATIONAHA.109.865881; Korkmaz A, 2012, CLIN APPL THROMB HEM; Lang IM, 2009, EUR RESPIR REV, V18, P24, DOI 10.1183/09059180.00011110; Mayer E, 2011, J THORAC CARDIOV SUR, V141, P702, DOI 10.1016/j.jtcvs.2010.11.024; Mereles D, 2006, CIRCULATION, V114, P1482, DOI 10.1161/CIRCULATIONAHA.106.618397; Miyamoto S, 2000, AM J RESP CRIT CARE, V161, P487, DOI 10.1164/ajrccm.161.2.9906015; Olschewski H, 2002, NEW ENGL J MED, V347, P322, DOI 10.1056/NEJMoa020204; Pengo V, 2004, NEW ENGL J MED, V350, P2257, DOI 10.1056/NEJMoa032274; Pepke-Zaba J, 2011, CIRCULATION, V124, P1973, DOI 10.1161/CIRCULATIONAHA.110.015008; RIEDEL M, 1982, CHEST, V81, P151, DOI 10.1378/chest.81.2.151; Saouti N, 2009, RESP MED, V103, P1013, DOI 10.1016/j.rmed.2009.01.017; Scholzel BE, 2011, LUNG; Suntharalingam J, 2007, RESP MED, V101, P2254, DOI 10.1016/j.rmed.2007.06.027; Ulrich S, 2007, SWISS MED WKLY, V137, P573; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wilkens H, 2011, INT J CARDIOL, V154, pS54, DOI 10.1016/S0167-5273(11)70493-4	32	79	82	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2012	7	7							e41603	10.1371/journal.pone.0041603	http://dx.doi.org/10.1371/journal.pone.0041603			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979GX	22848542	Green Submitted, Green Published, gold			2023-01-03	WOS:000306806600093
J	Campbell, RJ; Gill, SS; Bronskill, SE; Paterson, JM; Whitehead, M; Bell, CM				Campbell, Robert J.; Gill, Sudeep S.; Bronskill, Susan E.; Paterson, J. Michael; Whitehead, Marlo; Bell, Chaim M.			Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MACULAR DEGENERATION; COHORT ANALYSIS; RANIBIZUMAB; BEVACIZUMAB; THERAPY; SAFETY; PHARMACOKINETICS; MORTALITY; CANCER; RISKS	Objective To assess the risk of systemic adverse events associated with intravitreal injections of vascular endothelial growth factor inhibiting drugs. Design Population based nested case-control study. Setting Ontario, Canada. Participants 91 378 older adults with a history of physician diagnosed retinal disease identified between 1 April 2006 and 31 March 2011. Cases were 1477 patients admitted to hospital for ischaemic stroke, 2229 admitted for an acute myocardial infarction, 1059 admitted or assessed in an emergency department for venous thromboembolism, and 2623 admitted for congestive heart failure. Event-free controls (at a ratio of 5: 1) were matched to cases on the basis of year of birth, sex, history of the outcome in the previous 5 years, and diabetes. Main exposure measure Exposure to vascular endothelial growth factor inhibiting drugs identified within 180 days before the index date. Results After adjustment for potential confounders, participants who had ischaemic stroke, acute myocardial infarction, congestive heart failure, or venous thromboembolism were not more likely than control participants to have been exposed to either bevacizumab (adjusted odds ratios of 0.95 (95% confidence interval 0.68 to 1.34) for ischaemic stroke, 1.04 (0.77 to 1.39) for acute myocardial infarction, 0.81 (0.49 to 1.34) for venous thromboembolism, and 1.21 (0.91 to 1.62) for congestive heart failure) or ranibizumab (adjusted odds ratios 0.87 (0.68 to 1.10) for ischaemic stroke, 0.90 (0.72 to 1.11) for acute myocardial infarction, 0.88 (0.67 to 1.16) for venous thromboembolism, and 0.87 (0.70 to 1.07) for congestive heart failure). Similarly, a secondary analysis of exclusive users of bevacizumab or ranibizumab showed no differences in risk between the two drugs (adjusted odds ratios for bevacizumab relative to ranibizumab of 1.03 (0.67 to 1.60) for ischaemic stroke, 1.23 (0.85 to 1.77) for acute myocardial infarction, 0.92 (0.51 to 1.69) for venous thromboembolism, and 1.35 (0.93 to 1.95) for congestive heart failure). These findings were consistent for all but one outcome in subgroup analyses. Conclusions Intravitreal injections of bevacizumab and ranibizumab were not associated with significant risks of ischaemic stroke, acute myocardial infarction, congestive heart failure, or venous thromboembolism.	[Campbell, Robert J.] Queens Univ, Dept Ophthalmol, Kingston, ON, Canada; [Campbell, Robert J.] Hotel Dieu & Kingston Gen Hosp, Dept Ophthalmol, Kingston, ON, Canada; [Gill, Sudeep S.] Queens Univ, Div Geriatr Med, Kingston, ON, Canada; [Gill, Sudeep S.] St Marys Lake Hosp, Div Geriatr Med, Kingston, ON, Canada; [Bronskill, Susan E.; Paterson, J. Michael] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Paterson, J. Michael] McMaster Univ, Dept Family Med, Hamilton, ON L8S 4L8, Canada; [Bell, Chaim M.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Bell, Chaim M.] St Michaels Hosp, Dept Med, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Bell, Chaim M.] St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada	Queens University - Canada; Queens University - Canada; University of Toronto; McMaster University; University of Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto	Campbell, RJ (corresponding author), Hop Hotel Dieu, Dept Ophthalmol, 166 Brock St, Kingston, ON K7L 5G2, Canada.	rob.campbell@queensu.ca	Bell, Chaim/C-4611-2015	Bell, Chaim/0000-0002-3778-9469	Canadian Institutes of Health Research; Ontario Ministry of Health and Long-Term Care; Ontario Ministry of Health and Long-Term Care's (MOHLTC); Southeastern Ontario Academic Medical Organization; CIHR from the Institute of Aging; Canadian Patient Safety Institute chair in patient safety and continuity of care; CIHR; Ontario MOHLTC; MOHLTC	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Ontario Ministry of Health and Long-Term Care(Ministry of Health and Long-Term Care, Ontario); Ontario Ministry of Health and Long-Term Care's (MOHLTC)(Ministry of Health and Long-Term Care, Ontario); Southeastern Ontario Academic Medical Organization; CIHR from the Institute of Aging(Canadian Institutes of Health Research (CIHR)); Canadian Patient Safety Institute chair in patient safety and continuity of care; CIHR(Canadian Institutes of Health Research (CIHR)); Ontario MOHLTC(Ministry of Health and Long-Term Care, Ontario); MOHLTC(Ministry of Health and Long-Term Care, Ontario)	We thank Erica Campbell for assistance with project management, creation of tables, and manuscript editing. She is funded through research grants from the Canadian Institutes of Health Research and the Ontario Ministry of Health and Long-Term Care. We also thank Brogan Inc, Ottawa, Canada, for use of their drug product and therapeutic class database.; This study was funded by the Canadian Institutes of Health Research (CIHR) and the Ontario Ministry of Health and Long-Term Care's (MOHLTC) drug innovation fund. RJC is supported by a clinician scientist award from the Southeastern Ontario Academic Medical Organization. SSG and SEB are supported by CIHR new investigator awards from the Institute of Aging. CMB is supported by a CIHR and Canadian Patient Safety Institute chair in patient safety and continuity of care. The sponsors of this study had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit for publication. The authors are affiliated with the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario MOHLTC. The opinions, results, and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred.; All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: RJC is supported by a Clinician Scientist Award from the Southeastern Ontario Academic Medical Organization, which receives funding from the Ontario Ministry of Health and Long-Term Care (MOHLTC) and holds research grants from the Canadian Institutes of Health Research (CIHR) and the MOHLTC for related work; SSG and SEB are supported by CIHR new investigator awards from the Institute of Aging; CMB is supported by a CIHR and Canadian Patient Safety Institute chair in patient safety and continuity of care; no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years; SSG is a member of the Ontario MOHLTC Committee to Evaluate Drugs, which provides advice to the Ontario MOHLTC on drug related matters (such as drugs to list on provincial formulary), and RJC is an adviser to the Ontario MOHLTC Committee to Evaluate Drugs (in these roles, neither has reviewed bevacizumab or ranibizumab); no other relationships or activities that could appear to have influenced the submitted work.	Al-Qureshi S, 2012, CLIN EXP OPHTHALMOL, V40, P3, DOI 10.1111/j.1442-9071.2011.02739.x; [Anonymous], 2012, ANN REPORT 2011, P66; Bell CM, 2009, JAMA-J AM MED ASSOC, V301, P1991, DOI 10.1001/jama.2009.683; Berkrot B, 2011, REUTERS US EDITI SEP; Breslow N, 1987, FITTING MODELS CONTI, P178; BRESLOW NE, 1983, J AM STAT ASSOC, V78, P1, DOI 10.2307/2287093; Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655; Campbell RJ, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e2941; Campbell RJ, 2010, ARCH OPHTHALMOL-CHIC, V128, P359, DOI 10.1001/archophthalmol.2010.19; Chakravarthy U, 2012, OPHTHALMOLOGY; Choueiri TK, 2011, J CLIN ONCOL, V29, P632, DOI 10.1200/JCO.2010.31.9129; Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153; Csaky K, 2009, AM J OPHTHALMOL, V148, P647, DOI 10.1016/j.ajo.2009.06.014; Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223; Essebag Vidal, 2005, BMC Med Res Methodol, V5, P5, DOI 10.1186/1471-2288-5-5; Ferner RE, 2010, BMJ-BRIT MED J, V340, P245; Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7; French DD, 2011, RETINA-J RET VIT DIS, V31, P1036, DOI 10.1097/IAE.0b013e31821dc66f; Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601; Gill SS, 2009, ARCH INTERN MED, V169, P867, DOI 10.1001/archinternmed.2009.43; Gower EW, 2011, ADVERSE EVENT RATES; Gruneir A, 2010, J AM GERIATR SOC, V58, P510, DOI 10.1111/j.1532-5415.2010.02736.x; Hux JE, 2002, DIABETES CARE, V25, P512, DOI 10.2337/diacare.25.3.512; Institute for Clinical Evaluative Sciences, ONT STROK EV REP 201; Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012; Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537; Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0; Juurlink D, 2006, CANADIAN I HLTH INFO; Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813; Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069; Lee DS, 2005, MED CARE, V43, P182, DOI 10.1097/00005650-200502000-00012; Levy Adrian R, 2003, Can J Clin Pharmacol, V10, P67; LIDDELL FDK, 1977, J R STAT SOC A STAT, V140, P469, DOI 10.2307/2345280; Liew G, 2007, NEW ENGL J MED, V356, P747; Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673; Martin DF, 2012, OPHTHALMOLOGY; Medicare Payment Advisory Commission, 2010, DAT BOOK HEALTHC SPE; MITKA M, 2011, JAMA-J AM MED ASSOC, V306, P1073; Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507; Nalluri SR, 2008, JAMA-J AM MED ASSOC, V300, P2277, DOI 10.1001/jama.2008.656; National Institute for Health and Clinical Excellence, 2010, BEV AV EYE COND REP; National Institute for Health and Clinical Excellence, 2010, NICES REP FEAS APPR; Pollack A, 2011, NY TIMES        1004; Public Health Agency of Canada Canadian Institute for Health Information Canadian Stroke Network Heart and Stroke Foundation of Canada Statistics Canada, 2009, TRACK HEART DIS STRO; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Rosenfeld PJ, 2011, NEW ENGL J MED, V364, P1966, DOI 10.1056/NEJMe1103334; Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086; Schneeweiss S, 2001, AM J EPIDEMIOL, V154, P854, DOI 10.1093/aje/154.9.854; Snider KL, 2009, TARGET ONCOL, V4, P67, DOI 10.1007/s11523-009-0106-0; Suissa S, 2005, NOVEL APPROACHES PHA, P811; Tu Karen, 2007, Open Med, V1, pe18; Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459; Tunon J, 2009, SURV OPHTHALMOL, V54, P339, DOI 10.1016/j.survophthal.2009.02.003; Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046; Vandenbroucke JP, 2008, JAMA-J AM MED ASSOC, V300, P2417, DOI 10.1001/jama.2008.723; White RH, 2003, CIRCULATION, V107, pI4, DOI 10.1161/01.CIR.0000078468.11849.66; Williams JI, 1996, PATTERNS HLTH CARE O, V2nd, P339	57	55	56	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 4	2012	344								e4203	10.1136/bmj.e4203	http://dx.doi.org/10.1136/bmj.e4203			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	972KE	22763393	Green Published, hybrid			2023-01-03	WOS:000306275200002
J	Dunlay, SM; Weston, SA; Killian, JM; Bell, MR; Jaffe, AS; Roger, VL				Dunlay, Shannon M.; Weston, Susan A.; Killian, Jill M.; Bell, Malcolm R.; Jaffe, Allan S.; Roger, Veronique L.			Thirty-Day Rehospitalizations After Acute Myocardial Infarction A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							PERCUTANEOUS CORONARY INTERVENTION; HEART-DISEASE; READMISSION; TRENDS; MORTALITY; FAILURE; CARE	Background: Rehospitalization is a quality-of-care indicator, yet little is known about its occurrence and predictors after myocardial infarction (MI) in the community. Objective: To examine 30-day rehospitalizations after incident MI. Design: Retrospective cohort study. Setting: Population-based registry in Olmsted County, Minnesota. Patients: 3010 patients who were hospitalized in Olmsted County with first-ever MI from 1987 to 2010 and survived to hospital discharge. Measurements: Diagnoses, therapies, and complications during incident and subsequent hospitalizations were identified. Manual chart review was performed to determine the cause of all rehospitalizations. The hazard ratios and cumulative incidence of 30-day rehospitalizations were determined by using Cox proportional hazards regression models. Results: Among 3010 patients (mean age, 67 years; 40.5% female) with incident MI (31.2% ST-segment elevation), 643 rehospitalizations occurred within 30 days in 561 (18.6%) patients. Overall, 30.2% of rehospitalizations were unrelated to the incident MI and 42.6% were related; the relationship was unclear in 27.2% of rehospitalizations. Angiography was performed in 153 (23.8%) rehospitalizations. Revascularization was performed in 103 (16.0%) rehospitalizations, of which 46 (44.7%) had no revascularization during the index hospitalization. After adjustment for potential confounders, diabetes, chronic obstructive pulmonary disease, anemia, higher Killip class, longer length of stay during the index hospitalization, and a complication of angiography or reperfusion or revascularization were associated with increased rehospitalization risk. The 30-day incidence of rehospitalization was 35.3% in patients who experienced a complication of angiography during the index MI hospitalization and 31.6% in those who experienced a complication of reperfusion or revascularization during the index MI hospitalization, compared with 16.8% in patients who had reperfusion or revascularization without complications. Limitation: This study represents the experiences of a single community. Conclusion: Comorbid conditions, longer length of stay, and complications of angiography and revascularization or reperfusion are associated with increased 30-day rehospitalization risk after MI. Many rehospitalizations seem to be unrelated to the incident MI.	[Roger, Veronique L.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA	Mayo Clinic	Roger, VL (corresponding author), Mayo Clin, Dept Hlth Sci Res, 200 1st St SW, Rochester, MN 55905 USA.	roger.veronique@mayo.edu	Roger, Veronique/AAV-5951-2020		National Institutes of Health [RO1-HL59205]; Rochester Epidemiology Project from the National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01-AR30582]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG034676] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rochester Epidemiology Project from the National Institute of Arthritis and Musculoskeletal and Skin Diseases; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	National Institutes of Health.; By grants from the National Institutes of Health (RO1-HL59205) and the Rochester Epidemiology Project (R01-AR30582, from the National Institute of Arthritis and Musculoskeletal and Skin Diseases).	ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; Axon RN, 2011, JAMA-J AM MED ASSOC, V305, P504, DOI 10.1001/jama.2011.72; Curtis JP, 2009, J AM COLL CARDIOL, V54, P903, DOI 10.1016/j.jacc.2009.04.076; Dunlay SM, 2009, J AM COLL CARDIOL, V54, P1695, DOI 10.1016/j.jacc.2009.08.019; Ford ES, 2007, NEW ENGL J MED, V356, P2388, DOI 10.1056/NEJMsa053935; Fried TR, 2008, J AM GERIATR SOC, V56, P1839, DOI 10.1111/j.1532-5415.2008.01923.x; Gershon AS, 2010, ARCH INTERN MED, V170, P560, DOI 10.1001/archinternmed.2010.17; Gorodeski EZ, 2010, NEW ENGL J MED, V363, P297, DOI 10.1056/NEJMc1001882; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Joynt KE, 2011, JAMA-J AM MED ASSOC, V305, P675, DOI 10.1001/jama.2011.123; Kors JA, 2000, AM J EPIDEMIOL, V151, P790, DOI 10.1093/oxfordjournals.aje.a010279; Kostis WJ, 2010, CIRC-CARDIOVASC QUAL, V3, P581, DOI 10.1161/CIRCOUTCOMES.110.957803; Leibson CL, 2001, JAMA-J AM MED ASSOC, V285, P60, DOI 10.1001/jama.285.1.60; Levey AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003-4819-145-4-200608150-00004; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; Miller WL, 2006, EUR HEART J, V27, P1061, DOI 10.1093/eurheartj/ehi760; NCDR, 2008, NCDR CATHPCI REG V4; Parikh CR, 2008, ARCH INTERN MED, V168, P987, DOI 10.1001/archinte.168.9.987; Rihal CS, 2002, CIRCULATION, V105, P2259, DOI 10.1161/01.CIR.0000016043.87291.33; Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701; Roger VL, 2010, CIRCULATION, V121, P863, DOI 10.1161/CIRCULATIONAHA.109.897249; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Smith SC, 2001, CIRCULATION, V103, P3019, DOI 10.1161/01.CIR.103.24.3019; Thygesen K, 2007, EUR HEART J, V28, P2525; White AD, 1996, J CLIN EPIDEMIOL, V49, P223, DOI 10.1016/0895-4356(95)00041-0; Zhang X, 2011, COMPUT METH PROG BIO, V101, P87, DOI 10.1016/j.cmpb.2010.07.005	26	82	85	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2012	157	1					11	U46		10.7326/0003-4819-157-1-201207030-00004	http://dx.doi.org/10.7326/0003-4819-157-1-201207030-00004			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992NS	22751756	Green Accepted			2023-01-03	WOS:000307784900002
J	Li, L; Gu, Y; Liu, T; Bai, YP; Hou, LB; Cheng, Z; Hu, LQ; Gao, B				Li, Lun; Gu, Ye; Liu, Tao; Bai, Yupeng; Hou, Lingbo; Cheng, Zhong; Hu, Liqun; Gao, Bo			A Randomized, Single-Center Double-Blinded Trial on the Effects of Diltiazem Sustained-Release Capsules in Patients with Coronary Slow Flow Phenomenon at 6-Month Follow-Up	PLOS ONE			English	Article							BLOOD-FLOW; RESERVE; ARTERIES; ANGINA	Objective: The aim of this study is to observe the chronic effects of diltiazem release capsules on patients with coronary slow flow (CSF) phenomenon. Methods: From 2004 to 2009, 80 consecutive patients with chest pain and normal coronary arteries evidenced by coronary angiography and CSF were included in this randomized, double-blind, placebo-controlled trial. CSF patterns were evaluated by the corrected TIMI frame count. Patients were randomly assigned at 1:1 ratio to diltiazem sustained-release capsules treatment group (Dil, 90 mg twice daily) or placebo control group. Holter, liver and kidney function, treadmill exercise test, coronary angiography and left ventricular angiography were measured at baseline and after 6 months. The incidence of cardiovascular events (re-admission or progress in coronary heart disease, myocardial infarction, malignant arrhythmia or cardiac death) was evaluated during the 6 months follow up. Results: Thirty-nine patients in control and 40 patients in Dil group completed the 6 months follow-up. There was no medication induced drug withdraw during follow up. Left ventricular ejection fraction was similar between the 2 groups at baseline and during follow up. Heart rate was significantly lower in Dil group than in control group and there was no symptomatic bradycardia and II and III degree atrioventricular conduction block in both groups. Significant improvement was observed in the onset of chest pain, treadmill exercise test and coronary blood flow in Dil group while these parameters remained unchanged in control group at the end of 6 months follow up. The incidence of cardiovascular events was similar between the two groups. Conclusion: Diltiazem slow-release capsules improved coronary blood flow and alleviated angina in patients with CSF.	[Li, Lun; Gu, Ye; Liu, Tao; Bai, Yupeng; Hou, Lingbo; Cheng, Zhong; Hu, Liqun; Gao, Bo] Huazhong Univ Sci & Technol, Wuhan Puai Hosp, Dept Cardiol, Wuhan 430074, Peoples R China	Huazhong University of Science & Technology	Li, L (corresponding author), Huazhong Univ Sci & Technol, Wuhan Puai Hosp, Dept Cardiol, Wuhan 430074, Peoples R China.	yegu2003cn@163.com		Li, Mingzhou/0000-0001-8681-7684	Puai Hospital, Huazhong University of Science and Technology	Puai Hospital, Huazhong University of Science and Technology	The funding was provided by Puai Hospital, Huazhong University of Science and Technology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beltrame JF, 2004, J AM COLL CARDIOL, V44, P57, DOI 10.1016/j.jacc.2004.03.055; Beltrame JF, 2003, AM HEART J, V146, P84, DOI 10.1016/S0002-8703(03)00124-8; Beltrame JF, 2002, CARDIOLOGY, V97, P197, DOI 10.1159/000063121; Ellestad M.H., 1986, J OCCUP ENVIRON MED, V28, P1142; Fineschi M, 2008, INT J CARDIOL, V127, P358, DOI 10.1016/j.ijcard.2007.06.010; Gibson CM, 1996, CIRCULATION, V93, P879, DOI 10.1161/01.CIR.93.5.879; Konidala S, 2004, PROG CARDIOVASC DIS, V46, P349, DOI 10.1016/j.pcad.2003.10.001; Mangieri E, 1996, CATHETER CARDIO DIAG, V37, P375, DOI 10.1002/(SICI)1097-0304(199604)37:4<375::AID-CCD7>3.0.CO;2-8; Mangieri E, 2006, J CARDIOVASC MED, V7, P322, DOI 10.2459/01.JCM.0000223253.16686.4d; MCIVOR ME, 1995, CATHETER CARDIO DIAG, V35, P287; Rim SJ, 2001, CIRCULATION, V104, P2704, DOI 10.1161/hc4701.099580; Sadamatsu K, 2007, INTERNAL MED, V46, P1991, DOI 10.2169/internalmedicine.46.0355; Shirani S, 2009, CARDIOL J, V16, P146; Sutsch G, 1995, INT J CARDIOL, V52, P135, DOI 10.1016/0167-5273(95)02458-9; TAMBE AA, 1972, AM HEART J, V84, P66, DOI 10.1016/0002-8703(72)90307-9; Wang X, 2010, MED HYPOTHESES, V75, P334, DOI 10.1016/j.mehy.2010.03.016; Werner GS, 2002, CATHETER CARDIO INTE, V57, P444, DOI 10.1002/ccd.10375; Zheng Zhao-fen, 2006, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V31, P917	18	30	35	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2012	7	6							e38851	10.1371/journal.pone.0038851	http://dx.doi.org/10.1371/journal.pone.0038851			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	966GL	22761709	Green Published, gold, Green Submitted			2023-01-03	WOS:000305825800015
J	Metzger, ML; Weinstein, HJ; Hudson, MM; Billett, AL; Larsen, EC; Friedmann, A; Howard, SC; Donaldson, SS; Krasin, MJ; Kun, LE; Marcus, KJ; Yock, TI; Tarbell, N; Billups, CA; Wu, JR; Link, MP				Metzger, Monika L.; Weinstein, Howard J.; Hudson, Melissa M.; Billett, Amy L.; Larsen, Eric C.; Friedmann, Alison; Howard, Scott C.; Donaldson, Sarah S.; Krasin, Matthew J.; Kun, Larry E.; Marcus, Karen J.; Yock, Torunn I.; Tarbell, Nancy; Billups, Catherine A.; Wu, Jianrong; Link, Michael P.			Association Between Radiotherapy vs No Radiotherapy Based on Early Response to VAMP Chemotherapy and Survival Among Children With Favorable-Risk Hodgkin Lymphoma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INVOLVED-FIELD RADIOTHERAPY; PEDIATRIC-ONCOLOGY-GROUP; COMBINED-MODALITY TREATMENT; PROSPECTIVE CLINICAL-TRIAL; LONG-TERM SURVIVORS; LOW-DOSE RADIATION; STAGE-I; CHILDHOOD-CANCER; DISEASE; ADOLESCENTS	Context More than 90% of children with favorable-risk Hodgkin lymphoma can achieve long-term survival, yet many will experience toxic effects from radiation therapy. Pediatric oncologists strive for maintaining excellent cure rates while minimizing toxic effects. Objective To evaluate the efficacy of 4 cycles of vinblastine, Adriamycin (doxorubicin), methotrexate, and prednisone(VAMP) in patients with favorable-risk Hodgkin lymphoma who achieve a complete response after 2 cycles and do not receive radiotherapy. Design, Setting, and Patients Multi-institutional, unblinded, nonrandomized single group phase 2 clinical trial to assess the need for radiotherapy based on early response to chemotherapy. Eighty-eight eligible patients with Hodgkin lymphoma stage I and II (<3 nodal sites, no B symptoms, mediastinal bulk, or extranodal extension) enrolled between March 3, 2000, and December 9, 2008. Follow-up data are current to March 12, 2012. Interventions The 47 patients who achieved a complete response after 2 cycles received no radiotherapy, and the 41 with less than a complete response were given 25.5 Gy-involved-field radiotherapy. Main Outcome Measures Two-year event-free survival was the primary outcome measure. A 2-year event-free survival of greater than 90% was desired, and 80% was considered to be unacceptably low. Results Two-year event-free survival was 90.8% (95% CI, 84.7% - 96.9%). For patients who did not require radiotherapy, it was 89.4% (95% CI, 80.8%-98.0%) compared with 92.5% (95% CI, 84.5%-100%) for those who did (P = .61). Most common acute adverse effects were neuropathic pain (2% of patients), nausea or vomiting (3% of patients), neutropenia (32% of cycles), and febrile neutropenia (2% of patients). Nine patients (10%) were hospitalized 11 times (3% of cycles) for febrile neutropenia or nonneutropenic infection. Long-term adverse effects after radiotherapy were asymptomatic compensated hypothyroidism in 9 patients (10%), osteonecrosis and moderate osteopenia in 2 patients each (2%), subclinical pulmonary dysfunction in 12 patients (14%), and asymptomatic left ventricular dysfunction in 4 patients (5%). No second malignant neoplasms were observed. Conclusions Among patients with favorable-risk Hodgkin lymphoma and a complete early response to chemotherapy, the use of limited radiotherapy resulted in a high rate of 2-year event-free survival.	[Metzger, Monika L.; Hudson, Melissa M.; Howard, Scott C.] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA; [Krasin, Matthew J.; Kun, Larry E.] St Jude Childrens Res Hosp, Dept Radiol Sci, Memphis, TN 38105 USA; [Billups, Catherine A.; Wu, Jianrong] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA; [Metzger, Monika L.; Hudson, Melissa M.; Howard, Scott C.] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA; [Weinstein, Howard J.; Friedmann, Alison] Massachusetts Gen Hosp, Dept Pediat Hematol & Oncol, Boston, MA 02114 USA; [Yock, Torunn I.; Tarbell, Nancy] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; [Billett, Amy L.] Childrens Hosp Boston, Dept Pediat Oncol, Boston, MA USA; [Marcus, Karen J.] Childrens Hosp Boston, Dept Radiat Oncol, Boston, MA USA; [Billett, Amy L.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Marcus, Karen J.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA; [Larsen, Eric C.] Barbara Bush Childrens Hosp, Maine Med Ctr, Portland, Dorset, England; [Donaldson, Sarah S.] Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA; [Link, Michael P.] Dept Pediat Hematol & Oncol, Stanford, CA USA; Stanford Univ, Sch Med, Stanford, CA 94305 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Stanford University; Stanford University	Metzger, ML (corresponding author), 262 Danny Thomas Pl,MS 260, Memphis, TN 38015 USA.	monika.metzger@stjude.org	Krasin, Matthew J/D-4188-2018; Howard, Scott C/K-3401-2013; Hudson, Melissa M/N-4441-2018	Howard, Scott C/0000-0003-2244-1686; Hudson, Melissa M/0000-0001-6984-2407; Donaldson, Sarah/0000-0001-7125-3118	Seattle Genetics; Amgen; Millennium; American Society for Clinical Oncology; St Jude Children's Research Hospital; Pfizer; National Institutes of Health [CA-21765]; American Lebanese Syrian Associated Charities; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	Seattle Genetics; Amgen(Amgen); Millennium(Takeda Pharmaceutical Company Ltd); American Society for Clinical Oncology; St Jude Children's Research Hospital; Pfizer(Pfizer); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Lebanese Syrian Associated Charities(American Lebanese Syrian Associated Charities (ALSAC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Metzger reported that she has received funding for an international conference unrelated to the study from Seattle Genetics, Amgen, and Millennium. Dr Kun reported that he is a board member for the National Cancer Institute Brain Malignancies steering committee. Dr Link reported that he has received funding for his institution from American Society for Clinical Oncology for his role as president, and from St Jude Children's Research Hospital for patient enrollment on this study and for his roles on the Scientific Advisory Board and Cancer Center Advisory Board. Dr Link reported that he receives support from Seattle Genetics for clinical trial participation (unrelated to this study) and Pfizer (unrelated to this study). No other financial disclosures were reported.; Study supported by grant CA-21765 from the National Institutes of Health Cancer Support Core Grant and the American Lebanese Syrian Associated Charities.	Baez F, 1997, ANN ONCOL, V8, P247, DOI 10.1023/A:1008200210674; Behrendt H, 1996, MED PEDIATR ONCOL, V26, P244, DOI 10.1002/(SICI)1096-911X(199604)26:4<244::AID-MPO4>3.0.CO;2-J; Brepoels L, 2007, LEUKEMIA LYMPHOMA, V48, P1539, DOI 10.1080/10428190701422414; Campo E, 2011, BLOOD, V117, P5019, DOI 10.1182/blood-2011-01-293050; CARBONE PP, 1971, CANCER RES, V31, P1860; Castellino SM, 2011, BLOOD, V117, P1806, DOI 10.1182/blood-2010-04-278796; COX DR, 1972, J R STAT SOC B, V34, P187; Donaldson SS, 2007, J CLIN ONCOL, V25, P332, DOI 10.1200/JCO.2006.08.4772; DONALDSON SS, 1987, J CLIN ONCOL, V5, P742, DOI 10.1200/JCO.1987.5.5.742; Donaldson SS, 2002, J CLIN ONCOL, V20, P3081, DOI 10.1200/JCO.2002.12.101; Dorffel W, 2003, KLIN PADIATR, V215, P139; Friedmann AM, 2002, J CLIN ONCOL, V20, P3088, DOI 10.1200/JCO.2002.03.051; GEHAN EA, 1965, BIOMETRIKA, V52, P203, DOI 10.1093/biomet/52.1-2.203; Hakvoort-Cammel FGAJ, 2004, PEDIATR BLOOD CANCER, V43, P8, DOI 10.1002/pbc.20031; HUDSON MM, 1993, J CLIN ONCOL, V11, P100, DOI 10.1200/JCO.1993.11.1.100; Hudson MM, 2004, J CLIN ONCOL, V22, P4541, DOI 10.1200/JCO.2004.02.139; Hudson MM, 1998, J CLIN ONCOL, V16, P3592, DOI 10.1200/JCO.1998.16.11.3592; Hudson MM, 1997, J CLIN ONCOL, V15, P2205, DOI 10.1200/JCO.1997.15.6.2205; HUNGER SP, 1994, J CLIN ONCOL, V12, P2160, DOI 10.1200/JCO.1994.12.10.2160; JACOBS P, 1984, CANCER, V53, P210, DOI 10.1002/1097-0142(19840115)53:2<210::AID-CNCR2820530204>3.0.CO;2-Z; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Karayalcin G, 1997, MED PEDIATR ONCOL, V29, P519, DOI 10.1002/(SICI)1096-911X(199712)29:6<519::AID-MPO1>3.0.CO;2-N; Kung FH, 2006, J PEDIAT HEMATOL ONC, V28, P362, DOI 10.1097/00043426-200606000-00008; Landman-Parker J, 2000, J CLIN ONCOL, V18, P1500, DOI 10.1200/JCO.2000.18.7.1500; Mauz-Korholz C, 2007, CANCER-AM CANCER SOC, V110, P179, DOI 10.1002/cncr.22762; Mauz-Korholz C, 2010, J CLIN ONCOL, V28, P3680, DOI 10.1200/JCO.2009.26.9381; Murphy SB, 2003, J PEDIAT HEMATOL ONC, V25, P684, DOI 10.1097/00043426-200309000-00003; Nachman JB, 2002, J CLIN ONCOL, V20, P3765, DOI 10.1200/JCO.2002.12.007; Nogova L, 2005, ANN ONCOL, V16, P1683, DOI 10.1093/annonc/mdi323; OLWENY CLM, 1978, CANCER-AM CANCER SOC, V42, P787, DOI 10.1002/1097-0142(197808)42:2<787::AID-CNCR2820420251>3.0.CO;2-4; Sandoval C, 2002, J PEDIAT HEMATOL ONC, V24, P269, DOI 10.1097/00043426-200205000-00010; Schwartz CL, 2010, 2010 ED BOOK, P391; Straus DJ, 2004, BLOOD, V104, P3483, DOI 10.1182/blood-2004-04-1311; Tebbi CK, 2006, PEDIATR BLOOD CANCER, V46, P198, DOI 10.1002/pbc.20546; vandenBerg H, 1997, ANN ONCOL, V8, P15, DOI 10.1023/A:1008229211885; Weiner MA, 1997, J CLIN ONCOL, V15, P2769, DOI 10.1200/JCO.1997.15.8.2769; Wirth A, 2005, CANCER-AM CANCER SOC, V104, P1221, DOI 10.1002/cncr.21303	37	68	72	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 27	2012	307	24					2609	2616		10.1001/jama.2012.5847	http://dx.doi.org/10.1001/jama.2012.5847			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	964KF	22735430	Green Accepted, Bronze			2023-01-03	WOS:000305692600029
J	Guo, W; Liu, SP; Peng, JL; Wei, XH; Sun, Y; Qiu, YS; Gao, GW; Wang, P; Xu, YH				Guo, Wei; Liu, Shupeng; Peng, Jinliang; Wei, Xiaohui; Sun, Ye; Qiu, Yangsheng; Gao, Guangwei; Wang, Peng; Xu, Yuhong			Examining the Interactome of Huperzine A by Magnetic Biopanning	PLOS ONE			English	Article							CYTOCHROME-C-OXIDASE; ATTENUATES MITOCHONDRIAL DYSFUNCTION; AMYLOID-PRECURSOR-PROTEIN; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; NATURAL-PRODUCTS; KINASE-C; BINDING; TARGET; IDENTIFICATION	Huperzine A is a bioactive compound derived from traditional Chinese medicine plant Qian Ceng Ta (Huperzia serrata), and was found to have multiple neuroprotective effects. In addition to being a potent acetylcholinesterase inhibitor, it was thought to act through other mechanisms such as antioxidation, antiapoptosis, etc. However, the molecular targets involved with these mechanisms were not identified. In this study, we attempted to exam the interactome of Huperzine A using a cDNA phage display library and also mammalian brain tissue extracts. The drugs were chemically linked on the surface of magnetic particles and the interactive phages or proteins were collected and analyzed. Among the various cDNA expressing phages selected, one was identified to encode the mitochondria NADH dehydrogenase subunit 1. Specific bindings between the drug and the target phages and target proteins were confirmed. Another enriched phage clone was identified as mitochondria ATP synthase, which was also panned out from the proteome of mouse brain tissue lysate. These data indicated the possible involvement of mitochondrial respiratory chain matrix enzymes in Huperzine A's pharmacological effects. Such involvement had been suggested by previous studies based on enzyme activity changes. Our data supported the new mechanism. Overall we demonstrated the feasibility of using magnetic biopanning as a simple and viable method for investigating the complex molecular mechanisms of bioactive molecules.	[Guo, Wei; Liu, Shupeng; Wei, Xiaohui; Sun, Ye; Qiu, Yangsheng; Gao, Guangwei; Wang, Peng] Shanghai Jiao Tong Univ, Sch Pharm, Shanghai 200030, Peoples R China; [Liu, Shupeng] Shanghai Univ, Inst Biomed Engn, Shanghai, Peoples R China; [Peng, Jinliang; Xu, Yuhong] Shanghai Jiao Tong Univ, Med X Res Inst, Shanghai 200030, Peoples R China	Shanghai Jiao Tong University; Shanghai University; Shanghai Jiao Tong University	Guo, W (corresponding author), Shanghai Jiao Tong Univ, Sch Pharm, Shanghai 200030, Peoples R China.	yhxu@sjtu.edu.cn			Natural Science Foundation of China [30825045]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was funded by the Natural Science Foundation of China no. 30825045 (www.nsfc.gov.cn). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ankarcrona M, 2005, INT J GERIATR PSYCH, V20, P101, DOI 10.1002/gps.1260; Berger G, 2003, J CHROMATOGR B, V797, P51, DOI 10.1016/S1570-0232(03)00482-3; Busch MHA, 1997, J CHROMATOGR A, V777, P311, DOI 10.1016/S0021-9673(97)00369-5; Butcher RA, 2005, CURR OPIN CHEM BIOL, V9, P25, DOI 10.1016/j.cbpa.2004.10.009; Cheng DH, 1996, NEUROREPORT, V8, P97, DOI 10.1097/00001756-199612200-00020; Cottrell DA, 2002, NEUROPATH APPL NEURO, V28, P390, DOI 10.1046/j.1365-2990.2002.00414.x; Crouch PJ, 2005, J NEUROSCI, V25, P672, DOI 10.1523/JNEUROSCI.4276-04.2005; Fimognari C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021544; Gao X, 2006, J NEUROSCI RES, V83, P1048, DOI 10.1002/jnr.20791; Gao X, 2009, FREE RADICAL BIO MED, V46, P1454, DOI 10.1016/j.freeradbiomed.2009.02.028; Gnanasekar M, 2009, INT J MOL MED, V24, P421, DOI 10.3892/ijmm_00000248; Guo W, 2011, BIOORG MED CHEM LETT, V21, P7175, DOI 10.1016/j.bmcl.2011.09.070; Hemendinger RA, 2008, NEUROTOX RES, V13, P49, DOI 10.1007/BF03033367; Hsieh HV, 2004, BIOSENS BIOELECTRON, V19, P653, DOI 10.1016/S0956-5663(03)00271-9; Ji HF, 2009, EMBO REP, V10, P194, DOI 10.1038/embor.2009.12; Kim KB, 2006, PROTEOMICS, V6, P2444, DOI 10.1002/pmic.200500574; Leuner K, 2007, J NEURAL TRANSM-SUPP, P207; Liu SP, 2006, COLLOID SURFACE B, V51, P101, DOI 10.1016/j.colsurfb.2006.05.023; Lomenick B, 2009, P NATL ACAD SCI USA, V106, P21984, DOI 10.1073/pnas.0910040106; Luesch H, 2005, CHEM BIOL, V12, P55, DOI 10.1016/j.chembiol.2004.10.015; Maekawa N, 2011, BIOMED CHROMATOGR, V25, P466, DOI 10.1002/bmc.1469; Manczak M, 2006, HUM MOL GENET, V15, P1437, DOI 10.1093/hmg/ddl066; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; Maurer I, 2000, NEUROBIOL AGING, V21, P455, DOI 10.1016/S0197-4580(00)00112-3; Nakamura Y, 2008, ANGEW CHEM INT EDIT, V47, P7289, DOI 10.1002/anie.200801820; Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v; Nieba L, 1997, ANAL BIOCHEM, V252, P217, DOI 10.1006/abio.1997.2326; Ong SE, 2009, P NATL ACAD SCI USA, V106, P4617, DOI 10.1073/pnas.0900191106; Ostergaard J, 2003, ELECTROPHORESIS, V24, P2903, DOI 10.1002/elps.200305526; PANG YP, 1994, J COMPUT AID MOL DES, V8, P669, DOI 10.1007/BF00124014; Parihar MS, 2007, AM J PHYSIOL-CELL PH, V292, pC8, DOI 10.1152/ajpcell.00232.2006; Peng Y, 2007, NEUROSCIENCE, V150, P386, DOI 10.1016/j.neuroscience.2007.09.022; Petersen CAH, 2008, P NATL ACAD SCI USA, V105, P13145, DOI 10.1073/pnas.0806192105; Pratico D, 2001, J NEUROSCI, V21, P4183, DOI 10.1523/JNEUROSCI.21-12-04183.2001; Sato S, 2007, J AM CHEM SOC, V129, P873, DOI 10.1021/ja0655643; SAXENA A, 1994, PROTEIN SCI, V3, P1770, DOI 10.1002/pro.5560031017; Shimohama S, 2000, APOPTOSIS, V5, P9, DOI 10.1023/A:1009625323388; Tang LL, 2005, EUR J PHARMACOL, V519, P9, DOI 10.1016/j.ejphar.2005.06.026; Van Dorst B, 2011, TOXICOL IN VITRO, V25, P388, DOI 10.1016/j.tiv.2010.10.012; Vodnik M, 2011, MOLECULES, V16, P790, DOI 10.3390/molecules16010790; von Rechenberg M, 2005, PROTEOMICS, V5, P1764, DOI 10.1002/pmic.200301088; Wang GL, 2007, P NATL ACAD SCI USA, V104, P2068, DOI 10.1073/pnas.0610832104; Wang LS, 2002, BRAIN RES, V949, P162, DOI 10.1016/S0006-8993(02)02977-3; Wang R, 2005, NEUROSIGNALS, V14, P71, DOI 10.1159/000085387; Wang R, 2001, NEUROREPORT, V12, P2629, DOI 10.1097/00001756-200108280-00009; Wang R, 2001, EUR J PHARMACOL, V421, P149, DOI 10.1016/S0014-2999(01)01030-5; Wang XD, 2001, GENE DEV, V15, P2922; Wang ZF, 2008, J NEUROCHEM, V106, P1594, DOI 10.1111/j.1471-4159.2008.05504.x; Xiao XQ, 2000, NEUROSCI LETT, V286, P155, DOI 10.1016/S0304-3940(00)01088-0; Yan J, 2009, BIOORGAN MED CHEM, V17, P6937, DOI 10.1016/j.bmc.2009.08.017; Yang L, 2010, PLOS ONE, V5, pA71, DOI 10.1371/journal.pone.0009568; Zhang HY, 2004, NEUROSCI LETT, V360, P21, DOI 10.1016/j.neulet.2004.01.055; Zheng CY, 2008, J NEUROSCI RES, V86, P2432, DOI 10.1002/jnr.21681	53	4	5	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2012	7	5			1				e37098	10.1371/journal.pone.0037098	http://dx.doi.org/10.1371/journal.pone.0037098			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UR	22615909	gold, Green Submitted, Green Published			2023-01-03	WOS:000305341300070
J	Gentschev, I; Adelfinger, M; Josupeit, R; Rudolph, S; Ehrig, K; Donat, U; Weibel, S; Chen, NHG; Yu, YA; Zhang, Q; Heisig, M; Thamm, D; Stritzker, J; MacNeill, A; Szalay, AA				Gentschev, Ivaylo; Adelfinger, Marion; Josupeit, Rafael; Rudolph, Stephan; Ehrig, Klaas; Donat, Ulrike; Weibel, Stephanie; Chen, Nanhai G.; Yu, Yong A.; Zhang, Qian; Heisig, Martin; Thamm, Douglas; Stritzker, Jochen; MacNeill, Amy; Szalay, Aladar A.			Preclinical Evaluation of Oncolytic Vaccinia Virus for Therapy of Canine Soft Tissue Sarcoma	PLOS ONE			English	Article							BREAST-TUMORS; NUDE-MICE; IN-VITRO; CANCER; VIROTHERAPY; GLV-1H68; NEUTROPHILS; REGRESSION; EFFICACY	Virotherapy using oncolytic vaccinia virus (VACV) strains is one promising new strategy for canine cancer therapy. In this study we describe the establishment of an in vivo model of canine soft tissue sarcoma (CSTS) using the new isolated cell line STSA-1 and the analysis of the virus-mediated oncolytic and immunological effects of two different Lister VACV LIVP1.1.1 and GLV-1h68 strains against CSTS. Cell culture data demonstrated that both tested VACV strains efficiently infected and destroyed cells of the canine soft tissue sarcoma line STSA-1. In addition, in our new canine sarcoma tumor xenograft mouse model, systemic administration of LIVP1.1.1 or GLV-1h68 viruses led to significant inhibition of tumor growth compared to control mice. Furthermore, LIVP1.1.1 mediated therapy resulted in almost complete tumor regression and resulted in long-term survival of sarcoma-bearing mice. The replication of the tested VACV strains in tumor tissues led to strong oncolytic effects accompanied by an intense intratumoral infiltration of host immune cells, mainly neutrophils. These findings suggest that the direct viral oncolysis of tumor cells and the virus-dependent activation of tumor-associated host immune cells could be crucial parts of anti-tumor mechanism in STSA-1 xenografts. In summary, the data showed that both tested vaccinia virus strains and especially LIVP1.1.1 have great potential for effective treatment of CSTS.	[Gentschev, Ivaylo; Ehrig, Klaas; Chen, Nanhai G.; Yu, Yong A.; Zhang, Qian; Stritzker, Jochen; Szalay, Aladar A.] Genelux Corp, San Diego Sci Ctr, San Diego, CA USA; [Gentschev, Ivaylo; Adelfinger, Marion; Josupeit, Rafael; Rudolph, Stephan; Ehrig, Klaas; Donat, Ulrike; Weibel, Stephanie; Stritzker, Jochen; Szalay, Aladar A.] Univ Wurzburg, Dept Biochem, Wurzburg, Germany; [Szalay, Aladar A.] Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, Wurzburg, Germany; [Szalay, Aladar A.] Univ Wurzburg, Inst Mol Infect Biol, Wurzburg, Germany; [Chen, Nanhai G.; Yu, Yong A.; Zhang, Qian; Szalay, Aladar A.] Univ Calif San Diego, Moores Canc Ctr, Dept Radiat Oncol, La Jolla, CA 92093 USA; [Heisig, Martin] Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch MSZ, Wurzburg, Germany; [Thamm, Douglas] Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Clin Sci, Ft Collins, CO 80523 USA; [MacNeill, Amy] Univ Illinois, Coll Vet Med, Dept Pathobiol, Urbana, IL 61801 USA	University of Wurzburg; University of Wurzburg; University of Wurzburg; University of California System; University of California San Diego; University of Wurzburg; Colorado State University; University of Illinois System; University of Illinois Urbana-Champaign	Gentschev, I (corresponding author), Genelux Corp, San Diego Sci Ctr, San Diego, CA USA.	aaszalay@genelux.com	MacNeill, Amy L./D-6066-2017; Fiumefreddo, Andrea/T-2977-2019; Gentschev, Ivaylo/F-9454-2011; Thamm, Douglas/AAG-3672-2020; Gentschev, Ivaylo/AAJ-5819-2021; Thamm, Douglas H/I-5976-2013	MacNeill, Amy L./0000-0002-1690-3787; Gentschev, Ivaylo/0000-0003-3743-6329; Thamm, Douglas H/0000-0002-8914-7767	Research and Development Division of Genelux Corporation, San Diego, USA; University of Wurzburg, Germany; Genelux Corp., San Diego, USA; American Kennel Club Canine Health Foundation [01502-A]; Genelux Corporation	Research and Development Division of Genelux Corporation, San Diego, USA; University of Wurzburg, Germany; Genelux Corp., San Diego, USA; American Kennel Club Canine Health Foundation; Genelux Corporation	The research was supported by the Research and Development Division of Genelux Corporation, San Diego, USA, and a Service Grant to the University of Wurzburg, Germany also funded by Genelux Corp., San Diego, USA. This work also was supported in part by the American Kennel Club Canine Health Foundation (grant 01502-A). Individual employees of Genelux participated in the study as outlined in the Contributions section. Otherwise, the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors have read the journal's policy and have the following conflicts: IG QZ YAY NGC JS and AAS are employees and shareholders of Genelux Corporation. MA, KE and SW were supported by grants of Genelux Corporation. Sequences of the two Lister Vaccinia virus strains (LIVP1.1.1 and LIVP5.1.1.) tested in this study are subject of the patent application 'Clonal strains of attenuated vaccinia viruses and methods of use thereof (U.S. Application No. 61/517,297)'. There are no products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors (http://www.plosone.org/static/policies.action#sharing). The authors do not have any other relevant declarations relating to employment, consultancy, patents, products in development or marketed products, etc. The title and the permit number for the patent are: 'Clonal strains of attenuated vaccinia viruses and methods of use thereof (U.S. Application No. 61/517,297)'.	Arendt M, 2009, VET COMP ONCOL, V7, P153, DOI 10.1111/j.1476-5829.2009.00187.x; Breitbach CJ, 2007, MOL THER, V15, P1686, DOI 10.1038/sj.mt.6300215; Chen NHG, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-164; Dennis MM, 2011, VET PATHOL, V48, P73, DOI 10.1177/0300985810388820; Dobson JM, 2002, J SMALL ANIM PRACT, V43, P240, DOI 10.1111/j.1748-5827.2002.tb00066.x; Dorn R. C., 1976, Journal of the American Animal Hospital Association, V12, P307; Forrest LJ, 2000, J VET INTERN MED, V14, P578, DOI 10.1892/0891-6640(2000)014&lt;0578:PRFCST&gt;2.3.CO;2; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Garber K, 2006, J NATL CANCER I, V98, P298, DOI 10.1093/jnci/djj111; Gentschev I, 2009, CANCER GENE THER, V16, P320, DOI 10.1038/cgt.2008.87; Gentschev I, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/489759; Gentschev I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022069; Gentschev I, 2010, J ONCOL, V2010, DOI 10.1155/2010/736907; Gil M, 2011, BRIT J CANCER, V105, P1512, DOI 10.1038/bjc.2011.429; Gregory AD, 2011, CANCER RES, V71, P2411, DOI 10.1158/0008-5472.CAN-10-2583; Hemminki A, 2003, MOL THER, V7, P163, DOI 10.1016/S1525-0016(02)00049-7; Kelly KJ, 2008, HUM GENE THER, V19, P774, DOI 10.1089/hum.2008.036; Kelly KJ, 2009, INT J CANCER, V124, P911, DOI 10.1002/ijc.24037; Kuntz CA, 1997, J AM VET MED ASSOC, V211, P1147; Lin SF, 2007, SURGERY, V142, P976, DOI 10.1016/j.surg.2007.09.017; Lin SF, 2008, J CLIN ENDOCR METAB, V93, P4403, DOI 10.1210/jc.2008-0316; Liptak J.M., 2007, SMALL ANIMAL CLIN ON, V4th ed., P425; McKnight JA, 2000, J AM VET MED ASSOC, V217, P205, DOI 10.2460/javma.2000.217.205; McSporran KD, 2009, VET PATHOL, V46, P928, DOI 10.1354/vp.08-VP-0277-M-FL; Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785; O'Donoghue LE, 2011, J VET DIAGN INVEST, V23, P780, DOI 10.1177/1040638711408064; Patil SS, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-3; Prestwich RJ, 2009, HUM GENE THER, V20, P1119, DOI 10.1089/hum.2009.135; Seubert CM, 2011, CANCER GENE THER, V18, P42, DOI 10.1038/cgt.2010.49; Snyder SA, 2011, VET PATHOL, V48, P482, DOI 10.1177/0300985810383871; Suter SE, 2005, CLIN CANCER RES, V11, P1579, DOI 10.1158/1078-0432.CCR-04-1944; Theilen GHMB, 1979, TUMORS SKIN SUBCUTAN; THRALL DE, 1995, SEMIN VET MED SURG, V10, P173; TROJANI M, 1984, INT J CANCER, V33, P37, DOI 10.1002/ijc.2910330108; Weibel S, 2008, CELL MICROBIOL, V10, P1235, DOI 10.1111/j.1462-5822.2008.01122.x; Weibel S, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-68; Yu YA, 2009, MOL CANCER THER, V8, P141, DOI 10.1158/1535-7163.MCT-08-0533; Yu ZJ, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-45; Zhang Q, 2007, CANCER RES, V67, P10038, DOI 10.1158/0008-5472.CAN-07-0146; Zhang Q, 2009, MOL GENET GENOMICS, V282, P417, DOI 10.1007/s00438-009-0475-1	40	37	39	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2012	7	5							e37239	10.1371/journal.pone.0037239	http://dx.doi.org/10.1371/journal.pone.0037239			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TM	22615950	Green Published, gold			2023-01-03	WOS:000305336300082
J	Guengerich, F				Guengerich, Fred			Human Cytochrome P450s: The Work of Frederick Peter Guengerich	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									Vanderbilt Univ, Nashville, TN 37235 USA	Vanderbilt University	Guengerich, F (corresponding author), Vanderbilt Univ, Nashville, TN 37235 USA.								0	3	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2012	287	19					15798	15800		10.1074/jbc.O112.000003	http://dx.doi.org/10.1074/jbc.O112.000003			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941YS	22563099	Green Published, hybrid			2023-01-03	WOS:000304006300057
J	Walden, M; Atroshi, I; Magnusson, H; Wagner, P; Hagglund, M				Walden, Markus; Atroshi, Isam; Magnusson, Henrik; Wagner, Philippe; Hagglund, Martin			Prevention of acute knee injuries in adolescent female football players: cluster randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CRUCIATE LIGAMENT INJURY; SOCCER PLAYERS; NEUROMUSCULAR CONTROL; HIGH PREVALENCE; OSTEOARTHRITIS; PROGRAM; RISK; MODEL	Objective To evaluate the effectiveness of neuromuscular training in reducing the rate of acute knee injury in adolescent female football players. Design Stratified cluster randomised controlled trial with clubs as the unit of randomisation. Setting 230 Swedish football clubs (121 in the intervention group, 109 in the control group) were followed for one season (2009, seven months). Participants 4564 players aged 12-17 years (2479 in the intervention group, 2085 in the control group) completed the study. Intervention 15 minute neuromuscular warm-up programme (targeting core stability, balance, and proper knee alignment) to be carried out twice a week throughout the season. Main outcome measures The primary outcome was rate of anterior cruciate ligament injury; secondary outcomes were rates of severe knee injury (>4 weeks' absence) and any acute knee injury. Results Seven players (0.28%) in the intervention group, and 14 (0.67%) in the control group had an anterior cruciate ligament injury. By Cox regression analysis according to intention to treat, a 64% reduction in the rate of anterior cruciate ligament injury was seen in the intervention group (rate ratio 0.36, 95% confidence interval 0.15 to 0.85). The absolute rate difference was -0.07 (95% confidence interval -0.13 to 0.001) per 1000 playing hours in favour of the intervention group. No significant rate reductions were seen for secondary outcomes. Conclusions A neuromuscular warm-up programme significantly reduced the rate of anterior cruciate ligament injury in adolescent female football players. However, the absolute rate difference did not reach statistical significance, possibly owing to the small number of events.	[Walden, Markus] Linkoping Univ, Dept Med & Hlth Sci, Div Community Med, S-58183 Linkoping, Sweden; [Walden, Markus; Atroshi, Isam] Hassleholm Kristianstad Ystad Hosp, Dept Orthopaed, S-28125 Hassleholm, Sweden; [Atroshi, Isam] Lund Univ, Dept Clin Sci, S-22184 Lund, Sweden; [Magnusson, Henrik; Hagglund, Martin] Linkoping Univ, Dept Med & Hlth Sci, Div Physiotherapy, S-58183 Linkoping, Sweden; [Wagner, Philippe] Lund Univ, Natl Competence Ctr Musculoskeletal Disorders, S-22100 Lund, Sweden	Linkoping University; Lund University; Linkoping University; Lund University	Walden, M (corresponding author), Linkoping Univ, Dept Med & Hlth Sci, Div Community Med, S-58183 Linkoping, Sweden.	markus.walden@telia.com			Swedish Football Association; Folksam Insurance Company; Swedish National Centre for Research in Sports; Hassleholm Hospital	Swedish Football Association; Folksam Insurance Company; Swedish National Centre for Research in Sports; Hassleholm Hospital	The study was financially supported by the Swedish Football Association and the Folksam Insurance Company. This research also received grants from the Swedish National Centre for Research in Sports and from the Hassleholm Hospital. None of the sponsors had any role in the design or conduct of the study; the collection, analysis, and interpretation of the data; or the preparation, approval, and submission of the manuscript. No author or related institution has received any financial benefit from research in this study.	Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; Brophy RH, 2009, AM J SPORT MED, V37, P683, DOI 10.1177/0363546508328121; Emery CA, 2010, BRIT J SPORT MED, V44, P555, DOI 10.1136/bjsm.2010.074377; Federation Internationale de Football Association, 2007, FIFA BIG COUNT 2006; Fuller CW, 2006, BRIT J SPORT MED, V40, P193, DOI 10.1136/bjsm.2005.025270; Gilchrist J, 2008, AM J SPORT MED, V36, P1476, DOI 10.1177/0363546508318188; Greenland S, 2008, MODERN EPIDEMIOLOGY, P273; Hagglund M, 2005, BRIT J SPORT MED, V39, P340, DOI 10.1136/bjsm.2005.018267; Hagglund M, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-75; Heidt RS, 2000, AM J SPORT MED, V28, P659, DOI 10.1177/03635465000280050601; Hewett TE, 1999, AM J SPORT MED, V27, P699, DOI 10.1177/03635465990270060301; Hewett TE, 2005, AM J SPORT MED, V33, P492, DOI 10.1177/0363546504269591; Janssen KW, 2012, SCAND J MED SCI SPOR, V22, P495, DOI 10.1111/j.1600-0838.2010.01253.x; Kiani A, 2010, ARCH INTERN MED, V170, P43, DOI 10.1001/archinternmed.2009.289; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; Lohmander LS, 2004, ARTHRITIS RHEUM-US, V50, P3145, DOI 10.1002/art.20589; Mandelbaum BR, 2005, AM J SPORT MED, V33, P1003, DOI 10.1177/0363546504272261; Oiestad BE, 2009, AM J SPORT MED, V37, P1434, DOI 10.1177/0363546509338827; Olsen OE, 2005, BRIT MED J, V330, P449, DOI 10.1136/bmj.38330.632801.8F; Pasanen K, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a295; Pfeiffer RP, 2006, J BONE JOINT SURG AM, V88A, P1769, DOI 10.2106/JBJS.E.00616; Prodromos CC, 2007, ARTHROSCOPY, V23, P1320, DOI 10.1016/j.arthro.2007.07.003; Shea KG, 2004, J PEDIATR ORTHOPED, V24, P623, DOI 10.1097/01241398-200411000-00005; Soderman K, 2000, KNEE SURG SPORT TR A, V8, P356, DOI 10.1007/s001670000147; Soderman K, 2002, SCAND J MED SCI SPOR, V12, P65, DOI 10.1034/j.1600-0838.2002.120201.x; Soligard T, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2469; Steffen K, 2008, SCAND J MED SCI SPOR, V18, P605, DOI 10.1111/j.1600-0838.2007.00703.x; Swedish Football Association, 2006, REK FOTB SVER; United States Youth Soccer Association, 2009, LARG YOUTH SPORTS OR; von Porat A, 2004, ANN RHEUM DIS, V63, P269, DOI 10.1136/ard.2003.008136; Walden M, 2011, KNEE SURG SPORT TR A, V19, P11, DOI 10.1007/s00167-010-1170-9; Walden M, 2011, KNEE SURG SPORT TR A, V19, P3, DOI 10.1007/s00167-010-1172-7; Zazulak BT, 2007, AM J SPORT MED, V35, P1123, DOI 10.1177/0363546507301585	33	230	232	2	51	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 3	2012	344								e3042	10.1136/bmj.e3042	http://dx.doi.org/10.1136/bmj.e3042			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	939NG	22556050	Green Submitted, hybrid, Green Published			2023-01-03	WOS:000303817700001
J	Tran, K; Cimon, K; Severn, M; Pessoa-Silva, CL; Conly, J				Khai Tran; Cimon, Karen; Severn, Melissa; Pessoa-Silva, Carmem L.; Conly, John			Aerosol Generating Procedures and Risk of Transmission of Acute Respiratory Infections to Healthcare Workers: A Systematic Review	PLOS ONE			English	Review							SARS; PATHOGENS; INFLUENZA; LESSONS	Aerosol generating procedures (AGPs) may expose health care workers (HCWs) to pathogens causing acute respiratory infections (ARIs), but the risk of transmission of ARIs from AGPs is not fully known. We sought to determine the clinical evidence for the risk of transmission of ARIs to HCWs caring for patients undergoing AGPs compared with the risk of transmission to HCWs caring for patients not undergoing AGPs. We searched PubMed, EMBASE, MEDLINE, CINAHL, the Cochrane Library, University of York CRD databases, EuroScan, LILACS, Indian Medlars, Index Medicus for SE Asia, international health technology agencies and the Internet in all languages for articles from 01/01/1990 to 22/10/2010. Independent reviewers screened abstracts using pre-defined criteria, obtained full-text articles, selected relevant studies, and abstracted data. Disagreements were resolved by consensus. The outcome of interest was risk of ARI transmission. The quality of evidence was rated using the GRADE system. We identified 5 case-control and 5 retrospective cohort studies which evaluated transmission of SARS to HCWs. Procedures reported to present an increased risk of transmission included [n; pooled OR(95%CI)] tracheal intubation [n = 4 cohort; 6.6 (2.3, 18.9), and n = 4 case- control; 6.6 (4.1, 10.6)], non-invasive ventilation [n = 2 cohort; OR 3.1(1.4, 6.8)], tracheotomy [n = 1 case- control; 4.2 (1.5, 11.5)] and manual ventilation before intubation [n = 1 cohort; OR 2.8 (1.3, 6.4)]. Other intubation associated procedures, endotracheal aspiration, suction of body fluids, bronchoscopy, nebulizer treatment, administration of O2, high flow O2, manipulation of O2 mask or BiPAP mask, defibrillation, chest compressions, insertion of nasogastric tube, and collection of sputum were not significant. Our findings suggest that some procedures potentially capable of generating aerosols have been associated with increased risk of SARS transmission to HCWs or were a risk factor for transmission, with the most consistent association across multiple studies identified with tracheal intubation.	[Khai Tran; Cimon, Karen; Severn, Melissa] CADTH, Ottawa, ON, Canada; [Pessoa-Silva, Carmem L.; Conly, John] WHO, CH-1211 Geneva, Switzerland; [Conly, John] Univ Calgary, Dept Med, Fac Med, Calgary, AB, Canada; [Conly, John] Univ Calgary, Fac Med, Dept Microbiol, Calgary, AB, Canada; [Conly, John] Univ Calgary, Fac Med, Dept Immunol & Infect Dis, Calgary, AB, Canada; [Conly, John] Univ Calgary, Fac Med, Dept Pathol & Lab Med, Calgary, AB, Canada; [Conly, John] Univ Calgary, Fac Med, Calvin Phoebe & Joan Synder Inst Infect Immun & I, Calgary, AB, Canada	World Health Organization; University of Calgary; University of Calgary; University of Calgary; University of Calgary; University of Calgary	Tran, K (corresponding author), CADTH, Ottawa, ON, Canada.	khait@cadth.ca			Canadian federal, provincial and territorial governments	Canadian federal, provincial and territorial governments	This research was supported through a financial contribution from Canadian federal, provincial and territorial governments to the Canadian Agency for Drugs and Technologies in Health (CADTH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alberta Health and Wellness, 2004, ALB SARS RESP INF PR; Betsy Lehman Center for Patient Safety and Medical Error Reduction JSI Research and Training Institute Inc. Massachusetts Department of Public Health, 2008, PREV CONTR HEALTHC 1; British Thoracic Society British Infection Society Health Protection Agency, 2004, BRIT THOR SOC HOSP M; Carlson AL, 2010, CURR OPIN INFECT DIS, V23, P293, DOI 10.1097/QCO.0b013e32833bb804; Centers for Disease Control and Prevention, 2005, PUBL HLTH GUID CO S1; Chen WQ, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-81; College of Respiratory Therapists of Ontario, 2008, INF PREV CONTR CLIN; Davies A., 2009, Journal of Infection Prevention, V10, P122, DOI 10.1177/1757177409106456; Ferguson JK, 2009, MED J AUSTRALIA, V191, P454, DOI 10.5694/j.1326-5377.2009.tb02886.x; Fowler RA, 2004, AM J RESP CRIT CARE, V169, P1198, DOI 10.1164/rccm.200305-715OC; Gamage B, 2005, AM J INFECT CONTROL, V33, P114, DOI 10.1016/j.ajic.2004.12.002; Higgins JP, 2008, COCHRANE HDB SYST RE; Hui DSC, 2010, INFECT DIS CLIN N AM, V24, P619, DOI 10.1016/j.idc.2010.04.009; Liu W, 2009, TROP MED INT HEALTH, V14, P52, DOI 10.1111/j.1365-3156.2009.02255.x; Loeb M, 2004, EMERG INFECT DIS, V10, P251, DOI 10.3201/eid1002.030838; Ma Huai-jian, 2004, Zhonghua Liu Xing Bing Xue Za Zhi, V25, P741; Moore D, 2005, AM J INFECT CONTROL, V33, P88, DOI 10.1016/j.ajic.2004.11.003; Patsopoulos NA, 2008, INT J EPIDEMIOL, V37, P1148, DOI 10.1093/ije/dyn065; Pei Li-ying, 2006, Beijing Da Xue Xue Bao Yi Xue Ban, V38, P271; Raboud J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010717; Scales DC, 2003, EMERG INFECT DIS, V9, P1205, DOI 10.3201/eid0910.030525; Sepkowitz KA, 1996, ANN INTERN MED, V125, P826, DOI 10.7326/0003-4819-125-10-199611150-00007; Siegel JD, 2007, AM J INFECT CONTROL, V35, pS65, DOI 10.1016/j.ajic.2007.10.007; Teleman MD, 2004, EPIDEMIOL INFECT, V132, P797, DOI [10.1017/S0950268804002766, 10.1017/s0950268804002766]; Ter Chee VW, 2004, ANESTHESIOLOGY, V100, P1394, DOI 10.1097/00000542-200406000-00010; Weber DJ, 2010, CRIT CARE MED, V38, pS306, DOI 10.1097/CCM.0b013e3181e69ebd; Wong TW, 2004, EMERG INFECT DIS, V10, P269, DOI 10.3201/eid1002.030452; World Health Organization (WHO), 2008, EP PAND PRON AC RESP; Zimmerman JL, 2010, INTENS CARE MED, V36, pS65, DOI 10.1007/s00134-010-1766-z	29	1085	1124	6	45	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 26	2012	7	4							e35797	10.1371/journal.pone.0035797	http://dx.doi.org/10.1371/journal.pone.0035797			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959WQ	22563403	Green Published, gold, Green Submitted			2023-01-03	WOS:000305349100030
J	Meng, L; Yang, L; Zhao, XX; Zhang, L; Zhu, HZ; Liu, C; Tan, WH				Meng, Ling; Yang, Liu; Zhao, Xiangxuan; Zhang, Lucy; Zhu, Haizhen; Liu, Chen; Tan, Weihong			Targeted Delivery of Chemotherapy Agents Using a Liver Cancer-Specific Aptamer	PLOS ONE			English	Article							MOLECULAR RECOGNITION; SYSTEMATIC EVOLUTION; DRUG-DELIVERY; DOXORUBICIN; BINDING; CELLS; DNA; ELUCIDATION; CONJUGATE; LIGANDS	Background: Using antibody/aptamer-drug conjugates can be a promising method for decreasing toxicity, while increasing the efficiency of chemotherapy. Methodology/Principal Findings: In this study, the antitumor agent Doxorubicin (Dox) was incorporated into the modified DNA aptamer TLS11a-GC, which specifically targets LH86, a human hepatocellular carcinoma cell line. Cell viability tests demonstrated that the TLS11a-GC-Dox conjugates exhibited both potency and target specificity. Importantly, intercalating Dox into the modified aptamer inhibited nonspecific uptake of membrane-permeable Dox to the non-target cell line. Since the conjugates are selective for cells that express higher amounts of target proteins, both criteria noted above are met, making TLS11a-GC-Dox conjugates potential candidates for targeted delivery to liver cancer cells. Conclusions/Significance: Considering the large number of available aptamers that have specific targets for a wide variety of cancer cells, this novel aptamer-drug intercalation method will have promising implications for chemotherapeutics in general.	[Meng, Ling; Yang, Liu; Zhao, Xiangxuan; Zhang, Lucy; Liu, Chen; Tan, Weihong] Univ Florida, Dept Chem, Shands Canc Ctr, Gainesville, FL 32611 USA; [Meng, Ling; Yang, Liu; Zhao, Xiangxuan; Zhang, Lucy; Liu, Chen; Tan, Weihong] Univ Florida, Dept Physiol & Funct Gen, Ctr Res Bio Nano Interface, Gainesville, FL USA; [Meng, Ling; Yang, Liu; Zhao, Xiangxuan; Zhang, Lucy; Liu, Chen; Tan, Weihong] Univ Florida, Coll Med, Dept Pathol Immunol, Gainesville, FL USA; [Meng, Ling; Yang, Liu; Zhao, Xiangxuan; Zhang, Lucy; Liu, Chen; Tan, Weihong] Univ Florida, Coll Med, Lab Med, Gainesville, FL USA; [Zhu, Haizhen] Hunan Univ, Coll Chem & Chem Engn, State Key Lab Chemo Biosensing & Chemometr, Changsha, Peoples R China	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Hunan University	Meng, L (corresponding author), Univ Florida, Dept Chem, Shands Canc Ctr, Gainesville, FL 32611 USA.	liu@pathology.ufl.edu; tan@chem.ufl.edu	Tan, Weihong/A-5412-2008; Tan, Weihong/AAA-4536-2020	Tan, Weihong/0000-0002-8066-1524; 	National Institutes of Health (NIH) [GM066137, GM079359, CA133086]; NATIONAL CANCER INSTITUTE [R01CA133086] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066137, R01GM079359] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by National Institutes of Health (NIH) GM066137, GM079359, and CA133086. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bagalkot V, 2006, ANGEW CHEM INT EDIT, V45, P8149, DOI 10.1002/anie.200602251; Blank M, 2001, J BIOL CHEM, V276, P16464, DOI 10.1074/jbc.M100347200; Carter PJ, 2008, CANCER J, V14, P154, DOI 10.1097/PPO.0b013e318172d704; CHAIRES JB, 1990, BIOCHEMISTRY-US, V29, P6145, DOI 10.1021/bi00478a006; Chari RVJ, 2008, ACCOUNTS CHEM RES, V41, P98, DOI 10.1021/ar700108g; Chen HW, 2008, CHEMMEDCHEM, V3, P991, DOI 10.1002/cmdc.200800030; Chu TC, 2006, CANCER RES, V66, P5989, DOI 10.1158/0008-5472.CAN-05-4583; Daniels DA, 2003, P NATL ACAD SCI USA, V100, P15416, DOI 10.1073/pnas.2136683100; Farokhzad OC, 2004, CANCER RES, V64, P7668, DOI 10.1158/0008-5472.CAN-04-2550; Farokhzad OC, 2006, P NATL ACAD SCI USA, V103, P6315, DOI 10.1073/pnas.0601755103; Flinders J, 2004, CHEMBIOCHEM, V5, P62, DOI 10.1002/cbic.200300701; Haj HTB, 2003, CHEM-BIOL INTERACT, V145, P349, DOI 10.1016/S0009-2797(03)00061-9; Huang YF, 2009, CHEMBIOCHEM, V10, P862, DOI 10.1002/cbic.200800805; HUSAIN N, 1993, J PHYS CHEM-US, V97, P10857, DOI 10.1021/j100143a054; Kuo MT, 2010, ONCOTARGET, V1, P246, DOI 10.18632/oncotarget.135; Lee Y, 2008, BIOCONJUGATE CHEM, V19, P525, DOI 10.1021/bc700382z; LIPSCOMB LA, 1994, BIOCHEMISTRY-US, V33, P3649, DOI 10.1021/bi00178a023; Mallikaratchy P, 2008, CHEMMEDCHEM, V3, P425, DOI 10.1002/cmdc.200700260; Mallikaratchy P, 2007, MOL CELL PROTEOMICS, V6, P2230, DOI 10.1074/mcp.M700026-MCP200; Mann AP, 2011, ONCOTARGET, V2, P298; Patel DJ, 1997, J MOL BIOL, V272, P645, DOI 10.1006/jmbi.1997.1281; Seigneuric R, 2011, ONCOTARGET, V2, P557, DOI 10.18632/oncotarget.297; Shangguan D, 2008, J PROTEOME RES, V7, P2133, DOI 10.1021/pr700894d; Shangguan DH, 2008, ANAL CHEM, V80, P721, DOI 10.1021/ac701962v; Shangguan D, 2006, P NATL ACAD SCI USA, V103, P11838, DOI 10.1073/pnas.0602615103; Tang ZW, 2007, ANAL CHEM, V79, P4900, DOI 10.1021/ac070189y; Tang ZW, 2009, CLIN CHEM, V55, P813, DOI 10.1373/clinchem.2008.113514; Wall DM, 2010, ONCOTARGET, V1, P721; Yan Q, 1997, BIOSPECTROSCOPY, V3, P307, DOI 10.1002/(SICI)1520-6343(1997)3:4<307::AID-BSPY6>3.0.CO;2-0; Zhang LF, 2007, CHEMMEDCHEM, V2, P1268, DOI 10.1002/cmdc.200700121; Zhu HZ, 2007, GASTROENTEROLOGY, V133, P1649, DOI 10.1053/j.gastro.2007.09.017	31	88	91	10	102	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2012	7	4							e33434	10.1371/journal.pone.0033434	http://dx.doi.org/10.1371/journal.pone.0033434			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959VP	22558072	Green Published, Green Submitted, gold			2023-01-03	WOS:000305345200002
J	Dunford, L; Carr, MJ; Dean, J; Waters, A; Nguyen, LT; Thu, HTT; Lan, ABT; Do, HD; Thu, TDT; Nguyen, HT; Trinh, TDD; Luu, QP; Connell, J; Coughlan, S; Nguyen, HT; Hall, WW; Lan, ANT				Dunford, Linda; Carr, Michael J.; Dean, Jonathan; Waters, Allison; Linh Thuy Nguyen; Thu Hong Ta Thi; Lan Anh Bui Thi; Huy Duong Do; Thu Thuy Duong Thi; Ha Thu Nguyen; Trinh Thi Diem Do; Quynh Phuong Luu; Connell, Jeff; Coughlan, Suzie; Hien Tran Nguyen; Hall, William W.; Lan Anh Nguyen Thi			Hepatitis C Virus in Vietnam: High Prevalence of Infection in Dialysis and Multi-Transfused Patients Involving Diverse and Novel Virus Variants	PLOS ONE			English	Article							HO-CHI-MINH; COMMERCIAL SEX WORKERS; INJECTION-DRUG USERS; HUMAN-IMMUNODEFICIENCY-VIRUS; B-VIRUS; HEPATOCELLULAR-CARCINOMA; RISK-FACTORS; GENOTYPE 6; MOLECULAR EPIDEMIOLOGY; GLOBAL EPIDEMIOLOGY	Hepatitis C virus (HCV) is a genetically diverse pathogen infecting approximately 2-3% of the world's population. Herein, we describe results of a large, multicentre serological and molecular epidemiological study cataloguing the prevalence and genetic diversity of HCV in five regions of Vietnam; Ha Noi, Hai Phong, Da Nang, Khanh Hoa and Can Tho. Individuals (n = 8654) with varying risk factors for infection were analysed for the presence of HCV Ab/Ag and, in a subset of positive specimens, for HCV RNA levels (n = 475) and genotype (n = 282). In lower risk individuals, including voluntary blood donors, military recruits and pregnant women, the prevalence of infection was 0.5% (n = 26/5250). Prevalence rates were significantly higher (p < 0.001) in intravenous drug users (IDUs; 55.6%, n = 556/1000), dialysis patients (26.6%, n = 153/575) commercial sex workers (CSWs; 8.7%, n = 87/1000), and recipients of multiple blood transfusions (6.0%, n = 32/529). The prevalence of HCV in dialysis patients varied but remained high in all regions (11-43%) and was associated with the receipt of blood transfusions [OR: 2.08 (1.85-2.34), p = 0.001], time from first transfusion [OR: 1.07 (1.01-1.13), p = 0.023], duration of dialysis [OR: 1.31 (1.19-1.43), p < 0.001] and male gender [OR: 1.60 (1.06-2.41), p = 0.026]. Phylogenetic analysis revealed high genetic diversity, particularly amongst dialysis and multi-transfused patients, identifying subtypes 1a (33%), 1b (27%), 2a (0.4%), 3a (0.7%), 3b (1.1%), 6a (18.8%), 6e (6.0%), 6h (4.6%), 6l (6.4%) and 2 clusters of novel genotype 6 variants (2.1%). HCV genotype 1 predominated in Vietnam (60%, n = 169/282) but the proportion of infections attributable to genotype 1 varied between regions and risk groups and, in the Southern part of Vietnam, genotype 6 viruses dominated in dialysis and multi-transfused patients (73.9%). This study confirms a high prevalence of HCV infection in Vietnamese IDUs and, notably, reveals high levels of HCV infection associated with dialysis and blood transfusion.	[Dunford, Linda; Carr, Michael J.; Dean, Jonathan; Waters, Allison; Linh Thuy Nguyen; Thu Hong Ta Thi; Lan Anh Bui Thi; Huy Duong Do; Thu Thuy Duong Thi; Ha Thu Nguyen; Trinh Thi Diem Do; Quynh Phuong Luu; Connell, Jeff; Coughlan, Suzie; Hien Tran Nguyen; Hall, William W.; Lan Anh Nguyen Thi] Ireland Vietnam Blood Borne Virus Initiat IVVI, Dublin, Ireland; [Dunford, Linda; Carr, Michael J.; Dean, Jonathan; Waters, Allison; Linh Thuy Nguyen; Thu Hong Ta Thi; Lan Anh Bui Thi; Huy Duong Do; Thu Thuy Duong Thi; Ha Thu Nguyen; Trinh Thi Diem Do; Quynh Phuong Luu; Connell, Jeff; Coughlan, Suzie; Hien Tran Nguyen; Hall, William W.; Lan Anh Nguyen Thi] Ireland Vietnam Blood Borne Virus Initiat IVVI, Hanoi, Vietnam; [Dunford, Linda; Carr, Michael J.; Dean, Jonathan; Waters, Allison; Connell, Jeff; Coughlan, Suzie; Hall, William W.] Univ Coll Dublin, Natl Virus Reference Lab, Dublin 2, Ireland; [Linh Thuy Nguyen; Thu Hong Ta Thi; Lan Anh Bui Thi; Huy Duong Do; Thu Thuy Duong Thi; Ha Thu Nguyen; Trinh Thi Diem Do; Quynh Phuong Luu; Hien Tran Nguyen; Lan Anh Nguyen Thi] Natl Inst Hyg & Epidemiol, Lab Mol Diagnost, Hanoi, Vietnam	University College Dublin; National Institute of Hygiene & Epidemiology (NIHE)	Dunford, L (corresponding author), Ireland Vietnam Blood Borne Virus Initiat IVVI, Dublin, Ireland.	William.hall@ucd.ie; lananh_2003@yahoo.com	lan, A/HHZ-6588-2022	Waters, Allison/0000-0002-5048-5021; Carr, Michael/0000-0003-0011-6209	Irish Aid, the Government of Ireland; Atlantic Philanthropies	Irish Aid, the Government of Ireland; Atlantic Philanthropies	The Ireland Vietnam Blood-Borne Virus Initiative is supported by Irish Aid, the Government of Ireland's programme of assistance to developing countries, and by the Atlantic Philanthropies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali S, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-193; Alter MJ, 2011, SEMIN LIVER DIS, V31, P340, DOI 10.1055/s-0031-1297923; Alter MJ, 2006, J HEPATOL, V44, pS6, DOI 10.1016/j.jhep.2005.11.004; [Anonymous], 2000, Wkly Epidemiol Rec, V75, P18; Australia National Centre in HIV Epidemiology and Clinical Research, 2010, AUSTR NSP SURV NAT D; Burland T G, 2000, Methods Mol Biol, V132, P71; Chimparlee N, 2011, SE ASIAN J TROP MED, V42, P609; Cho LY, 2011, INT J CANCER, V128, P176, DOI 10.1002/ijc.25321; Clatts MC, 2010, J URBAN HEALTH, V87, P278, DOI 10.1007/s11524-009-9417-9; Daniel HDJ, 2008, DIAGN MICR INFEC DIS, V61, P415, DOI 10.1016/j.diagmicrobio.2008.04.001; El-Ottol AEY, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-210; Ferrero S, 2003, ACTA OBSTET GYN SCAN, V82, P229, DOI 10.1034/j.1600-0412.2003.00107.x; Fissell RB, 2004, KIDNEY INT, V65, P2335, DOI 10.1111/j.1523-1755.2004.00649.x; Frank C, 2000, LANCET, V355, P887, DOI 10.1016/S0140-6736(99)06527-7; Garcia-Garcia JA, 2006, AIDS RES HUM RETROV, V22, P1236, DOI 10.1089/aid.2006.22.1236; Gasim GI, 2012, J MED VIROL, V84, P52, DOI 10.1002/jmv.22256; Gish RG, 2012, J GASTROEN HEPATOL, V27, P238, DOI 10.1111/j.1440-1746.2011.06974.x; Hall TA, 1999, NUCL ACIDS S SER, V41, P91; Hutin Y, 2004, J CLIN PHARMACOL, V44, P20, DOI 10.1177/0091270003258669; Jadoul M, 2004, NEPHROL DIAL TRANSPL, V19, P904, DOI 10.1093/ndt/gfh012; Johnson DW, 2009, NEPHROL DIAL TRANSPL, V24, P1598, DOI 10.1093/ndt/gfn684; Kakumu S, 1998, J MED VIROL, V54, P243, DOI 10.1002/(SICI)1096-9071(199804)54:4&lt;243::AID-JMV2&gt;3.0.CO;2-4; Kallman JB, 2011, J VIRAL HEPATITIS, V18, P70, DOI 10.1111/j.1365-2893.2010.01278.x; Kumar M, 2007, J GASTROEN HEPATOL, V22, P1104, DOI 10.1111/j.1440-1746.2007.04908.x; Kweon SS, 2006, AM J TROP MED HYG, V74, P1117, DOI 10.4269/ajtmh.2006.74.1117; Laurent C, 2001, INT J EPIDEMIOL, V30, P872, DOI 10.1093/ije/30.4.872; Lavanchy D, 2011, CLIN MICROBIOL INFEC, V17, P107, DOI 10.1111/j.1469-0691.2010.03432.x; Lee YM, 2010, J MED VIROL, V82, P57, DOI 10.1002/jmv.21658; Lu L, 2008, J GEN VIROL, V89, P444, DOI 10.1099/vir.0.83460-0; Martin DP, 2010, BIOINFORMATICS, V26, P2462, DOI 10.1093/bioinformatics/btq467; Martin P, 2008, J HEPATOL, V49, P613, DOI 10.1016/j.jhep.2008.06.003; Murphy DG, 2007, J CLIN MICROBIOL, V45, P1102, DOI 10.1128/JCM.02366-06; Nakano T, 2004, J INFECT DIS, V190, P1098, DOI 10.1086/422606; NAKATA S, 1994, J GASTROEN HEPATOL, V9, P416, DOI 10.1111/j.1440-1746.1994.tb01265.x; Nelson PK, 2011, LANCET, V378, P571, DOI 10.1016/S0140-6736(11)61097-0; Nguyen VTT, 2007, HEPATOL INT, V1, P387, DOI 10.1007/s12072-007-9008-3; Ohsawa M, 2010, J EPIDEMIOL, V20, P30, DOI 10.2188/jea.JE20090043; Pawlotsky JM, 2004, TRENDS MICROBIOL, V12, P96, DOI 10.1016/j.tim.2003.12.005; PERZ JF, 2004, 42 ANN M INF DIS SOC; Pham DA, 2009, ASIAN PAC J ALLERGY, V27, P153; Pham VH, 2011, JPN J INFECT DIS, V64, P537; POWER JP, 1995, LANCET, V345, P1211, DOI 10.1016/S0140-6736(95)91993-7; Pybus OG, 2009, J VIROL, V83, P1071, DOI 10.1128/JVI.01501-08; Quan VM, 2009, AIDS CARE, V21, P7, DOI 10.1080/09540120802017610; Shepard CW, 2005, LANCET INFECT DIS, V5, P558, DOI 10.1016/S1473-3099(05)70216-4; Sievert W, 2011, LIVER INT, V31, P61, DOI 10.1111/j.1478-3231.2011.02540.x; Simmonds P, 2005, HEPATOLOGY, V42, P962, DOI 10.1002/hep.20819; SONG P, 1994, CLIN DIAGN LAB IMMUN, V1, P413, DOI 10.1128/CDLI.1.4.413-418.1994; Swofford D. L., 2003, PHYLOGENETIC ANAL US; Tahan V, 2005, AM J GASTROENTEROL, V100, P821, DOI 10.1111/j.1572-0241.2005.40879.x; Taketa K, 2003, HEPATOL RES, V27, P6, DOI 10.1016/S1386-6346(03)00163-3; Tanimoto T, 2010, J MED VIROL, V82, P1355, DOI 10.1002/jmv.21787; Thanachartwet V, 2007, NEPHROLOGY, V12, P399, DOI 10.1111/j.1440-1797.2007.00815.x; Todd CS, 2010, AIDS, V24, pS69, DOI 10.1097/01.aids.0000386736.25296.8d; Tran HTT, 2003, HEPATOL RES, V26, P275, DOI 10.1016/S1386-6346(03)00166-9; Wang YZ, 2009, J CLIN VIROL, V44, P195, DOI 10.1016/j.jcv.2008.12.009; WHO, 2008, GLOB DAT BLOOD SAF S; WHO, 2010, VIRAL HEPATITIS; Yan YX, 2011, EPIDEMIOL INFECT, V139, P354, DOI 10.1017/S0950268810001597; Zein NN, 2000, CLIN MICROBIOL REV, V13, P223, DOI 10.1128/CMR.13.2.223-235.2000; Zhou J, 2007, J GASTROEN HEPATOL, V22, P1510, DOI 10.1111/j.1440-1746.2007.05062.x	61	40	42	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2012	7	8							e41266	10.1371/journal.pone.0041266	http://dx.doi.org/10.1371/journal.pone.0041266			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	988OQ	22916104	Green Submitted, Green Published, gold			2023-01-03	WOS:000307500800004
J	Rupar, PA; Chabanne, L; Winnik, MA; Manners, I				Rupar, Paul A.; Chabanne, Laurent; Winnik, Mitchell A.; Manners, Ian			Non-Centrosymmetric Cylindrical Micelles by Unidirectional Growth	SCIENCE			English	Article							BLOCK-COPOLYMER MICELLES; DIBLOCK COPOLYMERS; CONTROLLED LENGTH; ARCHITECTURES; MORPHOLOGIES; COMPLEX; WATER; CORE	Although solution self-assembly of block copolymers (BCPs) represents one of the most promising approaches to the creation of nanoparticles from soft matter, the formation of non-centrosymmetric nanostructures with shape anisotropy remains a major challenge. Through a combination of crystallization-driven self-assembly of crystalline-coil BCPs in solution and selective micelle corona cross-linking, we have created short (about 130 nanometers), monodisperse cylindrical seed micelles that grow unidirectionally. These nanostructures grow to form long, non-centrosymmetric cylindrical A-B and A-B-C block co-micelles upon the addition of further BCPs. We also illustrate the formation of amphiphilic cylindrical A-B-C block co-micelles, which spontaneously self-assemble into hierarchical star-shaped supermicelle architectures with a diameter of about 3 micrometers. The method described enables the rational creation of non-centrosymmetric, high aspect ratio, colloidally stable core-shell nanoparticles in a manner that until now has been restricted to the biological domain.	[Winnik, Mitchell A.] Univ Toronto, Dept Chem, Toronto, ON M5S 3H6, Canada; [Rupar, Paul A.; Chabanne, Laurent; Manners, Ian] Univ Bristol, Sch Chem, Bristol BS8 1TS, Avon, England	University of Toronto; University of Bristol	Winnik, MA (corresponding author), Univ Toronto, Dept Chem, Toronto, ON M5S 3H6, Canada.	mwinnik@chem.utoronto.ca; ian.manners@bristol.ac.uk	Winnik, Mitchell A/R-8621-2018; Rupar, Paul/E-6496-2010	Rupar, Paul/0000-0002-9532-116X; Manners, Ian/0000-0002-3794-967X	Natural Science and Engineering Research Council (NSERC) of Canada; European Union (EU); Engineering and Physical Sciences Research Council; European Research Council Advanced Investigator Grant; Royal Society for a Wolfson Research Merit Award; NSERC of Canada	Natural Science and Engineering Research Council (NSERC) of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); European Union (EU)(CGIAREuropean Commission); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); European Research Council Advanced Investigator Grant(European Research Council (ERC)); Royal Society for a Wolfson Research Merit Award(Royal Society of London); NSERC of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC))	P.A.R. is grateful to the Natural Science and Engineering Research Council (NSERC) of Canada for a postdoctoral fellowship and the European Union (EU) for a Marie Curie fellowship. L. C. thanks the EU and Engineering and Physical Sciences Research Council for support. I. M. thanks the EU for a Marie Curie Chair, a Reintegration Grant, and a European Research Council Advanced Investigator Grant and the Royal Society for a Wolfson Research Merit Award. M. A. W. thanks the NSERC of Canada for financial support. The authors also thank T. Gadt for synthesizing PFS<INF>28</INF>-b-PDMS<INF>560</INF> and PFS<INF>64</INF>-b-P2VP<INF>837</INF>.	Chen Q, 2011, SCIENCE, V331, P199, DOI 10.1126/science.1197451; Cheng L, 2008, ANGEW CHEM INT EDIT, V47, P10171, DOI 10.1002/anie.200803315; Christian DA, 2009, NAT MATER, V8, P843, DOI [10.1038/NMAT2512, 10.1038/nmat2512]; Cui HG, 2007, SCIENCE, V317, P647, DOI 10.1126/science.1141768; Du ZX, 2007, MACROMOLECULES, V40, P7633, DOI 10.1021/ma070977p; Dupont J, 2010, SOFT MATTER, V6, P3654, DOI 10.1039/c0sm00044b; Gadt T, 2009, NAT MATER, V8, P144, DOI [10.1038/NMAT2356, 10.1038/nmat2356]; Gilroy JB, 2010, NAT CHEM, V2, P566, DOI [10.1038/NCHEM.664, 10.1038/nchem.664]; Glotzer SC, 2007, NAT MATER, V6, P557, DOI 10.1038/nmat1949; Howard J, 2003, NATURE, V422, P753, DOI 10.1038/nature01600; Jain S, 2003, SCIENCE, V300, P460, DOI 10.1126/science.1082193; Lazzari M, 2008, MACROMOL RAPID COMM, V29, P352, DOI 10.1002/marc.200700818; Lee E, 2011, J AM CHEM SOC, V133, P10390, DOI 10.1021/ja2038547; Li ZB, 2004, SCIENCE, V306, P98, DOI 10.1126/science.1103350; O'Reilly RK, 2006, CHEM SOC REV, V35, P1068, DOI 10.1039/b514858h; Park S, 2004, SCIENCE, V303, P348, DOI 10.1126/science.1093276; Patra SK, 2011, J AM CHEM SOC, V133, P8842, DOI 10.1021/ja202408w; Petzetakis N, 2011, CHEM SCI, V2, P955, DOI 10.1039/c0sc00596g; Pochan DJ, 2011, SOFT MATTER, V7, P2500, DOI 10.1039/c0sm00960a; Qian JS, 2011, ANGEW CHEM INT EDIT, V50, P1622, DOI 10.1002/anie.201006223; Rupar PA, 2011, J AM CHEM SOC, V133, P16947, DOI 10.1021/ja206370k; Schmelz J, 2011, ACS NANO, V5, P9523, DOI 10.1021/nn202638t; Voets IK, 2006, ANGEW CHEM INT EDIT, V45, P6673, DOI 10.1002/anie.200601000; Walther A, 2008, SOFT MATTER, V4, P663, DOI 10.1039/b718131k; Walther A, 2007, J AM CHEM SOC, V129, P6187, DOI 10.1021/ja068153v; Walther A, 2009, J AM CHEM SOC, V131, P4720, DOI 10.1021/ja808614q; Walther A, 2009, SOFT MATTER, V5, P385, DOI 10.1039/b812321g; Wang H, 2007, MACROMOLECULES, V40, P3784, DOI 10.1021/ma062728r; Wang XS, 2007, SCIENCE, V317, P644, DOI 10.1126/science.1141382; Wang XS, 2007, J AM CHEM SOC, V129, P5630, DOI 10.1021/ja068730f; Xia Y, 2009, J AM CHEM SOC, V131, P18525, DOI 10.1021/ja908379q; ZHANG LF, 1995, SCIENCE, V268, P1728, DOI 10.1126/science.268.5218.1728; Zhang W, 2011, SCIENCE, V334, P340, DOI 10.1126/science.1210369	33	301	301	7	499	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 3	2012	337	6094					559	562		10.1126/science.1221206	http://dx.doi.org/10.1126/science.1221206			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982PU	22859484				2023-01-03	WOS:000307058700039
J	Siegl, S; Uhlig, S				Siegl, Stephanie; Uhlig, Stefan			Using the One-Lung Method to Link p38 to Pro-Inflammatory Gene Expression during Overventilation in C57BL/6 and BALB/c Mice	PLOS ONE			English	Article							ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; INBRED MOUSE STRAINS; PULMONARY INFLAMMATION; MAP KINASE; XANTHINE OXIDOREDUCTASE; IMMUNE-RESPONSE; INJURY; VENTILATION; INFECTION	Introduction: The mechanisms of ventilator-induced lung injury (VILI), including the role of MAP kinases, are frequently studied in different mouse strains. A useful model for such studies is the isolated perfused mouse lung. As a further development we present the one-lung method that permits to continue perfusion and ventilation of the right lung after removal of the left lung. This method was used to compare the effect of high pressure ventilation (HPV) on pro-inflammatory signaling events in two widely used mouse strains (C57BL/6, BALB/c) and to further define the role of p38 in VILI. Methods: Lungs were perfused and ventilated for 30 min under control conditions before they were randomized to low (8 cm H2O) or high (25 cm H2O) pressure ventilation (HPV) for 210 min, with the left lung being removed after 180 min. In the left lung we measured the phosphorylation of p38, JNK, ERK and Akt kinase, and in the right lung gene expression and protein concentrations of Il1b, Il6, Tnf, Cxcl1, Cxcl2, and Areg. Results: Lung mechanics and kinase activation were similar in both mouse strains. HPV increased all genes (except Tnf in BALB/c) and all mediators in both strains. The gene expression of mRNA for Il1b, Il6, Cxcl1 and Cxcl2 was higher in BALB/c mice. Backward regression of the kinase data at t = 180 min with the gene and protein expression data at t = 240 min suggested that p38 controls HPV-induced gene expression, but not protein production. This hypothesis was confirmed in experiments with the p38-kinase inhibitor SB203580. Conclusions: The one-lung method is useful for mechanistic studies in the lungs. While C57BL/6 show diminished pro-inflammatory responses during HPV, lung mechanics and mechanotransduction processes appear to be similar in both mouse strains. Finally, the one-lung method allowed us to link p38 to gene expression during VILI.	[Siegl, Stephanie; Uhlig, Stefan] Rhein Westfal TH Aachen, Inst Pharmacol & Toxicol, Fac Med, Aachen, Germany	RWTH Aachen University	Siegl, S (corresponding author), Rhein Westfal TH Aachen, Inst Pharmacol & Toxicol, Fac Med, Aachen, Germany.	suhlig@ukaachen.de	Uhlig, Stefan/A-7290-2014	Uhlig, Stefan/0000-0003-2332-1280	Deutsche Forschungsgemeinschaft [TPC16, SFB542]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was funded by the Deutsche Forschungsgemeinschaft (TPC16 within the SFB542). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdulnour REE, 2006, AM J PHYSIOL-LUNG C, V291, pL345, DOI 10.1152/ajplung.00453.2005; Arcaroli J, 2001, CLIN IMMUNOL, V101, P211, DOI 10.1006/clim.2001.5108; BOHN E, 1994, INFECT IMMUN, V62, P3027, DOI 10.1128/IAI.62.7.3027-3032.1994; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Chen XL, 2003, SHOCK, V19, P475, DOI 10.1097/01.shk.0000055242.25446.84; DINARELLO CA, 1990, PROG CLIN BIOL RES, V349, P195; Dolinay T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001601; Dolinay T, 2006, PHYSIOL GENOMICS, V26, P68, DOI 10.1152/physiolgenomics.00110.2005; Dombrowsky H, 2007, EUR RESPIR J, V30, P865, DOI 10.1183/09031936.00134006; Dombrowsky H, 2009, PULM PHARMACOL THER, V22, P593, DOI 10.1016/j.pupt.2009.08.005; Donahoe Michael, 2011, Pulm Circ, V1, P192, DOI 10.4103/2045-8932.83454; Fanelli V, 2010, INTENS CARE MED, V36, P1935, DOI 10.1007/s00134-010-2018-y; Fonseca-Aten M, 2005, AM J RESP CELL MOL, V32, P201, DOI 10.1165/rcmb.2004-0197OC; Frank JA, 2008, THORAX, V63, P147, DOI 10.1136/thx.2007.079608; Held HD, 2000, J APPL PHYSIOL, V88, P2192, DOI 10.1152/jappl.2000.88.6.2192; Herlaar E, 1999, MOL MED TODAY, V5, P439, DOI 10.1016/S1357-4310(99)01544-0; Hill AVS, 1998, ANNU REV IMMUNOL, V16, P593, DOI 10.1146/annurev.immunol.16.1.593; Kang YJ, 2006, J BIOL CHEM, V281, P26225, DOI 10.1074/jbc.M606800200; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kitsiouli E, 2009, BBA-MOL BASIS DIS, V1792, P941, DOI 10.1016/j.bbadis.2009.06.007; Kobayashi N, 2003, KIDNEY INT, V64, P1675, DOI 10.1046/j.1523-1755.2003.00258.x; Kuebler WM, 2003, AM J RESP CRIT CARE, V168, P1391, DOI 10.1164/rccm.200304-562OC; Le A, 2008, J APPL PHYSIOL, V105, P1282, DOI 10.1152/japplphysiol.90689.2008; Lee JC, 1999, PHARMACOL THERAPEUT, V82, P389, DOI 10.1016/S0163-7258(99)00008-X; Li LF, 2004, AM J RESP CRIT CARE, V169, P518, DOI 10.1164/rccm.200305-660OC; Liu S, 2008, EUR J PHARMACOL, V584, P159, DOI 10.1016/j.ejphar.2008.02.009; MCDEVITT HO, 1969, SCIENCE, V163, P1207, DOI 10.1126/science.163.3872.1207; Miyahara T, 2007, AM J PHYSIOL-LUNG C, V293, pL11, DOI 10.1152/ajplung.00279.2005; Nick JA, 2000, J IMMUNOL, V164, P2151, DOI 10.4049/jimmunol.164.4.2151; Nick JA, 2002, J IMMUNOL, V169, P5260, DOI 10.4049/jimmunol.169.9.5260; Packiam M, 2010, INFECT IMMUN, V78, P433, DOI 10.1128/IAI.00711-09; Peng X, ACTA PHARM SIN, V31, P175; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pierrakos C, 2012, EUROPEAN RESP J OFFI; Reinhard C, 2002, MAMM GENOME, V13, P429, DOI 10.1007/s00335-002-3005-6; Reiss LK, EUROPEAN J CELL BIOL; Reiss LK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024527; Rocca NA, 2011, EXP LUNG RES, V37, P419, DOI 10.3109/01902148.2011.583712; Roggero E, 2002, CLIN EXP IMMUNOL, V128, P421, DOI 10.1046/j.1365-2249.2002.01874.x; ROSSIBERGMANN B, 1993, INFECT IMMUN, V61, P2266, DOI 10.1128/IAI.61.5.2266-2269.1993; Safholm J, 2011, PULM PHARMACOL THER, V24, P361, DOI 10.1016/j.pupt.2011.01.001; Sandler H, 2008, BIOCHEM SOC T, V36, P491, DOI 10.1042/BST0360491; Stamme C, 2002, PULM PHARMACOL THER, V15, P455, DOI 10.1006/pupt.2002.0383; Uhlig S, 2004, TRENDS PHARMACOL SCI, V25, P592, DOI 10.1016/j.tips.2004.09.002; Uhlig U, 2002, EUR RESPIR J, V20, P946, DOI 10.1183/09031936.02.01612001; Uhlig U, 2011, COMPREHENSIVE PHYSL; Uhlig U, 2006, ANESTHESIOLOGY, V105, P1192, DOI 10.1097/00000542-200612000-00019; Underwood DC, 2000, AM J PHYSIOL-LUNG C, V279, pL895, DOI 10.1152/ajplung.2000.279.5.L895; van Doorn NEM, 1999, INFECT IMMUN, V67, P3040, DOI 10.1128/IAI.67.6.3040-3046.1999; Villar J, 2011, INTENS CARE MED, V37, P1932, DOI 10.1007/s00134-011-2380-4; von Bethmann AN, 1998, AM J RESP CRIT CARE, V157, P263, DOI 10.1164/ajrccm.157.1.9608052; vonBethmann AN, 1996, ACP-APPL CARDIOPUL P, V6, P171; Wakeham J, 2000, INFECT IMMUN, V68, P6946, DOI 10.1128/IAI.68.12.6946-6953.2000; Watanabe H, 2004, SHOCK, V22, P460, DOI 10.1097/01.shk.0000142249.08135.e9; Weinberg JB, 2004, VIRAL IMMUNOL, V17, P69, DOI 10.1089/088282404322875467; Wilson MR, 2007, AM J PHYSIOL-LUNG C, V293, pL60, DOI 10.1152/ajplung.00284.2006; Wolthuis EK, 2009, CRIT CARE, V13, DOI 10.1186/cc7688; Yong HY, 2009, EXPERT OPIN INV DRUG, V18, P1893, DOI 10.1517/13543780903321490	58	16	16	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2012	7	7							e41464	10.1371/journal.pone.0041464	http://dx.doi.org/10.1371/journal.pone.0041464			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	978NX	22848503	Green Submitted, Green Published, gold			2023-01-03	WOS:000306751300043
J	Wang, ML; Hada, M; Saha, J; Sridharan, DM; Pluth, JM; Cucinotta, FA				Wang, Minli; Hada, Megumi; Saha, Janapriya; Sridharan, Deepa M.; Pluth, Janice M.; Cucinotta, Francis A.			Protons Sensitize Epithelial Cells to Mesenchymal Transition	PLOS ONE			English	Article							GROWTH; CANCER; EXPOSURE; RECEPTOR; THERAPY; TARGET; EMT	Proton radiotherapy has gained more favor among oncologists as a treatment option for localized and deep-seated tumors. In addition, protons are a major constituent of the space radiation astronauts receive during space flights. The potential for these exposures to lead to, or enhance cancer risk has not been well studied. Our objective is to study the biological effects of low energy protons on epithelial cells and its propensity to enhance transforming growth factor beta 1 (TGF beta 1)-mediated epithelial-mesenchymal transition (EMT), a process occurring during tumor progression and critical for invasion and metastasis. Non-transformed mink lung epithelial cells (Mv1Lu) and hTERT-immortalized human esophageal epithelial cells (EPC) were used in this study. EMT was identified by alterations in cell morphology, EMT-related gene expression changes determined using real-time PCR, and EMT changes in specific cellular markers detected by immunostaining and western blotting. Although TGF beta 1 treatment alone is able to induce EMT in both Mv1Lu and EPC cells, low energy protons (5 MeV) at doses as low as 0.1 Gy can enhance TGF beta 1 induced EMT. Protons alone can also induce a mild induction of EMT. SD208, a potent TGF beta Receptor 1 (TGF beta R1) kinase inhibitor, can efficiently block TGF beta 1/Smad signaling and attenuate EMT induction. We suggest a model for EMT after proton irradiation in normal and cancerous tissue based on our results that showed that low and high doses of protons can sensitize normal human epithelial cells to mesenchymal transition, more prominently in the presence of TGF beta 1, but also in the absence of TGF beta 1.	[Wang, Minli; Hada, Megumi; Saha, Janapriya] Univ Space Res Assoc, Div Space Life Sci, Houston, TX USA; [Sridharan, Deepa M.; Pluth, Janice M.] Lawrence Berkeley Natl Lab, Dept Canc & DNA Damage Responses, Berkeley, CA USA; [Cucinotta, Francis A.] NASA, Lyndon B Johnson Space Ctr, Space Radiat Program, Houston, TX 77058 USA	Universities Space Research Association (USRA); United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER	Wang, ML (corresponding author), Univ Space Res Assoc, Div Space Life Sci, Houston, TX USA.	francis.a.cucinotta@nasa.gov	Cucinotta, Francis/AAZ-5941-2020		National Aeronautics and Space Administration; Department of Environment	National Aeronautics and Space Administration(National Aeronautics & Space Administration (NASA)); Department of Environment	This work supported by National Aeronautics and Space Administration and Department of Environment. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andarawewa KL, 2011, INT J RADIAT ONCOL, V79, P1523, DOI 10.1016/j.ijrobp.2010.11.058; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; BARCELLOSHOFF MH, 1994, J CLIN INVEST, V93, P892, DOI 10.1172/JCI117045; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Chen C, 2001, PLOS ONE, V6; CUCINOTTA FA, 1991, RADIAT RES, V127, P130, DOI 10.2307/3577956; Cucinotta FA, 2006, LANCET ONCOL, V7, P431, DOI 10.1016/S1470-2045(06)70695-7; Ehrhart EJ, 1996, RADIAT RES, V145, P157, DOI 10.2307/3579170; Gal A, 2008, ONCOGENE, V27, P1218, DOI 10.1038/sj.onc.1210741; Harada H, 2003, MOL CANCER RES, V1, P729; Isacsson U, 1998, INT J RADIAT ONCOL, V41, P441, DOI 10.1016/S0360-3016(98)00047-9; Khan S, 2011, APOPTOSIS, V16, P1, DOI 10.1007/s10495-010-0534-4; Kong Fengming, 1995, International Journal of Radiation Oncology Biology Physics, V32, P239, DOI 10.1016/0360-3016(95)97858-X; Lamouille S, 2011, CELLS TISSUES ORGANS, V193, P8, DOI 10.1159/000320172; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Madani I, 2008, B CANCER, V95, P292, DOI 10.1684/bdc.2008.0598; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Lopez-Novoa JM, 2009, EMBO MOL MED, V1, P303, DOI 10.1002/emmm.200900043; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Ohashi S, 2010, CANCER RES, V70, P4174, DOI 10.1158/0008-5472.CAN-09-4614; Schulz-Ertner D, 2007, J CLIN ONCOL, V25, P953, DOI 10.1200/JCO.2006.09.7816; Sigurdsson V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023833; Terasawa T, 2009, ANN INTERN MED, V151, P556, DOI 10.7326/0003-4819-151-8-200910200-00145; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618; Uhl M, 2004, CANCER RES, V64, P7954, DOI 10.1158/0008-5472.CAN-04-1013; von Rahden BHA, 2006, MOL CARCINOGEN, V45, P786, DOI 10.1002/mc.20259; Wang ML, 2012, J RADIAT RES, V53, P51, DOI 10.1269/jrr.11121; Webber J, 2010, CANCER RES, V70, P9621, DOI 10.1158/0008-5472.CAN-10-1722; Xie YF, 2009, CANCER RES, V69, P7756, DOI 10.1158/0008-5472.CAN-09-0496; Zhou YC, 2011, INT J RADIAT ONCOL, V81, P1530, DOI 10.1016/j.ijrobp.2011.06.1956	31	15	17	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2012	7	7							e41249	10.1371/journal.pone.0041249	http://dx.doi.org/10.1371/journal.pone.0041249			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977TM	22844446	gold, Green Submitted, Green Published			2023-01-03	WOS:000306687700059
J	Bowen, A; Hesketh, A; Patchick, E; Young, A; Davies, L; Vail, A; Long, AF; Watkins, C; Wilkinson, M; Pearl, G; Ralph, MAL; Tyrrell, P				Bowen, Audrey; Hesketh, Anne; Patchick, Emma; Young, Alys; Davies, Linda; Vail, Andy; Long, Andrew F.; Watkins, Caroline; Wilkinson, Mo; Pearl, Gill; Ralph, Matthew A. Lambon; Tyrrell, Pippa			Effectiveness of enhanced communication therapy in the first four months after stroke for aphasia and dysarthria: a randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LANGUAGE THERAPY; SPEECH; SERVICE; CARERS	Objective To assess the effectiveness of enhanced communication therapy in the first four months after stroke compared with an attention control (unstructured social contact). Design Externally randomised, pragmatic, parallel, superiority trial with blinded outcome assessment. Setting Twelve UK hospital and community stroke services. Participants 170 adults (mean age 70 years) randomised within two weeks of admission to hospital with stroke (December 2006 to January 2010) whom speech and language therapists deemed eligible, and 135 carers. Interventions Enhanced, agreed best practice, communication therapy specific to aphasia or dysarthria, offered by speech and language therapists according to participants' needs for up to four months, with continuity from hospital to community. Comparison was with similarly resourced social contact (without communication therapy) from employed visitors. Outcome measures Primary outcome was blinded, functional communicative ability at six months on the Therapy Outcome Measure (TOM) activity subscale. Secondary outcomes (unblinded, six months): participants' perceptions on the Communication Outcomes After Stroke scale (COAST); carers' perceptions of participants from part of the Carer COAST; carers' wellbeing on Carers of Older People in Europe Index and quality of life items from Carer COAST; and serious adverse events. Results Therapist and visitor contact both had good uptake from service users. An average 22 contacts (intervention or control) over 13 weeks were accepted by users. Impairment focused therapy was the approach most often used by the speech and language therapists. Visitors most often provided general conversation. In total, 81/85 of the intervention group and 72/85 of the control group completed the primary outcome measure. Both groups improved on the TOM activity subscale. The estimated six months group difference was not statistically significant, with 0.25 (95% CI-0.19 to 0.69) points in favour of therapy. Sensitivity analyses that adjusted for chance baseline imbalance further reduced this difference. Per protocol analyses rejected a possible dilution of treatment effect from controls declining their allocation and receiving usual care. There was no added benefit of therapy on secondary outcome measures, subgroup analyses (such as aphasia), or serious adverse events, although the latter were less common after intervention (odds ratio 0.42 (95% CI 0.16 to 1.1)). Conclusions Communication therapy had no added benefit beyond that from everyday communication in the first four months after stroke. Future research should evaluate reorganised services that support functional communication practice early in the stroke pathway. This project was funded by the NIHR Health Technology Assessment programme (project No 02/11/04) and is published in full in Health Technology Assessment 2012;16(26):1-160.	[Bowen, Audrey; Hesketh, Anne; Patchick, Emma; Wilkinson, Mo] Univ Manchester, MAHSC, HCD, Manchester M13 9PL, Lancs, England; [Davies, Linda] Univ Manchester, Hlth Sci Res Grp Hlth Econ, MAHSC, Manchester M13 9PL, Lancs, England; [Vail, Andy] Univ Manchester, R&D Support Unit, Salford Royal NHS Fdn Trust, MAHSC, Salford M6 8HD, Lancs, England; [Long, Andrew F.] Univ Leeds, Sch Healthcare, Leeds LS2 9UT, W Yorkshire, England; [Watkins, Caroline] Univ Cent Lancashire, Clin Practice Res Unit, Preston PR1 2HE, Lancs, England; [Pearl, Gill] Speakeasy, Bolton BL6 4JF, England; [Ralph, Matthew A. Lambon] Univ Manchester, NARU, MAHSC, Manchester M13 9PL, Lancs, England	University of Manchester; University of Manchester; Salford Royal NHS Foundation Trust; University of Manchester; University of Leeds; University of Central Lancashire; University of Manchester	Bowen, A (corresponding author), Univ Manchester, MAHSC, HCD, Ellen Wilkinson Bldg, Manchester M13 9PL, Lancs, England.	audrey.bowen@manchester.ac.uk	Ralph, Matthew A Lambon/A-1695-2009; Bowen, Audrey/K-5544-2012; Watkins, Caroline L/E-6898-2013; Young, Alys/R-5348-2019	Ralph, Matthew A Lambon/0000-0001-5907-2488; Watkins, Caroline L/0000-0002-9403-3772; Young, Alys/0000-0001-8551-5078; Davies, Linda/0000-0001-8801-3559; /0000-0002-4198-5761; Bowen, Audrey/0000-0003-4075-1215; Hesketh, Anne/0000-0003-0583-0217; Vail, Andy/0000-0001-8274-2726; Tyrrell, Pippa/0000-0001-9609-1231	NIHR Health Technology Assessment programme [02/11/04]; NIHR Health Technology Assessment programme; UK's NIHR Health Technology Assessment Programme [02/1104]; Department of Health central subvention and the Stroke Association; National Institute for Health Research [02/11/04] Funding Source: researchfish	NIHR Health Technology Assessment programme(National Institute for Health Research (NIHR)); NIHR Health Technology Assessment programme(National Institute for Health Research (NIHR)); UK's NIHR Health Technology Assessment Programme; Department of Health central subvention and the Stroke Association; National Institute for Health Research(National Institute for Health Research (NIHR))	This project was funded by the NIHR Health Technology Assessment programme (project No 02/11/04) and is published in full in Health Technology Assessment 2012;16(26):1-160.; This project was funded by the NIHR Health Technology Assessment programme and is published in full in Health Technology Assessment 2012: 16(26) ISSN 1366-5278; ACT NoW was commissioned and funded by the UK's NIHR Health Technology Assessment Programme (ref 02/1104), with partial funding for participating NHS trusts' excess treatment costs provided by a Department of Health central subvention and the Stroke Association. An independent Trial Steering Committee and a Data Monitoring and Ethics Committee were appointed by the NIHR. The researchers were independent of the study funders, although several have served on their advisory or funding committees (AB, PT, CW, AH, LD, AV).	[Anonymous], 2010, NAT SENT STROK AUD O; Bakheit AMO, 2007, CLIN REHABIL, V21, P885, DOI 10.1177/0269215507078486; Bowen A, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16260; Brady MC, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000425.pub3, 10.1002/14651858.CD000425.pub4]; Brumfitt S, 1998, Int J Lang Commun Disord, V33 Suppl, P116; Collin C, 1988, Int Disabil Stud, V10, P61; DAVID R, 1982, J NEUROL NEUROSUR PS, V45, P957, DOI 10.1136/jnnp.45.11.957; ENDERBY P, 1989, BRIT J DISORD COMMUN, V24, P301; Enderby P., 2009, THERAPY OUTCOME MEAS; Enderby P M, 1987, Int Rehabil Med, V8, P166; French B, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006073.pub2; Gillham S, 2011, PSYCHOL CARE STROKE; Godecke E, 2012, INT J STROKE, V7, P635, DOI 10.1111/j.1747-4949.2011.00631.x; Hesketh A, 2008, APHASIOLOGY, V22, P970, DOI 10.1080/02687030801952709; Hilari K, 2010, CLIN REHABIL, V24, P181, DOI 10.1177/0269215509346090; Langhorne P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000197.pub3; Laska AC, 2011, CEREBROVASC DIS EXTR, V1, P66, DOI 10.1159/000329835; Lewin Simon, 2009, BMJ, V339, pb3496, DOI 10.1136/bmj.b3496; Long AF, 2008, CLIN REHABIL, V22, P1083, DOI 10.1177/0269215508090091; Long A, 2009, CLIN REHABIL, V23, P846, DOI 10.1177/0269215509336055; Matrix Evidence, 2010, EC EV SPEECH LANG TH; McKee KJ, 2003, AGING MENT HEALTH, V7, P39, DOI 10.1080/1360786021000006956; National Audit Office, 2010, PROGR IMPR STROK CAR; National Clinical Guideline Centre, 2011, STROK REH C IN PRESS; Pettitt DA, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c5972; Royal College of Physicians, 2011, NAT SENT STROK CLIN; Royal College of Physicians (Intercollegiate Stroke Working Party), 2008, NAT CLIN GUID STROK; Royal College of Speech and Language Therapists, 2009, RCSLT RES MAN COMM P; Scottish Intercollegiate Guideline Network, 2010, MAN PAT STROK 591 RE; Sellars C, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002088.pub2; Thomas SA, 2006, BRIT J CLIN PSYCHOL, V45, P49, DOI 10.1348/014466505X34183; University of Manchester School of Psychological Sciences, ASS COMM THER N W AC; Young A, CLIN REHABI IN PRESS	33	53	55	1	85	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 13	2012	345								e4407	10.1136/bmj.e4407	http://dx.doi.org/10.1136/bmj.e4407			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975NX	22797843	Green Submitted, Green Published, hybrid, Green Accepted			2023-01-03	WOS:000306519100001
J	Tong, CCL; Ko, EC; Sung, MW; Cesaretti, JA; Stock, RG; Packer, SH; Forsythe, K; Genden, EM; Schwartz, M; Lau, KHV; Galsky, M; Ozao-Choy, J; Chen, SH; Kao, J				Tong, Charles C. L.; Ko, Eric C.; Sung, Max W.; Cesaretti, Jamie A.; Stock, Richard G.; Packer, Stuart H.; Forsythe, Kevin; Genden, Eric M.; Schwartz, Myron; Lau, K. H. Vincent; Galsky, Matthew; Ozao-Choy, Junko; Chen, Shu-hsia; Kao, Johnny			Phase II Trial of Concurrent Sunitinib and Image-Guided Radiotherapy for Oligometastases	PLOS ONE			English	Article							STEREOTACTIC BODY RADIATION; METASTATIC COLORECTAL-CANCER; RENAL-CELL CARCINOMA; BREAST-CANCER; LUNG-CANCER; LIVER METASTASES; PLUS IRINOTECAN; PROSTATE-CANCER; I/II TRIAL; THERAPY	Background: Preclinical data suggest that sunitinib enhances the efficacy of radiotherapy. We tested the combination of sunitinib and hypofractionated image-guided radiotherapy (IGRT) in a cohort of patients with historically incurable distant metastases. Methods: Twenty five patients with oligometastases, defined as 1-5 sites of active disease on whole body imaging, were enrolled in a phase II trial from 2/08 to 9/10. The most common tumor types treated were head and neck, liver, lung, kidney and prostate cancers. Patients were treated with the recommended phase II dose of 37.5 mg daily sunitinib (days 1-28) and IGRT 50 Gy (days 8-12 and 15-19). Maintenance sunitinib was used in 33% of patients. Median follow up was 17.5 months (range, 0.7 to 37.4 months). Results: The 18-month local control, distant control, progression-free survival (PFS) and overall survival (OS) were 75%, 52%, 56% and 71%, respectively. At last follow-up, 11 (44%) patients were alive without evidence of disease, 7 (28%) were alive with distant metastases, 3 (12%) were dead from distant metastases, 3 (12%) were dead from comorbid illness, and 1 (4%) was dead from treatment-related toxicities. The incidence of acute grade >= 3 toxicities was 28%, most commonly myelosuppression, bleeding and abnormal liver function tests. Conclusions: Concurrent sunitinib and IGRT achieves major clinical responses in a subset of patients with oligometastases.	[Tong, Charles C. L.; Ko, Eric C.; Stock, Richard G.; Forsythe, Kevin; Lau, K. H. Vincent] Mt Sinai Med Ctr, Dept Radiat Oncol, New York, NY 10029 USA; [Tong, Charles C. L.; Genden, Eric M.] Mt Sinai Med Ctr, Dept Otolaryngol Head & Neck Surg, New York, NY 10029 USA; [Sung, Max W.; Packer, Stuart H.; Galsky, Matthew] Mt Sinai Med Ctr, Dept Med Oncol, New York, NY 10029 USA; [Cesaretti, Jamie A.] Florida Radiat Oncol Grp, Jacksonville, FL USA; [Ozao-Choy, Junko; Chen, Shu-hsia] Mt Sinai Med Ctr, Dept Oncol Sci, New York, NY 10029 USA; [Kao, Johnny] Good Samaritan Hosp, Med Ctr, Dept Radiat Oncol, W Islip, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Tong, CCL (corresponding author), Mt Sinai Med Ctr, Dept Radiat Oncol, New York, NY 10029 USA.	johnnykaomd@gmail.com	Ko, Eric/AAB-7870-2019	Ko, Eric/0000-0003-2308-115X; Tong, Charles/0000-0002-4471-5134; Cesaretti, Jamie/0000-0001-6294-0047	Pfizer [2005-1082]; Ellen Katz Foundation; NATIONAL CANCER INSTITUTE [R01CA109322] Funding Source: NIH RePORTER	Pfizer(Pfizer); Ellen Katz Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by Pfizer and the Ellen Katz Foundation Award. Sunitinib was provided by Pfizer. Financial disclosure: JK received the Pfizer investigator initiated award #2005-1082 and the Ellen Katz Foundation Award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chow LQM, 2007, J CLIN ONCOL, V25, P884, DOI 10.1200/JCO.2006.06.3602; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; HELLMAN S, 1995, J CLIN ONCOL, V13, P8, DOI 10.1200/JCO.1995.13.1.8; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Je YJ, 2009, LANCET ONCOL, V10, P967, DOI 10.1016/S1470-2045(09)70222-0; Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834; Kao J, 2010, CRIT REV ONCOL HEMAT; Kao J, 2009, CANCER-AM CANCER SOC, V115, P3571, DOI 10.1002/cncr.24412; Ko JS, 2009, CLIN CANCER RES, V15, P2148, DOI 10.1158/1078-0432.CCR-08-1332; Lee MT, 2009, J CLIN ONCOL, V27, P1585, DOI 10.1200/JCO.2008.20.0600; Lee YJ, 2009, BLOOD, V114, P589, DOI 10.1182/blood-2009-02-206870; MacDermed DM, 2008, J SURG ONCOL, V98, P202, DOI 10.1002/jso.21102; Marks LB, 2000, INT J RADIAT ONCOL, V48, P625, DOI 10.1016/S0360-3016(00)00697-0; Mauceri HJ, 1998, NATURE, V394, P287, DOI 10.1038/28412; Metha N, 2004, INT J ONCOL, V25, P1677; Milano MT, 2008, CANCER-AM CANCER SOC, V112, P650, DOI 10.1002/cncr.23209; Milano MT, 2008, RADIAT ONCOL, V3, DOI 10.1186/1748-717X-3-36; Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Ozao-Choy J, 2009, CANCER RES, V69, P2514, DOI 10.1158/0008-5472.CAN-08-4709; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Rusthoven KE, 2009, J CLIN ONCOL, V27, P1572, DOI 10.1200/JCO.2008.19.6329; Rusthoven KE, 2009, J CLIN ONCOL, V27, P1579, DOI 10.1200/JCO.2008.19.6386; Salama JK, 2008, CLIN CANCER RES, V14, P5255, DOI 10.1158/1078-0432.CCR-08-0358; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Schueneman AJ, 2003, CANCER RES, V63, P4009; Seiwert TY, 2007, NAT CLIN PRACT ONCOL, V4, P86, DOI 10.1038/ncponc0714; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Vu HL, 2010, CANCER LETT, V288, P149, DOI 10.1016/j.canlet.2009.06.026; Wahl RL, 2009, J NUCL MED, V50, p122S, DOI 10.2967/jnumed.108.057307	33	55	56	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2012	7	6							e36979	10.1371/journal.pone.0036979	http://dx.doi.org/10.1371/journal.pone.0036979			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	966GL	22761653	Green Published, gold, Green Submitted			2023-01-03	WOS:000305825800004
J	Lee, AS; Chen, WP; Kuo, YL; Ho, YJ; Lee, SS; Su, MJ				Lee, A. S.; Chen, W. P.; Kuo, Y. L.; Ho, Y. J.; Lee, S. S.; Su, M. J.			Thaliporphine Preserves Cardiac Function of Endotoxemic Rabbits by Both Directly and Indirectly Attenuating NF kappa B Signaling Pathway	PLOS ONE			English	Article							VENTRICULAR CONTRACTILITY; CANINE MODEL; TNF-ALPHA; SEPSIS; DYSFUNCTION; ACTIVATION; EXPRESSION; MECHANISMS; DEPRESSION; INHIBITION	Cardiac depression in sepsis is associated with the increased morbidity and mortality. Although myofilaments damage, autonomic dysfunction, and apoptosis play roles in sepsis-induced myocardial dysfunction, the underlying mechanism is not clear. All of these possible factors are related to NF kappa B signaling, which plays the main role in sepsis signaling. Thaliporphine was determined to possess anti-inflammatory and cardioprotective activity by suppressing NF kappa B signaling in rodents. The purpose of this study is to further prove this protective effect in larger septic animals, and try to find the underlying mechanisms. The systolic and diastolic functions were evaluated in vivo by pressure-volume analysis at different preloads. Both preload-dependent and - independent hemodynamic parameters were performed. Inflammatory factors of whole blood and serum samples were analyzed. Several sepsis-related signaling pathways were also determined at protein level. Changes detected by conductance catheter showed Thaliporphine could recover impaired left ventricular systolic function after 4 hours LPS injection. It could also reverse the LPS induced steeper EDPVR and gentler ESPVR, thus improve Ees, Ea, and PRSW. Thaliporphine may exert this protective effect by decreasing TNF alpha and caspase3 dependent cell apoptosis, which was consistent with the decreased serum cTnI and LDH concentration. Thaliporphine could protect sepsis-associated myocardial dysfunction in both preload-dependent and - independent ways. It may exert these protective effects by both increase of "good"-PI3K/Akt/mTOR and decrease of "bad"-p38/NF kappa B pathways, which followed by diminishing TNF alpha and caspase3 dependent cell apoptosis.	[Lee, A. S.] China Med Univ Hosp, Div Cardiol, Taichung, Taiwan; [Lee, A. S.] China Med Univ Hosp, Res Ctr L5, Taichung, Taiwan; [Lee, A. S.] China Med Univ, Taichung, Taiwan; [Chen, W. P.; Kuo, Y. L.; Ho, Y. J.; Su, M. J.] Natl Taiwan Univ, Coll Med, Inst Pharmacol, Taipei, Taiwan; [Lee, S. S.] Natl Taiwan Univ, Coll Med, Sch Pharm, Taipei 10764, Taiwan	China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; National Taiwan University; National Taiwan University	Lee, AS (corresponding author), China Med Univ Hosp, Div Cardiol, Taichung, Taiwan.	mingja@ntu.edu.tw		SU, MING-JAI/0000-0001-8887-6899; Lee, An-sheng/0000-0001-8176-3269; Chen, Wen-Pin/0000-0002-0143-5642	National Science Council [NSC96-3114-P-002-002-Y]; Taiwan Department of Health Clinical Trial and Research Center of Excellence [DOH100-TD-B-111-004]; China Medical University Hospital [DMR-99-172]	National Science Council(Ministry of Science and Technology, Taiwan); Taiwan Department of Health Clinical Trial and Research Center of Excellence; China Medical University Hospital	This study was supported by a research of grant of National Science Council (NSC96-3114-P-002-002-Y), Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH100-TD-B-111-004), and China Medical University Hospital (DMR-99-172). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADAMS JE, 1993, CIRCULATION, V88, P101, DOI 10.1161/01.CIR.88.1.101; Amadou A, 2002, AM J PHYSIOL-CELL PH, V282, pC1339, DOI 10.1152/ajpcell.00471.2001; Annane D, 2005, LANCET, V365, P63, DOI 10.1016/S0140-6736(04)17667-8; Balija TM, 2011, CURR OPIN INFECT DIS, V24, P248, DOI 10.1097/QCO.0b013e32834536ce; Barraud D, 2007, CRIT CARE MED, V35, P1376, DOI 10.1097/01.CCM.0000261889.18102.84; Brown KA, 2006, LANCET, V368, P157, DOI 10.1016/S0140-6736(06)69005-3; Bryant D, 1998, CIRCULATION, V97, P1375, DOI 10.1161/01.CIR.97.14.1375; CAPASSO JM, 1989, CIRC RES, V65, P1499, DOI 10.1161/01.RES.65.6.1499; Chen WP, 2010, N-S ARCH PHARMACOL, V382, P441, DOI 10.1007/s00210-010-0562-1; Chiao CW, 2005, N-S ARCH PHARMACOL, V371, P34, DOI 10.1007/s00210-004-1014-6; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; CUNNION RE, 1986, CIRCULATION, V73, P637, DOI 10.1161/01.CIR.73.4.637; Davani EY, 2006, CARDIOVASC RES, V72, P134, DOI 10.1016/j.cardiores.2006.06.029; Estes J E, 1980, Adv Shock Res, V3, P229; Fernandes A, 2007, EUR J NEUROSCI, V25, P1058, DOI 10.1111/j.1460-9568.2007.05340.x; Fernandes CJ, 1999, INTENS CARE MED, V25, P1165, DOI 10.1007/s001340051030; GUINAUDEAU H, 1975, LLOYDIA, V38, P275; Heumann D, 2002, CLIN CHIM ACTA, V323, P59, DOI 10.1016/S0009-8981(02)00180-8; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; HUNG J, 1993, CIRC RES, V73, P125, DOI 10.1161/01.RES.73.1.125; Issa R, 2007, J IMMUNOL, V178, P7366, DOI 10.4049/jimmunol.178.11.7366; KASS DA, 1987, CIRCULATION, V76, P1422, DOI 10.1161/01.CIR.76.6.1422; Klintman D, 2005, ANN SURG, V242, P830, DOI 10.1097/01.sla.0000189132.86878.f7; KUTSKY P, 1990, CIRC SHOCK, V30, P349; LEFER AM, 1970, AM J PHYSIOL, V218, P1423, DOI 10.1152/ajplegacy.1970.218.5.1423; Li MX, 2005, CIRCULATION, V111, P2494, DOI 10.1161/01.CIR.0000165117.71483.0C; Liaudet L, 2000, CRIT CARE MED, V28, pN37, DOI 10.1097/00003246-200004001-00005; LIU MS, 1991, BIOCHEM BIOPH RES CO, V174, P1248, DOI 10.1016/0006-291X(91)91555-Q; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; MCDONOUGH KH, 1988, CIRC SHOCK, V25, P291; Mebazaa A, 2001, CIRCULATION, V104, P3137, DOI 10.1161/hc5001.100662; Mendes SD, 2009, CELL SIGNAL, V21, P1109, DOI 10.1016/j.cellsig.2009.02.025; Merx MW, 2007, CIRCULATION, V116, P793, DOI 10.1161/CIRCULATIONAHA.106.678359; Munt B, 1998, CRIT CARE MED, V26, P1829, DOI 10.1097/00003246-199811000-00023; NATANSON C, 1989, J CLIN INVEST, V83, P243, DOI 10.1172/JCI113866; Neviere RR, 1999, AM J PHYSIOL-HEART C, V277, pH885, DOI 10.1152/ajpheart.1999.277.3.H885; ORCHARD CH, 1990, AM J PHYSIOL, V258, pC967, DOI 10.1152/ajpcell.1990.258.6.C967; Pathan N, 2004, LANCET, V363, P203, DOI 10.1016/S0140-6736(03)15326-3; PAWLUSH DG, 1990, CIRC SHOCK, V31, P269; Peng TQ, 2003, CARDIOVASC RES, V59, P893, DOI 10.1016/S0008-6363(03)00509-1; PETROS A, 1994, CARDIOVASC RES, V28, P34, DOI 10.1093/cvr/28.1.34; Poelaert J, 1997, INTENS CARE MED, V23, P553, DOI 10.1007/s001340050372; Seybold J, 2005, BLOOD, V105, P3569, DOI 10.1182/blood-2004-07-2729; SHAPIRO JI, 1990, AM J PHYSIOL, V258, pH1835, DOI 10.1152/ajpheart.1990.258.6.H1835; Sharma AC, 2007, SHOCK, V28, P265, DOI 10.1097/01.shk.0000235090.30550.fb; SOLOMON MA, 1994, AM J PHYSIOL, V266, pH757, DOI 10.1152/ajpheart.1994.266.2.H757; Tao WK, 2004, SHOCK, V21, P31, DOI 10.1097/01.shk.0000101673.49265.5d; Tavener SA, 2006, AM J PHYSIOL-HEART C, V290, pH800, DOI 10.1152/ajpheart.00701.2005; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Vieillard-Baron A, 2003, AM J RESP CRIT CARE, V168, P1270, DOI 10.1164/rccm.200306-816CC; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990; Yang M, 2008, AM J PHYSIOL-HEART C, V294, pH994, DOI 10.1152/ajpheart.01044.2007; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257	54	9	9	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2012	7	6							e39174	10.1371/journal.pone.0039174	http://dx.doi.org/10.1371/journal.pone.0039174			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	965QG	22761733	gold, Green Published, Green Submitted			2023-01-03	WOS:000305781700020
J	Rosenfeld, M; Ratjen, F; Brumback, L; Daniel, S; Rowbotham, R; McNamara, S; Johnson, R; Kronmal, R; Davis, SD				Rosenfeld, Margaret; Ratjen, Felix; Brumback, Lyndia; Daniel, Stephen; Rowbotham, Ron; McNamara, Sharon; Johnson, Robin; Kronmal, Richard; Davis, Stephanie D.		ISIS Study Grp	Inhaled Hypertonic Saline in Infants and Children Younger Than 6 Years With Cystic Fibrosis The ISIS Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PSEUDOMONAS-AERUGINOSA; PULMONARY-FUNCTION; FUNCTION TESTS; LUNG-FUNCTION; SAFETY; TOLERABILITY; INFECTION; EFFICACY	Context Inhaled hypertonic saline is recommended as therapy for patients 6 years or older with cystic fibrosis (CF), but its efficacy has never been evaluated in patients younger than 6 years with CF. Objective To determine if hypertonic saline reduces the rate of protocol-defined pulmonary exacerbations in patients younger than 6 years with CF. Design, Setting, and Participants The Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS), a multicenter, randomized, double-blind, placebo-controlled trial conducted from April 2009 to October 2011 at 30 CF care centers in the United States and Canada. Participants were aged 4 to 60 months and had an established diagnosis of CF. A total of 344 patients were assessed for eligibility; 321 participants were randomized; 29 (9%) withdrew prematurely. Intervention The active treatment group (n=158) received 7% hypertonic saline and the control group (n=163) received 0.9% isotonic saline, nebulized twice daily for 48 weeks. Both groups received albuterol or levalbuterol prior to each study drug dose. Main Outcome Measures Rate during the 48-week treatment period of protocol-defined pulmonary exacerbations treated with oral, inhaled, or intravenous antibiotics. Results The mean pulmonary exacerbation rate (events per person-year) was 2.3 (95% CI, 2.0-2.5) in the active treatment group and 2.3 (95% CI, 2.1-2.6) in the control group; the adjusted rate ratio was 0.98 (95% CI, 0.84-1.15). Among participants with pulmonary exacerbations, the mean number of total antibiotic treatment days for a pulmonary exacerbation was 60 (95% CI, 49-70) in the active treatment group and 52 (95% CI, 43-61) in the control group. There was no significant difference in secondary end points including height, weight, respiratory rate, oxygen saturation, cough, or respiratory symptom scores. Infant pulmonary function testing performed as an exploratory outcome in a subgroup (n=73, with acceptable measurements at 2 visits in 45 participants) did not demonstrate significant differences between groups except for the mean change in forced expiratory volume in 0.5 seconds, which was 38 mL (95% CI, 1-76) greater in the active treatment group. Adherence determined by returned study drug ampoules was at least 75% in each group. Adverse event profiles were also similar, with the most common adverse event of moderate or severe severity in each group being cough (39% of active treatment group, 38% of control group). Conclusion Among infants and children younger than 6 years with cystic fibrosis, the use of inhaled hypertonic saline compared with isotonic saline did not reduce the rate of pulmonary exacerbations over the course of 48 weeks of treatment.	[Rosenfeld, Margaret; McNamara, Sharon] Seattle Childrens Hosp, Div Pulm Med, Seattle, WA 98105 USA; [Rowbotham, Ron] Seattle Childrens Hosp, Cyst Fibrosis Fdn Therapeut Dev Network Coordinat, Seattle, WA USA; [Rosenfeld, Margaret] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; [Brumback, Lyndia; Daniel, Stephen; Kronmal, Richard] Univ Washington, Sch Med, Dept Biostat, Seattle, WA USA; [Ratjen, Felix] Univ Toronto, Hosp Sick Children, Dept Pediat, Div Resp Med, Toronto, ON M5G 1X8, Canada; [Johnson, Robin; Davis, Stephanie D.] Univ N Carolina, Dept Pediat, Div Pediat Pulmonol, Chapel Hill, NC 27515 USA	Seattle Children's Hospital; Cystic Fibrosis Foundation; Seattle Children's Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of North Carolina; University of North Carolina Chapel Hill	Rosenfeld, M (corresponding author), Seattle Childrens Hosp, Div Pulm Med, A5937,4800 Sandpoint Way NE, Seattle, WA 98105 USA.	margaret.rosenfeld@seattlechildrens.org		Milla, Carlos/0000-0001-5515-3053; Rosenfeld, Margaret/0000-0002-8105-614X; McIlwaine, Maggie/0000-0002-4646-3209; Weiner, Daniel/0000-0001-8245-1961; Jensen, Renee/0000-0002-0877-9579; Ratjen, Felix/0000-0003-4057-6592	CF Foundation Therapeutics Inc [ISIS07K1]; National Institutes of Health (NIH) [U01 HL 092931, U01 HL092932, UL1RR025014]; Genentech; CF Canada; Canadian Institute for Child Health; Inspire Inc; National Heart, Lung, and Blood Institute; subsidiary of the not-for-profit Cystic Fibrosis Foundation; Natinal Center for Research Resources; National Center for Advancing Translational Sciences, NIH [UL1RR025014]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025014] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL092931, U01HL092932] Funding Source: NIH RePORTER	CF Foundation Therapeutics Inc; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Genentech(Roche HoldingGenentech); CF Canada; Canadian Institute for Child Health; Inspire Inc; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); subsidiary of the not-for-profit Cystic Fibrosis Foundation; Natinal Center for Research Resources; National Center for Advancing Translational Sciences, NIH; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Rosenfeld reported receiving funding (institutional) from CF Foundation Therapeutics Inc and the National Institutes of Health (NIH) and serving as a consultant for Vertex Pharmaceuticals and for the North American Scientific Advisory Group of the Epidemiologic Study of CF sponsored by Genentech. Dr Ratjen reported receiving funding (institutional) from CF Foundation Therapeutics Inc, the NIH, CF Canada, the Canadian Institute for Child Health, and Inspire Inc; serving as a consultant for Inspire Inc, Vertex Pharmaceuticals, Novartis, Bayer, Talecris, CSL Behring, Roche, and Gilead; serving on a speakers board for Genentech; and receiving meeting expenses from Pari Respiratory Equipment. Ms Johnson reported serving as a consultant for nSpire Health. Dr Brumback, Dr Daniel, and Dr Kronmal reported receiving funding (institutional) from the National Heart, Lung, and Blood Institute and CF Foundation Therapeutics Inc. Dr Davis reported receiving funding (institutional) from CF Foundation Therapeutics Inc and the NIH and serving as a consultant or on the advisory board for Vertex Pharmaceuticals, Novartis and Inspire Inc. No other authors reported disclosures.; This study was jointly funded by the NIH (U01 HL 092931, U01 HL092932, UL1RR025014) and CF Foundation Therapeutics Inc (ISIS07K1), the subsidiary of the not-for-profit Cystic Fibrosis Foundation that sponsors research grants and contracts. The University of Washington site was also supported by the Natinal Center for Research Resources and the National Center for Advancing Translational Sciences, NIH (UL1RR025014). Study drug and placebo were supplied by Pari Respiratory Equipment and Catalent, respectively, which were not otherwise involved in any aspect of the study.	American Thoracic Society, 2005, Am J Respir Crit Care Med, V172, P1463; Boucher RC, 2007, J INTERN MED, V261, P5, DOI 10.1111/j.1365-2796.2006.01744.x; Castile R, 2000, PEDIATR PULM, V30, P215, DOI 10.1002/1099-0496(200009)30:3<215::AID-PPUL6>3.0.CO;2-V; Cystic Fibrosis Foundation, 2011, NAT PAT REG 2010 ANN; Davis SD, 2007, AM J RESP CRIT CARE, V175, P943, DOI 10.1164/rccm.200603-343OC; Davis SD, 2010, AM J RESP CRIT CARE, V182, P1387, DOI 10.1164/rccm.200908-1236OC; Dellon EP, 2008, PEDIATR PULM, V43, P1100, DOI 10.1002/ppul.20909; Dmello D, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2010-000019; Donaldson SH, 2006, NEW ENGL J MED, V354, P241, DOI 10.1056/NEJMoa043891; Elkins MR, 2006, NEW ENGL J MED, V354, P229, DOI 10.1056/NEJMoa043900; Eng PA, 1996, PEDIATR PULM, V21, P77, DOI 10.1002/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.0.CO;2-M; Liou TG, 2001, AM J EPIDEMIOL, V153, P345, DOI 10.1093/aje/153.4.345; Livraghi A, 2007, TOXICOL PATHOL, V35, P116, DOI 10.1080/01926230601060025; Mayer-Hamblett N, 2002, AM J RESP CRIT CARE, V166, P1550, DOI 10.1164/rccm.200202-087OC; Mayer-Hamblett Nicole, 2007, Proc Am Thorac Soc, V4, P370, DOI 10.1513/pats.200703-040BR; Mott LS, 2012, THORAX, V67, P509, DOI 10.1136/thoraxjnl-2011-200912; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Quittner AL, 2000, J PEDIATR PSYCHOL, V25, P403, DOI 10.1093/jpepsy/25.6.403; Ranganathan SC, 2004, AM J RESP CRIT CARE, V169, P928, DOI 10.1164/rccm.200309-1344OC; Rosenfeld M, 2011, PEDIATR PULM, V46, P666, DOI 10.1002/ppul.21425; Rosenfeld M, 2010, PEDIATR PULM, V45, P934, DOI 10.1002/ppul.21279; Saiman L, 2003, INFECT CONT HOSP EP, V24, pS6, DOI 10.1086/503485; Saiman L, 2010, JAMA-J AM MED ASSOC, V303, P1707, DOI 10.1001/jama.2010.563; Stocks J, 2001, EUR RESPIR J, V17, P302, DOI 10.1183/09031936.01.17203020; Subbarao P, 2007, PEDIATR PULM, V42, P471, DOI 10.1002/ppul.20603; Treggiari MM, 2011, ARCH PEDIAT ADOL MED, V165, P847, DOI 10.1001/archpediatrics.2011.136; van Ewijk Bart E, 2005, J Cyst Fibros, V4 Suppl 2, P31, DOI 10.1016/j.jcf.2005.05.011; Wark P, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001506.pub3; West SEH, 2002, JAMA-J AM MED ASSOC, V287, P2958, DOI 10.1001/jama.287.22.2958; Zhang LJ, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006286.pub2	30	149	151	1	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 6	2012	307	21					2269	2277		10.1001/jama.2012.5214	http://dx.doi.org/10.1001/jama.2012.5214			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	952OL	22610452	Green Accepted			2023-01-03	WOS:000304801700021
J	Epstein, K				Epstein, Keith			Is spending on proton beam therapy for cancer going too far, too fast?	BRITISH MEDICAL JOURNAL			English	Editorial Material							COST-EFFECTIVENESS; RADIATION-THERAPY; PROSTATE					keith@kepstein.com						Chen R, 2012, JAMA            0418; Jakel O, 2007, RADIOTHER ONCOL, V83, P133, DOI 10.1016/j.radonc.2007.03.010; Kim S, 2011, EUR UROL, V60, P908, DOI 10.1016/j.eururo.2011.05.052; Konski A, 2007, J CLIN ONCOL, V25, P3603, DOI 10.1200/JCO.2006.09.0811; Lundkvist J, 2005, CANCER-AM CANCER SOC, V103, P793, DOI 10.1002/cncr.20844	5	11	12	0	12	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	APR 17	2012	344								e2488	10.1136/bmj.e2488	http://dx.doi.org/10.1136/bmj.e2488			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	931CN	22511301				2023-01-03	WOS:000303192100019
J	Lukianova-Hleb, EY; Ren, XY; Constantinou, PE; Danysh, BP; Shenefelt, DL; Carson, DD; Farach-Carson, MC; Kulchitsky, VA; Wu, XW; Wagner, DS; Lapotko, DO				Lukianova-Hleb, Ekaterina Y.; Ren, Xiaoyang; Constantinou, Pamela E.; Danysh, Brian P.; Shenefelt, Derek L.; Carson, Daniel D.; Farach-Carson, Mary C.; Kulchitsky, Vladimir A.; Wu, Xiangwei; Wagner, Daniel S.; Lapotko, Dmitri O.			RETRACTED: Improved Cellular Specificity of Plasmonic Nanobubbles versus Nanoparticles in Heterogeneous Cell Systems (Retracted article. See vol. 12, art no E0187820, 2017)	PLOS ONE			English	Article; Retracted Publication							SCATTERING SUBMICROSCOPIC PARTICLES; HIGHLY FLUORESCENT ANALOGS; GOLD NANOPARTICLES; DRUG-DELIVERY; PHOTOTHERMAL BUBBLES; BIOLOGICAL APPLICATIONS; OPTICAL-SCATTERING; NANO-THERMOLYSIS; LEUKEMIA-CELLS; TRACER LABELS	The limited specificity of nanoparticle (NP) uptake by target cells associated with a disease is one of the principal challenges of nanomedicine. Using the threshold mechanism of plasmonic nanobubble (PNB) generation and enhanced accumulation and clustering of gold nanoparticles in target cells, we increased the specificity of PNB generation and detection in target versus non-target cells by more than one order of magnitude compared to the specificity of NP uptake by the same cells. This improved cellular specificity of PNBs was demonstrated in six different cell models representing diverse molecular targets such as epidermal growth factor receptor, CD3 receptor, prostate specific membrane antigen and mucin molecule MUC1. Thus PNBs may be a universal method and nano-agent that overcome the problem of non-specific uptake of NPs by non-target cells and improve the specificity of NP-based diagnostics, therapeutics and theranostics at the cell level.	[Lukianova-Hleb, Ekaterina Y.; Constantinou, Pamela E.; Danysh, Brian P.; Shenefelt, Derek L.; Carson, Daniel D.; Farach-Carson, Mary C.; Wagner, Daniel S.; Lapotko, Dmitri O.] Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77251 USA; [Ren, Xiaoyang; Wu, Xiangwei] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; [Kulchitsky, Vladimir A.] Natl Acad Sci Belarus, Inst Physiol, Minsk, BELARUS; [Lapotko, Dmitri O.] Rice Univ, Dept Phys & Astron, Houston, TX USA	Rice University; University of Texas System; UTMD Anderson Cancer Center; National Academy of Sciences of Belarus (NASB); Institute of Physiology of the National Academy of Sciences of Belarus; Rice University	Lukianova-Hleb, EY (corresponding author), Rice Univ, Dept Biochem & Cell Biol, POB 1892, Houston, TX 77251 USA.	dl5@rice.edu	Kulchitsky, Vladimir/AAS-1322-2021; Wagner, Daniel S/C-9379-2009; ren, xianyan/J-3165-2018	Wagner, Daniel S/0000-0002-0595-2436; Farach-Carson, Mary/0000-0002-4526-3088; Danysh, Brian/0000-0001-6839-6337	National Institutes of Health [R01GM094816, P01 CA098912, S10RR026399 01]; MD Anderson Gynecologic Specialized Programs of Research Excellence (SPORE) in Uterine Cancer [2P50CA098258-06]; NATIONAL CANCER INSTITUTE [P50CA098258] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR026399, S10RR015961] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM094816] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MD Anderson Gynecologic Specialized Programs of Research Excellence (SPORE) in Uterine Cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by National Institutes of Health Grant R01GM094816 (DOL), P01 CA098912 (MCFC), MD Anderson Gynecologic Specialized Programs of Research Excellence (SPORE) in Uterine Cancer, Pilot Project Award 2P50CA098258-06 (DDC). Confocal microscopy was performed on equipment obtained through a Shared Instrumentation Grant from the National Institutes of Health (S10RR026399 01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamson A.W., 1997, PHYS CHEM SURFACES, Vsixth; Anderson LJE, 2010, J CONTROL RELEASE, V144, P151, DOI 10.1016/j.jconrel.2010.02.012; ANDERSON RR, 1983, SCIENCE, V220, P524, DOI 10.1126/science.6836297; Bernardi RJ, 2008, J NEURO-ONCOL, V86, P165, DOI 10.1007/s11060-007-9467-3; Bohren C.F., 1998, ADSORPTION SCATTERIN, DOI DOI 10.1002/9783527618156; Boisselier E, 2009, CHEM SOC REV, V38, P1759, DOI 10.1039/b806051g; Braun GB, 2009, ACS NANO, V3, P2007, DOI 10.1021/nn900469q; Cai WB, 2008, NANOTECHNOL SCI APPL, V1, P17, DOI 10.2147/NSA.S3788; Chen WX, 2010, MOL CANCER THER, V9, P1028, DOI 10.1158/1535-7163.MCT-09-0829; Chithrani BD, 2007, NANO LETT, V7, P1542, DOI 10.1021/nl070363y; Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o; Cho KJ, 2008, CLIN CANCER RES, V14, P1310, DOI 10.1158/1078-0432.CCR-07-1441; De Gennes P.G., 2004, CAPILLARY WETTING PH; Dean J. A., 1999, LANGES HDB CHEM; El-Sayed IH, 2005, NANO LETT, V5, P829, DOI 10.1021/nl050074e; Francois L, 2001, PHYS CHEM CHEM PHYS, V3, P4965, DOI 10.1039/b106690k; Gregor PD, 2005, INT J CANCER, V116, P415, DOI 10.1002/ijc.21014; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; Hauck TS, 2008, ADV MATER, V20, P3832, DOI 10.1002/adma.200800921; Hleb EY, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/35/355702; Hleb EY, 2008, NANOMEDICINE-UK, V3, P647, DOI 10.2217/17435889.3.5.647; Hleb EY, 2008, NANOMEDICINE-UK, V3, P797, DOI 10.2217/17435889.3.6.797; Hu M, 2006, CHEM SOC REV, V35, P1084, DOI 10.1039/b517615h; Huang XH, 2006, J AM CHEM SOC, V128, P2115, DOI 10.1021/ja057254a; Huschka R, 2010, NANO LETT, V10, P4117, DOI 10.1021/nl102293b; Hutson MS, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.158104; Jain PK, 2008, ACCOUNTS CHEM RES, V41, P1578, DOI 10.1021/ar7002804; Khlebtsov NG, 2004, NATO SCI SER II-MATH, V161, P265; Khlebtsov NG, 2000, COLLOID J+, V62, P765, DOI 10.1023/A:1026643111821; Kim B, 2010, NAT NANOTECHNOL, V5, P465, DOI [10.1038/NNANO.2010.58, 10.1038/nnano.2010.58]; Kohli V, 2005, BIOTECHNOL BIOENG, V92, P889, DOI 10.1002/bit.20689; Kumar S, 2007, NANO LETT, V7, P1338, DOI 10.1021/nl070365i; Lapotko D, 2005, PROC SPIE, V5697, P82, DOI 10.1117/12.596372; Lapotko D, 2002, PHOTOCHEM PHOTOBIOL, V75, P519, DOI 10.1562/0031-8655(2002)075<0519:PMORSO>2.0.CO;2; Lapotko D, 2006, CANCER LETT, V239, P36, DOI 10.1016/j.canlet.2005.07.031; Lapotko Dmitri, 2011, Cancers (Basel), V3, P802, DOI 10.3390/cancers3010802; Lapotko D, 2009, OPT EXPRESS, V17, P2538, DOI 10.1364/OE.17.002538; Lapotko D, 2009, INT J HEAT MASS TRAN, V52, P1540, DOI 10.1016/j.ijheatmasstransfer.2008.08.010; Lapotko DO, 2007, NANOMEDICINE-UK, V2, P241, DOI 10.2217/17435889.2.2.241; Lapotko DO, 2006, LASER SURG MED, V38, P631, DOI 10.1002/lsm.20359; Lewinski N, 2008, SMALL, V4, P26, DOI 10.1002/smll.200700595; Li JL, 2009, CANCER LETT, V274, P319, DOI 10.1016/j.canlet.2008.09.024; Liang XJ, 2010, P NATL ACAD SCI USA, V107, P7449, DOI 10.1073/pnas.0909707107; Lin CP, 1998, APPL PHYS LETT, V72, P2800, DOI 10.1063/1.121462; Loo C, 2005, NANO LETT, V5, P709, DOI 10.1021/nl050127s; Lukianova-Hleb EY, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/8/085102; Lukianova-Hleb E, 2010, ACS NANO, V4, P2109, DOI 10.1021/nn1000222; Lukianova-Hleb EY, 2012, ADV MATER, V24, P3831, DOI 10.1002/adma.201103550; Lukianova-Hleb EY, 2012, LANGMUIR, V28, P4858, DOI 10.1021/la205132x; Lukianova-Hleb Ekaterina Y, 2011, J Nanomed Nanotechnol, V2, P1; Lukianova-Hleb EY, 2012, BIOMATERIALS, V33, P1821, DOI 10.1016/j.biomaterials.2011.11.015; Lukianova-Hleb EY, 2011, THERANOSTICS, V1, P3, DOI 10.7150/thno/v01p0003; Lukianova-Hleb EY, 2011, J CONTROL RELEASE, V152, P286, DOI 10.1016/j.jconrel.2011.02.006; Lukianova-Hleb EY, 2011, J SURG RES, V166, pE3, DOI 10.1016/j.jss.2010.10.039; Lukianova-Hleb EY, 2009, NANO LETT, V9, P2160, DOI 10.1021/nl9007425; Lukianova-Hleb E, 2009, LASER SURG MED, V41, P240, DOI 10.1002/lsm.20749; Mallidi S, 2009, NANO LETT, V9, P2825, DOI 10.1021/nl802929u; Mandal D, 2009, J MATER SCI-MATER M, V20, P347, DOI 10.1007/s10856-008-3588-x; Meng HA, 2010, ACS NANO, V4, P4539, DOI 10.1021/nn100690m; Mie G, 1908, ANN PHYS-BERLIN, V25, P377, DOI 10.1002/andp.19083300302; Neumann J, 2007, J APPL PHYS, V101, DOI 10.1063/1.2740348; O'Neal DP, 2004, CANCER LETT, V209, P171, DOI 10.1016/j.canlet.2004.02.004; Oberdorster G, 2005, ENVIRON HEALTH PERSP, V113, P823, DOI 10.1289/ehp.7339; Paasonen L, 2007, J CONTROL RELEASE, V122, P86, DOI 10.1016/j.jconrel.2007.06.009; Paasonen L, 2010, J CONTROL RELEASE, V147, P136, DOI 10.1016/j.jconrel.2010.07.095; Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387; Pissuwan D, 2011, J CONTROL RELEASE, V149, P65, DOI 10.1016/j.jconrel.2009.12.006; Pitsillides CM, 2003, BIOPHYS J, V84, P4023, DOI 10.1016/S0006-3495(03)75128-5; Prentice P, 2005, NAT PHYS, V1, P107, DOI 10.1038/nphys148; Prigodich AE, 2009, ACS NANO, V3, P2147, DOI 10.1021/nn9003814; Qin GT, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/15/155605; Sajja Hari Krishna, 2009, Curr Drug Discov Technol, V6, P43; Salmaso S, 2009, J MATER CHEM, V19, P1608, DOI 10.1039/b816603j; Shukla R, 2005, LANGMUIR, V21, P10644, DOI 10.1021/la0513712; Sokolov I, 2007, SMALL, V3, P419, DOI 10.1002/smll.200600319; Sokolov K, 2003, CANCER RES, V63, P1999; Stevenson D, 2006, OPT EXPRESS, V14, P7125, DOI 10.1364/OE.14.007125; Tong L, 2009, NANOMEDICINE-UK, V4, P265, DOI [10.2217/nnm.09.4, 10.2217/NNM.09.4]; Vigderman L, 2012, ANGEW CHEM INT EDIT, V51, P636, DOI 10.1002/anie.201107304; Vogel A, 2005, APPL PHYS B-LASERS O, V81, P1015, DOI 10.1007/s00340-005-2036-6; Vogel A, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.038102; Wagner DS, 2010, BIOMATERIALS, V31, P7567, DOI 10.1016/j.biomaterials.2010.06.031; Wang F, 2011, ACS NANO, V5, P3679, DOI 10.1021/nn200007z; Wang LH, 2011, NAT PHOTONICS, V5, P183, DOI 10.1038/nphoton.2011.24; West JL, 2003, ANNU REV BIOMED ENG, V5, P285, DOI 10.1146/annurev.bioeng.5.011303.120723; Wu GH, 2009, METHOD ENZYMOL, V464, P279, DOI 10.1016/S0076-6879(09)64014-3; Yang LL, 2008, J BIOMED NANOTECHNOL, V4, P439, DOI 10.1166/jbn.2008.007; Yao CP, 2005, J BIOMED OPT, V10, DOI 10.1117/1.2137321; Yao CP, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3253320; Yguerabide J, 1998, ANAL BIOCHEM, V262, P137, DOI 10.1006/abio.1998.2759; Yguerabide J, 1998, ANAL BIOCHEM, V262, P157, DOI 10.1006/abio.1998.2760	91	30	30	0	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 3	2012	7	4							e34537	10.1371/journal.pone.0034537	http://dx.doi.org/10.1371/journal.pone.0034537			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	952PZ	22509318	gold, Green Published			2023-01-03	WOS:000304805900044
J	Stanford, SC				Stanford, S. Clare			PERSONAL VIEW The NHS is right to fund homoeopathy	BRITISH MEDICAL JOURNAL			English	Editorial Material									UCL, Dept Neurosci Physiol & Pharmacol, London WC1E 6BT, England	University of London; University College London	Stanford, SC (corresponding author), UCL, Dept Neurosci Physiol & Pharmacol, London WC1E 6BT, England.	c.stanford@ucl.ac.uk		Stanford, Susan/0000-0002-5623-1751					0	0	0	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 4	2011	342								d2642	10.1136/bmj.d2642	http://dx.doi.org/10.1136/bmj.d2642			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	762MB	22677223				2023-01-03	WOS:000290481700005
J	Walden, AP; Bonten, MJ; Wise, MP				Walden, Andrew P.; Bonten, Marc J.; Wise, Matt P.			Should selective digestive decontamination be used in critically ill patients?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							VENTILATOR-ASSOCIATED PNEUMONIA; INTENSIVE-CARE UNITS; TRACT; OROPHARYNX		[Walden, Andrew P.] Royal Berkshire Hosp, Wantage OX12 8HG, England; [Bonten, Marc J.] Univ Med Ctr, Utrecht, Netherlands; [Wise, Matt P.] Univ Wales Hosp, Cardiff CF4 4XW, S Glam, Wales	Royal Berkshire Hospital; Utrecht University; Utrecht University Medical Center; Cardiff University	Walden, AP (corresponding author), Royal Berkshire Hosp, Wantage OX12 8HG, England.	apwalden@hotmail.com		Wise, Matt/0000-0002-2763-4316				Bastin AJ, 2009, ANAESTHESIA, V64, P46, DOI 10.1111/j.1365-2044.2008.05676.x; Chan EY, 2007, BMJ-BRIT MED J, V334, P889, DOI 10.1136/bmj.39136.528160.BE; Cuthbertson BH, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-117; de Smet AMGA, 2009, NEW ENGL J MED, V360, P20, DOI 10.1056/NEJMoa0800394; de Smet AMGA, 2011, LANCET INFECT DIS, V11, P372, DOI 10.1016/S1473-3099(11)70035-4; de Smet AMGA, 2009, INTENS CARE MED, V35, P1609, DOI 10.1007/s00134-009-1554-9; GASTINNE H, 1992, NEW ENGL J MED, V326, P594, DOI 10.1056/NEJM199202273260903; Health Protection Agency, 2012, ENGL NAT POINT PREV; Julius Center, UMC UTR R GNOSIS; Liberati A, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000022.pub3; Lingnau W, 1998, J HOSP INFECT, V39, P195, DOI 10.1016/S0195-6701(98)90258-4; Melsen WG, 2011, CRIT CARE MED, V39, P2736, DOI 10.1097/CCM.0b013e3182281f33; Muscedere JG, 2008, J CRIT CARE, V23, P5, DOI 10.1016/j.jcrc.2007.11.012; Oostdijk EAN, 2010, AM J RESP CRIT CARE, V181, P452, DOI 10.1164/rccm.200908-1210OC; Rello J, 2010, INTENS CARE MED, V36, P773, DOI 10.1007/s00134-010-1841-5	15	4	4	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 9	2012	345								e6697	10.1136/bmj.e6697	http://dx.doi.org/10.1136/bmj.e6697			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	021TA	23047967				2023-01-03	WOS:000309907100011
J	Xie, WB; Yang, Y; Gu, XP; Zheng, YG; Sun, YE; Liang, Y; Bo, JH; Ma, ZL				Xie, Weibin; Yang, Yan; Gu, Xiaoping; Zheng, Yaguo; Sun, Yu-e; Liang, Ying; Bo, Jinhua; Ma, Zhengliang			Senegenin Attenuates Hepatic Ischemia-Reperfusion Induced Cognitive Dysfunction by Increasing Hippocampal NR2B Expression in Rats	PLOS ONE			English	Article							POLYGALA-TENUIFOLIA ROOT; LONG-TERM POTENTIATION; GENETIC ENHANCEMENT; NMDA RECEPTORS; MEMORY; TENUIGENIN; EXTRACT; DECLINE; MICE; SECRETION	Background: The root of Polygala tenuifolia, a traditional Chinese medicine, has been used to improve memory and intelligence, while the underlying mechanisms remain largely unknown. In this study, we investigated the protective effects of senegenin, an component of Polygala tenuifolia root extracts, on cognitive dysfunction induced by hepatic ischemia-reperfusion. Methodology/Principal Findings: Initially, we constructed a rat model of hepatic ischemia-reperfusion (HIR) and found that the memory retention ability of rats in the step-down and Y maze test was impaired after HIR, paralleled by a decrease of N-methyl-D-aspartate (NMDA) receptor NR2B subunit mRNA and protein expressions in hippocampus. Furthermore, we found that administration of senegenin by gavage attenuated HIR-induced cognitive impairment in a dose and time dependent manner, and its mechanisms might partly due to the increasing expression of NR2B in rat hippocampus. Conclusions/Significance: Cognitive dysfunction induced by HIR is associated with reduction of NR2B expression. Senegenin plays a neuroprotective role in HIR via increasing NR2B expression in rat hippocampus. These findings suggest that senegenin might be a potential agent for prevention and treatment of postoperative cognitive dysfunction (POCD) or other neurodegenerative diseases.	[Yang, Yan; Gu, Xiaoping; Zheng, Yaguo; Sun, Yu-e; Liang, Ying; Bo, Jinhua; Ma, Zhengliang] Nanjing Univ, Coll Med, Affiliated Drum Tower Hosp, Dept Anesthesiol, Nanjing 210008, Jiangsu, Peoples R China; [Xie, Weibin] Nanjing Univ Chinese Med, Drum Tower Clin Coll Chinese & Western Integrat M, Nanjing, Jiangsu, Peoples R China	Nanjing University; Nanjing University of Chinese Medicine	Ma, ZL (corresponding author), Nanjing Univ, Coll Med, Affiliated Drum Tower Hosp, Dept Anesthesiol, Nanjing 210008, Jiangsu, Peoples R China.	mazhengliang1964@yahoo.com.cn			National Natural Foundation of China [81070892, 81171047]; Jiangsu Province of China [BK2009030, BK2010105, RC2007012, RC2011006, 2009044, XK201140]	National Natural Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Province of China	This research was supported by grants from the National Natural Foundation of China(Research Grant 81070892 and 81171047), and funds from Jiangsu Province of China (BK2009030, BK2010105, RC2007012, RC2011006, 2009044 and XK201140). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Berthoud HR, 2004, ANAT REC PART A, V280A, P827, DOI 10.1002/ar.a.20088; Chen Qin, 2007, Zhongguo Zhong Yao Za Zhi, V32, P1336; Chen YL, 2004, J ETHNOPHARMACOL, V95, P47, DOI 10.1016/j.jep.2004.06.015; Chen YJ, 2010, EUR J PHARMACOL, V645, P1, DOI 10.1016/j.ejphar.2010.06.034; Chung IW, 2002, PHARMACOL BIOCHEM BE, V71, P191, DOI 10.1016/S0091-3057(01)00648-7; Cibelli M, 2010, ANN NEUROL, V68, P360, DOI 10.1002/ana.22082; Clayton DA, 2002, J NEUROSCI, V22, P3628; Colletti LM, 1996, HEPATOLOGY, V23, P506; Gu XP, 2010, EUR J PAIN, V14, P496, DOI 10.1016/j.ejpain.2009.09.001; Hawasli AH, 2007, NAT NEUROSCI, V10, P880, DOI 10.1038/nn1914; Ikeya Y, 2004, BIOL PHARM BULL, V27, P1081, DOI 10.1248/bpb.27.1081; Jia HX, 2004, NEUROSCI LETT, V367, P123, DOI 10.1016/j.neulet.2004.05.093; Kawashima K, 2004, BIOL PHARM BULL, V27, P1317, DOI 10.1248/bpb.27.1317; Kim B. G., 2003, J ORIENTAL NEUROPSYC, V14, P43; Kim HM, 1998, J ETHNOPHARMACOL, V61, P201, DOI 10.1016/S0378-8741(98)00040-3; KOO A, 1992, HEPATOLOGY, V15, P507, DOI 10.1002/hep.1840150325; Lee JY, 2009, NEUROSCI LETT, V454, P111, DOI 10.1016/j.neulet.2009.03.024; Liang ZG, 2011, NEUROSCI LETT, V497, P104, DOI 10.1016/j.neulet.2011.04.041; Lv J, 2009, ACTA PHYSIOL, V196, P419, DOI 10.1111/j.1748-1716.2009.01961.x; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORI H, 1995, NEUROPHARMACOLOGY, V34, P1219, DOI 10.1016/0028-3908(95)00109-J; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Niu QA, 2007, NEUROTOX RES, V12, P163, DOI 10.1007/BF03033913; Park CH, 2002, J NEUROSCI RES, V70, P484, DOI 10.1002/jnr.10429; Park HJ, 2008, PHYTOTHER RES, V22, P1324, DOI 10.1002/ptr.2488; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; RIEDEL G, 1994, NEUROREPORT, V5, P2061; Rodrigues SM, 2001, J NEUROSCI, V21, P6889, DOI 10.1523/JNEUROSCI.21-17-06889.2001; Rosczyk HA, 2008, EXP GERONTOL, V43, P840, DOI 10.1016/j.exger.2008.06.004; Shi F, 2011, NEURAL REGEN RES, V6, P171, DOI 10.3969/j.issn.1673-5374.2011.03.002; Shin KY, 2009, NEUROSCI LETT, V465, P157, DOI 10.1016/j.neulet.2009.08.033; Steinman L, 2010, P NATL ACAD SCI USA, V107, P20595, DOI 10.1073/pnas.1015282107; Sun Gui-bo, 2007, Zhong Yao Cai, V30, P991; Tang YP, 1999, NATURE, V401, P63, DOI 10.1038/43432; Terrando N, 2011, ANN NEUROL, V70, P986, DOI 10.1002/ana.22664; Terrando N, 2010, P NATL ACAD SCI USA, V107, P20518, DOI 10.1073/pnas.1014557107; Wan YJ, 2007, ANESTHESIOLOGY, V106, P436, DOI 10.1097/00000542-200703000-00007; Wan YJ, 2010, CRIT CARE MED, V38, P2190, DOI 10.1097/CCM.0b013e3181f17bcb; Wang DH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007486; Wong RWC, 2002, P NATL ACAD SCI USA, V99, P14500, DOI 10.1073/pnas.222371099	41	27	29	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2012	7	9							e45575	10.1371/journal.pone.0045575	http://dx.doi.org/10.1371/journal.pone.0045575			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014RG	23029109	Green Published, Green Submitted, gold			2023-01-03	WOS:000309392800060
J	Chi, X; Zhi, L; Gelderman, MP; Vostal, JG				Chi, Xuan; Zhi, Li; Gelderman, Monique P.; Vostal, Jaroslav G.			Host Platelets and, in Part, Neutrophils Mediate Lung Accumulation of Transfused UVB-Irradiated Human Platelets in a Mouse Model of Acute Lung Injury	PLOS ONE			English	Article							ULTRAVIOLET-A LIGHT; RED-BLOOD-CELLS; PHOTOCHEMICAL INACTIVATION; PATHOGEN INACTIVATION; AMOTOSALEN HCL; IN-VITRO; MICE; RECEPTORS; ANTIBODIES; AGGREGATION	We previously reported that ultraviolet light B (UVB)-treated human platelets (hPLTs) can cause acute lung injury (ALI) in a two-event SCID mouse model in which the predisposing event was Lipopolysaccharide (LPS) injection and the second event was infusion of UVB-treated hPLTs. To delineate contributions of host mouse platelets (mPLTs) and neutrophils in the pathogenesis of ALI in this mouse model, we depleted mPLTs or neutrophils and measured hPLT accumulation in the lung. We also assessed lung injury by protein content in bronchoalveolar lavage fluid (BALF). LPS injection followed by infusion of UVB-treated hPLTs resulted in sequestration of both mPLTs and hPLTs in the lungs of SCID mice, although the numbers of neutrophils in the lung were not significantly different from the control group. Depletion of mouse neutrophils caused only a mild reduction in UVB-hPLTs accumulation in the lungs and a mild reduction in protein content in BALF. In comparison, depletion of mPLTs almost completely abolished hPLTs accumulation in the lung and significantly reduced protein content in BALF. UVB-treated hPLTs bound to host mPLTs, but did not bind to neutrophils in the lung. Aspirin treatment of hPLTs in vitro abolished hPLT accumulation in the lung and protected mice from lung injury. Our data indicate that host mPLTs accumulated in the lungs in response to an inflammatory challenge and subsequently mediated the attachment of transfused UVB-hPLTs. Neutrophils also recruited a small percentage of platelets to the lung. These findings may help develop therapeutic strategies for ALI which could potentially result from transfusion of UV illuminated platelets.	[Chi, Xuan; Zhi, Li; Gelderman, Monique P.; Vostal, Jaroslav G.] US FDA, Lab Cellular Hematol, Div Hematol, OBRR,Ctr Biol Evaluat & Res, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Vostal, JG (corresponding author), US FDA, Lab Cellular Hematol, Div Hematol, OBRR,Ctr Biol Evaluat & Res, Rockville, MD 20857 USA.	Jaroslav.Vostal@fda.hhs.gov			Food and Drug Administration (FDA)	Food and Drug Administration (FDA)	This work was supported by the Food and Drug Administration's (FDA) Critical Path Research Funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AuBuchon JP, 2005, TRANSFUSION, V45, P1335, DOI 10.1111/j.1537-2995.2005.00202.x; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Doerschuk CM, 1996, J IMMUNOL, V157, P4609; DUARTE APT, 1986, THROMB RES, V43, P33, DOI 10.1016/0049-3848(86)90042-3; Faust N, 2000, BLOOD, V96, P719; Gelderman MP, 2011, TRANSFUSION, V51, P2343, DOI 10.1111/j.1537-2995.2011.03135.x; Gibbs DF, 1999, AM J RESP CELL MOL, V20, P1145, DOI 10.1165/ajrcmb.20.6.3482; Goodman RB, 2003, CYTOKINE GROWTH F R, V14, P523, DOI 10.1016/S1359-6101(03)00059-5; Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138; Heal JM, 2004, BLOOD REV, V18, P149, DOI 10.1016/S0268-960X(03)00057-2; Kelher MR, 2009, BLOOD, V113, P2079, DOI 10.1182/blood-2008-09-177857; Kleinman S, 2004, TRANSFUSION, V44, P1774, DOI 10.1111/j.0041-1132.2004.04347.x; Lin L, 1997, TRANSFUSION, V37, P423, DOI 10.1046/j.1537-2995.1997.37497265344.x; Looney MR, 2006, J CLIN INVEST, V116, P1615, DOI 10.1172/JCI27238; Looney MR, 2009, J CLIN INVEST, V119, P3450, DOI 10.1172/JCI38432; Lu SJ, 2011, CELL RES, V21, P530, DOI 10.1038/cr.2011.8; Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008; Oktay K, 1998, HUM REPROD, V13, P1133, DOI 10.1093/humrep/13.5.1133; Peters NC, 2008, SCIENCE, V321, P970, DOI 10.1126/science.1159194; Piper JT, 2007, TRANSFUSION, V47, P1540, DOI 10.1111/j.1537-2995.2007.01295.x; ROSENBLUM WI, 1982, THROMB RES, V28, P713, DOI 10.1016/0049-3848(82)90096-2; Ruane PH, 2004, TRANSFUSION, V44, P877, DOI 10.1111/j.1537-2995.2004.03355.x; Rumjantseva V, 2009, NAT MED, V15, P1273, DOI 10.1038/nm.2030; Salles II, 2009, BLOOD, V114, P5044, DOI 10.1182/blood-2009-02-205989; SCHNEIDER RC, 1980, AM REV RESPIR DIS, V122, P445; Sealey AL, 2002, J IMMUNOL METHODS, V260, P303, DOI 10.1016/S0022-1759(01)00524-5; Silliman CC, 1998, J CLIN INVEST, V101, P1458, DOI 10.1172/JCI1841; Silliman CC, 1997, TRANSFUSION, V37, P719, DOI 10.1046/j.1537-2995.1997.37797369448.x; Silliman CC, 2007, BLOOD, V109, P1752, DOI 10.1182/blood-2006-05-025106; Snyder E, 2005, TRANSFUSION, V45, P1864, DOI 10.1111/j.1537-2995.2005.00639.x; Snyder E, 2004, TRANSFUSION, V44, P1732, DOI 10.1111/j.0041-1132.2004.04145.x; Strait RT, 2011, J EXP MED, V208, P2525, DOI 10.1084/jem.20110159; Ware J, 2004, THROMB HAEMOSTASIS, V92, P478, DOI 10.1160/TH04-05-0308; Weissman A, 1999, BIOL REPROD, V60, P1462, DOI 10.1095/biolreprod60.6.1462; Zarbock A, 2006, J CLIN INVEST, V116, P3211, DOI 10.1172/JCI29499; Zhang JH, 2007, EXP HEMATOL, V35, P490, DOI 10.1016/j.exphem.2006.11.011	36	10	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2012	7	9							e44829	10.1371/journal.pone.0044829	http://dx.doi.org/10.1371/journal.pone.0044829			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014PP	23028636	gold, Green Published, Green Submitted			2023-01-03	WOS:000309388400042
J	Koga, T; Kai, Y; Fukuda, R; Morino-Koga, S; Suico, MA; Koyama, K; Sato, T; Shuto, T; Kai, H				Koga, Tomoaki; Kai, Yukari; Fukuda, Ryosuke; Morino-Koga, Saori; Suico, Mary Ann; Koyama, Kosuke; Sato, Takashi; Shuto, Tsuyoshi; Kai, Hirofumi			Mild Electrical Stimulation and Heat Shock Ameliorates Progressive Proteinuria and Renal Inflammation in Mouse Model of Alport Syndrome	PLOS ONE			English	Article							NF-KAPPA-B; GLOMERULAR PODOCYTE; EPITHELIAL-CELLS; HEME OXYGENASE-1; IV COLLAGEN; DISEASE; BLOCKADE; INJURY; HSP72; MICE	Alport syndrome is a hereditary glomerulopathy with proteinuria and nephritis caused by defects in genes encoding type IV collagen in the glomerular basement membrane. All male and most female patients develop end-stage renal disease. Effective treatment to stop or decelerate the progression of proteinuria and nephritis is still under investigation. Here we showed that combination treatment of mild electrical stress (MES) and heat stress (HS) ameliorated progressive proteinuria and renal injury in mouse model of Alport syndrome. The expressions of kidney injury marker neutrophil gelatinase-associated lipocalin and pro-inflammatory cytokines interleukin-6, tumor necrosis factor-a and interleukin-1 beta were suppressed by MES+HS treatment. The anti-proteinuric effect of MES+ HS treatment is mediated by podocytic activation of phosphatidylinositol 3-OH kinase (PI3K)-Akt and heat shock protein 72 (Hsp72)-dependent pathways in vitro and in vivo. The anti-inflammatory effect of MES+ HS was mediated by glomerular activation of c-jun NH2-terminal kinase 1/2 (JNK1/2) and p38-dependent pathways ex vivo. Collectively, our studies show that combination treatment of MES and HS confers anti-proteinuric and anti-inflammatory effects on Alport mice likely through the activation of multiple signaling pathways including PI3K-Akt, Hsp72, JNK1/2, and p38 pathways, providing a novel candidate therapeutic strategy to decelerate the progression of patho-phenotypes in Alport syndrome.	[Koga, Tomoaki; Kai, Yukari; Fukuda, Ryosuke; Morino-Koga, Saori; Suico, Mary Ann; Koyama, Kosuke; Sato, Takashi; Shuto, Tsuyoshi; Kai, Hirofumi] Kumamoto Univ, Dept Mol Med, Grad Sch Pharmaceut Sci, Kumamoto, Japan; [Koga, Tomoaki; Kai, Yukari; Fukuda, Ryosuke; Morino-Koga, Saori; Suico, Mary Ann; Koyama, Kosuke; Sato, Takashi; Shuto, Tsuyoshi; Kai, Hirofumi] Kumamoto Univ, Global COE Cell Fate Regulat Res & Educ Unit, Kumamoto, Japan; [Koga, Tomoaki] Japan Soc Promot Sci, Tokyo, Japan; [Koga, Tomoaki] Kyushu Univ, Dept Med Biochem, Grad Sch Med Sci, Fukuoka 812, Japan	Kumamoto University; Kumamoto University; Japan Society for the Promotion of Science; Kyushu University	Koga, T (corresponding author), Kumamoto Univ, Dept Mol Med, Grad Sch Pharmaceut Sci, Kumamoto, Japan.	hirokai@gpo.kumamoto-u.ac.jp	Sato, Takashi/AHB-5258-2022	Sato, Takashi/0000-0003-4203-0999; Shuto, Tsuyoshi/0000-0003-1275-4988; Suico, Mary Ann/0000-0002-6751-8352	Ministry of Education, Science, Sports and Culture (MEXT) of Japan [19390045]; Global COE Program (Cell Fate Regulation Research and Education Unit); JSPS [20-8140]	Ministry of Education, Science, Sports and Culture (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Global COE Program (Cell Fate Regulation Research and Education Unit)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by grants from the Ministry of Education, Science, Sports and Culture (MEXT) of Japan (#19390045), from the Global COE Program (Cell Fate Regulation Research and Education Unit) to H.K., and grant-in-aid from JSPS Research fellow (20-8140) to T.K. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrahamson DR, 2009, J AM SOC NEPHROL, V20, P1471, DOI 10.1681/ASN.2008101086; Akcay A, 2009, MEDIAT INFLAMM, V2009, DOI 10.1155/2009/137072; Asanuma K, 2006, NAT CELL BIOL, V8, P485, DOI 10.1038/ncb1400; Chuang PY, 2009, NEPHRON PHYSIOL, V111, P9, DOI 10.1159/000191075; Clauss S, 2009, J PATHOL, V218, P40, DOI 10.1002/path.2505; de Zeeuw D, 2004, KIDNEY INT, V65, P2309, DOI 10.1111/j.1523-1755.2004.00653.x; Duan Y, 2008, P NATL ACAD SCI USA, V105, P11418, DOI 10.1073/pnas.0804954105; Endemann M, 2007, AM J PHYSIOL-RENAL, V292, pF47, DOI 10.1152/ajprenal.00503.2005; Furst R, 2006, J PHARMACOL EXP THER, V318, P389, DOI 10.1124/jpet.106.102251; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; Gross O, 2003, KIDNEY INT, V63, P438, DOI 10.1046/j.1523-1755.2003.00779.x; Huber TB, 2003, HUM MOL GENET, V12, P3397, DOI 10.1093/hmg/ddg360; Hudson BG, 2003, NEW ENGL J MED, V348, P2543, DOI 10.1056/NEJMra022296; Jedlicka J, 2010, HUM PATHOL, V41, P582, DOI 10.1016/j.humpath.2009.08.024; Jo SK, 2006, J AM SOC NEPHROL, V17, P3082, DOI 10.1681/ASN.2005101077; Kai H, 2009, INT J HYPERTHER, V25, P655, DOI 10.3109/02656730903039605; Kaito H, 2006, PEDIATR NEPHROL, V21, P1824, DOI 10.1007/s00467-006-0270-8; Kaminska B, 2005, BBA-PROTEINS PROTEOM, V1754, P253, DOI 10.1016/j.bbapap.2005.08.017; Kietzmann T, 2003, J BIOL CHEM, V278, P17927, DOI 10.1074/jbc.M203929200; Kondo T, 2010, OBES RES CLIN PRACT, V4, pE101, DOI 10.1016/j.orcp.2009.09.007; Lian KC, 2010, TOXICOL APPL PHARM, V245, P21, DOI 10.1016/j.taap.2010.01.003; Meehan DT, 2009, KIDNEY INT, V76, P968, DOI 10.1038/ki.2009.324; Morino S, 2008, J PHARMACOL SCI, V108, P222, DOI 10.1254/jphs.08180SC; Morino S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004068; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; Ninichuk V, 2005, J AM SOC NEPHROL, V16, P977, DOI 10.1681/ASN.2004100871; Oba M, 2010, J SURG RES, V162, P213, DOI 10.1016/j.jss.2009.03.093; Pavenstadt H, 2003, PHYSIOL REV, V83, P253, DOI 10.1152/physrev.00020.2002; Proesmans W, 2004, PEDIATR NEPHROL, V19, P271, DOI 10.1007/s00467-003-1366-z; Rheault MN, 2004, J AM SOC NEPHROL, V15, P1466, DOI 10.1097/01.ASN.0000130562.90255.8F; Rico M, 2005, AM J PHYSIOL-RENAL, V289, pF431, DOI 10.1152/ajprenal.00389.2004; Ruchalski K, 2003, AM J PHYSIOL-CELL PH, V285, pC1483, DOI 10.1152/ajpcell.00049.2003; Sanchez-Wandelmer J, 2009, BBA-BIOMEMBRANES, V1788, P1731, DOI 10.1016/j.bbamem.2009.05.002; Sayers R, 1999, KIDNEY INT, V56, P1662, DOI 10.1046/j.1523-1755.1999.00744.x; Seegers JC, 2001, MED HYPOTHESES, V57, P224, DOI 10.1054/mehy.2001.1292; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Wang XM, 2006, AM J RESP CELL MOL, V34, P434, DOI 10.1165/rcmb.2005-0376OC; Wang YH, 2001, AM J PHYSIOL-CELL PH, V281, pC1667, DOI 10.1152/ajpcell.2001.281.5.C1667; Welsh GI, 2010, CELL METAB, V12, P329, DOI 10.1016/j.cmet.2010.08.015; Zeisberg M, 2003, NAT MED, V9, P964, DOI 10.1038/nm888; Zeisberg M, 2006, PLOS MED, V3, P535, DOI 10.1371/journal.pmed.0030100; Zhao M, 2006, NATURE, V442, P457, DOI 10.1038/nature04925	42	19	20	3	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2012	7	8							e43852	10.1371/journal.pone.0043852	http://dx.doi.org/10.1371/journal.pone.0043852			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	998GM	22937108	Green Submitted, gold, Green Published			2023-01-03	WOS:000308225500110
J	Hebert, C; Beaumont, J; Schwartz, G; Robicsek, A				Hebert, Courtney; Beaumont, Jennifer; Schwartz, Gene; Robicsek, Ari			The Influence of Context on Antimicrobial Prescribing for Febrile Respiratory Illness A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							TRACT INFECTIONS; DIAGNOSTIC-ACCURACY; ANTIBIOTICS; PREDICTORS; BRONCHITIS; A(H1N1); COLDS	Background: Little is known about the influence of contextual factors on a physician's likelihood to prescribe antimicrobials for febrile respiratory illness (FRI). Context includes epidemiologic context (for example, a pandemic period) and personal context (for example, recent exposure to other patients with FRI). Objective: To examine the association between contextual factors and antimicrobial prescribing for FRI. Design: 5.5-year retrospective cohort study. Setting: A network of Midwestern primary care providers. Patients: All patients presenting with FRI during influenza seasons between 2006 and 2011. Measurements: Antimicrobial prescribing for FRI during pandemic and seasonal influenza periods. Results: 28 301 unique patient encounters for FRI with 69 physicians in 26 practices were included. An antibiotic was prescribed in 12 795 (45.2%) cases. The range of prescribing among physicians was 17.9% to 83.7%. Antibiotics were prescribed in 47.5% of encounters during the seasonal period and 39.2% during the pandemic period (P < 0.001). After multivariable adjustment for patient and physician characteristics, antibiotic prescribing was lower in the pandemic period (odds ratio [OR], 0.72 [95% CI, 0.68 to 0.77]) than in the seasonal period. The likelihood of prescribing an antibiotic decreased as the number of FRI cases that a physician had seen in the previous week increased (OR, 0.93 [CI, 0.86 to 1.01] for 2 to 3 patients with FRI seen in the previous week; OR, 0.84 [CI, 0.77 to 0.91] for 4 to 6 patients; OR, 0.71 [CI, 0.64 to 0.78] for 7 to 11 patients; and OR, 0.57 [CI, 0.51 to 0.63] for >= 12 patients compared with the reference range of 0 to 1 patients). Pandemic season and recent personal context were also associated with antiviral prescribing. Limitation: Retrospective study in a single geographic area. Conclusion: Epidemiologic context and the number of cases of FRI that a physician had recently seen were associated with his or her likelihood to prescribe antimicrobials for FRI. Interventions that enhance a physician's contextual awareness may improve antimicrobial use.	[Hebert, Courtney] Ohio State Univ, Wexner Med Ctr, Dept Biomed Informat, Columbus, OH 43210 USA; Northwestern Univ, Feinberg Sch Med, Evanston, IL 60208 USA; Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA; NorthShore Univ HealthSyst, Evanston, IL USA	Ohio State University; Northwestern University; Feinberg School of Medicine; University of Chicago; NorthShore University Health System	Hebert, C (corresponding author), Ohio State Univ, Wexner Med Ctr, Dept Biomed Informat, 3190 Graves Hall,333 W 10th Ave, Columbus, OH 43210 USA.	courtney.hebert@osumc.edu	Beaumont, Jennifer/AAA-2825-2020; Hebert, Courtney/G-4900-2016	Beaumont, Jennifer/0000-0002-1484-260X; Schwartz, Gene/0000-0001-6918-1987	NorthShore University HealthSystem	NorthShore University HealthSystem	Dr. Robicsek was supported by a NorthShore University HealthSystem Research Career Development Award.	Aspinall SL, 2009, AM J EMERG MED, V27, P544, DOI 10.1016/j.ajem.2008.04.015; Butler CC, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b2242; Cadieux G, 2007, CAN MED ASSOC J, V177, P877, DOI 10.1503/cmaj.070151; *CDCP, 2009, UPD INT REC US ANT M; Centers for Disease Control and Prevention, CDC GIS FLUVIEW; Centers for Disease Control and Prevention, 2009, INV INT REC SWIN FLU; Centers for Disease Control and Prevention, 2010, 2009 H1N1 PANDEMIC S; Centers for Medicare & Medicaid Services (CMS) HHS, 2010, Fed Regist, V75, P44313; Dawood FS, 2009, NEW ENGL J MED, V360, P2605, DOI 10.1056/NEJMoa0903810; degli Atti MLC, 2006, EUR J CLIN PHARMACOL, V62, P1055, DOI 10.1007/s00228-006-0198-8; Dominguez-Cherit G, 2009, JAMA-J AM MED ASSOC, V302, P1880, DOI 10.1001/jama.2009.1536; Dosh SA, 2000, J FAM PRACTICE, V49, P407; Fine AM, 2011, ANN INTERN MED, V155, P345, DOI 10.7326/0003-4819-155-6-201109200-00002; Fischer Thomas, 2005, BMC Fam Pract, V6, P6, DOI 10.1186/1471-2296-6-6; Ganestam F, 2003, SCAND J INFECT DIS, V35, P836, DOI 10.1080/00365540310016880; Glass SK, 2010, J ANTIMICROB CHEMOTH, V65, P148, DOI 10.1093/jac/dkp391; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; Hopstaken RM, 2006, FAM PRACT, V23, P180, DOI 10.1093/fampra/cmi100; Hopstaken RM, 2005, J CLIN EPIDEMIOL, V58, P175, DOI 10.1016/j.jclinepi.2004.08.004; Horst MA, 2010, J AM BOARD FAM MED, V23, P32, DOI 10.3122/jabfm.2010.01.090137; Illinois Department of Public Health, H1N1 FLU; Khiabanian H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012658; Korppi M, 2008, ACTA PAEDIATR, V97, P943, DOI 10.1111/j.1651-2227.2008.00789.x; Linder JA, 2005, PHARMACOEPIDEM DR S, V14, P531, DOI 10.1002/pds.1067; Linder JA, 2009, J GEN INTERN MED, V24, P504, DOI 10.1007/s11606-009-0933-9; Louie JK, 2009, JAMA-J AM MED ASSOC, V302, P1896, DOI 10.1001/jama.2009.1583; Macfarlane J, 1997, BMJ-BRIT MED J, V315, P1211, DOI 10.1136/bmj.315.7117.1211; Mamede S, 2010, JAMA-J AM MED ASSOC, V304, P1198, DOI 10.1001/jama.2010.1276; Misurski DA, 2011, AM J MANAG CARE, V17, P601; Moro ML, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-69; Neuzil KM, 2000, NEW ENGL J MED, V342, P225, DOI 10.1056/NEJM200001273420401; Nyquist AC, 1998, JAMA-J AM MED ASSOC, V279, P875, DOI 10.1001/jama.279.11.875; Polgreen PM, 2011, INFECT CONT HOSP EP, V32, P706, DOI 10.1086/660859; Strahilevitz J, 2005, CLIN MICROBIOL INFEC, V11, P955, DOI 10.1111/j.1469-0691.2005.01255.x; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; Watson RL, 1999, PEDIATRICS, V104, P1251, DOI 10.1542/peds.104.6.1251	36	12	12	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 7	2012	157	3					160	+		10.7326/0003-4819-157-3-201208070-00005	http://dx.doi.org/10.7326/0003-4819-157-3-201208070-00005			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	992PB	22868833				2023-01-03	WOS:000307789900003
J	Vashisht, R; Mondal, AK; Jain, A; Shah, A; Vishnoi, P; Priyadarshini, P; Bhattacharyya, K; Rohira, H; Bhat, AG; Passi, A; Mukherjee, K; Choudhary, KS; Kumar, V; Arora, A; Munusamy, P; Subramanian, A; Venkatachalam, A; Gayathri, S; Raj, S; Chitra, V; Verma, K; Zaheer, S; Balaganesh, J; Gurusamy, M; Razeeth, M; Raja, I; Thandapani, M; Mevada, V; Soni, R; Rana, S; Ramanna, GM; Raghavan, S; Subramanya, SN; Kholia, T; Patel, R; Bhavnani, V; Chiranjeevi, L; Sengupta, S; Singh, PK; Atray, N; Gandhi, S; Avasthi, TS; Nisthar, S; Anurag, M; Sharma, P; Hasija, Y; Dash, D; Sharma, A; Scaria, V; Thomas, Z; Chandra, N; Brahmachari, SK; Bhardwaj, A				Vashisht, Rohit; Mondal, Anupam Kumar; Jain, Akanksha; Shah, Anup; Vishnoi, Priti; Priyadarshini, Priyanka; Bhattacharyya, Kausik; Rohira, Harsha; Bhat, Ashwini G.; Passi, Anurag; Mukherjee, Keya; Choudhary, Kumari Sonal; Kumar, Vikas; Arora, Anshula; Munusamy, Prabhakaran; Subramanian, Ahalyaa; Venkatachalam, Aparna; Gayathri, S.; Raj, Sweety; Chitra, Vijaya; Verma, Kaveri; Zaheer, Salman; Balaganesh, J.; Gurusamy, Malarvizhi; Razeeth, Mohammed; Raja, Ilamathi; Thandapani, Madhumohan; Mevada, Vishal; Soni, Raviraj; Rana, Shruti; Ramanna, Girish Muthagadhalli; Raghavan, Swetha; Subramanya, Sunil N.; Kholia, Trupti; Patel, Rajesh; Bhavnani, Varsha; Chiranjeevi, Lakavath; Sengupta, Soumi; Singh, Pankaj Kumar; Atray, Naresh; Gandhi, Swati; Avasthi, Tiruvayipati Suma; Nisthar, Shefin; Anurag, Meenakshi; Sharma, Pratibha; Hasija, Yasha; Dash, Debasis; Sharma, Arun; Scaria, Vinod; Thomas, Zakir; Chandra, Nagasuma; Brahmachari, Samir K.; Bhardwaj, Anshu		OSDD Consortium	Crowd Sourcing a New Paradigm for Interactome Driven Drug Target Identification in Mycobacterium tuberculosis	PLOS ONE			English	Article							ANTI-SIGMA-FACTOR; BINDING-SITES; DATABASE; NETWORK; BIOLOGY; INHIBITOR; ALGORITHM; PROTEINS	A decade since the availability of Mycobacterium tuberculosis (Mtb) genome sequence, no promising drug has seen the light of the day. This not only indicates the challenges in discovering new drugs but also suggests a gap in our current understanding of Mtb biology. We attempt to bridge this gap by carrying out extensive re-annotation and constructing a systems level protein interaction map of Mtb with an objective of finding novel drug target candidates. Towards this, we synergized crowd sourcing and social networking methods through an initiative 'Connect to Decode' (C2D) to generate the first and largest manually curated interactome of Mtb termed '3interactome pathway' (IPW), encompassing a total of 1434 proteins connected through 2575 functional relationships. Interactions leading to gene regulation, signal transduction, metabolism, structural complex formation have been catalogued. In the process, we have functionally annotated 87% of the Mtb genome in context of gene products. We further combine IPW with STRING based network to report central proteins, which may be assessed as potential drug targets for development of drugs with least possible side effects. The fact that five of the 17 predicted drug targets are already experimentally validated either genetically or biochemically lends credence to our unique approach.	[Vashisht, Rohit; Mondal, Anupam Kumar; Shah, Anup; Vishnoi, Priti; Bhattacharyya, Kausik; Mukherjee, Keya; Choudhary, Kumari Sonal; Anurag, Meenakshi; Dash, Debasis; Scaria, Vinod; Brahmachari, Samir K.] CSIR, Inst Genom & Integrat Biol, Delhi, India; [Vashisht, Rohit; Bhat, Ashwini G.; Chandra, Nagasuma] Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India; [Rohira, Harsha; Arora, Anshula; Raj, Sweety] Univ Delhi, Acharya Narendra Dev Coll, Delhi 110007, India; [Kumar, Vikas] Goethe Univ Frankfurt, Frankfurt, Germany; [Munusamy, Prabhakaran] PSG Coll Technol, Coimbatore, Tamil Nadu, India; [Subramanian, Ahalyaa; Venkatachalam, Aparna] SASTRA Univ, Thanjavur, Tamilnadu, India; [Gayathri, S.] SDM Coll, Ujire, Karnataka, India; [Chitra, Vijaya] Sree Narayan Guru Coll, Coimbatore, Tamil Nadu, India; [Verma, Kaveri] Maharshi Dayanand Univ, Rohtak, Haryana, India; [Zaheer, Salman] Amity Univ, Amity Inst Biotechnol, Lucknow, Uttar Pradesh, India; [Balaganesh, J.] Bharathiar Univ, Coimbatore, Tamil Nadu, India; [Gurusamy, Malarvizhi; Razeeth, Mohammed; Raja, Ilamathi; Thandapani, Madhumohan] Bharathidasan Univ, Tiruchirappall, Tamil Nadu, India; [Mevada, Vishal; Soni, Raviraj; Rana, Shruti] Hem N Gujarat Univ, Patan, Gujarat, India; [Ramanna, Girish Muthagadhalli; Raghavan, Swetha; Subramanya, Sunil N.] Business Intelligence Technol India Pvt Ltd, Bangalore, Karnataka, India; [Kholia, Trupti] Saurashtra Univ, Christ Coll, Rajkot 360005, Gujarat, India; [Patel, Rajesh] Hemchandracharya N Gujarat Univ, Dept Life Sci, Patan, Gujarat, India; [Bhavnani, Varsha] Univ Pune, Dept Biotechnol, Pune, Maharashtra, India; [Chiranjeevi, Lakavath] CSIR, Indian Inst Toxicol Res, Lucknow, Uttar Pradesh, India; [Sengupta, Soumi] Indian Stat Inst, Kolkata, W Bengal, India; [Singh, Pankaj Kumar] Maulana Azad Natl Inst Technol, Bhopal, Madhya Pradesh, India; [Atray, Naresh] Shri Ram Coll Pharm, Karnal, Haryana, India; [Gandhi, Swati] Maharaj Sayajirao Univ Baroda, Baroda, Gujarat, India; [Avasthi, Tiruvayipati Suma] Univ Hyderabad, Sch Life Sci, Dept Biotechnol, Pathogen Biol Lab, Hyderabad 500134, Andhra Pradesh, India; [Nisthar, Shefin] Univ Kerala, Thiruvananthapuram 695034, Kerala, India; [Sharma, Pratibha] All India Inst Med Sci, New Delhi, India; [Hasija, Yasha] Delhi Technol Univ, Dept Biotechnol, Delhi, India; [Sharma, Arun] CSIR, Inst Microbial Technol, Bioinformat Ctr, Chandigarh, India; [Avasthi, Tiruvayipati Suma] Univ Malaya, Inst Biol Sci, Fac Sci, Kuala Lumpur, Malaysia	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB); Indian Institute of Science (IISC) - Bangalore; University of Delhi; Goethe University Frankfurt; PSG College Technology; Shanmugha Arts, Science, Technology & Research Academy (SASTRA); Maharshi Dayanand University; Bharathiar University; Bharathidasan University; Hemchandracharya North Gujarat University; Saurashtra University; Hemchandracharya North Gujarat University; Savitribai Phule Pune University; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Toxicology Research (IITR); Indian Statistical Institute; Indian Statistical Institute Kolkata; National Institute of Technology (NIT System); Maulana Azad National Institute of Technology Bhopal; Maharaja Sayajirao University Baroda; University of Hyderabad; University of Kerala; All India Institute of Medical Sciences (AIIMS) New Delhi; Delhi Technological University; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH); Universiti Malaya	Vashisht, R (corresponding author), CSIR, Inst Genom & Integrat Biol, Delhi, India.	nchandra@biochem.iisc.ernet.in; skb@igib.res.in; anshu@csir.res.in	chitra, Vijaya/ABD-2593-2021; Scaria, Vinod/AAS-3151-2021; Shait Mohammed, Mohammed Razeeth/AAY-3154-2020; Scaria, Vinod/B-2819-2008; Patel, Rajesh/G-5669-2012; Vashisht, Rohit/K-6181-2019; Choudhary, Kumari Sonal/M-4517-2017; Patel, Rajesh/X-4517-2018; Mevada, Vishal/N-4048-2014; Kumari, Sonal/AAW-7588-2020; Passi, Anurag/AAN-5309-2021; Basheera, Shefin/ABI-1878-2020; Tiruvayipati, Suma/AAF-8331-2021; Dash, Debasis/F-3137-2012	Patel, Rajesh/0000-0002-4712-1921; Vashisht, Rohit/0000-0002-2938-7259; Choudhary, Kumari Sonal/0000-0001-9527-7958; Mevada, Vishal/0000-0003-0739-026X; Passi, Anurag/0000-0002-0448-794X; Basheera, Shefin/0000-0002-4368-2764; Tiruvayipati, Suma/0000-0003-0195-1097; Shah, Anup/0000-0002-3793-1998; bhardwaj, anshu/0000-0001-5830-2616; Sharma, Arun/0000-0003-3854-7944; Dash, Debasis/0000-0002-5647-3785; Kumar, Vikas/0000-0002-5263-9303; Mondal, Anupam/0000-0002-3572-6392; Scaria, Vinod/0000-0001-7644-7181; Subramanian, Ahalyaa/0000-0001-9669-8260; Janakiraman, Balaganesh/0000-0002-5893-8961; Shait Mohammed, Mohammed Razeeth/0000-0002-4711-1483; S, Gayathri/0000-0002-2776-1307; Chandra, Nagasuma/0000-0002-9939-8439; S, Gayathri/0000-0003-2431-9553; Raghavan, Swetha/0000-0001-6951-0592; Bhattacharyya, Kausik/0000-0002-4033-676X	Council of Scientific and Industrial Research, India [HCP0001]; Hewlett-Packard; Sun Microsystems	Council of Scientific and Industrial Research, India(Council of Scientific & Industrial Research (CSIR) - India); Hewlett-Packard; Sun Microsystems	This work was supported by the Council of Scientific and Industrial Research, India, Funding (Grant No. HCP0001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We would like to thank Dr. Vipin Singh, Assistant Professor, Amity University, Noida, for very constructive and detailed comments on the manuscript. We also thank Dr. TS Balganesh, CSIR, and Dr. Vani Brahmachari, ACBR, for fruitful discussions on the manuscript. We acknowledge India 800 foundation for support towards rewarding the best contributors with net books, Hewlett-Packard and Sun Microsystems for providing financial and logistics support for the on-site phase of C2D. We would also like to thank Mahanagar Telephone Nigam Limited, Delhi, India, for providing connectivity and the National Knowledge Network (NKN) for providing high-bandwidth support for C2D on-site phase activities. We also acknowledge School of Information Technology, Jawaharlal Nehru University, Delhi, India, for hosting the on-site phase and Dr. Andrew Michael Lynn and his group, School of Information Technology, Jawaharlal Nehru University, and Dr. S Ramachandran, CSIR-Institute of Genomics and Integrative Biology and his group, Delhi, for providing logistics support. We also thank Dr. GPS Raghava, CSIR-Institute of Microbial Technology, Chandigarh, for hosting the IPW web server. The authors thank all the OSDD members for their active participation.	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Anurag M, 2009, MOL BIOSYST, V5, P1752, DOI [10.1039/b905518p, 10.1039/B905518p]; Aranda B, 2010, NUCLEIC ACIDS RES, V38, pD525, DOI 10.1093/nar/gkp878; Arora P, 2009, NAT CHEM BIOL, V5, P166, DOI 10.1038/nchembio.143; Bader GD, 2001, NUCLEIC ACIDS RES, V29, P242, DOI 10.1093/nar/29.1.242; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Bhardwaj A, 2011, TUBERCULOSIS, V91, P479, DOI 10.1016/j.tube.2011.06.004; Camus JC, 2002, MICROBIOL-SGM, V148, P2967, DOI 10.1099/00221287-148-10-2967; Chandra N, 2011, TUBERCULOSIS, V91, P487, DOI 10.1016/j.tube.2011.02.008; Chatr-Aryamontri A, 2007, NUCLEIC ACIDS RES, V35, pD572, DOI 10.1093/nar/gkl950; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; FREEMAN LC, 1977, SOCIOMETRY, V40, P35, DOI 10.2307/3033543; Greenstein AE, 2007, PLOS PATHOG, V3, P475, DOI 10.1371/journal.ppat.0030049; Grigorov MG, 2005, DRUG DISCOV TODAY, V10, P365, DOI 10.1016/S1359-6446(05)03369-6; Guinn KM, 2004, MOL MICROBIOL, V51, P359, DOI 10.1046/j.1365-2958.2003.03844.x; Hey A. J. G., 2009, 4 PARADIGM DATA INTE; Hu YM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020958; Hu YM, 2006, INFECT IMMUN, V74, P861, DOI 10.1128/IAI.74.2.861-868.2006; Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760; Kalidas Y, 2008, J STRUCT BIOL, V161, P31, DOI 10.1016/j.jsb.2007.09.005; Kelley LA, 2009, NAT PROTOC, V4, P363, DOI 10.1038/nprot.2009.2; Kitano H, 2011, NAT CHEM BIOL, V7, P323, DOI 10.1038/nchembio.574; Kumar D, 2010, CELL, V140, P731, DOI 10.1016/j.cell.2010.02.012; Lew JM, 2011, TUBERCULOSIS, V91, P1, DOI 10.1016/j.tube.2010.09.008; Magnet S, 2010, TUBERCULOSIS, V90, P354, DOI 10.1016/j.tube.2010.09.001; Mason O, 2007, IET SYST BIOL, V1, P89, DOI 10.1049/iet-syb:20060038; Menon S, 2011, BIOCHEMISTRY-US, V50, P5948, DOI 10.1021/bi2005575; Munos B, 2010, CLIN PHARMACOL THER, V87, P534, DOI 10.1038/clpt.2010.26; Newman MEJ, 2005, SOC NETWORKS, V27, P39, DOI 10.1016/j.socnet.2004.11.009; Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29; Pieper U, 2011, NUCLEIC ACIDS RES, V39, pD465, DOI 10.1093/nar/gkq1091; Prakash T, 2005, J MOL BIOL, V345, P937, DOI 10.1016/j.jmb.2004.11.008; Prieto C, 2006, NUCLEIC ACIDS RES, V34, pW298, DOI 10.1093/nar/gkl128; Raman Karthik, 2010, Autom Exp, V2, P2, DOI 10.1186/1759-4499-2-2; Raman K, 2008, BMC SYST BIOL, V2, DOI 10.1186/1752-0509-2-109; Reddy TBK, 2009, NUCLEIC ACIDS RES, V37, pD499, DOI 10.1093/nar/gkn652; Sachdeva P, 2010, FEBS J, V277, P605, DOI 10.1111/j.1742-4658.2009.07479.x; Sharma S, 2010, J ANTIMICROB CHEMOTH, V65, P1694, DOI 10.1093/jac/dkq186; Singh S, 2008, CELL, V133, P201, DOI 10.1016/j.cell.2008.04.003; Song TS, 2003, MOL MICROBIOL, V50, P949, DOI 10.1046/j.1365-2958.2003.03739.x; Velmurugan K, 2007, PLOS PATHOG, V3, P972, DOI 10.1371/journal.ppat.0030110; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Williams Antony J, 2011, COLLABORATIVE TOOLS; World Health Organization, 2010, WHOHTMTB20107; Xenarios I, 2001, NUCLEIC ACIDS RES, V29, P239, DOI 10.1093/nar/29.1.239; Yeturu K, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-543	48	29	31	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2012	7	7							e39808	10.1371/journal.pone.0039808	http://dx.doi.org/10.1371/journal.pone.0039808			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973LU	22808064	Green Published, gold, Green Submitted			2023-01-03	WOS:000306362400021
J	Bedell, RA; Anderson, STB; van Lettow, M; Akesson, A; Corbett, EL; Kumwenda, M; Chan, AK; Heyderman, RS; Zachariah, R; Harries, AD; Ramsay, AR				Bedell, Richard A.; Anderson, Suzanne T. B.; van Lettow, Monique; Akesson, Ann; Corbett, Elizabeth L.; Kumwenda, Moses; Chan, Adrienne K.; Heyderman, Robert S.; Zachariah, Rony; Harries, Anthony D.; Ramsay, Andrew R.			High Prevalence of Tuberculosis and Serious Bloodstream Infections in Ambulatory Individuals Presenting for Antiretroviral Therapy in Malawi	PLOS ONE			English	Article							NEGATIVE PULMONARY TUBERCULOSIS; SUB-SAHARAN AFRICA; EARLY MORTALITY; CRYPTOCOCCAL ANTIGENEMIA; SPUTUM INDUCTION; SCALE-UP; HIV; ADULTS; DIAGNOSIS; SMEAR	Background: Tuberculosis (TB) and serious bloodstream infections (BSI) may contribute to the high early mortality observed among patients qualifying for antiretroviral therapy (ART) with unexplained weight loss, chronic fever or chronic diarrhea. Methods and Findings: A prospective cohort study determined the prevalence of undiagnosed TB or BSI among ambulatory HIV-infected adults with unexplained weight loss and/or chronic fever, or diarrhea in two routine program settings in Malawi. Subjects with positive expectorated sputum smears for AFB were excluded. Investigations Bacterial and mycobacterial blood cultures, cryptococcal antigen test (CrAg), induced sputum (IS) for TB microscopy and solid culture, full blood count and CD4 lymphocyte count. Among 469 subjects, 52 (11%) had microbiological evidence of TB; 50 (11%) had a positive (non-TB) blood culture and/or positive CrAg. Sixty-five additional TB cases were diagnosed on clinical and radiological grounds. Nontyphoidal Salmonellae (NTS) were the most common blood culture pathogens (29 cases; 6% of participants and 52% of bloodstream isolates). Multivariate analysis of baseline clinical and hematological characteristics found significant independent associations between oral candidiasis or lymphadenopathy and TB, marked CD4 lymphopenia and NTS infection, and severe anemia and either infection, but low positive likelihood ratios (<2 for all combinations). Conclusions: We observed a high prevalence of TB and serious BSI, particularly NTS, in a program cohort of chronically ill HIV-infected outpatients. Baseline clinical and hematological characteristics were inadequate predictors of infection. HIV clinics need better rapid screening tools for TB and BSI. Clinical trials to evaluate empiric TB or NTS treatment are required in similar populations.	[Bedell, Richard A.; van Lettow, Monique; Kumwenda, Moses; Chan, Adrienne K.] Dignitas Int, Zomba, Malawi; [Bedell, Richard A.] Univ British Columbia, Div Global Hlth, Vancouver, BC V5Z 1M9, Canada; [Anderson, Suzanne T. B.; Corbett, Elizabeth L.; Heyderman, Robert S.] Malawi Liverpool Wellcome Trust, Clin Res Programme, Blantyre, Malawi; [Anderson, Suzanne T. B.] Brighton & Sussex Med Sch, Dept Med, Falmer, Sussex, England; [van Lettow, Monique] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Akesson, Ann] Med Sans Frontieres Operat Ctr Brussels, Thyolo, Malawi; [Corbett, Elizabeth L.; Harries, Anthony D.] London Sch Hyg & Trop Med, London WC1, England; [Chan, Adrienne K.] Univ Toronto, St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada; [Zachariah, Rony] Med Sans Frontieres Operat Ctr Brussels, Brussels, Belgium; [Harries, Anthony D.] Int Union TB & Lung Dis, Paris, France; [Ramsay, Andrew R.] World Hlth Org, Geneva, Switzerland; [Ramsay, Andrew R.] Univ St Andrews, Sch Med, St Andrews KY16 9AJ, Fife, Scotland	University of British Columbia; University of Malawi; University of Brighton; University of Sussex; University of Toronto; University of London; London School of Hygiene & Tropical Medicine; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; World Health Organization; University of St Andrews	Bedell, RA (corresponding author), Dignitas Int, Zomba, Malawi.	r.bedell@dignitasinternational.org	Bedell, Richard/AAC-2595-2020	Bedell, Richard/0000-0002-5687-8053; Kumwenda, Moses Kelly/0000-0003-3091-7330; zachariah, rony/0000-0002-2915-9328; Corbett, Elizabeth/0000-0002-3552-3181	TREAT TB - An initiative; USAID (United States Agency for International Development); MSF-OCB	TREAT TB - An initiative; USAID (United States Agency for International Development)(United States Agency for International Development (USAID)); MSF-OCB	This study was funded through TREAT TB - An initiative led by the International Union Against Tuberculosis and Lung Disease (the Union) and supported by a USAID Cooperative Agreement (United States Agency for International Development). MSF-OCB self-funded their involvement in this study and did not receive funds from USAID. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al Zahrani K, 2001, INT J TUBERC LUNG D, V5, P855; Andrews JM, 2001, J ANTIMICROB CHEMOTH, V48, P29, DOI 10.1093/jac/48.suppl_1.29; Ansari NA, 2002, INT J TUBERC LUNG D, V6, P55; Archibald LK, 2000, J INFECT DIS, V181, P1414, DOI 10.1086/315367; Attia A, 2001, J ACQ IMMUN DEF SYND, V28, P478, DOI 10.1097/00042560-200112150-00012; Bell M, 2001, Int J Infect Dis, V5, P63, DOI 10.1016/S1201-9712(01)90027-X; Boehme CC, 2010, NEW ENGL J MED, V363, P1005, DOI 10.1056/NEJMoa0907847; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Brown M, 2007, CLIN INFECT DIS, V44, P1415, DOI 10.1086/516782; Cain KP, 2010, NEW ENGL J MED, V362, P707, DOI 10.1056/NEJMoa0907488; Colebunders R, 2000, INT J TUBERC LUNG D, V4, P97; Cox JA, 2010, AIDS REV, V12, P183; Feltham R.K.A., 2003, COWAN STEELS MANUAL; Getahun H, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000391; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; Gordon MA, 2001, J INFECTION, V42, P44, DOI 10.1053/jinf.2000.0779; Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST; Hargreaves NJ, 2001, INT J TUBERC LUNG D, V5, P847; Jarvis JN, 2009, CLIN INFECT DIS, V48, P856, DOI 10.1086/597262; Kassa-Kelembho E, 2003, ACTA TROP, V89, P67, DOI 10.1016/j.actatropica.2003.09.004; Kingsley RA, 2009, GENOME RES, V19, P2279, DOI 10.1101/gr.091017.109; Lawn SD, 2011, INT J TUBERC LUNG D, V15, P287; Lawn SD, 2005, AIDS, V19, P2141, DOI 10.1097/01.aids.0000194802.89540.e1; Lawn SD, 2008, AIDS, V22, P1897, DOI 10.1097/QAD.0b013e32830007cd; Lawn SD, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001067; Liechty CA, 2007, TROP MED INT HEALTH, V12, P929, DOI 10.1111/j.1365-3156.2007.01874.x; LUCAS SB, 1994, BRIT MED J, V308, P1531, DOI 10.1136/bmj.308.6943.1531; May M, 2010, LANCET, V376, P449, DOI 10.1016/S0140-6736(10)60666-6; Monkongdee P, 2009, AM J RESP CRIT CARE, V180, P903, DOI 10.1164/rccm.200905-0692OC; Mtunthama N, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-137; Murray J, 2007, AIDS, V21, pS97, DOI 10.1097/01.aids.0000299416.61808.24; Ngoma D, 2008, TROP DOCT, V38, P159, DOI 10.1258/td.2007.070244; Payongayong E., 2006, SIMPLE HOUSEHOLD POV; Peters RPH, 2004, TROP MED INT HEALTH, V9, P928, DOI 10.1111/j.1365-3156.2004.01288.x; Saathoff E, 2011, INT J TUBERC LUNG D, V15, P925, DOI 10.5588/ijtld.10.0477; Saranchuk P, 2007, SAMJ S AFR MED J, V97, P517; Ssali FN, 1998, J ACQ IMMUN DEF SYND, V19, P484, DOI 10.1097/00042560-199812150-00007; Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782; Were W, 2009, INT J TUBERC LUNG D, V13, P47; WHO, 2011, POL STAT AUT REAL TI; Wilson D, 2006, INT J TUBERC LUNG D, V10, P31	41	27	29	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2012	7	6							e39347	10.1371/journal.pone.0039347	http://dx.doi.org/10.1371/journal.pone.0039347			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	964XV	22761767	Green Accepted, Green Published, gold			2023-01-03	WOS:000305730900047
J	Callaway, E				Callaway, Ewen			EVOLUTIONARY BIOLOGY The lost appetites	NATURE			English	Editorial Material																		Campbell MC, 2012, MOL BIOL EVOL, V29, P1141, DOI 10.1093/molbev/msr293; Fisher RA, 1939, NATURE, V144, P750, DOI 10.1038/144750a0; Imai H, 2012, BIOL LETTERS, V8, P652, DOI 10.1098/rsbl.2011.1251; Jiang PH, 2012, P NATL ACAD SCI USA, V109, P4956, DOI 10.1073/pnas.1118360109; Li X, 2005, PLOS GENET, V1, P27, DOI 10.1371/journal.pgen.0010003; Wooding S, 2006, NATURE, V440, P930, DOI 10.1038/nature04655; Zhao HB, 2012, GENOME BIOL EVOL, V4, P73, DOI 10.1093/gbe/evr126	7	9	9	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 21	2012	486	7403					S16	S17		10.1038/486S16a	http://dx.doi.org/10.1038/486S16a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	046RB	22717398				2023-01-03	WOS:000311781000009
J	Killaspy, H; White, S; Wright, C; Taylor, TL; Turton, P; Kallert, T; Schuster, M; Cervilla, JA; Brangier, P; Raboch, J; Kalisova, L; Onchev, G; Alexiev, S; Mezzina, R; Ridente, P; Wiersma, D; Visser, E; Kiejna, A; Piotrowski, P; Ploumpidis, D; Gonidakis, F; Caldas-de-Almeida, JM; Cardoso, G; King, M				Killaspy, Helen; White, Sarah; Wright, Christine; Taylor, Tatiana L.; Turton, Penny; Kallert, Thomas; Schuster, Mirjam; Cervilla, Jorge A.; Brangier, Paulette; Raboch, Jiri; Kalisova, Lucie; Onchev, Georgi; Alexiev, Spiridon; Mezzina, Roberto; Ridente, Pina; Wiersma, Durk; Visser, Ellen; Kiejna, Andrzej; Piotrowski, Patryk; Ploumpidis, Dimitris; Gonidakis, Fragiskos; Caldas-de-Almeida, Jose Miguel; Cardoso, Graca; King, Michael			Quality of Longer Term Mental Health Facilities in Europe: Validation of the Quality Indicator for Rehabilitative Care against Service Users' Views	PLOS ONE			English	Article							INSTITUTIONAL CARE; COMMUNITY; CONSEQUENCES; PEOPLE; SCALE	Background: The Quality Indicator for Rehabilitative Care (QuIRC) is a staff rated, international toolkit that assesses care in longer term hospital and community based mental health facilities. The QuIRC was developed from review of the international literature, an international Delphi exercise with over 400 service users, practitioners, carers and advocates from ten European countries at different stages of deinstitutionalisation, and review of the care standards in these countries. It can be completed in under an hour by the facility manager and has robust content validity, acceptability and inter-rater reliability. In this study, we investigated the internal validity of the QuIRC. Our aim was to identify the QuIRC domains of care that independently predicted better service user experiences of care. Method: At least 20 units providing longer term care for adults with severe mental illness were recruited in each of ten European countries. Service users completed standardised measures of their experiences of care, quality of life, autonomy and the unit's therapeutic milieu. Unit managers completed the QuIRC. Multilevel modelling allowed analysis of associations between service user ratings as dependent variables with unit QuIRC domain ratings as independent variables. Results: 1750/2495 (70%) users and the managers of 213 units from across ten European countries participated. QuIRC ratings were positively associated with service users' autonomy and experiences of care. Associations between QuIRC ratings and service users' ratings of their quality of life and the unit's therapeutic milieu were explained by service user characteristics (age, diagnosis and functioning). A hypothetical 10% increase in QuIRC rating resulted in a clinically meaningful improvement in autonomy. Conclusions: Ratings of the quality of longer term mental health facilities made by service managers were positively associated with service users' autonomy and experiences of care. Interventions that improve quality of care in these settings may promote service users' autonomy.	[Killaspy, Helen; Taylor, Tatiana L.; King, Michael] UCL, Mental Hlth Sci Unit, London, England; [White, Sarah; Wright, Christine; Turton, Penny] St Georges Univ London, Div Populat Hlth Sci & Educ, London, England; [Kallert, Thomas] Pk Hosp Leipzig, Dept Psychiat Psychosomat Med & Psychotherapy, Leipzig, Germany; [Schuster, Mirjam] Tech Univ Dresden, Dept Psychiat & Psychotherapy, Univ Hosp, Dresden, Germany; [Cervilla, Jorge A.] Univ Granada, San Cecilio Univ Hosp, Mental Hlth Unit, Granada, Spain; [Brangier, Paulette] Univ Granada, Biomed Res Ctr, Mental Hlth Network, Granada, Spain; [Raboch, Jiri; Kalisova, Lucie] Charles Univ Prague, Dept Psychiat, Prague, Czech Republic; [Onchev, Georgi; Alexiev, Spiridon] Med Univ Sofia, Dept Psychiat, Sofia, Bulgaria; [Mezzina, Roberto; Ridente, Pina] Trieste Healthcare Agcy, Dept Mental Hlth, Trieste, Italy; [Wiersma, Durk; Visser, Ellen] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands; [Kiejna, Andrzej; Piotrowski, Patryk] Wroclaw Med Univ, Dept Psychiat, Wroclaw, Poland; [Ploumpidis, Dimitris; Gonidakis, Fragiskos] Univ Mental Hlth Res Inst, Athens, Greece; [Caldas-de-Almeida, Jose Miguel; Cardoso, Graca] Univ Nova Lisboa, Fac Med Sci, Lisbon, Portugal	University of London; University College London; St Georges University London; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Hospital Universitario San Cecilio; University of Granada; University of Granada; Charles University Prague; Medical University Sofia; University of Groningen; Wroclaw Medical University; Universidade Nova de Lisboa	Killaspy, H (corresponding author), UCL, Mental Hlth Sci Unit, London, England.	h.killaspy@ucl.ac.uk	Salisbury, Tatiana/CAF-8877-2022; Kališová, Lucie/N-1373-2017; raboch, jiri/N-7445-2017; gonidakis, fragiskos/AAC-5296-2020; King, Michael B/D-7477-2011; Cervilla, Jorge A/O-2106-2016; Piotrowski, Patryk/ABD-4063-2021	Kališová, Lucie/0000-0003-0695-2048; raboch, jiri/0000-0001-6667-1497; King, Michael B/0000-0003-4715-7171; Cervilla, Jorge A/0000-0001-6891-1992; Piotrowski, Patryk/0000-0001-7208-0562; Taylor Salisbury, Tatiana/0000-0002-8249-3886; White, Sarah/0000-0003-2468-6193; Urban, Mirjam/0000-0003-1714-4847; caldas de almeida, jose miguel/0000-0003-1902-6772; Cardoso, Graca/0000-0003-1756-0197; Killaspy, Helen/0000-0003-2481-4802; Onchev, Georgi/0000-0002-5139-5917	European Commission [SP5A-CT-2007-044088]	European Commission(European CommissionEuropean Commission Joint Research Centre)	This study was funded by a three-year grant from the European Commission's 6th Framework (SP5A-CT-2007-044088). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Cullen D, 1997, IRISH J PSYCHOL MED, V14, P92; Dunlap WP, 2004, BEHAV RES METH INS C, V36, P695, DOI 10.3758/BF03206551; European Commission, 2005, GREEN PAP IMPR MENT; Green MF, 1996, AM J PSYCHIAT, V153, P321; Hatton C, 2004, J INTELL DISABIL RES, V48, P103, DOI 10.1111/j.1365-2788.2004.00499.x; JONES SH, 1995, BRIT J PSYCHIAT, V166, P654, DOI 10.1192/bjp.166.5.654; Killaspy H, 2010, BMC PSYCHIATRY, V11, P35; Killaspy H, 2008, J MENT HEALTH, V17, P207, DOI 10.1080/09638230701506275; Killaspy H, 2010, PSYCHIATR BULL, V34, P265, DOI 10.1192/pb.bp.109.028530; Killaspy H, 2009, BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-36; Knapp M, 2011, HEALTH SOC CARE COMM, V19, P113, DOI 10.1111/j.1365-2524.2010.00969.x; Liegeois A, 2005, J MED ETHICS, V31, P452, DOI 10.1136/jme.2003.006999; Meltzer HY, 1997, CURR MED RES OPIN, V14, P1, DOI 10.1185/03007999709113338; Mueser K.T., 1998, HDB SOCIAL FUNCTIONI; Muijen M, 2008, PSYCHIAT SERV, V59, P479, DOI 10.1176/ps.2008.59.5.479; Priebe S, 1999, INT J SOC PSYCHIATR, V45, P7, DOI 10.1177/002076409904500102; Priebe S, 2005, BMJ-BRIT MED J, V330, P123, DOI 10.1136/bmj.38296.611215.AE; Rehabilitation Social Faculty, 2009, FRRS04 ROYAL COLL PS; Rossberg JI, 2003, ACTA PSYCHIAT SCAND, V108, P374, DOI 10.1034/j.1600-0447.2003.00191.x; Taylor TL, 2009, BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-55; Trauer T, 2001, SOC PSYCH PSYCH EPID, V36, P416, DOI 10.1007/s001270170032; Trieman N, 2002, BRIT J PSYCHIAT, V181, P428, DOI 10.1192/bjp.181.5.428; Turton P, 2010, PSYCHIAT SERV, V61, P293, DOI 10.1176/ps.2010.61.3.293; Webb Y, 2000, Int J Health Care Qual Assur Inc Leadersh Health Serv, V13, P273, DOI 10.1108/09526860010373253; World Health Organization (WHO), 2005, MENT HLTH ATL	25	30	30	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2012	7	6							e38070	10.1371/journal.pone.0038070	http://dx.doi.org/10.1371/journal.pone.0038070			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	959UU	22675508	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000305341700036
J	Seeger, MA; Mittal, A; Velamakanni, S; Hohl, M; Schauer, S; Salaa, I; Grutter, MG; van Veen, HW				Seeger, Markus A.; Mittal, Anshumali; Velamakanni, Saroj; Hohl, Michael; Schauer, Stefan; Salaa, Ihsene; Gruetter, Markus G.; van Veen, Hendrik W.			Tuning the Drug Efflux Activity of an ABC Transporter in vivo by in vitro Selected DARPin Binders	PLOS ONE			English	Article							MULTIDRUG-RESISTANCE; LACTOCOCCUS-LACTIS; ATP-BINDING; MEMBRANE-PROTEINS; CRYSTAL-STRUCTURE; RIBOSOME DISPLAY; REPEAT PROTEINS; FUNCTIONAL-ROLE; PHAGE DISPLAY; ANTIBODY	ABC transporters use the energy from binding and hydrolysis of ATP to import or extrude substrates across the membrane. Using ribosome display, we raised designed ankyrin repeat proteins (DARPins) against detergent solubilized LmrCD, a heterodimeric multidrug ABC exporter from Lactococcus lactis. Several target-specific DARPin binders were identified that bind to at least three distinct, partially overlapping epitopes on LmrD in detergent solution as well as in native membranes. Remarkably, functional screening of the LmrCD-specific DARPin pools in L. lactis revealed three homologous DARPins which, when generated in LmrCD-expressing cells, strongly activated LmrCD-mediated drug transport. As LmrCD expression in the cell membrane was unaltered upon the co-expression of activator DARPins, the activation is suggested to occur at the level of LmrCD activity. Consistent with this, purified activator DARPins were found to stimulate the ATPase activity of LmrCD in vitro when reconstituted in proteoliposomes. This study suggests that membrane transporters are tunable in vivo by in vitro selected binding proteins. Our approach could be of biopharmaceutical importance and might facilitate studies on molecular mechanisms of ABC transporters.	[Seeger, Markus A.; Velamakanni, Saroj; Salaa, Ihsene; van Veen, Hendrik W.] Univ Cambridge, Dept Pharmacol, Cambridge CB2 1QJ, England; [Seeger, Markus A.; Mittal, Anshumali; Hohl, Michael; Gruetter, Markus G.] Univ Zurich, Dept Biochem, Zurich, Switzerland; [Schauer, Stefan] Univ Zurich, Funct Genom Ctr Zurich, Zurich, Switzerland	University of Cambridge; University of Zurich; University of Zurich	Seeger, MA (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1QJ, England.	m.seeger@bioc.uzh.ch; hwv20@cam.ac.uk	Mittal, Anshumali/G-9685-2012; van Veen, Hendrik W./A-4162-2008	van Veen, Hendrik W./0000-0002-9658-8077; Seeger, Markus/0000-0003-1761-8571; Mittal, Anshumali/0000-0002-0478-2682	Swiss National Science Foundation Prospective Researcher; European Molecular Biology Organization; Novartis Foundation; Swiss National Science Foundation; Ambizione Fellowship; Research Credit (Forschungskredit) of the University of Zurich; British Society for Antimicrobial Chemotherapy; Biotechnology and Biological Sciences Research Council; BBSRC [BB/I002383/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/I002383/1] Funding Source: researchfish	Swiss National Science Foundation Prospective Researcher; European Molecular Biology Organization(European Molecular Biology Organization (EMBO)); Novartis Foundation(Novartis); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Ambizione Fellowship; Research Credit (Forschungskredit) of the University of Zurich; British Society for Antimicrobial Chemotherapy; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	Funding provided by the Swiss National Science Foundation Prospective Researcher (to MAS), European Molecular Biology Organization Long Term fellowship (to MAS), Novartis Foundation (to MAS), Swiss National Science Foundation, Ambizione Fellowship (to MAS), Research Credit (Forschungskredit) of the University of Zurich (to MAS), British Society for Antimicrobial Chemotherapy (to HWvV), and Biotechnology and Biological Sciences Research Council (to HWvV). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agustiandari H, 2008, J BACTERIOL, V190, P759, DOI 10.1128/JB.01151-07; Balakrishnan L, 2004, J BIOL CHEM, V279, P11273, DOI 10.1074/jbc.M308494200; BALL WJ, 1986, BIOCHEMISTRY-US, V25, P7155, DOI 10.1021/bi00370a058; Barrera NP, 2009, NAT METHODS, V6, P585, DOI 10.1038/nmeth.1347; Binz HK, 2004, NAT BIOTECHNOL, V22, P575, DOI 10.1038/nbt962; Binz HK, 2003, J MOL BIOL, V332, P489, DOI 10.1016/S0022-2836(03)00896-9; Boersma YL, 2011, J BIOL CHEM, V286, P41273, DOI 10.1074/jbc.M111.293266; Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; Cull MG, 2000, METHOD ENZYMOL, V326, P430; Davidson AL, 1996, J BIOL CHEM, V271, P4858; Dawson RJP, 2007, FEBS LETT, V581, P935, DOI 10.1016/j.febslet.2007.01.073; Dawson RJP, 2006, NATURE, V443, P180, DOI 10.1038/nature05155; DEBIEC H, 1993, J BIOL CHEM, V268, P13356; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; Ernst R, 2008, P NATL ACAD SCI USA, V105, P5069, DOI 10.1073/pnas.0800191105; Esteban O, 2008, J BIOL CHEM, V283, P2595, DOI 10.1074/jbc.M704941200; Forrer P, 2003, FEBS LETT, V539, P2, DOI 10.1016/S0014-5793(03)00177-7; Galian C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019677; Geertsma ER, 2011, BIOCHEMISTRY-US, V50, P3272, DOI 10.1021/bi200178z; Gottesman MM, 2009, NAT BIOTECHNOL, V27, P546, DOI 10.1038/nbt0609-546; Gutmann DAP, 2010, TRENDS BIOCHEM SCI, V35, P36, DOI 10.1016/j.tibs.2009.07.009; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; Hanes J, 1997, P NATL ACAD SCI USA, V94, P4937, DOI 10.1073/pnas.94.10.4937; Hotzel I, 2011, PROTEIN ENG DES SEL, V24, P679, DOI 10.1093/protein/gzr039; HOLLO Z, 1994, BBA-BIOMEMBRANES, V1191, P384, DOI 10.1016/0005-2736(94)90190-2; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Huber T, 2007, J STRUCT BIOL; Hunte C, 2002, CURR OPIN STRUC BIOL, V12, P503, DOI 10.1016/S0959-440X(02)00354-8; Jones PM, 2009, TRENDS BIOCHEM SCI, V34, P520, DOI 10.1016/j.tibs.2009.06.004; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; Kim J, 2011, METHODS; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kondratov RV, 2001, P NATL ACAD SCI USA, V98, P14078, DOI 10.1073/pnas.241314798; LEENHOUTS KJ, 1991, J BACTERIOL, V173, P4794, DOI 10.1128/jb.173.15.4794-4798.1991; LEPPERT G, 1990, GENETICS, V125, P13; Locher KP, 2009, PHILOS T R SOC B, V364, P239, DOI 10.1098/rstb.2008.0125; Lubelski J, 2006, BIOCHEMISTRY-US, V45, P648, DOI 10.1021/bi051276s; Lubelski J, 2004, J BIOL CHEM, V279, P34449, DOI 10.1074/jbc.M404072200; Lubelski J, 2006, MOL MICROBIOL, V61, P771, DOI 10.1111/j.1365-2958.2006.05267.x; MECHETNER EB, 1992, P NATL ACAD SCI USA, V89, P5824, DOI 10.1073/pnas.89.13.5824; Merz T, 2008, J MOL BIOL, V376, P232, DOI 10.1016/j.jmb.2007.11.047; Milovnik P, 2009, PROTEIN ENG DES SEL, V22, P357, DOI 10.1093/protein/gzp011; Monroe N, 2011, J STRUCT BIOL, V174, P269, DOI 10.1016/j.jsb.2011.01.014; Oldham ML, 2007, NATURE, V450, P515, DOI 10.1038/nature06264; Oldham ML, 2011, P NATL ACAD SCI USA, V108, P15152, DOI 10.1073/pnas.1108858108; Padan E, 1998, FEBS LETT, V441, P53, DOI 10.1016/S0014-5793(98)01524-5; Pajic M, 2009, CANCER RES, V69, P6396, DOI 10.1158/0008-5472.CAN-09-0041; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; Rees DC, 2009, NAT REV MOL CELL BIO, V10, P218, DOI 10.1038/nrm2646; Reuter G, 2003, J BIOL CHEM, V278, P35193, DOI 10.1074/jbc.M306226200; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; Rothlisberger D, 2004, FEBS LETT, V564, P340, DOI 10.1016/S0014-5793(04)00359-X; Rubinstein JL, 2003, ANAL BIOCHEM, V314, P294, DOI 10.1016/S0003-2697(02)00649-8; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schuck P, 2010, METHODS MOL BIOL, V627, P15, DOI 10.1007/978-1-60761-670-2_2; Seeger MA, 2009, BBA-PROTEINS PROTEOM, V1794, P725, DOI 10.1016/j.bbapap.2008.12.004; Sennhauser G, 2008, STRUCTURE, V16, P1443, DOI 10.1016/j.str.2008.08.010; Sennhauser G, 2007, PLOS BIOL, V5, P106, DOI 10.1371/journal.pbio.0050007; Stefan N, 2011, J MOL BIOL, V413, P826, DOI 10.1016/j.jmb.2011.09.016; Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984; Toyoshima C, 2008, ARCH BIOCHEM BIOPHYS, V476, P3, DOI 10.1016/j.abb.2008.04.017; Uysal S, 2009, P NATL ACAD SCI USA, V106, P6644, DOI 10.1073/pnas.0810663106; Velamakanni S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006137; Venter H, 2005, BIOCHEM SOC T, V33, P1008, DOI 10.1042/BST20051008; Venter H, 2003, NATURE, V426, P866, DOI 10.1038/nature02173; Venter H, 2008, BIOCHEM PHARMACOL, V75, P866, DOI 10.1016/j.bcp.2007.10.022; Wegmann U, 2007, J BACTERIOL, V189, P3256, DOI 10.1128/JB.01768-06; Woebking B, 2005, J BACTERIOL, V187, P6363, DOI 10.1128/JB.187.18.6363-6369.2005; Woebking B, 2008, BIOCHEMISTRY-US, V47, P10904, DOI 10.1021/bi800778d; Zahnd C, 2007, NAT METHODS, V4, P269, DOI 10.1038/NMETH1003; Zaitseva J, 2005, BIOCHEMISTRY-US, V44, P9680, DOI 10.1021/bi0506122; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V	76	14	15	2	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2012	7	6							e37845	10.1371/journal.pone.0037845	http://dx.doi.org/10.1371/journal.pone.0037845			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UU	22675494	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000305341700024
J	Xu, P; Chen, JC; Chen, Z; Zhou, SY; Hu, P; Chen, XY; Huang, MD				Xu, Peng; Chen, Jincan; Chen, Zhuo; Zhou, Shanyong; Hu, Ping; Chen, Xueyuan; Huang, Mingdong			Receptor-Targeting Phthalocyanine Photosensitizer for Improving Antitumor Photocytotoxicity	PLOS ONE			English	Article							GONADOTROPIN-RELEASING-HORMONE; PHOTODYNAMIC ACTIVITY; IN-VITRO; PHOTOCHEMICAL PROPERTIES; BASIC PRINCIPLES; CANCER-CELLS; THERAPY; BREAST; ANALOGS; ZINC	Photodynamic therapy (PDT) is a promising therapeutic modality which uses a photosensitizer to capture visible light resulting in phototoxicity in the irradiated region. PDT has been used in a number of pathological indications, including tumor. A key desirable feature of the photosensitizer is the high phototoxicity on tumor cells but not on normal cells. In this study, we conjugate a gonadotropin-releasing hormone (GnRH) to a photosensitizer, Zinc phthalocyanine (ZnPc), in order to enhance its specificity to breast cancer, which over-expresses GnRH receptor. ZnPc has unique advantages over other photosensitizers, but is difficult to derivatize and purify as a single isomer. We previously developed a straight-forward way to synthesize mono-substituted beta-carboxy-phthalocyanine zinc (ZnPc-COOH). Photophysical and photochemical parameters of this ZnPc-GnRH conjugate including fluorescence quantum yield (Phi(f)), fluorescence decay time (tau(s)) and singlet oxygen quantum yield (Phi(Delta)) were evaluated and found comparable with that of ZnPc, indicating that addition of a GnRH peptide does not significantly alter the generation of singlet oxygen from ZnPc. Cellular uptakes and phototoxicities of this conjugate were tested and found significantly enhanced on human breast cancer cell lines overexpressing GnRH receptors (MDA-MB-231 and MCF-7 cells) compared to cells with low levels of GnRH receptors, such as human embryonic lung fibroblast (HELF) and human liver carcinoma (HepG2) cells. In addition, the cellular uptake of this conjugate toward MCF-7 cells were found clearly alleviated by a GnRH receptor blocker Cetrorelix, suggesting that the cellular uptake of this conjugate was GnRH receptor-mediated. Put together, these findings revealed that coupling ZnPc with GnRH analogue was an effective way to improve the selectivity of ZnPc towards tumors with over-expressed GnRH receptors.	[Xu, Peng; Chen, Jincan; Chen, Zhuo; Zhou, Shanyong; Hu, Ping; Huang, Mingdong] Chinese Acad Sci, Fujian Inst Res Struct Matter, State Key Lab Struct Chem, Danish Chinese Ctr Proteases & Canc, Fuzhou 350002, Fujian, Peoples R China; [Xu, Peng; Chen, Jincan; Chen, Zhuo; Chen, Xueyuan; Huang, Mingdong] Chinese Acad Sci, Grad Univ, Beijing, Peoples R China; [Chen, Xueyuan] Chinese Acad Sci, Fujian Inst Res Struct Matter, Key Lab Optoelect Mat Chem & Phys, Fuzhou 350002, Fujian, Peoples R China	Chinese Academy of Sciences; Fujian Institute of Research on the Structure of Matter, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; Fujian Institute of Research on the Structure of Matter, CAS	Xu, P (corresponding author), Chinese Acad Sci, Fujian Inst Res Struct Matter, State Key Lab Struct Chem, Danish Chinese Ctr Proteases & Canc, Fuzhou 350002, Fujian, Peoples R China.	zchen@fjirsm.ac.cn; mhuang@fjirsm.ac.cn	Chen, Zhuo/A-6144-2011; Chen, Zhuo/O-2928-2019; Xu, Peng/GXF-8681-2022; Huang, Mingdong/J-4278-2017; Chen, Xueyuan/C-5613-2012	Chen, Zhuo/0000-0002-6351-8689; Chen, Zhuo/0000-0002-6351-8689; Xu, Peng/0000-0003-3968-7279; Huang, Mingdong/0000-0003-0085-9141; Chen, Xueyuan/0000-0003-0493-839X	Fujian Province Natural Science Foundation [2009I0029]; National Natural Science Foundation [30973567, 30811130467]; Chinese Ministry of Science and Technology [2006AA02A313]	Fujian Province Natural Science Foundation(Natural Science Foundation of Fujian Province); National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Chinese Ministry of Science and Technology(Ministry of Science and Technology, China)	This work was supported by Fujian Province Natural Science Foundation (2009I0029), National Natural Science Foundation (30973567 and 30811130467) and the Chinese Ministry of Science and Technology (2006AA02A313). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen CM, 2001, J PORPHYR PHTHALOCYA, V5, P161, DOI 10.1002/jpp.324; Allen Cynthia M., 2002, P329; Avetisov S E, 2007, Vestn Oftalmol, V123, P3; Bai M, 2011, ORG BIOMOL CHEM, V9, P7028, DOI 10.1039/c1ob05955f; BAJUSZ S, 1989, P NATL ACAD SCI USA, V86, P6318, DOI 10.1073/pnas.86.16.6318; Biyiklioglu Z, 2010, J PHOTOCH PHOTOBIO A, V211, P32, DOI 10.1016/j.jphotochem.2010.01.018; Brasseur N, 1999, PHOTOCHEM PHOTOBIOL, V69, P345, DOI 10.1562/0031-8655(1999)069<0345:RMTOPT>2.3.CO;2; Carcenac M, 1999, PHOTOCHEM PHOTOBIOL, V70, P930, DOI 10.1111/j.1751-1097.1999.tb08304.x; Chen JC, 2008, CHEM J CHINESE U, V29, P2131; Chen JC, 2006, INORG CHEM COMMUN, V9, P313, DOI 10.1016/j.inoche.2005.12.002; Chen JC, 2011, J PORPHYR PHTHALOCYA, V15, P293, DOI 10.1142/S1088424611003276; Chen Z, 2010, CHEMMEDCHEM, V5, P890, DOI 10.1002/cmdc.201000042; Choi Y, 2006, CHEMMEDCHEM, V1, P458, DOI 10.1002/cmdc.200500036; DOUGHERTY TJ, 1993, PHOTOCHEM PHOTOBIOL, V58, P895, DOI 10.1111/j.1751-1097.1993.tb04990.x; EIDNE KA, 1987, J CLIN ENDOCR METAB, V64, P425, DOI 10.1210/jcem-64-3-425; Ethirajan M, 2011, CHEM SOC REV, V40, P340, DOI 10.1039/b915149b; Harrison GS, 2004, ENDOCR-RELAT CANCER, V11, P725, DOI 10.1677/erc.1.00777; Huang D, 2000, SPECTROSC SPECT ANAL, V20, P95; JANAKY T, 1992, P NATL ACAD SCI USA, V89, P972, DOI 10.1073/pnas.89.3.972; Kakar SS, 2008, ADV EXP MED BIOL, V614, P285, DOI 10.1007/978-0-387-74911-2_32; Kakar SS, 2004, VITAM HORM, V69, P151, DOI 10.1016/S0083-6729(04)69006-6; KAKAR SS, 1994, MOL CELL ENDOCRINOL, V106, P145, DOI 10.1016/0303-7207(94)90196-1; Keller G, 2005, CANCER RES, V65, P5857, DOI 10.1158/0008-5472.CAN-04-3816; Kovacs M, 1997, P NATL ACAD SCI USA, V94, P1420, DOI 10.1073/pnas.94.4.1420; Kuznetsova NA, 2000, RUSS J GEN CHEM, V70, P133; Leuschner C, 2003, BREAST CANCER RES TR, V78, P17, DOI 10.1023/A:1022169525521; Leuschner C, 2006, BREAST CANCER RES TR, V99, P163, DOI 10.1007/s10549-006-9199-7; Liu JY, 2009, ORG BIOMOL CHEM, V7, P1583, DOI 10.1039/b822128f; Lo PC, 2007, BIOORG MED CHEM LETT, V17, P1073, DOI 10.1016/j.bmcl.2006.11.017; Morgan K, 2008, CANCER RES, V68, P6331, DOI 10.1158/0008-5472.CAN-08-0197; Nagy A, 2005, BIOL REPROD, V73, P851, DOI 10.1095/biolreprod.105.043489; Nagy A, 1996, P NATL ACAD SCI USA, V93, P7269, DOI 10.1073/pnas.93.14.7269; Nyk M, 2010, J LUMIN, V130, P2487, DOI 10.1016/j.jlumin.2010.08.017; Ogunsipe A, 2004, NEW J CHEM, V28, P822, DOI 10.1039/b315319c; Rahimipour S, 2003, J MED CHEM, V46, P3965, DOI 10.1021/jm020535y; Sharman WM, 2005, BIOCONJUGATE CHEM, V16, P1166, DOI 10.1021/bc0500241; Sharman WM, 2004, ADV DRUG DELIVER REV, V56, P53, DOI 10.1016/j.addr.2003.08.015; Sharman WM, 1999, DRUG DISCOV TODAY, V4, P507, DOI 10.1016/S1359-6446(99)01412-9; Smirnova Z. S., 2005, Khimiko-Farmatsevticheskii Zhurnal, V39, P3; Stefflova K, 2006, J MED CHEM, V49, P3850, DOI 10.1021/jm060146u; Taquet JP, 2007, CURR MED CHEM, V14, P1673, DOI 10.2174/092986707780830970; Tirand L, 2006, J CONTROL RELEASE, V111, P153, DOI 10.1016/j.jconrel.2005.11.017; Vrouenraets MB, 2003, ANTICANCER RES, V23, P505; World Health Organization, 2011, FACT SHEET 297; Xu CJ, 2009, J AM CHEM SOC, V131, P15346, DOI 10.1021/ja905938a	45	27	27	0	60	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2012	7	5							e37051	10.1371/journal.pone.0037051	http://dx.doi.org/10.1371/journal.pone.0037051			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TY	22693566	gold, Green Published, Green Submitted			2023-01-03	WOS:000305338500028
J	Lee, MJ; Ye, AS; Gardino, AK; Heijink, AM; Sorger, PK; MacBeath, G; Yaffe, MB				Lee, Michael J.; Ye, Albert S.; Gardino, Alexandra K.; Heijink, Anne Margriet; Sorger, Peter K.; MacBeath, Gavin; Yaffe, Michael B.			Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks	CELL			English	Article							GROWTH-FACTOR RECEPTOR; GENE-EXPRESSION PATTERNS; NEGATIVE BREAST-CANCER; ANTITUMOR-ACTIVITY; EGFR MUTATIONS; LINES; RESISTANCE; LAPATINIB; INHIBITION; ACTIVATION	Crosstalk and complexity within signaling pathways and their perturbation by oncogenes limit component-by-component approaches to understanding human disease. Network analysis of how normal and oncogenic signaling can be rewired by drugs may provide opportunities to target tumors with high specificity and efficacy. Using targeted inhibition of oncogenic signaling pathways, combined with DNA-damaging chemotherapy, we report that time-staggered EGFR inhibition, but not simultaneous coadministration, dramatically sensitizes a subset of triple-negative breast cancer cells to genotoxic drugs. Systems-level analysis-using high-density time-dependent measurements of signaling networks, gene expression profiles, and cell phenotypic responses in combination with mathematical modeling-revealed an approach for altering the intrinsic state of the cell through dynamic rewiring of oncogenic signaling pathways. This process converts these cells to a less tumorigenic state that is more susceptible to DNA damage-induced cell death by reactivation of an extrinsic apoptotic pathway whose function is suppressed in the oncogene-addicted state.	[Lee, Michael J.; Gardino, Alexandra K.; Heijink, Anne Margriet; Yaffe, Michael B.] MIT, Dept Biol, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [Lee, Michael J.; Gardino, Alexandra K.; Heijink, Anne Margriet; Yaffe, Michael B.] MIT, Dept Biol Engn, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [Lee, Michael J.; Ye, Albert S.; Gardino, Alexandra K.; Sorger, Peter K.; MacBeath, Gavin; Yaffe, Michael B.] MIT, Cell Decis Proc Ctr, Cambridge, MA 02139 USA; [Lee, Michael J.] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; [Sorger, Peter K.; MacBeath, Gavin] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Harvard University; Harvard Medical School	Yaffe, MB (corresponding author), MIT, Dept Biol, David H Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	myaffe@mit.edu		Heijink, Anne Margriet/0000-0001-9229-0575; MacBeath, Gavin/0000-0003-2585-6772; Lee, Michael/0000-0003-3378-6196; Sorger, Peter/0000-0002-3364-1838	NIH [CA112967, GM68762, ES015339]; DOD [BC097884]; NATIONAL CANCER INSTITUTE [U54CA112967] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM068762] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Sandra Morandell, Kylie Huang, Jose McFaline, and Jessica Reddy for technical assistance in the early stages of this study and the Swanson Biotechnology Center at the Koch Institute for their technical support, including Eliza Vasile (microscopy), Glen Paradis (flow cytometry), and especially Charlie Whittaker (bioinformatics) for his guidance in analyzing microarray experiments. We further thank Doug Lauffenburger and members of the CDP community for fruitful discussions and advice throughout the development and execution of this study. This work was supported by NIH grants CA112967 and GM68762 to P. K. S. and M.B.Y, ES015339 to M.B.Y., and DOD fellowship BC097884 to M.J.L. P. K. S., G. M., and M.B.Y. are founders and shareholders of Merrimack Pharmaceuticals. P. K. S. and M.B.Y. are scientific advisory board members, and G. M. is a current employee. G. M. is also a scientific advisory board member of Aushon Biosystems.	Abeloff M. D., 2008, CLIN ONCOLOGY, P1875; Albeck JG, 2008, PLOS BIOL, V6, P2831, DOI 10.1371/journal.pbio.0060299; Balko JM, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-289; Bosch A, 2010, CANCER TREAT REV, V36, P206, DOI 10.1016/j.ctrv.2009.12.002; Carey L., 2008, J CLIN ONCOL, V26, P26; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Corkery B, 2009, ANN ONCOL, V20, P862, DOI 10.1093/annonc/mdn710; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Diaz R, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-188; Ekins S, 2007, METH MOL B, V356, P319; Fitzgerald JB, 2006, NAT CHEM BIOL, V2, P458, DOI 10.1038/nchembio817; Gaudet S, 2005, MOL CELL PROTEOMICS, V4, P1569, DOI 10.1074/mcp.M500158-MCP200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Helfrich BA, 2006, CLIN CANCER RES, V12, P7117, DOI 10.1158/1078-0432.CCR-06-0760; Janes KA, 2005, SCIENCE, V310, P1646, DOI 10.1126/science.1116598; Janes KA, 2008, CELL, V135, P343, DOI 10.1016/j.cell.2008.08.034; Janes KA, 2006, NAT REV MOL CELL BIO, V7, P820, DOI 10.1038/nrm2041; Kang N, 2010, CANCER LETT, V294, P147, DOI 10.1016/j.canlet.2010.01.032; Kim R, 2005, CANCER-AM CANCER SOC, V103, P1551, DOI 10.1002/cncr.20947; LICHTER AS, 1995, NEW ENGL J MED, V332, P371, DOI 10.1056/NEJM199502093320607; Lopez JP, 2007, ARCH OTOLARYNGOL, V133, P1022, DOI 10.1001/archotol.133.10.1022; MacBeath G, 2002, NAT GENET, V32, P526, DOI 10.1038/ng1037; MONTESANO R, 1977, J NATL CANCER I, V59, P1651, DOI 10.1093/jnci/59.6.1651; Morgillo F, 2011, LUNG CANCER, V71, P283, DOI 10.1016/j.lungcan.2010.06.005; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Pawson T, 2008, FEBS LETT, V582, P1266, DOI 10.1016/j.febslet.2008.02.011; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Rusnak DW, 2007, CELL PROLIFERAT, V40, P580, DOI 10.1111/j.1365-2184.2007.00455.x; Sachs K, 2005, SCIENCE, V308, P523, DOI 10.1126/science.1105809; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; Sevecka M, 2006, NAT METHODS, V3, P825, DOI 10.1038/nmeth931; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun TT, 2011, CELL, V144, P703, DOI 10.1016/j.cell.2011.02.003; Turner JG, 2006, BLOOD, V108, P3881, DOI 10.1182/blood-2005-10-009084; Winer E.P., 2007, SABCS 2007 IMPROVING; Woehlecke H, 2003, INT J CANCER, V107, P721, DOI 10.1002/ijc.11444; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Yoon CH, 2009, MOL CANCER RES, V7, P361, DOI 10.1158/1541-7786.MCR-08-0069	42	480	492	1	120	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 11	2012	149	4					780	794		10.1016/j.cell.2012.03.031	http://dx.doi.org/10.1016/j.cell.2012.03.031			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	941AR	22579283	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000303934700012
J	Van Langenhove, L				Van Langenhove, Luk			Make social sciences relevant	NATURE			English	Editorial Material									[Van Langenhove, Luk] United Nations Univ, Inst Comparat Reg Integrat Studies, Brugge, Belgium		Van Langenhove, L (corresponding author), United Nations Univ, Inst Comparat Reg Integrat Studies, Brugge, Belgium.	lvanlangenhove@cris.unu.edu		Van Langenhove, Luk/0000-0002-8202-5804				[Anonymous], 2010, WORLD SOC SCI REP 20; Jonkers K., 2011, BIBLIOMETRIC REPORT; Van Langenhove L., 2007, INNOVATING SOCIAL SC	3	9	9	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 26	2012	484	7395					442	442		10.1038/484442a	http://dx.doi.org/10.1038/484442a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	931FF	22538586	Bronze			2023-01-03	WOS:000303200400021
J	Gornall, J				Gornall, Jonathan			Proton beam therapy: more than a leap of faith?	BRITISH MEDICAL JOURNAL			English	Editorial Material							RANDOMIZED CLINICAL-TRIAL; NEUTRON TREATMENT; ADVANCED TUMORS; GAMMA-RAYS; NECK; HEAD; CANCER; RADIOTHERAPY; RADIATION					jgornall@mac.com						Agency for Healthcare Research and Quality, 2012, PROT BEAM RAD US MED; [Anonymous], 2012, BMJ; CATTERALL M, 1975, BMJ-BRIT MED J, V2, P653, DOI 10.1136/bmj.2.5972.653; CATTERALL M, 1977, BRIT MED J, V1, P1642, DOI 10.1136/bmj.1.6077.1642; Chung CS, 2008, INT J RADIAT ONCOL, V72, pS8, DOI 10.1016/j.ijrobp.2008.06.785; De Ruysscher D, 2012, RADIOTHER ONCOL, V103, P5, DOI 10.1016/j.radonc.2012.01.003; Department of Health, 2007, CANC REF STRAT; Emanuel E, 2012, NY TIMES        1121; Epstein K, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e2488; ERRINGTON RD, 1991, BRIT MED J, V302, P1045, DOI 10.1136/bmj.302.6784.1045; Goitein M, 2008, J CLIN ONCOL, V26, P175, DOI 10.1200/JCO.2007.14.4329; Kunkler IH, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e3193; Lundkvist J, 2005, CANCER-AM CANCER SOC, V103, P793, DOI 10.1002/cncr.20844; MACDOUGALL RH, 1990, BRIT MED J, V301, P1241, DOI 10.1136/bmj.301.6763.1241; MAOR MH, 1995, INT J RADIAT ONCOL, V32, P599, DOI 10.1016/0360-3016(94)00595-C; Miralbell R, 2002, INT J RADIAT ONCOL, V54, P824, DOI 10.1016/S0360-3016(02)02982-6; National Radiotherapy Advisory Group, 2007, RAD DEV WORLD CLASS; National Radiotherapy Advisory Group, 2006, PROT TREATM CANC; National Specialised Commissioning Team, 2011, GUID REF PAT ABR NHS; WILSON RR, 1946, RADIOLOGY, V47, P487, DOI 10.1148/47.5.487	20	4	4	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 5	2012	345								e4917	10.1136/bmj.e4917	http://dx.doi.org/10.1136/bmj.e4917			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003TK	22951923				2023-01-03	WOS:000308634000001
J	Kuypers, KPC; Legrand, SA; Ramaekers, JG; Verstraete, AG				Kuypers, Kim Paula Colette; Legrand, Sara-Ann; Ramaekers, Johannes Gerardus; Verstraete, Alain Gaston			A Case-Control Study Estimating Accident Risk for Alcohol, Medicines and Illegal Drugs	PLOS ONE			English	Article							ORAL FLUID; CANNABIS; DRIVERS; CRASHES	Background: The aim of the present study was to assess the risk of having a traffic accident after using alcohol, single drugs, or a combination, and to determine the concentrations at which this risk is significantly increased. Methods: A population-based case-control study was carried out, collecting whole blood samples of both cases and controls, in which a number of drugs were detected. The risk of having an accident when under the influence of drugs was estimated using logistic regression adjusting for gender, age and time period of accident (cases)/sampling (controls). The main outcome measures were odds ratio (OR) for accident risk associated with single and multiple drug use. In total, 337 cases (negative: 176; positive: 161) and 2726 controls (negative: 2425; positive: 301) were included in the study. Results: Main findings were that 1) alcohol in general (all the concentrations together) caused an elevated crash risk; 2) cannabis in general also caused an increase in accident risk; at a cut-off of 2 ng/mL THC the risk of having an accident was four times the risk associated with the lowest THC concentrations; 3) when ranking the adjusted OR from lowest to highest risk, alcohol alone or in combination with other drugs was related to a very elevated crash risk, with the highest risk for stimulants combined with sedatives. Conclusion: The study demonstrated a concentration-dependent crash risk for THC positive drivers. Alcohol and alcohol-drug combinations are by far the most prevalent substances in drivers and subsequently pose the largest risk in traffic, both in terms of risk and scope.	[Kuypers, Kim Paula Colette; Ramaekers, Johannes Gerardus] Maastricht Univ, Fac Psychol & Neurosci, Dept Neuropsychol & Psychopharmacol, Maastricht, Netherlands; [Kuypers, Kim Paula Colette; Legrand, Sara-Ann; Verstraete, Alain Gaston] Univ Ghent, Dept Clin Chem Microbiol & Immunol, B-9000 Ghent, Belgium	Maastricht University; Ghent University	Kuypers, KPC (corresponding author), Maastricht Univ, Fac Psychol & Neurosci, Dept Neuropsychol & Psychopharmacol, Maastricht, Netherlands.	k.kuypers@maastrichtuniversity.nl	Kuypers, Kim/L-1206-2019; Verstraete, Alain G/B-4150-2013	Kuypers, Kim/0000-0001-7634-3809; Verstraete, Alain G/0000-0002-0956-3315	European Commission within EU	European Commission within EU	This article has been produced under the project Driving Under Influence of Drugs, Alcohol and Medicines (DRUID, www.druid-project.eu) financed by the European Commission within the framework of the EU 6th Framework Program. This report reflects only the authors' view. The European commission is not liable for any use that may be made of the information contained therein. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript	AAAM, 2008, INT INJ SCAL; Blomberg RD, 2005, CRASH RISK ALCOHOL I; Borkenstein R.F., 1974, BLUTALKOHOL, V11, P1; Brookhuis K, 1998, HUM PSYCHOPHARM CLIN, V13, pS64; Charlier C, 1998, Rev Med Liege, V53, P25; Dassanayake T, 2011, DRUG SAFETY, V34, P125, DOI 10.2165/11539050-000000000-00000; Degenhardt L, 2012, LANCET, V379, P55, DOI 10.1016/S0140-6736(11)61138-0; Drummer Olaf H., 2009, P93, DOI 10.1007/978-3-7643-9923-8_7; EMCDDA, 2007, SEL ISS 2007 DRUGS D; Field A, 2009, DISCOVERING STAT SPS, V2da; Garthe E, 1999, J TRAUMA, V47, P309, DOI 10.1097/00005373-199908000-00016; Gjerde H, 2011, ACCIDENT ANAL PREV, V43, P1197, DOI 10.1016/j.aap.2010.12.034; Gjerde H, 2010, FORENSIC SCI INT, V195, P153, DOI 10.1016/j.forsciint.2009.12.011; Houwing S., 2011, PREVALENCE ALCOHOL 1; Houwing Sjoerd, 2009, P107, DOI 10.1007/978-3-7643-9923-8_8; Isalberti C., 2011, PREVALENCE ALCOHOL O; Khiabani Hassan Z, 2006, Traffic Inj Prev, V7, P111, DOI 10.1080/15389580600550172; Kruger HP, 2004, ACCIDENT ANAL PREV, V36, P125, DOI 10.1016/S0001-4575(02)00134-3; Laumon B, 2005, BRIT MED J, V331, P1371, DOI 10.1136/bmj.38648.617986.1F; Moskowitz H, 2002, REV EXPT STUDIES LOW, P4; Movig KLL, 2004, ACCIDENT ANAL PREV, V36, P631, DOI 10.1016/S0001-4575(03)00084-8; Mura P, 2003, FORENSIC SCI INT, V133, P79, DOI 10.1016/S0379-0738(03)00052-5; Nemes S, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-56; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Raes E, 2008, FORENSIC SCI HDB ANA, P646; Ramaekers JG, 2006, DRUG ALCOHOL DEPEN, V85, P114, DOI 10.1016/j.drugalcdep.2006.03.015; Ramaekers JG, 2004, DRUG ALCOHOL DEPEN, V73, P109, DOI 10.1016/j.drugalcdep.2003.10.008; Romano E, 2011, J STUD ALCOHOL DRUGS, V72, P567, DOI 10.15288/jsad.2011.72.567; Wille SMR, 2009, THER DRUG MONIT, V31, P511, DOI 10.1097/FTD.0b013e3181ae46ea; Woratanarat P, 2009, ACCIDENT ANAL PREV, V41, P651, DOI 10.1016/j.aap.2009.03.002	30	52	52	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2012	7	8							e43496	10.1371/journal.pone.0043496	http://dx.doi.org/10.1371/journal.pone.0043496			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	998CA	22952694	gold, Green Published			2023-01-03	WOS:000308213600028
J	Scalley-Kim, ML; Hess, BW; Kelly, RL; Krostag, ARF; Lustig, KH; Marken, JS; Ovendale, PJ; Posey, AR; Smolak, PJ; Taylor, JDL; Wood, CL; Bienvenue, DL; Probst, P; Salmon, RA; Allison, DS; Foy, TM; Raport, CJ				Scalley-Kim, Michelle L.; Hess, Bruce W.; Kelly, Ryan L.; Krostag, Anne-Rachel F.; Lustig, Kurt H.; Marken, John S.; Ovendale, Pamela J.; Posey, Aaron R.; Smolak, Pamela J.; Taylor, Janelle D. L.; Wood, C. L.; Bienvenue, David L.; Probst, Peter; Salmon, Ruth A.; Allison, Daniel S.; Foy, Teresa M.; Raport, Carol J.			Novel Highly Potent Therapeutic Antibody Neutralizes Multiple Human Chemokines and Mimics Viral Immune Modulation	PLOS ONE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; COLLAGEN-INDUCED ARTHRITIS; CENTRAL-NERVOUS-SYSTEM; CCR5 D32 POLYMORPHISM; RHEUMATOID-ARTHRITIS; RECEPTOR CCR5; NEGATIVE ASSOCIATION; IN-VIVO; SCLEROSIS LESIONS; PERIPHERAL-BLOOD	Chemokines play a key role in leukocyte recruitment during inflammation and are implicated in the pathogenesis of a number of autoimmune diseases. As such, inhibiting chemokine signaling has been of keen interest for the development of therapeutic agents. This endeavor, however, has been hampered due to complexities in the chemokine system. Many chemokines have been shown to signal through multiple receptors and, conversely, most chemokine receptors bind to more than one chemokine. One approach to overcoming this complexity is to develop a single therapeutic agent that binds and inactivates multiple chemokines, similar to an immune evasion strategy utilized by a number of viruses. Here, we describe the development and characterization of a novel therapeutic antibody that targets a subset of human CC chemokines, specifically CCL3, CCL4, and CCL5, involved in chronic inflammatory diseases. Using a sequential immunization approach, followed by humanization and phage display affinity maturation, a therapeutic antibody was developed that displays high binding affinity towards the three targeted chemokines. In vitro, this antibody potently inhibits chemotaxis and chemokine-mediated signaling through CCR1 and CCR5, primary chemokine receptors for the targeted chemokines. Furthermore, we have demonstrated in vivo efficacy of the antibody in a SCID-hu mouse model of skin leukocyte migration, thus confirming its potential as a novel therapeutic chemokine antagonist. We anticipate that this antibody will have broad therapeutic utility in the treatment of a number of autoimmune diseases due to its ability to simultaneously neutralize multiple chemokines implicated in disease pathogenesis.	[Scalley-Kim, Michelle L.; Krostag, Anne-Rachel F.; Marken, John S.; Smolak, Pamela J.; Taylor, Janelle D. L.; Wood, C. L.; Allison, Daniel S.] VLST Corp, Dept Prot Engn, Seattle, WA USA; [Hess, Bruce W.; Lustig, Kurt H.; Ovendale, Pamela J.; Posey, Aaron R.; Probst, Peter; Salmon, Ruth A.; Foy, Teresa M.; Raport, Carol J.] VLST Corp, Dept Immunol & Preclin Pharmacol, Seattle, WA USA; [Kelly, Ryan L.; Bienvenue, David L.] VLST Corp, Dept Prot Sci, Seattle, WA USA		Scalley-Kim, ML (corresponding author), VLST Corp, Dept Prot Engn, Seattle, WA USA.	tfoy@vlstcorp.com			VLST Corporation	VLST Corporation	VLST Corporation funded the work in this manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alcami A, 2003, NAT REV IMMUNOL, V3, P36, DOI 10.1038/nri980; Amat M, 2006, BRIT J PHARMACOL, V149, P666, DOI 10.1038/sj.bjp.0706912; [Anonymous], 1991, SEQUENCES PROTEINS I; Armour KL, 1999, EUR J IMMUNOL, V29, P2613, DOI 10.1002/(SICI)1521-4141(199908)29:08<2613::AID-IMMU2613>3.0.CO;2-J; Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873; Barcellos LF, 2000, IMMUNOGENETICS, V51, P281, DOI 10.1007/s002510050621; Barnes DA, 1998, J CLIN INVEST, V101, P2910, DOI 10.1172/JCI2172; Berahovich RD, 2005, J IMMUNOL, V174, P7341, DOI 10.4049/jimmunol.174.11.7341; Buatois V, 2010, J IMMUNOL, V185, P2544, DOI 10.4049/jimmunol.1000182; Burns JM, 2002, J BIOL CHEM, V277, P2785, DOI 10.1074/jbc.M109884200; Carballido JM, 2003, J IMMUNOL METHODS, V273, P125, DOI 10.1016/S0022-1759(02)00422-2; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Carter PJ, 2006, NAT REV IMMUNOL, V6, P343, DOI 10.1038/nri1837; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; Conklyn MJ, 1996, CYTOKINE, V8, P762, DOI 10.1006/cyto.1996.0101; Coyle PK, 2010, AM J MANAG CARE, V16, pS164; Czaplewski LG, 1999, J BIOL CHEM, V274, P16077, DOI 10.1074/jbc.274.23.16077; Dahl ME, 2008, J PHARMACOL EXP THER, V327, P926, DOI 10.1124/jpet.108.142695; Deer JR, 2004, BIOTECHNOL PROGR, V20, P880, DOI 10.1021/bp034383r; Didier PJ, 1999, INFLAMMATION, V23, P75, DOI 10.1023/A:1020243701890; Dogan RNE, 2004, FRONT BIOSCI-LANDMRK, V9, P1500, DOI 10.2741/1284; Fagete S, 2009, MABS-AUSTIN, V1, P288, DOI 10.4161/mabs.1.3.8527; Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661; Fleishaker DL, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3685; Gade-Andavolu R, 2004, GENET MED, V6, P126, DOI 10.1097/01.GIM.0000127274.45301.54; Guan E, 2002, J BIOL CHEM, V277, P32348, DOI 10.1074/jbc.M203077200; Haringman JJ, 2006, ANN RHEUM DIS, V65, P294, DOI 10.1136/ard.2005.037176; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; Horuk R, 2009, NAT REV DRUG DISCOV, V8, P23, DOI 10.1038/nrd2734; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; Jones JM, 2008, CYTOKINE, V43, P220, DOI 10.1016/j.cyto.2008.05.016; JONES ST, 1991, BIO-TECHNOL, V9, P579; KASAMA T, 1995, J CLIN INVEST, V95, P2868, DOI 10.1172/JCI117993; Katschke KJ, 2001, ARTHRITIS RHEUM, V44, P1022, DOI 10.1002/1529-0131(200105)44:5<1022::AID-ANR181>3.3.CO;2-E; Kohem C, 2007, SCAND J RHEUMATOL, V36, P359, DOI 10.1080/03009740701393999; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Labrijn AF, 2009, NAT BIOTECHNOL, V27, P767, DOI 10.1038/nbt.1553; Mahad DJ, 2004, J NEUROPATH EXP NEUR, V63, P262, DOI 10.1093/jnen/63.3.262; Matsui M, 2002, J NEUROIMMUNOL, V128, P16, DOI 10.1016/S0165-5728(02)00121-2; Mueller A, 2006, BIOCHEM PHARMACOL, V72, P739, DOI 10.1016/j.bcp.2006.06.001; PlaterZyberk C, 1997, IMMUNOL LETT, V57, P117, DOI 10.1016/S0165-2478(97)00075-8; Pokorny V, 2005, ANN RHEUM DIS, V64, P487, DOI 10.1136/ard.2004.023333; Prahalad S, 2006, GENES IMMUN, V7, P264, DOI 10.1038/sj.gene.6364298; Reid C, 2006, PROTEIN ENG DES SEL, V19, P317, DOI 10.1093/protein/gzl015; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Rossol M, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2733; Rottman JB, 2000, EUR J IMMUNOL, V30, P2372, DOI 10.1002/1521-4141(2000)30:8<2372::AID-IMMU2372>3.0.CO;2-D; Russo RC, 2010, CURR OPIN DRUG DISC, V13, P414; Sallusto F, 2008, NAT IMMUNOL, V9, P949, DOI 10.1038/ni.f.214; Sapir Y, 2010, J IMMUNOL, V185, P2589, DOI 10.4049/jimmunol.1000666; Schall TJ, 2011, NAT REV IMMUNOL, V11, P355, DOI 10.1038/nri2972; Schier Robert, 1996, Human Antibodies and Hybridomas, V7, P97; Seet BT, 2003, ANNU REV IMMUNOL, V21, P377, DOI 10.1146/annurev.immunol.21.120601.141049; Sellebjerg F, 2000, J NEUROIMMUNOL, V102, P98, DOI 10.1016/S0165-5728(99)00166-6; Sidhu SS, 2000, METHOD ENZYMOL, V328, P333, DOI 10.1016/S0076-6879(00)28406-1; Silversides JA, 2004, MULT SCLER J, V10, P149, DOI 10.1191/1352458504ms994oa; Simpson JE, 1998, J NEUROIMMUNOL, V84, P238, DOI 10.1016/S0165-5728(97)00208-7; Smith CA, 1997, VIROLOGY, V236, P316, DOI 10.1006/viro.1997.8730; Sorensen TL, 1999, J CLIN INVEST, V103, P807, DOI 10.1172/JCI5150; Sorensen TL, 1998, SEMIN NEUROL, V18, P287, DOI 10.1055/s-2008-1040879; Tak P.P., 2012, ANN RHEUM DIS; Tran EH, 2000, EUR J IMMUNOL, V30, P1410, DOI 10.1002/(SICI)1521-4141(200005)30:5<1410::AID-IMMU1410>3.0.CO;2-L; Trebst C, 2001, AM J PATHOL, V159, P1701, DOI 10.1016/S0002-9440(10)63017-9; Volin MV, 1998, CLIN IMMUNOL IMMUNOP, V89, P44, DOI 10.1006/clin.1998.4590; Yang YF, 2002, EUR J IMMUNOL, V32, P2124, DOI 10.1002/1521-4141(200208)32:8<2124::AID-IMMU2124>3.0.CO;2-S; Zapico I, 2000, GENES IMMUN, V1, P288, DOI 10.1038/sj.gene.6363673	66	7	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 17	2012	7	8							e43332	10.1371/journal.pone.0043332	http://dx.doi.org/10.1371/journal.pone.0043332			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	996DG	22912856	Green Published, gold, Green Submitted			2023-01-03	WOS:000308063700084
J	Pozo-Rodriguez, F; Lopez-Campos, JL; Alvarez-Martinez, CJ; Castro-Acosta, A; Aguero, R; Hueto, J; Hernandez-Hernandez, J; Barron, M; Abraira, V; Forte, A; Nieto, JMS; Lopez-Gabaldon, E; Cosio, BG; Agusti, A				Pozo-Rodriguez, Francisco; Luis Lopez-Campos, Jose; Alvarez-Martinez, Carlos J.; Castro-Acosta, Ady; Agueero, Ramon; Hueto, Javier; Hernandez-Hernandez, Jesus; Barron, Manuel; Abraira, Victor; Forte, Anabel; Sanchez Nieto, Juan Miguel; Lopez-Gabaldon, Encarnacion; Cosio, Borja G.; Agusti, Alvar		AUDIPOC Study Grp	Clinical Audit of COPD Patients Requiring Hospital Admissions in Spain: AUDIPOC Study	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; QUALITY-OF-CARE; ACUTE EXACERBATIONS; IMPACT	Backgrounds: AUDIPOC is a nationwide clinical audit that describes the characteristics, interventions and outcomes of patients admitted to Spanish hospitals because of an exacerbation of chronic obstructive pulmonary disease (ECOPD), assessing the compliance of these parameters with current international guidelines. The present study describes hospital resources, hospital factors related to case recruitment variability, patients' characteristics, and adherence to guidelines. Methodology/Principal Findings: An organisational database was completed by all participant hospitals recording resources and organisation. Over an 8-week period 11,564 consecutive ECOPD admissions to 129 Spanish hospitals covering 70% of the Spanish population were prospectively identified. At hospital discharge, 5,178 patients (45% of eligible) were finally included, and thus constituted the audited population. Audited patients were reassessed 90 days after admission for survival and readmission rates. A wide variability was observed in relation to most variables, hospital adherence to guidelines, and readmissions and death. Median inpatient mortality was 5% (across-hospital range 0-35%). Among discharged patients, 37% required readmission (0-62%) and 6.5% died (0-35%). The overall mortality rate was 11.6% (0-50%). Hospital size and complexity and aspects related to hospital COPD awareness were significantly associated with case recruitment. Clinical management most often complied with diagnosis and treatment recommendations but rarely (<50%) addressed guidance on healthy life-styles. Conclusions/Significance: The AUDIPOC study highlights the large across-hospital variability in resources and organization of hospitals, patient characteristics, process of care, and outcomes. The study also identifies resources and organizational characteristics associated with the admission of COPD cases, as well as aspects of daily clinical care amenable to improvement.	[Pozo-Rodriguez, Francisco; Alvarez-Martinez, Carlos J.; Castro-Acosta, Ady] Hosp 12 Octubre, Inst Invest, E-28041 Madrid, Spain; [Pozo-Rodriguez, Francisco; Luis Lopez-Campos, Jose; Castro-Acosta, Ady; Cosio, Borja G.; Agusti, Alvar] Inst Salud Carlos III, Ctr Biomed Res Resp Dis CIBERES, Madrid, Spain; [Luis Lopez-Campos, Jose] Hosp Univ Virgen del Rocio, IBiS, Seville, Spain; [Agueero, Ramon] Hosp Univ Marques de Valdecilla, Santander, Spain; [Hueto, Javier] Complejo Hosp Navarra, Pamplona, Spain; [Hernandez-Hernandez, Jesus] Hosp Nuestra Sra Sonsoles, Avila, Spain; [Barron, Manuel] Complejo Hosp San Millan, Logrono, Spain; [Abraira, Victor] Hosp Univ Ramon y Cajal, IRYCIS, Madrid, Spain; [Abraira, Victor] Inst Salud Carlos III, Ctr Biomed Res Epidemiol & Publ Hlth CIBERESP, Madrid, Spain; [Forte, Anabel] Univ Castellon, Dept Stat & Operat Res, Castellon de La Plana, Spain; [Sanchez Nieto, Juan Miguel] Hosp Univ Morales Meseguer, Murcia, Spain; [Lopez-Gabaldon, Encarnacion] Hosp Virgen Salud, Toledo, Spain; [Cosio, Borja G.] Hosp Univ Son Espases, Balearic Isl, Spain; [Agusti, Alvar] Hosp Clin Barcelona, Inst Torax, Barcelona, Spain	Hospital Universitario 12 de Octubre; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Instituto de Salud Carlos III; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; Hospital Universitario Marques de Valdecilla (HUMV); Servicio Navarro de Salud - Osasunbidea; Hospital Universitario Ramon y Cajal; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Instituto de Salud Carlos III; Universitat Jaume I; Meseguer General University Hospital Morales; Complejo Hospitalario de Toledo; Hospital Universitari Son Espases; University of Barcelona; Hospital Clinic de Barcelona	Pozo-Rodriguez, F (corresponding author), Hosp 12 Octubre, Inst Invest, E-28041 Madrid, Spain.	fpozo@h12o.es	Alfageme, Inmaculada/K-2092-2014; Barbé, Ferran/A-5988-2010; Alcázar-Navarrete, Bernardino/X-8947-2018; Forte, Anabel/Q-1512-2015; Valle-Falcones, Manuel/AAB-5557-2019; Represas-Represas, Cristina/AAA-7143-2019; Forte, Anabel/GLT-9488-2022; Andújar-Espinosa, Rubén/ABD-6716-2020; López-Quílez, Antonio/H-5945-2011; Ussetti, Piedad/B-3853-2014; Marcos, Pedro J/K-9965-2015; Garcia-Navarro, Alvar Agusti/F-4474-2015; Clemente, Marta Garcia/P-6628-2016; Castro-Acosta, Ady Angelica/H-4163-2011; Perez, Nicolas/A-7850-2015; G.Cosio, Borja/P-4963-2017; Fernandez, Virginia Leiro/B-9679-2018; FERNANDEZ, DANIEL LOPEZ/H-8651-2015; Guardia, Sergi Pascual/L-7652-2014; Lopez-Campos Bodineau, Jose Luis/Q-1637-2018	Alfageme, Inmaculada/0000-0002-5106-1669; Barbé, Ferran/0000-0002-2340-8928; Alcázar-Navarrete, Bernardino/0000-0003-2356-9366; Forte, Anabel/0000-0001-9534-1817; Valle-Falcones, Manuel/0000-0002-0900-146X; Represas-Represas, Cristina/0000-0002-5908-6684; Forte, Anabel/0000-0001-9534-1817; Andújar-Espinosa, Rubén/0000-0002-6714-9438; López-Quílez, Antonio/0000-0002-7022-9260; Ussetti, Piedad/0000-0002-3439-5536; Marcos, Pedro J/0000-0001-9600-3537; Garcia-Navarro, Alvar Agusti/0000-0003-3271-3788; Clemente, Marta Garcia/0000-0003-0463-5946; Castro-Acosta, Ady Angelica/0000-0001-7591-6011; Perez, Nicolas/0000-0002-1192-5901; G.Cosio, Borja/0000-0002-6388-8209; Fernandez, Virginia Leiro/0000-0001-9613-430X; FERNANDEZ, DANIEL LOPEZ/0000-0003-2131-9515; Guardia, Sergi Pascual/0000-0002-6567-0916; Canon-Barroso, Lourdes/0000-0002-9164-8915; AYERBE GARCIA, RUTH/0000-0001-8459-5037; ESTEBAN, CRISTOBAL/0000-0001-9878-7806; Ordonez Gomez, Paola Lisseth/0000-0001-8463-7057; Hernandez Hernandez, Jesus R./0000-0002-7526-1120; Abraira, Victor/0000-0002-4615-8503; Lopez-Campos Bodineau, Jose Luis/0000-0003-1703-1367; Pajares, Virginia/0000-0002-0916-527X; FERNANDEZ-VILLAR, ALBERTO/0000-0001-7407-5249; Ruiz Albi, Tomas/0000-0003-4785-7151; Abascal-Bolado, Beatriz/0000-0001-6712-9923; Domenech del Rio, Adolfo/0000-0002-3127-9150; Villanueva, Manuel Angel/0000-0003-3256-9579; Boukichou Abdelkader, Nisa/0000-0002-7427-531X; Gullon, Jose Antonio/0000-0002-3007-0873; CORBACHO, DOLORES/0000-0003-1239-5276; Cascante, Jose Antonio/0000-0003-2830-9272; Borderias, Luis/0000-0003-3296-9644; Rio, Maria Teresa/0000-0003-2958-1067	Fondo de Investigacion Sanitaria (FIS); Instituto de Salud Carlos III; Ministerio de Ciencia e Innovacion [PI 08/90129, PI 90486, PI08/90578, PI 07/90503, PI 08/90251, PI 07/90516, PI 08/90529, PI 07/90309, PI 08/90457, PI 07/90721, PI 08/90550, PI08/90447, PI07/90403, PI 08/90486]; Spanish Respiratory Society (SEPAR); CIBER de Enfermedades Respiratorias (CIBERES)	Fondo de Investigacion Sanitaria (FIS)(Instituto de Salud Carlos III); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Spanish Respiratory Society (SEPAR); CIBER de Enfermedades Respiratorias (CIBERES)	This work was supported by Fondo de Investigacion Sanitaria (FIS), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion (PI 08/90129, PI 90486, PI08/90578, PI 07/90503, PI 08/90251, PI 07/90516, PI 08/90529, PI 07/90309, PI 08/90457, PI 08/90129, PI 07/90721, PI 08/90550, PI08/90447, PI07/90403, PI 08/90486), Spanish Respiratory Society (SEPAR) and CIBER de Enfermedades Respiratorias (CIBERES). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agabiti N, 2010, EUR RESPIR J, V35, P1031, DOI 10.1183/09031936.00056209; Agusti A, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-122; [Anonymous], 2011, NICE CLIN GUIDELINE; [Anonymous], 2010, GUIA PRACT CLIN DIAG; Barba R, 2012, EUR RESPIR J, V39, P46, DOI 10.1183/09031936.00013211; Berger Z, 2010, J EVAL CLIN PRACT, V16, P1045, DOI 10.1111/j.1365-2753.2009.01247.x; Calderon-Larranaga A, 2011, THORAX, V66, P191, DOI 10.1136/thx.2010.147058; Cody Ron, 2005, CODYS DATA CLEANING; Gutierrez PC, 2010, MED CLIN-BARCELONA, V134, P505, DOI 10.1016/j.medcli.2009.12.002; Davidoff F, 1999, ANN INTERN MED, V130, P1019, DOI 10.7326/0003-4819-130-12-199906150-00022; Donaldson GC, 2006, THORAX, V61, P164, DOI 10.1136/thx.2005.041806; Eddy D M, 1984, Health Aff (Millwood), V3, P74, DOI 10.1377/hlthaff.3.2.74; Flottorp SA, 2010, USING AUDIT FEEDBACK; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; Hernandez-Garcia I, 2011, REV CLIN ESP, V211, P219, DOI 10.1016/j.rce.2010.10.009; Holt JB, 2011, INT J CHRONIC OBSTR, V6, P321, DOI 10.2147/COPD.S19945; Hurst JR, 2009, AM J RESP CRIT CARE, V179, P369, DOI 10.1164/rccm.200807-1067OC; Instituto Nacional de Estadistica, 2011, INEBASE; Liaaen ED, 2010, RESP MED, V104, P1304, DOI 10.1016/j.rmed.2010.03.007; Lindenauer PK, 2006, ANN INTERN MED, V144, P894, DOI 10.7326/0003-4819-144-12-200606200-00006; Lynch SM, 2007, STAT SOC BEHAV SC, P1, DOI 10.1007/978-0-387-71265-9; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; NICE and the Healthcare Commission, 2002, PRINC BEST PRACT CLI; Pozo-Rodriguez F, 2010, ARCH BRONCONEUMOL, V46, P349, DOI 10.1016/j.arbres.2010.04.004; Pretto JJ, INTERN MED IN PRESS; Price LC, 2006, THORAX, V61, P837, DOI 10.1136/thx.2005.049940; [Royal College of Physicians of London British Thoracic Society British Lung Foundation], 2011, REP NAT CHRON OBSTR; Soriano JB, 2010, EUR RESPIR J, V36, P758, DOI 10.1183/09031936.00138409; Spiegelhalter DJ, 2003, STAT MED, V22, P3687, DOI 10.1002/sim.1586	29	66	66	0	48	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2012	7	7							e42156	10.1371/journal.pone.0042156	http://dx.doi.org/10.1371/journal.pone.0042156			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982LS	22911875	Green Published, Green Submitted, gold			2023-01-03	WOS:000307045600061
J	Tachibana, Y; Fukushima, A; Saito, H; Yoneyama, S; Ushida, K; Yoneyama, S; Kawashima, R				Tachibana, Yoshiyuki; Fukushima, Ai; Saito, Hitomi; Yoneyama, Satoshi; Ushida, Kazuo; Yoneyama, Susumu; Kawashima, Ryuta			A New Mother-Child Play Activity Program to Decrease Parenting Stress and Improve Child Cognitive Abilities: A Cluster Randomized Controlled Trial	PLOS ONE			English	Article							EXECUTIVE FUNCTIONS; FLUID INTELLIGENCE; PREFRONTAL CORTEX; SELF-REGULATION; WORKING-MEMORY; ATTACHMENT; INTERVENTIONS; SENSITIVITY; FAMILIES; ANXIETY	Background: We propose a new play activity intervention program for mothers and children. Our interdisciplinary program integrates four fields of child-related sciences: neuroscience, preschool pedagogy, developmental psychology, and child and maternal psychiatry. To determine the effect of this intervention on child and mother psychosocial problems related to parenting stress and on the children's cognitive abilities, we performed a cluster randomized controlled trial. Methodology/Principal Findings: Participants were 238 pairs of mothers and typically developing preschool children (ages 4-6 years old) from Wakakusa kindergarten in Japan. The pairs were asked to play at home for about 10 min a day, 5 days a week for 3 months. Participants were randomly assigned to the intervention or control group by class unit. The Parenting Stress Index (PSI) (for mothers), the Goodenough Draw-a-Man intelligence test (DAM), and the new S-S intelligence test (NSSIT) (for children) PSI (for maternal psychosocial problems related to parenting stress), and the score on the DAM (for child cognitive abilities). The results of the PSI suggested that the program may reduce parenting stress. The results of the cognitive tests suggested that the program may improve the children's fluid intelligence, working memory, and processing speed. Conclusions/Significance: Our intervention program may ameliorate the children's psychosocial problems related to parenting stress and increase their cognitive abilities.	[Tachibana, Yoshiyuki] Natl Ctr Child Hlth & Dev, Dept Psychosocial Med, Div Maternal Child Psychiat, Tokyo, Japan; [Tachibana, Yoshiyuki; Kawashima, Ryuta] Tohoku Univ, Smart Aging Int Res Ctr, IDAC, Dept Appl Brain Sci, Sendai, Miyagi 980, Japan; [Fukushima, Ai; Kawashima, Ryuta] Tohoku Univ, Dept Funct Brain Imaging, IDAC, Sendai, Miyagi 980, Japan; [Saito, Hitomi; Yoneyama, Satoshi; Ushida, Kazuo; Yoneyama, Susumu] Wakakusa Kindergarten, Sendai, Miyagi, Japan	National Center for Child Health & Development - Japan; Tohoku University; Tohoku University	Tachibana, Y (corresponding author), Natl Ctr Child Hlth & Dev, Dept Psychosocial Med, Div Maternal Child Psychiat, Tokyo, Japan.	tatibana@idac.tohoku.ac.jp			Ministry of Education, Culture, Sports, Science and Technology	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was supported by the promotion scheme "Researches for improvement of children's life style'' by the Ministry of Education, Culture, Sports, Science and Technology entitled "The research and practice of the play program for enhancing parent-child attachment and child cognitive abilities''. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abidin R. R., 1995, PSYCHOL ASSESSMENT R, V3rd; Abidin R.R., 1983, PARENTING STRESS IND; Abidin RR, 1995, PARENTING STRESS IND, V75; Anthony LG, 2005, INFANT CHILD DEV, V14, P133, DOI 10.1002/icd.385; Awh E, 2006, NEUROSCIENCE, V139, P201, DOI 10.1016/j.neuroscience.2005.08.023; Bakermans-Kranenburg MJ, 2003, PSYCHOL BULL, V129, P195, DOI 10.1037/0033-2909.129.2.195; Barkley RA, 2001, NEUROPSYCHOL REV, V11, P1, DOI 10.1023/A:1009085417776; Barnett DW, 2002, DESIGNING PRESCHOOL; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berk L. E., 1995, SCAFFOLDING CHILDREN; Bierman KL, 2008, DEV PSYCHOPATHOL, V20, P821, DOI 10.1017/S0954579408000394; Blair C, 2008, DEV PSYCHOPATHOL, V20, P899, DOI 10.1017/S0954579408000436; Blair C, 2007, CHILD DEV, V78, P647, DOI 10.1111/j.1467-8624.2007.01019.x; Booth P. B., 1999, THERAPLAY HELPING PA; Boutron I, 2008, ANN INTERN MED, V148, P295, DOI 10.7326/0003-4819-148-4-200802190-00008; BOWLBY J, 1977, BRIT J PSYCHIAT, V130, P201, DOI 10.1192/bjp.130.3.201; Bowlby J., 1988, SECURE BASE; Bowlby J., 1969, ATTACHMENT LOSS SEPA, V1; Bull R, 2001, DEV NEUROPSYCHOL, V19, P273, DOI 10.1207/S15326942DN1903_3; Campbell MJ, 2000, STAT METHODS MED RES, V9, P81, DOI 10.1191/096228000676246354; CARPENTER PA, 1990, PSYCHOL REV, V97, P404, DOI 10.1037/0033-295X.97.3.404; Cohen J., 2013, STAT POWER ANAL BEHA; Colom R, 2007, J BIOSOC SCI, V39, P79, DOI 10.1017/S0021932005001173; Creasey G, 2003, PLAY CHILDREN ATTACH, P133; Davidson RJ, 2002, BIOL PSYCHIAT, V51, P68, DOI 10.1016/S0006-3223(01)01328-2; Deary IJ, 2007, INTELLIGENCE, V35, P13, DOI 10.1016/j.intell.2006.02.001; Deater-Deckard K., 2004, PARENTING STRESS; Dehn MJ, 2008, WORKING MEMORY ACAD; Diamond A, 2007, SCIENCE, V318, P1387, DOI 10.1126/science.1151148; Dudoit S., 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1040; Edwards CP, 2000, CROSS-CULT RES, V34, P318, DOI 10.1177/106939710003400402; Fagan J, 1999, EARLY CHILD RES Q, V14, P243, DOI 10.1016/S0885-2006(99)00008-3; Fivush R, 2006, ATTACH HUM DEV, V8, P283, DOI 10.1080/08912960600858935; Fonagy P., 2002, AFFECT REGULATION ME; Fry AF, 1996, PSYCHOL SCI, V7, P237, DOI 10.1111/j.1467-9280.1996.tb00366.x; Goodenough FL., 1926, MEASUREMENT INTELLIG; Gottfredson LS, 1997, INTELLIGENCE, V24, P79, DOI 10.1016/S0160-2896(97)90014-3; Gray JR, 2004, NAT REV NEUROSCI, V5, P471, DOI 10.1038/nrn1405; Gray JR, 2003, NAT NEUROSCI, V6, P316, DOI 10.1038/nn1014; Greenberg MT, 2006, ANN NY ACAD SCI, V1094, P139, DOI 10.1196/annals.1376.013; Jaeggi SM, 2008, P NATL ACAD SCI USA, V105, P6829, DOI 10.1073/pnas.0801268105; Judge S, 2003, FAM RELAT, V52, P241, DOI 10.1111/j.1741-3729.2003.00241.x; Juffer F., 2008, PROMOTING POSITIVE P; Kazui M, 2005, ATTACHMENT; Kerr M, 1998, STRATEGIES MANAGING; Khatena J, 1967, GIFTED CHILD Q, V11, P227; Killip S, 2004, ANN FAM MED, V2, P204, DOI 10.1370/afm.141; Kobayashi S, 1967, P YAMAGATA U ED SCI, V5, P131; Love JM., 2002, MAKING DIFFERENCE LI, VI; LOYD BH, 1985, J PEDIATR PSYCHOL, V10, P169, DOI 10.1093/jpepsy/10.2.169; Magill-Evans J, 2006, J ADV NURS, V55, P248, DOI 10.1111/j.1365-2648.2006.03896.x; McBride BA, 1991, EARLY CHILD DEV CARE, V67, P73, DOI DOI 10.1080/0300443910670107; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Monk CS, 2008, DEV PSYCHOPATHOL, V20, P1231, DOI 10.1017/S095457940800059X; MOUTON PY, 1988, J CLIN CHILD PSYCHOL, V17, P217, DOI 10.1207/s15374424jccp1703_4; Narama M., 1999, SHOUNI HOKEN KENKYU, V58, P610; Neisser U, 1996, AM PSYCHOL, V51, P77, DOI 10.1037/0003-066X.51.2.77; Raven J.C., 1958, GUIDE USING COLOURED; Roberts C, 2005, CLIN TRIALS, V2, P152, DOI 10.1191/1740774505cn076oa; Rohde TE, 2007, INTELLIGENCE, V35, P83, DOI 10.1016/j.intell.2006.05.004; Russ HG, 1988, EFFECTS ADOPTION PRE; Seifer R, 1995, MONOGR SOC RES CHILD, V60, P146, DOI 10.2307/1166176; Sroufe LA, 2005, ATTACH HUM DEV, V7, P349, DOI 10.1080/14616730500365928; Swanson HL, 2006, J EDUC PSYCHOL, V98, P17; Takeuchi H, 2010, J NEUROSCI, V30, P3297, DOI 10.1523/JNEUROSCI.4611-09.2010; Thomas KM, 1999, NEUROIMAGE, V10, P327, DOI 10.1006/nimg.1999.0466; Thompson RA, 2000, CHILD DEV, V71, P145, DOI 10.1111/1467-8624.00128; Thorell LB, 2009, DEVELOPMENTAL SCI, V12, P106, DOI 10.1111/j.1467-7687.2008.00745.x; Tsujimoto S, 2008, NEUROSCIENTIST, V14, P345, DOI 10.1177/1073858408316002; Ukoumunne OC, 1999, HLTH TECHNOLOGY ASSE, V3, piii, DOI DOI 10.3310/HTA3050; van Ijzendoorn MH, 1992, MULTIPLE CARETAKER P; Ana B, 2007, PSYCHON B REV, V14, P320, DOI 10.3758/BF03194071; Vygotsky L. S., 1978, MIND SOC; Vygotsky LS, 1960, GENESIS HIGHER MENTA, P61; Warren SL, 1997, J AM ACAD CHILD PSY, V36, P637, DOI 10.1097/00004583-199705000-00014; Wechsler D, 1991, WISC 3 WECHSLER INTE; WEINER A, 1994, FAM PROCESS, V33, P441, DOI 10.1111/j.1545-5300.1994.00441.x; West BT, 2007, LINEAR MIXED MODELS, p[98, 268, 333]; WOOD D, 1976, J CHILD PSYCHOL PSYC, V17, P89, DOI 10.1111/j.1469-7610.1976.tb00381.x; Yamane K, 1977, MANUAL NEW S S INTEL	80	15	15	0	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2012	7	7							e38238	10.1371/journal.pone.0038238	http://dx.doi.org/10.1371/journal.pone.0038238			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	981ER	22848340	Green Published, Green Submitted, gold			2023-01-03	WOS:000306950200002
J	Landon, BE; Keating, NL; Barnett, ML; Onnela, JP; Paul, S; O'Malley, AJ; Keegan, T; Christakis, NA				Landon, Bruce E.; Keating, Nancy L.; Barnett, Michael L.; Onnela, Jukka-Pekka; Paul, Sudeshna; O'Malley, A. James; Keegan, Thomas; Christakis, Nicholas A.			Variation in Patient-Sharing Networks of Physicians Across the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY-CARE; SOCIAL NETWORKS; REGIONAL-VARIATIONS; QUALITY; COOPERATION; SPECIALIST; CHOICE	Context Physicians are embedded in informal networks that result from their sharing of patients, information, and behaviors. Objectives To identify professional networks among physicians, examine how such networks vary across geographic regions, and determine factors associated with physician connections. Design, Setting, and Participants Using methods adopted from social network analysis, Medicare administrative data from 2006 were used to study 4 586 044 Medicare beneficiaries seen by 68 288 physicians practicing in 51 hospital referral regions (HRRs). Distinct networks depicting connections between physicians (defined based on shared patients) were constructed for each of the 51 HRRs. Main Outcomes Measures Variation in network characteristics across HRRs and factors associated with physicians being connected. Results The number of physicians per HRR ranged from 135 in Minot, North Dakota, to 8197 in Boston, Massachusetts. There was substantial variation in network characteristics across HRRs. For example, the mean (SD) adjusted degree (number of other physicians each physician was connected to per 100 Medicare beneficiaries) across all HRRs was 27.3 (range, 11.7-54.4); also, primary care physician relative centrality (how central primary care physicians were in the network relative to other physicians) ranged from 0.19 to 1.06, suggesting that primary care physicians were more than 5 times more central in some markets than in others. Physicians with ties to each other were far more likely to be based at the same hospital (69.2% of unconnected physician pairs vs 96.0% of connected physician pairs; adjusted rate ratio, 0.12 [95% CI, 0.12-0.12]; P < .001), and were in closer geographic proximity (mean office distance of 21.1 km for those with connections vs 38.7 km for those without connections, P < .001). Connected physicians also had more similar patient panels in terms of the race or illness burden than unconnected physicians. For instance, connected physician pairs had an average difference of 8.8 points in the percentage of black patients in their 2 patient panels compared with a difference of 14.0 percentage points for unconnected physician pairs (P < .001). Conclusions Network characteristics vary across geographic areas. Physicians tend to share patients with other physicians with similar physician-level and patient-panel characteristics. JAMA. 2012;308(3):265-273 www.jama.com	[Landon, Bruce E.; Keating, Nancy L.; Barnett, Michael L.; Paul, Sudeshna; O'Malley, A. James; Keegan, Thomas; Christakis, Nicholas A.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02215 USA; [Landon, Bruce E.; Keating, Nancy L.; Barnett, Michael L.; Paul, Sudeshna; O'Malley, A. James; Keegan, Thomas; Christakis, Nicholas A.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Cambridge, MA 02138 USA; [Onnela, Jukka-Pekka] Harvard Univ, Sch Publ Hlth, Dept Biostat, Cambridge, MA 02138 USA; [Onnela, Jukka-Pekka] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA; [Christakis, Nicholas A.] Harvard Univ, Dept Sociol, Fac Arts & Sci, Cambridge, MA 02138 USA; [Christakis, Nicholas A.] Harvard Univ, Dept Sociol, Fac Arts & Sci, Boston, MA 02215 USA; [Landon, Bruce E.; Christakis, Nicholas A.] Beth Israel Deaconess Med Ctr, Dept Med, Div Primary Care & Gen Internal Med, Boston, MA 02215 USA; [Keating, Nancy L.; Barnett, Michael L.] Brigham & Womens Hosp, Dept Med, Div Gen Internal Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital	Landon, BE (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02215 USA.	landon@hcp.med.harvard.edu	Keating, Nancy L/I-9968-2019; Barnett, Michael/AAF-4017-2019; Barnett, Michael/ABA-4159-2021	Keating, Nancy L/0000-0002-8274-4681; Barnett, Michael/0000-0002-4884-6609; Barnett, Michael/0000-0002-4884-6609	National Institute on Aging [P-01 AG-031093]; Doris Duke Charitable Foundation Clinical Research Fellowship; Harvard Medical School Research Fellowship; NATIONAL INSTITUTE ON AGING [P01AG031093] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Doris Duke Charitable Foundation Clinical Research Fellowship(Doris Duke Charitable Foundation (DDCF)); Harvard Medical School Research Fellowship; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by grant P-01 AG-031093 from the National Institute on Aging. Dr Barnett was supported by a Doris Duke Charitable Foundation Clinical Research Fellowship and a Harvard Medical School Research Fellowship.	Apicella CL, 2012, NATURE, V481, P497, DOI 10.1038/nature10736; Baldwin LM, 2002, MED CARE, V40, P82; Barnett ML, 2012, J GEN INTERN MED, V27, P506, DOI 10.1007/s11606-011-1861-z; Barnett ML, 2012, MED CARE, V50, P152, DOI 10.1097/MLR.0b013e31822dcef7; Barnett ML, 2011, HEALTH SERV RES, V46, P1592, DOI 10.1111/j.1475-6773.2011.01262.x; BREIGER RL, 1974, SOC FORCES, V53, P181, DOI 10.2307/2576011; Bynum JPW, 2007, HEALTH SERV RES, V42, P45, DOI 10.1111/j.1475-6773.2006.00633.x; Coleman J. S., 1966, MED INNOVATION DIFFU; Dartmouth Medical School Center for the Evaluative Clinical Sciences, 1998, DARTM ATL HLTH CAR; DesRoches CM, 2008, NEW ENGL J MED, V359, P50, DOI 10.1056/NEJMsa0802005; Everett Martin G., 2005, MODELS METHODS SOCIA, P57, DOI [10.1017/cbo9780511811395.004, DOI 10.1017/CBO9780511811395.004]; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; FRUCHTERMAN TMJ, 1991, SOFTWARE PRACT EXPER, V21, P1129, DOI 10.1002/spe.4380211102; Ingenix Inc, WHAT AR ETGS; Iwashyna TJ, 2009, CHEST, V135, P827, DOI 10.1378/chest.08-1052; Keating NL, 2007, J GEN INTERN MED, V22, P794, DOI 10.1007/s11606-007-0190-8; Keating NL, 1998, JAMA-J AM MED ASSOC, V280, P900, DOI 10.1001/jama.280.10.900; Kinchen KS, 2004, ANN FAM MED, V2, P245, DOI 10.1370/afm.68; McPherson M, 2001, ANNU REV SOCIOL, V27, P415, DOI 10.1146/annurev.soc.27.1.415; Newman M, 2010, NETWORKS INTRO, DOI 10.1162/artl_r_00062; Pham HH, 2009, ANN INTERN MED, V150, P236, DOI 10.7326/0003-4819-150-4-200902170-00004; Pollack CE, 2012, HEALTH SERV RES, V47, P380, DOI 10.1111/j.1475-6773.2011.01331.x; Pope GC, RISK ADJUSTMENT MEDI; Rand DG, 2011, P NATL ACAD SCI USA, V108, P19193, DOI 10.1073/pnas.1108243108; Soumerai SB, 1998, JAMA-J AM MED ASSOC, V279, P1358, DOI 10.1001/jama.279.17.1358; Wasserman S., 1994, NETWORK ANAL METHODS; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102	28	171	171	1	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 18	2012	308	3					265	273		10.1001/jama.2012.7615	http://dx.doi.org/10.1001/jama.2012.7615			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	975AC	22797644	Green Accepted, Bronze, Green Published			2023-01-03	WOS:000306477900027
J	Chakraborti, A; Allen, A; Allen, B; Rosi, S; Fike, JR				Chakraborti, Ayanabha; Allen, Antino; Allen, Barrett; Rosi, Susanna; Fike, John R.			Cranial Irradiation Alters Dendritic Spine Density and Morphology in the Hippocampus	PLOS ONE			English	Article							LONG-TERM POTENTIATION; IN-VIVO; PREFRONTAL CORTEX; SPATIAL MEMORY; COGNITIVE IMPAIRMENT; GLUTAMATE RECEPTORS; SYNAPTIC PLASTICITY; ADULT NEUROGENESIS; PYRAMIDAL CELLS; RAT HIPPOCAMPUS	Therapeutic irradiation of the brain is a common treatment modality for brain tumors, but can lead to impairment of cognitive function. Dendritic spines are sites of excitatory synaptic transmission and changes in spine structure and number are thought to represent a morphological correlate of altered brain functions associated with hippocampal dependent learning and memory. To gain some insight into the temporal and sub region specific cellular changes in the hippocampus following brain irradiation, we investigated the effects of 10 Gy cranial irradiation on dendritic spines in young adult mice. One week or 1 month post irradiation, changes in spine density and morphology in dentate gyrus (DG) granule and CA1 pyramidal neurons were quantified using Golgi staining. Our results showed that in the DG, there were significant reductions in spine density at both 1 week (11.9%) and 1 month (26.9%) after irradiation. In contrast, in the basal dendrites of CA1 pyramidal neurons, irradiation resulted in a significant reduction (18.7%) in spine density only at 1 week post irradiation. Analysis of spine morphology showed that irradiation led to significant decreases in the proportion of mushroom spines at both time points in the DG as well as CA1 basal dendrites. The proportions of stubby spines were significantly increased in both the areas at 1 month post irradiation. Irradiation did not alter spine density in the CA1 apical dendrites, but there were significant changes in the proportion of thin and mushroom spines at both time points post irradiation. Although the mechanisms involved are not clear, these findings are the first to show that brain irradiation of young adult animals leads to alterations in dendritic spine density and morphology in the hippocampus in a time dependent and region specific manner.	[Chakraborti, Ayanabha; Allen, Antino; Allen, Barrett; Rosi, Susanna; Fike, John R.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Fike, John R.] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA; [Rosi, Susanna] Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, San Francisco, CA 94143 USA; [Chakraborti, Ayanabha; Allen, Antino; Allen, Barrett; Rosi, Susanna; Fike, John R.] Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Chakraborti, A (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.	john.fike@ucsf.edu	Chakraborti, Ayanabha/N-1898-2019	Chakraborti, Ayanabha/0000-0003-2060-8200	National Institutes of Health (NIH) grant [R01 NS046051, R01 CA133216]; NATIONAL CANCER INSTITUTE [R01CA133216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K12GM081266] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046051] Funding Source: NIH RePORTER	National Institutes of Health (NIH) grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by National Institutes of Health (NIH) grant R01 NS046051 and R01 CA133216. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Auffret A, 2009, J NEUROSCI, V29, P10144, DOI 10.1523/JNEUROSCI.1856-09.2009; Babus LW, 2011, BRAIN RES, V1415, P96, DOI 10.1016/j.brainres.2011.07.059; Bloss EB, 2011, J NEUROSCI, V31, P7831, DOI 10.1523/JNEUROSCI.0839-11.2011; Bock J, 2011, NEUROSCIENCE, V193, P34, DOI 10.1016/j.neuroscience.2011.07.048; Bourne J, 2007, CURR OPIN NEUROBIOL, V17, P381, DOI 10.1016/j.conb.2007.04.009; Boyer C, 1998, J NEUROSCI, V18, P5294, DOI 10.1523/JNEUROSCI.18-14-05294.1998; BROCK JW, 1992, DEV BRAIN RES, V66, P266, DOI 10.1016/0165-3806(92)90090-J; Christoffel DJ, 2011, J NEUROSCI, V31, P314, DOI 10.1523/JNEUROSCI.4763-10.2011; DAWIRS RR, 1991, NEUROPHARMACOLOGY, V30, P275, DOI 10.1016/0028-3908(91)90155-5; Diamond DM, 2006, HIPPOCAMPUS, V16, P571, DOI 10.1002/hipo.20188; Dimberg Y, 1997, TOXICOL LETT, V90, P35, DOI 10.1016/S0378-4274(96)03827-1; Dumitriu D, 2010, J NEUROSCI, V30, P7507, DOI 10.1523/JNEUROSCI.6410-09.2010; Ferre S, 2007, BRAIN RES REV, V55, P55, DOI 10.1016/j.brainresrev.2007.01.007; Fiala JC, 2002, BRAIN RES REV, V39, P29, DOI 10.1016/S0165-0173(02)00158-3; Fischer M, 2000, NAT NEUROSCI, V3, P887, DOI 10.1038/78791; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Geinisman Y, 2001, J NEUROSCI, V21, P5568, DOI 10.1523/JNEUROSCI.21-15-05568.2001; Gonzalez-Burgos I, 2012, NEURAL PLAST, V2012, DOI 10.1155/2012/309494; Halpain S, 1998, J NEUROSCI, V18, P9835; HARRIS KM, 1989, J NEUROSCI, V9, P2982; Izquierdo I, 1997, NEUROBIOL LEARN MEM, V68, P285, DOI 10.1006/nlme.1997.3799; Khuntia D, 2006, J CLIN ONCOL, V24, P1295, DOI 10.1200/JCO.2005.04.6185; KING MA, 1988, BRAIN RES, V459, P381, DOI 10.1016/0006-8993(88)90656-7; Kitanishi T, 2009, CEREB CORTEX, V19, P2572, DOI 10.1093/cercor/bhp012; Kondo S, 2011, MOL BRAIN, V4, DOI 10.1186/1756-6606-4-27; Kramar EA, 2003, NEUROSCIENCE, V118, P387, DOI 10.1016/S0306-4522(02)00916-8; Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003; Magarinos AM, 2011, HIPPOCAMPUS, V21, P253, DOI 10.1002/hipo.20744; MARTIN C, 1993, NEUROSCI LETT, V155, P77, DOI 10.1016/0304-3940(93)90677-D; Matsuo N, 2008, SCIENCE, V319, P1104, DOI 10.1126/science.1149967; Matsuzaki M, 2001, NAT NEUROSCI, V4, P1086, DOI 10.1038/nn736; Maul B, 2008, J MOL MED, V86, P563, DOI 10.1007/s00109-008-0316-4; Mizumatsu S, 2003, CANCER RES, V63, P4021; Monje M, 2008, DEV DISABIL RES REV, V14, P238, DOI 10.1002/ddrr.26; Nakamura JL, 2011, CANCER RES, V71, P106, DOI 10.1158/0008-5472.CAN-10-2732; Norrholm SD, 2001, SYNAPSE, V42, P151, DOI 10.1002/syn.10006; Ostroff LE, 2002, NEURON, V35, P535, DOI 10.1016/S0896-6273(02)00785-7; Peebles CL, 2010, P NATL ACAD SCI USA, V107, P18173, DOI 10.1073/pnas.1006546107; PETERS A, 1970, AM J ANAT, V127, P321, DOI 10.1002/aja.1001270402; Petrak LJ, 2005, J COMP NEUROL, V484, P183, DOI 10.1002/cne.20468; Raber J, 2004, RADIAT RES, V162, P39, DOI 10.1667/RR3206; Raber J, 2011, HIPPOCAMPUS, V21, P72, DOI 10.1002/hipo.20724; Raber J, 2010, TOXICOL PATHOL, V38, P198, DOI 10.1177/0192623309352003; Rao AAN, 2011, J NEURO-ONCOL, V105, P191, DOI 10.1007/s11060-011-0582-9; Rola R, 2004, EXP NEUROL, V188, P316, DOI 10.1016/j.expneurol.2004.05.005; Rosi S, 2008, CANCER RES, V68, P9763, DOI 10.1158/0008-5472.CAN-08-1861; Sajikumar S, 2011, LEARN MEMORY, V18, P327, DOI 10.1101/lm.2095811; Santos HR, 2004, NEUROTOXICOLOGY, V25, P481, DOI 10.1016/j.neuro.2004.01.007; Schultz SR, 1999, HIPPOCAMPUS, V9, P582, DOI 10.1002/(SICI)1098-1063(1999)9:5<582::AID-HIPO12>3.0.CO;2-P; Scoccianti S, 2012, J NEUROONCOL; Segal M, 2000, CURR OPIN NEUROBIOL, V10, P582, DOI 10.1016/S0959-4388(00)00123-9; Segal M, 2010, EUR J NEUROSCI, V31, P2178, DOI 10.1111/j.1460-9568.2010.07270.x; Shi L, 2006, RADIAT RES, V166, P892, DOI 10.1667/RR0588.1; Shimizu H, 1996, NEUROSCI LETT, V203, P195, DOI 10.1016/0304-3940(95)12293-1; Soussain C, 2009, LANCET, V374, P1639, DOI 10.1016/S0140-6736(09)61299-X; Spacek J, 1997, J NEUROSCI, V17, P190, DOI 10.1523/JNEUROSCI.17-01-00190.1997; Spires-Jones TL, 2011, NEUROSCI LETT, V487, P260, DOI 10.1016/j.neulet.2010.10.033; Staffend N.A., 2011, CURR PROTOC NEUROSCI, V55; Stranahan AM, 2011, NEUROSCI LETT, V495, P60, DOI 10.1016/j.neulet.2011.03.037; SUNANDA, 1995, BRAIN RES, V694, P312, DOI 10.1016/0006-8993(95)00822-8; Taupin P, 2008, HIPPOCAMPUS NEUROTRA; Titus ADJ, 2007, NEUROSCIENCE, V145, P265, DOI 10.1016/j.neuroscience.2006.11.037; Ultanir SK, 2007, P NATL ACAD SCI USA, V104, P19553, DOI 10.1073/pnas.0704031104; von Bohlen und Halbach O, 2006, J NEUROSCI RES, V83, P525, DOI 10.1002/jnr.20759; Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009; Yasumatsu N, 2008, J NEUROSCI, V28, P13592, DOI 10.1523/JNEUROSCI.0603-08.2008; Yau SY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024263; Yazlovitskaya EM, 2006, CANCER RES, V66, P11179, DOI 10.1158/0008-5472.CAN-06-2740; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	69	85	90	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2012	7	7							e40844	10.1371/journal.pone.0040844	http://dx.doi.org/10.1371/journal.pone.0040844			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	974VS	22815839	Green Published, gold			2023-01-03	WOS:000306466100080
J	Liu, B; Chen, J; Wang, JH; Liu, X; Duan, XH; Shang, XJ; Long, Y; Chen, ZG; Li, XF; Huang, Y; He, Y				Liu, Bo; Chen, Jun; Wang, Jinhui; Liu, Xian; Duan, Xiaohui; Shang, Xiaojing; Long, Yu; Chen, Zhiguang; Li, Xiaofang; Huang, Yan; He, Yong			Altered Small-World Efficiency of Brain Functional Networks in Acupuncture at ST36: A Functional MRI Study	PLOS ONE			English	Article							RESTING-STATE CONNECTIVITY; CONCURRENT TMS-FMRI; VISUAL-CORTEX; ACUPOINT STIMULATION; ALZHEIMERS-DISEASE; CEREBRAL-CORTEX; CORTICAL HUBS; FOLLOW-UP; ELECTROACUPUNCTURE; MODULATION	Background: Acupuncture in humans can produce clinical effects via the central nervous system. However, the neural substrates of acupuncture's effects remain largely unknown. Results: We utilized functional MRI to investigate the topological efficiency of brain functional networks in eighteen healthy young adults who were scanned before and after acupuncture at the ST36 acupoints (ACUP) and its sham point (SHAM). Whole-brain functional networks were constructed by thresholding temporal correlations matrices of ninety brain regions, followed by a graph theory-based analysis. We showed that brain functional networks exhibited small-world attributes (high local and global efficiency) regardless of the order of acupuncture and stimulus points, a finding compatible with previous studies of brain functional networks. Furthermore, the brain networks had increased local efficiency after ACUP stimulation but there were no significant differences after SHAM, indicating a specificity of acupuncture point in coordinating local information flow over the whole brain. Moreover, significant (P<0.05, corrected by false discovery rate approach) effects of only acupuncture point were detected on nodal degree of the left hippocampus (higher nodal degree at ACUP as compared to SHAM). Using an uncorrected P<0.05, point-related effects were also observed in the anterior cingulate cortex, frontal and occipital regions while stimulation-related effects in various brain regions of frontal, parietal and occipital cortex regions. In addition, we found that several limbic and subcortical brain regions exhibited point-and stimulation-related alterations in their regional homogeneity (P<0.05, uncorrected). Conclusions: Our results suggest that acupuncture modulates topological organization of whole-brain functional brain networks and the modulation has point specificity. These findings provide new insights into neuronal mechanism of acupuncture from the perspective of functional integration. Further studies would be interesting to apply network analysis approaches to study the effects of acupuncture treatments on brain disorders.	[Liu, Bo; Chen, Jun; Liu, Xian; Duan, Xiaohui; Shang, Xiaojing; Long, Yu; Chen, Zhiguang; Li, Xiaofang; Huang, Yan] Guangdong Prov Hosp Tradit Chinese Med, Dept Radiol, Guangzhou, Guangdong, Peoples R China; [Wang, Jinhui; He, Yong] Beijing Normal Univ, State Key Lab Cognit Neurosci & Learning, Beijing 100875, Peoples R China	Guangzhou University of Chinese Medicine; Beijing Normal University	Liu, B (corresponding author), Guangdong Prov Hosp Tradit Chinese Med, Dept Radiol, Guangzhou, Guangdong, Peoples R China.	lbgdhtcm@163.com	Chen, Jun/AAD-7667-2020; He, Yong/Q-5756-2018; Duan, Xiaohui/R-5693-2019; He, Yong/C-2161-2009; Wang, jinhui/AAF-8668-2019	CHEN, JUN/0000-0001-5049-5759; He, Yong/0000-0002-7039-2850; chen, jun/0000-0002-1936-9954	Guangdong Science and Technology Department [2008B080703041, 2010B080701025]; Natural Science Foundation of China [81030028, 30870667]; Beijing Natural Science Foundation [7102090]; Scientific Research Foundation for the Returned Overseas Chinese Scholars (State Education Ministry)	Guangdong Science and Technology Department; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation); Scientific Research Foundation for the Returned Overseas Chinese Scholars (State Education Ministry)(Scientific Research Foundation for the Returned Overseas Chinese Scholars)	This work was partly supported by the Guangdong Science and Technology Department (No. 2008B080703041 and 2010B080701025), the Natural Science Foundation of China (Grant Nos. 81030028 and 30870667), the Beijing Natural Science Foundation (Grant No. 7102090) and the Scientific Research Foundation for the Returned Overseas Chinese Scholars (State Education Ministry, YH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Achard S, 2006, J NEUROSCI, V26, P63, DOI 10.1523/JNEUROSCI.3874-05.2006; Achard S, 2007, PLOS COMPUT BIOL, V3, P174, DOI 10.1371/journal.pcbi.0030017; Bassett DS, 2009, CURR OPIN NEUROL, V22, P340, DOI 10.1097/WCO.0b013e32832d93dd; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Beijing University of Chinese Medicine Shanghai University of T.C.M Nanjing University Of Chinese Medicine, 2005, ESS CHIN AC; Biella G, 2001, NEUROIMAGE, V14, P60, DOI 10.1006/nimg.2001.0798; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Buckner RL, 2009, J NEUROSCI, V29, P1860, DOI 10.1523/JNEUROSCI.5062-08.2009; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Campbell Anthony, 2006, Acupunct Med, V24, P118; Chen K, 1995, J Tradit Chin Med, V15, P203; Cheng TO, 2000, HEART, V83, P256, DOI 10.1136/heart.83.3.256; Cho ZH, 1998, P NATL ACAD SCI USA, V95, P2670, DOI 10.1073/pnas.95.5.2670; Chung S C, 2000, J Physiol Anthropol Appl Human Sci, V19, P93, DOI 10.2114/jpa.19.93; Cole MW, 2010, NEUROIMAGE, V49, P3132, DOI 10.1016/j.neuroimage.2009.11.001; Dhond RP, 2008, PAIN, V136, P407, DOI 10.1016/j.pain.2008.01.011; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Fang JL, 2009, HUM BRAIN MAPP, V30, P1196, DOI 10.1002/hbm.20583; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Gareus IK, 2002, J MAGN RESON IMAGING, V15, P227, DOI 10.1002/jmri.10059; Gong GL, 2009, CEREB CORTEX, V19, P524, DOI 10.1093/cercor/bhn102; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; He Y, 2008, J NEUROSCI, V28, P4756, DOI 10.1523/JNEUROSCI.0141-08.2008; He Y, 2007, CEREB CORTEX, V17, P2407, DOI 10.1093/cercor/bhl149; He Y, 2010, CURR OPIN NEUROL, V23, P341, DOI 10.1097/WCO.0b013e32833aa567; He Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005226; Hsieh CW, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/951258; Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037; Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097-0193(2000)9:1<13::AID-HBM2>3.0.CO;2-F; Kong JA, 2002, J ALTERN COMPLEM MED, V8, P411, DOI 10.1089/107555302760253603; Kong J, 2007, J ALTERN COMPLEM MED, V13, P1059, DOI 10.1089/acm.2007.0524; Latora V, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.198701; Li G, 2003, HUM BRAIN MAPP, V18, P233, DOI 10.1002/hbm.10098; Luo F, 2008, NEUROCHEM RES, V33, P1950, DOI 10.1007/s11064-008-9692-y; Makris N, 2007, CEREB CORTEX, V17, P1364, DOI 10.1093/cercor/bhl047; Maslov S, 2002, SCIENCE, V296, P910, DOI 10.1126/science.1065103; Mayer DJ, 2000, ANNU REV MED, V51, P49, DOI 10.1146/annurev.med.51.1.49; Molsberger AF, 2002, PAIN, V99, P579, DOI 10.1016/S0304-3959(02)00269-5; Napadow V, 2005, HUM BRAIN MAPP, V24, P193, DOI 10.1002/hbm.20081; Qin W, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-55; RICHARDSON PH, 1986, PAIN, V24, P15, DOI 10.1016/0304-3959(86)90023-0; Ruff CC, 2008, CEREB CORTEX, V18, P817, DOI 10.1093/cercor/bhm128; Ruff CC, 2006, CURR BIOL, V16, P1479, DOI 10.1016/j.cub.2006.06.057; Salvador R, 2005, CEREB CORTEX, V15, P1332, DOI 10.1093/cercor/bhi016; Schwartz S, 2005, CEREB CORTEX, V15, P770, DOI 10.1093/cercor/bhh178; Sporns O, 2004, TRENDS COGN SCI, V8, P418, DOI 10.1016/j.tics.2004.07.008; Sporns O, 2004, NEUROINFORMATICS, V2, P145, DOI 10.1385/NI:2:2:145; Stam Cornelis J, 2007, Nonlinear Biomed Phys, V1, P3, DOI 10.1186/1753-4631-1-3; Tomasi D, 2010, P NATL ACAD SCI USA, V107, P9885, DOI 10.1073/pnas.1001414107; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Wang JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021976; Wang JH, 2009, HUM BRAIN MAPP, V30, P1511, DOI 10.1002/hbm.20623; Wang SM, 2008, ANESTH ANALG, V106, P611, DOI 10.1213/ane.0b013e318160644d; Wang SM, 2007, ANESTH ANALG, V105, P499, DOI 10.1213/01.ane.0000270216.71234.f5; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7; Wu MT, 1999, RADIOLOGY, V212, P133, DOI 10.1148/radiology.212.1.r99jl04133; Wu MT, 2002, NEUROIMAGE, V16, P1028, DOI 10.1006/nimg.2002.1145; Yan B, 2005, NEUROSCI LETT, V383, P236, DOI 10.1016/j.neulet.2005.04.021; Yeo S, 2010, J ALTERN COMPLEM MED, V16, P481, DOI 10.1089/acm.2009.0606; Zang YF, 2004, NEUROIMAGE, V22, P394, DOI 10.1016/j.neuroimage.2003.12.030; Zhang TJ, 2011, J PSYCHIATR NEUROSCI, V36, P23, DOI 10.1503/jpn.100006; Zhang WT, 2003, BRAIN RES, V982, P168, DOI 10.1016/S0006-8993(03)02983-4; Zuo XN, 2011, CEREB CORTE IN PRESS	64	19	27	1	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2012	7	6							e39342	10.1371/journal.pone.0039342	http://dx.doi.org/10.1371/journal.pone.0039342			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	964XV	22761766	gold, Green Published, Green Submitted			2023-01-03	WOS:000305730900046
J	Assefa, Y; Worku, A; Wouters, E; Koole, O; Mariam, DH; Van Damme, W				Assefa, Yibeltal; Worku, Alemayehu; Wouters, Edwin; Koole, Olivier; Mariam, Damen Haile; Van Damme, Wim			Simplified Tools for Measuring Retention in Care in Antiretroviral Treatment Program in Ethiopia: Cohort and Current Retention in Care	PLOS ONE			English	Article							INITIATION; THERAPY	Introduction: Patient retention in care is a critical challenge for antiretroviral treatment programs. This is mainly because retention in care is related to adherence to treatment and patient survival. It is therefore imperative that health facilities and programs measure patient retention in care. However, the currently available tools, such as Kaplan Meier, for measuring retention in care have a lot of practical limitations. The objective of this study was to develop simplified tools for measuring retention in care. Methods: Retrospective cohort data were collected from patient registers in nine health facilities in Ethiopia. Retention in care was the primary outcome for the study. Tools were developed to measure "current retention'' in care during a specific period of time for a specific "ART-age group'' and "cohort retention'' in care among patients who were followed for the last "Y'' number of years on ART. "Probability of retention'' based on the tool for "cohort retention'' in care was compared with "probability of retention'' based on Kaplan Meier. Results: We found that the new tools enable to measure "current retention'' and "cohort retention'' in care. We also found that the tools were easy to use and did not require advanced statistical skills. Both "current retention'' and "cohort retention'' are lower among patients in the first two "ART-age groups'' and "ART-age cohorts'' than in subsequent "ART-age groups'' and "ART-age cohorts''. The "probability of retention'' based on the new tools were found to be similar to the "probability of retention'' based on Kaplan Meier. Conclusion: The simplified tools for "current retention'' and "cohort retention'' will enable practitioners and program managers to measure and monitor rates of retention in care easily and appropriately. We therefore recommend that health facilities and programs start to use these tools in their efforts to improve retention in care and patient outcomes.	[Assefa, Yibeltal] Fed HIV AIDS Prevent & Control Off, Addis Ababa, Ethiopia; [Worku, Alemayehu; Mariam, Damen Haile] Univ Addis Ababa, Sch Publ Hlth, Addis Ababa, Ethiopia; [Wouters, Edwin] Univ Antwerp, Dept Social Sci, B-2020 Antwerp, Belgium; [Koole, Olivier] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; [Assefa, Yibeltal; Van Damme, Wim] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium	Addis Ababa University; University of Antwerp; Institute of Tropical Medicine (ITM); Institute of Tropical Medicine (ITM)	Assefa, Y (corresponding author), Fed HIV AIDS Prevent & Control Off, Addis Ababa, Ethiopia.	yibeltalassefa343@gmail.com	Wouters, Edwin/AAE-1649-2021; Assefa, Yibeltal/ABI-8057-2020; Assefa, Yibeltal/N-5984-2016; Van Damme, Wim/F-7404-2011	Wouters, Edwin/0000-0003-2268-3829; Assefa, Yibeltal/0000-0003-2393-1492; Assefa, Yibeltal/0000-0003-2393-1492; Van Damme, Wim/0000-0002-6344-3007; Koole, Olivier/0000-0002-1122-5382	Directorate General for Development and Cooperation of Belgium through the Institute of Tropical Medicine	Directorate General for Development and Cooperation of Belgium through the Institute of Tropical Medicine	The Directorate General for Development and Cooperation of Belgium supported this study through the Institute of Tropical Medicine. The funders had no role in study design, data collection, and analysis, decision to publish, or preparations of the manuscript.	Assefa Yibeltal, 2008, Ethiop Med J, V46, P401; Assefa Y, 2010, AIDS PATIENT CARE ST, V24, P521, DOI 10.1089/apc.2009.0286; Assefa Y, 2010, CURR OPIN HIV AIDS, V5, P78, DOI 10.1097/COH.0b013e328333b87a; Assefa Y, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000056; Berg MB, 2005, AIDS CARE, V17, P902, DOI 10.1080/09540120500101658; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; Hsiej JJ, 1999, BIOMETRICAL J, V83, P143; Ministry of Health of Ethiopia, SINGL POINT HIV PREV; Pox MP, 2009, TROP MED INT HEALTH, V15, P1; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Schilder AJ, 2001, SOC SCI MED, V52, P1643, DOI 10.1016/S0277-9536(00)00274-4; Tassie JM, 2010, JAIDS-J ACQ IMM DEF, V54, P437, DOI 10.1097/QAI.0b013e3181d73e1b; *WHO, UN ACC SCAL PRIOR HI; *WHO, TREAT 3 MILL 2005 MA; WHO, COUNTR EXP IMPL PAT	15	5	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2012	7	6							e38555	10.1371/journal.pone.0038555	http://dx.doi.org/10.1371/journal.pone.0038555			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	959TU	22701663	Green Submitted, Green Published, gold, Green Accepted			2023-01-03	WOS:000305337600029
J	Chalder, M; Wiles, NJ; Campbell, J; Hollinghurst, SP; Haase, AM; Taylor, AH; Fox, KR; Costelloe, C; Searle, A; Baxter, H; Winder, R; Wright, C; Turner, KM; Calnan, M; Lawlor, DA; Peters, TJ; Sharp, DJ; Montgomery, AA; Lewis, G				Chalder, Melanie; Wiles, Nicola J.; Campbell, John; Hollinghurst, Sandra P.; Haase, Anne M.; Taylor, Adrian H.; Fox, Kenneth R.; Costelloe, Ceire; Searle, Aidan; Baxter, Helen; Winder, Rachel; Wright, Christine; Turner, Katrina M.; Calnan, Michael; Lawlor, Deborah A.; Peters, Tim J.; Sharp, Deborah J.; Montgomery, Alan A.; Lewis, Glyn			Facilitated physical activity as a treatment for depressed adults: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PSYCHIATRIC-DISORDER; CLINICAL-TRIALS; PRIMARY-CARE; EXERCISE; SCALE	Objective To investigate the effectiveness of facilitated physical activity as an adjunctive treatment for adults with depression presenting in primary care. Design Pragmatic, multicentre, two arm parallel randomised controlled trial. Setting General practices in Bristol and Exeter. Participants 361 adults aged 18-69 who had recently consulted their general practitioner with symptoms of depression. All those randomised had a diagnosis of an episode of depression as assessed by the clinical interview schedule-revised and a Beck depression inventory score of 14 or more. Interventions In addition to usual care, intervention participants were offered up to three face to face sessions and 10 telephone calls with a trained physical activity facilitator over eight months. The intervention was based on theory and aimed to provide individually tailored support and encouragement to engage in physical activity. Main outcome measures The primary outcome was self reported symptoms of depression, assessed with the Beck depression inventory at four months post-randomisation. Secondary outcomes included use of antidepressants and physical activity at the four, eight, and 12 month follow-up points, and symptoms of depression at eight and 12 month follow-up. Results There was no evidence that participants offered the physical activity intervention reported improvement in mood by the four month follow-up point compared with those in the usual care group; adjusted between group difference in mean Beck depression inventory score -0.54 (95% confidence interval -3.06 to 1.99; P=0.68). Similarly, there was no evidence that the intervention group reported a change in mood by the eight and 12 month follow-up points. Nor was there evidence that the intervention reduced antidepressant use compared with usual care (adjusted odds ratio 0.63, 95% confidence interval 0.19 to 2.06; P=0.44) over the duration of the trial. However, participants allocated to the intervention group reported more physical activity during the follow-up period than those allocated to the usual care group (adjusted odds ratio 2.27, 95% confidence interval 1.32 to 3.89; P=0.003). Conclusions The addition of a facilitated physical activity intervention to usual care did not improve depression outcome or reduce use of antidepressants compared with usual care alone.	[Chalder, Melanie; Wiles, Nicola J.; Hollinghurst, Sandra P.; Costelloe, Ceire; Searle, Aidan; Baxter, Helen; Turner, Katrina M.; Lawlor, Deborah A.; Sharp, Deborah J.; Montgomery, Alan A.; Lewis, Glyn] Univ Bristol, Sch Social & Community Med, Bristol BS8 2BN, Avon, England; [Campbell, John; Winder, Rachel; Wright, Christine] Peninsula Med Sch, Primary Care Res Grp, Exeter, Devon, England; [Haase, Anne M.; Fox, Kenneth R.] Univ Bristol, Sch Policy Studies, Bristol BS8 2BN, Avon, England; [Taylor, Adrian H.] Univ Exeter, Exeter, Devon, England; [Calnan, Michael] Univ Kent, Sch Social Policy, Canterbury, Kent, England; [Peters, Tim J.] Univ Bristol, Sch Clin Sci, Bristol BS8 2BN, Avon, England	University of Bristol; University of Exeter; University of Bristol; University of Exeter; University of Kent; University of Bristol	Chalder, M (corresponding author), Univ Bristol, Sch Social & Community Med, Bristol BS8 2BN, Avon, England.	melanie.chalder@bristol.ac.uk	Taylor, Adrian/GME-5077-2022; Lewis, Glyn/E-9944-2012; Campbell, John/A-5792-2011; Fox, Kenneth/B-5897-2014	Taylor, Adrian/0000-0003-2701-9468; Lewis, Glyn/0000-0001-5205-8245; Campbell, John/0000-0002-6752-3493; sharp, deborah/0000-0003-3071-9860; Lawlor, Debbie A/0000-0002-6793-2262; Baxter, Helen/0000-0002-3320-2915; Winder, Rachel/0000-0002-9926-1280; Montgomery, Alan/0000-0003-0450-1606; Haase, Anne M/0000-0001-8556-2165; Chalder, Melanie/0000-0003-1964-2815; Turner, Katrina/0000-0002-6375-2918; Peters, Tim/0000-0003-2881-4180; Fox, Kenneth/0000-0003-2216-4287; Wiles, Nicola/0000-0002-5250-3553	Department of Health as part of the National Institute for Health Research; Medical Research Council [G0600705, G0800800] Funding Source: researchfish; National Institute for Health Research [03/45/07] Funding Source: researchfish; MRC [G0600705, G0800800] Funding Source: UKRI	Department of Health as part of the National Institute for Health Research; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This research was carried out independently by the University of Bristol, University of Exeter and the Peninsula Medical School. It is funded by the Department of Health as part of the National Institute for Health Research Health Technology Assessment programme.	Ainsworth BE, 2000, MED SCI SPORT EXER, V32, pS498, DOI 10.1097/00005768-200009001-00009; Baxter H, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-105; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Chalder M, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16100; Deci E. L., 1985, INTRINSIC MOTIVATION; Department of Health, 2011, START ACT STAY ACT R; Dunn G, 2005, STAT METHODS MED RES, V14, P369, DOI 10.1191/0962280205sm403oa; Ekkekakis P, 2005, J SPORT SCI, V23, P477, DOI 10.1080/02640410400021492; Haase AM, 2010, MENT HEALTH PHYS ACT, V3, P85, DOI DOI 10.1016/J.MHPA.2010.09.004; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hillsdon M, 2005, Cochrane Database Syst Rev, pCD003180; Hyde J, 2005, BRIT J GEN PRACT, V55, P755; Kessler D, 2009, LANCET, V374, P628, DOI 10.1016/S0140-6736(09)61257-5; Krogh J, 2011, J CLIN PSYCHIAT, V72, P529, DOI 10.4088/JCP.08r04913blu; LEWIS G, 1994, J EPIDEMIOL COMMUN H, V48, P207, DOI 10.1136/jech.48.2.207; LEWIS G, 1992, PSYCHOL MED, V22, P465, DOI 10.1017/S0033291700030415; Lewis G, 2011, BRIT J PSYCHIAT, V198, P464, DOI 10.1192/bjp.bp.110.082727; McCrone PR., 2008, PAYING PRICE COST ME; Mead GE, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004366.pub4; Moher David, 2012, Int J Surg, V10, P28, DOI 10.1016/j.ijsu.2011.10.001; National Institute for Health and Clinical Excellence, 2009, DEPR TREATM MAN DEPR; National Institute for Health and Clinical Excellence, 2004, DEPR MAN DEPR PRIM S; Pavey TG, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6462; Resnick B, 2000, J GERONTOL B-PSYCHOL, V55, pS352, DOI 10.1093/geronb/55.6.S352; Roberts C, 2005, CLIN TRIALS, V2, P152, DOI 10.1191/1740774505cn076oa; Searle A, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X567054; StataCorp, 2010, STAT STAT SOFTW REL; Sterne Jonathan A C, 2009, BMJ, V338, pb2393, DOI 10.1136/bmj.b2393; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007	29	127	127	1	125	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 6	2012	344								e2758	10.1136/bmj.e2758	http://dx.doi.org/10.1136/bmj.e2758			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	957TC	22674921	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000305184700002
J	Singh, A; Padmadas, SS; Mishra, US; Pallikadavath, S; Johnson, FA; Matthews, Z				Singh, Abhishek; Padmadas, Sabu S.; Mishra, Udaya S.; Pallikadavath, Saseendran; Johnson, Fiifi A.; Matthews, Zoe			Socio-Economic Inequalities in the Use of Postnatal Care in India	PLOS ONE			English	Article							MATERNAL HEALTH; NEONATAL SURVIVAL; SERVICES; PRADESH; PROGRAM	Objective: First, our objective was to estimate socio-economic inequalities in the use of postnatal care (PNC) compared with those in the use of care at birth and antenatal care. Second, we wanted to compare inequalities in the use of PNC between facility births and home births and to determine inequalities in the use of PNC among mothers with high-risk births. Methods and Findings: Rich-poor ratios and concentration indices for maternity care were estimated using the third round of the District Level Household Survey conducted in India in 2007-08. Binary logistic regression models were used to examine the socio-economic inequalities associated with use of PNC after adjusting for relevant socio-economic and demographic characteristics. PNC for both mothers and newborns was substantially lower than the care received during pregnancy and child birth. Only 44% of mothers in India at the time of survey received any care within 48 hours after birth. Likewise, only 45% of newborns received check-up within 24 hours of birth. Mothers who had home births were significantly less likely to have received PNC than those who had facility births, with significant differences across the socioeconomic strata. Moreover, the rich-poor gap in PNC use was significantly wider for mothers with birth complications. Conclusions: PNC use has been unacceptably low in India given the risks of mortality for mothers and babies shortly after birth. However, there is evidence to suggest that effective use of pregnancy and childbirth care in health facilities led to better PNC. There are also significant socio-economic inequalities in access to PNC even for those accessing facility-based care. The coverage of essential PNC is inadequate, especially for mothers from economically disadvantaged households. The findings suggest the need for strengthening PNC services to keep pace with advances in coverage for care at birth and prenatal services in India through targeted policy interventions.	[Singh, Abhishek] Int Inst Populat Sci, Dept Publ Hlth & Mortal Studies, Bombay, Maharashtra, India; [Padmadas, Sabu S.; Johnson, Fiifi A.; Matthews, Zoe] Univ Southampton, Ctr Global Hlth Populat Poverty & Policy, Southampton, Hants, England; [Padmadas, Sabu S.; Johnson, Fiifi A.; Matthews, Zoe] Univ Southampton, Div Social Stat & Demog, Southampton, Hants, England; [Mishra, Udaya S.] Ctr Dev Studies, Thiruvananthapuram, India; [Pallikadavath, Saseendran] Univ Portsmouth, Sch Hlth Sci & Social Work, Global Hlth & Social Care Unit, Portsmouth, Hants, England	International Institute for Population Sciences; University of Southampton; University of Southampton; University of Portsmouth	Singh, A (corresponding author), Int Inst Populat Sci, Dept Publ Hlth & Mortal Studies, Bombay, Maharashtra, India.	abhi_iips@yahoo.co.in	Singh, Abhishek/ABC-7813-2020; Matthews, Zoe/HGD-0506-2022; Amoako Johnson, Fiifi/GWC-1466-2022	Singh, Abhishek/0000-0001-6263-4410; Pallikadavath, Saseendran/0000-0002-2598-9949; Matthews, Zoe/0000-0003-1533-6618; Padmadas, Sabu/0000-0002-6538-9374	ESRC [RES-238-25-0009]; ESRC [ES/H024700/1] Funding Source: UKRI; Economic and Social Research Council [ES/H024700/1] Funding Source: researchfish	ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))	This research was conducted as part of the UK Economic & Social Research Council (ESRC) Brazil-India Pathfinder Programme for Collaborative Analysis of Microdata Resources. The authors gratefully acknowledge the ESRC for facilitating the study and providing financial support (Grant reference: RES-238-25-0009). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2008, ANAL HLTH EQUITY USI; Anwar A., 2004, BANGLADESH INEQUALIT; Baqui AH, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2826; Bhatia JC., 1995, HLTH TRANSITION REV, V5, P127; Dhakal Sulochana, 2007, BMC Pregnancy Childbirth, V7, P19, DOI 10.1186/1471-2393-7-19; Dilip TR, 2009, INT POP C IUSSP MARR; Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292; Grover A, 2010, SPECIAL RAPPORTEUR R; Gwatkin D.R., 2007, COUNTRY REPORTS HNP; Halder Amal Krishna, 2007, World Health Popul, V9, P48; Howe LD, 2009, J EPIDEMIOL COMMUN H, V63, P871, DOI 10.1136/jech.2009.088021; IIPS and Macro International, 2007, NATL FAMILY HLTH SUR, V1; Institute for Population Sciences (IIPS), 2010, DISTR LEV HOUS SURV; Jat TR, 2011, INT J EQUITY HEALTH, V10, DOI 10.1186/1475-9276-10-59; Kakwani N, 1997, J ECONOMETRICS, V77, P87, DOI 10.1016/S0304-4076(96)01807-6; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Lim SS, 2010, LANCET, V375, P2009, DOI 10.1016/S0140-6736(10)60744-1; Martines J, 2005, LANCET, V365, P1189, DOI 10.1016/S0140-6736(05)71882-1; Mavalankar D, 2008, B WORLD HEALTH ORGAN, V86, P243, DOI 10.2471/BLT.07.048454; Mavlankar DV, 1999, IMPLEMENTING REPROD; Mistry R, 2009, SOC SCI MED, V69, P926, DOI 10.1016/j.socscimed.2009.07.008; MoHFW, 1997, REPR CHILD HLTH PROG; Montgomery MR, 2000, DEMOGRAPHY, V37, P155, DOI 10.2307/2648118; Navaneetham K, 2002, SOC SCI MED, V55, P1849, DOI 10.1016/S0277-9536(01)00313-6; Pallikadavath S, 2004, SOC SCI MED, V59, P1147, DOI 10.1016/j.socscimed.2003.11.045; Patel V, 2002, AM J PSYCHIAT, V159, P43, DOI 10.1176/appi.ajp.159.1.43; Ram F, 2006, J HLTH DEV, V2, P67; RamaRao S, 2001, HEALTH POLICY PLANN, V16, P256, DOI 10.1093/heapol/16.3.256; Rasaily R, 2008, INDIAN PEDIATR, V45, P991; RGI, 2011, SPEC B MAT MORT IND; RGI, 2010, COMP IND FERT MORT I; Ronsman C, 2006, MATERNAL MORTALITY W, P13; Rutstein S., 2004, DHS WEALTH INDEX; Sines E, 2007, CRITICAL OPPORTUNITY; Sunil TS, 2006, SOC SCI MED, V62, P1943, DOI 10.1016/j.socscimed.2005.09.004; VANDOORSLAER E, 1992, J HEALTH ECON, V11, P389, DOI 10.1016/0167-6296(92)90013-Q; Vyas S, 2006, HEALTH POLICY PLANN, V21, P459, DOI 10.1093/heapol/czl029; Wagstaff A, 2004, HEALTH ECON, V13, P297, DOI 10.1002/hec.822; World Health Organization, 2005, WORLD HLTH REPORT 20; World Health Organization, 1998, BAS NEWB RES PRACT G	40	61	61	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2012	7	5							e37037	10.1371/journal.pone.0037037	http://dx.doi.org/10.1371/journal.pone.0037037			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	959VG	22623976	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000305343500053
J	Dwivedi, V; Anandan, EM; Mony, RS; Muraleedharan, TS; Valiathan, MS; Mutsuddi, M; Lakhotia, SC				Dwivedi, Vibha; Anandan, E. M.; Mony, Rajesh S.; Muraleedharan, T. S.; Valiathan, M. S.; Mutsuddi, Mousumi; Lakhotia, Subhash C.			In Vivo Effects Of Traditional Ayurvedic Formulations in Drosophila melanogaster Model Relate with Therapeutic Applications	PLOS ONE			English	Article							HEAT-SHOCK; STARVATION RESISTANCE; HNRNP PROTEIN; RNA; MERCURY; TRANSCRIPTS; STRESS; GENE; EVOLUTIONARY; MECHANISMS	Background: Ayurveda represents the traditional medicine system of India. Since mechanistic details of therapy in terms of current biology are not available in Ayurvedic literature, modern scientific studies are necessary to understand its major concepts and procedures. It is necessary to examine effects of the whole Ayurvedic formulations rather than their "active" components as is done in most current studies. Methods: We tested two different categories of formulations, a Rasayana (Amalaki Rasayana or AR, an herbal derivative) and a Bhasma (Rasa-Sindoor or RS, an organo-metallic derivative of mercury), for effects on longevity, development, fecundity, stress-tolerance, and heterogeneous nuclear ribonucleoprotein (hnRNP) levels of Drosophila melanogaster using at least 200 larvae or flies for each assay. Results: A 0.5% (weight/volume) supplement of AR or RS affected life-history and other physiological traits in distinct ways. While the size of salivary glands, hnRNP levels in larval tissues, and thermotolerance of larvae/adult flies improved significantly following feeding either of the two formulations, the median life span and starvation resistance improved only with AR. Feeding on AR or RS supplemented food improved fecundity differently. Feeding of larvae and adults with AR increased the fecundity while the same with RS had opposite effect. On the contrary, feeding larvae on normal food and adults on AR supplement had no effect on fecundity but a comparable regime of feeding on RS-supplemented food improved fecundity. RS feeding did not cause heavy metal toxicity. Conclusions: The present study with two Ayurvedic formulations reveals formulation-specific effects on several parameters of the fly's life, which seem to generally agree with their recommended human usages in Ayurvedic practices. Thus, Drosophila, with its very rich genetic tools and well-worked-out developmental pathways promises to be a very good model for examining the cellular and molecular bases of the effects of different Ayurvedic formulations.	[Dwivedi, Vibha; Lakhotia, Subhash C.] Banaras Hindu Univ, Dept Zool, Cytogenet Lab, Varanasi 221005, Uttar Pradesh, India; [Anandan, E. M.; Mony, Rajesh S.; Muraleedharan, T. S.] Arya Vaidya Sala, Kottakkal, India; [Valiathan, M. S.] Manipal Univ, Manipal, India; [Mutsuddi, Mousumi] Banaras Hindu Univ, Dept Mol & Human Genet, Varanasi 221005, Uttar Pradesh, India	Banaras Hindu University (BHU); Manipal Academy of Higher Education (MAHE); Banaras Hindu University (BHU)	Dwivedi, V (corresponding author), Banaras Hindu Univ, Dept Zool, Cytogenet Lab, Varanasi 221005, Uttar Pradesh, India.	lakhotia@bhu.ac.in	Lakhotia, Subhash C/D-2058-2011	Lakhotia, Subhash C/0000-0003-1842-8411	Office of the Principal Scientific Advisor to the Government of India, under the coordinated "Science & Ayurveda" projects [Prn.SA/ADV/Ayurveda/6/2006]; UGC Center of Advanced Studies in Zoology Junior Research Fellowship	Office of the Principal Scientific Advisor to the Government of India, under the coordinated "Science & Ayurveda" projects; UGC Center of Advanced Studies in Zoology Junior Research Fellowship	This work was supported by a research grant from the Office of the Principal Scientific Advisor to the Government of India, under the coordinated "Science & Ayurveda" projects (Grant no. Prn.SA/ADV/Ayurveda/6/2006). VD is recipient of a UGC Center of Advanced Studies in Zoology Junior Research Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AMERO SA, 1993, MOL CELL BIOL, V13, P5323, DOI 10.1128/MCB.13.9.5323; Ashburner M, 1972, Results Probl Cell Differ, V4, P101; Bier E, 2005, NAT REV GENET, V6, P9, DOI 10.1038/nrg1503; Bilen J, 2005, ANNU REV GENET, V39, P153, DOI 10.1146/annurev.genet.39.110304.095804; Blanchette M, 2009, MOL CELL, V33, P438, DOI 10.1016/j.molcel.2009.01.022; BOFFETTA P, 1993, SCAND J WORK ENV HEA, V19, P1; Borah S, 2009, P NATL ACAD SCI USA, V106, P2577, DOI 10.1073/pnas.0812826106; Brumby AM, 2005, NAT REV CANCER, V5, P626, DOI 10.1038/nrc1671; Buszczak M, 2007, GENETICS, V175, P1505, DOI 10.1534/genetics.106.065961; Chatterjee UR, 2011, INT J BIOL MACROMOL, V49, P637, DOI 10.1016/j.ijbiomac.2011.06.024; Chippindale AK, 1996, EVOLUTION, V50, P753, DOI [10.2307/2410848, 10.1111/j.1558-5646.1996.tb03885.x]; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Feder ME, 1999, ANNU REV PHYSIOL, V61, P243, DOI 10.1146/annurev.physiol.61.1.243; Govindarajan R, 2005, J ETHNOPHARMACOL, V99, P165, DOI 10.1016/j.jep.2005.02.035; Guzzi G, 2008, TOXICOLOGY, V244, P1, DOI 10.1016/j.tox.2007.11.002; Han SP, 2010, BIOCHEM J, V430, P379, DOI 10.1042/BJ20100396; Hao XM, 2007, CELL STRESS CHAPERON, V12, P364, DOI 10.1379/CSC-308.1; HAYNES SR, 1991, NUCLEIC ACIDS RES, V19, P25; HUEY RB, 1992, FUNCT ECOL, V6, P489, DOI 10.2307/2389288; Jolly C, 2006, NUCLEIC ACIDS RES, V34, P5508, DOI 10.1093/nar/gkl711; Khan K.H., 2009, BOT RES INT, V2, P218; Krishnaveni Mani, 2010, Journal of Basic and Clinical Physiology and Pharmacology, V21, P93; Kristensen TN, 2003, J GENET, V82, P89, DOI 10.1007/BF02715811; Lakhotia S C, 2010, J Ayurveda Integr Med, V1, P171, DOI 10.4103/0975-9476.72607; Lakhotia SC, 1998, CHROMOSOMA, V107, P127, DOI 10.1007/s004120050288; Lakhotia SC, 1999, CURR SCI INDIA, V77, P553; Lakhotia SC, 2012, CHROMOSOMA, V121, P49, DOI 10.1007/s00412-011-0341-x; Lakhotia SC, 2011, J BIOSCIENCES, V36, P399, DOI 10.1007/s12038-011-9078-1; Le Bourg E, 2001, BIOGERONTOLOGY, V2, P155, DOI 10.1023/A:1011561107055; Liu J, 2008, EXP BIOL MED, V233, P810, DOI 10.3181/0712-MR-336; Mallik M, 2010, J GENET, V89, P497, DOI 10.1007/s12041-010-0072-4; Miller A., 1950, BIOL DROSOPHILA, P420; Morin X, 2001, P NATL ACAD SCI USA, V98, P15050, DOI 10.1073/pnas.261408198; Murthy KRS, 2000, ASHTANGA HRIDAYA; Norry FM, 2009, J INSECT PHYSIOL, V55, P1050, DOI 10.1016/j.jinsphys.2009.07.009; Patel NG, 1986, ART SCI; Poltanov EA, 2009, PHYTOTHER RES, V23, P1309, DOI 10.1002/ptr.2775; Prasad B. R. Guru, 2011, Munis Entomology & Zoology, V6, P785; Prasad NG, 2003, J GENET, V82, P45, DOI 10.1007/BF02715881; Prasanth KV, 2000, J CELL SCI, V113, P3485; Priyadarshini S, 2010, J Ayurveda Integr Med, V1, P114, DOI 10.4103/0975-9476.65085; Restifo LL, 2005, MENT RETARD DEV D R, V11, P286, DOI 10.1002/mrdd.20083; ROY SA, 1977, INDIAN J EXP BIOL, V15, P794; Sarkar PK, 2010, J SCI IND RES INDIA, V69, P901; SAUMWEBER H, 1980, CHROMOSOMA, V80, P253, DOI 10.1007/BF00292684; Scartezzini P, 2000, J ETHNOPHARMACOL, V71, P23, DOI 10.1016/S0378-8741(00)00213-0; Sharma P V, 1999, SUSHRUTA SAMHITA; Sharma P V, 1994, CHARAKA SAMHITA; Sharma S., 1979, RASTARANGINI; Singh R. H., 2003, HOLISTIC PRINCIPLES; Singh SK, 2009, INDIAN J TRADIT KNOW, V8, P346; Sorensen JG, 2003, ECOL LETT, V6, P1025, DOI 10.1046/j.1461-0248.2003.00528.x; Swain U, 2011, MECH AGEING DEV; Tapadia MG, 1997, CHROMOSOME RES, V5, P359, DOI 10.1023/A:1018440224177; Valiathan MS, 2006, CURR SCI INDIA, V90, P5; VALLEE BL, 1972, ANNU REV BIOCHEM, V41, P91, DOI 10.1146/annurev.bi.41.070172.000515; Wayne ML, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-57; Wolf MJ, 2006, P NATL ACAD SCI USA, V103, P1394, DOI 10.1073/pnas.0507359103; Zhimulev I. F., 2009, ENCY LIFE SCI ELS; Zhou XR, 2011, J ETHNOPHARMACOL, V135, P110, DOI 10.1016/j.jep.2011.02.032; Zu K, 1998, RNA, V4, P1585, DOI 10.1017/S135583829898102X; Zu K, 1996, MOL BIOL CELL, V7, P1059, DOI 10.1091/mbc.7.7.1059	62	43	44	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2012	7	5							e37113	10.1371/journal.pone.0037113	http://dx.doi.org/10.1371/journal.pone.0037113			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UF	22606337	gold, Green Published, Green Submitted			2023-01-03	WOS:000305339400062
J	Palumbo, A; Hajek, R; Delforge, M; Kropff, M; Petrucci, MT; Catalano, J; Gisslinger, H; Wiktor-Jedrzejczak, W; Zodelava, M; Weisel, K; Cascavilla, N; Iosava, G; Cavo, M; Kloczko, J; Blade, J; Beksac, M; Spicka, I; Plesner, T; Radke, J; Langer, C; Ben Yehuda, D; Corso, A; Herbein, L; Yu, ZN; Mei, J; Jacques, C; Dimopoulos, MA				Palumbo, Antonio; Hajek, Roman; Delforge, Michel; Kropff, Martin; Petrucci, Maria Teresa; Catalano, John; Gisslinger, Heinz; Wiktor-Jedrzejczak, Wieslaw; Zodelava, Mamia; Weisel, Katja; Cascavilla, Nicola; Iosava, Genadi; Cavo, Michele; Kloczko, Janusz; Blade, Joan; Beksac, Meral; Spicka, Ivan; Plesner, Torben; Radke, Joergen; Langer, Christian; Ben Yehuda, Dina; Corso, Alessandro; Herbein, Lindsay; Yu, Zhinuan; Mei, Jay; Jacques, Christian; Dimopoulos, Meletios A.		MM-015 Investigators	Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREDNISONE PLUS THALIDOMIDE; ELDERLY-PATIENTS; INITIAL TREATMENT; MELPHALAN; DEXAMETHASONE; CHEMOTHERAPY; MALIGNANCY	Background Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone-lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-lenalidomide (MPR) or melphalan-prednisone (MP) followed by placebo in patients 65 years of age or older with newly diagnosed multiple myeloma. Methods We randomly assigned patients who were ineligible for transplantation to receive MPR-R (nine 4-week cycles of MPR followed by lenalidomide maintenance therapy until a relapse or disease progression occurred [152 patients]) or to receive MPR (153 patients) or MP (154 patients) without maintenance therapy. The primary end point was progression-free survival. Results The median follow-up period was 30 months. The median progression-free survival was significantly longer with MPR-R (31 months) than with MPR (14 months; hazard ratio, 0.49; P<0.001) or MP (13 months; hazard ratio, 0.40; P<0.001). Response rates were superior with MPR-R and MPR (77% and 68%, respectively, vs. 50% with MP; P<0.001 and P=0.002, respectively, for the comparison with MP). The progression-free survival benefit associated with MPR-R was noted in patients 65 to 75 years of age but not in those older than 75 years of age (P=0.001 for treatment-by-age interaction). After induction therapy, a landmark analysis showed a 66% reduction in the rate of progression with MPR-R (hazard ratio for the comparison with MPR, 0.34; P<0.001) that was age-independent. During induction therapy, the most frequent adverse events were hematologic; grade 4 neutropenia was reported in 35%, 32%, and 8% of the patients in the MPR-R, MPR, and MP groups, respectively. The 3-year rate of second primary tumors was 7% with MPR-R, 7% with MPR, and 3% with MP. Conclusions MPR-R significantly prolonged progression-free survival in patients with newly diagnosed multiple myeloma who were ineligible for transplantation, with the greatest benefit observed in patients 65 to 75 years of age.	[Palumbo, Antonio] Univ Turin, I-10126 Turin, Italy; [Petrucci, Maria Teresa] Sapienza Univ Rome, Dept Hematol, Rome, Italy; [Cascavilla, Nicola] Hosp Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy; [Cavo, Michele] Univ Bologna, Sch Med, Bologna, Italy; [Corso, Alessandro] Fdn IRCCS Policlin San Matteo, Pavia, Italy; [Hajek, Roman] Masaryk Univ Brno, Univ Hosp Brno, Fac Med, Brno, Czech Republic; [Spicka, Ivan] Charles Univ Prague, Prague, Czech Republic; [Delforge, Michel] Belgian Hematol Soc, Louvain, Belgium; [Kropff, Martin] Univ Munster, Munster, Germany; [Weisel, Katja] Univ Tubingen, Tubingen, Germany; [Radke, Joergen] Univ Hosp Carl Gustav Carus, Dresden, Germany; [Langer, Christian] Univ Ulm, Ulm, Germany; [Catalano, John] Frankston Hosp, Frankston, Australia; [Catalano, John] Monash Univ, Dept Clin Haematol, Melbourne, Vic 3004, Australia; [Gisslinger, Heinz] Med Univ Vienna, Dept Hematol, Vienna, Austria; [Wiktor-Jedrzejczak, Wieslaw] Med Univ Warsaw, Warsaw, Poland; [Kloczko, Janusz] Med Univ Bialystok, Bialystok, Poland; [Zodelava, Mamia] Clin Hematol & Chemotherapy Hema, Tbilisi, Georgia; [Iosava, Genadi] Inst Hematol & Transfusiol, Tbilisi, Georgia; [Blade, Joan] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain; [Beksac, Meral] Ankara Univ, Dept Hematol, TR-06100 Ankara, Turkey; [Plesner, Torben] Vejle Hosp, Dept Hematol, Vejle, Denmark; [Ben Yehuda, Dina] Hadassah Med Ctr, IL-91120 Jerusalem, Israel; [Herbein, Lindsay; Yu, Zhinuan; Mei, Jay; Jacques, Christian] Celgene, Summit, NJ USA; [Dimopoulos, Meletios A.] Univ Athens, Alexandra Hosp, Sch Med, GR-10679 Athens, Greece	University of Turin; Sapienza University Rome; IRCCS Casa Sollievo Della Sofferenza; University of Bologna; IRCCS Fondazione San Matteo; Masaryk University Brno; University Hospital Brno; Charles University Prague; University of Munster; Eberhard Karls University of Tubingen; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Ulm University; Frankston Hospital; Monash University; Medical University of Vienna; Medical University of Warsaw; Medical University of Bialystok; University of Barcelona; Hospital Clinic de Barcelona; Ankara University; University of Southern Denmark; Lillebaelt Hospital; Hebrew University of Jerusalem; Hadassah University Medical Center; Bristol-Myers Squibb; Celgene Corporation; Alexandra Hospital; Athens Medical School; National & Kapodistrian University of Athens	Palumbo, A (corresponding author), Univ Turin, Myeloma Unit, Div Hematol, Azienda Osped Univ, Via Genova 3, I-10126 Turin, Italy.	appalumbo@yahoo.com	Hajek, Roman/I-6639-2017; CAVO, MICHELE/AAK-8274-2020; Greil, Richard F/C-7673-2017; Dimopoulos, Meletios Athanasios/AAD-4130-2019; ALEGRE, ADRIAN/AAE-4268-2021; Beksac, Meral/D-6411-2013; Schey, Steve A/F-9317-2013	Hajek, Roman/0000-0001-6955-6267; CAVO, MICHELE/0000-0003-4514-3227; Greil, Richard F/0000-0002-4462-3694; ALEGRE, ADRIAN/0000-0002-2423-822X; Beksac, Meral/0000-0003-1797-8657; Schey, Steve A/0000-0002-2474-9484; Cascavilla, Nicola/0000-0002-8901-2379; Dimopoulos, Meletios/0000-0001-8990-3254; Spicka, Ivan/0000-0002-5451-5283; Stenner, Frank/0000-0003-4541-8817	Celgene [MM-015]; Janssen-Cilag; Merck; Amgen; Mundipharma; AOP Orphan; Novartis; Pfizer; Bayer; Genopharm; Genzyme; Bristol-Myers Squibb; Onyx; GenMark	Celgene(Bristol-Myers SquibbCelgene Corporation); Janssen-Cilag(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Merck(Merck & Company); Amgen(Amgen); Mundipharma; AOP Orphan; Novartis(Novartis); Pfizer(Pfizer); Bayer(Bayer AG); Genopharm; Genzyme(Sanofi-AventisGenzyme Corporation); Bristol-Myers Squibb(Bristol-Myers Squibb); Onyx; GenMark	Funded by Celgene; MM-015 ClinicalTrials.gov number, NCT00405756.; Supported by Celgene, including funding for editorial support in the preparation of the manuscript. Dr. Palumbo reports being a board member of and receiving consulting fees and payment for the development of educational presentations from Celgene and Janssen-Cilag and receiving lecture fees, including service on speakers bureaus, from Celgene, Janssen-Cilag, Merck, and Amgen; Dr. Hajek, receiving payment for the development of educational presentations from Merck, Celgene, and Janssen-Cilag; Dr. Delforge, receiving consulting fees, grant support, and lecture fees, including service on speakers bureaus, from Celgene and Janssen-Cilag; Dr. Petrucci, receiving consulting fees from Merck; Dr. Catalano, being a board member of and receiving lecture fees, including service on the speakers bureau, and funding for meeting attendance from Celgene; Dr. Gisslinger, being a board member of and receiving lecture fees, including service on speakers bureaus, from Celgene, Janssen-Cilag, Mundipharma, and AOP Orphan and receiving payment from AOP Orphan for expert testimony regarding interferon treatment in myeloproliferative neoplasms and grant support from Celgene; Dr. Wiktor-Jedrzejczak, receiving consulting fees from Janssen-Cilag, Amgen, Novartis, Pfizer, and Bayer, being an advisory board member of Bristol-Myers Squibb, receiving payment from Genopharm for a review article regarding melphalan in hematopoietic-cell transplantation in multiple myeloma, and receiving lecture fees, including service on speakers bureaus, from Celgene, Genzyme, Novartis, and Bristol-Myers Squibb; Dr. Weisel, receiving grant support from Celgene and being an advisory board member of and receiving lecture fees, including service on speakers bureaus, consulting fees, and funding for meeting attendance from Celgene and Janssen-Cilag; Dr. Cascavilla, receiving funding for meeting attendance from Celgene; Dr. Cavo, being a board member of and receiving lecture fees, including service on speakers bureaus, from Janssen-Cilag and Celgene; Dr. Kloczko, receiving funding for meeting attendance from Celgene; Dr. Blade, receiving consulting fees from Merck, Celgene, and Onyx, grant support from Janssen-Cilag, lecture fees, including service on speakers bureaus, from Janssen-Cilag, Celgene, Novartis, and Merck, and payment for the development of educational presentations from Janssen-Cilag, Celgene, and Novartis; Dr. Beksac, receiving lecture fees, including service on speakers bureaus, from Celgene, Janssen-Cilag, and Amgen and funding for meeting attendance from Novartis; Dr. Spicka, receiving payment for the development of educational presentations from Celgene and Janssen-Cilag, and receiving honoraria from Celgene and Janssen-Cilag; Dr. Plesner, receiving consulting fees from GenMark and being an advisory board member of and receiving lecture fees, including service on the speakers bureau, from Janssen-Cilag; Dr. Langer, receiving consulting fees from Celgene; Ms. Herbein, Dr. Yu, Dr. Mei, and Dr. Jacques, being employees of Celgene; and Dr. Dimopoulos, receiving consulting fees from Celgene, Merck, and Novartis and grant support from Celgene and Merck. No other potential conflict of interest relevant to this article was reported.	Attal M, 2011, HAEMATOLOGICA, V96, pS23; BERGSAGEL DE, 1979, NEW ENGL J MED, V301, P743, DOI 10.1056/NEJM197910043011402; Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x; Dimopoulos M, 2009, NEW ENGL J MED, V361, P544; Dimopoulos MA, 2009, LEUKEMIA, V23, P2147, DOI 10.1038/leu.2009.147; Dimopoulos M, 2007, NEW ENGL J MED, V357, P2123, DOI 10.1056/NEJMoa070594; Dimopoulos MA, 2012, BLOOD, V119, P2764, DOI 10.1182/blood-2011-08-373514; Dong C, 2001, BRIT J CANCER, V85, P997, DOI 10.1054/bjoc.2001.1998; Durie BGM, 2007, LEUKEMIA, V21, P1134, DOI 10.1038/sj.leu.2404582; Durie BGM, 2006, LEUKEMIA, V20, P2220, DOI 10.1038/sj.leu.2404428; Durie BGM, 2006, LEUKEMIA, V20, P1467, DOI 10.1038/sj.leu.2404284; Facon T, 2007, LANCET, V370, P1209, DOI 10.1016/S0140-6736(07)61537-2; Fayers PM, 2011, BLOOD, V118, P1239, DOI 10.1182/blood-2011-03-341669; Hulin C, 2009, J CLIN ONCOL, V27, P3664, DOI 10.1200/JCO.2008.21.0948; Mateos MV, 2010, LANCET ONCOL, V11, P934, DOI 10.1016/S1470-2045(10)70187-X; McCarthy P, 2011, HAEMATOLOGICA, V96, pS23; National Cancer Institute National Institutes of Health, COMM TERM CRIT ADV E; Palumbo A, 2006, LANCET, V367, P825, DOI 10.1016/S0140-6736(06)68338-4; Palumbo A, 2007, J CLIN ONCOL, V25, P4459, DOI 10.1200/JCO.2007.12.3463; Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442; Palumbo A, 2010, J CLIN ONCOL, V28, P5101, DOI 10.1200/JCO.2010.29.8216; Rajkumar SV, 2010, LANCET ONCOL, V11, P29, DOI 10.1016/S1470-2045(09)70284-0; San Miguel JF, 2008, NEW ENGL J MED, V359, P906, DOI 10.1056/NEJMoa0801479; Sevilla J, 2002, ANN HEMATOL, V81, P11, DOI 10.1007/s00277-001-0400-0; Waage A, 2010, BLOOD, V116, P1405, DOI 10.1182/blood-2009-08-237974; Weber DM, 2007, NEW ENGL J MED, V357, P2133, DOI 10.1056/NEJMoa070596; Zonder JA, 2010, BLOOD, V116, P5838, DOI 10.1182/blood-2010-08-303487	27	567	585	2	55	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 10	2012	366	19					1759	1769		10.1056/NEJMoa1112704	http://dx.doi.org/10.1056/NEJMoa1112704			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	939NB	22571200	Green Published			2023-01-03	WOS:000303817000005
J	Zhang, SF; Wei, JN; Kang, L				Zhang, Sufang; Wei, Jianing; Kang, Le			Transcriptional Analysis of Arabidopsis thaliana Response to Lima Bean Volatiles	PLOS ONE			English	Article							PLANT DEFENSE; TALKING TREES; COMMUNICATION; ETHYLENE; JASMONATE; EXPRESSION; GROWTH; GENES; RESISTANCE; CHEMISTRY	Background: Exposure of plants to herbivore-induced plant volatiles (HIPVs) alters their resistance to herbivores. However, the whole-genome transcriptional responses of treated plants remain unknown, and the signal pathways that produce HIPVs are also unclear. Methodology/Principal Findings: Time course patterns of the gene expression of Arabidopsis thaliana exposed to Lima bean volatiles were examined using Affymetrix ATH1 genome arrays. Results showed that A. thaliana received and responded to leafminer-induced volatiles from Lima beans through up-regulation of genes related to the ethylene (ET) and jasmonic acid pathways. Time course analysis revealed strong and partly qualitative differences in the responses between exposure at 24 and that at 48 h. Further experiments using either A. thaliana ET mutant ein2-1 or A. thaliana jasmonic acid mutant coi1-2 indicated that both pathways are involved in the volatile response process but that the ET pathway is indispensable for detecting volatiles. Moreover, transcriptional comparisons showed that plant responses to larval feeding do not merely magnify the volatile response process. Finally, (Z)-3-hexen-ol, ocimene, (3E)-4,8-dimethyl-1,3,7-nonatriene, and (3E, 7E)-4,8,12-trimethyl-1,3,7,11-tridecatetraene triggered responses in A. thaliana similar to those induced by the entire suite of Lima bean volatiles after 24 and 48 h. Conclusions/Significance: This study shows that the transcriptional responses of plants to HIPVs become stronger as treatment time increases and that ET signals are critical during this process.	[Zhang, Sufang; Wei, Jianing; Kang, Le] Chinese Acad Sci, Inst Zool, State Key Lab Integrated Management Pest Insects, Beijing, Peoples R China; [Zhang, Sufang] Chinese Acad Forestry, Key Lab Forest Protect, Res Inst Forest Ecol Environm & Protect, State Forestry Adm, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of Zoology, CAS; Chinese Academy of Forestry; Research Institute of Forest Ecology, Environment and Protection, CAF	Zhang, SF (corresponding author), Chinese Acad Sci, Inst Zool, State Key Lab Integrated Management Pest Insects, Beijing, Peoples R China.	lkang@ioz.ac.cn	Kang, Le/ABD-1116-2022; Wei, Jianing/L-7575-2019	Kang, Le/0000-0003-4262-2329; Wei, Jianing/0000-0002-8517-2164	National Basic Research Program of China (973 Program) [2012CB114105]; National Nature Science Foundation of China [30921063]; Chinese Academy of Sciences [KSCX2-EW-N-5, KSCX2-YW-N-045]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Academy of Sciences(Chinese Academy of Sciences)	The research was supported by the the National Basic Research Program of China (973 Program) (No. 2012CB114105), and National Nature Science Foundation of China (30921063), the Chinese Academy of Sciences (Project No. KSCX2-EW-N-5 and KSCX2-YW-N-045). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arimura G, 2000, BIOCHEM BIOPH RES CO, V277, P305, DOI 10.1006/bbrc.2000.3672; Arimura G, 2000, NATURE, V406, P512, DOI 10.1038/35020072; BALDWIN IT, 1983, SCIENCE, V221, P277, DOI 10.1126/science.221.4607.277; Baldwin IT, 2006, SCIENCE, V311, P812, DOI 10.1126/science.1118446; Bate NJ, 1998, PLANT J, V16, P561, DOI 10.1046/j.1365-313x.1998.00324.x; Blande JD, 2010, ECOL LETT, V13, P1172, DOI 10.1111/j.1461-0248.2010.01510.x; BRUIN J, 1992, EXPERIENTIA, V48, P525, DOI 10.1007/BF01928181; De Vos M, 2005, MOL PLANT MICROBE IN, V18, P923, DOI 10.1094/MPMI-18-0923; Dicke M, 2001, BIOCHEM SYST ECOL, V29, P979, DOI 10.1016/S0305-1978(01)00044-8; Donaldson JR, 2006, NEW PHYTOL, V169, P561, DOI 10.1111/j.1469-8137.2005.01613.x; Dong HP, 2004, PLANT PHYSIOL, V136, P3628, DOI 10.1104/pp.104.048900; Dotterl S, 2006, J CHROMATOGR A, V1113, P231, DOI 10.1016/j.chroma.2006.02.011; Dudareva N, 1996, PLANT CELL, V8, P1137, DOI 10.1105/tpc.8.7.1137; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ellis C, 2001, PLANT CELL, V13, P1025, DOI 10.1105/tpc.13.5.1025; Engelberth J, 2004, P NATL ACAD SCI USA, V101, P1781, DOI 10.1073/pnas.0308037100; FARMER EE, 1990, P NATL ACAD SCI USA, V87, P7713, DOI 10.1073/pnas.87.19.7713; Fine PVA, 2006, ECOLOGY, V87, pS150, DOI 10.1890/0012-9658(2006)87[150:TGTAHS]2.0.CO;2; FOWLER SV, 1985, AM NAT, V126, P181, DOI 10.1086/284408; Frost CJ, 2008, NEW PHYTOL, V180, P722, DOI 10.1111/j.1469-8137.2008.02599.x; Frost CJ, 2008, PLANT PHYSIOL, V146, P818, DOI 10.1104/pp.107.113027; Glazebrook J, 2001, CURR OPIN PLANT BIOL, V4, P301, DOI 10.1016/S1369-5266(00)00177-1; Glinwood R, 2004, ECOL ENTOMOL, V29, P188, DOI 10.1111/j.0307-6946.2004.00582.x; Godard KA, 2008, PHYTOCHEMISTRY, V69, P1838, DOI 10.1016/j.phytochem.2008.02.011; Heil M, 2007, P NATL ACAD SCI USA, V104, P5467, DOI 10.1073/pnas.0610266104; Heil M, 2006, ECOL LETT, V9, P813, DOI 10.1111/j.1461-0248.2006.00932.x; Heil M, 2010, TRENDS ECOL EVOL, V25, P137, DOI 10.1016/j.tree.2009.09.010; Himanen SJ, 2010, NEW PHYTOL, V186, P722, DOI 10.1111/j.1469-8137.2010.03220.x; Holopainen JK, 2004, TRENDS PLANT SCI, V9, P529, DOI 10.1016/j.tplants.2004.09.006; Kang L, 2009, ANNU REV ENTOMOL, V54, P127, DOI 10.1146/annurev.ento.54.110807.090507; Karban R, 2000, OECOLOGIA, V125, P66, DOI 10.1007/PL00008892; Kessler A, 2001, SCIENCE, V291, P2141, DOI 10.1126/science.291.5511.2141; Kessler A, 2006, OECOLOGIA, V148, P280, DOI 10.1007/s00442-006-0365-8; Kost C, 2006, J ECOL, V94, P619, DOI 10.1111/j.1365-2745.2006.01120.x; Lorenzo O, 2003, PLANT CELL, V15, P165, DOI 10.1105/tpc.007468; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Paschold A, 2006, PLANT J, V45, P275, DOI 10.1111/j.1365-313X.2005.02623.x; RHOADES DF, 1983, ACS SYM SER, V208, P55; ROMAN G, 1995, GENETICS, V139, P1393; Ruther J, 2005, J CHEM ECOL, V31, P2217, DOI 10.1007/s10886-005-6413-8; Shulaev V, 1997, NATURE, V385, P718, DOI 10.1038/385718a0; Ton J, 2007, PLANT J, V49, P16, DOI 10.1111/j.1365-313X.2006.02935.x; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van Hulten M, 2006, P NATL ACAD SCI USA, V103, P5602, DOI 10.1073/pnas.0510213103; Walker L, 1998, CURR OPIN PLANT BIOL, V1, P434, DOI 10.1016/S1369-5266(98)80269-0; Xu LH, 2002, PLANT CELL, V14, P1919, DOI 10.1105/tpc.003368; Zhang SF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011064	47	11	15	1	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2012	7	4							e35867	10.1371/journal.pone.0035867	http://dx.doi.org/10.1371/journal.pone.0035867			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959VP	22558246	Green Submitted, Green Published, gold			2023-01-03	WOS:000305345200089
J	Li, J; Gong, CY; Feng, XD; Zhou, XK; Xu, XP; Xie, L; Wang, RN; Zhang, DF; Wang, H; Deng, P; Zhou, M; Ji, N; Zhou, Y; Wang, Y; Wang, ZY; Liao, G; Geng, N; Chu, LY; Qian, ZY; Wang, Z; Chen, QM				Li, Jing; Gong, Changyang; Feng, Xiaodong; Zhou, Xikun; Xu, Xiaoping; Xie, Liang; Wang, Ruinan; Zhang, Dunfang; Wang, Hui; Deng, Peng; Zhou, Min; Ji, Ning; Zhou, Yu; Wang, Yun; Wang, Zhiyong; Liao, Ga; Geng, Ning; Chu, Liangyin; Qian, Zhiyong; Wang, Zhi; Chen, Qianming			Biodegradable Thermosensitive Hydrogel for SAHA and DDP Delivery: Therapeutic Effects on Oral Squamous Cell Carcinoma Xenografts	PLOS ONE			English	Article							SUBEROYLANILIDE HYDROXAMIC ACID; HISTONE DEACETYLASE INHIBITOR; PCL-PEG HYDROGEL; PHASE-II TRIAL; IN-VITRO; CISPLATIN; SYSTEM; ANGIOGENESIS; MECHANISMS; EXPRESSION	Background: OSCC is one of the most common malignancies and numerous clinical agents currently applied in combinative chemotherapy. Here we reported a novel therapeutic strategy, SAHA and DDP-loaded PECE (SAHA-DDP/PECE), can improve the therapeutic effects of intratumorally chemotherapy on OSCC cell xenografts. Objective/Purpose: The objective of this study was to evaluate the therapeutic efficacy of the SAHA-DDP/PECE in situ controlled drug delivery system on OSCC cell xenografts. Methods: A biodegradable and thermosensitive hydrogel was successfully developed to load SAHA and DDP. Tumor-beared mice were intratumorally administered with SAHA-DDP/PECE at 50 mg/kg (SAHA) +2 mg/kg (DDP) in 100 ul PECE hydrogel every two weeks, SAHA-DDP at 50 mg/kg(SAHA) +2 mg/kg(DDP) in NS, 2 mg/kg DDP solution, 50 mg/kg SAHA solution, equal volume of PECE hydrogel, or equal volume of NS on the same schedule, respectively. The antineoplastic actions of SAHA and DDP alone and in combination were evaluated using the determination of tumor volume, immunohistochemistry, western blot, and TUNEL analysis. Results: The hydrogel system was a free-flowing sol at 10 degrees C, become gel at body temperature, and could sustain more than 14 days in situ. SAHA-DDP/PECE was subsequently injected into tumor OSCC tumor-beared mice. The results demonstrated that such a strategy as this allows the carrier system to show a sustained release of SAHA and DDP in vivo, and could improved therapeutic effects compared with a simple additive therapeutic effect of SAHA and DDP on mouse model. Conclusions: Our research indicated that the novel SAHA-DDP/PECE system based on biodegradable PECE copolymer enhanced the therapeutic effects and could diminished the side effects of SAHA/DDP. The present work might be of great importance to the further exploration of the potential application of SAHA/DDP-hydrogel controlled drug release system in the treatment of OSCC.	[Li, Jing; Feng, Xiaodong; Xu, Xiaoping; Xie, Liang; Wang, Ruinan; Zhang, Dunfang; Wang, Hui; Deng, Peng; Zhou, Min; Ji, Ning; Zhou, Yu; Wang, Yun; Wang, Zhiyong; Liao, Ga; Geng, Ning; Chu, Liangyin; Wang, Zhi; Chen, Qianming] Sichuan Univ, W China Coll Stomatol, State Key Lab Oral Dis, Chengdu 610064, Peoples R China; [Gong, Changyang; Zhou, Xikun; Qian, Zhiyong] Sichuan Univ, W China Med Sch, W China Hosp, State Key Lab Biotherapy, Chengdu 610064, Peoples R China; [Gong, Changyang; Zhou, Xikun; Qian, Zhiyong] Sichuan Univ, W China Med Sch, W China Hosp, Ctr Canc, Chengdu 610064, Peoples R China	Sichuan University; Sichuan University; Sichuan University	Li, J (corresponding author), Sichuan Univ, W China Coll Stomatol, State Key Lab Oral Dis, Chengdu 610064, Peoples R China.	anderson-qian@163.com; wangzhi0506@vip.163.com; qmchen@scu.edu.cn	Zhou, Xikun/T-8272-2019	Zhang, Dunfang/0000-0001-7545-9930	National Science Foundation for Distinguished Young Scholars of China [30725041]; State Key Program of National Natural Science of China [30930100]; National Natural Science Foundation of China [30901676, 81072218, 30801294]; Science Funds for Talented Professionals of Sichuan Province in China [09ZQ026-037]; Fok Ying-Tong Education Foundation, China [122030]	National Science Foundation for Distinguished Young Scholars of China(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); State Key Program of National Natural Science of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science Funds for Talented Professionals of Sichuan Province in China; Fok Ying-Tong Education Foundation, China(Fok Ying Tung Education Foundation)	This work was supported by grants from the National Science Foundation for Distinguished Young Scholars of China (No. 30725041), State Key Program of National Natural Science of China (No. 30930100), the National Natural Science Foundation of China (No. 30901676, 81072218, 30801294), the Science Funds for Talented Professionals of Sichuan Province in China (No. 09ZQ026-037), the Fok Ying-Tong Education Foundation, China (No. 122030). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bagan J, 2010, ORAL ONCOL, V46, P414, DOI 10.1016/j.oraloncology.2010.03.009; Blumenschein GR, 2008, INVEST NEW DRUG, V26, P81, DOI 10.1007/s10637-007-9075-2; Brandwein-Gensler A, 2005, AM J SURG PATHOL, V29, P167; Crump M, 2007, EJC SUPPL, V5, P346, DOI 10.1016/S1359-6349(07)71294-6; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Debaere D, 2011, B-ENT, V7, P1; Dong GE, 2010, AM J PHYSIOL-RENAL, V298, pF293, DOI 10.1152/ajprenal.00410.2009; El-Awady EE, 2011, EUR J PHARMACOL, V650, P335, DOI 10.1016/j.ejphar.2010.09.085; Fang F, 2009, ACS NANO, V3, P4080, DOI 10.1021/nn900785b; Gong CY, 2009, J PHARM SCI-US, V98, P3707, DOI 10.1002/jps.21694; Gong CY, 2009, J BIOMED MATER RES B, V91B, P26, DOI 10.1002/jbm.b.31370; Gong CY, 2009, BMC BIOTECHNOL, V9, DOI 10.1186/1472-6750-9-8; Gong CY, 2009, GROWTH FACTORS, V27, P377, DOI 10.3109/08977190903159938; Gong CY, 2007, SMART MATER STRUCT, V16, P927, DOI 10.1088/0964-1726/16/3/043; Gong CY, 2011, J NANOPART RES, V13, P721, DOI 10.1007/s11051-010-0071-7; Gong CY, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/21/215103; Gong CY, 2009, J PHYS CHEM B, V113, P10183, DOI 10.1021/jp902697d; Gong CY, 2009, INT J PHARMACEUT, V365, P89, DOI 10.1016/j.ijpharm.2008.08.027; Gou ML, 2010, J BIOMED MATER RES A, V93A, P219, DOI 10.1002/jbm.a.32546; Gregorc V, 2011, CLIN CANCER RES, V17, P1964, DOI 10.1158/1078-0432.CCR-10-1376; Iamaroon A, 2003, J ORAL PATHOL MED, V32, P195, DOI 10.1034/j.1600-0714.2003.00128.x; Jin KL, 2010, J GYNECOL ONCOL, V21, P262, DOI 10.3802/jgo.2010.21.4.262; Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167; Kelly WK, 2003, CLIN CANCER RES, V9, P3578; Koberle B, 2010, BBA-REV CANCER, V1806, P172, DOI 10.1016/j.bbcan.2010.07.004; Maisch B, 2010, EUR HEART J, V31, P337; Marks PA, 2007, ONCOGENE, V26, P1351, DOI 10.1038/sj.onc.1210204; McCaul JA, 2008, ORAL ONCOL, V44, P261, DOI 10.1016/j.oraloncology.2007.02.010; Plummer R, 2011, BRIT J CANCER, V104, P593, DOI 10.1038/bjc.2011.6; Prestwich RJ, 2011, CLIN ONCOL-UK, V23, pS23, DOI 10.1016/j.clon.2011.01.376; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Rikiishi H, 2007, INT J ONCOL, V30, P1181; Sato T, 2006, INT J ONCOL, V28, P1233; Shen J, 2007, BIOCHEM PHARMACOL, V73, P1901, DOI 10.1016/j.bcp.2007.03.009; Shieh YS, 2004, J ORAL PATHOL MED, V33, P601, DOI 10.1111/j.1600-0714.2004.00252.x; Shivamallappa SM, 2011, INT J ORAL SCI, V3, P216, DOI 10.4248/IJOS11077; Suzuki M, 2009, CANCER CHEMOTH PHARM, V64, P1115, DOI 10.1007/s00280-009-0969-x; Wang YS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-402; Xu LP, 2011, MOL CANCER THER, V10, P550, DOI 10.1158/1535-7163.MCT-10-0571; Yin D, 2007, CLIN CANCER RES, V13, P1045, DOI 10.1158/1078-0432.CCR-06-1261	40	63	65	4	75	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2012	7	4							e33860	10.1371/journal.pone.0033860	http://dx.doi.org/10.1371/journal.pone.0033860			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959XD	22529899	Green Published, Green Submitted, gold			2023-01-03	WOS:000305350600006
J	Zhu, JY; Sharma, DB; Gray, SW; Chen, AB; Weeks, JC; Schrag, D				Zhu, Junya; Sharma, Dhruv B.; Gray, Stacy W.; Chen, Aileen B.; Weeks, Jane C.; Schrag, Deborah			Carboplatin and Paclitaxel With vs Without Bevacizumab in Older Patients With Advanced Non-Small Cell Lung Cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEER-MEDICARE DATA; PROPENSITY SCORE; TARGETED THERAPIES; COMORBIDITY INDEX; SUPPORTIVE CARE; CHEMOTHERAPY; CLAIMS; BIAS; EPIDEMIOLOGY; METAANALYSIS	Context A previous randomized trial demonstrated that adding bevacizumab to carboplatin and paclitaxel improved survival in advanced non-small cell lung cancer (NSCLC). However, longer survival was not observed in the subgroup of patients aged 65 years or older. Objective To examine whether adding bevacizumab to carboplatin and paclitaxel chemotherapy is associated with improved survival in older patients with NSCLC. Design, Setting, and Participants Retrospective cohort study of 4168 Medicare beneficiaries aged 65 years or older with stage IIIB or stage IV non-squamous cell NSCLC diagnosed in 2002-2007 in a Surveillance, Epidemiology, and End Results (SEER) region. Patients were categorized into 3 cohorts based on diagnosis year and type of initial chemotherapy administered within 4 months of diagnosis: (1) diagnosis in 2006-2007 and bevacizumab-carboplatin-paclitaxel therapy; (2) diagnosis in 2006-2007 and carboplatin-paclitaxel therapy; or (3) diagnosis in 2002-2005 and carboplatin-paclitaxel therapy. The associations between carboplatin-paclitaxel with vs without bevacizumab and overall survival were compared using Cox proportional hazards models and propensity score analyses including information about patient characteristics recorded in SEER-Medicare. Main Outcome Measure Overall survival measured from the first date of chemotherapy treatment until death or the censoring date of December 31, 2009. Results The median survival estimates were 9.7 (interquartile range [IQR], 4.4-18.6) months for bevacizumab-carboplatin-paclitaxel, 8.9 (IQR, 3.5-19.3) months for carboplatin-paclitaxel in 2006-2007, and 8.0 (IQR, 3.7-17.2) months for carboplatin-paclitaxel in 2002-2005. One-year survival probabilities were 39.6% (95% CI, 34.6%-45.4%) for bevacizumab-carboplatin-paclitaxel vs 40.1% (95% CI, 37.4%-43.0%) for carboplatin-paclitaxel in 2006-2007 and 35.6% (95% CI, 33.8%-37.5%) for carboplatin-paclitaxel in 2002-2005. Neither multivariable nor propensity score-adjusted Cox models demonstrated a survival advantage for bevacizumab-carboplatin-paclitaxel compared with carboplatin-paclitaxel cohorts. In propensity score-stratified models, the hazard ratio for overall survival for bevacizumab-carboplatin-paclitaxel compared with carboplatin-paclitaxel in 2006-2007 was 1.01 (95% CI, 0.89-1.16; P=.85) and compared with carboplatin-paclitaxel in 2002-2005 was 0.93 (95% CI, 0.83-1.06; P=.28). The propensity score-weighted model and propensity score-matching model similarly failed to demonstrate a statistically significant superiority for bevacizumab-carboplatin-paclitaxel. Subgroup and sensitivity analyses for key variables did not change these findings. Conclusion Adding bevacizumab to carboplatin and paclitaxel chemotherapy was not associated with better survival among Medicare patients with advanced NSCLC. JAMA. 2012; 307(15):1593-1601	[Chen, Aileen B.; Weeks, Jane C.; Schrag, Deborah] Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02215 USA; [Zhu, Junya] Dana Farber Canc Inst, Ctr Patient Safety, Boston, MA 02215 USA; [Sharma, Dhruv B.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA; [Gray, Stacy W.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Chen, Aileen B.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute	Schrag, D (corresponding author), Dana Farber Canc Inst, Ctr Outcomes & Policy Res, 450 Brookline Ave, Boston, MA 02215 USA.	deb_schrag@dfci.harvard.edu	Gray, Stacy/AAJ-2956-2020; Gray, Stacy/GRF-6833-2022	Gray, Stacy/0000-0001-6948-0143; Chen, Aileen/0000-0002-5385-3360	National Cancer Institute (NCI) [RC2CA148185-01, PO1-CA134294]; Agency for Healthcare Research and Quality (AHRQ) [HHSA290201000006I]; NCI's SEER [N01-PC-35136, N01-PC-35139, N02-PC-15105]; Centers for Disease Control and Prevention [U55/CCR921930-02]; Center for Patient Safety, Dana-Farber Cancer Institute; Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Center for Outcomes and Evidence, AHRQ; NATIONAL CANCER INSTITUTE [K05CA166208, P01CA134294, RC2CA148185] Funding Source: NIH RePORTER	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Agency for Healthcare Research and Quality (AHRQ)(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCI's SEER; Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Center for Patient Safety, Dana-Farber Cancer Institute; Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Center for Outcomes and Evidence, AHRQ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Project support was obtained from the National Cancer Institute (NCI) RC2CA148185-01 (to Dr Weeks). This project was also funded under contract HHSA290201000006I (to Dr Schrag) from the Agency for Healthcare Research and Quality (AHRQ) as part of the Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) program. Dr Sharma was supported by NCI grant PO1-CA134294. The collection of the California cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the NCI's SEER program under contract N01-PC-35136 awarded to the Northern California Cancer Center, contract N01-PC-35139 awarded to the University of Southern California, and contract N02-PC-15105 awarded to the Public Health Institute; and the Centers for Disease Control and Prevention's National Program of Cancer Registries under agreement U55/CCR921930-02 awarded to the Public Health Institute.; We acknowledge support from Saul Weingart, MD, PhD, Center for Patient Safety, Dana-Farber Cancer Institute; Sebastian Schneeweiss, MD, ScD, Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; and William Lawrence, MD, MS, Center for Outcomes and Evidence, AHRQ. No financial compensation was received. This study used the linked SEER-Medicare database. This resource has been made available to the research community through collaborative efforts of the NCI and CMS. We acknowledge the efforts of the Applied Research Program, NCI; the Office of Research, Development and Information, CMS; Information Management Services (IMS) Inc; and the SEER program tumor registries in the creation and ongoing maintenance of the SEER-Medicare database.	Altekruse S. F., 1975, SEER CANC STAT REV 1; Bach PB, 2002, MED CARE, V40, P19; Burdett S, 2008, J CLIN ONCOL, V26, P4617, DOI 10.1200/JCO.2008.17.7162; Centers for Medicaid and Medicare Services, MED NAT COV DET MA 2; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cohen MH, 2007, ONCOLOGIST, V12, P713, DOI 10.1634/theoncologist.12-6-713; D'Agostino RB, 2007, JAMA-J AM MED ASSOC, V297, P314, DOI 10.1001/jama.297.3.314; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Davidoff AJ, 2010, J CLIN ONCOL, V28, P2191, DOI 10.1200/JCO.2009.25.4052; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Engels EA, 2011, AM J EPIDEMIOL, V174, P860, DOI 10.1093/aje/kwr146; Goulart B, 2011, VALUE HEALTH, V14, P836, DOI 10.1016/j.jval.2011.04.004; Greene FL, 2002, AJCC CANC STAGING HD; Gridelli C, 2008, J CLIN ONCOL, V26, P13, DOI 10.1200/JCO.2007.14.1820; Gridelli C, 2007, ONCOLOGIST, V12, P1183, DOI 10.1634/theoncologist.12-10-1183; Gridelli C, 2009, LUNG CANCER, V66, P282, DOI 10.1016/j.lungcan.2009.08.006; Grusenmeyer PA, 2006, J CLIN ONCOL S, V24, p18S; Iannettoni MD, 2010, JAMA-J AM MED ASSOC, V304, P2296, DOI 10.1001/jama.2010.1723; Jacobson M, 2006, HEALTH AFFAIR, V25, P437, DOI 10.1377/hlthaff.25.2.437; Jatoi A, 2005, J CLIN ONCOL, V23, P9113, DOI 10.1200/JCO.2005.03.7465; Klabunde CN, 2007, ANN EPIDEMIOL, V17, P584, DOI 10.1016/j.annepidem.2007.03.011; Klabunde CN, 2000, J CLIN EPIDEMIOL, V53, P1258, DOI 10.1016/S0895-4356(00)00256-0; Lamont EB, 2005, J NATL CANCER I, V97, P1080, DOI 10.1093/jnci/dji189; Levesque LE, 2010, BRIT MED J, V340, DOI 10.1136/bmj.b5087; Lunceford JK, 2004, STAT MED, V23, P2937, DOI 10.1002/SIM.1903; MERZA T, 2007, J CLIN ONCOL S, V25, pS687; Mitka M, 2010, JAMA-J AM MED ASSOC, V304, P624, DOI 10.1001/jama.2010.1055; National Cancer Institute, SURV EP END RES; Ramalingam SS, 2008, J CLIN ONCOL, V26, P60, DOI 10.1200/JCO.2007.13.1144; Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648-200009000-00011; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Warren JL, 2002, MED CARE, V40, P3; Warren JL, 2002, MED CARE, V40, P55; Yang K, 2010, CLIN DRUG INVEST, V30, P229, DOI 10.2165/11532260-000000000-00000	37	95	97	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 18	2012	307	15					1593	1601		10.1001/jama.2012.454	http://dx.doi.org/10.1001/jama.2012.454			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	927GU	22511687	Green Accepted, Bronze			2023-01-03	WOS:000302896100021
J	Flaherty, KT; Infante, JR; Daud, A; Gonzalez, R; Kefford, RF; Sosman, J; Hamid, O; Schuchter, L; Cebon, J; Ibrahim, N; Kudchadkar, R; Burris, HA; Falchook, G; Algazi, A; Lewis, K; Long, GV; Puzanov, I; Lebowitz, P; Singh, A; Little, S; Sun, P; Allred, A; Ouellet, D; Kim, KB; Patel, K; Weber, J				Flaherty, Keith T.; Infante, Jeffery R.; Daud, Adil; Gonzalez, Rene; Kefford, Richard F.; Sosman, Jeffrey; Hamid, Omid; Schuchter, Lynn; Cebon, Jonathan; Ibrahim, Nageatte; Kudchadkar, Ragini; Burris, Howard A., III; Falchook, Gerald; Algazi, Alain; Lewis, Karl; Long, Georgina V.; Puzanov, Igor; Lebowitz, Peter; Singh, Ajay; Little, Shonda; Sun, Peng; Allred, Alicia; Ouellet, Daniele; Kim, Kevin B.; Patel, Kiran; Weber, Jeffrey			Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOSE-ESCALATION TRIAL; CELL LUNG-CANCER; RAF INHIBITORS; METASTATIC MELANOMA; IMPROVED SURVIVAL; RESISTANCE; KINASE; EFFICACY; PATHWAY; SAFETY	Background Resistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selective MAPK kinase (MEK) inhibitor. Methods In this open-label study involving 247 patients with metastatic melanoma and BRAF V600 mutations, we evaluated the pharmacokinetic activity and safety of oral dabrafenib (75 or 150 mg twice daily) and trametinib (1, 1.5, or 2 mg daily) in 85 patients and then randomly assigned 162 patients to receive combination therapy with dabrafenib (150 mg) plus trametinib (1 or 2 mg) or dabrafenib monotherapy. The primary end points were the incidence of cutaneous squamous-cell carcinoma, survival free of melanoma progression, and response. Secondary end points were overall survival and pharmacokinetic activity. Results Dose-limiting toxic effects were infrequently observed in patients receiving combination therapy with 150 mg of dabrafenib and 2 mg of trametinib (combination 150/2). Cutaneous squamous-cell carcinoma was seen in 7% of patients receiving combination 150/2 and in 19% receiving monotherapy (P = 0.09), whereas pyrexia was more common in the combination 150/2 group than in the monotherapy group (71% vs. 26%). Median progression-free survival in the combination 150/2 group was 9.4 months, as compared with 5.8 months in the monotherapy group (hazard ratio for progression or death, 0.39; 95% confidence interval, 0.25 to 0.62; P<0.001). The rate of complete or partial response with combination 150/2 therapy was 76%, as compared with 54% with monotherapy (P = 0.03). Conclusions Dabrafenib and trametinib were safely combined at full monotherapy doses. The rate of pyrexia was increased with combination therapy, whereas the rate of proliferative skin lesions was nonsignificantly reduced. Progression-free survival was significantly improved. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT01072175.)	[Kudchadkar, Ragini; Weber, Jeffrey] Univ S Florida, H Lee Moffitt Canc Ctr, Comprehens Melanoma Res Ctr, Tampa, FL 33612 USA; [Flaherty, Keith T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA; [Ibrahim, Nageatte] Dana Farber Canc Inst, Boston, MA 02115 USA; [Infante, Jeffery R.; Burris, Howard A., III] Vanderbilt Univ, Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA; [Sosman, Jeffrey; Puzanov, Igor] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Nashville, TN USA; [Daud, Adil; Algazi, Alain] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Gonzalez, Rene; Lewis, Karl] Univ Colorado, Ctr Canc, Aurora, CO USA; [Kefford, Richard F.; Long, Georgina V.] Univ Sydney, Melanoma Inst Australia, Westmead Inst Canc Res, Sydney, NSW 2006, Australia; [Kefford, Richard F.; Long, Georgina V.] Univ Sydney, Westmead Hosp, Sydney, NSW 2006, Australia; [Cebon, Jonathan] Austin Hosp, Ludwig Inst Canc Res, Heidelberg, Vic 3084, Australia; [Hamid, Omid] Angeles Clin & Res Inst, Los Angeles, CA USA; [Schuchter, Lynn] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Falchook, Gerald] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA; [Kim, Kevin B.] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Div Canc Med, Houston, TX 77030 USA; [Lebowitz, Peter; Singh, Ajay; Little, Shonda; Sun, Peng; Allred, Alicia; Ouellet, Daniele; Patel, Kiran] GlaxoSmithKline, Collegeville, PA USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Harvard University; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute; Sarah Cannon Research Institute; Tennessee Oncology; Vanderbilt University; Vanderbilt University; University of California System; University of California San Francisco; University of Colorado System; University of Colorado Anschutz Medical Campus; Melanoma Institute Australia; University of Sydney; University of Sydney; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Ludwig Institute for Cancer Research; Angeles Clinic & Research Institute; University of Pennsylvania; Pennsylvania Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; GlaxoSmithKline	Weber, J (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr, Comprehens Melanoma Res Ctr, Tampa, FL 33612 USA.	jeffrey.weber@moffitt.org	Cebon, Jonathan S/H-1643-2013; PUZANOV, IGOR/AAP-2966-2020; Long, Georgina V/C-1771-2013; gonzález, rene/W-2081-2019; Daud, Adil/T-3079-2019	PUZANOV, IGOR/0000-0002-9803-3497; Long, Georgina V/0000-0001-8894-3545; Daud, Adil/0000-0002-6617-8421; Cebon, Jonathan/0000-0002-3898-950X; Kefford, Richard/0000-0001-9251-9229	GlaxoSmithKline; NATIONAL CANCER INSTITUTE [P30CA016672, K24CA097588] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024148] Funding Source: NIH RePORTER	GlaxoSmithKline(GlaxoSmithKline); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Supported by GlaxoSmithKline.	Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Falchook GS, 2012, LANCET ONCOL, V13, P782, DOI 10.1016/S1470-2045(12)70269-3; Falchook GS, 2012, LANCET, V379, P1893, DOI 10.1016/S0140-6736(12)60398-5; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Kwak EL, 2011, NEW ENGL J MED, V364, P588; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Paraiso KHT, 2010, BRIT J CANCER, V102, P1724, DOI 10.1038/sj.bjc.6605714; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Shi HB, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1727; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Sturm OE, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001212; Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023	27	540	570	3	132	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 1	2012	367	18					1694	1703		10.1056/NEJMoa1210093	http://dx.doi.org/10.1056/NEJMoa1210093			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	028RS	23020132	Green Accepted			2023-01-03	WOS:000310440800006
J	Nolan, JP; Soar, J				Nolan, Jerry P.; Soar, Jasmeet			Duration of in-hospital resuscitation: when to call time?	LANCET			English	Editorial Material							CARDIAC-ARREST; CARDIOPULMONARY-RESUSCITATION; GUIDELINES; ETHICS		[Nolan, Jerry P.] Royal United Hosp NHS Trust, Bath BA1 3NG, Avon, England; [Soar, Jasmeet] N Bristol NHS Trust, Southmead Hosp, Bristol, Avon, England	North Bristol NHS Trust; Southmead Hospital	Nolan, JP (corresponding author), Royal United Hosp NHS Trust, Bath BA1 3NG, Avon, England.	jerry.nolan@nhs.net	Soar, Jasmeet/HGA-2279-2022; Nolan, Jerry P./ABF-2561-2020	Soar, Jasmeet/0000-0001-5970-6073; Nolan, Jerry/0000-0003-3141-3812				Carr BG, 2009, RESUSCITATION, V80, P30, DOI 10.1016/j.resuscitation.2008.09.001; Chen YS, 2008, LANCET, V372, P554, DOI 10.1016/S0140-6736(08)60958-7; Christenson J, 2009, CIRCULATION, V120, P1241, DOI 10.1161/CIRCULATIONAHA.109.852202; Goldberger ZD, 2012, LANCET; Heradstveit BE, 2012, RESUSCITATION, V83, P813, DOI 10.1016/j.resuscitation.2012.02.021; Idris AH, 2012, CIRCULATION, V125, P3004, DOI 10.1161/CIRCULATIONAHA.111.059535; Lippert FK, 2010, RESUSCITATION, V81, P1445, DOI 10.1016/j.resuscitation.2010.08.013; Morrison LJ, 2010, CIRCULATION, V122, pS665, DOI 10.1161/CIRCULATIONAHA.110.970905; Parnia S, 2012, RESUSCITATION, V83, P982, DOI 10.1016/j.resuscitation.2012.01.039; Shih CL, 2007, RESUSCITATION, V72, P394, DOI 10.1016/j.resuscitation.2006.07.020; Stiell IG, 2012, CRIT CARE MED, V40, P1192, DOI 10.1097/CCM.0b013e31823bc8bb; van Walraven C, 2001, JAMA-J AM MED ASSOC, V285, P1602, DOI 10.1001/jama.285.12.1602	12	11	11	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 27	2012	380	9852					1451	1453		10.1016/S0140-6736(12)61182-9	http://dx.doi.org/10.1016/S0140-6736(12)61182-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	026JJ	22958913				2023-01-03	WOS:000310272000006
J	Li, Y; Liu, H; Wang, J; Li, Y; Yu, GP; Ma, XM; Liang, MH; Zhang, J; Zhao, LP				Li, Yi; Liu, Hui; Wang, Jing; Li, Yan; Yu, Guo-Pei; Ma, Xie-Min; Liang, Ming-Hui; Zhang, Jun; Zhao, Lue Ping			Variable Lengths of Stay among Ischemic Stroke Subtypes in Chinese General Teaching Hospitals	PLOS ONE			English	Article							ACADEMIC MEDICAL-CENTERS; QUALITY-OF-CARE; UNIT; MORTALITY; COSTS	Background: Length of stay (LOS) is one of the most important quantitative indexes that measures health service utilization within a hospital. Many studies have examined the association of three major stroke categories with LOS. Our aim is to investigate the differences of LOS among ischemic stroke subtypes, results from which are helpful to healthcare providers and government agencies to improve health care delivery efficiency. Methodology/Principal Findings: Using the Beijing Municipal Health Bureau's hospitalization summary reports, we performed a retrospective study among first-ever in-hospital patients with ischemic stroke (ICD-10 I63) in three general teaching hospitals in Beijing, China, from 2006 to 2010 with generalized linear model. In our study, 5,559 patients (female, 36.0%; age, 64.4 +/- 12.9 years) were included. The estimated mean LOS of ischemic stroke was 17.4 +/- 1.8 days. After adjusting for confounders, LOS of lacunar infarction (14.7 days; p<0.001) and LOS of small cerebral infarction (17.0 days; p = 0.393) were shorter than that of single cerebral infarction (17.9 days, p<0.001). LOS of multi-infarct (19.0 days; p = 0.028), brainstem infarction (19.3 days; p = 0.045), basal ganglia infarction (18.5 days; p = 0.452) and other subtypes of ischemic stroke (18.9 days; p = 0.327) were longer than that of single cerebral infarction. Conclusions: LOS of ischemic stroke patient differes across single cerebral infarction, lacunar infarction, multi-infarct and brainstem infarction patients. The ascending order of LOS was lacunar infarction, small cerebral infarction, single cerebral infarction, basal ganglia infarction, other subtypes of ischemic stroke, multi-infarct and brainstem infarction.	[Zhang, Jun] Peking Univ, Hosp 3, Hlth Sci Ctr, Dept Hosp Management,Dept Neurol, Beijing 100871, Peoples R China; [Li, Yan] Peking Univ, Hosp 1, Hlth Sci Ctr, Dept Hosp Management,Dept Neurol, Beijing 100871, Peoples R China; [Li, Yi; Liu, Hui; Wang, Jing; Yu, Guo-Pei; Zhao, Lue Ping] Peking Univ, Med Informat Ctr, Beijing 100871, Peoples R China; [Ma, Xie-Min] Peking Univ, Hlth Sci Ctr, Sch Publ Hlth, Beijing 100871, Peoples R China; [Liang, Ming-Hui] Minist Hlth, Inst Hosp Management, Beijing, Peoples R China	Peking University; Peking University; Peking University; Peking University	Zhang, J (corresponding author), Peking Univ, Hosp 3, Hlth Sci Ctr, Dept Hosp Management,Dept Neurol, Beijing 100871, Peoples R China.	who626@163.com; lzhao@bjmu.edu.cn			"985" Project from Ministry of Education of China	"985" Project from Ministry of Education of China	This work is supported, in part, by the "985" Project from Ministry of Education of China. No additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beijing Health Bereau, 2011, 6 DIG COD CLASS STAN; Bonita R, 2004, LANCET NEUROL, V3, P391, DOI 10.1016/S1474-4422(04)00800-2; Candelise L, 2007, LANCET, V369, P299, DOI 10.1016/S0140-6736(07)60152-4; Chang KC, 2002, STROKE, V33, P2670, DOI 10.1161/01.STR.0000034396.68980.39; Chinese Medical Association Neurology Branch Cerebrovascular Disease Study Group, 2010, CHINESE J NEUROLOGY, V43, P146, DOI DOI 10.3969/J.ISSN.1672-7185.2013.08.004; Diringer MN, 1999, STROKE, V30, P724, DOI 10.1161/01.STR.30.4.724; Feigin VL, 2005, LANCET, V365, P2160, DOI 10.1016/S0140-6736(05)66755-4; George Mary G, 2011, Ann Neurol, V70, P713, DOI 10.1002/ana.22539; Gillum LA, 2001, STROKE, V32, P2137, DOI 10.1161/hs0901.094260; Goldstein LB, 2004, STROKE, V35, P1941, DOI 10.1161/01.STR.0000135225.80898.1c; Holloway RG, 1996, NEUROLOGY, V46, P854; Ingeman A, 2011, STROKE, V42, P3214, DOI 10.1161/STROKEAHA.110.610881; JORGENSEN HS, 1995, STROKE, V26, P1178, DOI 10.1161/01.STR.26.7.1178; Koton S, 2010, NEUROLOGY, V74, P1511, DOI 10.1212/WNL.0b013e3181dd4dc5; Laloux P, 2003, ACTA NEUROL BELG, V103, P71; Liu M, 2007, LANCET NEUROL, V6, P456, DOI 10.1016/S1474-4422(07)70004-2; Ma Y, 2010, EUR J NEUROL, V17, P1270, DOI 10.1111/j.1468-1331.2010.03007.x; Ministry of Health of the People's Republic of China, 2011, APPL DIS DIAGN REL G; Ministry of Health of the People's Republic of China, 2011, CHIN HLTH STAT YB, P160; Ministry of Health of the People's Republic of China, 2011, CHIN HLTH STAT YB, p[290, 329]; Palnum KD, 2009, STROKE, V40, P1134, DOI 10.1161/STROKEAHA.108.543819; Rao ML, 2007, GUIDELINES CEREBROVA; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Somerford PJ, 2004, ANN EPIDEMIOL, V14, P773, DOI 10.1016/j.annepidem.2004.02.003; Svendsen ML, 2009, MED CARE, V47, P575, DOI 10.1097/MLR.0b013e318195f852; Tirschwell D L, 1999, J Stroke Cerebrovasc Dis, V8, P336, DOI 10.1016/S1052-3057(99)80008-1; Yoneda Y, 2003, STROKE, V34, P718, DOI 10.1161/01.STR.0000056171.55342.FF; Zhu HF, 2009, STROKE, V40, P18, DOI 10.1161/STROKEAHA.108.527606	28	6	6	2	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2012	7	9							e45101	10.1371/journal.pone.0045101	http://dx.doi.org/10.1371/journal.pone.0045101			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022PZ	23028783	Green Submitted, Green Published, gold			2023-01-03	WOS:000309973900026
J	Shin, IS; Lee, MY; Lim, HS; Ha, H; Seo, CS; Kim, JC; Shin, HK				Shin, In Sik; Lee, Mee Young; Lim, Hye Sun; Ha, Hyekyung; Seo, Chang Seob; Kim, Jong-Choon; Shin, Hyeun Kyoo			An Extract of Crataegus pinnatifida Fruit Attenuates Airway Inflammation by Modulation of Matrix Metalloproteinase-9 in Ovalbumin Induced Asthma	PLOS ONE			English	Article							CELL-ADHESION MOLECULES; MURINE MODEL; TOLUENE DIISOCYANATE; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR; IN-VITRO; EXPRESSION; MIGRATION; EOSINOPHILS; MECHANISMS	Background: Crataegus pinnatifida (Chinese hawthorn) has long been used as a herbal medicine in Asia and Europe. It has been used for the treatment of various cardiovascular diseases such as myocardial weakness, tachycardia, hypertension and arteriosclerosis. In this study, we investigated the anti-inflammatory effects of Crataegus pinnatifida ethanolic extracts (CPEE) on Th2-type cytokines, eosinophil infiltration, expression of matrix metalloproteinase (MMP)-9, and other factors, using an ovalbumin (OVA)-induced murine asthma model. Methods/Principal Finding: Airways of OVA-sensitized mice exposed to OVA challenge developed eosinophilia, mucus hypersecretion and increased cytokine levels. CPEE was applied 1 h prior to OVA challenge. Mice were administered CPEE orally at doses of 100 and 200 mg/kg once daily on days 18-23. Bronchoalveolar lavage fluid (BALF) was collected 48 h after the final OVA challenge. Levels of interleukin (IL)-4 and IL-5 in BALF were measured using enzyme-linked immunosorbent (ELISA) assays. Lung tissue sections 4 mm in thickness were stained with Mayer's hematoxylin and eosin for assessment of cell infiltration and mucus production with PAS staining, in conjunction with ELISA, and Western blot analyses for the expression of MMP-9, intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 protein expression. CPEE significantly decreased the Th2 cytokines including IL-4 and IL-5 levels, reduced the number of inflammatory cells in BALF and airway hyperresponsiveness, suppressed the infiltration of eosinophil-rich inflammatory cells and mucus hypersecretion and reduced the expression of ICAM-1, VCAM-1 and MMP-9 and the activity of MMP-9 in lung tissue of OVA-challenged mice. Conclusions: These results showed that CPEE can protect against allergic airway inflammation and can act as an MMP-9 modulator to induce a reduction in ICAM-1 and VCAM-1 expression. In conclusion, we strongly suggest the feasibility of CPEE as a therapeutic drug for allergic asthma.	[Shin, In Sik; Lee, Mee Young; Lim, Hye Sun; Ha, Hyekyung; Seo, Chang Seob; Shin, Hyeun Kyoo] Korea Inst Oriental Med, Basic Herbal Med Res Grp, Taejon, South Korea; [Shin, In Sik; Kim, Jong-Choon] Chonnam Natl Univ, Coll Vet Med, Kwangju, South Korea	Korea Institute of Oriental Medicine (KIOM); Chonnam National University	Shin, HK (corresponding author), Korea Inst Oriental Med, Basic Herbal Med Res Grp, Taejon, South Korea.	toxkim@chonnam.ac.kr; hkshin@kiom.re.kr			Korea Research Council of Fundamental Science and Technology of the Republic of Korea	Korea Research Council of Fundamental Science and Technology of the Republic of Korea	This research was supported by grants from the Korea Research Council of Fundamental Science and Technology of the Republic of Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abel M, 2008, J IMMUNOL, V180, P3543, DOI 10.4049/jimmunol.180.5.3543; BOSCHETTO P, 1987, J ALLERGY CLIN IMMUN, V80, P261, DOI 10.1016/0091-6749(87)90028-5; BurkeGaffney A, 1996, BRIT J PHARMACOL, V119, P1149, DOI 10.1111/j.1476-5381.1996.tb16017.x; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Di Girolamo N, 2006, J IMMUNOL, V177, P2638, DOI 10.4049/jimmunol.177.4.2638; Gueders MM, 2008, BIOCHEM PHARMACOL, V75, P514, DOI 10.1016/j.bcp.2007.09.012; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V104, P356, DOI 10.1016/S0091-6749(99)70379-9; Kao ES, 2005, J AGR FOOD CHEM, V53, P430, DOI 10.1021/jf040231f; Kim CH, 2004, AM J PHYSIOL-LUNG C, V288, P307; Kong Ying-Jun, 2008, Zhonghua Jiehe He Huxi Zazhi, V31, P129; Korenblat PE, 2001, ANN ALLERG ASTHMA IM, V86, P31, DOI 10.1016/S1081-1206(10)62309-5; Kumagai K, 1999, J IMMUNOL, V162, P4212; Lee KS, 2003, J ALLERGY CLIN IMMUN, V111, P1278, DOI 10.1067/mai.2003.1501; Lee MY, 2010, INT IMMUNOPHARMACOL, V10, P474, DOI 10.1016/j.intimp.2010.01.008; Lee YC, 2001, J ALLERGY CLIN IMMUN, V108, P1021, DOI 10.1067/mai.2001.120132; Liu LY, 2002, AM J RESP CRIT CARE, V165, P1062, DOI 10.1164/ajrccm.165.8.2109065; Liu ZY, 2005, BIOMED PHARMACOTHER, V59, P481, DOI 10.1016/j.biopha.2005.06.009; Locke NR, 2007, AM J RESP CELL MOL, V36, P625, DOI 10.1165/rcmb.2006-0083OC; Lynch KR, 1999, NATURE, V399, P789; MAPP CE, 1987, B EUR PHYSIOPATH RES, V23, P583; MONTEFORT S, 1994, J CLIN INVEST, V93, P1411, DOI 10.1172/JCI117118; Niu CS, 2011, HORM METAB RES, V43, P625, DOI 10.1055/s-0031-1283147; OHKAWARA Y, 1995, AM J RESP CELL MOL, V12, P4, DOI 10.1165/ajrcmb.12.1.7529029; Okada S, 1997, AM J RESP CELL MOL, V17, P519, DOI 10.1165/ajrcmb.17.4.2877; Punithavathi VR, 2010, CARDIOVASC TOXICOL, V10, P181, DOI 10.1007/s12012-010-9077-8; Rosseau S, 2000, J IMMUNOL, V164, P427, DOI 10.4049/jimmunol.164.1.427; Scholz D, 1996, CELL TISSUE RES, V284, P415, DOI 10.1007/s004410050602; Sergejeva S, 2005, AM J RESP CELL MOL, V33, P248, DOI 10.1165/rcmb.2004-0213OC; Shan G, 2007, J SEP SCI, V30, P717; Soberon JR, 2010, J ETHNOPHARMACOL, V130, P329, DOI 10.1016/j.jep.2010.05.015; Tadic VM, 2008, J AGR FOOD CHEM, V56, P7700, DOI 10.1021/jf801668c; Wagner JG, 2000, PHARMACOL REV, V52, P349; Wang Q, 2002, ANTIOXID REDOX SIGN, V4, P39, DOI 10.1089/152308602753625843; Wang T, 2011, J AGR FOOD CHEM, V59, P4987, DOI 10.1021/jf1049062; Wills-Karp M, 2004, SCIENCE, V305, P1726, DOI 10.1126/science.1104134	36	30	33	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2012	7	9							e45734	10.1371/journal.pone.0045734	http://dx.doi.org/10.1371/journal.pone.0045734			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014RG	23029210	Green Submitted, gold, Green Published			2023-01-03	WOS:000309392800087
J	Wang, B; Xu, SB; Wu, LG				Wang, Bin; Xu, Shibin; Wu, Liguang			Intensified Arabian Sea tropical storms	NATURE			English	Letter							BLACK CARBON		[Wang, Bin; Xu, Shibin] Univ Hawaii Manoa, Dept Meteorol, Honolulu, HI 96822 USA; [Wang, Bin; Xu, Shibin] Univ Hawaii Manoa, Int Pacific Res Ctr, Honolulu, HI 96822 USA; [Wang, Bin; Wu, Liguang] Nanjing Univ Informat Sci & Technol, Minist Educ, Key Lab Meteorol Disaster, Nanjing 210044, Jiangsu, Peoples R China; [Xu, Shibin] Ocean Univ China, Phys Oceanog Lab, Qingdao 266100, Peoples R China	University of Hawaii System; University of Hawaii Manoa; University of Hawaii System; University of Hawaii Manoa; Nanjing University of Information Science & Technology; Ocean University of China	Wang, B (corresponding author), Univ Hawaii Manoa, Dept Meteorol, Honolulu, HI 96822 USA.	wangbin@hawaii.edu						Dee DP, 2011, Q J ROY METEOR SOC, V137, P553, DOI 10.1002/qj.828; Emanuel K. A., 2004, P 26 C HURR TROP MET, P240; Evan AT, 2011, NATURE, V479, P94, DOI 10.1038/nature10552; Evan AT, 2011, J CLIMATE, V24, P140, DOI 10.1175/2010JCLI3611.1; GRAY WM, 1968, MON WEATHER REV, V96, P669, DOI 10.1175/1520-0493(1968)096<0669:GVOTOO>2.0.CO;2; Kajikawa Y, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2011GL050540; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; Kanamitsu M, 2002, B AM METEOROL SOC, V83, P1631, DOI 10.1175/Bams-83-11-1631; Knapp KR, 2010, B AM METEOROL SOC, V91, P363, DOI 10.1175/2009BAMS2755.1; Lau KM, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL027546; LEPAGE Y, 1973, BIOMETRIKA, V60, P113, DOI 10.2307/2334912; Meehl G. A., 2007, CLIMATE CHANGE 2007, P499; Meehl GA, 2008, J CLIMATE, V21, P2869, DOI 10.1175/2007JCLI1777.1; Rienecker MM, 2011, J CLIMATE, V24, P3624, DOI 10.1175/JCLI-D-11-00015.1; Wang B, 2012, CLIM DYNAM, V39, P1123, DOI 10.1007/s00382-011-1266-z	15	44	46	4	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 20	2012	489	7416					E1	E2		10.1038/nature11470	http://dx.doi.org/10.1038/nature11470			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	007AK	22996560				2023-01-03	WOS:000308860900001
J	Yuan, YY; Kadiyala, CS; Ching, TT; Hakimi, P; Saha, S; Xu, H; Yuan, C; Mullangi, V; Wang, LW; Fivenson, E; Hanson, RW; Ewing, R; Hsu, AL; Miyagi, M; Feng, ZY				Yuan, Yiyuan; Kadiyala, Chandra S.; Ching, Tsui-Ting; Hakimi, Parvin; Saha, Sudipto; Xu, Hua; Yuan, Chao; Mullangi, Vennela; Wang, Liwen; Fivenson, Elayne; Hanson, Richard W.; Ewing, Rob; Hsu, Ao-Lin; Miyagi, Masaru; Feng, Zhaoyang			Enhanced Energy Metabolism Contributes to the Extended Life Span of Calorie-restricted Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS; PHOSPHOENOLPYRUVATE CARBOXYKINASE; INDUCED LONGEVITY; QUANTITATIVE PROTEOMICS; PYRUVATE-CARBOXYLASE; DIETARY RESTRICTION; SKELETAL-MUSCLE; LIPID-SYNTHESIS; ADIPOSE-TISSUE; AMINO-ACIDS	Caloric restriction (CR) markedly extends life span and improves the health of a broad number of species. Energy metabolism fundamentally contributes to the beneficial effects of CR, but the underlying mechanisms that are responsible for this effect remain enigmatic. A multidisciplinary approach that involves quantitative proteomics, immunochemistry, metabolic quantification, and life span analysis was used to determine how CR, which occurs in the Caenorhabditis elegans eat-2 mutants, modifies energy metabolism of the worm, and whether the observed modifications contribute to the CR-mediated physiological responses. A switch to fatty acid metabolism as an energy source and an enhanced rate of energy metabolism by eat-2 mutant nematodes were detected. Life span analyses validated the important role of these previously unknown alterations of energy metabolism in the CR-mediated longevity of nematodes. As observed in mice, the overexpression of the gene for the nematode analog of the cytosolic form of phosphoenolpyruvate carboxykinase caused a marked extension of the life span in C. elegans, presumably by enhancing energy metabolism via an altered rate of cataplerosis of tricarboxylic acid cycle anions. We conclude that an increase, not a decrease in fuel consumption, via an accelerated oxidation of fuels in the TCA cycle is involved in life span regulation; this mechanism may be conserved across phylogeny.	[Ching, Tsui-Ting; Fivenson, Elayne; Hsu, Ao-Lin] Univ Michigan, Dept Internal Med, Div Geriatr Med, Ann Arbor, MI 48109 USA; [Yuan, Yiyuan; Miyagi, Masaru; Feng, Zhaoyang] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; [Kadiyala, Chandra S.; Saha, Sudipto; Xu, Hua; Yuan, Chao; Mullangi, Vennela; Wang, Liwen; Ewing, Rob; Miyagi, Masaru] Case Western Reserve Univ, Sch Med, Ctr Prote & Bioinformat, Cleveland, OH 44106 USA; [Hakimi, Parvin; Hanson, Richard W.] Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; [Mullangi, Vennela] Cleveland State Univ, Dept Chem, Cleveland, OH 44114 USA; [Ewing, Rob] Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; [Hsu, Ao-Lin] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; [Miyagi, Masaru] Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Sch Med, Cleveland, OH 44106 USA	University of Michigan System; University of Michigan; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University System of Ohio; Cleveland State University; Case Western Reserve University; University of Michigan System; University of Michigan; Case Western Reserve University	Hsu, AL (corresponding author), Univ Michigan, Dept Internal Med, Div Geriatr Med, Ann Arbor, MI 48109 USA.	aolinhsu@umich.edu; masaru.miyagi@case.edu; john.feng@case.edu	Hakimi, Parvin/AAB-1643-2021; Saha, Sudipto/AAF-1034-2020; Hsu, Ao-Lin Allen/AAX-1856-2020	Ewing, Rodney/0000-0001-9472-4031; Hsu, Ao-Lin/0000-0002-2864-3134; Ewing, Rob/0000-0001-6510-4001; Saha, Sudipto/0000-0001-9433-8894; Ching, Tsui-Ting/0000-0001-7650-1766	National Institutes of Health [1R01 AG028516, P20-CA-103736]; Mt. Sinai Foundation; Proteomics Center, School of Medicine, Case Western Reserve University; Ellison Foundation [AG-SS-2420-10]; NATIONAL CANCER INSTITUTE [P20CA103736] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG028516] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mt. Sinai Foundation; Proteomics Center, School of Medicine, Case Western Reserve University; Ellison Foundation(Lawrence Ellison Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported, in whole or in part, by National Institutes of Health Grants 1R01 AG028516 (to A. L. H.) and P20-CA-103736 (to R. W. H.). This work was also supported by the Mt. Sinai Foundation (to Z. F.), a pilot award from the Proteomics Center, School of Medicine, Case Western Reserve University (to Z. F. and M. M.), and by Grants AG-SS-2420-10 from the Ellison Foundation (to R. W. H.).	Apfeld J, 2004, GENE DEV, V18, P3004, DOI 10.1101/gad.1255404; AVERY L, 1993, GENETICS, V133, P897; BALDNER GL, 1985, COMP BIOCHEM PHYS B, V82, P153, DOI 10.1016/0305-0491(85)90145-2; BALLARD FJ, 1967, BIOCHEM J, V104, P866, DOI 10.1042/bj1040866; BALLARD FJ, 1967, BIOCHEM J, V102, P952, DOI 10.1042/bj1020952; Bishop NA, 2007, NATURE, V447, P545, DOI 10.1038/nature05904; Braeckman Bart P, 2009, WormBook, P1, DOI 10.1895/wormbook.1.146.1; Braeckman BP, 2002, AGING CELL, V1, P82, DOI 10.1046/j.1474-9728.2002.00021.x; BRENNER S, 1974, GENETICS, V77, P71; Brock TJ, 2007, GENETICS, V176, P865, DOI 10.1534/genetics.107.071860; Calvo AC, 2008, FASEB J, V22, P3046, DOI 10.1096/fj.08-108522; CHANGEUX J, 1965, SCI AM, V212, P36, DOI 10.1038/scientificamerican0465-36; Chapman T, 1996, P ROY SOC B-BIOL SCI, V263, P755, DOI 10.1098/rspb.1996.0113; Ching TT, 2010, AGING CELL, V9, P545, DOI 10.1111/j.1474-9726.2010.00580.x; COUDRON PE, 1983, ARCH BIOCHEM BIOPHYS, V226, P324, DOI 10.1016/0003-9861(83)90299-0; Distler AM, 2009, METHOD ENZYMOL, V457, P97, DOI 10.1016/S0076-6879(09)05006-X; Dong MQ, 2007, SCIENCE, V317, P660, DOI 10.1126/science.1139952; ETIEMBLE J, 1984, AM J HEMATOL, V17, P251, DOI 10.1002/ajh.2830170305; Fei YJ, 1998, BIOCHEM J, V332, P565, DOI 10.1042/bj3320565; Fredens J, 2011, NAT METHODS, V8, P845, DOI [10.1038/NMETH.1675, 10.1038/nmeth.1675]; Gu T, 1998, MOL CELL BIOL, V18, P4556, DOI 10.1128/MCB.18.8.4556; Hakimi P, 2007, J BIOL CHEM, V282, P32844, DOI 10.1074/jbc.M706127200; Hansen M, 2005, PLOS GENET, V1, P119, DOI 10.1371/journal.pgen.0010017; Hansen M, 2007, WESTERN HUM REV, V61, P6; HANSON RW, 1967, BIOCHEM J, V105, P529, DOI 10.1042/bj1050529; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; Hoppel C, 2002, ANAL BIOCHEM, V302, P60, DOI 10.1006/abio.2001.5531; Horikawa M, 2008, J BIOCHEM, V144, P149, DOI 10.1093/jb/mvn055; Houthoofd K, 2002, EXP GERONTOL, V37, P1359, DOI 10.1016/S0531-5565(02)00172-9; Houthoofd K, 2006, EXP GERONTOL, V41, P1026, DOI 10.1016/j.exger.2006.05.007; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; JEKEL PA, 1983, ANAL BIOCHEM, V134, P347, DOI 10.1016/0003-2697(83)90308-1; Jia K, 2004, DEVELOPMENT, V131, P3897, DOI 10.1242/dev.01255; Jiang JC, 2000, FASEB J, V14, P2135; JOMAIN M, 1969, J LIPID RES, V10, P674; Joo HJ, 2009, BIOCHEM J, V422, P61, DOI 10.1042/BJ20090513; Kadiyala CSR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015332; Kayo T, 2001, P NATL ACAD SCI USA, V98, P5093, DOI 10.1073/pnas.081061898; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kim DH, 2002, SCIENCE, V297, P623, DOI 10.1126/science.1073759; Kruger M, 2008, CELL, V134, P353, DOI 10.1016/j.cell.2008.05.033; KUWABARA PE, 1994, NUCLEIC ACIDS RES, V22, P4414, DOI 10.1093/nar/22.21.4414; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Lane MA, 2002, MICROSC RES TECHNIQ, V59, P335, DOI 10.1002/jemt.10214; Larance M, 2011, NAT METHODS, V8, P849, DOI [10.1038/NMETH.1679, 10.1038/nmeth.1679]; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lee K, 2011, J BIOL CHEM, V286, P25655, DOI 10.1074/jbc.M111.228692; Li ZJ, 2010, ACTA CRYSTALLOGR F, V66, P426, DOI 10.1107/S1744309110005002; Liao VHC, 2001, DNA SEQUENCE, V12, P137, DOI 10.3109/10425170109047568; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Masoro Edward J, 2003, Sci Aging Knowledge Environ, V2003, pRE2, DOI 10.1126/sageke.2003.8.re2; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Masoro EJ, 2005, MECH AGEING DEV, V126, P913, DOI 10.1016/j.mad.2005.03.012; McGhee JD, 2007, DEV BIOL, V302, P627, DOI 10.1016/j.ydbio.2006.10.024; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mendenhall AR, 2006, GENETICS, V174, P1173, DOI 10.1534/genetics.106.061390; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Panowski SH, 2007, NATURE, V447, P550, DOI 10.1038/nature05837; Samuelson AV, 2007, GENE DEV, V21, P2976, DOI 10.1101/gad.1588907; STEFANINI M, 1972, AM J CLIN PATHOL, V58, P408; Stiernagle Theresa, 2006, WormBook, P1; Sury MD, 2010, MOL CELL PROTEOMICS, V9, P2173, DOI 10.1074/mcp.M110.000323; Tagawa A, 2001, DEV BIOL, V233, P412, DOI 10.1006/dbio.2001.0234; TAYLOR AL, 1967, BACTERIOL REV, V31, P332, DOI 10.1128/MMBR.31.4.332-353.1967; Van Gilst MR, 2005, P NATL ACAD SCI USA, V102, P13496, DOI 10.1073/pnas.0506234102; Veljkovic E, 2004, J BIOL CHEM, V279, P7655, DOI 10.1074/jbc.M309528200; VIDNES J, 1976, ACTA PAEDIATR SCAND, V65, P307, DOI 10.1111/j.1651-2227.1976.tb04890.x; Wang Y, 2006, MECH AGEING DEV, V127, P741, DOI 10.1016/j.mad.2006.05.005; Wang YL, 2007, J PROTEOME RES, V6, P1846, DOI 10.1021/pr060685n; Weindruch R, 1996, SCI AM, V274, P46, DOI 10.1038/scientificamerican0196-46; WEINDRUCH R, 1986, J NUTR, V116, P641, DOI 10.1093/jn/116.4.641; Weindruch R., 1988, RETARDATION AGING DI; Wright AJ, 2003, MOL BIOL CELL, V14, P4512, DOI 10.1091/mbc.E03-01-0017	74	46	48	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2012	287	37					31414	31426		10.1074/jbc.M112.377275	http://dx.doi.org/10.1074/jbc.M112.377275			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006AK	22810224	Green Published, hybrid			2023-01-03	WOS:000308791300052
J	Trainor, C; Butterworth, KT; McGarry, CK; McMahon, SJ; O'Sullivan, JM; Hounsell, AR; Prise, KM				Trainor, Colman; Butterworth, Karl T.; McGarry, Conor K.; McMahon, Stephen J.; O'Sullivan, Joe M.; Hounsell, Alan R.; Prise, Kevin M.			DNA Damage Responses following Exposure to Modulated Radiation Fields	PLOS ONE			English	Article							DOUBLE-STRAND BREAKS; PRIMARY HUMAN FIBROBLASTS; IRRADIATED GLIOMA-CELLS; BYSTANDER RESPONSES; NITRIC-OXIDE; CELLULAR-RESPONSE; TUMOR-CELLS; SURVIVAL; INDUCE; 53BP1	During the delivery of advanced radiotherapy treatment techniques modulated beams are utilised to increase dose conformity across the target volume. Recent investigations have highlighted differential cellular responses to modulated radiation fields particularly in areas outside the primary treatment field that cannot be accounted for by scattered dose alone. In the present study, we determined the DNA damage response within the normal human fibroblast AG0-1522B and the prostate cancer cell line DU-145 utilising the DNA damage assay. Cells plated in slide flasks were exposed to 1 Gy uniform or modulated radiation fields. Modulated fields were delivered by shielding 25%, 50% or 75% of the flask during irradiation. The average number of 53BP1 or gamma H2AX foci was measured in 2 mm intervals across the slide area. Following 30 minutes after modulated radiation field exposure an increase in the average number of foci out-of-field was observed when compared to non-irradiated controls. In-field, a non-uniform response was observed with a significant decrease in the average number of foci compared to uniformly irradiated cells. Following 24 hrs after exposure there is evidence for two populations of responding cells to bystander signals in-and out-of-field. There was no significant difference in DNA damage response between 25%, 50% or 75% modulated fields. The response was dependent on cellular secreted intercellular signalling as physical inhibition of intercellular communication abrogated the observed response. Elevated residual DNA damage observed within out-of-field regions decreased following addition of an inducible nitric oxide synthase inhibitor (Aminoguanidine). These data show, for the first time, differential DNA damage responses in-and out-of-field following modulated radiation field delivery. This study provides further evidence for a role of intercellular communication in mediating cellular radiobiological response to modulated radiation fields and may inform the refinement of existing radiobiological models for the optimization of advanced radiotherapy treatment plans.	[Trainor, Colman; Butterworth, Karl T.; McGarry, Conor K.; McMahon, Stephen J.; O'Sullivan, Joe M.; Hounsell, Alan R.; Prise, Kevin M.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland; [McGarry, Conor K.; O'Sullivan, Joe M.; Hounsell, Alan R.] Belfast Hlth & Social Care Trust, No Ireland Canc Ctr, Belfast, Antrim, North Ireland	Queens University Belfast	Trainor, C (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland.	ctrainor14@qub.ac.uk	Butterworth, Karl/I-7476-2019; Prise, Kevin/N-7872-2015	Butterworth, Karl/0000-0001-7170-6789; Prise, Kevin/0000-0001-6134-7946; McGarry, Conor/0000-0001-6396-2184; McMahon, Stephen/0000-0001-5980-6728; O'Sullivan, Joe/0000-0001-6999-2739	Cancer Research UK [C1513/A7047, C212/A11342]; Health and Social care Research and Development Office of the Northern Ireland; Northern Ireland Department of Education and Learning; Public Health Agency [EAT/3977/08] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Health and Social care Research and Development Office of the Northern Ireland; Northern Ireland Department of Education and Learning; Public Health Agency	Cancer Research UK grant C1513/A7047 to KMP. Cancer Research UK grant C212/A11342 to ARH. Health and Social care Research and Development Office of the Northern Ireland a Fellowship Award to CMcG Northern Ireland Department of Education and Learning for a studentship to CT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Burdak-Rothkamm S, 2007, ONCOGENE, V26, P993, DOI 10.1038/sj.onc.1209863; Burdak-Rothkamm S, 2008, CANCER RES, V68, P7059, DOI 10.1158/0008-5472.CAN-08-0545; Butterworth KT, 2011, INT J RADIAT ONCOL, V79, P1516, DOI 10.1016/j.ijrobp.2010.11.034; Butterworth KT, 2010, PHYS MED BIOL, V55, P1607, DOI 10.1088/0031-9155/55/6/005; Hall EJ, RADIOBIOLOGY RADIOLO, V7th; Han W, 2007, BRIT J RADIOL, V80, pS7, DOI 10.1259/bjr/44550200; Hu BR, 2006, CARCINOGENESIS, V27, P245, DOI 10.1093/carcin/bgi224; Mackonis EC, 2007, PHYS MED BIOL, V52, P5469, DOI 10.1088/0031-9155/52/18/001; Mothersill C, 1997, INT J RADIAT BIOL, V71, P421, DOI 10.1080/095530097144030; Mothersill C, 1998, RADIAT RES, V149, P256, DOI 10.2307/3579958; Prise KM, 2009, NAT REV CANCER, V9, P351, DOI 10.1038/nrc2603; Prise KM, 2005, LANCET ONCOL, V6, P520, DOI 10.1016/S1470-2045(05)70246-1; PRISE KM, 1994, INT J RADIAT BIOL, V66, P537, DOI 10.1080/09553009414551581; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Ryan LA, 2008, RADIAT RES, V169, P188, DOI 10.1667/RR1141.1; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Shao C, 2008, ONCOGENE, V27, P434, DOI 10.1038/sj.onc.1210653; Shao C, 2003, CANCER RES, V63, P8437; Shao C, 2002, INT J RADIAT BIOL, V78, P837, DOI 10.1080/09553000210149786; Shao C, 2008, MUTAT RES-FUND MOL M, V638, P139, DOI 10.1016/j.mrfmmm.2007.09.007; Smilenov LB, 2006, RADIAT PROT DOSIM, V122, P256, DOI 10.1093/rpd/ncl461; Sokolov MV, 2005, ONCOGENE, V24, P7257, DOI 10.1038/sj.onc.1208886; Suchowerska N, 2005, PHYS MED BIOL, V50, P3041, DOI 10.1088/0031-9155/50/13/005; Syme A, 2009, PHYS MED BIOL, V54, P6623, DOI 10.1088/0031-9155/54/21/012; Tartier L, 2007, CANCER RES, V67, P5872, DOI 10.1158/0008-5472.CAN-07-0188; Tomita M, 2010, RADIAT RES, V173, P380, DOI 10.1667/RR1995.1; Trainor C, 2012, RADIAT RES, V177, P44, DOI 10.1667/RR2656.1; Yang HY, 2007, RADIAT RES, V168, P292, DOI 10.1667/RR0864.1; Yang HY, 2005, ONCOGENE, V24, P2096, DOI 10.1038/sj.onc.1208439	29	39	39	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 17	2012	7	8							e43326	10.1371/journal.pone.0043326	http://dx.doi.org/10.1371/journal.pone.0043326			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	996DG	22912853	Green Published, Green Submitted, gold			2023-01-03	WOS:000308063700081
J	ter Horst, AC; Cole, J; van Lier, R; Steenbergen, B				ter Horst, Arjan C.; Cole, Jonathan; van Lier, Rob; Steenbergen, Bert			The Effect of Chronic Deafferentation on Mental Imagery: A Case Study	PLOS ONE			English	Article							MOTOR IMAGERY; CORTICOSPINAL EXCITABILITY; HAND RECOGNITION; VISUO-MOTOR; ROTATION; ANESTHESIA; POSTURE; REPRESENTATIONS; INTEGRATION; STRATEGIES	Visual- and motor imagery rely primarily on perceptual and motor processes, respectively. In healthy controls, the type of imagery used to solve a task depends on personal preference, task instruction, and task properties. But how does the chronic loss of proprioceptive and tactile sensory inputs from the body periphery influence mental imagery? In a unique case study, we investigated the imagery capabilities of the chronically deafferented patient IW when he was performing a mental rotation task. We found that IW's motor imagery processes were impaired and that visual imagery processes were enhanced compared to controls. These results suggest that kinaesthetic afferent signals from the body periphery play a crucial role in enabling and maintaining central sensorimotor representations and hence the ability to incorporate kinaesthetic information into the imagery processes.	[ter Horst, Arjan C.; van Lier, Rob; Steenbergen, Bert] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, NL-6525 ED Nijmegen, Netherlands; [ter Horst, Arjan C.; Steenbergen, Bert] Radboud Univ Nijmegen, Inst Behav Sci, NL-6525 ED Nijmegen, Netherlands; [Cole, Jonathan] Bournemouth Univ, Poole Hosp, Poole BH12 5BB, Dorset, England	Radboud University Nijmegen; Radboud University Nijmegen; Bournemouth University; Poole Hospital	ter Horst, AC (corresponding author), Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, NL-6525 ED Nijmegen, Netherlands.	a.terhorst@donders.ru.nl	van Lier, Rob/E-1654-2012	van Lier, Rob/0000-0002-4705-5725; Steenbergen, Bert/0000-0001-8863-2624				Bosbach S, 2005, NAT NEUROSCI, V8, P1295, DOI 10.1038/nn1535; Bosbach S, 2006, NEUROPSYCHOLOGIA, V44, P2950, DOI 10.1016/j.neuropsychologia.2006.06.018; Cole C, 1998, BODY SELF; COLE JD, 1992, J PHYSIOL-LONDON, V449, P503, DOI 10.1113/jphysiol.1992.sp019099; Curtze C, 2009, EXP BRAIN RES; de Lange FP, 2008, CORTEX, V44, P494, DOI 10.1016/j.cortex.2007.09.002; de Lange FP, 2006, NEUROIMAGE, V33, P609, DOI 10.1016/j.neuroimage.2006.07.017; de Lange FP, 2005, J COGNITIVE NEUROSCI, V17, P97, DOI 10.1162/0898929052880039; de Vignemont F, 2005, CURR BIOL, V15, P1286, DOI 10.1016/j.cub.2005.06.067; de Vignemont F, 2010, NEUROPSYCHOLOGIA, V48, P669, DOI 10.1016/j.neuropsychologia.2009.09.022; Decety J, 1996, BEHAV BRAIN RES, V72, P127; Decety J, 1996, BEHAV BRAIN RES, V77, P45, DOI 10.1016/0166-4328(95)00225-1; Funk M, 2008, J INT NEUROPSYCH SOC, V14, P81, DOI 10.1017/S1355617708080041; Gandevia SC, 1999, J PHYSIOL-LONDON, V514, P609, DOI 10.1111/j.1469-7793.1999.609ae.x; Gentilucci M, 1998, COGNITIVE BRAIN RES, V6, P185, DOI 10.1016/S0926-6410(97)00034-7; Grush R, 2004, BEHAV BRAIN SCI, V27, P377, DOI 10.1017/S0140525X04000093; Guillot A., 2010, NEUROPHYSIOLOGICAL F; Heil M, 2002, PSYCHOPHYSIOLOGY, V39, P414, DOI 10.1017/S0048577202001105; Helmich RC, 2007, NEUROPSYCHOLOGIA, V45, P2201, DOI 10.1016/j.neuropsychologia.2007.02.024; Ionta S, 2007, EXP BRAIN RES, V183, P1, DOI 10.1007/s00221-007-1020-2; Ionta S, 2009, EXP BRAIN RES, V195, P207, DOI 10.1007/s00221-009-1770-0; Jeannerod M, 2001, NEUROIMAGE, V14, pS103, DOI 10.1006/nimg.2001.0832; Karadi K, 2001, PERCEPT MOTOR SKILL, V93, P333, DOI 10.2466/PMS.93.5.333-337; Maravita A, 2003, CURR BIOL, V13, pR531, DOI 10.1016/S0960-9822(03)00449-4; Martucci KT, 2011, ANESTHESIOLOGY, V114, P21, DOI 10.1097/ALN.0b013e3182016521; Mercier C, 2008, CEREB CORTEX, V18, P272, DOI 10.1093/cercor/bhm052; Miall RC, 2007, EXP BRAIN RES, V176, P432, DOI 10.1007/s00221-006-0626-0; Miall RC, 1995, EXP BRAIN RES, V107, P267; Munzert J, 2009, BRAIN RES REV, V60, P306, DOI 10.1016/j.brainresrev.2008.12.024; Nico D, 2004, BRAIN, V127, P120, DOI 10.1093/brain/awh006; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Olsson CJ, 2010, SCAND J MED SCI SPOR, V20, P711, DOI 10.1111/j.1600-0838.2010.01101.x; PARSONS LM, 1994, J EXP PSYCHOL HUMAN, V20, P709, DOI 10.1037/0096-1523.20.4.709; PARSONS LM, 1987, COGNITIVE PSYCHOL, V19, P178, DOI 10.1016/0010-0285(87)90011-9; SEKIYAMA K, 1982, PERCEPT PSYCHOPHYS, V32, P89, DOI 10.3758/BF03204268; Silva S, 2011, ANESTHESIOLOGY, V114, P126, DOI 10.1097/ALN.0b013e31820164f1; ter Horst AC, 2012, PSYCHOPHYSIOLOGY, V49, P566, DOI 10.1111/j.1469-8986.2011.01322.x; ter Horst AC, 2011, EXP BRAIN RES, V212, P635, DOI 10.1007/s00221-011-2748-2; ter Horst AC, 2010, EXP BRAIN RES, V203, P347, DOI 10.1007/s00221-010-2235-1; Tomasino B, 2004, J COGNITIVE NEUROSCI, V16, P878, DOI 10.1162/089892904970753; Tsakiris M, 2005, J EXP PSYCHOL HUMAN, V31, P80, DOI 10.1037/0096-1523.31.1.80; Vargas CD, 2004, CEREB CORTEX, V14, P1200, DOI 10.1093/cercor/bhh080; Ziemann U, 1998, J NEUROSCI, V18, P1115	43	21	22	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 7	2012	7	8							e42742	10.1371/journal.pone.0042742	http://dx.doi.org/10.1371/journal.pone.0042742			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	987SL	22880095	Green Published, gold, Green Accepted			2023-01-03	WOS:000307437900052
J	Lehtinen, J; Raki, M; Bergstrom, KA; Uutela, P; Lehtinen, K; Hiltunen, A; Pikkarainen, J; Liang, HM; Pitkanen, S; Maatta, AM; Ketola, RA; Yliperttula, M; Wirth, T; Urtti, A				Lehtinen, Julia; Raki, Mari; Bergstrom, Kim A.; Uutela, Paivi; Lehtinen, Katariina; Hiltunen, Annukka; Pikkarainen, Jere; Liang, Huamin; Pitkanen, Sari; Maatta, Ann-Marie; Ketola, Raimo A.; Yliperttula, Marjo; Wirth, Thomas; Urtti, Arto			Pre-Targeting and Direct Immunotargeting of Liposomal Drug Carriers to Ovarian Carcinoma	PLOS ONE			English	Article							AVIDIN-BIOTIN TECHNOLOGY; PRETARGETED RADIOIMMUNOTHERAPY; IN-VITRO; MONOCLONAL-ANTIBODIES; PEGYLATED LIPOSOMES; COATED LIPOSOMES; ANTITUMOR DRUGS; SOLID TUMORS; MOUSE MODEL; CANCER	Background: Epidermal growth factor receptor (EGFR) is overexpressed in many solid tumor types, such as ovarian carcinoma. Immunoliposome based drug targeting has shown promising results in drug delivery to the tumors. However, the ratio of tumor-to-normal tissue concentrations should be increased to minimize the adverse effects of cytostatic drugs. Methodology/Principal Findings: We studied the EGFR-targeted doxorubicin immunoliposomes using pre-targeting and local intraperitoneal (i.p.) administration of the liposomes. This approach was used to increase drug delivery to tumors as compared to direct intravenous (i.v.) administration of liposomes. EGFR antibodies were attached on the surface of PEG coated liposomes using biotin-neutravidin binding. Receptor mediated cellular uptake and cytotoxic efficacy of EGFR-targeted liposomes were investigated in human ovarian adenocarcinoma (SKOV-3 and SKOV3.ip1) cells. In vivo distribution of the liposomes in mice was explored using direct and pre-targeting approaches and SPECT/CT imaging. Targeted liposomes showed efficient and specific receptor-mediated binding to ovarian carcinoma cells in vitro, but the difference in cytotoxicity between targeted and non-targeted liposomes remained small. The relatively low cytotoxic efficacy is probably due to insufficient doxorubicin release from the liposomes rather than lack of target binding. Tumor uptake of targeted liposomes in vivo was comparable to that of non-targeted liposomes after both direct and pre-targeting administration. For both EGFR-targeted and non-targeted liposomes, the i.p. administration increased liposome accumulation to the tumors compared to i.v. injections. Conclusions/Significance: Intraperitoneal administration of liposomes may be a beneficial approach to treat the tumors in the abdominal cavity. The i.p. pre-targeting method warrants further studies as a potential approach in cancer therapy.	[Lehtinen, Julia; Raki, Mari; Bergstrom, Kim A.; Uutela, Paivi; Ketola, Raimo A.; Urtti, Arto] Univ Helsinki, Ctr Drug Res, Fac Pharm, Helsinki, Finland; [Lehtinen, Julia; Lehtinen, Katariina; Hiltunen, Annukka; Liang, Huamin; Yliperttula, Marjo] Univ Helsinki, Div Biopharm & Pharmacokinet, Fac Pharm, Helsinki, Finland; [Pikkarainen, Jere; Maatta, Ann-Marie] Ark Therapeut, Kuopio, Finland; [Pikkarainen, Jere; Wirth, Thomas] Univ Eastern Finland, Dept Biotechnol & Mol Med, Kuopio, Finland; [Pitkanen, Sari] Univ Eastern Finland, Dept Biosci, Kuopio, Finland	University of Helsinki; University of Helsinki; University of Eastern Finland; University of Eastern Finland	Lehtinen, J (corresponding author), Univ Helsinki, Ctr Drug Res, Fac Pharm, Helsinki, Finland.	julia.lehtinen@helsinki.fi	Liang, Huamin/B-9909-2011	Liang, Huamin/0000-0001-8688-7404; Viitala, Sari/0000-0002-1401-3406; Kurkipuro, Jere/0000-0002-5239-6532	Ark Therapeutics (Kuopio, Finland); Finnish Funding Agency for Technology and Innovation (Helsinki, Finland); Finnish Cultural Foundation (Helsinki, Finland); TEKES	Ark Therapeutics (Kuopio, Finland); Finnish Funding Agency for Technology and Innovation (Helsinki, Finland)(Finnish Funding Agency for Technology & Innovation (TEKES)); Finnish Cultural Foundation (Helsinki, Finland)(Finnish Cultural Foundation); TEKES(Finnish Funding Agency for Technology & Innovation (TEKES))	This research was funded by Ark Therapeutics (Kuopio, Finland; www.arktherapeutics.com), TEKES, the Finnish Funding Agency for Technology and Innovation (Helsinki, Finland; www.tekes.fi) and the Finnish Cultural Foundation (Helsinki, Finland; www.skr.fi). The public funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Company funder, Ark Therapeutics, participated in study design and performed one of the animal experiments.	Axworthy DB, 2000, P NATL ACAD SCI USA, V97, P1802, DOI 10.1073/pnas.97.4.1802; Boerman OC, 2003, J NUCL MED, V44, P400; Bolotin Elijah M., 1994, Journal of Liposome Research, V4, P455, DOI 10.3109/08982109409037057; Chen LC, 2007, NUCL MED BIOL, V34, P415, DOI 10.1016/j.nucmedbio.2007.02.003; Chuang KH, 2010, MOL CANCER THER, V9, P1903, DOI 10.1158/1535-7163.MCT-09-0899; DEJONG J, 1993, TRAC-TREND ANAL CHEM, V12, P422, DOI 10.1016/0165-9936(93)80006-6; Forero A, 2004, BLOOD, V104, P227, DOI 10.1182/blood-2003-09-3284; GABIZON A, 1994, CANCER RES, V54, P987; Gabizon A, 1999, BIOCONJUGATE CHEM, V10, P289, DOI 10.1021/bc9801124; Goins Beth A., 2003, P319; Hamblett KJ, 2005, BIOCONJUGATE CHEM, V16, P131, DOI 10.1021/bc034049g; Harding JA, 1997, BBA-BIOMEMBRANES, V1327, P181, DOI 10.1016/S0005-2736(97)00056-4; Hsieh YJ, 2008, INT J PHARM, V350, P265, DOI 10.1016/j.ijpharm.2007.09.002; Huhtala T, 2010, NUCL MED BIOL, V37, P957, DOI 10.1016/j.nucmedbio.2010.03.001; Ishida T, 2006, INT J PHARM, V309, P94, DOI 10.1016/j.ijpharm.2005.11.010; Kirchmeier MJ, 2001, J LIPOSOME RES, V11, P15, DOI 10.1081/LPR-100103167; Kirpotin DB, 2006, CANCER RES, V66, P6732, DOI 10.1158/0008-5472.CAN-05-4199; Kullberg M, 2009, J DRUG TARGET, V17, P98, DOI [10.1080/10611860802471562, 10.1080/10611860802471562 ]; Lee CM, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-255; Lehtinen J, 2008, J CONTROL RELEASE, V131, P145, DOI 10.1016/j.jconrel.2008.07.018; Lehtinen J, 2012, EUR J PHARM SCI, V46, P121, DOI 10.1016/j.ejps.2012.02.009; Lesch HP, 2010, EXPERT OPIN DRUG DEL, V7, P551, DOI 10.1517/17425241003677749; Lin YY, 2009, CANCER BIOTHER RADIO, V24, P453, DOI 10.1089/cbr.2008.0572; Mamot C, 2005, CANCER RES, V65, P11631, DOI 10.1158/0008-5472.CAN-05-1093; Maruyama K, 2011, ADV DRUG DELIVER REV, V63, P161, DOI 10.1016/j.addr.2010.09.003; Mastrobattista E, 1999, ADV DRUG DELIVER REV, V40, P103, DOI 10.1016/S0169-409X(99)00043-5; Nobs L, 2006, BIOCONJUGATE CHEM, V17, P139, DOI 10.1021/bc050137k; Noske A, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-294; Paasonen L, 2007, J CONTROL RELEASE, V122, P86, DOI 10.1016/j.jconrel.2007.06.009; Pan H, 2008, J CONTROL RELEASE, V125, P228, DOI 10.1016/j.jconrel.2007.10.016; Perez-Soler R, 2004, ONCOLOGIST, V9, P58, DOI 10.1634/theoncologist.9-1-58; Phelps SLB, 2008, GYNECOL ONCOL, V109, P411, DOI 10.1016/j.ygyno.2008.02.030; Pulkkinen M, 2008, EUR J PHARM BIOPHARM, V70, P66, DOI 10.1016/j.ejpb.2008.04.018; Sadzuka Y, 1997, CANCER LETT, V111, P77, DOI 10.1016/S0304-3835(96)04513-2; Sharkey RM, 2003, CANCER RES, V63, P354; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Xiao Z, 2002, J BIOTECHNOL, V94, P171, DOI 10.1016/S0168-1656(01)00424-2; YU DH, 1993, CANCER RES, V53, P891; YUAN F, 1995, CANCER RES, V55, P3752; Zalevsky J, 2010, NAT BIOTECHNOL, V28, P157, DOI 10.1038/nbt.1601; Zavaleta CL, 2007, INT J PHARM, V337, P316, DOI 10.1016/j.ijpharm.2007.01.010	42	41	44	0	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 26	2012	7	7							e41410	10.1371/journal.pone.0041410	http://dx.doi.org/10.1371/journal.pone.0041410			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012MO	22844475	Green Submitted, Green Published, gold			2023-01-03	WOS:000309240600026
J	Huang, TT; Ojcius, DM; Young, JD; Wu, YH; Ko, YF; Wong, TY; Wu, CY; Lu, CC; Lai, HC				Huang, Tsung-Teng; Ojcius, David M.; Young, John D.; Wu, Yi-Hui; Ko, Yun-Fei; Wong, Tsui-Yin; Wu, Cheng-Yeu; Lu, Chia-Chen; Lai, Hsin-Chih			The Anti-Tumorigenic Mushroom Agaricus blazei Murill Enhances IL-1 beta Production and Activates the NLRP3 Inflammasome in Human Macrophages	PLOS ONE			English	Article							STREPTOCOCCUS-PNEUMONIAE INFECTION; NALP3 INFLAMMASOME; P2X(7) RECEPTOR; CATHEPSIN-B; BETA-GLUCAN; IN-VITRO; MICE; EXTRACT; SECRETION; RELEASE	Agaricus blazei Murill (AbM) has been reported to possess immune activity against tumors and infections through stimulation of mononuclear phagocytes. Recently, AbM extract was shown to induce the production of the pro-inflammatory cytokine, interleukin-1 beta (IL-1 beta), in human monocytes. IL-1 beta is a key pro-inflammatory cytokine produced by activated macrophages and monocytes and its secretion is strictly controlled by the inflammasome. The purpose of this study is to investigate the effect of AbM water extracts on the regulation of IL-1 beta production and activation of the NLRP3 inflammasome in human THP-1 macrophages. The NLRP3 inflammasome consists of an NLRP3 receptor, an adaptor protein called ASC, and the inflammatory protease, caspase-1. Typically, stimulation of immune cells with microbial products results in production of pro-IL-1 beta, but a second stress-related signal activates the inflammasome and caspase-1, leading to processing and secretion of IL-1 beta. Our results show that AbM enhances transcription of IL-1 beta and triggers NLRP3 inflammasome-mediated IL-1 beta secretion in human THP-1 macrophages. AbM-mediated IL-1 beta secretion was markedly reduced in macrophages deficient in NLRP3 and ASC, demonstrating that the NLRP3 inflammasome is essential for AbM-induced IL-1 beta secretion. In addition, caspase-1 was activated and involved in proteolytic cleavage and secretion of IL-1 beta in AbM-treated macrophages. AbM-mediated IL-1 beta secretion also decreased in cells treated with cathepsin B inhibitor, suggesting that AbM can induce the release of cathepsin B. Furthermore, our data show that AbM-induced inflammasome activation requires the release of ATP, binding of extracellular ATP to the purinergic receptor P2X(7), the generation of reactive oxygen species, and efflux of potassium. Taken together, these findings reveal that AbM activates the NLRP3 inflammasome via multiple mechanisms, resulting in the secretion of IL-1 beta.	[Huang, Tsung-Teng; Ojcius, David M.; Young, John D.; Wong, Tsui-Yin; Wu, Cheng-Yeu; Lai, Hsin-Chih] Chang Gung Univ, Ctr Mol & Clin Immunol, Tao Yuan, Taiwan; [Huang, Tsung-Teng; Lai, Hsin-Chih] Chang Gung Univ, Dept Med Biotechnol & Lab Sci, Coll Med, Tao Yuan, Taiwan; [Huang, Tsung-Teng; Young, John D.; Wong, Tsui-Yin; Wu, Cheng-Yeu] Chang Gung Univ, Lab Nanomat, Tao Yuan, Taiwan; [Huang, Tsung-Teng; Wong, Tsui-Yin; Wu, Cheng-Yeu; Lai, Hsin-Chih] Chang Gung Univ, Res Ctr Bacterial Pathogenesis, Tao Yuan, Taiwan; [Ojcius, David M.] Univ Calif Merced, Hlth Sci Res Inst, Merced, CA USA; [Ojcius, David M.] Univ Calif Merced, Sch Nat Sci, Merced, CA USA; [Young, John D.] Rockefeller Univ, Lab Cellular Physiol & Immunol, New York, NY 10021 USA; [Young, John D.; Ko, Yun-Fei] Mingchi Univ Technol, Biochem Engn Res Ctr, Taipei, Taiwan; [Wu, Yi-Hui] Natl Cheng Kung Univ Hosp, Canc Res Ctr, Tainan 70428, Taiwan; [Lu, Chia-Chen] Fu Jen Catholic Univ, Dept Resp Therapy, Taipei, Taiwan	Chang Gung University; Chang Gung University; Chang Gung University; Chang Gung University; University of California System; University of California Merced; University of California System; University of California Merced; Rockefeller University; Ming Chi University of Technology; National Cheng Kung University; National Cheng Kung University Hospital; Fu Jen Catholic University	Huang, TT (corresponding author), Chang Gung Univ, Ctr Mol & Clin Immunol, Tao Yuan, Taiwan.	hclai@mail.cgu.edu.tw	Ojcius, David/ABE-6557-2020	Ojcius, David/0000-0003-1461-4495; LAI, HSIN-CHIH/0000-0002-0605-5040	National Science Council [NSC100-2321-B-002-009]; Chang Gung Memorial Hospital [CMRPD190302]	National Science Council(Ministry of Science and Technology, Taiwan); Chang Gung Memorial Hospital(Chang Gung Memorial Hospital)	This work was supported by grants from the National Science Council (NSC100-2321-B-002-009) and Chang Gung Memorial Hospital (CMRPD190302). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdul-Sater AA, 2009, J BIOL CHEM, V284, P26789, DOI 10.1074/jbc.M109.026823; Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Bernardshaw S, 2006, SHOCK, V25, P420, DOI 10.1097/01.shk.0000209526.58614.92; Bernardshaw S, 2005, SCAND J IMMUNOL, V62, P393, DOI 10.1111/j.1365-3083.2005.01667.x; Bernardshaw S, 2007, APMIS, V115, P719, DOI 10.1111/j.1600-0463.2007.apm_619.x; Bernardshaw S, 2005, INFLAMMATION, V29, P147, DOI 10.1007/s10753-006-9010-2; Cassel SL, 2008, P NATL ACAD SCI USA, V105, P9035, DOI 10.1073/pnas.0803933105; Church LD, 2008, NAT CLIN PRACT RHEUM, V4, P34, DOI 10.1038/ncprheum0681; Cruz CM, 2007, J BIOL CHEM, V282, P2871, DOI 10.1074/jbc.M608083200; Di Virgilio F, 2007, TRENDS PHARMACOL SCI, V28, P465, DOI 10.1016/j.tips.2007.07.002; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612; Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995; Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938; Ebina T, 1998, BIOTHERAPY, V11, P259, DOI 10.1023/A:1008054111445; Ellertsen LK, 2006, INT IMMUNOPHARMACOL, V6, P133, DOI 10.1016/j.intimp.2005.07.007; Feldmeyer L, 2007, CURR BIOL, V17, P1140, DOI 10.1016/j.cub.2007.05.074; Ferrari D, 2006, J IMMUNOL, V176, P3877, DOI 10.4049/jimmunol.176.7.3877; Firenzuoli F, 2008, EVID-BASED COMPL ALT, V5, P3, DOI 10.1093/ecam/nem007; Forland DT, 2010, CYTOKINE, V49, P245, DOI 10.1016/j.cyto.2009.09.002; Franchi L, 2007, J BIOL CHEM, V282, P18810, DOI 10.1074/jbc.M610762200; Franchi L, 2009, NAT IMMUNOL, V10, P241, DOI 10.1038/ni.1703; Frlan R, 2006, CURR MED CHEM, V13, P2309, DOI 10.2174/092986706777935122; Fujimiya Y, 1998, CANCER IMMUNOL IMMUN, V46, P147, DOI 10.1007/s002620050473; Fujimiya Y, 1999, ANTICANCER RES, V19, P113; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hentze H, 2003, CELL DEATH DIFFER, V10, P956, DOI 10.1038/sj.cdd.4401264; Hetland G, 2008, SCAND J IMMUNOL, V68, P363, DOI 10.1111/j.1365-3083.2008.02156.x; Hetland G, 2000, FEMS IMMUNOL MED MIC, V27, P111, DOI 10.1111/j.1574-695X.2000.tb01420.x; Hetland G, 1998, SCAND J IMMUNOL, V47, P548; Hetland G, 2002, FEMS IMMUNOL MED MIC, V33, P41, DOI 10.1111/j.1574-695X.2002.tb00570.x; Hise AG, 2009, CELL HOST MICROBE, V5, P487, DOI 10.1016/j.chom.2009.05.002; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631; ITOH H, 1994, JPN J PHARMACOL, V66, P265, DOI 10.1254/jjp.66.265; Kankkunen P, 2010, J IMMUNOL, V184, P6335, DOI 10.4049/jimmunol.0903019; KAWAGISHI H, 1989, CARBOHYD RES, V186, P267, DOI 10.1016/0008-6215(89)84040-6; Labasi JM, 2002, J IMMUNOL, V168, P6436, DOI 10.4049/jimmunol.168.12.6436; Lopez-Castejon G, 2010, J IMMUNOL, V185, P2611, DOI 10.4049/jimmunol.1000436; Lutgens SPM, 2007, FASEB J, V21, P3029, DOI 10.1096/fj.06-7924com; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Martinon F, 2007, CELL DEATH DIFFER, V14, P10, DOI 10.1038/sj.cdd.4402038; Martinon F, 2005, TRENDS IMMUNOL, V26, P447, DOI 10.1016/j.it.2005.06.004; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Mizuno M, 1999, BIOCHEM MOL BIOL INT, V47, P707; Nakajima A, 2002, INT IMMUNOPHARMACOL, V2, P1205, DOI 10.1016/S1567-5769(02)00056-5; Petrilli V, 2007, CELL DEATH DIFFER, V14, P1583, DOI 10.1038/sj.cdd.4402195; Petrilli V, 2007, CURR OPIN IMMUNOL, V19, P615, DOI 10.1016/j.coi.2007.09.002; Piccini A, 2008, P NATL ACAD SCI USA, V105, P8067, DOI 10.1073/pnas.0709684105; Qu Y, 2007, J IMMUNOL, V179, P1913, DOI 10.4049/jimmunol.179.3.1913; Said-Sadier N, 2012, CHANG GUNG MED J, V35, P297; Said-Sadier N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010008; Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009; Smiderle FR, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-58; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Sorimachi K, 2001, CELL STRUCT FUNCT, V26, P103, DOI 10.1247/csf.26.103; Stehlik C, 2003, J IMMUNOL, V171, P6154, DOI 10.4049/jimmunol.171.11.6154; Takaku T, 2001, J NUTR, V131, P1409, DOI 10.1093/jn/131.5.1409; Vancompernolle K, 1998, FEBS LETT, V438, P150, DOI 10.1016/S0014-5793(98)01275-7; Wasser SP, 1999, CRIT REV IMMUNOL, V19, P65; Willingham SB, 2007, CELL HOST MICROBE, V2, P147, DOI 10.1016/j.chom.2007.07.009	63	15	18	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2012	7	7							e41383	10.1371/journal.pone.0041383	http://dx.doi.org/10.1371/journal.pone.0041383			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977TM	22844468	gold, Green Published, Green Submitted			2023-01-03	WOS:000306687700079
J	Olson, KL; Mandl, KD				Olson, Karen L.; Mandl, Kenneth D.			Temporal Patterns of Medications Dispensed to Children and Adolescents in a National Insured Population	PLOS ONE			English	Article							PEDIATRIC POPULATION; CLAIMS DATA; DRUG-USE; TRENDS; PRESCRIPTIONS; LIMITATIONS; ADHERENCE; NORWAY; AGE	This study aimed to comprehensively describe prevalence and temporal dispensing patterns for medications prescribed to children and adolescents in the United States. Participants were 1.6 million children (49% female) under 18 years old enrolled in a nation-wide, employer-provided insurance plan. All medication claims from 1999-2006 were reviewed retrospectively. Drugs were assigned to 16 broad therapeutic categories. Effects of trend over time, seasonality, age and gender on overall and within category prevalence were examined. Results: Mean monthly prevalence for dispensed medications was 23.5% (range 19.4-27.5), with highest rates in winter and lowest in July. The age group with the highest prevalence was one-year-old children. On average each month, 17.1% of all children were dispensed a single drug and 6.4% were dispensed two or more. Over time, prevalence for two or more drugs did not change, but the proportion of children dispensed a single drug decreased (slope -.02%, p = .001). Overall, boys had higher monthly rates than girls (average difference 0.9%, p = .002). However, differences by gender were greatest during middle childhood, especially for respiratory and central nervous system agents. Contraceptives accounted for a large proportion of dispensed medication to older teenage girls. Rates for the drugs with the highest prevalence in this study were moderately correlated (average Pearson r.66) with those from a previously published national survey. Conclusion: On average, nearly one quarter of a population of insured children in the United States was dispensed medication each month. This rate decreased somewhat over time, primarily because proportionally fewer children were dispensed a single medication. The rate for two or more drugs dispensed simultaneously remained steady.	[Olson, Karen L.; Mandl, Kenneth D.] Childrens Hosp, Informat Program, Harvard MIT Hlth Sci & Technol, Div Emergency Med, Boston, MA 02115 USA; [Olson, Karen L.; Mandl, Kenneth D.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Olson, KL (corresponding author), Childrens Hosp, Informat Program, Harvard MIT Hlth Sci & Technol, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	karen.olson@childrens.harvard.edu			National Library of Medicine, National Institutes of Health [R01 LM007677]; NATIONAL LIBRARY OF MEDICINE [R01LM007677] Funding Source: NIH RePORTER	National Library of Medicine, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	This work was supported by R01 LM007677 from the National Library of Medicine, National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ackers R, 2009, ARCH DIS CHILD, V94, P443, DOI 10.1136/adc.2008.144386; Berg C, 2009, NORWEGIAN PRESCRIPTI; Blix HS, 2007, J ANTIMICROB CHEMOTH, V59, P971, DOI 10.1093/jac/dkm032; Christensen L, 2010, CURR MED RES OPIN, V26, P977, DOI 10.1185/03007991003673617; Clavenna A, 2009, EUR J PEDIATR, V168, P173, DOI 10.1007/s00431-008-0725-y; Clavenna A, 2009, EUR J CLIN PHARMACOL, V65, P749, DOI 10.1007/s00228-009-0679-7; Cox ER, 2008, PEDIATRICS, V122, pE1053, DOI 10.1542/peds.2008-0214; Crystal S, 2007, MED CARE, V45, pS58, DOI 10.1097/MLR.0b013e31805371bf; Ellis Alan R, 2010, N C Med J, V71, P9; Fredheim OMS, 2010, PEDIATR ANESTH, V20, P537, DOI 10.1111/j.1460-9592.2010.03310.x; Hameen-Anttila K, 2010, PHARMACOEPIDEM DR S, V19, P400, DOI 10.1002/pds.1887; Hassanin Hanan, 2010, Hawaii Med J, V69, P17; Jain R, 2011, J AM ACAD CHILD PSY, V50, P171, DOI 10.1016/j.jaac.2010.11.005; Karlstad O, 2010, EUR J CLIN PHARMACOL, V66, P399, DOI 10.1007/s00228-009-0749-x; Karve S, 2008, MED CARE, V46, P1125, DOI 10.1097/MLR.0b013e31817924d2; Lasky T, 2009, CLIN THER, V31, P436, DOI 10.1016/j.clinthera.2009.02.003; May DE, 2010, DRUGS, V70, P15, DOI 10.2165/11530540-000000000-00000; Olfson M, 2002, J AM ACAD CHILD PSY, V41, P514, DOI 10.1097/00004583-200205000-00008; Olfson M, 2010, J AM ACAD CHILD PSY, V49, P13, DOI 10.1016/j.jaac.2009.09.003; Olfson M, 2009, ARCH GEN PSYCHIAT, V66, P848, DOI 10.1001/archgenpsychiatry.2009.81; Pathak P, 2010, PSYCHIAT SERV, V61, P123, DOI 10.1176/ps.2010.61.2.123; Simpson SH, 2006, BMJ-BRIT MED J, V333, P15, DOI 10.1136/bmj.38875.675486.55; Tournier M, 2010, PSYCHIAT RES, V179, P57, DOI 10.1016/j.psychres.2010.06.007; Vernacchio L, 2009, PEDIATRICS, V124, P446, DOI 10.1542/peds.2008-2869; Waxmonsky James G, 2005, Essent Psychopharmacol, V6, P262	25	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 19	2012	7	7							e40991	10.1371/journal.pone.0040991	http://dx.doi.org/10.1371/journal.pone.0040991			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981GZ	22829905	Green Published, gold, Green Submitted			2023-01-03	WOS:000306956300043
J	Neoptolemos, JP; Moore, MJ; Cox, TF; Valle, JW; Palmer, DH; McDonald, AC; Carter, R; Tebbutt, NC; Dervenis, C; Smith, D; Glimelius, B; Charnley, RM; Lacaine, F; Scarfe, AG; Middleton, MR; Anthoney, A; Ghaneh, P; Halloran, CM; Lerch, MM; Olah, A; Rawcliffe, CL; Verbeke, CS; Campbell, F; Buchler, MW				Neoptolemos, John P.; Moore, Malcolm J.; Cox, Trevor F.; Valle, Juan W.; Palmer, Daniel H.; McDonald, Alexander C.; Carter, Ross; Tebbutt, Niall C.; Dervenis, Christos; Smith, David; Glimelius, Bengt; Charnley, Richard M.; Lacaine, Francois; Scarfe, Andrew G.; Middleton, Mark R.; Anthoney, Alan; Ghaneh, Paula; Halloran, Christopher M.; Lerch, Markus M.; Olah, Attila; Rawcliffe, Charlotte L.; Verbeke, Caroline S.; Campbell, Fiona; Buechler, Markus W.		European Study Grp Pancreatic Canc	Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma The ESPAC-3 Periampullary Cancer Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PANCREATIC-CANCER; AMPULLARY CARCINOMA; PROGNOSTIC-FACTORS; TRACT CANCER; PANCREATICODUODENECTOMY; CHEMORADIOTHERAPY; DIFFERENTIATION	Context Patients with periampullary adenocarcinomas undergo the same resectional surgery as that of patients with pancreatic ductal adenocarcinoma. Although adjuvant chemotherapy has been shown to have a survival benefit for pancreatic cancer, there have been no randomized trials for periampullary adenocarcinomas. Objective To determine whether adjuvant chemotherapy (fluorouracil or gemcitabine) provides improved overall survival following resection. Design, Setting, and Patients The European Study Group for Pancreatic Cancer (ESPAC)-3 periampullary trial, an open-label, phase 3, randomized controlled trial (July 2000-May 2008) in 100 centers in Europe, Australia, Japan, and Canada. Of the 428 patients included in the primary analysis, 297 had ampullary, 96 had bile duct, and 35 had other cancers. Interventions One hundred forty-four patients were assigned to the observation group, 143 patients to receive 20 mg/m(2) of folinic acid via intravenous bolus injection followed by 425 mg/m(2) of fluorouracil via intravenous bolus injection administered 1 to 5 days every 28 days, and 141 patients to receive 1000 mg/m(2) of intravenous infusion of gemcitabine once a week for 3 of every 4 weeks for 6 months. Main Outcome Measures The primary outcome measure was overall survival with chemotherapy vs no chemotherapy; secondary measures were chemotherapy type, toxic effects, progression-free survival, and quality of life. Results Eighty-eight patients (61%) in the observation group, 83 (58%) in the fluorouracil plus folinic acid group, and 73 (52%) in the gemcitabine group died. In the observation group, the median survival was 35.2 months (95%% CI, 27.2-43.0 months) and was 43.1 (95%, CI, 34.0-56.0) in the 2 chemotherapy groups (hazard ratio, 0.86; (95% CI, 0.66-1.11; chi(2)=1.33; P=.25). After adjusting for independent prognostic variables of age, bile duct cancer, poor tumor differentiation, and positive lymph nodes and after conducting multiple regression analysis, the hazard ratio for chemotherapy compared with observation was 0.75 (95% CI, 0.57-0.98; Wald chi(2)=4.53, P=.03). Conclusions Among patients with resected periampullary adenocarcinoma, adjuvant chemotherapy, compared with observation, was not associated with a significant survival benefit in the primary analysis; however, multivariable analysis adjusting for prognostic variables demonstrated a statistically significant survival benefit associated with adjuvant chemotherapy	[Neoptolemos, John P.; Cox, Trevor F.; Ghaneh, Paula; Halloran, Christopher M.; Rawcliffe, Charlotte L.; Campbell, Fiona] Univ Liverpool, Canc Res United Kingdom Ctr, Liverpool Canc Trials Unit, Inst Translat Med, Liverpool L69 3GA, Merseyside, England; [Moore, Malcolm J.] Princess Margaret Hosp, Dept Med, Div Med Oncol & Hematol, Toronto, ON M4X 1K9, Canada; [Valle, Juan W.] Univ Manchester, Sch Canc & Enabling Sci, Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester M13 9PL, Lancs, England; [Palmer, Daniel H.] Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp, Sch Canc Sci, Canc Res UK Inst Canc Studies, Birmingham, W Midlands, England; [McDonald, Alexander C.] Beatson W Scotland Canc Ctr, Glasgow, Lanark, Scotland; [Carter, Ross] Glasgow Royal Infirm, Dept Surg, Glasgow G4 0SF, Lanark, Scotland; [Tebbutt, Niall C.] Austin Hlth, Ludwig Oncol Unit, Melbourne, Vic, Australia; [Dervenis, Christos] Agia Olga Hosp, Dept Surg, Athens, Greece; [Smith, David] Clatterbridge Ctr Oncol, Bebington, Merseyside, England; [Glimelius, Bengt] Uppsala Univ, Akad Sjukhuset, Dept Oncol, Uppsala, Sweden; [Charnley, Richard M.] Freeman Rd Hosp, Dept Surg, Newcastle Upon Tyne, Tyne & Wear, England; [Lacaine, Francois] Hop Tenon, Serv Chirurg Digest & Viscerale, F-75970 Paris, France; [Scarfe, Andrew G.] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada; [Middleton, Mark R.] Oxford Univ Hosp NHS Trust, Churchill Hosp, Dept Oncol, Oxford, England; [Anthoney, Alan] St James Univ Hosp, Dept Oncol, Leeds, W Yorkshire, England; [Lerch, Markus M.] Ernst Moritz Arndt Univ Greifswald, Dept Med, Greifswald, Germany; [Olah, Attila] Petz Aladar Hosp, Dept Surg, Gyor, Hungary; [Verbeke, Caroline S.] Karolinska Univ Hosp, Dept Pathol, Stockholm, Sweden; [Buechler, Markus W.] Heidelberg Univ, Dept Surg, D-6900 Heidelberg, Germany	University of Liverpool; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Christie NHS Foundation Trust; University of Manchester; Cancer Research UK; University of Birmingham; Beatson Oncology Centre; University of Glasgow; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Ludwig Institute for Cancer Research; General Hospital of N. Ionia Agia Olga; Clatterbridge Cancer Centre; Uppsala University; Uppsala University Hospital; Newcastle Freeman Hospital; Newcastle University - UK; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Alberta; Oxford University Hospitals NHS Foundation Trust; University of Oxford; Saint James's University Hospital; Ernst Moritz Arndt Universitat Greifswald; Karolinska Institutet; Karolinska University Hospital; Ruprecht Karls University Heidelberg	Neoptolemos, JP (corresponding author), Univ Liverpool, Canc Res United Kingdom Ctr, Liverpool Canc Trials Unit, Inst Translat Med, UCD Bldg,Daulby St,5th Floor, Liverpool L69 3GA, Merseyside, England.	j.p.neoptolemos@liverpool.ac.uk	Lerch, Markus M./E-2206-2016; Neoptolemos, John/HGU-7742-2022; Ibrahimov, Vagif/Q-1537-2015; Ibrahimov, Vagif R/U-2211-2017; Cox, Trevor F/E-5567-2013; Imanova, Mehriban M/F-9290-2016; Ibrahimov, Vagif/M-3971-2019; Valle, Juan W/J-3571-2015; Wyld, David/B-8893-2015	Lerch, Markus M./0000-0002-9643-8263; Ibrahimov, Vagif R/0000-0002-9148-4711; Imanova, Mehriban M/0000-0002-5383-8216; Ibrahimov, Vagif/0000-0002-9148-4711; Valle, Juan W/0000-0002-1999-0863; Halloran, Christopher/0000-0002-5471-4178; Spry, Nigel/0000-0001-8659-5065; Oza, Amit/0000-0002-9510-8641; Foukakis, Theodoros/0000-0001-8952-9987; Neoptolemos, John/0000-0002-6201-7399; Cox, Trevor/0000-0003-3045-5594; Katsourakis, Anastasios/0000-0002-5151-9449; Middleton, Gary/0000-0001-5695-3474; Madhusudan, Srinivasan/0000-0002-5354-5480; Wyld, David/0000-0001-9523-4333; Segersvard, Ralf/0000-0002-5702-7971	Cancer Research United Kingdom; National Cancer Institute of Canada, Canadian Cancer Society; Fonds de Recherche de la Societe Nationale Francaise de Gastroenterologie; Fondazioone Italiana Malattie del Pancreas; Health and Medical Research Council of Australia; Cancer Council of New South Wales; Cancer Council of Queensland; Cancer Council of Victoria; Cancer Council of South Australia; Australasian Gastro-Intestinal Trials Group; Liverpool NIHR Pancreas Biomedical Research Unit; Oxford NIHR Biomedical Research Centre; Cancer Research UK [11883, 8968] Funding Source: researchfish; National Institute for Health Research [NF-SI-0510-10126, 08/29/02] Funding Source: researchfish	Cancer Research United Kingdom(Cancer Research UK); National Cancer Institute of Canada, Canadian Cancer Society; Fonds de Recherche de la Societe Nationale Francaise de Gastroenterologie; Fondazioone Italiana Malattie del Pancreas; Health and Medical Research Council of Australia; Cancer Council of New South Wales(Cancer Council New South Wales); Cancer Council of Queensland(Cancer Council Queensland); Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Cancer Council of South Australia(Cancer Council South Australia); Australasian Gastro-Intestinal Trials Group; Liverpool NIHR Pancreas Biomedical Research Unit; Oxford NIHR Biomedical Research Centre(National Institute for Health Research (NIHR)); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))	The study was supported by Cancer Research United Kingdom; National Cancer Institute of Canada, Canadian Cancer Society; Fonds de Recherche de la Societe Nationale Francaise de Gastroenterologie; Fondazioone Italiana Malattie del Pancreas; Health and Medical Research Council of Australia, Cancer Councils of New South Wales, Queensland, Victoria and South Australia and The Australasian Gastro-Intestinal Trials Group. JPN is part funded Liverpool NIHR Pancreas Biomedical Research Unit. MM is part funded Oxford NIHR Biomedical Research Centre.	Albores-Saavedra J, 2009, J SURG ONCOL, V100, P598, DOI 10.1002/jso.21374; [Anonymous], 1997, J CLIN PATHOL; Berberat PO, 2009, EJSO-EUR J SURG ONC, V35, P187, DOI 10.1016/j.ejso.2008.01.030; Carter R, 2009, INT J CANCER, V124, P2960, DOI 10.1002/ijc.24270; COX DR, 1972, J R STAT SOC B, V34, P187; de Castro SMM, 2004, J GASTROINTEST SURG, V8, P775, DOI 10.1016/j.gassur.2004.08.006; Ehehalt F, 2011, ANN SURG, V254, P302, DOI 10.1097/SLA.0b013e31821994a8; Hatzaras I, 2010, ANN SURG ONCOL, V17, P991, DOI 10.1245/s10434-009-0883-9; Henson DE, 2009, ARCH PATHOL LAB MED, V133, P67, DOI 10.1043/1543-2165-133.1.67; Hruban RH, 2010, WHO CLASSIFICATION T, P87; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Klinkenbijl JH, 1999, ANN SURG, V230, P776, DOI 10.1097/00000658-199912000-00006; Neoptolemos JP, 2010, JAMA-J AM MED ASSOC, V304, P1073, DOI 10.1001/jama.2010.1275; Neoptolemos JP, 2001, LANCET, V358, P1576, DOI 10.1016/S0140-6736(01)06651-X; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; O'Connell JB, 2008, ANN SURG ONCOL, V15, P1820, DOI 10.1245/s10434-008-9886-1; Pedrazzoli Sergio, 1999, Digestive Surgery, V16, P337, DOI 10.1159/000018744; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; Riall TS, 2006, SURGERY, V140, P764, DOI 10.1016/j.surg.2006.04.006; Riall TS, 2005, J GASTROINTEST SURG, V9, P1191, DOI 10.1016/j.gassur.2005.08.034; Schonleben F, 2009, J GASTROINTEST SURG, V13, P1510, DOI 10.1007/s11605-009-0917-4; Sessa F, 2007, VIRCHOWS ARCH, V451, P649, DOI 10.1007/s00428-007-0444-1; Showalter TN, 2011, J GASTROINTEST SURG, V15, P1411, DOI 10.1007/s11605-011-1518-6; Smith RA, 2008, J GASTROINTEST SURG, V12, P1422, DOI 10.1007/s11605-008-0554-3; Valle J, 2010, NEW ENGL J MED, V362, P1273, DOI 10.1056/NEJMoa0908721; Westgaard A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-5; Westgaard A, 2009, HISTOPATHOLOGY, V54, P337, DOI 10.1111/j.1365-2559.2009.03227.x; Winter JM, 2010, J GASTROINTEST SURG, V14, P379, DOI 10.1007/s11605-009-1080-7	28	381	398	1	34	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2012	308	2					147	156		10.1001/jama.2012.7352	http://dx.doi.org/10.1001/jama.2012.7352			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	971QS	22782416				2023-01-03	WOS:000306219500028
J	Tsai, J; Grosse, SD; Grant, AM; Reyes, NL; Hooper, WC; Atrash, HK				Tsai, James; Grosse, Scott D.; Grant, Althea M.; Reyes, Nimia L.; Hooper, W. Craig; Atrash, Hani K.			Correlates of In-Hospital Deaths among Hospitalizations with Pulmonary Embolism: Findings from the 2001-2008 National Hospital Discharge Survey	PLOS ONE			English	Article							CASE-FATALITY RATE; VENOUS THROMBOEMBOLISM RISK; QUALITY-OF-LIFE; THROMBOLYTIC THERAPY; UNITED-STATES; EPIDEMIOLOGY; DIAGNOSIS; MORTALITY; CARE; MULTIMORBIDITY	Background: Deep vein thrombosis and pulmonary embolism (PE) are responsible for substantial mortality, morbidity, and impaired health-related quality of life. The aim of this study was to evaluate the correlates of in-hospital deaths among hospitalizations with a diagnosis of PE in the United States. Methods: By using data from the 2001-2008 National Hospital Discharge Survey, we assessed the correlates of in-hospital deaths among 14,721 hospitalizations with a diagnosis of PE and among subgroups stratified by age, sex, race, days of hospital stay, type of admission, cancer, pneumonia, and fractures. We produced adjusted rate ratios (aRR) and 95% confidence intervals using log-linear multivariate regression models. Results: Regardless of the listing position of diagnostic codes, we observed an increased likelihood of in-hospital death in subgroups of hospitalizations with ages 50 years and older (aRR = 1.82-8.48), less than 7 days of hospital stay (aRR = 1.43-1.57), cancer (aRR = 2.10-2.28), pneumonia (aRR = 1.79-2.20), or fractures (aRR = 2.18) (except for first-listed PE), when compared to the reference groups with ages 1-49 years, 7 days or more of hospital stay, without cancer, pneumonia, or fractures while adjusting for covariates. In addition, we observed an increased likelihood of in-hospital death for first-listed PE in hospitalizations of women, when compared to those of men (aRR = 1.45). Conclusions: The results of this study provide support for identifying, developing, and implementing effective, evidence-based clinical assessment and management strategies to reduce PE-related morbidity and mortality among hospitalized PE patients who may have concurrent health conditions including cancer, pneumonia, and fractures.	[Tsai, James; Grosse, Scott D.; Grant, Althea M.; Reyes, Nimia L.; Hooper, W. Craig; Atrash, Hani K.] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Tsai, J (corresponding author), Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA.	jxt9@cdc.gov		Grosse, Scott/0000-0003-1078-6855; Tsai, James/0000-0002-3114-124X				Abunasser Jafar, 2012, Conn Med, V76, P5; Agnelli G, 2010, NEW ENGL J MED, V363, P266, DOI 10.1056/NEJMra0907731; Alikhan R, 2004, ARCH INTERN MED, V164, P963, DOI 10.1001/archinte.164.9.963; Alikhan R, 2004, J CLIN PATHOL, V57, P1254, DOI 10.1136/jcp.2003.013581; [Anonymous], 2010, MULT CHRON COND STRA; Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716; Boyd CM, 2010, PUBLIC HEALTH REV, V32, P451, DOI 10.1007/BF03391611; Brogan D, 2005, ENCY BIOSTATISTICS, V8-Set, P5057; CDC, 2010, NAT HLTH STAT REP; CDC/National Center for Health Statistics, 2011, NAT HOSP DISCH SURV; Chughtai HL, 2011, CLIN APPL THROMB-HEM, V17, P656, DOI 10.1177/1076029611405033; Cohen AT, 2005, THROMB HAEMOSTASIS, V94, P750, DOI 10.1160/TH05-06-0385; Cushman M, 2007, SEMIN HEMATOL, V44, P62, DOI 10.1053/j.seminhematol.2007.02.004; DeMonaco NA, 2008, AM J MED, V121, P611, DOI 10.1016/j.amjmed.2008.02.035; DHHS, 2008, SURG GEN CALL ACT PR; Douma RA, 2010, NAT REV CARDIOL, V7, P585, DOI 10.1038/nrcardio.2010.106; Fortin M, 2007, BMJ-BRIT MED J, V334, P1016, DOI 10.1136/bmj.39201.463819.2C; Geerts W, 2009, J THROMB HAEMOST, V7, P1, DOI 10.1111/j.1538-7836.2009.03384.x; Goldhaber SZ, 2010, J AM COLL CARDIOL, V56, P1, DOI 10.1016/j.jacc.2010.01.057; Heit JA, 2005, J THROMB HAEMOST, V3, P1611, DOI 10.1111/j.1538-7836.2005.01415.x; Heit JA, 2008, ARTERIOSCL THROM VAS, V28, P370, DOI 10.1161/ATVBAHA.108.162545; Ho KM, 2010, BRIT J ANAESTH, V105, P596, DOI 10.1093/bja/aeq254; Horlander KR, 2003, ARCH INTERN MED, V163, P1711, DOI 10.1001/archinte.163.14.1711; Klok FA, 2010, J THROMB HAEMOST, V8, P523, DOI 10.1111/j.1538-7836.2009.03726.x; Klok FA, 2010, CHEST, V138, P1432, DOI 10.1378/chest.09-2482; Korn EL., 1999, ANAL HLTH SURVEYS; Kozak LJ, 1995, NATL CTR HLTH STAT N, V10; Mercer SW, 2009, FAM PRACT, V26, P79, DOI 10.1093/fampra/cmp020; Nicolaides AN, 2006, INT ANGIOL, V25, P101; Prasad V, 2012, ARCH INTERN MED, V172, P955, DOI 10.1001/archinternmed.2012.195; Rosendaal Frits R, 2005, Hematology Am Soc Hematol Educ Program, P1; Rubenfire M, 2007, CRIT CARE CLIN, V23, P801, DOI 10.1016/j.ccc.2007.07.006; Smith SB, 2012, J EMERG MED, V42, P1, DOI 10.1016/j.jemermed.2011.06.004; Smith SM, 2007, BRIT J GEN PRACT, V57, P268; Stein PD, 2012, AM J MED, V125, P465, DOI 10.1016/j.amjmed.2011.10.015; Stein PD, 2012, AM J MED, V125, P471, DOI 10.1016/j.amjmed.2011.12.003; Stein PD, 2012, AM J MED, V125, P478, DOI 10.1016/j.amjmed.2011.05.025; Stein PD, 2011, CLIN APPL THROMB-HEM, V17, P140, DOI 10.1177/1076029610389027; Stein PD, 2010, CLIN CHEST MED, V31, P611, DOI 10.1016/j.ccm.2010.07.001; Stein PD, 2006, AM J MED, V119, P163, DOI 10.1016/j.amjmed.2005.02.028; Stein PD, 2004, AM J CARDIOL, V93, P1194, DOI 10.1016/j.amjcard.2004.01.061; Stein PD, 2004, AM J CARDIOL, V93, P1197, DOI 10.1016/j.amjcard.2004.01.058; Tapson VF, 2008, NEW ENGL J MED, V358, P1037, DOI 10.1056/NEJMra072753; Tsai J, 2012, ARCH INTERN MED, V172, P960, DOI 10.1001/archinternmed.2012.198; Van Es J, 2010, NAT REV CARDIOL, V7, P613, DOI 10.1038/nrcardio.2010.141; Wiener RS, 2011, ARCH INTERN MED, V171, P831, DOI 10.1001/archinternmed.2011.178; Zhu TN, 2009, ARTERIOSCL THROM VAS, V29, P298, DOI 10.1161/ATVBAHA.108.182428	47	12	12	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2012	7	7							e34048	10.1371/journal.pone.0034048	http://dx.doi.org/10.1371/journal.pone.0034048			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	974UB	22792153	gold, Green Published, Green Submitted			2023-01-03	WOS:000306461800001
J	Lagiou, P; Sandin, S; Lof, M; Trichopoulos, D; Adami, HO; Weiderpass, E				Lagiou, Pagona; Sandin, Sven; Lof, Marie; Trichopoulos, Dimitrios; Adami, Hans-Olov; Weiderpass, Elisabete			Low carbohydrate-high protein diet and incidence of cardiovascular diseases in Swedish women: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; LOW-FAT DIET; WEIGHT-LOSS; RISK; OBESITY; MEN; POPULATION; HEALTH; MORTALITY; SURVIVAL	Objective To study the long term consequences of low carbohydrate diets, generally characterised by concomitant increases in protein intake, on cardiovascular health. Design Prospective cohort study. Setting Uppsala, Sweden. Participants From a random population sample, 43 396 Swedish women, aged 30-49 years at baseline, completed an extensive dietary questionnaire and were followed-up for an average of 15.7 years. Main outcome measures Association of incident cardiovascular diseases (ascertained by linkage with nationwide registries), overall and by diagnostic category, with decreasing carbohydrate intake (in tenths), increasing protein intake (in tenths), and an additive combination of these variables (low carbohydrate-high protein score, from 2 to 20), adjusted for intake of energy, intake of saturated and unsaturated fat, and several non-dietary variables. Results A one tenth decrease in carbohydrate intake or increase in protein intake or a 2 unit increase in the low carbohydrate-high protein score were all statistically significantly associated with increasing incidence of cardiovascular disease overall (n=1270)-incidence rate ratio estimates 1.04 (95% confidence interval 1.00 to 1.08), 1.04 (1.02 to 1.06), and 1.05 (1.02 to 1.08). No heterogeneity existed in the association of any of these scores with the five studied cardiovascular outcomes: ischaemic heart disease (n=703), ischaemic stroke (n=294), haemorrhagic stroke (n=70), subarachnoid haemorrhage (n=121), and peripheral arterial disease (n=82). Conclusions Low carbohydrate-high protein diets, used on a regular basis and without consideration of the nature of carbohydrates or the source of proteins, are associated with increased risk of cardiovascular disease.	[Lagiou, Pagona] Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, GR-11527 Athens, Greece; [Lagiou, Pagona; Trichopoulos, Dimitrios; Adami, Hans-Olov] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Sandin, Sven; Lof, Marie; Adami, Hans-Olov; Weiderpass, Elisabete] Karolinska Inst, Dept Med Epidemiol & Biostat, SE-17177 Stockholm, Sweden; [Lof, Marie] Linkoping Univ, Dept Clin & Expt Med, SE-58185 Linkoping, Sweden; [Trichopoulos, Dimitrios] Acad Athens, Bur Epidemiol Res, GR-10679 Athens, Greece; [Weiderpass, Elisabete] Canc Registry Norway, N-0310 Oslo, Norway; [Weiderpass, Elisabete] Univ Tromso, Dept Community Med, Tromso, Norway; [Weiderpass, Elisabete] Samfundet Folkhalsan, Folkhalsan Res Ctr, Helsinki, Finland	Athens Medical School; National & Kapodistrian University of Athens; Harvard University; Harvard T.H. Chan School of Public Health; Karolinska Institutet; Linkoping University; Academy of Athens; University of Oslo; UiT The Arctic University of Tromso; Folkhalsan Research Center; Samfundet Folkhalsan	Lagiou, P (corresponding author), Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, 75 M Asias St, GR-11527 Athens, Greece.	pdlagiou@med.uoa.gr	Sandin, Sven/ABE-2959-2021; Löf, Marie/AAW-3323-2020; Sandin, Sven/L-5357-2015; Weiderpass, Elisabete/M-4029-2016; Löf, Marie/ABB-2697-2020; Weiderpass, Elisabete/AAP-2747-2021	Sandin, Sven/0000-0001-6994-4884; Sandin, Sven/0000-0001-6994-4884; Weiderpass, Elisabete/0000-0003-2237-0128; Löf, Marie/0000-0002-2273-4430; Weiderpass, Elisabete/0000-0003-2237-0128	Swedish Cancer Society; Swedish Research Council	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission)	The study was supported by grants from the Swedish Cancer Society and the Swedish Research Council. The study sponsors were not involved in the study design and the collection, analysis, and interpretation of data, nor the writing of the article or the decision to submit it for publication. The authors were independent from the study sponsors.	Astrup A, 2010, ANN NY ACAD SCI, V1190, P25, DOI 10.1111/j.1749-6632.2009.05272.x; Astrup A, 2004, LANCET, V364, P897, DOI 10.1016/S0140-6736(04)16986-9; Bergstrom L., 1991, Var Foda, V43, P439; Bernstein AM, 2010, CIRCULATION, V122, P876, DOI 10.1161/CIRCULATIONAHA.109.915165; Bessesen DH, 2008, J CLIN ENDOCR METAB, V93, P2027, DOI 10.1210/jc.2008-0520; Bravata DM, 2003, JAMA-J AM MED ASSOC, V289, P1837, DOI 10.1001/jama.289.14.1837; Foo SY, 2009, P NATL ACAD SCI USA, V106, P15418, DOI 10.1073/pnas.0907995106; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; Fung TT, 2010, ANN INTERN MED, V153, P289, DOI 10.7326/0003-4819-153-5-201009070-00003; Halton TL, 2006, NEW ENGL J MED, V355, P1991, DOI 10.1056/NEJMoa055317; Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287; Khani BR, 2004, J NUTR, V134, P1541, DOI 10.1093/jn/134.6.1541; Kleinbaum D. G., 1988, STUDENTS PARTIAL SOL; Korn EL, 1997, AM J EPIDEMIOL, V145, P72; Lagiou P, 2007, J INTERN MED, V261, P366, DOI 10.1111/j.1365-2796.2007.01774.x; Larsson SC, 2011, AM J CLIN NUTR, V94, P417, DOI 10.3945/ajcn.111.015115; Li ZP, 2005, SURG CLIN N AM, V85, P681, DOI 10.1016/j.suc.2005.04.006; LUNN M, 1995, BIOMETRICS, V51, P524, DOI 10.2307/2532940; McCullough ML, 2002, AM J CLIN NUTR, V76, P1261, DOI 10.1093/ajcn/76.6.1261; Noakes M, 2005, AM J CLIN NUTR, V81, P1298; Ogden CL, 2007, GASTROENTEROLOGY, V132, P2087, DOI 10.1053/j.gastro.2007.03.052; Paddon-Jones D, 2008, AM J CLIN NUTR, V87, p1558S, DOI 10.1093/ajcn/87.5.1558S; Pawitan Y, 2001, ALL LIKELIHOOD STAT, P326; Pi-Sunyer X, 2009, POSTGRAD MED, V121, P21, DOI 10.3810/pgm.2009.11.2074; Preis SR, 2010, AM J CLIN NUTR, V92, P1265, DOI 10.3945/ajcn.2010.29626; Preis SR, 2010, AM J CLIN NUTR, V91, P39, DOI 10.3945/ajcn.2009.28060; Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637; Sjogren P, 2010, AM J CLIN NUTR, V92, P967, DOI 10.3945/ajcn.2010.29345; Steffen LM, 2006, LANCET, V367, P880, DOI 10.1016/S0140-6736(06)68357-8; Trichopoulou A, 2007, EUR J CLIN NUTR, V61, P575, DOI 10.1038/sj.ejcn.1602557; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; Veierod MB, 2003, J NATL CANCER I, V95, P1530, DOI 10.1093/jnci/djg075; Volek JS, 2002, CLEV CLIN J MED, V69, P849, DOI 10.3949/ccjm.69.11.849; WACHOLDER S, 1994, AM J EPIDEMIOL, V140, P848, DOI 10.1093/oxfordjournals.aje.a117333; Whitehead J., 1980, Applied Statistics, V29, P268, DOI 10.2307/2346901; Willett W., 1998, NUTR EPIDEMIOLOGY, V2nd ed., DOI [10.1093/acprof:oso/9780195122978.001.0001, DOI 10.1093/ACPROF:OSO/9780195122978.001.0001]; Willett WC, 2007, J INTERN MED, V261, P363, DOI 10.1111/j.1365-2796.2007.01804.x; Wolk A, 1998, ARCH INTERN MED, V158, P41, DOI 10.1001/archinte.158.1.41; Zyriax BC, 2005, EUR J CLIN NUTR, V59, P1201, DOI 10.1038/sj.ejcn.1602233	39	156	159	1	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 26	2012	344								e4026	10.1136/bmj.e4026	http://dx.doi.org/10.1136/bmj.e4026			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968MU	22735105	Green Submitted, hybrid, Green Published			2023-01-03	WOS:000305986700002
J	Heath, I				Heath, Iona			What's wrong with assisted dying	BRITISH MEDICAL JOURNAL			English	Editorial Material												iona.heath22@yahoo.co.uk						Carrere E, 2012, OTHER LIVES MINE; Rieff D, 2008, SWIMMING SEA GRIEF S	2	10	10	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	MAY 29	2012	344								e3755	10.1136/bmj.e3755	http://dx.doi.org/10.1136/bmj.e3755			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	953GT	22645214				2023-01-03	WOS:000304855700020
J	Lake, ET; Staiger, D; Horbar, J; Cheung, R; Kenny, MJ; Patrick, T; Rogowski, JA				Lake, Eileen T.; Staiger, Douglas; Horbar, Jeffrey; Cheung, Robyn; Kenny, Michael J.; Patrick, Thelma; Rogowski, Jeannette A.			Association Between Hospital Recognition for Nursing Excellence and Outcomes of Very Low-Birth-Weight Infants	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEONATAL INTENSIVE-CARE; MORTALITY; VOLUME; INFECTIONS; LEVEL	Context Infants born at very low birth weight (VLBW) require high levels of nursing intensity. The role of nursing in outcomes for these infants in the United States is not known. Objective To examine the relationships between hospital recognition for nursing excellence (RNE) and VLBW infant outcomes. Design, Setting, and Patients Cohort study of 72 235 inborn VLBW infants weighing 501 to 1500 g born in 558 Vermont Oxford Network hospital neonatal intensive care units between January 1, 2007, and December 31, 2008. Hospital RNE was determined from the American Nurses Credentialing Center. The RNE designation is awarded when nursing care achieves exemplary practice or leadership in 5 areas. Main Outcome Measures Seven-day, 28-day, and hospital stay mortality; nosocomial infection, defined as an infection in blood or cerebrospinal fluid culture occurring more than 3 days after birth; and severe (grade 3 or 4) intraventricular hemorrhage. Results Overall, the outcome rates were as follows: for 7-day mortality, 7.3% (5258/71 955); 28-day mortality, 10.4% (7450/71 953); hospital stay mortality, 12.9% (9278/71 936); severe intraventricular hemorrhage, 7.6% (4842/63 525); and infection, 17.9% (11 915/66 496). The 7-day mortality was 7.0% in RNE hospitals and 7.4% in non-RNE hospitals (adjusted odds ratio [OR], 0.87; 95% CI, 0.76-0.99; P=.04). The 28-day mortality was 10.0% in RNE hospitals and 10.5% in non-RNE hospitals (adjusted OR, 0.90; 95% CI, 0.80-1.01; P=.08). Hospital stay mortality was 12.4% in RNE hospitals and 13.1% in non-RNE hospitals (adjusted OR, 0.90; 95% CI, 0.81-1.01; P=.06). Severe intraventricular hemorrhage was 7.2% in RNE hospitals and 7.8% in non-RNE hospitals (adjusted OR, 0.88; 95% CI, 0.77-1.00; P=.045). Infection was 16.7% in RNE hospitals and 18.3% in non-RNE hospitals (adjusted OR, 0.86; 95% CI, 0.75-0.99; P=.04). Compared with RNE hospitals, the adjusted absolute decrease in risk of outcomes in RNE hospitals ranged from 0.9% to 2.1%. All 5 outcomes were jointly significant (P<.001). The mean effect across all 5 outcomes was OR, 0.88 (95% CI, 0.83-0.94; P<.001). In a subgroup of 68 253 infants with gestational age of 24 weeks or older, the ORs for RNE for all 3 mortality outcomes and infection were statistically significant. Conclusion Among VLBW infants born in RNE hospitals compared with non-RNE hospitals, there was a significantly lower risk-adjusted rate of 7-day mortality, nosocomial infection, and severe intraventricular hemorrhage but not of 28-day mortality or hospital stay mortality. JAMA. 2012; 307(16):1709-1716 www.jama.com	[Lake, Eileen T.] Univ Penn, Sch Nursing, Ctr Hlth Outcomes & Policy Res, Dept Sociol, Philadelphia, PA 19104 USA; [Lake, Eileen T.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; [Staiger, Douglas] Dartmouth Coll, Dept Econ, Hanover, NH 03755 USA; [Staiger, Douglas; Rogowski, Jeannette A.] Natl Bur Econ Res, Cambridge, MA 02138 USA; [Horbar, Jeffrey] Univ Vermont, Dept Pediat, Burlington, VT 05405 USA; [Kenny, Michael J.] Univ Vermont, Dept Med Biostat, Burlington, VT 05405 USA; [Horbar, Jeffrey] Vermont Oxford Network, Burlington, VT USA; [Cheung, Robyn] UK Healthcare Enterprise, Lexington, KY USA; [Patrick, Thelma] Ohio State Univ, Coll Nursing, Columbus, OH 43210 USA; [Rogowski, Jeannette A.] Univ Med & Dent New Jersey, Dept Hlth Syst & Policy, Sch Publ Hlth, Piscataway, NJ 08854 USA	University of Pennsylvania; University of Pennsylvania; Dartmouth College; National Bureau of Economic Research; University of Vermont; University of Vermont; University System of Ohio; Ohio State University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Lake, ET (corresponding author), Univ Penn, Sch Nursing, Ctr Hlth Outcomes & Policy Res, Dept Sociol, 418 Curie Blvd, Philadelphia, PA 19104 USA.	elake@nursing.upenn.edu	Patrick, Thelma/D-1423-2013; Patrick, Thelma/D-2482-2013; Kenny, Michael/N-3244-2013	Kenny, Michael/0000-0002-7750-654X	Robert Wood Johnson Foundation Interdisciplinary Nursing Quality Research Initiative; National Institute of Nursing Research, National Institutes of Health [R01NR010357]; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR010357] Funding Source: NIH RePORTER	Robert Wood Johnson Foundation Interdisciplinary Nursing Quality Research Initiative; National Institute of Nursing Research, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))	This study was supported by a Robert Wood Johnson Foundation Interdisciplinary Nursing Quality Research Initiative grant (to Dr Lake) and grant R01NR010357 (to Dr Rogowski) from the National Institute of Nursing Research, National Institutes of Health.	AIKEN LH, 1994, MED CARE, V32, P771, DOI 10.1097/00005650-199408000-00002; American Hospital Association, 2010, AHA ANN SURV DAT; American Nurses Credentialing Center, MAGN REC PROGR OV; American Nurses Credentialing Center, HLTH CAR ORG MAGN RE; American Nurses Credentialing Center, 2011, APPL MAN MAGN REC PR; American Nurses Credentialing Center, JOURN MAGN EXC; *ASS WOM HLTH OBST, 2010, GUID PROF REG NURS S; BECKER PT, 1991, NURS RES, V40, P150; Boardman JD, 2002, DEMOGRAPHY, V39, P353, DOI 10.2307/3088343; Boxwell G., 2010, NEONATAL INTENSIVE C, V2nd; Chung JH, 2011, J PERINATOL, V31, P770, DOI 10.1038/jp.2011.29; Cimiotti JP, 2006, ARCH PEDIAT ADOL MED, V160, P832, DOI 10.1001/archpedi.160.8.832; EFRON B, 1983, AM STAT, V37, P36, DOI 10.2307/2685844; Eichenwald EC, 2008, NEW ENGL J MED, V358, P1700, DOI 10.1056/NEJMra0707601; Grandi C, 2010, ARCH ARGENT PEDIATR, V108, P499, DOI 10.1590/S0325-00752010000600005; Hack M, 2002, NEW ENGL J MED, V346, P149, DOI 10.1056/NEJMoa010856; Hamilton KES, 2007, ARCH DIS CHILD-FETAL, V92, pF99, DOI 10.1136/adc.2006.102988; Hickey P, 2010, J NURS ADMIN, V40, P226, DOI 10.1097/NNA.0b013e3181da3f71; *I MED, 2006, PRET BIRTH CAUS CONS; Lemnos JA, 2007, GUIDELINES PERINATAL; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; Kilbride HW, 2003, PEDIATRICS, V111; Lake ET, 2010, RES NURS HEALTH, V33, P413, DOI 10.1002/nur.20399; March of Dimes, 2010, IMPR OUTC PREGN; Maternal and Child Health Bureau Health Resources and Services Administration US Department of Health and Human Services, 2010, CHILD HLTH US 2010; Mathews TJ, 2011, PEDIATRICS, V127, P146, DOI 10.1542/peds.2010-3175; McCourt M, 1994, J Perinat Neonatal Nurs, V7, P52; Medlock S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023441; Mitchell P H, 1998, Image J Nurs Sch, V30, P43; Murphy J, 2011, US NEWS WORLD REPORT; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; Phibbs CS, 2007, NEW ENGL J MED, V356, P2165, DOI 10.1056/NEJMsa065029; Pollack MM, 2003, CRIT CARE MED, V31, P1620, DOI 10.1097/01.CCM.0000063302.76602.86; Rogowski JA, 2004, JAMA-J AM MED ASSOC, V291, P202, DOI 10.1001/jama.291.2.202; *STAT CORP, 2007, STAT STAT SOFTW REL; Stoll BJ, 2004, JAMA-J AM MED ASSOC, V292, P2357, DOI 10.1001/jama.292.19.2357; Stoll BJ, 2002, PEDIATRICS, V110, P285, DOI 10.1542/peds.110.2.285; Vohr BR, 2005, PEDIATRICS, V116, P635, DOI 10.1542/peds.2004-2247; Volpe JJ., 2001, NEUROLOGY NEWBORN, V4	39	65	69	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 25	2012	307	16					1709	1716		10.1001/jama.2012.504	http://dx.doi.org/10.1001/jama.2012.504			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	930OA	22535856	Green Accepted			2023-01-03	WOS:000303147500024
J	Goldberger, ZD; Chan, PS; Berg, RA; Kronick, SL; Cooke, CR; Lu, MR; Banerjee, M; Hayward, RA; Krumholz, HM; Nallamothu, BK				Goldberger, Zachary D.; Chan, Paul S.; Berg, Robert A.; Kronick, Steven L.; Cooke, Colin R.; Lu, Mingrui; Banerjee, Mousumi; Hayward, Rodney A.; Krumholz, Harlan M.; Nallamothu, Brahmajee K.		Amer Heart Assoc Get Guidelines-Re	Duration of resuscitation efforts and survival after in-hospital cardiac arrest: an observational study	LANCET			English	Article							AMERICAN-HEART-ASSOCIATION; CARDIOPULMONARY-RESUSCITATION; CARE; GUIDELINES; OUTCOMES; REGISTRY; COUNCIL; RULE	Background During in-hospital cardiac arrests, how long resuscitation attempts should be continued before termination of efforts is unknown. We investigated whether duration of resuscitation attempts varies between hospitals and whether patients at hospitals that attempt resuscitation for longer have higher survival rates than do those at hospitals with shorter durations of resuscitation efforts. Methods Between 2000 and 2008, we identified 64 339 patients with cardiac arrests at 435 US hospitals within the Get With The Guidelines-Resuscitation registry. For each hospital, we calculated the median duration of resuscitation before termination of efforts in non-survivors as a measure of the hospital's overall tendency for longer attempts. We used multilevel regression models to assess the association between the length of resuscitation attempts and risk-adjusted survival. Our primary endpoints were immediate survival with return of spontaneous circulation during cardiac arrest and survival to hospital discharge. Findings 31 198 of 64 339 (48.5%) patients achieved return of spontaneous circulation and 9912 (15.4%) survived to discharge. For patients achieving return of spontaneous circulation, the median duration of resuscitation was 12 min (IQR 6-21) compared with 20 min (14-30) for non-survivors. Compared with patients at hospitals in the quartile with the shortest median resuscitation attempts in non-survivors (16 min [IQR 15-17]), those at hospitals in the quartile with the longest attempts (25 min [25-28]) had a higher likelihood of return of spontaneous circulation (adjusted risk ratio 1.12, 95% CI 1.06-1.18; p<0.0001) and survival to discharge (1.12, 1.02-1.23; 0.021). Interpretation Duration of resuscitation attempts varies between hospitals. Although we cannot define an optimum duration for resuscitation attempts on the basis of these observational data, our findings suggest that efforts to systematically increase the duration of resuscitation could improve survival in this high-risk population.	[Goldberger, Zachary D.; Lu, Mingrui; Nallamothu, Brahmajee K.] Univ Michigan, Div Cardiovasc Med, Ann Arbor, MI 48109 USA; [Goldberger, Zachary D.; Hayward, Rodney A.] Univ Michigan, Robert Wood Johnson Fdn, Clin Scholars Program, Ann Arbor, MI 48109 USA; [Kronick, Steven L.] Univ Michigan, Dept Emergency Med, Ann Arbor, MI 48109 USA; [Hayward, Rodney A.] Univ Michigan, Div Gen Internal Med, Ann Arbor, MI 48109 USA; [Cooke, Colin R.] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA; [Banerjee, Mousumi] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA; [Cooke, Colin R.; Banerjee, Mousumi; Nallamothu, Brahmajee K.] Univ Michigan, Ctr Healthcare Outcomes & Policy, Ann Arbor, MI 48109 USA; [Hayward, Rodney A.; Nallamothu, Brahmajee K.] Univ Michigan, VA Ann Arbor Ctr Clin Management Res, Ann Arbor, MI 48109 USA; [Chan, Paul S.] St Lukes Mid Amer Heart Inst, Kansas City, MI USA; [Berg, Robert A.] Univ Penn, Sch Med, Childrens Hosp Penn, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Berg, Robert A.] Univ Penn, Sch Med, Childrens Hosp Penn, Dept Pediat, Philadelphia, PA 19104 USA; [Krumholz, Harlan M.] Yale Univ, Yale Sch Med, Dept Med, Sect Cardiovasc Med, New Haven, CT USA; [Krumholz, Harlan M.] Yale Univ, Yale Sch Med, Dept Med, Robert Wood Johnson Fdn,Clin Scholars Program, New Haven, CT USA; [Krumholz, Harlan M.] Yale Univ, Yale Sch Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT USA; [Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA	University of Michigan System; University of Michigan; Robert Wood Johnson Foundation (RWJF); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Saint Luke's Mid America Heart Institute; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Yale University; Robert Wood Johnson Foundation (RWJF); Yale University; Yale University; Yale University	Nallamothu, BK (corresponding author), Univ Michigan Hlth Syst, Div Cardiovasc Med, Ann Arbor, MI 48109 USA.	bnallamo@umich.edu	, Harlan/AAI-2875-2020	Cooke, Colin/0000-0001-9713-5371	American Heart Association; Robert Wood Johnson Foundation Clinical Scholars Program; National Institutes of Health; Medtronic through Yale University; National Heart, Lung, and Blood Institute [K23HL102224, U01 HL105270-02]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL102224, U01HL105270] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); Robert Wood Johnson Foundation Clinical Scholars Program(Robert Wood Johnson Foundation (RWJF)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medtronic through Yale University; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	American Heart Association, Robert Wood Johnson Foundation Clinical Scholars Program, and the National Institutes of Health.; HMK is the recipient of a research grant from Medtronic through Yale University and is chair of a cardiac scientific advisory board for UnitedHealth. All other authors declare that they have no conflicts of interest.; The American Heart Association provides operational funding for Get With The Guidelines-Resuscitation. ZDG is a 2010-12 Robert Wood Johnson Foundation clinical scholar. PSC is supported by a career development grant award (K23HL102224) from the National Heart, Lung, and Blood Institute. HMK is supported by grant U01 HL105270-02 (Center for Cardiovascular Outcomes Research at Yale University) from the National Heart, Lung, and Blood Institute.	BALLEW KA, 1994, ARCH INTERN MED, V154, P2426, DOI 10.1001/archinte.154.21.2426; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; Chan PS, 2008, NEW ENGL J MED, V358, P9, DOI 10.1056/NEJMoa0706467; Chan PS, 2012, JAMA-J AM MED ASSOC, V307, P1917, DOI 10.1001/jama.2012.3504; Chan PS, 2010, JAMA-J AM MED ASSOC, V304, P2129, DOI 10.1001/jama.2010.1576; Eisenberg MS, 2001, NEW ENGL J MED, V344, P1304, DOI 10.1056/NEJM200104263441707; Girotra S, N ENGL J ME IN PRESS; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; Jain R, 2011, ARCH INTERN MED, V171, P89, DOI 10.1001/archinternmed.2010.475; JENNETT B, 1975, LANCET, V7905, P480; Jones PG, 2008, RESUSCITATION, V76, P369, DOI 10.1016/j.resuscitation.2007.08.021; Larkin GL, 2010, RESUSCITATION, V81, P302, DOI 10.1016/j.resuscitation.2009.11.021; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; Merchant RM, 2011, CRIT CARE MED, V39, P2401, DOI 10.1097/CCM.0b013e3182257459; Morrison LJ, 2006, NEW ENGL J MED, V355, P478, DOI 10.1056/NEJMoa052620; Morrison LJ, 2010, CIRCULATION, V122, pS665, DOI 10.1161/CIRCULATIONAHA.110.970905; Nolan JP, 2010, RESUSCITATION, V81, P1219, DOI 10.1016/j.resuscitation.2010.08.021; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Sandroni C, 2007, INTENS CARE MED, V33, P237, DOI 10.1007/s00134-006-0326-z; Schultz SC, 1996, RESUSCITATION, V33, P13, DOI 10.1016/S0300-9572(96)00986-0; Shih CL, 2007, RESUSCITATION, V72, P394, DOI 10.1016/j.resuscitation.2006.07.020; Snijders T.A.B., 2012, MULTILEVEL ANAL INTR, Vsecond; STEMMLER EJ, 1965, ANN INTERN MED, V63, P613, DOI 10.7326/0003-4819-63-4-613; van Walraven C, 1999, ARCH INTERN MED, V159, P129, DOI 10.1001/archinte.159.2.129; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	25	263	278	1	24	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 27	2012	380	9852					1473	1481		10.1016/S0140-6736(12)60862-9	http://dx.doi.org/10.1016/S0140-6736(12)60862-9			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	026JJ	22958912	Green Accepted			2023-01-03	WOS:000310272000027
J	Chen, W; Xia, YP; Zhao, XL; Wang, H; Chen, WJ; Yu, MH; Li, YM; Ye, HY; Zhang, Y				Chen, Wei; Xia, Yanping; Zhao, Xuelan; Wang, Hao; Chen, Wenjie; Yu, Maohua; Li, Yiming; Ye, Hongying; Zhang, Yu			The Critical Role of Astragalus Polysaccharides for the Improvement of PPRA alpha-Mediated Lipotoxicity in Diabetic Cardiomyopathy	PLOS ONE			English	Article							FATTY-ACID-METABOLISM; ACTIVATED RECEPTOR-ALPHA; CARDIAC-HYPERTROPHY; CONTRACTILE DYSFUNCTION; HEART; MICE; 1,2-DIACYLGLYCEROL; DISORDER; GLUCOSE; DB/DB	Background: Obesity-related diabetes mellitus leads to increased myocardial uptake and oxidation of fatty acids, resulting in a form of cardiac dysfunction referred to as lipotoxic cardiomyopathy. We have shown previously that Astragalus polysaccharides (APS) administration was sufficient to improve the systemic metabolic disorder and cardiac dysfunction in diabetic models. Methodology/Principal Findings: To investigate the precise role of APS therapy in the pathogenesis of myocardial lipotoxity in diabetes, db/db diabetic mice and myosin heavy chain (MHC)- peroxisome proliferator-activated receptor (PPAR) alpha mice were characterized and administrated with or without APS with C57 wide- type mice as normal control. APS treatment strikingly improved the myocyte triacylglyceride accumulation and cardiac dysfunction in both db/db mice and MHC-PPAR alpha mice, with the normalization of energy metabolic derangements in both db/db diabetic hearts and MHC-PPAR alpha hearts. Consistently, the activation of PPAR alpha target genes involved in myocardial fatty acid uptake and oxidation in both db/db diabetic hearts and MHC-PPAR alpha hearts was reciprocally repressed by APS administration, while PPAR alpha-mediated suppression of genes involved in glucose utilization of both diabetic hearts and MHC-PPAR alpha hearts was reversed by treatment with APS. Conclusions: We conclude that APS therapy could prevent the development of diabetic cardiomyopathy through a mechanism mainly dependent on the cardiac PPAR alpha-mediated regulatory pathways.	[Chen, Wei; Xia, Yanping; Zhao, Xuelan; Chen, Wenjie; Yu, Maohua; Zhang, Yu] Fudan Univ, Hushan Hosp, Dept Geriatr, Sch Med, Shanghai 200433, Peoples R China; [Wang, Hao] Fudan Univ, Core Ctr Anim Facil, Sch Med, Shanghai 200433, Peoples R China; [Li, Yiming; Ye, Hongying] Fudan Univ, Huashan Hosp, Dept Endocrinol, Sch Med, Shanghai 200433, Peoples R China	Fudan University; Fudan University; Fudan University	Zhang, Y (corresponding author), Fudan Univ, Hushan Hosp, Dept Geriatr, Sch Med, Shanghai 200433, Peoples R China.	dryehongying@hotmail.com; billycai56@yahoo.com.cn			Chinese State Natural Science Funds Commission [81001568]; Shanghai Health Bureau Science Funds for Chinese Medicine [2010QJ033A]	Chinese State Natural Science Funds Commission; Shanghai Health Bureau Science Funds for Chinese Medicine	This work was supported by Chinese State Natural Science Funds Commission (Grant No: 81001568), and Shanghai Health Bureau Science Funds for Chinese Medicine (Grant No: 2010QJ033A). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Battiprolu PK., 2010, DRUG DISCOV TODAY DI, V7, pE135, DOI [10.1016/j.ddmec.2010.08.001, DOI 10.1016/J.DDMEC.2010.08.001]; Belke DD, 2000, AM J PHYSIOL-ENDOC M, V279, pE1104, DOI 10.1152/ajpendo.2000.279.5.E1104; Belke DD, 1999, AM J PHYSIOL-REG I, V277, pR1210, DOI 10.1152/ajpregu.1999.277.4.R1210; Buchanan J, 2005, ENDOCRINOLOGY, V146, P5341, DOI 10.1210/en.2005-0938; Carley AN, 2005, BBA-MOL CELL BIOL L, V1734, P112, DOI 10.1016/j.bbalip.2005.03.005; Chen W, 2008, EXP CLIN ENDOCR DIAB, V116, P468, DOI 10.1055/s-2008-1058081; Chen W, 2010, J DIABETES COMPLICAT, V24, P199, DOI 10.1016/j.jdiacomp.2008.12.003; Chen W, 2010, ACTA DIABETOL, V47, pS35, DOI 10.1007/s00592-009-0116-5; Duncan JG, 2007, CIRCULATION, V115, P909, DOI 10.1161/CIRCULATIONAHA.106.662296; Finck BN, 2003, P NATL ACAD SCI USA, V100, P1226, DOI 10.1073/pnas.0336724100; Finck BN, 2002, J CLIN INVEST, V109, P121, DOI 10.1172/JCI200214080; GAMBLE J, 1994, BBA-MOL BASIS DIS, V1225, P191, DOI 10.1016/0925-4439(94)90078-7; Lopaschuk Gary D, 2002, Heart Fail Rev, V7, P149; Poornima IG, 2006, CIRC RES, V98, P596, DOI 10.1161/01.RES.0000207406.94146.c2; Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701; Rogers JH, 1999, J CLIN INVEST, V104, P567, DOI 10.1172/JCI6713; RUBLER S, 1972, AM J CARDIOL, V30, P595, DOI 10.1016/0002-9149(72)90595-4; Saburi Y, 2003, CARDIOVASC RES, V57, P92, DOI 10.1016/S0008-6363(02)00608-9; Schaffer JE, 2003, CURR OPIN LIPIDOL, V14, P281, DOI 10.1097/00041433-200306000-00008; Semeniuk LM, 2002, AM J PHYSIOL-HEART C, V283, pH976, DOI 10.1152/ajpheart.00088.2002; Stanley William C, 2002, Heart Fail Rev, V7, P115, DOI 10.1023/A:1015320423577; Taegtmeyer H, 2002, CIRCULATION, V105, P1727, DOI 10.1161/01.CIR.0000012466.50373.E8; Takahashi R, 2003, CARDIOVASC RES, V58, P565, DOI 10.1016/S0008-6363(03)00291-8; Thrainsdottir IS, 2004, J CARDIOVASC PHARM, V44, P101, DOI 10.1097/00005344-200407000-00014; Watanabe K, 2000, J BIOL CHEM, V275, P22293, DOI 10.1074/jbc.M000248200; Witteles RM, 2008, J AM COLL CARDIOL, V51, P93, DOI 10.1016/j.jacc.2007.10.021; Yang J, 2007, CIRC RES, V100, P1208, DOI 10.1161/01.RES.0000264104.25265.b6; Young ME, 2001, J BIOL CHEM, V276, P44390, DOI 10.1074/jbc.M103826200	28	20	29	2	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2012	7	10							e45541	10.1371/journal.pone.0045541	http://dx.doi.org/10.1371/journal.pone.0045541			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014PQ	23049681	Green Published, Green Submitted, gold			2023-01-03	WOS:000309388500008
J	Hoevenaar-Blom, MP; Nooyens, ACJ; Kromhout, D; Spijkerman, AMW; Beulens, JWJ; van der Schouw, YT; Bueno-de-Mesquita, B; Verschuren, WMM				Hoevenaar-Blom, Marieke P.; Nooyens, Astrid C. J.; Kromhout, Daan; Spijkerman, Annemieke M. W.; Beulens, Joline W. J.; van der Schouw, Yvonne T.; Bueno-de-Mesquita, Bas; Verschuren, W. M. Monique			Mediterranean Style Diet and 12-Year Incidence of Cardiovascular Diseases: The EPIC-NL Cohort Study	PLOS ONE			English	Article							CORONARY-HEART-DISEASE; PHYSICAL-ACTIVITY QUESTIONNAIRE; FOOD FREQUENCY QUESTIONNAIRE; VENOUS THROMBOEMBOLISM; RELATIVE VALIDITY; MYOCARDIAL-INFARCTION; RISK-FACTORS; 7 COUNTRIES; SURVIVAL; HEALTH	Background: A recent meta-analysis showed that a Mediterranean style diet may protect against cardiovascular diseases (CVD). Studies on disease-specific associations are limited. We evaluated the Mediterranean Diet Score (MDS) in relation to incidence of total and specific CVDs. Methods: The EPIC-NL Study is a cohort of 40,011 men and women aged 20-70 years, examined between 1993 and 1997, with 10-15 years of follow-up. Diet was assessed with a validated food frequency questionnaire and the MDS was based on the daily intakes of vegetables, fruits, legumes and nuts, grains, fish, fatty acids, meat, dairy, and alcohol. Cardiovascular morbidity and mortality were ascertained through linkage with national registries. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CI) adjusted for age, sex, cohort, smoking, physical activity, total energy intake, and educational level. Results: In 34,708 participants free of CVD at baseline, 4881 CVD events occurred, and 487 persons died from CVD. A two unit increment in MDS (range 0-9) was inversely associated with fatal CVD (HR: 0.78; 95% CI: 0.69-0.88), total CVD (HR: 0.95 (0.91-0.98)), myocardial infarction (HR: 0.86 (0.79-0.93)), stroke (HR: 0.88 (0.78-1.00)), and pulmonary embolism (HR: 0.74 (0.59-0.92)). The MDS was not related to incident angina pectoris, transient ischemic attack and peripheral arterial disease. Conclusion: Better adherence to a Mediterranean style diet was more strongly associated with fatal CVD than with total CVD. Disease specific associations were strongest for incident myocardial infarction, stroke and pulmonary embolism.	[Hoevenaar-Blom, Marieke P.; Nooyens, Astrid C. J.; Spijkerman, Annemieke M. W.; Verschuren, W. M. Monique] Natl Inst Publ Hlth & Environm, Ctr Prevent & Hlth Serv Res, NL-3720 BA Bilthoven, Netherlands; [Hoevenaar-Blom, Marieke P.; Kromhout, Daan] Wageningen Univ, Div Human Nutr, Wageningen, Netherlands; [Beulens, Joline W. J.; van der Schouw, Yvonne T.] Univ Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Bueno-de-Mesquita, Bas] Natl Inst Publ Hlth & Environm, Ctr Nutr & Hlth, NL-3720 BA Bilthoven, Netherlands; [Bueno-de-Mesquita, Bas] Univ Med Ctr, Dept Gastroenterol & Hepatol, Utrecht, Netherlands	Netherlands National Institute for Public Health & the Environment; Wageningen University & Research; Utrecht University; Utrecht University Medical Center; Netherlands National Institute for Public Health & the Environment; Utrecht University; Utrecht University Medical Center	Hoevenaar-Blom, MP (corresponding author), Natl Inst Publ Hlth & Environm, Ctr Prevent & Hlth Serv Res, NL-3720 BA Bilthoven, Netherlands.	marieke.hoevenaar@rivm.nl	Hoevenaar-Blom, Maria/AGI-1087-2022; Kromhout, Daan/A-8566-2014; van der Schouw, Yvonne T./F-8327-2014	van der Schouw, Yvonne T./0000-0002-4605-435X; Beulens, Joline/0000-0002-4181-0937	"Europe against Cancer" Programme of the European Commission (SANCO); Dutch Ministry of Health; Dutch Cancer Society; Netherlands Organization for Health Research and Development (ZonMW); World Cancer Research Fund (WCRF); ZonMw [40-00812-98-10040]	"Europe against Cancer" Programme of the European Commission (SANCO)(European CommissionEuropean Commission Joint Research Centre); Dutch Ministry of Health; Dutch Cancer Society(KWF Kankerbestrijding); Netherlands Organization for Health Research and Development (ZonMW)(Netherlands Organization for Health Research and Development); World Cancer Research Fund (WCRF)(World Cancer Research Fund International (WCRF)); ZonMw(Netherlands Organization for Health Research and Development)	The EPIC-NL study was funded by "Europe against Cancer" Programme of the European Commission (SANCO), the Dutch Ministry of Health, the Dutch Cancer Society, the Netherlands Organization for Health Research and Development (ZonMW), and World Cancer Research Fund (WCRF). The analysis was also supported by a grant of ZonMw; grant no 40-00812-98-10040. None of the study sponsors had a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beulens JWJ, 2010, INT J EPIDEMIOL, V39, P1170, DOI 10.1093/ije/dyp217; Buckland G, 2009, AM J EPIDEMIOL, V170, P1518, DOI 10.1093/aje/kwp282; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; DEBRUIN A, 2003, LINKING DATA NATL AM; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; Fung TT, 2009, CIRCULATION, V119, P1093, DOI 10.1161/CIRCULATIONAHA.108.816736; Gardener H, 2011, AM J CLIN NUTR, V94, P1458, DOI 10.3945/ajcn.111.012799; Harteloh P, 2010, EUR J EPIDEMIOL, V25, P531, DOI 10.1007/s10654-010-9445-5; Hu FB, 2002, CURR OPIN LIPIDOL, V13, P3, DOI 10.1097/00041433-200202000-00002; Joosten MM, 2010, AM J CLIN NUTR, V91, P1777, DOI 10.3945/ajcn.2010.29170; KEYS A, 1986, AM J EPIDEMIOL, V124, P903, DOI 10.1093/oxfordjournals.aje.a114480; Knoops KTB, 2004, JAMA-J AM MED ASSOC, V292, P1433, DOI 10.1001/jama.292.12.1433; KROMHOUT D, 1989, AM J CLIN NUTR, V49, P889, DOI 10.1093/ajcn/49.5.889; Lutsey PL, 2012, AM J EPIDEMIOL, V175, P127, DOI 10.1093/aje/kwr379; Lutsey PL, 2009, AM HEART J, V157, P1081, DOI 10.1016/j.ahj.2009.04.003; Martinez-Gonzalez MA, 2010, NUTR METAB CARDIOVAS; Merry AHH, 2009, EUR J EPIDEMIOL, V24, P237, DOI 10.1007/s10654-009-9335-x; Mitrou PN, 2007, ARCH INTERN MED, V167, P2461, DOI 10.1001/archinte.167.22.2461; Nordmann AJ, 2011, AM J MED, V124, P841, DOI 10.1016/j.amjmed.2011.04.024; Ocke MC, 1997, INT J EPIDEMIOL, V26, pS37, DOI 10.1093/ije/26.suppl_1.S37; Ocke MC, 1997, INT J EPIDEMIOL, V26, pS49, DOI 10.1093/ije/26.suppl_1.S49; Pols MA, 1997, INT J EPIDEMIOL, V26, pS181, DOI 10.1093/ije/26.suppl_1.S181; Sofi F, 2010, AM J CLIN NUTR, V92, P1189, DOI 10.3945/ajcn.2010.29673; Steffen LM, 2007, CIRCULATION, V115, P188, DOI 10.1161/CIRCULATIONAHA.106.641688; Trichopoulou A, 2005, ARCH INTERN MED, V165, P929, DOI 10.1001/archinte.165.8.929; TRICHOPOULOU A, 1995, BMJ-BRIT MED J, V311, P1457, DOI 10.1136/bmj.311.7018.1457; Trichopoulou A, 2005, BMJ-BRIT MED J, V330, P991, DOI 10.1136/bmj.38415.644155.8F; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; Trichopoulou A, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b2337; Varraso R, 2012, AM J EPIDEMIOL, V175, P114, DOI 10.1093/aje/kwr377; Wareham NJ, 2003, PUBLIC HEALTH NUTR, V6, P407, DOI 10.1079/PHN2002439; World Health Organization, 1977, INT CLASS DIS; World Health Organization, 1990, INT CLASS DIS, V10th; Zarraga IGE, 2006, CIRCULATION, V114, P961, DOI 10.1161/CIRCULATIONAHA.105.603910	34	93	95	0	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2012	7	9							e45458	10.1371/journal.pone.0045458	http://dx.doi.org/10.1371/journal.pone.0045458			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022PZ	23029021	gold, Green Published, Green Submitted			2023-01-03	WOS:000309973900042
J	Huan, ML; Zhang, B; Teng, ZH; Cui, H; Wang, JP; Liu, XY; Xia, H; Zhou, SY; Mei, QB				Huan, Menglei; Zhang, Bangle; Teng, Zenghui; Cui, Han; Wang, Jieping; Liu, Xinyou; Xia, Hui; Zhou, Siyuan; Mei, Qibing			In Vitro and In Vivo Antitumor Activity of a Novel pH-Activated Polymeric Drug Delivery System for Doxorubicin	PLOS ONE			English	Article							CELL LUNG-CANCER; MICELLES; PACLITAXEL; COPOLYMER; THERAPY; RELEASE; TARGET; GROWTH; MODEL	Background: Conventional chemotherapy agent such as doxorubicin (DOX) is of limited clinical use because of its inherently low selectivity, which can lead to systemic toxicity in normal healthy tissue. Methods: A pH stimuli-sensitive conjugate based on polyethylene glycol (PEG) with covalently attachment doxorubicin via hydrazone bond (PEG-hyd-DOX) was prepared for tumor targeting delivery system. While PEG-DOX conjugates via amid bond (PEG-ami-DOX) was synthesized as control. Results: The synthetic conjugates were confirmed by proton nuclear magnetic resonance (NMR) spectroscopy, the release profile of DOX from PEG-hyd-DOX was acid-liable for the hydrazone linkage between DOX and PEG, led to different intracellular uptake route; intracellular accumulation of PEG-hyd-DOX was higher than PEG-ami-DOX due to its pH-triggered profile, and thereby more cytotoxicity against MCF-7, MDA-MB-231 (breast cancer models) and HepG2 (hepatocellular carcinoma model) cell lines. Following the in vitro results, we xenografted MDA-MB-231 cell onto SCID mice, PEG-hyd-DOX showed stronger antitumor efficacy than free DOX and was tumor-targeting. Conclusions: Results from these in vivo experiments were consistent with our in vitro results; suggested this pH-triggered PEG-hyd-DOX conjugate could target DOX to tumor tissues and release free drugs by acidic tumor environment, which would be potent in antitumor drug delivery.	[Mei, Qibing] Fourth Mil Med Univ, Sch Pharm, State Adm Tradit Chinese Med, Key Lab Gastrointestinal Pharmacol Chinese Mat Me, Xian 710032, Peoples R China; [Huan, Menglei; Zhang, Bangle; Teng, Zenghui; Cui, Han; Zhou, Siyuan] Fourth Mil Med Univ, Sch Pharm, Dept Pharmaceut, Xian 710032, Peoples R China; [Wang, Jieping; Liu, Xinyou] Fourth Mil Med Univ, Tangdu Hosp, Dept Pharm, Xian 710032, Peoples R China; [Xia, Hui] Peoples Liberat Army Gen Hosp, Affiliated Hosp 1, Dept Thorac Cardio Surg, Beijing, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University; Chinese People's Liberation Army General Hospital	Mei, QB (corresponding author), Fourth Mil Med Univ, Sch Pharm, State Adm Tradit Chinese Med, Key Lab Gastrointestinal Pharmacol Chinese Mat Me, Xian 710032, Peoples R China.	meiqibing@hotmail.com		Zhang, Bang-Le/0000-0001-9008-5391	Natural Science Foundation of Shaanxi Province [2010JM4043]	Natural Science Foundation of Shaanxi Province(Natural Science Foundation of Shaanxi Province)	This work was supported by the Natural Science Foundation of Shaanxi Province (2010JM4043). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Blanco E, 2007, J CONTROL RELEASE, V122, P365, DOI 10.1016/j.jconrel.2007.04.014; Chen CH, 2008, BIOSCI BIOTECH BIOCH, V72, P1586, DOI 10.1271/bbb.80096; Chen W, 2010, J CONTROL RELEASE, V142, P40, DOI 10.1016/j.jconrel.2009.09.023; Cheng C, 2008, BIOCONJUGATE CHEM, V19, P1194, DOI 10.1021/bc8000062; Cuong N.V., 2011, CANCERS, V3, P61, DOI DOI 10.3390/CANCERS3010061; Denmeade SR, 1998, CANCER RES, V58, P2537; Fox ME, 2009, MOL PHARMACEUT, V6, P1562, DOI 10.1021/mp9001206; Gettinger S, 2008, SEMIN RESP CRIT CARE, V29, P291, DOI 10.1055/s-2008-1076749; Hu FQ, 2009, BIOMATERIALS, V30, P6955, DOI 10.1016/j.biomaterials.2009.09.008; Huan ML, 2009, BIOORG MED CHEM LETT, V19, P2579, DOI 10.1016/j.bmcl.2009.03.016; Kakinoki A, 2008, BIOL PHARM BULL, V31, P103, DOI 10.1248/bpb.31.103; Kim TH, 2010, BIOMATERIALS, V31, P7386, DOI 10.1016/j.biomaterials.2010.06.004; Ko J, 2007, J CONTROL RELEASE, V123, P109, DOI 10.1016/j.jconrel.2007.07.012; Kotsakis A, 2010, EXPERT OPIN PHARMACO, V11, P2363, DOI 10.1517/14656566.2010.498581; Kukowska-Latallo JF, 2005, CANCER RES, V65, P5317, DOI 10.1158/0008-5472.CAN-04-3921; Lacroix L, 2008, EXPERT REV MOL DIAGN, V8, P167, DOI 10.1586/14737159.8.2.167; Lee ALZ, 2009, BIOMATERIALS, V30, P919, DOI 10.1016/j.biomaterials.2008.10.062; Leroux JC, 2001, J CONTROL RELEASE, V72, P71, DOI 10.1016/S0168-3659(01)00263-2; Liao D, 2011, NANOMED-NANOTECHNOL, V7, P665, DOI 10.1016/j.nano.2011.03.001; Lin JP, 2009, BIOMATERIALS, V30, P108, DOI 10.1016/j.biomaterials.2008.09.010; Murakami T, 2008, NANOMEDICINE-UK, V3, P453, DOI 10.2217/17435889.3.4.453; Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947; Ryu BY, 2008, J BIOMAT SCI-POLYM E, V19, P311, DOI 10.1163/156856208783720994; Sethuraman VA, 2006, BIOMACROMOLECULES, V7, P64, DOI 10.1021/bm0503571; Xiong XB, 2010, BIOMATERIALS, V31, P757, DOI 10.1016/j.biomaterials.2009.09.080; Zhu SJ, 2010, BIOMATERIALS, V31, P1360, DOI 10.1016/j.biomaterials.2009.10.044	26	24	25	1	55	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2012	7	9							e44116	10.1371/journal.pone.0044116	http://dx.doi.org/10.1371/journal.pone.0044116			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	016YB	23028490	Green Published, Green Submitted, gold			2023-01-03	WOS:000309554700005
J	Brune, M; Scheele, D; Heinisch, C; Tas, C; Wischniewski, J; Gunturkun, O				Bruene, Martin; Scheele, Dirk; Heinisch, Christine; Tas, Cumhur; Wischniewski, Julia; Guentuerkuen, Onur			Empathy Moderates the Effect of Repetitive Transcranial Magnetic Stimulation of the Right Dorsolateral Prefrontal Cortex on Costly Punishment	PLOS ONE			English	Article							ALTRUISTIC PUNISHMENT; DECISION-MAKING; ULTIMATUM GAME; NEURAL BASIS; PSYCHOPATHY; COOPERATION; EVOLUTION; CHOICE; BASES	Humans incur considerable costs to punish unfairness directed towards themselves or others. Recent studies using repetitive transcranial magnetic stimulation (rTMS) suggest that the right dorsolateral prefrontal cortex (DLPFC) is causally involved in such strategic decisions. Presently, two partly divergent hypotheses are discussed, suggesting either that the right DLPFC is necessary to control selfish motives by implementing culturally transmitted social norms, or is involved in suppressing emotion-driven prepotent responses to perceived unfairness. Accordingly, we studied the role of the DLPFC in costly (i.e. third party) punishment by applying rTMS to the left and right DLPFC before playing a Dictator Game with the option to punish observed unfair behavior (DG-P). In addition, sham stimulation took place. Individual differences in empathy were assessed with the German version of the Interpersonal Reactivity Index. Costly punishment increased (non-significantly) upon disruption of the right - but not the left - DLPFC as compared to sham stimulation. However, empathy emerged as a highly significant moderator variable of the effect of rTMS over the right, but not left, DLPFC, suggesting that the right DLPFC is involved in controlling prepotent emotional responses to observed unfairness, depending on individual differences in empathy.	[Bruene, Martin; Heinisch, Christine; Tas, Cumhur; Wischniewski, Julia] Ruhr Univ Bochum, Landschaftsverband Westfalen Lippe Univ Hosp, Res Dept Cognit Neuropsychiat & Psychiat Prevent, Bochum, Germany; [Scheele, Dirk] Univ Bonn, Dept Psychol, Bonn, Germany; [Guentuerkuen, Onur] Ruhr Univ Bochum, Dept Biopsychol, Fac Psychol, Bochum, Germany	Ruhr University Bochum; University of Bonn; Ruhr University Bochum	Brune, M (corresponding author), Ruhr Univ Bochum, Landschaftsverband Westfalen Lippe Univ Hosp, Res Dept Cognit Neuropsychiat & Psychiat Prevent, Univ Str 150, Bochum, Germany.	martin.bruene@rub.de	Scheele, Dirk/K-1194-2015; Brüne, Martin/AAX-3202-2020	Scheele, Dirk/0000-0002-7613-0376; Brüne, Martin/0000-0002-2507-0561; Gunturkun, Onur/0000-0003-4173-5233	Friedrich Ebert Stiftung	Friedrich Ebert Stiftung	Julia Wischniewski was supported by the Friedrich Ebert Stiftung. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aleman A, 2008, NEUROPSYCHOBIOLOGY, V57, P44, DOI 10.1159/000129666; AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; Baumgartner T, 2011, NAT NEUROSCI, V14, P1468, DOI 10.1038/nn.2933; Brandstatter H, 2001, EUR J PERSONALITY, V15, pS53, DOI 10.1002/per.424; Buckholtz JW, 2008, NEURON, V60, P930, DOI 10.1016/j.neuron.2008.10.016; Crockett MJ, 2010, EMOTION, V10, P855, DOI 10.1037/a0019861; DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037/0022-3514.44.1.113; de Quervain DJF, 2004, SCIENCE, V305, P1254, DOI 10.1126/science.1100735; Falk A, 2003, ECON INQ, V41, P20, DOI 10.1093/ei/41.1.20; Fehr E, 2002, NATURE, V415, P137, DOI 10.1038/415137a; Fehr E, 2003, NATURE, V425, P785, DOI 10.1038/nature02043; Gintis H, 2000, J THEOR BIOL, V206, P169, DOI 10.1006/jtbi.2000.2111; Glenn AL, 2009, MOL PSYCHIATR, V14, P909, DOI 10.1038/mp.2009.76; Gospic K, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001054; Greene JD, 2004, NEURON, V44, P389, DOI 10.1016/j.neuron.2004.09.027; Herwig U, 2003, BRAIN TOPOGR, V16, P95, DOI 10.1023/B:BRAT.0000006333.93597.9d; Hobbes Thomas, 1651, LEVIATHAN-J MELVILLE; Judd CM, 2001, PSYCHOL METHODS, V6, P115, DOI 10.1037/1082-989X.6.2.115; Knoch D, 2008, CEREB CORTEX, V18, P1987, DOI 10.1093/cercor/bhm237; Knoch D, 2006, SCIENCE, V314, P829, DOI 10.1126/science.1129156; Lundqvist D., 1998, KAROLINSKA DIRECTED; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Paulus C., 2009, SAARBRUCKER PERSONLI; Rilling JK, 2007, BIOL PSYCHIAT, V61, P1260, DOI 10.1016/j.biopsych.2006.07.021; Rilling JK, 2011, ANNU REV PSYCHOL, V62, P23, DOI 10.1146/annurev.psych.121208.131647; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Rossi S, 2011, CLIN NEUROPHYSIOL, V122, P1686, DOI 10.1016/j.clinph.2010.12.037; Sanfey AG, 2003, SCIENCE, V300, P1755, DOI 10.1126/science.1082976; Scheele D, 2012, BIOL PSYCHIAT; Seymour B, 2007, NAT REV NEUROSCI, V8, P300, DOI 10.1038/nrn2119; Smith A, 1776, THEORY MORAL SENTIME; Solnick SJ, 1999, ORGAN BEHAV HUM DEC, V79, P199, DOI 10.1006/obhd.1999.2843; Strobel A, 2011, NEUROIMAGE, V54, P671, DOI 10.1016/j.neuroimage.2010.07.051; Thut G, 2010, BRAIN TOPOGR, V22, P219, DOI 10.1007/s10548-009-0115-4; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755; Van den Bergh B, 2006, P R SOC B, V273, P2091, DOI 10.1098/rspb.2006.3550; van't Wout M, 2005, NEUROREPORT, V16, P1849, DOI 10.1097/01.wnr.0000183907.08149.14; Wischniewski J, J PERSONAL IN PRESS	38	26	28	2	53	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 13	2012	7	9							e44747	10.1371/journal.pone.0044747	http://dx.doi.org/10.1371/journal.pone.0044747			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	005ZK	23028601	Green Submitted, Green Published, gold			2023-01-03	WOS:000308788700033
J	Chen, KY; Chang, SS; Chen, CYC				Chen, Kuan-Yu; Chang, Su-Sen; Chen, Calvin Yu-Chian			In Silico Identification of Potent Pancreatic Triacylglycerol Lipase Inhibitors from Traditional Chinese Medicine	PLOS ONE			English	Article							DRUG DISCOVERY; OBESITY; ORLISTAT; ABSORPTION; PROGRAM; PROTEIN; WEIGHT; DESIGN	Pancreatic triacylglycerol lipase (PNLIP) are primary lipases that are critical for triacylglyceride digestion in human. Since reduced metabolism of triacylglyceride might be a plausible concept for weight loss, we screened for potential PNLIP inhibitors from traditional Chinese medicine (TCM) with the aim to identify weight loss candidate compounds. TCM candidates Aurantiamide, Cnidiadin, and 2-hexadecenoic acid exhibited higher Dock Scores than the commercial drug Orlistat, and were also predicted to have inhibitory characteristics against PNLIP using constructed MLR (R-2 = 0.8664) and SVM (R-2 = 0.9030) models. Molecular dynamics indicated that the TCM-PNLIP complexes formed were stable. We identified that the PNLIP binding site has several residues that can serve as anchors, and a hydrophobic corridor that provides additional stability to the complex. Aurantiamide, Cnidiadin, and 2-hexadecenoic acid all have features that correspond to these binding site features, indicating their potential as candidates for PNLIP inhibitors. The information presented in this study may provide helpful insights to designing novel weight-control drugs.	[Chen, Kuan-Yu] China Med Univ, Dept Chinese Med, Taichung, Taiwan; [Chen, Kuan-Yu; Chang, Su-Sen; Chen, Calvin Yu-Chian] China Med Univ, Lab Computat & Syst Biol, Taichung, Taiwan; [Chang, Su-Sen; Chen, Calvin Yu-Chian] China Med Univ Hosp, Dept Med Res, Taichung, Taiwan; [Chen, Calvin Yu-Chian] Asia Univ, Dept Biotechnol, Taichung, Taiwan; [Chen, Calvin Yu-Chian] Asia Univ, Dept Biomed Informat, Taichung, Taiwan; [Chen, Calvin Yu-Chian] China Med Univ, Beigang Hosp, Yunlin, Taiwan	China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Asia University Taiwan; Asia University Taiwan; China Medical University Taiwan	Chen, KY (corresponding author), China Med Univ, Dept Chinese Med, Taichung, Taiwan.	ycc929@MIT.EDU	; Chen, Calvin Yu-Chian/E-9402-2010	Chen, Calvin Yu-Chian/0000-0001-9213-9832; Chen, Calvin Yu-Chian/0000-0003-3306-250X	National Science Council of Taiwan [NSC 100-2325-B-039-001]; Committee on Chinese Medicine and Pharmacy [CCMP100-RD-030]; China Medical University and Asia University [DMR-101-094]; Taiwan Department of Health Clinical Trial and Research Center of Excellence [DOH101-TD-B-111-004]; Taiwan Department of Health Cancer Research Center of Excellence [DOH101-TD-C111-005]; China Medical University Beigang Hospital [CMUBH R101-004]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Committee on Chinese Medicine and Pharmacy; China Medical University and Asia University; Taiwan Department of Health Clinical Trial and Research Center of Excellence; Taiwan Department of Health Cancer Research Center of Excellence; China Medical University Beigang Hospital(China Medical University)	The research was supported by grants from the National Science Council of Taiwan (NSC 100-2325-B-039-001), Committee on Chinese Medicine and Pharmacy (CCMP100-RD-030), China Medical University and Asia University (DMR-101-094). This study is also supported in part by Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH101-TD-B-111-004) and Taiwan Department of Health Cancer Research Center of Excellence (DOH101-TD-C111-005). Partial funding is also provided by China Medical University Beigang Hospital (CMUBH R101-004). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Borhani DW, 2012, J COMPUT AID MOL DES, V26, P15, DOI 10.1007/s10822-011-9517-y; Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287; Burbidge R, 2001, COMPUT CHEM, V26, P5, DOI 10.1016/S0097-8485(01)00094-8; Chang CL, 2011, GENOME RES, V21, P21, DOI 10.1101/gr.110593.110; Chang KW, 2011, J BIOMOL STRUCT DYN, V29, P243, DOI 10.1080/073911011010524988; Chang PC, 2011, J BIOMOL STRUCT DYN, V29, P471, DOI 10.1080/07391102.2011.10507399; Chang SS, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002315; Chen CYC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015939; Chen CYC, 2009, J MOL GRAPH MODEL, V28, P261, DOI 10.1016/j.jmgm.2009.08.004; Chen JH, 2012, CLIN RHEUMATOL, V31, P239, DOI 10.1007/s10067-011-1802-6; Chen KC, 2011, CHEM BIOL DRUG DES, V78, P679, DOI 10.1111/j.1747-0285.2011.01202.x; Chen KC, 2011, MOL BIOSYST, V7, P2711, DOI 10.1039/c1mb05164d; Ge H, 2010, NAT PROD REP, V27, P1758, DOI 10.1039/c0np00005a; Guerciolini R, 1997, INT J OBESITY, V21, pS12; Hodgson J, 2001, NAT BIOTECHNOL, V19, P722, DOI 10.1038/90761; Ivanciuc O., 2007, REV COMPUT CHEM, P291; James P T, 2001, Obes Res, V9 Suppl 4, p228S, DOI 10.1038/oby.2001.123; Karamadoukis L, 2009, CLIN NEPHROL, V71, P430; Lin HY, 2008, J CHIN MED ASSOC, V71, P305, DOI 10.1016/S1726-4901(08)70127-8; Lin WY, 2011, CAN MED ASSOC J, V183, pE329, DOI 10.1503/cmaj.101303; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; Mukherjee M, 2003, J MOL CATAL B-ENZYM, V22, P369, DOI 10.1016/S1381-1177(03)00052-3; Nakai M, 2005, J AGR FOOD CHEM, V53, P4593, DOI 10.1021/jf047814+; ROGERS D, 1994, J CHEM INF COMP SCI, V34, P854, DOI 10.1021/ci00020a020; Sampson HA, 2009, J ALLERGY CLIN IMMUN, V123, P317, DOI 10.1016/j.jaci.2008.12.1112; Shi YG, 2004, NAT REV DRUG DISCOV, V3, P695, DOI 10.1038/nrd1469; Slinker BK, 2008, CIRCULATION, V117, P1732, DOI 10.1161/CIRCULATIONAHA.106.654376; Thomson ABR, 1997, METHOD ENZYMOL, V286, P3; Tsai TY, 2011, J COMPUT AID MOL DES, V25, P525, DOI 10.1007/s10822-011-9438-9; Vapnik, 2013, NATURE STAT LEARNING; Vapnik V., 1963, AUTOMAT REM CONTR+, V24, P774; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WHO, 2010, 10 FACTS OB; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; Yang SC, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002189; ZHI JG, 1995, J CLIN PHARMACOL, V35, P1103, DOI 10.1002/j.1552-4604.1995.tb04034.x	36	20	21	0	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2012	7	9							e43932	10.1371/journal.pone.0043932	http://dx.doi.org/10.1371/journal.pone.0043932			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	001KC	22970152	Green Published, Green Submitted, gold			2023-01-03	WOS:000308458400026
J	Jasuja, S; Thompson, ND; Peters, PJ; Khudyakov, YE; Patel, MT; Linchangco, P; Thai, HT; Switzer, WM; Shankar, A; Heneine, W; Hu, DJ; Moorman, AC; Gerber, SI				Jasuja, Supriya; Thompson, Nicola D.; Peters, Philip J.; Khudyakov, Yury E.; Patel, Megan T.; Linchangco, Purisima; Thai, Hong T.; Switzer, William M.; Shankar, Anupama; Heneine, Walid; Hu, Dale J.; Moorman, Anne C.; Gerber, Susan I.			Investigation of Hepatitis B Virus and Human Immunodeficiency Virus Transmission among Severely Mentally Ill Residents at a Long Term Care Facility	PLOS ONE			English	Article							BLOOD-BORNE INFECTIONS; UNITED-STATES; HIV; ILLNESS; HEALTH; RECOMMENDATIONS; OUTBREAK; ADULTS	Background: A high prevalence of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections have been reported among persons with severe mental illness. In October, 2009, the Cook County Department of Public Health (CCDPH) initiated an investigation following notification of a cluster of HBV infections among mentally ill residents at a long term care facility (LTCF). Methods: LTCF staff were interviewed and resident medical records were reviewed. Residents were offered testing for HBV, HCV, and HIV. Serum specimens from residents diagnosed with HBV or HIV infection were sent to the Centers for Disease Control and Prevention (CDC) for analysis. Results: Eleven newly diagnosed HBV infections were identified among mentally ill residents at the LTCF. Of these 11 infections, 4 serum specimens were available for complete HBV genome sequencing; all 4 genomes were found to be closely related. Four newly diagnosed HIV infections were identified within this same population. Upon molecular analysis, 2 of 4 HIV sequences from these new infections were found to be nearly identical and formed a tight phylogenetic cluster. Conclusions: HBV and HIV transmission was identified among mentally ill residents of this LTCF. Continued efforts are needed to prevent bloodborne pathogen transmission among mentally ill residents in LTCFs.	[Jasuja, Supriya; Patel, Megan T.; Linchangco, Purisima; Gerber, Susan I.] Cook Cty Dept Publ Hlth, Oak Forest, IL USA; [Thompson, Nicola D.; Khudyakov, Yury E.; Thai, Hong T.; Hu, Dale J.; Moorman, Anne C.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA USA; [Peters, Philip J.; Switzer, William M.; Shankar, Anupama; Heneine, Walid] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Jasuja, S (corresponding author), Cook Cty Dept Publ Hlth, Oak Forest, IL USA.	sjasuja@cookcountyhhs.org; sgerber@cookcountyhhs.org		Moorman, Anne/0000-0003-2411-2798				Angelino Andrew F, 2008, Top HIV Med, V16, P99; Branson Bernard M., 2006, Morbidity and Mortality Weekly Report, V55, P1; Brooks JT, 2006, AIDS, V20, P923, DOI 10.1097/01.aids.0000218558.82402.59; Brunette MF, 2003, PSYCHIAT SERV, V54, P860, DOI 10.1176/appi.ps.54.6.860; de Oliveira T, 2006, NATURE, V444, P836, DOI 10.1038/444836a; Forbi JC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011615; Jafa K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005416; Mast Eric E., 2006, Morbidity and Mortality Weekly Report, V55, P1; Rosenberg SD, 2001, AM J PUBLIC HEALTH, V91, P31, DOI 10.2105/AJPH.91.1.31; Rosenberg SD, 2003, PSYCHIAT SERV, V54, P827, DOI 10.1176/appi.ps.54.6.827; Thompson ND, 2009, ANN INTERN MED, V150, P33, DOI 10.7326/0003-4819-150-1-200901060-00007; Willenbring ML, 2005, AIDS, V19, pS227, DOI 10.1097/01.aids.0000192094.84624.c2; Wise ME, 2012, AM J INFECT CONTROL, V40, P16, DOI 10.1016/j.ajic.2011.04.331	13	6	7	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2012	7	8							e43252	10.1371/journal.pone.0043252	http://dx.doi.org/10.1371/journal.pone.0043252			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	999CI	22937026	Green Submitted, Green Published, gold			2023-01-03	WOS:000308286300038
J	Wedzicha, JA; Vestbo, J				Wedzicha, Jadwiga A.; Vestbo, Jorgen			Can patients with COPD self-manage?	LANCET			English	Editorial Material							OBSTRUCTIVE PULMONARY-DISEASE; EXACERBATIONS; IMPACT; CARE		[Wedzicha, Jadwiga A.] UCL, Ctr Resp Med, London NW3 2PF, England; [Vestbo, Jorgen] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Vestbo, Jorgen] Univ So Denmark, Odense, Denmark	University of London; University College London; University of Manchester; University of Southern Denmark	Wedzicha, JA (corresponding author), UCL, Ctr Resp Med, Royal Free Campus, London NW3 2PF, England.	w.wedzicha@ucl.ac.uk	Vestbo, Jorgen/Y-2912-2019	Vestbo, Jorgen/0000-0001-6355-6362				Aaron SD, 2012, THORAX, V67, P238, DOI 10.1136/thoraxjnl-2011-200768; Bischoff EWMA, 2011, THORAX, V66, P26, DOI 10.1136/thx.2009.127621; Bourbeau J, 2003, ARCH INTERN MED, V163, P585, DOI 10.1001/archinte.163.5.585; Bucknall CE, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1060; Fan VS, 2012, ANN INTERN MED, V156, P673, DOI 10.7326/0003-4819-156-10-201205150-00003; Jeppesen E, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003573.pub2; Patel ARC, 2012, CHEST, V141, P851, DOI 10.1378/chest.11-0853; Price LC, 2006, THORAX, V61, P837, DOI 10.1136/thx.2005.049940; Rice KL, 2010, AM J RESP CRIT CARE, V182, P890, DOI 10.1164/rccm.200910-1579OC; Wedzicha JA, 2007, LANCET, V370, P786, DOI 10.1016/S0140-6736(07)61382-8; Wilkinson TMA, 2004, AM J RESP CRIT CARE, V169, P1298, DOI 10.1164/rccm.200310-1443OC	11	13	13	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 18	2012	380	9842					624	625		10.1016/S0140-6736(12)61339-7	http://dx.doi.org/10.1016/S0140-6736(12)61339-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	991SE	22901870				2023-01-03	WOS:000307721000005
J	Schmucker, C; Ehlken, C; Agostini, HT; Antes, G; Ruecker, G; Lelgemann, M; Loke, YK				Schmucker, Christine; Ehlken, Christoph; Agostini, Hansjuergen T.; Antes, Gerd; Ruecker, Gerta; Lelgemann, Monika; Loke, Yoon K.			A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus Goldstandard	PLOS ONE			English	Review							RANDOMIZED CLINICAL-TRIAL; VERTEPORFIN PHOTODYNAMIC THERAPY; VISION-RELATED FUNCTION; MACULAR DEGENERATION; INTRAVITREAL BEVACIZUMAB; SUBGROUP ANALYSIS; CANCER-PATIENTS; AVASTIN; PHARMACOKINETICS; TRIAMCINOLONE	Background: We set out a systemic review to evaluate whether off-label bevacizumab is as safe as licensed ranibizumab, and whether bevacizumab can be justifiably offered to patients as a treatment for age-related macular degeneration with robust evidence of no differential risk. Methods and Findings: Medline, Embase and the Cochrane Library were searched with no limitations of language and year of publication. We included RCTs with a minimum follow-up of one year which investigated bevacizumab or ranibizumab in direct comparison or against any other control group (indirect comparison). Direct comparison (3 trials, 1333 patients): The one year data show a significantly higher rate of ocular adverse effects (AE) with bevacizumab compared to ranibizumab (RR = 2.8; 95% CI 1.2-6.5). The proportion of patients with serious infections and gastrointestinal disorders was also higher with bevacizumab than with ranibizumab (RR = 1.3; 95% CI 1.0-1.7). Arterial thromboembolic events were equally distributed among the groups. Indirect comparison: Ranibizumab versus any control (5 trials, 4054 patients): The two year results of three landmark trials showed that while absolute rates of serious ocular AE were low (<= 2.1%), relative harm was significantly raised (RR = 3.1; 95% CI 1.1-8.9). A significant increase in nonocular haemorrhage was also observed with ranibizumab (RR = 1.7; 95% CI 1.1-2.7). Bevacizumab versus any control (3 trials, 244 patients): We were unable to judge the safety profile of bevacizumab due to the poor quality of AE monitoring and reporting in the trials. Conclusions: Evidence from head-to-head trials raises concern about an increased risk of ocular and multiple systemic AE with bevacizumab. Therefore, clinicians and patients should continue to carefully weight up the benefits and harms when choosing between the two treatment options. We also emphasize the need for studies that are powered not just for efficacy, but for defined safety outcomes based on the signals detected in this systematic review.	[Schmucker, Christine; Antes, Gerd] Univ Med Ctr Freiburg, Dept Med Biometry & Stat, Inst Med Biometry & Med Informat, German Cochrane Inst, Freiburg, Germany; [Ehlken, Christoph; Agostini, Hansjuergen T.] Univ Med Ctr Freiburg, Univ Eye Hosp, Freiburg, Germany; [Loke, Yoon K.] Univ E Anglia, Sch Med, Norwich NR4 7TJ, Norfolk, England; [Lelgemann, Monika] German Hlth Insurance Funds, Med Advisory Serv, Essen, Germany	University of Freiburg; University of Freiburg; University of East Anglia	Schmucker, C (corresponding author), Univ Med Ctr Freiburg, Dept Med Biometry & Stat, Inst Med Biometry & Med Informat, German Cochrane Inst, Freiburg, Germany.	schmucker@cochrane.de	Rücker, Gerta/B-2965-2009	Rücker, Gerta/0000-0002-2192-2560; Schmucker, Christine/0000-0002-1188-3158	German Federal Ministry of Education and Research [01KG1020]	German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF))	This research was supported by a grant from the German Federal Ministry of Education and Research (Grant number: 01KG1020, http://www.gesundheitsforschung-bmbf.de/de/4312.php). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011; Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012; Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357; Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023; Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045; Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024; Bradburn MJ, 2007, STAT MED, V26, P53, DOI 10.1002/sim.2528; Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900; Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562; Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655; Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018; Centre for Reviews and Dissemination, 2008, SYST REV CRDS GUID U, P177; Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460; Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004; Chou R, 2010, J CLIN EPIDEMIOL, V63, P502, DOI 10.1016/j.jclinepi.2008.06.007; Costagliola C, 2010, BRIT J OPHTHALMOL, V94, P180, DOI 10.1136/bjo.2009.159343; Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223; FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640; Food and Drug Administration, 2006, HIGHL PRESCR INF LUC; Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd; Hapani S, 2010, ONCOLOGY-BASEL, V79, P27, DOI 10.1159/000314980; KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428; Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012; Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030; Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006; Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673; Michels S, 2006, BRIT J OPHTHALMOL, V90, P1333, DOI 10.1136/bjo.2006.102293; Ranpura V, 2011, JAMA-J AM MED ASSOC, V305, P487, DOI 10.1001/jama.2011.51; Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14; Sacu S, 2009, EYE, V23, P2223, DOI 10.1038/eye.2008.423; Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004; Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574; Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185; Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147; Team R.C., 2021, R FOUN DATION STAT C; The Royal College of Ophthalmologists Statement, 2011, BEV AV US MED OPHTH; Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459; US Food and Drug Administration (FDA) MedWatch, 2005, SAF AV BEV; Van der Reis MI, 2011, RETINA-J RET VIT DIS, V31, P1449, DOI 10.1097/IAE.0b013e3182278ab4; Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823; Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z	43	92	96	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 3	2012	7	8							e42701	10.1371/journal.pone.0042701	http://dx.doi.org/10.1371/journal.pone.0042701			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	985QT	22880086	Green Published, Green Submitted, gold			2023-01-03	WOS:000307284100160
J	Khamduang, W; Gaudy-Graffin, C; Ngo-Giang-Huong, N; Jourdain, G; Moreau, A; Luekamlung, N; Halue, G; Buranawanitchakorn, Y; Kunkongkapan, S; Buranabanjasatean, S; Lallemant, M; Sirirungsi, W; Goudeau, A				Khamduang, Woottichai; Gaudy-Graffin, Catherine; Ngo-Giang-Huong, Nicole; Jourdain, Gonzague; Moreau, Alain; Luekamlung, Nuananong; Halue, Guttiga; Buranawanitchakorn, Yuwadee; Kunkongkapan, Sura; Buranabanjasatean, Sudanee; Lallemant, Marc; Sirirungsi, Wasna; Goudeau, Alain		Program HIV Prevention Treatment	Long-Term Hepatitis B Virus (HBV) Response to Lamivudine-Containing Highly Active Antiretroviral Therapy in HIV-HBV Co-Infected Patients in Thailand	PLOS ONE			English	Article							PATIENTS RECEIVING LAMIVUDINE; HIV-1-INFECTED ADULTS; INDIVIDUALS; RESISTANT; EFFICACY; ADOLESCENTS; GUIDELINES; MORTALITY; IMPACT; COHORT	Background: Approximately 4 million of people are co-infected with HIV and Hepatitis B virus (HBV). In resource-limited settings, the majority of HIV-infected patients initiate first-line highly active antiretroviral therapy containing lamivudine (3TC-containing-HAART) and long-term virological response of HBV to lamivudine-containing HAART in co-infected patients is not well known. Methodology/Principal Finding: HIV-HBV co-infected patients enrolled in the PHPT cohort (ClinicalTrials. gov NCT00433030) and initiating a 3TC-containing-HAART regimen were included. HBV-DNA, HIV-RNA, CD4+ T-cell counts and alanine transaminase were measured at baseline, 3 months, 12 months and then every 6 months up to 5 years. Kaplan-Meier analysis was used to estimate the cumulative rates of patients who achieved and maintained HBV-DNA suppression. Of 30 co-infected patients, 19 were positive for HBe antigen (HBeAg). At initiation of 3TC-containing-HAART, median HBV DNA and HIV RNA levels were 7.35 log10 IU/mL and 4.47 log10 copies/mL, respectively. At 12 months, 67% of patients achieved HBV DNA suppression: 100% of HBeAg-negative patients and 47% of HBeAg-positive. Seventy-three percent of patients had HIV RNA below 50 copies/mL. The cumulative rates of maintained HBV-DNA suppression among the 23 patients who achieved HBV-DNA suppression were 91%, 87%, and 80% at 1, 2, and 4 years respectively. Of 17 patients who maintained HBV-DNA suppression while still on 3TC, 4 (24%) lost HBsAg and 7 of 8 (88%) HBeAg-positive patients lost HBeAg at their last visit (median duration, 59 months). HBV breakthrough was observed only in HBeAg-positive patients and 6 of 7 patients presenting HBV breakthrough had the rtM204I/V mutations associated with 3TC resistance along with rtL180M and/or rtV173L. Conclusions: All HBeAg-negative patients and 63% of HBeAg-positive HIV-HBV co-infected patients achieved long-term HBV DNA suppression while on 3TC-containing-HAART. This study provides information useful for the management of co-infected patients in resource-limited countries where the vast majority of co-infected patients are currently receiving 3TC.	[Khamduang, Woottichai; Ngo-Giang-Huong, Nicole; Jourdain, Gonzague; Lallemant, Marc; Sirirungsi, Wasna] Chiang Mai Univ, Fac Associated Med Sci, Chiang Mai 50000, Thailand; [Khamduang, Woottichai; Gaudy-Graffin, Catherine; Moreau, Alain; Goudeau, Alain] Univ Tours, Fac Med, INSERM, U966,CHRU Tours, Tours, France; [Khamduang, Woottichai; Ngo-Giang-Huong, Nicole; Jourdain, Gonzague; Lallemant, Marc] IRD, UMI Programs HIV Prevent & Treatment PHPT 174, Chiang Mai, Thailand; [Ngo-Giang-Huong, Nicole; Jourdain, Gonzague; Lallemant, Marc] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; [Luekamlung, Nuananong] Lamphun Hosp, Lamphun, Thailand; [Halue, Guttiga] Phayao Hosp, Phayao, Thailand; [Buranawanitchakorn, Yuwadee] Chiang Kham Hosp, Phayao, Thailand; [Kunkongkapan, Sura] Mae Sai Hosp, Chiangrai, Thailand; [Buranabanjasatean, Sudanee] Mae Chan Hosp, Chiangrai, Thailand	Chiang Mai University; CHU Tours; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; Institut de Recherche pour le Developpement (IRD); Harvard University; Harvard T.H. Chan School of Public Health	Khamduang, W (corresponding author), Chiang Mai Univ, Fac Associated Med Sci, Chiang Mai 50000, Thailand.	kwoottichai@gmail.com; goudeau@med.univ-tours.fr	Jourdain, Gonzague/F-9117-2017; Ngo-Giang-Huong, Nicole/G-2860-2017; Khamduang, Woottichai/AFG-2454-2022	Jourdain, Gonzague/0000-0002-3365-7020; Ngo-Giang-Huong, Nicole/0000-0001-8950-3234; Khamduang, Woottichai/0000-0003-0196-5691	Agence Nationale de Recherches sur le Sida et les hepatites virales [ANRS 12-179]; Global Fund to fight AIDS, TB and Malaria; Institut de Recherche pour le Developpement (IRD), France; Thailand International Development Cooperation Agency (TICA), Thai Ministry of Foreign Affairs; IRD; Franco-Thai cooperation program in Higher Education and Research; Faculty of Associated Medical Sciences, Chiang Mai University; French Ministry of Foreign Affairs	Agence Nationale de Recherches sur le Sida et les hepatites virales(ANRSFrench National Research Agency (ANR)); Global Fund to fight AIDS, TB and Malaria(United States Agency for International Development (USAID)); Institut de Recherche pour le Developpement (IRD), France; Thailand International Development Cooperation Agency (TICA), Thai Ministry of Foreign Affairs; IRD; Franco-Thai cooperation program in Higher Education and Research; Faculty of Associated Medical Sciences, Chiang Mai University; French Ministry of Foreign Affairs	This work was supported by Agence Nationale de Recherches sur le Sida et les hepatites virales (grant number ANRS 12-179); the Global Fund to fight AIDS, TB and Malaria; the Institut de Recherche pour le Developpement (IRD), France; and Thailand International Development Cooperation Agency (TICA), Thai Ministry of Foreign Affairs. WK received scholarships from the IRD, the Franco-Thai cooperation program in Higher Education and Research, the Faculty of Associated Medical Sciences, Chiang Mai University, and the French Ministry of Foreign Affairs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alter MJ, 2006, J HEPATOL, V44, pS6, DOI 10.1016/j.jhep.2005.11.004; [Anonymous], 2011, GUID US ANT AG HIV 1, P111; Benhamou Y, 2006, HEPATOLOGY, V43, P548, DOI 10.1002/hep.21055; Benhamou Y, 1999, HEPATOLOGY, V30, P1302, DOI 10.1002/hep.510300525; Chasombat S, 2009, JAIDS-J ACQ IMM DEF, V50, P506, DOI 10.1097/QAI.0b013e3181967602; da Silva Luiz Caetano, 2000, Revista do Instituto de Medicina Tropical de Sao Paulo, V42, P189; de Vries-Sluijs TEMS, 2006, J CLIN VIROL, V36, P60, DOI 10.1016/j.jcv.2005.12.004; Dore GJ, 1999, J INFECT DIS, V180, P607, DOI 10.1086/314942; Ford N, 2008, S AFR J HIV MED, P8; Hoff J, 2001, CLIN INFECT DIS, V32, P963, DOI 10.1086/319368; Kiertiburanakul Sasisopin, 2007, Journal of the Medical Association of Thailand, V90, P237; Kim HN, 2011, J VIRAL HEPATITIS, V18, pE447, DOI 10.1111/j.1365-2893.2011.01466.x; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; Liaw YF, 2008, HEPATOL INT, V2, P263, DOI 10.1007/s12072-008-9080-3; Locarnini S, 2010, ANTIVIR THER, V15, P3, DOI 10.3851/IMP1619; Matthews GV, 2011, AIDS, V25, P1727, DOI 10.1097/QAD.0b013e328349bbf3; Matthews GV, 2006, AIDS, V20, P863, DOI 10.1097/01.aids.0000218550.85081.59; Nikolopoulos GK, 2009, CLIN INFECT DIS, V48, P1763, DOI 10.1086/599110; Nishizaki Y, 2006, TOKAI J EXP CLIN MED, V31, P111; Phanuphak P, 2004, AIDS, V18, pS33, DOI 10.1097/00002030-200406003-00007; Pillay D, 2000, AIDS, V14, P1111, DOI 10.1097/00002030-200006160-00007; Sheng WH, 2012, CLIN INFECT DIS, V54, P548, DOI 10.1093/cid/cir851; Snow-Lampart A, 2011, HEPATOLOGY, V53, P763, DOI 10.1002/hep.24078; Sungkanuparph Somnuek, 2008, Southeast Asian Journal of Tropical Medicine and Public Health, V39, P863; Sungkanuparph S, 2010, ASIAN BIOMED, V4, P515, DOI 10.2478/abm-2010-0066; Sungkanuparph Somnuek, 2008, Journal of the Medical Association of Thailand, V91, P1925; Thio CL, 2002, LANCET, V360, P1921, DOI 10.1016/S0140-6736(02)11913-1; Villeneuve JP, 2003, J HEPATOL, V39, P1085, DOI 10.1016/j.jhep.2003.09.022; WHO, 2010, ANT THER HIV INF AD; WHO UNAIDS Unicef, 2011, GLOB HIV AIDS RESP E; World Health Organization, 2009, RAP ADV ANT THER HIV, V3, P11	31	8	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2012	7	7							e42184	10.1371/journal.pone.0042184	http://dx.doi.org/10.1371/journal.pone.0042184			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982LS	22860080	Green Published, gold			2023-01-03	WOS:000307045600071
J	Joubert, MK; Hokom, M; Eakin, C; Zhou, L; Deshpande, M; Baker, MP; Goletz, TJ; Kerwin, BA; Chirmule, N; Narhi, LO; Jawa, V				Joubert, Marisa K.; Hokom, Martha; Eakin, Catherine; Zhou, Lei; Deshpande, Meghana; Baker, Matthew P.; Goletz, Theresa J.; Kerwin, Bruce A.; Chirmule, Naren; Narhi, Linda O.; Jawa, Vibha			Highly Aggregated Antibody Therapeutics Can Enhance the in Vitro Innate and Late-stage T-cell Immune Responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLERANT MICE; HEMOPHILIA-A; FC-RECEPTOR; FACTOR-VIII; WILD-TYPE; IMMUNOGENICITY; ACTIVATION; COMPLEXES; PARTICLES; MECHANISMS	Aggregation of biotherapeutics has the potential to induce an immunogenic response. Here, we show that aggregated therapeutic antibodies, previously generated and determined to contain a variety of attributes (Joubert, M. K., Luo, Q., Nashed-Samuel, Y., Wypych, J., and Narhi, L.O. (2011) J. Biol. Chem. 286, 25118-25133), can enhance the in vitro innate immune response of a population of naive human peripheral blood mononuclear cells. This response depended on the aggregate type, inherent immunogenicity of the monomer, and donor responsiveness, and required a high number of particles, well above that detected in marketed drug products, at least in this in vitro system. We propose a cytokine signature as a potential biomarker of the in vitro peripheral blood mononuclear cell response to aggregates. The cytokines include IL-1 beta, IL-6, IL-10, MCP-1, MIP-1 alpha, MIP-1 beta, MMP-2, and TNF-alpha. IL-6 and IL-10 might have an immunosuppressive effect on the long term immune response. Aggregates made by stirring induced the highest response compared with aggregates made by other methods. Particle size in the 2-10 mu m range and the retention of some folded structure were associated with an increased response. The mechanism of aggregate activation at the innate phase was found to occur through specific cell surface receptors ( the toll-like receptors TLR-2 and TLR-4, Fc gamma Rs, and the complement system). The innate signal was shown to progress to an adaptive T-cell response characterized by T-cell proliferation and secretion of T-cell cytokines. Investigating the ability of aggregates to induce cytokine signatures as biomarkers of immune responses is essential for determining their risk of immunogenicity.	[Joubert, Marisa K.; Narhi, Linda O.] Amgen Inc, Dept Prod Attribute Sci, Thousand Oaks, CA 91320 USA; [Hokom, Martha; Deshpande, Meghana; Chirmule, Naren; Jawa, Vibha] Amgen Inc, Dept Clin Immunol, Thousand Oaks, CA 91320 USA; [Zhou, Lei] Amgen Inc, Dept Med Sci, Thousand Oaks, CA 91320 USA; [Eakin, Catherine] Amgen Inc, Dept Drug Substance Dev, Seattle, WA 98119 USA; [Kerwin, Bruce A.] Amgen Inc, Dept Drug Prod Dev, Seattle, WA 98119 USA; [Goletz, Theresa J.] Amgen Inc, Dept Clin Immunol, Seattle, WA 98119 USA; [Baker, Matthew P.] Antitope Ltd, Babraham Inst, Cambridge CB22 3AT, England	Amgen; Amgen; Amgen; Amgen; Amgen; Amgen; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Joubert, MK (corresponding author), 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.	mjoubert@amgen.com; vjawa01@amgen.com						ANDERSON CL, 1980, J IMMUNOL, V125, P2735; Babiuk S, 2004, J MED VIROL, V72, P138, DOI 10.1002/jmv.10540; Bachmann MF, 1997, ANNU REV IMMUNOL, V15, P235, DOI 10.1146/annurev.immunol.15.1.235; Braun A, 1997, PHARMACEUT RES, V14, P1472, DOI 10.1023/A:1012193326789; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Brinks V, 2011, PHARM RES-DORDR, V28, P2379, DOI 10.1007/s11095-011-0523-5; Bussiere J L, 2003, Dev Biol (Basel), V112, P135; CANFIELD SM, 1991, J EXP MED, V173, P1483, DOI 10.1084/jem.173.6.1483; Carpenter JF, 2009, J PHARM SCI-US, V98, P1201, DOI 10.1002/jps.21530; Catelas I, 1998, J BIOMED MATER RES, V41, P600, DOI 10.1002/(SICI)1097-4636(19980915)41:4<600::AID-JBM12>3.0.CO;2-I; Corry DB, 2004, FASEB J, V18, P995, DOI 10.1096/fj.03-1412fje; Coxon A, 2001, IMMUNITY, V14, P693, DOI 10.1016/S1074-7613(01)00150-9; Demeule B, 2006, EUR J PHARM BIOPHARM, V62, P121, DOI 10.1016/j.ejpb.2005.08.008; den Engelsman J, 2011, PHARM RES-DORDR, V28, P920, DOI 10.1007/s11095-010-0297-1; Denis J, 2007, VIROLOGY, V363, P59, DOI 10.1016/j.virol.2007.01.011; Descotes J, 2007, CYTOKINES HUMAN HLTH, P193; Fifis T, 2004, J IMMUNOL, V173, P3148, DOI 10.4049/jimmunol.173.5.3148; Fradkin AH, 2011, J PHARM SCI-US, V100, P4953, DOI 10.1002/jps.22683; Fradkin AH, 2009, J PHARM SCI-US, V98, P3247, DOI 10.1002/jps.21834; Hazenbos WLW, 1998, J IMMUNOL, V161, P3026; Hermeling S, 2006, J PHARM SCI-US, V95, P1084, DOI 10.1002/jps.20599; Hermeling S, 2005, PHARM RES-DORDR, V22, P1997, DOI 10.1007/s11095-005-8177-9; Hertz CJ, 2001, J IMMUNOL, V166, P2444, DOI 10.4049/jimmunol.166.4.2444; Higgins SC, 2003, J IMMUNOL, V171, P3119, DOI 10.4049/jimmunol.171.6.3119; Jaber Amer, 2007, Drugs R D, V8, P335; Jaber A, 2007, J PHARMACEUT BIOMED, V43, P1256, DOI 10.1016/j.jpba.2006.10.023; Joubert MK, 2011, J BIOL CHEM, V286, P25118, DOI 10.1074/jbc.M110.160457; Kiese S, 2008, J PHARM SCI-US, V97, P4347, DOI 10.1002/jps.21328; Krutzik SR, 2005, NAT MED, V11, P653, DOI 10.1038/nm1246; Laborde EA, 2007, J IMMUNOL, V179, P673, DOI 10.4049/jimmunol.179.1.673; Lin Y, 2000, J BIOL CHEM, V275, P24255, DOI 10.1074/jbc.M002137200; Luo QZ, 2011, J BIOL CHEM, V286, P25134, DOI 10.1074/jbc.M110.160440; Maas C, 2007, J BIOL CHEM, V282, P2229, DOI 10.1074/jbc.M605984200; Magi M, 2004, J ALLERGY CLIN IMMUN, V114, P545, DOI 10.1016/j.jaci.2004.04.014; Mahler HC, 2009, J PHARM SCI-US, V98, P2909, DOI 10.1002/jps.21566; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Matzinger P, 2007, NAT IMMUNOL, V8, P11, DOI 10.1038/ni0107-11; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Morefield GL, 2005, VACCINE, V23, P1588, DOI 10.1016/j.vaccine.2004.07.050; Patten P A, 2003, Dev Biol (Basel), V112, P81; Perry LCA, 2008, DRUGS R&D, V9, P385, DOI 10.2165/0126839-200809060-00004; Popi AF, 2004, IMMUNOLOGY, V113, P348, DOI 10.1111/j.1365-2567.2004.01969.x; Prior S, 2002, EUR J PHARM SCI, V15, P197, DOI 10.1016/S0928-0987(01)00218-4; Purohit VS, 2006, J PHARM SCI-US, V95, P358, DOI 10.1002/jps.20529; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; Reichert JM, 2011, MABS-AUSTIN, V3, P76, DOI 10.4161/mabs.3.1.13895; Reichert JM, 2010, MABS-AUSTIN, V2, P84, DOI 10.4161/mabs.2.1.10677; Reipert BM, 2007, BRIT J HAEMATOL, V136, P12, DOI 10.1111/j.1365-2141.2006.06359.x; Roberts J. P., 2011, GENET ENG BIOTECHNOL, V31, P7; ROBINSON JJ, 1994, ANN RHEUM DIS, V53, P515, DOI 10.1136/ard.53.8.515; Ronnelid J, 2003, ANN RHEUM DIS, V62, P37, DOI 10.1136/ard.62.1.37; Rosenberg A, 2011, IMMUNOGENICITY 2011, P6; Rosenberg AS, 2006, AAPS J, V8, pE501, DOI 10.1208/aapsj080359; Ryff JC, 2002, TRENDS PHARMACOL SCI, V23, P254, DOI 10.1016/S0165-6147(02)02024-2; Schellekens H, 2002, CLIN THER, V24, P1720, DOI 10.1016/S0149-2918(02)80075-3; Schellekens H, 2002, NAT REV DRUG DISCOV, V1, P457, DOI 10.1038/nrd818; Seaver S, 2008, BIOQUALITY, V13, P3; Singh SK, 2010, J PHARM SCI-US, V99, P3302, DOI 10.1002/jps.22097; Singh SK, 2011, J PHARM SCI-US, V100, P354, DOI 10.1002/jps.22276; Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1; Vultaggio A, 2011, CURR OPIN ALLERGY CL, V11, P262, DOI 10.1097/ACI.0b013e3283464bcd; Wang W, 2003, PHARM RES-DORDR, V20, P693, DOI 10.1023/A:1023271405005; WILLS RJ, 1992, CLIN PHARMACOKINET, V23, P406, DOI 10.2165/00003088-199223060-00002; Wullner D, 2010, CLIN IMMUNOL, V137, P5, DOI 10.1016/j.clim.2010.06.018; Xiang SD, 2006, METHODS, V40, P1, DOI 10.1016/j.ymeth.2006.05.016	65	184	195	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2012	287	30					25266	25279		10.1074/jbc.M111.330902	http://dx.doi.org/10.1074/jbc.M111.330902			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	977IW	22584577	Green Published, hybrid			2023-01-03	WOS:000306651700035
J	da Costa, BR; Rutjes, AWS; Mendy, A; Freund-Heritage, R; Vieira, ER				da Costa, Bruno Roza; Rutjes, Anne Wilhelmina Saskia; Mendy, Angelico; Freund-Heritage, Rosalie; Vieira, Edgar Ramos			Can Falls Risk Prediction Tools Correctly Identify Fall-Prone Elderly Rehabilitation Inpatients? A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							HOSPITALS; STRATIFY	Background: Falls of elderly people may cause permanent disability or death. Particularly susceptible are elderly patients in rehabilitation hospitals. We systematically reviewed the literature to identify falls prediction tools available for assessing elderly inpatients in rehabilitation hospitals. Methods and Findings: We searched six electronic databases using comprehensive search strategies developed for each database. Estimates of sensitivity and specificity were plotted in ROC space graphs and pooled across studies. Our search identified three studies which assessed the prediction properties of falls prediction tools in a total of 754 elderly inpatients in rehabilitation hospitals. Only the STRATIFY tool was assessed in all three studies; the other identified tools (PJC-FRAT and DOWNTON) were assessed by a single study. For a STRATIFY cut-score of two, pooled sensitivity was 73% (95% CI 63 to 81%) and pooled specificity was 42% (95% CI 34 to 51%). An indirect comparison of the tools across studies indicated that the DOWNTON tool has the highest sensitivity (92%), while the PJC-FRAT offers the best balance between sensitivity and specificity (73% and 75%, respectively). All studies presented major methodological limitations. Conclusions: We did not identify any tool which had an optimal balance between sensitivity and specificity, or which were clearly better than a simple clinical judgment of risk of falling. The limited number of identified studies with major methodological limitations impairs sound conclusions on the usefulness of falls risk prediction tools in geriatric rehabilitation hospitals.	[da Costa, Bruno Roza; Rutjes, Anne Wilhelmina Saskia] Univ Bern, Inst Social & Prevent Med, Div Clin Epidemiol & Biostat, Bern, Switzerland; [Mendy, Angelico] Florida Int Univ, Dept Epidemiol & Biostat, Robert Stempel Sch Publ Hlth, Miami, FL 33199 USA; [Freund-Heritage, Rosalie; Vieira, Edgar Ramos] Glenrose Rehabil Hosp, Edmonton, AB, Canada; [Vieira, Edgar Ramos] Florida Int Univ, Dept Phys Therapy, Miami, FL 33199 USA	University of Bern; State University System of Florida; Florida International University; State University System of Florida; Florida International University	da Costa, BR (corresponding author), Univ Bern, Inst Social & Prevent Med, Div Clin Epidemiol & Biostat, Bern, Switzerland.	evieira@fiu.edu	Rutjes, Anne/L-8750-2017; Vieira, Edgar Ramos/I-7609-2013	Rutjes, Anne/0000-0001-9782-779X; Vieira, Edgar Ramos/0000-0002-1011-5077; Mendy, Angelico/0000-0002-8227-6830	Alberta Health Services; College of Nursing and Health Sciences, Florida International University, Miami	Alberta Health Services; College of Nursing and Health Sciences, Florida International University, Miami	This work was supported by the Alberta Health Services. Funding for publishing this paper was provided by the College of Nursing and Health Sciences, Florida International University, Miami. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BATES DW, 1995, AM J MED, V99, P137, DOI 10.1016/S0002-9343(99)80133-8; Centers for Disease Control and Prevention, 2007, PREV FALLS OLD AD; Coker E, 2003, OUTCOMES MANAG, V7, P15; Coker Esther, 2003, Outcomes Manag, V7, P8; Evans D., 1998, FALLS ACUTE HOSP SYS; Gillespie Lesley D, 2012, Cochrane Database Syst Rev, pCD007146, DOI 10.1002/14651858.CD007146.pub3; Haines TP, 2007, J GERONTOL A-BIOL, V62, P664, DOI 10.1093/gerona/62.6.664; Haines TP, 2006, J CLIN EPIDEMIOL, V59, P168, DOI 10.1016/j.jclinepi.2005.07.017; Harbord RM, 2009, STATA J, V9, P211, DOI 10.1177/1536867X0900900203; Hayden JA, 2006, ANN INTERN MED, V144, P427, DOI 10.7326/0003-4819-144-6-200603210-00010; Healey F, 2008, QUAL SAF HEALTH CARE, V17, P424, DOI 10.1136/qshc.2007.024695; Higgins J., 2009, COCHRANE HDB SYSTEMA; Macaskill P, 2010, COCHRANE HDB SYSTEMA; Morse JM, 2006, CAN J NURS RES, V38, P74; National Patient Safety Agency, 2007, SLIPS TRIPS FALLS HO; Oliver D, 1997, BMJ-BRIT MED J, V315, P1049, DOI 10.1136/bmj.315.7115.1049; Oliver D, 2008, AGE AGEING, V37, P621, DOI 10.1093/ageing/afn203; Oliver D, 2006, CAN J NURS RES, V38, P89; PHAC-Public Health Agency of Canada. Division of Aging and Seniors, 2005, REP SEN FALLS CAN; Rousseau P, 1993, Arch Fam Med, V2, P169, DOI 10.1001/archfami.2.2.169; Rousseau P, 1993, ARCH FAM MED, V2, P166; Saverino A, 2006, Eura Medicophys, V42, P179; UDEN G, 1985, J AM GERIATR SOC, V33, P833, DOI 10.1111/j.1532-5415.1985.tb05435.x; Vassallo M, 2003, AGE AGEING, V32, P338, DOI 10.1093/ageing/32.3.338; Vassallo M, 2008, AGE AGEING, V37, P277, DOI 10.1093/ageing/afn062; Vellas BJ, 1997, AGE AGEING, V26, P189, DOI 10.1093/ageing/26.3.189; Vieira ER, 2011, CLIN REHABIL, V25, P788, DOI 10.1177/0269215511400639; VLAHOV D, 1990, ARCH PHYS MED REHAB, V71, P8	28	63	65	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2012	7	7							e41061	10.1371/journal.pone.0041061	http://dx.doi.org/10.1371/journal.pone.0041061			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	975JG	22815914	Green Published, gold			2023-01-03	WOS:000306507000060
J	Banu, S; Mahmud, AM; Rahman, MT; Hossain, A; Uddin, MKM; Ahmed, T; Khatun, R; Akhanda, W; Brosch, R				Banu, Sayera; Mahmud, Asif Mujtaba; Rahman, Md Toufiq; Hossain, Arman; Uddin, Mohammad Khaja Mafij; Ahmed, Tahmeed; Khatun, Razia; Akhanda, Wahiduzzaman; Brosch, Roland			Multidrug-Resistant Tuberculosis in Admitted Patients at a Tertiary Referral Hospital of Bangladesh	PLOS ONE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; STRAIN DIFFERENTIATION; MOLECULAR EPIDEMIOLOGY; DRUG-RESISTANCE; IDENTIFICATION; DIAGNOSIS; GENOTYPE; ELEMENTS; PCR	Background: This study was set out to investigate the magnitude, patterns and molecular characterization of drug-resistant Mycobacterium tuberculosis strains at a tertiary referral hospital in Bangladesh. Methods: Pulmonary tuberculosis (TB) patients admitted at National Institute of Diseases of the Chest and Hospital from February 2002 to September 2005 with or without previous history of TB and/or other complications were randomly interviewed. Among 265 participants enrolled, M. tuberculosis isolates from 189 patients were finally tested for susceptibility to rifampicin (RMP), isoniazid (INH), ethambutol (ETM) and streptomycin (STM). Genotyping of M. tuberculosis was done using deletion analysis and spoligotyping. Results: Eighty-eight percent (n = 167) of the patients had history of previous anti-TB treatment while the remaining 12% were new TB cases. Of the 189 isolates, 9% were fully susceptible to the first line anti-TB drugs and 73.5% were multi-drug resistant TB. Other susceptibility results showed 79.4%, 77.2%, 76.7% and 78.8% resistance to INH, RMP, ETM and STM respectively. Multi-drug resistance was significantly higher among the 130 (78%) patients with previous history of anti-tuberculosis treatment (95% confidence interval, p = 0.001). Among the 189 analyzed isolates, 69% were classified as "modern" M. tuberculosis strains (i.e. TbD1-strains, lacking the M. tuberculosis-deletion region TbD1), whereas the remaining 31% were found to belong to the "ancestal" TbD1+ M. tuberculosis lineages. One hundred and five different spoligotype patterns were identified in which 16 clusters contained 100 strains and 89 strains had unique pattern. Strains with a spoligotype characteristic for the "Beijing" cluster were predominant (19%) and most of these strains (75%) were multi-drug resistant (MDR). Conclusions: A high level of drug resistance observed among the re-treatment patients poses a threat of transmission of resistant strains to susceptible persons in the community. Proper counseling of patients and attention towards the completion of the anti-TB treatment is needed.	[Banu, Sayera; Rahman, Md Toufiq; Hossain, Arman; Uddin, Mohammad Khaja Mafij; Ahmed, Tahmeed; Khatun, Razia] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh; [Mahmud, Asif Mujtaba; Akhanda, Wahiduzzaman] Natl Inst Dis Chest & Hosp, Dhaka, Bangladesh; [Brosch, Roland] Inst Pasteur, Integrated Mycobacterial Pathogen Unit, Paris, France	International Centre for Diarrhoeal Disease Research (ICDDR); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Banu, S (corresponding author), Int Ctr Diarrhoeal Dis Res, GPO Box 128, Dhaka 1000, Bangladesh.	sbanu@icddrb.org	Brosch, Roland/ABB-4108-2021; Brosch, Roland/AAZ-3850-2021	Brosch, Roland/0000-0003-2587-3863; Banu, Sayera/0000-0002-5121-1962	United Nations Development Programme/World Bank/World Health Organization special program for Research and Training in Tropical Diseases; Ellison Medical Foundation - International Nutrition Foundation; Tuberculosis Laboratory of International Centre for Diarrheal Diseases and Research, Bangladesh;  [GR-00278]	United Nations Development Programme/World Bank/World Health Organization special program for Research and Training in Tropical Diseases; Ellison Medical Foundation - International Nutrition Foundation(Lawrence Ellison Foundation); Tuberculosis Laboratory of International Centre for Diarrheal Diseases and Research, Bangladesh; 	This work was supported in part by grants from the United Nations Development Programme/World Bank/World Health Organization special program for Research and Training in Tropical Diseases, Ellison Medical Foundation - International Nutrition Foundation and the Tuberculosis Laboratory of International Centre for Diarrheal Diseases and Research, Bangladesh. The grant number was GR-00278. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anh DD, 2000, EMERG INFECT DIS, V6, P302; [Anonymous], 2009, OP MAN MAN MULT RES; [Anonymous], 2008, WHOHTMTB2008394 ANT; [Anonymous], 2010, WHOHTMTB20103; [Anonymous], 2009, NAT GUID OP MAN TUB; Banu S, 2004, J CLIN MICROBIOL, V42, P674, DOI 10.1128/JCM.42.2.674-682.2004; Banu S, 2012, INT J TUBERC LUNG D, V16, P319, DOI 10.5588/ijtld.11.0426; Bifani PJ, 1999, JAMA-J AM MED ASSOC, V282, P2321, DOI 10.1001/jama.282.24.2321; Borrell S, 2009, INT J TUBERC LUNG D, V13, P1456; Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299; CANETTI G, 1969, B WORLD HEALTH ORGAN, V41, P21; Chadha VK, 1997, GLOBAL TRENDS TUBERC, V33, P11; Chan ED, 2002, BMJ-BRIT MED J, V325, P1282, DOI 10.1136/bmj.325.7375.1282; Cox H, 2006, PLOS MED, V3, P1836, DOI 10.1371/journal.pmed.0030384; Diaz R, 1998, INT J TUBERC LUNG D, V2, P743; Djuretic T, 2002, THORAX, V57, P477, DOI 10.1136/thorax.57.6.477; Faustini A, 2006, THORAX, V61, P158, DOI 10.1136/thx.2005.045963; HERMANS PWM, 1991, INFECT IMMUN, V59, P2695, DOI 10.1128/IAI.59.8.2695-2705.1991; Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907, DOI 10.1128/JCM.35.4.907-914.1997; Kim SJ, 1997, INT J TUBERC LUNG D, V1, P302; KOLK AHJ, 1992, J CLIN MICROBIOL, V30, P2567, DOI 10.1128/JCM.30.10.2567-2575.1992; Kordy FNS, 2004, INT J TUBERC LUNG D, V8, P1007; KOX LFF, 1994, J CLIN MICROBIOL, V32, P672, DOI 10.1128/JCM.32.3.672-678.1994; Kurepina N. E., 1998, Tubercle and Lung Disease, V79, P31, DOI 10.1054/tuld.1998.0003; Miah M R, 2000, Bangladesh Med Res Counc Bull, V26, P33; Mistry NF, 2002, J CLIN MICROBIOL, V40, P2677, DOI 10.1128/JCM.40.7.2677-2680.2002; Mostafizur Rahman, 2009, Journal of Medicine, V10, P45; Mostofa Kamal SM, 2009, BANGLADESH J MED MIC, P23; Organization WH, 2008, GLOB TUB CONTR SURV; Parsons LM, 2002, J CLIN MICROBIOL, V40, P2339, DOI 10.1128/JCM.40.7.2339-2345.2002; Petroff SA, 1915, J EXP MED, V21, P38, DOI 10.1084/jem.21.1.38; Saltini C, 2006, RESP MED, V100, P2085, DOI 10.1016/j.rmed.2006.09.015; Singh UB, 2004, EMERG INFECT DIS, V10, P1138, DOI 10.3201/eid1006.030575; Sola C, 2001, EMERG INFECT DIS, V7, P390; Swaminathan S, 2008, J BIOSCIENCES, V33, P527, DOI 10.1007/s12038-008-0071-2; The World Health Organization, 2008, WHOHTMTB2008393; VANSOOLINGEN D, 1995, J CLIN MICROBIOL, V33, P3234, DOI 10.1128/JCM.33.12.3234-3238.1995; VANSOOLINGEN D, 1993, J CLIN MICROBIOL, V31, P1987, DOI 10.1128/JCM.31.8.1987-1995.1993; World Health Organization, 2007, WHOHTMTB2007387; World Health Organization (WHO), 2003, WHOCDSTB2003320; Zaman K, 2005, SCAND J INFECT DIS, V37, P21, DOI 10.1080/00365540410026095	41	21	21	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2012	7	7							e40545	10.1371/journal.pone.0040545	http://dx.doi.org/10.1371/journal.pone.0040545			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973LU	22808189	Green Submitted, gold, Green Published			2023-01-03	WOS:000306362400069
J	Hasan, S; Danishuddin, M; Adil, M; Singh, K; Verma, PK; Khan, AU				Hasan, Sadaf; Danishuddin, Mohd; Adil, Mohd; Singh, Kunal; Verma, Praveen K.; Khan, Asad U.			Efficacy of E. officinalis on the Cariogenic Properties of Streptococcus mutans: A Novel and Alternative Approach to Suppress Quorum-Sensing Mechanism	PLOS ONE			English	Article							ANTIMICROBIAL ACTIVITY; BIOFILM FORMATION; ACID PRODUCTION; ADHERENCE; CARIES; HYDROPHOBICITY; IDENTIFICATION; INHIBITION; PROTEINS; EXTRACTS	The present study was focused on evaluating the potential of Emblica officinalis against cariogenic properties of Streptococcus mutans, a causative microorganism for caries. The effect of crude extract and ethanolic fraction from Emblica officinalis fruit was analysed against S. mutans. The sub-MIC concentrations of crude and ethanolic fraction of E. officinalis were evaluated for its cariogenic properties such as acid production, biofilm formation, cell-surface hydrophobicity, glucan production, sucrose-dependent and independent adherence. Its effect on biofilm architecture was also investigated with the help of confocal and scanning electron microscopy (SEM). Moreover, expression of genes involved in biofilm formation was also studied by quantitative RT-PCR. This study showed 50% reduction in adherence at concentrations 156 mu g/and 312.5 mu g/ml of crude extract and ethanolic fraction respectively. However, the biofilm was reduced to 50% in the presence of crude extract (39.04 mu g/ml) and ethanolic fraction (78.08 mu g/ml). Furthermore, effective reduction was observed in the glucan synthesis and cell surface hydrophobicity. The qRT-PCR revealed significant suppression of the genes involved in its virulence. Confocal and scanning electron microscopy clearly depicted the obliteration of biofilm structure with reference to control. Hence, this study reveals the potential of E. officinalis fruit extracts as an alternative and complementary medicine for dental caries by inhibiting the virulence factors of Streptococcus mutans.	[Hasan, Sadaf; Danishuddin, Mohd; Adil, Mohd; Khan, Asad U.] Aligarh Muslim Univ, Interdisciplinary Biotechnol Unit, Med Microbiol & Mol Biol Lab, Aligarh, Uttar Pradesh, India; [Singh, Kunal; Verma, Praveen K.] Natl Inst Plant Genome Res, New Delhi, India	Aligarh Muslim University; Department of Biotechnology (DBT) India; National Institute of Plant Genome Research (NIPGR)	Hasan, S (corresponding author), Aligarh Muslim Univ, Interdisciplinary Biotechnol Unit, Med Microbiol & Mol Biol Lab, Aligarh, Uttar Pradesh, India.	asad.k@rediffmail.com	Singh, Kunal/AAS-1975-2021; Khan, Asad U/K-8157-2013; hasan, sadaf/J-4050-2019	Singh, Kunal/0000-0001-9375-1070; Khan, Asad U/0000-0001-9191-9423; 	(Interdisciplinary Biotechnology Unit) IBU; Aligarh Muslim University (AMU); Indian Council of Medical Research (ICMR) [531 59/6/2009/BMS/TRM]	(Interdisciplinary Biotechnology Unit) IBU; Aligarh Muslim University (AMU); Indian Council of Medical Research (ICMR)(Indian Council of Medical Research (ICMR))	This study was supported by internal funds of (Interdisciplinary Biotechnology Unit) IBU, Aligarh Muslim University (AMU) and Indian Council of Medical Research (ICMR) grant no. 531 59/6/2009/BMS/TRM to AUK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript	CIARDI JE, 1981, J DENT RES, V60, P756, DOI 10.1177/00220345810600031701; Dmitriev A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020127; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; HAMADA S, 1978, INFECT IMMUN, V20, P592, DOI 10.1128/IAI.20.3.592-599.1978; HARDIE JM, 1992, BRIT DENT J, V172, P271, DOI 10.1038/sj.bdj.4807849; Hazra B, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-20; IIO M, 1984, AGR BIOL CHEM TOKYO, V48, P2143, DOI 10.1080/00021369.1984.10866463; Islam B, 2009, J APPL MICROBIOL, V106, P1682, DOI 10.1111/j.1365-2672.2008.04135.x; Islam B, 2008, J ANTIMICROB CHEMOTH, V62, P751, DOI 10.1093/jac/dkn253; JONES G, 1995, J MOL BIOL, V245, P43, DOI 10.1016/S0022-2836(95)80037-9; Khan R, 2010, J APPL MICROBIOL, V109, P2151, DOI 10.1111/j.1365-2672.2010.04847.x; Khan R, 2009, MOLECULES, V14, P586, DOI 10.3390/molecules14020586; Koo H, 2000, ARCH ORAL BIOL, V45, P141, DOI 10.1016/S0003-9969(99)00117-X; Koo H, 2003, J ANTIMICROB CHEMOTH, V52, P782, DOI 10.1093/jac/dkg449; Laurie ATR, 2005, BIOINFORMATICS, V21, P1908, DOI 10.1093/bioinformatics/bti315; LOESCHE WJ, 1986, MICROBIOL REV, V50, P353, DOI 10.1128/MMBR.50.4.353-380.1986; Loo CY, 2000, J BACTERIOL, V182, P1374, DOI 10.1128/JB.182.5.1374-1382.2000; Lynch DJ, 2007, FEMS MICROBIOL LETT, V268, P158, DOI 10.1111/j.1574-6968.2006.00576.x; MARTIN MA, 1989, AM J INFECT CONTROL, V17, P130, DOI 10.1016/0196-6553(89)90199-5; Matsumoto M, 1999, CARIES RES, V33, P441, DOI 10.1159/000016549; MCBRIDE BC, 1984, INFECT IMMUN, V44, P68, DOI 10.1128/IAI.44.1.68-75.1984; Miller-Torbert TA, 2008, MICROB PATHOGENESIS, V45, P53, DOI 10.1016/j.micpath.2008.02.001; Nascimento MM, 2004, J BACTERIOL, V186, P6383, DOI 10.1128/JB.186.19.6383-6390.2004; Nostro A, 2004, LETT APPL MICROBIOL, V38, P423, DOI 10.1111/j.1472-765X.2004.01509.x; Pecharki D, 2005, ORAL MICROBIOL IMMUN, V20, P366, DOI 10.1111/j.1399-302X.2005.00244.x; Perianayagam JB, 2004, J ETHNOPHARMACOL, V95, P83, DOI 10.1016/j.jep.2004.06.020; Prabu GR, 2006, J APPL MICROBIOL, V101, P487, DOI 10.1111/j.1365-2672.2006.02912.x; Razak Fathilah Abdul, 2003, J Oral Sci, V45, P201; Ribeiro DA, 2004, J PERIODONTAL RES, V39, P358, DOI 10.1111/j.1600-0765.2004.00759.x; Senadheera D, 2008, ADV EXP MED BIOL, V631, P178, DOI 10.1007/978-0-387-78885-2_12; ULLMAN RF, 1988, HEART LUNG, V17, P209; VANDERHOEVEN JS, 1984, INFECT IMMUN, V45, P356, DOI 10.1128/IAI.45.2.356-359.1984; Wakabayashi H, 2010, BIOMETALS, V23, P419, DOI 10.1007/s10534-010-9304-6; Wen ZT, 2005, INFECT IMMUN, V73, P219, DOI 10.1128/IAI.73.1.219-225.2005; Wimpenny J, 2000, FEMS MICROBIOL REV, V24, P661, DOI 10.1111/j.1574-6976.2000.tb00565.x; YAMASHITA Y, 1993, INFECT IMMUN, V61, P3811, DOI 10.1128/IAI.61.9.3811-3817.1993	36	51	55	1	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 5	2012	7	7							e40319	10.1371/journal.pone.0040319	http://dx.doi.org/10.1371/journal.pone.0040319			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	974LI	22792279	Green Published, gold, Green Submitted			2023-01-03	WOS:000306436300054
J	Kripalani, S; Roumie, CL; Dalal, AK; Cawthon, C; Businger, A; Eden, SK; Shintani, A; Sponsler, KC; Harris, LJ; Theobald, C; Huang, RL; Scheurer, D; Hunt, S; Jacobson, TA; Rask, KJ; Vaccarino, V; Gandhi, TK; Bates, DW; Williams, MV; Schnipper, JL				Kripalani, Sunil; Roumie, Christianne L.; Dalal, Anuj K.; Cawthon, Courtney; Businger, Alexandra; Eden, Svetlana K.; Shintani, Ayumi; Sponsler, Kelly Cunningham; Harris, L. Jeff; Theobald, Cecelia; Huang, Robert L.; Scheurer, Danielle; Hunt, Susan; Jacobson, Terry A.; Rask, Kimberly J.; Vaccarino, Viola; Gandhi, Tejal K.; Bates, David W.; Williams, Mark V.; Schnipper, Jeffrey L.		PILL-CVD Pharmacist Intervent Low	Effect of a Pharmacist Intervention on Clinically Important Medication Errors After Hospital Discharge A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							ADVERSE DRUG EVENTS; PATIENTS AFTER-DISCHARGE; LOW-LITERACY; CARE; RECONCILIATION; PREVALENCE; INPATIENT	Background: Clinically important medication errors are common after hospital discharge. They include preventable or ameliorable adverse drug events (ADEs), as well as medication discrepancies or nonadherence with high potential for future harm (potential ADEs). Objective: To determine the effect of a tailored intervention on the occurrence of clinically important medication errors after hospital discharge. Design: Randomized, controlled trial with concealed allocation and blinded outcome assessors. (ClinicalTrials.gov registration number: NCT00632021) Setting: Two tertiary care academic hospitals. Patients: Adults hospitalized with acute coronary syndromes or acute decompensated heart failure. Intervention: Pharmacist-assisted medication reconciliation, inpatient pharmacist counseling, low-literacy adherence aids, and individualized telephone follow-up after discharge. Measurements: The primary outcome was the number of clinically important medication errors per patient during the first 30 days after hospital discharge. Secondary outcomes included preventable or ameliorable ADEs, as well as potential ADEs. Results: Among 851 participants, 432 (50.8%) had 1 or more clinically important medication errors; 22.9% of such errors were judged to be serious and 1.8% life-threatening. Adverse drug events occurred in 258 patients (30.3%) and potential ADEs in 253 patients (29.7%). The intervention did not significantly alter the per-patient number of clinically important medication errors (unadjusted incidence rate ratio, 0.92 [95% CI, 0.77 to 1.10]) or ADEs (unadjusted incidence rate ratio, 1.09 [CI, 0.86 to 1.39]). Patients in the intervention group tended to have fewer potential ADEs (unadjusted incidence rate ratio, 0.80 [CI, 0.61 to 1.04]). Limitation: The characteristics of the study hospitals and participants may limit generalizability. Conclusion: Clinically important medication errors were present among one half of patients after hospital discharge and were not significantly reduced by a health-literacy-sensitive, pharmacist-delivered intervention.	Vanderbilt Univ, Vanderbilt Ctr Hlth Serv Res, Vet Affairs Tennessee Valley Geriatr Res Educ Cli, Hlth Serv Res & Dev Serv,Targeted Res Enhancement, Nashville, TN USA; Clin Res Ctr Excellence, Nashville, TN USA; Harvard Univ, Brigham & Womens Hosp, Brigham & Womens Hosp Hospitalist Serv, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA; Med Univ S Carolina, Charleston, SC 29425 USA; Univ Washington, Hospitalist Serv, Seattle, WA 98195 USA; Emory Univ, Sch Med, Atlanta, GA USA; Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; NW Univ Feinberg, Sch Med, Chicago, IL USA	Geriatric Research Education & Clinical Center; Vanderbilt University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Medical University of South Carolina; University of Washington; University of Washington Seattle; Emory University; Emory University; Rollins School Public Health; Northwestern University; Feinberg School of Medicine	Kripalani, S (corresponding author), Vanderbilt Univ, Dept Med, Med Ctr E, 1215 21st Ave S,Suite 6000, Nashville, TN 37232 USA.	sunil.kripalani@vanderbilt.edu	Bates, David/AAE-7283-2019; Jacobson, Terry/AAK-4757-2020; Rask, Kimberly/L-5742-2019; rask, kimberly/M-8001-2016; , Viola/AAW-5600-2020	Jacobson, Terry/0000-0002-9926-2179; Rask, Kimberly/0000-0001-6806-4666; Harris, Leonard/0000-0002-4967-4618; Williams, Mark V/0000-0001-6107-0457; Reyes, Harry/0000-0001-7774-2561	National Heart, Lung, and Blood Institute; National Heart, Lung, and Blood Institute grant [R01 HL089755, K23 HL077597, K08 HL072806]; Veterans Affairs Career Development Award [04-342-2]; National Center for Research Resources grant [UL1 RR024975]; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024977, TL1RR024978, UL1RR024975] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL089755, K23HL077597, K08HL072806] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Heart, Lung, and Blood Institute grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Veterans Affairs Career Development Award; National Center for Research Resources grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	National Heart, Lung, and Blood Institute.; By National Heart, Lung, and Blood Institute grant R01 HL089755 (Dr. Kripalani) and in part by National Heart, Lung, and Blood Institute grant K23 HL077597 (Dr. Kripalani); National Heart, Lung, and Blood Institute grant K08 HL072806 (Dr. Schnipper); Veterans Affairs Career Development Award 04-342-2 (Dr. Roumie); and National Center for Research Resources grant UL1 RR024975 (Dr. Bernard).	BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Borson S, 2005, J AM GERIATR SOC, V53, P871, DOI 10.1111/j.1532-5415.2005.53269.x; Coleman EA, 2005, ARCH INTERN MED, V165, P1842, DOI 10.1001/archinte.165.16.1842; Cua YM, 2008, ANN ACAD MED SINGAP, V37, P136; Davis TC, 2006, ANN INTERN MED, V145, P887, DOI 10.7326/0003-4819-145-12-200612190-00144; Elhai JD, 2008, PSYCHIAT RES, V160, P129, DOI 10.1016/j.psychres.2007.07.003; Forster AJ, 2005, J GEN INTERN MED, V20, P317, DOI 10.1111/j.1525-1497.2005.30390.x; Forster AJ, 2004, CAN MED ASSOC J, V170, P345; Forster AJ, 2003, ANN INTERN MED, V138, P161, DOI 10.7326/0003-4819-138-3-200302040-00007; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; Kaboli PJ, 2006, ARCH INTERN MED, V166, P955, DOI 10.1001/archinte.166.9.955; Kripalani S, 2008, MAYO CLIN PROC, V83, P529, DOI 10.4065/83.5.529; Kripalani S, 2007, J HOSP MED, V2, P314, DOI 10.1002/jhm.228; Kripalani S, 2007, PATIENT EDUC COUNS, V66, P368, DOI 10.1016/j.pec.2007.01.020; Little RJA, 2002, STAT ANAL MISSING DA, p[85, 209]; Marvanova M, 2011, J HOSP MED, V6, P488, DOI 10.1002/jhm.925; McCullagh P., 1999, GEN LINEAR MODELS; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; Moore C, 2003, J GEN INTERN MED, V18, P646, DOI 10.1046/j.1525-1497.2003.20722.x; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; Paasche-Orlow MK, 2005, J GEN INTERN MED, V20, P175, DOI 10.1111/j.1525-1497.2005.40245.x; Parker RM, 1998, SHORT TEST FUNCTIONA; Poon EG, 2006, ANN INTERN MED, V145, P426, DOI 10.7326/0003-4819-145-6-200609190-00006; Rask KJ, 2005, AM J MANAG CARE, V11, P145; Schillinger D, 2003, ARCH INTERN MED, V163, P83, DOI 10.1001/archinte.163.1.83; Schnipper JL, 2011, J AM MED INFORM ASSN, V18, P309, DOI 10.1136/amiajnl-2010-000040; Schnipper JL, 2010, CIRC-CARDIOVASC QUAL, V3, P212, DOI 10.1161/CIRCOUTCOMES.109.921833; Schnipper JL, 2009, ARCH INTERN MED, V169, P771, DOI 10.1001/archinternmed.2009.51; Schnipper JL, 2006, ARCH INTERN MED, V166, P565, DOI 10.1001/archinte.166.5.565; Schnipper JL, 2010, J HOSP MED S1, V68, P68; van Buuren S, 2000, MULTIVARIATE IMPUTAT; Walker PC, 2009, ARCH INTERN MED, V169, P2003, DOI 10.1001/archinternmed.2009.398; [No title captured], DOI DOI 10.1016/J.JACC.2007.02.013	33	192	193	0	28	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2012	157	1					1	U35		10.7326/0003-4819-157-1-201207030-00003	http://dx.doi.org/10.7326/0003-4819-157-1-201207030-00003			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	992NS	22751755	Green Accepted			2023-01-03	WOS:000307784900001
J	Coombes, R				Coombes, Rebecca			NHS REFORMS How will secondary care need to shape up to survive? A roundtable discussion	BRITISH MEDICAL JOURNAL			English	Editorial Material									BMJ, London WC1H 9JR, England		Coombes, R (corresponding author), BMJ, London WC1H 9JR, England.	rcoombes@bmj.com							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	JUN 27	2012	344								e4384	10.1136/bmj.e4384	http://dx.doi.org/10.1136/bmj.e4384			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	968MX	22740570				2023-01-03	WOS:000305987100026
J	Craddock, TJA; George, MS; Freedman, H; Barakat, KH; Damaraju, S; Hameroff, S; Tuszynski, JA				Craddock, Travis J. A.; George, Marc St.; Freedman, Holly; Barakat, Khaled H.; Damaraju, Sambasivarao; Hameroff, Stuart; Tuszynski, Jack A.			Computational Predictions of Volatile Anesthetic Interactions with the Microtubule Cytoskeleton: Implications for Side Effects of General Anesthesia	PLOS ONE			English	Article							CENTRAL-NERVOUS-SYSTEM; ALPHA-BETA-TUBULIN; RAT-BRAIN PROTEINS; MOLECULAR-DYNAMICS; SEVOFLURANE ANESTHESIA; HIPPOCAMPAL-NEURONS; INHALED ANESTHETICS; COGNITIVE DECLINE; HALOTHANE BINDING; KINASE-C	The cytoskeleton is essential to cell morphology, cargo trafficking, and cell division. As the neuronal cytoskeleton is extremely complex, it is no wonder that a startling number of neurodegenerative disorders (including but not limited to Alzheimer's disease, Parkinson's disease and Huntington's disease) share the common feature of a dysfunctional neuronal cytoskeleton. Recently, concern has been raised about a possible link between anesthesia, post-operative cognitive dysfunction, and the exacerbation of neurodegenerative disorders. Experimental investigations suggest that anesthetics bind to and affect cytoskeletal microtubules, and that anesthesia-related cognitive dysfunction involves microtubule instability, hyper-phosphorylation of the microtubule-associated protein tau, and tau separation from microtubules. However, exact mechanisms are yet to be identified. In this paper the interaction of anesthetics with the microtubule subunit protein tubulin is investigated using computer-modeling methods. Homology modeling, molecular dynamics simulations and surface geometry techniques were used to determine putative binding sites for volatile anesthetics on tubulin. This was followed by free energy based docking calculations for halothane (2-bromo-2-chloro-1,1,1-trifluoroethane) on the tubulin body, and C-terminal regions for specific tubulin isotypes. Locations of the putative binding sites, halothane binding energies and the relation to cytoskeleton function are reported in this paper.	[Craddock, Travis J. A.; Barakat, Khaled H.; Tuszynski, Jack A.] Univ Alberta, Dept Phys, Edmonton, AB, Canada; [George, Marc St.; Damaraju, Sambasivarao] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB, Canada; [Freedman, Holly] Univ Algarve, Fdn Sci & Technol, Ctr Marine Sci, Faro, Portugal; [Hameroff, Stuart] Univ Arizona, Hlth Sci Ctr, Dept Anesthesiol, Ctr Consciousness Studies, Tucson, AZ USA; [Hameroff, Stuart] Univ Arizona, Hlth Sci Ctr, Dept Psychol, Ctr Consciousness Studies, Tucson, AZ USA; [Damaraju, Sambasivarao; Tuszynski, Jack A.] Univ Alberta, Dept Oncol, Cross Canc Inst, Edmonton, AB, Canada	University of Alberta; University of Alberta; Universidade do Algarve; University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences; University of Alberta	Craddock, TJA (corresponding author), Univ Alberta, Dept Phys, Edmonton, AB, Canada.	travisc@ualberta.ca; jackt@ualberta.ca	Tuszynski, Jack/AAA-2073-2020	Tuszynski, Jack/0000-0001-9976-0429; Barakat, Khaled/0000-0002-3567-7279; Craddock, Travis/0000-0001-7244-6317	NSERC (Natural Sciences and Engineering Research Council); Alberta Cancer Foundation [23783]; Alberta Advanced Education and Technology [TC-LSI-08-09]; Allard Foundation [23676]; Portuguese Foundation for Science and Technology (FCT)	NSERC (Natural Sciences and Engineering Research Council)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Alberta Cancer Foundation; Alberta Advanced Education and Technology; Allard Foundation; Portuguese Foundation for Science and Technology (FCT)(Portuguese Foundation for Science and Technology)	T.J.A.C. gratefully acknowledges funding support from NSERC (Natural Sciences and Engineering Research Council) (www.nserc-crsng.gc.ca). J.A.T. acknowledges support for this research from the Alberta Cancer Foundation (Grant #: 23783) (albertacancer.ca), Alberta Advanced Education and Technology (Grant #: TC-LSI-08-09) (www.advancededucation.gov.ab.ca), the Allard Foundation (Grant #: 23676), and NSERC (www.nserc-crsng.gc.ca). H. F. is grateful for postdoctoral fellowship funding from the Portuguese Foundation for Science and Technology (FCT) (www.fct.pt). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALLISON AC, 1968, LANCET, V2, P1326; ALLISON AC, 1970, J CELL SCI, V7, P483; ANTHONY BL, 1989, NEUROSCI LETT, V99, P191, DOI 10.1016/0304-3940(89)90288-7; Avidan MS, 2011, J ALZHEIMERS DIS, V24, P201, DOI 10.3233/JAD-2011-101680; Bai RL, 1996, CANCER RES, V56, P4398; Bennett MJ, 2010, CHEM BIOL, V17, P725, DOI 10.1016/j.chembiol.2010.05.019; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; BHATTACHARYYA B, 1985, J BIOL CHEM, V260, P208; Brady GP, 2000, J COMPUT AID MOL DES, V14, P383, DOI 10.1023/A:1008124202956; Bush AI, 2008, NEUROTHERAPEUTICS, V5, P421, DOI 10.1016/j.nurt.2008.05.001; Byrem WC, 2006, BBA-PROTEINS PROTEOM, V1764, P1320, DOI 10.1016/j.bbapap.2006.06.009; Campagna JA, 2003, NEW ENGL J MED, V348, P2110, DOI 10.1056/NEJMra021261; Carpenter EJ, 2006, EUR BIOPHYS J BIOPHY, V36, P35, DOI 10.1007/s00249-006-0088-0; Case D.A., 2006, AMBER, V9; Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290; Conde C, 2009, NAT REV NEUROSCI, V10, P319, DOI 10.1038/nrn2631; COVARRUBIAS M, 1995, J BIOL CHEM, V270, P19408, DOI 10.1074/jbc.270.33.19408; Craddock TJA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033552; Craddock TJA, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002421; DAIGLE I, 1993, BIOCHEM CELL BIOL, V71, P57, DOI 10.1139/o93-009; Delano W.L, 2002, DELANO SCI; Durieux ME, 1996, ANESTHESIOLOGY, V84, P173, DOI 10.1097/00000542-199601000-00020; Eckenhoff ME, 2002, J PHARMACOL EXP THER, V300, P172, DOI 10.1124/jpet.300.1.172; Eckenhoff MF, 1998, J PHARMACOL EXP THER, V285, P371; Eckenhoff RG, 2012, ANESTHESIOLOGY, V116, P751, DOI 10.1097/ALN.0b013e31824be8e1; ELMAGHRABI EA, 1993, ANESTHESIOLOGY, V78, P750, DOI 10.1097/00000542-199304000-00019; Ester M., 1996, KDD-96 Proceedings. Second International Conference on Knowledge Discovery and Data Mining, P226; Fodale V, 2010, J ALZHEIMERS DIS, V22, pS1, DOI 10.3233/JAD-2010-100809; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; Freedman H, 2011, PROTEINS, V79, P2968, DOI 10.1002/prot.23155; Furukawa K, 2003, J NEUROCHEM, V87, P427, DOI 10.1046/j.1471-4159.2003.02020.x; FURUKAWA K, 1995, BRAIN RES, V689, P141, DOI 10.1016/0006-8993(95)00537-Z; Futterer CD, 2004, ANESTHESIOLOGY, V100, P302; GASKIN F, 1977, J BIOL CHEM, V252, P6918; Ghersi D, 2009, PROTEINS, V74, P417, DOI 10.1002/prot.22154; Gigant B, 2005, NATURE, V435, P519, DOI 10.1038/nature03566; Greenberger Lee M., 2008, P227, DOI 10.1007/978-1-59745-336-3_10; Hameroff S, 2002, BIOSYSTEMS, V64, P149, DOI 10.1016/S0303-2647(01)00183-6; Hameroff SR, 2010, J INTEGR NEUROSCI, V9, P253, DOI 10.1142/S0219635210002482; Hemmings HC, 1996, ANESTHESIOLOGY, V84, P652, DOI 10.1097/00000542-199603000-00021; Hetenyi C, 2006, FEBS LETT, V580, P1447, DOI 10.1016/j.febslet.2006.01.074; Hetenyi C, 2002, PROTEIN SCI, V11, P1729, DOI 10.1110/ps.0202302; HINKLEY R E JR, 1971, Journal of Neurobiology, V2, P97, DOI 10.1002/neu.480020202; HINKLEY RE, 1972, J CELL BIOL, V53, P258, DOI 10.1083/jcb.53.1.258; HINKLEY RE, 1976, J ULTRA MOL STRUCT R, V57, P237, DOI 10.1016/S0022-5320(76)80113-X; HINKLEY RE, 1978, J CELL SCI, V32, P99; Huzil JT, 2008, J MOL BIOL, V378, P1016, DOI 10.1016/j.jmb.2008.03.026; Huzil JT, 2006, NANOTECHNOLOGY, V17, pS90, DOI 10.1088/0957-4484/17/4/014; Joe PA, 2009, J BIOL CHEM, V284, P4283, DOI 10.1074/jbc.M807491200; JOHNSON BD, 1994, PFLUG ARCH EUR J PHY, V429, P14, DOI 10.1007/BF02584025; JOHNSON BD, 1993, NEURON, V10, P797, DOI 10.1016/0896-6273(93)90196-X; Kaech S, 1999, P NATL ACAD SCI USA, V96, P10433, DOI 10.1073/pnas.96.18.10433; Kalenka A, 2007, ANESTH ANALG, V104, P1129, DOI 10.1213/01.ane.0000260799.37107.e6; Kar S, 2003, EMBO J, V22, P70, DOI 10.1093/emboj/cdg001; KARON BS, 1995, BIOPHYS J, V68, P936, DOI 10.1016/S0006-3495(95)80269-9; Khan IA, 2003, INVEST NEW DRUG, V21, P3, DOI 10.1023/A:1022946305242; KINGSTON DGI, 1994, TRENDS BIOTECHNOL, V12, P222, DOI 10.1016/0167-7799(94)90120-1; Kuehn BM, 2007, JAMA-J AM MED ASSOC, V297, P1760, DOI 10.1001/jama.297.16.1760; Le Freche H, 2012, ANESTHESIOLOGY, V116, P779, DOI 10.1097/ALN.0b013e31824be8c7; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; Li HL, 2002, STRUCTURE, V10, P1317, DOI 10.1016/S0969-2126(02)00827-4; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; LIVINGSTON A, 1979, CELL TISSUE RES, V198, P137; Livingston A, 1979, BR J PHARM, V67, p453P; Lobert S, 2000, BIOCHEMISTRY-US, V39, P12053, DOI 10.1021/bi001038r; Lowe J, 2001, J MOL BIOL, V313, P1045, DOI 10.1006/jmbi.2001.5077; Luduena Richard E., 2008, P123, DOI 10.1007/978-1-59745-336-3_6; Luduena Richard F., 2008, P105, DOI 10.1007/978-1-59745-336-3_5; MEJILLANO MR, 1992, BIOCHEMISTRY-US, V31, P3478, DOI 10.1021/bi00128a023; Meyer DK, 2000, J NEUROSCI, V20, P6743, DOI 10.1523/JNEUROSCI.20-18-06743.2000; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Minami K, 1998, J BIOL CHEM, V273, P8248, DOI 10.1074/jbc.273.14.8248; Mironov SL, 1999, EUR J NEUROSCI, V11, P1831, DOI 10.1046/j.1460-9568.1999.00584.x; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Okuda C, 1976, JAP J ANESTH, V35, p78S; Pan JZ, 2008, PROTEOMICS, V8, P2983, DOI 10.1002/pmic.200800057; Pan JZ, 2007, J PROTEOME RES, V6, P582, DOI 10.1021/pr060311u; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Pentyala SN, 1999, EUR J PHARMACOL, V384, P213, DOI 10.1016/S0014-2999(99)00625-1; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Raines DE, 1996, ANESTHESIOLOGY, V84, P663, DOI 10.1097/00000542-199603000-00022; Ravelli RBG, 2004, NATURE, V428, P198, DOI 10.1038/nature02393; Rehberg B, 1996, ANESTHESIOLOGY, V84, P1223, DOI 10.1097/00000542-199605000-00025; RICHARDS CD, 1976, BRIT J PHARMACOL, V58, P347, DOI 10.1111/j.1476-5381.1976.tb07711.x; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SACKETT DL, 1985, J BIOL CHEM, V260, P43; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanchez-Pedregal VM, 2009, TOP CURR CHEM, V286, P151, DOI 10.1007/128_2008_22; Santamaria LB, 2010, SURG ONCOL, V19, P63, DOI 10.1016/j.suronc.2009.03.007; SEGAL IS, 1988, ANESTHESIOLOGY, V69, P818, DOI 10.1097/00000542-198812000-00004; SERRANO L, 1984, P NATL ACAD SCI-BIOL, V81, P5989, DOI 10.1073/pnas.81.19.5989; SERRANO L, 1988, BIOCHEM J, V252, P683, DOI 10.1042/bj2520683; Shu NJ, 2008, BIOINFORMATICS, V24, P775, DOI 10.1093/bioinformatics/btm618; SLATER SJ, 1993, NATURE, V364, P82, DOI 10.1038/364082a0; Smith CD, 1996, J BIOL CHEM, V271, P6192, DOI 10.1074/jbc.271.11.6192; Streiff JH, 2006, BIOPHYS J, V91, P3405, DOI 10.1529/biophysj.106.082586; Tang JX, 2010, ANESTH ANALG, V110, P421, DOI 10.1213/ANE.0b013e3181b80939; Tang P, 2001, J COMPUT CHEM, V22, P436, DOI 10.1002/1096-987X(200103)22:4<436::AID-JCC1014>3.0.CO;2-U; Tesler A, 1977, EXP CELL RES, V107, P247; TYSON GE, 1973, Z ZELLFORSCH MIK ANA, V141, P443, DOI 10.1007/BF00307116; Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291; VERGARA GA, 1981, PHARMACOLOGY, V23, P264, DOI 10.1159/000137559; von Bergen M, 2001, J BIOL CHEM, V276, P48165, DOI 10.1074/jbc.M105196200; WANDOSELL F, 1986, J BIOL CHEM, V261, P332; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; WARFIELD RK, 1974, SCIENCE, V186, P1219, DOI 10.1126/science.186.4170.1219; WEST RR, 1991, J BIOL CHEM, V266, P21886; Wolff J, 1996, PROTEIN SCI, V5, P2020, DOI 10.1002/pro.5560051008; Woolf NJ, 2009, BIOL MED PHYS BIOMED, P177, DOI 10.1007/978-3-642-03584-5_5; Xi J, 2004, J BIOL CHEM, V279, P19628, DOI 10.1074/jbc.M313864200	112	49	50	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2012	7	6							e37251	10.1371/journal.pone.0037251	http://dx.doi.org/10.1371/journal.pone.0037251			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	965QG	22761654	Green Published, gold, Green Submitted			2023-01-03	WOS:000305781700002
J	Fassnacht, M; Terzolo, M; Allolio, B; Baudin, E; Haak, H; Berruti, A; Welin, S; Schade-Brittinger, C; Lacroix, A; Jarzab, B; Sorbye, H; Torpy, DJ; Stepan, V; Schteingart, DE; Arlt, W; Kroiss, M; Leboulleux, S; Sperone, P; Sundin, A; Hermsen, I; Hahner, S; Willenberg, HS; Tabarin, A; Quinkler, M; de la Fouchardiere, C; Schlumberger, M; Mantero, F; Weismann, D; Beuschlein, F; Gelderblom, H; Wilmink, H; Sender, M; Edgerly, M; Kenn, W; Fojo, T; Muller, HH; Skogseid, B				Fassnacht, Martin; Terzolo, Massimo; Allolio, Bruno; Baudin, Eric; Haak, Harm; Berruti, Alfredo; Welin, Staffan; Schade-Brittinger, Carmen; Lacroix, Andre; Jarzab, Barbara; Sorbye, Halfdan; Torpy, David J.; Stepan, Vinzenz; Schteingart, David E.; Arlt, Wiebke; Kroiss, Matthias; Leboulleux, Sophie; Sperone, Paola; Sundin, Anders; Hermsen, Ilse; Hahner, Stefanie; Willenberg, Holger S.; Tabarin, Antoine; Quinkler, Marcus; de la Fouchardiere, Christelle; Schlumberger, Martin; Mantero, Franco; Weismann, Dirk; Beuschlein, Felix; Gelderblom, Hans; Wilmink, Hanneke; Sender, Monica; Edgerly, Maureen; Kenn, Werner; Fojo, Tito; Muller, Hans-Helge; Skogseid, Britt		FIRM-ACT Study Grp	Combination Chemotherapy in Advanced Adrenocortical Carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-II TRIAL; SOUTHWEST-ONCOLOGY-GROUP; CLINICAL MANAGEMENT; MITOTANE; CANCER; ENDOCRINE; CISPLATIN; ETOPOSIDE; DOXORUBICIN; SERIES	BACKGROUND Adrenocortical carcinoma is a rare cancer that has a poor response to cytotoxic treatment. METHODS We randomly assigned 304 patients with advanced adrenocortical carcinoma to receive mitotane plus either a combination of etoposide (100 mg per square meter of body-surface area on days 2 to 4), doxorubicin (40 mg per square meter on day 1), and cisplatin (40 mg per square meter on days 3 and 4) (EDP) every 4 weeks or streptozocin (streptozotocin) (1 g on days 1 to 5 in cycle 1; 2 g on day 1 in subsequent cycles) every 3 weeks. Patients with disease progression received the alternative regimen as second-line therapy. The primary end point was overall survival. RESULTS For first-line therapy, patients in the EDP-mitotane group had a significantly higher response rate than those in the streptozocin-mitotane group (23.2% vs. 9.2%, P<0.001) and longer median progression-free survival (5.0 months vs. 2.1 months; hazard ratio, 0.55; 95% confidence interval [CI], 0.43 to 0.69; P<0.001); there was no significant between-group difference in overall survival (14.8 months and 12.0 months, respectively; hazard ratio, 0.79; 95% CI, 0.61 to 1.02; P=0.07). Among the 185 patients who received the alternative regimen as second-line therapy, the median duration of progression-free survival was 5.6 months in the EDP-mitotane group and 2.2 months in the streptozocin-mitotane group. Patients who did not receive the alternative second-line therapy had better overall survival with first-line EDP plus mitotane (17.1 month) than with streptozocin plus mitotane (4.7 months). Rates of serious adverse events did not differ significantly between treatments. CONCLUSIONS Rates of response and progression-free survival were significantly better with EDP plus mitotane than with streptozocin plus mitotane as first-line therapy, with similar rates of toxic events, although there was no significant difference in overall survival. (Funded by the Swedish Research Council and others; FIRM-ACT ClinicalTrials.gov number, NCT00094497.)	[Fassnacht, Martin; Allolio, Bruno; Kroiss, Matthias; Hahner, Stefanie; Weismann, Dirk] Univ Hosp, Dept Internal Med 1, Wurzburg, Germany; [Kenn, Werner] Univ Hosp, Dept Radiol, Wurzburg, Germany; [Fassnacht, Martin; Allolio, Bruno; Kenn, Werner] Univ Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany; [Terzolo, Massimo] Univ Turin, Dept Clin & Biol Sci, Orbassano, Italy; [Baudin, Eric; Leboulleux, Sophie; Schlumberger, Martin] Inst Gustave Roussy, Serv Med Nucl & Cancerol Endocrinienne, Villejuif, France; [Haak, Harm; Hermsen, Ilse] Maxima Med Ctr, Dept Internal Med, Eindhoven, Netherlands; [Welin, Staffan] Univ Uppsala Hosp, Dept Endocrine Oncol, Uppsala, Sweden; [Schade-Brittinger, Carmen] Univ Marburg, Coordinating Ctr Clin Trials, Marburg, Germany; [Lacroix, Andre] Ctr Hosp Univ Montreal, Dept Med, Montreal, PQ, Canada; [Jarzab, Barbara] Maria Sklodowska Curie Mem Canc Ctr, Dept Nucl Med & Endocrine Oncol, Gliwice, Poland; [Jarzab, Barbara] Inst Oncol, Gliwice, Poland; [Sorbye, Halfdan] Haukeland Hosp, Dept Oncol, N-5021 Bergen, Norway; [Torpy, David J.] Royal Adelaide Hosp, Endocrine & Metab Unit, Adelaide, SA 5000, Australia; [Stepan, Vinzenz] Elisabethinen Hosp, Dept Internal Med, Graz, Austria; [Schteingart, David E.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Arlt, Wiebke] Sch Clin & Expt Med, Ctr Endocrinol Diabet & Metab, Birmingham, W Midlands, England; [Sundin, Anders] Karolinska Inst, Dept Radiol, Inst Mol Med & Surg, Stockholm, Sweden; [Willenberg, Holger S.] Univ Dusseldorf, Dept Endocrinol Diabet & Rheumatol, Fac Med, D-40225 Dusseldorf, Germany; [Tabarin, Antoine] Univ Bordeaux, Dept Endocrinol, Bordeaux, France; [Quinkler, Marcus] Charite, Charite Campus Mitte, D-13353 Berlin, Germany; [de la Fouchardiere, Christelle] Ctr Leon Berard, F-69373 Lyon, France; [Mantero, Franco] Univ Padua, Sch Med, Endocrine Unit, Dept Med & Surg Sci, Padua, Italy; [Beuschlein, Felix] Klinikum Univ Munchen, Med Klin & Poliklin 4, Munich, Germany; [Gelderblom, Hans] Leiden Univ, Med Ctr, Dept Clin Oncol, Leiden, Netherlands; [Wilmink, Hanneke] Univ Amsterdam, Acad Med Ctr, Dept Med Oncol, NL-1105 AZ Amsterdam, Netherlands; [Sender, Monica] Sahlgrens Univ Hosp, Dept Oncol, Gothenburg, Sweden; [Edgerly, Maureen; Fojo, Tito] NCI, Med Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Muller, Hans-Helge] Univ Munich, Inst Med Informat Biometry & Epidemiol, Munich, Germany; [Skogseid, Britt] Uppsala Univ, Dept Med Sci, Uppsala, Sweden	University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Turin; UNICANCER; Gustave Roussy; Maxima Medical Center; Uppsala University; Uppsala University Hospital; Philipps University Marburg; Universite de Montreal; Maria Sklodowska-Curie National Research Institute of Oncology; Maria Sklodowska-Curie National Research Institute of Oncology; University of Bergen; Haukeland University Hospital; Royal Adelaide Hospital; University of Michigan System; University of Michigan; Karolinska Institutet; Heinrich Heine University Dusseldorf; UDICE-French Research Universities; Universite de Bordeaux; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; UNICANCER; Centre Leon Berard; University of Padua; University of Munich; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam; Sahlgrenska University Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Munich; Uppsala University	Fassnacht, M (corresponding author), Univ Hosp Wurzburg, Dept Internal Med 1, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany.	fassnacht_m@medizin.uni-wuerzburg.de	Jarząb, Barbara/AAI-7942-2020; Jarząb, Michał/G-4319-2012; de la Fouchardiere, Christelle/AAW-7887-2021; Kroiss, Matthias/AAF-1624-2019; Fassnacht, Martin/N-9614-2019; leboulleux, sophie/AAW-6534-2020; Arlt, Wiebke/B-6310-2009; Levesque, Isabelle/A-1899-2012; Kroiss, Matthias/B-4785-2014; Berruti, Alfredo/AAC-2069-2019; Lacroix, Andre/AAI-5645-2020; Barbara, Jarzab/I-4654-2019; Sbiera, Silviu/E-8128-2019; DO CAO, CHRISTINE/M-7950-2018; Terzolo, Massimo/D-5051-2015	Jarząb, Barbara/0000-0001-9811-9584; Jarząb, Michał/0000-0002-2642-9724; Kroiss, Matthias/0000-0002-7628-3161; Fassnacht, Martin/0000-0001-6170-6398; Arlt, Wiebke/0000-0001-5106-9719; Kroiss, Matthias/0000-0002-7628-3161; Sbiera, Silviu/0000-0002-6271-5533; della casa, silvia/0000-0002-1245-753X; CHABRE, Olivier/0000-0001-8756-7218; DO CAO, CHRISTINE/0000-0002-1617-0149; Hahner, Stefanie/0000-0003-1616-8986; /0000-0001-9732-4543; Beuschlein, Felix/0000-0001-7826-3984; DeVries, J. Hans/0000-0001-9196-9906; Terzolo, Massimo/0000-0002-4171-2851; Quinkler, Marcus/0000-0003-4028-1671; , Sophie/0000-0002-4824-8502; Gelderblom, Hans/0000-0001-9270-8636	German Ministry of Education and Research [01KG0501]; Italian Ministry of University and Research [PRIN 20085 P5S49]; Institut Gustave-Roussy Clinical Research Unit; Cortical and Medullary Endocrine Tumors Network of the French Institut National du Cancer; Swedish Cancer Society; Swedish Research Council; HRA Pharma; MRC [G0801473] Funding Source: UKRI; Medical Research Council [G0801473] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [ZIABC010626] Funding Source: NIH RePORTER	German Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Italian Ministry of University and Research(Ministry of Education, Universities and Research (MIUR)); Institut Gustave-Roussy Clinical Research Unit; Cortical and Medullary Endocrine Tumors Network of the French Institut National du Cancer; Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); HRA Pharma; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by grants from the German Ministry of Education and Research (01KG0501), the Italian Ministry of University and Research (PRIN 20085 P5S49), Institut Gustave-Roussy Clinical Research Unit, the Cortical and Medullary Endocrine Tumors Network of the French Institut National du Cancer, the Swedish Cancer Society, and the Swedish Research Council. Nested in the FIRM-ACT trial, a study on the pharmacokinetics of mitotane was organized in 40 patients who were enrolled in the FIRM-ACT trial. This substudy was funded by HRA Pharma.	Abiven G, 2006, J CLIN ENDOCR METAB, V91, P2650, DOI 10.1210/jc.2005-2730; Abraham J, 2002, CANCER-AM CANCER SOC, V94, P2333, DOI 10.1002/cncr.10487.abs; Assie G, 2007, J CLIN ENDOCR METAB, V92, P148, DOI 10.1210/jc.2006-0706; Baudin E., 2011, Hormones & Cancer, V2, P363, DOI 10.1007/s12672-011-0094-2; Baudin E, 2001, CANCER, V92, P1385, DOI 10.1002/1097-0142(20010915)92:6&lt;1385::AID-CNCR1461&gt;3.0.CO;2-2; Berruti A, 2005, ENDOCR-RELAT CANCER, V12, P657, DOI 10.1677/erc.1.01025; Berruti A, 1998, CANCER, V83, P2194, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2194::AID-CNCR19>3.3.CO;2-V; Berruti A, 2008, EXPERT OPIN EMERG DR, V13, P497, DOI 10.1517/14728214.13.3.497 ; Berruti A, 2012, EUR J ENDOCRINOL, V166, P451, DOI 10.1530/EJE-11-0918; BUKOWSKI RM, 1993, J CLIN ONCOL, V11, P161, DOI 10.1200/JCO.1993.11.1.161; Cancer Therapy Evaluation Program, 1999, COMM TERM CRIT ADV E; Fassnacht M, 2011, NAT REV ENDOCRINOL, V7, P323, DOI 10.1038/nrendo.2010.235; Fassnacht M, 2009, PHARMACOL THERAPEUT, V123, P117, DOI 10.1016/j.pharmthera.2009.03.013; Fassnacht M, 2009, CANCER-AM CANCER SOC, V115, P243, DOI 10.1002/cncr.24030; Fayers PM, 2001, EUR J CANCER, V37, P1331, DOI 10.1016/S0959-8049(01)00127-7; Golden SH, 2009, J CLIN ENDOCR METAB, V94, P1853, DOI 10.1210/jc.2008-2291; Gross DJ, 2006, ENDOCR-RELAT CANCER, V13, P535, DOI 10.1677/erc.1.01124; HAAK HR, 1994, BRIT J CANCER, V69, P947, DOI 10.1038/bjc.1994.183; Hermsen IG, 2011, J CLIN ENDOCR METAB, V96, P1844, DOI 10.1210/jc.2010-2676; Icard P, 2001, WORLD J SURG, V25, P891, DOI 10.1007/s00268-001-0047-y; Kebebew E, 2006, WORLD J SURG, V30, P872, DOI 10.1007/s00268-005-0329-x; Khan TS, 2000, ANN ONCOL, V11, P1281, DOI 10.1023/A:1008377915129; Kroiss M, 2011, CLIN ENDOCRINOL, V75, P585, DOI 10.1111/j.1365-2265.2011.04214.x; Libe R, 2007, ENDOCR-RELAT CANCER, V14, P13, DOI 10.1677/erc.1.01130; Lughezzani G, 2010, EUR J CANCER, V46, P713, DOI 10.1016/j.ejca.2009.12.007; Malandrino P, 2010, ENDOCR-RELAT CANCER, V17, P797, DOI 10.1677/ERC-09-0341; Quinkler M, 2008, J CLIN ENDOCR METAB, V93, P2057, DOI 10.1210/jc.2007-2564; Schteingart DE, 2005, ENDOCR-RELAT CANCER, V12, P667, DOI 10.1677/erc.1.01029; Terzolo M, 2007, NEW ENGL J MED, V356, P2372, DOI 10.1056/NEJMoa063360; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; van Erp NP, 2011, EUR J ENDOCRINOL, V164, P621, DOI 10.1530/EJE-10-0956; Williamson SK, 2000, CANCER, V88, P1159, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1159::AID-CNCR28>3.3.CO;2-I; Wortmann S, 2010, EUR J ENDOCRINOL, V162, P349, DOI 10.1530/EJE-09-0804; Zini L, 2011, EUR UROL, V60, P1055, DOI 10.1016/j.eururo.2011.07.062	34	492	512	3	68	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 7	2012	366	23					2189	2197		10.1056/NEJMoa1200966	http://dx.doi.org/10.1056/NEJMoa1200966			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	953JO	22551107	Green Published, Bronze			2023-01-03	WOS:000304863400008
J	Sheets, NC; Goldin, GH; Meyer, AM; Wu, Y; Chang, YK; Sturmer, T; Holmes, JA; Reeve, BB; Godley, PA; Carpenter, WR; Chen, RC				Sheets, Nathan C.; Goldin, Gregg H.; Meyer, Anne-Marie; Wu, Yang; Chang, YunKyung; Stuermer, Til; Holmes, Jordan A.; Reeve, Bryce B.; Godley, Paul A.; Carpenter, William R.; Chen, Ronald C.			Intensity-Modulated Radiation Therapy, Proton Therapy, or Conformal Radiation Therapy and Morbidity and Disease Control in Localized Prostate Cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; SEER-MEDICARE DATA; GASTROINTESTINAL TOXICITY; RADICAL PROSTATECTOMY; DOSE-ESCALATION; 70 GY; RADIOTHERAPY; URINARY; ADENOCARCINOMA	Context There has been rapid adoption of newer radiation treatments such as intensity-modulated radiation therapy (IMRT) and proton therapy despite greater cost and limited demonstrated benefit compared with previous technologies. Objective To determine the comparative morbidity and disease control of IMRT, proton therapy, and conformal radiation therapy for primary prostate cancer treatment. Design, Setting, and Patients Population-based study using Surveillance, Epidemiology, and End Results-Medicare-linked data from 2000 through 2009 for patients with nonmetastatic prostate cancer. Main Outcome Measures Rates of gastrointestinal and urinary morbidity, erectile dysfunction, hip fractures, and additional cancer therapy. Results Use of IMRT vs conformal radiation therapy increased from 0.15% in 2000 to 95.9% in 2008. In propensity score-adjusted analyses (N=12 976), men who received IMRT vs conformal radiation therapy were less likely to receive a diagnosis of gastrointestinal morbidities (absolute risk, 13.4 vs 14.7 per 100 person-years; relative risk [RR], 0.91; 95% CI, 0.86-0.96) and hip fractures (absolute risk, 0.8 vs 1.0 per 100 person-years; RR, 0.78; 95% CI, 0.65-0.93) but more likely to receive a diagnosis of erectile dysfunction (absolute risk, 5.9 vs 5.3 per 100 person-years; RR, 1.12; 95% CI, 1.03-1.20). Intensity-modulated radiation therapy patients were less likely to receive additional cancer therapy (absolute risk, 2.5 vs 3.1 per 100 person-years; RR, 0.81; 95% CI, 0.73-0.89). In a propensity score-matched comparison between IMRT and proton therapy (n=1368), IMRT patients had a lower rate of gastrointestinal morbidity (absolute risk, 12.2 vs 17.8 per 100 person-years; RR, 0.66; 95% CI, 0.55-0.79). There were no significant differences in rates of other morbidities or additional therapies between IMRT and proton therapy. Conclusions Among patients with nonmetastatic prostate cancer, the use of IMRT compared with conformal radiation therapy was associated with less gastrointestinal morbidity and fewer hip fractures but more erectile dysfunction; IMRT compared with proton therapy was associated with less gastrointestinal morbidity. JAMA. 2012;307(15):1611-1620	[Sheets, Nathan C.; Goldin, Gregg H.; Holmes, Jordan A.; Chen, Ronald C.] Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC USA; [Meyer, Anne-Marie; Godley, Paul A.; Carpenter, William R.; Chen, Ronald C.] Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC USA; [Holmes, Jordan A.] Univ N Carolina, Sch Med, Chapel Hill, NC USA; [Meyer, Anne-Marie; Wu, Yang; Reeve, Bryce B.; Godley, Paul A.; Carpenter, William R.; Chen, Ronald C.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Chang, YunKyung] Univ N Carolina, Sch Nursing, Chapel Hill, NC USA; [Stuermer, Til] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; [Reeve, Bryce B.; Carpenter, William R.] Univ N Carolina, Sch Publ Hlth, Dept Hlth Policy & Management, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Chen, RC (corresponding author), Univ N Carolina Hosp, Dept Radiat Oncol, CB 7512, Chapel Hill, NC 27599 USA.	ronald_chen@med.unc.edu	Carpenter, William/E-5125-2013; Reeve, Bryce/AAE-7657-2019; Stürmer, Til/AAB-5459-2022		National Institute on Aging at the National Institutes of Health (NIH) [RO1 AG023178, RO1 AG018833]; University of North Carolina (UNC) Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) center from the Agency for Healthcare Research and Quality; UNC Center of Excellence in Pharmacoepidemiology and Public Health; Merck; sanofi-aventis; Agency for Healthcare Research and Quality, US Department of Health and Human Services as part of the DEcIDE [HHSA290-2005-0040-I-TO6]; National Institute of Nursing Research (NINR) at the NIH [2T32NR008856]; NATIONAL CANCER INSTITUTE [P30CA016086, U54CA153602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [T32NR008856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018833, R01AG023178] Funding Source: NIH RePORTER	National Institute on Aging at the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); University of North Carolina (UNC) Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) center from the Agency for Healthcare Research and Quality; UNC Center of Excellence in Pharmacoepidemiology and Public Health; Merck(Merck & Company); sanofi-aventis(Sanofi-Aventis); Agency for Healthcare Research and Quality, US Department of Health and Human Services as part of the DEcIDE; National Institute of Nursing Research (NINR) at the NIH; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Sturmer reports receiving investigator-initiated research funding and support as principal investigator (RO1 AG023178) and coinvestigator (RO1 AG018833) from the National Institute on Aging at the National Institutes of Health (NIH), funding as principal investigator of the University of North Carolina (UNC) Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) center from the Agency for Healthcare Research and Quality, salary support from the UNC Center of Excellence in Pharmacoepidemiology and Public Health, consultancy on the Genentech CER advisory board, and from unrestricted research grants from Merck and sanofi-aventis to the UNC. Dr Godley reports receiving compensation for participating in the data and safety monitoring committee for Ferring Pharmaceuticals, which manufactures Degarelix, a hormonal treatment for prostate cancer that is not directly related to the subject of this study, and receiving compensation for consultancy with GlaxoSmithKline. No other disclosures were reported.; This research was funded by the Agency for Healthcare Research and Quality, US Department of Health and Human Services as part of the DEcIDE program, contract HHSA290-2005-0040-I-TO6. This publication was made possible by grant 2T32NR008856 from the National Institute of Nursing Research (NINR) at the NIH.	Al-Mamgani A, 2009, INT J RADIAT ONCOL, V73, P685, DOI 10.1016/j.ijrobp.2008.04.063; Bekelman JE, 2011, INT J RADIAT ONCOL, V81, pE325, DOI 10.1016/j.ijrobp.2011.02.006; Brookhart MA, 2010, PHARMACOEPIDEM DR S, V19, P537, DOI 10.1002/pds.1908; Brookhart M Alan, 2007, Int J Biostat, V3, P14; Chen RC, 2009, J CLIN ONCOL, V27, P3916, DOI 10.1200/JCO.2008.18.6486; Choe KS, 2010, INT J RADIAT ONCOL, V76, P755, DOI 10.1016/j.ijrobp.2009.02.026; Dearnaley DP, 2007, LANCET ONCOL, V8, P475, DOI 10.1016/S1470-2045(07)70143-2; Elliott SP, 2011, CANCER-AM CANCER SOC, V117, P4557, DOI 10.1002/cncr.25994; Fiorino C, 2009, RADIOTHER ONCOL, V93, P153, DOI 10.1016/j.radonc.2009.08.004; Giordano SH, 2006, CANCER, V107, P423, DOI 10.1002/cncr.21999; Goozner M, 2010, J NATL CANCER I, V102, P450, DOI 10.1093/jnci/djq112; Hu JC, 2009, JAMA-J AM MED ASSOC, V302, P1557, DOI 10.1001/jama.2009.1451; Hurwitz MD, 2008, NAT CLIN PRACT ONCOL, V5, P668, DOI 10.1038/ncponc1224; Institute for Clinical and Economic Review, 2009, MAN OPT LOW RISK PRO; Institute of Medicine, 2009, IN NAT PRIOR COMP EF; Kim S, 2011, EUR UROL, V60, P908, DOI 10.1016/j.eururo.2011.05.052; Klabunde CN, 2007, ANN EPIDEMIOL, V17, P584, DOI 10.1016/j.annepidem.2007.03.011; Lips I, 2007, INT J RADIAT ONCOL, V69, P656, DOI 10.1016/j.ijrobp.2007.04.013; Lowrance WT, 2010, J UROLOGY, V183, P1366, DOI 10.1016/j.juro.2009.12.021; LuYao GL, 1996, J NATL CANCER I, V88, P166, DOI 10.1093/jnci/88.3-4.166; Michalski JM, 2010, INT J RADIAT ONCOL, V76, pS123, DOI 10.1016/j.ijrobp.2009.03.078; Newhauser WD, 2008, PHYS MED BIOL, V53, P2327, DOI 10.1088/0031-9155/53/9/009; Nguyen PL, 2011, J CLIN ONCOL, V29, P1517, DOI 10.1200/JCO.2010.31.1217; Nutting CM, 2000, INT J RADIAT ONCOL, V48, P649, DOI 10.1016/S0360-3016(00)00653-2; Pollack A, 2000, J CLIN ONCOL, V18, P3904, DOI 10.1200/JCO.2000.18.23.3904; Pollack A, 2002, INT J RADIAT ONCOL, V53, P1097, DOI 10.1016/S0360-3016(02)02829-8; PONTES JE, 1993, CANCER, V71, P976, DOI 10.1002/1097-0142(19930201)71:3+<976::AID-CNCR2820711413>3.0.CO;2-M; Potosky AL, 2004, J NATL CANCER I, V96, P1358, DOI 10.1093/jnci/djh259; Potosky AL, 2002, MED CARE, V40, P62; Roach M, 2010, INT J RADIAT ONCOL, V76, pS130, DOI 10.1016/j.ijrobp.2009.04.094; Sanda MG, 2008, NEW ENGL J MED, V358, P1250, DOI 10.1056/NEJMoa074311; Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056/NEJMoa041943; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; StatBite, 2010, JNCI-J NATL CANCER I, V102, P450; Tepper JE, 2008, J CLIN ONCOL, V26, P2436, DOI 10.1200/JCO.2008.17.1165; Terasawa T, 2009, ANN INTERN MED, V151, P556, DOI 10.7326/0003-4819-151-8-200910200-00145; Trofimov A, 2007, INT J RADIAT ONCOL, V69, P444, DOI 10.1016/j.ijrobp.2007.03.018; Valdagni R, 2008, INT J RADIAT ONCOL, V71, P1065, DOI 10.1016/j.ijrobp.2007.11.037; Viswanathan AN, 2010, INT J RADIAT ONCOL, V76, pS116, DOI 10.1016/j.ijrobp.2009.02.090; Warren JL, 2002, MED CARE, V40, P3; Wilt TJ, 2008, ANN INTERN MED, V148, P435, DOI 10.7326/0003-4819-148-6-200803180-00209; Zelefsky MJ, 2008, INT J RADIAT ONCOL, V70, P1124, DOI 10.1016/j.ijrobp.2007.11.044; Zietman AL, 2005, JAMA-J AM MED ASSOC, V294, P1233, DOI 10.1001/jama.294.10.1233; Zietman AL, 2007, J CLIN ONCOL, V25, P3565, DOI 10.1200/JCO.2007.11.9768; Zietman AL, 2010, J CLIN ONCOL, V28, P1106, DOI 10.1200/JCO.2009.25.8475	45	345	350	2	55	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 18	2012	307	15					1611	1620		10.1001/jama.2012.460	http://dx.doi.org/10.1001/jama.2012.460			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	927GU	22511689	Bronze, Green Accepted, Green Published			2023-01-03	WOS:000302896100023
J	Booth, BBB; Dunstone, NJ; Halloran, PR; Andrews, T; Bellouin, N				Booth, Ben B. B.; Dunstone, Nick J.; Halloran, Paul R.; Andrews, Timothy; Bellouin, Nicolas			Aerosols implicated as a prime driver of twentieth-century North Atlantic climate variability	NATURE			English	Article							MULTIDECADAL OSCILLATION; RAINFALL; TEMPERATURES	Systematic climate shifts have been linked to multidecadal variability in observed sea surface temperatures in the North Atlantic Ocean(1). These links are extensive, influencing a range of climate processes such as hurricane activity(2) and African Sahel(3-5) and Amazonian(5) droughts. The variability is distinct from historical global-mean temperature changes and is commonly attributed to natural ocean oscillations(6-10). A number of studies have provided evidence that aerosols can influence long-term changes in sea surface temperatures(11,12), but climate models have so far failed to reproduce these interactions(6,9) and the role of aerosols in decadal variability remains unclear. Here we use a state-of-the-art Earth system climate model to show that aerosol emissions and periods of volcanic activity explain 76 per cent of the simulated multidecadal variance in detrended 1860-2005 North Atlantic sea surface temperatures. After 1950, simulated variability is within observational estimates; our estimates for 1910-1940 capture twice the warming of previous generation models but do not explain the entire observed trend. Other processes, such as ocean circulation, may also have contributed to variability in the early twentieth century. Mechanistically, we find that inclusion of aerosol-cloud microphysical effects, which were included in few previous multimodel ensembles, dominates the magnitude (80 per cent) and the spatial pattern of the total surface aerosol forcing in the North Atlantic. Our findings suggest that anthropogenic aerosol emissions influenced a range of societally important historical climate events such as peaks in hurricane activity and Sahel drought. Decadal-scale model predictions of regional Atlantic climate will probably be improved by incorporating aerosol-cloud microphysical interactions and estimates of future concentrations of aerosols, emissions of which are directly addressable by policy actions.	[Booth, Ben B. B.; Dunstone, Nick J.; Halloran, Paul R.; Andrews, Timothy; Bellouin, Nicolas] Met Off Hadley Ctr, Exeter EX1 3PB, Devon, England	Met Office - UK; Hadley Centre	Booth, BBB (corresponding author), Met Off Hadley Ctr, FitzRoy Rd, Exeter EX1 3PB, Devon, England.	ben.booth@metoffice.gov.uk	Kushnir, Yochanan/B-4472-2013; Dunstone, Nick/G-6304-2012; Halloran, Paul R/G-3965-2012; Andrews, Timothy/C-5912-2014	Dunstone, Nick/0000-0001-6859-6814; Halloran, Paul R/0000-0002-9227-0678; Andrews, Timothy/0000-0002-8248-8753; Bellouin, Nicolas/0000-0003-2109-9559	Office of Science, US Department of Energy; DECC/Defra Met Office Hadley Centre [GA01101]; EU	Office of Science, US Department of Energy(United States Department of Energy (DOE)); DECC/Defra Met Office Hadley Centre; EU(European Commission)	We are grateful for discussion and input from D. Smith, D. Sexton, J. Murphy, M. Palmer, C. Roberts and J. Knight during the analysis and writing of this paper. We acknowledge the modelling groups, the Program for Climate Model Diagnosis and Intercomparison and the WCRP's Working Group on Coupled Modelling for their roles in making available the WCRP CMIP3 multimodel data set. Support of this data set is provided by the Office of Science, US Department of Energy. The authors were supported by the Joint DECC/Defra Met Office Hadley Centre Climate Programme (GA01101) and the EU FP7 THOR project.	Ackerley D, 2011, J CLIMATE, V24, P4999, DOI 10.1175/JCLI-D-11-00019.1; Baines PG, 2007, J CLIMATE, V20, P2721, DOI 10.1175/JCLI4177.1; Bellouin N, 2011, J GEOPHYS RES-ATMOS, V116, DOI 10.1029/2011JD016074; Bjerknes J., 1964, ADV GEOPHYS, V10, P1, DOI [10.1016/S0065-2687(08)60005-9, DOI 10.1016/S0065-2687(08)60005-9]; Chang CY, 2011, J CLIMATE, V24, P2540, DOI 10.1175/2010JCLI4065.1; Chen W, 2010, J GEOPHYS RES-ATMOS, V115, DOI 10.1029/2009JD013596; Chylek P, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL042793; Collins WJ, 2011, GEOSCI MODEL DEV, V4, P1051, DOI 10.5194/gmd-4-1051-2011; Curtis S, 2008, CLIM DYNAM, V30, P343, DOI 10.1007/s00382-007-0295-0; Dong BW, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL025766; Enfield DB, 2001, GEOPHYS RES LETT, V28, P2077, DOI 10.1029/2000GL012745; Evan AT, 2009, SCIENCE, V324, P778, DOI 10.1126/science.1167404; FOLLAND CK, 1986, NATURE, V320, P602, DOI 10.1038/320602a0; Goldenberg SB, 2001, SCIENCE, V293, P474, DOI 10.1126/science.1060040; Hoerling M, 2006, J CLIMATE, V19, P3989, DOI 10.1175/JCLI3842.1; Jones CD, 2011, GEOSCI MODEL DEV, V4, P543, DOI 10.5194/gmd-4-543-2011; Kerr RA, 2000, SCIENCE, V288, P1984, DOI 10.1126/science.288.5473.1984; Knight JR, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL026242; Knight JR, 2009, J CLIMATE, V22, P1610, DOI 10.1175/2008JCLI2628.1; Knight JR, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL024233; Lohmann U, 2005, ATMOS CHEM PHYS, V5, P715, DOI 10.5194/acp-5-715-2005; Mann M. E, 2006, EOS T AM GEOPHYS UN, V87, P233, DOI [10.1029/2006EO240001, DOI 10.1029/2006EO240001]; Ottera OH, 2010, NAT GEOSCI, V3, P688, DOI 10.1038/NGEO955; Quaas J, 2009, ATMOS CHEM PHYS, V9, P8697, DOI 10.5194/acp-9-8697-2009; SATO M, 1993, J GEOPHYS RES-ATMOS, V98, P22987, DOI 10.1029/93JD02553; Smith TM, 2008, J CLIMATE, V21, P2283, DOI 10.1175/2007JCLI2100.1; Sutton RT, 2005, SCIENCE, V309, P115, DOI 10.1126/science.1109496; Ting MF, 2009, J CLIMATE, V22, P1469, DOI 10.1175/2008JCLI2561.1; Trenberth KE, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL026894; Zhang R, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL026267	30	651	664	13	283	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 12	2012	484	7393					228	U110		10.1038/nature10946	http://dx.doi.org/10.1038/nature10946			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	930OV	22498628	Green Accepted			2023-01-03	WOS:000303149900032
J	Belogurov, AA; Stepanov, AV; Smirnov, IV; Melamed, D; Bacon, A; Mamedov, AE; Boitsov, VM; Sashchenko, LP; Ponomarenko, NA; Sharanova, SN; Boyko, AN; Dubina, MV; Friboulet, A; Genkin, DD; Gabibov, AG				Belogurov, Alexey A., Jr.; Stepanov, Alexey V.; Smirnov, Ivan V.; Melamed, Dobroslav; Bacon, Andrew; Mamedov, Azad E.; Boitsov, Vitali M.; Sashchenko, Lidia P.; Ponomarenko, Natalia A.; Sharanova, Svetlana N.; Boyko, Alexey N.; Dubina, Michael V.; Friboulet, Alain; Genkin, Dmitry D.; Gabibov, Alexander G.			Liposome-encapsulated peptides protect against experimental allergic encephalitis	FASEB JOURNAL			English	Article						multiple sclerosis; myelin basic protein; small unilamellar vesicles; brain-derived neurotrophic factor; remyelination	MYELIN BASIC-PROTEIN; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS; T-CELLS; SUPPRESSION; ANTIGEN; AUTOANTIBODIES; IMMUNOTHERAPY; DEGRADATION; SPECIFICITY	Multiple sclerosis (MS) is a severe inflammatory and neurodegenerative disease with an autoimmune background. Despite the variety of therapeutics available against MS, the development of novel approaches to its treatment is of high importance in modern pharmaceutics. In this study, experimental autoimmune encephalomyelitis (EAE) in Dark Agouti rats has been treated with immunodominant peptides of the myelin basic protein (MBP) encapsulated in mannosylated small unilamellar vesicles. The results show that liposome-encapsulated MBP46-62 is the most effective in reducing maximal disease score during the first attack, while MBP124-139 and MBP147-170 can completely prevent the development of the exacerbation stage. Both mannosylation of liposomes and encapsulation of peptides are critical for the therapeutic effect, since neither naked peptides nor nonmannosylated liposomes, loaded or empty, have proved effective. The liposome-mediated synergistic effect of the mixture of 3 MBP peptides significantly suppresses the progression of protracted EAE, with the median cumulative disease score being reduced from 22 to 14 points, compared to the placebo group; prevents the production of circulating autoantibodies; down-regulates the synthesis of Th1 cytokines; and induces the production of brain-derived neurotrophic factor in the central nervous system. Thus, the proposed formulation ameliorates EAE, providing for a less severe first attack and rapid recovery from exacerbation, and offers a promising therapeutic modality in MS treatment.-Belogurov, A. A., Jr., Stepanov, A. V., Smirnov, I. V., Melamed, D., Bacon, A., Mamedov, A. E., Boitsov, V. M., Sashchenko, L. P., Ponomarenko, N. A., Sharanova, S. N., Boyko, A. N., Dubina, M. V., Friboulet, A., Genkin, D. D., Gabibov, A. G. Liposome-encapsulated peptides protect against experimental allergic encephalitis. FASEB J. 27, 222-231 (2013). www.fasebj.org	[Belogurov, Alexey A., Jr.; Stepanov, Alexey V.; Smirnov, Ivan V.; Mamedov, Azad E.; Ponomarenko, Natalia A.; Gabibov, Alexander G.] RAS, MM Shemyakin & YA Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia; [Belogurov, Alexey A., Jr.; Sashchenko, Lidia P.; Gabibov, Alexander G.] RAS, Inst Gene Biol, Moscow 117997, Russia; [Smirnov, Ivan V.; Gabibov, Alexander G.] Moscow MV Lomonosov State Univ, Dept Chem, Moscow, Russia; [Melamed, Dobroslav] Assaf Harofeh Med Ctr, IL-70300 Zerifin, Israel; [Bacon, Andrew; Genkin, Dmitry D.] Xenet Biosci, London, England; [Boitsov, Vitali M.; Dubina, Michael V.] St Petersburg Acad Univ, RAS, Nanotechnol Res & Educ Ctr, St Petersburg, Russia; [Sharanova, Svetlana N.; Boyko, Alexey N.] NI Pirogov Natl Res Med Univ, City Hosp 11, Dept Neurol & Neurosurg, Moscow Multiple Sclerosis Ctr, Moscow, Russia; [Friboulet, Alain] Univ Technol Compiegne, CNRS, UMR 6022, Compiegne, France	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences; Lomonosov Moscow State University; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; St Petersburg Academic University; Pirogov Russian National Research Medical University; Picardie Universites; Universite de Technologie de Compiegne; Centre National de la Recherche Scientifique (CNRS)	Gabibov, AG (corresponding author), RAS, MM Shemyakin & YA Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia.	gabibov@mx.ibch.ru	Boyko, Alexey N/Z-2106-2018; Stepanov, Alexey/AAN-8721-2020; Mamedov, Azad E/O-6863-2017; Boitsov, Vitali/E-1863-2014; Belogurov, Alexey/L-5859-2017; Dubina, Michael/E-1888-2014; Smirnov, Ivan/N-5635-2017; Smirnov, Ivan V/B-2491-2014	Stepanov, Alexey/0000-0003-1616-4408; Boitsov, Vitali/0000-0002-4857-2046; Belogurov, Alexey/0000-0002-2033-9621; Dubina, Michael/0000-0002-6606-3309; Smirnov, Ivan/0000-0002-0384-6568; Smirnov, Ivan V/0000-0002-0384-6568; Boyko, Alexei/0000-0003-3306-9541; Bacon, Andrew/0000-0002-9099-9158; Ponomarenko, Natalia/0000-0003-3129-3515; Mamedov, Azad/0000-0001-9343-4550	Ministry of Industry and Trade of the Russian Federation [11411.0810200. 13. B20, 3.1]; Russian Foundation for Basic Research [10-04-00673-a]; Presidium of the Russian Academy of Sciences [2046.2012.4, 24];  [CRP/RUS09-01]	Ministry of Industry and Trade of the Russian Federation; Russian Foundation for Basic Research(Russian Foundation for Basic Research (RFBR)); Presidium of the Russian Academy of Sciences(Russian Academy of Sciences); 	This work was performed within the framework of innovative projects launched by the Ministry of Industry and Trade of the Russian Federation (state contract 11411.0810200. 13. B20, code Copolymer 3.1) and supported by the Skolkovo program, Russian Foundation for Basic Research (project 10-04-00673-a); CRP/RUS09-01, The Role of B Cell Response in Multiple Sclerosis; Scientific Schools 2046.2012.4, Chemical Basis of Biocatalysis, Federal Special Purpose; and programs Detection of Viral Antigens as Possible Triggers of Autoimmune Neurodegeneration and Nanotechnologies and Nanomaterials (no. 24) of the Presidium of the Russian Academy of Sciences.	Aharoni R, 2003, P NATL ACAD SCI USA, V100, P14157, DOI 10.1073/pnas.2336171100; Aharoni R, 1998, J NEUROIMMUNOL, V91, P135, DOI 10.1016/S0165-5728(98)00166-0; Avnir Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025721; AVRILIONIS K, 1991, J NEUROIMMUNOL, V35, P201, DOI 10.1016/0165-5728(91)90174-6; Belogurov AA, 2009, AUTOIMMUNITY, V42, P362, DOI 10.1080/08916930902832090; Belogurov AA, 2008, J IMMUNOL, V180, P1258, DOI 10.4049/jimmunol.180.2.1258; Belogurov A, 2009, BIOESSAYS, V31, P1161, DOI 10.1002/bies.200900020; Bielekova B, 2004, J IMMUNOL, V172, P3893, DOI 10.4049/jimmunol.172.6.3893; Cavaletti G, 2009, MOL PHARMACEUT, V6, P1363, DOI 10.1021/mp8001478; Croxford JL, 1998, J IMMUNOL, V160, P5181; Durova OM, 2009, MOL IMMUNOL, V47, P87, DOI 10.1016/j.molimm.2008.12.020; Engering AJ, 1997, EUR J IMMUNOL, V27, P2417, DOI 10.1002/eji.1830270941; Espuelas S, 2003, BIOORG MED CHEM LETT, V13, P2557, DOI 10.1016/S0960-894X(03)00472-4; Gabibov AG, 2011, FASEB J, V25, P4211, DOI 10.1096/fj.11-190769; Garren H., 2009, RESULTS PROBLEMS CEL, P259; Garren H, 2008, ANN NEUROL, V63, P611, DOI 10.1002/ana.21370; Hikada Masaki, 2010, Nat Immunol, V11, P1065, DOI 10.1038/ni1210-1065; Hohlfeid R, 2004, P NATL ACAD SCI USA, V101, P14599, DOI 10.1073/pnas.0404874101; Katsara M, 2008, J NEUROIMMUNOL, V200, P77, DOI 10.1016/j.jneuroim.2008.06.013; Katsara M, 2009, J MED CHEM, V52, P214, DOI 10.1021/jm801250v; Keler T, 2004, EXPERT OPIN BIOL TH, V4, P1953, DOI 10.1517/14712598.4.12.1953; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Luca ME, 2005, J NEUROIMMUNOL, V160, P178, DOI 10.1016/j.jneuroim.2004.11.014; Miyakoshi A, 2003, J IMMUNOL, V170, P6371, DOI 10.4049/jimmunol.170.12.6371; Oliver AR, 2003, J IMMUNOL, V171, P462, DOI 10.4049/jimmunol.171.1.462; Ponomarenko NA, 2006, P NATL ACAD SCI USA, V103, P281, DOI 10.1073/pnas.0509849103; Sallusto F, 2018, J IMMUNOL, V200, P887, DOI 10.1084/jem.179.4.1109; Schweingruber N, 2011, J IMMUNOL, V187, P4310, DOI 10.4049/jimmunol.1101604; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; StLouis J, 1997, J NEUROIMMUNOL, V73, P90, DOI 10.1016/S0165-5728(96)00174-9; van Bergen J, 1999, IMMUNOL REV, V172, P87; Wiendl H, 2002, BIODRUGS, V16, P183, DOI 10.2165/00063030-200216030-00003	32	37	40	0	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2013	27	1					222	231		10.1096/fj.12-213975	http://dx.doi.org/10.1096/fj.12-213975			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	064VJ	23047895	Green Published			2023-01-03	WOS:000313103200021
J	Lo, B				Lo, Bernard			Euthanasia in the Netherlands: what lessons for elsewhere?	LANCET			English	Editorial Material							PHYSICIAN-ASSISTED SUICIDE; LIFE DECISION-MAKING; PALLIATIVE SEDATION; COUNTRIES; CARE		[Lo, Bernard] Greenwall Fdn, New York, NY USA; [Lo, Bernard] Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Lo, B (corresponding author), Greenwall Fdn, New York, NY USA.	bernie@medicine.ucsf.edu						Alpers A, 1999, ARCH FAM MED, V8, P200, DOI 10.1001/archfami.8.3.200; Brennan T, 2002, LANCET, V359, P520, DOI 10.1016/s0140-6736(02)07684-5; Buiting HM, 2010, J MED ETHICS, V36, P24, DOI 10.1136/jme.2009.030155; Cohen J, 2008, J MED ETHICS, V34, P247, DOI 10.1136/jme.2006.020297; Li D, 2008, J PAIN, V9, P2, DOI 10.1016/j.jpain.2007.08.009; Lo B, 2005, JAMA-J AM MED ASSOC, V294, P1810, DOI 10.1001/jama.294.14.1810; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; Onwuteaka-Philipsen BD, 2012, LANCET; Quill TE, 2009, ANN INTERN MED, V151, P421, DOI 10.7326/0003-4819-151-6-200909150-00007; Regional euthanasia review committees, ANN REP 2010; Schweickert WD, 2008, CRIT CARE, V12, DOI 10.1186/cc6151; Smets T, 2012, EUR J PUBLIC HEALTH, V22, P19, DOI 10.1093/eurpub/ckq180; van der Heide A, 2003, LANCET, V362, P345, DOI 10.1016/S0140-6736(03)14019-6	13	6	7	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 8	2012	380	9845					869	870		10.1016/S0140-6736(12)61128-3	http://dx.doi.org/10.1016/S0140-6736(12)61128-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	002QL	22789500				2023-01-03	WOS:000308547300009
J	Pronovost, PJ; Bo-Linn, GW				Pronovost, Peter J.; Bo-Linn, George W.			Preventing Patient Harms Through Systems of Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INTENSIVE-CARE		[Pronovost, Peter J.] Johns Hopkins Univ, Dept Hlth Policy & Management, Armstrong Inst Patient Safety & Qual, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA; [Pronovost, Peter J.] Johns Hopkins Carey Business Sch, Baltimore, MD 21218 USA; [Bo-Linn, George W.] Gordon & Betty Moore Fdn, Patient Care Program, Palo Alto, CA USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University	Pronovost, PJ (corresponding author), Johns Hopkins Med Inst, Dept Anesthesiol & Crit Care Med, 1909 Thames St,2nd Floor, Baltimore, MD 21231 USA.	ppronovo@jhmi.edu						Classen DC, 2011, HEALTH AFFAIR, V30, P581, DOI 10.1377/hlthaff.2011.0190; Emanuel EJ, 2012, JAMA-J AM MED ASSOC, V307, P39, DOI 10.1001/jama.2011.1927; Grossman C., 2011, ENG LEARNING HEALTHC; Gurses AP, 2008, QUAL SAF HEALTH CARE, V17, P351, DOI 10.1136/qshc.2006.021709; Pronovost P J, 2001, Eff Clin Pract, V4, P199; Pronovost PJ, 2010, AM J RESP CRIT CARE, V182, P1463, DOI 10.1164/rccm.201008-1255ED; US Department of Health and Human Services, PARTN PAT LEARN OUR	7	47	51	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 22	2012	308	8					769	770		10.1001/jama.2012.9537	http://dx.doi.org/10.1001/jama.2012.9537			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	991ML	22910751				2023-01-03	WOS:000307705300017
J	Sudfeld, CR; Wang, ML; Aboud, S; Giovannucci, EL; Mugusi, FM; Fawzi, WW				Sudfeld, Christopher R.; Wang, Molin; Aboud, Said; Giovannucci, Edward L.; Mugusi, Ferdinand M.; Fawzi, Wafaie W.			Vitamin D and HIV Progression among Tanzanian Adults Initiating Antiretroviral Therapy	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; D DEFICIENCY; 1,25-DIHYDROXYVITAMIN D-3; DISEASE PROGRESSION; REGRESSION-MODELS; IMMUNE-SYSTEM; ASSOCIATION; PREVALENCE; MORTALITY; RISK	Background: There is growing evidence of an association between low vitamin D and HIV disease progression; however, no prospective studies have been conducted among adults receiving antiretroviral therapy (ART) in sub-Saharan Africa. Methods: Serum 25-hydroxyvitamin D (25(OH)D) levels were assessed at ART initiation for a randomly selected cohort of HIV-infected adults enrolled in a trial of multivitamins (not including vitamin D) in Tanzania during 2006-2010. Participants were prospectively followed at monthly clinic visits for a median of 20.6 months. CD4 T-cell measurements were obtained every 4 months. Proportional hazard models were utilized for mortality analyses while generalized estimating equations were used for CD4 T-cell counts. Results: Serum 25(OH)D was measured in 1103 adults 9.2% were classified as vitamin D deficient (<20 ng/ml), 43.6% insufficient (20-30 ng/mL), and 47.2% as sufficient (>30 ng/mL). After multivariate adjustment, vitamin D deficiency was significantly associated with increased mortality as compared to vitamin D sufficiency (HR: 2.00; 95% CI: 1.19-3.37; p = 0.009), whereas no significant association was found for vitamin D insufficiency (HR: 1.24; 95% CI: 0.87-1.78; p = 0.24). No effect modification by ART regimen or change in the associations over time was detected. Vitamin D status was not associated with change in CD4 T-cell count after ART initiation. Conclusions: Deficient vitamin D levels may lead to increased mortality in individuals receiving ART and this relationship does not appear to be due to impaired CD4 T-cell reconstitution. Randomized controlled trials are needed to determine the safety and efficacy of vitamin D supplementation for individuals receiving ART.	[Sudfeld, Christopher R.; Giovannucci, Edward L.; Fawzi, Wafaie W.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Wang, Molin] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Giovannucci, Edward L.; Fawzi, Wafaie W.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; [Fawzi, Wafaie W.] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA; [Aboud, Said] Muhimbili Univ Hlth & Allied Sci, Dept Microbiol & Immunol, Dar Es Salaam, Tanzania; [Mugusi, Ferdinand M.] Muhimbili Univ Hlth & Allied Sci, Dept Internal Med, Dar Es Salaam, Tanzania; [Giovannucci, Edward L.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Muhimbili University of Health & Allied Sciences; Muhimbili University of Health & Allied Sciences; Harvard University; Brigham & Women's Hospital	Sudfeld, CR (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.	csudfeld@hsph.harvard.edu	Sudfeld, Christopher/AAW-3856-2021	Sudfeld, Christopher/0000-0002-3203-3638	National Institute of Child Health and Human development [R01 HD32257]; National Institute of Allergy and Infectious Diseases [T32AI007358]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032257] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007358] Funding Source: NIH RePORTER	National Institute of Child Health and Human development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the National Institute of Child Health and Human development (Grant Number R01 HD32257). C.R. Sudfeld was supported by Award Number T32AI007358 from the National Institute of Allergy and Infectious Diseases. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALROY I, 1995, MOL CELL BIOL, V15, P5789; Arpadi SM, 2009, PEDIATRICS, V123, pE121, DOI 10.1542/peds.2008-0176; BARSHAVIT Z, 1981, CALCIFIED TISSUE INT, V33, P673, DOI 10.1007/BF02409507; BHALLA AK, 1984, J IMMUNOL, V133, P1748; Bischoff-Ferrari HA, 2006, AM J CLIN NUTR, V84, P18, DOI 10.1093/ajcn/84.1.18; Boonstra A, 2001, J IMMUNOL, V169, P4974; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Brannon PM, 2011, ANNU REV NUTR, V31, P89, DOI 10.1146/annurev.nutr.012809.104807; Brown TT, 2010, ANTIVIR THER, V15, P425, DOI [10.3851/IMP1502, 10.3851/IMP15021]; Chen S, 2007, J IMMUNOL, V179, P1634, DOI 10.4049/jimmunol.179.3.1634; COX DR, 1972, J R STAT SOC B, V34, P187; Cozzolino M, 2003, AIDS, V17, P513, DOI 10.1097/00002030-200303070-00006; Dao CN, 2011, CLIN INFECT DIS, V52, P396, DOI 10.1093/cid/ciq158; Deeks Steven G, 2009, Top HIV Med, V17, P118; Deluca HF, 2001, FASEB J, V15, P2579, DOI 10.1096/fj.01-0433rev; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; Fabri M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003045; Fox J, 2011, AIDS RES HUM RETROV, V27, P29, DOI 10.1089/aid.2010.0081; Global HIV/AIDS Response, 2011, EP UPD HLTH SECT PRO; Glymour MM, 2005, AM J EPIDEMIOL, V162, P267, DOI 10.1093/aje/kwi187; Gombart AF, 2005, FASEB J, V19, P1067, DOI 10.1096/fj.04-3284com; Gorman S, 2007, J IMMUNOL, V179, P6273, DOI 10.4049/jimmunol.179.9.6273; Govindarajulu US, 2007, STAT MED, V26, P3735, DOI 10.1002/sim.2848; Hansen KE, 2008, J BONE MINER RES, V23, P1052, DOI 10.1359/JBMR.080230; HAUG C, 1994, J INFECT DIS, V169, P889, DOI 10.1093/infdis/169.4.889; Haug CJ, 1998, J CLIN ENDOCR METAB, V83, P3832, DOI 10.1210/jc.83.11.3832; Heaney RP, 2004, AM J CLIN NUTR, V80, p1706S, DOI 10.1093/ajcn/80.6.1706S; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Holick MF, 2009, ANN EPIDEMIOL, V19, P73, DOI 10.1016/j.annepidem.2007.12.001; Institute of Medicine, 2011, DIETARY REFERENCE IN; Ivers LC, 2005, CLIN INFECT DIS, V41, P217, DOI 10.1086/431199; Kakalia S, 2011, J PEDIATR-US, V159, P951, DOI 10.1016/j.jpeds.2011.06.010; Kamen DL, 2010, J MOL MED, V88, P441, DOI 10.1007/s00109-010-0590-9; Kovesdy CP, 2008, ARCH INTERN MED, V168, P397, DOI 10.1001/archinternmed.2007.110; Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203; LEMIRE JM, 1984, J CLIN INVEST, V74, P657, DOI 10.1172/JCI111465; Lensmeyer GL, 2006, CLIN CHEM, V52, P1120, DOI 10.1373/clinchem.2005.064956; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Martineau AR, 2012, P NUTR SOC, V71, P84, DOI 10.1017/S0029665111003326; Mehta S, 2011, AIDS PATIENT CARE ST, V25, P579, DOI 10.1089/apc.2011.0182; Mehta S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008770; Mehta S, 2009, J INFECT DIS, V200, P1022, DOI 10.1086/605699; Miettinen OS., 1985, THEORETICAL EPIDEMIO; Mora JR, 2008, NAT REV IMMUNOL, V8, P685, DOI 10.1038/nri2378; Overbergh L, 2000, DIABETES, V49, P1301, DOI 10.2337/diabetes.49.8.1301; Overton Edgar Turner, 2011, Curr Infect Dis Rep, V13, P83, DOI 10.1007/s11908-010-0144-x; Realegeno S, 2011, P NATL ACAD SCI USA, V108, P18861, DOI 10.1073/pnas.1116513108; RIGBY WFC, 1984, J CLIN INVEST, V74, P1451, DOI 10.1172/JCI111557; Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010-2704; Ross AC, 2011, ANTIVIR THER, V16, P555, DOI 10.3851/IMP1784; Souberbielle JC, 2010, AUTOIMMUN REV, V9, P709, DOI 10.1016/j.autrev.2010.06.009; Spiegelman D, 2005, AM J EPIDEMIOL, V162, P199, DOI 10.1093/aje/kwi188; Stein EM, 2011, OSTEOPOROSIS INT, V22, P477, DOI 10.1007/s00198-010-1299-x; Tang J, 2009, J IMMUNOL, V182, P4624, DOI 10.4049/jimmunol.0801543; Terrier B, 2011, J HEPATOL, V55, P756, DOI 10.1016/j.jhep.2011.01.041; Van Den Bout-Van Den Beukel CJP, 2008, AIDS RES HUM RETROV, V24, P1375, DOI 10.1089/aid.2008.0058; Vescini F, 2011, JAIDS-J ACQ IMM DEF, V58, P163, DOI 10.1097/QAI.0b013e31822e57e9; Viard JP, 2011, AIDS, V25, P1305, DOI 10.1097/QAD.0b013e328347f6f7; Villamor E, 2006, NUTR REV, V64, P226, DOI 10.1111/j.1753-4887.2006.tb00205.x; WACHOLDER S, 1986, AM J EPIDEMIOL, V123, P174, DOI 10.1093/oxfordjournals.aje.a114212; Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909; Welz T, 2010, AIDS, V24, P1923, DOI 10.1097/QAD.0b013e32833c3281; World Health Organization, 2004, SCAL ANT THER RES LT; YANG SL, 1993, ARCH BIOCHEM BIOPHYS, V303, P98, DOI 10.1006/abbi.1993.1260; Yin M, 2011, CLIN INFECT DIS, V52, P406, DOI 10.1093/cid/ciq169; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	66	48	48	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2012	7	6							e40036	10.1371/journal.pone.0040036	http://dx.doi.org/10.1371/journal.pone.0040036			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	967FO	22768212	Green Published, gold			2023-01-03	WOS:000305892100184
J	Seliktar, D				Seliktar, Dror			Designing Cell-Compatible Hydrogels for Biomedical Applications	SCIENCE			English	Review							HYALURONIC-ACID; GROWTH-FACTORS; DRUG-DELIVERY; DIFFERENTIATION; MORPHOGENESIS; BIOMATERIALS; FIBRINOGEN; POLYMERS; PROTEIN	Hydrogels are polymeric materials distinguished by high water content and diverse physical properties. They can be engineered to resemble the extracellular environment of the body's tissues in ways that enable their use in medical implants, biosensors, and drug-delivery devices. Cell-compatible hydrogels are designed by using a strategy of coordinated control over physical properties and bioactivity to influence specific interactions with cellular systems, including spatial and temporal patterns of biochemical and biomechanical cues known to modulate cell behavior. Important new discoveries in stem cell research, cancer biology, and cellular morphogenesis have been realized with model hydrogel systems premised on these designs. Basic and clinical applications for hydrogels in cell therapy, tissue engineering, and biomedical research continue to drive design improvements using performance-based materials engineering paradigms.	Technion Israel Inst Technol, Fac Biomed Engn, IL-32000 Haifa, Israel	Technion Israel Institute of Technology	Seliktar, D (corresponding author), Technion Israel Inst Technol, Fac Biomed Engn, IL-32000 Haifa, Israel.	dror@bm.technion.ac.il		Seliktar, Dror/0000-0001-6964-8567	European Union; Lorry I. Lokey Interdisciplinary Center for Life Sciences and Engineering; Russell Berrie Nanotechnology Institute; Singapore National Research Foundation	European Union(European Commission); Lorry I. Lokey Interdisciplinary Center for Life Sciences and Engineering; Russell Berrie Nanotechnology Institute; Singapore National Research Foundation(National Research Foundation, Singapore)	Support was provided by the European Union FP7 Program, the Lorry I. Lokey Interdisciplinary Center for Life Sciences and Engineering, the Russell Berrie Nanotechnology Institute, and the Singapore National Research Foundation. I thank I. Mironi-Harpaz, D. Yelin, O. Kossover, Y. Shachaf, R. Meller, and A. Wexler for helpful comments and support with the text and figures. I. Mironi-Harpaz and Y. Talmon are acknowledged for the scanning electron microscopy image in Fig. 2.	Almany L, 2005, BIOMATERIALS, V26, P2467, DOI 10.1016/j.biomaterials.2004.06.047; Bhattarai N, 2010, ADV DRUG DELIVER REV, V62, P83, DOI 10.1016/j.addr.2009.07.019; Burdick JA, 2011, ADV MATER, V23, pH41, DOI 10.1002/adma.201003963; DeForest CA, 2009, NAT MATER, V8, P659, DOI [10.1038/NMAT2473, 10.1038/nmat2473]; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Discher DE, 2009, SCIENCE, V324, P1673, DOI 10.1126/science.1171643; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Gilbert PM, 2010, SCIENCE, V329, P1078, DOI 10.1126/science.1191035; Gobaa S, 2011, NAT METHODS, V8, P949, DOI [10.1038/NMETH.1732, 10.1038/nmeth.1732]; Gong JP, 2003, ADV MATER, V15, P1155, DOI 10.1002/adma.200304907; Griset AP, 2009, J AM CHEM SOC, V131, P2469, DOI 10.1021/ja807416t; Hennink WE, 2002, ADV DRUG DELIVER REV, V54, P13, DOI 10.1016/j.addr.2012.09.009; Hoare TR, 2008, POLYMER, V49, P1993, DOI 10.1016/j.polymer.2008.01.027; Hu BH, 2003, J AM CHEM SOC, V125, P14298, DOI 10.1021/ja038593b; Hudalla GA, 2011, ADV FUNCT MATER, V21, P1754, DOI 10.1002/adfm.201002468; Hudalla GA, 2010, LANGMUIR, V26, P6449, DOI 10.1021/la1008208; Huebsch N, 2010, NAT MATER, V9, P518, DOI [10.1038/nmat2732, 10.1038/NMAT2732]; Kawata S, 2001, NATURE, V412, P697, DOI 10.1038/35089130; Khetan S, 2011, SOFT MATTER, V7, P830, DOI 10.1039/c0sm00852d; Khetan S, 2010, BIOMATERIALS, V31, P8228, DOI 10.1016/j.biomaterials.2010.07.035; Kloxin AM, 2010, ADV MATER, V22, P3484, DOI 10.1002/adma.200904179; Kloxin AM, 2009, SCIENCE, V324, P59, DOI 10.1126/science.1169494; Kogan G, 2007, BIOTECHNOL LETT, V29, P17, DOI 10.1007/s10529-006-9219-z; Krishna OD, 2010, BIOPOLYMERS, V94, P32, DOI 10.1002/bip.21333; Lee H, 2007, NATURE, V448, P338, DOI 10.1038/nature05968; Lee KY, 2001, CHEM REV, V101, P1869, DOI 10.1021/cr000108x; Lee SH, 2008, BIOMATERIALS, V29, P2962, DOI 10.1016/j.biomaterials.2008.04.004; Lin CC, 2006, ADV DRUG DELIVER REV, V58, P1379, DOI 10.1016/j.addr.2006.09.004; Luo Y, 2004, NAT MATER, V3, P249, DOI 10.1038/nmat1092; Lutolf MP, 2009, NATURE, V462, P433, DOI 10.1038/nature08602; Lutolf MP, 2005, NAT BIOTECHNOL, V23, P47, DOI 10.1038/nbt1055; Lutolf MP, 2003, P NATL ACAD SCI USA, V100, P5413, DOI 10.1073/pnas.0737381100; Lutolf MR, 2003, NAT BIOTECHNOL, V21, P513, DOI 10.1038/nbt818; Martino MM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002614; Martino MM, 2009, BIOMATERIALS, V30, P1089, DOI 10.1016/j.biomaterials.2008.10.047; Messersmith P. B., 2010, BIOMATERIALS, V31, P420; Nelson CM, 2006, SCIENCE, V314, P298, DOI 10.1126/science.1131000; Nicodemus GD, 2008, TISSUE ENG PT B-REV, V14, P149, DOI 10.1089/ten.teb.2007.0332; Nicolson PC, 2001, BIOMATERIALS, V22, P3273, DOI 10.1016/S0142-9612(01)00165-X; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Patterson J, 2010, BIOMATERIALS, V31, P6772, DOI 10.1016/j.biomaterials.2010.05.047; Patterson J, 2010, MATER TODAY, V13, P14, DOI 10.1016/S1369-7021(10)70013-4; Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612; Petka WA, 1998, SCIENCE, V281, P389, DOI 10.1126/science.281.5375.389; Reece TB, 2001, AM J SURG, V182, p40S, DOI 10.1016/S0002-9610(01)00742-5; Shachaf Y, 2010, BIOMATERIALS, V31, P2836, DOI 10.1016/j.biomaterials.2009.12.050; Tibbitt MW, 2009, BIOTECHNOL BIOENG, V103, P655, DOI 10.1002/bit.22361; van Dijk M, 2009, BIOCONJUGATE CHEM, V20, P2001, DOI 10.1021/bc900087a; Wang C, 1999, NATURE, V397, P417, DOI 10.1038/17092; Wylie RG, 2011, NAT MATER, V10, P799, DOI [10.1038/NMAT3101, 10.1038/nmat3101]; Young JL, 2011, BIOMATERIALS, V32, P1002, DOI 10.1016/j.biomaterials.2010.10.020	51	1318	1357	98	1703	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 1	2012	336	6085					1124	1128		10.1126/science.1214804	http://dx.doi.org/10.1126/science.1214804			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	950KK	22654050				2023-01-03	WOS:000304647900039
J	Li, M; Zhang, Q; Fu, PF; Li, P; Peng, AM; Zhang, GL; Song, XL; Tan, M; Li, X; Liu, Y; Wu, YP; Fan, SY; Wang, CH				Li, Ming; Zhang, Qian; Fu, Peifang; Li, Ping; Peng, Aimei; Zhang, Guoliang; Song, Xiaolian; Tan, Min; Li, Xuan; Liu, Yang; Wu, Yueping; Fan, Suyun; Wang, Changhui			Pemetrexed plus Platinum as the First-Line Treatment Option for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials	PLOS ONE			English	Article							PHASE-II; MULTITARGETED ANTIFOLATE; CLINICAL-TRIALS; CHEMOTHERAPY; CARBOPLATIN; CISPLATIN; LY231514; MULTICENTER; GEMCITABINE; CARCINOMA	To compare the efficacy and toxicities of pemetrexed plus platinum with other platinum regimens in patients with previously untreated advanced non-small cell lung cancer (NSCLC). Methods: A meta-analysis was performed using trials identified through PubMed, EMBASE, and Cochrane databases. Two investigators independently assessed the quality of the trials and extracted data. The outcomes included overall survival (OS), progression-free survival (PFS), response rate (RR), and different types of toxicity. Hazard ratios (HRs), odds ratios (ORs) and their 95% confidence intervals (CIs) were pooled using RevMan software. Results: Four trials involving 2,518 patients with previously untreated advanced NSCLC met the inclusion criteria. Pemetrexed plus platinum chemotherapy (PPC) improved survival compared with other platinum-based regimens (PBR) in patients with advanced NSCLC (HR = 0.91, 95% CI: 0.83-1.00, p = 0.04), especially in those with non-squamous histology (HR = 0.87, 95% CI: 0.77-0.98, p = 0.02). No statistically significant improvement in either PFS or RR was found in PPC group as compared with PBR group (HR = 1.03, 95% CI: 0.94-1.13, p = 0.57; OR = 1.15, 95% CI: 0.95-1.39, p = 0.15, respectively). Compared with PBR, PPC led to less grade 3-4 neutropenia and leukopenia but more grade 3-4 nausea. However, hematological toxicity analysis revealed significant heterogeneities. Conclusion: Our results suggest that PPC in the first-line setting leads to a significant survival advantage with acceptable toxicities for advanced NSCLC patients, especially those with non-squamous histology, as compared with other PRB. PPC could be considered as the first-line treatment option for advanced NSCLC patients, especially those with non-squamous histology.	[Li, Ming; Fu, Peifang; Li, Ping; Peng, Aimei; Zhang, Guoliang; Song, Xiaolian; Tan, Min; Li, Xuan; Liu, Yang; Wu, Yueping; Fan, Suyun; Wang, Changhui] Tongji Univ, Dept Resp Med, Shanghai Peoples Hosp 10, Shanghai 200092, Peoples R China; [Zhang, Qian] Fudan Univ, Huashan Hosp, Div Nephrol, Shanghai 200433, Peoples R China	Tongji University; Fudan University	Li, M (corresponding author), Tongji Univ, Dept Resp Med, Shanghai Peoples Hosp 10, Shanghai 200092, Peoples R China.	wangch63@yahoo.com.cn			National Nature Science Foundation of China [81172229]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was funded by the National Nature Science Foundation of China (NO. 81172229). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ceppi P, 2006, CANCER-AM CANCER SOC, V107, P1589, DOI 10.1002/cncr.22208; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ettinger DS, 2011, NCCN PRACTICE GUIDEL; Giovannetti E, 2008, MOL PHARMACOL, V73, P1290, DOI 10.1124/mol.107.042382; Govindan R, 2006, J CLIN ONCOL, V24, P4539, DOI 10.1200/JCO.2005.04.4859; Gronberg BH, 2009, J CLIN ONCOL, V27, P3217, DOI 10.1200/JCO.2008.20.9114; Grossi F, 2009, ONCOLOGIST, V14, P497, DOI 10.1634/theoncologist.2008-0260; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins Julian PT, 2011, COCHRANE HDB SYSTEMA, P649; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Manegold C, 2000, ANN ONCOL, V11, P435, DOI 10.1023/A:1008336931378; Pao W, 2009, CLIN CANCER RES, V15, P5317, DOI 10.1158/1078-0432.CCR-09-0913; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; PETERSON P, 2007, J THORAC ONCOL S4, V2, pS851, DOI DOI 10.1097/01.JTO.0000284677.33344.62; Rodrigues-Pereira J, 2011, J THORAC ONCOL, V6, P1907, DOI 10.1097/JTO.0b013e318226b5fa; Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Shepherd FA, 2001, CANCER, V92, P595, DOI 10.1002/1097-0142(20010801)92:3<595::AID-CNCR1359>3.0.CO;2-D; Shih C, 1998, ADV ENZYME REGUL, V38, P135, DOI 10.1016/S0065-2571(97)00017-4; Shih C, 1997, CANCER RES, V57, P1116; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Socinski MA, 2010, J THORAC ONCOL, V5, P1963, DOI 10.1097/JTO.0b013e3181fd42eb; Treat J, 2011, LUNG CANC       1122; WALLING J, 1994, RESP MED, V88, P649, DOI 10.1016/S0954-6111(05)80061-7; Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X; Zinner RG, 2005, CANCER-AM CANCER SOC, V104, P2449, DOI 10.1002/cncr.21480	27	35	35	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 17	2012	7	5							e37229	10.1371/journal.pone.0037229	http://dx.doi.org/10.1371/journal.pone.0037229			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UQ	22615946	Green Published, Green Submitted, gold			2023-01-03	WOS:000305341200051
J	Arulselvan, P; Wen, CC; Lan, CW; Chen, YH; Wei, WC; Yang, NS				Arulselvan, Palanisamy; Wen, Chih-Chun; Lan, Chun-Wen; Chen, Yung-Hsiang; Wei, Wen-Chi; Yang, Ning-Sun			Dietary Administration of Scallion Extract Effectively Inhibits Colorectal Tumor Growth: Cellular and Molecular Mechanisms in Mice	PLOS ONE			English	Article							HYPOXIA-INDUCIBLE FACTOR-1; COLON-CANCER CHEMOPREVENTION; CRYPT FOCI FORMATION; NITRIC-OXIDE; WELSH ONION; ADHESION MOLECULES; DOWN-REGULATION; KAPPA-B; ANGIOGENESIS; EXPRESSION	Colorectal cancer is a common malignancy and a leading cause of cancer death worldwide. Diet is known to play an important role in the etiology of colon cancer and dietary chemoprevention is receiving increasing attention for prevention and/or alternative treatment of colon cancers. Allium fistulosum L., commonly known as scallion, is popularly used as a spice or vegetable worldwide, and as a traditional medicine in Asian cultures for treating a variety of diseases. In this study we evaluated the possible beneficial effects of dietary scallion on chemoprevention of colon cancer using a mouse model of colon carcinoma (CT-26 cells subcutaneously inoculated into BALB/c mice). Tumor lysates were subjected to western blotting for analysis of key inflammatory markers, ELISA for analysis of cytokines, and immunohistochemistry for analysis of inflammatory markers. Metabolite profiles of scallion extracts were analyzed by LC-MS/MS. Scallion extracts, particularly hot-water extract, orally fed to mice at 50 mg (dry weight)/kg body weight resulted in significant suppression of tumor growth and enhanced the survival rate of test mice. At the molecular level, scallion extracts inhibited the key inflammatory markers COX-2 and iNOS, and suppressed the expression of various cellular markers known to be involved in tumor apoptosis (apoptosis index), proliferation (cyclin D1 and c-Myc), angiogenesis (VEGF and HIF-1 alpha), and tumor invasion (MMP-9 and ICAM-1) when compared with vehicle control-treated mice. Our findings may warrant further investigation of the use of common scallion as a chemopreventive dietary agent to lower the risk of colon cancer.	[Arulselvan, Palanisamy; Wen, Chih-Chun; Lan, Chun-Wen; Chen, Yung-Hsiang; Wei, Wen-Chi; Yang, Ning-Sun] Acad Sinica, Agr Biotechnol Res Ctr, Taipei 115, Taiwan; [Lan, Chun-Wen] Natl Chung Hsing Univ, Taiwan Int Grad Program, Taipei, Taiwan; [Lan, Chun-Wen] Natl Chung Hsing Univ, Grad Inst Biotechnol, Taichung 40227, Taiwan; [Lan, Chun-Wen] Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan; [Wei, Wen-Chi] Natl Sun Yat Sen Univ, Dept Marine Biotechnol & Resources, Kaohsiung 80424, Taiwan; [Yang, Ning-Sun] Natl Taiwan Univ, Inst Biotechnol, Taipei 10764, Taiwan	Academia Sinica - Taiwan; National Chung Hsing University; National Chung Hsing University; National Chung Hsing University; National Sun Yat Sen University; National Taiwan University	Arulselvan, P (corresponding author), Acad Sinica, Agr Biotechnol Res Ctr, Taipei 115, Taiwan.	nsyang@gate.sinica.edu.tw	Arulselvan, Palanisamy/M-6388-2014	Arulselvan, Palanisamy/0000-0002-1835-9738	National Science Council grant [NSC-99-2321-B-400-006]; Academia Sinica, Taiwan in the form of a Postdoctoral Research Fellowship	National Science Council grant; Academia Sinica, Taiwan in the form of a Postdoctoral Research Fellowship	This study was financially supported by a National Science Council grant (NSC-99-2321-B-400-006) and by Academia Sinica, Taiwan in the form of a Postdoctoral Research Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aggarwal BB, 2006, BIOCHEM PHARMACOL, V71, P1397, DOI 10.1016/j.bcp.2006.02.009; Aggarwal BB, 2003, ANTICANCER RES, V23, P363; Anto RJ, 1996, MUTAT RES-GENET TOX, V370, P127, DOI 10.1016/0165-1218(96)00074-2; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Chen JH, 1999, J CARDIOVASC PHARM, V33, P515, DOI 10.1097/00005344-199904000-00001; Chen JH, 2000, J NUTR, V130, P34; Chin YW, 2006, AAPS J, V8, pE239, DOI 10.1007/BF02854894; Chiu SC, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-513; Choi YL, 2004, J HISTOCHEM CYTOCHEM, V52, P591, DOI 10.1177/002215540405200504; Dolcetti L, 2008, CANCER LETT, V267, P216, DOI 10.1016/j.canlet.2008.03.012; Dowlati A, 2008, CLIN CANCER RES, V14, P1407, DOI 10.1158/1078-0432.CCR-07-1154; Duvoix A, 2005, CANCER LETT, V223, P181, DOI 10.1016/j.canlet.2004.09.041; Dymicka-Piekarska V, 2009, THROMB RES, V124, P80, DOI 10.1016/j.thromres.2008.11.021; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Gupta SC, 2010, CANCER METAST REV, V29, P405, DOI 10.1007/s10555-010-9235-2; Hagos GK, 2007, MOL CANCER THER, V6, P2230, DOI 10.1158/1535-7163.MCT-07-0069; Hardy G, 2003, CURR OPIN CLIN NUTR, V6, P661, DOI 10.1097/00075197-200311000-00010; Hirota K, 2006, CRIT REV ONCOL HEMAT, V59, P15, DOI 10.1016/j.critrevonc.2005.12.003; Hsu CH, 2007, ADV EXP MED BIOL, V595, P471; Hu CE, 2011, SCAND J GASTROENTERO, V46, P156, DOI 10.3109/00365521.2010.516450; Huerta S, 2008, EXPERT REV MOL DIAGN, V8, P277, DOI 10.1586/14737159.8.3.277; Kohno H, 2006, INT J CANCER, V118, P2936, DOI 10.1002/ijc.21719; La Vecchia C, 2004, PUBLIC HEALTH NUTR, V7, P965, DOI 10.1079/PHN2004562; Lee SJ, 2007, TOXICOL APPL PHARM, V225, P198, DOI 10.1016/j.taap.2007.07.010; Lee SI, 2008, J GASTROEN HEPATOL, V23, P138, DOI 10.1111/j.1440-1746.2007.05181.x; Liang S, 2008, ANN BIOMED ENG, V36, P661, DOI 10.1007/s10439-008-9445-8; Lin YC, 2006, CLIN CANCER RES, V12, P7165, DOI 10.1158/1078-0432.CCR-06-1393; Lopez-Lazaro M, 2006, CANCER EPIDEM BIOMAR, V15, P2332, DOI 10.1158/1055-9965.EPI-06-0369; Mehta RG, 2010, PHARM RES-DORDR, V27, P950, DOI 10.1007/s11095-010-0085-y; Melillo G, 2006, MOL CANCER RES, V4, P601, DOI 10.1158/1541-7786.MCR-06-0235; Misra S, 2006, J BIOL CHEM, V281, P34936, DOI 10.1074/jbc.C600138200; Mousa AS, 2005, NUTR CANCER, V53, P104, DOI 10.1207/s15327914nc5301_12; Naumov GN, 2006, CELL CYCLE, V5, P1779, DOI 10.4161/cc.5.16.3018; Patel BB, 2009, AM J PHYSIOL-GASTR L, V296, pG955, DOI 10.1152/ajpgi.90726.2008; Rao CV, 2004, MUTAT RES-FUND MOL M, V555, P107, DOI 10.1016/j.mrfmmm.2004.05.022; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; SANO H, 1995, CANCER RES, V55, P3785; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Singh RP, 2003, CURR CANCER DRUG TAR, V3, P205, DOI 10.2174/1568009033481985; Singh RP, 2005, ONCOGENE, V24, P1188, DOI 10.1038/sj.onc.1208276; Singh V, 2006, NUTR CANCER, V55, P178, DOI 10.1207/s15327914nc5502_9; Sinnamon MJ, 2008, INT J EXP PATHOL, V89, P466, DOI 10.1111/j.1365-2613.2008.00621.x; Sung YY, 2011, MOL MED REP, V4, P431, DOI 10.3892/mmr.2011.451; Takahashi M, 2000, CARCINOGENESIS, V21, P1319, DOI 10.1093/carcin/21.7.1319; Tsai TH, 2005, J FOOD SCI, V70, pC93, DOI 10.1111/j.1365-2621.2005.tb09028.x; Tu YY, 2011, NAT MED, V17, P1217, DOI 10.1038/nm.2471; Velmurugan B, 2010, MOL CARCINOGEN, V49, P641, DOI 10.1002/mc.20643; Wang BS, 2005, FOOD CHEM, V91, P147, DOI 10.1016/j.foodchem.2004.06.009; Wang SX, 2006, INT J CANCER, V118, P932, DOI 10.1002/ijc.21289; Warren CA, 2009, J NUTR, V139, P101, DOI 10.3945/jn.108.096271; Wiseman M, 2008, P NUTR SOC, V67, P253, DOI 10.1017/S002966510800712X; Yamamoto Y, 2005, BIOSCI BIOTECH BIOCH, V69, P1311, DOI 10.1271/bbb.69.1311	52	20	21	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2012	7	9							e44658	10.1371/journal.pone.0044658	http://dx.doi.org/10.1371/journal.pone.0044658			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	007AD	23024755	Green Published, gold, Green Submitted			2023-01-03	WOS:000308860100013
J	Lu, K; Chakroborty, D; Sarkar, C; Lu, TT; Xie, ZL; Liu, ZF; Basu, S				Lu, Kai; Chakroborty, Debanjan; Sarkar, Chandrani; Lu, Tingting; Xie, Zhiliang; Liu, Zhongfa; Basu, Sujit			Triphala and Its Active Constituent Chebulinic Acid Are Natural Inhibitors of Vascular Endothelial Growth Factor-A Mediated Angiogenesis	PLOS ONE			English	Article							AYURVEDIC FORMULATION; ELLAGIC ACID; GALLIC ACID; CANCER; PERMEABILITY; CELLS; BIOAVAILABILITY; COMPOUND; DISEASE; BREAST	Triphala churna (THL) is a combination of three fruits that has been used for many years in India for the treatment of various diseases. There are now reports which indicate that THL can inhibit growth of malignant tumors in animals. However, the mechanisms by which THL mediates its anti-tumor actions are still being explored. Because vascular endothelial growth factor-A (VEGF) induced angiogenesis plays a critical role in the pathogenesis of cancer, we therefore investigated whether tumor inhibitory effects of THL or its active constituents are through suppression of VEGF actions. We herein report that THL and chebulinic (CI) present in THL can significantly and specifically inhibit VEGF induced angiogenesis by suppressing VEGF receptor-2 (VEGFR-2) phosphorylation. These results are of clinical significance as these inexpensive and non-toxic natural products can be used for the prevention and treatment of diseases where VEGF induced angiogenesis has an important role.	[Lu, Kai; Chakroborty, Debanjan; Sarkar, Chandrani; Lu, Tingting; Basu, Sujit] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; [Xie, Zhiliang; Liu, Zhongfa] Ohio State Univ, Coll Pharm, Div Pharmaceut, Columbus, OH 43210 USA; [Liu, Zhongfa; Basu, Sujit] Ohio State Univ, Arthur G James Comprehens Canc Ctr, Columbus, OH 43210 USA; [Basu, Sujit] Ohio State Univ, Dorthy M Davis Heart & Lung Res Inst, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Lu, K (corresponding author), Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA.	sujit.basu@osumc.edu	Liu, Zhongfa/G-8549-2013		National Institutes of Health, United States of America [R01 CA124763]; NATIONAL CANCER INSTITUTE [R01CA124763] Funding Source: NIH RePORTER	National Institutes of Health, United States of America(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by National Institutes of Health, United States of America Grant R01 CA124763 to SB. No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antonescu CR, 2009, CANCER RES, V69, P7175, DOI 10.1158/0008-5472.CAN-09-2068; Baliga MS, 2010, J ALTERN COMPLEM MED, V16, P1301, DOI 10.1089/acm.2009.0633; Basu S, 2001, NAT MED, V7, P569, DOI 10.1038/87895; Bhattacharya Resham, 2008, J Mol Signal, V3, P14, DOI 10.1186/1750-2187-3-14; Blanchet B, 2010, EXPERT OPIN DRUG SAF, V9, P275, DOI 10.1517/14740330903510608; Chakroborty D, 2011, P NATL ACAD SCI USA, V108, P20730, DOI 10.1073/pnas.1108696108; Deep G, 2005, J EXP CLIN CANC RES, V24, P555; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Ferrara N, 2009, ARTERIOSCL THROM VAS, V29, P789, DOI 10.1161/ATVBAHA.108.179663; Ferruzzi MG, 2009, J ALZHEIMERS DIS, V18, P113, DOI 10.3233/JAD-2009-1135; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Hussain S, 2008, ANGIOGENESIS, V11, P245, DOI 10.1007/s10456-008-9108-2; Istivan TS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024809; Konishi Y, 2004, J AGR FOOD CHEM, V52, P2527, DOI 10.1021/jf035366k; Kumar B, 2011, ANGIOGENESIS, V14, P371, DOI 10.1007/s10456-011-9221-5; Labrecque L, 2005, CARCINOGENESIS, V26, P821, DOI 10.1093/carcin/bgi024; Li LX, 2011, APPL ENVIRON MICROB, V77, P2640, DOI 10.1128/AEM.01460-10; London CA, 2003, CANCER GENE THER, V10, P823, DOI 10.1038/sj.cgt.7700642; Mulder K, 2011, EXPERT OPIN BIOL TH, V11, P405, DOI 10.1517/14712598.2011.557657; Nadler E, 2006, ONCOLOGIST, V11, P90, DOI 10.1634/theoncologist.11-2-90; Pal S, 2000, MICROVASC RES, V60, P112, DOI 10.1006/mvre.2000.2246; Pawar V, 2009, INDIAN J PHARM SCI, V71, P382, DOI 10.4103/0250-474X.57286; Pyun BJ, 2008, CANCER RES, V68, P227, DOI 10.1158/0008-5472.CAN-07-2799; Ribatti D, 2006, NAT PROTOC, V1, P85, DOI 10.1038/nprot.2006.13; Russell LH, 2011, ANTICANCER RES, V31, P3739; Sandhya T, 2006, CANCER LETT, V231, P206, DOI 10.1016/j.canlet.2005.01.035; Sarkar C, 2008, CLIN CANCER RES, V14, P2502, DOI 10.1158/1078-0432.CCR-07-1778; Seeram NP, 2004, CLIN CHIM ACTA, V348, P63, DOI 10.1016/j.cccn.2004.04.029; Shi Y, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-294; Singh DP, 2008, PHYTOCHEM ANALYSIS, V19, P164, DOI 10.1002/pca.1032; SMART RC, 1986, CARCINOGENESIS, V7, P1663, DOI 10.1093/carcin/7.10.1663; Wang ZY, 2012, EXPERT OPIN THER TAR, V16, pS79, DOI 10.1517/14728222.2011.642371; West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421	33	32	37	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2012	7	8							e43934	10.1371/journal.pone.0043934	http://dx.doi.org/10.1371/journal.pone.0043934			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	998GM	22937129	Green Published, gold, Green Submitted			2023-01-03	WOS:000308225500125
J	Alves, M; Canoui, E; Deforges, L; Garderet, L; Guidet, B; Offenstadt, G; Maury, E				Alves, Mikael; Canoui, Etienne; Deforges, Lionel; Garderet, Laurent; Guidet, Bertrand; Offenstadt, Georges; Maury, Eric			An unexpected trismus	LANCET			English	Editorial Material							TETANUS		[Alves, Mikael; Canoui, Etienne; Guidet, Bertrand; Offenstadt, Georges; Maury, Eric] Hosp St Antoine, Med Intens Care Unit, F-75571 Paris, France; [Garderet, Laurent] Hosp St Antoine, Dept Haematol, F-75571 Paris, France; [Guidet, Bertrand; Offenstadt, Georges; Maury, Eric] Hosp St Antoine, INSERM, UMR S707, F-75571 Paris, France; [Deforges, Lionel] Hosp Henri Mondor, Dept Bacteriol, Creteil, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Alves, M (corresponding author), Hosp St Antoine, Med Intens Care Unit, 184 Rue Fauborg St Antoine, F-75571 Paris, France.	mikael.alves@sat.aphp.fr						Cooke MW, 2009, EMERG MED J, V26, P845, DOI 10.1136/emj.2008.070268; McQuillan GM, 2002, ANN INTERN MED, V136, P660, DOI 10.7326/0003-4819-136-9-200205070-00008; Pescovitz MD, 2011, J ALLERGY CLIN IMMUN, V128, P1295, DOI 10.1016/j.jaci.2011.08.008; Van Damme P, 2011, VACCINE, V29, P5932, DOI 10.1016/j.vaccine.2011.06.049; van Tilburg CM, 2006, LEUKEMIA, V20, P1717, DOI 10.1038/sj.leu.2404326	5	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 4	2012	380	9840					536	536		10.1016/S0140-6736(12)60524-8	http://dx.doi.org/10.1016/S0140-6736(12)60524-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983GY	22863054				2023-01-03	WOS:000307109000034
J	Gillis, VL; Senthinathan, A; Dzingina, M; Chamberlain, K; Banks, E; Baker, MR; Longson, D				Gillis, V. L.; Senthinathan, A.; Dzingina, M.; Chamberlain, K.; Banks, E.; Baker, M. R.; Longson, D.		Guideline Dev Grp	Management of an acute painful sickle cell episode in hospital: summary of NICE guidance	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ACUTE CHEST SYNDROME		[Longson, D.] Manchester Mental Hlth & Social Care Trust, Dept Psychiat, Manchester M8 5RB, Lancs, England; [Gillis, V. L.; Senthinathan, A.; Dzingina, M.; Chamberlain, K.; Banks, E.; Baker, M. R.] Natl Inst Hlth & Clin Excellence, Manchester M1 4BD, Lancs, England	Open University - UK; National Institute for Health & Care Excellence	Longson, D (corresponding author), Manchester Mental Hlth & Social Care Trust, Dept Psychiat, Manchester M8 5RB, Lancs, England.	damien.longson@manchester.ac.uk	Dzingina, Mendwas/C-4957-2014					Booker MJ, 2006, CHRONIC ILLN, V2, P39, DOI 10.1179/174592006X93860; Buchanan ID, 2005, PEDIATR BLOOD CANCER, V45, P716, DOI 10.1002/pbc.20403; Harris A, 1998, PSYCHOL HEALTH MED, V3, P171, DOI [10.1080/13548509808402233, DOI 10.1080/13548509808402233]; Joint Formulary Committee, 2017, BRIT NATL FORMULARY, V80th; National Institute for Health and Clinical Excellence (UK), 2012, SICKL CELL AC PAINF; NHS Sickle Cell & Thalassaemia Screening Programme, NHS SICKL CELL THAL; Serjeant GR, 1992, SICKLE CELL DIS, P455, DOI DOI 10.1007/S11999-007-0069-3; Styles LA, 2000, BLOOD, V96, P3276	8	11	11	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 27	2012	344								e4063	10.1136/bmj.e4063	http://dx.doi.org/10.1136/bmj.e4063			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	968MX	22740566				2023-01-03	WOS:000305987100010
J	Sharma, N; Castorena, CM; Cartee, GD				Sharma, Naveen; Castorena, Carlos M.; Cartee, Gregory D.			Tissue-Specific Responses of IGF-1/Insulin and mTOR Signaling in Calorie Restricted Rats	PLOS ONE			English	Article							SYNTHASE KINASE-3 ISOFORMS; SKELETAL-MUSCLE; GLYCOGEN-SYNTHASE; GLUCOSE-UPTAKE; INSULIN ACTION; LIFE-SPAN; INCREASES; LONGEVITY; PHOSPHORYLATION; TOR	Moderate calorie restriction (CR) (similar to 60% of ad libitum, AL, intake) has been associated with numerous favorable physiological outcomes in many species, and the insulin/IGF-1 and mTOR signaling pathways have each been proposed as potential mediators for many of CR's bioeffects. However, few studies have assessed the widely held idea that CR induces the down-regulation of the insulin/IGF-1 and/or mTOR pathways in multiple tissues. Accordingly, we analyzed the phosphorylation status of 11 key signaling proteins from the insulin/IGF-1 (IRTyr1162/1163, IGF-1R(Tyr1135/1136), IRS-1(Ser312), PTENSer380, Akt(Ser473), GSK3 alpha(Ser21), GSK3 beta(Ser9)) and mTOR (TSC2(Ser939), mTOR(Ser2448), P70S6K(Thr412), RPS6(Ser235/236)) pathways in 11 diverse tissues [liver, kidney, lung, aorta, two brain regions (cortex and cerebellum), and two slow-twitch and three fast-twitch skeletal muscles] from 9-month-old male AL and CR Fischer 344 x Brown Norway rats. The rats were studied under two conditions: with endogenous insulin levels (i.e., AL>CR) and with insulin infused during a hyperinsulinemic-euglycemic clamp so that plasma insulin concentrations were matched between the two diet groups. The most striking and consistent effect of CR was greater pAkt in 3 of the 5 skeletal muscles of CR vs. AL rats. There were no significant CR effects on the mTOR signaling pathway and no evidence that CR caused a general attenuation of mTOR signaling across the tissues studied. Rather than supporting the premise of a global downregulation of insulin/IGF-1 and/or mTOR signaling in many tissues, the current results revealed clear tissue-specific CR effects for the insulin signaling pathway without CR effects on the mTOR signaling pathway.	[Sharma, Naveen; Castorena, Carlos M.; Cartee, Gregory D.] Univ Michigan, Sch Kinesiol, Muscle Biol Lab, Ann Arbor, MI 48109 USA; [Cartee, Gregory D.] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; [Cartee, Gregory D.] Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Sharma, N (corresponding author), Univ Michigan, Sch Kinesiol, Muscle Biol Lab, Ann Arbor, MI 48109 USA.	gcartee@umich.edu	Sharma, Naveen/K-6672-2015	Sharma, Naveen/0000-0003-4705-5116; Cartee, Gregory/0000-0001-5311-1722	National Institute on Aging Grants [AG-010026, AG-013283]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG010026, P30AG013283, R01AG010026] Funding Source: NIH RePORTER	National Institute on Aging Grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research was supported by National Institute on Aging Grants AG-010026 and AG-013283. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Argentino DP, 2005, EXP GERONTOL, V40, P27, DOI 10.1016/j.exger.2004.09.005; Bjedov I, 2011, BIOCHEM SOC T, V39, P460, DOI 10.1042/BST0390460; Blagosklonny MV, 2010, CELL CYCLE, V9, P683, DOI 10.4161/cc.9.4.10766; Bonkowski MS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004567; Cox LS, 2009, AGING CELL, V8, P607, DOI 10.1111/j.1474-9726.2009.00509.x; Davidson RT, 2002, AM J PHYSIOL-ENDOC M, V282, pE270, DOI 10.1152/ajpendo.00232.2001; Dazert E, 2011, CURR OPIN CELL BIOL, V23, P744, DOI 10.1016/j.ceb.2011.09.003; Dean DJ, 1998, AM J PHYSIOL-ENDOC M, V275, pE957, DOI 10.1152/ajpendo.1998.275.6.E957; Dean DJ, 2000, ACTA PHYSIOL SCAND, V169, P133, DOI 10.1046/j.1365-201x.2000.00723.x; Feuers RJ, 1995, DIETARY RESTRICTION, P181; Gazdag AC, 1999, DIABETES, V48, P1930, DOI 10.2337/diabetes.48.10.1930; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Hasty P, 2010, J MOL CELL BIOL, V2, P17, DOI 10.1093/jmcb/mjp033; Hay N, 2011, BBA-MOL CELL RES, V1813, P1965, DOI 10.1016/j.bbamcr.2011.03.013; Kaeberlein M, 2009, NATURE, V460, P331, DOI 10.1038/460331a; Kapahi P, 2010, CELL METAB, V11, P453, DOI 10.1016/j.cmet.2010.05.001; Katewa SD, 2010, AGING CELL, V9, P105, DOI 10.1111/j.1474-9726.2010.00552.x; Katic M, 2005, CELL MOL LIFE SCI, V62, P320, DOI 10.1007/s00018-004-4297-y; Liang MH, 2007, J BIOL CHEM, V282, P3904, DOI 10.1074/jbc.M605178200; Liang MH, 2006, J BIOL CHEM, V281, P30479, DOI 10.1074/jbc.M607468200; Markou T, 2008, CELL SIGNAL, V20, P206, DOI 10.1016/j.cellsig.2007.10.004; Masoro EJ, 2005, MECH AGEING DEV; McCormick MA, 2011, PHILOS T R SOC B, V366, P17, DOI 10.1098/rstb.2010.0198; McCurdy CE, 2005, DIABETES, V54, P1349, DOI 10.2337/diabetes.54.5.1349; McCurdy CE, 2005, AM J PHYSIOL-ENDOC M, V288, pE996, DOI 10.1152/ajpendo.00566.2004; McCurdy CE, 2003, AM J PHYSIOL-ENDOC M, V285, pE693, DOI 10.1152/ajpendo.00224.2003; McManus EJ, 2005, EMBO J, V24, P1571, DOI 10.1038/sj.emboj.7600633; Mora A, 2005, FEBS LETT, V579, P3632, DOI 10.1016/j.febslet.2005.05.040; Richardson A, 2004, BEST PRACT RES CL EN, V18, P393, DOI 10.1016/j.beem.2004.02.002; Sharma N, 2011, AM J PHYSIOL-ENDOC M, V300, pE966, DOI 10.1152/ajpendo.00659.2010; Sharp ZD, 2010, J GERONTOL A-BIOL, V65, P580, DOI 10.1093/gerona/glp212; Soutar MPM, 2010, J NEUROCHEM, V115, P974, DOI 10.1111/j.1471-4159.2010.06988.x; Speakman JR, 2011, MOL ASPECTS MED, V32, P159, DOI 10.1016/j.mam.2011.07.001; Stanfel MN, 2009, BBA-GEN SUBJECTS, V1790, P1067, DOI 10.1016/j.bbagen.2009.06.007; Turturro A, 1999, J GERONTOL A-BIOL, V54, pB492, DOI 10.1093/gerona/54.11.B492; Wanagat J, 1999, TOXICOL SCI, V52, P35; Wang ZQ, 2009, DIABETES, V58, P1488, DOI 10.2337/db08-0977; Weindruch R, 1996, SCI AM, V274, P46, DOI 10.1038/scientificamerican0196-46; Wetter TJ, 1999, AM J PHYSIOL-ENDOC M, V276, pE728; Zheng YB, 2009, J ENDOCRINOL, V203, P337, DOI 10.1677/JOE-09-0181; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	41	35	36	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2012	7	6							e38835	10.1371/journal.pone.0038835	http://dx.doi.org/10.1371/journal.pone.0038835			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959WK	22701721	Green Published, gold, Green Submitted			2023-01-03	WOS:000305348400096
J	Hill, S; Yang, AN; Bero, L				Hill, Suzanne; Yang, Annie; Bero, Lisa			Priority Medicines for Maternal and Child Health: A Global Survey of National Essential Medicines Lists	PLOS ONE			English	Article							COUNTRIES; AVAILABILITY	Background: In April 2011, the World Health Organization (WHO) published a list of "priority medicines" for maternal and child health based on 1) the global burden of disease and 2) evidence of efficacy and safety. The objective of this study was to examine the occurrence of these priority medicines on national essential medicines lists. Methods and Findings: All essential medicines lists published since 1999 were selected from the WHO website collection. The most-up-to date list for each country was then selected, resulting in 89 unique country lists. Each list was evaluated for inclusion of medicines (chemical entity, concentration, and dosage form) on the Priority Medicines List. There was global variation in the listing of the Priority Medicines. The most frequently listed medicine was paracetamol, on 94% (84/89) of lists. Sodium chloride, gentamicin and oral rehydration solution were on 93% (83/89) of lists. The least frequently listed medicine was the children's antimalarial rectal artesunate, on 8% of lists (7/89); artesunate injection was on 16% (14/89) of lists. Pediatric artemisinin combination therapy, as dispersible tablets or flexible oral solid dosage form, appeared on 36% (32/89) of lists. Procaine benzylpenicillin, for treatment of pediatric pneumonia and neonatal sepsis, was on 50% (45/89) of the lists. Zinc, for treatment of diarrhoea in children, was included on only 15% (13/89) of lists. For prevention and treatment of postpartum hemorrhage in women, oxytocin was more prevalent on the lists than misoprostol; they were included on 55 (62%) and 31 (35%) of lists, respectively. Cefixime, for treatment of uncomplicated anogenital gonococcal infection in woman was on 26% (23/89) of lists. Magnesium sulfate injection for treatment of severe pre-eclampsia and eclampsia was on 50% (45/89) of the lists. Conclusions: The findings suggest that countries need to urgently amend their lists to provide all priority medicines as part of the efforts to improve maternal and child health.	[Hill, Suzanne] World Hlth Org, Dept Essential Med & Pharmaceut Policies, Geneva, Switzerland; [Yang, Annie] Stanford Hosp & Clin, Stanford, CA USA; [Bero, Lisa] Univ Calif San Francisco, San Francisco, CA 94143 USA	World Health Organization; Stanford University; University of California System; University of California San Francisco	Hill, S (corresponding author), Australian Pharmaceut Benefits Advisory Comm, Dept Hlth & Aging, Canberra, ACT, Australia.	berol@pharmacy.ucsf.edu		Bero, Lisa/0000-0003-1893-6651	World Health Organization	World Health Organization(World Health Organization)	The study was partially funded by the World Health Organization. No additional external funding was received for this study. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bhutta ZA, 2000, AM J CLIN NUTR, V72, P1516; Cham Mamady, 2009, Reprod Health, V6, P5, DOI 10.1186/1742-4755-6-5; Chen W, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-211; Gitanjali B, 2011, J PHARMACOL PHARMACO, V2, P95, DOI 10.4103/0976-500X.81900; Hill S, 2011, B WHO; Hogerzeil HV, 2004, BRIT MED J, V329, P1169, DOI 10.1136/bmj.329.7475.1169; Hoppu K, 2011, ARCH DIS CHILD, V96, P764, DOI 10.1136/adc.2009.180000; Lozano R, 2011, LANCET, V378, P1139, DOI 10.1016/S0140-6736(11)61337-8; Oshikoya KA, 2010, ANN AFR MED, V9, P203, DOI 10.4103/1596-3519.70954; Ridge AL, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-340; Robertson J, 2007, CLIN PHARMACOL THER, V82, P498, DOI 10.1038/sj.clpt.6100392; Robertson J, 2009, B WORLD HEALTH ORGAN, V87, P231, DOI 10.2471/BLT.08.053645; WHO, 2011, WORLD MALARIA REPORT 2011, P1; WHO, 2011, PRIOR MED MOTH CHILD; WHO, 2010, GUID TREATM MAL, V2nd; WHO, 2010, RAP ADV US ANT DRUGS; World Health Organization, 2010, DEF CONC ESS MED	17	29	31	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2012	7	5							e38055	10.1371/journal.pone.0038055	http://dx.doi.org/10.1371/journal.pone.0038055			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TY	22675435	Green Published, gold, Green Submitted			2023-01-03	WOS:000305338500082
J	Sami, H; Maparu, AK; Kumar, A; Sivakumar, S				Sami, Haider; Maparu, Auhin K.; Kumar, Ashok; Sivakumar, Sri			Generic Delivery of Payload of Nanoparticles Intracellularly via Hybrid Polymer Capsules for Bioimaging Applications	PLOS ONE			English	Article							POLYELECTROLYTE; EMULSIONS; SPHERES; SIZE; MICROCONTAINERS; MICROCAPSULES; DEPENDENCE; PARTICLES; NANORODS; SILICA	Towards the goal of development of a generic nanomaterial delivery system and delivery of the 'as prepared' nanoparticles without 'further surface modification' in a generic way, we have fabricated a hybrid polymer capsule as a delivery vehicle in which nanoparticles are loaded within their cavity. To this end, a generic approach to prepare nanomaterials-loaded polyelectrolyte multilayered (PEM) capsules has been reported, where polystyrene sulfonate (PSS)/polyallylamine hydrochloride (PAH) polymer capsules were employed as nano/microreactors to synthesize variety of nanomaterials (metal nanoparticles; lanthanide doped inorganic nanoparticles; gadolinium based nanoparticles, cadmium based nanoparticles; different shapes of nanoparticles; co-loading of two types of nanoparticles) in their hollow cavity. These nanoparticles-loaded capsules were employed to demonstrate generic delivery of payload of nanoparticles intracellularly (HeLa cells), without the need of individual nanoparticle surface modification. Validation of intracellular internalization of nanoparticles-loaded capsules by HeLa cells was ascertained by confocal laser scanning microscopy. The green emission from Tb3+ was observed after internalization of LaF3:Tb3+(5%) nanoparticles-loaded capsules by HeLa cells, which suggests that nanoparticles in hybrid capsules retain their functionality within the cells. In vitro cytotoxicity studies of these nanoparticles-loaded capsules showed less/no cytotoxicity in comparison to blank capsules or untreated cells, thus offering a way of evading direct contact of nanoparticles with cells because of the presence of biocompatible polymeric shell of capsules. The proposed hybrid delivery system can be potentially developed to avoid a series of biological barriers and deliver multiple cargoes (both simultaneous and individual delivery) without the need of individual cargo design/modification.	[Sami, Haider; Kumar, Ashok] Indian Inst Technol, Dept Biol Sci & Bioengn, Kanpur 208016, Uttar Pradesh, India; [Maparu, Auhin K.; Sivakumar, Sri] Indian Inst Technol, Unit Excellence Soft Nanofabricat, Dept Chem Engn, Kanpur 208016, Uttar Pradesh, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Kanpur; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Kanpur	Sami, H (corresponding author), Indian Inst Technol, Dept Biol Sci & Bioengn, Kanpur 208016, Uttar Pradesh, India.	ashokkum@iitk.ac.in; srisiva@iitk.ac.in	Kumar, Ashok/G-8515-2015; KUMAR, ASHOK/AAF-4055-2021; Sivakumar, Sri/F-2053-2013	KUMAR, ASHOK/0000-0002-9244-0622; Sivakumar, Sri/0000-0002-6472-2702; Kumar, Ashok/0000-0002-4910-9440	IIT Kanpur [IIT/CHE/20080352]; Department of Biotechnology [DBT/CHE/20100304]; Department of Science and Technology; India-UK Science Bridge [DST/BSBE/20090218]; DBT Junior Research Fellowship (DBT-JRF) programme	IIT Kanpur; Department of Biotechnology; Department of Science and Technology(Department of Science & Technology (India)); India-UK Science Bridge; DBT Junior Research Fellowship (DBT-JRF) programme	This work is funded by IIT Kanpur (IIT/CHE/20080352), Department of Biotechnology (DBT/CHE/20100304), Department of Science and Technology and India-UK Science Bridge (DST/BSBE/20090218). HS also acknowledges a senior research fellowship under the DBT Junior Research Fellowship (DBT-JRF) programme. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alric C, 2008, J AM CHEM SOC, V130, P5908, DOI 10.1021/ja078176p; Angelatos AS, 2005, J PHYS CHEM B, V109, P3071, DOI 10.1021/jp045070x; Bedard MF, 2009, SOFT MATTER, V5, P148, DOI 10.1039/b812553h; Buchel G, 1998, ADV MATER, V10, P1036, DOI 10.1002/(SICI)1521-4095(199809)10:13<1036::AID-ADMA1036>3.0.CO;2-Z; Caruso F, 2000, LANGMUIR, V16, P8932, DOI 10.1021/la000401s; Caruso F, 1998, SCIENCE, V282, P1111, DOI 10.1126/science.282.5391.1111; Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o; Choi WS, 2005, J AM CHEM SOC, V127, P16136, DOI 10.1021/ja053981u; Cortez C, 2006, ADV MATER, V18, P1998, DOI 10.1002/adma.200600564; Cui JW, 2010, ADV FUNCT MATER, V20, P1625, DOI 10.1002/adfm.201000209; De Geest BG, 2009, SOFT MATTER, V5, P282, DOI 10.1039/b808262f; del Mercato LL, 2010, NANOSCALE, V2, P458, DOI 10.1039/b9nr00341j; Gorin DA, 2008, PHYS CHEM CHEM PHYS, V10, P6899, DOI 10.1039/b809696a; Jana NR, 2001, J PHYS CHEM B, V105, P4065, DOI 10.1021/jp0107964; Javier AM, 2008, ADV MATER, V20, P4281, DOI 10.1002/adma.200703190; Johnston APR, 2006, CURR OPIN COLLOID IN, V11, P203, DOI 10.1016/j.cocis.2006.05.001; Kievit FM, 2011, ADV MATER, V23, pH217, DOI 10.1002/adma.201102313; Koo HY, 2008, SMALL, V4, P742, DOI 10.1002/smll.200800021; Melancon MP, 2009, MRS BULL, V34, P415, DOI 10.1557/mrs2009.117; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Pavlov AM, 2011, SOFT MATTER, V7, P4341, DOI 10.1039/c0sm01536a; Riehemann K, 2009, ANGEW CHEM INT EDIT, V48, P872, DOI 10.1002/anie.200802585; Rivera Gil P, 2008, NANO TODAY, V3, P12; Rogach AL, 2000, CHEM MATER, V12, P2676, DOI 10.1021/cm000244i; Sau TK, 2004, LANGMUIR, V20, P6414, DOI 10.1021/la049463z; Shchukin DG, 2004, J PHYS CHEM B, V108, P19109, DOI 10.1021/jp048052o; Shchukin DG, 2003, LANGMUIR, V19, P4427, DOI 10.1021/la0268707; Sivakumar S, 2008, CHEM MATER, V20, P2063, DOI 10.1021/cm703237a; Sivakumar S, 2006, CHEM-EUR J, V12, P5878, DOI 10.1002/chem.200600224; Sivakumar S, 2009, ADV FUNCT MATER, V19, P2260, DOI 10.1002/adfm.200900399; Sivakumar S, 2009, ADV MATER, V21, P1820, DOI 10.1002/adma.200802475; Skirtach AG, 2004, LANGMUIR, V20, P6988, DOI 10.1021/la048873k; Skirtach AG, 2006, ANGEW CHEM INT EDIT, V45, P4612, DOI 10.1002/anie.200504599; Song Y, 2009, ANGEW CHEM INT EDIT, V48, P9143, DOI 10.1002/anie.200904666; Stadler B, 2011, ADV FUNCT MATER, V21, P14, DOI 10.1002/adfm.201001676; Thurn KT, 2007, NANOSCALE RES LETT, V2, P430, DOI 10.1007/s11671-007-9081-5; Wang YJ, 2008, NANO LETT, V8, P1741, DOI 10.1021/nl080877c; Wang YJ, 2006, CHEM MATER, V18, P4089, DOI 10.1021/cm060866p; Xu XL, 2002, J AM CHEM SOC, V124, P13864, DOI 10.1021/ja026901k; YUAN F, 1995, CANCER RES, V55, P3752; Zhao F, 2011, SMALL, V7, P1322, DOI 10.1002/smll.201100001	41	18	20	0	70	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2012	7	5							e36195	10.1371/journal.pone.0036195	http://dx.doi.org/10.1371/journal.pone.0036195			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TH	22649489	gold, Green Published, Green Submitted			2023-01-03	WOS:000305335800006
J	Herzig, SJ; Rothberg, MB				Herzig, Shoshana J.; Rothberg, Michael B.			Prophylaxis rates for venous thromboembolism and gastrointestinal bleeding in general medical patients: too low or too high?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							STRESS-ULCER PROPHYLAXIS; AMERICAN-COLLEGE; RISK; PREVENTION; PLACEBO; METAANALYSIS		[Herzig, Shoshana J.] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA; [Herzig, Shoshana J.] Harvard Univ, Sch Med, Boston, MA USA; [Rothberg, Michael B.] Baystate Med Ctr, Div Gen Med, Springfield, MA USA; [Rothberg, Michael B.] Tufts Univ, Sch Med, Boston, MA 02111 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Baystate Medical Center; Tufts University	Herzig, SJ (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA.	sherzig@bidmc.harvard.edu						ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; Cohen AT, 2008, LANCET, V371, P387, DOI 10.1016/S0140-6736(08)60202-0; Cohen AT, 2006, BMJ-BRIT MED J, V332, P325, DOI 10.1136/bmj.38733.466748.7C; COOK DJ, 1994, NEW ENGL J MED, V330, P377, DOI 10.1056/NEJM199402103300601; Cook DJ, 1996, JAMA-J AM MED ASSOC, V275, P308, DOI 10.1001/jama.275.4.308; Dentali F, 2007, ANN INTERN MED, V146, P278, DOI 10.7326/0003-4819-146-4-200702200-00007; Department of Health, 2010, US COMM QUAL INN CQU; Dial S, 2004, CAN MED ASSOC J, V171, P33, DOI 10.1503/cmaj.1040876; Erstad BL, 1999, AM J HEALTH-SYST PH, V56, P347; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; Heidelbaugh JJ, 2006, AM J GASTROENTEROL, V101, P2200, DOI 10.1111/j.1572-0241.2006.00839.x; Herzig SJ, 2011, ARCH INTERN MED, V171, P991, DOI 10.1001/archinternmed.2011.14; Herzig SJ, 2009, JAMA-J AM MED ASSOC, V301, P2120, DOI 10.1001/jama.2009.722; Howell MD, 2010, ARCH INTERN MED, V170, P784, DOI 10.1001/archinternmed.2010.89; Janicki T, 2007, J HOSP MED, V2, P86, DOI 10.1002/jhm.177; Joint Commission on the Accreditation of Healthcare Organizations, 2011, VEN THROMB VEN THROM; Lederle FA, 2011, ANN INTERN MED, V155, P602, DOI 10.7326/0003-4819-155-9-201111010-00008; Leizorovicz A, 2004, CIRCULATION, V110, P874, DOI 10.1161/01.CIR.0000138928.83266.24; Maynard G, 2008, AHRQ PUBLICATION; Nardino RJ, 2000, AM J GASTROENTEROL, V95, P3118; Qaseem A, 2011, ANN INTERN MED, V155, P625, DOI 10.7326/0003-4819-155-9-201111010-00011; Rothberg MB, 2011, J HOSP MED, V6, P202, DOI 10.1002/jhm.888; Samama MM, 1999, NEW ENGL J MED, V341, P793, DOI 10.1056/NEJM199909093411103; Sanofi UK, 2010, SPONS 2010; Straube S, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-41; Tapson VF, 2007, CHEST, V132, P936, DOI 10.1378/chest.06-2993; Treasure T, 2010, J ROY SOC MED, V103, P210, DOI 10.1258/jrsm.2010.100086; Wein L, 2007, ARCH INTERN MED, V167, P1476, DOI 10.1001/archinte.167.14.1476	28	5	5	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 18	2012	344								e3248	10.1136/bmj.e3248	http://dx.doi.org/10.1136/bmj.e3248			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	946NV	22611168				2023-01-03	WOS:000304359600003
J	Xie, YC; Chen, SB; Murphy, T				Xie, Yicheng; Chen, Shangbin; Murphy, Timothy			Dendritic Spines and Pre-Synaptic Boutons Are Stable Despite Local Deep Hypothermic Challenge and Re-Warming In Vivo	PLOS ONE			English	Article							THERAPEUTIC HYPOTHERMIA; PROLONGED HYPOTHERMIA; CIRCULATORY ARREST; BLOOD-FLOW; PLASTICITY; TEMPERATURE; ANEURYSMS; TURNOVER; MODERATE; ONSET	Background and Purpose: Deep hypothermia to 20 degrees C is used clinically for major pediatric and adult surgical procedures. In particular, it is used in the "standstill operation" where blood flow is stopped for up to 30 min. Patients recovering from these procedures can exhibit neurological deficits. Such deficits could arise from changes to dendritic spines and plasticity-induced changes in network function as a result of cooling and/or re-warming. In the brain, each dendritic spine represents a single excitatory synapse and their number can be reflective of injury or plasticity-induced changes in network function. This research sought to determine whether deep hypothermia and re-warming have detrimental effects on synaptic stability and network function. Methods: In vivo 2-photon (2-P) imaging in green/yellow fluorescent protein (GFP/YFP)-expressing transgenic mice was performed to determine whether 4 hours of deep hypothermia and 2 hours of re-warming can have relatively covert effects on dendritic spine and presynaptic bouton stability. At the same time, electroencephalographic (EEG) activity was recorded to evaluate network function during deep hypothermia and re-warming. Results: We report that deep hypothermia and subsequent re-warming did not change the stability of dendritic spines or presynaptic boutons in mouse somatosensory cortex measured over 8 hours. As expected, deep hypothermia attenuated ongoing EEG activity over 0.1-80 Hz frequencies. The effects on EEG activity were fully reversible following re-warming. Conclusion: These results are consistent with deep hypothermia being a safe treatment which could be applied clinically to those undergoing major elective surgical procedures.	[Xie, Yicheng; Chen, Shangbin; Murphy, Timothy] Univ British Columbia, Dept Psychiat, Kinsmen Lab Neurol Res, Vancouver, BC V6T 1W5, Canada; [Xie, Yicheng; Chen, Shangbin; Murphy, Timothy] Univ British Columbia, Brain Res Ctr, Vancouver, BC V5Z 1M9, Canada	University of British Columbia; University of British Columbia	Xie, YC (corresponding author), Univ British Columbia, Dept Psychiat, Kinsmen Lab Neurol Res, Vancouver, BC V6T 1W5, Canada.	thmurphy@mail.ubc.ca	Murphy, Timothy H/I-4982-2014; Murphy, Timothy/AAW-1975-2021	Murphy, Timothy H/0000-0002-0093-4490; Murphy, Timothy/0000-0002-0093-4490	Heart and Stroke Foundation of British Columbia; Yukon; Canadian Institutes of Health Research (CIHR) [MOP-111009]; University of British Columbia	Heart and Stroke Foundation of British Columbia; Yukon; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); University of British Columbia	This work was supported by a grant in aid from the Heart and Stroke Foundation of British Columbia and the Yukon and a Canadian Institutes of Health Research (CIHR) operating grant MOP-111009 to TM and a Four Year Fellowship from the University of British Columbia to YX. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrew RD, 2007, CEREB CORTEX, V17, P787, DOI 10.1093/cercor/bhk032; BAKER CJ, 1991, SURG NEUROL, V36, P175, DOI 10.1016/0090-3019(91)90109-M; Brown CE, 2007, J NEUROSCI, V27, P4101, DOI 10.1523/JNEUROSCI.4295-06.2007; Clark DL, 2007, J CEREBR BLOOD F MET, V27, P115, DOI 10.1038/sj.jcbfm.9600327; De Paola V, 2006, NEURON, V49, P861, DOI 10.1016/j.neuron.2006.02.017; DELEON S, 1990, ANN THORAC SURG, V50, P714, DOI 10.1016/0003-4975(90)90668-V; Drew PJ, 2010, NAT METHODS, V7, P981, DOI 10.1038/NMETH.1530; Engelman RM, 1996, J THORAC CARDIOV SUR, V112, P1622, DOI 10.1016/S0022-5223(96)70021-1; Enomoto S, 1996, ANESTHESIOLOGY, V84, P1392, DOI 10.1097/00000542-199606000-00016; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Gao TM, 1998, NEUROSCIENCE, V87, P371, DOI 10.1016/S0306-4522(98)00150-X; Grutzendler J, 2002, NATURE, V420, P812, DOI 10.1038/nature01276; Guyton RA, 1996, J THORAC CARDIOV SUR, V112, P1632; Kim JH, 2011, RECENT PATENTS INFLA, V5, P155, DOI 10.2174/187221311795399219; Kirov SA, 2004, NEUROSCIENCE, V127, P69, DOI 10.1016/j.neuroscience.2004.04.053; Kleinfeld D, 1998, P NATL ACAD SCI USA, V95, P15741, DOI 10.1073/pnas.95.26.15741; Kurth CD, 1999, J THORAC CARDIOV SUR, V118, P1068, DOI 10.1016/S0022-5223(99)70103-0; Liu LP, 2007, FRONT BIOSCI-LANDMRK, V12, P816, DOI 10.2741/2104; Mack WJ, 2007, NEUROSURGERY, V60, P815, DOI 10.1227/01.NEU.0000255452.20602.C9; MacLellan CL, 2009, J NEUROTRAUM, V26, P313, DOI 10.1089/neu.2008.0580; Majewska AK, 2006, J NEUROSCI, V26, P3021, DOI 10.1523/JNEUROSCI.4454-05.2006; MOSER E, 1993, SCIENCE, V259, P1324, DOI 10.1126/science.8446900; Mostany R, 2010, J NEUROSCI, V30, P14116, DOI 10.1523/JNEUROSCI.3908-10.2010; Murphy TH, 2008, J NEUROSCI, V28, P1756, DOI 10.1523/JNEUROSCI.5128-07.2008; Paxinos G., 2008, MOUSE BRAIN STEREOTA, V3rd; POPOV VI, 1992, NEUROSCIENCE, V48, P53, DOI 10.1016/0306-4522(92)90337-2; POPOV VI, 1992, NEUROSCIENCE, V48, P45, DOI 10.1016/0306-4522(92)90336-Z; Shih AY, 2012, J CEREBR BLOOD F MET, V32, P1277, DOI 10.1038/jcbfm.2011.196; SILVERBERG GD, 1981, J NEUROSURG, V55, P337, DOI 10.3171/jns.1981.55.3.0337; STEEN PA, 1979, STROKE, V10, P522, DOI 10.1161/01.STR.10.5.522; Steiner T, 2001, STROKE, V32, P2833, DOI 10.1161/hs1201.99511; Svoboda K, 1997, NATURE, V385, P161, DOI 10.1038/385161a0; Trachtenberg JT, 2002, NATURE, V420, P788, DOI 10.1038/nature01273; Tran S, 2012, J CEREBR BLOOD F MET, V32, P437, DOI 10.1038/jcbfm.2011.178; Xu HT, 2007, NAT NEUROSCI, V10, P549, DOI 10.1038/nn1883; Zhang SX, 2005, J NEUROSCI, V25, P5333, DOI 10.1523/JNEUROSCI.1085-05.2005	36	5	5	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2012	7	5							e36305	10.1371/journal.pone.0036305	http://dx.doi.org/10.1371/journal.pone.0036305			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UN	22563488	Green Published, Green Submitted, gold			2023-01-03	WOS:000305340700037
J	Lu, N; Liu, JX; Liu, J; Zhang, CY; Jiang, FQ; Wu, H; Chen, LQ; Zeng, WJ; Cao, XH; Yan, TD; Wang, GH; Zhou, H; Lin, BZ; Yan, XM; Zhang, XK; Zeng, JZ				Lu, Na; Liu, Jinxing; Liu, Jie; Zhang, Chunyun; Jiang, Fuquan; Wu, Hua; Chen, Liqun; Zeng, Wenjun; Cao, Xihua; Yan, Tingdong; Wang, Guanghui; Zhou, Hu; Lin, Bingzhen; Yan, Xiaomei; Zhang, Xiao-kun; Zeng, Jin-Zhang			Antagonist Effect of Triptolide on AKT Activation by Truncated Retinoid X Receptor-alpha	PLOS ONE			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; KAPPA-B ACTIVATION; L-TYPE PROTEASE; RXR-ALPHA; CANCER-CELLS; INDUCED APOPTOSIS; TRIPTERYGIUM-WILFORDII; 9-CIS-RETINOIC ACID; SERINE-260 IMPAIRS; EPITHELIAL-CELLS	Background: Retinoid X receptor-alpha (RXR alpha) is a key member of the nuclear receptor superfamily. We recently demonstrated that proteolytic cleavage of RXR alpha resulted in production of a truncated product, tRXR alpha, which promotes cancer cell survival by activating phosphatidylinositol-3-OH kinase (PI3K)/AKT pathway. However, how the tRXR alpha-mediated signaling pathway in cancer cells is regulated remains elusive. Methodology/Principal Findings: We screened a natural product library for tRXR alpha targeting leads and identified that triptolide, an active component isolated from traditional Chinese herb Trypterygium wilfordii Hook F, could modulate tRXR alpha-mediated cancer cell survival pathway in vitro and in animals. Our results reveal that triptolide strongly induces cancer cell apoptosis dependent on intracellular tRXR alpha expression levels, demonstrating that tRXR alpha serves as an important intracellular target of triptolide. We show that triptolide selectively induces tRXR alpha degradation and inhibits tRXR alpha-dependent AKT activity without affecting the full-length RXR alpha. Interestingly, such effects of triptolide are due to its activation of p38. Although triptolide also activates Erk1/2 and MAPK pathways, the effects of triptolide on tRXR alpha degradation and AKT activity are only reversed by p38 siRNA and p38 inhibitor. In addition, the p38 inhibitor potently inhibits tRXR alpha interaction with p85 alpha leading to AKT inactivation. Our results demonstrate an interesting novel signaling interplay between p38 and AKT through tRXR alpha mediation. We finally show that targeting tRXR alpha by triptolide strongly activates TNF alpha death signaling and enhances the anticancer activity of other chemotherapies Conclusions/Significance: Our results identify triptolide as a new xenobiotic regulator of the tRXR alpha-dependent survival pathway and provide new insight into the mechanism by which triptolide acts to induce apoptosis of cancer cells. Triptolide represents one of the most promising therapeutic leads of natural products of traditional Chinese medicine with unfortunate side-effects. Our findings will offer new strategies to develop improved triptolide analogs for cancer therapy.	[Lu, Na; Liu, Jinxing; Liu, Jie; Zhang, Chunyun; Jiang, Fuquan; Wu, Hua; Chen, Liqun; Zeng, Wenjun; Yan, Tingdong; Wang, Guanghui; Zhang, Xiao-kun; Zeng, Jin-Zhang] Xiamen Univ, Sch Pharmaceut Sci, Xiamen, Peoples R China; [Lu, Na; Liu, Jinxing; Liu, Jie; Zhang, Chunyun; Jiang, Fuquan; Wu, Hua; Chen, Liqun; Zeng, Wenjun; Yan, Tingdong; Wang, Guanghui; Zhang, Xiao-kun; Zeng, Jin-Zhang] Xiamen Univ, Inst Biomed Res, Xiamen, Peoples R China; [Cao, Xihua; Zhou, Hu; Lin, Bingzhen; Zhang, Xiao-kun] Sanford Burnham Med Res Inst, Ctr Canc, La Jolla, CA USA; [Yan, Xiaomei] Xiamen Univ, Coll Chem & Chem Engn, Dept Biol Chem, Key Lab Analyt Sci,Key Lab Chem Biol Fujian Prov, Xiamen, Peoples R China	Xiamen University; Xiamen University; Sanford Burnham Prebys Medical Discovery Institute; Xiamen University	Lu, N (corresponding author), Xiamen Univ, Sch Pharmaceut Sci, Xiamen, Peoples R China.	xzhang@burnham.org; jzzeng@xmu.edu.cn	Wu, Hua/W-4204-2019; Zeng, JZ/G-3377-2010		National Natural Science Foundation of China [NSFC: 30971445, 90913015, 91129302]; NSFC/Hong Kong Research Grants Council [NSFC/RGC: 30931160431/N_HKU 735/09]; Natural Science Foundation of Fujian Province [2009J01198]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NSFC/Hong Kong Research Grants Council(Hong Kong Research Grants CouncilNational Natural Science Foundation of China (NSFC)); Natural Science Foundation of Fujian Province(Natural Science Foundation of Fujian Province)	This work was supported by National Natural Science Foundation of China (NSFC: 30971445, 90913015 and 91129302), NSFC/Hong Kong Research Grants Council (NSFC/RGC: 30931160431/N_HKU 735/09) and Natural Science Foundation of Fujian Province (2009J01198). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adachi S, 2002, HEPATOLOGY, V35, P332, DOI 10.1053/jhep.2002.31164; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Carter BZ, 2008, BLOOD, V111, P3742, DOI 10.1182/blood-2007-05-091504; Carter BZ, 2006, BLOOD, V108, P630, DOI 10.1182/blood-2005-09-3898; Chang WT, 2001, J BIOL CHEM, V276, P2221, DOI 10.1074/jbc.M009713200; Chen BJ, 2001, LEUKEMIA LYMPHOMA, V42, P253, DOI 10.3109/10428190109064582; Corson TW, 2007, CELL, V130, P769, DOI 10.1016/j.cell.2007.08.021; Dawson MI, 2002, CURR MED CHEM, V9, P623, DOI 10.2174/0929867023370789; Fidler JM, 2003, MOL CANCER THER, V2, P855; Fidler JM, 2002, TRANSPLANTATION, V74, P445, DOI 10.1097/00007890-200208270-00004; Germain P, 2006, PHARMACOL REV, V58, P760, DOI 10.1124/pr.58.4.7; HSIANG YH, 1988, CANCER RES, V48, P1722; Huang JP, 2002, CANCER RES, V62, P4812; Jiang XH, 2001, ONCOGENE, V20, P8009, DOI 10.1038/sj.onc.1204981; Kiviharju TM, 2002, CLIN CANCER RES, V8, P2666; Kunz C, 2009, PLOS BIOL, V7, P967, DOI 10.1371/journal.pbio.1000091; Lee KY, 2002, EXP MOL MED, V34, P462, DOI 10.1038/emm.2002.64; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Lefebvre P, 2010, TRENDS ENDOCRIN MET, V21, P676, DOI 10.1016/j.tem.2010.06.009; Leuenroth SJ, 2008, CANCER RES, V68, P5257, DOI 10.1158/0008-5472.CAN-07-6207; Li M, 2001, DEVELOPMENT, V128, P675; Liu J, 2008, CANCER RES, V68, P8871, DOI 10.1158/0008-5472.CAN-08-1972; Macoritto M, 2008, J BIOL CHEM, V283, P4943, DOI 10.1074/jbc.M707517200; Matsushima-Nishiwaki R, 2001, CANCER RES, V61, P7675; MatsushimaNishiwaki R, 1996, BIOCHEM BIOPH RES CO, V225, P946, DOI 10.1006/bbrc.1996.1276; Nagaya T, 1998, J BIOL CHEM, V273, P33166, DOI 10.1074/jbc.273.50.33166; Nakamura M, 2007, J HEPATOL, V46, P77, DOI 10.1016/j.jhep.2006.07.032; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nomura Y, 1999, BIOCHEM BIOPH RES CO, V254, P388, DOI 10.1006/bbrc.1998.9941; Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007; Petersen SL, 2007, CANCER CELL, V12, P445, DOI 10.1016/j.ccr.2007.08.029; Phillips PA, 2007, CANCER RES, V67, P9407, DOI 10.1158/0008-5472.CAN-07-1077; Picard E, 1999, J NATL CANCER I, V91, P1059, DOI 10.1093/jnci/91.12.1059; Qiu Daoming, 2003, Drugs R D, V4, P1, DOI 10.2165/00126839-200304010-00001; Takiyama Y, 2004, J CLIN ENDOCR METAB, V89, P5851, DOI 10.1210/jc.2003-032036; Tillman DM, 1999, CLIN CANCER RES, V5, P425; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wan CK, 2006, CANCER LETT, V241, P31, DOI 10.1016/j.canlet.2005.10.001; Westerheide SD, 2006, J BIOL CHEM, V281, P9616, DOI 10.1074/jbc.M512044200; Yamazaki K, 2007, GUT, V56, P1557, DOI 10.1136/gut.2007.129858; Yan TD, 2010, CANCER RES, V70, P2285, DOI 10.1158/0008-5472.CAN-09-2968; Yang SM, 2003, MOL CANCER THER, V2, P65; Zeisig BB, 2007, CANCER CELL, V12, P36, DOI 10.1016/j.ccr.2007.06.006; Zhao GH, 2000, AM J PHYSIOL-LUNG C, V279, pL958, DOI 10.1152/ajplung.2000.279.5.L958; Zhong C, 2003, CANCER BIOL THER, V2, P179, DOI 10.4161/cbt.2.2.281; Zhou H, 2010, CANCER CELL, V17, P560, DOI 10.1016/j.ccr.2010.04.023; Zhu J, 2007, CANCER CELL, V12, P23, DOI 10.1016/j.ccr.2007.06.004	48	17	20	0	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 24	2012	7	4							e35722	10.1371/journal.pone.0035722	http://dx.doi.org/10.1371/journal.pone.0035722			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959VE	22545132	Green Submitted, gold, Green Published			2023-01-03	WOS:000305343200052
J	Zhuang, PW; Zhang, YJ; Cui, GZ; Bian, YH; Zhang, MX; Zhang, JB; Liu, Y; Yang, XP; Isaiah, AO; Lin, YX; Jiang, YB				Zhuang, Pengwei; Zhang, Yanjun; Cui, Guangzhi; Bian, Yuhong; Zhang, Mixia; Zhang, Jinbao; Liu, Yang; Yang, Xinpeng; Isaiah, Adejobi Oluwaniyi; Lin, Yingxue; Jiang, Yongbo			Direct Stimulation of Adult Neural Stem/Progenitor Cells In Vitro and Neurogenesis In Vivo by Salvianolic Acid B	PLOS ONE			English	Article							TRANSIENT GLOBAL-ISCHEMIA; CEREBRAL-ISCHEMIA; STEM-CELLS; CHINESE MEDICINE; PROGENITOR CELLS; SPATIAL MEMORY; DENTATE GYRUS; BRAIN-INJURY; EXERCISE; NEURONS	Background: Small molecules have been shown to modulate the neurogenesis processes. In search for new therapeutic drugs, the herbs used in traditional medicines for neurogenesis are promising candidates. Methodology and Principal Findings: We selected a total of 45 natural compounds from Traditional Chinese herbal medicines which are extensively used in China to treat stroke clinically, and tested their proliferation-inducing activities on neural stem/progenitor cells (NSPCs). The screening results showed that salvianolic acid B (Sal B) displayed marked effects on the induction of proliferation of NSPCs. We further demonstrated that Sal B promoted NSPCs proliferation in dose-and time-dependent manners. To explore the molecular mechanism, PI3K/Akt, MEK/ERK and Notch signaling pathways were investigated. Cell proliferation assay demonstrated that Ly294002 (PI3K/Akt inhibitor), but neither U0126 (ERK inhibitor) nor DAPT (Notch inhibitor) inhibited the Sal B-induced proliferation of cells. Western Blotting results showed that stimulation of NSPCs with Sal B enhanced the phosphorylation of Akt, and Ly294002 abolished this effect, confirming the role of Akt in Sal B mediated proliferation of NSPCs. Rats exposed to transient cerebral ischemia were treated for 4 weeks with Sal B from the 7th day after stroke. BrdU incorporation assay results showed that exposure Sal B could maintain the proliferation of NSPCs after cerebral ischemia. Morris water maze test showed that delayed post-ischemic treatment with Sal B improved cognitive impairment after stroke in rats. Significance: Sal B could maintain the NSPCs self-renew and promote proliferation, which was mediated by PI3K/Akt signal pathway. And delayed post-ischemic treatment with Sal B improved cognitive impairment after stroke in rats. These findings suggested that Sal B may act as a potential drug in treatment of brain injury or neurodegenerative diseases.	[Zhuang, Pengwei; Zhang, Yanjun; Cui, Guangzhi; Zhang, Mixia; Zhang, Jinbao; Liu, Yang; Yang, Xinpeng; Isaiah, Adejobi Oluwaniyi; Lin, Yingxue; Jiang, Yongbo] Tianjin Univ Tradit Chinese Med, Chinese Mat Med Coll, Key Lab Tradit Chinese Med Pharmacol, Tianjin State Key Lab Modern Chinese Med, Tianjin, Peoples R China; [Bian, Yuhong] Tianjin Univ Tradit Chinese Med, Chinese Med Coll, Tianjin, Peoples R China	Tianjin University of Traditional Chinese Medicine; China Medical University; Tianjin University of Traditional Chinese Medicine	Zhuang, PW (corresponding author), Tianjin Univ Tradit Chinese Med, Chinese Mat Med Coll, Key Lab Tradit Chinese Med Pharmacol, Tianjin State Key Lab Modern Chinese Med, Tianjin, Peoples R China.	zyjsunye@163.com			National Natural Science Foundation of China [30873395, 30472177]; National Basic Research Program of China [2011CB505302]; National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program" [2012ZX09101202]; Program for Changjiang Scholars and Innovative Research Team in University [IRT0973]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China); National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program"; Program for Changjiang Scholars and Innovative Research Team in University(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT))	This work was supported by the National Natural Science Foundation of China (nos. 30873395 and 30472177), National Basic Research Program of China (no. 2011CB505302), National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program" (2012ZX09101202) and the Program for Changjiang Scholars and Innovative Research Team in University (no. IRT0973). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bruel-Jungerman E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007901; Canales JJ, 2010, BEHAV PHARMACOL, V21, P379, DOI 10.1097/FBP.0b013e32833e16b6; Chan CB, 2011, J NEUROSCI, V31, P8083, DOI 10.1523/JNEUROSCI.1129-11.2011; Chen T, 2011, BRAIN RES BULL, V84, P163, DOI 10.1016/j.brainresbull.2010.11.015; Choi YS, 2008, GLIA, V56, P791, DOI 10.1002/glia.20653; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; Doyle KP, 2008, NEUROPHARMACOLOGY, V55, P310, DOI 10.1016/j.neuropharm.2008.01.005; Du GH, 2000, J ASIAN NAT PROD RES, V2, P145, DOI 10.1080/10286020008039903; Duncan P, 2003, STROKE, V34, P2173, DOI 10.1161/01.STR.0000083699.95351.F2; Feigin VL, 2007, STROKE, V38, P1734, DOI 10.1161/STROKEAHA.107.487132; Heurteaux C, 2010, NEUROPHARMACOLOGY, V58, P987, DOI 10.1016/j.neuropharm.2010.01.001; Imayoshi I, 2010, J NEUROSCI, V30, P3489, DOI 10.1523/JNEUROSCI.4987-09.2010; Jacobs S, 2006, P NATL ACAD SCI USA, V103, P3902, DOI 10.1073/pnas.0511294103; Ji XY, 2000, ACTA PHARMACOL SIN, V21, P1089; Jiang M, 2011, AM J CHINESE MED, V39, P111, DOI 10.1142/S0192415X11008683; Johnson MA, 2009, BMB REP, V42, P245, DOI 10.5483/BMBRep.2009.42.5.245; Kee NJ, 2001, EXP BRAIN RES, V136, P313, DOI 10.1007/s002210000591; Khodosevich K, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-18; Kim DH, 2011, NEUROPHARMACOLOGY, V61, P1432, DOI 10.1016/j.neuropharm.2011.08.038; Kim H, 2005, NEUROL RES, V27, P287, DOI 10.1179/016164105X25234; Kim SJ, 2008, J BIOL CHEM, V283, P14497, DOI 10.1074/jbc.M708373200; Kwakkel G, 2004, STROKE, V35, P2529, DOI 10.1161/01.STR.0000143153.76460.7d; Lavenex PB, 2009, HIPPOCAMPUS, V19, P8, DOI 10.1002/hipo.20485; Le Belle JE, 2011, CELL STEM CELL, V8, P59, DOI 10.1016/j.stem.2010.11.028; Leker RR, 2009, J NEURAL TRANSM, V116, P1397, DOI 10.1007/s00702-009-0329-3; Lie DC, 2004, ANNU REV PHARMACOL, V44, P399, DOI 10.1146/annurev.pharmtox.44.101802.121631; Liu JL, 1998, J NEUROSCI, V18, P7768; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Mook-Jung I, 2001, J NEUROSCI RES, V63, P509, DOI 10.1002/jnr.1045; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; NITATORI T, 1995, J NEUROSCI, V15, P1001; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Quintard H, 2011, NEUROPHARMACOLOGY, V61, P622, DOI 10.1016/j.neuropharm.2011.05.003; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Shioda N, 2009, INT REV NEUROBIOL, V85, P375, DOI 10.1016/S0074-7742(09)85026-5; Takagi Y, 1999, BRAIN RES, V831, P283, DOI 10.1016/S0006-8993(99)01411-0; Tang MK, 2006, BEHAV PHARMACOL, V17, P493, DOI 10.1097/00008877-200609000-00015; Tang MK, 2002, PHYTOMEDICINE, V9, P405, DOI 10.1078/09447110260571634; Wang CM, 2011, NEUROSCI LETT, V488, P70, DOI 10.1016/j.neulet.2010.10.079; Weiss S, 1996, TRENDS NEUROSCI, V19, P387, DOI 10.1016/S0166-2236(96)10035-7; Wu B, 2007, STROKE, V38, P1973, DOI 10.1161/STROKEAHA.106.473165; Xu M, 2007, BIOMED CHROMATOGR, V21, P1052, DOI 10.1002/bmc.852; Yabe T, 2010, NEUROSCIENCE, V165, P515, DOI 10.1016/j.neuroscience.2009.10.023; Yagita Y, 2001, STROKE, V32, P1890, DOI 10.1161/01.STR.32.8.1890; Yonemori F, 1996, J CEREBR BLOOD F MET, V16, P973, DOI 10.1097/00004647-199609000-00022; Zhou LM, 2005, J CLIN PHARMACOL, V45, P1345, DOI 10.1177/0091270005282630	49	73	85	2	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 24	2012	7	4							e35636	10.1371/journal.pone.0035636	http://dx.doi.org/10.1371/journal.pone.0035636			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959VE	22545124	gold, Green Published, Green Submitted			2023-01-03	WOS:000305343200044
J	Ma, WN; Lu, S; Pan, P; Sadatmousavi, P; Yuan, YF; Chen, P				Ma, Weina; Lu, Sheng; Pan, Pei; Sadatmousavi, Parisa; Yuan, Yongfang; Chen, P.			Pharmacokinetics of Peptide Mediated Delivery of Anticancer Drug Ellipticine	PLOS ONE			English	Article							INDUCED APOPTOSIS; CANCER-CELLS	The amino acid pairing peptide EAK16-II (EAK) has shown the ability to stabilize the hydrophobic anticancer agent ellipticine (EPT) in aqueous solution. In this study, we investigate pharmacokinetics of the formulation of EAK-EPT complexes in vivo. The developed formulation can achieve a sufficiently high drug concentration required in vivo animal models. The nanostructure and surface properties of EAK-EPT complexes or nanoparticle were characterized by transmission electron microscopy (TEM) and zeta potential measurements, respectively. 12 healthy male SD rats were divided into EPT group and EAK-EPT group randomly. Rats in EPT group were tail intravenously injected with the EPT (20 mg/kg); rats in EAK-EPT group were injected with EAK-EPT complexes (EPT's concentration is 20 mg/kg). EPT was extracted from rat plasma with dexamethasone sodium phosphate as internal standards (IS). The pharmacokinetic parameters were obtained using high pressure liquid chromatography (HPLC). Significant differences in main pharmacokinetic parameters between EPT and EAK-EPT complexes were observed, demonstrating that the complexation with EAK prolongs the residence time of the drug and enlarges the area under the concentration-time curve (AUC). This means that EAK can serve as a suitable carrier to increase the bioavailability of EPT.	[Ma, Weina; Pan, Pei; Yuan, Yongfang] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 3, Dept Pharm, Shanghai 200030, Peoples R China; [Lu, Sheng; Sadatmousavi, Parisa; Chen, P.] Univ Waterloo, Dept Chem Engn, Waterloo, ON N2L 3G1, Canada	Shanghai Jiao Tong University; University of Waterloo	Ma, WN (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 3, Dept Pharm, Shanghai 200030, Peoples R China.	nmxyyf@yahoo.cn			Shanghai Committee of Science and Technology, China [10410711300]; Natural Sciences and Engineering Research Council of Canada; Canadian Foundation for Innovation; Canada Research Chairs Program	Shanghai Committee of Science and Technology, China(Shanghai Science & Technology Committee); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Canadian Foundation for Innovation(Canada Foundation for Innovation); Canada Research Chairs Program(Canada Research Chairs)	This project was supported by the Shanghai Committee of Science and Technology, China (Grant No. 10410711300). This research was financially supported by the Natural Sciences and Engineering Research Council of Canada, Canadian Foundation for Innovation and the Canada Research Chairs Program for one of the co-authors (PC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bawa R, 2011, NANOMEDICIN IN PRESS; Fang K, 2009, LUNG CANCER, V63, P227, DOI 10.1016/j.lungcan.2008.05.026; Fung SY, 2006, J PHYS CHEM A, V110, P11446, DOI 10.1021/jp062778y; Fung SY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001956; Fung SY, 2011, BIOMATERIALS, V32, P4000, DOI 10.1016/j.biomaterials.2011.02.005; FUNG SY, 2005, HDB NANOSTRUCTURED B, P1; Garbett Nichola C., 2004, Current Medicinal Chemistry - Anti-Cancer Agents, V4, P149, DOI 10.2174/1568011043482070; Kuo PL, 2005, CANCER LETT, V223, P293, DOI 10.1016/j.canlet.2004.09.046; Kuo YC, 2006, LIFE SCI, V78, P2550, DOI 10.1016/j.lfs.2005.10.041; Peng YH, 2003, ONCOGENE, V22, P4478, DOI 10.1038/sj.onc.1206777; Stiborova M, 2006, GEN PHYSIOL BIOPHYS, V25, P245; Stiborova Marie, 2006, Biomedical Papers (Olomouc), V150, P13; SUREAU F, 1993, BIOPHYS J, V65, P1767, DOI 10.1016/S0006-3495(93)81273-6; Zhang SG, 2003, NAT BIOTECHNOL, V21, P1171, DOI 10.1038/nbt874	14	44	44	1	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2012	7	8							e43684	10.1371/journal.pone.0043684	http://dx.doi.org/10.1371/journal.pone.0043684			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	998EY	23236514	Green Submitted, Green Published, gold			2023-01-03	WOS:000308221300022
J	Li, ZM; Huang, JJ; Xia, Y; Sun, J; Huang, Y; Wang, Y; Zhu, YJ; Li, YJ; Zhao, W; Wei, WX; Lin, TY; Huang, HQ; Jiang, WQ				Li, Zhi-Ming; Huang, Jia-Jia; Xia, Yi; Sun, Jian; Huang, Ying; Wang, Yu; Zhu, Ying-Jie; Li, Ya-Jun; Zhao, Wei; Wei, Wen-Xiao; Lin, Tong-Yu; Huang, Hui-Qiang; Jiang, Wen-Qi			Blood Lymphocyte-to-Monocyte Ratio Identifies High-Risk Patients in Diffuse Large B-Cell Lymphoma Treated with R-CHOP	PLOS ONE			English	Article							NON-HODGKIN-LYMPHOMA; ABSOLUTE MONOCYTE; RESPONSE CRITERIA; PROGNOSTIC-FACTOR; SURVIVAL; LYMPHOPENIA; EXPRESSION; COUNT; TUMOR; CHEMOTHERAPY	Background: Recent research has shown a correlation between immune microenvironment and lymphoma biology. This study aims to investigate the prognostic significance of the immunologically relevant lymphocyte-to-monocyte ratio (LMR), in diffuse large B-cell lymphoma (DLBCL) in the rituximab era. Methodology/Principal Findings: We analyzed retrospective data from 438 newly diagnosed DLBCL patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. We randomly selected 200 patients (training set) to generate a cutoff value for LMR by receiver operating characteristic (ROC) curve analysis. LMR was then analyzed in a testing set (n = 238) and in all patients (n = 438) for validation. The LMR cutoff value for survival analysis determined by ROC curve in the training set was 2.6. Patients with low LMR tended to have more adverse clinical characteristics. Low LMR at diagnosis was associated with worse survival in DLBCL, and could also identify high-risk patients in the low-risk IPI category. Multivariate analysis identified LMR as an independent prognostic factor of survival in the testing set and in all patients. Conclusions/Significance: Baseline LMR, a surrogate biomarker of the immune microenvironment, is an effective prognostic factor in DLBCL patients treated with R-CHOP therapy. Future prospective studies are required to confirm our findings.	[Li, Zhi-Ming; Huang, Jia-Jia; Xia, Yi; Sun, Jian; Huang, Ying; Wang, Yu; Zhu, Ying-Jie; Li, Ya-Jun; Zhao, Wei; Wei, Wen-Xiao; Lin, Tong-Yu; Huang, Hui-Qiang; Jiang, Wen-Qi] State Key Lab Oncol S China, Guangzhou, Guangdong, Peoples R China; [Li, Zhi-Ming; Huang, Jia-Jia; Xia, Yi; Wang, Yu; Zhu, Ying-Jie; Li, Ya-Jun; Zhao, Wei; Wei, Wen-Xiao; Lin, Tong-Yu; Huang, Hui-Qiang; Jiang, Wen-Qi] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou 510275, Guangdong, Peoples R China; [Sun, Jian] Sun Yat Sen Univ, Ctr Canc, Dept Clin Trial Ctr, Guangzhou 510275, Guangdong, Peoples R China; [Huang, Ying] Sun Yat Sen Univ, Ctr Canc, Dept Radiat Oncol, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Li, ZM (corresponding author), State Key Lab Oncol S China, Guangzhou, Guangdong, Peoples R China.	lzmlzmlzm@yahoo.com	jiang, wen/GYI-9662-2022; Wu, William K.K./A-3277-2009	Wu, William K.K./0000-0002-5662-5240; Qiu, Guixing/0000-0002-4597-9350	National Natural Science Foundation of China [81071950]; Fundamental Research Funds for the Central Universities [10ykpy36]; National-Eleventh Five Technology Major Project [2008ZX09312-002, 2012ZX09301]; Research Award Funds for Outstanding Young Researchers in Sun Yat-Sen Cancer Center	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); National-Eleventh Five Technology Major Project; Research Award Funds for Outstanding Young Researchers in Sun Yat-Sen Cancer Center	This work was supported by National Natural Science Foundation of China (NO. 81071950), Fundamental Research Funds for the Central Universities (NO. 10ykpy36), National-Eleventh Five Technology Major Project (NO. 2008ZX09312-002, 2012ZX09301), and Research Award Funds for Outstanding Young Researchers in Sun Yat-Sen Cancer Center. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abid Muhammad Bilal, 2005, Asian Pac J Cancer Prev, V6, P531; Alizadeh AA, 2011, BLOOD, V118, P1350, DOI 10.1182/blood-2011-03-345272; Ansell SM, 2001, J CLIN ONCOL, V19, P720, DOI 10.1200/JCO.2001.19.3.720; Bari A, 2010, ANN ONCOL, V21, P1486, DOI 10.1093/annonc/mdp531; Bhaskaran K, 2004, AIDS, V18, P673, DOI [10.1097/01.aids.0000111464.61782.64, 10.1097/00002030-200403050-00012]; Borg C, 2004, CANCER-AM CANCER SOC, V101, P2675, DOI 10.1002/cncr.20688; Challa-Malladi M, 2011, CANCER CELL, V20, P728, DOI 10.1016/j.ccr.2011.11.006; Cheson BD, 1999, J CLIN ONCOL, V17, P1244, DOI 10.1200/JCO.1999.17.4.1244; Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403; Coiffier B, 2007, ONCOGENE, V26, P3603, DOI 10.1038/sj.onc.1210376; Dave SS, 2004, NEW ENGL J MED, V351, P2159, DOI 10.1056/NEJMoa041869; Dworacki G, 2001, CLIN CANCER RES, V7, p947S; Huang JJ, 2011, ANN ONCOL, V22, P149, DOI 10.1093/annonc/mdq314; Huang JJ, 2011, HUM PATHOL, V42, P1459, DOI 10.1016/j.humpath.2010.12.014; Ishii H, 2012, INT J CANCER, V130, P48, DOI 10.1002/ijc.25969; Kim DH, 2007, LEUKEMIA, V21, P2227, DOI 10.1038/sj.leu.2404780; Kim YR, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-34; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Lin Y, 2011, BLOOD, V117, P872, DOI 10.1182/blood-2010-05-283820; Morton LM, 2008, BLOOD, V112, P5150, DOI 10.1182/blood-2008-01-133587; Moskowitz C, 2012, BEST PRACT RES CL HA, V25, P41, DOI 10.1016/j.beha.2012.01.008; Pileri SA, 2011, SEMIN DIAGN PATHOL, V28, P113, DOI 10.1053/j.semdp.2011.02.001; Porrata LF, 2007, LEUKEMIA, V21, P2554, DOI 10.1038/sj.leu.2404819; Porrata LF, 2004, CLIN EXP MED, V4, P78, DOI 10.1007/s10238-004-0041-4; Porrata LF, 2012, BRIT J HAEMATOL, V157, P321, DOI 10.1111/j.1365-2141.2012.09067.x; Porrata LF, 2012, HAEMATOL-HEMATOL J, V97, P262, DOI 10.3324/haematol.2011.050138; Ray-Coquard I, 2009, CANCER RES, V69, P5383, DOI 10.1158/0008-5472.CAN-08-3845; Sehn LH, 2007, BLOOD, V109, P1857, DOI 10.1182/blood-2006-08-038257; Steidl C, 2010, NEW ENGL J MED, V362, P875, DOI 10.1056/NEJMoa0905680; Vegso G, 2011, PATHOL ONCOL RES, V17, P443, DOI 10.1007/s12253-010-9329-8; Wada N, 2012, HISTOPATHOLOGY, V60, P924, DOI 10.1111/j.1365-2559.2011.04161.x; Wada N, 2012, HISTOPATHOLOGY, V60, P313, DOI 10.1111/j.1365-2559.2011.04096.x; Wilcox RA, 2011, LEUKEMIA, V25, P1502, DOI 10.1038/leu.2011.112; Wilcox RA, 2012, LEUKEMIA LYMPHOMA, V53, P575, DOI 10.3109/10428194.2011.637211; Wilcox RA, 2009, BLOOD, V114, P2936, DOI 10.1182/blood-2009-05-220111	35	221	232	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2012	7	7							e41658	10.1371/journal.pone.0041658	http://dx.doi.org/10.1371/journal.pone.0041658			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977TM	23300886	Green Published, Green Submitted, gold			2023-01-03	WOS:000306687700134
J	Yueh, MF; Li, T; Evans, RM; Hammock, B; Tukey, RH				Yueh, Mei-Fei; Li, Tao; Evans, Ronald M.; Hammock, Bruce; Tukey, Robert H.			Triclocarban Mediates Induction of Xenobiotic Metabolism through Activation of the Constitutive Androstane Receptor and the Estrogen Receptor Alpha	PLOS ONE			English	Article							WASTE-WATER TREATMENT; UDP-GLUCURONOSYLTRANSFERASE-1 UGT1 LOCUS; INHIBITORY CROSS-TALK; NUCLEAR RECEPTOR; IN-VITRO; ANTIMICROBIAL TRICLOCARBAN; SIGNALING PATHWAY; GENE-EXPRESSION; TRANSGENIC MICE; HUMAN LIVER	Triclocarban (3,4,4'-trichlorocarbanilide, TCC) is used as a broad-based antimicrobial agent that is commonly added to personal hygiene products. Because of its extensive use in the health care industry and resistance to degradation in sewage treatment processes, TCC has become a significant waste product that is found in numerous environmental compartments where humans and wildlife can be exposed. While TCC has been linked to a range of health and environmental effects, few studies have been conducted linking exposure to TCC and induction of xenobiotic metabolism through regulation by environmental sensors such as the nuclear xenobiotic receptors (XenoRs). To identify the ability of TCC to activate xenobiotic sensors, we monitored XenoR activities in response to TCC treatment using luciferase-based reporter assays. Among the XenoRs in the reporter screening assay, TCC promotes both constitutive androstane receptor (CAR) and estrogen receptor alpha (ER alpha) activities. TCC treatment to hUGT1 mice resulted in induction of the UGT1A genes in liver. This induction was dependent upon the constitutive active/androstane receptor (CAR) because no induction occurred in hUGT1Car(-/-) mice. Induction of the UGT1A genes by TCC corresponded with induction of Cyp2b10, another CAR target gene. TCC was demonstrated to be a phenobarbital-like activator of CAR in receptor-based assays. While it has been suggested that TCC be classified as an endocrine disruptor, it activates ER alpha leading to induction of Cyp1b1 in female ovaries as well as in promoter activity. Activation of ER alpha by TCC in receptor-based assays also promotes induction of human CYP2B6. These observations demonstrate that TCC activates nuclear xenobiotic receptors CAR and ER alpha both in vivo and in vitro and might have the potential to alter normal physiological homeostasis. Activation of these xenobiotic-sensing receptors amplifies gene expression profiles that might represent a mechanistic base for potential human health effects from exposure to TCC.	[Tukey, Robert H.] Salk Inst Biol Studies, Howard Hughes Med Inst, Dept Chem, Lab Environm Toxicol, La Jolla, CA 92037 USA; [Li, Tao; Evans, Ronald M.] Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, La Jolla, CA 92037 USA; [Hammock, Bruce] Univ Calif Davis, Ctr Canc, Dept Entomol, Davis, CA 95616 USA; [Tukey, Robert H.] Salk Inst Biol Studies, Howard Hughes Med Inst, Dept Biochem, Lab Environm Toxicol, La Jolla, CA 92037 USA; [Yueh, Mei-Fei; Tukey, Robert H.] Salk Inst Biol Studies, Howard Hughes Med Inst, Dept Pharmacol, Lab Environm Toxicol, La Jolla, CA 92037 USA	Howard Hughes Medical Institute; Salk Institute; Howard Hughes Medical Institute; Salk Institute; University of California System; University of California Davis; Howard Hughes Medical Institute; Salk Institute; Howard Hughes Medical Institute; Salk Institute	Yueh, MF (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, Dept Pharmacol, Lab Environm Toxicol, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rtukey@ucsd.edu	Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965; Evans, Richard/0000-0002-8651-6889	United States Public Health Service [P42ES010337]; ARRA Supplement [P42ES010337, P42ES004699, GM086713]; NATIONAL CANCER INSTITUTE [P30CA014195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004699, P42ES010337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM086713, R01GM100481] Funding Source: NIH RePORTER	United States Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); ARRA Supplement; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Funding for this work was provided by United States Public Health Service Grants P42ES010337 (RE and RHT), a 2009 ARRA Supplement to Superfund grant P42ES010337 (RHT and MFY) and P42ES004699 (BDH), and GM086713 (RHT). BDH is a George and Judy Marcus Senior Fellow of the American Asthma Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahn KC, 2008, ENVIRON HEALTH PERSP, V116, P1203, DOI 10.1289/ehp.11200; Cai HL, 2010, DRUG METAB DISPOS, V38, P879, DOI 10.1124/dmd.109.030130; Carthew P, 1998, TOXICOL SCI, V44, P46, DOI 10.1006/toxs.1998.2473; Chen F, 2011, ENVIRON POLLUT, V159, P1490, DOI 10.1016/j.envpol.2011.03.016; Chen JG, 2008, ENDOCRINOLOGY, V149, P1173, DOI 10.1210/en.2007-1057; Chen SJ, 2005, J BIOL CHEM, V280, P37547, DOI 10.1074/jbc.M506683200; Chen XS, 2011, LAB INVEST, V91, P1136, DOI 10.1038/labinvest.2011.68; Christen V, 2010, CHEMOSPHERE, V81, P1245, DOI 10.1016/j.chemosphere.2010.09.031; Downes M, 2003, MOL CELL, V11, P1079, DOI 10.1016/S1097-2765(03)00104-7; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Fujiwara R, 2010, P NATL ACAD SCI USA, V107, P5024, DOI 10.1073/pnas.0913290107; Giudice BD, 2010, ENVIRON TOXICOL CHEM, V29, P966, DOI 10.1002/etc.105; Halden RU, 2005, ENVIRON SCI TECHNOL, V39, P1420, DOI 10.1021/es049071e; Heidler J, 2008, ENVIRON SCI TECHNOL, V42, P6324, DOI 10.1021/es703008y; Heidler J, 2006, ENVIRON SCI TECHNOL, V40, P3634, DOI 10.1021/es052245n; Higgins CP, 2009, ENVIRON TOXICOL CHEM, V28, P2580, DOI 10.1897/09-013.1; HILES RA, 1978, DRUG METAB DISPOS, V6, P177; Kawamoto T, 2000, MOL ENDOCRINOL, V14, P1897, DOI 10.1210/me.14.11.1897; Kumar KS, 2010, ARCH ENVIRON CON TOX, V58, P275, DOI 10.1007/s00244-009-9383-y; Lee AJ, 2003, ENDOCRINOLOGY, V144, P3382, DOI 10.1210/en.2003-0192; Liu JY, 2011, TOXICOL APPL PHARM, V255, P200, DOI 10.1016/j.taap.2011.06.017; Lo R, 2010, BBA-GENE REGUL MECH, V1799, P469, DOI 10.1016/j.bbagrm.2010.01.005; Maglich JM, 2003, J BIOL CHEM, V278, P17277, DOI 10.1074/jbc.M300138200; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Miao J, 2006, J BIOL CHEM, V281, P14537, DOI 10.1074/jbc.M510713200; Min GS, 2002, J BIOL CHEM, V277, P34626, DOI 10.1074/jbc.M205239200; Nguyen N, 2008, J BIOL CHEM, V283, P7901, DOI 10.1074/jbc.M709244200; Perencevich EN, 2001, AM J INFECT CONTROL, V29, P281, DOI 10.1067/mic.2001.115469; Saez E, 2004, GENE DEV, V18, P528, DOI 10.1101/gad.1167804; Schebb NH, 2011, ENVIRON SCI TECHNOL, V45, P3109, DOI 10.1021/es103650m; Scientific Commitee on Consumer Products (2005) SCCP, 2005, SCCP085104; Senekeo-Effenberger K, 2007, DRUG METAB DISPOS, V35, P419, DOI 10.1124/dmd.106.013243d; Strassburg CP, 1997, MOL PHARMACOL, V52, P212, DOI 10.1124/mol.52.2.212; Strassburg CP, 1998, MOL PHARMACOL, V54, P647; Strassburg CP, 1997, CANCER RES, V57, P2979; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Tsuchiya Y, 2004, CANCER RES, V64, P3119, DOI 10.1158/0008-5472.CAN-04-0166; Tukey RH, 2001, MOL PHARMACOL, V59, P405, DOI 10.1124/mol.59.3.405; Ueda A, 2002, MOL PHARMACOL, V61, P1, DOI 10.1124/mol.61.1.1; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; Walsh SE, 2003, J APPL MICROBIOL, V94, P240, DOI 10.1046/j.1365-2672.2003.01825.x; Wang HB, 2008, CURR DRUG METAB, V9, P598, DOI 10.2174/138920008785821710; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Xie W, 2003, P NATL ACAD SCI USA, V100, P4150, DOI 10.1073/pnas.0438010100; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Yamamoto Y, 2004, CANCER RES, V64, P7197, DOI 10.1158/0008-5472.CAN-04-1459; Yueh MF, 2011, MOL PHARMACOL, V79, P1053, DOI 10.1124/mol.110.070649; Yueh MF, 2007, J BIOL CHEM, V282, P8749, DOI 10.1074/jbc.M610790200	51	59	61	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 15	2012	7	6							e37705	10.1371/journal.pone.0037705	http://dx.doi.org/10.1371/journal.pone.0037705			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959WX	22912892	Green Published, gold			2023-01-03	WOS:000305350000007
J	Chen, L; Huang, LZ; Min, DH; Phillips, A; Wang, SQ; Madgwick, PJ; Parry, MAJ; Hu, YG				Chen, Liang; Huang, Linzhou; Min, Donghong; Phillips, Andy; Wang, Shiqiang; Madgwick, Pippa J.; Parry, Martin A. J.; Hu, Yin-Gang			Development and Characterization of a New TILLING Population of Common Bread Wheat (Triticum aestivum L.)	PLOS ONE			English	Article							CHEMICALLY-INDUCED MUTATIONS; DETECT INDUCED MUTATIONS; GENE-FUNCTION; INSERTIONAL MUTAGENESIS; FUNCTIONAL GENOMICS; POINT MUTATIONS; INDUCED MUTANTS; DISCOVERY; RESOURCE; RICE	Mutagenesis is an important tool in crop improvement. However, the hexaploid genome of wheat (Triticum aestivum L.) presents problems in identifying desirable genetic changes based on phenotypic screening due to gene redundancy. TILLING (Targeting Induced Local Lesions IN Genomes), a powerful reverse genetic strategy that allows the detection of induced point mutations in individuals of the mutagenized populations, can address the major challenge of linking sequence information to the biological function of genes and can also identify novel variation for crop breeding. Wheat is especially well-suited for TILLING due to the high mutation densities tolerated by polyploids. However, only a few wheat TILLING populations are currently available in the world, which is far from satisfying the requirement of researchers and breeders in different growing environments. In addition, current TILLING screening protocols require costly fluorescence detection systems, limiting their use, especially in developing countries. We developed a new TILLING resource comprising 2610 M-2 mutants in a common wheat cultivar 'Jinmai 47'. Numerous phenotypes with altered morphological and agronomic traits were observed from the M-2 and M-3 lines in the field. To simplify the procedure and decrease costs, we use unlabeled primers and either non-denaturing polyacrylamide gels or agarose gels for mutation detection. The value of this new resource was tested using PCR with RAPD and Intron-spliced junction (ISJ) primers, and also TILLING in three selected candidate genes, in 300 and 512 mutant lines, revealing high mutation densities of 1/34 kb by RAPD/ISJ analysis and 1/47 kb by TILLING. In total, 31 novel alleles were identified in the 3 targeted genes and confirmed by sequencing. The results indicate that this mutant population represents a useful resource for the wheat research community. We hope that the use of this reverse genetics resource will provide novel allelic diversity for wheat improvement and functional genomics.	[Chen, Liang; Huang, Linzhou; Min, Donghong; Wang, Shiqiang; Hu, Yin-Gang] NW A&F Univ, Coll Agron, State Key Lab Crop Stress Biol Arid Areas, Yangling, Shaanxi, Peoples R China; [Phillips, Andy; Madgwick, Pippa J.; Parry, Martin A. J.] Rothamsted Res, Dept Plant Sci, Ctr Crop Genet Improvement, Harpenden, Herts, England; NW A&F Univ, Inst Water Saving Agr Arid Reg China, Yangling, Shaanxi, Peoples R China	Northwest A&F University - China; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research; Northwest A&F University - China	Hu, YG (corresponding author), NW A&F Univ, Coll Agron, State Key Lab Crop Stress Biol Arid Areas, Yangling, Shaanxi, Peoples R China.	huyingang@nwsuaf.edu.cn	Chen, Lei/A-2275-2011	Chen, Lei/0000-0003-3068-1583; Parry, Martin/0000-0002-4477-672X; cai, yudong/0000-0001-5664-7979	Ministry of Science and Technology [2006AA100201, 2006AA100223, 2006CB708208]; 111 Program of Introducing Talents of Discipline to Universities P. R. China [111-2-16]; ACIAR Project of Australia [CIM/2005/111]; Biotechnology and Biological Sciences Research Council [BBS/E/C/00005202, BBS/E/C/00004952, BB/E025161/1, BB/I000607/1, BBS/E/C/00004820] Funding Source: researchfish	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); 111 Program of Introducing Talents of Discipline to Universities P. R. China; ACIAR Project of Australia(Australian Ctr Intl Agr Res); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported by the sub-project of the 863 Program (2006AA100201, 2006AA100223), the pre-phase project of the 973 Program (2006CB708208) of the Ministry of Science and Technology, and the 111 Program of Introducing Talents of Discipline to Universities (111-2-16), P. R. China, as well as the ACIAR Project (CIM/2005/111) of Australia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aldrich C, 1993, PLANT MOL BIOL REP, V11, P128, DOI DOI 10.1007/BF02670471; Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; Bentley A, 2000, GENETICS, V156, P1169; Bibi S, 2009, PAK J BOT, V41, P1022; Caldwell DG, 2004, PLANT J, V40, P143, DOI 10.1111/j.1365-313X.2004.02190.x; Chawade A, 2010, BMC PLANT BIOL, V10, DOI 10.1186/1471-2229-10-86; Chen LA, 2011, AUST J CROP SCI, V5, P318; Chua NH, 2006, CURR OPIN BIOTECH, V17, P103, DOI 10.1016/j.copbio.2006.03.002; Cooper JL, 2008, BMC PLANT BIOL, V8, DOI 10.1186/1471-2229-8-9; Dahmani-Mardas F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015776; Dong CM, 2009, PLANT GENOME-US, V2, P39, DOI 10.3835/plantgenome2008.10.0012; Eversole K, 2009, ANN WHEAT N IN PRESS, P55; Fox JL, 2004, NAT BIOTECHNOL, V22, P1062, DOI 10.1038/nbt0904-1062; Fu DL, 2007, TRANSGENIC RES, V16, P689, DOI 10.1007/s11248-007-9150-7; Gonzalez FG, 2005, EUPHYTICA, V146, P253, DOI 10.1007/s10681-005-9021-3; Gottwald Sven, 2009, BMC Res Notes, V2, P258, DOI 10.1186/1756-0500-2-258; Greene EA, 2003, GENETICS, V164, P731; HALLORAN GM, 1982, ANN BOT-LONDON, V49, P115, DOI 10.1093/oxfordjournals.aob.a086220; Henikoff S, 2004, PLANT PHYSIOL, V135, P630, DOI 10.1104/pp.104.041061; Hirochika H, 2001, CURR OPIN PLANT BIOL, V4, P118, DOI 10.1016/S1369-5266(00)00146-1; Jaillon O, 2007, NATURE, V449, P463, DOI 10.1038/nature06148; Jeon JS, 2000, PLANT J, V22, P561, DOI 10.1046/j.1365-313x.2000.00767.x; Knoll JE, 2011, BMC PLANT BIOL, V11, DOI 10.1186/1471-2229-11-81; Matsumoto T, 2005, NATURE, V436, P793, DOI 10.1038/nature03895; McCallum CM, 2000, PLANT PHYSIOL, V123, P439, DOI 10.1104/pp.123.2.439; MERRIL CR, 1984, ELECTROPHORESIS, V5, P289, DOI 10.1002/elps.1150050509; Minoia Silvia, 2010, BMC Res Notes, V3, P69, DOI 10.1186/1756-0500-3-69; Muth J, 2008, PLANT BIOTECHNOL J, V6, P576, DOI 10.1111/j.1467-7652.2008.00340.x; Naghavi Mohammad Reza, 2004, Iranian Journal of Biotechnology, V2, P195; Nomura T, 2005, P NATL ACAD SCI USA, V102, P16490, DOI 10.1073/pnas.0505156102; Oleykowski CA, 1998, NUCLEIC ACIDS RES, V26, P4597, DOI 10.1093/nar/26.20.4597; Parry MAJ, 2009, J EXP BOT, V60, P2817, DOI 10.1093/jxb/erp189; Piron F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011313; Przetakiewicz J, 2002, CELL MOL BIOL LETT, V7, P671; Raghavan C, 2007, MOL BREEDING, V19, P87, DOI 10.1007/s11032-006-9046-x; Rothe N, 2010, THESIS KANSASS STATE; Sabetta W, 2011, PLANT METHODS, V7, DOI 10.1186/1746-4811-7-20; Slade AJ, 2005, NAT BIOTECHNOL, V23, P75, DOI 10.1038/nbt1043; Slafer GA, 1996, FIELD CROP RES, V46, P1, DOI 10.1016/0378-4290(95)00081-X; SONG WN, 1995, GENET RESOUR CROP EV, V42, P273, DOI 10.1007/BF02431262; Stephenson P, 2010, BMC PLANT BIOL, V10, DOI 10.1186/1471-2229-10-62; Suzuki T, 2008, MOL GENET GENOMICS, V279, P213, DOI 10.1007/s00438-007-0293-2; Talame V, 2008, PLANT BIOTECHNOL J, V6, P477, DOI 10.1111/j.1467-7652.2008.00341.x; Till B. J., 2007, GENOMICS ASSISTED CR, P333; Till BJ, 2003, METH MOL B, V236, P205; Till BJ, 2007, BMC PLANT BIOL, V7, DOI 10.1186/1471-2229-7-19; Till Bradley J., 2004, BMC Plant Biology, V4, P12, DOI 10.1186/1471-2229-4-12; Uauy C, 2009, BMC PLANT BIOL, V9, DOI 10.1186/1471-2229-9-115; Wang N, 2008, NEW PHYTOL, V180, P751, DOI 10.1111/j.1469-8137.2008.02619.x; Weigel D, 2000, PLANT PHYSIOL, V122, P1003, DOI 10.1104/pp.122.4.1003; Wu JL, 2005, PLANT MOL BIOL, V59, P85, DOI 10.1007/s11103-004-5112-0; Xin ZG, 2008, BMC PLANT BIOL, V8, DOI 10.1186/1471-2229-8-103	53	255	260	6	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2012	7	7							e41570	10.1371/journal.pone.0041570	http://dx.doi.org/10.1371/journal.pone.0041570			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977TM	22844501	Green Published, gold, Green Submitted			2023-01-03	WOS:000306687700113
J	Chen, L; Ma, YL; Kim, EY; Yu, W; Schwartz, RJ; Qian, L; Wang, J				Chen, Li; Ma, Yanlin; Kim, Eun Young; Yu, Wei; Schwartz, Robert J.; Qian, Ling; Wang, Jun			Conditional Ablation of Ezh2 in Murine Hearts Reveals Its Essential Roles in Endocardial Cushion Formation, Cardiomyocyte Proliferation and Survival	PLOS ONE			English	Article							HISTONE METHYLTRANSFERASE ACTIVITY; CARDIAC DEVELOPMENT; TRANSCRIPTION FACTOR; MOUSE DEVELOPMENT; NOTCH ACTIVATION; GENE-EXPRESSION; OUTFLOW-TRACT; BHLH FACTORS; CELL FATE; METHYLATION	Ezh2 is a histone trimethyltransferase that silences genes mainly via catalyzing trimethylation of histone 3 lysine 27 (H3K27Me3). The role of Ezh2 as a regulator of gene silencing and cell proliferation in cancer development has been extensively investigated; however, its function in heart development during embryonic cardiogenesis has not been well studied. In the present study, we used a genetically modified mouse system in which Ezh2 was specifically ablated in the mouse heart. We identified a wide spectrum of cardiovascular malformations in the Ezh2 mutant mice, which collectively led to perinatal death. In the Ezh2 mutant heart, the endocardial cushions (ECs) were hypoplastic and the endothelial-to-mesenchymal transition (EMT) process was impaired. The hearts of Ezh2 mutant mice also exhibited decreased cardiomyocyte proliferation and increased apoptosis. We further identified that the Hey2 gene, which is important for cardiomyocyte proliferation and cardiac morphogenesis, is a downstream target of Ezh2. The regulation of Hey2 expression by Ezh2 may be independent of Notch signaling activity. Our work defines an indispensible role of the chromatin remodeling factor Ezh2 in normal cardiovascular development.	[Chen, Li; Kim, Eun Young; Qian, Ling; Wang, Jun] Texas Heart Inst, Basic Res Labs, Dept Stem Cell Engn, Houston, TX 77025 USA; [Ma, Yanlin] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX USA; [Kim, Eun Young] Univ Texas Hlth Sci Ctr Houston, Program Genes & Dev, Houston, TX USA; [Yu, Wei; Schwartz, Robert J.] Univ Houston, Dept Biochem & Mol Biol, Houston, TX USA	Texas Heart Institute; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; University of Houston System; University of Houston	Chen, L (corresponding author), Texas Heart Inst, Basic Res Labs, Dept Stem Cell Engn, Houston, TX 77025 USA.	junwang@heart.thi.tmc.edu	Chen, Lei/A-2275-2011	Chen, Lei/0000-0003-3068-1583; Parry, Martin/0000-0002-4477-672X; cai, yudong/0000-0001-5664-7979	American Heart Association; National Health Institute; American Heart Association Southern Central Affiliate; Biotechnology and Biological Sciences Research Council [BBS/E/C/00005202, BBS/E/C/00004952, BB/E025161/1, BB/I000607/1, BBS/E/C/00004820] Funding Source: researchfish	American Heart Association(American Heart Association); National Health Institute; American Heart Association Southern Central Affiliate; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported in part by grants from the American Heart Association to JW. JW is also supported by a P30 grant from the National Health Institute as a Newly Independent Investigator (NII). LC is supported by a Postdoctoral Fellowship from the American Heart Association Southern Central Affiliate. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akiyama H, 2004, P NATL ACAD SCI USA, V101, P6502, DOI 10.1073/pnas.0401711101; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Brutsaert DL, 2003, PHYSIOL REV, V83, P59, DOI 10.1152/physrev.00017.2002; Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020; Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156; Conerly ML, 2011, GENE DEV, V25, P997, DOI 10.1101/gad.2054311; Curry CL, 2005, ONCOGENE, V24, P6333, DOI 10.1038/sj.onc.1208783; Danielian PS, 1998, CURR BIOL, V8, P1323, DOI 10.1016/S0960-9822(07)00562-3; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Diez H, 2007, EXP CELL RES, V313, P1, DOI 10.1016/j.yexcr.2006.09.009; Doetzlhofer A, 2009, DEV CELL, V16, P58, DOI 10.1016/j.devcel.2008.11.008; Donovan J, 2002, CURR BIOL, V12, P1605, DOI 10.1016/S0960-9822(02)01149-1; Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018; Ezhkova E, 2011, GENE DEV, V25, P485, DOI 10.1101/gad.2019811; Fischer A, 2007, NUCLEIC ACIDS RES, V35, P4583, DOI 10.1093/nar/gkm477; Fouse SD, 2008, CELL STEM CELL, V2, P160, DOI 10.1016/j.stem.2007.12.011; Fussbroich B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021651; Gessler M, 2002, CURR BIOL, V12, P1601, DOI 10.1016/S0960-9822(02)01150-8; Gordadze AV, 2001, J VIROL, V75, P5899, DOI 10.1128/JVI.75.13.5899-5912.2001; Han P, 2011, CIRC RES, V108, P378, DOI 10.1161/CIRCRESAHA.110.224287; Harrelson Z, 2004, DEVELOPMENT, V131, P5041, DOI 10.1242/dev.01378; High FA, 2008, NAT REV GENET, V9, P49, DOI 10.1038/nrg2279; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Jiang XB, 2000, DEVELOPMENT, V127, P1607; Kim EY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020803; Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011; Leimeister C, 2000, DEV BIOL, V227, P91, DOI 10.1006/dbio.2000.9884; Leimeister C, 1999, MECH DEVELOP, V85, P173, DOI 10.1016/S0925-4773(99)00080-5; Li X, 2009, AM J PATHOL, V175, P1246, DOI 10.2353/ajpath.2009.090042; Liu W, 2004, P NATL ACAD SCI USA, V101, P4489, DOI 10.1073/pnas.0308466101; Liu YG, 2010, AM J PHYSIOL-HEART C, V298, pH2082, DOI 10.1152/ajpheart.00747.2009; Ma Q, 2008, DEV BIOL, V323, P98, DOI 10.1016/j.ydbio.2008.08.013; Moses Kelvin A., 2001, Genesis The Journal of Genetics and Development, V31, P176, DOI 10.1002/gene.10022; Niessen K, 2008, CIRC RES, V102, P1169, DOI 10.1161/CIRCRESAHA.108.174318; Niessen K, 2008, J CELL BIOL, V182, P315, DOI 10.1083/jcb.200710067; Noseda M, 2004, CIRC RES, V94, P910, DOI 10.1161/01.RES.0000124300.76171.C9; O'Carroll D, 2001, MOL CELL BIOL, V21, P4330, DOI 10.1128/MCB.21.13.4330-4336.2001; Olson EN, 2004, NAT MED, V10, P467, DOI 10.1038/nm0504-467; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; Person AD, 2005, INT REV CYTOL, V243, P287, DOI 10.1016/S0074-7696(05)43005-3; Riising EM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002704; Rutenberg JB, 2006, DEVELOPMENT, V133, P4381, DOI 10.1242/dev.02607; Sakata Y, 2006, J MOL CELL CARDIOL, V40, P267, DOI 10.1016/j.yjmcc.2005.09.006; Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016; Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07; Shirai M, 2009, P NATL ACAD SCI USA, V106, P18604, DOI 10.1073/pnas.0900635106; Su IH, 2003, NAT IMMUNOL, V4, P124, DOI 10.1038/ni876; Tanay A, 2007, P NATL ACAD SCI USA, V104, P5521, DOI 10.1073/pnas.0609746104; Timmerman LA, 2004, GENE DEV, V18, P99, DOI 10.1101/gad.276304; van Weerd JH, 2011, CARDIOVASC RES, V91, P203, DOI 10.1093/cvr/cvr138; Wang J, 2008, J BIOL CHEM, V283, P23235, DOI 10.1074/jbc.M709748200; Wang J, 2007, MOL CELL BIOL, V27, P622, DOI 10.1128/MCB.01160-06; Wang J, 2011, WIRES SYST BIOL MED, V3, P446, DOI 10.1002/wsbm.130; Wang J, 2011, BIRTH DEFECTS RES A, V91, P468, DOI 10.1002/bdra.20816; Wilkinson FH, 2006, P NATL ACAD SCI USA, V103, P19296, DOI 10.1073/pnas.0603564103; Wu JC, 2004, CURR PROB CARDIOLOGY, V29, P641, DOI 10.1016/j.cpcardiol.2004.04.003; Wu SC, 2011, J BIOL CHEM, V286, P28511, DOI 10.1074/jbc.M111.240515; Wu ZL, 2010, CELL DEATH DIFFER, V17, P801, DOI 10.1038/cdd.2009.162; Wyngaarden LA, 2011, DEVELOPMENT, V138, P3759, DOI 10.1242/dev.063180	61	255	260	6	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 1	2012	7	2							e31005	10.1371/journal.pone.0031005	http://dx.doi.org/10.1371/journal.pone.0031005			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	914UG	22844501	Green Published, Green Submitted, gold			2023-01-03	WOS:000301977500025
J	Singh, A; Baranwal, V; Shankar, A; Kanwar, P; Ranjan, R; Yadav, S; Pandey, A; Kapoor, S; Pandey, GK				Singh, Amarjeet; Baranwal, Vinay; Shankar, Alka; Kanwar, Poonam; Ranjan, Rajeev; Yadav, Sandeep; Pandey, Amita; Kapoor, Sanjay; Pandey, Girdhar K.			Rice Phospholipase A Superfamily: Organization, Phylogenetic and Expression Analysis during Abiotic Stresses and Development	PLOS ONE			English	Article							GENOME-WIDE IDENTIFICATION; PATATIN-RELATED PHOSPHOLIPASES; LIPID ACYL HYDROLASE; GENE FAMILY; SHOOT GRAVITROPISM; PHOSPHATIDIC-ACID; DROUGHT STRESS; GUARD-CELL; REPRODUCTIVE DEVELOPMENT; SIGNAL-TRANSDUCTION	Background: Phospholipase A (PLA) is an important group of enzymes responsible for phospholipid hydrolysis in lipid signaling. PLAs have been implicated in abiotic stress signaling and developmental events in various plants species. Genome-wide analysis of PLA superfamily has been carried out in dicot plant Arabidopsis. A comprehensive genome-wide analysis of PLAs has not been presented yet in crop plant rice. Methodology/Principal Findings: A comprehensive bioinformatics analysis identified a total of 31 PLA encoding genes in the rice genome, which are divided into three classes; phospholipase A(1) (PLA(1)), patatin like phospholipases (pPLA) and low molecular weight secretory phospholipase A(2) (sPLA(2)) based on their sequences and phylogeny. A subset of 10 rice PLAs exhibited chromosomal duplication, emphasizing the role of duplication in the expansion of this gene family in rice. Microarray expression profiling revealed a number of PLA members expressing differentially and significantly under abiotic stresses and reproductive development. Comparative expression analysis with Arabidopsis PLAs revealed a high degree of functional conservation between the orthologs in two plant species, which also indicated the vital role of PLAs in stress signaling and plant development across different plant species. Moreover, sub-cellular localization of a few candidates suggests their differential localization and functional role in the lipid signaling. Conclusion/Significance: The comprehensive analysis and expression profiling would provide a critical platform for the functional characterization of the candidate PLA genes in crop plants.	[Singh, Amarjeet; Baranwal, Vinay; Shankar, Alka; Kanwar, Poonam; Ranjan, Rajeev; Yadav, Sandeep; Pandey, Amita; Kapoor, Sanjay; Pandey, Girdhar K.] Dept Plant Mol Biol, New Delhi, India		Singh, A (corresponding author), Dept Plant Mol Biol, Univ Delhi S Campus, New Delhi, India.	gkpandey@south.du.ac.in	Sharma, Prabhat/AAW-6558-2021; Ranjan, Rajeev/AAY-3243-2021	Ranjan, Rajeev/0000-0002-1344-4044; Ogollah, Reuben/0000-0002-5777-4117; SHARMA, PRABHAT/0000-0002-2638-2321; Pallikadavath, Saseendran/0000-0002-2598-9949; Kapoor, Sanjay/0000-0002-0283-1137; Pandey, Amita/0000-0001-8717-3227; SINGH, ASHUTOSH/0000-0002-0995-6696; PANDEY, GIRDHAR KUMAR/0000-0001-9180-0924; Kanwar, Poonam/0000-0002-9328-9274; Singh, Abhishek/0000-0001-6263-4410	Department of Biotechnology, Council of Scientific and Industrial Research, University Grant Commission, Government of India	Department of Biotechnology, Council of Scientific and Industrial Research, University Grant Commission, Government of India	This work was supported by the Department of Biotechnology, Council of Scientific and Industrial Research, University Grant Commission, Government of India. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; Agarwal P, 2007, PLANT MOL BIOL, V65, P467, DOI 10.1007/s11103-007-9199-y; Arora R, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-242; Bahn SC, 2003, FEBS LETT, V553, P113, DOI 10.1016/S0014-5793(03)00982-7; Balsinde J, 2005, CELL SIGNAL, V17, P1052, DOI 10.1016/j.cellsig.2005.03.002; Bargmann BO, 2006, CURR OPIN PLANT BIOL, V9, P515, DOI 10.1016/j.pbi.2006.07.011; Boss WF, 2008, ANNU PLANT REV, V33, P202, DOI 10.1111/b.9781405160025.2008.00008.x; Chakrabarty R, 2007, MOL PLANT MICROBE IN, V20, P740, DOI 10.1094/MPMI-20-7-0740; Chen GQ, 2011, CRIT REV PLANT SCI, V30, P239, DOI 10.1080/07352689.2011.572033; Clewley J P, 1997, Methods Mol Biol, V70, P119; Cusack BP, 2007, TRENDS GENET, V23, P270, DOI 10.1016/j.tig.2007.03.010; Dessen A, 2000, BBA-MOL CELL BIOL L, V1488, P40, DOI 10.1016/S1388-1981(00)00108-6; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; He XL, 2005, GENETICS, V169, P1157, DOI 10.1534/genetics.104.037051; Hetherington AM, 2001, CELL, V107, P711, DOI 10.1016/S0092-8674(01)00606-7; Higgs HN, 1998, J BIOL CHEM, V273, P5468, DOI 10.1074/jbc.273.10.5468; Hirschberg HJHB, 2001, EUR J BIOCHEM, V268, P5037, DOI 10.1046/j.0014-2956.2001.02411.x; Holk A, 2002, PLANT PHYSIOL, V130, P90, DOI 10.1104/pp.006288; Hong YY, 2008, PLANT CELL, V20, P803, DOI 10.1105/tpc.107.056390; Hong YY, 2009, PLANT J, V58, P376, DOI 10.1111/j.1365-313X.2009.03788.x; Horton P, 2007, NUCLEIC ACIDS RES, V35, pW585, DOI 10.1093/nar/gkm259; Huang SS, 2001, PLANT PHYSIOL, V125, P573, DOI 10.1104/pp.125.2.573; Hubbard KE, 2010, GENE DEV, V24, P1695, DOI 10.1101/gad.1953910; Ishiguro S, 2001, PLANT CELL, V13, P2191, DOI 10.1105/tpc.13.10.2191; Kato T, 2002, PLANT CELL, V14, P33, DOI 10.1105/tpc.010215; Kim HJ, 2011, PLANT CELL, V23, P94, DOI 10.1105/tpc.110.074799; Laxalt AM, 2002, CURR OPIN PLANT BIOL, V5, P332, DOI 10.1016/S1369-5266(02)00268-6; Lee HY, 2005, PROG LIPID RES, V44, P52, DOI 10.1016/j.plipres.2004.10.002; Lee HY, 2003, PLANT CELL, V15, P1990, DOI 10.1105/tpc.014423; Lee OR, 2010, PLANT CELL, V22, P1812, DOI 10.1105/tpc.110.074211; Li MY, 2011, PLANT CELL, V23, P1107, DOI 10.1105/tpc.110.081240; Li MY, 2009, BBA-MOL CELL BIOL L, V1791, P927, DOI 10.1016/j.bbalip.2009.02.017; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Mansfeld J, 2006, BIOCHEMISTRY-US, V45, P5687, DOI 10.1021/bi052563z; Matos AR, 2008, PHYSIOL PLANTARUM, V134, P110, DOI 10.1111/j.1399-3054.2008.01123.x; Matos AR, 2009, PLANT PHYSIOL BIOCH, V47, P491, DOI 10.1016/j.plaphy.2009.02.011; Matos AR, 2001, FEBS LETT, V491, P188, DOI 10.1016/S0014-5793(01)02194-9; Matsui K, 2004, FEBS LETT, V569, P195, DOI 10.1016/j.febslet.2004.05.064; MAY C, 1998, BBA-LIPID LIPID MET, V1393, P267; Morita MT, 2002, PLANT CELL, V14, P47, DOI 10.1105/tpc.010216; Munnik T, 2001, FEBS LETT, V498, P172, DOI 10.1016/S0014-5793(01)02492-9; Munnik T, 2009, J LIPID RES, V50, pS260, DOI 10.1194/jlr.R800098-JLR200; Nakashima K, 2009, PLANT CELL PHYSIOL, V50, P1345, DOI 10.1093/pcp/pcp083; Narusaka Y, 2003, PLANT CELL PHYSIOL, V44, P1246, DOI 10.1093/pcp/pcg138; Nelson BK, 2007, PLANT J, V51, P1126, DOI 10.1111/j.1365-313X.2007.03212.x; O'Luanaigh N, 2002, MOL BIOL CELL, V13, P3730, DOI 10.1091/mbc.E02-04-0213; Paul RU, 1998, PLANT J, V16, P601, DOI 10.1046/j.1365-313x.1998.00333.x; Prince VE, 2002, NAT REV GENET, V3, P827, DOI 10.1038/nrg928; Ray S, 2007, MOL GENET GENOMICS, V278, P493, DOI 10.1007/s00438-007-0267-4; Rietz S, 2010, MOL PLANT, V3, P524, DOI 10.1093/mp/ssp109; Rydel TJ, 2003, BIOCHEMISTRY-US, V42, P6696, DOI 10.1021/bi027156r; Ryu SB, 2004, TRENDS PLANT SCI, V9, P229, DOI 10.1016/j.tplants.2004.03.004; Scherer GFE, 2002, PLANT MOL BIOL, V49, P357, DOI 10.1023/A:1015290510483; Scherer GFE, 2010, TRENDS PLANT SCI, V15, P693, DOI 10.1016/j.tplants.2010.09.005; Schroeder JI, 2001, NATURE, V410, P327, DOI 10.1038/35066500; Singh A, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-435; Sirichandra C, 2009, J EXP BOT, V60, P1439, DOI 10.1093/jxb/ern340; Stahl U, 1998, PLANT PHYSIOL, V117, P197, DOI 10.1104/pp.117.1.197; Stahl U, 1999, PLANT MOL BIOL, V41, P481, DOI 10.1023/A:1006323405788; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Tuteja N, 2008, PLANT SIGNAL BEHAV, V3, P79, DOI 10.4161/psb.3.2.5303; Vij S, 2008, MOL PLANT, V1, P732, DOI 10.1093/mp/ssn047; Walter M, 2004, PLANT J, V40, P428, DOI 10.1111/j.1365-313X.2004.02219.x; Wang XM, 2001, ANNU REV PLANT PHYS, V52, P211, DOI 10.1146/annurev.arplant.52.1.211; Xiong LM, 2002, PLANT CELL, V14, pS165, DOI 10.1105/tpc.000596; Yamaguchi-Shinozaki K, 2006, ANNU REV PLANT BIOL, V57, P781, DOI 10.1146/annurev.arplant.57.032905.105444; Zhu JK, 2002, ANNU REV PLANT BIOL, V53, P247, DOI 10.1146/annurev.arplant.53.091401.143329	67	175	182	7	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 17	2012	7	2							e30947	10.1371/journal.pone.0030947	http://dx.doi.org/10.1371/journal.pone.0030947			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	926TC	22761908	Green Published, gold, Green Submitted			2023-01-03	WOS:000302853600094
J	Chen, LC; Hsu, C; Chiueh, CC; Lee, WS				Chen, Li-Ching; Hsu, Chin; Chiueh, Chuang Chin; Lee, Wen-Sen			Ferrous Citrate Up-Regulates the NOS2 through Nuclear Translocation of NF kappa B Induced by Free Radicals Generation in Mouse Cerebral Endothelial Cells	PLOS ONE			English	Article							NITRIC-OXIDE SYNTHASE; TRANSIENT FOREBRAIN ISCHEMIA; SUBARACHNOID HEMORRHAGE; OXIDATIVE STRESS; BRAIN-INJURY; PUTATIVE ROLE; IRON; ACTIVATION; EXPRESSION; FERRITIN	Previous studies indicate that the inducible nitric oxide synthase 2 (NOS2) of the brain vascular tissue in experimental subarachnoid hemorrhage (SAH) rats is a critical factor for inducing cerebral vasospasm. However, the underlying molecular mechanisms remain to be elucidated. Here, we applied ferrous citrate (FC) complexes to the primary cultured mouse cerebral endothelial cell (CEC) to mimic the SAH conditions and to address the issue how SAH-induced NOS2 up-regulation. Using immunocytochemical staining technique, we demonstrated that NOS2 was expressed in the cultured CEC. Treatment of the CEC with FC induced increases of the intracellular level of ROS, nuclear factor kappa-light-chain-enhancer of activated B cells (NF kappa B) nuclear translocation as well as NF kappa B binding onto the NOS promoter, and the levels of NOS2 mRNA and protein. These effects were abolished by pre-treatment of the cell with N-Acetyl-Cysteine (NAC), a reactive oxygen species (ROS) scavenger. In the present study, two previously predicted NFkB binding sites were confirmed in the NOS2 promoter within the range of -1529 bp to -1516 bp and -1224 bp to -1210 bp. Interestingly, both NF kappa B binding sites are involved in the FC-activated NOS2 transcriptional activity; the binding site located at -1529 bp to -1516 bp played a greater role than the other binding site located at -1224 bp to -1210 bp in the mouse CEC. These findings highlight the molecular mechanism underlying FC-induced up-regulation of NOS2 in the mouse CEC.	[Chen, Li-Ching; Lee, Wen-Sen] Taipei Med Univ, Grad Inst Med Sci, Sch Med, Taipei, Taiwan; [Hsu, Chin] Kaohsiung Med Univ, Dept Physiol, Kaohsiung, Taiwan; [Chiueh, Chuang Chin] Taipei Med Univ, Shuang Ho Hosp, Taipei, Taiwan; [Lee, Wen-Sen] Taipei Med Univ, Dept Physiol, Sch Med, Taipei, Taiwan; [Lee, Wen-Sen] Taipei Med Univ Hosp, Canc Res Ctr, Taipei, Taiwan	Taipei Medical University; Kaohsiung Medical University; Taipei Medical University; Shuang Ho Hospital; Taipei Medical University; Taipei Medical University; Taipei Medical University Hospital	Lee, WS (corresponding author), Taipei Med Univ, Grad Inst Med Sci, Sch Med, Taipei, Taiwan.	wslee@tmu.edu.tw	Chen, Lei/A-2275-2011	Chen, Lei/0000-0003-3068-1583; Parry, Martin/0000-0002-4477-672X; cai, yudong/0000-0001-5664-7979	National Science Council of Taiwan [NSC-101-2320-B-038-005, NSC-101-2629-B-037-001, NSC-95-2320-B-037-032-MY2, NSC97-2314-B-037-039-MY2, NSC-95-2320-B-038-027-MY2]; Biotechnology and Biological Sciences Research Council [BBS/E/C/00005202, BBS/E/C/00004952, BB/E025161/1, BB/I000607/1, BBS/E/C/00004820] Funding Source: researchfish	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported by research grants from the National Science Council of Taiwan (NSC-101-2320-B-038-005 and NSC-101-2629-B-037-001 to W. S. L.; NSC-95-2320-B-037-032-MY2 and NSC97-2314-B-037-039-MY2 to C. H.; NSC-95-2320-B-038-027-MY2 to C. C. C.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aladag MA, 2009, NEUROCHEM RES, V34, P1935, DOI 10.1007/s11064-009-9979-7; ALLEN DR, 1994, ARCH BIOCHEM BIOPHYS, V315, P235, DOI 10.1006/abbi.1994.1495; Amberg GC, 2010, CIRC RES, V107, P1002, DOI 10.1161/CIRCRESAHA.110.217018; Asehnoune K, 2004, J IMMUNOL, V172, P2522, DOI 10.4049/jimmunol.172.4.2522; Ayer RE, 2008, ACTA NEUROCHIR SUPPL, V104, P33; Berra L V, 2007, J Neurosurg Sci, V51, P1; BIEMOND P, 1988, FREE RADICAL BIO MED, V4, P185, DOI 10.1016/0891-5849(88)90026-3; Bishop GM, 2001, BRAIN RES, V907, P175, DOI 10.1016/S0006-8993(01)02303-4; Chen LC, 2009, J AGR FOOD CHEM, V57, P7331, DOI 10.1021/jf901477g; Chen TY, 2010, STROKE, V41, P160, DOI 10.1161/STROKEAHA.109.562850; Chiueh CC, 2001, PEDIATR NEUROL, V25, P138, DOI 10.1016/S0887-8994(01)00266-1; Chiueh CC, 2000, NEUROTOX RES, V2, P293, DOI 10.1007/BF03033799; Defrere S, 2008, MOL HUM REPROD, V14, P377, DOI 10.1093/molehr/gan033; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; Du WL, 2005, CHEST, V128, p556S, DOI 10.1378/chest.128.6_suppl.556S; Dumont AS, 2003, NEUROSURGERY, V53, P123, DOI 10.1227/01.NEU.0000068863.37133.9E; Gaasch JA, 2007, NEUROCHEM RES, V32, P1196, DOI 10.1007/s11064-007-9290-4; Hanggi D, 2006, ACTA NEUROCHIR, V148, P605, DOI 10.1007/s00701-005-0721-1; Ho PY, 2006, MOL CANCER THER, V5, P3130, DOI 10.1158/1535-7163.MCT-06-0457; Horky LL, 1998, J NEUROSURG, V88, P298, DOI 10.3171/jns.1998.88.2.0298; Hua Y, 2007, STROKE, V38, P759, DOI 10.1161/01.STR.0000247868.97078.10; Ishimaru H, 1996, BRAIN RES, V726, P23, DOI 10.1016/0006-8993(96)00294-6; Janjua Nazli, 2003, Curr Opin Crit Care, V9, P113, DOI 10.1097/00075198-200304000-00006; Jaramillo M, 2003, J IMMUNOL, V171, P4243, DOI 10.4049/jimmunol.171.8.4243; KONDO Y, 1995, J CEREBR BLOOD F MET, V15, P216, DOI 10.1038/jcbfm.1995.27; Lin CL, 2006, J NEUROSURG, V104, P298, DOI 10.3171/jns.2006.104.2.298; Lopez-Ongil S, 1998, BRIT J PHARMACOL, V124, P447, DOI 10.1038/sj.bjp.0701847; Mills E, 2010, FUTURE MED CHEM, V2, P51, DOI 10.4155/FMC.09.140; MOHANAKUMAR KP, 1994, ANN NY ACAD SCI, V738, P392; MORRIS SM, 1994, AM J PHYSIOL, V266, pE829, DOI 10.1152/ajpendo.1994.266.6.E829; Ong WY, 2005, REPROD NUTR DEV, V45, P647, DOI 10.1051/rnd:2005051; Ortego M, 2005, J CARDIOVASC PHARM, V45, P468, DOI 10.1097/01.fjc.0000159042.50488.e5; Osuka K, 2009, J NEUROTRAUM, V26, P1157, DOI 10.1089/neu.2008-0836; Otani H, 2009, ANTIOXID REDOX SIGN, V11, P1913, DOI [10.1089/ars.2009.2453, 10.1089/ARS.2009.2453]; Palmer C, 1999, J NEUROSCI RES, V56, P60, DOI 10.1002/(SICI)1097-4547(19990401)56:1<60::AID-JNR8>3.0.CO;2-A; Ql WN, 2004, MICROSURG, V24, P316, DOI 10.1002/micr.20030; Rauhala P, 1998, FREE RADICAL BIO MED, V24, P1065, DOI 10.1016/S0891-5849(97)00386-9; Regunathan S, 2003, ANN NY ACAD SCI, V1009, P20, DOI 10.1196/annals.1304.002; Shih HC, 2006, STROKE, V37, P3025, DOI 10.1161/01.STR.0000249008.18669.5a; Sorond FA, 2000, ANTIOXID REDOX SIGN, V2, P421, DOI 10.1089/15230860050192206; Taylor BS, 2001, PROG INFLAM RES, P1; Taylor BS, 2000, SHOCK, V13, P413, DOI 10.1097/00024382-200006000-00001; Van Bergen P, 1999, FREE RADICAL RES, V31, P631, DOI 10.1080/10715769900301201; Vijay A, 2006, NEUROL RES, V28, P759, DOI 10.1179/016164106X152034; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; Wilkinson DS, 2005, MOL CELL BIOL, V25, P1200, DOI 10.1128/MCB.25.3.1200-1212.2005; Won SM, 2011, EXP MOL MED, V43, P121, DOI 10.3858/emm.2011.43.2.020; Wong J M, 1995, Adv Pharmacol, V34, P155; Xu J, 2000, STROKE, V31, P1744, DOI 10.1161/01.STR.31.7.1744; Young HM, 1997, HISTOCHEM CELL BIOL, V107, P19, DOI 10.1007/s004180050085; Zhen JH, 2008, AM J HYPERTENS, V21, P28, DOI 10.1038/ajh.2007.14	51	255	260	6	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2012	7	9							e46239	10.1371/journal.pone.0046239	http://dx.doi.org/10.1371/journal.pone.0046239			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022PZ	22844501	Green Published, gold, Green Submitted			2023-01-03	WOS:000309973900115
J	Singh, A; Dey, AB; Mohan, A; Sharma, PK; Mitra, DK				Singh, Amar; Dey, Aparajita Ballave; Mohan, Anant; Sharma, Prabhat Kumar; Mitra, Dipendra Kumar			Foxp(3+) Regulatory T Cells among Tuberculosis Patients: Impact on Prognosis and Restoration of Antigen Specific IFN-gamma Producing T Cells	PLOS ONE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; PD-1 EXPRESSION; ACTIVE TUBERCULOSIS; PULMONARY TUBERCULOSIS; IMMUNE-RESPONSES; TH1 RESPONSES; INFECTION; SUPPRESSION; EXPANSION; LIGANDS	CD(4+)CD(25+)Foxp(3+) Regulatory T cells (Treg) and programmed death-1 (PD-1) molecules have emerged as pivotal players in immune suppression of chronic diseases. However, their impact on the disease severity, therapeutic response and restoration of immune response in human tuberculosis remains unclear. Here, we describe the possible role of Treg cells, their M. tuberculosis driven expansion and contribution of PD-1 pathway to the suppressive function of Treg cells among pulmonary tuberculosis (PTB) patients. Multicolor flow cytometry, cell culture, cells sorting and ELISA were employed to execute the study. Our results showed significant increase in frequency of antigen-reactive Treg cells, which gradually declined during successful therapy and paralleled with decline of M. tuberculosis-specific IL-10 along with elevation of IFN-gamma production, and raising the IFN-gamma/IL-4 ratio. Interestingly, persistence of Treg cells tightly correlated with MDR tuberculosis. Also, we show that blocking PD-1/PD-L1 pathway abrogates Treg-mediated suppression, suggesting that the PD-1/PD-L1 pathway is required for Treg-mediated suppression of the antigen-specific T cells. Treg cells possibly play a role in dampening the effector immune response and abrogating PD-1 pathway on Treg cells significantly rescued protective T cell response, suggesting its importance in immune restoration among tuberculosis patients.	[Singh, Amar; Sharma, Prabhat Kumar; Mitra, Dipendra Kumar] All India Inst Med Sci, Cellular Immunol Div, Dept TII, New Delhi, India; [Dey, Aparajita Ballave; Mohan, Anant] All India Inst Med Sci, Dept Med, New Delhi 110029, India	All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi	Mitra, DK (corresponding author), All India Inst Med Sci, Cellular Immunol Div, Dept TII, New Delhi, India.	salilmitra1@yahoo.com	Sharma, Prabhat/AAW-6558-2021; Ranjan, Rajeev/AAY-3243-2021	Ranjan, Rajeev/0000-0002-1344-4044; Ogollah, Reuben/0000-0002-5777-4117; SHARMA, PRABHAT/0000-0002-2638-2321; Pallikadavath, Saseendran/0000-0002-2598-9949; Kapoor, Sanjay/0000-0002-0283-1137; Pandey, Amita/0000-0001-8717-3227; SINGH, ASHUTOSH/0000-0002-0995-6696; PANDEY, GIRDHAR KUMAR/0000-0001-9180-0924; Kanwar, Poonam/0000-0002-9328-9274; Singh, Abhishek/0000-0001-6263-4410	Department of Biotechnology; Indian Council of Medical Research, Government of India, New Delhi, India	Department of Biotechnology; Indian Council of Medical Research, Government of India, New Delhi, India(Indian Council of Medical Research (ICMR))	The study was supported by the Department of Biotechnology and the Indian Council of Medical Research, Government of India, New Delhi, India. For this study the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alvarez IB, 2010, J INFECT DIS, V202, P524, DOI 10.1086/654932; Amarnath S, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000302; Antas PRZ, 2007, AM J RESP CRIT CARE, V176, P214, DOI 10.1164/ajrccm.176.2.214; Aramaki O, 2004, TRANSPLANTATION, V77, P6, DOI 10.1097/01.TP.0000108637.65091.4B; Barber DL, 2011, J IMMUNOL, V186, P1598, DOI 10.4049/jimmunol.1003304; Belkaid Y, 2009, ANNU REV IMMUNOL, V27, P551, DOI 10.1146/annurev.immunol.021908.132723; Burl S, 2007, CLIN EXP IMMUNOL, V149, P117, DOI 10.1111/j.1365-2249.2007.03399.x; Chen XC, 2007, CLIN IMMUNOL, V123, P50, DOI 10.1016/j.clim.2006.11.009; Cooper AM, 2009, ANNU REV IMMUNOL, V27, P393, DOI 10.1146/annurev.immunol.021908.132703; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; Dong HD, 1999, NAT MED, V5, P1365; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Golden-Mason L, 2007, J VIROL, V81, P9249, DOI 10.1128/JVI.00409-07; Gong JH, 1996, INFECT IMMUN, V64, P913, DOI 10.1128/IAI.64.3.913-918.1996; Green AM, 2010, J INFECT DIS, V202, P533, DOI 10.1086/654896; Guyot-Revol V, 2006, AM J RESP CRIT CARE, V173, P803, DOI 10.1164/rccm.200508-1294OC; Handzel ZT, 2007, ISR MED ASSOC J, V9, P479; Hirsch CS, 1996, P NATL ACAD SCI USA, V93, P3193, DOI 10.1073/pnas.93.8.3193; Hougardy JM, 2007, AM J RESP CRIT CARE, V176, P409, DOI 10.1164/rccm.200701-084OC; HUYGEN K, 1988, SCAND J IMMUNOL, V27, P187, DOI 10.1111/j.1365-3083.1988.tb02338.x; Jaron B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002833; Jurado JO, 2008, J IMMUNOL, V181, P116, DOI 10.4049/jimmunol.181.1.116; Katara GK, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001171; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Keir ME, 2007, CURR OPIN IMMUNOL, V19, P309, DOI 10.1016/j.coi.2007.04.012; Kitazawa Y, 2007, TRANSPLANTATION, V83, P774, DOI 10.1097/01.tp.0000256293.90270.e8; Kursar M, 2007, J IMMUNOL, V178, P2661, DOI 10.4049/jimmunol.178.5.2661; Lazar-Molnar E, 2010, P NATL ACAD SCI USA, V107, P13402, DOI 10.1073/pnas.1007394107; Maier H, 2007, J IMMUNOL, V178, P2714, DOI 10.4049/jimmunol.178.5.2714; Mitra DK, 2009, MICROBES INFECT, V11, P1122, DOI 10.1016/j.micinf.2009.08.006; Mitra DK, 2005, EUR J IMMUNOL, V35, P2367, DOI 10.1002/eji.200525977; O'Garra A, 2004, J CLIN INVEST, V114, P1372, DOI 10.1172/JCI200423215; Pandiyan P, 2007, NAT IMMUNOL, V8, P1353, DOI 10.1038/ni1536; Periasamy S, 2011, J INFECT DIS, V203, P1256, DOI 10.1093/infdis/jir011; Punkosdy GA, 2011, P NATL ACAD SCI USA, V108, P3677, DOI 10.1073/pnas.1100213108; Raimondi G, 2006, J IMMUNOL, V176, P2808, DOI 10.4049/jimmunol.176.5.2808; Scott-Browne JP, 2007, J EXP MED, V204, P2159, DOI 10.1084/jem.20062105; Sharma S, 2009, AM J RESP CRIT CARE, V179; Sharpe AH, 2007, NAT IMMUNOL, V8, P239, DOI 10.1038/ni1443; Shen T, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-279; TOOSSI Z, 1986, J EXP MED, V163, P1162, DOI 10.1084/jem.163.5.1162; TORRES M, 1994, CLIN EXP IMMUNOL, V96, P75, DOI 10.1111/j.1365-2249.1994.tb06233.x; Totsuka T, 2005, EUR J IMMUNOL, V35, P1773, DOI 10.1002/eji.200425109; Tousif S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019864; Trautmann L, 2006, NAT MED, V12, P1198, DOI 10.1038/nm1482; Tseng SY, 2001, J EXP MED, V193, P839, DOI 10.1084/jem.193.7.839; Urbani S, 2006, J VIROL, V80, P11398, DOI 10.1128/JVI.01177-06; von Boehmer H, 2005, NAT IMMUNOL, V6, P338, DOI 10.1038/ni1180; ZHANG M, 1994, J CLIN INVEST, V94, P2435, DOI 10.1172/JCI117611	49	175	182	7	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2012	7	9							e44728	10.1371/journal.pone.0044728	http://dx.doi.org/10.1371/journal.pone.0044728			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014PP	22761908	Green Published, gold, Green Submitted			2023-01-03	WOS:000309388400035
J	Wang, XM; Mao, XO; Xie, L; Sun, F; Greenberg, DA; Jin, KL				Wang, Xiaomei; Mao, XiaoOu; Xie, Lin; Sun, Fen; Greenberg, David A.; Jin, Kunlin			Conditional Depletion of Neurogenesis Inhibits Long-Term Recovery after Experimental Stroke in Mice	PLOS ONE			English	Article							FOCAL CEREBRAL-ISCHEMIA; SUBVENTRICULAR ZONE; FOREBRAIN NEUROGENESIS; BRAIN; CELLS; REPLACEMENT; PRECURSORS; MIGRATION; NEURONS	We reported previously that ablation of doublecortin (DCX)-immunopositive newborn neurons in mice worsens anatomical and functional outcome measured 1 day after experimental stroke, but whether this effect persists is unknown. We generated transgenic mice that express herpes simplex virus thymidine kinase under control of the DCX promoter (DCX-TK transgenic mice). DCX-expressing and recently divided cells in the rostral subventricular zone (SVZ) and hippocampus of DCX-TK transgenic mice, but not wild-type mice, were specifically depleted after ganciclovir (GCV) treatment for 14 days. Focal cerebral ischemia was induced by permanent distal middle cerebral artery occlusion (MCAO) on day 14 of vehicle or GCV treatment, and mice were killed 12 weeks after MCAO. Infarct volume was significantly increased and neurologic deficits were more severe in GCV- compared to vehicle-treated DCX-TK transgenic mice at first 8 weeks, after depletion of DCX- and bromodeoxyuridine-immunoreactive cells in the SVZ and dentate gyrus following focal ischemia. Our results indicate that endogenous neurogenesis in a critical period following experimental stroke influences the course of long-term recovery.	[Wang, Xiaomei; Mao, XiaoOu; Xie, Lin; Sun, Fen; Greenberg, David A.; Jin, Kunlin] Buck Inst Res Aging, Novato, CA USA; [Jin, Kunlin] Univ N Texas Hlth Sci Ctr Ft Worth, Dept Pharmacol & Neurosci, Ft Worth, TX USA; [Jin, Kunlin] Univ N Texas Hlth Sci Ctr Ft Worth, Inst Aging & Alzheimers Dis Res, Ft Worth, TX USA	Buck Institute for Research on Aging; University of North Texas System; University of North Texas Health Science Center; University of North Texas System; University of North Texas Health Science Center	Wang, XM (corresponding author), Buck Inst Res Aging, Novato, CA USA.	kunlin.jin@unthsc.edu	Sun, Fen/I-8516-2016; Pausch, Hubert/U-5934-2019; Prokopenko, Mikhail/A-3995-2008; Zeng, Maomao/M-1422-2013; Wang, Xuelong/GQB-3574-2022; Lizier, Joseph/B-8093-2008; Wang, X. Rosalind/B-7097-2008	Pausch, Hubert/0000-0002-0501-6760; Prokopenko, Mikhail/0000-0002-4215-0344; Wurmser, Christine/0000-0003-0649-6206; SUN, FEN/0000-0003-2094-9494; Zeng, Maomao/0000-0001-9259-1992; Wang, Xuelong/0000-0003-4616-1531; Yu, Zhuowei/0000-0002-9152-6491; Lizier, Joseph/0000-0002-9910-8972; Kou, Xiaoxing/0000-0001-9680-0077; Wang, X. Rosalind/0000-0001-5454-6197; Fries, Ruedi/0000-0002-4657-1787; Tang, Hailiang/0000-0003-1852-3128; Mao, Ying/0000-0001-8055-115X; Yan, Jizhou/0000-0001-7482-7842; Tetens, Jens/0000-0001-5352-464X; Miller, Jennifer/0000-0003-2110-3693	United States Public Health Service Grant [NS57186, AG21980, NS44921, NS62414]	United States Public Health Service Grant(United States Department of Health & Human ServicesUnited States Public Health Service)	This work was supported by United States Public Health Service Grants NS57186 and AG21980 (to KJ) and NS44921 and NS62414 (to DAG). The URL of any funder's website is www.nih.gov/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ameh EA, 2009, SURG INFECT, V10, P105, DOI 10.1089/sur.2007.082; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Encarnacion A, 2011, J NEUROSCI METH, V196, P247, DOI 10.1016/j.jneumeth.2011.01.010; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Gu WG, 2000, J CEREBR BLOOD F MET, V20, P1166, DOI 10.1097/00004647-200008000-00002; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Jin KL, 2010, AGING CELL, V9, P1076, DOI 10.1111/j.1474-9726.2010.00638.x; Jin KL, 2010, P NATL ACAD SCI USA, V107, P7993, DOI 10.1073/pnas.1000154107; Jorgensen H S, 1999, Phys Med Rehabil Clin N Am, V10, P887; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Lai B, 2008, NEUROSCI LETT, V442, P305, DOI 10.1016/j.neulet.2008.07.032; Liu JL, 1998, J NEUROSCI, V18, P7768; Mayo NE, 1999, DISABIL REHABIL, V21, P258; MCDERMOTT KW, 1991, J ANAT, V178, P45; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; OHLSSON AL, 1995, STROKE, V26, P644, DOI 10.1161/01.STR.26.4.644; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Raber J, 2004, ANN NEUROL, V55, P381, DOI 10.1002/ana.10853; REARDON JE, 1989, J BIOL CHEM, V264, P19039; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Yamashita T, 2006, J NEUROSCI, V26, P6627, DOI 10.1523/JNEUROSCI.0149-06.2006; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009; Zhu CL, 2009, J NEUROCHEM, V111, P1447, DOI 10.1111/j.1471-4159.2009.06413.x	26	657	679	34	86	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2012	7	6							e38932	10.1371/journal.pone.0038932	http://dx.doi.org/10.1371/journal.pone.0038932			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	963VI	23071805	Green Submitted, gold, Green Published			2023-01-03	WOS:000305652700041
J	Wang, XJ; Wei, DL; Song, ZG; Jiao, HC; Lin, H				Wang, Xiao Juan; Wei, Dai Lin; Song, Zhi Gang; Jiao, Hong Chao; Lin, Hai			Effects of Fatty Acid Treatments on the Dexamethasone-Induced Intramuscular Lipid Accumulation in Chickens	PLOS ONE			English	Article							ACTIVATED PROTEIN-KINASE; SKELETAL-MUSCLE CELLS; INDUCED INSULIN-RESISTANCE; MAMMALIAN TARGET; GENE-EXPRESSION; DOWN-REGULATION; PPAR-ALPHA; RAT; RECEPTOR; LIVER	Background: Glucocorticoid has an important effect on lipid metabolism in muscles, and the type of fatty acid likely affects mitochondrial utilization. Therefore, we hypothesize that the different fatty acid types treatment may affect the glucocorticoid induction of intramuscular lipid accumulation. Methodology/Principal Findings: The effect of dexamethasone (DEX) on fatty acid metabolism and storage in skeletal muscle of broiler chickens (Gallus gallus domesticus) was investigated with and without fatty acid treatments. Male Arbor Acres chickens (31 d old) were treated with either palmitic acid (PA) or oleic acid (OA) for 7 days, followed by DEX administration for 3 days (35-37 d old). The DEX-induced lipid uptake and oxidation imbalance, which was estimated by increased fatty acid transport protein 1 (FATP1) expression and decreased carnitine palmitoyl transferase 1 activity, contributed to skeletal muscle lipid accumulation. More sensitive than glycolytic muscle, the oxidative muscle in DEX-treated chickens showed a decrease in the AMP to ATP ratio, a decrease in AMP-activated protein kinase (AMPK) alpha phosphorylation and its activity, as well as an increase in the phosphorylation of mammalian target of rapamycin (mTOR) and ribosomal p70S6 kinase, without Akt activation. DEX-stimulated lipid deposition was augmented by PA, but alleviated by OA, in response to pathways that were regulated differently, including AMPK, mTOR and FATP1. Conclusions: DEX-induced intramuscular lipid accumulation was aggravated by SFA but alleviated by unsaturated fatty acid. The suppressed AMPK and augmented mTOR signaling pathways were involved in glucocortcoid-mediated enhanced intramuscular fat accumulation.	[Wang, Xiao Juan; Song, Zhi Gang; Jiao, Hong Chao; Lin, Hai] Shandong Agr Univ, Dept Anim Sci, Tai An, Shandong, Peoples R China; [Wei, Dai Lin] Taian Cent Hosp, Dept Endocrine, Tai An, Shandong, Peoples R China	Shandong Agricultural University	Wang, XJ (corresponding author), Shandong Agr Univ, Dept Anim Sci, Tai An, Shandong, Peoples R China.	hailin@sdau.edu.cn	Sun, Fen/I-8516-2016; Pausch, Hubert/U-5934-2019; Prokopenko, Mikhail/A-3995-2008; Zeng, Maomao/M-1422-2013; Wang, Xuelong/GQB-3574-2022; Lizier, Joseph/B-8093-2008; Wang, X. Rosalind/B-7097-2008	Pausch, Hubert/0000-0002-0501-6760; Prokopenko, Mikhail/0000-0002-4215-0344; Wurmser, Christine/0000-0003-0649-6206; SUN, FEN/0000-0003-2094-9494; Zeng, Maomao/0000-0001-9259-1992; Wang, Xuelong/0000-0003-4616-1531; Yu, Zhuowei/0000-0002-9152-6491; Lizier, Joseph/0000-0002-9910-8972; Kou, Xiaoxing/0000-0001-9680-0077; Wang, X. Rosalind/0000-0001-5454-6197; Fries, Ruedi/0000-0002-4657-1787; Tang, Hailiang/0000-0003-1852-3128; Mao, Ying/0000-0001-8055-115X; Yan, Jizhou/0000-0001-7482-7842; Tetens, Jens/0000-0001-5352-464X; Miller, Jennifer/0000-0003-2110-3693	Shandong Science Fund for Distinguished Youth Scholars; National Basic Research Program of China [2004CB117507]; National Natural Science Foundation of China [30771573]; Research Fund for the Doctoral Program of Higher Education of China	Shandong Science Fund for Distinguished Youth Scholars; National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Fund for the Doctoral Program of Higher Education of China(Research Fund for the Doctoral Program of Higher Education of China (RFDP)Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP))	This work was supported by grants from the Shandong Science Fund for Distinguished Youth Scholars, the National Basic Research Program of China (2004CB117507), the National Natural Science Foundation of China (No.30771573), and Research Fund for the Doctoral Program of Higher Education of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the sponsoring agencies.	Andrews RC, 1999, CLIN SCI, V96, P513, DOI 10.1042/cs0960513; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Berthiaume M, 2007, AM J PHYSIOL-ENDOC M, V293, pE1045, DOI 10.1152/ajpendo.00276.2007; BIEBER LL, 1972, ANAL BIOCHEM, V50, P509, DOI 10.1016/0003-2697(72)90061-9; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Bowes SB, 1996, J ENDOCRINOL, V148, P501, DOI 10.1677/joe.0.1480501; Braun EJ, 2008, COMP BIOCHEM PHYS B, V151, P1, DOI 10.1016/j.cbpb.2008.05.007; Cai YL, 2009, COMP BIOCHEM PHYS C, V150, P164, DOI 10.1016/j.cbpc.2009.04.005; Caton PW, 2011, BIOCHEM J, V437, P521, DOI 10.1042/BJ20110702; Christ-Crain M, 2008, FASEB J, V22, P1672, DOI 10.1096/fj.07-094144; Chuang JC, 2010, J LIPID RES, V51, P1344, DOI 10.1194/jlr.M002196; Clark H, 2004, EUR J BIOCHEM, V271, P2215, DOI 10.1111/j.1432-1033.2004.04151.x; Close B, 1997, LAB ANIM-UK, V31, P1, DOI 10.1258/002367797780600297; Coll T, 2006, DIABETES, V55, P2779, DOI 10.2337/db05-1494; Cota D, 2009, OBESITY, V17, P1641, DOI 10.1038/oby.2009.84; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; de Oliveira C, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-11; Duchene S, 2008, DOMEST ANIM ENDOCRIN, V34, P1, DOI 10.1016/j.domaniend.2006.09.002; Dupont J, 1999, J ENDOCRINOL, V162, P67, DOI 10.1677/joe.0.1620067; Dupont JL, 2004, DOMEST ANIM ENDOCRIN, V26, P127, DOI 10.1016/j.domaniend.2003.09.004; Dupont J, 2008, J ENDOCRINOL, V197, P531, DOI 10.1677/JOE-08-0055; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Foucaud L, 1998, BBA-LIPID LIPID MET, V1391, P204, DOI 10.1016/S0005-2760(97)00213-0; Gao D, 2009, BRIT J NUTR, V102, P1557, DOI 10.1017/S0007114509990948; Gaster M, 2005, DIABETES, V54, P648, DOI 10.2337/diabetes.54.3.648; GRIFFIN HD, 1982, BRIT POULTRY SCI, V23, P307, DOI 10.1080/00071688208447962; Halevy O, 2000, J NUTR, V130, P858, DOI 10.1093/jn/130.4.858; Hardie DG, 2007, ANNU REV PHARMACOL, V47, P185, DOI 10.1146/annurev.pharmtox.47.120505.105304; Hayat MA, 1973, PRINCIPLES TECHNIQUE, V3, P237; Hickson-Bick DLM, 2000, J MOL CELL CARDIOL, V32, P511, DOI 10.1006/jmcc.1999.1098; Holland WL, 2007, CELL METAB, V5, P167, DOI 10.1016/j.cmet.2007.01.002; Hu ZY, 2009, J CLIN INVEST, V119, P3059, DOI 10.1172/JCI38770; HUNNICUTT JW, 1994, DIABETES, V43, P540, DOI 10.2337/diabetes.43.4.540; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Kamara K, 1998, PHYSIOL BEHAV, V64, P1, DOI 10.1016/S0031-9384(97)00534-9; Khamzina L, 2005, ENDOCRINOLOGY, V146, P1473, DOI 10.1210/en.2004-0921; Koh EH, 2003, DIABETES, V52, P2331, DOI 10.2337/diabetes.52.9.2331; Korach-Andre M, 2005, AM J PHYSIOL-ENDOC M, V288, pE106, DOI 10.1152/ajpendo.00089.2004; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee WJ, 2006, BIOCHEM BIOPH RES CO, V340, P291, DOI 10.1016/j.bbrc.2005.12.011; Lillie RD, 1976, HISTOPATHOLOGIC TECH, Vfourth, P559; Lin H, 2004, COMP BIOCHEM PHYS B, V139, P737, DOI 10.1016/j.cbpc.2004.09.013; Liu ZQ, 2004, AM J PHYSIOL-ENDOC M, V287, pE275, DOI 10.1152/ajpendo.00457.2003; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mordier S, 2007, BIOCHEM BIOPH RES CO, V362, P206, DOI 10.1016/j.bbrc.2007.08.004; Nader N, 2010, MOL ENDOCRINOL, V24, P1748, DOI 10.1210/me.2010-0192; Nakken GN, 2010, J APPL PHYSIOL, V108, P298, DOI 10.1152/japplphysiol.00906.2009; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Prasad SSSV, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476-511X-9-111; Proszkowiec-Weglarz M, 2006, COMP BIOCHEM PHYS B, V143, P92, DOI 10.1016/j.cbpb.2005.10.009; Qi D, 2004, DIABETES, V53, P1790, DOI 10.2337/diabetes.53.7.1790; Qi D, 2006, AM J PHYSIOL-ENDOC M, V291, P420; Rivas DA, 2009, J ENDOCRINOL, V202, P441, DOI 10.1677/JOE-09-0202; Ruddock MW, 2008, J BIOCHEM, V144, P599, DOI 10.1093/jb/mvn105; Ruderman NB, 2006, OBESITY, V14, p25S, DOI 10.1038/oby.2006.279; Rutter GA, 2003, BIOCHEM J, V375, P1, DOI 10.1042/BJ20030048; RYDER JM, 1985, J AGR FOOD CHEM, V33, P678, DOI 10.1021/jf00064a027; Saha AK, 2003, MOL CELL BIOCHEM, V253, P65, DOI 10.1023/A:1026053302036; Schwartz GJ, 2008, CELL METAB, V8, P281, DOI 10.1016/j.cmet.2008.08.005; Sekulic A, 2000, CANCER RES, V60, P3504; Shah OJ, 2000, AM J PHYSIOL, V279, P74; SIMON J, 1974, ENDOCRINOLOGY, V95, P1439, DOI 10.1210/endo-95-5-1439; Sipula IJ, 2006, METABOLISM, V55, P1637, DOI 10.1016/j.metabol.2006.08.002; SMOLENSKI RT, 1993, BIOMED CHROMATOGR, V7, P189, DOI 10.1002/bmc.1130070404; Staiger H, 2005, DIABETOLOGIA, V48, P2115, DOI 10.1007/s00125-005-1895-z; Stuart M, 2010, END ABSTR, V21, P180; Tremblay F, 2007, P NATL ACAD SCI USA, V104, P14056, DOI 10.1073/pnas.0706517104; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Wang XJ, 2012, STRESS, V15, P443, DOI 10.3109/10253890.2011.639413; Wang XJ, 2010, COMP BIOCHEM PHYS C, V151, P447, DOI 10.1016/j.cbpc.2010.01.010; Watt MJ, 2006, J PHYSIOL-LONDON, V574, P139, DOI 10.1113/jphysiol.2006.107318; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; Wu QW, 2006, MOL CELL BIOL, V26, P3455, DOI 10.1128/MCB.26.9.3455-3467.2006; Zhang JL, 2004, AM J PHYSIOL-ENDOC M, V286, pE168, DOI 10.1152/ajpendo.00232.2003; Zhao JP, 2009, COMP BIOCHEM PHYS C, V149, P448, DOI 10.1016/j.cbpc.2008.10.106	75	657	679	34	86	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2012	7	5							e36663	10.1371/journal.pone.0036663	http://dx.doi.org/10.1371/journal.pone.0036663			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959VG	23071805	Green Published, Green Submitted, gold			2023-01-03	WOS:000305343500022
J	Wang, XL; Wurmser, C; Pausch, H; Jung, S; Reinhardt, F; Tetens, J; Thaller, G; Fries, R				Wang, Xiaolong; Wurmser, Christine; Pausch, Hubert; Jung, Simone; Reinhardt, Friedrich; Tetens, Jens; Thaller, Georg; Fries, Ruedi			Identification and Dissection of Four Major QTL Affecting Milk Fat Content in the German Holstein-Friesian Population	PLOS ONE			English	Article							QUANTITATIVE TRAIT LOCUS; GROWTH-HORMONE RECEPTOR; MISSENSE MUTATION; GENE; DGAT1; AGPAT6; YIELD; TRANSCRIPTION; EXPRESSION; TISSUE	Milk composition traits exhibit a complex genetic architecture with a small number of major quantitative trait loci (QTL) explaining a large fraction of the genetic variation and numerous QTL with minor effects. In order to identify QTL for milk fat percentage (FP) in the German Holstein-Friesian (HF) population, a genome-wide association study (GWAS) was performed. The study population consisted of 2327 progeny-tested bulls. Genotypes were available for 44,280 SNPs. Phenotypes in the form of estimated breeding values (EBVs) for FP were used as highly heritable traits. A variance components-based approach was used to account for population stratification. The GWAS identified four major QTL regions explaining 46.18% of the FP EBV variance. Besides two previously known FP QTL on BTA14 (P = 8.91x10-(198)) and BTA20 (P = 7.03x10(-12)) within DGAT1 and GHR, respectively, we uncovered two additional QTL regions on BTA5 (P = 2.00x10(-13)) and BTA27 (P = 9.83x10(-5)) encompassing EPS8 and GPAT4, respectively. EPS8 and GPAT4 are involved in lipid metabolism in mammals. Re-sequencing of EPS8 and GPAT4 revealed 50 polymorphisms. Genotypes for five of them were inferred for the entire study population. Two polymorphisms affecting potential transcription factor binding sites of EPS8 (P = 1.40x10(-12)) and GPAT4 (P = 5.18x10(-5)), respectively, were highly significantly associated with the FP EBV. Our results provide evidence that alteration of regulatory sites is an important aspect of genetic variation of complex traits in cattle.	[Wang, Xiaolong; Wurmser, Christine; Pausch, Hubert; Jung, Simone; Fries, Ruedi] Tech Univ Muenchen, Chair Anim Breeding, Freising Weihenstephan, Germany; [Reinhardt, Friedrich] Vereinigte Informat Syst Tierhaltung wV, Verden, Germany; [Tetens, Jens; Thaller, Georg] Univ Kiel, Inst Anim Breeding & Husb, Kiel, Germany	Technical University of Munich; University of Kiel	Wang, XL (corresponding author), Tech Univ Muenchen, Chair Anim Breeding, Freising Weihenstephan, Germany.	xiaolong.wang@tierzucht.tum.de	Sun, Fen/I-8516-2016; Pausch, Hubert/U-5934-2019; Prokopenko, Mikhail/A-3995-2008; Zeng, Maomao/M-1422-2013; Wang, Xuelong/GQB-3574-2022; Lizier, Joseph/B-8093-2008; Wang, X. Rosalind/B-7097-2008	Pausch, Hubert/0000-0002-0501-6760; Prokopenko, Mikhail/0000-0002-4215-0344; Wurmser, Christine/0000-0003-0649-6206; SUN, FEN/0000-0003-2094-9494; Zeng, Maomao/0000-0001-9259-1992; Wang, Xuelong/0000-0003-4616-1531; Yu, Zhuowei/0000-0002-9152-6491; Lizier, Joseph/0000-0002-9910-8972; Kou, Xiaoxing/0000-0001-9680-0077; Wang, X. Rosalind/0000-0001-5454-6197; Fries, Ruedi/0000-0002-4657-1787; Tang, Hailiang/0000-0003-1852-3128; Mao, Ying/0000-0001-8055-115X; Yan, Jizhou/0000-0001-7482-7842; Tetens, Jens/0000-0001-5352-464X; Miller, Jennifer/0000-0003-2110-3693	German Ministry of Education and Research, BMBF [0315134A, 0315134D, 0315131A]; Forderverein Biotechnologieforschung e.V. (FBF), Bonn; Lohmann Tierzucht GmbH, Cuxhaven; China Scholarship Council (CSC)	German Ministry of Education and Research, BMBF(Federal Ministry of Education & Research (BMBF)); Forderverein Biotechnologieforschung e.V. (FBF), Bonn; Lohmann Tierzucht GmbH, Cuxhaven; China Scholarship Council (CSC)(China Scholarship Council)	This study is part of the projects FUGATO-plus GenoTrack and FUGATO-plus MeGA-M and was financially supported by the German Ministry of Education and Research, BMBF (grants 0315134A, 0315134D and 0315131A), the Forderverein Biotechnologieforschung e.V. (FBF), Bonn, and Lohmann Tierzucht GmbH, Cuxhaven. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors acknowledge the vit w.V. Verden for providing phenotype data and the China Scholarship Council (CSC) for supporting X. Wang by a grant.	Beigneux AP, 2006, J LIPID RES, V47, P734, DOI 10.1194/jlr.M500556-JLR200; Bionaz M, 2008, J NUTR, V138, P1019, DOI 10.1093/jn/138.6.1019; Blott S, 2003, GENETICS, V163, P253; Bouwman AC, 2011, BMC GENET, V12, DOI 10.1186/1471-2156-12-43; Browning BL, 2009, AM J HUM GENET, V84, P210, DOI 10.1016/j.ajhg.2009.01.005; Buttchereit N, 2010, J DAIRY SCI, V93, P1702, DOI 10.3168/jds.2009-2198; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Chakravarty K, 2005, CRIT REV BIOCHEM MOL, V40, P129, DOI 10.1080/10409230590935479; Chatterjee S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005197; Cohen-Zinder M, 2005, GENOME RES, V15, P936, DOI 10.1101/gr.3806705; Ed L, 2009, BIOINFORMATICS, V25, P1836, DOI 10.1093/bioinformatics/btp314; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Gremme G, 2005, INFORM SOFTWARE TECH, V47, P965, DOI 10.1016/j.infsof.2005.09.005; Grisart B, 2002, GENOME RES, V12, P222, DOI 10.1101/gr.224202; Guo DL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000446; Hamza MS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004907; Hayes BJ, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001139; Jiang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013661; Kang HM, 2010, NAT GENET, V42, P348, DOI 10.1038/ng.548; Loor JJ, 2005, PHYSIOL GENOMICS, V23, P217, DOI 10.1152/physiolgenomics.00132.2005; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; Portales-Casamar E, 2009, JASPAR 2010 GREATLY; Quackenbush J, 2001, NUCLEIC ACIDS RES, V29, P159, DOI 10.1093/nar/29.1.159; Schennink A, 2007, ANIM GENET, V38, P467, DOI 10.1111/j.1365-2052.2007.01635.x; Schennink A, 2009, ANIM GENET, V40, P909, DOI 10.1111/j.1365-2052.2009.01940.x; Schug Jonathan, 2008, Curr Protoc Bioinformatics, VChapter 2, DOI 10.1002/0471250953.bi0206s21; Signorelli F, 2009, LIVEST SCI, V125, P74, DOI 10.1016/j.livsci.2009.02.014; Thaller G, 2003, J ANIM SCI, V81, P1911; VanRaden PM, 2008, J DAIRY SCI, V91, P4414, DOI 10.3168/jds.2007-0980; Vergnes L, 2006, J LIPID RES, V47, P745, DOI 10.1194/jlr.M500553-JLR200; Viitala S, 2006, GENETICS, V173, P2151, DOI 10.1534/genetics.105.046730; Winter A, 2002, P NATL ACAD SCI USA, V99, P9300, DOI 10.1073/pnas.142293799; Yang JA, 2011, AM J HUM GENET, V88, P76, DOI 10.1016/j.ajhg.2010.11.011; Zimin AV, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-4-r42	35	657	679	34	86	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2012	7	7							e40711	10.1371/journal.pone.0040711	http://dx.doi.org/10.1371/journal.pone.0040711			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	973LU	23071805	Green Published, gold, Green Submitted			2023-01-03	WOS:000306362400093
